<SEC-DOCUMENT>0001493152-26-030287.txt : 20260626
<SEC-HEADER>0001493152-26-030287.hdr.sgml : 20260626
<ACCEPTANCE-DATETIME>20260626160611
ACCESSION NUMBER:		0001493152-26-030287
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		113
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260626
DATE AS OF CHANGE:		20260626

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Beyond Air, Inc.
		CENTRAL INDEX KEY:			0001641631
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				473812456
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38892
		FILM NUMBER:		261129151

	BUSINESS ADDRESS:	
		STREET 1:		900 STEWART AVENUE
		STREET 2:		SUITE 301
		CITY:			GARDEN CITY
		STATE:			NY
		ZIP:			11530
		BUSINESS PHONE:		516-665-8200

	MAIL ADDRESS:	
		STREET 1:		900 STEWART AVENUE
		STREET 2:		SUITE 301
		CITY:			GARDEN CITY
		STATE:			NY
		ZIP:			11530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AIT Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KokiCare, Inc.
		DATE OF NAME CHANGE:	20150507
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:us-types="http://fasb.org/us-types/2026" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2026" xmlns:country="http://xbrl.sec.gov/country/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:cyd="http://xbrl.sec.gov/cyd/2026" xmlns:XAIR="http://beyondair.net/20260331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2026%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_039_XAIR_beyondair.net_20260331 -->
<!-- Field: Set; Name: xdx; ID: xdx_043_20250401_20260331 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0001641631 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_064_Integer_5_Integer -->
<!-- Field: Set; Name: xdx; ID: xdx_063_AUD_0_iso4217%2D%2DAUD -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_07B_SO_form10%2Dk.xdxs -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000004" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000006" name="dei:EntityCentralIndexKey">0001641631</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2026-03-31" id="xdx2ixbrl0150" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2025-03-31" id="xdx2ixbrl0151" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2026-03-31" id="xdx2ixbrl0156" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-03-31" id="xdx2ixbrl0157" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-03-31" id="xdx2ixbrl0176" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:SaleOfCommonStockAndPrefundedWarrants" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:SaleOfCommonStockAndPrefundedWarrants" contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:SaleOfCommonStockAndPrefundedWarrants" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:SaleOfCommonStockAndPrefundedWarrants" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:SaleOfCommonStockAndPrefundedWarrants" contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:SaleOfCommonStockAndPrefundedWarrants" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:SaleOfCommonStockAndPrefundedWarrants" contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:SaleOfCommonStockAndPrefundedWarrants" contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:SaleOfCommonStockAndPrefundedWarrants" contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:SaleOfCommonStockAndPrefundedWarrants" contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0466" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0554" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProvisionForOtherLosses" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossAfterTax" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0564" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:GainLossOnTerminationOfRightOfUseAsset" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:PaymentsToSecurityDepositsMadeOnOperatingLeases" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0636" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0642" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:DerivativesLiability" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0669" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:RightofuseAssetsAcquiredUnderOperatingLeases" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0678" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:DebtPrincipalBalanceConvertedToEquity" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0681" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl0686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl0687" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsMember" id="xdx2ixbrl0729" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsMember" id="xdx2ixbrl0730" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0734" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0735" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember" id="xdx2ixbrl0738" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember" id="xdx2ixbrl0739" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0743" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0744" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsMember" id="xdx2ixbrl0749" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsMember" id="xdx2ixbrl0750" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0754" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0755" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember" id="xdx2ixbrl0758" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember" id="xdx2ixbrl0759" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0763" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0764" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2025-03-31_us-gaap_DerivativeMember" id="xdx2ixbrl0830" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="From2025-04-012026-03-31_us-gaap_WarrantMember" id="xdx2ixbrl0832" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:FairValueMeasurementExtinguishment" contextRef="From2025-04-012026-03-31_us-gaap_WarrantMember" id="xdx2ixbrl0838" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2026-03-31_us-gaap_DerivativeMember" id="xdx2ixbrl0842" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2026-03-31_us-gaap_LeaseholdImprovementsMember" id="xdx2ixbrl0906" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">http://fasb.org/us-gaap/2026#UsefulLifeTermOfLeaseMember</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember" id="xdx2ixbrl1087" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember" id="xdx2ixbrl1089" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockMember" id="xdx2ixbrl1103" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockMember" id="xdx2ixbrl1105" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="xdx2ixbrl1145" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="xdx2ixbrl1147" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="xdx2ixbrl1159" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="xdx2ixbrl1165" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="xdx2ixbrl1167" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="xdx2ixbrl1179" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="xdx2ixbrl1187" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="xdx2ixbrl1241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="xdx2ixbrl1243" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="xdx2ixbrl1245" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="xdx2ixbrl1247" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="xdx2ixbrl1249" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="xdx2ixbrl1261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="xdx2ixbrl1263" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="xdx2ixbrl1265" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="xdx2ixbrl1267" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="xdx2ixbrl1269" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="xdx2ixbrl1281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="xdx2ixbrl1289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="xdx2ixbrl1301" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="xdx2ixbrl1303" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="xdx2ixbrl1305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="xdx2ixbrl1311" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="xdx2ixbrl1313" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="xdx2ixbrl1315" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="xdx2ixbrl1317" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="xdx2ixbrl1331" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="xdx2ixbrl1333" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" contextRef="AsOf2026-03-31_custom_NitricGenAgreementMember" id="xdx2ixbrl1450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" contextRef="AsOf2026-03-31_custom_AvenueAgreementMember" id="xdx2ixbrl1458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" contextRef="AsOf2026-03-31_custom_MarchTwoThousandTwentyFourRaiseMember" id="xdx2ixbrl1466" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" contextRef="AsOf2026-03-31_custom_AvenueExtensionAgreementMember" id="xdx2ixbrl1474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourEquityOfferingMember" id="xdx2ixbrl1482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourDebtInstrumentMember" id="xdx2ixbrl1490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFiveInducementMember" id="xdx2ixbrl1498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" contextRef="AsOf2026-03-31_custom_JanuaryTwoThousandTwentySixEquityOfferingMember" id="xdx2ixbrl1506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" contextRef="AsOf2026-03-31_custom_SubTotalMember" id="xdx2ixbrl1514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:InterestSeveranceCurrent" contextRef="AsOf2025-03-31" id="xdx2ixbrl1584" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2025-03-31" id="xdx2ixbrl1587" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2025-03-31" id="xdx2ixbrl1590" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1643" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:PaidInKindInterestAmount" contextRef="AsOf2026-12-31_custom_PromissoryNoteMember" id="xdx2ixbrl1707" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2026-03-31" id="xdx2ixbrl1893" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2025-03-31" id="xdx2ixbrl1894" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1904" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1906" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-04-01to2026-03-31" id="xdx2ixbrl1952" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss" contextRef="From2024-04-012025-03-31" id="xdx2ixbrl1974" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:CapitalExpendituresCost" contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2046" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2053" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2054" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2058" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2059" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2079" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2094" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="XAIR:CapitalExpendituresCost" contextRef="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2131" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2136" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2137" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2141" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2142" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2161" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2162" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2167" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2177" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2187" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2192" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2196" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2202" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2235" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="xdx2ixbrl2265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="xair-20260331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-04-01to2026-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-06-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-06-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-04_custom_BeyondCancerLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-24_custom_NeuroNosLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-142025-07-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-14</xbrli:startDate>
        <xbrli:endDate>2025-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-01-31_custom_StreetervilleCapitalLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:StreetervilleCapitalLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_StreetervilleCapitalLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:StreetervilleCapitalLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-042025-11-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-04</xbrli:startDate>
        <xbrli:endDate>2025-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_country_AU">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_country_BM">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BM</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_country_IE">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_country_CY">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CY</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-03-312026-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-03-31</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_AustralianTaxationOfficeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_AustralianTaxationOfficeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_FirstThirdPartyVendorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:FirstThirdPartyVendorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SecondThirdPartyVendorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:SecondThirdPartyVendorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_ThirdPartyVendorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:ThirdPartyVendorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:CustomersOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:CustomersTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:CustomersOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:CustomersTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_BeyondCancerLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_NeuroNosLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_MutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_MutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_ShortTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_ShortTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_ShortTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_ShortTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-04_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-04_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-04_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_DerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_DerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_DerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_DerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_DerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ClinicalAndMedicalEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:ClinicalAndMedicalEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ClinicalAndMedicalEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:ClinicalAndMedicalEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_EquipmentDeployableAsPartOfServiceOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:EquipmentDeployableAsPartOfServiceOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_ClinicalAndMedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:ClinicalAndMedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ClinicalAndMedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:ClinicalAndMedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_EquipmentDeployableAsPartOfServiceOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:EquipmentDeployableAsPartOfServiceOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-102025-02-10_custom_TwoThousandAndTwentyFiveATMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:TwoThousandAndTwentyFiveATMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-10</xbrli:startDate>
        <xbrli:endDate>2025-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-10_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TwoThousandAndTwentyFiveATMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:TwoThousandAndTwentyFiveATMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_TwoThousandAndTwentyFiveATMMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:TwoThousandAndTwentyFiveATMMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-042025-11-04_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-04</xbrli:startDate>
        <xbrli:endDate>2025-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-01-31_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-04_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-142026-01-14_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-14</xbrli:startDate>
        <xbrli:endDate>2026-01-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-14_custom_TwoThousandTwentySixPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandTwentySixPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-14_custom_TwoThousandTwentySixCommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandTwentySixCommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-14_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-142026-01-14_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-14</xbrli:startDate>
        <xbrli:endDate>2026-01-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-162026-01-16_custom_TwoThousandTwentySixPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandTwentySixPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-16</xbrli:startDate>
        <xbrli:endDate>2026-01-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-142026-01-14_custom_TwoThousandTwentySixPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandTwentySixPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-14</xbrli:startDate>
        <xbrli:endDate>2026-01-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-25_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TwoThousandThirteenBAPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandThirteenBAPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_TwoThousandThirteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TwoThousandThirteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-03-272026-03-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-03-27</xbrli:startDate>
        <xbrli:endDate>2026-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-04_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-042025-11-04_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-04</xbrli:startDate>
        <xbrli:endDate>2025-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-222024-11-22_custom_TwoThousandTwentyFiveOptionRepricingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:TwoThousandTwentyFiveOptionRepricingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-22</xbrli:startDate>
        <xbrli:endDate>2024-11-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TwoThousandTwentyFiveOptionRepricingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:TwoThousandTwentyFiveOptionRepricingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_TwoThousandTwentyFiveOptionRepricingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:TwoThousandTwentyFiveOptionRepricingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_TwoThousandTwentyFiveOptionRepricingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:TwoThousandTwentyFiveOptionRepricingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-032022-11-03_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-03</xbrli:startDate>
        <xbrli:endDate>2022-11-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-03_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember_custom_BeyondCancerLtdMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_CommonStockMember_custom_BeyondCancerLtdMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-08_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-082025-09-08_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-08</xbrli:startDate>
        <xbrli:endDate>2025-09-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-03_us-gaap_CommonStockMember_custom_AmendedLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:AmendedLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-16_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-16_custom_TwoThousandTwentySixPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandTwentySixPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-162025-01-16_custom_TwoThousandTwentySixPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandTwentySixPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-16</xbrli:startDate>
        <xbrli:endDate>2025-01-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_BeyondAirIncMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_BeyondAirIncMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_BeyondAirIncMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_BeyondAirIncMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_NeuroNosLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_NeuroNosLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_ResearchAndDevelopmentExpense">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_ResearchAndDevelopmentExpense">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_GeneralAndAdministrativeExpense">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_GeneralAndAdministrativeExpense">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_NitricGenAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NitricGenAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_NitricGenAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NitricGenAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_AvenueAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:AvenueAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_AvenueAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:AvenueAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_MarchTwoThousandTwentyFourRaiseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:MarchTwoThousandTwentyFourRaiseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_MarchTwoThousandTwentyFourRaiseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:MarchTwoThousandTwentyFourRaiseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_AvenueExtensionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:AvenueExtensionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_AvenueExtensionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:AvenueExtensionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SeptemberTwoThousandTwentyFourEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_SeptemberTwoThousandTwentyFourEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SeptemberTwoThousandTwentyFourEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourDebtInstrumentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SeptemberTwoThousandTwentyFourDebtInstrumentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_SeptemberTwoThousandTwentyFourDebtInstrumentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SeptemberTwoThousandTwentyFourDebtInstrumentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFiveInducementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SeptemberTwoThousandTwentyFiveInducementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_SeptemberTwoThousandTwentyFiveInducementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SeptemberTwoThousandTwentyFiveInducementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_JanuaryTwoThousandTwentySixEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:JanuaryTwoThousandTwentySixEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_JanuaryTwoThousandTwentySixEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:JanuaryTwoThousandTwentySixEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SubTotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubTotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_PreFundedWarrantsSepTwoThousandTwentyFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PreFundedWarrantsSepTwoThousandTwentyFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_PreFundedWarrantsSepTwoThousandTwentyFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PreFundedWarrantsSepTwoThousandTwentyFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_PreFundedWarrantsJanTwoThousandTwentySixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PreFundedWarrantsJanTwoThousandTwentySixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_PreFundedWarrantsJanTwoThousandTwentySixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PreFundedWarrantsJanTwoThousandTwentySixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SteveLisiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:SteveLisiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-03-012026-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-03-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_WarrantMember42283484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_WarrantMember42283484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_us-gaap_RestrictedStockMember42283484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_RestrictedStockMember42283484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">XAIR:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">XAIR:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-12-31_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-12-31_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">XAIR:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-02_custom_LoanAndSecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-03_custom_LoanAndSecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-022025-06-02_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-02</xbrli:startDate>
        <xbrli:endDate>2025-06-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-03_custom_AmendedLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:AmendedLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-04_custom_NotePurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NotePurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-042025-11-04_custom_NotePurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NotePurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-04</xbrli:startDate>
        <xbrli:endDate>2025-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_StreetervilleCapitalLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:StreetervilleCapitalLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-042026-02-04_custom_StreetervilleCapitalLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:StreetervilleCapitalLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-04</xbrli:startDate>
        <xbrli:endDate>2026-02-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_IsraelTaxAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RevenueCommissionersIrelandMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CypriotTaxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">XAIR:CypriotTaxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_NoExpirationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:NoExpirationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_NoExpirationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:NoExpirationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_ResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_ResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_country_IE">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_country_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-122017-01-13_custom_OptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:OptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-12</xbrli:startDate>
        <xbrli:endDate>2017-01-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-302018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NitricGenIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NitricGenAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-30</xbrli:startDate>
        <xbrli:endDate>2018-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-302018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember_custom_NextMilestonesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NitricGenIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NitricGenAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:NextMilestonesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-30</xbrli:startDate>
        <xbrli:endDate>2018-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-302018-01-31_custom_NitricGenAgreementMember_custom_AfterSixMonthsMember_custom_NitricGenIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NitricGenAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:AfterSixMonthsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NitricGenIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-30</xbrli:startDate>
        <xbrli:endDate>2018-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NitricGenIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NitricGenAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_NitricGenAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NitricGenAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember_custom_SupplierMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:SupplierMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-04_custom_BeyondCancerLtdMember_custom_CertainInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:CertainInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-022021-11-04_custom_BeyondCancerLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-02</xbrli:startDate>
        <xbrli:endDate>2021-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-04_custom_BeyondCancerLtdMember42285687">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-162021-11-18_custom_BeyondCancerLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-16</xbrli:startDate>
        <xbrli:endDate>2021-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-04_custom_BeyondCancerLtdMember_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-04_custom_BeyondCancerLtdMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-24_custom_SubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-242025-03-24_custom_SubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-24</xbrli:startDate>
        <xbrli:endDate>2025-03-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_SubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_SubscriptionAgreementMember_custom_NeuroNosLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_SubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SubscriptionAgreementMember_custom_NeuroNosLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-21_custom_SubscriptionAgreementMember_custom_NeuroNosLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_LungFitPHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">XAIR:LungFitPHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_LungFitPHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">XAIR:LungFitPHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_LungFitPHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">XAIR:LungFitPHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_LungFitPHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">XAIR:LungFitPHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_LungFitPHMember42286578">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LungFitPHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_LungFitPHMember42286593">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LungFitPHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_LungFitPHMember42286593">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LungFitPHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012026-03-31_custom_LungFitRPHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LungFitRPHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_LungFitRPHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LungFitRPHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>XAIR:Integer</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="AUD">
      <xbrli:measure>iso4217:AUD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000175" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="xdx2ixbrl0176" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000178" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000180" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000181" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000183" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000185" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000187" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000189" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000191" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000296" toRefs="Footnote000311"/>
  <ix:relationship fromRefs="Fact000298" toRefs="Footnote000311"/>
  <ix:relationship fromRefs="Fact000300" toRefs="Footnote000311"/>
  <ix:relationship fromRefs="Fact000302" toRefs="Footnote000311"/>
  <ix:relationship fromRefs="Fact000304" toRefs="Footnote000311"/>
  <ix:relationship fromRefs="Fact000306" toRefs="Footnote000311"/>
  <ix:relationship fromRefs="Fact000308" toRefs="Footnote000311"/>
  <ix:relationship fromRefs="Fact000310" toRefs="Footnote000311"/>
  <ix:relationship fromRefs="xdx2ixbrl0313" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact000321" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0323" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact000331" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0333" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact000341" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0343" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0351" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact000359" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0361" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact000369" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0371" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0379" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0387" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0395" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0403" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact000411" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact000413" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact000421" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0423" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0433" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact000441" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0443" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0451" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact000459" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0461" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact000469" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0471" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact000479" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0481" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0489" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0497" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="xdx2ixbrl0505" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact000513" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact000521" toRefs="Footnote000522"/>
  <ix:relationship fromRefs="Fact001583" toRefs="Footnote001600"/>
  <ix:relationship fromRefs="xdx2ixbrl1584" toRefs="Footnote001600"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_908_edei--DocumentType_c20250401__20260331_zoaV87k7kiO9"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000017" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Mark
One)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--DocumentAnnualReport_c20250401__20260331_zVxf5z8XSJYd"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleantrue" id="Fact000018" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE FISCAL YEAR ENDED <span id="xdx_900_edei--DocumentPeriodEndDate_c20250401__20260331_zPxVoVoaNz7b"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:datemonthdayyearen" id="Fact000019" name="dei:DocumentPeriodEndDate"><span id="xdx_90A_edei--CurrentFiscalYearEndDate_c20250401__20260331_zwGkmfZ4ggf"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:datemonthdayen" id="Fact000020" name="dei:CurrentFiscalYearEndDate">MARCH 31</ix:nonNumeric></span>, <span id="xdx_905_edei--DocumentFiscalYearFocus_c20250401__20260331_zXV5IxNGjp24"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000021" name="dei:DocumentFiscalYearFocus">2026</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--DocumentTransitionReport_c20250401__20260331_zQPWfXIfY8S5"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleanfalse" id="Fact000022" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
file number: <span id="xdx_90C_edei--EntityFileNumber_c20250401__20260331_zrJkHf8PNjCa"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000023" name="dei:EntityFileNumber">001-38892</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_907_edei--EntityRegistrantName_c20250401__20260331_zpxGtmNCBqn2"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000024" name="dei:EntityRegistrantName">BEYOND
AIR, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20250401__20260331_zmUkzOh3J7k7"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt-sec:stateprovnameen" id="Fact000025" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20250401__20260331_zoVpKaIuzK4h"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000026" name="dei:EntityTaxIdentificationNumber">47-3812456</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation or organization)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
    Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressAddressLine1_c20250401__20260331_zDWsoZuS4GBk"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000027" name="dei:EntityAddressAddressLine1">900
    Stewart Avenue</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressAddressLine2_c20250401__20260331_zON86vbZhzL9"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000028" name="dei:EntityAddressAddressLine2">Suite 301</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressCityOrTown_c20250401__20260331_zb4WCha25Xsb"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000029" name="dei:EntityAddressCityOrTown">Garden
    City</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20250401__20260331_zC8mnDza5R1a"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000030" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric> </span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressPostalZipCode_c20250401__20260331_zYg27Zovj1za"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000031" name="dei:EntityAddressPostalZipCode">11530</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
    of principal executive offices)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip
    Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--CityAreaCode_c20250401__20260331_zBBujYsT3cX7"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000032" name="dei:CityAreaCode">516</ix:nonNumeric></span>-<span id="xdx_907_edei--LocalPhoneNumber_c20250401__20260331_zSWyrMVTbLUi"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000033" name="dei:LocalPhoneNumber">665-8200</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Registrant&#8217;s
telephone number, including area code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered:</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--Security12bTitle_c20250401__20260331_zOQ7ccuA4lE7"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000034" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--TradingSymbol_c20250401__20260331_z8dxpMJqt9pg"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000035" name="dei:TradingSymbol">XAIR</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
    <span id="xdx_90A_edei--SecurityExchangeName_c20250401__20260331_zRN1U5COGOr3"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt-sec:exchnameen" id="Fact000036" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(g) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityWellKnownSeasonedIssuer_c20250401__20260331_zlP8vEOeHtI6"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000037" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>
    &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by a check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange
Act of 1934.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityVoluntaryFilers_c20250401__20260331_zwqLFzVX8RT9"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000038" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>
    &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityCurrentReportingStatus_c20250401__20260331_zChLUg5WOaf5"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000039" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>
    &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--EntityInteractiveDataCurrent_c20250401__20260331_zhyelQJ91mvl"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000040" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>
    &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 38%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--EntityFilerCategory_c20250401__20260331_zxfn4qlhW9Y2"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt-sec:entityfilercategoryen" id="Fact000041" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntitySmallBusiness_c20250401__20260331_zHpMMAcTknI2"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleantrue" id="Fact000042" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntityEmergingGrowthCompany_c20250401__20260331_zQgkuBYdGuHa"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleanfalse" id="Fact000043" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_905_edei--IcfrAuditorAttestationFlag_c20250401__20260331_zlgoVFP1Rpbl"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleanfalse" id="Fact000044" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_903_edei--DocumentFinStmtErrorCorrectionFlag_c20250401__20260331_znbSlVceyQm9"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleanfalse" id="Fact000045" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;&#8239;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    <span id="xdx_904_edei--EntityShellCompany_dbF_c20250401__20260331_z9YjMWyipQO3"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleanfalse" id="Fact000046" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market
value of the registrant&#8217;s voting stock held by non-affiliates was approximately $<span id="xdx_90A_edei--EntityPublicFloat_iI_pn5n6_c20250930_zHPHOmQ0n08b"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2025-09-30" id="Fact000047" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15.5</ix:nonFraction></span> million based on the last reported sale price
of the registrant&#8217;s common stock on the Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90C_edei--EntityCommonStockSharesOutstanding_iI_c20260623_zSx1PeLyGohg"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2026-06-23" id="Fact000048" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,410,621</ix:nonFraction></span> shares of common stock of the registrant, par value $<span id="xdx_900_edei--EntityListingParValuePerShare_c20250401__20260331_z5l3EInR7dLa"><ix:nonFraction name="dei:EntityListingParValuePerShare" contextRef="From2025-04-01to2026-03-31" id="Fact000049" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
per share, outstanding as of June 23, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS
INCORPORATED BY REFERENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--DocumentsIncorporatedByReferenceTextBlock_c20250401__20260331_z7nSyXqW07B1" title="Documents Incorporated by Reference"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000051" name="dei:DocumentsIncorporatedByReferenceTextBlock">None</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Beyond
Air, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Year Ended March 31, 2026</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_001">PART I</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_009">PART II</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">(Reserved)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">7<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Financial Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">7<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">79</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">Disclosure Regarding Foreign Jurisdictions that Prevent Inspection</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_019">PART III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">Executive Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">86</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_024">Principal Accountant Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_025">PART IV</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_027">Form 10-K Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_028">SIGNATURES</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">References
in this Annual Report on Form 10-K (this &#8220;Annual Report&#8221;) to the &#8220;Company,&#8221; &#8220;Beyond Air,&#8221; &#8220;we,&#8221;
&#8220;our,&#8221; or &#8220;us&#8221; mean Beyond Air, Inc. and its subsidiaries except where the context otherwise requires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORWARD-LOOKING
STATEMENTS AND MARKET DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions
for forward-looking statements contained in Section 27A of the Securities Act of 1933 (the &#8220;Securities Act&#8221;) and Section
21E of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;). All statements other than statements of historical facts
contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy,
approved product and product candidates, certifications or approvals, timing of our clinical development activities, research and development
costs, our commercialization plans and the expected timing thereof, timing and likelihood of success, and the plans and objectives of
management for future operations and future results of anticipated products are forward-looking statements. These statements involve
known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to
be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221;
&#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221;
&#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221;
&#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar conditional expressions. The forward-looking
statements in this Annual Report are only predictions. We have based these forward-looking statements largely on our current expectations
and projections about future events and financial trends that we believe may affect our business, financial condition and results of
operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of important
factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described
under the sections in this Annual Report titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations&#8221; as well as the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to successfully commercialize our LungFit<sup>&#174;</sup> PH system;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our expectation to incur losses for the next year;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to predict accurately the demand for our products, and products under development and to develop strategies to address markets
successfully;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
the possibility that products may contain undetected errors or defects or otherwise not perform as anticipated;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
the anticipated development of markets we sell our products into and the success of our products in these markets;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our future capital needs and our need to raise additional funds;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to build a pipeline of product candidates and develop and commercialize our approved products;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to enroll patients in clinical trials, timely and successfully complete those trials and receive necessary certifications
or regulatory approvals;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to maintain our existing or future collaborations or licenses;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to protect and enforce our intellectual property rights;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
federal, state, and foreign regulatory requirements, including the U.S. Food and Drug Administration (&#8220;FDA&#8221;) regulation of
our approved product and product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to obtain and retain key executives and attract and retain qualified personnel; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to successfully manage our growth, including as a commercial-stage company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management
to predict all risk factors and uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this Annual Report and the documents that we reference in this Annual Report completely and with the understanding that our
actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary
statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
Air, Inc., the Beyond Air logo, and other trademarks or service marks of Beyond Air, Inc. appearing in this Annual Report are the property
of Beyond Air, Inc. This Annual Report also includes trademarks, tradenames and service marks that are the property of other organizations.
Solely for convenience, trademarks and tradenames referred to in this Annual Report may appear without the <sup>&#174;</sup> and &#8482;
symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable
law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MARKET,
INDUSTRY AND OTHER DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report contains estimates, projections, market research and other information concerning our industry, our business, markets for
LungFit<sup>&#174;</sup> PH and our product candidates and the size of those markets, the prevalence of certain medical conditions, LungFit<sup>&#174;
</sup>PH market access, prescription data and other physician, patient and payor data. Unless otherwise expressly stated, we obtain this
information from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry,
medical and general publications, government data and similar sources as well as from our own internal estimates and research and from
publications, research, surveys and studies conducted by third parties on our behalf. Information that is based on estimates, projections,
market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially
from events and circumstances that are reflected in this information. As a result, you are cautioned not to give undue weight to such
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
OF PRINCIPAL RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary briefly lists the principal risks and uncertainties facing our business, which are only a select portion of those risks. A more
complete discussion of those risks and uncertainties is set forth in Part I, Item 1A of this Annual Report, entitled Risk Factors. Additional
risks not presently known to us or that we currently deem immaterial may also affect us. If any of these risks occur, our business, financial
condition or results of operations could be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3pt; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to the following principal risks and uncertainties:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Financial Position and Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    independent registered public accounting firm&#8217;s report contains an explanatory paragraph that expresses substantial doubt about
    our ability to continue as a &#8220;going concern.&#8221; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
    factors, including the incurring of significant losses, are relevant to our financial success and any or all such factors could have
    a disproportionate impact on our bottom line.&#8239;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will need to raise additional capital, and such capital raising may be costly or difficult to obtain, and could dilute current stockholders&#8217;
    ownership interests.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    failure to comply with the covenants or other terms of the Loan Agreement (as defined below), including as a result of events beyond
    our control, could result in a default under the Loan Agreement that could materially and adversely affect the ongoing viability
    of our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Commercialization of our Approved Product or Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the market opportunities for our approved product or product candidates are smaller than we believe they are, our revenue may be
    adversely affected, and our business may suffer.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intense
    competition and rapid technological changes may adversely affect our ability to successfully commercialize our approved product or
    product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to scale sales and marketing capabilities or enter into agreements with third parties to market and sell our approved
    product or product candidates, we may be unable to generate revenue.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    approved product and any future product candidates that we may bring to market may fail to achieve the degree of market acceptance
    by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market
    opportunity for our approved product or product candidates may be smaller than we estimate.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to properly manage our anticipated growth, our business could suffer.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    pressure from our competitors and our customers may impact our ability to sell our products at prices necessary to support our current
    business strategies.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
    of our current and potential competitors have substantially greater financial, technical and marketing resources than we do, and
    they may succeed in developing products that would render our approved product and any future product candidates obsolete or noncompetitive.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject to enforcement action if we engage in improper marketing or promotion of our products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
    legislative or regulatory reform measures, including government restrictions on pricing and reimbursement, may have a negative impact
    on our business and results of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity
    risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, and Internet
    applications and related tools and functions could result in harm to our business and/or subject us to costs, fines or lawsuits.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    to comply with applicable privacy, data and security regulations could result in substantial penalties, liability and negative publicity
    which could adversely affect our business operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Discovery and Development of Our Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    cannot give any assurance that any of our product candidates will receive certification or regulatory approval, which is necessary
    before they can be commercialized.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of our product
    candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have conducted, and may in the future conduct, clinical trials for certain of our product candidates at sites outside the United
    States, and the FDA may not accept data from trials conducted in such locations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we experience any of a number of possible unforeseen events in connection with clinical trials of our product candidates, potential
    certification or marketing approval or commercialization of our product candidates could be delayed or prevented.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    subsidiaries are exploring novel therapeutic processes with NO and once they develop product candidates, those product candidates
    are likely to be classified as pharmaceutical drugs by the FDA and thus face stringent regulation. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may experience delays or difficulties in the enrolment of patients in clinical trials.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serious
    adverse events (&#8220;SAEs&#8221;), or undesirable side effects of our product candidates may be identified.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we obtain certification or regulatory approvals for our product candidates, we will still face extensive, ongoing regulatory requirements
    and review, and our products may face future development and regulatory difficulties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Reliance on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    failure by a third-party supplier or manufacturer to produce or deliver supplies for us or to provide necessary servicing may delay
    or impair our ability to complete our clinical trials or commercialize our approved product or product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may seek to enter into collaborations with third parties for the development and commercialization of our product candidates. If
    we fail to enter into such collaborations, or such collaborations are not successful, we may not be able to capitalize on the market
    potential of our approved product or product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    third-party manufacturing facilities on which we rely are subject to significant regulation and may not continue to meet regulatory
    requirements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    reliance on third parties necessitates the sharing of trade secrets, which increases the possibility of their improper disclosure
    or appropriation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to obtain and maintain sufficiently broad patent protection of our technology, our competitors could develop and commercialize
    technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may
    be impaired.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming
    and unsuccessful.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or
    claiming ownership of what we regard as our own intellectual property.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
    policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the
    enforcement or defense of our issued patents.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be successful in obtaining or maintaining necessary intellectual or proprietary rights to our approved product or product
    candidates including, but not limited to acquisitions and in-licenses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Business Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    manage our business through a small number of employees and key consultants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may need to expand our operations and increase the size of our Company, which may expose us to difficulties in managing growth as
    well as additional regulatory operational and financial risks.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    international operations and plans to expand such operations present challenges and risks related to doing business internationally.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions
    in Israel may materially and adversely affect our business. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    use of our product or any of our product candidates could result in product liability or similar claims that could be expensive,
    damage our reputation and harm our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    disasters, geopolitical unrest, war, terrorism, public health issues or other catastrophic events could disrupt the supply, delivery
    or demand of products, which could negatively affect our operations and performance. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches
    and data leakage.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Ownership of our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    failure to maintain our compliance with Nasdaq&#8217;s continued listing standards or other requirements could result in our common
    stock being delisted from Nasdaq, which could adversely affect our liquidity and the trading volume and market price of our common
    stock and decrease or eliminate your investment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder
    disputes may be limited by the terms of our amended and restated certificate of incorporation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    in our common stock has been volatile and may continue to be volatile in the future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-takeover
    provisions in our amended and restated certificate of incorporation and bylaws, as well as Delaware law, may discourage, delay, or
    prevent a change of control of our Company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Employee Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business could suffer if we lose the services of key members of our senior management, key advisors or personnel.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    employees may engage in misconduct or other non-compliant activities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to various healthcare laws; failure to comply with such laws may result in substantial penalties.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
    litigation and unfavorable publicity could negatively affect our future business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the
    expertise of some of our former employees.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    increasing use and relevance of social media platforms may present new risks.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business may be affected by unfavorable global or U.S. economic conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>ITEM
1. BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (&#8220;NO&#8221;) generators
and delivery systems (the &#8220;LungFit<sup>&#174;</sup> platform&#8221;) capable of generating NO from ambient air. The Company&#8217;s
first device, LungFit<sup>&#174;</sup> PH received premarket approval (&#8220;PMA&#8221;) from the FDA in June 2022. The NO generated
by the LungFit<sup>&#174; </sup>PH system is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation
in term and near-term (&gt;34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic
evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. This condition is commonly referred
to as persistent pulmonary hypertension of the newborn (&#8220;PPHN&#8221;). The LungFit<sup>&#174; </sup>platform can generate NO up
to 400 parts per million (&#8220;ppm&#8221;) for delivery to a patient&#8217;s lungs directly or via a ventilator. LungFit<sup>&#174;
</sup>can deliver NO either continuously or for a fixed amount of time at various flow rates and has the ability to either titrate dose
on demand or maintain a constant dose. In July 2022, we commenced marketing LungFit<sup>&#174;</sup> PH in the United States for PPHN
as a medical device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November  2024, the Company received European CE mark approval of the LungFit PH&#174; system for the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    treatment of infants <span style="text-decoration: underline">&gt;</span>34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic
    evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;
    and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents,
    ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular
    function and oxygenation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LungFit<sup>&#174;
</sup>can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections
via delivery of NO at concentrations &gt; 100 parts per million (ppm) through a breathing mask or similar apparatus. Furthermore, we
believe that there is a high unmet medical need for patients suffering from certain severe lung infections that the LungFit<sup>&#174;
</sup>platform can potentially address. The Company&#8217;s other areas of focus with the LungFit<sup>&#174; </sup>platform beyond PPHN
are nontuberculous mycobacteria (&#8220;NTM&#8221;) lung infection and those with various severe lung infections with underlying chronic
obstructive pulmonary disease (&#8220;COPD&#8221;). Our current product candidates will be subject to premarket reviews and approvals
by the FDA, certification through the conduct of a conformity assessment by a notified body in the EU for the product to be CE marked,
as well as comparable foreign regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
Beyond Air&#8217;s focus on NO and its effect on the human condition, there are two additional programs that do not utilize our LungFit<sup>&#174;
</sup>system. Through our majority-owned affiliate Beyond Cancer, Ltd. (&#8220;Beyond Cancer&#8221;), NO is used to target solid tumors.
The LungFit<sup>&#174; </sup>platform is not utilized for the solid tumor indication due to the need for ultra-high concentrations of
gaseous nitric oxide (&#8220;UNO&#8221;). A proprietary delivery system has been developed that is designed to safely deliver UNO in
excess of 10,000 ppm directly to a solid tumor. This program recently completed a phase 1 human clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2021, Beyond Air reorganized its oncology business into a new private company called Beyond Cancer. Beyond Air&#8217;s preclinical
oncology team and the exclusive right to the intellectual property portfolio utilizing UNO for the treatment of solid tumors now reside
with Beyond Cancer. Beyond Air has 80% ownership in Beyond Cancer. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
second program, which does not utilize the LungFit<sup>&#174;</sup> platform, partially inhibits neuronal nitric oxide synthase
(&#8220;nNOS&#8221;) in the brain to treat neurological and neuro-oncology conditions. The first target indication is autism
spectrum disorder (&#8220;ASD&#8221;). On June 15, 2023, the Company announced that it has entered into an agreement with Yissum
Research Development Company of the Hebrew University of Jerusalem, LTD. (the &#8220;University&#8221;) to acquire the commercial
rights for nNOS inhibitors being developed for the treatment of ASD and other neurological conditions. Currently, there are no
FDA-approved therapies specifically for the treatment of ASD. Under the terms of the agreement, Beyond Air shall pay to the
University compensation for pre-clinical work over the three-year period from the date of the agreement. Also, the Company will pay
to the University a low single-digit royalty on net sales and certain one-time payments based on clinical, regulatory and sales
milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2025, Beyond Air reorganized its neurology business into a new private company called NeuroNOS Limited (&#8220;NeuroNOS&#8221;).
Beyond Air&#8217;s infrastructure, for example regulatory, quality, legal, etc, is currently supporting the NeuroNOS team. Beyond Air
has 84.75% ownership in NeuroNOS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
approved commercial product and development pipeline of product candidates is shown in the tables below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;<br/><img src="form10-k_001.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="form10-k_002.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_003.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LungFit<sup>&#174;
</sup>PH is the first FDA-approved and CE Mark system using our patented plasma pulse technology to generate on-demand NO from ambient
air and, regardless of dose or flow, deliver it to a ventilator circuit. The device uses a medical air compressor to drive room air through
a plasma chamber in the center of the unit where pulses of electrical discharge are created between two electrodes. The system uses the
power equivalent to a 60-watt lightbulb to ionize the nitrogen and oxygen molecules, which then combine as NO with low levels of nitrogen
dioxide (&#8220;NO<sub>2</sub>&#8221;) created as a byproduct. The products are then passed through a Smart Filter, which removes the
toxic NO<sub>2</sub> from the internal circuit. With respect to PPHN, the novel LungFit<sup>&#174;</sup> PH is designed to deliver a dosage
of NO to the lungs that is consistent with current guidelines for delivery of 20 ppm NO with a range of 0.5 ppm &#8211; 80 ppm (low concentration
NO) for ventilated patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the ability of LungFit<sup>&#174;</sup> PH to generate NO from ambient air provides us with many competitive advantages over the
current standard of NO delivery systems in the U.S., the EU, Japan and other markets. For example, LungFit<sup>&#174; </sup>PH does not
require the use of a high-pressure cylinder, does not require cumbersome purging procedures and places less burden on hospital staff
in carrying out safety procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
novel LungFit<sup>&#174; </sup>platform can also deliver a high concentration (<span style="text-decoration: underline">&gt;</span>150 ppm) of NO directly to the lungs, which
we believe has the potential to eliminate microbial infections including bacteria, fungi and viruses, among others. We believe that current
FDA-approved NO vasodilation treatments would have limited success in treating microbial infections given the low concentrations of NO
being delivered (&lt;100 ppm). Given that NO is produced naturally by the body as an innate immunity mechanism, at a concentration of
200 ppm, supplemental high dose NO should aid in the body&#8217;s fight against infection. Based on our preclinical studies and clinical
trials, we believe that 150 ppm is the minimum therapeutic dose to achieve the desired pulmonary antimicrobial effect of NO. To date,
neither the FDA nor comparable foreign regulatory agencies in other countries or regions have approved any NO formulation and/or delivery
system for &gt;80 ppm NO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LungFit<sup>&#174;
</sup>PH for the treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2022, the FDA approved LungFit<sup>&#174;</sup> PH to improve oxygenation and reduce the need for extracorporeal membrane oxygenation
in term and near-term (&gt;34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic
evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November  2024, the company received European CE mark approval of the LungFit PH<sup>&#174;</sup> system for the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    treatment of infants <span style="text-decoration: underline">&gt;</span>34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic
    evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;
    and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents,
    ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular
    function and oxygenation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LungFit<sup>&#174;</sup>
PH is the inaugural device from the LungFit<sup>&#174; </sup>platform of NO generators that use patented ionizer technology and is the
first FDA-approved and CE Marked product for Beyond Air.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
initiated the first phase of our commercial launch in July 2022 (the limited launch phase to introduce Lungfit<sup>&#174;</sup> PH and
Beyond Air to hospitals), and entered into phase 2 (target initial market share gains in certain geographies) with an expanded commercial
presence during the spring of 2023 in the U.S. Since receiving CE Mark in late November 2024, we have received regulatory approvals in
more than 27 other countries outside of the United States and EU. Additionally, we have signed distribution agreements covering over
40 countries outside of the United States. We anticipate significant contribution to revenues in fiscal 2027 and beyond from these and
future partnerships.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A PMA supplement to the US FDA for the expansion of the label to include certain cardiac surgeries was withdrawn
in favor of our submission of our second generation LungFit<sup>&#174;</sup> PH II. The LungFit<sup>&#174;</sup> PH II PMA supplement was
submitted to the FDA in June 2025. LungFit<sup>&#174;</sup> PH II is smaller, lighter, and fully transport-ready. The ability of the device
to be used in air and ground transportation significantly increases our addressable market compared to our first generation product. We
believe the estimated total addressable market for inhaled NO in the U.S. is approximately $350 million and worldwide to be approximately
$700 million or greater. We believe the approval and subsequent launch of the LungFit<sup>&#174;</sup> PH II will equip our commercial
organization to become the market leader in the U.S. in the near-term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LungFit<sup>&#174;
</sup>PRO for the treatment of viral lung infections in hospitalized patients</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Viral
Community-Acquired Pneumonia (including COVID-19)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Viral
pneumonia in adults is most commonly caused by rhinovirus, respiratory syncytial virus (&#8220;RSV&#8221;) and influenza virus. However,
newly emerging viruses (including SARS-CoV-1, SARS-CoV-2, avian influenza A, and H1N1 viruses) have been identified as pathogens contributing
to the overall burden of adult viral pneumonia. COVID-19 is an infectious disease caused by SARS-CoV-2, that resulted in a global pandemic,
causing millions of hospitalizations and over 7.1 million deaths worldwide reported as of March 2026, according to the World Health Organization.
Excluding the pandemic, there are approximately 350,000 annual viral pneumonia hospitalizations in the U.S., and up to 16 million annual
viral pneumonia hospitalizations globally. For the broader annual viral pneumonia hospitalizations, we believe U.S. market potential
to be greater than $1.5 billion and worldwide market potential to be greater than $3 billion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
initiated a pilot clinical trial in late 2020 using our novel LungFit&#174; PRO system at 150 ppm to treat patients with VCAP. The trial
was a multi-center, open-label, randomized clinical trial in Israel, including patients infected with COVID-19. Patients were randomized
in a 1:1 ratio to receive either inhalations of 150 ppm NO given intermittently for 40 minutes four times per day for up to seven days
in addition to standard supportive treatment (&#8220;NO+SST&#8221;) or standard supportive treatment alone (&#8220;SST&#8221;). Endpoints
related to safety (primary endpoint), oxygen saturation and ICU admission, among others, were assessed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
presented results from the pilot clinical trial at the 32<sup>nd</sup> European Congress of Clinical Microbiology &amp; Infectious Diseases
(ECCMID 2022), which took place from April 23, 2022 through April 26, 2022 as a hybrid event both onsite in Lisbon, Portugal and online.
At the time of the data cut off, the trial enrolled a total of 40 patients hospitalized for VCAP (SARS-CoV-2, n=39; other viruses n=1).
The intent-to-treat population included 35 patients with 16 patients in the inhaled NO group and 19 patients in the control group. The
primary COVID-19 treatments used during the clinical trial were Remdesivir (&gt;30%) and Dexamethasone (&gt;65%). Safety data from the
clinical trial show that inhaled NO treatment was well tolerated overall with no treatment related adverse events as assessed by the
investigators. There were two serious adverse events (&#8220;SAEs&#8221;) reported in the group receiving inhaled NO along with SST,
which were determined to be related to underlying conditions and unrelated to clinical trial drug/device. From an efficacy perspective,
results show a trend of shortening length of stay (&#8220;LOS&#8221;) by a factor 1.8 in favor of inhaled NO treatment. Duration of oxygen
support, measured in-hospital and at home, was significantly shorter (p=0.0339) for inhaled NO treated patients. Patients with unstable
oxygen saturation during hospitalization, 66.7% of the inhaled NO treatment group, reached stable saturation of &#8805;93% during hospital
stay as compared to 26.7% in the SST group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
completion of the clinical trial and the 180-day follow-up period, incremental data were provided in a poster presentation at IDWeek
2022. In addition to the positive clinical results provided at ECCMID 2022, the poster showed a larger decline in c-reactive protein
(&#8220;CRP&#8221;) from baseline for patients treated with NO + SST compared to the control group. Analysis of the data provides compelling
evidence that high concentration NO delivery with the LungFit&#174; PRO generator and delivery system can be a powerful tool against any
type of pneumonia, especially COVID-19. The Company commenced a clinical trial in the second half of calendar 2023 in the United States
and made the decision to terminate this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Bronchiolitis (BRO)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Bronchiolitis is the leading cause
of hospital admission in children less than 1 year of age. The incidence is estimated to be 150 million new cases a year worldwide, with
2-3% (over 3 million) of them severe enough to require hospitalization. Worldwide, 95% of all cases occur in developing countries. In
the U.S., there are approximately 120,000 annual bronchiolitis hospitalizations and approximately 3.2 million annual child hospitalizations
globally. Currently, there is no approved treatment for bronchiolitis. The treatment for acute viral lung infections that cause bronchiolitis
in infants is largely supportive care and is based primarily on prolonged hospitalization during which the infant receives a constant
flow of oxygen to treat hypoxemia, a reduced concentration of oxygen in the blood. In addition, systemic steroids and inhalation with
bronchodilators are sometimes utilized until recovery, but we believe that these treatments do not successfully reduce hospital LOS. We
believe the U.S. market potential for bronchiolitis to be greater than $500 million and worldwide market potential to be greater than
$1.2 billion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The pivotal clinical trial for
bronchiolitis was originally set to be performed in the winter of 2020/21 but was delayed due to the COVID-19 pandemic. We have completed
three successful pilot studies for bronchiolitis. A further analysis of the three previously reported pilot studies was presented at the
ATS International Conference 2021. Analysis across the studies (n=198 infants, mean age 3.9 months) showed that 150 ppm &#8211; 160 ppm
NO administered intermittently was generally safe and well tolerated with adverse event rates similar among treatment groups with no reported
treatment-related serious adverse events. The short course of treatments with intermittent high concentration inhaled NO was effective
in shortening hospital LOS and accelerating time to fit for discharge &#8211; a composite endpoint of clinical signs and symptoms to indicate
readiness to be evaluated for hospital discharge. This treatment was also effective in accelerating time to stable oxygen saturation &#8211;
measured as SpO2 &#8805; 92% in room air. Additionally, NO at a dose of 85 ppm NO showed no difference compared to control for all efficacy
endpoints, while 150 ppm NO showed statistical significance when compared to control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, long-term safety
data for high concentration inhaled NO in bronchiolitis was presented at the Pediatric Academic Societies Meeting 2022 (PAS 22). A total
of 101 infants from the three prior pilot studies for bronchiolitis (n=198) participated in the long-term follow-up clinical trial. Clinical
trial endpoints for the long-term safety clinical trial included percentage of patients re-hospitalized for bronchiolitis related reasons,
such reasons included wheezing episodes, pneumonia, and asthma and the percentage of patients re-hospitalized for any reason. Data from
the clinical trial showed the re-hospitalization rate per 100 Patient Exposure Years (PEY) due to bronchiolitis related reasons trended
favorably for the inhaled NO group. In addition, the long-term patient re-hospitalization rate for any reason was similar between inhaled
NO and control groups. As such, the clinical trial concluded that the treatment of hospitalized infants with acute bronchiolitis by intermittent
high dose inhaled NO shows a favorable long-term safety profile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe
that the entirety of data at 150 ppm &#8211; 160 ppm NO in both adult and infant patient populations supports further development of LungFit<sup>&#174;
</sup>PRO in a pivotal clinical trial for patients hospitalized with VCAP or bronchiolitis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LungFit<sup>&#174;
</sup>GO for the treatment of Nontuberculous mycobacteria (NTM)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NTM
lung infection is a rare and serious pulmonary disease associated with increased morbidity and mortality. Patients with NTM lung disease
may experience a multitude of symptoms such as fever, weight loss, cough, lack of appetite, night sweats, blood in the sputum and fatigue.
Patients with NTM lung disease, specifically <i>Mycobacterium abscessus </i>(<i>M. abscessus</i>) representing 20% to 25% of all NTM
and other forms of NTM that are refractory to antibiotic therapy<i>, </i>frequently require lengthy and repeated hospital stays to manage
their condition. There are no treatments specifically indicated for the treatment of <i>M. Abscessus </i>lung disease in North America,
Europe or Japan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are approximately 50,000 to 90,000 people with NTM infections in the U.S. In Asia, the number of patients suffering from NTM surpasses
what is seen in the U.S. There is one inhaled antibiotic approved for the treatment of refractory <i>Mycobacterium avium</i> complex
(&#8220;MAC&#8221;). Current guideline-based approaches to treat NTM lung disease involve multi-drug regimens of antibiotics that may
cause severe, long lasting side effects, and treatment can be longer than 18 months. Median survival for NTM MAC patients is approximately
13 years while median survival for patients with other variations of NTM is typically 4.6 years. The prevalence of human disease attributable
to NTM has increased over the past two decades. In a clinical trial conducted between 2007 and 2016, researchers found that the prevalence
of NTM in the U.S. is increasing at approximately 7.5% per year. <i>M. abscessus</i> treatment costs are estimated to be more than double
that of MAC. A 2015 publication by co-authors from several U.S. government departments stated that cases in 2014 alone cost the U.S.
healthcare system approximately $1.7 billion. For this indication, we believe U.S. sales potential to be greater than $1 billion and
worldwide sales potential to be greater than $2.5 billion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020 we began a 12-week, multi-center, open-label clinical trial in Australia intended to enroll approximately 20 adult
patients with chronic refractory NTM lung disease. We received a grant of up to $2.17 million from the Cystic Fibrosis Foundation
(&#8220;CFF&#8221;) to fund this clinical trial and advance the clinical development of inhaled NO to treat NTM pulmonary disease.
The trial enrolled both cystic fibrosis (&#8220;CF&#8221;) and non-CF patients infected with MAC, <i>M. abscessus </i>or any strain
of NTM. The clinical trial consisted of a run-in period followed by two treatment phases. The run-in period provided a baseline for
the efficacy endpoints. The first treatment phase took place over a two-week period and began in the hospital setting where patients
were titrated from 150 ppm NO up to 250 ppm NO over several days. During this phase patients received NO for 40 minutes, four times
per day while Methemoglobin (&#8220;MetHb&#8221;) levels were monitored. Patients were also trained to use LungFit<sup>&#174;</sup>
GO and subsequently discharged to complete the remaining portion of the two-week treatment period at their home at the highest
tolerated NO concentration. For the second treatment phase, a 10-week maintenance phase, the administration was twice daily at 250 ppm NO. The
clinical trial evaluated safety, quality of life, physical function, and bacterial load among other parameters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the American Thoracic Society International Conference 2022 (ATS 2022), we presented positive interim data from the aforementioned
clinical trial. At the time of data cutoff on April 4, 2022, a total of 15 patients were enrolled in the pilot clinical trial. The
mean age of patients was 62.1 years (range: 22 &#8211; 82 years) with the majority female (80%), a distribution consistent with
real-world NTM disease. All 15 patients were successfully titrated to 250 ppm NO in the hospital setting, and no patients required
dose reductions during the subsequent at-home portion of the clinical trial. Patients were followed up for 12 weeks after the
12-week treatment period was completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completion of the clinical trial, we presented positive results at the 2022 American College of Chest Physicians (&#8220;CHEST&#8221;)
annual meeting, further supporting development of intermittent high dose NO for the treatment of NTM. The clinical trial demonstrated
that high dose NO treatment was well-tolerated in both the home and hospital settings. During the 10-week at-home treatment period of
the clinical trial, a total of 2,492 inhalations were self-administered with overall high treatment compliance (&gt;90%). There were
no SAEs related to treatment discontinuations reported over the 12-week treatment or 12-week follow up periods. Key efficacy endpoints
showed strong results with improvement seen in the majority of quality-of-life domains. Respiratory function and physical function were
maintained during treatment and follow-up. Trends in the reduction of microbial load were observed and one patient achieved culture conversion
with three consecutive negative sputum samples. We anticipate having discussions with the FDA in calendar 2026 to identify a path forward.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
program in COPD is in the preclinical stage and will move forward subject to obtaining additional financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ultra-High
Concentration NO (UNO) in solid tumors through majority-owned affiliate Beyond Cancer.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the fourth calendar quarter of 2021, Beyond Cancer, our majority-owned subsidiary, raised $30.0 million in a private placement of common
shares. The investors purchased a 20% equity ownership in Beyond Cancer, while Beyond Air maintained 80% equity ownership. The funding
is being used to accelerate ongoing preclinical work, including the completion of IND-enabling studies, completion of a Phase 1 human
clinical trial, expansion of preclinical programs for combination studies, hiring of additional Beyond Cancer team members, and optimization
of the delivery system, as well as for general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
Cancer will benefit from Beyond Air&#8217;s NO expertise, IP portfolio,  and regulatory progress, and will
pay Beyond Air a single-digit royalty on all future revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNO
has shown anticancer properties in preclinical trials by eliciting an immune response from the host. We have released preclinical data
at several medical/scientific conferences showing the promise of delivering NO directly to tumors at concentrations of 20,000 ppm &#8211;
200,000 ppm. Results showed that local tumor ablation with NO conveyed anti-tumor immunity to the host. In April 2022, we presented <i>in
vivo </i>and <i>in vitro</i> preclinical data at the American Association for Cancer Research (&#8220;AACR&#8221;) 2022 annual meeting.
The <i>in vivo</i> study assessed the mode of action following a single 5-minute gaseous NO (&#8220;gNO&#8221;) treatment which provided
data showing an effect on the primary tumor 14 days post-treatment. These data showed that intratumoral injections of concentrations
of gNO at 20,000 and 50,000 ppm led to increased recruitment of T cells, B cells, macrophages, and dendrocytes to the primary tumor.
An elevated number of T cells and B cells were also detected in the spleen and blood 21 days following gNO treatment. In addition, at
the same time point, a marked reduction in the number of myeloid-derived suppressor cells was observed in the spleen. Results from the
<i>in vitro</i> study showed that exposure of six different cancer cell lines &#8211; including human ovarian and pancreatic and mouse
lung, melanoma, colon, and breast &#8211; to UNO ranging from 10,000 ppm to 100,000 ppm for up to 10 minutes resulted in a dose-dependent
cytotoxic response. The higher concentration doses of gNO led to near-instant cell death, while the lower concentration doses required
a longer exposure period to elicit cell death. Cell viability was assessed using two assays: XTT and clonogenic assay. After one minute
of exposure to 25,000 ppm gNO, less than 10% viability was observed in all cell lines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
second half of calendar year 2022 was a time of significant progress for Beyond Cancer. On August 23, 2022, we announced that the first
patient was treated in a first-in-human Phase 1 clinical trial to assess the safety and immune biomarkers of UNO therapy. In November,
at the annual meeting of the Society for Immunotherapy of Cancer (&#8220;SITC&#8221;), we presented new in vivo combination data that
support the potential of our novel UNO therapy to treat various types of solid tumors in combination with immune checkpoint inhibitor
(&#8220;ICI&#8221;) therapies, including anti-PD-1. The data presented at SITC appears to indicate that UNO in combination with anti-PD-1
treatment may lead to higher tumor regression rates and prolonged survival. On December 13, 2022, we announced the publication of preclinical
data in the peer-reviewed journal Cancer Cell International (CCI), which showed that our proprietary tumor ablation technology utilizing
UNO induced a potent innate and adaptive immune response that prevented metastases and resulted in a statistically significant survival
benefit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, Beyond Cancer presented additional preclinical data for UNO therapy in solid tumors during the AACR 2023 annual meeting.
Data showed a statistically significant survival benefit for repeat dosing of UNO compared to anti-mCTLA-4 as monotherapy and repeat
doses of UNO prolonged survival in combination with anti-PD-1 compared to gNO alone. With regard to tumor volume, statistically significant
reductions were observed with repeat dosing of UNO versus anti-mPD-1 as a monotherapy and in combination with anti-CTLA-4 versus anti-CTLA-4
alone. Additionally, the data shows that short exposures between 10 seconds to one minute of tumor cells to UNO at increasing concentrations
of 25,000 ppm to 100,000 ppm NO significantly upregulate mPD-L1 expression in a dose and time-dependent manner. Also, in vivo experiments
exhibited a statistically significant day 1 increase in M1 macrophages, decrease in Tregs, and reduction in tumor cell viability was
directionally maintained through day 5. We believe that together with the known ability of NO to activate and recruit the immune system,
the data presented at this year&#8217;s AACR annual meeting appears to indicate that repeat dosing of UNO is feasible and may be effective
even in difficult-to-treat, non-immunogenic tumor types.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, Beyond Cancer presented positive pre-clinical data at the EORTC International Conference on Molecular Targets and Cancer
Therapeutics, demonstrating a statistically significant survival benefit in mice treated with UNO plus anti-PD1 versus anti-PD1 alone.
This was a pooled analysis of multiple studies done with 50,000 or 100,000 ppm NO for a single administration of 5 or 10 minutes. Additionally,
Beyond Cancer&#8217;s second manuscript was published in the <i>Cells Journal</i> in an article titled &#8220;Intratumoral Administration
of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
late December 2023, the Company&#8217;s safety review committee completed its review of the first 6 human subjects treated with UNO and
reported that there were no dose limiting toxicities at the 25,000 ppm NO concentration and the study may progress to the next concentration
of 50,000 ppm NO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2024 at the American Society of Clinical Oncology (ASCO), the Company presented single agent treatment in relapsed or refractory
unresectable, primary or metastatic cutaneous and subcutaneous malignancies at UNO doses of 25,000 and 50,000 parts per million. The
immune biomarker data at Day 21, following a single 5-minute dose of UNO 50,000 ppm, demonstrated increases in dendritic cells, cytotoxic
T-cells, central memory T-cells and a favorable increase in the M1/M2 ratio. Myeloid Derived Suppressor Cells (MDSCs) also showed a 54%
decrease. In the 25,000 ppm cohort, the same stimulatory immune biomarkers were upregulated. UNO was generally well tolerated with primarily
Grade 1 related toxicities. One Grade 3 adverse event was deemed a dose limiting toxicity in the 50,000 ppm cohort resulting in the expansion
of the cohort to six total subjects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also reported a case of relapsed/refractory Triple Negative Breast Cancer (TNBC) in which the subject showed no evidence of malignancy
in a satellite lesion 21 days following UNO treatment and a corollary, rapid and durable clinical resolution of radiation-induced dermatitis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
phase 1a study, between August 2022 and November 2024, enrolled a total of 10 patients treated with either 25,000 ppm or 50,000 ppm NO
for a single intra-tumoral administration over 5 minutes. All subjects had significant advanced stage metastatic disease. The mean number
of treatments prior to entering the study was 10.3 (min 4, max 18), with 5.5 being medication treatments (min 2, max 14). Tumors were
a mix of squamous cell carcinoma, melanoma, breast and triple negative breast. At the time of treatment, life expectancy for all patients
was less than 12 months, with some as low as 3 months. The majority of patients are still alive as of February 2, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Phase 1b trial protocol was approved by the Israeli Ministry of Health (IMOH) in December 2024. The initiation of the study
is pending future funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Selective
neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions in collaboration with Hebrew University
of Jerusalem</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, we announced that we had entered into an agreement with Yissum Research Development Company of the Hebrew University of
Jerusalem, LTD. (the &#8220;University&#8221;) to acquire the commercial rights for neuronal nitric oxide synthase (nNOS) inhibitors
being developed for the treatment of autism spectrum disorder (&#8220;ASD&#8221;) and other neurological conditions. Currently, there
are no FDA-approved therapies utilizing nNOS inhibitors specifically for the treatment of ASD. Under the terms of the agreement, Beyond
Air shall pay to the University compensation for pre-clinical work over the three-year period from the date of the agreement. Also, we
will pay a low single-digit royalty on net sales and certain one-time payments based on clinical, regulatory and sales milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the first calendar quarter of 2025, NeuroNos, our majority-owned affiliate, raised $2.0 million in a private placement of common shares.
An additional $0.5 million and $0.2 million was raised in the private placement offering during the third and fourth calendar quarter
of 2025, respectively. In total, the investors purchased a 15.25% equity ownership in NeuroNos, while Beyond Air maintained 84.75% equity
ownership.  The funding is being used to accelerate ongoing preclinical work,
including IND-enabling studies as well as for general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April 2025, the FDA granted
Orphan Drug Designation (&#8220;ODD&#8221;) to NeuroNos&#8217;  investigational therapy, BA-102, for the treatment of Phelan-McDermid
Syndrome (&#8220;PMS&#8221;), a syndrome associated with ASD. PMS is a rare genetic disorder most commonly caused by deletions or mutations
affecting the SHANK3 gene leading to a range of symptoms, including global developmental delay, intellectual disability, severe speech
impairments, and in many cases features of ASD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In September 2025, the FDA
granted ODD to NeuroNos&#8217; investigational therapy, BA-101, for the treatment of Glioblastoma (&#8220;GBM&#8221;). GBM is an
aggressive primary brain tumor with limited treatment options and poor prognosis under current standard-of-care approaches.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background
and NO Mechanism of Action</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO
is recognized as a vital molecule involved in many physiological and pathological processes. NO is naturally produced by the body&#8217;s
immune system to provide a first line of defense against invading pathogens. It is a powerful molecule with a short half-life of a few
seconds in the blood, enabling it to be cleared rapidly from the body. NO has been shown to play a critical role in the function of several
body systems. For example, as vasodilator of smooth muscles, NO enhances blood flow and circulation. In addition, NO is involved in regulation
of wound healing and immune responses to infection. The pharmacology, toxicity and other data for NO in humans is generally well known,
and its use has been approved by the FDA as a vasodilator. The precise effect of inhaled NO is dependent on concentration, oxidation
state and type of pathogen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO
has multiple immunoregulatory and antimicrobial functions that are likely to be of relevance to inhaled NO therapy. <i>In vitro </i>studies
suggest that NO possesses anti-microbial activity against common bacteria, gram positive and gram negative, as well as mycobacteria,
fungi, yeast, parasites and helminths. It has the potential to eliminate multi-drug resistant strains of the above. Anti-viral activity
covers respiratory viruses such as influenza, corona viruses, RSV and others. In healthy humans, NO has been shown to stimulate mucociliary
clearance, and low levels of nasal NO correlate with impaired mucociliary function in the human upper airway. Unlike other inhaled drugs,
NO is also a smooth muscle relaxant and avoids the concomitant bronchial constriction often associated with inhaled antibiotics and mucolytics.
A potential benefit of these multiple mechanisms may be that in addition to treating lung infections in CF patients, this suggests that
NO may be useful in directly treating the mucus caused by CF, which is the principal manifestation of the disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nitric
Oxide and Infection</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO
possesses broad-spectrum anti-microbial activity acting against bacteria, fungi and viruses. NO is produced at high output as part of
the innate immune response. NO and its by-products (for example, reactive nitrogen species (&#8220;RNS&#8221;)) are responsible for the
process of killing microorganisms within white blood cells called macrophages and in organs such as the lungs and other mucolytic tissues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
than a decade ago, several research groups showed that NO and RNS possess anti-viral activity and affect several viruses including coxsackievirus,
RSV, influenza, severe acute respiratory syndrome (SARS), coronavirus, rhinovirus, herpes simplex virus, Epstein-Barr virus (EBV), and
others. NO has also been shown to be useful in preventing bacterial growth on surfaces.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuous
exposure to 150 ppm NO and above, especially in the lungs, may have side effects and cause damage to host cells. Intermittent exposure
to NO in cycles retains NO anti-microbial activity both in vitro and in animal model of infection. Exposure of bacteria to concomitant
30-minute treatments with 160 ppm NO resulted in a significant reduction in bacterial load. A similar dose has been shown to reduce viruses
(common influenza) by 30-100% in a canine kidney infection model. In vivo, in a pneumonia model in rats, inhaled 160 ppm NO, for 30 minutes,
every 4 hours, resulted in significant reduction in bacteria counts in the lungs, without affecting the body&#8217;s defense mechanisms,
and without any other adverse effect. In addition, we believe a daily dose of 160 ppm of NO can treat bovine respiratory disease (BRD)
in cattle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Importantly,
several studies report synergy between NO and antibiotic drugs. Adjunctive treatment combining NO together with inhaled tobramycin antibiotics
or other anti-microbial agents has been shown to greatly enhance the efficacy of the antibiotics in dispersing <i>P. aeruginosa</i> biofilms
and to increase their ability to elicit anti-microbial activity. These studies suggest that adjuvant treatment combining NO with antibiotics
might have a beneficial role by reducing bacterial infectivity, and therefore reduce the dependency on antibiotics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Beyond
Air Technology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed the Beyond Air NO generator and delivery system which we call LungFit<sup>&#174;</sup>, a novel and precise delivery system
that uses NO generated from ambient air with a novel NO generator, the ionizer. Our system provides continuous monitoring and control
of the gaseous content administered during intermittent and continuous NO inhalation treatments, as well as a precise and reliable monitoring
system that is able to monitor patient status and alert medical staff to any adverse effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LungFit<sup>&#174;</sup> system is innovatively designed to provide patients with a gaseous dose of NO (ranging from 0.5 ppm up to 400
ppm) combined with ambient air. The gaseous blend is supplied to the patient via a ventilator, face mask, or similar apparatus. LungFit<sup>&#174;
</sup>is designed to minimize the time that NO is mixed with oxygen and air. The system is also designed to continuously monitor inhaled
NO concentration, NO<sub>2 </sub>concentration and oxygen. A dedicated screen allows for monitoring of the gas mixture. Further, our
approved product and product candidates resemble other inhalation systems, making them user friendly, with operation and maintenance
that we believe will be immediately familiar to medical staff. Our LungFit<sup>&#174; </sup>system has been manufactured at commercial
scale with a contract manufacturer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
programmed for lung infections, the LungFit<sup>&#174;</sup>, is designed to specifically deliver NO at concentrations of 150 ppm and
higher. We believe that the LungFit<sup>&#174;</sup> has a number of advantages over other NO formulation delivery systems. For example,
it is:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">optimized
    to deliver 150 ppm and higher of NO, whereas existing NO delivery systems on the market consist of a maximum deliverable NO concentration
    of 80 ppm;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">equipped
    with a monitoring system that continuously monitors system parameters (e.g., NO, NO<sub>2</sub> and inhaled fraction of inspired
    oxygen (&#8220;FiO<sub>2</sub>&#8221;) concentrations); </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">capable
    of providing constant flow of NO, which we believe allows it to adequately cover the surface area of the lung to eliminate bacteria,
    viruses, fungi and other microbes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">programmable
    and able to deliver different dosage regimens for a wide range of lung infections;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">able
    to generate NO from ambient air, eliminating the need for the use of high-pressure cylinders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    to be used by the patient, thus convenient and portable; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administered
    non-invasively through a facial mask, which has the potential to address severe infections in large, underserved chronic-care markets,
    such as CF and COPD.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our solution has the potential for a number of additional benefits and opportunities, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    antimicrobial and multiple other properties of the NO molecule delivered to the lungs suggest the potential for application in a
    wide range of respiratory diseases. In contrast to the often arduous and slow drug discovery process for small molecules, proteins,
    and peptides, the use of NO in medicine is well-known, and therefore the identification of conditions where NO provides benefits
    has been, and we expect will continue to be, much simpler, quicker and less costly.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    FDA approved the use of NO as an inhaled drug for the treatment of PPHN in 1999. More than 20 years of clinical experience in the
    delivery, monitoring and understanding of NO in the clinical environment for vascular uses has been documented.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO
    is naturally produced by the immune system and acts as a first line of defense against infectious diseases. We believe therapeutic
    use of NO for viral and bacterial co-infections would potentially improve the success of antimicrobial and anti-viral treatments
    by mimicking the body&#8217;s natural defense mechanism and thereby directly reduce viral infectivity, as well as antibiotic drug
    resistant bacteria.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO
    is used naturally by the body for vasodilation and we believe that the benefits to patients with various medical conditions will
    be seen via vasodilation when delivered with our system.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NitricGen
License</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2018, the Company entered into a definitive agreement to acquire a global, exclusive, perpetual, transferable license to
the eNOGenerator and associated critical assets including intellectual property, know-how, trade secrets and confidential information
(the &#8220;License&#8221;) from NitricGen Inc. (&#8220;NitricGen&#8221;). The eNOGenerator is a novel and precise delivery system that
uses NO generated from ambient air with a novel NO generator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Beyond Air LungFit<sup>&#174;</sup> system, which incorporates the eNOGenerator, has been designated as a medical device by the FDA. The
eNOGenerator can generate NO on demand for delivery to the lungs at concentrations ranging from 0.5 to 400 ppm. With the License, the
Company expects that it will be able to target all conditions requiring NO at any concentration, regardless of the need for intermittent
or continuous dosing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the License, the Company agreed to pay NitricGen an aggregate of $2 million in up-front, clinical, and regulatory milestone
payments, with the majority pertaining to regulatory milestones, as well as royalties on net sales of the delivery system containing
the eNOGenerator at a percentage in the low-single digits. As partial consideration for the License, we issued to NitricGen warrants
to purchase 100,000 shares of our common stock at an exercise price of $6.90 per share. To date, $1.7 million has been paid for milestones
that were earned. As of March 31, 2026 the remaining future milestone payments totaled $0.3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strategies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
objective is to build a leading medical device and biopharmaceutical company that develops and commercializes patented and
proprietary products for the treatment of respiratory infections and diseases, with an initial focus on the treatment of PPHN, NTM
and severe infections in COPD patients, among others. We are exploring and testing the effects of NO on solid tumors through our
subsidiary, Beyond Cancer. Additionally, we are exploring the development of nNOS inhibitors for the treatment of ASD and other
neurological conditions through our subsidiary, NeuroNos. If our clinical trials for our product candidates are successful, we expect to seek certification or
marketing approval from the FDA and other worldwide authorities and notified regulatory bodies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cystic
Fibrosis and NTM Clinical Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2011, a prospective, open label, controlled, single-center pilot safety study was conducted on ten healthy adults between 20 and 62 years
of age. The data were published in the Journal of Cystic Fibrosis in 2012. Subjects received 160 ppm NO for 30 minutes, five times a
day, for five consecutive days via direct inhalation to the lungs using a prototype delivery system. The primary objective of the study
was to determine the effect of inhaled 160 ppm NO on pulmonary function tests and characterize the relationship between high-concentration
NO administration and MetHb &#8211; a form of hemoglobin that is a biproduct of NO and hemoglobin that cannot bind oxygen &#8211; and
establish a MetHb safety threshold level to assess adverse events associated with the treatment. Secondary objectives of the study were
to assess the changes in cytokine levels. Multiple safety markers were continuously monitored including: NO levels, NO<sub>2</sub> (a
biproduct of NO and O<sub>2</sub> that can be toxic at high concentrations), FiO<sub>2</sub>, as well as MetHb and oxygen saturation
(&#8220;SaO<sub>2</sub>&#8221;). Vital signs, lung function, blood chemistry (including nitrite/nitrates), hematology, prothrombin time,
inflammatory cytokine/chemokines levels and endothelial activation (angiopoietin ratio) were also closely monitored. All individuals
tolerated the NO formulation treatment courses well. No SAEs occurred. The maximum amount of air one can forcefully exhale in one second,
known as forced expiratory volume in one second (&#8220;FEV1&#8221;) and other lung function parameters, serum nitrites/nitrates, prothrombin,
pro-inflammatory cytokine and chemokine levels did not differ between baseline and day 5, while MetHb increased during the study period
by an average of 0.9%, as expected. These data suggest that inhalation of 160 ppm NO for 30 minutes, five times a day, for five consecutive
days is well tolerated in healthy individuals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2014, we completed a pilot open label, multi-center study in nine CF patients (&#8805;10 years old). Patients received intermittent (30
minutes, three times a day) inhalation of 160 ppm NO formulation, five days a week, over a two-week period. The study was performed in
two centers, Soroka Medical Center and Schneider Children&#8217;s Medical Center of Israel. The primary endpoints of the study were to
determine the MetHb percentage, adverse events associated with inhaled NO and the percentage of subjects who prematurely discontinued
the study due to adverse events (&#8220;AEs&#8221;) and/or SAEs, or for any other reason. AEs were reported by five (55.5%) subjects.
There were no SAEs related to NO therapy, no treatment-related withdrawals due to AEs, and no deaths. AEs considered by the investigator
as possibly or probably related to treatment were reported for two (22.2%) subjects. There were no AEs of MetHb elevation &gt;5% or NO
<sub>2</sub> elevation &gt;5 ppm (study safety threshold of MetHb and NO<sub>2</sub>, respectively). In total, seven cases of hemoptysis
were reported in two subjects and all events were mild in severity. There was no cumulative effect of MetHb exposure during the study.
The maximum MetHb level reported was 4.6%. Several secondary efficacy analyses were conducted in this study, and though the study was
not powered for efficacy, results show various positive effects of the treatment regime. Bacterial and fungal sputum load analysis results
were highly variable, though marked reductions of Methicillin-sensitive Staphylococcus aureus (&#8220;MSSA&#8221;), Achromabacter, <i>P.
aeruginosa</i>, and Aspergillus were seen in several subjects. These results suggest non-specific targeting of bacteria and fungi that
commonly manifest in CF patients. In subjects with systemic inflammation (CRP &gt;5 mg/mL) at baseline, CRP levels decreased over the
treatment period, showing the effect of NO in the reduction of systemic inflammation. There were no statistically significant or clinically
relevant changes in FEV1 over time, and lung function indices also remained relatively constant throughout the study duration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, Rambam healthcare campus in Israel conducted a compassionate use treatment for two patients with CF who suffer from <i>M, abscessus
</i>lung infections. The data were published in the Pediatric Infectious Disease Journal in 2017. The NO treatment regime, as well as
the device for this treatment, was supplied by BA Ltd. (as defined below), our wholly owned subsidiary. Patients received intermittent
30-minute treatments of 160 ppm NO, with two different regimes including hospitalization (5 times a day) and ambulatory treatment (2-3
inhalations a day). Treatment was well tolerated with no evidence of any serious side effects. We observed significant improvement in
sputum production (up to 5-10 times more sputum), and subjective improvement in the well-being of both patients. Significant reduction
in systemic inflammation was observed in the first patient, as observed by reduction of CRP (C-reactive protein, a systemic inflammation
marker that rises in response to inflammation) levels during treatment. In addition, the first patient had a 2 log (100-fold) reduction
in <i>M. abscessus </i>during treatment (an effect that was lost after the treatment regime changed to ambulatory). The second patient
showed a significant increase in the 6-minute walk (&#8220;6MW&#8221;) test and the sputum culture became negative, which is consistent
with eradication of <i>M. abscessus</i>. Further information is needed, but we believe these results suggest that the treatment of <i>M.
abscessus </i>with high-concentration inhaled NO is effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2017, we treated one patient with CF who suffered from NTM infections (specifically, <i>M. abscessus</i>) under compassionate use in
the United Sates at the National Heart, Lung and Blood Institute with our generator based NO delivery system. The patient saw improvements
in 6MW, FEV1, most Quality-of-Life measures and had no SAEs. The bacteria was not eradicated. The patient requested to be treated again
and this treatment commenced in February 2018. A total of 38 treatments were administered over 8 days, 29 of them at a concentration
of 240 ppm, with no SAEs believed to be related to NO reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally
in 2017, we completed a single-arm, open-label Pilot trial in nine patients with <i>M. abcessus </i>lung disease, who were refractory
to standard-of-care (&#8220;SOC&#8221;). The patients were treated with inhaled NO at a concentration of 160 ppm for 30 minutes, in addition
to treatment with SOC. Our inhaled NO treatment was administered intermittently five times per day over a 14-day period, followed by
a seven-day period with three treatments per day. The primary endpoint of safety, as measured by NO-related SAEs, over the 21-day treatment
period was met with no SAEs reported. Secondary endpoints of a 6MW test FEV1, Quality of Life and <i>M. abscessus </i>load in sputum
all trended positively. 6MW showed an increase of &gt;40 meters at the end of treatment at day 21 versus baseline and an increase of
&gt;25 meters on day 81 (60 days after the cessation of therapy). The mean percentage change in FEV1 at day 21 and day 51 (30 days after
the cessation of treatment) was &gt; 3.5% with FEV1 returning to baseline at day 81 (60 days after the cessation of therapy). At day
81 (60 days after the cessation of therapy) bacterial load was 65% lower than baseline. 1 of 9 patients saw culture conversion. This
study was published in the Journal of Cystic Fibrosis in 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2018, an additional CF patient infected with <i>M. abscessus </i>was treated over a 4-week period with 76 of 84 treatments at 250 ppm
NO in Israel at Soroka Medical Center. The patient saw improvements in 6MW, FEV1 and most Quality-of-Life measures. The bacteria were
not eradicated. Importantly, there were no SAE&#8217;s reported and all treatments were completed without incident.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020 we began a 12-week, multi-center, open-label clinical trial in Australia intended to enroll approximately 20 adult patients
with chronic refractory NTM lung disease. We received a grant of up to $2.2 million from the CFF to fund this study and advance the clinical
development of inhaled NO to treat NTM pulmonary disease. The trial enrolled both CF and non-CF patients infected with MAC, <i>M. abscessus
</i>or any strain of NTM. The study consisted of a run-in period followed by two treatment phases. The run-in period provided a baseline
for the efficacy endpoints. The first treatment phase took place over a two-week period and begun in the hospital setting where patients
were titrated from 150 ppm NO up to 250 ppm NO over several days. During this phase patients received NO for 40 minutes, four times per
day while MetHb levels were monitored. Patients were also trained to use LungFit<sup>&#174;</sup> GO and subsequently discharged to complete
the remaining portion of the two-week treatment period at their home at the highest tolerated NO concentration. For the second treatment
phase, a 10-week maintenance phase, the administration was twice daily. The study was evaluating safety, quality of life, physical function,
and bacterial load among other parameters. The mean age of subjects was 62.1 years (range: 22 &#8211; 82 years) with the majority female
(80%), a distribution consistent with real-world NTM disease. All 15 subjects were successfully titrated to 250 ppm NO in the hospital
setting, and no patients required dose reductions during the subsequent at-home portion of the study. Patients were followed up for 12
weeks after the 12-week treatment period was completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company presented positive results at the 2022 CHEST annual meeting, further supporting development of intermittent high dose NO for
the treatment of NTM. The study demonstrated that high dose NO treatment was safe and well-tolerated in both the home and hospital
settings. During the 10-week at-home treatment period of the study, a total of 2,492 inhalations were self-administered with overall
high treatment compliance (&gt;90%). There were no SAEs related to treatment discontinuations reported over the 12-week treatment or
12-week follow up periods. Key efficacy endpoints showed strong results with improvement seen in the majority of quality-of-life
domains. Respiratory function and physical function were maintained during treatment and follow-up. Trends in the reduction of
microbial load were observed and one subject achieved culture conversion with three consecutive negative sputum samples. We
anticipate having discussions with the FDA in calendar year 2026 with respect to commencing a pivotal clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
program in COPD is in the preclinical stage and will move forward subject to obtaining additional financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to further supporting development of intermittent high dose NO for the treatment of NTM, we believe this study breaks new ground
in the development of NO therapy by showing the potential for the Company&#8217;s at-home generator-based system to be used safely and
consistently by this patient population in a real-world setting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VCAP
and BRO Clinical Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2014, we completed a double blind, randomized Pilot study for infants with bronchiolitis (n=43) for which the data were published in
the Pediatric Pulmonology Journal in 2017. The study was performed at Soroka University Medical Center in Israel. Forty-three infants
between the ages of two to 12 months diagnosed with bronchiolitis were randomly assigned to either the treatment group or the control
group. The treatment group comprised 21 subjects who received intermittent (30 minutes, five times a day) inhalation of 160 ppm NO formulation,
in addition to supportive O<sub>2 </sub>treatment for up to five days. The control group, 22 subjects, received ongoing inhalation of
the supportive O<sub>2 </sub>treatment. Primary endpoints included determination of the MetHb levels, adverse events associated with
the inhaled NO formulation and proportion of subjects who prematurely discontinued the study. Baseline clinical score, indicating disease
severity at screening, was similar between treatment groups (~8). Results were encouraging, with similar overall incidence of AEs between
the treatment groups. Out of 43 patients, 39 (~90%) completed the study per protocol (&#8220;PP&#8221;), with similar percentages (90%)
for both the control and the treatment groups, individually. Only one subject from the treatment group discontinued treatment due to
an adverse event, namely &#8211; repeated MetHb levels above 5%. Adverse events were reported by 23 (53.5%) subjects overall, with ten
(47.6%) subjects in the NO group reporting a total of 22 AEs, and 13 (59.1%) subjects in the control group reporting a total of 22 AEs.
SAEs were reported by four (19.0%) subjects in the NO group and four (18.2%) in the standard treatment group. There were no treatment-related
SAEs in the NO treatment group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the NO group, six (28.6%) subjects had any MetHb measurement &gt;5% during the study treatment period, and three of these subjects had
more than one MetHb &gt;5%. The maximum MetHb level was 5.6% in one subject in the NO group. There was no cumulative effect of MetHb
exposure during the study. The MetHb levels in this study were defined to &lt;5% as a safety measure, though previous findings have shown
that higher levels (6.4%) are non-toxic in children. Secondary and exploratory analyses were performed, and results show positive impact
of the treatment regime. In a subgroup of subjects that stayed at the hospital at least 24 hours (LOS &gt;24 hours), a statistically
significant treatment benefit of NO versus standard treatment was demonstrated. Mean results for subjects with LOS &gt; 24 hours show
that LOS was shortened by approximately 34% in the NO group compared to the standard treatment group, with a one-day difference between
the groups (PP, N=24). Time to normal oxygenation (SaO2 of 92%) was shortened by approximately 44% (27.75 hours) in the NO group compared
to the standard treatment group (PP, N=24). An 80% improvement in time to clinical score (indicating improvement in disease severity)
and time to normal oxygenation (92%) was observed in favor of the NO group (PP, N=24).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2018 we completed a second pilot study in bronchiolitis in 6 centers in Israel. The data were published in Nature in 2020. The prospective,
randomized, double blind, controlled pilot study enrolled 67 patients, aged 0-12 months, who were hospitalized due to bronchiolitis.
The patients received either SOC (typically oxygen and hydration) or SOC plus inhaled NO at a concentration of 160 ppm for 30 minutes
5 times per day for up to 5 days. The primary endpoint of hospital LOS was met with a 26.7-hour reduction in hospital length of stay
demonstrated (p=0.04). Secondary endpoints of time required to achieve a clinical score of 5 or less on the modified Tal score and time
required to achieve SaO<sub>2</sub> of 92% or greater showed improvement versus the SOC. There were no issues with NO<sub>2</sub> or
MetHb and no SAEs were recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2020 we completed a third pilot study in bronchiolitis in 8 centers in Israel and presented the data at 2020 CHEST annual meeting. The
prospective, randomized, double blind, controlled pilot study enrolled 89 patients (ITT n=87), aged 0-12 months, who were hospitalized
due to bronchiolitis. The patients were randomized 1:1:1 to receive either SOC (typically oxygen and hydration) or SOC plus inhaled NO
at 85 ppm or SOC plus inhaled NO at 150 ppm for 40 minutes 4 times per day for up to 5 days. There were no SAEs related to NO therapy.
Efficacy results are shown in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">150 ppm vs. 85 ppm <br/> Hazard Ratio (p-value)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">150 ppm vs. SST <br/> Hazard Ratio (p-value)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: center">Fit for Discharge</td><td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">2.11 (0.041)</td><td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">2.32 (0.049)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Hospital Length of Stay (LOS)</td><td>&#160;</td>
    <td style="text-align: center">2.01 (0.046)</td><td>&#160;</td>
    <td style="text-align: center">2.28 (0.043)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oxygen Saturation of <span style="text-decoration: underline">&gt; </span>92%</span></td><td>&#160;</td>
    <td style="text-align: center">2.15 (0.056)</td><td>&#160;</td>
    <td style="text-align: center">2.62 (0.039)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to seek certification or regulatory approval for our remaining current product candidates and, if approved, we expect they will
be marketed as medical devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we reach the commercialization stage for any of our remaining product candidates, we expect that we will collaborate with companies outside
the U.S. for all indications. We are still determining whether to attempt to collaborate for any indication in the U.S. We are commercializing
LungFit<sup>&#174;</sup> PH in the U.S. ourselves and expect to partner with third parties to commercialize LungFit<sup>&#174; </sup>PH
outside the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
PreClinical Results to Date for LungFit<sup>&#174;</sup></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have completed 4 separate toxicology studies in animals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rats</b>:
    30 days of intermittent treatments with LungFit<sup>&#174;</sup> at 400 ppm NO showed no observations (differences) between control
    rats and treated rats on observation during the treatment period prior to sacrifice and no observations on histopathology </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rats</b>:
    12 weeks of intermittent treatments with LungFit<sup>&#174;</sup> at 250 ppm NO showed no observations (differences) between control
    rats and treated rats on observation during the treatment period prior to sacrifice and no observations on histopathology </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dogs</b>:
    12 weeks of intermittent treatments with LungFit<sup>&#174;</sup> at 250 ppm NO showed no observations (differences) between control
    dogs and treated dogs on observation during the treatment period prior to sacrifice and no observations on histopathology</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rats:
    </b>Geno toxicology study of intermittent with LungFit<sup>&#174;</sup> NO at 200 &#8211; 400 ppm showed a non-genotoxic response
    at all concentrations</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Additional
Programs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
Cancer&#8217;s research data has shown that UNO has anticancer properties and elicits an immune response from the host. Beyond Cancer
utilizes an intratumoral UNO technology as a gas delivery of NO at high concentrations to tumors to induce an immune response. Gas based
intratumoral therapies for the treatment of cancer are considered novel and new medical science. Beyond Cancer&#8217;s efforts are currently
also focused on utilizing UNO in combination with Keytruda, a PD-1 inhibitor or other PD-1 or PDL-1 inhibitors as a treatment for cancers.
To date, no such gas-based therapy has been approved for commercialization by the FDA or other regulatory agencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroNos
has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, LTD. to acquire the commercial
rights for neuronal nitric oxide synthase (nNOS) inhibitors being developed for the treatment of autism spectrum disorder (&#8220;ASD&#8221;)
and other neurological conditions. Currently, there are currently no FDA approved therapies utilizing nNOS inhibitors specifically for
the treatment of ASD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Competition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology, pharmaceutical and medical device industries are highly competitive. There are many pharmaceutical companies, biotechnology
companies, medical device companies, public and private universities and research organizations actively engaged in the research and
development (&#8220;R&amp;D&#8221;) of products that may be similar to our approved product or product candidates. We are aware of several
companies currently developing and selling NO therapies for various indications such as hypoxic respiratory failure (HRF). For example,
Mallinckrodt commercializes INOMAX<sup>&#174;</sup> (nitric oxide) for inhalation, which is approved for use to treat newborns suffering
from hypoxic respiratory failure (&#8220;HRF&#8221;)-PPHN, in the U.S., Canada, Australia, Mexico and Japan. Linde Group markets a generic
version of the Mallinckrodt offering with their delivery system called NOxBOX<sup>&#174;</sup>. The Linde Group has marketing rights to
INOMAX<sup>&#174; </sup>in Europe. Air Liquide sells a similar product in Europe, called KINOX&#8482;, together with their delivery platform
called SoKINOX&#8482;, for the treatment of pulmonary hypertension of the newborn. In Europe, EKU, International Biomedical, Cahouet
and ITC each have a device that delivers nitric oxide. VERO Biotech LLC received FDA approval
for their delivery system GENOSYL DS for HRF associated with PPHN in 2019, and received FDA approval for a third generation of that delivery
system in 2023. In addition, other companies may be developing inhaled NO delivery systems at various concentrations. Novan Inc. has
recently received approval for a nitric oxide-based prescription treatment called berdazimer for molluscum, a contagious skin infection.
SaNOtize has an NO nasal spray that has received approval in India, Israel and eight other countries for preventing COVID-19 after exposure.
Third Pole has reported the development of an NO generator and delivery system, but we are not aware of any display of any product at
any medical/scientific conference in recent years. Our patents surrounding LungFit<sup>&#174; </sup>have priority date over those of Third
Pole. NovLead Biotechnology (Nanjing, China) has a device that produces NO through a process of passing an electric current through an
electrolyte solution and Shenzhen Respomed Medical Technology (Shenzhen, China) has developed a machine that uses an electric charge
to generate nitric oxide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our competitors, either alone or through their strategic partners, might have substantially greater name recognition and financial,
technical, manufacturing, marketing and human resources than we do and greater experience and infrastructure in the research and clinical
development of pharmaceutical products, obtaining FDA and other regulatory approvals of those products and commercializing those products
around the world.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
it relates to Beyond Cancer&#8217;s programs, no such gas-based therapies have been approved for commercialization by the FDA or other
regulatory agencies to date. Similarly, as it relates to NeuroNos, there are currently no FDA approved therapies utilizing nNOS inhibitors
specifically for the treatment of ASD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Manufacturing
and Distribution</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have contracted with third-party contract manufacturers, Spartronics LLC (&#8220;Spartronics&#8221;), Plexus Corp.
(&#8220;Plexus&#8221;), and Medisize Ireland Limited (&#8220;Medisize&#8221;) who have completed a substantial portion of the
commercial manufacturing process for our LungFit<sup>&#174; </sup>PH system. Spartronics is the contract manufacturer and maintenance provider of our
first generation LungFit&#174; PH device, Plexus is the contract manufacturer of our second generation LungFit&#174; PH device and will
be the contract manufacturer of all devices beginning in April 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we will be reliant on our partners for commercial manufacture of our systems for both clinical studies and commercial
supply. In the year ended March 31, 2026, we purchased approximately 74% of our materials from Spartronics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a central warehouse in Atlanta, Georgia for the staging of products to be deployed to forward-stocking locations (&#8220;FSL&#8221;)
in major cities close to our potential customers. We contract with third-party logistics providers to manage both the central warehouse
and the FSLs. FSLs allow us to supply LungFit<sup>&#174;</sup> devices and consumables in a timely manner to customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
market directly to our customers through our field sales team. A separate team of clinical specialists provides the training necessary
to use the devices. Invoicing and cash collection are managed by our Garden City, New York headquarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
Property</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own or have exclusively licensed patents, pending patent applications, know-how and trade secrets that relate to our NO generator, NO<sub>2
</sub>filtration, delivery systems, devices configured for delivering NO to patients by inhalation, methods of exposing patients to inhalation
of NO, and methods for treating subjects in need of NO inhalation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are party to a global, exclusive, transferable license agreement with NitricGen for the eNOGenerator, its components, and all associated
patents and know how related thereto. Additionally, we have a broad intellectual property portfolio directed to our product candidates
and mode of delivery, monitoring parameters and methods of treating specific disease indications. Our intellectual property portfolio
consists of issued patents and pending applications, which includes patents we acquired pursuant to the exercise of an option in 2017
granted to us by Pulmonox Technologies Corporation (&#8220;Pulmonox&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 31, 2015 the Company entered into an agreement with Pulmonox (the &#8220;Option Agreement&#8221;) whereby we acquired the option
to purchase certain intellectual property assets, including Pulmonox&#8217;s rights in 17 issued U.S. patents, including eight patents
jointly owned with CareFusion which are directed to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">devices
    and methods for delivering NO formulations to a patient at steady and alternating concentrations (80-400 ppm), including intermittent
    delivery of NO;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    device and methods for treatment of surface infections; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
    of NO as a mucolytic agent and for treatment and disinfection of biofilms.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
exercised the Option in January 2017, acquiring Pulmonox&#8217;s rights in the patents described above. Upon exercise of the Option,
we became obligated to make certain one-time development and sales milestone payments to Pulmonox, commencing with the date on which
we receive regulatory approval for the commercial sale of the first product candidate qualifying under the agreement. These milestone
payments are almost entirely sales-related and are capped at a total of $87 million across three separate and distinct indications that
fall under the agreement with the majority of them, approximately $83 million, being sales-related based on cumulative sales milestones
for each of the three products. To date, no payments have been made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent
Applications</i>. We have over 40 pending patent applications worldwide, including U.S., foreign and Patent Corporation Treaty (&#8220;PCT&#8221;)
patent applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
PCT patent application is a filing under the Patent Cooperation Treaty to which the U.S. and a number of other countries are a party.
It provides a unified procedure for filing a single patent application to protect inventions in those countries. A search with respect
to the application is conducted by the International Searching Authority, accompanied by a written opinion regarding the patentability
of the invention. A PCT application does not itself result in the grant of a patent, and the grant of patent is a prerogative of each
national or regional authority where the PCT application is filed during national phase filings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Settlement
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 23, 2019, we entered into an agreement for commercial rights (the &#8220;Circassia Agreement&#8221;) with Circassia Limited and
its affiliates (collectively, &#8220;Circassia&#8221;) for PPHN and future related indications at concentrations of <span style="text-decoration: underline">&lt; </span>80 ppm
in the hospital setting in the United States and China. On December 18, 2019, we terminated the Circassia Agreement. Circassia contended
that the termination was wrongful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 25, 2021, the Company and Circassia entered into a settlement agreement (the &#8220;Settlement Agreement&#8221;) resolving all claims
by and between both parties and mutually terminating the Circassia Agreement. Pursuant to the terms of the Settlement Agreement, the
Company agreed to pay Circassia $10.5 million in three installments, all of which has been paid. Additionally, starting in 2025, Circassia
began receiving a quarterly royalty payment equal to 5% of LungFit<sup>&#174;</sup> PH net sales in the U.S. This royalty will terminate
once the aggregate payment reaches $6.0 million. As of March 31, 2026, approximately $0.4 million of royalties have been paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Government
Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Regulation.</i> In the U.S., the FDA regulates drug and medical device products under the Federal Food, Drug, and Cosmetic Act (&#8220;FD&amp;C
Act&#8221;), and its implementing regulations. Our products have been designated as devices by the FDA and will be regulated by the Center
for Devices and Radiological Health (&#8220;CDRH&#8221;). Given that currently approved NO products and delivery systems were approved
either separately (NO drug approval and NO delivery systems cleared as devices) or as drug-device combinations in the United States,
we expect our device to not only be reviewed by CDRH, but also have input from the Center for Drug Evaluation and Research (&#8220;CDER&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>FDA
Premarket Clearance and Approval Requirements for Medical Devices. </i>Unless an exemption applies, each medical device commercially
distributed in the United States requires either FDA clearance of a 510(k) premarket notification, authorization of a de novo application,
or approval of a PMA application. Under the FD&amp;C Act, medical devices are classified into one of three classes&#8212;Class I, Class
II or Class III&#8212;depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory
control needed to ensure its safety and effectiveness. Class I includes devices with the lowest risk to the patient and are those for
which safety and effectiveness can be assured by adherence to the FDA&#8217;s General Controls for medical devices, which include compliance
with the applicable portions of the Quality System Regulation (&#8220;QSR&#8221;) facility registration and product listing, reporting
of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials. Class II devices are subject
to the FDA&#8217;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the
device. These special controls can include performance standards, post-market surveillance, patient registries and FDA guidance documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
most Class I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class II devices are required
to submit to the FDA a premarket notification under Section 510(k) of the FFDCA requesting permission to commercially distribute the
device. The FDA&#8217;s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known
as 510(k) clearance. Devices deemed by the FDA to pose the greatest risks, such as life sustaining, life supporting or some implantable
devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally
marketed device, are placed in Class III, requiring approval of a PMA. Some pre-amendment devices are unclassified, but are subject to
FDA&#8217;s premarket notification and clearance process in order to be commercially distributed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>510(k)
Clearance Marketing Pathway.</i> To obtain 510(k) clearance, a company must submit to the FDA a premarket notification submission demonstrating
that the proposed device is &#8220;substantially equivalent&#8221; to a predicate device already on the market. A predicate device is
a legally marketed device that is not subject to PMA, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments
device) and for which a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was
found substantially equivalent through the 510(k) process. The FDA&#8217;s 510(k) clearance process usually takes from three to twelve
months, but often takes longer. The FDA may require additional information, including clinical data, to make a determination regarding
substantial equivalence. In addition, the FDA collects user fees for certain medical device submissions and annual fees for medical device
establishments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance
to commercially market the device. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously
cleared device, the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA
requirements or can request a risk-based classification determination for the device in accordance with the &#8220;de novo&#8221; process,
which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate
device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a device receives 510(k) marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would
constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification,
PMA approval. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k) or a PMA in
the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. If the FDA disagrees
with a manufacturer&#8217;s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified
device until 510(k) marketing clearance, authorization of a de novo application, or PMA approval is obtained. Also, in these circumstances,
the manufacturer may be subject to significant regulatory fines or penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PMA
Approval Pathway. </i>Class III devices require approval of a PMA before they can be marketed, although some pre-amendment Class III
devices for which the FDA has not yet required a PMA are cleared through the 510(k) process. The PMA process is more demanding than the
510(k) premarket notification process. In a PMA application, the manufacturer must demonstrate that the device is safe and effective,
and the PMA application must be supported by extensive data, including data from preclinical studies and human clinical trials. The PMA
application must also contain a full description of the device and its components, a full description of the methods, facilities, and
controls used for manufacturing, and proposed labeling. Following receipt of a PMA application, the FDA determines whether the application
is sufficiently complete to permit a substantive review. If the FDA accepts the application for review, it has 180 days under the FFDCA
to complete its review of a PMA application, although in practice, the FDA&#8217;s review often takes significantly longer, and can take
up to several years. An advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide
recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel&#8217;s recommendation. In
addition, the FDA will generally conduct a pre-approval inspection of the applicant or its third-party manufacturers&#8217; or suppliers&#8217;
manufacturing facility or facilities to ensure compliance with the QSR. PMA devices are also subject to the payment of user fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA application constitute
valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). A PMA
may include post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions
on labeling, promotion, sale and distribution, and collection of long-term follow-up data from patients in the clinical study that supported
the PMA or requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market
surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data for the device in a
larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for
a number of years and to make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions
of approval can result in material adverse enforcement action, including withdrawal of the approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
changes to an approved device, such as changes in manufacturing facilities, methods, or quality control procedures, or changes in the
design performance specifications, which affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA
supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed
to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of
an advisory panel. Certain other changes to an approved device require the submission of a new PMA, such as when the design change causes
a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a new
generation of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change
in demonstrating a reasonable assurance of safety and effectiveness. None of our products are currently marketed pursuant to a PMA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 10, 2020 we submitted a PMA application to the FDA for the use of LungFit<sup>&#174;</sup> PH in PPHN and subsequently received
PMA approval in June 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>De-Novo
Pathway</i>. Another pathway, known as de-novo down-classification also can be used for lower risk devices for which there is no existing
product code or predicate device. The Food and Drug Administration Modernization Act of 1997 established the de-novo down-classification
procedure as a new route to market for low to moderate risk medical devices that automatically require a PMA due to the absence of a
predicate device. This procedure allows a manufacturer whose novel device automatically requires a PMA to request down-classification
of its medical device (to allow clearance through the 510(k) pathway) on the basis that the device presents low or moderate risk, rather
than requiring the submission and approval of a PMA application. Manufacturers can request de-novo down-classification directly without
first submitting a 510(k) premarket notification to the FDA and receiving a &#8220;not substantially equivalent&#8221; determination.
Under this pathway, the FDA is required to classify the device within 120 days following receipt of the de-novo application. If the manufacturer
seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide
a reasonable assurance of the safety and effectiveness of the medical device. In addition, the FDA may reject the reclassification petition
if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low
to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trials</i>. Clinical trials are almost always required to support a PMA and are sometimes required to support a 510(k) submission. All
clinical investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s Investigational
Device Exemption (&#8220;IDE&#8221;) regulations which govern investigational device labeling, prohibit promotion of the investigational
device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If
the device presents a &#8220;significant risk,&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to
submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. A significant risk device
is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in supporting
or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment
of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate
data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol
is scientifically sound. The IDE will automatically become effective 30 days after receipt by the FDA unless the FDA notifies the Company
that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires
modification, the FDA may permit a clinical trial to proceed under a conditional approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the study must be approved by, and conducted under the oversight of, an Institutional Review Board (&#8220;IRB&#8221;) for
each clinical site. The IRB is responsible for the initial and continuing review of the IDE study, and may pose additional requirements
for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may begin at a
specific number of investigational sites with a specific number of patients, as approved by the FDA. If the device presents a non-significant
risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate
approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators
obtain informed consent, and labeling and record-keeping requirements. Acceptance of an IDE application for review does not guarantee
that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data
derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement
must be submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan that may
affect its scientific soundness, study plan or the rights, safety or welfare of human subjects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting
clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping
and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators
in the clinical study are also subject to FDA regulations and must obtain patient informed consent, rigorously follow the investigational
plan and study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements.
Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons,
including a belief that the risks to study subjects outweigh the anticipated benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Post-market
Regulation</i>. After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply.
These include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
    registration and device listing with the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QSR
    requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation
    and other quality assurance procedures during all aspects of the design and manufacturing process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">labelling
    regulations and FDA prohibitions against the promotion of investigational products, or the promotion of off-label (as defined below)
    uses of cleared or approved products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    related to promotional activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clearance
    or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness or that would
    constitute a major change in intended use of one of our cleared devices, or approval of certain modifications to PMA-approved devices;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">medical
    device reporting regulations which require that a manufacturer report to the FDA if a device it markets may have caused or contributed
    to death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute
    to a death or serious injury, if the malfunction were to recur.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">correction,
    removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls
    or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FFDCA that may present a
    risk to health;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation
    of governing laws and regulations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-market
    surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide
    additional safety and effectiveness data for the device.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing processes for medical devices are required to comply with the applicable portions of the QSR, which cover the methods and
the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging,
distribution, installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance
of a device master file, device history file, and complaint files. These requirements impose certain procedural and documentation requirements
upon us and our third-party manufacturers related to the methods used in and the facilities and controls used for designing, manufacturing,
packaging, labeling, storing, medical devices. As a manufacturer, we are subject to periodic scheduled or unscheduled inspections by
the FDA. Following these inspections, the FDA may assert noncompliance with QSR requirements on a Form 483, which is a report of observations
from an inspection, or by way of &#8220;untitled letters&#8221; or &#8220;warning letters&#8221; that could cause us or any third-party
manufacturers to modify certain activities. A Form 483 notice, if issued at the conclusion of an FDA inspection, can list conditions
the FDA investigators believe may have violated QSR or other FDA requirements. We cannot be certain that we or our present or any future
third-party manufacturers or suppliers will be able to comply with QSR or other FDA regulatory requirements to the agency&#8217;s satisfaction.
Failure to comply with these obligations may lead to possible legal or regulatory enforcement action by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has broad regulatory compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory
requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled
    letters, warning letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    expenditures to address or defend such actions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer
    notifications or repair, replacement, refunds, recall, detention or seizure of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    restrictions, partial suspension or total shutdown of production;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing
    or delaying our requests for regulatory approvals or clearances of new products or modified products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawing
    a PMA that has already been granted;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to grant export approval for our products; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
    prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Advertising
and Promotion.</i> The FDA and comparable foreign regulatory authorities closely regulate the post-approval marketing and promotion of
medical devices, including standards and regulations for direct-to-consumer advertising, communications about unapproved uses, industry-
sponsored scientific and educational activities and promotional activities involving the internet. Devices may be marketed only for the
approved or cleared indications and in accordance with the provisions of the approved or cleared label.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers are permitted to prescribe approved devices for &#8220;off-label&#8221; uses&#8212;that is, uses not approved by the FDA and
therefore not described in the product&#8217;s labeling. These off-label uses are common across medical specialties. Physicians may believe
that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of
physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers&#8217; communications
regarding off-label use. Thus, we may market our products, if approved by the FDA, only for their approved indications, but under certain
conditions may engage in non-promotional, balanced communication regarding off-label uses. Failure to comply with applicable FDA requirements
and restrictions in this area may subject us to adverse publicity and a variety of sanctions, which could harm our business and financial
condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Combination
Products.</i> A combination product is the combination of two or more regulated components, i.e., drug/device, biologic/device, drug/biologic,
or drug/device/biologic, that are combined or mixed and produced as a single entity; packaged together in a single package or as a unit;
or a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended
for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended
use, indication, or effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine which FDA center or centers will review a combination product candidate submission, companies may submit a request for assignment
to the FDA. Those requests may be handled formally or informally. In some cases, jurisdiction may be determined informally based on FDA
experience with similar products. However, informal jurisdictional determinations are not binding on the FDA. Companies also may submit
a formal Request for Designation to the FDA Office of Combination Products. The Office of Combination Products will review the request
and make its jurisdictional determination within 60 days of receiving a Request for Designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
will determine which center or centers within the FDA will review the product candidate and under what legal authority the product candidate
will be reviewed. Depending on how the FDA views the product candidates that are developed, the FDA may have aspects of the product candidate
reviewed by the Center for Biologics Evaluation and Research (&#8220;CBER&#8221;), CDRH, or CDER, though one center will be designated
as the center with primary jurisdiction, based on the product candidate&#8217;s primary mode of action. The FDA determines the primary
mode of action based on the single mode of action that provides the most important therapeutic action of the combination product candidate
&#8211; the mode of action expected to make the greatest contribution to the overall intended therapeutic effects of the combination
product candidate. The review of such combination product candidates is often complex and time-consuming, as the FDA may select the combination
product candidate to be reviewed and regulated by one or multiple of the FDA centers identified above, which could affect the path to
regulatory clearance or approval. Furthermore, the FDA may also require submission of separate applications to multiple centers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
post-market requirements that apply to the cleared or approved product will largely be aligned with the agency center determined to have
primary jurisdiction over the product candidate and that provided marketing authorization, but manufacturers must also comply with certain
post-market requirements with respect to the constituent parts of combination products. In April 2019, FDA published a final guidance
document entitled Compliance Policy for Combination Product Post-Marketing Safety Reporting, which is intended to assist manufacturers
of combination products comply with reporting requirements applicable to such products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
issuing marketing authorizations, the FDA has discretion in determining post-approval compliance requirements for combination products.
The FDA has also promulgated regulations pertaining to compliance with certain current good manufacturing practices (&#8220;cGMP&#8221;)
requirements for drug components as well as QSR requirements for device constituents of a combination product. Other post-market requirements
in the same vein as those described above for medical devices and drugs will also apply, depending on the application type and center
overseeing regulation of the combination product, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    record-keeping requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-market
    adverse event and Medical Device Reporting requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labelling
    regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label uses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
    and promotion requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restrictions
    on sale, distribution or use of the product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requirements
    for recalls being conducted and recall reporting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    order of repair, replacement or refund;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
    tracking requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-market
    surveillance or clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Coverage
and Reimbursement. </i>Coverage and reimbursement for medical devices in the U.S. is determined by third-party payors, including Medicare
and Medicaid, commercial health insurers, and managed care organizations. Each payor has a unique process for determining whether to
cover a device for a particular indication and how to set reimbursement rates for the device. A payor can decide to cover a device yet
not provide adequate reimbursement to ensure access to the device. New devices often face significant uncertainty about coverage and
reimbursement. Payors may require additional evidence, beyond the data required for FDA approval, to demonstrate that a device should
be covered for a particular indication or that it should be reimbursed at a higher rate than other technologies. In addition, health
care spending continues to be a concern for federal and state governments, as well as for commercial payors. Governments continue to
debate methods of controlling health care costs, including reductions in reimbursement or additional controls on utilization of new technologies
in Medicare and Medicaid, and commercial payors may similarly seek to limit spending on new devices. Restrictions on coverage and reimbursement
could harm our future revenues and ability to realize an appropriate return on our investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Orphan
Drug Designation and Exclusivity. </i>Under the Orphan Drug Act, the FDA may grant orphan drug designation to products that are intended
to treat rare diseases or conditions (i.e., those affecting fewer than 200,000 individuals in the U.S.), or diseases or conditions that
affect more than 200,000 individuals in the U.S. but there is no reasonable expectation that the cost of developing and making the drug
product would be recovered from sales in the U.S. Although orphan drug designation does not convey any advantage in the regulatory review
and approval process, it can provide certain tax benefits and access to certain grants. Additionally, FDA user fees, which can be substantial,
are waived for products that obtain orphan drug designation. Further, if a product with orphan drug designation subsequently receives
FDA approval for the designated disease or condition, the product is generally granted seven years of orphan drug exclusivity, which
(with certain limited exceptions) blocks for seven years FDA approval of another product with the same active ingredient for the same
indication. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the
same drug for a different disease or condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Healthcare
Fraud and Abuse Laws.</i> In addition to the FDA&#8217;s ongoing post-approval regulation of devices discussed above, manufacturers are
also subject to several other types of laws and regulations, subject to differing enforcement regimes. In recent years, marketing and
promotional activities regarding FDA-regulated products have come under intense scrutiny and have been the subject of enforcement action
brought by the U.S. Department of Justice and the Office of Inspector General of the Department of Health and Human Services, as well
as state authorities and even private individuals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians and third-party payors play a primary role in the recommendation and selection of medical devices for patients.
Arrangements with third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations.
Such restrictions under applicable federal and state healthcare laws and regulations include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal health care program Anti-Kickback Statute (&#8220;AKS&#8221;) prohibits, among other things, persons from knowingly and willfully
    soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or in return for
    purchasing, leasing, ordering or arranging for the purchase, lease or order of any good or service, for which payment may be made,
    in whole or in part, under a federal healthcare program such as Medicare and Medicaid. This statute has been interpreted to apply
    to arrangements between pharmaceutical or device manufacturers, on the one hand, and prescribers, purchasers and formulary managers
    and others on the other. The term &#8220;remuneration&#8221; has been broadly interpreted to apply to anything of value including,
    for example, gifts, cash payments, donations, waivers of payment, ownership interests, and providing any item, service, or compensation
    for something other than fair market value. Liability under the AKS may be established without proving actual knowledge of the statute
    or specific intent to violate it. Although there are a number of statutory exceptions and regulatory safe harbors to the AKS protecting
    certain common business arrangements and activities from prosecution or regulatory sanctions, the exceptions and safe harbors are
    drawn narrowly. Practices that involve remuneration to those who prescribe, purchase, or recommend medical device products, including
    certain discounts, or engaging such individuals as consultants, advisors and speakers, may be subject to scrutiny if they do not
    fit squarely within an exception or safe harbor. Moreover, there are no safe harbors for many common practices, such as educational
    grants and reimbursement support programs. Violations are punishable by up to 10 years in prison, criminal fines, administrative
    civil monetary penalties and exclusion from participation in federal healthcare programs. Any sales or marketing practices that involve
    remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny under the AKS;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal civil False Claims Act (&#8220;FCA&#8221;) imposes liability on individuals or entities for, among other things, knowingly
    presenting, or causing to be presented, false or fraudulent, claims for payment of government funds, knowingly making, using, or
    causing to be made or used a false statement or record material to an obligation to pay money to the government, or knowingly concealing
    or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. A claim including
    items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA. Actions
    under the FCA may be brought by the government or as a qui tam action by a private individual in the name of the government, who
    may also share in any monetary recovery. Qui tam actions are filed under seal and impose a mandatory duty on the U.S. Department
    of Justice to investigate such allegations. Manufacturers have faced liability under the FCA for providing inaccurate billing or
    coding information to customers or promoting a product off-label. FCA liability is potentially significant in the healthcare industry
    because the statute provides for treble damages and significant mandatory penalties per false or fraudulent claim or statement for
    violations, as well as exclusion from participation in federal healthcare programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic
    and Clinical Health Act, and their respective implementing regulations (collectively, &#8220;HIPAA&#8221;), imposes criminal and
    civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
    benefit program, including private third-party payors, or knowingly and willfully falsifying, concealing, or covering up a material
    fact or making any materially false, fictitious, or fraudulent statement or representation, or using any false writing or document
    knowing the same to contain any materially false, fictitious, or fraudulent statement or entry, in connection with the delivery of
    or payment for healthcare benefits, items, or services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Physician Payments Sunshine Act (the &#8220;Sunshine Act&#8221;) requires applicable manufacturers of devices, biologics
    and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with
    certain exceptions) to report annually to CMS information related to payments and other transfers of value to physicians, physician
    assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse midwives, and teaching
    hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
    state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements
    and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.
    Several states have enacted legislation requiring medical device manufacturers to, among other things, establish marketing compliance
    programs; file periodic reports with the state, including reports on gifts and payments to individual health care providers; and/or
    register their sales representatives. Some states prohibit certain sales and marketing practices, including the provision of gifts,
    meals, or other items to health care providers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
other laws such as the federal Lanham Act and similar state laws allow competitors and others to initiate litigation relating to advertising
claims. If we sell our device outside the United States, it must comply with the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and
local laws of other countries. FCPA is a complex patchwork of laws can change rapidly with relatively short notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Environmental
Laws.</i> Elements of our potential products may be classified as hazardous materials, subject to regulation by the Department of Transportation,
the International Air Transportation Association, the International Maritime Organization, the Environmental Protection Agency and the
Occupational Safety and Health Administration, which may impose various requirements pertaining to the way we manufacture, transport,
store, handle and dispose of our products. At this time, we have no material costs associated with environmental laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>European
Regulation of Medical Devices. In the European Economic Area (&#8220;EEA&#8221;), we expect our products to be regulated as a medical
device product falling within the scope of EU MDR.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, medical devices must currently comply with the General Safety and Performance Requirements laid down in Annex I to the EU MDR.
Compliance with these requirements is a prerequisite to be able to affix the CE mark on products, without which they cannot be marketed
or sold in the EEA. To demonstrate compliance with the General Safety and Performance Requirements of the EU MDR and obtain the right
to affix the CE mark, medical devices manufacturers must undergo a conformity assessment procedure, which varies according to the type
of medical device and its classification. Apart from low risk medical devices (Class I with no measuring function and which are not sterile),
in relation to which the manufacturer may issue an EC Declaration of Conformity based on a self-assessment of the conformity of its products
with the General Safety and Performance Requirements, a conformity assessment procedure requires the intervention of a notified body,
which is an organization designated by a Competent Authority of an EEA country to conduct conformity assessments. Depending on the relevant
conformity assessment procedure, the notified body would audit and examine the technical documentation and the quality system for the
manufacture, design and final inspection of the medical devices. The notified body issues a CE Certificate of Conformity following successful
completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity
with the General Safety and Performance Requirements. This Certificate and the related conformity assessment process entitles the manufacturer
to affix the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity. Notified bodies
must be accredited by the EEA countries&#8217; accreditation bodies to conduct assessment procedures for medical devices in accordance
with the EU MDR. There are currently a relatively small number of notified bodies that have been accredited to conduct these assessments.
This may delay conformity assessment procedures in the future in the EU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a general rule, demonstration of conformity of medical devices and their manufacturers with the General Safety and Performance Requirements
must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal
conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions
of use and that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits
of its intended performance, and that any claims made about the performance and safety of the device (e.g., product labeling and instructions
for use) are supported by suitable evidence. This assessment must be based on clinical data, which can be obtained from (1) clinical
studies conducted on the devices being assessed, (2) scientific literature from similar devices whose equivalence with the assessed device
can be demonstrated or (3) both clinical studies and scientific literature. The conduct of clinical studies in the EEA is governed by
detailed regulatory obligations. These may include the requirement of prior authorization by the competent authorities of the country
in which the study takes place and the requirement to obtain a positive opinion from a competent Ethics Committee. This process can be
expensive and time-consuming.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU MDR repeals and replaces the EU Medical Devices Directive 93/42/EEC. Unlike directives, which must be implemented into the national
laws of the EEA countries, the regulations is directly applicable, i.e., without the need for adoption of EEA country laws implementing
them, in all countries and are intended to eliminate current differences in the regulation of medical devices among EEA countries. The
EU MDR, among other things, establishes a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical
devices and ensures a high level of safety and health while supporting innovation. The EU MDR entered into application on May 26, 2021,
and among others things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthens
    the rules on placing devices on the market and reinforce surveillance once they are available;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishes
    explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices
    placed on the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improves
    the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sets
    up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available
    in the EU;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthens
    rules for the assessment of certain high-risk devices which may have to undergo an additional check by experts before they are placed
    on the market.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Continuing
Regulation. </i>As in the U.S., manufacturers of medical devices are subject to comprehensive regulatory oversight by notified bodies
and the competent authorities of the EEA countries. This oversight applies both before and after certification. It includes control of
compliance with the EU MDR General Safety and Performance Requirements and post-market surveillance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 21pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, the advertising and promotion of our products will also be subject to EEA countries national laws implementing Directive 2006/114/EC
concerning misleading and comparative advertising, and Directive 2005/29/EC on unfair commercial practices, as well as other national
legislation of individual EEA countries governing the advertising and promotion of medical devices. EEA countries&#8217; legislation
may also restrict or impose limitations on our ability to advertise our products directly to the general public. In addition, voluntary
EU and national Codes of Conduct provide guidelines on the advertising and promotion of our products to the general public and may impose
limitations on our promotional activities with healthcare professionals. Violations of the rules governing the promotion of medical devices
in the EEA could be penalized by administrative measures, fines and imprisonment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Data
Privacy Regulation.</i> The collection and use of personal health data in the EEA is governed by the data protection laws and regulations
adopted by the EEA countries and the EU General Data Protection Regulation (&#8220;GDPR&#8221;). The GDPR became applicable on May 25,
2018 and repealed the EU Data Protection Directive. The GDPR is directly applicable in each EEA country and imposes several requirements
on companies that process personal data, strict rules on the transfer of personal data out of the EEA, including to the U.S., and fines
and penalties for failure to comply with the requirements of the GDPR and the related national data protection laws of the EAA countries.
The GDPR confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities,
seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Failure to comply with the requirements
of GDPR may result in fines of up to 20,000,000 Euros or up to 4% of the total worldwide annual turnover of the preceding financial year,
whichever is higher, and other administrative penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Orphan
Designation and Exclusivity.</i> In the EU, the Committee for Medicinal Products for Human Use grants orphan drug designation to promote
the development of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating
conditions affecting not more than five in 10,000 persons in the EU Community and for which no satisfactory method of diagnosis, prevention
or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted
for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic
condition and when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary
investment in developing the medicinal product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market
exclusivity is granted following medicinal product approval. This period may be reduced to six years if the orphan drug designation criteria
are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey any
advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exceptional
Circumstances/Conditional Approval.</i> Orphan medicinal product or products for unmet medical needs may be eligible for EU approval
under exceptional circumstances or with conditional approval. Approval under exceptional circumstances is applicable to orphan products
and is used when an applicant is unable to provide comprehensive data on the efficacy and safety under normal conditions of use because
the indication for which the product is intended is encountered so rarely that the applicant cannot reasonably be expected to provide
comprehensive evidence, when the present state of scientific knowledge does not allow comprehensive information to be provided, or when
it is medically unethical to collect such information. Conditional marketing authorization is applicable to orphan medicinal products,
medicinal products for seriously debilitating or life- threatening diseases or medicinal products to be used in emergency situations
in response to recognized public threats. Conditional marketing authorization can be granted on the basis of less complete data than
is normally required in order to meet unmet medical needs and in the interest of public health, provided the risk-benefit balance is
positive, it is likely that the applicant will be able to provide the comprehensive clinical data, and unmet medical needs will be fulfilled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditional
marketing authorization is subject to certain specific obligations to be reviewed annually.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Regulations.</i> We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing
practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances. We may incur
significant costs to comply with such laws and regulations now or in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Regulation
in Israel.</i> In order to conduct clinical testing on humans in the State of Israel, special authorization must first be obtained from
the ethics committee and general manager of the institution in which the clinical studies are scheduled to be conducted, as required
under the Guidelines for Clinical Trials in Human Subjects implemented pursuant to the Israeli Public Health Regulations (Clinical Trials
in Human Subjects), as amended from time to time, and other applicable legislation. These regulations require authorization by the institutional
ethics committee and general manager as well as from the Israeli Ministry of Health, except in certain circumstances, and in the case
of genetic trials, special fertility trials and complex clinical trials, an additional authorization of the Ministry of Health&#8217;s
overseeing ethics committee. The institutional ethics committee must, among other things, evaluate the anticipated benefits that are
likely to be derived from the project to determine if it justifies the risks and inconvenience to be inflicted on the human subjects,
and the committee must ensure that adequate protection exists for the rights and safety of the participants as well as the accuracy of
the information gathered in the course of the clinical testing. Since we perform a portion of the clinical studies on certain of our
therapeutic candidates in Israel, we are required to obtain authorization from the ethics committee and general manager of each institution
in which we intend to conduct our clinical trials, and in most cases, from the Israeli Ministry of Health.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
History</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated on April 24, 2015. On June 25, 2019, our name was changed to Beyond Air, Inc. from AIT Therapeutics, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have the following wholly owned subsidiaries:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
    Air Ltd. (&#8220;BA Ltd.&#8221;), incorporated in Israel on May 1, 2011.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
    Air Australia Pty Ltd., incorporated on December 17, 2019 in Australia.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
    Air Ireland Limited, incorporated on March 5, 2020 in Ireland.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have 88.2% ownership in the following entity:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jodheary
    Holdco 18 Limited, incorporated on March 24, 2023 in Ireland. In April 2023, its name was changed to Beyond Air (NO) Limited. In
    March 2024, its name was changed to NeuroNOS Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroNOS
    Ltd. has the following wholly owned subsidiaries:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroNOS
    Ltd Israel, incorporated on March 12, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NNOS
    U.S., Inc, incorporated in Delaware on January 10, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
    Air Cyprus Limited, incorporated on October 13, 2021 in Cyprus.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have 80% ownership in the following entity:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
    Air Bermuda Limited, incorporated on August 13, 2021 in Bermuda. In September 2022, its name was changed to Beyond Cancer Bermuda
    Limited.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
    Air Bermuda Limited has the following wholly owned subsidiaries:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XAIR
    Israel Ltd, incorporated on October 3, 2021 in Israel.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
    Cancer U.S., Inc., incorporated on March 17, 2022 in Delaware.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Updates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 7, 2026, we received
a written notification (the &#8220;Notice&#8221;) from the Nasdaq Listing Qualifications Department (the &#8220;Listing Qualifications
Department&#8221;) notifying us that for the 30 consecutive business day period between February 23, 2026 through April 6, 2026, our common
stock had not maintained a minimum closing bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing
Rule 5550(a)(2) (the &#8220;Bid Price Rule&#8221;). While companies are typically afforded a 180-calendar day compliance period to comply
with the Bid Price Rule, the Notice stated that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), we were not eligible for any compliance
period specified in Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that we had effected a reverse stock split over the prior one-year
period. We had effected a 1-for-20 reverse stock split on July 14, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Notice stated that the Company&#8217;s
securities will be subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the
&#8220;Panel&#8221;) by April 14, 2026. Accordingly, on April 13, 2026, we timely requested a hearing before the Panel to appeal the Staff&#8217;s
determination. As a result of the timely hearing request, any suspension or delisting action with respect to our common stock was stayed
pending the issuance of a written decision by the Panel following the hearing process. The hearing was scheduled for May 14, 2026. On
May 28, 2026 we received a decision letter from the Panel granting our request for continued listing on Nasdaq, subject to certain conditions.
The Panel&#8217;s decision was issued following a hearing held on May 14, 2026, at which the Company presented its compliance plan to
address its non-compliance with the Bid Price Rule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Panel&#8217;s
decision, we must demonstrate compliance with the Bid Price Rule on or before July 31, 2026. In addition, pursuant to Nasdaq Listing Rule
5815(d)(4)(A), we will be subject to a Discretionary Panel Monitor for a period of one year from the date the Company regains compliance
with the Bid Price Rule. If the Panel or Listing Qualifications Department determines that the Company fails any listing standard during
the one-year monitoring period, then the Company will not be permitted to provide a plan of compliance with respect to any deficiency
that arises during the one-year monitoring period. Rather, the Listing Qualifications Department will promptly issue a written determination
to delist our securities (the &#8220;Staff Delisting Determination&#8221;). If the Company does not request review of the Staff Delisting
Determination then the Company&#8217;s common stock will be suspended as described in the Staff Delisting Determination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company intends to actively
monitor the bid price of its Common Stock and remain in compliance with the Nasdaq listing standards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file electronically with the Securities and Exchange Commission (the &#8220;SEC&#8221;) our annual reports on Form 10-K, quarterly reports
on Form 10-Q and current reports on Form 8-K, and amendments related thereto, pursuant to Section 13(a) or 15(d) of the Exchange Act.
We make available on our website at www.beyondair.net free of charge, copies of these reports, as soon as reasonably practicable after
we electronically file such material with, or furnish it to, the SEC. Reports filed with the SEC may be viewed at www.sec.gov. The information
in or accessible through the SEC and our website is not incorporated into, and is not considered part of, this filing. Further, our references
to the URLs for these websites are intended to be inactive textual references only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026, we had 54 employees globally, all of whom were full-time employees. None of our employees are represented by a labor
union and we consider our employee relations to be good.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
workforce is highly educated and diverse, which we believe is important for our continued success as a leading innovator in the medical
device market. We employ a number of strategies to best enable us to attract, retain, and engage our team members. Our human capital
resources objectives include, as applicable, identifying, recruiting, retaining, and incentivizing our management team and our clinical,
scientific and other employees and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain
and motivate personnel through the granting of stock-based and cash-based compensation awards, in order to align our interests and the
interests of our stockholders with those of our employees and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in our common stock involves a high degree of risk. You should consider carefully the risks described below, together with the other
information included or incorporated by reference in this Annual Report. If any of the following risks occur, our business, financial
condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the
market price of our common stock could decline. Other events that we do not currently anticipate or that we currently deem immaterial
may also affect our business, prospects, financial condition and results of operations. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Financial Position and Capital Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
independent registered public accounting firm&#8217;s report contains an explanatory paragraph that expresses substantial doubt about
our ability to continue as a &#8220;going concern.&#8221;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred recurring net losses, including a net loss of $34.3 million for the year ended March 31, 2026, compared to $48.5
million for the year ended March 31, 2025 and the Company&#8217;s operations have not provided net positive cash flows in the year ended
March 31, 2026. These factors, among others, raise substantial doubt about the Company&#8217;s ability to continue as a going concern.
The Company&#8217;s continuation as a going concern is dependent upon its ability to generate positive cash flows from operations and
to secure additional sources of equity and/or debt financing. Despite the Company&#8217;s intent to fund operations through equity and
debt financing arrangements, there is no assurance that such financing will be available on terms acceptable to the Company, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent auditors have included an explanatory paragraph in their audit report, included in this Annual Report on Form 10-K, regarding
the Company&#8217;s ability to continue as a going concern. This going concern risk may materially limit our ability to raise additional
funds through the issuance of new debt or equity or may adversely affect the terms upon which such capital may be available. The inability
to obtain sufficient financing on acceptable terms could have a material adverse effect on the Company&#8217;s financial condition, results
of operations, and business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is actively pursuing strategies to mitigate these risks. However, there can be no assurance that these efforts will prove successful
or that the Company will achieve its intended financial stability. The failure to successfully address these going concern risks may
materially and adversely affect the Company&#8217;s business, financial condition, and results of operations. Investors should consider
the substantial risks and uncertainties inherent in the Company&#8217;s business before investing in the Company&#8217;s securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Numerous
factors, including the incurring of significant losses, are relevant to our financial success and any or all such factors could have
a disproportionate impact on our bottom line.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision.
These are not the only risks we face. These risks include, among others, that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are a medical device and biopharmaceutical company with only one FDA/CE-approved product and a limited operating history on which
    to assess our business, have incurred significant losses since our inception and incurred a net cash used in operating activities
    for the year ended March 31, 2026 of approximately $18.1 million. As of March 31, 2026, we have an accumulated deficit of approximately
    $319.6 million and we anticipate losses declining in fiscal 2027 and 2028.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are unable to predict the extent of future losses or when we will become profitable based on the sale of any product, if at all.
    Even if we succeed in scaling the commercialization of our approved product and succeed in developing and commercializing our product
    candidates, we may never generate revenue to sustain profitability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    have only one FDA/CE-approved product, and we expect that we will need to raise additional funding before we can expect to become
    profitable from sales of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are heavily dependent upon the success of our approved product and product candidates (which are in various stages of clinical development),
    and we cannot provide any assurance that the FDA or comparable foreign regulatory authorities will allow us to conduct further clinical
    trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are in the process of further developing our proprietary NO delivery system, and unexpected delays will adversely impact the timing
    of our U.S.-based clinical trials and approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    might be unable to develop product candidates that will achieve commercial success in a timely and cost-effective manner, or ever;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitors may develop or commercialize products faster or more successfully than us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">because
    some of the target patient populations of our approved product or product candidates are small, we must be able to successfully identify
    patients and achieve a significant market share to maintain profitability and growth;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    rely on third parties to help conduct our preclinical studies, clinical trials and commercial scale manufacturing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we are unable to obtain and maintain effective intellectual property rights for our technologies, approved product or current or
    future product candidates, we may not be able to compete effectively in our markets; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    future success depends in part upon our ability to retain our executive and scientific teams, and to attract, retain and motivate
    other qualified personnel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with product development and commercialization, we are unable to accurately predict
the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities
to perform studies in addition to those expected or if there are any delays in the initiation and completion of our clinical trials or
the development of any of our product candidates, our expenses could increase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to raise additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult
to obtain, and could dilute current stockholders&#8217; ownership interests.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on many factors, including the success and costs of our commercialization activities, including
product marketing, sales, and distribution progress, the results of our clinical trials, the timing and outcome of regulatory review
of our product candidates, commercial manufacturing success, and the number and development requirements of product candidates that we
pursue. Because of the numerous risks and uncertainties associated with the development and commercialization of our approved product
and product candidates, we are unable to reasonably estimate the amounts of additional capital outlays and operating expenditures that
our business will require. We will need to raise additional funds through public or private debt or equity financings to meet various
objectives including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanding
    commercialization of our approved product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trials for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">researching
    and developing new products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursuing
    growth opportunities, including more rapid expansion;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquiring
    complementary businesses or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    capital improvements to improve our infrastructure;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hiring
    qualified management and key employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">responding
    to competitive pressures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complying
    with regulatory requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    compliance with applicable laws.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional capital raised through the sale of equity or equity-linked securities may dilute our current stockholders&#8217; ownership
in us and could also result in a decrease in the market price of our common stock. The terms of those securities issued by us in future
capital transactions may be more favorable to new investors and may include preferences, superior voting rights and the issuance of warrants
or other derivative securities, which may have a further dilutive effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
any debt or equity financing that we may need may not be available on terms favorable to us, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees,
securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses
in connection with certain securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain required additional capital, we may have to curtail our growth plans or cut back on existing business, and we
may not be able to continue operating if we do not generate sufficient revenues from operations needed to stay in business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to comply with the covenants or other terms of the Loan Agreement, including as a result of events beyond our control, could
result in a default under the Loan Agreement that could materially and adversely affect the ongoing viability of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2024 we entered into a loan and security agreement, and subsequently on November 3, 2025, we entered into an amended and
restated loan agreement (as amended, the &#8220;Amended Loan Agreement&#8221;) for a secured loan with certain lenders including our
former chief executive officer and chairman Steven Lisi and Robert Carey, our present Chairman. The Amended Loan Agreement provides
for a $13,500,000 loan. The loan bears interest at a rate per annum (subject to increase during an event of default) equal to 15% of
which 3% shall be payable in cash and 12% payable in kind through June 30, 2026 and thereafter all in cash. If not earlier repaid in
full, the outstanding principal amount of the loan, together with any accrued and unpaid interest, shall be due and payable on
October 4, 2034. The Company&#8217;s obligations under the Loan Agreement are secured by substantially all of the Company&#8217;s
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement contains affirmative and negative covenants customary for financings of this type that, among other things, limit the
ability of the Company and its subsidiaries to incur additional debtor or pay any dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement also includes events of default customary for financings of this type, in certain cases subject to customary periods to
cure, following which the lenders may accelerate all amounts outstanding under the loan. Events of default include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to pay any principal or interest under the Loan Agreement or any note in connection therewith;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    representation or warranty made shall prove to have been false or misleading in any material respect; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    specified insolvency and bankruptcy-related events.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to any applicable cure period set forth in the Loan Agreement, all amounts outstanding with respect to the loan (principal and accrued
interest), as well as any other obligations and amounts owing under the Loan Agreement, would become due and payable at the option of
the lenders. Our assets or cash flow may not be sufficient to fully repay our obligations under the Loan Agreement if the obligations
thereunder are accelerated upon any events of default. Further, if we are unable to repay, refinance or restructure our obligations,
the lenders could proceed to protect and enforce their rights under the Loan Agreement by exercising such remedies (including foreclosure
on the assets securing our obligations under the Loan Agreement) as are available to the lenders and in respect thereof under applicable
law, either by suit in equity or by action at law, or both, whether for specific performance of any covenant or other agreement contained
in the Loan Agreement or the other loan documents or in aid of the exercise of any power granted in the Loan Agreement or other loan
documents. The foregoing would materially and adversely affect the ongoing viability of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Loan Agreement contains restrictions that limit our flexibility in operating our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement contains various covenants that limit our ability to engage in specified types of transactions without the prior consent
of the lenders. These covenants limit our ability to, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">create,
    incur or assume additional indebtedness; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to certain exceptions, make restricted payments, including paying dividends on, repurchasing or making distributions with respect
    to our common stock; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidate,
    merge, sell or otherwise dispose of all or substantially all of our assets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
covenants in the Loan Agreement may limit our ability to take certain actions that may be in our long-term best interests. In the event
that we breach one or more covenants, the lenders may choose to declare an event of default and require that we immediately repay all
amounts outstanding under the Loan Agreement, plus penalties and interest and foreclose on the collateral granted to them to secure the
obligations under the Loan Agreement. Such repayment could have a material adverse effect on our business, operating results and financial
condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Commercialization of Our Approved Product or Product Candidates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the market opportunities for our approved product or product candidates are smaller than we believe they are, our revenue may be adversely
affected, and our business may suffer.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
projections of both the number of people who have our target diseases, as well as the subset of people with these diseases who have the
potential to benefit from treatment with LungFit<sup>&#174;</sup> PH and our product candidates, are based on our beliefs and estimates.
These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations
or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases.
The number of patients may turn out to be lower than expected. The effort to identify patients with diseases we seek to treat is in early
stages, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable
patient population for LungFit<sup>&#174;</sup> PH and each of our product candidates may be limited or may not be amenable to treatment
with LungFit<sup>&#174;</sup> PH or our product candidates, and new patients may become increasingly difficult to identify or gain access
to, which would adversely affect our results of operations and our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage
and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pricing, coverage and reimbursement of our approved product and product candidates, if approved, must be adequate to support our commercial
infrastructure. Our per-patient prices must be sufficient to recover our development and manufacturing costs and potentially achieve
profitability. Accordingly, the availability and adequacy of coverage and reimbursement by governmental and private payors are essential
for most patients to be able to afford expensive treatments such as ours, assuming certification or approval. Sales of our approved product
and product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our approved product
and product candidates will be paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations,
or reimbursed by government authorities, private health insurers and other third-party payors. If coverage and reimbursement are not
available, or are available only to limited levels, we may not be able to successfully commercialize our approved product and product
candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain
pricing sufficient to realize a return on our investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the U.S., there is no uniform
system among payors for making coverage and reimbursement decisions. In addition, the process for determining whether a payor will provide
coverage for a product or service may be separate from the process for setting the price or reimbursement rate that the payor will pay
for the product or service once coverage is approved. Payors may limit coverage to specific products or services on an approved list,
or formulary, which might not include all of the FDA-approved or -cleared products for a particular indication. In the U.S., the principal
decisions about Medicare coverage and reimbursement for new medical devices are typically made by the Centers for Medicare &amp; Medicaid
Services (&#8220;CMS&#8221;), an agency within the U.S. Department of Health and Human Services, or Medicare contractors that process
and pay claims, as CMS and/or the contractors decide whether and to what extent a new device will be covered and reimbursed under Medicare.
Private payors tend to, but are not required to, follow the coverage and reimbursement policies established by CMS to a substantial degree.
It is difficult to predict what CMS or the Medicare contractors will decide with respect to reimbursement for products such as ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the U.S., international operations are generally subject to extensive governmental price controls and other market regulations, and we
believe the increasing emphasis on cost-containment initiatives in the EEA, Canada and other countries has and will continue to put pressure
on the pricing and usage of our approved product or product candidates. In many countries, the prices of medical products are subject
to varying price control mechanisms as part of national health systems. In general, the prices of medical devices under such systems
are substantially lower than in the U.S. Other countries allow companies to fix their own prices for medical products, but monitor and
control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are
able to charge for our approved product or product candidates. Accordingly, in markets outside the U.S., the reimbursement for our products
may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenue and profits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
increasing efforts by governmental and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations
to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate
payment for our approved product and product candidates. We expect to experience pricing pressures in connection with the sale of any
of our approved product and product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance
organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs
and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the
entry of new products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
the certification or approval of our product and product candidates for insurance coverage and reimbursement by governmental and private
payors may impact our ability to generate revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face intense competition and rapid technological change and the possibility that our competitors may discover, develop or commercialize
therapies that are similar, more advanced or more effective than ours, which may adversely affect our financial condition and our ability
to successfully commercialize LungFit<sup>&#174;</sup> PH and our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are working on PPHN which is a highly competitive market. A delivery system with a generator of NO has never been commercialized anywhere
in the world, and market acceptance at an appropriate price is proving to be a somewhat difficult and lengthy process. The biotechnology,
pharmaceutical and medical device industries are highly competitive. There are many pharmaceutical companies, biotechnology companies,
medical device companies, public and private universities and research organizations actively engaged in the research and development
of products that may be similar to our approved product or our product candidates. We are aware of several companies currently developing
and selling NO therapies for various indications such as hypoxic respiratory failure (HRF). For example, Mallinckrodt commercializes
INOMAX<sup>&#174;</sup> (nitric oxide) for inhalation, which is approved for use to treat newborns suffering from HRF-PPHN in the U.S.,
Canada, Australia, Mexico and Japan. Linde Group markets a generic version of the Mallinckrodt offering with their delivery system called
NOxBOX<sup>&#174;</sup>. The Linde Group has marketing rights to INOMAX<sup>&#174; </sup>in Europe. Air Liquide sells a similar product
in Europe, called KINOX&#8482;, together with their delivery platform called SoKINOX&#8482;, for the treatment of pulmonary hypertension
of the newborn. In Europe, EKU, International Biomedical, Cahouet and ITC each have a device that delivers nitric oxide. VERO Biotech
LLC received FDA approval for their delivery system GENOSYL DS for HRF associated with PPHN in 2019 and received FDA approval for a third
generation of that delivery system in 2023. In addition, other companies may be developing inhaled NO delivery systems at various concentrations.
Novan Inc. has recently received approval for a nitric oxide-based prescription treatment called berdazimer for molluscum, a contagious
skin infection. SaNOtize has an NO nasal spray that has received approval in India, Israel, and eight other countries for preventing
COVID-19 after exposure. NovLead Biotechnology (Nanjing, China) has approval in China for a device that produces nitric oxide through
a process of passing an electric charge into an electrolyte solution and Shenzhen Respomed Medical Technology (Shenzhen, China) also
has approval in China for a device that uses electrical discharge to generate nitric oxide gas. Neither of these devices have approval
outside of China. Third Pole has reported the development of an NO generator and delivery system, but we are not aware of any display
of any product at any medical/scientific conference in recent years. Our patents surrounding LungFit<sup>&#174; </sup>have priority date
over those of Third Pole.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to NO treatments currently available or under development, we also face competition from non-NO-based drugs and therapies. For
example, the successful development of immunizations for bronchiolitis may render useless any product we develop for that indication.
Also, antibiotic treatments for infections associated with CF and other underlying lung conditions may be preferred over any product
that we develop. Even if we successfully develop our product candidates, and obtain certification or approval for them, other treatments
may be preferred and we may not be successful in commercializing our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff
and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the medical device, biotechnology and
pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain
certification or regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products
as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies
and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing
on an exclusive basis, products that are more effective or less costly than LungFit<sup>&#174;</sup> PH or any product candidate that
we may develop, or achieve earlier patent protection, certification or regulatory approval, product commercialization and market penetration
than we do. Additionally, technologies developed by our competitors may render LungFit<sup>&#174;</sup> PH or our potential product candidates
uneconomical or obsolete, and we may not be successful in marketing LungFit<sup>&#174;</sup> PH or our product candidates against competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have a limited marketing and sales organization. If we are unable to scale sales and marketing capabilities or enter into agreements
with third parties to market and sell LungFit<sup>&#174;</sup> PH or our product candidates, we may be unable to generate revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
some of our employees may have sold other similar products in the past while employed at other companies, we as a company have limited
experience selling and marketing our product candidates and we currently have a nascent marketing and sales organization. To successfully
commercialize LungFit<sup>&#174;</sup> PH or any other products that may result from our development programs, we will need to further
develop these capabilities, either on our own or with others. We continue to refine our commercialization efforts for LungFit<sup>&#174;
</sup>PH and intend to establish a more complete sales and marketing organization with technical expertise to potentially reach all U.S.
hospitals using or capable of using NO. This will be an expensive, difficult and time-consuming endeavor. Any failure or delay in the
development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
given our limited experience in marketing and selling medical device products, our estimate of the size of the required sales force may
be materially more or less than the size of the sales force actually required to effectively commercialize LungFit<sup>&#174; </sup>PH
and our product candidates. As such, we may be required to hire substantially more sales representatives to adequately support the commercialization
of LungFit<sup>&#174;</sup> PH and our product candidates, or we may incur excess costs as a result of hiring more sales representatives
than necessary. With respect to certain geographical markets, we may enter into collaborations with other entities to utilize their local
marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If our future
collaborators do not commit sufficient resources to commercialize our future products, if any, and we are unable to develop the necessary
marketing capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We may be competing
with companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support
of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
commercial success of LungFit<sup>&#174;</sup> PH and any current or future product candidate will depend upon the degree of market acceptance
by physicians, patients, third-party payors and others in the medical community.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
with approval from the FDA and potential future certification or approvals from comparable foreign regulatory authorities, the commercial
success of LungFit<sup>&#174;</sup> PH and our product candidates will depend in part on the medical community, patients and third-party
payors accepting LungFit<sup>&#174;</sup> PH and our product candidates as medically useful, cost-effective and safe. Any product that
we bring to the market may not gain market acceptance by physicians, patients, third-party payors and others in the medical community.
The degree of market acceptance of LungFit<sup>&#174;</sup> PH and any of our product candidates that become approved for commercial sale
will depend, in part, on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    safety and efficacy of the product(s) as demonstrated in clinical trials and potential advantages over competing treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications for which certification or approval is granted;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
    convenience and ease of administration;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">familiarity
    of group purchasing organizations with our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of treatment, particularly in relation to competing treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    strength of marketing and distribution support and timing of market introduction of competitive products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicity
    concerning our products or competing products and treatments; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sufficient
    third-party insurance coverage and reimbursement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance
of the product will not be fully known until after it is launched. Our efforts to educate the medical community and third-party payors
on the benefits of the product candidates may require significant resources and may never be successful. If the LungFit<sup>&#174;</sup>
PH or our product candidates are approved for commercialization but fail to achieve an adequate level of acceptance by physicians, patients,
third-party payors and others in the medical community, we will not be able to generate sufficient revenue to become or remain profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to properly manage our anticipated growth, our business could suffer.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
rapid growth has placed, and will continue to place, a significant strain on our management and on our operational and financial resources
and systems. Failure to manage our growth effectively could cause us to over-invest or under-invest in infrastructure, and result in
losses or weaknesses in our infrastructure, which could materially adversely affect us. Additionally, our anticipated growth will increase
the demands placed on our suppliers, resulting in an increased need for us to carefully monitor for quality assurance. Any failure by
us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pricing
pressure from our competitors and our customers may impact our ability to sell our products at prices necessary to support our current
business strategies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
industry in which we operate is characterized by intense competition, and the market continues to attract numerous new companies and
technologies, which has encouraged more established companies to intensify competitive pricing pressure. As a result of this increased
competition, as well as the challenges of third-party coverage and reimbursement practices, we believe there will be continued pricing
pressure in the future. If competitive forces drive down the prices we are able to charge for our products, our profit margins will shrink,
which will adversely affect our ability to maintain our profitability and to invest in and grow our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cybersecurity
risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, and Internet applications
and related tools and functions could result in harm to our business and/or subject us to costs, fines or lawsuits.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products may rely on embedded software, digital interfaces, electronic components and interoperability with hospital or clinical infrastructure,
including ventilators, monitoring systems and gas-delivery systems. Certain deployments of our systems may operate in limited-connectivity,
isolated or &#8220;air-gapped&#8221; clinical environments. Despite such architecture, these systems may remain vulnerable to cybersecurity
incidents through removable media, servicing activities, third-party maintenance tools, software updates, configuration errors, unauthorized
physical access or supply-chain compromise. Any cybersecurity incident affecting our products, infrastructure, suppliers, distributors,
hospital customers or service providers could result in device malfunction, interruption of therapy delivery, data integrity issues,
recalls, remediation costs, litigation, reputational harm, regulatory scrutiny or patient safety events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remediation
of cybersecurity vulnerabilities affecting our products may require extensive validation, customer coordination, regulatory review or
on-site servicing activities, which could delay implementation of corrective measures and increase operational costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in regulatory expectations relating to software-enabled medical devices, cybersecurity, or interoperability may increase our compliance
costs, require design modifications, delay approvals or require additional post-market controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on sophisticated information technology systems and network infrastructure to operate and manage our business. We also maintain
personally identifiable information (&#8220;PII&#8221;) about our employees, and given the nature of our business, we have access to
protected health information (&#8220;PHI&#8221;). Our business therefore depends on the continuous, effective, reliable, and secure operation
of our computer hardware, software, networks, Internet servers, and related infrastructure. To the extent that our hardware or software
malfunctions or access to our data by internal personnel, suppliers or customers through the Internet is interrupted or compromised,
our business could suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
integrity and protection of our customer, personnel, financial, research and development, and other confidential data is critical to
our business, and our customers and employees have a high expectation that we will adequately protect their personal information. The
regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve and a number
of states have adopted laws and regulations that may affect our privacy and data security practices regarding the use, disclosure and
protection of PII. For example, the California Consumer Privacy Act (&#8220;the CCPA&#8221;), among other things, creates individual
privacy rights and imposes increased obligations on companies handling PII.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our computer and communications hardware are protected through physical and software safeguards, they are still vulnerable to system
malfunction, computer viruses, malware and ransomware, and other cybersecurity threats such as phishing and social engineering attacks.
These events could lead to the unauthorized access of our information technology systems and result in financial loss and the misappropriation
or unauthorized disclosure of confidential information belonging to us, our employees, partners, customers, or suppliers. The techniques
used by criminal elements to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote
areas of the world. As a result, we may not be able to address these techniques proactively or implement adequate preventative measures.
If our information technology systems are compromised, we could be subject to fines, damages, litigation and enforcement actions, incur
financial losses, suffer reputational damage, and lose trade secrets or other confidential information, each of which could significantly
harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
legislative or regulatory reform measures, including government restrictions on pricing and reimbursement, may have a negative impact
on our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., there have been and continue to be a number of legislative and regulatory changes and proposed changes to contain healthcare
costs. For example, in March 2010, the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) was enacted, which, among other
things, substantially changes the way health care is financed by both governmental and private insurers, and significantly impacts the
U.S. medical device industry. Some of the provisions of the ACA have been subject to judicial challenges as well as efforts to modify
them or alter their interpretation or implementation. For example, the Tax Cuts and Jobs Act of 2017 (&#8220;Tax Act&#8221;), includes
a provision that eliminated the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain
qualifying health coverage for all or part of a year, commonly referred to as the &#8220;individual mandate,&#8221; effective January
1, 2019. It is unclear how efforts to modify or invalidate the ACA or its implementing regulations, or portions thereof, will affect
our business. Additional legislative changes, regulatory changes and judicial challenges related to the ACA remain possible. We cannot
predict what effect further changes related to the ACA would have on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be sure whether additional legislative changes will be enacted, or whether government regulations, guidance or interpretations
will be changed, or what the impact of such changes would be on the certification or marketing approvals, sales, pricing, or reimbursement
of our approved product or product candidates, if any, may be. We expect that any such healthcare reform measures that may be adopted
in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any
approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments
from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability, or commercialize our approved product or product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
in order to obtain reimbursement for our products in some EEA countries, including some EU Member States, we may be required to compile
additional data comparing the cost-effectiveness of our products to other available therapies. Health Technology Assessment (&#8220;HTA&#8221;)
of both medicinal products and medical devices is becoming an increasingly common part of the pricing and reimbursement procedures in
some EU Member States, including those representing the larger markets. The HTA process, which is currently governed by national laws
in each EU Member State, is the procedure to assess therapeutic, economic and societal impact of a given medical product in the national
healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted
to these medical products by the competent authorities of the respective EU Member State. The extent to which pricing and reimbursement
decisions are influenced by the HTA of the specific medical product currently varies between EU Member States. On December 13, 2021,
the EU adopted a new HTA Regulation which entered into force on January 11, 2022 and will become applicable to all EU Member States from
January 12, 2025. The new EU HTA regulation aims to harmonize the clinical benefit assessment of HTA across the EU and provides the basis
for permanent and sustainable cooperation at the EU level for joint clinical assessments in these areas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to additional federal and state laws and regulations relating to our business, and our failure to comply with those laws
could have a material adverse effect on our results of operations and financial conditions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to additional health care regulation and enforcement by the federal government and the states in which we conduct our business.
Of note, regulations that may relate to our operations include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal health care program AKS prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering,
    or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for,
    or the purchase, lease, or order or arranging for the purchase, lease or order of any good or service, for which payment may be made,
    in whole or in part, under federal health care programs such as Medicare and Medicaid. This statute has been interpreted to apply
    to arrangements between pharmaceutical or device manufacturers, on the one hand, and prescribers, purchasers and formulary managers
    and others on the other. The term &#8220;remuneration&#8221; has been broadly interpreted to apply to anything of value including,
    for example, gifts, cash payments, donations, waivers of payment, ownership interests, and providing any item, service, or compensation
    for something other than fair market value. Liability under the AKS may be established without proving actual knowledge of the statute
    or specific intent to violate it. Although there are a number of statutory exceptions and regulatory safe harbors to the AKS protecting
    certain common business arrangements and activities from prosecution or regulatory sanctions, the exceptions and safe harbors are
    drawn narrowly. Practices that involve remuneration to those who prescribe, purchase, or recommend medical device products, including
    certain discounts, or engaging such individuals as consultants, advisors and speakers, may be subject to scrutiny if they do not
    fit squarely within an exception or safe harbor. Moreover, there are no safe harbors for many common practices, such as educational
    grants and reimbursement support programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal civil FCA that prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented,
    false or fraudulent, claims for payment of government funds, knowingly making, using or causing to be made or used a false statement
    or record material to an obligation to pay money to the government, or knowingly concealing or knowingly and improperly avoiding,
    decreasing or concealing an obligation to pay money to the federal government. A claim including items or services resulting from
    a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA. Actions under the FCA may be brought by the
    government or as a qui tam action by a private individual in the name of the government, who may also share in any monetary recovery.
    Qui tam actions are filed under seal and impose a mandatory duty on the U.S. Department of Justice to investigate such allegations.
    Manufacturers have faced liability under the FCA for providing inaccurate billing or coding information to customers or promoting
    a product off-label. FCA liability is potentially significant in the healthcare industry because the statute provides for treble
    damages and significant mandatory penalties per false or fraudulent claim or statement for violations, as well as exclusion from
    participation in federal healthcare programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
    imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme
    to defraud any healthcare benefit program, including private third-party payors, or knowingly and willfully falsifying, concealing,
    or covering up a material fact or making any materially false, fictitious, or fraudulent statement or representation, or using any
    false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry, in connection
    with the delivery of or payment for healthcare benefits, items, or services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Sunshine Act requires applicable manufacturers of devices, biologics and medical supplies for which payment is available
    under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information
    related to payments and other transfers of value to physicians, physician assistants, nurse practitioners, clinical nurse specialists,
    certified nurse anesthetists, and certified nurse midwives, and teaching hospitals, as well as ownership and investment interests
    held by physicians and their immediate family members; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
    state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements
    and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.
    Several states have enacted legislation requiring medical device manufacturers to, among other things, establish marketing compliance
    programs; file periodic reports with the state, including reports on gifts and payments to individual health care providers; and/or
    register their sales representatives. Some states prohibit certain sales and marketing practices, including the provision of gifts,
    meals, or other items to health care providers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve
substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it
is possible that some of our business activities could be subject to challenge under one or more of such laws. The scope and enforcement
of these laws is uncertain and subject to change in the current environment of health care reform. We cannot predict the impact on our
business of any changes in these laws. Federal or state regulatory authorities may challenge our current or future activities under these
laws. Any such challenge, even if we are able to successfully defend against it, could have a material adverse effect on our reputation,
business, results of operations, and financial condition. Any state or federal regulatory review of us, regardless of the outcome, would
be costly and time-consuming. If our operations are found to be in violation of any of the laws described above or any other governmental
regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from
participation in government health care programs, such as Medicare and Medicaid, imprisonment and the curtailment or restructuring of
our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with applicable privacy, data protection and data security laws and regulations, we could face substantial penalties,
liability and adverse publicity and our business, operations and financial condition could be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to various laws and regulations globally regarding privacy and data protection, including laws and regulations relating to
the collection, storage, handling, use, disclosure, transfer and security of personal data. The restrictions under applicable privacy,
data protection and data security laws and regulations that may affect our ability to operate include but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
    governs the use, disclosure, and security of protected health information by HIPAA &#8220;covered entities&#8221; and their &#8220;business
    associates.&#8221; Covered entities are health plans, health care clearinghouses and health care providers that engage in specific
    types of electronic transactions. A business associate is any person or entity (other than members of a covered entity&#8217;s workforce)
    that performs a service for or on behalf of a covered entity involving the use or disclosure of protected health information. Most
    healthcare providers who prescribe our products and from whom we obtain patient health information are subject to privacy and security
    requirements under HIPAA, as are we in certain circumstances. The U.S. Department of Health and Human Services (through the Office
    for Civil Rights) has direct enforcement authority against covered entities and business associates with regard to compliance with
    HIPAA regulations. We also could be subject to criminal penalties if we knowingly obtain individually identifiable health information
    from a covered entity in a manner that is not authorized or permitted by HIPAA or for aiding and abetting and/or conspiring to commit
    a violation of HIPAA. We are unable to predict whether our actions could be subject to prosecution in the event of an impermissible
    disclosure of health information to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">numerous
    U.S. federal and state laws and regulations, including state data breach notification laws, state health information privacy laws
    and federal and state consumer protection laws, govern the collection, use, disclosure and protection of personal information. These
    laws may impose a number of compliance obligations on us, including requiring that we obtain consent before we collect, use, or disclose
    personal information, implement certain security protections to safeguard personal information, and notify individuals or regulators
    in the event of a breach;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    countries also have, or are developing, laws governing the collection, use, disclosure and protection of personal information. The
    GDPR, for example, imposes restrictions on the processing (e.g., collection, use, disclosure) of personal data in the EEA and also
    imposes strict restrictions on the transfer of personal data out of the EU to the U.S. Our business could be adversely impacted if
    our ability to transfer personal data outside of the EEA or Switzerland is restricted, which could adversely impact our operating
    results. For example, in July 2020, the Court of Justice of the European Union (the CJEU) declared the EU-U.S. Privacy Shield framework
    between the EU and U.S. to be invalid and raised concerns about other data transfer mechanisms in a case known colloquially as &#8220;Schrems
    II&#8221;, which could adversely impact our ability to transfer personal data from the EU to the U.S or otherwise may cause us to
    incur significant costs to do so legally. At present, there are few viable alternatives to the EU-U.S. Privacy Shield and the Standard
    Contractual Clauses (&#8220;SCCs&#8221;). If the level of protection in the U.S. or any other importing country is called into question
    under the SCCs, this could further impact our ability to transfer data outside of the EEA or Switzerland. Furthermore, following
    the Brexit and the UK&#8217;s exit from the EU, the UK became a third country to the EU in terms of personal data transfers. The
    European Commission has adopted an Adequacy Decision concerning the level of personal data protection in the UK under which personal
    data may now flow freely from the EU to the UK. However, personal data transfers from the EU to the UK may nevertheless be at a greater
    risk than before because the Adequacy Decision could in theory someday be suspended. On July 10, 2023, the European Commission adopted an adequacy decision for the EU-U.S. Data Privacy Framework (&#8220;EU-U.S.
DPF&#8221;), concluding that participating U.S. organizations certified under the framework provide an adequate level of protection for
personal data transferred from the European Economic Area (&#8220;EEA&#8221;) to the United States. The United Kingdom has also adopted
the UK Extension to the EU-U.S. DPF, and Switzerland has recognized the Swiss-U.S. Data Privacy Framework as a valid transfer mechanism
for personal data transferred from Switzerland to participating U.S. organizations. Accordingly, personal data transfers from the EEA,
the United Kingdom and Switzerland to the United States may, in certain circumstances, be based on participation in the applicable Data
Privacy Framework program. In addition, Standard Contractual Clauses (&#8220;SCCs&#8221;) and other lawful transfer mechanisms remain available
for cross-border transfers of personal data. However, the legal landscape governing international data transfers remains subject to ongoing
regulatory developments, judicial scrutiny and potential legal challenges. Future decisions by European courts, regulators or lawmakers
could invalidate, restrict or impose additional requirements on the EU-U.S. DPF, SCCs or other transfer mechanisms. Any such developments
could require us to implement additional safeguards, modify our business practices, incur significant compliance costs, suspend certain
data transfers or otherwise adversely affect our ability to process personal data across jurisdictions. If we are unable to transfer personal
data lawfully between jurisdictions in which we operate, our business, financial condition, results of operations and prospects could
be materially adversely affected; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    legislative and regulatory landscape for privacy and data security continues to evolve, and there has been an increasing amount of
    focus on privacy and data security issues with the potential to affect our business. For example, the CCPA, as amended by the California
    Privacy Rights Act (CPRA), contains disclosure obligations for businesses that collect personal information about California residents
    and affords those individuals new rights relating to their personal information that may affect our ability to use personal information.
    Other states, including Virginia, Colorado, Utah, Connecticut, Indiana, Iowa, Tennessee, Utah, and others have enacted privacy laws
    similar to the CCPA that impose new obligations or limitations in areas affecting our business and we continue to assess the impact
    of these state legislation, on our business as additional information and guidance becomes available. The federal government has
    also considered similar privacy laws that could impose new obligations or limitations in areas affecting our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
privacy and data security laws and regulations could increase our cost of doing business, and failure to comply with these laws and regulations
could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity
and could materially and negatively affect our operating results and business. Although a thorough privacy compliance program could mitigate
the risk of investigation and prosecution for violations of these laws and regulations, the risks cannot be entirely eliminated. Any
action against us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant
legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance
with applicable federal, state, and foreign privacy and data security laws and regulations may prove costly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we or our suppliers fail to comply with ongoing FDA or other foreign regulatory authority requirements, or if we experience unanticipated
problems with our products, these products could be subject to restrictions or withdrawal from the market.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product for which we obtain FDA certification, clearance or approval, and the manufacturing processes, post-market surveillance, post-certification/approval
clinical data and promotional activities for such product, remain subject to continued regulatory review, oversight, requirements, and
periodic inspections by the FDA and other domestic and foreign regulatory authorities and notified bodies. For such products, we must
also comply with equivalent standards in non-U.S. countries should we choose to engage in comparable activity in those jurisdictions.
These obligations extend to our third-party suppliers as well.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, we and our suppliers are required to comply with the FDA&#8217;s QSR in the U.S. and other regulations enforced outside the
United States which cover the manufacture of our products and the methods and documentation of the design, testing, production, control,
quality assurance, labeling, packaging, storage and shipping of medical devices. Regulatory authorities, such as the FDA, and notified
bodies enforce the QSR in the U.S. and other regulations through periodic inspections. The failure by us or one of our suppliers to comply
with applicable statutes and regulations administered by the FDA, or the failure to timely and adequately respond to any adverse inspectional
observations or product safety issues, could result in, among other things, any of the following enforcement actions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled
    letters, warning letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    expenditures to address or defend such actions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer
    notifications for repair, replacement, refunds;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall,
    detention or seizure of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    restrictions or partial suspension or total shutdown of production;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing
    or delaying our requests for 510(k) clearance, de novo authorization or PMA approval of new products or modified products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of 510(k) clearances on PMA approvals that have already been granted;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to grant export approval for our products; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
    prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these actions were to occur, it would harm our reputation and cause our product sales and profitability to suffer and may prevent
us from generating revenue. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with
all applicable regulatory requirements which could result in our failure to produce our products on a timely basis and in the required
quantities, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we are required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our approved
products, and we must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related
to our products. Later discovery of previously unknown problems with such products, including unanticipated adverse events or adverse
events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR,
may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market,
voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute,
fines, suspension of certification or regulatory approval, product seizures, injunctions or the imposition of civil or criminal penalties
which would adversely affect our business, operating results and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we may be required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our products in the
EEA. We must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to
our products. Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events
of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements may result in changes
to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory
recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of
certification, regulatory clearances or approvals, product seizures, injunctions or the imposition of civil or criminal penalties which
would adversely affect our business, operating results and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to
the FDA or comparable foreign regulatory authorities, and if we fail to do so, we would be subject to sanctions that could harm our reputation,
business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our
products either voluntarily or at the direction of the FDA or comparable foreign regulatory authorities, could have a negative impact
on us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a commercial-stage company, we are subject to the FDA&#8217;s medical device reporting regulations and similar foreign regulations, which
require us to report to the FDA when we receive or become aware of information that reasonably suggests that one or more of our products
may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could
cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware of
the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed
timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to
us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to
comply with our reporting obligations, the FDA could take action, including warning letters, untitled letters, administrative actions,
criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance or approval, seizure of our products
or delay in clearance or approval of future products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and comparable foreign regulatory authorities have the authority to require the recall of commercialized products in the event of
material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health.
The FDA&#8217;s authority to require a recall must be based on a finding that there is reasonable probability that the device could cause
serious injury or death. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated
or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing
defects, labeling or design deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations.
Product defects or other errors may occur in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
on the corrective action we take to redress a product&#8217;s deficiencies or defects, the FDA may require, or we may decide, that we
will need to obtain new clearances or approvals for the device before we may market or distribute the corrected device. Seeking such
clearances or approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address
problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure,
injunctions, administrative penalties or civil or criminal fines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies
are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary
withdrawals or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees
with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future
recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively
affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require
the dedication of our time and capital, will distract management from operating our business and may harm our reputation and financial
results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
manufacturers placing medical devices on the market in the EEA are legally bound to report to the relevant competent authorities (a)
any serious incident involving devices made available on the EEA market, except expected side-effects which are clearly documented in
the product information and quantified in the technical documentation and are subject to trend reporting, and (b) any field safety corrective
action in respect of devices made available on the EEA market, including any field safety corrective action undertaken in a third country
in relation to a device which is also legally made available on the EEA market, if the reason for the field safety corrective action
is not limited to the device made available in the third country. Reports should be submitted through the electronic system set up and
managed by the European Commission in collaboration with EEA countries. Reports of serious incidents will be automatically transmitted
to the competent authority of the EEA country in which the incident occurred and reports on field safety corrections actions will be
automatically transmitted to the competent authority of the EEA country in which the field safety corrective action is being or is to
be undertaken and the EEA country in which the manufacturer has its registered place of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the EU MDR, a &#8220;serious incident&#8221; means any incident that directly or indirectly led, might have led or might lead to any
of the following: (a) the death of a patient, user or other person; (b) the temporary or permanent serious deterioration of a patient&#8217;s,
user&#8217;s or other person&#8217;s state of health; or (c) a serious public health threat. A &#8220;field safety corrective action&#8221;
means corrective action taken by a manufacturer for technical or medical reasons to prevent or reduce the risk of a serious incident
in relation to a device made available on the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malfunction
of our products could result in future voluntary corrective actions, such as recalls, including corrections, or customer notifications,
or agency action, such as inspection or enforcement actions. If malfunctions do occur, we may be unable to correct the malfunctions adequately
or prevent further malfunctions, in which case we may need to cease manufacture and distribution of the affected products, initiate voluntary
recalls, and redesign the products. Regulatory authorities may also take actions against us, such as ordering recalls, imposing fines,
or seizing the affected products. Any corrective action, whether voluntary or involuntary, will require the dedication of our time and
capital, distract management from operating our business, and may harm our reputation and financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
approved product or product candidates may in the future be subject to product recalls that could harm our reputation, business and financial
results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices can experience performance problems in the field that require review and possible corrective action. The occurrence of component
failures, manufacturing errors, software errors, design defects or labeling inadequacies affecting a medical device could lead to a government-mandated
or voluntary recall by the device manufacturer, in particular when such deficiencies may endanger health. The FDA requires that certain
classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. Comparable foreign regulatory
authorities impose similar deadlines. Companies are required to maintain certain records of recalls, even if they are not reportable
to the FDA or to comparable foreign regulatory authorities. We may initiate voluntary recalls involving our products in the future that
we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those
actions as recalls. Product recalls may divert management attention and financial resources, expose us to product liability or other
claims, harm our reputation with customers and adversely impact our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to regulatory or enforcement actions if we engage in improper marketing or promotion of our approved product or product
candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
educational and promotional activities and training methods must comply with FDA and other applicable laws, including the prohibition
of the promotion of a medical device for a use that has not been cleared or approved by the FDA. Use of a device outside of its cleared
or approved indications is known as &#8220;off-label&#8221; use. Physicians may use our products off-label in their professional medical
judgment, as the FDA does not restrict or regulate a physician&#8217;s choice of treatment within the practice of medicine. However,
if the FDA determines that our educational and promotional activities or training constitutes promotion of an off-label use, it could
request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance
of warning letters, untitled letters, fines, penalties, injunctions, or seizures, any of which could have an adverse impact on our reputation
and financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also possible that other federal, state or comparable foreign regulatory authorities might take action if they consider our educational
and promotional activities or training methods to constitute promotion of an off-label use, which could result in significant fines or
penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could
be damaged, and adoption of the products could be impaired. Although our policy is to refrain from statements that could be considered
off-label promotion of our products, the FDA or comparable foreign regulatory authorities could disagree and conclude that we have engaged
in off-label promotion. It is also possible that other federal, state or comparable foreign regulatory authorities might take action,
including, but not limited to, through a whistleblower action under the FCA, if they consider our business activities constitute promotion
of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil or administrative penalties,
treble damages, fines, disgorgement, exclusion from participation in government healthcare programs, reporting requirements and compliance
oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with
these laws, and the curtailment or restructuring of our operations. In addition, the off-label use of our products may increase the risk
of product liability claims. Product liability claims are expensive to defend and could divert our management&#8217;s attention, result
in substantial damage awards against us, and harm our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
advertising and promotion of our products in the EEA is subject to EEA countries&#8217; national laws implementing Directive 2006/114/EC
concerning misleading and comparative advertising, and Directive 2005/29/EC on unfair commercial practices, as well as other national
legislation of individual EEA country governing the advertising and promotion of medical devices. EEA country legislation may also restrict
or impose limitations on our ability to advertise our products directly to the general public. In addition, voluntary EU and national
Codes of Conduct provide guidelines on the advertising and promotion of our products to the general public and may impose limitations
on our promotional activities with healthcare professionals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face extensive, ongoing regulatory requirements and review, and our products may face future development and regulatory difficulties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holder of an approved PMA, de novo authorization, or cleared 510(k) is subject to obligations to monitor and report adverse events and
instances of the failure of a product to meet the specifications in the marketing application. Application holders must submit new or
supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process.
Legal requirements have also been enacted to require disclosure of clinical trial results on publicly available databases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, manufacturers of FDA regulated products and their facilities are subject to continual review and periodic inspections by the
FDA and comparable foreign regulatory authorities for compliance with the FDA&#8217;s QSR and, as applicable, cGMP regulations. Our relationships
with healthcare providers, physicians and third-party payors must comply with FDA laws and regulations, the AKS, the FCA, HIPAA, various
transparency laws, and similar state and foreign laws. If products are made available to authorized users of the Federal Supply Schedule
of the General Services Administration and to low-income patients of certain hospitals, additional laws and requirements apply. Our activities
are also potentially subject to federal and state consumer protection and unfair competition laws. If we or our third-party collaborators
fail to comply with applicable regulatory requirements, a regulatory authority may take any of the following actions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conduct
    an investigation into our practices and any alleged violation of law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    warning letters or untitled letters asserting that we are in violation of the law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    an injunction or impose civil or criminal penalties or monetary fines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or withdraw certification or regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    that we suspend or terminate any ongoing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve pending applications or supplements to applications filed by us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or impose restrictions on operations, including costly new manufacturing requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain products, refuse to permit the import or export of products, or require us to initiate a product recall; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exclude
    us from providing our products to those participating in government health care programs, such as Medicare and Medicaid, and refuse
    to allow us to enter into supply contracts, including government contracts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any of the foregoing events or penalties may force us to expend significant amounts of time and money and may significantly
inhibit our ability to bring to market or continue to market our products and generate revenue. Similar regulations apply in foreign
jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to the Discovery and Development of Our Product Candidates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are heavily dependent on the success of our product candidates, which are in various stages of clinical development. We cannot give any
assurance that any of our product candidates will receive certification or regulatory approval, which is necessary before they can be
commercialized.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have invested substantially all of our efforts and financial resources to design and develop our product candidates, including
conducting clinical trials and providing general and administrative support for these operations. Our future success is dependent on
our ability to successfully develop, obtain regulatory certification or approval for, and then successfully commercialize one or more
product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
of our product candidates are in the early stages of development and will require additional clinical development (and in some cases
additional preclinical development), management of nonclinical, clinical and manufacturing activities, certification or regulatory approval,
obtaining adequate manufacturing supply, building of a commercial organization and significant marketing efforts before we generate any
revenue from product sales. To date, we have conducted 3 pilot clinical trials involving 198 patients with bronchiolitis (mainly caused
by RSV) and a pilot clinical trial in nine patients with CF. In addition, Rambam healthcare campus in Israel conducted a compassionate
treatment for two patients with CF who suffer from NTM infections (specifically M. abscessus). Additionally, two pilot clinical trials
were completed in 2022, one in viral pneumonia and one in NTM lung infection. Both of these studies were using our LungFit&#174; system
(PRO and GO, respectively). Although the results of these trials demonstrated improvements in various endpoints and clinical outcomes
which we believe support our efforts towards obtaining FDA approval, these trials were small and conducted outside the US, so it is unlikely
that the FDA will view them as significant because of their size and scope. Therefore, we intend to conduct larger clinical trials aiming
for statistically and clinically significant favorable results, or we will not be able to obtain certification or regulatory approval
to market such product candidates. It may be some time before a pivotal trial is initiated, if at all, for such product candidates. Before
a medical device clinical trial can be undertaken in the U.S., the sponsor of the trial must submit an IDE application for a medical
device and the FDA must permit the trial to go forward. We cannot assure that we will obtain such agency acquiescence in a timely manner,
or at all. In addition to our respiratory program using the LungFit&#174; device, we have programs in Cancer and Autism which require
significant further development before submission to the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we received approval of LungFit<sup>&#174;</sup> PH from the FDA, we can make no assurances as to what any other comparable foreign regulatory
authorities and notified bodies where we are seeking certification or regulatory approval will do. We are expending significant resources
to commercialize LungFit<sup>&#174;</sup> PH in the U.S. and we can make no assurances that our efforts will be successful. We cannot
be certain that any of our product candidates will be successful in clinical trials or receive certification or regulatory approval.
Further, our product candidates may not receive certification or regulatory approval even if they are successful in clinical trials.
If we do not receive certification or regulatory approvals for our other product candidates, we may not be able to continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally plan to seek certification or regulatory approval to commercialize our approved product and product candidates in the U.S.,
the EU and in additional foreign countries, as applicable. To obtain certification or regulatory approvals we must comply with the numerous
and varying regulatory requirements of such countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical trials,
commercial sales, pricing and distribution of our approved product and product candidates. Even if we are successful in obtaining marketing
certification or regulatory approval in one jurisdiction, we cannot ensure that we will obtain certification or regulatory approval in
any other jurisdictions. If we are unable to obtain certification, clearance or approval for our product candidates in multiple jurisdictions,
our revenue and results of operations would be negatively affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our product candidates may be considered a drug/device combination and the process for obtaining regulatory approval in the U.S. on
our product candidates will require compliance with complex procedures because concordance between two centers of the FDA (CDRH and CDER)
is necessary for approval of this combination product. A change in the FDA&#8217;s prior determination that CDRH would lead the review
of a marketing application for our product candidates would adversely impact our development timeline and significantly raise our costs
to complete clinical development and obtain regulatory approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
success of our business may also depend upon our ability to identify, license or discover additional product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
a substantial amount of our effort will focus on the continued clinical testing, potential certification, regulatory approval and commercialization
of LungFit<sup>&#174;</sup> PH and our existing product candidates, the success of our business may also depend upon our ability to identify,
license or discover additional product candidates. Our research programs or licensing efforts may fail to yield additional product candidates
for clinical development for a number of reasons, including but not limited to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    research or business development methodology or search criteria and process may be unsuccessful in identifying potential product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    product candidates may not succeed in preclinical or clinical testing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the product
    candidates unmarketable or unlikely to receive certification or marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitors
    may develop alternatives that render our product candidates obsolete or less attractive;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    candidates we develop may be covered by third parties&#8217; patents or other exclusive rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market for a product candidate may change during our program so that such a product may become unreasonable to continue to develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify,
license or discover additional product candidates, which would have a material adverse effect on our business and could potentially cause
us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources.
We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
certification or regulatory approval processes of the FDA and comparable foreign regulatory authorities and notified bodies are lengthy,
time-consuming and inherently unpredictable. If we are ultimately unable to obtain certification or regulatory approval for our product
candidates, our business will be substantially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain certification or regulatory approval by the FDA or notified bodies in the EU is unpredictable, typically takes
many years following the commencement of clinical trials and depends upon numerous factors. In addition, certification or regulatory
approval policies, regulations or the type and amount of clinical data necessary to gain certification or regulatory approval may change
during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the
certification or regulatory approval or the decision not to certify or approve an application. We have not obtained certification or
regulatory approval for any product other than LungFit<sup>&#174;</sup> PH, and it is possible that none of our existing product candidates
or any product candidates we may seek to develop in the future will ever obtain certification or regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a new medical device may be marketed in the U.S. generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of or reference to extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the FDA&#8217;s
    Good Laboratory Practice (&#8220;GLP&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials to establish the safety and efficacy of the medical device candidate for each
    proposed indication; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of a 510(k), de novo application, or PMA, after completion of all pivotal clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Applications
for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit
    ratio for its proposed indication is acceptable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may determine that the population studied in the clinical program was not sufficiently broad or representative to assure safety
    in the full population for which we seek approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from clinical trials of our product candidates may not be sufficient to support the submission of a PMA in the U.S.
    or elsewhere;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications
    or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA or comparable foreign regulatory authorities and notified bodies may significantly change
    in a manner rendering our clinical data insufficient for certification or approval; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
lengthy certification or regulatory approval process, as well as the unpredictability of the results of clinical trials, may result in
our failing to obtain certification or regulatory approval to market any of our product candidates, which would significantly harm our
business, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and sale of our approved product and product candidates are subject to extensive regulatory requirements, including compliance
with labelling, manufacturing and reporting controls. If we fail or are unable to timely obtain the necessary 510(k) clearances, de-novo
authorizations, or PMA approvals for new products, or equivalent steps in third countries including the EEA, our ability to generate
revenue could be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
approved product and product candidates are classified as medical devices and are subject to extensive regulation in the United States
by the FDA and other federal, state and local authorities and by comparable foreign regulatory authorities. The FDA can delay, limit
or deny 510(k) clearance, authorization of a de novo application, or PMA approval of a device for many reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to demonstrate to the FDA&#8217;s satisfaction that our systems are safe and effective for its intended use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data from our preclinical studies and clinical trials may be insufficient to support clearance or approval, where required;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    manufacturing process or facilities we use or contract to use may not meet applicable requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions
    at the FDA caused by funding shortages or global health concerns.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may refuse our requests for 510(k) clearance, de-novo or PMA of new products, new intended uses or modifications to existing products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, legislation is drafted and introduced in the United States that could significantly change the statutory provisions governing
any regulatory approval or clearance that we receive in the United States. In addition, the FDA may change its clearance and approval
policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance
of our test kits under development or impact our ability to modify our currently approved or cleared test kits on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are also subject to approval, certification and regulation by foreign regulatory and safety agencies. For example, the EU has
adopted the EU MDR, which imposes stricter requirements for the marketing and sale of medical devices, including in the area of clinical
evaluation requirements, quality systems and post-market surveillance. Complying with the requirements of the EU MDR may require us to
incur significant expenditures. Failure to meet these requirements could adversely impact our business in the EEA and other regions that
tie their product registrations to the EU requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Once
commercialized, modifications to our marketed products may require new 510(k) clearances or approval of PMA supplements, or equivalent
steps in other countries or regions including the EEA, or may require us to cease marketing or recall the modified products until certification,
clearances or regulatory approvals are obtained.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modifications
to any of our products once they are commercialized may require new regulatory approvals or clearances, including 510(k) clearances or
approval of PMA supplements, or require us to recall or cease marketing the modified systems until these clearances or approvals are
obtained. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires
a new approval, supplement or clearance. A manufacturer may determine that a modification could not affect safety or efficacy and does
not represent a major change in its intended use, so that no new clearance or approval is necessary. However, the FDA can review a manufacturer&#8217;s
decision and may disagree. The FDA may also on its own initiative determine that a new clearance or approval of a PMA Supplement is required.
We may make modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees
and requires new clearances or approvals for the modifications, we may be required to recall and to stop marketing our products as modified,
which could require us to redesign our products and/or seek new marketing authorizations and harm our operating results. In these circumstances,
we may be subject to significant enforcement actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, if a manufacturer determines that a modification to a PMA approved device could affect its safety or effectiveness or would
constitute a major change in its intended use, then the manufacturer must file for a new a new PMA or approval of a PMA supplement. Where
we determine that modifications to our products require a new PMA approval, we may not be able to obtain those additional approvals for
the modifications or additional indications in a timely manner, or at all. Obtaining new approvals can be a time-consuming process, and
delays in obtaining required future approvals would adversely affect our ability to introduce new or enhanced products in a timely manner,
which in turn would harm our future growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
those products sold in the EEA, we must notify our EU notified body if significant changes are made to the products or if there are substantial
changes to our quality assurance systems affecting those products. Obtaining certification can be a time-consuming process, and delays
in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced products in a timely
manner, which in turn would harm our future growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive
of future study results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during
the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive
of the results of later-stage clinical trials. Product candidates that have shown promising results in early-stage clinical trials may
still suffer significant setbacks in subsequent advanced clinical trials. There is a high failure rate for product candidates proceeding
through clinical trials, and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits
despite having progressed satisfactorily through preclinical studies and initial clinical trials. A number of companies in the medical
device and biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse
safety profiles, notwithstanding promising results in earlier studies. Moreover, preclinical and clinical data are often susceptible
to varying interpretations and analyses. We do not know whether any pivotal clinical trials we may conduct will demonstrate consistent
or adequate efficacy and safety sufficient to obtain certification or regulatory approval to market our product candidates. Nor do we
know whether the FDA will permit us to proceed directly to pivotal trials without performing pilot trials in the U.S. using the same
delivery system that we will seek approval by the agency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legislative
or regulatory reforms may make it more difficult and costly for us to obtain certification, regulatory clearance or approval of any future
products and to manufacture, market and distribute our products after certification, clearance or approval is obtained.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the
regulatory approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, the FDA may change its
clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent
or delay approval or clearance of our future products under development or impact our ability to modify our currently cleared products
on a timely basis. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen
review times of planned or future products. It is impossible to predict whether legislative changes will be enacted or FDA regulations,
guidance or interpretations changed, and what the impact of such changes, if any, may be.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products.
Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review
times of any future products or make it more difficult to obtain clearance or approval for, manufacture, market or distribute our products.
We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted
or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to obtaining
clearance or approval; changes to manufacturing methods; recall, replacement or discontinuance of our products; or additional record
keeping.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s and comparable foreign regulatory authorities&#8217; policies may change and additional government regulations may be promulgated
that could prevent, limit or delay certification, regulatory clearance or approval of our product candidates. We cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad.
For example, the results of the upcoming mid-term Congressional elections may impact our business and industry. Any change in the laws
or regulations that govern the clearance and approval processes relating to our current, planned and future products could make it more
difficult and costly to obtain clearance or approval for new products or to produce, market and distribute existing products. Significant
delays in receiving clearance or approval or the failure to receive clearance or approval for any new products would have an adverse
effect on our ability to expand our business. If we are slow or unable to adapt to changes in existing requirements or the adoption of
new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing clearance that we may
have obtained and we may not achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, on May 25, 2017, the new EU MDR entered into force for medical devices marketed in the EEA. Implementation of the EU MDR was
delayed by one year due to the COVID-19 pandemic. Following its entry into application on May 26, 2021, the EU MDR introduced substantial
changes to the obligations with which medical device manufacturers must comply in the EEA. High risk medical devices are subject to additional
scrutiny during the conformity assessment procedure. Specifically, the EU MDR repeals and replaces the EU Medical Devices Directive.
Unlike directives, which must be implemented into the national laws of the EEA countries, the regulations is directly applicable, i.e.,
without the need for adoption of EEA country laws implementing them, in all EEA countries and are intended to eliminate current differences
in regulation of medical devices among EEA countries. The EU MDR, among other things, is intended to establish a uniform, transparent,
predictable and sustainable regulatory framework across the EEA for medical devices to ensure a high level of safety and health while
supporting innovation. The EU MDR entered into application on May 26, 2021 and among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthens
    the rules on placing devices on the market and reinforce surveillance once they are available;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishes
    explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices
    placed on the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improves
    the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sets
    up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available
    in the EEA; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthens
    rules for the assessment of certain high-risk devices which may have to undergo an additional check by experts before they are placed
    on the market.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU MDR imposes a number of new requirements on manufacturers of medical devices. Notified bodies need to be accredited by the EU Member
States&#8217; accreditation bodies to conduct assessment procedures for medical devices in accordance with the EU MDR. There are currently
a relatively small number of notified bodies that have been accredited to conduct these assessments and their capacity to deal with new
applications is currently limited. In addition, the timeline to go through an EU MDR conformity assessment is substantially longer than
under the previous Directive (currently between 13 and 18 months in average). This may delay conformity assessment procedures in the
future in the EEA, and may impact any of our future activities in the EEA and the UK, the renewal of our existing CE Certificates of
Conformity and conformity assessment related to future bodies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the EU MDR imposes increased compliance obligations for us to access the EEA market. Our failure to comply with applicable foreign regulatory
requirements, including those administered by authorities of the EEA countries, could result in enforcement actions against us, including
refusal, suspension, variation, or withdrawal of any CE Certificates of Conformity by the applicable EU notified body, which could impair
our ability to market products in the EEA. Any changes to the membership of the EU, such as the departure of the United Kingdom (Brexit),
may impact the regulatory requirements for the impacted countries and impair our business operations and our ability to market products
in such countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brexit
has created significant uncertainty concerning the future relationship between the UK and the EU. On 24 December 2020, the EU and UK
reached an agreement in principle on the framework for their future relationship, the EU-UK Trade and Cooperation Agreement (the &#8220;Trade
Agreement&#8221;), which took effect on May 1, 2021. The Trade Agreement primarily focuses on ensuring free trade between the EU and
the UK in relation to goods. The Trade Agreement does not however, specifically address medical devices. The Trade Agreement seeks to
ensure that the parties ensure &#8220;regulatory cooperation&#8221;. Among the changes that will now occur are that Great Britain (England,
Scotland and Wales) will be treated as a third country. Northern Ireland will, with regard to EU regulations, continue to follow the
EU regulatory rules. In light of the fact that the CE marking process is set out in EU law, which no longer applies in the UK, the UK
has devised a new route to market culminating in a UK Conformity Assessed (&#8220;UKCA&#8221;) mark to replace the CE mark. Northern
Ireland will, however, continue to be covered by the regulations governing CE marks. As part of the Trade Agreement, the EU and the UK
have agreed to continue to recognize declarations of conformity based on a self-assessment in the other territory. On July 1, 2023, The
UK Medical Device Regulations 2002 (SI 2002 No 618, as amended) (&#8220;UK MDR&#8221;) was amended to extend the acceptance of CE marked
medical devices on the Great Britain market up to June 30, 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are working on NTM lung infection which is very rare.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NTM
lung infection is a very rare disease and only a small number of people suffer from this condition. As a result of these small numbers,
we may not be able to complete the study related to NTM or, even if approved, the device for that indication may never be profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are working on bronchiolitis that usually is caused by the RSV virus and any related trials we conduct are dependent on a number of factors
outside of our control, which may lead to varied trial results and possibly delays in our plans.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSV
is a seasonal virus (only in the winter). For any RSV related clinical trial that we pursue, we are heavily dependent on the occurrence
and the severity of this virus. Treating for RSV is highly reliant on the weather conditions in winter. The weather in the winter is
not predictable. For example, if the winter is warm or short, or the RSV infection was not severe enough when we conducted our trial,
or the length of stay in the hospital at the year that trial was conducted was different from previous seasons, then we might miss the
optimal trial season or the results can be significantly different between two seasons or between different countries or even between
different sites. Due to these factors, it may take us longer than anticipated to obtain data from RSV related trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
subsidiaries are exploring novel therapeutic processes with NO and once they put forth product candidates, those product candidates are
likely to be classified as pharmaceutical drugs by the FDA; pharmaceutical regulation is more stringent than the standards to which our
current approved product is subject, and as such, as our subsidiaries&#8217; research and results expand, the Company&#8217;s regulatory
and related costs will increase, which may affect our financial results, in particular, to the extent that these therapies remain investigative
and do not lead to the outcomes anticipated.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect the novel nature of our subsidiaries&#8217; product candidates to create challenges in obtaining regulatory approval, and we anticipate
that they may likely be classified as drug product candidates based on the therapeutic processes being created. The FDA has limited experience
with the commercial development of NO-related drug therapies for cancer and autism, respectively. Accordingly, the regulatory approval
pathway for such future product candidates may be uncertain, and complex, in addition to being expensive and lengthy, and approval may
not be obtained. Beyond Cancer&#8217;s research data has shown that UNO has anticancer properties and elicits an immune response from
the host. Beyond Cancer utilizes an intratumoral UNO technology as a gas delivery of NO at high concentrations to tumors to induce an
immune response. Gas based intratumoral therapies for the treatment of cancer are considered novel and new medical science. Beyond Cancer&#8217;s
efforts are currently also focused on utilizing UNO in combination with Keytruda, a PD-1 inhibitor or other PD-1 or PDL-1 inhibitors
as a treatment for cancers. To date, no such gas-based therapy has been approved for commercialization by the FDA or other regulatory
agencies. As a result, the processes and requirements imposed by relevant regulatory authorities in multiple jurisdictions for these
future pharmaceutical product candidates may cause delays and additional costs in obtaining approvals for marketing authorization. Likewise,
pharmaceutical regulation as opposed to medical device regulation, requires different clearance standards than those the Company is currently
subject to, in order to conduct business. As a result, once our subsidiaries go through initial preclinical research and expand into
clinical trials, they are likely to face additional cost burdens in order to get a product candidate to market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
trials are necessary to support our future product submissions to the FDA and such trials involve regulatory complexity, are lengthy,
iterative and involve working with third parties, including CROs and patients for enrollment. These and other factors may affect our
ability to complete clinical trials and may lead to delays or failures that would affect our business and financial prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiating
and completing clinical trials necessary to support any future PMAs, and additional safety and efficacy data beyond that typically required
for a 510(k) clearance, for our possible future product candidates, will be time-consuming and expensive and the outcome uncertain. Moreover,
the results of early clinical trials are not necessarily predictive of future results, and any product we advance into clinical trials
may not have favorable results in later clinical trials. The results of preclinical studies and clinical trials of our products and product
candidates conducted to date and ongoing or future studies and trials of our current, planned or future products may not be predictive
of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Our interpretation
of data and results from our clinical trials do not ensure that we will achieve similar results in future clinical trials. In addition,
preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their
products performed satisfactorily in preclinical studies and earlier clinical trials have nonetheless failed to replicate results in
later clinical trials. Products in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed
through nonclinical studies and earlier clinical trials. Failure can occur at any stage of clinical testing. Our clinical trials may
produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and non-clinical
testing in addition to those we have planned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initiation and completion of our clinical trials may be prevented, delayed, or halted for numerous reasons. We may experience delays
in our ongoing clinical trials for a number of reasons, which could adversely affect the costs, timing or successful completion of our
clinical trials, including related to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to submit an IDE application to the FDA, which must become effective prior to commencing certain human clinical trials
    of medical devices, and the FDA may reject our IDE application and notify us that we may not begin clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
    and other comparable foreign regulatory authorities may disagree as to the design or implementation of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
    and/or an IRB, or other reviewing bodies may not authorize us or our investigators to commence a clinical trial, or to conduct or
    continue a clinical trial at a prospective or specific trial site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not reach agreement on acceptable terms with prospective contract research organizations (&#8220;CROs&#8221;) and clinical trial
    sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical
    trials or abandon product development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of subjects or patients required for clinical trials may be larger than we anticipate, enrollment in these clinical trials
    may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time may be high
    and result in fewer available patients for any given clinical trial, or patients may drop out of these clinical trials at a higher
    rate than we anticipate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    third-party contractors, including those manufacturing products or conducting clinical trials on our behalf, may fail to comply with
    regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    might have to suspend or terminate clinical trials for various reasons, including a finding that the subjects are being exposed to
    unacceptable health risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may have to amend clinical trial protocols or conduct additional studies to reflect changes in regulatory requirements or guidance,
    which we may be required to submit to an IRB and/or regulatory authorities for re-examination;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators,
    IRBs, or other parties may require or recommend that we or our investigators suspend or terminate clinical research for various reasons,
    including safety signals or noncompliance with regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of clinical trials may be greater than we anticipate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    sites may not adhere to the clinical protocol or may drop out of a clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to recruit a sufficient number of clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators,
    IRBs, or other reviewing bodies may fail to approve or subsequently find fault with our manufacturing processes or facilities of
    third-party manufacturers with which we enter into agreement for clinical and commercial supplies, the supply of devices or other
    materials necessary to conduct clinical trials may be insufficient, inadequate or not available at an acceptable cost, or we may
    experience interruptions in supply;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    policies or regulations of the FDA or comparable foreign regulatory authorities may change in a manner rendering our clinical data
    insufficient for certification or approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    current or future products may have undesirable side effects or other unexpected characteristics; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impacts
    of regional or global public health crises, such as the COVID-19 pandemic, could adversely affect any clinical trials we are conducting
    or plan to conduct, including delays or difficulties in enrolling or onboarding patients, initiating clinical sites, or obtaining
    the requisite certification or regulatory approvals, interruption of key clinical trial activities, or supply chain disruptions that
    delay or make it more difficult or costly to obtain the supplies and materials we need for clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause,
or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of certification or regulatory
approval of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials must be conducted in accordance with the laws and regulations of the FDA and other comparable foreign regulatory authorities&#8217;
legal requirements, regulations or guidelines, and are subject to oversight by these governmental authorities and IRBs at the medical
institutions where the clinical trials are conducted. Conducting successful clinical trials will require the enrollment of large numbers
of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of
patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol,
the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of
appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites and able to comply with the eligibility
and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged from
enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess
the safety and effectiveness of our products or if they determine that the treatments received under the trial protocols are not attractive
or involve unacceptable risks or discomforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with Good Clinical Practice
(&#8220;GCP&#8221;) requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail
to conduct the study to GCP standards or are delayed for a significant time in the execution of trials, including achieving full enrollment,
we may be affected by increased costs, program delays or both. In addition, clinical trials that are conducted in countries outside the
United States may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements
and the engagement of non-U.S. CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA,
and different standards of diagnosis, screening and medical care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
of sufficient and appropriate clinical protocols to demonstrate safety and efficacy are required and we may not adequately develop such
protocols to support clearance and approval. Further, the FDA may require us to submit data on a greater number of patients than we originally
anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical
trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs
and delays in the approval and attempted commercialization of our products or result in the failure of the clinical trial. In addition,
despite considerable time and expense invested in our clinical trials, the FDA may not consider our data adequate to demonstrate safety
and efficacy. Such increased costs and delays or failures could adversely affect our business, operating results and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our products are approved or cleared in the United States and CE marked in the EEA in the future, comparable regulatory authorities
of additional foreign countries must also approve the manufacturing and marketing of our products in those countries, should we desire
to access those markets. Certification, approval and clearance procedures vary among jurisdictions and can involve requirements and administrative
review periods different from, and greater than, those in the United States or the EEA, including additional preclinical studies or clinical
trials. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may experience delays in obtaining a CE mark in the EEA for our approved product due to possible EU MDR regulatory classification that
differs from the FDA&#8217;s regulatory paradigm.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, we expect that, if approved, our products would be classified as a medical device. However, competent regulatory authorities
in EEA countries or notified bodies could disagree and consider our products to be a drug-delivery combination product composed of a
medical device and a medicinal product. In the EEA, drug-delivery systems can fall within the scope of the medical device legislation
or the pharmaceutical legislation depending on their combination with the relevant medicinal substance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our device is considered as being intended to administer a medicinal product and our device and the medicinal product are placed on the
market in such a way that they form a single integral product which is intended exclusively for use in the given combination and which
is not reusable, that single integral product shall be governed by Directive 2001/83/EC and be subject to a marketing authorization.
The medical device part of the drug-delivery combination product would not need to be CE marked. However, the relevant general safety
and performance requirements set out in Annex I to the EU MDR would apply as far as the safety and performance of the device part of
the single integral product are concerned. As a result, we would need to pursue different regulatory pathways for placing our product
on the EEA market which may lead to additional costs and time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may find it difficult to enroll patients in our clinical trials. Difficulty in enrolling patients could delay or prevent clinical trials
of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical
trials depends in part on the speed at which we can recruit patients to participate in testing our product candidates, and we may experience
delays in our clinical trials if we encounter difficulties in enrollment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the conditions for which we plan to evaluate our current product candidates are for rare diseases. For example, we estimate that 15,000
patients suffer from refractory NTM lung infection in the U.S. Accordingly, there is a limited patient pool from which to draw for clinical
trials. Further, the eligibility criteria of our clinical trials will further limit the pool of available study participants as we will
require that patients have specific characteristics that we can measure or to assure their disease is either severe enough or not too
advanced to include them in a study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the process of finding patients may prove costly. We also may not be able to identify, recruit and enroll a sufficient number of patients
to complete our clinical trials because of the perceived risks and benefits of the product candidate under study, particularly the toxicity
of NO in certain doses, the availability and efficacy of competing therapies and clinical trials, the proximity and availability of clinical
trial sites for prospective patients and the patient referral practices of physicians. If patients are unwilling to participate in our
studies for any reason, the timeline for recruiting patients, conducting studies and obtaining certification or regulatory approval of
potential products will be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in the completion or termination of any clinical trial of our product candidates, the commercial prospects of our
product candidates will be harmed, and our ability to generate product revenue from any of these product candidates could be delayed
or prevented. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development
and certification or approval process and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences
may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay
in the commencement or completion of clinical trials may also ultimately lead to the denial of certification or regulatory approval of
our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may encounter substantial delays in our clinical trials, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable
regulatory authorities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining certification or marketing approval from regulatory authorities and notified bodies for the sale of our product candidates,
we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing
is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or
completed on schedule, if at all. Our clinical trials involve infants, children, and adults and, before we are permitted to enroll them
in clinical trials, we must demonstrate that although the research may pose a risk to the subjects, there is a prospect of direct benefit
to each patient. We must do so to the satisfaction of each research site&#8217;s IRB. If we fail to adequately demonstrate this to the
satisfaction of the relevant IRB, it will decline to approve the research, which could have significant adverse consequences for us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Events
that may prevent successful or timely completion of clinical development include but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of human clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching a consensus with regulatory authorities on study design;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive
    negotiation and may vary significantly among different CROs and clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining required IRB approval at each clinical trial site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of a clinical hold by regulatory authorities, after review of an IDE application or equivalent application, or an inspection of our
    clinical trial operations or study sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in recruiting suitable patients to participate in our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    collaborating with patient groups and investigators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by our CROs, other third parties or us to adhere to clinical trial requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to perform in accordance with the FDA&#8217;s GCP requirements, or applicable regulatory guidelines in other foreign countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in having patients complete participation in a study or return for post-treatment follow-up;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
    of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of clinical trials of our product candidates being greater than we anticipate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trials of our product candidates producing negative or inconclusive results, which may result in us deciding, or regulators requiring
    us, to conduct additional clinical trials or abandon product development programs; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for
    use in clinical trials or the inability to do any of the foregoing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability
to generate revenue. We may also be required to conduct additional safety, efficacy and comparability studies before we will be allowed
to start clinical trials. Clinical trial delays could also shorten any periods during which our products have patent protection and may
allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product
candidates and may harm our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates may cause undesirable side effects or have other properties that could delay or prevent their certification or regulatory
approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval,
if any.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and
could result in a more restrictive marketing label or the delay or denial of certification or regulatory approval by the FDA or other
comparable foreign regulatory authorities. There is currently limited data regarding possible side effects for an antimicrobial dosage
of NO treatments, such as our product candidates. Potential side effects of NO treatments may include high MetHb, NO<sub>2</sub> toxicity,
nose bleeding and low blood pressure. Results of our studies may identify unacceptable severity and prevalence of these or other side
effects. In such an event, our studies could be suspended or terminated, and the FDA or comparable foreign regulatory authorities or
notified bodies could order us to cease further development of or deny certification or approval of our product candidates for any or
all targeted indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO-related
side effects could affect patient recruitment, the ability of enrolled patients to complete the study or result in potential product
liability claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if our product candidates receive certification or marketing approval, and we or others later identify undesirable side effects caused
by such products, a number of potentially significant negative consequences could result, including but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities and notified bodies may withdraw certification or approvals of such product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the label;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and
could significantly harm our business, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Reliance on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on third parties to conduct our preclinical studies and clinical trials and perform other tasks for us. If these third parties do
not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able
to obtain certification or regulatory approval for or commercialize our approved product or product candidates and our business could
be substantially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied on and plan to continue to rely on third-party CROs to monitor and manage data for our ongoing preclinical and clinical programs.
We rely on these parties for execution of our preclinical studies and clinical trials, and we directly control only certain aspects of
their activities, although from a regulatory perspective we are responsible for their actions. We are responsible for ensuring that each
of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on
the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with GCP, QSR
and GLP, which are regulations and guidelines enforced by the FDA, the competent authorities of the EEA countries, and comparable foreign
regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these regulations through
periodic inspections of study sponsors, principal investigators, study sites and other contractors. If we or any of our CROs or vendors
fail to comply with applicable regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or
comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications.
We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical
trials comply with GCP regulations. In addition, our clinical trials must be conducted with products that are produced under QSR regulations.
Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the certification or regulatory
approval process, or have other adverse consequences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or
do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our
agreements with such CROs, we cannot control whether they devote sufficient time and resources to our on-going clinical, nonclinical
and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if
they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to
our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and
we may not be able to obtain certification or regulatory approval for or successfully commercialize our approved product or product candidates.
CROs may also generate higher costs than anticipated. As a consequence, our results of operations and the commercial prospects for our
approved product or product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Switching
or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition
period when a new CRO commences work. As a result, delays may occur, which could materially impact our ability to meet our desired clinical
development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter
similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business,
financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on third parties to manufacture our NO generator and delivery system. Our business could be harmed if those third parties fail to
provide us with sufficient quantities of our needed supplies, or fail to do so at acceptable quality levels or prices. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have the infrastructure or capability internally to manufacture the components of our NO generator and delivery system,
and we lack the resources and the capability to manufacture our approved product or any of our product candidates on a clinical or commercial
scale. We rely on third parties for such supplies. There are a limited number of manufacturers who have the ability to produce our delivery
system, and there may be a need to identify alternate manufacturers to prevent a possible disruption of our clinical trials. Any significant
delay or discontinuity in the supply of these components could considerably delay commercialization of our approved product, completion
of our clinical trials, product testing and potential certification or regulatory approval of our product candidates, which could harm
our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
and our collaborators and contract manufacturers are subject to significant regulation with respect to manufacturing our approved product
or product candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited
capacity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
entities involved in the preparation of medical devices for clinical trials or commercial sale, including our existing contract manufacturers
for our approved product and product candidates, are subject to extensive regulation. Components of a finished medical device product
approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with QSR in the U.S., and similar
requirements in foreign countries. These regulations govern manufacturing processes and procedures (including record keeping) and the
implementation and operation of quality systems to control and assure the quality of investigational products and products approved for
sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or
stability of our approved product or product candidates that may not be detectable in final product testing. We, our collaborators or
our contract manufacturers must supply all necessary documentation in support of any marketing application on a timely basis and must
adhere to GLP and QSR regulations enforced by the FDA and comparable foreign regulatory authorities through their facilities inspection
program. The facilities and quality systems of some or all of our collaborators and third-party contractors must pass a pre-approval
inspection for compliance with the applicable regulations as a condition of certification or regulatory approval of our product candidates
or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility
involved with the preparation of our approved product, product candidates or our other potential products or the associated quality systems
for compliance with the regulations applicable to the activities being conducted. We do not control the manufacturing process of, and
are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities
do not pass a pre-approval plant inspection, certification or regulatory approval of the products may not be granted or may be substantially
delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulatory authorities also may, at any time following certification or approval of a product for sale, audit the manufacturing facilities
of our collaborators and third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations
or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the
relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement,
and that may include the temporary or permanent suspension of a clinical trial or commercial sales, or the temporary or permanent closure
of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.
If we, our collaborators, or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or comparable foreign
regulatory authorities can impose regulatory sanctions including, among other things, refuse to approve a pending application for a new
product, withdrawal of a certification or approval, suspend production, suspend clinical trials, require a recall or suspension of production.
As a result, our business, financial condition and results of operations may be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through a PMA Supplement
or Marketing Authorization Application amendment, or equivalent foreign regulatory filing, which could result in further delays. The
regulatory authorities may also require additional studies if a new manufacturer is relied on for commercial production. Switching manufacturers
may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors could cause us to incur higher costs and could cause the delay or termination of clinical trials, regulatory submissions, required
certification or approvals or commercialization of our approved product or product candidates. Furthermore, if our suppliers fail to
meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially
equivalent cost, our clinical trials may be delayed or we could lose potential revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we encounter issues with our contract manufacturers or suppliers, we may need to qualify alternative manufacturers or suppliers, which
could impair our ability to sufficiently and timely manufacture and supply LungFit<sup>&#174;</sup> PH</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently depend on contract manufacturers and suppliers for LungFit<sup>&#174;</sup> PH and its components. Although we could obtain
each of these components from other third-party suppliers, we would need to qualify and obtain FDA approval for another contract manufacturer
or supplier as an alternative source for each such component, which could be costly and cause significant delays. Each of our current
commercial manufacturing and supply agreements include limitations on our ability to utilize alternative manufacturers or suppliers for
these components above certain specified thresholds during the terms of the agreements, which impairs our ability to fully implement
any future manufacturing strategies to prevent supply shortages or quality issues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, some of our suppliers and contract manufacturers, including Spartronics and Medisize, conduct their manufacturing operations
for us at a single facility. Unless and until we qualify additional facilities, we may face limitations in our ability to respond to
manufacturing and supply issues. For example, if regulatory, manufacturing or other problems require one of these manufacturers or suppliers
to discontinue production at their respective facility, or if the equipment used for the production of LungFit<sup>&#174;</sup> PH in
these facilities is significantly damaged or destroyed by fire, flood, earthquake, power loss or similar events, the ability of such
manufacturer or supplier to provide components needed for LungFit<sup>&#174;</sup> PH, or to manufacture LungFit<sup>&#174;</sup> PH may
be significantly impaired. In the event that these parties suffer a temporary or protracted loss of its facility or equipment, we would
still be required to obtain FDA approval to qualify a new manufacturer or supplier, as applicable, as an alternate manufacturer or source
for the respective component before any components manufactured by such manufacturer or by such supplier could be sold or used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
production shortfall that impairs the supply of LungFit<sup>&#174;</sup> PH or any of these components could have a material adverse effect
on our business, financial condition and results of operations and adversely affect our ability to satisfy demand for LungFit<sup>&#174;
</sup>PH, which could adversely affect our product sales and operating results materially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on third-party manufacturers, including sole source suppliers, to manufacture LungFit<sup>&#174;</sup> PH and our product candidates
and the materials we require for our clinical trials. We may not be able to maintain these relationships and could experience supply
disruptions outside of our control.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on a network of third-party manufacturers to manufacture and supply LungFit<sup>&#174;</sup> PH for commercial sale and post-certification/approval
clinical trials, and our product candidates for clinical trials and any commercial sales if they are approved. As a result of our reliance
on these third-party manufacturers and suppliers, including sole source suppliers of certain components of LungFit<sup>&#174;</sup> PH
and our product candidates, we could be subject to significant supply disruptions, in particular, should any issues occur with our sole
source suppliers. Our supply chain for sourcing raw materials and manufacturing our products ready for distribution is a multi-step endeavor.
In some cases, third-party contract manufacturers supply us with raw materials, and contract manufacturers in the United States convert
these raw materials into substances from which we need to test our product&#8217;s final dosage. Establishing and managing this supply
chain requires a significant financial commitment and the creation and maintenance of numerous third-party contractual relationships.
Although we attempt to effectively manage the business relationships with companies in our supply chain, we do not have control over
their operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
require a supply of LungFit<sup>&#174;</sup> PH for sale in the United States and international markets. We currently rely, and expect
to continue to rely, on sole source third party manufacturers to produce starting materials, substance, and final product, and to package
and label LungFit<sup>&#174;</sup> PH and our product candidates. While we have identified and expect to qualify and engage back-up third
party manufacturers as additional or alternative suppliers for the commercial supply of LungFit<sup>&#174; </sup>PH, we currently do not
have such arrangements in place. Moreover, some of these alternative manufacturers will have to be approved by the FDA before we can
use them for manufacturing LungFit<sup>&#174;</sup> PH. It is also possible that supplies of materials that cannot be second-sourced can
be managed with inventory planning. There can be no assurance, however, that failure of any of our original sole source third-party manufacturers
to meet our commercial demands for LungFit<sup>&#174;</sup> PH in a timely manner, or our failure to engage qualified additional or back-up
suppliers for the commercial supply of LungFit<sup>&#174;</sup> PH, would not have a material adverse effect on commercialization of LungFit<sup>&#174;</sup>
and our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supply
disruptions may result from a number of factors, including shortages in product raw materials, labor or technical difficulties, regulatory
inspections or restrictions, shipping or customs delays or any other performance failure by any third-party manufacturer on which we
rely. Any supply disruptions could disrupt sales of LungFit<sup>&#174;</sup> PH and/or the timing of our clinical trials, which could
have a material adverse impact on our business. Furthermore, we may be required to modify our production methods to permit us to economically
manufacture our product for sale and our product candidates for clinical trials. These modifications may require us to re-evaluate our
resources and the resources of our third-party manufacturers, which could result in abrupt changes in our production methods and supplies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the course of providing its services, a contract manufacturer may develop process technology related to the manufacture of our products
or product candidates that the manufacturer owns, either independently or jointly with us. This would increase our reliance on that manufacturer
or require us to obtain a license from that manufacturer in order to have LungFit<sup>&#174;</sup> PH or our product candidates manufactured
by other suppliers utilizing the same process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the year ended March 31, 2026, the Company purchased approximately 74% and 18% of its materials from two third-party vendors. In the
year ended March 31, 2025, the Company purchased approximately 85% of its materials from a third-party vendor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure of our third-party manufacturers to meet our commercial demands for LungFit<sup>&#174;</sup> PH in a timely manner, or our failure
to engage qualified additional or back-up suppliers for the commercial supply of LungFit<sup>&#174;</sup> PH, would have a material adverse
effect on our business, results of operations and financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover
them or that our trade secrets will be misappropriated or disclosed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we rely on third parties to develop and manufacture LungFit<sup>&#174;</sup> PH and our product candidates, we must, at times, share trade
secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable,
material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators,
advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit
the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions
employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that
such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or
used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s
discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material
adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to obtain and maintain effective patent rights for LungFit<sup>&#174;</sup> PH, our product candidates or any future product
candidates, we may not be able to compete effectively in our markets.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related
to our technologies, approved product and product candidates. Our success depends in large part on our and our licensors&#8217; ability
to obtain and maintain intellectual property protection in the U.S. and in other countries with respect to our proprietary technology
and products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have sought to protect our proprietary position by filing patent applications in the U.S. and abroad related to our novel technologies
and products that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute
all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may also fail to identify patentable aspects
of our research and development output before it is too late to obtain patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of medical device, biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal
and factual questions for which legal principles remain unsolved. The patent applications that we own or in-license may fail to result
in issued patents with claims that cover our approved product or product candidates in the U.S. or in other foreign countries. There
is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate
a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such
patents cover our approved product or product candidates, third parties may challenge their validity, enforceability or scope, which
may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patents
and patent applications may not adequately protect our intellectual property, provide exclusivity for our approved product or product
candidates or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition
from third parties, which may have an adverse impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed several patent applications directed to various aspects of our approved product and product candidates. We cannot offer any
assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid
and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or
licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of our approved product
or any product candidates that we may develop. Further, if we encounter delays in certification or regulatory approvals, the period of
time during which we could market a product candidate under patent protection could be reduced. In addition, some or all of our patent
applications may not result in issued patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot obtain and maintain effective patent rights for our approved product or product candidates, we may not be able to compete effectively
and our business and results of operations would be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights of third parties could adversely affect our ability to commercialize our approved product or product candidates, and
we might be required to litigate or obtain licenses from third parties in order to develop or market our approved product or product
candidates. Such litigation or licenses could be costly or not available on commercially reasonable terms.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the number of companies developing various types of NO devices, it is difficult to conclusively assess our freedom to operate without
infringing on third-party rights. There are numerous companies that have pending patent applications and issued patents in the field
of therapeutic NO delivery. Our competitive position may suffer if patents issued to third parties or other third-party intellectual
property rights cover our products or elements thereof, or our manufacture or uses relevant to our development plans. In such cases,
we may not be in a position to develop or commercialize our approved product or product candidates unless we successfully pursue litigation
to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual
property right holder, if available on commercially reasonable terms. There may be pending patent applications of which we are not aware,
that if they result in issued patents, could be alleged to be infringed by our approved product or product candidates. If such an infringement
claim should be brought and be successful, we may be required to pay substantial damages, be forced to abandon our approved product or
product candidates or seek a license from any patent holders. No assurances can be given that a license will be available on commercially
reasonable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also possible that we have failed to identify relevant third-party patents or applications. Patent applications in the U.S. and elsewhere
are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly
referred to as the priority date. Therefore, patent applications covering our approved product, product candidates or platform technology
could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject
to certain limitations, be later amended in a manner that could cover our platform technologies, our approved product or product candidates
or the use of our approved product or product candidates. Third-party intellectual property right holders may also actively bring infringement
claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If
we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable
and time-consuming litigation and may be prevented from or experience substantial delays in pursuing the development of and/or marketing
our approved product or product candidate. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily
or permanently prohibited from commercializing our approved product or product candidate that is held to be infringing. We might, if
possible, also be forced to redesign our approved product or product candidate so that we no longer infringe the third-party intellectual
property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management
resources that we would otherwise be able to devote to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
terms are limited and we may not be able to effectively protect our products and business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan. In the U.S., the natural expiration of a patent is generally 20 years after it is filed. Although various extensions
may be available, the life of a patent, and the protection it affords, is limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, upon issuance in the U.S., the patent term may be extended based on certain delays caused by the applicant(s) or the U.S. Patent
and Trademark Office (&#8220;USPTO&#8221;). Even if we obtain effective patent rights for our approved product or product candidates,
we may not have sufficient patent terms or regulatory exclusivity to protect our products, and our business and results of operations
would be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement
or defense of our issued patents.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of our patents
or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws
of the U.S. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications
in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. We therefore
cannot be certain that we or our licensor were the first to make the invention claimed in our owned and licensed patents or pending applications,
or that we or our licensor were the first to file for patent protection of such inventions. Assuming the other requirements for patentability
are met, in the U.S. prior to March 15, 2013, the first to invent the claimed invention is entitled to the patent, while outside the
U.S., the first to file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act
(&#8220;Leahy-Smith Act&#8221;), enacted on September 16, 2011, the U.S. moved to a first-to-file system. The Leahy-Smith Act also includes
a number of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. The
effects of these changes are currently unclear as the USPTO must still implement various regulations, the courts have yet to address
these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and
would need to be reviewed. In general, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding
the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse
effect on our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to maintain effective proprietary rights for our approved product, product candidates or any future product candidates,
we may not be able to compete effectively in our markets.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary
know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements
of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not
covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes,
in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, vendors, collaborators and
contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security
of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals,
organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In
addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology
enter into confidentiality agreements and we expect they will assign all rights in their inventions to us pursuant to the terms of such
agreements; however, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and
other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets
or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade
secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken
to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the
trade secret.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third-party
claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There have been
many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries,
including with respect to NO delivery systems and formulations, including patent infringement lawsuits, interferences, oppositions and
reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending
patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology
and pharmaceutical industries expand and more patents are issued, the risk increases that our approved product or product candidates
may be subject to claims of infringement of the patent rights of third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent
applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture
of our approved product or product candidates. We do not know whether there are any third-party patents that would impair our ability
to commercialize our approved product or such product candidates. We also cannot be sure that we have identified each and every patent
and pending patent application in the U.S. and abroad that is relevant or necessary to the commercialization of our approved product
and product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications
that may later result in issued patents that our approved product or product candidates may infringe. In addition, third parties may
obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held
by a court of competent jurisdiction to cover the manufacturing process of our approved product or any of our product candidates, any
molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our
ability to continue commercializing our approved product or such product candidates unless we obtained a license under the applicable
patents, or until such patents expire or are finally determined to be invalid or unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture
or methods of use, the holders of any such patents may be able to block our ability to develop and commercialize our approved product
or the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid
or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties
making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop
and further commercialize our approved product or one or more of our product candidates. Defense of these claims, regardless of their
merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In
the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217;
fees for willful infringement, pay royalties, redesign our &#8220;infringing&#8221; products or obtain one or more licenses from third
parties, which may be impossible or require substantial time and monetary expenditure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in obtaining or maintaining necessary rights to our approved product or product candidates through acquisitions
and in-licenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently own and have in-licensed rights to intellectual property through licenses from third parties and under patents that we own,
to develop our approved product and product candidates. Because our programs may require the use of proprietary rights held by third
parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.
In addition, our approved product or product candidates may require specific formulations to work effectively and efficiently and the
rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes
or other third-party intellectual property rights from third parties that we identify as necessary for our approved product or product
candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established
companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive.
These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development
and commercialization capabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development underwritten
agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s
rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the
specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property
rights to other parties, potentially blocking our ability to pursue our program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to
license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.
If we are unable to successfully obtain rights to required third-party intellectual property rights, we may have to abandon development
of that program and our business and financial condition could suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with our obligations in the agreements under which we license intellectual property and other rights from third parties
or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important
to our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are party to intellectual property license agreements that are important to our business, and we may enter into additional license agreements
in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone
payment, royalty and other obligations on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensing
of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes
may arise regarding intellectual property subject to a licensing agreement, including but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing
    agreement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sublicensing of patent and other rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and
    our collaborators; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    priority of invention of patented technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current licensing
arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected approved product or product
candidates and this may affect our financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be involved in lawsuits or post-grant proceedings to protect or enforce our patents or the patents of our licensor, which could be
expensive, time-consuming and unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may face risk if our competitors infringe the patents of any licensor with whom we may be involved. If any such licensing partner were
to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim
that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims
alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any
of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion
could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a
misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
patent applications may be subject to third-party pre-issuance submission of prior art to the USPTO, and any patents issuing thereon
may become involved in derivation, reexamination, inter parties review, post grant review, interference proceedings or other patent office
proceedings in the U.S. challenging our patent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceedings
provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect
to our patents or patent applications or those of our licensor. An unfavorable outcome could require us to cease using the related technology
or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer
us a license on commercially reasonable terms. Our defense of litigation or proceedings may fail and, even if successful, may result
in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could
have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs,
license necessary technology from third parties or enter into development partnerships that would help us bring our approved product
and product candidates to market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements
of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, it could have a material adverse effect on the price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information
of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors
or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary
information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent
contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information,
of any of our employee&#8217;s former employer or other third parties. Litigation may be necessary to defend against these claims. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel,
which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management and other employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims challenging the inventorship of our patents and other intellectual property.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to claims that former employees, collaborators or other third parties have an interest in or right to compensation with
respect to our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise
from conflicting obligations of consultants or others who are involved in developing our approved product or product candidates. Litigation
may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation. If we fail
in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive
ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management
and other employees. To the extent that our employees have not effectively waived the right to compensation with respect to inventions
that they helped create, they may be able to assert claims for compensation with respect to our future revenue may be successful. As
a result, we may receive less revenue from future products if such claims are successful which in turn could impact our future profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity. Therefore, obtaining
and enforcing biotechnology patents is costly, time-consuming and inherently uncertain. In addition, the U.S. has recently enacted and
is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent
protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing
uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect
to the value of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws
and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce
our existing patents and patents that we might obtain in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property rights throughout the world.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents on our approved product or product candidates in all countries throughout the world would be prohibitively
expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition,
the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export
otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These
products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent
them from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets
and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for
us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings
to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts
and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our
patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits
that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce
our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we develop or license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
manage our business through a small number of employees and key consultants.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026, we had a total of 54 full-time employees between us and our subsidiaries and a number of dedicated consultants, all
of whom work for us on a part-time basis. In addition, any of our employees and consultants may leave the Company at any time, subject
to certain notice periods. The loss of the services of any of our executive officers or any key employees or consultants would adversely
affect our ability to execute our business plan and harm our operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently carry &#8220;key person&#8221; insurance on the lives of members of management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may need to expand our organization and we may experience difficulties in recruiting needed additional employees and consultants, which
could disrupt our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our development and commercialization plans and strategies develop, we may need additional managerial, operational, sales, marketing,
financial, legal and other resources. The competition for qualified personnel in the life sciences field is intense. Due to this intense
competition, we may be unable to attract and retain qualified personnel necessary for the development of our business or to recruit suitable
replacement personnel. We may experience difficulty retaining and motivating existing employees and attracting qualified personnel to
fill key positions. In addition, labor shortages and employee mobility may make it more difficult to hire and retain employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial
amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may
result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity
among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from
other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth,
our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to
implement our business strategy. Our future financial performance and our ability to commercialize our approved product and compete effectively
will depend, in part, on our ability to effectively manage any future growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
international operations and plans to expand such operations present challenges and risks related to doing business internationally.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
expansion of our business further exposes us to business, regulatory, political, operational, financial and economic risks associated
with doing business outside of the U.S., the EEA or Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than our operations that are located in the EEA and Israel (as further described below), we currently have limited international operations,
but our business strategy incorporates potentially significant international expansion, particularly in anticipation of certification
or regulatory approval of our product candidates. We plan to maintain non-commercial infrastructure and conduct physician and patient
association outreach activities, as well as clinical trials, outside of the U.S., the EEA and Israel. Doing business internationally
involves a number of risks, including but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple,
    conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws,
    regulatory requirements and other governmental certification, approvals, permits and licenses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by us to obtain certification or regulatory approvals for the use of our products in various countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    potentially relevant third-party patent rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities
    and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in staffing and managing foreign operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities
    associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits
    on our ability to penetrate international markets;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
    risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises
    on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
    disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment
    of trade and other business restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    expenses including, among others, expenses for travel, translation and insurance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the
    purview of the FCPA, its books and records provisions or its anti-bribery provisions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conditions
in Israel may materially and adversely affect the Company&#8217;s business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are currently operating in
a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due
to the ongoing conflicts in the Middle East, including conflicts involving Iran and Israel. On February 28, 2026, a significant military
conflict commenced involving the United States, the State of Israel, and Iran, significantly escalating regional hostilities. This situation
has led to the declaration of a nationwide state of emergency in Israel, the closure of regional airspace, and retaliatory missile strikes
impacting multiple nations in the Middle East.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any armed conflicts, terrorist activities or political instability involving
Israel or other countries in the region could adversely affect the Company&#8217;s business. Moreover, the Company has a significant
number of employees located in Israel. The Company&#8217;s operations could also be disrupted by the absence for significant periods
of one or more key employees or a significant number of other employees because of military service. While there are business continuity
plans in place to address the military call-ups, any of these circumstances could have a material adverse effect on the Company&#8217;s
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although the length and impact
of the ongoing military conflict is highly unpredictable, the impact of these military conflicts could lead to market disruptions, including
significant volatility in prices, credit and capital markets, as well as supply chain interruptions. Disruption of global financial markets
and a recession or market correction, including the significant tariffs imposed by the United States on imports from other countries and
other global macroeconomic factors such as inflation and rising interest rates, could reduce our ability to access capital, which could
in the future negatively affect our liquidity and could materially affect our business. Our business, financial condition and results
of operations may be materially and adversely affected by any negative impact on the global economy and capital markets resulting from
such conflicts or any other geopolitical tensions. U.S. and global markets have experienced and will likely continue to experience volatility
and disruption following the escalation of geopolitical tensions and the start of the conflicts in the Middle East.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
use of any of our products could result in product liability or similar claims that could be expensive, damage our reputation and harm
our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to an inherent risk of potential product liability or similar claims. The medical device industry has historically
been litigious, and we face financial exposure to product liability or similar claims if the use of any of our products were to cause
or contribute to injury or death. There is also the possibility that defects in the design or manufacture of any of our products might
necessitate a product recall. Although we maintain product liability insurance, the coverage limits of these policies may not be adequate
to cover future claims. In the future, we may be unable to maintain product liability insurance on acceptable terms or at reasonable
costs and such insurance may not provide us with adequate coverage against potential liabilities. A product liability claim, regardless
of merit or ultimate outcome, or any product recall could result in substantial costs to us, damage to our reputation, customer dissatisfaction
and frustration and a substantial diversion of management attention. A successful claim brought against us in excess of, or outside of,
our insurance coverage could have a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Natural
disasters, geopolitical unrest, war, terrorism, public health issues or other catastrophic events could disrupt the supply, delivery
or demand of products, which could negatively affect our operations and performance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the risk of disruption by earthquakes, floods and other natural disasters, fire, power shortages, geopolitical unrest,
war, terrorist attacks and other hostile acts, public health issues, epidemics or pandemics such as the COVID-19 pandemic, and other
events beyond our control and the control of the third parties on which we depend. Any of these catastrophic events, whether in the United
States, Europe or abroad, may have a strong negative impact on the global economy, our employees, facilities, partners, suppliers, distributors
or customers, and could decrease demand for our products, create delays and inefficiencies in our supply chain and make it difficult
or impossible for us to deliver products to our customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches
and data leakage. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted,
provided and/or used for third parties or their vendors. We may collect, store and transmit large amounts of confidential information
(including personal information and pseudonymized information), and we deploy and operate an array of technical and procedural controls
to maintain the confidentiality and integrity of such confidential information. A significant breakdown, invasion, corruption, destruction,
interruption, or unavailability of critical information technology systems or infrastructure, by our workforce, others with authorized
access to our systems or unauthorized persons could negatively impact operations. Hardware, software, or applications we develop or obtain
from third parties may contain defects in design or manufacture or other supply chain problems that could unexpectedly compromise our
information and network security.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination
or intentional destruction of confidential information stored in our or our third-party providers&#8217; systems, portable media or storage
devices. We could also experience a business interruption, theft of confidential information or reputational damage from industrial espionage
attacks, malware or other cyber-attacks (including ransomware), which may compromise our system infrastructure or lead to data leakage,
either internally or at our third-party providers. While we have invested in the protection of data and information technology, there
can be no assurance that our efforts will prevent service interruptions or security breaches. Any such interruption or breach of our
systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or
intellectual property, and could result in financial, legal, business and reputational harm to us. In addition, as the regulatory environment
related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing
requirements applicable to our business, compliance with those requirements could also result in additional costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Ownership of our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are currently listed on The Nasdaq Capital Market. Our failure to maintain our compliance with Nasdaq&#8217;s continued listing standards
or other requirements could result in our common stock being delisted from Nasdaq, which could adversely affect our liquidity and the
trading volume and market price of our common stock and decrease or eliminate your investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently listed on the Nasdaq Capital Market on Nasdaq under the symbol &#8220;XAIR.&#8221; Nasdaq requires listed issuers
to comply with certain standards in order to remain listed on its exchange. If, for any reason, Nasdaq should delist our securities from
trading on its exchange and we are unable to obtain listing on another reputable national securities exchange, a reduction in some or
all of the following may occur, each of which could materially adversely affect our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we violate Nasdaq&#8217;s listing requirements, or if we fail to meet any of Nasdaq&#8217;s listing standards, our common stock may be
delisted. A delisting of our common stock from Nasdaq may materially impair our stockholders&#8217; ability to buy and sell our common
stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. The delisting
of our common stock could significantly impair our ability to raise capital and the value of your shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 7, 2026, we received a letter from Nasdaq notifying us that we were no longer in compliance with the $1.00 minimum bid price
requirement for continued listing on Nasdaq under the Bid Price Rule. While companies are typically afforded a 180-calendar day
compliance period to comply with the Bid Price Rule, the Notice stated that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), we
were not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that we had effected a
reverse stock split over the prior one-year period. We had effected a 1-for-20 reverse stock split on July 14, 2025. Following a
delisting appeal and hearing, Nasdaq hearing Panel granted our request for continued listing on Nasdaq, subject to certain
conditions. pursuant to Nasdaq Listing Rule 5815(d)(4)(A), we will be subject to a Discretionary Panel Monitor for a period of one
year from the date the Company regains compliance with the Bid Price Rule. If we fail to regain compliance with the Bid Price Rule
by July 31, 2026, or if we fail to continue to meet all applicable continued listing requirements for Nasdaq in the future, Nasdaq
would promptly issue a written determination to delist our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delisting determination by Nasdaq could seriously decrease or eliminate the value of an investment in our common stock and other securities
linked to our common stock. While a listing on an over-the-counter exchange could maintain some degree of a market in our common stock,
we could face substantial material adverse consequences, including, but not limited to, the following: limited availability for market
quotations for our common stock; reduced liquidity with respect to and decreased trading prices of our common stock; a determination
that shares of our common stock are &#8220;penny stock&#8221; under the SEC rules, subjecting brokers trading our common stock to more
stringent rules on disclosure and the class of investors to which the broker may sell the common stock; limited news and analyst coverage
for our Company, in part due to the &#8220;penny stock&#8221; rules; decreased ability to issue additional securities or obtain additional
financing in the future; and potential breaches under or terminations of our agreements with current or prospective large stockholders,
strategic investors and banks. The perception among investors that we are at heightened risk of delisting could also negatively affect
the market price of our securities and trading volume of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive
forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable
judicial forum for disputes with us or our directors, officers or employees.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for (A) any derivative
action or proceeding brought on behalf of us; (B) any action asserting a claim of breach of a fiduciary duty owed by any of our directors,
officers or other employees to us or our stockholders; (C) any action asserting a claim against us arising pursuant to any provision
of the Delaware General Corporation Law, our Amended and Restated Certificate of Incorporation or our Bylaws; or (D) any action asserting
a claim against us governed by the internal affairs doctrine. Section 27 of the Exchange Act creates exclusive federal jurisdiction over
all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result,
the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other
claim for which the federal courts have exclusive jurisdiction. In addition, Section 22 of the Securities Act creates concurrent jurisdiction
for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations
thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the
Securities Act or any other claim for which the federal and state courts have concurrent jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes
with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and
other employees. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation to
be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions,
which could adversely affect our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>T<b>rading
in our common stock has been volatile and may continue to be volatile in the future.</b></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock market in general has experienced extreme price and volume fluctuations. The market prices of the securities of biotechnology and
specialty pharmaceutical companies, particularly companies like ours without product revenues and earnings, have been highly volatile
and may continue to be highly volatile in the future. This volatility has often been unrelated to the operating performance of particular
companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of
our common stock:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
announcements of technological innovations or new products by us or our competitors;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
announcement of FDA/CE approval, disapproval or delay of approval of our product candidates or other product-related actions;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
developments involving our discovery efforts and clinical trials;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
developments or disputes concerning patents or proprietary rights, including announcements of infringement, interference or other litigation
against us or our potential licensees;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
developments involving our efforts to commercialize our products, including developments impacting the timing of commercialization;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
announcements concerning our competitors, or the biotechnology, pharmaceutical or drug delivery industry in general;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
public concerns as to the safety or efficacy of our approved product or product candidates or our competitors&#8217; products;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
changes in government regulation of the pharmaceutical or medical industry;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
changes in the reimbursement policies of third-party insurance companies or government agencies;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
actual or anticipated fluctuations in our operating results;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
changes in financial estimates or recommendations by securities analysts;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
developments involving corporate collaborators, if any;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
changes in accounting principles; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the loss of any of our key scientific or management personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, securities class action litigation has often been brought against companies that experience volatility in the market price
of their securities. Whether or not meritorious, litigation brought against us could result in substantial costs and a diversion of management&#8217;s
attention and resources, which could adversely affect our business, operating results and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that our common stock price and volume will remain at current levels in which case investors may sustain large losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock market in general, and the stocks of small-cap biotechnology companies in particular, have experienced extreme price
and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market
and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The
realization of any of the above risks or any of a broad range of other risks, including those described in these &#8220;Risk Factors,&#8221;
could have a dramatic and material adverse impact on the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions in our amended and restated certificate of incorporation and our amended and restated bylaws, as well as provisions of Delaware
law, might discourage, delay or prevent a change in control of the Company or changes in our Board of Directors or management and, therefore,
depress the trading price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that may depress the
market price of our common stock by acting to discourage, delay or prevent a merger, acquisition or other change in control that stockholders
may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These
provisions may also prevent or frustrate attempts by our stockholders to replace or remove members of our Board of Directors or our management.
Our corporate governance documents include provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
    that directors may be removed by stockholders with or without cause;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
    the ability of our stockholders to call and bring business before special meetings and to take action by written consent in lieu
    of a meeting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
    advance notice of stockholder proposals for business to be conducted at meetings of our stockholders and for nominations of candidates
    for election to our Board of Directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorizing
    blank check preferred stock, which could be issued with voting, liquidation, dividend and other rights superior to our common stock;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
    the liability of, and providing indemnification to, our directors and officers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Delaware corporation, we are also subject to provisions of Delaware law, including Section 203 of the Delaware General Corporation
Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock from engaging in certain business
combinations with us. Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware
law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium
for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the
future for shares of our common stock. They could also deter potential acquirers of the Company, thereby reducing the likelihood that
you could receive a premium for your common stock in an acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Employee Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business could suffer if we lose the services of key members of our senior management, key advisors or personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent upon the continued services of key members of our senior management and a limited number of key advisors and personnel.
The loss of any one of these individuals could disrupt our operations or our strategic plans. Additionally, our future success will depend
on, among other things, our ability to continue to hire and retain the necessary qualified scientific, technical and managerial personnel,
for whom we compete with numerous other companies, academic institutions and organizations. The loss of members of our management team,
key advisors or personnel, or our inability to attract or retain other qualified personnel or advisors, could have a material adverse
effect on our business, results of operations and financial condition. Though members of our sales force generally enter into noncompetition
agreements that restrict their ability to compete with us, most of the members of our executive management team are not subject to such
agreements. Accordingly, the adverse effect resulting from the loss of certain executives could be compounded by our inability to prevent
them from competing with us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and
insider trading.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
FDA regulations, to provide accurate information to the FDA, to comply with federal and state healthcare fraud and abuse laws and regulations,
to report financial information or data accurately, to disclose unauthorized activities to us or to comply with our code of business
conduct and ethics. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws
and regulations intended to prevent fraud, kickbacks, false claims, inappropriate promotion, self-dealing and other abusive practices.
These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission,
customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained
in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. The precautions we take
to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from
governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If
any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could
have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to applicable fraud and abuse laws, including anti-kickback and false claims, transparency, health information privacy and
security and other healthcare laws. Failure to comply with such laws may result in substantial penalties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to broadly applicable healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we conduct research, market, sell and distribute any product candidates for which we obtain marketing approval. The healthcare
laws that may affect us include: the federal fraud and abuse laws, including the federal anti-kickback, and false claims and civil monetary
penalties laws; federal data privacy and security laws; and federal transparency laws related to ownership and investment interests and
payments and/or other transfers of value made to or held by physicians (including doctors, dentists, optometrists, podiatrists and chiropractors)
and teaching hospitals and, information regarding payments and transfers of value provided to and other healthcare professionals during
the previous year. In addition, many states have similar laws and regulations that may differ from each other and federal law in significant
ways, thus complicating compliance efforts. Moreover, several states require biopharmaceutical companies to comply with the biopharmaceutical
industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require
medical device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare
providers or marketing expenditures. Additionally, some state and local laws require the registration of biopharmaceutical sales representatives
in the jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
that our operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve
substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships
with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided,
may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other
healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental
laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, disgorgement,
fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, additional reporting
requirements and/or oversight if a corporate integrity agreement or similar agreement is executed to resolve allegations of non-compliance
with these laws and the curtailment or restructuring of operations. In addition, violations may also result in reputational harm, diminished
profits and future earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
litigation and unfavorable publicity could negatively affect our future business. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employees may, from time to time, bring lawsuits against us regarding injury, creating a hostile work place, discrimination, wage and
hour disputes, sexual harassment, or other employment issues. In recent years, there has been an increase in the number of discrimination
and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access
to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment-
or harassment-related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm that has
negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Under
applicable employment laws, such as in Israel, we may not be able to enforce covenants not to compete and therefore may be unable to
prevent our competitors from benefiting from the expertise of some of our former employees.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally enter into non-competition agreements with our employees and certain key consultants. These agreements prohibit our employees
and certain key consultants, if they cease working for us, from competing directly with us or working for our competitors or clients
for a limited period of time. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees
work and it may be difficult for us to restrict our competitors from benefitting from the expertise our former employees or consultants
developed while working for us. For example, Israeli courts have required employers seeking to enforce non-compete undertakings of a
former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests
of the employer which have been recognized by the courts, such as the secrecy of a company&#8217;s confidential commercial information
or the protection of its intellectual property. If we cannot demonstrate that such interests will be harmed, we may be unable to prevent
our competitors from benefiting from the expertise of our former employees or consultants and our ability to remain competitive may be
diminished.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
increasing use of social media platforms presents new risks and challenges. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social
media is increasingly being used to communicate about our research, development candidates, investigational medicines, and the diseases
our development candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical
industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of
noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, subjects
may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event.
When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or
we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures
generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There
is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social
networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability,
face regulatory actions, or incur other harm to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unfavorable
U.S. or global economic conditions could adversely affect our business, financial condition, or results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
results of operations could be adversely affected by general conditions in the global economy and financial markets, including global
pandemics, recent geopolitical events, unfavorable changes related to interest rates and rising inflation. The most recent global financial
crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as
the most recent global financial crisis, could result in a variety of risks to our business, including weakened demand for our investigational
medicines and our ability to raise additional capital when needed on favorable terms, if at all. A weak or declining economy could strain
our suppliers, possibly resulting in supply disruption, or cause delays in payments for our services by third-party payors or our collaborators.
Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial
market conditions could adversely impact our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>ITEM
1C. CYBERSECURITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_987_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20250401__20260331_gBFCRMPFAIAMT-VHQINQ_zCRFEoOu6B84" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" continuedAt="ConU000055-01" escape="true" id="Fact000055" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on sophisticated information technology systems and network infrastructure to operate and manage our business. We also maintain
personally identifiable information (&#8220;PII&#8221;) about our employees, and given the nature of our business, we have access to
protected health information (&#8220;PHI&#8221;). Our business therefore depends on the continuous, effective, reliable, and secure operation
of our computer hardware, software, networks, Internet servers, and related infrastructure. To the extent that our hardware or software
malfunctions or access to our data by internal personnel, suppliers or customers through the Internet is interrupted or compromised,
our business could suffer.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_C02_gBFCRMPFAIAMT-VHQINQ_zjc4W58rGV64"><ix:continuation continuedAt="ConU000055-02" id="ConU000055-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<div id="xdx_C05_gBFCRMPFAIAMT-VHQINQ_zcStSSMQd0cg"><ix:continuation continuedAt="ConU000055-03" id="ConU000055-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
integrity and protection of our customer, personnel, financial, research and development, and other confidential data is critical to
our business, and our customers and employees have a high expectation that we will adequately protect their personal information. The
regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve and a number
of states have adopted laws and regulations that may affect our privacy and data security practices regarding the use, disclosure and
protection of PII. For example, the California Consumer Privacy Act (&#8220;the CCPA&#8221;), among other things, creates individual
privacy rights and imposes increased obligations on companies handling PII.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our computer and communications hardware are protected through physical and software safeguards, they are still vulnerable to system
malfunction, computer viruses, malware and ransomware, and other cybersecurity threats such as phishing and social engineering attacks.
These events could lead to unauthorized access to our information technology systems and result in financial loss and the misappropriation
or unauthorized disclosure of confidential information belonging to us, our employees, partners, customers, or suppliers. The techniques
used by criminal elements to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote
areas of the world. As a result, we may not be able to address these techniques proactively or implement adequate preventative measures.
If our information technology systems are compromised, we could be subject to fines, damages, litigation and enforcement actions, incur
financial losses, suffer reputational damage, and lose trade secrets or other confidential information, each of which could significantly
harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cybersecurity
Program </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the importance of cybersecurity to our business, we maintain a robust cybersecurity program to support both the effectiveness of our
systems and our preparedness for information security risks. This program includes a number of administrative, physical, and technical
safeguards with regular evaluations of our cybersecurity program, including periodic internal and external audits, penetration tests,
and incident response simulations. We also require cybersecurity training when onboarding new employees and contractors, as well as required
cybersecurity awareness training for our employees and contractors/other workforce members. Our program leverages industry frameworks,
including the National Institute of Standards and Technology (NIST) Cybersecurity Framework (CSF) to strengthen our program effectiveness
and reduce cybersecurity risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use a risk-based approach with respect to our use and oversight of <span id="xdx_903_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250401__20260331_zOJNnD4VcKS4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleantrue" id="Fact000056" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">third-party</ix:nonNumeric></span> service providers. We use a number of means to assess
cyber risks related to our third-party service providers, including maintaining vendor questionnaires/conducting due diligence in connection
with onboarding new vendors and engaging in periodic reviews thereafter as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Process
for Assessing, Identifying and Managing Material Risks from Cybersecurity Threats </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250401__20260331_ztjs18riHI85" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleantrue" id="Fact000057" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">In
the event of a cybersecurity incident, we maintain a regularly tested incident response program. Pursuant to the program and its escalation
protocols, designated personnel are responsible for assessing the severity of an incident and associated threat, and handling it in accordance
with that severity level. We have relationships with a number of third-party service providers to assist with cybersecurity containment
and remediation efforts.</ix:nonNumeric></span></span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span id="xdx_C01_gBFCRMPFAIAMT-VHQINQ_zexNMY1xcGje"><ix:continuation id="ConU000055-03"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<p id="xdx_98B_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20250401__20260331_gBFCRBODOTB-PM_zTgsxPa7W8R4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" continuedAt="ConU000064-01" escape="true" id="Fact000064" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Governance</i></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span id="xdx_C05_gBFCRBODOTB-PM_zym9OyA7p8i2"><ix:continuation continuedAt="ConU000064-02" id="ConU000064-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<div id="xdx_C0A_gBFCRBODOTB-PM_zOVqRcA48VJk"><ix:continuation continuedAt="ConU000064-03" id="ConU000064-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
a notification of concerning factors which may be indicative that a notable cybersecurity incident has occurred, the Cyber Security Subcommittee
(Cyber Security Subcommittee) consisting of General Counsel, Head of HR &amp; Chief Technical Officer (CTO) meets to make an initial
assessment. If the Cyber Security Subcommittee determines there is a reasonable likelihood a notable cybersecurity incident has occurred,
then notice will promptly be given to certain members of the Company Executive Team including our Chief Executive Officer, Chief Operating
Officer, Chief Commercial Officer &amp; Chief Financial Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
team leverages over 25 years of experience in various cyber security functions. Our CTO, and their team, are responsible for the day-to-day
management of the cybersecurity program.</span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span id="xdx_C0F_gBFCRBODOTB-PM_zxTZmGe71kl"><ix:continuation continuedAt="ConU000064-04" id="ConU000064-03"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_C0A_gBFCRBODOTB-PM_z1iBZVYC2w4k"><ix:continuation continuedAt="ConU000064-05" id="ConU000064-04"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<div id="xdx_C08_gBFCRBODOTB-PM_zd50HkZ00Aj8"><ix:continuation continuedAt="ConU000064-06" id="ConU000064-05"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CTO provides periodic briefings for our senior management team on cybersecurity matters, including the prevention, detection, mitigation,
and remediation of cybersecurity incidents and cybersecurity threats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Board
Oversight</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the <span id="xdx_904_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20250401__20260331_z3eUtle6fKG6" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleantrue" id="Fact000065" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">Board of Directors</ix:nonNumeric></span> has overall responsibility for risk oversight, our Audit Committee oversees cybersecurity risk matters. The Audit
Committee is responsible for reviewing, discussing with management, and overseeing the Company&#8217;s cybersecurity and privacy risk
exposures and policies. On a quarterly basis, the CTO reports to the Audit Committee on information technology and cybersecurity matters,
including key information technology risks. The CTO also apprises the Audit Committee and full Board of cyber security incidents consistent
with our incident response program, promptly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cybersecurity
Risks</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250401__20260331_zhCF0LHHwgka" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000066" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">Our
cybersecurity risk management processes are <span id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250401__20260331_ziJok1OLMwVj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleantrue" id="Fact000067" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">integrated</ix:nonNumeric></span> into our overall Enterprise Risk Management (&#8220;ERM&#8221;) process. As part
of our ERM process, department leaders identify, assess, and evaluate risks impacting our operations across the Company, including those
risks related to cybersecurity.</ix:nonNumeric></span> Department leaders are asked to consider the severity and likelihood of certain risk factors, drawing
upon their company knowledge and past business experience. While we maintain a robust cybersecurity program, the techniques used to infiltrate
information technology systems continue to evolve. Accordingly, we may not be able to timely detect threats or anticipate and implement
adequate security measures. For additional information, see &#8220;Item 1A&#8212;Risk Factors.&#8221; To date, we have not experienced
any material cybersecurity incidents or threats.</span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span id="xdx_C04_gBFCRBODOTB-PM_zNEMGxbvkBs9"><ix:continuation id="ConU000064-06"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>ITEM
2. PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 18, 2026, the Company leased facilities for corporate and R&amp;D purposes at locations throughout the United States and in various
locations outside of the United States. Our executive office is located at 900 Stewart Avenue, Suite 310, Garden City, NY 11530, and
is under a lease that expires in June 2031. We have an office in Dublin, Ireland under a lease that expires in September 2026. The Company
has a research and development facility in Madison, Wisconsin under a lease that expires in May 2029. The Company believes the existing
facilities which are used by all reportable segments of the Company and are in good operating condition and are suitable for the conduct
of its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>ITEM
3. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company is involved in various legal matters arising in the normal course of business. Litigation and other disputes
are inherently unpredictable and subject to substantial uncertainties and unfavorable resolutions could occur. At the same time, the
Company does not expect the outcome of such proceedings, either individually or in aggregate, to have a material effect on its financial
position, cash flows or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock has been listed under the symbol &#8220;XAIR&#8221; on the Nasdaq Capital Market since May 7, 2019. From August 28, 2018
until May 6, 2019, our common stock was quoted on the OTC Pink.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2026, the closing price for our common stock as reported on The Nasdaq Capital Market was $0.468 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 23, 2026, there were approximately 98 holders of record for shares of our common stock. This does not reflect beneficial stockholders
who held their common stock in &#8220;street&#8221; or nominee name through brokerage firms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance Under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding securities authorized for issuance under our equity compensation plans is contained in Part III, Item 12 of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future
earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on
our common stock for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unregistered
Sales of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)
Sales of Unregistered Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended March 31, 2026, the Company issued only unregistered equity securities previously reported in the Current Reports on Form
8-K and in the Quarterly Reports on Form 10-Q filed by the Company with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)
Use of Proceeds</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)
Issuer Purchases of Equity Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>ITEM
6. [RESERVED]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated
financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this
Annual Report contain forward-looking statements that involve risks and uncertainties, such as statements regarding our plans, objectives,
expectations, intentions and projections. Our actual results could differ materially from those discussed in these forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Item 1A &#8220;Risk Factors.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Introduction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (&#8220;NO&#8221;) generators
and delivery systems (the &#8220;LungFit<sup>&#174;</sup> platform&#8221;) capable of generating NO from ambient air. The Company&#8217;s
first device, LungFit<sup>&#174;</sup> PH received premarket approval (&#8220;PMA&#8221;) from the FDA in June 2022. The NO generated
by the LungFit<sup>&#174; </sup>PH system is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation
in term and near-term (&gt;34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic
evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. This condition is commonly referred
to as persistent pulmonary hypertension of the newborn (&#8220;PPHN&#8221;). The LungFit<sup>&#174; </sup>platform can generate NO up
to 400 parts per million (&#8220;ppm&#8221;) for delivery to a patient&#8217;s lungs directly or via a ventilator. LungFit<sup>&#174;
</sup>can deliver NO either continuously or for a fixed amount of time at various flow rates and has the ability to either titrate dose
on demand or maintain a constant dose. In July 2022, we commenced marketing LungFit<sup>&#174;</sup> PH in the United States for PPHN
as a medical device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November  2024, the Company received European CE mark approval of the LungFit PH&#174; system for the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    treatment of infants <span style="text-decoration: underline">&gt;</span>34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic
    evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;
    and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents,
    ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular
    function and oxygenation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LungFit<sup>&#174;
</sup>can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections
via delivery of NO at concentrations &gt; 100 parts per million (ppm) through a breathing mask or similar apparatus. Furthermore, we
believe that there is a high unmet medical need for patients suffering from certain severe lung infections that the LungFit<sup>&#174;
</sup>platform can potentially address. The Company&#8217;s other areas of focus with the LungFit<sup>&#174; </sup>platform beyond PPHN
are nontuberculous mycobacteria (&#8220;NTM&#8221;) lung infection and those with various severe lung infections with underlying chronic
obstructive pulmonary disease (&#8220;COPD&#8221;). Our current product candidates will be subject to premarket reviews and approvals
by the FDA, certification through the conduct of a conformity assessment by a notified body in the EU for the product to be CE marked,
as well as comparable foreign regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the above-mentioned programs, we have two subsidiaries that are currently engaging in novel preclinical stage pharmaceutical
research, Beyond Cancer and NeuroNos.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
Operations Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation
of our consolidated financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect
the reported amount of assets, liabilities, costs and expenses and related disclosures. Our critical accounting estimates are those estimates
that involve a significant level of uncertainty at the time the estimate was made, and changes in them have had or are reasonably likely
to have a material effect on our financial condition or results of operations. Accordingly, actual results could differ materially from
our estimates. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances,
and we evaluate these estimates on an ongoing basis. Our most critical accounting estimates include determining the accruals associated
with third party providers supporting research and development efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accrued
Research and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development
expenses. This process involves reviewing purchase orders, open contracts, reconciling payments and invoices and communicating with our
personnel and suppliers to identify services that have been performed on our behalf. It also includes the research and development vendors
providing us with milestone and percentage of completion reports on the statuses within each active purchase order and contract along
with estimating the level of service performed and the associated cost incurred for the services when we have not yet been invoiced or
otherwise notified of the actual cost. Our vendors invoice us in various ways via advance payments, as contractual milestones are met,
or monthly in arrears for services performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances
known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and adjust if necessary. The
significant estimates in our accrued research and development expenses include the costs incurred for services performed by clinical
and pre-clinical vendors in connection with research and development activities for which we have not yet been invoiced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
contract with these vendors to conduct clinical and pre-clinical services on our behalf. We base our expenses on our estimates of the
services received and efforts expended pursuant to quotes and contracts with the research and development vendors. The financial terms
of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances
in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development
expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended
in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual
or amount of prepaid expense accordingly. Non-refundable advance payments for goods and services that will be used in future research
and development activities are expensed when the activity has been performed or when the goods have been received rather than when the
payment is made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing
of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts
that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such
expenses and the amounts actually incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations and Other Comprehensive Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">(in thousands, except number of shares and loss per share)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p>
                                                                                                                                                                                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2026</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p>
                                                                                                                                                                                                                                                                          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; padding-bottom: 1pt">Revenues</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">7,679</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">3,705</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,427</td><td style="padding-bottom: 1pt; text-align: left"/><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,368</td><td style="padding-bottom: 1pt; text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Gross profit (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,663</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,241</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,857</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">19,055</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">26,017</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">29,296</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">42,874</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(29,044</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(44,537</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Dividend/investment income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">705</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest and finance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,515</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,019</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,395</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,314</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(165</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,447</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss on disposal/impairment of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(431</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(738</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Foreign exchange gain/(loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(108</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other income/(expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(14</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total other income/(expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,290</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,942</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Provision for income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(34,334</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(48,479</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Less: net loss attributable to non-controlling interests</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,085</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,854</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Net loss attributable to Beyond Air, Inc.</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(33,249</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(46,625</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(45</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Comprehensive loss attributable to Beyond Air, Inc</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(33,055</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(46,670</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net basic and diluted loss per share attributable to Beyond Air, Inc.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4.01</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(13.77</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average number of shares of common stock outstanding &#8211; basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,300,916</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,385,327</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the year ended March 31, 2026 to the year ended March 31, 2025</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue
and Cost of Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">Revenue
was </span> $7.7 million and $3.7 for the years ended March 31, 2026 and March 31, 2025 respectively.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of revenue of <span style="background-color: white">$7.4 </span>million and gross profit of <span style="background-color: white">$0.3 </span>million
were recognized for the year ended March 31, 2026 compared to a cost of revenue of $5.4 million and gross losses of $1.7 million for
the year ended March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
continue to expand as we continue to sign new hospital contracts and begin selling into international markets. The increase in gross
profit is primarily associated with sales growth, partially offset by one-time costs required to upgrade our existing fleet of devices
and provisions for excess inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses for the year ended March 31, 2026 were <span style="background-color: white">$10.2 </span>million as compared
to $16.9 million for the year ended March 31, 2025. The decrease of <span style="background-color: white">$6.7 </span>million was primarily
attributed primarily to a decrease in salaries of <span style="background-color: white">$2.8 </span>million ($1.5 million in Beyond Air
and $1.5 million in Beyond Cancer, partially offset by increase of $0.2 million in NeuroNos), pre-clinical expenses of <span style="background-color: white">$0.8
</span>million ($0.3 million in Beyond Cancer and $0.5 million in NeuroNos), professional fees of $0.4 million ($0.4 million in Beyond
Air and $0.3 million in Beyond Cancer, partially offset by increase of $0.3 million in NeuroNos), and a reduction in Gen II device development
costs of $2.3 million, partially offset by increased stock-based compensation costs of $0.7 million ($1.4 million in Beyond Cancer, partially
offset by a decrease of $0.7 million in Beyond Air).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Selling,
General and Administrative Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
general and administrative expenses for the year ended March 31, 2026 were $19.1 million as compared to $26.0 million for the year ended
March 31, 2025. The decrease of $6<span style="background-color: white">.<span style="background-color: white">9</span></span> million was attributed primarily to a decrease in salaries
of $1.0 million ($0.6 million in Beyond Air and $0.5 million in Beyond Cancer, partially offset by increase of $0.1 million in NeuroNos),
stock-based compensation costs of $4.5 million ($3.4 million in Beyond Air and $1.1 million in Beyond Cancer, partially offset by increase
of $0.1 million in NeuroNos), legal fees of $0.7 million, travel expenses of $0.3 million, and facility expenses of $0.2 million, partially
offset by an increase of $0.4 million in royalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Income and Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expense for the year ended March 31, 2026 were $5.3 million as compared to other expense of $3.9 million for the year ended March 31,
2025. The increase in expense of $1.4 million was attributed primarily to the change in fair value of the prior year derivative liability of $1.3 million
gain compared to the loss of $1.4 million associated with the remeasurement of the Note derivative liability that occurred during the
current period. This was partially offset by the prior period loss associated with extinguishment of debt
of $2.5 million as compared to current period loss associated with extinguishment of debt of $0.2 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss Attributable to Non-controlling Interest</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss attributed to non-controlling interests for the year ended March 31, 2026 was $1.1 million, compared to $1.9 million for the year
ended March 31, 2025. Non-controlling interests represent 20% of the net loss of our Beyond Cancer subsidiary and the applicable ownership
structure during each reporting period of the net loss of our NeuroNos subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss Attributed to Common Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss attributed to common stockholders of Beyond Air, Inc. for the year ended March 31, 2026 was $33.2 million or a loss of $4.01 per
share, basic and diluted. Our net loss attributed to common stockholders of Beyond Air, Inc. for the year ended March 31, 2025 was $46.6
million or a loss of $13.77 per share, basic and diluted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have generated revenue of $12.5 million from the sale of products to date. We had an operating cash flow decrease of $18.1 million for
the year ended March 31, 2026 and we have experienced an accumulated loss of $319.6 million since inception through March 31, 2026. As
of March 31, 2026, we had cash, cash equivalents and marketable securities of $11.6 million and $5.6 million in restricted cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to incur net losses and have net cash outflows for at least the next twelve months. Management believes these factors raise substantial
doubt about the Company&#8217;s ability to meet its obligations with cash on hand and concluded that the Company will require additional
funding within one year from the date these financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is confident that the efforts to arrange financing as described below, while not assured, will enable them to meet the Company&#8217;s
obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s future capital needs and the adequacy of its available funds will depend on many factors, including, but not necessarily
limited to, the success and costs of commercialization of the Company&#8217;s approved product and the actual cost and time necessary
for current and anticipated preclinical studies, clinical trials and other actions needed to obtain certification or regulatory approval
of the Company&#8217;s product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2024, the Company entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) and subsequently on
November 3, 2025 the Company amended and restated the Loan Agreement (as amended, the &#8220;Amended Loan Agreement&#8221;) for a
secured loan with certain lenders, including its former chief executive officer, Steven Lisi, and director Robert Carey, for an
aggregate principal amount of $13.5 million. The Loan Agreement was approved by each of the Company&#8217;s independent and
disinterested directors, following the receipt of a recommendation from an independent investment bank. The Amended Loan Agreement
provides for the following terms: (i) principal amount of $13,500,000; (ii) ten-year term; (iii) interest of 15% per annum, of which
3% shall be payable in cash and 12% payable in kind through June 30, 2026 and thereafter all in cash; (iv) a royalty interest of 8%
of the Company&#8217;s net sales on a quarterly basis from July 2026 until the facility is repaid in full; (v) the Company&#8217;s
obligations will be secured by substantially all of the Company&#8217;s assets and (vi) the Company issued the lenders warrants to
purchase shares of the Company&#8217;s common stock</span>. Concurrent with entering into the Amended Loan Agreement, the parties entered into a waiver agreement pursuant to
which the Lender consented to the Company&#8217;s issuance of the Note in exchange for reducing the exercise price of the warrants from $7.586 per share to $1.95 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 10, 2025, we entered into the At-The Market Offering Sales Agreement with BTIG, Inc. (the &#8220;2025 ATM&#8221;). Under
the 2025 ATM, we may sell shares of our common stock having aggregate sales proceeds of up to $35.0 million, from time to time and
at various prices. Pursuant to the &#8220;baby shelf rules&#8221; promulgated by the SEC, if our public float is less than $75.0
million as of specified measurement periods, the number of shares of common stock that may be offered and sold by us under a Form
S-3 registration statement, including pursuant to the 2025 ATM, in any twelve-month period is limited to an aggregate amount that
does not exceed one-third of our public float. As of March 31, 2026, due to the SEC&#8217;s &#8220;baby shelf rules,&#8221; we are
permitted to sell up to $0 million of shares of common stock pursuant to the 2025 ATM. We will remain subject to the &#8220;baby
shelf rules&#8221; under the Form S-3 registration statement until such time as our public float exceeds $75.0 million. If shares of
our common stock are sold, there is a 2.5% fee paid to the sales agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 8, 2025, we entered into an inducement offer letter agreement (&#8220;Inducement Letter&#8221;) with certain holders of our
existing common stock purchase warrants (&#8220;Existing Warrants&#8221;). Pursuant to the Inducement Letter, such holders immediately
exercised some or all of their respective outstanding Existing Warrants to purchase up to an aggregate of 1,439,128 shares of common
stock at a reduced exercise price of $2.21. The proceeds to the Company from the exercise of the Existing Warrants were approximately
$2.9 million, net of placement agent fees and other offering expenses of $0.2 million and $0.1 million, respectively. In consideration
of the inducement offer, the Company issued new common stock warrants to purchase up to 719,562 shares of common stock for a purchase
price of $0.125 per share of common stock underlying the new warrant. The new warrants have an exercise price of $2.21 per share and
are immediately exercisable, with a term of five years from the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2025, the Company entered into and closed on a note purchase agreement (the &#8220;Note Purchase Agreement&#8221;) with Streeterville
Capital LLC (&#8220;Streeterville&#8221; or &#8220;Investor&#8221;), which provided for the issuance of a secured promissory note in
the principal amount of $12.0 million (the &#8220;Note&#8221;). The principal amount of the Note is due 24 months following the date
of issuance. Interest will accrue at the rate of 15% per annum, with no interest accruing for the first 12 months following issuance;
provided however, that Streeterville is guaranteed 12 months of interest, of $1.8 million even if the Note is redeemed or prepaid prior
to the maturity date. Of the total $12.0 million Note, $6.0 million will be placed in a restricted account and will be accessible by
the Company as the first $6.0 million is repaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
on November 4, 2025, the Company entered into an equity purchase agreement (the &#8220;Purchase Agreement&#8221;) with Streeterville
for the purchase of up to $20.0 million of the Company&#8217;s shares of common stock. In connection with the Purchase Agreement, the
Company and Streeterville entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to
which the Company agreed to file with the Securities and Exchange Commission a registration statement (the &#8220;Registration Statement&#8221;)
covering the resale of the shares by November 24, 2025. Pursuant to the Purchase Agreement, upon effectiveness of the Registration Statement
and so long as there is no balance outstanding on the Note, the Company shall have the right, but not the obligation, to direct Streeterville,
by its delivery to Streeterville of a put notice from time to time during a period of up to two years, to purchase newly issued shares
of the Company&#8217;s common stock, subject to customary limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2026, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional
investor. Pursuant to the Purchase Agreement, the Company sold to the investor, and the investor purchased from the Company, in a private
placement offering, an aggregate of (i) 524,990 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, at a purchase
price of $1.272 per Share, (ii) pre-funded warrants to purchase up to 3,405,828 shares of Common Stock (the &#8220;Pre-funded Warrants&#8221;)
at a purchase price of $1.2719 per Pre-funded Warrant and (iii) warrants to purchase up to 3,930,818 shares of Common Stock (the &#8220;Common
Warrants&#8221;, and together with the Pre-funded Warrants the &#8220;Warrants&#8221;), for aggregate gross proceeds under the Purchase
Agreement of $5,000,000. The Pre-funded Warrants have an exercise price of $0.0001 per share, and the Common Warrants have an exercise
price of $1.147 per share. The offering closed on January 16, 2026, on satisfaction of customary closing conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to Beyond Cancer, discussions with investors continue in parallel to the advancement to a phase 1b combination study of UNO with
anti-PD1 therapy and other strategic alternatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroNOS continues to evaluate and pursue a variety of strategic financing opportunities to support its operations,
advance its development programs and execute its long-term business objectives. NeuroNOS is actively engaged in discussions with potential
investors and other financing sources and may seek to raise additional capital through equity investments, strategic partnerships, licensing
arrangements, debt financings or other transactions. While no assurance can be given that any such financing or transaction will be completed
on acceptable terms, or at all, NeuroNOS remains focused on securing the resources necessary to further its strategic initiatives and
support future growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue operating as a going concern.
This basis of accounting contemplates the recovery of the Company&#8217;s assets and the satisfaction of liabilities in the normal course
of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital needs and the adequacy of our available funds will depend on many factors, including, but not necessarily limited to,
the cost and time necessary for the development, preclinical studies, clinical trials and certification or regulatory approval of our
other medical devices, indications as well as the commercial success of our approved product and any product candidates that receive
marketing approval by the FDA. We may be required to raise additional funds through sale of equity or debt securities or through strategic
collaborations and/or licensing agreements in order to fund operations until we are able to generate enough product or royalty revenues,
if any. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could have a material
adverse effect on our strategic objectives, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 25, 2021, the Company and Circassia entered into a settlement agreement (&#8220;the Settlement Agreement&#8221;) resolving all claims
by and between the parties and mutually terminating the agreement with Circassia. Pursuant to the terms of the Settlement Agreement,
the Company agreed to pay Circassia $10.5 million in three installments, all of which has been paid. Additionally, starting in 2025, Circasia began receiving a quarterly royalty payment equal to 5% of LungFit<sup>&#174;</sup> PH net sales in the
U.S. This royalty will terminate once the aggregate payment reaches  $6.0 million. As of March 31, 2026, approximately $0.4 million of royalties have been paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to continue to operate beyond the fourth fiscal quarter of 2027 will be largely dependent upon the successful commercial launch
of LungFit<sup>&#174;</sup> PH, obtaining partners in other parts of the world, the timing of the FDA approval for LungFit PH 2 and possibly
raising additional funds to finance our activities until we are generating cash flow from operations. Further, there are no assurances
that we will be successful in obtaining an adequate level of financing for the development and commercialization of our other product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are numerous risks and uncertainties associated with the development of our NO delivery system and we are unable to estimate the amounts
of increased capital outlays and operating expenses associated with completing the research and development of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress and costs of our preclinical studies, clinical trials and other research and development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of commercializing the LungFit<sup>&#174;</sup> system;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, prioritization and number of our clinical trials and other research and development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of obtaining certification or regulatory approval for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of, and timing for, strengthening our manufacturing agreements for production of sufficient clinical quantities of our product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities
    internally;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of acquiring or undertaking the development and commercialization efforts for additional, future therapeutic applications of
    our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    magnitude of our general and administrative expenses; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    cost that we may incur under current and future in-and-out-licensing arrangements relating to our product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
between Fiscal Years Ended March 31, 2026 and March 31, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a summary of the statements of cash flow activities for the years ended March 31, 2026 and March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For The Year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p>
                                                                                                                                                                                                                                                                                                                                                                                                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2026</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For The Year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p>
                                                                                                                                                                                                                                                                                                                                                                                                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by (used in):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(18,144</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(38,218</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,674</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,905</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29,090</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,646</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Effect of exchange rate changes on cash and cash equivalents</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">194</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(45</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net increase (decrease) in cash, cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,712</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2026, the net cash used in operating activities was $18.1 million, which was primarily due to our net loss of
$34.3 million which includes $5.3 million of stock-based compensation, $3.0 million of depreciation and amortization, $1.8 million of
paid-in-kind interest associated with the Loan Agreement, $1.4 million loss on the change in fair value of derivative liability, $0.7
million provision for inventory losses, and $0.4 million loss on disposal of fixed assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2025, the net cash used in operating activities was $38.2 million, which was primarily due to our net loss of
$48.5 million which includes $9.1 million of stock-based compensation, $3.0 million of depreciation and amortization, a non-cash loss
of $2.4 million on the extinguishment of debt, an impairment of fixed assets charge $0.5 million, a $0.4 million increase in accounts
receivable, a $0.4 million increase in inventory, partially offset by a $1.0 million decrease in prepaid accounts, a decrease in accrued
liabilities $6.4 million (which included $4.5 million in payment of the final tranche of a May 2021 settlement with Circassia).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investing
Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2026, net cash used in investing activities was $3.7 million which was attributable to a net purchase of investments
in marketable securities of $2.7 million and investment of $1.0 million for the purchase of property and equipment, mainly LungFit<sup>&#174;</sup>
PH devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2025, cash provided by investing activities was $14.9 million which was attributable to a net redemption of
investments in marketable securities of $20.8 million and investment of $5.9 million for the purchase of property and equipment, mainly
LungFit<sup>&#174;</sup> PH devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financing
Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities for the year ended March 31, 2026 was $29.1 million, mainly from the issuance of common stock in
connection with the At-The-Market Offering Sales Agreement with BTIG, Inc (the &#8220;2025 ATM&#8221;) of $8.1 million in addition to
$3.0 million from the issuance of common stock in connection with the warrant inducement and issuance of additional warrants. Additionally,
the Company received $2.0 million of Additional Loans from a related party, a director of the Company who is also an existing lender
under its Loan Agreement. Further, the Company entered into the Note Purchase Agreement with Streeterville, which provided for the issuance
of the Note in the principal amount of $12.0 million, partially offset by $1.0 million of fees paid at closing. Finally, the Company
entered into a Securities Purchase Agreement with an institutional investor, which provided for the sale of common stock and warrants
for aggregate proceeds of $5.0 million, partially offset by $0.5 million of fees paid at closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2025, net cash provided by financing activities was $16.6 million, mainly from the issuance of securities through
securities purchase agreements which the net proceeds were $18.8 million, $11.3 million payment received on the loan agreement, and the
issuance of common stock in connection with an At-The-Market Offering Sales Agreement with Truist Securities, Inc. (the &#8220;2022 ATM&#8221;)
of $0.7 million and $1.5 million in connection with the 2025 ATM partially offset by $18.0 million from the payment of long- and short-term
loans, including a $17.5 million repayment to Avenue Capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_013"></span>ITEM
7A. Quantitative and Qualitative Disclosure about Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
qualify as a smaller reporting company, as defined by SEC Rule 229.10(f)(1) and are not required to provide the information required
by this Item 7A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements together with the report of our independent registered public accounting firm, required to be filed
pursuant to this Item 8 are appended to this Annual Report. An index of those consolidated financial statements is found in Part IV,
Item 15 of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_015"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_016"></span>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Disclosure Controls and Procedures</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
performed an evaluation of the effectiveness of our disclosure controls and procedures that are designed to ensure that information required
to be disclosed in this Annual Report and filed with the SEC is recorded, processed, summarized and reported timely within the time period
specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures
designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange
Act, is accumulated and communicated to the issuer&#8217;s management, including its principal executive and principal financial officers,
or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. There can be no assurance
that our disclosure controls and procedures will detect or uncover all failures of persons within the Company to disclose information
otherwise required to be set forth in our reports. Nevertheless, our disclosure controls and procedures are designed to provide reasonable
assurance of achieving the desired control objectives. Based on our evaluation, our Chief Executive Officer (our principal executive
officer) and Chief Financial Officer (our principal financial officer) have concluded that our disclosure controls and procedures (as
defined in Rules 13a-15(e) and 15(d)-15(e) of the Exchange Act) were effective at such reasonable assurance level as of March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f)
and 15d-15(f) under the Exchange Act. Because of its inherent limitations, internal control over financial reporting may not prevent
or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our
principal financial officer), conducted an evaluation of the effectiveness of our internal control over financial reporting as of March
31, 2026, based on the framework in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of
the Treadway Commission (2013 framework). Based on this evaluation, management concluded that our internal control over financial reporting
was effective as of March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Attestation Report of Registered Public Accounting Firm</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report does not include an attestation report of our registered public accounting firm as we are not an accelerated filer or a large
accelerated filer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Changes in Internal Control over Financial Reporting</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting, as defined in Rules 13a-15(t) and 15d-15(f) under the Exchange Act,
during the year ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_017"></span>ITEM
9B. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_904_ecustom--NoInsiderTradingFlag_dbT_c20250401__20260331_zqsVsbLRSLS2" title="No insider trading flag" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleantrue" id="Fact000069" name="XAIR:NoInsiderTradingFlag">None</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_018"></span>ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_019"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_020"></span>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the name, age and position of each of our directors and executive officers and as of the date of this Annual Report
on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    S. Goodman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Member of the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
    Moorhead</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Gaul</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erick
    J. Lucera</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Chairperson of Audit Committee, Member of Compensation Committee, Chairperson of Nominating Committee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoori
    Lee</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Chairperson of Compensation Committee, Member of Nominating Committee and Member of Audit Committee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    William Forbes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Member of Nominating Committee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    F. Carey</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Chairman and Member of Audit Committee</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Robert
S. Goodman, Chief Executive Officer and Director </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr. Goodman was appointed as
a director of the Company on June 16, 2025. Mr. Goodman has also served as Chief Commercial Officer since November 2025. He was
appointed to serve as the Chief Executive Officer. He brings over 25 years of experience in sales strategy, go-to-market execution,
strategic partnerships and growth management. He has been instrumental in shaping the Company&#8217;s recent commercial approach and
is widely recognized for his ability to expand market penetration and accelerate product adoption in competitive healthcare sectors.
Prior to joining Beyond Air, Mr. Goodman served as Chief Commercial Officer at WEP Clinical from 2023 to 2024, and ActiGraph from
2022 to 2023, where he led global commercial operations and go to market execution. Earlier in his career, he spent more than nine
years at BioTelemetry, Inc. (acquired by Royal Philips), including as Division President and Business Head of BioTel Care and
Alliance from and Senior Vice President of Global Sales and Marketing at BioTel Research, helping scale multiple businesses through
periods of accelerated growth and strategic transformation. He previously held senior leadership roles at Cardiocore (acquired by
BioTelemetry), Thermo Fisher Scientific, and Pfizer, where he spent 15 years in progressively senior commercial positions. Mr.
Goodman currently serves on the board of Fourth Frontier. He is a retired U.S. Army officer and holds a B.S. degree from Norwich
University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Daniel
Moorhead, Chief Financial Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Moorhead was appointed to serve as the Chief Financial Officer of the Company effective as of January 5, 2026.
Mr. Moorhead most recently served as the Chief Financial Officer of Zynex, Inc. from June 2017 to August 2025. Prior to his role with
Zynex, Mr. Moorhead previously served as Chief Financial Officer of Evolving Systems, Inc. (Nasdaq: EVOL) from January 2016 until May
2017, after having served as Vice President of Finance &amp; Administration from December 2011 through December 2015 and in other financial
management roles from 2002-2005 and 2008-2011. Mr. Moorhead is a CPA and holds a B.B.A. in Accounting from the University of Northern
Colorado.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Michael
Gaul, Chief Operating Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Michael
Gaul has been our Chief Operating Officer since July 1, 2022. Mr. Gaul joined the Company in May 2020 as Senior VP, Operations, a title
he held until June 2022. Mr. Gaul has led teams in operations, sales and marketing, supply chain, distribution, quality, regulatory,
human resources, and finance. He has had P&amp;L experience with multi-plant responsibility in both the U.S. and Asia, including roles
with Sparton Corporation (Group VP, Manufacturing &amp; Design Services Business Unit; Group VP, Medical Business Unit), a defense contractor
for maritime defense, from September 2011 to February 2020, SynCardia Systems (COO; VP Operations), a manufacturer and provider of the
commercially approved Total Artificial Heart, from June 2005 to February 2011, Ventana Medical Systems (now known as Roche Tissue Diagnostics)
(VP &amp; General Manager, Operations), a medical device company, from September 2003 to April 2005, and Robotic Vision Systems, Inc.
(General Manager, Vanguard Division; VP Operations, Systemation Division), a maker of machine vision systems, from September 1997 to
June 2003. He also currently serves on the Board of Directors of the Ohio Life Sciences Association to support and promote Ohio&#8217;s
bioscience industry. Mr. Gaul has a BS, Business Administration from Delaware Valley University, and an MBA from Florida Institute of
Technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Robert F. Carey, Chairman of the Board</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Robert Carey joined our Board
of Directors in February 2019 and serves as Chairman and as a Member on our audit and nominating committee. He has an extensive track
record of accomplishment within the biopharmaceutical and healthcare investment banking industry. He has assisted biotech and specialty
pharma companies raise more than $10 billion in initial public offerings, follow-on offerings, debt offerings, and private placements.
He has served as a financial advisor on mergers, acquisitions, and strategic alliance transactions with a total deal value of more than
$10 billion. From July 2020 until December 2023, Mr. Carey was co-founder and President of ACELYRIN, INC., a biopharmaceutical company
developing life-changing drug therapies. Mr. Carey previously served as Executive Vice President and Chief Business Officer at Horizon
Therapeutics plc from March 2014 to September 2019, during which Horizon Therapeutics deployed in excess of $3.5 billion to acquire or
license eight commercial products and three products in development and grew net sales from $74 million in 2013 to approximately $1.2
billion in 2018, a compound annual growth rate of 75%. Before Horizon, he spent more than 11 years as Managing Director and Head of the
Life Sciences Investment Banking Group at JMP Securities. Mr. Carey was also Managing Director in the healthcare groups at Dresdner Kleinwort
Wasserstein and Vector Securities. He received his B.B.A. in Accounting from the University of Notre Dame. Mr. Carey currently serves
on the Board of Beyond Cancer Ltd. and Sangamo Therapeutics, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board of Directors believes
that Mr. Carey&#8217;s experience and perspective advising the Company and other life sciences companies in connection with financing
and strategic transactions, as well as his depth of operating and senior management experience in our industry, provide him with the qualifications
and skills to serve as a director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Erick
J. Lucera, Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erick
J. Lucera joined our Board of Directors in August 2017 and serves on our audit committee, compensation committee and nominating committee.
He previously served as Executive Vice President and Chief Financial Officer of Editas Medicine, Inc., a leading gene editing company
focused on developing CRISPR medicines for people with serious diseases, from May 2023 to March 2025. Mr. Lucera previously served as
Chief Financial Officer of AVEO Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on targeted medicines for
oncology and other unmet medical needs, from January 2020 until March 2023, following its acquisition by LG Chem, Ltd. Since April 2023,
Mr. Lucera has served on the board of directors of SAB Biotherapeutics, Inc., a public clinical-stage biopharmaceutical company. Mr.
Lucera was the Chief Financial Officer of Valeritas Holdings, Inc., a U.S. Nasdaq traded commercial stage company developing new technology
for diabetes, from 2016 to 2019. Mr. Lucera served as Chief Financial Officer, Treasurer and Secretary of Viventia Bio from 2015 to 2016.
From 2012 to 2015, he was Vice President, Corporate Development at Aratana Therapeutics, a veterinary biopharmaceutical company. While
at Aratana, he helped grow the company&#8217;s product pipeline through a series of acquisitions and in licensing transactions financed
through five public and private offerings of nearly $250 million. Before his career as a healthcare company executive, Mr. Lucera spent
over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund
at Intrepid Capital and as head of the healthcare research team at Independence Investments. He has served on the board of directors
of Bone Biologics, a Nasdaq traded orthobiologics company, since October 2021. He holds a CPH from Harvard University, an MS in quantitative
finance from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr.
Lucera has obtained CFA, CMA, and CPA designations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors believes that Mr. Lucera&#8217;s experience and perspective advising the Company and other life sciences companies
on strategic transactions and financings, as well as his depth of operating and senior management experience in our industry, provide
him with the qualifications and skills to serve as a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Yoori
Lee, Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoori
Lee joined our Board of Directors in January 2018. Ms. Lee serves on our compensation committee and audit committee. She has served as
Co-founder and President of Trio Health Advisory Group, Inc. since 2013. Trio Health&#8217;s mission is to improve the quality of care
in patient outcomes through coordinating the efforts of all patient care stakeholders. Prior to Trio Health, Ms. Lee spent over 15 years
at Leerink Partners LLC, a leading healthcare investment bank, where she was Managing Director, and Director of MEDACorp Services. Additionally,
she helped found the MEDACorp network, a cadre of experts including more than 35,000 healthcare professionals in diverse areas of practice
such as clinical medicine, biomedical research, regulatory affairs, public policy, healthcare administration and healthcare information
technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors believes that Ms. Lee&#8217;s experience and perspective advising the Company as well as her experience with Leerink
Partners LLC and MEDACorp. provide her with the qualifications and skills to serve as a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
William Forbes, Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
William Forbes joined our Board of Directors in August 2018 and serves on our compensation and nominating committee. He brings to our
Board of Directors more than 30 years of pharmaceutical product development experience and, working with health authorities in the U.S.
and Europe, has contributed to numerous marketing approvals spanning a diverse range of therapeutic areas. Dr. Forbes has served as the
Chief Development Officer of Trevi Therapeutics, a clinical-stage pharmaceutical company focused on serious neurologically mediated diseases
since February 2021. Prior to joining Trevi, Dr. Forbes was at Salix Pharmaceuticals as the Chief Development Officer and also Head of
Medical and R&amp;D from February 2015 to June 2015. Prior to Salix, Dr. Forbes spent 15 years in Clinical Development &amp; Regulatory
Affairs and Clinical Research at a number of global pharmaceutical companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors believes that Dr. Forbes&#8217; experience and perspective advising the Company, as well as his depth of operating
and senior management experience in our industry, provide him with the qualifications and skills to serve as a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term
of Office of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors are elected at each annual meeting of stockholders and serve until their successors are elected and qualified at the next annual
meeting of stockholders, or until their prior death, resignation or removal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our current or former directors or executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Involvement
in Certain Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erick
J. Lucera was the Chief Financial Officer of Valeritas Holdings, Inc. until January 3, 2020. On February 9, 2020, Valeritas Holdings,
Inc. filed a voluntary petition for bankruptcy protection under Chapter 11 of Title 11 of the U.S. Bankruptcy Code in the United States
Bankruptcy Court for the District of Delaware in order to facilitate its sale to a Denmark-based biotechnology company. The plan of liquidation
was approved on June 8, 2020 and became effective on June 30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Daniel Moorhead was the Chief Financial Officer of Zynex, Inc. until August 29, 2025. On December 15, 2025, Zynex, Inc. filed a voluntary
petition for bankruptcy protection under Chapter 11 of Title 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for
the Southern District of Texas. The reorganization plan was confirmed on March 19, 2026 and became effective on March 26, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth above, none of our directors, executive officers, significant employees, promoters or control persons has been involved
in any legal proceeding in the past ten years that would require disclosure under Item 401(f) of Regulation S-K promulgated under the
Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delinquent
Section 16(a) Reports</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of Exchange Act requires our directors, executive officers and persons who own more than 10% of our outstanding shares of
common stock (&#8220;Ten Percent Holders&#8221;) to file with the SEC reports of their share ownership and changes in their share
ownership of our common stock. Directors, executive officers and ten percent holders are also required to furnish us with copies of
all ownership reports they file with the SEC. To our knowledge, based solely on a review of the copies of such reports furnished to
us, the following directors, executive officers and 10% holders did not comply with all Section 16(a) filing requirements as of
March 31, 2026 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Lisi, our former chief executive officer and chairman, filed his form 4 regarding cancellation of certain old warrants and issuance
    of new warrants as of November 3, 2025, one business day late on November 6, 2025;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Carey filed his form 4 regarding certain transactions related to option repricing effective as of November 4, 2025, one business day
     late on November 7, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">(iii)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mr. Gaul filed his form 4 regarding certain transactions related to option repricing effective as of November 4,
2025, fourteen business days late on November 24, 2025.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">(iv)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Ms. Yoori filed her form 4 regarding certain transactions related to option repricing effective as of November 4,
2025, fourteen business days late on November 24, 2025.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has established four standing committees: the audit committee, the compensation committee, the nominating committee
and the compliance committee. The current members of our audit committee are Erick Lucera, Yoori Lee, and Robert F. Carey with Erick Lucera serving
as chairperson. The current members of our compensation committee are Yoori Lee, Dr. William Forbes, and Erick J. Lucera, with Yoori Lee serving as chairperson.
The current members of our nominating committee are Erick Lucera, Robert F. Carey, and Dr. William Forbes, with Erick Lucera serving as chairperson.
The compliance committee currently has four members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has determined that Erick Lucera, Yoori Lee, and Robert F. Carey meet the additional test for independence for audit committee
members imposed by SEC regulations and Section 5605(c)(2)(A) of the Nasdaq Stock Market listing rules and that Erick J. Lucera, Dr. William Forbes, and Yoori
Lee meet the additional test for independence for compensation committee members imposed by Section 5605(d)(2)(A) of the Nasdaq Stock
Market listing rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of our audit committee is to assist the Board of Directors in the oversight of the integrity of our accounting and financial
reporting process, the audits of our consolidated financial statements, and our compliance with legal and regulatory requirements. It
also oversees internal controls and discusses Company policies related to risk assessment and risk management, including cybersecurity
matters. Our audit committee met five times during the fiscal year ended March 31, 2026. The functions of our audit committee include,
among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hiring
    the independent registered public accounting firm to conduct the annual audit of our consolidated financial statements and monitoring
    its independence and performance; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving the planned scope of the annual audit and the results of the annual audit; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving
    all audit services and permissible non-audit services provided by our independent registered public accounting firm;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the significant accounting and reporting principles to understand their impact on our consolidated financial statements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    our internal financial, operating and accounting controls with management, our independent registered public accounting firm and
    our internal audit provider;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    with management and our independent registered public accounting firm, as appropriate, our financial reports, earnings announcements
    and our compliance with legal and regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically
    reviewing and discussing with management the effectiveness and adequacy of our system of internal controls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    consultation with management and the independent auditors, reviewing the integrity of our financial reporting process and adequacy
    of disclosure controls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    potential conflicts of interest under and violations of our code of conduct;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    procedures for the treatment of complaints received by us regarding accounting, internal accounting controls or auditing matters
    and confidential submissions by our employees of concerns regarding questionable accounting or auditing matters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving related-party transactions; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and evaluating, at least annually, our audit committee&#8217;s charter.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to reviewing and approving related-party transactions, our audit committee will review related-party transactions for potential
conflicts of interests or other improprieties. Under SEC rules, related-party transactions are those transactions to which we are or
may be a party in which the amount involved exceeds the lesser of $120,000 or 1% of the average of our total assets at year-end for the
last two completed fiscal years, and in which any of our directors or executive officers or any other related person had or will have
a direct or indirect material interest, excluding, among other things, compensation arrangements with respect to employment and Board
of Directors membership. Our audit committee could approve a related-party transaction if it determines that the transaction is in our
best interests. Our directors are required to disclose to this committee or the full Board of Directors any potential conflict of interest,
or personal interest in a transaction that our Board of Directors is considering. Our executive officers are required to disclose any
related-party transaction to the audit committee. We also poll our directors on an annual basis with respect to related-party transactions
and their service as an officer or director of other entities. Any director involved in a related-party transaction that is being reviewed
or approved must recuse himself or herself from participation in any related deliberation or decision. Whenever possible, the transaction
should be approved in advance and if not approved in advance, must be submitted for ratification as promptly as practical. The Company
has written policies and procedures with respect to related person transactions for managing such situations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial literacy requirements of the SEC require that each member of our audit committee be able to read and understand fundamental
financial statements. In addition, at least one member of our audit committee must qualify as an audit committee financial expert, as
defined in Item 407(d)(5) of Regulation S-K promulgated under the Securities Act, and have financial sophistication in accordance with
the Nasdaq Stock Market listing rules. Our Board of Directors has determined that Erick Lucera qualifies as an audit committee financial
expert. Mr. Lucera is independent director, as independence for audit committee members is defined in the Nasdaq Stock Market listing
rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
our independent registered public accounting firm and management periodically meet privately with our audit committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 83; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of our compensation committee is to assist our Board of Directors in exercising its responsibilities relating to
compensation of our executive officers and employees and to administer our equity compensation and other benefit plans. In carrying
out these responsibilities, this committee reviews all components of executive officer and employee compensation for consistency
with its compensation philosophy, as in effect from time to time. Our compensation committee met two times during the year ended
March 31, 2026. The functions of our compensation committee include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">designing
    and implementing competitive compensation, retention and severance policies to attract and retain key personnel; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and formulating policy and determining the compensation of our Chief Executive Officer, our other executive officers and certain
    employees; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and recommending to our Board of Directors the compensation of our non-employee directors; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and evaluating our compensation risk policies and procedures; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our equity incentive plans and granting equity awards to our employees, consultants and directors under these plans; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our performance bonus plans and granting bonus opportunities to our employees, consultants and non-employee directors under these
    plans; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    required from time to time, preparing the analysis or reports on executive officer compensation required to be included in our annual
    proxy statement; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">engaging
    compensation consultants or other advisors it deems appropriate to assist with its duties; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and evaluating, at least annually, our compensation committee&#8217;s charter. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee retains sole authority to hire any compensation consultant, approve such consultant&#8217;s compensation, determine
the nature and scope of its services, evaluate its performance, and terminate its engagement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee reviews our compensation policies and practices for all employees, including our named executive officers, as
they relate to risk management practices and risk-taking incentives to assess and determine that there are no risks arising from these
policies and practices that are reasonably likely to have a material adverse effect on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nominating
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of our nominating committee is to assist our Board of Directors in promoting the best interest of the Company and our
stockholders through the implementation of sound corporate governance principles and practices. Our nominating committee met two times
during the fiscal year ended March 31, 2026. The functions of our nominating committee include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    reviewing and evaluating candidates to serve on our Board of Directors; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
    the minimum qualifications for service on our Board of Directors; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and recommending to our Board of Directors an annual self-evaluation process for our Board of Directors and overseeing the annual
    self-evaluation process; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing,
    as appropriate, a set of corporate governance principles, and reviewing and recommending to our Board of Directors any changes to
    such principles; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically
    reviewing and evaluating our nominating committee&#8217;s charter. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compliance
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of our compliance committee is to assist our Board of Directors with oversight of healthcare compliance risk management
arising from the FDA, Office of Inspector General, the U.S. Department of Justice and other federal, state or foreign corporate compliance
requirements related to medical devices that specifically govern the AKS, FCA, FD&amp;C Act, FCPA, Sunshine Act and similar state laws,
HIPAA, the AdvaMed Code, and similar applicable state and local regulations and (when applicable) equivalent global requirements. Our
compliance committee met one time during the fiscal year ended March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has a critical role in guiding our strategic direction and overseeing the management of our business, and accordingly,
we seek to attract and retain highly qualified directors who have sufficient time to engage in the activities of our Board of Directors
and to understand and enhance their knowledge of our industry and business plans. In evaluating the suitability of individual candidates,
our Board of Directors, in approving (and, in the case of vacancies, appointing) such candidates, may take into account many factors,
including: personal and professional integrity; ethics and values; experience in corporate management, such as serving as an officer
or former officer of a publicly held company; strong finance experience; experience relevant to our industry; experience as a board member
or executive officer of another publicly held company; relevant academic expertise or other proficiency in an area of our operations;
diversity of expertise and experience in substantive matters pertaining to our business relative to other board members; diversity of
background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience;
practical and mature business judgment, including, but not limited to, the ability to make independent analytical inquiries; and any
other relevant qualifications, attributes or skills. The core competencies of directors should address accounting or finance experience,
market familiarity, business or management experience, industry knowledge, customer-base experience or perspective, crisis response,
leadership, and/or strategic planning. Our Board of Directors evaluates each individual in the context of the Board as a whole, with
the objective of assembling a group that can best perpetuate the success of the business and represent stockholder interests through
the exercise of sound judgment using its diversity of experience in these various areas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 84; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the date of our most recent periodic report, there were no changes to the procedure by which our security holders may recommend nominees
to our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholder
Communications</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we do not have a formal policy regarding stockholder communications with our Board of Directors, stockholders may communicate with our
Board of Directors, or any individual director on our Board of Directors, by writing to us at the address of our principal executive
offices, addressing the communication to the attention of our Chief Executive Officer, and specifying the Board of Directors or, if applicable,
the individual member thereof as the intended recipient of the communication. Our Corporate Secretary will forward to the directors all
communications that, in his judgment, are appropriate for consideration by the directors. Examples of communications that would not be
appropriate for consideration by the directors include commercial solicitations and matters not relevant to the stockholders, to the
functioning of the Board of Directors or to the affairs of our Company. Any correspondence received that is addressed generically to
the Board of Directors will be forwarded to the Chairman of the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Leadership Structure and Role in Risk Oversight</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Currently, Robert F. Carey serves as Chairman of the Board and Robert S. Goodman serves as Chief Executive Officer. Mr. Goodman sets
the strategic direction for the Company and provides day-to-day leadership. As Chairman of the Board of Directors, Mr. Carey
oversees the agenda for board meetings in collaboration with the other board members. We believe that this structure provides appropriate leadership and oversight of the Company and facilitates effective
functioning of both management and our Board of Directors. Our Board of Directors will continue to reassess the structure to
determine what is in the best interests of the Company and stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors oversees our exposure to risk through its interaction with management and receipt from management of periodic reports
outlining matters related to financial, operational, regulatory, legal and strategic risks. Risk assessment and oversight are an integral
part of our governance and management processes. Our Board of Directors encourages management to promote a culture that incorporates
risk management into our corporate strategy and day-to-day business operations. Management discusses strategic and operational risks
at regular management meetings and conducts specific strategic planning and review sessions during the year that include a focused discussion
and analysis of the risks facing us. Throughout the year, senior management reviews these risks with the Board of Directors at regular
board meetings as part of management presentations that focus on particular business functions, operations or strategies and presents
the steps taken by management to mitigate or eliminate such risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct and Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a Code of Business Conduct and Ethics that applies to all our directors, officers (including our Chief Executive Officer,
Chief Financial Officer and any person performing similar functions) and employees. We have made our Code of Business Conduct and Ethics
available on our website at www.beyondair.net under &#8220;<i>Investors&#8212;Governance&#8212;Governance Documents</i>&#8221;. We expect
that any future amendments to our Code of Business Conduct and Ethics or any waivers of its requirements will be disclosed on our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted an Insider Trading Policy. The Insider Trading Policy establishes clear guidelines to prevent insider trading
and upholds the Company&#8217;s reputation for integrity and ethical conduct.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Insider Trading Policy applies to all transactions in the Company&#8217;s securities, including but not limited to common stock,
options to purchase common stock, and any other securities the Company may issue. It covers all directors, officers, employees
of the Company, and any family members or entities whose transactions in Company securities are directed by or under the influence
or control of those persons. The Company is committed to rigorously enforcing this policy to prevent insider trading and protect all
stakeholders&#8217; interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policies
and practices for granting certain equity awards</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policies and practices regarding the granting of equity awards are carefully designed to ensure compliance with applicable
securities laws and to maintain the integrity of our executive compensation program. The compensation committee of the Board of Directors
is responsible for the timing and terms of equity awards to executives and other eligible employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timing of equity award grants is determined with consideration to a variety of factors, including but not limited to, the achievement
of pre-established performance targets, market conditions, and internal milestones. The Company does not follow a predetermined schedule
for the granting of equity awards; instead, each grant is considered on a case-by-case basis to align with the Company&#8217;s strategic
objectives and to ensure the competitiveness of our compensation packages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the timing and terms of an equity award, the Board of Directors or compensation committee may consider material nonpublic
information to ensure that such grants are made in compliance with applicable laws and regulations. The Board of Directors or compensation
committee&#8217;s procedures to prevent the improper use of material nonpublic information in connection with the granting of equity
awards include oversight by legal counsel and, where appropriate, delaying the grant of equity awards until the public disclosure of
such material nonpublic information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is committed to maintaining transparency in its executive compensation practices and to making equity awards in a manner that
is not influenced by the timing of the disclosure of material nonpublic information for the purpose of affecting the value of executive
compensation. The Company regularly reviews its policies and practices related to equity awards to ensure they meet the evolving standards
of corporate governance and continue to serve the best interests of the Company and its stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 85; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_021"></span>ITEM
11. EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Processes
and Procedures for Compensation Decisions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee is responsible for the executive compensation programs for our executive officers and reports to our Board of
Directors on its discussions, decisions and other actions. Our compensation committee reviews and approves corporate goals and objectives
relating to the compensation of our Chief Executive Officer, evaluates the performance of our Chief Executive Officer in light of those
goals and objectives and determines and approves the compensation of our Chief Executive Officer based on such evaluation. Our compensation
committee has the sole authority to determine our Chief Executive Officer&#8217;s compensation. In addition, our compensation committee,
in consultation with our Chief Executive Officer, reviews and approves all compensation for other officers, as well as the directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee is authorized to retain the services of one or more executive compensation and benefits consultants or other outside
experts or advisors as it sees fit, in connection with the establishment of our compensation programs and related policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee has full authority to form and delegate authority to one or more subcommittees consisting solely of one or more
members of the compensation committee as it deems appropriate from time to time. The compensation committee may delegate to the Chief
Executive Officer or any other executive officer the authority to grant equity awards to employees of the Company who are not directors
or officers of the Company, on such terms and subject to such limitations as the compensation committee may determine in compliance with
Delaware corporate law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes compensation for the years ended March 31, 2026 and 2025 for our &#8220;named executive officers&#8221;, namely
our (i) principal executive officer (PEO); (ii) our two other most highly compensated executive officers whose total compensation exceeded
$100,000 for the fiscal year ended March 31, 2026; and (iii) up to two additional individuals for whom disclosure would have been provided
pursuant to Item 402(m)(2)(ii) of Regulation S-K but for the fact that the individual was not serving as an executive officer of the
Company at the end of the last completed fiscal year:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Salary Cost</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(A)(B)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Robert Goodman (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center">2026</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">125,616</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">7,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">132,950</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Chief Executive Officer and Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Steven A. Lisi (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2026</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">757,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">757,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Former Chief Executive Officer and Chairman of the Board</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">555,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">266,140</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">821,140</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Daniel Moorhead (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2026</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">75,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">44,723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">120,556</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Michael Gaul</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2026</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">396,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">396,923</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Chief Operating Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">372,669</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">92,203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">464,872</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Douglas Larson (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2026</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">236,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">236,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Former Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">324,423</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">80,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">405,276</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    column represents the grant date fair value of awards from Beyond Air, Beyond Cancer and NeuroNos in accordance with stock-based
    compensation rules under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    respective agreements include a change of control provision that would automatically vest any unvested restricted stock units or
    unvested stock options if triggered. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Mr. Goodman joined the Board of Directors in June 2025, served as Chief
Commercial Officer from November 5, 2025 through March 26, 2026, at which point he was appointed Chief Executive Officer.</span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Mr. Lisi resigned as Chief Executive Officer and Chairman of the Board,
effective March 26, 2026.</span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Mr. Moorhead was appointed as Chief Financial Officer effective January
5, 2026.</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                         <tr style="vertical-align: top">
<td>(4)</td><td style="text-align: justify">Mr. Larson resigned as Chief Financial Officer effective December 31, 2025.</td></tr>
                         </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements with Named Executive Officers </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employment agreements with our named executive officers contain provisions standard for a company in our industry regarding non-competition,
confidentiality of information and assignment of inventions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 86; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Steven Lisi</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2018, we entered into an employment agreement with Mr. Lisi to serve as our Chief Executive Officer with an annual base salary
of $450,000, subject to review of the compensation committee at least annually. On April 1, 2022, Mr. Lisi&#8217;s annual salary was
increased to $650,000. In addition to his base salary, Mr. Lisi is eligible to receive a short-term incentive bonus equal to a percentage
of his base salary in effect at the end of the fiscal year, based partially on performance weighted bonus objectives established for
Mr. Lisi by the Board of Directors (which includes both corporate objectives and individual objectives) for the fiscal year, with such
objectives to be discussed with Mr. Lisi prior to being established, and partially based on the discretion of the Board of Directors.
The target bonus percentage each fiscal year is an amount equal to 60% of Mr. Lisi&#8217;s base salary in effect at the end of each fiscal
year. However, the actual short-term incentive bonus as determined by the Board of Directors may range from 0% to higher than 100% of
the base salary. Any short-term incentive bonus shall be paid on or before April 15 of the following year and may include cash, stock
options and restricted stock awards. If paid in stock options or restricted stock awards, the short-term incentive bonus must be paid
separately from, and independently of, any long-term equity incentive award. Pursuant to the employment agreement, Mr. Lisi is also eligible
to receive awards of stock options or restricted stock grants as may be determined from time to time by the Board of Directors or the
compensation committee of the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Lisi&#8217;s employment agreement contains restrictive covenants relating to non-disclosure of confidential information, assignment of
inventions, and non-solicitation of employees and customers that runs for a period of one year following his termination of employment
for any reason.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 26, 2026, Mr. Lisi resigned
as the Company&#8217;s chief executive officer and member of the Board and from all his positions with the Company and its subsidiaries,
effective March 27, 2026. Mr. Lisi&#8217;s resignation is not the result of any disagreement with the Company or its Board or any matter
relating to the Company&#8217;s operations, policies, or practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 27, 2026, the Company
executed a Separation and Release of Claims Agreement with Mr. Lisi (&#8220;Release Agreement&#8221;). The Release Agreement contains
customary protections, including a general release of claims by Mr. Lisi in favor of the Company and certain other related parties. Pursuant
to the terms of the Release Agreement, the Company shall be obligated to pay Mr. Lisi $650,000 separation pay in the form of compensation
continuation over 12 months pursuant to the Company&#8217;s regular and customary payroll schedule, less all regular and customary payroll
withholdings. The Company shall also pay Mr. Lisi COBRA premiums for 12 months. All unvested options and all unvested stock restriction
unit awards held by Mr. Lisi as of March 27, 2026, shall be accelerated and shall immediately vest, and shall continue to remain exercisable
for twenty-four (24) months from March 27, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Daniel Moorhead</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of an employment agreement between the Company and Mr. Moorhead effective December 25, 2025. Mr. Moorhead was to be
paid an annual salary of $325,000 per year and he will be eligible for a discretionary bonus and to participate in the Plan. In addition, Mr. Moorhead was granted an employment inducement stock option award exercisable for the purchase of
70,000 shares of the Company&#8217;s Common Stock, subject to the terms of the Plan, and the applicable award agreement to be entered
into by and between the Company and Mr. Moorhead. The stock option will vest 25% on the first anniversary and annually thereafter in 3
equal installments, provided that, no portion of the stock option that is not exercisable at the time of termination of employment for
any reason shall thereafter become exercisable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Mr. Moorhead&#8217;s employment agreement, in the event of his termination of employment without &#8220;cause&#8221; or
resignation for &#8220;good reason,&#8221; as such terms are defined in his employment agreement, subject to Mr. Moorhead&#8217;s
execution of a release, Mr. Moorhead will be entitled to receive (i) his base salary for a period of six months, payable in
accordance with the Company&#8217;s regular payroll practices, with an accelerated payment of any balance upon the occurrence of a
&#8220;change in control,&#8221; as such term is defined in his employment agreement, provided that if such termination of
employment occurs within three months before or within 12 months after the occurrence of a change in control, the severance payable
to Mr. Moorhead will be increased to an amount equal to Mr. Moorhead&#8217;s base salary for a period of 18 months and be payable in
a single lump sum payment; and (ii) payment or reimbursement (upon presentation of proof of payment) of Mr. Moorhead&#8217;s medical
insurance premiums at the same level as was in effect on the termination date for a period of six months, which period will increase
to 18 months if such termination of employment occurs within three months before or within 12 months after the occurrence of a
change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Moorhead&#8217;s employment agreement contains restrictive covenants relating to non-disclosure of confidential information, assignment
of inventions, and non-solicitation and non-competition covenants that run for a period of 12 months following his termination of employment
for any reason.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 87; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Michael Gaul</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2020, we entered into an Employment Agreement with Michael Gaul to serve as Senior VP, Operations of the Company, effective
May 4, 2020. Mr. Gaul&#8217;s Employment Agreement provides that his employment will continue until either the Company or Mr. Gaul terminates
his employment in accordance with the terms of the Employment Agreement. Pursuant to the employment Agreement, Mr. Gaul is entitled to
receive an annual base salary of $250,000, which is subject to adjustment pursuant to the Company&#8217;s employee compensation practices.
In April 2022, Mr. Gaul&#8217;s base salary was increased to $350,000. On April 1, 2023, Mr. Gaul&#8217;s annual salary was increased
to $400,000. In addition, pursuant to the Employment Agreement, Mr. Gaul is eligible to be considered for an incentive bonus for each
fiscal year of the Company, which will be awarded based on objective or subjective criteria established by the Chief Executive Officer
and approved by the Board or a committee thereof. On July
1, 2022, Mr. Gaul stepped down as Senior VP, Operations of the Company and assumed the role of Chief Operating Officer. Notwithstanding
this titular change, the other terms of his Employment Agreement with us did not change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Employment Agreement, termination of Mr. Gaul&#8217;s employment by the Company without cause, or by Mr. Gaul for &#8220;Good Reason&#8221;
(as such term is defined in the Employment Agreement), will require the Company to pay severance to Mr. Gaul. Upon any such termination,
and subject to the terms of the Employment Agreement and the Company&#8217;s policies, Mr. Gaul will be entitled to receive his base
salary for a period of six months, plus an additional month of severance payments for every two months of employment, with such additional
amounts to be cumulative and not to exceed a total of 12 months of severance payments. The Company will also continue to contribute to
Mr. Gaul&#8217;s health and dental benefits in the same proportion as during employment for the same duration as severance payments are
made. In the event of a Change of Control (as defined in the Employment Agreement), Mr. Gaul will receive severance payments equal to
six months&#8217; base salary and the Company will continue to provide health and dental benefits in the same proportion as during employment
for six months. Mr. Gaul will also receive an additional month of severance for every two years of employment, with such amounts to be
cumulative and not to exceed a total of 12 months of severance payments. In addition, all of Mr. Gaul&#8217;s options to acquire Company
stock and restricted common stock awards which have not vested as of the date of termination will become immediately vested as of the
date of termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employment Agreement also contains customary non-solicitation and non-competition covenants, which covenants remain in effect for 1 year
following any cessation of employment with respect to Mr. Gaul.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employment Agreement with Douglas Larson</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of an employment
agreement between the Company and Mr. Larson dated August 20, 2021. Mr. Larson was to be paid an annual salary of $275,000 per year. In
April 2022, Mr. Larson&#8217;s annual salary was increased to $300,000. On April 1, 2023, Mr. Larson&#8217;s annual salary was increased
to $350,000. In connection with the commencement of his employment, we issued Mr. Larson options to purchase 3,750 shares of common stock
at an exercise price that has since been repriced to $1.95 per share. The options vest over four years at 25% per year and were 75% vested as of March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr. Larson&#8217;s employment
agreement contains restrictive covenants relating to non-disclosure of confidential information, assignment of inventions, and non-solicitation
and non-competition covenants that run for a period of 12 months following his termination of employment for any reason.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr. Larson resigned as the Company&#8217;s Chief Financial Officer effective December 31, 2025.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 88; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
Awards Granted During the Year Ended March 31, 2026</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 13, 2025, Mr. Goodman was granted options to purchase 3,750 shares of
our common stock with an exercise price of $2.45 per share, which was equal to the closing price of our common stock
on the date of grant. The options vest in equal annual installments over four years commencing on December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 5, 2026, Mr. Moorhead was granted options to purchase 70,000 shares of our common stock with an exercise price of $0.79 per
share, which was equal to the closing price of our common stock on the date prior to the grant. The options vest in equal annual installments
over four years commencing on December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards as of March 31, 2026</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="29" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity awards</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unexercised</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options (#)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercisable</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unexercised</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options (#)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unexercisable</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>incentive</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>plan</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>awards:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unexercised</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unearned</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options (#)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>price ($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>expiration</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>date</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares or</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>units of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>that</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>have not</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>vested (#)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>value of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares or</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>units of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>that</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>have not</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>vested ($)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(5)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-align: left">Steven A. Lisi*</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: center">08/31/2018</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">20,000</td><td style="width: 1%; text-align: left">(1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/2028</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/31/2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/11/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,500</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/04/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/03/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,000</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/29/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/20/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,500</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/26/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,500</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Robert Goodman</td><td>&#160;</td>
    <td style="text-align: center">08/13/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">938</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,812</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/13/2035</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,940</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Daniel Moorhead</td><td>&#160;</td>
    <td style="text-align: center">01/05/2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.79</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/05/2036</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mike Gaul</td><td>&#160;</td>
    <td style="text-align: center">03/11/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/11/2030</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">05/04/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500</td><td style="text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/04/2030</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/04/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,250</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/04/2031</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/03/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,500</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/03/2032</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/29/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,375</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/29/2033</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,466</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/20/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,750</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/20/2034</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,038</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/26/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/26/2035</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,350</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/03/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">207</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Doug Larson**</td><td>&#160;</td>
    <td style="text-align: center">09/01/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,750</td><td style="text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/03/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/29/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,500</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/20/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/26/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,375</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
option, share and exercise prices in the table have been adjusted for the 2025 Reverse Stock Split which was effectuated on July 14,
2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Mr. Lisi resigned as Chief Executive Officer and Chairman of the Board, effective March 26, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**Mr.
Larson resigned as Chief Financial Officer, effective December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    options vests immediately, 25% vests December 31, 2018, 25% vests each following December 31.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    options vests in December of the year of grant, 25% vests each following December.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock units vest 20% per year with the first tranche vesting in December in the year of grant</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    options vests on the anniversary date of the grant, 25% each following year on the anniversary date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    value was calculated based upon the closing stock price on the last trading day of the fiscal year ended March 31, 2026 ($0.69).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 89; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons
serving as both an officer and a director of the Company are only included in the Summary Compensation Table above for the year ended
March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">Name</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fees <br/> earned <br/> or paid <br/> in cash <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Stock <br/> awards <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Option <br/> awards <br/> ($) <br/> (1) (2)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Non-equity <br/> incentive <br/> plan <br/> compensation <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Nonqualified <br/> deferred <br/> compensation <br/> earnings <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">All Other <br/> Compensation <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Dr. William Forbes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Erick J. Lucera</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Yoori Lee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Robert F. Carey</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended March 31, 2026, there were no equity awards granted to directors. As of
    March 31, 2026, the aggregate number of options to purchase Beyond Air&#8217;s common stock held by each director on the Board of
    Directors was as follows: (i) 13,652 by Dr. Forbes; (ii) 14,252 by Mr. Lucera; (iii) 14,004 by Ms. Lee; and (v) 21,802 by Mr.
    Carey. As of March 31, 2026, Mr. Carey additionally held an aggregate of 65,000 options to purchase Beyond Cancer&#8217;s common
    stock and 19,125 options to purchase NeuroNos common stock. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    respective agreements include a change of control provision that would automatically vest any unvested stock options if triggered.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_022"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth information with respect to the beneficial ownership of our common stock by each person known by us to beneficially
own more than 5.0% of any class of our voting securities together with:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#8239;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our named executive officers; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of our directors and executive officers as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
percentages of common stock beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial
ownership of securities. Except as indicated in the footnotes to this table, each beneficial owner named in the table below has sole
voting and sole investment power with respect to all shares beneficially owned. Percentage computations are based on 14,410,621 shares of our
common stock outstanding as of June 23, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of the warrants issued by us to each of Atlas Diversified
Master Fund, Ltd. (&#8220;ADMF&#8221;) and Robert Carey, they may not exercise a warrant to the extent such exercise would cause them,
together with their affiliates and any other persons acting as a group with them or any of their affiliates, to have acquired a number
of shares of Common Stock which would exceed 9.99%, excluding for purposes of such determination shares of Common Stock issuable upon
exercise of warrants that have not been exercised. We refer to the foregoing limitations as the &#8220;Ownership Cap.&#8221; The share
numbers in the table below do not reflect the Ownership Cap, but the figures contained in the &#8220;Percentage of Outstanding Shares&#8221;
column reflect the Ownership Cap applicable to the relevant parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 90; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name and Address of Beneficial Owner (1)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares (2)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares % (2)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic">5% Owners</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Atlas Diversified Master Fund, Ltd.</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">763,266</td><td style="width: 1%; text-align: left">(3)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">5.19</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Named Executive Officers and Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bob Goodman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,938</td><td style="text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. William Forbes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,957</td><td style="text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Robert F. Carey</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,450,962</td><td style="text-align: left">(6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.31</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Erick Lucera</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,994</td><td style="text-align: left">(7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Yoori Lee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,197</td><td style="text-align: left">(8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Michael Gaul</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,197</td><td style="text-align: left">(9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Daniel Moorhead</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">All executive officers and directors (7 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,517,831</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.70</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than one percent (1.0%). </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    address of these persons, unless otherwise noted, is c/o Beyond Air, Inc., 900 Stewart Avenue, Suite 301 Garden City, New York, 11530<span style="text-transform: uppercase">.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of Common Stock beneficially owned and, except as limited by the Ownership Cap as discussed above, the respective percentages of
    beneficial ownership of Common Stock includes for each person or entity shares issuable on the exercise of all options and warrants
    and the conversion of other convertible securities beneficially owned by such person or entity that are currently exercisable or
    will become exercisable or convertible within 60 days following June 23, 2026. Such shares, however, are not included for the purpose
    of computing the percentage ownership of any other person.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our records and a Schedule 13G/A filed on May 15, 2026. Includes 150,384 pre-funded warrants and 148,721 warrants to purchase Common
Stock. By virtue of its position as the investment manager of ADMF, the direct holder of our securities, Balyasny Asset Management L.P.,
a Delaware limited partnership (&#8220;BAM&#8221;) may be deemed to exercise voting and investment power over our securities held by
ADMF and thus may be deemed to beneficially own such securities. By virtue of its position as the General Partner of BAM, BAM GP LLC,
a Delaware limited liability company (&#8220;BAM GP&#8221;) may be deemed to exercise voting and investment power over our securities
held directly by ADMF and thus may be deemed to beneficially own such securities. By virtue of its position as the Sole Member of BAM
GP, Balyasny Asset Management Holdings LP, a Delaware limited partnership (&#8220;BAM Holdings&#8221;) may be deemed to exercise voting
and investment power over our securities held directly by ADMF and thus may be deemed to beneficially own such securities. By virtue
of its position as the General Partner of BAM Holdings, Dames GP LLC, a Delaware limited liability company (&#8220;Dames&#8221;) may
be deemed to exercise voting and investment power over our securities held directly by ADMF and thus may be deemed to beneficially own
such securities. By virtue of his position as the Managing Member of Dames, Dmitry Balyasny may be deemed to exercise voting and investment
power over our securities held directly by ADMF and thus may be deemed to beneficially own our securities.</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal business address of each of BAM, BAM GP, BAM Holdings, Dames, and Mr. Balyasny is located at 444 West Lake Street, 50th Floor,
Chicago, IL 60606.</span></p>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 938 vested options to purchase Common Stock. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 9,216 vested options to purchase Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 25,317 pre-funded warrants, 1,136,422 warrants and 11,552 vested
options to purchase Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 9,816 vested options to purchase Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 9,568 vested options to purchase Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 27,375 vested options to purchase Common Stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 91; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plan Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
January 30, 2026, we maintained the Seventh Amended and Restated 2013 Beyond Air Equity Incentive Plan. As of January 30, 2026, we maintain
the Eighth Amended and Restated 2013 Beyond Air Equity Incentive Plan (the &#8220;2013 BA Plan&#8221;). The 2013 BA Plan provides for
the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation
rights, performance share awards, and other stock-based awards (collectively, the &#8220;stock awards&#8221;). Stock awards may be granted
under the 2013 BA Plan to our employees, directors and consultants, other than incentive stock options which may only be granted to employees
of the Company. The maximum number of shares of common stock available for issuance under the 2013 BA Plan is 1,680,000 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2025, the board of directors approved a one-time stock option repricing of 726,618 options (the &#8220;2026 Option Repricing&#8221;),
effective November 4, 2025, in accordance with, and as permitted by, the Company&#8217;s 2013 BA Plan. Pursuant to the 2026 Option Repricing,
all options granted pursuant to the 2013 BA Plan that were held by Company Board members, officers, and employees expected to continue
providing services to the Company were repriced, to the extent such options had an exercise price in excess of $1.95, the closing price
per share of the Company&#8217;s common stock as reported on The Nasdaq Stock Market on November 3, 2025. All such options were repriced
such that the exercise price per share was reduced to $1.95.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2013 BA Plan is scheduled to terminate on August 13, 2028. No stock awards shall be granted pursuant to the 2013 BA Plan after such date
but awards theretofore granted may extend beyond that date. The Board may suspend or terminate the 2013 BA Plan at any earlier date.
No stock awards may be granted under the 2013 BA Plan while the Plan is suspended or after it is terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the total number of outstanding options and shares available for other future issuances of options under the
2013 BA Plan and the 2021 Employee Stock Purchase Plan as of March 31, 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Plan Category</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>to be Issued</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Upon</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>and Rights</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>and Rights</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available for</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Future Issuance</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Under the Equity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plan</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Excluding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares in First</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Column)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Equity compensation plans approved by stockholders (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">625,543</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">931,776</td><td style="width: 1%; text-align: left">(3)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by stockholders (2)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">131,206</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1.33</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(</b>1)
Represents shares of common stock reserved for future issuance upon exercise of outstanding stock options under the 2013 BA Plan that
were approved by our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Represents shares of common stock issuable upon exercise of outstanding stock options under the 2013 BA Plan that were not approved by
our stockholders including 73,750 options issued as inducement awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Represents 894,276 shares of common stock available to be granted under the 2013 BA Plan and 37,500 shares of common stock reserved for
future issuance under the 2021 Employee Stock Purchase Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 92; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_023"></span>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transactions
with Related Persons</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
SEC rules, related-party transactions are those transactions to which we are or may be a party in which the amount involved exceeds the
lesser of $120 thousand or 1% of the average of total assets at year-end for the last two completed fiscal years, and in which any of
our directors or executive officers or any other related person had or will have a direct or indirect material interest, excluding, among
other things, compensation arrangements with respect to employment and Board of Directors membership. Our audit committee could approve
a related-party transaction if it determines that the transaction is in our best interests. Our directors are required to disclose to
this committee or the full Board of Directors any potential conflict of interest, or personal interest in a transaction that our Board
of Directors is considering. Our executive officers are required to disclose any related-party transaction to the audit committee. We
also poll our directors on an annual basis with respect to related-party transactions and their service as an officer or director of
other entities. Any director involved in a related-party transaction that is being reviewed or approved must recuse himself or herself
from participation in any related deliberation or decision. Whenever possible, the transaction should be approved in advance and if not
approved in advance, must be submitted for ratification as promptly as practical.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
April 1, 2023, there were no transactions to which we have been a party in which the amount involved exceeded or will exceed the lesser
of $120,000 or one percent of the average of the Company&#8217;s total assets at year-end for the last two completed fiscal years, and
in which any of our directors, executive officers or beneficial owners of more than 5% of our capital stock, or any members of their
immediate family, had or will have a direct or indirect material interest, other than the Term Sheet described below and compensation
arrangements that are described in the <i>&#8220;Executive Compensation&#8221;</i>, <i>&#8220;Director Compensation&#8221;</i> and &#8220;<i>Long
Term Debt&#8221; </i>sections of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2024, Beyond Air entered into a binding term sheet (&#8220;Term Sheet&#8221;) for a secured loan with certain lenders including
its Chief Executive Officer Steven Lisi and director Robert Carey. The Term Sheet was approved by each of the Company&#8217;s independent
and disinterested directors, and the Audit Committee following the receipt of a recommendation from an independent investment bank. The
Term Sheet provides for the following expected terms: (i) principal amount of $11,500,000; (ii) ten-year term; (iii) interest of 15%
per annum of which 3% shall be payable in cash and 12% payable in kind through June 30, 2026 and thereafter all in cash; (iv) a royalty
interest of 8% of the Company&#8217;s net sales on a quarterly basis from July 2026 until the facility is repaid in full; and (v) the Company issued the lenders warrants to purchase shares of the Company&#8217;s
common stock at an exercise price, adjusted for the 2025 Reverse Stock Split, of $7.59 per share. On November 3, 2025, the parties entered
into a waiver agreement pursuant to which the Loan Agreement lenders consented to the Company&#8217;s issuance of the Streeterville Note
in exchange for reducing the exercise price from $7.59 per share to $1.95 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2025, the Company received $2.0 million of advanced financing from a related party, director Robert Carey who is also an existing
lender under its Loan Agreement (&#8220;Additional Loans&#8221;). On November 3, 2025, the Company amended and restated the original
Loan Agreement (as amended, the &#8220;Amended Loan Agreement&#8221;) to provide for and finalize the terms of the $2.0 million Additional
Loans and the issuance of new five-year warrants to purchase up to 512,821 shares of the Company&#8217;s common stock (the &#8220;Supplemental
Warrants&#8221;) with an exercise price of $1.95 per share and subject to the same terms and conditions applicable to the existing warrants
issued under the original Loan and Security Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has determined that each of Erick Lucera, Yoori Lee, William Forbes and Robert F. Carey is independent within the
meaning of Rule 5605(a)(2) of the Nasdaq Listing Rules and the rules and regulations promulgated by the SEC. In making its independence
determinations, the Board of Directors sought to identify and analyze all of the facts and circumstances related to any relationship
between a director, his immediate family and the Company and our affiliates and did not rely on categorical standards other than those
contained in the Nasdaq rule referenced above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_024"></span>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Fees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 17, 2024, our audit committee dismissed Marcum as the Company&#8217;s independent registered public accounting firm and approved
the engagement of Withum as the Company&#8217;s independent registered public accounting firm for the fiscal year ending March 31, 2025,
effective immediately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate fees billed for (i) the fiscal year ended March 31, 2026 for professional services rendered in part by Withum, and (ii) the
fiscal year ended March 31, 2025 for professional services rendered by Withum for the audit of our annual financial statements provided
by Withum and in part by Marcum, in connection with statutory and regulatory filings or engagements for this fiscal period:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">(usd)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2026</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Audit Fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">467,005</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">425,673</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audit Related Fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax Fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">All Other Fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">467,005</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">425,673</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the above table, &#8220;audit fees&#8221; are fees billed by our independent registered public accounting firm for services provided
in auditing our annual financial statements for the subject year. Audit fees also include professional services performed for filing
of our registration statement on Form S-3 for equity offerings and for the resale of certain shares of our common stock, Form S-8 for
shares of our common stock underlying our 2013 BA Plan and other filings. &#8220;Audit-related fees&#8221; are fees not included in audit
fees that are billed by the independent registered public accounting firm for assurance and related services that are reasonably related
to the performance of the audit review of our financial statements. &#8220;Tax fees&#8221; are fees billed by the independent registered
public accounting firm for professional services rendered for tax compliance, tax advice and tax planning. &#8220;All other fees&#8221;
are fees billed by the independent registered public accounting firm for products and services not included in the foregoing categories.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policy
on Pre-Approval by Audit Committee of Services Performed by Independent Auditors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee pre-approves all services provided by our independent registered public accounting firm. All of the above services and
fees were reviewed and approved by the audit committee before the respective services were rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors has considered the nature and amount of fees billed by Withum and Marcum and believes that the provision of services
for activities unrelated to the audit, if any, is compatible with maintaining Marcum and Withum&#8217;s independence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 93; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_025"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_026"></span>ITEM
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
Financial Statements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Index to Consolidated Financial Statements on page F-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
Finance Statement Schedules.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225006902/ex1-1.htm" style="-sec-extract: exhibit">At-The-Market Equity Offering Sales Agreement, dated as of February 14, 2025, filed as Exhibit 1.1 to our Current Report on Form 8-K, filed with the SEC on February 14, 2025 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_2-1.htm" style="-sec-extract: exhibit">Agreement and Plan of Merger and Reorganization, dated as of December 29, 2016, by and among AIT Therapeutics, Inc. and Advanced Inhalation Therapies Ltd., filed as Exhibit 2.1 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_2-2.htm" style="-sec-extract: exhibit">First Amendment to Agreement and Plan of Merger and Reorganization, dated as of January 12, 2017, by and among AIT Therapeutics, Inc. and Advanced Inhalation Therapies Ltd., filed as Exhibit 2.2 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_2-3.htm" style="-sec-extract: exhibit">Merger Completion Certificate, dated as of December 29, 2016, by and among Red Maple Ltd. And Advance Inhalation (AIT) Ltd., filed as Exhibit 2.3 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_3-1.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation of AIT Therapeutics, Inc., dated as of January 9, 2017, filed as Exhibit 3.1 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_3-2.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws of AIT Therapeutics, Inc. filed as Exhibit 3.2 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315219009826/ex3-3.htm" style="-sec-extract: exhibit">Certificate of Amendment of Amended and Restated Certificate of Incorporation, dated as of June 25, 2019, filed as Exhibit 3.3 to our Annual Report on Form 10-K filed with the SEC on June 28, 2019 and incorporated herein by reference.</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224047830/ex3-1.htm" style="-sec-extract: exhibit">Second Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Beyond Air, Inc., dated November 22, 2024, filed as Exhibit 3.1 to our Current Report on Form 8-K, as filed with the SEC on November 26, 2024 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">3.5</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000164117225018520/form8-k.htm" style="-sec-extract: exhibit">Third Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Beyond Air, Inc., dated July 9, 2025, filed as Exhibit 3.1 to our Current Report on Form 8-K, as filed with the SEC on July 10, 2025 and incorporated herein by reference.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_4-1.htm" style="-sec-extract: exhibit">Form of Common Stock Certificate, filed as Exhibit 4.1 to our Current Report on Form 8-K, as filed with the SEC on March 15, 2017 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315220011662/ex4-7.htm" style="-sec-extract: exhibit">Description of the Company&#8217;s Securities Registered under Section 12 of the Securities Exchange Act of 1934, as amended, filed as Exhibit 4.7 to our Annual Report on Form 10-K, as filed with the SEC on June 23, 2020 and incorporated herein by reference.</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_10-3.htm" style="-sec-extract: exhibit">Form of Warrant to Purchase Common Stock, by and among AIT Therapeutics, Inc. and the Holders party thereto, filed as Exhibit 10.3 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017, and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000117891317001048/exhibit_4-1.htm" style="-sec-extract: exhibit">Form of Warrant to Purchase Common Stock, by and among AIT Therapeutics, Inc. and the Holders party thereto, filed as Exhibit 4.1 to our Current Report on Form 8-K, as filed with the SEC on April 4, 2017, and incorporated herein by reference.</a></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315220004447/ex4-1.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant, by and among Beyond Air, Inc. and the Holders party thereto, filed as Exhibit 4.1 to our Current Report on Form 8-K, as filed with the SEC on March 20, 2020 and incorporated herein by reference.</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315223021898/ex4-1.htm" style="-sec-extract: exhibit">Warrant to Purchase Common Stock, by and between Beyond Air, Inc. and Avenue Venture Opportunities Fund, L.P., dated as of June 15, 2023, filed as Exhibit 4.1 to our Current Report on Form 8-K, as filed with the SEC on June 20, 2023, and incorporated herein by reference.</a></span></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 94; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315223021898/ex4-2.htm" style="-sec-extract: exhibit">Warrant to Purchase Common Stock, by and between Beyond Air, Inc. and Avenue Venture Opportunities Fund II, L.P., dated as of June 15, 2023, filed as Exhibit 4.2 to our Current Report on Form 8-K, as filed with the SEC on June 20, 2023, and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224010974/ex4-1.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant, by and between Beyond Air, Inc. and the Holders party thereto, filed as Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on March 22, 2024 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224025433/ex4-1.htm" style="-sec-extract: exhibit">Warrant to Purchase Common Stock, by and between Beyond Air, Inc. and Avenue Venture Opportunities Fund, L.P., dated as of June 21, 2024, filed as Exhibit 4.1 to our Current Report on Form 8-K filed with the SEC on June 27, 2024</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224025433/ex4-2.htm" style="-sec-extract: exhibit">Warrant to Purchase Common Stock, by and between Beyond Air, Inc. and Avenue Venture Opportunities Fund II, L.P., dated as of June 21, 2024, filed as Exhibit 4.2 to our Current Report on Form 8-K filed with the SEC on June 27, 2024.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224038433/ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-funded Warrant, by and between Beyond Air, Inc. and the purchasers, filed as Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on September 27, 2024 and incorporated herein by reference</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224038433/ex4-2.htm" style="-sec-extract: exhibit">Form of Common Warrant, by and between Beyond Air, Inc. and the purchasers, filed as Exhibit 4.2 to our Current Report on Form 8-K, filed with the SEC on September 27, 2024 and incorporated herein by reference.</a></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224043852/ex4-1.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant filed as Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on November 6, 2024, and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">4.14</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225012866/ex4-1.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant filed as Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on September 9, 2025, and incorporated herein by reference.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">4.15</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225020888/ex4-1.htm" style="-sec-extract: exhibit">Form of Supplemental Warrant filed as Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on November 5, 2025, and incorporated herein by reference.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">4.16</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225020888/ex4-2.htm" style="-sec-extract: exhibit">Secured Promissory Note filed as Exhibit 4.2 to our Current Report on Form 8-K, filed with the SEC on November 5, 2025, and incorporated herein by reference.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">4.17</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315226002884/ex4-1.htm" style="-sec-extract: exhibit">Form of Pre Funded Warrant filed as Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on January 20, 2026, and incorporated herein by reference.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">4.18</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315226002884/ex4-2.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant filed as Exhibit 4.2 to our Current Report on Form 8-K, filed with the SEC on January 20, 2026, and incorporated herein by reference.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_10-1.htm" style="-sec-extract: exhibit">Amended and Restated Agreement for the Transfer and Assumption of Obligations Under the Securities Purchase and Registration Rights Agreements, dated as of January 12, 2017, by and among AIT Therapeutics, Inc. and Advanced Inhalation Therapies Ltd., filed as Exhibit 10.1 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated herein by reference.</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_10-10.htm" style="-sec-extract: exhibit">License Agreement, dated as of November 1, 2011, by and between Advanced Inhalation Therapies Ltd. And The UBC, filed as Exhibit 10.10 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&#x5E;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000132/exhibit_10-9.htm" style="-sec-extract: exhibit">Non-Exclusive Patent License Agreement, dated as of October 22, 2013, by and between Advanced Inhalation Therapies Ltd. And SensorMedics Corporation, filed as Exhibit 10.9 to our Current Report on Form 8-K. as filed with the SEC on January 20, 2017 Registration Statement on Form S-1(File No. 333-216287), and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_10-13.htm" style="-sec-extract: exhibit">Option Agreement, dated as of August 31, 2015, by and between Advanced Inhalation Therapies Ltd. And Pulmonox Technologies Corporation, filed as Exhibit 10.13 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_10-14.htm" style="-sec-extract: exhibit">Tenth Amendment to Option Agreement, dated as of December 31, 2016, by and between Advanced Inhalation Therapies Ltd. And Pulmonox Technologies Corporation, filed as Exhibit 10.14 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated herein by reference.</a></span></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 95; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315221019206/ex10-2.htm" style="-sec-extract: exhibit">Executive Employment Agreement, dated as of June 30, 2018, by and between AIT Therapeutics Inc. and Steven Lisi, filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q, as filed with the SEC on August 10, 2021 and incorporated herein by reference.</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315219002083/ex10-1.htm" style="-sec-extract: exhibit">License, Development and Commercialization Agreement, dated January 23, 2019, by and between AIT Therapeutics, Inc. and Circassia Limited, filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q on February 14, 2019 and incorporated herein by reference.</a></span></td></tr>
</table>

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315221019206/ex10-1.htm" style="-sec-extract: exhibit">Settlement Agreement and Release, dated May 26, 2021, by and between Beyond Air, Inc. and Circassia Limited, filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q, as filed with the SEC on August 10, 2021 and incorporated herein by reference.</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315220015377/ex10-1.htm" style="-sec-extract: exhibit">Supply Agreement, dated as of August 6, 2020, by and between Beyond Air, Inc. and Spartronics Watertown, LLC, filed as Exhibit 10.1 to our Current Report on Form 8-K, as filed with the SEC on August 12, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315220016215/ex10-1.htm" style="-sec-extract: exhibit">Manufacture and Supply Agreement, dated as of July 30, 2020, by and between Beyond Air, Inc. and Medisize Ireland Limited, filed as Exhibit 10.1 to our Current Report on Form 8-K, as filed with the SEC on August 18, 2020 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315221005676/ex10-2.htm" style="-sec-extract: exhibit">Beyond Air, Inc. 2021 Employee Stock Purchase Plan, filed as Exhibit 10.2 to our Current Report on Form 8-K, as filed with the SEC on March 9, 2021 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315222018575/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement, dated as of April 24, 2020, by and between Beyond Air, Inc. and Michael Gaul, filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on July 5, 2022 and incorporated herein by reference.</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224010974/ex1-1.htm" style="-sec-extract: exhibit">Form of Placement Agency Agreement, dated March 20, 2024, by and among Beyond Air, Inc. and Roth Capital Partners, LLC and Laidlaw &amp; Company (UK) Ltd., filed as Exhibit 1.1 to our Current Report on Form 8-K, as filed with the SEC on March 22, 2024, and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224010974/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement dated March 20, 2024, by and among Beyond Air, Inc and the Purchasers, filed as Exhibit 10.1 to our Current Report on Form 8-K, as filed with the SEC on March 22, 2024 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224025433/ex10-1.htm" style="-sec-extract: exhibit">First Amendment to Loan Documents, by and among Beyond Air, Inc., Beyond Air Ltd., Avenue Capital Management II, L.P., as Agent, and the Lenders party thereto, dated as of June 21, 2024, filed as Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on June 27, 2024.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224038433/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement dated September 26, 2024, by and between Beyond Air, Inc. and the purchasers, filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on September 27, 2024 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224038433/ex10-2.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement dated September 26, 2024, by and between Beyond Air, Inc. and the purchasers dated September 27, 2024, filed as Exhibit 10.2 to our Current Report on Form 8-K, filed with the SEC on September 27, 2024 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224038433/ex10-3.htm" style="-sec-extract: exhibit">Engagement Letter dated August 16, 2024, by and among Beyond Air, Inc., BTIG, LLC, Laidlaw &amp; Company (UK) LTD, Arcadia Securities, LLC, and Jones Trading Institutional Services LLC, filed as Exhibit 10.3 to our Current Report on Form 8-K, filed with the SEC on September 27, 2024 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224043195/formdef14a.htm#a_010" style="-sec-extract: exhibit">Beyond Air, Inc. Seventh Amended and Restated 2013 Equity Incentive Plan (incorporated by reference from Appendix A to the Proxy Statement for Beyond Air, Inc.&#8217;s 2025 Annual Meeting of Stockholders, filed with the SEC on October 31, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315224043852/ex10-1.htm" style="-sec-extract: exhibit">Loan and Security Agreement, dated November 1, 2024, by and between Beyond Air, Inc. and BCR8V LLC, filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on November 6, 2024 and incorporated herein by reference.</a></span></td></tr>


<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225012866/ex10-1.htm" style="-sec-extract: exhibit">Form of Inducement Letter, filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on September 9, 2025 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225020888/ex10-1.htm" style="-sec-extract: exhibit">Equity Purchase Agreement, dated November 4, 2025, by and between Beyond Air, Inc. and Streeterville Capital, LLC, filed as Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on November 5, 2025 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225020888/ex10-2.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated November 4, 2025, by and between Beyond Air, Inc. and Streeterville Capital, LLC, filed as Exhibit 10.2 to our Current Report on Form 8-K filed with the SEC on November 5, 2025 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225020888/ex10-3.htm" style="-sec-extract: exhibit">Amended and Restated Loan and Security Agreement, dated November 3, 2025, filed as Exhibit 10.3 to our Current Report on Form 8-K filed with the SEC on November 5, 2025 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225020888/ex10-4.htm" style="-sec-extract: exhibit">Waiver dated November 3, 2025, filed as Exhibit 10.4 to our Current Report on Form 8-K filed with the SEC on November 5, 2025 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225020888/ex10-5.htm" style="-sec-extract: exhibit">Note Purchase Agreement, dated November 4, 2025, by and between Beyond Air, Inc. and Streeterville Capital, LLC, filed as Exhibit 10.5 to our Current Report on Form 8-K filed with the SEC on November 5, 2025 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225020888/ex10-6.htm" style="-sec-extract: exhibit">XAIR Holdings Guaranty, dated November 4, 2025, filed as Exhibit 10.6 to our Current Report on Form 8-K filed with the SEC on November 5, 2025 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225020888/ex10-7.htm" style="-sec-extract: exhibit">Foreign Subsidiary Guaranty, dated November 4, 2025, by and between Beyond Air Australia Pty Ltd, Beyond Air Ireland Ltd, Beyond Air Ltd, and Streeterville Capital, LLC, filed as Exhibit 10.7 to our Current Report on Form 8-K filed with the SEC on November 5, 2025 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225020888/ex10-8.htm" style="-sec-extract: exhibit">Security Agreement, dated November 4, 2025, by and between Beyond Air, Inc. and Streeterville Capital, LLC, filed as Exhibit 10.8 to our Current Report on Form 8-K filed with the SEC on November 5, 2025 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225020888/ex10-9.htm" style="-sec-extract: exhibit">Intellectual Property Security Agreement, dated November 4, 2025, filed as Exhibit 10.9 to our Current Report on Form 8-K filed with the SEC on November 5, 2025 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225020888/ex10-10.htm" style="-sec-extract: exhibit">BA Israel Security Agreement, dated November 4, 2025, by and between Beyond Air Ltd. and Streeterville Capital, LLC, filed as Exhibit 10.10 to our Current Report on Form 8-K filed with the SEC on November 5, 2025 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225020888/ex10-11.htm" style="-sec-extract: exhibit">BA Israel IP Security Agreement, by and between Beyond Air Ltd. and Streeterville Capital, LLC, dated November 4, 2025, filed as Exhibit 10.11 to our Current Report on Form 8-K filed with the SEC on November 5, 2025 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225020888/ex10-12.htm" style="-sec-extract: exhibit">Pledge Agreement, dated November 4, 2025, by and between Beyond Air, Inc. and Streeterville Capital, LLC, filed as Exhibit 10.12 to our Current Report on Form 8-K filed with the SEC on November 5, 2025 and incorporated herein by reference.</a></span></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 96; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225029637/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement, by and between the Company and Daniel Moorhead, filed as Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on December 30, 2025 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315226002884/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, filed as Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on January 20, 2026 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315226002884/ex10-2.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, filed as Exhibit 10.2 to our Current Report on Form 8-K filed with the SEC on January 20, 2026 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315226002884/ex10-3.htm" style="-sec-extract: exhibit">Form of Placement Agency Agreement, filed as Exhibit 10.3 to our Current Report on Form 8-K filed with the SEC on January 20, 2026 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315225028563/formdef14a.htm#Y-004" style="-sec-extract: exhibit">Beyond Air, Inc. Eighth Amended and Restated 2013 Equity Incentive Plan, incorporated by reference from Appendix A to the Proxy Statement for Beyond Air, Inc.&#8217;s 2026 Annual Meeting of Stockholders, filed with the SEC on December 19, 2025.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1641631/000149315226014676/ex10-1.htm" style="-sec-extract: exhibit">Separation and Release of Claims Agreement by and between the Company and Steven A. Lisi dated March 27, 2026, filed as Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on April 1, 2026 and incorporated herein by reference.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex19-1.htm">Insider Trading Policy</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21-1.htm">List of subsidiaries of Beyond Air, Inc.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of WithumSmith+Brown LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Rule 13a-14(a) / 15d-14(a) Certification of Principal Executive Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Rule 13a-14(a) / 15d-14(a) Certification of Principal Financial Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1***</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Section 1350 Certification of Principal Executive Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2***</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Section 1350 Certification of Principal Financial Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97+**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex97.htm">Beyond Air, Inc. Incentive Compensation Recovery Policy, effective October 2, 2023, filed as Exhibit 97 to our Annual Report on Form 10-K, as filed with the SEC on June 24, 2024, and incorporated herein by reference</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document &#8211; The instance document does not appear in the Interactive Data File because its XBRL tags are embedded
    within the XBRL document. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Labels Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+
Management contract or compensation plan arrangement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit have been omitted as the registrant has determined that the omitted
information is not material and is the type that registrant treats as private or confidential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Filed herewith</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***
Furnished herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_027"></span>Item
16. Form 10-K Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to this item is not required and has been omitted at the Company&#8217;s option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 97; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_028"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
June 26, 2026</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
    AIR, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Robert S. Goodman</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    S. Goodman</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief
    Executive Officer</i></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Principal
    Executive Officer)</i></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Robert S. Goodman</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    26, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    S. Goodman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Daniel Moorhead</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    26, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
    Moorhead</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer
    and Principal Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Erick Lucera</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    26, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erick
    Lucera</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Yoori Lee</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    26, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoori
    Lee</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    William Forbes</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    26, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Forbes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Robert Carey</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    26, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Carey</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 98; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AS
OF MARCH 31, 2026</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_029">Report of Independent Registered Public Accounting Firm WithumSmith+Brown, PC</a> (PCAOB ID:<span id="xdx_90F_edei--AuditorFirmId_c20250401__20260331_zPWatQRmNNz2"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000070" name="dei:AuditorFirmId">100</ix:nonNumeric></span>)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-2</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_030">Consolidated Balance Sheets</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-3</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_031">Consolidated Statements of Operations and Comprehensive Loss</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-4</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_032">Consolidated Statements of Changes in Stockholders&#8217; Equity</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-5</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_033">Consolidated Statements of Cash Flows</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-6</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_034">Notes to Consolidated Financial Statements</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-7
    &#8211; F-32</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 99; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_029"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
of Directors and Stockholders</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
Air, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--AuditorOpinionTextBlock_c20250401__20260331_zdAgnYUuXw8d"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000071" name="dei:AuditorOpinionTextBlock">We
have audited the accompanying consolidated balance sheets of Beyond Air, Inc. (the &#8220;Company&#8221;) as of March 31, 2026 and
2025, and the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and cash
flows for each of the two years in the period ended March 31, 2026, and the related notes (collectively referred to as the
&#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all
material respects, the financial position of Beyond Air, Inc. as of March 31, 2026 and 2025, and the results of its operations and
its cash flows for each of the two years in the period ended March 31, 2026, in conformity with accounting principles generally
accepted in the United States of America.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Substantial
Doubt About the Company&#8217;s Ability to Continue as a Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations, has experienced negative
cash flows from operating activities since inception, and has an accumulated deficit that raise substantial doubt about its ability
to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect
to this matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to Beyond Air,
Inc. in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether these consolidated financial statements are free of material misstatement, whether due to error or
fraud. Beyond Air, Inc. is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose
of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express
no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due
to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements
that was communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are
material to the consolidated financial statements and (2) involved especially challenging, subjective, or complex judgments. The
communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as
a whole, and we are not, by communicating the critical audit matter below, providing separate opinion on the critical audit matter
or on the accounts or disclosures to which it relates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting
for Debt/Equity Financing and Embedded Features</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matter Description</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its debt/equity issuances to determine if those contracts or embedded components of those contracts qualify as derivative
instruments requiring separate recognition in the Company&#8217;s consolidated financial statements. As described in Note 4 and 9, on
November 4, 2025, the Company entered into an equity purchase agreement for the purchase of up to $20 million of the Company&#8217;s
shares of common stock and a note purchase agreement in the principal amount of $12 million with an investor. In connection with the
equity purchase agreement, the investor and the Company also entered into a registration rights agreement, pursuant to which the Company
filed a registration statement for the resale of up to 1.6 million shares of common stock. We identified the accounting for debt/equity
financing as a critical audit matter because of the complexity in applying the accounting framework, including identifying and valuing
any embedded features. This required extensive audit effort related to the application of the accounting framework.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>How
the Critical Audit Matter Was Addressed in the Audit</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addressing
the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated
financial statements. These procedures included the following, among others: as part of walkthrough procedures we reviewed the design
and the operating effectiveness of controls over management&#8217;s process for the accounting treatment, read the agreements, and evaluated
the accounting for the note purchase and equity purchase agreement and any embedded features. We tested management&#8217;s process, which
included (i) evaluating the application of the accounting framework used by management; (ii) testing the mathematical accuracy of management&#8217;s
calculations; and (iii) testing the completeness and accuracy of the underlying data used. Professionals with specialized skill and knowledge
were used to assist in (i) evaluating management&#8217;s application of the accounting framework and (ii) recalculating management&#8217;s
calculation of the fair value of the embedded feature.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_902_edei--AuditorName_c20250401__20260331_zf2h65Au1bo2"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000072" name="dei:AuditorName">WithumSmith+Brown, PC</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as Beyond Air, Inc.&#8217;s auditor since 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--AuditorLocation_c20250401__20260331_zFAa6oWFsdkf"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000073" name="dei:AuditorLocation">East
Brunswick, New Jersey</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
26, 2026</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_030"></span>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_111_pn3n3_zM8GZ9kwFa1i" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20260331_zoqj0r1q0vp8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250331_z3prZLStqpGi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_zuzKJZTqldEe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrentAbstract_i01B_znN2Vm2WQfxe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pn3n3_maACzE7T_zypV1sDpWzcb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2026-03-31" id="Fact000081" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,740</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31" id="Fact000082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,665</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MarketableSecuritiesCurrent_i02I_pn3n3_maACzE7T_zmXnHIiYONt1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2026-03-31" id="Fact000084" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,901</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2025-03-31" id="Fact000085" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,252</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RestrictedCashCurrent_i02I_pn3n3_maACzE7T_zz6soMRomn5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2026-03-31" id="Fact000087" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,622</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2025-03-31" id="Fact000088" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">231</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_i02I_pn3n3_maACzE7T_z2wrductsf14" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2026-03-31" id="Fact000090" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,086</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2025-03-31" id="Fact000091" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">710</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InventoryNet_i02I_pn3n3_maACzE7T_zL0o2OAePwS9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Inventory, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2026-03-31" id="Fact000093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,406</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2025-03-31" id="Fact000094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,417</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pn3n3_maACzE7T_zkKoPWEb2Go3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other current assets and prepaid expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2026-03-31" id="Fact000096" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,012</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-03-31" id="Fact000097" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,743</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrent_i02TI_pn3n3_mtACzE7T_maAzyoV_zNXuOC9KPO4j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2026-03-31" id="Fact000099" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,767</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-03-31" id="Fact000100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,018</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedLicenseAgreementsGross_i01I_pn3n3_maAzyoV_zvPim2bVh3zf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Licensed right to use technology</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedLicenseAgreementsGross" contextRef="AsOf2026-03-31" id="Fact000102" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,018</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedLicenseAgreementsGross" contextRef="AsOf2025-03-31" id="Fact000103" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,222</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3n3_maAzyoV_zCnbPIWGrlrk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Right-of-use lease assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2026-03-31" id="Fact000105" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,193</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-03-31" id="Fact000106" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,706</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pn3n3_maAzyoV_z7Zi1rhnh45a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2026-03-31" id="Fact000108" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,249</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-03-31" id="Fact000109" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,013</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherAssetsNoncurrent_i01I_pn3n3_maAzyoV_zlEAUd3xc1v9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2026-03-31" id="Fact000111" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2025-03-31" id="Fact000112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">103</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Assets_i01TI_pn3n3_mtAzyoV_zOBqLaSA6nm6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2026-03-31" id="Fact000114" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35,385</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-03-31" id="Fact000115" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,062</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z0QqZoYmqJMb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccountsPayableCurrent_i02I_pn3n3_maLCzI5u_zdWhZQvgh1m4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2026-03-31" id="Fact000123" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-03-31" id="Fact000124" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,950</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_i02I_pn3n3_maLCzI5u_zPStYyW0NJX5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2026-03-31" id="Fact000126" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,372</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2025-03-31" id="Fact000127" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,045</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pn3n3_maLCzI5u_zSdFYH0c9rWd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease liabilities, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2026-03-31" id="Fact000129" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">321</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-03-31" id="Fact000130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LoansPayableCurrent_i02I_pn3n3_maLCzI5u_zqyXNYTBmTw" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Loans payable, current portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="AsOf2026-03-31" id="Fact000132" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">401</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="AsOf2025-03-31" id="Fact000133" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">609</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesCurrent_i02TI_pn3n3_mtLCzI5u_maLzZO2_zeI9yt0a1QW4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2026-03-31" id="Fact000135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,511</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact000136" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_pn3n3_maLzZO2_zKYuXLv4tdXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2026-03-31" id="Fact000138" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,023</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-03-31" id="Fact000139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,486</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermLoansPayable_i02I_pn3n3_maLzZO2_zpoF9srTpq69" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Long-term debt, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermLoansPayable" contextRef="AsOf2026-03-31" id="Fact000141" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,639</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermLoansPayable" contextRef="AsOf2025-03-31" id="Fact000142" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,197</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityNonCurrent_i02I_pn3n3_maLzZO2_zSU810kGtLBc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="XAIR:WarrantLiabilityNonCurrent" contextRef="AsOf2026-03-31" id="Fact000144" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="XAIR:WarrantLiabilityNonCurrent" contextRef="AsOf2025-03-31" id="Fact000145" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Liabilities_i01TI_pn3n3_mtLzZO2_maLASEz6ph_z62zntmsRAo" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2026-03-31" id="Fact000147" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,175</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-03-31" id="Fact000148" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,721</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--CommitmentsAndContingencies_i01I_maLASEz6ph_zoVaRiZ0FABd" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments and contingencies (Note 12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0150">-</span>&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0151">-</span>&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 16%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 16%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquityAbstract_i01B_z52IIrTb1flf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockValue_i02I_pn3n3_maSEziqf_zXbatRfGqAZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Preferred Stock, $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20260331_zKjVCUSyspC7" title="Preferred stock, par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250331_zMHaPtG0qNja" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31" id="Fact000159" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" id="Fact000161" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value per share: <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260331_zxMTHYMC3Ilh" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250331_zeSHLiOEpdfc" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2026-03-31" id="Fact000163" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-03-31" id="Fact000165" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pid_c20260331_zi7NV7tbNS2" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20260331_zvBUIdojQYV2" title="Preferred stock, shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250331_z4fCDYf7LM6i" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250331_zeEoGXVetQnf" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2026-03-31" id="Fact000167" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2026-03-31" id="Fact000169" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-03-31" id="Fact000171" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-03-31" id="Fact000173" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0156">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0157">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CommonStockValue_i02I_pn3n3_maSEziqf_zwKxh7kFRIEk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Common Stock, $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260331_fKDEp_zDXNip81vOt8" title="Common stock, par value"><span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250331_fKDEp_zJC2sHyv0In7" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31" id="Fact000178" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" id="Fact000180" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>
    par value per share: <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20260331_fKDEp_zV9IbQKhIfGa"><span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250331_fKDEp_zWLyJr5QAgB" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-03-31" id="Fact000181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-03-31" id="Fact000183" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000,000</ix:nonFraction></ix:nonFraction></span></span> shares
    authorized, <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_pid_c20260331_fKDEp_zxoMp4tkVMVe" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20260331_fKDEp_zQdE6zQlAoN1" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2026-03-31" id="Fact000185" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2026-03-31" id="Fact000187" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,792,684</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pid_c20250331_fKDEp_z6qVSQ2wkfh2" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250331_fKDEp_zLzA45SCtfJl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-03-31" id="Fact000189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-03-31" id="Fact000191" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,128,539</ix:nonFraction></ix:nonFraction></span></span>
    shares issued and outstanding as of March 31, 2026 and 2025, respectively <span id="xdx_F47_zWmwg1nLiUd3">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2026-03-31" id="Fact000175" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0176">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--TreasuryStockValue_i02NI_pn3n3_di_msSEziqf_zyzU3aXXYS1b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Treasury stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2026-03-31" id="Fact000193" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2025-03-31" id="Fact000194" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--AdditionalPaidInCapital_i02I_pn3n3_maSEziqf_zK0j50cyphil" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2026-03-31" id="Fact000196" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">325,587</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-03-31" id="Fact000197" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">299,990</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_maSEziqf_z1ija4Yo1mMh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2026-03-31" id="Fact000199" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">319,571</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-03-31" id="Fact000200" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">286,322</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_pn3n3_maSEziqf_z2eY4Hz7YT3b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated other comprehensive income/(loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2026-03-31" id="Fact000202" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">134</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-03-31" id="Fact000203" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">60</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquity_i02TI_pn3n3_mtSEziqf_maSEIPAzxNF_zGef6izHXGM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity attributable to Beyond Air, Inc.</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31" id="Fact000205" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,126</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000206" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,583</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--MinorityInterest_i02I_pn3n3_maSEIPAzxNF_zDqo2WumCNn2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2026-03-31" id="Fact000208" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2025-03-31" id="Fact000209" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">758</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pn3n3_mtSEIPAzxNF_maLASEz6ph_zyC4MCSqoec7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2026-03-31" id="Fact000211" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,210</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31" id="Fact000212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,341</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_mtLASEz6ph_zYg6BzbdSC34" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2026-03-31" id="Fact000214" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35,385</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000215" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,062</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F00_z5S1BQetW3e6" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zxUF9wLOb3yl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000216" xml:lang="en-US">Prior
    period results have been adjusted to reflect the one-for-twenty stock split in July 2025. See Note 1, <i>Organization and Business</i>
    for details.</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_031"></span>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except share and per share data)</b></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" id="xdx_30B_113_pn3n3_zFWFMBZkVw5e" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20250401__20260331_z8QRHVsTIOZ3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    Ended</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
    31,</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2026</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240401__20250331_zED1zNIPgnT7" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    Ended</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
    31,</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPz61M_zZYcNEgNs2b7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-04-01to2026-03-31" id="Fact000218" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,679</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31" id="Fact000219" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,705</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfRevenue_msGPz61M_zz9228NpyH8e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of revenues</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-04-01to2026-03-31" id="Fact000221" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,427</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"/>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-04-012025-03-31" id="Fact000222" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,368</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--GrossProfit_iT_pn3n3_maOILz7Cs_mtGPz61M_zqbCDijbEGBe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    profit (loss)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2025-04-01to2026-03-31" id="Fact000224" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">252</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-04-012025-03-31" id="Fact000225" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,663</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEzuAT_zOtDS5jTg6qi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-04-01to2026-03-31" id="Fact000230" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,241</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-04-012025-03-31" id="Fact000231" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,857</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pn3n3_maOEzuAT_z5mtJrrlSK28" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
    general and administrative</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-04-01to2026-03-31" id="Fact000233" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,055</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-04-012025-03-31" id="Fact000234" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,017</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpenses_i01T_mtOEzuAT_msOILz7Cs_zmmCqqmt9Z3d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-04-01to2026-03-31" id="Fact000236" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,296</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-04-012025-03-31" id="Fact000237" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42,874</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OperatingIncomeLoss_iT_mtOILz7Cs_maILFCOzzqP_zxGi98VeevOk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from operations</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-04-01to2026-03-31" id="Fact000239" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,044</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-04-012025-03-31" id="Fact000240" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">44,537</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income/(expense):</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--InterestAndDividendIncomeOperating_i01_maNIEz7S9_zYMjsATdKeNd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend/investment
    income</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestAndDividendIncomeOperating" contextRef="From2025-04-01to2026-03-31" id="Fact000245" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">303</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestAndDividendIncomeOperating" contextRef="From2024-04-012025-03-31" id="Fact000246" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">705</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpenseNonoperating_i01N_di_msNIEz7S9_zFlyWteInM0f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CAEDFB">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    and finance expense</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-04-01to2026-03-31" id="Fact000248" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,515</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-04-012025-03-31" id="Fact000249" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,019</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_msNIEz7S9_zBqx7p1Flvi2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of warrant liability</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-04-01to2026-03-31" id="Fact000251" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-04-012025-03-31" id="Fact000252" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">237</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maNIEz7S9_z9wKBqtBo0I5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CAEDFB">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of derivative liability</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2025-04-01to2026-03-31" id="Fact000254" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,395</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-04-012025-03-31" id="Fact000255" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,314</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maNIEz7S9_zgbvnMXP4djc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    exchange loss</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2025-04-01to2026-03-31" id="Fact000257" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">108</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-04-012025-03-31" id="Fact000258" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maNIEz7S9_zoC2NjqafGI" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CAEDFB">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    on extinguishment of debt</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-04-01to2026-03-31" id="Fact000260" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">165</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-04-012025-03-31" id="Fact000261" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,447</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--GainLossOnDispositionOfAssets1_i01_maNIEz7S9_z6hUVnw59rR" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    on disposal/impairment of fixed assets</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2025-04-01to2026-03-31" id="Fact000263" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">431</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2024-04-012025-03-31" id="Fact000264" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">738</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEz7S9_zO5x2ewgI5bk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income/(expense)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-04-01to2026-03-31" id="Fact000266" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14</ix:nonFraction>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-04-012025-03-31" id="Fact000267" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_i01T_pn3n3_maILFCOzzqP_mtNIEz7S9_zQOuO1YG7zjg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other income/(expense)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-04-01to2026-03-31" id="Fact000269" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,290</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-04-012025-03-31" id="Fact000270" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,942</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzzqP_maPLz8Wb_zIO2URZeYfS6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    before income taxes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-04-01to2026-03-31" id="Fact000272" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">34,334</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-04-012025-03-31" id="Fact000273" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">48,479</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msPLz8Wb_zbpJoWuj8eq8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision
    for income taxes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0275">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0276">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ProfitLoss_iT_mtPLz8Wb_maNILzjdL_zFBPsXyMch07" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-04-01to2026-03-31" id="Fact000278" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">34,334</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012025-03-31" id="Fact000279" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">48,479</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_msNILzjdL_zjsVgN3T4c7d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    net loss attributable to non-controlling interest</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2025-04-01to2026-03-31" id="Fact000281" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,085</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2024-04-012025-03-31" id="Fact000282" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,854</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iT_mtNILzjdL_maCINOTzLNg_zncP97Xo2ab9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss attributable to Beyond Air, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-01to2026-03-31" id="Fact000284" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">33,249</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012025-03-31" id="Fact000285" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">46,625</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_iB_zmcNEs0kPel2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    comprehensive income/(loss), net of tax:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_maCINOTzLNg_znDUJViAMib8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    currency translation adjustment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2025-04-01to2026-03-31" id="Fact000290" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">194</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-04-012025-03-31" id="Fact000291" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">45</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCINOTzLNg_zrJRjTRQ4mfg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
    loss attributable to Beyond Air, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-04-01to2026-03-31" id="Fact000293" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">33,055</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-04-012025-03-31" id="Fact000294" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">46,670</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    basic and diluted loss per share attributable to Beyond Air, Inc. (1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_pid_c20250401__20260331_fKDEp_zXGh0pHusyme" title="Net basic loss per share attributable to Beyond Air, Inc." class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_pid_c20250401__20260331_fKDEp_zALqjTYcP1wk" title="Net diluted loss per share attributable to Beyond Air, Inc." class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-04-01to2026-03-31" id="Fact000296" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-04-01to2026-03-31" id="Fact000298" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">4.01</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_pid_c20240401__20250331_fKDEp_zdPRj5JcWeZ6" title="Net basic loss per share attributable to Beyond Air, Inc." class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20240401__20250331_fKDEp_zqjFZlHC5gYa" title="Net diluted loss per share attributable to Beyond Air, Inc." class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-04-012025-03-31" id="Fact000300" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-012025-03-31" id="Fact000302" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">13.77</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average number of shares of common stock outstanding &#8211; basic and diluted <span>(1)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250401__20260331_fKDEp_zvJdjFK7MLCf" title="Weighted average number of shares of common stock outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250401__20260331_fKDEp_zJbm5ZKyNPM" title="Weighted average number of shares of common stock outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-04-01to2026-03-31" id="Fact000304" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-04-01to2026-03-31" id="Fact000306" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,300,916</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240401__20250331_fKDEp_z14UnLIRAx5b" title="Weighted average number of shares of common stock outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240401__20250331_fKDEp_zT18tbF6td75" title="Weighted average number of shares of common stock outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012025-03-31" id="Fact000308" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012025-03-31" id="Fact000310" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,385,327</ix:nonFraction></ix:nonFraction></span></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F09_zDQo9yPF4iO8" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zl3i1kfZio67" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000311" xml:lang="en-US">Prior
    period results have been adjusted to reflect the one-for-twenty stock split in July 2025. See Note 1, <i>Organization and Business</i>
    for details.</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_032"></span>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_114_pn3n3_z7Py6bCXQd3" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Number</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_ztXatq84XPRk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Amount
    <span id="xdx_F5C_zgBSaViS5h22">(1)</span></td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockCommonMember_zm3dX8SJdK3j" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Stock</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zYXzMnRxNQN2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Capital</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zF0JTd0czEK5" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Deficit</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zRdsNvCU17D2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Income</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zclI9Cuv0WHk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Interest</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_z2cEgZWrY0Q5" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Equity</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock (1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Treasury</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid-in</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comprehensive</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Controlling</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Income/(Loss)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Interest</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_431_c20240401__20250331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zfeuWnEWrTWe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold">Balance as of March 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_z5Wh0lHWr1v6" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000321" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,295,042</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000314" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">25</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000315" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">264,785</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000316" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">239,697</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000317" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_NoncontrollingInterestMember" id="Fact000318" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,138</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31" id="Fact000319" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,186</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zYW7bjYngxoi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock &#8211; At The Market equity offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zXTCyYA3kNcc" title="Issuance of common stock - At The Market equity offering, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="Fact000331" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">337,101</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000325" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,151</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012025-03-31" id="Fact000329" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,151</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--SaleOfCommonStockAndPrefundedWarrants_zsSAmpspvhXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sale of common stock and pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--IssuanceOfCommonStockAtMarketEquityOfferingShares_pid_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zmTB34lSVEj5" title="Sale of common stock and pre-funded warrants, shares" style="text-align: right"><ix:nonFraction name="XAIR:IssuanceOfCommonStockAtMarketEquityOfferingShares" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="Fact000341" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:SaleOfCommonStockAndPrefundedWarrants" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000335" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,858</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:SaleOfCommonStockAndPrefundedWarrants" contextRef="From2024-04-012025-03-31" id="Fact000339" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zSaWvYqJpZW1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issue of common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000345" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,159</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-04-012025-03-31" id="Fact000349" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,159</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zJ8mWp3BsBJe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_z2stYwYyL8t6" title="Issuance of common stock upon exercise of warrants, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="Fact000359" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">234,156</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000353" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-04-012025-03-31" id="Fact000357" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">365</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_ztnmkSvblVO6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock upon vesting of restricted shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zoRQI2KHcA87" title="Issuance of common stock upon vesting of restricted shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="Fact000369" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,240</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueOther_z4kw5kcaVhda" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NeuroNos issuance of stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000373" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,765</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember" id="Fact000376" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">235</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-04-012025-03-31" id="Fact000377" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zQxm3ruG86vc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000381" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,907</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember" id="Fact000384" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">239</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012025-03-31" id="Fact000385" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,146</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherComprehensiveIncomeLossBeforeTax_zbqZobhwiWmi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000391" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">45</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2024-04-012025-03-31" id="Fact000393" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">45</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ProfitLoss_zZmxCGsJrqf6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="Fact000398" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">46,625</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember" id="Fact000400" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,854</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012025-03-31" id="Fact000401" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">48,479</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20250401__20260331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zwRsGrVKLjtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance as of March 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zrY6lGC3wVZf" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000411" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,128,539</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000404" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">25</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000405" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">299,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" id="Fact000406" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">286,322</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000407" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">60</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_NoncontrollingInterestMember" id="Fact000408" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">758</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31" id="Fact000409" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,341</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zxWjKjEGMQI2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock &#8211; At The Market equity offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zwEwfUMZE4f9" title="Issuance of common stock - At The Market equity offering, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="Fact000421" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,441,775</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="Fact000413" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000415" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,134</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-01to2026-03-31" id="Fact000419" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueReverseStockSplits_ztt1lyrOQIl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Issuance of common stock &#8211; 2025 Reverse Stock Split rounding</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20250401__20260331_z0cqd8iul8q3" title="Issuance of common stock - 2025 Reverse Stock Split rounding, shares" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2025-04-01to2026-03-31" id="Fact000431" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0424">-</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0425">-</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0426">-</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0427">-</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></span></td>
    <td>&#160;</td></tr>
<tr id="xdx_409_ecustom--SaleOfCommonStockAndPrefundedWarrants_zGyjxFUOQnEf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sale of common stock and pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--IssuanceOfCommonStockAtMarketEquityOfferingShares_pid_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zrqzT6wYTdG1" title="Sale of common stock and pre-funded warrants, shares" style="text-align: right"><ix:nonFraction name="XAIR:IssuanceOfCommonStockAtMarketEquityOfferingShares" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="Fact000441" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">524,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:SaleOfCommonStockAndPrefundedWarrants" contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000435" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:SaleOfCommonStockAndPrefundedWarrants" contextRef="From2025-04-01to2026-03-31" id="Fact000439" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zLZ6x6CbKjel" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issue of common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0444">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,183</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-04-01to2026-03-31" id="Fact000449" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,183</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_z88SQfZYa0T3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zXxS3tAusra3" title="Issuance of common stock upon exercise of warrants, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="Fact000459" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,088,704</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,868</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-04-01to2026-03-31" id="Fact000457" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,868</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zyPhOwLlAbeh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock upon vesting of restricted shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_ztK5WTJttBUk" title="Issuance of common stock upon vesting of restricted shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="Fact000469" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,630</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zeue6CexNlBk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock for conversion of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zbCFgnJMseW4" title="Issuance of common stock for conversion of debt, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember" id="Fact000479" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,600,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0471">-</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0472">-</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000473" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,341</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0474">-</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0475">-</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0476">-</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-04-01to2026-03-31" id="Fact000477" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,341</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueOther_zkIS8tGaKlch" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NeuroNos issuance of stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0481">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000483" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">573</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember" id="Fact000486" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-04-01to2026-03-31" id="Fact000487" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">700</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z1sK4uNCm6f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000491" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,998</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember" id="Fact000494" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">284</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-04-01to2026-03-31" id="Fact000495" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,282</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherComprehensiveIncomeLossBeforeTax_zxjeC3RMnEK1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other comprehensive gain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0500">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000501" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">194</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0502">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2025-04-01to2026-03-31" id="Fact000503" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">194</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProfitLoss_zj6tuKt6NoO1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0505">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0506">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0507">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember" id="Fact000508" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">33,249</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0509">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember" id="Fact000510" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,085</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-04-01to2026-03-31" id="Fact000511" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">34,334</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20250401__20260331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zmx6D3ac8Kyb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKDEp_zHVQWJqVGt96" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-03-31_us-gaap_CommonStockMember" id="Fact000521" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,792,684</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2026-03-31_us-gaap_CommonStockMember" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2026-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000514" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">25</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000515" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">325,587</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember" id="Fact000516" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">319,571</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000517" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">134</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2026-03-31_us-gaap_NoncontrollingInterestMember" id="Fact000518" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2026-03-31" id="Fact000519" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,210</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F05_zknlhrx0ljZ1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zsJPPGzYV2be" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000522" xml:lang="en-US">Prior
    period results have been adjusted to reflect the one-for-twenty stock split in July 2025. See Note 1, <i>Organization and Business</i>
    for details.</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_033"></span>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_112_pn3n3_zOMMEvfHdUxe" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250401__20260331_zRUHOuyHXAlj" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p>
                                                                                                                                                                                                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2026</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240401__20250331_zL8WnczFQYdd" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p>
                                                                                                                                                                                                                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zylbxq9kCv79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfitLoss_i01_maNCPBUzeMr_zPNJHVYkxli4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-04-01to2026-03-31" id="Fact000527" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">34,334</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012025-03-31" id="Fact000528" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">48,479</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_z5Tk5YiJbBE5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Depreciation_i02_maNCPBUzeMr_zI2ZvnIpmQZd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-04-01to2026-03-31" id="Fact000533" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,047</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-04-012025-03-31" id="Fact000534" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,999</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_i02_maNCPBUzeMr_zHorwxWdKrva" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-04-01to2026-03-31" id="Fact000536" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,282</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012025-03-31" id="Fact000537" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,146</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_maNCPBUzeMr_zGVHMtgSZmgh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of debt discount and accretion of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2025-04-01to2026-03-31" id="Fact000539" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">551</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2024-04-012025-03-31" id="Fact000540" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,028</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AmortizationOfIntangibleAssets_i02_maNCPBUzeMr_zd639m2o7Tza" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Amortization of licensed right to use technology</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2025-04-01to2026-03-31" id="Fact000542" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">204</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-04-012025-03-31" id="Fact000543" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">205</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maNCPBUzeMr_zzBPyyt8hvz7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of operating lease assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2025-04-01to2026-03-31" id="Fact000545" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2024-04-012025-03-31" id="Fact000546" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">367</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FairValueAdjustmentOfWarrants_i02_maNCPBUzeMr_zxA6gEhSqEci" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-04-01to2026-03-31" id="Fact000548" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-04-012025-03-31" id="Fact000549" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">237</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_msNCPBUzeMr_zPERlgePF2Td" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2025-04-01to2026-03-31" id="Fact000551" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,395</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-04-012025-03-31" id="Fact000552" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,314</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i02N_di_msNCPBUzeMr_zj0VxIW7UIWj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Unrealized loss on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-04-012025-03-31" id="Fact000555" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">60</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InventoryWriteDown_i02_maNCPBUzeMr_zc2Ln4kLgsAe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Provision for inventory losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2025-04-01to2026-03-31" id="Fact000557" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">672</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2024-04-012025-03-31" id="Fact000558" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">177</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProvisionForOtherLosses_i02_maNCPBUzeMr_zdHYopUdV3xc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Provision for bad debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForOtherLosses" contextRef="From2025-04-01to2026-03-31" id="Fact000560" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ForeignCurrencyTransactionGainLossAfterTax_i02N_di_msNCPBUzeMr_zGbPOMYXKGTf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Foreign currency adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossAfterTax" contextRef="From2025-04-01to2026-03-31" id="Fact000563" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">119</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msNCPBUzeMr_zSdhQToLyM3k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-04-01to2026-03-31" id="Fact000566" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-04-012025-03-31" id="Fact000567" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,447</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--GainLossOnTerminationOfRightOfUseAsset_i02N_di_msNCPBUzeMr_z4173hRvU4ya" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Impairment of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:GainLossOnTerminationOfRightOfUseAsset" contextRef="From2024-04-012025-03-31" id="Fact000570" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">505</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--GainLossOnDispositionOfAssets_i02N_di_msNCPBUzeMr_zh3YwQ1W9NH4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss on disposal of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" contextRef="From2025-04-01to2026-03-31" id="Fact000572" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">431</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" contextRef="From2024-04-012025-03-31" id="Fact000573" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">334</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PaidInKindInterest_i02_maNCPBUzeMr_zkeduVe4kK9l" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Paid in kind interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2025-04-01to2026-03-31" id="Fact000575" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,762</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2024-04-012025-03-31" id="Fact000576" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">696</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zEBsyLjAbgF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInInventories_i03N_di_msNCPBUzeMr_zx5zVeeF2ot4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2025-04-01to2026-03-31" id="Fact000581" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2024-04-012025-03-31" id="Fact000582" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">466</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUzeMr_zOPpKOGSlrm7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2025-04-01to2026-03-31" id="Fact000584" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">468</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-04-012025-03-31" id="Fact000585" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">390</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzeMr_zm4SzMZ3Dg89" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other current assets and prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2025-04-01to2026-03-31" id="Fact000587" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">683</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-04-012025-03-31" id="Fact000588" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,048</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzeMr_zXYjrI5Dq2rf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2025-04-01to2026-03-31" id="Fact000590" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-04-012025-03-31" id="Fact000591" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">399</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOtherAccruedLiabilities_i03_maNCPBUzeMr_zXPAinVlQT08" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2025-04-01to2026-03-31" id="Fact000593" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2024-04-012025-03-31" id="Fact000594" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,358</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzeMr_z1OfVxBIaxz1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2025-04-01to2026-03-31" id="Fact000596" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">373</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-04-012025-03-31" id="Fact000597" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">385</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzeMr_maCCERCz7yM_zmnotfZea6Xc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-04-01to2026-03-31" id="Fact000599" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,144</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-04-012025-03-31" id="Fact000600" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,218</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zrp1OPVWsVS5" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentsToAcquireMarketableSecurities_i01N_di_msNCPBUz4Wj_zDO8K9f2Iut2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Purchase of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2025-04-01to2026-03-31" id="Fact000605" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,053</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2024-04-012025-03-31" id="Fact000606" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,878</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_i01_maNCPBUz4Wj_z3we2fxao1h7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sale of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2025-04-01to2026-03-31" id="Fact000608" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,404</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2024-04-012025-03-31" id="Fact000609" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51,656</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PaymentsToSecurityDepositsMadeOnOperatingLeases_i01N_di_msNCPBUz4Wj_z5VDwxtwtJ9i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Security deposits made on operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0611">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:PaymentsToSecurityDepositsMadeOnOperatingLeases" contextRef="From2024-04-012025-03-31" id="Fact000612" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUz4Wj_zEYv413xmlu4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Purchase of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2025-04-01to2026-03-31" id="Fact000614" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,025</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-04-012025-03-31" id="Fact000615" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,883</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUz4Wj_maCCERCz7yM_zU7PgBPlSTs6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash (used in)/provided by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-04-01to2026-03-31" id="Fact000617" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,674</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-04-012025-03-31" id="Fact000618" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,905</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zwOeGVlh70ul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_maNCPBUzsWk_zicVwrkrWGph" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock through at the market offerings, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2025-04-01to2026-03-31" id="Fact000623" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2024-04-012025-03-31" id="Fact000624" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,151</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ProceedsFromSaleOfCommonStockOfNeuronos_i01_maNCPBUzsWk_zSfIWcgAAWIa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from the sale of common stock of NeuroNos</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:ProceedsFromSaleOfCommonStockOfNeuronos" contextRef="From2025-04-01to2026-03-31" id="Fact000626" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:ProceedsFromSaleOfCommonStockOfNeuronos" contextRef="From2024-04-012025-03-31" id="Fact000627" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzsWk_z3AiaVnTGj77" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock and pre-funded warrants through securities purchase, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-04-01to2026-03-31" id="Fact000629" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-04-012025-03-31" id="Fact000630" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUzsWk_zoV5AZfVk0aa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock through exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-04-01to2026-03-31" id="Fact000632" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,869</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-04-012025-03-31" id="Fact000633" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">365</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromIssuanceOfWarrants_i01_maNCPBUzsWk_zHk06YsITy78" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2025-04-01to2026-03-31" id="Fact000635" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0636">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ProceedsFromLongTermDebt_i01_maNCPBUzsWk_zYjzpDBLG1pl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from long term loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:ProceedsFromLongTermDebt" contextRef="From2025-04-01to2026-03-31" id="Fact000638" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:ProceedsFromLongTermDebt" contextRef="From2024-04-012025-03-31" id="Fact000639" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,324</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PaymentsOfDebtIssuanceCosts_i01N_di_msNCPBUzsWk_znNct5pk5kQf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2025-04-01to2026-03-31" id="Fact000641" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">996</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RepaymentsOfBankDebt_i01N_di_msNCPBUzsWk_zMSOXjc6BqQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Payment of loan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfBankDebt" contextRef="From2025-04-01to2026-03-31" id="Fact000644" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">208</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfBankDebt" contextRef="From2024-04-012025-03-31" id="Fact000645" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,052</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzsWk_maCCERCz7yM_z1bXaRUEKJlj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-04-01to2026-03-31" id="Fact000647" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,090</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-04-012025-03-31" id="Fact000648" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,646</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCCERCz7yM_zEQFXS24TMN2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of exchange rate changes on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2025-04-01to2026-03-31" id="Fact000650" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">194</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2024-04-012025-03-31" id="Fact000651" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">45</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCz7yM_zTqPklS8DoEk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Increase/(decrease) in cash, cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-04-01to2026-03-31" id="Fact000653" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,466</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-04-012025-03-31" id="Fact000654" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,712</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_z98JU0Ost898" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Cash, cash equivalents and restricted cash at beginning of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2025-03-31" id="Fact000656" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,896</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-03-31" id="Fact000657" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,608</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zNxwsp5U7MG5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash at end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2026-03-31" id="Fact000659" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,362</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2025-03-31" id="Fact000660" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,896</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zQqZIMLJezXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Supplemental disclosure of non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DebtDiscount_i01_z0u9ZwXT8sy4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Debt discount</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="XAIR:DebtDiscount" contextRef="From2025-04-01to2026-03-31" id="Fact000665" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,094</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="XAIR:DebtDiscount" contextRef="From2024-04-012025-03-31" id="Fact000666" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,249</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DerivativesLiability_i01_zB60aXBqk6Fa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Derivative liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="XAIR:DerivativesLiability" contextRef="From2025-04-01to2026-03-31" id="Fact000668" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">775</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0669">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ShortTermFinanceLiability_i01_zgF67zyiXXod" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short term finance liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="XAIR:ShortTermFinanceLiability" contextRef="From2025-04-01to2026-03-31" id="Fact000671" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">457</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="XAIR:ShortTermFinanceLiability" contextRef="From2024-04-012025-03-31" id="Fact000672" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">693</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CapitalExpendituresIncurredButNotYetPaid_i01_zXiMwfRroYMl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed assets recorded in accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="From2025-04-01to2026-03-31" id="Fact000674" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="From2024-04-012025-03-31" id="Fact000675" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--RightofuseAssetsAcquiredUnderOperatingLeases_i01_znKHPhf7Zlca" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets acquired under operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="XAIR:RightofuseAssetsAcquiredUnderOperatingLeases" contextRef="From2025-04-01to2026-03-31" id="Fact000677" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0678">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DebtPrincipalBalanceConvertedToEquity_i01_z4oTfvOFM87e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt principal balance converted to equity</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="XAIR:DebtPrincipalBalanceConvertedToEquity" contextRef="From2025-04-01to2026-03-31" id="Fact000680" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,171</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0681">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InterestPaidNet_i01_zf2nj1E8Jmxg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2025-04-01to2026-03-31" id="Fact000683" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">423</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-04-012025-03-31" id="Fact000684" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,197</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxesPaidNet_i01_z2TrS6SUyhZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income taxes paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0687">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_034"></span>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000689" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z3WmsQszL7N" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 <span id="xdx_821_zIxTspTZWQjb">ORGANIZATION AND BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
Air, Inc. (together with its subsidiaries, &#8220;Beyond Air&#8221; or the &#8220;Company&#8221;) was incorporated on April 28, 2015
under Delaware law. On June 25, 2019, the Company&#8217;s name was changed to Beyond Air, Inc. from AIT Therapeutics, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (&#8220;NO&#8221;) generators
and delivery systems (the &#8220;LungFit<sup>&#174;</sup> platform&#8221;) capable of generating NO from ambient air. The Company&#8217;s
first device, LungFit<sup>&#174; </sup>PH (&#8220;LungFit<sup>&#174; </sup>PH&#8221;) received premarket approval (&#8220;PMA&#8221;) from
the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in June 2022. The NO generated by the LungFit&#174; PH system is indicated to
improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (&gt;34 weeks gestation) neonates
with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with
ventilatory support and other appropriate agents. This condition is commonly referred to as persistent pulmonary hypertension of the
newborn (&#8220;PPHN&#8221;). The LungFit<sup>&#174;</sup> platform can generate NO up to 400 parts per million (&#8220;ppm&#8221;) for
delivery to a patient&#8217;s lungs directly or via a ventilator. LungFit<sup>&#174; </sup>can deliver NO either continuously or for a
fixed amount of time at various flow rates and has the ability to either titrate dose on demand or maintain a constant dose. In July
2022, the Company commenced marketing LungFit<sup>&#174;</sup> PH in the United States for PPHN as a medical device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November  2024, the Company received European CE mark approval of the LungFit PH&#174; system for the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    treatment of infants <span style="text-decoration: underline">&gt;</span>34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic
    evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;
    and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents,
    ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular
    function and oxygenation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LungFit<sup>&#174;</sup>
can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections via delivery
of NO at concentrations &gt; 100 parts per million (ppm) through a breathing mask or similar apparatus. The Company&#8217;s other areas
of focus with the LungFit<sup>&#174;</sup> platform beyond PPHN are nontuberculous mycobacteria (&#8220;NTM&#8221;) lung infection and
those with various severe lung infections with underlying chronic obstructive pulmonary disease (&#8220;COPD&#8221;). The Company&#8217;s
current product candidates will be subject to premarket reviews and approvals by the FDA, certification through the conduct of a conformity
assessment by a notified body in the EU for the product to be CE marked, as well as comparable foreign regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
Beyond Air&#8217;s focus on NO and its effect on the human condition, the Company has two additional programs that do not utilize
the LungFit<sup>&#174;</sup> system. Through the Company&#8217;s majority-owned affiliate Beyond Cancer, Ltd. (&#8220;Beyond
Cancer&#8221;), NO is used to target solid tumors. The LungFit<sup>&#174; </sup>platform is not utilized for the solid tumor
indication due to the need for ultra-high concentrations of gaseous nitric oxide (&#8220;UNO&#8221;). A proprietary delivery system
has been developed that is designed to safely deliver UNO in excess of 10,000 ppm directly to a solid tumor. This program has
completed a phase 1a human clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2021, Beyond Air reorganized its oncology business into a new private company called Beyond Cancer. Beyond Air&#8217;s preclinical
oncology team and the exclusive right to the intellectual property portfolio utilizing UNO for the treatment of solid tumors now reside
with Beyond Cancer. Beyond Air has <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211104__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeyondCancerLtdMember_zTJQOonCGnPe" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-11-04_custom_BeyondCancerLtdMember" id="Fact000691" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% ownership in Beyond Cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
second program which does not utilize the LungFit&#174; platform partially inhibits neuronal nitric oxide synthase (&#8220;nNOS&#8221;) in the brain
to treat neurological conditions. The first target indication is autism spectrum disorder (&#8220;ASD&#8221;). On June 15, 2023, the
Company announced that it has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem,
LTD. (the &#8220;University&#8221;) to acquire the commercial rights for nNOS inhibitors being developed for the treatment of ASD and
other neurological conditions. Currently, there are no FDA-approved therapies specifically for the treatment of ASD. Under the terms
of the agreement, Beyond Air will make payments to the University over the three-year period from the date of the agreement for pre-clinical
work. Also, the Company will pay a low single-digit royalty on net sales and certain one-time payments based on clinical, regulatory
and sales milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2025, Beyond Air reorganized its neurology business into a new private company called NeuroNOS. Beyond Air&#8217;s infrastructure,
for example regulatory, quality, legal, etc., is currently supporting the NeuroNOS team. Beyond Air has <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20250324__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NeuroNosLtdMember_z9io6NDSdA6l" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2025-03-24_custom_NeuroNosLtdMember" id="Fact000693" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">84.75</ix:nonFraction></span>% ownership in NeuroNOS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s current product candidates will be subject to premarket reviews and approvals by the FDA, certification through the conduct
of a conformity assessment by a notified body in the European Union (the &#8220;EU&#8221;), as well as comparable foreign regulatory
authorities&#8217; reviews or approvals in other countries or regions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2025, the Company effectuated a <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20250714__20250714_z1Gz5F2NAKc1" title="Reverse stock split"><ix:nonNumeric contextRef="From2025-07-142025-07-14" id="Fact000695" name="us-gaap:StockholdersEquityReverseStockSplit">one-for-twenty (1:20) reverse stock split</ix:nonNumeric></span> (the &#8220;2025 Reverse Stock Split&#8221;). The
Company&#8217;s common stock began trading on the Nasdaq Stock Market on a split-adjusted basis on July 14, 2025. There was no change
to the number of authorized shares of the Company&#8217;s common stock or the par value per share of common stock. Any fraction of a
share of common stock created as a result of the 2025 Reverse Stock Split was rounded up to the nearest whole share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share and per share information in these accompanying consolidated financial statements have been retroactively adjusted to reflect the
2025 Reverse Stock Split for all periods presented. In addition, (i) a proportionate adjustment has been made to the per share exercise
price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of common
stock, and (ii) the number of shares reserved for issuance pursuant to the 2013 Beyond Air Equity Incentive Plan has been reduced proportionately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000697" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zAeRh970iBXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 <span id="xdx_826_zeupzJcGwgk6">SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000699" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zePT0szFLvt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zaK8ogn2fPr">Basis
of Presentation and Principles of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements include the accounts of Beyond Air, Inc. and its subsidiaries and have been prepared in accordance
with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;). The Company determined that Beyond Cancer
Ltd. and its affiliates (&#8220;Beyond Cancer&#8221;) and NeuroNOS Ltd. and its affiliates (&#8220;NeuroNos&#8221;) are each a
variable interest entity (&#8220;VIE&#8221;) for which the Company is the primary beneficiary and consolidates in its financial
statements. All intercompany balances and transactions have been eliminated in the accompanying consolidated financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000701" name="us-gaap:UseOfEstimates"><p id="xdx_843_eus-gaap--UseOfEstimates_zyP03rkfswnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zrfYmDguqYR8">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could
significantly differ from those estimates. On an ongoing basis, the Company evaluates its significant estimates and assumptions
including expense recognition and accrual assumptions under consulting and clinical trial agreements, stock-based compensation,
allowance for credit losses, excess and obsolete inventory reserves, impairment assessments, accounting for licensed rights to use
technologies and other long-lived assets, the valuation of warrants, the valuation of derivatives, contingency recognition and
accruals and the determination of valuation allowance requirements on deferred tax attributes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000703" name="XAIR:GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock"><p id="xdx_843_ecustom--GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock_zyfgdhMi85s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zqY2Bjw1vIe6">Going
Concern, Liquidity and Other Uncertainties</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used cash in operating activities of $<span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250401__20260331_z3ZU6LUFtdn3" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-04-01to2026-03-31" id="Fact000705" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">18.1</ix:nonFraction></span> million for the year ended March 31, 2026, and has an accumulated deficit attributable
to the stockholders of Beyond Air, Inc. of $<span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20260331_zSPwmvk8ZqKe" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2026-03-31" id="Fact000707" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">319.6</ix:nonFraction></span> million. The Company had cash, cash equivalents and marketable securities of $<span id="xdx_902_ecustom--CashAndCashEquivalentsAndMarketableSecurities_iI_pn5n6_c20260331_zw8mJaARiHIj" title="Cash equivalents and marketable securities"><ix:nonFraction name="XAIR:CashAndCashEquivalentsAndMarketableSecurities" contextRef="AsOf2026-03-31" id="Fact000709" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">11.6</ix:nonFraction></span>
million as of March 31, 2026. In addition, $<span id="xdx_905_eus-gaap--DepositAssets_iI_pn5n6_c20260331_zZ5ML2x09EY3" title="Cash deposit"><ix:nonFraction name="us-gaap:DepositAssets" contextRef="AsOf2026-03-31" id="Fact000711" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.4</ix:nonFraction></span> million of cash is held on deposit by the Company&#8217;s contract manufacturer to be
applied against future purchases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to incur net losses and have significant cash outflows for at least the next year, including making significant
investments in research and development. Management believes these factors raise substantial doubt about the Company&#8217;s ability
to meet its obligations with cash on hand and concluded that the Company will require additional funding within one year from the
date these consolidated financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is confident that the efforts to arrange financing, while not assured, will enable the Company to meet its obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s future capital needs and the adequacy of its available funds will depend on many factors, including, but not necessarily
limited to, the success and costs of commercialization of the Company&#8217;s approved product and the actual cost and time necessary
for current and anticipated preclinical studies, clinical trials and other actions needed to obtain certification or regulatory approval
of the Company&#8217;s product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000713" name="XAIR:OtherRisksAndUncertaintiesPolicyTextBlock"><p id="xdx_84C_ecustom--OtherRisksAndUncertaintiesPolicyTextBlock_zmSOMpTsR0dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_z9BkdE6WELm2">Other
Risks and Uncertainties</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to development and early-stage medical device companies including, but not limited to, new technological
innovations, certifications or regulatory approval, dependence on key personnel, protection of proprietary technology, compliance with
government regulations, product liability, uncertainty of market acceptance of approved products and the potential need to obtain additional
financing. The Company is also dependent on third-party suppliers and, in some cases, single-source suppliers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s products require approval or clearance from the FDA prior to commencement of commercial sales in the United States. There
can be no assurance that the Company&#8217;s products beyond LungFit&#174; PH in the U.S. will receive the required approvals or clearances.
Certifications, approvals or clearances are also required in foreign jurisdictions in which the Company may license or sell its products.
If the Company is denied such certifications or approvals or clearances or such certifications, approvals or clearances are delayed,
such denial or delay may have a material adverse impact on the Company&#8217;s results of operations, financial position and liquidity.
Further, there can be no assurance that the Company&#8217;s product will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or
that such products will be successfully marketed, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000715" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zVF0qxX5X7Ag" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zlJminLqUXwk">Revenue
Recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates revenue from the leases of its LungFit&#174; PH devices to its customers under fixed fee arrangements over periods of
up to three years. The fixed fee is typically broken down into ratable monthly payments over the term of the arrangement. The Company&#8217;s
customers include hospitals and medical facilities. The Company&#8217;s LungFit&#174; PH leases include filters, calibration gas, bagging
kits, cables, adapters, and other components and accessories required to use the LungFit&#174; PH device (the &#8220;Consumables&#8221;).
The consumables&#8217; quantities are varied and may be supplied upon demand of the customers and are unlimited, or the arrangement may
provide for the maximum quantities available to the customer over the term of the arrangement. The Company&#8217;s LungFit&#174; PH leases
also include maintenance and training required to use the LungFit&#174; PH device, as well as device back-up services (the &#8220;Services&#8221;),
which are recorded in cost of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its rental arrangements of LungFit&#174; PH devices in accordance with Accounting Standards Codification 842, <i>Leases</i>
(&#8220;ASC 842&#8221;). Under ASC 842, leases may be classified as either financing, sales-type, or operating, and the Company is
required to disclose key information about leasing arrangements. The classification determines the pattern of revenue recognition
and classification within the consolidated statements of operations and comprehensive loss. The Company typically classifies the
rental arrangement of its LungFit&#174; PH contracts as operating leases. The Company&#8217;s leases do not contain any restrictive
covenants or any material residual value guarantees. The Company&#8217;s equipment leases may contain renewal options which range
from one month to two years. The lease term is adjusted for renewal or termination options that the Company believes the customer is
reasonably certain to exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company elected the practical expedient applied to operating leases not to separate lease and non-lease components as long as the lease
and non-lease components have the same timing and pattern of transfer. As such, the non-lease components, including the Consumables and
Services, are combined with the predominant lease component. The total fixed fees that the Company is reasonably certain to collect are
recognized on a straight line basis over the term of the arrangement. Additionally, the Company made an accounting policy election to
present LungFit&#174; PH revenue net of sales and other similar taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the lease commencement date, the Company will defer initial direct costs, including commission expense and the cost is recognized over
the lease term on the same basis as lease income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 15 to the consolidated financial statements for more information regarding leasing arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also generates revenue from the sale of its LungFit&#174; PH devices and consumables to its customers under distribution arrangements.
Contracts include one performance obligation as any individual promised good or services other than delivery of the devices and consumables
are generally either not capable of being distinct or not distinct within the context of the contracts. Purchased quantities of devices
and consumables are varied and may be supplied upon demand of the customers. Revenue is recognized at a point in time when the Company
delivers the goods to its customer. The transaction includes a fixed component based on contractual rates. Revenue recognized reflects
the consideration the Company expects to receive in exchange for delivering the goods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
billed in advance of performance obligations being satisfied are recognized as deferred revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records the costs of shipping devices and consumables in cost of revenues in its consolidated statements of operations and comprehensive
loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000717" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJRcS9cpNhq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zpAyVX7HJsB8">Accounts
Receivable</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company extends credit to its customers on an unsecured basis. Accounts receivable are recorded at the invoiced amount, based on agreed
contract terms, less an allowance for credit losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company establishes an allowance for accounts receivable that are considered to be at increased risk of becoming uncollectible. When
evaluating the adequacy of this allowance for credit losses, the Company considers factors such as, historical collection experience
and creditworthiness, the composition of outstanding receivables by customer class, and expected economic conditions and other trends.
The Company&#8217;s estimates are reflected in the period they are made. The charges recorded for credit losses are reported within Selling,
general and administrative expenses on the consolidated statements of operations and comprehensive loss. Receivables are written off
against the allowance for credit losses when it is definitively determined that amounts are uncollectible. As of March 31, 2026 and 2025,
the allowance for credit losses were $<span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivableNoncurrent_iI_pn5n6_c20260331_zYeSgdAczWwa" title="Allowance for credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableNoncurrent" contextRef="AsOf2026-03-31" id="Fact000719" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million and $<span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivableNoncurrent_iI_pn5n6_c20250331_z7SLja1nsgK6" title="Allowance for credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableNoncurrent" contextRef="AsOf2025-03-31" id="Fact000721" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000723" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z5m4LoVsv315" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zbf3gxuIpLl5">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820, <i>Fair Value Measurements and Disclosures</i> (&#8220;ASC 820&#8221;), defines fair value as the price that would be received to
sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market
participants on the measurement date. The fair value standard also establishes a three-level hierarchy, which requires an entity to maximize
the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based
upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1&#8212;inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2&#8212;inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived
valuations in which all significant inputs are observable for substantially the full term of the asset or liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3&#8212;inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026 and March 31, 2025, the Company&#8217;s financial instruments included restricted cash, marketable securities,
accounts payable, long-term debt and liability classified warrants. The carrying amounts reported in the accompanying consolidated
financial statements for cash and cash equivalents, restricted cash and marketable securities approximate their respective fair
values because of the short-term nature of these accounts. The carrying value of the Company&#8217;s long-term debt approximates
fair value based on current interest rates for similar types of borrowings. The liability classified warrants are recorded at fair
value and are included in Level 3 of the fair value hierarchy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000725" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zSz2dHLbWKHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value amounts as of March 31, 2026 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zXpIL3M7zN37" style="display: none">SCHEDULE
OF FAIR VALUE ON A RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20260331_z0foNQr9g2b6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z38n6cDnwlu8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z00wG26yyZg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsZd0BuskkP8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_ze7sjfLFgEgg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2026-03-31_custom_MutualFundsMember" id="Fact000727" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,901</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsMember" id="Fact000728" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,901</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0729">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0730">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zjHwT9v6ZS32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2026-03-31" id="Fact000732" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,901</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member" id="Fact000733" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,901</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0734">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0735">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zRC5TAbEqGGb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_WarrantMember" id="Fact000737" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0739">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000740" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_z468H5pC9PIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31" id="Fact000742" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0743">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member" id="Fact000745" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value amounts as of March 31, 2025 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250331_z3Jt5bx4bnYc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjwMihH6oIy5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQyMh8LZAtai" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWF9wGvB3aei" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zQgGzALhxHx" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-03-31_custom_MutualFundsMember" id="Fact000747" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,252</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsMember" id="Fact000748" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,252</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0750">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zKl8QiSE9w77" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-03-31" id="Fact000752" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,252</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member" id="Fact000753" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,252</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0755">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z7teyQQZeWch" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-03-31_us-gaap_WarrantMember" id="Fact000757" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0758">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0759">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000760" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zIpton2TLu3e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-03-31" id="Fact000762" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0763">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member" id="Fact000765" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zXsqfKoRIw8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000767" name="us-gaap:MarketableSecuritiesTextBlock"><p id="xdx_89F_eus-gaap--MarketableSecuritiesTextBlock_z4HgtsibLNA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s short-term marketable securities with unrealized gains and losses as of March 31, 2026,
aggregated by major security type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zCu1EyrKbD71" style="display: none">SUMMARY
OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrealized Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_z5wtCioRRxGi" title="Total short-term marketable securities, fair value" style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2026-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember" id="Fact000769" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,901</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20250401__20260331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zB1niEE5K80j" title="Total short-term marketable securities, unrealized loss" style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-04-012026-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember" id="Fact000771" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total short-term marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zu1R3CSkgizd" title="Total short-term marketable securities, Fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2026-03-31_us-gaap_ShortTermDebtMember" id="Fact000773" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,901</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20250401__20260331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zSGHtLg4kMfj" title="Total short-term marketable securities, Unrealized gains and (losses)" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-04-012026-03-31_us-gaap_ShortTermDebtMember" id="Fact000775" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s short-term marketable securities with unrealized gains and losses as of March 31, 2025,
aggregated by major security type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrealized Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zQg58g0FROi4" title="Total short-term marketable securities, fair value" style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2025-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember" id="Fact000777" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,252</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20240401__20250331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zWNdUiwZjpf7" title="Total short-term marketable securities, unrealized loss" style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-04-012025-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember" id="Fact000779" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Total short-term marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zpU8N2T4NHZ1" title="Total short-term marketable securities, Fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2025-03-31_us-gaap_ShortTermDebtMember" id="Fact000781" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,252</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20240401__20250331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zr2SOMcBc0If" title="Total short-term marketable securities, Unrealized gains and (losses)" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-04-012025-03-31_us-gaap_ShortTermDebtMember" id="Fact000783" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zgvFuIOypEj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Level
3 Valuation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
liability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liability is remeasured each reporting period with the change in fair value recorded to other income (expense) in the consolidated
statements of operations and comprehensive loss until the warrants are exercised, expired, reclassified or otherwise settled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000785" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zHT5mdEx3482" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant assumptions used in valuing the warrants were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zMM5k5MZuJid" style="display: none">SCHEDULE
OF ASSUMPTIONS USED IN VALUING WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">At March 31, 2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Expected term (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgvjyxQ3NFWj" title="Expected term warrants"><ix:nonNumeric contextRef="AsOf2026-03-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact000787" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.25</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ziOPdUBHgXR1" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2026-03-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">132.1</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z70biNE9YS8c" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2026-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000791" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.8</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">At March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Expected term (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyJjQ346E25f" title="Expected term warrants"><ix:nonNumeric contextRef="AsOf2025-03-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact000793" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.25</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zeuiYAT9gYHk" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000795" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">99.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdcmXtcs2u7b" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000797" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.9</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zG73FmtTGsBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative
liability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementDifferenceDescription_c20250401__20260331_zzvT3Ss7G3gc" title="Derivative liability description"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact000799" name="us-gaap:DerivativeLiabilityMeasurementDifferenceDescription">The
derivative liability represents an embedded redemption feature (embedded put option) that meets the criteria to be classified as a
derivative and is bifurcated from the Note (see Note 9). On any trading day during which the Registration Statement (Note 4) remains
effective and the Note remains outstanding and (i) any trading price of the Company&#8217;s common stock is at least 5% greater than
the current Nasdaq minimum price as defined under Nasdaq Rule 5635(d) (the &#8220;Nasdaq Minimum Price&#8221;) or (ii) the total
dollar trading volume has reached $750,000.00, Streeterville may elect to purchase shares of common stock up to the Beneficial
Ownership Limitation at a purchase price equal to 85% of the Nasdaq Minimum Price, subject to a floor of $0.39 per share. The
aggregate purchase price for these shares shall be offset by an equal amount outstanding under the Note.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
feature was concluded to not be clearly and closely related to the host instrument and is required to be measured at fair value at each
reporting period. The fair value was determined using the Monte Carlo valuation model. The key inputs of the simulation are the valuation
date, the Company&#8217;s common stock share price and volatility, the risk-free rate, and the maximum convertible shares eligible to
offset the outstanding balance on the Note.</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000801" name="XAIR:FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock"><p id="xdx_895_ecustom--FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock_zsfFhj7pnTGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zHcIVEJ0tXp1" style="display: none">SCHEDULE
OF KEY INPUTS DERIVATIVE </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">At November 4, 2025 (issuance)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20251104_zE3kHp0WJLG6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Maximum convertible shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20251104__20251104_zx3BaNOFcG5f" title="Maximum convertible shares" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2025-11-042025-11-04" id="Fact000803" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,600,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zh4ViqIooue7" style="vertical-align: bottom; background-color: White">
    <td>Share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2025-11-04_us-gaap_MeasurementInputSharePriceMember" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.86</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zsrRCqjWT2u6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2025-11-04_us-gaap_MeasurementInputOptionVolatilityMember" id="Fact000807" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">125</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z17Mb19aVOfg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2025-11-04_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000809" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.6</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zboQEfYurVni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
January 2026, Streeterville elected to purchase <span id="xdx_903_eus-gaap--StockRepurchasedDuringPeriodShares_pn5n6_c20260101__20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zkC1OrbXBar4" title="Purchase of common stock, shares"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2026-01-012026-01-31_custom_StreetervilleCapitalLLCMember" id="Fact000811" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">1.6</ix:nonFraction></span>
million shares of common stock at an average of $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zYhINvXrjrD" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2026-01-31_custom_StreetervilleCapitalLLCMember" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span>
per share which offset principal of approximately $<span id="xdx_905_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pn5n6_c20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zRkMG7rKJgb7" title="Debt amount"><ix:nonFraction name="us-gaap:DebtDefaultLongtermDebtAmount" contextRef="AsOf2026-01-31_custom_StreetervilleCapitalLLCMember" id="Fact000815" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span>
million outstanding under the Note (Note 9). The fair value of the issued common stock was approximately $<span id="xdx_90C_eus-gaap--CommonStockValueOutstanding_iI_pn5n6_c20260331_znX2AazFVE9a" title="Fair value of issued common stock"><ix:nonFraction name="us-gaap:CommonStockValueOutstanding" contextRef="AsOf2026-03-31" id="Fact000817" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction></span>
million (Note 4). The Company remeasured the fair value of the derivative liability to $<span id="xdx_902_eus-gaap--CreditRiskDerivativeLiabilitiesAtFairValue_iI_pn5n6_c20260331_ziVcopMq8KCa" title="Fair value of the derivative liability"><ix:nonFraction name="us-gaap:CreditRiskDerivativeLiabilitiesAtFairValue" contextRef="AsOf2026-03-31" id="Fact000819" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.2</ix:nonFraction></span>
million immediately prior to the conversion. Accordingly, the embedded derivative was extinguished as of March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000821" name="XAIR:ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock_znFmSd1AcC0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuation for the warrants and derivatives
for the years ended March 31, 2026 and March 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zjA246EL3fBa" style="display: none">SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--FinancialInstrumentAxis_us-gaap--WarrantMember_zKomqjJB3SX7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_zr6VZOcny8w2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43D_c20240401__20250331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_ztdzelDPDHeh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance at March 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2024-03-31_us-gaap_WarrantMember" id="Fact000823" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">275</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2024-03-31_us-gaap_DerivativeMember" id="Fact000824" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,314</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zCFopjQvCLGg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2024-04-012025-03-31_us-gaap_WarrantMember" id="Fact000826" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">237</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2024-04-012025-03-31_us-gaap_DerivativeMember" id="Fact000827" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,314</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20250401__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zWLun7K8xSJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at March 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2025-03-31_us-gaap_WarrantMember" id="Fact000829" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zCbqV14l7zv" style="vertical-align: bottom; background-color: White">
    <td>Issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="From2025-04-012026-03-31_us-gaap_DerivativeMember" id="Fact000833" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">775</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zlVdshaDBc45" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2025-04-012026-03-31_us-gaap_WarrantMember" id="Fact000835" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">36</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2025-04-012026-03-31_us-gaap_DerivativeMember" id="Fact000836" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,395</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--FairValueMeasurementExtinguishment_zmcY92DcW479" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Extinguishment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="XAIR:FairValueMeasurementExtinguishment" contextRef="From2025-04-012026-03-31_us-gaap_DerivativeMember" id="Fact000839" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,170</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_435_c20250401__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zob4KlfS1AB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Balance at March 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2026-03-31_us-gaap_WarrantMember" id="Fact000841" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_z5XCy7ic64Ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000844" name="XAIR:WarrantLiabilityPolicyTextBlock"><p id="xdx_84A_ecustom--WarrantLiabilityPolicyTextBlock_zD4209tMhPkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zRWUm4WOeCxf">Warrant
Liability</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies warrants as equity for any contracts that (i) require physical settlement or net-share settlement or (ii) gives
the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The
Company classifies warrants as assets or liabilities for any contracts that (i) require net-cash settlement (including a requirement
to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the
counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). Such warrants
are subject to remeasurement at each consolidated balance sheet date and any change in fair value is recognized as a component of
other income/expense on the consolidated statements of operations and comprehensive loss. The Company will continue to adjust the liability
for changes in fair value until the earlier of the exercise or expiration of such warrants. At that time, the portion of the warrant
liability related to warrants will be reclassified to additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000846" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_843_eus-gaap--DerivativesPolicyTextBlock_zSNkPmULVEX" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zLgVSHtIY1bj">Derivative
Liability</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as
embedded derivatives in accordance with ASC 815, <i>Derivatives and Hedging.</i> For derivative financial instruments that are
accounted for as assets or liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is
then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations and
comprehensive loss. The classification of derivative instruments, including whether such instruments should be recorded as assets or
liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the
consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument
could be required within 12 months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000848" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p id="xdx_847_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zkxOhR4JB6D6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zaLdwLtGklG3">Cash
and Cash Equivalents, Short-Term Investments and Restricted Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with original maturities of three months or less at the date of purchase and an investment
in a U.S. government money market fund to be cash equivalents. The Company maintains its cash and cash equivalents in highly rated financial
institutions in Australia, Israel, Ireland and the U.S., the balances of which, at times, may exceed federally insured limits. Marketable
securities may include investment in a combination of fixed income bonds, U.S. Treasury securities, and mutual funds that are considered
to be highly liquid and easily tradeable. The marketable securities are considered trading securities and are measured at fair value
and are accounted for in accordance with ASC 320. The marketable securities are valued using inputs observable in active markets for
identical securities and are therefore classified as Level 1 within the Company&#8217;s fair value hierarchy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026 and March 31, 2025, restricted cash included approximately $<span id="xdx_904_eus-gaap--RestrictedCash_iI_pn5n6_c20260331_z4rXtZexOB4b" title="Restricted cash"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2026-03-31" id="Fact000850" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.6</ix:nonFraction></span> million and $<span id="xdx_90F_eus-gaap--RestrictedCash_iI_pn5n6_c20250331_zhHpnQ2lF6F8" title="Restricted cash"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2025-03-31" id="Fact000852" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million, respectively. Restricted
cash as of March 31, 2026 includes $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_pn5n6_c20251104__20251104_zvX9YlzYQEr2" title="Proceeds from issuance of secured promissory note"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" contextRef="From2025-11-042025-11-04" id="Fact000854" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.4</ix:nonFraction></span> million of proceeds from the Company&#8217;s secured promissory note issued on November 4, 2025
that is required to be held in a restricted account pursuant to the Note Purchase Agreement. Amounts held in the restricted account become
available to the Company as the outstanding principal of the Note is repaid (see Note 9).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000856" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zE3MMSGbrn05" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zifwhxa60YWk">Concentration
of Credit Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_uUSD_c20260331__srt--StatementGeographicalAxis__country--US_z7gUpbeMZPEg" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2026-03-31_country_US" id="Fact000858" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> in the United States, A$<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_uAUD_c20260331__srt--StatementGeographicalAxis__country--AU_zLkdEA4hIpqb" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2026-03-31_country_AU" id="Fact000860" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">250,000</ix:nonFraction></span> in Australia, $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_uUSD_c20260331__srt--StatementGeographicalAxis__country--BM_z8jflRkUGJZe" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2026-03-31_country_BM" id="Fact000862" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span>
in Bermuda, &#8364;<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_uEUR_c20260331__srt--StatementGeographicalAxis__country--IE_zvzsqbKTFD9a" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2026-03-31_country_IE" id="Fact000864" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">100,000</ix:nonFraction></span> in Ireland and &#8364;<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_uEUR_c20260331__srt--StatementGeographicalAxis__country--CY_zhbZ2tY5spQa" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2026-03-31_country_CY" id="Fact000866" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">100,000</ix:nonFraction></span> in Cyprus. There is currently no official federal depository insurance in Israel.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. <span id="xdx_906_eus-gaap--ConcentrationRiskBenchmarkDescription_c20260331__20260331_zwBsDcqjI1ci" title="Concentration risk benchmark description"><ix:nonNumeric contextRef="From2026-03-312026-03-31" id="Fact000868" name="us-gaap:ConcentrationRiskBenchmarkDescription">As of March 31, 2026, the Company had greater than $250,000 at United States financial institutions, less than A$250,000
at Australian financial institutions, greater than &#8364;100,000 at Irish financial institutions and also has funds on deposit in Israel.</ix:nonNumeric></span>
Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition,
results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000870" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zO39TGqE6eHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table is the reconciliation of the presentation and disclosure of cash, cash equivalents, marketable securities by major security
type and restricted cash as shown on the Company&#8217;s consolidated statements of cash flows for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z0jfOmMC4Fy7" style="display: none">SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20260331_zKbwo92hRnU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250331_zIIVYqgiz4Xl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCEASz3pW_maRCACEzZrO_zQj3UHc54oZf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2026-03-31" id="Fact000872" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,740</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31" id="Fact000873" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,665</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RestrictedCashCurrent_iI_pn3n3_maRCACEzZrO_zFxqdPDYOz83" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2026-03-31" id="Fact000875" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,622</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2025-03-31" id="Fact000876" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">231</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RestrictedCashAndCashEquivalents_iTI_pn3n3_mtRCACEzZrO_maCCEASziVz_zCa0NYeQZvO8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total cash, cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="AsOf2026-03-31" id="Fact000878" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,362</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="AsOf2025-03-31" id="Fact000879" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,896</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--MarketableSecuritiesAbstract_iB_zy0yiyUF65n9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--MarketableSecuritiesCurrent_i01I_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z213JS7INxXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2026-03-31_us-gaap_MutualFundMember" id="Fact000884" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,901</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2025-03-31_us-gaap_MutualFundMember" id="Fact000885" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,252</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MarketableSecuritiesCurrent_i01I_pn3n3_maCCEASziVz_zJBHKOVrL1Ok" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2026-03-31" id="Fact000887" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,901</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2025-03-31" id="Fact000888" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,252</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iTI_pn3n3_mtCCEASziVz_zHJeioG91Fig" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents, marketable securities and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2026-03-31" id="Fact000890" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,263</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2025-03-31" id="Fact000891" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,148</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zPNalkSO2Hci" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000893" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zeVEjAVtjFMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zgbsc8xF2Yja">Fixed
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000895" name="XAIR:ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock"><p id="xdx_895_ecustom--ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock_zpfWmIi8fGMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation and accumulated amortization. Depreciation and amortization are calculated
using the straight-line method over the estimated useful life of the assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zziOzbX9ZBq2" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS</span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zGOdAUEMpnMl" title="Estimated useful life of assets"><ix:nonNumeric contextRef="AsOf2026-03-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:durwordsen" id="Fact000897" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">Three
    years</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z0YAIfctOaLa" title="Estimated useful life of assets"><ix:nonNumeric contextRef="AsOf2026-03-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:durwordsen" id="Fact000899" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">Five
    years</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    and medical equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember__srt--RangeAxis__srt--MinimumMember_zeg8FPWttisb" title="Estimated useful life of assets" style="display: none"><ix:nonNumeric contextRef="AsOf2026-03-31_custom_ClinicalAndMedicalEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000901" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span>/<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember__srt--RangeAxis__srt--MaximumMember_zL0oHTEqzoq9" title="Estimated useful life of assets"><ix:nonNumeric contextRef="AsOf2026-03-31_custom_ClinicalAndMedicalEquipmentMember_srt_MaximumMember" format="ixt-sec:durwordsen" id="Fact000903" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">Five
    years</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment
    deployable as part of a service offering</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentDeployableAsPartOfServiceOfferingMember_zbKoyiHEMEGc" title="Estimated useful life of assets"><ix:nonNumeric contextRef="AsOf2026-03-31_custom_EquipmentDeployableAsPartOfServiceOfferingMember" format="ixt-sec:durwordsen" id="Fact000905" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">Five
    years</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zIOJZqQidfNf" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2026%23UsefulLifeTermOfLeaseMember"><span style="-sec-ix-hidden: xdx2ixbrl0906">Shorter
    of term of lease or estimated useful life of the asset</span></span></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A0_zcPMD6dQyzx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000908" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWhSe7IFIEI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zw5wt5bfBJHc">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity for which both discrete financial information is available and regularly reviewed by
the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing
performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company&#8217;s CODM evaluates performance and allocates resources for all
of the Company&#8217;s reportable segments based on income/loss from operations. The CODM is involved in determining and reviewing projected
income/loss from operations as part of the annual budget process. Throughout the year, the CODM considers forecast to actual results
and variances to allocate resources. The CODM also considers this information in strategic decisions related to capital allocations,
including investments in assets, research and development activities, and human capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s reportable segments at March 31, 2026 included <span id="xdx_905_ecustom--NumberOfReportableSegmentsDisclosedByDefinitionFlag_dbT_c20250401__20260331_zg48RG5VSya9" title="Number of repotable segments"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt:booleantrue" id="Fact000910" name="XAIR:NumberOfReportableSegmentsDisclosedByDefinitionFlag">Beyond Air, Beyond Cancer, and NeuroNos</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Beyond Air segment includes unallocated corporate expenses associated with the public company fees as well as all corporate related assets
and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000912" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zUPk5S2yRd52" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zQVSCnoOtmF">Inventories</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
consist primarily of purchased filters, bagging kits, cables, adapters, and other components and accessories required to use the LungFit&#174;
PH device held for sale to customers. Inventories are recorded at the lower of cost or net realizable value. Cost comprises direct materials,
third-party manufacturing costs and shipping costs incurred to deliver goods to the Company&#8217;s central warehouse location. Costs
are assigned to individual items of inventory on the basis of weighted average costs. Inventory items are tracked by batch/lot number
for specific identification whenever possible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
reserves are established for estimated excess and obsolete inventory equal to the difference between the cost of the inventory and the
estimated net realizable value of the inventory based on historical usage, known trends, and market conditions and judgment about the
anticipated future consumption and the Company&#8217;s ability to sell the inventory. At March 31, 2026 and March 31, 2025, excess and obsolescence reserves
were $<span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_pn5n6_c20260331_ztjhcafgaG3f" title="Obsolescence reserves"><ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2026-03-31" id="Fact000914" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million and $<span id="xdx_908_eus-gaap--InventoryValuationReserves_iI_pn5n6_c20250331_zH80QGz5OvLl" title="Obsolescence reserves"><ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2025-03-31" id="Fact000916" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000918" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zTwdbBYwhUzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zVQil3J6jCZ1">Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease assets are included within operating lease right-of-use assets, and the corresponding operating lease obligation on the consolidated
balance sheets in accordance with ASC 842, <i>Leases</i>. The Company has elected not to present short-term leases as these leases have
a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably
certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the
lease term at commencement date. Operating lease expense is recognized on a straight-line basis over the lease term and is included in
general and administrative and research development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interest rate implicit in the Company&#8217;s leases is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate in determining the present value of lease payments, which reflects the fixed rate at which the Company could borrow on
a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000920" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zBYK3lPY60Yh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z5irVTKx8dx6">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to the consolidated statements of operations and comprehensive loss as incurred. Research and development
expenses include salaries, benefits, stock-based compensation and costs incurred by outside laboratories, manufacturers, clinical research
organizations, consultants, and accredited facilities in connection with preclinical studies and clinical trials. Research and development
expenses are partially offset by the benefit of tax incentive payments for qualified research and development expenditures from the Australian
tax authority (&#8220;AU Tax Rebates&#8221;). The Company does not record AU Tax Rebates until payment is received due to the uncertainty
of receipt. For the years ended March 31, 2026 and March 31, 2025, the Company received $<span id="xdx_903_ecustom--TaxRebate_pn5n6_c20250401__20260331__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--AustralianTaxationOfficeMember_zRpYbVFqB6W2" title="Tax Rebate"><ix:nonFraction name="XAIR:TaxRebate" contextRef="From2025-04-012026-03-31_us-gaap_AustralianTaxationOfficeMember" id="Fact000922" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million and $<span id="xdx_903_ecustom--TaxRebate_pn5n6_c20240401__20250331__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--AustralianTaxationOfficeMember_zmlzooNdSbHh" title="Tax Rebate"><ix:nonFraction name="XAIR:TaxRebate" contextRef="From2024-04-012025-03-31_us-gaap_AustralianTaxationOfficeMember" id="Fact000924" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.0</ix:nonFraction></span> million, respectively,
in AU Tax Rebates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000926" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84C_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zWyTcYHOwBAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zee0Dj2iQdC3">Foreign
Exchange Transactions</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s subsidiaries transact in U.S. dollars, Euros, New Israeli Shekels and Australian dollars. The Company&#8217;s main operations
are in the United States and the U.S. dollar is the currency of the primary economic environment in which the Company operates and expects
to continue to operate in the foreseeable future. The Company translated its non-U.S. operations&#8217; assets and liabilities denominated
in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the
average exchange rate for the reporting period. Gains or losses from foreign currency transactions are included in other income (expense)
in the consolidated statements of operations and comprehensive loss as foreign currency exchange gain/(loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive
income and loss. The accumulated other comprehensive income and loss account includes the cumulative results of translating certain balance
sheet assets and liabilities at current exchange rates and some accounts at historical rates. For the year ended March 31, 2026, the
Company recorded gains of $<span id="xdx_90B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20260331_z7YLqXHZMmJ7" title="Accumulated other comprehensive income"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" contextRef="AsOf2026-03-31" id="Fact000928" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million in accumulated other comprehensive income. For the year ended March 31, 2025, the Company recorded
losses of $<span id="xdx_90F_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20250331_z4Km4oWtws39" title="Accumulated other comprehensive income"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" contextRef="AsOf2025-03-31" id="Fact000930" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million in accumulated other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000932" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zoq7zmHFHfej" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zCmkfEn80O85">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the cost of employee and non-employee services received in exchange for an award of equity instruments based on the
grant date fair value of the award. Fair value for restricted stock unit awards is valued using the closing price of the Company&#8217;s
common stock on the date of grant. The grant date fair value is recognized over the requisite service period during which an employee
and non-employee is required to provide service in exchange for the award, using the accelerated method with each tranche being expensed
over its vesting period. The grant date fair value of employee and non-employee share options is estimated using the Black-Scholes option
pricing model. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term
of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception
and does not anticipate paying dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Starting in 2023,
Beyond Air used its own historical volatility as an input for expected volatility, but due to Beyond Cancer&#8217;s and NeuroNos&#8217;
lack of marketability, the Company utilizes the implied volatility based on an aggregate of guideline companies for expected volatility.
The Company uses the simplified method to estimate the expected term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000934" name="XAIR:SupplierConcentrationPolicyTextBlock"><p id="xdx_844_ecustom--SupplierConcentrationPolicyTextBlock_zKF0PPuy2u2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_znqew8oyzWYi">Supplier
Concentration</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on third-party suppliers to provide materials for its devices and consumables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the year ended March 31, 2026, the Company purchased approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FirstThirdPartyVendorsMember_zWOjQrfo8Lg9" title="Concentration percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-04-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_FirstThirdPartyVendorsMember" id="Fact000936" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">74</ix:nonFraction></span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondThirdPartyVendorsMember_zPKH5GFKgKkk" title="Concentration percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-04-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SecondThirdPartyVendorsMember" id="Fact000938" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span>% of its materials from two third-party vendors. In the
year ended March 31, 2025, the Company purchased approximately <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorsMember_zzzCD2frilml" title="Concentration percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-04-012025-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_ThirdPartyVendorsMember" id="Fact000940" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85</ix:nonFraction></span>% of its materials from one third-party vendor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000942" name="XAIR:CustomerrConcentrationPolicyTextBlock"><p id="xdx_849_ecustom--CustomerrConcentrationPolicyTextBlock_zt0y7eVOQCR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zZK72rqbNr5k">Customer
Concentration</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2026, the Company derived <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zYh7HM53rlHa" title="Concentration percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-04-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember" id="Fact000944" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11</ix:nonFraction></span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zqCNA4uF7rjc" title="Concentration percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-04-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember" id="Fact000946" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of its revenues from two customers. For the year ended March 31, 2025,
the Company derived <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_z8mTZnZnEwR7" title="Concentration percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-04-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember" id="Fact000948" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zjovfV2GnvV8" title="Concentration percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-04-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember" id="Fact000950" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of its revenues from two customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000952" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_847_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zYiYbUZ0aaWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zBR8SZsHLuE4">Licensed
Right to Use Technology</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed
right to use technology that is considered platform technology with alternative future uses is recorded as an intangible asset and is
amortized on a straight-line method over its estimated useful life, determined to be thirteen years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000954" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zPqdqDxadk6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected amortization expense for the next five years and thereafter is as follows for the year ended March 31 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zfGTZeVvBHb1" style="display: none">SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_490_20260331_zTDHWIObOgA5" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANz72H_ztGt05u0vLWc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: left">2027</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2026-03-31" id="Fact000956" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">205</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANz72H_zdQScyCDpJTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2026-03-31" id="Fact000958" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">205</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANz72H_zdimKZ1UaNT8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2026-03-31" id="Fact000960" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">205</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANz72H_zoImxPVfM5fi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2026-03-31" id="Fact000962" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">205</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANz72H_zoRKAth2Mncg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2031</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2026-03-31" id="Fact000964" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">198</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANz72H_ziR28fJCHfik" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2026-03-31" id="Fact000966" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,018</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_z0prWWE0AGMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000968" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zWfi9ADUtDcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z8VqivzDPyKg">Long-Lived
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses the impairment of long-lived assets on an ongoing basis and whenever events or changes in circumstances indicate that
the carrying value may not be recoverable. Factors that the Company considers as potential triggers of an impairment review include the
following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    underperformance relative to expected historical or projected future operating results,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    changes in the manner of the Company&#8217;s use of the acquired assets or the strategy for its overall business,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    negative regulatory or economic trends, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    technological changes, which would render the platform technology, equipment, and manufacturing processes obsolete. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recoverability
of assets that will continue to be used in the Company&#8217;s operations is measured by comparing the carrying value to the future net
undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future
revenues, driven by market growth rates, and estimates of future costs. There were no events during the reporting periods that were deemed
to be a triggering event that would require an impairment assessment, other than the impairment of $<span id="xdx_900_eus-gaap--OtherAssetImpairmentCharges_pn5n6_c20240401__20250331_zfqvadaSCqaj" title="Other asset impairment charges"><ix:nonFraction name="us-gaap:OtherAssetImpairmentCharges" contextRef="From2024-04-012025-03-31" id="Fact000970" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million recorded during the year
ended March 31, 2025 associated with certain R&amp;D assets following Management&#8217;s decision to put its VCAP clinical trial on hold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000972" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_z1EpRTJlMHf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_z6dWFnrUzn86">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities
and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are
recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than
not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future
deductibility is uncertain. As of March 31, 2026 and March 31, 2025, the Company recorded a valuation allowance to the full extent of
the Company&#8217;s net deferred tax assets since the likelihood of realization of the benefit does not meet the more-likely-than-not
threshold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s reserves related to taxes are based on a determination of whether and how much of a tax benefit taken by the Company
in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related
to the tax benefit. The Company would recognize both estimated accrued interest and penalties related to unrecognized benefits within
income tax expense in the consolidated statements of operations and comprehensive loss. The Company&#8217;s uncertain tax positions are
related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position,
the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which
a loss carryforward is available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000974" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zUjUHEdFaDd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zboUTYq1V7Xd">Net
Loss Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to Beyond Air, Inc.,
by the weighted average number of shares of common stock outstanding for the period. The dilutive effect of outstanding options, warrants,
restricted stock and other stock-based compensation awards is reflected in diluted net loss per share by application of the treasury
stock method. The calculation of diluted net loss attributed to common stockholders per share excludes all anti-dilutive shares of common
stock. For periods in which the Company has reported net losses, diluted net loss per share attributable to common stockholders is the
same as basic net loss per share attributable to common stockholders, because such shares of common stock are not assumed to have been
issued if their effect is anti-dilutive (Note 8).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000976" name="us-gaap:ConsolidationVariableInterestEntityPolicy"><p id="xdx_84C_eus-gaap--ConsolidationVariableInterestEntityPolicy_zXmJuTlw0mS" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zvtldgtakaPf">Variable
Interest Entity</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company has the power to direct activities of both Beyond Cancer and NeuroNos  that most significantly impact their economic
performance and the right to receive benefits and losses that may potentially be significant, these financial statements are fully consolidated
with those of the Company. The non-controlling owners&#8217; <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20260331__srt--OwnershipAxis__custom--BeyondCancerLtdMember_zVO1dsDjeZKb" title="Non-controlling owners interest"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember" id="Fact000978" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% interest in Beyond Cancer&#8217;s net assets and result of operations
and the non-controlling owners&#8217; <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20260331__srt--OwnershipAxis__custom--NeuroNosLtdMember_zGruHsD1j4A8" title="Non-controlling owners interest"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember" id="Fact000980" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.25</ix:nonFraction></span>% interest in NeuroNos&#8217; net assets and result of operations are reported as &#8220;non-controlling
interest&#8221; on the Company&#8217;s consolidated balance sheets and as &#8220;net loss attributable to non-controlling interest&#8221;
in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000982" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z2e5hTyHtoI" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z3xqho5VK4fa">Recently
Adopted Accounting Standards</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;)
2023-09, <i>Improvements to Tax Disclosures (Topic 740), </i>to enhance the disclosures related to income taxes, including the rate
reconciliation and information on income taxes paid. This ASU is effective for fiscal years beginning after December 15, 2024
(fiscal 2026 for the Company), with early adoption permitted. The Company adopted this standard effective April 1, 2025
prospectively. See Note 11, &#8220;Income Taxes,&#8221; for further information regarding the
Company&#8217;s effective income tax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000984" name="XAIR:RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock"><p id="xdx_84D_ecustom--RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_zypEtiThyZ79" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_ztIW2GOFmu92">Recently
Issued Accounting Standards Not Yet Adopted</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40).</i> This standard requires disclosure of specific information about costs and expenses and becomes effective for fiscal
years beginning after December 15, 2026 (fiscal 2028 for the Company), with early adoption permitted. The Company is assessing the impact
of this ASU and, upon adoption, may be required to include certain additional disclosures in the footnotes to the Consolidated Financial
Statements.</span></p>

</ix:nonNumeric><p id="xdx_85A_zRvKbt6JbRYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000986" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_800_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zknGdoUxPgC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 <span id="xdx_82F_zCAFy9urtsij">PROPERTY AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact000988" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zMLxG8Xv4tae" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_za6Zd0dRYAWe" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20260331_zDU3FrgE1UK3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2026</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250331_z8F8ZR3n9Atd" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember_zIGK6yflbM0b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Clinical and medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2026-03-31_custom_ClinicalAndMedicalEquipmentMember" id="Fact000990" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">206</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-03-31_custom_ClinicalAndMedicalEquipmentMember" id="Fact000991" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,048</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentDeployableAsPartOfServiceOfferingMember_zSOgUnmfLmx6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equipment deployable as part of a service offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2026-03-31_custom_EquipmentDeployableAsPartOfServiceOfferingMember" id="Fact000993" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,871</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-03-31_custom_EquipmentDeployableAsPartOfServiceOfferingMember" id="Fact000994" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,511</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpz3vKbJKZ4e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2026-03-31_us-gaap_ComputerEquipmentMember" id="Fact000996" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">853</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-03-31_us-gaap_ComputerEquipmentMember" id="Fact000997" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">927</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zlu4qQjjp4k8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2026-03-31_us-gaap_FurnitureAndFixturesMember" id="Fact000999" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">458</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-03-31_us-gaap_FurnitureAndFixturesMember" id="Fact001000" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">506</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zN2v5XsHcI9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2026-03-31_us-gaap_LeaseholdImprovementsMember" id="Fact001002" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">521</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-03-31_us-gaap_LeaseholdImprovementsMember" id="Fact001003" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">521</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzruM_zdxqruQDXCsk" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2026-03-31" id="Fact001005" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,909</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-03-31" id="Fact001006" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,513</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzruM_zd7ivrOPoKl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2026-03-31" id="Fact001008" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,660</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2025-03-31" id="Fact001009" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,500</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzruM_zqkpMFbHCKn2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment, net</span></span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2026-03-31" id="Fact001011" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,249</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-03-31" id="Fact001012" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,013</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zxjZ6EdJJSVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization for the years ended March 31, 2026 and March 31, 2025 was $<span id="xdx_901_eus-gaap--DepreciationAndAmortization_pn5n6_c20250401__20260331_zTuSWbKYOdD5" title="Depreciation and amortization"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2025-04-01to2026-03-31" id="Fact001014" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million and $<span id="xdx_90D_eus-gaap--DepreciationAndAmortization_pn5n6_c20240401__20250331_zwk7UJyxPls9" title="Depreciation and amortization"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-04-012025-03-31" id="Fact001016" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction></span> million, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001018" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zgbqHstXpIc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 <span id="xdx_823_z2bzvYxgVhx7">STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 10, 2025, the Company entered into an At-The-Market Equity Offering Sales Agreement with BTIG, Inc. (the &#8220;2025 ATM&#8221;).
Under the 2025 ATM, the Company may sell shares of its common stock having aggregate sales proceeds of up to $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20250210__20250210__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember_zeIU2Z6ZhADc"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2025-02-102025-02-10_custom_TwoThousandAndTwentyFiveATMMember" id="Fact001019" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">35.0</ix:nonFraction></span> million, from time
to time and at various prices. If shares of the Company&#8217;s common stock are sold, there is a<span id="xdx_902_ecustom--SaleOfStockFeePercentage_pid_dp_uPure_c20250210__20250210__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember_zJTEkPL3x7gd" title="Sale of stock fee percentage"> <ix:nonFraction name="XAIR:SaleOfStockFeePercentage" contextRef="From2025-02-102025-02-10_custom_TwoThousandAndTwentyFiveATMMember" id="Fact001021" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span>% fee paid to the sales agent. Pursuant
to the &#8220;baby shelf rules&#8221; promulgated by the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), if the Company&#8217;s public float is less than $<span id="xdx_90B_ecustom--PublicFloatValue_iI_pn5n6_c20250210__srt--RangeAxis__srt--MaximumMember_zLygtgUpxcnj" title="Public float value"><ix:nonFraction name="XAIR:PublicFloatValue" contextRef="AsOf2025-02-10_srt_MaximumMember" id="Fact001023" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">75.0</ix:nonFraction></span> million as of specified
measurement periods, the number of shares of common stock that may be offered and sold by the Company under a Form S-3 registration statement,
including pursuant to the 2025 ATM, in any twelve-month period is limited to an aggregate amount that does not exceed one-third of the
Company&#8217;s public float. As of March 31, 2026, due to the SEC&#8217;s &#8220;baby shelf rules,&#8221; the Company may currently
not sell any shares of common stock pursuant to the 2025 ATM. The Company will remain subject to the &#8220;baby shelf rules&#8221; under
the Form S-3 registration statement until such time as its public float exceeds $<span id="xdx_90F_ecustom--PublicFloatValue_iI_pn5n6_c20250210__srt--RangeAxis__srt--MaximumMember_zfFcQoG5Qisj" title="Public float value"><ix:nonFraction name="XAIR:PublicFloatValue" contextRef="AsOf2025-02-10_srt_MaximumMember" id="Fact001025" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">75.0</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended March 31, 2026, the Company received net proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember_zVVQzppfBhGa" title="Sale of net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-04-012026-03-31_custom_TwoThousandAndTwentyFiveATMMember" id="Fact001027" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.1</ix:nonFraction></span> million from the sale of <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember_zCDBFQ3984X4" title="Number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-04-012026-03-31_custom_TwoThousandAndTwentyFiveATMMember" id="Fact001029" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,441,775</ix:nonFraction></span> shares of common stock through
the 2025 ATM. During the year ended March 31, 2025, the Company received net proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240401__20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSuX9wEFBw7a" title="Sale of net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-04-012025-03-31_custom_TwoThousandAndTwentyFiveATMMember_us-gaap_CommonStockMember" id="Fact001031" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span> million from the sale of <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240401__20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7G3641MMQa5" title="Number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-04-012025-03-31_custom_TwoThousandAndTwentyFiveATMMember_us-gaap_CommonStockMember" id="Fact001033" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">337,100</ix:nonFraction></span> shares
of common stock through the 2025 ATM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2025, the Company entered into an equity purchase agreement (the &#8220;Streeterville Purchase Agreement&#8221;) with
Streeterville Capital, LLC (&#8220;Streeterville&#8221;) for the purchase of up to $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn6n6_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_znOjc9Zwtdzf" title="Share purchase value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-11-042025-11-04_custom_PurchaseAgreementMember" id="Fact001035" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span>
million of the Company&#8217;s shares of Common Stock. In connection with the Streeterville Purchase Agreement, Streeterville and
the Company entered into a Registration Rights Agreement, pursuant to which the Company filed a registration statement for the
resale of up to <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zDDznPqtRfOh" title="Shares available for resale"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-11-042025-11-04_custom_PurchaseAgreementMember" id="Fact001037" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,600,000</ix:nonFraction></span>
shares of Common Stock (the &#8220;Registration Statement&#8221;). During January 2026, Streeterville elected to purchase <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z52Ft1NKzaF5" title="Shares available for resale"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2026-01-012026-01-31_custom_PurchaseAgreementMember" id="Fact001039" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">1.6</ix:nonFraction></span> million shares of common stock with an average fair market
value of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zBKQRmndzor3" title="Price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2026-01-31_custom_PurchaseAgreementMember" id="Fact001041" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction></span> per share over each issuance date, resulting in approximately $<span id="xdx_907_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_pn5n6_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zGyjGeXSmCmg" title="Adjustments in additional paid in capital"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2026-01-012026-01-31_custom_PurchaseAgreementMember" id="Fact001043" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction></span> million recorded to additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Streeterville Purchase Agreement (so long as there is no balance outstanding on the Note (Note 9), the Company has the right,
but not the obligation, to direct Streeterville, by delivery to Streeterville of a put notice from time to time during a period of up
to two years, to purchase shares of Common Stock (i) in a minimum amount not less than $<span id="xdx_908_eus-gaap--PaymentsForRepurchaseOfCommonStock_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zpv9aIITfbb6" title="Common stock minimum purchase amount"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2025-11-042025-11-04_custom_PurchaseAgreementMember" id="Fact001045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span>, and (ii) in a maximum amount up to the
median daily trading volume of the Common Stock during the five trading days immediately preceding delivery of the put notice, or such
other greater amount mutually agreed upon by the parties; provided, however, that the number of put shares shall not exceed the beneficial
ownership limitation, of <span id="xdx_90D_ecustom--BeneficialOwnershipLimitationPercentage_iI_pid_dp_uPure_c20251104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zpoGWaSpC8C8" title="Beneficial ownership limitation percentage"><ix:nonFraction name="XAIR:BeneficialOwnershipLimitationPercentage" contextRef="AsOf2025-11-04_custom_PurchaseAgreementMember" id="Fact001047" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span>% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock issuable pursuant to a put notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2026, the Company entered into the Securities Purchase Agreement with an institutional investor pursuant to which the Company
sold, in a private placement offering, an aggregate of (i) <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260114__20260114__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWTvubm0W5Be" title="Stock issued during the period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2026-01-142026-01-14_us-gaap_CommonStockMember" id="Fact001049" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">524,990</ix:nonFraction></span> shares of common stock (ii) <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_znYpEJq6iY32" title="Purchase warrants"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2026-01-14_custom_TwoThousandTwentySixPreFundedWarrantsMember" id="Fact001051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,405,828</ix:nonFraction></span> pre-funded stock purchase warrants,
(the &#8220;2026 Pre-funded Warrants&#8221;) and (iii) <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixCommonWarrantsMember_z4phR7Yseq9f" title="Purchase warrants"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2026-01-14_custom_TwoThousandTwentySixCommonWarrantsMember" id="Fact001053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,930,818</ix:nonFraction></span> stock purchase warrants (the &#8220;2026 Common Warrants&#8221; and
together with the 2026 Pre-funded Warrants, the &#8220;2026 Warrants&#8221;). Each common share and accompanying 2026 Common Warrant
were sold together at a combined offering price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260114__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7tgU63ae217" title="Common  stock warrant offering price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixCommonWarrantsMember_zTqwSFJvTRqa" title="Common  stock warrant offering price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-01-14_us-gaap_CommonStockMember" id="Fact001055" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-01-14_custom_TwoThousandTwentySixCommonWarrantsMember" id="Fact001057" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.272</ix:nonFraction></ix:nonFraction></span></span> per share, and each 2026 Pre-Funded Warrant was sold at an offering price of
$<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_zzZkt8yUcgBe" title="Common  stock warrant offering price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-01-14_custom_TwoThousandTwentySixPreFundedWarrantsMember" id="Fact001059" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.2719</ix:nonFraction></span> per 2026 Pre-funded Warrant for gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfWarrants_pn6n6_c20260114__20260114__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_z6EHlv298lWb" title="Proceeds from issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2026-01-142026-01-14_custom_PreFundedWarrantsMember" id="Fact001061" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million. The 2026 Pre-Funded Warrants have an exercise price of $<span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20260116__20260116__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_z8Go3PBAMiyg" title="Warrant exercise price"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2026-01-162026-01-16_custom_TwoThousandTwentySixPreFundedWarrantsMember" id="Fact001063" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
per share, and the 2026 Common Warrants have an exercise price of $<span id="xdx_902_eus-gaap--WarrantExercisePriceIncrease_c20260114__20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_zFn9LGBLK7w5" title="Warrant exercise price"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2026-01-142026-01-14_custom_TwoThousandTwentySixPreFundedWarrantsMember" id="Fact001065" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.147</ix:nonFraction></span> per share. The private placement offering closed on January
16, 2026. The Company received total net proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250401__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z1561Zkn5Jkg" title="Proceeds from private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2025-04-012026-03-31_us-gaap_PrivatePlacementMember" id="Fact001067" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million after deductions for placement agent commissions and other offering
costs of $<span id="xdx_90E_eus-gaap--PaymentsForCommissions_pn5n6_c20250401__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z13PQlq2Khm" title="Commission paid"><ix:nonFraction name="us-gaap:PaymentsForCommissions" contextRef="From2025-04-012026-03-31_us-gaap_PrivatePlacementMember" id="Fact001069" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million and $<span id="xdx_90E_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zptzsNoadK86" title="Deferred costs current"><ix:nonFraction name="us-gaap:DeferredCostsCurrent" contextRef="AsOf2026-03-31_us-gaap_PrivatePlacementMember" id="Fact001071" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million, respectively, during the year ended March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 STOCKHOLDERS&#8217; EQUITY (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Option Plans</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Eighth Amended and Restated 2013 Beyond Air Equity Incentive Plan (the &#8220;2013 BA Plan&#8221;) allows for awards
to officers, directors, employees, and consultants of stock options, restricted stock units and restricted shares of the Company&#8217;s
common stock. On November 25, 2025, the Company&#8217;s Board of Directors approved an amendment to the 2013 BA Plan to increase the
number of shares in the 2013 BA Plan by <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20251125__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zVsR1uSTAMB3" title="Stock option shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2025-11-25_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001073" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">850,000</ix:nonFraction></span>, which was approved by the Company&#8217;s stockholders at the 2026 annual stockholder
meeting on January 30, 2026. The 2013 BA Plan has <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRxr6sjZ04Sd" title="Stock option shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001075" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,680,000</ix:nonFraction></span> shares authorized for issuance. As of March 31, 2025, <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zK2utwD7IXq6" title="Stock option available shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001077" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">894,276</ix:nonFraction></span> shares were
available under the 2013 BA Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value for the restricted stock unit awards was valued at the closing price of the Company&#8217;s common stock on the date of grant.
Restricted stock units vest annually over <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zp3oWF5SWlp8" title="Vesting period"><ix:nonNumeric contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:durwordsen" id="Fact001079" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">five years</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001081" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zLPikjit4Xa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s restricted stock unit awards for the years ended March 31, 2026 and March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zExED22KtKVf" style="display: none">SCHEDULE OF RESTRICTED STOCK AWARDS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number Of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date Fair </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Unvested as of March 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6MuNpET45r8" title="Unvested Number of Shares, Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-03-31_us-gaap_RestrictedStockMember" id="Fact001083" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,945</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB0SKhNOdUK3" title="Weighted Average Grant Date Fair Value, Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-03-31_us-gaap_RestrictedStockMember" id="Fact001085" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">139.60</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzCJpLPJ4tW7" title="Number of Shares, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1087">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zW9veaMoeSR8" title="Weighted Average Grant Date Fair Value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMg8cv71H9Og" title="Number of Shares, Vested" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember" id="Fact001091" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,240</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zbnKrhCW15E" title="Weighted Average Grant Date Fair Value, Vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember" id="Fact001093" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">137.20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkc6cTHzSkZ2" title="Number of Shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember" id="Fact001095" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">440</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjoEnOhgqtnl" title="Weighted Average Grant Date Fair Value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember" id="Fact001097" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">229.60</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Unvested as of March 31, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zeg4dH5hz1Ul" title="Unvested Number of Shares, Beginning balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2025-03-31_us-gaap_RestrictedStockMember" id="Fact001099" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,265</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1iho2up2q8b" title="Weighted Average Grant Date Fair Value, Beginning balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-03-31_us-gaap_RestrictedStockMember" id="Fact001101" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">139.40</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zlnBw6qwW5lf" title="Number of Shares, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zroJU2kT7Eq8" title="Weighted Average Grant Date Fair Value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1105">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB3PfQsrwQCg" title="Number of Shares, Vested" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockMember" id="Fact001107" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,630</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjrLsw2vGFIe" title="Weighted Average Grant Date Fair Value, Vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockMember" id="Fact001109" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">150.26</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zacVs3383fwl" title="Number of Shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockMember" id="Fact001111" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhQ6nv5gB0rg" title="Weighted Average Grant Date Fair Value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockMember" id="Fact001113" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">137.40</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Unvested as of March 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zx0uM3ife9Ta" title="Unvested Number of Shares, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2026-03-31_us-gaap_RestrictedStockMember" id="Fact001115" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,485</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyzVzIbf5x27" title="Weighted Average Grant Date Fair Value, ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2026-03-31_us-gaap_RestrictedStockMember" id="Fact001117" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">129.41</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zGi1YhK8Cy3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense related to these stock issuances for the years ended March 31, 2026 and March 31, 2025 was $<span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20250401__20260331_z7HQw3yN6kL8" title="Employee benefits and share based compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2025-04-01to2026-03-31" id="Fact001119" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million and $<span id="xdx_906_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20240401__20250331_z7p8ylKZbkfa" title="Employee benefits and share based compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-04-012025-03-31" id="Fact001121" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction>
</span>million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026, the Company had unrecognized stock-based compensation expense for the restricted stock unit awards in the 2013 BA
Plan of approximately $<span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandThirteenBAPlanMember_zpeMcRV8t2f3" title="Share based compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2025-04-012026-03-31_custom_TwoThousandThirteenBAPlanMember" id="Fact001123" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million, which is expected to be expensed over the weighted average remaining service period of <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zb6nOFhmwMc3" title="Weighted average remaining service, period"><ix:nonNumeric contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001125" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.0</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026, all vested shares had been issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 STOCKHOLDERS&#8217; EQUITY (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
vesting terms of the options issued under the 2013 BA Plan are generally <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zfI8jrxnK5Re" title="Vesting period"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" format="ixt-sec:durwordsen" id="Fact001127" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">four years</ix:nonNumeric></span> and expire <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zPcgrtQL7ulg" title="Expiration period"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" format="ixt-sec:durwordsen" id="Fact001129" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">ten years</ix:nonNumeric></span> from the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" escape="true" id="Fact001131" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcILgvnqjbS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the change in stock options for the years ended March 31, 2026 and March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zPMO2ul4ry35" style="display: none">SCHEDULE OF OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price&#8211;-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life- </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(thousands)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Options outstanding as of March 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zDIuTD1HmBn" title="Number of Options, Outstanding at beginning of period" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001133" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">566,645</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRrEUPyqxF9d" title="Weighted Average Exercise Price - Options, Outstanding at beginning of period" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001135" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">88.39</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zfw3evrr2Fr4" title="Weighted Average Remaining Contractual Life - Options"><ix:nonNumeric contextRef="From2023-04-012024-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001137" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.0</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zylzEpHSyxIi" title="Aggregate Intrinsic Value, Outstanding at beginning of period" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">760</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zoGAg1pOcH3b" title="Number of Options Outstanding, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">227,550</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRupONoHugJj" title="Weighted Average Exercise Price - Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001143" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.06</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zquTALQYQDWd" title="Number of Options Outstanding, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zVGjiqWEuihd" title="Weighted Average Exercise Price - Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1147">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zLvDY8NIKuYd" title="Number of Options Outstanding, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">54,976</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zVt55UyXj6sf" title="Weighted Average Exercise Price - Options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001151" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">61.74</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding as of March 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zNHc46gRgZF3" title="Number of Options, Outstanding at beginning of period" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001153" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">739,219</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zAkxzGO3xqE7" title="Weighted Average Exercise Price - Options, Outstanding at beginning of period" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001155" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRMUh8b5pHG5" title="Weighted Average Remaining Contractual Life - Options, Outstanding at beginning of period"><ix:nonNumeric contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001157" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.9</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zdQWrl0Ptc3c" title="Aggregate Intrinsic Value, Outstanding at beginning of period" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1159">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zb0DsRAuUdI1" title="Number of Options Outstanding, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001161" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">94,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zKPnzEy7Uty3" title="Weighted Average Exercise Price - Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001163" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zuv9Dih4ZqF3" title="Number of Options Outstanding, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1165">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zdBZ78oloXib" title="Weighted Average Exercise Price - Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_z63B4wYthsHf" title="Number of Options Outstanding, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001169" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,270</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zMHfWM2AW9B2" title="Weighted Average Exercise Price - Options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001171" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.95</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcVHxVYaJAw2" title="Number of Options, Outstanding at ending of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001173" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">756,749</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_z28O37ZACZJ8" title="Weighted Average Exercise Price - Options, Outstanding at ending of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001175" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.82</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zSybYciOzyp5" title="Weighted Average Remaining Contractual Life - Options, Outstanding at end of period"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001177" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.2</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zjffWXBkOv75" title="Aggregate Intrinsic Value, Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1179">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcU09AUzmzRi" title="Number of Options Outstanding, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">497,591</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zZWvfCXaIUQ4" title="Weighted Average Exercise Price - Options, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001183" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.95</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zc3N8Wp4PdLi" title="Weighted Average Remaining Contractual Life - Options, Exercisable"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001185" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">6.3</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zONx7x7i0Pkc" title="Aggregate Intrinsic Value, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zupB4LrDc0Sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026, the Company had unrecognized stock-based compensation expense for the stock options in the 2013 BA Plan of approximately
$<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityIncentivePlanMember_zsRiif8TSjNi" title="Unrecognized stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2026-03-31_custom_TwoThousandThirteenEquityIncentivePlanMember" id="Fact001189" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million which is expected to be expensed over the weighted average remaining service period of <span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityIncentivePlanMember_zcKNzMhoHNuf" title="Weighted average remaining service period"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandThirteenEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001191" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.7</ix:nonNumeric> </span>years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended March 31, 2026 and March 31, 2025, the weighted average fair value of options granted was $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zlpLvLlXYavi" title="Weighted average fair value of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001193" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.80</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcGG23degHWi" title="Weighted average fair value of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" id="Fact001195" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.03</ix:nonFraction></span> per share,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2026, the Company executed a Separation and Release of Claims Agreement with the former CEO, Steven Lisi (&#8220;Release Agreement&#8221;).
All unvested options held by Mr. Lisi as of March 27, 2026, were accelerated and immediately vested, and remain exercisable for twenty-four
months from March 27, 2026. The Company recorded $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20260327__20260327_zecRCsZ4qK47" title="Share compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2026-03-272026-03-27" id="Fact001197" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million of non-cash stock compensation expense reflecting the acceleration of expense
recognition of these equity awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2025, the Company&#8217;s Board of Directors approved a  stock option repricing of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251104__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9IOg0ad5b4j" title="Option repricing"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-11-04_us-gaap_EmployeeStockOptionMember" id="Fact001199" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">726,618</ix:nonFraction></span>
options (the &#8220;2026 Option Repricing&#8221;), effective November 4, 2025. The 2026 Option Repricing was undertaken in
accordance with, and as permitted by, the Company&#8217;s 2013 BA Plan. Pursuant to the 2026 Option Repricing, all options granted
pursuant to the 2013 BA Plan that are held by Company Board members, officers, and employees expected to continue providing services
to the Company were repriced, to the extent such options had an exercise price in excess of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_c20251104__20251104__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zupOm3WT8XFl" title="Exercise price in excess"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="From2025-11-042025-11-04_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" id="Fact001201" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.95</ix:nonFraction></span>,
the closing price per share of the Company&#8217;s common stock as reported on The Nasdaq Stock Market on November 3, 2025. All such
options were repriced such that the exercise price per share was reduced to $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_c20251104__20251104__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqtMWmaGajge" title="Exercise price in excess"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="From2025-11-042025-11-04_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" id="Fact001203" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.95</ix:nonFraction></span>.
The modification resulted in incremental stock compensation expense of $<span id="xdx_90E_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_pn5n6_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwJ4LKvwi23j" title="Incremental stock compensation expense"><ix:nonFraction name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" contextRef="From2025-04-012026-03-31_us-gaap_EmployeeStockOptionMember" id="Fact001205" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span>
million recognized during the year ended March 31, 2026. There is approximately $<span id="xdx_906_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_pn5n6_c20250401__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv2zFyzwkV2i" title="Incremental stock compensation expense"><ix:nonFraction name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" contextRef="From2025-04-012025-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001207" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million of unrecognized stock-based compensation expense for the 2026 Option Repricing which is expected to be expensed over the
weighted average remaining service period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8GgcLZxmMqi" title="Weighted average remaining service, period"><ix:nonNumeric contextRef="From2025-04-012026-03-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001209" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.5</ix:nonNumeric></span>
years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 22, 2024, the Company&#8217;s Board of Directors approved a  stock option repricing (&#8220;2025 Option
Repricing&#8221;), effective November 22, 2024 (&#8220;Effective Date&#8221;). The 2025 Option Repricing was undertaken in
accordance with, and as permitted by, the Company&#8217;s Amended 2013 Plan. Pursuant to the 2025 Option Repricing, all options
granted pursuant to the Amended 2013 Plan that are held by Company Board members, officers, and employees expected to continue
providing services to the Company were repriced, to the extent such options had an exercise price in excess of $<span id="xdx_905_eus-gaap--StockOptionExercisePriceIncrease_c20241122__20241122__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_z0rsuvyTo3o7" title="Option exercise price"><ix:nonFraction name="us-gaap:StockOptionExercisePriceIncrease" contextRef="From2024-11-222024-11-22_custom_TwoThousandTwentyFiveOptionRepricingMember" id="Fact001211" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.80</ix:nonFraction></span>,
the closing price per share of the Common Stock as reported on The Nasdaq Stock Market on November 22, 2024. As of the Effective
Date, all such options were repriced such that the exercise price per share was reduced to $<span id="xdx_90E_eus-gaap--StockOptionExercisePriceIncrease_c20241122__20241122__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zsObHSdTdk2g" title="Option exercise price"><ix:nonFraction name="us-gaap:StockOptionExercisePriceIncrease" contextRef="From2024-11-222024-11-22_custom_TwoThousandTwentyFiveOptionRepricingMember" id="Fact001213" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.80</ix:nonFraction></span>.
The modification resulted in incremental stock compensation expense of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pn5n6_c20250401__20260331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zDDutejXQDq6" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyFiveOptionRepricingMember" id="Fact001215" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">0.3</ix:nonFraction></span>
million and $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pn5n6_c20240401__20250331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zfvgpZ0uQEsf" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyFiveOptionRepricingMember" id="Fact001217" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">1.6</ix:nonFraction></span>
million recognized during the years ended March 31, 2026 and March 31, 2025, respectively. There is approximately $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20260331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zAOkbh72vTs6" title="Unrecognized share based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyFiveOptionRepricingMember" id="Fact001219" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million of unrecognized stock-based compensation expense for the 2025 Option Repricing which is expected to be expensed over the
weighted average remaining service period of <span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zvv4n4uVfeua" title="Weighted average remaining service, period"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyFiveOptionRepricingMember" format="ixt-sec:duryear" id="Fact001221" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.0</ix:nonNumeric></span>
years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 STOCKHOLDERS&#8217; EQUITY (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s 2021 Beyond Cancer Ltd. Equity Incentive Plan (the &#8220;2021 BC Plan&#8221;) allows for awards to officers, directors,
employees, and consultants of stock options, restricted stock units and restricted shares of Beyond Cancer Ltd.&#8217;s common stock.
The vesting terms of the options issued under the 2021 BC Plan are generally <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zLWQXUFSoA44" title="Vesting period"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" format="ixt-sec:durwordsen" id="Fact001223" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">four years</ix:nonNumeric></span> and they expire <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_ze5Wci8JlHvg" title="Expiration period"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" format="ixt-sec:durwordsen" id="Fact001225" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">ten years</ix:nonNumeric></span> from the grant date.
On November 3, 2022, the Company&#8217;s Board of Directors approved an amendment to reserve for issuance an additional <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20221103__20221103__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z8RMuCVDnyid" title="Number of additionl shares reserve for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2022-11-032022-11-03_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001227" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> shares
of common stock. The 2021 BC Plan has <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20221103__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zWjat4ZfK3Kc" title="Number of shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2022-11-03_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction></span> shares authorized for issuance. As of March 31, 2026, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_ztc8XZqE76fb" title="Number of shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001231" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,745,500</ix:nonFraction></span> shares were available
under the 2021 BC Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" escape="true" id="Fact001233" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zIGS8sGiUi2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the change in stock options for Beyond Cancer for the years ended March 31, 2026 and March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zfNCVrREUPoa" style="display: none">SCHEDULE
OF OPTION ACTIVITY FOR BEYOND CANCER</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price&#8211;-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life- </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(thousands)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Options outstanding as of March 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zltD0lFKYr29" title="Number of Options, Outstanding at beginning of period" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001235" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,819,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zPStOfDJJPha" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001237" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.50</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zC49XGIPXeB4" title="Weighted average remaining contractual life - options, outstanding at beginning of period"><ix:nonNumeric contextRef="From2023-04-012024-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001239" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.3</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zQkQLohCA7H2" title="Aggregate Intrinsic Value, Outstanding at beginning of period" style="width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z9HQ10n1f8q1" title="Number of Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1243">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXJCIIyEQqsi" title="Weighted Average Exercise Price of Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zltdWXYxbUwe" title="Number of Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zlfL50p2nf13" title="Weighted Average Exercise Price of Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1249">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zJVpcZOWGyt5" title="Number of Options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,002,750</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zAOoFNdvqLue" title="Weighted Average Exercise Price of Options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001253" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.50</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding as of March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXK1Ydo1CHvg" title="Number of Options, Outstanding at beginning of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001255" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,816,250</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_ziyVB8iwOtZ9" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001257" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.50</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXJXgcJK8rt6" title="Weighted average remaining contractual life - options, outstanding at beginning of period"><ix:nonNumeric contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001259" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.2</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zxp6GCLrGnW5" title="Aggregate Intrinsic Value, Outstanding at beginning of period" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1261">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zlzImYg5etR9" title="Number of Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zZDm8lqi3LR7" title="Weighted Average Exercise Price of Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zoq5ry3qY7ag" title="Number of Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1267">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zD5GzidrBIub" title="Weighted Average Exercise Price of Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBUKt3EcL5bd" title="Number of Options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001271" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">561,750</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z3mQDWmOLBU7" title="Weighted Average Exercise Price of Options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001273" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.50</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z5dckoFlZlg9" title="Number of Options, Outstanding at ending of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001275" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,254,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zyCXarkEuvMa" title="Weighted Average Exercise Price of Options, Outstanding at ending of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001277" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.50</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zIckJ2fTos8i" title="Weighted average remaining contractual life - options, outstanding at beginning of period"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001279" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.2</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zqkBxlY4doP" title="Aggregate intrinsic value, outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1281">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBQOTMmBnKuh" title="Number of Options Outstanding, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001283" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,975,750</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBInmxPusKql" title="Weighted Average Exercise Price of Options, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001285" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.50</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zC6JnOcvBVvk" title="Weighted Average Remaining Contractual Life of Options, Exercisable"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001287" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">6.1</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zmg18381u15a" title="Aggregate Intrinsic Value, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zpuVNGb6PPE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026, the Company had unrecognized stock-based compensation expense for the stock options in the 2021 BC Plan of approximately
$<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zNY33knzW7lc" title="Unrecognized stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" id="Fact001291" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million which is expected to be expensed over the weighted average remaining service period of <span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zcvrBj2eEqGi" title="Weighted average remaining service period"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001293" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.0</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s 2023 NeuroNos Ltd. Equity Incentive Plan (the &#8220;2023 NNOS Plan&#8221;) allows for awards to officers, directors,
employees, and consultants of stock options, restricted stock units and restricted shares of NeuroNos Ltd.&#8217;s common stock. The
vesting terms of the options issued under the 2023 NNOS Plan are generally four years and they expire ten years from the grant date.
On March 31, 2025, the Company&#8217;s Board of Directors approved to reserve for issuance <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zBNAjntTRQ85" title="Stock option shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,725,000</ix:nonFraction></span> shares of common stock. As of March
31, 2026, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zFZlWNrsgHt" title="Number of shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001297" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">465,670</ix:nonFraction></span> shares were available under the 2023 NNOS Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" escape="true" id="Fact001299" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zh9GKH4NRrL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the change in stock options for NeuroNos for the years ended March 31, 2026 and March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zzqGzZlZI6Se">SCHEDULE
OF OPTION ACTIVITY FOR NEURONOS</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price&#8211;-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life- </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(thousands)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding as of March 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zzh1y1MycSpa" title="Number of Options, Outstanding at beginning of period" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zePHo2mON8Nk" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zRuWKHUO1Mxc" title="Aggregate Intrinsic Value, Outstanding at beginning of period" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zKXJyXen5OXc" title="Number of Options, Granted" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001307" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,224,139</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z3HPlgV7lHh9" title="Weighted Average Exercise Price of Options, Granted" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001309" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.14</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zBGUDjzUIFMg" title="Number of Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1311">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zYMwGOOXRvJi" title="Weighted Average Exercise Price of Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1313">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zapFoZDRg2ni" title="Number of Options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zEolIhcf8rt8" title="Weighted average exercise price - options, forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1317">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding as of March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zgHjMFZpIVri" title="Number of Options, Outstanding at beginning of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001319" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,224,139</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zqTaYDZ2V9xf" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001321" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.14</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zzFD91herDCk" title="Weighted average remaining contractual life - options, outstanding at beginning of period"><ix:nonNumeric contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001323" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.1</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_za87e7pYMJwa" title="Aggregate Intrinsic Value, Outstanding at beginning of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001325" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,501</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z5YWYvHEN6g1" title="Number of Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001327" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">169,913</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_ziEsb2HyfQW3" title="Weighted Average Exercise Price of Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001329" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zecF9JIVa7hf" title="Number of Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1331">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z3K6NYELNkK4" title="Weighted Average Exercise Price of Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1333">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zCx9aDsAiMYh" title="Number of Options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001335" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">134,723</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zRDQ9XILrgp" title="Weighted average exercise price - options, forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.82</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zfEaOkfKvcG1" title="Number of Options, Outstanding at ending of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001339" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,259,329</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zx5hb3vD5vla" title="Weighted Average Exercise Price of Options, Outstanding at ending of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001341" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.24</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zhz8aKY5TdIa" title="Weighted Average Remaining Contractual Life of Options, Outstanding"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001343" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.1</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_znqU4pApiRS8" title="Aggregate Intrinsic Value, Outstanding at ending of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001345" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,477</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zCGea6Lpnox2" title="Number of Options Outstanding, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001347" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">622,341</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zNIF39u3q2A1" title="Weighted Average Exercise Price of Options, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001349" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zLCSAYm36C8j" title="Weighted Average Remaining Contractual Life of Options, Exercisable"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001351" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">8.1</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_znZ7QXjs68d9" title="Aggregate Intrinsic Value, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001353" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,748</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zVs91w4EOC65" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, the Company had unrecognized stock-based compensation expense for the stock options in the 2023 NNOS Plan of approximately
$<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zagRgEKWfWx7" title="Unrecognized stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001355" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million which is expected to be expensed over the weighted average remaining service period of <span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_ze9eKe5Zg4K6" title="Weighted average remaining service period"><ix:nonNumeric contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001357" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.5</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended March 31, 2026 and March 31, 2025, the weighted average fair value of options granted was $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z4oMCTJiTphg" title="Weighted average fair value of options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001359" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z4dSNfx9BgQ" title="Weighted average fair value of options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" id="Fact001361" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.11</ix:nonFraction></span> per share,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 STOCKHOLDERS&#8217; EQUITY (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001363" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_znuBCNu7JmO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following was utilized to calculate the fair value of options on the date of grant:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z5l5Hkq90oM9" style="display: none">SCHEDULE
OF FAIR VALUE OF OPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk -free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250401__20260331__srt--RangeAxis__srt--MinimumMember_ztqHuUTMVkU6" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-04-012026-03-31_srt_MinimumMember" id="Fact001365" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.7</ix:nonFraction></span>-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250401__20260331__srt--RangeAxis__srt--MaximumMember_z5Weo3qWwYK6" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-04-012026-03-31_srt_MaximumMember" id="Fact001367" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.2</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MinimumMember_zOk3WASdJaOc" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-04-012025-03-31_srt_MinimumMember" id="Fact001369" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.6</ix:nonFraction></span>-<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MaximumMember_zD0V6CXOeHYk" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-04-012025-03-31_srt_MaximumMember" id="Fact001371" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.4</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (Beyond Air)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MinimumMember_zV4T83F0opSe" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-04-012026-03-31_custom_BeyondAirIncMember_srt_MinimumMember" id="Fact001373" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">91.6</ix:nonFraction></span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MaximumMember_z8EHPpW1UOH2" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-04-012026-03-31_custom_BeyondAirIncMember_srt_MaximumMember" id="Fact001375" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">106.2</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MinimumMember_z8BzrqrUvkL6" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-04-012025-03-31_custom_BeyondAirIncMember_srt_MinimumMember" id="Fact001377" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">83.6</ix:nonFraction></span>-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MaximumMember_z8rmUTALNZgf" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-04-012025-03-31_custom_BeyondAirIncMember_srt_MaximumMember" id="Fact001379" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">89.9</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (Beyond Cancer)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zl2io9hAH0Rl" title="Expected volatility">N/A</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zaRevvw1K9Bc" title="Expected volatility">N/A</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Expected volatility (NeuroNos)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember_zVJpALKf2QR1" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember" id="Fact001385" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.0</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember_zJibdoGTAv21" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember" id="Fact001387" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.0</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250401__20260331_zYE7J99l4Uc7" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2025-04-01to2026-03-31" id="Fact001389" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240401__20250331_zh1kgth8vmC5" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-04-012025-03-31" id="Fact001391" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected terms (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250401__20260331_zXpIeUoRAko2" title="Expected term (in years)"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" format="ixt-sec:duryear" id="Fact001393" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240401__20250331_zh1VdwzsZHpd" title="Expected term (in years)"><ix:nonNumeric contextRef="From2024-04-012025-03-31" format="ixt-sec:duryear" id="Fact001395" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_zoeQvMI5zFue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that the fair value per share of NeuroNos&#8217; common stock to be $<span id="xdx_902_eus-gaap--SharePrice_iI_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--BeyondCancerLtdMember__srt--RangeAxis__srt--MinimumMember_zxB9DeC3pbbe" title="Fair value per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember_custom_BeyondCancerLtdMember_srt_MinimumMember" id="Fact001397" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.14</ix:nonFraction></span> at the grant date during the year ended
March 31, 2025 based on a third-party valuation, and to be $<span id="xdx_905_eus-gaap--SharePrice_iI_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--BeyondCancerLtdMember__srt--RangeAxis__srt--MinimumMember_zFL8ZWaYAvEg" title="Fair value per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_BeyondCancerLtdMember_srt_MinimumMember" id="Fact001399" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span> at the grant date during the year ended March 31, 2026 based on the
valuation of common stock purchased by external investors during the fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001401" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zC0pH738OJH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the components of stock-based compensation expense which included stock options and restricted stock for the years
ended March 31, 2026 and March 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zEz0Aj0KcgYk" style="display: none">SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250401__20260331_zq7dXjpYPMUl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240401__20250331_zveT734dr9Ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--ResearchAndDevelopmentExpense_zphXUEaGZq5c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-04-012026-03-31_us-gaap_ResearchAndDevelopmentExpense" id="Fact001403" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,153</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012025-03-31_us-gaap_ResearchAndDevelopmentExpense" id="Fact001404" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">471</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zRBl1sXybtyd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-04-012026-03-31_us-gaap_GeneralAndAdministrativeExpense" id="Fact001406" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,129</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012025-03-31_us-gaap_GeneralAndAdministrativeExpense" id="Fact001407" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,675</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_pn3n3_z3LePV7u1DXh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-04-01to2026-03-31" id="Fact001409" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,282</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012025-03-31" id="Fact001410" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,146</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zfF4diNi9jN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 8, 2025, the Company entered into an inducement offer letter agreement (&#8220;Inducement Letter&#8221;) with certain holders
of the September 2024 equity offering common stock warrants (&#8220;Existing Warrants&#8221;). Pursuant to the Inducement Letter, such
holders immediately exercised some of all of their respective outstanding Existing Warrants to purchase up to an aggregate of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCWggDhRYsrf" title=" Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-09-08_us-gaap_WarrantMember" id="Fact001412" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,439,128</ix:nonFraction></span>
shares of common stock at a reduced exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXRCVt4TGSg4" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-08_us-gaap_WarrantMember" id="Fact001414" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.21</ix:nonFraction></span>. The proceeds to the Company from the exercise of the Existing Warrants were
approximately $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250908__20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcY3l8xsTcV3" title="Warrants Exercise"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-09-082025-09-08_us-gaap_WarrantMember" id="Fact001416" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.9</ix:nonFraction></span> million, net of placement agent fees and other offering expenses of $<span id="xdx_900_eus-gaap--PaymentsForFees_pn5n6_c20250908__20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOBFXVVzcqni" title="Other fees"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2025-09-082025-09-08_us-gaap_WarrantMember" id="Fact001418" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million and $<span id="xdx_906_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhPEtRmUtj17" title="Other fees"><ix:nonFraction name="us-gaap:DeferredCostsCurrent" contextRef="AsOf2025-09-08_us-gaap_WarrantMember" id="Fact001420" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million, respectively. In
consideration of the inducement offer, the Company issued new common stock warrants to purchase up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250908__20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTNLVz8hWp3c" title="Stock issues during the period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-09-082025-09-08_us-gaap_WarrantMember" id="Fact001422" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">719,562</ix:nonFraction></span> shares of common stock
for a purchase price of $<span id="xdx_901_eus-gaap--WarrantExercisePriceIncrease_c20250908__20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBCIjLgWKzq6" title="Warrant exercise price"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2025-09-082025-09-08_us-gaap_WarrantMember" id="Fact001424" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.125</ix:nonFraction></span> per share of common stock underlying the new warrant. The new warrants have an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z29sbL2ZXUv9" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-08_us-gaap_WarrantMember" id="Fact001426" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.21</ix:nonFraction></span>
per share and are immediately exercisable, with a term of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcd4mUbteaX7" title="Weighted average remaining service period"><ix:nonNumeric contextRef="AsOf2025-09-08_us-gaap_WarrantMember" format="ixt-sec:durwordsen" id="Fact001428" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2025, warrants to purchase up to an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251103__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zpsuzE1mXdri" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-11-03_us-gaap_CommonStockMember_custom_AmendedLoanAgreementMember" id="Fact001430" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">512,821</ix:nonFraction></span> of Company common stock were issued as part of the Amended Loan
Agreement with certain lenders including its director Robert Carey at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251103__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zJrg5qzIF9O9" title="Warrants price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-11-03_us-gaap_CommonStockMember_custom_AmendedLoanAgreementMember" id="Fact001432" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.95</ix:nonFraction></span> per common stock warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 16, 2026, warrants to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260116__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSBViBSPGM7f" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-01-16_us-gaap_CommonStockMember" id="Fact001434" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,930,818</ix:nonFraction></span> of Company common stock were issued to certain institutional investors
at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260116__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJVtliP4DcM" title="Warrants price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-01-16_us-gaap_CommonStockMember" id="Fact001436" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.147</ix:nonFraction></span> per common stock warrant. The warrant exercise price was calculated at the 5-trading day average closing
share price as of January 13, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 16, 2026, pre-funded warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260116__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_z4FMmTJtfNxl" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-01-16_custom_TwoThousandTwentySixPreFundedWarrantsMember" id="Fact001438" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,405,828</ix:nonFraction> </span>of Company common stock were issued to certain institutional investors
at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260116__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_zAvFRcAkgBal" title="Warrants price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-01-16_custom_TwoThousandTwentySixPreFundedWarrantsMember" id="Fact001440" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per common stock warrant. During the year ended March 31, 2026, holders exercised <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250116__20250116__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_zOYbEb15o8a8" title="Stock issued during the period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2025-01-162025-01-16_custom_TwoThousandTwentySixPreFundedWarrantsMember" id="Fact001442" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,263,215</ix:nonFraction></span> of these 2026
Pre-Funded Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001444" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVuaGqiwngbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s outstanding warrants as of March 31, 2026 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_znadyXZOO54l" style="display: none">SUMMARY
OF OUTSTANDING WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Warrant Holders</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify">NitricGen agreement</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z4kShwuooEzd" title="Number of Warrants" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_NitricGenAgreementMember" id="Fact001446" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_zrrfqWfjyFs9" title="Exercise Price" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_NitricGenAgreementMember" id="Fact001448" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">138.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z82UsnuOhuai" title="Intrinsic Value" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1450">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 17%; text-align: center"><span id="xdx_90B_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z67dCquqcvBe" title="Date of Expiration"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_NitricGenAgreementMember" id="Fact001452" name="XAIR:WarrantsExpirationDateDescription">January 2028</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Avenue agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_z3qE4BXpSG88" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_AvenueAgreementMember" id="Fact001454" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,693</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zE1o60N5QRK3" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_AvenueAgreementMember" id="Fact001456" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zYBi17WHaRG6" title="Intrinsic Value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1458">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zV23M8znsHYj" title="Date of Expiration"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AvenueAgreementMember" id="Fact001460" name="XAIR:WarrantsExpirationDateDescription">June 2028</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">March 2024 raise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zw5FeoLMNUkg" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_MarchTwoThousandTwentyFourRaiseMember" id="Fact001462" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">481,936</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zvFMa9PYPi5" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_MarchTwoThousandTwentyFourRaiseMember" id="Fact001464" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">45.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_z4lkHpV5luNi" title="Intrinsic Value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1466">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zLdjKKNcg7hk" title="Date of Expiration"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_MarchTwoThousandTwentyFourRaiseMember" id="Fact001468" name="XAIR:WarrantsExpirationDateDescription">March 2027</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Avenue extension agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zPAZzCg5Omcj" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_AvenueExtensionAgreementMember" id="Fact001470" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zcfOWm9cqmn5" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_AvenueExtensionAgreementMember" id="Fact001472" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zx4ik2vBNlC5" title="Intrinsic Value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1474">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zwt1QWSGlGCl" title="Date of Expiration"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_AvenueExtensionAgreementMember" id="Fact001476" name="XAIR:WarrantsExpirationDateDescription">June 2029</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">September 2024 equity offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zP5rs7vYn62b" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourEquityOfferingMember" id="Fact001478" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">555,229</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_z8gTZM698Bt8" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourEquityOfferingMember" id="Fact001480" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zeKM7h9fB06" title="Intrinsic Value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1482">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zmGsa4tmgTH2" title="Date of Expiration"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_SeptemberTwoThousandTwentyFourEquityOfferingMember" id="Fact001484" name="XAIR:WarrantsExpirationDateDescription">September 2029</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">September 2024 debt instrument</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zFkIDRzrQlDh" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourDebtInstrumentMember" id="Fact001486" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,270,796</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zicWS367XVkj" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourDebtInstrumentMember" id="Fact001488" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zvtoJXRSuLOc" title="Intrinsic Value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1490">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zKYCGJ3Wszh7" title="Date of Expiration"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_SeptemberTwoThousandTwentyFourDebtInstrumentMember" id="Fact001492" name="XAIR:WarrantsExpirationDateDescription">September 2029 / November 2030</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">September 2025 inducement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zrk8L3PstUP1" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFiveInducementMember" id="Fact001494" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">719,562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zcTuX5vJXQ04" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFiveInducementMember" id="Fact001496" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.21</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zJ9gj1dntk87" title="Intrinsic Value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1498">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zTonXyrH1eCj" title="Date of Expiration"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_SeptemberTwoThousandTwentyFiveInducementMember" id="Fact001500" name="XAIR:WarrantsExpirationDateDescription">September 2030</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">January 2026 equity offering</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zMqAK5J6CSs3" title="Number of Warrants" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_JanuaryTwoThousandTwentySixEquityOfferingMember" id="Fact001502" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,930,818</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zUXDNfH4EXAj" title="Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_JanuaryTwoThousandTwentySixEquityOfferingMember" id="Fact001504" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.147</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_z5zH5sGpVSNl" title="Intrinsic Value" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1506">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zReAqHOnTIq8" title="Date of Expiration"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_JanuaryTwoThousandTwentySixEquityOfferingMember" id="Fact001508" name="XAIR:WarrantsExpirationDateDescription">January 2031</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zpqKgoG7zFA3" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_SubTotalMember" id="Fact001510" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,979,034</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zRyE1w5e87e4" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_SubTotalMember" id="Fact001512" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.05</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zpF3Vh78GCg2" title="Intrinsic Value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1514">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pre-funded warrants (Sep-2024 offering)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_ziNtUpjIizjh" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_PreFundedWarrantsSepTwoThousandTwentyFourMember" id="Fact001516" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">220,006</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_zut3bvqrXnz9" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_PreFundedWarrantsSepTwoThousandTwentyFourMember" id="Fact001518" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.002</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_ziio5DBdmHZj" title="Intrinsic Value" style="text-align: right"><ix:nonFraction name="XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" contextRef="AsOf2026-03-31_custom_PreFundedWarrantsSepTwoThousandTwentyFourMember" id="Fact001520" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">151</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_zTe4TE5Bfixi" title="Date of Expiration"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_PreFundedWarrantsSepTwoThousandTwentyFourMember" id="Fact001522" name="XAIR:WarrantsExpirationDateDescription">September 2029</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Pre-funded warrants (Jan-2026 offering)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zTM446FKRBO9" title="Number of Warrants" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_PreFundedWarrantsJanTwoThousandTwentySixMember" id="Fact001524" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,142,613</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zzgI25s9Rhc1" title="Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_PreFundedWarrantsJanTwoThousandTwentySixMember" id="Fact001526" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zzhhUwr98aWk" title="Intrinsic Value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" contextRef="AsOf2026-03-31_custom_PreFundedWarrantsJanTwoThousandTwentySixMember" id="Fact001528" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,479</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_901_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zTy0FS3fMkb9" title="Date of Expiration"><ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_PreFundedWarrantsJanTwoThousandTwentySixMember" id="Fact001530" name="XAIR:WarrantsExpirationDateDescription">January 2031</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331_zDKoi3QCk5ye" title="Number of Warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31" id="Fact001532" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,341,653</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331_zGE9blo9TObb" title="Exercise Price" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31" id="Fact001534" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.773</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331_zsRu6JJ5ajh5" title="Intrinsic Value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" contextRef="AsOf2026-03-31" id="Fact001536" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,630</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zCs78da6MJB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ESPP</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 4, 2021, the stockholders approved the 2021 Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The purpose of the ESPP is to encourage
and to enable eligible employees of the Company, through after-tax payroll deductions, to acquire proprietary interests in the Company
through the purchase and ownership of shares of Stock. The ESPP is intended to benefit the Company and its stockholders by (a) incentivizing
participants to contribute to the success of the Company and to operate and manage the Company&#8217;s business in a manner that will
provide for the Company&#8217;s long-term growth and profitability and that will benefit its stockholders and other important stakeholders
and (b) encouraging participants to remain in the employ of the Company. As of March 31, 2026 and March 31, 2025, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEmployeeStockPurchasePlanMember_zTKJ4Bf4f9Lc" title="Number of shares issued"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEmployeeStockPurchasePlanMember_zXsTm3f4PXRl" title="Number of shares issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" id="Fact001538" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" id="Fact001540" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares were issued
under the ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001542" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_80A_eus-gaap--OtherCurrentAssetsTextBlock_zFJmrFKcjcPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 <span id="xdx_829_z8Bw8CKCb5M5">OTHER CURRENT ASSETS AND PREPAID EXPENSES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001544" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z12r0YX9rOK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of other current assets and prepaid expenses as of March 31, 2026 and March 31, 2025 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zWlHKa80qD8c" style="display: none">SCHEDULE
OF OTHER CURRENT ASSETS AND PREPAID EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20260331_zTQvj9c1CA6i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20250331_z3gnSdYgdLL5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzff3_z3DrsaFKYFsj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="XAIR:PrepaidResearchAndDevelopment" contextRef="AsOf2026-03-31" id="Fact001546" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">696</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="XAIR:PrepaidResearchAndDevelopment" contextRef="AsOf2025-03-31" id="Fact001547" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">108</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidInsurance_iI_maPEAOAzff3_z17lBgx71299" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2026-03-31" id="Fact001549" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">579</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2025-03-31" id="Fact001550" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">817</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidRent_iI_maPEAOAzff3_zzYTebrULgoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid rents and tenant improvement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidRent" contextRef="AsOf2026-03-31" id="Fact001552" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidRent" contextRef="AsOf2025-03-31" id="Fact001553" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidTaxes_iI_maPEAOAzff3_zVlyDEphLZT3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Value added tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2026-03-31" id="Fact001555" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">105</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2025-03-31" id="Fact001556" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DepositsAssets_iI_maPEAOAzff3_zsExCHma4Syg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deposits to secure manufacturing materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2026-03-31" id="Fact001558" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2025-03-31" id="Fact001559" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,377</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Supplies_iI_maPEAOAzff3_zLHwcz0ZdJjc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Demonstration materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Supplies" contextRef="AsOf2026-03-31" id="Fact001561" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Supplies" contextRef="AsOf2025-03-31" id="Fact001562" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_maPEAOAzff3_zAoTAMHnW28f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2026-03-31" id="Fact001564" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">190</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2025-03-31" id="Fact001565" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">203</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzff3_z1LDZg4eceVg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total other current assets and prepaid expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2026-03-31" id="Fact001567" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,012</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-03-31" id="Fact001568" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,743</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zZjeLdcENH49" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001570" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_80E_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zcVMWyY4y1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 <span id="xdx_828_zKczuug6aX78">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001572" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zZTkvZpdS6Ah" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of accrued expenses and other current liabilities as of March 31, 2026 and March 31, 2025 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zIdDrAHEKJdb" style="display: none">SUMMARY OF ACCRUED EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20260331_zgmGMcKnZwQ" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250331_zt51FMOpjwUb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentExpenses_iI_pn3n3_maTSAEzACS_zI7vqb8Et3Ib" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="XAIR:AccruedResearchAndDevelopmentExpenses" contextRef="AsOf2026-03-31" id="Fact001574" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="XAIR:AccruedResearchAndDevelopmentExpenses" contextRef="AsOf2025-03-31" id="Fact001575" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">360</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maTSAEzACS_z07t4i6zH1yf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2026-03-31" id="Fact001577" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">252</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2025-03-31" id="Fact001578" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">440</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maTSAEzACS_zSO1iQsJpyy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Employee salaries and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2026-03-31" id="Fact001580" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">465</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2025-03-31" id="Fact001581" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">924</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--InterestSeveranceCurrent_iI_pn3n3_maTSAEzACS_z2jeCUo66EU9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued severance<span id="xdx_F4C_zPEwRQVV9dUg">*</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:InterestSeveranceCurrent" contextRef="AsOf2026-03-31" id="Fact001583" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">696</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1584">-</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_pn3n3_maTSAEzACS_zAZ3jpsVd2n5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2026-03-31" id="Fact001586" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1587">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredRevenueCurrent_iI_pn3n3_maTSAEzACS_z9sLbDACDPh1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2026-03-31" id="Fact001589" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">777</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1590">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--GoodsReceivedNotInvoiced_iI_pn3n3_maTSAEzACS_z6hXfThxgJmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Goods received not invoiced</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:GoodsReceivedNotInvoiced" contextRef="AsOf2026-03-31" id="Fact001592" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">273</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:GoodsReceivedNotInvoiced" contextRef="AsOf2025-03-31" id="Fact001593" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">98</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maTSAEzACS_zFG2iVnQ3jS" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2026-03-31" id="Fact001595" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">143</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact001596" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_pn3n3_mtTSAEzACS_zMAwvGTeAEbc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2026-03-31" id="Fact001598" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,372</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2025-03-31" id="Fact001599" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,045</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zBXqbMPPsWId" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F08_zPeN4BuLIU4e" style="width: 15pt; text-align: right">*</td><td style="text-align: justify"><span id="xdx_F15_zBxnU1wW0g4i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001600" xml:lang="en-US">Pursuant to the
terms of the Release Agreement with Steve Lisi, former CEO, the Company is obligated to pay Mr. Lisi $<span id="xdx_901_eus-gaap--Cash_iI_c20260331__srt--TitleOfIndividualAxis__custom--SteveLisiMember_zzRrwFGbAO1b" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQUNDUlVFRCBFWFBFTlNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2026-03-31_custom_SteveLisiMember" id="Fact001601" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">650,000</ix:nonFraction></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in cash compensation over 12 months. After expected employer
taxes and benefits, the Company accrued $<span id="xdx_904_eus-gaap--TaxesPayableCurrent_iI_pn5n6_c20260331__srt--TitleOfIndividualAxis__custom--SteveLisiMember_zi71LrIwbDJe" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQUNDUlVFRCBFWFBFTlNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="AsOf2026-03-31_custom_SteveLisiMember" id="Fact001602" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million The Company shall also pay Mr. Lisi COBRA premiums
for 12 months, as more specifically described in the Release Agreement. All unvested options and all unvested stock restriction unit
awards held by Mr. Lisi as of March 27, 2026, shall be accelerated and shall immediately vest, and shall continue to remain exercisable
for twenty-four (24) months from March 27, 2026.</span></ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001604" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zcWR3kj6vu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 <span id="xdx_820_zlb7WdAgQu14">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lease
population</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases various office facilities under non-cancelable operating leases that expire at various dates through 2031. The
Company does not have any finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2026, <span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20260301__20260331_zzqP9gcxdedc" title="Operation lease description"><ix:nonNumeric contextRef="From2026-03-012026-03-31" id="Fact001606" name="us-gaap:LesseeOperatingLeaseDescription">the Company entered into a second amendment to lease of one of its facilities (the &#8220;Lease Amendment&#8221;). The Lease
Amendment extended the lease for an additional three years through May 31, 2029 with fixed monthly base rent amounts through the extended
term</ix:nonNumeric></span>. The Company accounted for the Lease Amendment on the effective date, resulting in the remeasurement of the operating lease liability
with a corresponding adjustment to the right-of-use asset in the amount of $<span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_pn5n6_c20260301__20260331_zKALk18yntGe" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2026-03-012026-03-31" id="Fact001608" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2025, <span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20250401__20250430_zvnCLbyvoJU4" title="Operation lease description"><ix:nonNumeric contextRef="From2025-04-012025-04-30" id="Fact001610" name="us-gaap:LesseeOperatingLeaseDescription">the Company entered into an agreement to sublease the Beyond Cancer office space in Atlanta, Georgia beginning June 1, 2025
and continuing through September 30, 2026 coinciding with the termination of the existing lease.</ix:nonNumeric></span> The sublease has been classified as
an operating lease by the Company. Sublease rental income offsets the monthly rental expense from the Company&#8217;s lease of the office,
and is recorded as reduction of selling, general, and administrative expenses in the Company&#8217;s consolidated statements of operation
and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no new leases entered into during the years ended March 31, 2026 and March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lease
position</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the lease-related assets and liabilities recorded on the Company&#8217;s consolidated balance sheets as of
March 31, 2026 and March 31, 2025 (in thousands):</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001612" name="XAIR:ScheduleOfOperatingLeaseLiabilityTableTextBlock"><p id="xdx_895_ecustom--ScheduleOfOperatingLeaseLiabilityTableTextBlock_zzGG9uvKCL88" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zWw6wivgAbN8" style="display: none">SCHEDULE
OF OPERATING LEASE LIABILITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20260331_ztxAbLxHn2Sk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20250331_zUIRFzHnw3P6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zGiI7WhnLF96" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Right-of-use assets</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2026-03-31" id="Fact001614" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,193</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-03-31" id="Fact001615" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,706</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzD8e_zijA2SGcibBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability short-term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2026-03-31" id="Fact001617" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">321</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-03-31" id="Fact001618" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzD8e_zZY66ViD8VS6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Operating lease liability long-term</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2026-03-31" id="Fact001620" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,023</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-03-31" id="Fact001621" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,486</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzD8e_zwYBqLLf2B5h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2026-03-31" id="Fact001623" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,344</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-03-31" id="Fact001624" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,882</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average remaining lease term &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260331_znOjxmBlimJ4" title="Weighted Average Remaining Lease Term"><ix:nonNumeric contextRef="AsOf2026-03-31" format="ixt-sec:duryear" id="Fact001626" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.5</ix:nonNumeric> </span>years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250331_zzCirPO695al" title="Weighted Average Remaining Lease Term"><ix:nonNumeric contextRef="AsOf2025-03-31" format="ixt-sec:duryear" id="Fact001628" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">5.0</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260331_zWu3VTFvafml" title="Weighted-average discount rate - operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2026-03-31" id="Fact001630" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.9</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20250331_zaZgJwELdgHh" title="Weighted-average discount rate - operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2025-03-31" id="Fact001632" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.3</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_z2t3MkU6Ptg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lease
costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001634" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zF2ZNa3nJYH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the lease-related costs for the years ended March 31, 2026 and March 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zpu05L1SLtJ7">SCHEDULE
OF LEASE RELATED COSTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250401__20260331_zENbH7iuWro5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240401__20250331_zBYPaefONGOj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseCost_pn3n3_maLCzzCQ_z0My6r6OOnOd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2025-04-01to2026-03-31" id="Fact001636" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">505</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-04-012025-03-31" id="Fact001637" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">539</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzzCQ_z2H9Zw5Chtsc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short-term lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2025-04-01to2026-03-31" id="Fact001639" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">88</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2024-04-012025-03-31" id="Fact001640" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">261</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--SubleaseIncome_iN_pn3n3_di_msLCzzCQ_zxSykFRXTka2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Sublease income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2025-04-01to2026-03-31" id="Fact001642" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1643">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LeaseCost_iT_pn3n3_mtLCzzCQ_zXlAIoIONgAi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2025-04-01to2026-03-31" id="Fact001645" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">544</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-04-012025-03-31" id="Fact001646" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zWf1ZEDrGz98" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
lease information</i></span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001648" name="XAIR:OtherLeaseTableTextBlock"><p id="xdx_890_ecustom--OtherLeaseTableTextBlock_zKiHMb2MucUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zb9C4Lawqlg" style="display: none">SCHEDULE OF LEASE OTHER INFORMATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250401__20260331_zWe37xsnyjM2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeasePayments_pn3n3_zOlj2msqDkfl" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Operating cash flows for operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2025-04-01to2026-03-31" id="Fact001650" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">532</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zzcHPX81UPI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash
operating lease right-of-use assets&#160;obtained in exchange for operating lease liabilities were $<span id="xdx_90B_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn5n6_c20250401__20260331_zKuv5wkJEpOg"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2025-04-01to2026-03-31" id="Fact001651" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
and $<span id="xdx_901_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20240401__20250331_zYEConylG9sf" title="Operating lease liability in exchange"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2024-04-012025-03-31" id="Fact001653" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
during the years ended March 31, 2026 and March 31, 2025, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001655" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zYXW08BCXxjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zfZ5k3klDSH3">SCHEDULE
OF MATURITY OF LEASE LIABILITIES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Maturity of Lease Liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20260331_zhBNqVEJf3R2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payments remaining for the year ended March 31:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzQlL_z6NZJokfnDB4" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">2027</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2026-03-31" id="Fact001657" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">419</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzQlL_zRBqnociW0W5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2026-03-31" id="Fact001659" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">301</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzQlL_zEHihp9ptXke" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2026-03-31" id="Fact001661" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">309</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzQlL_zxRICOmjHPt5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2026-03-31" id="Fact001663" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">268</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzQlL_zYy81r2jjSLd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2031</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2026-03-31" id="Fact001665" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">266</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzQlL_zNPYuOxJJLYb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2026-03-31" id="Fact001667" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzQlL_zEIJB56tliha" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2026-03-31" id="Fact001669" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,623</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zJZIK5zKLAK6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: amount of lease payments representing interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2026-03-31" id="Fact001671" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">279</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z6oBkRfqQNGg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of future lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2026-03-31" id="Fact001673" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,344</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zA20lp6ReG84" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001675" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zIltlnQJNM19" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 <span id="xdx_820_zKKZ4fiPRS2">BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 260, <i>Earnings Per Share,</i> warrants that are accounted for as liabilities which are potentially dilutive have
not been included in diluted earnings per share as they would have been anti-dilutive during the years ended March 31, 2026 and March
31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001677" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znacKb9NFTD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following potentially dilutive securities were not included in the calculation of diluted net loss per share attributable to common stockholders
of Beyond Air, Inc. because their effect would have been anti-dilutive for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z0HFVm5qSmd3" style="display: none">SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250401__20260331_zyCJZViThJc3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240401__20250331_zvW3CQlTZx3h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zYcoqRAL4887" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Common stock warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-04-012026-03-31_us-gaap_WarrantMember42283484" id="Fact001679" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,979,034</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-04-012025-03-31_us-gaap_WarrantMember42283484" id="Fact001680" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,254,967</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zsqFJjyPz7d7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-04-012026-03-31_us-gaap_StockOptionMember" id="Fact001682" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">756,749</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember" id="Fact001683" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">739,214</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zHMyFKgsmVJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Restricted shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockMember42283484" id="Fact001685" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,485</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember42283484" id="Fact001686" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,265</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zShpzar5v0Ak" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-04-01to2026-03-31" id="Fact001688" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,745,268</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-04-012025-03-31" id="Fact001689" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,012,446</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_znCfEUbDVO44" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Anti-dilutive securities</span></td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-04-01to2026-03-31" id="Fact001691" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,745,268</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-04-012025-03-31" id="Fact001692" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,012,446</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_zI6lxCq6umm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s pre-funded warrants of <span id="xdx_90B_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_c20250401__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantsMember_zTydC4CF8WE4" title="Warrants included in calculation of diluted net loss per share"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="From2025-04-012026-03-31_custom_PreFundedWarrantsMember" id="Fact001694" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,362,619</ix:nonFraction></span> and <span id="xdx_90A_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantsMember_zkgDqDhZVBQj" title="Warrants included in calculation of diluted net loss per share"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="From2024-04-012025-03-31_custom_PreFundedWarrantsMember" id="Fact001696" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">606,367</ix:nonFraction></span> as of March 31, 2026 and March 31, 2025, respectively, were included in
the calculation of diluted net loss per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001698" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_804_eus-gaap--LongTermDebtTextBlock_zPjnGYjQDMTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 <span id="xdx_82A_zvqtcOxFaPn6">LOANS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001700" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zzHzFpRkT6p1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of long-term debt as of March 31, 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zojEY2G15B6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z3ToXf20G5Gk" style="display: none">SCHEDULE
OF LONG-TERM DEBT</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20261231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zL5Ig4WSDLR9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Loan</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Agreement</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20261231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zMhw6lWWPJd6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Promissory</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Note</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20261231_zX7s1Eq1UJHe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_maDICAzlrH_zCCbDbJ9awai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Principal balance outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2026-12-31_custom_LoanAgreementMember" id="Fact001702" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2026-12-31_custom_PromissoryNoteMember" id="Fact001703" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,799</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2026-12-31" id="Fact001704" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,299</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PaidInKindInterestAmount_iI_pn3n3_maDICAzlrH_ztTaDTxYSjp2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Paid in kind interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:PaidInKindInterestAmount" contextRef="AsOf2026-12-31_custom_LoanAgreementMember" id="Fact001706" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,459</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1707">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:PaidInKindInterestAmount" contextRef="AsOf2026-12-31" id="Fact001708" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,459</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msDICAzlrH_zLKaDOiByFV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2026-12-31_custom_LoanAgreementMember" id="Fact001710" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,343</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2026-12-31_custom_PromissoryNoteMember" id="Fact001711" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,576</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2026-12-31" id="Fact001712" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,919</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--AmortizationOfDebtDiscount_iI_pn3n3_maDICAzlrH_zfUWhpFBibKb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Amortization of debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="XAIR:AmortizationOfDebtDiscount" contextRef="AsOf2026-12-31_custom_LoanAgreementMember" id="Fact001714" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">427</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="XAIR:AmortizationOfDebtDiscount" contextRef="AsOf2026-12-31_custom_PromissoryNoteMember" id="Fact001715" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">373</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="XAIR:AmortizationOfDebtDiscount" contextRef="AsOf2026-12-31" id="Fact001716" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzlrH_zG0CTfZdDvje" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2026-12-31_custom_LoanAgreementMember" id="Fact001718" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,043</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2026-12-31_custom_PromissoryNoteMember" id="Fact001719" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,596</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2026-12-31" id="Fact001720" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,639</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of long-term debt as of March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20260331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zGAkSp7buzkh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Loan</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Agreement</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_maDICAzlrH_zc6Xv80Oarij" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Principal balance outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2026-03-31_custom_LoanAgreementMember" id="Fact001722" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PaidInKindInterestAmount_iI_pn3n3_maDICAzlrH_zTk7sSSosZaf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Paid in kind interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:PaidInKindInterestAmount" contextRef="AsOf2026-03-31_custom_LoanAgreementMember" id="Fact001724" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">696</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msDICAzlrH_zAnx0rBu8kUj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2026-03-31_custom_LoanAgreementMember" id="Fact001726" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,249</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--AmortizationOfDebtDiscount_iI_pn3n3_maDICAzlrH_zSSEH88fYNYj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Amortization of debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="XAIR:AmortizationOfDebtDiscount" contextRef="AsOf2026-03-31_custom_LoanAgreementMember" id="Fact001728" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzlrH_zunJpsAhuoKe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2026-03-31_custom_LoanAgreementMember" id="Fact001730" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,197</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zfumGkXDjAvf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loan
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2024, the Company entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) for a secured loan with certain
lenders, including its former Chief Executive Officer Steven Lisi and director Robert Carey, for an aggregate principal balance of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zSeJPuwhb726" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember" id="Fact001732" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">11.5</ix:nonFraction></span>
million. The Loan Agreement was approved by each of the Company&#8217;s independent and disinterested directors, following the receipt
of a recommendation from an independent investment bank. The Loan Agreement provides for the following terms: (i) principal amount of
$<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zRQL7pDpS4Dk" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember" id="Fact001734" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,500,000</ix:nonFraction></span>; (ii) ten-year term; (iii) interest of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zv4Ssb4RvABg" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember" id="Fact001736" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% per annum of which <span id="xdx_900_ecustom--DebtInstrumentInterestRatePayableInCashPercentage_iI_pid_dp_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zzCfJ9qBsOXj" title="Percentage of interest payable in cash"><ix:nonFraction name="XAIR:DebtInstrumentInterestRatePayableInCashPercentage" contextRef="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember" id="Fact001738" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>% shall be payable in cash and <span id="xdx_90A_ecustom--DebtInstrumentInterestRatePayableInKindPercentage_iI_pid_dp_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zHW6qMqYPyX1" title="Percentage of interest payable in kind"><ix:nonFraction name="XAIR:DebtInstrumentInterestRatePayableInKindPercentage" contextRef="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember" id="Fact001740" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% payable in kind through
June 30, 2026 and thereafter all in cash; (iv) a royalty interest of <span id="xdx_907_ecustom--RoyaltyInterestPercentage_iI_pid_dp_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z9cYMlNaL328" title="Royalty interest percentage"><ix:nonFraction name="XAIR:RoyaltyInterestPercentage" contextRef="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember" id="Fact001742" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% of the Company&#8217;s net sales on a quarterly basis from July
2026 until the facility is repaid in full; (v) the Company&#8217;s obligations will be secured by substantially all of the Company&#8217;s
assets and (vi) the Company issued the lenders warrants to purchase shares of the Company&#8217;s common stock at an exercise price,
adjusted for the 2025 Reverse Stock Split, of $<span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zB33Q5uLvPx2" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember" id="Fact001744" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.59</ix:nonFraction></span> per share. On November 3, 2025, the parties entered into a waiver agreement pursuant
to which the Loan Agreement lenders consented to the Company&#8217;s issuance of the Streeterville Note in exchange for reducing the
exercise price from $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251102__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z8g3hh55rqac" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-11-02_custom_LoanAndSecurityAgreementMember" id="Fact001746" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.59</ix:nonFraction></span> per share to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251103__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zAXn0zNfRGfl" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-11-03_custom_LoanAndSecurityAgreementMember" id="Fact001748" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.95</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2025, the Company received $<span id="xdx_90F_eus-gaap--ProceedsFromSaleOfLoansReceivable_pn5n6_c20250602__20250602__srt--TitleOfIndividualAxis__srt--DirectorMember_znqGLQQn1lSg" title="Advanced financing from related party"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfLoansReceivable" contextRef="From2025-06-022025-06-02_srt_DirectorMember" id="Fact001750" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million of advanced financing from a related party, director Robert Carey who is also an existing
lender under its Loan Agreement (&#8220;Additional Loans&#8221;). On November 3, 2025, the Company amended and restated the original
Loan Agreement (as amended, the &#8220;Amended Loan Agreement&#8221;) to provide for and finalize the terms of the $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20251103__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zT8xvJ2u5Tel" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-11-03_custom_AmendedLoanAgreementMember" id="Fact001752" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million Additional
Loans and the issuance of new <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dtY_c20251103__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zdJ0ifcXUBie" title="Warrants term" style="display: none"><ix:nonNumeric contextRef="AsOf2025-11-03_custom_AmendedLoanAgreementMember" format="ixt-sec:duryear" id="Fact001754" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span>five-year warrants to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251103__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zX9VFPNobrT6" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-11-03_custom_AmendedLoanAgreementMember" id="Fact001756" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">512,821</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;Supplemental
Warrants&#8221;) with an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251103__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zqjqxcdpwhOl" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-11-03_custom_AmendedLoanAgreementMember" id="Fact001758" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.95</ix:nonFraction></span> per share and subject to the same terms and conditions applicable to the existing warrants
issued under the original Loan and Security Agreement. The amendment was accounted for as a modification under ASC 470, <i>Debt</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the repayments under the Amended Loan Agreement are based on a fixed percentage of future net sales, the timing and amounts of future
principal payments may vary with the Company&#8217;s performance. The outstanding debt balance has been classified in the consolidated
balance sheets based on the Company&#8217;s current estimate of the repayment timing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Promissory
Note</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2025, the Company entered into and closed on a note purchase agreement (the &#8220;Note Purchase Agreement&#8221;) with Streeterville
Capital LLC (&#8220;Streeterville&#8221;), which provided for the issuance of a secured promissory note in the principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zCBNIXvczykb" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-11-04_custom_NotePurchaseAgreementMember" id="Fact001760" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.0</ix:nonFraction></span>
million (the &#8220;Note&#8221;). The principal amount of the Note is due <span id="xdx_906_eus-gaap--DebtInstrumentTerm_pid_dtM_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zSiqX6fqwHSb" title="Debt instrument term"><ix:nonNumeric contextRef="From2025-11-042025-11-04_custom_NotePurchaseAgreementMember" format="ixt-sec:durmonth" id="Fact001762" name="us-gaap:DebtInstrumentTerm">24</ix:nonNumeric></span> months following the date of issuance. <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateTerms_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zMrBQLqdvquk" title="Interest rate description"><ix:nonNumeric contextRef="From2025-11-042025-11-04_custom_NotePurchaseAgreementMember" id="Fact001764" name="us-gaap:DebtInstrumentInterestRateTerms">Interest will accrue
at the rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z5kx00jXTu8k" title="Debt instrument, interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2025-11-042025-11-04_custom_NotePurchaseAgreementMember" id="Fact001766" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% per annum, with no interest accruing for the first 12 months following issuance; provided however, that Streeterville
is guaranteed 12 months of interest, or $1.8 million, even if the Note is redeemed or prepaid prior to the maturity date.</ix:nonNumeric></span> Of the total
$<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zZSx1ylf8VO7" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-11-04_custom_NotePurchaseAgreementMember" id="Fact001768" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.0</ix:nonFraction></span> million Note, $<span id="xdx_909_ecustom--DebtInstrumentOfRestrictedAccount_pn5n6_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zI4KD9inYF8j" title="Principal in restricted account"><ix:nonFraction name="XAIR:DebtInstrumentOfRestrictedAccount" contextRef="From2025-11-042025-11-04_custom_NotePurchaseAgreementMember" id="Fact001770" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction></span> million was placed in a restricted account and will be accessible by the Company as the first $<span id="xdx_902_eus-gaap--DebtInstrumentRepaidPrincipal_pn5n6_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z9uOGdR4QJkg" title="Debt instrument, principal repayable"><ix:nonFraction name="us-gaap:DebtInstrumentRepaidPrincipal" contextRef="From2025-11-042025-11-04_custom_NotePurchaseAgreementMember" id="Fact001772" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction></span> million is
repaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Note contains an embedded put feature that meet the definition of an embedded derivative in accordance with ASC 815 (Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
January 2026, Streeterville elected to purchase <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pn5n6_c20260101__20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zcFwmtSSawUe" title="Shares issued of common stock"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2026-01-012026-01-31_custom_StreetervilleCapitalLLCMember" id="Fact001774" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">1.6</ix:nonFraction></span>
million shares of common stock at an average price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zxyUVRsywd98" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2026-01-31_custom_StreetervilleCapitalLLCMember" id="Fact001776" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span>
per share based on the average closing stock price during the five trading days immediately preceding delivery of the offset notice,
which offset principal of approximately $<span id="xdx_908_eus-gaap--DebtConversionOriginalDebtAmount1_pn5n6_c20260101__20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zM6t6AWrO1yf" title="Debt amount"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2026-01-012026-01-31_custom_StreetervilleCapitalLLCMember" id="Fact001778" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction> </span>million
outstanding under the Note. The average fair value of the <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zF3tFo0PyJJf" title="Shares available for resale"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2026-01-012026-01-31_custom_PurchaseAgreementMember" id="Fact001780" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">1.6</ix:nonFraction> </span>million shares of common stock issued during January 2026 was $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zzHkEVtbanTi" title="Price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2026-01-31_custom_PurchaseAgreementMember" id="Fact001782" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction></span>
per share (Note 4). The difference in the principal offset and the fair value of stock issued of $<span id="xdx_902_eus-gaap--CreditRiskDerivativeLiabilitiesAtFairValue_iI_pn5n6_c20260331_zg1IjJM7KZFl" title="Fair value of the derivative liability"><ix:nonFraction name="us-gaap:CreditRiskDerivativeLiabilitiesAtFairValue" contextRef="AsOf2026-03-31" id="Fact001784" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.2</ix:nonFraction></span> million was recorded to the
fair value of the embedded derivative liability and subsequent settlement of such feature (Note 2). The conversion of debt to equity
through the embedded put feature is treated as a partial extinguishment of the Note, and therefore proportionate amounts of
unamortized debt discount and financing costs were written-off during the year ended March 31, 2026, resulting in a loss of $<span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20250401__20260331__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zHv1yINTMnJk" title="Loss on extinguishment of debt"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-04-012026-03-31_custom_StreetervilleCapitalLLCMember" id="Fact001786" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million recorded within Loss on extinguishment of debt in the consolidated statement of operations and comprehensive loss. In
connection with this reduction to the principal balance outstanding, approximately $<span id="xdx_90E_ecustom--UnrestrictedCash_pn5n6_c20250401__20260331__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zhC1OZx6xyN9" title="Unrestricted cash"><ix:nonFraction name="XAIR:UnrestrictedCash" contextRef="From2025-04-012026-03-31_custom_StreetervilleCapitalLLCMember" id="Fact001788" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span>
million was released from restricted cash during the year ended March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the contractual terms of the Note, the Company was charged a one-time monitoring fee (as defined within the Note) of $<span id="xdx_90C_eus-gaap--ProfessionalFees_pn5n6_c20260204__20260204__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zkKSyLMEbBo8" title="Monitoring fees"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2026-02-042026-02-04_custom_StreetervilleCapitalLLCMember" id="Fact001790" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span> million
that is recognized as part of the Note&#8217;s principal outstanding balance on February 4, 2026. The monitoring fee will be credited
back to the Company, on a pro-rata basis, if any principal payment is made in cash and certain market conditions are met. The Company
determined the monitoring fee is accounted for as an additional debt discount equivalent, with the offsetting increase to the long-term
debt principal balance and will be amortized into interest expense over the remaining term of the Note under the effective interest method.
If cash principal payments occur in the future, a pro-rata portion of the monitoring fee will be waived, which will reduce the obligation
and a gain on extinguishment (or reduction of interest expense) will be recognized at such time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001792" name="us-gaap:ShortTermDebtTextBlock"><p id="xdx_808_eus-gaap--ShortTermDebtTextBlock_zHH8DUE0t7B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 <span><span id="xdx_822_zVsF2eJzsJce">LOAN PAYABLE</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001794" name="us-gaap:ScheduleOfShortTermDebtTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfShortTermDebtTextBlock_zWmY6WlW2Bhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026 and March 31, 2025 in connection with the Company&#8217;s insurance policy, a loan was used to finance part of the
premium. The details concerning the loan are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zZnUqiWNQjDe" style="display: none">SCHEDULE
OF LOAN PAYABLE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Amount outstanding (thousands)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--LoansPayable_iI_pn3n3_c20260331_ztKcuScFwnHj" title="Amount outstanding" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2026-03-31" id="Fact001796" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">401</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--LoansPayable_iI_pn3n3_c20250331_zRCA5yIsJiHc" title="Amount outstanding" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2025-03-31" id="Fact001798" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">579</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Monthly payments (thousands)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20250401__20260331_z1kwqspy89c" title="Monthly payments" style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2025-04-01to2026-03-31" id="Fact001800" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20240401__20250331_zW8jO4dHw282" title="Monthly payments" style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2024-04-012025-03-31" id="Fact001802" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Number of monthly payments remaining</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfPayments_pp0p0_uInteger_c20250401__20260331_zHgrPBwgodW1" title="Amount outstanding" style="text-align: right"><ix:nonFraction name="XAIR:NumberOfPayments" contextRef="From2025-04-01to2026-03-31" id="Fact001804" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Integer">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--NumberOfPayments_pp0p0_uInteger_c20240401__20250331_zjA4lwbY4aC7" title="Amount outstanding" style="text-align: right"><ix:nonFraction name="XAIR:NumberOfPayments" contextRef="From2024-04-012025-03-31" id="Fact001806" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Integer">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260331_zqdl6NpFItlj" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2026-03-31" id="Fact001808" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.60</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250331_zkMSnfzxTKt2" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2025-03-31" id="Fact001810" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.25</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Due date</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--LoanPayableDueDateDescription_c20250401__20260331_zGarnnkgKp2i" title="Due date"><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" id="Fact001812" name="XAIR:LoanPayableDueDateDescription">October 2026</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--LoanPayableDueDateDescription_c20240401__20250331_zXXQMTKBYW6j" title="Due date"><ix:nonNumeric contextRef="From2024-04-012025-03-31" id="Fact001814" name="XAIR:LoanPayableDueDateDescription">August 2025</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_z8TM3awNRtB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001816" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zeqA2gPyTPbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 <span id="xdx_82A_zcexPyvWrTHi">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026, the Company has approximately $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zBe4VGp0mmo7" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-03-31_us-gaap_DomesticCountryMember" id="Fact001818" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">185.0</ix:nonFraction></span> million, $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--IsraelTaxAuthorityMember_zrNJtb4XaJh2" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-03-31_us-gaap_IsraelTaxAuthorityMember" id="Fact001820" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">30.9</ix:nonFraction></span> million, $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--RevenueCommissionersIrelandMember_zWxZwPTLyqMc" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-03-31_us-gaap_RevenueCommissionersIrelandMember" id="Fact001822" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.2</ix:nonFraction></span> million and $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__custom--CypriotTaxMember_zTcCBz1t9Gxk" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-03-31_custom_CypriotTaxMember" id="Fact001824" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span> million of net operating losses
(&#8220;NOL&#8221;) carryforwards for U.S. federal, Israeli, Irish and Cypriot tax purposes, respectively. The U.S. federal NOL carryforwards
of approximately $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331_zRZUv0hWphqk" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-03-31" id="Fact001826" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million, which were generated prior to March 2018 expire starting in 2035 through 2037. The NOL of approximately
$<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--AwardDateAxis__custom--NoExpirationMember_zHImlo3wUwcc" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-03-31_custom_NoExpirationMember" id="Fact001828" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">183.6</ix:nonFraction></span> million can be carried forward indefinitely but limited to offset <span id="xdx_908_ecustom--OffsetTaxableIncomeRate_pid_dp_uPure_c20240401__20250331__us-gaap--AwardDateAxis__custom--NoExpirationMember_zjdKM5XtW356" title="Taxable income"><ix:nonFraction name="XAIR:OffsetTaxableIncomeRate" contextRef="From2024-04-012025-03-31_custom_NoExpirationMember" id="Fact001830" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% of taxable income. The entire NOL for Israel, Ireland and
Australia can be carried forward indefinitely. The Company also has state NOL carryforwards in the amount of approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zefIREUv0yhf" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-03-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001832" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">89.6</ix:nonFraction></span> million
<span id="xdx_90D_ecustom--OperatingLossCarryforwardsExpirationYears_c20240401__20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zdkNjzcW7mOg"><ix:nonNumeric contextRef="From2024-04-012025-03-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001833" name="XAIR:OperatingLossCarryforwardsExpirationYears">expiring during the years from 2036 to 2043</ix:nonNumeric></span>. The Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) has modified the Internal Revenue
Code (&#8220;IRC&#8221;) 174 expenses related to research and development for tax years beginning after December 31, 2021. Under the
TCJA, the Company must now capitalize the expenditures related to research and development activities and amortize over five years for
U.S. activities and 15 years for non-U.S. activities using a mid-year convention. Therefore, the capitalization of research and development
costs in accordance with IRC 174 resulted in a gross deferred tax asset of $<span id="xdx_903_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_pn5n6_c20250331_zBIwA0oQSA7" title="Deferred tax liabilities, deferred expense, capitalized research and development costs"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" contextRef="AsOf2025-03-31" id="Fact001835" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">27.2</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has R&amp;D tax credits of $<span id="xdx_905_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20250331__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zw4fPTsn8Arg" title="Tax credit carryforward, amount"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2025-03-31_us-gaap_ResearchMember" id="Fact001837" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction></span>
million <span id="xdx_90F_eus-gaap--TaxCreditCarryforwardDescription_c20240401__20250331__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zWIDdc2o6qo8" title="Tax credit carryforward, description"><ix:nonNumeric contextRef="From2024-04-012025-03-31_us-gaap_ResearchMember" id="Fact001839" name="us-gaap:TaxCreditCarryforwardDescription">expiring
during the years from 2038 to 2042</ix:nonNumeric></span>. The Company has not, as yet, conducted a study of R&amp;D credit carryforwards. This
study may result in an adjustment to the Company&#8217;s R&amp;D credit carryforwards. The Company assessed its uncertain tax
positions and determined that a <span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage_pid_dp_uPure_c20240401__20250331_zDkwvLdOdANe" title="Federal tax percentage"><ix:nonFraction name="XAIR:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage" contextRef="From2024-04-012025-03-31" id="Fact001841" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%
reserve on federal research and development credit is appropriate and in line with industry standards. As of March 31, 2026, the
total amount of unrecognized tax benefits was $<span id="xdx_900_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20260331_zpQZf5PLtSC2" title="Unrecognized tax benefits"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2026-03-31" id="Fact001843" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span>
million, exclusive of interest and penalties. A full valuation allowance has been provided against the Company&#8217;s R&amp;D
credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there
would be no impact to the consolidated balance sheets and the consolidated statements of operations and comprehensive loss if an
adjustment were required. No estimated interest or penalties related to unrecognized tax benefits have been recorded as of March 31,
2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 382 of the Internal Revenue Code, changes in the Company&#8217;s ownership may limit the amount of its NOL carryforwards that
could be utilized annually to offset future taxable income, if any. <span id="xdx_90F_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20240401__20250331_zTT7mIhN47Se" title="Income tax limitation description"><ix:nonNumeric contextRef="From2024-04-012025-03-31" id="Fact001845" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse">This limitation would generally apply in the event of a cumulative
change in ownership of the Company of more than 50% within a three-year period.</ix:nonNumeric></span> The Company has performed a study as of March 31, 2021
and determined that on or around February 15, 2017 and February 15, 2020 ownership changes for purposes of Section 382 have occurred.
The annual limitations caused by these prior ownership changes will no longer impact the utilizations of NOL&#8217;s after March 31,
2022. The Company has not updated the study since March 31, 2021 and therefore has not determined if any other NOL limitations exist.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001847" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zNLfHyoe1cL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of net loss before the provision for income taxes are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zIJHDNGoDaSe" style="display: none">SCHEDULE
OF PROFIT (LOSS) BEFORE TAXES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20250401__20260331_zxB4ZQUTwzIj" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p>
                                                                                                                                                                                                                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2026</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240401__20250331_zVAMGKvLM326" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p>
                                                                                                                                                                                                                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maCITEBzGXx_zjogKc9EmxT4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2025-04-01to2026-03-31" id="Fact001849" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">27,066</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2024-04-012025-03-31" id="Fact001850" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">42,186</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maCITEBzGXx_z2q1Y7cILYui" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2025-04-01to2026-03-31" id="Fact001852" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,268</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2024-04-012025-03-31" id="Fact001853" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,293</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCITEBzGXx_zQEImN4wkX2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-04-01to2026-03-31" id="Fact001855" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">34,334</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-04-012025-03-31" id="Fact001856" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">48,479</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zH8hVD7BoDRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001858" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zZjOPK0bXZmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zNonrJrOSKbj" style="display: none">SCHEDULE
OF DEFERRED TAX ASSET/LIABILITY</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20260331_zllFfvIlsgTh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250331_zH5Q6jejfeY9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz1sA_zL1Z4GsGKgkb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2026-03-31" id="Fact001860" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55,607</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2025-03-31" id="Fact001861" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48,702</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz1sA_znnSsjr9QRUj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2026-03-31" id="Fact001863" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,506</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2025-03-31" id="Fact001864" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,197</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ResearchAndDevelopmentTaxCreditCapitalization_iI_pn3n3_maDTAGz1sA_zI2WPQtet8x3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development tax credit capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:ResearchAndDevelopmentTaxCreditCapitalization" contextRef="AsOf2026-03-31" id="Fact001866" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,572</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:ResearchAndDevelopmentTaxCreditCapitalization" contextRef="AsOf2025-03-31" id="Fact001867" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,066</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz1sA_z2scwFmtHa5" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2026-03-31" id="Fact001869" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">111</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2025-03-31" id="Fact001870" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation_iI_pn3n3_maDTAGz1sA_zPSD444Stk56" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="XAIR:DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" contextRef="AsOf2026-03-31" id="Fact001872" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,803</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="XAIR:DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" contextRef="AsOf2025-03-31" id="Fact001873" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,337</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz1sA_z2ADsIKu6imb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2026-03-31" id="Fact001875" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,714</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2025-03-31" id="Fact001876" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,556</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsReservesAndAccruels_iI_pn3n3_maDTAGz1sA_zuLImAvDWkO2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Reserves and accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:DeferredTaxAssetsReservesAndAccruels" contextRef="AsOf2026-03-31" id="Fact001878" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:DeferredTaxAssetsReservesAndAccruels" contextRef="AsOf2025-03-31" id="Fact001879" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAsset_iI_pn3n3_maDTAGz1sA_z49r2VUBTyRl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="XAIR:DeferredTaxAssetsRightofuseAsset" contextRef="AsOf2026-03-31" id="Fact001881" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">282</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="XAIR:DeferredTaxAssetsRightofuseAsset" contextRef="AsOf2025-03-31" id="Fact001882" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">298</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxAssetsLeaseLiability_iI_pn3n3_maDTAGz1sA_ziQc5X8Kf8j6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="XAIR:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2026-03-31" id="Fact001884" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">314</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="XAIR:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2025-03-31" id="Fact001885" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">333</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_maDTALNzJp8_mtDTAGz1sA_zbZ8VTOv1jya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net deferred tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2026-03-31" id="Fact001887" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69,550</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2025-03-31" id="Fact001888" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64,240</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzJp8_z4uqPMwirJv" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2026-03-31" id="Fact001890" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69,550</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-03-31" id="Fact001891" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64,240</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzJp8_zfAyL6nNPT1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net deferred tax asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1893">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1894">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zZrPOmSULSM" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<ix:exclude><!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>BEYOND AIR, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 11 INCOME TAXES (continued)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001896" name="XAIR:ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock_zoRiUd8BE8gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the principal reasons for the difference between the effective tax rate and the U.S. federal enacted
statutory income tax rate of <span id="xdx_905_ecustom--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_pid_dp_uPure_c20250401__20260331_zmMXL9IdAiP" title="Federal income tax rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIElOQ09NRSBUQVhFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__"><ix:nonFraction name="XAIR:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" contextRef="From2025-04-01to2026-03-31" id="Fact001898" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>%
for the year ended March 31, 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_z0aG5edMi1p3" style="display: none">SCHEDULE
OF DIFFERENCE EFFECTIVE INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250401__20260331_zF8Hw48YEEAb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzUaV_zb2NKG1uDnL3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt">U.S. federal statutory tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2025-04-01to2026-03-31" id="Fact001900" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,210</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250401__20260331_zTy0B0cm9yB9" title="U.S. federal statutory tax rate" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2025-04-01to2026-03-31" id="Fact001902" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40C_ecustom--IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes_pn3n3_maITEBzUaV_zjl1AesKcEP4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Current state and local income taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1904">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes_pid_dp_uPure_c20250401__20260331_zjNpHs698BZk" title="Current state and local income taxes, net of federal benefit" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1906">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Foreign Tax Effects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 10pt">Ireland</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_hsrt--StatementGeographicalAxis__country--IE_zt0Laqf10zx7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-04-012026-03-31_country_IE" id="Fact001908" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">440</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IE_zn3rzANx1XP8" title="Change in valuation allowance" style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-04-012026-03-31_country_IE" id="Fact001910" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.28</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_hsrt--StatementGeographicalAxis__country--IE_z9jkx9jgZP7" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 20pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2025-04-012026-03-31_country_IE" id="Fact001912" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">235</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IE_zXIOqsaaI4sj" title="Other" style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2025-04-012026-03-31_country_IE" id="Fact001914" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.69</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 10pt">Israel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_hsrt--StatementGeographicalAxis__country--IL_maITEBzUaV_zq2weZSM9Nk5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-04-012026-03-31_country_IL" id="Fact001916" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">371</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IL_zFCvdfFx5DQ9" title="Change in valuation allowance" style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-04-012026-03-31_country_IL" id="Fact001918" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.08</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_hsrt--StatementGeographicalAxis__country--IL_maITEBzUaV_zTsqgrFydRuc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 20pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2025-04-012026-03-31_country_IL" id="Fact001920" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">101</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IL_zaRkF3HMSD61" title="Other" style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2025-04-012026-03-31_country_IL" id="Fact001922" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.29</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maITEBzUaV_zpeZ9pXeYC6e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Other foreign jurisdictions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="From2025-04-01to2026-03-31" id="Fact001924" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">88</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_pid_dpi_uPure_c20250401__20260331_zZWVvzKz8NUh" title="Other foreign jurisdictions" style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2025-04-01to2026-03-31" id="Fact001926" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.26</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IncomeTaxReconciliationDifferenceTaxCreditsResearch_iN_pn3n3_di_msITEBzUaV_zHeUTb8N4yp" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="XAIR:IncomeTaxReconciliationDifferenceTaxCreditsResearch" contextRef="From2025-04-01to2026-03-31" id="Fact001928" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">308</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch_iN_pid_dpi_uPure_c20250401__20260331_z4zOLsxtNNq1" title="Other foreign jurisdictions" style="text-align: right"><ix:nonFraction name="XAIR:EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch" contextRef="From2025-04-01to2026-03-31" id="Fact001930" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.90</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationTaxCreditsOther_pn3n3_msITEBzUaV_zWZSRF3WbmM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Changes in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" contextRef="From2025-04-01to2026-03-31" id="Fact001932" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,759</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20250401__20260331_zaEKltgnCeYk" title="Changes in valuation allowance" style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2025-04-01to2026-03-31" id="Fact001934" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">10.95</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Effect of cross-border tax laws</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IncomeTaxReconciliationTaxSubpartFIncome_pn3n3_msITEBzUaV_zKYQySrZlrMe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Subpart F Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:IncomeTaxReconciliationTaxSubpartFIncome" contextRef="From2025-04-01to2026-03-31" id="Fact001936" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--EffectiveIncomeTaxRateReconciliationSubpartFIncome_iN_pid_dpi_uPure_c20250401__20260331_z1fCXvjJqqN9" title="Subpart F Income" style="text-align: right">(<ix:nonFraction name="XAIR:EffectiveIncomeTaxRateReconciliationSubpartFIncome" contextRef="From2025-04-01to2026-03-31" id="Fact001938" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.02</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Nontaxable or nondeductible items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount_pn3n3_maITEBzUaV_z2jxG5Lijki8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Share-based payment awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2025-04-01to2026-03-31" id="Fact001940" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,878</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_uPure_c20250401__20260331_zcOHtY9CV2k9" title="Share-based payment awards" style="text-align: right">(<ix:nonFraction name="XAIR:EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent" contextRef="From2025-04-01to2026-03-31" id="Fact001942" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.47</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationDifferenceOtherAdjustments_pn3n3_maITEBzUaV_z8fwdzqDUi9a" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 10pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="XAIR:IncomeTaxReconciliationDifferenceOtherAdjustments" contextRef="From2025-04-01to2026-03-31" id="Fact001944" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">293</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331_zjcogF9fNaWf" title="Other" style="text-align: right">(<ix:nonFraction name="XAIR:EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments" contextRef="From2025-04-01to2026-03-31" id="Fact001946" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.85</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--IncomeTaxReconciliationDifferenceOtherReconcilingItems_pn3n3_maITEBzUaV_zpssULizKaLk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0pt">Other adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="XAIR:IncomeTaxReconciliationDifferenceOtherReconcilingItems" contextRef="From2025-04-01to2026-03-31" id="Fact001948" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">346</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent_iN_pid_dpi_uPure_c20250401__20260331_zYUlD6ISgii6" title="Other adjustments" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="XAIR:EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent" contextRef="From2025-04-01to2026-03-31" id="Fact001950" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.01</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzUaV_zTL6ep64Xhqj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt">Provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1952">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_c20250401__20260331_zgCeK0OrfWD2" title="Other adjustments" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2025-04-01to2026-03-31" id="Fact001954" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zT3o1gYW48q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001956" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zZO1ZpwSPAT2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of income tax expense calculated at the federal enacted statutory income tax rate of 21% is as follows
for the year ended March 31 2025:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_z6TWAqXJARvi" style="display: none">SCHEDULE
OF STATUTORY US FEDERAL EFFECTIVE RATE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240401__20250331_zclPp73dxxf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March
31, 2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_iN_pid_dpi_uPure_maancd_z5YdzhxqsDTe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 77%; text-align: left">Federal income tax at statutory rate</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right"><ix:nonFraction name="XAIR:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" contextRef="From2024-04-012025-03-31" id="Fact001958" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">21.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maancd_zfuIl3OK4d96" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax, net of federal benefit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-04-012025-03-31" id="Fact001960" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.73</ix:nonFraction></td><td style="text-align: left"/></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_pid_dp_uPure_maancd_zkTjVegcMzhd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Permanent items</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="From2024-04-012025-03-31" id="Fact001962" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.58</ix:nonFraction></td><td style="text-align: left"/></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_pid_dpi_uPure_maancd_zZQ5gY3Ikow8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Non-deductible compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2024-04-012025-03-31" id="Fact001964" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.45</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_maancd_z2xfmwl9ERYh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in valuation allowance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-04-012025-03-31" id="Fact001966" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.46</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msancd_zlYSTgFCY1t2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development tax credits</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="From2024-04-012025-03-31" id="Fact001968" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.12</ix:nonFraction></td><td style="text-align: left"/></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_iN_pid_dpi_uPure_maancd_z2RpVoJJqTE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Foreign tax rate differential</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2024-04-012025-03-31" id="Fact001970" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.65</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_maancd_z9DaXmyYvOUf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Other</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2024-04-012025-03-31" id="Fact001972" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.87</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss_pid_dp_uPure_maancd_zm7BOtXE93a3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change to foreign NOL&#8217;s</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1974">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtancd_zDncT245Hms5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Effective income tax expense rate</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-04-012025-03-31" id="Fact001976" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zcrMT1YsFO1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Taxes paid across all jurisdictions were immaterial
for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 4, 2025, the One Big Beautiful Bill Act (the
&#8220;OBBBA&#8221;) was signed into law. The OBBBA includes significant tax provisions, including the permanent extension of certain provisions
of the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;), modifications to the international tax framework, and the restoration of favorable
tax treatment for certain business expenditures. The legislation contains multiple effective dates, with certain provisions effective
for tax years beginning in 2025 and others phased in through 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated the provisions of the OBBBA and their applicability to its operations. Based on this assessment,
the OBBBA did not have a material impact on the Company&#8217;s consolidated financial statements for the fiscal year ended March 31, 2026.
The Company will continue to monitor regulatory guidance and assess the potential impact of provisions with future effective dates on
its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<ix:exclude><!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact001978" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_807_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zULR8jPfhpQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 <span id="xdx_82C_zrwgeOAWCRvh">COMMITMENTS AND CONTINGENCIES</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>License
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2015, Beyond Air Ltd., a wholly-owned subsidiary of the Company (&#8220;BA Ltd.&#8221;) entered into an Option Agreement (the
&#8220;Option Agreement&#8221;) with Pulmonox Technologies Corporation (&#8220;Pulmonox&#8221;) whereby BA Ltd. acquired the option (the
&#8220;Option&#8221;) to purchase certain intellectual property assets and rights. On January 13, 2017, BA Ltd. exercised the Option
and paid $<span id="xdx_90B_ecustom--PaymentsForDevelopmentAndMilestonePayment_pn5n6_c20170112__20170113__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember_zudNIE6PbzKd" title="Payments for development and milestone payment"><ix:nonFraction name="XAIR:PaymentsForDevelopmentAndMilestonePayment" contextRef="From2017-01-122017-01-13_custom_OptionAgreementMember" id="Fact001980" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million to Pulmonox. BA Ltd. became obligated to make certain one-time development and sales milestone payments to Pulmonox,
commencing with the date on which BA Ltd. receives regulatory approval for the commercial sale of the first product candidate qualifying
under the Option Agreement. These milestone payments are capped at a total of $<span id="xdx_905_ecustom--MilestonePayments_pn6n6_c20170112__20170113__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember_zv6nmTh67RZf" title="Milestone payments"><ix:nonFraction name="XAIR:MilestonePayments" contextRef="From2017-01-122017-01-13_custom_OptionAgreementMember" id="Fact001982" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">87</ix:nonFraction></span> million across three separate and distinct indications
that fall under the agreement, with the majority of them, approximately $<span id="xdx_902_ecustom--SalesRelatedMilestonesPayments_pn6n6_c20170112__20170113__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember_zM49v1QyKc4g" title="Sales related milestones payments"><ix:nonFraction name="XAIR:SalesRelatedMilestonesPayments" contextRef="From2017-01-122017-01-13_custom_OptionAgreementMember" id="Fact001984" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">83</ix:nonFraction></span> million, being sales-related based on cumulative sales milestones
for each of the three products. BA Ltd. is not currently developing any qualifying products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2018, the Company entered into an agreement (the &#8220;NitricGen Agreement&#8221;) with NitricGen, Inc. (&#8220;NitricGen&#8221;)
to acquire a global, exclusive, transferable license and associated assets including intellectual property, know-how, trade secrets and
confidential information from NitricGen related to the LungFit<sup>&#174;</sup>. The Company acquired the licensing right to use the technology
and agreed to pay NitricGen a total of $<span id="xdx_902_ecustom--MilestonePayments_pn5n6_c20180130__20180131__dei--LegalEntityAxis__custom--NitricGenIncMember__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_zMa61sn70Ild" title="Future payments based on certain milestones"><ix:nonFraction name="XAIR:MilestonePayments" contextRef="From2018-01-302018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember" id="Fact001986" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million in future payments based upon achieving certain milestones, as defined in the NitricGen
Agreement, and single-digit royalties on sales of the LungFit<sup>&#174;</sup>. The Company paid NitricGen $<span id="xdx_905_ecustom--PaymentForMilestoneMethodRevenueRecognized_pn5n6_c20180130__20180131__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember__dei--LegalEntityAxis__custom--NitricGenIncMember_zXlV4mRAxEx4" title="Payment for Milestone method revenue recognized"><ix:nonFraction name="XAIR:PaymentForMilestoneMethodRevenueRecognized" contextRef="From2018-01-302018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember" id="Fact001988" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction> </span>million upon the execution
of the NitricGen Agreement, $<span id="xdx_90B_ecustom--PaymentForMilestoneMethodRevenueRecognized_pn5n6_c20180130__20180131__dei--LegalEntityAxis__custom--NitricGenIncMember__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember__us-gaap--AwardDateAxis__custom--NextMilestonesMember_zVUSrIjhD0ua" title="Payment for Milestone method revenue recognized"><ix:nonFraction name="XAIR:PaymentForMilestoneMethodRevenueRecognized" contextRef="From2018-01-302018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember_custom_NextMilestonesMember" id="Fact001990" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million upon achieving the next milestone and $<span id="xdx_901_ecustom--PaymentForMilestoneMethodRevenueRecognized_pn5n6_c20180130__20180131__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember__us-gaap--AwardDateAxis__custom--AfterSixMonthsMember__dei--LegalEntityAxis__custom--NitricGenIncMember_zFtV2xaT1ikd" title="Future payments based on certain milestones"><ix:nonFraction name="XAIR:PaymentForMilestoneMethodRevenueRecognized" contextRef="From2018-01-302018-01-31_custom_NitricGenAgreementMember_custom_AfterSixMonthsMember_custom_NitricGenIncMember" id="Fact001992" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million in January 2023, six months after approval
of the LungFit<sup>&#174; </sup>by the FDA, and issued <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pp0p0_c20180131__dei--LegalEntityAxis__custom--NitricGenIncMember__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z0tpDPjUmhn" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember" id="Fact001994" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">100,000</ix:nonFraction></span> warrants to purchase the Company&#8217;s common stock valued at $<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20180131__dei--LegalEntityAxis__custom--NitricGenIncMember__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_zLbX0YfyYeM6" title="Warrants to purchase common stock, value"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember" id="Fact001996" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million
upon executing the NitricGen Agreement. As of March 31, 2026, the remaining future milestone payments total $<span id="xdx_901_ecustom--MilestonePayments_pn5n6_c20240401__20250331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_zAGAgqkmf932" title="Remaining future milestone payments"><ix:nonFraction name="XAIR:MilestonePayments" contextRef="From2024-04-012025-03-31_custom_NitricGenAgreementMember" id="Fact001998" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Supply
Agreement and Purchase Order</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the Company entered into a supply agreement with an initial expiration date of December 31, 2024. The Company has opened several non-cancellable purchase orders
and the outstanding amount remaining under the purchase order as of March 31, 2026 was approximately $<span id="xdx_904_eus-gaap--PurchaseObligation_iI_pn5n6_c20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierMember_zCzR94Su0Cc3" title="Outstanding amount under purchase"><ix:nonFraction name="us-gaap:PurchaseObligation" contextRef="AsOf2026-03-31_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember_custom_SupplierMember" id="Fact002000" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million with this supplier.
This supplier holds $<span id="xdx_90A_eus-gaap--DepositAssets_iI_pn5n6_c20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierMember_zUG20OVBzI0h" title="Cash deposits"><ix:nonFraction name="us-gaap:DepositAssets" contextRef="AsOf2026-03-31_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember_custom_SupplierMember" id="Fact002002" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.4</ix:nonFraction></span> million of restricted cash to partially secure materials on the Company&#8217;s behalf recorded in other current
assets and prepaid expenses. This agreement will expire on March 31, 2027. At that time all excess inventory will be returned to the Company and
any excess restricted cash will be released.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a new supply agreement with Plexus Corp.  for the manufacturing of its second generation device
and service of all devices beginning on April 1, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contingencies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company is involved in various legal matters arising in the normal course of business. The Company does not expect
the outcome of such proceedings, either individually or in the aggregate, to have a material effect on its financial position, cash
flows or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002004" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zWaHnwDxRDnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 <span id="xdx_826_z7PRuJXLaYK9">SEGMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2021, the Company announced that Beyond Air and Beyond Cancer, Ltd agreed to terms to which the Company, through its subsidiaries
would be licensing certain intellectual property and other assets related to, or necessary for the development, commercialization, manufacture
and distribution of certain cancer treatment products and/or technologies to a subsidiary of the Company (the &#8220;2021 Transaction&#8221;).
In connection and concurrently with the closing of the 2021 Transaction, Beyond Cancer issued and sold common shares, par value $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20211104__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__srt--TitleOfIndividualAxis__custom--CertainInvestorsMember_zBnRPrEDnaYj" title="Sle of stock per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2021-11-04_custom_BeyondCancerLtdMember_custom_CertainInvestorsMember" id="Fact002006" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span>
to certain investors pursuant to a subscription agreement (the &#8220;2021 Offering&#8221;). The 2021 Offering consisted of an aggregate
of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn6n6_c20211102__20211104__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zBdh0Uh3aUyh" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-11-022021-11-04_custom_BeyondCancerLtdMember" id="Fact002008" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="Shares">3</ix:nonFraction> </span>million common shares of Beyond Cancer at a purchase price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20211104__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zcVOfNO3lY0k" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-11-04_custom_BeyondCancerLtdMember42285687" id="Fact002010" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per share. On November 18, 2021, the Company announced that
the maximum amount of shares offered had been purchased for a total of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20211116__20211118__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_ztvWMCK1QWy7" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-11-162021-11-18_custom_BeyondCancerLtdMember" id="Fact002012" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">30</ix:nonFraction></span> million (including $<span id="xdx_907_ecustom--AmountOfTerminatedLoan_pn5n6_c20211116__20211118__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_z9klbz9tOtC4" title="Amount of terminated loan"><ix:nonFraction name="XAIR:AmountOfTerminatedLoan" contextRef="From2021-11-162021-11-18_custom_BeyondCancerLtdMember" id="Fact002014" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.8</ix:nonFraction></span> million from the terminated Loan Facility
and $<span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_pn5n6_c20211116__20211118__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zmEWJGUo1HJc" title="Proceeds from related party debt"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2021-11-162021-11-18_custom_BeyondCancerLtdMember" id="Fact002016" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million from related parties) for <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20211104__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeyondCancerLtdMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zmqjedVuAQx2" title="Equity, ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-11-04_custom_BeyondCancerLtdMember_custom_InvestorsMember" id="Fact002018" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% of the equity in Beyond Cancer. The Company retained <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20211104__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeyondCancerLtdMember_zXDMFuY96PV9" title="Equity, ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-11-04_custom_BeyondCancerLtdMember" id="Fact002020" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% ownership of Beyond Cancer, which
will have exclusive right to the intellectual property portfolio utilizing UNO for the treatment of solid tumors. Beyond Cancer will
pay Beyond Air a single digit royalty on all future revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
of the Board of Directors of Beyond Air who are also members of the Board of Directors of Beyond Cancer, and their families, are considered
related parties to the 2021 Offering. Related parties invested $<span id="xdx_90E_eus-gaap--OtherReceivables_iI_pn5n6_c20211104__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zB6EiR63vtj7" title="Related party invested"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2021-11-04_custom_BeyondCancerLtdMember_us-gaap_RelatedPartyMember" id="Fact002022" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million in the 2021 Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2025, the Company announced that Beyond Air and NeuroNos Limited agreed to terms to which the Company, through its subsidiaries
would be licensing certain intellectual property and other assets related to, or necessary for the development, commercialization, manufacture
and distribution of certain neurological treatment products and/or technologies to a subsidiary of the Company (the &#8220;2025 Transaction&#8221;).
In connection and concurrently with the closing of the 2025 Transaction, NeuroNos issued and sold common shares, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250324__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z9rSsC0H6jSe" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-03-24_custom_SubscriptionAgreementMember" id="Fact002024" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> to
certain investors pursuant to a subscription agreement (the &#8220;2025 Offering&#8221;). The 2025 Offering consisted of an aggregate
of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250324__20250324__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zmry5MeFyxok" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-03-242025-03-24_custom_SubscriptionAgreementMember" id="Fact002026" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">666,667</ix:nonFraction></span> common shares of NeuroNos at a purchase price of $<span id="xdx_905_eus-gaap--SharePrice_iI_c20250324__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zeKQrGgnY1fe" title="Per share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-03-24_custom_SubscriptionAgreementMember" id="Fact002028" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span> per share. On March 31, 2025, the offered shares had been purchased
for a total of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240401__20250331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z1kYqCtaezhf" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-04-012025-03-31_custom_SubscriptionAgreementMember" id="Fact002030" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million for <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20250331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NeuroNosLtdMember_zBqkQYrjI9Qa" title="Equity ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2025-03-31_custom_SubscriptionAgreementMember_custom_NeuroNosLtdMember" id="Fact002032" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.76</ix:nonFraction></span>% of the equity in NeuroNos. During the year ended March 31, 2026, an additional <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zikgfPzEKlf8" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-04-012026-03-31_custom_SubscriptionAgreementMember" id="Fact002034" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">233,333</ix:nonFraction></span> common
shares of NeuroNos were issued and sold to certain investors at a purchase price of $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zLOJgFx6U5B9" title="Per share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2026-03-31_custom_SubscriptionAgreementMember" id="Fact002036" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span> per share. As of March 31, 2026, <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NeuroNosLtdMember_zULQlSUxhmi6" title="Equity ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2026-03-31_custom_SubscriptionAgreementMember_custom_NeuroNosLtdMember" id="Fact002038" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.25</ix:nonFraction></span>% of
the equity in NeuroNos was held by non-controlling interests. Beyond Air retained <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20260321__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NeuroNosLtdMember_zA79IQmRIqPj" title="Equity ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2026-03-21_custom_SubscriptionAgreementMember_custom_NeuroNosLtdMember" id="Fact002040" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">84.75</ix:nonFraction></span>% ownership of NeuroNos and will have exclusive
right to the intellectual property portfolio for the regulation of nitric oxide as it relates to neurological therapies. NeuroNos will
pay Beyond Air a single digit royalty on all future revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 SEGMENTS (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_VariableInterestEntitiesMember" escape="true" id="Fact002042" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_hus-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zi35rnQZDH44" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes segment financial information by business segment for the year ended and at March 31, 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zZcAXe4hCHL7" style="display: none">SCHEDULE
OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zgNStXblWzyk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Air</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20250401__20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zrohAMv6szfk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Cancer</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250401__20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zW4cVuxAUe2e" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NeuroNos</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250401__20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zfzya6K0k5If" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Capital expenditures</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zaRmoaTQJekb" title="Capital expenditures" style="width: 11%; text-align: right"><ix:nonFraction name="XAIR:CapitalExpendituresCost" contextRef="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002044" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,024</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zJ4ykdiSy4E6" title="Capital expenditures" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2046">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zqfUEiOI5Ytd" title="Capital expenditures" style="width: 11%; text-align: right"><ix:nonFraction name="XAIR:CapitalExpendituresCost" contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002048" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zPOCp9oyeNOk" title="Capital expenditures" style="width: 11%; text-align: right"><ix:nonFraction name="XAIR:CapitalExpendituresCost" contextRef="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,026</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zYC7W16bsKIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002052" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,679</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2053">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2054">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002055" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,679</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_iN_pn3n3_di_zsF7fuTED9V5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002057" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,427</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2058">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2059">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002060" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,427</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_iN_pn3n3_di_zv81KCo3nG5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002062" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,677</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002063" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,170</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002064" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,394</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002065" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,241</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_iN_pn3n3_di_zU1UMJJfVMkg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Selling, general, and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002067" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,418</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002068" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,207</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002069" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,430</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002070" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,055</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_pn3n3_z5DvcCbw0551" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002072" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,843</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002073" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,377</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002074" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,824</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002075" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,044</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestExpenseNonoperating_iN_pn3n3_di_zwm6AW51Md8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest and finance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002077" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,515</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2078">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2079">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002080" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,515</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_ztk81NjYlHV7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other non-operating income/(expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002082" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,668</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002083" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">323</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002084" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">216</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002085" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,775</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_zOPF7kgxtz2a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002087" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28,026</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002088" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,700</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002089" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,608</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002090" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">34,334</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating activities included in net loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_pn3n3_z9J9woXZHIW5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002092" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,228</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2094">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,251</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_zeJR6trJe1Z8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002097" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,813</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,373</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002099" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,282</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn3n3_zbbBYU29PRel" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash used in operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002102" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,775</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002103" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,314</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002104" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,055</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002105" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,144</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_pn3n3_z3RK8MDJS42i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash used in (provided by) investing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002107" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,660</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002108" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002109" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002110" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,674</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_pn3n3_zh70pOLjOBnd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash provided by financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,390</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2113">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002114" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002115" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,090</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_pn3n3_zYgHbHhOoasj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impact of exchange rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002117" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">228</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002118" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">164</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002119" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">198</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002120" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">194</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_pn3n3_zw5LfUvnRZbe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change for the year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,183</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002123" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">162</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002124" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,555</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002125" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,466</ix:nonFraction></td><td style="text-align: left"/></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes segment financial information by business segment for the year ended and at March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zDUICAtIvEQ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Air</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240401__20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zCttKZP1DMJf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Cancer</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240401__20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zrtcmnTEofrl" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NeuroNos</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240401__20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zxYQug0DaJD1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Capital expenditures</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z5bLU8nNP0Qk" title="Capital expenditures" style="width: 11%; text-align: right"><ix:nonFraction name="XAIR:CapitalExpendituresCost" contextRef="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002127" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,859</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zyTaBK3RHHF4" title="Capital expenditures" style="width: 11%; text-align: right"><ix:nonFraction name="XAIR:CapitalExpendituresCost" contextRef="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002129" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z9aaCtJIZigl" title="Capital expenditures" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2131">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zZWsdloUZI1i" title="Capital expenditures" style="width: 11%; text-align: right"><ix:nonFraction name="XAIR:CapitalExpendituresCost" contextRef="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002133" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,883</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zj9qM7N2ZII6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,705</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2136">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2137">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002138" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,705</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_iN_pn3n3_di_zYttFNkJGdmi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,368</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2141">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2142">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002143" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,368</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_iN_pn3n3_di_zkl7QSK36Gvh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002145" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,780</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002146" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,062</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002147" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002148" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,857</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_iN_pn3n3_di_z4VhBJnqO6Q8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Selling, general, and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002150" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,565</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002151" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,344</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002152" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">108</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002153" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,017</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_pn3n3_zRjKyHfJzj02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002155" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35,008</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002156" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,406</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002157" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">123</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002158" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">44,537</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestExpenseNonoperating_iN_pn3n3_di_zRE84GqWecie" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest and finance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002160" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,019</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2161">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2162">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002163" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,019</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zsOS9HV5kXQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other non-operating income/(expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002165" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,132</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002166" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">209</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2167">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002168" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">923</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_z2z2DFjUjva7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002170" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">39,159</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002171" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,197</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002172" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">123</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002173" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">48,479</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating activities included in net loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_pn3n3_zqq3H6aDymtb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002175" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,143</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002176" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2177">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002178" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,204</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_zQVdfhJgEsya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002180" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,920</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002181" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,154</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002182" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002183" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,146</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn3n3_zYjo82QwFx87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash used in operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002185" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,599</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002186" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,619</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2187">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002188" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,218</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_pn3n3_zAZ1ayaZF4c5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash provided by investing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002190" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,844</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002191" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,061</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2192">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002193" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,905</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_pn3n3_z5OGb8uYgR6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash provided by financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002195" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,646</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2196">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002197" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002198" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,646</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_pn3n3_zaOK9HH5cgU8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impact of exchange rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002200" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">39</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002201" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2202">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002203" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">45</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_pn3n3_zNXBQkkl7Kd6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change for the year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002205" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,148</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002206" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,564</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002207" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002208" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,712</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes financial information by business segment at March 31, 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zkHW1x9eSm2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Air</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z0tiVauo7HOk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Cancer</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z2knifpaVRRk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NeuroNos</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zAla1t9MXcQ3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_zCfjlHyodPn7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Cash, cash equivalents and marketable securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002210" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,140</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002211" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,043</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">458</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002213" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,641</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAssets_iI_pn3n3_z3ayk8KTRVHl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">All other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002215" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,901</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002216" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">219</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002217" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002218" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,744</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_iTI_pn3n3_zlGW8DL0F2wf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002220" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,041</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002221" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">824</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002222" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">520</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002223" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35,385</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_iNI_pn3n3_di_zE1rBqqEVTYa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002225" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,224</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002226" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">378</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002227" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">573</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002228" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,175</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNet_iI_pn3n3_zDt5YU21tEvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNet" contextRef="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002230" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,817</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNet" contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002231" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">446</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AssetsNet" contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002232" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">53</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNet" contextRef="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002233" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,210</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--MinorityInterest_iI_pn3n3_zVnZK7fL9DEh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2235">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002236" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002237" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002238" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes financial information by business segment at March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zSA9AsWRpzMg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Air</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zCxOqn4syFP9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Cancer</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zOxgLgxbG0k8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NeuroNos</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z8gsJTjpZK0e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_zLnYOb3zGpcf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Cash, cash equivalents and marketable securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002240" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,750</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002241" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,167</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002243" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,917</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAssets_iI_pn3n3_zW5DAdFO3a42" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">All other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002245" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,116</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002246" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,029</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2247">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002248" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,145</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_iTI_pn3n3_zcP9z74j4n6a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002250" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,866</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002251" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,196</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002252" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002253" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,062</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_iNI_pn3n3_di_zyKjyhnoMRT1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002255" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,082</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002256" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">589</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002257" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002258" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,721</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNet_iI_pn3n3_zHfTWeM53Vcj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNet" contextRef="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002260" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,784</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNet" contextRef="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002261" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,607</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNet" contextRef="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002262" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,950</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNet" contextRef="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002263" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,341</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--MinorityInterest_iI_pn3n3_zhU46w6oGcCc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002266" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">529</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002267" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">229</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember" id="Fact002268" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">758</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zJAkw7x9kMB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002270" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z1TtN1x98yCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14 <span id="xdx_829_zMQBLvLkaLq4">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the exception of the related party transactions referred to in Note 4 and Note 9, there were no additional related party transactions
in the fiscal years ended March 31, 2026 and March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002272" name="XAIR:OperatingLeasesTextBlock"><p id="xdx_809_ecustom--OperatingLeasesTextBlock_zQQFLTbxl6If" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 <span id="xdx_828_zm9El36vu4Si">LEASE REVENUES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases the LungFit&#174; PH device to customers and receives a fixed rental fee over the term of the arrangement. Contract terms
(generally one<span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20260331__srt--RangeAxis__srt--MinimumMember_z4ODoxPTi5y6" title="Contract term" style="display: none"><ix:nonNumeric contextRef="AsOf2026-03-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact002274" name="us-gaap:LesseeOperatingLeaseTermOfContract">1</ix:nonNumeric></span>-to-<span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dc_c20260331__srt--RangeAxis__srt--MaximumMember_zt1uSwsGzKij" title="Contract term"><ix:nonNumeric contextRef="AsOf2026-03-31_srt_MaximumMember" format="ixt-sec:durwordsen" id="Fact002276" name="us-gaap:LesseeOperatingLeaseTermOfContract">three years</ix:nonNumeric></span>) vary by customer and may include options to terminate the contract or options to extend the contract.
The LungFit&#174; PH lease agreements are accounted for as operating leases. The non-lease components, including consumables and device-related
services are combined with the predominant lease component under the practical expedient. The fixed rental fee is recognized over the
period of the lease agreement on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized $<span id="xdx_906_ecustom--OperatingLeaseIncome_pn5n6_c20250401__20260331__srt--ConsolidatedEntitiesAxis__custom--LungFitPHMember_z8ATVr61rtXl" title="Lease revenue"><ix:nonFraction name="XAIR:OperatingLeaseIncome" contextRef="From2025-04-012026-03-31_custom_LungFitPHMember" id="Fact002278" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.2</ix:nonFraction></span> million and $<span id="xdx_907_ecustom--OperatingLeaseIncome_pn5n6_c20240401__20250331__srt--ConsolidatedEntitiesAxis__custom--LungFitPHMember_zVkudFLhyJ36" title="Lease revenue"><ix:nonFraction name="XAIR:OperatingLeaseIncome" contextRef="From2024-04-012025-03-31_custom_LungFitPHMember" id="Fact002280" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.7</ix:nonFraction> </span>million in LungFit&#174; PH lease revenues for the years ended March 31, 2026 and March 31, 2025,
respectively, reported as revenues in the consolidated statements of operations and comprehensive loss. The Company received approximately
$<span id="xdx_907_eus-gaap--Cash_iI_pn5n6_c20260331__srt--ConsolidatedEntitiesAxis__custom--LungFitPHMember_zvs4AmWWTw26" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2026-03-31_custom_LungFitPHMember" id="Fact002282" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.8</ix:nonFraction></span> million and $<span id="xdx_90C_eus-gaap--Cash_iI_pn5n6_c20250331__srt--ConsolidatedEntitiesAxis__custom--LungFitPHMember_zbpvfmxHQLSj" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-03-31_custom_LungFitPHMember" id="Fact002284" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.2</ix:nonFraction></span> million in cash associated with leases which the Company is the lessor for the years ended March 31, 2026 and March
31, 2025, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-04-012026-03-31_custom_LungFitRPHMember" escape="true" id="Fact002286" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_hdei--LegalEntityAxis__custom--LungFitRPHMember_z7Y2qSMmBDJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following schedule presents the minimum future lease payments under the LungFit&#174; PH lease arrangements that were in place as of March
31, 2026 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zsIXGXh71AE" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF MATURITY OF FUTURE LEASE PAYMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Future lease payments under the LungFit&#174; PH lease arrangements (in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20260331__dei--LegalEntityAxis__custom--LungFitRPHMember_zNvnnCb3rpc6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzQlL_zIa0UjmJMzD8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2027</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2026-03-31_custom_LungFitRPHMember" id="Fact002288" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,919</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzQlL_zegw9FRxUGJa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2026-03-31_custom_LungFitRPHMember" id="Fact002290" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,512</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzQlL_zo5adO8PMz6l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2026-03-31_custom_LungFitRPHMember" id="Fact002292" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,560</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzQlL_zKzjTDVvGvzl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2026-03-31_custom_LungFitRPHMember" id="Fact002294" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,991</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zT2Rs0h3kuy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LungFit&#174; PH devices are included in Property and Equipment (Note 3) and have the useful life of <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__dei--LegalEntityAxis__custom--LungFitPHMember_zuFKS1oPrS2f" title="Useful Life"><ix:nonNumeric contextRef="AsOf2026-03-31_custom_LungFitPHMember42286578" format="ixt-sec:durwordsen" id="Fact002296" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">five years</ix:nonNumeric></span>. Depreciation expense
related to leased LungFit&#174; PH devices was $<span id="xdx_901_eus-gaap--Depreciation_pn5n6_c20250401__20260331__dei--LegalEntityAxis__custom--LungFitPHMember_z2xJ4qSmHzSb" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-04-012026-03-31_custom_LungFitPHMember42286593" id="Fact002298" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million and $<span id="xdx_90D_eus-gaap--Depreciation_pn5n6_c20240401__20250331__dei--LegalEntityAxis__custom--LungFitPHMember_zA9JgDd2w5Zd" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-04-012025-03-31_custom_LungFitPHMember42286593" id="Fact002300" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction> </span>million for the years ended March 31, 2026 and March 31, 2025, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depreciation expense related to customer leased devices is included in the cost of revenues in the consolidated statements of operations
and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Capitalized
sales commissions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
commissions related to obtaining LungFit&#174; PH lease agreements are accounted for as initial direct costs and are capitalized and amortized
on a straight-line basis over the lease term. Total capitalized costs for the years ended March 31, 2026 and March 31, 2025 were immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-04-01to2026-03-31" escape="true" id="Fact002302" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_ziqoSPmcnM0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 16 <span id="xdx_82A_zgJYNhHoEbEg">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 24, 2026, the Company&#8217;s Board of Directors
approved a change in Company&#8217;s fiscal year from the twelve-month period ending on March 31 to the twelve-month period ending on
December 31 of each year. The Company will complete a transition period commencing on April 1, 2026, and ending on December 31, 2026,
after which the Company&#8217;s fiscal years shall consist of the twelve-month periods ending on December 31 of each calendar year.</p>



</ix:nonNumeric><p id="xdx_81F_zC8yFdNkDs2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 130; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxNjkFqwzAQRU/gOwxaB0cWjRfetSYJoa4pxpRuRTQxIrbGSEqaHKm37NhOaYVAI/33ZiTESuxpZ3v08PnSVNDiMPY6IjR4Qo/uiEyUh9cC+GywsyF67eJ8/RVLYgfZydON5veZvNqApgC5WWf5WuVcFE8Knt9EMuUluZM16KLVPWhn4N3T6C1G7e9Lh1bfyNFwnyd9oA+WXAFZKpf4G5TMFNR01V/kzwGqqhTJal6J2Hu6jExtbxHdZMK2x4HHhcX+2/NvjpcQaShqOjBs0LdeG+u6Xa87TqVUKpNZzmVN8EDgwcAEpf/6/QAFH2HQ -->
<!-- Field: Set; Name: xdx; ID: xdx_088_labels -->
<!-- eJyNjrsKwkAQRftA/kG21mzQLl2EFAERIf7A7INkcdiJs7NE/96ojaXdLc65HNU6FyRQBNycwHhMaqsmkbnRelmW6mEYK+JR7+v6oJnQ69lzIDcIsHyMP4Uuui9eFiqn3QgwN4OQvU2EznPq7jnIs48WswtxvBC/s1oRDiYLGPRXOlO0FGV9xRXpo3j2SdaAIyBE639WWbwALs1OBA== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>2
<FILENAME>ex19-1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
19.1</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex19-1_001.jpg" ALT="" style="width:800px">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex19-1_002.jpg" ALT="" style="width:800px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex19-1_003.jpg" ALT="" style="width:800px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex19-1_004.jpg" ALT="" style="width:800px">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex19-1_005.jpg" ALT="" style="width:800px">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex19-1_006.jpg" ALT="" style="width:800px">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex19-1_007.jpg" ALT="" style="width:800px">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex19-1_008.jpg" ALT="" style="width:800px">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex19-1_009.jpg" ALT="" style="width:800px">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ex21-1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiary
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction
    of Incorporation </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
    Air Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
    Air Ireland Limited </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ireland</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
    Air Australia Pty. Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
    Cancer Bermuda Limited</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bermuda</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
    Cancer U.S., Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroNos
    Limited</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ireland</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroNos
    Israel Limited</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XAIR
    Israel Ltd</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
    Air Cyprus Limited</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyprus</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroNos
    US Inc</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>CONSENT
OF Independent Registered Public Accounting Firm</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statements of Beyond Air, Inc. on Form S-3 (File Nos. 333-284653, 333-282834,
333-281667, 333-233283, 333-237958, 333-273942 and 333-262311) and Form S-8 (File Nos. 333-283811, 333-227697, 333-238239, 333-257562,
333-269861 and 333-276171) of our report dated June 26, 2026, which includes an explanatory paragraph as to the Company&rsquo;s ability
to continue as a going concern, relating to the consolidated financial statements of Beyond Air, Inc. as of and for
the years ended March 31, 2026 and March 31, 2025, which appears in this Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
WithumSmith+Brown, PC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">East
Brunswick, New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
26, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 63pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert Goodman, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of Beyond Air, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    26, 2026</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Robert Goodman</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Goodman</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Executive Officer</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Executive Officer)</I></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Daniel Moorhead, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of Beyond Air, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
    control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    26, 2026</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Daniel Moorhead</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
    Moorhead</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Financial Officer</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Financial Officer and Principal Accounting Officer)</I></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 63pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert Goodman, Chief Executive Officer of Beyond Air, Inc. (the &ldquo;Company&rdquo;), hereby certify, pursuant to 18 U.S.C. &sect;1350,
as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Annual Report on Form 10-K of the Company for the year ended March 31, 2026 (the &ldquo;Report&rdquo;) fully complies with the requirements
    of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    26, 2026</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Robert Goodman</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Goodman</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Executive Officer</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Executive Officer)</I></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex32-2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 63pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Daniel Moorhead, Chief Financial Officer of Beyond Air, Inc. (the &ldquo;Company&rdquo;), hereby certify, pursuant to 18 U.S.C. &sect;1350,
as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Annual Report on Form 10-K of the Company for the year ended March 31, 2026 (the &ldquo;Report&rdquo;) fully complies with the requirements
    of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    26, 2026</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Daniel Moorhead</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
    Moorhead</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Financial Officer</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Financial Officer and Principal Accounting Officer)</I></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>9
<FILENAME>ex97.htm
<DESCRIPTION>EX-97
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
97</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Beyond
Air, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incentive
Compensation Recovery Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Adopted
by the Board of Directors (the &ldquo;Board&rdquo;) of Beyond</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Air,
Inc. (the</B> &ldquo;<B>Company</B>&rdquo;) <B>on November 20, 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a
culture that emphasizes integrity and accountability is in the best interests of the Company and its stockholders and essential to the
Company&rsquo;s success. The Board is therefore adopting this Incentive Compensation Recovery Policy (this &ldquo;Policy&rdquo;) to provide
for the recovery of certain incentive compensation in the event of an Accounting Restatement. This Policy is intended to foster a culture
of compliance and accountability, to reward integrity, and to reinforce the Company&rsquo;s pay-for-performance compensation philosophy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Statement
of Policy</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the Company is required to prepare an Accounting Restatement, except as otherwise set forth in this Policy, the Company
shall recover, reasonably promptly, the Excess Incentive Compensation received by any Covered Executive during the Recoupment Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to all Incentive Compensation received during the Recoupment Period by a person (a) after beginning service as a Covered
Executive, (b) who served as a Covered Executive at any time during the performance period for that Incentive Compensation and (c) while
the Company has a class of securities listed on the Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) or another national securities exchange
or association. This Policy may therefore apply to a Covered Executive even after that person is no longer a Company employee or a Covered
Executive at the time of recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
Compensation is deemed &ldquo;received&rdquo; for purposes of this Policy in the fiscal period during which the financial reporting measure
specified in the Incentive Compensation award is attained, even if the payment or issuance of such Incentive Compensation occurs after
the end of that period. For example, if the performance target for an award is based on total stockholder return or revenue for the year
ended December 31, 2024, the award will be deemed to have been received in 2024 even if paid in 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exceptions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not required to recover Excess Incentive Compensation pursuant to this Policy to the extent the [Compensation Committee of
the Board] (the &ldquo;Committee&rdquo;) makes a determination that recovery would be impracticable for one of the following reasons
(and the applicable procedural requirements are met):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">after
    making a reasonable and documented attempt to recover the Excess Incentive Compensation, which documentation will be provided to
    Nasdaq to the extent required, the Committee determines that the direct expenses that would be paid to a third party to assist in
    enforcing this Policy would exceed the amount to be recovered;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 142; Options: NewSection -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">based
    on a legal opinion of counsel acceptable to the Nasdaq, the Committee determines that recovery would violate a home country law adopted
    prior to November 28, 2022; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Committee determines that recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly
    available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations
    thereunder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definitions</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Accounting
Restatement</I>&rdquo; means an accounting restatement due to the material noncompliance of the Company with any financial reporting
requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial
statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error
were corrected in the current period or left uncorrected in the current period. For the avoidance of doubt, a restatement resulting solely
from any one or more of the following is not an Accounting Restatement: retrospective application of a change in generally accepted accounting
principles; retrospective revision to reportable segment information due to a change in the structure of an issuer&rsquo;s internal organization;
retrospective reclassification due to a discontinued operation; retrospective application of a change in reporting entity, such as from
a reorganization of entities under common control; retrospective adjustment to provisional amounts in connection with a prior business
combination; and retrospective revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Covered
Executive</I>&rdquo; means the Company&rsquo;s Chief Executive Officer, President, Chief Financial Officer, principal accounting officer
(or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit,
division, or function, any other officer who performs a policy-making function for the Company, any other person who performs similar
policy-making functions for the Company, and any other employee who may from time to time be deemed subject to this Policy by the Committee.
For purposes of the foregoing, designation by the Board as an &ldquo;Officer&rdquo; for purposes of Rule 16a-1(f) under the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) shall constitute designation as a Covered Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Excess
Incentive Compensation</I>&rdquo; means the amount of Incentive Compensation received during the Recoupment Period by any Covered Executive
that exceeds the amount of Incentive Compensation that otherwise would have been received by such Covered Executive if the determination
of the Incentive Compensation to be received had been determined based on restated amounts in the Accounting Restatement and without
regard to any taxes paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Incentive
Compensation</I>&rdquo; means any compensation (including cash and equity compensation) that is granted, earned, or vested based wholly
or in part upon the attainment of a financial reporting measure. For purposes of this definition, a &ldquo;<I>financial reporting measure</I>&rdquo;
is (i) any measure that is determined and presented in accordance with the accounting principles used in preparing the Company&rsquo;s
financial statements and any measure derived wholly or in part from such measures, or (ii) the Company&rsquo;s stock price and/or total
shareholder return. A financial reporting measure need not be presented within the financial statements or included in a filing with
the U.S. Securities and Exchange Commission. Incentive Compensation subject to this Policy may be provided by the Company or subsidiaries
or affiliates of the Company (&ldquo;Company Affiliates&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 143 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Recoupment
Period</I>&rdquo; means the three completed fiscal years preceding the Trigger Date, and any transition period (that results from a change
in the Company&rsquo;s fiscal year) of less than nine months within or immediately following those three completed fiscal years, provided
that any transition period of nine months or more shall count as a full fiscal year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Trigger
Date</I>&rdquo; means the earlier to occur of: (a) the date the Board, the Audit Committee of the Board (or such other committee of the
Board as may be authorized to make such a conclusion), or the officer or officers of the Company authorized to take such action if action
by the Board is not required concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement;
and (b) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement; in the
case of both (a) and (b) regardless of if or when restated financial statements are filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Administration</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy is intended to comply with Nasdaq Listing Rule 5608, Section 10D of the Exchange Act, and Rule 10D-1(b)(1) as promulgated under
the Exchange Act, and shall be interpreted in a manner consistent with those requirements. The Committee has full authority to interpret
and administer this Policy. The Committee&rsquo;s determinations under this Policy shall be final and binding on all persons, need not
be uniform with respect to each individual covered by the Policy, and shall be given the maximum deference permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee has the authority to determine the appropriate means of recovering Excess Incentive Compensation based on the particular facts
and circumstances, which could include, but is not limited to, seeking direct reimbursement, forfeiture of awards, offsets against other
payments, and forfeiture of deferred compensation (subject to compliance with Section 409A of the Internal Revenue Code).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to any limitations under applicable law, the Committee may authorize any officer or employee of the Company to take actions necessary
or appropriate to carry out the purpose and intent of this Policy, provided that no such authorization shall relate to any recovery under
this Policy that involves such officer or employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Committee cannot determine the amount of excess Incentive Compensation received by a Covered Executive directly from the information
in the Accounting Restatement, such as in the case of Incentive Compensation tied to stock price or total stockholder return, then it
shall make its determination based on its reasonable estimate of the effect of the Accounting Restatement and shall maintain documentation
of such determination, including for purposes of providing such documentation to Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
where an action is required by Nasdaq Listing Rule 5608, Section 10D of the Exchange Act or Rule 10D-1(b)(1) promulgated under the Exchange
Act to be determined in a different matter, the Board may act to have the independent directors of the Board administer this Policy in
place of the Committee in any particular circumstance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 144 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Covered Executive shall sign an Incentive Compensation Recovery Policy Acknowledgment and Agreement in the form attached to this Policy
as <U>Exhibit A</U> or such other form as approved by the Committee in its sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Indemnification or Advancement of Legal Fees</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the terms of any indemnification agreement, insurance policy, contractual arrangement, the governing documents of the Company or other
document or arrangement, the Company shall not indemnify any Covered Executive against, or pay the premiums for any insurance policy
to cover, any amounts recovered under this Policy or any expenses that a Covered Executive incurs in opposing Company efforts to recoup
amounts pursuant to the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Non-Exclusive
Remedy; Successors</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recovery
of Incentive Compensation pursuant to this Policy shall not in any way limit or affect the rights of the Company to pursue disciplinary,
legal, or other action or pursue any other remedies available to it. This Policy shall be in addition to, and is not intended to limit,
any rights of the Company to recover Incentive Compensation from Covered Executives under any legal remedy available to the Company and
applicable laws and regulations, including but not limited to the Sarbanes-Oxley Act of 2002, as amended, or pursuant to the terms of
any other Company policy, employment agreement, equity award agreement, or similar agreement with a Covered Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be binding and enforceable against all Covered Executives and their successors, beneficiaries, heirs, executors, administrators,
or other legal representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendment</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy may be amended from time to time by the Committee of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Effective
Date</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy is adopted as of November 20, 2023 and shall apply to any Incentive Compensation received on or after October 2, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 145 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INCENTIVE
COMPENSATION RECOVERY POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACKNOWLEDGMENT
AND AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Acknowledgment and Agreement (this &ldquo;Agreement&rdquo;) is entered into as of the __ day of ______, 20[__], between Beyond Air, Inc.,
a Delaware corporation (the &ldquo;Company&rdquo;), and&#9;(the &ldquo;Executive&rdquo;), under the following circumstances:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Board of Directors of the Company (the &ldquo;Board&rdquo;) has adopted the [COMPANY] Incentive Compensation Recovery Policy (the
&ldquo;Policy&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Executive has been designated as a &ldquo;Covered Executive&rdquo; of the Company as defined in the Policy;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
in consideration of, and as a condition to the receipt of, future cash and equity-based awards, performance-based compensation, and other
forms of cash or equity compensation made under the Company&rsquo;s Fifth Amended and Restated 2013 Equity Incentive Plan or any other
incentive compensation plan or program of the Company, the Executive and the Company are entering into this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
defined terms used but not defined in this Agreement shall have the meanings set forth in the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, the Company and the Executive hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Executive hereby acknowledges receipt of the Policy, to which this Agreement is attached, and the terms of which are hereby incorporated
    into this Agreement by reference. The Executive has read and understands the Policy and has had the opportunity to ask questions
    to the Company regarding the Policy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Executive hereby acknowledges and agrees that the Policy shall apply to any Incentive Compensation granted to the Executive by the
    Board or the Compensation Committee of the Board (the &ldquo;Committee&rdquo;) as set forth in the Policy and that all such Incentive
    Compensation shall be subject to recovery under the Policy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    applicable award agreement or other document setting forth the terms and conditions of any Incentive Compensation granted to the
    Executive by the Board or the Committee shall be deemed to include the restrictions imposed by the Policy and incorporate the Policy
    by reference. In the event of any inconsistency between the provisions of the Policy and the applicable award agreement or other
    document setting forth the terms and conditions of any Incentive Compensation granted to the Executive, the terms of the Policy shall
    govern unless the terms of such other agreement or other document would result in a greater recovery by the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 146; Options: NewSection -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Executive hereby acknowledges that, notwithstanding any indemnification agreement or other arrangement between the Company and the
    Executive, the Company shall not indemnify the Executive against, or pay the premiums for any insurance policy to cover, losses incurred
    under the Policy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the event it is determined by the Company that any amounts granted, awarded, earned or paid to the Executive must be forfeited or
    reimbursed to the Company, the Executive will promptly take any action necessary to effectuate such forfeiture and/or reimbursement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Agreement and the Policy shall survive and continue in full force and in accordance with their terms notwithstanding any termination
    of the Executive&rsquo;s employment with the Company and its affiliates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Agreement may be executed in two or more counterparts, and by facsimile or electronic transmission (such as PDF), each of which will
    be deemed to be an original but all of which, taken together, shall constitute one and the same Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Agreement shall be governed by the laws of the State of [INSERT STATE], without reference to principles of conflict of laws.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    modifications or amendments of the terms of this Agreement shall be effective unless in writing and signed by the parties hereto
    or their respective duly authorized agents. The provisions of this Agreement shall inure to the benefit of, and be binding upon,
    the successors, administrators, heirs, legal representatives and assigns of the Executive, and the successors and assigns of the
    Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 147 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the parties hereto have executed this Agreement as of the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[COMPANY]</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[<FONT STYLE="text-transform: uppercase">Executive</FONT>]</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 225pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 148; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %? KP# 2(  A$! Q$!_\0
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M0]N_^3VK\&M/_86^-W@CQIHOC77/A_\ #Z]/P_U#]K'Q)X^^->E_$7Q#K_Q
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M"?\ $G_P@]>_^1Z /2:*\V_X699?]"?\2?\ P@]>_P#D>C_A9EE_T)_Q)_\
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M/7O_ )'HLOZ_K[^_4#T@9ZGKWQT]O\__ %J,<Y^F.!P!V'UYKS?_ (699?\
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MI;_A@/2,=2.I_P YY]/3./:C'Z8Y_')_/CN?\?-_^%F67_0G_$G_ ,(/7O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8V$8X('\\]/!]&\2?"7QQ91>,/VI/C?XU\*^./&/PF?]H70O#>E>/O&WPO\
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M5[<Z?J%E<:%8)-:WEI*T,T+C^V\$AD)5E)22,K(C,C FC_PVY\)?^@7XW_\
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MY9_X/E_\SA_KMPC_ -%%EG_@ZI_\S'W+17PU_P -_P#P7_Z!'C__ ,$.F?\
MR^H_X;_^"_\ T"/'_P#X(=,_^7U'^N/"O_0_RS_P?+_YG#_7;A'_ **++/\
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MS_Z_\%?]%/E'_A1/_P"93]!J*_/G_AY+\!O^@+\2O_":TS_YHJ/^'DOP&_Z
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MW/\ 9F_Z%[XN_P#A)Z)_\UE'_#W/]F;_ *%[XN_^$GHG_P UE<W_ !$SP_\
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M_'WB/XS^+]9_9'\2_$*V;3O#?C:XGU_X>W>J>&9+F+3-)\10?%"Z^$&J^--
M-T\M[9VUK=QW7BS3;:_GNKK30D-M>WEY);27,OF'@S1OC'XW^(OQ O/#-WXQ
MAA\)_M-WNE#Q[K'QW\47'AFQ\ ^$M8\,2^(O!K?!EVU'0M6&I^&4U?PW:"XM
M;*;^U-4B\0OJ]E<VR3G[T\3_  _\*^+/!?B3X?ZGI5O;^&/%6E:WI&J6.EQQ
M::1#X@%TVI7=H]M&JVNI2W5W/J27\2"X34V%^6:Y'F'?TG1M/T:W:WL((HS-
M*UQ>W AMXKG4K^1(DNM3U*2WAA%YJ=Z8DDO;V53-<2 ,Y("@$4U*<M.9\CA_
M)=4</&=XZ\L'5I59<D7:4,0Z<O=BTU:7+RWTYJC;Z\KJ57!><E3J0CS6TG14
MU:<E)?E_\)K?XV:]X%TGXGV6J>,M$TO3D^-.K>+?&VN_'+Q-XRL_&7AS3V^)
M&DZ+HNB?"Z^:\T3PKJ%EK4/AJ_TW5M/GT27PY9^'I+>W>]%W-I]QV>A?%GXV
M:AH'[&9\2>&M0\)Z7XLU#24UGQ='\4=-U^Z\<;OV<OB/XACM==TFQTRSO+E-
M3U/3K3Q'-)-=2K:ZCIEM-*LDPBE3]$+?1])LM/.DV>EZ=:Z48[B+^S+:QMH-
M/\N\DEDNXS911K;>7<R3S27*>5MF>65Y S2,2S^P]$,.EVQT?2C;Z&R-HL']
MGVAAT=X[&;3$;2XC#LT]DTZYN=/0VBPE;&XFM!B"62-E%-1C%V<8>Q4=7=^S
MC551R=TVY2G!QBFH1Y))QES753]Z<YJZ<W5EI]GGE3<$EJK149)MIR?,N5Q2
M:?Y:_"OXH?%!_!/[(GPQ^)'C_P 4:CJOQ7_X1_6?"_Q3@U"XT[6?B9X0UOX(
M>.M9\4>'?$>IZ<$@3QY\.=>ETV],^Z >)]#B\-^+K+SM8T_Q3'IGT+\-K'QW
M\:?!?[)OQ.U:S\!ZJFF>%]'\4>--:UA;ZS\<W&O#3[*"VO/"NHV>C:@EOIE]
M<1WNL:YI*W^C)K-RNEV=U>MHR:CI]_\ 6&J>#M U/0D\.+96^EV-I87-AHLF
MC6UE877ACS]+NM%CO/#$BVSQZ'J%GIU]<VMC=6<*&VAE>%%,+R1M;\,>&=%\
M&^'?#_A/P]9)8:%X8T;3M T:R0EEL],TFSAL;& .V6<Q6T$<;.Y+R'+L2S,3
M2OS\R24H58U(/HU&*A#F6ZG3IQM)QE%5:D_;-1G[6-69)O3[,HSC);6]I.I.
M:CTY93J)PBT_90@Z2<H.E[+=VC&,9QT/<CJ?3'.0.>.N:4#C!'3(Y';)_F/S
MI:*=E:RT^7R_(JPF.3QCIR#U[]/Y^M!'^?Q!]NF/_P!?2EHHLOPL,0=>1CDD
M=/\ #CK]>N?= N,YP1VXZ=>/U(^A/TIU%%OZMJ PKD_3.#WR23^G\Z<< ' Q
M]!^O'IU_"EI&Z'Z'^5%D*V[OT9QGQ!X\!^-ASD>#_$PY_P"P+?=.G'ITK\<X
MU;8F ,!$QP/[H]?U]Z_8[XA?\B+XV_[$_P 2_P#IEOJ_':/_ %<?^XO_ *"*
M_,/$#_>\L\\+B=O^PFD?E'B/_ON5:?\ ,)BN_P#T%4O,;AO0?DM&&]!^2U+1
M7Y]\W]Y^<7\E^/\ F18;T'Y+1AO0?DM2T4?-_>%_)?C_ )D6".HXSSC _/&.
M/KQ2%<Y!'!Y)QU&1G'ICJ",'I[5-2,< _2GY7T\V%[Z?K_P_S\CJ/&6F?\+(
M\)OXLM5,OCOP+IL%OXM@4*)_$_@;3HA;V7BO _?7>L^& 8-.\0N0TEQI#V.I
M2N6M9Z^=5"G)P",]>/TXX'H,GWYKZ(\#R^(8?%WA\^%8O/UZ348+:SMI%9[2
M]CN6\FZM-40'8=%N;)KB+63-^X32VN9)65$W+Y5\0H/#5MXZ\5V_@Z5)?#46
MLW2:8T$C36:J"OVJ'3)W DN-)MK\W=MI%S*/-N-+BLYI,.["L\TIJO1I9BWR
MUI55A,2I.WUFI&BJE/%4]4Y5?8PC2QRM_%CA\1)\V(J1EGFM-5Z%+,6^2O*L
ML)BN;3ZU5A056GBX7=YU?8QA2QZL_P!['#8F34\34C/CL#T'Y"C ]!^0I:*\
M/^NO_P D>%\Q,#T'Y"C ]!^0I:*/ZZ__ "0?,:0,<#ISP!GV['OBNM\%>*E\
M):P]Q=V"ZQX>U>QN- \8^'Y21#X@\*ZCY:ZII[98"*]546\TB\QYEAJMM:W:
M,=C*W*4A!Y[\<#M_G^>?:M*-6I0JTZU*7+4I24H.RDKJZ:E&5XSC.,ITZD)*
M4*E.I4ISBX3DC2C6JX>K3KTI\M2E)3@VE)72::E&5X3A.,IPJ0G%PJ4ZE2G.
M,H3E%Y7Q-\"'P'XBCM;&].K^%=?L(O$?@;Q !E=;\,7\DGV1KC8 L.LZ6\<F
MDZ_8@"6RU6UG!C2*6 OYZ/ICVKZ=N-MW\"/%:>+#%'HFD^)+%_A==RF3^USX
M^O?L_P#PD6BZ*#'MG\,S^'%EU'Q4GF+;V.I0:/<Q(]_<LI^80<^OXC'^?2N7
M-,/2H5Z52@G2H8W#PQE/#-OGPJJ3JTY47=N3HJI2JSP<Y^]5P<J4G>5*<ZO!
MF^%I8>O1JX=>RHX[#QQM+#.3Y\*JLZM.=!IR<W15:C6G@ZLWS5<%.BY7G0J5
M*RT445YO];O_ #/)L^_Y_P"84444?UN_\PL^_P"?^8C ,"",@@@C@@@C!!!X
MQ@\UZIXBTT_&?X?#484^T?%KX2>'U6ZC !N_'_PCT:$8N,EGFU'Q;\._,(E.
MTW.H^#G!)GGT< >5GH<_Y_/'\Q]175^!+OQ98^-?"MUX$%T_C%-<T]/#D-HA
MFDNM2EN%BCLYH "L]C>*[VNIP2@V\NG2W27.+<R$=>#J14Y8:M"I6PN-4,/B
M*-).=:7-47L*V&B[WQ>%Q$X5L-_S\E[7"R_=XVIR]F"J1YYX2O3JU\)CXPPV
M(H44YUFY5%]6KX6+O?&X3$SA7PB7\2;K827[K'5.7YW#A@& 5E(R& R&!Z,"
M."#ZC@T;O]E?RKU?XY6GA&P^+'C6T\#O8'0X=3431:-,]QX?L_$)M8&\5Z?X
M8N76.2X\,:=XE;4[+P_.Z1E],BMPBF$1D^5KC<<?KR>W0Y.0/PQD9SV\/$T7
MAL3B,-*<*LL/7K4'4I2<J=1T:LZ;G"5W>,G"ZU=GS1;DX.4OGL50>$Q6)PLJ
MD*KPV(K8=U:,W*E4=&K.DYTY<SO"3A=:RM[T7*3IRE)F[_97\J-W^ROY5-16
M%_ZN_P#,YK^O_@3(=W^ROY49!Z@#Z#CG(YZ_A^>#C%344?UN_P#,+^O_ ($_
M\SK_  !XVN_ ?B2'6DL;;6M*O+&^\.^+O#&H*'TKQAX+UV);/Q+X5U.,':UM
MJVGET@F.7L-0CLM2@"SVD9'@'Q]^$MM\+/%=A<^%[NYUKX6?$'3I/%WPJ\07
M)C>YG\.37+Q7?A?77A+10^,/ ]\6\/\ B:RW"0S06NI!%M]2ASZ>W3\1_,>X
M_F/J*])N4M+_ /9F^,$7CWR(O NC:EIE_P###4;AYUUBV^/EXD<6GZ%X.78T
M=W9:]X62_E^)%F)!;6FBV>EZO,$OTLO-SQV"IYKEF)P=5J%7 T<9FF Q4VHP
MPL\/AW7QV'KS<HJG@,PH4(QJ2;Y:&8T\NQ,(3EB*].KI7PL,URW%8"LU"I@J
M&-S;+L5)VA@ZF&P[Q&.H5ZDGRT\!F6'H1IU92?+A\RIY7BH0G/$UZ=7\]AT_
MS^?X]:6D'0=>..>O'%+7Y7=_S27E=_KKZWUO>^MS\RU[R_\  FOPZ=K;[WUN
M%%%%&O\ -+[POYR_\"84444:_P TOO"_G+_P)A3&4."K@,I!#>X/;CG_ /4.
M<\4^BAW::;;OW?\ 6_4=_5^K;_,_H^_X)K_M;M\8? I^#_CW5%F^*'PXTR!-
M,OKV;-YXW\#PXM;+4P\LTDU[KGAP+;Z7XB?:KSP3:5JS>=-=Z@\/ZC;CD\K^
MI_4"OXT/@9J?Q0T?XQ_#G4/@K'=S_%*/Q-9Q>$+2UCEE2^O+D/;WNGZI'$"6
M\.WFE/?1>)O,*V\7A\ZE<W#Q10-+'_9#9&\:SM6U!+:'4&MH#?Q64TEQ917I
MB0W4=I<3V]M//:I.72WFGMK>:2%4>2")R8U_M+P8XOQ_$W#E7 YE3Q-7%\/S
MP^!_M*I&3I8["U*4G@XSKRNIX_"T:*HXI7G.I06$Q4Y\]6HI_P!O>"/&./XH
MX:K8#,J>)J8OAV>'P']ISC)TL?A9T7+!QGB)OW\PPE"DJ.*C><ZE".#Q52?M
M*M13TJ\,\5? KPKXT^(VI^//%6F>&/$D5U\/M-\$Z?I'B/PGI.O#2)[#6M=U
M>;6+2ZU5+M8C>+K$-M-:P6L!86$<DEU)F..'W/Z5R5OXST>X\;:QX B^V'7]
M$\,^'_%M[NMB+$:5XFU3Q%I&F"&[WXENOM?A?5#<VXC4PQ&VDWL9\+^L8_ 8
M',:<*&.H4\324YSC2J)2BYO"XS#SERM2C)K#8S%*+<7R.?M(\M2G"4?V'$X7
M#XRDJ6*HTZ]&%6A7=.K"-2G[2C5YJ$ITYPJ0FE6FK1G3G!R<;Q=HN/R]H'[*
MMYH,/A70AXZM+OPCI?\ PJC6/$.G2^$X_P"U]5\6_!_0+#0O#MSI6JMK#P:1
MX9U1-(TB?6_#]SI^JW+I;7MII^LV4&KW(CYA/V?/BUX7UOX:OX7\7>'YX] \
M6>*M3M!)X>U.[^'OP[T&;X:ZCX5TW2=$\'ZYX]O?$%I9:IJ%RLSZ9X=\3VFB
M:/-]GM])TC3--&H"^^R[#QGX.U:ZNK/2_%GAK4[JPUN7PW?6MAKNE7MQ9^(H
M;:>ZFT"ZAMKR26WUN*TM;BZDTJ9$OH[>VGG:V6.&1EOV6MZ'J+6\5AK6E7SW
MEM>7UDEGJ-G=/>65E=165]>6RPSR-<6UE>SPV=U<Q;HK>ZFAMYI$F=$/E5>&
M<HK*+]E6IM3I5%.EB:T7*%.K&M"CS7;]BESPI13E[&EB,3[!PJ5YUUXTN&<J
M]E&C2IXC#*DZ?LY4,56A4HJB\.X0IRDY2A%3PT9\CO&->I4Q'LWB'2E0^5-!
M_9:N_"<>B#0/'@=]#UWX?ZC"VJ>'O,CO-.\+?#/5/A=K]C<QZ=JNFBWN]<TO
M7=1U32KNP^S6_A_44L(/L.HV$$L$U+2?V5]>MY?#*:M\1-.O;+P1IGPN\,>&
MH;+P7_9UTWACX5?$"T\:Z2-<N!XAN(K_ %[5+2T72=1O;.VTW2H9E&I6.BV_
MFW-G+]5W7C'PA9:S/X<N_%7ARU\0VNC2>(+K0KG7-+M]:MO#\#.)M<N-+FND
MOH=&A:-UDU.2W6RC*L'G&QL91^)WPVBTS2=;D^(7@:/1?$+*F@ZL_BWP^NEZ
MXSWD>GHNCW[:C]DU,O?RQ6*K933%KR1+89G98VU7#N4*=&4<+)1HSI3HPC7Q
M"I1E1JN='EI*HXR]G64Y4XW:53G2BY)P5/AK)G"%)X:HJ5-)*E'%XN--15JE
MG%5=8WY*LKR2<E"I)VLY>1?$[]G&R^)1^*4MWXHO=#OO'7ASPIIWAS6M*L8E
MUCP'KWA6S\7V,7B#3KN6X>.\.I6?BV\TK4].:&U@O]!FU31KV2>TU6818]K^
MSKK?AS7/^$U\(>.-/L/&5EK4E[I$FL>&)]2\.2:%J7PV^'OP]\0>&]:TRTU_
M3=3N8KV7X=Z5XDT_4=+UK2;S3=0C@M91?62W<=Y]#77CGP5:WVN:5>>,/"MI
MJGAG3%USQ'IMSX@TF#4/#^C/&LL>KZY9RWB7&DZ8\;!Q?W\=O:%"'64J0:K?
M\+!\ ,^@Q#QSX.\WQ2MD_A>/_A)M%\SQ&FII=R:<^@H+[=JZZ@EE>R6+::+@
M7:6ERUN9%@E,>G]A97[5UX89T\0Y1G&O1KUX554C6KUX5H2C.2553J5U&HH2
ME*ES4)>UHTE3H[U\CRNOB'BZE"2Q/O/V\,1B*4XR]O+%*HN2K&,:E&O5]K2J
M<CE1YHQ4O8RC1GX/XI^ WCOQ%_;Y3XH:79R_$SP1H_@;XLW7_"#YGO;72O[9
M@.K^ $B\1Q6_A74[K2=?U/27CUR/Q=8QQIIM_';?;+6Y-]V'QC^$.H?$?P[I
M7A?3[CX?MH5M87.FW6E_$3X>+X]MXC+:16=AKFASIK^@7FC>(-'B646ETLUQ
M!,;AO,CB>.*0=+X2^-OPA\>:?8ZIX3^)/@O6+34=>U;POIK6WB/2!+J&OZ)J
MDVBZAI=E;R7:W%U>)?1J((8(W>[M[FRO+436E[:S30:G\>O@OIK^%HKKXI>
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M2JRYE:<?>:*0,"2O<?K_ )Y_+ZX6O9NG_7?5'MA1110 4444 %%%% !1110
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M_"W_ $.WBO\ \!]"_P#E;1_J;Q!_T"4?_"S#_P"8?ZD\1_\ 0+0_\+L-_D?
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MHBW>GW.K:0L=[N7WB#X%?#6W2UCCT6Z,=IHOPL\/Q1RZSJ\T;:3\&=3U/5_
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M^*XY'T;3--6Y72O 1FBO[&=);SQ#&C^#7MSJ>M1JUM?VTL$FB00NSZ3I.FW
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MXT\1A74P^)Q6$Q.%Q$Y****^G/GPHHHH **** "BBB@ HHHH **** "BBB@
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M:QT_Q9>VFL:!XAU)-*U.XC5X+RSB=?L\'[/W['7C/X0>(_@1KFO^/-!\3O\
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M^N/#^A6&DSWEM#<-YZ6]Q+:-+%',?,B0JC88ON^$]!_8\^,7PX\"_LG'X?\
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MI_X@MQKVR;_PZ2_^=Y^I>1ZC\Q1D>H_,5^6G_#6/QA_Y^O#/_A/#_P"3J/\
MAK'XP_\ /UX9_P#">'_R=1_Q&_@O^3.__#93_P#GD'_$%N->V3?^'27_ ,[S
M]2\@]"#^-&1ZC\_3K^5?EI_PUC\8?^?KPS_X3X_^3:T]&_:V^)D.JZ?+K?\
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M]W@=_)QO_P"(Q1_^B$]'_B2?QJ_GX(_\2BM_]#I_4CD>H_,49'J/S%?RW?\
M#U_]K[_H*?#G_P ("#_Y<T?\/7_VOO\ H*?#G_P@(/\ Y<T?\3W>!W\G&_\
MXC%'_P"B$/\ B2?QJ_GX(_\ $HK?_0Z?U(Y'J/S%*"#T.?I7\MO_  ]?_:_[
M:K\.1V/_ !;^#OVXUG^?8&OTP_X)[?M]ZU^T1J>O_"[XORZ):?$^V6Y\0^$K
M[1=.;1],\4^&[>* :IID=@7N8H=<\/RDWK!+QGU71[J6ZAM8AHFH32_8\!?2
MY\'_ !#XIRSA#)\7GV S;.9U:&6RSW)X9;@<5C(4Y5:6 ABXYKC5'&8M0J0P
M=*=*$<16INA&K&M.C"M\EQQ]%CQ9X!X9S+BS-\+D&.RG*(4JV8QR/.9YEC<+
MA)U8TJN.EA)93@I2P>$=2E/&U:=6<L-0J+$3I2H0KU*'ZQ44#H._'7UHK^GC
M^<@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KS*^^&&DW_C;Q3XWFOKTWWBGP#H_@"ZLBEHUG;:=HVH^)]2CO+;?;
MM,UW<R^)[A+F.:62T*6EFRP+(KL_IM>>R?$/28_'?B+P)+:W4-_X<\%>&_&T
M]_++91V5W9>)=5\7:5;6-J'N5N/MMK-X0NY;II88[81WEF(YI',JQ^9F>6Y;
MF=*G2S/"T<72HU*F(ITZ\92C"K]1S'"5*BBFDY+ YCF-+6,[0Q%5QBJBISI]
M6%Q>+P;K3P=>I0E6HK#UI4FDYT9XK!553D[-J,L5A,#+W7%\]&G>7(YQGXIH
MG[*V@:!+X9L['QMXM'AO03\/]6N_##0^''M-<\;?#+POI?A/PEXTNKZ;2)=0
ML[NVL=!\/WE]HEC<0Z#J.I:'I\US8M;R:C::APB_LI^*/#?B3P/>^"OB3JFE
M)8^)?'WB+7=?M=&\&Z7_ &+)XB\"6_A2PM_"_@2V\.2>"8$OKN ZEKDD.EVD
MESJK+JI.(HK-/9]"_:0^&E]X1T'QMXDUS2/ VD^)=(\#:II</B+7M)&J"7QS
MX,M_'-GI>H6%A/=26-_8:-)/<W8=I+<V%E=ZO'/_ &7$UR+WAG]HCX3^*O%T
MW@W3_%VB#5KB?0%\*@ZOITL'CC3O$W@31OB#H^L>%I+>XF2\L+_0=7DDL?,:
M&?4%TK5+JQ@GM+22>OF\3X=\)XF$*3RN=!T:]&K&6#Q^:8:K'ZO5P]>.'C4H
MYE&5+#J.&C2CAZ4J2H8:KC(8)81XO&5*OO4>-^)J'/5>9*O"KAZU"<<7@LNQ
M%"<,3#$TJE6=*ME[IU:G-BI3=6K"K[2I3PJQ/UBEA<-AX<%I/[)WA+P]#I,&
M@>)_%%A'I'B3PMKEL+@Z5J/G66@?"QO@]JFA7OVFQ/VBV\4^$KF_?4M03R=2
ML=8O#?Z3<VBPQVYATC]E/3+"^T.ZU+XC^-=?3PK!\,]*\,VVH6OA>!-*\-_"
MCQ@WBWPKHK26&BVLVHS,Q32M6UF^>74M2LX+>1I8KI#,WO\ XP^(_@3X?G1H
M_&GBK1/#DGB"\:PT6'5+Q()M1N8PAF^S08:9X+82PF\NRBVEEY\'VJ>'SXM_
M,2_'GX+VO_"4&Y^)W@N >#;VSTSQ0\^N6<,>D:A?:RWARTMKF21U1I+CQ&K>
M'T\AIA_;JOI#,-15K8="X'X4YJ%19-ATL+*C*A"&(Q\</3EA*D*E"V&AF*PS
M6&JU*52E&="<:-6=.<(1J.#,X\7\30511S:NI5U-5*CH8&5:?M^:-1JO/+W7
M3K0A.G.4:T9U*4:E*4I4N>#P_B1\$F^)VI6=OXA\=:\W@>+4_#6L7G@,:+X0
MFM7U#PQJ5MJUI/I/B670?^$KT%KZ]L[1]2EL-6:]VPE=&O=&>:20^?:1^R1X
M8T#PUXH\,:!XFNM%M-5O_#6I^'=2TSP;\/+'7_#-UX2\9P>.=#:^UVT\,0:E
MXX2TU>TL[7R_&%QJ:3Z7;E;H7&ISW&JR>Q1?'+X0W,/@^>#XA^%IH_']S=6O
M@TQZG$\FO7%AJD>AW\5G$ 98VL-<DBT6_P#M,<"V>KRQZ9<F.^D6 UI_V@/@
MK:V=_?S_ !.\'QV>FZU'X=NYCJ\+'^W)[75KZVTRU1=TNHW5[:Z!KDFGI8)<
M_P!H?V/J<=DT\MA<I%=?@OAC$X[%9EB,IIU<PQD*]'%8V>*Q[Q=2E5C3HSP_
MMUCU5IT*+=-X:A2J4J>!Q$H5L%]5K--9X7BOB+!8/#9=A,SJ4,!A9T:V'P=.
MA@EAHUJ$_:TL2Z4L%*G5Q,O8.-7$5HU:V)H4I4<5+$45)/R7Q)^R1X?\4CQ%
M;W_CGQ7'IVN7WQ!U*VL+:T\/JNB7?Q0TRQM/%IL[EM,>YNK>?4;-]7T^WOVN
M3ITMU+8QRO816\$6-\7/V?/$W]K>)/''PJU#6I/'?C:^U^SU6ZD\0^'=#L]-
MT#Q'\/\ POX.O=,QJ_A3Q''=:<][X'\,:R;NV@7Q%I=]!/-IMQ<VCRZ7/ZD?
MVI/@3%KVL:%<_$/0K--$\#^#OB%<^(+N[C@\*W'ACQUJ-]I?AV[LO$+,=/N'
MNKNU@C\D2J6?5=+AMS///+% OB3]I_X#^';'Q!>7OQ)\-W-SX9\.ZOXHO]$T
MZ^CN]>GT[0= 'B?5(-/TH%)[W4;+19(;N\T^/_2M/6ZM?[1CLQ.A/+CN ^%\
M7A<716 E@YXN3G/&X3%XRGCJ,XTL7AI5<-B*F+KRP]2EA*V88.#ITTJ&$K8B
MC2IQHQBH;X+C'B'!XC#588R.(CAH1HPP>(PN$J8*K1J/!OV&(P\,+2C6HUIX
M? 3J0E-*O4HT'5E*?-?TKX>>%)O!G@;P/X2NKN*^N/"GA#PSX<GO(5DCBNYM
M T2RTJ6ZBCE9I$BN)+7SD20EU60*Y+ FNXKPR']HGX31Z(_BK5_&?AO0?"TW
M_"-C2M7U/6K.*2^;Q-H#^)+.&;2\C4M+N4TR"\O9(+Z!&_LVQN]6)33K>6X3
MI[3XS?"C4/%L'@33_B%X3OO&%RXB@\/VFLVEQJ$LSZ)9^)HK>-(9'1KNX\-W
M]IX@M+0/]IO-$F&J6L4UBDDZ?8T,/#"T:.%I0E"GAZ5+#4Z;<I.$,-0ITH4V
MY<TG*%##T[\S<FH.HV^9R?S=;$2Q-;$8RK.,ZN+KU\;6J)1C&=7%XBMB*M11
M5HQC.OBJEHQM&+FJ:2Y5%>F45\^>(_VC/!WA+XB^$?AYK=I=I/XR\6>(_!MI
MX@TZZT[5-$T'6]$TGPCJ5E:>,)+:Y-UX9G\2W/C'2](T2*]MV#ZE<Z;!=26Q
MUK2_M&6O[1+ZO.FE^ _ACXP\<:_;6OB?5M>T:QU'PKI#Z%HGASQMXC\!6]Q/
M?:WK-E87>J>*-9\*ZW+X9T:WG:>XM+"YFU2XTE$B\ZW)<JE=<LN:TG\-H).H
MV]DJ<91G4;LH4VIR?*U)RTTW%JS2@[-I?&Y*%KM)N<HRC!)WE.+@ES:'TO17
M+>#/&.A>/?"OAWQIX9NGO?#_ (IT>PUS2+J6&6UFEL=1@CG@\ZUG1)K:X17\
MNXMI566"97C=0RD5U-6TTVFFFFTT]TT[-=5]S:[-IIN4U))IW35TU_7X-)K5
M-)II%%%%(84444 <?X^\ ^$?BAX-\2?#_P =Z/'K_A#Q=I=QHWB#1Y;J_L1?
M:?=!1)''?:7=66I6$Z,B2VU]IUY:7]G<1QW-I<P7$:2KR_B;X&_"OQA!I=KX
M@\)07=KHGA*X\"Z3;6^IZYI<%CX3NM9\(>()M&@ATG4[&-83JW@/PG<QSE3=
MPII"VL-Q'9WFH6]WZQ01D$>HQ4M+5\J;<HRV6LH*48R?G&,YQB]XQE)*RDTV
MFU9IM-*233LTI2A*23Z*4J=.4K;RA!N[C&W@OCWX"_!3Q#JNK^/O&VA7*3)-
MX9\5>([J'QGXWT#P_J%]\,[NSUWPMXB\3>'-"\2:9X:UW4O"LNCV,MCJVM:1
M?7T%C80Z>UP^G1"UKCO VO? #QA\,O&W@./PU=:-\/-,\+VWC7Q;X7\>6UZD
M+^#OBMI]]\2QXG>2^U359VTR_N;W7Y'E6^BNM!U[1M7TZ"'3Y-'MT3V;XN>$
M;[Q[\+?B3X)TVX2UU#QAX#\6^&;"XE)6*"]UW0+_ $RVEE8$$1+/<Q&7!'[L
M-7S5XB^!GB+XO:!\%]?M9?\ A7BZGX%\.^!?CYX0UW3[^+5O$OPM$>F^([WP
M)&EO+&FG:]8^*=);0!>W*O;)X0\6^/;:$FYU#3YHH2E+FIVC"+]E%73<$ZJK
M7JS2M>%*=*$)Q3;Y9QE%)J*);4>2=GSKGDN6SE:BJ34([6G.$YJ#;C'GBHMM
M<YS>FW?P)U[2I-*\.?"_]HGXA1+IWP[\;^);^/QA\1O$/BSX6-=:5'K_ ('6
M+Q'XK^+">-M"\76?AWQ!_;,OA'X1ZCJWC#3]&UI/[5T2)-;M;>^[V7P[^S/H
MGQ$L_@#)X6U6+Q'\0/@SXMT*[::]\92Z?J?@CQ=KFMZSKGAWQ'XJNM;>\?Q[
MX_OXO'?BR&_O[F7QSK\/A?QKK4VMA]*F:7JXOA]\6O GC;XA:Q\+9OAUJ?A?
MXJ:_I?BW5;#QS=>(],U+P3XIM_#/ASP=J>HZ0N@:7JD7C'1M1T7POH]W#X:O
M+[P;/8:I!>K'XDDLM2BBTKSG6OV7/'NLS>,/')^+^K67Q,U7XJ6OQ9\/Z1:V
M/A5_AK:ZMX*EATKX;Z#J=Q>>!KOXD)H+>"--M?#GC"'2/%MG'<2:_P"+KS3+
M1?[4DCN+B^=P<E)0EK6<M:E[.FH*,?B]FZGM5-?Q(4I0>M=/#RXM1G%<KLG[
M**5X-ODJ<TF[6YI4O9N+2492IS2_=-5HU\:_!5/',_CFX^$'Q)M%T?XS_P#"
M$P?%2:XT^?PM-\5_"VG:_P# C1+:#1;'XD7GB2*UU!-<U+P%I6HZIX&LO#-S
MJ6KV6HZM<6UR;36(/4?"GPL^ OQ'^'?@_5-&\)C4/!>N?"_6/"^@6U[JGB-9
M(O /Q)O-#\2Z]HUS%)K$D\5]<:KHFD7+WDTTFM:'J&F*NE:C9;9-^)\._P!F
MSPAX&U'Q?XX\5:!I?BCQ?>?%KXE_%;1[RUEU_55TX>)?$FK>(-!2RT._N#I:
M^)M)TZ]CLH[W3])29;Y7FL9Q++YK:O[->@^/?!GPU^'?@WQ+X5BTNRMO %MK
MVI:C/K"_VMI?B_Q'X@U76-0\$S^'A8_)%X?T_4+>.76%U4I)=(]DM@@C$YF6
MJE%^_+V5-R>J@W.,U4A?12]Z6(:=HIJ44ES3<I'PRBX+EBI.,=+2C&FH2I-)
M7E%1?L[7;2:;5E%QCA>$?"7[,W@K4-$\8-=Z;X7\5:GXRN?$>FWOC_XRWOB7
MQ/K'BV^\/W_P>MM3EU76_B-XK3Q'=ZOX7T>X\.Z7:RZIJF(K3R3:6GB#3[F.
MSQ/'WA3]DWX<^%?B!I&MPV$;^'_!?A[Q%XG\(>&_'_B ?$BS\-?#?Q;X@^)?
MA;6-%L[+QE8^+M%O="\7>+=;\0:7X@TF[TK4//U&*%]4>RMM/M[;S>U_8[UR
M3P=\2_#TVM^ -0USQ7^SEXP^"NC:BUG>W/\ 8VK^)OB1\4_'"ZA=,]E)=6^B
MA/&7AT7<5JIO'U70Y9EB<06,A[+Q-^SK\1M3\+?'#X<Z>_PNF\/?%*_^)7B?
M2?'NKG7O^%@:?X@^(=F%_LK5[&#1)[*YL=#EFET2S\36_B$WLG@FPT3P[_PC
M<)L3=R.+4W3Y[Q;A2E)Z-1_>IN$>B<%!UN;X92<(4DJB4B](RDE\/M)P>J3<
M%:*DUJW&<9\G+:\8PG*HG3?(_6O OP_\)^'?BGX]^*^H^*O#&L^-?B =#^&N
MF&P":<^EZ#X BUB_L/!LC7?B#7+_ ,1>-DDN=4U+Q=J\LMIJ&H0:7IEO-HUC
M9>'(2:MG\3_@G<?%C6;CPO=V'BWX@W_A3PEHFM:]X?\ $NB:KI-MH=O\0KKP
MMI?AXWFH>*H-!TO5],\5>*+Z]U'0[&&W\0:LLL,$5MKFK0:1I8\BU[]F;XD:
MYXDNM'7Q%X,TWX<7'Q=^*_Q5;7K23Q /B)&?BQ\+O''@BYT:STQ=/CT+3[KP
MOX@\:3:K9Z\NNW;:QIEK;VLFE:+>1275WBZ?^RU\3;WQ%X7UO76^#?AV#PGX
M<_9S\'65IX*M_$.=6TSX%_&_P[\3;C4;DWFBZ8FG+JVA:+<6/A[PK$FI6_A?
M4[F6&3Q%JUG<27<*CS-Q3TC&$U#F2YN5TVVG=64G7J5HS5N>M&<JJ<8SFDGI
MHG?F47)KW8\RTBE&[;BJ=&A;7DHR2I/G<8M^UZ5\-?V9]3\3"'PUJFD1>*_"
ML6M:S?:?X,^+_B?2=5M-&U;QM?\ C/4[;Q1I/A?QK9R:EX+3QMJ&J7]KX=\2
MVUWX1TBZO[_3M-TNQM+NYLY.-TKX"?L]>.O&V@>-_ 'B;P[KWA[1M/\ BI;^
M)O"&C^,]4\=>$-5T;XQV-[I/B2STC2G\:ZAX:^'VD:CJMOJMY?VOA?0;*QUF
M]AN[=H[>6VFD7@M=_9 U63X<Z=X3BUKPSI=U8>%_VKK+Q!>Z#HM]>7^J#X^W
MVJ:MI[6^EP1V-UKL<=W)9GQ1I-U=6K:_);M;6MR9C!<1=7^SMH?BW7?B?\9/
MB7XO\#Z9X'T;Q5\/OA!\/[2&P\->+O!L6J7_ ()3QX=9EBL_'OASP9XMO+:T
MLO%&B6%IJMWX6TK3H8DA\.:-=ZY%X>FUBZF+ETBE.%"O-7:4/:RH2@J=VI7A
M7G4>':NYI*5730)-JTKN2E7A!M:R4%7351K2TZ=."Q,6K0UA3NGME?#S0/V;
MKC48?%/AGX5_%6X\(7=_;:A8?'/Q1XD\:^(/!VIR?#+PCXV\+:5JC:MXH^)&
ML^.+3PII?A7Q1XSTC0?$NO>&M.\":O:7=M/I6KZBB>&;L5V\1?L^7>A?#N9O
MA;\</"?A_3?AWJ^B_!#7M'U3QKX+OOB5X&\*>'G\4'P3I%UX0^(^G>--1&H^
M&_#,GB'PYX.^,T&@W7B:VL+F]TO3[Z[^W&O2/"?P@^)NC_#^U_9^\17OP\U/
MX.VG@[6/AQ!XLM;WQ)9_$?4_ DGA^[T#0-(;PN-+C\.Z;XBTG3)K6WU+Q5#X
MJU:VU<Z=+?1>%=,DU%H=/P+CP?X[T:+X/R?'7QE\,-)\!_!'7]-U2QU_P])X
MA37_ (F^*=-\/:OX0\'RZEH6H:=;67@6*"UU>?6=5T/0]6\<R:KJ=O'%!?Z7
MH]M=17&U&G5KU:5*DJE6K.=.-*,*<IU7-^TO.-*FI3^L0FX\F'A&?M5*HW*3
M]YXUZ]+#4*^(Q,Z-"A0A5J5ZM6O"G1I480A[TZU5TJ<:$J,+5:]2=*%&,(7Y
M(P453^(9_95\(7?@[X[ZIHWB#7;KQ!=:Y\>?"C^$O$?C>XT-[OPC\+]4\0ZW
M\4H_ 2>*],\$6MX_@N!=,O\ 6I="2_UO5M=T:PU#[7J.J1R#K+SXP_#7P=X]
M^,7C*+X:?$J1/#9\%>&?C'\5=+M=*U7PQI%EHGA:#QEH<MSX=C\;S>,I=+\-
M:%\0'N]9U7PO\/+I(%N[R;4;B[MM*>XM/$YO@1IUK/\ &KX.2?$WPK+KGCGX
M7^.OAY^S3X6O;;6H+KX>_#OQQ:ZEXP\4V>J2[9HM3;_A*+V&SC?28\Z=\._!
M'@G3!$MY!?M=>J:O\'/C8;WX^>'?#-Y\,;#PG\==5TZ67QEJ>J^)[[Q7X0TR
M7X6>#_ASKRVW@.+PM!HFNZDJ^';^\T66Y\>Z99J;VTEO[686LUE<CHUJ<*:K
M8>I052BL1A(5HRIPG"NU:,9N"BZ:]E.E4Q%-RC.M2Y8N2@J:FCB:&)GB(4<3
M0Q2PV(6$QDZ%2%6I2K4N2K*-2DIR<:\:=>C6AAJG))0JJH[*K&9[5=_#/X1P
M:7<>)Y="^U:8GCA_CK)=6%_XFU87?C1-%6S_ .$GL[+3;Z[GU/S]&C2&W\/V
M-K<Z3?*RB#1I[F8%OF;3F_9KU+X6^#YO#?@/XP>(M*^*WB"31_A_\,K?Q;\0
M]/\ %>C:M\,=<U;6_,\&Z7XM^).AZ7\$$\#ZAX7NM1M;C1==\ ?V&;/2M&M/
M(U"32]&;ZET'X7:?X#A%_P"#;GQ)?ZII7@W3/"F@^'_$?Q%\8KX',/A_1].T
MK1T;P_YNL^'M GGCTFS&H:YH_A2;4=\U_>>1=3W=Q'/\U:#^S_\ %:V^$OA3
MPGXB\/\ PKU+Q?X'^)'C/QCH-[HWQ5^+OA!XK/QKJ/B_5KF?2_'_ (0\+^'O
M%GAC5+-_%MQH=_IT>E:_H_BC0X9UO'TR>ZA6PAIQ=6-/X(QH^S7*XJSQ<X2C
M&S49R6&H8*M91IJDX/E?/&+I]'OR5.4K.;=1R<G?WOJD7&4EK*"5>IB*3:G/
MVL7RN\)-3Q=,OOV5=!L?AO/X-\.QW$OQOU'XD^![R'Q5\0/%6D^(=/T[XF^*
MM/L_C8/$*>+/$%_K%]XJD^(?A_1/#^M:7%(_B.W\2)=KINHZ?:IJMQ+V&F:!
M\,_$7C7XA>%OB+\.-.\ VED/ASH?@[Q,?BCXD@UGQ/I'PY\0ZOH'PXUG1K_3
M+S1KGP%K>EZYK=U8:%-I>NV_B_5Y]9:%[G4;9H97]A^"_P $=+^%OPDT/X9Z
MDNE^(1#=^)-:UUFM+B329];\9Z]J_B7Q"FFP:M<:EJ(TZ._UN]L]/FU*^O-6
MGLE2?5+ZYU">ZN).ROO#\/A"&ZU/X>?#[PO=:YK>L^%;774MSIWA.>_T>*_L
M=*OM8U#5[?2+R?5;KPMX?DNK_3+&]5Y+Y;)-(MKRQ^U)/'ZSQ&5QP4L.LNG+
M%RPSHRQDL0Y1^M2QF%J4ZU&G%T8TJ%'"+$8!QG"NYTE3KWIOGJ0\&6"SN>90
MQ4<TIT<!2QU+$1P%/"Q@ZN"IY=F%"OA\35E"O.M6KXZ>$S"DZ53"JE4@Z$O:
MIJA5YK3OV>?@_I5I>V5CX2=8M3\&^*O 6JS3^(_%=[?:MX:\;:O-KOBV#5M3
MO=<N=2U/5O$&LW-QJ.I>)[^[N/%$]S(SG60#@5KG]FWX.7#131^&-1TZ^M]:
M@\06VKZ'XV\>^'=>M-2A\':#\/Y#9^(-!\3:=K=I8WW@[PQH.AZOH]M?Q:/K
M=OID$VL6-[>&6YD]Q'?Z]?7\/I@\=<\4ZO*:C._-%2O'E?-%.\;M\K35N6[?
MNVY=6N6S<7[Z]WX?=]--;*-_6R2O=NR6MTFN0\ ^ _"GPP\'>'O '@;2%T'P
MCX4TV'2- T9+S4+]-.TZ!G:*V2\U6ZO=1N%1I'Q)=W<\N" 7P !U]%%7*3DY
M2DW*4KMR;NVVMVWJWHM?)=A)**48I))622LDE?1):):O[V<3\1/^1"\;CL?!
M?B?/_@DO:_%>($Q1X; ")VS_  *>_P!:_:CXB?\ (A>-O^Q+\3_^F2]K\6(?
M]4G^Y'_Z+6OYB\>V_P"U.&?^Q7F7_JSPY_2/@0E_9G$FB_Y&66]$_P#F75^Z
M8_#?WO\ QT48;^]_XZ*=17X)=]S]XLNR^Y?Y#<-_>_\ '11AO[W_ (Z*=11=
M]PLNR^Y?Y#<-_>_\=%(P8 G=TYZ#J.GZT^FM]T_Y[_I^/%";NM7^/Z-/[FGV
M8679?='_ .1_KSV?/_$?X6V/[07PXF^%]PT%MXWT6XOO$/P5UNX>*)8_%5U
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MI%SE3]=/P+\2+XLL]1TWXL>!HOC%IF@Z3=7%C>>"[V_T$^&[OP*?AAK&J_\
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MYT;0U)-OJ.O-K/B 1MNTZ5/@+SX.?WT/7M(F/3H" .?UYK^U0_L[?L_$L?\
MA17P;)R6)/PO\$9)+9)/_$CSDDDDGG))/-(?V=?V?<\_ KX-'W_X5AX(/_N#
MK^>>.?H1<:\=\1X[B',_%'ARB\0X8? 8"EPUQ%/#95E6%4Z>797A'4S+F='"
M8>3YZLHJKB\77Q^/KN6(QU5Q_=>#_IE<$\&Y!@<AR_PVXGJK#QG7QV-J<1<,
MQQ&:9KBG"KF6:8KDR_E]MC,2KQIQ;I83!T,OR_#J.'P--3_BL\^#_GM%_P!_
M$_QH\^#_ )[1?]_$_P :_M2_X9U_9]_Z(3\&O_#7^"/_ )1T?\,Z_L^_]$)^
M#7_AK_!'_P HZ^/_ .*>'$7_ $=/A[_Q%\__ /GB?3_\3Y\,_P#1M>)?_$DX
M;_\ F _BM\^#_GM%_P!_$_QH\^#_ )[1?]_$_P :_M2_X9U_9]_Z(3\&O_#7
M^"/_ )1T?\,Z_L^_]$)^#7_AK_!'_P HZ/\ BGAQ%_T=/A[_ ,1?/_\ YXA_
MQ/GPS_T;7B7_ ,23AO\ ^8#^*WSX3_RVB_[^+^'?GG'%?H9_P3P_9);]I/XG
MIXH\66+R_![X;7]CJ'B9W4&S\7>(8);:_P!)\"J7AEBNK.[C"W_BE(R&BT3R
M[!GMYM;M+A?Z1O\ AG;]GW_HA/P:_P##7^"/_E'7HWA;PAX3\%:6=$\&^&/#
MOA+1_M,UX-)\,:)IF@:8+NX""XNQ8:5:VMI]HG\M!-.(?-E$:"1FVKC[CPY^
M@91X:XQR3/N,>,LIXJR/*,4LPJY!A,CS/ K,\7A>2M@*.,K8[&5Z$LNABX4J
M^.P_LG/%TJ$,*VJ-;%*?QW'WTVWG_"6<Y)P?PEG/#.>9KAG@:.?8W.\IQBRS
M"XGGHX^O@Z.7X2C7CF4L'.K0P.(=14\'5Q%3%\LJU#".GOQ0QPQ1PPQI!%$D
M<<,,4:I%#'&@2...- J(B(H5$555% 50  *FHHK_ $7BE%))))))**44DDDD
ME%))))))))))))))?P*VVVVVVVVVVVVWJVVVVVW=MMMMMMMMMLHHHI@%%%%
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MEFFN)?">@O/<WVA:G/*VFVS23:CX9@-KX?O9'*9>YT:V/D:=,?GM8LI$5!P
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MDA8&J7_"KOAU]D_L_P#X0GPU]A&@2>%1:_V3:>0/#<UZ=1ET/R_+VC3)+_\
MTQK3'E-<9E*[N: .\HKA-0^&/P\U6._AU'P7X;O8M4N=,O-1CNM)M9DO;O1;
M*33M(N+E63$LNFV$LMI:.V6AMY&BC*J2"LGPQ^'DMO+:R>"_#;VTVBZ5X;E@
M?2K1HI-!T.=+K1](=#'M;3],N42>RM3^[@E4/&JGF@#NJ*Y'_A O!9NWOSX6
MT(WK^((_%;77]G6WG-XEAM_LD.N-)L+'4XK4"W2\SYRQ (&"X%5XOAMX!@CM
MX8?!_AZ.*ULM;TVVC32[55@L/$DKS:_9Q 1X2WUB61Y-0B4!;EW9I0Q8T =M
M17$R_#;P!/!<6TW@[P[+;W=CHFFW4+Z7:M'/I_AN19M LY5,9#VVCRHCZ?$W
MR6K*#$%P*LCP'X,%X-0_X1?0_MJZ]+XH6Z_LZW^T+XBGMA9S:UYNS=_:4MJ/
ML[W>1*T.(RQ44 =;17#1_#/X?16T5G'X-\.):P:5JFA0VZZ5:K%'HVMSO<ZO
MIB((\"SU&>22:\@'[NXE=G=22:DE^''@*9;A9O"'AZ1;J+08;A7TNU830^%E
M5?#D4H*$.FB!%&F*>+0*HA"XH [6BN03P!X)CNTOD\+:$EW'KVI^*4N5TZW$
MZ>)-9MA9ZMK:R!-PU/4;4+;W=V,331#9([+P,W3_ (4?#32H!;:;X%\+V-NN
MJZ7K@AM='LX8AK&B&9M(U,(D07[;IK7$YLY\>9 9I"A&XY /0:*X^/X?>"(9
MK>>'PIH,<UI>ZSJ5M(FF6P>"_P#$4)M]>O(F" I<:O!^YOY5P]S'E92P.!6/
MPR^'IM/L)\&>'/L?]A'PQ]E_LJT\C_A'3=_;SHOE^7M_LTWO^E&TQY1G_>;=
MW- '<T5Q\OP^\#SSW-S-X3T&6>\O=!U*[F?3;9I+B_\ "]N+7PY>3,8R9+C1
M+8"#396RUI$-D14<41_#_P $0W$-W%X4T*.YMM3UO6;>==.MEEAU;Q)!]EU_
M48W$>Y+S6+?]QJ$X_>74?RREAQ0!V%%<,/AE\/5M19#P9X<%F-!E\+BV_LJT
M\D>')[HWTVB!/+Q_9LMX3=/:?ZIIR9"N[FK$WP]\#7#7#S^$]!E>[N-#N[EG
MTVV9I[KPU&(?#]Q(3'EI=&B41Z<Y^:T0!8BH% '8T5P&H_"KX;:O#+;:GX&\
M,7]O/K&I^(9H;O2+.:.37-:,1U?571XBIO\ 4?(A^UW)'F3F--[':*OO\/\
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MA4PN%6#P\:.#PU:2P/#N0X;$1RRMB<QQ& PL*N&P+KO+<)B,^S.K@LMI35/
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M[_H[OQ/_ .&\^#7_ ,[:NK_B!/%7_0SR#_P=F7_SO-?]2<R_Z"L#_P"!5_\
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M3#*8KJZJS3::LTVFNS6_X]KKLVFFTFI)-.Z:3379_EZ/56::332****!B,<
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M>9X:MB\#BL)A<75P%;%8?$T:.-H\RK86I*G&E3KT.2=";G1C5=3GA4I58/\
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M .#_ /[D?R$_:(/^>]O_ -_8?_BJ/M$'_/>W_P"_L/\ \57]>WV>W_YX0_\
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M+X30.\L"^&8-3\31,+GQ=-Y?Y4#4M-/)OK//M<Q#_P!GS^?_ -<_Z\HT^P
M%C9@   "VA  '   3  '04OV"Q_Y\K3_ ,!H?_B*^ZRKQLPF3X##Y?A>%:GL
MJ$6YU)YU%U<3B*C4\3BZ\EEJ4J^)K.56;2Y8KV5&"5+#T8Q]C"\8TL)0A0IY
M9+E@FW)XM<]2I)\U2I-_5]9U)WE*VB7+"*4812_R&O[1TS_G^L__  )B_P#B
MZ/[1TS_G^L__  )B_P#BZ_UY?L%C_P ^5I_X#0__ !%'V"Q_Y\K3_P !H?\
MXBO1_P"(_P /^B5G_P"'I?\ SN.C_7I?]"V7_A8O_F<_R&O[1TS_ )_K/_P)
MB_\ BZ/[1TS_ )_K/_P)B_\ BZ_UY?L%C_SY6G_@-#_\11]@L?\ GRM/_ :'
M_P"(H_XC_#_HE9_^'I?_ #N#_7I?]"V7_A8O_F<_R&3J.F=KZSZC_EYB/<9X
MWG/'L:_H)_X(+_\ !-A/VN_C1'^TO\5M$%[^SC\ ?$]A=:-97D+2Z;\5?C5H
M=SIFN:'X<:-\6VI>$/!"M9^(?&D4GVFRU74)=!\*WEK=V%_K\5M_>[]@L?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?K[CZ]L_ECC.:Y"/X>^ HA (O!/A*,6J:Y';"/P[I""W3Q.I3Q(D 6S A3Q
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M _@L7G]H#PCX9%__ &\WBC[<-"TO[6/$S6XM6\0_:?LOG?VVUJ!;-JH?[<8
>(3.8_EKF!\$?@R  /A+\-,#@#_A!?#''_E+H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $D KP# 2(  A$! Q$!_\0
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M0ZO/91Z9K,,6N,NCEM#N]2W:G+%81AKF6*-_0? ?QC\ _%CP5?>._A3KEO\
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MX":#_P#+^C_A/M4_Z)KX^_\  30?_E_0!Z117F__  GVJ?\ 1-?'W_@)H/\
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M_P"B:^/O_ 30?_E_0!Z117F__"?:I_T37Q]_X":#_P#+^C_A/M4_Z)KX^_\
M 30?_E_0!Z117F__  GVJ?\ 1-?'W_@)H/\ \OZ/^$^U3_HFOC[_ ,!-!_\
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M2**\W_X3[5/^B:^/O_ 30?\ Y?T?\)]JG_1-?'W_ (":#_\ +^@#TBBO-_\
MA/M4_P"B:^/O_ 30?_E_1_PGVJ?]$U\??^ F@_\ R_H ](HKS?\ X3[5/^B:
M^/O_  $T'_Y?T?\ "?:I_P!$U\??^ F@_P#R_H ](ZT5YO\ \)]JG_1-?'W_
M (":#_\ +^C_ (3[5/\ HFOC[_P$T'_Y?T >D45YO_PGVJ?]$U\??^ F@_\
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M .7] 'I%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 44A('7_'/!/ '7@&EH ***/\_Y_P \]J "BBC_ #_G_/\ (T %%%%
M!1110 4444 %%&?\/3I_G\1STHH **** "BBB@ HHHH **3(QG/&,Y]NN:7_
M #_G_//:@ HHHH ***K7A*VMPRDJRQ.58'!! )!![$'D'UII7:7=I?>TOU)E
M+EC*5K\L92MWY8RE;Y\MOF6,CU'YBC(]1^8K\X6\9^,0S_\ %6^)L"23 _MO
M4L8#L.#]IXP.Y]@.F"A\:>,1_P S=XG&>PUO4>.<8_X^N<8K]+7AEF#5UFV
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M'_H;_$__ (.]1_\ DJC_ (ACF/\ T-<!_P"$^-_^2#_B.F5?]$[FW_A9EO\
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M +Z'^-&]/[R_]]#_ !K^%?\ X:R_:B_Z./\ CM_X>'XA_P#S14?\-9?M1?\
M1Q_QV_\ #P_$/_YHJ]S_ (DLXL_Z+OA?_P -/$?_ ,F?+_\ %2_@7_HUG&G_
M (?^%O\ YG/[J-Z?WE_[Z'^-&]/[R_\ ?0_QK^%?_AK+]J+_ *./^.W_ (>'
MXA__ #14?\-9?M1?]''_ !V_\/#\0_\ YHJ/^)+.+/\ HN^%_P#PT\1__)A_
MQ4OX%_Z-9QI_X?\ A;_YG/[J-Z?WE_[Z'^-&]/[R_P#?0_QK^%?_ (:R_:B_
MZ./^.W_AX?B'_P#-%1_PUE^U%_T<?\=O_#P_$/\ ^:*C_B2SBS_HN^%__#3Q
M'_\ )A_Q4OX%_P"C6<:?^'_A;_YG/[J-Z?WE_P"^A_C1N7^\OYC_ !K^%?\
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M0U;4KRZFN-1UC6=0=$DO]7U6[O-1NBB":Y=8XU7V=LX..OX_T(I:PJ9KFE;
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MB;A.67)E&+4N67+S8K#<KERRY5+DAS<O,X\W*U+EYN5\W*XU#P+S+GA[3B+
M*FYP]HZ> Q_M.3GCS^SYZSI^TY%+D]HG3Y^3G3@I1G_++_P4=_:>M+V1_P!F
M/P!K4$VDZ#JEMJ7QEUG3;ZW-MK_C;3&,FG^!$NH966]T#P!<EI=5C4M8WOC,
M%PTK:' ]?DAOM_\ GM%_X$Q?_%5_=U+^S5^SY<2RSS_ _P"%$T]Q-+<W$\WP
M_P##$DT]Q<2-+---+)I;2232RR/++([,[R,SN2Q)+/\ AF3]G?\ Z(7\(_\
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MH>I)<M%H'B-+=O$SS2'2+F!&\2M*FA16YB74;&222_N)A(]KJ%JA5%=<0?%
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M'WI17Q'XL^('QN\3S_ K1]0COO@3#\3OB7%I\]_X'U[P5XW\07GA6;X3>/\
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MYG\;.:7V5]T?_E?<EY_O3?\ ?3?XT<_WIO\ OIO\:BP/?\S_ (T8'O\ F?\
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M.L7<USX9\"Z;;:_K6LQR6UA?>+-/\1Z?X"_L5[73&N;/=7X2_%I?#.BVNO\
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MGA2VGTR_^'6C_">[M6N]0"S> -!EN9])\/,ZW8D$%I+=W#K<*XO',A$MPX
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M)&9O3GGU6 MLT[KN<;179_\ "N/'_P#T*6L_^ R?_'Z/^%<>/_\ H4M9_P#
M9/\ X_3_ +7RK_H:Y9_X<,%_\UD_ZO\ $'_0ASO_ ,-&:?\ S <9179_\*X\
M?_\ 0I:S_P" R?\ Q^C_ (5QX_\ ^A2UG_P&3_X_1_:^5?\ 0URS_P .&"_^
M:P_U?X@_Z$.=_P#AHS3_ .8#C**[/_A7'C__ *%+6?\ P&3_ ./T?\*X\?\
M_0I:S_X#)_\ 'Z/[7RK_ *&N6?\ APP7_P UA_J_Q!_T(<[_ /#1FG_S <91
M79_\*X\?_P#0I:S_ . R?_'Z/^%<>/\ _H4M9_\  9/_ (_1_:^5?]#7+/\
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MKG_A@G]LO_HVWXI?^$[#_P#)U'_#!/[9?_1MOQ2_\)V'_P"3J_:_^(@<!_\
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M6&PV(6"R15(PRIU\+&&)SBK]<I^TI972J.Y$,9XQD+_4>G]3DY/%2TU1C_\
M7QU/3@8_S^+J_P _EM_7]?UII9+_ %T6B_K]?Z[ZWN4444QA1110 4444 %%
M%% !1110 4444 %%%%  1D$'H>#7*:MX)\,:OJL'B2?0]%3Q?865U9:+XR.A
M:+>>)M!2YAGA\S2=3U+3[V2W,0N)62%UEM)"\B7%O-#++%)U=% ' ^!OAMX8
M\!>'=)\.Z9;R:E_96HZIKK:WKBVE]KVI>)M>N[Z_U_Q/J%]':VT9US6[W4]0
MGOKFRMK.%4NY+.TM[6P6*TCU'\"^"9;C3;J3P?X7DN='AN;;2;A] TIYM+M[
MV\BU&\@T^5K0O9PW6H00WUQ';M&DUY%'<R*TZ*XZJB@#D]8\!>!_$">5KW@W
MPKK<0U1M<\O5O#VDZC'_ &T]LMD^KE+RTF4ZF]FJVCWQ'VEK91 TIB 4+;^!
M/!%KK,OB*U\'>%[?7YM,BT6;6X- TJ+5I='AMXK2'2I-1CM%NWTZ*T@AM8[)
MIC;);PQ0+&(HT4=710!R^D^"/!F@Z+>>&M#\)>&=&\.ZBUX^H:!I>A:78:-?
M/J$:Q7SWFF6MK%97+7D2K%=&:%S<1JL<I9% %R?PQX;N4\NY\/Z)<)]HU*[V
M3Z58RK]JUB">VU:YVO P^T:I;7-S;ZC-_K+V"XFBN6D25U;<HH PIO"_AJXN
M'NY_#VAS74L7D2W,VDV$L\L'V"XTKR))GMVD:'^S+NYT[RV8I]AN)[3;]GFD
MC:IHW@CP9X=01^'_  EX9T.,:G+K032-!TO34&L3VIL9M5"V=K"JZC+9,;22
M] %P]J3;F0PG97444 <9;_#CX>VEQHEU:^!?!]M<^&I[^Z\.W%OX:T:&?0;G
M59VNM3N-&ECLE?3)M0N6:XO9+)H'N9R99B\GS5U%C86.F6R6>G6=K86D1E:*
MULK>*UMHVFFDN)F2"!4B1I9Y99I2J@R2R22/EW8FW10 4444 %%%% !1110
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MH$NO%!2TTK4]'B+^,_%<LK6FK2F6Z>>:36&EN+Y'.++4IWDO].0".QN+= %
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M0W?BORI-!A\.,P\:^+1-_9\%P+E)EN!K(G353(H636ED&K2Q9@DO&A)0V)O
M>ASR7,KW/B0-=ZCHNJ2B+Q;XFA07.@PF"Q2&.+542WM)8SG4K&%8[/5I,3:G
M#=2@/3Y8]E]R_P @_K=__)'6^0.,L<X]./\ /IW_ "-'D#^\?TKE(? NB07-
MK=1W/B,RV>M:IK\2R>+/$LT+7VL6_P!ENXIX)=5>&YTV.+FQTB=)-,TV;]_8
M6EO-\]5(_AQX>CMH+477BIHK?0K[PZC2>-?%LDS:?J-S+=7$LMP^LM--JB2S
M.MKK,LCZK9PA+>UO(8(XXU7+'LON7^0?UN__ )([;R!V8_E1Y _O'\JXZ;X?
M:#.EU&]UXG"WEKHEG+Y?C'Q5$RPZ RO8M \6KH]M/*4 U*Y@:.XU=2RZG)=J
MS SGP+HANS>_:?$8F.OGQ)M'BSQ*(/[1,)M_*^S?VK]G_LH1G(T3R_[($F)A
M9"4!Z.6/9?<O\@_K=_\ R1U7D#^\?R%.6(*<YSU'(P3GCKU^F.".><YKC8OA
M]H,,=M$EUXG*VEKKEI$7\8^*I':+Q 9&OVF=]79[B>(R-_9ES.TD^C@*NER6
M@10(I?ASX?EM9[1KOQ4(KC1;'0)&3QKXMCF6QT^=;F"6&X365G@U)Y% NM7B
MD34[R+,-U=2Q,R%\J[+[E_D'];O_ .2.S^S+SSR3G[H_Q_SSQ1]F'J/^^/\
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MH_*O(Y86U4Q3:=&O-AI4J/IVF/\ O-/M;9_FHLNR_P# 8_\ R N5=G_X%/\
M^6'4_9U]1_WQG^1H^SCCD<_[/_U_K7'1?#OP_%;P6J77BDQV^BZAH$;/XT\6
M23&QU.9Y[F66>36&FFU)'D86FKRN^IV,86*SNX(T50Z?X>Z#<)=1R77B<+>6
M>C6,QB\8^*H7$.A,C63PO%JZ-;W,A0?VC=P&.YU4%AJ4MT&()9=E_P" Q_\
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M_P"BMR'_ ,0GAK_Y6?TC?\/T?AI_T;W\2_\ PK_!?_Q5'_#]'X:?]&]_$O\
M\*_P7_\ %5_-SEO;\F_PHRWM^3?X4?\ $J_@M_T3F9_^)5GO_P L#_B?#Z2G
M_16Y#_XA/#7_ ,K/Z1O^'Z/PT_Z-[^)?_A7^"_\ XJC_ (?H_#3_ *-[^)?_
M (5_@O\ ^*K^;G+>WY-_A1EO;\F_PH_XE7\%O^B<S/\ \2K/?_E@?\3X?24_
MZ*W(?_$)X:_^5G](W_#]'X:?]&]_$O\ \*_P7_\ %4?\/T?AI_T;W\2__"O\
M%_\ Q5?S<Y;V_)O\*,M[?DW^%'_$J_@M_P!$YF?_ (E6>_\ RP/^)\/I*?\
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M3X5+#\,-&LA::MX4ETOS;<K[I^T%X*N/A_8Z/<_#>#XM?9M1U+Q%XF\3^%_
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M;^%-5^+,R^&=8O<7?Q(BD)M99/TWI #GKGC&,#D^O_UNE 'YD^#[OXWV.N_
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MQ:*3#>A_[^1__$T8;T/_ '\C_P#B:UL_/_P&7_R)S<OG'_P./^8M%)AO0_\
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MK7P;KGB..\E\!^$]:L2DCC6?%T>@^*1%&DR?V?-H\$<ZDZO8M+T7Q+^)6J>
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MB2UA@\4Z'-+?7NKZ=9HFH6[-<W^@IYNLVD(#_//ID9#WD8RT"X+XS4"?$GP
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M_P .*_'7_1R?@K_PT_B'_P">!1_PXK\=?]')^"O_  T_B'_YX%?T*R_$/P'
MEU)-XLT"..RM='O;MFU&V M[3Q RIHES+\_R0ZJ[JMC(?EN&8!"214Y\=^"A
M=&R/B;0Q=C73X9-L;^W$P\0K"9SHQ3?G^T!"#*;;'F;!NQBC_B9[QL_Z*S"?
M^(QPY_\ ,(?\2-?1K_Z(C,O_ !-.+?\ YN/YX_\ AQ7XZ_Z.3\%?^&G\0_\
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MNJ+K#Z:8M1MW%\GA_)UMK;#_ +Y=*Q_II3(@/#X- '8T5Q:?$;P&\"7*>+M
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M_P#GWZ^W3\:.>^.@_/O^'I110 4>@]NO^?6BB@!.>?3C&.OOGU_3CCWI:**
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M9H__ (;OP-_\IJ?_ !)[XJ_]!_!G_AZS#_YP$_\ %1?P,_Z$_B'_ .&'*/\
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MF+CP+!;)-<Z_%>./%EA,;*WL(BV@W*JM@OVH^(9<0O A1M'!\RY>X VUW%%
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M#$XUKQG]K\H^"(!:_P#"2)IOVO\ X2FQS_PCK0J[^)?L_P!AW^8DQ: :'O\
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M%/\ )C_P]J_;M_Z*IX:_\-9X%_\ E;1_P]K_ &[?^BJ^&O\ PUG@7_Y6T?\
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M?[#N$D5QBW&C%_M,@/G"Y"C;5>WUWQS)]D^T> 8+?SEUPW>/%VGS?8VL0_\
M8B+ML%^T_P!NE4$C)Y8TD/F?[1M(/=T4 < WB#Q\+1Y5^'ML]VOA^WU!+/\
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M_LXW/C'3-!-SJEO<6GP[UKPG#XE33/)MX+G4;.R%I/J%N3:1R3VUF)'MT<E
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MR(MOZ['^AW^;_/3[T%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[7TKS/*_M33O,^U"P\O[;;>9]O*AQ9;?-W?:BA#"VQYVTA@A!% &C1_G_/\
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M%7_Q.7X9?]"3C7_PWY)_\_3'_BG%XW?]#[PX_P##SQ!_]#1_(;@_[7_?IO\
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M6?[ /F>3_P *Q?S?M1L?+_X7#\3O,^W!2YLMG_";;OM80;S;8\[9\VS&:/\
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M8BLI$D=KL?[2Z96 *?,*X;"'6]&">8=7TP)]C74-YO[0)]@9S&M]N,VW[&9
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M%+=?!_A9;>/2I=#C@7P_I(A31)Y1//HZ1"T"+I4TX$TNGJHM))0)'A+\T44
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M@!9/!'@R:.>&7PCX8EBNM/L-)N8I- TIX[C2M+*-IFF3HUH5ET_3FCC:PLY
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'$4 HH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #D KP# 2(  A$! Q$!_\0
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M$GCWXGWWB^'X@3ZXYU'2=#U_Q5I/AF^TGP_JU^\-S-="VN[JU^J/VK/VT/\
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M\%/C9;>./C1KWPW^)?@7PGHOQHUCPIJE[=ZQX'U3Q#XK\(R:#\//#WP_NYM
M9/$>G:%>7LL'A]-3TR75;&2WLKNX(N;>]BB5&^B/AQX%T3X9>!O"7P^\-BX_
ML/P9X?TSP]ILE[+]HOKBWTZV6W^UWT^%$U[>2+)=WDJHBO<S2,B(I"CS<4L%
M'#T?8NA]8?L+QHSKRER/"Q==XE5?W<*KQ?-[.-%V<%.\?9JG)^%F$,J6"PTL
M+]66+?U/F6%JXVI-TO[.@\;/'QQ2]A3Q/]IWC1CA9)>Q57F@J2H5)=O1117
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MWBFVU"#1-9U'PQ::Q-I/PO\ #VN^.K/2VU+PMX7U^^\1K?Z6T4FMV?8^&_\
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MLN@Z'-'J<4VC:5-%K;I)K,<NGVDD>KR1PQ6Z2:HCPE=0=+>""!7NQ,RPPQ1
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M,>?[ @]>*3_A87@/;C_A,O#.<]M8L,8Z@?ZX=\?EQCI74?V5I?\ T#;#_P
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M7P%_T.7AK_P<V'_Q^ND_LK2_^@;8?^ =O_\ &Z/[*TO_ *!MA_X!V_\ \;H
MYO\ X6+X"_Z'+PU_X.;#_P"/T?\ "Q? 7_0Y>&O_  <V'_Q^ND_LK2_^@;8?
M^ =O_P#&Z/[*TO\ Z!MA_P" =O\ _&Z .;_X6+X"_P"AR\-?^#FP_P#C]'_"
MQ? 7_0Y>&O\ P<V'_P ?KI/[*TO_ *!MA_X!V_\ \;H_LK2_^@;8?^ =O_\
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M_P ;H YO_A8O@+_H<O#7_@YL/_C]'_"Q? 7_ $.7AK_P<V'_ ,?KI/[*TO\
MZ!MA_P" =O\ _&Z/[*TO_H&V'_@';_\ QN@#F_\ A8O@+_H<O#7_ (.;#_X_
M1_PL7P%_T.7AK_P<V'_Q^ND_LK2_^@;8?^ =O_\ &Z/[*TO_ *!MA_X!V_\
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MK4:D)2A4I5(3BVI*W]/7_"Q_ 7_0X^&O_!S9?_':/^%C^ O^AQ\-?^#FR_\
MCM?S"_\ $1;-_P!&=:1_X<^U_P#F,H_XB+9O^C.M(_\ #GVO_P QE5_Q#CB_
M_H60_P#"[ ?_ #6:_P#$HWT@O^B$A_XE'"'_ ,_3^GK_ (6/X"_Z''PU_P"#
MFR_^.T?\+'\!?]#CX:_\'-E_\=K^87_B(MF_Z,ZTC_PY]K_\QE+_ ,1%DQ'_
M "9WI  Y_P"2G6O./^Y+]_P^G!3\.>+_ /H60_\ "[+_ /YJ?_!V#_B4;Z0/
M_1"0_P#$GX1?Y9[?T[MI+5I/^GH?$;P%G'_"8^&A_P!QFQ_K*,__ *SVI?\
MA8W@+_H<O#7_ (.;#_X_7\\'P(_X+^?#_P"('Q<\$>!_BQ^S_I7PE\#>+-8A
MT#4OB.WC>QURP\)WFI?Z/I6HZY9R^&]+6+06U%[>VU74OMB+I5M.U_,CV\$N
M/Z/X].TJ1$==.T\JZAD86EL0RE58,"(R""&!&#R.1D<UX&<9!FV05:-+-<)+
M#2Q%-U*,O:4JU.I&,N2:C5H3J4W.$K<\.93BI0DX\LXR?Y9Q_P"%W'?A=C<O
MP''.05LDKYKA:N,RZ;Q6 S#"XNA0K?5ZZHX[+,5C,'*MAZKIK$89UXXFC&MA
MZM2C&EB*-6IS_P#PL7P%_P!#EX:_\'-A_P#'Z/\ A8O@+_H<O#7_ (.;#_X_
M72?V5I?_ $#;#_P#M_\ XW1_96E_] VP_P# .W_^-UXQ\ <W_P +%\!?]#EX
M:_\ !S8?_'Z/^%B^ O\ H<O#7_@YL/\ X_72?V5I?_0-L/\ P#M__C=']E:7
M_P! VP_\ [?_ .-T <W_ ,+%\!?]#EX:_P#!S8?_ !^C_A8O@+_H<O#7_@YL
M/_C]=)_96E_] VP_\ [?_P"-T?V5I?\ T#;#_P  [?\ ^-T <W_PL7P%_P!#
MEX:_\'-A_P#'Z/\ A8O@+_H<O#7_ (.;#_X_72?V5I?_ $#;#_P#M_\ XW1_
M96E_] VP_P# .W_^-T <W_PL7P%_T.7AK_P<V'_Q^C_A8O@+_H<O#7_@YL/_
M (_72?V5I?\ T#;#_P  [?\ ^-T?V5I?_0-L/_ .W_\ C= '-_\ "Q? 7_0Y
M>&O_  <V'_Q^C_A8O@+_ *'+PU_X.;#_ ./UTG]E:7_T#;#_ , [?_XW1_96
ME_\ 0-L/_ .W_P#C= '-_P#"Q? 7_0Y>&O\ P<V'_P ?H_X6+X"_Z'+PU_X.
M;#_X_72?V5I?_0-L/_ .W_\ C=']E:7_ - VP_\  .W_ /C= '-_\+%\!?\
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M\L5%\N7U:5?]L!(=I))^]@$?R_GU/USQ3BYWD G!7('OQTXR<>W6OR=\./\
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M.O)JMD]QK%Q*\%E%HEI:/8ZLUMJTUO826;+X6_&G1KGQ_:^";KXPZ1=:5/\
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M[80S>(6EUB%)C]<<Y]L?CFD2+111G'^<]P/ZC^?2@ HHSS_+Z\_X44 %%%%
M!17-:NWC$7%U_8,?AM[7^R2;(ZM+J:3G7/ML "W0LX9(QI7]G_:6+Q$W?VP0
MJ$\@NPB+>-_MA B\*_8/[5F )FU;[7_8?V FW8J(/)_M7^U,+.F[[(+'+1N9
M\*0#JJ*XK?\ $3[,"8?!?VS^S+$N/M&M_9AK!U _VFH;[.)?[-72MK6+E?M+
M7^5G1;?#U:W>.?.8>5X4^S_;]6"'SM7\[^RQ9(="9AY.S[>^H^8-64'[.EEL
M:S>2?<M '5T5QBM\0O+&Z+P;YIMM&SMGULQ_;#.W_"0#)M]WV9+78='8XDDN
M-RWH2/::E9O'F\[8O"7E^;K>W=-K&_R0O_%.%@(-OFR-_P AH [8U_X\3(>
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M^$H"DVX;R8XL?V 6'F2R;O[06)16),OC%[C4SJ%K\.FE%U:#1S)+J[S/I?\
M:!^U'4S-;;DNUTGYK-;0M =1RLK);?-7J93F']G8IU_8.O\ N:E+DC/D?ONF
M^9ODJ:+DVY=;K56U^QX&XJ?!V=SS=9?+,^; 8O!?5HXAX9KZS]6_>^T6'Q.E
M/V'P^S2DY_'&VO\ .)A_^>4W_?B;_P"-T8;_ )YS?]^)O_B*_H]V:YO?%K\/
MO+\[7?+.;[>;<6__ !3)<?9R/.>ZR->"_NX[?!TYI)>*0)KW&ZV^'@^71-VT
MW_WBQ_X23 -O]U$V_P!AY.9&R-0\L $_1_ZV2_Z%M3_P>_\ Y0?KW_$>I_\
M1)5?_#O+_P"=)_.'AO\ GG-_WXF_^(HPW_/.;_OQ-_\ $5_1V5U[G;:_#SIK
MF,M??>5E_P"$;)Q;_=D3<=<ZF-BHL/,&2'[=:R,VOP^"^=HN[F^S]G,+'Q&5
MS;X\Y+C9_8@/[N2'=]O,<F*/];)?]"VI_P"#W_\ * _XCU/_ *)*K_X=Y?\
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M?9-OVN.]V+HZG]S):[FO628!3#_PBNN^3_R+GPU\_P"QZR0/L5]Y7]H"<_\
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MJRK>-OM #Q^%_LWV_2\E9=6,W]EFU/\ ;3 &$1_;UO=HTQ"?(DM2S73)*-I
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ML11JX>O0HU:->G.C6ISI4W&I3J1E"<))4KVE&35XN,D[234HQE'EQ^29-FN
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MSHHHH **** "C'&.O&.><_7UHHH * ,=*** "DQUY/(QUZ=>1Z'GK]/2EHH
M.E!Y!'KZ=:** $QU]R#^6.GY9^N?6@#'KT Y.>G?ZGN>]+10 >GM_@1S^?YT
M8Z^_)_+'\@*** "BBB@ H]??_#''Y?GFBB@ Q_GMV[>HQQZ<TF!@#L,?ITI:
M* #OG_\ 5QG_ !Y_"BBB@ H]??\ PQQ^7YYHHH /7W_PQQ^7YYHZ?KU]SG_]
M7M110 4444 %<-X+^'GAKP(NJ#0[11+JFL^(=6DN[B&T:]MHO$GB+4_%-WHU
MM>16T-PNAVFM:SJ=UING222167VN18SSFNO-]9+(86O+595FBMVB-Q$)!<3*
MSPP%"^X32HK/%$1OD569%(!-1_VGINSS/[0L=GDO<;_M=OL\A)1 \^[S,>2D
MQ$+R9V+*1&6#G% 'G"_ WX0!O&KGX<^$W;XCLK^/#)I-O,/%<J7*WD,VMB56
M%]<6UTD<]G<2@SV<L,#VKPF"'RUO_@C\*-5L9-)U+P)X?O\ 0Y-&\/:"GA^Z
MLDET"UTSPK<ZG=Z%#8:*Q_LZPELIM8U$?:K2VANIX;EK:XFEMP(J])^WV._R
M_MMIO\UH"GVF'>)UC\YH=F_/FK#^]:/[ZQ_.5V\AO]IZ=M#_ -H66TQQ3!OM
M<&TQ32>5#(&\S!CFE_=1/G;))\BDMQ0!RZ_#CP"GBBP\:Q^#?#<7BS2M'3P_
MIGB&+2+*/5+#18HY88=-M+E(5>"T@@GGMK>.,KY%K<7%K#Y=O/+')@2?!?X<
MP> O%?PW\/>&=)\'^%_&5MJD&M6?A73['21*^KV_V6\N1'';/;-,UNL=O&LT
M$D,5M%';)$+:..%?2#J%@"5^W688/,A!N800]LH>Y0C?G?;H0\Z]8E(:38I!
MH&HZ><8OK,Y^S@8NH#DW63:@8D.3<X/D8_UV#Y>[% 'BUY^S9\%KUO#=O+X
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MJ<Y/FWT*+%<M*@"UT5% ',CP7X/5%B7PKX<6-8M'@5!HFFA%A\.N9= B"BV
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M.,9P\*^,YPG&,X3AEV&G"<)QC.$X3AG$H3A.$X3A.$IPG"<)PG.$X3E^V?\
MPBGACS!+_P (SX=\T7.FWHD_L>PWB\T:W-IH]T&^S[OM.E6K-;:=-GS+*!C%
M;M&A*U$/!OA(1^2/"GAD1?9=3LO*&AZ<(_L>M2F?6;38+;;]FU:9FFU*#'EW
MLI+W"R,2:_%'_B(&_8F_Z%;X]?\ A!:)_P#-I1_Q$#?L3?\ 0K?'K_P@M$_^
M;2C_ %)XK_Z$.9?^"H?_ "XK_B73QV_Z-3QK_P"&RA_\]C]L_P#A$_#'F^?_
M ,(UX>\_[7I-_P"?_8]AYWV_0;=;30[WS/L^[[7HUJB6VEW&?-L(%6&V:*,!
M1"?!GA'RA;GPGX9\@VNHV'D_V)IHB^PZQ<&[U:RV?9MIM=4NF:XU"WP8KR=F
MEN$D<DG\4O\ B(&_8F_Z%;X]?^$%HG_S:4?\1 W[$V1_Q2WQZ[<_\(%H?<X[
M^-1]?_KT/@GBNS_X0<R^=*'_ ,N#_B77QV_Z-3QK_P"&RCZ_]#9]$S]M$\+>
M&!,)AX:T 3?:M,O_ #1I%B)?MVC1&VTB\\P6X(NM+@+0Z=/GS;.)F2W:-"12
M+X(\&+$(1X2\-+$+34; 1#0],$8LM8G%UJUF%%MM^RZG<@7%_!CRKR8"6X61
MP&K\HO@;_P %L/V-?CE\5_!OPDT@_$GP=KWCO4QH7A[5_'GA?3-#\,RZ]<*Q
MTK1[S5K?Q-J7V*[UNX"Z?I9FMEAN-1FM[0SQ2W$6?V$!&T'(Y Z'CD9X_I[5
MX^993F645:=',\%B<%5JT_:TX8FGR.I3YG!R@TY1DHRBXRM-N+TE&-U?X/BO
M@?C'@/&X?+N,^&LXX9QV,PKQN$PV<81X6IB<*J\\/*O0:JXBE6IPKTYT:CIU
MY2IU$HU*=/GINIRT/@/P1;P16MOX/\+P6T%MJ=E#;PZ#I44,-GK2JNKVD426
MJI';:HBJFH0*HCO%51<+)@58_P"$/\)"03#PQX?\T7&DW8E_L?3_ #!=:# M
MMH=P'^S[A/H]NB0:7*#OL(56.U:) %KHZ*\X^6.8/@GP:8C ?"?ALP&UU*R,
M)T33?*-GK-P;O5[0Q_9MIMM4NB;C4(,>5>3DRW"R.=U3KX2\*K-]H7PWH*W'
MVRPU#SUTBP$OV_2K=K33+WS!;[Q=Z=:LUO8W&?-M8&:*!T0E3T%% '+#P-X+
M$/V8>$?#0MOL-WIGV<:%IGD_V;?W(O;ZP\K[+L^QWEX!=7-L (9[@":5'D :
MK/\ PB7A;SQ=?\(WH/VE;^VU47']D6'GC5+.S_LZTU$2_9]XOK:P_P!"@N@W
MGQ6A-O&ZP_)7044 <H? G@DV_P!C/A#PP;0Z=)I!MCH.E^0=)FOSJLNF&'[+
MY9L)-3)U%[3;Y#WQ-VT9G)DH7P)X)2V6R3PAX86S33KK2$M%T'2Q;)I-]=&^
MO=,2 6HC73[N]9KRYLPOV>>Y9IY(VD.ZNKHH Y\>$_"ZS_:1X<T(7(O[/5!.
M-)L1,-3T^V-G8:AYOD;_ +;96A-K:76[S[>W)AB=(_EJM_P@_@OR?LW_  B/
MAG[.-/N]*$']A:9Y(TN_N1>7VG"+[+L%C>W8%S=6NWR+BX FE1Y!NKJ:* .?
M/A/PL9Q<GPWH)N1J%EJPG_LBP\X:KIMG_9VG:EYOV??]OL=/_P!!L[O=Y]M:
M?Z/#(D/R56'@?P8(/LH\)>&A;?8+K2Q;_P!AZ9Y TR^O/[1O=.$7V79]AO-0
M)OKFUV^3/=DW$B-+\]=310!SX\)^%A.+H>&]"%R-0M-6%P-)L//&J6%N+2QU
M(2^1Y@OK.U MK6[W>?;P 112)& M5O\ A!O!7DBV_P"$1\,_9QI]SI(@_L+3
M/)&EWEV=0N].$?V78+&ZOB;RXM /(FNB;B2-I3OKJ:* .43P)X)BMX[2+P?X
M8CM8;&_TR&VCT'2T@BTW59%FU.PCA6U$:66H2JLE[:JHANG4-.CD U:_X1'P
MH9!*?#6@&476F7PD.D:>7%[HML;/1[L.;?=]ITJT)MM.GSYME;DPV[1QG;70
MT4 <Q_PA/@WRO(_X13PWY/V74['R?[$TWROL6M3&XUBTV?9MIMM5G)GU&#'E
M7LO[RY61_FJ7_A$/"GF^?_PC.@>>+S2M1$W]D6'FC4-"@%KHE\)/L^\7FCVR
MK;Z9<AO.L(5$5J\2 +7144 <O_PA'@SR1!_PB?AOR!9ZAIXA_L/3/+%CJUPU
MWJMEL^S;?LNI73-<W]OCRKN=FEG21R6J<>$O"HE\\>&M!$_VS3=0\X:18>9]
MOT> VNDWN_[/N^UZ7;,UOI]QGS;.%FBMWC0D5T-% '+KX(\&+&(5\)>&EA%G
MJ.GB(:'I@C%AK$XNM6L@@MMOV34[D"XO[?'E7DX$MPDD@#5'%X#\#V]NEI!X
M.\+PVL5IJ=A';1:!I4=O'8ZUC^V+-(4M1&EKJNU?[1@51%>[5^TK)@5UE% '
M.CPAX46=;E?#.@+<)>Z?J23C1]/$RZAI-J++2KY9!;[UO--LU6TL+D$36EL!
M# \<8"U7/@3P2;?[*?"'A@VWV!M+^SG0=+,/]F/>MJ3Z?Y7V79]B?47:_:UV
M^0UXS7)0S,7/544 <\?"/A5IC<GPUH!N#>W.I&<Z1IYF.H7EH+"[OC(;?>;N
MZL56SN+C=YLUJ!!([1 +4 \$>#%C6%?"?AL1);Z=:I$-#TT1K:Z//]JTFV5!
M;!5@TRY_TC3X@ EG-^]MUCD^:NHHH YH^#/![%BWA7PZ2YU<N3HNG$N=?7;K
MA8_9OF.LJ2NJ$Y^WKQ=>:.*4>#O"2RK,/#'A\3)<:5=I*-&TX2)=:%"+?1+E
M7%MO6?2+<"#3)00]C%^[MFB3 KI** .5/@7P4T!MF\(>&6MC8W>F& Z%IAA.
MFW]Z=2OK#RS:[/L=YJ#-?75MCR9[PFYE1IB7K0A\-^'K>2ZE@T+2(9;ZX^UW
MLD6FV<;W=T+>"U%S<LD(,T_V:UMK?S9"S^3;PQ;MD2*-JB@"HP)((R/F'WL$
M#T)P02.N0""<C!ST_*+PA<:KX$^&_BC4]-\&?$:+]L;3;+Q"GQ4\;7G@7QQX
M@D>SU+XFZ3;^-/%&AWUY;/X'\;V5OX5NSXC^$_AC29=6$>DZ9;V-KHR"SO\
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M?QM=^%[;X#>,[[QQK.L^&?BVUMIUS>V5_K5GH5]HL^LV7A"YO$L]3\.MX?\
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MCZPEW\<H;GXS>#?%L>KR063)?>')O#O@;2/$-B%O'M;VWFU7_A$=$:?P\HU
M^W^#_@]XC\'?M WGB;P_X/L=/\#SVEW:7.MZSXDM]5DLM%B\.Z3I>@^'OAY8
MV"6.KZ#IMO?V!FU+PGXAL]1\-V3/?:QH6K?VGJ+6Z 'U_1110 4444 %%%%
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MSM?YVTO>Z=M+IVT2;****!A1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@!".G)&/U^O\ GBEHHH *3';CKGI[Y_//?UYZTM%
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MYQZ$9_T+T_X)J_\ !/\ C1(T_8Z_9Y5$4(BK\,/# "J  %'^@=   /3M3_\
MAVQ^P#_T9W^SU_X;#PQ_\@>P_*OM\O\ $_(,MP='!T,JS;EIIN=253 >TKUI
MOGK5ZS4K.I6J7D[64(JE2A[E&"/Z,X2^FGX8<&\/Y?P]E? /'$Z.#A.>)QE;
M,>%5B\TS'$R5;,LUQTH.,9XO,,4YUIJ-Z6'H0P6 PZCA,OPT%_GG@KZ_DQ _
M 9Z?_JI?E_O?^/'_ !K_ $+_ /AVQ^P%_P!&>?L]?^&P\,?_ "!1_P .V/V
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MM[KMGYR:*S0'^P;=+G[4)!<<V6L;_(T*?&-1N%>(+%MR>NHH XM?&0,:2?\
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M %>?M^']:_B)_P""[W_*0?6>O'P0^$I_)_%WH0?_ -9^M?V[3]OP_K7\1/\
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M1X;15\W);7(/WNE@#-['\\&]>:B;XD^ %MVNV\9>'%M4LM8U)[@ZM9B%-/\
M#]Y_9^N7C2>;L6VTF^_T34)B0EK<?NIBK\4 =M17)IX\\%R72V,?BG0GO'U2
MQT1+5=3M3.VKZG8'5-.TT1B3<;V]TX&^M;?'F36O[Y%9.:I?\+-^'GV0W_\
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MA.C:SJ#Z3I.IB3S=OV'4=3C>PL[C/EW%TC0QLS@B@#MZ*Y%O'_@A9VMF\5Z
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M.<VS^*]!6X6]UW3FA;4[42"_\,6Z7?B*S*&3<+G1;61+C4H<;[2%UDF"J0:
M.FG[?A_6OXA/^"\-Q;Q_\%"=962>%&_X4A\)#L>2-&P6\7G.'(.,=#P#R.2,
M'^T\?$/P$\:S#Q?X=,3P>'KA)!JMGL:#Q9(T7AF96\W!CUZ56BTMP=MZZE(=
M[ BO&_%WA7]E'XBZ]J_B#QIX8^!GC7Q#HYTS0-;UKQ/X?\%>(=8TYFU&71](
MTC4-1U2PO+N#.K2S:?8V4LP47DLD$$8DD85]5P?Q#1X9S:695L+5Q<)8/$87
MV5*I3I2YJ[H-3YJL)QM%46FDDWS*ST:?[7X!>+&"\&>/*O&&89)C>(,/4X>S
M?)%@,!C<'@*ZJ9G++7#$/$8ZAB:#IT?J$N:G[+VDW5@X2CR2O_G!&ZM/^?JU
M_&X3/U^\.O7@8]*/M5I_S]6G_@0G_P 77^B__P *1_8O#O&?A-^SB'2?7K9T
M_P"$ ^'FY;CPM;B[\2P$?V/GS=!M2+C54^]9Q?/,%7FFCX)_L6M@CX4?LX$,
MNA,"/ 7P[(*^*&V>'&&-'^[KC@KI9Z7;<1;CQ7Z?_P 1?R[_ *$>-_\ "W"?
M_*3^T/\ BH%PQ_T:_B7_ ,2CAW_YU'^=%]JM/^?JT_\  A/_ (NC[5:?\_5I
M_P"!"?\ Q=?Z+I^"G[%H&3\*/V< -NN/G_A ?AWC9X994\1-_P @?[NB.ZKJ
M9_Y=&8"7:>*>/@A^Q@651\)?V<MSS:);(O\ P@'P\RT_B6!KGP]"H_L?F36[
M='FTQ>MW&I:+(&:/^(OY;_T(\;_X6X3_ .4A_P 5 N&/^C7\2_\ B4<._P#S
MJ/\ .?\ M5I_S\VA]A.G/X;^?IWKT+X4_#?QC\;_ (E>"/A%\+]+/B7Q]\0?
M$%CX<\-Z5;R*4-S>2,;G4M1F7<MCHFBV*7.L:]JD^RUTW2+&[O)G58OF_P!!
MG_A2_P"Q48C./A5^S<85M-:OS+_P@?P[V"R\.3&VU^[W?V/C[/H]P##J,N=E
MK)\LI4UU_@_P#^S!X"\20ZQX(\%_!3P?XI273_#UOJGACPQX,T/78[CQ;9)=
MZ;I$-]I>G6M\DGB#3_+GM[2.4?;[0JVQTQ65?Q?PGL:JPV2XF.(=.:H2K8O#
M2I1K.,E2E5C3I*<Z<9N,IPA*,I1BXJ2YW*/'F'[0#*)X#&QRGPTSFCFDL)B8
MY=6S'B/)<1@*./E0JQPE;&T,)EM+%8C"4<1*E6Q&'P]6E5KTJ4J$:E/VTJE/
ME/V*OV3? O[&?P&\+?!?P;%!>W=FCZYXZ\5FW$5]XY\>ZK#;#Q!XFOR?WA29
MK:WT_2;9P%T[0].TS3XU5;7GZUV@<8]1^?6N'_X65\/4@%TWC/PRMLVFZAK*
MW']KV0B.DZ5J!TG4M1\PR[39V.IJUA=3@^7#=CR'(D^6DB^)WP[GM(;^'QKX
M9ELKC3M6UB"Z36+)H)M+T*9+?6=0BD$NU[32YY$BOIU)CMW=5D92PS^)XK%8
MC&XFOB\55E6Q.)JSK5ZLW>52I4DY2D^B5W:,5:,(QC"*4812_P X\ZSG-.(L
MWS//L[QM;,<XSG'8G,LRQ^(DYUL5C,75E5K59O9)R:A3IP4:5"C2H8>C"%&A
M1A#N@,<"BN2/CWP4)?(/BK01-]LT;3_+_M.UW_;O$5HU]H-H5\S(N-7LT>ZT
M^(_/=0JTD09034 ^(_@$Q>>/&/ATP_8M:U'S?[6L_+%AX<G:VUZ\+^;M%OH]
MPK0:A+G9:R@I*5;BN<\P[2BN2_X3WP5]H%I_PE6@_:3?Z%I8@_M.U\TZEXGM
M4OO#MCL\S=]JUNSD2ZTR'&^\@998 Z'-5S\2/ (@%S_PF/AS[.;#5]4$W]K6
M9B.G>'[IK'6[[>)=OV;2;Q&MK^;.RVF4QRE6&* .UHKDU\=^#'F^S+XIT)I_
MMVC:68AJ5J9!J/B&!KK0K$KYF1=:O;HTVGP_?NHU+Q*PJJ/B3X :(3CQEX<,
M)L=7U,2_VM9[#IWA^Y%GK=[N\W'V;2KHBWOYON6TQ$<I5B!0!VU%<+;_ !.^
M'=W;0WMKXV\,7%I<66LZC!<Q:S8O#-8>'D637;R.19BKV^D(ZMJ$JDI:JRF4
MJ"*M_P#"?^"/-$/_  EF@><;G0;(1?VI:>8;OQ1;+>>'+8)YNXS:W:NEQID8
M&Z\A820AUYH Z^BN*/Q'\ K";D^,?#@MQ8ZOJ9F.K6?EC3_#]TUCK=[O\W'V
M;2;Q&MK^7.RUF4QRE6&*LKX\\%M<"U7Q3H1N3J&E:4(!J=KYIU+7+5KW1[$)
MYFXW6IV:-<V4(&^X@4RQAD&: .LHKB!\2_A\UM]K7QGX;-K_ &9?ZU]H&K69
MA_LG2[Q=/U'4=_F[?L=E?,MI<SY\N&X81.P<@5<_X3KP9]J%E_PE&A?:VU6S
MT-;;^T[7SSK.H:<=7L=,$?F;S?7>E@W\%OCS)+0&=5*<T =717#?\+-^'@LS
MJ!\:^&18C29=>-V=8LA -%@U0Z'-JOFF;;]@BU@'3)+G/E+>C[.6$ORT)\3?
MAY)9IJ">-?#36,FD7^OQW:ZO9FW?1-+OFTS4=527S=C6%GJ"-97%R"8HKE3$
MS!^* .YHKE!XZ\&M<_8U\4:&UW_:EAHGV<:E:F;^U]5M#?Z;IHC$A8WM]9 W
M5K;X\R> >9&K+S5,?$KX?&V%Z/&?ALVATJ_UP7(U>S,/]CZ7>#3]1U/S!+M^
MQ65\PM+FXSY4,Y$;L&XH [>BN4/CKP8+D69\4:$+MM5T[0A;_P!I6OG'6=7T
MXZOI>E^7YF[[=J&E@W]I;8\V>T!FC5DYJI_PLGP ;07P\9>&S9'2[[6Q=#5K
M,P'1],U!M)U#4Q()=ILK+4U:PN;@'RHKH&!V#C% ';45RB^.O!C7(LE\4:&U
MV=6L-"%L-2M3.=9U2T6_T[2Q&)-YOKVR9;JVMP/,E@82HI0YJG_PLOX??9Q=
M_P#"9^&_LK:5=ZZ+C^U[/R3HUA?G2KW4Q)YNW[#::DK6,]SGRHKH&%F#\4 =
MO17#1?$WX>3VL5]#XV\,RV<^FZIK,-S'K-B\,NDZ),EOK&HQR+,5>STV>1(K
MV=28[>1E61E)JZ?'G@L3" ^*M!$QO=&TX1'4[4.;_P 0VAO]"LPIDS]HU:R!
MNK"+[]S /,B#+S0!UE%<6/B/X!,!N1XQ\._9Q8ZUJ9G_ +5L_*_L_P .7#6N
MO7N_S=OV;1[E6@U&7.RUE4I*5((J?_A/?!7VC[)_PE6@_:CJ&AZ2(/[3M?-.
MI^)K9;SP]8!/,R;O6K5EN--@ \R[A820JRG- '6T5Q)^)/@ 6XNCXR\."V;3
M]6U83_VM9^4=,T&[:QUJ^#^;M-KI=XK6U]-G9;3@QRE6XJT/'?@LS_9AXIT(
MW'V_2-+\D:G:F3^T=?MFO-$L=GF9^U:K:HUQ80XWW4*EX@R\T =917%#XC^
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-C_Z_UHHH 6BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex19-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex19-1_001.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9"ET7+$'L<8P, G/6_#[P5=6,TXNXO+MYX74HL@*DLPP.'9N%+ $G(&><GD
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MYNTY!R"Q.<]B1Z8](LO#5M82_:88E20IL)0;1MSN^Z,+G(ZXSVSB@#3HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ** .*^&_@J;PQYWGLC>;Y>/++'[N[.<JO\ >%=K110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5YEJWA/4-,U!M4LE6;S"Q E925RH!!W%, <A=IR%&"<$@^FT4 >;
MZ=X/O=<O$U/4=L7DE=J1D$_NR&4<%@%+$DDL6Z@  @CTBBB@ HHHH **** "
MBBB@ JOJ+R)$[0@-*$8H#T+ ':#R."?<?6K%% '!?"SP9+H2RS7*A99"%4?*
MQ"KR3N4GAB>1Q]T'GC'>T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !4-W=+:(TTAPD:EF."<!1DG YZ5-7&?
M$[4&$,>GQ,%EO95C&=P^4D;CE>@R5!ZY4D8/8 Z/1-?@UM#-;-O0,5)VLO(
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M#%2<;_+(R ?X=Q4-E>1N%;^H:]Y,*7,$;S^=MV",8SO4E68MC8O3+$?+GD4
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M52U3QI'IEDFIR*?WJ(50'.6==P7=C@#G)QT' )P" :>OZVFB0/>2ABD>W(0
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MM@MG)!))!^8X(.1G@BJNF> ;'3'$T4*AQT+%GP0000'+ $$<$<CUH Y_6?\
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M"I<]2I9,DDDDA"H))/)/)]:U=,TJ+2T$,"*B#LHQDX R3U)P!DG)/<T <O\
M";4([BP2%&!>(N'7N-SLR\>A!X/3J.H.,WXLW2ZGIZ3P'?&+@9902N%$B$Y]
M-W /0Y&"<BNBU#X>6&H2-/)""[G+$.ZY/<X5@,GOQR>3S6K-HD$L)LS&ODL"
M"@4*O)SP!C!SSD<@\CF@#F/BIJL2Z>R;U)GV>7@YW .KDC';'.>G3G)&>?\
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MHQC:P). HVYX520=ASQZ;7/Z9X!L=,<310J''0L6?!!!! <L 01P1R/6N@H
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M#EMH/J%)VC'; XXQC K0T30(-$0PVR[$+%B-S-R0!G+$GH!0!B?%+_D'3_\
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MP0IX.<Y^<=AWH V**** "BBN/\:Z_/IMS8PPMM2>;;(-JG(WQC&2"1PQZ8H
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MK;W$-TB(]LRKB,'J2X8$EF!P5[?K784 %%%% !116?XANFM+:>:,X>.&1E.
M<%4)!P>.M &A17/^ M4DU6RBN9VW2/OR< 9Q(P'  '0#M704 %%%% !1110
M45S_ (XU233[;_1VVW$LD<<7 .69AQ\P*C*@\GCWSBJEQJES+JB6D+9MHX=T
MP 4A6;?MRV,@GY2%!R1SC&30!U=%<O9:Q+;:C)ITSAHY8A+#G:"N"0R8"KN/
M4CDD*O.221U% !117%>+=?NC>P:1:,L32KO:0J'.!OR I!' 0GW.!E1DD [6
MBJFEV\EM&L<\GFR#.7V!,Y)(^4<# P/PS5N@ HHHH **** "BBL_7];31('O
M)0Q2/;D( 6^9@HQD@=3ZT :%%5].O5OXDN$R%E16 /7# $9QGGFK% !1110
M445Q_@K7Y]2N;Z&9MR03;8QM48&^08R ">%'7- '845C^%[F[N(BU_&L<N\@
M!""-N!@\,_.<]^W2MB@ HHHH ***Q_%%S=V\0:PC627> 0Y &W!R>63G.._X
M4 ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@<=<8!P-+0?%,^CPI975G<&2%53,$?F(551M.X-C..#@D9';[HM^,TGU32Y
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M0EW8E6VAER5&T\' YW A@153X86<NJ3_ &NY!!L(A F5*\Y;.>0-R*=I&.C
MGGD[&M:=/H>H'6((FFBFC"3*G,B\JN57@GA5/?HV=HP0 8NF^+DTV[ABM+F6
MZBN&5)%N"Y9"6 5U9E7^]T YP<]5*W?&7B\&\.FO<-;01HI=T0EW8E6VAER5
M&T\' YW A@174:7XHDU.18TM9DCYWO.!%MX)7"DDODC!QC;P3UK$UK3I]#U
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M,OAYY_!$DUBUO+-;LYDCD@0R-SA0&^Z,X49Z$$'@JP(E\*V=T=6GN[F(IYD
MY4,8Q_JL+OQAF &&QQN!QQ0!;\ ZC+=7>H)([,L<^$#,6"C?*, $\#@=/05S
M_P /-,NO$L333W<ZQ(Y51'*P<L0I)+'/R@8P.>22,<[N@\ Z=+:W>H/(C*LD
M^4+*5##?*<@D<CD=/44?"+3I;"T=)D9&,[$!U*G&Q!G! XXH S_&7B\&\.FO
M<-;01HI=T0EW8E6VAER5&T\' YW A@15+3?%R:;=PQ6ES+=17#*DBW!<LA+
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MD=I$\_:S.Q88A4C#$Y&#R/>CP=H5WX@LUN)KR9<[_*\M\$?,02Y^\_S#@9X
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M '/^!O#1\.VJVS[?,+,SE"2I). 1N _A"CH.GXGH*** "BBB@ HHHH ****
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MB@#'\*^&8_#D M8R3SN9C_$Q !..PX  [ <Y.2=BBB@ HHHH **** "BBB@
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M7.,9QDC.,BK$,RS*'0@JP!!!R"#R"".H->;^)M'EM=1.HS6S7=LRHJJOSE.
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M2(4*2I<1;U*$<Y&UF./5NOS=0*L?%7S/[-M_/_UOF1;^GWO*?=]WCKGIQZ4
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M8/$6GQ^&M1L[BT4)]I<QR(O$9&47.U<<_-GTW*IQG.0#NKW7+>P;9-+&C$9
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M#@X(XZU-7G_PO_T::_LDXBAN/D7KC+.IY/)X11R3T]S70>/M3?3+&:>(X<*
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M; ;:2.&P>#@\X[UQ6I>'-4UR(6-U+;K$=N]XE=I&V\CA@J\L 3C;[<<'NZ*
M*^G62V$26Z9*Q(J@GKA0 ,XQSQ6)J<&I),SVKP-"P7"SJX*$#! *#D'KDGV
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M@9 (Z#3_  G=7MVNH:B\;>2/W4<.XQ@D<MAQP1USR2V#D!0*V[;PO%;W<FJ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&U(('GDDW8"D*@VX)W2'A<@G;P<D8K*T;QNUQ=?V;=P-!,5W("XD5A@D_,H
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M7];31('O)0Q2/;D( 6^9@HQD@=3ZUE7_ (OBT:PCOV3:KQQ^7&G3+)N5 0
M !UQT' S@'E/'?BN>>Q>*ZM7@\_R_+;>KKD,'(;[I0X' (R>>!@T >D:=>K?
MQ)<)D+*BL >N& (SC//-6*Y>RU^/0]/M9I S;XH$58UW.S,@PH''/![CI@<X
M!J-XZN+)4N+RS:&W8J&D$@D*;NA9 H8#. <X(Z8+8! .SHKG/&'C%?#UNEXB
MB59'51A]HPRLP8, V1Q^O6JMIXZ<Q/?SV[16BH620NK.^6"H/+ R"V<@D[??
M!S0!UM%<EHGC"ZU$1S-9LL$I7YQ*K$!C@-Y>U6VY()/9?FY%=;0!@^)/&4&@
M,D4FYY92 L<0#.<\ X)'!/ [D] <'&GI>H?VA&L^QX]V?EE7:XP2.5R<9QD>
MV*\UU[4;E=9AD6WS(D;K&GFJ/,7]Z ^[&%R"3M//&.];6K_$J32)([::U82R
MQ[MB2AV#%G5%&U<'<5'(.1NZ$C! .[HK!'B1[*VDO;Z(P>6?NAUE)' 4@K@9
M+'&#TZD@5D?\)[<^7]N^Q/\ 9?O;_-7?Y>?O^5C/3GKC'.[;\U ':T5SE_XT
MCBL#J\*ETPI"D[#RX0@G!P02?4''!QS6/_PLB>:#[?#9NT"KEV:15P1][: &
M+*O][ Z'(&#0!W=%<//\3#/$UU9VTDT40!D=B(PN0#@<,6*Y._ PN,Y*D&NJ
MT76(]8A2[ASLD&1D8(P2""/4$$>GH2.: +U9^OZVFB0/>2ABD>W(0 M\S!1C
M) ZGUJOXJ\31^'(#=2 GG:JC^)B"0,]AP23V XR< \/X[\5SSV+Q75J\'G^7
MY;;U=<A@Y#?=*' X!&3SP,&@#N+KQ9;V5O'?3,4BF"%<J2?G7< 0@;G ^GO6
MQ7!:MK<6CZ7:2S0+.I2!0CXP"8B=W*MSQCIWZUL>)_&?]D2Q64,337$W(0':
M O(R6((Z@^P )8@ 9 .EHK)T+5)[W<MS T#KM(!=9%8-GHR\9!!R.PP>]85M
MX_EU9F.GVK3Q(<%VD6$$\] P.1C![$9&5'&0#;\4>*(O#<0N)@Q5G"@( 3D@
MGN5X^6MBO-/BMJ2ZEIT4Z!@&N!PZE6!59%92#T*D$'W'&176^*O%T?AY4#*T
MDLQ(C1!DL1COV&2!QD\\*>: -ZBN,N?'\NDLIU"U:")S@.LBS 'CJ% P,9/<
MG!PIYQ>\3^,_[(EBLH8FFN)N0@.T!>1DL01U!]@ 2Q  R =+6?HFOP:VAFMF
MWH&*D[67D '&& /0BH="U2>]W+<P- Z[2 7616#9Z,O&00<CL,'O6%X2\4Q7
M%C/?0VZPK"9"8T( 8I&K9R$7!/3H>E '9T5PFF_$B?5HC/:V;R;-WF?O%"@C
MD!3C+G') 4$<#!R*Z#0_%D6JVG]H_=158N,[BA3E@=O/3D<9((.!G% &W17%
M77CVY6(WT5D[6VT,'>54?;W8Q@,0.^>1M^;I71>']2EU&+SIHA$2?E E64,I
M (8,G&#G],]Z -.BN?\ %_B]?#JH-C22S-MCC7(+$$9YP?48&"22 !U(ET36
M;F[<Q7-LT'RDJPD653@@$$KC:>1@'J,^E &W17/^&_%?]M37-MLV?99-F=V[
M=\SC.,#'W?4]:++Q7]IOY=*V8\F,/OW9SD(<;<<??]3T]Z .@K/U_6TT2![R
M4,4CVY" %OF8*,9('4^M85QXZ>XGDL[&W:X: D2$NL2 @XP&8')SD<XZ$C<.
M11\;ZM_:6E7#,C1R(T:2(W56$D9(ST8$$%6'!!!]@ =GIUZM_$EPF0LJ*P!Z
MX8 C.,\\U8KSS3O&TUE912P6K2P001J\F\)\R* ^%*EF53P6 QD-V&:[C2M3
M35(DNHCE)%!'3(SU!P2,@\$9X((H BU+7X-->*&9MKSMMC&UCDY QD @<L.N
M*T*Y?Q;K<6GW%I%) LK32[4=L9C.Y!N&5;GY@>".@Y](O$WQ 70;J.R:)G$B
M!LQG+Y9F4*$P,DD#^(=>G'(!UM8_B;Q5!X<C$TY/S'"JN"[>N 2.!W)( Z=2
M <JS\;RI<QV-[;FW,X.QC*KJ2/X<@ 9/3 ).2HQ\P-<Y\2KV<7UF!#D1S Q'
MS%_>DF(E<?P8/RY/7.>E 'H&B:O_ &JAE\N6+#$;9TV,< '(&3QSU]0:T*YJ
MZ\9'2;<WE_"T)\P(J(ZRLV1D$$8 []2.GJ0*S[CQ[<Z>BW5W9/' <9995=AN
M'RY3"D9. =Q7!..N 0#M:*YKQ5XV71+:._C3S4F9 OS%.'0N&Y4GH.F!UJ&P
M\8SW44EZUJR6Z0R21N\B[G"<J"@&5W#G/(],@@D ZNBN$TWXD3ZM$9[6S>39
MN\S]XH4$<@*<9<XY("@C@8.13[3XF'5(]UG;232(@:1<A53J"-V#N;C*@+E@
M>.05 !W%%8_A7Q-'XC@%U&".=K*?X6 !(SW'((/<'G!R!B:AXXNK>-KM;&3R
M%&=TDBQR8'!)BPS  Y_X#\W H [.BN2\1>(#J6FO=VB&1)HI V6"%%V.'8@]
M2I&,#KV)'-9GPMU&Y^S00?9_]'_>?OO-7^\Y_P!7C=][Y?UZ4 =AINOP:D\L
M,+;G@;;(-K#!R1C) !Y4],UH5R_A+6XM0N+N*.!8FAEVNZXS(=SC<<*O/RD\
MD]3SZU+;Q_+JS,=/M6GB0X+M(L()YZ!@<C&#V(R,J.,@'9T5@^%?%T?B%7"J
MT<L) D1Q@J3GOW&01S@\<J.*P-#^)LNNJRVUHSRH?F'FJJ!3T/F,!\Q/1<<@
M$YX(H [VBL'PCXJ7Q#&S%#'+$Y5XV.64CIV!P>G('(8=LUIZI<26T;201^;(
M,83>$SD@'YCP,#)_#% %NBO*OA)J-S!"8HK?S(FN/FE\U5VY5 WR$9.!SQUZ
M5U%QXZ>XGDL[&W:X: D2$NL2 @XP&8')SD<XZ$C<.0 =;17.>&_&2ZM*]E)&
MT-S$"7C;YAC.,AAU'*GH,Y&W<.:Z.@ HKC+;Q_+JS,=/M6GB0X+M(L()YZ!@
M<C&#V(R,J.,Z&@>,EUR*5HHV$\ PT+_*=^#A=QXP6!7)P1C)44 ='6/<^*(K
M>[CTLAO-E0L" -F &/)SG/R'L>U>>>"M5N[>YOGAM?,=YLR+YR)L.^3Y<D8;
MDD9'I[UH>+=273=9MIW#$+;GA%+,2WG*J@#J6) 'N><"@#TNBN2L_&\J7,=C
M>VYMS.#L8RJZDC^'( &3TP"3DJ,?,#5C5O&+03FQM('N)DV[\$)&H92PS(P(
M!( QQ@YP#D8H Z6BN<T/Q<;N9K&ZB-O<@;E1G#AUQG*N  2.<@>AZX;;FZM\
M1FL[Q]+CMVED&P)M<#<656.<K\H )).3TYP"2 #M:*X_4O'DEB8;4VS->3Y/
MDB0$*N6 )D"D'.W/3 &2Q&.=K0M4GO=RW,#0.NT@%UD5@V>C+QD$'([#![T
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MR< [BN"<=< ]?:72W:+-&<I(H93@C(89!P>>E $U%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7*?%+_D'3_]L_\ T:E=7535-+CU6-K:==T;XR,D9P01R"#U [T
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M,: ,#G&,8SSVYZ$&N7U_4(X-5L=3=@MM+ 0KG@<A\9!Y _>+R0 ,\]#CH_\
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M%Q 59=NYCP^=PR3GG)[_ $J72]+CTJ-;:!=L:9P,DXR23R23U)[T <5\4/\
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M(RQR3C)QDG'0<5#I_A:VT^%[*)-L4N[<NYCG<H5N221D#'!H ROA;_R#H/\
MMI_Z->N7^'94:1=EP2N9\@'!(\E<@$@X/O@_0UZ1I>EQZ5&MM NV-,X&2<9)
M)Y))ZD]ZPM5T3^P;&>+3(R'8$A59BV6PK,"6SN"C*X/4# )X(!R5GJ,]S:1V
M/VRS6%X45F=\3JK*-R%<[<J"5[$@9)#'(]-TZR6PB2W3)6)%4$]<* !G&.>*
M\_FUW0X8C$\2AE0J8S;L)@0,%"Q7AQTSOZ\[N];?PPT>?2K,1W&06=F523E5
M8# (/W3G)QVSS@Y  +7B[PY!KABCDD,4ZES"RL ^0 3A2?F P"<8(QPPYK%T
M77KG2K]-$N)%N%9,B3&V1<(6 8 GGY3URQ#!BW:NJUSPW;ZZJI<H'"'*\E2,
M]>5(.#W&<' ]!3-$\*VNB9-M&J$YRW+-@XXW,2<<#C.,\XS0!ROP]_<W^HQ/
M\KM,&"GABN^0[@#SC#+STY'J*K^%]0CU#6[J:%@R&# 8=#M\E3@]QD'GH>HX
MKJM8\#6>L2?:)X@TA !(9USCIG:PR>V3SC Z 58T_P *VNFRM=01JDCKM)3(
M7'' 4':/NCH!^IH Y+X/3+:Q3Z>Y GBG<LF>0 %0GC@@,I!P3CC/49T/B/J$
M=YIUT(V#>4\:-CLPDC)7/J,C/H>#R"*U=8\#6>L2?:)X@TA !(9USCIG:PR>
MV3SC Z 58;PK:F V C40-C*KE<E<8)(()/RC))R<<DT 97_,&_[A_P#[0H^%
MO_(.@_[:?^C7KH/[+C\G[%M_=>7Y>W)^[MVXSG/3C.<^]&EZ7'I4:VT"[8TS
M@9)QDDGDDGJ3WH XKXC_ /'YIO\ U\?^SPT:S_R'K7_KW;^4]=AJ6@0:D\4T
MR[G@;=&=S#!R#G (!Y4=<T3:!!-.E^RYGC7:K;FX!W<8S@_>/4=Z ./^(_\
MQ^:;_P!?'_L\-'Q'_P"/S3?^OC_V>&NPU+0(-2>*:9=SP-NC.YA@Y!S@$ \J
M.N:-2T"#4GBFF7<\#;HSN88.0<X! /*CKF@#C_BA_HTUA>OQ%#<?.W7&61AP
M.3PC'@'I[BN@\9ZK%!832LZ[9875"#D,9$(4#&<YSGCMST!-;5U:)=J8I55T
M.,JX#*<'(R#QUK M?AOI]JPD6!21G[[.Z\C'*NQ!_$>_6@#S_P 16K6NAVB.
M,$S!NH/#B5U/'J"#_/FO3_%G_'G<_P#7O-_Z U3:WH$&MH(;E=Z!@P&YEY (
MSE2#T)JU=VJW:-#(,I(I5ADC(88(R.>E '-?"W_D'0?]M/\ T:]97P4_X\Y/
M^OAO_0(Z[72]+CTJ-;:!=L:9P,DXR23R23U)[U%HF@0:(AAMEV(6+$;F;D@#
M.6)/0"@#A/A5??V?IMQ<XW>5)*^,XSMB0XS@XSCTJN=2O->L)M2DNHXXBD@,
M*1(1PNW868[E9ST&2?F!'4 >AZ)H$&B(8;9=B%BQ&YFY( SEB3T K*/PWT\L
M9/(7+;L_,^WY@0<+NP.O& -O!7! H Q/#7_(!;_KWNOYR5I_"J97TZ( @E3(
M" <X/F,<'T."#]"#71:7I<>E1K;0+MC3.!DG&22>22>I/>LRP\#6>GS"\AB"
MR@L00SX&X$'"[MH&">,8':@#C?#-JUV^LPQC+R-(JC(&2QG &3QUK=^$VH1W
M%@D*,"\1<.O<;G9EX]"#P>G4=0<='IN@0::\LT*[7G;=(=S')R3G!) Y8],5
MGZGX!L=3<S2PJ7/4J63))))(0J"23R3R?6@#G/"LRZEK%W>0D/"(E3>#QNQ&
M./4?NVY'''7D9?\ !3_CSD_Z^&_] CKM=,TJ+2T$,"*B#LHQDX R3U)P!DG)
M/<U%HF@0:(AAMEV(6+$;F;D@#.6)/0"@#C_AQ_Q^:E_U\?\ L\U>@5GZ;H$&
MFO+-"NUYVW2'<QR<DYP20.6/3%:% 'GGP3F4VDB C<)R2,\@%$ ./0X./H?2
MCX/3+:Q3Z>Y GBG<LF>0 %0GC@@,I!P3CC/49Z67P-9R3_;C$/.WA]P9Q\P(
M(;:&"YR,GCD\G.33]9\%V>LMYL\2L_\ >!9&/ ')0@G  QG..U '+W$RZEKL
M1A(86T#"0@_=/[P$>Y!=0<9P3@]#CL_$-JUW;3PQC+R0R*HR!DLA &3QUHT;
M0(-%7R[:-4!ZXY8\DC+').,G&2<=!Q6A0!QGPFU".XL$A1@7B+AU[C<[,O'H
M0>#TZCJ#C/\ "LRZEK%W>0D/"(E3>#QNQ&./4?NVY'''7D9Z/4_ -CJ;F:6%
M2YZE2R9))))"%022>2>3ZUJZ9I46EH(8$5$'91C)P!DGJ3@#).2>YH X?X<S
M*+[4D)&XSD@9Y($DH)QZ#(S]1ZT_6?\ D/6O_7NW\IZZ+6/ UGK$GVB>(-(0
M 2&=<XZ9VL,GMD\XP.@%7IM @FG2_9<SQKM5MS< [N,9P?O'J.] ''_$?_C\
MTW_KX_\ 9X:Q]#T59]1O;66>6"5Y2Z+#+LWJQ9^2 02%8$#J 3QP<>D:EH$&
MI/%-,NYX&W1G<PP<@YP" >5'7-0ZWX5M=;P;F-7(QAN5; SQN4@XY/&<9YQF
M@#(T[P7;V5VEP;B66YC0D+-*KML(9,XVAMN6..V:S-&_Y#UU_P!>Z_R@KJM$
M\*VNB9-M&J$YRW+-@XXW,2<<#C.,\XS4T.@00SO?JN)Y%VLVYN0-O&,X'W1T
M':@#$\4^$XM;F5TG:&\CC^4QM\VS=C)3(..6&01R>2>E5?"'B>>:[FTFY9)3
M I(E0;2<, 0RCC(W $#&TJ0=QYK=USPC:ZXRO<QAV08!RRG'7&5(R/3/3)QU
M-6-&T"#15\NVC5 >N.6/)(RQR3C)QDG'0<4 6KNU6[1H9!E)%*L,D9##!&1S
MTKR#29VO5@\,OM)CO)!)M9U5HXB78$@<[B6QTQM7(!YKV6LQ/#=NEP=1"#SV
M&"Y)/8+P"< X&,@ XSZG(!Y;?ROHR7F@PA=TUU$L05R&VSC.,L>1M5$;.!EC
MEB,9Z#XP6JVEA##&,)'-&JC). L;@#)YZ5V5WX;M[R=+Z1 TT0 5B3Q@DCY<
M[<@DD'&0>1T%/UO0(-;00W*[T#!@-S+R 1G*D'H30!B?%+_D'3_]L_\ T:E<
MKXD_T:'1[U^(H?)WMUQE8F' Y/",> >GN*]*U32X]5C:VG7=&^,C)&<$$<@@
M]0.] TJ+RA:%%:)550CC<N%QM!W9SC ZT 97C/58H+":5G7;+"ZH0<AC(A"@
M8SG.<\=N>@)J+X;VK6NGP(XP2K-U!X=V=3QZ@@_SYHM?AOI]JPD6!21G[[.Z
M\C'*NQ!_$>_6NEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HJOJ-ZMA$]P^2L2,Q ZX4$G&<<\57T#6TUN!+R(,$DW8#@!OE8J<X
M)'4>M &A1110 4444 %%<?J>OSPZM;V"MB"2$LR[5Y($O.<9'W1T/:NPH **
M** "BBB@ HHHH ***Q_"_BB+Q)$;B$,%5RI#@ Y ![%N/FH V**X_P %:_/J
M5S?0S-N2";;&-JC WR#&0 3PHZYKL* "BBB@ HK/\0W36EM/-&</'#(RG ."
MJ$@X/'6L_P !:I)JME%<SMND??DX SB1@.  .@':@#H**** "BBB@ HK'MKF
M[:[DB>-1:! 4<$;RV%R"-QXY;^$=!SZ[% !1110 445R_P 1?$TGAZU\Z$#S
M'<("?X<JQW8[D;> >,\G(&" =116/X=T^ZM%)O)Q,S!< 1J@4C.X KC<#D<D
M#ITYH\4>*(O#<0N)@Q5G"@( 3D@GN5X^6@#8HKG_ ![JDFE64MS VV1-F#@'
M&9%!X((Z$]JT/#UTUW;032'+R0QLQP!DL@).!QUH T**** "BL_7];31('O)
M0Q2/;D( 6^9@HQD@=3ZU8TZ]6_B2X3(65%8 ]<, 1G&>>: +%%9^OS3PP.]H
MJO.-NU7X4_,,Y^9>@R>HJQISR/$C3 +*44N!T#$#<!R> ?<_6@"Q116/XNUQ
MM#M9+Q%#,@& >F68*"<=AG..,],CK0!L45R_@J&\FC2\N[@2+-$&$8B1=N[#
M*=X ).WJ,8R>^ 3U% !1110 4444 %%%% !116/HGBB+6)9[>,,&M7VN6  )
MRPXP3Q\IZX[4 ;%%8]S<W:W<<21J;0H2[DC>&PV !N''"_PGJ>?38H ****
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M(7MW CSDMP.1R68$;>_R8Y&17H&@:,NBP1VB<B-<9YY)Y9L$G&22<9XS@<4
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M^ODWXQGIP,9SSZX%<5\:]/\ W,=UO?\ UBILW?N_NR-NVX^]VSGIQ7I=<?\
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M8ZA<:1)*TT4:>8K2DLXSLP-Q/3#X/;(R N2#I>(]-5Y/,N;YX(V_U21R)!C
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MRQM*P$KS+B-=A#':XR&&1][N!\JDL, $OB[7GEFTR6!W2.YD4E0Q7<K-$0&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!S6N>&I-5O;:Y;9]GMMS8)82%SR#P,$ JA
MZCOG(XKI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#E_%OA>76+BTN(RH6UEW.&)!(W(>, \_*>N
M.U=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&UF=0IR,C#$X.1R/:N%^&W@VTN[$3RQK(\^_<7&2 K,@"GJO SD<Y[\#&?\
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M.H-/K)\,W5K<P V)7R0SX"@@ EBS#:<%>3D# X(P,8KF/BC,UPUGII)$5U.
MY4X; 9 !Z8^?/(/(4]J .OLM<M[]MD,L;L!DA'5CCIG )XYILGB&VBW;IHAL
M;:V9$&UN?E//!^4\'G@^E5$\&VD/EF*-8VA92KQC:_R\8+=6##(8-G()SSS7
M#^"_#D&JZA?33J'\F=PJL 4^=Y,DJ>I&WC/ SG&<$ '8:]$MY+:RI=B%0^X(
M'XG!*$*,.NX=NC?>Z<\[;ZC$D@MRZB5AD(6 <CGD+G)'!_(UPGQ"A6&[TQ$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M- D;##O"',C #H0=JX8_>QMX]LJ>XHH \T^*NF)I>FP6L0PD<R =,G$<F2<
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MZ(^MVDEG$5#R;,%R0ORNK'. 3T'I5W0[)K"WAMWP6BB121TRJ@'&<<<5>HH
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MEV,)2C'GY0-F=O&/_'L_-7:T4 <5K2-X-TU;:V=C,&1(SL#,SN^Y@%PPY&[
M.>PR3C/7VF_8OF[?,VC=LSMW8^;&><9Z9YQ45QI<=S)'<NN9(-^PY(QO&&X!
MP<CU!]JMT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 445S^J>(;F&1H+:T>79C<S.L*'< 1M9
ML[^X;&-I'O0!T%%<_P"$/%Z^(E<;&CEA;;)&V25))QS@>AR, @@@CH3E6?Q
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M[A%_3.2 2 <8H [6L_7];31('O)0Q2/;D( 6^9@HQD@=3ZU7\5>)H_#D!NI
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M_-R*ZV@"&[NEM$::0X2-2S'!. HR3@<]*YK_ (6EIW_/;_R'+_\ $5U=>?\
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M8/WAT/>JFO>)?[+EM[58VD>ZDVC!P%5<;F/!)P#G&,8!)(QS2T_6XIM3GLA
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M&)Y[AU#!$X4*6"[F<Y"C.><$#'S8!!JOI_C-Q.MG?0&V>4?NB9%D1SG!7<H
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M$\]PZA@B<*%+!=S.<A1G/."!CYL @U7T_P 9N)UL[Z VSRC]T3(LB.<X*[E
M ;I@=\]B5# '445QFH_$4VEX^EK TD@ V;&'S,R*P!! VKR<MDX SC'2WH?C
M-[NY;3KJ V\P3<H,BN&'?! &3WXST;.-M '445Y5KVHW*ZS#(MOF1(W6-/-4
M>8O[T!]V,+D$G:>>,=Z]*TNXDN8UDGC\J0YRF\/C!('S#@Y&#^.* +=%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7G]MK]YXDNY[."9+9+5F'"++(^&VYP_& 03D8QN .[.1Z!6#K'@:
MSUB3[1/$&D( )#.N<=,[6&3VR><8'0"@#E?A.2;B_)<2'S4RX  ?YI?F '&&
MZ\<>E%QX?/AR*34],N@(%!?RG(DA8AN5#9ZG 0<%R1MW\\=KI'ANWT=G>W0(
M92"V"<'&<8!)  R>  *S?^%;Z?O\[R%W;MV-S[<YS]S=MQ_LXQCC&* +OA'7
M&URUCO'4*S@Y Z95BI(SV.,XYQTR>M<O\1_^/S3?^OC_ -GAKO885A4(@ 50
M  !@ #@  = *I:EH$&I/%-,NYX&W1G<PP<@YP" >5'7- ''_ !K_ ././_KX
M7_T"2CXU_P#'G'_U\+_Z!)78:WH$&MH(;E=Z!@P&YEY (SE2#T)HUO0(-;00
MW*[T#!@-S+R 1G*D'H30!S7B_P 3SPW<.DVS)$9U!,KC<1EB %4\9.T@ YW%
M@!M/-8,4$MOK=O'/.)Y%B;+!%CVY24A2JD\\YYYPP[8KT#7/#=OKJJER@<(<
MKR5(SUY4@X/<9P<#T%5-.\#6>FR)<0Q!9(@0I#/_ !;LYRW)^8C)R<8'0# !
MB_$!!I$UMKBJ28'\N0 %OW;AAG[P *Y(&>K,,G@ O\#;M7N+G6'Y1V\J _./
MW:'DA6XPQ"G_ '@W Y!L?%.]2VT^17P3(450=W+;@W\..0%+#/&1@YZ':\-:
M.-'MHK08S&@#8)(+'ER"><%B3V^@Z4 :=>>?#F91?:DA(W&<D#/) DE!./09
M&?J/6O0ZP=8\#6>L2?:)X@TA !(9USCIG:PR>V3SC Z 4 <[HW_(>NO^O=?Y
M04:S_P AZU_Z]V_E/780Z!!#.]^JXGD7:S;FY V\8S@?='0=J)M @FG2_9<S
MQKM5MS< [N,9P?O'J.] 'F^AZ*L^HWMK+/+!*\I=%AEV;U8L_) ()"L"!U )
MXX..KT[P7;V5VEP;B66YC0D+-*KML(9,XVAMN6..V:U];\*VNMX-S&KD8PW*
MM@9XW*0<<GC.,\XS1HGA6UT3)MHU0G.6Y9L''&YB3C@<9QGG&: )O$-JUW;3
MPQC+R0R*HR!DLA &3QUKG/A-J$=Q8)"C O$7#KW&YV9>/0@\'IU'4''9USFH
M?#RPU"1IY(07<Y8AW7)[G"L!D]^.3R>: .:^(.H1SO8:FC VT5RP9QR.'7.
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M:?'+$;4J/*9"A4?*-I&W:,8P,<<=.U,TO2X]*C6V@7;&F<#).,DD\DD]2>]
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M&NU6W-P#NXQG!^\>H[UH4 >>:3,J:]<@D M H )QD[83@>IP"?H":?\ $?\
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M6L>!K/6)/M$\0:0@ D,ZYQTSM89/;)YQ@= *MV?ANWLIC>1(%E9 A() VJ%
M4+G:  HZ =* /-?ASX=6[6:T>XGAGAE;=%#-L&!A2V ""=P()!/09ZC/:^'?
M"5OI=S)<)-)+/L"R"6178!MI7.%# D*,9[=*NZSX+L]9;S9XE9_[P+(QX Y*
M$$X &,YQVJWHV@0:*OEVT:H#UQRQY)&6.2<9.,DXZ#B@#A[CP^?#D4FIZ9=
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M/#6W\2+5KK3YT09(56Z@<(ZNQY] "?Y<UJZEH$&I/%-,NYX&W1G<PP<@YP"
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MFM7-P481- H#E2$)Q#P&Q@G@_D:-6TZ5]:MK@(QB6!@7"DH#B;@MC /(_,4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %5]1LEOXGMWR%E1E)'7# @XSGGFK%% ''VFF:KI:+:PO;21Q*%5I5D5R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7.UL\_+GTW,QQG&#Q%I\?AK4;.XM%"?:7,<B+Q&1E%SM7'/S9]-RJ<9SD ]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_%'A)M;MTC\S%S!M9)@ IWJ.3\O*ACS\O0@'G;@]+10!P6L^%=2UZW-M<S1
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M0!R^H>%Y;C4X-4!7RHHBI!)WY(D' QC'SCN.]8_QDMPMO%= [989AL8%@WS
MD@;> <J&R<8V\')P?0*R=:\.IJ[PRR,X^SR"151@%+ @@L"#G&..A )YYH ?
MX:T<:/;16@QF- &P206/+D$\X+$GM]!TJEX*TBYTJ%HKR3S9#(2&WN^%*J ,
MN >H/'3FN@HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT,S;D@FVQC:HP-\@QD $\*.N:["@ HK'T2YNYI9UNHU2)7Q"5()9<MR?F;G
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M]WOZ=MV/FIFB>%9-%TJ:U8$S2Q3,RK\WS,FT*,#DX '&?FS@D8H K_"W0/\
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MY\N54L%&^(Y) X'!Z^AH S_&7B\&\.FO<-;01HI=T0EW8E6VAER5&T\' YW
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8H **** "BBB@ HHHH **** "BJ]EJ,5^N^%U=0<$HP89ZXR">>:L4 %%%%
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M8YCRW"A@#NSG[P/.<'*Y9<8B^'UI?Q6B2VBV@23=\T@D$K;78?,4X.#G'H*
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MM N$8Y$<P5>!P"\3X]^6)Y]?2NPM]*BM]%9%10'LS(W&<N8M^XY[YP0>V!C
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MA02<9QSQ63X*\,CPY;+;$@N26<C."Q],]@ !VSC. 2:M^)X6FM+A$!+-!*
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M;%WH.I7,#6.RQ6)U(VHLH SSD#& 0>0<=>: .[JIJ>JQ:6AFG=40=V.,G!.
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M%["8;S8=IX9&! 9MK#. =I..1\N"Q88KD?AT+^[26]MA;%Y)GWO.KB0E@K,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M='CT>%+2'.R,8&3DG))))]223V'H .*L7=JMVC0R#*2*589(R&&",CGI4U%
M''P^!I],)6QNWAB/_+-T695.6/R[R-HY^IZDGM=3P3'+#+!<223-<A?,=VP?
ME.Y=@'"*K$LJX(&<'(XKHZ* .*_X0*Y\O[#]M?[+]W9Y2[_+S]SS<YZ<=,8X
MV[?EK2O_  7'+8'2(6*)A0&(WGAPY)&1DD@^@&>!CBNCHH R?["_T/\ LW=_
MR[^5OV_[&S=MS^.,_C573/"GV&P.E;\YCE3?MQ_K"QSMR>F[UYQVKH** .4?
M0O[!TJ6RW;_+M[CYMNW.X.W3)]<=:YKP)X4GGL4EM;IX//\ ,\Q=BNN0Q0%?
MNE#@<D')XY&!7I5W:K=HT,@RDBE6&2,AA@C(YZ5%I>EQZ5&MM NV-,X&2<9)
M)Y))ZD]Z ,73_ ,%I9-I9W,DG+MG#%N/F'4#!48'(X&=W.<>7X;7$]O]@DO6
M:%0-J^4!C!!&3N+,H&<+G .TC[H%=[10!RFO^!?[7LX=-\W;Y'E_/LSG8A3[
MNX8SG/4XK5\4Z%_;UL]ENV>9M^;;NQM8-TR/3'6M:B@"CIVEK:VZ6;X=4B6,
MY'#!5"G*G/!].:X7X-:(L$<UZ,D2/L0LFUMB<E@<GAB<$ D KU../0KNU6[1
MH9!E)%*L,D9##!&1STJ+2]+CTJ-;:!=L:9P,DXR23R23U)[T 6ZY?6/!)N+C
M^TK69H+A@ S!1(C #'*-CG@=\?*#MW<UU%% &)HFASVCF>YN7F<J5 VK'&!D
M'/EKQNSGYL]#C'%1>&_"G]BS7-SOW_:I-^-NW;\SG&<G/WO0=*Z"B@#G[+PI
M]FOY=5WY\Z,)LVXQ@(,[L\_<]!U]J++PI]FOY=5WY\Z,)LVXQ@(,[L\_<]!U
M]JZ"B@#RR71CJFMW 61HI(HE='3'#!(E&01ROS'*\9'&<5U&C>"&M[K^TKN=
MIY@NU"4$:J,$'Y5)'0GC@<DD$G(VX= @AG>_5<3R+M9MS<@;>,9P/NCH.U:%
M '/V7A3[-?RZKOSYT839MQC 09W9Y^YZ#K[5F6W@"7268:?=-!$YR4:-9@#S
MT+$8&,#N3@98\8[.B@#!\*^$8_#RN59I)9B#([G)8C/;L,DGG)YY8\5ROQ7T
M1=4GLX5R)9G9,JF[Y,J2Q.0<)DD#I@L<KW](K/FT"":=+]ES/&NU6W-P#NXQ
MG!^\>H[T &J:%%J4#6+C$3*%PGRX"X*XQP-I P,8XP01Q7/VO@R[M%%LE\XM
MUR OE)Y@3/W1*3D$#@,!QQ@  "NPHH S+_0(]0MCI\Q9D**I8M\YVXPQ;NV0
M#TP3U&.*PK7P9=VBBV2^<6ZY 7RD\P)G[HE)R"!P& XXP  !7844 0VEO]F1
M8LLVQ0-SG+' QDGN3W/K6/XJ\(Q^(50LS1RPDF-T."I..W<9 /&#QPPYK>HH
M XRY\ 2ZLRC4+IIXD.0BQK"">.I4G(QD=B,G##G.GXD\*?VU-;7._9]EDWXV
M[MWS(<9R,?=]#UKH** "JFK6/]H0R6V=OFQNF<9QN4C.,C.,^M6Z* .*TOP3
M>Z5&MM!?;8TS@?9HSC))/)8GJ3WK2@\!VT=O+9'<PN#F21FS*S9W!BV.JGD<
M8]0<MGHZ* .*_P"$"N?+^P_;7^R_=V>4N_R\_<\W.>G'3&.-NWY:T-0\ P7=
MDNEC<J1\HV<L&Y^8] <ECD<#DXV\8Z6B@#@M5^&UQJ\2P7%ZSB,C;F( < @[
M@&RS=,,3D?-UW9&[XU\*?\)/"MMO\O;('SMW=%88QE?[WK7044 %<59_#R33
M&D2TNGBMY6R8P@9@",$+(Q)4XX# 9'&=Q&:[6B@#FO"'@E?#3SO&^4G92J[2
M-@4MA<EF+<-C/'3WK:U:Q_M"&2VSM\V-TSC.-RD9QD9QGUJW10!B:#X873;,
M:9(?,3;(K'!3(D9B1@$D<-CK[U7\$^#E\+Q/$&#L[[B^S8<8 "]6R!R1SW/%
M='10!S_AOPI_8LUS<[]_VJ3?C;MV_,YQG)S][T'2J5QX%>WGDO+&X:W:<DR
MHLJ$DYR%8C!SD\YZD#:.#UM% &3H6CR6&YYYWGDDVY+ *@VY VQCA<@C=R<D
M9JKX*\*?\(Q"UMO\S=(7SMV]548QEO[OK7044 <_X;\*?V+-<W._?]JDWXV[
M=OS.<9R<_>]!TH\-^%/[%FN;G?O^U2;\;=NWYG.,Y.?O>@Z5T%% '!:'\,I=
M"5FMKMDE<_,?*5D*CH/+8GY@>C9X!(QR36[X0\(+X=5SO:269MTDC9!8@G'&
M3ZG)R2222>@'044 <9;> )=)9AI]TT$3G)1HUF //0L1@8P.Y.!ECQCH]$TM
MM.0I)*\SLQ9FD(ZD#(4#A5R,A>V>M:%% '/^"O"G_",0M;;_ #-TA?.W;U51
MC&6_N^M4K:ZFU'5&:%V%K;1>7(.#&TA).T<_>7<-Q R"NTX!&>MJ&WM$MMWE
MJJ[V+-M &6/5CCJ3W/6@":N2\9?#R/Q-+'.SE"@VM@9++G( ).%(RW.#UYSC
M%=;10!SGC/P>/$BH!(8I(RV' +?*Z[77 9>&XS[#'0FM";0U-H=.1B%\@Q!C
MR0-FP$@8R>_;\*TZ* ,GPMH7]@VR66[?Y>[YMNW.YBW3)]<=:RM \"_V19S:
M;YN[S_,^?9C&] GW=QSC&>HS75T4 <I_P@O_ !+O[&\W_MIL_P"FOF?=W?AU
M]_:K=_X,BU*TCTV<L5A6,!D^5LQKMW '<.1G@YZ^N#7044 <E#X1O&40S7\A
MB  /EQ)'(<=/WN6;.0,GDD9!ZUUM%% '/WOA3[3?Q:KOQY,939MSG(<9W9X^
M_P"AZ>]%EX4^S7\NJ[\^=&$V;<8P$&=V>?N>@Z^U=!10!S][X4^TW\6J[\>3
M&4V;<YR'&=V>/O\ H>GO70444 >3^%M!?4;Z_GAF:&:*=@K*%9</))N#(WWA
M\O'(P<'G KL_#'@S^R)9;V:5IKB;@N1M 7@X"@D=0/8  *  <ZNFZ!!IKRS0
MKM>=MTAW,<G).<$D#ECTQ6A0!R5QX%>WGDO+&X:W:<DR HLJ$DYR%8C!SD\Y
MZD#:.#:\-^#5TF5[V21IKF4$/(WRC&<X"CH.%'4XP-NT<5T=% '&3>![J9#:
MO?2&W8D%3&ID*%LE3*3N)(XSC&.-NWY:O3>#FMXH8+&=X/L^[!P)%8/][<I(
M!.>1V&3@=,=+10!R^C^"3;W']I74S3W"@A6*B-%!&.$7//)[X^8G;NYJ*X\"
MO;SR7EC<-;M.29 465"2<Y"L1@YR><]2!M'!ZVB@#$TWP_) DJSW$LDDZX+#
M$87 (!C4#"'!&3SD@&L6X\!7.H(MK=WKR0#&56)48[1\N7RQ.#@G<&R1GK@C
MM:* .<U'PO-NC-E<M;K'$(]FT2IM7[IVN>&'0L<DC XYR>&_!JZ3*][)(TUS
M*"'D;Y1C.<!1T'"CJ<8&W:.*Z.B@#FO"O@E=$MI+"1_-29G+?*4X= A7AB>@
MZY'6L^W\!7.GHUK:7KQP'.%:)78;A\V'RI&3DC:%P3GKDGM:* .?L/!D6FVD
MFFP%@LRR L_S-F1=NX@;1P,<#'3UR:M>%M"_L&V2RW;_ "]WS;=N=S%NF3ZX
MZUK44 <_X*\*?\(Q"UMO\S=(7SMV]548QEO[OK6EK6CQZQ"]I-G9(,'!P1@@
M@@^H(!]/4$<5>HH XK_A KGR_L/VU_LOW=GE+O\ +S]SS<YZ<=,8XV[?EK=C
M\,QV]FVEPDJAB= 3\Q^<'+'IDY)..!V&!6Q10!D^%M"_L&V2RW;_ "]WS;=N
M=S%NF3ZXZT>*="_MZV>RW;/,V_-MW8VL&Z9'ICK6M10!D_V%_H?]F[O^7?RM
M^W_8V;MN?QQG\:JZ9X4^PV!TK?G,<J;]N/\ 6%CG;D]-WKSCM7044 <Y8>"X
MXK :1,Q=,,"P&P\N7! R<$$CU!QR,<5BR_#:XGM_L$EZS0J!M7R@,8((R=Q9
ME SA<X!VD?= KO:* ,>3PS'<6:Z7,2R")$)'RGY ,,.N#D XY'8Y%5/"OANX
MT0"*2Y,T*)M5#$%QR"#OW,Q &0!T /'05T=% '&6W@"7268:?=-!$YR4:-9@
M#ST+$8&,#N3@98\8V(O#K"VEM))GD>=7#228.#(FT[5& J@\A<\=,UMT4 9/
MA;0O[!MDLMV_R]WS;=N=S%NF3ZXZU5LO"GV:_EU7?GSHPFS;C& @SNSS]ST'
M7VKH** .*L_AY)IC2):73Q6\K9,80,P!&"%D8DJ<<!@,CC.XC-6M \"_V19S
M:;YN[S_,^?9C&] GW=QSC&>HS75T4 9/A;0O[!MDLMV_R]WS;=N=S%NF3ZXZ
MU5\:^%/^$GA6VW^7MD#YV[NBL,8RO][UKH** ,GQ3H7]O6SV6[9YFWYMN[&U
M@W3(],=:JW_@R+4K2/39RQ6%8P&3Y6S&NW< =PY&>#GKZX-=!10!Q5QX"N=0
M1;6[O7D@&,JL2HQVCY<OEB<'!.X-DC/7!&AXJ\$KK=M'81OY20LA7Y2_"(4"
M\L#T/7)Z5TM% &3XIT+^WK9[+=L\S;\VW=C:P;ID>F.M6])L?[/ACML[O*C1
M,XQG:H&<9.,X]:MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 445Q]]\0OLUY)IBPL\B*OE[
M6Y=F56"XVX4 ,2S$X 4GVH ["BN4T;QNUQ=?V;=P-!,5W("XD5A@D_,H Z \
M\C@@D$8-NR\5_:;^72MF/)C#[]V<Y"'&W''W_4]/>@#H*Q[;Q1%<7<FE@-YL
M2!B2!LP0IX.<Y^<=AWJO>^*_LU_%I6S/G1E]^[&,!SC;CG[GJ.OM7'MJW]FZ
MW<LJ-)(\*)&B]68K"0,]%  )9CP "?8@'J%8]MXHBN+N32P&\V) Q) V8(4\
M'.<_..P[UF:-XW:XNO[-NX&@F*[D!<2*PP2?F4 = >>1P02",'*T;_D/77_7
MNO\ *"@#L--U^#4GEAA;<\#;9!M88.2,9( /*GIFM"N7\):W%J%Q=Q1P+$T,
MNUW7&9#N<;CA5Y^4GDGJ>?6I;>/Y=69CI]JT\2'!=I%A!//0,#D8P>Q&1E1Q
MD [.L_4M?@TUXH9FVO.VV,;6.3D#&0"!RPZXJ72]274HUG0, V>'4JP*DJRD
M'H5((/N.,BL+Q;K<6GW%I%) LK32[4=L9C.Y!N&5;GY@>".@Y] #J**Y+Q-\
M0%T&ZCLFB9Q(@;,9R^69E"A,#)) _B'7IQR6?C>5+F.QO;<VYG!V,95=21_#
MD #)Z8!)R5&/F!H U?$WBJ#PY&)IR?F.%5<%V]< D<#N20!TZD V-$U?^U4,
MOERQ88C;.FQC@ Y R>.>OJ#7G_Q*O9Q?68$.1',#$?,7]Z28B5Q_!@_+D]<Y
MZ5T>H>.GTF)6NK=DGE=EBA1UE+8 P=RC !9@N.6[@&@#K:*XRY\?RZ2RG4+5
MH(G. ZR+, >.H4# QD]R<'"GG&GXU\5_\(Q"MSL\S=($QNV]58YSAO[OI0!T
M%%<I8>,9[J*2]:U9+=(9)(W>1=SA.5!0#*[ASGD>F003GZ;\2)]6B,]K9O)L
MW>9^\4*".0%.,N<<D!01P,'(H [NBN'M/B8=4CW6=M)-(B!I%R%5.H(W8.YN
M,J N6!XY!4=!X5\31^(X!=1@CG:RG^%@ 2,]QR"#W!YP<@ &Q17&:AXXNK>-
MKM;&3R%&=TDBQR8'!)BPS  Y_P" _-P*F\1>(#J6FO=VB&1)HI V6"%%V.'8
M@]2I&,#KV)'- '6UGZ;K\&I/+#"VYX&VR#:PP<D8R0 >5/3-<?\ "W4;G[-!
M!]G_ -'_ 'G[[S5_O.?]7C=][Y?UZ5L>$M;BU"XNXHX%B:&7:[KC,AW.-QPJ
M\_*3R3U//J =117&6WC^75F8Z?:M/$AP7:1803ST# Y&,'L1D94<9U?"OBZ/
MQ"KA5:.6$@2(XP5)SW[C((YP>.5'% &]17!:'\39==5EMK1GE0_,/-54"GH?
M,8#YB>BXY )SP16_X1\5+XAC9BACEB<J\;'+*1T[ X/3D#D,.V: -ZBH;NZ6
MT1II#A(U+,<$X"C).!STKDK+QY/J2_:;>SD>V!^^9$5R%^\5CYW$<@ ,<D8R
M#D  [.BN<U_QQ#I,44JAI6N1^Y1%.6R 1UZ [E'0MSPIYK/N?'\NDLIU"U:"
M)S@.LBS 'CJ% P,9/<G!PIYP =G17+^-/'*^%FA#QEUF+9(;!4+MR0".3\W3
M(Z=>>*D_C^6RDB^U6K0P3OM65Y%XS]TNN/D/<AF! W8SM- '9T5@^*O%T?AY
M4#*TDLQ(C1!DL1COV&2!QD\\*>:;I?B.>218+NW: R9\LB1958J"S*2@^4X&
M1GJ >XY .@HKE+GQK)-*]O8VSS^4S*[EA%&&7 *AF!!()Y'![C(YJ[X;\5+J
M[/;R(8;F$G?$QR0.S X&Y3D<CU'8J2 ;U%>?Z)\3I]<RMK9L[IDL/.55 XV_
M,R@9)SQQP,C/.-/Q-\0%T&ZCLFB9Q(@;,9R^69E"A,#)) _B'7IQR =;6?#K
M\$T[V"MF>-=S+M;@';SG&#]X=#WK"L_&\J7,=C>VYMS.#L8RJZDC^'( &3TP
M"3DJ,?,#4NGZW%-J<]D(%66.(,9AC>P(C^4_*#CYA_$?NCCT .HHKAX?B2]S
M<36$-LTDT3LJA9%"L$8JS,S ;!Z?>R2%R.,ZOA?Q<=8DEM9HC!/ 1E&<-D'^
M(' R/4@8P5()W4 ='17+W'C"6>22&QMFG\ARDC%UA0,/X5+9W$<YX&.#R"#3
M_"7BJ?7BQ>W\J-=P+&568.I *%,!E/4\@?J* .EHJIJEQ);1M)!'YL@QA-X3
M.2 ?F/ P,G\,5YK\)-1N8(3%%;^9$UQ\TOFJNW*H&^0C)P.>.O2@#O=$\41:
MQ+/;QA@UJ^URP !.6'&">/E/7':MBO*O"NM-I]YJ$4,333R7!VHI"C"/+N9G
M/"@9 YZD@#KD=EX7\7'6));6:(P3P$91G#9!_B!P,CU(&,%2"=U '1T5RESX
MUDFE>WL;9Y_*9E=RPBC#+@%0S @D$\C@]QD<U=\-^*EU=GMY$,-S"3OB8Y('
M9@<#<IR.1ZCL5) -ZL36?&EGHS>5/*JO_= 9V' /(0$C((QG&>U'C366T:SF
MNH_OJH"]."[! W((."<XQSC%4OA_H,=C;1W) :>=/,>4CYSYN'P6))P.!UP2
M-V,DT ;&C:_!K2^9;2*X'7'##D@94X(S@XR!GJ.*T*J+I42RF["*)2I4N!AB
M#MX..OW1C.<8P,9-<O;>/Y=69CI]JT\2'!=I%A!//0,#D8P>Q&1E1QD [.BL
M'PKXNC\0JX56CEA($B.,%2<]^XR".<'CE1Q6!H?Q-EUU66VM&>5#\P\U50*>
MA\Q@/F)Z+CD G/!% '>T5P^G?$PZD/(AMI&NP7#0Y"A=A&2TC 8'..5SN&T@
M9!.QX0\7KXB5QL:.6%MLD;9)4DG'.!Z'(P"""".A(!T%%<)HGQ*DUQ#]FM6>
M56.Y!*%55P,,9&4#+$D!0"<*3VYV_"'B]?$2N-C1RPMMDC;)*DDXYP/0Y& 0
M001T) .@HKC-0\<75O&UVMC)Y"C.Z218Y,#@DQ89@ <_\!^;@5MQ^)H[BS;5
M(0601.X!^4_(#E3UP<@C/([C(H V**X33?B1/JT1GM;-Y-F[S/WBA01R IQE
MSCD@*".!@Y%::>.5N-/.K0QER@^:,-R"& 8$@'  .[)'W<$@9X .HHJC#K$;
MVXOCE8C$)#D<A2N[D#/('89]JB\-ZNVL6\=VR&,R G:3G R0#G R" "..AH
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M!N+*K'.5^4 $DG)Z<X!)#O%WB/[!9QW-[:JS-+M,+NKA3A\-NVL"<#L.^,T
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MD*JJN &"LP9V8J @&!U)R6 'K0!VM%<UX8\9_P!KRRV4T30W$/)0G<"O R&
M ZD>Q!!4D$X9J/BFZC9_L]E))'$6!9W6,DKG)1"&9U(P5(^]T R* .HHK!T#
MQA#K%J=0&46,-Y@()VE%W,.!\PQR"!R.P.0,C3?'MSJ:FYALG:W#-\XE4.54
M\D1D L<=@2"WR@Y% ':T5S7B?QG_ &1+%90Q--<3<A =H"\C)8@CJ#[  EB
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MF]CJ$=GKUP)&"^;$B+GNQ6(A<^IP<>IX') KTBO-(=*BU36[N&=%=#;KPPS@
M[81D'J#@G!&".QH L>.9EO\ 4;"UB(:6*4NZ@_=7*/R3QG:A..N,<<C+],_<
M:]<;_E\VW&S=QNP(L[<]?NMT]#Z&NHT/PC:Z&S/;1A&<8)RS''7&6)P/7'7
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MF&#D'. 0#RHZYJ74]*BU1##.BNA[,,X.",@]0<$X(P1V- '+_%G4([>P>%V
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MC_B/_P ?FF_]?'_L\-&C?\AZZ_Z]U_E!78:EH$&I/%-,NYX&W1G<PP<@YP"
M>5'7-$.@00SO?JN)Y%VLVYN0-O&,X'W1T':@#C_AQ_Q^:E_U\?\ L\U&C?\
M(>NO^O=?Y05V&FZ!!IKRS0KM>=MTAW,<G).<$D#ECTQ1#H$$,[WZKB>1=K-N
M;D#;QC.!]T=!VH \_P!-UB6PENQ;36T:M>39CO'PP(QEU*[20QSP1\NT $G)
MKL/!&EBQ@+^:LSSR/*\B$%"[<-MV\8!&/KG@=!RFG:Q8V@;^UXE2\>1V?SH6
MDR"Q"E&(?]V  JX./E./4V/A_IXDO+G4+52EC(-J Y4,P*Y94_N@AL=,;MH
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M(E3>#QNQ&./4?NVY'''7D9?\%/\ CSD_Z^&_] CKM=,TJ+2T$,"*B#LHQDX
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M=J[F&-JE5Y!!. <<FK>J:7'JL;6TZ[HWQD9(S@@CD$'J!WH Y+4]!&M:/%&
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MAV08!RRG'7&5(R/3/3)QU-.L?"MK8Q/:Q1JL<BE7 SN8'/!;.X_>.,GC/&*
M,KX6_P#(.@_[:?\ HUZRO@I_QYR?]?#?^@1UVNEZ7'I4:VT"[8TS@9)QDDGD
MDGJ3WJ+1- @T1##;+L0L6(W,W) &<L2>@% &A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 445CVUS=M=R1/&HM @*."-
MY;"Y!&X\<M_".@Y]0#8HHHH **X34M:O-4U%M*M9%@2"/<SE%D9LA3T88X+
M8R.Y)/ ':VD;1(J2-O<* S8"[B!RV!P,GG':@":BBB@ HHHH **** "BBL?Q
M1XHB\-Q"XF#%6<* @!.2">Y7CY: -BBJ^HO(D3M" TH1B@/0L =H/(X)]Q]:
MKZ!-/- CW:JDYW;E3E1\QQCYF[8/4T :%%%% !1110 45GZ_K::) ]Y*&*1[
M<A "WS,%&,D#J?6K&G7JW\27"9"RHK 'KA@",XSSS0!8HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHKG_'NJ2:592W,#;9$V8. <9D4'
M@@CH3VH Z"BL_P /737=M!-(<O)#&S' &2R DX''6M"@ HHHH **S]?FGA@=
M[15><;=JOPI^89S\R]!D]15C3GD>)&F 64HI<#H&(&X#D\ ^Y^M %BBBB@ H
MHHH **** "BL?1/%$6L2SV\88-:OM<L  3EAQ@GCY3UQVK8H **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[(_]D^1M;S/L.W;@[MWDXV[>N<\8ZYH^'%H]I80Q2JR./,RK@JPS(Q&0>>E
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M&TK 2O,N(UV$,=KC(89'WNX'RJ2PQ8\1^&9M*EM=1LD,QLXO+9&8;BBJ0",
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M$2%&=A.I(12QQL<9P >.:[B@#R3X7Z'+JULZ^<\4"S,<0-LD9RB9RV#\H&,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNMY%M(KD9RO*M@8YVL <<CG&,\9S7)>!H5O]1O[J4!I8I0B,1]U<NG '&=J
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M!0$?J6V@'Y?E.?7'&#T(-<_I_A>XT*TU SF/;-%(RI"6V*=C[L*P&!R ,9X
M!Z"M#X3:?';V"3(H#RER[=SM=E7GT ' Z=3U)R ;%[XTL[&1[:654DB7<P8,
M., \'&&)!&%4DGL*?H?BZUUQF2VD#L@R1AE..F<,!D>N.F1GJ*X^QT^.\UZX
M,BAO*B1USV8+$ V/49./0\CD U8U/]QKUOL^7S;<[]O&[ EQNQU^ZO7T'H*
M-C3[:T74YY4D8W9B ="#L"XCP0=HYX7^(]3QZ6)_'UC 9%>90T#;7!#!LY*X
M QEL$<[<XZGBN?T;_D/77_7NO\H*K_#W3XYM0U"X909(IV"$_P .]Y-V/<X
MSUQD="<@':Z'XDM]=5GMG#A#AN"I&>G# '!['&#@^AJOK/C2ST9O*GE57_N@
M,[#@'D("1D$8SC/:N:T#]SKEW$GRHT*L5'"EL1'<0.,Y9N>O)]347A_6_P"Q
M9;S%O+,)+R7]Y;1[SD8)C8':1LW<'D$EMO R0#JM$\9VFMN8;:3>X4L1L=>
M0,Y90.I%;$TRPJ7<@*H)))P !R22>@%<[X L);2!C,GE^;-)(D6?]6CX(3&
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M#?\ H$=>@4 <OX2MK2&XNVM9&>5I<S!@0%;<_ ^5>,EN[=!SZO\ ^%D:?O\
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M\;=V[YD.,Y&/N^AZU%XG\&?VO+%>PRM#<0\!P-P*\G!4D#J3[$$A@01CI:*
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M..F,<;=ORUVM% '.7_@N.6P.D0L43"@,1O/#AR2,C))!] ,\#'%7?["_T/\
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MBR\*?9K^75=^?.C";-N,8"#.[//W/0=?:N@HH XJS^'DFF-(EI=/%;RMDQA
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MG2_9<SQKM5MS< [N,9P?O'J.]:% !1110 4444 %%%% !1110 4444 %%%%
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MU=%<)X1\3ZEXB"3B.%( P#LWF N-QW&, GH..<C=GGJ%[B:985+N0%4$DDX
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M [\D1GDYQCYSV':L>P\:W^IW-Q86\41\F1E61]ZHH5R/GP26+ 8 7'.3@@'
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MY&/=00, G)&/4 %OPIXUA\3^9Y"NOE;<^8%'WLXQAF_NFN@KS3^SE\%ZA:%
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MEO'YUS/G8F0  !]YN^,_0$!LL,5F:GXHU#PX!<7L44D!.&-L7#)DC!._J#R
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MH7( '"\[PJ@'&X%>U:UMK.K:G']K@AMTC90R)*[-(P*A@=RD+\V>,[<=#ZD
M[6BN,N?B"+C37U6V4;XRJE) 2 Q9 PX*Y&&R",=LX.0)O"6LZAK.RZECBCMG
M'0[_ #3\OWEYQM9N1GG;Z\,0#K:*X+1O%FH>)3)/9) D"/M4W&_>> 3]PGGD
M$\8&0 6P36UXC\7'0X(I7B+3S%56%7!;<0"PR <A>F0#DE1WS0!T=%</>Z]J
MND1?;+B&!XU&72$N)%!'4D[EPI^]C=Q[982^+?';:?91:E:!6$SJ,2<X#*Q(
M.UA\P*X/)P<B@#LZ*X+5_%FI:="-2>")8,INC9G,ZJQ Y/RJ"3[$KD97@UH>
M+?&S:=';_9%$DMZ1Y6[A,';R<E3D[@ .,9R2,8(!UM%8FB27X<I>+"4*DAH"
M_!!'RD/R=P.01TVG/45MT %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7G_C*['AB_AU<AO*EC>*41H"
M20,KEB0,DX[@X3J1Q7H%5[W3HK]=DR*Z@Y =0PSTS@@\\T <Y\-],-O:_:I1
M^_NV,LC';D[R2OW1TQ\V.Q8].@Y7P!_R!KS_ +>/_1"UZE#"L*A$ "J   ,
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M<G\S1;:=%:LSQHJM(<N54*6/)R2!R>3U]30!P_P4_P"/.3_KX;_T".CX<?\
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M%<D8/0Y'L:["QTF'3\^1&D>[&?+15SC.,X SC)H XK1O^0]=?]>Z_P H*?\
M%&%K=K/4B"8K6<%PHRV"R$'TQ\F.2.2H[UVJ:=$DAN BB5A@N% <CC@MC)'
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M%&>F< #GBA-.B20W 11*PP7"@.1QP6QDC@?D* .'UG_D/6O_ %[M_*>C6?\
MD/6O_7NW\IZ[A].B>07!13*HP'*@N!SP&QD#D_F:'TZ)Y!<%%,JC <J"X'/
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MF!7&-ISR0 RDX'(]*L=)AT_/D1I'NQGRT5<XSC. ,XR:ENK1+M3%*JNAQE7
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M-OABC1B,$HBJ<=<9 ''%37.G173*\B*S1G*%E#%3P<@D<'@=/04 </\ &O\
MX\X_^OA?_0)*] JO>Z=%?KLF174'(#J&&>F<$'GFK% &/?\ BVVTZ<6<[B-V
M0,"_"$$L/O= 1M[XSD8R>*X?7;F+5]5M6T_YY8V5IY(C\I0%>K X.%R">X(3
M)/RCTB]TZ*_79,BNH.0'4,,],X(//-%EIT5@NR%%12<D(H49Z9P .>* ,^Y\
M416]W'I9#>;*A8$ ;, ,>3G.?D/8]JY+Q5;OXDU.*Q@D6,V<?FERA9E8LI P
M<!OX#Z<G))XKO7TZ)Y!<%%,JC <J"X'/ ;&0.3^9IT=HD3-*JJ'DQN8 !FVC
M R>IP.F>E 'G7CKPC>SVCR377GK#^\V>1'']W()W!NRDG'.>F,XKH+7X@1&.
MS>0,7O<*/+7Y0X*HX.X@@!FQWX'?C/5U1&AVX" 11XB)*#8OR$G)*\?*<\\8
MYYH O5YUXJMW\2:G%8P2+&;./S2Y0LRL64@8. W\!].3DD\5Z+4,=HD3-*JJ
M'DQN8 !FVC R>IP.F>E 'G7CKPC>SVCR377GK#^\V>1'']W()W!NRDG'.>F,
MXJK?ZX!=6'B"7_4/"8W**V%D <,,'L"QQR20K$ X&?5:J?V3#Y?V7RT\K^YL
M79UW?=QCKSTZ\T >;_%WQ'!?VZ6\#"0B569HR&1?E< %AQN;D@=< DXXSH>-
M)1HNIVNJS9\@(T9*@G:</R>.GSY&,DA6P..>S_X1ZVV>1Y,7E[MVWRTV[L8W
M;<8SCC/7%6KJT2[4Q2JKH<95P&4X.1D'CK0!YE\7?$<%_;I;P,)")59FC(9%
M^5P 6'&YN2!UP"3CC.G\1_\ C\TW_KX_]GAKL/\ A'K;9Y'DQ>7NW;?+3;NQ
MC=MQC..,]<58N=.BNF5Y$5FC.4+*&*G@Y!(X/ Z>@H X3XHRBUN+"Z?(BBG)
M=L$@?-&W8'G"D@=3@XJ+XNZC%?V*/"ZNHN5!*,&&?+<XR">>:]"NK1+M3%*J
MNAQE7 93@Y&0>.M5?^$>MMGD>3%Y>[=M\M-N[&-VW&,XXSUQ0!QGC24:+J=K
MJLV?("-&2H)VG#\GCI\^1C)(5L#CE_Q)\46]Y:&R@=99;AD55A(D.0ZMSM)Q
MG& .I)X'4CO9H5F4HX!5@001D$'@@@]0:J66AV]@V^&*-&(P2B*IQUQD <<4
M <!\3[)K#2[:W?!:)X5)'3*Q.#C...*Z+XI?\@Z?_MG_ .C4KH[W3HK]=DR*
MZ@Y =0PSTS@@\\TZZM$NU,4JJZ'&5<!E.#D9!XZT ><>(]>GTRQT^.)S%%-%
M&LLH0L5'EH./0X+'C#';\I&#63K<<$-]8I!=27)\]"WF2B8+F1,8(& 3@Y&<
M\#..,^MRZ=%+']G9%,6 -A4%,+C VXQ@8&/2J\?AZVBV[88AL;<N(T&UN/F'
M'!^4<CG@>E ''ZS_ ,AZU_Z]V_E/1HW_ "'KK_KW7^4%=P^G1/(+@HIE48#E
M07 YX#8R!R?S-":=$DAN BB5A@N% <CC@MC)' _(4 >=>+M3;P9=RW$0(COH
M&Y79Q,@(#;<=!D%L]2Y/S$8KK_!&@G0[2.V8 28W/@ ?,QR02"<E>%SGD =N
M*R/&>F-K-[9VOEL8HV:21S$'CP.0A;MNV$,,@?,I(;  Z77Y)XX)#:KNGVX0
M94<GC=EN/ESNP>N,=Z ':/K4.L1^?;N'3)&1D8(Z@@@$'ZCI@]"*Q?B5K TR
MQE/&Z4>6H()SOX;IT(3<03QD=^ATO#'AY/#\"VD9SMR6; !9CU)Q^0ZD  9.
M*T+BT2YV^8JML8,NX X8=&&>A'8]: .-T7P5?Z7"EO'>A%4?=%NC@%B68!F.
M2,D\G'T'2N4T_2Y8;?4/#W!EC*RH,'<ZJ4)/R[ADJJ;5ZY;![X]CJ'[(F_S]
MJ^9MV[L#=MSG;NZXSSCIF@#DO"/CBS%E%OE5##$JLKD!\QJ <+G+ XR,9STZ
MY Q_$FI+:7UCKKAA;20[<[264NKD;@..DF< DG:V <<]W_PCUMO\_P F+S-V
M[=Y:;MV<[MV,YSSGKFK5U:)=J8I55T.,JX#*<'(R#QUH S4\76LLL=K'*LDD
MQ8 1LKXVJ6))!X'&!W)/ P"1YEX0T'3X&FL=4"K<0R'#/(\:%< #:=R@\\C(
M!*L",C./6K'28=/SY$:1[L9\M%7.,XS@#.,FB^TF'4,>?&DFW./,16QG&<9!
MQG H Y?0K#2;(SRVH4B*(B8AGE38PW$<EE8$+SMR>,'TKE=;%GX?B.H:3=%)
M'*8B5Q(K @C!1LL" 2V7S@Y& 2,>KVMHEHHBB5409PJ *HR<G ''6JMKX>MK
M1A+%#$CC.&2-%89&#@@9Z4 <IKMO8:ZL,>I%8;IK='R28F4,1E<O\OWLC:V2
M.2 .347@+6Y9KN>P69KBUA4E)7&6!W#Y2_\ %G+#)SNVY7"\5VM]I,.H8\^-
M)-N<>8BMC.,XR#C.!4MK:):*(HE5$&<*@"J,G)P!QUH FKS+X1:';W]H[S11
MNPG8 NBL<;$.,D'CFO3:KV6G16"[(45%)R0BA1GIG  YXH Q_'VF/J=C-!$,
MN5! Y).Q@Y  !))"X [G%<5X7TO1-0MXY)=BRA0)!+,T;;@!N.#(!@GD$<=N
M""!ZK6?=>'K:[8RRPQ.YQEGC1F.!@9)&>E '%>([6TAT:9[ 8@D9&'+\D2HA
M/S\C[N/PKK_"?_'G;?\ 7O#_ .@+6A=6B7:F*55=#C*N RG!R,@\=:?#"L*A
M$ "J   ,  <  #H!0!Y;JL.FVR/JNG7/D3!252-\!B'SM,+#=AB ,<(!AMNT
M'+->O)[JVT[6KA2?(ES+M4AB"Z[7QP &"=<@$LN.#QZ1_P (];;_ #_)B\S=
MNW>6F[=G.[=C.<\YZYK0H XSQ=XXLS92[)5<S1,JJA!?,BD#*YRH&<G.,=.N
M >2\6Z8^F:+:P2C#B8$CD$;Q*X!! ((#8(['->H6OAZVM&$L4,2.,X9(T5AD
M8."!GI5B]TZ*_79,BNH.0'4,,],X(//- '.?%+_D'3_]L_\ T:E9]Q;V%Y96
M5M?E5+VZ^6Q)4@B)=Q#]!U'#'!.."0*[6ZM$NU,4JJZ'&5<!E.#D9!XZU%<:
M3#<HL$D:-&F-JLBE1@8&%(P,#@>U 'G_ (8U-K#4%TNTG:YM/+).[$GEX3@"
M0<8!"@8^4;MN-W->EU7LM.BL%V0HJ*3DA%"C/3. !SQ5B@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*@$ Y4<Y(X^8=,]ZL:_-/# [VBJ\XV[5?A3\PSGYEZ#)ZB@#0HJOISR/$C3
M+*44N!T#$#<!R> ?<_6K% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7-P481- H#E2$)Q#P&Q@G@_D:/ .G2VMWJ#R(RK)/E"RE0PWRG()'(Y'3U%
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M!>A\<37*A8[*X\X@?+(HCCSU8>:W0#G!*C)P,#- &#XYURXNO[.DM7:%[KG
M<[<OY14-@88 MW4\9XYQ746/@]K>%X'NKAVE"9<R_,I0Y)3(.T-W&3QQGO65
MX^TZ6ZN]/>-&98Y\N54L%&^(Y) X'!Z^AKN* /*OA)H'VR$W7G3)Y=Q]R.3;
M&VU4;YEP<YS@\\CBN@U[2E+N;G47AD;<8U65(%523L!3(+X.06R"P&.,5F>
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M%1R>?0X*CG#';\P&!6?X >?PN7TN>WE;=.")8D+Q?.%7);C"C .>3R00",4
M5-"M+KQ!>WD)N94@AG;(21@_WI BJ3G:HP<CH< 8Z%>SUS2CY4:-=/#!$N)'
MW*LC_="$S-]TY') ^;)'>L?P#ITMK=Z@\B,JR3Y0LI4,-\IR"1R.1T]153X@
M:1*]Y;7S0M<6L8VM$F6(;+$ML'4'CV;;M8@$9 *^A:JVGZFEC#=-<V\\9),D
M@E*E5<X# X!ROH.&P02 :JZ]H'F:S#!YTP\Z-WW"3#IGS3M1L?*HQ@#G@GUJ
M73;)I]5M[N*T>WMQ&XYB"#.V0;F"C"DDX )R0%/0BM/QA9SV.H6^KQQ--%&G
MELL0+.,[\G:!TP^1VR,$KD$@$/Q),N@6$20S2[A. 9&D/F$%9&P6&,C^@'I6
MA;7TVE:JUI(6:"\3=%EG8*R EP"QPH^\2%SC*=!P,_XDB77[")X89=QG!,;1
MGS  LBY*C.!_0CUK3^).E23QQ7MNF^>TF1U7#,2,C("KUY"D], '!'< /M\N
MH:MY".ZP6<.74#Y&>0< D'GA@1N[H<#J:Y*/QG%KDCS75Y+;QAV$44"LC;?E
MVLSH'R3SD'.#D@@'%=E\.M->"![J==D]U-)(ZE"C+EB OS<XZL,]-WXG%\/B
M?P.TMFUO+-;/(SQ/ OF/T488#&.,=E^8'&X'( )?A]XJ-U<2Z:LC3PHI>.:3
M(DQE<HVX9;!;@G'0\8("]U=QM*C)&VQRI"M@-M)'#8/!P><=ZS]"UB35-SO
M\,8V[#*0';J&S&,E<$<9/S @BHO&FFRZG9S6]N<2.HQ\VW(# LN?]H CG@YP
M<#- '#^+!_9$37,.HR/=1.I:,S*5+;@& A!^4 G.T[@ "I&.1L>-/$MQ#I<5
MY#\KSK%O9 ?D$B9)!R=O.%!/3/!W8-<K<V?G:>+.+3I5N55=TC0\\.-S*Y&]
MBQ_A X!/\*UZ!!?RZ+86SK \K+' LB)Q(HV ,0I&20>-O'N0 30!1\&64<Q6
MYM[Z6XVC$BR/N4Y!'^K8;HSN&5)R< CD'-<Z^KG4M0N(+Z[EM5C8I$D;&%2
M20Q8Y494 Y;[VX;3@ 5*-(;5KZWN;*T>U2!E,KR*(-PSDJ$'7@$9&<[L-A0#
M6QXAUM;DRV]UI\LIC+K&5C\Q"I PPD RA;C.W)7UR,  L>,Q+H^ER!97:2/8
M!)G;)@RJ!EEQDA3M)_BY)ZUA>+=>N+:RL%61HTN$C\Z<!F<?*ASN!SDY9B!\
MS;<9QG+%\,7=AHLUG*K-*TBE8T/F,%\R/@!<CJ&; R.<GG-=&-2DTBSM8GMI
M)HW@5)51=SKB,?*8R.0>0<X QSR0" 6/"-BB_P"DV]W+<1.N")9!)AOE*G.
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M6T4B*RO#N8$<,5$I!/K]T#GJ!@\<58U:%4UZV( !:!B2!C)VS#)]3@ ?0 4
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M<''0UUOBS_CSN?\ KWF_] :L#X5Z5$NGJ^Q29]_F9&=P#L@!SVQQCIUXR3D
MZ>+6H98/MRN##L+[AD_*H)/&,Y&#D8R#QC-/TO5(]5C6Y@;=&^<'!&<$@\$
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M69<L,@+F3@@$$[ V 001GJ.1FLBWTJ*WT5D5% >S,C<9RYBW[CGOG!![8&,
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MRX+*Q&P-^[(<9RRE?O >_P"%6]6\1Z?XDM)T:9O(3R_,9$<,N7&S&Y#G)7'
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M .N_X61I^_R?/7=NVYVOMSG'W]NW'^UG&.<XK=U#4(].C:XF8+&@R2?\\D]
M!R3P.:XR[T'4KF!K'98K$ZD;464 9YR!C (/(..O-87B+2I;*/3-(NF#JTY$
M@!)! D55 8@, $<KQC'X"@#3\<^-+/6;">*"56?]W\I#(Q_>*> X!. #G&<=
MZZ_PG_QYVW_7O#_Z M8'Q4TJ)M/9]B@P;/+P,;075"!CMCC'3IQD#&_X3_X\
M[;_KWA_] 6@#E?C7_P ><?\ U\+_ .@254\:^"H/#L']J6.Z&6W93PS,&#,$
MP=Y/K]",@@YXM_&O_CSC_P"OA?\ T"2KMSX EU9E&H733Q(<A%C6$$\=2I.1
MC([$9.&'.0#;MO$<<5I%?73+&)(D8Y.!EDW$*#DD]< 9)]ZAT?QS9ZQ)]G@E
M#2$$@%77..N-RC)[X'.,GH#7)>.A+?:I;6D8B?$+,J7"[HLMYFXM@9/"#'H0
M/>K'B3POJFOJ@D-JC1.&1XS*K@^S$' Z'CN >U '5ZMXNM=(D$%Q($<H7 (;
M[HSW (S\IP,Y)X R1G,UC6+'Q%8RR/*WV8,JNZ*P8$,C  ,A/4K_  GK^6%X
MHT^/4-;M89E#(8,E3T.WSF&1W&0..AZ'BMWXI?\ (.G_ .V?_HU* -C3KB"P
MM8G#@0)%&%>0A?EV@*23MP3QV')Z5FVOQ(T^Z81K.H)S]]71>!GEG4 ?B?;K
M7'^)/])AT>R?F*;R=Z],X6)1R.1P[#@CK["NU\9Z5%/831,B[8H79 !@*8T)
M4C&,8QCCMQT)% &QJ&H1Z=&UQ,P6-!DD_P">2>@ Y)X'-<%XY\:6>LV$\4$J
ML_[OY2&1C^\4\!P"< '.,X[US]Q=-J=KI-K,=T<LS*PP!D1R")1D8(PC$<'G
MJ>>:[#XJ:5$VGL^Q08-GEX&-H+JA QVQQCITXR!@ TM*UJ'1]/MY[APB>1",
MG)R2@P  "2?H.@)Z U;T/Q=:ZXS);2!V09(PRG'3.& R/7'3(SU%<EJOA.76
M[.PG@V,]M#&WERCY7!1#M].2H&#@$$Y88YV-#\8&XN%L+V$PWFP[3PR," S;
M6&< [2<<CY<%BPQ0!UM<?X3C.H7MYJ+_ ,$GV= 6)*B+&_C@ ,=K>QS[D]A7
MG_P4_P"/.3_KX;_T".@#H-3\?6.F.899E#CJ%#/@@D$$H& ((Y!Y'I6QI^H1
MZC&MQ"P:-QD$?YX(Z$'D'@\UQEIXN_M/S4TZR\Z LWF,S)"KLV=W# [LC!.?
MFP1N XSG_"JQ_M#3;BVSM\V25,XSC=$@SC(SC/K0!TW_  LC3]_D^>N[=MSM
M?;G./O[=N/\ :SC'.<5TM>9:9<7'@> VM[;+):9PTL.&SO!SN5L;@<A,L%
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M]X#W_"L+Q3=SW=]8/<VP@;SU /F)(6 DC.,J!@+GC/\ >..];'QK_P"/./\
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MN&]<#KS0!Z%H?B2WUU6>V<.$.&X*D9Z<, <'L<8.#Z&JFL>.;/1Y/L\\H60
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5S]EX4^S7\NJ[\^=&$V;<8P$&=V>?
MN>@Z^U=!10!S][X4^TW\6J[\>3&4V;<YR'&=V>/O^AZ>]%[X4^TW\6J[\>3&
M4V;<YR'&=V>/O^AZ>]=!10!RFL^"&N+K^TK2=H)BNUR$$BL, #Y6('0#CD<
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M<@ @8QZ=<G).%9_#B6VC:Q%W)]D8MF-44/AOX?,.<#^\  &YX&XUW%% '/\
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M*FP,&8?+DG:5!VD9.>0><'L, ',6?P\DTQI$M+IXK>5LF,(&8 C!"R,25..
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MOXM5WX\F,ILVYSD.,[L\??\ 0]/>J^L>"3<7']I6LS07# !F"B1& &.4;'/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT'3X&FL=4"K<0R'#/(\:%< #:=R@\\C(!*L",C./8H85A4(@ 50  !@ #@
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M*4*EAR.?4X"GG+#=\Q.1757NAV]^V^:*-V P"Z*QQUQD@\<U;AA6%0B !5
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ME>H/W@.,;B,#FKOC[3'U.QF@B&7*@@<DG8P<@  DDA< =SBMV&%85"( %4
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M@PQ60<NG*M@JP*MC..#D=1FN@\/737=M!-(<O)#&S' &2R DX''6@#0HHHH
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MU1=-,TLT5S#N'G/N9"NXYR1S]P]-OWAG.T9L:3ITJ:U<W!1A$T"@.5(0G$/
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M>1G!P>0,G&"3C Y-><>);!O$SQBQLY8)UD+M-*@@QDCG(/S')W9Y88.T')H
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M%E @.6+9,A(&!D\ D-@8;YN&>"-)FMM)NX)(W61_/VJR,&.85 PI&3D\#WH
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M*T */&,DE3D J ,Y^=LGG'RG:0&K$^(=W=>);=1#;2K$DHR)(V$Q;:W1%SA
M#RQZD@#H: -OQ]J,MK=Z>D;LJR3X<*Q4,-\0P0#R.3U]31\7=1EL+1'A=D8S
MJ"48J<;'.,@CCBG_ !)TJ64VVH0(TK6DP8QH,LP)4Y&,G@H!P#UST!KG_B)?
M7?B2%$@M)EB63),D>)"P4@ 1@D[<$_-C!/'&.0#5^)][<0S645K(T;RR,O#$
M*3NC"[@,@@$]"#QGBG^)=*E\.:=/(MS/)*1#\[R'@B102G=0V3D9/&!FI?'V
MG2W5WI[QHS+'/ERJE@HWQ')(' X/7T-:?Q'M'N[":*)6=SY>%0%F.)%)P!ST
MH YGQOJTUMI-I/'(ZR/Y&YE=@QS"Q.6!R<GD^]/\5Z/=Z1:G4VO)3<QF,N%8
M" Y8+@1@ 8&1R00V#E?FX9XWTF:YTFT@CC=I$\C<JHQ88A8'*@9&#P?>NF^(
M]H]W8311*SN?+PJ LQQ(I. .>E %3Q-XGD2TMKF)EA-W) "[ .(UD4L3\V <
M8Y)&,9Z'D8_B706TB2V47ET1<3K&5-QA\-QO4XZ*<9^4YR!E>]O7;64:?8PA
M"SA[4-"V1YFQ,M&1@@#C+;\* I)Y %9EKL\(L+Z736A094R)<"=EW#C"DX&3
MQNR.N,\X(!Z5:6_V9%BRS;% W.<L<#&2>Y/<^M87BBP\YA)-=M;P8 "HRQ$O
MR<^:>2"O\'3C/:MVTNENT6:,Y210RG!&0PR#@\]*\Z\1Z6]KJ?VZXMWNK9X\
M((U,NPA0#E#QUR<'CYMP)8$  L>!=7D2^N--$YN(%3S$D9M[?P<!P3D#=@]L
MC("Y(/H=>;^"M/D75)[G[,UO"\'R IM4<Q8Z#:&(&2HY!R#R#7I% 'EGP\M+
MKQ+;L9KF58DE.#'(PF+;5ZNV<( >%'4DD]!6GX7\0RZ+)=:;>.TWV2,RJXY8
MH &()8Y)PRX!S@Y&[ 6L+X7:_-I5N^;>26 RG#0 .X?:N04R#MV@'=T!XYSQ
MN^%_#TNM276I7B-#]KC,2H.&"$!22&&0<*N"<9.3MP5H Y_3_%$.K#[1?W\T
M4C9Q%;AXU0!FXRJL&R,8/4#@D]NK^&?B=]766V=O,^S, LI!#.K%@I*GG.%Z
MDY.>>02:/A?5+GPI%_9US:RN(RVQ[9/-5E9F)SR,'/(Z'!&5&,GL]$U"2_0R
MRQ-#ECM5V!8K@%6('W2<\J>010!YO\/-,NO$L333W<ZQ(Y51'*P<L0I)+'/R
M@8P.>22,<[N@TG497UJYMR[&)8%(0L2@.(>0N< \G\S1\(M.EL+1TF1D8SL0
M'4J<;$&<$#CBC2=.E36KFX*,(F@4!RI"$XAX#8P3P?R- %+P^9_'#2WC7$L-
MLDC)$D#>6_13EB,YXQW;YB<;0,&UHNHSZ'J T>>5IHIHR\+/S(O+-AFX)X5A
MWZ+C:,@5?#XG\#M+9M;RS6SR,\3P+YC]%&& QCC'9?F!QN!R+6BZ=/KFH#6)
MXFABAC*0J_$C<LN67DCAF/;JN-PR2 5UEG\7WT\*SR06UF=A$+%)&8Y!.1D8
MW*>3T4 !068C/BL)K#6[>*:4R@1-Y;,!OV;)0 Q &6!SEN2W4]<#06*?PA?3
MS+!)/;7AWDPJ7D5ADD8&!C<QX/52"&)5@8HHKK4-7M[Z2!DB\IMORL=J[9=O
MF'[JN2<[<\ J#SF@#T#4;U;")[A\E8D9B!UPH).,XYXKA/"^EW/BN+^T;FZE
M02%MB6S^4JJK,#G@Y.>!U. ,L<X'=ZC9+?Q/;OD+*C*2.N&!!QG//-<)X7U2
MY\*1?V=<VLKB,ML>V3S5969B<\C!SR.AP1E1C) +W@O69X;J?1KM_->!59),
M8)7"\,>I.&4]SG=ECQ7,Z9X8\W5KBS\^X&R$'S%EQ*W$7#/CD?-TQV'I73>"
M]&GFNI]9NT\IYU54CSDA<+RPZ@X51V.=V5'%4;^*?0-5DU+R))H;B(+F!2[+
MM"#E?7*=R 0<@D@B@"EXBLY8]6M(+=\2"U"B27YS@"4,YZ;FQDC/!;&>,U;O
MUE\)WUHJSS3173&-DGDWX)*KN!QC@L#P >"-V&XL7=M+>:O:7HBD$7V;DLA&
MTLLIVL>0&&0",]:E\?:=+=7>GO&C,L<^7*J6"C?$<D@<#@]?0T 9_C+Q>#>'
M37N&MH(T4NZ(2[L2K;0RY*C:>#@<[@0P(JEIOBY--NX8K2YENHKAE21;@N60
ME@%=695_O= .<'/52NUK6G3Z'J!UB")IHIHPDRIS(O*KE5X)X53WZ-G:,$;>
ME^*)-3D6-+69(^=[S@1;>"5PI)+Y(P<8V\$]: .2O4NM7U>>QCN)(H51&8*[
M#"A8B0@Z*Q8CGC@G.>5/H6EZ?_9\:P;WDVY^:5MSG))Y; SC.![8KDM)TZ5-
M:N;@HPB:!0'*D(3B'@-C!/!_(UW% 'FGQKT_]S'=;W_UBILW?N_NR-NVX^]V
MSGIQ5OQKH']D:=<_OII=_D_Z^3?C$J].!C.>?7 K0^*6A2ZQ:;(!N:.0.5'W
MB K @#N?FSCOCC)P#2\2ZK+XCTZ>-;:>.4"'Y'C/),BDA.[!<')P.,'% %$:
M!<2Z:+YKJ6-X[56C2%BD01(P5! P69@/F;/!. "J@'IM U"?Q%I\<R2>5/(N
M/,VJ_*/M9MI 'S;3QVSQTH^R/_9/D;6\S[#MVX.[=Y.-NWKG/&.N:Y&X\.75
MSHD5M&K"2-V9XR&5V4/(<;3U/(8 ]<<9. 0"OXGU$>'1%=V-^\["3#1R3B92
M""<E5(XXP>.X(*D#/1_%W49;"T1X79&,Z@E&*G&QSC((XXKDO%5G_:5M'%::
M=+$R,F]C#AON$!00-[C.<L<<@9Y85UOQ=TZ6_M$2%&=A.I(12QQL<9P >.:
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M4[T4A6494\'!)(!RVW .,Y/%&J7/BN+^SK:UE02%=[W*>4JJK*1CDY.>3U.
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M,ML>V3S5969B<\C!SR.AP1E1C)F\.>&9M5ENM1O4,)O(O+5%8;@C* 2<@X;
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M+#&,)&H51DG 48 R>>E357MM1BNF9(W5FC.'"L&*GD8(!X/!Z^AJQ0 4444
M<O\ #SPO+X;MVMYBI9I2P*$D8*J.X7GY:ZBBB@ HHHH **** "BBB@ HHHH
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MN<,2"1N0\8!Y^4]<=JZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** .7O_#]U:7$E_8O'NN @DCG5MGR# 8,GS @<8Z<DD] *\'A:YU2XCO-2
M:(BVYB2WWA=Q(.YBW/&!QG!P.@R&["B@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KSK6/B.MIJ20^=BUC5EF'EDXD7S!C.W=UV_=X_6O1:\_P!9
M_P"0]:_]>[?RGH Z)_'-FB13-* EP6$;%7 .UMK9)7Y0">K8'?I4VD>+K75U
M=X) 5A +DAD"@Y.27"\?*?ICFN2^*5JMW<Z?#(,I),RL,D9#/$",CGI79:U>
M0:/;/),H\B-,% H((.%"!>F#D#' ]<"@#-_X61I^_P GSUW;MN=K[<YQ]_;M
MQ_M9QCG.*VM4U2/2HVN9VVQIC)P3C) ' !/4CM7FOC'7)M5T]B+/R[7Y#'(T
MB JH<*A$6,C(X&.,-P2O75\2_P#(!7_KWM?YQT ;=Q\2-/@VYG7YE##:KMP?
M7:IP?53@CN*VKK58K6(W;NHB"AM^<K@]",9SG/&,YR ,YKE;?2HK?16144![
M,R-QG+F+?N.>^<$'M@8P ,8]EX;E\5:-;P(X$B.6!D)((1Y$"Y&2 %/'!Z 8
M Y !U^C^.;/6)/L\$H:0@D JZYQUQN49/? YQD] :?K/C2ST9O*GE57_ +H#
M.PX!Y" D9!&,XSVK"TKQ:]E)!8:E;"&1B!"T85HL\H  "VP@$+P3][G:IJ63
MQ?ON9H-/M3-*AQ,^5A&4^51O8'<1R!G'0[<CD '2Z/K4.L1^?;N'3)&1D8(Z
M@@@$'ZCI@]"*S=3\?6.F.899E#CJ%#/@@D$$H& ((Y!Y'I7#^"+E[)=6E11%
M)&&8(-K!&7SB%&!M(4C'3!QTQ72_";3X[>P29% >4N7;N=KLJ\^@ X'3J>I.
M0";X@>+ETBUWPR 33 &$@;PP#(6(.&7&UN_7/%6/!WC.#6T2$2;[@0JT@V,O
M("ASG:%^\>WX<51^(>GQZ?I<T,*A4!0A1T&Z96.!V&2>.@Z#BMWPG_QYVW_7
MO#_Z M &5X"CLK"V<V<K/ )&9GE^7!"+NZJG  !SCUYJ;_A9&G[_ "?/7=NV
MYVOMSG'W]NW'^UG&.<XKRF&Z:'1713@27VUN!R!$KX]N5!X]/2O:_P"P(/(^
MP>6OD;=NSMCKUZYSSNSG/.<\T 6)M0CBB-T6'E*A<L/F&T#=N&,Y&.>.O:L*
M3XD:?&JR&=</G&%<MP<'*A25]MP&>HR*Y3P/=--HMTC'(C6X5>!P#$'Q[\L3
MSZ^E;?PKTJ)=/5]BDS[_ #,C.X!V0 Y[8XQTZ\9)R =5:ZK%=1"[1U,14MOS
MA<#J3G&,8YSC&"#C%8^G_$.PU"18(Y@7<X4%'7)[#+*!D]N>3P.:XWP-I+^(
M-(GL@^"9B$+9*C;Y<F/8$YSCIDG!/!T+#Q!)X4CCLM2MU6!6"I+#AD)0J0S+
MDD$D%]W#$\A,@X /1:HZ=K4.HM(D+AFA<HXY!5AQT(''!P>AP<'@U>K@FN%\
M-:K*SY6"\@,AVQ_*'A!9CD<DA59CCDEQD'@T =?!K4,\SV:N#-$%+)R" P!!
MY'(Y&<9QD9QFG_VI'YWV+=^]\OS-N#]W=MSG&.O&,Y]J\J\-)+I=S;:Q)NQJ
M4DJR*L> ID?Y!EB>&.''0[0<;AG/5^ )%U:>\U8;3YLWEH0I!V1*,')Y^<%2
M1QR,^@ !1TW5;+PWITTEE,Q5GD",ZDGSC$"JX\M>/E!Y&/4U>\!>/8]5CBMI
MY=UX^_(V$9P6(Y"A/N =_P!:Y_P!_P @:\_[>/\ T0M=5\+?^0=!_P!M/_1K
MT <[X/UJ'1[G4Y[APB?:0,G)R3)-@  $D_0= 3T!KNM#\26^NJSVSAPAPW!4
MC/3A@#@]CC!P?0UQ7P]T^.;4-0N&4&2*=@A/\.]Y-V/<X SUQD="<V- _<ZY
M=Q)\J-"K%1PI;$1W$#C.6;GKR?4T =U=W2VB--(<)&I9C@G 49)P.>E>=>&_
MBE'YUS]KF_=>9^X_=G[NY_[B9Z;?O<_K7I=>?_#C_C\U+_KX_P#9YJ *]MJ$
M>G:U>7$S!8TME))^D'YD] !R3P.:[#0_%UKKC,EM('9!DC#*<=,X8#(]<=,C
M/45Q]CI\=YKUP9%#>5$CKGLP6(!L>HR<>AY'(!JQJ?[C7K?9\OFVYW[>-V!+
MC=CK]U>OH/04 =5K?BJUT3 N9%0G&%Y9L'/.U03C@\XQGC.:?H?B2WUU6>V<
M.$.&X*D9Z<, <'L<8.#Z&O/="%W?:A>SVXMVDCFV[KA6W* 710A0<?*N&]<#
MKS6[IWA>^.H)JEP8% 0JX@,@WC:P&0P^8YV]3T4>@H [BO/_ (<?\?FI?]?'
M_L\U>@5Y_P##C_C\U+_KX_\ 9YJ .ZNKM+13+*RH@QEG(51DX&2>.M86G_$.
MPU"18(Y@7<X4%'7)[#+*!D]N>3P.:Y_XK2R22V-JFTB2?.V090LI15W<9V_.
M00.H/TI^N>&=2UF#[#(+-8QMV[!*"NWIMR"!QQTZ$B@#M=3U6+2T,T[JB#NQ
MQDX)P!U)P#@#)/85S_\ PM+3O^>W_D.7_P"(K*\21O82Z8TB^?+"LFY!EG<K
M$I>12PPQ4KN )#,V,<Y(MV=S+KM_#=QP2P1V\<@D:=?+9PX^5 .=P4C=UP#G
MH<;@#?UOQ5:Z)@7,BH3C"\LV#GG:H)QP><8SQG-/T/Q);ZZK/;.'"'#<%2,]
M.& .#V.,'!]#6+K'BM;>[^R6MN9[Q4 8C;'M0C?@R,#QR#C[N6'.[BN?\&N[
MZS<M)$(7:#+1AE;!)B).Y< EOO'W//- %WX<?\?FI?\ 7Q_[/-7H%>?_  X_
MX_-2_P"OC_V>:O0* /)/A?X,M-;MGFN8][B9E!WNO 1#C"L!U)K;M)9/!U[#
M8/*\EG<KMC\TAF1QM4+D#./N@#Y5&_\ V22?!3_CSD_Z^&_] CH\>?Z9J.GV
MT?,B2&1ATPNY#G)XZ1MQG/'3D9 .JUOQ5:Z)@7,BH3C"\LV#GG:H)QP><8SQ
MG-/T/Q);ZZK/;.'"'#<%2,].& .#V.,'!]#7GNA"[OM0O9[<6[21S;=UPK;E
M +HH0H./E7#>N!UYK=T[PO?'4$U2X,"@(5<0&0;QM8#(8?,<[>IZ*/04 ;4W
MCFSA$I:4#[.X1\J_#$D!0-OS'Y3]W/ )Z<U;T/Q);ZZK/;.'"'#<%2,].& .
M#V.,'!]#7%?#W3XYM0U"X909(IV"$_P[WDW8]S@#/7&1T)S+<0KINNQ"$!1<
MP,9 !]X_O"3[$E%)QC)&3U.0#H]3\?6.F.899E#CJ%#/@@D$$H& ((Y!Y'I6
MQI^H1ZC&MQ"P:-QD$?YX(Z$'D'@\UQEIXN_M/S4TZR\Z LWF,S)"KLV=W# [
MLC!.?FP1N XS%\%/^/.3_KX;_P! CH V#\3=."A_/&"2/N29XQVVY YX)&#S
MCH<86L?$=;34DA\[%K&K+,/+)Q(OF#&=N[KM^[Q^M,^">GQBWDNMH\TRE-W?
M:%1MOL,G)QUXST&+&L_\AZU_Z]V_E/0!T3^.;-$BF:4!+@L(V*N =K;6R2OR
M@$]6P._2FVOCZQNY1:I,ID9BH&&VD^@8C:<]L'GC&<BN:^*5JMW<Z?#(,I),
MRL,D9#/$",CGI1\9K1(K.+:JC9,JK@ ;5V/\H]!\HX'' ]* .GA\<V4TPLTF
M4R,0!C)4DC( <#82>G7KQUXK8NKM+13+*RH@QEG(51DX&2>.M>=?%S2HK"PA
MCB156.8*N!R 4<D9Z\D GU(R<FK'Q6EDDEL;5-I$D^=L@RA92BKNXSM^<@@=
M0?I0!T&G_$.PU"18(Y@7<X4%'7)[#+*!D]N>3P.:T-7\26^CLB7#A#*2%R#@
MXQG) ( &1R2!7):YX9U+68/L,@LUC&W;L$H*[>FW(('''3H2*S_'FFEWTJTN
M3O)8)(=Q.XYA5SNX////!_&@#L+7Q]8W<HM4F4R,Q4##;2?0,1M.>V#SQC.1
M6)\4/&;:(B0VTFRX+*Q&P-^[(<9RRE?O >_X57^,,*VEI \0"-%.@0J-I4;&
M.%(Z#Y1T]!Z"G_&O_CSC_P"OA?\ T"2@#JM"\4VVO;OLS[_+V[OE9<;LX^\!
MZ'I6M110!PGQ4U1[58+<LR6UQ(5G= =P7*Y4'!QD%CC!+;<<C(.A9?#RQB:*
M[M0R,C*ZO%*Q##'3YBP*L#SC&1QG!-=!J>E1:HAAG170]F&<'!&0>H."<$8(
M[&O-]9TR3X<&.\M)&>W9]LD,K=2P)R-H !(7KC(('WE)  /0]9U^#15\RYD5
M >F>6/(!PHR3C(S@''4\57T/Q=:ZXS);2!V09(PRG'3.& R/7'3(SU%</J N
M+_694@$+O!"FS[2I*J!Y;Y&T9W!F)![ GGI6G=>%]1U&ZM[V8VZFW<9,)E5V
M3<"RDD'(QD 9 ^8YZF@#I];\56NB8%S(J$XPO+-@YYVJ"<<'G&,\9S3]#\26
M^NJSVSAPAPW!4C/3A@#@]CC!P?0UY[H0N[[4+V>W%NTD<VW=<*VY0"Z*$*#C
MY5PWK@=>:W=.\+WQU!-4N# H"%7$!D&\;6 R&'S'.WJ>BCT% '6ZM</;0R2Q
M#=(D;E5P3E@I*C Y.3V'->>^!_#UGXKA:[NLS73.QE+.ZE<G"#:I4!=H&.HZ
M@' P/3:XK7?AC%<,;NS9K>X"_+Y1V1YQCHHR,C@[2/7!.<@'2Z7IZ:' L&]C
M'"I^:5@2%&3RV  %' Z  #TK*_X61I^_R?/7=NVYVOMSG'W]NW'^UG&.<XK@
M=?\ &$VMZ0'DP&-RL3D ?.%3S <8^4YQG'<<8!P.HN]!U*Y@:QV6*Q.I&U%E
M &><@8P"#R#CKS0!W$TRPJ7<@*H)))P !R22>@%85KX^L;N46J3*9&8J!AMI
M/H&(VG/;!YXQG(KC/&UI/H6CPV4KAF\T(Y!+ J"[JH+ ' VKZ8QCI7H?]@0>
M1]@\M?(V[=G;'7KUSGG=G.><YYH X_QQX]_LJ[@MHI=JI(/M(V9PIV$<E3_"
M3]TY_'%6/%&JZ;XDM!)-,P@6< ,BL#O"$[<&-CC:V>F/>J_Q'_X_--_Z^/\
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M20" <=<GBW3_ .T-9MH-[Q[K<_-$VUQCSCPV#C.,'VS5?Q5IDG@J:'5TD:<
M^6RW+;W^8,?E?'RC&>1@@_W@Q% 'J=%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]ST'7VKH*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQJ5[J6ISZ;!<>3'%&KC]U')_#'D<@'DN3UJQH7B*ZT^].CWY$IE!:*50JY4
MGE1C .T^X8$?,I! !W%%%% !17#^ =1ENKO4$D=F6.?"!F+!1OE& ">!P.GH
M*Z#PO;7=O$5OY%DEWD@H !MP,#A4YSGM^- &Q1110 4444 %%%% !117#_"+
M49;^T=YG9V$[ %V+'&Q#C))XYH [BBBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=NX  N/O,  ,@ '(;&<C%OX<^';K29;J2\ W3.I# J0Q!D+, O0'<#R!UZ4
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M;F.Y)8-O2)UW,6*Y8GCGG (;"G(((H ;\(;W<;JUC=GMX9%\G=UVL7YZ C(
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M*A$ "J   ,  <  #H!7->//#,FL1QSVQ N;9]\9/?&"5Y^7)(!!((R,' )-
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MKABN0<D# V\@XR"><@ @'&_;;*QO[1](=AYD@CE4>9M*LZC'[P9.X$]R!@$
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MR.*ZOPS<3WVGLFI/);E'"^:289-HV%26?N2=N>XX.3DDT>XU31(ELWMEN!$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 8/B?PP=>: ,X$4,HD9"@</C& 22,#&X=P=W(XK>HHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K!3PP3?'5'<-B+RT0H/DZ$D/GDG
MYNV<,1G%;U% !1110!D^*="_MZV>RW;/,V_-MW8VL&Z9'ICK5O2;'^SX8[;.
M[RHT3.,9VJ!G&3C./6K=% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M?K^F-JD$EJC^695V[MH; /WA@D=1D=>,Y'-:%% %'1-+72H([5<8B15R!MR0
M.6QZL<D^YZFFZ7HB:<TLJEF>>0NS.06Z8"@X!VJ/N@YQS6A10 5S_@KPI_PC
M$+6V_P S=(7SMV]548QEO[OK7044 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS]T'U'6@#U/POXHB\21&XA#!5<J0X .0 >Q;CYJS_%'Q#M_#<HMYED+,@8%
MI&"2.[+S\M;&B:_!K:&:V;>@8J3M9>0 <88 ]"*T* //_P#A==G_ ')O^^4_
M^.58?XNVB1+<%)=KNZ@;4SE A/\ 'T^<8_'\<+P!_P AF\_[>/\ T>M'QS_Y
M=?\ MM_[3H ]-U&]6PB>X?)6)&8@=<*"3C..>*S_  OXHB\21&XA#!5<J0X
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M!VM%<5\-]3O[[SO[0#C;Y>SS(A'UW;L85<]!ZX_&NUH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK<9"]UZGGTT-<\76NALJ7,@1G&0,,QQTSA0<#TSUP<=#7+_$?_C\TW_KX_\
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MC=QN4JW/H0>1TZ'J!CA]$O%\)75Y9R\1,K7,2J$4;0"751G.0!@#IA"V%'4
M[6WU2.YDDMD;,D&S>,$8WC*\D8.1Z$^]6ZY+X:V;"W:^D $MY*\K?+MP&)VC
MDDE>K+[-QZGK: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K$NO#7VJ]BU)I&Q!&RK&!\NYL@MG/<'&  >!S@8K;HH
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M\\?_ ")+_P#%T?\ "K=._P">/_D27_XN@"EK]GINK111+=1Q-;#]RZ3IE<
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M!\[T;HK#&-Z_WO6L>\T6"YC6Q.J+]D4KB-FA+X7^'S PR/[H((7C@[171?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBB+PW$+B8,59PH" $Y()[E>/EIWA/_CSMO\ KWA_] 6N5^-?_'G'_P!?"_\
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M7M5TB+[9<0P/&HRZ0EQ(H(ZDG<N%/WL;N/;+  ZK6M8CT>%[N;.R,9.!DG)
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M>JGA_P 6RRW#:7?1K'<*I960_NY!D\J&YZ<]3T;.T@BLK1O^0]=?]>Z_R@H
MZC1/%$6L2SV\88-:OM<L  3EAQ@GCY3UQVK8KE/#'BY]2FO8I]BQV<F PROR
MAI 2Q+$<!!SP.M4M,\4:AXC!N+***. '"FY+EGP3DC9T X!'(!R QP< '<45
MR0\831W5M;S1"**Z1Q^\8!UE1B"N<X93A0O W;@0?X:O^(=>DL9K:TA4,]S*
M0=W01H,R'.X?, <CKT/&< @&]6)J'B,V]W#IT:;WE5G<Y*A$' 8X5@<D$ 9'
M. 2-P-;=<5X4N5U+4KZX^8F'RXEW$\ ;@X R1@NF1^?!)H [6BN,U;Q9=3WI
MTJP2/=&FZ1Y]VWD*1C:0<?,!W))Z #)O7OB:70K1[J_5/,1MJB%OED)P5V[N
M1U(8') 5F (P* .EHKBKO6=6M(VO9(;<1QY9HM[&4(IY^8'9G;SG_P =S\M:
M5[XY@M[+^UERR,/D4X5BV=NWGN"#G&> 2,@<@'1T5Q5WK.K6D;7LD-N(X\LT
M6]C*$4\_,#LSMYS_ ..Y^6NGT76(]8A2[ASLD&1D8(P2""/4$$>GH2.: *_B
M#Q+%H2JTNYFD8*D<8W2.20,*N1G&>?P'4@&EIGC>.]F6T>&>%Y Q3SXM@;8,
ML <GD#GT]\D X7CZRGTV[AUV!/,6WC(D7IA1NR>N>0YY (7;N.171>&?&MMX
MC!$#$.HR4<8<#.,]P1]"<9&<$XH WJ*Y*^\4W-]</8Z='&Q@*B269_W8+!CM
MVH=Q.1C(SA@05'6G:-XIFCNO[+OU19W7?&T.XQLN#D?-D@C:>N <'IQN .KI
MDTRPJ7<@*H)))P !R22>@%<;%XMN]=EDCTV.+RH6*F:<L4<C'"^7^)_BRN"=
MN0#+XAO+NYL)P41)8UD67?N*,@C)9XB.3N!&W=T.5;D4 =5:W:7:B6)E=#G#
M(0RG!P<$<=:S?"_BB+Q)$;B$,%5RI#@ Y ![%N/FKE_A;]L^S0?ZG[)^\_O^
M=]Y_^ _>_P#'?>KOA+QVVH64NI7851"[#$?&0JJ0!N8_,2V!R,G H [.BN'L
MM>U75XOMEO# D;#*),7,C #J"-JX8_=SMX]L,;NF^./[2M+B[5/+GMEEW1.<
MD,BDC(^4X.,<A3D,.V: .KHKS_0_%>J:]!]I@AA7;NYD+@2$= BY&,8P2S8)
MZ$8('1>"O$P\1VRW) #@E7 S@,/3/8@@]\9QDD&@#;FF6%2[D!5!)).  .22
M3T KDKCXG06VUY(KA8G8!96AQ&0>C DY((Y'&<=NU=;-"LRE' *L""",@@\$
M$'J#7FOCKQW;:W;G3[1@[S$9+'RD4(0^2TNT9., 9_'. 0#TJ&99E#H058 @
M@Y!!Y!!'4&HM0U"/3HVN)F"QH,DG_/)/0 <D\#FF:38_V?#';9W>5&B9QC.U
M0,XR<9QZUQ7Q0_TF:PLGYBFN/G7IG#(HY'(X=AP1U]A0!H+\3H%"R2Q7$44G
M226'$?(+#E2Q.0., ^O3FM7Q1XC.@*D[)NB:15D8$YC#'[^ K9 ^HYP!G/!X
MVM5NK&X1QD"%VZD<H-ZGCT(!_GQ7-:9_Q,]!/G?-MMY<=O\ 4EO+Z8Z;%^N.
M<Y- 'H%%8/@;5&U2R@G?.XIM))W$E"4+$GNVW/X]3UJ]K=Q/ @^RQK)(S!?G
M?:J@@_.>Y .,J.2.E &A17#MXLO='NH+6_2(QW)VJUONX8L!SO/09&>!P<@D
M@K5OQQXPE\/2VR1H'6=V#@*6?"E!A &'S'<<9SSB@#K:*X35O%>HZ%LN[J&(
MVS-\XA+-)&&Z!F)"DC.,@;21C*[@:M^,O&KZ*]KY"K)'<L<[078J"F-F& )(
M8XZ@G% '85S_ (D\5_V+-;6VS?\ :I-F=VW;\R#.,'/WO4=*Q-6\5ZCH6R[N
MH8C;,WSB$LTD8;H&8D*2,XR!M)&,KN!JO\0IEFN],=""K3Y!!R""\)!!'4&@
M#T.BN<@\22+J#Z9*JJAB62%LX9N@88R<G.['0@*3@@YJ6\UZ1;Z+3HU!4Q/)
M*Q[+RJ;3N'.\8(P>",=\ &]5>VU&*Z9DC=6:,X<*P8J>1@@'@\'KZ&G7>_8W
ME;?,VG;OSMW8^7..<9ZXYQ7E7@K[?]IOOL_V?S/._>^9YFW=OD^YMYQG/7G&
M/>@#UNBN/O\ Q;<7MT^G:=&C-#CS)923$IP?EPG.<X'7.0PVX!8%AXMN+*Z3
M3M1C16FSY<L1(B8X'RX?G.<CKG)4;<$,0#L***X35H=;NGDD@:**-&<(GREG
M522K997 +# Y91D<@=2 =W7%>&_B1_;4-S<^3L^RQ[\>9NW?*YQG:,?=]#UH
M^&7C.7Q&DB3A=\.SYEXW!@>HZ9RI)Q@<\ 8YXGX<?\>>I?\ 7O\ ^R34 >E^
M"O%?_"3PM<[/+VR%,;MW15.<X7^]Z5T%>?\ P4_X\Y/^OAO_ $".K?Q=U-[&
MQ*QG'G2+&QY!VD,Q P1UVX/4$$C'- %J3XCP,[16\<UQL^\UO%O4')&,Y'IP
M1D$=":V-#\10ZTK&$G=&<.C JZ-_=93T(Y'<9! )P:L:5IB:7$EK$,)&H Z9
M..I. !DGDG'))-4O$VN1>'H7OG4%L*H P&<Y.U<GL,D]\#<0#S0!L45Q7]L:
MOY?VWR(=GWO)S)]HVY^[_=W;>>F?]G=\M2WGCSS=-;5K<+O7:"CG<%8NJL#M
M(/0Y'0D$' SB@#L**\__ .$KU2XM/[2CAA2-8]Q60N78#EI%&5 4CD G.!D%
MLKD;QS?:C;MJ%G BPQ+EC.Q+/@ OL"[1A"#DD_-V&X%: /0**Y^V\4_;M/;5
M(EP1#(X5^0&C#9!QC(ROL2/0],+1O%6I:];BYMH8@5#;C+O =@3@1@-T  !9
MF +$@8VF@#O:*YKPOXM;6[=Y/+Q<P;E>$D*=ZC@?-RH8\?-T((YVY.3KGB/5
M-%C^W2Q6_DAEW(K.9%5CC!;(4D9"DJ",G(!% '=T5Q_C+QJ^E6<.H6RJ?/:/
M E!.%=&?HK#G@=R.M4M7\6:EIT(U)X(E@RFZ-F<SJK$#D_*H)/L2N1E>#0!W
MM%<OX@\7MIQM+B,*UK<N%=V.W:) "C#)&!C+'(Z#!*DYJUXQUZ31X5:!0\TL
MJ1QAONEG/?YEP, \YZXSQF@#>HHKDK[Q3<WUP]CIT<;& J))9G_=@L&.W:AW
M$Y&,C.&!!4=: .MHKE-&\4S1W7]EWZHL[KOC:'<8V7!R/FR01M/7 .#TXW95
MAXUO]3N;BPMXHCY,C*LC[U10KD?/@DL6 P N.<G! . #T"BO/[/QS?-/)I3P
M(UVK<,C$0JI7/F-G<<#*G'!8-M^5@ VGX5\63WES-I=XBK/"-P,6=A7Y?4DY
M.X$>QP0I'(!UM%</=^-+H:A-I4$2OM1=APPP65"6D;=]Q=QZ#).U1R<U+I_B
MRZLKM=/U%(U\X?NI(=PC) Y7+GDGIC@AL#!# T :=EXK^TW\NE;,>3&'W[LY
MR$.-N./O^IZ>]=!7G^C?\AZZ_P"O=?Y05;B\6W>NRR1Z;'%Y4+%3-.6*.1CA
M?+_$_P 65P3MR 0#M:*Y3P_XMEEN&TN^C6.X52RLA_=R#)Y4-STYZGHV=I!%
M6/!/B236HY%N%5)X)6C=4.>G0XR<#J.I!*D@]@ ='17+V?C$L;VXE 6VM'V*
M> [,@_>+RV"2V G3.X#KG%*VUG5M3C^UP0VZ1LH9$E=FD8%0P.Y2%^;/&=N.
MA]2 =K17))\1X'L3JH!^4[#&2 ?,X^0$]1SG(!^7)QD%17N]9U:TC:]DAMQ'
M'EFBWL90BGGY@=F=O.?_ !W/RT =K17%:]\1/+@MY+)/,DO6VQB3A058*P;D
M<Y.T<XZG=@#.UHDE^'*7BPE"I(: OP01\I#\G<#D$=-ISU% &W117%:KK.K6
MT3WHAMT1%+&-W9Y0%^\2RE4/ +<'IQRW% ':T5S]MXI^W:>VJ1+@B&1PK\@-
M&&R#C&1E?8D>AZ<_H?BO5->@^TP0PKMW<R%P)".@1<C&,8)9L$]",$  ] HK
ME] \<QW]B=3EPOE!A(%_O+V&['+9&T9/+!<DUF:;XGU2[B.HBWB,'S,L0+B=
ME[$'D'U^Z"P'RKRN0#;\%>*_^$GA:YV>7MD*8W;NBJ<YPO\ >]*Z"O/_ (*?
M\><G_7PW_H$=>@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!Y_HW_ "'KK_KW7^4%'QK_ ././_KX7_T"2NX3
M3HDD-P$42L,%PH#D<<%L9(X'Y"B]TZ*_79,BNH.0'4,,],X(//- '.?%+_D'
M3_\ ;/\ ]&I7)>,-/#V6FWDBEH(4B$H7.[:ZQ^F, [2,Y')4#KQZE=6B7:F*
M55=#C*N RG!R,@\=:?#"L*A$ "J   ,  <  #H!0!YU+I'A^./SR8]N <":0
MOSC'R!R^>>1C([XP:]"M+5;1%AC&$C4*HR3@*, 9//2JMKX>MK1A+%#$CC.&
M2-%89&#@@9Z5H4 >>>);>3PUJ"ZVH)MI@L<YZ[<X7. I(7A2,9)8%<C< =;Q
M-XPLY[*8I/&3) X50P+DNI"C9]X')&<CCOC!KK:S(?#%I"P=((@RD$$1("".
M000."* .'TO3'U/0/(B&7*N0.23LG+D  $DD+@#N<55\+Z7HFH6\<DNQ90H$
M@EF:-MP W'!D P3R"..W!! ]5K/NO#UM=L9988G<XRSQHS' P,DC/2@#BO$=
MK:0Z-,]@,02,C#E^2)40GY^1]W'X5M?\P;_N'_\ M"NENK1+M3%*JNAQE7 9
M3@Y&0>.M'V1-GD;5\O;MVX&W;C&W;TQCC'3% 'DMWICWV@0M&,^3(TC#DG:'
ME4D8!Z;LGH  3GBM6UTO0+B(7/R*"I)5YG$@QU!3S,Y]@#G^'((SZ+:VB6BB
M*)51!G"H JC)R< <=:J_\(];;_/\F+S-V[=Y:;MV<[MV,YSSGKF@#S_XEVL%
MKI=NEJ,0&9&3ECPZ2/GYN><YYKT75KA[:&26(;I$C<JN"<L%)48')R>PYI][
MIT5^NR9%=0<@.H89Z9P0>>:L4 >-1:BFJV,M[=7TOV@JX\E9!&I.-J+Y0'S!
MN"Q4 8)SR&-:'_,N?Y_Y^J]%/AZV+&7R8M[;MS>6FX[P0V3C)W G/KDYJ7^R
M8?+^R^6GE?W-B[.N[[N,=>>G7F@"IX3_ ./.V_Z]X?\ T!:Y7XU_\><?_7PO
M_H$E=[#"L*A$ "J   ,  <  #H!45[IT5^NR9%=0<@.H89Z9P0>>: .:^)NC
MF]M&N(\B:U(D1E(5AM/S_,>0 OS8!!)5>N,5S/CVY37;>RU<J6ME?]\J[BP#
ME0PSA> 4*[LKDE<=:]3J&UM$M%$42JB#.%0!5&3DX XZT >>RZ1X?CC\\F/;
M@' FD+\XQ\@<OGGD8R.^,&M/Q1HNEW)2PN66*2.%?+8OL81@[0-[Y5NA&&R>
MI &2:Z6U\/6UHPEBAB1QG#)&BL,C!P0,]*EOM)AU#'GQI)MSCS$5L9QG&0<9
MP* .*\!:W+-=SV"S-<6L*DI*XRP.X?*7_BSEADYW;<KA>*J>#-5BTF_U".Y=
M8FDFW+YIV @/(<Y; Y#@CU!R,C->BVMHEHHBB5409PJ *HR<G ''6J][H=O?
MMOFBC=@, NBL<=<9(/'- '&Z-_R'KK_KW7^4%'QK_P"/./\ Z^%_] DKN$TZ
M))#<!%$K#!<* Y''!;&2.!^0HO=.BOUV3(KJ#D!U##/3."#SS0!PGC24:+J=
MKJLV?("-&2H)VG#\GCI\^1C)(5L#CGJT\76LLL=K'*LDDQ8 1LKXVJ6))!X'
M&!W)/ P"1I75HEVIBE570XRK@,IP<C(/'6HK'28=/SY$:1[L9\M%7.,XS@#.
M,F@#@HM0CTK7)Y+AA&LL"A&?Y5/RQ_Q'C'R,,YQD8Z\5+JDRS:Y9NA!5K8D$
M'((*S$$$=0:[B^TF'4,>?&DFW./,16QG&<9!QG H7284991&@>-=J,$7<J@$
M;0<9 P3P..: ."\.ZA'X:U&\M[M@GVEQ)&[<1D9=L;FQS\V/3<K#.<9/$6H1
M^)=1L[>T8/\ 9G,DCKS&!E&QN7//RX]-S*,YSCT"]TZ*_79,BNH.0'4,,],X
M(//-%EIT5@NR%%12<D(H49Z9P .>* .'T;_D/77_ %[K_*"C6?\ D/6O_7NW
M\IZ[A-.B20W 11*PP7"@.1QP6QDC@?D*'TZ)Y!<%%,JC <J"X'/ ;&0.3^9H
M X+7=.TN[DENTN/LUS$TH9HWV-O PQV'!;O]S&\D\DFMKX:ZY/K5IY]SRWF,
M%;;MW*,<\8!P25R !QCJ#6W=>'K:[8RRPQ.YQEGC1F.!@9)&>E:% '!?%&%K
M=K/4B"8K6<%PHRV"R$'TQ\F.2.2H[U:\7>.+,V4NR57,T3*JH07S(I RN<J!
MG)SC'3K@'LZS[7P];6C"6*&)'&<,D:*PR,'! STH X35-,?3- \B48<*A(Y!
M&^<. 00"" V".QS7:^$_^/.V_P"O>'_T!:T+JT2[4Q2JKH<95P&4X.1D'CK3
MX85A4(@ 50  !@ #@  = * .:^)L+2Z=.%!)PAP!GA9%)/T !)]!S4O@;6X+
MVU@ACD5I$@0,@8;QL4*V5Z@ ]\8/!'!%='5&RT.WL&WPQ1HQ&"415..N,@#C
MB@#C?@I_QYR?]?#?^@1T?#C_ (_-2_Z^/_9YJ[BRTZ*P79"BHI.2$4*,],X
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MS\B@J25>9Q(,=04\S.?8 Y_AR",]WH%K!:P1I:C$!7<G+'A_GS\W/.<\T?\
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M/%=:?]I>^EEN)=I,/F?)N+Y93#C("@'!X7(!7@J*]HAA6%0B !5   &  .
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M^M '&_!3_CSD_P"OAO\ T".O0*KV6G16"[(45%)R0BA1GIG  YXJQ0 4444
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MNBN?LM7N9;^6S>/%LD8*2;'&YL)D;R=I^\W &>/8UT% 'G_Q'_X_--_Z^/\
MV>&NJ\6?\>=S_P!>\W_H#5SOC[3I;J[T]XT9ECGRY52P4;XCDD#@<'KZ&NE\
M3PM-:7"("6:"4  9))0@  =2: .%\#^&I]7L(V-S)"JB01"!BO5VRTG=CNZ
M$ *.#ECBUX9\<R)I,E]+EY+<F,%OFW'Y=A/W>!O ;G) )R2:WOAQ:/:6$,4J
MLCCS,JX*L,R,1D'GI7+^"_"DM[I=Q83*T3R2L5$BE.0L94G()V[EP<#IG'-
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MU.18TM9DCYWO.!%MX)7"DDODC!QC;P3UH XI]7.I:A<07UW+:K&Q2)(V,*D
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M?8$8@[ -O.,9 "X(.1M^"]&GFNI]9NT\IYU54CSDA<+RPZ@X51V.=V5'%,\
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M9W3OO89DC& <#CCIZDUGC0+B731?-=2QO':JT:0L4B")&"H(&"S,!\S9X)P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$AD(4Y"C>"!D@<]O<94]?:6JVB+#&,)&H51DG 48 R>>E344 %%%% !1110
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M+T X02HHX]  /Y\T >BW7CZQM)3:O,HD5@I&&V@^A8#:,=\GCG.,&N?^-?\
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MQQ5CX<?\?FI?]?'_ +/-0 ?!3_CSD_Z^&_\ 0(Z] KS_ ."G_'G)_P!?#?\
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M!.0>#SQ7&ZEX=F\/Z+<6MPRL?,0KL9BH4R1\#<!CG)P!CG/4FNR\#:?'964
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M\C;MV=L=>O7.>=V<YYSGFN/UG_D/6O\ U[M_*>@#L(=?@FG>P5LSQKN9=K<
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M=#\26^NJSVSAPAPW!4C/3A@#@]CC!P?0U2U/Q]8Z8YAEF4..H4,^""002@8
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M.@+-YC,R0J[-G=PP.[(P3GYL$;@.,Y7PUNFM-)NIHSAXVF93@'!6%"#@\=:
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M1@;AV^;CU/5:II<>JQM;3KNC?&1DC."".00>H'>I;2U6T188QA(U"J,DX"C
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M &[$\G&!QSG>HH YSPWX-7297O9)&FN900\C?*,9S@*.@X4=3C V[1Q6?;>
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MBL31+R[#F"]1,E2RR0;C'@$ H=_(;G([,,XY4U2^'GBB7Q);M<3!0RRE0$!
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M.Y<*?O8W<>V6&GKWB[R-/.JVVULK&5#\CYG52#M;J,D$ \$8H Z6LGQ3KO\
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M-P% &Q9>*_M-_+I6S'DQA]^[.<A#C;CC[_J>GO5C1/%$6L2SV\88-:OM<L
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M1,<#Y</SG.1USDJ-N"&(!V%%<)?>-;L:A)I5O$DF%7:3N7:616WN<D%03R
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MD9B!UPH).,XYXH L45PFA^(]4UJ/[=%%;^26;:C,XD95.,!LE03@J"P R,D
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M%$?)E<>8X<(JJS*-V&.6; QCT/RXR5[VTW[%\W;YFT;MF=N['S8SSC/3/.*
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MD=44)/(Y+-P.$<X'N< =S3;JZ7P[K+7-R=L5W"%1\':"-@(8G '*<XS@,I.
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MW=</\P +$J<[>V<8P<5E?#C_ (_-2_Z^/_9YJ[JUM$M%$42JB#.%0!5&3DX
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M'?BVVTZS^RW#B*6V,@=9/E;EV;@'ECV( W C&.1GT"&%85"( %4   8  X
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M^^>.2V ,\8R2>GILT*S*4< JP(((R"#P00>H-$,*PJ$0 *H   P !P  .@%
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M^0HMM.BM69XT56D.7*J%+'DY) Y/)Z^IH \\\&:K%I-_J$=RZQ-)-N7S3L!
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M'I@#&1S7I>HRQQ1.\V/*5&+Y&X;0#NR,'(QVQS3+;28;5O-CC17VA=RHH;:
M %R!G  &!TX'I5N@#R+6Q9^'XCJ&DW121RF(E<2*P((P4;+ @$ME\X.1@$C&
MEXQN'N9M(EE&V1Y%++@C#%H2PP>1@]CS7=VOAZVM&$L4,2.,X9(T5AD8."!G
MI5BYTZ*Z97D16:,Y0LH8J>#D$C@\#IZ"@#A_C7_QYQ_]?"_^@24?&O\ X\X_
M^OA?_0)*[B]TZ*_79,BNH.0'4,,],X(//-%[IT5^NR9%=0<@.H89Z9P0>>:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH\B-^"[@#)P> OOF@#T6BN,\%^)KB6>72;X W$ +;UQM925QD#'/S C &1U
M8'/9T %%%% !1110 4444 %%%% !1110 4444 %%%% !17#^/M1EM;O3TC=E
M62?#A6*AAOB&" >1R>OJ:-6U&5-:MK<.PB:!B4#$(3B;DKG!/ _(4 =Q1110
M 445P^DZC*^M7-N78Q+ I"%B4!Q#R%S@'D_F: .XHHKSK1KZ_P!?N;N&.Z\I
M+:8JH\B-^"[@#)P> OOF@#T6BN,\%^)KB6>72;X W$ +;UQM925QD#'/S C
M&1U 8'/9T %%%% !117->)_%+V4L6G6JJ]U/R/,R(U49RS$8)X4X YX)] P!
MTM%<E#H^JP*)/M<<D@ S') %C)/!&],/@=00!D@9 !-9]WJLYU>TA8LBR6VY
MX@Y*!MLI(./E8@@<X[ T =[1110 4444 %%%% !1110 4444 %%%% !117/^
M/=4DTJREN8&VR)LP< XS(H/!!'0GM0!T%%>=3R:K;VB:HERLO[M)6B:&-!M*
M[V&X<G ZXVDC.#G /9>&]<77;>.\52HD!^4\X*DJ1GN,@X/&1V'2@#3HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ[D.XVL""I)1AQO.SH0I..E>AUY_<Z!>>)+N"\GA2V2U93RZRR/AMV,IQ@$
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M[UZK7'^"M GTVYOIIEVI/-NC.Y3D;Y#G )(X8=<4 /\ !_AF>VFEU2]*FYN
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MP+93W%FI$FQ 6+$DMG8KD-E<@N6P  >F .G'V-A:WL(DN;6^GFE129MC-R4
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M&2=O4_*2, &?_P RY_G_ )^J/'W_ "!K/_MW_P#1#5J_\(M<_P!B_P!F[/\
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M+;7RHC39VB,LVP<%-QR-S*W7!"G'H:Q-"75;2(::T2+L^1;G>I547@'RARQ
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M\OS!&X?:I+[F&"I& 1G.<$ <YZWP5X<GAEFU2^VBYN/EVKT11CC@D'.U<=2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S]+T1-.:652
MS//(79G(+=,!0< [5'W0<XYK0HH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <_>^%/M-_%JN_'DQE-FW.<AQG=GC[_H>GO70444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5@^-?$P\.6S7( +DA4!S@L?7'8 $]LXQD$BM
MZN$^,EJTUB'49$<R,W(X!#)GWY8#CU]* )M.^'$=ZHN-2+SW#J"V]R%0DEBB
MA"  "V.I'&5 !Q6[I&C+H"O^]8P  JLK9$07.0'/(0+@ '[NTG/)K2M+I;M%
MFC.4D4,IP1D,,@X//2N*^,ETT-B$4X$DR*W Y #/CVY4'CT]* -;_A9&G[_)
M\]=V[;G:^W.<??V[<?[6<8YSBM>_UJ&PA-Y(X$("G>,L,,0%(V@Y!R.E-_L"
M#R/L'EKY&W;L[8Z]>N<\[LYSSG/->5:9=--H%PC'(CF"KP. 7B?'ORQ//KZ4
M >@7'Q(T^#;F=?F4,-JNW!]=JG!]5.".XJ?4_'-EIA EF7+#("YDX(!!.P-@
M$$$9ZCD9K(M]*BM]%9%10'LS(W&<N8M^XY[YP0>V!C  QD^%]*B70Y9=B[I8
M9V<D9),9<(>?[N 1Z'D<DF@#T.;4(XHC=%AY2H7+#YAM W;AC.1CGCKVK$G^
M(=A B2M, LH8K\CDD*Q4G:%R!D$#(&<'&<5A>&O^0"W_ %[W7\Y*M_"O2HET
M]7V*3/O\S(SN =D .>V.,=.O&2<@'56NJQ740NT=3$5+;\X7 ZDYQC&.<XQ@
M@XQ6+_PLC3]_D^>N[=MSM?;G./O[=N/]K.,<YQ7*>#M2BT0:G%*/]%MYCA-N
M_AV>/;SR=P55^8X]<<FHO&.N3:KI[$6?EVOR&.1I$!50X5"(L9&1P,<8;@E>
MH!Z5JFJ1Z5&US.VV-,9."<9( X )ZD=JQ;CXD:?!MS.OS*&&U7;@^NU3@^JG
M!'<5B>)?^0"O_7O:_P XZMV^E16^BLBHH#V9D;C.7,6_<<]\X(/; Q@ 8 .E
MU#7X-/1)Y9%6.5E56ZJ2P)7YAD $#.X\8[U:N[I;1&FD.$C4LQP3@*,DX'/2
MN TG1F\1:&D'WI-KE"V"<QR-M4%B,9 V YX!].*KZQXD/B6RM+%"6EO75)&V
MABOE%3(VU6&#G# =-F2=O% 'H]I=+=HLT9RDBAE.",AAD'!YZ5Y[KLR:QJHT
MV_)%LJ PIED61V P2PZGE@N"!D;1R6#>BPPK"H1  J@  #  '   Z 5C^)?!
M]OXB7;.OS#&)$P)  2<!B#QR>#D<YQG!  S0_!=OH4K3VVY Z;63>60X.0V&
MR=PZ#G !/')I^L^-+/1F\J>55?\ N@,[#@'D("1D$8SC/:N7\/W$_AG4%T1W
M,T$R%HBY.] JM@?3Y",#CHPV\J<?X="_NTEO;86Q>29][SJXD)8*S &,8VYP
M<>N>.E 'INCZU#K$?GV[ATR1D9&".H((!!^HZ8/0BLW4_'UCICF&690XZA0S
MX()!!*!@"".0>1Z5SEMH-[HKWFJRM$IDMI#M@W;?,505?:ZX)X)).>6/J:T/
MA-I\=O8),B@/*7+MW.UV5>?0 <#IU/4G(!T&J^)+?2HENIG B<@*P!<'<"PQ
ML!X(&<]*L:IJD>E1M<SMMC3&3@G&2 . ">I':N"^+FGQZ?81PPJ%07((4=!N
M65C@=ADGCH.@XK=^*7_(.G_[9_\ HU* -74/%-MI\*7LK[8I=NUMK'.Y2R\
M$C(&>15";Q78ZTEQ:"7(6&7S"BMP@&UV#;2#C/&,Y[9%<?X^_P"0-9_]N_\
MZ(:NWUS3X].T^>WA4+&EM* !_N-^9/4D\D\GF@#(76+7P[I8DM96\LK*L+NI
M+&0[V (V#^('JH''/N> O'L>JQQ6T\NZ\??D;",X+$<A0GW ._ZU4\-?\@%O
M^O>Z_G)6K\+?^0=!_P!M/_1KT /\)6UI#<7;6LC/*TN9@P("MN?@?*O&2W=N
M@Y];&I^/K'3',,LRAQU"AGP02""4# $$<@\CTKC_  S=-:/K,T9P\;2,IP#@
MJ9R#@\=:/A]:7\5HDMHMH$DW?-()!*VUV'S%.#@YQZ"@#T6UU6*ZB%VCJ8BI
M;?G"X'4G.,8QSG&,$'&*Q]/^(=AJ$BP1S NYPH*.N3V&64#)[<\G@<USMC\.
M[G[->6LKQ+]J9'18M_EJRL6(VD#:#A5XR0 .N "6'B"3PI''9:E;JL"L%26'
M#(2A4AF7)()(+[N&)Y"9!P >BT444 >96L47BC4;BUU+),)*V\1+1KM!)+#!
M!+%0K=>020"H&WM?#_A6'0#(+?<$E*G86+(I P2N><MWR3G Z  54\3> K7Q
M"0\JE9 <EX]JN>,8)(.1P,9&1C@@9SP6HZ_=Z5#?:--)YK0Q@K*>6*R/&I4[
MLYRLGKE3D D;2 #N[KXD:?:L8VG4D8^XKNO(SPR*0?P/MUKHH9EF4.A!5@""
M#D$'D$$=0:\_\.:=J*6D:0I9"&6)20RRY8,@&7 &"Q'WO6J]SH]QX5T:X@D=
M2V[Y=A+*$D9$91N48SEN@[Y'- '377Q(T^U8QM.I(Q]Q7=>1GAD4@_@?;K71
M0S+,H=""K $$'((/(((Z@UY_X<T[44M(TA2R$,L2DAEERP9 ,N ,%B/O>M;W
MP_\ #LWA^W-K<,K'S&*[&8J%(' W 8YR< 8YSU)H R?BIJCVJP6Y9DMKB0K.
MZ [@N5RH.#C(+'&"6VXY&0="R^'EC$T5W:AD9&5U>*5B&&.GS%@58'G&,CC.
M":Z#4]*BU1##.BNA[,,X.",@]0<$X(P1V->;ZSIDGPX,=Y:2,]NS[9(96ZE@
M3D;0 "0O7&00/O*2  >AZSK\&BKYES(J ],\L>0#A1DG&1G ..IXJOH?BZUU
MQF2VD#L@R1AE..F<,!D>N.F1GJ*X?4!<7^LRI (7>"%-GVE254#RWR-HSN#,
M2#V!//2M.Z\+ZCJ-U;WLQMU-NXR83*KLFX%E)(.1C( R!\QSU- '3ZWXJM=$
MP+F14)QA>6;!SSM4$XX/.,9XSFFIXNM7MSJ D!@4X+ ,<'(7!7&X')';H0>G
M-<IX&A6_U&_NI0&EBE"(Q'W5RZ< <9VH!GKC//)SW<6GQPR/<*H$DH4.1_%L
MSMS[C)&>N,#H!@ X+X?_ !'6[3R;Z;-Q)-M0>61D,%"C*+M^]GK^/%;OA*VM
M(;B[:UD9Y6ES,&! 5MS\#Y5XR6[MT'/KC_!3_CSD_P"OAO\ T".L_P ,W36C
MZS-&</&TC*< X*F<@X/'6@#L-3\?6.F.899E#CJ%#/@@D$$H& ((Y!Y'I6KI
MFJQ:H@F@=70]U.<' .".H.",@X([BN7^$VGQV]@DR* \I<NW<[795Y] !P.G
M4]2<Y_A6%=-UB[LX0$A,2OL XW8C/'H/WC<#CGIP, &]_P +(T_9YWGKMW;<
M;7W9QG[FW=C_ &L8SQG-:^CZU#K$?GV[ATR1D9&".H((!!^HZ8/0BN%^">GQ
MBWDNMH\TRE-W?:%1MOL,G)QUXST&+'PS_=7.HP+Q&EQ\JCA5^>0<+T'"@<=@
M/2@#T"O*OB1='7DG="P@L-J]"H:=I%1ASPP1<CL03QE6KO\ Q5?2V-K++;JS
MRA<($&YLL0NX##9VYW8QSCFO,M0OUL-);3A;7",0A>22':F_>K,2V1QQM7(S
MC:#0!Z;X3_X\[;_KWA_] 6CQ9_QYW/\ U[S?^@-5#P#J_P!NMHXO+E3R881N
MD3:K_)C*')W#CKQP1ZU?\6?\>=S_ ->\W_H#4 <1X'^']GK%A'/-&?-D$@+A
MW!&'900,[<@ =L>H-;7PHUB75+,F9BS1RNH9B68C"OR23DC=CZ "L+P;X)_M
M?3T?[3<)YBRC8LG[H?.R_<QR#U89&<GD9K8^%^IR%)M,E"YL7V;DX#99QTP.
M05/S<%LY(SDD [BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-K?,2N: .SHKE/ %_(5FL+AV>6TF9=SAM[(Q)1R6)SNYQ@_= ]B>KH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LGQ
M9_QYW/\ U[S?^@-6M6?XAM6N[:>&,9>2&15&0,ED( R>.M '"> O[2^Q1?9O
MLWE?/M\WS=_^L;.=O'7.,=L5-X\W_:=*\W;YGG#=LSMW;X=V,\XSTSSBNE\!
M:7)I5E%;3KMD3?D9!QF1B.02.A'>J7Q \.S:B(+NU :>TE#*C$!6!()ZXY!4
M?Q#C=WQ0!F?&O_CSC_Z^%_\ 0)*K_%BV:ZN+")&*,\KJ''52S1 ,,$<CKU'U
MJ+QMI6J>)XD7R%C1'SY7FH[DX/S[N%V@'  .<DD@C&-WQKH$^I7-C-"NY()M
MTAW*,#?&<X)!/"GIF@"[8_#^SLX7M%C)24(),N^6\LY4D@C!SS\N![8XKC?A
M)X6MM0A-[*FZ6*X^5MS#&U49> 0#@G/(KU6O/_!NDWWA5FL?)66W>8$3"14(
M# !F*$DG  ^7 Y! + @T 97A7P^NMWFH1S,WD"X):-25#G?+MW,"#A>3@=3@
MG[N#I>"XAHNIW6E0Y\@(L@#$G:<)P.>GSX.<DA5R>.=/P5H$^FW-]-,NU)YM
MT9W*<C?(<X!)'##KBC3- GAU:XOV7$$D(56W+R0(N,9R/NGJ.U '%:;J,?B5
MI+R^@N[C]XX1(07AC4A2 "I0[@!@]B,$C/-=+\/I9K:XEM$BFCL=I>(7",&5
MLKE0QXP26.,D\9Z[B7Z9HU[X1DDCM(EN+65V94$@C="<=6?.1CCJV=H/RDD'
MI]"N+NYW274:1*=NQ%?>XQD-N8?*<\%=O8X/- 'FOPO\%0:Y"\]UN=$D95CW
M,J@[4+/\I!R1@=N!SGC'L%<?\+] GT2V>&Y78YF9@-RMP409RI(Z@U=UWQ))
M8W=K8Q*K_:"^\$X=54###G@#YCR#NVD#!H Z.N$\6Q:4LY;496=SC$9>1ECP
MJYPD7*[A@G=UZCO7=UYY:Z'>>'+VXNH(%N8[DE@V](G7<Q8KEB>.>< AL*<@
M@B@!OPAO=QNK6-V>WAD7R=W7:Q?GH",@ D8 SDX!)K/\ ?\ (&O/^WC_ -$+
M70?#[0+K39KR:[55,\BL"C J3ND+$#)('S#&[!Q[YJIX0\+7.GZ;<V4J;99?
M.VKN4YW1*J\@D#)&.30!J_"W_D'0?]M/_1KU5^).JRQ&VT^!VB:[F"F1#AE
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MP'<G&2<FNC_M'6/+^R_9T\W[OVCS4V=<>9Y>,].<8Z\[/X*KW/@62QTE]-A
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M,M9&!V^8Q"GY6V@YW+R Q4G().>N*X_X2>%K;4(3>RINEBN/E;<PQM5&7@$
MX)SR*Z7X>^$Y=$\Z>?8KW+*WEQ#Y4 W';Z<%B,#(  PQSQG^#=)OO"K-8^2L
MMN\P(F$BH0& #,4)). !\N!R" 6!!H Q/#/A2/7[^^^T%C%%<,3&"55F9Y I
M)!!^49QCGGKC(.MX\M5M+G2H8QA(Y@JC). KP@#)YZ5J^"M GTVYOIIEVI/-
MNC.Y3D;Y#G )(X8=<4>-= GU*YL9H5W)!-ND.Y1@;XSG!()X4],T 9FKJWBC
M5&TJ1V6VMXE9T5L"0Y1N<8X^9?7&T[<%LCH]/\%0:=OBAW+;S1LLD)9F4EL#
M>"264[<J<'D8Z%><KQ!H%U8WJZO8*LC.H2:,L%+ 8Y#,<#A0.,8(!PP+"M?1
M;J]O)?-N(E@A",/+\P2.7RI#[E& H&0!G.<D@\8 ."\%>#+34KF^AFCW)!-M
MC&]Q@;Y!C(8$\*.N:V]&_P"0]=?]>Z_R@HM-)OO#=W<SV\*W$5TV_B18F4[F
M./F)Z;B.ASP<CE:T-,T">'5KB_9<020A5;<O) BXQG(^Z>H[4 87A+2$\<F7
M4;XLZB5ECB+L$085N"I7G! X S@DY)XM:0K>%]472HW9K:XB9D1FR(SEVXSG
MCY6],[ANR5R9M,T:]\(R21VD2W%K*[,J"01NA..K/G(QQU;.T'Y22#:T+P[<
MWEX=8OPJ,J%8HE.XH,D<L."<$_WL[B?EP  #FO"WAI-<OK\3,WDI.VZ)695<
MF23:6VD9"XR!ZD'/!!U?!<0T74[K2H<^0$60!B3M.$X'/3Y\'.20JY/'.GX*
MT"?3;F^FF7:D\VZ,[E.1OD.< DCAAUQ1IF@3PZM<7[+B"2$*K;EY($7&,Y'W
M3U':@#A]&@M3/(FNK(+J5\AI2RQXR%&"A'!.>?\ 5A5&"!U]@TY52) CEU"+
MARVXL,##%AU)ZY[]:XS59-3U2!["6TB)DRAE\U?* +<.(SE^!R.<@@'&?EKH
M_".AMH=K'9NP9D!R1TRS%B!GL,XSQGK@=* .<^(MTRW.G0@_(UTK$8'5'C"G
M/7@,?S^E:'Q2_P"0=/\ ]L__ $:E4OB7:B)K/46)$=M<IOPI.%9E)8D= -@'
M3DL._!V/'NER:K92VT"[I'V8&0,XD4GDD#H#WH XKQ]_R!K/_MW_ /1#58\:
M^"(M*LVO@\C7<)C)G:1M['>J]R< 9^7'(P/F/.;OB_PM<ZAIMM91)NEB\G<N
MY1C;$RMR2 <$XX-=!X]TN35;*6V@7=(^S R!G$BD\D@= >] '.>+?$<]U!80
M1L8I-0,99XR1MR$R .N,N#]X' P2036WIWP]M])9);0M'*A7<^XMO48WJRD[
M<,/0##88=,5GZWX/FO;*U\K"WEDD93)!^957<G4KG*@@G(R,9 )-7;/4=3O3
M'&]ND&&0R2&57#*"-ZJBAB"PSC)( R,YP: ,K1O^0]=?]>Z_R@H^''_'YJ7_
M %\?^SS5H:9H$\.K7%^RX@DA"JVY>2!%QC.1]T]1VJE#I5YX<O+F>U@$\-T0
M_,J1L&R21EL<99N,'@K\V010 S1O^0]=?]>Z_P H*S_"&AQ^.&FU6^W/F0QI
M&6(5% # 97:3@-CL.K$$MQI^$_#M[;:C-?7@4B2(C?&1L)S'A0O#8 7'([<D
M]2S2])OO"4LL-I"L]I(Q= )%C9">,9<DG  '?. 00=PH I>#=.;3M9N8&D:4
MK!]^0Y<@F(@$]R 0,]\=!TJ[\./^/S4O^OC_ -GFJ7PQX<O+74IKZZVLLL.-
MZ;0NX^6=H7.["X*@D9(&3R:M^"M GTVYOIIEVI/-NC.Y3D;Y#G )(X8=<4 <
ME\+O"$6MV[R7)9XA*0L6]E0,%4F3Y2,M@X'H,]<C'0?"Z9K=KS3028K6<A"Q
MRV"S@CTQ\F> .2Q[U=^%^@3Z);/#<KL<S,P&Y6X*(,Y4D=0:9X/T:71[B_NK
M@!(I9=ZL67!4-(Q8X)P "#SB@#FM)MM/U>W:XU64_:P90_FRLDB8)PJ1\<#J
M%"L-Q(Q_".H^%VD):6:7 C\N2=1OY?Y@K,$;#$XR#GC .<CC%<_X>\,7<EM%
MLBLY(]I,;74;&78S,ZYV[@,[LX!.,X/.:ZOP9XM;7?-AFC\N>V8+( 0RD\@X
M/U4\<X&/F- &?\6M+CN;)[EUS)!MV')&-\B!N <'(]0?:JFG^%K;3]->]B3;
M++I[;FW,<[H@S<$D#)&>!74>+M#;7+62S1@K.!@GIE6# ''8XQGG'7!Z5S^E
MQ7\UD^FSVP0K:/&CB5#N8+L1=H)P2.I)QD=LX !E>!_ \.NV$<ET6?(D$8#%
M1$-[ E0."Q;DE@?X1C Y9X6\62VFC2W'5[=C&ASR VP*3NW ["_ QC "^]=A
MX"TN32K**VG7;(F_(R#C,C$<@D=".]<_X.\$2+IT^FWB[&FD8CD-CY4VM\C<
MX9<XR,XYX- '.6-A:WL(DN;6^GFE129MC-R4 RIW %1U7<#QC.1Q7=_#J\NK
MFUQ>JPDC<J#(K*[*%4@G=U/)&>^.<G).?H]QJFB1+9O;+<"(!5D2=(P5 &!A
MAG*],X&<=_O'K=+\[RU^T[/-YW>5NV=3C&[GIC.>^: .*^-?_'G'_P!?"_\
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MMJE[-JT\T2A/W,"R.BL%'+/A@I^;/!ZC<RG@"O1:R?\ A$[/_GWA_P"_*?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV@'Y?E.?7'&#T(-7?%G_ !YW/_7O-_Z U87PFT^.WL$F10'E+EV[G:[*O/H
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M +4C\[[%N_>^7YFW!^[NVYSC'7C&<^U>5>&DETNYMM8DW8U*259%6/ 4R/\
M(,L3PQPXZ':#C<,YZOP!(NK3WFK#:?-F\M"%(.R)1@Y//S@J2..1GT  '>$;
MO3]"LY)[>5FMEER[NK$AF"+C 13CE>QZ]?3-^'_Q'6[3R;Z;-Q)-M0>61D,%
M"C*+M^]GK^/%2_!3_CSD_P"OAO\ T".CX*?\><G_ %\-_P"@1T 4O!^M0Z/<
MZG/<.$3[2!DY.29)L   DGZ#H">@-=UH?B2WUU6>V<.$.&X*D9Z<, <'L<8.
M#Z&N*^'NGQS:AJ%PR@R13L$)_AWO)NQ[G &>N,CH3FQH'[G7+N)/E1H58J.%
M+8B.X@<9RS<]>3ZF@#NKNZ6T1II#A(U+,<$X"C).!STKSKPW\4H_.N?M<W[K
MS/W'[L_=W/\ W$STV_>Y_6O2Z\_^''_'YJ7_ %\?^SS4 ,U^98=<MG<@*MLY
M))P  LY))/0"NET?QS9ZQ)]G@E#2$$@%77..N-RC)[X'.,GH#7*^*-/CU#6[
M6&90R&#)4]#M\YAD=QD#CH>AXJQ\0OW-_ITJ?*[3%2PX8KOC&TD<XPS<=.3Z
MF@#L-9U^#15\RYD5 >F>6/(!PHR3C(S@''4\57T/Q=:ZXS);2!V09(PRG'3.
M& R/7'3(SU%</J N+_694@$+O!"FS[2I*J!Y;Y&T9W!F)![ GGI6G=>%]1U&
MZM[V8VZFW<9,)E5V3<"RDD'(QD 9 ^8YZF@#O:\\L%;X@2RR2.RV$+A$2-MH
ME((8L_1L8"G&!C(VD$,3Z'7G_P '?]&AGLGXEAN&WKUQE0HY'!Y1AP3T]Q0!
MMVG@*#3'6:S9X"K LJNS(X!Y5E<G/&X*1C:3GD@5:UGQI9Z,WE3RJK_W0&=A
MP#R$!(R",9QGM6W7GGP>A6ZBGU!P#/+.X9\<D$*Y'' !9B3@#/&>@P =GHVO
MP:TOF6TBN!UQPPY(&5.",X.,@9ZCBL^?Q]8P&17F4- VUP0P;.2N ,9;!'.W
M..IXKG+B%=-UV(0@*+F!C( /O']X2?8DHI.,9(R>IS%\/=/CFU#4+AE!DBG8
M(3_#O>3=CW. ,]<9'0G(!U5MXYLKF)KE9E\N,X8ME3G!8#:P#$D XP#G! R0
M:MZ'XDM]=5GMG#A#AN"I&>G# '!['&#@^AKA],TJ*;7KC<BGRXQ(HQP'(B^;
M'0G+$Y/<[NO-6-!A6+7;L* !Y . ,<MY))^I))/J>: .KN?%UK:R2P22!7@3
M>X(;A3MQSC!)W# !)). ,T:'XNM=<9DMI [(,D893CIG# 9'KCID9ZBN/L=/
MCO->N#(H;RHD=<]F"Q -CU&3CT/(Y -2^.85L-1L+J(!9992CL!]Y<HG(/&=
MKD9ZXQSP, '4:SXTL]&;RIY55_[H#.PX!Y" D9!&,XSVJ[H^M0ZQ'Y]NX=,D
M9&1@CJ"" 0?J.F#T(KFI/%^^YF@T^U,TJ'$SY6$93Y5&]@=Q'(&<=#MR.1E?
M"<$7%^"@C/FIE 00GS2_*".,+TXXXXH ZB?Q]8P&17F4- VUP0P;.2N ,9;!
M'.W..IXJQIWBZUU&*2YAD#1P@ESA@5 &[.T@-C ...<$#D&N/^'NGQS:AJ%P
MR@R13L$)_AWO)NQ[G &>N,CH3F71H5_MJ]M\#RI( 63'R,2(LDKT).YLY_O'
MU- '=Z?J$>HQK<0L&C<9!'^>".A!Y!X/-,T_5(]0W^4V[RI&C;@C#+C<.0,X
MSU''O7G^@Z^?"5K=V,IW2V+$Q@A<%92/+. V2-S;FYRH8#.>!U?@+1O[(LHH
M2,.R[WRNUMS_ #8(ZY4$+SSQVZ  VKJ[2T4RRLJ(,99R%49.!DGCK6%I_P 0
M[#4)%@CF!=SA04=<GL,LH&3VYY/ YKG_ (K2R22V-JFTB2?.V090LI15W<9V
M_.00.H/TI^N>&=2UF#[#(+-8QMV[!*"NWIMR"!QQTZ$B@#K=7\26^CLB7#A#
M*2%R#@XQG) ( &1R2!5*U\?6-W*+5)E,C,5 PVTGT#$;3GM@\\8SD5Q_CS32
M[Z5:7)WDL$D.XG<<PJYW<'GGG@_C5OXS6B16<6U5&R957  VKL?Y1Z#Y1P..
M!Z4 =/#XYLIIA9I,ID8@#&2I)&0 X&PD].O7CKQ5[6]?@T1!-<ML0L%!VLW)
M!.,*">@-<)\7-*BL+"&.)%58Y@JX'(!1R1GKR0"?4C)R:M_&O_CSC_Z^%_\
M0)* .@NO'UC:2FU>91(K!2,-M!]"P&T8[Y/'.<8-<_\ &O\ X\X_^OA?_0)*
MV_%.@0)ITML(U$<,+L@_NLBDA@>N<]3G)R<YR<^?^(KIKK0[1W.2)@O0#A!*
MBCCT  _GS0!ZUJ>JQ:6AFG=40=V.,G!. .I. < 9)["LK3/'UCJ;B&*92YZ!
M@R9)(  +A022> .3Z5SGBJ%=2UBTLY@'A$3/L(XW8D//J/W:\'CCIR<Z'Q9T
M^.XL'F=07B*%&[C<ZJW/H0>1TZ'J!@ Z5]:A2<6)<"9DWA3D97)'!Q@G@\9S
M@$XQ3]0U2/3]GFMM\V18UX)RS9VC@'&<=3Q[UPOB*1XH;#Q >7@6(S%53<R2
MJH;K@=20 .A<D;<$U=DG7Q#JL:* T-C%YF[;N5GF"E<-DC&"K*<9RK8[$ '1
M:WXJM=$P+F14)QA>6;!SSM4$XX/.,9XSFGZ'XDM]=5GMG#A#AN"I&>G# '![
M'&#@^AKSW0A=WVH7L]N+=I(YMNZX5MR@%T4(4''RKAO7 Z\UNZ=X7OCJ":I<
M&!0$*N(#(-XVL!D,/F.=O4]%'H* -W6?&EGHS>5/*JO_ '0&=AP#R$!(R",9
MQGM5W1]:AUB/S[=PZ9(R,C!'4$$ @_4=,'H17F7PZ%_=I+>VPMB\DS[WG5Q(
M2P5F ,8QMS@X]<\=*ZCPKX7N["\FO[@Q!9T^9("X7>"N&VL!SPQ)R3ECZF@#
MLZYJZ^)&GVK&-IU)&/N*[KR,\,BD'\#[=:/B1=-:Z?.Z'!*JO0'AW5&'/J"1
M_+FI?!FE106$,2HNV6%&<$9#&1 6)SG.<XY[<= !0!JG58O*-V'5HE5F+H=R
MX7.XC;G.,'I]*Q[?XAV%PT<23 M*0% 1^I;: ?E^4Y]<<8/0@UQOAO\ T:'6
M+).(H?.V+UQE95/)Y/"*.2>GN:Z+X3:?';V"3(H#RER[=SM=E7GT ' Z=3U)
MR =G7E[:!!K>MW,-RN]!"C ;F7D+",Y4@]":]0KR]M(_M76[F+S)8L0H=T#[
M&.%A&"<'CGIZ@4 6[&V'AG5H]/MMPM[B%F:-F9E#8;YE!/7]V.3DX)'3&.JU
MGQI9Z,WE3RJK_P!T!G8< \A 2,@C&<9[5QLEI)X,U&)@YGCORL9,QW3#!1<[
M\=!D$=B/E(RJM5KX/0K=13Z@X!GEG<,^.2"%<CC@ LQ)P!GC/08 .ST;7X-:
M7S+:17 ZXX8<D#*G!&<'&0,]1Q536?&EGHS>5/*JO_= 9V' /(0$C((QG&>U
M<O<0KINNQ"$!1<P,9 !]X_O"3[$E%)QC)&3U.="3Q?ON9H-/M3-*AQ,^5A&4
M^51O8'<1R!G'0[<CD '2Z/K4.L1^?;N'3)&1D8(Z@@@$'ZCI@]"*Q3\3=."A
M_/&"2/N29XQVVY YX)&#SCH<<_\ "<$7%^"@C/FIE 00GS2_*".,+TXXXXH^
M">GQBWDNMH\TRE-W?:%1MOL,G)QUXST& #M=<\26^A*KW+A YPO!8G'7A03@
M=SC R/45P7B_7X-:NM-DMI%<"XYQPP_>1 94X(S@XR!GJ.*NV\*ZEKLHF 86
MT"F,$?=/[L@^Y!=B,YP3D=!B+XA:?'#J&GW"J!)+.H<C^+8\>W/N,D9ZXP.@
M& #TBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF/I@Y;@$#YB#N'%16_@5[B>.\OKAKAH"#& BQ("#G)52<G.#QCH =PX'6T4
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M<D#! *D!LXH ZBBN/@\4W.E7$=GJ2Q 7/$3V^\KN! VL&YYR.<8&1U&2I?\
MBVXO;I].TZ-&:''F2RDF)3@_+A.<YP.N<AAMP"P .PJO9:C%?KOA=74'!*,&
M&>N,@GGFL>WO+^2.2%DB6ZCV%7.\VSACV_C!4 @@]\'HU<5\)/MGDGR/)^S_
M &CY_,W^9]U-VW;\OW<8SWZ\4 >JU7MM1BNF9(W5FC.'"L&*GD8(!X/!Z^AI
MUWOV-Y6WS-IV[\[=V/ESCG&>N.<5Y5X*^W_:;[[/]G\SSOWOF>9MW;Y/N;><
M9SUYQCWH ];HKC[_ ,6W%[=/IVG1HS0X\R64DQ*<'Y<)SG.!USD,-N 6!8>+
M;BRNDT[48T5IL^7+$2(F.!\N'YSG(ZYR5&W!#$ ["JZ:C$\AMPZF51DH&!<#
MCDKG('(_,58KR33/M_\ :UQL^S_:?)&_=YGE;<18VX^;/W>O'7VH [OQ)XK_
M +%FMK;9O^U2;,[MNWYD&<8.?O>HZ5T%>:?$>X>VFTV64;I$DRRP@G+!H2P0
M'DY/W0>>E:&J>+;_ $)HI[V.%;:60*VPNTD889 8]"0,D[5(.T@8R* .[HKG
M/%/BE]->.SMHQ+=3ARB%U4 *I.YLD<<<#C=AOF!%9MYXIO/#K1R:DL)MY&V%
M[??N1B,@D/R1@'H,\9ZX# ':T45P6I^-+W^T)-*M8HWVA-K,&&W*HS,Y#?=&
M2.,')&,GA@#O:*YK5/$TNAP1"X5)+N:0(L<+;$8EN""_( &,G!^8@< Y&9>>
M(M2T2-;V\C@, *^8L)?S5#<9^9MI() (!.?7'S  [BBN,U_QM+YUO9:>JO)=
M() TN0FQ@2#@%6SA23W & "3QL:;)?E)4N%A$H7,31E_+)(.%8'YAM(!)'4-
MQR#0!IVVHQ73,D;JS1G#A6#%3R,$ \'@]?0U8KR3P5]O^TWWV?[/YGG?O?,\
MS;NWR?<V\XSGKSC'O6]J?C2]_M"32K6*-]H3:S!AMRJ,S.0WW1DCC!R1C)X8
M Z7Q1XHB\-Q"XF#%6<* @!.2">Y7CY:V*XSQ=XHN_#=G'<.(C.TNU@H<QX(<
MC&2K9PHZ]\U>\6^+6TAH[2WC\ZYGSL3(   ^\W?&?H" V6&* .EJNFHQ/(;<
M.IE49*!@7 XY*YR!R/S%8^EWE_#(L5XD3))D![;?A"H+?.'YPP& 1T(P?O"N
M$TS[?_:UQL^S_:?)&_=YGE;<18VX^;/W>O'7VH ]#N?%$5O=QZ60WFRH6! &
MS #'DYSGY#V/:MBN2E\47%OJ%MI<@CQ+!ND*AOOA9"=I)^[E.,@G%,O_ !;<
M7MT^G:=&C-#CS)923$IP?EPG.<X'7.0PVX!8 '845Q]AXMN+*Z33M1C16FSY
M<L1(B8X'RX?G.<CKG)4;<$,:E]XUNQJ$FE6\2285=I.Y=I9%;>YR05!/( !/
M !SU .[HKC]&\4W,5[_9=^L0=X]\;0[]K8SD?-D] >NW&T]<BNPH *QYO$2K
M<FS &V*(R32%L+&/X5/!^8]<,5POS GI6Q7)6W@(P"] F/\ IY)R$'R9+DCD
MG<#OP?NG'0@X( +^F>*EO;:742A$,9E*$'<72+/S@$+M)P1M/(QUYJ]H&MIK
M<"7D08))NP' #?*Q4YP2.H]:S]6L?[/TV2VSN\JS=,XQG;$1G&3C./6N,L/%
M$OAO1K:XA"EFE=2'!(P7E/8KS\M 'J=%<%J_BS4M.A&I/!$L&4W1LSF=58@<
MGY5!)]B5R,KP:9J7CF^B@&JQP(MIN7Y96/G,I; DXP%#9  ^8@_-\R\T >@4
M5Q_C+QJ^E6<.H6RJ?/:/ E!.%=&?HK#G@=R.M4M7\6:EIT(U)X(E@RFZ-F<S
MJK$#D_*H)/L2N1E>#0!WM%>?ZEXYOHH!JL<"+:;E^65CYS*6P).,!0V0 /F(
M/S?,O-=%J_B^+3K,:F02KHC(A(5F+@%5ZGGG)QG !(!Q0!O45Q5WK.K6D;7L
MD-N(X\LT6]C*$4\_,#LSMYS_ ..Y^6K&L_$&."TCO+93))<G;"A'S%LD'*@Y
M(4C!VYR< '#!J -?Q3KO]@VSWNW?Y>WY=VW.Y@O7!]<]*I:EXVBTNTAU&96V
MSB/"IAB"Z%\9)7(&,9_2N2\=ZAJ*6+I>11%)O+^:!FS&0P;#@[@<D8!!P#W.
M5SIZMXHE\-Z7:7$(4LR0*0X)&#$3V*\_+0!WM%9.NW%W'MCLXT9GW9>5\(F,
M$94?,V[D#'0X)XK"TGQ9=07HTJ_2/=(FZ-X-VW@,3G<2<?*1V((Z$'( .KN=
M1BM65)'56D.$#,%+'@8 )Y/(Z>HJQ7E_Q*^T_;K/'E;?.'D9WYW9BSYGMNQC
M;SC/>NEOO$UQH<2"[6*2YFF"11P,45@<<DR<C!SDX(Y4'&<@ ZNBN'O/$6I:
M)&M[>1P& %?,6$OYJAN,_,VTD$@$ G/KCYAV5I=+=HLT9RDBAE.",AAD'!YZ
M4 8_B;QA%X>:))$D=IRP01*&.5VC&"PY.X8QFFZ7XO\ [0D6#[-<Q[L_-+#M
M08!/+;CC.,#WQ7-?%*Z6TN=/FD.$CF9F."<!7B).!STKI=+\>V6JR+;02[I'
MS@;)!G )/)4#H#WH Z"BN7U&\U1V=K>*!40L%$KLSOMSAAL(50PQ@,00<Y.*
ML>!_%/\ PDMN+@KM=6*.!]W< #D=\$$=>1TYQD@'045YUX6\:ZEXE1O)BA4H
MW,DGF"/&/N!022W?.< <$ D$RZ+XYOM7+64<""ZB9Q([L?(3:<#(7<23@K@-
MU&X$C(4 ] KG--\;1:I:3:C"K;8!)E7PI)1 ^,@M@'.,_I47@?Q9)K@E@N$"
M3VS[7"_<Y+ 8Y/(VD'DCN#S@96D^*)?$FEW=Q,%#*DZ@("!@1 ]RW/S4 =/X
M6UW^WK9+W;L\S=\N[=C:Q7K@>F>E:U>::)K\N@:-;W<**X21O,#''R&5P<'/
M7. .#C.<$5V?B3Q NE6DE^F'"H"A'S*2Y 0\$97)!.#TZ4 ;%<_XK\:P^&/+
M\]7;S=V/+"G[N,YRR_WA6QISR/$C3 +*44N!T#$#<!R> ?<_6N$^)L*S7>G(
MX!5IR"",@@O$""#U!H [C2M335(DNHCE)%!'3(SU!P2,@\$9X((K'\5>.[?P
MTR),&9I 2!'M) &!D@LN >WK@^E9_P /9O[/:XT9R=UK*QC#%<F)_F4_+U/.
M6XXW >PY?Q=G5%U*_.[9#Y5M'G:!\DJ-(,#G[V"">S?@ #U/3KU;^)+A,A94
M5@#UPP!&<9YYJQ7'Q^)AH=A9A5\R6:.!(XPP0L2B\Y/0#UP>2 <9R*]YXBU+
M1(UO;R. P KYBPE_-4-QGYFVD@D @$Y]<?, #N**XKQEX[DTG[+):HLJ763@
MAMS#Y"H7&""P;NIYQQVJOK/C"_\ #QCN;R*+[-(^"L3,94R"0I)(4L!GH-IV
MD97(- '>US_C7Q7_ ,(Q"MSL\S=($QNV]58YSAO[OI7/ZIXYOM'$5[<P(EK,
MP!0,3.N1D9)VC)P6 V]!M8J>:/C7_P ><?\ U\+_ .@24 >@45P^L>)=2LH_
M[06"/[,""8VW_: G=FP=JG')P&*9^8':QK3U/QQ';P07,*^:]VR+%'O522W4
M$Y(&T\-UPV <9R #I:*X>\\1:EHD:WMY' 8 5\Q82_FJ&XS\S;202 0"<^N/
MF#_&7CN32?LLEJBRI=9."&W,/D*A<8(+!NZGG'':@#M:*Y1M?N]&M9;[4$B^
M14*I 6W98[2K%B1U(Y4GN>>,Q>']5U2^6*ZECM_)EVDJA=90KGAADLO .[&<
MD<<-T -K^W?],_LW;_R[^;OW?[>S;MQ^.<_A57P5XK_X2>%KG9Y>V0IC=NZ*
MISG"_P![TH3PP\8NG67$]XW^LV$%% VHH"N,E!G#9!R03G%:NE:8FEQ):Q#"
M1J .F3CJ3@ 9)Y)QR230!;HJIJEQ);1M)!'YL@QA-X3.2 ?F/ P,G\,5QNL^
M+-0\-&.>]2!X'?:QM]^\<$C[Y'/!(XP<$$KD&@#O:*Y?QQXLDT,106Z!Y[E]
MJ!ON<%0<\CD[@!R!W)XP;NB27X<I>+"4*DAH"_!!'RD/R=P.01TVG/44 ;=5
M[;48KIF2-U9HSAPK!BIY&" >#P>OH:==[]C>5M\S:=N_.W=CY<XYQGKCG%>5
M>"OM_P!IOOL_V?S/._>^9YFW=OD^YMYQG/7G&/>@#N[+Q7]IOY=*V8\F,/OW
M9SD(<;<<??\ 4]/>N@KR]KR6VUNY%NF^62%%7/"*2L)WN>H50.<<DX4<FN@T
M;Q3<Q7O]EWZQ!WCWQM#OVMC.1\V3T!Z[<;3UR* .PHKG]4N-1DD:.UCA6-,8
M>=V._(!X6/E=IR#NZ\$=ZK^!_%DFN"6"X0)/;/M<+]SDL!CD\C:0>2.X/.
M= FHQ/(;<.IE49*!@7 XY*YR!R/S%6*\DTS[?_:UQL^S_:?)&_=YGE;<18VX
M^;/W>O'7VKU6TW[%\W;YFT;MF=N['S8SSC/3/.* &OJ,22"W+J)6&0A8!R.>
M0N<D<'\C5BO*M>^V?VS#M\GS?+?RL[]GE_O<;^^[&<XXSCWKJ-4\4W.FK#9^
M7'+?SB0A(WVQ@+N(8[R&Q@=#C<0V&&!0!UM%<5>>*;SPZT<FI+";>1MA>WW[
MD8C()#\D8!Z#/&>N S/%WC2ZTN\CT^UB64RQ9 (;=N)<#D,!M&T$Y'0'YAU
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M$\ '=T5DZ%)=G<EZL0(VE6@+;2#G*D/R"N,YZ$,,<@U8UR]:PMYKA,%HHG8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,+@R$*I!55P&)QD$=/0\9YQ+HUL?%%WJ%[;_ .JEMV@1G!4%F15ST/ V9/\
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MX1\<68LHM\JH88E5E<@/F-0#A<Y8'&1C.>G7('5V6G16"[(45%)R0BA1GIG
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M.H8\^-)-N<>8BMC.,XR#C.!0!P_Q"F6:[TQT(*M/D$'((+PD$$=0:?\ &O\
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M@#S_ .(WBVVOK!XH'$C2A#B/YMJAT.Y_[@Z+\V#N(&.N,WQ]_P @:S_[=_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***J:M??V?#)<XW>5&[XSC.U2<9P<9QZ4 6Z*R?
M"VN_V];)>[=GF;OEW;L;6*]<#TSTKG?A%J,M_:.\SL["=@"[%CC8AQDD\<T
M=Q116/X7MKNWB*W\BR2[R04  VX&!PJ<YSV_&@#8HHHH **X3Q/JUVVI0Z9;
M3>2DL.XGRTDY'F'.&&>0H'7WIJZ]>>'+R*TO7$\-T0L;JB1L&R ?E7'&6&<Y
MX(*G(*T =[1110 45P^DZC*^M7-N78Q+ I"%B4!Q#R%S@'D_F:Z#1+:[AEG:
MZD5XF?,(4 %5RW!^5><%>[=#SZ@&Q1110 4444 %%%8]M;7:W<DKR*;0H B
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MEP"-N#D<J_.<=NW6@#8HKA_'VHRVMWIZ1NRK)/APK%0PWQ#! /(Y/7U-=Q0
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M@JJAE.-PZJ#G#?=QT)-6(=8U6=1']DCCD(&9))PT8(Y)V)E\'H "<$C)(!H
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M.0S' X4#C&" <,"PH YSQ3X:30[ZP$+-Y+SKMB9F94(DCW%=Q. V<D>H)SR
M+'CC2?[7U>WM=[()+?#,GWMO[TL!_O %>XYY!'!MZSHNH:U<VE[)&J)%,"8E
M=&,:AT)9GR-Q;!.%& %'\1-:NIZ!/-JUO?JN8(X2K-N7@D2\8SD_>'0=Z ,?
MQGL\*QP:?9+)&ES/N<P.QE(78"J[LG<V1C!'3&"&-8EYI\5G&LFGVE[%=Q%2
MDC1MSCAMPW,,$9R H!/'W<BN^\;^%GUM8I;=E2XMY \;/G;U&0>HZ@'E3TQT
M)JO#K&JSJ(_LD<<A S)).&C!').Q,O@]  3@D9) - &#\5;A[G3;>64;9'DB
M++@C#&)RPP>1@]CS3?&O@B+2K-KX/(UW"8R9VD;>QWJO<G &?EQR,#YCSG=^
M*&@3ZW;)#;+O<3*Q&Y5X".,Y8@=2*T/'NER:K92VT"[I'V8&0,XD4GDD#H#W
MH TM#O6O[>&X? :6)&('3+*"<9SQS5ZN2U75I/"NEQR843110(%<Y!;"JR_*
M1D@9/![9Z5T]I(TJ*\B['*@LN0VTD<KD<'!XSWH XKQ:\=Q?QVE](R6;6Y(4
ML8XGD#\AF&,X ! )&#MQ][#9OA[PY82ZDRVJB2&&*.0,KNRI*'&%#AL$$?-@
M[N00",$5I>(=.EU&_8VHAD*6JI*MR-T8#2%T&%))8[<X*X  .26&&V>NS^&)
MXK&Y@@6.Z<!&M 44,2%.5;J>5R>,#IN(P #'N?#ZZ[K=Q!(S",1QLZJ2-X58
ML(2#TS@GZ<8.".E\0Z-I^F01P7+M%;1[\1"1]K[F!.5!+OM8AA@_+G)XHTS0
M)X=6N+]EQ!)"%5MR\D"+C&<C[IZCM5?QEX;N)+R#5K9%F,("M$Y"]"Q# L0,
M_-QW5@IPW. #G/#%[;6NJQQ:8[?9IXSYBG=MW*KD#YQGC .>3R0#@D5>\9:<
MVHZS;0+(T1:#[\9PX ,I(![$@$9[9Z'I5VWTF^O]3@U.>%8XTC9<+(KE1MD
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M[OK>\NI7S\ZJQB #MPFQDP.>1T!R !78?#.>X"RVTR2K#"P\@SH5DV$MA2>
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MLN0VTD<KD<'!XSWH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD>F.M:U% %32;'^SX8[;.[RHT3.,9VJ!G&3C./6K=%% !1110 4444 %%%%
M!115>VU&*Z9DC=6:,X<*P8J>1@@'@\'KZ&@"Q6?J&B)?R0SR%O\ 1V9E7(V%
MB,!BI!R5ZJ>"#6A10 4444 %%%% !1110!S_ (;\*?V+-<W._?\ :I-^-NW;
M\SG&<G/WO0=*Z"BB@#G_  WX4_L6:YN=^_[5)OQMV[?F<XSDY^]Z#I70444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&V^PR<G'7C/08?\ #[?%-J<$&T;)CY:MD1JVZ4#Y5Z#Y5!QS@#T% 'HM>?\
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M^UG&.<XK5UO7X-$037+;$+!0=K-R03C"@GH#7G7C'7)M5T]B+/R[7Y#'(TB
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(C5PP[9!(R>W.>BXQMKJ** .,T[X=&TO$U1IVDD ._>H^9F1E)!!&U>1A<'
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M*?V+-<W._?\ :I-^-NW;\SG&<G/WO0=*Z"B@ KFM&\$K8/=O(_F)?,2R[2N
MQ?*Y#$GA\9XZ5TM% '"0?#>>WB>Q2\<6S[\)Y:[@&Z#?G.,XW !0WS# W$UT
MOA;0O[!MDLMV_P O=\VW;G<Q;ID^N.M:U% ')6?P\CM=0;5E<\EF$8'1G7#$
ML2<@Y8X &"1V&"[4_ 2WUZFH^8RJK1N\8!P[Q9V,26P,# QMZ9P06)KJZ* .
M7^(5])';BUMRWVFX=5B$;;7X(9CG((4*,,>@R,X!S716D;1(J2-O<* S8"[B
M!RV!P,GG':B2T25EE95+QYVL0"R[A@X/49'7'6IJ .<U/P[=2S-/;7;1+(%R
MC1K*H*C&5W$;0>X Y.23T - \#PZ3%+$Q:5KD?OG=CEL@@].@.YCU+<\L>*Z
M.B@#BK?P%<Z>C6MI>O' <X5HE=AN'S8?*D9.2-H7!.>N2=6P\&1:;:2:; 6"
MS+("S_,V9%V[B!M' QP,=/7)KH** ,GPMH7]@VR66[?Y>[YMNW.YBW3)]<=:
MR-$\!MI5G+IZ3L&E<L)8QL93A<=&/'R\\C()''6NMHH XRY\ 2ZLRC4+IIXD
M.0BQK"">.I4G(QD=B,G##G/9T44 <_XU\*?\)/"MMO\ +VR!\[=W16&,97^]
MZT>)/"G]M36USOV?99-^-N[=\R'&<C'W?0]:Z"B@#G_&OA3_ (2>%;;?Y>V0
M/G;NZ*PQC*_WO6N@HHH Y_QKX4_X2>%;;?Y>V0/G;NZ*PQC*_P![UJ+Q/X,_
MM>6*]AE:&XAX#@;@5Y."I('4GV()# @C'2T4 <?8^ Y(KR/5)[EI9(U8$-&%
M!RK*-N&PH 8<8.3DY^;C5\7^&%\20&U8[3N5E;!.TCOC*YR"1R>^>HK;HH Y
MR+P7&FG_ -CEB5V$;B/XBQ<-@$<!^0,]!@D\DV/"7AK_ (1^)H3(TKR2-([L
M,$LV!G&2>@&<DDG)SS@;=% ')>%;J;4[NZO [?8R52)6P49D 5G0Y.%R#R.&
MW<\K@=/=VJW:-#(,I(I5ADC(88(R.>E%K:):*(HE5$&<*@"J,G)P!QUJ:@#B
MM-^'DEDIL_M3FS+,3#L 8J3G9Y@.0#_%M"ALMP-QJQHGP\CL;.72YG,B3.6)
M V$<+C'+<@J#Z=B".O6T4 <%+\-KB>W^P27K-"H&U?* Q@@C)W%F4#.%S@':
M1]T"MW4?!Z:A8KI<C?<C15?:,AHP & .<9QR,YP2,\YKH** .$U+X;SZM$(+
MJ\>39M\O]VH4$<$L,Y<XX!+ CDY.33_$UA'&EAHSN5)= LH^4CR$QE?FX=B0
MJYW 9/!(%=Q534]*BU1##.BNA[,,X.",@]0<$X(P1V- '"^+])D\+P&_@O+C
MS$90%GE$BMN^4@*0 2 2W0\ \=QM7WAQ_$?V&^E;RI+?9(R;#RS>6S+RP*X*
MXYR?RJQI_P /+#3Y%GCA =#E27=L'L<,Q&1VXX/(YKHZ .?\:^%/^$GA6VW^
M7MD#YV[NBL,8RO\ >]:L>*O#,?B. VLA(YW*P_A8 @''<<D$=P>,'!&Q10!S
M5OX2DG@DL;ZX:XCD5 OR"-EV\YW DL<X.6SR.<Y-5+7P9=VBBV2^<6ZY 7RD
M\P)G[HE)R"!P& XXP  !7844 <UXJ\&?V];1V/FLOE,AWN/,9MJ%>>5R3G)/
MKVK?N[?[2C199=ZD;D.&&1C(/8CL?6IJ* .*N/ 5SJ"+:W=Z\D QE5B5&.T?
M+E\L3@X)W!LD9ZX(Z^TM5M$6&,82-0JC). HP!D\]*FHH Y_QKX4_P"$GA6V
MW^7MD#YV[NBL,8RO][UH\2>%/[:FMKG?L^RR;\;=V[YD.,Y&/N^AZUT%% '/
M^-?"G_"3PK;;_+VR!\[=W16&,97^]ZUT%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5!!(W..<D\_*.F.] '445YUX6\:ZEXE1O)BA4HW,DGF"/&/N!022W?.< <$
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MF?.Q,@  #[S=\9^@(#988H Z6BN'U/Q1J'AP"XO8HI("<,;8N&3)&"=_4'D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPIY(VG.1D=?0X[BJ,6AV\4GVA8HQ+DG>$4/ELY.[&<G)SZT <5\&H5FL94<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M37-MLV?99-F=V[=\SC.,#'W?4]: .@HKA])U&5]:N;<NQB6!2$+$H#B'D+G
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M.#QZ@&]1110 4444 %%%% !116/XHMKNXB"V$BQR[P27 (VX.1RK\YQV[=:
M-BBBB@ HKA]6U&5-:MK<.PB:!B4#$(3B;DKG!/ _(5W% !1110 4444 %%%%
M !1110 4444 %%%<_P"&_%?]M37-MLV?99-F=V[=\SC.,#'W?4]: .@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)J.EKII(27R(5.>0&C"G!(SQE<9&<=1GI6?I.F76J6ATB^@$2" *)1(K?,A
MC^16SD8!/S8)&. <4 <I8V%K>PB2YM;Z>:5%)FV,W)0#*G< 5'5=P/&,Y'%=
M-HUY=7.DW(O5821Q3J#(K*[*(L@G=U/)&>^.<G),NCW&J:)$MF]LMP(@%61)
MTC!4 8&&&<KTS@9QW^\=V]M;B[L989@AN)(95Q$2$)8,% +\],9SWSVH X_X
M9>"H+JWBU&?=)(&)C!9@L8CD;  !YRV6.>.>G4FW\./^/S4O^OC_ -GFKH/
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M:/<0" %#E.AZ[QD],@D+\QK%T4P:L@N[ZWO+J5\_.JL8@ [<)L9,#GD= <@
M5V'A7PE+*UQ?:D%\Z[4H44X"QXVE<JV.0!CDD  [LDU7T*TU+PJALDA6ZA4D
MQLLJQ$ L200PY)Z]\9(W'L 6/AG/<!9;:9)5AA8>09T*R;"6PI/ .T =.F<=
M, <I\+_!4&N0O/=;G1)&58]S*H.U"S_*0<D8';@<YXQZAHDEQ*A>[5$<L2JQ
MDMM4@85B>"P.02/E/:N?^%^@3Z);/#<KL<S,P&Y6X*(,Y4D=0: ./U)8$U"9
M];64H[,L#'=Y0122.4()P"HPN<%CO&[D='XQU=?#^F*+%RRN_EI(LF_:I+,0
M&YR%"E%YRHQSE:T-3U+4E,T M(YD8N$;S55"C#Y0R.<L?[W*@\@<<G)M/A@R
MZ<^G2.IF:4RJPW;%8 *!G@D%003CC=P#@9 +W_"JK;R_O/\ :OO?:-[;_,SN
MW[=V.OXX_BW?-7.-KTFLZ%,TQ)>)TC+$Y+8DC8$\#G# =R<9)R:Z/^T=8\O[
M+]G3S?N_:/-39UQYGEXSTYQCKSL_@JO<^!9+'27TV$!YW*LV#@%MZ$X+D# 5
M<=LXS@$XH S/^$"@FTO[7,SR3BU\Q'9V^0!-ZQJI)&T=.G<D8XQV'@'4WU.Q
MAGE.7*D$\DG8Q0$DDDDA<D]SFC^RY/[-^Q;?WOV/R]N1][RMN,YQUXSG'O1X
M"TN32K**VG7;(F_(R#C,C$<@D=".] '/_&O_ (\X_P#KX7_T"2J_Q8MFNKBP
MB1BC/*ZAQU4LT0##!'(Z]1]:V/BAH$^MVR0VR[W$RL1N5> CC.6('4BCQKH$
M^I7-C-"NY()MTAW*,#?&<X)!/"GIF@#G/'GAZ+PFL&IVN[STG4,SNS>9E69B
M_/5MO.W:"&8$=,>IUQ_Q0T"?6[9(;9=[B96(W*O 1QG+$#J1784 >=:U;_\
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MD.WYA\RLTN?NG(X8=<'F@#,\&^$(O$T U+4"T\LQ;&YV4(%=AM 4C@G)QT'
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M'-Y$IE,^X[F9 6QM!PHXPNW!7"\G!SGZKXNGU2TL(4=HI+V38\B'YAY;B,D
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M<QQ\Q/3<1T.>#D<K0!Z!17/V7VW[?+YG_'EY8\O_ %?WL)GI\_7=UX_2N@H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KG_&OA3_A)X5MM_E[9 ^=N[HK#&,K_ 'O6N@HH
M *Y_QKX4_P"$GA6VW^7MD#YV[NBL,8RO][UKH** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7+-T(*M;$@@Y!!68@@CJ#6+%HUG!J-U;ZH /-<R0NS.D>&+,1N!7GD#GC<K
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MMMM.L_LMPXBEMC('63Y6Y=FX!Y8]B -P(QCD9(?B%=PJ$3390J@  ;P !P
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M%ZE+J=G#<7 Q(ZG/R[<@,0K8_P!H 'C@YR,#%<U\:_\ CSC_ .OA?_0)*/\
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M2,8]JS+[QC-J&//TEY-N<>8K-C.,XS"<9P*FM?'ES:*(HM,E1!G"H'51DY.
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M>.: +7@N4:UJ=UJL.?(*+&"P(W'"<CCI\F3G! 9<CGCK?%G_ !YW/_7O-_Z
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M4$[3A^3QT^?(QDD*V!QR_P")/BBWO+0V4#K++<,BJL)$AR'5N=I.,XP!U)/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0\+3V\\NK7K+]HG4+LC^ZJ_*<$]R-H7@D8&=S$Y !V%>5>%?MGVS4/L7D_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+^*/"5QK$HEANY(%"!
M2B;L$@D[N'7GG'3MUKJ** //_P#A7%Y_T$9O_'__ (]1_P *XO/^@C-_X_\
M_'J] HH \_\ ^%<7G_01F_\ '_\ X]1_PKB\_P"@C-_X_P#_ !ZO0** //\
M_A7%Y_T$9O\ Q_\ ^/4?\*XO/^@C-_X__P#'J] HH \__P"%<7G_ $$9O_'_
M /X]1_PKB\_Z",W_ (__ /'J] HH \__ .%<7G_01F_\?_\ CU'_  KB\_Z"
M,W_C_P#\>KT"B@#S_P#X5Q>?]!&;_P ?_P#CU'_"N+S_ *",W_C_ /\ 'J]
MHH \_P#^%<7G_01F_P#'_P#X]1_PKB\_Z",W_C__ ,>KT"B@#S__ (5Q>?\
M01F_\?\ _CU'_"N+S_H(S?\ C_\ \>KT"B@#S_\ X5Q>?]!&;_Q__P"/5%'\
M+;F)FE6_E#R8W,%<,VT8&3YN3@=,]*]%HH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
.*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex19-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex19-1_002.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M".H->7^"_#D&JZA?33J'\F=PJL 4^=Y,DJ>I&WC/ SG&<$>H0PK"H1  J@
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MSC) )(/S#3^'FOKK-HC*FSR<1%025RBKC!))Q@CKR.F3C) )_&OB8>'+9KD
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MW>8FW=C.W=G&<<XZXKC/!<0T74[K2H<^0$60!B3M.$X'/3Y\'.20JY/'.?\
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MMC;Q6?\ "+4WOK$+(<^3(T:GDG: K ')/3=@=   ,<4 =E-,L*EW("J"22<
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M4W"51L)!*D94<9PXZ8Q@CYLYJW-\/H0Q-O+/;JQ)*6\I1"QZMM(.#T'&!@
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MMWB>T>4-B7=YH' ;&T ;L#')P< X7)%=Q10!R^G^%Y;?4Y]4)7RI8@H )WY
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M6GXM\)-J[1W=O)Y-S!G8^ 001]UN^,_4 %@5.:Z6B@#A]3\+ZAXC M[V6*.
M'+"V#EGP1@'?T Y(/(!P2IP,7?$_A%]2FLI8-BQV<F2IRORAHR H"D<!#QP.
ME=710!R_Q#\+R^)+=;>$J&64,2Y(& K#L&Y^:K6N07_FK+9/%Y>S#1SJV-V<
MAPR#<21Q@D 8S@D\;U% '*>&/"4MG<2ZI=R*]Q,NTK&,1J,C !/)X50.!CG.
MX\UT>HVS743Q(Q1G1E#CJI8$!A@CD=>H^M6** .,FTS5Y4-J9X-K$@S!76?:
M6ZA0 @;;Q@=.S9^:M#2_"(T6R>QMF(D='_>$E?WC+M#<9V@8&,= .YR3T=%
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M64CKW!P>O!'(4]L5BWN@ZKJ\7V.XF@2-AAWA#F1@!T(.U<,?O8V\>V5/<44
M<9XC\ &XAMTLW$<MD08RP&T\J26PI^;*ALX()SD<Y%74/">H:O<6UW<O!BVE
M#;(]X& RL2"P)+-C&#@# QU..]HH Y?QEX3DU9H[NU<174!^5CT(/56(!.!S
M@<CE@1ALC$\4>"]0\2Q 3RQ!T<;4C+K#C!RQ)5F+Y( [* <<L:]#HH ****
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MGE0_,/-54"GH?,8#YB>BXY )SP16UX<\:1ZM!+<R*86MRPE1CN9=H)S@ -C
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MK=RRHTDCPHD:+U9BL) ST4  EF/  )]CU&A^,WN[EM.NH#;S!-R@R*X8=\$
M9/?C/1LXVT =117-:MXQ:"<V-I ]Q,FW?@A(U#*6&9&! ) &.,'. <C%.T/Q
M<;N9K&ZB-O<@;E1G#AUQG*N  2.<@>AZX;: ='17")\2I+FXET^WM6DEBD=1
MB4*I5"P9B2N%Y P#D'.,YP#VMI(TJ*\B['*@LN0VTD<KD<'!XSWH FHKE-9\
M;M;W7]FVD#3S!=S@.(U48!'S,".A'/ Y !).!H1:_(MM+=SPM%) KDQLP(.Q
M-XVN 0000,XX.1CB@#;HK)\+:[_;ULE[MV>9N^7=NQM8KUP/3/2J'A7QLNMV
MTE_(GE)"SAOF+\(@<MPH/0],'I0!TM8^M^*(M'E@MY Q:Z?:A4 @'*CG)''S
M#IGO6)9>/)]27[3;V<CVP/WS(BN0OWBL?.XCD !CDC&0<@8_Q'U2/SM-O=W[
MKS/,W8/W=T+9QC/3G&,^U 'I=%<9/X_ELI(OM5JT,$[[5E>1>,_=+KCY#W(9
M@0-V,[379T %%>7_ !*O9Q?68$.1',#$?,7]Z28B5Q_!@_+D]<YZ5T&M^.)]
M$MA=W-ML<S!!'YRMP4+;]RJ1U!&,>^: .PHKFM%\5SZBK7+6KI;B-WC;>K2.
M ?E B&""PY'.#Q@D$&L_4O'MSIBBYFLG6W++\YE4N%8\$Q@$J<=B0 WRDY-
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MD)&XSD@9Y($DH)QZ#(S]1ZUV>FZ!!IKRS0KM>=MTAW,<G).<$D#ECTQ5'6/
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M):M-8AU&1',C-R. 0R9]^6 X]?2GQ>$(-1@^T"^NF@="26N!LVX.[.5X Y#
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M##.BNA[,,X.",@]0<$X(P1V-96F> ;'3'$T4*AQT+%GP0000'+ $$<$<CUH
MS]8\'IJ-TUY:7#0W2[!)L(<8QE0R9!&0%X)VD+]TY)K,T+7U\46]U9:BT>R
MHK31OM1LDA7!/&=R9!X5L@;<<'I=8\#6>L2?:)X@TA !(9USCIG:PR>V3SC
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M1,DX&3DGJ2222?J>@ Z 4W3= @TUY9H5VO.VZ0[F.3DG."2!RQZ8H X_1O\
MD/77_7NO\H*POASX=6[6:T>XGAGAE;=%#-L&!A2V ""=P()!/09ZC/IL.@00
MSO?JN)Y%VLVYN0-O&,X'W1T':JFL^"[/66\V>)6?^\"R,> .2A!. !C.<=J
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M6:%=KSMND.YCDY)S@D@<L>F*T* ./UCP>FHW37EI<-#=+L$FPAQC&5#)D$9
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M-6VOWGB2[GLX)DMDM68<(LLCX;;G#\8!!.1C&X [LY%?X3DFXOR7$A\U,N
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MK6/ UGK$GVB>(-(0 2&=<XZ9VL,GMD\XP.@%6](\-V^CL[VZ!#*06P3@XSC
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M]O#</@-+$C$#IEE!.,YXYH O4444 %%%% !1110 4451UR]:PMYKA,%HHG8
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MZ .HHHHH ***Q/&>MOHEI)>1!2\>S <$K\SJIS@@]#ZT ;=%4=#O6O[>&X?
M:6)&('3+*"<9SQS5Z@ HHHH **** "BBB@ HKE]0\42V^IP:6 OE2Q%B2#OR
M!(>#G&/D'8]ZZB@ HHHH **Q[;6Y9KN2R,#+%&@83'.QB0ORCY0,_,?XC]T\
M>FQ0 445CZ)K<NH2SQ20-$L+[4=LXD&6&X95>/E!X)ZCGU -BBBL_6]?@T1!
M-<ML0L%!VLW)!.,*">@- &A1110 4444 %%9^FZ_!J3RPPMN>!ML@VL,')&,
MD 'E3TS6A0 4444 %%%% !1110 4454U35(]*C:YG;;&F,G!.,D < $]2.U
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M "BL_3=?@U)Y886W/ VV0;6&#DC&2 #RIZ9K0H **** "BBB@ HHHH ****
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M:A\2:-<*/)MUDE8 B*.T!D]2/N[<J,D_-C .": .[TZ]6_B2X3(65%8 ]<,
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MX<L.03]\@9].,[1S_P#S+G^?^?JNUTFQ_M#38[;.WS;-$SC.-T0&<9&<9]:
M,+0KO4O%2&]29;6%B1&JQ+*2 Q!)+'@CIVS@G:.^AX/\33W,TNEWH47-N%.4
MSAUP/F] >0>V=V-HP:Q/!OB^+PS --U -!+"6QN1F#AG8[@5!X!R,]#P03R!
M;\$6\FJWMQK;(T44J*D8<8+#"?/],(#P"#NP&.TY +O@K7Y]2N;Z&9MR03;8
MQM48&^08R ">%'7-&F:_/-JUQ8,V8(X0RKM7@D1<YQD_>/4]ZPM'UF+PC?WL
M=Z2@N'$B,%9E(+.V.!G/SXX&,JPSP,G@W46U'6;F=HVB+0?<D&' !B )'8D
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MU6W6.>(M\TL'F;P6;#!@C9 ^[GD$ %2>0.]\+26]PC36L/DHS8SY0BW@#*N
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M:8=2@_=R-'"XZ-M\QDR.1@\,1TKS*_?3KBP,D8D>_(4R,WF$@EQO=CG9M).
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MT!W$<$=>M5/$.JZAX6,-]<3K)"\H62)(E7;N!)"'[S  '!)!R%SG)P_XC_\
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M:W8DH(2P*E2NZ1< Y&">#T)''6NM\)_\>=M_U[P_^@+0!FZCI>IW3.\=S'$
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M5WN0?ER>0WIC@@D$8JQXLU32+UY4O$9+B(NO",LC84;6!7Y6! &S><8[!3R
M=[I<<L4:I<,KR#(+*-H8 G:V.Q(P6 X!SCC%6ZXSP->W-A8/<:AYA,1D8"3_
M %FQ5!_BP<Y#8W<XQ_#BNET76(]8A2[ASLD&1D8(P2""/4$$>GH2.: +U%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYU*WGABN+2UEMG$BLLODB%2"I(PR'!.0"I[ $@CG/5_&O_CSC_Z^%_\ 0)*
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M"ZA\MC VYSDY&/6N%^+NG16%BB0HJ*;E20BA1GRW&< #GBI?B!X2MK#3I'5
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MN,\)ZQ8W$WEI"+:\"$&-H_+;!".W0 ,. 1D!L D* 372ZY>M86\UPF"T43L
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M]<]J -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7BZUU:5K:WD#R("2 &QA2%)#$;2,D="<]1Q6K-,L*EW("J"22<  <DDGH!0
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MC+C&,G ],Y[9J72]4CU6-;F!MT;YP<$9P2#P0#U![4 6Z*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1ZK&MS VZ-\X.",X)!X(!Z@]J +=%%9^B:_!K:&:V;>@8J3M9>0 <88 ]"*
M-"BBB@ HHHH **** "BJFJ:I'I4;7,[;8TQDX)QD@#@ GJ1VJ6TNENT6:,Y2
M10RG!&0PR#@\]* )J*** "BBB@ HHHH **J:IJD>E1M<SMMC3&3@G&2 . ">
MI':I;2Z6[19HSE)%#*<$9##(.#STH FHHHH ***KW.HQ6K*DCJK2'"!F"ECP
M, $\GD=/44 6**HZQK4.CQ^?<.$3(&3DY)Z   DGZ#H">@--T37X-;0S6S;T
M#%2=K+R #C# 'H10!H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX(SGBN7UOQA+!JT8"7'E1HZF)5/[PCS!O5-V&7H0WHN>U7?B/_Q^:;_U\?\
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MB4^*K:STI"2\[A;CYP7"PX+'+CJP^<'U4K\QR* /4-.O5OXDN$R%E16 /7#
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M.XLXR!C_ %<B[R>>A&"[<Y+G&,!1G !V7B'Q/!X?02W#8W9VJ!EF(&< ?U.
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MW&_(CH0>0>#S7*Z)JK:;H:NBR%F2=08ADH2TI#D@C:JXY;MQ5CPU_P @%O\
MKWNOYR4>&O\ D M_U[W7\Y* )?AQXJ>[@AMI8[AW/F9G="T1PS$9D)ST^7IU
MXK"^&'B>/2;1HMDDLK3N?+@3S'"A(QO(R,+GC)ZGIG!QUOPM_P"0=!_VT_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ^*5JMW<Z?#(,I),RL,D9#/$",CGI6P/AG;-(DDCRR)$3LBEDWQ*.R@$9VC
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HKDKN_N]7NI[&VD6!+41%GV"5V,BE
M@,-A0N.O?('."0*.@WUW!<7"WEUNCL>9%$"!61XRRMN7# C&2H!Z8!;- '=T
M5YII_BFXUT?:6OK>T1L[8L1N^ S#Y_,((.,8QP1SA>_0> O%C:VLD$NUI;9@
MK21D&-P2P#KTZ[3GC'0C&<  ZNBO,O!.JZIXGB=O/6-$?'F^4CN3@?)MX7:
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MH-P(=L;,,!C ''I[U7\0W>JZ3;_VH\T8*E"]NL0* $A<;R68G)&[D=3M;@9
M/0ZS]?U)]-@>XBC:9UVXC3.XY8 XP&/ .>G:N'U?7M32U&M!XXX\HP@"!LQL
MPVEG.3N.X9 V_+S\K9%;OB?Q')%IAU*#]W(T<+CHVWS&3(Y&#PQ'2@#H].N6
MNHDE=2C.BL4/52P!*G('(Z=!]*L5YYXE\9W%E:V2QLJS7B(6FDP%7Y4+$C!4
M EN3C  .!T(V[5[K28I+R:X6ZA6!Y!B-8CE1N7:R9!5AG)/3Y<9R: .HK'UO
M6Y=/E@BC@:59GVNZYQ&,J-QPK<?,3R1T//IR7A2_U#Q%&;Q+N(,&)\CRD8 9
M.U7(^=0Q! ZG;R"3TU?&NOSZ;<V,,+;4GFVR#:IR-\8QD@D<,>F* +&H>*);
M?4X-+ 7RI8BQ)!WY D/!SC'R#L>]=17FGBV26/6;8VZJTOV<A0YPN3YPW$]<
M*#N(') P.35O5-6OO"4L4UW,L]I(P1R8UC9"><X0$G !/?."" =IH V-0\42
MV^IP:6 OE2Q%B2#OR!(>#G&/D'8]ZZBO/]9_Y#UK_P!>[?RGHU/QA)J%U+9P
M7$-K%;L%:27!D9L-N"K)A2 PP>_ 8,0<4 >@45PGASQ<\=Y_9<TR70E7='-$
M$&"%)9&"<#[I(P2>F>&^7NZ "BH;NZ6T1II#A(U+,<$X"C).!STKSK3_ !3<
M:Z/M+7UO:(V=L6(W? 9A\_F$$'&,8X(YPO< ]+HKS>'QG<ZE97/E,/M5B1ND
MCV-'(H)!8;P1C:K-P!D@%>#M'2S>,$.GG5DP/W1(!#$!_NA#@ D;_ESP.^0.
M: .CHK@KCQG/I-E:-*T;75V1AI,K&%8[MS;0H 564'IR<\@'.?>>)KC1HUO#
M?P7)0KO@41+N!X8*R?,2"<@X' R1QM(!Z;17#^/_ !9+96,-]:,4,SQD952=
MKQLV""&&>!T_.JGB&[U72;?^U'FC!4H7MUB!0 D+C>2S$Y(W<CJ=K<#(!Z'6
M/<ZW+#=QV0@9HI$+&89V*0&^4_*1GY1_$/O#CUT-.O5OXDN$R%E16 /7# $9
MQGGFN7U/7YX=6M[!6Q!)"69=J\D"7G.,C[HZ'M0 _P 5>+)[.YATNS16GF&X
MF7.P+\WH0<C:2?88 8GCHM+\[RU^T[/-YW>5NV=3C&[GIC.>^:\UU[3KEM9A
MC6XQ(\;M&_E*?+7]Z0FW.&P 1N//.>U>E:7;R6T:QSR>;(,Y?8$SDDCY1P,#
M _#- %NN7\6^*)='N+2WC"E;J7:Y8$D#<@XP1S\QZY[52\0:_=7UZND6#+&R
M*'FD*ABH.. K#!X8'C.20,J QKG/%,5W;WUA#=NLJK.ICE50C-F2/<&4$@%>
M,8&",').< 'K%%<?J>OSPZM;V"MB"2$LR[5Y($O.<9'W1T/:CQKK\^FW-C#"
MVU)YML@VJ<C?&,9()'#'IB@#L*Q_%&MRZ/$)88&G8N%*)G(!!.[A6XXQT[]:
MY?QCK]]#J$6GV3*/.ASAU7;DF0%R2,_*!G'/3[IS@GC74KWPQ9K)]H\R5K@#
M?Y4:_*48[=N&'5<YZ]J /0**X?XC>(KK29;6.S(W3.P*D*0Q!C"J2W0'<1P1
MUZU4\0ZKJ'A8PWUQ.LD+RA9(DB5=NX$D(?O,  <$D'(7.<G !Z'17.>*-8G@
MEM["VVK)=&0>8X+;!&N20O=N<C/&1@C!R,*]BU&TNH;)KWBY63:PMHLAHQN(
M*^F.A!)SQ@#F@#T"L'Q)XNCT0K"%:6>0$I%$-SG )R<=%XZX)ZD X.-ZO/\
MP'_IFHZA<R<R)((U/3"[G&,#CI&O.,\=>3D U?\ A+[FS_>7EF\47=XY%GV]
MRS*@!"@ DMSC&,<T_3_%$MQJ<^ED+Y4408$ [\D1GDYQCYSV':NHKS_1O^0]
M=?\ 7NO\H* /0**X+3-9O?%TDDEI*MO:Q.RJXC$CN1CJKXP,<]%QN ^8@D6M
M"\17-G>'1[\J[,A:*51M+C)/*C@' /\ =QM(^;() .SHKS3PQKM[XO:66.Z2
MW ;Y81''*X4 98[L''(^;H6SPHP*Z#Q9XLDT&*!#Y7VF=E7+EA"IX\QR>NT$
MCJ0<'/."* .KHKS*\\37&C1K>&_@N2A7? HB7<#PP5D^8D$Y!P.!DCC:=WQ9
MXS:VMX&M!F>^VB$/C(#@'<>JY&Y1@G&3GD B@#5\9ZV^B6DEY$%+Q[,!P2OS
M.JG."#T/K5W0[UK^WAN'P&EB1B!TRR@G&<\<UY[X[LM1LK%_/F2>-_+\S]V$
M:,A@1M*XW M@'(ST( R<=UX3_P"/.V_Z]X?_ $!: *'B_P 8-H#P0QQ>:]RS
M*H\P)R"H R5(Y+>V*HCX@O8SI;:A;FV$H.US*LB9SC!*@ #U.>,@D '(S?BE
M=+:7.GS2'"1S,S'!. KQ$G YZ57\6ZNGCDQ:=8AG42JTDH1@B##+R&"\X)/)
M&< #)/ !Z;17#^*/%\@NO[+MYHH-J*TDTW;+*=JAOE+;3GG((.,J1FJEGXOD
MTJZBMI;F.\BN2%#1"-7C?< ,A"1M.X=3GJ1]W# 'H=8_BC6Y='B$L,#3L7"E
M$SD @G=PK<<8Z=^M<EJ&M:A>:G+IEK(J1JJ'+(AV+MC9F&1EB2< '(^;M]Y;
M7CS5KOPW8QNLVZ?S@K2>6@W AVQLPP&, <>GO0!W=%<EXP\33VTT6EV04W-P
M&.7SA%P?F]">">^-N-IR*S]=N]2\*H+UYENH5($BM$L1 +  @J>2>G?&0=I[
M '>UR_Q#\42^&[=;B$*6:4*0X)&"K'L5Y^6J7BKQ;+*UO8Z:5\Z[4.'88"QX
MW!L,N.0#G@D $;<D5R_Q1M;VSMTBN)5GA,H/F>6(W#[6 3:IP5(R0<9SD$CC
M(!Z[17">-_%4]K=PZ;!(EN)%WO-)M( ^88PPP/NG_>) RHSGI="LKJTW)=3+
M,#M*L(Q&P/.Y2%XQT(/7).> * -:N?\ #^NRZM/<C"BWMY/*4X^=G7&_)WD8
M!Z?*,AAR""*U=6OO[/ADN<;O*C=\9QG:I.,X.,X]*YWX50JFG1$  L9"2!C)
M\QAD^IP /H * .MHKA];M=5MX)+TW4:-&C,8HX08\(,G#N"V2!GD?>XX'-6/
M^$X?^RO[8V+YFW[N3MW>9Y>?7&?FQG..,]Z .PHKA_")O]1CBO3>1R@E=\0B
M3 !P64NF"'53G&.&P#QS7<4 9\VOP0SI8,V)Y%W*NUN0-W.<8'W3U/:L?Q;X
MHET>XM+>,*5NI=KE@20-R#C!'/S'KGM7):]IURVLPQK<8D>-VC?RE/EK^](3
M;G#8 (W'GG/:I?'T<]E+IH=OM$Z3.<X6+>?,C*K@9"]ES^)H ]0HKSSQ#JNH
M>%C#?7$ZR0O*%DB2)5V[@20A^\P !P20<A<YR<=;KMO=W.V.UD2)3NWNR;W&
M,%=JGY3GD-N['(YH UJS]2U^#37BAF;:\[;8QM8Y.0,9 ('+#KBN4TW6KS2]
M172KJ19TGCW*X18V7 8]%&.2I&,GL01R#E?$JRG-]9D38$DP$0\M?W1!B!;/
M\>3\V#TQCI0!ZA6?K>OP:(@FN6V(6"@[6;D@G&%!/0&C1+*>T0I<S><Y8D-Y
M:QX&!\N%XZY.??VKA/C7;R>3'+YG[KS%7RM@^]MD._?UZ<;>G>@#TNBN,UC5
M;CPA;27-S.+AV*K$#$(@&.<YV9R,<\X^[@$$UCW>NW5M&UW_ &C;-(F7\A!&
M4(!SL#YWG*\#C.>,_P 5 'I=%>>>+/'4ITZ'4[0F)I90I!"MC D##D$8W+P<
M X].171^&K*^4^?>S*=ZG]RD:A4)((Q(.3@<=^O4XR0#H**\R\$ZKJGB>)V\
M]8T1\>;Y2.Y.!\FWA=H!R21G) !(SB7PYKVIZTTNG;XT>V=EEN-@8_>(4*GR
MJ22K#)&-OHP^8 ](JOJ-RUK$\J*79$9@@ZL5!(48!Y/3H?I7+_#[Q'/J1N+.
M[VM+:2;2Z\!LEAT  X*G!P,C&1D$GH/$-TUI;3S1G#QPR,IP#@JA(.#QUH -
M U)]2@2XEC:%VW9C?.X88@9R%/(&>G>M"O-[CQU<6>D17Y(:>9V3>0!CYI,-
MM  ) 7 '3/)SR#T'ANVO"8[B2[CN(F!#!8T"C@\I(GWB'&.0!C/ ( H ZBBB
MO/\ 2]6OO%LLLUI,L%I&Q1"(UD9R.<X< C((/;&0 "=QH V-/\42W&ISZ60O
ME11!@0#OR1&>3G&/G/8=JZBO,O!KSOK-R;H*)O(PPCSLX,04C))P5P>>>>0.
M@EC\92Z_([17<%I!&[*FX*TKXVX8K+MPIY(Q@C[I!QF@#TBN'7Q9>ZQ=3VM@
MD0CMCM9KC=RP8CC8>AP<<'@9)!(6CPMXIEU&2?26E62:-&:.YB"LA!Q@E1\N
MY2PX'!P0>F6YSP5I5W<7-\D-UY;I-B1O)1]YWR?-@G"\@G ]?:@#T.VUN6:[
MDLC RQ1H&$QSL8D+\H^4#/S'^(_=/'IL5Q^F:_/-JUQ8,V8(X0RKM7@D1<YQ
MD_>/4]ZQ]'UG4M:N[NSBE5(H96'F-&K,@#L%55XW%L8.[. "<@XR >D45QGA
M'7K@7=QI-XXEDB ='5 N5(7@@8Y^92!@\[OF(Q65'XREU^1VBNX+2"-V5-P5
MI7QMPQ67;A3R1C!'W2#C- 'I%%</X6\;DR3V5U(LOV9&D^T18V-&,$Y"_P 2
M[APN>XZC+5_#]YJ?B-6U%)4AB9CY41C5U8*2"&;A@"1@D<]2 HVY -CPEXHE
MUBXN[>0*%M9=J%002-SCG)//RCICO70:C<M:Q/*BEV1&8(.K%02%& >3TZ'Z
M5Y_\)WD>XOVF 64RH7 Z!BTNX#D\ ^Y^M=QXANFM+:>:,X>.&1E. <%4)!P>
M.M !H&I/J4"7$L;0NV[,;YW##$#.0IY ST[UH5Y__P )3<_V+_:6_P#TC^_M
M7_GOL^[C;]WCI^M1?:-5N;'^TS.D96'>(UB5MRJ-V]F.[#,.< ;>@^4DX /1
M:Q_$WB:/08P[ O(YVQQK]]V[ #GCD9../<D N\*ZW_;=K%>8P9%^88P-RDJV
M.3QD''.<8SS61\0/"\VL+#<6I GM7+(&( /0]P1NW*N,X7KF@"6W\37BR1I/
M9,D<CA2Z3)+MW="54<*.Y)  ]\ ]17&>'/B(+N1+*]B:WN' VAP51NPQNP06
M.< Y'&-Q8XJ+Q1XOD%U_9=O-%!M16DFF[993M4-\I;:<\Y!!QE2,T =Q17GE
MGXODTJZBMI;F.\BN2%#1"-7C?< ,A"1M.X=3GJ1]W#6YM>N_$%W+8V+K##;$
M"24H'<M@C:%; QN!'3^$G=R%(!W%9^B:_!K:&:V;>@8J3M9>0 <88 ]"*S[>
MROC'):R3*'&PQW*QKD@G+*T70%<8SG!# _>!KBOA)IUS/"98KCRXEN/FB\I6
MW85"WSDY&1QQTZT =[HFMRZA+/%) T2POM1VSB098;AE5X^4'@GJ.?78KBO"
MOBF2>;4/M+YBM)#M^4?*JM+G[HR>%'7)XJOH5WJ7BI#>I,MK"Q(C58EE) 8@
MDECP1T[9P3M'< [VBN2\'^)I[F:72[T*+FW"G*9PZX'S>@/(/;.[&T8-8FCZ
MSJ6M7=W9Q2JD4,K#S&C5F0!V"JJ\;BV,'=G !.0<9 /2**XSPCKUP+NXTF\<
M2R1 .CJ@7*D+P0,<_,I P>=WS$8KLZ "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#R_7E!U"Y++<E@L&U[#&\*4.Y9-I_B(!&X;L*,87&=#PU)97$<^DQ>;%
M<W"R;_M2_OV+KG<>S8#9"Y!QEL<ECH)%?Z%),8HENH[B9I ?-$;ID*-IWY!
M  7'0+SC( 9I.@W&IWHU>\00F%-D<2N')R&RS,.,?.< 8/3.,?, <UX7OK'1
M8OL6JVZQSQ%OFE@\S>"S88,$;('W<\@@ J3R!WOA:2WN$::UA\E&;&?*$6\
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M)VG#\GCI\^1C)(5L#CG*\4^)4UR^L#"K>2DZ[965E5R9(]P7<!D+C!/J2,<
MGUBB@#S_ %G_ )#UK_U[M_*>CXU_\><?_7PO_H$E>@44 >?_ !'_ ./S3?\
MKX_]GAH^-?\ QYQ_]?"_^@25Z!10!PGQ(4--:!U=TW3<08-QN" HR<AOE/S'
M'R\#=GY16?H6I66E7 FNA=K*Z[8Y-07@#."%;M][DG@#/(R<]-KMC=V]RNHV
MP655A:-H6?8?F<-N5CE03@;LXX7')(QCZSI5YXP,=K<P"V@1][MYJ2N< @*N
MWH3N/)!'?MM8 [VO/[N*3P=>S7Z1/)9W*[I/* 9D<;F+8)SC[Q)^51O_ -D
M^@44 <I_PL>VNOW=F'N)3T2-&7V#,S@!5S@%N<9SBLK1O^0]=?\ 7NO\H*]
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MP0S*.=N-Q+#.,8P<BM:B@#RSQIJ2>.3%9:>AE*N&:8JRH@(8;267(!QD^NT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ16?:^(;:[81131.YSA4D1F.!DX .>E:% !15&RURWOVV0RQNP&2$=6..F<
MGCFIKW48K!=\SJBDX!=@HSUQDD<\4 6**KV6HQ7Z[X75U!P2C!AGKC()YYJO
M=>(;:T8Q2S1(XQE7D16&1D9!.>E &A14-U=I:*9965$&,LY"J,G R3QUJ*QU
M:'4,^1(DFW&?+=6QG.,X)QG!H MT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT'4-8LYK&Z: R,(@C)O&=KAG+Y7J<#&T8SG@"@#/3PE;#23,R!Y6M/,\Q^9
MPB#* W4*N  HXVC!SDYQ]4UV6/08"#S*WE$]#L4R  8QV0*<YR,YY.:] _L1
M_L']GY7S/LOE9R=N[R]F<XSC/MG':LJS\!^;IJZ3<%=Z[B'0;@K%V92-P!Z'
M!Z$@D C.: .?N_#TLL#6D>E(F5(5_M$3.I/(;<?F.#VW<CY>G%=QX1BN(K6-
M+S/GJ"&R0QX8[<E203MQSG)[\YK'M=/U>W46WFV[(,J)760S;<X#%?NE@.Q)
M!(^8GDGJK2-HD5)&WN% 9L!=Q Y; X&3SCM0!S7C/4+"V>+[8GG3#/E1*ID8
M[R%/R9VG/;=W!V\BN2TJXC_MF$V\,ELLD3!XW3RMV$DYV D;?E7VW+G&>:ZO
MQ5X3GO+F'5+-U6>$;2)<["OS>@)R=Q!]CD%2.:EIX3O9M0AU6Z>(^6C*5CW#
M;E74!<CD?-N)8@Y) X R 97C+1X]8UFVM9LF-H,D XSM,K8SZ'&#CG'0@\U+
MXNTZ+1+_ $^6U18FDE*-L4*"I9%/R@8SAV&<9YZ\#'0:AX7EN-3@U0%?*BB*
MD$G?DB0<#&,?..X[T>+?"\NL7%I<1E0MK+N<,2"1N0\8!Y^4]<=J .?^).G1
M&]L"47,L^'.T?. T0 ;CYACCG/'%'Q=TZ*PL42%%13<J2$4*,^6XS@ <\5T'
MCCPG)K@BGMW"3VS[D+?<Y*DYX/(V@C@CL1SD9_BCPO?>)+06\Q@$RSA@4,@3
M8$([ACNRWTQ0!4\:1#6M3M=*FSY!1I"%)&XX?@\]/DP,8(#-@\\=;#X7M[:1
M+B%%B>/=_J@$#!A@JP4 ,,X(ST(!'?.;XR\)R:LT=W:N(KJ _*QZ$'JK$ G
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M<,?O8V\>V5.AK_@:._L1ID6%\H*8RW]Y>YVXY;)W'!Y8M@F@!GQ2_P"0=/\
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MBO0/&>B/K=I)9Q%0\FS!<D+\KJQS@$]!Z5CZEX$DN(;5X9!%=V<2J'495MJ
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M.23DG.XY!RP!XQBNEO=!U75XOL=Q- D;##O"',C #H0=JX8_>QMX]LJ;NO>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .?UOQO!I4@M,/+.<?NH$WN 03DC@=!G&<X(.,<T
M[1O&$6K&2-$D6:$9,,JA)2, @@%L8.0.2,9&< @GBO#]I=7=_?I%<F"3S<X>
M-9&9 S!" Y!"JI&,<89>V*Z.Q\#SK>1ZG<W/G/$K*!Y*Q\%6&,JV."Q/3VH
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M.0 <7X6VJVESJ$,8PD<RJHR3@*\H R>>E2Q1:A9WUQ?FU\[?^[B/VA$"QJ>
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MK9^%8+*U;38P5C=&5B,;SO7:S$XY8_3 X & !6E:VB6BB*)51!G"H JC)R<
M<=:FH Y]? ]N;,:4P9HESM+$;P2Q;<"  ""QQQTX.03G*N/A1;W*+%)+<.$Q
MLWR@[ !@JH*X /&>/X1C SGM:* ,?6_"\6L2P7$A8-:ON0*0 3E3SD'CY1TQ
MWHN?"\5Q=QZH2WFQ(5 !&S!##D8SGYSW':MBB@#'UOPO%K$L%Q(6#6K[D"D
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M)/WI0+&$S*6<9";<\,.<C/; R< @&Q17&-XZN+)4N+RS:&W8J&D$@D*;NA9
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MWS(D;K&GFJ/,7]Z ^[&%R"3M//&.] 'JM%<U<^+9+ VJW%NR&ZD,;8<.(VR
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M^)AU2/=9VTDTB(&D7(54Z@C=@[FXRH"Y8'CD%1T'A7Q-'XC@%U&".=K*?X6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR(S!!U8J"0HP#R>G0_2J^@:D^I0)<2QM"[;LQOG<,,0,Y"GD#/3O0!H4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.T-D@9R1QD'H[_F#?]P__P!H5S5MG_A'3MVYVM][;C'GG/WN,X^[WSC;\V*
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ME6P",X(!QGG&#Q7'^'O&7_".Q)8:HKPO&NU7*[HV5<;0#&#D@$ XR..6W'%
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MV[<,.JYSU[54^-=O)Y,<OF?NO,5?*V#[VV0[]_7IQMZ=ZM_&O_CSC_Z^%_\
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MQ?8M5MUCGB+?-+!YF\%FPP8(V0/NYY! !4GD#O?"TEO<(TUK#Y*,V,^4(MX
MRK@  E2&^4GWX% &AJGG>6WV;9YO&WS=VSJ,YV\],XQWQ7"^)]2U#P@(KR2X
M6XB,FUD,21$Y!(P5!/0'G/!QPPR*V/B?-<PV9>T+ JZES&<,$ ))R.0 <9QS
MC.?ES7F/BI=--M&=/5S(&3S';?P"A^5LG9N8C/RC'RMC Z@'O=>?ZS_R'K7_
M *]V_E/7H%>?ZS_R'K7_ *]V_E/0!8FUZ[\07<MC8NL,-L0))2@=RV"-H5L#
M&X$=/X2=W(4D.O7?A^[BL;YUFAN21'*$".&P!M*KD8W$#I_$#NX*C/L[P>"K
MZZ:Z5A;W;AUF"DH"=[["%W<_,1Z_*#MVG(+R\'C6^M6M58V]HY=IBI"$C8^P
M!MO/R@>OS$[=HR0#J-4TZ_O)&\JX2")<;-L0E=L@;MV\@#!'R[>H//2L_P"'
MWB.?4C<6=WM:6TDVEUX#9+#H !P5.#@9&,C()/)7\T!O[A-<,FP$FW!+^6$+
M8! CYR5"].,AM_S"M+X1*J37PC5D02)M1\AE&Z7"G))R!P>3S0 _1]9U+6KN
M[LXI52*&5AYC1JS( [!55>-Q;&#NS@ G(.,ZOA'7K@7=QI-XXEDB ='5 N5(
M7@@8Y^92!@\[OF(Q5+X<?\?FI?\ 7Q_[/-1HW_(>NO\ KW7^4% 'H%%9-KXE
MBN;J731N$L*JQR/E(8 Y!!/3<,YQUXSS5O5O,\F3R/\ 6^6^SI][:=OWN.N.
MO'K0!R6MVNJV\$EZ;J-&C1F,4<(,>$&3AW!;) SR/O<<#FJGB/7&US0VO'4*
MSA,@=,K.JDC/8XSCG'3)ZUQ]L]C/:S&[$LFI 2@A_-+@JN%/!QM0#+;^1M;C
M  K>_P"9<_S_ ,_5 %KQ=;R2:-#(DFV-+>#>FP'?GR@OS'E=IYXZ]#70> ].
MN8(899;CS(FMX]L7E*NW*J5^<')P..>O6J6KZ?)J&B)#"I9S;6Y"CJ=NQC@=
MS@'CJ>@YJW\/O%EOJ<$5G&Q\Z*!0RE2,; J$YQM()QCG.#R!R  <C\+[>\O+
M9XK:18(UF9C*465F8H@V!&P  !DL>22 .C5O>'_'4EO;W9O2'FL'*LRC:KY)
M5!D#J7!&=H &TGO3/@I_QYR?]?#?^@1UB:9HS:R=8M8_OM,"O3DI+(X7D@#)
M&,YXSF@#H-,@U76H1>_:4@,J[DB6%67!4;26;<1NZG[V ?7Y1-I/C.74+2[:
M0+'=V:RA@G*@JK%6&=PZJ1C+?=ST(%5-!^(]MI=LEM=AXI[>-4,;(VX[$&TC
M@ ;AC&XC!]L,6>$O#D]U!?SR*8I-0,@5) 1MR'P2>N,N1]T' R 010!T?@+5
M)-5LHKF=MTC[\G &<2,!P !T [5B>!?%L]W83W]R?,>!I2.%3(2-7V_*N.N>
M<'K6;X*\;Q:59K8E)&NX3(! L;;V.]F[ X S\V>1@_*>,L^&N?[)NMNW=NFQ
MOV[<^2F,[_EQZ[N,=>* -"ZDU.:T.JK<HF81+Y20J4"[=V [[FSMYY!&[C..
M:9XF,KZ-)--*9C*(75C&L1"N\9"E4)&1ZY[X[5SMG% +>/S8M1\@1HSH@_T8
MX 9F&3]UB"V<CKD8XQU7C75(-2TB62T93$/+4;1M VRH-NT@%<#&!@<8(X(H
M I0C4ET];V*985AMD*Q;%?<D: [RY!PS $A0, ;02#N-=EX5UO\ MNUBO,8,
MB_,,8&Y25;')XR#CG.,9YK*_Y@W_ '#_ /VA1\+?^0=!_P!M/_1KT 5_B-XH
MFT<06]NRH]RY'FR8VH%*Y)R",'=R3G !XR01J^'[2ZA;?-<K<0R)D$1K&0>"
MI4H2&5@3G/HN.IJ+QGJEI:*D-^A:&4L-Q0LBD+QDCYE8@G:5&>IXP37)>$,?
MV@/[+\W^S]K>9NW>5OV?P[^<YV?[?7^"@#H/!6OSZE<WT,S;D@FVQC:HP-\@
MQD $\*.N:-,U^>;5KBP9LP1PAE7:O!(BYSC)^\>I[UA:/K,7A&_O8[TE!<.)
M$8*S*06=L<#.?GQP,95AG@9/!NHMJ.LW,[1M$6@^Y(,. #$ 2.Q( ..V>IZT
M :&F:S>^+I))+25;>UB=E5Q&)'<C'57Q@8YZ+C<!\Q!(=XW\]=*N([K:71HU
M#KP)%\R,A]O\).<,O3()'RD5E>$-<C\#M-I5]N3$AD20J2KJ0%!PNXC(7/<=
M5)!7G3\::V-8TNYF5&6,/&$+@KO7?$1( 0/E.3CU SP>  5(1J2Z>M[%,L*P
MVR%8MBON2- =Y<@X9@"0H& -H)!W&NR\*ZW_ &W:Q7F,&1?F&,#<I*MCD\9!
MQSG&,\UE?\P;_N'_ /M"CX6_\@Z#_MI_Z->@"+XH:_/HELDULVQS,JD[5;@H
MYQA@1U JIKK:K:1'4EE1=GSM;;%*JB\D>:>6( ^;&W/S;#]T&+XU_P#'G'_U
M\+_Z!)3/$?Q&BN+5[01R"[G0QF!D8.ID7&<E>1SE<<MD<#)P 4OB7K*ZUI=O
M=IP))D..>"$D#+D@9P01G'.,CBN@\;>+GTZ2/3[=XHY9E9C).2J(H!VG.,9)
M!QG(!&"IW"N4\;Z,VC:/;6LGWUF4MTX+K*Y7@D'!.,YYQFMCX@Z8;:[@U9XC
M/!&C)*@0-M #'>0<Y W$\@ %1EAD8 *]YXQE\.M'.]Y%>1,VUXXUB6101D.N
MPG.,'.2!T'?*ZWB#7[J^O5TBP98V10\TA4,5!QP%88/# \9R2!E0&-0VFK:1
M?NL-M DSLP!$=K]T$XWL610%!(R>V>E5=:N/^$4U0ZG,&-O=1B,N!PC#:,$#
M)/" ]B03M!*D$ S/%,5W;WUA#=NLJK.ICE50C-F2/<&4$@%>,8&",').<=AK
MFIW-S=KI5JRQ9@\UI67>P&_: J'"YR.<]B<8(YY+Q5X@76[S3Y(5;R!< +(P
M*ASOBW;5(!PO R>IR!]W)T/'"AK]"RS-BU.PV>/M"MYF"W!W;=OR_-E?F.WG
M) !:L!?QW_V"6[W*L:3#%O& Z;]K*>A0YX&-W'.0>*I1^,I=?D=HKN"T@C=E
M3<%:5\;<,5EVX4\D8P1]T@XS5CP?J5E83M$XN$NI]N&OEQ(XZ!0W0#*XYQN.
M ,X &)X?BM/"C2V.J0K_ *QC%/)#O5U 48&%8CC#8!(&2#@CD ZCP7XM>\GE
MTR9UF>(%EGBV['0E>H7@,-P'&1U'49;'\,:[>^+VEECNDMP&^6$1QRN% &6.
M[!QR/FZ%L\*,"NH\*W%G>L\ME $50 )1 (E<-G(4X!(4KAL@8..M<5XCU32]
M35YHTDCU#)"*B.DPE#\9"_(6+=3DMC@?,   >I6F_8OF[?,VC=LSMW8^;&><
M9Z9YQ6?KMO=W.V.UD2)3NWNR;W&,%=JGY3GD-N['(YJ+P7Y_V.'[7N\[:=V_
M[V-QVY]]N,YYS][G-<E\2IF2ZMQ=&0:<P D$9PI?<3AMO)'"GUP&*?-F@"[I
MNM7FEZBNE74BSI/'N5PBQLN QZ*,<E2,9/8@CD&KJ&M:A>:G+IEK(J1JJ'+(
MAV+MC9F&1EB2< '(^;M]Y<30UM%UBV-@K+ 8WP6WX8[)067><X_A[<J?J>@T
M;_D/77_7NO\ *"@#0\1>(Y?#$$,#R)+<S2;1)*OEQXW<NP3@!05!Y'7=S@BL
M*\\37&C1K>&_@N2A7? HB7<#PP5D^8D$Y!P.!DCC:=7XG:))=BWO(XS-]FER
MT07.Y6*D^O'R@$;3PV3P#52'Q)HUPH\FW625@"(H[0&3U(^[MRHR3\V, X)H
M [O3KU;^)+A,A945@#UPP!&<9YYKG]<U.YN;M=*M66+,'FM*R[V W[0%0X7.
M1SGL3C!'/2PPK"H1  J@  #  '   Z 5Y[XX4-?H669L6IV&SQ]H5O,P6X.[
M;M^7YLK\QV\Y( +5@+^._P#L$MWN58TF&+>,!TW[64]"ASP,;N.<@\52C\92
MZ_([17<%I!&[*FX*TKXVX8K+MPIY(Q@C[I!QFK'@_4K*PG:)Q<)=3[<-?+B1
MQT"AN@&5QSC<< 9P ,3P_%:>%&EL=4A7_6,8IY(=ZNH"C PK$<8; ) R0<$<
M@'4>"_%KWD\NF3.LSQ LL\6W8Z$KU"\!AN XR.HZC+96CZSJ6M7=W9Q2JD4,
MK#S&C5F0!V"JJ\;BV,'=G !.0<9Z7PK<6=ZSRV4 15  E$ B5PV<A3@$A2N&
MR!@XZUA?#C_C\U+_ *^/_9YJ +OA'7K@7=QI-XXEDB ='5 N5(7@@8Y^92!@
M\[OF(Q65'XREU^1VBNX+2"-V5-P5I7QMPQ67;A3R1C!'W2#C-6-&_P"0]=?]
M>Z_R@K$\/Q6GA1I;'5(5_P!8QBGDAWJZ@*,#"L1QAL D#)!P1R =1X+\6O>3
MRZ9,ZS/$"RSQ;=CH2O4+P&&X#C(ZCJ,MA>"M2U7Q0C2?:%CCC8C?Y4;LS$*=
MNW  "CG/!RV/F_AZWPK<6=ZSRV4 15  E$ B5PV<A3@$A2N&R!@XZUA?!3_C
MSD_Z^&_] CH Z#5-.O[R1O*N$@B7&S;$)7;(&[=O( P1\NWJ#STK/^'WB.?4
MC<6=WM:6TDVEUX#9+#H !P5.#@9&,C()/)7\T!O[A-<,FP$FW!+^6$+8! CY
MR5"].,AM_P PK2^$2JDU\(U9$$B;4?(91NEPIR2<@<'D\T 6_AQ_Q^:E_P!?
M'_L\U8_@.>:WTBYEMF"2QRNP8@'A$C9N"",E00..OIUK8^''_'YJ7_7Q_P"S
MS4?!3_CSD_Z^&_\ 0(Z .@M?%BOIXU5MIQ"6(R44NHP4!;)&7&T=<\8SWL>$
M)YKBTAEN6#RR)N+  <.=R\  9"D \=?7K7F4EI(]RWA8'; ;KS 5=N(MID,?
M(.>,$9& X).<Y'LM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:ZNBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8S<E ,J=P!4=5W \8SD<5>F@O=2TP74ZLMU83;T:2/$A1%4DDOC.,Y)P=VP
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MO7G]IIJ^-M0N3=EC#9-Y:1!B%R2RELK@\E"WKR 6PN" :>K:C*FM6UN'81-
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M@R<>@X'  H ZC7X9YH'2T94G.W:S\J/F&<_*W;(Z&K&G)(D2+,0TH10Y'0L
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M00&(&[ (X(/RDDX/0YFE>*[O1[A--U0*?.P(IHQ\K,3T. !U(7A5*\$@AMU
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRJ\*8OFP6SR%)P,TWQ9X=O;G48;ZS"@1Q ;Y"-@.9,J5Y;!#8X'?@CJ.]HH
M\_U32;[Q;+%#=PK!:1L'<&19&<CC&4((R"1VQDDDG:*T-3T">;5K>_5<P1PE
M6;<O!(EXQG)^\.@[UV%% '#S:#=^'[N6^L46:&Y(,D1<(X;!.X,V1C<2>O\
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M6K>'[K3M2.K6T2W"RI@J65&0A57(9CU..H!X+*0."7>&-%O%U*;4KJ-46:'
MVNK ']WA>N20%PQP 2#C@BN[HH XKQ;H%T+V#5[15E:)=C1E@AP=^2&) Y#D
M>QP<,,@=5I=Q)<QK)/'Y4ASE-X?&"0/F'!R,'\<5;HH X_X@^')]2-O>6FUI
M;23<$;@-DJ>I('!49&1D9P<@ Q:YH=UXGBCG,:VUW;3;HM\@E7'RDDE00,D
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MD'LZ* ."U/1KWQ=)''=Q+;VL3JS(9!([D9Z,F,#''5<;B?F( '>T44 %%%%
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M'C>((B^S< 5R3@?,#Q@GH<XJQX9\50>(XS- 3\IPRM@.OID G@]B"0>G4$
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M7;(KQ+).(9"Q,0E_=Y/0XQR5P",D\J,Y[]!HWA^+2K<6"Y>)0PQ)ALAR20>
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M@PQMW$>[G))^4\GC/8D9(SDFQ)X(@>U?3\N$F8,[;]TC,"I+EFR,L5&>,=<
M4 </XI,@M])*N8TQ%ER,HC;8MC,#\N5&XC/8-VS71ZIX)O=5C:VGOMT;XR/L
MT8S@@CD,#U [UOS^&(+JW33Y5WQ1J@&X_-\@P#E<$''4C'4CH<5D0_#:$*(I
M)KB2$ #RI)CY9 ^Z,*%X'!&",$"@"OJ.ORZ&UMH5HBR7!A0!Y#MC 0;2Q4')
MX1B1GCC&X\5B+]I_MNV^V>5YGDOCR-^W;MFQG?SG.?;&*[+Q)X-@U]DEDW)+
M$05DB(5QCD#)!X!Y'<'H1DYJZ=\/8+&X34 \KS(""TCA]V0RY8E<Y"G P0,
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M!).!P>2.#TK(^%NCG3;%"V0TQ,A!(/WL!<8[% IP><D_0 '6UY_HW_(>NO\
MKW7^4%>@5SFN>!8-6F6\W213*,;X&",>,<G!Y XR,''!R , '/Z]"LNNV@8
MCR"<$9Y7SB#]00"/0\T_XC_\?FF_]?'_ +/#71+X/B^T0WY>1I;>(1@LP.X
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M/R#N>]&B>%XM'EGN(RQ:Z?<X8@@'+'C ''S'KGM0!R^C?\AZZ_Z]U_E!6/\
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MBUB>'_",.@O-+!N_TA@2IV[5P6("@*, ;CQSQBMN@#S_ ."G_'G)_P!?#?\
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MK^W^Q333NHE\P,\@9\[=NW)4_+SG&.O>@"+XF0K#IDR( %41  #  $B   =
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ML,%PH#D<<%L9(X'Y"K%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 57N=.BNF5Y$5FC.4+*&*G@Y!(X/ Z>@JQ10 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.N?+\S.>G&<]>-_\=5[GQU)?:2^I0D).A56P,@-O0' <$8*MGOC.,DC-6/\
MA:MMY?W7^U?=^S[&W^9G;LW;<=?QQ_#N^6N<;09-&T*99@5>5TD*D8*YDC4
M\GG"@]B,X(R* -/[1JMS8_VF9TC*P[Q&L2MN51NWLQW89AS@#;T'RDG'7^%=
M;_MNUBO,8,B_,,8&Y25;')XR#CG.,9YK*_Y@W_</_P#:%'PM_P"0=!_VT_\
M1KT 7?&NNMHULTD8)FD(CB &27?@8&&R1R<$8.,=ZXCQ!HG]C2Z5 3ND-P6D
M;.2TC21%V+8!// )YP!FNW\3>#XO$+1/(\B- 6*&)@IRVTYR5/(VC&,5P7C7
MPQ]AN;&+S[A_.FQNDEW,GSQC*' VGGKSR!Z4 >MUY_\ &O\ X\X_^OA?_0)*
MU;_7/^$5:TT_YYOM$A3S)9,N,NO).WYL;^.G  K*^-?_ !YQ_P#7PO\ Z!)0
M!2\?>,A?VIM3!/")G13)<1E$7#!L\;B3\O0#.,D9Q@]_H=LMK;PQ(P=4B10X
MZ,%4 ,,$\'KU/UKDO$'CJRUFWELX"TTLL;!(TAD9BV." 5 ^4_-GJ,9'(%-3
M5)/ &F0":,/)O*E0^,;R\GWMK9(Z''&>A(Z@'>UY_P")/^)]JMM91_\ +E^]
MD;TR48+@X]%&03]_I\IK5^(7BT^'XE6,JLL[;59P2J ?>D("MG;D<>^<-@@X
M_AGQ9I6@QE%G+R.=TDC1R[W;N2=IXY.!GCW))(!Z'17/^)/%?]BS6UMLW_:I
M-F=VW;\R#.,'/WO4=*Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMM\4@NY(-R,V5V*5D)5EW\,/F!^4X)Z^@!UM%<_K?C>#2I!:8>6<X_=0)O<
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MMIK<"7D08))NP' #?*Q4YP2.H]: -"BN?TCQK#JMM+J$:N(X-^X,%#'8@<X
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M@D'!.<9YH YK_F7/\_\ /U1X^_Y UG_V[_\ HAJ[7_A"H?L7]D;G\KURN_\
MUGF==N.OMT_.C5_!4.JVT6GR,XC@V;2I4,=B%!DE2.AYX'- %+XF0K#IDR(
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MS9S!+FU@6(%U&Q@HVYZ-M.&;LW8<8S5N'X;0A1%)-<20@ >5),?+('W1A0O
MX(P1@@5?USPA'JTJW7F2Q2JFS=!)L)7.[:>#P#SQCWS@8 *7ACQ;+>7$NEW<
M:I<0KN+1G,;#(P0#R.&4CDYYSM/%97PX_P"/S4O^OC_V>:NE\/\ A"#0BTD8
M9I9,[Y)&W2-DEN3TZ]< 9P"<D9JEJ'P]@N9VO8WE@DD&&-NXCW<Y)/RGD\9[
M$C)&<D@&)KT*RZ[:!@"/()P1GE?.(/U! (]#S3_C7_QYQ_\ 7PO_ *!)747/
MA>*XNX]4);S8D*@ C9@AAR,9S\Y[CM1XH\+Q>)(A;S%@JN&!0@'(!'<-Q\U
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M99KB-9V9GCBEQ&2XPQVE3G=WS].F!6[H^BPZ/'Y%N@1,DX&3DGJ2222?J>@
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M'B?4Q/&=UO90Y1E(P7G49R"-WW<@C^$IS@D@]+XKG2&TG:7[GDR _,%)RI
M)! ))P.#R1P>E9'PMT<Z;8H6R&F)D()!^]@+C'8H%.#SDGZ  ZVO/_AQ_P ?
MFI?]?'_L\U>@5R^H?#V"YG:]C>6"2088V[B/=SDD_*>3QGL2,D9R2 8]E_R'
MI?._Y]QY._Z)G9G_ ('G;_M^]'QB_P!3!Y?_ !\?:%\O;_K/NG.W'S?>V].^
MWOBNE\0>$(-=*R2!EECQLDC;;(N"&X/3KTR#C)(P3FJNG> (+647<C2SRIC8
MUQ)YA7&>G '4YYS@\C!H Z6O/_ ?_(1U#S?];Y@V[_O^7N?IGG;C9TXQM]J]
M KG-<\"P:M,MYNDBF48WP,$8\8Y.#R!QD8..#D 8 *_Q&_X\KGRO];Y<>[9]
M_P OS.^.=N-_7C&[WK-\,Z/?75K#)#?@1F),*+>)]N% V[L\E<8.><CGFNET
MCPK#IBN/FD:8 2/.QD9P,@!L\8 .. ..N:RD^&T-N2+>:X@1CG9#,53. ">0
M3DXYR3^6!0!@ZYX4_P"$8T>YMM_F;I$?.W;U>(8QEO[OK79^#H5BLK8* !Y$
M9P!CEE!)^I))/J>:9=>$()K0Z6H9(#CA&RP^??P7W=3ZYK3TZR6PB2W3)6)%
M4$]<* !G&.>* .'^''_'YJ7_ %\?^SS5H:IXMN)KQM)L8T,D:AG><G8 5!X5
M>3]Y1GU)&W'S58U#X>P7,[7L;RP22##&W<1[N<DGY3R>,]B1DC.29=<\"P:M
M,MYNDBF48WP,$8\8Y.#R!QD8..#D 8 .7\)>=_;-S]IV>;]G&[RMVS_ECC&[
MGIC.>^:M_#C_ (_-2_Z^/_9YJW=!\"P:).UY&TADD3:WF,&SDJ68G&=S%<GG
M&2< # %O1/"\6CRSW$98M=/N<,00#ECQ@#CYCUSVH Y3X)PJ+21P!N,Y!..2
M B$#/H,G'U/K3_AQ_P ?FI?]?'_L\U=1X7\+Q>&XC;PEBK.6)<@G) '8+Q\M
M&B>%XM'EGN(RQ:Z?<X8@@'+'C ''S'KGM0!L5Y_\%/\ CSD_Z^&_] CKT"N7
MM?A[!93FZ@>6+<ZL8XG"Q':<X*[>5//&<#) P.* ,3285?7KDD E8%()&<';
M",CT."1]"16QXG\6RV=Q%I=I&KW$R[@TAQ&HR<D@<GA6)Y&.,;CQ6G;>%XK>
M[DU0%O-E0*02-F %' QG/R#N>]0^)/!L&OLDLFY)8B"LD1"N,<@9(/ /([@]
M",G(!QJ_:?[;MOMGE>9Y+X\C?MV[9L9W\YSGVQBKNO0K+KMH& (\@G!&>5\X
M@_4$ CT/-;>G?#V"QN$U /*\R @M(X?=D,N6)7.0IP,$# ''7.A<^%XKB[CU
M0EO-B0J "-F"&'(QG/SGN.U '+_$?_C\TW_KX_\ 9X:NZSX/N4NSJMA*JRR!
M5=)ERA50,C< 2 =J\8!ZD,.E;>M^%XM8E@N)"P:U?<@4@ G*GG(/'RCICO53
M4_!$=[,UVDT\+R!0_D2[ VP84D8/(''I[9)) ,JP^))-O<S7$16:R*JZJP*E
MF.P8/8;P<_>P.06Z5B>+M2U#4].>ZE6!+:4(P4%S,%:12G/W"3P3TX[ \#M=
M-\$6FGP-9K&#'* 'W9+-@<$GL1U&,!3RH!K(_P"%46[1_9FEN&C'W5:4;5.<
M[E7;C/4<@\,>_( .?\2?ZG1_,_X]_P!SYF[_ %?W8L;L_+]W=U[;NV:]/N=F
M!YFW;N7&[&-VX;.O?=C;WSC'-9MYX5@O;5=-D!:-$55)QO&Q=JL#CAA],'D$
M8)%9^G?#Z&T9"\L\JPE3&DLI**R8VL%4+R.@[8)&* ,?6?\ D/6O_7NW\IZ/
MC7_QYQ_]?"_^@25T7B3P;!K[)+)N26(@K)$0KC'(&2#P#R.X/0C)S%JG@>+5
M+9+":25EC?<'9PTA/S=6*G(&['3H!0!A>)?^0S9^;_JO+;;O^YYG[SIGC=G9
MTYSM]JT/BQL_L^3?MW;H]F[&=V\9VY[[=W3G&>V:VO$/AB#Q @BN%SMSM8'#
M*2,9!_H<@D#(.*RH_AQ SK+<237&S[JW$N]0<@YQ@>G(.01U!H Y?Q9"TS:.
MEP"68H)!(,DD^2&#!NI/.<_C6G\:_P#CSC_Z^%_] DKJ-;\+Q:Q+!<2%@UJ^
MY I !.5/.0>/E'3'>CQ1X7B\21"WF+!5<,"A .0".X;CYJ ,KQ9X/FU"=-2L
MY1'<Q)M&]04()/L<'#-V;/'3K3O#'BV6\N)=+NXU2XA7<6C.8V&1@@'D<,I'
M)SSG:>*NZYX0CU:5;KS)8I539N@DV$KG=M/!X!YXQ[YP,/\ #_A"#0BTD89I
M9,[Y)&W2-DEN3TZ]< 9P"<D9H E\6?\ 'G<_]>\W_H#5D?#.98=,A=R JB4D
MDX  D<DDGH!76UQ]O\+K6'=&'F,#L6,/FD1$GID  G&!@EL\#)- '-> /^0-
M>?\ ;Q_Z(6NH^%4*IIT1  +&0D@8R?,89/J< #Z "KND>"H=*MI=/C9S'/OW
M%BI8;T"'!"@=!QP>:T- T1-$@2SB+%(]V"Y!;YF+'. !U/I0!Y5X=W_V'=^7
MNW><<[<YVXBW].VW.[MC.>*]%\*>3_9T.=GE?9UW_=V?=_>;NW7.[/?.>]2^
M'?",.@PM9Q[GCD9BPEVMG<H4CA0,8'3'K6;9?#.VLVPKRF$ON,#29@)ZC*8^
M8# ZDYP,YH X?P[O_L.[\O=N\XYVYSMQ%OZ=MN=W;&<\5U'AG1[ZZM89(;\"
M,Q)A1;Q/MPH&W=GDKC!SSD<\UT7AWPC#H,+6<>YXY&8L)=K9W*%(X4#&!TQZ
MUFI\-H;<D6\UQ C'.R&8JF< $\@G)QSDG\L"@#!USPI_PC&CW-MO\S=(CYV[
M>KQ#&,M_=]:[/P="L5E;!0 /(C. ,<LH)/U)))]3S3+KPA!-:'2U#) <<(V6
M'S[^"^[J?7-:>G62V$26Z9*Q(J@GKA0 ,XQSQ0!#KEDU_;S6Z8#2Q.H)Z992
M!G&>.:YKX47JO9BU.5EMG=75N&!+LPXZ@<XY Y##M79USFK> [;4)!<KNAF!
M)\RW;RW.<YSP1D[CDXW'IG'% &AXDF9+:41DB5HI!&%.'+^6Q 7');C(QSQF
ML+X3[/[/CV;=VZ3?MQG=O.-V.^W;UYQCMBM+1_!T.G2?:2TDTP! DG<R.JG^
M$= !U[9Y(S@XJE)\.(%=I;>2:WW_ 'EMY=BDY)SC!]> , #H!0!E>&O^0S>>
M5_JO+7=L^YYG[OKCC=G?UYSN]Z9\$X5%I(X W&<@G') 1"!GT&3CZGUKK?#W
MAB#P^ABMUQNQN8G+,0,9)_H, $G &:;X7\+Q>&XC;PEBK.6)<@G) '8+Q\M
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M8ZYXQ6K\6-G]GR;]N[='LW8SNWC.W/?;NZ<XSVS6EXF\&P>(VB:XW8A+$!2
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M "BBB@ IDT*S*4< JP(((R"#P00>H-/HH S[7P];6C"6*&)'&<,D:*PR,'!
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MI9%OV*E5MUD1A\OS@J/E "YSLY)YR5W&@#T/QK]M\E?[._UOF#/^K^[M;/\
MK..N/?\ 6N@KE-?\5R>&+.&YG3S)6\M'&X+\Q0ECE0PZJ>@QZ5U= !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/ '2@#HZKWNHQ6"[YG5%)P"[!1GKC)(YXK"M?B1I]TPC6=03G[ZNB\#/+.H
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MQJ_B2WT=D2X<(920N0<'&,Y(!  R.20* -.BN?M?'UC=RBU293(S%0,-M)]
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M(K#  ^5B!T XY' ( (R=/0=!?3F>>:9III0@9F"JN$W;0J+]T?-SR<G)XR:
M.7^"G_'G)_U\-_Z!'6?<736FJZC-&</'8LRG ."L<1!P>.M=!I'@.31)2UI<
MLENTBL83&'&!C*AV;(R.,@9QC))&:T++PI]FOY=5WY\Z,)LVXQ@(,[L\_<]!
MU]J ,SX3:?';V"3(H#RER[=SM=E7GT ' Z=3U)SG^%85TW6+NSA 2$Q*^P#C
M=B,\>@_>-P..>G QH6W@"7268:?=-!$YR4:-9@#ST+$8&,#N3@98\8U?"OA&
M/P\KE6:268@R.YR6(SV[#))YR>>6/% '*_#W3XYM0U"X909(IV"$_P .]Y-V
M/<X SUQD="<LMK'[5JNH6*'8D]J0<#Y=SK&-Y4$ G+L?7D\\FNK\-^%/[%FN
M;G?O^U2;\;=NWYG.,Y.?O>@Z5$/!G^F3ZCYK#[3#Y>$&UE^5!N#Y/(V9'R\$
M^W(!R^F7%QX'@-K>VRR6F<-+#AL[P<[E;&X'(3+!0 ,?-QGT>TNENT6:,Y21
M0RG!&0PR#@\]*Y"X\!7.H(MK=WKR0#&56)48[1\N7RQ.#@G<&R1GK@CK[2U6
MT188QA(U"J,DX"C &3STH YC6/%:V]W]DM;<SWBH Q&V/:A&_!D8'CD''W<L
M.=W%<_X-=WUFY:2(0NT&6C#*V"3$2=RX!+?>/N>>:Z+6?!#7%U_:5I.T$Q7:
MY""16& !\K$#H!QR. 0 1DGA[P0VE7<FHR3M*\L>UMR ')V$G(. ,K\JX^48
M&>.0#"L=/CO->N#(H;RHD=<]F"Q -CU&3CT/(Y -2^.85L-1L+J(!9992CL!
M]Y<HG(/&=KD9ZXQSP,9\NC'5-;N LC1211*Z.F.&"1*,@CE?F.5XR.,XKJ-&
M\$-;W7]I7<[3S!=J$H(U48(/RJ2.A/' Y)().0 85CI\=YKUP9%#>5$CKGLP
M6(!L>HR<>AY'(!J7QS"MAJ-A=1 +++*4=@/O+E$Y!XSM<C/7&.>!C/ET8ZIK
M=P%D:*2*)71TQPP2)1D$<K\QRO&1QG%=1HW@AK>Z_M*[G:>8+M0E!&JC!!^5
M21T)XX'))!)R #*T;_D/77_7NO\ *"C1+Q?"5U>6<O$3*US$JA%&T EU49SD
M 8 Z80MA1UZ"R\*?9K^75=^?.C";-N,8"#.[//W/0=?:N7^*^B+JD]G"N1+,
M[)E4W?)E26)R#A,D@=,%CE>X!M_#6S86[7T@ EO)7E;Y=N Q.T<DDKU9?9N/
M4Z_BS_CSN?\ KWF_] :M.&%85"( %4   8  X  '0"F7=JMVC0R#*2*589(R
M&&",CGI0!Q7@ZZ:TT3SHSAXX;AE. <%6D(.#QUJQ\)M/CM[!)D4!Y2Y=NYVN
MRKSZ #@=.IZDYL>&?!T^@,$2Z9K96<B)HUSA@<#?G(P<$X !.>!DU7MO $ND
MLPT^Z:")SDHT:S 'GH6(P,8'<G RQXP 9_A6%=-UB[LX0$A,2OL XW8C/'H/
MWC<#CGIP,;WQ(NFM=/G=#@E57H#P[JC#GU!(_ES4_A7PC'X>5RK-)+,09'<Y
M+$9[=ADD\Y//+'BMB[M5NT:&09212K#)&0PP1D<]* ."\.:=J*6D:0I9"&6)
M20RRY8,@&7 &"Q'WO6K&E>#FTW3)["^=2GSN&0NZHH4,"!A3\K*6VC@_B:L6
M7@:YTE?(L[UHX0<JCPI*1GK\Q(X)R<  <^N2;VJ>#3?P16+3.T4<@:3S27DE
M ;=L+ADP.?0]%(QMY .,\ W+:U=1-J))DA@!MUE5AORQ/FC)PS #&<$L &ZH
M6J[XZ$M]JEM:1B)\0LRI<+NBRWF;BV!D\(,>A ]ZZCQ#X.743#+;L+>:W(V2
M(F<( 1Y>T%1MYZ'( R,88U+XJ\(Q^(50LS1RPDF-T."I..W<9 /&#QPPYH Y
MKQ)X7U37U02&U1HG#(\9E5P?9B#@=#QW /:HO%&GQZAK=K#,H9#!DJ>AV^<P
MR.XR!QT/0\5T=IX:NRZO<WKR(C!@L<:0Y*GHQ7)92,@KW]>*EO?"GVF_BU7?
MCR8RFS;G.0XSNSQ]_P!#T]Z ,3XR730V(13@23(K<#D ,^/;E0>/3TKJ_P"P
M(/(^P>6OD;=NSMCKUZYSSNSG/.<\T[6M'CUB%[2;.R08.#@C!!!!]00#Z>H(
MXKF+7P%<K$+&6]=K;:5*)$J/M[*)"6(';'(V_+TH J:S_P AZU_Z]V_E/5+1
MK&[^'XDS"L]J3N>6(@2@9 Y!.2%4%MN,#<3OQFNMO?"GVF_BU7?CR8RFS;G.
M0XSNSQ]_T/3WK,F\#W4R&U>^D-NQ(*F-3(4+9*F4G<21QG&,<;=ORT 87Q+U
M*+4M+MY[<8B:9-HV[<!4D7;CH-I&....,BK?Q2M5N[G3X9!E))F5ADC(9X@1
MD<]*V-;^'D=]9Q:7"YC2%PP)&\GALYY7DEB?3L !TN^)/"G]M36USOV?99-^
M-N[=\R'&<C'W?0]: .<^,,*VEI \0"-%.@0J-I4;&.%(Z#Y1T]!Z"KWCI_(N
M[&8)YIC:<^4!ER @)901@E,9 R"6P%YY&KXU\*?\)/"MMO\ +VR!\[=W16&,
M97^]ZUF>*+>/6+ZWL"[121Q22AXVV2'=\FQ&SU."S?*3M7C +4 -L[F77;^&
M[C@E@CMXY!(TZ^6SAQ\J <[@I&[K@'/0XW=K7FGBV&?PAY,]K<S2R22;/*G?
MSMX//"X!Z@*<#/S  COZ70!QDGB_?<S0:?:F:5#B9\K",I\JC>P.XCD#..AV
MY'(ROA."+B_!01GS4R@((3YI?E!'&%Z<<<<5L3^ Y+>XDO;&Y:#S^74QB52Q
M))/S-CKST)&3@@' M^$/!G_".//)YK2_:&4_./F&TL>6R=Q.[DX'/..: .<^
M">GQBWDNMH\TRE-W?:%1MOL,G)QUXST&)?AS"IN-2M2!Y(G($>/D +2J1MZ8
M( !XZ #M71^"O"G_  C$+6V_S-TA?.W;U51C&6_N^M'AOPI_8LUS<[]_VJ3?
MC;MV_,YQG)S][T'2@#E-!U\^$K6[L93NEL6)C!"X*RD>6<!LD;FW-SE0P&<\
M#J_ 6C?V1910D8=EWOE=K;G^;!'7*@A>>>.W0<IXL\/IJ>L6\8'6-9)?W892
ML;-@L<\[L;#D8 V\MG ]+H \_P#BA_I,UA9/S%-<?.O3.&11R.1P[#@CK["N
M@\9Z5%/831,B[8H79 !@*8T)4C&,8QCCMQT)%6O$OAJ+Q%%]FGW;0P8%#A@1
MD9&01T)'(/7UP1@7'@*YU!%M;N]>2 8RJQ*C':/ER^6)P<$[@V2,]<$ ''^(
MKIKK0[1W.2)@O0#A!*BCCT  _GS7H'BG0($TZ6V$:B.&%V0?W6120P/7.>IS
MDY.<Y.>?^,%JMI80PQC"1S1JHR3@+&X R>>E7;SX<2W,:V)NY/LBE<1LBE\+
M_#Y@QD?W000O'!VB@#'N;IKKPZ'<Y(55Z <).$4<>@ '\^:Z7_F#?]P__P!H
M5L7_ (=AO;8Z<P(AV*H )R F-N"<\C /.<XYSS6+I?@VXM('L9+HR0M \:J8
M@-NX8#;MQ8A1D!<XQP,8% '#ZG=-#H%NBG DF*MP.0'E?'MRH/'IZ5ZK_8$'
MD?8/+7R-NW9VQUZ]<YYW9SGG.>:S+#P7'%8#2)F+IA@6 V'ERX(&3@@D>H..
M1CBLW_A KGR_L/VU_LOW=GE+O\O/W/-SGIQTQCC;M^6@#$\#W33:+=(QR(UN
M%7@< Q!\>_+$\^OI6W\*]*B73U?8I,^_S,C.X!V0 Y[8XQTZ\9)SNQ^&8[>S
M;2X250Q.@)^8_.#ECTR<DG' [# IWA;0O[!MDLMV_P O=\VW;G<Q;ID^N.M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.@00SO?JN)Y%VLVYN0-O&,X'W1T':M"BB@#/AT""&=[]5Q/(NUFW-R!MXQG
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@\]*T-4\6W^A-%/>QPK;2R!6V%VDC##(#'H2!DG:I!VD#&147Q'_ ./S3?\
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M,"#YZG!&.&:4@_0@@CU'-<_%HUG!J-U;ZH /-<R0NS.D>&+,1N!7GD#GC<K
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M-]4TW[5;%#;R*ADW9\P9=-H7:2N0V0X)XQ@<UI^"9KN&WB>Z, M5MD*E"X<
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MXHBM[N/2R&\V5"P( V8 8\G.<_(>Q[4 ;%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!1O=#M[]M\T4;L!@%T5CCKC)!XYJ:VTZ*U9GC15:0
MY<JH4L>3DD#D\GKZFK%% %>VTZ*U9GC15:0Y<JH4L>3DD#D\GKZFA-.B20W
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M#8R!R?S-6** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8QM.I(Q]Q7=>1GAD4@_@?;K0!TM%5+K58K6(W;NHB"AM^<K@]",9SG/&,YR
M,YK,T?QS9ZQ)]G@E#2$$@%77..N-RC)[X'.,GH#0!O45YUK'Q'6TU)(?.Q:Q
MJRS#RR<2+Y@QG;NZ[?N\?K73OXYLT2*9I0$N"PC8JX!VMM;)*_* 3U; []*
M-ZBN<'B:S\0V]PJ2$Q)$PE(5U*JRMDC<O)P#T!Z=*E\(BVLK-#;2%K9 Y#R?
M+P'8L3D+@ Y[#@?C0!O45S]KX^L;N46J3*9&8J!AMI/H&(VG/;!YXQG(KG_'
M'CW^RKN"VBEVJD@^TC9G"G81R5/\)/W3G\<4 >@45P_BC5=-\26@DFF80+.
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M<CI65>?$.PLBHDF +HK@!';Y7&5SA3@D<X.#@@XY% '1T51O]:AL(3>2.!"
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MR,C!'4$$ @_4=,'H161_PLC3]_D^>N[=MSM?;G./O[=N/]K.,<YQ0!TM%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUII-U-&</&TS*< X*PH0<'CK6W9_#R33&D2TNGBMY6R8P@9@",$+(Q)4XX#
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M> X&X%>3@J2!U)]B"0P((Q#?^"Y-1:TEGGW26<A<MY07?EU8# 8!<!0.^>M
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M5R,FCXD736NGSNAP2JKT!X=U1ASZ@D?RYIWAOP:NDRO>R2--<R@AY&^48SG
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MK2%5R>@&Q<8Z 8Z<5ZG_ &!!Y'V#RU\C;MV=L=>O7.>=V<YYSGFLRP\%QQ6
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MB2</(HY] &  ]@,#M7444 ,AA6%0B !5   &  .  !T I]%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% %35-+CU6-K:==T;XR,D9P01R"#U [U+:6JVB+#&,)&H51DG 48
MR>>E344 5-4TN/58VMIUW1OC(R1G!!'((/4#O4MI:K:(L,8PD:A5&2<!1@#)
MYZ5-10 5#=VJW:-#(,I(I5ADC(88(R.>E344 5-+TN/2HUMH%VQIG R3C))/
M))/4GO5NBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH A^R)O\ /VKYFW;NP-VW.=N[KC/..F:FHHH **** "BBB@ HHHH
M**** "BBB@ HHHH J:GI46J(89T5T/9AG!P1D'J#@G!&".QK'T_X>6&GR+/'
M" Z'*DN[8/8X9B,CMQP>1S71T4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF-920Q@,2^6,MG89!EL <<9.> W\5 &GXI\2G2'MH4VE[FX1"&!/R$@.000
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M'I][9RL+F=9X2G!\L1N'STPO!4CJ2<YQ@#G.]0!GZW>SVB![:'SG+ %?,6/
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MF7!V_*S9VO+G[H/J.M:7A-FN;JZ\0RHT,#1 *'7ED"J2_'.-J \ @[L G;R
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M906\EJH::]*>4DG'# ')P0,_,!C<.3G) - '6U4U35(]*C:YG;;&F,G!.,D
M< $]2.U<?J<&JZ+";W[2DYB7<\30JJX"G<0R[2=O4?=R!Z_*:OCO4&UW2A?P
MR;(BJF2/:&W$R(NW>0"-C \@?-]* ._M+I;M%FC.4D4,IP1D,,@X//2IJY3P
M'IUS!##++<>9$UO'MB\I5VY52OS@Y.!QSUZUT&J>=Y;?9MGF\;?-W;.HSG;S
MTSC'?% %NBO.O$^I:AX0$5Y)<+<1&3:R&)(B<@D8*@GH#SG@XX89%:OQ0U^?
M1+9)K9MCF95)VJW!1SC# CJ!0!V%%<)KK:K:1'4EE1=GSM;;%*JB\D>:>6(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH;6:*VFW2%<$@%HR.,CKM(!Z9P"1D5G_ !0U^#6[!)K9MZ"Z52=K+R(W.,,
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MC!S7I=% 'G5]=+=ZW931G*26I93@C(99B#@\]*VOBE_R#I_^V?\ Z-2NKHH
M\R\1:?(++3M3C4O]B2%V0=UVQL6SV V '@X!R> :Z*S^(]MJ1CCM0\LDC(&0
M(P**Q 9V." $SS@D9P,X.1U=% 'G7C.X_L;5+74Y@PMQ&8RX&0&/F#! YX#
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M8[F&1Q@,2![=SUH V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT.GX\^1(]V<>8ZKG&,XR1G&13++7+>_;9#+&[ 9(1U8XZ9P">.: +U%%9_\
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M W?+DD $XYZ=#0!L45GVOB&VNV$44T3N<X5)$9C@9. #GI7.>(8?[(U"VU%
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M,22"W+J)6&0A8!R.>0N<D<'\C4-EKEO?MLAEC=@,D(ZL<=,X!/'- %ZBBB@
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M"&'(&<C (SF@#,\+ZM8"2*"2V^R72X\L2(5+9#(,28!;(X^?&6/&YAFC1O\
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M;PR6RR1,'C=/*W823G8"1M^5?;<N<9YKJ_%7A.>\N8=4LW59X1M(ESL*_-Z
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M-;F.3*M+L82E&//R@;,[>,?^/9^:@"OX[AMKK23- %:.-(A$V-Q5=Z*0"WS
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MR,I+Y&.N#\H]>.@JI9^ _-TU=)N"N]=Q#H-P5B[,I&X ]#@]"02 1G- %O\
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M$ZJTZ1QH\T>\AGRB'/J3@,,C+9;@')K8\)ZQ8W$WEI"+:\"$&-H_+;!".W0
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M5()._)$@X&,8^<=QWH XR"236-0NYFM%NS!)Y:AI0B(JET VOD-NQD\8#9(
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MZ/%OA>76+BTN(RH6UEW.&)!(W(>, \_*>N.U '44444 %%%% !1110 4444
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M16/XH\41>&XA<3!BK.% 0 G)!/<KQ\M &Q1110 4444 %%%% !1110 4444
M8_A?PO%X;B-O"6*LY8ER"<D =@O'RUL444 8_A?PO%X;B-O"6*LY8ER"<D =
M@O'RUL444 %%%% !1110 45CZWXHBT>6"WD#%KI]J%0" <J.<D<?,.F>];%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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METW6+2\F(2$Q,F\GC=B0<^@_>+R>.>O!QH?%G4([>P>%V >4H$7N=KJS<>@
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M0-@L8B-P('.,XQSNV_-5?XR6K36(=1D1S(S<C@$,F??E@./7TI\7A"#48/M
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M^Z1RR$XPR+N*[L<@\8..AY .0,WPW\0)_$!4P6C>6&59',JA4)/.,J-^%PQ
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M\V-]C!@7[\[1\Z@DC&">>#C5U7X=V\RJEU=W!5G 42SJ07.0  R\L><8YZT
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M]D2Q64,337$W(0': O(R6((Z@^P )8@ 9H_%G4([>P>%V >4H$7N=KJS<>@
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ME344 0W=JMVC0R#*2*589(R&&",CGI5?1]%AT>/R+= B9)P,G)/4DDDD_4]
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M0)E%D,A+L26)!V*#\HP"?O$C&T5L>'?'WGZ:VI3\O!N5N-H9AC;C&<;MR@G
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M<8(!TM%>?ZY%J.DM &O=R3S+$2+:(,K.#M.WH1D<\@CL#TKNK2-HD5)&WN%
M9L!=Q Y; X&3SCM0!-17&:[XBN;R\&CV!5&5 TLK#<4&0>%/!."/[V=P'RX)
M%74]9O?",D<EW*MQ:RNJLYC$;H3GHJ9R,<]&SM(^4D$@&KXX\62:&(H+= \]
MR^U WW."H.>1R=P Y [D\8.QHGVG8?MGE>9N./(W[=N!C._G.<^V,5Y_\2K*
M<WUF1-@23 1#RU_=$&(%L_QY/S8/3&.E>@:)93VB%+F;SG+$AO+6/ P/EPO'
M7)S[^U &A5'7+UK"WFN$P6BB=@#TRJDC.,<<5QNM>);F\U$Z5!,ELD:C+L%=
MG9PI"@.,$Y8 *"#]XY/ &WJ5O/;6%U'<R+*PAFVNJ;"5,9/S*. 0<CCC !ZY
MH M>#-;?6[2.\E"AY-^0@(7Y791C))Z#UK;KS+P/9ZA?6$?V:5;=(Q($RBR&
M0EV)+$@[%!^48!/WB1C:*Z+P1XEE\06)F&W[0F],L,(7 RI(4YP01NQCG. !
MB@#JZ*\_\32:GH4!U$W*-L9"\0A4( S ;0W+$ D#G:2O.0:U?$_B.2+3#J4'
M[N1HX7'1MOF,F1R,'AB.E '5T5Q7ABXOI(EU2^G58!&7,2Q*<H(^'+#D$_?(
M&?3C.T9.G^*;C71]I:^M[1&SMBQ&[X#,/G\P@@XQC'!'.%[@'I=%<5X8\=-=
MV]RTH5Y;%6W-&1Y<@4,0RG'&[8<\8Z$==HS_  I?ZAXBC-XEW$&#$^1Y2, ,
MG:KD?.H8@@=3MY!)Z 'HM<OI_BB6XU.?2R%\J*(," =^2(SR<XQ\Y[#M745Y
M>WGMK=S':[0[PHI=N1&NV$E]O\1&,*O3)!/R@T >H45PD&M7GA^]CL[Z19H+
MKY8Y BHP88XVH.Y('.1R&###"M#PWK\LE[=Z;<,K-$P>+"X/EMS@D #Y0R=>
M<D\L.@!U=%<UI>MR:CJ%Q C+]GMHT4@$$F1SG=D#(V@,I&>".F<XVM4MY+F-
MHX)/*D.,/L#XP03\IX.1D?CF@"+1-?@UM#-;-O0,5)VLO( .,, >A%8^G^*)
M;C4Y]+(7RHH@P(!WY(C/)SC'SGL.U<E\)-.N9X3+%<>7$MQ\T7E*V["H6^<G
M(R...G6I6\]M;N8[7:'>%%+MR(UVPDOM_B(QA5Z9()^4&@#U"BN'TG6;K2]0
M&E7DHG6:+=&PC5""-Q.0N, [6_O?PXQDU7U/QA)J%U+9P7$-K%;L%:27!D9L
M-N"K)A2 PP>_ 8,0<4 >@45PGASQ<\=Y_9<TR70E7='-$$&"%)9&"<#[I(P2
M>F>&^7J_$-TUI;3S1G#QPR,IP#@JA(.#QUH Q]2\;$3&RLH6N94(#[6"1IPQ
MP9#D!N.AXSD9W BK&E^)Y)9%M;NW>"23.PY$L;8!.WS%X#85CM(Z#.>0*S_A
M/:K#I\;J,&1I&;D\D.4S[<*!QZ>M=5=W2VB--(<)&I9C@G 49)P.>E $U%<%
MH5WJ7BI#>I,MK"Q(C58EE) 8@DECP1T[9P3M'?0\'^)I[F:72[T*+FW"G*9P
MZX'S>@/(/;.[&T8- '6T5YEX)U75/$\3MYZQHCX\WRD=R<#Y-O"[0#DDC.2
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M;!][;(=^_KTXV].] 'I=%<9K&JW'A"VDN;F<7#L56(&(1 ,<YSLSD8YYQ]W
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MW<X4#)&UNBCC;P3FL?3_ !3<:Z/M+7UO:(V=L6(W? 9A\_F$$'&,8X(YPO<
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MAO\ T".CX<?\?FI?]?'_ +/-7H%% !7E_P ,]<C\/A])N]T=P;@84J2"7"J
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MN:9K744*O&$*NR.-P()^5X_F*@D@@X&[.,D<8_A?S_L%_P"9YOV;R7^S^?\
M>V>6_3VV[.GR9SM[UZA10!RGPM_Y!T'_ &T_]&O7'^"//_L>Y^R;O.\YMNS[
MV-L6['OMSC'.?N\XKUNB@#P>_?3KBP,D8D>_(4R,WF$@EQO=CG9M). >3\RY
M^;)'<>)?^0"O_7O:_P XZ] HH Y_2;'^T--CML[?-LT3.,XW1 9QD9QGUKA_
M"]]8Z+%]BU6W6.>(M\TL'F;P6;#!@C9 ^[GD$ %2>0/6** .?T&\MQ#)=VMN
MT:#/"PB-I0J[E95&"P8'Y,XR<CBO/-?O-.O5$VE+(M^Q4JMNLB,/E^<%1\H
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M1QEMV"N&X.!GT"B@#S_X*?\ 'G)_U\-_Z!'78>(;5KNVGAC&7DAD51D#)9"
M,GCK6A10!Y_\,/$T$<$>DN66Y1I5*,C Y#,YYQ@8&00<'((QTR?!3_CSD_Z^
M&_\ 0(Z] HH \T\'6/\ :$VKVV=OFR,F<9QN:89QD9QGUJEX7OK'18OL6JVZ
MQSQ%OFE@\S>"S88,$;('W<\@@ J3R!ZQ10!B>%I+>X1IK6'R49L9\H1;P!E7
M  !*D-\I/OP*VZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK-$K*7CQN4$%EW#(R.HR.F>M $U%0R7:1,L3,H>3.U20&;:,G ZG ZXZ5-0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y)!))K&H7<S6
MBW9@D\M0TH1$52Z ;7R&W8R>,!LD $UL>'](O+?4%NDMA:VSH5E1)8W0E5;:
MVU<8.=H^4>IS\S9T[_PE<65T^HZ=(BM-CS(I01$QP?FRG.<X/3.2QW8)4Z6E
M07X9IKIXC\A"Q1*P0MP0YD8%P>JD $8P<$\4 >>Z[J<GA>XGTFU=$CNV5E;<
M%\EI"H;)"_*, \=57:P(.<]GXDB'A32Y([7(\I JDD[OWCA6;((^;YB1C !Z
M#'%&E>!0]O-%?,9)[LYF=6/\))CV\# 7@@8QGCE0 +&B>')6L3IE^4?Y2@,?
M/R  (?F4#<IZ''93R<F@#C]!TAQ;(HTM)%DC4F1KB/<VY!\P+ LF>H (VD\8
M-.O;"ZT_1)X+T$,CH$!96PF^+ RI/ .<9.0..F*WM,T75=%06L$MO+$GW&G$
M@<# ^7"Y& <XY/'H, :&O^')]3L'L&E62=MO[QU\M3B0/RJ!L8 QQUH A\!>
M%[?3[:"=$4RO&KF1@"^9$!(#8R!@X ';KDDD\_\ #;2HO$0GU6[19)9)F7#C
M>B@!6PJMGUP,YPH &.<][H=DUA;PV[X+11(I(Z950#C...*Y6#PG>Z%/+)IS
MQ>1,=WE3[@JL3SM$8X Z#!'& 0=H- !X]T>/2M,N8X<A&=&"Y^5=TD>0H_A7
M.3CH"3C X&5XCT&?4['3Y(D,L4,4;2Q!RI8>6AX]3@,.,L-WR@Y-=!JOA>ZU
M*RFM995>>X=6R0RQI@QG8OWCM&TX.,DG)&235B32KZS@MHK22(/!&J2+*"8W
MP@7.X#<-I'&,9SSTP0#$T[Q+90K++# MM?0V\I\IX_+)PBR$?+M##(!&<-@$
M@ $UA>#;.26 7/\ 9ZW+2EBTTL\9+$.W.V0-M/8XQNQDYKJK#P9/>W0U/47C
M9E1D6*)28]K*5.2_)!W-D$'DCYL?+46F>%]0\. V]E+%) 3E1<APR9)R!LZ@
M\$G@$Y(49.0"7X<Z5=:8)XKA#%"7#0QF19-H8L64,"3@?+UZG)QDFMWQ9_QY
MW/\ U[S?^@-4VB6\\"'[5(LDC,6^1-JJ"!\@[D YPQY(ZU#XL_X\[G_KWF_]
M :@#DOASX2MKZP26=!(TH<9D^;:H=QM3^X.K?+@[B3GIC/\ #4S6]KJFF@DQ
M6HF"%CEL%9 1Z8^3/ ')8]Z?X$T_44L4>SEB*3>9\LZMF,ABN4(W Y(R01@'
ML<MGH]'\$MIUE/:E@]S=))OD;N[J0!NQN*@GJ<DDL<#.* ,SX5^%[<6D=ZR*
MTLC,VYP&*E'95VY'RXQG(YSWX %+PG>M82ZQ<)@M$[L >F5,Q&<8XXKLO!FB
M/HEI'9RE2\>_)0DK\SLPQD ]#Z5G^&/"+Z;->RS[&CO),A1EOE+2$A@5 Y#C
MCD=: ,KX;>%[>\M!>SHLLMPSLS3 2'(=EXW XSC)/4D\GH!4^(<1TU+/28@T
MD4LQRC2$,P5UVQ;\\+\^!G.,*<\9.AI/AC4O#N^WLY(7M]V4%QYFY0>2/D&.
MO7G!/S *216AJO@AM4MHX)9V-Q#(76<( P)8MC&<@8( "L,%5(X&* .7U?P_
M<74(AM]-6"1"A25+B+>I0CG(VLQQZMU^;J!4WBS1;N22TOYH3<I# @EA##_6
M_P 1VJ"""Q&=H8$+AAMQ700V>KRJ(9);=!@ RQH[R<=]K (22.>  "2!TJ_K
MD%_YJRV3Q>7LPT<ZMC=G(<,@W$D<8) &,X)/ !5\'ZI8WC2"T00S8 DB*>4X
MV,P&5'RY!)R1DC(#8X%6/'VIOIEC-/$<.% !Y!&]@A(((((#9!['%5/#'A*6
MSN)=4NY%>XF7:5C&(U&1@ GD\*H' QSG<>:Z#5=,35(GM91E)%(/3(ST(R",
M@\@XX(!H Y?PCX'LS91;XE<S1*S,X!?,B@G#8RH&<#&,=>N2>?\ #4S6]KJF
MF@DQ6HF"%CEL%9 1Z8^3/ ')8]ZV[+0=5TB+[';S0/&HPCS!Q(H(Z #<N%/W
M<[N/;"B[IO@?^S;2XM%?S)[E9=TKC!+.I R?F.!G/)8Y+'OB@#*^%?A>W%I'
M>LBM+(S-N<!BI1V5=N1\N,9R.<]^ !Z!6)X,T1]$M([.4J7CWY*$E?F=F&,@
M'H?2MN@#R_P5H46IW]^\XWK%<-A&YC)9Y1N*G@D#(7/3)[X(MVMJOAW65MK8
M;8KN$LZ9.T$;R"H& .4XSG 9@, @#,\+65U+?7\]G(JM'.P*2AC&^^23J5.0
M5P2" 3GC@$YZOPWX3GBN7U2_=9)R"J!,E$4^FX @]0,=BQ)8L< &/<:EI<SS
M1PVKW1=F:1X8?-PSD@X=B",X)!7Y>ZG.:=\(HA?Z?+;RY:,RR)@D_=9%RHYX
M!W$\8Y)/6IM&\'W_ (>,EM9RQ?9I'R&E5C*F0 6  "E@,=3M.T'"Y(K5^'GA
M>7PW;M;S%2S2E@4)(P54=PO/RT 8GA#7?^$<LKBWN /,T]V&T!AN#G,9R1T=
MR0#CA<$C')WOAWIILK*-W.9)\RNVXL6,G()+=]NT'W!Z]3R/C/0%O=7A@4@"
MZ13,NYQN6,DG..,%8P% /WER<<,?4Z /.OC7:)]FCGVKYGG*N[ W;=DAV[NN
M,\XZ9KK;S3K/2H)2Z1Q0NA$A50F5((P=@!)Y(&.<G Y-5_''A;_A);<VX;:Z
ML'0G[NX C![X()Z<CKSC!J-H%WK-K+8Z@\7SJ@5X V[*G<68, .H'"@=QQQ@
M X?Q9>6-U9L+2TD4(5"7 AVQG:X4DR9W$$9'S9)8C(W=.F\0VAO-+@OBX$]M
M%#,DCD9W!5)!+ Y+=A_$^W-5[GPAJEY9C2Y)+<1HJ@%0^Y@C#:K':   .H7)
M*@'JQK5O/"$U_':6$K+]EAC03JCL&D9% 4#Y/N@C/W@3G. 54T 9G@*\;Q9.
MVJW!&Z *D<2MPA9,2/MQT?G:23W!SM4C'@DDUC4+N9K1;LP2>6H:4(B*I= -
MKY#;L9/& V2 ":[._P#"\L=\FJ6A52XVW D).Y/E V@ X; ]0,A?5LU[_P )
M7%E=/J.G2(K38\R*4$1,<'YLISG.#TSDL=V"5(!F>'](O+?4%NDMA:VSH5E1
M)8W0E5;:VU<8.=H^4>IS\S9S;K3VT*]N+R^M6N89F9ED $H1!EN4;@8&U<MM
MVA3M)&<]UHEO?;S+>21;=I410(=N<@AR[_-GJ-O3&#UK/O;75E:58)+=HW9B
MC2JPD0,.%PH*G;V)W9ZGT !J^&;JUN8 ;$KY(9\!00 2Q9AM."O)R!@<$8&,
M5S7C_&D75GK'R@))Y4A.XG:X/(4?W07/KDC@C@;O@WPJOAF VP<N6<L6(V\D
M <#)P, =SSD^PL>*M$_MNUEL\X,B_*<X&Y2&7/!XR!GC.,XYH \X\>WDMY=R
M7T)4QZ48,AF+ N[YR% P"&^5QD'Y>N>!TM]>)XCU"U@C(:&"+[2WS,,EL>5\
MH PRY5ANQ\K'CL;OA;P<^GVDME=/O>Y:0NR$D_O%"G#,,DX&<D=3T.,F+P%X
M-ET,R3W3(\KK&BE!]U(U"@;B%/( !&/X022>@!C^'=/C\2ZC>7%VH?[,XCC1
MN8P,NN=K9Y^7/IN9CC.,'B+3X_#6HV=Q:*$^TN8Y$7B,C*+G:N.?FSZ;E4XS
MG.Q?^$KBRNGU'3I$5IL>9%*"(F.#\V4YSG!Z9R6.[!*DL/"5Q>W2:CJ,B,T.
M?+BB!,2G ^;+\YSD],Y"G=@!0 9^L_\ (>M?^O=OY3T?$?\ X_--_P"OC_V>
M&M7Q7X6FO)X-2LV1;B#*GS=VUE.>.,^K#@ D,?F! K*O_!5_J=S;W]Q+$?)D
M5FC3>J*%<'Y,@EBP&26QS@9( P &L_\ (>M?^O=OY3U7\.Z?'XEU&\N+M0_V
M9Q'&C<Q@9=<[6SS\N?3<S'&<8Z#4/"\MQJ<&J KY4414@D[\D2#@8QCYQW'>
MJFH>$[JRNVU#3GC7SA^]CFW",D#AL(.2>N>"&R<D,10!A'0HM'UV!(!M62-W
M*C[H)24$ =A\N<=L\8& /4*X>T\%W0U"'59Y5?:C;QEA@LK@+&NW[B[AU.2=
MS'DXKN* /+_!6A1:G?W[SC>L5PV$;F,EGE&XJ>"0,A<],GO@AFI./!VI.+0
M)/:2R,ASL#(LCC"@C S'T[!F"X!&-.P\%7^F7-Q?V\L0\Z1F6-][(P9R?GP
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MN\O9G.,XS[9QVK%_X0J;^R?[(W)YOKEMG^N\SKMST]NOYT <_P"/O^0-9_\
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M7J9?#>D7-C-<RW$F^.:3,2[W;8NYSC# !>".!D<>PH Z"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ&ZNT
MM%,LK*B#&6<A5&3@9)XZU-0 4444 %5]1LEOXGMWR%E1E)'7# @XSGGFK%%
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M$&,LY"J,G R3QUI\,RS*'0@JP!!!R"#R"".H- #Z*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BJ]SJ,5JRI(ZJTAP@9@I8\# !/)Y'3U%6* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:(%Z AO,).3GD*<GDDGGJ31X@L7A?2]+0J0DBL6(()^RHO3!.,@MQSSCD#-
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MZCCWKS_X=7"6?]HZB@_T82,4V #*Q^8Y 4XQA67 .!SCL<;'PWA32-,6>0%
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MK>$_ 5EY-M>^5^]\N&3=OD^]M5LXW8Z\XQCVJU\4O^0=/_VS_P#1J5J^$_\
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MQ;(""@).[RC@<*_&,]NW6K'Q4TJ)M/9]B@P;/+P,;075"!CMCC'3IQD#'/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*000>,<<<C(R,C(ZUS5SX EU9E&H733Q(<A%C6$$\=2I.1C([$9.&'.>SHH
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MKG?L^RR;\;=V[YD.,Y&/N^AZT>-?"G_"3PK;;_+VR!\[=W16&,97^]ZUT%%
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MG(.UB &[$\G&!QSF+PWX-7297O9)&FN900\C?*,9S@*.@X4=3C V[1Q71T4
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MU)/3)QT R0,D\ 9Y) KDK+7M5U>+[9;PP)&PRB3%S(P Z@C:N&/W<[>/;#$
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MJ[199%A5@7'RYD1=Q*_=.?<<=L4 .\,^,H/$;2K;[L0E02P !W;L$<DX^7N
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M[K^R[]46=UWQM#N,;+@Y'S9((VGK@'!Z<;LW1O%FH>)3)/9) D"/M4W&_>>
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MMKRV55$D4OF++DX15=9 I7JV1\I. 1U Z52^%OVS[-!_J?LG[S^_YWWG_P"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-N<>8BMC.,XR#C.!0NDPHRRB- \:[48(NY5 (V@XR!@G@<<T <5HW_(>NO\
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MJ&//C23;G'F(K8SC.,@XS@4 <;X^\1P:K8W<,#!_)$!9E(*?/*, ,.I&WG'
MSC.<@9.BPMX-\C44!^Q74$/VC WE'*\/ZA26]2.6&,[!7I']DP^7]E\M/*_N
M;%V==WW<8Z\].O-/ETZ*6/[.R*8L ;"H*87&!MQC P,>E %BO/\ 6?\ D/6O
M_7NW\IZ[V&%85"( %4   8  X  '0"HGTZ)Y!<%%,JC <J"X'/ ;&0.3^9H
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MP& 716..N,D'CF@#@OA$RO-?&-F=#(FUWR68;I<,<@')')X'-6_@I_QYR?\
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M;B?6=&@NYA\XD5G.-OR_.BO@_P![*GCCG( 7IH?$GQE:7=B8(I%D>?9M"')
M5E<EAU7@8P><]N#CT*:%9E*. 58$$$9!!X((/4&J4?AZVB5HEAB"28W*(T"M
MM.1D8P<'IGI0!YUX^_Y UG_V[_\ HAJV/C1"SV2D D+.A) S@;7&3Z#) ^I
MKLKC28;E%@DC1HTQM5D4J,# PI&!@<#VJQ-"LRE' *L""",@@\$$'J#0!Q7C
M[6X-5TR=[>17&(2=K D;I$QD=5/L0#U]*PO'W_(&L_\ MW_]$-7HL?AZVB5H
MEAB"28W*(T"MM.1D8P<'IGI4MQI,-RBP21HT:8VJR*5&!@84C P.![4 <_\
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M#=(DDI5<$Y81(5&!R<GL.:Q8M135;&6]NKZ7[05<>2L@C4G&U%\H#Y@W!8J
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MH;2X="0RP2D$'!!"$@@CH10!IT5S7PXNWN["&65F=SYF6<EF.)& R3STKI:
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M<8^5>@P.@H T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/+&]@L0W%3M&<9)&XY!!XXX.=#X;J/$>FFTNAOC20QXRP)5=KJ"0<\$X&,#
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MJ(U8.['85W,R\'[QYZX4+MQ\U=7K^C+K4$EH_ D7&>>".5; (S@@'&><8/%
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M0R8*M\J!@3D*0"O(S@@G!Z MUG3=0UZYM+F2W6*.WF!($J.P&]"S$Y Q@<
MG(.>JT ,^+%LUU<6$2,49Y74..JEFB 88(Y'7J/K53QYX>B\)K!J=KN\])U#
M,[LWF95F8OSU;;SMV@AF!'3'1^-= GU*YL9H5W)!-ND.Y1@;XSG!()X4],T?
M%#0)];MDAMEWN)E8C<J\!'&<L0.I% '85YIXMLVO=9MH4=HRUN1O3&X#]]NQ
MGH2,@'^$G(Y%>EUYEXR2=]9MA:E1-Y&5,F=G!E+ X!."N1QSSP1U  SQ?H<?
M@=H=5L=R8D$;QAB5=2"Q&6W$9"X[CHP *\Z&L_\ (>M?^O=OY3T:II-]XMEB
MANX5@M(V#N#(LC.1QC*$$9!([8R223M%7?%V@W N[?5K-!+)$"CHSA<J0W()
MQS\S G)YV_*1F@"E\1_^/S3?^OC_ -GAK/\ '&D_VOJ]O:[V026^&9/O;?WI
M8#_> *]QSR".#8UC1M2UJ[M+R6)4BAE4^6LBLR .I9F;C<6QD;<X  P#G.QJ
M>@3S:M;WZKF".$JS;EX)$O&,Y/WAT'>@"EXU\-MI5@UKIB, \H,BQEG8JR[6
MZDM@D*"%[9SQNJ'P%'I4KI)9,R3J""KN0[C:P(*DE&'&\[.A"DXZ5V&OSW-O
M&'LT61PZ[D=MN4_B"MD -TY/&,\$X!Y*YT"\\27<%Y/"ELEJRGEUED?#;L93
MC ( P<8W$C=G  #1O^0]=?\ 7NO\H*-9_P"0]:_]>[?RGJQJVC76EZ@=5LXA
M.LT6V13(J$$;0,%L8!VK_>_BSC(JI::#J%SJD.IW**(PC#".I\L%' 0]"S M
MR0",G@XX !8\6Q:4LY;496=SC$9>1ECPJYPD7*[A@G=UZCO57X0WNXW5K&[/
M;PR+Y.[KM8OST!&0 2, 9R< DTZUT.\\.7MQ=00+<QW)+!MZ1.NYBQ7+$\<\
MX!#84Y!!%7OA]H%UILUY-=JJF>16!1@5)W2%B!DD#YAC=@X]\T <O\+O"$6M
MV[R7)9XA*0L6]E0,%4F3Y2,M@X'H,]<C&U\.8@XOM'?+00RLB[B=VURZLN01
M@';G@#DL>_&G\+] GT2V>&Y78YF9@-RMP409RI(Z@T>"M GTVYOIIEVI/-NC
M.Y3D;Y#G )(X8=<4 <IX*\&6FI7-]#-'N2";;&-[C WR#&0P)X4=<UZW7G]I
MI-]X;N[F>WA6XBNFW\2+$RG<QQ\Q/3<1T.>#D<K7H% 'E6O>%K:768;9D_=W
M$;R2#<WS,?-).<Y'*C@$#VJ[XBLQ]IM?#=NS06S([OL8DL&WDIDY./E;J2/F
MY4[0*T_%N@70O8-7M%65HEV-&6"'!WY(8D#D.1['!PPR S7-!N]1:#5X$6&\
M@#AHG<.&7YL+N'RY()]/O\L"HH S_&7A"+PS =2T\M!+"5SM=F#AG4;2&)X!
MP<=#R"#P1WNDWW]H0QW.-OFQH^,YQN4'&<#.,^E<;KMIJ7BI!9/"MK"Q!D9I
M5E) 8$ !1P1U[9P!N'?M[2U6T188QA(U"J,DX"C &3STH Y7QK%I^]7U&5MN
MT 0[WVYRV)/+C^;/5=W3''7%<_\ #>]CCU"XM;-V:S,?F*ISC=F,$C< 1C<5
M]2 ,DX!K3U;P_=:=J1U:VB6X65,%2RHR$*JY#,>IQU /!92!P2[PQHMXNI3:
ME=1JBS0X&UU8 _N\+UR2 N&. "0<<$4 =AJWF>3)Y'^M\M]G3[VT[?O<=<=>
M/6O)?"EMI[9AU#S8K_<6,DS/&0QRRLK9 !  ;+C)8\;A@5Z_=[]C>5M\S:=N
M_.W=CY<XYQGKCG%<%K]MJ7B> 6,EK'$6*EI7F5E!49)55W,I)X_BP"0>N0 5
M_C7I<?DQWNW][YBQ[LG[NV1L8SCKSG&?>NML_"EKHD4P@!A65#O<2-D !OF#
M.3M*Y)SVZGI65XO\%R:CI\=A"P,EN(R,C&_RT*8Z_*3G(SD9X) Y#[RSO/$]
MG-97,2V\A6/:WF+(K,&W'A<E1E0.2Q /?'(!P_BS^RH(F>SE8WL;J1(&E9G8
M,-S%R-A)Y;<N,D @XX.Q\2KIKO2;6:0Y>1H68X R6A<DX''6BYTO4KK3QI(M
M43:J@L)4^8*X/"@X#$_,Q)P<-W(%:'B_PM<ZAIMM91)NEB\G<NY1C;$RMR2
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MG!/W<'U6O)_"TMW;WU_-:(LJK.PDB9@C-F23:58@@%><Y.",C!., &GHMO\
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M@^Z2X:-6#LS?*&C"A N<853@9S[8& -+QQHKW]A)9VR L1&$0;5&%=3@9(
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M8C.0<BN@TN*_FLGTV>V"%;1XT<2H=S!=B+M!."1U).,CMG BMO LE]I*:;,
MDZ%F7)R V]R,E"1@JV.^,YP2,4 6/^%56WE_>?[5][[1O;?YF=V_;NQU_''\
M6[YJYQM>DUG0IFF)+Q.D98G);$D; G@<X8#N3C).371_VCK'E_9?LZ>;]W[1
MYJ;.N/,\O&>G.,=>=G\%5[GP+)8Z2^FP@/.Y5FP< MO0G!<@8"KCMG&< G%
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M$D@MRZB5AD(6 <CGD+G)'!_(U8H **** "BBB@ HHHH **** "BBB@ HHHH
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M@P* A5Q 9!O&U@,AA\QSMZGHH]!0!W%>9>#]:AT>YU.>X<(GVD#)R<DR38
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M,D]R>Y]:VOB3.YM5M8N'NYHX0VXJ!O.3G )((7:1Z$]>AROAQ_Q^:E_U\?\
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M5T.<,A#*<'!P1QUK%\&:5%!80Q*B[9849P1D,9$!8G.<YSCGMQT %<_\+_\
M1IK^R3B*&X^1>N,LZGD\GA%')/3W- &W_P +(T_9YWGKMW;<;7W9QG[FW=C_
M &L8SQG-:^CZU#K$?GV[ATR1D9&".H((!!^HZ8/0BN%^">GQBWDNMH\TRE-W
M?:%1MOL,G)QUXST&&>";'[6^JZ>IV1M(Z* /E7>94R%R!T Z8R !VH Z;_A9
M&G[_ "?/7=NVYVOMSG'W]NW'^UG&.<XKI:\RTRXN/ \!M;VV62TSAI8<-G>#
MG<K8W Y"98* !CYN,^CVETMVBS1G*2*&4X(R&&0<'GI0!P&L?$=;34DA\[%K
M&K+,/+)Q(OF#&=N[KM^[Q^M0_%;5(]5TZ*Y@;=&]P,'!&<+(#P0#U![5;UG_
M )#UK_U[M_*>CXU_\><?_7PO_H$E '077CZQM)3:O,HD5@I&&V@^A8#:,=\G
MCG.,&M74]5BTM#-.ZH@[L<9."< =2< X R3V%<K\1=*BLM*DAC152+R]@Q]T
M^8H)!/.2"<GJ<G)Y-%WXHBTVSLWN$:>>6.)HEV[V,@1<-DYP<L!D9;+< \T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<@$G@_+UP>O3BJ5Y\/)-3:-+NZ>6WB;(C*!6( P TBD%CC@L1D\XVDYKM:*
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M;MV_,YQG)S][T'2K'BKPS'XC@-K(2.=RL/X6 (!QW')!'<'C!P1L44 <?<>
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MO8Y&AN8@ DB_,,9S@J>HY8=1G)W;AQ71T4 <_I?AZYAD6>YNWEV9VJJ+"AW
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M..!QNPWS B@#HZ*XJ\\4WGAUHY-26$V\C;"]OOW(Q&02'Y(P#T&>,]<!NUH
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M+/\ CSN?^O>;_P! :N0\&^*+33=*1;AT.U9=T659R&D;Y=F<G<#WXP<G YH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M. 26*H" <MEOF/(QZ5>Z';W[;YHHW8# +HK''7&2#QS5N&%85"( %4   8
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M !1110 4444 %%%% !17+^+?%$NCW%I;QA2MU+M<L"2!N0<8(Y^8]<]JZB@
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M4%AU#[3$\<K!GB$8"*A)RH< L67I@]&&&8X.<?P9K<.AV*27I9DOI9F9RA=
M?N%7.227VDC@YYR, FF>#+9#J)DTO>+'R_WI8/Y;,!PJE@3D%E/S$-]_'RD
M@'J%%<_9>*_M-_+I6S'DQA]^[.<A#C;CC[_J>GO704 >?_&O_CSC_P"OA?\
MT"2O0*\_^-?_ !YQ_P#7PO\ Z!)7H% 'E_@K4M5\4(TGVA8XXV(W^5&[,Q"G
M;MP  HYSP<MCYOX>UUNRO;MPEM,D,04$MY?F2%LGY<-\NW&#G[V1Z&N:^"G_
M !YR?]?#?^@1UF>,)D&I;-5,GV$H#$ 6\LL% )(3G();I\V2N?D- &]X2U^Z
M%[/I%VRRM$N]9 H0X.S *@ <AP?8Y&6&",S1]9U+6KN[LXI52*&5AYC1JS(
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MI=E?6$BB:9;F)\AB8UA:,@$A@%R&!/RD=02".-U<_P".U;1;VWUS:SQ1*8Y
MN,J#N ;.>^\XX R "PW"MW3O'4&K2I!:;I0Q.]PCJD8"L06+*.6(P!]>> "
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M,(;UO,24*2N068KA<G@N5]> 2N&R #II)KS3+:Y\]U=H87>.9552QV,<-'R
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M@Y;'S?P[?B#7[J^O5TBP98V10\TA4,5!QP%88/# \9R2!E0&-5/@I_QYR?\
M7PW_ *!'46M7'_"*:H=3F#&WNHQ&7 X1AM&"!DGA >Q()V@E2" 9GBF*[M[Z
MPANW655G4QRJH1FS)'N#*"0"O&,#!&#DG..]UNRO;MPEM,D,04$MY?F2%LGY
M<-\NW&#G[V1Z&N%\5>(%UN\T^2%6\@7 "R,"H<[XMVU2 <+P,GJ<@?=R7>,)
MD&I;-5,GV$H#$ 6\LL% )(3G();I\V2N?D- &]X2U^Z%[/I%VRRM$N]9 H0X
M.S *@ <AP?8Y&6&",S1]9U+6KN[LXI52*&5AYC1JS( [!55>-Q;&#NS@ G(.
M,TOAZL"ZK.+562#[/\@;<#@F([OF).&^\N>Q'3I6K\./^/S4O^OC_P!GFH N
M^$=>N!=W&DWCB62(!T=4"Y4A>"!CGYE(&#SN^8C%5=,UF]\72226DJV]K$[*
MKB,2.Y&.JOC QST7&X#YB"0S1O\ D/77_7NO\H*S_"&N1^!VFTJ^W)B0R)(5
M)5U("@X7<1D+GN.JD@KR ='K7B:?PU9O-<A6F5_+C89"RY *N5'W3C.Y<@94
MA2 5K!N]=NK:-KO^T;9I$R_D((RA .=@?.\Y7@<9SQG^*K?C%'\8V#R6\;CR
M9@T892&E4)]]0<'!#DKU)VXQDX$5KXETB10'MT6XY!@^S;I-X.-@PF"2>!DC
MMG!R  =EX;UQ==MX[Q5*B0'Y3S@J2I&>XR#@\9'8=*Q]<U^72M0MHF9?LURK
M)M*Y82 \'(&1DLB]2.N0.M=!I2(D2>5'Y2%00FT(5W?,05' .3R/7-<_\3--
M:\LFDC+"2W995*L%(*9R<^RDD8(.0,>A ,KQI\0&T6^@MD91$N#/T;ASC! &
MX%5&X8/.1D$==OQ)K<D5U::?;LH>:0M)D@GRXQEEP02-XS@\<KC/4CE]#TU_
M%=G?7;AA)>/\BY4#$ !B )4 C=\C-WQV.34OPTN9-;N'U!RQ6*VA@!=>IPK2
M'=GDAU)YR2'!..!0!L:9K\\VK7%@S9@CA#*NU>"1%SG&3]X]3WKE-,TJ[?5K
MB%;K;.L(+2^2AW#$7R[,X'4<CT]ZV]&_Y#UU_P!>Z_R@JI>:DOAK69;N[#)#
M<0A4<*67(6//W<G@H1C&1D$C!S0 ?$?S+:;3?^6LJ2>R;V#0_@NX_@,U8\0Z
MKJ'A8PWUQ.LD+RA9(DB5=NX$D(?O,  <$D'(7.<G#?'ETMW<Z5-&<I),&4X(
MR&>$@X//2I?C7_QYQ_\ 7PO_ *!)0!Z!7/ZIIU_>2-Y5PD$2XV;8A*[9 W;M
MY &"/EV]0>>E=!7D5_- ;^X37#)L!)MP2_EA"V 0(^<E0O3C(;?\PH ZWX?>
M(Y]2-Q9W>UI;23:77@-DL.@ '!4X.!D8R,@D]1J*2/$ZPD+*48(3T#$':3P>
M ?8_2O//A$JI-?"-61!(FU'R&4;I<*<DG('!Y/->ET <?X;\;?:=-.HS%6DA
M5P_\ ++]T9(QEP5Z<9; ':HOAKXQ;6;>1[IU\R!CN8@(-A&0Q/"]F'&, <^I
MY3Q!9R07TFC#?Y.H7$,IP0QVDDRD#!Q\W.>"!&,Y'-6_B)YFCW,K1;S_ &C;
MB,!<,#(KHC#;U_U? ."<N=IZX -)O%5T^E3:KN"N\I,6 K;$,JIL.5 )'S<D
M$D$'.>FGX-74+]8KZZG41NH/DK&GS*4PK%QR"3\Q R.W&=HB\>6/]GZ.UMG=
MY4<"9QC.UXQG&3C./6M_PG_QYVW_ %[P_P#H"T <UX>U:[UN6_M1-L,,P6)O
M+1M@\Q\C&!NR%QR3Z]:Q?A)IUS/"98KCRXEN/FB\I6W85"WSDY&1QQTZUJ_#
MC_C\U+_KX_\ 9YJS_AGKD?A\/I-WNCN#<#"E202X50 5R.HZG ((()'0 J:9
MI5V^K7$*W6V=806E\E#N&(OEV9P.HY'I[UTWBOQ5+I)@TV.2(7$L9+S3_(B@
M*0'P 5!9@<#D C!4@BLF\U)?#6LRW=V&2&XA"HX4LN0L>?NY/!0C&,C()&#F
MG^-K96N+;71$;BU\K#J$W80AF#D-VPY/( !49()& !EYXQE\.M'.]Y%>1,VU
MXXUB6101D.NPG.,'.2!T'?*WO%GB*]MM1AL;,J1)$#LD V$YDRQ;AL +G@]N
M >A=::MI%^ZPVT"3.S $1VOW03C>Q9% 4$C)[9Z5%K/_ "'K7_KW;^4] #YM
M5O/#EY;074XGANB4XB2-@V0 <+CC++SD\%OER :[VO/_ (C_ /'YIO\ U\?^
MSPUZ!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<?XUT"?4KFQFA7<D$VZ0[E&!OC.<$@GA3TS7844 %%%% !1110 5RGC
M_1Y]:6&SB5C$\RF9E=5(12.,-][.=PZX*C@\5U=% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+/\ Y^(?^_R?_%5IPS+,H=""K $$'((/(((Z@UYE>RZ?KD]M%IT2.ZS!I-L
M5!#TDW!U4'.1M."01P0Q&?3885A4(@ 50  !@ #@  = * *[:M"C-$9$#QKN
M=2Z[E4 '<1G(&".3QS18ZM#J&?(D23;C/ENK8SG&<$XS@UY['H\>JZY<1S9*
M+$C%<_*VU8<!A_$N<''0D#.1P9?$6GQ^&M1L[BT4)]I<QR(O$9&47.U<<_-G
MTW*IQG.0"QHW_(>NO^O=?Y05V5[KEO8-LFEC1B,@.ZJ<=,X)''%<;HW_ "'K
MK_KW7^4%17&I:7,\T<-J]T79FD>&'S<,Y(.'8@C."05^7NISF@#T*&99E#H0
M58 @@Y!!Y!!'4&J7_"0VVSS_ #HO+W;=WF)MW8SMW9QG'..N*Y+X+S,]DP))
M"SN "<X&U#@>@R2?J2:Q_A#X7M[Z&2[F19'\PH!( R@!5;(4C&23U]!@8YR
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M "CC:,'.3D ]#KFOB/=O:6$TL3,CCR\,A*L,R*#@CGI1\-[IKK3X'<Y(5EZ
M<([(HX]  /Y\U#\4O^0=/_VS_P#1J4 8H\/RQV U-+NY\U;=9L/+OCR$$A4J
M1R#TY)]\]#TOA[Q8E]9Q7]RR1>9D'<X5=RLR\%B.NTD#D@=SC-<)K&A7C:9%
M,\[2VZQPNT"1K&WE[1P'4,3M&#\PQQO/*@5;^)2Q+I5L;==D321,B]P&C=N>
M3SSR<G)R23UH ]*NKM+13+*RH@QEG(51DX&2>.M<%\99EFL8G0@JTZ$$'((,
M<A!!'4&MCXI?\@Z?_MG_ .C4KE?'W_(&L_\ MW_]$-0!ZE-,L*EW("J"22<
M <DDGH!52RURWOVV0RQNP&2$=6..F< GCFN"^(D[WU_;:=Y7GQ^6TGE"0Q;V
M(<9+9P-H7([]1GFJ^LZ+>W!CEL[!;6:)]PDBFAZ8(*E1M!!XZYXR,8)H ]3K
MC/&4VH.)_(*P6T,3-YF=TKXC9B%'\(S@9.&'WE)Z5V=9/BS_ (\[G_KWF_\
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M^"_#D&JZA?33J'\F=PJL 4^=Y,DJ>I&WC/ SG&<$ 'I<NHQ11_:&=1%@'>6
M3#8P=V<8.1CUIECJT.H9\B1)-N,^6ZMC.<9P3C.#7!2:?'KFL&RF4&"R@4QQ
MCA.D9Y7ICY^@P"%4'(!!9\2=*B\.B#5;1%CECF5<(-B,"&;#*N/3!QC*D@YX
MP >AOJ,22"W+J)6&0A8!R.>0N<D<'\C4-EKEO?MLAEC=@,D(ZL<=,X!/'-<!
MXRT>/6-9MK6;)C:#) .,[3*V,^AQ@XYQT(/-0_$3PY!!=64<*B'[0[1N80$R
MK,BG@<9P[ G'(.#D<4 >D6^K0W+M!'(C2)G<JNI88.#E0<C!X/O3[G48K5E2
M1U5I#A S!2QX& ">3R.GJ*\Z\7:+#HE[IQM4$1:4(2F1E0T8YYY)#$$GE@<,
M35WXC_\ 'YIO_7Q_[/#0!W%[J,5@N^9U12< NP49ZXR2.>*X?XC_ /'YIO\
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M0>H'>O/;W2KOX?I]JMYC-:*_SPR8&U6;"X.3R2W)4+\V"589  /2IIEA4NY
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3[1MS][^[NV\=<_[6[YJ[6B@#C[SP'Y6FMI-N5WMM)=QM#,'5F)V@GH,#J0
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M8\)2V=Q+JEW(KW$R[2L8Q&HR, $\GA5 X&.<[CS75T44 </X)\ R^'[F2=Y
MT01HXER68(TF_DD* >.0 02Q/'<M? $D>H?;&=3;++),B,-S^9*JAC]T  ,
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M8''<9 R.,CN.M<_I>@Z@EJ^G7#0&/[,\<;)OWY*[4W':!M XR!G@=3G/9T4
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MI>VNK*TJP26[1NS%&E5A(@8<+A05.WL3NSU/H+O@WPJOAF VP<N6<L6(V\D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOHWBF"'3AJ9C$,(#'RXP#C]X5 & HRS>P&3R>IJE_P )[<^7]N^Q/]E^]O\
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M& /7#-*1G&>>: /0-1O5L(GN'R5B1F('7"@DXSCGBJ^@:VFMP)>1!@DF[ <
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >=>([1+O7+6*55=#;G*N RG F
M(R#QUKM[+0[>P;?#%&C$8)1%4XZXR ..*I:WX,M-;<37,>]PH4'>Z\ DXPK
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MNQ"Q8C<S<D 9RQ)Z 4 >=> /^0->?]O'_HA:ZKX6_P#(.@_[:?\ HUZU=/\
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MXCWZU7^*=ZEMI\BO@F0HJ@[N6W!OX<<@*6&>,C!ST(!7\#;M7N+G6'Y1V\J
M_./W:'DA6XPQ"G_>#<#D'I=-U^#4GEAA;<\#;9!M88.2,9( /*GIFF>&M'&C
MVT5H,9C0!L$D%CRY!/."Q)[?0=*?IN@0::\LT*[7G;=(=S')R3G!) Y8],4
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MD\2-)(J_*JJ6)8\+\H() )RV.<9JCX*\,CPY;+;$@N26<C."Q],]@ !VSC.
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M-B)C964+7,J$!]K!(TX8X,AR W'0\9R,[@15C2_$\DLBVMW;O!))G8<B6-L
MG;YB\!L*QVD=!G/(% '04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%5]1N6M8GE12[(C,$'5BH)"C /)Z=#]* +%%9.EZX9[7[
M=<1M!A79T?)90A/)^4'H,]._&:MZ7JD>JQK<P-NC?.#@C."0>" >H/:@"W16
M/HFMRZA+/%) T2POM1VSB098;AE5X^4'@GJ.?78H **** "BBB@ HHHH ***
M* "BN7\)>*)=8N+NWD"A;67:A4$$C<XYR3S\HZ8[UU% !1110 4444 %%%%
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M0!I^)]2U#P@(KR2X6XB,FUD,21$Y!(P5!/0'G/!QPPR*E^-?_'G'_P!?"_\
MH$E<)XJ733;1G3U<R!D\QVW\ H?E;)V;F(S\HQ\K8P.O=_&O_CSC_P"OA?\
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M +?4XU+_ &*7>R#NN58MGL!L /!P#D\ T :&G:?J5BR22SK< E1)'Y:Q[0V
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M P#D[2!@T =;_:DG]F_;=W[W['YF[ ^]Y6[.,8Z\XQCVKG_^$IN?[%_M+?\
MZ1_?VK_SWV?=QM^[QT_6L_\ X3V";2_LD*O).+7RW14;Y $V-(S $;1UZ]P#
MCG$7_,N?Y_Y^J .E\&KJ%^L5]=3J(W4'R5C3YE*85BXY!)^8@9';C.T4M,UF
M]\72226DJV]K$[*KB,2.Y&.JOC QST7&X#YB"1T_A/\ X\[;_KWA_P#0%KA?
M"&N1^!VFTJ^W)B0R)(5)5U("@X7<1D+GN.JD@KR :OC?SUTJXCNMI=&C4.O
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M.WGK&B/CS?*1W)P/DV\+M .22,Y( )&<7?@I_P ><G_7PW_H$='P4_X\Y/\
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M#H&+2[@.3P#[GZUZ17G7PMD:6YU!Y%V.9E++D-M)>7*Y'!P>,]Z]%H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC],T">'5K
MB_9<020A5;<O) BXQG(^Z>H[5V%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5Q_C70)]2N;&:%=R03;I#
MN48&^,YP2">%/3-=A10 4444 %%%% !1110 4444 %%%% !1110 4444 <?I
MF@3PZM<7[+B"2$*K;EY($7&,Y'W3U':NPHHH **** "BBB@ HHHH **** "B
MBB@ KG_'NER:K92VT"[I'V8&0,XD4GDD#H#WKH** ,_P]:M:6T$,@P\<,:L,
M@X*H 1D<=:T*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X_P %:!/IMS?3
M3+M2>;=&=RG(WR'. 21PPZXKL** "BBB@ HHHH *Y231Y[S5%NY%9;>VA(C(
M=2K.W#'9U'#$=.=@.<8%=710 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% '&:EX^6TU".PWQ>04;S'+<JXW_*6W;0<J!@C//N*S?'MVEW=:9+$R
MNAN#AD(93B2('!''6H=;TF%]<MXC&A22%F=2B[68B8[B,8)R!R>>*/B1IB)/
MIUK$/*0S,!Y6$*[GBR5P, Y.0<=>: .]BURWED^SK+&9<D; ZE\KG(VYSD8.
M?2K%U=I:*9965$&,LY"J,G R3QUKSCXG:)!H-O!=6L:QRQ3H%95&>%9AG/WC
ME0<MD]?4YZ+QGJ%A;/%]L3SIAGRHE4R,=Y"GY,[3GMN[@[>10!T%CJT.H9\B
M1)-N,^6ZMC.<9P3C.#7->+O'/]C7%O:HT1$DF)MY^9%)3!.&&WAB<L,<9Z5R
M^E7$?]LPFWADMEDB8/&Z>5NPDG.P$C;\J^VY<XSS6A\2=.B-[8$HN99\.=H^
M<!H@ W'S#''.>.* /0++48K]=\+JZ@X)1@PSUQD$\\TZZNTM%,LK*B#&6<A5
M&3@9)XZTVRTZ*P79"BHI.2$4*,],X '/%<YXSU"PMGB^V)YTPSY42J9&.\A3
M\F=ISVW=P=O(H Z"QU:'4,^1(DFW&?+=6QG.,X)QG!HN=6AM6\J21%?:6VLZ
MAMH!);!.<  Y/3@^E>9:5<1_VS";>&2V62)@\;IY6["2<[ 2-ORK[;ESC/-6
M_&6CQZQK-M:S9,;09(!QG:96QGT.,''..A!YH ]%LM1BOUWPNKJ#@E&##/7&
M03SS5?\ X2&VW^1YT7F;MNWS$W;LXV[<YSGC'7-<E\3V70[ Q6J+&L\JJPC7
M9P5)/W<<G8%.<Y7(K,N_#TLL#6D>E(F5(5_M$3.I/(;<?F.#VW<CY>G% 'J%
M0W5VEHIEE9408RSD*HR<#)/'6LWPC%<16L:7F?/4$-DACPQVY*D@G;CG.3WY
MS7*>-(AK6IVNE39\@HTA"DC<</P>>GR8&,$!FP>> "+XNZC%?V*/"ZNHN5!*
M,&&?+<XR">>:]%FF6%2[D!5!)).  .223T KRWXO>%[>QACNX46-_,"$1@*I
M!5FR5 QD$=?0X.>,6OB).]]?VVG>5Y\?EM)Y0D,6]B'&2V<#:%R._49YH [V
MRURWOVV0RQNP&2$=6..F< GCFGWVK0Z?CSY$CW9QYCJN<8SC)&<9%>;ZSHM[
M<&.6SL%M9HGW"2*:'I@@J5&T$'CKGC(Q@FK'B;1Y;743J,ULUW;,J*JK\Y3@
M _N\'.,,0"-N6!W!N@!W=Y<)?V\CQ2JJ/&X$J,"J\$%PP('RGGJ,8ZBH?"T'
MD6R)YWVC&[][G=N^8]]S=.G4]/PK AU*ROM/NWL JJ89&= NPJQAQRO0<+C*
M_*2#@DY-8EL6'AT[#M.UN=P7CSSN&21U&1C^+.T DXH [V;Q/:0L4>>(,I((
M,J @C@@@G@BI1KEN0A$L>)20AWK\Y!P0O/S'/'&>>*\UU^XT^^A2RL(!]MWQ
MA$\C#JRGYA(7&&  (;<6&>3D L+?Q.T>)YM/LE4)$\KKB,!<!WB!P,8!Y)Z=
M: ._BURWED^SK+&9<D; ZE\KG(VYSD8.?2K<TRPJ7<@*H)))P !R22>@%>:_
M$[1(-!MX+JUC6.6*= K*HSPK,,Y^\<J#ELGKZG+OB).]]?VVG>5Y\?EM)Y0D
M,6]B'&2V<#:%R._49YH [VRURWOVV0RQNP&2$=6..F< GCFK%U=I:*9965$&
M,LY"J,G R3QUKS+6=%O;@QRV=@MK-$^X2130],$%2HV@@\=<\9&,$UH>-(AK
M6IVNE39\@HTA"DC<</P>>GR8&,$!FP>> "+XNZC%?V*/"ZNHN5!*,&&?+<XR
M">>:](KRKXO>%[>QACNX46-_,"$1@*I!5FR5 QD$=?0X.>,>JT <?XN\<_V-
M<6]JC1$228FWGYD4E,$X8;>&)RPQQGI7466HQ7Z[X75U!P2C!AGKC()YYKS_
M .).G1&]L"47,L^'.T?. T0 ;CYACCG/'%/^(EHD)M-*B58H+NX'F"(!"<%%
M[<?Q9Y!Y53VH [6U\0VUVPBBFB=SG"I(C,<#)P <]*T*XSQ=X'LQ92[(E0PQ
M,RL@ ?,:DC+8RP.,'.<]>N"-/P#J;ZG8PSRG+E2">23L8H"22220N2>YS0!N
MS3+"I=R J@DDG  ')))Z 57L=6AU#/D2))MQGRW5L9SC."<9P:X?QI$-:U.U
MTJ;/D%&D(4D;CA^#ST^3 Q@@,V#SQUL/A>WMI$N(46)X]W^J 0,&&"K!0 PS
M@C/0@$=\@%N^U:'3\>?(D>[./,=5SC&<9(SC(J6UNTNU$L3*Z'.&0AE.#@X(
MXZUYU\-M*B\1"?5;M%DEDF9<.-Z* %;"JV?7 SG"@ 8YS-:VJ^'=96VMAMBN
MX2SID[01O(*@8 Y3C.<!F P"  #MSKEN Y,L>(B YWK\A)P W/RG/'..>*?;
MZM#<HT\<B-&F=S*ZE1@9.6!P,#D^U>;^"_#D&JZA?33J'\F=PJL 4^=Y,DJ>
MI&WC/ SG&<$-T[PQ!/K,]F5Q!&JRB(']V6"IC*]" 9&('09Q]W((!Z;9:C%?
MKOA=74'!*,&&>N,@GGFH3KEN Y,L>(B YWK\A)P W/RG/'..>*XCPM:KIVLW
M=M"-D7DAMBDA<GRCG'3@LV/0$@8'%5/!6A1:G?W[SC>L5PV$;F,EGE&XJ>"0
M,A<],GO@@ ](LM1BOUWPNKJ#@E&##/7&03SS7"?#V98;O4W<@*L^22<  /,2
M23T IMK:KX=UE;:V&V*[A+.F3M!&\@J!@#E.,YP&8# ( / =JMW<ZK#(,I),
M589(R&>8$9'/2@#T*&99E#H058 @@Y!!Y!!'4&F6]VESN\ME;8Q5MI!PPZJ<
M=".XZUP7A#7?^$<LKBWN /,T]V&T!AN#G,9R1T=R0#CA<$C')WOAWIILK*-W
M.9)\RNVXL6,G()+=]NT'W!Z]2 ;\EVD3+$S*'DSM4D!FVC)P.IP.N.E%Q=I;
M;?,95WL%7<0,L>BC/4GL.M<A\4[4QP1:D@7S+*9'&XG&"P!&!URVW/3@'!'?
MG_B1<GQ,RP6SKY<%JUTQ+$ @@8&W'#!>1NQP_;N >GW5VEHIEE9408RSD*HR
M<#)/'6L6]M=U_%+]JV8C(^S;OO\ #_/MWC.,_P!T_=Z^G-:OK(\5I860*G[6
MPDF 9D&V$'S$V_>P6#!3G&4X)^\)=9_Y#UK_ ->[?RGH NZEX^6TU".PWQ>0
M4;S'+<JXW_*6W;0<J!@C//N*S?'MVEW=:9+$RNAN#AD(93B2('!''6H=;TF%
M]<MXC&A22%F=2B[68B8[B,8)R!R>>*/B1IB)/IUK$/*0S,!Y6$*[GBR5P, Y
M.0<=>: .]BURWED^SK+&9<D; ZE\KG(VYSD8.?2KU>9?$[1(-!MX+JUC6.6*
M= K*HSPK,,Y^\<J#ELGKZG/IM '!?$FYE%Q8V\<LD:SRLKF)RA(+1CMW&3C.
M:K^)UE\#B*_BGFF4R;'CN)-ZL&!;(.!M(V]<'KZ9#'Q2C:6YT](VV.9F"M@-
MM)>+#8/!P><=ZJ:WHDEM?6CZD[7<,C>6N$$:K(Q&T,@RI!R#U!8 Y!"[6 /2
M+G48K5E21U5I#A S!2QX& ">3R.GJ*+W48K!=\SJBDX!=@HSUQDD<\5P_P 1
M_P#C\TW_ *^/_9X:/C7_ ,><?_7PO_H$E !\1_\ C\TW_KX_]GAKNKJ[2T4R
MRLJ(,99R%49.!DGCK7"_$?\ X_--_P"OC_V>&LSQ#-)JFK/;FW%RMM$I2,R^
M6HSL<N=QVDY;:1C!&,@XH ](L=6AU#/D2))MQGRW5L9SC."<9P:MUYHFC7GV
MNWNK>S6T5&"RF.6(JT989!5=HX&>Q)X[JN/2Z /.O'EWJ2PSW&Y;>WA;"B,Y
MED!=%5BP^Z#DG@@_PL".:ZW0]0$5C#=3,<+;([L<L>(PS,>I)[^IK,^*7_(.
MG_[9_P#HU*/^8-_W#_\ VA0!E>'[.?QBK:E//- CL1%';R;%"J2"2>=Q)R,D
M \?W2H%WP/K4R33Z1=N7FMR"CG&6CP "< \\J>6+'?@]#5CX6_\ (.@_[:?^
MC7K*T;_D/77_ %[K_*"@"O\ "+48K"Q=YG5%-RP!=@HSY:'&21SQ7H5K=I=J
M)8F5T.<,A#*<'!P1QUKS+X1>'(+^W>XG42$2LJK( R+\J$D*>-S< GK@ #'.
M=#P7$-%U.ZTJ'/D!%D 8D[3A.!ST^?!SDD*N3QR 5?#MA+XAN[Y)+FX18)R$
M$4Q489Y!C!!X&T8QBN]T32/[*0Q>9++EB=T[[V&0!@' XXZ>I-<_<?#=-\UQ
M!<7$4D[,Q\N0!=Q)(R H) )/&<X[]ZS_  5XCO&CNK5U^T7%G(J#YU3<,E"-
MQ4=-A;<V2V<'F@#T"O.O'EWJ2PSW&Y;>WA;"B,YED!=%5BP^Z#DG@@_PL".:
MZK1-5N[MRES:^2@4D-YR29.1\N%&>F3GV]ZS_BE_R#I_^V?_ *-2@#8\,3--
M:6[N26:"(DDY))0$DD]2:TZR?"?_ !YVW_7O#_Z M6-;FAB@D-R0(=C!R21\
MK#!''.3G QR3P.: &_\ "0VV_P CSHO,W;=OF)NW9QMVYSG/&.N:M75VEHIE
ME9408RSD*HR<#)/'6O(O%EY8W5FPM+210A4)<"';&=KA23)G<01D?-DEB,C=
MTZ;Q7,TVAAW)+-!;$DG))+1DDD]2: .OAURWF<0I+&9& (4.I8@KN! !R05Y
M^G/2B]URWL&V32QHQ&0'=5..F<$CCBN5\.Z)!H.G#4(HU,ZVQFWNH9MQBW8S
MP0O; (X]R2>:\&V<DL N?[/6Y:4L6FEGC)8AVYVR!MI['&-V,G- 'K4,RS*'
M0@JP!!!R"#R"".H-$TRPJ7<@*H)))P !R22>@%<?\.=*NM,$\5PABA+AH8S(
MLFT,6+*&!)P/EZ]3DXR36[XL_P"/.Y_Z]YO_ $!J )I/$-M$JRM-$$DSM8R(
M%;:<'!S@X/7'2KL,RS*'0@JP!!!R"#R"".H->>_#;P;:7=B)Y8UD>??N+C)
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MK;=[8P. "8UR!CID8;FKLNGQZ5KD$=NHC66!BZI\JGY9/X1QCY%.,8R,]>:
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MRX;&,,P8*V!@ K_"*/"^K6 DB@DMOLETN/+$B%2V0R#$F 6R./GQECQN89H
M] JB=<MP')ECQ$0'.]?D). &Y^4YXYQSQ5ZO+_!6A1:G?W[SC>L5PV$;F,EG
ME&XJ>"0,A<],GO@@ ](LM1BOUWPNKJ#@E&##/7&03SS5>3Q#;1;MTT0V-M;,
MB#:W/RGG@_*>#SP?2N*M;5?#NLK;6PVQ7<)9TR=H(WD%0, <IQG. S 8! %'
MP7X<@U74+Z:=0_DSN%5@"GSO)DE3U(V\9X&<XS@@ ]-^UIL\_<OE[=V[(V[<
M9W;NF,<YZ8JO9:Y;W[;(98W8#)".K''3. 3QS7 >/RUQ>VNEI")85B+"%7\D
M,<.H^8$ ! F5X]1WJ'6=%O;@QRV=@MK-$^X2130],$%2HV@@\=<\9&,$T >I
MTR:985+N0%4$DDX  Y))/0"L+5-9O;:1HX+/S8QC#_:(TSD GY2,C!R/PS7+
M^*=VO:A9:9<J5B:+S7C5_P"/:Y*EAP0-F 0 <%L$9X .]L=6AU#/D2))MQGR
MW5L9SC."<9P:XKX<?\?FI?\ 7Q_[/-750^%[>VD2XA18GCW?ZH! P88*L% #
M#.",]" 1WSQ'A.]:PEUBX3!:)W8 ],J9B,XQQQ0!W][KEO8-LFEC1B,@.ZJ<
M=,X)''%6X9EF4.A!5@""#D$'D$$=0:\E\&V<DL N?[/6Y:4L6FEGC)8AVYVR
M!MI['&-V,G-;OA2PDT>"[CU%?)LCDHC2!PJON#H&4ENZ@=R3D#<30!V'_"0V
MV_R/.B\S=MV^8F[=G&W;G.<\8ZYJU=7:6BF65E1!C+.0JC)P,D\=:\B\67EC
M=6;"TM)%"%0EP(=L9VN%),F=Q!&1\V26(R-W3IO%<S3:&'<DLT%L22<DDM&2
M23U)H Z^'7+>9Q"DL9D8 A0ZEB"NX$ ')!7GZ<]*+W7+>P;9-+&C$9 =U4XZ
M9P2..*Y7P[HD&@Z<-0BC4SK;&;>ZAFW&+=C/!"]L CCW))YKP;9R2P"Y_L];
MEI2Q::6>,EB';G;(&VGL<8W8R<T >M0S+,H=""K $$'((/(((Z@U4EURWBD^
MSM+&)<@;"ZA\MC VYSDY&/6N-\*6]YX=M[QY8_+CC5Y((V=9%7AV*Y5LX^[G
M)&>2.2:9\._"5MJ-G]JN$$LMR9"[2?,W#LO!/*GN2#N).<\#  _X<?\ 'YJ7
M_7Q_[/-75>+/^/.Y_P"O>;_T!JXWX3V2V%Q?VZ9*Q2HH)ZX5I0,XQSQ79>+/
M^/.Y_P"O>;_T!J ,#X>:M#I^G6_GR)'N\W'F.JYQ*V<9(SC(KK9=1BBC^T,Z
MB+ .\L F&Q@[LXP<C'K7"?#GPE;7U@DLZ"1I0XS)\VU0[C:G]P=6^7!W$G/3
M%+PGIIU"#4="SNCAD98B['()9]N2.P9 V .I;(.<4 >H5#:W:7:B6)E=#G#(
M0RG!P<$<=:\]B\8?8M&W-E9XP;;: R,KJ"HYP2&5,.>@R,9!X':^&M'&CVT5
MH,9C0!L$D%CRY!/."Q)[?0=* -.BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MDO%7A.>\N8=4LW59X1M(ESL*_-Z G)W$'V.05(YAUCPO=ZP]E<2F(26LI:0(
M7"D;T(VY!.=J\YQS[5V=% '+_$/PO+XDMUMX2H990Q+D@8"L.P;GYJB\5>$Y
M[RYAU2S=5GA&TB7.PK\WH"<G<0?8Y!4CGK:* .'M/"=[-J$.JW3Q'RT92L>X
M;<JZ@+D<CYMQ+$')(' &=#QQX3DUP13V[A)[9]R%ON<E2<\'D;01P1V(YR.H
MHH S]$^T[#]L\KS-QQY&_;MP,9W\YSGVQBL+Q5X3GO+F'5+-U6>$;2)<["OS
M>@)R=Q!]CD%2.>MHH X>T\)WLVH0ZK=/$?+1E*Q[AMRKJ N1R/FW$L0<D@<
M9T-0\+RW&IP:H"OE11%2"3OR1(.!C&/G'<=ZZBB@#)\3^'D\00-:2'&[!5L
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M#U\LG!/&0,GK6G+\.8[@;)KBZDCR"4DGRC8(."-HXX[$'T(-=5#"L*A$ "J
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M>6 /0X Q@ #![#L** .'\(> )-%N3<2NKQQ(\< QEU5I"^2=JX;D@XSG<1D
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MZ>\!@D<N%G$@*$\;05))&T*,D\XZ#G.QX0\+?V&KR2-ON+AM\SCA2V2< <
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M <5_8^K^7]B\^'9]WSL2?:-N?O?W=VWCKG_:W?-6_P"&/#R>'X%M(SG;DLV
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8(L>W*2D*54GGG//.&';%:>C?\AZZ_Z]U_E!71:=X&L]-D2XAB"R1 A2&?\
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MX8;>&)RPQQGI5CQ1-%K%N##>K HE&94D&"0I_=Y#KSSG&>W2N?\ B3IT1O;
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !69K^@1ZY&(9"R['5U:-MKJR]&!YYY/
M8]<CG!&G10!B6WV^V'EL(9L8PY=X6(P,Y01R#.<]&Q[#I5NUL7=A/<%2ZYV*
M@.Q,CG&3EFP=N\A?EX54W-NT** ,?PO;7=O$5OY%DEWD@H !MP,#A4YSGM^-
M;%%% !5'7+)K^WFMTP&EB=03TRRD#.,\<U>KE_%'P\M_$DHN)FD#*@4!"H&
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M2MU+N0*22!N<\Y Y^8=,]Z-/\+RV^ISZH2OE2Q!0 3OR!&.1C&/D/<]JQ_\
MA2EG_?F_[Z3_ .-T?\*4L_[\W_?2?_&Z -CPEX7ET>XN[B0J5NI=R!220-SG
MG('/S#IGO6>OA.]T>ZGNK!XC'<G<RW&[ABQ/&P=!DXY'!P02 U5_^%*6?]^;
M_OI/_C='_"E+/^_-_P!])_\ &Z -C3_"\MOJ<^J$KY4L04 $[\@1CD8QCY#W
M/:J47A*[T*62339(O*F8L89PP1"<<KY?XC^'"X!W8!%3_A2EG_?F_P"^D_\
MC='_  I2S_OS?]])_P#&Z -7P_X2EBN&U2^D62X92JJ@_=QC)X4MSTXZ#JV=
MQ)-/\)>%Y='N+NXD*E;J7<@4DD#<YYR!S\PZ9[UC_P#"E+/^_-_WTG_QNC_A
M2EG_ 'YO^^D_^-T ;&G^%Y;?4Y]4)7RI8@H )WY C'(QC'R'N>U=+-"LRE'
M*L""",@@\$$'J#7!?\*4L_[\W_?2?_&Z/^%*6?\ ?F_[Z3_XW0!8TSPOJ'AP
M&WLI8I("<J+D.&3).0-G4'@D\ G)"C)SI^$O"3:0TEW<2>=<SXWO@   ?=7O
MC/T! 4!1BL3_ (4I9_WYO^^D_P#C='_"E+/^_-_WTG_QN@#8\)>%Y='N+NXD
M*E;J7<@4DD#<YYR!S\PZ9[UU%>?_ /"E+/\ OS?]])_\;H_X4I9_WYO^^D_^
M-T ;'A+PO+H]Q=W$A4K=2[D"DD@;G/.0.?F'3/>JFD^!6LM0DU!F#0DR/&I9
MMRR2[=[;0 N"-PZGC;GD9%+_ (4I9_WYO^^D_P#C='_"E+/^_-_WTG_QN@#8
MU#PO+<:G!J@*^5%$5()._)$@X&,8^<=QWJIJWA.Z@O3JM@\>Z1-LB3[MO 4#
M&T$X^4'L01U(.!2_X4I9_P!^;_OI/_C='_"E+/\ OS?]])_\;H N^&_"=U9W
MTNIW+QOYT6T^7N&#\G !'W5VX!SD@ GDG!JWA.Z@O3JM@\>Z1-LB3[MO 4#&
MT$X^4'L01U(.!2_X4I9_WYO^^D_^-T?\*4L_[\W_ 'TG_P ;H T-5\)7$LL>
MJ6TB1WBQJLBX/DR'C<"1\V.HY!. N-I&:T-+M]1DD62ZDA6-,Y2!&._((Y:3
ME=IP1MZ\@]JY_P#X4I9_WYO^^D_^-T?\*4L_[\W_ 'TG_P ;H V-0\+RW&IP
M:H"OE11%2"3OR1(.!C&/G'<=Z/B'X7E\26ZV\)4,LH8ER0,!6'8-S\U8_P#P
MI2S_ +\W_?2?_&Z/^%*6?]^;_OI/_C= &GXJ\)SWES#JEFZK/"-I$N=A7YO0
M$Y.X@^QR"I'-2T\)WLVH0ZK=/$?+1E*Q[AMRKJ N1R/FW$L0<D@< 9K_ /"E
M+/\ OS?]])_\;H_X4I9_WYO^^D_^-T ;&H>%Y;C4X-4!7RHHBI!)WY(D' QC
M'SCN.]=17G__  I2S_OS?]])_P#&Z/\ A2EG_?F_[Z3_ .-T ;&G^%Y;?4Y]
M4)7RI8@H )WY C'(QC'R'N>U9_Q%^'S>)6CG@95E0%6WE@"O4<@'!!)[<YY/
M %5_^%*6?]^;_OI/_C='_"E+/^_-_P!])_\ &Z +NI>!)+B&U>&017=G$JAU
M&5;:@&TG .W(XR",%LJ<U%J?A?4/$8%O>RQ1P Y86P<L^", [^@')!Y ."5.
M!BO_ ,*4L_[\W_?2?_&Z/^%*6?\ ?F_[Z3_XW0!J^/?"+Z];)9VVQ/+D4@-E
M5"JC+@;5/J,#&,5H>,]$?6[22SB*AY-F"Y(7Y75CG )Z#TKFO^%*6?\ ?F_[
MZ3_XW1_PI2S_ +\W_?2?_&Z .RT.R:PMX;=\%HHD4D=,JH!QG''%87Q2_P"0
M=/\ ]L__ $:E97_"E+/^_-_WTG_QNC_A2EG_ 'YO^^D_^-T 1:3H^J&QC@MI
MXC'+"C!I ZRH' .Q67<, <!CR,\8PN.@M_ L4-@VD@Y#J<OC!+D[@Y (S@@8
M!/0!22*Q/^%*6?\ ?F_[Z3_XW1_PI2S_ +\W_?2?_&Z #_A%-4N+3^S9)H4C
M6/:&C#EV X6-CA0%(X) S@8(;+9M_P#"%3?V3_9&Y/-]<ML_UWF==N>GMU_.
MJG_"E+/^_-_WTG_QNC_A2EG_ 'YO^^D_^-T /A\-:K8VPL(9XBNP#>^]9$SU
M1& ;*CHK$!@#P%PN+MYX#\K36TFW*[VVDNXVAF#JS$[03T&!U(  R<9K/_X4
MI9_WYO\ OI/_ (W1_P *4L_[\W_?2?\ QN@"WXG\%3:K86^GQL@D@\K<6+!3
MLC*'!"D]3QP.*N^,O"<FK-'=VKB*Z@/RL>A!ZJQ )P.<#D<L",-D8_\ PI2S
M_OS?]])_\;H_X4I9_P!^;_OI/_C= &[IUEJ$\J2W<D2QQ$G9;A_GW*R_,7(P
M%SD 9!/7D UT=>?_ /"E+/\ OS?]])_\;H_X4I9_WYO^^D_^-T 6].\%36W]
MH[F3_3M_EX+<;O,QN^7C[XZ9[UM>#-$?1+2.SE*EX]^2A)7YG9AC(!Z'TKFO
M^%*6?]^;_OI/_C='_"E+/^_-_P!])_\ &Z -CX>>%Y?#=NUO,5+-*6!0DC!5
M1W"\_+1\//"\OANW:WF*EFE+ H21@JH[A>?EK'_X4I9_WYO^^D_^-T?\*4L_
M[\W_ 'TG_P ;H MQ>$KO0I9)--DB\J9BQAG#!$)QROE_B/X<+@'=@$6O#_A*
M6*X;5+Z19+AE*JJ#]W&,GA2W/3CH.K9W$DUE?\*4L_[\W_?2?_&Z/^%*6?\
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M\*4L_P"_-_WTG_QN@#T"BL?POX7B\-Q&WA+%6<L2Y!.2 .P7CY:V* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZDNFZS;3N&(6W/"*68EO.55 '4L2 /<\X%;<'CR2WN([*^MF@\_A&$@E4L2
M!\JXZ\=21D9 !R #L**Y36?&[6]U_9MI T\P7<X#B-5& 1\S CH1SP.0 23@
M:$.LW,L#R_9F%PC8\EI% ;[IRLGW2-K9SCJ"O44 ;=%>5?"34;F"$Q16_F1-
M<?-+YJKMRJ!OD(R<#GCKTKK=1\4W4;/]GLI)(XBP+.ZQDE<Y*(0S.I&"I'WN
M@&10!U%%8_A7Q-'XC@%U&".=K*?X6 !(SW'((/<'G!R!S6A_$V7759;:T9Y4
M/S#S55 IZ'S& ^8GHN.0"<\$4 =[17.>'/%QUR"65(BL\)96A9P&W $J,D#
M;ID@8(8=LUP_@K5;NWN;YX;7S'>;,B^<B;#OD^7)&&Y)&1Z>] 'I<.OP33O8
M*V9XUW,NUN =O.<8/WAT/>M"N7T_6XIM3GLA JRQQ!C,,;V!$?RGY0<?,/XC
M]T<>AJ/BFZC9_L]E))'$6!9W6,DKG)1"&9U(P5(^]T R* .HK'\+^*(O$D1N
M(0P57*D. #D 'L6X^:CPKXFC\1P"ZC!'.UE/\+  D9[CD$'N#S@Y Y?X*?\
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M*<CD>H[%20 T_P 907K7*C<HLB1(6 Q\N[)&TDD?(>P/3BGW7B^"&T.J*6>
M8Y1<,?GV<!]O0^N*XWPG<K:RZQ*ZAU1W8H>C!3,2IR#P>G0_2K&OZDFI:&]Q
M%&L*-MQ&F-HQ< '& HY(ST[T =[IUZM_$EPF0LJ*P!ZX8 C.,\\U8KSS3O&T
MUE912P6K2P001J\F\)\R* ^%*EF53P6 QD-V&:ZN7Q5!':?VH2?)V!N,%N2
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M74YP&.1L3[H!(&0-Q7/3Y0 !@T_X;LM\UYJ"LS>==,H)SC8@S'@$9'#XP>@
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M[5;<W .[C&<'[QZCO1#H$$,[WZKB>1=K-N;D#;QC.!]T=!VH X_6?^0]:_\
M7NW\IZ-9_P"0]:_]>[?RGKL)M @FG2_9<SQKM5MS< [N,9P?O'J.]$V@033I
M?LN9XUVJVYN =W&,X/WCU'>@#C+>9=-UV4S$*+F!1&2?O']V /8DHP&<9(P.
MHR?&&9;J*#3T(,\LZ%4SR00R \\ %F &2,\XZ''9ZSH$&M+Y=S&K@=,\,.03
MAA@C.!G!&>AXJIHW@NST9O-@B57_ +Q+.PX(X+DD9!.<8SWH YK6?^0]:_\
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M_P Q?(V[M_;'3IUSGC;C.>,9XIUAHL-A"+.- (0&&PY888DL#N)R#D]:R/\
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MZD]Z .*^"G_'G)_U\-_Z!'53X57W]GZ;<7.-WE22OC.,[8D.,X.,X]*[O1-
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M.-@C20@<MO8N1@8XW< [3P,<]Q#H$$,[WZKB>1=K-N;D#;QC.!]T=!VK/NO
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M+$;F;D@#.6)/0"C1- @T1##;+L0L6(W,W) &<L2>@% ''_&O_CSC_P"OA?\
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M  = * .=\+:_ FG17)D41PPHKG^ZR* 5(ZYST&,G(QG(SB?!3_CSD_Z^&_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45R^G^*);C4Y]+
M(7RHH@P(!WY(C/)SC'SGL.U=10 45R^G^*);C4Y]+(7RHH@P(!WY(C/)SC'S
MGL.U=10 4457U&Y:UB>5%+LB,P0=6*@D*, \GIT/TH L45GZ!J3ZE EQ+&T+
MMNS&^=PPQ SD*>0,].]:% !1110 4444 %%%% !16?HFOP:VAFMFWH&*D[67
MD '&& /0BM"@ HHHH **** "BBB@ HHHH **** "BN7\)>*)=8N+NWD"A;67
M:A4$$C<XYR3S\HZ8[UU% !17+^$O%$NL7%W;R!0MK+M0J""1N<<Y)Y^4=,=Z
MZB@ HHHH **** "BBB@ HHK'\+ZW+K$1EF@:!@Y4(^<D  [N57CG'3MUH V*
M**Y?X>>*)?$ENUQ,%#+*5 0$# 53W+<_-0!U%%%% !1110 45@Z%XE:]MY+R
MZA:W$1;*ON)VJH8M@JIQR>@/2M/2]4CU6-;F!MT;YP<$9P2#P0#U![4 6Z**
MQ_"^MRZQ$99H&@8.5"/G)  .[E5XYQT[=: -BBBB@ HHHH **** "BBB@ HK
M/FU^"&=+!FQ/(NY5VMR!NYSC ^Z>I[5H4 %%%% !116?J6OP::\4,S;7G;;&
M-K')R!C(! Y8=<4 :%%%8^MZW+I\L$4<#2K,^UW7.(QE1N.%;CYB>2.AY] #
M8HHHH **** "BN7U#Q1+;ZG!I8"^5+$6)(._($AX.<8^0=CWKJ* "BBB@ HK
M/U_4GTV![B*-IG7;B-,[CE@#C 8\ YZ=JL:=<M=1)*ZE&=%8H>JE@"5.0.1T
MZ#Z4 6**Q/&>MOHEI)>1!2\>S <$K\SJIS@@]#ZU5O/%$UM9P7T<#3R3+&62
M+<,;TW$\*YP#Q^(YH Z6BBB@ HHHH **** "BBJ.N7K6%O-<)@M%$[ 'IE5)
M&<8XXH O45B>#-;?6[2.\E"AY-^0@(7Y791C))Z#UK;H **** "BL_1-?@UM
M#-;-O0,5)VLO( .,, >A%8_A+Q1+K%Q=V\@4+:R[4*@@D;G'.2>?E'3'>@#J
M**** "BBB@ HHK/FU^"&=+!FQ/(NY5VMR!NYSC ^Z>I[4 :%%%% !117+ZAX
MHEM]3@TL!?*EB+$D'?D"0\'.,?(.Q[T =11110 4444 %%%% !117+_#SQ1+
MXDMVN)@H992H" @8"J>Y;GYJ .HHHHH ***Y?X>>*)?$ENUQ,%#+*5 0$# 5
M3W+<_-0!U%%4=<O6L+>:X3!:*)V /3*J2,XQQQ5+P9K;ZW:1WDH4/)OR$!"_
M*[*,9)/0>M &W1110 4444 %%%% !1110 45R^G^*);C4Y]+(7RHH@P(!WY(
MC/)SC'SGL.U'A+Q1+K%Q=V\@4+:R[4*@@D;G'.2>?E'3'>@#J**** "BBB@
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MC6-(9O%&J+JL:,MM;Q,J.RX$ARZ\9QQ\S>N-HW8+8#_AQ_Q^:E_U\?\ L\U
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M?'_L\U '=7>_8WE;?,VG;OSMW8^7..<9ZXYQ7"^)I-3T* ZB;E&V,A>(0J$
M9@-H;EB 2!SM)7G(-=+XT\_['-]DW>=M&W9][&X;L>^W.,<Y^[SBO(K]].N+
M R1B1[\A3(S>82"7&]V.=FTDX!Y/S+GYLD 'MNDWW]H0QW.-OFQH^,YQN4'&
M<#.,^E6ZR?"?_'G;?]>\/_H"UK4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!G^(;5KNVGAC&7DAD51D#)9" ,GCK6
M?X"TN32K**VG7;(F_(R#C,C$<@D=".]=!10 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <UKMC=V]RNHVP65
M5A:-H6?8?F<-N5CE03@;LXX7')(QCZSI5YXP,=K<P"V@1][MYJ2N< @*NWH3
MN/)!'?MM;O:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *YSQ_:7%[:/;6BEI)2%.'"87.6.21D'&TC/(;TR*Z.B@"OIU
MDMA$ENF2L2*H)ZX4 #.,<\5D^%M ;31)<3D-<W#EI"K,4X)V*N[!"JIP,\]L
MD 8WJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *9-,L*EW("J"22<  <DDGH!3ZY3XE:'/K5IY%MRWF*
M67=MW*,\<X!P2&P2!QGJ!0!NV6N6]^VR&6-V R0CJQQTS@$\<U->ZC%8+OF=
M44G +L%&>N,DCGBN'\+ZM8"2*"2V^R72X\L2(5+9#(,28!;(X^?&6/&YAFL2
M"236-0NYFM%NS!)Y:AI0B(JET VOD-NQD\8#9( )H ]3LM1BOUWPNKJ#@E&#
M#/7&03SS3+[5H=/QY\B1[LX\QU7.,9QDC.,BN'\/Z1>6^H+=);"UMG0K*B2Q
MNA*JVUMJXP<[1\H]3GYFS7^&VE1>(A/JMVBR2R3,N'&]% "MA5;/K@9SA0 ,
M<Y /0Y=1BBC^T,ZB+ .\L F&Q@[LXP<C'K3OM:;//W+Y>W=NR-NW&=V[IC'.
M>F*XWQ[H\>E:9<QPY",Z,%S\J[I(\A1_"N<G'0$G&!P+O_,&_P"X?_[0H Z#
M^UH?+^U>8GE?W]Z[.NW[V<=>.O7BF0ZY;S.(4EC,C $*'4L05W @ Y(*\_3G
MI7G'_,N?Y_Y^JZKP%X7M]/MH)T13*\:N9& +YD0$@-C(&#@ =NN222 6-!B6
MSENI7NQ,I?<4+\0 %R5.7;:.W1?N]..,WPW\1$OIKF*XDA2.&3$3;PN]=SC.
M68AN .1@<^XJC\/85FN]31P"K3X((R""\P((/4&JO@'0[>ZN]022*-ECGP@9
M%8*-\HP 1P.!T]!0!Z/;W:7.[RV5MC%6VD'##JIQT([CK1]K3?Y&Y?,V[MN1
MNVYQNV]<9XSTS7&Z5#_86K308 BOT\Q#ACETR77)X!Y=B.@!7!&<4_P1.-<N
MKK5QRA80Q99B0J %N"  '.UL8R#GW) .UHHIDTRPJ7<@*H)))P !R22>@% '
MFOQ(U>XO)VM+)V0V<#2R[)&3()3CC )52&Z]"0.1@]_HFJ+JL$=TN,2HK8!W
M8)'*Y]5.0?<=!7FO@SQI9H;JYO7(DNY3E'5Y5\L [5R$.0-Q7![ < ==/X/Z
MJI6?3U?>L,A:-B2"R,<9"'E0",GW?GGJ =K_ ,)#;;//\Z+R]VW=YB;=V,[=
MV<9QSCKBK$6HQ2Q_:%=3%@G>&!3"YR=V<8&#GTKS+X0^%[>^ADNYD61_,* 2
M ,H 56R%(QDD]?08&.<Z'PZM59]1TPC_ $=9F4)D]',B,-WWN54#KVSUS0!Z
M%#,LRAT(*L 00<@@\@@CJ#3+>[2YW>6RML8JVT@X8=5..A'<=:X+PAKO_".6
M5Q;W 'F:>[#: PW!SF,Y(Z.Y(!QPN"1CD[WP[TTV5E&[G,D^97;<6+&3D$EN
M^W:#[@]>I )?&MK]IA5?M7V3]X#YF[;GY6^3.].O7KVZ5L7.HQ6K*DCJK2'"
M!F"ECP, $\GD=/45P_QK_P"/./\ Z^%_] DJO\6+);^XL+=\A9974D=<,T0.
M,YYYH [J+7+>63[.LL9ER1L#J7RN<C;G.1@Y]*Y#XP:V;.U%O'(%DE=0RAAO
M,95\\==I( )[]#P2*S_B=HD&@V\%U:QK'+%.@5E49X5F&<_>.5!RV3U]3FQ\
M:[1/LT<^U?,\Y5W8&[;LD.W=UQGG'3- '1>#M)L=.5EL&5R0@D*R^83C.TG!
M(!//0 'GCBM.U\0VUVPBBFB=SG"I(C,<#)P <]*X?XAZ=%;M:Z;"BQ17DZB4
MPJ$8A64 <#! WD\@\@'ZZOB[P/9BREV1*AAB9E9  ^8U)&6QE@<8.<YZ]<$
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MM.^(GA*VTZS^U6Z"*6V,91H_E;EU7DCECW!)W C.>3D ] FF6%2[D!5!)).
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M/EN<9!//->D5Y5\7O"]O8PQW<*+&_F!"(P%4@JS9*@8R".OH<'/&/5: ./\
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MR+1K1?"[2+JUH90[[C<E?/0 L%!.0< G+$_?.0"IXH ]:FF6%2[D!5!)).
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0KF.$<1W]G#(N5;_ %B+EE#9(Z%G/3&0!CC(!Z!JFJ1Z5&US.VV-,9."<9(
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MD!!Q@,P.3G(YQT)&X<BUX;\9+JTKV4D;0W,0)>-OF&,XR&'4<J>@SD;=PYH
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M+<?-7+_#C_C\U+_KX_\ 9YJS/AQJ[:/I<]VJ&0QSD[0<9&V($YP<  DGCH*
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MOA?_ $"2O0* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M22220A4$DGDGD^M &./#5OH]I?O;RM*TD4HD+NKD.B.2"5 ^;YN<\U=^%O\
MR#H/^VG_ *->MNWT""VA:RCC58G4JRKQD%=IR1R21P6SGWJ72]+CTJ-;:!=L
M:9P,DXR23R23U)[T <5HW_(>NO\ KW7^4%5] \07GBQ9;M+F.UBA.-@C20@<
MMO8N1@8XW< [3P,<]Q#H$$,[WZKB>1=K-N;D#;QC.!]T=!VK/NO -C=RFZ>%
M3(S!B<MM)]2H.TY[Y'/.<Y- '%> /^0->?\ ;Q_Z(6NJ^%O_ "#H/^VG_HUZ
MU=/\+6VGPO91)MBEW;EW,<[E"MR22,@8X-6]+TN/2HUMH%VQIG R3C))/))/
M4GO0!Q7QK_X\X_\ KX7_ - DH^(__'YIO_7Q_P"SPUV&MZ!!K:"&Y7>@8,!N
M9>0",Y4@]":-2T"#4GBFF7<\#;HSN88.0<X! /*CKF@#C_C7_P ><?\ U\+_
M .@24?&O_CSC_P"OA?\ T"2NPUO0(-;00W*[T#!@-S+R 1G*D'H31K>@0:V@
MAN5WH&# ;F7D C.5(/0F@#C_ (H?Z--87K\10W'SMUQED8<#D\(QX!Z>XKH/
M&>JQ06$TK.NV6%U0@Y#&1"% QG.<YX[<] 36U=6B7:F*55=#C*N RG!R,@\=
M:P+7X;Z?:L)%@4D9^^SNO(QRKL0?Q'OUH Y2YM6M?#H1Q@E5;J#P\X=3QZ@@
M_P ^:[KPG_QYVW_7O#_Z M6]4TN/58VMIUW1OC(R1G!!'((/4#O4MI:K:(L,
M8PD:A5&2<!1@#)YZ4 <+\%/^/.3_ *^&_P#0(Z/AQ_Q^:E_U\?\ L\U=AHF@
M0:(AAMEV(6+$;F;D@#.6)/0"C3= @TUY9H5VO.VZ0[F.3DG."2!RQZ8H X_X
M<?\ 'YJ7_7Q_[/-5?0/$%YXL66[2YCM8H3C8(TD('+;V+D8&.-W .T\#'/<:
M;H$&FO+-"NUYVW2'<QR<DYP20.6/3%9]UX!L;N4W3PJ9&8,3EMI/J5!VG/?(
MYYSG)H Y_P""G_'G)_U\-_Z!'3/@G,IM)$!&X3DD9Y *( <>AP<?0^E=GHF@
M0:(AAMEV(6+$;F;D@#.6)/0"J,O@:SDG^W&(>=O#[@SCY@00VT,%SD9/')Y.
M<F@#C?#-JUV^LPQC+R-(JC(&2QG &3QUK=^$VH1W%@D*,"\1<.O<;G9EX]"#
MP>G4=0<='IN@0::\LT*[7G;=(=S')R3G!) Y8],5GZGX!L=3<S2PJ7/4J63)
M)))(0J"23R3R?6@#G/"LRZEK%W>0D/"(E3>#QNQ&./4?NVY'''7D9?\ #C_C
M\U+_ *^/_9YJ[73-*BTM!# BH@[*,9. ,D]2< 9)R3W-1:;H$&FO+-"NUYVW
M2'<QR<DYP20.6/3% ''Z-_R'KK_KW7^4%=AXAM6N[:>&,9>2&15&0,ED( R>
M.M$.@00SO?JN)Y%VLVYN0-O&,X'W1T':M"@#C/A-J$=Q8)"C O$7#KW&YV9>
M/0@\'IU'4'$7C/QVUHD LFC_ -*>1!,Y^1=C!"WI@,<[CE<#.&!K5U#X>6&H
M2-/)""[G+$.ZY/<X5@,GOQR>3S6A>^&K:]A^QO$OD@Y"*-@!SG(VXP>3TQG)
MSU- 'G7BFTGM+ZP2YN1.WGJ0/+2,J#)&,X4G(;'&?[IQWK8UG_D/6O\ U[M_
M*>MVU^'EA:LCI" T3[U.]\AA@CDMR!M& <@<X')SIS:!!-.E^RYGC7:K;FX!
MW<8S@_>/4=Z ./\ B/\ \?FF_P#7Q_[/#7H%9^I:!!J3Q33+N>!MT9W,,'(.
M< @'E1US6A0!YO8ZA'9Z]<"1@OFQ(BY[L5B(7/J<''J>!R0*E\<S+?ZC86L1
M#2Q2EW4'[JY1^2>,[4)QUQCCD9ZB]\%V=](]S+$KR2KM8L6/& .!G"D ##*
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MT3PK:Z)DVT:H3G+<LV#CC<Q)QP.,XSSC- %#XD6K76GSH@R0JMU X1U=CSZ
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M<^+5DMAIT%NF2L4L:@GKA8G SC'/%=EXL_X\[G_KWF_] :IM;T"#6T$-RN]
MP8#<R\@$9RI!Z$U:N[5;M&AD&4D4JPR1D,,$9'/2@#S73?%+^&]%M[B)59VD
M=!OSM&9)&)(&">%QU'7/;!S/B-;7,5I"]S=K.)'4JBQHH^X275UP649QG !W
M \<5ZA%X;MX[?^S@@\C!&PDGJ2QY))SDY!SD'IC K*'PRTX*4\@8)!^_)GC/
M?=D#GD X/&>@P 8_QK_X\X_^OA?_ $"2O0*S];T"#6T$-RN] P8#<R\@$9RI
M!Z$UH4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^%CWG_0.F_\ '_\ XS0!Z!17G_\ PL>\_P"@=-_X_P#_ !FC_A8]Y_T#IO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MP8)[E;W9*RB%XI2D:#./+:(!V8@'<V\_*/E  Y)YK>K$DM[E[E+C9%Y:+(G^
MN?<5D>,[L>5C("?=S@D_>XR0#;KGW\91)--$2ODVL8,LN[A7+$"/;C).!V)Y
M^7&[BN@KGY_!4,T$]F6?9=3&5R"NX,65L#Y< 94=03[T $7B]8K2*_N$9#/C
M9&F968MDHHV@9+@9&<8)P<&F:9XWCO9EM'AGA>0,4\^+8&V#+ ')Y Y]/?)
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MMC^U)/[2^Q;OW7V/S-N!][S=N<XSTXQG'M0!T%%<_K.J26U[9VR-B.?[1O&
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M_;ULE[MV>9N^7=NQM8KUP/3/2M:O,OA_8ZA?6<8BF6WA0N$(B65WRY+%MQP
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MQW-O9;<_:?-^;=C;Y2ANF#G.<=1CWK6KA_';SI>6!M0IFS<!1)G9RBAB<$'
M7)XYXX!Z&62]O/#LT"W,PN(;F41D^4D;(S [,;6&0Q^\2#@+QR>0#LZ*X34_
M$CZA/)%#>0VL4#,A+[&D=QMW';)M 4$E00>2#U!&-;P;XA;4C-;2.DKVS(/-
MBQL=77*MP2-V0=P&%!X&: .EHKSSPG/JGB.W6X:X6%<L%80H[R<D$L"0JA2,
M# !/.1T)V/#^H76MVLL+2+%<P3-"944.I,94E@C #Y@<?J .@ .EM;M+M1+$
MRNASAD(93@X."..M35Y_\+=.N?LT$_VC_1_WG[GRE_O./]9G=][YOTZ5T'@+
M5)-5LHKF=MTC[\G &<2,!P !T [4 =!17'V.OSRVVH3%OGMIKI8SM7Y1&F4&
M,8.#ZYSWS3/#=W>S0QZI>S*D*Q%FC2('<@0D2,P)(8_>VJ,8 & 20 #LZ*\Z
MMO$-Q?C[7]OMH=V&2W/ELH& 0CN2K@D\/@<<E>P&A>^-W?3H=00;#,RH[["R
MQ9)5Y-@SD CY03SE<Y/RD [6BN?\-0W(/FR7274#J<,L:H0P( P4)# _-NSR
M"!CO6EKEZUA;S7"8+11.P!Z9521G&..* *NA>(#J\DZ!"L=O*8PY8'<R_?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2+A\M&0Q< G8,@!0>O4$YP-C0;1XK^^E96"2?9MK$$*VV,@X/0X/7'2NEHH
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MD]!D],]:VM6L?[0ADML[?-C=,XSC<I&<9&<9]:MT4 </H_B:?1(EL;FUG9X
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M,B*X?9*S;B S*2P4?*O4EAV'/IM% 'GFNZI<Z]+:>7:RI!'=Q,[2IM?<I_N
MDA I)+'C/&1CG>UZT>6_L955BD?VG<P!*KNC &3T&3TSUKI:* .:T&T>*_OI
M65@DGV;:Q!"MMC(.#T.#UQTH^R/_ &MY^UO+^P[=V#MW>=G;NZ9QSCKBNEHH
M \BT_3)-80R2V(NW$L@:X%UY8D(;&5^[E   N/E&#@ Y%=UX+U6.>-K-83;R
M6I"O$>=N<E2&Q\P;DYZDY/((8TK?P3<Z;NBLKMHH"Q*QM"LNW/4!G.<9Z#\\
MG).QX?\ #:Z09)2[2S3E3)(YZE1@ *.%49.!V!QD@# !E>)+>?3+M-7A0S)Y
M0AEC0$R!2^[>H_B.>H]/8EEE34)O$JRVPAD@@D@D0O.H5][8 Q'NSM"DG/0G
MC(QSU%% '#Z/XFGT2);&YM9V> ! ]O&9(V50 K DCDCJ/7T.5#XM&G:WO[R=
M-MQ>1N!$AWX5(BD8XSECDYP2#Q@ Y%=K10!F>&(6AM+='!#+!$"",$$( 00>
MA%<;:>&GO-#%K(C+*BR.JM&2X99&8 *<$%A\H[X;OT/HM% '&> +">X>?5KR
M,1S7!50NPJ0L:A<_,2P#$#(./N@\@C&;-I8T*XF-Q:?:HKB1Y4DB@$LBEB-T
M;!N@'8Y]QG)"^BT4 <_X499/,>.T^RQG;M)5(W?&0=T:C*[3TR3D'(J+X<6C
MVEA#%*K(X\S*N"K#,C$9!YZ5TM% '"2:C+H&H74K6\TL5RL)5H$W\QIMP1TZ
MYZD$8'!!S6M]D?\ M;S]K>7]AV[L';N\[.W=TSCG'7%=+10!YYH6J7.@RW?F
M6LKP27<K(T2;GW,?[A()0J 0PXSQDYXV_!FGSEY]3N5$;WAC(B&<HL:E5W$_
MQ$'D8&/8DJO444 >;V7A:>]TFWA" 36\IE$4ZD!]KR?(P.,!@W?@]#@'(EAO
M(;E0L>DMYQ ^62WCCCSU8>:PX YP2HR<# S7H=% !7#V=U-X5FN4>"6:&XG:
M6-K>,.<N 7# /P!P%R!G#'Z=Q10!QG@B.Y>ZO;B[B,32F# ZKA58 !QD,0,;
MB._8=!BZ9IJ^&P;&[L3<[#F.:&W67>K$GYMW1ATQD\<= &;TVB@#@M?M'O-+
MG2&T,!=T*1(JEV7?&0Y2,?*V.JG)&.33M3UZ]U.$Z;]D=+F9=CNP_P!&4,IW
M.)%)SQT'8G&6(PW=T4 <EXMT&3^RFL(09'CBB48&"WE%,D#)YPI..3V&36KX
M=\0-K"DO!+"R!<B9-H);.0I/W@,=<#J..:V** "BBB@ HHHH **** "BBB@
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M0#!VG:ZEMP!')P.AQ[D52N/',]CMGN;1XK5F \TNK,H;[K-$H)7MD$\$XY.
M0#L*J7&J1VTD=L[8DGW[!@G.P9;D# P/4CVK,\2>*ETADMXT,US,1LB4X)'=
MB<':HP>3Z'L&(YJ37GU'4[*":%H9HA<%E8JRX>,[2KK]X?+SP,'(YP: /0Z*
M*Y2?QC/<2R0V5JTZP-L=S(L2[QG<HWCG'<_I@@D ZNBL$^)9/LT=T+:4RRG:
M(=N&5N1\Q.-J9'WR.A!([5!I?BV22=;&\MVMY)5)C^<2J^W)8;E  ( SCTZX
MRNX VK?5([F22V1LR0;-XP1C>,KR1@Y'H3[T:7JD>JQK<P-NC?.#@C."0>"
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M$QF5RY\K@E1\P+ EN>G0\T:'XLN%M(3:6C3Q10(K/Y@CRR( X5""S 'C('+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#H"U2^(>GR:A830PJ6<A"%'4[75C@=S@'CJ>@YKH(85A4(@ 50  !@ #@
M = *?0!S]KX]L;B(7/G(H*DE78"08Z@IG.?8 Y_AR",X6E0L=-OKH@A;LW<R
M!AA@CH0N1ZG&>"1@@@UUO_"/6V_S_)B\S=NW>6F[=G.[=C.<\YZYK0H X>SU
MN"]TEH8Y%:1+!@R!AO&R+:V5Z@ ]\8/!'!%=%X3_ ./.V_Z]X?\ T!:FM_#U
MM;;O+AB7>I5ML:#*GJIP.0>XZ5=AA6%0B !5   &  .  !T H \G6U:71;25
M0^V"X,DAB($BHLDH9ESW&<@]NIX!-7K^PTZ>$M-J,[Q,%)4W <G)!&8]A;(.
M#C;D=\8KT>UM$M%$42JB#.%0!5&3DX XZU5M?#UM:,)8H8D<9PR1HK#(P<$#
M/2@#$_YC/_</_P#:]=74/V1-_G[5\S;MW8&[;G.W=UQGG'3-34 <5::I'H^I
MW:W++&+B.!T9V55(C781DGKG.!Z GIC,.CZ[%K&L.\!W+'9E"P^Z2)5)(/<?
M-C/?'&1@GL[W3HK]=DR*Z@Y =0PSTS@@\\T0Z=%"P=$4,J! 0H!"#D("!PH]
M.E 'FEI810W5U!=W,]H[3R2H%F$43H[<,"006]><]NJMCJ/!=I:027!MKA[B
M0^5YK2/YG0-LPX4 \9'!.,8XKH+[28=0QY\:2;<X\Q%;&<9QD'&<"I;6T2T4
M11*J(,X5 %49.3@#CK0!S7PM_P"0=!_VT_\ 1KTWP-"LRWR. 5:_N001D$':
M""#U!KI[6T2T411*J(,X5 %49.3@#CK1;VB6V[RU5=[%FV@#+'JQQU)[GK0!
MY+\__(J?/_Q^?],_^/;_ %OWO[W\?3V_V:ZOQ;J;?:X["6=K:VDA+>8F$9G#
M?<$IR%P #QC.=ISN7'6IIT22&X"*)6&"X4!R.."V,D<#\A1>Z=%?KLF174'(
M#J&&>F<$'GF@#S_P>T)U1Q;SR7"K:,"\KER&$JY4,0,KT(QD<D@UIZAJL6FZ
MPK3NJ*]CM!<X7/FEL$G@<*>N/3J1756NDPVA#11HA"E0415(4G<5&!TSSCIG
MGK1?:3#J&//C23;G'F(K8SC.,@XS@4 <[#,LVKAT(*MIP((.009L@@CJ#7(Z
M[</X?>[T6 ,/MS1FW $>W]\=LH[;0<%%&. ,\?>/J<.G10L'1%#*@0$* 0@Y
M" @<*/3I0^G1/(+@HIE48#E07 YX#8R!R?S- ''^/]'-M901Q^88[26$LT9'
MFK'&I4N#Q\PX.<<=3@ XRK^PTZ>$M-J,[Q,%)4W <G)!&8]A;(.#C;D=\8KT
MVL^U\/6UHPEBAB1QG#)&BL,C!P0,]* -"O/]2^PI+->6UY]EG5F$@!&PLF=Q
M,# &0X) *\%N1ELY] K/NO#UM=L9988G<XRSQHS' P,DC/2@#S_Q!?/JL5AJ
MMP)8(QYHE> D.GF85'&02%;&>A^4X!)(S=&FV EA+W\LS">,QH;A9@7!^7*J
MIP.V> ,XR,UZ!-"LRE' *L""",@@\$$'J#52RT.WL&WPQ1HQ&"415..N,@#C
MB@#F(-330]2N?M1\M+M83$[X$9\I-K MG .3T/\ 5<P^.==BUJRNX+8^885A
M9BGS+AI W!&<[0I+$< =\@X[.]TZ*_79,BNH.0'4,,],X(//-.M;1+11%$JH
M@SA4 51DY. ..M ')>+O'%F;*79*KF:)E54(+YD4@97.5 SDYQCIUP#2U+_C
MSTK_ *^++_T UV%OX>MK;=Y<,2[U*MMC094]5.!R#W'2K#:=$ZHA12L14H"H
MPI7A2HQP1VQT[4 4?%G_ !YW/_7O-_Z U<KXE_Y *_\ 7O:_SCKO9H5F4HX!
M5@001D$'@@@]0:9]D39Y&U?+V[=N!MVXQMV],8XQTQ0!QOC[6X-5TR=[>17&
M(2=K D;I$QD=5/L0#U]*9\2K?;):W<AE2")I1)+ <.GF!0ISR0"1@G!XXZD
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex19-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex19-1_003.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "LGQ3!Y]LZ>=]GSM_>YV[?F'?<O7IU'7\*UJY3XI?\@Z
M?_MG_P"C4H V+:]BTRWB,TRE=B*)7< .=OWLDG);&>I^IJ677+>*3[.TL8ER
M!L+J'RV,#;G.3D8]:\X\??\ (&L_^W?_ -$-6AX[\&VFE::_E1J'A\O#D?O"
M2X4DL,$Y#'@\#L!@8 -WXCZV=+LY#'($F8 )\P#GYU#[0><A3U'(Z\=:S_AO
MI-C:QQRV[*UT\ ,F)=SC=M9@4!P &P.@(P 3G.:_C4#4-&6[E"M+Y,#!RHW
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MSR%SDC@_D:Y34O'RVFH1V&^+R"C>8Y;E7&_Y2V[:#E0,$9Y]Q5+6?^0]:_\
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M9ZXR2.>*L5S5YHB>,[.#[267>L<I\H@?,4Z?,&X^8^_3FNEH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXW<,6)XV#H,G'(X.""0&K0U#PO+<:G!J@*^5%$5()._)$@X&,8^<=QWKJ**
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M85*-Q''Y@CQC[Y8@DMVQC '(()(/HM% '+^,O"<FK-'=VKB*Z@/RL>A!ZJQ
M)P.<#D<L",-D8GBCP7J'B6(">6(.CC:D9=8<8.6)*LQ?) '90#CEC7H=% '-
M>+?"3:NT=W;R>3<P9V/@$$$?=;OC/U !8%3FBTM]4G=?/DMXXU8,?(1V9@#R
MA\S@ C/S#D'&.]=+10 5PE]X*NSJ$FJV\J1Y5=H.YMQ5%78XP %)')!)'! S
MT[NB@#C-/\)W5[=KJ&HO&WDC]U'#N,8)'+8<<$=<\DM@Y 4"GZSX6N8KW^U+
M!H@[Q[)%FW[6QC!^7)Z =-N-HZY-=A10!PECX*NQJ$>JW$J285MP&Y=I9&78
M@P05!/!)!/)(SUO>*O"<]Y<PZI9NJSPC:1+G85^;T!.3N(/L<@J1SUM% %32
M_.\M?M.SS>=WE;MG4XQNYZ8SGOFN7U;PG=07IU6P>/=(FV1)]VW@*!C:"<?*
M#V((ZD' [.B@#C/#?A.ZL[Z74[EXW\Z+:?+W#!^3@ C[J[< YR0 3R3BWI_A
M>6WU.?5"5\J6(* "=^0(QR,8Q\A[GM7444 <UXM\)-J[1W=O)Y-S!G8^ 001
M]UN^,_4 %@5.:+2WU2=U\^2WCC5@Q\A'9F /*'S. ",_,.0<8[UTM% !7+ZA
MX7EN-3@U0%?*BB*D$G?DB0<#&,?..X[UU%% '+^+?"\NL7%I<1E0MK+N<,2"
M1N0\8!Y^4]<=J9X@\)2RW"ZI8R+'<*H5E<?NY!D<,5YZ<=#T7&T@&NKHH XJ
M7PE=Z[+')J4D7E0L&$, 8HY&>6\S\!_%E<@;<DF[XX\)R:X(I[=PD]L^Y"WW
M.2I.>#R-H(X([$<Y'444 9^B?:=A^V>5YFXX\C?MVX&,[^<YS[8Q6/XM\+RZ
MQ<6EQ&5"VLNYPQ()&Y#Q@'GY3UQVKJ** .7U#PO+<:G!J@*^5%$5()._)$@X
M&,8^<=QWHT_PO+;ZG/JA*^5+$% !._($8Y&,8^0]SVKJ** .7U#PO+<:G!J@
M*^5%$5()._)$@X&,8^<=QWHU#PO+<:G!J@*^5%$5()._)$@X&,8^<=QWKJ**
M .7U#PO+<:G!J@*^5%$5()._)$@X&,8^<=QWJIJWA.Z@O3JM@\>Z1-LB3[MO
M 4#&T$X^4'L01U(.!V=% '*>(O"4NKB&[218;V!?OH,H21RO/S;=W3.<*6!4
MYJ:TM]4G=?/DMXXU8,?(1V9@#RA\S@ C/S#D'&.]=+10!R7B3PG/+<IJE@ZQ
MS@!7#Y".H]=H))Z Y[!2"I49S]0\%WNJ7%M?3RQEH90S(I81JJLI 0%22S8)
M8L1S@=%KO:* "N2\5>$Y[RYAU2S=5GA&TB7.PK\WH"<G<0?8Y!4CGK:* ./U
MGPE<:NL-V9$AOX-^'B!,9!)VJ=WS8Z9SD#+C:0:KZGX7U#Q&!;WLL4< .6%L
M'+/@C ._H!R0>0#@E3@8[BB@#G/&&A7%_;I;V#B%D=>0S1C8%8;1L!XY''3C
MVKHZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BH;J[2T4RRLJ(,99R%49.!DGCK7.P_$W3I6""<98@#*2
M*.?4E0 /<G [T =113(9EF4.A!5@""#D$'D$$=0:?0 4444 %%%% !1110 4
M444 %%8^M^*(M'E@MY Q:Z?:A4 @'*CG)''S#IGO6Q0 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXSN)+FXTN2>/RI#<-E-X?&)8@/F'!R,'\<5V%KXE\Z]ETQHV4QQK(KD_*ZG
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MGH,9.1C.1G$^"G_'G)_U\-_Z!'0!TOBWQ+_PCL2W1C:1/,57VG!56S\W3'7
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M\Z(,D*K=0.$=78\^@!/\N:E\&:K%/80RJZ[8H45R3@*8T 8'.,8QGGMST(-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!Y4=<UH44 9\V@033I?LN9XUVJVYN =W&,X/WCU'>B;0()ITOV7,\:[5;<W
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M* ,_4M @U)XIIEW/ VZ,[F&#D'. 0#RHZYK0HHH SYM @FG2_9<SQKM5MS<
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MCH10!W=CJDUO:&[OD"2QI(SI'@\(6(Q\Q&2H'\77TJQH&MIK<"7D08))NP'
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M\JM\S8VC'&2W;&"OS9!!'MI_%U[!<O"\-K:,6!E&R5F^5L;3GC(7MC ;YLD
M>@44 >?ZE#+X?U1M2$,LT5S#M/DIN9"NT8P#S]P==OWCC.TYJ6XN]2UB"]EM
MWCB$;!25SA2DFTN1D*Q+<J<$9 YZGTNB@#@O&%G/8ZA;ZO'$TT4:>6RQ LXS
MOR=H'3#Y';(P2N03#\21+K]A$\,,NXS@F-HSY@ 61<E1G _H1ZUZ'10!Q7C3
M1IX;J#6;1/->!65X\X)7#<J.I.&8=SG;A3S5'Q1JESXKB_LZVM94$A7>]RGE
M*JJRD8Y.3GD]3@'"G.1Z'10!P7B/PS-I4MKJ-DAF-G%Y;(S#<452 1@#+8+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **R?$/B>#P^@EN&QNSM4#+,0,X _J<
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M=#(FUWR68;I<,<@')')X'- %NP\:W^IW-Q86\41\F1E61]ZHH5R/GP26+ 8
M7'.3@@'&KX4\4S7D\^FWBHMQ!AAY6[:RG'/.?53R02&'R@@UE?#C_C\U+_KX
M_P#9YJ-&_P"0]=?]>Z_R@H T_P#A(+W5Y)4L$B6.WE:-GN&8[F7&=JQ] /4D
MY!&,'(%?0/%URT<UY?>2L5OYBNL>\2"1"/D^9BAR#QACDE1GK7,_VP-,GNE-
MVUF[74A,9@:967C;( P.TMR20<,,8 4"M8Z7!?Z5/;6$OGR-^\D8EC(SA@S$
MH<L"VPA01SQR<EB :%MK.K:G']K@AMTC90R)*[-(P*A@=RD+\V>,[<=#ZFU#
M\0HIK!]656/E\,G<.2HV[NA&6!W#L<XS\M<KX7TO1-0MXY)=BRA0)!+,T;;@
M!N.#(!@GD$<=N""!U%I#IEII[R(!]AE)+9$C9)81YPV7!W 8QT(R,=: &>']
M5U2^6*ZECM_)EVDJA=90KGAADLO .[&<D<<-T["O(M7GB\*,CZ/<F1I93FW#
M"9"#CH%Z'@+R=[ \-P<^NT <OI_BB6XU.?2R%\J*(," =^2(SR<XQ\Y[#M6/
M8>-;_4[FXL+>*(^3(RK(^]44*Y'SX)+%@, +CG)P0#@T;_D/77_7NO\ *"CX
M<?\ 'YJ7_7Q_[/-0!J^%/%,UY//IMXJ+<088>5NVLIQSSGU4\D$AA\H(-=1-
M,L*EW("J"22<  <DDGH!7!:-_P AZZ_Z]U_E!79:Y9-?V\UNF TL3J">F64@
M9QGCF@#DM)\5ZCKN^[M88A;*WR"8LLD@7J%8$J"<8R1M!.,MM)K/^%M]YDVH
M7,H\O,BNP<XV9:4L"2!C;WR!T[58^'?BVVTZS^RW#B*6V,@=9/E;EV;@'ECV
M( W C&.1G/\ !$+:NVK(@*-.6 $@VE3)YP 8#.",\]<4 ;VG^(]1\0#[39Q0
MQVYSL-PS,SX9@3B,_+C'((Z]"PZ">*?[<L+R.1=EQ;PS),@Y4-L<9!Y!!*GN
M2,8Y&">4\%:5I5S!Y=\%2YB9ED$TC1$G<<8&]1P.", @CD<@GJ(;"P@L;U].
M VF*5'(9V!9(V/!<G(&[JO!SU- &5X'O[]K"-+**/;$),M.6'F,79L1A2.!T
M+,0"QQQM)KHM \4S>(+5VA5$O(F".DVX(&!&20/G (SC/(8$<X).+\-O&5I:
M6(@ED6-X-^X.<$AF9P5'5N#C YSVY&;'PNA:X:\U( B*ZG)0,,-@,Y)],?/C
M@GD,.U &/\)/MGDGR/)^S_:/G\S?YGW4W;=OR_=QC/?KQ7JM>:?"'58K&&2R
MF=8Y_M!^20[&)954 !L9.5(P.0>HY&?2Z /-_"_C34_$JDP10*$)W/() ASC
M"@!B=PY)ZC!&<<;NMUNXOMXBLXXMNT,99W.W.2"@1/FST.[IC(ZUS7P4_P"/
M.3_KX;_T".J_B+69+G4CIUQ<-:VJH&1D/EESM_YZ'H,EA_=.W;C=S0!M^%?%
MD]Y<S:7>(JSPC<#%G85^7U).3N!'L<$*1SR.F?;_ .UKC9]G^T^2-^[S/*VX
MBQMQ\V?N]>.OM5CP'Y?]KW AE:9! 0))&WLV#$#\V!D Y /3 &,CFK<6H1Z5
MKD\EPPC66!0C/\JGY8_XCQCY&&<XR,=>* -OQ%XHN-'EL;<B,M=.%E(#$ YC
M!V<CCYCC.>U5_%/C6XTJ^BL((EF$L8;;RKDDN.&R0 -H))7@9R0.11^(4RS7
M>F.A!5I\@@Y!!>$@@CJ#3]9_Y#UK_P!>[?RGH MIXIO-*NX;34%A\NYRJ/!O
MX;@ $-D]2!T ^8'=P16EKGB"=+A=-LT5IFB\PO*Q$:J&V\A?F8D@C Q@D'D9
MQA?$?_C\TW_KX_\ 9X:B\<7@L;])FE:V_P!%(298VD#-YG,;)RK *2<8!!()
M)PHH T+#6]2>[^P3"V&U4D;:)<M&6VL4.2,@\8;'/0$<U7T;Q9J'B4R3V20)
M C[5-QOWG@$_<)YY!/&!D %L$T[P/=VMU.]P;O[3=.H0%D,.$'S;5C. >5RQ
M&<=<#)+8NJPZ;;(^JZ=<^1,%)5(WP&(?.TPL-V&( QP@&&V[0<@'=:]JEQ:6
M9N88LW 6,^5@R8+,H9?DP6V@GD>F>E:&DW#W,,<LHVR/&A9<$88J"PP>1@]C
MS6+H'B8KI\>HWQV?+\S;"."^U6V@$_,,'@8YR,"M^TNENT6:,Y210RG!&0PR
M#@\]* )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\>QWPP94 [@;3SG W$X!P&[/_A'K;?Y_DQ>9NW;O+3=NSG=NQG.><]<UH44
M<UXWTF?6EBL8QB&60&=]R@A$(;: 022QZ$#@@ \$UOVEJMHBPQC"1J%49)P%
M& ,GGI4U% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-<1XCM$N]<M8I55T-N<JX#*<"8C(/'6NWLM#M[!M\,4:,1@E$53CKC( XXH
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M>$>8-ZINPR]"&]%SVKI;_P"(4%@D32)*)9R0L.P>?]XJ"4+< D?+SEL\ \X
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M>2,986Z"3;S@@_,.1QGL"<$YR!SGA+5(]5UFYN8&W1O;C!P1G'D@\$ ]0>U
M'I=%<YJ'CF&VD:"))9WC.'%O&9-A[!CD#)YZ$X((."*- \<1:T"ZQRQQ*C-Y
MLR!8L*<'Y]Q&1S^1]* .CHKCV^)T#!I(HKB6*/K)%#F/@!CRQ4C /.0/7IS5
MOQ/XE5;![NWWR++&X1X025)1OG/(*A2/F/53QC- '2T5PGPX\5/=P0VTL=P[
MGS,SNA:(X9B,R$YZ?+TZ\5>/Q*@DD>&"*>?RB 6MXQ(G/ON''!P<8."1D<T
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M&,Y!!R!QD T[;48KIF2-U9HSAPK!BIY&" >#P>OH:R=8\<V>CR?9YY0L@ )
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MPA\2H(Y$AGBG@\TD!KB,1IQ[[CQR,G&!D$X'-9GQK_X\X_\ KX7_ - DH ]
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M"1V(!YZ9Z.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD1"N,<@9(/ /([@]",G-6?P!'-L?S[A98T9/-6;$C*6+[6;'(!/& .,9S@8
M&>&/%LMY<2Z7=QJEQ"NXM&<QL,C! /(X92.3GG.T\5-\2-_]GS^7NW;5SMSG
M;O7?T[;<[NV,YXJUX?\ "$&A%I(PS2R9WR2-ND;)+<GIUZX S@$Y(S6Q-"LR
ME' *L""",@@\$$'J#0!C^"=GV&W\O;M\E,[<8W8^?IWW9W=\YSS7"^&_]3K'
ME_\ 'O\ OO+V_P"K^[+G;CY?N[>G;;VQ72M\,8%#1Q2W$44G6.*;$?("GA@Q
M.0.<D^G3BMJ#PQ!:V[Z?$NR*17!VGYOG&"<MDDXZ$YZ =!B@#(^%4*IIT1
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MR"<G'.2?RP*TKKPA!-:'2U#) <<(V6'S[^"^[J?7- #_  ="L5E;!0 /(C.
M,<LH)/U)))]3S6AJ-DM_$]N^0LJ,I(ZX8$'&<\\T:=9+81);IDK$BJ">N%
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MH& (\@G!&>5\X@_4$ CT/-;'Q2_Y!T__ &S_ /1J5IW/A>*XNX]4);S8D*@
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M<@D4 <%\2WU![2-KT0*AE4@1;]X8H_!R2N ,YP3SC!Q6[\:_^/./_KX7_P!
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M/@%1PH4C /&"/3IQ6[K/A^+5;<V#92)@HQ'A<!"" ." . .G2@#%BA6+1L*
M!]@)P!CEH22?J223ZGFL30/"J^)M'@MBY0J[L& W<B20<C(R,$]QS@^Q[C^Q
M$^S?V?EO+\GRLY&[;LV9SC&<>V,]JS#X%@^RQZ<&D"POO1PP$BMN+;@0 ,_,
M1TZ>^#0!CVWB>]T":"QU$)+]I8*DL)P<EL$,I"@X++T"X'/S'(KNZYK3O $%
MK*+N1I9Y4QL:XD\PKC/3@#J<\YP>1@UTM !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@'"C).,C. <=3Q5?0_%UKKC,EM('9!DC#*<=,X8#(]<=,C/45P^H"XO]9E2
M0N\$*;/M*DJH'EOD;1G<&8D'L">>E:=UX7U'4;JWO9C;J;=QDPF579-P+*20
M<C&0!D#YCGJ: .]KG-0^(=AI\C023 .APP".V#W&54C([\\'@\UT=>9:-8W?
MP_$F85GM2=SRQ$"4#('()R0J@MMQ@;B=^,T >BRZC%%']H9U$6 =Y8!,-C!W
M9Q@Y&/6L33_B'8:A(L$<P+N<*"CKD]AEE R>W/)X'-<?XVU==633EM ODS2_
M*DB83<C(BJP ^ZNYE('!'3/!K3USPSJ6LP?89!9K&-NW8)05V]-N00...G0D
M4 =KJ>JQ:6AFG=40=V.,G!. .I. < 9)["J6A^+K77&9+:0.R#)&&4XZ9PP&
M1ZXZ9&>HKBM4LFN=2T_3KO$JQVP+ _,&<*^YB3@L"8U//!QR.3GT6?3X[ATF
M=07B+%&[C<I5N?0@\CIT/4# !7TW7X-2>6&%MSP-MD&UA@Y(QD@ \J>F:(=?
M@FG>P5LSQKN9=K< [><XP?O#H>]<?\./^/S4O^OC_P!GFHT;_D/77_7NO\H*
M -VZ^(=A:LZ/, T3[&&Q\AAD'@+R!M.2,@<9/(S5\1&RU&6QN)I&5BX:W"@X
M<L8R,_(<#[O7;U/X8GP]T^.;4-0N&4&2*=@A/\.]Y-V/<X SUQD="<V/B/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0L6(W,W) &<L2>@% &?X0\(+X=5SO:269MTDC9!8@G'&3ZG)R2222>@%30/
MO]D6<VF^;N\_S/GV8QO0)]W<<XQGJ,UU=% &)H/AA=-LQIDA\Q-LBL<%,B1F
M)& 21PV.OO6?X9\'3Z P1+IFME9R(FC7.&!P-^<C!P3@ $YX&375T4 <9-X'
MNID-J]](;=B05,:F0H6R5,I.XDCC.,8XV[?EIOBBV_L*Q32['>)I65(@C8DR
M&WNQ.00,9W$<#<,X7IVM0R6B2LLK*I>/.UB 67<,'!ZC(ZXZT %I&T2*DC;W
M"@,V NX@<M@<#)YQVK"U/P[=2S-/;7;1+(%RC1K*H*C&5W$;0>X Y.23T Z.
MB@#C&\(Q^'K&\*LTDLT$AD=SDL1&W;L,DGG)YY8\5A>!/"D\]BDMK=/!Y_F>
M8NQ77(8H"OW2AP.2#D\<C KTJ[M5NT:&09212K#)&0PP1D<]*BTO2X]*C6V@
M7;&F<#).,DD\DD]2>] &/I?@N/3+)],C8_O4<,Y&<LZ[2VW/ '&!GH.23DFO
M_P (+_Q+O[&\W_MIL_Z:^9]W=^'7W]JZNB@#)_L+_0_[-W?\N_E;]O\ L;-V
MW/XXS^-'A;0O[!MDLMV_R]WS;=N=S%NF3ZXZUK44 0W=JMVC0R#*2*589(R&
M&",CGI7(6_@*YT]&M;2]>. YPK1*[#</FP^5(R<D;0N"<]<D]K10!D^&O#47
MAV+[-!NVEBQ+G+$G R< #H . .GKDFKX;\*?V+-<W._?]JDWXV[=OS.<9R<_
M>]!TKH** .?LO"GV:_EU7?GSHPFS;C& @SNSS]ST'7VJI>^%+R1I?)OG2.5F
M.UHUD9=PY"N6!4#^$#&WMSR>KHH X^]TV+P;I\L%N7W2;E3#9E:64;%QC;R.
M.%&<+G!.<[OAJVFMK:*.Y8O,$&\G&<]<$@G)7INS\V,]ZNW%HESM\Q5;8P9=
MP!PPZ,,]".QZU-0!D^)?#47B*+[-/NVA@P*'# C(R,@CH2.0>OK@C N/ 5SJ
M"+:W=Z\D QE5B5&.T?+E\L3@X)W!LD9ZX([6B@#FO%7@E=;MH["-_*2%D*_*
M7X1"@7E@>AZY/2NEHHH R?%G_'G<_P#7O-_Z U<+X$\*3SV*2VMT\'G^9YB[
M%=<AB@*_=*' Y(.3QR,"O2KNU6[1H9!E)%*L,D9##!&1STJ+2]+CTJ-;:!=L
M:9P,DXR23R23U)[T 9_AKPG%H5O]B7YU;)D+C(<L &RIR "!C'IUR<DX5G\.
M);:-K$7<GV1BV8U10^&_A\PYP/[P  ;G@;C7<44 <59?#?[-82Z5YV?.D#[_
M "\8P4.-N[G[GJ.OM4/_  K>>&#[!#>.L#+AU:-6R3][:05*JW]W)ZG).37=
MT4 <Y?\ @N.6P.D0L43"@,1O/#AR2,C))!] ,\#'%5]?\"_VO9PZ;YNWR/+^
M?9G.Q"GW=PQG.>IQ75T4 <_XO\(+XB5#O:.6%MT<BY)4DC/&1Z#!R"" 0>H+
M-.\,SK*EQ=W33&$DHHC2) 65D)8+G<<'CICGU-='10 5QEMX ETEF&GW301.
M<E&C68 \]"Q&!C [DX&6/&.SHH P?"OA&/P\KE6:268@R.YR6(SV[#))YR>>
M6/%-\-^%/[%FN;G?O^U2;\;=NWYG.,Y.?O>@Z5T%% !7EDNC'5-;N LC1211
M*Z.F.&"1*,@CE?F.5XR.,XKU.L^'0((9WOU7$\B[6;<W(&WC&<#[HZ#M0!B:
M-X(:WNO[2NYVGF"[4)01JHP0?E4D=">.!R202<BW9>%/LU_+JN_/G1A-FW&,
M!!G=GG[GH.OM7044 <_XU\*?\)/"MMO\O;('SMW=%88QE?[WK6AK^C+K4$EH
M_ D7&>>".5; (S@@'&><8/%:%% '.>"?!R^%XGB#!V=]Q?9L., !>K9 Y(Y[
MGBJ4_@.2WN)+VQN6@\_EU,8E4L223\S8Z\]"1DX(!P.PHH YKPAX,_X1QYY/
M-:7[0RGYQ\PVECRV3N)W<G YYQS52?P');W$E[8W+0>?RZF,2J6)))^9L=>>
MA(R<$ X'844 <YXD\&KJTJ7L<C0W,0 21?F&,YP5/4<L.HSD[MPXI^E^'KF&
M19[F[>79G:JHL*'<"#N5<[^Q7.-I'O7044 %<9-X'NID-J]](;=B05,:F0H6
MR5,I.XDCC.,8XV[?EKLZ* .<N_ =M<VB:6=PBC(*D-\X;));)!&3N.>,<\ <
M8JP^$;QE$,U_(8@ #Y<21R''3][EFSD#)Y)&0>M=;10!S_B_P@OB)4.]HY86
MW1R+DE22,\9'H,'(((!!Z@LT[PS.LJ7%W=-,822BB-(D!960E@N=QP>.F.?4
MUT=% ')7G@B5+F2^LK@VYG WJ(E=21_%@D#)ZY()R6.?F(H\,_#]=!NI+U96
M<2(5Q(,OEF5BQ?(R20?X1UZ\<];10!S_ (;\*?V+-<W._?\ :I-^-NW;\SG&
M<G/WO0=*/$GA3^VIK:YW[/LLF_&W=N^9#C.1C[OH>M=!10!S7B?P9_:\L5[#
M*T-Q#P' W KR<%20.I/L02&!!&(?$/@N37K2.RGGS(DF\R^4!N^^ -@8 8#
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M.,[L\??]#T]ZZ"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\+VUW;Q%;^19)=Y(*  ;<# X5.<Y[?C0!L4444 %%%% !1110 4444 %%%%
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M%#$%AG&20!D9S@UCVNAWGAR]N+J"!;F.Y)8-O2)UW,6*Y8GCGG (;"G(((H
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M^X6(P1@A0  .:T-!^'%MJELES=EY9[B-7,C.VX;T&T#D@[1C&X')]L*.HO\
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M %%%% !1110 4444 %%%% !1110 4444 <YJ?A-Y)FO;2=H)I0HD^59$8*,
M[&Z,. "#P,\<DU%I_@QS.MY?3FY>(?N@8UC1#G);:I(+=,'MCN0I7J** "BB
MB@ HHHH **** .?\%>%/^$8A:VW^9ND+YV[>JJ,8RW]WUKH*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?\
M&OA3_A)X5MM_E[9 ^=N[HK#&,K_>]:Z"B@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S(- CAN7U#+-+(B
MI\S955&/E4=@2,G.><D8R<Z=% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV$3W#Y*Q(S$#KA02<9QSQ7)?V=K'E_:OM">;][[/Y2;.N?+\S.>G&<]>-_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@^V&-OX;:5+$;G4)T:)KN8L(W&&4 L<G.#R7(Y Z9Z$5VM% 'G_P4_X\Y/\
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M/52S2DJ<@<CIT'TJO\--033]+N)Y4:2-9GW*JAB5*1AOE) ( .6SQC->H44
M>.:O+;2RH^@>9]J9R7\D.J;21]X.  N[;QC8!G=QMKH]9_Y#UK_U[M_*>O0*
M* /.O&=Q_8VJ6NIS!A;B,QEP,@,?,&"!SP&!]2 =H)!%0^,]4CU6XTNY@;=&
M]PV#@C.)8@>" >H/:O2Z* //-79O"^J-JLB,UM<1*KNJY$9RB\XSQ\J^F=QV
MY*X-7Q;JZ>.3%IUB&=1*K22A&"(,,O(8+S@D\D9P ,D\>FT4 >?_ !'_ ./S
M3?\ KX_]GAH^-?\ QYQ_]?"_^@25Z!10 5YO9W@\%7UTUTK"WNW#K,%)0$[W
MV$+NY^8CU^4';M.1Z110!YO>7@\:WUJUJK&WM'+M,5(0D;'V -MY^4#U^8G;
MM&38UG_D/6O_ %[M_*>O0** "O/_ !VK:+>V^N;6>*)3'(%QE0=P#9SWWG'
M&0 6&X5Z!10!Y)\4/%<>N6R"V#/$LR[I2"JAMCXC 8 DXR21PHQ_>XV_B/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BJ^HWJV$3W#Y*Q(S$#KA02<9QSQ6?X
M7\41>)(C<0A@JN5(< '( /8MQ\U &Q1110 457348GD-N'4RJ,E P+@<<E<Y
M Y'YBK% !1110 445S]EXK^TW\NE;,>3&'W[LYR$.-N./O\ J>GO0!T%%%%
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M#=7:6BF65E1!C+.0JC)P,D\=: )J*9#,LRAT(*L 00<@@\@@CJ#3Z "BBB@
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M&!<#CDKG('(_,5GW/BB*WNX]+(;S94+ @#9@!CR<YS\A['M0!L4444 %%%%
M!1110 445RFL^-VM[K^S;2!IY@NYP'$:J, CYF!'0CG@<@ DG  .KHJ&TD:5
M%>1=CE067(;:2.5R.#@\9[U-0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ]W=@!CSBLSXC_\ 'YIO_7Q_[/#5OXNZ8]]8EHQGR9%D8<D[0&4D8!Z;LGH
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M>%*B0'O($8$ CD<C@XR."1UQ_P#A*]4N+3^THX84C6/<5D+EV Y:11E0%(Y
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M[@Z+\V#N(&.N #K?"?\ QYVW_7O#_P"@+6+X]\8S>'7MT@19//9@5(8L=I3
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MP@^;:L9P#RN6(SCK@9);G]%UG^VO.GU&]EMY(F(\J)_(P!DGY<$N<Y7&"XP
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M!W<$5I:YX@G2X73;-%:9HO,+RL1&JAMO(7YF)((P,8)!Y&<87Q'_ ./S3?\
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M-N[D\94#G(Z\#Y3G;A>%]+T34+>.278LH4"02S-&VX ;C@R 8)Y!'';@@@=
MMKI$=DHPHL[B;Y2QEQYG*YW-\R?<()R!C.3@G(!I:+/J1=#=I!Y;CYA$SAT.
MTD$[B5(R-I"D\D$$@&J5_P"+;B]NGT[3HT9H<>9+*28E.#\N$YSG ZYR&&W
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH HC0[<! (H\1$E!L7Y"3DE>/E.>>,<\T^^TF'4,>?&DFW./,16QG&<9!QG
MJW10!4MM)AM6\V.-%?:%W*BAMH  7(&<  8'3@>E/33HDD-P$42L,%PH#D<<
M%L9(X'Y"K%% !5&]T.WOVWS11NP& 716..N,D'CFKU% #(85A4(@ 50  !@
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MB@"O9:=%8+LA144G)"*%&>F< #GBA-.B20W 11*PP7"@.1QP6QDC@?D*L44
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MM][<-IP *Z7QF)='TN0+*[21[ ),[9,&50,LN,D*=I/\7)/6@#L**YK[6_\
M9/G[F\S[#NW9.[=Y.=V[KG/.>N:YF'QA+I6BQW>YFGD9D5W^<@F1^3N/.%4X
MZ\X!!&: /2ZX_4]?GAU:WL%;$$D)9EVKR0)><XR/NCH>U%KX/N[=1<?:Y6NA
MEB';-L6)R5,>,[<<9&"/O*!@*,3Q;'++K-LENRI(;<@,PW!0?.W-CN0,E0>"
M<9XS0!Z717G5^LOA.^M%6>::*Z8QLD\F_!)5=P.,<%@> #P1NPW'HM ''Z9K
M\\VK7%@S9@CA#*NU>"1%SG&3]X]3WK8T2YNYI9UNHU2)7Q"5()9<MR?F;G 7
MLO4\>G+Z-_R'KK_KW7^4%/\ !ES+J=QJ5O)+)M$I5"'.4!:4?)G.TC QCT'I
M0!TNB>*(M8EGMXPP:U?:Y8  G+#C!/'RGKCM1;7-VUW)$\:BT" HX(WEL+D$
M;CQRW\(Z#GU\\\%>&/MUS?1>?<)Y,V-T<NUG^>09<X.X\=>.2?6NCTG497UJ
MYMR[&)8%(0L2@.(>0N< \G\S0!W%%<)IT,GBJ6Y\RYEC%M</&D=LXC(5>-S'
M!+;L<9X!#8X. _X:P-,)9VN)9C'+)#EY=\3!2K"15YP2,?Q-WYYX .XJOJ-Z
MMA$]P^2L2,Q ZX4$G&<<\5Y_XEL/L<4KR:E)]K1"VT2K$I(&540J0067 X/)
M.[!SBK;W$GB31OM4SLL@BF8F([-_EB1<,.<JV,L!@$],#B@#K= UM-;@2\B#
M!)-V X ;Y6*G."1U'K5?1+F[FEG6ZC5(E?$)4@EERW)^9N<!>R]3QZ<O\+=
M_P!&@OO.F_Y:?NO,_<_>=?N8_'K][FCPCKSQ3:G+.[O';2,0I8MM56E)"@G
MX4<<#@4 >@45YYX7TNY\5Q?VC<W4J"0ML2V?RE559@<\')SP.IP!ECG O>"]
M9GANI]&NW\UX%5DDQ@E<+PQZDX93W.=V6/% ':T5Y5\.[&[\20N\]W,L2R8
MCDQ(6"@DF0@G;@CY<X)YXQST'PVU664W.GSNTK6DQ42.<LP)88.<G@H3R3UQ
MT H [6BN?\-Z1<V,US+<2;XYI,Q+O=MB[G.,, %X(X&1Q["MJ[C:5&2-MCE2
M%; ;:2.&P>#@\X[T 345Y9XL']D1-<PZC(]U$ZEHS,I4MN 8"$'Y0"<[3N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAO%> JQ"LR,R. >&5D!SQM+ XVDXY(-8/@6SDO[ZXUD1&&"9,(&&UFW;&W@
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MG[KS%7RM@^]MD._?UZ<;>G>JOC[_ ) UG_V[_P#HAJU?C7_QYQ_]?"_^@24
M6_$$E[X>LI[E[GS9!Y6P^3&FW,@#<#(.0>XXQQ1JWC.73[2T:,+)=WBQ!0_"
MDLJEF.-HZL!C*_>ST!%6OBE_R#I_^V?_ *-2N=\1:?(++3M3C4O]B2%V0=UV
MQL6SV V '@X!R> : .ET[3]2L6226=;@$J)(_+6/:&P&=7&,E.N"!N7/ ;%6
M-4TZ_O)&\JX2")<;-L0E=L@;MV\@#!'R[>H//2JEG\1[;4C'':AY9)&0,@1@
M45B SL<$ )GG!(S@9P<CC;^: W]PFN&38"3;@E_+"%L @1\Y*A>G&0V_YA0!
MUOP^\1SZD;BSN]K2VDFTNO ;)8=  ."IP<#(QD9!)PO!.JZIXGB=O/6-$?'F
M^4CN3@?)MX7: <DD9R0 2,X=\(E5)KX1JR()$VH^0RC=+A3DDY X/)YJW\%/
M^/.3_KX;_P! CH N^"M>N-6CN;&9Q]JMG9/-5!MYW!6QP"593QA01MSSFN7\
M%:5=W%S?)#=>6Z38D;R4?>=\GS8)PO()P/7VK;^''_'YJ7_7Q_[/-6?H6N1^
M%+^]2^W1_:)/,1BI92N]R#\N3R&],<$$@C% 'J%</-KUWX@NY;&Q=88;8@22
ME [EL$;0K8&-P(Z?PD[N0I[BO-+34E\$ZA<B[#"&];S$E"DKD%F*X7)X+E?7
M@$KAL@ Z"_CNK>SNX;IEDVV\A250$+!D?*L@X!4CJ."".X-<[X'L]0OK"/[-
M*MND8D"919#(2[$EB0=B@_*, G[Q(QM%=!?>)4URTO#"K>2EL^V5E95<E'W!
M=P&0N,$^I(QP"7?"W_D'0?\ ;3_T:] !X(\2R^(+$S#;]H3>F6&$+@94D*<X
M((W8QSG  Q65XFDU/0H#J)N4;8R%XA"H0!F VAN6(!('.TE><@UB>"//_L>Y
M^R;O.\YMNS[V-L6['OMSC'.?N\XK"OWTZXL#)&)'OR%,C-YA()<;W8YV;23@
M'D_,N?FR0 =[XZ\6SVEA!?VQ\MYVB)X5\!XV?;\RXZXYP.E5_$-WJNDV_P#:
MCS1@J4+VZQ H 2%QO)9B<D;N1U.UN!G-\??\@:S_ .W?_P!$-75?%+_D'3_]
ML_\ T:E $VO>*7@M[>XM54O>20HGFY"KYHW L%YZ<'!XSGG&#B:Y%J.DM &O
M=R3S+$2+:(,K.#M.WH1D<\@CL#TJ+Q$H?2[$,N]"UIO08+LNSE4R0=QZ#:0V
M,_P[JHV=Y::?-'=7JWV$)"/?*6C1B,Y&,G=\O& >><< @ WO%?BJ723!IL<D
M0N)8R7FG^1% 4@/@ J"S X'(!&"I!%9-YXQE\.M'.]Y%>1,VUXXUB6101D.N
MPG.,'.2!T'?*S>.[()=6^M>7]IMEC*R*JAU"X9@_<$88D' 4;1EAN!%JTU;2
M+]UAMH$F=F (CM?N@G&]BR* H)&3VSTH BUKQ+<WFHG2H)DMDC49=@KL[.%(
M4!Q@G+ !00?O')X [#1+>>V0QW,BRL&.UU382I /S*. 0<CCC !ZYKE_%VJ:
M7-,UKJ*%7C"%79'&X$$_*\?S%0200<#=G&2.&?"OS]DWF>;]FW+]G\_[VS!Z
M>VW9T^3.=O>@#;\>ZI)I5E+<P-MD39@X!QF10>"".A/:N?\ %_BFYT_3;:]B
M?;++Y.YMJG.Z)F;@@@9(SP*U?BE_R#I_^V?_ *-2N5\??\@:S_[=_P#T0U &
MEXAN]5TFW_M1YHP5*%[=8@4 )"XWDLQ.2-W(ZG:W SW>G7JW\27"9"RHK 'K
MA@",XSSS7.?%+_D'3_\ ;/\ ]&I6KX3_ ./.V_Z]X?\ T!: .:\;^*I[6[AT
MV"1+<2+O>:3:0!\PQAA@?=/^\2!E1G/0::L^D)+)>SK+&B[PXCV,  2X*ID$
M  $8Y))'I6;XTU33T9;34D.UD++(48K]X9573YPW )Q@8QD\@'G/!UB^H/=V
MUL95TV6&1(C("5#,<90,02 2_0YQC?\ -B@"73_%-QKH^TM?6]HC9VQ8C=\!
MF'S^800<8QC@CG"]]#0_&TFH6EV&*FXLHWS)'@QN0K[9%XQR5R1C!X(X.T87
MA>^L=%B^Q:K;K'/$6^:6#S-X+-A@P1L@?=SR" "I/('4/);W%A=S6L/DHT,H
MSY0BW@1DJX  )4AOE)]^!0!E>&;C5?$5J+D3I%C?L/E*S2$$CYNH4 C:-JYZ
MD@\$Z'A[Q?)JNERWI.)X(Y06V@ LB;E8#D=""> ,YXQBK7PM_P"0=!_VT_\
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MW:[59-Z);IA0[!3L+<MM)&-Q7(Y)!J7Q%XEGT7R=,$T1N95=FGG'E(J_-M.
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M89&+%IJVD7[K#;0),[, 1':_=!.-[%D4!02,GMGI0 WQ9XBO;;48;&S*D21
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HKS_ ,+_ !'DU>]-JRK]GD:5875&!)C^89+-C[G) &02O !K
MH/&NORZ-$C6Z*\LTR1('.%R^3SR/3'4=<D\8(!T%%%% !1110 4444 %%%%
M!117->+=<DL9;2U@W;[BX7=A0P,:8\P'.2.&!R!P 3D=P#I:**YK4]<D74;;
M3XMVPQR22X4%=I!"'/)&&7V'(&3G% '2T5CW-S=K=QQ)&IM"A+N2-X;#8 &X
M<<+_  GJ>?38H ***Y_QSXE/AVU:Y3;YA950."5))R0=I'\(8]1T_ @'044R
M$,% <@M@9(& 3W(!)P/;)^II] !17.>//%#>&[;[0@!D9U50PRN3DG."IQM4
M].^.U6_#NGW5HI-Y.)F8+@"-4"D9W %<;@<CD@=.G- &Q1110 4444 %%%%
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MLT<81X$+X 50P(! Y*]SD;1@8;- &AXLU61[VSTV!]K-)YLF"RDHF3MR."&
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M\P.-P.1:T73I]<U :Q/$T,4,92%7XD;EERR\D<,Q[=5QN&20#*\/PW>NWE[
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M1E36K:W#L(F@8E Q"$XFY*YP3P/R%8[6<M[K=S#"_E[H4#N/OA-L.=G8,3@
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MEM;O4'D1E62?*%E*AAOE.02.1R.GJ*/A%ITMA:.DR,C&=B ZE3C8@S@@<<4
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M7& O/3(R.5W9 QDC"U.T.H7=G-:V,D$4<Z[V, C)^="=RH#A5'1B<'+ ?=-
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MMJ1NN3M'TR<8S7H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\B-5&,*H.">%&2>> /4MTM% !1110 4444 %%%,FF6%2[D!5!)).  .223T
MH ?14-K=I=J)8F5T.<,A#*<'!P1QUJ:@ HHHH AN]^QO*V^9M.W?G;NQ\N<<
MXSUQSBL7P-X:/AVU6V?;YA9F<H25))P"-P'\(4=!T_$]!10 4444 %%5[;48
MKIF2-U9HSAPK!BIY&" >#P>OH:L4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !4-U=I:*9965$&,LY"J,G R3QUJ:L3Q?K5OI,!DNUWQLRKLV!]QZ@8;CC&
M>2.GK@4 5]/^(=AJ$BP1S NYPH*.N3V&64#)[<\G@<UJSZS%;S)9N2)90Q0;
M6P=H);YL;<@#D9ST]1GRWXF:I<ZE;127%IY"^8"KM*KM\R,=FW 9<XR<XY4
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M18(Y@7<X4%'7)[#+*!D]N>3P.:Z.O/\ 7/#.I:S!]AD%FL8V[=@E!7;TVY!
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M51DG 5Y0!D\]*]%H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q5X9C\1
MP&UD)'.Y6'\+ $ X[CD@CN#Q@X(V** ."U7X;7&KQ+!<7K.(R-N8@!P"#N ;
M+-TPQ.1\W7=D=O=VJW:-#(,I(I5ADC(88(R.>E344 <EX&\ +X6:1RXD:0*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4@E20>PE\/:])JTURI4"&"41H?XBRC]YGYCP#C:<#@^N< &]117/^-]?ET"
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MN[I;1&FD.$C4LQP3@*,DX'/2N:\,^,9]?8.EJRVS,X$K2+G"@X.S&3DX!P2
M<\G!JWX\\[['-Y&S_5R;_,W?ZO8V[;M_BZ8SQZUS_P +?MGV:#_4_9/WG]_S
MOO/_ ,!^]_X[[T >@45Q6JZSJUM$]Z(;=$12QC=V>4!?O$LI5#P"W!Z<<MQ1
MJ/CUTL[?5XD_=/(!*I4LRKN*L0P90,%2 6&"67.WH0#M:*P?%GB==%M&OHRK
MDA?+RWRL7(P1C[PQ\V!U /(ZBAKOC";3%@MEB$E]<(/W:L-JMMY)Y)VALXY
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M!'BE];66*X54N+>0I(J9V]3@CJ.H(X8],]"*VM5U--+B>ZE.$C4D],G'0#)
MR3P!GDD"@"W17#V6O:KJ\7VRWA@2-AE$F+F1@!U!&U<,?NYV\>V&-W3?'']I
M6EQ=JGESVRR[HG.2&121D?*<'&.0IR&';- '5T5PGA'Q/J7B().(X4@# .S>
M8"XW'<8P">@XYR-V>>H7NZ "BN2_X2"]U>25+!(ECMY6C9[AF.YEQG:L?0#U
M).01C!R!4T;Q1?7$%S=SB "V2<%$$F\2Q#.ULDJ5Q_=8]1SUP =Q17">$?$^
MI>(@DXCA2 , [-Y@+C<=QC )Z#CG(W9YZA;=_P"+;B]NGT[3HT9H<>9+*28E
M.#\N$YSG ZYR&&W +  ["BN/L/%MQ972:=J,:*TV?+EB)$3' ^7#\YSD=<Y*
MC;@AC8T_Q1+<:G/I9"^5%$&! ._)$9Y.<8^<]AVH ZBBN7U#Q1+;ZG!I8"^5
M+$6)(._($AX.<8^0=CWK/N_&ET-0FTJ")7VHNPX88+*A+2-N^XNX]!DG:HY.
M: .XHKC-/\675E=KI^HI&OG#]U)#N$9('*Y<\D],<$-@8(8&NSH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)',0>/ Y"%NV[80PR!\RDAL #I=?DGC@D-JNZ?;A!E1R>-V6X^7.[!ZXQWH
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M8)1%4XZXR ..*FN=.BNF5Y$5FC.4+*&*G@Y!(X/ Z>@H H^+/^/.Y_Z]YO\
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M)+;QV\AO,>1@!\@GJ0!PH)SDC!'(//&,UYKJ\\7A1D?1[DR-+*<VX83(0<=
MO0\!>3O8'AN#GUJ:%9E*. 58$$$9!!X((/4&JEEH=O8-OABC1B,$HBJ<=<9
M''% ' >,M8CT?6;:ZFR(U@P2!G&XRKG'H,Y..<= 3Q3OB3JL7B(0:5:.LDLD
MRME#O10 RY9ESZY.,X4$G'&=/5M.E?6K:X",8E@8%PI* XFX+8P#R/S%=59:
M';V#;X8HT8C!*(JG'7&0!QQ0!YQXDTNVAU9GU%<V]U&OEMEE4,H1?F8%<8VG
M/) #*3@<C:T[0M%CGB2#8TY;='Y<LDG,?SY.'8#&,_-U[9KM;JT2[4Q2JKH<
M95P&4X.1D'CK45CI,.GY\B-(]V,^6BKG&<9P!G&30!P7AW4(_#6HWEO=L$^T
MN)(W;B,C+MC<V.?FQZ;E89SC/0:QXC@U6VO88&#^3;,692"GSQO@!AU(V\XX
M&<9SD#=OM)AU#'GQI)MSCS$5L9QG&0<9P*?%IT44?V=4418(V!0$PV<C;C&#
MDY]: /,K?7)]%T.">VX;S&#-MW;5,DG/.0,D!<D$<XZD5B>.4@2VB,=[+<R.
MRDJ\N]0-ARVS&4.2  QR 2.<''M$6G111_9U11%@C8% 3#9R-N,8.3GUJH/#
M%H%*""+:2"1Y28)&0#C'49./J?6@#DOB/_Q^:;_U\?\ L\->@57N=.BNF5Y$
M5FC.4+*&*G@Y!(X/ Z>@JQ0!Y>-=BT?79WG.U9(T0,?N@E(B"3V'RXSVSS@9
M(L>(M0C\2ZC9V]HP?[,YDD=>8P,HV-RYY^7'IN91G.<7=/TEWUFZEDC8P26X
M7<R'RVRL(*Y(P>AR/8UV%CI,.GY\B-(]V,^6BKG&<9P!G&30!Y;%HUG!J-U;
MZH /-<R0NS.D>&+,1N!7GD#GC<K '.,]5X=T?28;D?8MIGC0N"DCR *?D/.Y
MDS\V,'GG..]=7>Z=%?KLF174'(#J&&>F<$'GFBRTZ*P79"BHI.2$4*,],X '
M/% '#_#C_C\U+_KX_P#9YJT/&>GZ;JD@M[UUCG$>Y7+>6P7=C[S#8>0?E.2.
M2 .3746VG16K,\:*K2'+E5"ECR<D@<GD]?4TR^TF'4,>?&DFW./,16QG&<9!
MQG H \]\/7T^J27ND1S&XMQ!(L<L@)PS\ &0#D?,PSSD+E,+Q5WX;>*+>SM!
M93NL4MNSJRS$1G)=FXW$9QG!'4$<CH3W5K:):*(HE5$&<*@"J,G)P!QUJO>Z
M';W[;YHHW8# +HK''7&2#QS0!Q7@N4:UJ=UJL.?(*+&"P(W'"<CCI\F3G! 9
M<CGA_P %/^/.3_KX;_T".N]AA6%0B !5   &  .  !T J*RTZ*P79"BHI.2$
M4*,],X '/% '#_#C_C\U+_KX_P#9YJZ#Q]ICZG8S01#+E00.23L8.0  220N
M .YQ6Q;:=%:LSQHJM(<N54*6/)R2!R>3U]35B@#C/"/CBS%E%OE5##$JLKD!
M\QJ <+G+ XR,9STZY Y_PU"UQ:ZIJ0!$5T)B@88; 60D^F/GQP3R&':O0[KP
M];7;&66&)W.,L\:,QP,#)(STJ[-"LRE' *L""",@@\$$'J#0!R_PM_Y!T'_;
M3_T:]=74-K:):*(HE5$&<*@"J,G)P!QUJ:@#R3^V!ID]TINVLW:ZD)C,#3*R
M\;9 &!VEN22#AAC "@5T&G"U32[E;67SB89GD<D[R[(P+,K<KG;P#U SDG))
MHFL3^'$-M=6LSRF21VDMHUD20NY.\E2N">F",A0O3( /"?A]KR[N-6EB\J*X
M5D6&11N(.W<[+T&XKD@YR23TP6 -#X6_\@Z#_MI_Z->L+P[J$?AK4;RWNV"?
M:7$D;MQ&1EVQN;'/S8]-RL,YQGT*UM$M%$42JB#.%0!5&3DX XZTV]TZ*_79
M,BNH.0'4,,],X(//- 'G_B+4(_$NHV=O:,'^S.9)'7F,#*-C<N>?EQZ;F49S
MG#UNTT?7)I;EEC2>W78SD!3Q&.3T',;=<=/<9[VRTZ*P79"BHI.2$4*,],X
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MTK;G.23RV!G&<#VQ0!;HHHH ***R?%.N_P!@VSWNW?Y>WY=VW.Y@O7!]<]*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,L%+ 8Y#,<#A0.,8(!PP+"N?\5275Q>:?-=*L>ZX 2)2'*A7BRS.."6)Z#@
M#N30!JZS_P AZU_Z]V_E/1\1_P#C\TW_ *^/_9X:N^+M!N!=V^K6:"62(%'1
MG"Y4AN03CGYF!.3SM^4C-96L:-J6M7=I>2Q*D4,JGRUD5F0!U+,S<;BV,C;G
M  & <Y -CQK%I^]7U&5MNT 0[WVYRV)/+C^;/5=W3''7%<_\-[V./4+BULW9
MK,Q^8JG.-V8P2-P!&-Q7U( R3@&M/5O#]UIVI'5K:);A94P5+*C(0JKD,QZG
M'4 \%E('!+O#&BWBZE-J5U&J+-#@;75@#^[PO7)("X8X )!QP10!BZ]X6MI=
M9AMF3]W<1O)(-S?,Q\TDYSD<J. 0/:I?&4BZ=+;Z%"LRVWEN[):DM*X??\HW
M9) ()8$D$$\?**V_%N@70O8-7M%65HEV-&6"'!WY(8D#D.1['!PPR S7-!N]
M1:#5X$6&\@#AHG<.&7YL+N'RY()]/O\ + J* .7O$_LQH[G2;.[AF1OF$D3F
M-T(Y5@6<GD#&,=SU"D>P5S5IJNHW;JAM4A0,"[23"3*Y^95$8SNQR"?EXYZB
MNEH \JU[PM;2ZS#;,G[NXC>20;F^9CYI)SG(Y4< @>U6OBMI<>E:=%;0+MC2
MX&!DG&5D)Y))ZD]ZUO%N@70O8-7M%65HEV-&6"'!WY(8D#D.1['!PPR!#X\T
MF[\26,:+#MG\X,T?F(=H =<[\J#G(/'K[4 9OC+3FU'6;:!9&B+0??C.' !E
M) /8D C/;/0]*J>+?#2>';JU73V: W9:)BK,V S(N?F.<_/GKU"D8(S74:GH
M$\VK6]^JY@CA*LVY>"1+QC.3]X=!WH\:Z!/J5S8S0KN2";=(=RC WQG."03P
MIZ9H Y_7=%7PM?V4MJSAKF39*6<L7&] Q;/4MN)/;(! !&:M_$;66DNH=+_?
M>4\;/(+7!E<,'4*!CD#:2PS@@G(X%:OC70)]2N;&:%=R03;I#N48&^,YP2">
M%/3-/\8>&9[F:+5+(J+FW###YPZX/R^@/)';.[.X8% '&7B?V8T=SI-G=PS(
MWS"2)S&Z$<JP+.3R!C&.YZA2/8*YJTU74;MU0VJ0H&!=I)A)E<_,JB,9W8Y!
M/R\<]172T >5:]X6MI=9AMF3]W<1O)(-S?,Q\TDYSD<J. 0/:K#Z0FIW_P#8
M*EH[*TBW&)78B0LRR'))SC+CJ3C:=NTMD;NIZ!/-JUO?JN8(X2K-N7@D2\8S
MD_>'0=Z9KOAVYL[P:Q8!79D"RQ,=I<9 X8\ X _NXV@_-D@@&+XMTA/ QBU&
MQ+(IE59(@[%'&&;DL6YP".0<9!&".9?BQ;-=7%A$C%&>5U#CJI9H@&&".1UZ
MCZU;U/1KWQ=)''=Q+;VL3JS(9!([D9Z,F,#''5<;B?F( %WQKH$^I7-C-"NY
M()MTAW*,#?&<X)!/"GIF@#8\.^$[?P\I6W4@N%#$L6+;<X)R< \GH .>E87Q
M:TN.YLGN77,D&W8<D8WR(&X!P<CU!]J[6L?Q=H;:Y:R6:,%9P,$],JP8 X['
M&,\XZX/2@#E]/\+6VGZ:][$FV673VW-N8YW1!FX)(&2,\"J7@?P/#KMA')=%
MGR)!& Q41#>P)4#@L6Y)8'^$8P.=72XK^:R?39[8(5M'C1Q*AW,%V(NT$X)'
M4DXR.V<#8\!:7)I5E%;3KMD3?D9!QF1B.02.A'>@#C_"WBR6TT:6XZO;L8T.
M>0&V!2=VX'87X&,8 7WK,L;"UO81)<VM]/-*BDS;&;DH!E3N *CJNX'C&<CB
MNC\'>")%TZ?3;Q=C32,1R&Q\J;6^1N<,N<9&<<\&K&CW&J:)$MF]LMP(@%61
M)TC!4 8&&&<KTS@9QW^\0#0^'5Y=7-KB]5A)&Y4&165V4*I!.[J>2,]\<Y.2
M6?%+_D'3_P#;/_T:E=!I?G>6OVG9YO.[RMVSJ<8W<],9SWS7/_%+_D'3_P#;
M/_T:E &/IWPYAUJRBDG=FG>"/9)D_NUV@H@0';M4=<\L2QR">,IM>DUG0IFF
M)+Q.D98G);$D; G@<X8#N3C).36GI-[JMM8QPPPI(6A0QRK(J[58#:K(^W+*
M._W>F=Q!SI6GP^$&F/I6X>9("S,"0IDR&7J#\HVJIP!D#. 30!8_Y@W_ '#_
M /VA7*_\RY_G_GZK0^SZK<V/]F"!(RL.PR-*K;E4;=BJ-V&8<9)V]3\I(Q+_
M ,(M<_V+_9NS_2/[FY?^>^_[V=OW>>OZT ,T[X<PZU9123NS3O!'LDR?W:[0
M40(#MVJ.N>6)8Y!/&4VO2:SH4S3$EXG2,L3DMB2-@3P.<,!W)QDG)K8M&UC2
M[1;)($>01@)*LB#8.@5D; 9E'&02O3.[!R^Y\"R6.DOIL(#SN59L' +;T)P7
M(& JX[9QG )Q0!C^/O\ D#6?_;O_ .B&K8\;W$FJWMOHBNT44J,\A0X+##_)
M],(1R2#NR5.T99XO\+7.H:;;642;I8O)W+N48VQ,K<D@'!..#6AXU\.3S2PZ
MI8[3<V_R[6Z.ISQR0!C<V>A(8X8$+0!H:7X*@T:19K3=$.1(@9G608.W.\G!
M4\@CMD=&XU=4TN/58VMIUW1OC(R1G!!'((/4#O6/IU]J%]*AEA6WA0DN#*LK
MOE6"A=HP &P3G!/&#U!Z.@#RKX2>%K;4(3>RINEBN/E;<PQM5&7@$ X)SR*N
MV=F/&M]=+=,QM[1PBPAB$)&]-Y*[>?E)]?F W;1@V/!NDWWA5FL?)66W>8$3
M"14(# !F*$DG  ^7 Y! + @U8FT&[\/W<M]8HLT-R09(BX1PV"=P9LC&XD]?
MXB-O 8 &?>68\%7UJMJS"WNW*-"6)0$[$W@MNY^8'U^4C=M.!Z17#PZ#=^(+
MN*^OD6&&V),<0<.Y; .XLN!C< >O\(&WDL>XH \O\(:''XX:;5;[<^9#&D98
MA44 ,!E=I. V.PZL02W#_!NG-IVLW,#2-*5@^_(<N03$0">Y (&>^.@Z5=TO
M2;[PE++#:0K/:2,70"18V0GC&7))P !WS@$$'<*E\,>'+RUU*:^NMK++#C>F
MT+N/EG:%SNPN"H)&2!D\F@"+X<?\?FI?]?'_ +/-6/I-MI^KV[7&JRG[6#*'
M\V5DD3!.%2/C@=0H5AN)&/X1TO@_1I='N+^ZN $BEEWJQ9<%0TC%C@G  (/.
M*PO#WAB[DMHMD5G)'M)C:ZC8R[&9G7.W<!G=G )QG!YS0!2$_P#PC>CK=P(8
MI[PJC,&8' +E7 8M@L@ZKM^]N7&!3+O2K;RV,5I?_:N66=T;?YF=RL2&QUZD
M+G'/WN:W3.WQ MI]/E0175JZY.[<F\;AG@]#AE(^8 $$%C6G:ZKJL2B![5'D
M&5\[SE6,G.!(8P-V.Y P3S@+T !S7BN>]U*QM7N4E$99_M2QIM?:C?*Q4]/E
M4MR F[!./EKHO D>FNQFTYBK,F'B+MG^$Y9')Y7. R_+\S#)[:NJWE]:+"\,
M4<S8Q,@?9SM&"C.<!0V<Y!.,<=2,+2_#EUJ&H+K%S&EN(U*B-6#NQV%=S,O!
M^\>>N%"[<?-0!S^F>#+2;5KBP:/,$<(95WOP2(N<[LG[QZGO7JMI:K:(L,8P
MD:A5&2<!1@#)YZ5Q6I:+>:7J+:K:QK.D\>UD+K&RX"CJQQR5!S@]P0.">UM)
M&E17D78Y4%ER&VDCE<C@X/&>] 'FOQ*T"![ZS<KS=3!9?F;Y@#$@'7C@XXQ^
M='Q0T"#1+!(;9=B&Z5B-S-R8W&<L2>@%=!\0?#D^I&WO+3:TMI)N"-P&R5/4
MD#@J,C(R,X.0 <_QKIM[XGLUC^S^7*MP#L\V-OE",-V[*CJV,=>] %3QWX-C
MT^T?4=SM>1M&QFW$,S%POW0<*!GY0N"N%&>#GH]2N8=2L8;B]E,,<B1NX1S&
M'W1DM%W9E8$_*/F...:L>/=+DU6REMH%W2/LP,@9Q(I/)('0'O7.>)?!EQ>V
MMDT:JTUFB!H9,%6^5 P)R%(!7D9P03@] 0#G?MME8W]H^D.P\R01RJ/,VE6=
M1C]X,G<">Y P" ",G5^)6@0/?6;E>;J8++\S?, 8D Z\<''&/SJWK.FZAKUS
M:7,ENL4=O,"0)4=@-Z%F)R!C X !.0<]5K5^(/AR?4C;WEIM:6TDW!&X#9*G
MJ2!P5&1D9&<'( (!T&B:!!HB&&V78A8L1N9N2 ,Y8D] *X_XU_\ 'G'_ -?"
M_P#H$E=AHE[/=H7N8?)<,0%\Q9,C ^;*\=<C'M[US_Q0T"?6[9(;9=[B96(W
M*O 1QG+$#J10!C_%BV:ZN+")&*,\KJ''52S1 ,,$<CKU'UJIX\\/1>$U@U.U
MW>>DZAF=V;S,JS,7YZMMYV[00S CICH_&N@3ZE<V,T*[D@FW2'<HP-\9S@D$
M\*>F:/BAH$^MVR0VR[W$RL1N5> CC.6('4B@#$^->EQ^3'>[?WOF+'NR?N[9
M&QC..O.<9]Z/%FEIX<,&GZ?N@:_F57D1W+ (0 !N.>LF>"O3!R#6W\4- GUN
MV2&V7>XF5B-RKP$<9RQ ZD5;\;^%GUM8I;=E2XMY \;/G;U&0>HZ@'E3TQT)
MH Q->^'%MI=L]S:%XI[>-G$BNVX[$.X'D ;AG.T#!]LJ<3QOK+:SH]M=2??:
M90W3DHLJ%N  ,D9QCC.*Z#4Y]5UJ$V7V9(#*NUY6F5EP5.X!5W$;N@^]@'U^
M81>,?!$C:=!IMFN]H9%)Y"Y^5]S?.W&6;.,G&>.!0!T'AKP5!H1\Y=SW#*1)
M*[,6<L0S$@D@9(^OJ2<D\%\+O"$6MV[R7)9XA*0L6]E0,%4F3Y2,M@X'H,]<
MC'KM<?\ "_0)]$MGAN5V.9F8#<K<%$&<J2.H- '+^"O#@U.:YTZ:21K2SE95
MAW$!MSL 6*D<#9NP,#<<C'(;8^%C-;27FG[F:*VFVQAL$@%I ><#KM!(Z9R0
M!DUH>"M GTVYOIIEVI/-NC.Y3D;Y#G )(X8=<54T#PE.KZDDPV)>,PC;*MPQ
ME^; ;/ 8'!Q0!SOB6WT=8I4,S2W80E92\DC,P&4!8 QD=%]AQD$9KL/",0\2
MZ9&EYF02 ALD@G9(=N2I!R-HYSD]\Y-<_IFD:EIUG+I"VT?S"4><)5 8,#R5
M^\6(^52=N/EW !376^ M+DTJRBMIUVR)OR,@XS(Q'()'0CO0!Q7PD\+6VH0F
M]E3=+%<?*VYAC:J,O (!P3GD5:\'7W]GS:O<XW>5(SXSC.UICC.#C./2K?@W
M2;[PJS6/DK+;O,")A(J$!@ S%"23@ ?+@<@@%@0:M^%?"TD$VH?:4Q%=R';\
MP^96:7/W3D<,.N#S0!F>#?"$7B: :EJ!:>68MC<[*$"NPV@*1P3DXZ#@ #DF
MWX(N)-*O;C1&=I8HD5XRYR5&$^3Z8<#@@#;D*-QP:%::EX50V20K=0J28V65
M8B 6)((8<D]>^,D;CVT/!_AF>VFEU2]*FYN HPF<(N!\OH3P!WQMSN.30!Q_
MPN\(1:W;O)<EGB$I"Q;V5 P529/E(RV#@>@SUR,=!\+IFMVO--!)BM9R$+'+
M8+."/3'R9X Y+'O5WX7Z!/HEL\-RNQS,S ;E;@H@SE21U!H\%:!/IMS?33+M
M2>;=&=RG(WR'. 21PPZXH ["BN?\%?;?);^T?];YAQ_J_N[5Q_J^.N??]*Z"
M@#R3X7_;_LS_ &/[/Y?G-GS_ #-V[8F<;.,8Q[YS78>(?#DVM68$VP7L67C:
M'< &5L@*S%2-P !R< _-_"*Y_P %6VH^&(6MOL?F;I"^?M$2]548Q\W]WUK;
MUF6_UFW^S"#R&FDV2$R1RA82 &?[RY)R1@ G /()4T 86C:J_P 1)8DE4+!:
MA9)5 4AY<L%7YB3L*Y.,?WE)/RM6[XUBT_>KZC*VW: (=[[<Y;$GEQ_-GJN[
MICCKBJFH^#GT.2WO=,3<\2B*2/*1B1,'+LWR@MGJ2#D[3CY<%NK>'[K3M2.K
M6T2W"RI@J65&0A57(9CU..H!X+*0."0#,^&][''J%Q:V;LUF8_,53G&[,8)&
MX C&XKZD 9)P#5?PMX:37+Z_$S-Y*3MNB5F57)DDVEMI&0N,@>I!SP0=WPQH
MMXNI3:E=1JBS0X&UU8 _N\+UR2 N&. "0<<$5;\%:!/IMS?33+M2>;=&=RG(
MWR'. 21PPZXH Y?2O#@&I7&C1R2)9J!*T:L?FRJ IN!!"GS,'N5 !R0&&GX,
MM_[&U2ZTR$L+<1B0(3D!CY9R">> Q'J0!N)(!K5TS0)X=6N+]EQ!)"%5MR\D
M"+C&<C[IZCM1IF@3PZM<7[+B"2$*K;EY($7&,Y'W3U':@#GVTG^U=;N8&=EC
M,*>8%X+KMAS'NZ@$XW$<D KQG-2W>FKX)U"V-H6$-ZWEO$6)7(*J&RV3P7#>
MO! ;#8%>4W*:W</:!69(E+(YV[T"190-@X8G&#P 1R<9!V(-%O/$%['>7T:P
MP6OS1QAU=BQQSN0]B ><#@*%.6- $6C?\AZZ_P"O=?Y05S6FZC'XE:2\OH+N
MX_>.$2$%X8U(4@ J4.X 8/8C!(SS7:Z9H$\.K7%^RX@DA"JVY>2!%QC.1]T]
M1VJEIFC7OA&22.TB6XM979E02"-T)QU9\Y&..K9V@_*200"CX4EN[9KJTM8I
MH[?R9'MQ<)AEDP,*&;Y<%B3@D],GG<3B^%+;3VS#J'FQ7^XL9)F>,ACEE96R
M "  V7&2QXW# KTK3;B^N4EDECBB8K^Y0N7(8 C]XR\$$X(V\X)!YKE]?MM2
M\3P"QDM8XBQ4M*\RLH*C)*JNYE)/'\6 2#UR #T.O/-75O%&J-I4CLMM;Q*S
MHK8$ARC<XQQ\R^N-IVX+9'<:38_V?#';9W>5&B9QC.U0,XR<9QZUR^N^';FS
MO!K%@%=F0++$QVEQD#ACP#@#^[C:#\V2" 8OBW2$\#&+4;$LBF55DB#L4<89
MN2Q;G (Y!QD$8(Y9\2M @>^LW*\W4P67YF^8 Q(!UXX..,?G6GJ>C7OBZ2..
M[B6WM8G5F0R"1W(ST9,8&..JXW$_,0 +OC70)]2N;&:%=R03;I#N48&^,YP2
M">%/3- '0:)H$&B(8;9=B%BQ&YFY( SEB3T KA/%MFU[K-M"CM&6MR-Z8W ?
MOMV,]"1D _PDY'(KTNN"\6>';VYU&&^LPH$<0&^0C8#F3*E>6P0V.!WX(Z@
MS/%^AQ^!VAU6QW)B01O&&)5U(+$9;<1D+CN.C  KR>.-)_M?5[>UWL@DM\,R
M?>V_O2P'^\ 5[CGD$<'0U32;[Q;+%#=PK!:1L'<&19&<CC&4((R"1VQDDDG:
M*T-3T">;5K>_5<P1PE6;<O!(EXQG)^\.@[T 4O&NSP78-'8J8_.E"Y#L2I9<
MLP+;CDJF.",9R#D58_X55;>7]Y_M7WOM&]M_F9W;]N['7\<?Q;OFK7\:^&1X
MCMFM@0'!#(3G 8>N.Q!([XSG!(%9']HZQY?V7[.GF_=^T>:FSKCS/+QGISC'
M7G9_!0!7\':T=>TQOM4S1>6_EM,) C_*593O(X)W!3G);N<FN,\3WNG:>(KK
M2'9+B.3MYN-I!R3Y@QUP,9P02"".G5ZA\,W73%L(F4SI)YK=0KMM*E02>."
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&US.VV-,9."<9( X )ZD=JXKX9_NKG48%XC2X^51PJ_/(.%Z#A0..P'I7H%
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M#A#AN"I&>G# '!['&#@^AKSW0A=WVH7L]N+=I(YMNZX5MR@%T4(4''RKAO7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0\!P-P*\G!4D#J3[$$A@01CI:* ./L? <D5Y'JD]RTLD:L"&C"@Y5E&W#84
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MUJ:B@#S?XL62W]Q86[Y"RRNI(ZX9H@<9SSS6G>?#R34VC2[NGEMXFR(R@5B
M, -(I!8XX+$9/.-I.:Z74M @U)XIIEW/ VZ,[F&#D'. 0#RHZYK0H Y_Q)X4
M_MJ:VN=^S[+)OQMW;OF0XSD8^[Z'K6U=VJW:-#(,I(I5ADC(88(R.>E344 <
M99>!KG25\BSO6CA!RJ/"DI&>OS$C@G)P !SZY)U;OPU(UNEK#<RI)$X82LV]
MSR3A^F]><8/' SD#!WJ* .2M_ KW$\=Y?7#7#0$&,!%B0$'.2JDY.<'C'0 [
MAP'7OA2\D:7R;YTCE9CM:-9&7<.0KE@5 _A QM[<\GJZ* ,GPUX:B\.Q?9H-
MVTL6)<Y8DX&3@ = !P!T]<DU?&OA3_A)X5MM_E[9 ^=N[HK#&,K_ 'O6N@HH
M AN[5;M&AD&4D4JPR1D,,$9'/2N2LO USI*^19WK1P@Y5'A24C/7YB1P3DX
M Y]<D]G10!DMH/\ HCZ?YCMOCD3S)3O?Y\\D\9QGCIP *I6'@N.*P&D3,73#
M L!L/+EP0,G!!(]0<<C'%='10!Q]KX,N[11;)?.+=<@+Y2>8$S]T2DY! X#
M<<8   JWXD\$+K,44?F.LMMCRYB2SY&,D\KDG:#G@AAD'J#TM% '%3_#^>]F
M@N[F[:1[>0, 8E5<!E; 56 !)!RW.1@8^7G7US0KB\E6XMKEH"$VLNP2(><@
M[6( ;L3R<8''.=ZB@#E]&\!QVC2SW#M/-<HR2.WR@JW50JGY1C ZG&!MVCBJ
MEEX&N=)7R+.]:.$'*H\*2D9Z_,2."<G  '/KDGLZ* ,>;P^QM38I/*&P<3%\
MR@[MP)88R.V./EXR.M8ESX EU9E&H733Q(<A%C6$$\=2I.1C([$9.&'.>SHH
M Y+6;J:]U"WMK9V5;<,]P5P4VOC:C#/WFVG (R P=<X..MJ&.T2)FE55#R8W
M,  S;1@9/4X'3/2IJ .?LO"GV:_EU7?GSHPFS;C& @SNSS]ST'7VHO?"GVF_
MBU7?CR8RFS;G.0XSNSQ]_P!#T]ZZ"B@#G[+PI]FOY=5WY\Z,)LVXQ@(,[L\_
M<]!U]J/#?A3^Q9KFYW[_ +5)OQMV[?F<XSDY^]Z#I7044 <_X*\*?\(Q"UMO
M\S=(7SMV]548QEO[OK5?3-!7PLUYJ+N768M*5"8*A=[D EN3\V.W3WXZBB@#
MS_PKX*6[M8IDNKA%D7=LMYBL2EB244'>?E)P<L22"3SQ5?PK)=^((Y[7[2P^
MRSH(;A%!W[-P(;!Q(I #8))RP+%A@5T=U\-]/NF,C0*"<?<9T7@8X5& 'X#W
MZUNZ?I\>G1K;PJ%C08 '^>2>I)Y)Y/- '-6_@5[B>.\OKAKAH"#& BQ("#G)
M52<G.#QCH =PX'6T44 <EXR^'D?B:6.=G*%!M; R67.0 2<*1EN<'KSG&*M>
M,_!X\2*@$ABDC+8< M\KKM=<!EX;C/L,=":Z.B@#,FT-3:'3D8A?(,08\D#9
ML!(&,GOV_"J^@^&%TVS&F2'S$VR*QP4R)&8D8!)'#8Z^];=% '*>&?!T^@,$
M2Z9K96<B)HUSA@<#?G(P<$X !.>!DU;\%>%/^$8A:VW^9ND+YV[>JJ,8RW]W
MUKH** .?\-^%/[%FN;G?O^U2;\;=NWYG.,Y.?O>@Z5T%%% ''Z1X#DT24M:7
M+);M(K&$QAQ@8RH=FR,CC(&<8R21FM#PWX4_L6:YN=^_[5)OQMV[?F<XSDY^
M]Z#I7044 <_9>%/LU_+JN_/G1A-FW&,!!G=GG[GH.OM5*X\"O;SR7EC<-;M.
M29 465"2<Y"L1@YR><]2!M'!ZVB@#)T+1Y+#<\\[SR2;<E@%0;<@;8QPN01N
MY.2,U;U335U*-H'+ -CE&*L"I#*P(Z%2 1[CG(JW10!QE[X#GU)?LUQ>2/;
M_<$:*Y"_=#2<[B."25.2,X!P1JZSX2CO;,Z7#B*,A0,+NQM<-TR,DXY).23D
MY-;U% ''VGA._M$6&._PD:A5'V6,X"C &2V>E;&J^&8]:MUM+LF0J 2X^0[P
MI7> . >2<'*^QK8HH Y*+PC>1CR1?R>3D\&)#+M).1YQ);=@\-CCJ , 54\1
MV\EH+72+!Y!,9?,9PV]@@),DDF2,AG;.#\K$%1V%=Q4/V1-_G[5\S;MW8&[;
MG.W=UQGG'3- $U<IK/@AKBZ_M*TG:"8KM<A!(K#  ^5B!T XY' ( (R>KHH
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M& &.4;'/ [X^4';NYJ[HFASVCF>YN7F<J5 VK'&!D'/EKQNSGYL]#C'%;=%
M'/\ AOPI_8LUS<[]_P!JDWXV[=OS.<9R<_>]!THLO"GV:_EU7?GSHPFS;C&
M@SNSS]ST'7VKH** ./G\!R6]Q)>V-RT'G\NIC$JEB22?F;'7GH2,G! .!H1^
M#DDMY;.X=Y?M#;Y'8@-NPHRH PH!0%5Y QCD<5T%% ''VO@R[M%%LE\XMUR
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9M.W?G;NQ\N<<XSUQSBO*O!7V_[3??9_L_F>=^]\SS-N[?)]S;SC.>O.,>]
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MMXUGK-M+&C2.+<A47 )+><HY/ &3ECV&3VK63Q3>:5=PVFH+#Y=SE4>#?PW
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M9RDBAE.",AAD'!YZ5E:W<7V\16<<6W:&,L[G;G)!0(GS9Z'=TQD=: -NN?\
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MC3CWW'CD9.,#()P.:ZVO//B9XCM;^U^QPLLTTKH(Q$5D((89/RYP2,J.YS@
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M FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC+>W5]+]H*N/)601J3C:B^4!\P;@L5 &"<\AC74>$9;>/14-YCR,.'R">LS
M<*"<Y(P1R#SQC-=:?#UL6,ODQ;VW;F\M-QW@ALG&3N!.?7)S5B+3HHH_LZHH
MBP1L"@)ALY&W&,')SZT >5:O/%X49'T>Y,C2RG-N&$R$''0+T/ 7D[V!X;@Y
MVOBC*+6XL+I\B**<EVP2!\T;=@><*2!U.#BNULM#M[!M\,4:,1@E$53CKC(
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M\\F/;@' FD+\XQ\@<OGGD8R.^,&O2*S[7P];6C"6*&)'&<,D:*PR,'! STH
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MI707&DPW*+!)&C1IC:K(I48&!A2,# X'M4MU:)=J8I55T.,JX#*<'(R#QUH
M\P\??\@:S_[=_P#T0U:7C24:+J=KJLV?("-&2H)VG#\GCI\^1C)(5L#CGN+C
M28;E%@DC1HTQM5D4J,# PI&!@<#VJ6ZM$NU,4JJZ'&5<!E.#D9!XZT 9J>+K
M666.UCE6228L (V5\;5+$D@\#C [DG@8!(\\T76?[:\Z?4;V6WDB8CRHG\C
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M/)Z^IH X?1O^0]=?]>Z_R@K*U6'3;9'U73KGR)@I*I&^ Q#YVF%ANPQ &.$
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M>'K:[8RRPQ.YQEGC1F.!@9)&>E6+W3HK]=DR*Z@Y =0PSTS@@\\T <Y\4O\
MD'3_ /;/_P!&I6KX3_X\[;_KWA_] 6M"ZM$NU,4JJZ'&5<!E.#D9!XZT^&%8
M5"( %4   8  X  '0"@!]%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7!]<]*MZ3??VA#'<XV^;&CXSG&Y0<9P,XSZ4 6Z*Q_"]M=V\16_D627>2"@
M&W P.%3G.>WXUL4 %%%% !1110 4444 %%%% !117#^/M1EM;O3TC=E62?#A
M6*AAOB&" >1R>OJ: .XHHKG[WQ7]FOXM*V9\Z,OOW8Q@.<;<<_<]1U]J .@H
MKA_B[J,MA:(\+LC&=02C%3C8YQD$<<5W% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%<_9>*_M-_+I6S'DQA]^[.<A#C;CC[_J>GO704 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?XOU;^TM0;3YDN'MX(U)BM?F+L2CY<#!VX('7((!4@DUZA7&:[X=N;.\&L6
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M^IZ5RO\ S+G^?^?JNM$UYJUI<07%N(I6@95Q*C!V9&!P ?E&<=2>O7C-8_\
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MR(6+6R.8_D28S*J!1PI*#YB![ ,5XQNR2_Q+X=NK^73I,!VMW4SL"H&<Q%F
M.W(.TG@?@* ,3QYX>B\)K!J=KN\])U#,[LWF95F8OSU;;SMV@AF!'3'J=<?\
M4- GUNV2&V7>XF5B-RKP$<9RQ ZD5V% 'G^L_P#(>M?^O=OY3UF2Z(-8UNXA
M9V6,1*7"$KO79$#&2"/E.1GU QP>1T>IZ!/-JUO?JN8(X2K-N7@D2\8SD_>'
M0=Z-,T">'5KB_9<020A5;<O) BXQG(^Z>H[4 8]A8)X8UB.SM05ANH"60LS
M%0Y!&3U^3OG&YL8SQ2U[PM;2ZS#;,G[NXC>20;F^9CYI)SG(Y4< @>U=+J>@
M3S:M;WZKF".$JS;EX)$O&,Y/WAT'>C4] GFU:WOU7,$<)5FW+P2)>,9R?O#H
M.] &$^D)J=__ &"I:.RM(MQB5V(D+,LAR2<XRXZDXVG;M+9!XMTA/ QBU&Q+
M(IE59(@[%'&&;DL6YP".0<9!&".=K7?#MS9W@UBP"NS(%EB8[2XR!PQX!P!_
M=QM!^;)!JZGHU[XNDCCNXEM[6)U9D,@D=R,]&3&!CCJN-Q/S$   J?%BV:ZN
M+")&*,\KJ''52S1 ,,$<CKU'UJ7Q?X3M_#VF7"VZD%Q"&)8L6VR+@G)P#R>@
M YZ5I^-= GU*YL9H5W)!-ND.Y1@;XSG!()X4],UH>/=+DU6REMH%W2/LP,@9
MQ(I/)('0'O0!Q_\ P@4$VE_:YF>2<6OF([.WR )O6-5)(VCIT[DC'&*]GX<&
MO:6^IWDDDLHBD:/<QQ'Y0*X S@E]@WDC)_WLL>X_LN3^S?L6W][]C\O;D?>\
MK;C.<=>,YQ[UGZ'H$]KI+6#KB<PSKMW*>7+[1D''.1W^M $O@V];4M,26XD8
M%HY0TNX*P"LR[MW8J!G<>XR<FN"\6?V5!$SV<K&]C=2) TK,[!AN8N1L)/+;
MEQD@$''!["P\'S3Z0-*DQ',0W4A@")C(H)4G@\<C.,]#C%8]SI>I76GC21:H
MFU5!82I\P5P>%!P&)^9B3@X;N0* +?CFU75-)COYANG2&%@V2,&4Q[S@8'/T
MX[8K:\!^%K;3X8;V)-LLMO'N;<QSN56;@D@9(SP*?>^&9-1TM=-)"2^1"ISR
M T84X)&>,KC(SCJ,]*/!4UY#&EG=VXC6&(*)!*C;MN%4; 20=O4YQD=L@  \
MZT37I-&T>5H25>6[,88'!7,:L2.#SA2.Q&<@Y%=Q_P *JMO+^\_VK[WVC>V_
MS,[M^W=CK^./XMWS5CZ)\.II]-ET^X41S&<R1DL& (10"=A/!^9>^,YP<"MC
M^T=8\O[+]G3S?N_:/-39UQYGEXSTYQCKSL_@H H^'->DUG1[AIB2\44\98G)
M;$>X$\#G# =R<9)R:I>!/ 4&M6*2W3.^_P SRQO8+$-Q4[1G&21N.00>..#G
MH],\'MI&FRZ>F&FDBEW$' 9W0@ ;CP!PN> <9(&35WP%I<FE645M.NV1-^1D
M'&9&(Y!(Z$=Z ,KX1:F]]8A9#GR9&C4\D[0%8 Y)Z;L#H  !CBNUKC/AIHTO
MAVTD2[ C/FLYRRD!=B?,2"0!P>I[5I^!M?EUZU6[G149F8#8?E8 XW $DCG(
MP3VST(H E\71020_Z7*T40;+;7V;P%;,9QRP89RHY..*\U^VV5C?VCZ0[#S)
M!'*H\S:59U&/W@R=P)[D# ( (R>R^(WA>;6!!<6ZJ[VSD^5)C:X8KD') P-O
M(.,@GG( .;K.FZAKUS:7,ENL4=O,"0)4=@-Z%F)R!C X !.0<]5H 9\6+9KJ
MXL(D8HSRNH<=5+-$ PP1R.O4?6JGCSP]%X36#4[7=YZ3J&9W9O,RK,Q?GJVW
MG;M!#,".F.C\:Z!/J5S8S0KN2";=(=RC WQG."03PIZ9H^*&@3ZW;)#;+O<3
M*Q&Y5X".,Y8@=2* ,K6K?_A*]4.F3%A;VL8D* \.QVG)(P1PX'<@ [2"Q(S/
M%/AI-#OK 0LWDO.NV)F9E0B2/<5W$X#9R1Z@G/( Z/Q!H%U8WJZO8*LC.H2:
M,L%+ 8Y#,<#A0.,8(!PP+"L_6=%U#6KFTO9(U1(I@3$KHQC4.A+,^1N+8)PH
MP H_B)H ]%KRK7O"UM+K,-LR?N[B-Y)!N;YF/FDG.<CE1P"![5ZK7%>+= NA
M>P:O:*LK1+L:,L$.#OR0Q('(<CV.#AAD  R?BMI<>E:=%;0+MC2X&!DG&5D)
MY))ZD]Z/'?@V/3[1]1W.UY&T;&;<0S,7"_=!PH&?E"X*X49X.=#QYI-WXDL8
MT6';/YP9H_,0[0 ZYWY4'.0>/7VK;\>Z7)JME+;0+ND?9@9 SB12>20.@/>@
M#FO&7BR7[/8JN]6O?+:0VYQ)C"%D0')R2_'/;!R":P;S3XK.-9-/M+V*[B*E
M)&C;G'#;AN88(SD!0">/NY%==JW@R74+2T6,K'=V:Q%2_*@JJAE.-PZJ#G#?
M=QT)-6(=8U6=1']DCCD(&9))PT8(Y)V)E\'H "<$C)(!H Z+2;A[F&.64;9'
MC0LN",,5!88/(P>QYKS_ ,6V;7NLVT*.T9:W(WIC<!^^W8ST)&0#_"3D<BO2
MZ\R\9).^LVPM2HF\C*F3.S@RE@< G!7(XYYX(Z@ 9XOT./P.T.JV.Y,2"-XP
MQ*NI!8C+;B,A<=QT8 %>3QQI/]KZO;VN]D$EOAF3[VW]Z6 _W@"O<<\@C@Z&
MJ:3?>+98H;N%8+2-@[@R+(SD<8RA!&02.V,DDD[16AJ>@3S:M;WZKF".$JS;
MEX)$O&,Y/WAT'>@"EXUV>"[!H[%3'YTH7(=B5++EF!;<<E4QP1C.0<BK'_"J
MK;R_O/\ :OO?:-[;_,SNW[=V.OXX_BW?-6OXU\,CQ';-; @."&0G. P]<=B"
M1WQG."0*R/[1UCR_LOV=/-^[]H\U-G7'F>7C/3G&.O.S^"@#F?\ A/)_['\W
M+>=YWD>9N^;&W?NZ==ORYSG/S[LUU=K\-(+51(CN+P9/VC<Q?>3DL4+%2#G!
M4YRI()).ZJG_  K,?V;_ &9N7SMWF;_FV^9TZ9Z;?DSCI\VW/%36NHZQ-$+=
MK=$F*D>>\J% ?[QC0,<X],C=SC;Q0!B>+]6_M+4&T^9+A[>"-28K7YB[$H^7
M P=N"!UR" 5()-1:;NTV[A?3;6YABD94G6:-_+*EAAN2Q!4$G.0!@=BV>BUW
MP[<V=X-8L KLR!98F.TN,@<,> < ?W<;0?FR0=/2]1O[R1?-MT@B7._=*)7;
M(.W;L  P1\V[J#QTH \_U)8$U"9];64H[,L#'=Y0122.4()P"HPN<%CO&[D=
M'XQLY!IBP:8S2Q[\'RV\TF(ELH",DJIPN!D[1@Y&ZM#4]2U)3- +2.9&+A&\
MU50HP^4,CG+'^]RH/('')J>'_#MYX3L_*@$<TQGWNF2H*$!2JL=OS?*#E@ .
M1@X&0"IX"CTJ5TDLF9)U!!5W(=QM8$%22C#C>=G0A2<=*]#KS^YT"\\27<%Y
M/"ELEJRGEUED?#;L93C ( P<8W$C=G ] H \DTSP9:3:M<6#1Y@CA#*N]^"1
M%SG=D_>/4]ZT[RS&N:A_8A9DL[.!"8U8XDQL(!/!Q\RCDL1M)!!;(NZEHMYI
M>HMJMK&LZ3Q[60NL;+@*.K'')4'.#W! X)?J6@W=O<IK5HB^:\2K/ SC)^[D
M!S\N0 .1M'R _-N((!E>+=(3P,8M1L2R*9562(.Q1QAFY+%N< CD'&01@CGT
MVN"U/1KWQ=)''=Q+;VL3JS(9!([D9Z,F,#''5<;B?F( '>T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !114-U=I:*9965$&,LY"J,G R3Q
MUH FHID,RS*'0@JP!!!R"#R"".H-/H *Y^]\*?:;^+5=^/)C*;-N<Y#C.[/'
MW_0]/>N@HH **9-,L*EW("J"22<  <DDGH!5>QU:'4,^1(DFW&?+=6QG.,X)
MQG!H MT45#=7:6BF65E1!C+.0JC)P,D\=: )J*J7&K0VR+/)(BQOC:S.H4Y&
M1AB<'(Y'M5N@ HHHH **** "BBB@ HHJNFHQ/(;<.IE49*!@7 XY*YR!R/S%
M %BBBJ-[KEO8-LFEC1B,@.ZJ<=,X)''% %ZBBB@ HHHH **** "BBB@#G[WP
MI]IOXM5WX\F,ILVYSD.,[L\??]#T]ZZ"BJ]SJ,5JRI(ZJTAP@9@I8\# !/)Y
M'3U% %BBBB@ K!\3^&#KS0!G BAE$C(4#A\8P"21@8W#N#NY'%;U5[G48K5E
M21U5I#A S!2QX& ">3R.GJ* +%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!@IX8)OCJCN&Q%Y:(4'R=
M"2'SR3\W;.&(SBMZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K,U_0(]<C$,A9=CJZM&VUU9>C \\\GL>N1S@
MC3HH X^Z\'WM^I@GOF:)\!U2".-BN>0&!R,CCN/4$9%=1I^GQZ=&MO"H6-!@
M ?YY)ZDGDGD\U8HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *.M:4NK0O:NS*L@P3&=K8R"1D@\'H>.02*
MMPPK"H1  J@  #  '   Z 4^B@ HHHH **** "BBB@ HHHH **** "BBB@ K
MG[WPI]IOXM5WX\F,ILVYSD.,[L\??]#T]ZZ"B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KE/BE_P @Z?\ [9_^C4KJZY3XI?\ (.G_ .V?_HU* *^E>.;/1[:W
MMYY0L@MH20%=L9C&,[5.#WP><8/0BNM^UIL\_<OE[=V[(V[<9W;NF,<YZ8K
M\+:! ^G16QC4QS0HSC^\SJ"6)ZYST.<C QC QY?_ &I)_8GE;OE^V>7C ^[L
M\W'3/W^<]>V<<4 >H?\ "R-/W^3YZ[MVW.U]N<X^_MVX_P!K.,<YQ72UPEWH
M.I7,#6.RQ6)U(VHLH SSD#& 0>0<=>:Z/PCI4NDVL=K.P:2,$$@EAC<2H!8
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MSN&?')!"N1QP 68DX SQGH,%Q"NFZ[$(0%%S QD 'WC^\)/L244G&,D9/4Y
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M:_!K:&:V;>@8J3M9>0 <88 ]"*Q/A;_R#H/^VG_HUZX7P[=-:Z'=NAP3,5Z
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M".L_PS=-:/K,T9P\;2,IP#@J9R#@\=: .PU/Q]8Z8YAEF4..H4,^""002@8
M@CD'D>E:NF:K%JB":!U=#W4YP< X(Z@X(R#@CN*Y?X3:?';V"3(H#RER[=SM
M=E7GT ' Z=3U)SG^%85TW6+NSA 2$Q*^P#C=B,\>@_>-P..>G P ;W_"R-/V
M>=YZ[=VW&U]V<9^YMW8_VL8SQG-:^CZU#K$?GV[ATR1D9&".H((!!^HZ8/0B
MN%^">GQBWDNMH\TRE-W?:%1MOL,G)QUXST&+'PS_ '5SJ,"\1I<?*HX5?GD'
M"]!PH''8#TH ] HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=:@DM'X$BXSSP1RK8!&<$ XSSC!XK0HH YSPQX+CT2U>P9C(LI<N2-N=ZA2
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M;I"^=NWJJC&,M_=]:Z"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y+Q=\0X]!
MD6UC0S3L1E%.,9^[D@-\QXPN,XY.,C(!UM%>=#Q1K4*BX>T0Q_*2J ^802.
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MM8_)8%ESDOMYQQYBLQQTPHW=0.17H&G7+7422NI1G16*'JI8 E3D#D=.@^E
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M?#=NMQ"%+-*%(<$C!5CV*\_+0!U%%4=#O6O[>&X? :6)&('3+*"<9SQS5Z@
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MZ#.,94;L=SR* /2**Q/"6J7&H1,UY%Y4J2,A !"D#!##.>.<9!(.,@\X&W0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC(? X YQR>I'$OQ!^&D5M LUA"WF*X#*C,^5(/.UBQ)!Q]WL22,#( &^/O\
MD,V?_;O_ .CVKU6O'/%#7=_=6>IBVE+1Q1,Z")Q\\<KEEZ-@'&1G)VD$BNST
M#QK<ZE.EO+92PHV[,C[]HPI(SF-1R1CKWH VO%G_ !YW/_7O-_Z U>4>!_'$
MOARU<"V:6+S2QD#%4!*HNTG8PSP._<<5ZUXGA::TN$0$LT$H  R22A   ZDU
MR_PGTE[:SD@N8V7?,^5E0C*E$'W6'(/(].M %7X5:3]J:76W=3)<-(-B=%W.
M&;.<D$D @9X7!).[CC_AO>W]MYW]GQ))GR]_F$#&-VW&73KSZ].U=5X$TF;P
MQ?SV)C=K>7[LNQBOR@LF7PJ_=8AL#[^ .*Y_P+?7GA7S?]"FD\W9_ Z8V;O^
MF;9SNH ] CTVZ\2V4MKJ*K#([87RL$87:RM]Y\_,#D9&1Z=:X>RO]4\ )Y<D
M0>V#]22R@;L':RGY ^>-XZ\A<[@>SLO$E]K,$QBMFMYXO+,8FSM?YLLOS(G4
M+C_@0Y7K6)JOBW4=0B?3_L+B253&S_,8\M\K$?+C'7!WD#@DD#D [7PQXA3Q
M! MW&,;LAER"58=0<?F.A((.!FN _P"9C_S_ ,^M=A\/?#3>'[00R?ZQV+N,
M@@$X  ('8 9Z\YP2,5S/]DS?V_\ :O+?RO[^QMG_ ![[?O8QUXZ]>* +?QK_
M ././_KX7_T"2N:OOB+-;6"6#6S()+<1K(Y;:R[ I91L7.0<C#$#(/(Z];\7
M=.EO[1$A1G83J2$4L<;'&< 'CFKLWAG^V=+CL9!MD%O%MW#!614&,Y!(YX;C
M."10!SNJ>&UT#1)8@XD,ACD+*<H2SQCY3W7 &#WZ\9P,35IF30;8 D!IV! .
M,C=,<'U&0#]0#5VPAN9]&GT]X)5DB9-@,3@LK2AS@'DD'=G P!CWK;TGPF^J
MZ,EA(OER_.5\U""K"5F'!&1D<9ZX8\'H0#I?!-JMK8VZ(, PHW4GEQO8\^I)
M/\N*VZ\LT'Q)J7AR,6,UG)*(@ K+O/')P742*P ( QC:!CZ=WX7>[DB,E^%6
M5G)")C"J  !P3R2"WWCUZCH #@O^9C_S_P ^M:OQK_X\X_\ KX7_ - DJI_9
M,W]O_:O+?RO[^QMG_'OM^]C'7CKUXK3^+NG2W]HB0HSL)U)"*6.-CC. #QS0
M!B>.YF31K0 D!A;@@'&1Y).#ZC(!^H!KN_!T*Q65L%  \B,X QRR@D_4DDGU
M/-95WX8;6M+BL2 DH@AQYB_==%7@]U/52>H!/!Z'G-$\0:GX9C6RGLWF"*-C
M(68@9/!91(#C@ ?+@ <$$4 1?&W]P]K.GRR#S/F7AOE*%?F'/!)(]"3BJ^HV
M2W^O/;OD+*C*2.N&M"#C.>>:T-/\.7?B^Z6_U!3%;Q',<+ <X;[I5NQQ\Y8
ML, #;C:[^R9O[?\ M7EOY7]_8VS_ (]]OWL8Z\=>O% '.VUXUMIM_I,A!>VE
M3'S9R/.56"J0#M#+G/J_(!Z]%HOA;_A)=%AMPVUU:1T)^[N$D@P>^"">G(Z\
MXP:OQ6\(S22B]M4=_/4)*L89CE<%20"200H[8!0$\D5L:!;WVGZ7 +5!Y\;N
M6CF&W*EY.,-MP>0PY7@=3T(!SEEXKU+P2B6]W#NA7A2QYP0=J"52RC&,@$$X
MXX&,>JZ5J::I$EU$<I(H(Z9&>H."1D'@C/!!%>;^(O$%_P"*(3IZ6,D?FD99
M]V,*=^,LJ*#D#DGV R17>^%=$_L2UBL\Y,:_,<Y&YB6;' XR3CC.,9YH S?B
M5K TRQE/&Z4>6H()SOX;IT(3<03QD=^A\WUBPM_[)@"R0FXB8NRK(-Y$IY&T
M<E@-F[(X"D X'/2_$/29O$5];V:QN8$QOD5& &\@O\[#8<(H(QGG(Y/ WIOA
M5ISJ5$14D$ B23(SW&6(R/<$>HH R?$6L'6-"-T<EF2(,2 ,LLJJQP.,%@2/
M;L.E<UH_CZ*#3?[(2.1YW22,8 VDRLV,8)8D!NFWD\>],TS3KNVL+S2GMY=Q
M9'0B-B"1)&K@,,AN "NW/ 8YQBO1OAQ:/:6$,4JLCCS,JX*L,R,1D'GI0!QC
M:#)HVA3+,"KRNDA4C!7,D:@'D\X4'L1G!&16?H_CZ*#3?[(2.1YW22,8 VDR
MLV,8)8D!NFWD\>]>A_$>T>[L)HHE9W/EX5 68XD4G '/2CX<6CVEA#%*K(X\
MS*N"K#,C$9!YZ4 8/AS09-&T>X68%7EBGD*D8*YCV@'D\X4'L1G!&13_ (*?
M\><G_7PW_H$==;XGA::TN$0$LT$H  R22A   ZDUYEX*UR\\,0M;?89I-TA?
M.UUZJHQCRV_N^M %OXY_\NO_ &V_]ITSXEQ"]U2TM9,F)A$"N2!\\K*W0\$@
M $CG@>@IGQ&CN?$4%I<+;2J_[_=&$=V7YE S\H(R!D9 KH_B7X/FUD175ICS
MX#V(5R"000^1@H1D D=20<\$ [BN7^)6L#3+&4\;I1Y:@@G._ANG0A-Q!/&1
MWZ'"M?'6J72B%;%A.<_.X=(N#GD.!CCCF3K^54?&6C76O7-G8R(SK$B":5$9
M5W/CS2'90F J@C ZG&"?E !A:Q86_P#9, 62$W$3%V59!O(E/(VCDL!LW9'
M4@' YZWQ%K!UC0C=')9DB#$@#++*JL<#C!8$CV[#I6M-\*M.=2HB*D@@$229
M&>XRQ&1[@CU%<#IFG7=M87FE/;R[BR.A$;$$B2-7 89#< %=N> QSC% #]'G
MU6;3?LUM"IMF20;Q@R%2S;P%+\D\CA,XZ<X-=;\(+Z"6T,$(99(VS*&.<LW
M8' &"%P!U&.<_>;"\.>*;[0[5;)+&5F0/ARLF,LS,"5$?09Z;AGU%='\+_"$
MGA^*1[@;99F&5#!@%3.WIQDDD\$C&.AS0!S_ ,#/^7K_ +8_^U*U?C7_ ,><
M?_7PO_H$E<IX%OKSPKYO^A32>;L_@=,;-W_3-LYW5M^-;JY\3V"M]EECD6Z
M\O:[-M$;?/C8IQEL=,9[T /T/5M:2WA6&VB:(1($)89*A1M)_?#DCV'TKTVO
M--)\<WFGPQVW]GS-Y4:)GYQG:H&<>4<9QZUZ'IURUU$DKJ49T5BAZJ6 )4Y
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M,DF3CN<,!D^P ]!7/_#_ $R?PW?3V1BD\B4D+(4)'R9,9+C"X*DY[[L# Y%
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M@,^=HC4YW+R 0K *<XZ@/UG6=3\5K]AAMGMU?_6-(6 *D@8W,J8'/S  LPX
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>R$"K+'$&,PQO8$1_*?E!Q\P_B/W1QZ '445R5QXZ>XGDL[&W:X: D2$NL2
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M2OSB56(#' ;R]JMMR02>R_-R*ZV@ HKFM6\8M!.;&T@>XF3;OP0D:AE+#,C
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M$=B.X]: *^L:U#H\?GW#A$R!DY.2>@  ))^@Z GH#6?H_CFSUB3[/!*&D()
M*NN<=<;E&3WP.<9/0&N8^(+OI=];:I(C2VT*D,H!(1LD;^1M!^92O(+%<9&
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MKI>EQZ5&MM NV-,X&2<9))Y))ZD]ZQ=2T"#1+"ZAMEV(89F(W,W)C(SEB3T
MH S_ (5ZK$VGJF]08-_F9.-H+LX)SVQSGIUYR#CG_#?^DPZQ>IS%-YVQNF<+
M*QX/(X=3R!U]C6AX&\%V>LV$$L\2L_[SY@61C^\8<E""< #&<X[5V\6BPQ0?
M850"'84VC(^5@0><YR<G)SDGG.: //=-\4OX;T6WN(E5G:1T&_.T9DD8D@8)
MX7'4=<]L',^(UM<Q6D+W-VLXD=2J+&BC[A)=77!91G&< '<#QQ7J$7ANWCM_
M[."#R,$;"2>I+'DDG.3D'.0>F,"LH?#+3@I3R!@D'[\F>,]]V0.>0#@\9Z#
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M 4 <?\./^/S4O^OC_P!GFKT"L_3= @TUY9H5VO.VZ0[F.3DG."2!RQZ8K0H
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M#@CZ9NW_ (&MYH2\][<&!@I)DN5,9!(*G++M()QCWQBNRNK1+M3%*JNAQE7
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M?"-KJ,4=M-&&CA "#+ J -N-P(;& ,\\X!/(%0Z=X&L]-D2XAB"R1 A2&?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M')'. :ZB@ HHHH **** "BN/U/7YX=6M[!6Q!)"69=J\D"7G.,C[HZ'M784
M%%%<)J6M7FJ:BVE6LBP)!'N9RBR,V0IZ,,<%@,9'<DG@  [NBL'2Y;U+AH)U
M5K9(EVS !7=P$W$J'. 3NXV@# Y]=Z@ HHHH **** "BN/\ !6OSZE<WT,S;
MD@FVQC:HP-\@QD $\*.N:ZC47D2)VA :4(Q0'H6 .T'D<$^X^M %BBL_0)IY
MH$>[54G.[<J<J/F.,?,W;!ZFM"@ HHKG_%_BG^PU2.-=]Q<-LA0\*6R!DG@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_6;:?8\FVW/RQ+N<Y\X<+D9QG)]LUZ77#ZMITKZU;7 1C$L# N%)0'$W!;&
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M=+86CI,C(QG8@.I4XV(,X(''%1>#+.>PN-2F,39>4M&&!028:4@!F&,'(YY
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MFN=)M((XW:1/(W*J,6&(6!RH&1@\'WKJ_'NC?VO92P@9=5WIA=S;D^; '7+
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MEK;V[A56%&$CLH97/F(&( ;L>"N. P)K;U;3I7UJVN C&)8&!<*2@.)N"V,
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M,)'90RN?,0,0 W8\%<<!@35N**ZU#5[>^D@9(O*;;\K':NV7;YA^ZKDG.W/
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M8$8@[ -O.,9 "X(.1JZ+IT^N:@-8GB:&*&,I"K\2-RRY9>2.&8]NJXW#)+_
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M=%<_9:O<RW\MF\>+9(P4DV.-S83(WD[3]YN ,\>QKH* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#E]/\+RV^ISZH2OE2Q!0 3OR!&.
M1C&/D/<]JZBBB@ HHHH **** "N:\%^&I-(\^:XV&>YF+L8BQ7!Y PP&,%F_
M C)/;I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S/$ME+?VTMO!M$D
MJ%09,[<-PWW<G.TG'OC/%:=% &9X:T<:/;16@QF- &P206/+D$\X+$GM]!TK
M3HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_#^A2Z3/<G*
MFWN)/-49^=7;&_(V 8)Z?,<!1P22:Z"BB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K!\':#)H\++.P>:65Y)"OW2SGM\JX& .,=<XXQ6]10 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!'0D T-$U^#6T,ULV] Q4G:R\@ XPP!Z$5H5QGA'Q']OLY+FRM55EEVB%'5
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MBBTFIF#1X"/,N'+'Y]N%0'[P[J>6^J< GIWM47T6%YQ?% 9E38&.3A<D\#.
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M-)!RQVA3(Y(55P .@Q^)I:+XSM-,O;B=8W%G<1[?*"J1D[<Y0MMQ]_ R<!L
M '% &KXFDN[[33?SW:&.?81"D:;<EP0@DSNRF,D<D;2"3@FMOQ+_ ,@%?^O>
MU_G'7+IKVA("!:R_,,')SW!X)FX/'48.,CH2#L7/Q,TRZ@%@\,Q@"JNW"CA,
M;1D2YXP._P!: (O'W_(&L_\ MW_]$-75?%+_ )!T_P#VS_\ 1J5RNH?$+2M0
MA2RE@F:*+;M7@8VJ57D2@G ..35K5/BMIVJQM;3Q3-&^,C"C."".1(#U [T
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MR_%'398/L+0RF'8$VE4/RJ !SYF<C P<Y!YSF@#8^*FJQ+I[)O4F?9Y>#G<
MZN2,=L<YZ=.<D9YGQ?;_ .C:5<.62)%C#R(<,NY(R",9.0$8@@'!'TS7@\4:
M) CQ+;2A90H;N2%8,!N,V0,@$X(S@9SBM@?%73?*%H896B554(Z1LN%QM!W2
M'.,#K0!IW_@:WFA+SWMP8&"DF2Y4QD$@J<LNT@G&/?&*S_&]DMA<:3;IDK%*
MJ@GKA6A SC'/%85KXBT.U82+:RDC/WP'7D8Y5Y2#^(]^M:NI?$S3-2>*::&9
MG@;=&<*,'(.<"4 \J.N: /4**\__ .%UV?\ <F_[Y3_XY1_PNNS_ +DW_?*?
M_'* #X<?\?FI?]?'_L\U'Q'_ ./S3?\ KX_]GAK/TWXF:9IKRS0PS*\[;I#A
M3DY)S@RD#ECTQ1J7Q,TS4GBFFAF9X&W1G"C!R#G E /*CKF@#N/%VN-H=K)>
M(H9D P#TRS!03CL,YQQGID=:\\\327=]IIOY[M#'/L(A2--N2X(029W93&2.
M2-I!)P36Q-\9;&92CQ2E6!!!2,@@\$$&3D&N:37M"0$"UE^88.3GN#P3-P>.
MHP<9'0D$ V/'%JTVBVKJ,B-;=FY' ,13/ORP''KZ5U?BG7X'TZ6Y$BF.:%U0
M_P!YG4@*!USGJ,9&#G&#CG(?BWI\40M1%+Y2H$"E48;0-NTYD.1CCGKWK$L_
M%&B618QVTH+HR$GYOE<8;&9C@D<9&#@D9Y- %[_F7/\ /_/U1X^_Y UG_P!N
M_P#Z(:C_ (6%I7V;^S?(F^S_ -SC^]O^]YN[[W/7]*-0^(6E:A"EE+!,T46W
M:O QM4JO(E!. <<F@#JOBE_R#I_^V?\ Z-2L7Q P73=..[RV\RSVR'&U#Y?W
MR&&" ,\9'J3@$&'5/BMIVJQM;3Q3-&^,C"C."".1(#U [UFZG\2;.Y^SVJQ2
M?9(3^\1@,L$7$2_ZPAE#8+!NN!UY! -VV:7Q%/ ES<VA2&02K':/N=W3E<[L
MG &2<=L\="OH%>)>+/%6F:G;M#;6QCFRI5A%&F,$9R4;)!7/&",X/8$>M>&)
MFFM+=W)+-!$22<DDH"22>I- &G1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%<YX,\2-X@6:<E?*2=DCVJRDJN"
M&)9CR0PXPN,'UP#Q?XD;26MX(BOFW,ZH-ZLP"GAFPK+R"R\9YS^( .CHHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBYWG+(1@ 'CY<'&2,YP1G !4UC1[KP];_P!J->2-/$0SJ[,UNVXX*",#@'<
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MP21\F">2,YP1DBIXON+KQ7'';Q0RPP-/&LAD1A)SGGRU/^K3@DL0"VW&-I-
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M,L2.>O-='K\2RP2"21XD"[F>(E74)\Q((!/0<\'(R*9H>MG5E9_)EB"G'[]
MA/T&XG ]2 /3.#B+QA#+-9SI  9&B8 $$Y!&& "\EBN=O^UC/% ''_#3PDLE
MM#>B:="SLQC23;$2CE>5V\@A0#SS08+C6]6N1!(%BBB2)Y%QO56PQ1,?QEPP
MW'.SGN%%='X(U5IX8[5H)HS!#&K-,@1254+A<G)Z$].!UP2 :/PVLV"W-Y+$
MT4MQ<NQ5PP.WAE&& R 6;G S^' !%X7N9M.O+NR>5I+6W1&,EPX9U9D5OO''
MRD;B>,#:.A)W9EGXF7Q6TDLMW]DMT;;'&DJ13,0/OLQYP0?NC(S[KEKVE:=<
M:C+JHD0H;@".-F5E1@JR1JP)!R,8)(SUR!R!6/X9$>E0"UO--EDEC9P76V64
M,-Q(.XXSC.!@D8 (/.  =%\-=0GNTFWLTELLI$$LF2[KN;.2<$@<<D#DD=L+
MJ^.=4;2[*>=,[@FT$':07(0,".Z[L_AU'6M/2[B2YC62>/RI#G*;P^,$@?,.
M#D8/XXJIXJT3^V[66SS@R+\IS@;E(9<\'C(&>,XSCF@"E\/=+73K&%1@ET$A
M(&,F3YN?4@$+GN .G2K?BWQ N@6SW1QN P@/=SPHQD9'<X.=H)'2N<T'Q3/H
M\*65U9W!DA54S!'YB%54;3N#8SC@X)&1V^Z(O%VBW_B6QVR1HLRW&]8U<9\L
M!E +$[2WS9/(!'H?EH ETSP?=ZG"+BZN[A+B5<[8V\M$RHV@Q@+R/X@-O.1U
M^8O\$>,)KW3YKZXP[VYEZ )N"(' .!@'G&0.F."<Y+WQ9=:M%]EMK6>*>8;2
M\R,D<>1\S!QSE?X> <\X)PII>)/#KZ-I(TZ"-I9)&0.8P6.[/F,_RKDC*A1D
M XVY/&" 5-,TZ[O=--]<7$R&*&5XEC=E9@-S!I&.2V>-H! " $'+&M70+&]\
M401W-W</"C+\J6X\IVQP)&<@GYAD[0-I&UACI6GXNL9++3'M;4,S+$D:@+O<
MKE4;@#DE,Y(''48IERCP:0(O+=I#9K'L527W-&$QMZ\$_-W !XH J^"?$,[:
M8U]<C>8EE*$GYG6->YYYR"N2,\9()Y.?X6T"[UVS26XNIHSM;RO+9@Q!8D/(
M3R^>-H! " 8.6-'B%3I&C16D:NLDZQ1A5SNWR?/(I!.?FPP(]3MQCH+KUZ+1
M=+@M)EN5C\HNPVQ (I4NLN0,X&5Y R>"V!N ,_2OB%.FF;B=]TTWDP\;G/RJ
M=Q&<L0&QG!RQ7<#DDZ6L:/=>'K?^U&O)&GB(9U=F:W;<<%!&!P#N !X'?"=5
MI:[X+ET6"REMX_-:SDWRJGWV9F1B1A<D97;G!8+MX(!(L>+[BZ\5QQV\4,L,
M#3QK(9$82<YY\M3_ *M."2Q +;<8VDT :$NHRZ3HOVAG:25H =Y8AP9R,'=D
MG*;QCUV]NU2;0;I[$WUS<SI-';%@D3M&HV1Y4."-S.2,N20<D@< 5>^)=@^K
M?9;%8W:.2X4R/&"=BCY3GY2!D.3D\#;T/:U\3D>:Q>"*-Y'E9 !&I8C#!R2!
MR!A<9]2* ,+7=4NKW1H[]I&BF4JS%-T9<%S&.A& P8/QP>P (QM^,?%#0V"W
M%N&\R["+$ /F!E7(^Z<A@N<8S\V.HJ_K>CK'I\EF,%4MF5?,*_P)\I).%!!
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M,T6^$'KE.#(6)0Y5CM'&1UQR.H+]9?"=]:*L\TT5TQC9)Y-^"2J[@<8X+ \
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MC)\%/^/.3_KX;_T".G^'/$5Y! FG&TD%S&!&KLI%OA!@.SYZ #)VYW8^4_,
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MX9"&4X.#@CCK4U !1110 4444 %%%% !1110 4444 %%,FF6%2[D!5!)).
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'J#VKS7PW_HT.L62<10^=L7KC*RJ>3R>$4<D]/<UU7PM_P"0=!_VT_\ 1KT
M3:EK\&MV%U-;-O00S*3M9>1&3C# 'H16#X)\76NAZ?;I<R!&<2D##,<>:XSA
M0<#TSUP<=#6;X _Y UY_V\?^B%KH/A7I42Z>K[%)GW^9D9W .R '/;'&.G7C
M).0#7US4(]1T^>XA8-&]M*01_N-^1'0@\@\'FN8T"&";0T2[9D@.[<R<L/\
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M&5 P%SQG^\<=ZV/B/_Q^:;_U\?\ L\- &KK&L6/B*QED>5OLP95=T5@P(9&
M 9">I7^$]?RT[;4K;2+2*0R 0+$@1G."RA,KQ@$L5&< 9/85F?%+_D'3_P#;
M/_T:E<DL*ZE>:79S /"+)'V$<;O+8\^H_=KP>..G)R =QIGCZQU-Q#%,I<]
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M+XIT"!-.EMA&HCAA=D']UD4D,#USGJ<Y.3G.3GG-)\6Q6&FV;7$9GF8L(4"
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M_'G<_P#7O-_Z U<;H6A-K.BQ1QDB:,O)$0<$.DKD8.5P3R,DX&<]J +&L_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZY'J#6+%X1O(QY(OY/)R>#$AEVDG(\XDMNP>&QQU & *ZVB@#E]6^'\-_#%
M'D22W+-'*')?>YW,S$]27PQQ@Y'RE152Y\ 2ZLRC4+IIXD.0BQK"">.I4G(Q
MD=B,G##G/9T4 <_XD\*?VU-;7._9]EDWXV[MWS(<9R,?=]#UH\:^%/\ A)X5
MMM_E[9 ^=N[HK#&,K_>]:Z"B@#G_ !KX4_X2>%;;?Y>V0/G;NZ*PQC*_WO6N
M?^-?_'G'_P!?"_\ H$E>@5GZWH$&MH(;E=Z!@P&YEY (SE2#T)H Y>\^'$MS
M&MB;N3[(I7$;(I?"_P /F#&1_=!!"\<':*T_$G@:/5XHH8V:%[;'DNI)*@8&
M,9!/"C!SD$ YZ@]+10!Q4_P_GO9H+NYNVD>WD# &)57 96P%5@ 20<MSD8&/
MEYU?$GA3^VIK:YW[/LLF_&W=N^9#C.1C[OH>M=!10!S_ (U\*?\ "3PK;;_+
MVR!\[=W16&,97^]ZU4^*$"2Z?,9/X=A4[0Q#;P!C)&,YP3U )X/0]76?K>@0
M:V@AN5WH&# ;F7D C.5(/0F@#/\  6C?V1910D8=EWOE=K;G^;!'7*@A>>>.
MW0=!110!S_@KPI_PC$+6V_S-TA?.W;U51C&6_N^M'AOPI_8LUS<[]_VJ3?C;
MMV_,YQG)S][T'2N@HH Y_P -^%/[%FN;G?O^U2;\;=NWYG.,Y.?O>@Z52O/!
M$J7,E]97!MS.!O41*ZDC^+!(&3UR03DL<_,176T4 <EX9^'ZZ#=27JRLXD0K
MB09?+,K%B^1DD@_PCKUXYAF\#W4R&U>^D-NQ(*F-3(4+9*F4G<21QG&,<;=O
MRUV=% &)_P (A!]C_LG#>3MQ][YL[MV[/KN^;IC/&,<57\*^&[C1 (I+DS0H
MFU4,07'((._<S$ 9 '0 \=!71T4 5-6L?[0ADML[?-C=,XSC<I&<9&<9]:J>
M%M"_L&V2RW;_ "]WS;=N=S%NF3ZXZUK44 <5I?PR33+[^THI,(&<B+8 !O4@
M@,"  "W V\# ]ZU?%/@R+Q!MD):.>+[DL?# ]1GU //4$'H1DYZ"B@#DIO"%
MY>J8+F]9X7!#K'#'$Q'IO&<#UXY&1WKI=/T^/3HUMX5"QH, #_/)/4D\D\GF
MK%% '/V7A3[-?RZKOSYT839MQC 09W9Y^YZ#K[5:\4Z%_;UL]ENV>9M^;;NQ
MM8-TR/3'6M:B@"II-C_9\,=MG=Y4:)G&,[5 SC)QG'K7+_$VV$44.I@ M93Q
MO@L1E2P!4<$9+;>2. #CT/9U#=VJW:-#(,I(I5ADC(88(R.>E &%XP\,KXMM
MTB20*N]9 X7>"-K 8PPX.[.<U2^)\_FVRV"[?,O)HXUW-C'S!MV,$D @ XZ;
MA]#U&GV":?&L$8(1!A069L#L,L2<#MSP.!Q3+C2X[F2.Y=<R0;]AR1C>,-P#
M@Y'J#[4 2VEJMHBPQC"1J%49)P%& ,GGI6/XJ\(Q^(50LS1RPDF-T."I..W<
M9 /&#QPPYK>HH YJT\-79=7N;UY$1@P6.-(<E3T8KDLI&05[^O%2^)/"G]M3
M6USOV?99-^-N[=\R'&<C'W?0]:Z"B@#G_&OA3_A)X5MM_E[9 ^=N[HK#&,K_
M 'O6LSQ1;QZQ?6]@7:*2.*24/&VR0[ODV(V>IP6;Y2=J\8!:NSK/UG0(-:7R
M[F-7 Z9X8<@G##!&<#.",]#Q0!PGBV&?PAY,]K<S2R22;/*G?SMX//"X!Z@*
M<#/S  COMS^ Y+>XDO;&Y:#S^74QB52Q))/S-CKST)&3@@' TM'\#6>CR?:(
M(@L@! )9VQGKC<QP>V1SC(Z$UO4 <UX0\&?\(X\\GFM+]H93\X^8;2QY;)W$
M[N3@<\XYK!\,^'X_$*2:A%<3Q">>5O+@EV!?FQ\PR_SL &/('(   %>AUS^I
M^ ;'4W,TL*ESU*EDR2222$*@DD\D\GUH Y_PO/+-=W6BRR-<6L<9&]^6!?&4
M,BG).&8')SE/EVX(J[9>!KG25\BSO6CA!RJ/"DI&>OS$C@G)P !SZY)Z71]%
MAT>/R+= B9)P,G)/4DDDD_4] !T J]0!4TO3_P"SXU@WO)MS\TK;G.23RV!G
M&<#VQ65XU\*?\)/"MMO\O;('SMW=%88QE?[WK7044 <_XD\*?VU-;7._9]ED
MWXV[MWS(<9R,?=]#UH\:^%/^$GA6VW^7MD#YV[NBL,8RO][UKH** "N4UGP0
MUQ=?VE:3M!,5VN0@D5A@ ?*Q Z <<C@$ $9/5T4 <IX>\$-I5W)J,D[2O+'M
M;<@!R=A)R#@#*_*N/E&!GCFWX;\*?V+-<W._?]JDWXV[=OS.<9R<_>]!TKH*
M* .?LO"GV:_EU7?GSHPFS;C& @SNSS]ST'7VKE_BOHBZI/9PKD2S.R95-WR9
M4EB<@X3)('3!8Y7OZ16?-H$$TZ7[+F>-=JMN;@'=QC.#]X]1WH NPPK"H1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM]/W^=Y"[MV[&Y]N<Y^YNVX_V<8QQC%:][HD%]%]EEC5H@,!2HP,#:-N/ND
MX!&".U '-?%G4([>P>%V >4H$7N=KJS<>@ Y/3H.I&<+Q-:M:/HT,@P\;1JP
MR#@J8 1D<=:[#3/ -CICB:*%0XZ%BSX((((#E@"".".1ZUH:EH$&I/%-,NYX
M&W1G<PP<@YP" >5'7- ''_&O_CSC_P"OA?\ T"2CXU_\><?_ %\+_P"@25V&
MMZ!!K:"&Y7>@8,!N9>0",Y4@]":-;T"#6T$-RN] P8#<R\@$9RI!Z$T <?\
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M!!IKRS0KM>=MTAW,<G).<$D#ECTQ1-H$$TZ7[+F>-=JMN;@'=QC.#]X]1WH
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M ^88.7D/<'@EN#QU&#C(Z$@@&/XE_P"0"O\ U[VO\XZZKPG_ ,>=M_U[P_\
MH"U-<Z!!=0"P=<P!57;N8<)C:,@YXP._UJU:6JVB+#&,)&H51DG 48 R>>E
M'"_$?_C\TW_KX_\ 9X:/C7_QYQ_]?"_^@25V&I:!!J3Q33+N>!MT9W,,'(.<
M @'E1US1K>@0:V@AN5WH&# ;F7D C.5(/0F@#C/%4RZ;K%I>3$)"8F3>3QNQ
M(.?0?O%Y/'/7@XT/BSJ$=O8/"[ /*4"+W.UU9N/0 <GIT'4C/4:GI46J(89T
M5T/9AG!P1D'J#@G!&".QK*TSP#8Z8XFBA4..A8L^"""" Y8 @C@CD>M ''^)
MK5K1]&AD&'C:-6&0<%3 ",CCK6A\:_\ CSC_ .OA?_0)*[#4M @U)XIIEW/
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MTZ7[+F>-=JMN;@'=QC.#]X]1WH X_P"(_P#Q^:;_ -?'_L\-'Q'_ ./S3?\
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M&>] '-:S_P AZU_Z]V_E/1\1_P#C\TW_ *^/_9X:[";0()ITOV7,\:[5;<W
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MZ#-L08L$J%QMQ@*0,#:.",<52U3P%9:K(US/%ND?&3OD&<  <!@.@':@#/\
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M32X]5C:VG7=&^,C)&<$$<@@]0.]2VEJMHBPQC"1J%49)P%& ,GGI0!-1110
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MX.3RR<YQW_"@#8HHHH **** "BBN/^%^OSZW;/-<MO<3,H.U5X"(<84 =2:
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MYYCH,E3_ '3MW9W<4>'GG\$236+6\LUNSF2.2!#(W.% ;[HSA1GH00>"K @
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M1N-3:]I2EW-SJ+PR-N,:K*D"JI)V ID%\'(+9!8#'&*9I.G2IK5S<%&$30*
MY4A"<0\!L8)X/Y&N<\.Z8VC--!>6+W-P\F5EV"2-B1QEW&%!)R6Y/)W@%<4
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MW]HB0HSL)U)"*6.-CC. #QS0!L>)M"6ZS=R7%Q"D49W""0JN%RQ8J%))Q^@
MKFO ,DL,=QK$\LSVP63REDDWL40DLQ4G ;Y0!R.=W8@U+\3)9KUXK 13-;'#
MRO;HSL<%@(P.%[9.2>2IQ\N&V]/U1->1]/\ L]Q!&T++F2(1*%(";5.2,X/
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M?V=;6LJ"0KO>Y3RE5592,<G)SR>IP#A3G(?XNT%XIM,B@1WCMI%!8*6VJK1
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MICD%3_".-O?-9^C^*KG1K=;.XLYVF@0*ODIOC8*HV9<$X/9L;L'G_9&A\/\
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M!''6@":BBB@ HHHH ***P9_%JVTD44L4J+.^Q'95V$G[H(#%U+=@R@^H&&P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)Y]?2@#T"X^)&GP;<SK\RAAM5VX/KM4X/JIP1W%3ZGXYLM,($LRY89 7,G!
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MC  P =+J&OP:>B3RR*L<K*JMU4E@2OS#( (&=QXQWJU=W2VB--(<)&I9C@G
M49)P.>E<!I.C-XBT-(/O2;7*%L$YCD;:H+$8R!L!SP#Z<57UCQ(?$ME:6*$M
M+>NJ2-M#%?**F1MJL,'.& Z;,D[>* -KQ+9_\););6J@FUPMP\A5@K+T2-6!
M&&8,<@X(&".1@[>N>+K70V5+F0(SC(&&8XZ9PH.!Z9ZX..AK5AA6%0B !5
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M9.6'^D'&/E;O@=#6?X;_ -&AUBR3B*'SMB]<9653R>3PBCDGI[FC_F7/\_\
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M/0\CD T =AH?BZUUQF2VD#L@R1AE..F<,!D>N.F1GJ*AU'QS9Z;(]O-*%DB
M+ J_\6W&,+R?F!P,G&3T!QS7CF%;#4;"ZB 6664H[ ?>7*)R#QG:Y&>N,<\#
M$5CI\=YKUP9%#>5$CKGLP6(!L>HR<>AY'(!H [)?%5J8!?F11 V<,V5R5SD
M$ D_*< #)QP#5?1_'-GK$GV>"4-(02 5=<XZXW*,GO@<XR>@-<EXZ$M]JEM:
M1B)\0LRI<+NBRWF;BV!D\(,>A ]ZL>)/"^J:^J"0VJ-$X9'C,JN#[,0<#H>.
MX![4 =AKGB2WT)5>Y<('.%X+$XZ\*"<#N<8&1ZBF:3XJM=61YH)%9(OODY7:
M,9R0P! QGGIP>>#7.^-/"]S/=1:M:+'(\"!?*E[D,V&'(!(W9Y*X*@@D\5%=
M:BOC&.XTHQFWO0B[@XW#$<FY1O7JO(YQQORH89R ;6G_ !#L-0D6".8%W.%!
M1UR>PRR@9/;GD\#FL+6?^0]:_P#7NW\IZBL/$$GA2..RU*W58%8*DL.&0E"I
M#,N20207W<,3R$R#B76?^0]:_P#7NW\IZ .RT[6H=1:1(7#-"Y1QR"K#CH0.
M.#@]#@X/!I_]J1^=]BW?O?+\S;@_=W;<YQCKQC.?:N20?\(_JQR0L.HIQ@*H
M\V/'!YSDY)S_ !,X&"1D/^'Q_M:2YUEEQ]HD"1Y3!\N,  YR<[N V.-R_@ #
MK[NZ6T1II#A(U+,<$X"C).!STK"G^(=A B2M, LH8K\CDD*Q4G:%R!D$#(&<
M'&<5=\6?\>=S_P!>\W_H#5@?"O2HET]7V*3/O\S(SN =D .>V.,=.O&2<@'3
MQ:U#+!]N5P8=A?<,GY5!)XQG(P<C&0>,9K*M_B'87#1Q),"TI 4!'ZEMH!^7
MY3GUQQ@]"#7&^&_]&AUBR3B*'SMB]<9653R>3PBCDGI[FNB^$VGQV]@DR* \
MI<NW<[795Y] !P.G4]2<@&[K?BJUT3 N9%0G&%Y9L'/.U03C@\XQGC.:-$\5
M6NMY%M(KD9RO*M@8YVL <<CG&,\9S7)>!H5O]1O[J4!I8I0B,1]U<NG '&=J
M 9ZXSSR<GCF%;#4;"ZB 6664H[ ?>7*)R#QG:Y&>N,<\# !%;:A'IVM7EQ,P
M6-+922?I!^9/0 <D\#FNPT/Q=:ZXS);2!V09(PRG'3.& R/7'3(SU%<?8Z?'
M>:]<&10WE1(ZY[,%B ;'J,G'H>1R :L:G^XUZWV?+YMN=^WC=@2XW8Z_=7KZ
M#T% &QI]M:+J<\J2,;LQ .A!V!<1X(.T<\+_ !'J>/3FO!^M0Z/<ZG/<.$3[
M2!DY.29)L   DGZ#H">@-7=&_P"0]=?]>Z_R@JO\/=/CFU#4+AE!DBG8(3_#
MO>3=CW. ,]<9'0G(!VNA^)+?759[9PX0X;@J1GIPP!P>QQ@X/H:Q?#ILM.EO
MKB&1F8.6N P.$*F0G'R#(^]TW=!^.3<0KINNQ"$!1<P,9 !]X_O"3[$E%)QC
M)&3U.7_#C_C\U+_KX_\ 9YJ *GAOXI1^=<_:YOW7F?N/W9^[N?\ N)GIM^]S
M^M=KK?BJUT3 N9%0G&%Y9L'/.U03C@\XQGC.:Y7X<?\ 'YJ7_7Q_[/-65H0N
M[[4+V>W%NTD<VW=<*VY0"Z*$*#CY5PWK@=>: /0M#\26^NJSVSAPAPW!4C/3
MA@#@]CC!P?0U4UCQS9Z/)]GGE"R  D!7;&>F=JG![X/.,'H16+IWA>^.H)JE
MP8% 0JX@,@WC:P&0P^8YV]3T4>@JI\'H5NHI]0< SRSN&?')!"N1QP 68DX
MSQGH, #?#EVEWKEU+$RNAMQAD(93@0@X(XZUZ+7F_A?3X]/UNZAA4*@@R%'0
M;O)8X'89)XZ#H.*](H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPI*1GK\Q(X)R<  <^N2=/5/"7VZR;3/-<[L?O)?WC\2!^?NYZ8'3 QZ5T%%
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MLVYSD.,[L\??]#T]ZB\3^#/[7EBO896AN(> X&X%>3@J2!U)]B"0P((QTM%
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M!':KC$2*N0-N2!RV/5CDGW/4TW4M @U)XIIEW/ VZ,[F&#D'. 0#RHZYK0H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M &<8QQC%:6J^&[?58EM9D!B0@JH)0#:"HQL(X .,=* -.BBB@#SSX)S*;21
M1N$Y)&>0"B ''H<''T/I3_AQ_P ?FI?]?'_L\U=%+X&LY)_MQB'G;P^X,X^8
M$$-M#!<Y&3QR>3G)J]IN@0::\LT*[7G;=(=S')R3G!) Y8],4 <?HW_(>NO^
MO=?Y05A?#GPZMVLUH]Q/#/#*VZ*&;8,#"EL $$[@02">@SU&?38= @AG>_5<
M3R+M9MS<@;>,9P/NCH.U5-9\%V>LMYL\2L_]X%D8\ <E""< #&<X[4 4O#OA
M*WTNYDN$FDEGV!9!+(KL VTKG"A@2%&,]NE=16?HV@0:*OEVT:H#UQRQY)&6
M.2<9.,DXZ#BM"@#R3X7^#+36[9YKF/>XF90=[KP$0XPK =2:[#Q]I0739H+=
M%554,%0!5 5P[$#@= 3[_6MO1- @T1##;+L0L6(W,W) &<L2>@%:% '/^#-5
MBGL(95==L4**Y)P%,: ,#G&,8SSVYZ$&N?\ A?\ Z3-?WJ<Q37'R-TSAG8\'
MD<.IY Z^QK;NOAOI]TQD:!03C[C.B\#'"HP _ >_6M^UM$M%$42JB#.%0!5&
M3DX XZT >8> /^0->?\ ;Q_Z(6L_4[5IM MW49$<Q9N1P"\J9]^6 X]?2O3]
M/\+6VGPO91)MBEW;EW,<[E"MR22,@8X-6+#18;"$6<: 0@,-ARPPQ)8'<3D'
M)ZT -_M^#R/M_F+Y&W=O[8Z=.N<\;<9SQC/%<EXFG3PMJ$6JL#Y5RC13$*S;
M2-I5LYZG X ^ZK$ D\;%K\-]/M6$BP*2,_?9W7D8Y5V(/XCWZUD_%G%W%!8#
M;YMQ<($W;L#'RELKQP6 .<\$X&1D %OX:VLDD4FI7 _>WLA?JWW!P@PW0#G;
MC/RE>3QCH--U^#4GEAA;<\#;9!M88.2,9( /*GIFK5I:K:(L,8PD:A5&2<!1
M@#)YZ55TW0(-->6:%=KSMND.YCDY)S@D@<L>F* -"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HJO>ZC%8+OF=44G +L%&>N,DCGBK% !1110 4444 %%%%
M!1110 4444 %%%% !1110 45#=7:6BF65E1!C+.0JC)P,D\=:?#,LRAT(*L
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ]>N<\[LYSSG/-<I\&[IIK$HQR(YG5>!P"%?'ORQ//KZ4 :?CSQ-)H\<<%L
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MD]\#G&3T!KG?B/\ \?FF_P#7Q_[/#6/XINY[N^L'N;80-YZ@'S$D+ 21G&5
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M6QI]M:+J<\J2,;LQ .A!V!<1X(.T<\+_ !'J>/3'UG_D/6O_ %[M_*>C1O\
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M'3!Z$5FZGX^L=,<PRS*''4*&?!!(()0, 01R#R/2N<^&4*PW>HH@ 59P  ,
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MU)R =1IFJQ:H@F@=70]U.<' .".H.",@X([BLJ?Q]8P&17F4- VUP0P;.2N
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M/^VG_HUZY7P!_P @:\_[>/\ T0M '0> O'L>JQQ6T\NZ\??D;",X+$<A0GW
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MCD@A7(XX +,2< 9XST&.E\0Z?'9V=X8U"^;%,[8[L8\%L>IP,^IY/))H R/
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MMW;OF0XSD8^[Z'K7044 %<_>^%/M-_%JN_'DQE-FW.<AQG=GC[_H>GO7044
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MX>2:8TB6ET\5O*V3&$#, 1@A9&)*G' 8#(XSN(S7:T4 <_X*\*?\(Q"UMO\
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M/+7< W0;\YQG&X *&^88&XFM#_A!?^)=_8WF_P#;39_TU\S[N[\.OO[5U=%
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MMT&AK>@0:V@AN5WH&# ;F7D C.5(/0FM"@#DO"MU-J=W=7@=OL9*I$K8*,R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F_AW4
M(_#6HWEO=L$^TN)(W;B,C+MC<V.?FQZ;E89SC/I%5[W3HK]=DR*Z@Y =0PST
MS@@\\T >?^(M0C\2ZC9V]HP?[,YDD=>8P,HV-RYY^7'IN91G.<6-&_Y#UU_U
M[K_*"NXLM.BL%V0HJ*3DA%"C/3. !SQ0FG1)(;@(HE88+A0'(XX+8R1P/R%
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MC=S79VWBB*XNY-+ ;S8D#$D#9@A3P<YS\X[#O6A9:=%8+LA144G)"*%&>F<
M#GBA-.B20W 11*PP7"@.1QP6QDC@?D* +%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\!I8D8@=,LH)QG/'- %76[:[FE@:UD5(E?,P8 EERO ^5N<!NZ]1SZ;%>?\
MQ'_X_--_Z^/_ &>&LR71!K&MW$+.RQB)2X0E=Z[(@8R01\IR,^H&.#R #U.B
MO-["P3PQK$=G:@K#=0$LA9F *AR",GK\G?.-S8QGCTB@#C+SQ%<ZY<26&G%4
M6W($TT@R0V[!5$/4C:PY&#@X*_*S7K2RU'3W4M,ES&S .&C$+J,XW*5R#C.Y
M@W9<+R:Q/@I_QYR?]?#?^@1UZ!0 45YO9V8\:WUTMTS&WM'"+"&(0D;TWDKM
MY^4GU^8#=M&"7EF/!5]:K:LPM[MRC0EB4!.Q-X+;N?F!]?E(W;3@ 'I%%>62
MZ(-8UNXA9V6,1*7"$KO79$#&2"/E.1GU QP>1%>^'!I>J)IEE))!%=1*S[&)
M/R%VP"3D$[."22-S=5)6@#UBBO-+/35\-:S%:6A9(;B$LZ%BRY"R8^]D\% <
MYR,D X.*B;2?[5UNY@9V6,PIY@7@NNV',>[J 3C<1R0"O&<T >H45YI=Z:O@
MG4+8VA80WK>6\18E<@JH;+9/!<-Z\$!L-@:'BV+2EG+:C*SN<8C+R,L>%7.$
MBY7<,$[NO4=Z .[HKSKX0WNXW5K&[/;PR+Y.[KM8OST!&0 2, 9R< DUF>%O
M#2:Y?7XF9O)2=MT2LRJY,DFTMM(R%QD#U(.>"" >L45YYX+B&BZG=:5#GR B
MR ,2=IPG YZ?/@YR2%7)XYL?#^<:,UWI4K;5M9"Z&20$^4PSG'    9B.,OR
M >H!W=%<?\/,W_VC5FW?Z7,=F[:/W<653A>A'*G)YP#[E_Q/AN9K,I:!B6=0
MXC&6*$$$8')!.,XYQG/RYH ZVBO// 4>E2NDEDS).H(*NY#N-K @J248<;SL
MZ$*3CI6/J&J+KU[<)=Q7,T-O($2*W!:,%=Z%G"[3DG)4YSU4D@4 >MT5YIX2
M:2QOA#:07$5E,IWK<1L%5U5OF4DG&<*.2<Y([+AOA+2$\<F74;XLZB5ECB+L
M$085N"I7G! X S@DY)X /3:*X3QOI/\ 96E7$"NS1AH_+#<E%\R/$>[J0#G:
M3R 0O.,UH?\ ,&_[A_\ [0H ZNBO*O\ F7/\_P#/U70> O!4%K%!J#[I+AHU
M8.S-\H:,*$"YQA5.!G/M@8  -W1+:[AEG:ZD5XF?,(4 %5RW!^5><%>[=#SZ
MU_#?BO\ MJ:YMMFS[+)LSNW;OF<9Q@8^[ZGK7-> [5;NYU6&09228JPR1D,\
MP(R.>E9/@KP9::E<WT,T>Y()ML8WN,#?(,9# GA1US0!Z';6UVMW)*\BFT*
M(@ WAL+DD[1QPW\1ZCCTV*\_T;_D/77_ %[K_*"N:TW48_$K27E]!=W'[QPB
M0@O#&I"D %2AW #![$8)&>: /9:*\T\*2W=LUU:6L4T=OY,CVXN$PRR8&%#-
M\N"Q)P2>F3SN)Q?"EMI[9AU#S8K_ '%C),SQD,<LK*V0 0 &RXR6/&X8% 'L
MM%<_XU\*?\)/"MMO\O;('SMW=%88QE?[WK704 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5C^)O"L'B.,0S@_*<JRX#KZX)!X/<$$'KU
M(V** .?\+>![?PUN,(9G?J\A!;']T8  &>>G)ZYP,=!110 4444 %9_B&U:[
MMIX8QEY(9%49 R60@#)XZUH44 >?^%I=1T&V2R^Q;_+W?-]IB7.YBW3GUQUJ
M7QYI-WXDL8T6';/YP9H_,0[0 ZYWY4'.0>/7VKNZ* .?\>Z7)JME+;0+ND?9
M@9 SB12>20.@/>L37=/D6UT^S3:+J.2 HC$%=T,9+[B&!VJ,DE=QZ #Y@:[N
ML?Q!X;75S'*':*: L8Y$/0L,$%3PRG R.X&,@$Y .2NI+OPBIOWMK/RUPK_9
ME:.3#' ^9ATW;<C!^G<$NF7*WJZ_:0K/'<PJ=CLL;IF-0.6) ) ZC/!9<#@G
M5N/!-SJ6V*]NVE@# M&L*Q;L= 60YQGJ/RP<$=;#"L*A$ "J   ,  <  #H!
M0!P_AC1;Q=2FU*ZC5%FAP-KJP!_=X7KDD!<,< $@XX(JO<Z3/J-Y=RVJV\L3
M/"K_ &I2RB2*/!"A"W*AOF) P25'0FO0ZY>X\'RP2236-RT'GN7D4HLR%C_$
MH;&TGG/)SP.  * ,S2]8>&?_ (1Z]@B431OM-L2L15E)(V\$9P^3D'/;!W4W
M0K34O"J&R2%;J%23&RRK$0"Q)!##DGKWQDC<>VUH?A$VDS7UU*;BY(VJ[($"
M+C&%0$@$\Y(]3TRV[HZ ,_1)+B5"]VJ(Y8E5C);:I PK$\%@<@D?*>U'B&U:
M[MIX8QEY(9%49 R60@#)XZUH44 >?_\ "+7/]B_V;L_TC^YN7_GOO^]G;]WG
MK^M=!_9<G]F_8MO[W['Y>W(^]Y6W&<XZ\9SCWKH** .?\!:7)I5E%;3KMD3?
MD9!QF1B.02.A'>LSXC>%YM8$%Q;JKO;.3Y4F-KABN0<D# V\@XR"><@ ]G10
M!YUK.FZAKUS:7,ENL4=O,"0)4=@-Z%F)R!C X !.0<]5K5U/0)YM6M[]5S!'
M"59MR\$B7C&<G[PZ#O7844 <?XUT"?4KFQFA7<D$VZ0[E&!OC.<$@GA3TS3_
M (HV9GLFF5BKV[I(A#!.5.WJ<<X8X (); &3P>MK$\7^'F\00&T63RPS*6.P
M/D+SMQD8YP<@]L=#0!G_  WTPV]K]JE'[^[8RR,=N3O)*_='3'S8[%CTZ#JZ
M9#"L*A$ "J   ,  <  #H!3Z //[32;[PW=W,]O"MQ%=-OXD6)E.YCCYB>FX
MCH<\'(Y6M#3- GAU:XOV7$$D(56W+R0(N,9R/NGJ.U=A10!QGQ&\+S:P(+BW
M57>V<GRI,;7#%<@Y(&!MY!QD$\Y !S=9TW4->N;2YDMUBCMY@2!*CL!O0LQ.
M0,8'  )R#GJM>BT4 <?XUT"?4KFQFA7<D$VZ0[E&!OC.<$@GA3TS1\4- GUN
MV2&V7>XF5B-RKP$<9RQ ZD5V%% &#KFH7MG*IMH%GA*<CS!&X?/7+<%2.@ S
MG.2.,\[H_@F>ZENKZY"0&\ADC$:?.5WX!9B" 3\H)P?F)).T\5Z!10!YEIFD
M:EIUG+I"VT?S"4><)5 8,#R5^\6(^52=N/EW !36A;>!9+[24TV8!)T+,N3D
M!M[D9*$C!5L=\9S@D8KO:* .*M=1UB:(6[6Z),5(\]Y4* _WC&@8YQZ9&[G&
MWBI?B#X<GU(V]Y:;6EM)-P1N V2IZD@<%1D9&1G!R #V%% ''^([>[\0:?-"
MT'ESLR!8_-1\A71MV[@#OP?3WJE?^#[E$L[VUVK=VD"HRN<A@$P4R"5SDL.V
M=V=XP*[VB@#@M=M-2\5(+)X5M86(,C-*LI(# @ *.".O;. -P[V/B+X6DU"S
MBLK--WE2)A=P&%5&4<N1G&0.N:[6B@#G_'NER:K92VT"[I'V8&0,XD4GDD#H
M#WK0\/6K6EM!#(,/'#&K#(."J $9''6M"B@#C_&N@3ZE<V,T*[D@FW2'<HP-
M\9S@D$\*>F:-,T">'5KB_9<020A5;<O) BXQG(^Z>H[5V%% ''ZGH$\VK6]^
MJY@CA*LVY>"1+QC.3]X=!WKL*** .*N/#EWH5Q+?Z?LD2X8-) _RMG(R5<G&
M22YYP!G[K< :%I>ZCJ#J&A2VC5@7+2"9V&<[5"X SC:Q;LV5Y%=+10!P\V@W
M?A^[EOK%%FAN2#)$7".&P3N#-D8W$GK_ !$;> P(=!N_$%W%?7R+##;$F.(.
M'<M@'<67 QN /7^$#;R6/<44 <?IF@3PZM<7[+B"2$*K;EY($7&,Y'W3U':C
M4] GFU:WOU7,$<)5FW+P2)>,9R?O#H.]=A10!Q^IZ!/-JUO?JN8(X2K-N7@D
M2\8SD_>'0=ZYR4W*:W</:!69(E+(YV[T"190-@X8G&#P 1R<9!]3KG[+PI]F
MOY=5WY\Z,)LVXQ@(,[L\_<]!U]J ,2#1;SQ!>QWE]&L,%K\T<8=78L<<[D/8
M@'G X"A3EC5>UT.\\.7MQ=00+<QW)+!MZ1.NYBQ7+$\<\X!#84Y!!%>AT4 <
M5\/M NM-FO)KM54SR*P*,"I.Z0L0,D@?,,;L''OFI?!6@3Z;<WTTR[4GFW1G
M<IR-\AS@$D<,.N*["B@#C],T">'5KB_9<020A5;<O) BXQG(^Z>H[5A?%BSE
MCG@FMF(DN4>W*[E&X,>%VGJ#O.3T!VGY3@GTVL'4_#!U&[@OG<&.V#8B* _,
MP/S;L\$?*1P<%<C!- &GI6F)I<26L0PD:@#IDXZDX &2>2<<DDU7U^>YMXP]
MFBR.'7<CMMRG\05L@!NG)XQG@G .G10!Y_<Z!>>)+N"\GA2V2U93RZRR/AMV
M,IQ@$ 8.,;B1NS@6)M!N_#]W+?6*+-#<D&2(N$<-@G<&;(QN)/7^(C;P&'<4
M4 8FB7M[=N7N84AB"D!?,\R0MD?-E?EVXR,?>R/0US6EZ3?>$I98;2%9[21B
MZ 2+&R$\8RY).  .^< @@[A7H%% '+WFBW.O6<]O=[4DF.8U1LA  K(C-MY(
M=?G(SG)VG& ,+[/JMS8_V8($C*P[#(TJMN51MV*HW89AQDG;U/RDC'HM% 'G
M_P#PBUS_ &+_ &;L_P!(_N;E_P">^_[V=OW>>OZUV'AZU:TMH(9!AXX8U89!
MP50 C(XZUH44 <?X*T"?3;F^FF7:D\VZ,[E.1OD.< DCAAUQ6?::3?>&[NYG
MMX5N(KIM_$BQ,IW,<?,3TW$=#G@Y'*UZ!10!Q^F:!/#JUQ?LN()(0JMN7D@1
M<8SD?=/4=JI:9HU[X1DDCM(EN+65V94$@C="<=6?.1CCJV=H/RDD'O:* ,33
M;B^N4EDECBB8K^Y0N7(8 C]XR\$$X(V\X)!YKE]?MM2\3P"QDM8XBQ4M*\RL
MH*C)*JNYE)/'\6 2#UR/0Z* .,\4:U+X0M+:"WVR39CB564DL%3!(16!SD+W
M.,@=Q79UF3Z!'<7*:@Y8O$C*B[OD&[.YMO\ >(.#SC&.,@$:= !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#5/$,*V\\EO^[93\@<;CM(+,=O!'8* #N.<8 K=^(?A>7Q);K;PE0RRAB7)
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MQ'44_P &:(^B6D=G*5+Q[\E"2OS.S#&0#T/I0!PMUI[:%>W%Y?6K7,,S,RR
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M :%%%% !1110 4444 %%%% !116(?%T(2XG^;R[1F5F.T!F4?,BY8$D$A>0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/&5W<W'V)[/8R["^;A,A&.-X&T;P.^TGG@X-=5=R-$C/&N]PI*KD+N('"Y/
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M)9B1&B#)8C'?L,D#C)YX4\TW2_$<\DBP7=NT!DSY9$BRJQ4%F4E!\IP,C/4
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M'T/15GU&]M99Y8)7E+HL,NS>K%GY(!!(5@0.H!/'!P =KH?BXW<S6-U$;>Y
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MO\7KX=5!L:269ML<:Y!8@C/.#ZC P220 .I$NB:S<W;F*YMF@^4E6$BRJ<$
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MQD@ \J>F:T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-,NYX&W1G<PP<@YP" >5'7-&LZ!!K2^7<QJX'3/##D$X88(S@9P1GH>*T**
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MW/844 9^FZ!!IKRS0KM>=MTAW,<G).<$D#ECTQ6A110 4444 %%%% !1110
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M_B[J,MA:(\+LC&=02C%3C8YQD$<<5G^*]'N](M3J;7DIN8S&7"L! <L%P(P
M,#(Y((;!ROS< 'I%<_X]U232K*6Y@;;(FS!P#C,B@\$$=">U8GB_Q9+);VL5
MM^[FU'8 Q.0@<+GYAR#EP,A>F2,'%97COPO/I5B[K=2RI^[\Y9SO#?,,%,@E
M,,<D9Y'4_+R >@>'KIKNV@FD.7DAC9C@#)9 2<#CK6A63X3_ ./.V_Z]X?\
MT!:UJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT188QA(U"J,DX"C &3STJ:@#C-6EN_$UK<QQ1-"'1!%YI"2/ACYH(!.T$#:
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M<%&$30* Y4A"<0\!L8)X/Y&C5M.E?6K:X",8E@8%PI* XFX+8P#R/S%=Q10
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M_7?"ZNH."48,,]<9!//-<5\8-;-G:BWCD"R2NH90PWF,J^>.NTD $]^AX)%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAW9.,[BVX 9/'W0!UXZ52^(:K/:&T8_-<R111\D#>S@KDA6P!C)XY (!!(H
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M[T <N-"BUC79TG&Y8XT<*?NDA(@ 1W'S9QWQSD9!MM:)H^N0Q6RK&D]NV]4
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M[F6XW<,6)XV#H,G'(X.""0&K0T_PO+;ZG/JA*^5+$% !._($8Y&,8^0]SVH
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MP9V/@$$$?=;OC/U !8%3FBTM]4G=?/DMXXU8,?(1V9@#RA\S@ C/S#D'&.]
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M;C4M+F>:.&U>Z+LS2/##YN&<D'#L01G!(*_+W4YS6[I_A>6WU.?5"5\J6(*
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M%2"3OR1(.!C&/G'<=ZSU\)WNCW4]U8/$8[D[F6XW<,6)XV#H,G'(X.""0&H
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M'KU(!T4T*S*4< JP(((R"#P00>H->:^ =#M[J[U!)(HV6.?"!D5@HWRC !'
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M\YA#+)(%Z%E(*@G&< [03G#;0*T_%'@PZB8KBT<03VP(C*J-N,<(<=%'0=0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#,?P_$]T-2.3*L7E@'!4#<3N'&0W)&<]"1BK']EQ^=]MV_O?+\O=D_=
MW;L8SCKSG&?>K=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %8^B>%XM'EGN(RQ:Z?<X8@@'+'C ''S'KGM6Q10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5DW7AU+JZBU!F?? K
M!5##R_F!!.W&<D'J".@]*UJ* "BBB@ K'UOPO%K$L%Q(6#6K[D"D $Y4\Y!X
M^4=,=ZV** "L?6_"\6L2P7$A8-:ON0*0 3E3SD'CY1TQWK8HH **** ,GQ+X
M=3Q!%]EE9U3<"?+8 G&< Y!!&><8Z@'M6M110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %8^M^%XM8E@N)"P:U?<@4@ G*GG(/'RCICO6Q10 5CZWX
M7BUB6"XD+!K5]R!2 "<J><@\?*.F.];%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M><@XY_PW_I,.L7J<Q3>=L;IG"RL>#R.'4\@=?8T ;MA\1)M4A%Q:VC2[0WF
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8Y.2<X)('+'IBM"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*KZC<M:Q/*BEV1&8(.K%02%& >3TZ'Z5P_\ PL>\_P"@=-_X_P#_ !F@#T"B
MO/\ _A8]Y_T#IO\ Q_\ ^,T?\+'O/^@=-_X__P#&: /0**\__P"%CWG_ $#I
MO_'_ /XS1_PL>\_Z!TW_ (__ /&: /0**\__ .%CWG_0.F_\?_\ C-'_  L>
M\_Z!TW_C_P#\9H ] HKS_P#X6/>?] Z;_P ?_P#C-'_"Q[S_ *!TW_C_ /\
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MG_0.F_\ '_\ XS1_PL>\_P"@=-_X_P#_ !F@#T"BO/\ _A8]Y_T#IO\ Q_\
M^,UZ!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6#J@GM&299
MB=\Z+Y6Q-A1FP0./,W*F7)W$?*QVA>!O5S3:7<_:FO62*3'RP[YW41K@ X40
M$!G/+-DG&%!P.0#I:P=8\8PZ=)]F"R33  F.!#(ZJ?XCT '3OGD'&#FMZN2^
M&<*RVQOR );N661R!WWL H[[1C(!)P2>>: -+0/%L6LL\*J\<L>-T<R[),$
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MB.0+]T,DR=/F;(P1SGKG'&* /2**Y?Q;K$NBS6UP' MGE$4J-M ^<':^XJ2
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M5@(VP5+8W$]!C R: .]HKAY;_4-1O[FQMY%CAB$1WLBNR;D#84<;BYSG=D
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MG Y +'') R68]3@DD=:I>&/M-R5N1>I=0'(8>2L9&5R""AR&!VY5@."<\XH
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MK U'5)-*T:.Y@;;(EO;8. <9\L'@@CH3VH [6J.M:Q'H\+W<V=D8R<#).2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5P^G+/X,:2W\F2>S9RT1@!D=-W)C*,V=HQG<.,\G);"]Q10!S45U/XD26%H6
M@MY(716F_P!:6<;<^6#\H7YLY.6RI&!FLS1_$T^B1+8W-K.SP ('MXS)&RJ
M%8$D<D=1Z^ARH[BB@#FO#&C2,;B\O$59+Q@&BR'41HNQ0>H)()W<D$8X'(KE
M/!_ARX:YCMIX\6^FM/Y;M&5\PNYP?F;'7YU*@XP,G)!KU"B@#@M>TDZ;>/?2
M6PNX+D("%B$DL;1I@84YRK8Y/'OC #:OA>1)I2\-B;>/809'C2)RV0=FP?,5
M(YW9QD8QD5U%% '->"+1[;[7YBLN^^G9=P(RIVX89Z@]CTK'U[23IMX]]);"
M[@N0@(6(22QM&F!A3G*MCD\>^, -WM% '&:;:IJRS0PV9M8Y8)(S*\21ON;
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M([1.1&N,\\D\LV"3C)).,\9P.* -"O.FT65+\61B?[,UX+L3 9 81L2I(!4
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M,L$0((P00@!!!Z$5IT4 >9:9IJ^&P;&[L3<[#F.:&W67>K$GYMW1ATQD\<=
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MVZR[U8D_-NZ,.F,GCCH S=KX7YB)%N+92Y*H H)4@8=E0#:QZ%3DC&":V**
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M)8' Q(3@*3_%R .[ 9/844 >>2^')[:&V9U)FEU..XF$8+*FXMGIG"J,9))
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MR/\ VMY^UO+^P[=V#MW>=G;NZ9QSCKBNEHH S/$\+36EPB EF@E  &224(
M'4FN:\0Z=++HJVZHQE\BV&P*2^5,>1MQG(P<^E=Q10!F>)X6FM+A$!+-!*
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M MSMB^T*JLHEP)^> 3TVXW =\5NZCXL>U:.U2!I+N2(2&)64*@Z'=*?E !R
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M[4 =KI^J1ZAO\IMWE2-&W!&&7&X<@9QGJ./>K=>=>&]?DM'O+>VA:>7[=.[
M,(U520 2[#&20<*.2 3QCGJO#7B7^V/,BDC:*>!@)(V.<9SM(; #!@.#_3!(
M!MT5R47C2?41YMC:--#D@2/*D.XJ2"55LDK[\<Y! (-6M/\ &D=]:RWBJ1);
MHYDA8X=6122IXZ'!P<?@""  ='5>RU&*_7?"ZNH."48,,]<9!//-<_X;\82Z
M^8Y([9E@8'=*[J,, <A5ZNN<#=QSG(&#5+PM=_9K!+G3K7/G2,3%Y^,8)0MO
MDZ_<'&!U]C0!VM%<EH_C.>\N_P"S9;81L$+N1.DFU<<9"CJ20,9S@AL8J6Z\
M67$DKQ6=HTR1':9&D$*E@2K!=X^8*002.^>V"0#J*AN[I;1&FD.$C4LQP3@*
M,DX'/2LVS\507%NU\Q,<<98.),!T*G!5E!.&Z87J<CC)Q7*:YXXEN+.::2UD
M2VFB=8Y-RL?G!5"R<%5/KDCH!G(- '>VETMVBS1G*2*&4X(R&&0<'GI4U9/A
M/_CSMO\ KWA_] 6J7BKQDOAV2"-HVD%P7'[OEP5VX 7^(DL!U'X]* .CHKE[
M/QC)'-':WMN;=IR1&?-CD4E1D@D$8/("\'<3BKNMZY/:.(+:V>9RH8G<L<8&
M2,>8W&[./EQT.<\4 ;=%8GAKQ+_;'F121M%/ P$D;'.,YVD-@!@P'!_I@G'\
M.>/Y?$ 1H+5BN\+*QD4(F3U4D9<A>2  1P.<@T =G17G]WX@OHM2:..W9P+<
M[8OM"JK*)<"?G@$]-N-P'?%=!HGB=[R=["XB\F5(TD WEPRM]XAMBCY20IP2
M"<X)P30!T%%8\'B(7%X^G(A(BB5G?G 9B-J8VXR5.X'/J,<'&Q0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!!!R"#R"".H-5[[28=0QY\:2;<X\Q%;&<9QD'&<"K$,*PJ$0 *H   P !P
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M+-M &6/5CCJ3W/6J]YI:RK*(\1RSH5,BC#YVE58D8)*YXYX[$4 >4:7K<-K
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MNR9%=0<@.H89Z9P0>>:++3HK!=D**BDY(10HSTS@ <\4 <YX _Y?/^PA<?\
MLM'_ #&?^X?_ .UZZ6WM$MMWEJJ[V+-M &6/5CCJ3W/6C[(F_P _:OF;=N[
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MPK3NJ*]CM!<X7/FEL$G@<*>N/3J13+/6(M)U&X>=@D5ZD+0RDCRF$<>&^?.
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MP&HU*:ZU<@8GEV1G85S'$-H8%N<-QN''S+^ Z#Q/"TUI<(@)9H)0 !DDE"
M!U)I^@:,NBP1VB<B-<9YY)Y9L$G&22<9XS@<5H4 <9H?CBSL+"&1Y5)B@0%
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MD9SV)K3\4>.[26PD99%+3PE5C5E:0&1" &4$[=N?FSTQCDX![*&%85"( %4
M  8  X  '0"JBZ';HSN(HPTH8.0BY8-RP8XY![YZ]Z *_A/_ (\[;_KWA_\
M0%KG?'>L1Z/>6%U-D1J;@$@9QN15SCT&<G'..@)XKM885A4(@ 50  !@ #@
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M4DM[DJ!GC'57VDPZACSXTDVYQYB*V,XSC(.,X%8OC;1)-2M5T^V50DDD2O@
M!(U.=P&5'RE1P.W '< %?X:V;"W:^D $MY*\K?+MP&)VCDDE>K+[-QZG=T37
MX-;0S6S;T#%2=K+R #C# 'H15JTM5M$6&,82-0JC). HP!D\]*;9:=%8+LA1
M44G)"*%&>F< #GB@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex19-1_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex19-1_004.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M><?0@#_ 7BNXUM[B&Z1$>V95Q&#U)<,"2S X*]OUKL*\_P#AQ_Q^:E_U\?\
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M $?=G=M\O'W>WIWVX^6@#M:*YKX>^)6\06@FD_UB,4<X !(P00 >X(STYS@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOM?W?N?Z/NSMW>9G[O?T[;L?-7:T4 <U\/?#3>'[00R?ZQV+N,@@$X  ('8
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M2B5R@/0L&BV@\C@GW'UKTBN7\6^%Y=8N+2XC*A;67<X8D$C<AXP#S\IZX[4
M87BO5;OQ)&-+BM98VE8"5YEQ&NPACM<9##(^]W ^526&+'B/PS-I4MKJ-DAF
M-G%Y;(S#<452 1@#+8+ XR<[<(>17>T4 <U:>,)+YUBBM+@98;FG40JJYPS
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MM0!MT51T?6H=8C\^W<.F2,C(P1U!! (/U'3!Z$5E'XAV B%R9AY9<H#L?)8
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MS0!K45DZAXJM=-E6UGD5)'7< ^0N.>2Q&T?=/4C]15?1_'-GK$GV>"4-(02
M5=<XZXW*,GO@<XR>@- &]117/S^/K& R*\RAH&VN"&#9R5P!C+8(YVYQU/%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9/KCK7%?#_P^BZC>72#]W#(\:9C"@,S'<%() V ;>.2K D+G% 'I$,*PJ$0
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MVQMFBC;RDB1#C8"J[^<A>.H.<9QG!$7Q+A:!M/T^ +Y9E 5)!N0E-B(&ZL5
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M_*".,+TXXXXK8G\!R6]Q)>V-RT'G\NIC$JEB22?F;'7GH2,G! .!;\(>#/\
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M>:EL=/CO->N#(H;RHD=<]F"Q -CU&3CT/(Y -;OA[P0VE7<FHR3M*\L>UMR
M')V$G(. ,K\JX^48&>.;=EX4^S7\NJ[\^=&$V;<8P$&=V>?N>@Z^U '/ZG^X
MUZWV?+YMN=^WC=@2XW8Z_=7KZ#T%,\#0K?ZC?W4H#2Q2A$8C[JY=. .,[4 S
MUQGGDYZ.]\*?:;^+5=^/)C*;-N<Y#C.[/'W_ $/3WJOK'@DW%Q_:5K,T%PP
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MV/@.2*\CU2>Y:62-6!#1A0<JRC;AL* &'&#DY.?FXM^)_!G]KRQ7L,K0W$/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HKE)/B/ SM%;QS7&S[S6\6]0<D8SD>G!&0
M1T)K8T/Q%#K2L82=T9PZ,"KHW]UE/0CD=QD$ G!H TZ*** "BBB@"&[M5NT:
M&09212K#)&0PP1D<]*BTO2X]*C6V@7;&F<#).,DD\DD]2>]6Z* "BBB@ HHH
MH *S]$T"#1$,-LNQ"Q8C<S<D 9RQ)Z 5H44 %%%% !1110 4444 %%%% !11
M6/XH\41>&XA<3!BK.% 0 G)!/<KQ\M &Q15>]U&*P7?,ZHI. 78*,]<9)'/%
M&HWJV$3W#Y*Q(S$#KA02<9QSQ0!8HK/T#6TUN!+R(,$DW8#@!OE8J<X)'4>M
M:% !1110!#:VB6BB*)51!G"H JC)R< <=:FHHH **** "BL?POXHB\21&XA#
M!5<J0X .0 >Q;CYJV* "BN?\:^*_^$8A6YV>9ND"8W;>JL<YPW]WTKH* "L_
M1- @T1##;+L0L6(W,W) &<L2>@%6KJ[2T4RRLJ(,99R%49.!DGCK3X9EF4.A
M!5@""#D$'D$$=0: 'T444 %%8^M^*(M'E@MY Q:Z?:A4 @'*CG)''S#IGO6Q
M0 445S_B3Q7_ &+-;6VS?]JDV9W;=OS(,XP<_>]1TH Z"BBB@ HJNFHQ/(;<
M.IE49*!@7 XY*YR!R/S%6* "BBB@ HJNFHQ/(;<.IE49*!@7 XY*YR!R/S%8
M_B3Q7_8LUM;;-_VJ39G=MV_,@SC!S][U'2@#H**** "BBB@ HKG[+Q7]IOY=
M*V8\F,/OW9SD(<;<<??]3T]ZZ"@ HHHH **** "BBB@ HHHH **9-,L*EW("
MJ"22<  <DDGH!3+6[2[42Q,KH<X9"&4X.#@CCK0!-17/^"O%?_"3PM<[/+VR
M%,;MW15.<X7^]Z5T% !16/X7\41>)(C<0A@JN5(< '( /8MQ\U;% !117.:]
MXXBT>=;(QRR2NFX"% ^1EATW Y&TD\=* -.;0()ITOV7,\:[5;<W .[C&<'[
MQZCO6A7.:'XZ@U:9K/;)%,HSLG4(QXSP,GD#G!P<<C(!QT= !117/V7BO[3?
MRZ5LQY,8??NSG(0XVXX^_P"IZ>] '045CZ)XHBUB6>WC#!K5]KE@ "<L.,$\
M?*>N.U;% !1110 445@^)[P6BEWNA;#8VWY8R21U.'#%P.,*@4]>3D8 -ZBL
MGPK<3W%K%)=C;.5^88P>IP2.Q(P2.,$D8'0:U !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8FL
M^"[/66\V>)6?^\"R,> .2A!. !C.<=JL:'X;M]"5DMD"!SEN2Q..G+$G [#.
M!D^IK3HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KBOB[J;V-B5C./.D6-CR#M(9B!@CKMP>H()&.:[6N7^(
M_A]M;LW1,F2(B10.Y4$%< $DE2< =6QSB@#=TK3$TN)+6(82-0!TR<=2< #)
M/)..22:I>)M<B\/0O?.H+850!@,YR=JY/89)[X&X@'FL_0?B!;7T8$\BQ3H
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M;M_'/M74"]OK"WN+B[\@M%$S1B'S,956)W;L<<#I[UB_&B%GLE(!(6="2!G
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MO$46ZS@0/&O[QY6/EEAG]V@&#DC!R6PN<-V8]!X'\4_\)+;BX*[75BC@?=W
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MB3JL7B(0:5:.LDLDRME#O10 RY9ESZY.,X4$G'&;?Q'_ ./S3?\ KX_]GAH
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MYN5M[R1R7C&&2-2ZC&>C_.3G/#+@D<4 >A>'O%ZZC8_VG( "B.9%C.<&/)(
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M*BDY(10HSTS@ <\5Y_X=U"/PUJ-Y;W;!/M+B2-VXC(R[8W-CGYL>FY6&<XR
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C>Z';W[;YHHW8#
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MDECS7:T4 %4;W0[>_;?-%&[ 8!=%8XZXR0>.:O44 ,AA6%0B !5   &  .
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M]A10!7?3HGD%P44RJ,!RH+@<\!L9 Y/YFK%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M )KLM%UB/6(4NX<[)!D9&",$@@CU!!'IZ$CF@"]1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !17'Z9K\\VK7%@S9@CA#*NU>"1%SG&3]X]
M3WKL* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB0RS_,AR6^4X7&[&T\CJ,GCFWX7L'GU*]OY8WC^[&FX$*RCY2P)49SY:D8X
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MQFWYB!7;&Q&U 2-[X&?NKT)-:'AK0Y]'6YU2Y427<P9]B$M@!=PB!P2#GY<
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MBWY8MN9_09/"YW8&TY;AFBZ=<:=H\Y=)))[DRDH5;S,R$1$D$%B<#?TY'YT
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MLP^6.<@ [LL021M(QCMV'CSPJ=:L_LL  :(JT:C"K\H*[>F -I('09QD@9H
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M54S!'YB%54;3N#8SC@X)&1V^Z !NB?$&2;2Y=2E4&6 E,@<,V%"L5R,#+C<
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MZG]BN;B2UMD1=AB+)O+A>KC(QN)^8_* I'!)-=UX?L391;1,TZ,=R/(0S;6
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ME*2,QP0,'(QN4<#HH)+ LH !GZSXQ34+N:WGNI+6WMW"JL*,)'90RN?,0,0
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M>W?(65&4D=<,"#C.>>: .$\+Z7<^*XO[1N;J5!(6V);/Y2JJLP.>#DYX'4X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N4\3:!=Z\QM&>)+)F0MM#&<A0"5Y!498<
M$=!CKRIZNB@"&TM5M$6&,82-0JC). HP!D\]*FHHH ***KOJ,22"W+J)6&0A
M8!R.>0N<D<'\C0!8HHHH **** "BBB@ HHHH **** "BBB@ HJN^HQ)(+<NH
ME89"%@'(YY"YR1P?R-6* "BJ[ZC$D@MRZB5AD(6 <CGD+G)'!_(U8H ****
M"N?O] EN[^"^+J(+>-\+CYB[@JW;IC'<\C&.2:Z"B@ HHIDTRPJ7<@*H)))P
M !R22>@% #Z*J6.K0ZAGR)$DVXSY;JV,YQG!.,X-6Z "BBB@ HHHH **** "
MBBB@#CX/"USJEQ'>:DT1%MS$EOO"[B0=S%N>,#C.#@=!D-V%%% !1110 444
M4 %%%0W5VEHIEE9408RSD*HR<#)/'6@":BF0S+,H=""K $$'((/(((Z@T^@
MHHHH **** "BBB@ HHHH ***KIJ,3R&W#J95&2@8%P..2N<@<C\Q0!8HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LGQ5I\
MNI6LMM;LJR2+M!?[N"0&!X;JN1T[]NM:U% %32;'^SX8[;.[RHT3.,9VJ!G&
M3C./6K=5[;48KIF2-U9HSAPK!BIY&" >#P>OH:L4 %%%% !1110 4444 %%%
M% !115>VU&*Z9DC=6:,X<*P8J>1@@'@\'KZ&@"Q1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 457MM1BNF9(W5FC.'"L&*GD8(!X/
M!Z^AJQ0 4444 %%%% !1110 4444 %0W>_8WE;?,VG;OSMW8^7..<9ZXYQ4U
M% '/^!O#1\.VJVS[?,+,SE"2I). 1N _A"CH.GXGH*** "BJ,6N6\LGV=98S
M+DC8'4OE<Y&W.<C!SZ5>H **** "BBB@ HHHH **** "BF33+"I=R J@DDG
M ')))Z 4RUNTNU$L3*Z'.&0AE.#@X(XZT 34444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7<2?*C0JQ4<*6Q$=Q XSEFYZ\GU-,^#T*W44^H. 9Y9W#/CD@A7(XX +,2<
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MADY..O&>@P =UH^M0ZQ'Y]NX=,D9&1@CJ"" 0?J.F#T(JW-,L*EW("J"22<
M <DDGH!7!?#/]U<ZC O$:7'RJ.%7YY!PO0<*!QV ]*[#7]2BTV"2>X&8E7YA
MMW9#?+MQT.XG'/'/.!0!E?\ "R-/W^3YZ[MVW.U]N<X^_MVX_P!K.,<YQ4/Q
M2_Y!T_\ VS_]&I7*^,=<FU73V(L_+M?D,<C2("JAPJ$18R,C@8XPW!*]=7Q+
M_P @%?\ KWM?YQT 7=*\<V>CVUO;SRA9!;0D@*[8S&,9VJ<'O@\XP>A%=;]K
M39Y^Y?+V[MV1MVXSNW=,8YSTQ6!X6T"!].BMC&ICFA1G']YG4$L3USGH<Y&!
MC&!CR_\ M23^Q/*W?+]L\O&!]W9YN.F?O\YZ]LXXH ]0_P"%D:?O\GSUW;MN
M=K[<YQ]_;MQ_M9QCG.*U[_6H;"$WDC@0@*=XRPPQ 4C:#D'(Z4W^P(/(^P>6
MOD;=NSMCKUZYSSNSG/.<\UY5IETTV@7",<B.8*O X!>)\>_+$\^OI0!ZU_:D
M?D_;=W[KR_,W8/W=N[.,9Z<XQGVK%USQG!#8M?Q28$BNL3;&YD ;:,%>.5/W
MACCGBH?^8-_W#_\ VA65X:_Y +?]>]U_.2@"WX"\>QZK'%;3R[KQ]^1L(S@L
M1R%"?< [_K7:URGPM_Y!T'_;3_T:]3?$BZ:UT^=T."55>@/#NJ,.?4$C^7-
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M7@S2HH+"&)47;+"C.",AC(@+$YSG.<<]N.@ KE]?T^.?5;'3'4&VB@)5#R.
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M 3>4(M^.=DDB!E]P>W<9.,9-7?!FE106$,2HNV6%&<$9#&1 6)SG.<XY[<=
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M5D>%M @?3HK8QJ8YH49Q_>9U!+$]<YZ'.1@8Q@8\_P!,NFFT"X1CD1S!5X'
M+Q/CWY8GGU]* /1]/\<V>HRK:PRAI'&0 K_W=_7;@$#J"<@\'GBGZSXTL]&;
MRIY55_[H#.PX!Y" D9!&,XSVIG@;3X[*R@$:A=\2.V.[.H+,3W)_08 X %<U
M\'H5NHI]0< SRSN&?')!"N1QP 68DX SQGH, '8:9XDM]4C,\#AU49(4$N.O
M5,;\G!P,9/;-6-+U2/58UN8&W1OG!P1G!(/! /4'M7#W$*Z;KL0A 47,#&0
M?>/[PD^Q)12<8R1D]3D\,SKX3N+VP8-Y,:&YC 7^ #YP"QRQ^ZH)."5/0YH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *Y^R\*?9K^75=^?.C";-N,8"#.[//W/0=?:N@HH Y^]\*?:;^+5=^/)C
M*;-N<Y#C.[/'W_0]/>B]\*?:;^+5=^/)C*;-N<Y#C.[/'W_0]/>N@HH Y36?
M!#7%U_:5I.T$Q7:Y""16& !\K$#H!QR. 0 1DGA[P0VE7<FHR3M*\L>UMR '
M)V$G(. ,K\JX^48&>.>KHH Y36?!#7%U_:5I.T$Q7:Y""16& !\K$#H!QR.
M0 1DOUGP2=1:*Z$S)>0(JB95&&QU)CZ8.6X! ^8@[AQ7444 <_I?AZYAD6>Y
MNWEV9VJJ+"AW @[E7._L5SC:1[T7OA3[3?Q:KOQY,939MSG(<9W9X^_Z'I[U
MT%% '/\ C7PI_P )/"MMO\O;('SMW=%88QE?[WK47B?P9_:\L5[#*T-Q#P'
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M)&1D>@)Q@L"#NK*F^&SW-Q#?S7+231.K,6C4*P1@RJJJ1L'K][)); YSW%%
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M[/*7?Y>?N>;G/3CIC'&W;\M;L7A6".T_LL ^3L*\X+<DDMD@C=N.X<8!Z 8
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ME3CN  &^8#)K0UKP)%J4,, =T>U4"*13\P(4 $] >5!.,'(X(YKI:* .,N?
M$NK,HU"Z:>)#D(L:P@GCJ5)R,9'8C)PPYSJ^+O"J^(8U4.8Y8G#)(HRRD=>X
M.#UX(Y"GMBMZB@#@M<^&4NNJK7-VSRH?E/E*J!3U'EJ1\Q/5L\@ 8X!K=\2>
M%/[:FMKG?L^RR;\;=V[YD.,Y&/N^AZUT%% %'6M.;487@21HF8</&<,I!!!X
MQQQR,C(R,CK7-7/@"75F4:A=-/$AR$6-803QU*DY&,CL1DX8<Y[.B@#G/$G@
MU=6E2]CD:&YB "2+\PQG."IZCEAU&<G=N'%/TOP]<PR+/<W;R[,[55%A0[@0
M=RKG?V*YQM(]ZZ"B@ KBK/X>2:8TB6ET\5O*V3&$#, 1@A9&)*G' 8#(XSN(
MS7:T4 <_X*\*?\(Q"UMO\S=(7SMV]548QEO[OK1X*\*?\(Q"UMO\S=(7SMV]
M548QEO[OK7044 <_X;\*?V+-<W._?]JDWXV[=OS.<9R<_>]!TK*L_AY)IC2)
M:73Q6\K9,80,P!&"%D8DJ<<!@,CC.XC-=K10!S7A#P2OAIYWC?*3LI5=I&P*
M6PN2S%N&QGCI[UKZUIS:C"\"2-$S#AXSAE(((/&...1D9&1D=:O44 <9<^ )
M=691J%TT\2'(18UA!/'4J3D8R.Q&3AASF]XG\&?VO+%>PRM#<0\!P-P*\G!4
MD#J3[$$A@01CI:* .<L/";EFDO9VN&>)XL;5B0(^TL-J?Q''+ YQ@=@:S;?P
M%<Z>C6MI>O' <X5HE=AN'S8?*D9.2-H7!.>N2>UHH R?#7AJ+P[%]F@W;2Q8
MESEB3@9. !T ' '3UR3YQ\+O#LMU;O=6UPT$IE*-\BR(5558?(V/FRW#9X&1
MCDUZ[6?HF@0:(AAMEV(6+$;F;D@#.6)/0"@#/\(>$%\.JYWM)+,VZ21L@L03
MCC)]3DY))))/0#,MO $NDLPT^Z:")SDHT:S 'GH6(P,8'<G RQXQV=% &?HF
MEMIR%))7F=F+,TA'4@9"@<*N1D+VSUIVM:/'K$+VDV=D@P<'!&"""#Z@@'T]
M01Q5ZB@#BO\ A KGR_L/VU_LOW=GE+O\O/W/-SGIQTQCC;M^6MV/PS';V;:7
M"2J&)T!/S'YP<L>F3DDXX'88%;%% &3X6T+^P;9++=O\O=\VW;G<Q;ID^N.M
M97Q2_P"0=/\ ]L__ $:E=7535-+CU6-K:==T;XR,D9P01R"#U [T <+I/@:>
MZL8X8;MXX)X49XV17YD 9@K J54Y^[]<D[C717_@N.6P.D0L43"@,1O/#AR2
M,C))!] ,\#'%;MI:K:(L,8PD:A5&2<!1@#)YZ5-0!4TFQ_L^&.VSN\J-$SC&
M=J@9QDXSCUKG;CP*]O/)>6-PUNTY)D!194))SD*Q&#G)YSU(&T<'K:* .<\-
M^#5TF5[V21IKF4$/(WRC&<X"CH.%'4XP-NT<52\<?#M?%#I,)/+=%*D[2^X9
MRHQN4#!)^N?85V%% %'4=+6ZMWLTPBO$T8P.%#*5&%&.!Z<5E6'@N.*P&D3,
M73# L!L/+EP0,G!!(]0<<C'%='10!P\7P[F>#[#/=M) J$(GEA<-@["6#%F5
M"<A"0,A>PQ5W_A!?^)=_8WF_]M-G_37S/N[OPZ^_M75T4 <IK_@7^U[.'3?-
MV^1Y?S[,YV(4^[N&,YSU.*U?%.A?V];/9;MGF;?FV[L;6#=,CTQUK6HH X?Q
M-81QI8:,[E270+*/E(\A,97YN'8D*N=P&3P2!5+Q?I,GA> W\%Y<>8C* L\H
MD5MWRD!2 "0"6Z'@'CN.ZU/2HM40PSHKH>S#.#@C(/4'!.",$=C6/I_P\L-/
MD6>.$!T.5)=VP>QPS$9';C@\CF@#8TFX>YACEE&V1XT++@C#%06&#R,'L>:M
MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<?/X\DN+B2RL;
M9I_(X=C((E# D$?,N.O'4$X. 0,D ["BL>;Q(MG:F_N4:+8#O0C<P8-LP,<$
M%ONMP""&X'3$F\<74*&Z>QD%NI)+&11($#8+&(C<"!SC.,<[MOS4 =G17+^)
MO'<>DVL>HPJ)HY7"C#;>JL<YVGD;<$$ @]<$8J*U\97%S#)>BU*P)$\B-)*%
M+A3G&T*2I*Y8=0< 9P0U '6U4U35(]*C:YG;;&F,G!.,D < $]2.U1:!K*ZU
M!'=IP)%SCG@CAER0,X((SCG&1Q7-3>-TU#3YM1DM]T22!5CE(Q(N] &Y4CJ>
MGS %2,^@!U]I=+=HLT9RDBAE.",AAD'!YZ5-7.7/BZ#1[*&^D4I'(D6V., X
MWKN"C[HP!GT&!QS@5%IWBRX9D-W:-!%*557\P289\! R !E!/&2.&(!QG@ Z
MBBN:U;QBT$YL;2![B9-N_!"1J&4L,R," 2 ,<8.< Y&*=H?BXW<S6-U$;>Y
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M+^UFRJ*/G489@V=NWCN21C..""< \ '1T5R6B>,+K41',UFRP2E?G$JL0&.
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MO!6JW=O<WSPVOF.\V9%\Y$V'?)\N2,-R2,CT]Z /6Z*Y*X\=/<3R6=C;M<-
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M]8H Y_5/'MEI4C6T\NV1,9&R0XR 1R%(Z$=ZNZ'XDM]=5GMG#A#AN"I&>G#
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MGE\YG8!A&JJ40 EV&,D@X4<D GC'/>^$?%2^(8V8H8Y8G*O&QRRD=.P.#TY
MY##MF@#>HKC+;Q_+JS,=/M6GB0X+M(L()YZ!@<C&#V(R,J.,ZOA7Q='XA5PJ
MM'+"0)$<8*DY[]QD$<X/'*CB@#6U&]6PB>X?)6)&8@=<*"3C..>*KZ!K::W
MEY$&"2;L!P WRL5.<$CJ/6H?%G_'G<_]>\W_ * U<1X'\436UA'%:VS7'DB3
MS"&$84EV8*N02[;>2%!QE1R3@ 'IM%8FA^*4U>T_M"-6.%8M&N'<,G5 !U)_
MAZ$@@X&:Q=2\>W.F*+F:R=;<LOSF52X5CP3& 2IQV) #?*3DT =K17.>(/&2
M:1%!> !H)W0%\LI57&X/MV$D;021P>@QSQH>)-<70K>2\92PC ^4<9+$*!GL
M,D9/.!V/2@#3HKG-5\8C3887:*1I[A,I BDOD(&8'@8"Y )QGOM.#BJ/&\MC
M(B:A;FWCE)59/-61 W8,5 V@^I/Z D '6T45Q\_CR2XN)+*QMFG\CAV,@B4,
M"01\RXZ\=03@X! R0#L**Y_5/%+:;9-J,D+*Z8#1,P!!\P1GY@"",\J<?,,'
MC-6O[=_T/^TMO_+OYNS=_L;]N['X9Q^% &M17.6'C2.6P&KS*43#$J#O/#E
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M@ HHHH **** "BBB@ KA+[PD$DFU'3KOR7W2&4%@\6\#)#<X7!))W!MN<@#
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MK?3]_G>0N[=NQN?;G.?N;MN/]G&,<8Q710PK"H1  J@  #  '   Z 4 <O\
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MRYMY%8$MN+1@$=B%W$1KG!'4D#K7HM9^MZ!!K:"&Y7>@8,!N9>0",Y4@]":
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M&6G("! /F&#EY#W!X);@\=1@XR.A(( 0:.-8TJ.T.,R6D07)( 8(I0DCG 8
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M:EH$&I/%-,NYX&W1G<PP<@YP" >5'7-&MZ!!K:"&Y7>@8,!N9>0",Y4@]":
M./\ C7_QYQ_]?"_^@25H?$+Q9+HGDP0;%>Y9E\R4_*@&T;O3@L#DY  .5.>.
M@UO0(-;00W*[T#!@-S+R 1G*D'H33M8T6'6(_(N$#ID'!R,$=""""#]#TR.A
M- 'FOBFTGM+ZP2YN1.WGJ0/+2,J#)&,X4G(;'&?[IQWK8^-?_'G'_P!?"_\
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MAMK)&VTXSACPG&#_ !$=1CUXI_AJ6>6VB>ZQYS("V 5Z],@@8;&-PQ@-G'%
M&G1110 4444 %%%% !1110 4444 %%8]S<W:W<<21J;0H2[DC>&PV !N''"_
MPGJ>?0N?%$5O=QZ60WFRH6! &S #'DYSGY#V/:@#8HK'UNYNX98%M8U>)GQ,
M6(!5<KR/F7G!;LW0<>NQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%8]MXHBN+N32P&\V) Q) V8(4\'.<_..P[T ;%%<?J>OSPZM;V"MB"2$LR[
M5Y($O.<9'W1T/:NPH **** "BL>Y\416]W'I9#>;*A8$ ;, ,>3G.?D/8]JV
M* "BL>YN;M;N.)(U-H4)=R1O#8;  W#CA?X3U//IL4 %%%<5XMU^Z-[!I%HR
MQ-*N]I"H<X&_("D$<!"?<X&5&20#M:*J:7;R6T:QSR>;(,Y?8$SDDCY1P,#
M_#-6Z "BBB@ HHHH **** "BL_7];31('O)0Q2/;D( 6^9@HQD@=3ZT?V@UW
M;?:K9<O)#OC5\#)9-R \XZX!Y_'O0!H45GZ!-/- CW:JDYW;E3E1\QQCYF[8
M/4UH4 %%%% !116/XHN;NWB#6$:R2[P"'( VX.3RR<YQW_"@#8HHHH ****
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M07WG3?\ +3]UYG[G[SK]S'X]?O<UB?"_0Y=6MG7SGB@69CB!MDC.43.6P?E
MQ@#J22>@KH/AUJ,NGQQZ3/;S(\;2#S-F8L99\E^G7(&,@\$'GA_PBTZ6PM'2
M9&1C.Q =2IQL09P0..* (O _B.2UCO8+EFE_L]W.\G+LHWY&#W^0D98]<9
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M,!@LQ'5B<Y/\6WDF\'RZ5HLEIM9IY&5V1/G()D3@;1SA5&>O.<$C%=-]D?\
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MMZHI!=P5(QMXSD_=)]R.KKRSX86<NJ3_ &NY!!L(A F5*\Y;.>0-R*=I&.C
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M;:2+*I"!FP#@_0#ACU'R\CN#X::<5@?49!B6]D:1A@J -S;0 2>.2P/<,.N
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M9&,[$!U*G&Q!G! XXH B\#WD]_'>Z5)*S26[O&LY)+_/O4'KG*E2P^8GG (
M%:'@/Q$T]B9;HL'M3(LK2#YOW?S<@<DA2 <C<2#G)Y-3P#ITMK=Z@\B,JR3Y
M0LI4,-\IR"1R.1T]17.>--)EBOVL81B+5/*W8CR%*."S#!&2N"[=.&.[LU '
M5^#M/;6;5+J]W.[W!N$5BX$9!P@7+9VX^91TPW0]34^*FLS6"P11NT,4TA$D
MJ!BR@%<8*\],G Y;;@'&0>UM+5;1%AC&$C4*HR3@*, 9//2LKQ-J[:>$'V=Y
MXI-RR>4 [ 8X'E_Q!N0>0!WSD @%7PC8HO\ I-O=RW$3K@B6028;Y2IS@%"
M3N4C)R,XP*VM6N'MH9)8AND2-RJX)RP4E1@<G)[#FN"\.Z-)<ZD-1M[=K6U5
M"KJX\LN=O_/,=!DJ?[IV[L[N*]"NY&B1GC7>X4E5R%W$#A<G@9/&>U 'F'@I
M_P#A(%WOJ$RWA9F$8?" Y)7]VPPXXW%5P IVD#J=CXA^+&LIHM.68VZR(S22
MB/>0I#*H4 YR2#D@ CY2#UK)\5,?%$7EQ:?*MW(5)DDC$87:.?WIQN&!M ;
M/!Z@"M/7O#UW8/::I"OGSVL(29=V2P"'++D DG<W/))*X4\T <_>>,8=#:.Y
MLKN:Y^;$D5P7*E2,Y#,BA2".N">?0$'I=:U&?7-0.CP2M#%#&'F9.)&Y5L*W
M)'#*.W5L[A@'6M/&$E\ZQ16EP,L-S3J(55<X9@23N(S]T<D9]*Q]=LY] U :
MO!$TT4Z".54!9UQCD*!TPBD9R"=P)7*F@#HM$T.727*^<\L#*3B=M\BN",8;
M ^4C.0>A (ZFL+X1:C+?VCO,[.PG8 NQ8XV(<9)/'-;6BZ_-JLO%O)% $;+3
M@(Y?*X 3).W:2=W0GCC'/)>$)I_"(FTTVTTI\XF-T3$;;@%7<Q.$!P"3EL9.
M0"O(!I^ =1ENKO4$D=F6.?"!F+!1OE& ">!P.GH*Y_X>:9=>)8FFGNYUB1RJ
MB.5@Y8A226.?E Q@<\DD8YW;'PPLKB&:]ENHVC>616Y4A2=TA;:3D$ GJ">,
M<U8^$6G2V%HZ3(R,9V(#J5.-B#."!QQ0 :MJ,J:U;6X=A$T#$H&(0G$W)7."
M>!^0K"U[0/,UF&#SIAYT;ON$F'3/FG:C8^51C '/!/K6[JVG2OK5M<!&,2P,
M"X4E <3<%L8!Y'YBHO&%G/8ZA;ZO'$TT4:>6RQ LXSOR=H'3#Y';(P2N02 0
M^*C+HLVFVL<TI5IR'+R$LX,D9PQ&-P&X@9'3BHO&7B\&\.FO<-;01HI=T0EW
M8E6VAER5&T\' YW A@14OBH2ZU-IMU'#*%6<EP\9#(!)&,L!G:#M)&3TYJQK
M6G3Z'J!UB")IHIHPDRIS(O*KE5X)X53WZ-G:,$ &+IOBY--NX8K2YENHKAE2
M1;@N60E@%=695_O= .<'/52H^KG4M0N(+Z[EM5C8I$D;&%2 20Q8Y494 Y;[
MVX;3@ 5VNE^*)-3D6-+69(^=[S@1;>"5PI)+Y(P<8V\$]:Q_$.MK<F6WNM/E
ME,9=8RL?F(5(&&$@&4+<9VY*^N1@ '6Z79M91K"[M(5R-[XW$9.W..I P"?X
MB,GDU;KBO!=C/X5TZ5KD9:+S9%3?G"JN=N1D#)!/&1SGKD5TN@:M_:\$=WL9
M/,7.UNH_Q!ZJ>,@@X&: ,+X@>(IM.$%I:D+/=RA5=@"J@$ ]<\DL/X3QN[XK
M/UCPK<Z-;M>6]Y.TT"%F\Y]\;!5._"$'![KG=@\?[0T/B!X=FU$07=J T]I*
M&5&("L"03UQR"H_B'&[OBL_6/%5SK-NUG;V<ZS3H5;SDV1J&4[\.2,GLN=N3
MS_LD S_&GBN6]TNWOX6:)Y)5#&-BG(60,!@D[=RY&3TQGFNM\->')=./GW%Q
M++*ZG>I?]R"Q#?*F!C&,#IQG &<#DO&GA26RTNWL(5:5XY5+"-2_)60L1@ [
M=S8&1TQGFO3: ,SQ/,T-I<.A(98)2"#@@A"001T(K-^'%V]W80RRLSN?,RSD
MLQQ(P&2>>E;6K6/]H0R6V=OFQNF<9QN4C.,C.,^M<%X4UB[TBU&F+9RFYC,@
M0LH$!RQ;)D) P,G@$AL##?-P 5/"WB.ZCTBYO%9I)HY2%+EI"!B/)YSPH);G
M@=2,9J]X$@74ECG2_F>X3:TD;R$IC(WJ8WY(PVW>"1N^8<C%'P\2XT+3IG,#
MM*LS,(F!C9AMC!(R,],XP#DC YK/\2V#>)GC%C9RP3K(7::5!!C)'.0?F.3N
MSRPP=H.30 [6?&*:A=S6\]U):V]NX55A1A([*&5SYB!B &['@KC@,":L>$O%
M@COAI\$[W-O.I(:;=YB,JL2-S %@0O3  R,<AMUM+:?PC>SW*0O-:W;!B8AO
ME5OF;&T8XR6[8P5^;((/2Z)X@DU5S_H\L404_//A&+ CY1'DG&#G=G&010!M
MUY)IGACS=6N+/S[@;(0?,67$K<1<,^.1\W3'8>E>MUYY?Q3Z!JLFI>1)-#<1
M!<P*79=H0<KZY3N0"#D$D$4 4O$5G+'JUI!;OB06H422_.< 2AG/3<V,D9X+
M8SQFK=^LOA.^M%6>::*Z8QLD\F_!)5=P.,<%@> #P1NPW%B[MI;S5[2]$4@B
M^S<ED(VEEE.UCR PR 1GK4OC[3I;J[T]XT9ECGRY52P4;XCDD#@<'KZ&@#5\
M46'G,))KMK>#  5&6(E^3GS3R05_@Z<9[5S_ (%U>1+ZXTT3FX@5/,21FWM_
M!P'!.0-V#VR,@+D@U_$>EO:ZG]NN+=[JV>/""-3+L(4 Y0\=<G!X^;<"6! ?
MX*T^1=4GN?LS6\+P?("FU1S%CH-H8@9*CD'(/(- %+7M \S688/.F'G1N^X2
M8=,^:=J-CY5&, <\$^M>E:7I_P#9\:P;WDVY^:5MSG))Y; SC.![8KC?&%G/
M8ZA;ZO'$TT4:>6RQ LXSOR=H'3#Y';(P2N03V6EZA_:$:S['CW9^65=KC!(Y
M7)QG&1[8H Y+5M1E36K:W#L(F@8E Q"$XFY*YP3P/R%9EP;O4M8GLHKAXXA&
MI8!LX4I'N" Y"L2W##!&2>>AT]6TZ5]:MK@(QB6!@7"DH#B;@MC /(_,4:3I
MTJ:U<W!1A$T"@.5(0G$/ ;&">#^1H KZ;-+X?U1=-,TLT5S#N'G/N9"NXYR1
MS]P]-OWAG.T9RM>T#S-9A@\Z8>=&[[A)ATSYIVHV/E48P!SP3ZUNZMITKZU;
M7 1C$L# N%)0'$W!;& >1^8HU;3I7UJVN C&)8&!<*2@.)N"V, \C\Q0!2F,
M]Y=C0(+B58K>/?-(S9G?+*^!)UX#*!]W W9W  $\0&?P.T5XMQ+-;/(J2I.W
MF/T8Y4G&.,]U^8#.X' M:UIT^AZ@=8@B::*:,),J<R+RJY5>">%4]^C9VC!%
M7Q )_'#16:V\L-LDBO*\Z^6_1AA0<YXSV;YB,[0,D 9XUENKG5(+&VG:(2P<
MX9MHYEW-M'!;:.#P<@<C (T_%MF_A_39_*GF9]R$/)(3(,NBD!A@@8[>Y]:9
MJVG2OK5M<!&,2P,"X4E <3<%L8!Y'YBM/XCVCW=A-%$K.Y\O"H"S'$BDX YZ
M4 <S_85W<:=_:$MY,)5M_,41OM3:J[U# 8+,1U8G.3_%MYB@2]U[3WU66Z=&
M2-VC6#Y%Q$,.7VX)+E#CG"YR.#M'5_9'_LGR-K>9]AV[<'=N\G&W;USGC'7-
M9GA[3I8M%:W9&$OD7(V%2'RQDP-N,Y.1CUH T/#=_<>(=.CF$@CGD!'F! WW
M)"I.P\98+ST&3D <"N,\3ZB/#HBN[&_>=A)AHY)Q,I!!.2JD<<8/'<$%2!FQ
M<>'+JYT2*VC5A)&[,\9#*[*'D.-IZGD, >N.,G .;XJL_P"TK:.*TTZ6)D9-
M[&'#?<("@@;W&<Y8XY SRPH [#XM:?Y]D\^]U\K;\JMA&W2(/F7'..J^AJOI
M6BMING->I/.6:P)"O+E$)B# H !M*XPO/ K?\<Z/)K%G+:PX,C!2 3C.UU;&
M?4XP,\9ZD#FL#2]5EO=/?3VMIXY8[)UR\9",538 IX)9N#C'J.<9(!1A\82Z
M5HL=WN9IY&9%=_G()D?D[CSA5..O. 01FM;_ (0B[\OS?MLWVO[WW_\ 1]V=
MVWR\?=[>G?;CY:R8?!\NJZ+':;66>-F=4?Y"2)'X.X<95CCISC) S6M_PF]W
MY?E?8IOM?W?N?Z/NSMW>9G[O?T[;L?-0 S1/%4FM:5-=,2)HHIE9E^7YE3<&
M&#P<$'C'S9P ,5F>#M"N_$%FMQ->3+G?Y7EO@CYB"7/WG^8<#/ '!&<#3T3P
MK)HNE36K F:6*9F5?F^9DVA1@<G  XS\V<$C%:?PXM'M+"&*561QYF5<%6&9
M&(R#STH K_##7I-9LPTQ)>)VC+$Y+8 8$\#G# =R<9)R:J?%W49;"T1X79&,
MZ@E&*G&QSC((XXH^$6G2V%HZ3(R,9V(#J5.-B#."!QQ1\7=.EO[1$A1G83J2
M$4L<;'&< 'CF@"O\3[VXAFLHK61HWED9>&(4G=&%W 9! )Z$'C/%5/%\,_A$
M0ZD+F:4^<!(COB-MP+-M4#" X( PV,C!!7G3\?:=+=7>GO&C,L<^7*J6"C?$
M<D@<#@]?0T?%W3I;^T1(49V$ZDA%+'&QQG !XYH [BN<\46'G,))KMK>#  5
M&6(E^3GS3R05_@Z<9[5T=>:>(]+>UU/[=<6[W5L\>$$:F780H!RAXZY.#Q\V
MX$L"  6/ NKR)?7&FB<W$"IYB2,V]OX. X)R!NP>V1D!<D&O<&[U+6)[**X>
M.(1J6 ;.%*1[@@.0K$MPPP1DGGH7^"M/D75)[G[,UO"\'R IM4<Q8Z#:&(&2
MHY!R#R#6AI.G2IK5S<%&$30* Y4A"<0\!L8)X/Y&@"OILTOA_5%TTS2S17,.
MX><^YD*[CG)'/W#TV_>&<[1G0\-W\MMJ%WITSNZG$T18?*%8_,H)). 6"C'R
M_*W0Y%5]6TZ5]:MK@(QB6!@7"DH#B;@MC /(_,5%\45DTPP:Q !YENY4_)NR
MK@_>/91ROU?@@]0#2T._DU34+F4.WV>W5854!@C/G<[<G&Y""O ^Z1VY.KXJ
MUO\ L2UEO,9,:_*,9&YB%7/(XR1GG.,XYJE\/]!&BV<<9!#N/,?((.YP.""3
M@J,+VZ9P"35WQ5HG]MVLMGG!D7Y3G W*0RYX/&0,\9QG'- ',:/X5N=9MUO+
MB\G6:= R^2^R-0RC9E !D]VQMR>/]HR^%-2F\117.FW4C+/;R[6E@(C)&XXP
M0.N4(/RCY<=R:BT?Q5<Z-;K9W%G.TT"!5\E-\;!5&S+@G![-C=@\_P"R-#X?
M^'9M.$]W= +/=REF12"J@$D=,\DL?XCQM[YH Y?X2:!]LA-UYTR>7<?<CDVQ
MMM5&^9<'.<X//(XKTK5-/_M"-H-[Q[L?-$VUQ@@\-@XSC!]LUR7PBTZ6PM'2
M9&1C.Q =2IQL09P0..*[B@#RKX2:!]LA-UYTR>7<?<CDVQMM5&^9<'.<X//(
MXH\*Z7+J=YJ$*2M%%]H)D:(XE)#R[%5N0HSDL>IP .":N^ 'G\+E]+GMY6W3
M@B6)"\7SA5R6XPHP#GD\D$ C%:'@'3I;6[U!Y$95DGRA92H8;Y3D$CD<CIZB
M@!G@Z]EL+^YT>21YD15D1Y6RP!"97G)/#CN!E20HW&N=C\9Q:Y(\UU>2V\8=
MA%% K(VWY=K,Z!\D\Y!S@Y((!Q72Z3ITJ:U<W!1A$T"@.5(0G$/ ;&">#^1J
MEX?$_@=I;-K>6:V>1GB>!?,?HHPP&,<8[+\P.-P.0 2_#[Q4;JXETU9&GA12
M\<TF1)C*Y1MPRV"W!..AXP0%] K)T+6)-4W.\#PQC;L,I =NH;,8R5P1QD_,
M""*UJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJO>ZC%8+OF=44G +L%&>N,D
MCGBK% !1110 4444 %%%% !1110 5S6N>&I-5O;:Y;9]GMMS8)82%SR#P,$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)+1!X0A/4J(GVD\#DCV'TJ&69I?#N6))P!DG/"W( 'T   ]!Q3?'W_(&L_\
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M^4*Q4D@ D+C=G/S$;2,FMWPEXHBUX2%$:.6-AYR.N&#$;>3W^[MYPWR\@<4
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MVM^*K71,"YD5"<87EFP<\[5!..#SC&>,YKDM6A5->MB  6@8D@8R=LPR?4X
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M=,C/45QGB72HKS7+:*1%97AW,".&*B4@GU^Z!SU P>.*L:M"J:];$  M Q)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *Y?6/!)N+C^TK69H+A@ S!1(C #'*-CG@=\?*#MW<UU%%
M '+Z/X)-O<?VE=3-/<*"%8J(T4$8X1<\\GOCYB=N[FG^)_!G]KRQ7L,K0W$/
M <#<"O)P5) ZD^Q!(8$$8Z6B@#E/$/@N37K2.RGGS(DF\R^4!N^^ -@8 8#
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M)DD#I@L<KW[K4=+6ZMWLTPBO$T8P.%#*5&%&.!Z<4V;0()ITOV7,\:[5;<W
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MPHH AM+?[,BQ99MB@;G.6.!C)/<GN?6L?Q5X1C\0JA9FCEA),;H<%2<=NXR
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M65XD\*?VU-;7._9]EDWXV[MWS(<9R,?=]#UKH** .?\ &OA3_A)X5MM_E[9
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MX\F,ILVYSD.,[L\??]#T]ZJ:SX(:XNO[2M)V@F*[7(02*PP /E8@= ..1P"
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MX SC'0 [.BN7T/QF]W<MIUU ;>8)N4&17##O@@#)[\9Z-G&VGZMXQ:"<V-I
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M%NI)+&11($#8+&(C<"!SC.,<[MOS4 =G6?J6OP::\4,S;7G;;&-K')R!C(!
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MN_R]OR[MN=S!>N#ZYZ5ROQ$U>2\TQ94B_=W$<;NV\?N\M&RC! +9)QQC'4T
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M KLM$\*VNB9-M&J$YRW+-@XXW,2<<#C.,\XS45[X+L[Z1[F6)7DE7:Q8L>,
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M]%6?4;VUEGE@E>4NBPR[-ZL6?D@$$A6! Z@$\<''I$V@033I?LN9XUVJVYN
M=W&,X/WCU'>H=;\*VNMX-S&KD8PW*M@9XW*0<<GC.,\XS0!D:=X+M[*[2X-Q
M++<QH2%FE5VV$,F<;0VW+'';-9/@:9;#4;^UE(6664.BD_>7+OP1QG:X..N,
M\<''6Z)X5M=$R;:-4)SEN6;!QQN8DXX'&<9YQFFZYX1M=<97N8P[(, Y93CK
MC*D9'IGIDXZF@#C[[4([S7K<1L&\J)T;'9@LI*Y]1D9]#P>017I%8]MX1M;6
M2*>.,*\";$(+<*=V>,X).XY)!))R3FMB@#SS29E37KD$@%H% !.,G;"<#U.
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ME"#GKQ\J\G:!OZ_*:]#J&ZM$NU,4JJZ'&5<!E.#D9!XZT -EU&**/[0SJ(L
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MG<PP<@YP" >5'7- '+_$!!I$UMKBJ28'\N0 %OW;AAG[P *Y(&>K,,G@ O\
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MRAHW&"#_ )X(Z@CD'D<T <U\3)EFTR9T(*L(B"#D$&1""".H-._Y@W_</_\
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MT""&=[]5Q/(NUFW-R!MXQG ^Z.@[43:!!-.E^RYGC7:K;FX!W<8S@_>/4=Z
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MG'_U\+_Z!)78:!HRZ+!':)R(UQGGDGEFP2<9))QGC.!Q1K>@0:V@AN5WH&#
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ML\I<\LS,48G<3N'/0CIT !H:_P"'Q9:*]I;MYBI&KALC# 2"5F'.,8R0,GC
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M/S*1N& ?O88C@5MT %%%% !1110 4444 %%%% !16?XANFM+:>:,X>.&1E.
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M^?3;FQAA;:D\VV0;5.1OC&,D$CACTQ0!V%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7G_P]_?7^HRO\SK,%#'E@N^0;03R!A5XZ<#T%>@5P
M^J:/<Z!=R:K91B6*9/WL(;:Q8 G>H P3P/[S$LV!\V0 =Q7GZ7,_BZ]GMDF>
M&UM&"D1'9*S?,N=PSQD-WQ@+\N22-7_A,)[[]U:VDPD/\5RODQJ.FXG)+8)'
MRCDC..E926T_A&]GN4A>:UNV#$Q#?*K?,V-HQQDMVQ@K\V000 >YG\(WL%L\
MSS6MVQ4"4[Y5;Y5SN..,E>^,%OER 34N#=ZEK$]E%</'$(U+ -G"E(]P0'(5
MB6X88(R3ST-M[:?Q=>P7+PO#:VC%@91LE9OE;&TYXR%[8P&^;) %C2=.E36K
MFX*,(F@4!RI"$XAX#8P3P?R- &/=)>Z1J"Z5;73LMS&K!KC]ZR!2Q8C/!.$/
M8 YP>0&%VPEGT#58]-\^2:&XB+8G8NR[0YX;URG8 $'!!(!JWJVG2OK5M<!&
M,2P,"X4E <3<%L8!Y'YBC5M.E?6K:X",8E@8%PI* XFX+8P#R/S% %3Q5>71
MU:"TMI2GF0'ABQC'^MRVS.&8 97/&X#/%1>(4G\$20WRW$LUNSB.2.=S(W.6
M)7[HSA3CH00.2K$"+QE/-;ZS;/;())1!PA8+D9EW#<2 #MS@^O8]#+XA>?QO
M)#8K;RPVZN))))T,;<94A?O#.&..I)(X"J20#I?%%AYS"2:[:W@P %1EB)?D
MY\T\D%?X.G&>U<_X%U>1+ZXTT3FX@5/,21FWM_!P'!.0-V#VR,@+D@U_$>EO
M:ZG]NN+=[JV>/""-3+L(4 Y0\=<G!X^;<"6! ?X*T^1=4GN?LS6\+P?("FU1
MS%CH-H8@9*CD'(/(- #+@W>I:Q/917#QQ"-2P#9PI2/<$!R%8EN&&",D\]#;
MTV:7P_JBZ:9I9HKF'</.?<R%=QSDCG[AZ;?O#.=HS8TG3I4UJYN"C")H% <J
M0A.(> V,$\'\C1JVG2OK5M<!&,2P,"X4E <3<%L8!Y'YB@"QX;OY;;4+O3IG
M=U.)HBP^4*Q^9022< L%&/E^5NAR*-.D;7[V[5F8VL4?V?8-ZHS-S(<Y W*<
MKD#.TCGN:7Q1633#!K$ 'F6[E3\F[*N#]X]E'*_5^"#UVOA_H(T6SCC((=QY
MCY!!W.!P02<%1A>W3. 2: '^*;A]!L':T'S0QJ$&"^U00I/.<[5R<G(XR<C-
M<UX$@74ECG2_F>X3:TD;R$IC(WJ8WY(PVW>"1N^8<C%=OK5[)8PO/#&9709"
M [2>1G!P>0,G&"3C Y-><>);!O$SQBQLY8)UD+M-*@@QDCG(/S')W9Y88.T'
M)H ]5KR]K.6]UNYAA?R]T*!W'WPFV'.SL&)P 3]T$D<@5ZA7FEP+O3=8GO8K
M=Y(C&H8A<94)'N*$X#,"O"C)."..H +#2S^$+Z"%IY)[:\.P"9B\BL, ')P,
M;F'(ZJ2"I*J3;TG497UJYMR[&)8%(0L2@.(>0N< \G\S51HI_%]]!,T$D%M9
MG>#,I21F."!@Y&-RC@=%!)8%E ?J4,OA_5&U(0RS17,.T^2FYD*[1C //W!U
MV_>.,[3D L:MJ,J:U;6X=A$T#$H&(0G$W)7.">!^0K"?5SJ6H7$%]=RVJQL4
MB2-C"I )(8L<J,J <M][<-IP *M6XN]2UB"]EMWCB$;!25SA2DFTN1D*Q+<J
M<$9 YZG3\0ZVMR9;>ZT^64QEUC*Q^8A4@882 90MQG;DKZY&  6/&8ET?2Y
MLKM)'L DSMDP95 RRXR0IVD_Q<D]:Q/&^K36VDVD\<CK(_D;F5V#',+$Y8')
MR>3[U$OAB[L-%FLY59I6D4K&A\Q@OF1\ +D=0S8&1SD\YJ7QOI,USI-I!'&[
M2)Y&Y51BPQ"P.5 R,'@^] #_ !7H]WI%J=3:\E-S&8RX5@(#E@N!& !@9')!
M#8.5^;B[XO\ '+6=O:R1MY+7FQBY42"-,*SG'\1&X?P\C/0XK6^(]H]W8311
M*SN?+PJ LQQ(I. .>E8FL^&)[NTL+BW7-S9K"1&YV@_*FX$''(*C@E>-W?%
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M206UF=X,RE)&8X(&#D8W*.!T4$E@64  MZ3J,KZU<VY=C$L"D(6)0'$/(7.
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M3*G,B\JN57@GA5/?HV=HP0 5?$!G\#M%>+<2S6SR*DJ3MYC]&.5)QCC/=?F
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MHC,%=AA0L1(0=%8L1SQP3G/*G2\8ZVWA."WLXYGW2R$&>8"9U0,"['^\1N
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MPZFUT\DQD"R(?]025)P$&T  +@\9).X;36Q\7=.EO[1$A1G83J2$4L<;'&<
M'CFCXNZ=+?VB)"C.PG4D(I8XV.,X /'- &[XGLC<*K-<M;0+GS"A5&.2-F)6
M^Y@^GWLXKC]"U5M/U-+&&Z:YMYXR29)!*5*JYP&!P#E?0<-@@D U8^(&D2O>
M6U\T+7%K&-K1)EB&RQ+;!U!X]FV[6(!&:6FV33ZK;W<5H]O;B-QS$$&=L@W,
M%&%))P 3D@*>A% !\2M(W7UFWF2_Z1,!@/Q'@Q+F/CY2<Y)YYP:T/%6IMX.B
MBM8YY2UQ-DS3XG9$7:'P.,XR"!@_Q=#BK'Q*TN>5K6_@C,OV27<R+G><LA&
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MAD'!YZ5-110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<9.<<J 1F@#U#6]?@T1!-<ML0L%!VLW)!.,*">@-5]*\76NK2M;6\@>1 20
MV,*0I(8C:1DCH3GJ.*Y?XU_\><?_ %\+_P"@25I^.85T72Y8K8!%5%0 #/RN
MZJW7/)#')ZY.<YYH L77Q(T^U8QM.I(Q]Q7=>1GAD4@_@?;K710S+,H=""K
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MA73=8N[.$!(3$K[ .-V(SQZ#]XW XYZ<# !T%U\0["U9T>8!HGV,-CY##(/
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M;'&UL],>]9_BC3X]0UNUAF4,A@R5/0[?.89'<9 XZ'H>*L?&O_CSC_Z^%_\
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MLI;.["@!@%4# "@>]=A10 5YO\6+);^XL+=\A9974D=<,T0.,YYYKTBL_4M
M@U)XIIEW/ VZ,[F&#D'. 0#RHZYH YJ\^'DFIM&EW=/+;Q-D1E K$ 8 :12"
MQQP6(R><;2<UH>)_!G]KRQ7L,K0W$/ <#<"O)P5) ZD^Q!(8$$8Z6B@#C['P
M')%>1ZI/<M+)&K AHPH.591MPV% ##C!R<G/S<:%EX4^S7\NJ[\^=&$V;<8P
M$&=V>?N>@Z^U=!10!1UK1X]8A>TFSLD&#@X(P000?4$ ^GJ".*RO"OANXT0"
M*2Y,T*)M5#$%QR"#OW,Q &0!T /'05T=% 'FEKX?2ZUV651\D"K(P,8V>8R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K/AU^":=[!6S/&NYEVMP#MYSC!^\.A[UH5R^GZW%-J<]D(%66.
M(,9AC>P(C^4_*#CYA_$?NCCT .HHKAX?B2]S<36$-LTDT3LJA9%"L$8JS,S
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M4#!S@<9Z@G:.2 =;17/^)/%?]BS6UMLW_:I-F=VW;\R#.,'/WO4=*/&OBO\
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M_0],CH361_PK?3]GD^0NW=NSN?=G&/O[MV/]G.,\XS0!B?&O_CSC_P"OA?\
MT"2N]AF690Z$%6 ((.00>001U!J+4-/CU&-K>90T;C!!_P \$=01R#R.:HZ%
MX6MM!W?9DV>9MW?,S9VYQ]XGU/2@#*^*7_(.G_[9_P#HU*;%,LNC94@C[ 1D
M'/*PD$?4$$'T/%=5-"LRE' *L""",@@\$$'J#6%I_@*RT_?Y46WS8VC;YY#E
M6QN'+'&<=1S[T 5/A;_R#H/^VG_HUZX7P[:M=:'=H@R1,6Z@<((G8\^@!/\
M+FO6M+TN/2HUMH%VQIG R3C))/))/4GO46B:!!HB&&V78A8L1N9N2 ,Y8D]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"0F)7V <;L1GCT'[QN!QSTX&(O@GI\8MY+K:/-,I3=WVA4;;[#)R<=>,]!@
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M.2I?!UTUIHGG1G#QPW#*< X*M(0<'CK0!MZGX^L=,<PRS*''4*&?!!(()0,
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M!+'JW8=^:=I_CFSU&5;6&4-(XR %?^[OZ[< @=03D'@\\52^*7_(.G_[9_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&23SD\\L>*;X*-GX8A:V^V0R;I"^=Z+U51C&]O[OK5K_ (5;IW_/'_R)+_\
M%T?\*MT[_GC_ .1)?_BZ *OALV>BS7-S]LA?[5)OQO1=OS.<9WG/WO0=*J:!
M8V>D6<VF_;86\_S/GWH,;T"?=\PYQC/49K5_X5;IW_/'_P B2_\ Q='_  JW
M3O\ GC_Y$E_^+H YK3=$ATF(P6NJ)'OW>9S$5)/ *C?E#C@D,2>#D8%;&EV^
MGZ99/ID=U%^]1PSF5#EG7:6V[N .,#/0<DG)-W_A5NG?\\?_ ")+_P#%T?\
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M^1)?_BZ/^%6Z=_SQ_P#(DO\ \70!E>'K2UTJ[DU&2_BE>6/:VYXP<G82<A\
M97Y5Q\HP,\<Q3V%O;W$E[8ZC%!Y_+J6BE4L223\SXZ\]"1DX(!P-K_A5NG?\
M\?\ R)+_ /%T?\*MT[_GC_Y$E_\ BZ &Z9<V-M#)!-=QS&X+&5GFC&XN@1@
MI&U<#@ _*. >!69X9BAT!@B:E$ULK.1$QBSA@<#?OR,'!.  3G@9-:O_  JW
M3O\ GC_Y$E_^+H_X5;IW_/'_ ,B2_P#Q= &?HUM86#W;R7<,B7S$LOF(N Q?
M*Y#DGA\9XZ5GV^G1Z>C6MIJJ1P'.%8PNPW#YL/O4C)R1M"X)SUR3T'_"K=._
MYX_^1)?_ (NC_A5NG?\ /'_R)+_\70 >&I]-\.Q?9H+B+:6+$O/&6).!DX('
M0 < =/7)-7P4;/PQ"UM]LADW2%\[T7JJC&-[?W?6K7_"K=._YX_^1)?_ (NC
M_A5NG?\ /'_R)+_\70!GZ-!9Z<]W)]MB_P!-8GY)$1DR7/#;SR-_!P,$9Q6?
M<:='J"+:W>JI) ,953"C':/ER^]B<'!.X-DC/7!'0?\ "K=._P">/_D27_XN
MC_A5NG?\\?\ R)+_ /%T :%IXBL+1%ACN(0D:A5'G(<!1@#);/2N:UFTM;BZ
M_M*TOXH)BNUR'CD5A@ ?*S@= ..1P" ",G5_X5;IW_/'_P B2_\ Q='_  JW
M3O\ GC_Y$E_^+H RO#UI:Z5=R:C)?Q2O+'M;<\8.3L).0^ ,K\JX^48&>.;?
MALV>BS7-S]LA?[5)OQO1=OS.<9WG/WO0=*M?\*MT[_GC_P"1)?\ XNC_ (5;
MIW_/'_R)+_\ %T 5;(V=M?RZK]LA/G1A-F]!C 09W;^?N>@Z^U9\]A;V]Q)>
MV.HQ0>?RZEHI5+$DD_,^.O/0D9." <#:_P"%6Z=_SQ_\B2__ !='_"K=._YX
M_P#D27_XN@#*\/:=8:)=R7R7D3"2/;M>5"V3L+.7+\EBI)X')XX%=%J/B.TN
MHGB2[B1G1E#B9,J6! 888<CKU'UJE_PJW3O^>/\ Y$E_^+H_X5;IW_/'_P B
M2_\ Q= #_#>H6.A6\=FMU$PC!^8RQC)8EB<;N!DG YP.YZU4UUK'4YX+U;N*
M.6W<'*R1_,F<E"=P.#R!R0 6X.:L?\*MT[_GC_Y$E_\ BZ/^%6Z=_P \?_(D
MO_Q= &5K-I:W%U_:5I?Q03%=KD/'(K#  ^5G Z <<C@$ $9.GH-_:Z<SSS7T
M<TTH0,S21*N$W;0J*?E'S<\G)R>,FG?\*MT[_GC_ .1)?_BZ/^%6Z=_SQ_\
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MW# ;=YA8A1D!<XQP,8%;'_"K=._YX_\ D27_ .+H_P"%6Z=_SQ_\B2__ !=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/)!(8?*"#56+Q;=Z[+)'IL<7E0L5,TY8HY&.%\O\3_%E<$[<@$ [6BN4\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<O\ $?P^VMV;HF3)$1(H'<J""N "22I. .K8YQ7444 <OH/Q
M MKZ,">18IT $J2_NL/R& WGD9!Z$D#&[!XKG_B+?IXELY#:$NMI*C.P5MIX
M=6"G'S%<AF(^4*0<FNZO=#M[]M\T4;L!@%T5CCKC)!XYJW#"L*A$ "J   ,
M <  #H!0!SO_  L6Q\C[9YJXVY\O(\W/3;LSG.>/3OG;S69\*-':"P(F4%;A
MW8*PZHRJG((Z-MSW!4@]ZZC_ (1ZVW^?Y,7F;MV[RTW;LYW;L9SGG/7-:% '
MC5K([J/"C;RPO""=J(# IWD@MD@DCS!P<C !(X.K\0]*@M+VUN;I/]"\ORF"
M!@%*[BOW<8 W @ Y(5L XP?1?[)A\S[5Y:>;_?V+OZ;?O8STXZ].*L30K,I1
MP"K @@C((/!!!Z@T >?MX=T(,B#RV:1U10D\CDLW X1S@>YP!W-/^(__ !^:
M;_U\?^SPUV5EH=O8-OABC1B,$HBJ<=<9 ''%37.G173*\B*S1G*%E#%3P<@D
M<'@=/04 <E\7=,>^L2T8SY,BR,.2=H#*2, ]-V3T  )SQ63:Z7H%Q$+GY%!4
MDJ\SB08Z@IYF<^P!S_#D$9]+K/\ ^$>MM_G^3%YF[=N\M-V[.=V[&<YYSUS0
M!Q7CW0DDTI!8C]Q$RR@?.3L8,21G)_CW'.,#/IBM#7_'5I?6$C1/N>:&11&O
M,H)1L[D!R H!+,>,#()R,]K6?;^'K:VW>7#$N]2K;8T&5/53@<@]QTH Q/A;
M_P @Z#_MI_Z->LKXU_\ 'G'_ -?"_P#H$E=U:VB6BB*)51!G"H JC)R< <=:
M;>Z=%?KLF174'(#J&&>F<$'GF@"&RT.WL&WPQ1HQ&"415..N,@#CBN ^).GQ
M17UM>7BEK1D,;[=W!&\@DKCCY@1@Y(5N#C!]-IDT*S*4< JP(((R"#P00>H-
M 'G[>'="#(@\MFD=44)/(Y+-P.$<X'N< =S3_B/_ ,?FF_\ 7Q_[/#7966AV
M]@V^&*-&(P2B*IQUQD <<5-<Z=%=,KR(K-&<H64,5/!R"1P>!T]!0!F>+?L;
M1+'J&WRI)%4;MP&XY(^9>5X!RV0,9!.#7"V=X/#UW;6.FW+3PS,!)&2)54;C
ME@R !>"S$#&-NY\@@5Z?=6B7:F*55=#C*N RG!R,@\=:BL=)AT_/D1I'NQGR
MT5<XSC. ,XR: ."\.ZA'X:U&\M[M@GVEQ)&[<1D9=L;FQS\V/3<K#.<9/$6H
M1^)=1L[>T8/]F<R2.O,8&4;&Y<\_+CTW,HSG./0+W3HK]=DR*Z@Y =0PSTS@
M@\\T66G16"[(45%)R0BA1GIG  YXH X?1O\ D/77_7NO\H*-9_Y#UK_U[M_*
M>NX33HDD-P$42L,%PH#D<<%L9(X'Y"A].B>07!13*HP'*@N!SP&QD#D_F: .
M"UW3M+NY);M+C[-<Q-*&:-]C;P,,=AP6[_<QO)/))K5\ >)I;^Q:]O3_ *MI
M/GV8RB ,6PHP<'(^4=L=<UT%UX>MKMC++#$[G&6>-&8X&!DD9Z54\7VL][ ;
M6W',[*CME?DC;[[X;&[CC (/.0<B@#3T_4(]1C6XA8-&XR"/\\$="#R#P>:X
M3XN:>'%M>2*6@AE(E"YW;7*^F, [2,Y')4#KQW&E:8FEQ):Q#"1J .F3CJ3@
M 9)Y)QR235N@#S>72/#\<?GDQ[< X$TA?G&/D#E\\\C&1WQ@UI_$71O(LDFM
MAM>P:-X\+O8*F%QDY. ,,<Y!V\^HZ6U\/6UHPEBAB1QG#)&BL,C!P0,]*NS0
MK,I1P"K @@C((/!!!Z@T </X-N%\37DVLX;RXU2*'>$!'R[I.!DYR>#GHQ'L
M.=BT:S@U&ZM]4 'FN9(79G2/#%F(W KSR!SQN5@#G&?5;+3HK!=D**BDY(10
MHSTS@ <\47NG17Z[)D5U!R ZAAGIG!!YYH Y3P[H^DPW(^Q;3/&A<%)'D 4_
M(>=S)GYL8//.<=ZI?#C_ (_-2_Z^/_9YJ[BRTZ*P79"BHI.2$4*,],X '/%%
MMIT5JS/&BJTARY50I8\G)(')Y/7U- '#Z-_R'KK_ *]U_E!7H%5TTZ))#<!%
M$K#!<* Y''!;&2.!^0JQ0!XUK2-I\T_A\?+'>W4+(?+ 55D;+%0",X(11_#A
M6^Z:M>,G_P"$4FNDB"K%>VJA4$>U-P98V *\9"%F[#+#(/&?4WTZ)Y!<%%,J
MC <J"X'/ ;&0.3^9HN=.BNF5Y$5FC.4+*&*G@Y!(X/ Z>@H XSQCIG]EZ*;7
M"@QQP!MGW2PD3<1P.IR<XR<Y/-:'_,&_[A__ +0KI;JT2[4Q2JKH<95P&4X.
M1D'CK1]D39Y&U?+V[=N!MVXQMV],8XQTQ0!Y+=Z8]]H$+1C/DR-(PY)VAY5)
M& >F[)Z  $YXK5M=+T"XB%S\B@J25>9Q(,=04\S.?8 Y_AR",^BVMHEHHBB5
M409PJ *HR<G ''6JO_"/6V_S_)B\S=NW>6F[=G.[=C.<\YZYH \_^)=K!:Z7
M;I:C$!F1DY8\.DCY^;GG.>:Z7XI?\@Z?_MG_ .C4KH[W3HK]=DR*Z@Y =0PS
MTS@@\\TZZM$NU,4JJZ'&5<!E.#D9!XZT 9_A/_CSMO\ KWA_] 6N ^.?_+K_
M -MO_:=>I0PK"H1  J@  #  '   Z 57OM)AU#'GQI)MSCS$5L9QG&0<9P*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@XYVL"M '9T5B:)J%VSFWO(E5@I(EA;=$V",C!^92-PP#][#$<"MN@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK3A\<37*A8[*X\X@?+(HCCSU8>:W0#G!*C)P,#- &#XYURXNO[.DM7:%[KG
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M?C[3I;J[T]XT9ECGRY52P4;XCDD#@<'KZ&CXNZ=+?VB)"C.PG4D(I8XV.,X
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MTV0;AW+N00,<X/.?ES_%1\2=*EE-MJ$"-*UI,&,:#+,"5.1C)X* < ]<] :
M&?%W49;"T1X79&,Z@E&*G&QSC((XXJO\3[VXAFLHK61HWED9>&(4G=&%W 9!
M )Z$'C/%97Q$OKOQ)"B06DRQ+)DF2/$A8*0 (P2=N"?FQ@GCC'.[X^TZ6ZN]
M/>-&98Y\N54L%&^(Y) X'!Z^AH B\2Z5+X<TZ>1;F>24B'YWD/!$B@E.ZALG
M(R>,#-5/&=JU[H\5T\DFY(("0'^5RYC!+@YW$=1SP>:Z/XCVCW=A-%$K.Y\O
M"H"S'$BDX YZ54U+0I=2TA;)!B4V\'RO\IRFQBIST/RXYQSUQUH I:5HK:;I
MS7J3SEFL"0KRY1"8@P*  ;2N,+SP*HP^,)=*T6.[W,T\C,BN_P Y!,C\G<><
M*IQUYP"",U>TO59;W3WT]K:>.6.R=<O&0C%4V *>"6;@XQZCG&31A\'RZKHL
M=IM99XV9U1_D)(D?@[AQE6..G.,D#- &5=ZY;Q1M-'J=P]T,NHVR+$S [@OE
M%< 'IC=M'7&/EJ[XE\:W%]9V<ZL;=+EV$TD88[-CA>".0#AFV@[B!MR1G/1V
MOC>?:(I;*X^T<J0B?N2P.!B0G 4G^+D =V R=#6M;DLXXC):O*DRD3)%B5D)
M7.W;C#@G()X''N 0"+PC8HO^DV]W+<1.N")9!)AOE*G. 4(!.Y2,G(SC KI:
M\W\.Z-)<ZD-1M[=K6U5"KJX\LN=O_/,=!DJ?[IV[L[N*ZVP\2_:[R?3O+8>0
MJ'S <J=Z@X/ VGG@<Y )XQ0!MUYOXEL/L<4KR:E)]K1"VT2K$I(&540J0067
M X/).[!SBN]U:W>YADBB.V1XW"MDC#%2%.1R,'N.:\GTS3C:6<MB^GR-=XE
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MFM7-P481- H#E2$)Q#P&Q@G@_D:-6TZ5]:MK@(QB6!@7"DH#B;@MC /(_,4
M8FL^,4U"[FMY[J2UM[=PJK"C"1V4,KGS$#$ -V/!7' 8$U8\)>+!'?#3X)WN
M;>=20TV[S$958D;F + A>F !D8Y#;K:6T_A&]GN4A>:UNV#$Q#?*K?,V-HQQ
MDMVQ@K\V00>ET3Q!)JKG_1Y8H@I^>?",6!'RB/).,'.[.,@B@#EUEG\7WT\*
MSR06UF=A$+%)&8Y!.1D8W*>3T4 !068C/BL)K#6[>*:4R@1-Y;,!OV;)0 Q
M&6!SEN2W4]<#06*?PA?3S+!)/;7AWDPJ7D5ADD8&!C<QX/52"&)5@8HHKK4-
M7M[Z2!DB\IMORL=J[9=OF'[JN2<[<\ J#SF@#TBBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBH;J[2T4RRLJ(,99R%49.!DG
MCK0!-13(9EF4.A!5@""#D$'D$$=0:?0 5@^)/#\FH/#=V[A)[8N4W+N1MZX9
M6'4 X R.0,X&<$;U5[W48K!=\SJBDX!=@HSUQDD<\4 <EJ6@:EKRBTNWMTMV
M93)Y D,A"G(4;P0,D#GM[C*GK[2U6T188QA(U"J,DX"C &3STJ:B@ KDO^$?
MO=(DE>P>)H[B5I&2X5AM9L9VM'U!]"!@ 8R<D];10!RFC>%II+K^U+]D:=%V
M1K#N$:K@Y/S8))W'KD#)Z\;>KHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JOJ-DM_$
M]N^0LJ,I(ZX8$'&<\\U8HH X^TTS5=+1;6%[:2.)0JM*LBN0!P"$)''0<\@
MGG-:'A#PM_8:O)(V^XN&WS..%+9)P!P  6/8$YSP, =!10 4444 %%%% !11
M10 4444 %%%% !1110!R_P //"\OANW:WF*EFE+ H21@JH[A>?EKJ*** "BB
MB@ HHHH YK0_#4EM>W.I3["TVU8]A;(1>,," ,D*F>O(.,"NEHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "L?PUX=714;)#S2NSRR;=I=F8GIDX
MS@ <=2 ,FMBB@ HHHH **** "BBB@ HHHH Q/&>B/K=I)9Q%0\FS!<D+\KJQ
MS@$]!Z5=T.R:PMX;=\%HHD4D=,JH!QG''%7J* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *Y3XI?\@Z?_ +9_^C4KJZY3XI?\@Z?_ +9_^C4H KZ5XYL]'MK>WGE"R"VA
M) 5VQF,8SM4X/?!YQ@]"*ZW[6FSS]R^7MW;LC;MQG=NZ8QSGIBL#PMH$#Z=%
M;&-3'-"C./[S.H)8GKG/0YR,#&,#'E_]J2?V)Y6[Y?MGEXP/N[/-QTS]_G/7
MMG'% 'J'_"R-/W^3YZ[MVW.U]N<X^_MVX_VLXQSG%8GQK_X\X_\ KX7_ - D
MJ6[T'4KF!K'98K$ZD;464 9YR!C (/(..O-87CS2I=)TBWM9V#21S@$@EAC$
MI4 L <!<#IQC XH ]-U/58M+0S3NJ(.['&3@G '4G . ,D]A65IGCZQU-Q#%
M,I<] P9,DD  %PH))/ ')]*YSQ5"NI:Q:6<P#PB)GV$<;L2'GU'[M>#QQTY.
M=#XLZ?'<6#S.H+Q%"C=QN=5;GT(/(Z=#U P =+>ZU#8R1P2N%><D(#GDKC(S
MC /(QDC).!DT:KK4.DJKW#A%=P@)SC<V2,D#@<'DX [FN-\712:AIEOJ2G-Q
M;K!,&"!FR57=VP!D[SQCY>1CIE>,4/C:0)!N"6UGYW$99B\H5UB.#C+*%(QG
MG/7L >E:IJD>E1M<SMMC3&3@G&2 . ">I':K=>92ZVOBLZ;9N03(?-EWIG)A
M#+T!V[7*N,>F#@=#Z;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M376HMI\2KY$$8,K,K;MS#*A6!QSE>" >'QT% %VY\416]W'I9#>;*A8$ ;,
M,>3G.?D/8]JV*YS1O%0O[B\A)40VA0!N5[-YFXL<85E/. ,#//6L>Q\5ZCKZ
MO=6,,2P+D+]H+;Y""?N[2 .PY. V1O.#@ Z-/$2O>G3  2L'F%@V<'<%V%<<
M'!#=>A''>C1/%$6L2SV\88-:OM<L  3EAQ@GCY3UQVKE/A_J8U!KS7IPJ*Q
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M/S)[O4+F3E6N!&IX_P"6.\8P/12O..?4G- '2Z)J_P#:J&7RY8L,1MG38QP
M<@9/'/7U!K0KE/$_C%]*NH+*%/->57+( =_3$>&)"@%@=Q.=J@G'J77B&Y\/
MP2W>HB$[=HC6W+@LQSD'S/P/&2 &.#B@#JZ*X=_$NI6<8U">"/[-G+QIO^T(
MAS\QR=N5&"> ?4)R5NKXR:QTY=4NU42.N0B$ ,7)\L#);JN&/4@9..,4 =77
M/Z7XP2^AN+S;^[M9)5RC!]ZQ*&W#H/F!X&<>]<_J?BO5--@.HRPPK$?^69+^
M:@;(0MD@'!*Y Y.<87G;%9:D?!NC13J$\V3:RY4E6,K;QG&TY$?<G^'&3QD
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MVY Y; (!TM%<)K'BV_\ #X2[O(X?L[R!2D1<S*&#,!N.$)4#G'!/ P#D=W0
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MR>OJ: .'T35+>'4[ZXG98G'E(OG,(R0%PQ )P02BD'TP>,U;N)O[2UF.(/\
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MN>-6;!.T@Y7CYE8X''/X5WLT*S*4< JP(((R"#P00>H-,M;1+11%$JH@SA4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC8*HV9<$X/9L;L'G_9&A\/\ P[-IPGN[H!9[N4LR*054 DCIGDEC_$>-O?-
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M *\@&GX!U&6ZN]021V98Y\(&8L%&^48 )X' Z>@KG/A?H<NK6SKYSQ0+,QQ
MVR1G*)G+8/R@8P!U))/05M_#"RN(9KV6ZC:-Y9%;E2%)W2%MI.00">H)XQS6
M5\.[Z[\-PND]I,T329!CCS(&*@$&,D';@#YL8!XYSP ;O@?5)[2YGT6ZD,K0
M .DAR25."0Q)SGYUP.<?,-Q 6L3X=S-#I%VZ$AE,Y!!P01"I!!'0BMOP/I<]
MW<SZU=1F)IP$2,Y!"C )8$9S\BX/&?F.T K69X(TF:VTF[@DC=9'\_:K(P8Y
MA4#"D9.3P/>@ A\82Z5HL=WN9IY&9%=_G()D?D[CSA5..O. 01FMNU\'W=NH
MN/M<K70RQ#MFV+$Y*F/&=N.,C!'WE P%&)#X/EU718[3:RSQLSJC_(21(_!W
M#C*L<=.<9(&:UK7QO=W40C6RF%T5/WTV0;AW+N00,<X/.?ES_%0!VM</I.HR
MOK5S;EV,2P*0A8E <0\A<X!Y/YFNXKA])TZ5-:N;@HPB:!0'*D(3B'@-C!/!
M_(T 8_A^&[UV\O8#<RI;QS,"$?Y_OOL",0=@&WG&,@!<$'(U?!U[+87]SH\D
MCS(BK(CRME@"$RO.2>''<#*DA1N-/\ Z=+:W>H/(C*LD^4+*5##?*<@D<CD=
M/44:3ITJ:U<W!1A$T"@.5(0G$/ ;&">#^1H YS3/#'FZM<6?GW V0@^8LN)6
MXBX9\<CYNF.P]*UK$S^);J6Q2XECM;':A*MMG=E#)N+C.<E6)/0@+\N22+ND
MZ=*FM7-P481- H#E2$)Q#P&Q@G@_D:KI;3^$;V>Y2%YK6[8,3$-\JM\S8VC'
M&2W;&"OS9!! ![F?PC>P6SS/-:W;%0)3OE5OE7.XXXR5[XP6^7(!-?QK+=7.
MJ06-M.T0E@YPS;1S+N;:."VT<'@Y Y& 18>VG\77L%R\+PVMHQ8&4;)6;Y6Q
MM.>,A>V,!OFR0!8U;3I7UJVN C&)8&!<*2@.)N"V, \C\Q0!G_$."7PW8J(;
MB<LUR,N\I+X,;?+N&WY?ESCUYH\5Z/=Z1:G4VO)3<QF,N%8" Y8+@1@ 8&1R
M00V#E?FXT/B[ITM_:(D*,["=20BECC8XS@ \<UI_$>T>[L)HHE9W/EX5 68X
MD4G '/2@#E-;2]6Q&N/=.LO[MUCB^6$([#:FW^(C<"2V[(^4@_>KN()9M7LX
MY8W$,TT43;P@<*6"LV%8\@\CD\9S7/\ B'3I9=%6W5&,OD6PV!27RICR-N,Y
M&#GTJOXIT*XO](@@A#;XXX2\?(8A(\%=O<@X.T]QQ\V!0!B>)]1'AT17=C?O
M.PDPT<DXF4@@G)52..,'CN""I SH?&O3_P!S'=;W_P!8J;-W[O[LC;MN/O=L
MYZ<5B^*K/^TK:.*TTZ6)D9-[&'#?<("@@;W&<Y8XY SRPKM?BEH4NL6FR ;F
MCD#E1]X@*P( [GYLX[XXR< @%BZT5M"M+ITGGD8P.09I=Y4JC$%2 ,'G]!Z5
MSD/C"72M%CN]S-/(S(KO\Y!,C\G<><*IQUYP"",UT$FMOKUG<I]GFBD%NXVR
M1D;F=&X3NV",= >1QS7/P^#Y=5T6.TVLL\;,ZH_R$D2/P=PXRK''3G&2!F@#
M6_X0B[\OS?MLWVO[WW_]'W9W;?+Q]WMZ=]N/EK)F\82ZKHLEWN99XV5&=/D)
M(D3D;3QE6&>G.0 !BM;_ (3>[\OROL4WVO[OW/\ 1]V=N[S,_=[^G;=CYJR9
MO!\NE:+):;6:>1E=D3YR"9$X&T<X51GKSG!(Q0 ?V%=W&G?VA+>3"5;?S%$;
M[4VJN]0P&"S$=6)SD_Q;>>P\%ZRVLV<-U)]]E(;IR48H6X  R1G&.,XJK]D?
M^R?(VMYGV';MP=V[R<;=O7.>,=<U4\'.^B:4))48/!'.Y1P4;Y6=@#D9&1[=
M\T =A7#_ !=U&6PM$>%V1C.H)1BIQL<XR"..*ZC0-6_M>".[V,GF+G:W4?X@
M]5/&00<#-<O\7=.EO[1$A1G83J2$4L<;'&< 'CF@#/\ %>CW>D6IU-KR4W,9
MC+A6 @.6"X$8 &!D<D$-@Y7YN+&O>)Y]6>TT^T;R'O(1*[8W%59"=JMUR &Y
MPIR%PR\UM_$>T>[L)HHE9W/EX5 68XD4G '/2N<O=!N;(6.K6\9DEMK9$DB8
M[6VB,YP, [OF8$<G.W"GF@"7Q1I=SX4B_M&VNI7$97>ER_FJRLR@8X&#G@]#
M@G##&#W>G7JW\27"9"RHK 'KA@",XSSS7">*-4N?%<7]G6UK*@D*[WN4\I55
M64C')R<\GJ< X4YR.[TZR6PB2W3)6)%4$]<* !G&.>* .'U_]]KEI$_S(L+,
M%/*AL2G< > <JO/7@>@KT"N4\:^&I;YH;^SVBYMFR-QVAUP24) R<G@ L%PS
M9/--B\<3$>6UE<";)7 4&+=D@?O>!M/&6Q@=>1R0"OXTUF>:Z@T:T?RGG5F>
M3&2%PW"GJ#A6/8YVX8<U1\4:7<^%(O[1MKJ5Q&5WI<OYJLK,H&.!@YX/0X)P
MPQ@OU_2KU9;?7$B5IX5<20J^<(=Y4 X^9@K$,1G+8VJ1FF>*-4N?%<7]G6UK
M*@D*[WN4\I5564C')R<\GJ< X4YR "Q>:Y):7MI?+O-I?QHA4EB%=\%3MW;%
M)!7H3D!R 3R;?B2_EN=0M-.A=T49FE*CY2JGY5)!!P2I4Y^7YEZG I_C3PJ+
MK3C9Q LUNB&/.2Q\H8Z*.6*9 &,$GMU%?X>VLUV]QJEW'Y<\S(FTQLA"QH.1
MO).&XSVROY '+Q^,XM<D>:ZO);>,.PBB@5D;;\NUF= ^2><@YP<D$ XK=^'W
MBHW5Q+IJR-/"BEXYI,B3&5RC;AEL%N"<=#Q@@+%X?$_@=I;-K>6:V>1GB>!?
M,?HHPP&,<8[+\P.-P.1U^A:Q)JFYW@>&,;=AE(#MU#9C&2N".,GY@010!P6A
M6EUX@O;R$W,J00SMD)(P?[T@15)SM48.1T. ,="LWB?Q.(+D:2]S)!!!$F^0
M*7FD;Y3C>N2"5YW8'.[(((%:O@'3I;6[U!Y$95DGRA92H8;Y3D$CD<CIZBF:
MUIT^AZ@=8@B::*:,),J<R+RJY5>">%4]^C9VC! !BZ;XN33;N&*TN9;J*X94
MD6X+ED)8!75F5?[W0#G!SU4KL:[>3Z_J TB"5H8H$$DK(2KMG' 8'IAU S@
M[B0V%%;NE^*)-3D6-+69(^=[S@1;>"5PI)+Y(P<8V\$]:PM=LY] U :O!$TT
M4Z".54!9UQCD*!TPBD9R"=P)7*F@#$\4Z1-IE]81O,TT/GKY?FX,BGS(]X+
M#<#D8)Z#C QD^L5YEXB>ZUV[L;D6\B01SC&Y&\P8>/>S@9"+QA<G)"ECP17I
MM 'E[:O_ &5K=S+Y<LN84&V!-[#*PG)&1QQU]2*U=%TZ?7-0&L3Q-#%#&4A5
M^)&Y9<LO)'#,>W5<;ADE^DZ=*FM7-P481- H#E2$)Q#P&Q@G@_D:[B@#R*/Q
MG%KDCS75Y+;QAV$44"LC;?EVLSH'R3SD'.#D@@'%;OP^\5&ZN)=-61IX44O'
M-)D28RN4;<,M@MP3CH>,$!8O#XG\#M+9M;RS6SR,\3P+YC]%&& QCC'9?F!Q
MN!R.OT+6)-4W.\#PQC;L,I =NH;,8R5P1QD_,""* ."T*TNO$%[>0FYE2"&=
MLA)&#_>D"*I.=JC!R.AP!CH5-<U%DU!=-N;J6WMH8D".K,KR$JHW-(!@DMG+
M$;1M(X))K;\ Z=+:W>H/(C*LD^4+*5##?*<@D<CD=/45=\0ZX$D:UN;*6>)=
MK(T<0G4D@Y)!P%(.1U)(YX!&0!]S>'PO8RW(E:X51NB:0AS\^T*"P(WKO.<]
M=IP.@K*T?PK<ZS;K>7%Y.LTZ!E\E]D:AE&S* #)[MC;D\?[1S_#7@>>XM+RW
ME4PQW15H8V<G802ZYX.!]U6R-Y"G(! K0T?Q5<Z-;K9W%G.TT"!5\E-\;!5&
MS+@G![-C=@\_[( &:-XGGN[2_M[ALW-FLP,B#:#\K[2",<@J>0%XV]\U4\':
M%=^(+-;B:\F7._RO+?!'S$$N?O/\PX&> .",X%O1O#$]I:7]Q<+BYO%F)C0[
M@/E?: !GDECP"W&WOFMOX<6CVEA#%*K(X\S*N"K#,C$9!YZ4 5_AAKTFLV8:
M8DO$[1EB<EL ,">!SA@.Y.,DY-'Q/UB?2K,R6^06=59@#E58')!'W3G SVSQ
M@X(J?"+3I;"T=)D9&,[$!U*G&Q!G! XXKI=?U632XQ-'"TWSJ&6/[X4]6"X.
MXCCCCKDD $T <_X,LHYBMS;WTMQM&)%D?<IR"/\ 5L-T9W#*DY. 1R#FL)K.
M6]UNYAA?R]T*!W'WPFV'.SL&)P 3]T$D<@4#2&U:^M[FRM'M4@93*\BB#<,Y
M*A!UX!&1G.[#84 UL:3ITJ:U<W!1A$T"@.5(0G$/ ;&">#^1H KZ;-+X?U1=
M-,TLT5S#N'G/N9"NXYR1S]P]-OWAG.T9$N9_%U[/;),\-K:,%(B.R5F^9<[A
MGC(;OC 7Y<DD6-6TZ5]:MK@(QB6!@7"DH#B;@MC /(_,572VG\(WL]RD+S6M
MVP8F(;Y5;YFQM&.,ENV,%?FR"" #W,_A&]@MGF>:UNV*@2G?*K?*N=QQQDKW
MQ@M\N0";&DZC*^M7-N78Q+ I"%B4!Q#R%S@'D_F:KO;3^+KV"Y>%X;6T8L#*
M-DK-\K8VG/&0O;& WS9( -2AE\/ZHVI"&6:*YAVGR4W,A7:,8!Y^X.NW[QQG
M:<@%C5M1E36K:W#L(F@8E Q"$XFY*YP3P/R%5]&_Y#UU_P!>Z_R@JI;B[U+6
M(+V6W>.(1L%)7.%*2;2Y&0K$MRIP1D#GJ=/2=.E36KFX*,(F@4!RI"$XAX#8
MP3P?R- &?X>2?QO)-?-<2PVZN8XXX',;<88%OO#.&&>I))Y"J 8O!L$UOK-R
MERXDE$'+A0N1F+:=H  .W&1Z]SU,OAYY_!$DUBUO+-;LYDCD@0R-SA0&^Z,X
M49Z$$'@JP(E\*V=T=6GN[F(IYD Y4,8Q_JL+OQAF &&QQN!QQ0!W>HWJV$3W
M#Y*Q(S$#KA02<9QSQ7">%]+N?%<7]HW-U*@D+;$MG\I5568'/!R<\#J< 98Y
MP.[U&R6_B>W?(65&4D=<,"#C.>>:X+PIK%QX7C.FW-K,_DL=CV\9D5@Q+'DD
M#J>,=C@@$'(!=\5Z]=Z3%;6*NOVNYEV"78-F P 8@YPS;ER,,!\V/X:BUCPK
M<Z-;M>6]Y.TT"%F\Y]\;!5._"$'![KG=@\?[0=XGT6\UF&WOA&JWEM,7$1=2
MNW?D#=G!.%0GYE&-W0X ;K'BJYUFW:SM[.=9IT*MYR;(U#*=^')&3V7.W)Y_
MV2 9_C3Q7+>Z7;W\+-$\DJAC&Q3D+(& P2=NY<C)Z8SS4OBO1[O2+4ZFUY*;
MF,QEPK 0'+!<", # R.2"&P<K\W$7C3PI+9:7;V$*M*\<JEA&I?DK(6(P =N
MYL#(Z8SS74?$>T>[L)HHE9W/EX5 68XD4G '/2@#E-;2]6Q&N/=.LO[MUCB^
M6$([#:FW^(C<"2V[(^4@_>K=\6:Q*^D?;58I*\4#9C)7!=D)P<Y Y(Z]*B\0
MZ=++HJVZHQE\BV&P*2^5,>1MQG(P<^E'B'3I9=%6W5&,OD6PV!27RICR-N,Y
M&#GTH S/["N[C3O[0EO)A*MOYBB-]J;57>H8#!9B.K$YR?XMO,4"7NO:>^JR
MW3HR1NT:P?(N(AAR^W!)<H<<X7.1P=HZO[(_]D^1M;S/L.W;@[MWDXV[>N<\
M8ZYK,\/:=+%HK6[(PE\BY&PJ0^6,F!MQG)R,>M %2Y\>36^D1Z@<?:)28PP4
M8W!F&XC.,[4)Z$;L?+MXK"N]<MXHVFCU.X>Z&74;9%B9@=P7RBN #TQNVCKC
M'RUJP^#Y=5T6.TVLL\;,ZH_R$D2/P=PXRK''3G&2!FMNU\;S[1%+97'VCE2$
M3]R6!P,2$X"D_P 7( [L!D@'/^+_ !9-?:5;W\;-%)), WE.R_=$BGD$'!*Y
MQSCCDXS5CQ7H]WI%J=3:\E-S&8RX5@(#E@N!& !@9')!#8.5^;BW\4K.?5+&
M()$QE,J,R(#(5_=OD94<@$XSTK8^(]H]W8311*SN?+PJ LQQ(I. .>E &)\1
M!_:^F+J&YT_=QOY:O\A\UH^&&/FV_P /3!YK5\!Z!]CAANO.F?S+>/Y))-T:
M[E5OE7 QC&!SP.*BU+0I=2TA;)!B4V\'RO\ *<IL8J<]#\N.<<]<=:E\":V\
M\4=E+;S1/#"H+21E8SLPHPQP<D<XQQSR<9(!U=%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6 <CGD+G)'!_(U8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHJO>ZC%8+OF=44G +L%&>N,DCGBK% !63XDT+^W(Q;,VV,R(T@VYWJIR4SD%
M<D#Y@<C%:U% #(85A4(@ 50  !@ #@  = *?110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%5[W48K!=\SJBDX!=@HSUQDD<\4 6**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBF33+"I=R J@DDG  ')))Z 4 /HJ&UNTN
MU$L3*Z'.&0AE.#@X(XZU-0 4444 %%%5TU&)Y#;AU,JC)0,"X'')7.0.1^8H
M L4444 %%%% !1110 4444 %%%% !1110 4444 %%5[G48K5E21U5I#A S!2
MQX& ">3R.GJ*L4 %%%% !15>YU&*U94D=5:0X0,P4L>!@ GD\CIZBK% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?K4.CW.ISW#A$^T@9.3DF2;   ))^@Z GH#7=:'XDM]=5GMG#A#AN"I&>G#
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MC_T0M=%\)M/CM[!)D4!Y2Y=NYVNRKSZ #@=.IZDY )O#ILM.EOKB&1F8.6N
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MVXZ#:1CCCCC(K0H HP:U#/,]FK@S1!2R<@@, 0>1R.1G&<9&<9H?6H4G%B7
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M#(H;RHD=<]F"Q -CU&3CT/(Y ->D4 9EYXDM[*86<KA960N 00-JAB6+8V@
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M0 "0!O;@<<X X&&7WB1]4L9EM+'_ $+RY '9XXP,#<SB+!SM;)&TG)'4-D
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M!J^"H)9)+J]>-H8KB13'$_# J"KN4QA2YP3W)'.1@D ZNBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ./G\!R6]Q)>V-RT'G\NIC$JEB22?F;'7GH2,G! .!;\(>#/^
M$<>>3S6E^T,I^<?,-I8\MD[B=W)P.><<UTM% '#P_#9[:XFOX;EHYI79E*QJ
M54.Q9E96)WCT^[@@-@\8T_#'@S^R)9;V:5IKB;@N1M 7@X"@D=0/8  *  <]
M+10!R5QX%>WGDO+&X:W:<DR HLJ$DYR%8C!SD\YZD#:.#:\-^#5TF5[V21IK
MF4$/(WRC&<X"CH.%'4XP-NT<5T=% ')7G@B5+F2^LK@VYG WJ(E=21_%@D#)
MZY()R6.?F(H\,_#]=!NI+U96<2(5Q(,OEF5BQ?(R20?X1UZ\<];10!RFL^"&
MN+K^TK2=H)BNUR$$BL, #Y6('0#CD< @ C)Z6TC:)%21M[A0&; 7<0.6P.!D
M\X[5-10!S_B/P;'K3"X#/%<(NU)8F(8##<8S@C+'.,$]-P%5/^$0N;S]W>7C
MRQ=TCC6#=V*LR$DJ02"O&<YSQ75T4 <OK'@DW%Q_:5K,T%PP 9@HD1@!CE&Q
MSP.^/E!V[N:-'\$FWN/[2NIFGN%!"L5$:*",<(N>>3WQ\Q.W=S7444 <_9>%
M/LU_+JN_/G1A-FW&,!!G=GG[GH.OM1>^%/M-_%JN_'DQE-FW.<AQG=GC[_H>
MGO7044 <_>^%/M-_%JN_'DQE-FW.<AQG=GC[_H>GO7)>,M*75=9MK=F9 T&=
MT9VN"AE<$'!P<@5Z;6?-H$$TZ7[+F>-=JMN;@'=QC.#]X]1WH Y^#P')<7$=
M[?7+3^1RBB,1*&!!!^5L=>>@)P,D@8,NL^"&N+K^TK2=H)BNUR$$BL, #Y6(
M'0#CD< @ C)ZNB@#E/#W@AM*NY-1DG:5Y8]K;D .3L).0< 97Y5Q\HP,\<V[
M+PI]FOY=5WY\Z,)LVXQ@(,[L\_<]!U]JZ"B@#G[WPI]IOXM5WX\F,ILVYSD.
M,[L\??\ 0]/>L+XQV:W%K'@$R^>JIM7<Q+*V5ZY .,\9R0HQW'>UGZEH$&I/
M%-,NYX&W1G<PP<@YP" >5'7- #M$TM=*@CM5QB)%7(&W) Y;'JQR3[GJ:-:T
MYM1A>!)&B9AP\9PRD$$'C'''(R,C(R.M7J* .,N? $NK,HU"Z:>)#D(L:P@G
MCJ5)R,9'8C)PPYS;UCP2;BX_M*UF:"X8 ,P42(P QRC8YX'?'R@[=W-=110!
MB:)H<]HYGN;EYG*E0-JQQ@9!SY:\;LY^;/0XQQ6?K/@AKBZ_M*TG:"8KM<A!
M(K#  ^5B!T XY' ( (R>KHH Q-'\.&U\Q[F5KB2=55RZJ$VKN 41@8 PQR,D
M$Y/<UA6?PXEMHVL1=R?9&+9C5%#X;^'S#G _O  !N>!N-=Q10!RF@>!?[(LY
MM-\W=Y_F?/LQC>@3[NXYQC/49K5\+:%_8-LEENW^7N^;;MSN8MTR?7'6M:B@
M#G_#?A3^Q9KFYW[_ +5)OQMV[?F<XSDY^]Z#I6?/X#DM[B2]L;EH//Y=3&)5
M+$DD_,V.O/0D9." <#L** .?O?"GVF_BU7?CR8RFS;G.0XSNSQ]_T/3WJOK'
M@DW%Q_:5K,T%PP 9@HD1@!CE&QSP.^/E!V[N:ZBB@#$T30Y[1S/<W+S.5*@;
M5CC R#GRUXW9S\V>AQCBL>;P/=3(;5[Z0V[$@J8U,A0MDJ92=Q)'&<8QQMV_
M+79T4 <5XHMO["L4TNQWB:5E2((V),AM[L3D$#&=Q' W#.%Z=?:1M$BI(V]P
MH#-@+N('+8' R><=J)+1)665E4O'G:Q ++N&#@]1D=<=:FH Q/%_AA?$D!M6
M.T[E96P3M([XRN<@D<GOGJ*KQ>"XTT_^QRQ*["-Q'\18N&P". _(&>@P2>2>
MCHH Q/"7AK_A'XFA,C2O)(TCNPP2S8&<9)Z 9R22<G/.!%X;\*?V+-<W._?]
MJDWXV[=OS.<9R<_>]!TKH** .?LO"GV:_EU7?GSHPFS;C& @SNSS]ST'7VJE
M<>!7MYY+RQN&MVG),@*+*A).<A6(P<Y/.>I VC@];10!DZ%H\EAN>>=YY)-N
M2P"H-N0-L8X7((W<G)&:Q9_ <EO<27MC<M!Y_+J8Q*I8DDGYFQUYZ$C)P0#@
M=A10!S][X4^TW\6J[\>3&4V;<YR'&=V>/O\ H>GO1XD\*?VU-;7._9]EDWXV
M[MWS(<9R,?=]#UKH** .<\2>#5U:5+V.1H;F( )(OS#&<X*GJ.6'49R=VX<4
M_2_#US#(L]S=O+LSM546%#N!!W*N=_8KG&TCWKH** .?LO"GV:_EU7?GSHPF
MS;C& @SNSS]ST'7VKH*** /,O&6E+JNLVUNS,@:#.Z,[7!0RN"#@X.0*W8/
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MN6@\_EU,8E4L223\S8Z\]"1DX(!P+&L>"3<7']I6LS07# !F"B1& &.4;'/
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M))/S-CKST)&3@@' E\/> ET2[DODD9A)'MVN"6R=A9RY;DL5)/ Y/' KJZ*
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ME.'0(5X8GH.N1UK/TWP%<Z8IMH;UUMRS?((E+A6/($A)*G'<  -\P&37:T4
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MFH;"_FT+4AIWGM-;&)I)#.0[184G+2=A\H/.%P_3)#'J-9\%V>LMYL\2L_\
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M$*H88P&((.<G%6/ _BG_ (26W%P5VNK%' ^[N !R.^"".O(Z<XR0 \%>*_\
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MK,\:*K2'+E5"ECR<D@<GD]?4T)IT22&X"*)6&"X4!R.."V,D<#\A0!P^C?\
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MPR1HK#(P<$#/2KLT*S*4< JP(((R"#P00>H- 'GOAK[&VD6\>H;?*DD91NW
M;C+(1\R\KP#EL@8R"<&L^SO!X>N[:QTVY:>&9@)(R1*JC<<L&0 +P68@8QMW
M/D$"O2O[)A\O[+Y:>5_<V+LZ[ONXQUYZ=>:+'28=/SY$:1[L9\M%7.,XS@#.
M,F@#@O#NH1^&M1O+>[8)]I<21NW$9&7;&YL<_-CTW*PSG&>EO=8B\00W=G:,
M)'6 C*D%"TJ.%4-G!/'/89ZYR!L7VDPZACSXTDVYQYB*V,XSC(.,X%2VMHEH
MHBB5409PJ *HR<G ''6@#@/ GC*TTK34\V10\/F90']X27+ !3@G(8<C@=R,
M'%'X<2V\>ESF\QY'GD/D$]5B X4$YR1@CD'GC&:]%BT.WBD^T+%&)<D[PBA\
MMG)W8SDY.?6GV^DPVR-!'&BQOG<JHH4Y&#E0,'(X/M0!Y;J\\7A1D?1[DR-+
M*<VX83(0<= O0\!>3O8'AN#GI?$NFZ7J=PWG2B"ZA,99UD$3],IRXVL<8.1E
MAA1D# KJK+0[>P;?#%&C$8)1%4XZXR ..*+W0[>_;?-%&[ 8!=%8XZXR0>.:
M . \.:]/J=CJ$<KF6*&*18I2A4L/+<<^IP%/.6&[YB<BLR[TQ[[0(6C&?)D:
M1AR3M#RJ2, ]-V3T  )SQ7K7V1-GD;5\O;MVX&W;C&W;TQCC'3%%K:):*(HE
M5$&<*@"J,G)P!QUH P/^%BV/D?;/-7&W/EY'FYZ;=F<YSQZ=\[>:X2TTQ['0
M)FD&/.D611R#M+Q*"<@==N1U!!!SS7J'_"/6V_S_ "8O,W;MWEINW9SNW8SG
M/.>N:M75HEVIBE570XRK@,IP<C(/'6@#FO\ F#?]P_\ ]H5B^&OL;:1;QZAM
M\J21E&[<!N,LA'S+RO .6R!C()P:[_[(FSR-J^7MV[<#;MQC;MZ8QQCIBHO[
M)A\O[+Y:>5_<V+LZ[ONXQUYZ=>: /-;.\'AZ[MK'3;EIX9F DC)$JJ-QRP9
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MT56D.7*J%+'DY) Y/)Z^IKDKS3&U35XY&C816D.0S1#8[GH _?;O!')VLK8
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M25Y=C),"VW ?."K#(RORMT*G..:O6G]K;U\W[)Y>X;MGG;MN?FQGC..F>,T
M=+16#XD\5+I#);QH9KF8C9$IP2.[$X.U1@\GT/8,1FW5YK%DIF9+:14P2D7F
M^8P!Y"[N,XZ=?8$\$ ["BL?PKXFC\1P"ZC!'.UE/\+  D9[CD$'N#S@Y V*
M"BBB@ HHHH ***X_XH:_/HELDULVQS,JD[5;@HYQA@1U H ["BBN7\6^*)='
MN+2WC"E;J7:Y8$D#<@XP1S\QZY[4 =11110 4444 %%%% !116/K?BB+1Y8+
M>0,6NGVH5 (!RHYR1Q\PZ9[T ;%%%% !1110 445YYX7\4:IXDB-Q"+4*KE2
M'$H.0 >Q;CYJ /0Z*Y_PAXI_MQ7CD79<6[;)D'*ALD9!Y!!*GN2,8Y&">@H
M**S_ !#=-:6T\T9P\<,C*< X*H2#@\=:S_ 6J2:K917,[;I'WY. ,XD8#@ #
MH!VH Z"BBL?Q1XHB\-Q"XF#%6<* @!.2">Y7CY: -BBJ^HO(D3M" TH1B@/0
ML =H/(X)]Q]:KZ!-/- CW:JDYW;E3E1\QQCYF[8/4T :%%%% !1110 4444
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M*** "BBN/TS7YYM6N+!FS!'"&5=J\$B+G.,G[QZGO0!V%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!YI<&[U+6)[**X>.(1J6 ;
M.%*1[@@.0K$MPPP1DGGH8KI+W2-072K:Z=EN8U8-<?O60*6+$9X)PA[ '.#R
M PV-)TZ5-:N;@HPB:!0'*D(3B'@-C!/!_(T:MITKZU;7 1C$L# N%)0'$W!;
M& >1^8H J6$L^@:K'IOGR30W$1;$[%V7:'/#>N4[  @X() -=!XHL/.8237;
M6\&  J,L1+\G/FGD@K_!TXSVK*U;3I7UJVN C&)8&!<*2@.)N"V, \C\Q69X
MCTM[74_MUQ;O=6SQX01J9=A"@'*'CKDX/'S;@2P( !8\"ZO(E]<::)S<0*GF
M)(S;V_@X#@G(&[![9&0%R0:7A^&[UV\O8#<RI;QS,"$?Y_OOL",0=@&WG&,@
M!<$'(L>"M/D75)[G[,UO"\'R IM4<Q8Z#:&(&2HY!R#R#6AX!TZ6UN]0>1&5
M9)\H64J&&^4Y!(Y'(Z>HH 9X.O9;"_N='DD>9$59$>5LL 0F5YR3PX[@94D*
M-QJ;7M*4NYN=1>&1MQC594@55).P%,@O@Y!;(+ 8XQ3-)TZ5-:N;@HPB:!0'
M*D(3B'@-C!/!_(USGAW3&T9IH+RQ>YN'DRLNP21L2.,NXPH).2W)Y.\ KB@#
MJ_A;KLNL6F^<[FCD*!C]X@*I!)[GYL9[XYR<DY6B6LGBFU.I37DL3GS.(7$<
M404G 91R<#YB2P)4@$\;C=^$6G2V%HZ3(R,9V(#J5.-B#."!QQ7+Z3X=>]A2
M22P^TL=Y\_[283(&=F#E6VL<YX+#)&#TQ0!=MO$,FB:4-2625YKDA%\Y_-5&
M4N"P! P"%)P=W.T'(!)I7>N6\4;31ZG</=#+J-LBQ,P.X+Y17 !Z8W;1UQCY
M:V]2=/'=B]K;(T4]HR'R6 0!E!79TQC&Y5^Z00-P45JVOC>?:(I;*X^T<J0B
M?N2P.!B0G 4G^+D =V R0"EJGQ!DCTI-250LTQV+@;E# L"V">F$) .<' .1
MDU7U;P?=Z?8R2_:Y7E$+^:LC;XF7!+JH8$@XZ-U./X=W&UXW\/2>);$1A=LZ
M[) FX8W 89"V,'AB > 3@Y S65>>)[O6;22V6TE2=H7$AD1EBQM(;9GYF9NB
MKC@GDD*20#5^%O\ R#H/^VG_ *->LKXU_P#'G'_U\+_Z!)6W\.+1[2PABE5D
M<>9E7!5AF1B,@\]*S/B[ITM_:(D*,["=20BECC8XS@ \<T 1>(_#MY! ^HB[
MD%S&#(R*Q%OA!DHJ8Z # W9W8^8?,2*^L^*99;6RUQ&=463$Z(/E8$[7)!8C
M *$)N_O#E6J77?$M[=VYL/L<HN95\MR%S  XP6$@)'0]R I/S,=ISNV'A!8=
M/&DN0<Q,I8C> [Y8L 0N0KG*]#P.<\T 5_']_(%AL+=V26[F5=R!MZHI!=P5
M(QMXSD_=)]R.KKRSX86<NJ3_ &NY!!L(A F5*\Y;.>0-R*=I&.C GGD^IT >
M2:9X8\W5KBS\^X&R$'S%EQ*W$7#/CD?-TQV'I6A\1[=[:;38HCND23"M,2<L
M&A"ER.3D_>(YZU8OXI] U634O(DFAN(@N8%+LNT(.5]<IW(!!R"2"*F\9VTN
MIW&FW$<4FT2AG!0Y0%HC\^,[2,'.?0^E %'Q?#/X1$.I"YFE/G 2([XC;<"S
M;5 P@." ,-C(P05YO?$/Q8UE-%IRS&W61&:241[R%(95"@'.20<D $?*0>M2
M_%W3I;^T1(49V$ZDA%+'&QQG !XYI_C31IX;J#6;1/->!65X\X)7#<J.I.&8
M=SG;A3S0!REYXQAT-H[FRNYKGYL217!<J5(SD,R*%((ZX)Y] 0?8*YJT\827
MSK%%:7 RPW-.HA55SAF!).XC/W1R1GTKI: //_A[^^O]1E?YG68*&/+!=\@V
M@GD#"KQTX'H*] KA]4T>YT"[DU6RC$L4R?O80VUBP!.]0!@G@?WF)9L#YLB[
M_P )A/??NK6TF$A_BN5\F-1TW$Y);!(^4<D9QTH RDN9_%U[/;),\-K:,%(B
M.R5F^9<[AGC(;OC 7Y<DD#W,_A&]@MGF>:UNV*@2G?*K?*N=QQQDKWQ@M\N0
M"1+:?PC>SW*0O-:W;!B8AOE5OF;&T8XR6[8P5^;(((]M/XNO8+EX7AM;1BP,
MHV2LWRMC:<\9"]L8#?-D@  J7!N]2UB>RBN'CB$:E@&SA2D>X(#D*Q+<,,$9
M)YZ&*Z2]TC4%TJVNG9;F-6#7'[UD"EBQ&>"<(>P!S@\@,-C2=.E36KFX*,(F
M@4!RI"$XAX#8P3P?R-&K:=*^M6UP$8Q+ P+A24!Q-P6Q@'D?F* *EA+/H&JQ
MZ;Y\DT-Q$6Q.Q=EVASPWKE.P (.""0#1XJO+HZM!:6TI3S(#PQ8QC_6Y;9G#
M, ,KGC<!GBK>K:=*^M6UP$8Q+ P+A24!Q-P6Q@'D?F*RO&4\UOK-L]L@DE$'
M"%@N1F7<-Q( .W.#Z]CT(!+XA2?P1)#?+<2S6[.(Y(YW,C<Y8E?NC.%..A!
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M6X>-4 9N,JK!LC&#U X)/;0T?QS<26-V(V\V2SVB.8J=SHS$;RA[JH+9.?\
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M]8J;-W[O[LC;MN/O=LYZ<5B^*K/^TK:.*TTZ6)D9-[&'#?<("@@;W&<Y8XY
MSRPKM?BEH4NL6FR ;FCD#E1]X@*P( [GYLX[XXR< @%BZT5M"M+ITGGD8P.0
M9I=Y4JC$%2 ,'G]!Z5SD/C"72M%CN]S-/(S(KO\ .03(_)W'G"J<=>< @C-=
M!)K;Z]9W*?9YHI!;N-LD9&YG1N$[M@C'0'D<<US\/@^75=%CM-K+/&S.J/\
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M,92%7XD;EERR\D<,Q[=5QN&27Z3ITJ:U<W!1A$T"@.5(0G$/ ;&">#^1KN*
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MPRI.3@$<@YKLZ\O&D-JU];W-E:/:I RF5Y%$&X9R5"#KP",C.=V&PH!KU"@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!B7OC2SL9'MI9522)=S!@PXP#P<88D$8522>PIFF^.;+40QCF7
M$8!8OF/ )P#\X7C) ]B0#U%<K8Z?'>:]<&10WE1(ZY[,%B ;'J,G'H>1R :9
MXETJ*\URVBD165X=S CABHE()]?N@<]0,'CB@#L]#\76NN,R6T@=D&2,,IQT
MSA@,CUQTR,]13M;\56NB8%S(J$XPO+-@YYVJ"<<'G&,\9S7):M"J:];$  M
MQ) QD[9AD^IP /H *UM8\5K;W?V2UMS/>*@#$;8]J$;\&1@>.0<?=RPYW<4
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MBHH#V9D;C.7,6_<<]\X(/; Q@ 8Y'5]0D&@VXW$^9+L;/.55I"JY/0#8N,=
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MTP>A%9%U\2-/M6,;3J2,?<5W7D9X9%(/X'VZUS_P^NET^;4PQVP03%MH!VJ
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MD@=,%CE>_I%9\V@033I?LN9XUVJVYN =W&,X/WCU'>@"[#"L*A$ "J   ,
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MHWET@_=PR/&F8PH#,QW!2"0-@&WCDJP)"YQ7I=9^B:!!HB&&V78A8L1N9N2
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M&,YP5/4<L.HSD[MPXI^E^'KF&19[F[>79G:JHL*'<"#N5<[^Q7.-I'O7044
M<_9>%/LU_+JN_/G1A-FW&,!!G=GG[GH.OM5CQ!HTVH&-[>X:!XRW10Z,&&"&
M0D D=B>G/&<$;%% '+Z/X)-O<?VE=3-/<*"%8J(T4$8X1<\\GOCYB=N[FNBN
M[5;M&AD&4D4JPR1D,,$9'/2IJ* .$@^&\]O$]BEXXMGWX3RUW -T&_.<9QN
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MPQ7<44 9/A;0O[!MDLMV_P O=\VW;G<Q;ID^N.M:U%% !1110 4444 %%%%
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MOBF9;@:98QK)/L#NSN D:E@.0#N)P<D#! *D!LXH ZBBN/@\4W.E7$=GJ2Q
M7/$3V^\KN! VL&YYR.<8&1U&2M2^\:W8U"32K>)),*NTG<NTLBMO<Y(*@GD
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MC9G,ZJQ Y/RJ"3[$KD97@T =O=7:6BF65E1!C+.0JC)P,D\=:?#,LRAT(*L
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M9PC;B. 26*H" <MEOF/(QZ5>Z';W[;YHHW8# +HK''7&2#QS5N&%85"( %4
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M/&NQ:/KL[SG:LD:(&/W02D1!)[#Y<9[9YP,D>BVVDPVK>;'&BOM"[E10VT
M+D#.  ,#IP/2AM)A=FE,:%Y%VNQ1=S*0!M)QDC '!XXH X+Q%J$?B74;.WM&
M#_9G,DCKS&!E&QN7//RX]-S*,YS@\.ZA'X:U&\M[M@GVEQ)&[<1D9=L;FQS\
MV/3<K#.<9[VQTF'3\^1&D>[&?+15SC.,X SC)I][IT5^NR9%=0<@.H89Z9P0
M>>: //\ Q%J$?B74;.WM&#_9G,DCKS&!E&QN7//RX]-S*,YSAZW::/KDTMRR
MQI/;KL9R IXC')Z#F-NN.GN,][9:=%8+LA144G)"*%&>F< #GBF7VDPZACSX
MTDVYQYB*V,XSC(.,X% 'G1UV+6-=@> [ECC="P^Z2$E)(/<?-C/?'&1@FWXI
MNET[6;2YF.R+R2N]@0N3YHQGIP67/H""<#FNZ7284991&@>-=J,$7<J@$;0<
M9 P3P..:?>Z=%?KLF174'(#J&&>F<$'GF@!UK=I=J)8F5T.<,A#*<'!P1QUK
MS#Q)I=M#JS/J*YM[J-?+;+*H90B_,P*XQM.>2 &4G Y'I]K:):*(HE5$&<*@
M"J,G)P!QUHNK1+M3%*JNAQE7 93@Y&0>.M '%:=H6BQSQ)!L:<MNC\N623F/
MY\G#L!C&?FZ]LU%HW_(>NO\ KW7^4%=K8Z3#I^?(C2/=C/EHJYQG&< 9QDT]
M-.B20W 11*PP7"@.1QP6QDC@?D* .'UG_D/6O_7NW\IZ-9_Y#UK_ ->[?RGK
MN'TZ)Y!<%%,JC <J"X'/ ;&0.3^9H?3HGD%P44RJ,!RH+@<\!L9 Y/YF@#SK
MQEK$>CZS;74V1&L&"0,XW&5<X]!G)QSCH">*=\2=5B\1"#2K1UDEDF5LH=Z*
M &7+,N?7)QG"@DXXSIZMITKZU;7 1C$L# N%)0'$W!;& >1^8KJK+0[>P;?#
M%&C$8)1%4XZXR ..* .-UG_D/6O_ %[M_*>J_AW4(_#6HWEO=L$^TN)(W;B,
MC+MC<V.?FQZ;E89SC/H#Z=$\@N"BF51@.5!<#G@-C(')_,T7NG17Z[)D5U!R
M ZAAGIG!!YYH \_\1:A'XEU&SM[1@_V9S)(Z\Q@91L;ESS\N/3<RC.<XM^-K
MG_A&+N'654E) T4X7:,C&4ZC);@G.>0BKE1U[6RTZ*P79"BHI.2$4*,],X '
M/%<I\3+*35(X+"-&/G3KN=8_,5%'!8G^$_,"#QD!@2!G(!7\(>'I)M.F>0K]
MHU!97+$ ?ZU2$R5SQSNZ<;B,9S7->"M*TJY@\N^"I<Q,RR":1HB3N.,#>HX'
M!& 01R.03Z[#"L*A$ "J   ,  <  #H!52]T.WOVWS11NP& 716..N,D'CF@
M#BKSP[9W>GW::2 2Q4-M,C;FA8/M&[=DX/R[>&)'/IF^%]+T34+>.278LH4"
M02S-&VX ;C@R 8)Y!'';@@@>I0PK"H1  J@  #  '   Z 52NO#UM=L9988G
M<XRSQHS' P,DC/2@#FEM=(CLE&%%G<3?*6,N/,Y7.YOF3[A!.0,9R<$YY^SO
M!X>N[:QTVY:>&9@)(R1*JC<<L&0 +P68@8QMW/D$"O3[JT2[4Q2JKH<95P&4
MX.1D'CK45CI,.GY\B-(]V,^6BKG&<9P!G&30!;HHHH \L\%^(X-*U"^AG8)Y
MT[E68@)\CR9!8]"=W&>#C&<X!O6MTOB+65N;8[HK2$J[X.TD[P I&0>7XSC(
M5B,@ FQX+T-C<ZB+F(^5+."HE3Y' DD((W###H>_8UVMEIT5@NR%%12<D(H4
M9Z9P .>* /(O"&@Z? TUCJ@5;B&0X9Y'C0K@ ;3N4'GD9 )5@1D9QW7A+2]-
M@ED;3]IDC4*Y1W=</\P +$J<[>V<8P<5T%]I,.H8\^-)-N<>8BMC.,XR#C.!
M4MK:):*(HE5$&<*@"J,G)P!QUH X7X*?\><G_7PW_H$=6/$NFZ7J=PWG2B"Z
MA,99UD$3],IRXVL<8.1EAA1D# KL++3HK!=D**BDY(10HSTS@ <\5#>Z';W[
M;YHHW8# +HK''7&2#QS0!YKIUW=>)M/O;3<9EA*"&0HP9PC;B. 26*H" <ME
MOF/(QTOA'QQ9BRBWRJAAB565R ^8U .%SE@<9&,YZ=<@=A#"L*A$ "J   ,
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MJO"?_'G;?]>\/_H"U>ETZ*6/[.R*8L ;"H*87&!MQC P,>E2PPK"H1  J@
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MKIME#<36@7R!N68Y=U(C4DC#;MPPQ^[D,#WKC=;%GX?B.H:3=%)'*8B5Q(K
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M"%HQGR9&D8<D[0\JDC /3=D]  "<\5JVNEZ!<1"Y^105)*O,XD&.H*>9G/L
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MX4DCD$;V+@$$ @@-@CL<UH6OAZVM&$L4,2.,X9(T5AD8."!GI6A0!Y_\:_\
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MXIUW^P;9[W;O\O;\N[;G<P7K@^N>E6])OO[0ACN<;?-C1\9SC<H.,X&<9]*
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MU2% P+M),),KGYE41C.['()^7CGJ*GUS4+VSE4VT"SPE.1Y@C</GKEN"I'0
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MH9!E)%*L,D9##!&1STH \]\&^$(O$T U+4"T\LQ;&YV4(%=AM 4C@G)QT'
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MH-'@K0)]-N;Z:9=J3S;HSN4Y&^0YP"2.&'7% &?\+&:VDO-/W,T5M-MC#8)
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MR7-V7EGN(U<R,[;AO0;0.2#M&,;@<GVPH[#7]&76H)+1^!(N,\\$<JV 1G!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO[>MGLMVSS-OS;=V-K!NF1Z8ZU;TFQ_L^&.VSN\J-$SC&=J@9QDXSCUJW10
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(BNQ/)81JP"G&T@[4(R"/O9QP*E^+%C'<16MC&%662=4C^7 "XVD9 .%!*9
M]L XX -CPG/%X=TV!YY%5/+WY;CF3,NT#))(!( ')QP.U6(/B'83H\JS K$%
M+?(X(#,%!VE<D9(!P#C(SC-<_J,*^)-8%G, 8;*+?L(R'9@AYZ<?,O!W [.G
MS&IOB/;P7\]I9E \TLZ%MH&_R5)W D?.%.XD=OE8Y&* .B\70P7< L[IF1+F
M2.-2GWBQ8,H'RL!DKU(Q[BI4O8-!6&Q=]O[LA-_=84!8E@ HPHR2<#TK \4?
M\3+4K*Q^?;%NG?;]WY?]63UZ,A!R.C8!R:HZG:1^(M9%M+DQV<&XHPRC,2#P
M,]/G4G(YV[2"* .ET?QS9ZQ)]G@E#2$$@%77..N-RC)[X'.,GH#5[6=?@T5?
M,N9%0'IGECR <*,DXR,X!QU/%<EXQ"ZCJEA9@D-&6E)QD8!W =>I\H@^F0>>
ME0Z!"OB/5+F[F (LB(XU(S@AF ?/'(*L1D'!;@_** .EL_'-G>J'CE!#2K$/
ME<'>^=HP5R <'!(V\'G@UO5P6NV\%_J]K"J R1!Y)F4#LH\K<R\Y4J.&XPRC
MD-BN]H *YPZ7;:CJ'VL.QN;-%5D'" 2*Y7.5Y)#'HW'&:Z.N"\"WJB*]UM_,
M*RRR, W4QQ E<9[C)7[V/E &,&@#?O/'-G9*7DE "RM$?E<G>F-PP%R0,C)
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M  V><9[5H:AXDM].9HIG"LD7FG(/W-VW.<8)+< #YB>@KG?^0GK/\>VQM_\
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MX4TC3%GD!0$22N2&Z G#8Y.-BC&!R.1UYB^%,#30S:C(H$EW.[9!X*@]ADX
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MMHI$5E>'<P(X8J)2"?7[H'/4#!XXJQJT*IKUL0 "T#$D#&3MF&3ZG  ^@ H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10!R7A[P7/I,?V4W;& (ZA8XDC8%\_,'^9L@DD>^.<#!KW'@*YU!%M;N]>2
M8RJQ*C':/ER^6)P<$[@V2,]<$=K10 R&%85"( %4   8  X  '0"N=\3^#/[
M7EBO896AN(> X&X%>3@J2!U)]B"0P((QTM% ')0> BUQ#J%Q,9IHBQ8N@ ;C
M$850=J!#\W )+$G(XQ?OO#+75[#J1D(6!&41[<@E@P+9W<$[AGCG:.?3>HH
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M(R,CT!.,%@0=U94WPV>YN(;^:Y:2:)U9BT:A6",&5552-@]?O9)+8'.>XHH
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M2Z/<6EO&%*W4NURP)(&Y!Q@CGYCUSVKG/%MXUGK-M+&C2.+<A47 )+><HY/
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MSDL!CD\C:0>2.X/.!CV'C6_U.YN+"WBB/DR,JR/O5%"N1\^"2Q8# "XYR<$
MX /0**Y3PIXIFO)Y]-O%1;B###RMVUE..><^JGD@D,/E!!JE!XLO==GECTY(
MO(A.WS9]Q5F!YVF,\@]1@'C!)&X"@#8LO%?VF_ETK9CR8P^_=G.0AQMQQ]_U
M/3WKH*\R\&WLE[K-S+-&8I#!@H3NQM,2]<#(.,@C@@\9'->E33+"I=R J@DD
MG  ')))Z 4 /HKA],\4:AXC!N+***. '"FY+EGP3DC9T X!'(!R QP<;LVJ7
M4L"2P08G=MK)*X41D;E+DC[Z@@$;>64@C% &W7/WOBO[-?Q:5LSYT9??NQC
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M'+!>>G/4=5QN) H ZNBN*E\6W>A2QQZE'%Y4S!1- 6"(3GAO,_ _PX7)&[!
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MTD:5%>1=CE067(;:2.5R.#@\9[U-4-IOV+YNWS-HW;,[=V/FQGG&>F><5-0
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M>B@!ERS+GUR<9PH)..,V]9_Y#UK_ ->[?RGKLK+0[>P;?#%&C$8)1%4XZXR
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M!@%T5CCKC)!XYH X+X1,KS7QC9G0R)M=\EF&Z7#'(!R1R>!S5OX<?\?FI?\
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M0.3^9H X?1O^0]=?]>Z_R@K*U6'3;9'U73KGR)@I*I&^ Q#YVF%ANPQ &.$
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M$$9!!X((/4&@"II>MP:JN^WD5Q@$[6!(W=,CJI]B >OI7&_&O_CSC_Z^%_\
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M #@  = *B33HDD-P$42L,%PH#D<<%L9(X'Y"@"Q1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<_9>*_M-
M_+I6S'DQA]^[.<A#C;CC[_J>GO0!T%%%% !116/XHMKNXB"V$BQR[P27 (VX
M.1RK\YQV[=: -BBBB@ HKA]6U&5-:MK<.PB:!B4#$(3B;DKG!/ _(5W% !11
M10 4444 %%%% !1110 4444 %%%</JVHRIK5M;AV$30,2@8A"<3<E<X)X'Y"
M@#N***X?5M1E36K:W#L(F@8E Q"$XFY*YP3P/R% '<45CVUM=K=R2O(IM"@"
M( -X;"Y).T<<-_$>HX]-B@ HHK'\46UW<1!;"18Y=X)+@$;<'(Y5^<X[=NM
M&Q1110 45Q_Q2UV71[3? =K22!"P^\ 58D@]C\N,]L\8."-CP[X?;1U(>>69
MG"Y,S[@"N<E0?N@YZ9/0<\4 ;%%%% !1110 4444 %%%% !17/\ @KQ7_P )
M/"USL\O;(4QNW=%4YSA?[WI5C1+:[AEG:ZD5XF?,(4 %5RW!^5><%>[=#SZ@
M&Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'EDNB#6-;N(6=EC$2EPA*[UV1 QD@CY
M3D9]0,<'D17OAP:7JB:992201742L^QB3\A=L DY!.S@DDC<W525KJ-,T">'
M5KB_9<020A5;<O) BXQG(^Z>H[4:GH$\VK6]^JY@CA*LVY>"1+QC.3]X=!WH
M Q+/35\-:S%:6A9(;B$LZ%BRY"R8^]D\% <YR,D X.*V_&L6G[U?496V[0!#
MO?;G+8D\N/YL]5W=,<=<4:GH$\VK6]^JY@CA*LVY>"1+QC.3]X=!WJEJWA^Z
MT[4CJUM$MPLJ8*EE1D(55R&8]3CJ >"RD#@D S/AO>QQZA<6MF[-9F/S%4YQ
MNS&"1N (QN*^I &2< U4TSP9:3:M<6#1Y@CA#*N]^"1%SG=D_>/4]ZZ#PQHM
MXNI3:E=1JBS0X&UU8 _N\+UR2 N&. "0<<$4:EHMYI>HMJMK&LZ3Q[60NL;+
M@*.K'')4'.#W! X) ,7Q)>+/>_V0R7#6EK#&!#:Y8L1L8%QP2H!"]200"""3
M1IN[3;N%]-M;F&*1E2=9HW\LJ6&&Y+$%02<Y &!V+9W=2T&[M[E-:M$7S7B5
M9X&<9/W<@.?ER !R-H^0'YMQ!V-+U&_O)%\VW2")<[]THE=L@[=NP #!'S;N
MH/'2@#C_ !QI/]KZO;VN]D$EOAF3[VW]Z6 _W@"O<<\@C@GQ0T"#1+!(;9=B
M&Z5B-S-R8W&<L2>@%=!J>@3S:M;WZKF".$JS;EX)$O&,Y/WAT'>CXH:!/K=L
MD-LN]Q,K$;E7@(XSEB!U(H M^-HK-E1K^5DB&[]V'95DR5ZHGS-M.",=.IXK
MB?#%[;6NJQQ:8[?9IXSYBG=MW*KD#YQGC .>3R0#@D5T?C+PW<27D&K6R+,8
M0%:)R%Z%B&!8@9^;CNK!3AN<5[?2;Z_U.#4YX5CC2-EPLBN5&V0 ,<C));/R
MC ! /(- !K/_ "'K7_KW;^4]>@5Q^IZ!/-JUO?JN8(X2K-N7@D2\8SD_>'0=
MZ["@#R?PMX:37+Z_$S-Y*3MNB5F57)DDVEMI&0N,@>I!SP0=7P7$-%U.ZTJ'
M/D!%D 8D[3A.!ST^?!SDD*N3QSI^"M GTVYOIIEVI/-NC.Y3D;Y#G )(X8=<
M4:9H$\.K7%^RX@DA"JVY>2!%QC.1]T]1VH PO"6D)XY,NHWQ9U$K+'$78(@P
MK<%2O."!P!G!)R3Q:TA6\+ZHNE1NS6UQ$S(C-D1G+MQG/'RMZ9W#=DKDS:9H
MU[X1DDCM(EN+65V94$@C="<=6?.1CCJV=H/RDD&UH7AVYO+PZQ?A494*Q1*=
MQ09(Y8<$X)_O9W$_+@  '->%O#2:Y?7XF9O)2=MT2LRJY,DFTMM(R%QD#U(.
M>"#J^"XAHNIW6E0Y\@(L@#$G:<)P.>GSX.<DA5R>.=/P5H$^FW-]-,NU)YMT
M9W*<C?(<X!)'##KBC3- GAU:XOV7$$D(56W+R0(N,9R/NGJ.U %NT\;_ &EU
MB^RW:[V W/!A1DXR3NX [GTKF?%MFU[K-M"CM&6MR-Z8W ?OMV,]"1D _P )
M.1R*]+KS+QDD[ZS;"U*B;R,J9,[.#*6!P"<%<CCGG@CJ !GB_0X_ [0ZK8[D
MQ((WC#$JZD%B,MN(R%QW'1@ 5YT-9_Y#UK_U[M_*>C5-)OO%LL4-W"L%I&P=
MP9%D9R.,90@C()';&222=HJ[XNT&X%W;ZM9H)9(@4=&<+E2&Y!..?F8$Y/.W
MY2,T 4OB/_Q^:;_U\?\ L\-5/%MFU[K-M"CM&6MR-Z8W ?OMV,]"1D _PDY'
M(I^L:-J6M7=I>2Q*D4,JGRUD5F0!U+,S<;BV,C;G  & <YM^+/#M[<ZC#?68
M4".(#?(1L!S)E2O+8(;' [\$=0 9GB_0X_ [0ZK8[DQ((WC#$JZD%B,MN(R%
MQW'1@ 5YT-9_Y#UK_P!>[?RGHU32;[Q;+%#=PK!:1L'<&19&<CC&4((R"1VQ
MDDDG:*T-3T">;5K>_5<P1PE6;<O!(EXQG)^\.@[T 9^C?\AZZ_Z]U_E!5+PE
MI">.3+J-\6=1*RQQ%V"(,*W!4KS@@< 9P2<D\;NF:!/#JUQ?LN()(0JMN7D@
M1<8SD?=/4=JS]+TF^\)2RPVD*SVDC%T D6-D)XQER2<  =\X!!!W"@#L-$TG
M^RD,"NS1ACY8;DHN!B/=U(!SM)Y (7G&:X_XU_\ 'G'_ -?"_P#H$E=;H)N7
M5GNPJL[Y5$.[8A5<(6P,L#G)Y!)X., 87Q0T"?6[9(;9=[B96(W*O 1QG+$#
MJ10!C_%BV:ZN+")&*,\KJ''52S1 ,,$<CKU'UJIX\\/1>$U@U.UW>>DZAF=V
M;S,JS,7YZMMYV[00S CICH_&N@3ZE<V,T*[D@FW2'<HP-\9S@D$\*>F:/BAH
M$^MVR0VR[W$RL1N5> CC.6('4B@#$^->EQ^3'>[?WOF+'NR?N[9&QC..O.<9
M]Z/%FEIX<,&GZ?N@:_F57D1W+ (0 !N.>LF>"O3!R#6W\4- GUNV2&V7>XF5
MB-RKP$<9RQ ZD5;\;^%GUM8I;=E2XMY \;/G;U&0>HZ@'E3TQT)H Q->^'%M
MI=L]S:%XI[>-G$BNVX[$.X'D ;AG.T#!]LJ<3QOK+:SH]M=2??:90W3DHLJ%
MN  ,D9QCC.*Z#4Y]5UJ$V7V9(#*NUY6F5EP5.X!5W$;N@^]@'U^81>,?!$C:
M=!IMFN]H9%)Y"Y^5]S?.W&6;.,G&>.!0!T'AKP5!H1\Y=SW#*1)*[,6<L0S$
M@D@9(^OJ2<D\%\+O"$6MV[R7)9XA*0L6]E0,%4F3Y2,M@X'H,]<C'KM<?\+]
M GT2V>&Y78YF9@-RMP409RI(Z@T <OX*\.#4YKG3II)&M+.5E6'<0&W.P!8J
M1P-F[ P-QR,<AMCX6,UM)>:?N9HK:;;&&P2 6D!YP.NT$CIG) &36AX*T"?3
M;F^FF7:D\VZ,[E.1OD.< DCAAUQ530/"4ZOJ23#8EXS"-LJW#&7YL!L\!@<'
M% '.^);?1UBE0S-+=A"5E+R2,S 90%@#&1T7V'&01FNP\(Q#Q+ID:7F9!("&
MR2"=DAVY*D'(VCG.3WSDUS^F:1J6G6<ND+;1_,)1YPE4!@P/)7[Q8CY5)VX^
M7< %-=;X"TN32K**VG7;(F_(R#C,C$<@D=".] '%?"3PM;:A";V5-TL5Q\K;
MF&-JHR\ @'!.>15KP=??V?-J]SC=Y4C/C.,[6F.,X.,X]*M^#=)OO"K-8^2L
MMN\P(F$BH0& #,4)). !\N!R" 6!!JWX5\+203:A]I3$5W(=OS#YE9I<_=.1
MPPZX/- &9X-\(1>)H!J6H%IY9BV-SLH0*[#: I'!.3CH.  .2;?@BXDTJ]N-
M$9VEBB17C+G)483Y/IAP." -N0HW'!H5IJ7A5#9)"MU"I)C995B(!8D@AAR3
MU[XR1N/;0\'^&9[::75+TJ;FX"C"9PBX'R^A/ '?&W.XY- ''_"[PA%K=N\E
MR6>(2D+%O94#!5)D^4C+8.!Z#/7(QT'PNF:W:\TT$F*UG(0L<M@LX(],?)G@
M#DL>]7?A?H$^B6SPW*[',S,!N5N"B#.5)'4&CP5H$^FW-]-,NU)YMT9W*<C?
M(<X!)'##KB@#L**Y_P %?;?);^T?];YAQ_J_N[5Q_J^.N??]*Z"@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **A^UIO\C<OF;=VW(W;<XW;>N,\9Z9J:@ HHHH **** "BBB@
MHHHH ***ADNTB98F90\F=JD@,VT9.!U.!UQTH FHHHH **** "BBB@ KG[WP
MI]IOXM5WX\F,ILVYSD.,[L\??]#T]ZZ"B@ HHHH **** "BBB@ HHHH **KI
MJ,3R&W#J95&2@8%P..2N<@<C\Q5B@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBJ-EKEO?MLAEC=@,D(ZL<=,X!/'- %ZBBB@ HHHH **** "BBB@ HHHH *
M*** "BH;J[2T4RRLJ(,99R%49.!DGCK3X9EF4.A!5@""#D$'D$$=0: 'T444
M %%%% !1110 4444 %%%% !115>]U&*P7?,ZHI. 78*,]<9)'/% %BBBJ][J
M,5@N^9U12< NP49ZXR2.>* +%%%% !1110 4444 %%%48M<MY9/LZRQF7)&P
M.I?*YR-N<Y&#GTH O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <IJW@*
MUU#S+F]9G<[SYC.4$:<[54 [0$'.2#DY8]<55^$5U+<6(\XL0LC+&6'\ "X
M/< Y ZXQMZ# N^)/ BZZ9"T\ZB0#Y ^805 P?+QR,@$C(R>XJE\--8DF$^GS
M*@:SDV[HE"*=S/GY550,%3R ,@C(SDD [6BBB@ HHHH \\\=7DE_?6^C&4PP
M3)ERIVLV[>NPDGHVW:!TRW(;@5T&F> ;729ENK8-&RA@0KL58,,88,6R!U&"
M.<$YP*M^)O"L'B.,0S@_*<JRX#KZX)!X/<$$'KU (YKP/J5S9WD^C74AF\E
MR.3SC(/.1N)(D'5CMQ@9'- $*:Y':ZI=WT\JB"WBCA'<Y<AMH"@EB&5]W4CZ
M X[71]:AUB/S[=PZ9(R,C!'4$$ @_4=,'H17%?##2X[]IM:>,B6:>79NY"JW
M)VG R<DJ6]B!CY@9O"973%U/40"S+<W&5S@$0Y<#.#@G<03SVX]0#HM9\:6>
MC-Y4\JJ_]T!G8< \A 2,@C&<9[5;T;7X-:7S+:17 ZXX8<D#*G!&<'&0,]1Q
M7+_"O2U,!U1\-/=O(S/C! WD%>.,%@6. .H!'RBLS1KA+?5-0U!!F""%M^P
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MB@U! !/%.@5\<@ ,X'/! 901D''..IR =AJ_B2WT=D2X<(920N0<'&,Y(!
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M8N&MPH.'+&,C/R' ^[UV]3^&9HW_ "'KK_KW7^4%'Q'_ ./S3?\ KX_]GAH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!QB>![JT4V]M?2)"1@*\:R.HVA<"3*
MD#CC;MV]N>3M^&?"L'AR,PP _,<LS8+MZ9( X'8  #KU))V** .?\%>%/^$8
MA:VW^9ND+YV[>JJ,8RW]WUKH*** "BBB@#C++P-<Z2OD6=ZT<(.51X4E(SU^
M8D<$Y.  .?7).GIW@V/2XIHH&<2W"L&F=BTA8[L.>0,J6/3!/<YYKH** ,GP
MMH7]@VR66[?Y>[YMNW.YBW3)]<=:H>%?!*Z);26$C^:DS.6^4IPZ!"O#$]!U
MR.M=+10!Q5OX"N=/1K6TO7C@.<*T2NPW#YL/E2,G)&T+@G/7).A)X&CALGTR
MU9HA+C<^2S$_*&)&1]X+@@8')XQQ72T4 5-)L?[/ACML[O*C1,XQG:H&<9.,
MX]:Y_5/!<DMVVI6D_D221A'_ '0EW8QS\S8'"J.!V]S75T4 ,A0HH4DL0 "3
MC)QW. !D^P ]!7*MX+GM)99;.[:%9W+NC1)*-[$DD9Q@<@=,\#)/&.MHH P=
M!\(QZ7(UVS-+<RC#RN>N=N0%'RA<J,#D@<9Q619_#R33&D2TNGBMY6R8P@9@
M",$+(Q)4XX# 9'&=Q&:[6B@#!\*>$H_#BRI'@B65F'RX(7C:F226"\X)/<\=
M:B\->#QI5O+9S2&87#NSL05)\Q0K G<3DXZYSS71T4 <5IO@6[TA3!:WK)%N
M8JK0)(0">F6/YX !.3@9-:5YX6F\N)+>ZE1X2_SR8EWA\Y#J=H8C^$G[H[9P
M1T=% '-:)X--I.=0N9FGN-I569%157C[JC.#UY! (8\9))NZ)HDNGRSRR3M*
MLS[D1LXC&6.T99N/F X Z#CTV** "N/OO \[7DFIVUSY+RJJD>2LG 51C+-C
MDJ#T]J["B@#$T32KNT<O<W7G(5("^2D>#D?-E3GID8]_:L?7_AM'JUXFHEP
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MI&>OS$C@G)P !SZY)U;OPU(UNEK#<RI)$X82LV]SR3A^F]><8/' SD#!WJ*
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MSN!)8YP<MGD<YR:J6O@R[M%%LE\XMUR OE)Y@3/W1*3D$#@,!QQ@  "NPHH
MYKQ5X,_MZVCL?-9?*9#O<>8S;4*\\KDG.2?7M72T44 <EHGP\CL;.72YG,B3
M.6) V$<+C'+<@J#Z=B".N?+\-KB>W^P27K-"H&U?* Q@@C)W%F4#.%S@':1]
MT"N]HH Y_4_"GVZP&E;\8CB3?MS_ *LJ<[<CKM]>,]ZU=)L?[/ACML[O*C1,
MXQG:H&<9.,X]:MT4 <_XD\*?VU-;7._9]EDWXV[MWS(<9R,?=]#UH\:^%/\
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M=!PHZG&!MVCBNCHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML&.W:AW$Y&,C.&!!4=: .MHKE-&\4S1W7]EWZHL[KOC:'<8V7!R/FR01M/7
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M#Y@C8?*1D=<'CL2!TH ZVBO/_P#A*]4N+3^THX84C6/<5D+EV Y:11E0%(Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=@!AU(V\XX&<9SD"Q?:3#J&//C23;G'F(K8SC.,@XS@5+:VB6BB*)51!G"H
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MDD+@#N<5NPPK"H1  J@  #  '   Z 4^@#RKPOI>B:A;QR2[%E"@2"69HVW
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M.V8 28W/@ ?,QR02"<E>%SGD =N*WJ** "BBB@ HHHH **** "BBB@ HHHH
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M;3%5'D1OP7< 9.#P%]\T >BT5QG@OQ-<2SRZ3? &X@!;>N-K*2N,@8Y^8$8
MR.H# Y[.@ HHHH **** "BBB@ HHHH **** "BBB@ HKS3P1JTUSI-W/)([2
M)Y^UF=BPQ"I&&)R,'D>]:WA:6[U+24:"7_26W8DE.[I,<Y)#Y^4$#@]J .UH
MJOIR2)$BS$-*$4.1T+ #<1P."?8?2K% !1110 445S][XK^S7\6E;,^=&7W[
ML8P'.-N.?N>HZ^U '045P_C[49;6[T](W95DGPX5BH8;XA@@'D<GKZFNXH *
M*** "BBB@ HHHH **** "BBB@ HHK'\46UW<1!;"18Y=X)+@$;<'(Y5^<X[=
MNM &Q17/^-?%?_",0K<[/,W2!,;MO56.<X;^[Z5T% !1110 445SGC_6&TRT
M<Q9\Z4B.,*&+%G..-O(8+DJ?4#KT(!T=%8-U/+X?MHXXTDNI<HGWCEF/WG9F
M+;5Z\G(&0.!R,#PEXBO;K4);*\*C9 &\N,#:K'RS][EB0&.?F(SG'&* .]HK
MDO&]T^D26^I*["))0DR_.8]CY&\JIQE><'!)8KUP >MH ***YKXCW;VEA-+$
MS(X\O#(2K#,B@X(YZ4 =+169X8F::TMW<DLT$1))R22@)))ZDUIT %%%% !1
M110 4444 %%%% !117/^"O%?_"3PM<[/+VR%,;MW15.<X7^]Z4 =!1110 44
M44 %%%% !1110 45D^*==_L&V>]V[_+V_+NVYW,%ZX/KGI5?4=4:ZTY[Q,HS
MVC2#!Y4M$6&&&.1Z\4 ;U%<U\.+M[NPAEE9G<^9EG)9CB1@,D\]*Z6@ HHHH
M **** "BBB@ HHHH **** "BBL?PO;7=O$5OY%DEWD@H !MP,#A4YSGM^- &
MQ17/^"O%?_"3PM<[/+VR%,;MW15.<X7^]Z5T% !1110 4444 %%%</I.HROK
M5S;EV,2P*0A8E <0\A<X!Y/YF@#N***X?2=1E?6KFW+L8E@4A"Q* XAY"YP#
MR?S- '<445R6C73ZOJ%Q,';R+4+$JC>J,_)<D9"ED.5Z$8*GL"0#K:*** "B
MJ^HWJV$3W#Y*Q(S$#KA02<9QSQ7GB^)9I;,7"O\ Z1JEP8XP\C 1*6,8VA?[
MF.655.6!;) ! /2Z*AM+?[,BQ99MB@;G.6.!C)/<GN?6J7B>9H;2X="0RP2D
M$'!!"$@@CH10!IT5S7PXNWN["&65F=SYF6<EF.)& R3STKI: "BBB@ HHKG[
MWQ7]FOXM*V9\Z,OOW8Q@.<;<<_<]1U]J .@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,DJPPPR>09T*R;"DF%)X!V@#ITSCI@ ^&7@J"ZMXM1GW22!B8P68+&(Y&P
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M,JGRUD5F0!U+,S<;BV,C;G  & <Y *_CC2?[7U>WM=[()+?#,GWMO[TL!_O
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MSD, F"F02N<EAVSNSO&!1KMIJ7BI!9/"MK"Q!D9I5E) 8$ !1P1U[9P!N'<
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MSC=Y4;OC.,[5)QG!QG'I7!>#?"$7B: :EJ!:>68MC<[*$"NPV@*1P3DXZ#@
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M+KF2#;L.2,;Y$#< X.1Z@^U5-/\ "UMI^FO>Q)MEET]MS;F.=T09N"2!DC/
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M,JK@*-H*MM)V]#]W('K\QUO!'A9]$666X97N+B0O(R9V]3@#H.I)X4=<= *
M.$^%_@J#7(7GNMSHDC*L>YE4':A9_E(.2,#MP.<\8MZ]X6MI=9AMF3]W<1O)
M(-S?,Q\TDYSD<J. 0/:NE^%^@3Z);/#<KL<S,P&Y6X*(,Y4D=0:B\6Z!="]@
MU>T596B78T98(<'?DAB0.0Y'L<'##( !U6EZ7'I4:VT"[8TS@9)QDDGDDGJ3
MWJW532[B2YC62>/RI#G*;P^,$@?,.#D8/XXJW0 4444 %%%% !1110 4444
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M_7?"ZNH."48,,]<9!//-6* "BBB@ HHHH **J:IJD>E1M<SMMC3&3@G&2 .
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MHH **** "BBB@ HHHH **KV6HQ7Z[X75U!P2C!AGKC()YYJQ0 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMK(@V1>6V[:-I&QCR-@ P,Y]ZM_"?9_9\>S;NW2;]N,[MYQNQWV[>O.,=L4
M:&L>.+?3+=-0RTD4K!5,0!.2&/1BN,;2".H/!'6M#7];31('O)0Q2/;D( 6^
M9@HQD@=3ZUQ7QAV?84\O;M^U<[<8W8EW].^[.[OG.>:V/BK,J:=*"0"QC !.
M,GS%.!ZG )^@)H NZOXUATJVBU"17,<^S:%"EAO0N,@L!T'/)YIV@>+X]=8K
M#'*(P&(E>/;$VUMORMGDGT(!X.<$8KB/'W_(&L_^W?\ ]$-7J4,*PJ$0 *H
M  P !P  .@% ''^$=9M+>SDN;""7RDEP8U!>0L0@) +MD8([C@$X]<7X8^,)
M7B\F9+B9GGP)0ID100@PSEN .I] <]ZN_!3_ (\Y/^OAO_0(Z/@I_P ><G_7
MPW_H$= '5>&O$L7B*+[3!NVABI#C# C!P<$CH0>">OKD!^G>((M1FFM8\EK8
MH'/&W+@G ()Y&"&R!@\5QO\ :Z^#+V[BD.4N(S<1AG(&_P"8LGW< N00#Z*H
M^9B!6[\.+)X+03RY,MT[3/G;UD/!&W@ J <=B3TZ  ZBL_7==BT.(W,YPJ]
M/O,>R@=R?_KG !(T*\_^*'^NL/,_X]_M'[S=_J_O)C=GY?N[NO;=VS0!2\<>
M.8=4L)(MDL33",Q^=&5$@#JQ*L"P( YY(ZC&:ZK2M:AT?3[>>X<(GD0C)R<D
MH,   DGZ#H">@-4OBQL_L^3?MW;H]F[&=V\9VY[[=W3G&>V:YKQ)_J='\S_C
MW_<^9N_U?W8L;L_+]W=U[;NV: .E7XG0*%DEBN(HI.DDL.(^06'*EB<@<8!]
M>G-=!J6OP:;$+N611$=N&'S [NF-N2V1SQGCGH*J>-MGV&X\S;M\E\;L8W8^
M3KWW8V]\XQS7F5Z9Q9Z46=HQYK9=P2J?O!Y3$-\N%3)7/&T''&: .[M_B5 Y
MC,D4\,<I 66:,+%\PROS;CP>QZ=S@9(U?$WBJ#PY&)IR?F.%5<%V]< D<#N2
M0!TZD X6J>";W58VMI[[=&^,C[-&,X((Y# ]0.]2Z[X#:]AM4AEVSV*KY;%0
M58JJXR.<<H#_ !8&>&H U=$\4KJCF$Q30N%+ 3QE-P! 8@Y(."1GZCWQMUQF
MB^*KFUNDT>_13*Z;DEB/RL I.2I P3M;)&.< +CFNSH XRR^*EM?K^YCG>0'
MF-(MS[?[_!*[<G'7.>V.:V] \50:Y ;R,E8T+!O,PNW:,G)R1C!!SDC!YYR!
MRGP3A46DC@#<9R"<<D!$(&?09./J?6N=._R]:\O=N\Y<[<YV^=)OZ=MN=W;&
M<\4 =JWQ.@8-)%%<2Q1]9(H<Q\ ,>6*D8!YR!Z].:W;/Q%#J$#7EN3*BAN(P
M2Y*C)4*<'<>P.,Y'8@U7\$[/L-OY>W;Y*9VXQNQ\_3ONSN[YSGFN:^%_^NO_
M "_^/?[1^[V_ZO[SYVX^7[NWIVV]L4 9GA+QQ+'<79DCNIE:7Y$5#(8AN?Y2
MI;Y#T&!_=([5ZG7G_P ./^/S4O\ KX_]GFKT"@#E]0^(4%M.UE&DL\D8RPMT
M$FWG!!^8<CC/8$X)SD#G/"6J1ZKK-S<P-NC>W&#@C./)!X(!Z@]JM_!W_4S^
M9_Q\?:&\S=_K/NC&[/S?>W=>^[OFHO#NS^W+OR]NWR3G;C&[,6_IWW9W=\YS
MS0!T&H^/X+64VD:RSRIG>MO'YA7&.O('4XXS@\'!J_X?\2Q:ZK-%N5HV*O'(
M-LB$$C#+DXSCC\1U! \]^'.GWE[%,([LPNL[>8C0I(^X@99BYW D@CGNI[YK
MK?#W@N33;N34IY_.DECV']T(_P"Y@\,1P$ Z4 <[\,'C32[EI@6B#S%P.I41
M)N Y')'N/K6[I7BJTTJTMI(HW2VFD**6*X0EVR7+2$@$ACD$X YQP*YKP!_R
M!KS_ +>/_1"UH:!H0UO0UM\9?;*R= =ZR.5P6X&3P3QP2,C- ';ZUK$>CPO=
MS9V1C)P,DY(  'J20.P]2!S6?J/C6VTZWCO9F*K,@9%QEVRN[&!GGD G.T$C
M)Y%<1+K'_"6V]AI>_P">9CYV)<OM@!SN&"<R ;UW#&X#KU%WQHDSZM:JDIA#
M1,$D90R!SO# *V%+,-JGOROM0!T=AX\BN)4MI8YH&ESL-Q'Y:L1CY0<GGG^G
M4@$\1_$"W\/2BVG#[FCW@JH*X^8 =0<DK@<8Y&2!DC)UOX?W>MH(;F]WH&#
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M$ Z4 =71110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<N[;<[<D\< X& .,9S60?AK!'(\T$L\'FD$K;R"-./;:>.3@9P,D# XKK:*
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MHB:) EG$6*1[L%R"WS,6.< #J?2M"B@#FK'X?V]I:2:8"[13-N)9AN!^7!!
M X*@C(//7(XJ&/X<0,ZRW$DUQL^ZMQ+O4'(.<8'IR#D$=0:ZNB@#'\3>%8/$
M<8AG!^4Y5EP'7UP2#P>X((/7J 18T32/[*0Q>9++EB=T[[V&0!@' XXZ>I-:
M%% &/X@\,1ZV8W9Y(Y(2Q1X7V.-PPPS@\'C/&>.N"<U]$\$0:5(;O+RSG/[V
M=][@$ 8!X'08SC."1G'%=!10!S6J> XK^=KY9)H974*Q@DV9 P.>">@' ..
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MVYVL#AE)&,@_T.02!D'%94?PX@9UEN))KC9]U;B7>H.0<XP/3D'((Z@UU=%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV?VS#M\GS?+?RL[]GE_O<;^^[&<XXSCWJ7Q]<36TNFRW(5I4F<LMN&(.)(R
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M4LH)WSN*;22=Q)0E"Q)[MMS^/4]:J_$/Q1+X;MUN(0I9I0I#@D8*L>Q7GY:
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M3KGB/5-%C^W2Q6_DAEW(K.9%5CC!;(4D9"DJ",G(!% '=T5SGB+Q0UEIYU2
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M=\2=5B\1"#2K1UDEDF5LH=Z* &7+,N?7)QG"@DXXSZ&^G1/(+@HIE48#E07
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MQ2UHR&-]N[@C>025QQ\P(P<D*W!Q@VF\.Z$&1!Y;-(ZHH2>1R6;@<(YP/<X
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M*_79,BNH.0'4,,],X(//-0C0[<! (H\1$E!L7Y"3DE>/E.>>,<\T <;\:_\
MCSC_ .OA?_0)*I?$G3XHKZVO+Q2UHR&-]N[@C>025QQ\P(P<D*W!Q@^BWNG1
M7Z[)D5U!R ZAAGIG!!YYJ6:%9E*. 58$$$9!!X((/4&@#S]O#NA!D0>6S2.J
M*$GD<EFX'".<#W. .YI^L_\ (>M?^O=OY3UV5EH=O8-OABC1B,$HBJ<=<9 '
M'%3/IT3R"X**95& Y4%P.> V,@<G\S0!#K>EKJL$EJV,2HRY(W8)'#8]5."/
M<=17F'@V8^([BVL;E01I\$NY9(QR=WEA2#QA5V=1G<ISGK7KM5[;3HK5F>-%
M5I#ERJA2QY.20.3R>OJ: /(M/B=Y+?PZY5A!?2,1(A7,<8#KQ@@B0&0X.<Y'
M(7&>E^(__'YIO_7Q_P"SPUW":=$DAN BB5A@N% <CC@MC)' _(47.G173*\B
M*S1G*%E#%3P<@D<'@=/04 <?XETW2]3N&\Z4074)C+.L@B?IE.7&UCC!R,L,
M*,@8%<_IUW=>)M/O;3<9EA*"&0HP9PC;B. 26*H" <MEOF/(QZ5>Z';W[;YH
MHW8# +HK''7&2#QS5N&%85"( %4   8  X  '0"@#RWPOI>B:A;QR2[%E"@2
M"69HVW #<<&0#!/((X[<$$#NO"%K:0P![ 8@D9F'+\D?(3\_(^[C\*MW7AZV
MNV,LL,3N<99XT9C@8&21GI6A0!Y_\:_^/./_ *^%_P#0)*L>(_B!9W-A(Z2
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M(_A]M;LW1,F2(B10.Y4$%< $DE2< =6QSBNEAA6%0B !5   &  .  !T I]
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MZ!'7=6MHEHHBB5409PJ *HR<G ''6FV6G16"[(45%)R0BA1GIG  YXH \R\
M?\@:\_[>/_1"UH?#;QE:6EB()9%C>#?N#G!(9F<%1U;@XP.<]N1GJM9TE+:S
MN(+:-5WPRX6) ,L4(^ZHY)X'KTK*\#>'DEL((KN%2\?F?+-&"R[I&/1QD9&/
MKQ0!R^@WD]K;:CK5NI'GRYBW*2P =MSXY!"A^N2 5;/ YS-<GBNM/^TO?2RW
M$NTF'S/DW%\LIAQD!0#@\+D KP5%>T0PK"H1  J@  #  '   Z 5GIX8M$!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK/\
M^$AMM_D>=%YF[;M\Q-V[.-NW.<YXQUS6A0 4444 %%%,FF6%2[D!5!)).  .
M223T H ?14-K=I=J)8F5T.<,A#*<'!P1QUJ:@ HHJ&[NEM$::0X2-2S'!. H
MR3@<]* )J*S[77X+J 7RR*(#GYW^1>&V\[\8YXYJ[#,LRAT(*L 00<@@\@@C
MJ#0 ^BBJ[ZC$D@MRZB5AD(6 <CGD+G)'!_(T 6***SYM?@AG2P9L3R+N5=K<
M@;N<XP/NGJ>U &A1110 4444 %%9^B:_!K:&:V;>@8J3M9>0 <88 ]"*NS3+
M"I=R J@DDG  ')))Z 4 /HK)_P"$LL_^?B'_ +_)_P#%5K4 %%%% !1110 4
M444 %%%% !1110 44R:985+N0%4$DDX  Y))/0"J5UK\%K ;YI%, Q\Z?.O+
M;>-F<\\<4 :%%0VETMVBS1G*2*&4X(R&&0<'GI1=7:6BF65E1!C+.0JC)P,D
M\=: )J*S-5\26^E1+=3.!$Y 5@"X.X%AC8#P0,YZ5;N=1BM65)'56D.$#,%+
M'@8 )Y/(Z>HH L4444 %%%% !169KGB2WT)5>Y<('.%X+$XZ\*"<#N<8&1ZB
MK&EZI'JL:W,#;HWS@X(S@D'@@'J#VH MT444 %%%5[W48K!=\SJBDX!=@HSU
MQDD<\4 6**S[7Q#;7;"**:)W.<*DB,QP,G !STK0H **** "BBB@ HHHH **
M** "BBJ[ZC$D@MRZB5AD(6 <CGD+G)'!_(T 6**** "BJZ:C$\AMPZF51DH&
M!<#CDKG('(_,58H **** "BBF33+"I=R J@DDG  ')))Z 4 /HJI8ZM#J&?(
MD23;C/ENK8SG&<$XS@U8FF6%2[D!5!)).  .223T H ?152QU:'4,^1(DFW&
M?+=6QG.,X)QG!JW0 4444 %%%% !115=]1B206Y=1*PR$+ .1SR%SDC@_D:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M33+"I=R J@DDG  ')))Z 5X_;0RW%CJ>I1!@EU*"@P0^P2DN3CC;M<@X)'#
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M1KT*RZ[:!@"/()P1GE?.(/U! (]#S0!T&A^.H-6F:SVR13*,[)U",>,\#)Y
MYP<''(R <1:A<VBZG!$\;&[,1*."=@7$F01N'/#?PGJ.?3'UG_D/6O\ U[M_
M*>C6?^0]:_\ 7NW\IZ -C4?B);:?</82"3S4 P%3=O9@I5%P2=QW8&0!GOTJ
MQH'C6+697M DL<L:ABDR;&P<<\$^HZXZC&><<YI,*OKUR2 2L"D$C.#MA&1Z
M'!(^A(I^L_\ (>M?^O=OY3T ;&GW-HVISQ)&PNQ$"[DG85Q'@ ;CSRO\(Z'G
MUB;XF6PEEM0DK31.5")'N9RI(;;M)X&,G=MXZ9Z5F:-_R'KK_KW7^4%,^',*
MF^U)R!N$Y ..0#)*2,^AP,_0>E '4>&O%L7B#S!&KH\+!725=K G..A(Z@C&
M<@@Y XS7U#QS#;2-!$DL[QG#BWC,FP]@QR!D\]"<$$'!%86C?\AZZ_Z]U_E!
M3- U"ZLI+O[+ +B)KV;.9%A=7^7<#NW KR I'/!) R  #H_#7C)/$!_=13*F
MTD/)&!&<$*0&#$$Y[>Q]*M>+/^/.Y_Z]YO\ T!JJ^"M&ETV)VN-OFW$SS.J?
M=4R8^4')SC'] 3C)M>+/^/.Y_P"O>;_T!J /-?AN/[$EM9BW[O4(Y4(+X DB
MD.TXQ@Y&%7G.6;V![/XE7C"W6QC($MY*D2_-MP&(W'@$E>BM[-SZ'EX=-:\T
M&.2,L)+=FE4JP4@I*^3GV4DC!!R!CT.KH.JGQ7J"70&(K.W4C:RL!)<(-P)P
M"< E2.Q3/&2" 1?"VU6TN=0AC&$CF55&2<!7E &3STK=U'X@PVC.$BGE6$L)
M'BB)163.Y2S%>1U/;!!S6/\ #C_C\U+_ *^/_9YJETGQ;?\ B;?-8QPI C;0
M;@N68]>D?3@KD<\GACS@ Z"V\6Q7EK_:$"O*HQE(EW2@D@%=N>HSD\].1D8)
MXWX8^,)7B\F9+B9GGP)0ID100@PSEN .I] <]ZN_!3_CSD_Z^&_] CH^"G_'
MG)_U\-_Z!'0!MZCX_@M93:1K+/*F=ZV\?F%<8Z\@=3CC.#P<&K_A_P 2Q:ZK
M-%N5HV*O'(-LB$$C#+DXSCC\1U! \]^'.GWE[%,([LPNL[>8C0I(^X@99BYW
M D@CGNI[YKK?#W@N33;N34IY_.DECV']T(_[F#PQ' 0#I0!%+\3[=)7M%CF>
M6.1DV1QAF8KNW%<-R!MYS@\CCKA\NHVD^H6V^*07<D&Y&;*[%*R$JR[^&'S
M_*<$]?3)^',*F^U)R!N$Y ..0#)*2,^AP,_0>E/UG_D/6O\ U[M_*>@#H-4\
M:1V,C6R1S321XWB"(OLW %<DX'S \8)Z'.*L>&?%4'B.,S0$_*<,K8#KZ9 )
MX/8@D'IU! PAXMN]8N)K2PCB"VK%7>X+8)SM "IR.5;UR!SM/!S_ (6[_M.H
M>;M\SSEW;,[=V^7=C/.,],\XH E^''_'YJ7_ %\?^SS5Z!7G_P ./^/S4O\
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MYYSGKGG- '<>*/%$7AN(7$P8JSA0$ )R03W*\?+7*?$V98;O3G<@*LY)).
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M<YI,*OKUR2 2L"D$C.#MA&1Z'!(^A(I^L_\ (>M?^O=OY3T >@4444 %%%%
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M3O$^CV$EQ,LI/VL@R*T<C)_%G ,?1MQR"2.<# XKK?\ A$[/_GWA_P"_*?\
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M&<9P2,XXJQ<^*M)N+N/5#<-YL2%0 C[,$,.1Y><_.>X[5UO_  B=G_S[P_\
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M^*M)UB6"XDN&#6K[D"HX!.5/.8SQ\HZ8[UUO_")V?_/O#_WY3_XFC_A$[/\
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M(!" PV&.9AAB2P.Y3D')ZUT7_")V?_/O#_WY3_XFC_A$[/\ Y]X?^_*?_$T
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M^S "C@>7G/R#N>]&B>*M)T>6>XCN&+73[G#(Y .6/&(QQ\QZY[5UO_")V?\
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MJ"ZEBW.K&.(2+$=IS@KY?*GGC.!D@8'%=[_PB=G_ ,^\/_?E/_B:/^$3L_\
MGWA_[\I_\30!PNHZGHUU*;N.YE@E?.]K<2QELXZ_NR.HSQC)Y.36AH7B[2=&
MW,EP[R2;=\DHF=VVYVY)3' .!@#C&<UU7_")V?\ S[P_]^4_^)H_X1.S_P"?
M>'_ORG_Q- '):)XJTG1Y9[B.X8M=/N<,CD Y8\8C''S'KGM1<^*M)N+N/5#<
M-YL2%0 C[,$,.1Y><_.>X[5UO_")V?\ S[P_]^4_^)H_X1.S_P"?>'_ORG_Q
M- '!:AJ&CW,[7L=U+!)(,,;<21[N<DG]V>3QGL2,D9R3;\,Z_H_AQI6MYVQ,
M5)#)(0-N[ '[L''S=R3TYKLO^$3L_P#GWA_[\I_\31_PB=G_ ,^\/_?E/_B:
M .2T3Q5I.CRSW$=PQ:Z?<X9'(!RQXQ&./F/7/:MC_A:6G?\ /;_R'+_\16K_
M ,(G9_\ /O#_ -^4_P#B:/\ A$[/_GWA_P"_*?\ Q- ')>%_%6D^&XC;PW#%
M6<L2Z.3D@#M&O'RU2U'4M%O[M=3:=Q*K(V%23:3'C!(,9/0 '!' ]<FNZ_X1
M.S_Y]X?^_*?_ !-'_")V?_/O#_WY3_XF@#BM;UO1M5D%WY[Q3C'[V!94<@ C
M!.PCH<9QG  SCBC1-;T;2I#=^>\LYS^]G65W ( P#L Z#&<9P2,XXKM?^$3L
M_P#GWA_[\I_\31_PB=G_ ,^\/_?E/_B: .2MO%6DV]W)J@N&\V5 I!1]F %'
M \O.?D'<]Z+GQ5I-Q=QZH;AO-B0J $?9@AAR/+SGYSW':NM_X1.S_P"?>'_O
MRG_Q-'_")V?_ #[P_P#?E/\ XF@#*_X6EIW_ #V_\AR__$5Q7Q!\4V6O36>U
M]\4<C>;\LBX5FCSV!Z ].?TKTK_A$[/_ )]X?^_*?_$T?\(G9_\ /O#_ -^4
M_P#B: //1-HK2)))<RR)$3LBE\UXE'90#'G:,#C/. &R*V/$OBW2/$47V:>9
MMH8,"B2A@1D9&4(Z$CD'KZX(ZK_A$[/_ )]X?^_*?_$T?\(G9_\ /O#_ -^4
M_P#B: /.+U=%OU_?7<[R \2.96?;_<YC*[<G/3.>^.*U?$VOZ/XC:)KB=L0E
MB J2 '=MR#^[)Q\O8@]>:[+_ (1.S_Y]X?\ ORG_ ,31_P (G9_\^\/_ 'Y3
M_P")H \]$VBM(DDES+(D1.R*7S7B4=E ,>=HP.,\X ;(K5UOQ5I.L2P7$EPP
M:U?<@5' )RIYS&>/E'3'>NM_X1.S_P"?>'_ORG_Q-'_")V?_ #[P_P#?E/\
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MP ,XXHT36]&TJ0W?GO+.<_O9UE=P" , [ .@QG&<$C..*[7_ (1.S_Y]X?\
MORG_ ,31_P (G9_\^\/_ 'Y3_P")H Y*V\5:3;W<FJ"X;S94"D%'V8 4<#R\
MY^0=SWHN?%6DW%W'JAN&\V)"H 1]F"&'(\O.?G/<=JZW_A$[/_GWA_[\I_\
M$T?\(G9_\^\/_?E/_B: -:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD\J&YZ<]3T;.T@BLJP\:W^IW-Q86\41\F1E61]ZHH5R/GP26+ 8 7'.3@@'
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M[&,!SC;CG[GJ.OM5BV\417%W)I8#>;$@8D@;,$*>#G.?G'8=ZY?6?^0]:_\
M7NW\IZV-/\42W&ISZ60OE11!@0#OR1&>3G&/G/8=J .@348GD-N'4RJ,E P+
M@<<E<Y Y'YBK%>2:9]O_ +6N-GV?[3Y(W[O,\K;B+&W'S9^[UXZ^U=G<>))]
M.N[:SN%C$=S%@NI(_?*,L!D\J?E"@@$EAR2"* .HHK!\0Z])8S6UI"H9[F4@
M[N@C09D.=P^8 Y'7H>,X!V+O?L;RMOF;3MWYV[L?+G'.,]<<XH Y6?QY)<7$
MEE8VS3^1P[&01*&!((^9<=>.H)P< @9/85Y)X*^W_:;[[/\ 9_,\[][YGF;=
MV^3[FWG&<]><8]ZZN_\ %MQ>W3Z=IT:,T./,EE),2G!^7"<YS@=<Y##;@%@
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MF"11P,45@<<DR<C!SDX(Y4'&<BE>>(M2T2-;V\C@, *^8L)?S5#<9^9MI()
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M4W)<L^"<D;.@' (Y .0&.#@ [BBN:\)>+6U=I+2XC\FY@QO3((((^\O?&?J
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MDJ\SB08Z@IYF<^P!S_#D$9UM4TW2FM[>TE*I%(KM Q9E(##<Q#MT^\#AS@G
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M9"%4@JJX#$XR".GH>,\XHW5BWBR74;ZU!,1B1%W*P+E#$Q"@ Y)$1P.#\RY
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M$@&<9XYKT6RTZ*P79"BHI.2$4*,],X '/%%EIT5@NR%%12<D(H49Z9P .>*
M.'^&WBBWL[064[K%+;LZLLQ$9R79N-Q&<9P1U!'(Z$L\%RC6M3NM5ASY!18P
M6!&XX3D<=/DR<X(#+D<\=K>Z';W[;YHHW8# +HK''7&2#QS5N&%85"( %4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !116/K=M=S2P-:R*D2OF8, 2RY7@?*W. W=>HY] #8HKG_$GBO\
ML6:VMMF_[5)LSNV[?F09Q@Y^]ZCI6/\ %W49;"T1X79&,Z@E&*G&QSC((XXH
M [BBBB@ HHHH **** "BBB@ HHHH **X_P %:_/J5S?0S-N2";;&-JC WR#&
M0 3PHZYK'TM)_%=[=K)<2Q1VK^6J6[F/^)P">O/RG/&23P0 !0!Z11110 44
M44 %%%% !117#_%W49;"T1X79&,Z@E&*G&QSC((XXH [BBBB@ HHHH ****
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MJ.?38H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHK@O&%Y/?:A;Z1'*T,4B>8S1$JYQOR-P/3"8'
M;)R0V   =[1532]/_L^-8-[R;<_-*VYSDD\M@9QG ]L5;H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?G56,0 =N$V,F!SR.@.0 *ZKP?IMY8Q?V/=VZFW_ 'JF595 *MN/W0=QW$D
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M%&4^=<EN ,J,DXXSR.M<[\)[)[B)]4N,M-.0H=MI)2(!!R.<D@ALG+;03ZD
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M;TQN _?;L9Z$C(!_A)R.147B_0X_ [0ZK8[DQ((WC#$JZD%B,MN(R%QW'1@
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MR1NP2.&QZJ<$>XZBN0^'/A*>R\Z6_1=TB1Q*#L8[$7:0=N1M(VC&<G;EAT)
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ML8!/4*3DCG&.: +=%5-+U2/58UN8&W1OG!P1G!(/! /4'M5N@ HHHH ****
M"BBB@ HHHH P?"GA@Z$LI=Q++/*TCOL"$YQQ@$\ Y([#)P!6]5>RU&*_7?"Z
MNH."48,,]<9!//-6* "BJFJ:I'I4;7,[;8TQDX)QD@#@ GJ1VJ*YU^"U@%^[
M8@*JV[:QX?&TX SSD=OK0!H45GS:_!#.E@S8GD7<J[6Y W<YQ@?=/4]JT* "
MBBB@ HHHH **J7FJ1V;1Q.V'F;:B@%F) R>%!. .K'@=R*+?5([F22V1LR0;
M-XP1C>,KR1@Y'H3[T 6Z*** "BBB@ HHHH S]?TQM4@DM4?RS*NW=M#8!^\,
M$CJ,CKQG(YIVB:6NE01VJXQ$BKD#;D@<MCU8Y)]SU-7J* "BBB@ HHK/T37X
M-;0S6S;T#%2=K+R #C# 'H10!H445F:5XDM]5B:ZA<&)"0S$% -H#'.\#@ Y
MSTH TZ*AM;M+M1+$RNASAD(93@X."..M34 %8*>&";XZH[AL1>6B%!\G0DA\
M\D_-VSAB,XK>JI<:I';21VSMB2??L&"<[!EN0,# ]2/:@"W16?INOP:D\L,+
M;G@;;(-K#!R1C) !Y4],UH4 %%%% !1110 4444 %%%% !116?HFOP:VAFMF
MWH&*D[67D '&& /0B@#0HHHH **** "BH;J[2T4RRLJ(,99R%49.!DGCK3X9
MEF4.A!5@""#D$'D$$=0: ,3PIX8.A+*7<2RSRM([[ A.<<8!/ .2.PR< 5O5
M#=W2VB--(<)&I9C@G 49)P.>E1:7JD>JQK<P-NC?.#@C."0>" >H/:@"W111
M0 445GZ)K\&MH9K9MZ!BI.UEY !QA@#T(H T**** "BBF33+"I=R J@DDG
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M[42Q,KH<X9"&4X.#@CCK0!-1110 4444 %%%% !1110 4444 %%%% !1110
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MW/\ U[S?^@-0!A1?%2VGC\Z*.>0*"7"19\L#."YSM (!(P3P#G%='I>NQ:E
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M(8,&ZD\YS^- '40?$>"26.W,<R"=L1R/%MC?.-I4DY(;(P<=QG J[XD\90:
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M@C)>"(LP4*Y.U23O7#9)Z\\]Z=\4O^0=/_VS_P#1J5J^$_\ CSMO^O>'_P!
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M$Y9B!C)/]!@ DX S6M10!CZ)X7BT>6>XC+%KI]SAB" <L>, <?,>N>U;%%%
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M^21MTC9);D].O7 &< G)&:VZ* "N4D^'$"NTMO)-;[_O+;R[%)R3G&#Z\ 8
M'0"NKHH S]$T./1D,46[YF+,SL69F( 9R3W..<8&>U5_"_A>+PW$;>$L59RQ
M+D$Y( [!>/EK8HH Y^UT!/#OVJ^@#R23[I"A(.67>P5<+D9+$?Q'I^/'Z!HF
MC7D$<T[1>:ZY?=-Y1#'EAL5D"@'(4!0, 8SU/J%9]UX>MKMC++#$[G&6>-&8
MX&!DD9Z4 <)X(T3^WH+FUG+R67F 6SR'Y@$W+N4D C "]MN<KC[PK6N/A1;W
M*+%)+<.$QLWR@[ !@JH*X /&>/X1C SGLH85A4(@ 50  !@ #@  = *?0!Q_
MQ!FB<VUK=#%M+,?,D/0%%)1=VT[=Y/+ J0H;G!)'+^*M*TW3X?-TUP+O>HC^
MSSL[DL=I7 9B 5)].<#/.#ZK-"LRE' *L""",@@\$$'J#5*U\/6UHPEBAB1Q
MG#)&BL,C!P0,]* ,RR\+_:);?5+DM]JB@56 *[-Q5@V0!URYZ$#ICBK=MX7B
MM[N35 6\V5 I!(V8 4<#&<_(.Y[UL44 8]SX7BN+N/5"6\V)"H (V8(8<C&<
M_.>X[5Q[6^GZQ=73ZCM26.4(JR2>5\BJ K@C9N+\G)+$+M XQGTBJE]I,.H8
M\^-)-N<>8BMC.,XR#C.!0!Y_X<@6UU/R-,=FLA'NF"N7B5F4@8)R"250Y!+?
M>&< @>AZC9+?Q/;OD+*C*2.N&!!QG//-%EIT5@NR%%12<D(H49Z9P .>*L4
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M4 <DOPSMA+%=%Y6FB<,7>3<SE2"N[<#P,8&W;QUSUK5N?"\5Q=QZH2WFQ(5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'791:';Q2?:%BC$N2=X10^6SD[L9R<G/K4UEIT5@NR%%12<D(H49Z9P .>*
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MZQ2V[.K+,1&<EV;C<1G&<$=01R.A.?\ $.XCUN&TU50SVD<SB0 $,5+A2>V
M=A )*G+*.">/0+KP];7;&66&)W.,L\:,QP,#)(STK0H \WETCP_''YY,>W .
M!-(7YQCY Y?//(QD=\8->A6EJMHBPQC"1J%49)P%& ,GGI56U\/6UHPEBAB1
MQG#)&BL,C!P0,]*T* /.KJZ7P[K+7-R=L5W"%1\':"-@(8G '*<XS@,I. 21
M#\2=5B\1"#2K1UDEDF5LH=Z* &7+,N?7)QG"@DXXSZ+=6B7:F*55=#C*N RG
M!R,@\=:BL=)AT_/D1I'NQGRT5<XSC. ,XR: .*^(_P#Q^:;_ -?'_L\->@57
MN=.BNF5Y$5FC.4+*&*G@Y!(X/ Z>@JQ0!Y_X]UN6&[@L&F:WM9E!>5!AB=Q^
M4/\ PXPHR,;=V6RO%8FFK$FM6Z03O<*L;Y>23S2#Y<AVA@ " "#QG!)[Y ]3
MO=.BOUV3(KJ#D!U##/3."#SS4,&AV]NRND4:M&"%*HH*@Y) (' .X]/4^M %
MZO-XM0CTK7)Y+AA&LL"A&?Y5/RQ_Q'C'R,,YQD8Z\5Z152^TF'4,>?&DFW./
M,16QG&<9!QG H X?5)EFURS=""K6Q((.005F(((Z@UL?$K7)]%M//MN&\Q0S
M;=VU3GGG(&2 N2".<=2*Z!=)A1EE$:!XUVHP1=RJ 1M!QD#!/ XYJQ-"LRE'
M *L""",@@\$$'J#0!XEXY2!+:(QWLMS([*2KR[U V'+;,90Y( #'(!(YP<=A
M\:_^/./_ *^%_P#0)*ZT>&+0*4$$6TD$CRDP2,@'&.HR<?4^M6[W3HK]=DR*
MZ@Y =0PSTS@@\\T <Y\4O^0=/_VS_P#1J5GW%O87EE96U^54O;KY;$E2"(EW
M$/T'4<,<$XX) KM;JT2[4Q2JKH<95P&4X.1D'CK45QI,-RBP21HT:8VJR*5&
M!@84C P.![4 >?\ AC4VL-072[2=KFT\LD[L2>7A. )!Q@$*!CY1NVXW<UGZ
M+K/]M>=/J-[+;R1,1Y43^1@#)/RX)<YRN,%Q@ DY%>IV6G16"[(45%)R0BA1
MGIG  YXJ&70[>63[0T49ER#O**7RN,'=C.1@8]* /+?"6F/J>BW4$0RYF) Y
M).P1.0  220N .YQ76^$?'%F+*+?*J&&)597(#YC4 X7.6!QD8SGIUR!U=EI
MT5@NR%%12<D(H49Z9P .>*K_ /"/6V_S_)B\S=NW>6F[=G.[=C.<\YZYH XK
MXKW']I:;#=1AMC212<CD*\;8)QD#E@.N,G&:Z+6-;@U6QN7MY%<?9I"=K D;
MHVQD=5/L0#U]*Z":%9E*. 58$$$9!!X((/4&JEMH=O:JR1Q1JL@PX5%4,.1@
M@#D<GKZF@#R7R6M[#3=2()BM9W+A1EL&?(/ICY,<D<E1WKM?%WCBS-E+LE5S
M-$RJJ$%\R*0,KG*@9R<XQTZX!ZVUM$M%$42JB#.%0!5&3DX XZU5M?#UM:,)
M8H8D<9PR1HK#(P<$#/2@#A-4TQ],T#R)1APJ$CD$;YPX!! ((#8(['-=!_S!
MO^X?_P"T*Z6ZM$NU,4JJZ'&5<!E.#D9!XZT?9$V>1M7R]NW;@;=N,;=O3&.,
M=,4 <U\+?^0=!_VT_P#1KUF_&B%GLE(!(6="2!G VN,GT&2!]2!7;VMHEHHB
MB5409PJ *HR<G ''6J7B71QK%M+:'&9$(7)( 8<H21S@, ?Z'I0!C_$K7)]%
MM//MN&\Q0S;=VU3GGG(&2 N2".<=2*\Z\<I EM$8[V6YD=E)5Y=Z@;#EMF,H
M<D !CD D<X./4O"5PVHV:+<HP<)Y<BS*V6P-I)W@;@XY/4<D9)!JV/#%H%*"
M"+:2"1Y28)&0#C'49./J?6@#-\:6]A>".VORJE]_EL25(('S$/T'4<,<$XX)
M KF?#&IM8:@NEVD[7-IY9)W8D\O"< 2#C (4#'RC=MQNYKT.]TZ*_79,BNH.
M0'4,,],X(//-%EIT5@NR%%12<D(H49Z9P .>* ,?Q]ICZG8S01#+E00.23L8
M.0  220N .YQ7%>%]+T34+>.278LH4"02S-&VX ;C@R 8)Y!'';@@@>JUGW7
MAZVNV,LL,3N<99XT9C@8&21GI0!CZ5>V&@637MKD6N2W&\DMD1\!^<D@#G [
M\#FN'TK2Y?"DD.MSQ*$G9Q*@CP+<2,-K#!8C@],<#]V?F85ZQ>Z=%?KLF174
M'(#J&&>F<$'GFG75HEVIBE570XRK@,IP<C(/'6@#SKXI:FEM-I]YG=&DC293
M!RH:)LCG!R.G./>K'Q$\6VVHV?V6W<2RW)C"+'\S<.K<@<J>P!&XDXQP<6/'
M.DO)<Z=Y$;&.&;GRT)5%#Q8S@84  ^@P/:NMBT.WBD^T+%&)<D[PBA\MG)W8
MSDY.?6@#@/%EDUA+H]N^"T3HI(Z94P@XSCCBI?$6LR7.I'3KBX:UM50,C(?+
M+G;_ ,]#T&2P_NG;MQNYKT"YTZ*Z97D16:,Y0LH8J>#D$C@\#IZ"F7VDPZAC
MSXTDVYQYB*V,XSC(.,X% 'F_@/R_[7N!#*TR" @22-O9L&('YL#(!R >F ,9
M'-:>C?\ (>NO^O=?Y05VMMI,-JWFQQHK[0NY44-M  "Y S@ # Z<#TIZ:=$D
MAN BB5A@N% <CC@MC)' _(4 </\ #C_C\U+_ *^/_9YJI/9-?ZMJ%NF TMDR
M@GIEDA SC/'->BVVG16K,\:*K2'+E5"ECR<D@<GD]?4T)IT22&X"*)6&"X4!
MR.."V,D<#\A0!Y/X*TK2KF#R[X*ES$S+()I&B).XXP-ZC@<$8!!'(Y!/8:3H
M=E/;746F;?WJO$S;I"NX(0.6SP-_5<@@\9KHKW0[>_;?-%&[ 8!=%8XZXR0>
M.:MPPK"H1  J@  #  '   Z 4 >?_#OQ;;:=9_9;AQ%+;&0.LGRMR[-P#RQ[
M$ ;@1C'(RWX6W'VFYU"7#+OF4[7&&&7E.".Q'<>M=O+H=O+)]H:*,RY!WE%+
MY7&#NQG(P,>E36VG16K,\:*K2'+E5"ECR<D@<GD]?4T 4?%G_'G<_P#7O-_Z
M U<!_P RY_G_ )^J]2FA692C@%6!!!&00>""#U!JO_9,/E_9?+3RO[FQ=G7=
M]W&.O/3KS0!S_P#S!O\ N'_^T*/A;_R#H/\ MI_Z->NE^R)L\C:OE[=NW V[
M<8V[>F,<8Z8HM;1+11%$JH@SA4 51DY. ..M %+5_$4.CL@N"464D!R#L#<8
M5F'W2<DC/&%8DC%>?_$J^@UJ2WAL2);W>"KPL#A1DX+J< AOF']T L2H//J$
MT*S*4< JP(((R"#P00>H-5['28=/SY$:1[L9\M%7.,XS@#.,F@#S7Q)I=M#J
MS/J*YM[J-?+;+*H90B_,P*XQM.>2 &4G Y&UIVA:+'/$D&QIRVZ/RY9).8_G
MR<.P&,9^;KVS7:W5HEVIBE570XRK@,IP<C(/'6HK'28=/SY$:1[L9\M%7.,X
MS@#.,F@#@O#NH1^&M1O+>[8)]I<21NW$9&7;&YL<_-CTW*PSG&>UTOQ'!JLD
MD,#!_)"%F4@I\^[ ##J1MYQP,XSG(%B^TF'4,>?&DFW./,16QG&<9!QG J6U
MM$M%$42JB#.%0!5&3DX XZT >=?"'58K&&2RF=8Y_M!^20[&)954 !L9.5(P
M.0>HY&6^$[)K^76+=,!I7=03TRQF SC/'-=_+H=O+)]H:*,RY!WE%+Y7&#NQ
MG(P,>E36VG16K,\:*K2'+E5"ECR<D@<GD]?4T </\-O%%O9V@LIW6*6W9U99
MB(SDNS<;B,XS@CJ".1T)9X+E&M:G=:K#GR"BQ@L"-QPG(XZ?)DYP0&7(YX[6
M]T.WOVWS11NP& 716..N,D'CFK<,*PJ$0 *H   P !P  .@% '!?!3_CSD_Z
M^&_] CH^''_'YJ7_ %\?^SS5W%EIT5@NR%%12<D(H49Z9P .>*+;3HK5F>-%
M5I#ERJA2QY.20.3R>OJ: *GB32&UBWDM%<QF0 ;@,X&02,9&00"#ST-<%XR\
M-W>EZ>Z/=^9!$L2^7Y"+D!U51O!)XX/OCFO4*ANK1+M3%*JNAQE7 93@Y&0>
M.M ',>$C+I-B+NXE,L2VT;J@C52BK'N*@@_,<8&3CI[U8OM;36],FO(@P22W
MGP' #?*KJ<X)'4>M;_V1-GD;5\O;MVX&W;C&W;TQCC'3%-BTZ**/[.J*(L$;
M H"8;.1MQC!R<^M '%?#W7+2+3HK>>6('$@9)'0<-(_!5CT(/?J*9\*+4Q&Z
MDC#"T>;]QDG:0I<$@-STV@D]<8)RIQU7_")V?_/O#_WY3_XFKVHW+6L3RHI=
MD1F"#JQ4$A1@'D].A^E '%?#F%A=ZDY!VFY(!QP2'E)&?49&?J/6MWQ]ICZG
M8S01#+E00.23L8.0  220N .YQ3/ &CMIEH@ESYTI,DA8L6+.<\[N0P7 8>H
M/7J>CH XKPMXZM$L8OG_ 'D4:1^4.9690% 5,Y;<<8(XYY(P<<IX2TQ]3T6Z
M@B&7,Q('))V")R  "22%P!W.*]2BT.WBD^T+%&)<D[PBA\MG)W8SDY.?6IK+
M3HK!=D**BDY(10HSTS@ <\4 <IX1\<68LHM\JH88E5E<@/F-0#A<Y8'&1C.>
MG7('*Z9H\NMV>I7<2G;=R[HU8'<1%(9#P <DYVC!.6!'&,UZ;=>'K:[8RRPQ
M.YQEGC1F.!@9)&>E:% 'E7A?2]$U"WCDEV+*% D$LS1MN &XX,@&">01QVX(
M('46D.F6FGO(@'V&4DMD2-DEA'G#9<'<!C'0C(QUK=NO#UM=L9988G<XRSQH
MS' P,DC/2KLT*S*4< JP(((R"#P00>H- 'DNKSQ>%&1]'N3(TLIS;AA,A!QT
M"]#P%Y.]@>&X.?7:HV6AV]@V^&*-&(P2B*IQUQD <<5>H \_T;_D/77_ %[K
M_*"C6?\ D/6O_7NW\IZ[A-.B20W 11*PP7"@.1QP6QDC@?D*'TZ)Y!<%%,JC
M <J"X'/ ;&0.3^9H \\^&VJQ>'1/I5VZQRQS,V7.Q&!"KE6;'ID9QE2",\XF
MM;I?$6LK<VQW16D)5WP=I)W@!2,@\OQG&0K$9 !/=7VDPZACSXTDVYQYB*V,
MXSC(.,X%2VMHEHHBB5409PJ *HR<G ''6@#@/%-TNG:S:7,QV1>25WL"%R?-
M&,]."RY] 03@<UW]K=I=J)8F5T.<,A#*<'!P1QUIM[IT5^NR9%=0<@.H89Z9
MP0>>:=:VB6BB*)51!G"H JC)R< <=: . NKI?#NLM<W)VQ7<(5'P=H(V AB<
M <ISC. RDX!)'17^MP:ZLNF6TBO++;2G*L&09^099<\DMT&3@$G'&=N]TZ*_
M79,BNH.0'4,,],X(//-%EIT5@NR%%12<D(H49Z9P .>* .'^&WBBWL[064[K
M%+;LZLLQ$9R79N-Q&<9P1U!'(Z$L\%RC6M3NM5ASY!18P6!&XX3D<=/DR<X(
M#+D<\=K>Z';W[;YHHW8# +HK''7&2#QS5N&%85"( %4   8  X  '0"@#@O@
MI_QYR?\ 7PW_ *!'5?P1+'%<:L\V/*65B^1N&T--NR,'(QVQS7H%EIT5@NR%
M%12<D(H49Z9P .>*+;3HK5F>-%5I#ERJA2QY.20.3R>OJ: /*M;%GX?B.H:3
M=%)'*8B5Q(K @C!1LL" 2V7S@Y& 2,:OQ1:6\TR":1"'WQ-( I&TM&P.0<D
M,<<]\#K7<6OAZVM&$L4,2.,X9(T5AD8."!GI5V:%9E*. 58$$$9!!X((/4&@
M#BO'VMP:KID[V\BN,0D[6!(W2)C(ZJ?8@'KZ5%XAA:70E"@D_9K8X SPOEDG
MZ  D^@YKK8_#UM$K1+#$$DQN41H%;:<C(Q@X/3/2KL,*PJ$0 *H   P !P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 45P^K:C*FM6UN'81- Q*
M!B$)Q-R5S@G@?D*[B@ HKA_ .HRW5WJ"2.S+'/A S%@HWRC !/ X'3T%=Q0
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MSWK0R#S78EG=OFR0Q*C+ =?Q)Y)X7PI;:>V8=0\V*_W%C),SQD,<LK*V0 0
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MA%XF@&I:@6GEF+8W.RA KL-H"D<$Y..@X  Y)ZW35N-425+Z)(XY5VB-7+.
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M)Z 5S^IZ!/-JUO?JN8(X2K-N7@D2\8SD_>'0=Z["@#S_ .-?_'G'_P!?"_\
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MOE %N'$9R_ Y'.00#C/RT =GIRJD2!'+J$7#EMQ88&&+#J3USWZU8KBKB1_
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MXA*0L6]E0,%4F3Y2,M@X'H,]<C$O@KPX-3FN=.FDD:TLY658=Q ;<[ %BI'
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MWOA3[3?Q:KOQY,939MSG(<9W9X^_Z'I[UT%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 0W=TMHC32'"1J68X)P%&2<#GI7-?\+2T[_GM_Y#E_\ B*ZB:%9E
M*. 58$$$9!!X((/4&LS_ (1.S_Y]X?\ ORG_ ,30!E?\+2T[_GM_Y#E_^(H_
MX6EIW_/;_P AR_\ Q%:O_")V?_/O#_WY3_XFC_A$[/\ Y]X?^_*?_$T 97_"
MTM._Y[?^0Y?_ (BC_A:6G?\ /;_R'+_\16K_ ,(G9_\ /O#_ -^4_P#B:/\
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M &5_PM+3O^>W_D.7_P"(H_X6EIW_ #V_\AR__$5J_P#")V?_ #[P_P#?E/\
MXFC_ (1.S_Y]X?\ ORG_ ,30!E?\+2T[_GM_Y#E_^(KJZR?^$3L_^?>'_ORG
M_P 36M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH=""K $$'((/(((Z@T^@ HHJIJFJ1Z5&US.VV-,9."<9( X )ZD=J +=%%%
M!1153^U(_.^Q;OWOE^9MP?N[MN<XQUXQG/M0!;HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJIJ&J1Z?L\UMOFR+&
MO!.6;.T< XSCJ>/>K= !1110 4444 %%%5-+U2/58UN8&W1OG!P1G!(/! /4
M'M0!;HIDTRPJ7<@*H)))P !R22>@%4I=?@B6.7S%*3R"-&3YU9F)  *Y'4'G
MH,<F@#0HHJO<ZC%:LJ2.JM(<(&8*6/ P 3R>1T]10!8HHJO<ZC%:LJ2.JM(<
M(&8*6/ P 3R>1T]10!8HHHH **** "BBB@ HHHH ***ANKM+13+*RH@QEG(5
M1DX&2>.M $U%,AF690Z$%6 ((.00>001U!I] !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%5[;48KIF2-U9HSAPK!BIY&" >#P>OH: +%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.-A(JHHD*G*$2AAM#*>3@<XZ9ZYR!YYI@DU%K7P_.,M:7$C2[E9P4B&8S\P
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M:7:PF)WP(SY2;6!;. <GH?ZKFOX^\1P:K8W<,#!_)$!9E(*?/*, ,.I&WG'
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ML*78C/+<G'!/RDUU'PM_Y!T'_;3_ -&O0!8\5>,E\.R01M&T@N"X_=\N"NW
M"_Q$E@.H_'I6?+\0GTYO*OK62)W \I8V6;S"6"E05P-PR#C/3T)4-8\1?\A'
M3_\ MZ_]%"CQ%_R$=/\ ^WK_ -%"@";2_%LDDZV-Y;M;R2J3'\XE5]N2PW*
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M_9JZN@#C(?'\M[+-:VUJTLMO*RM^\5$VJ2H;>PX8D<+CIDY.#6WX;\2+K:N
MI26%RDB,5)5AUY4G*YR W&<'BN7\&^*+>QFO;29UC?[9.X,A"J06"X#$XR".
MGH>,\XT/!-Q_:5S>:C&&\B=H1&S#&[RE*,0.N,]#^'4$  9X<\?R^( C06K%
M=X65C(H1,GJI(RY"\D  C@<Y!K0U/Q8\<S65I T\T04R?,L:*&&0-[=6/!
MY&>>"*K_  M_Y!T'_;3_ -&O5+PSK$6B3W=G=L(7>YDF0R$*C)(0 0Q.">.1
MU_$,  :NA^+C=S-8W41M[D#<J,X<.N,Y5P "1SD#T/7#;>7\!>(YX[**"TMV
MG,>_S"9%B52TC,J@N/F.#DXZ CN>-B34(]>U*W-LP=;))6D=>4_>J%50PR"W
M?TP#R2"!8^%O_(.@_P"VG_HUZ )H_$L>L6$]RT;?NXY5EB<E6#(A+QEL9Z=P
M,\] <@<YXEGATNPL+B-"D*W-O+L#%R RO(P!8\GD]<?A5C3?^//5?^OB]_\
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M;[V1N%;OB7_D K_U[VO\XZ -C7_%$?A(VUH(F>.0%%$9W./+"A5"G[Q.0/O
M_4\4R#QC/;RQPWMJT"SML1Q(LJ[SC:IV#C/8_I@$@\1?\A'3_P#MZ_\ 10H\
M??\ +G_V$+?_ -FH L:GXHE29K2S@-P\(4R_O%B"[QE!EOO$@$G' XYSD"+Q
M%K5P+![B.%EE*2!U,@1HMJN&D#?Q!2,KMP6!!&*I:_#8SW3R"Y^RWD2J&8.(
MPV0&3<' $@&!D \C"L?NX+37'UG2[J63YMD=PBR;2@E54.) IZ9[CH"#TZ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4-K:):*(HE5$&<*@"J,G)P
M!QUJ:B@"O<Z=%=,KR(K-&<H64,5/!R"1P>!T]!5?_A'K;?Y_DQ>9NW;O+3=N
MSG=NQG.><]<UH44 %4;W0[>_;?-%&[ 8!=%8XZXR0>.:O44 ,AA6%0B !5
M &  .  !T JE:^'K:T82Q0Q(XSADC16&1@X(&>E:%% %>]TZ*_79,BNH.0'4
M,,],X(//-.M;1+11%$JH@SA4 51DY. ..M344 0R6B2LLK*I>/.UB 67<,'!
MZC(ZXZTV]TZ*_79,BNH.0'4,,],X(//-6** *]EIT5@NR%%12<D(H49Z9P .
M>*=':)$S2JJAY,;F  9MHP,GJ<#IGI4U% $-U:)=J8I55T.,JX#*<'(R#QUJ
MO#H=O"H1(HPJN' "* '' < #AAZ]:O44 0W5HEVIBE570XRK@,IP<C(/'6IJ
M** *DVDPS[]\:-YNW?E%.[;]W=D<X[9Z=JEM;1+11%$JH@SA4 51DY. ..M3
M44 4;W0[>_;?-%&[ 8!=%8XZXR0>.:FETZ*6/[.R*8L ;"H*87&!MQC P,>E
M6** &30K,I1P"K @@C((/!!!Z@U4LM#M[!M\,4:,1@E$53CKC( XXJ]10!#=
M6B7:F*55=#C*N RG!R,@\=:;+IT4L?V=D4Q8 V%04PN,#;C&!@8]*L44 ,AA
M6%0B !5   &  .  !T K/\2Z.-8MI;0XS(A"Y) ##E"2.<!@#_0]*TZ* ,G2
MH'O[5([^-?,*@2(^QU)4_>.!MYP&P.F<=JMV.DPZ?GR(TCW8SY:*N<9QG &<
M9-6Z* *-[H=O?MOFBC=@, NBL<=<9(/'-6X85A4(@ 50  !@ #@  = *?10!
MGVOAZVM&$L4,2.,X9(T5AD8."!GI6A110!GW7AZVNV,LL,3N<99XT9C@8&21
MGI5V&%85"( %4   8  X  '0"GT4 9__  CUMO\ /\F+S-V[=Y:;MV<[MV,Y
MSSGKFKLT*S*4< JP(((R"#P00>H-/HH J6.DPZ?GR(TCW8SY:*N<9QG &<9-
M,O=#M[]M\T4;L!@%T5CCKC)!XYJ]10!#':)$S2JJAY,;F  9MHP,GJ<#IGI5
M6Z\/6UVQEEAB=SC+/&C,<# R2,]*T** &30K,I1P"K @@C((/!!!Z@T0PK"H
M1  J@  #  '   Z 4^B@"&UM$M%$42JB#.%0!5&3DX XZTV]TZ*_79,BNH.0
M'4,,],X(//-6** *]EIT5@NR%%12<D(H49Z9P .>*$TZ))#<!%$K#!<* Y''
M!;&2.!^0JQ10!F3>&+29B[P1%F)))B0DD\DDD<DU=M;1+11%$JH@SA4 51DY
M. ..M344 5[+3HK!=D**BDY(10HSTS@ <\51_P"$3L_^?>'_ +\I_P#$UK44
M 47T.W>,6YBC,2G(0HI0'GD+C /)_,UE>,=,FU<0V:*# \JF=BP'R(0VS'WL
ML>A7!!') )(Z.B@#$\1>'O[<:%)"OD12>8ZD99F481>>-IRV[()/ '4D;=%%
M %2^TF'4,>?&DFW./,16QG&<9!QG I\.G10L'1%#*@0$* 0@Y" @<*/3I5BB
M@"&2T25EE95+QYVL0"R[A@X/49'7'6B.T2)FE55#R8W,  S;1@9/4X'3/2IJ
M* ,^U\/6UHPEBAB1QG#)&BL,C!P0,]*T*** (8[1(F:554/)C<P #-M&!D]3
M@=,]*FHHH S[KP];7;&66&)W.,L\:,QP,#)(STJ[-"LRE' *L""",@@\$$'J
M#3Z* *[:=$ZHA12L14H"HPI7A2HQP1VQT[47NG17Z[)D5U!R ZAAGIG!!YYJ
MQ10!#:VB6BB*)51!G"H JC)R< <=:YWPYX?DCN[K4[A0LDK[(P#_ ,LD  ;A
MCR^%R" 05[ XKJ** "J-[H=O?MOFBC=@, NBL<=<9(/'-7J* *ZZ=$BN@10L
MI8N HPQ;ABPQR3WSU[T2Z=%+']G9%,6 -A4%,+C VXQ@8&/2K%% %2QTF'3\
M^1&D>[&?+15SC.,X SC)IE[H=O?MOFBC=@, NBL<=<9(/'-7J* &0PK"H1
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M=<9 ''%7J** *,NAV\LGVAHHS+D'>44OE<8.[&<C QZ58M;1+11%$JH@SA4
M51DY. ..M344 0R6B2LLK*I>/.UB 67<,'!ZC(ZXZT26B2LLK*I>/.UB 67<
M,'!ZC(ZXZU-10!#):)*RRLJEX\[6(!9=PP<'J,CKCK45]I,.H8\^-)-N<>8B
MMC.,XR#C.!5NB@"&UM$M%$42JB#.%0!5&3DX XZT6]HEMN\M57>Q9MH RQZL
M<=2>YZU-10!7O=.BOUV3(KJ#D!U##/3."#SS19:=%8+LA144G)"*%&>F< #G
MBK%% &3XJTE]7M9;6)]CR+@-SCJ"0<<X8#:>O!/!Z'"AU'47B%J;"-04"$F>
M/R1D;>8QD[!_=!)QP#79T4 8/AOPPNG6<>G3A90H.X%<H27+XPW4 G@D<XS@
M=*T['28=/SY$:1[L9\M%7.,XS@#.,FK=% $-O:);;O+55WL6;: ,L>K''4GN
M>M$=HD3-*JJ'DQN8 !FVC R>IP.F>E344 9]UX>MKMC++#$[G&6>-&8X&!DD
M9Z5:NK1+M3%*JNAQE7 93@Y&0>.M344 %9B>&+1 0((@&&"!$@R,@X/'(R ?
MJ :TZ* (;BT2YV^8JML8,NX X8=&&>A'8]:FHHH Y?P[X:PMREW$K+)>S2H'
M"N"K8"MCG!Z]<$5TL,*PJ$0 *H   P !P  .@%/HH AM;1+11%$JH@SA4 51
MDY. ..M17VDPZACSXTDVYQYB*V,XSC(.,X%6Z* (;6T2T411*J(,X5 %49.3
M@#CK1:VB6BB*)51!G"H JC)R< <=:FHH KKIT2*Z!%"REBX"C#%N&+#')/?/
M7O0VG1.J(44K$5* J,*5X4J,<$=L=.U6** *EOI,-L[3QQHLCYW,J*&.3DY8
M#)R>3[U+):)*RRLJEX\[6(!9=PP<'J,CKCK4U% %2^TF'4,>?&DFW./,16QG
M&<9!QG IXTZ(%"$7,0(0[1\@(P0O'RC''&..*L44 5+[28=0QY\:2;<X\Q%;
M&<9QD'&<"I;6T2T411*J(,X5 %49.3@#CK4U% $-O:);;O+55WL6;: ,L>K'
M'4GN>M$=HD3-*JJ'DQN8 !FVC R>IP.F>E344 ,FA692C@%6!!!&00>""#U!
MJE!X>MH/N0Q+AE;Y8T'S+G:W ZC)P>HR<5H44 <?J%G>:9>R7\$2W*3QJN#(
ML;Q[,?*&?(VL<L0!RW7&,L6>E76K7D.I7,26XMUD4*'$DCEUQRR@ *-QP.H.
M>,-D=A10!GGP];%C+Y,6]MVYO+3<=X(;)QD[@3GUR<U8ETZ*6/[.R*8L ;"H
M*87&!MQC P,>E6** (9+1)665E4O'G:Q ++N&#@]1D=<=:+BT2YV^8JML8,N
MX X8=&&>A'8]:FHH HWNAV]^V^:*-V P"Z*QQUQD@\<U;AA6%0B !5   &
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MEO;NYO)K7[*76YD0M,&\X*N%5<QC[F$&,]2">30!WNF:K%JB":!U=#W4YP<
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M"/(&?09./J?6J(NFM+C5YHSAXX864X!P5@8@X/'6@#8U#XAV&GR-!), Z'#
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M0S+,H=""K $$'((/(((Z@URNNZ?!X7TN>&)2$\IEXP69I!Y>YCQDY(SZ#@#
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M'(8V7#%@R]?E SC_ &L;<\9S45GX>N+J>&_O9$WP+(%C@0A 7^4L7<EFRO;
MP<8Z'=F?"C1XTMAJ!RT]P7+NQRW#L, GL<9/<GDDX& #HM;\56NB8%S(J$XP
MO+-@YYVJ"<<'G&,\9S5C1]:AUB/S[=PZ9(R,C!'4$$ @_4=,'H17GO@VUU"[
M#ZO"+8O=LQ+3&8N &*[!C("@KP,GC&3P -77[&7PW:WNH^;ON+CRP6"^6JC(
MC7: Q(*AC@[CT&>020#;NO'UC:2FU>91(K!2,-M!]"P&T8[Y/'.<8-4OAB&F
MM6O'(W7<\LI & I+;2!DGCY<_CCMDPZWI=MX:TN2U;: 8F7)'WY2O#8Y.XL
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ML\$H:0@D JZYQUQN49/? YQD] :PKW1EO+ZVTE_FMK2U$NULG>5/E+NP0#C
M/3^\",-QVLEHDK+*RJ7CSM8@%EW#!P>HR.N.M $U%%% !1110 4444 %%%%
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M_J<]+10!F1>'XHK7^S5R(O*,>1@-AE(+=,;CDDG')YQ5>X\'V]Q:+IC+F)%
M4\!@1_&"!C=G))QR2<@@D';HH YJT\"1Q.LLLUQ/Y;!E6>8LJLIRK@ +R/?(
MP3Q72T44 8FO^$HM99)F9XY8\[9(6V28((*[L'CG\.<8R<Q:;X(@M&,TA>>0
MJR[[E_-8*PP4 /&.O;/S,,X.*Z"B@#C_ /A6,&/)\VX\C=GR?._=8W;MNW&<
M9]\]\YYKK885A4(@ 50  !@ #@  = *?10!C^&?"L'AR,PP _,<LS8+MZ9(
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M_N\E4R5X3))(&"3U/ QI3>&HIKM-3;<98X]BC/R@'=SC&2<,1R<8/3/-:U%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M925C)4.%P5=<]P,_Q5MVOPXCU*(2:B7ENI%)9RY!0MSL4*2@"$G'!&<G&"
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M"J.,*N<#@?0#"C>HH XI?"U_;M<00311P7,TDAD"N9U,@&0!D+VQG.<?,,'
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MY14RYQRH&2V%/M@]*)+V\\.S0+<S"XAN91&3Y21LC,#LQM89#'[Q(. O')Y
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M(B-6.V+:P0+CDGE<G)YSSBG_ /"7G^R?[3RWF>3C.U<^9GRMV/NXW\_3MVH
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ME8Y#87C  P"2  =;4-K=I=J)8F5T.<,A#*<'!P1QUJ+5+>2YC:."3RI#C#[
M^,$$_*>#D9'XYKBOA;IUS]F@G^T?Z/\ O/W/E+_><?ZS.[[WS?ITH ] HK@O
M!%WJ6O11W<LRI$K]HE9Y5#?,&Y 0#!4%0#U)'0G2\1RW,<G-Y#:1?\L\JK._
M W;O,( VGIM['GM0!U=%<9HWBB:]T^YG9E,UJ)T\R/#([1IN$@&,8.1VP>N
M#@5]*@U76+=+K[2D+-&"J"%6##&5=F.=I;N%& ,?+G(H [NBN'N?'$LFFQ:B
M $:9PCN%+K$-S(TNWN!MX4GJ0"6Z'8\-0W(/FR7274#J<,L:H0P( P4)# _-
MNSR"!CO0!T%%<5KUQ=Q.^Z^M[8_-Y<95#N7)V,S2'()Z':"HQD9.14L7CAY=
M/BOU1?M%PPCC3)VM(7*#GL/E+8)''R[L\T =A4/VM-_D;E\S;NVY&[;G&[;U
MQGC/3-<U9:1J=NT4CW22C<OFQM"J+M(^;:ZC)(_AR%!ZGC@XMWI5W+JS)'=;
M'-J65O)1ML9FXBP3@X/.[J: .MN?%$5O=QZ60WFRH6! &S #'DYSGY#V/:MB
MN:M-0GBOUL))-Z"Q#M\JKND$FPOP,C([9P*KR7]WK\TT-I(L$%N^PR[!([2*
M/G7:V %7/)QU *D@G !UM%<EIFIW6DW2Z=>L)EN QAF550Y1<NC(.@'4$9ZC
MDY(3)\)SZIXCMUN&N%A7+!6$*.\G)!+ D*H4C P 3SD="0#T.BN*M/%]Q%87
M%Q(BO<6<CQ-MSM8H5!DP "  V6'' )^4'BUX8^TW)6Y%ZEU <AAY*QD97((*
M'(8';E6 X)SSB@#JZQ_"_BB+Q)$;B$,%5RI#@ Y ![%N/FK8KC]#U^>ZTEK]
MVS.(9VW;5'*%]IP!CC [?6@#L**X32H-5UBW2Z^TI"S1@J@A5@PQE79CG:6[
MA1@#'RYR*Z/PCKC:Y:QWCJ%9P<@=,JQ4D9['&<<XZ9/6@"UK&M0Z/'Y]PX1,
M@9.3DGH  "2?H.@)Z UA+\1(D95GAN(%=MHDGBV1@D$@%MQQG'X=3@ D-U&%
M=1U6&&0 K;6SS)Q_&[A.<YX& 5Q@AN<UU4T*S*4< JP(((R"#P00>H- #Z*Y
M*2_N]?FFAM)%@@MWV&78)':11\Z[6P JYY..H!4D$X-,U.ZTFZ73KUA,MP&,
M,RJJ'*+ET9!T Z@C/4<G)" '6T5P6E7>I:Y+<Q),L4,-S(JR>4KO\IP(]I(&
MT#!+$;LX )YP:)?ZGKP>#S(X?LSF-Y502-)(A(.%; "X().!STX)50#O:*X_
M3/$<\]A=22[1<6?GQETY5FB3(< C'7MC!QG !P*FE?VKJ-NE]YR*WEAEA$2L
M) !E2SEAM,G?:0 ,'@Y  .[HKG]*UN;6[%+RV"">11Q*&$>Y6VO]TDXX.WG/
M3/>N<B\1S:9/ #>Q7D<\JQ,BB-'7><*X\LMD#OGCMU.5 /0Z*XS7M3O7U!=/
MM&54>VW,74-LR[*9!T)8< +DJ2>1C)#[.\O-'O(;*YE6XCNEDVMY:Q,C1+N/
M"Y!!! Y.<^F/F .PHKE_"NL2M<76FW+AY('5D;Y0QC< @;55>5XW''5L=,9?
MX.UJ76VN+LG_ $8R!8 1@X0$,^2JDAC@\YP05XQR =+1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5Y_X=\$1:ZLE_J,+>;/,[*KO*'1,X5",
MKTP<<?=Q]!Z!10!PD/AE/#&H02VD;"">-XY,+)($((96+9;&X[1SP "?4C/U
MV\_M92#ITRWV["R*N%5P=J/]H7:2%&",_+P.< -7I=% %?3DD2)%F(:4(H<C
MH6 &XC@<$^P^E<5KVDG3;Q[Z2V%W!<A 0L0DEC:-,#"G.5;')X]\8 ;O:* .
M2T*\1&DN(;!H8TB8EC$D<S,,'RUC'S$$<@YP2,=17/S>&+HJ?$2!A?;S((2J
MD"/[@C(&"6\OOPW\.T/S7IM% 'G_ (KU266YTZYM8F:0_:"(I1Y38VJ'4[L;
M2!G!Y&<$;AC-BXN)_%D\"+#)!!;2I,[W"%'9D)VHJYY!YR<\>V 'Z+4="^V7
M-O>[L?9O-^7;G=YJA>N1C&,]#GVK6H YK[(_]K>?M;R_L.W=@[=WG9V[NF<<
MXZXKD=*M3I*-:W&GM<W?FG,I021R;V!#&9P=HP?3&1EL$MCU.B@#A_#VG2Q:
M*UNR,)?(N1L*D/EC)@;<9R<C'K1J&G2O::8@1BT4]F7 4Y4*A#%AC@#OGIWK
MN** .:^(]H]W8311*SN?+PJ LQQ(I. .>E9_C'1VCN8]4\E;F(1B*2+8'<#>
M6$B Y!()P1CI[$LO:T4 <?H$\5Q.A@T]H0N[=++#' RY4XVCDMGD'&,9&>#5
M+P]?7'A:+^S'MI961W$+Q(/+968E2[[R$)8G.?NK@D>O>T4 <E\.+>>**X:Z
M0QRR7<KD$$#Y@N2N<Y7.<$$@^IJQ\1[1[NPFBB5G<^7A4!9CB12< <]*Z6B@
M#FO&]H]S]D\M6;9?0,VT$X4;LL<= .YZ4?$>T>[L)HHE9W/EX5 68XD4G '/
M2NEHH *Y>X\:26DDD,EI<'8Y"M#'YJ,O\+;LK@GN.<="<Y ZBB@#S>]\&3:H
MLVH)&J/+/%,EO*HY$2L,/@@!I-Q9E['AFR25EAO(;E0L>DMYQ ^62WCCCSU8
M>:PX YP2HR<# S7H=% ')>)+>?3+M-7A0S)Y0AEC0$R!2^[>H_B.>H]/8EEO
MZ+K\VJR\6\D4 1LM. CE\K@!,D[=I)W=">.,<[U% '">'-1ET:XN+26WF*SW
MCNDB)NCQ*0,LW    )()ZD$ CEMOX8EU2UO[,@QM->RLA=2 0&1E/^ZVW&1G
MU&<8KO:* ./M?&\^T12V5Q]HY4A$_<E@<#$A. I/\7( [L!DYFK>')X=*N$9
M2US<R^<Z1@OAGE0E5 R<!0,\GG/)%>AT4 9GB>%IK2X1 2S02@ #))*$  #J
M31X8A:&TMT<$,L$0((P00@!!!Z$5IT4 <UJ'@5+N>2\6>XB>;;N$,H13L4*/
MX<]/4GJ:R?"OA5[&_N96DN"D?E;6D<E9=T9!W' #[">,?=KNZ* ,?1-;EU"6
M>*2!HEA?:CMG$@RPW#*KQ\H/!/4<^O)>#/$CZ):1V<MI=EX]^2D!*_,[,,9(
M/0^E>BT4 <?X>:2T%WK5U&T7G*C^5D,P6&+KGCELGY2%((YK=\-ZNVL6\=VR
M&,R G:3G R0#G R" "..AJQJFFKJ<;6\A8(^-VUBI(!!*Y'.& PWJ"1Q5B&%
M85"( %4   8  X  '0"@#E?$EO/IEVFKPH9D\H0RQH"9 I?=O4?Q'/4>GL2R
MRIJ$WB59;80R00202(7G4*^]L 8CW9VA23GH3QD8YZBB@#S33!'I2"TO--:2
M6'Y?,@MEE1P ,/N.#DCK[]<'*C6\4V,ESI+PI;^5(=N((L/C$P/'EC!R/F.!
MW.>]=K10 5PGAS49=&N+BTEMYBL]X[I(B;H\2D#+-P   "2">I! (Y[NB@#R
MS2K4Z2C6MQI[7-WYIS*4$D<F]@0QF<':,'TQD9;!+8L?V3-_8'V7RW\W^YL;
M?_Q\;ONXSTYZ=.:]+HH YKQO:/<_9/+5FV7T#-M!.%&[+''0#N>E'Q'M'N["
M:*)6=SY>%0%F.)%)P!STKI:* "N:T&T>*_OI65@DGV;:Q!"MMC(.#T.#UQTK
MI:* .:^R/_:WG[6\O[#MW8.W=YV=N[IG'..N*P;%)]+T(@$P3(DAS)E&'[UB
M1R,AF4X7ODC!'!KT.J.M:/'K$+VDV=D@P<'!&"""#Z@@'T]01Q0!YP-"P!=?
MV1]U58#[5SA0,9BQDG Y4J2QSN!)-=%)>#7;G3M0@5C#BY);:?ER@7#'H#N!
M'7!(X)J:'PK?A1$]^QCP%.($#E>AQ(26#8_BY.>>36_HNCQZ/"EI#G9&,#)R
M3DDDD^I))[#T '% &1XWM'N?LGEJS;+Z!FV@G"C=ECCH!W/2M*;PQ:3,7>"(
MLQ)),2$DGDDDCDFM.B@#FOLC_P!K>?M;R_L.W=@[=WG9V[NF<<XZXKE],TU?
M#8-C=V)N=AS'-#;K+O5B3\V[HPZ8R>..@#-Z;10!B>'85GA93:K;QNS8C(3Y
ME91\S(HP"1P5.2,8-<5X/\.7#7,=M/'BWTUI_+=HROF%W.#\S8Z_.I4'&!DY
M(->H44 <%KVDG3;Q[Z2V%W!<A 0L0DEC:-,#"G.5;')X]\8 ;5\+R)-*7AL3
M;Q["#(\:1.6R#LV#YBI'.[.,C&,BNHHH YKP1:/;?:_,5EWWT[+N!&5.W##/
M4'L>E'Q'M'N[":*)6=SY>%0%F.)%)P!STKI:* .:UZT>6_L955BD?VG<P!*K
MNC &3T&3TSUH\;VCW/V3RU9ME] S;03A1NRQQT [GI72T4 <9=M-X>O9[T12
M307219\E [J\8*@;=P.W:"2V,9('UBT&2YO]3:\F@:*(VFV/</X?,5AN() <
M\DKP5'!'&3W%% '->"+1[;[7YBLN^^G9=P(RIVX89Z@]CTKD4\+SO>'2Q$/L
M*W?VDN8B$^X#Y0R=A7G9@ GJ<8! ]3HH YK7K1Y;^QE56*1_:=S $JNZ, 9/
M09/3/6J-VTWAZ]GO1%)-!=)%GR4#NKQ@J!MW [=H)+8QD@?7LZ* .'T&2YO]
M3:\F@:*(VFV/</X?,5AN() <\DKP5'!'&2S3M1E\+RW,,MO-*LUP\R/;IYBD
M2?PGI@C'^1@MW=% '!>'K.\O)-1>:,P33I&(SD[01&ZJ1(N<E?EW%>A[#I6"
M+<0VGV!=,<W(C=&D:(%<A6S(LI!+'/*@8Z[4)PN?6Z* .'U#3I7M-,0(Q:*>
MS+@*<J%0ABPQP!WST[UI^*=4$#K!-9O<P%=P:.,38<'&"A''!SNSSG !YQTM
M% ')?#^SEMUF/EM#:LX\B&0DNH&0Y(;) <\[23@YQP=S,\?Z<\[6UQY33P02
M,984R6;< %8)T;:<\=\X/REB.PHH \WTZ,W>H6T\-DUM#&9P7,0C+9B_B51\
MH!.%))#9..00.CT&T>*_OI65@DGV;:Q!"MMC(.#T.#UQTKI:* .*\8Z.T=S'
MJGDK<Q",121; [@;RPD0'()!.",=/8EEET">*XG0P:>T(7=NEEAC@9<J<;1R
M6SR#C&,C/!KL** *^HW+6L3RHI=D1F"#JQ4$A1@'D].A^E9/@;2VTNR@@?.X
M)N((VD%R7*D'NN['X=!TK>HH \OT.VCT./[%>:>\TL3,/-BMUF5P3N#;R >A
MQCL ,X.0.H\26%QXATZ2$QB.>0 ^67#?<D# ;QQE@O'09."1R:ZBB@#SKQ7X
MPGO;&;9;RP_NU$C3C8!YC*A5 02^06!.%VCGJ0*L:]H3P6%E%Y)?[-+;M-%&
MJN2%4B3Y1PQ+'G&<Y)/&372^)_#HU^-+=G*QB5&<#/SJN<H<,N >#GG! .,U
ML4 >>:K:W/BRXMG>%HK..4';*N7<@,Q+QY(5?DV#=_?R-P; V[.UEGU26Y*%
M8HK9(@QS\Y=A)E>,87E3R<''KQU%% '->%[1VN;V]D5D\V9456!&5@7:) 3C
M(?.1Q@8ZFL35K(:;?3W-Q:-<Q7*QE&CB$S(8U"LI5AQGKG/.!C/.WT"B@#E[
M3?J]K/:QVYMHGB=8O,"IDNK!LQJ"4 ;Z[@<BL>UU^]AM!8P6LJ7,$)4O(N8L
M1+C*$9\QFP-J@$9.<E02?0** ,3P5IG]F64$&&!$8+!^&#/\[ C Q@L1CJ._
M-5_B'I\FH6$T,*EG(0A1U.UU8X'<X!XZGH.:Z.B@#A]2N)_%4"O##)#/:2Q3
M!+A"J.RAOD5LC(]R!VSMSD6/^$WGNDV065P+AEX$J;(@V,G,A*\#G' +<#@G
MCL** ,GPKHG]B6L5GG)C7YCG(W,2S8X'&2<<9QC/-<QKU_-8:LLL,1E LOWB
MJ1OV>:Q)4$C+ XPO);H.N1WM9/\ 87^F?VEN_P"7?RMFW_;W[MV?PQC\: ,*
MP\_Q%>1WS1-!!:!P@F4K*[2IAOESPHXP>>G?)"7M!M'BO[Z5E8))]FVL00K;
M8R#@]#@]<=*Z6B@#BO&.CM'<QZIY*W,0C$4D6P.X&\L)$!R"03@C'3V)99=
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex19-1_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex19-1_005.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "LGQ/XA3P_ UW(,[<!5R 68] ,_F>I !.#BM:N"^-$+/
M9*0"0LZ$D#.!M<9/H,D#ZD"@"QIWA>[UA1=WMU-&\B@B*W/DJ@))VD$$D@$#
MD9&,$MP:W]"T^>PW132^=&-OELRXD Y!5B.&P OS=22V>U:<,RS*'0@JP!!!
MR"#R"".H-<;\7=3>QL2L9QYTBQL>0=I#,0,$==N#U!!(QS0!TO\ PD-MO\CS
MHO,W;=OF)NW9QMVYSG/&.N:M75VEHIEE9408RSD*HR<#)/'6L#_A75CY'V/R
MEQMQYF!YN>N[?C.<\^G;&WBN$M-3>^T"99#GR9%C4\D[0\3 ')/3=@=   ,<
M4 >H7'B&VMMOF31+O4,NZ1!E3T89/(/8]*EOM6AT_'GR)'NSCS'5<XQG&2,X
MR*X6W\&VD.D-+Y:M(UJ9=[#+[C'O&&X( (& .,=<Y.<_0/#$%SI$M[*N^9X9
M3O<Y9?)W+&%/50 @X'7H<K@  ]2FF6%2[D!5!)).  .223T JE)XAMHE65IH
M@DF=K&1 K;3@X.<'!ZXZ5R7AZ9I="8L23]FN1DG/"^8 /H  !Z#BH?ASX2MK
MZP26=!(TH<9D^;:H=QM3^X.K?+@[B3GI@ ] AF690Z$%6 ((.00>001U!JE_
MPD-MO\CSHO,W;=OF)NW9QMVYSG/&.N:X3P1=QV,>H:?<M_HEK(RY<G.URZ%<
MC'7;P% )9CCDBL?Q9>6-U9L+2TD4(5"7 AVQG:X4DR9W$$9'S9)8C(W= #UV
MZNTM%,LK*B#&6<A5&3@9)XZU5N/$-M;;?,FB7>H9=TB#*GHPR>0>QZ5R7BN9
MIM##N26:"V)).226C)))ZDU7M_!MI#I#2^6K2-:F7>PR^XQ[QAN" "!@#C'7
M.3D [^XNTMMOF,J[V"KN(&6/11GJ3V'6GS3+"I=R J@DDG  ')))Z 5YO'IC
M^(]"1<;Y8U)3KG]R[*  HY/E@J!@Y)&>>:L>)O%']KZ?;PQL!-J)2/(W(H.X
M"7L3M#?(1W!R-PZ@'H$,RS*'0@JP!!!R"#R"".H-17NHQ6"[YG5%)P"[!1GK
MC)(YXIUI:K:(L,8PD:A5&2<!1@#)YZ5R7BC4M/AN0)HC<7>P*(TC\U@O+_=)
MV CK_?P<_=- '5V6HQ7Z[X75U!P2C!AGKC()YYJ$ZY;@.3+'B(@.=Z_(2< -
MS\ISQSCGBO/? 4JC5;E(8WAB:'=Y3@H0<Q\E,D#EF*^@;C .*9X+\.0:KJ%]
M-.H?R9W"JP!3YWDR2IZD;>,\#.<9P0 >EV6HQ7Z[X75U!P2C!AGKC()YYJ&]
MURWL&V32QHQ&0'=5..F<$CCBN*\*PKINL7=G" D)B5]@'&[$9X]!^\;@<<].
M!BO\-M*B\1"?5;M%DEDF9<.-Z* %;"JV?7 SG"@ 8YR 6]&_Y#UU_P!>Z_R@
MKT"O,O!NCQZ/K-S:PY$:P9 )SC<8FQGT&<#/..I)YKTV@#/_ .$AMMGG^=%Y
M>[;N\Q-N[&=N[.,XYQUQ5JUNTNU$L3*Z'.&0AE.#@X(XZUYA\(?"]O?0R7<R
M+(_F% ) &4 *K9"D8R2>OH,#'.;'@J];1UU2.+'EVCR-&IY (\P<G[Q&(U'7
MMZDT =_>ZY;V#;)I8T8C(#NJG'3."1QQ5C[6FSS]R^7MW;LC;MQG=NZ8QSGI
MBN%^&WA>WO+07LZ+++<,[,TP$AR'9>-P.,XR3U)/)Z 1>$+5=,U&\T9!FV,8
M?8Y+ $A,CGC!#X.020%R3CD T/#?Q$2^FN8KB2%(X9,1-O"[UW.,Y9B&X Y&
M!S[BNUKS+P#H=O=7>H))%&RQSX0,BL%&^48 (X' Z>@KTV@#BM5UF?7[I]*L
M7\I(5/G3@;SDC C7' .3R<JV0V,;?FM?\(?/8_O;6[F,@_AN6\Z-AUVD8!7)
M ^8<@9QUK*^'O[F_U&)_E=I@P4\,5WR'< ><89>>G(]17H% %>]U&*P7?,ZH
MI. 78*,]<9)'/%%EJ,5^N^%U=0<$HP89ZXR">>:\_P##NGQ^)=1O+B[4/]F<
M1QHW,8&77.UL\_+GTW,QQG&#Q%I\?AK4;.XM%"?:7,<B+Q&1E%SM7'/S9]-R
MJ<9SD ] LM1BOUWPNKJ#@E&##/7&03SS3OM:;_(W+YFW=MR-VW.-VWKC/&>F
M:XK16.A:K-8ELQWJF= <DAR26'  &</VY"H-V>*J^'[AI3J'B(!3E7$!(<!E
MA7KM.,AMJ9/7(8?+TH [>]URWL&V32QHQ&0'=5..F<$CCBK'VM-GG[E\O;NW
M9&W;C.[=TQCG/3%>4>#;.26 7/\ 9ZW+2EBTTL\9+$.W.V0-M/8XQNQDYK5T
M72KK3+*_BN$,4)BE:&,R+)M#+(64,"3@?+UZG)QDF@#N%\0VSE5$T1,GW )$
MRV25XYYY!''<8ZU8O=1BL%WS.J*3@%V"C/7&21SQ7#_"OPO;BTCO616ED9FW
M. Q4H[*NW(^7&,Y'.>_  Q())-8U"[F:T6[,$GEJ&E"(BJ70#:^0V[&3Q@-D
M@ F@#U.RU&*_7?"ZNH."48,,]<9!//-0WNN6]@VR:6-&(R [JIQTS@D<<5Q7
MA_2+RWU!;I+86MLZ%9426-T)56VMM7&#G:/E'J<_,V:_PVTJ+Q$)]5NT6262
M9EPXWHH 5L*K9]<#.<* !CG(!;T;_D/77_7NO\H*] KS+P;H\>CZS<VL.1&L
M&0"<XW&)L9]!G SSCJ2>:]-H \R\.V$OB&[ODDN;A%@G(013%1AGD&,$'@;1
MC&*TO!&JW%I=S:)<OYWDKO64D[L':<'.2>'!Y/RG(RPQC%\*_;/MFH?8O)_X
M^#O\_?\ WY=N-GXYS[5T6F^'Y/#4-UJ<SB:[>)G+,ORC8A;8.AVY'.-H("@*
MN* .EO=<M[!MDTL:,1D!W53CIG!(XXJQ]K39Y^Y?+V[MV1MVXSNW=,8YSTQ7
ME'@VSDE@%S_9ZW+2EBTTL\9+$.W.V0-M/8XQNQDYK5T72KK3+*_BN$,4)BE:
M&,R+)M#+(64,"3@?+UZG)QDF@#N%\0VSE5$T1,GW )$RV25XYYY!''<8ZTZ]
MURWL&V32QHQ&0'=5..F<$CCBN-^%?A>W%I'>LBM+(S-N<!BI1V5=N1\N,9R.
M<]^ !E76GMH5[<7E]:M<PS,S+( )0B#+<HW P-JY;;M"G:2,Y /4H9EF4.A!
M5@""#D$'D$$=0:I6OB&VNV$44T3N<X5)$9C@9. #GI7GGBO4+?48[+3[)@+2
MYN6#^7E2/WBY7!Z#,A8*5P/E(&,5T'B[P/9BREV1*AAB9E9  ^8U)&6QE@<8
M.<YZ]<$ '6W5VEHIEE9408RSD*HR<#)/'6JMQXAMK;;YDT2[U#+ND094]&&3
MR#V/2N$U34WU/0//E.7*H">23LG" DDDDD+DGN<U-;^#;2'2&E\M6D:U,N]A
ME]QCWC#<$ $# '&.N<G(!Z%-,L*EW("J"22<  <DDGH!52RURWOVV0RQNP&2
M$=6..F< GCFO/3IMUXCT2".$[G#<KN";DC9T5>P.,*>?[N>6QG0\+ZM8"2*"
M2V^R72X\L2(5+9#(,28!;(X^?&6/&YAF@#T"N?\ #=KY,URWVKS]TF?+W9\G
MYG^3&]L=<=%^[T].@KS_ .''_'YJ7_7Q_P"SS4 =A_PD-ML\_P Z+R]VW=YB
M;=V,[=V<9QSCKBK5K=I=J)8F5T.<,A#*<'!P1QUKS#X0^%[>^ADNYD61_,*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYV>9ND"8W;>JL<YPW]WTH Z"BN,O?'-SI*^?>631P@X9TF24C/3Y0!P3@9)
MY]< V/'OBY]!MDO+;8_F2* 6RRE61FR-K#T&#G&* .KHHHH ***HZY>M86\U
MPF"T43L >F54D9QCCB@"]16)X,UM];M([R4*'DWY" A?E=E&,DGH/6MN@ HH
MHH ***J:IJD>E1M<SMMC3&3@G&2 . ">I':@"W14-I=+=HLT9RDBAE.",AAD
M'!YZ5-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[Y78UWQ%<WEX-'L"J,J!I96&XH,@\*>"<$?WL[@/EP2*]IJVD7[K#;0),[,
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M,D8D>_(4R,WF$@EQO=CG9M). >3\RY^;)'<>)?\ D K_ ->]K_..@#JO"?\
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M/\4^$Y;31HK?J]NPD<8Y ;>6 V[@=A?DYQ@%O:@#L/'NJ2:592W,#;9$V8.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R_BC4-3MY0MA#
M')%L!)<@'=DY',B<8QV_&NHHH \__MG7O^?6'_OH?_'ZQ];L-9UB6"XDMHPU
MJ^Y KH 3E3SF4\?*.F.]>L44 >?_ -LZ]_SZP_\ ?0_^/T?VSKW_ #ZP_P#?
M0_\ C]>@44 >?_VSKW_/K#_WT/\ X_1_;.O?\^L/_?0_^/UZ!10!Y_\ VSKW
M_/K#_P!]#_X_1_;.O?\ /K#_ -]#_P"/UZ!10!Y__;.O?\^L/_?0_P#C]']L
MZ]_SZP_]]#_X_7H%% 'G_P#;.O?\^L/_ 'T/_C]']LZ]_P ^L/\ WT/_ (_7
MH%% 'G_]LZ]_SZP_]]#_ ./T?VSKW_/K#_WT/_C]>@44 >?_ -LZ]_SZP_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYBJVR&5EW '#!&PPST(['K6+\+=)A^Q077EIYO[SY]B[_P#6.OWL9Z<=>G%
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M>Z+LS2/##YN&<D'#L01G!(*_+W4YS5CX+S,]DP))"SN "<X&U#@>@R2?J2:
M.M_X2&VV>?YT7E[MN[S$V[L9V[LXSCG'7%6K6[2[42Q,KH<X9"&4X.#@CCK7
MF'PA\+V]]#)=S(LC^84 D 90 JMD*1C))Z^@P,<YJ:;J;Z';ZK#;G:D$P$8Y
MROF2-$2&SNR% P2>" ?7(!ZE%KEO+)]G66,RY(V!U+Y7.1MSG(P<^E<;\%/^
M/.3_ *^&_P#0(ZL>'/A_9W-A&CQ@M/$KM(<>8&=0WRMC@#L.F.H.3FO\%/\
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MY&<MN\O9YF,Y_P" ^FSY<=Z]&_X5U8^1]C\I<;<>9@>;GKNWXSG//IVQMXH
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M''..A!YK:^(FG16&F3I"BHI,9(10HSYB#. !SQ0!T=G<)86\;RRJR)&@,KL
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M(RH6UEW.&)!(W(>, \_*>N.U=110!4U73$U2)[649212#TR,]",@C(/(.."
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M5G-I]RRGSVDR8B3A714ZLHYX/8CI699^#]2L[9]*26#R&$@5BK^9M;)VXQM
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MGY:ZBB@#E_AYX7E\-V[6\Q4LTI8%"2,%5'<+S\M5-(\"-&U^+DJT5\Y*A>6
MW.03N7 8;@1UP1GM79T4 </H_AK4K*/^SVGC^S D"1=_V@)V5<C:IQP,EBF?
ME)VJ*T/AYX7E\-V[6\Q4LTI8%"2,%5'<+S\M=110!D^)_#R>((&M)#C=@JV
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MH,+]W*CD*20/NYV@8MZ[X)DO5@FAF*7=J@ E*YWX7'S=3@GU+ !F!5LUUM%
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MS!PA\F,@MPH.]\!@,*Q92,C.<\#)SZ/=V_VE&BRR[U(W(<,,C&0>Q'8^M5=
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M$,W0\\X&<X  ).*RO"GAN]T=182M!)9@R#D-YA5L\8QMP2<D'=P2,D8KLZ*
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M8<@XQWKI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFV@U%3YB/@1[?XF.<#./EQ@[L\C!&-W!9HOB*ZO'1;BT:&.0</YBO@[2P#*
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MZ>XK;^'VAR:1:[;C=Y\LCR2;F#'<3C.1G.0H)Y)R3SV&_=6B7:F*55=#C*N
MRG!R,@\=: ,7QGJL4%A-*SKMEA=4(.0QD0A0,9SG.>.W/0$UYUXBM6M=#M$<
M8)F#=0>'$KJ>/4$'^?->@6OPWT^U82+ I(S]]G=>1CE78@_B/?K6KK>@0:V@
MAN5WH&# ;F7D C.5(/0F@#0KA/C):M-8AU&1',C-R. 0R9]^6 X]?2N[IDT*
MS*4< JP(((R"#P00>H- %+^WX/(^W^8OD;=V_MCITZYSQMQG/&,\5RGP;M6A
ML2[# DF=EY'( 5,^W*D<^GI6M_PK?3]_G>0N[=NQN?;G.?N;MN/]G&,<8Q71
M0PK"H1  J@  #  '   Z 4 >?_!.93:2("-PG)(SR 40 X]#@X^A]*?\./\
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MYF9C@G 5XB3@<]*[74M @U)XIIEW/ VZ,[F&#D'. 0#RHZYKC/B;"LUWIR.
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MY (SE2#T)H X_P ,?\4I>RZ=/RETV^*>3[\C<9C9N02"3C.#NR<?O%%&L_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS0(]VJI.=VY4Y4?,<8^9NV#U-:% !1110 4444 %%%% !1110 4444 %%%%
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M+ C>N\YSUVG Z"F>(=<"2-:W-E+/$NUD:.(3J20<D@X"D'(ZDD<\ C/.^&O
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M\JM\S8VC'&2W;&"OS9!!'MI_%U[!<O"\-K:,6!E&R5F^5L;3GC(7MC ;YLD
M %+Q1K+2ZG]BN;B2UMD1=AB+)O+A>KC(QN)^8_* I'!)-=+<WA\+V,MR)6N%
M4;HFD(<_/M"@L"-Z[SG/7:<#H*9XAUP)(UK<V4L\2[61HXA.I)!R2#@*0<CJ
M21SP",\[X:\#SW%I>6\JF&.Z*M#&SD[""77/!P/NJV1O(4Y (% &9;:Y;WL?
MFW.IW"W#J#B)9$C0[1\NQ%P<'J5*[O8\UII\2YCI9O" +CS?)#  @MM#;RO
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MV[OK8W$B01SG.UV\P8>38J$Y"+QEL#)"A1P379:)X@DU5S_H\L404_//A&+
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M6;M/*>=55(\Y(7"\L.H.%4=CG=E1Q3/A%ITMA:.DR,C&=B ZE3C8@S@@<<4
M5_!NNW$<5]:,6GEL6D\MGRS.?GVJ0/F/S)_>)^;:.@K*\%/_ ,) N]]0F6\+
M,PC#X0')*_NV&''&XJN %.T@=3L>#+.>PN-2F,39>4M&&!028:4@!F&,'(YY
M R#63XJ8^*(O+BT^5;N0J3))&(PNT<_O3C<,#: V >#U % &WX^U&6UN]/2-
MV59)\.%8J&&^(8(!Y')Z^IH^+NHRV%HCPNR,9U!*,5.-CG&01QQ5?QEH5Q'%
M8W:AIY;%H_,5,LSGY-S GYC\R?W2?FW'H:ROB)?7?B2%$@M)EB63),D>)"P4
M@ 1@D[<$_-C!/'&.0#5^(_\ Q^:;_P!?'_L\-9_Q*TC=?6;>9+_I$P& _$>#
M$N8^/E)SDGGG!K8\?:=+=7>GO&C,L<^7*J6"C?$<D@<#@]?0T?$K2YY6M;^"
M,R_9)=S(N=YRR$8 !X^7!QDC.<$9P ;L/A^2S@>W@N)?,9LB6?$S+]W( ( Q
M@'CL237G_B?41X=$5W8W[SL),-').)E(()R54CCC!X[@@J0,[WC7S_%5@QMX
MI8RDH+1RJ8W=57)PH)W#)! [E3CD 'E_%5G_ &E;1Q6FG2Q,C)O8PX;[A 4$
M#>XSG+''(&>6% &U\:]/_<QW6]_]8J;-W[O[LC;MN/O=LYZ<5T=UHK:%:73I
M//(Q@<@S2[RI5&(*D 8//Z#TJO\ %+0I=8M-D W-'('*C[Q 5@0!W/S9QWQQ
MDX!EDUM]>L[E/L\T4@MW&V2,C<SHW"=VP1CH#R..: .7M_%MS#I]E#$Y^U7D
MKJ))/GP!*5Y+;N?F4=&^7/?%:VL>%;G1K=KRWO)VF@0LWG/OC8*IWX0@X/=<
M[L'C_:&3;^$KF;3[*:)#]JLY781R?)D&4MR&V\_*IZK\N>^*UM8\57.LV[6=
MO9SK-.A5O.39&H93OPY(R>RYVY//^R0!VO>)GU#1CJ$9:.1ECR4)4AA*J/@@
MD@$@XYSCK6?_ &%=W&G?VA+>3"5;?S%$;[4VJN]0P&"S$=6)SD_Q;>=#7O#+
MZ?HQT^,-)(JQY" L2QE5WP  2 2<<9QUK6^R/_9/D;6\S[#MVX.[=Y.-NWKG
M/&.N: +7@O66UFSANI/OLI#=.2C%"W  &2,XQQG%;=<U\.+1[2PABE5D<>9E
M7!5AF1B,@\]*Z6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "L3QGHCZW:26<14/)LP7)"_*ZL<X!/0>E;=% %'0[)K"WAMWP6BB12
M1TRJ@'&<<<5>HHH **** "L3QGHCZW:26<14/)LP7)"_*ZL<X!/0>E;=% %'
M0[)K"WAMWP6BB121TRJ@'&<<<5>HHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "H;O?L;RMOF;3MWYV[L?+G'.,]<<XJ:B@#G_  -X:/AVU6V?;YA9
MF<H25))P"-P'\(4=!T_$]!110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% %'7+)K^WFMTP&EB=03TR
MRD#.,\<U2\&:(^B6D=G*5+Q[\E"2OS.S#&0#T/I6W10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!C^&O#JZ*C9(>:5V>63;M+LS$],G &< #CJ0!DUL444 %%%% !1110 44
M44 %%%% !7.:YX?G>X74K-U698O+*2J3&REMW)7YE())R,Y( X&<]'10!Q5Y
MX6O/$31QZDT(MXVWE+??N=@, $OR!@GH<\XZX*]K110 4444 %%%% !1110
M5R_A+PO+H]Q=W$A4K=2[D"DD@;G/.0.?F'3/>NHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *S]?TQM4@DM4?RS*NW=M#8!^\,$CJ,CKQG(YK0HH KZ?I\
M>G1K;PJ%C08 '^>2>I)Y)Y/-6*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;DKYZ %@H)R#@$Y8G[YR 5/%>GZ)-#+!&;8@P[%"$$GY5& .><C&#GD'@\T
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M)+?RV;R0BV2,%)-X&YL)D;RVT_>;@#/'L:M> O"]OI]M!.B*97C5S(P!?,B
MD!L9 P< #MUR22>=TG0[=]:N;<Q1F)8%(0HI0'$/(7& >3^9H ]"N-6AMD6>
M21%C?&UF=0IR,C#$X.1R/:GV6HQ7Z[X75U!P2C!AGKC()YYKDO$5YIMG.L4D
M'GW*QK&L44?FE4&6 V'"# '^\ 1QM-8G@*51JMRD,;PQ-#N\IP4(.8^2F2!R
MS%?0-Q@'% '8>&[7R9KEOM7G[I,^7NSY/S/\F-[8ZXZ+]WIZ:'_"0VVSS_.B
M\O=MW>8FW=C.W=G&<<XZXKC_ (<?\?FI?]?'_L\U97PA\+V]]#)=S(LC^84
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MXYYY!''<8ZT77B&VM&,4LT2.,95Y$5AD9&03GI7'_"OPO;BTCO616ED9FW.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M X_6?"5QJZPW9D2&_@WX>($QD$G:IW?-CIG.0,N-I!JOJ?A?4/$8%O>RQ1P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBN?\>7$D%G-Y4?F;HY%;YPNU2C;GYZX_
MNCDT =!17G_PMU&Y^S00?9_]'_>?OO-7^\Y_U>-WWOE_7I1HGQ.GUS*VMFSN
MF2P\Y54#C;\S*!DG/'' R,\X /0**Q-;UR>T<06UL\SE0Q.Y8XP,D8\QN-V<
M?+CH<YXJKX8\9_VO++931-#<0\E"=P*\#(8 #J1[$$%203@ Z6BN,U'XBFTO
M'TM8&DD &S8P^9F16 ((&U>3ELG &<8Z6]#\9O=W+:==0&WF";E!D5PP[X(
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M( QQ@YP#D8H Z6BN<T/Q<;N9K&ZB-O<@;E1G#AUQG*N  2.<@>AZX;;FV?Q
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M-$/^6CNL*L<L/EW@[AQ]1T('?8\,^)H]>C+J"DB';)&WWT;N"...#@XY]B"
M ;%%9/BG7?[!MGO=N_R]OR[MN=S!>N#ZYZ5SLOQ$F>#[=!:-) J N_F!<-@;
MP%*EF5"<%P ,ANPS0!W%%8G_  E\'V/^ULMY.W/W?FSNV[<>N[Y>N,\YQS6+
M_P )[<^7]N^Q/]E^]O\ -7?Y>?O^5C/3GKC'.[;\U ':T5R7B+Q =2TU[NT0
MR)-%(&RP0HNQP[$'J5(Q@=>Q(YK,^%NHW/V:"#[/_H_[S]]YJ_WG/^KQN^]\
MOZ]* /0**X^'QS/J9+6-H\T0_P"6CNL*L<L/EW@[AQ]1T('?8\,^)H]>C+J"
MDB';)&WWT;N"...#@XY]B"  ;%%<%H?Q-EUU66VM&>5#\P\U50*>A\Q@/F)Z
M+CD G/!%;7ASQ<=<@EE2(K/"65H6<!MP!*C) P&Z9(&"&';- '1UGPZ_!-.]
M@K9GC7<R[6X!V\YQ@_>'0]Z\T\%:K=V]S?/#:^8[S9D7SD38=\GRY(PW)(R/
M3WKL]/UN*;4Y[(0*LL<08S#&]@1'\I^4''S#^(_=''H =117+ZCXINHV?[/9
M221Q%@6=UC)*YR40AF=2,%2/O= ,BM#PKXFC\1P"ZC!'.UE/\+  D9[CD$'N
M#S@Y  *^D>-8=5MI=0C5Q'!OW!@H8[$#G #$=#QR.:T- UM-;@2\B#!)-V X
M ;Y6*G."1U'K7G7@#_D#7G_;Q_Z(6M#P7XE_L>SL(6C9DN9)8RX/"L96"@C&
M#N)]0< D XQ0!Z+16/XJ\1#08?/"&1V=41!D%F8_=!"MS@$].<8ZD5L4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGBFF7<\#;HSN88.0<X! /*CKFM"@#S_1O^0]=?\ 7NO\H*/AQ_Q^:E_U\?\
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M#)[9/.,#H!6A9:)!8Q?98HU6(C!4*,'(VG=G[Q(&"3DGO0!S%QJL5OHJNSJ
M]F(UYSES%LVC'?.01VP<X ..?_YES_/_ #]5V%O\-]/@W8@7YE*G<SMP?3<Q
MP?1A@CL:O_\ "+6WV;^S=G^C_P!S<W][?][.[[W/7]* #PG_ ,>=M_U[P_\
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M  <  #H!3+NU6[1H9!E)%*L,D9##!&1STH \HU/3E\7Q7^K#!$9"P%G?Y5A
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI#@ Y ![%N/FHT2YNYI9UNHU2)7Q"5()9<MR?F;G 7LO4\>@!L4444 %%%%
M!1110 4444 %%%% !1110 445C^%[F[N(BU_&L<N\@!""-N!@\,_.<]^W2@#
M8HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***X_QKK\^FW-C#"VU)YML
M@VJ<C?&,9()'#'IB@#L***X_QKK\^FW-C#"VU)YML@VJ<C?&,9()'#'IB@#L
M**Q[FYNUNXXDC4VA0EW)&\-AL #<..%_A/4\^FQ0 444R:985+N0%4$DDX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MENKO3WC1F6.?+E5+!1OB.20.!P>OH: .XKRI]7.I:A<07UW+:K&Q2)(V,*D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRW5L9SC."<9P:YWQ==:?8-"ES&))$!$,*)O.&PF!'PF.!C=Z?+R*Y32KB/\
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MRURWOVV0RQNP&2$=6..F< GCFN:U+Q\MIJ$=AOB\@HWF.6Y5QO\ E+;MH.5
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M9QGGKP,>D4 <_96NV_EE^U;\Q@?9MWW.$^?;O.,X_NC[W7UTCKEN Y,L>(B
MYWK\A)P W/RG/'..>*XW1O\ D/77_7NO\H*S/!?AR#5=0OIIU#^3.X56 *?.
M\F25/4C;QG@9SC." #TNRU&*_7?"ZNH."48,,]<9!//-2S3+"I=R J@DDG
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M_1UF90F3T<R(PW?>Y50.O;/7-.\(:[_PCEE<6]P!YFGNPV@,-P<YC.2.CN2
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MJ,5JRI(ZJTAP@9@I8\# !/)Y'3U%%[J,5@N^9U12< NP49ZXR2.>*X?XC_\
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M(/(((Z@UR7B[QS_8UQ;VJ-$1))B;>?F124P3AAMX8G+#'&>E=;#"L*A$ "J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*!C:"<?*#V((ZD' [.B@#C/#?A.ZL[Z74[EXW\Z+:?+W#!^3@ C[J[< YR0
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M-Z$;<@G.U><XY]JL>(/"4LMPNJ6,BQW"J%97'[N09'#%>>G'0]%QM(!KJZ*
M.*E\)7>NRQR:E)%Y4+!A# &*.1GEO,_ ?Q97(&W))NZAX7EN-3@U0%?*BB*D
M$G?DB0<#&,?..X[UU%% '+^+?"\NL7%I<1E0MK+N<,2"1N0\8!Y^4]<=JZBB
MB@#E]/\ "\MOJ<^J$KY4L04 $[\@1CD8QCY#W/:CPEX7ET>XN[B0J5NI=R!2
M20-SGG('/S#IGO7444 <OI_A>6WU.?5"5\J6(* "=^0(QR,8Q\A[GM74444
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M\@1CD8QCY#W/:J]_X2N+*Z?4=.D16FQYD4H(B8X/S93G.<'IG)8[L$J>PHH
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M!!P00>#TS@XSG!Q7):MX2O\ Q-LAOI(4@1MQ%N'+,>G63IP6P>>3RIXQW=%
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MAFK?CC6(]8TB2[ASLD$9&1@C$R@@CU!!'IZ$CF@#L-.O5OXDN$R%E16 /7#
M$9QGGFK%<UINJ-IUA:O'$\SM#"JK&!U,8P6)X5<C!;MGI52#QY);W$=E?6S0
M>?PC"02J6)  ^5<=>.I(R,@ Y !V%%8/BKQ='X>5 RM)+,2(T09+$8[]AD@<
M9//"GFFZ7XCGDD6"[MV@,F?+(D656*@LRDH/E.!D9Z@'N.0"QHGBB+6)9[>,
M,&M7VN6  )RPXP3Q\IZX[5L5YOX'U"/3KG5+B9@L:3Y)/_727\R>@ Y)X'-=
M;H?B,WUI_:,Z>2FUGQDN0B\[C\JGD D  Y&"#S@ &W17%6_CVYU!&NK2R>2
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MO%T?AY4#*TDLQ(C1!DL1COV&2!QD\\*>: -ZBN,N?'\NDLIU"U:")S@.LBS
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MMWOO V8D0K\IY;<>..G4U:\!ZC<SPPQ2V_EQ+;Q[9?-5MV%4+\@&1D<\].E
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M!! VKR<MDX SC'0 [.BN'_X68;*5K6]MI(I<(41")B^XXP,!1GGC!(.&&0P
M-W1O&[7%U_9MW T$Q7<@+B16&"3\R@#H#SR.""01@@'5T5B:WKD]HX@MK9YG
M*AB=RQQ@9(QYC<;LX^7'0YSQ57PQXS_M>66RFB:&XAY*$[@5X&0P '4CV((*
MD@G !TM%8GA+Q+_PD$33&-HGCD:-T8Y(9<'&< ]",Y (.1CC)?HWB(:K-<0(
MA"6SJF_G#-@[UP5&"A&#R<Y!Z$9 -BBLGQ3KO]@VSWNW?Y>WY=VW.Y@O7!]<
M]*YK_A9$\T'V^&S=H%7+LTBK@C[VT ,65?[V!T.0,&@#NZ*QY?%4$=I_:A)\
MG8&XP6Y( 7 )&[<=IYP#U(P36%_PGMSY?V[[$_V7[V_S5W^7G[_E8STYZXQS
MNV_-0!VM%<EXB\0'4M->[M$,B312!LL$*+L<.Q!ZE2,8'7L2.:S/A;J-S]F@
M@^S_ .C_ +S]]YJ_WG/^KQN^]\OZ]* /0**AN[I;1&FD.$C4LQP3@*,DX'/2
MN-L_B/+<QM?"TD^R*6S(KJ7PO\7EG&1_>()"\\G:: -K0O&4&L6\E\FY(HBP
M;>!D;%#$X4MD8/U]JT]+U2/58UN8&W1OG!P1G!(/! /4'M7GOPPN5M=+N974
M.J/,Q0]&"Q(2IR#P>G0_2MJV\<0:=IJ:B(A&KEE2&/&-VYQC(4  [2Q...>I
MP" =G17.:+XBNKQT6XM&ACD'#^8KX.TL R@!E! (R1PV%(R:BUCQL;>X_LVU
MA:>X4 LH81HH(SR[9YY';'S ;MW% '0:C>K81/</DK$C,0.N%!)QG'/%5] U
MM-;@2\B#!)-V X ;Y6*G."1U'K6)?ZTVH6=W%-$T,\=O)N1B&&'1]K*XX8'!
M''0@@],FEX'UB/1](CNYL[(Q(3@9)S,P  ]22!V'J0.: .XHKBO^$]N?+^W?
M8G^R_>W^:N_R\_?\K&>G/7&.=VWYJT-0\?06EDNJ#<R2<(N,,6Y^4]0,%3D\
MC@XW<9 .EHKG-%\175XZ+<6C0QR#A_,5\':6 90 R@@$9(X;"D9--U;QBT$Y
ML;2![B9-N_!"1J&4L,R," 2 ,<8.< Y&* .EHKG-#\7&[F:QNHC;W(&Y49PX
M=<9RK@ $CG('H>N&V]'0!GZ)K\&MH9K9MZ!BI.UEY !QA@#T(K0KC/"/B/[?
M9R7-E:JK++M$*.J!CA,MNVJ <'N.V,USOPDU&Y@A,45OYD37'S2^:J[<J@;Y
M",G YXZ]* /5:*XJS^($^KM(;&T::*-MOF&58@3CL'7],Y () SBNOM+C[2B
MRX9=Z@[7&&&1G!'8CN/6@":BL3Q-XH70PB['EEEW>7'$I+,4&3] .,]3SD X
M.,T>-Y;&1$U"W-O'*2JR>:LB!NP8J!M!]2?T!( .MHK!O?$YL+N.QF0+'< ^
M7+O'+*!E2I P><#!.25 Y)VEMXH%Y>-I\*AUB3,L@8X5LD>7C:06_P"!#^+N
MI% %[3=?@U)Y886W/ VV0;6&#DC&2 #RIZ9K0KDO#OB6"66^(A6$6KGS'7!+
M[3)EB%4'(VD_Q'D_C7TWQ[<ZFIN8;)VMPS?.)5#E5/)$9 +''8$@M\H.10!V
MM%>:?&NXD\F.+R_W7F*WF[Q][;(-FSKTYW=.U=0GBB6SAEN[^ P)$%(Q(LQ;
M<<8 7&#G YXYZ@ F@#HZ*XR;QQ=0H;I[&06ZDDL9%$@0-@L8B-P('.,XQSNV
M_-5OQ-X[CTFUCU&%1-'*X48;;U5CG.T\C;@@@$'K@C% '445P]Y\1Y;:-;XV
MDGV1BN)&=0^&_B\L9P/[I) ;CD;A70:_XJ@T. 7DA+1N5"^7AMVX9&#D#& 3
MG(&!QS@$ V**Y?3O%EPS(;NT:"*4JJOY@DPSX"!D #*">,D<,0#C/#]6\8M!
M.;&T@>XF3;OP0D:AE+#,C @$@#'&#G .1B@#I:*YS0_%QNYFL;J(V]R!N5&<
M.'7&<JX !(YR!Z'KAMN[=R-$C/&N]PI*KD+N('"Y/ R>,]J )J*\D\%:K=V]
MS?/#:^8[S9D7SD38=\GRY(PW)(R/3WKL]8\;&WN/[-M86GN% +*&$:*",\NV
M>>1VQ\P&[=Q0!U%%<OH_C8W%Q_9MU"T%PP)52PD1@!GAUQSP>V/E(W;N*ZB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N4^*7_(.
MG_[9_P#HU*ZNJFJ:7'JL;6TZ[HWQD9(S@@CD$'J!WH Q?"VOP)IT5R9%$<,*
M*Y_NLB@%2.N<]!C)R,9R,^?Z9:M#H%P[# DF#+R.0'B3/MRI'/IZ5Z!<?#?3
MY]N8%^50HVLZ\#UVL,GU8Y)[FM>_T6&_A-G(@,)"C8,J,*05 VD8 P.E '$:
MKXLET2SL((-BO<PQKYDI^5 $0;O3@L#DY  .5.>,SQ3:3VE]8)<W(G;SU('E
MI&5!DC&<*3D-CC/]TX[UZ+>>&[>]@6QD0-"@4*I)XV#"X;.X$#C.<D9!ZFL^
MU^'EA:LCI" T3[U.]\AA@CDMR!M& <@<X')R <_XJF73=8M+R8A(3$R;R>-V
M)!SZ#]XO)XYZ\''=SZA';ND+L \I8(O<[5+-QZ #D].@ZD9AUC18=8C\BX0.
MF0<'(P1T((((/T/3(Z$U2T;P79Z,WFP1*K_WB6=AP1P7)(R"<XQGO0!Y:-!D
MU*;4)X07>VNQ((2-R28DER&7(R0,X[D;E RW':^)M47Q/I$L\&"2BLR@_=*,
MKR*2<<J >PR,$#D9ZC3= @TUY9H5VO.VZ0[F.3DG."2!RQZ8IVG:-%IS2/$"
MIF<N_P S$%CU;!) )[X SQZ"@#-\&:K%/80RJZ[8H45R3@*8T 8'.,8QGGMS
MT(-<9X6A:_BU:YB!:.X,HC('+'$K8"_>SAU[=\=<UUUU\-]/NF,C0*"<?<9T
M7@8X5& 'X#WZUOVMHEHHBB5409PJ *HR<G ''6@#D/AUJL5EI4<TCJJ1>9O.
M?NGS&(! YR01@=3D8'(JI\%/^/.3_KX;_P! CK=B^'>GQR>>(%W9)P2Q3G.?
MD)*8YX&,#MC K3T30(-$0PVR[$+%B-S-R0!G+$GH!0!QGP3F4VDB C<)R2,\
M@%$ ./0X./H?2O0ZP9? UG)/]N,0\[>'W!G'S @AMH8+G(R>.3R<Y-;U 'F_
MP3U",V\EKN'FB4OM[[2J+N]QD8..G&>HS4MHCKM_J4UKB1&M&B# @ NR(J@$
MD9!*-S]WC.<$9;\+_"MKK=FYN8U<BX;#<JV B<;E(..3QG&><9KT?1]%AT>/
MR+= B9)P,G)/4DDDD_4] !T H \Z^'6@1ZQ:J4N[A'0L'CBFV*N6)7"[>C#G
M/0G/<$#;'AJWT>TOWMY6E:2*42%W5R'1')!*@?-\W.>:V-3\ V.IN9I85+GJ
M5+)DDDDD(5!))Y)Y/K6A;Z!!;0M91QJL3J595XR"NTY(Y)(X+9S[T 8GPM_Y
M!T'_ &T_]&O65HW_ "'KK_KW7^4%=KI>EQZ5&MM NV-,X&2<9))Y))ZD]ZBA
MT""&=[]5Q/(NUFW-R!MXQG ^Z.@[4 <9\'IEM8I]/<@3Q3N63/( "H3QP0&4
M@X)QQGJ,EQ,NI:[$82&%M PD(/W3^\!'N074'&<$X/0XZC6?!=GK+>;/$K/_
M '@61CP!R4()P ,9SCM5O1M @T5?+MHU0'KCECR2,L<DXR<9)QT'% '&?!Z9
M;6*?3W($\4[EDSR  J$\<$!E(."<<9ZC,7A?4(]0UNZFA8,A@P&'0[?)4X/<
M9!YZ'J.*ZK6/ UGK$GVB>(-(0 2&=<XZ9VL,GMD\XP.@%6[/PW;V4QO(D"RL
M@0D$@;5"@*%SM  4= .E #]-U^#4GEAA;<\#;9!M88.2,9( /*GIFKLTRPJ7
M<@*H)))P !R22>@%4M-T"#37EFA7:\[;I#N8Y.2<X)('+'IBK5W:K=HT,@RD
MBE6&2,AA@C(YZ4 >:^#8]2O#/JMMY(6\D)Q<-(S (6  *=ADKSC[O  QE^CF
MXT'5O]+$:B_0_P"I++#O'0_,!ER1@CKF3.?FP?1=/T^/3HUMX5"QH, #_/)/
M4D\D\GFH=1T6'46C>9 S0N'0\@JPYZ@CC@9'0X&1P* .-T;_ )#UU_U[K_*"
MC6?^0]:_]>[?RGKL(= @AG>_5<3R+M9MS<@;>,9P/NCH.U$V@033I?LN9XUV
MJVYN =W&,X/WCU'>@#A-6U0>![VXD ^2]A,B$JQ43)N^4G=R&));'3<H^5>:
MZCP!H[:9:()<^=*3)(6+%BSG/.[D,%P&'J#UZG"^(-JFLWMEII"EBS.^2X/E
M\$@$<?,$;W! Y4$Y] H Y3XI?\@Z?_MG_P"C4J;PMK\":=%<F11'#"BN?[K(
MH!4CKG/08R<C&<C,/Q2_Y!T__;/_ -&I571O -CJ=M;S2PJ7-O%DJ63)* DD
M(5!))Y)Y/K0!Y_\ V7)_8GF[?E^V>9G(^[L\K/7/W^,=>^,<UWL7A"#48/M
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M6(_(N$#ID'!R,$=""""#]#TR.A-95K\/+"U9'2$!HGWJ=[Y##!');D#:, Y
MYP.3D Z.LSS;770T)\N;RG(9&"MM92R\JPX/!P<<CD9%:=8FL^"[/66\V>)6
M?^\"R,> .2A!. !C.<=J ./^'C+;ZA=6MFS-9*NX=60/E1PQ'^\ <_,J@Y;
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M#7,\J%!EOD R#(0H/R@9!SV)89VFCX9W0MA/IDH(NH96:0LQ/F;S_K!NPV,
M9XP05;.6KJDT:))S? 'SF386+,?ER#M"D[0,C/ '.3W.6S:!!-.E^RYGC7:K
M;FX!W<8S@_>/4=Z .'\$11RW&K)-CRFE8/D[1M+3;LG(P,=\\5%J-C-X&@^V
MV5T)+8E-L,V&4AP>592,G)+X4+D<DG'/=6?ANWLVF=$&;DDRY)8-G=G(8D8.
MX\ 8YK-M?AOI]JPD6!21G[[.Z\C'*NQ!_$>_6@#F?BK??VAIMO<XV^;)$^,Y
MQNB<XS@9QGTJ]\7XC>V"S189%E1RP((VLK*&!SR"6'3/7/2NUU#3X]1C:WF4
M-&XP0?\ /!'4$<@\CFL_2/"-KI"ND$8"S !P2SA@,C!#EN/F/USS0!S\7A"#
M48/M OKIH'0DEK@;-N#NSE> .0P/3D'O6)\1]*BTK2X+>!B\2S@JQ(;(=97S
ME0 1SQCM77?\*WT_?YWD+NW;L;GVYSG[F[;C_9QC'&,5I:KX;M]5B6UF0&)"
M"J@E -H*C&PC@ XQTH Q_BE_R#I_^V?_ *-2N5\2?Z-#H]Z_$4/D[VZXRL3#
M@<GA&/ /3W%>E:II<>JQM;3KNC?&1DC."".00>H'>F2Z+#+!]A9 8=@3:<GY
M5  YSG(P,'.0><YH ?/JL4"I*SKME9%0@Y#&0X4#&<YSGCMST!->9:'HJSZC
M>VLL\L$KRET6&79O5BS\D @D*P('4 GC@X[C3/ -CICB:*%0XZ%BSX((((#E
M@"".".1ZU:UOPK:ZW@W,:N1C#<JV!GC<I!QR>,XSSC- &1IW@NWLKM+@W$LM
MS&A(6:57;80R9QM#;<L<=LUUM9.B>%;71,FVC5"<Y;EFP<<;F)..!QG&><9K
M6H \\^',RB^U)"1N,Y(&>2!)*"<>@R,_4>M'@:9;#4;^UE(6664.BD_>7+OP
M1QG:X..N,\<''2ZQX&L]8D^T3Q!I" "0SKG'3.UAD]LGG&!T JQK?A6UUO!N
M8U<C&&Y5L#/&Y2#CD\9QGG&: .2\<S+?ZC86L1#2Q2EW4'[JY1^2>,[4)QUQ
MCCD9]#K)T3PK:Z)DVT:H3G+<LV#CC<Q)QP.,XSSC-:U !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 45CW/BB*WNX]+(;S94+ @#9@!CR<YS\A['M6/XUU^?3;FQAA;:D\VV0;5.
M1OC&,D$CACTQ0!V%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"D6H$$5EN#&5&$@2,84H 2 ZY/.<="#6AHWBF"'3AJ9C$,(#'RXP#C]X5
M& HRS>P&3R>IH ZBBN*_X3VY\O[=]B?[+][?YJ[_ "\_?\K&>G/7&.=VWYJT
MK_QI'%8'5X5+IA2%)V'EPA!.#@@D^H..#CF@#HZ*X3_A9$\T'V^&S=H%7+LT
MBK@C[VT ,65?[V!T.0,&MC5?',%A9KJ8RRR ;%&,EF!.TD9"D8.[KC!')P"
M='17.:+XBNKQT6XM&ACD'#^8KX.TL R@!E! (R1PV%(R:Z.@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_P#C7_QY
MQ_\ 7PO_ *!)7H%9^MZ!!K:"&Y7>@8,!N9>0",Y4@]": &0^&+2%@Z01!E((
M(B0$$<@@@<$4^;7X(9TL&;$\B[E7:W(&[G.,#[IZGM6)_P *MT[_ )X_^1)?
M_BZVYM @FG2_9<SQKM5MS< [N,9P?O'J.] &A1110 5D^+/^/.Y_Z]YO_0&K
M6KDO&?CBUT=C8W22.)8B3L"X*ON4C)=2#P>GYT 8GP\\#6>H6<-Y-$&E)<DE
MGP=LC 97=M(P!QC![U;^+^GG[ HB4!(94) P J[608''&6 P/Y51TOXK:=I4
M:VT$4RQIG PIQDDGDR$]2>]6)OC+8S*4>*4JP((*1D$'@@@R<@T =G_;\'D?
M;_,7R-N[?VQTZ=<YXVXSGC&>*\Z\#^&X=3TP0WAV)-=%HB'56+;0@QG())5A
MM()/4#H:S_\ A(M#W^=]EEW;MV,#;G.?N>;MQ_LXQCC&*U=2^)>EZE$+26"4
MQ#;A0B*!MZ8VR K@<<8XXZ&@"V-5N_"5S;Z?+.MU'<LH^<;94W/MSG+$@EN"
MQ.=I4;<9IVO3+%KMH6( \@C)..6\X ?4D@#U/%8^C>-]'T9O-@MI5?\ O%5=
MAP1P7E)&03G&,]ZL:Y\1]+UU52Y@E<(<KPJD9Z\K*#@]QG!P/04 =QK?AC^U
M7$OGW$6% VP2[%."3DC!YYZ^@%:&EZ?_ &?&L&]Y-N?FE;<YR2>6P,XS@>V*
M\_TOXK:=I4:VT$4RQIG PIQDDGDR$]2>]6_^%UV?]R;_ +Y3_P".4 &C?\AZ
MZ_Z]U_E!47Q;M_GL[ARR1),0\B'#+N*$$8R<@(Q! ."/IFI#\3-,AG>_6&83
MR+M9L+R!MXQYN!]T=!VJW=?&"PNU,4L,KH<95XXV4X.1D%\=: +M_P"!K>:$
MO/>W!@8*29+E3&02"IRR[2"<8]\8K/\ &]DMA<:3;IDK%*J@GKA6A SC'/%8
M5KXBT.U82+:RDC/WP'7D8Y5Y2#^(]^M:NI?$S3-2>*::&9G@;=&<*,'(.<"4
M \J.N: .E^*7_(.G_P"V?_HU*/\ F#?]P_\ ]H5S^J?%;3M5C:VGBF:-\9&%
M&<$$<B0'J!WH_P"%K:=Y/V+RIO*\OR]N%^[MVXSYF>G&<Y]Z +?AK_D M_U[
MW7\Y*/#7_(!;_KWNOYR5GVWQ,TRU@-@D,P@*LNW"GA\[ADRYYR>_THMOB9IE
MK ;!(9A 59=N%/#YW#)ESSD]_I0!%_S+G^?^?JNJ_P"8-_W#_P#VA7*_\+"T
MK[-_9OD3?9_[G'][?][S=WWN>OZ5:_X6MIWD_8O*F\KR_+VX7[NW;C/F9Z<9
MSGWH BTWQ2_AO1;>XB56=I'0;\[1F21B2!@GA<=1USVP<SXC6US%:0O<W:SB
M1U*HL:*/N$EU=<%E&<9P =P/'%:$7Q'TN.W_ +.$$OD8(V$*>I+'DRDYR<@Y
MR#TQ@5E#7M""E/LLN"0>O/&>_G9 YY .#QGH, '>_%+_ )!T_P#VS_\ 1J4V
M*99=&RI!'V C(.>5A((^H((/H>*R9OC+8S*4>*4JP((*1D$'@@@R<@UA:?XM
MT;3]_E6\R^;&T;<YRK8W#F8XSCJ.?>@"+4[5IM MW49$<Q9N1P"\J9]^6 X]
M?2O5?[?@\C[?YB^1MW;^V.G3KG/&W&<\8SQ7!6'Q1TVPA%G'#*(0&&PJC##$
ME@=TAR#D]:Q_^$BT/?YWV67=NW8P-N<Y^YYNW'^SC&.,8H -,M6AT"X=A@23
M!EY'(#Q)GVY4CGT]*[K_ )@W_</_ /:%<[?_ !1TV_A-G)#*82%&P*BC"D%0
M-L@P!@=*=_PM;3O)^Q>5-Y7E^7MPOW=NW&?,STXSG/O0!T'PM_Y!T'_;3_T:
M]=77FFE_%;3M*C6V@BF6-,X&%.,DD\F0GJ3WJW_PNNS_ +DW_?*?_'* #X<?
M\?FI?]?'_L\U'Q'_ ./S3?\ KX_]GAK/TWXF:9IKRS0PS*\[;I#A3DY)S@RD
M#ECTQ1J7Q,TS4GBFFAF9X&W1G"C!R#G E /*CKF@#J_B!XI?PW;BXB56=I%0
M;\[1D%B2!@GA<=1USVP>!^(UM<Q6D+W-VLXD=2J+&BC[A)=77!91G&< '<#Q
MQ6WJ'Q;T_48VMYHI6C<8(*I_\<X(Z@CD'D<USXU[0@I3[++@D'KSQGOYV0.>
M0#@\9Z# !U'QK_X\X_\ KX7_ - DK5^*7_(.G_[9_P#HU*YK6_B9IFMH(;F&
M9T#!@,*O(!&<K*#T)J75/BMIVJQM;3Q3-&^,C"C."".1(#U [T :;>'(-<L[
M&.20Q3K AA96 ?(C4G"D_,!@$XP1CAAS46BZ]<Z5?IHEQ(MPK)D28VR+A"P#
M $\_*>N6(8,6[5B:CX\TC48H[::WE:.$ (, %0!MQN$H;& ,\\X!/(%/T3X@
MZ3HF3;6\J$YRVU6;!QQN:0G' XSC/.,T 7= \07GBQ9;M+F.UBA.-@C20@<M
MO8N1@8XW< [3P,<U_AK:M=Z3=0QC+R-,JC(&2T* #)XZUGW7BW1;N4W3VLID
M9@Q.!M)]2HEVG/?(YYSG)K0T3XF:9HB&&VAF1"Q8C"MR0!G+2D] * -WX3:A
M'<6"0HP+Q%PZ]QN=F7CT(/!Z=1U!P?$/4(]0TN::%@R$H PZ';,JG![C(//0
M]1Q7'ZAXHT34)&GDMI2[G+$?+D]SA9@,GOQR>3S6W%\6M.BC^SK!((L$;!'$
M$PV<C;OQ@Y.?6@#;BF671LJ01]@(R#GE82"/J""#Z'BN'U.U:;0+=U&1',6;
MD< O*F??E@./7TJ73_%NC:?O\JWF7S8VC;G.5;&X<S'&<=1S[UIV'Q1TVPA%
MG'#*(0&&PJC##$E@=TAR#D]: .]_M^#R/M_F+Y&W=O[8Z=.N<\;<9SQC/%>5
M:9:M#H%P[# DF#+R.0'B3/MRI'/IZ4?\)%H>_P [[++NW;L8&W.<_<\W;C_9
MQC'&,5L7_P 4=-OX39R0RF$A1L"HHPI!4#;(, 8'2@#HO^8-_P!P_P#]H5B^
M&M%M]9TBWMKIMBM(VPAPK;_-D  SD$D$C&#[#."(?^%K:=Y/V+RIO*\OR]N%
M^[MVXSYF>G&<Y]ZI/X\TA[<:>;>4P*<A2 <');(;S=P.2>_0D=.* -,:K=^$
MKFWT^6=;J.Y91\XVRIN?;G.6)!+<%B<[2HVXS7HM>2:-XWT?1F\V"VE5_P"\
M55V'!'!>4D9!.<8SWKUN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?GFU:XL&;,$<(95VKP2(N<XR?O'J>]=A0 4444 %%%% !1110 4444 %%%%
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MY'3U%&DZ=*FM7-P481- H#E2$)Q#P&Q@G@_D: .:C\9Q:Y(\UU>2V\8=A%%
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MB$ZDD')(. I!R.I)'/ (R -U22;0-/EFMY6G( :-Y,2,$;;D[A]\#+."> ,
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M*DAC152+R]@Q]T^8H)!/.2"<GJ<G)Y- '5:GJL6EH9IW5$'=CC)P3@#J3@'
M&2>PK,T?QS9ZQ)]G@E#2$$@%77..N-RC)[X'.,GH#7 :G+/JESIUN/+D8V2N
M!<@O&6=&WLV 6)(0$=?F /K6UXD\+ZIKZH)#:HT3AD>,RJX/LQ!P.AX[@'M0
M!V&K^)+?1V1+APAE)"Y!P<8SD@$ #(Y) IFA>*;;7MWV9]_E[=WRLN-V<?>
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MV.OW5Z^@]!0!L:?;6BZG/*DC&[,0#H0=@7$>"#M'/"_Q'J>/2U-XYLX1*6E
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M1B@Q@CJ._'K7._!>9GLF!)(6=P 3G VH<#T&23]2373^+/\ CSN?^O>;_P!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"*L:K@C[NXDL65?[N1T&","M#_A!?^)=_8WF_P#;39_TU\S[N[\.OO[5U=%
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M<[]GV63?C;NW?,AQG(Q]WT/6CQKX4_X2>%;;?Y>V0/G;NZ*PQC*_WO6N@HH
M*YSQ)X-75I4O8Y&AN8@ DB_,,9S@J>HY8=1G)W;AQ71T4 <_I?AZYAD6>YNW
MEV9VJJ+"AW @[E7._L5SC:1[U%XX\$KXI1$+^6\;$AMI;AA\RXW*.2 <]L>Y
MKI:* *.B:6NE01VJXQ$BKD#;D@<MCU8Y)]SU-<U;> )=)9AI]TT$3G)1HUF
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M;=V[YD.,Y&/N^AZTSQ)X-75I4O8Y&AN8@ DB_,,9S@J>HY8=1G)W;AQ71T4
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M4^TW\6J[\>3&4V;<YR'&=V>/O^AZ>]=!10!R^L>"3<7']I6LS07# !F"B1&
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M"HE=5W"3=@L<#C8O&2,\\#GGI6[XZ\=?\(KY7[KS/-W_ ,>S&S;_ ++9SNH
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M_P#B8UK9P:F+?*3LZD>:!M*L0HSLR=P4GH,8QW% '=T57TZ]6_B2X3(65%8
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M' DM;LY.%S@K$4.3U"N.%P?O$],Y[/0O"<MC:7NIW?\ Q\7-O,<$890RLS9
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M_I72_&O_ (\X_P#KX7_T"2JGBCPP^M:5:20KNE@AB( )W%3&-P Z$Y"G'7C
MY." >AZ?I\>G1K;PJ%C08 '^>2>I)Y)Y/->9>+_^)?K=M+%\K2^3N/7.YVB;
MKD#*#''UZ\U=L?B^MDH@OH95G0*&PJ\_*/F(8IM+=<8P!C!JOX;TJX\77JZS
M=IY<,6TQ*002!\R8/!(!.XL>&/ &,A0#,UO2UU77)+5L8E1ER1NP3:\-CU4X
M(]QU%16EZZZ1>:=+D26DJ CY< -,ORY'4AU8GZC!(Z:?_,Q_Y_Y]:S_BSH;:
M3,UW#Q%>+MDP!C<K*Y'W<#<5#==Q(?M0!I67AF3Q#HD$,)'F([N ?XL/*-N>
MQ.[@GC/!P#D5] ^)LOAY([&_@<;%P&QL?8!A/D8 '!&,Y''J0<['A759]+TF
MWGMX3.0[AT7.[:7D&1@$Y#;>QXSQW&/XO^(,/BF V%M#*\KLI7<BDC;\Q*A2
MY)P".,<$\]B >JVETMVBS1G*2*&4X(R&&0<'GI7(?%O6?[/LC"IP]PP08;:V
MT?,QQU(P-I[?-SZ':\%Z,VC6<-K)]]5);IP78N5X)!P3C.><9KS_ ,4V_P#P
ME^K+IX+>5"N&*'>!@;G/HI)(C).<$#.?NT 5?&>@-X;CL+Y%P\"HKAF#*)%/
MF@<')W,7S@XP !CC/:_$>Z6[TJ6:,Y21864X(R&D0@X//2L+6_@W;V\$DL#R
MF5$9E!VODJ,[=JJ"2<8&#U.<'H<FUUX:CH4UL23);&-3DD_*TJE#DC@#E0,G
M 7L"!0!-I'C:ULM(-BSDSF*9=@5NLC/CYL!<88$\]/?BF6FF/8Z!,T@QYTBR
M*.0=I>)03D#KMR.H((.>:ZCX9:';RV,%PT49ERYWE%+Y65L'=C.1@8]*N_%+
M_D'3_P#;/_T:E '&Z1XVM;+2#8LY,YBF78%;K(SX^; 7&&!//3WXIEIICV.@
M3-(,>=(LBCD':7B4$Y Z[<CJ""#GFNH^&6AV\MC!<-%&9<N=Y12^5E;!W8SD
M8&/2KOQ2_P"0=/\ ]L__ $:E !\+?^0=!_VT_P#1KUROC[_D,V?_ &[_ /H]
MJA\&?%"VT2TCLY4E+Q[\E%0K\SLPQEP>A]*;XNO5O]4T^X3(65+5@#UPTK$9
MQGGF@!VM6PUG7EMI_FC39@8&,+%YNTY!R"Q.<]B1Z8]8FA692C@%6!!!&00>
M""#U!KS7Q]I<^CWL>NVT995 \W;DGY00V00=JF/Y=P&!@DX.";4/Q9.J*(;*
MWDDN6 RIQL7/&XL#DJ&(Y(08Y)6@#H_'NL_V192S X=EV)AMK;G^7(/7*@EN
M.>.W4>9:SX3,&CV]V%(=79W^8$;9B K8R><+& !TR<C.2-KXH3-K=Y;:/&3U
M!?:=V"YQDH.Z("W)^ZQZ#DZ$WP3M"I"22AL'!)0@'L2 @R/;(^HH F\6ZP-8
MT5KL8S(D1; ( 82H' !YP&!']3UKD=,\5W,&F&QCM7:,QR@S8<IM9F+G 7'
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M.<' [' SM) ZUQ7P\ED?5(1-D.@=""-I'EPL@4C Y 4#UXYYH Z/_F8_\_\
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MS$5*MC')^;'.> !VJ;XY_P#+K_VV_P#:=0K93?$6[6Z=&2QBZ;]P#*&.0,$
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M*_*"2!PIZ='\,-!DT:S"S J\KM(5(P5R H!Y/.%![$9P1D4 =;1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?E;MD=#5C3DD2)%F(:4(H<CH6 &XC@<$^P^E %BBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHKA]6U&5-:MK<.PB:!B4#$(3B;DKG!/ _(4 =Q117#Z
MMJ,J:U;6X=A$T#$H&(0G$W)7.">!^0H [BBL>VMKM;N25Y%-H4 1 !O#87))
MVCCAOXCU''I7LO%?VF_ETK9CR8P^_=G.0AQMQQ]_U/3WH Z"BL>YMKMKN.5)
M%%H$(="!O+8;!!VGCE?XAT/'KL4 %%%% !1110 445P_@'49;J[U!)'9ECGP
M@9BP4;Y1@ G@<#IZ"@#N***Y_P %>*_^$GA:YV>7MD*8W;NBJ<YPO][TH Z"
MBBB@ HHHH **X?Q]J,MK=Z>D;LJR3X<*Q4,-\0P0#R.3U]3707-M=M=QRI(H
MM A#H0-Y;#8(.T\<K_$.AX]0#8HHHH **** "BBB@ HHHH ***R?%.N_V#;/
M>[=_E[?EW;<[F"]<'USTH UJ*J:3??VA#'<XV^;&CXSG&Y0<9P,XSZ5;H **
MQ[:VNUNY)7D4VA0!$ &\-A<DG:..&_B/4<>FQ0 454U:^_L^&2YQN\J-WQG&
M=JDXS@XSCTJIX6UW^WK9+W;L\S=\N[=C:Q7K@>F>E &M16/X7MKNWB*W\BR2
M[R04  VX&!PJ<YSV_&MB@ HHHH **** "BBB@ HHHH **** "BN:\>ZZ^F0+
M';G%S<2(D0&PG)89.'XQCC.#@L.F<T?#[7)-7M=UQN\^*1XY-RA3N!SC QC
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M#C./2@"W163X6UW^WK9+W;L\S=\N[=C:Q7K@>F>E-\+VUW;Q%;^19)=Y(*
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MNV1-^1D'&9&(Y!(Z$=Z ./\ "VIW=]HTJVY8S0L8T*\OM&QB!DGD*Q"XP0
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MEN[)E-S91"/YP0)%5<8QD@$\CM][[XV@U%KMIJ7BI!9/"MK"Q!D9I5E) 8$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BJ]EJ,5^N^%U=0<$HP89ZXR">>:L4 %%%% !1110 4444
M <_XU\*?\)/"MMO\O;('SMW=%88QE?[WK70444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO##(S0RNR1,R.=S,Y^4D( #N)QD#(&><$TS_ )@W_</_ /:%<[IN@C6M"2,
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M?>49)Q@ 9)/'4BN=^-?_ !YQ_P#7PO\ Z!)6W\0/"S^)+<6\3*KK(KC?G:<
MJ02,D<-GH>F.^0 3Z/XYL]8D^SP2AI""0"KKG'7&Y1D]\#G&3T!K>KA]*\6O
M9206&I6PAD8@0M&%:+/*   ML(!"\$_>YVJ:[B@#$UGQI9Z,WE3RJK_W0&=A
MP#R$!(R",9QGM5O1M?@UI?,MI%<#KCAAR0,J<$9P<9 SU'%<9\'H5NHI]0<
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MMW.UV5>?0 <#IU/4G./\1[3[&UCI]LJ"-[AF$;C,9;>N,CKMS(V5'&#@#@8
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M4H(Y[<8B9?E&W;@+\NW'0;2,<<<<9% !K.OP:*OF7,BH#TSRQY .%&2<9&<
MXZGBJ^A^+K77&9+:0.R#)&&4XZ9PP&1ZXZ9&>HK/\4>)XM.GBMTA,]XP)B4
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M+M^]GK^/%=5K/C2ST9O*GE57_N@,[#@'D("1D$8SC/:N:^"G_'G)_P!?#?\
MH$=8GPZ%_=I+>VPMB\DS[WG5Q(2P5F ,8QMS@X]<\=* /3='UJ'6(_/MW#ID
MC(R,$=000"#]1TP>A%9MUX^L;24VKS*)%8*1AMH/H6 VC'?)XYSC!KG+;0;W
M17O-5E:)3);2';!NV^8J@J^UUP3P22<\L?4U>^%>E1+IZOL4F??YF1G< [(
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M#UU_U[K_ "@KNKNZ6T1II#A(U+,<$X"C).!STKA=&_Y#UU_U[K_*"NJ\6?\
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M:T74YY4D8W9B ="#L"XCP0=HYX7^(]3QZ5/A-I\=O8),B@/*7+MW.UV5>?0
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M[M>#QQTY.=#XLZ?'<6#S.H+Q%"C=QN=5;GT(/(Z=#U P 4OB/_Q^:;_U\?\
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MPPNFV8TR0^8FV16."F1(S$C )(X;'7WK%TWX>262FS^U.;,LQ,.P!BI.=GF
MY /\6T*&RW W&NUHH XJR^&_V:PETKSL^=('W^7C&"AQMW<_<]1U]JW_ .PO
M]#_LW=_R[^5OV_[&S=MS^.,_C6M10!S^F>%/L-@=*WYS'*F_;C_6%CG;D]-W
MKSCM1IGA3[#8'2M^<QRIOVX_UA8YVY/3=Z\X[5T%% '*?\(+_P 2[^QO-_[:
M;/\ IKYGW=WX=??VK5_L+_0_[-W?\N_E;]O^QLW;<_CC/XUK44 <I_P@O_$N
M_L;S?^VFS_IKYGW=WX=??VJQ=>%YO)MXK>Y:)[9 NX*&1QL"G=&3@GC(R3MY
M[X(Z.B@#E]'\$FWN/[2NIFGN%!"L5$:*",<(N>>3WQ\Q.W=S3-9\$-<77]I6
MD[03%=KD()%88 'RL0.@''(X! !&3U=% '-'P>TEY!J<DNYX(=C#RP-YVN"^
M0V%R7SC!],U=\5>&8_$<!M9"1SN5A_"P! ..XY(([@\8."-BB@#@M5^&UQJ\
M2P7%ZSB,C;F( < @[@&RS=,,3D?-UW9'7ZUH\>L0O:39V2#!P<$8(((/J" ?
M3U!'%7J* .2TOP;<6D#V,ET9(6@>-5,0&W<,!MVXL0HR N<8X&,"M?PMH7]@
MVR66[?Y>[YMNW.YBW3)]<=:UJ* .,\,?#:/0+I[U7#*0X1"GW-S C#EF)(7*
MYP"036KXJ\(Q^(50LS1RPDF-T."I..W<9 /&#QPPYK>HH YJT\-79=7N;UY$
M1@P6.-(<E3T8KDLI&05[^O%=+110!Q\_@.2WN)+VQN6@\_EU,8E4L223\S8Z
M\]"1DX(!P)?#?@3^Q?M(\YW^U?Q?=D7[_P V_)RWS9W8'(SBNKHH XJX\!7.
MH(MK=WKR0#&56)48[1\N7RQ.#@G<&R1GK@C2U'PO-NC-E<M;K'$(]FT2IM7[
MIVN>&'0L<DC XYST=% '.>&_!JZ3*][)(TUS*"'D;Y1C.<!1T'"CJ<8&W:.*
MJZ)X#;2K.73TG8-*Y82QC8RG"XZ,>/EYY&02..M=;10!QESX EU9E&H733Q(
M<A%C6$$\=2I.1C([$9.&'.=/Q?X07Q$J'>T<L+;HY%R2I)&>,CT&#D$$ @]0
M>@HH X_5/ <FKQ*MQ<LUQ%(6BF6,1E0=N5V*P!Y7(.00<8. 08I_A_/>S07=
MS=M(]O(& ,2JN RM@*K  D@Y;G(P,?+SVM% '/\ B3PI_;4UM<[]GV63?C;N
MW?,AQG(Q]WT/6CQKX4_X2>%;;?Y>V0/G;NZ*PQC*_P![UKH** ,?Q5X9C\1P
M&UD)'.Y6'\+ $ X[CD@CN#Q@X(S$\*7AB\E[YRZ-&8W$:J1LR"&&[,@8$9#'
MJ 3GD'JZ* .2M_ KW$\=Y?7#7#0$&,!%B0$'.2JDY.<'C'0 [AP.MHHH Y*X
M\"O;SR7EC<-;M.29 465"2<Y"L1@YR><]2!M'!M>&_!JZ3*][)(TUS*"'D;Y
M1C.<!1T'"CJ<8&W:.*Z.B@#G[+PI]FOY=5WY\Z,)LVXQ@(,[L\_<]!U]JZ"B
MB@#$T'PU_9<MQ=-(TCW4FXY& JKG:HY). <9SC   &.9?$_AY/$$#6DAQNP5
M; )5AT(S^1Z$@D9&:UJ* .2U;P&UZ;>X2=DNK9%7SL;MX4<Y4MU)))Y.02&W
M C%_1?#LMK+]JN;AIY0C(OR+&@5BK'Y%S\V5Y;/(P,<"MZB@#BK/X?SZ0T@L
M;MH8I&W>68EE ..Q=OUQD@ $G&:TKSP+!>VHTZ5I&57+ARP,FYF9BQ.,$G<1
MR#P?7FNCHH Y*'PC>,HAFOY#$  ?+B2.0XZ?O<LV<@9/)(R#UJ_KFA7%Y*MQ
M;7+0$)M9=@D0\Y!VL0 W8GDXP..<[U% '+Z-X%6R:6XDFDDN;A&5Y0=A ;^X
M!G:1A<=<;1MP.*I7'@*YU!%M;N]>2 8RJQ*C':/ER^6)P<$[@V2,]<$=K10!
M#:6JVB+#&,)&H51DG 48 R>>E8OB3PI_;4UM<[]GV63?C;NW?,AQG(Q]WT/6
MN@HH *YSQ)X-75I4O8Y&AN8@ DB_,,9S@J>HY8=1G)W;AQ71T4 <_I?AZYAD
M6>YNWEV9VJJ+"AW @[E7._L5SC:1[T67A3[-?RZKOSYT839MQC 09W9Y^YZ#
MK[5T%% &/X@T:;4#&]O<- \9;HH=&##!#(2 2.Q/3GC.",_1_!)M[C^TKJ9I
M[A00K%1&B@C'"+GGD]\?,3MW<UU%% ')7'@5[>>2\L;AK=IR3("BRH23G(5B
M,'.3SGJ0-HX-KPWX-7297O9)&FN900\C?*,9S@*.@X4=3C V[1Q71T4 <_X;
M\*?V+-<W._?]JDWXV[=OS.<9R<_>]!THLO"GV:_EU7?GSHPFS;C& @SNSS]S
MT'7VKH** .,F\#W4R&U>^D-NQ(*F-3(4+9*F4G<21QG&,<;=ORUTNBZ/'H\*
M6D.=D8P,G).2223ZDDGL/0 <5>HH YKQ/X,_M>6*]AE:&XAX#@;@5Y."I('4
MGV()# @C%2Q\!R17D>J3W+2R1JP(:,*#E64;<-A0 PXP<G)S\W'844 <I>^%
M+R1I?)OG2.5F.UHUD9=PY"N6!4#^$#&WMSR=7PUX:B\.Q?9H-VTL6)<Y8DX&
M3@ = !P!T]<DZU% '/\ C7PI_P )/"MMO\O;('SMW=%88QE?[WK1XD\*?VU-
M;7._9]EDWXV[MWS(<9R,?=]#UKH** .?\:^%/^$GA6VW^7MD#YV[NBL,8RO]
M[UH\7^$%\1*AWM'+"VZ.1<DJ21GC(]!@Y!! (/4'H** .$UOX:R:X@^TW3/*
MK#:YB"JJX.5$:L!EB02Q).% [<[?B3PI_;4UM<[]GV63?C;NW?,AQG(Q]WT/
M6N@HH YKQ/X,_M>6*]AE:&XAX#@;@5Y."I('4GV()# @C#K#PFY9I+V=KAGB
M>+&U8D"/M+#:G\1QRP.<8'8&NCHH X2#X;SV\3V*7CBV??A/+7< W0;\YQG&
MX *&^88&XFNE\+:%_8-LEENW^7N^;;MSN8MTR?7'6M:B@#C](\!R:)*6M+ED
MMVD5C"8PXP,94.S9&1QD#.,9)(S3[CP*]O/)>6-PUNTY)D!194))SD*Q&#G)
MYSU(&T<'K:* ,G0M'DL-SSSO/))MR6 5!MR!MC'"Y!&[DY(S6!9_#R33&D2T
MNGBMY6R8P@9@",$+(Q)4XX# 9'&=Q&:[6B@#E_"W@^/PHUQ,)!Y4I# $;1&J
M;S@L6.0 W4XZ9-,\ 23W:S7DS/Y5Q,SPI+]Y8R20<Y) (( 7H-N5R&S7430K
M,I1P"K @@C((/!!!Z@T0PK"H1  J@  #  '   Z 4 5-:T>/6(7M)L[)!@X.
M",$$$'U! /IZ@CBN0E^&UQ/;_8)+UFA4#:OE 8P01D[BS*!G"YP#M(^Z!7>T
M4 <_J?A3[=8#2M^,1Q)OVY_U94YVY'7;Z\9[U:_L+_0_[-W?\N_E;]O^QLW;
M<_CC/XUK44 <Y8>"XXK :1,Q=,,"P&P\N7! R<$$CU!QR,<5E1?#N9X/L,]V
MTD"H0B>6%PV#L)8,694)R$) R%[#%=Q10!D^%M"_L&V2RW;_ "]WS;=N=S%N
MF3ZXZU5\7^$%\1*AWM'+"VZ.1<DJ21GC(]!@Y!! (/4'H** .*G^'\][-!=W
M-VTCV\@8 Q*JX#*V JL "2#EN<C Q\O.EJ?AVZEF:>VNVB60+E&C6505&,KN
M(V@]P!R<DGH!T=% &#X5\(Q^'E<JS22S$&1W.2Q&>W89)/.3SRQXK>HHH Y+
MPI\/(_#MQ+=HY(D#*B8P%4L&QDEBQ&  >.^<YX=:> EMKXZF)&V[G=8@#M#R
M*%=LECG=R< #L,X7%=710!S_ (D\*?VU-;7._9]EDWXV[MWS(<9R,?=]#UH\
M7^$%\1*AWM'+"VZ.1<DJ21GC(]!@Y!! (/4'H** ./UOP//K=L+2YN=[B8.)
M/)5> A79M5@.I)SGVQ6UXIT+^WK9[+=L\S;\VW=C:P;ID>F.M:U% %32;'^S
MX8[;.[RHT3.,9VJ!G&3C./6L7Q/X,_M>6*]AE:&XAX#@;@5Y."I('4GV()#
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MQ)>V-RT'G\NIC$JEB22?F;'7GH2,G! .!L:9X;6VAD@F=IC<%C*SG&XN@1@
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MD[]Q .X'CC=7I=9^FZ!!IKRS0KM>=MTAW,<G).<$D#ECTQ6A0 4444 %%%%
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M7\U0W&?F;:2"0" 3GUQ\P .XHKDO$_C9K58(K%1-/=@-&#T"'!W,N58 CIG
M&&)(VD''\4^-=2\-(OG10L7;B2/S#'C'W"I((;OG.". "02 #T6BN7\6^*)=
M'N+2WC"E;J7:Y8$D#<@XP1S\QZY[4?$/Q1+X;MUN(0I9I0I#@D8*L>Q7GY:
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MEBP& %QSDX(!P >@45Y_9^.;YIY-*>!&NU;AD8B%5*Y\QL[C@94XX+!MORL
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MR;F#&],@@@C[R]\9^H *X8YK$L/&M_J=S<6%O%$?)D95D?>J*%<CY\$EBP&
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M:V*X?PS="SU6]L$!V.$F^\2 Q";S@YY8ODGV QC&.XH **** "BBB@ HHHH
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M!8$;CA.1QT^3)S@@,N1SQVM[H=O?MOFBC=@, NBL<=<9(/'-6X85A4(@ 50
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M.4+*&*G@Y!(X/ Z>@KG_ (DF1K*2&&-I'E*J D?F8YW$D8.!@'!QD,01@\@
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MG &<9-%]I,.H8\^-)-N<>8BMC.,XR#C.!0!7TOQ'!JLDD,#!_)"%F4@I\^[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ&ZNTM%,LK*B#&6<A5
M&3@9)XZT 344R&99E#H058 @@Y!!Y!!'4&GT %%%% !1110 4457348GD-N'
M4RJ,E P+@<<E<Y Y'YB@"Q1110 4444 %%%% !1110 4444 %%5TU&)Y#;AU
M,JC)0,"X'')7.0.1^8JQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '+^(/B/9
MZ(WENQ>0'!6(!B.H.22%!!&",[AQQBNHKR_XI:!!HM@D=M&J W"9QRQ^24C+
M').,G&2<=!Q7J% !1110 4444 %<YH7CNWUNXDLH0Q:(,2QV["%8+E2&.0<Y
M''(J+Q[KDME$MI:J6N;LLD8&00,?,X(Q@KD<DC&=W136);:&WAS4+&&)AY;V
MTD3>K%-TKG!S@,[!A@\<CIU /0Z*P?%WBI?#T:L$,DLKA4C4X9B>O8G Z< \
ME1WS5*RNM65HFGCMVC=E#K$S"1 PY;+$J=O<#=GH/4 '5T5Q47BV[UV62/38
MXO*A8J9IRQ1R,<+Y?XG^+*X)VY .DOB232;9[G4U6-HW91Y1W"3^Z4!.<MTP
M3G@L=HS@ Z.BN$U3Q3J5A!_:;PPI -A,3M(9P&8+@D *"<YY'R@X()!%7O$?
MCLV,5NUO&7EO@/*#$*!N"XW<]<NO&0.OS#'(!UM%8.ASW_FM%>I%Y>S*R0,V
M-V<%"KG<21SD  8QDD\8&G>,+_Q&LEQI\40AC)4"=F+NPYP-I !P5X/ )^\>
M< '>UGZ_K::) ]Y*&*1[<A "WS,%&,D#J?6K5I(TJ*\B['*@LN0VTD<KD<'!
MXSWKA?B[(DZ6UB[;/.N =YQM55&UB<D=/,!], Y(H TW^),-N0;B&X@1CC?-
M"53."0."3DXXP#^63750S+,H=""K $$'((/(((Z@UP7Q!\21:M!_95FRSSW#
M( L3;@ &W%MPRO&S!!(P#N/ K3FUQM(\G1;11/=)$JDGY4154 2/C.!T.T')
M!ZY*[@#K:*X_3?%-S;7JZ7?+$7FCWHUOOVC&[(;?SR%/3IQUSP:IXQF6^;2[
M5%D80@\A@$D)!R[9QY80@G ))(4')X .PHKA+SQ;?V<L>EF.%[R;YE92XA5/
M4AOF)^5R<$8&W&XY%=!HM[=H)?[06)!'@K)$W[LKC+<,<C;CDG .>!@9(!MT
M5P^F>*-0\1@W%E%%' #A3<ERSX)R1LZ < CD Y 8X.-/P9XM;7?-AFC\N>V8
M+( 0RD\@X/U4\<X&/F- '2T5PFD>,;SQ#YHLDBVQS.!+*'6,QC&P8!+&0YRW
M0*,9&6%7O#OC9KJ.Z^TJ!+8%_,\KE&"[^5W'.?D(P?8YYP #K:*X33/$^IZQ
M&+^W@A\@M\L;.WFL 0K8?A!SG&0,8Z'C/=T 0W=Q]F1I<,VQ2=J#+' S@#N3
MV'K7)7OQ/BL%WS6UTBDX!>$*,]<9+CGBNSKS_P"-?_'G'_U\+_Z!)0!T&E^+
M_P"T)%@^S7,>[/S2P[4& 3RVXXSC ]\4>"O%?_"3PM<[/+VR%,;MW15.<X7^
M]Z5T%>2?"^\NS;/!9(F1,S-)/N$>"B (-G);C)[*,9Y84 >MT5R_@[Q>VJQS
M"Z"QS6KLLH!P@ S\V22 ."#\Q^[G(!%4M/\ $>H^(!]ILXH8[<YV&X9F9\,P
M)Q&?EQCD$=>A8= #M:*Y_P (>*?[<5XY%V7%NVR9!RH;)&0>002I[DC&.1@G
M*^+NIO8V)6,X\Z18V/(.TAF(&".NW!Z@@D8YH M2?$>!G:*WCFN-GWFMXMZ@
MY(QG(].",@CH36QH?B*'6E8PD[HSAT8%71O[K*>A'([C((!.#5C2M,32XDM8
MAA(U '3)QU)P ,D\DXY))IFJ7L6E1R7LF $3YCP&(7)5<G&3DD*,]3QUH O4
M5P]EKVJZO%]LMX8$C891)BYD8 =01M7#'[N=O'MAC=TWQQ_:5I<7:IY<]LLN
MZ)SDAD4D9'RG!QCD*<AAVS0!U=%>?Z'XKU37H/M,$,*[=W,A<"0CH$7(QC&"
M6;!/0C! -&\<WWB*+=9P('C7]X\K'RRPS^[0#!R1@Y+87.&[,0#T"BN2T/QL
MVK:?+J(4++ DF0>4+QINR.<[3D<9R.1DXR<_1O%6I:];BYMH8@5#;C+O =@3
M@1@-T  !9F +$@8VF@#O:*YKPOXM;6[=Y/+Q<P;E>$D*=ZC@?-RH8\?-T((Y
MVY.3KGB/5-%C^W2Q6_DAEW(K.9%5CC!;(4D9"DJ",G(!% '=T5SGB+Q0UEIY
MU2  DI$RB0=I&4<A2.<-V/6L+_A*]4N+3^THX84C6/<5D+EV Y:11E0%(Y )
MS@9!;*Y /0**X_5_'#Q6$6KVR*RLR>8K$_*I)5P#\IR'PH.".^"*V/$GB!=*
MM)+],.%0%"/F4ER AX(RN2"<'ITH V*Y^]\5_9K^+2MF?.C+[]V,8#G&W'/W
M/4=?:MC3GD>)&F 64HI<#H&(&X#D\ ^Y^M>>>+;QK/6;:6-&D<6Y"HN 26\Y
M1R> ,G+'L,GM0!Z717%)XIO-*NX;34%A\NYRJ/!OX;@ $-D]2!T ^8'=P16U
MK=Q?;Q%9QQ;=H8RSN=N<D% B?-GH=W3&1UH VZ*Y+PKXLGO+F;2[Q%6>$;@8
ML["OR^I)R=P(]C@A2.<_1O%FH>)3)/9) D"/M4W&_>> 3]PGGD$\8&0 6P30
M!WM%0VDC2HKR+L<J"RY#;21RN1P<'C/>N=\9>+)-):.TM4$MU.?E4] !U9@"
M#@\X/ X8DX7! +'C7Q7_ ,(Q"MSL\S=($QNV]58YSAO[OI705Y%\4;V]%NEO
M>1QX,H82P%MG"L-A##(;DG.<$=!P<=UXI\4OIKQV=M&);J<.40NJ@!5)W-DC
MCC@<;L-\P(H Z.J][J,5@N^9U12< NP49ZXR2.>*Y*\\4WGAUHY-26$V\C;"
M]OOW(Q&02'Y(P#T&>,]<!LGXU^=Y,?W/L_F+_>\SS-LG_ =NW\<^U 'I=%<I
M=>(;GP_!+=ZB(3MVB-;<N"S'.0?,_ \9( 8X.*JW>LZM:1M>R0VXCCRS1;V,
MH13S\P.S.WG/_CN?EH [6BN*\4_$ VEC%J=F%832!<2J>!A\C (Y!7'4CKC(
MP:L6VLZ@L$U]<1Q1QK!+)''\YE!4;D#\@8P.<8/3A3D  ZVBO/\ 0_%>J:]!
M]I@AA7;NYD+@2$= BY&,8P2S8)Z$8(!HWCF^\11;K.! \:_O'E8^66&?W: 8
M.2,');"YPW9B >@5C^%_%$7B2(W$(8*KE2' !R #V+<?-5?P/XI_X26W%P5V
MNK%' ^[N !R.^"".O(Z<XR<KPQXUFU6PN-0D5!)!YNT*&"G9&'&06)ZGGD<4
M =K17G^A^*]4UZ#[3!#"NW=S(7 D(Z!%R,8Q@EFP3T(P0-C0/',=_8G4Y<+Y
M082!?[R]ANQRV1M&3RP7)- '445Q5MK.K:G']K@AMTC90R)*[-(P*A@=RD+\
MV>,[<=#ZFPGQ'@>Q.J@'Y3L,9(!\SCY 3U'.<@'Y<G&05 !T6K7W]GPR7.-W
ME1N^,XSM4G&<'&<>E5/"VN_V];)>[=GF;OEW;L;6*]<#TSTKD-6UC5#8R3W,
M$1CEA=2L9=94#@C>RMN& .2HY&><8;&U\+?^0=!_VT_]&O0!TMU=I:*9965$
M&,LY"J,G R3QUI\,RS*'0@JP!!!R"#R"".H-<;\6O.^Q/Y>SROE\W=NW_P"L
M39MQQU^]GMTJUX#^V>3#Y_D_9_L\>SR]_F?=7;NW?+]W.<=^G% %OP5XK_X2
M>%KG9Y>V0IC=NZ*ISG"_WO2N@KR3X7WEV;9X+)$R)F9I)]PCP40!!LY+<9/9
M1C/+"NV\$>*7UM98KA52XMY"DBIG;U.".HZ@CACTST(H Z6F33+"I=R J@DD
MG  ')))Z 5QNJZSJUM$]Z(;=$12QC=V>4!?O$LI5#P"W!Z<<MQ3M8UR77=+:
M\ME51)%+YBRY.$5760*5ZMD?*3@$=0.E '6VMVEVHEB970YPR$,IP<'!''6I
MJ\_^%OVS[-!_J?LG[S^_YWWG_P" _>_\=]Z[75/.\MOLVSS>-OF[MG49SMYZ
M9QCOB@!]EJ,5^N^%U=0<$HP89ZXR">>:Q[+Q7]IOY=*V8\F,/OW9SD(<;<<?
M?]3T]ZXKX2?;/)/D>3]G^T?/YF_S/NINV[?E^[C&>_7BI6O);;6[D6Z;Y9(4
M5<\(I*PG>YZA5 YQR3A1R: /4**X_1O%-S%>_P!EWZQ!WCWQM#OVMC.1\V3T
M!Z[<;3UR*??>*;F^N'L=.CC8P%1)+,_[L%@QV[4.XG(QD9PP(*CK0!UM%<IH
MWBF:.Z_LN_5%G==\;0[C&RX.1\V2"-IZX!P>G&[I;O?L;RMOF;3MWYV[L?+G
M'.,]<<XH Y6?QY)<7$EE8VS3^1P[&01*&!((^9<=>.H)P< @9/85Y)X*^W_:
M;[[/]G\SSOWOF>9MW;Y/N;><9SUYQCWKIHO%MWKLLD>FQQ>5"Q4S3EBCD8X7
MR_Q/\65P3MR 0#M:Y_PWXK_MJ:YMMFS[+)LSNW;OF<9Q@8^[ZGK53P_XMEEN
M&TN^C6.X52RLA_=R#)Y4-STYZGHV=I!%97PX_P"/S4O^OC_V>:@#H/!7BO\
MX2>%KG9Y>V0IC=NZ*ISG"_WO2N@KS3X5:FFEZ;/=2G"1S.3TR<1QX R0,D\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#S+XNZY;W]HB0RQNPG4D(ZL<;'&< GCFO0K'5H=0SY$B2;<9\M
MU;&<XS@G&<&JG_")V?\ S[P_]^4_^)JW8Z3#I^?(C2/=C/EHJYQG&< 9QDT
M4O"_BB+Q)$;B$,%5RI#@ Y ![%N/FK8JO9:=%8+LA144G)"*%&>F< #GBK%
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M_P!D39Y&U?+V[=N!MVXQMV],8XQTQ47]DP^7]E\M/*_N;%V==WW<8Z\].O-
M'FMELT/4(+;2I_-BN&8R1;P\:C.6(8'&0H..2XVC)8-@][<^*(K>[CTLAO-E
M0L" -F &/)SG/R'L>U7;'28=/SY$:1[L9\M%7.,XS@#.,FGOIT3R"X**95&
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MNU,4JJZ'&5<!E.#D9!XZT >9?%WQ'!?VZ6\#"0B569HR&1?E< %AQN;D@=<
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MP];7;&66&)W.,L\:,QP,#)(STK0H XK7_'5I?6$C1/N>:&11&O,H)1L[D!R
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR<8)QC(&<@'<45GZ)I']E(8O,EERQ.Z=][#( P#@<<=/4FM"@ HHHH ****
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M% !1110 4444 %%<EXWNGTB2WU)781)*$F7YS'L?(WE5.,KS@X)+%>N #UM
M!1110 4444 %%%% !1110 4444 %%%% !17#^ =1ENKO4$D=F6.?"!F+!1OE
M& ">!P.GH*[B@ HHHH **** "BBB@ HHHH **** "BBB@ HHK'\46UW<1!;"
M18Y=X)+@$;<'(Y5^<X[=NM &Q1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M POB?KTFC69:$E7E=8PP."N06)'!YPI'8C.0<BJ__"JK;R_O/]J^]]HWMO\
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M34+.*RLTW>5(F%W 85491RY&<9 ZYKI?$-JUW;3PQC+R0R*HR!DLA &3QUH
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M9_94$3/9RL;V-U(D#2LSL&&YBY&PD\MN7&2 0<<'K?&-TUWHGG2'+R0V[,<
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MB-W0?>P#Z_,-:Z\&*VG'2$/2, -R 7!W[CG<0&?D@9P"0.U $/\ S!O^X?\
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M444 %%%% !1110 4444 <_9>%/LU_+JN_/G1A-FW&,!!G=GG[GH.OM70444
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MUQD$\\U8H **** "L%/#!-\=4=PV(O+1"@^3H20^>2?F[9PQ&<5O44 %%%%
M!1110 5@ZYX7-]*M[!*T-RB; Z@.I4G.UD;AAUQTY()S@8WJKV6HQ7Z[X75U
M!P2C!AGKC()YYH YH>");Z1'U"X-Q'$2RQ^4L:%NQ8*3N ]"/T)!ZVBB@"&[
MM5NT:&09212K#)&0PP1D<]*YB'PA>62B"VO62%  BR0QRL!Z;SC(]..!@=JZ
MVB@#'\,^&8]!C**2\CG=)(WWW;N2>>.3@9X]R23L444 %%%% !1110 4444
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M!PRXVMWZYXJ'X3:?';V"3(H#RER[=SM=E7GT ' Z=3U)R?$/3X]/TN:&%0J
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MGQS:AJ%PR@R13L$)_AWO)NQ[G &>N,CH3D [70_$EOKJL]LX<(<-P5(STX8
MX/8XP<'T-7;NZ6T1II#A(U+,<$X"C).!STKA= _<ZY=Q)\J-"K%1PI;$1W$#
MC.6;GKR?4UV'B&U:[MIX8QEY(9%49 R60@#)XZT <9H6D-XZ4ZC?EO)+GRH%
M?$>U<KN.#DMDD9^4Y!_A(4='I?@V/1I%DM&>./G?%N+QMD'YL,20V=OS ]%V
MXY)K/^$]TLVGQHIR8VD5N#P2Y?'OPP/'KZUT'B&Z:TMIYHSAXX9&4X!P50D'
M!XZT 9^I^/K'3',,LRAQU"AGP02""4# $$<@\CTK5TS58M4030.KH>ZG.#@'
M!'4'!&0<$=Q7+_";3X[>P29% >4N7;N=KLJ\^@ X'3J>I.<_PK"NFZQ=V<("
M0F)7V <;L1GCT'[QN!QSTX& #>_X61I^SSO/7;NVXVONSC/W-N['^UC&>,YJ
M<^.;(0B\,R^620.NXD$ C9C?D9!/'0@]#FN5^">GQBWDNMH\TRE-W?:%1MOL
M,G)QUXST&&?#C2HOM]])L7=!,5CP,!0SR @#H.% ]AP."<@'>Z/K4.L1^?;N
M'3)&1D8(Z@@@$'ZCI@]"*RC\0[ 1"Y,P\LN4!V/DL &/R[=V ",G&.0,Y-<_
M\,H5AN]11  JS@  8  >4  #H!47P3T^,6\EUM'FF4IN[[0J-M]ADY..O&>@
MP =UH^M0ZQ'Y]NX=,D9&1@CJ"" 0?J.F#T(K(NOB1I]JQC:=21C[BNZ\C/#(
MI!_ ^W6N<T"6/0M5OH4Q';+ )64#(&T(Q( !( WMP..< <##+[Q(^J6,RVEC
M_H7ER .SQQ@8&YG$6#G:V2-I.2.H;( !Z'-J$<41NBP\I4+EA\PV@;MPQG(Q
MSQU[5A2?$C3XU60SKA\XPKEN#@Y4*2OMN SU&16)X:_Y +?]>]U_.2K?PKTJ
M)=/5]BDS[_,R,[@'9 #GMCC'3KQDG(!T4OB2WCM_[1+CR, [P">I"C@ G.3@
MC&0>N,&M"&99E#H058 @@Y!!Y!!'4&O-_AE8_P!LZ7/9R'Y6DD1=PW!<HA!
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M&Y#G)7' /X5E?%*U6[N=/AD&4DF96&2,AGB!&1STK8^)D*PZ9,B !5$0  P
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MN^,;21SC#-QTY/J:EU^[_L_54N1$TVVS.5B7=*@\P@2!2 #DMMPIR 6)P!R
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MK>]F-NIMW&3"95=DW LI)!R,9 &0/F.>IJ'P-"M_J-_=2@-+%*$1B/NKETX
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MH49Q_>9U!+$]<YZ'.1@8Q@8\O_M23^Q/*W?+]L\O&!]W9YN.F?O\YZ]LXXH
M]0_X61I^_P GSUW;MN=K[<YQ]_;MQ_M9QCG.*U=;U^#1$$URVQ"P4':S<D$X
MPH)Z UREWH.I7,#6.RQ6)U(VHLH SSD#& 0>0<=>:PO'FE2Z3I%O:SL&DCG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '->)_!G]KR
MQ7L,K0W$/ <#<"O)P5) ZD^Q!(8$$8AO_!<FHM:2SS[I+.0N6\H+ORZL!@,
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M#N!XXW5Z76?IN@0::\LT*[7G;=(=S')R3G!) Y8],4 :%8.N:%<7DJW%M<M
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M56)48[1\N7RQ.#@G<&R1GK@CJO[+C\G[%M_=>7Y>W)^[MVXSG/3C.<^]6Z*
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M6KX*\*?\(Q"UMO\ ,W2%\[=O55&,9;^[ZUT%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7/WOBO[-?Q:5LSYT9??NQ
MC <XVXY^YZCK[5F:AXLNKV[;3].2-O)'[V2;<8P2.%RAX(Z8Y);(P I-<_%>
MSW6MVXN8Q')'$RG:2R/A)3O4D#Y3G@<D8P3D$  ]3HKDK[Q3<WUP]CIT<;&
MJ))9G_=@L&.W:AW$Y&,C.&!!4=:=HWBF:.Z_LN_5%G==\;0[C&RX.1\V2"-I
MZX!P>G&X ZNL?Q1XHB\-Q"XF#%6<* @!.2">Y7CY:YK1O%FH>)3)/9) D"/M
M4W&_>> 3]PGGD$\8&0 6P36AXX\63Z!:1W:(HE=T5D?+A=R,Q&5*Y((QGH:
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M'RRPS^[0#!R1@Y+87.&[,>@\#^*?^$EMQ<%=KJQ1P/N[@ <CO@@CKR.G.,D
MZ"BO//"_C34/$L1,$40='.YY ZPXP,* &9B^22>R@#/+"MOP;XLDU9I+2Z01
M74!^91T(/1E!).!QD\CE2#AL  ZBBN*U76=6MHGO1#;HB*6,;NSR@+]XEE*H
M> 6X/3CEN*U;;Q3]NT]M4B7!$,CA7Y :,-D'&,C*^Q(]#T .@HKS_0_%>J:]
M!]I@AA7;NYD+@2$= BY&,8P2S8)Z$8(#V^(LLFGIJL4:LR2JLZDD #H=I..3
ME<?>V[N<X- '>T5C^)/$"Z5:27Z8<*@*$?,I+D!#P1E<D$X/3I6AISR/$C3
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M;]P)#8(SE>.& .[*\#=QGWNO:KI$7VRXA@>-1ETA+B101U).Y<*?O8W<>V6
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M?XHZQ'K&FPW<.=DDZD9&",)(""/4$$>GH2.: /3:*YS4_$DFG7T%FZJ(+E&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#*3@$D=O9:';V#;X8HT8C!*(JG'7&0!QQ4U[IT5^NR9%=0<@.H89Z9P0>>:
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MR<^M '.?"W_D'0?]M/\ T:]<_P#"K3$U339[649229P>F1F./!&01D'D''!
M->BVMHEHHBB5409PJ *HR<G ''6FV6G16"[(45%)R0BA1GIG  YXH \GT2XF
M\1/:Z+,,?8)',X8(RE82%0=LXR8R!D$$,=W./8*XKX?Z8S2W>I2QM&T\Q"+)
M$(W"#YL_\"R-V.K+DECS7:T <%K4+#7+1R#M,#@''!(68D9]1D9^H]:V/&EO
M87@CMK\JI??Y;$E2"!\Q#]!U'#'!.."0*A\?V$A6&_MT9Y;296VH6WLC$!T
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M';RR?:&BC,N0=Y12^5Q@[L9R,#'I4UMIT5JS/&BJTARY50I8\G)(')Y/7U-
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M,XR%8C( )[J^TF'4,>?&DFW./,16QG&<9!QG J6UM$M%$42JB#.%0!5&3DX
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M;KP];7;&66&)W.,L\:,QP,#)(STH X3QQJ2Z@EEKD09K>WN#NPIW8$BC=CH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !17">)]6NVU*'3+:;R4EAW$^
M6DG(\PYPPSR% Z^]-77KSPY>16EZXGANB%C=42-@V0#\JXXRPSG/!!4Y!6@#
MO:*** "BBB@ HHHH **** "BBB@ HKFO%%V\T]K8P,PD,PE?:2 (H\[@VWG#
MD@+D;6(P2*J>'WFOM1NKD2,;6/\ =!2S;1(HCWX0\#:0<G SGC.3@ ["BN2\
M*W3V5W=:7*[.%*RPF3>S;' # ,Q;*H<*.<D[CZ@=;0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5)W2D$A22!\PST./>J.OVVI>)X!8R6L<18J6E>964%1DE57<RDGC^+ )!ZY
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV;=VZ3?MQG=O.-V.^W;UYQCMBLKX6[/M.H>5M\OSEV[,;=N^7;C'&,=,<8H
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M_P!>Z_R@H^''_'YJ7_7Q_P"SS4:-_P AZZ_Z]U_E!1\./^/S4O\ KX_]GFH
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M\E<8.><CGFJ.N>%/^$8T>YMM_F;I$?.W;U>(8QEO[OK0!L2_%2V$?VA(YWB
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M&2,UE1_$>!76*XCFM]_W6N(MBDY QG)]>2< #J165XE_Y#-GYO\ JO+;;O\
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ML!N&1D=B0.N0.OEUJ&*#[<S@0[ ^XY'RL 1QC.3D8&,D\8S6!%"L6C84 #[
M3@#'+0DD_4DDGU/-</J>_P#L"WV;MOG'?MSC;OEQNQVW;>O&<=\4 =K_ ,+.
M@QYWE7'D;L>=Y/[K&[;NW9SC/MGMC/%=;#,LRAT(*L 00<@@\@@CJ#7'S>&+
M[48BAU /%*A!Q;1897'8ANA!Z@_2MWPMH7]@VR66[?Y>[YMNW.YBW3)]<=:
M.=\<:A)J%S!H43%!< M*PX)C&<JK<X)"MGCGY1G!85M1>!;&./R!;Q[<$9*Y
M?G.?G.7SSP<Y';&!7.^+_P#B5ZI9ZE+Q 5,1;LK'> 6)P /GSUSA6...?0*
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M^/@;/(W_ -^+=G?^&,>] '8>(_B!;^'I1;3A]S1[P54%<?, .H.25P.,<C)
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M\$X5%I(X W&<@G') 1"!GT&3CZGUK0UGP?<I=G5;"55ED"JZ3+E"J@9&X D
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MD9BPEVMG<H4CA0,8'3'K6W10!R2?#:&W)%O-<0(QSLAF*IG !/()R<<Y)_+
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M2K:73XV<QS[]Q8J6&] AP0H'0<<'FN@HH S] T1-$@2SB+%(]V"Y!;YF+'.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW=%<_KOC!-.BAFB7S7NF00H&"%M^"#EN0,$<XX) .,Y&/>>(M2T2-;V\C@,
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MZ&QN=1%S$?*EG!42I\C@22$$;AAAT/?L: *]K=+XBUE;FV.Z*TA*N^#M).\
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M$EBJ @'+9;YCR,>E7NAV]^V^:*-V P"Z*QQUQD@\<U;AA6%0B !5   &  .
M !T H X_PCXXLQ91;Y50PQ*K*Y ?,:@'"YRP.,C&<].N0.?\-0M<6NJ:D 1%
M="8H&&&P%D)/ICY\<$\AAVKT.Z\/6UVQEEAB=SC+/&C,<# R2,]*NS0K,I1P
M"K @@C((/!!!Z@T <O\ "W_D'0?]M/\ T:]<O\.);>/2YS>8\CSR'R">JQ <
M*"<Y(P1R#SQC->FVMHEHHBB5409PJ *HR<G ''6HK?28;9&@CC18WSN544*<
MC!RH&#D<'VH \MU>>+PHR/H]R9&EE.;<,)D(..@7H> O)WL#PW!SZ[5&RT.W
ML&WPQ1HQ&"415..N,@#CBKU 'G^C?\AZZ_Z]U_E!5?P1+'%<:L\V/*65B^1N
M&T--NR,'(QVQS7H":=$DAN BB5A@N% <CC@MC)' _(46VG16K,\:*K2'+E5"
MECR<D@<GD]?4T >5:V+/P_$=0TFZ*2.4Q$KB16!!&"C98$ ELOG!R, D8U?B
MBTMYID$TB$/OB:0!2-I:-@<@Y( 8XY[X'6NXM?#UM:,)8H8D<9PR1HK#(P<$
M#/2KLT*S*4< JP(((R"#P00>H- 'G_Q)N(_$=@9;1UD$+I(X0Y8*58<J,D$9
MR0V, -GIBJ]KI>@7$0N?D4%22KS.)!CJ"GF9S[ '/\.01GT"QTF'3\^1&D>[
M&?+15SC.,X SC)J+_A'K;?Y_DQ>9NW;O+3=NSG=NQG.><]<T <5X]T))-*06
M(_<1,LH'SD[&#$D9R?X]QSC SZ8K0U_QU:7UA(T3[GFAD41KS*"4;.Y <@*
M2S'C R"<C/:UGV_AZVMMWEPQ+O4JVV-!E3U4X'(/<=* ,3X6_P#(.@_[:?\
MHUZROC7_ ,><?_7PO_H$E=U:VB6BB*)51!G"H JC)R< <=:;>Z=%?KLF174'
M(#J&&>F<$'GF@#A_B/\ \?FF_P#7Q_[/#1\:_P#CSC_Z^%_] DKN+G3HKIE>
M1%9HSE"RABIX.02.#P.GH*+W3HK]=DR*Z@Y =0PSTS@@\\T 6*\Z\4W2Z=K-
MI<S'9%Y)7>P(7)\T8STX++GT!!.!S7HM5[W3HK]=DR*Z@Y =0PSTS@@\\T <
M%\8+M+NPCEB970W"X9"&4X20'!''6MKXI?\ (.G_ .V?_HU*W7T.W>,6YBC,
M2G(0HI0'GD+C /)_,U8NK1+M3%*JNAQE7 93@Y&0>.M 'EOC#3P]EIMY(I:"
M%(A*%SNVNL?IC .TC.1R5 Z\:$ND>'XX_/)CVX!P)I"_.,?('+YYY&,COC!K
MT6&%85"( %4   8  X  '0"J5KX>MK1A+%#$CC.&2-%89&#@@9Z4 6K2U6T1
M88QA(U"J,DX"C &3STKA=>!\,:D-7(8V]Q'LF8*6\LC:H/   )"=22?GP,X%
M>@44 8,OCJQCC\\W$>W . V7YQCY!E\\\C&1WQ@UR0U)=&U;[=<AHXKZW387
M4C:<1@J^>%(*?-@G;E2<#)'=VOAZVM&$L4,2.,X9(T5AD8."!GI5JZM$NU,4
MJJZ'&5<!E.#D9!XZT >=?$G58O$0@TJT=9)9)E;*'>B@!ERS+GUR<9PH)..,
MV]9_Y#UK_P!>[?RGKM;'28=/SY$:1[L9\M%7.,XS@#.,FGOIT3R"X**95& Y
M4%P.> V,@<G\S0!P_P 1_P#C\TW_ *^/_9X:/B/_ ,?FF_\ 7Q_[/#7<7.G1
M73*\B*S1G*%E#%3P<@D<'@=/047.G173*\B*S1G*%E#%3P<@D<'@=/04 >?_
M !8O5L+BPN'R5BE=B!UPK1$XSCGBI?B)XMMM1L_LMNXEEN3&$6/YFX=6Y Y4
M]@"-Q)QC@XM^/M.ENKO3WC1F6.?+E5+!1OB.20.!P>OH:ZJ+0[>*3[0L48ER
M3O"*'RV<G=C.3DY]: . \0WT^ER66D23&WMS!&LDL8(RR<$"0C@?*HSQ@-E\
MKQ5'35B36K=()WN%6-\O))YI!\N0[0P ! !!XS@D]\@>IWNG17Z[)D5U!R Z
MAAGIG!!YYJ&#0[>W972*-6C!"E44%0<D@$#@'<>GJ?6@#C=&_P"0]=?]>Z_R
M@HUG_D/6O_7NW\IZ[A-.B20W 11*PP7"@.1QP6QDC@?D*'TZ)Y!<%%,JC <J
M"X'/ ;&0.3^9H XKQM<_\(Q=PZRJDI(&BG"[1D8RG49+<$YSR$5<J.NA\--+
M>VMC=S8,UXYE8X4'#\KRO4'[P'&-Q&!S4/Q,LI-4C@L(T8^=.NYUC\Q44<%B
M?X3\P(/&0&!(&<]A#"L*A$ "J   ,  <  #H!0!%J,L<43O-CRE1B^1N&T [
MLC!R,=L<UY5K8L_#\1U#2;HI(Y3$2N)%8$$8*-E@0"6R^<'(P"1CUVL^U\/6
MUHPEBAB1QG#)&BL,C!P0,]* )=)N'N88Y91MD>-"RX(PQ4%A@\C!['FN%\56
M[^)-3BL8)%C-G'YI<H696+*0,' ;^ ^G)R2>*]%J&.T2)FE55#R8W,  S;1@
M9/4X'3/2@#SKQUX1O9[1Y)KKSUA_>;/(CC^[D$[@W923CG/3&<57^(VL#6-*
MMKL8S)*A; ( 8)(' !YP&!']3UKU.J+Z';O&+<Q1F)3D(44H#SR%Q@'D_F:
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MWT#<KLXF0$!MN.@R"V>I<GYB,5U_@C03H=I';, ),;GP /F8Y()!.2O"YSR
M.W%9'C/3&UF]L[7RV,4;-)(YB#QX'(0MVW;"&&0/F4D-@ =K0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !17/^./%/_"-6YN NYV8(@/W=Q!.3WP #TY/3C.1GC1-
M5B42"\1Y!M)1X%6,G(W*74;L=>0H)_V>H .PHKG_ !KXK_X1B%;G9YFZ0)C=
MMZJQSG#?W?2N@H ***R?%.N_V#;/>[=_E[?EW;<[F"]<'USTH UJ*J:3??VA
M#'<XV^;&CXSG&Y0<9P,XSZ5;H **** "BBB@ HHHH ***J:M??V?#)<XW>5&
M[XSC.U2<9P<9QZ4 6Z*R?"VN_P!O6R7NW9YF[Y=V[&UBO7 ],]*UJ "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPR=R @\]-PP=JL,AL8V]R: ./O-/BLXUDT^TO8KN(J4D:-N<<-N&YA@C.0%
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MN[B-Y)!N;YF/FDG.<CE1P"![5I6F@ZA<ZI#J=RBB,(PPCJ?+!1P$/0LP+<D
MC)X..!>\6Z!="]@U>T596B78T98(<'?DAB0.0Y'L<'##( !D^,]+CTJXTNV@
M7;&EPV!DG&98B>22>I/>M#GP]JW\(@U)?]E0)(Q^)))/MN,G<BCQ#I-WK<MA
M=&'889BTJ^8C;!YB8.<C=D+G@'TZUI_$#09=4A22U ^TV\J21\+G@\C+$ #H
MQSP=H&* ,^V8ZUK#2 DQ:?%M!5P5\R0$'Y>QP6!QW09/:N2TW48_$K27E]!=
MW'[QPB0@O#&I"D %2AW #![$8)&>:]"\!Z/+IMN3<Y$\TLDD@)4_,QQQLXP0
M <>I/T&+IFC7OA&22.TB6XM979E02"-T)QU9\Y&..K9V@_*200!GP^EFMKB6
MT2*:.QVEXA<(P96RN5#'C!)8XR3QGKN)Z7QIK+:-9S74?WU4!>G!=@@;D$'!
M.<8YQBI="N+NYW274:1*=NQ%?>XQD-N8?*<\%=O8X/-3:_HRZU!):/P)%QGG
M@CE6P",X(!QGG&#Q0!Q^@_#BVU2V2YNR\L]Q&KF1G;<-Z#:!R0=HQC<#D^V%
M!X+)UI+O1[TM.MO-MWNQ#,-YP#@[N&3/WCUQT%2Z9/JNBPBR^S).8EVI*LRJ
MN HV@JVTG;T/W<@>OS'6\$>%GT199;AE>XN)"\C)G;U. .@ZDGA1UQT H XG
MX7^#+36[9YKF/>XF90=[KP$0XPK =2:/!7@RTU*YOH9H]R03;8QO<8&^08R&
M!/"CKFNK^%^@3Z);/#<KL<S,P&Y6X*(,Y4D=0:/!6@3Z;<WTTR[4GFW1G<IR
M-\AS@$D<,.N* ,1+[^S]8O[G&[RK,OC.,[4A.,X.,X]*?X-\(1>)H!J6H%IY
M9BV-SLH0*[#: I'!.3CH.  .2=.W\+22ZG=7,R?Z-<6_EYW#YLK$", [A]T\
MX'UZ54\/V^I>%U:Q6!;F%&/EN)4B.&)8Y#9/4]QP<C+#& !GCK4IM$BM=/$D
MKF:4AI(R!.41AA!@<N0P&[(+%>1\Q%<_>:?%9QK)I]I>Q7<14I(T;<XX;<-S
M#!&<@* 3Q]W(KL->\)W6L00R.\8OK>4NKC=Y8R^0HR.@ 7DJQRN#U)J:'6-5
MG41_9(XY"!F22<-&".2=B9?!Z  G!(R2 : ,'XJW#W.FV\LHVR/)$67!&&,3
MEA@\C!['FM"_\%'0K2::RWO?-'AI=Q,C[G5I" 20"0#C'S=,$MR;?Q0T"?6[
M9(;9=[B96(W*O 1QG+$#J171:T\Z0NUJ%:8#*B3.TX(R.".2,XY SC)Q0!YQ
MX$MM,)CC^>&^B9=WF,T;EP1N4#.PAB2FW&\KG(SS6Q\99FAM(G0D,MRA!!P0
M0DA!!'0BJ_B71+[QEY<$MNELD;%C(\JRM@X!5=G/3D@X#$#YACF[\4K4:FMM
MIP)$D]RN,*6PJJP=L#LNX$\CCV!( .B\4Z%_;UL]ENV>9M^;;NQM8-TR/3'6
MK>DV/]GPQVV=WE1HF<8SM4#.,G&<>M9GC;Q V@6KW2;?,!4*'Z$E@", @D[<
MG@]L]!6GI-P]S#'+*-LCQH67!&&*@L,'D8/8\T 6Z*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !535=332XGNI3A(U)/3)QT R
M0,D\ 9Y) JW63XJT3^V[66SS@R+\IS@;E(9<\'C(&>,XSCF@#D-,^,\-U,(9
M(F2-FPKEU/5@ 6!P%&.2=QQ[]:]%KP_3/A#>2S".<*L2M\SAU^90P!V@;CDC
M)&Y0/7'2O<* ,GQ5K?\ 8EK+>8R8U^48R-S$*N>1QDC/.<9QS6%X.\*17, O
MKQ5GN+H"1FD4/@,,HH!&% 4C( Z\9VA<:'Q$LFO=/N$7 (0-SZ1L'/KSA3CW
MI_@+4TU"Q@:,_<C6-AQD-& I!P3C.,CO@@XYH Y?QAI\?@ZX@UBV4)&7\N:-
M. 0PZA!M&<*3U W!3C.3787/BB*WNX]+(;S94+ @#9@!CR<YS\A['M7+_%C_
M (F0M]*BYGFF# =0% 92S8R0/FSG!&%8]J-9_P"0]:_]>[?RGH ZC6_%$6CR
MP6\@8M=/M0J 0#E1SDCCYATSWIFM^+(]*<6^R664J&\N",NP4DC>>@QD8ZYR
M1Q7+_$:93?::@(W"<$C/(!DB ./0X./H?2M/5/%MQ->-I-C&ADC4,[SD[ "H
M/"KR?O*,^I(VX^:@#2\-^,H-?9XH]R2Q$AHY0%<8X)P"> >#W!Z@9&>=^''_
M !^:E_U\?^SS54\)>=_;-S]IV>;]G&[RMVS_ )8XQNYZ8SGOFK?PX_X_-2_Z
M^/\ V>:@"[X1UFTM[.2YL()?*27!C4%Y"Q" D NV1@CN. 3CUYKX1ZTME$81
M!*[2S@&6.+<@&% #/D8"Y)/H#GO6Q\%/^/.3_KX;_P! CH^"G_'G)_U\-_Z!
M'0!L>$KFTFN+M;6-DE67$Q8DAFW/R/F;C(;LO4<>C)/B/ SM%;QS7&S[S6\6
M]0<D8SD>G!&01T)KFO#._?K/E;O,W2;=F=V[,^W&.<YZ8YS3_A_I=Y>6<;6]
MZ(T!<>6((Y-IWDD%B<Y.=W/8CMB@#NM'\1P:M!]MC8>7@EBQ VX&6#>A'?MC
MD$@@UA6_Q1M9MT@280(Q4S>43$".F2"2,Y& 5SR,@5B:UX/ET"ROIA*TLESL
M9BL>PX$A,APK'@ACNZ #/:NK\*>3_9T.=GE?9UW_ '=GW?WF[MUSNSWSGO0!
MS_P4_P"/.3_KX;_T".NJ\6?\>=S_ ->\W_H#5ROP4_X\Y/\ KX;_ - CKJO%
MG_'G<_\ 7O-_Z U '-?#CP];7=A#++#$[GS,L\:,QQ(P&21GI7076KPZ"\-G
MY;)',VU&C11$&8G"':<@D_[.#G.>&QQ_@+P%9:K917,\6Z1]^3OD&<2,!P&
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M(50> ,GZL..,C/S"N/\ %7VS[9I_VWR?^/@;/(W_ -^+=G?^&,>] &K\1_\
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MG>*88R>2 &'NS8Y3' )(R:PO&7BIO$VEBYC1D"W(610=PP%)&2 ,KDKU ^;
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MXCQ5XDCUF\T]4#I)'<#?'*A1UW/%MR#QR!D8)XQG%:ME_P AZ7SO^?<>3O\
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M8-D8( .#WZX?I?CR*_G6Q:.:&5U+*)X]F0,GCDGH#R1C@C.>*P=>A677;0,
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M/#5CQLXT.[MM9+$1Y\B49(^5@S X"G(7EB.Y"X&>: .EO/$$5K<16!R99PY
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MRI!7=N!X&,#;MXZYZU:USP+!JTRWFZ2*91C? P1CQCDX/('&1@XX.0!CHZ*
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M_$'AB/6S&[/)')"6*/"^QQN&&&<'@\9XSQUP3FOHG@B#2I#=Y>6<Y_>SOO<
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M6*Z>6>26%PP:20.3M(95.5^Z"">,'YCD],=;10!CZWX7BUB6"XD+!K5]R!2
M"<J><@\?*.F.]%MX7BM[N35 6\V5 I!(V8 4<#&<_(.Y[UL44 %>2?"_PG'J
MML]QOEBE$S+YD$A1BH1#L/48R<],Y YKUNJ]EIT5@NR%%12<D(H49Z9P .>*
M ,_PSX5@\.1F& 'YCEF;!=O3) ' [   =>I).9)\.(%=I;>2:WW_ 'EMY=BD
MY)SC!]> , #H!75T4 8]KX5AM;>2R3=MG#^8Q8L[,Z[6<EL_,>O3&>U6- T1
M-$@2SB+%(]V"Y!;YF+'. !U/I6A10!RE[\.XKEI66:XC6=F9XXI<1DN,,=I4
MYW=\_3I@5JV_A6UMX&L%C40/G<O)R3W))SGI@YR,#!&!C6HH X__ (5C!CR?
M-N/(W9\GSOW6-V[;MQG&??/?.>:Z Z%$MN=/0;(FC9,)U 8$$@G//.<G.3R<
MUH44 9^@:(FB0)9Q%BD>[!<@M\S%CG  ZGTK$MOAQ;V]O]A5I=HF$JN' D5P
M  00H'0=P>N>N".KHH YK3O $%K*+N1I9Y4QL:XD\PKC/3@#J<\YP>1@UTM%
M% ')'X9VRR/)&\L:2D;XHI-D3#NI &=IR>,\9(7 J_H7@V#1[>2Q3<\4I8MO
M(R=ZA2,J%P,#Z^];U% ''K\,8&"QRRW$L4?2.6;,? *CA0I& >,$>G3BNMAA
M6%0B !5   &  .  !T I]% &#XD\&P:^R2R;DEB(*R1$*XQR!D@\ \CN#T(R
M<TA\.+??%.S2M+#)O\QW#.Y!4@.Q4DA0H  Q@9[DFNKHH Q/$'A"#72LD@99
M8\;)(VVR+@AN#TZ],@XR2,$YJ+2_!<=C(MR\DTTD>=AGE+[-P(; &!\P/.0>
M@QBN@HH Y2]^'<5RTK+-<1K.S,\<4N(R7&&.TJ<[N^?ITP*NS^"K9[5M,13'
M"Y!.P_-D,&SN;=D\ <YXX'08WJ* .'\8V\%FEEIEP#]D+A6D;''E)A%+;?E+
MGJP*G:&Y )(Y_P 5:5INGP^;IK@7>]1']GG9W)8[2N S$ J3Z<X&><'U6:%9
ME*. 58$$$9!!X((/4&J5KX>MK1A+%#$CC.&2-%89&#@@9Z4 9EEX7^T2V^J7
M);[5% JL 5V;BK!L@#KEST('3'%6];\+Q:Q+!<2%@UJ^Y I !.5/.0>/E'3'
M>MBB@#G-<\"P:M,MYNDBF48WP,$8\8Y.#R!QD8..#D 8-!\"P:).UY&TADD3
M:WF,&SDJ68G&=S%<GG&2< # '1T4 8/B3P;!K[)+)N26(@K)$0KC'(&2#P#R
M.X/0C)RV]\$0:A MG<%Y?+W;9)'S*"V>=_&<9Z$$<#(.*Z"B@#FK3P)'$ZRR
MS7$_EL&59YBRJRG*N  O(]\C!/%3^)/!L&OLDLFY)8B"LD1"N,<@9(/ /([@
M]",G.]10!R@^'%OOBG9I6EADW^8[AG<@J0'8J20H4  8P,]R375T44 <_K_@
MJ+694NR\L<L:E0\+[&P<\<@^IZ8ZD'/&*^G?#NVT^X2_C,GFH#DL^[>S!@SM
MD$[CNR<$#/;K7444 8]MX7BM[N35 6\V5 I!(V8 4<#&<_(.Y[T7/A>*XNX]
M4);S8D*@ C9@AAR,9S\Y[CM6Q10!SFN>!8-6F6\W213*,;X&",>,<G!Y XR,
M''!R ,-L?A_;V4\=\A?S(E89+ [RV[<[DC+,=YR<CL ,#%=+10!S^M^"(-5D
M%WEXIQC][ ^QR ",$\CH<9QG  SCBI=$\)QZ4YN-\LLI4KYD\A=@I(.P=!C(
MSTSDGFMNB@#'T3PO%H\L]Q&6+73[G#$$ Y8\8 X^8]<]JV*** ,?Q-X5@\1Q
MB&<'Y3E67 =?7!(/![@@@]>H!&?>^ (K^W^Q333NHE\P,\@9\[=NW)4_+SG&
M.O>NHHH S]?T1-;@>SE+!)-N2A ;Y6##&01U'I4,_AB"ZMTT^5=\4:H!N/S?
M(, Y7!!QU(QU(Z'%:U% ')0_#:$*(I)KB2$ #RI)CY9 ^Z,*%X'!&",$"NMH
MHH J:GI46J(89T5T/9AG!P1D'J#@G!&".QKG8OAM#$/+6:X$.3^Y$Q$6UB24
MQC.TY(/.3ZYYKK:* ,'4O!%IJ$"V;1@1Q A-N0RY')![D]3G(8\L":I1_#B!
MG66XDFN-GW5N)=Z@Y!SC ].0<@CJ#75T4 8^M^%XM8E@N)"P:U?<@4@ G*GG
M(/'RCICO1XH\+Q>)(A;S%@JN&!0@'(!'<-Q\U;%% &/XH\+Q>)(A;S%@JN&!
M0@'(!'<-Q\U<E\4K5;NYT^&09229E89(R&>($9'/2O1:KW.G173*\B*S1G*%
ME#%3P<@D<'@=/04 <T/AG;-(DDCRR)$3LBEDWQ*.R@$9VC XSS@!LBK_ (D\
M&P:^R2R;DEB(*R1$*XQR!D@\ \CN#T(R<[U% '+Z=\/8+&X34 \KS(""TCA]
MV0RY8E<Y"G P0, <=<Z%SX7BN+N/5"6\V)"H (V8(8<C&<_.>X[5L44 8^M^
M%XM8E@N)"P:U?<@4@ G*GG(/'RCICO69\4)TBT^82?Q; HW!26W@C&0<XQDC
MJ0#R.HZNJ][IT5^NR9%=0<@.H89Z9P0>>: ,_P (:.='M(;4Y#*F6!(.&8[F
M&1Q@,2![=SUK8HHH X__ (5C!CR?-N/(W9\GSOW6-V[;MQG&??/?.>:ZC3]/
MCTZ-;>%0L:#  _SR3U)/)/)YJQ10 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.:A
MXYAMI&@B26=XSAQ;QF38>P8Y R>>A.""#@BG^/M3?3+&:>(X<* #R"-[!"00
M000&R#V.*/ 6F)I]C L8^_&LC'C):0!B3@#.,X'?  SQ0 :)XW@U60VF'BG&
M?W4Z;'( !R!R.ASC.< G&.:Z"O/_ (L?\2T6^JQ<3PS!0>@*D,Q5L8)'RXQD
M##,.];&H>*);?4X-+ 7RI8BQ)!WY D/!SC'R#L>] '445R_BWQ1+H]Q:6\84
MK=2[7+ D@;D'&".?F/7/:KNMW%]O$5G'%MVAC+.YVYR04")\V>AW=,9'6@#;
MKG_#?BO^VIKFVV;/LLFS.[=N^9QG&!C[OJ>M4O"OBR>\N9M+O$59X1N!BSL*
M_+ZDG)W CV."%(YS/AQ_Q^:E_P!?'_L\U '4>%_%$7B2(W$(8*KE2' !R #V
M+<?-6/I'CR36Y2MI;,]NLBJ9C($&#C+!&7)P.< YQC(!.*9X1\47?B2SDN$$
M0G67:H8.(\ (3G!9LX8].^*YWX2?;/)/D>3]G^T?/YF_S/NINV[?E^[C&>_7
MB@#O=$\41:Q+/;QA@UJ^URP !.6'&">/E/7':MBN4\,>+GU*:]BGV+'9R8##
M*_*&D!+$L1P$'/ ZU5T_Q'J/B ?:;.*&.W.=AN&9F?#,"<1GY<8Y!'7H6'0
M[6BN4T7QXEQ!--<CRY;/(F0$8W#(&TDX.X@@#.<\9/!.?IOB?5+N(ZB+>(P?
M,RQ N)V7L0>0?7[H+ ?*O*Y -OP5XK_X2>%KG9Y>V0IC=NZ*ISG"_P![TK8U
M&]6PB>X?)6)&8@=<*"3C..>*X?X*?\><G_7PW_H$==5XL_X\[G_KWF_] :@#
M%M?B4EVHEBM;MT.<,D(93@X."'QUKI=+U#^T(UGV/'NS\LJ[7&"1RN3C.,CV
MQ7G_ ("\>V6E645M/+MD3?D;)#C,C$<A2.A'>NC\0>*GTQ8+]-KV4I02':^]
M5DY63(S\O(R"N<X Y;Y0#J**YI_$[WMXEE9A7C50\\A4LJJRAHPK!E!+#_>&
M"",[6 KWWBFYOKA['3HXV,!422S/^[!8,=NU#N)R,9&<,""HZT =;17*:-XI
MFCNO[+OU19W7?&T.XQLN#D?-D@C:>N <'IQNJQ>+;O799(]-CB\J%BIFG+%'
M(QPOE_B?XLK@G;D @':T5RFL>)[C3;&6[>-5N(&52#DQ,2R#>I!!*D-D9P0<
MJ>0<Z']MO]@_M#"^9]E\W&#MW>7OQC.<9]\X[T ;$TRPJ7<@*H)))P !R22>
M@%,M;M+M1+$RNASAD(93@X."..M<5<ZW<ZWI!O%$0>2.;S 0X7RU\Q6VX).[
M &,G'6HOA;]L^S0?ZG[)^\_O^=]Y_P#@/WO_ !WWH ZC1/%$6L2SV\88-:OM
M<L  3EAQ@GCY3UQVK8KBM-\7W.H'4(T5-]FQ$0".Q;!DX(#Y)(0 8QR<X/2M
MKPQXF36;1;XE5PI\SD *R_?SR<#N,G.T@F@#;HKA+#XB2/:I=R1*9+FX,=O$
MKA2RY R68GH<@G &=O !S3[SQ%J6B1K>WD<!@!7S%A+^:H;C/S-M)!(! )SZ
MX^8 '<45R7BWQLVG1V_V11)+>D>5NX3!V\G)4Y.X #C&<DC&#I:))?AREXL)
M0J2&@+\$$?*0_)W Y!'3:<]10!MUQEE\3XK]=\-M=.H."4A##/7&0YYYKLZ\
M_P#@I_QYR?\ 7PW_ *!'0!U'A_Q;;:^N;=P6QDH>''3.5/89 R,KG@$UL5Y_
MXP_XE.IV5Y%P]RQBD'167<BY.,$G#]R1\J\<5IWWBFYOKA['3HXV,!422S/^
M[!8,=NU#N)R,9&<,""HZT =;7->)_&?]D2Q64,337$W(0': O(R6((Z@^P )
M8@ 9AT;Q3-'=?V7?JBSNN^-H=QC9<'(^;)!&T]< X/3C=RNO?;/[9AV^3YOE
MOY6=^SR_WN-_?=C.<<9Q[T =E:>,/W\.GW$317,Z,VT,KHH!?&7!&20F>!W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%)'D 4_(>=S)GYL8//.<=ZI:S_R'K7_KW;^4]=Q9:=%8+LA144G)"*%&>F<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGPX5BH8;XA@@'D<GKZFNXH **** "BBB@ HK'\+VUW;Q%;^19)=Y(*  ;<#
MX5.<Y[?C6Q0 4444 %%%% !1110 4444 %%%% !16?K\,\T#I:,J3G;M9^5'
MS#.?E;MD=#5'6-:D\/67VN8"66)(P^#M#,2JL0=O R<_=_ 4 ;U%5-)OO[0A
MCN<;?-C1\9SC<H.,X&<9]*MT %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM;LX2?D6&1@,#JZRACGKR%'Y?6N[KA_$UJ+/5;*_<G8X>'[I(#$/L&1GEB^
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MZ);/#<KL<S,P&Y6X*(,Y4D=0:/!6@3Z;<WTTR[4GFW1G<IR-\AS@$D<,.N*
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M].?,;;=R!V(4@L-VU_F4MTYQD*,=,F?7-0O;.53;0+/"4Y'F"-P^>N6X*D=
M!G.<D<9R/"'AB>&[FU:Y5(C.I B0[B,L"2S#C)V@DC.XL2=IXH Y_P  ?\@:
M\_[>/_1"U+X$\!0:U8I+=,[[_,\L;V"Q#<5.T9QDD;CD$'CC@YT/"'A:YT_3
M;FRE3;++YVU=RG.Z)57D$@9(QR:Z#P%I<FE645M.NV1-^1D'&9&(Y!(Z$=Z
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M0DOD0J<\@-&%."1GC*XR,XZC/2@#"M_"PT_3?MNGHRWDMK'ED9BQ#;&DP"2
M2 2-HSG[O.*S_ EMIA,<?SPWT3+N\QFC<N"-R@9V$,24VXWE<Y&>:Z#0[G4[
M:U^R_9D62"$!&>561RA4!2JMD$IGG=C<.< \9_B71+[QEY<$MNELD;%C(\JR
MM@X!5=G/3D@X#$#YACD ]%HKG-=\226-W:V,2J_V@OO!.'55 PPYX ^8\@[M
MI P:Z.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\LRKMW;0V ?O#!(ZC(Z\9R.:=HFEKI4$=JN,1(JY VY('+8]6.2?<]35ZB@
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MEY !QA@#T(K0H **** "BBB@ HHK/FU^"&=+!FQ/(NY5VMR!NYSC ^Z>I[4
M:%%%8^N>+K70V5+F0(SC(&&8XZ9PH.!Z9ZX..AH V**HV.MP7Y"Q2*S%%?:&
M&_:P!#%?O $,.H'45>H *Q_$'AM=7,<H=HIH"QCD0]"PP05/#*<#([@8R 3G
M8HH X^X\$W.I;8KV[:6 ,"T:PK%NQT!9#G&>H_+!P1UL,*PJ$0 *H   P !P
M  .@%/HH **** "BJ][J,5@N^9U12< NP49ZXR2.>*L4 %%%9\VOP0SI8,V)
MY%W*NUN0-W.<8'W3U/:@#/LO"GV:_EU7?GSHPFS;C& @SNSS]ST'7VKH***
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!?!J98;&5W("K.Y))P !'&223T K3;XG0,&DBBN)8H^LD4.8^ &/+%2, \Y
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M\>S;NW2;]N,[MYQNQWV[>O.,=L4 'C/6;"XM([JY5IK>21=GE$@[MK<_>0\
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M^,[<]LXSVH \]^$MZMAIT]P^2L4LC$#KA8D)QG'/%=QH&MIK<"7D08))NP'
M#?*Q4YP2.H]:\Z\ ?\@:\_[>/_1"UU'PSF6'3(7<@*HE)).  )')))Z 4 :7
MAWQ=#KT+7D>Y(XV8,9=JXVJ&)X8C&#USZUE6_P 4;6;=($F$",5,WE$Q CID
M@DC.1@%<\C(%<5X=W_V'=^7NW><<[<YVXBW].VW.[MC.>*]%\*>3_9T.=GE?
M9UW_ '=GW?WF[MUSNSWSGO0!R7PP>--+N6F!:(/,7 ZE1$FX#D<D>X^M=%I?
MB&TTK3EOH$=;9,X3JXS*5/5S_$2?O=/RKE? '_(&O/\ MX_]$+1_S+G^?^?J
M@#HI?BI;"/[0D<[Q #<Z1?(C''R,S$#<,CID<C!-=++K4,4'VYG AV!]QR/E
M8 CC&<G(P,9)XQFL"*%8M&PH 'V G &.6A))^I))/J>:YF(*?#OS$@8/09Y^
MTG ZC@G )[#G!Z$ Z.X^)D4.T^1<E)&"HXAPKEON[=S G<.0,9([5TNEZA_:
M$:S['CW9^65=KC!(Y7)QG&1[8KC]<M]1\0Q_V;) D2.RB2<2AUPAW%ECX89(
M& <\<''WAW= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$X&<8YXK8N/A=:S;8R\P@1@PA\TF($=< @D9R<D-GDX(KJ+W3HK]=DR*Z@Y
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8_N?9_,7^]YGF;9/^ [=OXY]J /2Z*Y^WN-1MHY))XX99!L\M('9,Y.&RTG
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ME '1L!1NYVE@!T)!')M>(O&K6(AAMXFDN;I<I&V%9 1G+KG(P>HX'RMEAMH
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MW/UJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 4=;TM=5@DM6QB5&7)&[!(X;'JIP1[CJ*
M\P\&S'Q'<6UC<J"-/@EW+)&.3N\L*0>,*NSJ,[E.<]:]=JO;:=%:LSQHJM(<
MN54*6/)R2!R>3U]30!Y%I\3O);^'7*L(+Z1B)$*YCC =>,$$2 R'!SG(Y"XS
MTOQ'_P"/S3?^OC_V>&NX33HDD-P$42L,%PH#D<<%L9(X'Y"BYTZ*Z97D16:,
MY0LH8J>#D$C@\#IZ"@#A/BC*+6XL+I\B**<EVP2!\T;=@><*2!U.#BHOB[J,
M5_8H\+JZBY4$HP89\MSC()YYKT*ZM$NU,4JJZ'&5<!E.#D9!XZU5_P"$>MMG
MD>3%Y>[=M\M-N[&-VW&,XXSUQ0!B?%+_ )!T_P#VS_\ 1J5R_B6%K>UTO4B"
M8K40EPHRV"L9!],?)CDCDJ.]>FW5HEVIBE570XRK@,IP<C(/'6GPPK"H1  J
M@  #  '   Z 4 <?XN\<69LI=DJN9HF550@OF12!E<Y4#.3G&.G7 .;=:%+;
M:";9A^\6,.1T('F^:0=V,%5ZCU! S7:VOAZVM&$L4,2.,X9(T5AD8."!GI6A
M0!YU<>,K2'2%B\Q6D:U$6Q3E]QCV'*\$ $')/&.F<C-CPI"TVAE$!+-!<@ #
M))+2   =2:ZVW\/6UMN\N&)=ZE6VQH,J>JG Y![CI5JUM$M%$42JB#.%0!5&
M3DX XZT <;\*M;@>SBM!(OG*9 4+ /\ ?9^%/)&TYR,CKZ''1>+/^/.Y_P"O
M>;_T!JL1:';Q2?:%BC$N2=X10^6SD[L9R<G/K5N:%9E*. 58$$$9!!X((/4&
M@#RW_F7/\_\ /U1X^_Y UG_V[_\ HAJ]*_LF'R_LOEIY7]S8NSKN^[C'7GIU
MYHN-)AN46"2-&C3&U612HP,#"D8&!P/:@#G_ (I?\@Z?_MG_ .C4K*\2_P#(
M!7_KWM?YQUW5U:)=J8I55T.,JX#*<'(R#QUILNG12Q_9V13%@#85!3"XP-N,
M8&!CTH \R\??\@:S_P"W?_T0U;'QHA9[)2 2%G0D@9P-KC)]!D@?4@5V5QI,
M-RBP21HT:8VJR*5&!@84C P.![58FA692C@%6!!!&00>""#U!H XKQMXW,5G
M]JTZ17.^,,RX<HK@D$J<[22 OS#N1C/3A_'*0);1&.]EN9'925>7>H&PY;9C
M*')  8Y )'.#CV*VT.WM59(XHU608<*BJ&'(P0!R.3U]340\,6@4H((MI()'
ME)@D9 .,=1DX^I]: ,KXFPM+ITX4$G"' &>%D4D_0 $GT'-9]GK<%[I+0QR*
MTB6#!D##>-D6ULKU ![XP>"."*[BL^W\/6UMN\N&)=ZE6VQH,J>JG Y![CI0
M!Y?=Z8]]H$+1C/DR-(PY)VAY5)& >F[)Z  $YXKN_P#A8MCY'VSS5QMSY>1Y
MN>FW9G.<\>G?.WFM^UM$M%$42JB#.%0!5&3DX XZU5_X1ZVW^?Y,7F;MV[RT
MW;LYW;L9SGG/7- 'E]IICV.@3-(,>=(LBCD':7B4$Y Z[<CJ""#GFNU_Y@W_
M '#_ /VA72W5HEVIBE570XRK@,IP<C(/'6C[(FSR-J^7MV[<#;MQC;MZ8QQC
MIB@#E?AQ=+::5%-(<)&LS,<$X"R.2<#GI74:?J$>HQK<0L&C<9!'^>".A!Y!
MX/-8_B72G:U^P62*BRL$8H$58XW)\QPIP#QD8&#\V0<BM72M,32XDM8AA(U
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MEK$>CZS;74V1&L&"0,XW&5<X]!G)QSCH">*=\2=5B\1"#2K1UDEDF5LH=Z*
M&7+,N?7)QG"@DXXSZ&^G1/(+@HIE48#E07 YX#8R!R?S-0V6AV]@V^&*-&(P
M2B*IQUQD <<4 ><>)-+MH=69]17-O=1KY;995#*$7YF!7&-ISR0 RDX'(VM.
MT+18YXD@V-.6W1^7+))S'\^3AV QC/S=>V:[6ZM$NU,4JJZ'&5<!E.#D9!XZ
MU%8Z3#I^?(C2/=C/EHJYQG&< 9QDT <5HW_(>NO^O=?Y05M^-+>PO!';7Y52
M^_RV)*D$#YB'Z#J.&."<<$@5NIIT22&X"*)6&"X4!R.."V,D<#\A1>Z=%?KL
MF174'(#J&&>F<$'GF@#SSPQJ;6&H+I=I.US:>62=V)/+PG $@XP"% Q\HW;<
M;N:ZOQ]ICZG8S01#+E00.23L8.0  220N .YQ6Q9:=%8+LA144G)"*%&>F<
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MQ&"415..N,@#CBK%U:)=J8I55T.,JX#*<'(R#QUH \P^+WBBWOH8[2%UD?S
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M')_,T 6*\J\ ?\@:\_[>/_1"UZK52WTF&V1H(XT6-\[E5%"G(P<J!@Y'!]J
M.?\ A;_R#H/^VG_HUZX_P1J4NF:/<W%N,R),V/EW8!6(,V/]D$GG@8R<C->J
MVMHEHHBB5409PJ *HR<G ''6FV6G16"[(45%)R0BA1GIG  YXH \<UR>*ZT_
M[2]]++<2[28?,^3<7RRF'&0% .#PN0"O!45K>/O^0-9_]N__ *(:O0D\,6B
M@01 ,,$")!D9!P>.1D _4 U8N-)AN46"2-&C3&U612HP,#"D8&!P/:@#G_BE
M_P @Z?\ [9_^C4KE_$L+6]KI>I$$Q6HA+A1EL%8R#Z8^3')')4=Z]-NK1+M3
M%*JNAQE7 93@Y&0>.M'V1-GD;5\O;MVX&W;C&W;TQCC'3% &.?'%F1'LE5S,
M\:JJ$%\R$ 97.5 SDYQCIUP#P$6C6<&HW5OJ@ \US)"[,Z1X8LQ&X%>>0.>-
MRL <XSZ?9:';V#;X8HT8C!*(JG'7&0!QQ4U[IT5^NR9%=0<@.H89Z9P0>>:
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MR1D@<#@\G '<U>KFO$6A/KMQ##(/]$A_>L?D8/(#A8RIY  R2>0P)'!P1TM
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,#J7&=QPA)48XY+8#9Y*U+:ZKJL2B![5'D&5\[SE6,G.!(8P-V.Y P3S@+T
M!7U#5[QM':Y<,ET$^;"%7 $FUFVXRIV98D8Q]X8&,<UXITG2_LZSVK":Z=XR
MH\UY))2Q&X.@.X%@23@(=V ""<'LO'4+7.GFWE*B>;R4 3&&E+J0J[V7@D=2
M<A<M@XQ65=VM_H^[4FM[%C'EW,2NLI'\9#L.N,Y)SWX)X( S7=-C\)75E=P
MI!EH'!DP@$C,P)+9) +,YR2/E'W>#6AXAF_M?4+;3D)*VY-Q+M*\%?\ 5=<G
M.3R,?=<'W$VHW2^+M*>8 H)(F8 LHPT1)P6/&W<G4X^7D[>V?\)[)[B)]4N,
MM-.0H=MI)2(!!R.<D@ALG+;03ZD [VO,O%,5QXJN'^P($:Q++]HWLCLV.8E.
M!R"6'.1WW*&^;TVN$MM+O_#=Q/+!&MS!=2-)M$HB9&)SGY^.<D<9)V@DKC!
M(O#NMVVE:?->1#;<QK^_$H8R&?&T;\DMAGZ<@#+?=.[':Z3</<PQRRC;(\:%
MEP1ABH+#!Y&#V/->?ZMX!NO$TIU&416\@5=D>!-DIG_6-]TYXZ!OEP".,'N/
M#]Y<746Z[B$4H." X<'@?,,$X!.>"21CJ: .2^-?_'G'_P!?"_\ H$E>@5Q_
MQ0T"?6[9(;9=[B96(W*O 1QG+$#J11<ZKJMZ/*BM4@9L_O)9ED51@_PH,YSC
M'##U&.0 <IIFLMHQUBZC^^LP"]."\LB!N00<$YQCG&*KV-A:WL(DN;6^GFE1
M29MC-R4 RIW %1U7<#QC.1Q7=VG@"&VL7TH$D2 EG.>7XP^T$< J,+G&!@D\
MDY^CW&J:)$MF]LMP(@%61)TC!4 8&&&<KTS@9QW^\0#"F@O=2TP74ZLMU83;
MT:2/$A1%4DDOC.,Y)P=VP @MS6QXU\1G4=/B6#'FZ@8T55D&1NP77/&0#^[;
MH!NYQTKK["&6:$)>",R,&#B,$QD$D8P_)!7&<]\]JX7P9X/O+"Z1;G)MK,3>
M0P,8R9&P20"6PP);!Z' SV(!%XVNS:2VVAKYY@$'SBW(,S@*R*N,#(&TEAT(
M)XX%9EXG]F-'<Z39W<,R-\PDB<QNA'*L"SD\@8QCN>H4CL_&'AF>YFBU2R*B
MYMPPP^<.N#\OH#R1VSNSN&!5BTU74;MU0VJ0H&!=I)A)E<_,JB,9W8Y!/R\<
M]10!B?$?_C\TW_KX_P#9X:KV=F/&M]=+=,QM[1PBPAB$)&]-Y*[>?E)]?F W
M;1@['C70)]2N;&:%=R03;I#N48&^,YP2">%/3-5YM!N_#]W+?6*+-#<D&2(N
M$<-@G<&;(QN)/7^(C;P& !GWEF/!5]:K:LPM[MRC0EB4!.Q-X+;N?F!]?E(W
M;3@5VTG^U=;N8&=EC,*>8%X+KMAS'NZ@$XW$<D KQG-;$.@W?B"[BOKY%AAM
MB3'$'#N6P#N++@8W 'K_  @;>2QQ)3<IK=P]H%9DB4LCG;O0)%E V#AB<8/
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M0T74[K2H<^0$60!B3M.$X'/3Y\'.20JY/'-+PAH<?CAIM5OMSYD,:1EB%10
MP&5VDX#8[#JQ!+<=!IF@3PZM<7[+B"2$*K;EY($7&,Y'W3U':L_2])OO"4LL
M-I"L]I(Q= )%C9">,9<DG  '?. 00=PH I>#=.;3M9N8&D:4K!]^0Y<@F(@$
M]R 0,]\=!TKTVN$\,>'+RUU*:^NMK++#C>FT+N/EG:%SNPN"H)&2!D\FN[H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)\6?\ 'G<_]>\W_H#5S'P]
M\,VNHZ=$TT,;,XD!8HN__6./O8W @="#D=JZ?Q9_QYW/_7O-_P"@-65\+?\
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MB>]T":"QU$)+]I8*DL)P<EL$,I"@X++T"X'/S'(J+XC_ /'YIO\ U\?^SPT
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M5N6)5%9B,NW48 Y'/YTR+XJ6T\?G11SR!02X2+/E@9P7.=H! )&"> <XKG?
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MY()[E>/EK'N/BC:P[9"DQ@=@HF\HB(D]<$D$XP<@+G@X!KFO'W_(&L_^W?\
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M3LSO%,,9/) ##W9L<IC@$D9-;O@WQ4OB: W(0H5<J5)W<@ \' R,$=ASD>Y
M+VMZY'HR"67=\S!55%+,S$$J@ [G'&<#/>L?3_B%!<SK92)+!)(,J+A!'NYP
M /F/)YQV)& <X!?XS\6MH7E0PQ^9/<L5C!(50> ,GZL..,C/S"N/\5?;/MFG
M_;?)_P"/@;/(W_WXMV=_X8Q[T =OXF\90>'&B6XW8F+ %0"!MVY)Y!Q\W8$]
M>*I0?$>"26.W,<R"=L1R/%MC?.-I4DY(;(P<=QG K'^)L*S7>G(X!5IR"",@
M@O$""#U!I_QK_P"/./\ Z^%_] DH ZCQ-XJ@\.1B:<GYCA57!=O7 )' [DD
M=.I /GGQ0\61ZK;);[)8I1,K>7/&48J$<;QU&,G'7.0>*V_$O_(9L_-_U7EM
MMW_<\S]YTSQNSLZ<YV^U1?&W9]FBSM\SSOESC=MV-NQWQG;GMG&>U 'HM%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!7U&R6_B>W?(65&4D=<,"#C.>>:Y2+X8111_9U
MN;H18(V"8!,-G(V[,8.3GUKLZ* *.CZ+#H\?D6Z!$R3@9.2>I))))^IZ #H!
M61J/@""ZE-W&TL$KYWM;R>66SCKP1U&>,9/)R:Z6B@#)T+PW'HVYD+O))MWR
M2N7=MN=N2>. <# '&,YKSKX7^$X]5MGN-\L4HF9?,@D*,5"(=AZC&3GIG('-
M>MU7LM.BL%V0HJ*3DA%"C/3. !SQ0!F>'_!]OH436T2[EDSO,F&9P<C#< $
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MS^&(+JW33Y5WQ1J@&X_-\@P#E<$''4C'4CH<5D0_#:$*(I)KB2$ #RI)CY9
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M6XEBCZ1RS9CX!4<*%(P#Q@CTZ<5U7V1-GD;5\O;MVX&W;C&W;TQCC'3%344
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M% ')0_#:$*(I)KB2$ #RI)CY9 ^Z,*%X'!&",$"M7Q1X7B\21"WF+!5<,"A
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MT^-G,<^_<6*EAO0(<$*!T''!YK0T#1$T2!+.(L4CW8+D%OF8L<X '4^E:%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ<<\  8W+CH2&&5!#57UNUU6W@DO3=1HT:,QBCA!CP@R<.X+9(&>1][C@<T
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M6SW-L%9XAN(<$@J/O=&7! Y[YQC&2*T-.O5OXDN$R%E16 /7# $9QGGFN?\
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M^;7X(9TL&;$\B[E7:W(&[G.,#[IZGM7.:%XBN;.\.CWY5V9"T4JC:7&2>5'
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M;O+**2>GWL'##KU[UH7EY>>&+.:]N95N) L>U?+6-58MM/*X+#+ \A20.V>
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M-9,[$),I:/S  ?F"@B3;P,_,,CH2.P.  ;NFZ_!J3RPPMN>!ML@VL,')&,D
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M_$EPF0LJ*P!ZX8 C.,\\T 6**** "BBB@ HHHH **** "BBB@ HHHH ****
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MSH\>[&I21-&S28"F1_G.%!X8Y0]#M SN&,^P44 0VEJMHBPQC"1J%49)P%&
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M*C21JOS*JAB5/#?*2 0 <MGC&:T** /'-7EMI94?0/,^U,Y+^2'5-I(^\'
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M8^6YO(E$0@VG<S( N=Q&%'&6W8*X;@X&<3P1HS:SH]S:Q_?:9BO3DHL3A>2
M,D8SGC.:];HH \OT'7=+M(4@OH$AN(E5766WW,2%&'R(R?F'//.<]1@G3\8"
M(Z1,\,)@5RA,;1B)@1,BY*CN<?EBN]KG_'NER:K92VT"[I'V8&0,XD4GDD#H
M#WH YK2?B7!I-C&DR.L\<*!(V5AY@ "JZN5QM;&<]L' ; SD_P!C7N@:/F+>
MDCS>;(%^5TCVXZ@Y'W59L8(!(8 !J]+\/6K6EM!#(,/'#&K#(."J $9''6M"
M@#P3Q4NFFVC.GJYD#)YCMOX!0_*V3LW,1GY1CY6Q@=>[^-?_ !YQ_P#7PO\
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MTYQC?\V*]%HH *\O^&>N1^'P^DW>Z.X-P,*5)!+A5 !7(ZCJ< @@@D=/4**
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRN[K2Y79PI66$R;V;8X 8!F+95#A1SDG<?4  ZVBBB@ HHHH **** "BN?\
M#?BO^VIKFVV;/LLFS.[=N^9QG&!C[OJ>M=!0 445CZ);7<,L[74BO$SYA"@
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ME4[@ $"[5)()7J<]1QC(  .'T4P:L@N[ZWO+J5\_.JL8@ [<)L9,#GD= <@
M5JZ/X@N]%L;LNDJI;[1;&=-L@61BBY)&&V?*<8Q_#G;C&GH5IJ7A5#9)"MU"
MI)C995B(!8D@AAR3U[XR1N/;=ETN;7K26VOE1&FSM$99M@X*;CD;F5NN"%./
M0T <YX<^',5Q:I=F207<Z"03J[!U,BYQ@-R.<-GELGD9&'_!3_CSD_Z^&_\
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M2;.[AF1OF$D3F-T(Y5@6<GD#&,=SU"D=GXP\,SW,T6J6147-N&&'SAUP?E]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 5-4U2/2HVN9VVQIC)P3C) ' !/4CM7.CXE0
M1R)#/%/!YI(#7$8C3CWW'CD9.,#()P.:O^,O%2^&8!<E"Y9PH4';R03R<' P
M#V/.![C@/B6^H/:1M>B!4,JD"+?O#%'X.25P!G."><8.* /3==UV+0XC<SG"
MKT ^\Q[*!W)_^N< $C@O''CF'5+"2+9+$TPC,?G1E1( ZL2K L" .>2.HQFK
MOQ0_UUAYG_'O]H_>;O\ 5_>3&[/R_=W=>V[MFM#XL;/[/DW[=VZ/9NQG=O&=
MN>^W=TYQGMF@!\?BB+PWIUK<3!BK10J @!.3%GN5X^6F7'Q1M8=LA28P.P43
M>41$2>N"2"<8.0%SP< US7C[_D#6?_;O_P"B&KJ/B9"L.F3(@ 51$  ,  2(
M  !T H +WXG6EJW_ "T>+?L,R(3"&[KN)&2!\WRALCD9IWCV_LEMDEO$::!I
M%V^4>Y1BK9#KD8SW[BL?Q#"L6@J%  \BV. ,<LT9)^I))/J>:S?'W_(&L_\
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M1I)3@1P[G0%W)5N1M)XR.Y7VKU>[N/LR-+AFV*3M098X&< =R>P]:X7X<?\
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M&.:RI_ =S?307-S=^9]FD#J/(5.C*2,JPZ[1U!Q53P'_ ,A'4/-_UOF#;O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S]=T*+7(C;3C*MT(
M^\I[,#V(_P#K'()!YJX^%%O<HL4DMPX3&S?*#L &"J@K@ \9X_A&,#.>UHH
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M.'W9#+EB5SD*<#! P!QUSH>)O"L'B.,0S@_*<JRX#KZX)!X/<$$'KU (V**
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MV22>CHH P=.\%6VG6\EE"I59D*NV<NV5VYR<\\D@8V@DX')J(^!8/LL>G!I
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:XF 7YLKD*I^3<5.['((. 5*YH [VBO/+/Q?)I5U%;2W,=Y%<D*&B$:O&^X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJME+;0+ND?9@9 SB12>20.@/>M#P]:M:6T$,@P\<,:L,@X*H 1D<=: /-/\
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MN** //(?$FC7"CR;=9)6 (BCM 9/4C[NW*C)/S8P#@FO0(85A4(@ 50  !@
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M(Z=*]5HH \_^''_'YJ7_ %\?^SS5Z!110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5C^%_"\7AN(V\)8JSEB7()R0!V"\?+6Q10 4444 %%%% !1110 4444 %%
M%% !1110 51U718=654N$#JCAP#G&Y<@9 /(Y/!R#W%7J* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex19-1_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex19-1_006.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *9-,L*EW("J"22<  <DDGH!3ZP?'-E+>V4\4&?,*< 9R0
M""RC;DDLH*X[YP>#0 67CFRO9?LT<RF3. #D G.W"L0%8DGC:3GJ,BMZOF?1
M]'N+NX6WA5A,KC) 8%"& W-@94*>I[5],4 %>3^+?$UP]W)>6S-]GT]X5E19
M60.2[9^7 &-PV'@]CRO3TK6]472H)+IL8B1FP3MR0.%SZL< >YZ&O,/#/B&P
M73Y+.ZF(FN3*TA>-Y,.W"MPO)&U6ZYW<Y'8 ]:AF690Z$%6 ((.00>001U!J
ME_PD-ML\_P Z+R]VW=YB;=V,[=V<9QSCKBN:^$FL_P!H60A8Y>W8H<MN;:?F
M4XZ@8.T=OEX]!S_PA\+V]]#)=S(LC^84 D 90 JMD*1C))Z^@P,<Y /38M1B
MEC^T*ZF+!.\,"F%SD[LXP,'/I4L,RS*'0@JP!!!R"#R"".H->>_#JU5GU'3"
M/]'69E"9/1S(C#=][E5 Z]L]<T[PAKO_  CEE<6]P!YFGNPV@,-P<YC.2.CN
M2 <<+@D8Y(!WMO=I<[O+96V,5;:0<,.JG'0CN.M/FF6%2[D!5!)).  .223T
M KG?AWIILK*-W.9)\RNVXL6,G()+=]NT'W!Z]2[QM>V5K$AU##*'W(G)+,@/
M\(ZCG!W?)R W44 :MEKEO?MLAEC=@,D(ZL<=,X!/'-3/J,22"W+J)6&0A8!R
M.>0N<D<'\C7D^K747V^QDMK:6U8S*K;XO)# N@P IP>&(;U! .1C&GXRT>/6
M-9MK6;)C:#) .,[3*V,^AQ@XYQT(/- '?V6N6]^VR&6-V R0CJQQTS@$\<U-
M>ZC%8+OF=44G +L%&>N,DCGBO/\ Q=IT6B7^GRVJ+$TDI1MBA05+(I^4#&<.
MPSC//7@8?=6J^(M9:VN1NBM(0R)D[23L)+ Y!Y?G&,A5!R 00 \>W:7=UIDL
M3*Z&X.&0AE.)(@<$<=:]%KRSQIX<@TK4+&:!0GG3H&50 GR/'@A1T)W<XX.,
MXSDGU.@"I?:M#I^//D2/=G'F.JYQC.,D9QD5+:W:7:B6)E=#G#(0RG!P<$<=
M:XK5]4TU+J11;M=7+8\T11>>5V */O' Z@';W&&YQ5+X1N!+>Q(&2)95*1OG
M*9,@P02<-@ 'OQR3B@"Q\./^/S4O^OC_ -GFH^"G_'G)_P!?#?\ H$='PX_X
M_-2_Z^/_ &>:CX*?\><G_7PW_H$= '6^)YFAM+AT)#+!*00<$$(2"".A%8O@
M77%33H;B[E +%QOF?&3YCX&YCR<#CV%:_BS_ (\[G_KWF_\ 0&KRK6?^0#:_
M]?#?SGH ]=EURWBD^SM+&)<@;"ZA\MC VYSDY&/6GW&K0VSK!)(BR/C:K.H8
MY.!A2<G)X'O7"^._!MII6FOY4:AX?+PY'[PDN%)+#!.0QX/ [ 8&,_7?#$$.
MC?;-NZ=UBE:5SF0M*R;LMUQAB,=.YRW- 'I]U=I:*9965$&,LY"J,G R3QUJ
MK<>(;:VV^9-$N]0R[I$&5/1AD\@]CTKDO%<S3:&'<DLT%L22<DDM&223U)JO
M;^#;2'2&E\M6D:U,N]AE]QCWC#<$ $# '&.N<G(!W5]JT.GX\^1(]V<>8ZKG
M&,XR1G&15NO*M \,07.D2WLJ[YGAE.]SEE\G<L84]5 "#@=>ARN *^H:Q+;Z
M#  QS*YB)).=@:0X!STP@7'(VY&* /3?^$AMM_D>=%YF[;M\Q-V[.-NW.<YX
MQUS6A7E]WX>EE@:TCTI$RI"O]HB9U)Y#;C\QP>V[D?+TXI_BZ^N],T>.*Y)$
M\C^7(2P+;<N1\RG!)50"3G()SR<T =5K^N6]_:7*0RQNPMIB0CJQQL(S@$\<
MUA>%H//T5$\[[/G=^]SMV_OSWW+UZ=1U_"K'B/X?V=M82(D8#01,ZR#'F%D4
MM\S8Y![CICH!@8PO^9<_S_S]4 >CZ<RVMNA>0.J1+F4GA@JC,A))X/7.3]:+
M+7+>_;9#+&[ 9(1U8XZ9P">.:Y6ZO;*UTZT.H891%"R)R2S)$/X1U'.#N^3D
M!NHKE]6NHOM]C);6TMJQF56WQ>2&!=!@!3@\,0WJ" <C& #L/%WCG^QKBWM4
M:(B23$V\_,BDI@G##;PQ.6&.,]*ZBRU&*_7?"ZNH."48,,]<9!//->?_ !)T
MZ(WM@2BYEGPYVCYP&B #<?,,<<YXXJW\3V70[ Q6J+&L\JJPC79P5)/W<<G8
M%.<Y7(H ZW_A(;;?Y'G1>9NV[?,3=NSC;MSG.>,=<UH5Y?=^'I98&M(]*1,J
M0K_:(F=2>0VX_,<'MNY'R].*[CPC%<16L:7F?/4$-DACPQVY*D@G;CG.3WYS
M0!S_ ,7=1EL+1'A=D8SJ"48J<;'.,@CCBM.T\$?9G67[5=ML8':\^5.#G!&W
MD'N/2L3XU_\ 'G'_ -?"_P#H$E;=IH-_$ZO)>[T# LOV:-=P!Y7(.1D<9[4
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MKFO+[O4WL= A6,X\Z1HV/(.TO*Q P1UVX/4$$C'-:%WX>EE@:TCTI$RI"O\
M:(F=2>0VX_,<'MNY'R].* /2+W48K!=\SJBDX!=@HSUQDD<\5#+KEO%)]G:6
M,2Y V%U#Y;&!MSG)R,>M>:^/(KB+2+=+S/GK. V2&/ EVY*D@G;CG.3WYS6G
MX[\&VFE::_E1J'A\O#D?O"2X4DL,$Y#'@\#L!@8 .ZN-6AMG6"21%D?&U6=0
MQR<#"DY.3P/>N?\ BE_R#I_^V?\ Z-2N5UWPQ!#HWVS;NG=8I6E<YD+2LF[+
M=<88C'3N<MS6QXKF:;0P[DEF@MB23DDEHR22>I- &UH&N6]A:6R32QHQMH2
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MM>+O ]F+*79$J&&)F5D #YC4D9;&6!Q@YSGKUP0 6_B/K9TNSD,<@29@ GS
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MBBB@ HHHH Y_QOH$NOP"TA=4#R)YA89^0<G QUS@CD9QC(%;L,*PJ$0 *H
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M%B>-@Z#)QR.#@@D!JM^!_"<^A2W,UPZR&X=6#+D$X+DDK@!2=W0$@<BNMHH
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M^]_=W;>.N?\ :W?-4MYX#\K36TFW*[VVDNXVAF#JS$[03T&!U(  R<9KL**
M,3^Q'^P?V?E?,^R^5G)V[O+V9SC.,^V<=JS=+\.WFDV$5I;R1K/"Y)R"T;*7
M9BA)7< 0PY SD8!&<UUM% '%'PE=ZQ<0W=_)$%M6#(EN&P3G<26?D<JOKD#
MVGDZMEI%S%?RWCR9MGC 2/>YVMA,G81M'W6Y!SS[FN@HH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***R==U&YL]OV:W\_=NW?O
M5BVXQC[P.<Y/3ICWH UJ*X2'X@7<T[V"V69XUW,OVE. =O.=N#]X=#WI_BCQ
MK=Z/:"[>!8I3.$V.XE!4H6W90K@Y&,>WO0!W%%%% !1110 45S_B3Q7_ &+-
M;6VS?]JDV9W;=OS(,XP<_>]1TKH* "BBB@ HHHH ***Y?Q;XHET>XM+>,*5N
MI=KE@20-R#C!'/S'KGM0!U%%%<IXA\:2:;=QZ;!!YTDL>\?O1'_?R.5(X"$]
M: .KHKCV\?MIK!=1MWMU;&V0,)H\D,<%D'!^7@#)[D <UV% !1110 4444 %
M%%% !14-W=+:(TTAPD:EF."<!1DG YZ5%I>J1ZK&MS VZ-\X.",X)!X(!Z@]
MJ +=%%% !1110 4444 %%%9^FZ_!J3RPPMN>!ML@VL,')&,D 'E3TS0!H444
M4 %%%5]1N6M8GE12[(C,$'5BH)"C /)Z=#]* +%%<IJGBR:VTYM3\KRY1C]W
M+N.,RA.?N'D<CIU'6JOB?QK-I5A;ZA&J&2?RMP8,5&^,N< ,#U'')XH [6BB
MB@ HHHH **** "BN7U#Q1+;ZG!I8"^5+$6)(._($AX.<8^0=CWKJ* "BBL^'
M7X)IWL%;,\:[F7:W .WG.,'[PZ'O0!H4444 %%%<_P")]=ELI+>TM@IEN9",
MN,JJ(,NV Z'(!! SR 1UQ0!T%%%% !1110 445R^G^*);C4Y]+(7RHH@P(!W
MY(C/)SC'SGL.U '44444 %%%% !1110 45GZ)K\&MH9K9MZ!BI.UEY !QA@#
MT(K'\)>*)=8N+NWD"A;67:A4$$C<XYR3S\HZ8[T =11110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !117+_$/Q1+X;MUN(0I9I0I#@D8*L>Q
M7GY: .HHHHH **** "BBB@ HHHH ***J:IJD>E1M<SMMC3&3@G&2 . ">I':
M@"W14-I=+=HLT9RDBAE.",AAD'!YZ5-0 4444 %%<_X8UV6]DN+2Y"B6VD R
M@PK(XRC8+N<D DC/ ('7-=!0 4444 %%%% !1110 45C^%];EUB(RS0- P<J
M$?.2  =W*KQSCIVZUL4 %%%9^B:_!K:&:V;>@8J3M9>0 <88 ]"* -"BBB@
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M#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \_P!&_P"0]=?]>Z_R@H^-?_'G'_U\+_Z!)1HW_(>N
MO^O=?Y04?&O_ (\X_P#KX7_T"2@ \37FIZ7 =4,J*%9"UOY:LJJ6"A?,ZL>1
MNQM'+;2 !G3\3>.1806\L.T27A39Y^0BJP!+,5[+N //?(R 13OBE_R#I_\
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M<F,A 7!\LJA9@VTG<1D'C.<\5##XDT:X4>3;K)*P!$4=H#)ZD?=VY49)^;&
M<$U7^*3_ -GS:>T2;O*D8K&@QG:T6U  #C.,# _"@"WX@O-3\.*NHO*DT2L/
M-B$:HJAB  K<L0"< GGH2&&['2ZDUQJB1/8RI''*NXR,A9P" R%4.!SR&W=
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M)P!G%P .  .@':JOC[_D#6?_ &[_ /HAJ/\ F7/\_P#/U1X^_P"0-9_]N_\
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M=(KB59X3*#YGEB-P^U@$VJ<%2,D'&<Y!(XSN^.U;1;VWUS:SQ1*8Y N,J#N
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MRPP1VM>5?#U8%U6<6JLD'V?Y VX'!,1W?,2<-]Y<]B.G2O5: "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7'_ !0T"?6[9(;9=[B96(W*O 1Q
MG+$#J17844 %%%% !1110 4444 %%%% !1110!S7AO1)(KJ[U"X50\T@6/ !
M/EQC"MD$D;QC(XY7..@$XT!KB].H3$%8D"P*K-QN!\QF4\;CG P<;<9&0"-Z
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S]?MYKF"2*V*K*ZX5F+
M#/!.5Y! SM([XIVBZ/'H\*6D.=D8P,G).2223ZDDGL/0 <5>HH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD\ ^Y^M %BBBB@ HKFOB#KDFD6NZWW>?+(D<>U0QW$YQ@YSD*0."<D<=QTM
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M9(WCA$V,LQQ\PX)W?-R""HX((- &AX;NY(M0^RVD\EU:B(&9Y9/-"-\Q7:_
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M (_-2_Z^/_9YJ] KSQ;.X\)7T]VD4DUI=G)\D!Y YRWW< X!W#LNUAEBPQ0
M_P"-?_'G'_U\+_Z!)1\3[VXAFLHK61HWED9>&(4G=&%W 9! )Z$'C/%&L0R^
M.V2T\F6"VC8/(\Z;)"<,H1%R1T)R><=P, /8\?:=+=7>GO&C,L<^7*J6"C?$
M<D@<#@]?0T 9GB^&?PB(=2%S-*?. D1WQ&VX%FVJ!A <$ 8;&1@@KS;^(_\
MQ^:;_P!?'_L\-6/B[ITM_:(D*,["=20BECC8XS@ \<T>/M.ENKO3WC1F6.?+
ME5+!1OB.20.!P>OH: ,_QEXO!O#IKW#6T$:*7=$)=V)5MH9<E1M/!P.=P(8$
M52TWQ<FFW<,5I<RW45PRI(MP7+(2P"NK,J_WN@'.#GJI7:UK3I]#U ZQ!$TT
M4T8294YD7E5RJ\$\*I[]&SM&"-O2_%$FIR+&EK,D?.]YP(MO!*X4DE\D8.,;
M>">M '%/JYU+4+B"^NY;58V*1)&QA4@$D,6.5&5 .6^]N&TX %;OCN\N?#VG
MA8I&=]^QI2/G"-NP21T8?*F_J2<\,1@\0ZVMR9;>ZT^64QEUC*Q^8A4@882
M90MQG;DKZY&!%X5@N_"-B!+"TK>?S'&P9TC; ) &03N!.U3_ !9)'S8 +7@R
MRCF*W-O?2W&T8D61]RG((_U;#=&=PRI.3@$<@YKLZ\O&D-JU];W-E:/:I RF
M5Y%$&X9R5"#KP",C.=V&PH!KU"@#BM>TI2[FYU%X9&W&-5E2!54D[ 4R"^#D
M%L@L!CC%2_"W79=8M-\YW-'(4#'[Q 52"3W/S8SWQSDY)Y3P[IC:,TT%Y8O<
MW#R9678)(V)'&7<84$G);D\G> 5Q71_"+3I;"T=)D9&,[$!U*G&Q!G! XXH
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M-/@G>YMYU)#3;O,1E5B1N8 L"%Z8 &1CD-NB\/PW>NWE[ ;F5+>.9@0C_/\
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M?V=;6LJ"0KO>Y3RE5592,<G)SR>IP#A3G(M_%W3I;^T1(49V$ZDA%+'&QQG
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M:RWF,F-?E&,C<Q"KGD<9(SSG&<<US&C^%;G6;=;RXO)UFG0,ODOLC4,HV90
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MX'.X$,"*B\1/=:[=V-R+>1((YQC<C>8,/'O9P,A%XPN3DA2QX(K2UK3I]#U
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M><'3\9PMJMQIMU;JSQ>:'+*C$!6:)@QX^48YYQW]* */B^&?PB(=2%S-*?.
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MKGAJ35;VVN6V?9[;<V"6$A<\@\#! *H>H[YR.*Z6BB@ HHHH **** "BBB@
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M@#S_ $;_ )#UU_U[K_*"NUOM6AT_'GR)'NSCS'5<XQG&2,XR*XK1O^0]=?\
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MG:HMU;I>/A%>)9#D\*&4,<L<<#UXKE=3\+ZAXC M[V6*. '+"V#EGP1@'?T
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M<X9"&4X.#@CCK3YIEA4NY 50223@ #DDD] *PO!NI65]&SV 55+!G0+L*L5
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M8@@'+'C ''S'KGM0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI. =N1QD$8+94YKLZ* .'U/POJ'B,"WO98HX <L+8.6?!& =_0#D@\@'!*G
MQJ^+O""ZU L4)$4L!#0LHQM*C 7(&57I]WH0IP<8/1T4 <%K/A74M>MS;7,T
M0*A=HBW@.P(R9"5Z  D*J@%B"<;177Z'9-86\-N^"T42*2.F54 XSCCBKU%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45QGB3Q1=
MV]]%I=H(LRQ;LS!^HWD\J>F$XX/-$?BJ[TJYAL]02+;<G"20%\!AQM*L"222
MH[ 9SD\X .SHHHH **** "BL?PO<W=Q$6OXUCEWD (01MP,'AGYSGOVZ5L4
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M9C#Y9$9)0,0,YW;B%)'()^8\:WA#7(M.D&C-;-:RG<RKN\Q6&-V?,ZDX!ZY
M"[=V1M !D^"-6FN=)NYY)':1//VLSL6&(5(PQ.1@\CWH\':%=^(+-;B:\F7.
M_P KRWP1\Q!+G[S_ ##@9X X(S@'@C29K;2;N"2-UD?S]JLC!CF%0,*1DY/
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M */&,DE3D J ,Y^=LGG'RG:0&K5T[Q/-JDJ)';2QQ GS7N%$>!M;:%7=EB6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <E_PC][I$DKV#Q-'<2M(R7"L-K-C.UH^H/H0, #&3DEVC>%II+K^U+]D
M:=%V1K#N$:K@Y/S8))W'KD#)Z\;>KHH **** "BBB@ HHHH *Q_$_A\ZW&B*
MYCDBE21'"AL,F<94]1R>,CG'4<'8HH XS4--U;4XVM9&M4CE&UVC$I<*W#8#
M<$D9';V(/(Z71='CT>%+2'.R,8&3DG))))]223V'H .*O44 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <98>']0T!!:63P/ I8K]H5PZ[F)VYCX8
M=\G!))X  %7O#'A9[*674;IE>ZGX/EY$:J,850<$\*,D\\ >I;I:* "BBB@
MHHHH AN]^QO*V^9M.W?G;NQ\N<<XSUQSBL7P-X:/AVU6V?;YA9F<H25))P"-
MP'\(4=!T_$]!10 5R^G^%Y;?4Y]4)7RI8@H )WY C'(QC'R'N>U=110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_A++/_GXA_[_ "?_ !5<KXMN6O=.LY9=SB62U,JH0K2!ERRA05W$G!"KWY&
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M5;M%DEDF9<.-Z* %;"JV?7 SG"@ 8YS-:VJ^'=96VMAMBNX2SID[01O(*@8
MY3C.<!F P"  #MSKEN Y,L>(B YWK\A)P W/RG/'..>*FLM1BOUWPNKJ#@E&
M##/7&03SS7FG@OPY!JNH7TTZA_)G<*K %/G>3)*GJ1MXSP,YQG!&AX5A73=8
MN[.$!(3$K[ .-V(SQZ#]XW XYZ<# !VM[KEO8-LFEC1B,@.ZJ<=,X)''%<;H
MW_(>NO\ KW7^4%5/AMI47B(3ZK=HLDLDS+AQO10 K856SZX&<X4 #'.6^#='
MCT?6;FUAR(U@R 3G&XQ-C/H,X&><=23S0!Z5-,L*EW("J"22<  <DDGH!7&^
M&_B(E]-<Q7$D*1PR8B;>%WKN<9RS$-P!R,#GW%=E-"LRE' *L""",@@\$$'J
M#7FO@'0[>ZN]022*-ECGP@9%8*-\HP 1P.!T]!0!W\^N6]NS(\L:M& 6#.H*
M@X )!/ .X=?4>M31:C%+']H5U,6"=X8%,+G)W9Q@8.?2O-QH46L:[.DXW+'&
MCA3]TD)$ ".X^;..^.<C(/4>+&T_2H$2[11$C[HXE7&64$\(N 1R<[ODR?FZ
MT ;5EKEO?MLAEC=@,D(ZL<=,X!/'-37NHQ6"[YG5%)P"[!1GKC)(YXKR?5KJ
M+[?8R6UM+:L9E5M\7DA@708 4X/#$-Z@@'(QC;NK5?$6LM;7(W16D(9$R=I)
MV$E@<@\OSC&0J@Y (( >/;M+NZTR6)E=#<'#(0RG$D0."..M=+>VNZ_BE^U;
M,1D?9MWW^'^?;O&<9_NG[O7TXSQIX<@TK4+&:!0GG3H&50 GR/'@A1T)W<XX
M.,XSDG3UG_D/6O\ U[M_*>@#M6U:%&:(R('C7<ZEUW*H .XC.0,$<GCFBQU:
M'4,^1(DFW&?+=6QG.,X)QG!KSH:%%K&NSI.-RQQHX4_=)"1  CN/FSCOCG(R
M#;:T31]<ABME6-)[=MZH %/$AX'0<QKTQT]SD [V]U&*P7?,ZHI. 78*,]<9
M)'/%5[7Q#;7;"**:)W.<*DB,QP,G !STKA]1O+2TU*YDU%0R;(!&SJ9D3*Y*
M%1NVLQ!8 @' 8C /S7? %C#<3W-[!"JVYD7R',:AL[2LI4GY@I/0< 9( !W
M '=U1EURWBD^SM+&)<@;"ZA\MC VYSDY&/6C7+UK"WFN$P6BB=@#TRJDC.,<
M<5Q7P[\)6VHV?VJX02RW)D+M)\S<.R\$\J>Y(.XDYSP, #_AQ_Q^:E_U\?\
ML\U=A=>(;:T8Q2S1(XQE7D16&1D9!.>E<)\+;=-*FU"+.(X)%&YR!A4:49)X
M'0<G@52U.\TR:UFAL[21T5'"SI"2JMMW@F5B' 4D9SVXP5Z@'J5Q=I;;?,95
MWL%7<0,L>BC/4GL.M/FF6%2[D!5!)).  .223T KS6VT=M>T)$&7EC#,F2Q/
M[N1Q@ 9).S*J.G0<<$6O$WBC^U]/MX8V FU$I'D;D4'<!+V)VAOD([@Y&X=0
M#T"&99E#H058 @@Y!!Y!!'4&O.OBIJ:W$MMIQE"Q22XG"NH(&8]I;.<  EAG
MCH<' QZ%:6JVB+#&,)&H51DG 48 R>>E>>_$G3HC>V!*+F6?#G:/G :( -Q\
MPQQSGCB@#K?#MM9:9"QLV00!F9F63>H(4;B6+-C  SSP.:NV6N6]^VR&6-V
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M:NH>%Y;C4X-4!7RHHBI!)WY(D' QC'SCN.]=110!R^G^%Y;?4Y]4)7RI8@H
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M H21@JH[A>?EJ+P[H+>');Z^N&7RIG,@V[B0JF1CD;1SAN@SWKK:9-"LRE'
M*L""",@@\$$'J#0!P7A7PS>I:Q&"[\J)UWI'Y,<I59"7 +D*6.#SP!G..,5I
M^ _$T^JM/:704RVCA"Z9 ;[RDX/?*$Y& <_=&.7?\*\CB^6">YAC'2.*<A%]
M< ACR<D\]2:V]"T*+0XA;0#"KU)^\Q[L3W)_^L,    T**** "BBB@ HHHH
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M@[2P#* &4$ C)'#84C)H Z.N<USQU!I,RV>V269AG9 H=AQGD9')'.!DXY.
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M",XSSS5BO-/%UQ)'HT,:1[HWMX-[[P-F/**_*>6W'CCIU-:?AWQ1+IMFDUW
M8[:&VC*R"17+\(J (.06SW.!T)'6@#N**Y+1/&%UJ(CF:S98)2OSB56(#' ;
MR]JMMR02>R_-R*ZV@#!\2>,H- 9(I-SRRD!8X@&<YX!P2.">!W)Z X.-/2]0
M_M"-9]CQ[L_+*NUQ@D<KDXSC(]L5YKKVHW*ZS#(MOF1(W6-/-4>8O[T!]V,+
MD$G:>>,=ZZB_\=/9>5;-;L;V<$B!75@!N*@F0#&" 6X!Q@[L#F@#K:*Y*W\=
M/;SQV=];M;M.0(R'65"2<8+*!@YP.,]03M')9XK^(7_"/W"67DM(9(PR[&^8
MLQ954+M.<E0,YSSP"1@@'845GZ)>SW:%[F'R7#$!?,63(P/FRO'7(Q[>]<U\
M6KB2.R>-(]T;[=[[P-F)$*_*>6W'CCIU- '6ZC>K81/</DK$C,0.N%!)QG'/
M%5] UM-;@2\B#!)-V X ;Y6*G."1U'K7'Z?J-S/IKQ2V_EQ+I[;9?-5MV(@%
M^0#(R.>>G2J7@?Q1-;6$<5K;-<>2)/,(81A279@JY!+MMY(4'&5').  >FT5
MB:'XLBU6T_M'[J*K%QG<4*<L#MYZ<CC)!!P,XK'3QQ=7:FXMK&1X0,AGD6-V
M&T-D1X8D<\;=V[MSP #LZ*S]"UV+7(A<P'*MU!^\I[J1V(_^N,@@F'Q+XEB\
M.Q?:9]VTL% 098DY.!D@= 3R1T]< @&M17+Z=XLN&9#=VC012E55_,$F&? 0
M,@ 903QDCAB <9XL67BO[3?RZ5LQY,8??NSG(0XVXX^_ZGI[T =!17/WOBO[
M-?Q:5LSYT9??NQC <XVXY^YZCK[5E:M\1FL[Q]+CMVED&P)M<#<656.<K\H
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ML>U8\'CR2WN([*^MF@\_A&$@E4L2 !\JXZ\=21D9 !R,_6?^0]:_]>[?RGH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT5T-NO##.#MA&0>H."<$8([&NST/PC:Z&S/;1A&<8)RS''7&6)P/7'7 ST%
M'+Z9^XUZXW_+YMN-F[C=@19VYZ_=;IZ'T-5[[4([S7K<1L&\J)T;'9@LI*Y]
M1D9]#P>0178:YX1M=<97N8P[(, Y93CKC*D9'IGIDXZFF67@NSL9$N8HE22)
M=JE2PXP1R,X8D$Y9@2>YH Y*QU".SUZX$C!?-B1%SW8K$0N?4X./4\#D@5+X
MYF6_U&PM8B&EBE+NH/W5RC\D\9VH3CKC''(SU%[X+L[Z1[F6)7DE7:Q8L>,
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MK&BPZQ'Y%P@=,@X.1@CH0000?H>F1T)K*'P\L!$;80CRRX<C>^2P!4?-NW8
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M(Z[#1- @T1##;+L0L6(W,W) &<L2>@%&B:!!HB&&V78A8L1N9N2 ,Y8D] *
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M&L]8D^T3Q!I" "0SKG'3.UAD]LGG&!T JWI'ANWT=G>W0(92"V"<'&<8!)
MR>  * .2^"G_ !YR?]?#?^@1UZ!6?HF@0:(AAMEV(6+$;F;D@#.6)/0"M"@
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MM!(;@ %CEF/H!744 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 >>++/XOOIX5GD@MK,["(6*2,QR"<C(Q
MN4\GHH "@LQ%>W-WINL064MP\D1C8J"V,J$DVAP,!F!7ECDG /'06%BG\(7T
M\RP23VUX=Y,*EY%89)&!@8W,>#U4@AB58&DMY+>ZW;33)Y>Z%RB'[X3;-C?V
M#$Y) ^Z" >0: -C2=1E?6KFW+L8E@4A"Q* XAY"YP#R?S-&K:C*FM6UN'81-
M Q*!B$)Q-R5S@G@?D*KZE#+X?U1M2$,LT5S#M/DIN9"NT8P#S]P==OWCC.TY
MJ6XN]2UB"]EMWCB$;!25SA2DFTN1D*Q+<J<$9 YZD Z#Q'IJO)YES?/!&W^J
M2.1(,8 #Y8\OS@\_=SCO6?\ ##6I;LW-I++YRVT@"2$Y9@Q<9W9.0=N1R<9Q
MDC&,?^S6TJ_N9KVTDNDF):-TC\\!2QPNUN 0,#GE=N%!5LUI_##39;2:]>6%
MH1)(I52N% W2?*IP P7(&5XQC'!H S-"M+KQ!>WD)N94@AG;(21@_P!Z0(JD
MYVJ,'(Z' &.A5OC_ $#R+NQ3SIF\V14RTF2NWRDW*<<,?O,>[<UN^ =.EM;O
M4'D1E62?*%E*AAOE.02.1R.GJ*/B5I<\K6M_!&9?LDNYD7.\Y9",  \?+@XR
M1G.",X '^)[UO!5BQCDEEDDD"H\["0J6'/7' "D@8/S'D$$UREWKEO%&TT>I
MW#W0RZC;(L3,#N"^45P >F-VT=<8^6NK\3V3>-;%A''+%)'(&1)U$98J.>N>
M"&(!R/F') !J6U\;S[1%+97'VCE2$3]R6!P,2$X"D_Q<@#NP&2 <_P"+_%DU
M]I5O?QLT4DDP#>4[+]T2*>00<$KG'...3C-=AX:\.2Z<?/N+B665U.]2_P"Y
M!8AOE3 QC&!TXS@#.!A?%*SGU2QB"1,93*C,B R%?W;Y&5'(!.,]*[V@#)\5
M:W_8EK+>8R8U^48R-S$*N>1QDC/.<9QS7,:/X5N=9MUO+B\G6:= R^2^R-0R
MC9E !D]VQMR>/]H]/XJT3^V[66SS@R+\IS@;E(9<\'C(&>,XSCFN8T?Q5<Z-
M;K9W%G.TT"!5\E-\;!5&S+@G![-C=@\_[( &:-XGGN[2_M[ALW-FLP,B#:#\
MK[2",<@J>0%XV]\U%\/='N-5ACU"YNIB WR(LA (1VSYF0=V3D?[N!G& LNC
M>&)[2TO[BX7%S>+,3&AW ?*^T #/)+'@%N-O?-;?PXM'M+"&*561QYF5<%6&
M9&(R#STH W=1MFNHGB1BC.C*''52P(##!'(Z]1]:YKP'XB:>Q,MT6#VID65I
M!\W[OYN0.20I .1N)!SD\GK:\D\::3+%?M8PC$6J>5NQ'D*4<%F&",E<%VZ<
M,=W9J - ^*;C2-+.HR,QGNYF,88$K&'S@ .Q^4*A9.HY'!&2<J[URWBC::/4
M[A[H9=1MD6)F!W!?**X /3&[:.N,?+7:^-_"']JV(LK<8:#88EW8!V#:%).?
MX20,D<XR<9J*U\;S[1%+97'VCE2$3]R6!P,2$X"D_P 7( [L!D@$MCJ,GB:P
MCNO-^S;MQE9,'Y4+*X#-]S.-P;DK[]:Y>74SHE[:K:7C7,=PXCD22838RRC/
MRG@G=\O (*GD@D5I_$G2KC4XK:X$3.L3!IK=')8EMO VCG'S+N'(SD#&<8^I
MVAU"[LYK6QD@BCG7>Q@$9/SH3N5 <*HZ,3@Y8#[IH V/B?>W$,UE%:R-&\LC
M+PQ"D[HPNX#((!/0@\9XKJ/#OA]M'4AYY9F<+DS/N *YR5!^Z#GID]!SQ7/^
M/M.ENKO3WC1F6.?+E5+!1OB.20.!P>OH:[B@#G/B)>M9:?<.N"2@7GTD8(?3
MG#''O5CP]:K=V$$,@RDEK&K#)&0T8!&1STJO\1+)KW3[A%P"$#<^D;!SZ\X4
MX]ZM^#IEELK8J01Y$8R#GE5 (^H((/H>* "/PC:QI#$(QMMGWQ<ME6W;OO9R
M03R020>,C@5R^O\ [[7+2)_F1868*>5#8E.X \ Y5>>O ]!7H%<IXU\-2WS0
MW]GM%S;-D;CM#K@DH2!DY/ !8+AFR>: .KKS_P"(_P#Q^:;_ -?'_L\-:<7C
MB8CRVLK@39*X"@Q;LD#][P-IXRV,#KR.3D^*K.ZOYM-FDB.Y)RT@B#.L8,D9
M4,P&,A1R> 2"1Q0!8UK49]<U Z/!*T,4,8>9DXD;E6PK<D<,H[=6SN& :OB
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<OJ'A>6XU.#5 5\J*(J02=^2)!P,8Q\X[CO7444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7-?\(U)-J7]IR[#''#LB"EMX)ZEAC!
M^\XZ]".,\UTM% !1110 4444 %%%% !7/^#="ET*-[20JT22,82#E@C$G:PV
M*,@\YR<DD< "N@HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH P;S09+N^BOF8>3;Q.$4?>\Q\JQ/R\J4QWZ@<=<[
MU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYM(T;S-JW,F)H\NV!Q@-_>!9>2>FW%>AC1$TE;BXLXQY\P9B"S$,XW%<[FP
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MS>;!$JO_ 'B6=AP1P7)(R"<XQGO0!S6L_P#(>M?^O=OY3T?&O_CSC_Z^%_\
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MP/NCH.U$V@033I?LN9XUVJVYN =W&,X/WCU'>@#C/@],MK%/I[D">*=RR9Y
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MJEK+-(T,+Q%/-C?8P8%^_.T?.H)(Q@GG@XU=5^'=O,JI=7=P59P%$LZD%SD
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!F#PW;^=)>% 99DV.220RX VE22N,*.W]:S=?4^%]/D%BN/)7Y
M1R^T,^6;DDG );G(&.>!BNEJCK5[)8PO/#&9709" [2>1G!P>0,G&"3C Y-
M'$>!(%U)8YTOYGN$VM)&\A*8R-ZF-^2,-MW@D;OF'(Q71>*+#SF$DUVUO!@
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M/X!TZ6UN]0>1&59)\H64J&&^4Y!(Y'(Z>HH 9X.O9;"_N='DD>9$59$>5LL
M0F5YR3PX[@94D*-QJ;7M*4NYN=1>&1MQC594@55).P%,@O@Y!;(+ 8XQ3-)T
MZ5-:N;@HPB:!0'*D(3B'@-C!/!_(USGAW3&T9IH+RQ>YN'DRLNP21L2.,NXP
MH).2W)Y.\ KB@#J_A;KLNL6F^<[FCD*!C]X@*I!)[GYL9[XYR<D\O\/-,NO$
ML333W<ZQ(Y51'*P<L0I)+'/R@8P.>22,<[N@^$6G2V%HZ3(R,9V(#J5.-B#.
M"!QQ1\(M.EL+1TF1D8SL0'4J<;$&<$#CB@#':SEO=;N887\O="@=Q]\)MASL
M[!B< $_=!)'(%76EG\(7T$+3R3VUX=@$S%Y%88 .3@8W,.1U4D%254FO<"[T
MW6)[V*W>2(QJ&(7&5"1[BA. S KPHR3@CCJ+#13^+[Z"9H)(+:S.\&92DC,<
M$#!R,;E' Z*"2P+*  /2YG\77L]LDSPVMHP4B([)6;YESN&>,AN^,!?ER20/
M<S^$;V"V>9YK6[8J!*=\JM\JYW''&2O?&"WRY )$MI_"-[/<I"\UK=L&)B&^
M56^9L;1CC);MC!7YL@@CVT_BZ]@N7A>&UM&+ RC9*S?*V-ISQD+VQ@-\V2
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M)!R2#@*0<CJ21SP",@#[RQ-EIURHF:=&@E9'D(9MK19QO'WAG)!]"!T KFO
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MQ7+9:7<7\S-*\<K!3(Q?DK&%!R0=NYLG!Z9QS7=>&(6AM+='!#+!$"",$$(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***KW.HQ6K*DCJK2'
M"!F"ECP, $\GD=/44 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K$\1>&1KK0B1OW4,F]H]H8.0/E!)Z <Y&#N!(XX(VZ* "BBJ][J,5@N^9U
M12< NP49ZXR2.>* +%%%% !1110 4444 %%%5[;48KIF2-U9HSAPK!BIY&"
M>#P>OH: +%%%% !1110!C^)_#YUN-$5S')%*DB.%#89,XRIZCD\9'..HX.)J
M&FZMJ<;6LC6J1RC:[1B4N%;AL!N"2,CM[$'D=G10!1T71X]'A2TASLC&!DY)
MR222?4DD]AZ #BKU%% !1110 457LM1BOUWPNKJ#@E&##/7&03SS5B@ HHHH
M *YKP7X:DTCSYKC89[F8NQB+%<'D## 8P6;\",D]NEHH **** "BBB@ HJO<
MZC%:LJ2.JM(<(&8*6/ P 3R>1T]15B@ HHHH **** "BBB@ HHHH ***KOJ,
M22"W+J)6&0A8!R.>0N<D<'\C0!8HHHH **** "BBB@ HHHH **ANKM+13+*R
MH@QEG(51DX&2>.M/AF690Z$%6 ((.00>001U!H ?1110 4444 %%%% !1110
M 444R:985+N0%4$DDX  Y))/0"@!]%0VMVEVHEB970YPR$,IP<'!''6IJ "B
MBB@ HHHH **KIJ,3R&W#J95&2@8%P..2N<@<C\Q5B@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **KIJ,3R&W#J95&2@8%P..2N<@<C\Q5B@ HHJ&ZN
MTM%,LK*B#&6<A5&3@9)XZT 344R&99E#H058 @@Y!!Y!!'4&GT %%%% !111
M0 4444 %%%% '.:YX?G>X74K-U698O+*2J3&REMW)7YE())R,Y( X&<YMYX6
MO/$31QZDT(MXVWE+??N=@, $OR!@GH<\XZX*]K10 4444 %4=<LFO[>:W3 :
M6)U!/3+*0,XSQS5ZB@#$\&:(^B6D=G*5+Q[\E"2OS.S#&0#T/I6W15=]1B20
M6Y=1*PR$+ .1SR%SDC@_D: +%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  2!DY.0"*9\+?\ D'0?]M/_ $:]97Q0_P!&FL+U^(H;CYVZXRR,.!R>$8\
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MGO@<XR>@-/UGQI9Z,WE3RJK_ -T!G8< \A 2,@C&<9[5H3Z5%.J1,B[8F1D
M& IC.5(QC&,8X[<="17+R>+]]S-!I]J9I4.)GRL(RGRJ-[ [B.0,XZ';D<@
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MW;MV?7=\W3&>,8XK;HH X^U\&7=HHMDOG%NN0%\I/,"9^Z)2<@@<!@..,
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M!UD68 \=0H&!C)[DX.%/.+WB?QG_ &1+%90Q--<3<A =H"\C)8@CJ#[  EB
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M?XO+.,C^\02%YY.TU7^"G_'G)_U\-_Z!'0!Z!4-W=+:(TTAPD:EF."<!1DG
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M3**#SR-A7^\?SJWJ>E1:HAAG170]F&<'!&0>H."<$8([&@#E_BSJ$=O8/"[
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MYN =W&,X/WCU'>M"@#S_ .''_'YJ7_7Q_P"SS4?#C_C\U+_KX_\ 9YJ[#3=
M@TUY9H5VO.VZ0[F.3DG."2!RQZ8HTW0(-->6:%=KSMND.YCDY)S@D@<L>F*
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M2"V"<'&<8!)  R>  *L:II<>JQM;3KNC?&1DC."".00>H'>@#G_^8-_W#_\
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M;*A8$ ;, ,>3G.?D/8]J -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/Y&@"IXJ,NBS:;:QS2E6G(<O(2S@R1G#$8W ;B!D=.*I?$K2-U]9MYDO^D3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .:T/PU);7MSJ4^PM-M6/86R$7C# @#)"IGKR#C KI:** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6A7+Z?K<4VISV0@598X@QF&-[ B/Y3\H./F'\1^Z./0U'Q3=1L_V>RDDCB+
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MP3@C!'8T <O\6=0CM[!X78!Y2@1>YVNK-QZ #D].@ZD9PO%=JVG_ -D&8;1
MT:R,2-JD>3D%N@^Z>_0$]!78:9X!L=,<310J''0L6?!!!! <L 01P1R/6M+6
M-%AUB/R+A Z9!P<C!'0@@@@_0],CH30!POQLU",6\=KN'FF4/M[[0KKN]ADX
M&>O..AQZ17-?\*WT_9Y/D+MW;L[GW9QC[^[=C_9SC/.,UTM '":IXCNM0U!M
M'MI$MQ&H8R,H=V.P-M56X/WAQUPI;=CY:S?!J.FLW*R2B9U@PT@55R08@1M7
M(!7[I]QSS7:ZYX1M=<97N8P[(, Y93CKC*D9'IGIDXZFC2?"-KI$AGMXPCE
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MG<H5N221D#'!JWI>EQZ5&MM NV-,X&2<9))Y))ZD]Z .*^-?_'G'_P!?"_\
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MO[KR_+VY/W=NW&<YZ<9SGWH X_P1I']JZ5;Q>9+%AI#N@?8QQ)(,$X/'/3U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'6IJ "BBB@ HHHH ***KOJ,22"W+J)6&0A8!R.>0N<D<'\C0!8HHHH ****
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MS_"L*Z;K%W9P@)"8E?8!QNQ&>/0?O&X''/3@8 .ST37X-;0S6S;T#%2=K+R
M#C# 'H14,'BFVG\_:^?LF?-^5OEV[L]N?NGIGI]*Y7X*?\><G_7PW_H$='PX
M_P"/S4O^OC_V>:@"IX;^*4?G7/VN;]UYG[C]V?N[G_N)GIM^]S^M>EUY_P##
MC_C\U+_KX_\ 9YJ] H P9O'-G")2TH'V=PCY5^&)("@;?F/RG[N> 3TYJWH?
MB2WUU6>V<.$.&X*D9Z<, <'L<8.#Z&N*^'NGQS:AJ%PR@R13L$)_AWO)NQ[G
M &>N,CH3F6XA73==B$("BY@8R #[Q_>$GV)**3C&2,GJ<@'4:SXTL]&;RIY5
M5_[H#.PX!Y" D9!&,XSVJ[H^M0ZQ'Y]NX=,D9&1@CJ"" 0?J.F#T(KS+X="_
MNTEO;86Q>29][SJXD)8*S &,8VYP<>N>.E=1X5\+W=A>37]P8@LZ?,D!<+O!
M7#;6 YX8DY)RQ]30!H77Q#L+5G1Y@&B?8PV/D,,@\!>0-IR1D#C)Y&:LILKW
M4+:[\QOM+09B0 A&1ED.XY3@X+=6!X''KB?#W3XYM0U"X909(IV"$_P[WDW8
M]S@#/7&1T)S8UG_D/6O_ %[M_*>@#JM;\56NB8%S(J$XPO+-@YYVJ"<<'G&,
M\9S1HGBJUUO(MI%<C.5Y5L#'.U@#CD<XQGC.:Y+P-"M_J-_=2@-+%*$1B/NK
METX XSM0#/7&>>3D\<PK8:C8740"RRRE'8#[RY1.0>,[7(SUQCG@8 .KUSQ=
M:Z&RI<R!&<9 PS''3.%!P/3/7!QT-<9-JL6J:W:30.KH;=N5.<';,<$=0<$9
M!P1W%6/ T*W^HW]U* TL4H1&(^ZN73@#C.U ,]<9YY.8K[3X[/7K<QJ%\V)W
M;'=BLH+8]3@9]3R>230!Z17+^$K:TAN+MK61GE:7,P8$!6W/P/E7C);NW0<^
MO45YIX.L?[0FU>VSM\V1DSC.-S3#.,C.,^M '3?\+(T_?Y/GKNW;<[7VYSC[
M^W;C_:SC'.<5TM>9:9<7'@> VM[;+):9PTL.&SO!SN5L;@<A,L%  Q\W&?1[
M2Z6[19HSE)%#*<$9##(.#STH YW4+:T;4X)7D878B(1 #L*XDR2=IYY;^(=!
MQZW;WQI9V,CVTLJI)$NY@P8<8!X.,,2",*I)/85S6L_\AZU_Z]V_E/5>QT^.
M\UZX,BAO*B1USV8+$ V/49./0\CD T =AH?BZUUQF2VD#L@R1AE..F<,!D>N
M.F1GJ*V*\_U/]QKUOL^7S;<[]O&[ EQNQU^ZO7T'H*] H Q-9\:6>C-Y4\JJ
M_P#= 9V' /(0$C((QG&>U6+/Q);WL#7T;AH4#%F /&P9;*XW @<XQDC!'45Y
MO\.A?W:2WML+8O),^]YU<2$L%9@#&,;<X./7/'2NH\*^%[NPO)K^X,06=/F2
M N%W@KAMK <\,2<DY8^IH XWP]KVGR7=Y=WY5Q))^Y,L;R#;N;^':V, *!D
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M#CD+C<?O#.!QGG%1:-XTL]9;RH)59_[I#(QX)X#@$X .<9QWKE[>%=2UV43
M,+:!3&"/NG]V0?<@NQ&<X)R.@P?&&%;6*#4$ $\4Z!7QR  S@<\$!E!&0<<X
MZG(!Z'5'3M:AU%I$A<,T+E''(*L..A XX.#T.#@\&KU<.@_X1_5CDA8=13C
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M6'0#(+?<$E*G86+(I P2N><MWR3G Z  57U/Q]8Z8YAEF4..H4,^""002@8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M51,JC#8ZDQ],'+< @?,0=PXJ*W\"O<3QWE]<-<- 08P$6) 0<Y*J3DYP>,=
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M&W%Y:RV%Q=&02",*QB *[&#'.&RY; Y)SWYS76T4 <_?^#(M2M(]-G+%85C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^K1&>ULWDV;O,_>*%!'("G&7..2 H(X&#D5T&A^+(M5M/[1^ZBJQ<9W%"G+
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M;(-FSKTYW=.U '=Z_K::) ]Y*&*1[<A "WS,%&,D#J?6K&G7JW\27"9"RHK
M'KA@",XSSS7#^-=1N;S3KG[3;^1M\G;^]67=F5<_= QC Z]<^U,T[QM-9644
ML%JTL$$$:O)O"?,B@/A2I9E4\%@,9#=AF@#T.BL>7Q5!':?VH2?)V!N,%N2
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MG.,9[UMT >;Z^JZ)JMC/,Y$(@,?F2-DEE#KECZ_.N6( YSV./0)]0CMW2%V
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M>,9P/NCH.U $/BS_ (\[G_KWF_\ 0&KD/#6BV^LZ1;VUTVQ6D;80X5M_FR
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M[?755+E X0Y7DJ1GKRI!P>XS@X'H* -.O//B;,L-WISN0%6<DDG  #Q$DD]
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M 445R_A+6)=:FN;@N#;)*8HD7:1\@&Y]P4$AN"OS$<D<X!H ZBBBB@ HHHH
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M%V&(LF\N%ZN,C&XGYC\H"D<$DUW7A^Q-E%M$S3HQW(\A#-M8 XWC[PSD@^A
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M&2"*.==[& 1D_.A.Y4!PJCHQ.#E@/NFN@U;3I7UJVN C&)8&!<*2@.)N"V,
M\C\Q0!NP^'Y+.![>"XE\QFR)9\3,OW<@ @#& >.Q)->?^)]1'AT17=C?O.PD
MPT<DXF4@@G)52..,'CN""I SUWQ/T>?5;,QV^25=6903EE4'( 'WCG!QWQQD
MX!X?Q59_VE;1Q6FG2Q,C)O8PX;[A 4$#>XSG+''(&>6% '6_%W49;"T1X79&
M,Z@E&*G&QSC((XXK/\5Z/=Z1:G4VO)3<QF,N%8" Y8+@1@ 8&1R00V#E?FXT
M/B[ITM_:(D*,["=20BECC8XS@ \<UI_$>T>[L)HHE9W/EX5 68XD4G '/2@#
M,\5>,)A!:+:XCGU Q[2P#*@8*2,D=<N!G:>-W .*T-.\)SZ6R2QW4LC J)%N
M'+QLIQOVKU5NZG)Y&TY!)K$U[PY/-96-U"I-Q8I$WEL",X5"PV\$L"HXR#C<
M!EL"MBS\83ZB8XXK29'+)YAF79&JY'F$,2"Q /RC )^]CC:0#C8_&<6N2/-=
M7DMO&'8110*R-M^7:S.@?)/.0<X.2" <5N_#[Q4;JXETU9&GA12\<TF1)C*Y
M1MPRV"W!..AXP0%B\/B?P.TMFUO+-;/(SQ/ OF/T488#&.,=E^8'&X'(Z_0M
M8DU3<[P/#&-NPRD!VZALQC)7!'&3\P((H UJ\L^'EI=>);=C-<RK$DIP8Y&$
MQ;:O5VSA #PHZDDGH*]3KR+X7:_-I5N^;>26 RG#0 .X?:N04R#MV@'=T!XY
MSP :%AXOG\,B\L+ES-):H'B<@G.\J &)8'&9%..2!N 8@+6AH_A6YUFW6\N+
MR=9IT#+Y+[(U#*-F4 &3W;&W)X_VCGV'A"?Q,+R_N4,,ET@2)"2,;"I!8%2<
M9C49X)&XA0"M:&C^*KG1K=;.XLYVF@0*ODIOC8*HV9<$X/9L;L'G_9 !H?#_
M ,13:B)[2Z(:>TE*LZ@!6!) Z8Y!4_PCC;WS7,_#N9H=(NW0D,IG((.""(5(
M((Z$5TWP_P##LVG">[N@%GNY2S(I!50"2.F>26/\1XV]\U@^"-)FMM)NX)(W
M61_/VJR,&.85 PI&3D\#WH (?&$NE:+'=[F:>1F17?YR"9'Y.X\X53CKS@$$
M9K;M?!]W;J+C[7*UT,L0[9MBQ.2ICQG;CC(P1]Y0,!1B0^#Y=5T6.TVLL\;,
MZH_R$D2/P=PXRK''3G&2!FM:U\;W=U$(ULIA=%3]]-D&X=R[D$#'.#SGY<_Q
M4 2_;Y=/U;R'=V@O(<HI'R*\8Y )/'"DG;W<9'0U+)?R7^J+;1NPBM(2T@4-
MM9Y>%1CD*<*0Z\'HWOB+XH6#26HO(O\ 6VDBRJ0@9L X/T X8]1\O([@^&FG
M%8'U&08EO9&D88*@#<VT $GCDL#W##K@&@#HM<O6L+>:X3!:*)V /3*J2,XQ
MQQ6%\+?^0=!_VT_]&O6[KEDU_;S6Z8#2Q.H)Z992!G&>.:P/A5,KZ=$ 02ID
M! .<'S&.#Z'!!^A!H Y'PQ?GQ%+*+Z\F@N#)A88W,*C&%P-P(SD[0OWN"3N)
M)'3>.O$\GA^*WM_-VRS,JO.8PP"IM\Q]F<9)(.W!&,@8.#69XCU Z[$\$FG2
M_:V!C5C&"BG=\I$_'RC[W0*>03M)-%YX+NQ9V3KA[NR?<$9P5(+[@N3C)7"C
M[P  8 GY: ,2\\20Z7&MQ:7\\UQ&5)2;S&B?LPVLHP.<C+$C& =V&&WXM\=L
M_P!FMUE-JMS )9) GF%5=3M5<8.<@@D $?*01R*VX?'$URH6.RN/.('RR*(X
M\]6'FMT YP2HR<# S5?QIHT\-U!K-HGFO K*\><$KAN5'4G#,.YSMPIYH Y2
M\\8PZ&T=S97<US\V)(K@N5*D9R&9%"D$=<$\^@(/L%<U:>,)+YUBBM+@98;F
MG40JJYPS DG<1G[HY(SZ5TM 'G^J^%KW1+I]1TS:XG8^9"YPN2,[B6<9^;)X
M*E<X&5)K5T+XA1:E%-(ZM'+;*[20GEP$SDC.W/3!SC#<'&03-=^*)],=HY[6
M5UW'RWM1YH9<Y&Y<@H0" <Y#'<1P*Q/#OAB?59[G4KU?)%W"8A&#EPKJHW$G
M." H&",ELY50 " <_I_BB'5A]HO[^:*1LXBMP\:H S<956#9&,'J!P2>VKX=
M^(3Q6=T[GSC9;1'*009 [%(RRD@]0"3G)!Y^8$FQX7U2Y\*1?V=<VLKB,ML>
MV3S5969B<\C!SR.AP1E1C)WK^UD\5V4T$L;0&3_5AV&X@;7C9@ =N2,,O)&#
MWH R=!\-76J0I?SWDPGE5741L!$H*@H#'@!NQ8< \C_:.5\8-/?[-#=2NWF;
MHT9$8^1NV.S,%(SG/ ).=O%:?ASQ5<V$"6,UG.9H@(U*)^Z;:-JDR$X4>K#*
M_P 0X.!+\0M%N=<T^,!!YZ%))$7U",'5>3D@MP,\@<$G ( SQ7I;^';"XEBN
M+AW/E8:64LRXD .T@ C(//KQ46L^)Y[2TL+>W;%S>+"!(XW ?*FXDG/)+#DA
MN-W?%/\ $NJR^(].GC6VGCE A^1XSR3(I(3NP7!R<#C!Q3-9\,3W=I87%NN;
MFS6$B-SM!^5-P(..05'!*\;N^* 'ZQX5N=&MVO+>\G::!"S><^^-@JG?A"#@
M]USNP>/]H.U[Q,^H:,=0C+1R,L>2A*D,)51\$$D D''.<=:;K'BJYUFW:SM[
M.=9IT*MYR;(U#*=^')&3V7.W)Y_V2[7O#+Z?HQT^,-)(JQY" L2QE5WP  2
M2<<9QUH S_["N[C3O[0EO)A*MOYBB-]J;57>H8#!9B.K$YR?XMO/8>"]9;6;
M.&ZD^^RD-TY*,4+<  9(SC'&<55^R/\ V3Y&UO,^P[=N#NW>3C;MZYSQCKFC
MX<6CVEA#%*K(X\S*N"K#,C$9!YZ4 5/']ZUUY6C0-B6\;#$$96)>7;&Y3R >
M.C .O6LJ^M5M-;LH8QA([4JHR3@*LP R>>E=5K?@RTUMQ-<Q[W"A0=[KP"3C
M"L!U)KA]0^'<*:G! D#?9&B)<@R%-V),9?/!X7C([>O(!ZG7G_QK_P"/./\
MZ^%_] DK;UF]GT9[2TLXMT#,$<[7?8BE%!W \<$\MGI[&LSXNZ=+?VB)"C.P
MG4D(I8XV.,X /'- &5X^UR\N+4Q7%J887= \@D28@!@>%4K@Y Y) _AX)!'>
M^'VB:WB%NV^)8U5&[D*-O/ YXY&!@Y! Z5S6K>*9-7ADLX+.Y\R:-T!EC$2#
M<I!)<M@8&2/4X'>F6D=WX5CL=.A02JSL)G".P0-(I)!!& -[<L.<9P.10!=^
M*7_(.G_[9_\ HU*V_#UTUW;032'+R0QLQP!DL@).!QUK"^*LRIITH) +&, $
MXR?,4X'J< GZ FC6KJ[\-V,"6L8FFC$4; (\@PL9!8!=IQE1R?7I0!UM%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M."1@JQ[%>?EJOX]\8S>'7MT@19//9@5(8L=I3 7!X)W$=&YQQZ@'0:_K::)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>?\ QK_X\X_^OA?_ $"2O0*KWNG17Z[)D5U!R ZAAGIG!!YYH Y3
MQQKEA?V<R/+$Y"$H%=6;?@A" I)SD_3&<_+FHM)UX^$=,MY+Y9-V=FT8+C)=
MD!#,, ( ,9R.!@8XZBU\/6UHPEBAB1QG#)&BL,C!P0,]*L7NG17Z[)D5U!R
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M"!HQ 88($>,C(.#^XY&0#]0#0!8\8:8]]HMNT8SY,<$C#DG:(MI(P#TW9/0
M G/%=-_PL6Q\C[9YJXVY\O(\W/3;LSG.>/3OG;S6##\0KN%0B:;*%4  #>
M.  !#P!5*U\3/:,)8M'9'&<,D95AD8."(,]* +OQ1E%K<6%T^1%%.2[8) ^:
M-NP/.%) ZG!Q47Q=U&*_L4>%U=1<J"48,,^6YQD$\\T^Z\>7-VIBETR5T.,J
MX=E.#D9!AQUJI_PDS[/(_L=O+W;MOEG;NQC=M\C&<<9ZXH N^-)1HNIVNJS9
M\@(T9*@G:</R>.GSY&,DA6P..7_$GQ1;WEH;*!UEEN&156$B0Y#JW.TG&<8
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MHWD\J>F$XX/--M/&-SIUVMAJ2(HGP(I( Y0L>,'<2>I [%3C(VL& !VM%%%
M!1110 45GZ[KL6AQ&YG.%7H!]YCV4#N3_P#7. "1S]MJ&KZ@/.2*WA0XVI.T
MC28P#DE..O8@$=".Y .PHKC_ !'XEN8-/FN_+:WN(F088K(.73E6P58%6QG'
M!R.HS70>'KIKNV@FD.7DAC9C@#)9 2<#CK0!H4444 %%%% !1110 4444 %%
M%% !1110 445YUX=\5ZKX@A:Z@2VPC,NUA(&)"AL#YL<Y &2.>N!S0!Z+17.
M>"_%P\0QL'4I/"0LJ$$8/(R,]C@\'E2"#V)Z.@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI9IMDT^JV]W%:/;VXC<<Q!!G;(-S!1A22< $Y("GH16QI.G2IK5S<%&$30*
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M-RD,N>#QD#/&<9QS7-:#XIGT>%+*ZL[@R0JJ9@C\Q"JJ-IW!L9QP<$C([?=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !115>RU&*_7?"ZNH."48,,]<9!//- %BBBJ]EJ,5^N^%U=0<$HP89ZXR">>
M: +%%%% !1110 4444 %%%% !1110 4444 %%%% !115=]1B206Y=1*PR$+
M.1SR%SDC@_D: +%%%% !1110 4444 %%%% !1110 4444 %%%,FF6%2[D!5!
M)).  .223T H ?14-K=I=J)8F5T.<,A#*<'!P1QUJ:@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **KWNHQ6"[YG5%)P"[!
M1GKC)(YXJQ0 4444 %%5TU&)Y#;AU,JC)0,"X'')7.0.1^8JQ0 4444 %%%%
M !1110 4444 %%%5[+48K]=\+JZ@X)1@PSUQD$\\T 6**** "BBB@ HJC%KE
MO+)]G66,RY(V!U+Y7.1MSG(P<^E7J "BBJEOJT-RC3QR(T:9W,KJ5&!DY8'
MP.3[4 6Z*AM;M+M1+$RNASAD(93@X."..M34 %%%% !1110 4444 %%%% !1
M110 4444 %%5[G48K5E21U5I#A S!2QX& ">3R.GJ*L4 %%%% !1110 4444
M %%%% !15&]URWL&V32QHQ&0'=5..F<$CCBKU !1110 4444 %%%% !1110
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M@)"8E?8!QNQ&>/0?O&X''/3@8B^">GQBWDNMH\TRE-W?:%1MOL,G)QUXST&
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M ZC3_B'8:A(L$<P+N<*"CKD]AEE R>W/)X'-:NL:U#H\?GW#A$R!DY.2>@
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MR,]17'V.GQWFO7!D4-Y42.N>S!8@&QZC)QZ'D<@&I?',*V&HV%U$ LLLI1V
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MW ._ZU@_##Q);Z%8L]RX0/<N%X+$XCCSPH)P.YQ@9'J*ZCX6_P#(.@_[:?\
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M1=LL*,X(R&,B L3G.<YQSVXZ "@#:M;M+M1+$RNASAD(93@X."..M>8> /\
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M5!YA D"D ');;A3D L3@#FWX<,NI7TNH^4\$!A6/;*-CR."&#E/]D$J"2>,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ')3>#;B\M9;"XNC()!&%8Q %=C!CG#9<M@<DY[\YJ[?^#(M2M(]-G+%85C
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M$X."=P;)&>N".UHH AM+5;1%AC&$C4*HR3@*, 9//2N8\*?#R/P[<2W:.2)
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M\X?G# 8!'0C!^\* .@HKBHO%MWKLLD>FQQ>5"Q4S3EBCD8X7R_Q/\65P3MR
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M[6:XW<L&(XV'H<''!X&202%KK=+DEDC4W"JLO(8(<KD$C<#UPP&X \@'!Y%
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MZ$@@X&<5F>/KVXO]*2X'EB.6*)I@=V[+&,KLZC&X\[NW3F@#T"&99E#H058
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M+%NVJ#YA8[P!NW;0N5&XD'"Y-13^++W0IXH]12+R)CM\V#<%5B>-QD/ '4Y
MXR03M(H [BBL36[B^WB*SCBV[0QEG<[<Y(*!$^;/0[NF,CK6;X5\63WES-I=
MXBK/"-P,6=A7Y?4DY.X$>QP0I'(!UM%<)?>-;L:A)I5O$DF%7:3N7:616WN<
MD%03R  3P <];>C>*;F*]_LN_6(.\>^-H=^UL9R/FR>@/7;C:>N10!V%%<YX
M>\227MS<V$ZJKV[@IM/+1M]TXR>0,$D?W@" >LMGKTEW?2V*J/)MXD+L?O>8
M^&4#YN5*9[=0>>F0#>HK,\2:XNA6\EXREA&!\HXR6(4#/89(R><#L>E87A_5
M=4OEBNI8[?R9=I*H764*YX89++P#NQG)''#= #L**Y?7?%,RW TRQC62?8'=
MG<!(U+ <@'<3@Y(&" 5(#9Q5>#Q3<Z5<1V>I+$!<\1/;[RNX$#:P;GG(YQ@9
M'49*@'845Q]_XMN+VZ?3M.C1FAQYDLI)B4X/RX3G.<#KG(8;< L+HUFZM;>X
M:YC436\3.&3<8'^5F7&2&R"N&4\]"#AA@ Z.BL3P9K;ZW:1WDH4/)OR$!"_*
M[*,9)/0>M8OACQK-JMA<:A(J"2#S=H4,%.R,.,@L3U//(XH [6L?1/%$6L2S
MV\88-:OM<L  3EAQ@GCY3UQVKG/"/B?4O$02<1PI & =F\P%QN.XQ@$]!QSD
M;L\]0M[P[XHN-8EOK<",-:N5B)# $YD W\GCY1G&.] '2VVHQ73,D;JS1G#A
M6#%3R,$ \'@]?0UGW/BB*WNX]+(;S94+ @#9@!CR<YS\A['M7GG@K[?]IOOL
M_P!G\SSOWOF>9MW;Y/N;><9SUYQCWKL]0\42V^IP:6 OE2Q%B2#OR!(>#G&/
MD'8]Z .HHKDK[Q3<WUP]CIT<;& J))9G_=@L&.W:AW$Y&,C.&!!4=:=HWBF:
M.Z_LN_5%G==\;0[C&RX.1\V2"-IZX!P>G&X ZNBN"T;Q9J'B4R3V20) C[5-
MQOWG@$_<)YY!/&!D %L$UV]I(TJ*\B['*@LN0VTD<KD<'!XSWH FHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV,YSSGKF@"IX+U*74[.&XN!B1U.?EVY 8A6Q_M  \<'.1@8KFOC7_P ><?\
MU\+_ .@25Z!5>]TZ*_79,BNH.0'4,,],X(//- $-EH=O8-OABC1B,$HBJ<=<
M9 ''%<!\2=/BBOK:\O%+6C(8WV[N"-Y!)7''S C!R0K<'&#Z;3)H5F4HX!5@
M001D$'@@@]0: //V\.Z$&1!Y;-(ZHH2>1R6;@<(YP/<X [FGZS_R'K7_ *]V
M_E/7966AV]@V^&*-&(P2B*IQUQD <<5,^G1/(+@HIE48#E07 YX#8R!R?S-
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MT3R"X**95& Y4%P.> V,@<G\S0!P_P 1_P#C\TW_ *^/_9X:/B/_ ,?FF_\
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M_P!>[?RGKLKW0[>_;?-%&[ 8!=%8XZXR0>.:F?3HGD%P44RJ,!RH+@<\!L9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45R_BK
M6)5N+73;9PDD[LSM\I81H"2-K*W+<[3CJN.F<=10 4444 %%%% !1110 445
M7U%Y$B=H0&E",4!Z%@#M!Y'!/N/K0!8HK$MM5GM;)KR[C59XXY'9$/R_)N(
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M*S_#UTUW;032'+R0QLQP!DL@).!QUK0H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** .'T^]:XUR=#C$5H%&/0M&_/OESZ<8K/\9>+P;PZ:]PUM!&BEW1"7=B
M5;:&7)4;3P<#G<"&!%7;*W^QZY*SE?\ 2+4%!GDX**1SW_=L<#/'/K@UK3I]
M#U ZQ!$TT4T8294YD7E5RJ\$\*I[]&SM&" #%TWQ<FFW<,5I<RW45PRI(MP7
M+(2P"NK,J_WN@'.#GJI7HK:^FTK56M)"S07B;HLL[!60$N 6.%'WB0N<93H.
M!IZ7XHDU.18TM9DCYWO.!%MX)7"DDODC!QC;P3UK/^).E23QQ7MNF^>TF1U7
M#,2,C("KUY"D], '!'< KZCKDAU)R&D%MI]LTDJJ/E=F4G'4 G:05W=U. .6
MKE]/\40ZL/M%_?S12-G$5N'C5 &;C*JP;(Q@]0."3VZWP7H#7%I.URI26_>9
MI!LV.H<E=OS9.!RRYZ;NAZG/\+ZI<^%(O[.N;65Q&6V/;)YJLK,Q.>1@YY'0
MX(RHQD@%[X9^)WU=9;9V\S[,P"RD$,ZL6"DJ><X7J3DYYY!)Y_X=V-WXDA=Y
M[N98EDP!')B0L%!),A!.W!'RYP3SQCGT71-0DOT,LL30Y8[5=@6*X!5B!]TG
M/*GD$5R_PBTZ6PM'29&1C.Q =2IQL09P0..* '_#;5993<Z?.[2M:3%1(YRS
M EA@YR>"A/)/7'0"NB\3S-#:7#H2&6"4@@X((0D$$="*YKP#ITMK=Z@\B,JR
M3Y0LI4,-\IR"1R.1T]172^)X6FM+A$!+-!*  ,DDH0  .I- '&V<3ZQH?FRR
MR[UCG<L'.YMAE 5B<EE(ZCV%2_"W0/\ 1H+[SIO^6G[KS/W/WG7[F/QZ_>YJ
MQX>TZ6+16MV1A+Y%R-A4A\L9,#;C.3D8]:T_AQ:/:6$,4JLCCS,JX*L,R,1D
M'GI0 ?$>[>TL)I8F9''EX9"589D4'!'/2N9_L*[N-._M"6\F$JV_F*(WVIM5
M=ZA@,%F(ZL3G)_BV\]-\1[1[NPFBB5G<^7A4!9CB12< <]*/LC_V3Y&UO,^P
M[=N#NW>3C;MZYSQCKF@#$OO'TD&DQZ@/]?+^[!P"-P+!G(X'(0D#! ) P1FK
M?_"$7?E^;]MF^U_>^_\ Z/NSNV^7C[O;T[[<?+63#X/EU718[3:RSQLSJC_(
M21(_!W#C*L<=.<9(&:UO^$WN_+\K[%-]K^[]S_1]V=N[S,_=[^G;=CYJ ,^'
M56\6Z1)-([I) LN\QD('*1D@$#.58,-PXR<X &*E^%N@?Z-!?>=-_P M/W7F
M?N?O.OW,?CU^]S5WPSX-DT[39+%L":X24MDY56D3:!D#H !G&><X)&*K_#K4
M9=/CCTF>WF1XVD'F;,Q8RSY+].N0,9!X(// !U'B>9H;2X="0RP2D$'!!"$@
M@CH17#_VM-_8'VKS'\W^_O;?_P ?&W[V<]..O3BNX\3PM-:7"("6:"4  9))
M0@  =2:X?^R9O[ ^R^6_F_W-C;_^/C=]W&>G/3IS0 ?V%=W&G?VA+>3"5;?S
M%$;[4VJN]0P&"S$=6)SD_P 6WGL/!>LMK-G#=2??92&Z<E&*%N  ,D9QCC.*
MJ_9'_LGR-K>9]AV[<'=N\G&W;USGC'7-'PXM'M+"&*561QYF5<%6&9&(R#ST
MH TO$%H]S%A)C H.9' 7.P [@&;[A[[^JXS7G\NIG1+VU6TO&N8[AQ'(DDPF
MQEE&?E/!.[Y> 05/)!(K8^*FC37ZP2QHTT4,A,D2%@S E<8"\],C(Y7=D#&2
M,+4[0ZA=V<UK8R011SKO8P",GYT)W*@.%4=&)P<L!]TT >L5Y_IG[_7KC?\
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M\BW\1[1[NPFBB5G<^7A4!9CB12< <]*Q]=M91I]C"$+.'M0T+9'F;$RT9&"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#G_$^A2WLEO=VQ42VTA.'.%9'&'7(1SD@  XX!)ZXKH*** "BBB@
MHHHH ***KOJ,22"W+J)6&0A8!R.>0N<D<'\C0!8HHHH **** "BBB@ HHHH
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M0W5VEHIEE9408RSD*HR<#)/'6GPS+,H=""K $$'((/(((Z@T /HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KDO^$?
MO=(DE>P>)H[B5I&2X5AM9L9VM'U!]"!@ 8R<D]+9:C%?KOA=74'!*,&&>N,@
MGGFK% '*:-X6FDNO[4OV1IT79&L.X1JN#D_-@DG<>N0,GKQMZNJ]MJ,5TS)&
MZLT9PX5@Q4\C! /!X/7T-.DNTB98F90\F=JD@,VT9.!U.!UQTH FHJO;:C%=
M,R1NK-&<.%8,5/(P0#P>#U]#5B@ HHHH **** "BBB@ HHHH **** "BBB@
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MT;AH4#%F /&P9;*XW @<XQDC!'45RNL^&[NPU ZQ:)'/Y@52CD*Z_*%8J20
M2%QNSGYB-I&35@>*(M>LKTHC1RQPR><CKA@QB*\GO]W;SAOEY XH ZK2]4CU
M6-;F!MT;YP<$9P2#P0#U![57TKQ);ZK$UU"X,2$AF(* ;0&.=X' !SGI6/\
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M7+MW.UV5>?0 <#IU/4G(!U&F:K%JB":!U=#W4YP< X(Z@X(R#@CN*RI_'UC
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M!V09(PRG'3.& R/7'3(SU%0ZCXYL]-D>WFE"R1 %@5?^+;C&%Y/S X&3C)Z
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MB)7.=B98.2&!P0..F,@YH Z+X87\H-SILK[ULI B,1AL9=<=3P-G YQG&<
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MRPHS@C(8R("Q.<YSG'/;CH *XKPW_HT.L62<10^=L7KC*RJ>3R>$4<D]/<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI+"1_-29G+?*4X= A7AB>@ZY'6J-EX&N=)7R+.]:.$'*H\*2D9Z_,2."<G
M'/KDGLZ* ,EM!_T1]/\ ,=M\<B>9*=[_ #YY)XSC/'3@ 4>%M"_L&V2RW;_+
MW?-MVYW,6Z9/KCK6M10!S7A7P2NB6TEA(_FI,SEOE*<.@0KPQ/0=<CK4/AGP
M=/H#!$NF:V5G(B:-<X8' WYR,'!.  3G@9-=710 5Q7@"-=)GO-)&T>5-YB
M,2=DJC P>?D 4$\\G'H3VM47T:)YQ?$'SE38&#,/ER3M*@[2,G/(/.#V& #
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MN=S%NF3ZXZUK44 %%%% '/WOA3[3?Q:KOQY,939MSG(<9W9X^_Z'I[UT%%%
M'/V7A3[-?RZKOSYT839MQC 09W9Y^YZ#K[5:\2^&HO$47V:?=M#!@4.&!&1D
M9!'0D<@]?7!&M10!R4/A&\91#-?R&(  ^7$D<AQT_>Y9LY R>21D'K76T44
M5-4TN/58VMIUW1OC(R1G!!'((/4#O7-6W@R[T\>5:WSK$,;5EB29@  ,;F(X
MXX   ].I/844 <U?>"%GLY-.61\S,K-+*3*Y(93D\KGA HQC  []9;_P9%J5
MI'ILY8K"L8#)\K9C7;N .X<C/!SU]<&N@HH Y*'PC>,HAFOY#$  ?+B2.0XZ
M?O<LV<@9/)(R#UJQXG\&?VO+%>PRM#<0\!P-P*\G!4D#J3[$$A@01CI:* ./
ML? <D5Y'JD]RTLD:L"&C"@Y5E&W#84 ,.,')R<_-QH67A3[-?RZKOSYT839M
MQC 09W9Y^YZ#K[5T%% '/^+_  @OB)4.]HY86W1R+DE22,\9'H,'(((!!Z@Y
M4_P_GO9H+NYNVD>WD# &)57 96P%5@ 20<MSD8&/EY[6B@#G_$GA3^VIK:YW
M[/LLF_&W=N^9#C.1C[OH>M'C7PI_PD\*VV_R]L@?.W=T5AC&5_O>M=!10!S_
M (O\(+XB5#O:.6%MT<BY)4DC/&1Z#!R"" 0>H+-.\,SK*EQ=W33&$DHHC2)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNS2,"H8'<I"_-GC.W'0^I9>_$^-;#^THD)=G\O8W19-N[D\94#G(Z\#Y3G:
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M]=DR*Z@Y =0PSTS@@\\U8H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&E1?;[Z38NZ"8K'@8"AGD! '0<*![#@<$Y .]T?6H=8C\^W<.F2,C(P1U!!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV_,YQG)S][T'2L>'X;/;7$U_#<M'-*[,I6-2JAV+,K*Q.\>GW<$!L'C'<44
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M&..>O>@#E/AU-/?_ &C4)&8P7$I,"NY8JJL^?ER0HY P#_#Z8)[.F0PK"H1
M J@  #  '   Z 4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-TCS[MO(4C&T@X^8#N23T &3T>B27#H1=JBR*Q&8B2C# (8!N1UVD'N">A%
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M.#4;JWU0 >:YDA=F=(\,68C<"O/('/&Y6 .<9ZKP[H^DPW(^Q;3/&A<%)'D
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MSEAN^8G(KJKW0[>_;?-%&[ 8!=%8XZXR0>.:MPPK"H1  J@  #  '   Z 4
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M[>&)'/IH>$?'%F+*+?*J&&)597(#YC4 X7.6!QD8SGIUR!V$,*PJ$0 *H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?LT38VL5Z\>F>E=KI=O);1K'/)YL@SE]@3.22/E' P,#\,T 6Z*** "BBB@
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M.X^H !UM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5S_C_S/L%QY/WO+.>GW<CS.O'W-WOZ<XKH** /E_2?,\Z/R/\
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M0!U+,S<;BV,C;G  & <YMZMX?NM.U(ZM;1+<+*F"I949"%5<AF/4XZ@'@LI
MX) ,SX;WL<>H7%K9NS69C\Q5.<;LQ@D;@",;BOJ0!DG -:'PX_X_-2_Z^/\
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MW^9Y8WL%B&XJ=HSC)(W'((/''!SM_"+4WOK$+(<^3(T:GDG: K ')/3=@=
M ,<5J^ M+DTJRBMIUVR)OR,@XS(Q'()'0CO6?\+] GT2V>&Y78YF9@-RMP40
M9RI(Z@T ;OB+P_%K\)M9L[2005QN!!SD$@X/;IT)'>N'6ZU#P&J^>5N+)6VY
M4'S$7)"]<8SD8!+*,! RY!/=ZW'<.@-HR+(K XE!*,,$%25Y'7<".X Z$UR6
MNVFI>*D%D\*VL+$&1FE64D!@0 %'!'7MG &X=P"CX[\1_;Y[>Q3SC;SPF1OL
MO^MD5U8* I&< #+ \$$Y&5%95XG]F-'<Z39W<,R-\PDB<QNA'*L"SD\@8QCN
M>H4CJ_$'@R6$VUWIY7S[./8!+_&BJ0%STSU'1<[B=RX%:%IJNHW;JAM4A0,"
M[23"3*Y^95$8SNQR"?EXYZB@#!U=6\4:HVE2.RVUO$K.BM@2'*-SC''S+ZXV
MG;@MD='I_@J#3M\4.Y;>:-EDA+,RDM@;P22RG;E3@\C'0KSE>(- NK&]75[!
M5D9U"31E@I8#'(9C@<*!QC! .&!85KZ+=7MY+YMQ$L$(1AY?F"1R^5(?<HP%
M R ,YSDD'C !P7@KP9::E<WT,T>Y()ML8WN,#?(,9# GA1US6WK/_(>M?^O=
MOY3T6FDWWAN[N9[>%;B*Z;?Q(L3*=S''S$]-Q'0YX.1RM:&IZ!/-JUO?JN8(
MX2K-N7@D2\8SD_>'0=Z ,+PEI">.3+J-\6=1*RQQ%V"(,*W!4KS@@< 9P2<D
M\6M(5O"^J+I4;LUM<1,R(S9$9R[<9SQ\K>F=PW9*Y,VF:->^$9)([2);BUE=
MF5!((W0G'5GSD8XZMG:#\I)!M:%X=N;R\.L7X5&5"L42G<4&2.6'!."?[V=Q
M/RX  !S\NB#6-;N(6=EC$2EPA*[UV1 QD@CY3D9]0,<'D6["P3PQK$=G:@K#
M=0$LA9F *AR",GK\G?.-S8QGC8TS0)X=6N+]EQ!)"%5MR\D"+C&<C[IZCM1J
M>@3S:M;WZKF".$JS;EX)$O&,Y/WAT'>@#L*\Z\.Z];:I>S:M/-$H3]S LCHK
M!1RSX8*?FSP>HW,IX KT6LG_ (1.S_Y]X?\ ORG_ ,30!QOP7U&)+9K<NHE:
M=R$+ .1Y:<A<Y(X/Y&O2*X?X9>$&T>$M=0JLXE8JQV,X4HHX9<X'7C/KZUH>
M&GU%+25KL!KH%S&#Y>#A!L!\L@8+9ZD'WQB@#"TO6H+K5;F[N)406RB&(3%%
M.<D.RDGL0WJ</@X'%'PVNTLKN[TR)E:+=YL1C(= IP"-_4G#(.XRIY]=7P=X
M"AT^U2.ZAB:<Y+EE60Y)X&6!Z# ('&<D9SDQ:MX--I>VNH6,: (VR55"HH5L
M@N%&W) 9L\D_=P" : .UK@M6F9-=M@"0&MF! .,C]\<'U&0#]0#6[9?;?M\O
MF?\ 'EY8\O\ U?WL)GI\_7=UX_2L>6U&HZVLB$XM+8;_ )3C<^_:N> "5DW#
MKG!'K@ V+WPI]IOXM5WX\F,ILVYSD.,[L\??]#T]ZZ"N7N?%$HU./2XPK1&(
MM(0"70X8C)!PH^[U'\0]1744 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !4-K:):*(HE5$&<*@"J,G)
MP!QUJ:B@ HJO>ZC%8+OF=44G +L%&>N,DCGBK% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B1^'#!>MJ,
M;X66,+)&02&*_=?.X $  ?=/&>[$UMT4 %%%% !1110 4444 %%%% !1110
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M8SG&<$XS@T 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ J&[NEM$::0X2-2S'!. HR3@<]*FK$\::,VLV<
MUK']]E!7IR48.%Y( R1C.>,YH RM,^*EEJ$PM5+@LVU69/E8E@J@8)(SG(W
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M%@)(SC*@8"YXS_>..]='\0X#I[V^M)_RZR 2;54L8Y"%/+$9QD@#U<D$8)H
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MC&!@ Q/@I_QYR?\ 7PW_ *!'6W=?$C3[5C&TZDC'W%=UY&>&12#^!]NM>?\
MAVZ:UT.[=#@F8KT!X<1(PY]02/Y<UT7AS3M12TC2%+(0RQ*2&67+!D RX P6
M(^]ZT =Q=:K%:Q&[=U$04-OSE<'H1C.<YXQG.0!G-9FC^.;/6)/L\$H:0@D
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M>N[=MSM?;G./O[=N/]K.,<YQ6KK^I1:;!)/<#,2K\PV[LAOEVXZ'<3CGCGG
MKSKQCKDVJZ>Q%GY=K\ACD:1 54.%0B+&1D<#'&&X)7J >BZWK\&B()KEMB%@
MH.UFY()QA03T!K,E^(FGQR>09UW9 R Q3G&/G *8YY.<#OC!KC?'W_(&L_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%CG;D]-WKSCM7044 <_IGA3[#8'2M^<QRIOVX_UA8YVY/3=Z\X[4RP\%QQ6
MTB9BZ88%@-AY<N"!DX()'J#CD8XKHZ* ./M?!EW:*+9+YQ;KD!?*3S F?NB4
MG((' 8#CC   %:6O^$8]:M18R,QV!=LC'<^Y5VACTW$Y.[UR<8."-ZB@#A[_
M .'<VJ0FWNKMI=H7RR8PH4@C+, V9&*C:"QXRQY)KK=)L?[/ACML[O*C1,XQ
MG:H&<9.,X]:MT4 <_P"-?"G_  D\*VV_R]L@?.W=T5AC&5_O>M6O%.A?V];/
M9;MGF;?FV[L;6#=,CTQUK6HH J:38_V?#';9W>5&B9QC.U0,XR<9QZUR]MX
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M^//.^QS>1L_U<F_S-W^KV-NV[?XNF,\>M<_\+?MGV:#_ %/V3]Y_?\[[S_\
M ?O?^.^] '4>%_%$7B2(W$(8*KE2' !R #V+<?-6Q7%>&/&LVJV%QJ$BH)(/
M-VA0P4[(PXR"Q/4\\CBJFA^*]4UZ#[3!#"NW=S(7 D(Z!%R,8Q@EFP3T(P0
M#T"BO/\ 1O'-]XBBW6<"!XU_>/*Q\LL,_NT P<D8.2V%SANS'=\&^+UU^U-Y
M(!&8R5DR<("JABP)/"X.>>G(R<9(!T=%<5I_B/4?$ ^TV<4,=N<[#<,S,^&8
M$XC/RXQR".O0L.FKX0\4_P!N*\<B[+BW;9,@Y4-DC(/(()4]R1C'(P2 ;LTR
MPJ7<@*H)))P !R22>@%,M;M+M1+$RNASAD(93@X."..M8OCSSOL<WD;/]7)O
M\S=_J]C;MNW^+IC/'K7.?#.:[AM87<P"R42DDEQ* &<DDGY  W_COO0!Z'17
M#Z9XHU#Q&#<6444< .%-R7+/@G)&SH!P".0#D!C@XT_"7BUM7:2TN(_)N8,;
MTR"""/O+WQGZ@ KACF@#I:KV6HQ7Z[X75U!P2C!AGKC()YYIFJ>=Y;?9MGF\
M;?-W;.HSG;STSC'?%>:_"3[9Y)\CR?L_VCY_,W^9]U-VW;\OW<8SWZ\4 =[;
M>*(KB[DTL!O-B0,20-F"%/!SG/SCL.];%<OI_BB6XU.?2R%\J*(," =^2(SR
M<XQ\Y[#M6%X6\:ZEXE1O)BA4HW,DGF"/&/N!022W?.< <$ D$@'HM%>?Z+XY
MOM7+64<""ZB9Q([L?(3:<#(7<23@K@-U&X$C(78\#^+)-<$L%P@2>V?:X7[G
M)8#')Y&T@\D=P><  ZBBN,C\4WFN2.-.CB\F)V0RSN2KLNW[HC.0.<@\@C!R
M#Q5[PQXI>]EETZZ54NH.3Y>3&RG&&4G)'##(//(/J% -K5K[^SX9+G&[RHW?
M&<9VJ3C.#C./2JGA;7?[>MDO=NSS-WR[MV-K%>N!Z9Z4>+/^/.Y_Z]YO_0&K
MB/ ]_?M81I911[8A)EIRP\QB[-B,*1P.A9B 6..-I- 'IM%<5:^.I;ZPFNXH
MU%U:\21OT!4@NVW<& V[B <'(*_-CG?M?$*36@U+'R>29&"$,1A<LH/ )!!'
M;D<XH UJKWNHQ6"[YG5%)P"[!1GKC)(YXJCX5U"74K6*YN%59)%W$)]W!)*D
M<MU7!Z]^W2N*^-?G>3']S[/YB_WO,\S;)_P';M_'/M0!VOBG7?[!MGO=N_R]
MOR[MN=S!>N#ZYZ5;TF^_M"&.YQM\V-'QG.-R@XS@9QGTKBO&OVS^SKG[;Y/_
M "QV>1O_ .>J[L[_ ,,8]ZBL]=U&WL([JVBB$$%NG$V[S6"(-T@ ( 7KM!.2
M!N'W@* /1:*YJX\=10V"ZL1D.HPF<$N3M* D#."#D@= 6 (K/N]9U:TC:]DA
MMQ''EFBWL90BGGY@=F=O.?\ QW/RT =K6/XH\41>&XA<3!BK.% 0 G)!/<KQ
M\M6M%UB/6(4NX<[)!D9&",$@@CU!!'IZ$CFN-^-?_'G'_P!?"_\ H$E 'H%%
M%<9'XIO-<D<:='%Y,3LAEG<E79=OW1&<@<Y!Y!&#D'B@#LZ*YKPQXI>]EETZ
MZ54NH.3Y>3&RG&&4G)'##(//(/J%S[;Q'J.N1F]L8H5A.[8L[,9'VDC(VD*N
M<8P3P0><8- ':T5R_A/7+O5+9KV18GW)F)8=Z$LNX,C&3@'< ,C(ZG)&*S-<
M\1ZIHL?VZ6*W\D,NY%9S(JL<8+9"DC(4E01DY (H V_&OBO_ (1B%;G9YFZ0
M)C=MZJQSG#?W?2N@KS?XM7JW^G07"9"RRQL >N&B<C.,\\UZ10!@^)O&$7AY
MHDD21VG+!!$H8Y7:,8+#D[AC&:I1_$>!76*XCFM]_P!UKB+8I.0,9R?7DG
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M!8$;CA.1QT^3)S@@,N1SQVM[H=O?MOFBC=@, NBL<=<9(/'-6X85A4(@ 50
M !@ #@  = * 'UYI\(=5BL89+*9UCG^T'Y)#L8EE50 &QDY4C Y!ZCD9]+JC
M+H=O+)]H:*,RY!WE%+Y7&#NQG(P,>E '&Z-_R'KK_KW7^4%'P4_X\Y/^OAO_
M $".NX33HDD-P$42L,%PH#D<<%L9(X'Y"BRTZ*P79"BHI.2$4*,],X '/% '
M#_#C_C\U+_KX_P#9YJ/AQ_Q^:E_U\?\ L\U=Q;:=%:LSQHJM(<N54*6/)R2!
MR>3U]31;:=%:LSQHJM(<N54*6/)R2!R>3U]30!Y%X0T'3X&FL=4"K<0R'#/(
M\:%< #:=R@\\C(!*L",C..Z\):7IL$LC:?M,D:A7*.[KA_F !8E3G;VSC&#B
MN@OM)AU#'GQI)MSCS$5L9QG&0<9P*EM;1+11%$JH@SA4 51DY. ..M &?XL_
MX\[G_KWF_P#0&KD/AMXRM+2Q$$LBQO!OW!S@D,S."HZMP<8'.>W(SZ%-"LRE
M' *L""",@@\$$'J#5*3P];2JL30Q%(\[5,:%5W')P,8&3UQUH X_X9VGV\WM
M\R_N+R9MJN.2H+DY'((^?'!(R&':N:D\X[O"2[A_I7RL=C?N.9.?N\CB3@Y/
M*\8P?8H85A4(@ 50  !@ #@  = *XW0],:\U2YU"2-D6)5CCWQ!=QZ,ZMW^Z
M0#R2K 9 P* .RAA6%0B !5   &  .  !T KA?C1"SV2D D+.A) S@;7&3Z#)
M ^I KO:9-"LRE' *L""",@@\$$'J#0!Q7C[6X-5TR=[>17&(2=K D;I$QD=5
M/L0#U]*N_P#,&_[A_P#[0K;C\/6T2M$L,023&Y1&@5MIR,C&#@],]*M?9$V>
M1M7R]NW;@;=N,;=O3&.,=,4 >2W>F/?:!"T8SY,C2,.2=H>521@'INR>@ !.
M>*U;72] N(A<_(H*DE7F<2#'4%/,SGV .?X<@C/HMK:):*(HE5$&<*@"J,G)
MP!QUJK_PCUMO\_R8O,W;MWEINW9SNW8SG/.>N: #0+6"U@C2U&("NY.6/#_/
MGYN><YYKC_C7_P ><?\ U\+_ .@25Z!5>]TZ*_79,BNH.0'4,,],X(//- %2
M'Q/:3,$2>(LQ  $J$DG@  'DFO+?"&@Z? TUCJ@5;B&0X9Y'C0K@ ;3N4'GD
M9 )5@1D9QZE#X8M(6#I!$&4@@B) 01R""!P15B^TF'4,>?&DFW./,16QG&<9
M!QG H Y_PEI>FP2R-I^TR1J%<H[NN'^8 %B5.=O;.,8.*X+1]96S@^S&^:T)
M,@>#[.\GEDNPPKGYE&,<;B0V3G)->M36)MX&@M L;;'$>% 16(.#@ C&XY/!
M^AKE=$\1OH4$=E)97 >%%5O)B62,G'+!E8 ENI]&)!)/- $L^H1Z1I32:6P<
M0H-I'SD;B"[,.S ,6(( 7NH Q7#ZY/%=:?\ :7OI9;B7:3#YGR;B^64PXR H
M!P>%R 5X*BNX^'/AR33A/>2*(OM;AEA _P!6H+%0>G/S=,#  S@Y Z!/#%H@
M($$0##! B09&0<'CD9 /U - 'GOC[_D#6?\ V[_^B&KU6JEQI,-RBP21HT:8
MVJR*5&!@84C P.![5;H \\^)LRPW>G.Y 59R22<  /$223T K;U[X@6UC&1!
M(LL[@B)(OWN7X"@[#P,D=2"1G;D\5NWVDPZACSXTDVYQYB*V,XSC(.,X%,LM
M#M[!M\,4:,1@E$53CKC( XXH \RUOP/+IFCB,C,B3">50=V 5*$# _A!!;L,
M,=Q&*T+72] N(A<_(H*DE7F<2#'4%/,SGV .?X<@C/I=9_\ PCUMO\_R8O,W
M;MWEINW9SNW8SG/.>N: //\ XEVL%KI=NEJ,0&9&3ECPZ2/GYN><YYK8\1_$
M"SN;"1TD!:>)D6,8\P,ZE?F7/ '<],="<C)\7=.EO[1$A1G83J2$4L<;'&<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1E6!^YM&, ;FQP1C;SG(K/\ "'A:YT_3;FRE3;++YVU=RG.Z)57D$@9(QR:
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M)!N;YF/FDG.<CE1P"![5T6A>';F\O#K%^%1E0K%$IW%!DCEAP3@G^]G<3\N
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M\MNQV ^\22<;P#C%6-"\.W-Y>'6+\*C*A6*)3N*#)'+#@G!/][.XGY< #/\
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MBBB@ HHHH **** "BBJ[ZC$D@MRZB5AD(6 <CGD+G)'!_(T 6**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 6E4C;TP0 #QT ':J^@Z^?"5K=V,IW2V+$Q@A<%92/+. V2-S;FYRH8#.>
M>@:?JD>H;_*;=Y4C1MP1AEQN'(&<9ZCCWHU/58M+0S3NJ(.['&3@G '4G .
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M[T'4KF!K'98K$ZD;464 9YR!C (/(..O-='X1TJ72;6.UG8-)&""02PQN)4
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MG!K=A+")-]P+%VD&QEY$>'.=H7[Q[?AQ6A\4O^0=/_VS_P#1J4?\P;_N'_\
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M&<N8M^XY[YP0>V!C  QCV7AN7Q5HUO C@2(Y8&0D@A'D0+D9( 4\<'H!@#D
M'7Z/XYL]8D^SP2AI""0"KKG'7&Y1D]\#G&3T!K>KA]*\6O9206&I6PAD8@0M
M&%:+/*   ML(!"\$_>YVJ:[B@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M! .!;\(>#/\ A''GD\UI?M#*?G'S#:6/+9.XG=R<#GG'-=+10!S_ (*\*?\
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MQCBMNB@ KR+X7>'9;JW>ZMKAH)3*4;Y%D0JJJP^1L?-EN&SP,C')KUVL_1-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***Q-;TJ[NW#VUUY*!0"ODI)DY/S98YZ8&/;WH VZ*\T\-W.
MHZU-<VWVS9]EDV9^SQ-N^9QG'&/N^IZU8\57%SIDVFP/.SL\Y$C+^Z#CS(\
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MR'8=<9R3GOP3P8O$5E)XTMK75+5%+1,Q\F7!#?, PR2 0"G0XW*3T/! .?\
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MFTNAOC20QXRP)5=KJ"0<\$X&,#  Q65\)/"UMJ$)O94W2Q7'RMN88VJC+P"
M<$YY%=+\+] GT2V>&Y78YF9@-RMP409RI(Z@UG^#=)OO"K-8^2LMN\P(F$BH
M0& #,4)). !\N!R" 6!!H [C4;);^)[=\A94921UPP(.,YYYKS_P_P")WTO2
MIUD)$]B7B^\KL&)VQG!XVJS;1U&$.,]*](KS?7/ D]SJ DC53:2RPRR@A NZ
M/<"".68L"QZ8)?YNF: #X<ZD^@PW5C=@A[,>;MWJS;&3<0HSC QG@XR_.#UJ
M7=D\&A33RY,MTZS/G;UDE3!&W@ J <=B3TZ#0^('@RXU*;S;15(N(A%*3A=N
MV1'#DY!). . 2%7'.1C>\9: UUI[V%JN2%B5%W <(Z\98]@.Y_6@#C_'W_(&
ML_\ MW_]$-6K\1_^/S3?^OC_ -GAH\7^%KG4--MK*)-TL7D[EW*,;8F5N20#
M@G'!K0\:Z!/J5S8S0KN2";=(=RC WQG."03PIZ9H ["O/_AQ_P ?FI?]?'_L
M\U>@5P4.E7GAR\N9[6 3PW1#\RI&P;))&6QQEFXP>"OS9!% #-&_Y#UU_P!>
MZ_R@K*\*^'UUN\U".9F\@7!+1J2H<[Y=NY@0<+R<#J<$_=P=CPGX=O;;49KZ
M\"D21$;XR-A.8\*%X; "XY';DGJ<3PM+=V]]?S6B+*JSL)(F8(S9DDVE6((!
M7G.3@C(P3C !IZ+;_P#"*:H-,A+&WNHS($)X1AN.03DGA".Q((W$E034\(:'
M'XX:;5;[<^9#&D98A44 ,!E=I. V.PZL02W&WX?T"ZOKUM7OU6-D4I#&&#%0
M<\EE.#PQ'.<DDX4!1532])OO"4LL-I"L]I(Q= )%C9">,9<DG  '?. 00=PH
M I>#=.;3M9N8&D:4K!]^0Y<@F(@$]R 0,]\=!TJ7Q';Z/YLBWLS/,Q;DO)(8
M\D_(NP%5"'.%8$CN"*N^&/#EY:ZE-?76UEEAQO3:%W'RSM"YW87!4$C) R>3
M5+POH>H>%#+:0P1RK(XVSEU3M@%ER7*KUVCD'=@G(- %OX53-J^GO!<$N@=X
M@"?X"B_+D8./F..<@<#@#&#X*\&6FI7-]#-'N2";;&-[C WR#&0P)X4=<UU?
MPOT"?1+9X;E=CF9F W*W!1!G*DCJ#6?::3?>&[NYGMX5N(KIM_$BQ,IW,<?,
M3TW$=#G@Y'*T 8FH:HNO7MPEW%<S0V\@1(K<%HP5WH6<+M.2<E3G/522!6AX
M2:2QOA#:07$5E,IWK<1L%5U5OF4DG&<*.2<Y([+C3FT&[\/W<M]8HLT-R09(
MBX1PV"=P9LC&XD]?XB-O 8;NB7M[=N7N84AB"D!?,\R0MD?-E?EVXR,?>R/0
MT ;=<)X!NFNK[4G<Y(F1>@'"&1%''H !_/FN[KA_"%J-,U&_MF)W3%)DRI&5
M)8L0>00K.%SGD@\<$  Q)=$&L:W<0L[+&(E+A"5WKLB!C)!'RG(SZ@8X/(MV
M%@GAC6([.U!6&Z@)9"S, 5#D$9/7Y.^<;FQC/&QIF@3PZM<7[+B"2$*K;EY(
M$7&,Y'W3U':C4] GFU:WOU7,$<)5FW+P2)>,9R?O#H.] &/9V8\:WUTMTS&W
MM'"+"&(0D;TWDKMY^4GU^8#=M&"7EF/!5]:K:LPM[MRC0EB4!.Q-X+;N?F!]
M?E(W;3@:$V@W?A^[EOK%%FAN2#)$7".&P3N#-D8W$GK_ !$;> P(=!N_$%W%
M?7R+##;$F.(.'<M@'<67 QN /7^$#;R6(!W%>:>#K[^SYM7N<;O*D9\9QG:T
MQQG!QG'I7I=<5X5\+203:A]I3$5W(=OS#YE9I<_=.1PPZX/- ''Z*8-607=]
M;WEU*^?G56,0 =N$V,F!SR.@.0 *U='GU 6-W;1),OD[?LQE0K-Y98[ER< E
M4'&WD$X7^$#3T*TU+PJALDA6ZA4DQLLJQ$ L200PY)Z]\9(W'MOB>_-M)+LB
M%SG,<>YBH7@[&;(R_49!"YP<@9H XCP);:83''\\-]$R[O,9HW+@C<H&=A#$
ME-N-Y7.1GFCQJJKJ/F:HLK6(55B*Y\L,P&<E2#U#$@'><+P5P*T/$NB7WC+R
MX);=+9(V+&1Y5E;!P"J[.>G)!P&('S#'/1:GJFH6<S+%;+/"0I0K*L;#CY@V
M_.3GI@ 8QR3G !8\(P6L,.+%]T!;(&\N$)525&<E?[Q4\@L>F<5%X\TN/4+.
M;S5W>5')(O)&&5&VG@C.,]#Q[5G_  ]\)RZ)YT\^Q7N65O+B'RH!N.WTX+$8
M&0 !ACGCI=6L?[0ADML[?-C=,XSC<I&<9&<9]: .*^%OA:V^S0:EL_TC]Y\^
MYO[SI]W.W[O'3]:Q/A?X4CURV<W)9XEF;;$"54-L3,A*D$G&  >%&?[W'3>!
M+>^T94TV>!?*1I,3+*N,$EA\G+'+'C[O!&1P<R_"_0)]$MGAN5V.9F8#<K<%
M$&<J2.H- %+X73-;M>::"3%:SD(6.6P6<$>F/DSP!R6/>N?\2V^CK%*AF:6[
M"$K*7DD9F R@+ &,CHOL.,@C-=%H'A*=7U))AL2\9A&V5;AC+\V V> P.#BL
MW3-(U+3K.72%MH_F$H\X2J P8'DK]XL1\JD[<?+N "F@#5TC4)-0T1YIF+.;
M:X!8]3MWJ,GN< <]3U/-8_@3P%!K5BDMTSOO\SRQO8+$-Q4[1G&21N.00>..
M#GH-#T">UTEK!UQ.89UV[E/+E]HR#CG([_6M#P%I<FE645M.NV1-^1D'&9&(
MY!(Z$=Z ,KX1:F]]8A9#GR9&C4\D[0%8 Y)Z;L#H  !CBK'Q/UZ31K,M"2KR
MNL88'!7(+$C@\X4CL1G(.13/A?H$^B6SPW*[',S,!N5N"B#.5)'4&M+QKX9'
MB.V:V! <$,A.<!AZX[$$COC.<$@4 9'_  JJV\O[S_:OO?:-[;_,SNW[=V.O
MXX_BW?-7.-KTFLZ%,TQ)>)TC+$Y+8DC8$\#G# =R<9)R:Z/^T=8\O[+]G3S?
MN_:/-39UQYGEXSTYQCKSL_@JO<^!9+'27TV$!YW*LV#@%MZ$X+D# 5<=LXS@
M$XH S/\ A H)M+^US,\DXM?,1V=OD 3>L:J21M'3IW)&.,/U'QC/#HL5R"1-
M,?*W@G<-I<%LG)+%4P3D')W C KK?[+D_LW[%M_>_8_+VY'WO*VXSG'7C.<>
M]85MX%DOM)339@$G0LRY.0&WN1DH2,%6QWQG."1B@"[:_#2"U42([B\&3]HW
M,7WDY+%"Q4@YP5.<J2"23NKG_%^K?VEJ#:?,EP]O!&I,5K\Q=B4?+@8.W! Z
MY! *D$FMNUU'6)HA;M;HDQ4CSWE0H#_>,:!CG'ID;N<;>*=KOAVYL[P:Q8!7
M9D"RQ,=I<9 X8\ X _NXV@_-D@@'.Z;NTV[A?3;6YABD94G6:-_+*EAAN2Q!
M4$G.0!@=BV?5:Y_2]1O[R1?-MT@B7._=*)7;(.W;L  P1\V[J#QTKH* /&M-
MU&/Q*TEY?07=Q^\<(D(+PQJ0I !4H=P P>Q&"1GFNE^'TLUM<2VB131V.TO$
M+A&#*V5RH8\8)+'&2>,]=Q+],T:]\(R21VD2W%K*[,J"01NA..K/G(QQU;.T
M'Y22#NP0W>LPSQ72) LT91%5O,==RLK%B,*>Q7;CC@\T <%XEM]'6*5#,TMV
M$)64O)(S,!E 6 ,9'1?8<9!&:Z"P\436VBC4&8O,$90QQG/FF)6.0<E>#R/F
MQR>2:S],TC4M.LY=(6VC^82CSA*H#!@>2OWBQ'RJ3MQ\NX *:W=!\)-+I0TN
MZ&QRL@/(;:3(SHWRM@X.#C//0]Z *7ASX?07UO'>7#227,R+)YQD<.I905VG
M=U3C!.>1Z844?B/;R>=IL7F?O?,V^;L'WMT(W[.G7G;T[5H:%/JNF1"Q:V1S
M'\B3&950*.%)0?,0/8!BO&-V27^)?#MU?RZ=)@.UNZF=@5 SF(LP!VY!VD\#
M\!0!B>//#T7A-8-3M=WGI.H9G=F\S*LS%^>K;>=NT$,P(Z8]3KC_ (H:!/K=
MLD-LN]Q,K$;E7@(XSEB!U(KL* /.M:M_^$KU0Z9,6%O:QB0H#P[':<DC!'#@
M=R #M(+$C,\4^&DT.^L!"S>2\Z[8F9F5")(]Q7<3@-G)'J"<\@#H_$&@75C>
MKJ]@JR,ZA)HRP4L!CD,QP.% XQ@@'# L*Y_Q5)=7%YI\UTJQ[K@!(E(<J%>+
M+,XX)8GH.  .Y- &KK/_ "'K7_KW;^4]'Q'_ ./S3?\ KX_]GAJ[XNT&X%W;
MZM9H)9(@4=&<+E2&Y!..?F8$Y/.WY2,UE:QHVI:U=VEY+$J10RJ?+6169 '4
MLS-QN+8R-N<  8!SD V/&L6G[U?496V[0!#O?;G+8D\N/YL]5W=,<=<5S_PW
MO8X]0N+6S=FLS'YBJ<XW9C!(W $8W%?4@#). :T]6\/W6G:D=6MHEN%E3!4L
MJ,A"JN0S'J<=0#P64@<$N\,:+>+J4VI74:HLT.!M=6 /[O"]<D@+AC@ D''!
M% &+<^'UUW6[B"1F$8CC9U4D;PJQ80D'IG!/TXP<$'Q6\+6VE6D4D";6201@
M[F.%/F2$<D_Q$G/7MG'%=+IF@3PZM<7[+B"2$*K;EY($7&,Y'W3U':K'Q%\,
MR>(;7R82/,1PX!_BPK#;GL3NX)XSP< Y !7U?3X/!%G<75E'L<JH^\S<EMBM
M\Y8?*7SC'/0UQEC86M[")+FUOIYI44F;8S<E ,J=P!4=5W \8SD<5W:6UQXE
MMI;._@$!9% 82"0%NNX*IR K '!8YZ9/-9^CW&J:)$MF]LMP(@%61)TC!4 8
M&&&<KTS@9QW^\0#$O;RZN=$G%ZK"2-T4&165V4/$03NZGDC/?'.3DG>\!>"H
M+6*#4'W27#1JP=F;Y0T84(%SC"J<#.?; P!:\4Z7=ZKISVSJC7+[<B(X0XE!
MX,A'\(YR>N<=JV_#UJUI;00R##QPQJPR#@J@!&1QUH Y+19F&N7: G:8$)&>
M"0L(!QZC)Q]3ZUWM</X9M1>:K>WZ$[$"0_=(!8!-XR<<J4P1[@YQC.J_B20Z
MB-,15:,0;W(/SH<G&>>0?E^7&?F#9Q0!T=>1?"[PA%K=N\ER6>(2D+%O94#!
M5)D^4C+8.!Z#/7(QZ[7'_"_0)]$MGAN5V.9F8#<K<%$&<J2.H- '+^"O#@U.
M:YTZ:21K2SE95AW$!MSL 6*D<#9NP,#<<C'(;8^%C-;27FG[F:*VFVQAL$@%
MI ><#KM!(Z9R0!DUH>"M GTVYOIIEVI/-NC.Y3D;Y#G )(X8=<4>"M GTVYO
MIIEVI/-NC.Y3D;Y#G )(X8=<4 8_B.WT?S9%O9F>9BW)>20QY)^1=@*J$.<*
MP)'<$5%X+U"2\T:Z$C%O*2=%SV40@A<^@R<>@X'  J7POH>H>%#+:0P1RK(X
MVSEU3M@%ER7*KUVCD'=@G(-6/"'A:YT_3;FRE3;++YVU=RG.Z)57D$@9(QR:
M ,K_ )ES_/\ S]5+_P (%!-I?VN9GDG%KYB.SM\@";UC522-HZ=.Y(QQC0_X
M1:Y_L7^S=G^D?W-R_P#/??\ >SM^[SU_6N@_LN3^S?L6W][]C\O;D?>\K;C.
M<=>,YQ[T <^JCQ'HHGNAO>.&5E.6SNA#HKDYR3@9.<@DGBCX6^%K;[-!J6S_
M $C]Y\^YO[SI]W.W[O'3]:U?#'AR2+3!IL_[N1HYD/1MOF,^#P<'A@>M5? E
MO?:,J:;/ OE(TF)EE7&"2P^3ECECQ]W@C(X.0#,\1V^C^;(M[,SS,6Y+R2&/
M)/R+L!50ASA6!([@BHO!>H27FC70D8MY23HN>RB$$+GT&3CT' X %2^%]#U#
MPH9;2&".59'&V<NJ=L LN2Y5>NT<@[L$Y!JQX0\+7.GZ;<V4J;99?.VKN4YW
M1*J\@D#)&.30!E?\RY_G_GZJ7_A H)M+^US,\DXM?,1V=OD 3>L:J21M'3IW
M)&.,:'_"+7/]B_V;L_TC^YN7_GOO^]G;]WGK^M=!_9<G]F_8MO[W['Y>W(^]
MY6W&<XZ\9SCWH / .IOJ=C#/*<N5()Y).QB@)))))"Y)[G-2^+HH)(?]+E:*
M(-EMK[-X"MF,XY8,,Y4<G'%1> M+DTJRBMIUVR)OR,@XS(Q'()'0CO69\1O"
M\VL""XMU5WMG)\J3&UPQ7(.2!@;>0<9!/.0 0#C?MME8W]H^D.P\R01RJ/,V
ME6=1C]X,G<">Y P" ",G=^+%LUU<6$2,49Y74..JEFB 88(Y'7J/K3]9TW4-
M>N;2YDMUBCMY@2!*CL!O0LQ.0,8'  )R#GJM:OC70)]2N;&:%=R03;I#N48&
M^,YP2">%/3- '.>//#T7A-8-3M=WGI.H9G=F\S*LS%^>K;>=NT$,P(Z8O:U;
M_P#"5ZH=,F+"WM8Q(4!X=CM.21@CAP.Y !VD%B1J_%#0)];MDAMEWN)E8C<J
M\!'&<L0.I%1>(- NK&]75[!5D9U"31E@I8#'(9C@<*!QC! .&!84 <YXI\-)
MH=]8"%F\EYUVQ,S,J$21[BNXG ;.2/4$YY 'K%>=:SHNH:U<VE[)&J)%,"8E
M=&,:AT)9GR-Q;!.%& %'\1->BT %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 45#=7:6BF65E1!C+.0JC)P,D\=:?#,LRAT(*L
M00<@@\@@CJ#0 ^BBB@ HHHH ***KW.HQ6K*DCJK2'"!F"ECP, $\GD=/44 6
M*S-?T"/7(Q#(678ZNK1MM=67HP///)['KD<X(TZ* ./NO!][?J8)[YFB? =4
M@CC8KGD!@<C(X[CU!&174:?I\>G1K;PJ%C08 '^>2>I)Y)Y/-6** "BBB@ H
MHHH **** "N?O?"GVF_BU7?CR8RFS;G.0XSNSQ]_T/3WK8348GD-N'4RJ,E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<_XD\*?VU-;7._9]EDWXV[MWS(<
M9R,?=]#UKH** "BBB@ HHHH **** "BBB@ HHHH Q_"OAT:##Y!<R.SL[N<@
MLS'[Q!9N< #KSC/4FK&EZ(FG-+*I9GGD+LSD%NF H. =JC[H.<<UH44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5]0U"/3HVN)F"QH
M,DG_ #R3T ')/ YJQ7G_ ,4/])FL+)^8IKCYUZ9PR*.1R.'8<$=?84 1>.?&
MEGK-A/%!*K/^[^4AD8_O%/ < G !SC..]6-6MK2XTNT6_D:.+9 04!)W>4<#
MA7XQGMVZU8^*FE1-I[/L4&#9Y>!C:"ZH0,=L<8Z=.,@8Y_Q]_P @:S_[=_\
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M4,A@R5/0[?.89'<9 XZ'H>*L?$+]S?Z=*GRNTQ4L.&*[XQM)'.,,W'3D^IH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN/N[+5;M
M&N!,D+A24@CC63/&55I).-V?E)'R\9'4U=\!^*&\26WVAP!(KLK!1A<C!&,E
MCC:PZ]\]J .CHHHH **** "BN$\3ZM=MJ4.F6TWDI+#N)\M).1YASAAGD*!U
M]Z:NO7GAR\BM+UQ/#=$+&ZHD;!L@'Y5QQEAG.>""IR"M '>T444 %%%% !16
M/XJ\31^'(#=2 GG:JC^)B"0,]AP23V XR< X]MI6JWH\V6Z2!FQ^[BA615&!
M_$YSG.<\L/0XX !V%%<5XMO[NVTV>2?;'.C( ]N[!2"Z?,N<,O4J0?0GH171
M>&)FFM+=W)+-!$22<DDH"22>I- &G1110 4444 %%%% !1110 4444 %%%%
M!117F7@^[U/Q+;O=)=A&5V4*8(R"0JL,L!P#NQT..O/2@#TVBN4\!>*9-962
MWN5VW%JP20C&TG+#/'&<J<XX[C@X'5T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '/^-O$?]BP$Q\W$OR0J.6+-
M@9"X;.W.>F"<+U84>!?#G]@6B0-_K&^>3_>;&1U(^4 +QP<9[UR^G6^H07,F
MHS61EF8D1EKF("-.R*,'GG!;J>>!EMW9:%J-S>;OM-OY&W;M_>K+NSG/W0,8
MP.O7/M0!K45S_@K[;Y+?VC_K?,./]7]W:N/]7QUS[_I704 %%%% 'FGBVXDM
MM9MI((_-D%N<)O"9SYP/S'@8&3^&*TX=!N_$%W%?7R+##;$F.(.'<M@'<67
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6\3[<*!MW9Y*XP<\Y'/- ':Z?J$>HQK<0L&C<9!'^>".A!Y!X/-2S3+"I=R
MJ@DDG  ')))Z 5R6B>!Y]$MC:6USL<S%S)Y*MP4"[-K,1U .<^V*J>*].O+/
M3[KS;AIV94QMB6(JH<>9]PG(*GYL\  ]B: +R?$NWF):..=X5.&F2$F)> 6)
M/# *#D_+GT!XSD_$*99KO3'0@JT^00<@@O"001U!KJ/!.S[#;^7MV^2F=N,;
ML?/T[[L[N^<YYKE?'FS[3I7E;?+\X;=F-NW?#MQCC&.F.,4 =5X@\7P:$5CD
M+-+)C9'&NZ1LD+P.G7IDC."!DC%1:-XUBU*7[(R2PR[=RI<)Y;,.<E>3G&/Y
MXS@XY*[@N+C6IHXYS S0+Y;,@DW* A*JKD#&X,>.ZM[UL3^ [F^F@N;F[\S[
M-('4>0J=&4D95AUVCJ#B@#:UOQ9'I3BWV2RRE0WEP1EV"DD;ST&,C'7.2.*9
MX;\90:^SQ1[DEB)#1R@*XQP3@$\ \'N#U R,YNJ>+;B:\;2;&-#)&H9WG)V
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MY2[.JV$JK+(%5TF7*%5 R-P!(!VKQ@'J0PZ5CZKXMEUW3[R$QM'<6VQ9 AW
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MJ%(P>>X(RI!H^%4*IIT1  +&0D@8R?,89/J< #Z "LGX)PJ+21P!N,Y!..2
MB$#/H,G'U/K0!V>A:[%KD0N8#E6Z@_>4]U([$?\ UQD$$\_=?$Z"%3.L5P\
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MSC/:@#T6O-_B#XHEL[RUBC$ZK'*-X0$+*"8SM7!&\CE2#W..]>D5Y_\ $?\
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MBT;"@ ?8"< 8Y:$DGZDDD^IYKA]3W_V!;[-VWSCOVYQMWRXW8[;MO7C..^*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH R=%\-1:0\TT>XO<R%W+'/))
M(     +''?GDGC%C6M'CUB%[2;.R08.#@C!!!!]00#Z>H(XJ]10!7TZR6PB2
MW3)6)%4$]<* !G&.>*S[GPO%<7<>J$MYL2%0 1LP0PY&,Y^<]QVK8HH HZQH
ML.L1^1<('3(.#D8(Z$$$$'Z'ID=":P(?AM"%$4DUQ)" !Y4DQ\L@?=&%"\#@
MC!&"!76T4 9^NZ%%KD1MIQE6Z$?>4]F![$?_ %CD$@\)XU\%1:182R;Y96C6
M-8_/?>(P9$!"# "Y  /L,# SGTNH;JT2[4Q2JKH<95P&4X.1D'CK0!A:;H\>
ML:;#:39V26T(.#@C"*00?4$ ^GJ".*SY?A7;3Q^3+)/(% "%Y<^6!C(08V@$
M  Y!X QBNPAA6%0B !5   &  .  !T I] &3/X8@NK=-/E7?%&J ;C\WR# .
M5P0<=2,=2.AQ61#\-H0HBDFN)(0 /*DF/ED#[HPH7@<$8(P0*ZVB@#!USPA'
MJTJW7F2Q2JFS=!)L)7.[:>#P#SQCWS@8?X?\(0:$6DC#-+)G?)(VZ1LDMR>G
M7K@#. 3DC-;=% '+ZA\/8+F=KV-Y8))!AC;N(]W.23\IY/&>Q(R1G)/4444
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MH5F4HX!5@001D$'@@@]0: /-? _@:'5+".7?+$TPD$GDR%1( [* RD," ..
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M9-R2Q$%9(B%<8Y R0> >1W!Z$9.:0^'%OOBG9I6EADW^8[AG<@J0'8J20H4
M 8P,]R375T4 %<OJ/P[MM0N'OY#)YK@8*OMV,H4*ZX .X;<C)(SVZ5U%% '.
M:'X%@TF9KS=)+,PQOG8.PXQP<#DCC)R<<# )R_6_!$&JR"[R\4XQ^]@?8Y !
M&">1T.,XS@ 9QQ7044 8FB>$X]*<W&^664J5\R>0NP4D'8.@QD9Z9R3S6W11
M0!RDGPX@5VEMY)K??]Y;>78I.2<XP?7@#  Z 5IVOA6&UMY+)-VV</YC%BSL
MSKM9R6S\QZ],9[5L44 9^@:(FB0)9Q%BD>[!<@M\S%CG  ZGTJOX7\+Q>&XC
M;PEBK.6)<@G) '8+Q\M;%% &)X=\(PZ#"UG'N>.1F+"7:V=RA2.% Q@=,>M8
MZ_"NV17B62<0R%B8A+^[R>AQCDK@$9)Y49SW[.B@#'L?"\5E:'2U+&(I(N21
MOQ(6)YP!GYCCBJ__  A4/V+^R-S^5ZY7?_K/,Z[<=?;I^==!10!@ZCX*MM1M
MX[*92RPH%1LX=<+MSD8YX!(QM) R.!4%IX$CB=999KB?RV#*L\Q9593E7  7
MD>^1@GBNEHH Q_$WA6#Q'&(9P?E.59<!U]<$@\'N""#UZ@$8]Y\,+>^39-)-
M(^X'S)) \@"@@(&92 N6)P!R>IX&.PHH *Q_$WA6#Q'&(9P?E.59<!U]<$@\
M'N""#UZ@$;%% &"G@Z%X#9W#27",^[,[EG!P ,,-I X[>I[$BLU?AC P6.66
MXEBCZ1RS9CX!4<*%(P#Q@CTZ<5V%% #(85A4(@ 50  !@ #@  = *BU#3X]1
MC:WF4-&XP0?\\$=01R#R.:L44 <>?AG$JF%)[E(FW?NTF_=@,22H4J>.>^<]
M\UNZ5X;M]*B:UA0")R2RDEP=P"G.\G@@8QTK3HH Y)/AM#;DBWFN($8YV0S%
M4S@ GD$Y..<D_E@5I77A"":T.EJ&2 XX1LL/GW\%]W4^N:VZ* ,_^Q$^S?V?
MEO+\GRLY&[;LV9SC&<>V,]JKV'A6"TM1IA!>'# B3!)W,6Z@#D$\$8(X(Y&:
MV** .2B^&T,0\M9K@0Y/[D3$1;6))3&,[3D@\Y/KGFM?5/#46H6O]FG<L6U%
M&P_, A!4 L&_NCKFM:B@"I::8EM"MGC=&D8CP^#E0NW!XP<CKQCVKEU^%=LB
MO$LDXAD+$Q"7]WD]#C')7 (R3RHSGOV=% &/8^%XK*T.EJ6,121<DC?B0L3S
M@#/S''%6- T1-$@2SB+%(]V"Y!;YF+'. !U/I6A10 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK)+%'*R2*@4D!-P+)RN0V1QP0!GG- '045S_ ("U235;**YG;=(^_)P!G$C
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M!"F3)5NA/RC:S#)&0,9!- '9T5YI=Z[=6T;7?]HVS2)E_(01E" <[ ^=YRO
MXSGC/\56/%GCJ4Z=#J=H3$TLH4@A6Q@2!AR",;EX. <>G(H ]#HKG_#5E?*?
M/O9E.]3^Y2-0J$D$8D')P.._7J<9)X]U232K*6Y@;;(FS!P#C,B@\$$=">U
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M&!%T20"HP^?+V [@"H.[U4\]1VA\0ZKJ'A8PWUQ.LD+RA9(DB5=NX$D(?O,
M <$D'(7.<G !Z'116)K=E>W;A+:9(8@H);R_,D+9/RX;Y=N,'/WLCT- &W17
M%>$M?NA>SZ1=LLK1+O60*$.#LP"H '(<'V.1EA@C/@\0W?B"^GM(;A+9(&**
MI1)'<J6!(#X)X4DX/RC P>6H ]%JIJFJ1Z5&US.VV-,9."<9( X )ZD=J-+C
MEBC5+AE>09!91M# $[6QV)&"P' .<<8KE?BU;R263R))MC3;O38#OS(@7YCR
MNT\\=>AH Z+4=8"6CWT.& @:1,@X.$++D<'!].#5?P9K;ZW:1WDH4/)OR$!"
M_*[*,9)/0>M<UI^G7,&FO++<>9$VGMMB\I5VYB!7YP<G XYZ]:I>![/4+ZPC
M^S2K;I&) F460R$NQ)8D'8H/RC )^\2,;10!Z;17%>'?'WGZ:VI3\O!N5N-H
M9AC;C&<;MR@G  )/ 45DVVNW6HQ_:6U&V@=U!6)1&5&5! 9G)93G[PPV.V>@
M /2ZKZAJ$>G1M<3,%C09)/\ GDGH .2>!S6/X'\4_P#"2VXN"NUU8HX'W=P
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M#PP5D^8D$Y!P.!DCC:0#TVBN$\;>-I+:*U^R%8S>X(DEQA%^0\@A@/OC)Y
M. 3@C=\/VEU"V^:Y6XAD3((C6,@\%2I0D,K G.?1<=30!-HFMRZA+/%) T2P
MOM1VSB098;AE5X^4'@GJ.?78KC_!6OSZE<WT,S;D@FVQC:HP-\@QD $\*.N:
MJ:7<:CXG@_M"&=+=7W^7$(@XPK$#<[Y()(P<#& "!DD4 =W17F\>OWD6E2:J
M;@N[B/9F&--A$NQQQD,#V)'09P">'_:-5N;'^TS.D96'>(UB5MRJ-V]F.[#,
M.< ;>@^4DX /1:*Y_2M;FUNQ2\M@@GD4<2AA'N5MK_=)..#MYSTSWKFO$^I:
MAX0$5Y)<+<1&3:R&)(B<@D8*@GH#SG@XX89% '=:IJD>E1M<SMMC3&3@G&2
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M^C4KJZ* .7@T<:QI4=H<9DM(@N20 P12A)'. P!_H>E<I\/+R7Q1<QW<Q/\
MH$ 0?,3N=]R[R"#R4^\<Y+!3TX'IMW(T2,\:[W"DJN0NX@<+D\#)XSVK ^'V
MAR:1:[;C=Y\LCR2;F#'<3C.1G.0H)Y)R3SV !TM>?_#C_C\U+_KX_P#9YJ]
MHH \_P!&_P"0]=?]>Z_R@HT;_D/77_7NO\H*] HH \BOYH#?W":X9-@)-N"7
M\L(6P"!'SDJ%Z<9#;_F%:7PB54FOA&K(@D3:CY#*-TN%.23D#@\GFO2Z* /+
M_B+?R>&+HW</"WMN\;8=@V]!@2#L"H*[<?[0X)W5W7A71/[$M8K/.3&OS'.1
MN8EFQP.,DXXSC&>:RO$FCSZK>V@VM]F@8R.X=0"XY0%#R<%1S@\.0,<FNKH
MX?XG:?(!;ZG&I?[%+O9!W7*L6SV V '@X!R> :RO''CB'7;"2.U#/D1F0E2H
MB&]2 Q/!8MP I/\ $<X'/IM% 'F7B+1)+NRTZ\CC,WV9(2T07.Y66,GUX^4
MC:>&R> :M0^)-&N%'DVZR2L 1%': R>I'W=N5&2?FQ@'!->AT4 <UXMO[+3H
MX[:]C_T=\J"(\QH57 'R\J2"0NT9'., 9KE/"&/[0']E^;_9^UO,W;O*W[/X
M=_.<[/\ ;Z_P5ZA10!Y_\./^/S4O^OC_ -GFKE]'MUE@V.E]ES()/L04VSDN
MP) 7*$;<*=ORX& .Y]@U&V:ZB>)&*,Z,H<=5+ @,,$<CKU'UKE-.O-2TB)+/
M[(LWDHJB2.X5%8* !\KC<"!P<]2"1QB@#*\0ZQ::AH\J6.!'$(04P0RYD0X(
M/4GG+9(8YY)S6[_S!O\ N'_^T*?X'\,R:4);JX(\^[?>ZK]Q.6(4=<D;CDY(
M[#.-QZB@#R=9KF'0H7M"P*NY<QG#!!)(2<CD '&<<XSGY<USGBI=--M&=/5S
M(&3S';?P"A^5LG9N8C/RC'RMC Z^]T4 <Y\0]/DU"PFAA4LY"$*.IVNK' [G
M /'4]!S7-66IP^+-,_LFW8_:4MDRA4CF$IQN.%PQ  .[@')'!%>D44 >7Z#K
MNEVD*07T"0W$2JKK+;[F)"C#Y$9/S#GGG.>HP3WOAT1&$/#"8%<DF-HQ$P(.
MW)4=SC\L5IUC^+X)KBTFBME#RR)M"D@<.=K<D@9"DD<]?7I0!SGP;M6AL2[#
M DF=EY'( 5,^W*D<^GI4WQ=M9;BQ/DAB%D5I I_@ ;)([@'!/7&-W09'3Z)I
M:Z5!':KC$2*N0-N2!RV/5CDGW/4U>H ^=[R*VN;13:0R>; %:XF=OE&X[0H
M8C!9N. V%Z'YB/4-7T^34-$2&%2SFVMR%'4[=C' [G /'4]!S7<44 >:?"WQ
MK#Y<&D;7\W]YSA=G5Y.N[/3VZ_G7:^+/^/.Y_P"O>;_T!JUJ* /$M$T&36='
ME6$$O%=F0*!DMB-5('(YPQ/<G& ,FK6B^+;&UA2TGL@]V@V%1!'\SJ2J@EB7
MW'C=\I.[.!VKV.B@#SSXA6<D^EQ_9XC$H*221(-NQ2K,P*@+D*Y!/'!&X@8)
M'G5Y%;7-HIM(9/-@"M<3.WRC<=H4 ,1@LW' ;"]#\Q'T110!YYJNNP:;864=
MW 9H)8$#$ '81$NW&<?,<G!W*0 2,XKG?A]9>=J7VJQ25;,;P2_  *?<)!(.
M'(P,DXPQZ$U[+10!Y%XFNSX<UH:E.C>2PRI4 [OW/EG&2!D-U!(('/<9]-T#
M6TUN!+R(,$DW8#@!OE8J<X)'4>M:%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 45Y_K_Q+^QWD-K T+V\GE[WW;MNYRK?,KA1A0#R..IXKK8?$]I,P1)X
MBS$  2H22>   >2: -.BJ][J,5@N^9U12< NP49ZXR2.>*)=1BBC^T,ZB+ .
M\L F&Q@[LXP<C'K0!8HJO%J,4L?VA74Q8)WA@4PN<G=G&!@Y]*ALM<M[]MD,
ML;L!DA'5CCIG )XYH O445P7C_XC-H31I:&*1B9!("=Y4KM !"L,'D]?3VH
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M639G=NW?,XSC Q]WU/6L?2=1E?6KFW+L8E@4A"Q* XAY"YP#R?S- '<4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'BGB_PM;:?J
M5M91)MBE\G<NYCG=*RMR22,@8X-:'Q0\#P:3;QSVB;520AP S'#@88LQ) !4
M #IEN,$\[?Q!\)75Y<P:G9A7>'8-C$+RCEPV2R@@DX(R".,9R<:J6-WXAL9K
M:_C2.5]P0*WR\!2C$JSGA^O/0=/4 X?Q[K7_  DT-FL;C<T$TTB_,J9C0D\$
M')!CD5>OUP<FEXD\2KJ&DVD!_P!8LA4X!"@0+M .3U*NAXR.O3I72_#?P==Z
M=/Y]XBJL,)2+)1F!9RY(VY]6R2<_-@9&<9OAWX=7EI=Q),I^RV\[R*X:,9(
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MD]F_$?P>WB. >5CSH22F3C((^9.N 3@$$]QC(!)H Y3QU\-K?2;+[3%D2P!
MYY(DW%4)P6.TY.1CCJ,'@C0T06SZ'''>R&.%RP++][(G9@ ,-D\=@>,GMD5+
MW0-8U^W^R7&V..).@8,\S*ORACO8$[@,DE1D[L,0,6[CP+<7FD16! 6>%V?8
M2#GYI,+N!(!(;(/3/!QR0 <%XIO=-N47[!%+'(&^;><J5(]W<Y!QC&!@G.>*
MZWX@:.;[3;74CEI8XH0[$C)61!RQ/S,=^,<_Q,<<DB*\\)ZIJEHMD\4<<=L%
M*(A3=(V=I).\@$ LQ.1DGH2<KW\.@FZT]=.F #&V2,Y ?:P0#.,X)5AD8/4<
M'O0!Y[X^\2GQ'!96L6UI+C:[  KA^8@ 6.,;]XY)Z YQR:GC31AHE[%)<H\U
MDL<2+RP^58]FW<-H# J7V@@'VR<5_A1I;:G>+(^3':H6&X;E!).U>>%.YBX]
MP2!G)'?>(Y-5BGD2VBBGMI%7"R;<*-N'4@LA.3DG.X8(QCD4 7? $UD\+C3R
M=A<,R,3N1F11CYLG'R]<L"=V#@8#/BE_R#I_^V?_ *-2JOPR\&2^'$D><KOF
MV?*O.T*#U/3.6(.,CC@G/&KX]TN35;*6V@7=(^S R!G$BD\D@= >] '%>/O^
M0-9_]N__ *(:K'C7P1%I5FU\'D:[A,9,[2-O8[U7N3@#/RXY&!\QYS=\7^%K
MG4--MK*)-TL7D[EW*,;8F5N20#@G'!KH/'NER:K92VT"[I'V8&0,XD4GDD#H
M#WH TM#O6O[>&X? :6)&('3+*"<9SQS61XVBLV5&OY62(;OW8=E63)7JB?,V
MTX(QTZGBM7P]:M:6T$,@P\<,:L,@X*H 1D<=:Y?QEX;N)+R#5K9%F,("M$Y"
M]"Q# L0,_-QW5@IPW. #G/#%[;6NJQQ:8[?9IXSYBG=MW*KD#YQGC .>3R0#
M@D5K:U;_ /"5ZH=,F+"WM8Q(4!X=CM.21@CAP.Y !VD%B1+;Z3?7^IP:G/"L
M<:1LN%D5RHVR !CD9)+9^48 (!Y!JWX@T"ZL;U=7L%61G4)-&6"E@,<AF.!P
MH'&,$ X8%A0!SGBGPTFAWU@(6;R7G7;$S,RH1)'N*[B<!LY(]03GD ;O/A[5
MOX1!J2_[*@21C\222?;<9.Y%5=9T74-:N;2]DC5$BF!,2NC&-0Z$LSY&XM@G
M"C "C^(FMWX@:#+JD*26H'VFWE22/A<\'D98@ =&.>#M Q0!GVS'6M8:0$F+
M3XMH*N"OF2 @_+V."P..Z#)[5G^([?1_-D6]F9YF+<EY)#'DGY%V JH0YPK
MD=P172^ ]'ETVW)N<B>:6220$J?F8XXV<8( ./4GZ#FO"^AZAX4,MI#!'*LC
MC;.75.V 67)<JO7:.0=V"<@T 1>"]0DO-&NA(Q;RDG1<]E$((7/H,G'H.!P
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M7UJMJS"WNW*-"6)0$[$W@MNY^8'U^4C=M.!7^)6@0/?6;E>;J8++\S?, 8D
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MWRVD-N<28PA9$!R<DOQSVP<@FL&\T^*SC633[2]BNXBI21HVYQPVX;F&",Y
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M8.X,BR,Y'&,H01D$CMC))).T5H:GH$\VK6]^JY@CA*LVY>"1+QC.3]X=!WH
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MD^F$(Y)!W9*G:,V_&7A"+PS =2T\M!+"5SM=F#AG4;2&)X!P<=#R"#P1;O\
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MAQ\P;?G)STP ,8Y)SC"\/^"9["VO3($$M[&VV*+A5)1\+DG Y?&.0 !\QSP
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MV@='W$;%2,,D84?+M &#D$DEFR">-76XK_Q!836LML(YB(MH$J,'(<%R.?E
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M-=KJWF>3)Y'^M\M]G3[VT[?O<=<=>/6N:\%:!/IMS?33+M2>;=&=RG(WR'.
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MED=FW.)#E\C=@9/IS[DY)Q/&/@B1M.@TVS7>T,BD\A<_*^YOG;C+-G&3C/'
MKT"@#R3P5X,M-2N;Z&:/<D$VV,;W&!OD&,A@3PHZYJVVD_VKK=S SLL9A3S
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M8!(/7([C2;'^SX8[;.[RHT3.,9VJ!G&3C./6@"W1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M4U73$U2)[649212#TR,]",@C(/(.." :X)?A'+ KPPWLB0N6R@4X(;C#8D4,
M<<$X&?3M7I%% &/X9\*P>'(S# #\QRS-@NWID@#@=@  .O4DG8HHH **** "
MJ^HVS743Q(Q1G1E#CJI8$!A@CD=>H^M6** .:\#^"5\+(Z!_,>1@2VTKPH^5
M<;F'!).>^?85TM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex19-1_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex19-1_007.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
M0$! 0$! _]L 0P(-"PL0#A ;%!LD,B@A*#([-#(R,CL[.SL[.SL[.SL[.SL[
M.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$! 0$! 0$! _\  $0@(F :D P B  $1
M 0(1 O_$ !\   $% 0$! 0$!           ! @,$!08'" D*"__$ +40  (!
M P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A""-"L<$54M'P
M)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F
M9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!
M  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$
M  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A
M)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V
M=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G/B!KP
MT6SDD!(=QY:8)!W.#R" <%1ENW3&02*ROAQ>SV[W&EWCEYX'# M(7)5U'3/.
MT8!_X& 0#US_ !YXAA34+6WG<K#;GS7*DM\_6,% #R-H]]KG&.IS]3\76O\
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M<?\ &O\ X\X_^OA?_0)*Z73/!EIIT8@6%&&W:Q=%9F&0WS$CGD XZ @8  &
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M>""#U!H XWPW\1$OIKF*XDA2.&3$3;PN]=SC.68AN .1@<^XJCI<RPZY>.Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[BB@#E_"7A>71[B[N)"I6ZEW(%)) W.><@<_,.F>]&G^%Y;?4Y]4)7RI8@H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+"*,,N 5#,""03R.#W&1S5WPWXJ75V>WD0PW,).^)CD@=F!P-RG(Y'J.Q4D
MWJ*\_P!$^)T^N96ULV=TR6'G*J@<;?F90,DYXXX&1GG'H% !6/<^*(K>[CTL
MAO-E0L" -F &/)SG/R'L>U9FL^-VM[K^S;2!IY@NYP'$:J, CYF!'0CG@<@
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MN8D(*H"0IW28P #D;L$<<[00: .EHKE]/\9N)UL[Z VSRC]T3(LB.<X*[E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH X2^\)!))M1TZ[\E]TAE!8/%O R0W.%P22
M=P;;G( P!6;>^))?%6C7$[H!(CA2(P2"$>-RV#D@!3SR>A.0.!U6H?#RPU"1
MIY(07<Y8AW7)[G"L!D]^.3R>:VXM.BBC^SJBB+!&P* F&SD;<8P<G/K0!R5Q
MJL5OHJNSJ ]F(UYSES%LVC'?.01VP<X ..?_ .9<_P _\_5=A;_#?3X-V(%^
M92IW,[<'TW,<'T88([&K_P#PBUM]F_LW9_H_]S<W][?][.[[W/7]* *'A;7X
M$TZ*Y,BB.&%%<_W610"I'7.>@QDY&,Y&?/\ 3+5H= N'88$DP9>1R \29]N5
M(Y]/2O0+CX;Z?/MS ORJ%&UG7@>NUAD^K')/<UKW^BPW\)LY$!A(4;!E1A2"
MH&TC &!TH PO^8-_W#__ &A65X:_Y +?]>]U_.2NU_LN/R?L6W]UY?E[<G[N
MW;C.<].,YS[U%;:!!:P&P1<0%67;N8\/G<,DYYR>_P!* ./\-?\ (!;_ *][
MK^<E1>&M%M]9TBWMKIMBM(VPAPK;_-D  SD$D$C&#[#.".UMM @M8#8(N("K
M+MW,>'SN&2<\Y/?Z57?PC:O;C3S&# IR%)8X.2V0V=P.2>_0D=.* .2&JW?A
M*YM]/EG6ZCN64?.-LJ;GVYSEB02W!8G.TJ-N,U:OO"022;4=.N_)?=(906#Q
M;P,D-SA<$DG<&VYR , 5T&C>"[/1F\V")5?^\2SL."."Y)&03G&,]ZKZA\/+
M#4)&GDA!=SEB'=<GN<*P&3WXY/)YH Y+4O%+^)-%N+B555UD1#LSM.)(V! .
M2.&QU/3/? B\2?Z-#H]Z_$4/D[VZXRL3#@<GA&/ /3W%>BW6@074!L6C40''
MR)\B\-NXV8QSSQ4HTJ+RA:%%:)550CC<N%QM!W9SC ZT 97C/58H+":5G7;+
M"ZH0<AC(A"@8SG.<\=N>@)KSKQ%:M:Z':(XP3,&Z@\.)74\>H(/\^:] M?AO
MI]JPD6!21G[[.Z\C'*NQ!_$>_6M76] @UM!#<KO0,& W,O(!&<J0>A- &)\4
MO^0=/_VS_P#1J5J^$_\ CSMO^O>'_P! 6K>J:7'JL;6TZ[HWQD9(S@@CD$'J
M!WJ6TM5M$6&,82-0JC). HP!D\]* ."\53+INL6EY,0D)B9-Y/&[$@Y]!^\7
MD\<]>#C0^+.H1V]@\+L \I0(O<[75FX] !R>G0=2,]1J>E1:HAAG170]F&<'
M!&0>H."<$8([&LK3/ -CICB:*%0XZ%BSX((((#E@"".".1ZT <?\2K5K32;6
M&08>-H589!P5A<$9''6O4*S];T"#6T$-RN] P8#<R\@$9RI!Z$UH4 <5XO\
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M5+66:1H87B*>;&^Q@P+]^=H^=021C!//!QJZK\.[>952ZN[@JS@*)9U(+G(
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MLN9XUVJVYN =W&,X/WCU'>@#G_B%XLET3R8(-BO<LR^9*?E0#:-WIP6!R<@
M'*G/'+^*;2>TOK!+FY$[>>I \M(RH,D8SA2<AL<9_NG'>O2M8T6'6(_(N$#I
MD'!R,$=""""#]#TR.A-95K\/+"U9'2$!HGWJ=[Y##!');D#:, Y YP.3D PO
MB/\ \?FF_P#7Q_[/#7H%9^I:!!J3Q33+N>!MT9W,,'(.< @'E1US6A0!YUHU
MVGA;4[JWN654N\2I(Y"K]YCM/4#EF&21G;T^85W6IZK%I:&:=U1!W8XR<$X
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MT""&=[]5Q/(NUFW-R!MXQG ^Z.@[43:!!-.E^RYGC7:K;FX!W<8S@_>/4=Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M TJS/M=USB,94;CA6X^8GDCH>?2QJ6OP::\4,S;7G;;&-K')R!C(! Y8=<4
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MQ[T =11110 45CZ)K<NH2SQ20-$L+[4=LXD&6&X95>/E!X)ZCGUV* "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=>1TYQDY_P 4-?GT2V2:V;8YF52=JMP4<XPP(Z@5N^'1$80\,)@5R28VC$3
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MR*\B9MKQQK$LB@C(==A.<8.<D#H.^5;XKTR6VEL]6NHC.L< 2X0(K;2%8LY
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M"G )*FJD/B31KA1Y-NLDK $11V@,GJ1]W;E1DGYL8!P31XVMSX?N[;650M!
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MY_WMF#T]MNSI\F<[>]97PSUR/P^'TF[W1W!N!A2I()<*H *Y'4=3@$$$$CH
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MRRP4 DA.<@ENGS9*Y^0TWX>K NJSBU5D@^S_ "!MP."8CN^8DX;[RY[$=.E
M&A!XAN_$%]/:0W"6R0,452B2.Y4L"0'P3PI)P?E&!@\M7=:7'+%&J7#*\@R"
MRC:& )VMCL2,%@. <XXQ7!>+-4TB]>5+Q&2XB+KPC+(V%&U@5^5@0!LWG&.P
M4\[OPU^U_9/]-W[_ #&V^;]_;QUS\WWMV-W.,8^7% $7Q0U^?1+9)K9MCF95
M)VJW!1SC# CJ!69XAN]5TFW_ +4>:,%2A>W6(% "0N-Y+,3DC=R.IVMP,O\
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MW[#Y2LTA!(^;J% (VC:N>I(/!.AX=\?>?IK:E/R\&Y6XVAF&-N,9QNW*"<
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M@ HHHH **** "N/^%^@3Z);/#<KL<S,P&Y6X*(,Y4D=0:["B@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.E<EX>F:70F+$D_9KD9)SPOF #Z   >@XJO\-O!MI=V(GEC61Y]^XN,D!69
M%/5>!G(YSWX& #O6U&)%1RZA92H0EAABW*A3GDGMCKVJ6:985+N0%4$DDX
MY))/0"O(O#^F/X@T66 #<]O,QB'.1M"N0 HRQ(=P <\L.F!C=\3>*/[7T^WA
MC8";42D>1N10=P$O8G:&^0CN#D;AU /0(9EF4.A!5@""#D$'D$$=0:B?48DD
M%N742L,A"P#D<\A<Y(X/Y&G6EJMHBPQC"1J%49)P%& ,GGI7G7BW35U/6;:W
MD+!'MSNVL5) \XE<CG# 8;U!(XH [VRURWOVV0RQNP&2$=6..F< GCFK%U=I
M:*9965$&,LY"J,G R3QUKSKXDZ5%X=$&JVB+'+',JX0;$8$,V&5<>F#C&5)!
MSQB:ZM5\1:RUM<C=%:0AD3)VDG826!R#R_.,9"J#D @@'=6.K0ZAGR)$DVXS
MY;JV,YQG!.,X-%]JT.GX\^1(]V<>8ZKG&,XR1G&17G_Q)TJ+PZ(-5M$6.6.9
M5P@V(P(9L,JX],'&,J2#GC!XFT>6UU$ZC-;-=VS*BJJ_.4X /[O!SC#$ C;E
M@=P;H >BVMVEVHEB970YPR$,IP<'!''6JMKXAMKMA%%-$[G.%21&8X&3@ YZ
M5RC>1XAT^XATC:CR;2R#]V02%RI'0;E7;Q\C'//WC65X=O++2A%:7]K]FFC8
M;99$R'>-E.X2XS][GJ4"\;MIQ0!V%[:[K^*7[5LQ&1]FW??X?Y]N\9QG^Z?N
M]?3G-+F6'7+QW("K; DDX  6$DDGH!3]9_Y#UK_U[M_*>J4>CQZKKEQ'-DHL
M2,5S\K;5AP&'\2YP<="0,Y'! /0K'5H=0SY$B2;<9\MU;&<XS@G&<&N*T;_D
M/77_ %[K_*"J_B+3X_#6HV=Q:*$^TN8Y$7B,C*+G:N.?FSZ;E4XSG-C1O^0]
M=?\ 7NO\H* .UOM6AT_'GR)'NSCS'5<XQG&2,XR*EM;M+M1+$RNASAD(93@X
M."..M>1>$GEU<RZ@UBMW))*P+O,JJN0IV!)-W"\8/4 [<X%=1X(TF[L+N9WA
M^SVLJ[A$)$D42?*,C:<C(W= !C [+0!W$TRPJ7<@*H)))P !R22>@%4I/$-M
M$JRM-$$DSM8R(%;:<'!S@X/7'2H?%G_'G<_]>\W_ * U<A\-O!MI=V(GEC61
MY]^XN,D!69 %/5>!G(YSWX& #NKC5H;9%GDD18WQM9G4*<C(PQ.#D<CVJQ#,
MLRAT(*L 00<@@\@@CJ#7EOPI\,0:O;R3W*^80S1*'.55<!SM'\))<G(Y';!)
MSJ_!V[V6#M(V$CF?EC\JJ$1CUX R23VY)H ["Z\0VUHQBEFB1QC*O(BL,C(R
M"<]*M75VEHIEE9408RSD*HR<#)/'6O+=3O-,FM9H;.TD=%1PLZ0DJK;=X)E8
MAP%)&<]N,%>O5_#R%=1TR%)P)%(<$2#>,+(P48;/ P,>F!CI0!#X$\?+K<1-
MT\23&7:J!MI(PN,*S$DDDCCKTKJ+[5H=/QY\B1[LX\QU7.,9QDC.,BO/_@YI
M,-S;-/)&C2)<':S(I881",,1D8/(]ZQ_"3RZN9=0:Q6[DDE8%WF557(4[ DF
M[A>,'J =N<"@#UVUNTNU$L3*Z'.&0AE.#@X(XZU2/B>T"AS/%M)(!\U,$C!(
MSGJ,C/U'K7+^"-)N["[F=X?L]K*NX1"1)%$GRC(VG(R-W0 8P.RUB_"'PO;W
MT,EW,BR/YA0"0!E "JV0I&,DGKZ# QSD [6RM=M_++]JWYC ^S;ON<)\^W><
M9Q_='WNOKI7NN6]@VR:6-&(R [JIQTS@D<<5QNC?\AZZ_P"O=?Y05%<:EI<S
MS1PVKW1=F:1X8?-PSD@X=B",X)!7Y>ZG.: /0H9EF4.A!5@""#D$'D$$=0:X
M+X*?\><G_7PW_H$=/^"\S/9,"20L[@ G.!M0X'H,DGZDFF?!3_CSD_Z^&_\
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M<^3(L:GDG:'B8 Y)Z;L#H  !CBMNW\&VD.D-+Y:M(UJ9=[#+[C'O&&X( (&
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M."48,,]<9!//-6*KV6G16"[(45%)R0BA1GIG  YXJQ0 4444 %%%% !1110
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M!);M&[,4:56$B!APN%!4[>Q.[/4^@F\.^!TTBTDTXNSB;?O8 *?G79P/FQ@
M=<\\].!TM% '&>%/#=[HZBPE:"2S!D'(;S"K9XQC;@DY(.[@D9(Q46F>%]0\
M. V]E+%) 3E1<APR9)R!LZ@\$G@$Y(49.>XHH YKPEX2;2&DN[B3SKF?&]\
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M64^>TF3$2<*Z*G5E'/![$=*["B@#SRS\'ZE9VSZ4DL'D,) K%7\S:V3MQC:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'!#$]3QP.*Z"O'_A5??VAJ5Q<XV^;'*^,YQNE0XS@9QGTK=N/B#=ZK/);:7
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MM^\PVJ78!5(!!R1ZE< J>0:M>%M:U"XF:WOX%C'E[U>/)7.[&TG<XR<YQD$
M="#D %OPIXUA\3^9Y"NOE;<^8%'WLXQAF_NFN@KQ_P"$.III<5[=2G"1K$3T
MR<>9@#) R3P!GDD"M"+XB:EJ4<E]:V\7V>+.XNVYAL4,V?G0G@YX7VY- 'J%
M%<OX<\>Q:Q:RWQ4J;<,70,&8!5+ CID$#C('(([9KG-/^(&I:N&N[6U1K=&P
MPW9D^4 L =RDD@\80]0,$CD ]+HKE/''CC_A'MD$2>;<39VJ#T[*2HRQRQP
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MP R1GG'0X[/6= @UI?+N8U<#IGAAR"<,,$9P,X(ST/%5-&\%V>C-YL$2J_\
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M7T#_ (5OI^_SO(7=NW8W/MSG/W-VW'^SC&.,8K:NM*BNHC:.BF(J%V8PN!T
MQC&,<8QC QC% '!?$3QK:WVG^5&X:2X$9"J5++AE<[\$[2,8QUSTR 2.?U:%
MGT&V(!(6=B2!G W3#)]!D@?4@5T?CGP79Z-83RP1*K_N_F)9V'[Q1P7)(R"<
MXQGO6E\/=/CU'2HK>90T;B0$'_KJ_P"1'4$<@\CF@#FO$?BVVDT>*S1PTKQ0
MKM7JIB*%MP[#Y<#UX(R,D4M3M6FT"W=1D1S%FY' +RIGWY8#CU]*]%L? -C8
MAQ'"H\Q2I)+,V&!4@,Q)7(8@[2,UI6&BPV$(LXT A 8;#EAAB2P.XG(.3UH
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MZG+<1':+B%V&T!CF12 3OZ?OEW'';CI\M=1\&]'%I:&Z.-UPY.03]U"5 (Z
MAMQX[$9/88GQE<WUQ:V,8)EPQ'0 ^:P51DGKE#G.!TYZX]0TZR6PB2W3)6)%
M4$]<* !G&.>* ,+XD6K76GSH@R0JMU X1U=CSZ $_P N:P?AOXNM;/3UCFE5
M&A,@(=E#'YB^57.XC#8X&200!7H=<Y+\.]/DD\\P+NR#@%@G&,?("$QQR,8/
M?.30!P7Q!U +>6.KE6\AHX7'3=A'\QAC/4!AWQD]>M7?C!XCM[VWBMX9%D8R
M[B8V5P JD<X)P3NX]<'TKTC4]*BU1##.BNA[,,X.",@]0<$X(P1V-96F> ;'
M3'$T4*AQT+%GP0000'+ $$<$<CUH \Z^*5JUI;:?#(,/'"RL,@X*I$",CCK7
M2_&O_CSC_P"OA?\ T"2NJUWPM;:]M^TIO\O=M^9EQNQG[I'H.M3:WH$&MH(;
ME=Z!@P&YEY (SE2#T)H \_U;1['6;>T@N)U@N$LXF5F "E2%'); ."#M4,",
MDX(S3_A?XEN;BYETZ>43)$CD/G?RL@&0_5E.[(SG@#&!Q77ZCX&L]16-)8@P
MA0(GS."%'1<A@2!VR3CGU-7M&T"#15\NVC5 >N.6/)(RQR3C)QDG'0<4 >5:
M%:M=W^IPQC+R0WBJ,@9+2  9/'6M#X2^*+?3;::*=UC*2%_G(&0R 849RQ&P
MY '<8R37?Z?X6MM/F>]B3;++NW-N8YW,&;@D@9(SP*JW7@&QNY3=/"ID9@Q.
M6VD^I4':<]\CGG.<F@#@OAA>K?ZI<W"9"RI,P!ZX:5",XSSS7.>$O#MK=336
MFHR-"\70AXU7*MM=2S9!.<8QV!]J]ML_#=O93&\B0+*R!"02!M4* H7.T !1
MT Z57UGP79ZRWFSQ*S_W@61CP!R4()P ,9SCM0!A>!/#EAI\\LEE,TKH@5\L
MK( Y###*@!/R]B<<@\UA? S_ )>O^V/_ +4KT71M @T5?+MHU0'KCECR2,L<
MDXR<9)QT'%0Z%X6MM!W?9DV>9MW?,S9VYQ]XGU/2@#6KQR_UZYUR_EM'NQ:P
MPO* 0WEC"-M X9=S' /+<?,1CI7L=8.L>!K/6)/M$\0:0@ D,ZYQTSM89/;)
MYQ@= * /.OA*0=1G(<R#RI,.007_ 'J?,0><MUYY]:O> /\ D,WG_;Q_Z/6O
M0K/PW;V4QO(D"RL@0D$@;5"@*%SM  4= .E,T_PM;:?,][$FV67=N;<QSN8,
MW!) R1G@4 <!_P S'_G_ )]:J?"?5(]"FN;2Z98W^7EV4*#$S*R[B<9RW&,Y
M ->E?\(M;?:?[2V?Z1_?W-_=V?=SM^[QT_6J^L>!K/6)/M$\0:0@ D,ZYQTS
MM89/;)YQ@= * /.M&UB/6->%U#DQL6 )&,[8"N<>AQD9YQU /%>QUDQ^%;6*
M5+I(U62%2J%,JJ@[L@*I"\[V[=ZUJ /*O '_ "&;S_MX_P#1ZU#J5TNF:^)Y
MSLC.W#,"%PT&P'/INX)Z#!R1@UZ+I_A:VT^9[V)-LLN[<VYCG<P9N"2!DC/
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M!S@#-<Y\./\ CSU+_KW_ /9)J](B^'>GQR>>(%W9)P2Q3G.?D)*8YX&,#MC
MJ[!X6MH//VIC[7GS?F;YMV[/?C[QZ8Z_2@#@/A\T TFX%V<0&9@QQN(W+& 0
M,-R"00<'!P>U8.H7;^")5.GW:S0R%B4#*X&".&4$C)&!O&UC@@;<5ZW:>$;6
MT@>Q2,>3*264EFR2 ,Y8D@\#&#P1D8-5],\ V.F.)HH5#CH6+/@@@@@.6 ((
MX(Y'K0!PFM7(T;7EN9_EC?9@Y&,-%Y6XY(P P.<]@3Z9]%L_%%O?3?9(761_
M++DQD,H 8+@L#C))Z>@YQQF;6= @UI?+N8U<#IGAAR"<,,$9P,X(ST/%,T/P
MW;Z$K);($#G+<EB<=.6).!V&<#)]30!XOX4M6NM/U%$&2%MVZ@<([.QY] "?
MY<UVWP\\8VUAIP65U5X/-RA9 [<F0;5+ G(; Z9;(]ZZ_0O"UMH.[[,FSS-N
M[YF;.W./O$^IZ50NOAOI]TQD:!03C[C.B\#'"HP _ >_6@#C/@]"L%O=W,X'
MD$*&)&X$(KLX*\D@*P[<YP,\UB:K$OA7;>Z5>!ED(!CW*7&5."R=&'7[R@H2
M!C/(]KBTZ**/[.J*(L$; H"8;.1MQC!R<^M85K\-]/M6$BP*2,_?9W7D8Y5V
M(/XCWZT >;_$9S>RV5]< B*>VB+^7C/7=(%#$X(#C&>.>IYK5;P)HX9$%TS-
M(ZHH26-R6;@<(AP/<X [FO3=3TJ+5$,,Z*Z'LPS@X(R#U!P3@C!'8UE:9X!L
M=,<310J''0L6?!!!! <L 01P1R/6@#H*\G^(DRPZO:.Y 51 22<  3,223T
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MT H ?17G_P --2GUZ6XU*9G\LMLC0OF,9^8C;QRHVC=@9R<Y)./0* "BBB@
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MO[YW_>^;[N.GX<T =71110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0PE<*Y 8>7AE4 J&8%SDDC&,@-D"@!OC[_D,V?\ V[_^CVH^.?\ RZ_]MO\
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M\H-@D\GECUSZ= *M_!3_ (\Y/^OAO_0(ZJ>"-)FMM)NX)(W61_/VJR,&.85
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<5_PA4W]K?VON3RO3+;_ /4^7TVXZ^_3\J[6BB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^>/E-_SPQ_K,[?N_-^G6NEUGQI9Z,WE3RJK_ -T!G8< \A 2,@C&<9[5PO\
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MJ7+10QW$B/*-LP&P*C",'&Y 2!@#.?7&>0 >P:'XDM]=5GMG#A#AN"I&>G#
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M[QJT</G;%?YE&V0(,@YS@$]<^O4 U=^&D0LM4N[6/(B42@+DD?)*JKU/) )
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MTS@D<<5E#1(/"EK)-;1J)(8)"'907;:I;YF&"02.1D#L, #'"^#;.26 7/\
M9ZW+2EBTTL\9+$.W.V0-M/8XQNQDYH ]:AF690Z$%6 ((.00>001U!I]<%X-
ML[_0XK@& [=ZM;P&9#@,S;U$F3@ $'GJ<D#)-:I\17B13336HA$4$CJQF24%
MD&0I5,'!]<]L=Z -J]URWL&V32QHQ&0'=5..F<$CCBN-^-?_ !YQ_P#7PO\
MZ!)1\-O"]O>6@O9T666X9V9I@)#D.R\;@<9QDGJ2>3T J?%;35TS3HK>,L42
MX&W<Q8@%9"%R><*#A?0 #F@#TB:985+N0%4$DDX  Y))/0"JEEKEO?MLAEC=
M@,D(ZL<=,X!/'-<%\1)WOK^VT[RO/C\MI/*$ABWL0XR6S@;0N1WZC/-5]9T6
M]N#'+9V"VLT3[A)%-#TP05*C:"#QUSQD8P30!Z;=7:6BF65E1!C+.0JC)P,D
M\=:BL=6AU#/D2))MQGRW5L9SC."<9P:Y_P 9ZA86SQ?;$\Z89\J)5,C'>0I^
M3.TY[;NX.WD5R6E7$?\ ;,)MX9+99(F#QNGE;L))SL!(V_*OMN7.,\T >E3Z
MY;V[,CRQJT8!8,Z@J#@ D$\ [AU]1ZU-%J,4L?VA74Q8)WA@4PN<G=G&!@Y]
M*\W&A1:QKLZ3C<L<:.%/W20D0 ([CYLX[XYR,@]1XL;3]*@1+M%$2/NCB5<9
M903PBX!')SN^3)^;K0!M66N6]^VR&6-V R0CJQQTS@$\<U,^HQ)(+<NHE89"
M%@'(YY"YR1P?R->3ZM=1?;[&2VMI;5C,JMOB\D,"Z# "G!X8AO4$ Y&,:?C+
M1X]8UFVM9LF-H,D XSM,K8SZ'&#CG'0@\T =_9:Y;W[;(98W8#)".K''3. 3
MQS5BZNTM%,LK*B#&6<A5&3@9)XZUY[XNTZ+1+_3Y;5%B:24HVQ0H*ED4_*!C
M.'89QGGKP,/NK5?$6LM;7(W16D(9$R=I)V$E@<@\OSC&0J@Y ((!WMEJ,5^N
M^%U=0<$HP89ZXR">>:AO=<M[!MDTL:,1D!W53CIG!(XXK-OM*BT%)M0MD6-T
MMY/D0;8V*C>I9%P"000",'#$9Z8X+P;9R2P"Y_L];EI2Q::6>,EB';G;(&VG
ML<8W8R<T >M0S+,H=""K $$'((/(((Z@T33+"I=R J@DDG  ')))Z 5Q_P .
M=*NM,$\5PABA+AH8S(LFT,6+*&!)P/EZ]3DXR36[XL_X\[G_ *]YO_0&H F7
MQ#;.5431$R?< D3+9)7CGGD$<=QCK4M]JT.GX\^1(]V<>8ZKG&,XR1G&17%?
M"OPO;BTCO616ED9FW. Q4H[*NW(^7&,Y'.>_  YSPD\NKF74&L5NY))6!=YE
M55R%.P))NX7C!Z@';G H ]=M;M+M1+$RNASAD(93@X."..M5[W7+>P;9-+&C
M$9 =U4XZ9P2..*Y+P1I-W87<SO#]GM95W"(2)(HD^49&TY&1NZ #&!V6L_X;
M:5%XB$^JW:+)+),RX<;T4 *V%5L^N!G.%  QSD ]#348GD-N'4RJ,E P+@<<
ME<Y Y'YBBVU&*Z9DC=6:,X<*P8J>1@@'@\'KZ&O.O!NCQZ/K-S:PY$:P9 )S
MC<8FQGT&<#/..I)YJ[\./^/S4O\ KX_]GFH [A-1B>0VX=3*HR4# N!QR5SD
M#D?F*9?:M#I^//D2/=G'F.JYQC.,D9QD5Q6C?\AZZ_Z]U_E!7.>$GEU<RZ@U
MBMW))*P+O,JJN0IV!)-W"\8/4 [<X% 'KMK=I=J)8F5T.<,A#*<'!P1QUJK_
M ,)#;;_(\Z+S-VW;YB;MV<;=N<YSQCKFN*\/:#?0R7:K%]E@N(7\M!*K*DQ"
MJ&!3)7N>  !@?PK6/H4=MH$1LM6LRF209V3S%)8$XWJ"5(4 #83SD_*030!V
M'Q#\9MX;B4PF,S,XRCG)V$-\VT,IQE<9Z=JZ*QU:'4,^1(DFW&?+=6QG.,X)
MQG!K@OC+#%-:172!2S2H!( "2A21@ PZJ>O7'>N]L=)AT_/D1I'NQGRT5<XS
MC. ,XR: +=<_XX\4_P#"-6YN NYV8(@/W=Q!.3WP #TY/3C.1T%>>?%&46MQ
M873Y$44Y+M@D#YHV[ \X4D#J<'% %[3/!EU>()KZ[N%G?DK!*(T48 "X QGU
M(P,^OWCOZ%I\]ANBFE\Z,;?+9EQ(!R"K$<-@!?FZDEL]J-=TZYO-OV:X\C;N
MW?NEEW9QC[Q&,8/3KGVKDO#7BBZ"ZB)Y!*UB&V$HJ E/-Y(3'!V#C/T- ':W
MNN6]@VR:6-&(R [JIQTS@D<<58^UIL\_<OE[=V[(V[<9W;NF,<YZ8KRCP;9R
M2P"Y_L];EI2Q::6>,EB';G;(&VGL<8W8R<UJZ+I5UIEE?Q7"&*$Q2M#&9%DV
MAED+*&!)P/EZ]3DXR30!W$GB&VB596FB"29VL9$"MM.#@YP<'KCI5V&99E#H
M058 @@Y!!Y!!'4&O/?AMX-M+NQ$\L:R//OW%QD@*S( IZKP,Y'.>_ QD^&==
MEL]#GD0_-%(R(>A42%,D%<'(,C$'/!QV&* /2[KQ#;6C&*6:)'&,J\B*PR,C
M()STJU=7:6BF65E1!C+.0JC)P,D\=:\PT'2'%LBC2TD62-29&N(]S;D'S L"
MR9Z@ C:3Q@TZ]L+K3]$G@O00R.@0%E;";XL#*D\ YQDY XZ8H ]%AURWF<0I
M+&9& (4.I8@KN! !R05Y^G/2B]URWL&V32QHQ&0'=5..F<$CCBL+P%X7M]/M
MH)T13*\:N9& +YD0$@-C(&#@ =NN223BW&I:7,\T<-J]T79FD>&'S<,Y(.'8
M@C."05^7NISF@#T*&99E#H058 @@Y!!Y!!'4&N"^"G_'G)_U\-_Z!'3_ (+S
M,]DP))"SN "<X&U#@>@R2?J2:9\%/^/.3_KX;_T".@#JO$_B%/#\#7<@SMP%
M7(!9CT S^9ZD $X.*P-.\+W>L*+N]NIHWD4$16Y\E4!).T@@DD @<C(Q@EN#
M5?XT0L]DI )"SH20,X&UQD^@R0/J0*[J&99E#H058 @@Y!!Y!!'4&@#,T+3Y
M[#=%-+YT8V^6S+B0#D%6(X; "_-U)+9[5-_PD-MO\CSHO,W;=OF)NW9QMVYS
MG/&.N:YKXNZF]C8E8SCSI%C8\@[2&8@8(Z[<'J""1CFM#_A75CY'V/REQMQY
MF!YN>N[?C.<\^G;&WB@#?NKM+13+*RH@QEG(51DX&2>.M'VM-GG[E\O;NW9&
MW;C.[=TQCG/3%>2VFIO?:!,LASY,BQJ>2=H>)@#DGINP.@  &.*[7_F#?]P_
M_P!H4 =!_:T/E_:O,3RO[^]=G7;][..O'7KQ45QXAMK;;YDT2[U#+ND094]&
M&3R#V/2O.O\ F7/\_P#/U6A;^#;2'2&E\M6D:U,N]AE]QCWC#<$ $# '&.N<
MG(!Z%-,L*EW("J"22<  <DDGH!52RURWOVV0RQNP&2$=6..F< GCFO/3IMUX
MCT2".$[G#<KN";DC9T5>P.,*>?[N>6QG0\+ZM8"2*"2V^R72X\L2(5+9#(,2
M8!;(X^?&6/&YAF@#N+W48K!=\SJBDX!=@HSUQDD<\466HQ7Z[X75U!P2C!AG
MKC()YYKRR"236-0NYFM%NS!)Y:AI0B(JET VOD-NQD\8#9( )K8\/Z1>6^H+
M=);"UMG0K*B2QNA*JVUMJXP<[1\H]3GYFR /^''_ !^:E_U\?^SS5WLTRPJ7
M<@*H)))P !R22>@%<%\./^/S4O\ KX_]GFKJO%G_ !YW/_7O-_Z U $TGB&V
MB596FB"29VL9$"MM.#@YP<'KCI4MQJT-LBSR2(L;XVLSJ%.1D88G!R.1[5PO
MPV\&VEW8B>6-9'GW[BXR0%9D 4]5X&<CG/?@8S_A3X8@U>WDGN5\PAFB4.<J
MJX#G:/X22Y.1R.V"3D ]2AF690Z$%6 ((.00>001U!JE=>(;:T8Q2S1(XQE7
MD16&1D9!.>E<?\';O98.TC82.9^6/RJH1&/7@#))/;DFL?4[S3)K6:&SM)'1
M4<+.D)*JVW>"96(<!21G/;C!7J >I7%VEMM\QE7>P5=Q RQZ*,]2>PZT^:98
M5+N0%4$DDX  Y))/0"O-;;1VU[0D09>6,,R9+$_NY'& !DD[,JHZ=!QP1:\3
M>*/[7T^WAC8";42D>1N10=P$O8G:&^0CN#D;AU /0(9EF4.A!5@""#D$'D$$
M=0:9=7:6BF65E1!C+.0JC)P,D\=:+2U6T188QA(U"J,DX"C &3STK@+JU7Q%
MK+6UR-T5I"&1,G:2=A)8'(/+\XQD*H.0"" =[9:C%?KOA=74'!*,&&>N,@GG
MFH;W7+>P;9-+&C$9 =U4XZ9P2..*S;[2HM!2;4+9%C=+>3Y$&V-BHWJ61< D
M$$ C!PQ&>F.?^&WA>WO+07LZ+++<,[,TP$AR'9>-P.,XR3U)/)Z  '>PS+,H
M=""K $$'((/(((Z@U2_X2&VV>?YT7E[MN[S$V[L9V[LXSCG'7%<9X+B&BZG=
M:5#GR BR ,2=IPG YZ?/@YR2%7)XYS?A#X7M[Z&2[F19'\PH!( R@!5;(4C&
M23U]!@8YR >GVMVEVHEB970YPR$,IP<'!''6JO\ PD-MO\CSHO,W;=OF)NW9
MQMVYSG/&.N:X3P+;O_Q,].MSL5)'$7)&UF\Q =W+<;%YY(QD<YSFZ%';:!$;
M+5K,IDD&=D\Q26!.-Z@E2%  V$\Y/RD$T >JW.HQ6K*DCJK2'"!F"ECP, $\
MGD=/447NHQ6"[YG5%)P"[!1GKC)(YXKA/B%,LUWICH05:?((.007A(((Z@T_
MXU_\><?_ %\+_P"@24 'Q'_X_--_Z^/_ &>&M#Q=XY_L:XM[5&B(DDQ-O/S(
MI*8)PPV\,3EACC/2L_XC_P#'YIO_ %\?^SPU7^).G1&]L"47,L^'.T?. T0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,FA692C@%6!
M!!&00>""#U!I]% '":3X2O\ PSOAL9(7@=MP%P'#*>G6/KP%R>.1PHYSK>'_
M  L\,K:C>LLETV0-N?+C7G"H#STZGKR1W8MTM% 'EDME/=:W<&VD$<D<2L-P
M+(^$B&Q@"/E.>3R1C(&0".@T_P )W5[=KJ&HO&WDC]U'#N,8)'+8<<$=<\DM
M@Y 4"MNV\+Q6]W)J@+>;*@4@D;, *.!C.?D'<]ZV* ./O_"5Q973ZCITB*TV
M/,BE!$3'!^;*<YS@],Y+'=@E26'A*XO;I-1U&1&:'/EQ1 F)3@?-E^<YR>F<
MA3NP H["B@#E]/\ "\MOJ<^J$KY4L04 $[\@1CD8QCY#W/:C4/"\MQJ<&J K
MY4414@D[\D2#@8QCYQW'>NHHH *Y?PEX7ET>XN[B0J5NI=R!220-SGG('/S#
MIGO7444 <UXM\)-J[1W=O)Y-S!G8^ 001]UN^,_4 %@5.:+2WU2=U\^2WCC5
M@Q\A'9F /*'S. ",_,.0<8[UTM% ')>)/"<\MRFJ6#K'. %</D(ZCUV@DGH#
MGL%(*E1F[I>F7<[F6_>(H8V3R858QD,5)=BYR3@%<$$ =#R<]!10!P^F>%]0
M\. V]E+%) 3E1<APR9)R!LZ@\$G@$Y(49.=HZ3<W%I-;W$BO-.D@!"[$3>F
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MAC\S;N"<]#D#BN=@\)WNA3RR:<\7D3'=Y4^X*K$\[1&. .@P1Q@$':#7<44
M>:>$K-K/6;F*1VD<6X+.V 26\ECP. ,G"CL,#M6L_A:\TJ[FN]/:'R[G#.D^
M_AN22"N3U)/4#YB-O -;MMX7BM[N35 6\V5 I!(V8 4<#&<_(.Y[UL4 <5X6
M\%7&E7TM_/*LPEC*[N5<DE#RN" !M( #<#& !P"+PE=Z%+))ILD7E3,6,,X8
M(A..5\O\1_#A< [L CM:* ,33;*]*2FXF022+A!%'\D1 (W MR^>&(;H00.*
MY_4O#FJ:Y$+&ZEMUB.W>\2NTC;>1PP5>6 )QM]N.#W=% '+^)_!*ZM9)IT;%
M3 $\LMSDQJ5 ; Z$'D@<'G!Q@Q7&HWNCV<\]\\6Z.+$;PAB2Y!4%@RXR6*]
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MNW:%RIV@$X7 KLZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME4N%8\$Q@$J<=B0 WRDY-:'C'4VEL'FMD\U)H6R=P3;&\;'S,,,G Q\O!.:
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MF@^4E6$BRJ<$ @E<;3R, ]1GTK;H **X+0_B;+KJLMM:,\J'YAYJJ@4]#YC
M?,3T7'(!.>"*ET[XF'4AY$-M(UV"X:'(4+L(R6D8# YQRN=PVD#() .XHKG_
M  AXO7Q$KC8T<L+;9(VR2I)..<#T.1@$$$$=":^H^*;J-G^SV4DD<18%G=8R
M2N<E$(9G4C!4C[W0#(H ZBBL'0/&$.L6IU 918PWF @G:47<PX'S#'(('([
MY Q;/XCRW,;7PM)/LBELR*ZE\+_%Y9QD?WB"0O/)VF@#H/"_BB+Q)$;B$,%5
MRI#@ Y ![%N/FK8KSKX/W2VEA--(<)'-(S'!. L:$G YZ5I)XXNKM3<6UC(\
M(&0SR+&[#:&R(\,2.>-N[=VYX !V=%9^A:[%KD0N8#E6Z@_>4]U([$?_ %QD
M$$Z% !63_P )3;?:?[-W_P"D?W-K?W=_WL;?N\]?UK0N[I;1&FD.$C4LQP3@
M*,DX'/2O'1;RK;IXH;+3?:R[;9"H\K.S8=V2!N&T 9^1L'(' ![114-I=+=H
MLT9RDBAE.",AAD'!YZ5B^-?%?_",0K<[/,W2!,;MO56.<X;^[Z4 =!17%:E\
M0Y+)1>?97-F64";> Q4G&_RR,@'^'<5#97D;A6AXJ\;+HEM'?QIYJ3,@7YBG
M#H7#<J3T'3 ZT =+17/^&O$<^M'S&MVBMV4M'(\BEF&0%S&!D9'.<D>A((-9
M\/CF?4R6L;1YHA_RT=UA5CEA\N\'<./J.A [@'845C^&?$T>O1EU!21#MDC;
M[Z-W!'''!P<<^Q! V* "L_7];31('O)0Q2/;D( 6^9@HQD@=3ZUA7'CI[B>2
MSL;=KAH"1(2ZQ("#C 9@<G.1SCH2-PY%'QOJW]I:5<,R-'(C1I(C=5821DC/
M1@0058<$$'V !V>G7JW\27"9"RHK 'KA@",XSSS5BN7LM?CT/3[6:0,V^*!%
M6-=SLS(,*!QSP>XZ8'. :C>.KBR5+B\LVAMV*AI!()"F[H60*& S@'.".F"V
M 0#LZ*Q]7UY[94^S0M<-,"4\LJ(\#!RTAX4$'*]=Q&*S-&\;M<77]FW<#03%
M=R N)%88)/S* .@//(X()!&" =717'^*_B%_PC]PEEY+2&2,,NQOF+,655"[
M3G)4#.<\\ D8.K#KD\4#W-S;.CHV!%$RSNP.T;AMP.I.1V )H VZ*XJ\^($^
MD-&;ZT:&*1MOF"590#CN$7],Y(!(!QBKOC3QROA9H0\9=9BV2&P5"[<D CD_
M-TR.G7G@ ZBBN,G\?RV4D7VJU:&"=]JRO(O&?NEUQ\A[D,P(&[&=IK5\5>+H
M_#RH&5I)9B1&B#)8C'?L,D#C)YX4\T ;U%<_I?B.>218+NW: R9\LB1958J"
MS*2@^4X&1GJ >XYJ7/C62:5[>QMGG\IF5W+"*,,N 5#,""03R.#W&1S0!U=%
M8/AOQ4NKL]O(AAN82=\3') [,#@;E.1R/4=BI.Q=W2VB--(<)&I9C@G 49)P
M.>E $U8_A?Q1%XDB-Q"&"JY4AP <@ ]BW'S5S]G\1Y;F-KX6DGV12V9%=2^%
M_B\LXR/[Q!(7GD[35+X/W2VEA--(<)'-(S'!. L:$G YZ4 >BT5QB>.+J[4W
M%M8R/"!D,\BQNPVALB/#$CGC;NW=N>!L6WB8:G:_;;%?.;C$981MG(W*2<A2
MH.??MD$&@#;HKRKX2:C<P0F**W\R)KCYI?-5=N50-\A&3@<\=>E=5<^-9)I7
MM[&V>?RF97<L(HPRX!4,P()!/(X/<9'- '5T5@^&_%2ZNSV\B&&YA)WQ,<D#
MLP.!N4Y'(]1V*D\[HGQ.GUS*VMFSNF2P\Y54#C;\S*!DG/'' R,\X /0**XS
M4?B*;2\?2U@:20 ;-C#YF9%8 @@;5Y.6R< 9QCI%_P +,-E*UK>VTD4N$*(A
M$Q?<<8& HSSQ@D'##(8 $ [BL^;7X(9TL&;$\B[E7:W(&[G.,#[IZGM6)HWC
M=KBZ_LV[@:"8KN0%Q(K#!)^90!T!YY'!!((P7ZAK<4.IP61@5I9(BPF.-Z@"
M3Y1\I./E/\0^\>/4 ZBBN,U'XBFTO'TM8&DD &S8P^9F16 ((&U>3ELG &<8
MZ6]#\9O=W+:==0&WF";E!D5PP[X( R>_&>C9QMH ZBBN?U3Q#<PR-!;6CR[,
M;F9UA0[@"-K-G?W#8QM(]Z/"'B]?$2N-C1RPMMDC;)*DDXYP/0Y& 0001T)
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M P.E '):Y:M=:&J(,D6L#=0.$".QY] "?Y<UM^#-5BGL(95==L4**Y)P%,:
M,#G&,8SSVYZ$&MJTM5M$6&,82-0JC). HP!D\]*P+KX;Z?=,9&@4$X^XSHO
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MI0!S'PJF5].B ()4R @'.#YC'!]#@@_0@UP_AVU:ZT.[1!DB8MU X01.QY]
M"?Y<UZ/8>!K/3YA>0Q!906((9\#<"#A=VT#!/&,#M5[1- @T1##;+L0L6(W,
MW) &<L2>@% &?X,U6*>PAE5UVQ0HKDG 4QH P.<8QC//;GH0:XKPW_I,.L7J
M<Q3>=L;IG"RL>#R.'4\@=?8UV%U\-]/NF,C0*"<?<9T7@8X5& 'X#WZUM'2H
MO*-H$58F5E*(-JX;.X#;C&<GI0!S_P +?^0=!_VT_P#1KUE?!3_CSD_Z^&_]
M CKM=+TN/2HUMH%VQIG R3C))/))/4GO46B:!!HB&&V78A8L1N9N2 ,Y8D]
M* ,3XI?\@Z?_ +9_^C4JDWAR#7+.QCDD,4ZP(865@'R(U)PI/S 8!.,$8X8<
MUUNJ:7'JL;6TZ[HWQD9(S@@CD$'J!WJEJ/A&UU&*.VFC#1P@!!E@5 &W&X$-
MC &>>< GD"@#FM%UZYTJ_31+B1;A63(DQMD7"%@& )Y^4]<L0P8MVKO:R=$\
M*VNB9-M&J$YRW+-@XXW,2<<#C.,\XS6M0!Y_\%/^/.3_ *^&_P#0(Z/AQ_Q^
M:E_U\?\ L\U=AHF@0:(AAMEV(6+$;F;D@#.6)/0"C3= @TUY9H5VO.VZ0[F.
M3DG."2!RQZ8H X_X<?\ 'YJ7_7Q_[/-5?0/$%YXL66[2YCM8H3C8(TD('+;V
M+D8&.-W .T\#'/<:;H$&FO+-"NUYVW2'<QR<DYP20.6/3%9]UX!L;N4W3PJ9
M&8,3EMI/J5!VG/?(YYSG)H \Z\.VK76AW:(,D3%NH'"")V//H 3_ "YKT#PM
MK\":=%<F11'#"BN?[K(H!4CKG/08R<C&<C.KHF@0:(AAMEV(6+$;F;D@#.6)
M/0"L^U\ V-I*+I(5$BL6!RVT'U"D[1CM@<<8Q@4 >=>';5KK0[M$&2)BW4#A
M!$['GT )_ES71>$?#$>K6L4T=Y=?<4,L<^%5@HW(%V\ =AZ8(R"#79Z)H$&B
M(8;9=B%BQ&YFY( SEB3T K*NOAOI]TQD:!03C[C.B\#'"HP _ >_6@!WAC3+
M7PW:N\$A>#+R%RRO]U0&P4 R!MZ $YS6QI>J1ZK&MS VZ-\X.",X)!X(!Z@]
MJ#I47E&T"*L3*RE$&U<-G<!MQC.3THTO2X]*C6V@7;&F<#).,DD\DD]2>] '
M-?%"_:.U%G%_K;N18E <*V"<GZ@\*>@^;D]C2E\/ZI+:_P!FM]D,7E"/)\TM
MA5 #=,;A@$''!YQ77WNBPWTD<\J!G@)*$YX+8R<9P3P,9!P1D8-7J .,^%6J
M-<VGV:3(EM7:-@QRX&<KE3RH&2H'^SQZ"E\:_P#CSC_Z^%_] DKLK+18;&22
M>) KSD%R,\E<X.,X!Y.< 9)R<FN-^-?_ !YQ_P#7PO\ Z!)0!M^*=?@?3I;D
M2*8YH75#_>9U("@=<YZC&1@YQ@X\_P#$5JUKH=HCC!,P;J#PXE=3QZ@@_P ^
M:]"E^'>GR2>>8%W9!P"P3C&/D!"8XY&,'OG)K3UO0(-;00W*[T#!@-S+R 1G
M*D'H30 >(;5KNVGAC&7DAD51D#)9" ,GCK7GGPZT"/6+52EW<(Z%@\<4VQ5R
MQ*X7;T8<YZ$Y[@@>IUS^I^ ;'4W,TL*ESU*EDR2222$*@DD\D\GUH K^'/"5
MO8+<"WFD=IR5D?S%9U==V?F51AQOR<Y.<&K&E^$/[/D6?[3<R;<_++-N0Y!'
M*[1G&<CWQ6KIFE1:6@A@140=E&,G &2>I. ,DY)[FK= 'GGP>F6UBGT]R!/%
M.Y9,\@ *A/'! 92#@G'&>HSH?$?4([S3KH1L&\IXT;'9A)&2N?49&?0\'D$5
MJZQX&L]8D^T3Q!I" "0SKG'3.UAD]LGG&!T JPWA6U,!L!&H@;&57*Y*XP20
M02?E&23DXY)H \Z\7V_^C:5<.62)%C#R(<,NY(R",9.0$8@@'!'TST=_X&MY
MH2\][<&!@I)DN5,9!(*G++M()QCWQBNM&E1>4+0HK1*JJ$<;EPN-H.[.<8'6
ML6U^&^GVK"18%)&?OL[KR,<J[$'\1[]: ,?7M:FTJ>VT"T=8@T2#SI<,P )4
M # 4L0F.1\Q8 ;>M9,4$MOK=O'/.)Y%B;+!%CVY24A2JD\\YYYPP[8KT#7/#
M=OKJJER@<(<KR5(SUY4@X/<9P<#T%5-.\#6>FR)<0Q!9(@0I#/\ Q;LYRW)^
M8C)R<8'0# !SNL_\AZU_Z]V_E/6W\0/%+^&[<7$2JSM(J#?G:,@L20,$\+CJ
M.N>V#JS:!!-.E^RYGC7:K;FX!W<8S@_>/4=ZL:AI\>HQM;S*&C<8(/\ G@CJ
M".0>1S0!Y)\1K:YBM(7N;M9Q(ZE46-%'W"2ZNN"RC.,X .X'CBNC^(__ !^:
M;_U\?^SPUL#X9:<%*>0,$@_?DSQGONR!SR <'C/08V-2T"#4GBFF7<\#;HSN
M88.0<X! /*CKF@#C_C7_ ,><?_7PO_H$E,\53+INL6EY,0D)B9-Y/&[$@Y]!
M^\7D\<]>#CL];T"#6T$-RN] P8#<R\@$9RI!Z$T[6-%AUB/R+A Z9!P<C!'0
M@@@@_0],CH30!-/J$=NZ0NP#RE@B]SM4LW'H .3TZ#J1GRKX<^'5NUFM'N)X
M9X96W10S;!@84M@ @G<""03T&>HSZ%HW@NST9O-@B57_ +Q+.PX(X+DD9!.<
M8SWHUGP79ZRWFSQ*S_W@61CP!R4()P ,9SCM0!2\.^$K?2[F2X2:26?8%D$L
MBNP#;2N<*&!(48SVZ4_XD6K76GSH@R0JMU X1U=CSZ $_P N:U=&T"#15\NV
MC5 >N.6/)(RQR3C)QDG'0<5H4 <UX6U^!-.BN3(HCAA17/\ =9% *D=<YZ#&
M3D8SD9\_\.VK76AW:(,D3%NH'"")V//H 3_+FO1;7P#8VDHNDA42*Q8'+;0?
M4*3M&.V!QQC&!6AHF@0:(AAMEV(6+$;F;D@#.6)/0"@#C/"/AB/5K6*:.\NO
MN*&6.?"JP4;D"[> .P],$9!!KI?!NA6^CP%+1S)$[EMQ97R<!3@J ,#;^>:@
MNOAOI]TQD:!03C[C.B\#'"HP _ >_6M^UM$M%$42JB#.%0!5&3DX XZT <%\
M$YE-I(@(W"<DC/(!1 #CT.#CZ'TK%^'/AU;M9K1[B>&>&5MT4,VP8&%+8 ()
MW @D$]!GJ,]_+X&LY)_MQB'G;P^X,X^8$$-M#!<Y&3QR>3G)I^L^"[/66\V>
M)6?^\"R,> .2A!. !C.<=J *7AWPE;Z7<R7"322S[ L@ED5V ;:5SA0P)"C&
M>W2L?X*?\><G_7PW_H$==AHV@0:*OEVT:H#UQRQY)&6.2<9.,DXZ#BC1- @T
M1##;+L0L6(W,W) &<L2>@% ''Z-_R'KK_KW7^4%&L_\ (>M?^O=OY3UV$.@0
M0SO?JN)Y%VLVYN0-O&,X'W1T':B;0()ITOV7,\:[5;<W .[C&<'[QZCO0!Q^
ML_\ (>M?^O=OY3T:S_R'K7_KW;^4]=A-H$$TZ7[+F>-=JMN;@'=QC.#]X]1W
MHFT"":=+]ES/&NU6W-P#NXQG!^\>H[T <?HW_(>NO^O=?Y04:S_R'K7_ *]V
M_E/780Z!!#.]^JXGD7:S;FY V\8S@?='0=J)M @FG2_9<SQKM5MS< [N,9P?
MO'J.] ''VVOWGB2[GLX)DMDM68<(LLCX;;G#\8!!.1C&X [LY%?X3DFXOR7$
MA\U,N  '^:7Y@!QANO''I75:QX&L]8D^T3Q!I" "0SKG'3.UAD]LGG&!T JW
MI'ANWT=G>W0(92"V"<'&<8!)  R>  * ./TF94UZY!(!:!0 3C)VPG ]3@$_
M0$T_6?\ D/6O_7NW\IZZC7/"-KKC*]S&'9!@'+*<=<94C(],],G'4TZ+PM;1
M217*I^\MXQ'&=S?*H! &,X/#'D@GWH Y+P-,MAJ-_:RD+++*'12?O+EWX(XS
MM<''7&>.#@\<S+?ZC86L1#2Q2EW4'[JY1^2>,[4)QUQCCD9ZW6_"MKK>#<QJ
MY&,-RK8&>-RD'')XSC/.,T:)X5M=$R;:-4)SEN6;!QQN8DXX'&<9YQF@#E=&
M_P"0]=?]>Z_R@HUG_D/6O_7NW\IZ["'0((9WOU7$\B[6;<W(&WC&<#[HZ#M1
M-H$$TZ7[+F>-=JMN;@'=QC.#]X]1WH T*\_^''_'YJ7_ %\?^SS5Z!7&2S?V
M+JV6)$6H1 9)7'FQ8 '8@;< =<LV.?X0#*O=3DL=1NVMY8(F(MPRW;X1_P!W
MG<I&&!48&.0=Q)/W0.@\$V)S-?231S37#KO,!!B7RQA%!'.0IYSSTZ_>;$FU
M.UM+BX;5XP':7$+2Q-)&8E "A#AP",[GQCYFYYX%?PY:1ZEJ?V_35V6D<>V1
M@#&CL5/RJO&<94D8 !7<>2I8 M_#C_C\U+_KX_\ 9YJEU3Q'=:AJ#:/;2);B
M-0QD90[L=@;:JMP?O#CKA2V['RUU>FZ!!IKRS0KM>=MTAW,<G).<$D#ECTQ5
M?7/"-KKC*]S&'9!@'+*<=<94C(],],G'4T <5X-1TUFY6243.L&&D"JN2#$"
M-JY *_=/N.>:NZ-_R'KK_KW7^4%=1I/A&UTB0SV\81R@0D%ONC'8DC/RC)QD
MGDG).;$.@00SO?JN)Y%VLVYN0-O&,X'W1T':@#C]9_Y#UK_U[M_*>F:],L6N
MVA8@#R",DXY;S@!]22 /4\5V<V@033I?LN9XUVJVYN =W&,X/WCU'>F:YX;M
M]=54N4#A#E>2I&>O*D'![C.#@>@H Y+XC_\ 'YIO_7Q_[/#1K/\ R'K7_KW;
M^4]=*G@RT00H(^+5BT7SO\I+!R?O<\C/.?RJW-H$$TZ7[+F>-=JMN;@'=QC.
M#]X]1WH X_XC_P#'YIO_ %\?^SPT>*;UK/4EDADBBD%GUN6 B<&7 3L5(Y;(
M)S@# &2>PU+0(-2>*:9=SP-NC.YA@Y!S@$ \J.N:Y37+^"UO9)-4C_T<1QK
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MF.3DG."2!RQZ8K0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMO!*X4DE\D8.,;>">M &)X^NFM;[370X)F=>@/#F-&'/J"1_+FN[KA/'%O\
M;M0TZ!"N]9'D()Y"H4?.!D\A& [$CKUQW= ''^&[^6VU"[TZ9W=3B:(L/E"L
M?F4$DG +!1CY?E;H<BL3PGXOFO=2?>7-M=>8(/E81GR>C#?T^53NV_Q'D>EO
MXFZ5.CPZE9HS2JLD3; [. Z,%8!>FW+?-QABO7LS6?"S6%E92Q1%IK%XG,:E
MF8[B&E4;=P)+X.>0 #CC@@&QH=_)JFH7,H=OL]NJPJH#!&?.YVY.-R$%>!]T
MCMR>=\':C+?Z1>/,[.P%P 78L<>2IQDD\<UTOPXT>33;0&?<)IG:1Q(<MEC@
M9[Y*@$@\Y)SZ#G/!&DS6VDW<$D;K(_G[59&#',*@84C)R>![T 5?^9<_S_S]
M5W_A/_CSMO\ KWA_] 6N*_LF;^P/LOEOYO\ <V-O_P"/C=]W&>G/3IS7<>&(
M6AM+='!#+!$"",$$( 00>A% '&_%+?\ :=/\K;YGG-MWYV[M\6W..<9ZXYQ1
MXKTJ[\-QC5(KJ61HF!E29LQMO(4[4& HR?N]@?E8%1F7XGV5Q--92VL;2/%(
MS<*2H.Z,KN(P "1U)'&>:B\5ZK=^)(QI<5K+&TK 2O,N(UV$,=KC(89'WNX'
MRJ2PP 'C/QSDV]O'*UM'<P^:\ICWLJNIV* I)!)!R1R#@ANM8EYXQAT-H[FR
MNYKGYL217!<J5(SD,R*%((ZX)Y] 0>C\1^&9M*EM=1LD,QLXO+9&8;BBJ0",
M 9;!8'&3G;A#R*V+3QA)?.L45I<#+#<TZB%57.&8$D[B,_=')&?2@#I:\TN#
M=ZEK$]E%</'$(U+ -G"E(]P0'(5B6X88(R3ST/I=</I.G2IK5S<%&$30* Y4
MA"<0\!L8)X/Y&@#'NDO=(U!=*MKIV6YC5@UQ^]9 I8L1G@G"'L <X/(#"[82
MSZ!JL>F^?)-#<1%L3L79=H<\-ZY3L "#@@D U;U;3I7UJVN C&)8&!<*2@.)
MN"V, \C\Q1JVG2OK5M<!&,2P,"X4E <3<%L8!Y'YB@#5\46'G,))KMK>#  5
M&6(E^3GS3R05_@Z<9[5S_@75Y$OKC31.;B!4\Q)&;>W\' <$Y W8/;(R N2#
M7\1Z6]KJ?VZXMWNK9X\((U,NPA0#E#QUR<'CYMP)8$!_@K3Y%U2>Y^S-;PO!
M\@*;5',6.@VAB!DJ.0<@\@T 'AY)_&\DU\UQ+#;JYCCC@<QMQA@6^\,X89ZD
MDGD*H!B\&P36^LW*7+B240<N%"Y&8MIV@  [<9'KW/4R^'GG\$236+6\LUNS
MF2.2!#(W.% ;[HSA1GH00>"K B7PK9W1U:>[N8BGF0#E0QC'^JPN_&&8 8;'
M&X''% &+'XSBUR1YKJ\EMXP["**!61MOR[69T#Y)YR#G!R00#BMWX?>*C=7$
MNFK(T\**7CFDR),97*-N&6P6X)QT/&" L7A\3^!VELVMY9K9Y&>)X%\Q^BC#
M 8QQCLOS XW Y'7Z%K$FJ;G>!X8QMV&4@.W4-F,9*X(XR?F!!% #_$\S0VEP
MZ$AE@E((.""$)!!'0BN'_M:;^P/M7F/YO]_>V_\ X^-OWLYZ<=>G%=QXGA::
MTN$0$LT$H  R22A   ZDUP_]DS?V!]E\M_-_N;&W_P#'QN^[C/3GITYH /["
MN[C3O[0EO)A*MOYBB-]J;57>H8#!9B.K$YR?XMO/8>"]9;6;.&ZD^^RD-TY*
M,4+<  9(SC'&<55^R/\ V3Y&UO,^P[=N#NW>3C;MZYSQCKFCX<6CVEA#%*K(
MX\S*N"K#,C$9!YZ4 5/B'?RZ3]GU"-W$<,P$J(,AD?&2><<8P,]V&"#BLSXI
M^(KBS:*WLRPD0&:0QAB0B<*3CY2A.[<#D<#.!U[#Q+HXUBVEM#C,B$+DD ,.
M4)(YP& /]#TKBOASH<U[YTM_$R@P1VZ!]Z?NU7#J%)R <*2>/F)VXY% &KXN
MUQKZ"U@M69)-0>/:5#>8L> [M\A&"N1NY^Z3VR1E>-9;JYU2"QMIVB$L'.&;
M:.9=S;1P6VC@\'('(P"*_@/P]<1W4:W".L>GQRHK<B-W>1\LH8#(*L>1_=4D
M\@5L:MITKZU;7 1C$L# N%)0'$W!;& >1^8H ?XMLW\/Z;/Y4\S/N0AY)"9!
MET4@,,$#';W/K69XSM6O='BNGDDW)! 2 _RN7,8)<'.XCJ.>#S71_$>T>[L)
MHHE9W/EX5 68XD4G '/2JFI:%+J6D+9(,2FW@^5_E.4V,5.>A^7'..>N.M %
M+2M%;3=.:]2><LU@2%>7*(3$&!0 #:5QA>>!5'^UIO[ ^U>8_F_W][;_ /CX
MV_>SGIQUZ<5>TO59;W3WT]K:>.6.R=<O&0C%4V *>"6;@XQZCG&31_LF;^P/
MLOEOYO\ <V-O_P"/C=]W&>G/3IS0 ?V%=W&G?VA+>3"5;?S%$;[4VJN]0P&"
MS$=6)SD_Q;>=.7QA,='_ +47 FV 9(!^;S!$7Q@#)Y8#& >,$==/[(_]D^1M
M;S/L.W;@[MWDXV[>N<\8ZYKG(K&:#0?LY#1RD$;2KASNG.$V@;LN#M Q@[N>
M"30 SQ=I3:5:C41>W#L6C) F")('(W",+PN02RXW *.A'(] TO3_ .SXU@WO
M)MS\TK;G.23RV!G&<#VQ7G7V$:,_]HR:7L$;;V9+D2;1GEA$./ESD# "XSE0
M,CT+1=8CUB%+N'.R09&1@C!(((]001Z>A(YH \]^)6D;KZS;S)?](F P'XCP
M8ES'Q\I.<D\\X-:?B6ZF\,QPZ?:S2//>3X62Y82;1\JD9(X&2/X6X+'KBI?B
M5I<\K6M_!&9?LDNYD7.\Y9",  \?+@XR1G.",XB\2VLWB:.'4+6&1)[.?*QW
M*B/</E8G!/(R!_$O 8=<4 &L>%;G1K=KRWO)VF@0LWG/OC8*IWX0@X/=<[L'
MC_:'3^%=;_MNUBO,8,B_,,8&Y25;')XR#CG.,9YKF-8\57.LV[6=O9SK-.A5
MO.39&H93OPY(R>RYVY//^R>G\*Z)_8EK%9YR8U^8YR-S$LV.!QDG'&<8SS0!
M@?%K3_/LGGWNOE;?E5L(VZ1!\RXYQU7T-5-/T#['IKW7G3/YFGM\DDFZ-=T0
M;Y5P,8Q@<\#BNB\<Z/)K%G+:PX,C!2 3C.UU;&?4XP,\9ZD#FL#2]5EO=/?3
MVMIXY8[)UR\9",538 IX)9N#C'J.<9(!G^!_#4^KV$;&YDA51((A Q7J[9:3
MNQW= " %'!RQQ:\,^.9$TF2^ER\EN3&"WS;C\NPG[O W@-SD@$Y)-;WPXM'M
M+"&*561QYF5<%6&9&(R#STKE_!?A26]TNXL)E:)Y)6*B12G(6,J3D$[=RX.!
MTSCF@#,MM<M[V/S;G4[A;AU!Q$LB1H=H^78BX.#U*E=WL>:[CX=>)I/$-KYT
MP'F(Y0D?Q853NQV)W<@<9Y& <#,T'Q3/H\*65U9W!DA54S!'YB%54;3N#8SC
M@X)&1V^Z.PTNXDN8UDGC\J0YRF\/C!('S#@Y&#^.* .?^*7_ "#I_P#MG_Z-
M2N2U/Q!>QZ;%!Y B@>**,SEQ(-C(%W%%!90P[D$C. -Q%=G\1[1[NPFBB5G<
M^7A4!9CB12< <]*EL]&^WZ;'8RC:7M40[UR5;RP 2IQRIY[$$=C0!S6MZJ/!
MMG:6-M+CS6_U^P2 )N#.X4$@\N-HPWRY&<X-8-YXDATN-;BTOYYKB,J2DWF-
M$_9AM91@<Y&6)&, [L,-!=!O=0M+>3RR+O39]JI(0JNBE2".%! PH!#8(5CN
M)(KIH?'$URH6.RN/.('RR*(X\]6'FMT YP2HR<# S0!1\7^+)9+>UBMOW<VH
M[ &)R$#A<_,.0<N!D+TR1@XK/\8Z%=^'[-KB&\F;&SS?,?)/S  H?O)\QY&>
M0>2<8.W\1="EO%AOK8;YK.3>$/1AD$C Y)RHX!&1D#)P*PO''B6?5["11;20
MJHC,IG4KU=<+'W8[NI( "CD988 '>-]6FMM)M)XY'61_(W,KL&.86)RP.3D\
MGWKIOB/=O:6$TL3,CCR\,A*L,R*#@CGI6#XCT&36='MUA!+Q102!0,EL1[2!
MR.<,3W)Q@#)JOXQUV[\06;6\-G,N=GF^8F"/F! 0?>?YAR<< <@9R "QKWC"
M32K*Q42%)+E(MTS+YFU0J&1L$\M\P['(W=#@US]YXDATN-;BTOYYKB,J2DWF
M-$_9AM91@<Y&6)&, [L,.CUGPQ/=VEA<6ZYN;-82(W.T'Y4W @XY!4<$KQN[
MXK3A\<37*A8[*X\X@?+(HCCSU8>:W0#G!*C)P,#- '.>,/%4EQ)9J\CVMK/"
MLKO%NW9()*;E&3@8' X+!F!X [#0]'"Q2+'=2S13+A7,@=U/S*S+*!],#^%E
M)[FF>)M:-HPMY;22X@D3),:"7Y@WW3&>@'!!)Z]!P2,+P%HDL-W/?K"UO:S*
M0D3G#$[A\Q3^'&&.#C;NPN5YH Q/!7AC[=<WT7GW">3-C='+M9_GD&7.#N/'
M7CDGUK;2YG\77L]LDSPVMHP4B([)6;YESN&>,AN^,!?ER217TMY_"E[=M);R
MRQW3^8KVZ&3^)R >G/S'/.01P""#5A+:?PC>SW*0O-:W;!B8AOE5OF;&T8XR
M6[8P5^;((( /<S^$;V"V>9YK6[8J!*=\JM\JYW''&2O?&"WRY )I7J76KZO/
M8QW$D4*HC,%=AA0L1(0=%8L1SQP3G/*FZ]M/XNO8+EX7AM;1BP,HV2LWRMC:
M<\9"]L8#?-D@"QI.G2IK5S<%&$30* Y4A"<0\!L8)X/Y&@#K=+T_^SXU@WO)
MMS\TK;G.23RV!G&<#VQ7G_QKT_\ <QW6]_\ 6*FS=^[^[(V[;C[W;.>G%>EU
MQ_Q2T*76+39 -S1R!RH^\0%8$ =S\V<=\<9. 0"IXEF;P1:231S32R3,B(;A
MQ*$/S$D @8XSZY(7(QFIO^$(N_+\W[;-]K^]]_\ T?=G=M\O'W>WIWVX^6J_
MB"*3QQ9O"L$L,T)1U69=BLV&!4,?O#&>2%Y*DX&:L?\ ";W?E^5]BF^U_=^Y
M_H^[.W=YF?N]_3MNQ\U &A\/?$K>(+032?ZQ&*.<  D8(( /<$9Z<YP ,5G_
M !:T_P ^R>?>Z^5M^56PC;I$'S+CG'5?0UH?#WPTWA^T$,G^L=B[C((!.  "
M!V &>O.<$C%3^.='DUBSEM8<&1@I )QG:ZMC/J<8&>,]2!S0!SNGZ!]CTU[K
MSIG\S3V^223=&NZ(-\JX&,8P.>!Q5+P/X:GU>PC8W,D*J)!$(&*]7;+2=V.[
MH 0 HX.6.-#2]5EO=/?3VMIXY8[)UR\9",538 IX)9N#C'J.<9.Q\.+1[2PA
MBE5D<>9E7!5AF1B,@\]* ,'PSXYD329+Z7+R6Y,8+?-N/R["?N\#> W.2 3D
MDUA6VN6]['YMSJ=PMPZ@XB61(T.T?+L1<'!ZE2N[V/-:?@OPI+>Z7<6$RM$\
MDK%1(I3D+&5)R"=NY<' Z9QS6EH/BF?1X4LKJSN#)"JIF"/S$*JHVG<&QG'!
MP2,CM]T &G\.O$TGB&U\Z8#S$<H2/XL*IW8[$[N0.,\C . _XA>)6\/VAFC_
M -8[!$. 0"<DD@GL <=><9!&:VM+N)+F-9)X_*D.<IO#XP2!\PX.1@_CBL7X
MA>&F\06AAC_UB,'09 !(R""2.X)QTYQD@9H X2[URWBC::/4[A[H9=1MD6)F
M!W!?**X /3&[:.N,?+6[>ZW<7UG!X@AW*\1S+$CMY;HKLC_)AAGC.2,JI)))
M536G:^-Y]HBELKC[1RI")^Y+ X&)"<!2?XN0!W8#)/%KW.K)#ID:-&UTN9GP
M[+$H&63>H"L6P5ZX(X( <$ %?1]8?Q?=+<0LR6=J!D NIE=U!VM@A<1GJ/F'
MU5^,+7M \S688/.F'G1N^X28=,^:=J-CY5&, <\$^M;5EI4GA&]6.W1WLKK
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MTC^RD,7F2RY8G=.^]AD 8!P...GJ37+_ !*TN>5K6_@C,OV27<R+G><LA&
M>/EP<9(SG!&<=1HFK_VJAE\N6+#$;9TV,< '(&3QSU]0: .:^+6G^?9//O=?
M*V_*K81MTB#YEQSCJOH:Q)IF\):='J$<TSR3PQ(B2.'B0NH<D(0,;0I"]<<
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M8T;79;RPO[&Y.^:SCF0N.C#8X!R>2<J>2!D8)R<FH?!VNW?A^S6WFLYFQO\
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M5<')^;!).X]<@9/7C;U=% !7+_#SPO+X;MVMYBI9I2P*$D8*J.X7GY:ZBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P;/09%O
MI=1D8%3$D<2CLO#/N&T<[QD')X)SVQO444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-W87<SO#]GM95W"(2)(HD^49&TY&1NZ #&!V6@#K3KEN Y,L>(B YWK\A)P
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M.>HR,_4>M6+[5H=/QY\B1[LX\QU7.,9QDC.,BO-?A#X7M[Z&2[F19'\PH!(
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M?,V[MN1NVYQNV]<9XSTS5+PUHXT>VBM!C,: -@D@L>7()YP6)/;Z#I7+^/\
M&D75GK'R@))Y4A.XG:X/(4?W07/KDC@C@ ':R7:1,L3,H>3.U20&;:,G ZG
MZXZ47%VEMM\QE7>P5=Q RQZ*,]2>PZUY1X]O);R[DOH2ICTHP9#,6!=WSD*!
M@$-\KC(/R]<\#I;Z\3Q'J%K!&0T,$7VEOF89+8\KY0!AERK#=CY6/'8@&K!$
MMO>S7#W8*B+FW+\1@!,R$%^!QG.T?>Z^N;X;^(B7TUS%<20I'#)B)MX7>NYQ
MG+,0W '(P.?<51TN%9M<O$< JUL 01D$%8000>H-5? .AV]U=Z@DD4;+'/A
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M<5U\=VDK-$K*7CQN4$%EW#(R.HR.F>M><> =#M[J[U!)(HV6.?"!D5@HWRC
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MQ7Z[X75U!P2C!AGKC()YYKS_ ,;^&Y8)[>YC@-Q:6L07R Y.""0/E^8D<KG
M;(7#\5T'@_5+&\:06B"&; $D13RG&QF RH^7().2,D9 ;' H ZBL^Z\0VUHQ
MBEFB1QC*O(BL,C(R"<]*S_'VIOIEC-/$<.% !Y!&]@A(((((#9!['%9GA'P/
M9FRBWQ*YFB5F9P"^9%!.&QE0,X&,8Z]<D@'6W5VEHIEE9408RSD*HR<#)/'6
MO*OAU#::NS7]](K7C7"[ \NULJ%*E4!7.2< 8(X  &#G8^'$*O\ ;-(D D@M
MI\()!OX+.,$'Y<90-P!\Q)[\5_@YI,-S;-/)&C2)<':S(I881",,1D8/(]Z
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M>2\7:+#HE[IQM4$1:4(2F1E0T8YYY)#$$GE@<,35WXC_ /'YIO\ U\?^SPT
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M &W!R<C'?/-<E9?$1);^6S>2$6R1@I)O W-A,C>6VG[S< 9X]C790PK"H1
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#,"^P_,.%W[S(!T)VAL G&2.< ]+7@GPW)HL<C7#*\\\K2.R#'7H,X&1U/0
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MO((U#/\ *TIV\!L9(12K$]2!C=@&O4ZR?#OAU-!1HHV=_,D:1FE8,Q9@ 3D
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MV3Q-OB<<$,.V1R >.G((!YQ@]!10!REGI^J7!C2YEA5(V1F:%7,C[""5.=H
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M#Y<+D8!SCD\>@P!JZGX5.KV9L+J3S)#SYOEJI#!B5(4<# ^4X()&>1FN@HH
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M%I)]D4MF174OA?XO+.,C^\02%YY.TU2^#]TMI8332'"1S2,QP3@+&A)P.>E
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MM7$D=D\:1[HWV[WW@;,2(5^4\MN/''3J: .UK'\+^*(O$D1N(0P57*D. #D
M'L6X^:LSP'J-S/##%+;^7$MO'ME\U6W850OR 9&1SSTZ5Q_POU^2TMGM[:%I
MY?.9V 81JJE$ )=AC)(.%') )XQR >MT5SGASQI'JT$MS(IA:W+"5&.YEV@G
M.  V, _P@Y#  XK/3QQ=7:FXMK&1X0,AGD6-V&T-D1X8D<\;=V[MSP #LZ*S
M]"UV+7(A<P'*MU!^\I[J1V(_^N,@@F'Q3KO]@VSWNW?Y>WY=VW.Y@O7!]<]*
M -:BN'E^(DSP?;H+1I(%0%W\P+AL#> I4LRH3@N !D-V&:U;_P :1Q6!U>%2
MZ84A2=AY<(03@X()/J#C@XYH Z.BN4\,>,9_$!61+5EMVR#*TB\$+DX3 +#=
M\H(^IP00(H?',^IDM8VCS1#_ ):.ZPJQRP^7>#N''U'0@=P#L**Q_#/B:/7H
MRZ@I(AVR1M]]&[@CCC@X..?8@@;% !6?K^MIHD#WDH8I'MR$ +?,P48R0.I]
M:PKCQT]Q/)9V-NUPT!(D)=8D!!Q@,P.3G(YQT)&X<BCXWU;^TM*N&9&CD1HT
MD1NJL)(R1GHP((*L.""#[  [/3KU;^)+A,A945@#UPP!&<9YYJQ7+V6OQZ'I
M]K-(&;?% BK&NYV9D&% XYX/<=,#G -1O'5Q9*EQ>6;0V[%0T@D$A3=T+(%#
M 9P#G!'3!; (!V=%8^KZ\]LJ?9H6N&F!*>65$>!@Y:0\*"#E>NXC%9FC>-VN
M+K^S;N!H)BNY 7$BL,$GYE '0'GD<$$@C! .KHKC_%?Q"_X1^X2R\EI#)&&7
M8WS%F+*JA=ISDJ!G.>> 2,'5AUR>*![FYMG1T; BB99W8':-PVX'4G([ $T
M;=%<5>?$"?2&C-]:-#%(VWS!*LH!QW"+^F<D D XQ5WQIXY7PLT(>,NLQ;)#
M8*A=N2 1R?FZ9'3KSP =117&3^/Y;*2+[5:M#!.^U97D7C/W2ZX^0]R&8$#=
MC.TUJ^*O%T?AY4#*TDLQ(C1!DL1COV&2!QD\\*>: -ZBN?TOQ'/)(L%W;M 9
M,^61(LJL5!9E)0?*<#(SU /<<U+GQK)-*]O8VSS^4S*[EA%&&7 *AF!!()Y'
M![C(YH ZNBL'PWXJ75V>WD0PW,).^)CD@=F!P-RG(Y'J.Q4G3U:^_L^&2YQN
M\J-WQG&=JDXS@XSCTH MT5Q7AOX@3^("I@M&\L,JR.95"H2><94;\+AB!@\X
MQT)T-6\8M!.;&T@>XF3;OP0D:AE+#,C @$@#'&#G .1B@#I:*YS0_%QNYFL;
MJ(V]R!N5&<.'7&<JX !(YR!Z'KAMM*?QY)<7$EE8VS3^1P[&01*&!((^9<=>
M.H)P< @9(!V%%<EX9^("Z]=262Q,@C0MF0X?*LJE2F#@@D_Q'ITYXN^&_%?]
MM37-MLV?99-F=V[=\SC.,#'W?4]: .@HKG[+Q7]IOY=*V8\F,/OW9SD(<;<<
M??\ 4]/>JESXUDFE>WL;9Y_*9E=RPBC#+@%0S @D$\C@]QD<T =717.:-XTC
MNUE6X4P36P8RQL=Q"KSO! ^9<=P/3L5)S=-\>W.IJ;F&R=K<,WSB50Y53R1&
M0"QQV!(+?*#D4 =K17FGQKN)/)CB\O\ =>8K>;O'WML@V;.O3G=T[5VNA:C<
MWF[[3;^1MV[?WJR[LYS]T#&,#KUS[4 :U%%<5\6KB2.R>-(]T;[=[[P-F)$*
M_*>6W'CCIU- '6ZC>K81/</DK$C,0.N%!)QG'/%5] UM-;@2\B#!)-V X ;Y
M6*G."1U'K7'Z?J-S/IKQ2V_EQ+I[;9?-5MV(@%^0#(R.>>G2J7@?Q1-;6$<5
MK;-<>2)/,(81A279@JY!+MMY(4'&5').  >FT5B:'XLBU6T_M'[J*K%QG<4*
M<L#MYZ<CC)!!P,XK'3QQ=7:FXMK&1X0,AGD6-V&T-D1X8D<\;=V[MSP #LZ*
MS]"UV+7(A<P'*MU!^\I[J1V(_P#KC(()K^*O$T?AR W4@)YVJH_B8@D#/8<$
MD]@.,G (!8U_6TT2![R4,4CVY" %OF8*,9('4^M6-.O5OXDN$R%E16 /7# $
M9QGGFO-_'?BN>>Q>*ZM7@\_R_+;>KKD,'(;[I0X' (R>>!@UU>FZHVG6%J\<
M3S.T,*JL8'4QC!8GA5R,%NV>E '2T5Q\'CR2WN([*^MF@\_A&$@E4L2 !\JX
MZ\=21D9 !R,3XUW$GDQQ>7^Z\Q6\W>/O;9!LV=>G.[IVH ]+HKG$\42V<,MW
M?P&!(@I&)%F+;CC "XP<X'/'/4 $UGS>.+J%#=/8R"W4DEC(HD"!L%C$1N!
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M7';M+(-@3:X&XLJL<Y7Y0 22<GIS@$D;4VN3V\"3/;.9Y&V^5&RO@G=M+.,
M*<#+?PYY% &W17'P>/)+>XCLKZV:#S^$82"52Q( 'RKCKQU)&1D '(L>-/'*
M^%FA#QEUF+9(;!4+MR0".3\W3(Z=>> #J**XR?Q_+921?:K5H8)WVK*\B\9^
MZ77'R'N0S @;L9VFM7Q5XNC\/*@96DEF)$:(,EB,=^PR0.,GGA3S0!O45S^E
M^(YY)%@N[=H#)GRR)%E5BH+,I*#Y3@9&>H![CG/A\<SZF2UC:/-$/^6CNL*L
M<L/EW@[AQ]1T('< ["BL?PSXFCUZ,NH*2(=LD;??1NX(XXX.#CGV((&Q0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M">XFA692C@%6!!!&00>""#U!H RO!TRRV5L5((\B,9!SRJ@$?4$$'T/%<O\
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ME1:6@A@140=E&,G &2>I. ,DY)[FK= 'GGP>F6UBGT]R!/%.Y9,\@ *A/'!
M92#@G'&>HSH?$?4([S3KH1L&\IXT;'9A)&2N?49&?0\'D$5JZQX&L]8D^T3Q
M!I" "0SKG'3.UAD]LGG&!T JPWA6U,!L!&H@;&57*Y*XP2002?E&23DXY)H
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M$'@@@]0: .5BF671LJ01]@(R#GE82"/J""#Z'BG?"W_D'0?]M/\ T:]6]/\
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M (YXQVKC_%4RZ;K%I>3$)"8F3>3QNQ(.?0?O%Y/'/7@X] AA6%0B !5   &
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M]\Y-:>MZ!!K:"&Y7>@8,!N9>0",Y4@]": ,KXD6K76GSH@R0JMU X1U=CSZ
M$_RYK!\(^&(]6M8IH[RZ^XH98Y\*K!1N0+MX [#TP1D$&O0ZYJZ^&^GW3&1H
M%!./N,Z+P,<*C #\![]: &:#X2M[>T:UM)I/*E?=YL<B[\@J#M=5QCY,'@]Q
M3)O!S6L-P(Y[B9Y;>5%2>4,N67@C( !SQG/0FNEM;1+11%$JH@SA4 51DY.
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M24SQ5,NFZQ:7DQ"0F)DWD\;L2#GT'[Q>3QSUX..SUO0(-;00W*[T#!@-S+R
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<YS\A['M0!L45C^*+F[MX@UA&LDN\ AR -N#D\LG.<=_PK8H **** "BBB@
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MA@1GC'('?JZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KFOB%XE;P_:&:/_6.P1#@$ G))()[ ''7G&01FNEKFOB%X
M:;Q!:&&/_6(P=!D $C(()([@G'3G&2!F@#G]6\'W>GV,DOVN5Y1"_FK(V^)E
MP2ZJ&!(..C=3C^'=Q4T_Q*WA_0XIH_\ 6.SHAP" 3)(22">P!QUYQD$9K0O/
M$]WK-I);+:2I.T+B0R(RQ8VD-LS\S,W15QP3R2%)-2'P?+JNBQVFUEGC9G5'
M^0DB1^#N'&58XZ<XR0,T 95WKEO%&TT>IW#W0RZC;(L3,#N"^45P >F-VT=<
M8^6M/Q9>-XCTA=3<LC*.4C;$;'SE0EE(Y VY49^4GJ>M;MKXWGVB*6RN/M'*
MD(G[DL#@8D)P%)_BY '=@,F[XNTR;7=/>!5"S2(AV%@<,K*Y3=T)X(!X!/<#
MF@#/\*::NB6BZD\L[J+16,;R;D V!SL4@8(QA>>!Q7):?XHAU8?:+^_FBD;.
M(K</&J ,W&55@V1C!Z@<$GMUOA6];5K4:5/!/"1;>6S.FU" HC^5F'WB#G!7
MCGKCG/\ "^J7/A2+^SKFUE<1EMCVR>:K*S,3GD8.>1T.",J,9(!%X:\6RZA9
M7L1<N;2)_+G&5=U*OL8CJ&&W.<YY&>027_#W1[C588]0N;J8@-\B+(0"$=L^
M9D'=DY'^[@9Q@+T5Y=S:K8W)>%HV>*41H2&=E,?RDJOW6.<;.2",4WX<6CVE
MA#%*K(X\S*N"K#,C$9!YZ4 <IX?AN]=O+V W,J6\<S A'^?[[[ C$'8!MYQC
M( 7!!R#34O?MTVAI=/Y2X=I'^:8(57**QS@G>!GC!&Y0.5.QX!TZ6UN]0>1&
M59)\H64J&&^4Y!(Y'(Z>HHTG3I4UJYN"C")H% <J0A.(> V,$\'\C0!%X/O)
M['4+C2))6FBC3S%:4EG&=F!N)Z8?![9&0%R09=)U&5]:N;<NQB6!2$+$H#B'
MD+G /)_,T:3ITJ:U<W!1A$T"@.5(0G$/ ;&">#^1HTG3I4UJYN"C")H% <J0
MA.(> V,$\'\C0!C^'X;O7;R]@-S*EO',P(1_G^^^P(Q!V ;><8R %P0<C5\'
M7LMA?W.CR2/,B*LB/*V6 (3*\Y)X<=P,J2%&XT_P#ITMK=Z@\B,JR3Y0LI4,
M-\IR"1R.1T]11I.G2IK5S<%&$30* Y4A"<0\!L8)X/Y&@!^O:4I=S<ZB\,C;
MC&JRI JJ2=@*9!?!R"V06 QQBCX<:K+XAL'6=VW*SQ"13B3&Q2&W<_,-W#>P
M)R<D\SX=TQM&::"\L7N;AY,K+L$D;$CC+N,*"3DMR>3O *XKH_A%ITMA:.DR
M,C&=B ZE3C8@S@@<<4 <YX*\,?;KF^B\^X3R9L;HY=K/\\@RYP=QXZ\<D^M=
M'I.HROK5S;EV,2P*0A8E <0\A<X!Y/YFL_2WG\*7MVTEO++'=/YBO;H9/XG(
M!Z<_,<\Y!' ((-:&DZ=*FM7-P481- H#E2$)Q#P&Q@G@_D: *7A\S^.&EO&N
M)8;9)&2)(&\M^BG+$9SQCNWS$XV@8-K1=1GT/4!H\\K3131EX6?F1>6;#-P3
MPK#OT7&T9 J^'Q/X':6S:WEFMGD9XG@7S'Z*,,!C'&.R_,#C<#D6M%TZ?7-0
M&L3Q-#%#&4A5^)&Y9<LO)'#,>W5<;ADD RO#\-WKMY>P&YE2WCF8$(_S_??8
M$8@[ -O.,9 "X(.1J^#KV6PO[G1Y)'F1%61'E;+ $)E><D\..X&5)"C<:?X!
MTZ6UN]0>1&59)\H64J&&^4Y!(Y'(Z>HHTG3I4UJYN"C")H% <J0A.(> V,$\
M'\C0!W%%8EAXE^UWD^G>6P\A4/F Y4[U!P>!M// YR 3QBM#5K=[F&2*([9'
MC<*V2,,5(4Y'(P>XYH X+Q+8?8XI7DU*3[6B%MHE6)20,JHA4@@LN!P>2=V#
MG%2W_B.>]T,WQ8K,0H+1DH?EG"9XZ$@<XP.3@ <5S^F:<;2SEL7T^1KO$H$A
MB#+T/S"0YP5'W0N0Q VG+5L?V3-_8'V7RW\W^YL;?_Q\;ONXSTYZ=.: #^PK
MNXT[^T);R82K;^8HC?:FU5WJ& P68CJQ.<G^+;S;OO'TD&DQZ@/]?+^[!P"-
MP+!G(X'(0D#! ) P1FMO[(_]D^1M;S/L.W;@[MWDXV[>N<\8ZYKF8?!\NJZ+
M':;66>-F=4?Y"2)'X.X<95CCISC) S0!-JW@^[T^QDE^URO*(7\U9&WQ,N"7
M50P)!QT;J<?P[N-KX6_\@Z#_ +:?^C7K*O/$]WK-I);+:2I.T+B0R(RQ8VD-
MLS\S,W15QP3R2%).W\.+1[2PABE5D<>9E7!5AF1B,@\]* *_Q \13:<(+2U(
M6>[E"J[ %5 (!ZYY)8?PGC=WQ6?K'A6YT:W:\M[R=IH$+-YS[XV"J=^$(.#W
M7.[!X_VAH?$#P[-J(@N[4!I[24,J,0%8$@GKCD%1_$.-W?%9^L>*KG6;=K.W
MLYUFG0JWG)LC4,IWX<D9/9<[<GG_ &2 4?&%W_PD6D+J6YT(4;D4[8V8RJC;
MEYR 02G.1U/-=!X#T#['##=>=,_F6\?R22;HUW*K?*N!C&,#G@<57O\ P;(F
MDG2HL-*$4\G@L'$C ' X)R%SCMD]35CP)K;SQ1V4MO-$\,*@M)&5C.S"C#'!
MR1SC''/)QD@''_"_0Y=6MG7SGB@69CB!MDC.43.6P?E Q@#J22>@K>\#^(Y+
M6.]@N6:7^SW<[R<NRC?D8/?Y"1ECUQD "I?A%ITMA:.DR,C&=B ZE3C8@S@@
M<<57\(Z"\LVIQ3HZ1W,C ,5*[E9I02I(P>&'/(Y% '/Z?XHAU8?:+^_FBD;.
M(K</&J ,W&55@V1C!Z@<$GML>&O%LNH65[$7+FTB?RYQE7=2K[&(ZAAMSG.>
M1GD$F7POJESX4B_LZYM97$9;8]LGFJRLS$YY&#GD=#@C*C&3T%Y=S:K8W)>%
MHV>*41H2&=E,?RDJOW6.<;.2",4 <[\/='N-5ACU"YNIB WR(LA (1VSYF0=
MV3D?[N!G& OHM<U\.+1[2PABE5D<>9E7!5AF1B,@\]*Z6@#S+PZEUKMW?6QN
M)$@CG.=KMY@P\FQ4)R$7C+8&2%"C@FK%EK4OA&\DL+F5YX'A>:,L=\@"*S%2
M6([(P]"=I&W+5F>%M7FTR^OY$A::'SV\SRL&13YDFPA21N!R<@=!SD8P=.RT
M67Q=>27]S$\$"0O#&&&R0AU92Q# ]G8^@.T#=AJ ,33_ !1#JP^T7]_-%(V<
M16X>-4 9N,JK!LC&#U X)/;J_AGXG?5UEMG;S/LS +*00SJQ8*2IYSA>I.3G
MGD$FCX7U2Y\*1?V=<VLKB,ML>V3S5969B<\C!SR.AP1E1C)[/1-0DOT,LL30
MY8[5=@6*X!5B!]TG/*GD$4 >;_#S3+KQ+$TT]W.L2.541RL'+$*22QS\H&,#
MGDDC'.Y^O:!YFLPP>=,/.C=]PDPZ9\T[4;'RJ,8 YX)]:W?A%ITMA:.DR,C&
M=B ZE3C8@S@@<<5%XPLY['4+?5XXFFBC3RV6(%G&=^3M Z8?([9&"5R"0"'X
MDF70+")(9I=PG ,C2'S""LC8+#&1_0#TI_Q/O;B&:RBM9&C>61EX8A2=T87<
M!D$ GH0>,\4SXDB77[")X89=QG!,;1GS  LBY*C.!_0CUJWX^TZ6ZN]/>-&9
M8Y\N54L%&^(Y) X'!Z^AH S/%\,_A$0ZD+F:4^<!(COB-MP+-M4#" X( PV,
MC!!7F]\0_%C64T6G+,;=9$9I)1'O(4AE4* <Y)!R0 1\I!ZU+\7=.EO[1$A1
MG83J2$4L<;'&< 'CFG^--&GANH-9M$\UX%97CS@E<-RHZDX9AW.=N%/- '*7
MGC&'0VCN;*[FN?FQ)%<%RI4C.0S(H4@CK@GGT!!V_%]S=R:K;V=K,T6^$'KE
M.#(6)0Y5CM'&1UQR.HZ"T\827SK%%:7 RPW-.HA55SAF!).XC/W1R1GTK,U;
M3I7UJVN C&)8&!<*2@.)N"V, \C\Q0!2OUE\)WUHJSS3173&-DGDWX)*KN!Q
MC@L#P >"-V&XJ?$K2-U]9MYDO^D3 8#\1X,2YCX^4G.2>><&MCQ]ITMU=Z>\
M:,RQSY<JI8*-\1R2!P.#U]#1\2M+GE:UOX(S+]DEW,BYWG+(1@ 'CY<'&2,Y
MP1G !U&B:1_92&+S)9<L3NG?>PR , X'''3U)KE_'VHRVMWIZ1NRK)/APK%0
MPWQ#! /(Y/7U-=1HFK_VJAE\N6+#$;9TV,< '(&3QSU]0:Y?Q]ITMU=Z>\:,
MRQSY<JI8*-\1R2!P.#U]#0!2\7W-W)JMO9VLS1;X0>N4X,A8E#E6.T<9'7'(
MZ@OUE\)WUHJSS3173&-DGDWX)*KN!QC@L#P >"-V&XNZMITKZU;7 1C$L# N
M%)0'$W!;& >1^8H\?:=+=7>GO&C,L<^7*J6"C?$<D@<#@]?0T 8_Q*TC=?6;
M>9+_ *1,!@/Q'@Q+F/CY2<Y)YYP:MZR9[">'0;2XEWW&]WEG;S'"E2-JMP1P
MC'& =V,,,FKOC[3I;J[T]XT9ECGRY52P4;XCDD#@<'KZ&G^--&GANH-9M$\U
MX%97CS@E<-RHZDX9AW.=N%/- %'Q1I=SX4B_M&VNI7$97>ER_FJRLR@8X&#G
M@]#@G##&"_XFZ\_V""\MG>/S9(R"K%&VO&[8.T_3(SC-,\4:I<^*XO[.MK65
M!(5WO<IY2JJLI&.3DYY/4X!PISD/^)N@O]@@L[9'D\J2, *I=MJ1NN3M'TR<
M8S0!=;09](M;B[FN99)S;3$_.1$K%2V47 VE<8!&.^ ,X&/X.T*[\06:W$UY
M,N=_E>6^"/F()<_>?YAP,\ <$9P.X\3PM-:7"("6:"4  9))0@  =2:S?AQ:
M/:6$,4JLCCS,JX*L,R,1D'GI0!RG@Q+WQ?;EI;IXTB^1#%Q(S@9WNW5@ P&
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M8L?X0. 3_"M '6^-KUK_ $8W#X#2Q6[$#IEGC)QG/'-=%X3_ ./.V_Z]X?\
MT!:YWQ#ITLNBK;JC&7R+8; I+Y4QY&W&<C!SZ5TOAB%H;2W1P0RP1 @C!!"
M$$'H10!R7QK_ ././_KX7_T"2O0*X?XNZ=+?VB)"C.PG4D(I8XV.,X /'-6+
MGQO/<#R[2RN#*V<>>GE1C@G)8G'7'&5ST!!QD YKP[K?_"/_ -JRJ/D@F_=H
M!\@9GD1?E!  SMSC!VCCH*J6VN6]['YMSJ=PMPZ@XB61(T.T?+L1<'!ZE2N[
MV/-=7:_#ORK":R=]UQ<_.\A[R AE&X@L5##G.2<L1@G AT'Q3/H\*65U9W!D
MA54S!'YB%54;3N#8SC@X)&1V^Z #-;QC/JVC379)2:)T0O&2I.'C.[C&TD-@
M@<=<8!P+MGX8N]9M([EKN5)VA0QB-V6+&T%=^/F9FZLV>"> 0H!M^/;B2YTF
M62>/RI#LRF\/C$R@?,.#D8/XXK/TGQA=Z?8QQ?9)7E$*>4T:[XF7 ",Q4D@X
MZKU./X=W !J^$=<G\4V&]9/*N%;8TGEJPRI5LA"<'<I /3!)P  *Y3Q/J(\.
MB*[L;]YV$F&CDG$RD$$Y*J1QQ@\=P05(&;%[X#N;/2/LL>3,9?-E16SD8QL&
M!\Q&%..<L#M)^45F^*K/^TK:.*TTZ6)D9-[&'#?<("@@;W&<Y8XY SRPH Z7
MXGWMQ#-916LC1O+(R\,0I.Z,+N R" 3T(/&>*W;'P>UO"\#W5P[2A,N9?F4H
M<DID':&[C)XXSWK*\?:=+=7>GO&C,L<^7*J6"C?$<D@<#@]?0UW% 'E7PDT#
M[9";KSID\NX^Y')MC;:J-\RX.<YP>>1Q4OA^&[UV\O8#<RI;QS,"$?Y_OOL"
M,0=@&WG&,@!<$'(L> 'G\+E]+GMY6W3@B6)"\7SA5R6XPHP#GD\D$ C%:'@'
M3I;6[U!Y$95DGRA92H8;Y3D$CD<CIZB@#'TU+W[=-H:73^4N':1_FF"%5RBL
M<X)W@9XP1N4#E3I^#[R>QU"XTB25IHHT\Q6E)9QG9@;B>F'P>V1D!<D&72=.
ME36KFX*,(F@4!RI"$XAX#8P3P?R-&DZ=*FM7-P481- H#E2$)Q#P&Q@G@_D:
M ,36?&*:A=S6\]U):V]NX55A1A([*&5SYB!B &['@KC@,":L>$O%@COAI\$[
MW-O.I(:;=YB,JL2-S %@0O3  R,<AMUM+:?PC>SW*0O-:W;!B8AOE5OF;&T8
MXR6[8P5^;((/2Z)X@DU5S_H\L404_//A&+ CY1'DG&#G=G&010!Q7A^&[UV\
MO8#<RI;QS,"$?Y_OOL",0=@&WG&,@!<$'(U?!U[+87]SH\DCS(BK(CRME@"$
MRO.2>''<#*DA1N-/\ Z=+:W>H/(C*LD^4+*5##?*<@D<CD=/44:3ITJ:U<W!
M1A$T"@.5(0G$/ ;&">#^1H YS3/#'FZM<6?GW V0@^8LN)6XBX9\<CYNF.P]
M*]5M+?[,BQ99MB@;G.6.!C)/<GN?6N"OXI] U634O(DFAN(@N8%+LNT(.5]<
MIW(!!R"2"*WCK]S)>00)"PMIH=[L\;AD8JY"E@=JD84$')R?<4 =+7">/\:O
M=6>C_*0\GFR [@=J \!A_> <>N0.0.3W=>?VWA(>)+VZNK^)_+1A'"K,RJ0F
M06&-IP<!ACY?F;[QY  _49FT'6(Y<D0WZ!&R<C>@VKA5Z$?(,D$?.W/7#/B?
M>W$,UE%:R-&\LC+PQ"D[HPNX#((!/0@\9XJ+Q?\ #.&V@,^G1LEQ$RN-C.S$
M#J!E^"/O#'.5P.34OBZWFU2;3+E8G&)%>0!6;R]S1$AC@8Q@]0.AH J>+X9_
M"(AU(7,TI\X"1'?$;;@6;:H&$!P0!AL9&""O.WXDOY=*U"TFWO\ 9Y\PN@&4
M#$_(QR< DL/1MJ'&1D57^+NG2W]HB0HSL)U)"*6.-CC. #QS6QX]T;^U[*6$
M#+JN],+N;<GS8 ZY8 KQSSWZ$ J>)+^2XO;33H79?F,TI4-G8GW5)! VN<J<
MYYV^P/5UY_\ "Z!]3,NM7'^MFVQ@[2H*QJH9AS@[B!G P"IQC) ] H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHJC+KEO%)]G:6,2Y V%U#Y;&!MSG)R,>M %ZBBB@
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MG;AN&^[DYVDX]\9XK3HH S/#6CC1[:*T&,QH V"2"QY<@GG!8D]OH.E:=%%
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M8;:3Z!B-ISVP>>,9R*\\U?4)!H-N-Q/F2[&SSE5:0JN3T V+C'0#'3BO4_[
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M?>SG';IS71>)O&MMX< $[$NPR$09<C.,]@!]2,X.,D8KB/'W_(9L_P#MW_\
M1[5#J)6X\0*DYRB,FW<Q !$0= .?^>F"!W)Z'/(!E?$SQ?!XD6W> ME/-W*Z
MX9<E,9Z@YVD\$^^#7N%>/_&VUBBEAD0*)75]^#\Q"[0A(_[Z /?&,_*,>P4
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MX7_T"2@#/^)6S^R;7RMWE[H=N_&[;Y+[<XXSCKCC-=UX3_X\[;_KWA_] 6N
M\??\@:S_ .W?_P!$-7?^$_\ CSMO^O>'_P! 6@#S+XE>/FN)1;VCRQ-;O*LA
M#; Q! &-K<@;3UQUK8\3>-8?$^G77D*Z^5Y&?,"C[THQC#-_=-5?CG_RZ_\
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MN+JMI8RQ*8XG$O[O^$&,J@&!QA>0IP.#T&2*T-1\!:GKL4:236[Q( 8]H"@
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M1SR>OX]QH-[8V%]>W$7GF:)+AI0_E[,+("^S&#G(^7/;K5+X&?\ +U_VQ_\
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M@. 3@ YQG'>N7MX5U+791, PMH%,8(^Z?W9!]R"[$9S@G(Z#!\885M8H-00
M3Q3H%?'( #.!SP0&4$9!QSCJ<@#]9_Y#UK_U[M_*>C1O^0]=?]>Z_P H*-9_
MY#UK_P!>[?RGHT;_ )#UU_U[K_*"@#I=9\:6>C-Y4\JJ_P#= 9V' /(0$C((
MQG&>U6]&U^#6E\RVD5P.N.&') RIP1G!QD#/4<5QGP>A6ZBGU!P#/+.X9\<D
M$*Y'' !9B3@#/&>@P7$*Z;KL0A 47,#&0 ?>/[PD^Q)12<8R1D]3D [71]:A
MUB/S[=PZ9(R,C!'4$$ @_4=,'H11IVM0ZBTB0N&:%RCCD%6''0@<<'!Z'!P>
M#7!6>K?\(?+J%L>$5?M$(,>(\OA=OR\XW,B<<?*?N\U2\&0MX+N%2<L(KNT\
MULQXVO&"[*>I)10V<<Y897I0!Z!J>HV]XEU:.Y BB(FP#E5D0G(.T@G;D\9]
MQVJEH%]9Z)8)-%(QM8]V'=6+?-(0<@*#]XX^[_C7/^'(/-TJ[OVV^9>+=2-M
M7&.'7;G)) ()&>FX_4Y__,N?Y_Y^J .PN/B1I\&W,Z_,H8;5=N#Z[5.#ZJ<$
M=Q6_]K39Y^Y?+V[MV1MVXSNW=,8YSTQ7(6^E16^BLBHH#V9D;C.7,6_<<]\X
M(/; Q@ 8Q-QN/#N7;HO5LGA)\*O )Z *O8<9P.0 =1-\3=.B8H9QE20<)(PX
M]"%((]P<'M6[I>J1ZK&MS VZ-\X.",X)!X(!Z@]JX?7[^;6X4TR"TEAF#Q[7
M=0D,1C.2R2+G@8PI4#(/R]E/H= !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7+_$:XC%K]GE( N98XMS?=3<V[>?F7A0I/7&
M0,\9KJ*ANK1+M3%*JNAQE7 93@Y&0>.M '%:_P"%VT>"2\CO;D/"N]?-F#(2
MO(4J0 =Q^4#U(X/0FGZ-+XMAL-1N'V26[%R/+^^-ZE3U&-P0'(!!W9  P*TX
M?AEIT3!Q ,J01EY&''J"Q!'L1@]ZZB@"CK6CQZQ"]I-G9(,'!P1@@@@^H(!]
M/4$<5R$OPVN)[?[!)>LT*@;5\H#&"",G<690,X7. =I'W0*[VB@#G]3\*?;K
M :5OQB.)-^W/^K*G.W(Z[?7C/>K7]A?Z'_9N[_EW\K?M_P!C9NVY_'&?QK6H
MH Q-!\,+IMF-,D/F)MD5C@ID2,Q(P"2.&QU]ZS_#/@Z?0&")=,ULK.1$T:YP
MP.!OSD8."<  G/ R:ZNB@"&[M5NT:&09212K#)&0PP1D<]*Y"W\!7.GHUK:7
MKQP'.%:)78;A\V'RI&3DC:%P3GKDGM:* ,GPUX:B\.Q?9H-VTL6)<Y8DX&3@
M = !P!T]<DU?!7A3_A&(6MM_F;I"^=NWJJC&,M_=]:Z"B@ KR+X7>'9;JW>Z
MMKAH)3*4;Y%D0JJJP^1L?-EN&SP,C')KUVL_1- @T1##;+L0L6(W,W) &<L2
M>@% &?X0\(+X=5SO:269MTDC9!8@G'&3ZG)R2222>@!X*\*?\(Q"UMO\S=(7
MSMV]548QEO[OK7044 <OK'@DW%Q_:5K,T%PP 9@HD1@!CE&QSP.^/E!V[N:N
MZ)H<]HYGN;EYG*E0-JQQ@9!SY:\;LY^;/0XQQ6W10 5S7B?P9_:\L5[#*T-Q
M#P' W KR<%20.I/L02&!!&.EHH P=%\.RVLOVJYN&GE",B_(L:!6*L?D7/S9
M7EL\C QP*@\*^"5T2VDL)'\U)F<M\I3AT"%>&)Z#KD=:Z6B@#C++P-<Z2OD6
M=ZT<(.51X4E(SU^8D<$Y.  .?7).AJW@F/4[0:?))(VTEEDD;?(&R<$GC<!N
M(Q_=X&#@CHZ* ."U7X;7&KQ+!<7K.(R-N8@!P"#N ;+-TPQ.1\W7=D;OC7PI
M_P )/"MMO\O;('SMW=%88QE?[WK7044 4=:T>/6(7M)L[)!@X.",$$$'U! /
MIZ@CBN0E^&UQ/;_8)+UFA4#:OE 8P01D[BS*!G"YP#M(^Z!7>T4 <_J?A3[=
M8#2M^,1Q)OVY_P!65.=N1UV^O&>]6O["_P!#_LW=_P N_E;]O^QLW;<_CC/X
MUK44 <Y8>"XXK :1,Q=,,"P&P\N7! R<$$CU!QR,<5FVO@*Y6(6,MZ[6VTJ4
M2)4?;V42$L0.V.1M^7I7:T4 <OK'@DW%Q_:5K,T%PP 9@HD1@!CE&QSP.^/E
M!V[N:NZ)H<]HYGN;EYG*E0-JQQ@9!SY:\;LY^;/0XQQ6W10 5QGC;X<+XGE2
MX$IC94VD;-X(!)'\2X/)SUSQTQSV=% ')>)_AY'K5O!:*Y0VP"JY&\[0H4@@
M%1DX4Y]N.M:OA/PZOAZW6T!#%2Q+!=NXL2<D9/(&!U/ %;%% '%>&_AO_8L-
MS;>=O^U1[,^7MV_*XSC<<_>]1TJUH'@7^R+.;3?-W>?YGS[,8WH$^[N.<8SU
M&:ZNB@#G_!7A3_A&(6MM_F;I"^=NWJJC&,M_=]:/&OA3_A)X5MM_E[9 ^=N[
MHK#&,K_>]:Z"B@"II-C_ &?#';9W>5&B9QC.U0,XR<9QZUQ4GPH-J[/8W4MN
MC]57)Y!..0Z' !P,Y/7DYKT"B@#G--\&K86DUB)&9K@2%Y'Y.^1 K-CCCC."
M2?5C3_!7A3_A&(6MM_F;I"^=NWJJC&,M_=]:Z"B@#E/ O@7_ (17S?WOF>;L
M_@V8V;O]ILYW5%X0^':Z D\,DGFI<JJL-I3@!@1D,3R&]L5V%% 'GEE\(Q;M
MY37,C6I?<T(!4-CD!B&P3P,D*"<<;3@C8T#P+_9%G-IOF[O/\SY]F,;T"?=W
M'.,9ZC-=710!RF@>!?[(LYM-\W=Y_F?/LQC>@3[NXYQC/49JWX*\*?\ ",0M
M;;_,W2%\[=O55&,9;^[ZUT%% '*>!? O_"*^;^]\SS=G\&S&S=_M-G.ZNKHH
MH \\T7X/QZ9<I=F4ND;[E0I@\9*9<-U4X/W<''3!KH/&G@N/Q1&J,Q22,DHX
M&[&[&X%<C(.!W!! YQD'HZ* /.KSX0F^3]]=/)/N&))%+80 _(%+]R<YSVP
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M#WMI</;M+DL$!)RQRV&#J<$X..>>G& )M'^%\6C745Y [;8E8%7&YF+!QN+
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MV 81JJE$ )=AC)(.%') )XQR >MT5@^$?%2^(8V8H8Y8G*O&QRRD=.P.#TY
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MN(>2A.X%>!D, !U(]B""I()P =+17#P_$E[FXFL(;9I)HG95"R*%8(Q5F9F
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MC)*YR40AF=2,%2/O= ,BI=+\:1ZG9/J<:G]TCED)QAD7<5W8Y!XP<=#R <@
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MEM_+B6WCVR^:K;L*H7Y ,C(YYZ=*W=:UB/1X7NYL[(QDX&2<D  #U)('8>I
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MO(!&<J0>A-.O]%AOX39R(#"0HV#*C"D%0-I& ,#I0!R'@F^9+6[UQT.Z9Y9
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MB8BW#+=OA'_=YW*1A@5&!CD'<23]T#TBO/)M3M;2XN&U>,!VEQ"TL321F)0
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M:L&C1"=W)/S9+ XS[\G@+V%>6>3;ZY?VTND*%%N0T[HAB3;N&%Q@98@,.GS
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M4J#M.>^1SSG.35K3_"UMI\+V42;8I=VY=S'.Y0K<DDC(&.#0!E?"W_D'0?\
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M9,@C("\$[2%^Z<DT?#WQ9+K?G03[&>V95\R(_*X.X;O3DJ3D8!!&%&.=+6/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHKC],U^>;5KBP9LP1PAE7:O!(BYSC)^\>I[T =A1110 4444 %%9^OZ
MVFB0/>2ABD>W(0 M\S!1C) ZGUJQIUZM_$EPF0LJ*P!ZX8 C.,\\T 6****
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M_P!I;_\ 2/[^U?\ GOL^[C;]WCI^M 'H%%9_AZZ:[MH)I#EY(8V8X R60$G
MXZUH4 %%%% !116/<W-VMW'$D:FT*$NY(WAL-@ ;AQPO\)ZGGT -BBBB@ HH
MHH ***\_\&ZM?>*F:^\Y8K=)@!"(U<D* 64N0",@CYLGDD@* !0!Z!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8CG%2M+/X0OH(6GDGMKP[ )F+R*PP <G QN8<CJI(*DJI.?+?S6&MW$L,1E
MB7S%4C?LV1$E02,L#C"\EN@ZY&@T4_B^^@F:"2"VLSO!F4I(S'! P<C&Y1P.
MB@DL"R@ %6]2ZU?5Y[&.XDBA5$9@KL,*%B)"#HK%B.>."<YY4W=?N9[66W\/
MVDSAY5=GFE.^3:=YP&ZY #8X!X0!AR:L:3ITJ:U<W!1A$T"@.5(0G$/ ;&">
M#^1I_C31IX;J#6;1/->!65X\X)7#<J.I.&8=SG;A3S0!1\4:7<^%(O[1MKJ5
MQ&5WI<OYJLK,H&.!@YX/0X)PPQ@V+S7)+2]M+Y=YM+^-$*DL0KO@J=N[8I(*
M]"<@.0">37\4:I<^*XO[.MK65!(5WO<IY2JJLI&.3DYY/4X!PISD:WC3PJ+K
M3C9Q LUNB&/.2Q\H8Z*.6*9 &,$GMU  SQ)?RW.H6FG0NZ*,S2E1\I53\JD@
M@X)4J<_+\R]3@57TG497UJYMR[&)8%(0L2@.(>0N< \G\S3_ (>VLUV]QJEW
M'Y<\S(FTQLA"QH.1O).&XSVROY,TG3I4UJYN"C")H% <J0A.(> V,$\'\C0!
MG^'DG\;R37S7$L-NKF...!S&W&&!;[PSAAGJ22>0J@&+P;!-;ZS<I<N))1!R
MX4+D9BVG:  #MQD>O<]3+X>>?P1)-8M;RS6[.9(Y($,C<X4!ONC.%&>A!!X*
ML")?"MG='5I[NYB*>9 .5#&,?ZK"[\89@!AL<;@<<4 8L?C.+7)'FNKR6WC#
ML(HH%9&V_+M9G0/DGG(.<')! .*U?!WC<127-J9&N+>WB>9)6SYI5<%D.[&X
MC=@$XZ?W2 K_  ^)_ [2V;6\LUL\C/$\"^8_11A@,8XQV7Y@<;@<CI[.[?Q%
M%-%+#)##(A53(561@X97^3G85[9SD$&@#F/"FE7?B2,ZI+=2QM*Q,20MB-=A
M*C<AR&&1]WN!\S$L<,^$Z2)<7ZS$-*)4#D="P:7<1P."?8?2G^%-5N_#<9TN
M6UED:)B(GA7,;;R6&YS@*,G[W8'YE!4YL?#;3KBUN+Y[E"K22J<A65&.Z0L4
M+#E>>/8B@#I_%G_'G<_]>\W_ * U<1X'\-3ZO81L;F2%5$@B$#%>KMEI.['=
MT ( 4<'+''=>)X6FM+A$!+-!*  ,DDH0  .I-</X.UV[\/V:V\UG,V-_E>6F
M2?F)(<?>3YCP<<@\ XR0!^DZI=:K97FGM(WVNR)421[MS;"2 ""&+,49<X!(
M()R<YW;7Q?C2QJC'YQ">77@R#Y.0G9I!VQP>W:+X=:%+9K-?7(V37DF\H.BC
M)(&#R#ECP2<# .#D5Q\GA]Y=0;0B/]$:X^T\1E0%V'(!4C"G/EYS@$#&#D$
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M[2H;S%CP'=OD(P5R-W/W2>V2(M6U&5-:MK<.PB:!B4#$(3B;DKG!/ _(5C^
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M#,%+'@8 )Y/(Z>HH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!YKG/%-W/=WU@]S;"!O/4 ^8DA8"2,XRH& N>,_WCCO0!L?$?_C\TW_KX_\
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MDEPO'RGZ8YJE_P +(T_?Y/GKNW;<[7VYSC[^W;C_ &LXQSG%9/QDNFAL0BG
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MC6/$A\2V5I8H2TMZZI(VT,5\HJ9&VJPP<X8#ILR3MXKTJ&%85"( %4   8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M((\M7W;E#;BQ!!'IR">I-='10!QEEX&N=)7R+.]:.$'*H\*2D9Z_,2."<G
M'/KDGH[;15B@-E(SRH596:5RSL'SD%A@]#@=,#%:%% '%:;X"N=,4VT-ZZVY
M9OD$2EPK'D"0DE3CN  &^8#)K0UWP.FI6\-HCM&]ML\J4 %QL '4;3R #P5^
M8 ]L5TM% '!:Y\,I==56N;MGE0_*?*54"GJ/+4CYB>K9Y  QP#72^*O#,?B.
M VLA(YW*P_A8 @''<<D$=P>,'!&Q10!S5OX2DG@DL;ZX:XCD5 OR"-EV\YW
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MXP,94.S9&1QD#.,9)(S7844 %<5HL:Z-JMS;?*!>1I,OS'.5+!EP>I8EFX/
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M-S[E7<5'3<3D;?7(S@Y  -ZBN*U+Q[<Z8HN9K)UMRR_.95+A6/!,8!*G'8D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%&.>EUCP-9ZQ)]HGB#2$ $AG7..F=K#)[9/.,#H!6GIFE1:6@A@140=E&,G
M&2>I. ,DY)[F@#E?AUJL5EI4<TCJJ1>9O.?NGS&(! YR01@=3D8'(JI\%/\
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MPJ  !U)KL[7P#8VDHNDA42*Q8'+;0?4*3M&.V!QQC&!7/_!3_CSD_P"OAO\
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M%J2!?,LID<;B<8+ $8'7+;<]. <$=]*U^'EA:LCI" T3[U.]\AA@CDMR!M&
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M\#6>L2?:)X@TA !(9USCIG:PR>V3SC Z 4 <K\)R3<7Y+B0^:F7  #_-+\P
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M^/\ V>&NZM;1+11%$JH@SA4 51DY. ..M5=2T"#4GBFF7<\#;HSN88.0<X!
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M'0GM0!T%%9_AZZ:[MH)I#EY(8V8X R60$G XZUH4 %%%8_B[7&T.UDO$4,R
M8!Z99@H)QV&<XXSTR.M &Q17+^"H;R:-+R[N!(LT081B)%V[L,IW@ D[>HQC
M)[X!/44 %%%% !1110 445CZ)XHBUB6>WC#!K5]KE@ "<L.,$\?*>N.U &Q1
M7'Z9K\\VK7%@S9@CA#*NU>"1%SG&3]X]3WKL* "BBB@ HHK'T3Q1%K$L]O&&
M#6K[7+  $Y8<8)X^4]<=J -BBBB@ HHHH **** "BBB@ HHHH **Q];\41:/
M+!;R!BUT^U"H! .5'.2./F'3/>K&OS3PP.]HJO.-NU7X4_,,Y^9>@R>HH T*
M*KZ<\CQ(TP"RE%+@= Q W <G@'W/UJQ0 4444 %%%8^MW-W#+ MK&KQ,^)BQ
M *KE>1\R\X+=FZ#CU -BBBB@ HHHH **** "BBB@ HHHH ***X_4]?GAU:WL
M%;$$D)9EVKR0)><XR/NCH>U '84444 %%8]MXHBN+N32P&\V) Q) V8(4\'.
M<_..P[UL4 %%%% !17'^-=?GTVYL886VI/-MD&U3D;XQC)!(X8],5V% !116
M/HES=S2SK=1JD2OB$J02RY;D_,W. O9>IX] #8HHHH **** "BBN/^*&OSZ)
M;)-;-L<S*I.U6X*.<88$=0* .PHHK'\47-W;Q!K"-9)=X!#D ;<')Y9.<X[_
M (4 ;%%%% !17'^"M?GU*YOH9FW)!-MC&U1@;Y!C( )X4=<UV% !1110 444
M4 %%%% !1110 457U&]6PB>X?)6)&8@=<*"3C..>*KZ!K::W EY$&"2;L!P
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M"@#L**** "BBB@ HK'UOQ1%H\L%O(&+73[4*@$ Y4<Y(X^8=,]ZV* "BBB@
MHHHH **** "BBB@ HHJOJ-ZMA$]P^2L2,Q ZX4$G&<<\4 6**S] UM-;@2\B
M#!)-V X ;Y6*G."1U'K5?1+F[FEG6ZC5(E?$)4@EERW)^9N<!>R]3QZ &Q11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRQW3^8KVZ&3^)R >G/S'/.01P""#0!7:SEO=;N887\O="@=Q]\)MASL[!B<
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MQ@$9/SH3N5 <*HZ,3@Y8#[IH T_B-K<EO=P6CS/;VK+O>2(,&)&X%=R\],#
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M?P_IL_E3S,^Y"'DD)D&712 PP0,=O<^M,^)6ESRM:W\$9E^R2[F1<[SED(P
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MY 4VJ.8L=!M#$#)4<@Y!Y!H L)<S^+KV>V29X;6T8*1$=DK-\RYW#/&0W?&
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M \(B9]A'&[$AY]1^[7@\<=.3G0^+.GQW%@\SJ"\10HW<;G56Y]"#R.G0]0,
M%?XH>,VT1$AMI-EP65B-@;]V0XSEE*_> ]_PKI="\4VVO;OLS[_+V[OE9<;L
MX^\!Z'I7"_$JZ:[TFUFD.7D:%F. ,EH7).!QUKU"@#S_ .-?_'G'_P!?"_\
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MH$7VBX)"YP  22V"0HQW.#UP/4BN=TSXNV-\XB.^//1I5 7)(&,JS8Z]3@
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M^,YP, ':Z)XG@UF$WD3?NUSN+C;M(4,P.>. >2"1[US5U\9+&%BBB5P,?,B
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M<@'!P213/#/Q%M?$,AMX]R28R!(%&[UQAFR1U(ZXY&0#CS_Q6)KK6C'#(JR
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M 8]H"@ CC:4A'RD8X!P<#T% '<:]XUAT.:.UG5QYV,/A1&,MM.6+#&W@MP<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M([G)8C/;L,DGG)YY8\4WP5X4_P"$8A:VW^9ND+YV[>JJ,8RW]WUKH** .?\
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M(R021GI@#%=Q10!S_A3PE_8/F2/*\TLVW>\G?9D+@')Z''+'IQCI53_A!?\
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ML> VOH;:*.=HI;--JR(.H*!6X# @G:/XNF0<YXZVB@#C_#7PZ72I_M\\SSW
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV1\NXYSEN@(;&"%"@C'4'ZG5UO0(-;00W*[T#!@-S+R 1G*D'H30!Q_B7_D
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M? ##J1MYQP,XSG('!>';5KK0[M$&2)BW4#A!$['GT )_ES7J5GX;M[*!K&-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !115>]U&*P7?,ZHI. 78*,]<9)'/% %BBBB@ H
MHHH **** "BBB@ HHHH ***KW.HQ6K*DCJK2'"!F"ECP, $\GD=/44 6****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHJN^HQ)(+<NHE89"%@'(YY"YR1P?R- %BBBB@ HHHH ****
M"BBB@ HHHH ***KOJ,22"W+J)6&0A8!R.>0N<D<'\C0!8HHJN^HQ)(+<NHE8
M9"%@'(YY"YR1P?R- %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJO9:C%?KOA=74'
M!*,&&>N,@GGF@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !15>VU&*Z9DC=6:,X<*P8J>1@@'@\'KZ&K% !1110 4444 %%%% !1110
M457N=1BM65)'56D.$#,%+'@8 )Y/(Z>HJQ0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRI;+8Z>N!0 [3_B'8:A(L$<P+N<*"CKD]AEE R>W/)X'-87Q'_X_--_Z^/\
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M:?H?B2WUU6>V<.$.&X*D9Z<, <'L<8.#Z&O/="%W?:A>SVXMVDCFV[KA6W*
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MRWR-HSN#,2#V!//2M.Z\+ZCJ-U;WLQMU-NXR83*KLFX%E)(.1C( R!\QSU-
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M#OO^%D:?O\GSUW;MN=K[<YQ]_;MQ_M9QCG.*Z6N$N]!U*Y@:QV6*Q.I&U%E
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M=NWYG.,Y.?O>@Z5GS^ Y+>XDO;&Y:#S^74QB52Q))/S-CKST)&3@@' ["B@
MKFM&\&?V<]W)YK?Z:Q/R#8R9+GALGD;^#@8(SBNEHH XJX\!7.H(MK=WKR0#
M&56)48[1\N7RQ.#@G<&R1GK@CK[2U6T188QA(U"J,DX"C &3STJ:B@#G/%'A
M$ZQ)%=0RF"> G#J@;(/\)&1D>@)Q@L"#NK*F^&SW-Q#?S7+231.K,6C4*P1@
MRJJJ1L'K][)); YSW%% '/WOA3[3?Q:KOQY,939MSG(<9W9X^_Z'I[T>)/"G
M]M36USOV?99-^-N[=\R'&<C'W?0]:Z"B@#E-9\$-<77]I6D[03%=KD()%88
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M10!S_AOPI_8LUS<[]_VJ3?C;MV_,YQG)S][T'2LJS^'DFF-(EI=/%;RMDQA
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>K$"-I5H"VT@YRI#\@KC.>A##'(- &M1535=332XGNI3A(U)/3)QT R0,D\
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M^2, ]!GC/7 :QXD\63Q7*:78(LDY 9R^2B*?7:00>A.>Q4 ,6& #K:*\_O\
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M>PG$BPK(JR!R"Y1HO+)+(.H;G: W&03T(K/^%OVS[-!_J?LG[S^_YWWG_P"
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MND^++J"]&E7Z1[I$W1O!NV\!B<[B3CY2.Q!'0@Y !V=8]MXHBN+N32P&\V)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(T&UN/F''!^4<CG@>E ''ZS_ ,AZU_Z]V_E/7H%5WTZ)Y!<%%,JC <J"X'/
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M_P#+U(1'N50PCC)4<J3C. "/5 23D&KOQ),C64D,,;2/*54!(_,QSN)(P<#
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M,6]MVYO+3<=X(;)QD[@3GUR<T >7W>F/?:!"T8SY,C2,.2=H>521@'INR>@
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M =0PSTS@@\\TZZM$NU,4JJZ'&5<!E.#D9!XZT <Q'XHB\-Z=:W$P8JT4*@(
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MZ8P#M(SD<E0.O'IO]DP^7]E\M/*_N;%V==WW<8Z\].O-6(85A4(@ 50  !@
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M0[+3HK!=D**BDY(10HSTS@ <\5#>Z';W[;YHHW8# +HK''7&2#QS0!QNC?\
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MG&"W<4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI;^T1(49V$ZDA%+'&QQG !XYH\?:=+=7>GO&C,L<^7*J6"C?$<D@<#@]?0T
M9GB^&?PB(=2%S-*?. D1WQ&VX%FVJ!A <$ 8;&1@@KSZ77#_ !=TZ6_M$2%&
M=A.I(12QQL<9P >.:[B@#R_XE:1NOK-O,E_TB8# ?B/!B7,?'RDYR3SS@T?%
M#2/[*L$B\R67-TIW3OO89C<8!P...GJ36Q\2M+GE:UOX(S+]DEW,BYWG+(1@
M 'CY<'&2,YP1G&?\0YY?$EBIAMYPRW(RCQ$/@1M\VT;OE^;&?7B@!_C'2KO2
M[9M4-U*+A&1F1&Q;\L%VJGH,CEL[L'<,MQ:\7^.6L[>UDC;R6O-C%RHD$:85
MG./XB-P_AY&>AQ6M\1[1[NPFBB5G<^7A4!9CB12< <]*Q-9\,3W=I87%NN;F
MS6$B-SM!^5-P(..05'!*\;N^* .<O/$D.EQK<6E_/-<1E24F\QHG[,-K*,#G
M(RQ(Q@'=AAZQI-]_:$,=SC;YL:/C.<;E!QG SC/I7.P^.)KE0L=E<><0/ED4
M1QYZL/-;H!S@E1DX&!FNMH \_P!?_?:Y:1/\R+"S!3RH;$IW '@'*KSUX'H*
M] KE/&OAJ6^:&_L]HN;9LC<=H=<$E"0,G)X +!<,V3S38O'$Q'EM97 FR5P%
M!BW9('[W@;3QEL8'7D<D K^--9GFNH-&M'\IYU9GDQDA<-PIZ@X5CV.=N&'-
M4?%&EW/A2+^T;:ZE<1E=Z7+^:K*S*!C@8.>#T."<,,8+]?TJ]66WUQ(E:>%7
M$D*OG"'>5 ./F8*Q#$9RV-JD9IGBC5+GQ7%_9UM:RH)"N][E/*555E(QR<G/
M)ZG .%.<@ B\?:W/<-I[V4C1&Z.5RQ4?/Y6S>!D$#=R"&'7K47C2WN?"2Q:C
M'=2R.90'24YB8LK$X08"KP1MYQD;2"N3=\7:"\4VF10([QVTB@L%+;55H@"Q
M P.%// X-6/B[ITM_:(D*,["=20BECC8XS@ \<T 8_B]+WPO'#J;73R3&0+(
MA_U!)4G 0;0  N#QDD[AM-:?Q)U&XM;BQ2V<JTDK#!9E1CNC"APIY7GGV)J7
MXNZ=+?VB)"C.PG4D(I8XV.,X /'-9_Q8>1+BP:$!I1*Y0'H6#1;0>1P3[CZT
M /\ %>E7?AN,:I%=2R-$P,J3-F-MY"G:@P%&3]WL#\K J,]%J_\ Q-X(KH7#
M6ULZ!GP51R'"E/WA)V$'KC.[.*YWQ7JMWXDC&EQ6LL;2L!*\RXC780QVN,AA
MD?>[@?*I+#$/C#PV]G/9R^4]S9V\:QF-<NV5S\Q0#!R-I/&&*[6P",@!H6JM
MI^II8PW37-O/&23)()2I57. P. <KZ#AL$$@&IO%]S=R:K;V=K,T6^$'KE.#
M(6)0Y5CM'&1UQR.HJ:;9-/JMO=Q6CV]N(W',009VR#<P484DG !.2 IZ$5L:
MMITKZU;7 1C$L# N%)0'$W!;& >1^8H I7ZR^$[ZT59YIHKIC&R3R;\$E5W
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M <J0A.(> V,$\'\C6?X>>?P1)-8M;RS6[.9(Y($,C<X4!ONC.%&>A!!X*L"
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MF64$XSGCFJ7B>R-PJLURUM N?,*%48Y(V8E;[F#Z?>SBK'AB%H;2W1P0RP1
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MXYQGKCG%344 <_X&\-'P[:K;/M\PLS.4)*DDX!&X#^$*.@Z?B>@HHH ****
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M)0,"X'')7.0.1^8H L4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW*,GO@<XR>@-6]7\26^CLB7#A#*2%R#@XQG) ( &1R2!7G7BF[GN[ZP>YMA
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M4'CT]* /0/\ A9&G[_)\]=V[;G:^W.<??V[<?[6<8YSBM?6-:AT>/S[APB9
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MY;8A8*#M9N2"<84$] :\O^)FJ7.I6T4EQ:>0OF J[2J[?,C'9MP&7.,G..5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *R?%.A?V];/9;MGF;?FV[L;6#=,CTQUK6HH J:38_P!GPQVV=WE1HF<8
MSM4#.,G&<>M<[<>!7MYY+RQN&MVG),@*+*A).<A6(P<Y/.>I VC@];10!B:;
MX?D@259[B622=<%AB,+@$ QJ!A#@C)YR0#6+<> KG4$6UN[UY(!C*K$J,=H^
M7+Y8G!P3N#9(SUP1VM% &#K_ (/AUBU&GG*+&%\L@D[2B[5/)^88X()Y'<'!
M%";P;<7EK+87%T9!((PK&( KL8,<X;+EL#DG/?G-=;10!4TFQ_L^&.VSN\J-
M$SC&=J@9QDXSCUK*\-^%/[%FN;G?O^U2;\;=NWYG.,Y.?O>@Z5T%% '%6?P_
MGTAI!8W;0Q2-N\LQ+* <=B[?KC)  ).,UM'PE$]H=,=G>-MV6=LR$LYDW%@!
MDACGD<]\\YVZ* .2TOP;<6D#V,ET9(6@>-5,0&W<,!MVXL0HR N<8X&,"K5A
MX+CBL!I$S%TPP+ ;#RY<$#)P02/4''(QQ71T4 <5_P (%<^7]A^VO]E^[L\I
M=_EY^YYN<]..F,<;=ORUI7_@N.6P.D0L43"@,1O/#AR2,C))!] ,\#'%='10
M!D_V%_H?]F[O^7?RM^W_ &-F[;G\<9_&LK_A!?\ B7?V-YO_ &TV?]-?,^[N
M_#K[^U=710!4TFQ_L^&.VSN\J-$SC&=J@9QDXSCUK/U[PU_;$MO,TC*EM)YA
M0#AF&"I)S@;2/0G!(!&<UMT4 %8/ASPJN@R3M&Y,4[AECQA4/.[&#C!R .!@
M  YQFMZB@#)\4Z%_;UL]ENV>9M^;;NQM8-TR/3'6K>DV/]GPQVV=WE1HF<8S
MM4#.,G&<>M6Z* .,MO $NDLPT^Z:")SDHT:S 'GH6(P,8'<G RQXQNZ?H/DP
MO;3R//YV[>9#C.]0&50N-B]<*#\N>#6M10!Q6F_#R2R4V?VIS9EF)AV ,5)S
ML\P'(!_BVA0V6X&XU1^#4*S6,J. 5:=P01D$&.,$$'J#7H=9^B:!!HB&&V78
MA8L1N9N2 ,Y8D] * .7L_AQ+;1M8B[D^R,6S&J*'PW\/F'.!_>  #<\#<:T_
M"O@E=$MI+"1_-29G+?*4X= A7AB>@ZY'6NEHH XRR\#7.DKY%G>M'"#E4>%)
M2,]?F)'!.3@ #GUR3MS>'V-J;%)Y0V#B8OF4'=N!+#&1VQQ\O&1UK8HH XRY
M\ 2ZLRC4+IIXD.0BQK"">.I4G(QD=B,G##G.GXO\(+XB5#O:.6%MT<BY)4DC
M/&1Z#!R"" 0>H/044 9^B64]HA2YF\YRQ(;RUCP,#Y<+QUR<^_M6?XU\*?\
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MT-MSR#SD9Z'@@X(KV?A"Y)C6ZO'ECB9&51&L9+1D%=S98L..0>2<'.175T4
M<OK'@DW%Q_:5K,T%PP 9@HD1@!CE&QSP.^/E!V[N:NZ)H<]HYGN;EYG*E0-J
MQQ@9!SY:\;LY^;/0XQQ6W10 5R6J?#R._ODU7>5V%&9 ,[FC^Z=Q/ X4$!>@
M[$YKK:* .4\7^ E\1R)-YC1X79)M!)=-P<+]X 8()!P>2"0<"M7Q3H7]O6SV
M6[9YFWYMN[&U@W3(],=:UJ* .4U_P+_:]G#IOF[?(\OY]F<[$*?=W#&<YZG%
M6_$GA3^VIK:YW[/LLF_&W=N^9#C.1C[OH>M=!10 5QFH_#HW=X^J+.T<A V;
M%'RLJ*H)))W+P<K@9!QG'7LZ* .4T;P0UO=?VE=SM/,%VH2@C51@@_*I(Z$\
M<#DD@DY#]8\$FXN/[2M9F@N& #,%$B, ,<HV.>!WQ\H.W=S7444 8FB:'/:.
M9[FY>9RI4#:L<8&0<^6O&[.?FST.,<5JW=JMVC0R#*2*589(R&&",CGI4U%
M'"0?#>>WB>Q2\<6S[\)Y:[@&Z#?G.,XW !0WS# W$UT?ASPZND6JZ>Y$BJ'!
M)7 8.S,05);CYL=3FMBB@#A[/X<2VT;6(NY/LC%LQJBA\-_#YAS@?W@  W/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !117/^-]?ET" 7<**X21/,#''R'@X.>N< <'&<X(
MH Z"BN:\;^+O[!M!>0[7:1D$9^\AW?-DX8<;0<$'KCM3K_Q>L.GG5D .8E8*
M#O =\*%)!7(5SANAX/&>* .CHKDM=\83:8L%LL0DOKA!^[5AM5MO)/).T-G'
M(! 8[QC-5-3\4:AX< N+V**2 G#&V+ADR1@G?U!Y ' )P"PR,@'<45RGB?Q<
M^FS644&QH[R3!8Y;Y2T8!4A@.0YYY'2G_$/Q1+X;MUN(0I9I0I#@D8*L>Q7G
MY: +'B3Q7_8LUM;;-_VJ39G=MV_,@SC!S][U'2N@KS_XC_\ 'YIO_7Q_[/#6
MGXD\63Q7*:78(LDY 9R^2B*?7:00>A.>Q4 ,6& "[XD\5_V+-;6VS?\ :I-F
M=VW;\R#.,'/WO4=*Z"O)_%-[=2WUA!>1JK1SJ0\18QOODCZ!AD%< $$DYYX!
M&?6* "BN/O\ Q;<7MT^G:=&C-#CS)923$IP?EPG.<X'7.0PVX!8%AXMN+*Z3
M3M1C16FSY<L1(B8X'RX?G.<CKG)4;<$,0#L**X^_\6W%[=/IVG1HS0X\R64D
MQ*<'Y<)SG.!USD,-N 6&A;Z_+I\4LFH(J-;J&+Q']TX;. F\@[LC:5/?:0<,
M* .@HKBM,U_5-607L4,*PMRL<C/YK* .C8"C=SM+ #H2".38\1>,);"6Q2-
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M+.0L*J<[BPR&P#EEZ?=ZDJ,C.1R7CO4-12Q=+R*(I-Y?S0,V8R&#8<'<#DC
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M/(F0$8W#(&TDX.X@@#.<\9/!-73-?U35D%[%#"L+<K'(S^:R@#HV HW<[2P
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M,G)P!QUH X"X\96D.D+%YBM(UJ(MBG+[C'L.5X( (.2>,=,Y&<__ )ES_/\
MS]5Z+;^'K:VW>7#$N]2K;8T&5/53@<@]QTJ7^R8?+^R^6GE?W-B[.N[[N,=>
M>G7F@"IX3_X\[;_KWA_] 6N5^''_ !^:E_U\?^SS5WL,*PJ$0 *H   P !P
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MP];7;&66&)W.,L\:,QP,#)(STK0H \TM=+T"XB%S\B@J25>9Q(,=04\S.?8
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M ''% '&ZS_R'K7_KW;^4]:OQ2_Y!T_\ VS_]&I71OIT3R"X**95& Y4%P.>
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MM[6907E088G<?E#_ ,.,*,C&W=ELKQ6)IJQ)K5ND$[W"K&^7DD\T@^7(=H8
M @ @\9P2>^0/4[W3HK]=DR*Z@Y =0PSTS@@\\U#!H=O;LKI%&K1@A2J*"H.2
M0"!P#N/3U/K0!>K$3QE:;W@DD6*2)B&68^6>IP1NP&# ;@03P03C-;=5+[28
M=0QY\:2;<X\Q%;&<9QD'&<"@#S_X>*MQJ%U=6:LMDR[1U5"^5/"D_P"\0,?*
MK 87(%5?A#XHM[&&2TF=8W\PN#(0JD%57 8G&01T]#QGG'J4,*PJ$0 *H
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MG:(MI(P#TW9/0  G/%=PGABT0$""(!A@@1(,C(.#QR,@'Z@&M"&%85"( %4
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M41H'C7:C!%W*H!&T'&0,$\#CFK= !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 78*,]<9)'/% %BBBB@ HHHH ***KW.HQ6K*DCJK2'"!F"ECP, $\GD=/44
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MC\0V>APVT32[8Y(T$3.&^9550"3M 7@C).T<]N<5/BE_R#I_^V?_ *-2N/\
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MA>SVXMVDCFV[KA6W* 710A0<?*N&]<#KS0!Z%H?B2WUU6>V<.$.&X*D9Z<,
M<'L<8.#Z&J4_CZQ@,BO,H:!MK@A@V<E< 8RV".=N<=3Q6/IWA>^.H)JEP8%
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M5O,EFY(EE#%!M;!V@EOFQMR .1G/3U&36-:AT>/S[APB9 R<G)/0  $D_0=
M3T!KA?$FEM+I=I?Q9$UG%!(A W<;4W<=,# 8D@X"^A-6]>G_ .$JN;*T0'R=
MBW4@=5(*<! 03R3RI R/FS\V. #K=9U^#15\RYD5 >F>6/(!PHR3C(S@''4\
M57T/Q=:ZXS);2!V09(PRG'3.& R/7'3(SU%</J N+_694@$+O!"FS[2I*J!Y
M;Y&T9W!F)![ GGI6G=>%]1U&ZM[V8VZFW<9,)E5V3<"RDD'(QD 9 ^8YZF@#
MO:Y^?Q]8P&17F4- VUP0P;.2N ,9;!'.W..IXKH*\W^'NGQS:AJ%PR@R13L$
M)_AWO)NQ[G &>N,CH3D ZJV\<V5S$URLR^7&<,6RIS@L!M8!B2 <8!S@@9(-
M6]#\26^NJSVSAPAPW!4C/3A@#@]CC!P?0UP^F:5%-KUQN13Y<8D48X#D1?-C
MH3EB<GN=W7FK&@PK%KMV%  \@' &.6\DD_4DDGU/- '4:SXTL]&;RIY55_[H
M#.PX!Y" D9!&,XSVJQ9^)+>]@:^C<-"@8LP!XV#+97&X$#G&,D8(ZBN?D\7[
M[F:#3[4S2H<3/E81E/E4;V!W$<@9QT.W(Y&5\)P1<7X*",^:F4!!"?-+\H(X
MPO3CCCB@!GAOXI1^=<_:YOW7F?N/W9^[N?\ N)GIM^]S^M=WK.OP:*OF7,BH
M#TSRQY .%&2<9&< XZGBN/\ AQ_Q^:E_U\?^SS5GZ@+B_P!9E2 0N\$*;/M*
MDJH'EOD;1G<&8D'L">>E '<:'XNM=<9DMI [(,D893CIG# 9'KCID9ZBH=1\
M<V>FR/;S2A9(@"P*O_%MQC"\GY@<#)QD] <8%UX7U'4;JWO9C;J;=QDPF579
M-P+*20<C&0!D#YCGJ:J6.GQWFO7!D4-Y42.N>S!8@&QZC)QZ'D<@&@#5\77>
MGZ[9QSW$K+;-+E'16!+*'7&"C''#=ATZ^O1ZSK\&BKYES(J ],\L>0#A1DG&
M1G ..IXKC_C7_P ><?\ U\+_ .@25L>*/$\6G3Q6Z0F>\8$Q* !M#':3YA!V
M@@'.,\+\V!S0!H:'XNM=<9DMI [(,D893CIG# 9'KCID9ZBN7T;_ )#UU_U[
MK_*"LR*>6XUNWDG@$$C1-E0ZR;L)* Q90.>,<\X4=L5IZ-_R'KK_ *]U_E!0
M!Z!7-?\ "R-/V>=YZ[=VW&U]V<9^YMW8_P!K&,\9S72UYO\ !/3XQ;R76T>:
M92F[OM"HVWV&3DXZ\9Z# !W6CZU#K$?GV[ATR1D9&".H((!!^HZ8/0BLW4_'
MUCICF&690XZA0SX()!!*!@"".0>1Z5Q_A2Z;3_[7$)VB!I&C4 ;5(\[!"]!]
MT=N@ Z"MWX3:?';V"3(H#RER[=SM=E7GT ' Z=3U)R =1IFJQ:H@F@=70]U.
M<' .".H.",@X([BL7_A9&G[/.\]=N[;C:^[.,_<V[L?[6,9XSFL'PK"NFZQ=
MV<("0F)7V <;L1GCT'[QN!QSTX&(O@GI\8MY+K:/-,I3=WVA4;;[#)R<=>,]
M!@ [K1]:AUB/S[=PZ9(R,C!'4$$ @_4=,'H15ZO/_AG^ZN=1@7B-+CY5'"K\
M\@X7H.% X[ >E;=I_:V]?-^R>7N&[9YV[;GYL9XSCIGC- '2T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/V7A3
M[-?RZKOSYT839MQC 09W9Y^YZ#K[4>-?"G_"3PK;;_+VR!\[=W16&,97^]ZU
MT%% &3XIT+^WK9[+=L\S;\VW=C:P;ID>F.M5;_P9%J5I'ILY8K"L8#)\K9C7
M;N .X<C/!SU]<&N@HH Y*'PC>,HAFOY#$  ?+B2.0XZ?O<LV<@9/)(R#UKK:
M** .?\2>%/[:FMKG?L^RR;\;=V[YD.,Y&/N^AZU:\3^'D\00-:2'&[!5L E6
M'0C/Y'H2"1D9K6HH YK6O!"ZO##%)(XGME&R920VX* 6().<E0QYW9'##G):
M>&KLNKW-Z\B(P8+'&D.2IZ,5R64C(*]_7BNEHH YKQ/X,_M>6*]AE:&XAX#@
M;@5Y."I('4GV()# @C''^*M%;3[S3Y9I6FGDN!N=@%&$>+:JH.% R3QU))/7
M ]5K/U+0(-2>*:9=SP-NC.YA@Y!S@$ \J.N: ,SQ1X1.L2174,I@G@)PZH&R
M#_"1D9'H"<8+ @[JRIOAL]S<0W\URTDT3JS%HU"L$8,JJJD;!Z_>R26P.<]Q
M10!SGB3P:NK2I>QR-#<Q !)%^88SG!4]1RPZC.3NW#BGZ7X>N89%GN;MY=F=
MJJBPH=P(.Y5SO[%<XVD>]=!10!RE[X4O)&E\F^=(Y68[6C61EW#D*Y8%0/X0
M,;>W/)T-%\(0:3;M8(&:.3?OWM\S;QM.2,8XP.,=/7)K;HH Y3PSX.GT!@B7
M3-;*SD1-&N<,#@;\Y&#@G  )SP,FJ]MX ETEF&GW301.<E&C68 \]"Q&!C [
MDX&6/&.SHH P?"OA&/P\KE6:268@R.YR6(SV[#))YR>>6/%-\-^%/[%FN;G?
MO^U2;\;=NWYG.,Y.?O>@Z5T%% !7/V7A3[-?RZKOSYT839MQC 09W9Y^YZ#K
M[5T%% '&3>![J9#:O?2&W8D%3&ID*%LE3*3N)(XSC&.-NWY:Z71='CT>%+2'
M.R,8&3DG))))]223V'H .*O44 8/B[PJOB&-5#F.6)PR2*,LI'7N#@]>".0I
M[8K USX92ZZJM<W;/*A^4^4JH%/4>6I'S$]6SR !C@&N]HH Y_Q)X4_MJ:VN
M=^S[+)OQMW;OF0XSD8^[Z'K1XO\ ""^(E0[VCEA;='(N25)(SQD>@P<@@@$'
MJ#T%% '-7WA6?4K.2PN;CS'D92)/*5<!65MNQ2 >5/.>_M4-]X%^U?8?WN/[
M/V?P9W[?+_VOESL]^OMSU=% '/\ C7PI_P )/"MMO\O;('SMW=%88QE?[WK1
MXU\*?\)/"MMO\O;('SMW=%88QE?[WK7044 <_P"+_""^(E0[VCEA;='(N25)
M(SQD>@P<@@@$'J#E3_#^>]F@N[F[:1[>0, 8E5<!E; 56 !)!RW.1@8^7GM:
M* ,?Q5X9C\1P&UD)'.Y6'\+ $ X[CD@CN#Q@X(I6_A*2>"2QOKAKB.14"_((
MV7;SG<"2QS@Y;/(YSDUTM% ''VO@R[M%%LE\XMUR OE)Y@3/W1*3D$#@,!QQ
M@  "K?BKP9_;UM'8^:R^4R'>X\QFVH5YY7).<D^O:NEHH R?%<"36DZR_<\F
M0GY0Q&%)! ) )!&1R.0.1UK ^$FC?V?9"9AA[ABYRNUMH^51GJ1@;AV^;CU/
M5:II<>JQM;3KNC?&1DC."".00>H'>I;2U6T188QA(U"J,DX"C &3STH FKG_
M  WX4_L6:YN=^_[5)OQMV[?F<XSDY^]Z#I7044 <YXD\&KJTJ7L<C0W,0 21
M?F&,YP5/4<L.HSD[MPXI^E^'KF&19[F[>79G:JHL*'<"#N5<[^Q7.-I'O704
M4 <YJ?AVZEF:>VNVB60+E&C6505&,KN(V@]P!R<DGH!GMX1C\/6-X59I)9H)
M#([G)8B-NW89)/.3SRQXKLZAN[5;M&AD&4D4JPR1D,,$9'/2@#S7P)X4GGL4
MEM;IX//\SS%V*ZY#% 5^Z4.!R0<GCD8%=EH'@^'1[4Z>,NL@;S"21N+KM8\'
MY1C@ '@=R<DZ>EZ7'I4:VT"[8TS@9)QDDGDDGJ3WJW0!Q5OX"N=/1K6TO7C@
M.<*T2NPW#YL/E2,G)&T+@G/7).K8>#(M-M)--@+!9ED!9_F;,B[=Q VC@8X&
M.GKDUT%% &3X6T+^P;9++=O\O=\VW;G<Q;ID^N.M9&B> VTJSET])V#2N6$L
M8V,IPN.C'CY>>1D$CCK76T4 <9<^ )=691J%TT\2'(18UA!/'4J3D8R.Q&3A
MASG3O?"GVF_BU7?CR8RFS;G.0XSNSQ]_T/3WKH** .,U'X=&[O'U19VCD(&S
M8H^5E15!)).Y>#E<#(.,XZV-&\$-;W7]I7<[3S!=J$H(U48(/RJ2.A/' Y)(
M).1U=% '/V7A3[-?RZKOSYT839MQC 09W9Y^YZ#K[52N/ KV\\EY8W#6[3DF
M0%%E0DG.0K$8.<GG/4@;1P>MHH R="T>2PW//.\\DFW)8!4&W(&V,<+D$;N3
MDC-:U%% '/\ @KPI_P (Q"UMO\S=(7SMV]548QEO[OK69;> )=)9AI]TT$3G
M)1HUF //0L1@8P.Y.!ECQCLZ* ,'PKX1C\/*Y5FDEF(,CN<EB,]NPR2><GGE
MCQ3?#?A3^Q9KFYW[_M4F_&W;M^9SC.3G[WH.E=!10 5R^L>"3<7']I6LS07#
M !F"B1& &.4;'/ [X^4';NYKJ** ,31-#GM',]S<O,Y4J!M6.,#(.?+7C=G/
MS9Z'&.*B\-^%/[%FN;G?O^U2;\;=NWYG.,Y.?O>@Z5T%% '/V7A3[-?RZKOS
MYT839MQC 09W9Y^YZ#K[5F3>![J9#:O?2&W8D%3&ID*%LE3*3N)(XSC&.-NW
MY:[.B@#G+WP-!<67]DKE44?(QPS!L[MW/<DG.,<$@8!XQ]2^&\^K1""ZO'DV
M;?+_ ':A01P2PSESC@$L".3DY-=W10!RFO\ @7^U[.'3?-V^1Y?S[,YV(4^[
MN&,YSU.*ZNBB@#E- \"_V19S:;YN[S_,^?9C&] GW=QSC&>HS6KX6T+^P;9+
M+=O\O=\VW;G<Q;ID^N.M:U% '"#1%\$:9<QNWG*VX_=*@F15C"D!\XSU(8'&
M<<T^'P(L-N&2^N JQ AQ-B$ +PP4=$'7&[I_%WKM9H5F4HX!5@001D$'@@@]
M0:YJ;X9:=*Q<P#+$DX>11SZ , ![ 8':@!GPUUR?6K3S[GEO,8*VW;N48YXP
M#@DKD #C'4&M/Q5X9C\1P&UD)'.Y6'\+ $ X[CD@CN#Q@X(U885A4(@ 50
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M9M^;;NQM8-TR/3'6JM_X,BU*TCTV<L5A6,!D^5LQKMW '<.1G@YZ^N#7044
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M= BY&,8P2S8)Z$8( !Z!7'Z1X\DUN4K:6S/;K(JF8R!!@XRP1ER<#G .<8R
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MM2X\C?MV^6^,[^<YS[8Q6KKGBO4=-C_M'R8A;;E_=N6%P%)P"W.T$\<#<5W
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MM>DTYK>WM]IEN9@N&1G 0#YWPI7[N03DCC/H2.@KBM)@&M:I/?'E+)1#&0K
M%CN\SDD E267&,88'T)8OBR]UBZGM;!(A';':S7&[E@Q'&P]#@XX/ R2"0M
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MGK705Y_\./\ C\U+_KX_]GFKT"@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#0(ZI?#"R:_P!+N;=,!I7F4$],M$@&<9XYKT6RTZ*P79"BHI.2$4*,],X
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M<C(/'6@#SKXDZK%XB$&E6CK)+),K90[T4 ,N69<^N3C.%!)QQFWK/_(>M?\
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M#P.GH* .2^(\9T[R=:B7,EK( V-HS&_RL"2">IP,9V[B<=P?#R Z@]QK3_\
M+U(1'N50PCC)4<J3C. "/5 23D&KOQ),C64D,,;2/*54!(_,QSN)(P<# .#C
M(8@C!Y&UHFEKI4$=JN,1(JY VY('+8]6.2?<]30 0:U#/,]FK@S1!2R<@@,
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MD9Z4 >2>(=<GUK2(Y[GEOMF%;;MW*(WYXP#@DKD #C'4&O0/BE_R#I_^V?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M** "BBL?POXHB\21&XA#!5<J0X .0 >Q;CYJ -BBBB@ HHHH **** "BBB@
MHHHH **Q[GQ1%;W<>ED-YLJ%@0!LP QY.<Y^0]CVH\47-W;Q!K"-9)=X!#D
M;<')Y9.<X[_A0!L4444 %%%% !116/<W-VMW'$D:FT*$NY(WAL-@ ;AQPO\
M">IY] #8HHHH ***Y35/%LL\S6&G1K++'CS)'.(HR6 P<8+'&<@'(QP&(8
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MY:O\A\UH^&&/FV_P],'FL^:9O"6G1ZA'-,\D\,2(DCAXD+J')"$#&T*0O7'
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MW\Q1&^U-JKO4,!@LQ'5B<Y/\6WG3E\83'1_[47 FV 9(!^;S!$7Q@#)Y8#&
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M.?N'IM^\,YVC-C2=.E36KFX*,(F@4!RI"$XAX#8P3P?R-&K:=*^M6UP$8Q+
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M0*R-M^7:S.@?)/.0<X.2" <5J^#O&XBDN;4R-<6]O$\R2MGS2JX+(=V-Q&[
M)QT_ND!7^'Q/X':6S:WEFMGD9XG@7S'Z*,,!C'&.R_,#C<#D=/9W;^(HIHI8
M9(89$*J9"JR,'#*_R<["O;.<@@T <UX7TNY\5Q?VC<W4J"0ML2V?RE559@<\
M')SP.IP!ECG /B3>76EV$1:4B83A6>$M'N&V3!(!X) !8#C=TXQ3?"FL7'A>
M,Z;<VLS^2QV/;QF16#$L>20.IXQV." 0<VO&VD77B#3LO'LN(Y#)Y2$.< NH
M4$'!.QMW'4C 4$X !K?$>[>TL)I8F9''EX9"589D4'!'/2N9\;ZM-;:3:3QR
M.LC^1N978,<PL3E@<G)Y/O1XQUV[\06;6\-G,N=GF^8F"/F! 0?>?YAR<< <
M@9R#QOI,USI-I!'&[2)Y&Y51BPQ"P.5 R,'@^] '5^&O#DNG'S[BXEEE=3O4
MO^Y!8AOE3 QC&!TXS@#.!SGPV,NOV$J332[C.0)%D/F !8VP&.<#^A/K7H=<
M/\(M.EL+1TF1D8SL0'4J<;$&<$#CB@#"^$F@?;(3=>=,GEW'W(Y-L;;51OF7
M!SG.#SR.*U?".O/%-J<L[N\=M(Q"EBVU5:4D*"<#A1QP.!5?P \_A<OI<]O*
MVZ<$2Q(7B^<*N2W&%& <\GD@@$8JQX1T%Y9M3BG1TCN9& 8J5W*S2@E21@\,
M.>1R* .?T_Q1#JP^T7]_-%(V<16X>-4 9N,JK!LC&#U X)/;0T?QS<26-V(V
M\V2SVB.8J=SHS$;RA[JH+9.?]H'!+7?"^J7/A2+^SKFUE<1EMCVR>:K*S,3G
MD8.>1T.",J,9/2C7;@VTEV+9@ZG*1%QO=.#N. =K8)^3ELC')(H YCP) NI+
M'.E_,]PFUI(WD)3&1O4QOR1AMN\$C=\PY&*]%KRKQ+8-XF>,6-G+!.LA=II4
M$&,D<Y!^8Y.[/+#!V@Y-=K>ZO<Q7\5FD>;9XR7DV.=K8? W@[1]U>",\^XH
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MX\X)7#<J.I.&8=SG;A3S6A:>,)+YUBBM+@98;FG40JJYPS DG<1G[HY(SZ4
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M SGHZ* .*O/"UYXB:./4FA%O&V\I;[]SL!@ E^0,$]#GG'7!7M:** "BBB@
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M.[(P3GYL$;@.,Q?!3_CSD_Z^&_\ 0(Z *GAOXI1^=<_:YOW7F?N/W9^[N?\
MN)GIM^]S^M='I]M:+J<\J2,;LQ .A!V!<1X(.T<\+_$>IX],?X<?\?FI?]?'
M_L\U&C?\AZZ_Z]U_E!0!TNL^-+/1F\J>55?^Z SL. >0@)&01C.,]JMZ-K\&
MM+YEM(K@=<<,.2!E3@C.#C(&>HXKC/@]"MU%/J#@&>6=PSXY((5R.. "S$G
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MS7%>*;N>[OK![FV$#>>H!\Q)"P$D9QE0,!<\9_O''>@#TK6-:AT>/S[APB9
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M> "1D#/(K ^*FE1-I[/L4&#9Y>!C:"ZH0,=L<8Z=.,@8Y_Q]_P @:S_[=_\
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M0,5)VLO( .,, >A%</XHT^/4-;M89E#(8,E3T.WSF&1W&0..AZ'BO2* //\
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MH+,N6) (SC:0RD[0#C! KM?!>FRZ99PV]P<R(IS\V[ +$JN?]D$#C@8P,C%
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MHXDF!:4@* C]2VT _+\ISZXXP>A!KHZXSX3:?';V"3(H#RER[=SM=E7GT '
MZ=3U)SV= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%4=:T>/6(7M)L[)!@X.",$$$'U! /IZ@CBKU% '#Q?#N9X/L,]VTD"H0B>6%
MPV#L)8,694)R$) R%[#%:MAX+CBL!I$S%TPP+ ;#RY<$#)P02/4''(QQ71T4
M <?:^#+NT46R7SBW7("^4GF!,_=$I.00. P''&   *W;_0(]0MCI\Q9D**I8
MM\YVXPQ;NV0#TP3U&.*TZ* .<\*^&[C1 (I+DS0HFU4,07'((._<S$ 9 '0
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M[!)>LT*@;5\H#&"",G<690,X7. =I'W0*[VB@#G]3\*?;K :5OQB.)-^W/\
MJRISMR.NWUXSWK5TFQ_L^&.VSN\J-$SC&=J@9QDXSCUJW10!S_B3PI_;4UM<
M[]GV63?C;NW?,AQG(Q]WT/6F>)/!JZM*E['(T-S$ $D7YAC.<%3U'+#J,Y.[
M<.*Z.B@#G]+\/7,,BSW-V\NS.U5184.X$'<JYW]BN<;2/>L*RT>/Q'=7=PDT
ML)258F6"3RV/E+MWMRV03D+@*,+ZDUWM8FL^"[/66\V>)6?^\"R,> .2A!.
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MBN?E9 2"H!R1D,-V< $DY7D@]110!Q]KX,N[11;)?.+=<@+Y2>8$S]T2DY!
MX# <<8   K2U_P (QZU:BQD9CL"[9&.Y]RKM#'IN)R=WKDXP<$;U% 'F7CCP
MO-;6$DMU<M<>2(_+!41A2752S8)+MMX!8G&6/).1T47AY/$&EPVDAQNMX2K8
M!*L$7!&?R/0D$C(S70:II<>JQM;3KNC?&1DC."".00>H'>I;2U6T188QA(U"
MJ,DX"C &3STH XK4OAO/JT0@NKQY-FWR_P!VH4$<$L,Y<XX!+ CDY.36W?\
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MUE2XN[IIC"2441I$@+*R$L%SN.#QTQSZFNCHH XJS^'DFF-(EI=/%;RMDQA
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M*YU!%M;N]>2 8RJQ*C':/ER^6)P<$[@V2,]<$=K10!F7_AV&]MCIS B'8J@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW^9]U-VW;\OW<8SWZ\4>%;RXCO-0AM$5I)+@G?+D1(%>7.[;R2V<*![GHIH
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MTB;HW@W;> Q.=Q)Q\I'8@CH0<BO?>-;L:A)I5O$DF%7:3N7:616WN<D%03R
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M)/L#NSN D:E@.0#N)P<D#! *D!LXH ZBBN/@\4W.E7$=GJ2Q 7/$3V^\KN!
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M"NW=S(7 D(Z!%R,8Q@EFP3T(P0 #T"BN/T_XA+-IS:LZY:+Y71,@;\A0 6Z
M[E/? ./F(H\/ZKJE\L5U+';^3+M)5"ZRA7/##)9> =V,Y(XX;H =A6/HGBB+
M6)9[>,,&M7VN6  )RPXP3Q\IZX[5L5R_A+Q1+K%Q=V\@4+:R[4*@@D;G'.2>
M?E'3'>@#J**\Z\+>-=2\2HWDQ0J4;F23S!'C'W H));OG. ." 2"=WP=XO;5
M8YA=!8YK5V64 X0 9^;)) '!!^8_=SD B@#J*Y_PWXK_ +:FN;;9L^RR;,[M
MV[YG&<8&/N^IZUB:3XKU'7=]W:PQ"V5OD$Q99) O4*P)4$XQDC:"<9;:35+X
M3W+75Q?RNI1GE1BAZJ6:4E3D#D=.@^E '8>%_%$7B2(W$(8*KE2' !R #V+<
M?-6Q7GFG>/+N^TZ74U2/S89<;0CE2@"$G&_((W$DYQ@=.XZN;Q/$+,ZHA!C\
MHN 6 R<<(2,@-N^7'/S<<F@ \4>*(O#<0N)@Q5G"@( 3D@GN5X^6MBN"UGQQ
M=:;IT&HLD8FF< J0Q3:P=E( ?.2H4\GN>/35\9>+)-):.TM4$MU.?E4] !U9
M@"#@\X/ X8DX7! +'C7Q7_PC$*W.SS-T@3&[;U5CG.&_N^E=!7D7Q1O;T6Z6
M]Y''@RAA+ 6V<*PV$,,AN2<YP1T'!QVOBWQ1+H]Q:6\84K=2[7+ D@;D'&".
M?F/7/:@#J**Y?XA^*)?#=NMQ"%+-*%(<$C!5CV*\_+6EKMQ=Q[8[.-&9]V7E
M?")C!&5'S-NY QT.">* -:N?O?%?V:_BTK9GSHR^_=C& YQMQS]SU'7VK,TG
MQ9=07HTJ_2/=(FZ-X-VW@,3G<2<?*1V((Z$'(I:S_P AZU_Z]V_E/0!T%EXK
M^TW\NE;,>3&'W[LYR$.-N./O^IZ>]=!7G^C?\AZZ_P"O=?Y05N^"?$DFM1R+
M<*J3P2M&ZH<].AQDX'4=2"5)![  Z.BL'P]KTFK37*E0(8)1&A_B+*/WF?F/
M .-IP.#ZYQO4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<I\4O^0=/_ -L__1J5U=0W5HEVIBE570XRK@,IP<C(/'6@#/\
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MJ7,3,L@FD:(D[CC WJ.!P1@$$<CD$^P51O=#M[]M\T4;L!@%T5CCKC)!XYH
MY6&PL(+&]?3@-IBE1R&=@62-CP7)R!NZKP<]35+X;>,K2TL1!+(L;P;]P<X)
M#,S@J.K<'&!SGMR,]?XAM/\ 0YX(E_Y=Y%54'^P0JA1^0 K%\#>'DEL((KN%
M2\?F?+-&"R[I&/1QD9&/KQ0!R^@WD]K;:CK5NI'GRYBW*2P =MSXY!"A^N2
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ME/7<)IT22&X"*)6&"X4!R.."V,D<#\A0^G1/(+@HIE48#E07 YX#8R!R?S-
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MYQGO;'28=/SY$:1[L9\M%7.,XS@#.,FB^TF'4,>?&DFW./,16QG&<9!QG H
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M+M3%*JNAQE7 93@Y&0>.M 'F7Q=\1P7]NEO PD(E5F:,AD7Y7 !8<;FY('7
M)..,Z?Q0_P!&FL+U^(H;CYVZXRR,.!R>$8\ ]/<5V'_"/6VSR/)B\O=NV^6F
MW=C&[;C&<<9ZXJU=6B7:F*55=#C*N RG!R,@\=: /,/B]XHM[Z&.TA=9'\P.
M3&0R@!67!8'&23T]!SCC.KX]UN6&[@L&F:WM9E!>5!AB=Q^4/_#C"C(QMW9;
M*\5V'_"/6VSR/)B\O=NV^6FW=C&[;C&<<9ZXJQ>Z=%?KLF174'(#J&&>F<$'
MGF@#RS35B36K=()WN%6-\O))YI!\N0[0P ! !!XS@D]\@;>L_P#(>M?^O=OY
M3UV4&AV]NRND4:M&"%*HH*@Y) (' .X]/4^M3/IT3R"X**95& Y4%P.> V,@
M<G\S0!P^C?\ (>NO^O=?Y052\7:FW@R[EN(@1'?0-RNSB9 0&VXZ#(+9ZER?
MF(Q7HJ:=$DAN BB5A@N% <CC@MC)' _(5R7C/3&UF]L[7RV,4;-)(YB#QX'(
M0MVW;"&&0/F4D-@  &OX(T$Z':1VS "3&Y\ #YF.2"03DKPN<\@#MQ6AH^M0
MZQ'Y]NX=,D9&1@CJ"" 0?J.F#T(INOR3QP2&U7=/MP@RHY/&[+<?+G=@]<8[
MU#X8\/)X?@6TC.=N2S8 +,>I./R'4@ #)Q0!K4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45S7Q'NWM+"
M:6)F1QY>&0E6&9%!P1STK2\,3--:6[N26:"(DDY))0$DD]2: -.BBN'^+NHR
MV%HCPNR,9U!*,5.-CG&01QQ0!W%%%% !1110 4444 %%%% !1110 454U:^_
ML^&2YQN\J-WQG&=JDXS@XSCTJIX6UW^WK9+W;L\S=\N[=C:Q7K@>F>E &M11
M6/X7MKNWB*W\BR2[R04  VX&!PJ<YSV_&@#8HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BL>VMKM;N25Y%-H4 1 !O#87))VCCAOXCU''IL4 %
M%%% !1110 45P_Q=U&6PM$>%V1C.H)1BIQL<XR"..*[B@ HHKG[WQ7]FOXM*
MV9\Z,OOW8Q@.<;<<_<]1U]J .@HHHH **** "BBB@ HHHH **Q]$MKN&6=KJ
M17B9\PA0 57+<'Y5YP5[MT//KL4 %%%% !17#^ =1ENKO4$D=F6.?"!F+!1O
ME& ">!P.GH*Z#PO;7=O$5OY%DEWD@H !MP,#A4YSGM^- &Q116/XHMKNXB"V
M$BQR[P27 (VX.1RK\YQV[=: -BBBN'^+NHRV%HCPNR,9U!*,5.-CG&01QQ0!
MW%%%% !1110 45P^DZC*^M7-N78Q+ I"%B4!Q#R%S@'D_F:[B@ HKS?2TG\5
MWMVLEQ+%':OY:I;N8_XG )Z\_*<\9)/!  %>D4 %%%% !1110 4444 %%</X
M^U&6UN]/2-V59)\.%8J&&^(8(!Y')Z^IKH+FVNVNXY4D46@0AT(&\MAL$':>
M.5_B'0\>H!L4444 %%</\(M1EO[1WF=G83L 78L<;$.,DGCFNXH **Y01WMA
M87)O)5><1S,KQ?+@"/Y>BIR""<X].:J^%I;O4M)1H)?]);=B24[NDQSDD/GY
M00.#VH [6BL'6-:D\/67VN8"66)(P^#M#,2JL0=O R<_=_ 5IZ3??VA#'<XV
M^;&CXSG&Y0<9P,XSZ4 6Z*** "BBB@ HHHH ***X?XNZC+86B/"[(QG4$HQ4
MXV.<9!''% '<4444 %%%% !1535K[^SX9+G&[RHW?&<9VJ3C.#C./2JGA;7?
M[>MDO=NSS-WR[MV-K%>N!Z9Z4 :U%</\(M1EO[1WF=G83L 78L<;$.,DGCFN
MXH **** "BBB@ HHHH **** "BBB@ HHK'T2VNX99VNI%>)GS"% !5<MP?E7
MG!7NW0\^H!L45S_AOQ7_ &U-<VVS9]EDV9W;MWS.,XP,?=]3UJQ;6UVMW)*\
MBFT* (@ WAL+DD[1QPW\1ZCCT -BBBB@ HHHH **X?5M1E36K:W#L(F@8E Q
M"$XFY*YP3P/R%=Q0 4444 %%%% !1110 445Y?XB\<W>E:C+&K;K6W\II$VI
MD(PC5B"<,3N?CYNN,_+F@#U"BN<\<:T]A827ELX# 1E'&UAAG49&0000:T_#
MUTUW;032'+R0QLQP!DL@).!QUH T**** "BBB@ HK,\3S-#:7#H2&6"4@@X(
M(0D$$="*S?AQ=O=V$,LK,[GS,LY+,<2,!DGGI0!TM%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!G$BD\D@= >]8^M^#YKVRM?*PMY9)&4R0?F55W)U*YRH()R,C&0"30!C^._
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MC8<?,&WYR<], #&.2<XI?#WPG+HGG3S[%>Y96\N(?*@&X[?3@L1@9  &&.>
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M"_0)]$MGAN5V.9F8#<K<%$&<J2.H- &/X$U1M'CU"V&7BL'D9 Q^8@>9E<]
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MZB5ECB+L$085N"I7G! X S@DY)XTO&^D_P!E:5<0*[-&&C\L-R47S(\1[NI
M.=I/(!"\XS46EZ3?>$I98;2%9[21BZ 2+&R$\8RY).  .^< @@[A6Q>:+<Z]
M9SV]WM228YC5&R$ "LB,VWDAU^<C.<G:<8  &?\ ,&_[A_\ [0KE?^9<_P _
M\_5:'V?5;FQ_LP0)&5AV&1I5;<JC;L51NPS#C).WJ?E)&)?^$6N?[%_LW9_I
M']S<O_/??][.W[O/7]: +?@+P5!:Q0:@^Z2X:-6#LS?*&C"A N<853@9S[8&
M ,_P':K=W.JPR#*23%6&2,AGF!&1STKM?#UJUI;00R##QPQJPR#@J@!&1QUK
MG_!6@3Z;<WTTR[4GFW1G<IR-\AS@$D<,.N* .4\%>#+34KF^AFCW)!-MC&]Q
M@;Y!C(8$\*.N:V]&_P"0]=?]>Z_R@HM-)OO#=W<SV\*W$5TV_B18F4[F./F)
MZ;B.ASP<CE:T-,T">'5KB_9<020A5;<O) BXQG(^Z>H[4 <5INHQ^)6DO+Z"
M[N/WCA$A!>&-2%( *E#N &#V(P2,\UM>%);NV:ZM+6*:.W\F1[<7"899,#"A
MF^7!8DX)/3)YW$WM,T:]\(R21VD2W%K*[,J"01NA..K/G(QQU;.T'Y22#T6F
MW%]<I+)+'%$Q7]RA<N0P!'[QEX()P1MYP2#S0!YKX4MM/;,.H>;%?[BQDF9X
MR&.65E;( ( #9<9+'C<,"O9:\\U^VU+Q/ +&2UCB+%2TKS*R@J,DJJ[F4D\?
MQ8!(/7([C2;'^SX8[;.[RHT3.,9VJ!G&3C./6@#BM9_Y#UK_ ->[?RGJ7Q;%
MI2SEM1E9W.,1EY&6/"KG"1<KN&"=W7J.]6]3T">;5K>_5<P1PE6;<O!(EXQG
M)^\.@[UF6NAWGAR]N+J"!;F.Y)8-O2)UW,6*Y8GCGG (;"G(((H J_#(+J,=
M[IHD9K4';&3]X)+Y@)&1P2 #C& <G&2:E\/^)WTO2IUD)$]B7B^\KL&)VQG!
MXVJS;1U&$.,]*T_A]H%UILUY-=JJF>16!1@5)W2%B!DD#YAC=@X]\UF:YX$G
MN=0$D:J;266&64$(%W1[@01RS%@6/3!+_-TS0 ?#G4GT&&ZL;L$/9CS=N]6;
M8R;B%&<8&,\'&7YP>M*YTR\&D>9"'::\F,LP3:6*RYZ!1G# (2!SR0<+D#2^
M('@RXU*;S;15(N(A%*3A=NV1'#DY!). . 2%7'.1CJ]42?3($2PC5_**+Y;L
M1F-1@A6)X8<<L3QGJ< @'*> H]*E=)+)F2=005=R'<;6!!4DHPXWG9T(4G'2
MO0Z\_N= O/$EW!>3PI;):LIY=99'PV[&4XP" ,'&-Q(W9P.@LOMOV^7S/^/+
MRQY?^K^]A,]/GZ[NO'Z4 =!7G5C:K=ZW>PR#*26H5ADC(9801D<]*]%KC],T
M">'5KB_9<020A5;<O) BXQG(^Z>H[4 <IJ5ZUKIUYHT[9ELVC"DD9:)I4*-C
M<QX!''1047K6AKFJRQ6FFZ? [1-=K"ID0X90%C&!C!Y+@\$=,=":L?$_P7<:
MPR7-IEF*>7(N\+E0V]3S@$;NN3UVD#@FKVK>#)=0M+18RL=W9K$5+\J"JJ&4
MXW#JH.<-]W'0DT 5->^'%MI=L]S:%XI[>-G$BNVX[$.X'D ;AG.T#!]LJ<3Q
MOK+:SH]M=2??:90W3DHLJ%N  ,D9QCC.*Z#4Y]5UJ$V7V9(#*NUY6F5EP5.X
M!5W$;N@^]@'U^81>,?!$C:=!IMFN]H9%)Y"Y^5]S?.W&6;.,G&>.!0!T'AKP
M5!H1\Y=SW#*1)*[,6<L0S$@D@9(^OJ2<DTOB?KTFC69:$E7E=8PP."N06)'!
MYPI'8C.0<BNMK!\:^&1XCMFM@0'!#(3G 8>N.Q!([XSG!(% ',:M\-(-)L9'
MA=UGCA<O(K,/, !9D9 V-K8QCM@9+8.<Q=>DT;0H6A)5Y7>,,#@KF21B1P><
M*1V(SD'(K;F.K:K:M92PK&YB<-+O1M_RD; @.%9^ 6)V@;B #M +;P+)?:2F
MFS ).A9ER<@-O<C)0D8*MCOC.<$C% %C_A55MY?WG^U?>^T;VW^9G=OV[L=?
MQQ_%N^:LS1/&\W]CRWC9:: F,.2"225"N<J<E=XZYW;>3R:T_P"T=8\O[+]G
M3S?N_:/-39UQYGEXSTYQCKSL_@JQI7@!+;3VTJ0@M*"78;L;S@JP&1D+A?0-
MMY R: .)L;"UO81)<VM]/-*BDS;&;DH!E3N *CJNX'C&<CBKUU/J=_I)C9)?
M-68(PV,)6AV]2#\S98@$@9(!W9^8G=T>XU31(ELWMEN!$ JR).D8*@# PPSE
M>F<#.._WCM7<]_;VZ.J127(<>8BLRH4R>$9B,-C'+<=>#P" <UX"CTJ5TDLF
M9)U!!5W(=QM8$%22C#C>=G0A2<=*]#KS^YT"\\27<%Y/"ELEJRGEUED?#;L9
M3C ( P<8W$C=G ] H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ***J:IJD>E1M<SMMC3&3@G&2 . ">I
M':@"W14-I=+=HLT9RDBAE.",AAD'!YZ5-0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!GZ_IC:I!):H_EF5=N[:&P#]X8)'49'7C.1S3M
M$TM=*@CM5QB)%7(&W) Y;'JQR3[GJ:O44 %%%% !14-W=+:(TTAPD:EF."<!
M1DG YZ5%I>J1ZK&MS VZ-\X.",X)!X(!Z@]J +=0W<;2HR1ML<J0K8#;21PV
M#P<'G'>IJ* ,?PGX=7P];K: ABI8E@NW<6).2,GD# ZG@"MBBB@ HHHH **S
M]-U^#4GEAA;<\#;9!M88.2,9( /*GIFM"@ HHHH ***R?^$LL_\ GXA_[_)_
M\50!K44R&99E#H058 @@Y!!Y!!'4&GT %%%% !1110 4444 %%%% !1110 4
M444 %%%% !11534-4CT_9YK;?-D6->"<LV=HX!QG'4\>] %NBBB@ HHHH **
M*J7&J1VTD=L[8DGW[!@G.P9;D# P/4CVH MT454N-4CMI([9VQ)/OV#!.=@R
MW(&!@>I'M0!;HHHH **** "BBB@ HHHH **** "BBB@ HHJO9:C%?KOA=74'
M!*,&&>N,@GGF@"Q1110 4444 8.C>&#87-Q?R.)'N"N/D"E%7.%R"<C&T'IG
M:"<FMZL_1-?@UM#-;-O0,5)VLO( .,, >A%:% !1110 4444 %%%% !1110
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M%VI:AJ>G/=2K EM*$8*"YF"M(I3G[A)X)Z<=@>  =GXQUO['9O/$'?S(V"M
M-VW<C%9"P(PHQG<.G%8GPX\5/=P0VTL=P[GS,SNA:(X9B,R$YZ?+TZ\5H?\
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M!+R(,$DW8#@!OE8J<X)'4>M>=> /^0->?]O'_HA:ZCX9S+#ID+N0%42DDG
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M!MZ=X_@NI1:2++!*^-BW$?EELYZ<D=1CG&3P,FM*\\016MQ%8')EG#D 8X"
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MO\+ MXUYJ*$[;BY;"D8( RX)()Y/F8QVQU.: .ZFF6%2[D!5!)).  .223T
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M,=>0.IQQG!X.#5KP_P"+X-=+1QEEECSOCD7;(N"5Y'3KUP3C(!P3BN:^#O\
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M -SI%\B,<?(S,0-PR.F1R,$UUMI=+=HLT9RDBAE.",AAD'!YZ5S$4*Q:-A0
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M+-&2?J223ZGFG^)?^0"O_7O:_P XZ -"Y^)]O"@G6.:2/:I9XXP40L =C-N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$31($LXBQ2/=@N06^9BQS@ =3Z58U#3X]1C:WF4-&XP0?\\$=01R#R.:L44
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M<;2P2OG>UO)Y9;..O!'49XQD\G)J_H7AN/1MS(7>23;ODE<N[;<[<D\< X&
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MCL*9X=\(PZ#"UG'N>.1F+"7:V=RA2.% Q@=,>M;=% ')67PSMK-L*\IA+[C
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M_8^%3XCT^&'4@WG*"=W E7YCCG!Y*8W!@2>K?,,B9?AK 98KIY9Y)87#!I)
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MTCE_=LQ4,7*L&&2<>W P*[JZM$NU,4JJZ'&5<!E.#D9!XZT^&%85"( %4
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MS\C[!Y2^3NW;<MG=_>W9W9[9SG'R].*RE^&,#!8Y9;B6*/I'+-F/@%1PH4C
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M@0#OR1&>3G&/G/8=JJ1^*;S7)'&G1Q>3$[(99W)5V7;]T1G('.0>01@Y!XH
M[.BN:\,>*7O99=.NE5+J#D^7DQLIQAE)R1PPR#SR#ZA<?1O%FH>)3)/9) D"
M/M4W&_>> 3]PGGD$\8&0 6P30!WM%0VDC2HKR+L<J"RY#;21RN1P<'C/>IJ
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M6620+U"L"5!.,9(V@G&6VDUG_"V^\R;4+F4>7F178.<;,M*6!) QM[Y Z=J
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M+$HO.3T ]<'D@'&<BO>>(M2T2-;V\C@, *^8L)?S5#<9^9MI() (!.?7'S
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MT5RFC>*9H[K^R[]46=UWQM#N,;+@Y'S9((VGK@'!Z<;NHFF6%2[D!5!)).
M.223T H ?7/^&_%?]M37-MLV?99-F=V[=\SC.,#'W?4]:Q-)\5ZCKN^[M88A
M;*WR"8LLD@7J%8$J"<8R1M!.,MM)K/\ A;?>9-J%S*/+S(KL'.-F6E+ D@8V
M]\@=.U 'I=%<5I_B/4?$ ^TV<4,=N<[#<,S,^&8$XC/RXQR".O0L.FEX6\7K
MJT<@F BFM25G!/R*1G+!LD;?E/?C!R2,,0#HZQ_%'BB+PW$+B8,59PH" $Y(
M)[E>/EKG],\4:AXC!N+***. '"FY+EGP3DC9T X!'(!R QP<2^+O&D^CV<=Z
MD025Y=C),"VW ?."K#(RORMT*G..: .SHKDO%7BR>SN8=+LT5IYAN)ESL"_-
MZ$'(VDGV& &)XU]"DNSN2]6($;2K0%MI!SE2'Y!7&<]"&&.0: &^%_%$7B2(
MW$(8*KE2' !R #V+<?-6Q7!:)\26DL)=3NE7='*45(_EW':I ^9FY^8DXSA0
M3@XJQ_;&K^7]M\B'9][R<R?:-N?N_P!W=MYZ9_V=WRT =K17.6?B]=1L'U.$
M ,D4C%&.[:Z*3M."..,]B5(.!FL+0_%>J:]!]I@AA7;NYD+@2$= BY&,8P2S
M8)Z$8( !Z!16#X*\3#Q';+<D ."5<#. P],]B"#WQG&20:B\5^))-"DMFVJ8
M)9?+E9CMV[L;2#G@#YB<@C QE<YH Z.BN2^('C9O"ZPE%#M*YR&Z;$QN&0>&
M.X8.".N1TJ[XL\1MIL"2VP622>2-(NA0F3D$G<O! ."#UQVS0 7OBO[-?Q:5
MLSYT9??NQC <XVXY^YZCK[5T%>:>+;QK/6;:6-&D<6Y"HN 26\Y1R> ,G+'L
M,GM6LGBF\TJ[AM-06'R[G*H\&_AN  0V3U('0#Y@=W!% ':T5R^N^*9EN!IE
MC&LD^P.[.X"1J6 Y .XG!R0,$ J0&SBJ\'BFYTJXCL]26("YXB>WWE=P(&U@
MW/.1SC R.HR5 .H?48DD%N742L,A"P#D<\A<Y(X/Y&L?QKXK_P"$8A6YV>9N
MD"8W;>JL<YPW]WTKBM>^V?VS#M\GS?+?RL[]GE_O<;^^[&<XXSCWJU\5O._L
MZ+[3L\W[0-WE;MGW9,8W<],9SWS0!Z717":YXKU'38_[1\F(6VY?W;EA<!2<
M MSM!/' W%=P!!P:T]>\9F#R8;)!-/=H7C4L$ 7;N#L&P<'L#C.&&010!U%%
M<5>>*;SPZT<FI+";>1MA>WW[D8C()#\D8!Z#/&>N TOCWQC-X=>W2!%D\]F!
M4ABQVE,!<'@G<1T;G''J =A4-U=I:*9965$&,LY"J,G R3QUK-\.O>NI:^$2
MDA2HAW9&<[@VXD9''W21UYZ5A?%KSOL3^7L\KY?-W;M_^L39MQQU^]GMTH [
M*&99E#H058 @@Y!!Y!!'4&GUR7@F:[AMXGNC +5;9"I0N' "J07+?* %SNQW
M]JJ:9XHU#Q&#<6444< .%-R7+/@G)&SH!P".0#D!C@X .XHKFO"7BUM7:2TN
M(_)N8,;TR"""/O+WQGZ@ KACFMK5=332XGNI3A(U)/3)QT R0,D\ 9Y) H M
MT5Q5MK.K:G']K@AMTC90R)*[-(P*A@=RD+\V>,[<=#ZEUS\01<::^JVRC?&5
M4I("0&+(&'!7(PV01CMG!R  =G17G_\ PE>J7%I_:4<,*1K'N*R%R[ <M(HR
MH"D<@$YP,@ME<[LOC2--/_M@*2NP':#_ !%@A7) X#\$XZ#(!X! .CHKA-<U
M_5=*C^UR);+%N7()D=HPYP-Q! ;:2 =@.3R!BMNXN-1CCCC2.%IWW[WWL(4P
M<K\I^=MR\<=&Y/% '045QFD^++J"]&E7Z1[I$W1O!NV\!B<[B3CY2.Q!'0@Y
M&AKGB"=+A=-LT5IFB\PO*Q$:J&V\A?F8D@C Q@D'D9P ='17%6&MZD]W]@F%
ML-JI(VT2Y:,MM8H<D9!XPV.>@(YIT?BF\UR1QIT<7DQ.R&6=R5=EV_=$9R!S
MD'D$8.0>* .SHKFO#'BE[V673KI52Z@Y/EY,;*<892<D<,,@\\@^H7I: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\9QD*Q&0 3V^N637]O-;I@-+$Z@GIEE(&<9XYJQ:VB6BB*)51!G"H JC)R<
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M>K87%A</DK%*[$#KA6B)QG'/%>D57N=.BNF5Y$5FC.4+*&*G@Y!(X/ Z>@H
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M8_3& =I&<CDJ!UXT)=(\/QQ^>3'MP#@32%^<8^0.7SSR,9'?&#7HL,*PJ$0
M*H   P !P  .@%4K7P];6C"6*&)'&<,D:*PR,'! STH XKQEJ+Z=<6VE+*UM
M9-&H,B9#?*<!1(<D8"J,YXW9?(XK)TU8DUJW2"=[A5C?+R2>:0?+D.T,  0
M0>,X)/?('J=[IT5^NR9%=0<@.H89Z9P0>>:A@T.WMV5TBC5HP0I5%!4')(!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHK/U^&>:!TM&5)SMVL_*CYAG/RMVR.AH
M T**KZ<DB1(LQ#2A%#D="P W$<#@GV'TJQ0 445S_C7Q7_PC$*W.SS-T@3&[
M;U5CG.&_N^E '045S7Q'NWM+":6)F1QY>&0E6&9%!P1STK2\,3--:6[N26:"
M(DDY))0$DD]2: -.BBB@ HHK)\4Z[_8-L][MW^7M^7=MSN8+UP?7/2@#6HJI
MI-]_:$,=SC;YL:/C.<;E!QG SC/I5N@ HHHH **** "BBB@ HHHH ***Y_PW
MXK_MJ:YMMFS[+)LSNW;OF<9Q@8^[ZGK0!T%%8]M;7:W<DKR*;0H B #>&PN2
M3M''#?Q'J./38H **** "BBB@ HHHH **** "BBB@ HHKFOB/=O:6$TL3,CC
MR\,A*L,R*#@CGI0!TM%9GAB9IK2W=R2S01$DG))* DDGJ35+QKXK_P"$8A6Y
MV>9ND"8W;>JL<YPW]WTH Z"BN:^(]V]I832Q,R./+PR$JPS(H.".>E:7AB9I
MK2W=R2S01$DG))* DDGJ30!IT444 %%%% !1110 4444 %%%% !1110 4444
M %%%9^OPSS0.EHRI.=NUGY4?,,Y^5NV1T- &A17G_P 3;VXTVP@/F,L_F1J[
MQ,4R?+?=]W;P2,XP.W%>@4 %%8_BBVN[B(+82+'+O!)< C;@Y'*OSG';MUKG
M_'VHRVMWIZ1NRK)/APK%0PWQ#! /(Y/7U- '<45CW-M=M=QRI(HM A#H0-Y;
M#8(.T\<K_$.AX]:][XK^S7\6E;,^=&7W[L8P'.-N.?N>HZ^U '04444 %%%<
M%XPO)[[4+?2(Y6ABD3S&:(E7.-^1N!Z83 [9.2&P  #O:*J:7I_]GQK!O>3;
MGYI6W.<DGEL#.,X'MBK= !1110 445S7Q'NWM+":6)F1QY>&0E6&9%!P1STH
M Z6BLSPQ,TUI;NY)9H(B23DDE 223U)K3H **Q_%%M=W$06PD6.7>"2X!&W!
MR.5?G..W;K6Q0 4444 %%%% !1110 4444 %%%% !116/;6UVMW)*\BFT* (
M@ WAL+DD[1QPW\1ZCCT -BBBB@ HHHH **X?Q]J,MK=Z>D;LJR3X<*Q4,-\0
MP0#R.3U]36QXD\5_V+-;6VS?]JDV9W;=OS(,XP<_>]1TH Z"BL?Q1;7=Q$%L
M)%CEW@DN 1MP<CE7YSCMVZUL4 %%%% !1110 45S_B3Q7_8LUM;;-_VJ39G=
MMV_,@SC!S][U'2N@H ***X?XNZC+86B/"[(QG4$HQ4XV.<9!''% '<4444 %
M%%<_X;\5_P!M37-MLV?99-F=V[=\SC.,#'W?4]: .@HKA]6U&5-:MK<.PB:!
MB4#$(3B;DKG!/ _(5W% !1110 45S]EXK^TW\NE;,>3&'W[LYR$.-N./O^IZ
M>]=!0 4444 %%</\2M4GB:UL()#%]KEVLZYWC#(!@@CCYLG&"<8R!G/4:)I'
M]E(8O,EERQ.Z=][#( P#@<<=/4F@#0HKG_$GBO\ L6:VMMF_[5)LSNV[?F09
MQ@Y^]ZCI6/\ %W49;"T1X79&,Z@E&*G&QSC((XXH [BBBB@ HHHH **Q[FVN
MVNXY4D46@0AT(&\MAL$':>.5_B'0\>NQ0 4444 %%</JVHRIK5M;AV$30,2@
M8A"<3<E<X)X'Y"N@MK:[6[DE>13:% $0 ;PV%R2=HXX;^(]1QZ &Q115?44D
M>)UA(64HP0GH&(.TG@\ ^Q^E %BBL_0(9X8$2[97G&[<R<*?F.,?*O08'04S
MQ/,T-I<.A(98)2"#@@A"001T(H TZ*YKX<7;W=A#+*S.Y\S+.2S'$C 9)YZ5
MTM !1110 45P_C[49;6[T](W95DGPX5BH8;XA@@'D<GKZFNXH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *Y3XI?\@Z?_MG_ .C4KJZY_P >Z7)JME+;0+ND?9@9 SB12>20.@/>@#BO
M'W_(&L_^W?\ ]$-5CQKX(BTJS:^#R-=PF,F=I&WL=ZKW)P!GY<<C ^8\YN^+
M_"USJ&FVUE$FZ6+R=R[E&-L3*W)(!P3C@UT'CW2Y-5LI;:!=TC[,#(&<2*3R
M2!T![T :6AWK7]O#</@-+$C$#IEE!.,YXYK@OC7I<?DQWNW][YBQ[LG[NV1L
M8SCKSG&?>N[\/6K6EM!#(,/'#&K#(."J $9''6L?XB^&9/$-KY,)'F(X< _Q
M85AMSV)W<$\9X. <@ Q_&OA:VT'3KG[,FSS/)W?,S9VRKC[Q/J>E4I? \-UI
MGVV<M).MH'1]Q&Q4C#)&%'R[0!@Y!))9L@GC5UN*_P#$%A-:RVPCF(BV@2HP
M<AP7(Y^4#&<$GKC)Q6Q_9<G]F_8MO[W['Y>W(^]Y6W&<XZ\9SCWH Y+4?&,\
M.BQ7()$TQ\K>"=PVEP6R<DL53!.0<G<","LR[TJV\MC%:7_VKEEG=&W^9G<K
M$AL=>I"YQS][FNCMO LE]I*:;, DZ%F7)R V]R,E"1@JV.^,YP2,5=M=5U6)
M1 ]JCR#*^=YRK&3G D,8&['<@8)YP%Z  V/"-Y/>VL<MTI68@A@5*'Y6(!*G
MH2 #V'/  XK"^+6EQW-D]RZYD@V[#DC&^1 W .#D>H/M77VF_8OF[?,VC=LS
MMW8^;&><9Z9YQ6;XNT-M<M9+-&"LX&">F58, <=CC&><=<'I0!R^G^%K;3]-
M>]B3;++I[;FW,<[H@S<$D#)&>!53X9>"H+JWBU&?=)(&)C!9@L8CD;  !YRV
M6.>.>G4G3TN*_FLGTV>V"%;1XT<2H=S!=B+M!."1U).,CMG V/ 6ER:5916T
MZ[9$WY&0<9D8CD$CH1WH Q/%L6E+.6U&5G<XQ&7D98\*N<)%RNX8)W=>H[U5
M^$-[N-U:QNSV\,B^3NZ[6+\] 1D $C &<G )-.M=#O/#E[<74$"W,=R2P;>D
M3KN8L5RQ/'/. 0V%.0015[X?:!=:;->37:JIGD5@48%2=TA8@9) ^88W8./?
M- '+_"[PA%K=N\ER6>(2D+%O94#!5)D^4C+8.!Z#/7(QJ^!)IK>/4--MR2;5
MY! 6(+;CY@4<_+C* ] ,EB>M;'POT"?1+9X;E=CF9F W*W!1!G*DCJ#47A70
M+K39M0F*JIGD+0EV!4G=*02%)('S#/0X]Z ./\*6VGMF'4/-BO\ <6,DS/&0
MQRRLK9 !  ;+C)8\;A@5Z!XVBLV5&OY62(;OW8=E63)7JB?,VTX(QTZGBL'7
M[;4O$\ L9+6.(L5+2O,K*"HR2JKN923Q_%@$@]<@USP9<6<UG>VRK<&TBCB9
M'PF?+!PX+' //'4JP4_-S@ Q_#%[;6NJQQ:8[?9IXSYBG=MW*KD#YQGC .>3
MR0#@D5L:NK>*-4;2I'9;:WB5G16P)#E&YQCCYE]<;3MP6R'V^DWU_J<&ISPK
M'&D;+A9%<J-L@ 8Y&22V?E& " >0:M^(- NK&]75[!5D9U"31E@I8#'(9C@<
M*!QC! .&!84 :NG^"H-.WQ0[EMYHV62$LS*2V!O!)+*=N5.#R,="O/">"O!E
MIJ5S?0S1[D@FVQC>XP-\@QD,">%'7-=[HMU>WDOFW$2P0A&'E^8)'+Y4A]RC
M 4#( SG.20>,<[::3?>&[NYGMX5N(KIM_$BQ,IW,<?,3TW$=#G@Y'*T &C?\
MAZZ_Z]U_E!5+PEI">.3+J-\6=1*RQQ%V"(,*W!4KS@@< 9P2<D\;NF:!/#JU
MQ?LN()(0JMN7D@1<8SD?=/4=JI:9HU[X1DDCM(EN+65V94$@C="<=6?.1CCJ
MV=H/RDD$ ATA6\+ZHNE1NS6UQ$S(C-D1G+MQG/'RMZ9W#=DKDY7A;PTFN7U^
M)F;R4G;=$K,JN3))M+;2,A<9 ]2#G@@]+H7AVYO+PZQ?A494*Q1*=Q09(Y8<
M$X)_O9W$_+@ /\%:!/IMS?33+M2>;=&=RG(WR'. 21PPZXH S/!<0T74[K2H
M<^0$60!B3M.$X'/3Y\'.20JY/'/<:IJ']GQM/L>3;CY8EW.<D#A<C.,Y/MFN
M:TS0)X=6N+]EQ!)"%5MR\D"+C&<C[IZCM784 <I_PGW_ $YWG_@/_P#95;TO
MQ?\ VA(L'V:YCW9^:6':@P">6W'&<8'OBN@HH S]?B26!UEE:%#MS(CB-E^8
M8PYX&3Q[YQWKQ_Q/>Z=IXBNM(=DN(Y.WFXVD')/F#'7 QG!!(((Z>D?$7PS)
MXAM?)A(\Q'#@'^+"L-N>Q.[@GC/!P#D<OXJTO4O$%M':_94B$3(<+*G)"%1M
M&0%4<\$D\KC@&@#0^-?_ !YQ_P#7PO\ Z!)5+QKX(BTJS:^#R-=PF,F=I&WL
M=ZKW)P!GY<<C ^8\YW?BAH$^MVR0VR[W$RL1N5> CC.6('4BM#Q[I<FJV4MM
M NZ1]F!D#.)%)Y) Z ]Z .:\9:[+J%O8VBGRVU+R_,9.@#!-R@'G!+_WAP-I
MR":J>._ 4&BV+RVK.FSR_,&]BLHW!1N&<9!.X8  YXY&-C6_!\U[96OE86\L
MDC*9(/S*J[DZE<Y4$$Y&1C(!)JIXCMM4\1VK6[0+$0$+ 2(YE.Y>%YPBC!8Y
M))PJ@GF@#K?"?_'G;?\ 7O#_ .@+7%?&O2X_)CO=O[WS%CW9/W=LC8QG'7G.
M,^]=WX>M6M+:"&08>.&-6&0<%4 (R..M8_Q%\,R>(;7R82/,1PX!_BPK#;GL
M3NX)XSP< Y !C^-?"UMH.G7/V9-GF>3N^9FSME7'WB?4]*I2^!X;K3/MLY:2
M=;0.C[B-BI&&2,*/EV@#!R"22S9!/&KK<5_X@L)K66V$<Q$6T"5&#D."Y'/R
M@8S@D]<9.*V/[+D_LW[%M_>_8_+VY'WO*VXSG'7C.<>] '):CXQGAT6*Y!(F
MF/E;P3N&TN"V3DEBJ8)R#D[@1@5F7>E6WEL8K2_^U<LL[HV_S,[E8D-CKU(7
M..?O<UT=MX%DOM)339@$G0LRY.0&WN1DH2,%6QWQG."1BKMKJNJQ*('M4>09
M7SO.58R<X$AC W8[D#!/. O0 &QX1O)[VUCENE*S$$,"I0_*Q )4]"0 >PYX
M '%<?\6+9KJXL(D8HSRNH<=5+-$ PP1R.O4?6O0K3?L7S=OF;1NV9V[L?-C/
M.,],\XKE?&N@3ZE<V,T*[D@FW2'<HP-\9S@D$\*>F: &:CID/@6RGN+-2)-B
M L6));.Q7(;*Y!<M@  ], =./L;"UO81)<VM]/-*BDS;&;DH!E3N *CJNX'C
M&<CBO4]?T9=:@DM'X$BXSSP1RK8!&<$ XSSC!XKE]'N-4T2);-[9;@1 *LB3
MI&"H P,,,Y7IG SCO]X@&%=3ZG?Z28V27S5F",-C"5H=O4@_,V6(!(&2 =V?
MF)TO 4>E2NDEDS).H(*NY#N-K @J248<;SLZ$*3CI72W<]_;VZ.J127(<>8B
MLRH4R>$9B,-C'+<=>#P#SMSH%YXDNX+R>%+9+5E/+K+(^&W8RG& 0!@XQN)&
M[.  9[:3_:NMW,#.RQF%/,"\%UVPYCW=0"<;B.2 5XSFI;O35\$ZA;&T+"&]
M;RWB+$KD%5#9;)X+AO7@@-AL"O*;E-;N'M K,D2ED<[=Z!(LH&P<,3C!X (Y
M.,@[$&BWGB"]CO+Z-88+7YHXPZNQ8XYW(>Q /.!P%"G+&@"E9V8\:WUTMTS&
MWM'"+"&(0D;TWDKMY^4GU^8#=M&"7EF/!5]:K:LPM[MRC0EB4!.Q-X+;N?F!
M]?E(W;3@:$V@W?A^[EOK%%FAN2#)$7".&P3N#-D8W$GK_$1MX# AT&[\07<5
M]?(L,-L28X@X=RV =Q9<#&X ]?X0-O)8@&)+H@UC6[B%G98Q$I<(2N]=D0,9
M((^4Y&?4#'!Y%NPL$\,:Q'9VH*PW4!+(69@"H<@C)Z_)WSC<V,9XV-,T">'5
MKB_9<020A5;<O) BXQG(^Z>H[4:GH$\VK6]^JY@CA*LVY>"1+QC.3]X=!WH
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MGA3TS0!GZS_R'K7_ *]V_E/65KWA:VEUF&V9/W=Q&\D@W-\S'S23G.1RHX!
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M))7G& <D$$'AGCSPX/"\,&HQ22&[655:9F)+Y1CDAB>!MV@=-O#;NM=1\4-
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ME+"L;F)PTN]&W_*1L" X5GX!8G:!N( .T  Q_P#F7/\ /_/U75?\P;_N'_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '/V7A3[-?RZKOSYT839MQC 09W9Y^YZ#K[5T%%% !1110 4444 %%%% !11
M10 4444 %%%% $-W&TJ,D;;'*D*V VTD<-@\'!YQWK-\)^'5\/6ZV@(8J6)8
M+MW%B3DC)Y P.IX K8HH **** "BBB@ HHHH **** "BBB@ HHHH *P=<\+F
M^E6]@E:&Y1-@=0'4J3G:R-PPZXZ<D$YP,;U% ')#P1+?2(^H7!N(XB66/REC
M0MV+!2=P'H1^A(/6T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 9^OZ8VJ026J/Y9E7;NVAL _>&"1U&1UXSD<T
M[1-+72H([5<8B15R!MR0.6QZL<D^YZFKU% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !5?4-0CTZ-KB9@L:#))_SR3T ')/ YJQ7G_B__B::I9Z;+S %,I7LS#>0
M&!R"/DQTSAF&>> #3B^),,H\Q8;@PY/[X0DQ;5)!?.<[1@D\9'IGBNET_4(]
M1C6XA8-&XR"/\\$="#R#P>:L4R*%8AA0 ,DX QRQ))^I))/J>: 'T444 %5]
M0U"/3HVN)F"QH,DG_/)/0 <D\#FK%<I\2O#DFO6GE0<R)(KA>!NZJ1DD 8#$
M_ACO0!$/B9$JB9X+E(FV_O'A_=@,0 Q8,>.>V<]LUV%<9X7^)<.J,MI< PW6
M=I5@0I?D$ GH>.C8.2%&XUH>*?%+Z:\=G;1B6ZG#E$+JH 52=S9(XXX'&[#?
M,"* .CHKBKSQ3>>'6CDU)83;R-L+V^_<C$9!(?DC /09XSUP&M>(/%LL5PNE
MV,:R7#*&9G/[N,9'+!>>G/4=5QN) H ZNJ]MJ,5TS)&ZLT9PX5@Q4\C! /!X
M/7T-8^GWE^-\%PD7FF-FBDCWF#(P CY^8')!X^\N<<J:X3P5]O\ M-]]G^S^
M9YW[WS/,V[M\GW-O.,YZ\XQ[T >AW/BB*WNX]+(;S94+ @#9@!CR<YS\A['M
M6Q7+ZAXHEM]3@TL!?*EB+$D'?D"0\'.,?(.Q[U7O_%MQ>W3Z=IT:,T./,EE)
M,2G!^7"<YS@=<Y##;@%@ =A17'V'BVXLKI-.U&-%:;/ERQ$B)C@?+A^<YR.N
M<E1MP0QJ7WC6[&H2:5;Q))A5VD[EVED5M[G)!4$\@ $\ '/4 [NBN/T;Q3<Q
M7O\ 9=^L0=X]\;0[]K8SD?-D] >NW&T]<BNPH Y_Q'XZM- ^65\R#_EG'\S]
MNHR O!S\Q&1TS6QIUZM_$EPF0LJ*P!ZX8 C.,\\UQGQ"T"#3[&ZGBC59)65F
M;JQ+3(6^8Y(!(SM'&>U=+X3_ ./.V_Z]X?\ T!: *NM^-X-*D%IAY9SC]U F
M]P""<D<#H,XSG!!QCFK6A>(EU?<!'+$\>W*3H4;#9VL.H()4CKU!]L^>^ ?$
MR W&HR1RS74TH#+!$TFQ",K@G[JYR,;B<*N!@9KT#P[XJAUX.(MRO$<.DBE7
M4DL #U&?E/0G'?!XH V**R?$_B%/#\#7<@SMP%7(!9CT S^9ZD $X.*P/[8U
M?R_MOD0[/O>3F3[1MS]W^[NV\],_[.[Y: .UKC](\>2:W*5M+9GMUD53,9 @
MP<98(RY.!S@'.,9 )Q6AIGB%_$%F+NR""5N-LQ)56##<&V<].5Z$@J2!FN*^
M$GVSR3Y'D_9_M'S^9O\ ,^ZF[;M^7[N,9[]>* /5:KV6HQ7Z[X75U!P2C!AG
MKC()YYIFJ>=Y;?9MGF\;?-W;.HSG;STSC'?%>:_"3[9Y)\CR?L_VCY_,W^9]
MU-VW;\OW<8SWZ\4 =KX;\5_VU-<VVS9]EDV9W;MWS.,XP,?=]3UKH*\J\*WE
MQ'>:A#:(K227!.^7(B0*\N=VWDELX4#W/1375>%/%,UY//IMXJ+<088>5NVL
MIQSSGU4\D$AA\H(- '5T5QD?BF\UR1QIT<7DQ.R&6=R5=EV_=$9R!SD'D$8.
M0>*O>&/%+WLLNG72JEU!R?+R8V4XPRDY(X89!YY!]0H!T4TRPJ7<@*H)))P
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M(#R'.6P.0X(]0<C(S3[+QO<6"[(=*D12<D(K*,],X$(YXJ*]\62W[;YM(9V
MP"Z%CCKC)A/'- %W6?\ D/6O_7NW\IZK^'=0C\-:C>6]VP3[2XDC=N(R,NV-
MS8Y^;'IN5AG.,C^-[AY!<'2I#*HP'*L7 YX#>3D#D_F:+WQO<7Z[)M*D=0<@
M.K,,],X,)YYH /$6H1^)=1L[>T8/]F<R2.O,8&4;&Y<\_+CTW,HSG.+&C?\
M(>NO^O=?Y057LO&]Q8+LATJ1%)R0BLHSTS@0CGBA/&]PDAN!I4@E88+A6#D<
M<%O)R1P/R% %C6?^0]:_]>[?RGKT"O-W\;W#R"X.E2&51@.58N!SP&\G(')_
M,U8_X6/>?] Z;_Q__P",T 6/B;KEO+8SVZRQF7*#8'4OE95R-N<Y&#GTK8\%
MZM#<VT$$<B-(EO%N574L,(H.5!R,'@^]<9-XA:9B[Z,2S$DDQY))Y)),')-3
M67BR6P;?#I#(Q&"40J<=<9$(XXH =\-M5B\.B?2KMUCECF9LN=B,"%7*LV/3
M(SC*D$9YQ8\%RC6M3NM5ASY!18P6!&XX3D<=/DR<X(#+D<\5[[QC-J&//TEY
M-N<>8K-C.,XS"<9P*L0_$*[A4(FFRA5   W@ #@  0\ 4 7OB[ICWUB6C&?)
MD61AR3M 921@'INR>@ !.>*T/^%BV/D?;/-7&W/EY'FYZ;=F<YSQZ=\[>:Q/
M^%CWG_0.F_\ '_\ XS6?_P ),^_S_P"QV\S=NW>6=V[.=V[R,YSSGKF@#;^$
M6F/8V(:08\Z1I%'(.TA5!.0.NW(Z@@@YYJI\%/\ CSD_Z^&_] CH_P"%CWG_
M $#IO_'_ /XS5>R\;W%@NR'2I$4G)"*RC/3.!".>* /2*\T^$.JQ6,,EE,ZQ
MS_:#\DAV,2RJH #8R<J1@<@]1R,V_P#A8]Y_T#IO_'__ (S5*7Q9++)]H;2&
M,N0=Y0E\KC!W>3G(P,>E %WX<?\ 'YJ7_7Q_[/-1HW_(>NO^O=?Y057MO&]Q
M:LSQZ5(K2'+E592QY.21#R>3U]30GC>X20W TJ02L,%PK!R.."WDY(X'Y"@#
M"\(:#I\#36.J!5N(9#AGD>-"N !M.Y0>>1D E6!&1G'=>$M+TV"61M/VF2-0
MKE'=UP_S  L2ISM[9QC!Q7/WWC&;4,>?I+R;<X\Q6;&<9QF$XS@5-:^/+FT4
M11:9*B#.%0.JC)R< 0XZT =UJFI+ID;7$@8HF-VU2Q ) +8'.%!RWH 3S7'^
M.O%&GWUBX+I*77]VJD%PY!V-C(*X_BSCC*G).TQ?\+'O/^@=-_X__P#&:I1>
M+)8I/M"Z0PER3O"$/ELY.[R<Y.3GUH R=>T66WL-/GO$8QV[L)D.2X21P5'7
M@;%"\E2I*KP>FW+I'A^./SR8]N <":0OSC'R!R^>>1C([XP:L?\ "Q[S_H'3
M?^/_ /QFL^U\3/:,)8M'9'&<,D95AD8."(,]* +OQ&T\:6+&\13Y%C*H8+EF
M"Y3;U[?)C)(Y*CO72GQQ9D1[)5<S/&JJA!?,A &5SE0,Y.<8Z=< \U-\0KN9
M2CZ;*58$$'>00>""##R#56R\62V#;X=(9&(P2B%3CKC(A''% %A;M-'UR:6Y
M98TGMUV,Y 4\1CD]!S&W7'3W&:AUV+6-=@> [ECC="P^Z2$E)(/<?-C/?'&1
M@F6^\8S:ACS])>3;G'F*S8SC.,PG&<"A?&,R,LHTEP\:[48*VY5 (V@^3D#!
M/ XYH MZ-_R'KK_KW7^4%'Q'_P"/S3?^OC_V>&JZ>-[A)#<#2I!*PP7"L'(X
MX+>3DC@?D*+GQO<73*\FE2,T9RA968J>#D$P\'@=/04 2_%&46MQ873Y$44Y
M+M@D#YHV[ \X4D#J<'%:'Q$U&*_TR=X75U!C!*,&&?,0XR">>:S;KQY<W:F*
M73)70XRKAV4X.1D&''6JZ>+)4C-N-(81,<E A"$\<E?)P3P/R% &3KNGQ1-I
MMY>*6M&M(HWV[N"$)!)7''S C!R0K<'&#T#>'="#(@\MFD=44)/(Y+-P.$<X
M'N< =S3?^$\N=GD?V9+Y>W;MP^W;C&W;Y.,8XQTQ5>R\62V#;X=(9&(P2B%3
MCKC(A''% &[XST_3=4D%O>NL<XCW*Y;RV"[L?>8;#R#\IR1R0!R:S_ 6MRS7
M<]@LS7%K"I*2N,L#N'RE_P"+.6&3G=MRN%XJI?>,9M0QY^DO)MSCS%9L9QG&
M83C.!4UKX\N;11%%IDJ(,X5 ZJ,G)P!#CK0!U_BS_CSN?^O>;_T!JYKX<>(;
M:TL(8I9HD<>9E7D16&9&(R"<]*KS?$*[F4H^FRE6!!!WD$'@@@P\@UF_VW_U
M!?\ R%_]HH Z7QUK:75J+2W"SR7N4B"@.AVD;VW X&SJ#GY6P>@)&5X-@_X0
MVZ;2I]NRXPT4Y7878  Q]6'!)P"00?7>M5X/%DMNRNFD,K1@A2J$%0<D@$0\
M [CT]3ZU+<^-[BZ97DTJ1FC.4+*S%3P<@F'@\#IZ"@!]U=+X=UEKFY.V*[A"
MH^#M!&P$,3@#E.<9P&4G )(Z^S\46]]-]DA=9'\LN3&0R@!@N"P.,DGIZ#G'
M&>-O?&]Q?KLFTJ1U!R ZLPSTS@PGGFBR\;W%@NR'2I$4G)"*RC/3.!".>* +
M'P4_X\Y/^OAO_0(ZJ>#KA[:;5Y8AND21BJX)RP:8J,#DY/8<T^R\;W%@NR'2
MI$4G)"*RC/3.!".>*+;QO<6K,\>E2*TARY564L>3DD0\GD]?4T 846HIJMC+
M>W5]+]H*N/)601J3C:B^4!\P;@L5 &"<\AC6A_S+G^?^?JI3XF<L9?[';>V[
M<WEG<=X(;)\C)W G/KDYJ7_A,9O+^R_V2_E?W-K;.N[[ODXZ\].O- '0?\P;
M_N'_ /M"N:ME+>'2 N_Y6XY/ G)+?*0?E'S>G'.1D5;_ .$\N=GD?V9+Y>W;
MMP^W;C&W;Y.,8XQTQ69JGB2ZNXDM(].DCA65&9!&Q1E5MY3;Y0 #-@D_F#DT
M #:I:ZFR6MQJ326V]?W;0M&6 ^Z'FP,CIN8XSC/!P1I_%>U6Y6UOV'F6T4G[
MS8224D*'((P,$+C.X<E<'FJ^M^,[O58)+5M.EQ*C+DAVP2.&QY753@CW'457
M\+>*KS0;9++[!,_E[OFPZYW,6Z>4?7'6@"[+I'A^./SR8]N <":0OSC'R!R^
M>>1C([XP:]"M+5;1%AC&$C4*HR3@*, 9//2O-;7Q,]HPEBT=D<9PR1E6&1@X
M(@STK0_X6/>?] Z;_P ?_P#C- $7BJW?Q)J<5C!(L9LX_-+E"S*Q92!@X#?P
M'TY.23Q4/CKPC>SVCR377GK#^\V>1'']W()W!NRDG'.>F,XJ:/QY<Q,TJZ9*
M'DQN8!PS;1@9/DY.!TSTJ7_A8]Y_T#IO_'__ (S0!E7^N 75AX@E_P!0\)C<
MHK860!PPP>P+''))"L0#@9[U/%UK++':QRK)),6 $;*^-JEB20>!Q@=R3P,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_*CYAG/RMVR.AJQIR2)$BS$-*$4.1T+ #<1P."?8?2@"Q1110 4444 %%%%
M!17GE_+/K^JR:;Y\D,-O$&Q Q1FR$/+>N7[@@ 8 !)-3>/[R>R%GI<$K)]H<
M1M+DF7Y3&H.X$<G=EL8)QC(!((!WM%<O_P (]=V#0I:W#-$)2TWVEA([*=GR
MJ=AP,!NXY/7TZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MN'^$6HRW]H[S.SL)V +L6.-B'&23QS7<4 %%8^B6UW#+.UU(KQ,^80H *KEN
M#\J\X*]VZ'GUV* "BBB@ HKG_$GBO^Q9K:VV;_M4FS.[;M^9!G&#G[WJ.E=!
M0 45D^*==_L&V>]V[_+V_+NVYW,%ZX/KGI5O2;[^T(8[G&WS8T?&<XW*#C.!
MG&?2@"W1110 454U:^_L^&2YQN\J-WQG&=JDXS@XSCTJIX6UW^WK9+W;L\S=
M\N[=C:Q7K@>F>E &M17#_"+49;^T=YG9V$[ %V+'&Q#C))XYKN* "BBB@ HH
MHH **** "BBB@ HHHH ***Y_Q)XK_L6:VMMF_P"U2;,[MNWYD&<8.?O>HZ4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7-C-"NY()MTAW*,#?&<X)!/"GIFHO$&@75C>KJ]@JR,ZA)HRP4L!CD,QP.%
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M,=,F?7-0O;.53;0+/"4Y'F"-P^>N6X*D= !G.<D<9R/"'AB>&[FU:Y5(C.I
MB0[B,L"2S#C)V@DC.XL2=IXH J?!3_CSD_Z^&_\ 0(Z/AQ_Q^:E_U\?^SS4S
MP]I6H>%C-8V\"R0O*6CE>55V[@ "X^\P  R  <AL9R,6_ASX=NM)ENI+P#=,
MZD,"I#$&0LP"] =P/('7I0!SGPO\*1ZY;.;DL\2S-MB!*J&V)F0E2"3C  /"
MC/\ >XV_ C-HM[<:'N9XHE$D9;&5!VDKC'?>,\@9!(4;C5+P3I6J>&(G7R%D
M1WSY7FHC@X'S[N5VD#!!.<@$ #.=WP5X<GAEFU2^VBYN/EVKT11CC@D'.U<=
M2 HRQ):@#E-,UEM&.L74?WUF 7IP7ED0-R"#@G.,<XQ5>QL+6]A$ES:WT\TJ
M*3-L9N2@&5.X J.J[@>,9R.*T_"^C+K4NK6C\"2;&>>"))2K8!&<$ XSSC!X
MK8T>XU31(ELWMEN!$ JR).D8*@# PPSE>F<#.._WB 85UXKOM/TDM<!TG,PA
M5W!23;MW;SN&2< KN&#WSN!)Z6U^&D%JHD1W%X,G[1N8OO)R6*%BI!S@J<Y4
MD$DG=5CQ!X9F\1V7V:Y,8N0=P,>_RPP)V]><%3@YS@DD X%4K74=8FB%NUNB
M3%2//>5"@/\ >,:!CG'ID;N<;>* ,3XE:! ]]9N5YNI@LOS-\P!B0#KQP<<8
M_.O0-$T"#1$,-LNQ"Q8C<S<D 9RQ)Z 5S_Q!\.3ZD;>\M-K2VDFX(W ;)4]2
M0."HR,C(S@Y !Z#1+V>[0O<P^2X8@+YBR9&!\V5XZY&/;WH YKXM:7'<V3W+
MKF2#;L.2,;Y$#< X.1Z@^U9]OI\'A;3?[7MH\7#VL8+;F/,NSYL,67AB&QCG
M&. :ZWQ=H;:Y:R6:,%9P,$],JP8 X['&,\XZX/2N?TG3+K5+0Z1?0")! %$H
MD5OF0@1_(K9R, GYL$C' .* *^@_#BVU2V2YNR\L]Q&KF1G;<-Z#:!R0=HQC
M<#D^V%%OX;:K+*;G3YW:5K28J)'.68$L,'.3P4)Y)ZXZ 5#ID^JZ+"++[,DY
MB7:DJS*JX"C:"K;2=O0_=R!Z_,=;P1X6?1%EEN&5[BXD+R,F=O4X Z#J2>%'
M7'0"@"7QYI<>H6<WFKN\J.21>2,,J-M/!&<9Z'CVKG_A;X6MOLT&I;/](_>?
M/N;^\Z?=SM^[QT_6NUU:Q_M"&2VSM\V-TSC.-RD9QD9QGUKE? EO?:,J:;/
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M7_T"2NB\&^*E\30&Y"%"KE2I.[D '@X&1@CL.<CW/._&O_CSC_Z^%_\ 0)*
M#Q1\/HTMY+[S'-Y$IE,^X[F9 6QM!PHXPNW!7"\G!SB>-]9;6='MKJ3[[3*&
MZ<E%E0MP !DC.,<9Q6]K U>\@_L[RHRS@(]PLB["K##'80&!P<,<'OM7E<,\
M8^")&TZ#3;-=[0R*3R%S\K[F^=N,LV<9.,\<"@"6_P!#C\$VDVH1;GNO+VM*
M[$LS2.H+%3N7AB#C!)Q@DY),6@_#BVU2V2YNR\L]Q&KF1G;<-Z#:!R0=HQC<
M#D^V%'8:_HRZU!):/P)%QGG@CE6P",X(!QGG&#Q7*:9/JNBPBR^S).8EVI*L
MRJN HV@JVTG;T/W<@>OS$ / 5V^H+=Z3=,TPMY&C+N3N97+J0>_\).=Q/S8!
M  KG_!7@RTU*YOH9H]R03;8QO<8&^08R&!/"CKFNV\$>%GT199;AE>XN)"\C
M)G;U. .@ZDGA1UQT JIX*T"?3;F^FF7:D\VZ,[E.1OD.< DCAAUQ0!E> [5;
MNYU6&09228JPR1D,\P(R.>E9/@KP9::E<WT,T>Y()ML8WN,#?(,9# GA1US7
M5^"M GTVYOIIEVI/-NC.Y3D;Y#G )(X8=<5GVFDWWAN[N9[>%;B*Z;?Q(L3*
M=S''S$]-Q'0YX.1RM 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%49=<MXI/L[2QB7(&PNH?+8P-N<Y.1CUH O4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%4;W7+>P;9-+&C$9 =U4X
MZ9P2..*O4 %%%5WU&))!;EU$K#(0L Y'/(7.2.#^1H L4444 %%%% !1110
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M2 . ">I':K=<I\4O^0=/_P!L_P#T:E %W3_'-GJ,JVL,H:1QD *_]W?UVX!
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MZ!0!YIX;^*4?G7/VN;]UYG[C]V?N[G_N)GIM^]S^M6-?F6'7+9W("K;.22<
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M0!Z1K.OP:*OF7,BH#TSRQY .%&2<9&< XZGBF:'XDM]=5GMG#A#AN"I&>G#
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M[]GV63?C;NW?,AQG(Q]WT/6CQKX4_P"$GA6VW^7MD#YV[NBL,8RO][UKH**
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M.>!WQ\H.W=S7444 8FB:'/:.9[FY>9RI4#:L<8&0<^6O&[.?FST.,<5MT44
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MX*D@=2?8@D,"",3Z+X=EM9?M5S<-/*$9%^18T"L58_(N?FRO+9Y&!C@5O44
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HKS_P#X4I9_WYO^^D_^-T?\*4L_[\W_ 'TG_P ;H ] HKS_ /X4I9_WYO\
MOI/_ (W1_P *4L_[\W_?2?\ QN@#T"BO/_\ A2EG_?F_[Z3_ .-T?\*4L_[\
MW_?2?_&Z /0**\__ .%*6?\ ?F_[Z3_XW1_PI2S_ +\W_?2?_&Z /0**\_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 445GMKL0D-N-Y=6"G;%*R@L P!<(5'# G)X!Y
MQ0!H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$8RN2>-V,]1Q5C7/%UKH;*ES($9QD##,<=,X4' ],]<''0UB?";3X[>P29%
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M%C:?V@CJ5=3Y1PQ5GVL54@<CE<'.,<@X-5-0T2[T^ZDU&R*.)U7S8I3M),8
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M,5T'P_$<C3/*C+J"$+<&4[F.<E2I'RA"!P% & .H"L0#5UCQS9Z/)]GGE"R
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M#X(S)@,N,#Y>.AS[DUBQ?#:&(>6LUP(<G]R)B(MK$DIC&=IR0><GUSS76T4
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M44 <E#\-H0HBDFN)(0 /*DF/ED#[HPH7@<$8(P0*VM2\/Q7ZPH<JMO+'(@3
M&8\A5Q@_+ST&/8BM.B@#/U_1$UN![.4L$DVY*$!OE8,,9!'4>E:%%% 'G\7A
MN/6=1OF<NDD?V;9)$Y1UW1?-@CCD#!R#QG&*ZKP_X:BT)66+<S2,6>20[I')
M).6; SC/'XGJ23K44 8]OX5@CCGMV!>.ZE>1P^#R^,@8 P!@$=P><YK"F^%%
MO<*(Y9;AU1=J!Y00@ROW1MP.%QC!&.V0".UHH R?$'AJ+7559=RM&P9)(SMD
M0@@Y5L'&<<_@>H!$6B>$X]*<W&^664J5\R>0NP4D'8.@QD9Z9R3S6W10!RC?
M#N)&9H)KB!7;<8X)=D8) !(7:<9Q^'08  %V[\%V\]NEBNZ..)P\9C<AT8$G
M<&;=S\QZYQGC! (WJ* .?T;P5%ILOVMGEFEV[5>X?S&4<Y"\#&<_S QDYV-0
MT^/48VMYE#1N,$'_ #P1U!'(/(YJQ10!Q4WPHM[A1'++<.J+M0/*"$&5^Z-N
M!PN,8(QVR 1TM[HB7<\-XQ;?;>9M (VGS%VG/&>G3!'XUH44 9^KZ(FJ^5YA
M8>1,DJ[2!EDS@'(/'//0^]:%%% '-7_@.*XE>YBDF@:7&\6\GEJQ&?F(P>>?
MZ]22=+0_#L.BJPA!W2'+NQ+.[?WF8]2>3V&22 ,FM.B@#/T#1$T2!+.(L4CW
M8+D%OF8L<X '4^E9^J>"X[Z1KE))H9),;S!*4W[0 N0<CY0., =3G-=!10!B
M>'O"$'A]I'M@RB;9E2VY1L!QC//.23DGVP*SV^'<2,S037$"NVXQP2[(P2 "
M0NTXSC\.@P  .KHH Q+KPA!-:'2U#) <<(V6'S[^"^[J?7-;=%% !6#X9\&P
M>'&E:WW8F*DAB"!MW8 X!Q\W<D].:WJ* ,'PSX-@\.-*UONQ,5)#$$#;NP!P
M#CYNY)Z<U>LM$2TGFO%+;[GR]P)&T>6NT8XSTZY)_"M"B@#FH_ <4%PU]%)-
M&TD@=T23$;$'.&&"2"2<@GN0,#BM72-$32O-\LL?/F>5MQ!PSXR!@#CCCJ?>
MM"B@#/LM$2TGFO%+;[GR]P)&T>6NT8XSTZY)_"K5W:K=HT,@RDBE6&2,AA@C
M(YZ5-10!S_AKP:GA\_NI9F3:0$DD!C&2&)"A0 <]_<^M:&@:(FB0)9Q%BD>[
M!<@M\S%CG  ZGTK0HH Q[?PK!''/;L"\=U*\CA\'E\9 P!@# ([@\YS65#\-
MH0HBDFN)(0 /*DF/ED#[HPH7@<$8(P0*ZVB@ K'USPK#J[+*VY)D&%EB8I(H
M/4 CJ#R.0< G&,UL44 8.C^#H=.D^TEI)I@"!).YD=5/\(Z #KVSR1G!Q4%_
MX#BN)7N8I)H&EQO%O)Y:L1GYB,'GG^O4DGI:* ,S0_#L.BJPA!W2'+NQ+.[?
MWF8]2>3V&22 ,FGZ!HB:) EG$6*1[L%R"WS,6.< #J?2M"B@#/T#1$T2!+.(
ML4CW8+D%OF8L<X '4^E<IXST1-$T>2SB+%(]F"Y!;YIU8YP .I]*[NB@#E%^
M&UJK+S*88VW+ TA: '!YVMD]22>>22#P2*T-?\)1:RR3,SQRQYVR0MLDP005
MW8/'/X<XQDYVZ* .<T#P+!H<QNXVD:1T96,C!MVY]Y8\#YN .PP.1G).G9:(
MEI/->*6WW/E[@2-H\M=HQQGIUR3^%:%% &?_ &(GVG^T,MYGD^5C(V[=^_.,
M9SGWQCM7)-I*ZKK1G"@+9Q)YA*K\TC E.^<A2"&QP4QQP:[VB@ K!USPA'JT
MJW7F2Q2JFS=!)L)7.[:>#P#SQCWS@8WJ* ,GP_X:BT)66+<S2,6>20[I')).
M6; SC/'XGJ22WQ!X8CULQNSR1R0EBCPOL<;AAAG!X/&>,\=<$YV** ,30/"4
M6C,\RL\DLF-TDS;Y,  !=V!QQ^/&<X&*L?@.*"X:^BDFC:20.Z))B-B#G##!
M)!).03W(&!Q72T4 <U?^ XKB5[F*2:!I<;Q;R>6K$9^8C!YY_KU))TM#\.PZ
M*K"$'=(<N[$L[M_>9CU)Y/89)( R:TZ* .4;X<0!F*231Q2-EH8I=D)R &&T
M#.& P0#TX&!@#5;PU%OMY5W+]C5EC4'Y<,@3!R"3@#CGZYK6HH R8_#J0W3:
M@C.KR* ZAAY;[1A25()R!C!!'3W;)XL_X\[G_KWF_P#0&K6HH X+0_AY;WMK
M Q:58Y(HGDB24B)V*JQ9E.>3QT(Q@8P1FNJU+P_%?K"ARJV\L<B!, 9CR%7&
M#\O/08]B*TZ* ,37_"46LLDS,\<L>=LD+;),$$%=V#QS^'.,9.:^@>!8-#F-
MW&TC2.C*QD8-NW/O+'@?-P!V&!R,Y)Z.B@#/TC1$TKS?++'SYGE;<0<,^,@8
M XXXZGWHLM$2TGFO%+;[GR]P)&T>6NT8XSTZY)_"M"B@#/UW0HM<B-M.,JW0
MC[RGLP/8C_ZQR"0<*/X:P"5+J26>26)T96ED#D;"6"\K]TDY/?C@C)SUM% &
M)K?A./57%QOEBE"A?,@D*,5!)V'J,9.>F<@<U%HG@B#1IC>1%_,:,HQ=]VXE
M@S.<\[B1S@@>U=!10!GV6B):3S7BEM]SY>X$C:/+7:,<9Z=<D_A19:(EI/->
M*6WW/E[@2-H\M=HQQGIUR3^%:%% &?9:(EI/->*6WW/E[@2-H\M=HQQGIUR3
M^%9__"%0_8O[(W/Y7KE=_P#K/,Z[<=?;I^==!10!7U&R6_B>W?(65&4D=<,"
M#C.>>:SY_"\4T5O;DMMM'B9"",DQ#"[N.0>^,>V*V** .<U/P1'>S-=I-/"\
M@4/Y$NP-L&%)&#R!QZ>V22;NF^&(-.MSIZ+^Z96#9/S-N&&)(P<D=QC'08
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M>N%  SC'/%<OI(76-3GO0/EM(Q I*D@ON9G() P5R5(&<@YS@\]A10 4444
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M.*<8=/,#%ACD@$C(&3QSU))B\-?\@%O^O>Z_G)0!V'AZZ:[MH)I#EY(8V8X
MR60$G XZUH5YOJL/]GVFGZR@.ZU2 2%0N3$Z!6'S=3SA>>-Q/N-777.LZC!I
MP8".U N9,$9+*<(N-IP1D$C(RK>H!H [.N?\!:I)JME%<SMND??DX SB1@.
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M%H,1:*UC@>9U1V_>!I"OEEB=P7))/)R#C (! !W%%>>>*/"\7A*+^U=/S%)
M5W+N9TD5V52K!F/'.>/YX*WK[35\5WTMK<%OL]DL?[L,0KO*I;>2,$;1P!GW
M! + @'2^(;IK2VGFC.'CAD93@'!5"0<'CK1X>NFN[:":0Y>2&-F. ,ED!)P.
M.M85YX5AT"SO1;[@DL$AV%BR*1&P)7/.6[Y)S@=  *P=#3_A*TBTZ5_+AMH;
M<O"#^\F'EJP8L#@1Y*X R>[;6VX /2ZQ[:YNVNY(GC46@0%'!&\MA<@C<>.6
M_A'0<^NK#"L*A$ "J   ,  <  #H!7):1:K=WVIPR#*2+;*PR1D-"P(R.>E
M!I=Y>:[<2RI*L-O;7!B\L1J[/Y9^<EFP5W C&.GID9;J-1>1(G:$!I0C% >A
M8 [0>1P3[CZUP_P\\+6T4EQ<JG[RWO)XXSN;Y5   QG!X8\D$^]=5XL_X\[G
M_KWF_P#0&H J_P#"0R:59?;M03;(GWTBP<9DVKC+D=""?F]?I705YIXNTN.Y
MT:&Y=<R06\&PY(QO\H-P#@Y'J#[5VNA>%K;0=WV9-GF;=WS,V=N<?>)]3TH
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M.1AF$<L>&/)YY_QR<D]EX?\ "$6CM]H):2Y9-KS2.Q9NAZ$D < #N  ,GDD
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MN9U0\,5&&C*LJ[0>4RIP,=L"@#UVBL3P7<33V<+7(990I#!PP;Y6*@G=SD@
MDGJ3FL+QW8M-/$\\,EQ9;"#'"6WK+DD2%5*EAM^49.!D]"0& .XK/T#6TUN!
M+R(,$DW8#@!OE8J<X)'4>M8^@Z18:I:-;VY,EI(_W"[_ "D%25&2'4;ANP3U
M8GH16/\ "WPM;?9H-2V?Z1^\^?<W]YT^[G;]WCI^M 'H%%<%X>\/1>,(O[3O
MMTGG.YCC+L$B4,5VKM*Y)VC)P,X'&<DY^H:A)X(:YL[=BT/V;SHE;DQ-)*(L
M G.5!;=@CG@=2S, >FUS_P#:DG]I?8MW[K['YFW ^]YNW.<9Z<8SCVK,A^%=
MJ$!<R&XR&,XD82%]VXL,DJ#GV)QW+?-6?XLUQM$U%KE5!(L%&6^XNZX"AVQ\
MQ4$\A06/0#J0 >AT5S_A;PTFG[KQI//GN.6F('S*>5"@$@+C' .#QV"@5/BE
M_P @Z?\ [9_^C4H ZNBN7M?#T7A>*343NFN4@<O)([;GVC=CDL /E '!( ')
MYSQ5C%;WBB[GMKZ6YE"N9U0\,5&&C*LJ[0>4RIP,=L"@#UVBN"?4%ET^W34F
ME25R5\J/>LTVS<GEE>6(<8W<@$D<C(K,\/O'8:A!'9PW%M'.LHD2=2%?8A92
M-S,<@]3G@8 ZMD ]0KG_ ![JDFE64MS VV1-F#@'&9%!X((Z$]JRK[35\5WT
MMK<%OL]DL?[L,0KO*I;>2,$;1P!GW! + T?&7A6'0-.NA;[@DIA.PL612)$!
M*YYRW?).<#H !0!Z'17">(/ 4$-O+>NSM>1QM)Y^]E<N@W A0=J@8P !\JX
M.1FJ_B377N+6RMI!*WVV+=*;8+YK!8@Q4+C&&9@6QCY01C!H ]#HKR_3U2QG
M@;3[2[@W3*)1*DGE-&V5);YVY3.5/ ').>*N^++%3=M)J,,DUH47RGB+E8=H
M'F[U0K@'[Q8Y.  ,X(4 ]#K/U?6TTKRO,#'SYDB7: <,^<$Y(XXYZGVIGAM8
M5MXQ;.7AP=A+%L*22%R><+]T \@#!Y%<O\2M @NWM9I%R\EU#"QW,,QL7)7
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MKW?A"58;62 QK>6:1J'8$HRA-CH2!G:<D@XR.VTL376T4 ,A+%07 #8&0#D
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MZ!=M=IJ5D\080F)EF#;2-Q8<J">I]L8')!(KJZ* .7N(-51]\3V[*R1Y617
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M0',G\(('&"&YS@@$7?&.@2ZJD;VKK'<02!T=AVP0RY ) (/(P0V ",<CH**
M./U'P;*;2VAMF2*YM-A5P/ESMQ(,@9PY.3\IW8PPYR-"T\(1_8%TF4?+Y8#;
M&/WL[F8$\_?^89&.V,<5T%% ''VNGZO;J+;S;=D&5$KK(9MN<!BOW2P'8D@D
M?,3R3H76@2SW%G<LZM]E642,1M9B\87<% (&2,D9&.V:Z"B@#!\;:Q)I5J\L
M&/.8JD8(R2SL!A5_B;&2!STY!&16MIR2)$BS$-*$4.1T+ #<1P."?8?2I7A5
MR"0"5.02,X.",CT."1]"13Z .7UCPW<17']HZ>ZK+( LJ3%C$X485OER0R]!
MC'U'S!BS\/W5_-'=:@\9$!)2&!6\O=C D8OR6&3@8^4@$$<@]110!B:5HCVE
MW=7C%=ESY.T G</+0J<\8Z],$_A6W110!R5QX;N],GDN-.>/9<$M)%<%R@<G
MEUV\Y;N.GU&T++/X1EU.W:*[F)F:42H\0*B)PH"A!GE5P>N"<D\-\U=110!Q
M_P#9^KW2?9Y9;>-67#2Q+(9>G4 [5R>Y&,9)7! JWJ7A',5I:V^T):7$,AW<
M$K'G<?E7!9B<G@ G)S72T4 8GC/1'UNTDLXBH>39@N2%^5U8YP">@]*I>._#
M$VMK$]JXCGA<E7+NF%92' * \GCMT!YY.>HHH R=+\.1V-HNFGYHQ&4;J-V[
M.\]21N))X/&>*PK+1M3T9?LMM)!) A_=FX\SS O93L&,+T'MZ#"CLZ* .:U_
MPY/J=@]@TJR3MM_>.OEJ<2!^50-C &..M:^M033PNELXCF(^1BH8 @@X((/!
MZ9P<9S@XJ]10!QYT"_U:6%KYX5BMY!*%MP^YG7[N3(. .>G7ICH5?<>&[O3)
MY+C3GCV7!+217!<H')Y==O.6[CI]1M"];10!DZ%;W<>Z2\D1F?;A(DPB8R#A
MC\S;N"<]#D#BJ_A'P^VE6:6$^URH<,!\R$.[''S 9&#@Y%;U% 'F_P +=*VS
M7$ZL6AMRUO"V5(*>8TC?=')Y4@]#N.,]O2*J:7I<>E1K;0+MC3.!DG&22>22
M>I/>K= ''WF@7]I>37UD\)2X6/<LX?@HNT8V#/3W'4@C@&K&L>&[B*X_M'3W
M599 %E28L8G"C"M\N2&7H,8^H^8-U%% '+V?A^ZOYH[K4'C(@)*0P*WE[L8$
MC%^2PR<#'RD @CD'HKN-I49(VV.5(5L!MI(X;!X.#SCO4U% '#WGAW4M;C6R
MO)(! 2OF-"'\U@O./F7:"2 20!CTQ\IT-8\-W$5Q_:.GNJRR +*DQ8Q.%&%;
MY<D,O08Q]1\P;J** ,31+>^WF6\DBV[2HB@0[<Y!#EW^;/4;>F,'K5+2/"\M
MEIATMBIE,4RY!.S,A<CG ./F&>*ZBB@"CH=DUA;PV[X+11(I(Z950#C...*I
M?V(_V_\ M#*^7]E\K&3NW>9OSC&,8]\Y[5MT4 8G]B/]O_M#*^7]E\K&3NW>
M9OSC&,8]\Y[5MT44 <?I>@7^D7$K1/"UM/<&5@X<2 .<OMVC&<<#)(. <#)%
M:NE:(]I=W5XQ79<^3M )W#RT*G/&.O3!/X5MT4 <_=^&C=WC74FTP269@9<D
M,2S[CT'3'&<YS^=9EEHVIZ,OV6VD@D@0_NS<>9Y@7LIV#&%Z#V]!A1V=% %3
M2[>2VC6.>3S9!G+[ F<DD?*.!@8'X9K,UR"_\U9;)XO+V8:.=6QNSD.&0;B2
M.,$@#&<$GC>HH Y_PMH$M@TUW=.K7%RRE_+&(U" A%7(!. >2?8<D%CG^#M
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M4K-(02/FZA0"-HVKGJ2#P38T>_U/Q3!]LBDCMEP0@""3S"!ABQ;.Q=X., D
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M08Q]P+@\DG.,#G=M9J?B1]0GDBAO(;6*!F0E]C2.XV[CMDV@*"2H(/)!Z@C
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M'#)N!+@J,["?O%1DD$FF:WY[:L([7:'>Q"EVY$:^<27V_P 1&,*O3)!/R@T
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M%2V-Q/08P,FN]H S](UM-5\WRPP\B9XFW #+)C)&">.>.A]JT*Y3P!_R^?\
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MD X)Q6?X _Y?/^PA<?\ LM1>-[86\]E?)Q*+I(L@#E)<A@<C/3..>-Q(Y.0
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MJ: .SMO%$5Q=R:6 WFQ(&)(&S!"G@YSGYQV'>MBN?T;5)+F]O+9VS'!]GV#
M&-\9+<@9.3ZD^U86E7>I:Y+<Q),L4,-S(JR>4KO\IP(]I(&T#!+$;LX )YP
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M[(R6!V;>AP"<=BJKFWX>TV6.POXVA:)Y)+HK$%[-& JK@ ,,\ J,''%>@44
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M'4EY8(X BY&7#'.67@A1R>2#Q7<444 >?Z'KCZ"]U%);7+^9>32*T4)92K$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWG"KY:\JQ)4;2>K8)X)JE#XTG@"RWEHT$+E!YGFH^TN0 77Y2B\\D]#@$9-
M'6T45B>)?$O]C^7%'&TL\[$1QJ<9QC<2V"%"@\G^F2 #;JII>J1ZK&MS VZ-
M\X.",X)!X(!Z@]JS-#UVXO)6M[FV: A-RMO$B'G!&Y0 &[@<G&3QQG(\!:DN
MFZ3%.X8A=_"*68EIF55 '4L2 /<\X% ':T5R4/C2> ++>6C00N4'F>:C[2Y
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MLK8SI"YC=S,D7SK]Y0K#) R.>A.<<<GHK2X^THLN&7>H.UQAAD9P1V([CUH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M//- '*>%[*SANRT-U)<3^00=\HE 3>/X@N 0W;=GG..<UN^+/^/.Y_Z]YO\
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex19-1_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex19-1_008.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD2/=G'F.JYQC.,D9QD5;KS3X;:5%XB$^JW:+)+),RX<;T4 *V%5L^N!G.%
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M:$=9T%(T&Z1-[H.<Y65\@!<Y)4L ,=2/J+OB;Q1_:^GV\,; 3:B4CR-R*#N
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MW[;(98W8#)".K''3. 3QS7 >*-'CO=8M;,Y6(VV"(SL^51-\G'12!M(&/E)
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M[75RV/-$47GE=@"C[QP.H!V]QAN<4 =K:W:7:B6)E=#G#(0RG!P<$<=:J_\
M"0VVSS_.B\O=MW>8FW=C.W=G&<<XZXKA_A&X$M[$@9(EE4I&^<IDR#!!)PV
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M_1IK^R3B*&X^1>N,LZGD\GA%')/3W-=+XTTV74[.:WMSB1U&/FVY 8%ES_M
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M1MS][^[NV\=<_P"UN^:NUHH X^\\!^5IK:3;E=[;27<;0S!U9B=H)Z# ZD
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M\$(E$"[W+)O;KMVJH)7.['&3G'0C8\6^$FU=H[NWD\FY@SL? (((^ZW?&?J
M"P*G-=+10!P^I^%]0\1@6][+%' #EA;!RSX(P#OZ <D'D X)4X&+OB?PB^I3
M64L&Q8[.3)4Y7Y0T9 4!2. AXX'2NKHH Y+Q)X3GEN4U2P=8YP KA\A'4>NT
M$D] <]@I!4J,Y^H>"[W5+BVOIY8RT,H9D4L(U564@("I)9L$L6(YP.BUWM%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%<_P"/+B2"SF\J/S-T<BM\X7:I1MS\]<?W1R:
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MMC91DID2,H!R02.&ST]JS_#'C&?Q 5D2U9;=L@RM(O!"Y.$P"PW?*"/J<$$
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M1N^,XSM4G&<'&<>E<E8?$2;5(1<6MHTNT-Y@$@4*03A5)7,C%1N(4<94<DT
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MB1&B#)8C'?L,D#C)YX4\UE7/C^7264ZA:M!$YP'619@#QU"@8&,GN3@X4\X
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MB%XLET3R8(-BO<LR^9*?E0#:-WIP6!R<@ '*G/'0:WH$&MH(;E=Z!@P&YEY
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MGH>*J:-X+L]&;S8(E5_[Q+.PX(X+DD9!.<8SWH YK6?^0]:_]>[?RGH^(_\
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M>&_])AUB]3F*;SMC=,X65CP>1PZGD#K[&NPNOAOI]TQD:!03C[C.B\#'"HP
M_ >_6MHZ5%Y1M BK$RLI1!M7#9W ;<8SD]* .?\ A;_R#H/^VG_HUZROAQ_Q
M^:E_U\?^SS5VNEZ7'I4:VT"[8TS@9)QDDGDDGJ3WJ+3= @TUY9H5VO.VZ0[F
M.3DG."2!RQZ8H X_1O\ D/77_7NO\H*-&_Y#UU_U[K_*"NPAT""&=[]5Q/(N
MUFW-R!MXQG ^Z.@[40Z!!#.]^JXGD7:S;FY V\8S@?='0=J ./MM?O/$EW/9
MP3);):LPX199'PVW.'XP""<C&-P!W9R*_P )R3<7Y+B0^:F7  #_ #2_, .,
M-UXX]*ZK6/ UGK$GVB>(-(0 2&=<XZ9VL,GMD\XP.@%6](\-V^CL[VZ!#*06
MP3@XSC )( &3P !0!Q^DS*FO7() +0* "<9.V$X'J< GZ FGZS_R'K7_ *]V
M_E/74:YX1M=<97N8P[(, Y93CKC*D9'IGIDXZFG1>%K:*2*Y5/WEO&(XSN;Y
M5 ( QG!X8\D$^] ')>!IEL-1O[64A9990Z*3]Y<N_!'&=K@XZXSQP<'CF9;_
M %&PM8B&EBE+NH/W5RC\D\9VH3CKC''(SUNM^%;76\&YC5R,8;E6P,\;E(..
M3QG&><9HT3PK:Z)DVT:H3G+<LV#CC<Q)QP.,XSSC- '*Z-_R'KK_ *]U_E!1
MK/\ R'K7_KW;^4]=A#H$$,[WZKB>1=K-N;D#;QC.!]T=!VHFT"":=+]ES/&N
MU6W-P#NXQG!^\>H[T $.OP33O8*V9XUW,NUN =O.<8/WAT/>M"L^'0((9WOU
M7$\B[6;<W(&WC&<#[HZ#M6A0!Y_HW_(>NO\ KW7^4%6/B9JBW4/]DP8DN;AT
M7RU/S*%(DW$=AP/O$<$MG"FMC5/ 5EJLC7,\6Z1\9.^09P !P& Z =JM:)X5
MM=$R;:-4)SEN6;!QQN8DXX'&<9YQF@#BO&-C_9\VD6V=WE2*F<8SM:$9QDXS
MCUJWHW_(>NO^O=?Y05V&I:!!J3Q33+N>!MT9W,,'(.< @'E1US1#H$$,[WZK
MB>1=K-N;D#;QC.!]T=!VH XKXMV_SV=PY9(DF(>1#AEW%"",9.0$8@@'!'TS
M=O\ P-;S0EY[VX,#!23)<J8R"05.67:03C'OC%=E=6B7:F*55=#C*N RG!R,
M@\=:P+7X;Z?:L)%@4D9^^SNO(QRKL0?Q'OUH YG6K=/#VIV$DAVVZ6_E*[D=
M45UYQT^^N3@#G/0''H<^H1V[I"[ /*6"+W.U2S<>@ Y/3H.I&8=8T6'6(_(N
M$#ID'!R,$=""""#]#TR.A-4M&\%V>C-YL$2J_P#>)9V'!'!<DC()SC&>] '+
MZ3,J:]<@D M H )QD[83@>IP"?H":+>9=-UV4S$*+F!1&2?O']V /8DHP&<9
M(P.HSU>N>$;77&5[F,.R# .64XZXRI&1Z9Z9..IIU]X5M;Z)+66-6CC4*@.=
MR@8X#9W#[HS@\XYS0!R7QAF6ZB@T]"#/+.A5,\D$,@// !9@!DC/..AP_P"(
M_P#Q^:;_ -?'_L\-=+HW@NST9O-@B57_ +Q+.PX(X+DD9!.<8SWJWJ6@0:D\
M4TR[G@;=&=S#!R#G (!Y4=<T 5/%NBV^LQ+;73;%:1=A#A6W\@ 9R"2"1C!]
MAG!'*C5;OPE<V^GRSK=1W+*/G&V5-S[<YRQ();@L3G:5&W&:[?6-%AUB/R+A
M Z9!P<C!'0@@@@_0],CH35+1O!=GHS>;!$JO_>)9V'!'!<DC()SC&>] &W7F
M^@>(+SQ8LMVES':Q0G&P1I(0.6WL7(P,<;N =IX&.?2*Y^Z\ V-W*;IX5,C,
M&)RVTGU*@[3GOD<\YSDT <_\%/\ CSD_Z^&_] CH^"G_ !YR?]?#?^@1UV&B
M:!!HB&&V78A8L1N9N2 ,Y8D] *-$T"#1$,-LNQ"Q8C<S<D 9RQ)Z 4 >?^&;
M5KM]9AC&7D:15&0,EC. ,GCK6W\*]5B;3U3>H,&_S,G&T%V<$Y[8YSTZ\Y!Q
MTNFZ!!IKRS0KM>=MTAW,<G).<$D#ECTQ6?=> ;&[E-T\*F1F#$Y;:3ZE0=IS
MWR.><YR: .:^%MTMW<ZA-&<I),K*<$9#/*0<'GI7HM9^FZ!!IKRS0KM>=MTA
MW,<G).<$D#ECTQ6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP<$9P2#P0#U![5;H **S]-U^#4GEAA;<\#;9!M88.2,9( /*GIFM"@ HHHH
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MD '&& /0BJ^B:W+J$L\4D#1+"^U';.)!EAN&57CY0>">HY]0#8HHHH ****
M"BBB@ HHHH **** "BBN7^'GBB7Q);M<3!0RRE0$! P%4]RW/S4 =11110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %8/C7Q,/#ELUR "Y(5 <X+'UQV !/;.,9!(K>KDOB?H,
MFLV96$$O$ZR!0,EL J0.1SAB>Y., 9- &#=Z[=6T;7?]HVS2)E_(01E" <[
M^=YRO XSGC/\5:&H^+YC;6^N0EA;[@)X2J-\NXHS!OE;(;@<X/RD@ ,#5M?$
MND2* ]NBW'(,'V;=)O!QL&$P23P,D=LX.0+OBC4<P1:191B.6^0X0A8_+0C=
M(63G!(W# &<[B#N ! +%IXE?Q#>+%9/BU@4-,XV'>9%W(@#*Q&,8;[I'S X(
M7-?Q1XOD%U_9=O-%!M16DFF[993M4-\I;:<\Y!!QE2,U4T5#X&NQIS$FTNSF
M%CAG$N$4ABH7 / Z$<KR/GJOXDL4T;4FU&[A\ZTGC4,QC#K$PV)DCYO[HYX)
M#$+DC! +%GXODTJZBMI;F.\BN2%#1"-7C?< ,A"1M.X=3GJ1]W#6YM>N_$%W
M+8V+K##;$"24H'<M@C:%; QN!'3^$G=R%,NBZEI>HS(EG KL#DR1VP58RH+*
M69E7:3@[<9Y':L>TU)?!.H7(NPPAO6\Q)0I*Y!9BN%R>"Y7UX!*X;( .FDFO
M-,MKGSW5VAA=XYE55+'8QPT?(!0@>H8$=PU2^ M4DU6RBN9VW2/OR< 9Q(P'
M  '0#M42ZP/%<-S!;*WEM"525U94=I%=3C*YPA !/7.>. 3R_@KQO%I5FMB4
MD:[A,@$"QMO8[V;L#@#/S9Y&#\IXR :7@/5KOQ)8R.TVV?SBJR>6AV@!&QLP
MH.<D<^OM6+\)-.N9X3+%<>7$MQ\T7E*V["H6^<G(R...G6M7X*?\><G_ %\-
M_P"@1UG_  SUR/P^'TF[W1W!N!A2I()<*H *Y'4=3@$$$$CH :>B:W>:JVI0
M+(=]NY$&%C&"&DVKRN"#M .[MW!YK8\(>+5U2Q%]*<&)6$IP>#&,LV HZC#8
M4<9P.16)\./^/S4O^OC_ -GFKG_$KRZ7<W.CQ[L:E)$T;-)@*9'^<X4'ACE#
MT.T#.X8R ;MGXZGL],;5;@J\DTK"%0"%'.T*<#HNUFY.2 !NR>*]WKMU;1M=
M_P!HVS2)E_(01E" <[ ^=YRO XSGC/\ %6Q\1/"[7M@+:V4_Z.49$'S$JBE-
MHR<Y"G/<G&,$FLVU\2Z1(H#VZ+<<@P?9MTF\'&P83!)/ R1VS@Y  .R\-ZXN
MNV\=XJE1(#\IYP5)4C/<9!P>,CL.E8OC#Q-/;31:79!3<W 8Y?.$7!^;T)X)
M[XVXVG(KHM*1$B3RH_*0J"$VA"N[YB"HX!R>1ZYKC?&]O)I5[;ZVJ-+%$C)(
M$&2HP_S_ $PY/( &W!8;A@ -=N]2\*H+UYENH5($BM$L1 +  @J>2>G?&0=I
M[9GQ@9KNVANXY<V\C1[8]@&2R.PDW'YON\;<>_6K'C+Q?%XF@.FZ>&GEF*YV
MHRA KJ=Q+ <$X&>@Y)(X!9\5;'^S]-M[;.[RI(DSC&=L3C.,G&<>M &MK^C7
ML-G<>9>;_P!VS'_1XURJH^].#_'D?-U7''6L3P=!=VFF_;H[G$4<-PRQ>2AP
M5\S!WGG[WS=/;I7=>+/^/.Y_Z]YO_0&KE?#7_(!;_KWNOYR4 /MO'4ECI*:E
M,0\[EE7(P"V]P,A !@*N>V<8R"<U=M;+58U%V\R,_+&V\M53!/\ JQ,.00.A
M.1NP"2N2>7709-9T*%802\3O(% R6Q)(I Y'.&)[DXP!DUT=K\5;:[B#1*[W
M)4X@1&9RPZ@,%QCOGKMYQGY: &>*/%\@NO[+MYHH-J*TDTW;+*=JAOE+;3GG
M((.,J1FJEGXODTJZBMI;F.\BN2%#1"-7C?< ,A"1M.X=3GJ1]W#5_$EBFC:D
MVHW</G6D\:AF,8=8F&Q,D?-_='/!(8A<D8.QHNI:7J,R)9P*[ Y,D=L%6,J"
MREF95VDX.W&>1VH S=0UK4+S4Y=,M9%2-50Y9$.Q=L;,PR,L23@ Y'S=OO+8
M\9>(+KP]%;V8E5I[AV!N)%5%4!EY*X*@88 GG !.,G(9HW_(>NO^O=?Y05N^
M,]4M+14AOT+0REAN*%D4A>,D?,K$$[2HSU/&": )?#]I=0MOFN5N(9$R"(UC
M(/!4J4)#*P)SGT7'4UO5Y?X0Q_: _LOS?[/VMYF[=Y6_9_#OYSG9_M]?X*]%
MU;S/)D\C_6^6^SI][:=OWN.N.O'K0!R6MVNJV\$EZ;J-&C1F,4<(,>$&3AW!
M;) SR/O<<#FB_P#&$T^D'58\1S$+T 8 B81L0&!X//!SC/4XS7"6SV,]K,;L
M2R:D!*"'\TN"JX4\'&U ,MOY&UN, "M[_F7/\_\ /U0!TO@U=0OUBOKJ=1&Z
M@^2L:?,I3"L7'()/S$#([<9VC'C\92Z_([17<%I!&[*FX*TKXVX8K+MPIY(Q
M@C[I!QFNR\)_\>=M_P!>\/\ Z M>=>'XK3PHTMCJD*_ZQC%/)#O5U 48&%8C
MC#8!(&2#@CD ZCP7XM>\GETR9UF>(%EGBV['0E>H7@,-P'&1U'49;;\7:XVA
MVLEXBAF0# /3+,%!..PSG'&>F1UJIX5N+.]9Y;* (J@ 2B 1*X;.0IP"0I7#
M9 P<=:T]?U!-/@DGE1I(U7YE50Q*GAOE) ( .6SQC- '+^$3?ZC'%>F\CE!*
M[XA$F #@LI=,$.JG.,<-@'CFK&IZ_/#JUO8*V()(2S+M7D@2\YQD?='0]JXS
M5Y;:65'T#S/M3.2_DAU3:2/O!P %W;>,; ,[N-M=!XTE&BZG:ZK-GR C1DJ"
M=IP_)XZ?/D8R2%; XY -/QKK\^FW-C#"VU)YML@VJ<C?&,9()'#'IBL3Q;)+
M'K-L;=5:7[.0H<X7)\X;B>N%!W$#D@8')JEXI\2IKE]8&%6\E)UVRLK*KDR1
M[@NX#(7&"?4D8X!-OQEJ+:=K-M.L;2E8/N1C+D$R@D#N0"3COCJ.M %W5-6O
MO"4L4UW,L]I(P1R8UC9"><X0$G !/?."" =IK0\:Z_/IMS8PPMM2>;;(-JG(
MWQC&2"1PQZ8KG_%^N1^.&ATJQW/F02/(%(5% *DX;:3@-GL.B@DMQH?$?_C\
MTW_KX_\ 9X: #4_&$FH74MG!<0VL5NP5I)<&1FPVX*LF%(##![\!@Q!Q4OAS
MQ<\=Y_9<TR70E7='-$$&"%)9&"<#[I(P2>F>&^7':U@\-7UPVHPA[>Y?>DSQ
M!T4MN<IC#8)R1QS\H.W:<CJ/#5[I^H2YLH%^12?.2W"(#P"@<JIW8;.,?=/6
M@#-TS6;WQ=))):2K;VL3LJN(Q([D8ZJ^,#'/1<;@/F()%WQ#;WDMA/'+(J/$
MLFYU16$T8C)^Z?\ 5ELX;'0J2ORD5S_A#7(_ [3:5?;DQ(9$D*DJZD!0<+N(
MR%SW'5205YZU]1;Q)9W/DQL Z2I%O&SS T8VN-V,*Q; )[#)QR  87PMTZY^
MS03_ &C_ $?]Y^Y\I?[SC_69W?>^;].E=U=QM*C)&VQRI"M@-M)'#8/!P><=
MZX7X8>)H(X(])<LMRC2J49&!R&9SSC P,@@X.01CIGT"@#R3P5I5W<7-\D-U
MY;I-B1O)1]YWR?-@G"\@G ]?:NCFUZ[\07<MC8NL,-L0))2@=RV"-H5L#&X$
M=/X2=W(4X^A:Y'X4O[U+[=']HD\Q&*EE*[W(/RY/(;TQP02",58L[P>"KZZ:
MZ5A;W;AUF"DH"=[["%W<_,1Z_*#MVG( -"'7KOP_=Q6-\ZS0W)(CE"!'#8 V
ME5R,;B!T_B!W<%1W%>;WEX/&M]:M:JQM[1R[3%2$)&Q]@#;>?E ]?F)V[1D^
MD4 >7Z>+OX>N\7E-/9.S.&CY9 " 68A0,[ ,@X4G[K##5V#>-H&LFU6,[D1?
MNGAMW $9P#@DD#/(YW<KS5*;XE6]BI6[62"90<Q.A)./[C ;64D$*Q(!QG@5
MR^B>#9[ZTOF,?D_:V5HHB,,/+=G"X.T*"2%!./7&,9 +5MKMUJ,?VEM1MH'=
M05B41E1E00&9R64Y^\,-CMGH+R?$\-IQU(H!,'\H*<[#)@'(QD[=IW8..A7/
M1CF:#KNEVD*07T"0W$2JKK+;[F)"C#Y$9/S#GGG.>HP3H>+M &M:;FS@:$K)
MYOD^4(W)7<ARH/7'S#J2  !DB@#0M;+58U%V\R,_+&V\M53!/^K$PY! Z$Y&
M[ )*Y)Y_XE64YOK,B; DF B'EK^Z(,0+9_CR?FP>F,=*V[7XJVUW$&B5WN2I
MQ B,SEAU 8+C'?/7;SC/RU4^*:M;26>H;6:*VFW2%<$@%HR.,CKM(!Z9P"1D
M4 'C74KWPQ9K)]H\R5K@#?Y4:_*48[=N&'5<YZ]JT_&'B:>VFBTNR"FYN QR
M^<(N#\WH3P3WQMQM.17.?%#7X-;L$FMFWH+I5)VLO(C<XPP!Z$5I^-[>32KV
MWUM4:6*)&20(,E1A_G^F')Y  VX+#<, !KMWJ7A5!>O,MU"I D5HEB(!8 $%
M3R3T[XR#M/:Q\1?%,FGV<5[9OM\V1,-M!RK(S#AP<9P#TS69XR\7Q>)H#ING
MAIY9BN=J,H0*ZG<2P'!.!GH.22. 6?%6Q_L_3;>VSN\J2),XQG;$XSC)QG'K
M0!8\0W>JZ3;_ -J/-&"I0O;K$"@!(7&\EF)R1NY'4[6X&>[TZ]6_B2X3(65%
M8 ]<, 1G&>>:YSXI?\@Z?_MG_P"C4K5\)_\ 'G;?]>\/_H"T :'V1-_G[5\S
M;MW8&[;G.W=UQGG'3-<+\%/^/.3_ *^&_P#0(ZZ76_&=IHCB&YDV.5# ;';@
MDC.54CJ#7"_"3Q3;:?";*5]LLMQ\J[6.=RHJ\@$#)&.30!=\9W9.KV<3HTJ1
MIO5(P-V\E\-DE> 44G)V@*2>,YV'\=3:<Z+?VK01RL%602I(H8D?>(P%&,G)
M.< X!P<4O&]O)I5[;ZVJ-+%$C)($&2HP_P _TPY/( &W!8;AC/\ %NKIXY,6
MG6(9U$JM)*$8(@PR\A@O."3R1G  R3P >FUP6F:S>^+I))+25;>UB=E5Q&)'
M<C'57Q@8YZ+C<!\Q!([VO,O"6KIX&,NG7P9%,K-'*48HXPJ\!0W. #P3C)!P
M1R ;6A>(KFSO#H]^5=F0M%*HVEQDGE1P#@'^[C:1\V03R^F:5=OJUQ"MUMG6
M$%I?)0[AB+Y=F<#J.1Z>];&D,WBC5%U6-&6VMXF5'9<"0Y=>,XX^9O7&T;L%
ML!^C?\AZZ_Z]U_E!0!W5I&T2*DC;W"@,V NX@<M@<#)YQVKS#7M.N6UF&-;C
M$CQNT;^4I\M?WI";<X; !&X\\Y[5ZK7G7C.X_L;5+74Y@PMQ&8RX&0&/F#!
MYX# ^I .T$@B@"IX^CGLI=-#M]HG29SG"Q;SYD95<#(7LN?Q-7?$.JZAX6,-
M]<3K)"\H62)(E7;N!)"'[S  '!)!R%SG)Q7\9ZI'JMQI=S VZ-[AL'!&<2Q
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M^=% H92I&-@5"<XVD$XQSG!Y Y  +OCRWDGLYO*D\O;'(S?(&W*$;<G/3/\
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M!D=N,[12\8"(Z1,\,)@5RA,;1B)@1,BY*CN<?EBNG\)_\>=M_P!>\/\ Z M
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MK32Z=OC1[9V66XV!C]XA0J?*I)*L,D8V^C#YK'P4_P"/.3_KX;_T".CX<?\
M'YJ7_7Q_[/-0!H?#[Q'/J1N+.[VM+:2;2Z\!LEAT  X*G!P,C&1D$G'C\92Z
M_([17<%I!&[*FX*TKXVX8K+MPIY(Q@C[I!QFK'PX_P"/S4O^OC_V>:L3P_%:
M>%&EL=4A7_6,8IY(=ZNH"C PK$<8; ) R0<$<@'4>"_%KWD\NF3.LSQ LL\6
MW8Z$KU"\!AN XR.HZC+='XANFM+:>:,X>.&1E. <%4)!P>.M9GA6XL[UGELH
M BJ !*(!$KALY"G )"E<-D#!QUK5URR:_MYK=,!I8G4$],LI SC/'- &;X"U
M235;**YG;=(^_)P!G$C <  = .U<_P"$/%-SJ&FW-[*^Z6+SMK;5&-L2LO
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MVUVZU&/[2VHVT#NH*Q*(RHRH(#,Y+*<_>&&QVST%N;Q])J&E2:C%^[GB94.
M&7=N3) ;/!#=^1TYQDY^@Z[I=I"D%] D-Q$JJZRV^YB0HP^1&3\PYYYSGJ,$
MZ?C 1'2)GAA,"N4)C:,1,")D7)4=SC\L4 7?!JZA?K%?74ZB-U!\E8T^92F%
M8N.02?F(&1VXSM'85D^$_P#CSMO^O>'_ - 6M:@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "N$U;1;SQ!?P221K#;V<A9
M7+J[/AU(X!R-P4<$?+R22<"N[HH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG[YR 5/%>GZ)-#+!&;8@P[%"$$GY5& .><C&#GD'@\T 6YIEA4NY 50223@
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M3]FN1DG/"^8 /H  !Z#BF?"OPO;BTCO616ED9FW. Q4H[*NW(^7&,Y'.>_
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MU:&?($5^GEN,L<NF C8' /**#T +9 SFLRTG&N)J>KCE##)#%EF)"I&2W!
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M ((.00>001U!I]<9\.=*NM,$\5PABA+AH8S(LFT,6+*&!)P/EZ]3DXR379T
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M^8N1@+G( R">O(!J+PEX7ET>XN[B0J5NI=R!220-SGG('/S#IGO7444 <O\
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M1,<'YLISG.#TSDL=V"5.KHEO?;S+>21;=I410(=N<@AR[_-GJ-O3&#UK;HH
MXJ[T;5KN-K*2:W,<F5:78PE*,>?E V9V\8_\>S\U=%X;T-="MX[-6+",'YCQ
MDL2Q..PR3@<X'<]:TZ* .:\6^$FU=H[NWD\FY@SL? (((^ZW?&?J "P*G-%I
M;ZI.Z^?);QQJP8^0CLS 'E#YG !&?F'(.,=ZZ6B@#G_&_AU]>@$4+;)8Y$DC
M;<5 9>,D@$]"<8YSCFG>"] ;0[<0RD-,[N\C!F;<S'[V6P<[0,\#D9]SO44
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MA'9F /*'S. ",_,.0<8[UT4,*PJ$0 *H   P !P  .@%/H Y?4/"\MQJ<&J
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M/W=P!&#WP03TY'7G&#S7B+PAJGB&%;>>2W_=LI^0.-QVD%F.W@CL% !W'.,
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M2-(TIR75RY().\<Y7 /'//7.3CZ9X7U#PX#;V4L4D!.5%R'#)DG(&SJ#P2>
M3DA1DY[BB@#/T2WG@0_:I%DD9BWR)M500/D'<@'.&/)'6M"BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]=\-C(Z@X)1V89ZXR(CSS79>+/\ CSN?^O>;_P! :N5^"G_'G)_U\-_Z!'0
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MCN,\XXYR.SKBO"'Q0B\02"U9&CE;=M&=ZD*,_>P"#C)Y&,#KDXKM: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[N<'&XY5<98A<-T&!Z[110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"62VLU?")%\LK[007,G89/0;EX(QE=QW=+\/SZ5(NRX>6 YWI<?.X)!PRR
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M "/.B\S=MV^8F[=G&W;G.<\8ZYH T***YS7]<M[^TN4AEC=A;3$A'5CC81G
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M+*RH@QEG(51DX&2>.M $U%5[+48K]=\+JZ@X)1@PSUQD$\\UPGP:F6&QE=R
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M?"=[H]U/=6#Q&.Y.YEN-W#%B>-@Z#)QR.#@@D!JT-/\ "\MOJ<^J$KY4L04
M$[\@1CD8QCY#W/:@ \6-I^E0(EVBB)'W1Q*N,LH)X1< CDYW?)D_-UKA]6NH
MOM]C);6TMJQF56WQ>2&!=!@!3@\,0WJ" <C&.X\<>$Y-<$4]NX2>V?<A;[G)
M4G/!Y&T$<$=B.<C*U#PGJ&KW%M=W+P8MI0VR/>!@,K$@L"2S8Q@X P,=3@ A
M\:1#6M3M=*FSY!1I"%)&XX?@\]/DP,8(#-@\\=7_ ,(C:HZRI$J%0X(C555U
M=<,CJ!AEZ'!Z$#'<'/\ &7A.35FCN[5Q%=0'Y6/0@]58@$X'.!R.6!&&R)=.
MLM0GE26[DB6.(D[+</\ /N5E^8N1@+G( R">O(!H Y7P#H=O=7>H))%&RQSX
M0,BL%&^48 (X' Z>@JQ=6J^(M9:VN1NBM(0R)D[23L)+ Y!Y?G&,A5!R 0;J
M^$[W1[J>ZL'B,=R=S+<;N&+$\;!T&3CD<'!!(#5=\0>$I9;A=4L9%CN%4*RN
M/W<@R.&*\]..AZ+C:0#0!S_Q)TJ+PZ(-5M$6.6.95P@V(P(9L,JX],'&,J2#
MGC#?&6CQZQK-M:S9,;09(!QG:96QGT.,''..A!YK8E\)7>NRQR:E)%Y4+!A#
M &*.1GEO,_ ?Q97(&W))NZAX7EN-3@U0%?*BB*D$G?DB0<#&,?..X[T =!9:
M=%8+LA144G)"*%&>F< #GBK%%% !7G5QJ6ES/-'#:O=%V9I'AA\W#.2#AV((
MS@D%?E[J<YKT6N"T;P??^'C);6<L7V:1\AI58RID %@  I8#'4[3M!PN2* *
MGPN66\TR>&-R'WRK&2Q&TM&I&",D ,<\=\GK65H4=MH$1LM6LRF209V3S%)8
M$XWJ"5(4 #83SD_*0378>!_"<^@6DEH[J)7=V5TRX7<BJ#A@N2",XZ&J.I>'
M-4UR(6-U+;K$=N]XE=I&V\CA@J\L 3C;[<<$ [B&99E#H058 @@Y!!Y!!'4&
MN"UG_D/6O_7NW\IZ[C3K);")+=,E8D503UPH &<8YXKG/%?A::\G@U*S9%N(
M,J?-W;64YXXSZL. "0Q^8$"@#*^(_P#Q^:;_ -?'_L\-95UI[:%>W%Y?6K7,
M,S,RR "4(@RW*-P,#:N6V[0IVDC.=6_\%7^IW-O?W$L1\F16:--ZHH5P?DR"
M6+ 9);'.!D@#&K>VNK*TJP26[1NS%&E5A(@8<+A05.WL3NSU/H #G_&VNP1:
M7C3BODRS&,[-R[0V^1U X*Y(Z$8VM@#!%17?AZ66!K2/2D3*D*_VB)G4GD-N
M/S'![;N1\O3BMVT^&<4-B^ELY8NY?S-H^5^ "%YP,  \Y(+<C/#[73]7MU%M
MYMNR#*B5UD,VW. Q7[I8#L202/F)Y) ,+Q=?7>F:/'%<DB>1_+D)8%MN7(^9
M3@DJH!)SD$YY.:U?$?P_L[:PD1(P&@B9UD&/,+(I;YFQR#W'3'0# QNZYX9&
MMVGV*=LOM7]YM .]?XPO09.<@$<$@$9S7/GPWJE[;FPN9XMGEL-\9<RN<$*K
ML5QMSC<0-S 8.=Q- &A\+?\ D'0?]M/_ $:]97QK_P"/./\ Z^%_] DKI?!F
MB/HEI'9RE2\>_)0DK\SLPQD ]#Z52^(?A>7Q);K;PE0RRAB7) P%8=@W/S4
M8GQ \)6UAITCJ@,L90^:W,K,T@#,S]6)W'.>/0# Q2\;:O+>6^G0,/,^U^6T
MBAO+,A C^3(( #%_3@@$8Q7:^,]$?6[22SB*AY-F"Y(7Y75CG )Z#TK/U+P/
M_:5I;VC/Y<]LL6V5!DAD4 X/RG!QG@J<A3VQ0!R^K^'[BZA$-OIJP2(4*2I<
M1;U*$<Y&UF./5NOS=0*/B%9/?MIEO=9$DIVRD;<[F\D/C&5SDGIQ^%=-#9ZO
M*HADEMT& #+&CO)QWVL A)(YX  )('2I?%OA>76+BTN(RH6UEW.&)!(W(>,
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M^U7""66Y,A=I/F;AV7@GE3W)!W$G.>!C8\,>$7TV:]EGV-'>29"C+?*6D)#
MJ!R'''(ZUGZ3X4U'0M]I:S1&V9OD,P9I(PW4JH 4D9S@G:2,X7<10!B^ _\
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M* "BJZ:C$\AMPZF51DH&!<#CDKG('(_,58H R;KPZEU=1:@S/O@5@JAAY?S
M@G;C.2#U!'0>E:U%8^N>+K70V5+F0(SC(&&8XZ9PH.!Z9ZX..AH V**AM+I;
MM%FC.4D4,IP1D,,@X//2IJ "BBB@ HHHH **** "BBF33+"I=R J@DDG  ')
M))Z 4 /HJ&UNTNU$L3*Z'.&0AE.#@X(XZU-0 4444 %%%% %?4;);^)[=\A9
M4921UPP(.,YYYJOH&B)HD"6<18I'NP7(+?,Q8YP .I]*T** "BJ[ZC$D@MRZ
MB5AD(6 <CGD+G)'!_(U8H **S]2U^#37BAF;:\[;8QM8Y.0,9 ('+#KBM"@
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M_P @%O\ KWNOYR4 :"_$^WDC$\<<T@VEG$<88Q@$@%R&PN=I(YZ#)P,5;O\
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MW2X+Q5*B2<?*><%5E4C/<9!P>,CL.E '37OQ,MK-LLDIA+[1.L>8">AP^?F
MP>@.<'&:W]8UJ'1X_/N'")D#)R<D]   23]!T!/0&L#XF0K#IDR( %41  #
M $B   = *Y?Q)_J='\S_ (]_W/F;O]7]V+&[/R_=W=>V[MF@#I5^)T"A9)8K
MB**3I)+#B/D%ARI8G('& ?7IS6KXB\70Z#"MY)N>.1E"F+:V=RE@>6 Q@=<^
ME'C;9]AN/,V[?)?&[&-V/DZ]]V-O?.,<UYKXBW_V':>9NW><,;LYVXEV=>VW
M&WMC&.* /5=?UM-$@>\E#%(]N0@!;YF"C&2!U/K7#_%J]6_TZ"X3(666-@#U
MPT3D9QGGFMOXJS*FG2@D L8P 3C)\Q3@>IP"?H":Y?Q]_P @:S_[=_\ T0U
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MA^TNKN_OTBN3!)YN</&LC,@9@A <@A54C&.,,O;%='8^!YUO(]3N;GSGB5E
M\E8^"K#&5;'!8GI[4 =A7&67Q4MK]?W,<[R \QI%N?;_ '^"5VY..N<]L<UV
M=>>?!.%1:2. -QG()QR0$0@9]!DX^I]: -:V^)UI=1K)'YCR.6 A1"TQVXS\
MH)&,'=G=@@''((&KX9\50>(XS- 3\IPRM@.OID G@]B"0>G4$#E/AS"IOM2<
M@;A.0#CD R2DC/H<#/T'I3_AQ_Q^:E_U\?\ L\U &QJ/Q!AM&<)%/*L)82/%
M$2BLF=REF*\CJ>V"#FKMMXMBO+7^T(%>51C*1+NE!) *[<]1G)YZ<C(P3S^D
M^+;_ ,3;YK&.%($;:#<%RS'KTCZ<%<CGD\,><1?!3_CSD_Z^&_\ 0(Z *7PQ
M\82O%Y,R7$S//@2A3(B@A!AG+< =3Z Y[UU&H^/X+64VD:RSRIG>MO'YA7&.
MO('4XXS@\'!K$^"G_'G)_P!?#?\ H$=8_P .=/O+V*81W9A=9V\Q&A21]Q R
MS%SN!)!'/=3WS0!Z%X?\2Q:ZK-%N5HV*O'(-LB$$C#+DXSCC\1U! Q9?B?;I
M*]HL<SRQR,FR.,,S%=VXKAN0-O.<'D<=<2^'O!<FFW<FI3S^=)+'L/[H1_W,
M'AB. @'2L?X<PJ;[4G(&X3D XY ,DI(SZ' S]!Z4 :TNHVD^H6V^*07<D&Y&
M;*[%*R$JR[^&'S _*<$]?2[JGC2.QD:V2.::2/&\01%]FX KDG ^8'C!/0YQ
M7/ZS_P AZU_Z]V_E/5L>+;O6+B:TL(X@MJQ5WN"V"<[0 J<CE6]<@<[3P0#=
M\,^*H/$<9F@)^4X96P'7TR 3P>Q!(/3J"!R_PX_X_-2_Z^/_ &>:HOA;O^TZ
MAYNWS/.7=LSMW;Y=V,\XSTSSBI?AQ_Q^:E_U\?\ L\U '<:C>K81/</DK$C,
M0.N%!)QG'/%<I%\5+:>/SHHYY H)<)%GRP,X+G.T @$C!/ .<5N^+/\ CSN?
M^O>;_P! :LCX50JFG1$  L9"2!C)\QAD^IP /H * -W2]=BU*!;Y#B)E+9?Y
M<!<ALYX&T@Y.<<9!(YKGV^)T#!I(HKB6*/K)%#F/@!CRQ4C /.0/7IS7%>'=
M_P#8=WY>[=YQSMSG;B+?T[;<[NV,YXKTKP3L^PV_E[=ODIG;C&['S].^[.[O
MG.>: )8/$\%U;OJ$3;XHU<G:/F^09(PV"#CH#CJ#T.:PHOBI;3Q^=%'/(%!+
MA(L^6!G!<YV@$ D8)X!SBN=\-_ZG6/+_ ./?]]Y>W_5_=ESMQ\OW=O3MM[8K
MJ/A5"J:=$0 "QD)(&,GS&&3ZG  ^@ H W]%UB/6(4NX<[)!D9&",$@@CU!!'
MIZ$CFKU>:?"FWDN=.EC@D\J0W!P^P/C"QD_*>#D9'XYKL-$TJ[M'+W-UYR%2
M ODI'@Y'S94YZ9&/?VH RK/XGV]\F^&.:1]Q'EQQAY % )<JK$!<L!DGD]!P
M<;'AGQ5!XCC,T!/RG#*V Z^F0">#V()!Z=00.2^"6S[-+C;YGG?-C&[;L7;G
MOC.[';.<=ZE\-?\ (9O/*_U7EKNV?<\S]WUQQNSOZ\YW>] '4>%_%$7B2(W$
M(8*KE2' !R #V+<?-1HGBB+6)9[>,,&M7VN6  )RPXP3Q\IZX[5R_P %/^/.
M3_KX;_T".F?#*99KO470@JTX((.007E(((Z@T 97PP\3QZ3:-%LDEE:=SY<"
M>8X4)&-Y&1A<\9/4],X./0/#/BJ#Q'&9H"?E.&5L!U],@$\'L02#TZ@@<E\$
MMGV:7&WS/.^;&-VW8NW/?&=V.V<X[U+X:_Y#-YY7^J\M=VS[GF?N^N.-V=_7
MG.[WH I?#!XTTNY:8%H@\Q<#J5$2;@.1R1[CZUU7AS5K2UL%NH08K50Y D))
M'SL#W8DELX&23D <\5QO@#_D#7G_ &\?^B%K/U/?_8%OLW;?.._;G&W?+C=C
MMNV]>,X[XH [JU^(\%P0WES+ 6($[Q8@Z[02^> 3QD@8)^;'..KJI^Y\G^#[
M/Y?^SY?E[?\ OG;M_#'M5N@#E]/N;1M3GB2-A=B(%W).PKB/  W'GE?X1T//
MK$WQ,MA++:A)6FB<J$2/<SE20VW:3P,9.[;QTSTK,T;_ )#UU_U[K_*"F?#F
M%3?:DY W"<@''(!DE)&?0X&?H/2@#J/#7BV+Q!Y@C5T>%@KI*NU@3G'0D=01
MC.00<@<9\]T_Q$HU>>]-O.Q,0Q&(<S(=L:[BN?E&,C.>C#UK=T;_ )#UU_U[
MK_*"C1O^0]=?]>Z_R@H Z#5?&\&EK&9 _FS*I2$)F8[B!@KT!R<8)&2"!DC%
M1:=X_@NI1:2++!*^-BW$?EELYZ<D=1CG&3P,FL2R_P"0]+YW_/N/)W_1,[,_
M\#SM_P!OWH^,7^I@\O\ X^/M"^7M_P!9]TYVX^;[VWIWV]\4 ;?B/X@6_AZ4
M6TX?<T>\%5!7'S #J#DE<#C'(R0,D,O?'\5A;_;9H9T4R^6%>,*^=N[=@L/E
MXQG/7M6)KT*RZ[:!@"/()P1GE?.(/U! (]#S3_C7_P ><?\ U\+_ .@24 :%
MQ\4;6';(4F,#L%$WE$1$GK@D@G&#D!<\' -/O?B=:6K?\M'BW[#,B$PANZ[B
M1D@?-\H;(Y&:/B9"L.F3(@ 51$  ,  2(  !T K)\0PK%H*A0 /(MC@#'+-&
M2?J223ZGF@#M;_6H;"$WDC@0@*=XRPPQ 4C:#D'(Z5@#XE01R)#/%/!YI(#7
M$8C3CWW'CD9.,#()P.:AF\5+X9TRVN2A<M% H4';R8P>3@X& >QYP/<<K\2W
MU![2-KT0*AE4@1;]X8H_!R2N ,YP3SC!Q0!UOQ0UM]-M&6(2AY,8DB!"IM=,
M[G!!7<#@>O2HM$\4+?V9CN8;C8EF6D>1"%D 0!]K[LDL"2#QD<Y%6OBE_P @
MZ?\ [9_^C4H_Y@W_ '#_ /VA0!8\.:M:6M@MU"#%:J'($A)(^=@>[$DMG R2
M<@#GBJ7_  LZ#'G>5<>1NQYWD_NL;MN[=G.,^V>V,\5Q6I[_ .P+?9NV^<=^
MW.-N^7&[';=MZ\9QWQ7K7[GR?X/L_E_[/E^7M_[YV[?PQ[4 4K_Q5!:6IU,$
MO#A2#'@D[F"]"1R">0<$<@\C%8DOQ4MA']H2.=X@!N=(OD1CCY&9B!N&1TR.
M1@FN-TS?_8%QOW;?.&S=G&W?%G;GMNW=.,Y[YKN(H5BT;"@ ?8"< 8Y:$DGZ
MDDD^IYH Z>TNENT6:,Y210RG!&0PR#@\]*S]6\2Q:5+!;2[MURQ5"!E01M&#
MSD9+ # /O@<UE?"W_D'0?]M/_1KT?$S36O+)I(RPDMV652K!2"F<G/LI)&"#
MD#'H0#3\2>*H/#JH]P2!(X4;<$CU;&<[5[X!/(XYJ7Q%X@BT"$W4V=H( "XW
M$DXP 2,GOUZ GM7GNJ1_\+"D8Q[MEM9AE563'GR@,$W'DC VMTP5/W>\NFZR
MWB1],MFW_(IFD/#9,):.-RQ!/+(=V<?? R3@@ ZC4+FT74X(GC8W9B)1P3L"
MXDR"-PYX;^$]1SZ<UK?C"6#5HP$N/*C1U,2J?WA'F#>J;L,O0AO1<]JNZS_R
M'K7_ *]V_E/1K/\ R'K7_KW;^4] %+QQJJW4VF73JT2^>Q(G&QE"R1 E@3P.
M,]>G-=%!\1X))8[<QS()VQ'(\6V-\XVE23DALC!QW&<"L?XFPK-=Z<C@%6G(
M((R""\0((/4&G_&O_CSC_P"OA?\ T"2@#T"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0!7T_3X].C6WA4+&@P /\\D]23R3R>:X3X>:<MQ>WNI)GRS*\:'>K*V6WN>
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M[NY;:Z@K'\N\X(/.%)4_[)&&/3T.J[Z=$\@N"BF51@.5!<#G@-C(')_,U8H
MS-?T"/7(Q#(678ZNK1MM=67HP///)['KD<X(S=.\ 06LHNY&EGE3&QKB3S"N
M,]. .ISSG!Y&#72T4 >7MH<>LZW<Q2[OEA1E9&*LK!80K@CN,\9R,]JZW0_
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M.>CHH Q];\+Q:Q+!<2%@UJ^Y I !.5/.0>/E'3'>CQ1X7B\21"WF+!5<,"A
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M9$EVOM_N< +MR,],Y[XXK;\,^%8/#D9A@!^8Y9FP7;TR0!P.P  '7J23L44
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M=.\ 06LHNY&EGE3&QKB3S"N,]. .ISSG!Y&#72T4 8]SX7BN+N/5"6\V)"H
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M44 9^@:(FB0)9Q%BD>[!<@M\S%CG  ZGTJ[-"LRE' *L""",@@\$$'J#3Z*
M,'PKX-@\,JZP;B9""Q<@GY<X'  P,GMGGD],-T'P/;Z'-)=PAM\N>"1M4%MQ
M554  9QUS@  =\]!10!CW/A>*XNX]4);S8D*@ C9@AAR,9S\Y[CM4/B3P;!K
M[)+)N26(@K)$0KC'(&2#P#R.X/0C)SO44 <Y-X'BN/LQDDE=K-RR,[AF8E@_
MS$KR!M &,<<5;\4>%XO$D0MYBP57# H0#D CN&X^:MBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHKAYM>N_$%W+8V+K##;$"24H'<M@C:%;
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M[,A:*51M+C)/*C@' /\ =QM(^;() .SHKS?1]9U+6KN[LXI52*&5AYC1JS(
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M^IZUT%% !7G_ ,%/^/.3_KX;_P! CKT"B@#S_P""G_'G)_U\-_Z!'75>+/\
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M2GMII)DUL2R7H?"H=YR#DA$$9 R6)P,A,%=O!->T44 >?_!3_CSD_P"OAO\
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M0IEF!5Y720J1@KF2-0#R><*#V(S@C(KUBB@#)\)_\>=M_P!>\/\ Z M:U%%
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MV25V"#JQ5HB%& >3TZ'Z5Z17'^-= GU*YL9H5W)!-ND.Y1@;XSG!()X4],T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%4;W7+>P;9-+&C$9 =U4XZ9P2..* +U%,AF690Z$%6 ((.00>001U!JE_P
MD-MO\CSHO,W;=OF)NW9QMVYSG/&.N: -"BJ][J,5@N^9U12< NP49ZXR2.>*
MKMXAMD+*9H@8_O@R)E<$+SSQR0.>YQUH T**9#,LRAT(*L 00<@@\@@CJ#6/
MXAD34+:5([E8=K!6E5Q\C*RY4D,N">A&0>?PH VZ*J:2GEPQKO\ ,Q&@\S.=
M^%'SYR<[NO4]>IIEEKEO?MLAEC=@,D(ZL<=,X!/'- %ZBJ][J,5@N^9U12<
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MD?F*KR>(;:+=NFB&QMK9D0;6Y^4\\'Y3P>>#Z4 :%%5Y=1BBC^T,ZB+ .\L
MF&Q@[LXP<C'K3+'5H=0SY$B2;<9\MU;&<XS@G&<&@"W117&:EX^6TU".PWQ>
M04;S'+<JXW_*6W;0<J!@C//N* .SHKSKQ[=I=W6F2Q,KH;@X9"&4XDB!P1QU
MKMXM<MY9/LZRQF7)&P.I?*YR-N<Y&#GTH O45#=7:6BF65E1!C+.0JC)P,D\
M=:BL=6AU#/D2))MQGRW5L9SC."<9P: +=%<?XN\<_P!C7%O:HT1$DF)MY^9%
M)3!.&&WAB<L,<9Z5U%EJ,5^N^%U=0<$HP89ZXR">>: +%%<E\0_&;>&XE,)C
M,S.,HYR=A#?-M#*<97&>G:J_Q#U:'4-.N/(D23;Y6?+=6QF5<9P3C.#0!VM%
M<YH&N6]A:6R32QHQMH2 [JIQL S@D<<5T= !16?_ ,)#;;_(\Z+S-VW;YB;M
MV<;=N<YSQCKFM"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "O*KK3VT*]N+R^M6N89F9ED $H1!EN4;@8&U<MMVA3M)&<^JURE[:Z
MLK2K!);M&[,4:56$B!APN%!4[>Q.[/4^@ .?\;:[!%I>-.*^3+,8SLW+M#;Y
M'4#@KDCH1C:V ,$5%=^'I98&M(]*1,J0K_:(F=2>0VX_,<'MNY'R].*W;3X9
MQ0V+Z6SEB[E_,VCY7X (7G P #SD@MR,\/M=/U>W46WFV[(,J)760S;<X#%?
MNE@.Q)!(^8GDD Y?QY%<1:1;I>9\]9P&R0QX$NW)4D$[<<YR>_.:[JS\%6ME
M UI&@7?$T;2 +YI#CYB7QR3U]!Q@8 %4/''A.?7[2.T1U,J.C,[Y0-M1E)PH
M;!).<=!76T >=>%O$[:187,,S*9=.9XQP[ \E8@3U(+Y48QA0,@=:J7NA'1M
M!>-QMD?8[CG.6E3 (;&"%"@C'4'ZG3\2?#V;4[S[2C@6TQA,\;.Z[O+(&,*N
M"-H&,G(;)!'%=%XST1];M)+.(J'DV8+DA?E=6.< GH/2@#A_$LS7%KI>FDD1
M70A#E3AL!8P!Z8^?/(/(4]J[A/!MI#Y9BC6-H64J\8VO\O&"W5@PR&#9R"<\
M\UFZQX);4;*"U#!+FU2/9(O9T4 C=C<%)'48((4X.,4ZST_5+@QI<RPJD;(S
M-"KF1]A!*G.T -_$5'MC:2* ./@DDUC4+N9K1;LP2>6H:4(B*I= -KY#;L9/
M& V2 ":V/#^D7EOJ"W26PM;9T*RHDL;H2JMM;:N,'.T?*/4Y^9LZ=_X2N+*Z
M?4=.D16FQYD4H(B8X/S93G.<'IG)8[L$J=71+>^WF6\DBV[2HB@0[<Y!#EW^
M;/4;>F,'K0!Y[HUHOA=I%U:T,H=]QN2OGH 6"@G(. 3EB?OG(!4\5Z?HDT,L
M$9MB##L4(02?E48 YYR,8.>0>#S7,7>C:M=QM9236YCDRK2[&$I1CS\H&S.W
MC'_CV?FKHO#>AKH5O'9JQ81@_,>,EB6)QV&2<#G [GK0!QOQKM$^S1S[5\SS
ME7=@;MNR0[=W7&><=,U+\3D30;%EM8TB^T2)&YC4(2N&;'RX],<Y&"1CFN@\
M<>%O^$EMS;AMKJP="?N[@",'O@@GIR.O.,&E+X;NM=MI++4FBR0GEO"&+!ES
MEB& &3Q]W;D%AQF@"Q_PKJQ\C['Y2XVX\S \W/7=OQG.>?3MC;Q6?\(M3>^L
M0LASY,C1J>2=H"L <D]-V!T   QQ1_8^K^7]B\^'9]WSL2?:-N?O?W=VWCKG
M_:W?-6_X8\/)X?@6TC.=N2S8 +,>I./R'4@ #)Q0!B_%:T26PEE95+Q[-K$
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M3+(<^3(L:GDG:'B8 Y)Z;L#H  !CBMNW\&VD.D-+Y:M(UJ9=[#+[C'O&&X(
M(& .,=<Y.=6\\!^5IK:3;E=[;27<;0S!U9B=H)Z# ZD  9.,UJ_V(_V#^S\K
MYGV7RLY.W=Y>S.<9QGVSCM0!PN@>&(+G2);V5=\SPRG>YRR^3N6,*>J@!!P.
MO0Y7 #I9FE\.Y8DG &2<\+<@ ?0  #T'%=7I'A>6RTPZ6Q4RF*9<@G9F0N1S
M@''S#/%86OZ(^B:&]G*5+Q[<E"2OS7 88R >A]* -#0/ MI?6$:RIN>:&-C(
MW,H)1<;7(R H "J.,#!!R<X_@[6(+K2634F'D1R^4,E\D#:ZCY3N)!/ 7HJ]
M, U8TG1]4-C'!;3Q&.6%&#2!UE0. =BLNX8 X#'D9XQA<:&H?#5)=/73(GP\
M;>8'( #28()8 9P0<#J5 7EL8(!Q/CG4K>>&*XM+66V<2*RR^2(5(*DC#(<$
MY *GL 2".<]7\:_^/./_ *^%_P#0)*B\1>$-4\0PK;SR6_[ME/R!QN.T@LQV
M\$=@H .XYQ@"MWXA^%Y?$ENMO"5#+*&)<D# 5AV#<_-0!A>._!MII6FOY4:A
MX?+PY'[PDN%)+#!.0QX/ [ 8&'>+89;RPM-74!Y[80S$D'D%59_E7 QN"L>F
M%!P1WZCQGHCZW:26<14/)LP7)"_*ZL<X!/0>E6-.T<):)8S88"!8WP3@X0*V
M#P<'UX- '+^,-137Y+/2XSE+EEF?ET!A4%@IP 3O )'((*C.,@CNZ\R^#6E8
M$UVS!PA\F,@MPH.]\!@,*Q92,C.<\#)STNNZS.E]:V-L1\P=YE921Y? #;@.
M#PP7!'S8#<$9 .HKS+2=#MWUJYMS%&8E@4A"BE <0\A<8!Y/YFO3:XS5O"=U
M!>G5;!X]TB;9$GW;> H&-H)Q\H/8@CJ0<  Q?%&CQWNL6MF<K$;;!$9V?*HF
M^3CHI VD#'RD@8J7Q=IT6B7^GRVJ+$TDI1MBA05+(I^4#&<.PSC//7@8VY?"
M]Q<:A;:I(8\10;9 I;[Y60':"/NY?C)!Q4OBWPO+K%Q:7$94+:R[G#$@D;D/
M& >?E/7':@#E/$,TFJ:L]N;<7*VT2E(S+Y:C.QRYW':3EMI&,$8R#BK":->?
M:[>ZM[-;148+*8Y8BK1EAD%5VC@9[$GCNJXZ#Q!X2EEN%U2QD6.X50K*X_=R
M#(X8KSTXZ'HN-I -6]+M]1DD62ZDA6-,Y2!&._((Y:3E=IP1MZ\@]J .2\9:
M/'K&LVUK-DQM!D@'&=IE;&?0XP<<XZ$'FI?%VG1:)?Z?+:HL322E&V*%!4LB
MGY0,9P[#.,\]>!CH-0\+RW&IP:H"OE11%2"3OR1(.!C&/G'<=Z/%OA>76+BT
MN(RH6UEW.&)!(W(>, \_*>N.U '45YIK>DPOKEO$8T*20LSJ47:S$3'<1C!.
M0.3SQ7I=<EXJ\)SWES#JEFZK/"-I$N=A7YO0$Y.X@^QR"I'(!@_$C3$2?3K6
M(>4AF8#RL(5W/%DK@8!R<@XZ\TWXG:)!H-O!=6L:QRQ3H%95&>%9AG/WCE0<
MMD]?4YVM8\+W>L/97$IB$EK*6D"%PI&]"-N03G:O.<<^U6_B'X7E\26ZV\)4
M,LH8ER0,!6'8-S\U '.?$2=[Z_MM.\KSX_+:3RA(8M[$.,ELX&T+D=^HSS5?
M6=%O;@QRV=@MK-$^X2130],$%2HV@@\=<\9&,$UUWBWPDVKM'=V\GDW,&=CX
M!!!'W6[XS]0 6!4YHM+?5)W7SY+>.-6#'R$=F8 \H?,X (S\PY!QCO0!TM>2
M022:QJ%W,UHMV8)/+4-*$1%4N@&U\AMV,GC ;) !->MUQ]_X2N+*Z?4=.D16
MFQYD4H(B8X/S93G.<'IG)8[L$J0#,\/Z1>6^H+=);"UMG0K*B2QNA*JVUMJX
MP<[1\H]3GYFSG^"_#D&JZA?33J'\F=PJL 4^=Y,DJ>I&WC/ SG&<$=QHEO?;
MS+>21;=I410(=N<@AR[_ #9ZC;TQ@]:I>$O"\NCW%W<2%2MU+N0*22!N<\Y
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M6PT2YE1CN24JI)/RA_+!VX(P1O+#'\7-=!HW@^_\/&2VLY8OLTCY#2JQE3(
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ME>-7,C %\R("0&QD#!P .W7)))BO/ ?E::VDVY7>VTEW&T,P=68G:">@P.I
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M26W08 ,L:.\G'?:P"$DCG@  D@=*E^(?A>7Q);K;PE0RRAB7) P%8=@W/S4
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MA#JMT\1\M&4K'N&W*NH"Y'(^;<2Q!R2!P!D S_B3IT1O; E%S+/ASM'S@-$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD]RQ6,$A5!X R?JPXXR,_,*X_P 5?;/MFG_;?)_X^!L\C?\ WXMV=_X8Q[T
M=EKWCRVT*=;2XW*73=O"[D )8#."6SE>RGJ/?#=+\>17\ZV+1S0RNI91/'LR
M!D\<D] >2,<$9SQ6#KT*RZ[:!@"/()P1GE?.(/U! (]#S3_B/_Q^:;_U\?\
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M7%>(M_\ 8=IYF[=YPQNSG;B79U[;<;>V,8XKN/B9"L.F3(@ 51$  ,  2(
M!T H ZVJ^H:A'IT;7$S!8T&23_GDGH .2>!S7.6&G7-Y9VGV:X\C;;Q[OW2R
M[LHF/O$8Q@].N?:N?^)5E=6FG;)IFF)N%+,L8C 3:<*P3C&_!R>Y'<"@"WJ_
MQ'@U"TF_=S1I+#*J/)%^[9BI4(&4L,DY]N#DU%H$T$.AH]VK/ -VY4X8_P"D
M'&/F7H<'J*Z7Q7Y/]G38V>5]G;9]W9]W]WM[=<;<=\8[5Q7_ #+G^?\ GZH
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MVS[#<>9MV^2^-V,;L?)U[[L;>^<8YH /$'C"WT*);F5MRR8V"/#,X.#E>0"
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M .''_'YJ7_7Q_P"SS5W":C$\AMPZF51DH&!<#CDKG('(_,4 6**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KG-<\"P:M,MYNDBF48WP,$8\8Y.#
MR!QD8..#D 8Z.B@#'TCPK#IBN/FD:8 2/.QD9P,@!L\8 .. ..N:QV^&,"AH
MXI;B**3K'%-B/D!3PP8G('.2?3IQ7844 9,'AB"UMWT^)=D4BN#M/S?.,$Y;
M))QT)ST Z#%3:!HB:) EG$6*1[L%R"WS,6.< #J?2M"B@#'\+^%XO#<1MX2Q
M5G+$N03D@#L%X^6L^U^'L%E.;J!Y8MSJQCB<+$=IS@KMY4\\9P,D# XKJ**
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M#(2NX9 "[>VT'( SN%=G=>'K:[8RRPQ.YQEGC1F.!@9)&>E7885A4(@ 50
M!@ #@  = * *6@:(FB0)9Q%BD>[!<@M\S%CG  ZGTJIX=\(PZ#"UG'N>.1F+
M"7:V=RA2.% Q@=,>M;=% '))\-H;<D6\UQ C'.R&8JF< $\@G)QSDG\L"MJ+
MPW;QV_\ 9P0>1@C823U)8\DDYR<@YR#TQ@5IT4 <?;?#"WA0P-)-)'M8*DD@
M*(6!&]5V@!AN."0<$YQGFN@T#1$T2!+.(L4CW8+D%OF8L<X '4^E:%% &/XF
M\*P>(XQ#.#\IRK+@.OK@D'@]P00>O4 C*7X:P&6*Z>6>26%PP:20.3M(95.5
M^Z"">,'YCD],=;10!CW/A>*XNX]4);S8D*@ C9@AAR,9S\Y[CM1K?A>+6)8+
MB0L&M7W(%( )RIYR#Q\HZ8[UL44 %<OJ'P]@N9VO8WE@DD&&-NXCW<Y)/RGD
M\9[$C)&<D]110!@^&?!L'AQI6M]V)BI(8@@;=V . <?-W)/3FN(\*^&X]9O-
M09RZ21W!V21.4==SR[L$<<@8.0>,XQ7JM5[;3HK5F>-%5I#ERJA2QY.20.3R
M>OJ: ,GPWX-@T!GECW/+*26DE(9SGDC( X)Y/<GJ3@8XCPKX;CUF\U!G+I)'
M<'9)$Y1UW/+NP1QR!@Y!XSC%>JU7MM.BM69XT56D.7*J%+'DY) Y/)Z^IH R
M?#?@V#0&>6/<\LI):24AG.>2,@#@GD]R>I.!B;1/"\6CRSW$98M=/N<,00#E
MCQ@#CYCUSVK8HH R?$/AB#Q @BN%SMSM8'#*2,9!_H<@D#(.*RH_AQ SK+<2
M37&S[JW$N]0<@YQ@>G(.01U!KJZ* /.OBE:K=W.GPR#*23,K#)&0SQ C(YZ5
ML#X9VS2))(\LB1$[(I9-\2CLH!&=HP.,\X ;(KI;G3HKIE>1%9HSE"RABIX.
M02.#P.GH*L4 8^M^%XM8E@N)"P:U?<@4@ G*GG(/'RCICO6AJ-DM_$]N^0LJ
M,I(ZX8$'&<\\U8HH Y]? ]N;,:4P9HESM+$;P2Q;<"  ""QQQTX.03G*N/A1
M;W*+%)+<.$QLWR@[ !@JH*X /&>/X1C SGM:* ,_7="BUR(VTXRK="/O*>S
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M?1/"\6CRSW$98M=/N<,00#ECQ@#CYCUSVHT3PO%H\L]Q&6+73[G#$$ Y8\8
MX^8]<]JV** .:U'P!!=2F[C:6"5\[VMY/++9QUX(ZC/&,GDY-7]"\-QZ-N9"
M[R2;=\DKEW;;G;DGC@' P!QC.:UJ* ,?POX7B\-Q&WA+%6<L2Y!.2 .P7CY:
M-$\+Q:/+/<1EBUT^YPQ! .6/& ./F/7/:MBB@#E]0^'L%S.U[&\L$D@PQMW$
M>[G))^4\GC/8D9(SDG0MO"\5O=R:H"WFRH%()&S "C@8SGY!W/>MBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ%U.0A?#$$#& H![%^YXKI?AGKK:Q9*\A9I(V9&9L9)&"#GO\K $GDD'.>I
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M\.1B&'!GE!P3@[ .-Q7N3_#D8)!)SC!S;7P;JH47?VUA<'),;Y:(%CR#RR\
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M(/(((Z@UY?\ $>]N#J-O9PS21+,D2G8[  O*R[MH(R?\.M 'J=%>3^)+6_\
M!"I>K=M.K.$990Q'/S#AF?@[2"058=CR</\ B?XEF\FRN8'>+SXV<B.1AU6,
M@$C&<9/:@#U6BO/_ /A7%Y_T$9O_ !__ ./5F?$>]N#J-O9PS21+,D2G8[
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M@2<\G;R0"3MQDD9)Y.>M &G1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y5X(_T;6KM)/E9_/VAN
M"<RJXP#UROS#VYZ5ZK7#^,/AVVIS?VC9RF*YP >6 / 7.Y>5.W(. 0>.!R2
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MDA2#P>GYUD_#[X;2^'YVNKAHV(0J@3+8+$9;+*N#@8XSD,>1W ,W_F8_\_\
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MW"A"$!&=F23M((QC!Z]B <EX5\>0V%W<:E<B4O/D*$*N K-D@EBI^4*H7'&
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M H\ :S]A(T"[MO+=]V/E^5QM;>S[B=V=I 894C@ *!0!;^"G_'G)_P!?#?\
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MY8$ ZWPQ"T-I;HX(98(@01@@A ""#T(KS7XGI(^J6RPD+*4A"$] QE?:3P>
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MR5 ([AG@#PE)X?24W#*\\TFYG5F;( XSN YR6)..<\D]@#E?'W_(9L_^W?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBJ-[KEO8-LFEC1B,@.ZJ<=,X)''% %ZBL^U\0VUVPBBFB=SG"I(C,<#)
MP <]*T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,^;0
M()ITOV7,\:[5;<W .[C&<'[QZCO6A110 445#=W2VB--(<)&I9C@G 49)P.>
ME $U%5-+U2/58UN8&W1OG!P1G!(/! /4'M5N@ HJO9:C%?KOA=74'!*,&&>N
M,@GGFK% !1110 4444 %%%% !1110 445#=W2VB--(<)&I9C@G 49)P.>E $
MU%5-+U2/58UN8&W1OG!P1G!(/! /4'M5N@ HHHH **ANKM+13+*RH@QEG(51
MDX&2>.M4H?$]I,P1)XBS$  2H22>   >2: -.BBB@ HK/UO7X-$037+;$+!0
M=K-R03C"@GH#5BYU&*U94D=5:0X0,P4L>!@ GD\CIZB@"Q1110 4444 %%0W
M=TMHC32'"1J68X)P%&2<#GI3=/OTU"-9XR2CC*DJRY'8X8 X/;CD<CB@"Q11
M10 45GZEK\&FO%#,VUYVVQC:QR<@8R 0.6'7%:% !1110 445GZWK\&B()KE
MMB%@H.UFY()QA03T!H T**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHK/FU^"&=+!FQ/(NY5VMR!NYSC ^Z>I[4 :%%%% !6?IN@0::\LT*[7G
M;=(=S')R3G!) Y8],5H44 %%%% !1110 445#=7:6BF65E1!C+.0JC)P,D\=
M: )J*S(?$]I,P1)XBS$  2H22>   >2:TZ "BBB@ HHHH **** "BL_1-?@U
MM#-;-O0,5)VLO( .,, >A%79IEA4NY 50223@ #DDD] * 'T54L=6AU#/D2)
M)MQGRW5L9SC."<9P:L33+"I=R J@DDG  ')))Z 4 /HJI8ZM#J&?(D23;C/E
MNK8SG&<$XS@U;H **** "BBB@ HK/T37X-;0S6S;T#%2=K+R #C# 'H16A0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !15'6-:AT>/S[APB9 R<G)/0  $D_0= 3T!INB:_!K:&:V
M;>@8J3M9>0 <88 ]"* -"BBJFJ:I'I4;7,[;8TQDX)QD@#@ GJ1VH MT5#:7
M2W:+-&<I(H93@C(89!P>>E34 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7G7B.T2[URUBE570VYRK@,IP)B,@\=:]%
MKS3Q;I<>JZS;6TZ[HWMSD9(SCSB.00>H'>@#N(M!MK ^?#!&)$!(\N.-7Z'@
M'Y<$].2!SR<4>'?$$6OPBZASM)((;&X$'&" 3@]^O0@]ZKZ)X,M-$<S6T>QR
MI4G>[<$@XPS$=0*Y*SU!?!=W>VY $+Q?:(5:144D#E%4# +,2HXSA!PW!H [
M#3O%4%_)<0J2/LA D9L*G\6<$GHNTY) '&1D<UCM\3H&#2117$L4?62*',?
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MM+;2">HP..F.".2779=8BL7NSNBCO"CL_P!P@>45,A/RD[6<9/50<Y^8D ]
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MHHR&9^0JA2,'GN",J0:W="UV+7(A<P'*MU!^\I[J1V(_^N,@@GC/@G"HM)'
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M.O3)&<$#)&*JZ=X_@NI1:2++!*^-BW$?EELYZ<D=1CG&3P,FL2R_Y#TOG?\
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M#Q2H0<6T6&5QV(;H0>H/TK=\+:%_8-LEENW^7N^;;MSN8MTR?7'6@#6HHHH
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MYLSQS1^7B20-L7:5PGR@+P?0C@<<5T%% &?H&B)HD"6<18I'NP7(+?,Q8YP
M.I]*J>'?",.@PM9Q[GCD9BPEVMG<H4CA0,8'3'K6W10!R2?#:&W)%O-<0(QS
MLAF*IG !/()R<<Y)_+ KHM+TN/2HUMH%VQIG R3C))/))/4GO5NB@#/U_1$U
MN![.4L$DVY*$!OE8,,9!'4>E6-.LEL(DMTR5B15!/7"@ 9QCGBK%% &3XA\,
M0>($$5PN=N=K X921C(/]#D$@9!Q65'\.(&=9;B2:XV?=6XEWJ#D'.,#TY!R
M".H-=710!C^*/"\7B2(6\Q8*KA@4(!R 1W#<?-1K?A>+6)8+B0L&M7W(%( )
MRIYR#Q\HZ8[UL44 8/B3P;!K[)+)N26(@K)$0KC'(&2#P#R.X/0C)R_1/"<>
ME.;C?++*5*^9/(78*2#L'08R,],Y)YK;HH \\U_3EU?6K=%R3;Q"20JZ\;&+
M(-I&0=Q7/))5A@#&3Z'5=-.B20W 11*PP7"@.1QP6QDC@?D*L4 <E\2K-C;K
M?1@&6SE25?EW9"D;AP00O1F]EY]1T]I=+=HLT9RDBAE.",AAD'!YZ4^:%9E*
M. 58$$$9!!X((/4&F6MHEHHBB5409PJ *HR<G ''6@#%T'P/;Z'-)=PAM\N>
M"1M4%MQ554  9QUS@  =\EOX'MX+QM54-YK9XR @)7:6  !R1G.2<DD]<8Z"
MB@#'UOPO%K$L%Q(6#6K[D"D $Y4\Y!X^4=,=Z/%'A>+Q)$+>8L%5PP*$ Y (
M[AN/FK8HH R?$/AB#Q @BN%SMSM8'#*2,9!_H<@D#(.*H6G@2.)UEEFN)_+8
M,JSS%E5E.5< !>1[Y&">*Z6B@#'\3>%8/$<8AG!^4Y5EP'7UP2#P>X((/7J
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M** &30K,I1P"K @@C((/!!!Z@URME\,[:S;"O*82^XP-)F GJ,ICY@,#J3G
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M=QM+!*^=[6\GEELXZ\$=1GC&3R<FK7A_PA!H1:2,,TLF=\DC;I&R2W)Z=>N
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MU0+E2%X(&.?F4@8/.[YB,52TO5K[Q;++-:3+!:1L40B-9&<CG.' (R"#VQD
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MW/T"YRP !P,G." 16/X[LM1LK%_/F2>-_+\S]V$:,A@1M*XW M@'(ST( R<
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MY@,C% ':Z7JD>JQK<P-NC?.#@C."0>" >H/:L+X>>*)?$ENUQ,%#+*5 0$#
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M(R_9[:-%(!!)D<YW9 R-H#*1G@CIG..EH *Y+QSX_7PLT:!!(T@8D>9M*@8
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M)*@0-M #'>0<Y W$\@ %1EAD8]#HH X2TU;2+]UAMH$F=F (CM?N@G&]BR*
MH)&3VSTKNZ** //]&_Y#UU_U[K_*"CX<?\?FI?\ 7Q_[/-7H%% 'G^C?\AZZ
M_P"O=?Y05G^$-<C\#M-I5]N3$AD20J2KJ0%!PNXC(7/<=5)!7GU"B@#S3PE>
M->ZS<S.C1EK<'8^-P'[G;G'0D8)'\).#R*M_#C_C\U+_ *^/_9YJ] HH \?\
M2O+I=S<Z/'NQJ4D31LTF ID?YSA0>&.4/0[0,[AC/8?$>U6TTJ6&,82-8549
M)P%D0 9//2NPHH \R\1:?(++3M3C4O\ 8DA=D'==L;%L]@-@!X. <G@&CQQX
MXAUVPDCM0SY$9D)4J(AO4@,3P6+< *3_ !'.!SZ;10!YIXPTQ[[1;=HQGR8X
M)&').T1;21@'INR>@ !.>*B\=^/8-:L7BM5=]_E^8=C!8AN##<<8R2-HP2#S
MSP,^H44 >6>+9IHM/L"#(+7RHQ<&$@-M9$ 'T(+#GY2<!N<5CWRV O+$Z:K!
M#<)O<^9M)#QX4>8<Y4')P.C#KV]KHH \_P!9_P"0]:_]>[?RGKT"BB@#S_X<
M?\?FI?\ 7Q_[/-3/B#IAMKN#5GB,\$:,DJ! VT ,=Y!SD#<3R  5&6&1CT.B
M@#A+35M(OW6&V@29V8 B.U^Z"<;V+(H"@D9/;/2G^+M4TN:9K744*O&$*NR.
M-P()^5X_F*@D@@X&[.,D<=Q10!Y?X7\_[!?^9YOV;R7^S^?][9Y;]/;;LZ?)
MG.WO1X$\>P:+8I%=*Z;/,\L[&*RC<6.TXQD$[3D@#CGDX] \0VK7=M/#&,O)
M#(JC(&2R$ 9/'6L_P%I<FE645M.NV1-^1D'&9&(Y!(Z$=Z .,T7PO-K5G?7)
M4HU^XDC0X/".9%Y)7AR=H) X&[D$5IZ#\1[;2[9+:[#Q3V\:H8V1MQV(-I'
M W#&-Q&#[88^@44 <5\-M*EB-SJ$Z-$UW,6$;C#* 6.3G!Y+D<@=,]"*J?!3
M_CSD_P"OAO\ T".O0** /.O =Q]FN=5EPS;)B=J#+'#S' '<GL/6L'7[S3KU
M1-I2R+?L5*K;K(C#Y?G!4?* %SG9R3SDKN->QT4 >:>,?,\[2//_ -;YB[^G
MWMT.[[O'7/3CTIOC+46T[6;:=8VE*P?<C&7()E!('<@$G'?'4=:]-HH \O\
M%^N1^.&ATJQW/F02/(%(5% *DX;:3@-GL.B@DMQH:S_R'K7_ *]V_E/7H%%
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M-S!CN)QG(SG(4$\DY)Y["<: UQ>G4)B"L2!8%5FXW ^8S*>-QS@8.-N,C(!
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MZ110!YO>7@\:WUJUJK&WM'+M,5(0D;'V -MY^4#U^8G;M&3;^(]TV@36^LQ
M$J3%(I9AO5@65<#C PQSV;:<-CCO:Y3Q_H\^M+#9Q*QB>93,RNJD(I'&&^]G
M.X=<%1P>* *_@[PVQTUHG<F2^1W9R=^#.F ><$G;@G)^]GG%<UX7OK'18OL6
MJVZQSQ%OFE@\S>"S88,$;('W<\@@ J3R!ZQ10!Q5WI4/B&PN([&'R?,QM/DK
M%YGED2(P^[E6Z*QQC)..U8F@Z[I=I"D%] D-Q$JJZRV^YB0HP^1&3\PYYYSG
MJ,$^H44 9GAT1&$/#"8%<DF-HQ$P(.W)4=SC\L5SOQ)TJ64VVH0(TK6DP8QH
M,LP)4Y&,G@H!P#UST!KM:* //]>^(]MJEL]M:!Y9[B-D$:HVX;T.XG@@[1G.
MTG)]LL,3QOHS:-H]M:R??692W3@NLKE>"0<$XSGG&:];HH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC'K5Z@ HK/M?$-M=L(HIHG<YPJ2(S' R< '/2K%SJ,5JRI(ZJTAP@9@I8\#
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M/$-M;;?,FB7>H9=TB#*GHPR>0>QZ5H4 %%9]KXAMKMA%%-$[G.%21&8X&3@
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MZ*TA#(F3M).PDL#D'E^<8R%4'(!!TKOPK=^(BB:D\0AC<-Y=N'^<X(^9G.5
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M#G Y'+ C#9&)XH\%ZAXEB GEB#HXVI&76'&#EB2K,7R0!V4 XY8T >AUY_\
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M 98T=Y..^U@$))'/  !) Z5+XM\+RZQ<6EQ&5"VLNYPQ()&Y#Q@'GY3UQVH
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M+_#SPO+X;MVMYBI9I2P*$D8*J.X7GY: .,@DDUC4+N9K1;LP2>6H:4(B*I=
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M);<VX;:ZL'0G[NX C![X()Z<CKSC!L>'4O44K?&)B H4P[LG&=Q;< ,GC[H
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M=YE55R%.P))NX7C!Z@';G KJ/!&DW=A=S.\/V>UE7<(A(DBB3Y1D;3D9&[H
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M4 345RG_  M+3O\ GM_Y#E_^(KJ(9EF4.A!5@""#D$'D$$=0: 'UGZ_HB:W
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MMHH 9#"L*A$ "J   ,  <  #H!3Z** "BBB@ HHK'\4>*(O#<0N)@Q5G"@(
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MJV$3W#Y*Q(S$#KA02<9QSQ5?0-;36X$O(@P23=@. &^5BIS@D=1ZT :%%%%
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M 4444 %%%% !4-U:)=J8I55T.,JX#*<'(R#QUJ:B@!D,*PJ$0 *H   P !P
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MDTLD N(D\MH9-C,<(H7.#@$JW!QD@8ZC/0-X#MTG@>:YG>5'W1+-,K9*$,<
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M1GZS_P AZU_Z]V_E/3/C#,MU%!IZ$&>6="J9Y((9 >> "S #)&><=#A^L_\
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M;(,K2+P0N3A, L-WR@CZG!! YJYM6M?#H1Q@E5;J#P\X=3QZ@@_SYKNO"?\
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MIM%=U&1'?;FY' ,2IGWY8#CU]*]K_M^#R/M_F+Y&W=O[8Z=.N<\;<9SQC/%
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M2>I. ,DY)[FL4_#?3RQD\A<MNS\S[?F!!PN[ Z\8 V\%<$"NEHH S[;0(+6
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MY7>@8,!N9>0",Y4@]":T** *FIZ5%JB&&=%=#V89P<$9!Z@X)P1@CL:RM,\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(<'9@%0 .0X/L<C+#!%&[U[4+G5)M,MG41A%.713Y8*(2XZ%F!;@$D9/(QR
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MTP'F(Y0D?Q853NQV)W<@<9Y& <#"\-Z_/K>DWDURV]PLZ@[57@0@XPH ZDT
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M)"I0+MW8#ON;.WGD$;N,XYKJ/"AE>W6::4S&4*ZL8UB(5U!"E4)&1ZY[X[4
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ME1SL&T%OF7 YPV0=R\KI^$M?NA>SZ1=LLK1+O60*$.#LP"H '(<'V.1EA@@
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MM( ^88PPP/NG_>) RHSGH--6?2$EDO9UEC1=X<1[&  )<%4R"  ",<DDCTH
MVZ*\TT_Q3<:Z/M+7UO:(V=L6(W? 9A\_F$$'&,8X(YPO?0T'XB;K6XDN-K26
M7#/&?W<I)*H5(!QN(P3C'(88!P #NZ*X?1X]5U:);\SQQ>8 R0B(,A7 *[GR
M7 ?J<$D \8/RA_BKQ'<V,VGQK^[^TR 2I\K]6B!7=@]-Q&1C/7TH [6BN/\
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MAN)&V(6C#085MLA1R6\P<G ^7'0]: /0-?U)]-@>XBC:9UVXC3.XY8 XP&/
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M_0(ZRO '_(&O/^WC_P!$+7JM% ''_#BU6[TJ*&09219E89(R&D<$9'/2N/\
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M'89. *WJ .4_Y@W_ '#_ /VA7)+H,FLZ%"L()>)WD"@9+8DD4@<CG#$]R<8
MR:]8HH \ZM?$ND2* ]NBW'(,'V;=)O!QL&$P23P,D=LX.0(?BJB)IL'E1^4A
MF0A-H0KNCD8@J. <GD>N:]+HH **** /+_AGKD?A\/I-WNCN#<#"E202X50
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M.-P0X;:3S@D''!.:N^!_"W_"-6XMRVYV8NY'W=Q &!WP !UY/7C.  >:7RV
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MM% 'D7Q1\7Q:W;I';!GB$H+2[&5 P5@(_F RV#D^@QUR<;OQ'_X_--_Z^/\
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M=#G#(0RG!P<$<=: )J**S[KQ#;6C&*6:)'&,J\B*PR,C()STH T**Y3XI?\
M(.G_ .V?_HU*L:!KEO86ELDTL:,;:$@.ZJ<; ,X)''% '1T5RGQ2_P"0=/\
M]L__ $:E:OA/_CSMO^O>'_T!: -:BL^U\0VUVPBBFB=SG"I(C,<#)P <]*T*
M "BN/\7>.?[&N+>U1HB)),3;S\R*2F"<,-O#$Y88XSTKJ++48K]=\+JZ@X)1
M@PSUQD$\\T 6**S[7Q#;7;"**:)W.<*DB,QP,G !STK0H ***S[7Q#;7;"**
M:)W.<*DB,QP,G !STH T**KW.HQ6K*DCJK2'"!F"ECP, $\GD=/45#%KEO+)
M]G66,RY(V!U+Y7.1MSG(P<^E %ZBF33+"I=R J@DDG  ')))Z 5F?\)99_\
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MBH?M:;_(W+YFW=MR-VW.-VWKC/&>F:FH **S[7Q#;7;"**:)W.<*DB,QP,G
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MW;IHAL;:V9$&UN?E//!^4\'G@^E.N=<M[55>26-5D&4+.JAAP<@D\CD=/44
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M/1X]5URXCFR46)&*Y^5MJPX##^)<X..A(&<C@^FUR^G^%Y;?4Y]4)7RI8@H
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M1UR:J6/@J[&H1ZK<2I)A6W ;EVED9=B#!!4$\$D$\DC/4 BT;_D/77_7NO\
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MC?*, $<#@=/05Z;7#KX3O='NI[JP>(QW)W,MQNX8L3QL'09..1P<$$@-7<4
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M@+*V$VK@94G@'.,G(''3%4M,T75=%06L$MO+$GW&G$@<# ^7"Y& <XY/'H,
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M*. 58$$$9!!X((/4&N*TSPOJ'AP&WLI8I("<J+D.&3).0-G4'@D\ G)"C)R
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-W;_ &E&BRR[U(W(<,,C&0>Q'8^M5=;U^#1$$URVQ"P4':S<D$XPH)Z UH4
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M9P1V([CUJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4]&L_P#(>M?^O=OY3T =!X@\6_V9(MG#$\]PZA@B<*%+!=S.<A1G/."!CYL
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M(S;6\=PKR7,D:J$7YF:14 ;+<_Q$ D;B2<@'FJ]SX_ETEE.H6K01.<!UD68
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MGI0!GZ[K$EAM2"!YY)-V I"H-N"=TAX7()V\')&*RM&\;M<77]FW<#03%=R
MN)%88)/S* .@//(X()!&#5\7^)YX;N'2;9DB,Z@F5QN(RQ "J>,G:0 <[BP
MVGFL&*"6WUNWCGG$\BQ-E@BQ[<I*0I52>><\\X8=L4 =!J/Q%-I>/I:P-)(
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M!I#MP  ZG(!'#$YQU.UX7U)O$^H+=L 5M;2/E7R@EF4,Q"YX."R$<XV\G.,
M'1ZIXAN89&@MK1Y=F-S,ZPH=P!&UFSO[AL8VD>]'A#Q>OB)7&QHY86VR1MDE
M22<<X'H<C ((((Z$\_;:_>>)+N>S@F2V2U9APBRR/AMN</Q@$$Y&,;@#NSD5
M_A.2;B_)<2'S4RX  ?YI?F '&&Z\<>E %C1/B=/KF5M;-G=,EAYRJH'&WYF4
M#).>..!D9YQT'B#Q;_9DBV<,3SW#J&")PH4L%W,YR%&<\X(&/FP"#7/_  4_
MX\Y/^OAO_0(ZS-3TU7UJ1)I9(!<1)Y;0R;&8X10N<' )5N#C) QU&0#J]/\
M&;B=;.^@-L\H_=$R+(CG."NY0 &Z8'?/8E0W45QC> [=)X'FN9WE1]T2S3*V
M2A#' *Y(X&[':NSH Y*X\=/<3R6=C;M<- 2)"76) 0<8#,#DYR.<="1N'(M>
M&_&2ZM*]E)&T-S$"7C;YAC.,AAU'*GH,Y&W<.:Y_X/3+:Q3Z>Y GBG<LF>0
M%0GC@@,I!P3CC/49+B9=2UV(PD,+:!A(0?NG]X"/<@NH.,X)P>AP 8^F:K=I
MJUQ,MKNG:$!HO.0;1B+YM^,'H.!Z^U>JVDC2HKR+L<J"RY#;21RN1P<'C/>N
M%T;_ )#UU_U[K_*"O0* /)-,U6[35KB9;7=.T(#1><@VC$7S;\8/0<#U]JT/
MB/?>1-IMS./+VR;W&=VW#0EAE1SCGH.>U6-)F5->N02 6@4 $XR=L)P/4X!/
MT!-/^(__ !^:;_U\?^SPT 79_'\ME)%]JM6A@G?:LKR+QG[I=<?(>Y#,"!NQ
MG::V/$WBA=#"+L>667=Y<<2DLQ09/T XSU/.0#@XYKXU_P#'G'_U\+_Z!)5+
MQ_:JNJ6LLTC0PO$4\V-]C!@7[\[1\Z@DC&">>#@ Z >-Y;&1$U"W-O'*2JR>
M:LB!NP8J!M!]2?T!(ZVN'U7X=V\RJEU=W!5G 42SJ07.0  R\L><8YZUW% '
M&:C\13:7CZ6L#22 #9L8?,S(K $$#:O)RV3@#.,=+>A^,WN[EM.NH#;S!-R@
MR*X8=\$ 9/?C/1LXVUCZ-_R'KK_KW7^4%&L_\AZU_P"O=OY3T ;>K>,6@G-C
M:0/<3)MWX(2-0REAF1@0"0!CC!S@'(Q3M#\7&[F:QNHC;W(&Y49PX=<9RK@
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MP[(, Y93CKC*D9'IGIDXZFK&C:!!HJ^7;1J@/7'+'DD98Y)QDXR3CH.*T**
M//\ 0[5-5UFYO5"[;953(+AC(5V$X/!P%=>PZ$ GYJ] HHH S-<\-V^NJJ7*
M!PARO)4C/7E2#@]QG!P/054T[P-9Z;(EQ#$%DB!"D,_\6[.<MR?F(R<G&!T
MQO44 9\.@00SO?JN)Y%VLVYN0-O&,X'W1T':B;0()ITOV7,\:[5;<W .[C&<
M'[QZCO6A10!CZYX1M=<97N8P[(, Y93CKC*D9'IGIDXZFBV\(VMK)%/'&%>!
M-B$%N%.[/&<$G<<D@DDY)S6Q10 5GZ;H$&FO+-"NUYVW2'<QR<DYP20.6/3%
M:%% &?#H$$,[WZKB>1=K-N;D#;QC.!]T=!VHAT""&=[]5Q/(NUFW-R!MXQG
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MG+<EB<=.6).!V&<#)]36G10!@ZQX&L]8D^T3Q!I" "0SKG'3.UAD]LGG&!T
MJWI'ANWT=G>W0(92"V"<'&<8!)  R>  *TZ* ,_1- @T1##;+L0L6(W,W) &
M<L2>@%&LZ!!K2^7<QJX'3/##D$X88(S@9P1GH>*T** ,31O!=GHS>;!$JO\
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M& 'X#WZUJW6@074!L6C40''R)\B\-NXV8QSSQ6A10!#:6JVB+#&,)&H51DG
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MT5?+MHU0'KCECR2,L<DXR<9)QT'%&B:!!HB&&V78A8L1N9N2 ,Y8D] *T**
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MF\CE!*[XA$F #@LI=,$.JG.,<-@'CF@#N**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!W8#':<][10!Y_\ !3_CSD_Z^&_] CH^''_'YJ7_ %\?^SS5Z!10!Y_\./\
MC\U+_KX_]GFK'\+>)4T.^OS,K>2\[;I55F5"))-H;:#@-G /J ,<DCUBN/\
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MK^+2MF?.C+[]V,8#G&W'/W/4=?:N@HHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***SYM?@AG2P9L3R+N5
M=K<@;N<XP/NGJ>U &A1110 4444 %%%% !16/X7\41>)(C<0A@JN5(< '( /
M8MQ\U;% !16#H7C*#6+>2^3<D418-O R-BAB<*6R,'Z^U:>EZI'JL:W,#;HW
MS@X(S@D'@@'J#VH MT45GZ;K\&I/+#"VYX&VR#:PP<D8R0 >5/3- &A1110
M4444 %%%% !1110 445R^H?$*"VG:RC26>2,986Z"3;S@@_,.1QGL"<$YR
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MV%(/R+N( <+S@_3WH V**S] UM-;@2\B#!)-V X ;Y6*G."1U'K6A0 4444
M%%%% !1110 445CVWBB*XNY-+ ;S8D#$D#9@A3P<YS\X[#O0!L445GZEK\&F
MO%#,VUYVVQC:QR<@8R 0.6'7% &A1110 4444 %%%% !1110 4444 %%5]1O
M5L(GN'R5B1F('7"@DXSCGBJ^@:VFMP)>1!@DF[ < -\K%3G!(ZCUH T****
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MH **** "BBB@ HHHH **** "BBB@ HHHH *\_P!9_P"0]:_]>[?RGKT"O/\
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MQ.5>-CEE(Z=@<'IR!R&';-<[\%/^/.3_ *^&_P#0(Z/AQ_Q^:E_U\?\ L\U
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M>!DAN<+@DD[@VW.0!@"@#8U;QDND6@OKB-D<DJ(CUW@D;=PR-ORDANA7D#)
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MKSQ2O/B')IC1O=VKQ6\K8$A<,P!&06C4$J<<E2<CG&XC%5/B/_Q^:;_U\?\
ML\-'QK_X\X_^OA?_ $"2@"Q/\3#;&*>6VD2TG.%F8C/3J8U!P.X^;++\R@]*
MT/B'K<6CVZRS0+.IE"A'Q@$JQW<JW/&.G?K6/\:_^/./_KX7_P! DH^-?_'G
M'_U\+_Z!)0!L>-/'*^%FA#QEUF+9(;!4+MR0".3\W3(Z=>>*D_C^6RDB^U6K
M0P3OM65Y%XS]TNN/D/<AF! W8SM-4OB/_P ?FF_]?'_L\-'QK_X\X_\ KX7_
M - DH ZK7=8DL-J00//))NP%(5!MP3ND/"Y!.W@Y(Q65HWC=KBZ_LV[@:"8K
MN0%Q(K#!)^90!T!YY'!!((P:OB_Q//#=PZ3;,D1G4$RN-Q&6( 53QD[2 #G<
M6 &T\U@Q02V^MV\<\XGD6)LL$6/;E)2%*J3SSGGG##MB@#3T;_D/77_7NO\
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M; D+AF (R"T:@E3CDJ3D<XW$8K:\3>*%T,(NQY99=WEQQ*2S%!D_0#C/4\Y
M.#C%^*FJQ+I[)O4F?9Y>#G< ZN2,=L<YZ=.<D9Y?7=+-E=:>+IVMT^R)$9(W
M"LKHK!AN&<#+*"?NX)YQD@ [ >-Y;&1$U"W-O'*2JR>:LB!NP8J!M!]2?T!(
ME\:>.5\+-"'C+K,6R0V"H7;D@$<GYNF1TZ\\9^J_#NWF54NKNX*LX"B6=2"Y
MR  &7ECSC'/6J_Q'_P"/S3?^OC_V>&@"[/X_ELI(OM5JT,$[[5E>1>,_=+KC
MY#W(9@0-V,[36[KNL26&U(('GDDW8"D*@VX)W2'A<@G;P<D8KE?C7_QYQ_\
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MBB6SAEN[^ P)$%(Q(LQ;<<8 7&#G YXYZ@ FLW_A/;GR_MWV)_LOWM_FKO\
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M0\'@^XY4@D<XK/MO'$&G::FHB(1JY94ACQC=N<8R%  .TL3CCGJ< \[X _Y
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MY6(925)R,@@8PQ)&0%/3)- &[KOB(:7)!;A"\ES*% &>%'WWX4\+D$CCCG.
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MAMEV(6+$;F;D@#.6)/0"L^U\ V-I*+I(5$BL6!RVT'U"D[1CM@<<8Q@5T%%
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M23R23U)[UP_Q-A6:[TY' *M.001D$%X@00>H->AT4 <_:^ ;&TE%TD*B16+
MY;:#ZA2=HQVP..,8P*U=3TJ+5$,,Z*Z'LPS@X(R#U!P3@C!'8U;HH Y_3/ -
MCICB:*%0XZ%BSX((((#E@"".".1ZUH:EH$&I/%-,NYX&W1G<PP<@YP" >5'7
M-:%% &?K>@0:V@AN5WH&# ;F7D C.5(/0FF:YX;M]=54N4#A#E>2I&>O*D'!
M[C.#@>@K3HH P=.\#6>FR)<0Q!9(@0I#/_%NSG+<GYB,G)Q@= ,7H= @AG>_
M5<3R+M9MS<@;>,9P/NCH.U:%% &/KGA&UUQE>YC#L@P#EE..N,J1D>F>F3CJ
M:=/X6MI_(W)G[)CROF;Y=NW'?G[HZYZ?6M:B@#)UOPK:ZW@W,:N1C#<JV!GC
M<I!QR>,XSSC-&B>%;71,FVC5"<Y;EFP<<;F)..!QG&><9K6HH YS4/AY8:A(
MT\D(+N<L0[KD]SA6 R>_')Y/-'BJV:VM#96D0S.?*4(G[M!*2'=@GW5 ).<'
M#$9!YKHZ* ,_0-&718([1.1&N,\\D\LV"3C)).,\9P.*EU/2HM40PSHKH>S#
M.#@C(/4'!.",$=C5NB@#G],\ V.F.)HH5#CH6+/@@@@@.6 ((X(Y'K5W7/#=
MOKJJER@<(<KR5(SUY4@X/<9P<#T%:=% &#IW@:STV1+B&(+)$"%(9_XMV<Y;
MD_,1DY.,#H!B;7/"-KKC*]S&'9!@'+*<=<94C(],],G'4UL44 9-CX5M;&)[
M6*-5CD4JX&=S YX+9W'[QQD\9XQ5O2]+CTJ-;:!=L:9P,DXR23R23U)[U;HH
M S]$T"#1$,-LNQ"Q8C<S<D 9RQ)Z 5B?%+_D'3_]L_\ T:E=710!Q6C> ;'4
M[:WFEA4N;>+)4LF24!)(0J"23R3R?6NO^R)L\C:OE[=NW V[<8V[>F,<8Z8J
M:B@#FO\ A6^G[_.\A=V[=C<^W.<_<W;<?[.,8XQBM+5?#=OJL2VLR Q(054$
MH!M!48V$< '&.E:=% #)H5F4HX!5@001D$'@@@]0:YVU^&^GVK"18%)&?OL[
MKR,<J[$'\1[]:Z6B@"IJ>E1:HAAG170]F&<'!&0>H."<$8([&LK3/ -CICB:
M*%0XZ%BSX((((#E@"".".1ZUT%% &?J6@0:D\4TR[G@;=&=S#!R#G (!Y4=<
MT:WH$&MH(;E=Z!@P&YEY (SE2#T)K0HH *P=8\#6>L2?:)X@TA !(9USCIG:
MPR>V3SC Z 5O44 5-,TJ+2T$,"*B#LHQDX R3U)P!DG)/<UCQ?#O3XY//$"[
MLDX)8ISG/R$E,<\#&!VQ@5T=% &3I_A:VT^%[*)-L4N[<NYCG<H5N221D#'!
MJA)\-]/D58S N$SC#.&Y.3E@P+>VXG'08%=+10!B:AJ5KX0MU+#9$GRHJ*22
M<%L#W.#RQ&3R3SFN?^$NE-%8,LZ?+/(S . 0R,BKD@]C@]>HYZ$5W=% '-?\
M*WT_?YWD+NW;L;GVYSG[F[;C_9QC'&,5O_9$V>1M7R]NW;@;=N,;=O3&.,=,
M5-10!S5K\-]/M6$BP*2,_?9W7D8Y5V(/XCWZUI:YX;M]=54N4#A#E>2I&>O*
MD'![C.#@>@K3HH J:7I<>E1K;0+MC3.!DG&22>22>I/>GZAI\>HQM;S*&C<8
M(/\ G@CJ".0>1S5BB@#'TCPC:Z0KI!& LP <$LX8#(P0Y;CYC]<\U2_X5OI^
M_P [R%W;MV-S[<YS]S=MQ_LXQCC&*Z6B@!D,*PJ$0 *H   P !P  .@%$T*S
M*4< JP(((R"#P00>H-/HH Y_3_ 5EI^_RHMOFQM&WSR'*MC<.6.,XZCGWK5T
MO2X]*C6V@7;&F<#).,DD\DD]2>]6Z* ,G3_"UMI\+V42;8I=VY=S'.Y0K<DD
MC(&.#37\(VKVXT\Q@P*<A26.#DMD-G<#DGOT)'3BMBB@#$T;P79Z,WFP1*K_
M -XEG8<$<%R2,@G.,9[UMT44 9\.@00SO?JN)Y%VLVYN0-O&,X'W1T':M"BB
M@#G]3\ V.IN9I85+GJ5+)DDDDD(5!))Y)Y/K6KIFE1:6@A@140=E&,G &2>I
M. ,DY)[FK=% &?IN@0::\LT*[7G;=(=S')R3G!) Y8],4:)H$&B(8;9=B%BQ
M&YFY( SEB3T K0HH YK_ (5OI^_SO(7=NW8W/MSG/W-VW'^SC&.,8JUXKN(]
M,L9BP41K"RA<$+\PV*F$P0"2!QC [CK6W10!R_PUT<:98Q#C=*/,8@DYW\KU
MZ$)M! XR._4]1110!F7?ANWO)TOI$#31 !6)/&"2/ESMR"20<9!Y'04:OX;M
M]89'N$#F(DKDG SC.0" 0<#@@BM.B@"IJFEQZK&UM.NZ-\9&2,X((Y!!Z@=Z
M/[+C\G[%M_=>7Y>W)^[MVXSG/3C.<^]6Z* *-AHL-A"+.- (0&&PY888DL#N
M)R#D]:R/^%;Z?O\ .\A=V[=C<^W.<_<W;<?[.,8XQBNEHH 9#"L*A$ "J
M,  <  #H!5?5-+CU6-K:==T;XR,D9P01R"#U [U;HH KPZ?'%$+4*/*5 @4_
M,-H&W:<YR,<<]>]<^GPRTY 0(!\PP<O(>X/!+<'CJ,'&1T)!ZBB@#)U#PM;:
MA"EE*FZ*+;M7<PQM4JO(()P#CDU-J6@0:D\4TR[G@;=&=S#!R#G (!Y4=<UH
M44 8.L>!K/6)/M$\0:0@ D,ZYQTSM89/;)YQ@= *T],TJ+2T$,"*B#LHQDX
MR3U)P!DG)/<U;HH *P;#P-9Z?,+R&(+*"Q!#/@;@0<+NV@8)XQ@=JWJ* .?U
M/P#8ZFYFEA4N>I4LF22220A4$DGDGD^M:NF:5%I:"&!%1!V48R< 9)ZDX R3
MDGN:MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9<[_ "O+?!'S$$N?O/\ ,.!G@#@C.!%X,2]\7VY:6Z>-(OD0Q<2,X&=[MU8
M,!@$;L9)##+ 'J%%>>>$_$<^I:3<32,3)"DRJX)#_+$&4D_WAGKUX!/.28O"
M.BW7B*S2>:[E3AQ'Y3L#]]LM(3RYSP " % P<DX .X\0W36EM/-&</'#(RG
M."J$@X/'6N?T#6[R_P!+2\B"RW3;L!PJJ<2E3G!0<*/4=.]96C:[+>6%_8W)
MWS6<<R%QT8;' .3R3E3R0,C!.3DU4M;M[3P\)8F9'&<,A*L,W.#@CGI0!Z1I
MSR/$C3 +*44N!T#$#<!R> ?<_6K%<U#%)?V%NWGM#F&)I9."Q7R_G^=ONDYS
MOZ@C-<C+J9T2]M5M+QKF.X<1R)),)L991GY3P3N^7@$%3R02* /4Z*\_^)][
M<0S645K(T;RR,O#$*3NC"[@,@@$]"#QGBJGB^&?PB(=2%S-*?. D1WQ&VX%F
MVJ!A <$ 8;&1@@KR >ET5Q7C369YKJ#1K1_*>=69Y,9(7#<*>H.%8]CG;AAS
M6KI?AR729%>.XEEC;(D6Y?S#C!VLAP-I!X(Z$'U44 =!17D4?C.+7)'FNKR6
MWC#L(HH%9&V_+M9G0/DGG(.<')! .*W?A]XJ-U<2Z:LC3PHI>.:3(DQE<HVX
M9;!;@G'0\8("@'8>(;IK2VGFC.'CAD93@'!5"0<'CK6?X"U235;**YG;=(^_
M)P!G$C <  = .U6O%G_'G<_]>\W_ * U<1X'\-3ZO81L;F2%5$@B$#%>KMEI
M.['=T ( 4<'+' !Z;17F^DZI=:K97FGM(WVNR)421[MS;"2 ""&+,49<X!((
M)R<YW;7Q?C2QJC'YQ">77@R#Y.0G9I!VQP>W8 ZNL?6[F[AE@6UC5XF?$Q8@
M%5RO(^9><%NS=!QZGA"VEM[2%9V9Y2FYC)G?ESNVG<2<KG;SZ=!TKG_'VHRV
MMWIZ1NRK)/APK%0PWQ#! /(Y/7U- '<45YUXON;N35;>SM9FBWP@]<IP9"Q*
M'*L=HXR.N.1U%3Q)#=^%[BWCM;F5_M>Z,"Y?S%5B54-TQP6!'RY&.=P)6@#U
M"BO-]4^T^&+VTQ<23"[?9(LIRF2R!F50<*/FRH'W<8R02*?XON;N35;>SM9F
MBWP@]<IP9"Q*'*L=HXR.N.1U !Z+17E_B2&[\+W%O':W,K_:]T8%R_F*K$JH
M;IC@L"/ER,<[@2M6-4^T^&+VTQ<23"[?9(LIRF2R!F50<*/FRH'W<8R02* /
M2**X+XA^+&LIHM.68VZR(S22B/>0I#*H4 YR2#D@ CY2#UKG+SQC#H;1W-E=
MS7/S8DBN"Y4J1G(9D4*01UP3SZ @@'L%<?XUU^?3;FQAA;:D\VV0;5.1OC&,
MD$CACTQ5+7;R?7]0&D02M#% @DE9"5=LXX# ],.H&< '<2&PHK$\4Z1-IE]8
M1O,TT/GKY?FX,BGS(]X+ #<#D8)Z#C QD@'H%S<W:W<<21J;0H2[DC>&PV !
MN''"_P )ZGGTV*X?5M1E36K:W#L(F@8E Q"$XFY*YP3P/R%7?$>FJ\GF7-\\
M$;?ZI(Y$@Q@ /ECR_.#S]W..] '5UCVWBB*XNY-+ ;S8D#$D#9@A3P<YS\X[
M#O7.?##6I;LW-I++YRVT@"2$Y9@Q<9W9.0=N1R<9QDC&.?TSPQYNK7%GY]P-
MD(/F++B5N(N&?'(^;ICL/2@#UNBO,O$_B<07(TE[F2""")-\@4O-(WRG&]<D
M$KSNP.=V000*KZ;XN33;N&*TN9;J*X94D6X+ED)8!75F5?[W0#G!SU4J >JU
MPFI:U>:IJ+:5:R+ D$>YG*+(S9"GHPQP6 QD=R2> .[KR33/#'FZM<6?GW V
M0@^8LN)6XBX9\<CYNF.P]* /5;2-HD5)&WN% 9L!=Q Y; X&3SCM4U<?K&C+
M"5%S?RQ1A5$0$J0L=JJ'+.>9"3@Y.-I)]:J?##6I;LW-I++YRVT@"2$Y9@Q<
M9W9.0=N1R<9QDC& #NZ*\O\ #\-WKMY>P&YE2WCF8$(_S_??8$8@[ -O.,9
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MLR+%EFV*!N<Y8X&,D]R>Y]: )J*X_P -W\MMJ%WITSNZG$T18?*%8_,H)).
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M4<>@ '\^: .EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOA3U8+@[B....N20 37!#2&U:^M[FRM'M4@93*\BB#<,Y*A!UX!&1G.[#84
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MW'I(Q<>G.&&?>I?&.@R:["MHC!4:5#+G@F-3DA3M;YL@$=.G)QP=Z@ HHHH
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M_P#A(;;?Y'G1>9NV[?,3=NSC;MSG.>,=<U:NKM+13+*RH@QEG(51DX&2>.M
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M19'QM5G4,<G PI.3D\#WH MT45S_ (W\3?\ "/VS3H4\WC8LA^]\RAL*""<
MYXZ=Z .@HKDKGQ'%J^G2D21F9K)V=$8$J3%\WRY) !..>G0U7^'FK0Z?IUOY
M\B1[O-QYCJN<2MG&2,XR* .UHID,RS*'0@JP!!!R"#R"".H-4KKQ#;6C&*6:
M)'&,J\B*PR,C()STH T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR\:%%K&NSI.-RQQHX4_=)
M"1  CN/FSCOCG(R#ZA7+Z?X7EM]3GU0E?*EB"@ G?D",<C&,?(>Y[4 <EK_A
MB!]7ALE7RX9X09$B.Q6V[VQ@< $QKD#'3(PW-79=/CTK7(([=1&LL#%U3Y5/
MRR?PCC'R*<8QD9Z\UT&H>%Y;C4X-4!7RHHBI!)WY(D' QC'SCN.]&H>%Y;C4
MX-4!7RHHBI!)WY(D' QC'SCN.] %3Q1J6GPW($T1N+O8%$:1^:P7E_ND[ 1U
M_OX.?NFL+P%*HU6Y2&-X8FAW>4X*$',?)3) Y9BOH&XP#BMW5O"=U!>G5;!X
M]TB;9$GW;> H&-H)Q\H/8@CJ0< \-^$[JSOI=3N7C?SHMI\O<,'Y. "/NKMP
M#G) !/). "KX.E7PS->Z?+A(HR;B/ <_NB/F.2.0H"CUW;AEL<7?AM&;N.75
M'^_>3.P^8L0B$JB'.!\IW 8'3'T&%\6]*^T3VIB8+-.6ASEAE6( Z @*-Y#=
MR&QAAG'H]I:K:(L,8PD:A5&2<!1@#)YZ4 <U\4O^0=/_ -L__1J55T#P+:7U
MA&LJ;GFAC8R-S*"47&UR,@*  JCC P0<G.UXST1];M)+.(J'DV8+DA?E=6.<
M GH/2N=A\-:K8VPL(9XBNP#>^]9$SU1& ;*CHK$!@#P%PN #D?\ A)IO[$\O
M/_+QY&<MN\O9YF,Y_P" ^FSY<=ZV[OP]++ UI'I2)E2%?[1$SJ3R&W'YC@]M
MW(^7IQ72_P#"O(?L']DY_P!KS-J[O,SG?C_QWKG9\N[O45KI^KVZBV\VW9!E
M1*ZR&;;G 8K]TL!V)()'S$\D@&QX1BN(K6-+S/GJ"&R0QX8[<E203MQSG)[\
MYKE/B%HL\EU#?B$W-O"F#"&/WMQYVX.0<KG ;(7##;7>VD;1(J2-O<* S8"[
MB!RV!P,GG':L?7(+_P U9;)XO+V8:.=6QNSD.&0;B2.,$@#&<$G@ J^#]4L;
MQI!:((9L 21%/*<;&8#*CY<@DY(R1D!L<"L?X*?\><G_ %\-_P"@1UJ^&/"4
MMG<2ZI=R*]Q,NTK&,1J,C !/)X50.!CG.X\UGZ7X2O\ 0FE@LI(5MI9"R[P[
M21AA@E1T) P!N8@[03C)H B^''_'YJ7_ %\?^SS5F?"+PY!?V[W$ZB0B5E59
M &1?E0DA3QN;@$]<  8YST?@+P=-X=>X>=UD\]E(8%BQVE\ELC@G<#U;G//K
ME>%O!6I>&D;R986+MS')YACQC[X8 $-VQC!'))(   [P7$-%U.ZTJ'/D!%D
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MM7$5U ?E8]"#U5B 3@<X'(Y8$8;(ETZRU">5);N2)8XB3LMP_P ^Y67YBY&
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M.5VG!&WKR#VH Z"BN7UW69TOK6QMB/F#O,K*2/+X ;<!P>&"X(^; ;@C/44
M>:?#;2HO$0GU6[19)9)F7#C>B@!6PJMGUP,YPH &.<V/B/$/#M@\-ME4N)P"
MN3A0ZEF5 "-JL5Y7D?,PQ@C%N#PG>Z%/+)ISQ>1,=WE3[@JL3SM$8X Z#!'&
M 0=H-:%SX1DU:UEM;V4/),^\,J?+$=J@*@8GY1@C/RE@3G!)- #_ /A75CY'
MV/REQMQYF!YN>N[?C.<\^G;&WBN$M-3>^T"99#GR9%C4\D[0\3 ')/3=@=
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M6.2W!&,8 Z'DY .2^#FDPW-LT\D:-(EP=K,BEAA$(PQ&1@\CWJWHW_(>NO\
MKW7^4%6/#?A.]\-2-!;O$]H\H;$N[S0. V-H W8&.3@X!PN2*T-/\+RV^ISZ
MH2OE2Q!0 3OR!&.1C&/D/<]J ,?P3>CPY)>:5,_[NUS*A.YB(R-S=!C@%20
M/F9B,UF:>\VEZ7=ZN0$GO'+Y&\861PH(&1@C>S(03P5))Z5M^/? ]QK<JW%I
M($8Q-%(&=E!3.0/E4Y!R=P/!XXKJ+K0HKFW.GD?NC&$ ZD #"D%L\K@$$YY
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M/EQQCCICK5OXB6B0FTTJ)5B@N[@>8(@$)P47MQ_%GD'E5/:MW4/"\MQJ<&J
MKY4414@D[\D2#@8QCYQW'>K7B[PJOB&-5#F.6)PR2*,LI'7N#@]>".0I[8H
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M3YMJAW&U/[@ZM\N#N).>F-#2]!U!+5].N&@,?V9XXV3?OR5VIN.T#:!QD#/
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M !1110!DW7AU+JZBU!F?? K!5##R_F!!.W&<D'J".@]*UJ** "BBB@ HHHH
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M#1$T2!+.(L4CW8+D%OF8L<X '4^E:%8.N^,H-'MX[Y]SQ2E0NP#)WJ6!PQ7
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M -"BBB@ HHK/FU^"&=+!FQ/(NY5VMR!NYSC ^Z>I[4 :%%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M##2!57)!B!&U<@%?NGW'/- &UJ/Q%-I>/I:P-)( -FQA\S,BL 00-J\G+9.
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M[6:T>XGAGAE;=%#-L&!A2V ""=P()!/09ZC(!W_AOQ4NKL]O(AAN82=\3')
M[,#@;E.1R/4=BI.:?',]XIN+*T>:!=WSEUC+%2<[4(+,/3C).5QD8JQX=\)6
M^EW,EPDTDL^P+()9%=@&VE<X4,"0HQGMTKC/"^MSVUHL5M<VD:-YFU;F3$T>
M7; XP&_O LO)/3;B@#L]'\82WMNU]);,(P$*"%UG=]QP<*N,%>X/(Y[@BJ5Y
M\0)](:,WUHT,4C;?,$JR@''<(OZ9R0"0#C%0ZMJ?_"":;"+8K-\P57;[IW[I
M"V%/(/.T \ CDXYY?XC6US%:0O<W:SB1U*HL:*/N$EU=<%E&<9P =P/'% 'H
M?C7Q7_PC$*W.SS-T@3&[;U5CG.&_N^E'AKQ'/K1\QK=HK=E+1R/(I9AD!<Q@
M9&1SG)'H2"#7/_&O_CSC_P"OA?\ T"2NP\0VK7=M/#&,O)#(JC(&2R$ 9/'6
M@#FK/XAR:FTCVEJ\MO$V#('"L0!DE8V +''(4')XSM)Q69\)[U;^XO[A,A99
M48 ]<,TI&<9YYK3^%>JQ-IZIO4&#?YF3C:"[."<]L<YZ=><@XS_A;=+=W.H3
M1G*23*RG!&0SRD'!YZ4 'P?NEM+"::0X2.:1F."<!8T).!STK23QQ=7:FXMK
M&1X0,AGD6-V&T-D1X8D<\;=V[MSP.-\.VK76AW:(,D3%NH'"")V//H 3_+FN
MB\(^&(]6M8IH[RZ^XH98Y\*K!1N0+MX [#TP1D$&@#;O?B';06?]IH2ZL=JH
M.&WXSL;KM(QDGICD;LC,NB^(KJ\=%N+1H8Y!P_F*^#M+ ,H 900",D<-A2,F
MLJ'P1IYLQ9^<6AEG#(_FIDR8V85@ I) (Q@]^X&*0U6[\)7-OI\LZW4=RRCY
MQME3<^W.<L2"6X+$YVE1MQF@#5G\>27%Q)96-LT_D<.QD$2A@2"/F7'7CJ"<
M' (&3TNEWC7D:RR(T;G(9&P2"I*GD<$9&5/<8/>N/OO"022;4=.N_)?=(906
M#Q;P,D-SA<$DG<&VYR , 5K?#_Q2_B2W-Q*JJZR,AV9VG # @')'#8ZGIGO@
M %_Q+XEB\.Q?:9]VTL% 098DY.!D@= 3R1T]< X%QX]N=/1;J[LGC@.,LLJN
MPW#Y<IA2,G .XK@G'7 -3XH?Z--87K\10W'SMUQED8<#D\(QX!Z>XKH/&>JQ
M06$TK.NV6%U0@Y#&1"% QG.<YX[<] 30!B?$_4VN-/WPIO@F5&,FX+M&]&0[
M",G=G';'>M#P'J-S/##%+;^7$MO'ME\U6W850OR 9&1SSTZ5S5S:M:^'0CC!
M*JW4'AYPZGCU!!_GS7=>$_\ CSMO^O>'_P! 6@"+7O$O]CRV\+1LR7,GEEP>
M%8X"@C&#N)]0< D XQ5?QEXTC\+K&SJ7,KXP#@A1]YAQ@D9'!(SGKP:B^)6C
MC4[&4<;HAYBDDC&SENG4E-P /&3VZCDK>/\ X6+))(VTB"S15!9U43RC=O"]
M@I!4YW9"@_,.@!WOBKQ$-!A\\(9'9U1$&069C]T$*W. 3TYQCJ17&>+=273=
M9MIW#$+;GA%+,2WG*J@#J6) 'N><"J7AC4F\12Z=:D I:Q-)(%? !C)CB)7/
MWEVJ>^=YX"YSL:S_ ,AZU_Z]V_E/0!IV?C>5+F.QO;<VYG!V,95=21_#D #)
MZ8!)R5&/F!J[X@\6_P!F2+9PQ//<.H8(G"A2P7<SG(49SS@@8^; (-<_\1_^
M/S3?^OC_ -GAK,U/35?6I$FED@%Q$GEM#)L9CA%"YP< E6X.,D#'49 .KT_Q
MFXG6SOH#;/*/W1,BR(YS@KN4 !NF!WSV)4-R6O:C<KK,,BV^9$C=8T\U1YB_
MO0'W8PN02=IYXQWKHF\!VZ3P/-<SO*C[HEFF5LE"&. 5R1P-V.U9^O3+%KMH
M6( \@C)..6\X ?4D@#U/% %+Q]J;)+IMU=)Y)69V==PDVA9(^<J.>!G@>W6M
MV?Q_+921?:K5H8)WVK*\B\9^Z77'R'N0S @;L9VFJ7Q'_P"/S3?^OC_V>&CX
MU_\ 'G'_ -?"_P#H$E '2^)O%"Z&$78\LLN[RXXE)9B@R?H!QGJ><@'!QFCQ
MO+8R(FH6YMXY2563S5D0-V#%0-H/J3^@)'/^/[55U2UEFD:&%XBGFQOL8,"_
M?G:/G4$D8P3SP<:NJ_#NWF54NKNX*LX"B6=2"YR  &7ECSC'/6@#0\:>.5\+
M-"'C+K,6R0V"H7;D@$<GYNF1TZ\\:'AW5KC45+W%N8!A2N9 Y;=G.0 "I''!
M&>?:N7^(_P#Q^:;_ -?'_L\->@4 <5\6KB2.R>-(]T;[=[[P-F)$*_*>6W'C
MCIU-5-/U&YGTUXI;?RXET]MLOFJV[$0"_(!D9'//3I6K\4O^0=/_ -L__1J4
MV*99=&RI!'V C(.>5A((^H((/H>* .?\#^*)K:PCBM;9KCR1)YA#",*2[,%7
M()=MO)"@XRHY)P.RT/Q9%JMI_:/W456+C.XH4Y8';STY'&2"#@9Q6?\ "W_D
M'0?]M/\ T:]<+X=M6NM#NT09(F+=0.$$3L>?0 G^7- '9)XXNKM3<6UC(\(&
M0SR+&[#:&R(\,2.>-N[=VYX'1Z%KL6N1"Y@.5;J#]Y3W4CL1_P#7&003QGA'
MPQ'JUK%-'>77W%#+'/A58*-R!=O '8>F",@@UTO@W0K?1X"EHYDB=RVXLKY.
M IP5 &!M_/- #?'EQ)!9S>5'YFZ.16^<+M4HVY^>N/[HY-<U\.-9N;:SB3[,
MS6Z+,?-212QPSM@1?>)+?*!GKSTKK_%G_'G<_P#7O-_Z U<EX<UQM#T-;Q%#
M,@? /3+3LH)QV&<XXSTR.M %[4O'MSIBBYFLG6W++\YE4N%8\$Q@$J<=B0 W
MRDY-:OBC7(H+%KXQK/$5C8(_"L'9=I.Y3Z@\CMVKA/$TEW?::;^>[0QS["(4
MC3;DN"$$F=V4QDCDC:02<$UM^)?^0"O_ %[VO\XZ *7Q/N5NM+MI44(KO"P0
M=%#1.0HP!P.G0?2NM\2>*_[%FMK;9O\ M4FS.[;M^9!G&#G[WJ.E<5X^_P"0
M-9_]N_\ Z(:M7XF?NKG3IVXC2X^9CPJ_/&>6Z#A2>>P/I0!T'C7Q7_PC$*W.
MSS-T@3&[;U5CG.&_N^E5_&GCE?"S0AXRZS%LD-@J%VY(!')^;ID=.O/'/_&S
M4(Q;QVNX>:90^WOM"NN[V&3@9Z\XZ'%CXC_\?FF_]?'_ +/#0!MV_BV2""2^
MOK=K>.-4*_.)&;=QC: "IS@8;')YQ@U1F\<74*&Z>QD%NI)+&11($#8+&(C<
M"!SC.,<[MOS57^,EJTUB'49$<R,W(X!#)GWY8#CU]*?%X0@U&#[0+ZZ:!T))
M:X&S;@[LY7@#D,#TY![T =AI^H1ZC&MQ"P:-QD$?YX(Z$'D'@\UYY\:[B3R8
MXO+_ '7F*WF[Q][;(-FSKTYW=.U=QX;TJ+2K>.W@8O$H)5B0V0Y+YRH (YXQ
MVKDOC7_QYQ_]?"_^@24 ;J>*);.&6[OX# D04C$BS%MQQ@!<8.<#GCGJ ":S
M?^$]N?+^W?8G^R_>W^:N_P O/W_*QGISUQCG=M^:J_Q?B-[8+-%AD65'+ @C
M:RLH8'/()8=,]<]*ZW^WX/(^W^8OD;=V_MCITZYSQMQG/&,\4 .T76(]8A2[
MASLD&1D8(P2""/4$$>GH2.:-:UB/1X7NYL[(QDX&2<D  #U)('8>I YKDO@W
M:M#8EV&!),[+R.0 J9]N5(Y]/2CXR6K36(=1D1S(S<C@$,F??E@./7TH MVO
MCF>51=O:.EF<GS=ZLX3. YB W8[G&<+EAN'6QK'C8V]Q_9MK"T]PH!90PC10
M1GEVSSR.V/F W;N*V/[?@\C[?YB^1MW;^V.G3KG/&W&<\8SQ7&>!IEL-1O[6
M4A9990Z*3]Y<N_!'&=K@XZXSQP< &WH_C8W%Q_9MU"T%PP)52PD1@!GAUQSP
M>V/E(W;N*B\3?$!=!NH[)HF<2(&S&<OEF90H3 R20/XAUZ<<Y/CF9;_4;"UB
M(:6*4NZ@_=7*/R3QG:A..N,<<C+]9_Y#UK_U[M_*>@"Q=?$E](D$>H6S0!D9
ME99%ER5_A^4 9/3KP2N0 <BQ!X_:.XCM;JW>!;C_ %3LP8DD@*&4#Y2<C(R2
MI(R,'-9_Q'_X_--_Z^/_ &>&CXC_ /'YIO\ U\?^SPT :OB'QZNB7<=B\;,)
M(]VY"2V3O"H$"\EBH Y')YX%10>/)+>XCLKZV:#S^$82"52Q( 'RKCKQU)&1
MD '(Q_%&H1Z?K=K-,P5!!@L>@W><HR>PR1ST'4\5+\89ENHH-/0@SRSH53/)
M!#(#SP 68 9(SSCH< #]9_Y#UK_U[M_*>NET'Q+_ &I+<6K1M&]K)M.3D,K9
MVL. 1D#.,8P003GCFM9_Y#UK_P!>[?RGI_B:=/"VH1:JP/E7*-%,0K-M(VE6
MSGJ<#@#[JL0"3P =+!XB%Q>/IR(2(HE9WYP&8C:F-N,E3N!SZC'!Q+XDU=M'
MMY+M4,AC .T'&1D G.#@ $D\=!6%\-;622*34K@?O;V0OU;[@X08;H!SMQGY
M2O)XQU5W:K=HT,@RDBE6&2,AA@C(YZ4 9M_XFCM+,ZH0=GE*Z@\$[P-BG&[!
M)(&>0.O2C1O$T>HV@U,@I'L9F!YV["0W3J!M..,D=@>*\RTF=KU8/#+[28[R
M02;6=5:.(EV!('.XEL=,;5R >:+^5]&2\T&$+NFNHEB"N0VV<9QECR-JHC9P
M,L<L1C(!U6O^,D.GPZC<6JN)I !%*00.'VOED.<A<CY1PW!QUS_C7<2>3'%Y
M?[KS%;S=X^]MD&S9UZ<[NG:IOC!:K:6$,,8PD<T:J,DX"QN ,GGI4OQK_P"/
M./\ Z^%_] DH /&NHW-YIUS]IM_(V^3M_>K+NS*N?N@8Q@=>N?:F:=XVFLK*
M*6"U:6"""-7DWA/F10'PI4LRJ>"P&,ANPS6M\3)EFTR9T(*L(B"#D$&1""".
MH-._Y@W_ '#_ /VA0!T&E:FFJ1)=1'*2*".F1GJ#@D9!X(SP017*_%JXDCLG
MC2/=&^W>^\#9B1"ORGEMQXXZ=35KX6_\@Z#_ +:?^C7H^*7_ "#I_P#MG_Z-
M2@#*T_4;F?37BEM_+B73VVR^:K;L1 +\@&1D<\].E4O _BB:VL(XK6V:X\D2
M>80PC"DNS!5R"7;;R0H.,J.2<#H(IEET;*D$?8",@YY6$@CZ@@@^AXIWPM_Y
M!T'_ &T_]&O0!8L_%46K6#Z@$#*(I"\3$'E%.Y#P>#[CE2"1SBL^V\<0:=IJ
M:B(A&KEE2&/&-VYQC(4  [2Q...>IP#SO@#_ ) UY_V\?^B%K0\-:+;ZSI%O
M;73;%:1MA#A6W^;( !G()()&,'V&<$ '1:+XBNKQT6XM&ACD'#^8KX.TL R@
M!E! (R1PV%(R:Z.O.AJMWX2N;?3Y9UNH[EE'SC;*FY]N<Y8D$MP6)SM*C;C-
M>BT >?Z-_P AZZ_Z]U_E!5>&*-]=!L\86)S<;#@;OF!R,X)W%,@9^;D_,&(K
MMH$&MZW<PW*[T$*,!N9>0L(SE2#T)KT#1M @T5?+MHU0'KCECR2,L<DXR<9)
MQT'% &%<>.GN)Y+.QMVN&@)$A+K$@(.,!F!R<Y'..A(W#D6O#?C)=6E>RDC:
M&YB!+QM\PQG&0PZCE3T&<C;N'-<_\'IEM8I]/<@3Q3N63/( "H3QP0&4@X)Q
MQGJ,EQ,NI:[$82&%M PD(/W3^\!'N074'&<$X/0X '_#C_C\U+_KX_\ 9YJT
M_ _B6"]M)+Q(5MXHG?<J8(^5%8MA57G!]">*S/AQ_P ?FI?]?'_L\U<UX=M6
MNM#NT09(F+=0.$$3L>?0 G^7- '967CR?4E^TV]G(]L#]\R(KD+]XK'SN(Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&,)&H51DG 48 R>>E344 %9FA^&[?0E9+9 @<Y;DL3CIRQ)P.PS@9/J:TZ*
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MZ7[+F>-=JMN;@'=QC.#]X]1WK0HHH Q-9\%V>LMYL\2L_P#>!9&/ ')0@G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKE_B/JK6%FZ(I:2X(A4
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M*Q[;4K;2+2*0R 0+$@1G."RA,KQ@$L5&< 9/857TSQ]8ZFXABF4N>@8,F22
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M23[]@P3G8,MR!@8'J1[5;H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M11?9I]VT,&!0X8$9&1D$="1R#U]<$9$/A&\91#-?R&(  ^7$D<AQT_>Y9LY
MR>21D'K0!T6DV[VT,<4IW2)&@9LDY8* QR>3D]SS7#V\*ZEKLHF 86T"F,$?
M=/[L@^Y!=B,YP3D=!CT.N<\2>#5U:5+V.1H;F( )(OS#&<X*GJ.6'49R=VX<
M4 <_\885M8H-00 3Q3H%?'( #.!SP0&4$9!QSCJ<O^-?_'G'_P!?"_\ H$E:
M=OX%>XGCO+ZX:X: @Q@(L2 @YR54G)S@\8Z '<.!=\:^%/\ A)X5MM_E[9 ^
M=N[HK#&,K_>]: .@KE_%'B>+3IXK=(3/>,"8E  VACM)\P@[00#G&>%^; YK
MJ*YKQ/X,_M>6*]AE:&XAX#@;@5Y."I('4GV()# @C !R,4\MQK=O)/ ()&B;
M*AUDW824!BR@<\8YYPH[8KU.N/L? <D5Y'JD]RTLD:L"&C"@Y5E&W#84 ,.,
M')R<_-QV% 'F]CI\=YKUP9%#>5$CKGLP6(!L>HR<>AY'(!J7QS"MAJ-A=1 +
M++*4=@/O+E$Y!XSM<C/7&.>!C/ET8ZIK=P%D:*2*)71TQPP2)1D$<K\QRO&1
MQG%=1HW@AK>Z_M*[G:>8+M0E!&JC!!^521T)XX'))!)R #'^#T*W44^H. 9Y
M9W#/CD@A7(XX +,2< 9XST&"XA73==B$("BY@8R #[Q_>$GV)**3C&2,GJ<Z
MUQX%>WGDO+&X:W:<DR HLJ$DYR%8C!SD\YZD#:.#:\-^#5TF5[V21IKF4$/(
MWRC&<X"CH.%'4XP-NT<4 86L_P#(>M?^O=OY3U4\="6^U2VM(Q$^(694N%W1
M9;S-Q; R>$&/0@>]=-XG\&?VO+%>PRM#<0\!P-P*\G!4D#J3[$$A@01AFK>"
M3K$,27$S&Y@+%)T41D$G(^0<8&%Z$'Y>&&30!B>)/"^J:^J"0VJ-$X9'C,JN
M#[,0<#H>.X![5%XHT^/4-;M89E#(8,E3T.WSF&1W&0..AZ'BNCM/#5V75[F]
M>1$8,%CC2')4]&*Y+*1D%>_KQ4M[X4^TW\6J[\>3&4V;<YR'&=V>/O\ H>GO
M0!S_ ,0OW-_ITJ?*[3%2PX8KOC&TD<XPS<=.3ZFCXC_\?FF_]?'_ +/#70>)
M/"G]M36USOV?99-^-N[=\R'&<C'W?0]:/%_A!?$2H=[1RPMNCD7)*DD9XR/0
M8.000"#U! .?^-?_ !YQ_P#7PO\ Z!)6QXH\3Q:=/%;I"9[Q@3$H &T,=I/F
M$':" <XSPOS8'-5];\#SZW;"TN;G>XF#B3R57@(5V;58#J2<Y]L5;\3^#/[7
MEBO896AN(> X&X%>3@J2!U)]B"0P((P <C%/+<:W;R3P""1HFRH=9-V$E 8L
MH'/&.><*.V*T]9_Y#UK_ ->[?RGK0L? <D5Y'JD]RTLD:L"&C"@Y5E&W#84
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M/_C7_P ><?\ U\+_ .@25Z!6/XJ\,Q^(X#:R$CG<K#^%@" <=QR01W!XP<$
M&9\4O^0=/_VS_P#1J55M]*BM]%9%10'LS(W&<N8M^XY[YP0>V!C  Q8F\&W%
MY:RV%Q=&02",*QB *[&#'.&RY; Y)SWYS6O_ &%_H?\ 9N[_ )=_*W[?]C9N
MVY_'&?QH X*69I?#N6))P!DG/"W( 'T   ]!Q5[5?"<NMV=A/!L9[:&-O+E'
MRN"B';Z<E0,' ()RPQSM?\(+_P 2[^QO-_[:;/\ IKYGW=WX=??VJQ=>%YO)
MMXK>Y:)[9 NX*&1QL"G=&3@GC(R3MY[X( *NA^,#<7"V%["8;S8=IX9&! 9M
MK#. =I..1\N"Q88KK:Y?1_!)M[C^TKJ9I[A00K%1&B@C'"+GGD]\?,3MW<UU
M% 'E7A73KF\O-0^S7'D;;@[OW2R[LO+C[Q&,8/3KGVKJ+;PVOA.TN9XG9YVB
M=VD<Y)=$8@X.1C<2><GGDFKOAOPI_8LUS<[]_P!JDWXV[=OS.<9R<_>]!TKH
M* .,^$VGQV]@DR* \I<NW<[795Y] !P.G4]2<Y_A6%=-UB[LX0$A,2OL XW8
MC/'H/WC<#CGIP,:%MX ETEF&GW301.<E&C68 \]"Q&!C [DX&6/&-7PKX1C\
M/*Y5FDEF(,CN<EB,]NPR2><GGECQ0!Q'@#_D#7G_ &\?^B%K/U.Z:'0+=%.!
M),5;@<@/*^/;E0>/3TKNM \"_P!D6<VF^;N\_P SY]F,;T"?=W'.,9ZC-6+#
MP7'%8#2)F+IA@6 V'ERX(&3@@D>H..1CB@#3_L"#R/L'EKY&W;L[8Z]>N<\[
MLYSSG/-<OXE']@ZA;ZKD+#./(F("CDY*,Q)'' R?X53J<@4^U\!7*Q"QEO7:
MVVE2B1*C[>RB0EB!VQR-OR]*M?%"!)=/F,G\.PJ=H8AMX QDC&<X)Z@$\'H0
M"KH)_MK4[B^*X2T7[.F4ZL&)=@V2,@Y''.UAG'.>UKG_  %HW]D644)&'9=[
MY7:VY_FP1URH(7GGCMT'04 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@#/AT""&=[]5Q/(NUFW-R!MXQG ^Z.@[5H444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !6?K>@0:V@AN5WH&# ;F7D C
M.5(/0FM"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N/G\>27%Q)96-L
MT_D<.QD$2A@2"/F7'7CJ"<' (&3V%<)?>$@DDVHZ==^2^Z0R@L'BW@9(;G"X
M)).X-MSD 8 H F\>WC7FDRRR(T;G8&1L$@K,JGD<$9&5/<8/>J.G>-IK*RBE
M@M6E@@@C5Y-X3YD4!\*5+,JG@L!C(;L,U2U+Q2_B31;BXE55=9$0[,[3B2-@
M0#DCAL=3TSWP.E_Y@W_</_\ :% &G+XJ@CM/[4)/D[ W&"W) "X!(W;CM/.
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MYK1O^0]=?]>Z_P H*J:MJ@\#WMQ(!\E["9$)5BHF3=\I.[D,22V.FY1\J\T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5SFH?#RPU"1IY(07<Y8AW7)[G"L!D]^.3R>:Z.B@#/NM @
MNH#8M&H@./D3Y%X;=QLQCGGBI?[+C\G[%M_=>7Y>W)^[MVXSG/3C.<^]6Z*
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M=Z!@P&YEY (SE2#T)IFN>&[?755+E X0Y7DJ1GKRI!P>XS@X'H*TZ* ,'3O
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M]$T"#1$,-LNQ"Q8C<S<D 9RQ)Z 5H444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex19-1_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex19-1_009.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0\[EE7(P"V]P,A !@*N>V<8R"<U7\.2:U-]GO)'22"5D+)B,,(V_C.%7H.0
MQ.<97J* /1:ANY&B1GC7>X4E5R%W$#A<G@9/&>U<+X9\4W,>I3:3=ON7YO*W
M*N[CYEYC 'S1G<<CJ .#P7^$/$ESKM_<#>#:0%@H0)M/S;4^;!8A@"V0<9'8
M8! -_P &^*E\30&Y"%"KE2I.[D '@X&1@CL.<CW.]7EGPR<6.HWEC& (LN1U
M)'E2[5&2>F'.<Y/3GKGU.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M##&,)'-&JC). L;@#)YZ5U_A/_CSMO\ KWA_] 6M:B@ KRKP!_R&;S_MX_\
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MPS_T[4KR]CYB/F8;I_K)0R<'!Y"D].,<XKU6N7^'WA!O#,#12%6ED<LQ0=@
M%7<0"0.3T&"Q '<]10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M08))NP' #?*Q4YP2.H]: -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH/EQ1+( V,L!E,*!D[0S%F_O< 9]%\(>*)M>T^2=F5)HQ(GF-@)N5 PD(P0
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ME\M_-_N;&W_\?&[[N,].>G3F@"KKOQ"G33+>0'%Q=>8"ZC&%C8JQ'/#'CD#
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MWCW>5CS$9<XWYQD#.,B@#TNBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *J:KIB:I$]K*,I(I!Z9&>A&01D'D''! -6Z* /.C\*)HU-O
M%?2K =P$>UBNUB<@@2*#G// !YXYKK_#7AJ+P[%]F@W;2Q8ESEB3@9. !T '
M '3UR3K44 %%%% !1110 4444 %%%% '*>$O O\ 8<TU[)+YLL_5MGEXW-N?
M@,0=QP>@QCCK75T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5D^*="_MZV>RW;/,V_-MW8VL&Z9
M'ICK6M10!D^%M"_L&V2RW;_+W?-MVYW,6Z9/KCK6M110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%>?Q>%K;7M1OOM*;_+^S;?F9<;HN
M?ND>@ZT >@45Y_K&C_\ "#[=0LV<6XD43P%MZ;7VJ74,P.[('<G)'(4$'JM=
M\21Z-M5P[R2;MD<2%W;;C=@#C@')R1QG&: -:BL30/%L6LL\*J\<L>-T<R[)
M,$ AMN3QS^'&<9&>?N_'<EM?M;^3<-$D)'EI""Q828\T<Y,9' .<9[4 =W16
M/J/BJ'3HHYIMRM,!LBVDS,Q&=FP9^;D ]@2 3R*KZ7XTCOI%MGCFADDSL$\1
M3?M!+8(R/E YR1U&,T =!117.:AXYAMI&@B26=XSAQ;QF38>P8Y R>>A.""#
M@B@#HZQ[SQ=:V4ZV,D@$SE0% 9N7.%!(! )]R."#T(IFE>+8M4BDGB5]T&[?
M$5Q,"N?EV9ZG''/)XZ@@<O\ #O6E>:X002AI[N9C(8L*H W!';/##GY><%O>
M@#T.BBO,O _@>PO[".\N8P6(D+N9'485V&3A@  !0!Z;17-> ;M[B"169I$C
MN)DCD<EF>-6^5BYX;DD9''&.U,F^(,)8BWBGN%4D%[>(N@8=5W$C)Z'C(P00
M: .HHK,B\26\EO\ VB''D8)WD$="5/! .<C &,D],Y%87_"SH(T\^6*XCC*Y
M5I(<*Y(RJJP)!+#D9P,#J* .PHK'OO%$5E:#5&#&(I&V !OQ(5 XR!GYAGFM
M#4;U;")[A\E8D9B!UPH).,XYXH L45DS^)X+6W34)6V12*A&X?-\XR!A<DG'
M4#/0GH,U0M/'<<KK%+#<0>8P56GA*JS,<*@(+<GWP, \T =+16/KGB>/266+
M9)+*PSY<">8X4<;R,C"YXR>IZ9P<,A\4K- ]VL4Q,;;6B\L^<"=O&S//#!N#
M]T^O% &W17%> O&DFJQQ13QS-(^_,WE 0G!8CYA@= %Z?>X]ZW;;Q1%<7<FE
M@-YL2!B2!LP0IX.<Y^<=AWH V**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"8;.1MQC!R<^M<O?^ ;338)Y+6']Z;>95P7=LLA& &+<GIQSSCN: ,_Q+_R
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M*@#JZ*Y3_A/O^G.\_P# ?_[*C_A/O^G.\_\  ?\ ^RH ZNBN4_X3[_ISO/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3VK,U&SU+2(GO/M:S>2C,8Y+=45@H)/S(=P('(QU( /&:L?%+_D'3_\ ;/\
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MK/QMC+A&;YE!QP2< Y. :YJYTA]*GGFN+1;R"60R"15229 W CV/DL%P ,8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML_\ GXA_[_)_\51_PEEG_P _$/\ W^3_ .*H_P"$3L_^?>'_ +\I_P#$T?\
M")V?_/O#_P!^4_\ B: #_A++/_GXA_[_ "?_ !5'_"66?_/Q#_W^3_XJC_A$
M[/\ Y]X?^_*?_$T?\(G9_P#/O#_WY3_XF@ _X2RS_P"?B'_O\G_Q5'_"66?_
M #\0_P#?Y/\ XJC_ (1.S_Y]X?\ ORG_ ,31_P (G9_\^\/_ 'Y3_P")H /^
M$LL_^?B'_O\ )_\ %4?\)99_\_$/_?Y/_BJ/^$3L_P#GWA_[\I_\31_PB=G_
M ,^\/_?E/_B: #_A++/_ )^(?^_R?_%4?\)99_\ /Q#_ -_D_P#BJ/\ A$[/
M_GWA_P"_*?\ Q-'_  B=G_S[P_\ ?E/_ (F@ _X2RS_Y^(?^_P G_P 51_PE
MEG_S\0_]_D_^*H_X1.S_ .?>'_ORG_Q-'_")V?\ S[P_]^4_^)H /^$LL_\
MGXA_[_)_\51_PEEG_P _$/\ W^3_ .*H_P"$3L_^?>'_ +\I_P#$T?\ ")V?
M_/O#_P!^4_\ B: #_A++/_GXA_[_ "?_ !5'_"66?_/Q#_W^3_XJC_A$[/\
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M$#/2@#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\50!K45D_P#"66?_ #\0_P#?Y/\ XJC_ (2RS_Y^(?\ O\G_ ,50!K45D_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.S_Y]X?^_*?_ !-:U% &3_PB=G_S[P_]^4_^)H_X1.S_ .?>'_ORG_Q-:U%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !114,=VDK-$K*7CQN4$%EW#(R.HR.F>M $U%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !113)IEA4NY 50223@ #DDD] * 'T4R&9
M9E#H058 @@Y!!Y!!'4&GT %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7G7C/PV^B6DEY%=W9>/9@/.2OS.J
MG. #T/K7HM<I\4O^0=/_ -L__1J4 6]+\(?V?(L_VFYDVY^66;<AR".5VC.,
MY'OBB#Q]8SF-4F4M.VU  Q;.0N",97)/&[&>HXKH*XSX3:?';V"3(H#RER[=
MSM=E7GT ' Z=3U)R ;NM^*K71,"YD5"<87EFP<\[5!..#SC&>,YJQH^M0ZQ'
MY]NX=,D9&1@CJ"" 0?J.F#T(K O]5GN[N2WL88O.MT0233YZ.-XC 0;R#USG
M&0<CH34\"0RQ7E^)Q&)<VY80@B/+(QR-W.3G)SU;)H VM8\<V>CR?9YY0L@
M) 5VQGIG:IP>^#SC!Z$5F^$[M+N_OY8F5T/V7#(0RG$; X(XZT?"[9/:?:_E
M,\\DC3,,;BV]L9QTX((7@#.0.>8O!5K%:7VH16X41JT& A^4':Y8#TPV1CMT
MP,8H N^#I%L;-KI[EKB++R>:ZN"%48888LV 5)_'@>K[CXD:?!MS.OS*&&U7
M;@^NU3@^JG!'<5B>&O\ D M_U[W7\Y*Z#P9I44%A#$J+MEA1G!&0QD0%B<YS
MG..>W'0 4 ;7VM-GG[E\O;NW9&W;C.[=TQCG/3%<U_PM+3O^>W_D.7_XBN7M
M@LV@Q6Q)WW#^7& ,[G,[,J\D  [>23@#GDX!T]:TR^U^)=+>VBAC#(#,)%=%
M"?Q1QC#+G&%!Z*=IQDD '=6ETMVBS1G*2*&4X(R&&0<'GI7%#2WUN_O(FN+B
M-(/L^U892B_/'D\8(ZCMCJ:[NN4\._\ (1U#_MU_]%&@#/OC<>"V2X:9Y[)Y
M L@FR\D88 >9O )(!'3 '(4 LVX=7K.OP:*OF7,BH#TSRQY .%&2<9&< XZG
MBN?^*-R&M/L2\RW4D:1J" 2=ZMGDCCC&>Q(SUS5CQ!JLC74=E:PQO<K$T@DF
MX2-2VPXP"Y+8VD+CJ"<C. #5T/Q);ZZK/;.'"'#<%2,].& .#V.,'!]#7.W?
MQ.M[2\:UD=1!'&0S;)"PF5]I3@=,<YQC/\7:J^@PW":LQNQ$)6LLY@#!2/-4
M G=R6XQ] !6E_P QG_N'_P#M>@#;N-?@MH5O9)%6)U#*S<9!7<, \DD<A<9]
MJJ:-XTL]9;RH)59_[I#(QX)X#@$X .<9QWKFO%?G76J00P^26BMS)&MSNV[B
MY#$;.2V%! .0 "P (S5NYT34M1E@EG-LH@F5]T)E$FWHZ@L#PPZC@'C/% ':
MUY_H>AOKSW4LES<IY=Y-&JQ3%5"J00,$'U^F,<5Z!7F^@^%VU9KV1+B>%A>W
M"@12;4SP0Q4=3SSR,@ 9'6@#H_"=[(DUSITKM+]E:+;(^-Q61,JIP!DKCECR
MQ.>*EU/Q]8Z8YAEF4..H4,^""002@8 @CD'D>E9_POF1;4V@54FMY&291C.X
M'[Q^9B<@8STR"%^4"JFG7]WKL;3V,%M';3,^1/N+2')5G81C'S8P0<G(/)&*
M .SFU".*(W18>4J%RP^8;0-VX8SD8YXZ]JPKCXD:?!MS.OS*&&U7;@^NU3@^
MJG!'<5B>&O\ D M_U[W7\Y*Z#P9I44%A#$J+MEA1G!&0QD0%B<YSG..>W'0
M4 ;7VM-GG[E\O;NW9&W;C.[=TQCG/3%<U_PM+3O^>W_D.7_XBN7M@LV@Q6Q)
MWW#^7& ,[G,[,J\D  [>23@#GDX!T]:TR^U^)=+>VBAC#(#,)%=%"?Q1QC#+
MG&%!Z*=IQDD '87&OP6T*WLDBK$ZAE9N,@KN& >22.0N,^U5-&\:6>LMY4$J
ML_\ =(9&/!/ < G !SC..]<UXK\ZZU2"&'R2T5N9(UN=VW<7(8C9R6PH(!R
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M.4D4,IP1D,,@X//2N%\-?\@%O^O>Z_G)74>&)EAL;=W("K;1$DG  $8)))Z
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MMA%(0(9GLTER< ILW'+=A\H.00>.M=!XXT^!K"9)%4)%$2@.%"LJD1[>F#G
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M3]X@+T8D @BC7-$U;68_(D-HN&5E9#,'5E.0RL0<'MGK@F@#NZ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP2L^Z#;LE#8F!7'S;\=3CGCD\]0"(M+\%QV,BW+R3321YV&>4OLW AL 8'S
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M2P\OY0 #MQG( ZDGJ?6J%_X#BN)7N8I)H&EQO%O)Y:L1GYB,'GG^O4DGI:*
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MV2N2RGY5*D =QV(X. 7:]\1A93FRM(6N9$!,@C)^7! Q\JMDC/S= #@9SD
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M1R$Y(QGC*J<XYQCIR,C.(M?\?/83O9VUK+.\6WS"F=HWJ&7&U7/()Z@=.,T
M=A17'^&?B1'JWG),C026ZL[JV6^5/O'A005/!7&>F,\XRO\ A;;X^T?8Y?LV
M[_6Y.-N[;G[FW/;&_&>,]Z /1:*Y_P 8>,XO#"*\@9GDW;%7N5'.2> ,D ]3
MSP#@UF:#\1A>SBRNX6MI' ,8D)^;)(Q\RK@G'R]03D9S@$ [.BBO/+CXL,YD
MDMK22:",D>:"RK\HR2?W;;1WY.<8) Z  ]#HKE_$OCE='M(M12,NLY3"EMA
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MY V\8S@?='0=J /)_$T+>%X[S26!$%P4DMSCC(D0LF?F)(7@[F'W <?.*?\
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M'!R,$=""""#]#TR.A-4H?!EI# ]@L>()&W,N]^2-O.=V1]T=#VH X7_F7/\
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M+ ,75"<<!BS Y(/H< $@9%>[ZQHL.L1^1<('3(.#D8(Z$$$$'Z'ID=":R/\
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MW*/O#RXRC9';D\9Z]1D<UZU=:5%=1&T=%,14+LQA<#H!C&,8XQC&!C&*RH?
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M'M7?Z[X6MM>V_:4W^7NV_,RXW8S]TCT'6C4/"UMJ$R7LJ;I8MNUMS#&UBR\
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M]9M?LK+)Y?E;BA!7Y':1L-T.%YX)].O%8HM"=4N8GN&LRTDQ#\KD%]P4G<F
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MME2ICYDWL,C(XZXQQCFO3:R=$\*VNB9-M&J$YRW+-@XXW,2<<#C.,\XS6M0
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M[V-WWN>OZ4 >@4444 %%<_X4\:P^)_,\A77RMN?,"C[V<8PS?W3704 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K'\4>%XO$D0MYBP57# H0#D CN&X^
M:MBB@"OIUDMA$ENF2L2*H)ZX4 #.,<\58HHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/4L?+3><[LG)W8.<]">] 'IM%>3PV5L5#S6FH27( S.4<2;AT8?O" 5XV\'
M SGJ>U\.0RZMIZPW@99)(GC?(*OCYDW'?D[BN#D]2<XQ0!T=%9^@:(FB0)9Q
M%BD>[!<@M\S%CG  ZGTK0H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4Q[_ #,@@*#D*N N1TSP,YY-6O!FB/HEI'9RE2\>_)0DK\SLPQD ]#Z5MT4
M<9+X=O\ 3))_L$D7E7+M)^_#;T=_O%=JD$="-V1P!CJ6O>&/"SV,-Q;7;++]
MIFE9BN5W+(H!R!C:3@Y .!G@UTM% '&66@ZEI:_8[>:(VX.$>8.TZ(>P PA*
M?PYX/LN%#]!\"&&TGT^\?S!/,S[U)#$';ACGHV5R1\PSU)&:["B@#C[73]7M
MU%MYMNR#*B5UD,VW. Q7[I8#L202/F)Y)Z*:"86YB1P9_*($A4 %]N Y4 @#
M=SC!';!J]10!GZ!#/# B7;*\XW;F3A3\QQCY5Z# Z"M"BN?U3P%9:K(US/%N
MD?&3OD&<  <!@.@':@#H**Y3_A5NG?\ /'_R)+_\71_PJW3O^>/_ )$E_P#B
MZ .KHKE/^%6Z=_SQ_P#(DO\ \71_PJW3O^>/_D27_P"+H ZNBN4_X5;IW_/'
M_P B2_\ Q='_  JW3O\ GC_Y$E_^+H ZNBN4_P"%6Z=_SQ_\B2__ !='_"K=
M._YX_P#D27_XN@#JZ*Y3_A5NG?\ /'_R)+_\71_PJW3O^>/_ )$E_P#BZ .K
MHKE/^%6Z=_SQ_P#(DO\ \71_PJW3O^>/_D27_P"+H ZNBN4_X5;IW_/'_P B
M2_\ Q='_  JW3O\ GC_Y$E_^+H ZNBN4_P"%6Z=_SQ_\B2__ !='_"K=._YX
M_P#D27_XN@#JZ*Y3_A5NG?\ /'_R)+_\71_PJW3O^>/_ )$E_P#BZ .KHKE/
M^%6Z=_SQ_P#(DO\ \71_PJW3O^>/_D27_P"+H ZNBN4_X5;IW_/'_P B2_\
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MDO\ \71_PJW3O^>/_D27_P"+H ZNBN4_X5;IW_/'_P B2_\ Q='_  JW3O\
MGC_Y$E_^+H ZNBN4_P"%6Z=_SQ_\B2__ !='_"K=._YX_P#D27_XN@#JZ*Y3
M_A5NG?\ /'_R)+_\71_PJW3O^>/_ )$E_P#BZ .KHKE/^%6Z=_SQ_P#(DO\
M\71_PJW3O^>/_D27_P"+H ZNBN4_X5;IW_/'_P B2_\ Q='_  JW3O\ GC_Y
M$E_^+H ZNBN4_P"%6Z=_SQ_\B2__ !='_"K=._YX_P#D27_XN@#JZ*Y3_A5N
MG?\ /'_R)+_\71_PJW3O^>/_ )$E_P#BZ .KHKE/^%6Z=_SQ_P#(DO\ \71_
MPJW3O^>/_D27_P"+H ZNBN4_X5;IW_/'_P B2_\ Q='_  JW3O\ GC_Y$E_^
M+H ZNBN4_P"%6Z=_SQ_\B2__ !='_"K=._YX_P#D27_XN@#JZ*Y3_A5NG?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6\;%%DN"Y\PJ2&9/+.-N> >_KG(5_B379$TV2\F@42 @&&8>8G$P3G[NX?Q
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M0!KZWXJM=$P+F14)QA>6;!SSM4$XX/.,9XSFGZ'XDM]=5GMG#A#AN"I&>G#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAA>7\23:5/;,UHLLERRJS2-YA*G<FYI"S;<MDC*@C<>V17N%% '*>/O^7/\
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M5IM&Y5\P_,WE1Q[67/N<#&3Z _?##NZ* .*\#71T5VT"<KOART+8*^:CDN2
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M.,RB1AP3PN3D],#/ K6NO%EOXAL;IK=B2ELY8%2I7=&V <C!/!Z$CCK76T4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **ANKM+13+*R
MH@QEG(51DX&2>.M%K=I=J)8F5T.<,A#*<'!P1QUH FHHHH **AM;M+M1+$RN
MASAD(93@X."..M34 %%%% !113)IEA4NY 50223@ #DDD] * 'T4R&99E#H0
M58 @@Y!!Y!!'4&GT %%%% !114-O=I<[O+96V,5;:0<,.JG'0CN.M $U%%%
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M9/%<M$)"9%15?$R@(Y!P5 &T?Q#^(\=J9_S&?^X?_P"UZ/$7_(1T_P#[>O\
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MK(\0PJ-3T]P!N(N03CD@1Y SZ#)Q]3ZU@Z%]LNKN]N;7[,9!</&QGW^8%3A
M G 7"]<98@Y)P, '=Z-K\&M+YEM(K@=<<,.2!E3@C.#C(&>HXJ'Q9_QYW/\
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M1)O!)R1E_P"$XYQW ]*W?'W_ "Y_]A"W_P#9J -O1-?@UM#-;-O0,5)VLO(
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MT^/4+_3X9E#(3<DJ>AVHK#([C(''0]#Q0!T>B:_!K:&:V;>@8J3M9>0 <88
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MKKXD:?:L8VG4D8^XKNO(SPR*0?P/MUKC]5_XE<6K+:_+ &@50O,8:3"SJ,Y
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M(R",9QGM6?X=_P"0CJ'_ &Z_^BC47PNV3VGVOY3//)(TS#&XMO;&<=.""%X
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MKH;*ES($9QD##,<=,X4' ],]<''0UF>(O^0CI_\ V]?^BA47@C9=3WMRVTW
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MH=.D^TEI)I@"!).YD=5/\(Z #KVSR1G!Q3=9\%1:E+]K5Y89=NUGMW\MF'&
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MHM2E^UJ\L,NW:SV[^6S#C ;@YQC^0.<#'044 8^A^%8=(9I5W/,XPTLK%Y&
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M?*SD;MNS9G.,9Q[8SVK0HH P=0\&P7T$5JVX?9P@CD4@2KL  (;'4X&>,=\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M69I"9&)8AL!0#\H'4D$GC;0!Z717->%M9N-2MY5?9]IMY)(=W/EL\8&&( !
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M#_MI_P"C7H ZNBN:\=:S/I20/;<O)=1(5^4;PP;Y,L"%W$ 9[5GZFNIZ.AU
MSI,L?SR0"-8UVX)<+)RQV]L\D#)R?E(!VM%<?XO\2SQ6UM=6/W[F:$*KA?F$
MB,P0Y.!DX!((QV8=:MO>3^'H)KZ^E67"AE1(]BJQR-@898@L0H9AD 9/>@#I
M:*\\AUJXG47#:C:QR$ ^0!$T8(_@,F\O@_Q$9P2=I( J])XSEU&TMC:A1=7N
MY5W<*ICR)9/XAA2/E!.2"#AL%2 =K6)X8UM]5^T>8%'D74L2[01E4Q@G)///
M/0>U5].L=0L94$LRW$+DAR8EB=,*Q4KM.""V <Y(XP.I%?P!_P OG_80N/\
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M=LSMW>8F[&><9Z9YQ46JKJ<$3ZCYZ1[%,AMO+5D"KR4,OWB=HY(P"V0I P0
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M?RPI\^ZBB;<"<*^<D8(YXXZCVJKXEU2>6:/3+)E25U,DDC#/EQA@,A2,,6/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/PW+Z@L^K2@AKN7Y1E2 D7RH. .1RI)Y.T''.3T>OZ8VJ026J/Y9E7;NVAL
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M1,*[V!$A?H/PZD9R2"<$5:U-'O;S3[I8W"!;@MN4@IOB& _4*<\8)Z\5U=%
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M.W=YV=N[IG'..N*K^/=$DNC#?1QK-]E+EH77.]7 #8Z_,,9 P>>1D@*W6T4
M<):/;WSK%%I;#+#<T]O%"JKG#,"<[B,_=')&?2M;Q3J@@=8)K-[F KN#1QB;
M#@XP4(XX.=V><X /..EHH X_P)"]BD\KHUO9[LPQS,=R*H/F,=W*AC\V"< Y
M(X.YMKPMKO\ ;ULE[MV>9N^7=NQM8KUP/3/2K&M:4NK0O:NS*L@P3&=K8R"1
MD@\'H>.02*MPPK"H1  J@  #  '   Z 4 <EX_TYYVMKCRFG@@D8RPIDLVX
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MEO''-)+%(R-'%%O;"'!?@XVYXZYSCB@#JZ*Y2/XDVLB_*)3,69?($9,^4/S
MJ.!@<\GH".H(&KX?\2Q:ZK-%N5HV*O'(-LB$$C#+DXSCC\1U!  -:BN2@^)4
M%TBR013RE@2RQ1AV3YBHWX; +8) R3CDXR,[NA:[%KD0N8#E6Z@_>4]U([$?
M_7&002 :%%<E+\2[=!YHCG,&0//$)\GD@$[C@X!X/&<C !XSM:SX@BTJW-^V
M7B4*<QX;(<@ CD CD'KTH TZ*Y*7XEVZ#S1'.8,@>>(3Y/) )W'!P#P>,Y&
M#QG5N_%,-K-!;-G%T"8Y 4,9P,XSNSDY&, @E@ 3S@ V*J?VI'YWV+=^]\OS
M-N#]W=MSG&.O&,Y]JJ:]XCCT7RPX9GGD"(B;=Q)[_,RC . 3G@D9ZU7TC0&A
MN9M0G(:60[(]K,56$8VK@]&)&6ZC/(QDY -ZBN<U#QO';2-#'#//Y9PS6\7F
M(K=T+9'S#C([9P><@;MI=+=HLT9RDBAE.",AAD'!YZ4 345RGB+_ )".G_\
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MT*72*RK(,@2#:V,D X!/!ZCGD$&N2UO0(-;U80W*[T%B& W,O(F(SE2#T)H
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M/^$CC:[_ +,4,T@CWL5V[5'3#?-G/3@ \,#TY !K45#=W2VB--(<)&I9C@G
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M8T2[]IVL0[ ]%4CYLC@\$4WP=XI;6$1)(IE?R59I)(PD;'"@E6!P=Q.1P.*
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M[@YD13GYMV 6)5<_[(('' Q@9&*T/[+C\[[;M_>^7Y>[)^[NW8QG'7G.,^]
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MLD:R%1_&'BR">Y P#UQC;U&!J^,]5B@L)I6==LL+JA!R&,B$*!C.<YSQVYZ
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MXU9(ON 97:,8P"I! QCCIP..!3]#\-V^A*R6R! YRW)8G'3EB3@=AG R?4T
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ML0@&E2[V0* ;=5&2,8,QPP&?^6AY'WCS70:'X3$VGQ:?J"ARHR06)V_,2H#
M@@JI"\'&,@$KU *GQ U",2V5KN'FF]@?;WV@E=WL,G SUYQT.+'B+_D(Z?\
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M[*(M-L'?/DJ]F9N"R^6$YW  Y7..".3COBMX_#?3RQD\A<MNS\S[?F!!PN[
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MZ>/38H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KE/!'[^2]N6YD:\>,G_9A $8P.. 3S
MC)[DUU=<E>:'<:-<R:A8JLBS@>; 2(R6' 9'Q@'DEMW7YCR2-H!UM<9''-XJ
MFG_?R0VUO*8E6 A)"Z ;V9\-\OS8 '!&"0".=/2[B_OI%DGC2WA7.4WB61S@
M@?,,*J\@_P![*XZ&LS[!>>'9Y7M(Q<P7+M(4+I$Z2,1N^8]5/88/3M@EP L/
M/\.WD=BTK3P78<H9F+2HT29;YL<J>,#CKVP2][P1=O<_:_,9FV7TZKN).%&W
M"C/0#L.E,TS3+G4KE=1O56,0HPAA5M[*S\.[., D@8 &1@C@,"32MK>^\.RS
MK! MQ%<3-,K"58F4R?>4ALYQ@8Q]<\X4 T-!NWEO[Z)F8I']FVJ22J[HR3@=
M!D]<=:YSP3H=SK]JEQ<W<X4EO+$4FUL!B&+N02QR. <[1T/.!M^#='N[.XN[
MB]VEIS$0T9&P[0PP!PP"@@?,,GU/6KO@+2Y-*LHK:==LB;\C(.,R,1R"1T([
MT 4O">I7,MK<1DB6>TEFBC9AC>8U&S=\W4DX)R..ISDG'\(S)J3H_P!LN%O%
M8&6"9@%W GS4$14#& V-IR@P2 1BN@\-Z7/IZ7GRJLDMU/)%O.5(8#83M)(!
M(Y'7':L35;74/$:QV\MJD#AE)N/,1V3!#,453N4DJ,88^A/\0 &>+/%J&[:P
MEN&MH(D7>8U;S7=@& 5U5]JJ,9/!.2N"#D-\,>)HX[R*SMKF6YBG63<)\ED9
M5#!@[(I((4C:. <MWQ6QJ>F76DW3:C9*)EN HFA9E0Y1<(ZN>@'0@YZG@Y!3
M2T2]O;MR]S"D,04@+YGF2%LCYLK\NW&1C[V1Z&@#/\._\A'4/^W7_P!%&NKK
MG]&TN2VO;RY=<1S_ &?8<@YV1D-P#D8/J![4[PAK[:[')<$ 1B>18B%9=T:X
MVM\W4GD'IR,8!!H @^(]V]I832Q,R./+PR$JPS(H.".>E9_Q:T_S[)Y][KY6
MWY5;"-ND0?,N.<=5]#6KX]TN35;*6V@7=(^S R!G$BD\D@= >]'CW2Y-5LI;
M:!=TC[,#(&<2*3R2!T![T :&B:1_92&+S)9<L3NG?>PR , X'''3U)KG]>O9
M-%U"WGW.T%W^Y=,L45R1L89;:">!T^ZK$ DFNPKG/B%I:ZC8S*< HAD!(S@Q
M_-QZ$@%<]@3UZ4 4KR[EU/5([6-F$%I'OFVF1 6?[BDC ;^%@#P1O!SR*9''
M-XJFG_?R0VUO*8E6 A)"Z ;V9\-\OS8 '!&"0".7_#6UDDBDU*X'[V]D+]6^
MX.$&&Z <[<9^4KR>,,^P7GAV>5[2,7,%R[2%"Z1.DC$;OF/53V&#T[8)< +#
MS_#MY'8M*T\%V'*&9BTJ-$F6^;'*GC XZ]L$O>\$7;W/VOS&9ME].J[B3A1M
MPHST [#I3-,TRYU*Y74;U5C$*,(85;>RL_#NSC )(& !D8(X# DTK:WOO#LL
MZP0+<17$S3*PE6)E,GWE(;.<8&,?7/.% -#0;MY;^^B9F*1_9MJDDJNZ,DX'
M09/7'6K_ (L_X\[G_KWF_P#0&K(\&Z/=V=Q=W%[M+3F(AHR-AVAA@#A@%! ^
M89/J>M;OB&U:[MIX8QEY(9%49 R60@#)XZT <EH?A.?5+2&62ZEC8P((UMW*
M1JH0;-R]6;NQR.3M&  :T-%UJ75=,2[DF6"5A@S%5VC;(5R58A<L!CL,G@#@
M5N^'K5K2V@AD&'CAC5AD'!5 ",CCK7&)X,N'TN"U*KY]M*9?+DPR/AW(0D'&
M&#>N.QQDD &;:^(H;.XM_L5Y-/YLRQR1W&]EVR$#<"RH 5/U)SZ9!ZCQ5J+Z
M+=VMX786TA:&4;E\L%@3&VUB,'.2S=E7'L<_4XM2UR6W,ELL4,-S#(1YJN_R
MEMS9! V@=1C=G&,\XZ+QEH0UNTEM\9?:63H#O7E<%N!D\$\<$C(S0!FZSJ+W
MVH6^G0NP6$--/Y;*.!CRU/.2"?O+CE6!]QRB^,8-:9YKJ]E@7>WE16X="J=
M794;<QP#C)"\X/.!U?@#1[FV\^[O\BYG=0>4P5C4!3B/@'D@_0<=S4TRTO\
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MKR>,=1J-DM_$]N^0LJ,I(ZX8$'&<\\T <?H_AVYU>)=1FNY4FF D186Q @8
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MG$0*8(5MQW \8.>V& .XHK'N;F[6[CB2-3:%"7<D;PV&P -PXX7^$]3SZ;%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 0W=JMVC0R#*2*589(R&&"
M,CGI1:6JVB+#&,)&H51DG 48 R>>E344 %%%% !5'6M*75H7M79E608)C.UL
M9!(R0>#T/'()%7J* (;2U6T188QA(U"J,DX"C &3STJ:BB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *HZUI2ZM"]J[,JR#!,9VMC()&2#P>AXY!(J
M]10!#:6JVB+#&,)&H51DG 48 R>>E3444 %9^D:(FE>;Y98^?,\K;B#AGQD#
M ''''4^]:%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!#=[]C>5M\S:=N_.W=CY<XYQGKCG%8O
MAOQ6-1M#>3CRVAWB9<-\C1\MP1GI@XY(SMR2#705YEXN\,NU\MK$P2#4R#,H
M"@DP?.Q!V'!(Y'7+D[N* .R\(:M-J\ NYT5/,9BBKNR(_P"'=NZD\G(P"""
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M<@=2!SC->MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117*?\*MT[_GC_ .1)
M?_BZ .KHKE/^%6Z=_P \?_(DO_Q='_"K=._YX_\ D27_ .+H ZNBN4_X5;IW
M_/'_ ,B2_P#Q='_"K=._YX_^1)?_ (N@#JZ*Y3_A5NG?\\?_ ")+_P#%T?\
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M%F1X2WE@D_=(;)*LH ;(//8KE3U%% '-6EOJD[KY\EO'&K!CY".S, >4/F<
M$9^8<@XQWJ[<VUVUW'*DBBT"$.A WEL-@@[3QRO\0Z'CUV** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KE/\ B<_].?\ Y'KJZ* .4_XG/_3G_P"1Z/\
MB<_].?\ Y'KJZ* .4_XG/_3G_P"1Z/\ B<_].?\ Y'KJZ* .4_XG/_3G_P"1
MZ/\ B<_].?\ Y'KJZ* .4_XG/_3G_P"1Z/\ B<_].?\ Y'KJZ* .4_XG/_3G
M_P"1Z/\ B<_].?\ Y'KJZ* .4_XG/_3G_P"1Z/\ B<_].?\ Y'KJZ* .4_XG
M/_3G_P"1Z/\ B<_].?\ Y'KJZ* .4_XG/_3G_P"1Z/\ B<_].?\ Y'KJZ* .
M4_XG/_3G_P"1Z/\ B<_].?\ Y'KJZ* .4_XG/_3G_P"1Z/\ B<_].?\ Y'KJ
MZ* .4_XG/_3G_P"1Z/\ B<_].?\ Y'KJZ* .4_XG/_3G_P"1Z/\ B<_].?\
MY'KJZ* .4_XG/_3G_P"1Z/\ B<_].?\ Y'KJZ* .4_XG/_3G_P"1Z/\ B<_]
M.?\ Y'KJZ* .4_XG/_3G_P"1Z/\ B<_].?\ Y'KJZ* .4_XG/_3G_P"1Z/\
MB<_].?\ Y'KJZ* .4_XG/_3G_P"1Z/\ B<_].?\ Y'KJZ* .4_XG/_3G_P"1
MZ/\ B<_].?\ Y'KJZ* .4_XG/_3G_P"1Z/\ B<_].?\ Y'KJZ* .4_XG/_3G
M_P"1Z/\ B<_].?\ Y'KJZ* .4_XG/_3G_P"1Z/\ B<_].?\ Y'KJZ* ,31/M
M^\_;/L_E[3CR/,W;LC&=_&,9]\XK;HHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K)UW[9\OV+R?XM_G[_;;C9^.<^U:U% '*?\ $Y_Z<_\
MR/1_Q.?^G/\ \CUU=% '*?\ $Y_Z<_\ R/1_Q.?^G/\ \CUU=% '*?\ $Y_Z
M<_\ R/1_Q.?^G/\ \CUU=% '*?\ $Y_Z<_\ R/1_Q.?^G/\ \CUU=% '*?\
M$Y_Z<_\ R/1_Q.?^G/\ \CUU=% '*?\ $Y_Z<_\ R/1_Q.?^G/\ \CUU=% '
M*?\ $Y_Z<_\ R/1_Q.?^G/\ \CUU=% '*?\ $Y_Z<_\ R/1_Q.?^G/\ \CUU
M=% '*?\ $Y_Z<_\ R/1_Q.?^G/\ \CUU=% '*?\ $Y_Z<_\ R/1_Q.?^G/\
M\CUU=% '*?\ $Y_Z<_\ R/1_Q.?^G/\ \CUU=% '*?\ $Y_Z<_\ R/1_Q.?^
MG/\ \CUU=% '*?\ $Y_Z<_\ R/75T44 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$UEX^MKB>:W:2)4A\O;(9DVOO7)QT'RG@X)_"I[EKAKZ-4FC$ B)>$D>:?O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %<_X]U232K*6Y@;;(FS!P#C,B@\$$=">U=!7*?%+_D'3_\ ;/\ ]&I0
M V70M4A&^.]5V!!V26Z(C<C(++E@,>@S[CJ+_A'Q(=;C82*$G@<QRH"#AEXR
M,$_*><>X(!.,G>KC- OT2\U*\)/DH8@7VMC,,;"0=.2N.<9[8ZC(!TLNN6\4
MGV=I8Q+D#874/EL8&W.<G(QZTW7M931H7N9"ORJQ4,P7<P4D(">YQQP3[5YO
MJ-JD]F[6VF@6YB9DFDD190 "V_!W.0#R!N.Y<?PG%=7>PK?Z1OF =A9;P7&X
M[_)SOR<_-SUZT :^@^)8=91&C=/,:-7:-9%9ER!D$#G@G!X'-6+W7+>P;9-+
M&C$9 =U4XZ9P2..*P-'MHM(TY;^&*,3+9!BP0 L1$'^8C!()&3SS7,^'-/E2
M!'.FK<&4"0RS3PL[EQG=\ZD@'L.W?)R2 >IT5S7@#3Y]/@:&>/R@)I#''N5]
ML;88+N4G."6Y//X8KI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<C AAAMYSVRHR Q..,B;7K^:PU9988C*!9?O%4C?L\UB2H)&6!QA>2W0=<@
MM?;[SP[/$EW(+F"Y=8PX1(G21B=ORCJI[G)Z=L .V34+[4+VZL()%CCC\D^8
MRJQC#1[BJI@;BY[L<* <<D4/<R^*YX4\B6&WMI%F9IU\MV==VQ5'((SRWMW4
MXW48]7FTS4[V1(6FAQ;^9Y6#(I\L;"%)&X')R!T'.1C! -;3-3NM)NETZ]83
M+<!C#,JJARBY=&0= .H(SU')R0E26_U#4;^YL;>18X8A$=[(KLFY V%'&XN<
MYW9  ."#@&QIIE\17B7TD3PP6BN(Q*-DCO(H#$KS\H'3GK@Y/(6WH-H\5_?2
MLK!)/LVUB"%;;&0<'H<'KCI0 S5=3N4DATJW96N&BW2RNN-J#">8$& 69NBY
M(!&"-IR,_4[N_P#"H%[/,+JV!Q*OE)$ZAB '7!^8YXP3WZ<[EM^)+>?3+M-7
MA0S)Y0AEC0$R!2^[>H_B.>H]/8EEJ:O>3>+T%A';RQ0NZ>=)<*(B$5@V$&6W
M,=N,X('&1SD &G_;$MIJ7V*5LP7$.Z(%,8=/O(&'7@%CGID 8_BAN_$3_;VA
M#[;:SMS)/B,MEB,A2V.,+AQMY.".>S?B-I+7$4=["I>>TE1T4*S[OF7*[5(X
MX#$]<+@8R35?PCX?>YLKAIQY<]^TY?,95DW[E PQR0.6 )'WOQ(!GVOB.?6%
M%RU_;VF[.V("*5@N<J69VSNQU  ' X!R!L:;XY!LIK^;:6MGD1O*SY;LI&S8
M?F.UMRC<>Y)QBL'3!'I2"TO--:26'Y?,@MEE1P ,/N.#DCK[]<'*CH+WPV=6
MT][-8DM9)>2B[2H97!&2@ .X*,D D ]#C% %>*QU=(_M1FC,N"WV8Q+Y?.<)
MY@(;('3G&X8+$98V/A;_ ,@Z#_MI_P"C7JO%XSNY(_)%G+]KP1RH%ON&<GS"
MP^7C(&>?NACD-5[X<6CVEA#%*K(X\S*N"K#,C$9!YZ4 5/B5<?9DM9<,VR^A
M.U!EC@.< =R>P]:RO%WBE=9@%@\4ULMQ)&IEN8RD:@,'Z@G).W !P.Y8 &MK
MXA(^RVECC>3RKR&1EB4NVU Q)P/_ -6<<U2UGQ5-J\+V=O9W&^9'3,R") &1
M@6W$D9'8'&?7. 0#H/%OA]=?MGM3C<1E">SCE3G!P.QP,[20.M<?X2FF\6W*
M75TA5=/39A@/FG/#-C8,$8!*YRC!2.IKO=)L?[/ACML[O*C1,XQG:H&<9.,X
M]:Q?!%H]M]K\Q67??3LNX$94[<,,]0>QZ4 7=;MKN:6!K614B5\S!@"67*\#
MY6YP&[KU'/IL5CZWK<NGRP11P-*LS[7=<XC&5&XX5N/F)Y(Z'GTV* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K)_L+_3/[2W?\N_E;-O^WOW;L_AC
M'XUK44 %9.G:%]CN;B]W9^T^5\NW&WRE*]<G.<YZ#'O6M10 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !117*?\(!_T^7G_@1_]C0!U=%<
MI_P@'_3Y>?\ @1_]C1_P@'_3Y>?^!'_V- '5T5RG_" ?]/EY_P"!'_V-'_"
M?]/EY_X$?_8T =717*?\(!_T^7G_ ($?_8T?\(!_T^7G_@1_]C0!U=%<I_P@
M'_3Y>?\ @1_]C1_P@'_3Y>?^!'_V- '5T5RG_" ?]/EY_P"!'_V-'_" ?]/E
MY_X$?_8T =717*?\(!_T^7G_ ($?_8T?\(!_T^7G_@1_]C0!U=%<I_P@'_3Y
M>?\ @1_]C1_P@'_3Y>?^!'_V- '5T5RG_" ?]/EY_P"!'_V-'_" ?]/EY_X$
M?_8T =717*?\(!_T^7G_ ($?_8T?\(!_T^7G_@1_]C0!U=%<I_P@'_3Y>?\
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M?_8T =717*?\(!_T^7G_ ($?_8T?\(!_T^7G_@1_]C0!U=%<I_P@'_3Y>?\
M@1_]C1_P@'_3Y>?^!'_V- '5T5RG_" ?]/EY_P"!'_V-'_" ?]/EY_X$?_8T
M =717*?\(!_T^7G_ ($?_8T?\(!_T^7G_@1_]C0!U=%<I_P@'_3Y>?\ @1_]
MC1_P@'_3Y>?^!'_V- '5T5RG_" ?]/EY_P"!'_V-'_" ?]/EY_X$?_8T =71
M7*?\(!_T^7G_ ($?_8T?\(!_T^7G_@1_]C0!U=%<I_P@'_3Y>?\ @1_]C1_P
M@'_3Y>?^!'_V- '5T5RG_" ?]/EY_P"!'_V-'_" ?]/EY_X$?_8T =717*?\
M(!_T^7G_ ($?_8T?\(!_T^7G_@1_]C0!U=%<I_P@'_3Y>?\ @1_]C1_P@'_3
MY>?^!'_V- '5T5RG_" ?]/EY_P"!'_V-'_" ?]/EY_X$?_8T =717*?\(!_T
M^7G_ ($?_8T?\(!_T^7G_@1_]C0!U=%<I_P@'_3Y>?\ @1_]C1_P@'_3Y>?^
M!'_V- '5T5RG_" ?]/EY_P"!'_V-'_" ?]/EY_X$?_8T =717*?\(!_T^7G_
M ($?_8T?\(!_T^7G_@1_]C0!U=%<I_P@'_3Y>?\ @1_]C1_P@'_3Y>?^!'_V
M- '5T5RG_" ?]/EY_P"!'_V-'_" ?]/EY_X$?_8T =717*?\(!_T^7G_ ($?
M_8T?\(!_T^7G_@1_]C0!U=%<I_P@'_3Y>?\ @1_]C1_P@'_3Y>?^!'_V- '5
MT5RG_" ?]/EY_P"!'_V-'_" ?]/EY_X$?_8T =717*?\(!_T^7G_ ($?_8UU
M= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>E1M<SMMC3&3@G&2 . ">I':K=<?\1[I;O2I9HSE)%A93@C(:1"#@\]*["@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHKS^+PM;:]J-]]I3?Y?V;;\S+C=%S]TCT'6@#T"BO/]8T?_ (0?;J%F
MSBW$BB> MO3:^U2ZAF!W9 [DY(Y"@@]5KOB2/1MJN'>23=LCB0N[;<;L <<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNYKBXC$44J,=J,FS<7!4!58X !8#T'&>:[+Q9_QYW/\ U[S?^@-0!2G^(=A
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N?U3Q[9:5(UM/+MD3&1LD.,@$<A2.A'>N@KS^+Q3;:#J-]]I?9YGV
M;;\K-G;%S]T'U'6@#I=$\9VFMN8;:3>X4L1L=> 0,Y90.I%;=9.A>*;;7MWV
M9]_E[=WRLN-V<?> ]#TKF/#OBC4_$4(GAB@0 D%Y3)M?G^!5R0%Z$DD$].A
M .]HKA],\67^M PV\$:2P';,\S,8MZDAD4)DD]&SD@=#G*LV[X2U]M9B9I4V
M2PR-%(H(*[TQNP03QS^'3)QD@&W535-4CTJ-KF=ML:8R<$XR0!P 3U([5R^H
M:UJEK&UZ88%BC&YHC(S3!5^]\XPF< L.N!Q@G@V_%NNJ--:_1%=72)@DZ[E(
M=DQN4'J,YZ\$4 79O$ZB:UAC&Y+U9&5\D8"('!VD9.X'VQ6W7):Y"L.H:<B
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M"64$LA_=[T<' ^5L'Y<[@.I!H ZBBN*M-=U3585N[:*%5,8.V;>'=MN25 .
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M$\X., %3R>V;\6O.^Q/Y>SROE\W=NW_ZQ-FW''7[V>W2@#=\.ZM<:BI>XMS
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M0GH"JEFRV#A<Y (.6&2*]OXDN],GCM]12/9<$+'+;AR@<GA&W<Y;L>GU&XJ
M=;16)I6MO=W=U9L%V6WD[2 =Q\Q"QSSCKTP!^-']MO\ ;_[/POE_9?-S@[MW
MF;,9SC&/;.>] &W17#V7BC4-6EN+>VBB MYW3S92X0A20$PN27[D@X Z@9&>
MXH **XRY\47L]Y/IMK%&WE",B20L$3<@8[\9W%LX4+@CJ<@'&AJOB">T,-E&
MBR7DR98!B(DP &D;JVS<>!P6P0#NP" ='17*1:[>:7)%'?K#Y=Q((U>!G^5B
M"5!5@2=Q& 1@+R6/2IM;U^X:<:?8(C2*H>5Y2?+0'.U3L.=S8R!Z8.""2H!T
MM%<Y;>()[".9]014^SHK;XF)CDW;N%#XPPP%P3DL1T!&:7]H:O=)]HBBMXU9
M<K%*TAEZ="1M7)[ XQD!L$&@#L**YRV\7"^LIKZ-2LD"2[HY ?EDC7<5/3(Z
M>G'7!R!7\*ZU?ZT(KF2***W9?F!+F5C@X=1T"DXP&R<9.2"#0!U=9.G:[]LN
M;BRVX^S>5\V[.[S5+=,#&,8ZG/M6*FOW^LN[V"0BWC8HLEP7/F%20S)Y9QMS
MP#W]<Y"Y_A76F6XU*]N(FB:-86>/(9@(XWZ'Y0<A<@]#D8..: /0**Y+1-8U
M#41'=A;=K:4J=L;OYJJQP?F/R%DS\PXSM(&#BNMH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-+J D*F,^86.YOE6,(RIMPV0,C))VY!7/0>&O^0"W_7O=?SDKT"B@#)\)_\
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M@42XGDGBE 9T8.1E/E!(9>,_T&TMWM% '!:#K8UC5FF5&6,66$+@KO7S5(D
M('RG)QZ@9X/ [VBB@#A_!-DU_HPMTP&EBN%!/3+/(!G&>.:9H/C^VTF%+&]+
M03VZK&R,K-]Q0 P**00PY'Z9&">[HH Y?P?;R3RW.IR(T7VIT"QR##A85VAC
MZ%LGC'&."00:9\+?^0=!_P!M/_1KUU=% '*>'?\ D(ZA_P!NO_HHT?\ ,9_[
MA_\ [7KJZ* .4_YC/_</_P#:]<KJNN:?(7NK7SH=19B D:NLC29P$=/FC(+
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M806FC3&VB>%)&1BDNX.#YJ+DAF8C(48YZ8/>NO\ %G_'G<_]>\W_ * U:U%
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M%% '*?"W_D'0?]M/_1KU-X\L);B**:!/,:VN(YB@.&81YRHX///^&3@'I:*
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M^:I$@! ^4Y./4#/!X'>T4 <IX _Y?/\ L(7'_LM=7110!RGAW_D(ZA_VZ_\
MHHUC^/M)B2[CU"]B,EGY0B<JS QMO)#D+@E><<'U[[0WH=% 'G6@6&CWD\8L
MHG=U;=O7S]D97YE+%V &2/EX.2,&KMWJ8\*W\]U= BVO1%ME7+!6B0C:P SE
MN2,9[=?FV]Q10!Q6MWQ\:6EQ;V:L5VQ&.1P420A]S*NX#ILQDX^8X. ,F6U^
M*-I(H#[UN.08/+=I-X.-@PN"2>!DCMG!R!V%% '#V6GR6VFWD\RE'NA=3%#U
M3S$.%)[G !Z C." 171>$_\ CSMO^O>'_P! 6M:B@#SSPOXHB\)1?V5J&8I(
M"VUMK.DBNS,&4JIXYQS_ #R%F\'ZRUQ<ZC>-%(A @/E%?WN$1P!MX^9@ 0/?
M&3UKO:* /)VUBS1DET7S%O)74^2@<1MGEA(K?)M5=P&P@*3D' R/0-;\41:/
M+!;R!BUT^U"H! .5'.2./F'3/>MBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*$EU #CDH23PP].M6+6[2[42Q,KH<X9"&4X.#@CCK0!-17*?"W_D'0?]M/\
MT:];=UXAMK1C%+-$CC&5>1%89&1D$YZ4 :%%5[G48K5E21U5I#A S!2QX& "
M>3R.GJ*==7:6BF65E1!C+.0JC)P,D\=: )J*KRZC%%']H9U$6 =Y8!,-C!W9
MQ@Y&/6BRU&*_7?"ZNH."48,,]<9!//- %BBJ][J,5@N^9U12< NP49ZXR2.>
M*=:W:7:B6)E=#G#(0RG!P<$<=: )J**KW.HQ6K*DCJK2'"!F"ECP, $\GD=/
M44 6**ANKM+13+*RH@QEG(51DX&2>.M'VM-GG[E\O;NW9&W;C.[=TQCG/3%
M$U%4;+7+>_;9#+&[ 9(1U8XZ9P">.:L?:TW^1N7S-N[;D;MN<;MO7&>,],T
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M Y90F_S#C.>.5*D'G+$]<T ,UDRZEJ4H^RBZ6T2-51I51%\U=Q8J^0S'IQ@
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MR[<;?*4KUR<YSGH,>]8MOX&GL=T%M=O%:LQ/E!%9E#?>596)*]\$#@G/)R2
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M4.C!A@AD) )'8GISQG!%+2_!GEM+/>2M<2SQF(L1Y:B,CE JG R>21^&#DD
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MDUKZ=H7V.YN+W=G[3Y7R[<;?*4KUR<YSGH,>] '*_"OPO;BTCO616ED9FW.
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MXA_[_)_\51_PEEG_ ,_$/_?Y/_BJ -:BLG_A++/_ )^(?^_R?_%4?\)99_\
M/Q#_ -_D_P#BJ -:BLG_ (2RS_Y^(?\ O\G_ ,51_P )99_\_$/_ '^3_P"*
MH UJKZAI\>HQM;S*&C<8(/\ G@CJ".0>1S5>U\0VUVPBBFB=SG"I(C,<#)P
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M/;S16"6QBF4M)'+"?W;?+(I50N<@]>2/X>35K6-"BUC6$2<;ECLPX4_=)$K
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M.S_Y]X?^_*?_ !-:U% &3_PB=G_S[P_]^4_^)H_X1.S_ .?>'_ORG_Q-:U%
M&3_PB=G_ ,^\/_?E/_B:/^$3L_\ GWA_[\I_\36M10!D_P#")V?_ #[P_P#?
ME/\ XFC_ (1.S_Y]X?\ ORG_ ,36M10!D_\ ")V?_/O#_P!^4_\ B:/^$3L_
M^?>'_ORG_P 36M10!D_\(G9_\^\/_?E/_B:/^$3L_P#GWA_[\I_\36M10!D_
M\(G9_P#/O#_WY3_XFC_A$[/_ )]X?^_*?_$UK44 9/\ PB=G_P ^\/\ WY3_
M .)H_P"$3L_^?>'_ +\I_P#$UK44 9/_  B=G_S[P_\ ?E/_ (FC_A$[/_GW
MA_[\I_\ $UK44 9/_")V?_/O#_WY3_XFC_A$[/\ Y]X?^_*?_$UK44 9/_")
MV?\ S[P_]^4_^)H_X1.S_P"?>'_ORG_Q-:U% &?:^'K:T82Q0Q(XSADC16&1
M@X(&>E:%%% !1110 45#:W:7:B6)E=#G#(0RG!P<$<=:FH **** "BH9+M(F
M6)F4/)G:I(#-M&3@=3@=<=*FH **** "BBB@ HHHH ***Q/#&MOJOVCS H\B
MZEB7:",JF,$Y)YYYZ#VH VZ*** "BBB@ HHK'\+^*(O$D1N(0P57*D. #D '
ML6X^:@#8HHHH **P=4\:VVG3I8LQ::1T7:@SM\PX!8\ #IQG=@@XP:WJ "BB
MN2N/B5 AD,<4\T<1(:6&,-%\HRWS;AP.YZ=QD8) .MHJI:ZK%=1"[1U,14MO
MSA<#J3G&,8YSC&"#C%<[-\280IECAN)(0"?-CA/ED#[QRQ7@<@Y P0: .MHK
M/_M^#R/M_F+Y&W=O[8Z=.N<\;<9SQC/%84OQ)AB'F-#<"'(_?&$B+:Q #YSG
M:<@CC)],\4 =;13(9EF4.A!5@""#D$'D$$=0:?0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %</+?ZAJ-_<V-O(L<,0B.]D5V3<@;"CC<7.
M<[L@ '!!P#W%<UH-H\5_?2LK!)/LVUB"%;;&0<'H<'KCI0!4\1>))--:'35E
MB69X\RSS8154#;O"DA2S-DJN2!CD;3D4K7Q+)ILT*/>17<<\JQD(L:R(6!"L
M!&V"I;&XGH,8&35CQCH[1W,>J>2MS$(Q%)%L#N!O+"1 <@D$X(QT]B65VBF&
M]F3RM.,2J<M)-#'"4(!*%1@ECD8XQMX- #];U2\:_&GVK*%>U#$L%(C/F$&7
M&,L0!A5SC)!/ -,^WWGAV>)+N07,%RZQAPB1.DC$[?E'53W.3T[8 >KKU_-8
M:LLL,1E LOWBJ1OV>:Q)4$C+ XPO);H.N18>YE\5SPIY$L-O;2+,S3KY;LZ[
MMBJ.01GEO;NIQN &2W^H:C?W-C;R+'#$(CO9%=DW(&PHXW%SG.[( !P0< V/
M$7B2336ATU98EF>/,L\V$55 V[PI(4LS9*KD@8Y&TY%O0;1XK^^E96"2?9MK
M$$*VV,@X/0X/7'2L_P 8Z.T=S'JGDK<Q",121; [@;RPD0'()!.",=/8EE *
M]KXEDTV:%'O(KN.>58R$6-9$+ A6 C;!4MC<3T&,#)JQK&MSW5ZVG)<+:;%0
MH6B5S,7ZX+X VG"@#))W=<85VBF&]F3RM.,2J<M)-#'"4(!*%1@ECD8XQMX-
M/\3ZDCR-;75C+/&%'ER11B7(<?/SP8R",<')P#QQD MZWKLOAVS$DQ22X+"-
M#]Q&9F(5FSPORC<W(7((# 8-<_=Z_<62-=C4;:1U4MY&V/83C)165_,./X>[
M$ 'J:%\,7>H:>JLJAXKCSH8)CO C4'9 Q.#T)^]VPIV_PNAO(;E0L>DMYQ ^
M62WCCCSU8>:PX YP2HR<# S0!I^+_$L\5M;75C]^YFA"JX7YA(C,$.3@9. 2
M",=F'6JFN7&H^'H_[2DG25$93) (@BX<[2JR<L<$C!...3G[IT_&.G,ZV:0H
M2L5[;DA%X5%W#. .%'Y"G_$>T>[L)HHE9W/EX5 68XD4G '/2@#)^)5E/*]J
M\<VQ#=0JJ^6K;9"7Q+D\G XV]#700V5[:0.@F2:X+91I8_+0#Y<J1'STR0?4
MCL*S_B)!*T4,\$;2M;W44I1/O$)NZ8!/4@< XZXP#5+Q5)+XEL]\4$H$4ZM)
M#*#$\B(,LH )R#D8[Y4X!8 $ J1>(YM,G@!O8KR.>58F11&CKO.%<>66R!WS
MQVZG*V/B593RO:O'-L0W4*JOEJVV0E\2Y/)P.-O0UE7RC4)K;[+I[PI'=0,\
MC0B-L;CD;5&=N.2V< @ @9!/2_$2"5HH9X(VE:WNHI2B?>(3=TP">I X!QUQ
M@&@"+Q'<7?A_3YIFG\R=60K)Y2)@,Z+MV\@]^3Z^U6]<UB72[VV!;_1KC=&P
M*9"R=4.\<Y<D+@\8!/N,_P 6WC^(--G\J"97W( DD9$APZ,2%&21CO['TK2^
M(&@C6K.2, ET'F)@$G<@/  (R6&5[]<X) H ;KFL2_;;;3K=MN[=),0FXB->
M@R> '(*YZ@X^AP5\62:XSR1WD%I"KL(P1&\CJ.-["1AM!QE1@'!.1P";WP]M
M9KM[C5+N/RYYF1-IC9"%C0<C>2<-QGME?RQ],TU?#8-C=V)N=AS'-#;K+O5B
M3\V[HPZ8R>..@#, =1X-\0MJ1FMI'25[9D'FQ8V.KKE6X)&[(.X#"@\#-;6J
M6\ES&T<$GE2'&'V!\8()^4\'(R/QS6?X6A4(TJVJVN]N% 0,R@95F" ;3R?E
M.2IS6W0!Y_\ "W3KG[-!/]H_T?\ >?N?*7^\X_UF=WWOF_3I5VSN[WQ.&N;>
M9;>V#L(B(A*\BJ=I=MY&T9' P#R01P":_P .M1ET^./29[>9'C:0>9LS%C+/
MDOTZY QD'@@\\-T+4)_""'3)K>69(R3%+;1EPRNQ;YAGY6!/3/Z ,P!J^&]8
MN(KA]*O</*B&1)5 4/&6V\J/NL"<8'H?0,UWQ?XA_L& S*%,C,J1ASM4LW3+
M<   $G) P,9&<U2\/V<U_=2:K/&8@8EBA0D;]F[>6<#.&)Q@9!7D$< F7QUH
M,FL0*(0K20RK*$D&4?8"-AY'!SWX/0X!R #G;O7[BR1KL:C;2.JEO(VQ["<9
M**ROYAQ_#W8@ ]36UXDUR>&WBU:TYB51))$R_,\;@'.X;BI0')QQU))"X./#
M>0W*A8]);SB!\LEO'''GJP\UAP!S@E1DX&!FMCQCYLB1Z39HR^?A'=8LQQPX
M(;GA0<<!>N,@8)4T 1:9XBD\2W8-H[+90+\[^6!YDAP?+!<9  ZD $<_WD:L
MQ?%DFN,\D=Y!:0J[",$1O(ZCC>PD8;0<948!P3D< FWX?TJ3PA<_84$DEG<#
M<K;-Y27A2&9.BD <D =,8 =JRM,TU?#8-C=V)N=AS'-#;K+O5B3\V[HPZ8R>
M..@#, =1X-\0MJ1FMI'25[9D'FQ8V.KKE6X)&[(.X#"@\#-8_@B[U+7HH[N6
M94B5^T2L\JAOF#<@(!@J"H!ZDCH3T7A:%0C2K:K:[VX4! S*!E68(!M/)^4Y
M*G-5?AQ:/:6$,4JLCCS,JX*L,R,1D'GI0!4EO+S7YY8[.58+>V8QE_+61GD&
M"PVOC 7.,]SR"P/RW7N;NQL[E[@J984E,<B*!N"Q@JY4D@-NSD8QD<#&"<JW
MN)_"<\Z-#)/!<RO,CVZ%W5G(W(RYX XP<\^^2$T[FZGU6RNFDA:,O'*(D/,A
M4Q?*2 3AB2?EZCIR>2 9FJ^*)H;:RS((C=HF^X9 RHWEJP&WA07)QDX"@,<<
M9'0>'8+B)29YUN$<*T;J@0\YR,*2I7&"I')R<\8K'DO&TZSM(9;5YXVAC655
M0.R%44J#$1SR.<XVD>N!47@JV<7$TT,+VUFR_P"KE!5FE)!,@0YV  [< A3A
M<9QA0"BOBR37&>2.\@M(5=A&"(WD=1QO82,-H.,J, X)R. 3O>#?$+:D9K:1
MTE>V9!YL6-CJZY5N"1NR#N PH/ S7+Z9IJ^&P;&[L3<[#F.:&W67>K$GYMW1
MATQD\<= &;LO"T*A&E6U6UWMPH"!F4#*LP0#:>3\IR5.: '^*M<;2(=\:AII
M'6.)3P&=S@ GL!R>2 <8R,UCW6E:K$IG2Z1Y!AO)\E5C)SDQB0G=CL"<$\9*
M]1H>-=&EU*)&M]OFV\R3(K_=8QY^4G(QG/\ 0D9R,_\ X3>>Z39!97 N&7@2
MILB#8R<R$KP.<< MP."> "OJWC26XM+2_M%(:>YC0QDK\W+AH]Q! !9<!N#C
MGCD4_4UU/1T.H&=)EC^>2 1K&NW!+A9.6.WMGD@9.3\IS/$NCR:!8V-K#AYH
MKN$@$_*9#O;&?E^7><#...I[UH:QXBN=7B;3H;25)I@8W:9<0(&!#L) 3N Y
MVG SU /"D J>.3+JBV-W#*4BFGMMB&-25=]S+(3GD@'&S[OO6GXCN+OP_I\T
MS3^9.K(5D\I$P&=%V[>0>_)]?:F>--+DLK6U6VC:7['/ VT<N5B4J.@Y)XS@
M'&<XP#3?%MX_B#39_*@F5]R ))&1(<.C$A1DD8[^Q]* -?Q1KDMB8K:V56N;
MER$$F0@5!N=SCLH[9!YR <8.1J<&I:&AO?M*W*1?,\30I%E #N(9<G('(_K]
MTW?&>GSAX-3ME$CV9D)B.<NLBA6VD?Q #@8.?<@*U+5?$,^O1/96MK,CS*59
M[E/*C56^5FSN)) / '/?!Q@@!XB\2W3O8_8-O^EJ[;90-I&Q&!8@Y&T$D[3S
MC'S="7-Q?>'98&GG6XBN)EA93$L3*9/NL"N<XP<Y^F.<K8O=':UN]-2-6:*W
M2=2V,X B55W$# )Q[9/2K'C>T>Y^R>6K-LOH&;:"<*-V6..@'<]* *GBW7Y(
M+B.Q69;5'C+^>Z!U9@<>7\^%7 ^8DG/W1QGYN@T2WGMD,=S(LK!CM=4V$J0#
M\RC@$'(XXP >N:RO%.J"!U@FLWN8"NX-'&)L.#C!0CC@YW9YS@ \XK_#^SEM
MUF/EM#:LX\B&0DNH&0Y(;) <\[23@YQP=S &KXJUQM(AWQJ&FD=8XE/ 9W.
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M=BD!OE/RD9^4?Q#[PX]0#8KE/'W_ "Y_]A"W_P#9JZNN:\;VCW/V3RU9ME]
MS;03A1NRQQT [GI0!?\ %G_'G<_]>\W_ * U<QH>GZE?6D,D4ZVX$""./RUD
MW!4 5V<YP7ZX .U<<%LUU7B>%IK2X1 2S02@ #))*$  #J31X8A:&TMT<$,L
M$0((P00@!!!Z$4 95AXT#Z:-7F4 A&)4$X+!B@ ."0&8#UVYY)QFL2'6KB=1
M<-J-K'(0#Y $31@C^ R;R^#_ !$9P2=I( J;1O#$NHZ*-.8&*5@W$BD8(F+@
M$=0#@<XX!S@]*KVMW%M$4NE-]HY4A+:/R2P.!B0\!2?XN0!W8#) .O\ "NM_
MVW:Q7F,&1?F&,#<I*MCD\9!QSG&,\UK54TJ 01(HC6+Y03&F-JD\LHV@ X)/
M(Z]:MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <UXEU
M2>6:/3+)E25U,DDC#/EQA@,A2,,6/ ';N!G<'6!N](9FO)5FMEB=S+Y8C=2N
MWY=JD@KMR00"<Y!QQFKXDMY],NTU>%#,GE"&6- 3(%+[MZC^(YZCT]B665-0
MF\2K+;"&2""2"1"\ZA7WM@#$>[.T*2<]">,C'(!4T^/4M>C6\$ZVRR#*1I$L
MOR'E69F/WB#VP,8X!) ++Q-<?9KN"<!;NQB8EUP4;,;-&X'J<9((Q[#)58M'
M\33Z)$MC<VL[/  @>WC,D;*H 5@21R1U'KZ'*A\6C3M;W]Y.FVXO(W B0[\*
MD12,<9RQR<X)!XP <B@"'2H-5UBW2Z^TI"S1@J@A5@PQE79CG:6[A1@#'RYR
M*V-%U.;Q+8)<1L()I1]X*) "CE6(5NS;3P>F>IQFM#PQ"T-I;HX(98(@01@@
MA ""#T(K-^'%H]I80Q2JR./,RK@JPS(Q&0>>E &)\+=.N?LT$_VC_1_WG[GR
ME_O./]9G=][YOTZ5;UZXNXG?=?6]L?F\N,JAW+D[&9I#D$]#M!48R,G(J'X=
M:C+I\<>DSV\R/&T@\S9F+&6?)?IUR!C(/!!YXQ]*M3I*-:W&GM<W?FG,I021
MR;V!#&9P=HP?3&1EL$M@ ZNP\:!]-&KS* 0C$J"<%@Q0 '!(#,!Z[<\DXS52
M*QU=(_M1FC,N"WV8Q+Y?.<)Y@(;('3G&X8+$98U=&\,2ZCHHTY@8I6#<2*1@
MB8N 1U .!SC@'.#TJU%XSNY(_)%G+]KP1RH%ON&<GS"P^7C(&>?NACD-0!2\
M7:=<RZC:>7<;/,\_ROW2MY>V)=_4_/O]_N]J[72[>2VC6.>3S9!G+[ F<DD?
M*.!@8'X9KFO&QEM+FSOXXGF2!I@XB&Y@)%"@X'/3)],@ D9%=+I>H?VA&L^Q
MX]V?EE7:XP2.5R<9QD>V* .7U[4[U]073[1E5'MMS%U#;,NRF0="6' "Y*DG
MD8R0^SO+S1[R&RN95N([I9-K>6L3(T2[CPN0000.3G/ICYK?V1_[6\_:WE_8
M=N[!V[O.SMW=,XYQUQ1KUH\M_8RJK%(_M.Y@"57=& ,GH,GIGK0!+HVJ27-[
M>6SMF.#[/L& ,;XR6Y R<GU)]J/[4D_M+[%N_=?8_,VX'WO-VYSC/3C&<>U9
M5Q<R^';ZXN6@EFBNUB*M;KYC*8EVE67C&<YSGTQGG:S09+F_U-KR:!HHC:;8
M]P_A\Q6&X@D!SR2O!4<$<9( 2W^H:C?W-C;R+'#$(CO9%=DW(&PHXW%SG.[(
M !P0< Q"_P!3M[DZ0)(Y&=!()V0*4C.4;]VN 6#8VCG_ &N#\FQH-H\5_?2L
MK!)/LVUB"%;;&0<'H<'KCI1]D?\ M;S]K>7]AV[L';N\[.W=TSCG'7% $.@:
MA=6EV^EW<BS?N1,D@41MC<$*E5&.N2.?J3G"XOANWO+Q[R*VD6"-;Z=C*465
MF8D#8$;   &2QY)( Z-70?9'_M;S]K>7]AV[L';N\[.W=TSCG'7%8.A:I<Z#
M+=^9:RO!)=RLC1)N?<Q_N$@E"H!##C/&3G@ UM&\13:=++8:@0S0Q-,LR@ -
M$#@DHO1ATP!S@^@9L>U\1SZPHN6O[>TW9VQ 12L%SE2S.V=V.H  X' .0-"P
MTJ7Q&]Q?3HT FMVMXE<?.$))9W0]\XP,CC(Y&&.3I@CTI!:7FFM)+#\OF06R
MRHX &'W'!R1U]^N#E0 ;VG^*I-0L+FZRHFMQ<*6BYC+1J65DW%LK@@\]3GC%
M'A ZAJ*PWMU*JQLF?*2-3O!7Y79\_*QR&PO& !@$D"Q+8G^SID6W6"22&;,,
M6UOF*LH^X &+ #H,]!VK2\,0M#:6Z."&6"($$8((0 @@]"* -.N*TOQ7.ND?
MVFP\V<*YZ8'$I7)" <*.3C' /(ZUVM<9X1:?1M*1A"SS1ASY1RCG]ZQ/4$YV
MG(&,GH.HH L>&/M-R5N1>I=0'(8>2L9&5R""AR&!VY5@."<\XKJZ\ZMHOMEW
M!)86DMJRL/-DDC\E#$/O1[!E6+9ZXW @'H,KZ+0!P_B[18=.:V>% K3:G [G
MDEF.\]23QR<#H,G Y-=E=7:6BF65E1!C+.0JC)P,D\=:X7QEKCWCPQ1VUR?L
MUY'(S"$E66(L"5()SG/'0$=Q75:?>)X@B;S8'5-V"ES& 3C# [3D$9Z'U'M0
M!8LM<M[]MD,L;L!DA'5CCIG )XYK@-+\3OX=B>QMT$\,)?R[B/>\2AFWXE94
MP2BL6<IGLH .2.UN?#D4,4HM(XX9I(G571!&06''S(,@ X/'IFN?T3Q&^A01
MV4EE<!X456\F)9(R<<L&5@"6ZGT8D$D\T 5]45-)T-EM)-Z>6 'P/F$L@$G!
MZ?>88/*]"=PS7=6EJMHBPQC"1J%49)P%& ,GGI7&Z?X*>?3[BTD41/=2R2",
M%=L9W QIN7(*_(,X X.  15BT\87-NBV\]I<-<A0"553$S8X/F@[0#P6.,)D
MCG% '+I$$MSIPSY#:SY!0DG]UD-L!)R!D9R"#G//)SZE=VJW:-#(,I(I5ADC
M(88(R.>E<0_@VX;3P!@7XG^TD@C!EW$\Y!7.TXP,+N YVY)NW?C"YN$:W@M+
MA;DJ0"RJ(E;')\TG:0.2IQA\ <9H 9X UR*TTZW-S*J%A(%,KA<A)&  W'HH
MP/88%='_ ,)#;;//\Z+R]VW=YB;=V,[=V<9QSCKBJ.D>$8+>VAM)HHW,*8^9
M0XW-RY!<9PS<]NW QBKW_"/6VSR/)B\O=NV^6FW=C&[;C&<<9ZXH 8/$]H5+
MB>+:" 3YJ8!.2!G/4X./H?2GQ^(;:56E6:(I'C<PD0JNXX&3G R>F>M,'ABT
M"E!!%M)!(\I,$C(!QCJ,G'U/K3X_#UM$K1+#$$DQN41H%;:<C(Q@X/3/2@!U
MEKEO?MLAEC=@,D(ZL<=,X!/'-7JHV6AV]@V^&*-&(P2B*IQUQD <<55\+ZW+
MK$1EF@:!@Y4(^<D  [N57CG'3MUH V**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** ,G^PO],_M+=_R[^5LV_[>_=NS^&,?C6M110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!DZ_H7]K^3\VWR+B.7[N<[,_+U&,YZ\X]*
MUJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,_7],;5
M()+5'\LRKMW;0V ?O#!(ZC(Z\9R.:L:=9+81);IDK$BJ">N%  SC'/%6** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "N?U31KVYD:2"\\J,XPGV>-\8 !^8G)R<G\<5T%%
M'*?\([J/_/\ _P#DK%_C1_PCNH_\_P#_ .2L7^-=710!RG_".ZC_ ,__ /Y*
MQ?XT?\([J/\ S_\ _DK%_C75T4 <I_PCNH_\_P#_ .2L7^-'_".ZC_S_ /\
MY*Q?XUU=% '*?\([J/\ S_\ _DK%_C1_PCNH_P#/_P#^2L7^-=710!RG_".Z
MC_S_ /\ Y*Q?XT?\([J/_/\ _P#DK%_C75T4 <I_PCNH_P#/_P#^2L7^-'_"
M.ZC_ ,__ /Y*Q?XUU=% '*?\([J/_/\ _P#DK%_C1_PCNH_\_P#_ .2L7^-=
M710!RG_".ZC_ ,__ /Y*Q?XT?\([J/\ S_\ _DK%_C75T4 <I_PCNH_\_P#_
M .2L7^-;>B64]HA2YF\YRQ(;RUCP,#Y<+QUR<^_M6A10 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>22
<FILENAME>xair-20260331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa6L+bP9z5Z82ekhvWB3bRl6zywgTxd3fiR6IYAGEbgM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:us-types="http://fasb.org/us-types/2026" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2026" xmlns:country="http://xbrl.sec.gov/country/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:cyd="http://xbrl.sec.gov/cyd/2026" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:XAIR="http://beyondair.net/20260331" elementFormDefault="qualified" targetNamespace="http://beyondair.net/20260331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://beyondair.net/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/OrganizationAndBusiness" id="OrganizationAndBusiness">
          <link:definition>999014 - Disclosure - ORGANIZATION AND BUSINESS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertainties" id="SignificantAccountingPoliciesAndOtherRisksAndUncertainties">
          <link:definition>999015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999016 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999017 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpenses" id="OtherCurrentAssetsAndPrepaidExpenses">
          <link:definition>999018 - Disclosure - OTHER CURRENT ASSETS AND PREPAID EXPENSES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
          <link:definition>999019 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/Leases" id="Leases">
          <link:definition>999020 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStock" id="BasicAndDilutedNetLossPerShareOfCommonStock">
          <link:definition>999021 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/Loans" id="Loans">
          <link:definition>999022 - Disclosure - LOANS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/LoanPayable" id="LoanPayable">
          <link:definition>999023 - Disclosure - LOAN PAYABLE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999024 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999025 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/Segments" id="Segments">
          <link:definition>999026 - Disclosure - SEGMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999027 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/LeaseRevenues" id="LeaseRevenues">
          <link:definition>999028 - Disclosure - LEASE REVENUES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999029 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies" id="SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies">
          <link:definition>999030 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables" id="SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables">
          <link:definition>999031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999032 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999033 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpensesTables" id="OtherCurrentAssetsAndPrepaidExpensesTables">
          <link:definition>999034 - Disclosure - OTHER CURRENT ASSETS AND PREPAID EXPENSES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
          <link:definition>999035 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/LeasesTables" id="LeasesTables">
          <link:definition>999036 - Disclosure - LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockTables" id="BasicAndDilutedNetLossPerShareOfCommonStockTables">
          <link:definition>999037 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/LoansTables" id="LoansTables">
          <link:definition>999038 - Disclosure - LOANS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/LoanPayableTables" id="LoanPayableTables">
          <link:definition>999039 - Disclosure - LOAN PAYABLE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999040 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/SegmentsTables" id="SegmentsTables">
          <link:definition>999041 - Disclosure - SEGMENTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/LeaseRevenuesTables" id="LeaseRevenuesTables">
          <link:definition>999042 - Disclosure - LEASE REVENUES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative" id="OrganizationAndBusinessDetailsNarrative">
          <link:definition>999043 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails" id="ScheduleOfFairValueOnRecurringBasisDetails">
          <link:definition>999044 - Disclosure - SCHEDULE OF FAIR VALUE ON A RECURRING BASIS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails" id="SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails">
          <link:definition>999045 - Disclosure - SUMMARY OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails" id="ScheduleOfAssumptionsUsedInValuingWarrantsDetails">
          <link:definition>999046 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN VALUING WARRANTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails" id="ScheduleOfKeyInputsDerivativeDetails">
          <link:definition>999047 - Disclosure - SCHEDULE OF KEY INPUTS DERIVATIVE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails" id="ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails">
          <link:definition>999048 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" id="ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails">
          <link:definition>999049 - Disclosure - SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails" id="ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails">
          <link:definition>999050 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails" id="ScheduleOfFutureExpectedAmortizationExpenseDetails">
          <link:definition>999051 - Disclosure - SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative" id="SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative">
          <link:definition>999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>999053 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>999054 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails" id="ScheduleOfRestrictedStockAwardsDetails">
          <link:definition>999055 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARDS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfOptionActivityDetails" id="ScheduleOfOptionActivityDetails">
          <link:definition>999056 - Disclosure - SCHEDULE OF OPTION ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails" id="ScheduleOfOptionActivityForBeyondCancerDetails">
          <link:definition>999057 - Disclosure - SCHEDULE OF OPTION ACTIVITY FOR BEYOND CANCER (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails" id="ScheduleOfOptionActivityForNeuronosDetails">
          <link:definition>999058 - Disclosure - SCHEDULE OF OPTION ACTIVITY FOR NEURONOS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails" id="ScheduleOfFairValueOfOptionDetails">
          <link:definition>999059 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
          <link:definition>999060 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails" id="SummaryOfOutstandingWarrantsDetails">
          <link:definition>999061 - Disclosure - SUMMARY OF OUTSTANDING WARRANTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999062 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails" id="ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails">
          <link:definition>999063 - Disclosure - SCHEDULE OF OTHER CURRENT ASSETS AND PREPAID EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/SummaryOfAccruedExpensesDetails" id="SummaryOfAccruedExpensesDetails">
          <link:definition>999064 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical" id="SummaryOfAccruedExpensesDetailsParenthetical">
          <link:definition>999065 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails" id="ScheduleOfOperatingLeaseLiabilityDetails">
          <link:definition>999066 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails" id="ScheduleOfLeaseRelatedCostsDetails">
          <link:definition>999067 - Disclosure - SCHEDULE OF LEASE RELATED COSTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfLeaseOtherInformationDetails" id="ScheduleOfLeaseOtherInformationDetails">
          <link:definition>999068 - Disclosure - SCHEDULE OF LEASE OTHER INFORMATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" id="ScheduleOfMaturityOfLeaseLiabilitiesDetails">
          <link:definition>999069 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999070 - Disclosure - LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" id="ScheduleOfPotentialAnti-dilutiveSecuritiesDetails">
          <link:definition>999071 - Disclosure - SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative" id="BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative">
          <link:definition>999072 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfLong-termDebtDetails" id="ScheduleOfLong-termDebtDetails">
          <link:definition>999073 - Disclosure - SCHEDULE OF LONG-TERM DEBT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/LoansDetailsNarrative" id="LoansDetailsNarrative">
          <link:definition>999074 - Disclosure - LOANS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfLoanPayableDetails" id="ScheduleOfLoanPayableDetails">
          <link:definition>999075 - Disclosure - SCHEDULE OF LOAN PAYABLE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails" id="ScheduleOfProfitLossBeforeTaxesDetails">
          <link:definition>999076 - Disclosure - SCHEDULE OF PROFIT (LOSS) BEFORE TAXES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails" id="ScheduleOfDeferredTaxAssetliabilityDetails">
          <link:definition>999077 - Disclosure - SCHEDULE OF DEFERRED TAX ASSET/LIABILITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails" id="ScheduleOfDifferenceEffectiveIncomeTaxRateDetails">
          <link:definition>999078 - Disclosure - SCHEDULE OF DIFFERENCE EFFECTIVE INCOME TAX RATE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails" id="ScheduleOfStatutoryUsFederalEffectiveRateDetails">
          <link:definition>999079 - Disclosure - SCHEDULE OF STATUTORY US FEDERAL EFFECTIVE RATE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999080 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999081 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/SegmentsDetailsNarrative" id="SegmentsDetailsNarrative">
          <link:definition>999082 - Disclosure - SEGMENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails" id="ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails">
          <link:definition>999083 - Disclosure - SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/LeaseRevenuesDetailsNarrative" id="LeaseRevenuesDetailsNarrative">
          <link:definition>999084 - Disclosure - LEASE REVENUES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails" id="ScheduleOfMaturityOfFutureLeasePaymentsDetails">
          <link:definition>999085 - Disclosure - SCHEDULE OF MATURITY OF FUTURE LEASE PAYMENTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="xair-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="xair-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="xair-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="xair-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd" />
    <import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd" />
    <import namespace="http://fasb.org/us-types/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2026" schemaLocation="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2026" schemaLocation="https://xbrl.sec.gov/country/2026/country-2026.xsd" />
    <import namespace="http://fasb.org/srt/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2026" schemaLocation="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd" />
    <element id="XAIR_BeyondCancerLtdMember" name="BeyondCancerLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_NeuroNosLtdMember" name="NeuroNosLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_StreetervilleCapitalLLCMember" name="StreetervilleCapitalLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_FirstThirdPartyVendorsMember" name="FirstThirdPartyVendorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SecondThirdPartyVendorsMember" name="SecondThirdPartyVendorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ThirdPartyVendorsMember" name="ThirdPartyVendorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CustomersOneMember" name="CustomersOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CustomersTwoMember" name="CustomersTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_MutualFundsMember" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ClinicalAndMedicalEquipmentMember" name="ClinicalAndMedicalEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EquipmentDeployableAsPartOfServiceOfferingMember" name="EquipmentDeployableAsPartOfServiceOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TwoThousandAndTwentyFiveATMMember" name="TwoThousandAndTwentyFiveATMMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TwoThousandTwentySixPreFundedWarrantsMember" name="TwoThousandTwentySixPreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TwoThousandTwentySixCommonWarrantsMember" name="TwoThousandTwentySixCommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" name="TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TwoThousandThirteenBAPlanMember" name="TwoThousandThirteenBAPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TwoThousandThirteenEquityIncentivePlanMember" name="TwoThousandThirteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TwoThousandTwentyFiveOptionRepricingMember" name="TwoThousandTwentyFiveOptionRepricingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" name="TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" name="TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AmendedLoanAgreementMember" name="AmendedLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_BeyondAirIncMember" name="BeyondAirIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_NitricGenAgreementMember" name="NitricGenAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AvenueAgreementMember" name="AvenueAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_MarchTwoThousandTwentyFourRaiseMember" name="MarchTwoThousandTwentyFourRaiseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AvenueExtensionAgreementMember" name="AvenueExtensionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember" name="SeptemberTwoThousandTwentyFourEquityOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember" name="SeptemberTwoThousandTwentyFourDebtInstrumentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SeptemberTwoThousandTwentyFiveInducementMember" name="SeptemberTwoThousandTwentyFiveInducementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember" name="JanuaryTwoThousandTwentySixEquityOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SubTotalMember" name="SubTotalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember" name="PreFundedWarrantsSepTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember" name="PreFundedWarrantsJanTwoThousandTwentySixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SteveLisiMember" name="SteveLisiMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LoanAgreementMember" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PromissoryNoteMember" name="PromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_NotePurchaseAgreementMember" name="NotePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CypriotTaxMember" name="CypriotTaxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_NoExpirationMember" name="NoExpirationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OptionAgreementMember" name="OptionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_NitricGenIncMember" name="NitricGenIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_NextMilestonesMember" name="NextMilestonesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AfterSixMonthsMember" name="AfterSixMonthsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SupplierMember" name="SupplierMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CertainInvestorsMember" name="CertainInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_InvestorsMember" name="InvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SubscriptionAgreementMember" name="SubscriptionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_VariableInterestEntitiesMember" name="VariableInterestEntitiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_BeyondAirMember" name="BeyondAirMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SegmentMember" name="SegmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LungFitPHMember" name="LungFitPHMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LungFitRPHMember" name="LungFitRPHMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_WarrantLiabilityNonCurrent" name="WarrantLiabilityNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SaleOfCommonStockAndPrefundedWarrants" name="SaleOfCommonStockAndPrefundedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares" name="IssuanceOfCommonStockAtMarketEquityOfferingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_StockIssuedDuringPeriodValueReverseStockSplits" name="StockIssuedDuringPeriodValueReverseStockSplits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_GainLossOnTerminationOfRightOfUseAsset" name="GainLossOnTerminationOfRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases" name="PaymentsToSecurityDepositsMadeOnOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ProceedsFromSaleOfCommonStockOfNeuronos" name="ProceedsFromSaleOfCommonStockOfNeuronos" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ProceedsFromLongTermDebt" name="ProceedsFromLongTermDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DebtDiscount" name="DebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DerivativesLiability" name="DerivativesLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ShortTermFinanceLiability" name="ShortTermFinanceLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RightofuseAssetsAcquiredUnderOperatingLeases" name="RightofuseAssetsAcquiredUnderOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DebtPrincipalBalanceConvertedToEquity" name="DebtPrincipalBalanceConvertedToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_NoInsiderTradingFlag" name="NoInsiderTradingFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DisclosureLeaseRevenuesAbstract" name="DisclosureLeaseRevenuesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OperatingLeasesTextBlock" name="OperatingLeasesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock" name="GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock" name="OtherRisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SupplierConcentrationPolicyTextBlock" name="SupplierConcentrationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CustomerrConcentrationPolicyTextBlock" name="CustomerrConcentrationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" name="RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock" name="FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock" name="ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock" name="ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfOperatingLeaseLiabilityTableTextBlock" name="ScheduleOfOperatingLeaseLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OtherLeaseTableTextBlock" name="OtherLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock" name="ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="XAIR_FairValueMeasurementExtinguishment" name="FairValueMeasurementExtinguishment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CashAndCashEquivalentsAndMarketableSecurities" name="CashAndCashEquivalentsAndMarketableSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag" name="NumberOfReportableSegmentsDisclosedByDefinitionFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TaxRebate" name="TaxRebate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfFairValueOfOptionAbstract" name="ScheduleOfFairValueOfOptionAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfFairValueOfOptionTable" name="ScheduleOfFairValueOfOptionTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="XAIR_ScheduleOfStockBasedCompensationExpenseAbstract" name="ScheduleOfStockBasedCompensationExpenseAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfStockBasedCompensationExpenseTable" name="ScheduleOfStockBasedCompensationExpenseTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_WarrantsExpirationDateDescription" name="WarrantsExpirationDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SaleOfStockFeePercentage" name="SaleOfStockFeePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PublicFloatValue" name="PublicFloatValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_BeneficialOwnershipLimitationPercentage" name="BeneficialOwnershipLimitationPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PrepaidResearchAndDevelopment" name="PrepaidResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_InterestSeveranceCurrent" name="InterestSeveranceCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_GoodsReceivedNotInvoiced" name="GoodsReceivedNotInvoiced" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PayablesAndAccrualsTable" name="PayablesAndAccrualsTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="XAIR_PaidInKindInterestAmount" name="PaidInKindInterestAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AmortizationOfDebtDiscount" name="AmortizationOfDebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DebtInstrumentInterestRatePayableInCashPercentage" name="DebtInstrumentInterestRatePayableInCashPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DebtInstrumentInterestRatePayableInKindPercentage" name="DebtInstrumentInterestRatePayableInKindPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RoyaltyInterestPercentage" name="RoyaltyInterestPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DebtInstrumentOfRestrictedAccount" name="DebtInstrumentOfRestrictedAccount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_UnrestrictedCash" name="UnrestrictedCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_NumberOfPayments" name="NumberOfPayments" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LoanPayableDueDateDescription" name="LoanPayableDueDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ResearchAndDevelopmentTaxCreditCapitalization" name="ResearchAndDevelopmentTaxCreditCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DeferredTaxAssetsReservesAndAccruels" name="DeferredTaxAssetsReservesAndAccruels" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DeferredTaxAssetsRightofuseAsset" name="DeferredTaxAssetsRightofuseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateAbstract" name="ScheduleOfDifferenceEffectiveIncomeTaxRateAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateTable" name="ScheduleOfDifferenceEffectiveIncomeTaxRateTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes" name="IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes" name="EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch" name="IncomeTaxReconciliationDifferenceTaxCreditsResearch" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch" name="EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_IncomeTaxReconciliationTaxSubpartFIncome" name="IncomeTaxReconciliationTaxSubpartFIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome" name="EffectiveIncomeTaxRateReconciliationSubpartFIncome" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount" name="EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent" name="EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments" name="IncomeTaxReconciliationDifferenceOtherAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments" name="EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems" name="IncomeTaxReconciliationDifferenceOtherReconcilingItems" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent" name="EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" name="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss" name="EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OffsetTaxableIncomeRate" name="OffsetTaxableIncomeRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OperatingLossCarryforwardsExpirationYears" name="OperatingLossCarryforwardsExpirationYears" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage" name="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PaymentsForDevelopmentAndMilestonePayment" name="PaymentsForDevelopmentAndMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_MilestonePayments" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SalesRelatedMilestonesPayments" name="SalesRelatedMilestonesPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PaymentForMilestoneMethodRevenueRecognized" name="PaymentForMilestoneMethodRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AmountOfTerminatedLoan" name="AmountOfTerminatedLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CapitalExpendituresCost" name="CapitalExpendituresCost" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OperatingLeaseIncome" name="OperatingLeaseIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>23
<FILENAME>xair-20260331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#Cover" roleURI="http://beyondair.net/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BalanceSheets" roleURI="http://beyondair.net/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BalanceSheetsParenthetical" roleURI="http://beyondair.net/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://beyondair.net/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StatementsOfCashFlows" roleURI="http://beyondair.net/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#OrganizationAndBusiness" roleURI="http://beyondair.net/role/OrganizationAndBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SignificantAccountingPoliciesAndOtherRisksAndUncertainties" roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertainties" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#PropertyAndEquipment" roleURI="http://beyondair.net/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StockholdersEquity" roleURI="http://beyondair.net/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#OtherCurrentAssetsAndPrepaidExpenses" roleURI="http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#Leases" roleURI="http://beyondair.net/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BasicAndDilutedNetLossPerShareOfCommonStock" roleURI="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStock" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#Loans" roleURI="http://beyondair.net/role/Loans" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LoanPayable" roleURI="http://beyondair.net/role/LoanPayable" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#IncomeTaxes" roleURI="http://beyondair.net/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#CommitmentsAndContingencies" roleURI="http://beyondair.net/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#Segments" roleURI="http://beyondair.net/role/Segments" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#RelatedPartyTransactions" roleURI="http://beyondair.net/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeaseRevenues" roleURI="http://beyondair.net/role/LeaseRevenues" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SubsequentEvents" roleURI="http://beyondair.net/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies" roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables" roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#PropertyAndEquipmentTables" roleURI="http://beyondair.net/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StockholdersEquityTables" roleURI="http://beyondair.net/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#OtherCurrentAssetsAndPrepaidExpensesTables" roleURI="http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeasesTables" roleURI="http://beyondair.net/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BasicAndDilutedNetLossPerShareOfCommonStockTables" roleURI="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LoansTables" roleURI="http://beyondair.net/role/LoansTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LoanPayableTables" roleURI="http://beyondair.net/role/LoanPayableTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#IncomeTaxesTables" roleURI="http://beyondair.net/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SegmentsTables" roleURI="http://beyondair.net/role/SegmentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeaseRevenuesTables" roleURI="http://beyondair.net/role/LeaseRevenuesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#OrganizationAndBusinessDetailsNarrative" roleURI="http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfFairValueOnRecurringBasisDetails" roleURI="http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails" roleURI="http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfAssumptionsUsedInValuingWarrantsDetails" roleURI="http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfKeyInputsDerivativeDetails" roleURI="http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails" roleURI="http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails" roleURI="http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfFutureExpectedAmortizationExpenseDetails" roleURI="http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative" roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfRestrictedStockAwardsDetails" roleURI="http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOptionActivityDetails" roleURI="http://beyondair.net/role/ScheduleOfOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOptionActivityForBeyondCancerDetails" roleURI="http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOptionActivityForNeuronosDetails" roleURI="http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfFairValueOfOptionDetails" roleURI="http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfStock-basedCompensationExpenseDetails" roleURI="http://beyondair.net/role/ScheduleOfStock-basedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SummaryOfOutstandingWarrantsDetails" roleURI="http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StockholdersEquityDetailsNarrative" roleURI="http://beyondair.net/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails" roleURI="http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SummaryOfAccruedExpensesDetails" roleURI="http://beyondair.net/role/SummaryOfAccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SummaryOfAccruedExpensesDetailsParenthetical" roleURI="http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOperatingLeaseLiabilityDetails" roleURI="http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfLeaseRelatedCostsDetails" roleURI="http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfLeaseOtherInformationDetails" roleURI="http://beyondair.net/role/ScheduleOfLeaseOtherInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfMaturityOfLeaseLiabilitiesDetails" roleURI="http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeasesDetailsNarrative" roleURI="http://beyondair.net/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" roleURI="http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative" roleURI="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfLong-termDebtDetails" roleURI="http://beyondair.net/role/ScheduleOfLong-termDebtDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LoansDetailsNarrative" roleURI="http://beyondair.net/role/LoansDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfLoanPayableDetails" roleURI="http://beyondair.net/role/ScheduleOfLoanPayableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfProfitLossBeforeTaxesDetails" roleURI="http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfDeferredTaxAssetliabilityDetails" roleURI="http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfDifferenceEffectiveIncomeTaxRateDetails" roleURI="http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfStatutoryUsFederalEffectiveRateDetails" roleURI="http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#IncomeTaxesDetailsNarrative" roleURI="http://beyondair.net/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SegmentsDetailsNarrative" roleURI="http://beyondair.net/role/SegmentsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails" roleURI="http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeaseRevenuesDetailsNarrative" roleURI="http://beyondair.net/role/LeaseRevenuesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfMaturityOfFutureLeasePaymentsDetails" roleURI="http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedLicenseAgreementsGross" xlink:label="loc_us-gaapFiniteLivedLicenseAgreementsGross" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedLicenseAgreementsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_WarrantLiabilityNonCurrent" xlink:label="loc_XAIRWarrantLiabilityNonCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_XAIRWarrantLiabilityNonCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="loc_us-gaapInterestAndDividendIncomeOperating" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestAndDividendIncomeOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProvisionForOtherLosses" xlink:label="loc_us-gaapProvisionForOtherLosses" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForOtherLosses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossAfterTax" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossAfterTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_GainLossOnTerminationOfRightOfUseAsset" xlink:label="loc_XAIRGainLossOnTerminationOfRightOfUseAsset" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_XAIRGainLossOnTerminationOfRightOfUseAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases" xlink:label="loc_XAIRPaymentsToSecurityDepositsMadeOnOperatingLeases" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_XAIRPaymentsToSecurityDepositsMadeOnOperatingLeases" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ProceedsFromSaleOfCommonStockOfNeuronos" xlink:label="loc_XAIRProceedsFromSaleOfCommonStockOfNeuronos" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_XAIRProceedsFromSaleOfCommonStockOfNeuronos" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ProceedsFromLongTermDebt" xlink:label="loc_XAIRProceedsFromLongTermDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_XAIRProceedsFromLongTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="loc_us-gaapRepaymentsOfBankDebt" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfBankDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/OrganizationAndBusiness" xlink:title="999014 - Disclosure - ORGANIZATION AND BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertainties" xlink:title="999015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipment" xlink:title="999016 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StockholdersEquity" xlink:title="999017 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpenses" xlink:title="999018 - Disclosure - OTHER CURRENT ASSETS AND PREPAID EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999019 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/Leases" xlink:title="999020 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStock" xlink:title="999021 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/Loans" xlink:title="999022 - Disclosure - LOANS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoanPayable" xlink:title="999023 - Disclosure - LOAN PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes" xlink:title="999024 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/Segments" xlink:title="999026 - Disclosure - SEGMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/RelatedPartyTransactions" xlink:title="999027 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeaseRevenues" xlink:title="999028 - Disclosure - LEASE REVENUES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SubsequentEvents" xlink:title="999029 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies" xlink:title="999030 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables" xlink:title="999031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipmentTables" xlink:title="999032 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StockholdersEquityTables" xlink:title="999033 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpensesTables" xlink:title="999034 - Disclosure - OTHER CURRENT ASSETS AND PREPAID EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999035 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeasesTables" xlink:title="999036 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockTables" xlink:title="999037 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoansTables" xlink:title="999038 - Disclosure - LOANS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoanPayableTables" xlink:title="999039 - Disclosure - LOAN PAYABLE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SegmentsTables" xlink:title="999041 - Disclosure - SEGMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeaseRevenuesTables" xlink:title="999042 - Disclosure - LEASE REVENUES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative" xlink:title="999043 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails" xlink:title="999044 - Disclosure - SCHEDULE OF FAIR VALUE ON A RECURRING BASIS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails" xlink:title="999045 - Disclosure - SUMMARY OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN VALUING WARRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails" xlink:title="999047 - Disclosure - SCHEDULE OF KEY INPUTS DERIVATIVE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails" xlink:title="999048 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="999049 - Disclosure - SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails" xlink:title="999051 - Disclosure - SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative" xlink:title="999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999053 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999054 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails" xlink:title="999055 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARDS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOptionActivityDetails" xlink:title="999056 - Disclosure - SCHEDULE OF OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails" xlink:title="999057 - Disclosure - SCHEDULE OF OPTION ACTIVITY FOR BEYOND CANCER (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails" xlink:title="999058 - Disclosure - SCHEDULE OF OPTION ACTIVITY FOR NEURONOS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails" xlink:title="999059 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999060 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails" xlink:title="999061 - Disclosure - SUMMARY OF OUTSTANDING WARRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StockholdersEquityDetailsNarrative" xlink:title="999062 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails" xlink:title="999063 - Disclosure - SCHEDULE OF OTHER CURRENT ASSETS AND PREPAID EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PrepaidResearchAndDevelopment" xlink:label="loc_XAIRPrepaidResearchAndDevelopment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_XAIRPrepaidResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaapPrepaidRent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidRent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Supplies" xlink:label="loc_us-gaapSupplies" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapSupplies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SummaryOfAccruedExpensesDetails" xlink:title="999064 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_XAIRAccruedResearchAndDevelopmentExpenses" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_XAIRAccruedResearchAndDevelopmentExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_InterestSeveranceCurrent" xlink:label="loc_XAIRInterestSeveranceCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_XAIRInterestSeveranceCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_GoodsReceivedNotInvoiced" xlink:label="loc_XAIRGoodsReceivedNotInvoiced" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_XAIRGoodsReceivedNotInvoiced" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical" xlink:title="999065 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails" xlink:title="999066 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails" xlink:title="999067 - Disclosure - SCHEDULE OF LEASE RELATED COSTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaapSubleaseIncome" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapSubleaseIncome" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfLeaseOtherInformationDetails" xlink:title="999068 - Disclosure - SCHEDULE OF LEASE OTHER INFORMATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:title="999069 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeasesDetailsNarrative" xlink:title="999070 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" xlink:title="999071 - Disclosure - SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative" xlink:title="999072 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfLong-termDebtDetails" xlink:title="999073 - Disclosure - SCHEDULE OF LONG-TERM DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PaidInKindInterestAmount" xlink:label="loc_XAIRPaidInKindInterestAmount" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_XAIRPaidInKindInterestAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AmortizationOfDebtDiscount" xlink:label="loc_XAIRAmortizationOfDebtDiscount" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_XAIRAmortizationOfDebtDiscount" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoansDetailsNarrative" xlink:title="999074 - Disclosure - LOANS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfLoanPayableDetails" xlink:title="999075 - Disclosure - SCHEDULE OF LOAN PAYABLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails" xlink:title="999076 - Disclosure - SCHEDULE OF PROFIT (LOSS) BEFORE TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails" xlink:title="999077 - Disclosure - SCHEDULE OF DEFERRED TAX ASSET/LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ResearchAndDevelopmentTaxCreditCapitalization" xlink:label="loc_XAIRResearchAndDevelopmentTaxCreditCapitalization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_XAIRResearchAndDevelopmentTaxCreditCapitalization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" xlink:label="loc_XAIRDeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_XAIRDeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DeferredTaxAssetsReservesAndAccruels" xlink:label="loc_XAIRDeferredTaxAssetsReservesAndAccruels" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_XAIRDeferredTaxAssetsReservesAndAccruels" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DeferredTaxAssetsRightofuseAsset" xlink:label="loc_XAIRDeferredTaxAssetsRightofuseAsset" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_XAIRDeferredTaxAssetsRightofuseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DeferredTaxAssetsLeaseLiability" xlink:label="loc_XAIRDeferredTaxAssetsLeaseLiability" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_XAIRDeferredTaxAssetsLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails" xlink:title="999078 - Disclosure - SCHEDULE OF DIFFERENCE EFFECTIVE INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:label="loc_XAIRIncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_XAIRIncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch" xlink:label="loc_XAIRIncomeTaxReconciliationDifferenceTaxCreditsResearch" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_XAIRIncomeTaxReconciliationDifferenceTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsOther" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationTaxSubpartFIncome" xlink:label="loc_XAIRIncomeTaxReconciliationTaxSubpartFIncome" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_XAIRIncomeTaxReconciliationTaxSubpartFIncome" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments" xlink:label="loc_XAIRIncomeTaxReconciliationDifferenceOtherAdjustments" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_XAIRIncomeTaxReconciliationDifferenceOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems" xlink:label="loc_XAIRIncomeTaxReconciliationDifferenceOtherReconcilingItems" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_XAIRIncomeTaxReconciliationDifferenceOtherReconcilingItems" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails" xlink:title="999079 - Disclosure - SCHEDULE OF STATUTORY US FEDERAL EFFECTIVE RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxesDetailsNarrative" xlink:title="999080 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999081 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SegmentsDetailsNarrative" xlink:title="999082 - Disclosure - SEGMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails" xlink:title="999083 - Disclosure - SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeaseRevenuesDetailsNarrative" xlink:title="999084 - Disclosure - LEASE REVENUES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails" xlink:title="999085 - Disclosure - SCHEDULE OF MATURITY OF FUTURE LEASE PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>24
<FILENAME>xair-20260331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#Cover" roleURI="http://beyondair.net/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BalanceSheets" roleURI="http://beyondair.net/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BalanceSheetsParenthetical" roleURI="http://beyondair.net/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://beyondair.net/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StatementsOfCashFlows" roleURI="http://beyondair.net/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#OrganizationAndBusiness" roleURI="http://beyondair.net/role/OrganizationAndBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SignificantAccountingPoliciesAndOtherRisksAndUncertainties" roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertainties" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#PropertyAndEquipment" roleURI="http://beyondair.net/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StockholdersEquity" roleURI="http://beyondair.net/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#OtherCurrentAssetsAndPrepaidExpenses" roleURI="http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#Leases" roleURI="http://beyondair.net/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BasicAndDilutedNetLossPerShareOfCommonStock" roleURI="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStock" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#Loans" roleURI="http://beyondair.net/role/Loans" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LoanPayable" roleURI="http://beyondair.net/role/LoanPayable" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#IncomeTaxes" roleURI="http://beyondair.net/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#CommitmentsAndContingencies" roleURI="http://beyondair.net/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#Segments" roleURI="http://beyondair.net/role/Segments" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#RelatedPartyTransactions" roleURI="http://beyondair.net/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeaseRevenues" roleURI="http://beyondair.net/role/LeaseRevenues" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SubsequentEvents" roleURI="http://beyondair.net/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies" roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables" roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#PropertyAndEquipmentTables" roleURI="http://beyondair.net/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StockholdersEquityTables" roleURI="http://beyondair.net/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#OtherCurrentAssetsAndPrepaidExpensesTables" roleURI="http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeasesTables" roleURI="http://beyondair.net/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BasicAndDilutedNetLossPerShareOfCommonStockTables" roleURI="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LoansTables" roleURI="http://beyondair.net/role/LoansTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LoanPayableTables" roleURI="http://beyondair.net/role/LoanPayableTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#IncomeTaxesTables" roleURI="http://beyondair.net/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SegmentsTables" roleURI="http://beyondair.net/role/SegmentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeaseRevenuesTables" roleURI="http://beyondair.net/role/LeaseRevenuesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#OrganizationAndBusinessDetailsNarrative" roleURI="http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfFairValueOnRecurringBasisDetails" roleURI="http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails" roleURI="http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfAssumptionsUsedInValuingWarrantsDetails" roleURI="http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfKeyInputsDerivativeDetails" roleURI="http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails" roleURI="http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails" roleURI="http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfFutureExpectedAmortizationExpenseDetails" roleURI="http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative" roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfRestrictedStockAwardsDetails" roleURI="http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOptionActivityDetails" roleURI="http://beyondair.net/role/ScheduleOfOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOptionActivityForBeyondCancerDetails" roleURI="http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOptionActivityForNeuronosDetails" roleURI="http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfFairValueOfOptionDetails" roleURI="http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfStock-basedCompensationExpenseDetails" roleURI="http://beyondair.net/role/ScheduleOfStock-basedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SummaryOfOutstandingWarrantsDetails" roleURI="http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StockholdersEquityDetailsNarrative" roleURI="http://beyondair.net/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails" roleURI="http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SummaryOfAccruedExpensesDetails" roleURI="http://beyondair.net/role/SummaryOfAccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SummaryOfAccruedExpensesDetailsParenthetical" roleURI="http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOperatingLeaseLiabilityDetails" roleURI="http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfLeaseRelatedCostsDetails" roleURI="http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfLeaseOtherInformationDetails" roleURI="http://beyondair.net/role/ScheduleOfLeaseOtherInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfMaturityOfLeaseLiabilitiesDetails" roleURI="http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeasesDetailsNarrative" roleURI="http://beyondair.net/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" roleURI="http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative" roleURI="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfLong-termDebtDetails" roleURI="http://beyondair.net/role/ScheduleOfLong-termDebtDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LoansDetailsNarrative" roleURI="http://beyondair.net/role/LoansDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfLoanPayableDetails" roleURI="http://beyondair.net/role/ScheduleOfLoanPayableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfProfitLossBeforeTaxesDetails" roleURI="http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfDeferredTaxAssetliabilityDetails" roleURI="http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfDifferenceEffectiveIncomeTaxRateDetails" roleURI="http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfStatutoryUsFederalEffectiveRateDetails" roleURI="http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#IncomeTaxesDetailsNarrative" roleURI="http://beyondair.net/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SegmentsDetailsNarrative" roleURI="http://beyondair.net/role/SegmentsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails" roleURI="http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeaseRevenuesDetailsNarrative" roleURI="http://beyondair.net/role/LeaseRevenuesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfMaturityOfFutureLeasePaymentsDetails" roleURI="http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SaleOfCommonStockAndPrefundedWarrants" xlink:label="loc_XAIRSaleOfCommonStockAndPrefundedWarrants_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRSaleOfCommonStockAndPrefundedWarrants_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares" xlink:label="loc_XAIRIssuanceOfCommonStockAtMarketEquityOfferingShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIssuanceOfCommonStockAtMarketEquityOfferingShares_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossBeforeTax_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossBeforeTax_80" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_80" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="loc_XAIRStockIssuedDuringPeriodValueReverseStockSplits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringPeriodValueReverseStockSplits_80" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_80" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/OrganizationAndBusiness" xlink:title="999014 - Disclosure - ORGANIZATION AND BUSINESS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertainties" xlink:title="999015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipment" xlink:title="999016 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/StockholdersEquity" xlink:title="999017 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpenses" xlink:title="999018 - Disclosure - OTHER CURRENT ASSETS AND PREPAID EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999019 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/Leases" xlink:title="999020 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStock" xlink:title="999021 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/Loans" xlink:title="999022 - Disclosure - LOANS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoanPayable" xlink:title="999023 - Disclosure - LOAN PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes" xlink:title="999024 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/Segments" xlink:title="999026 - Disclosure - SEGMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/RelatedPartyTransactions" xlink:title="999027 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeaseRevenues" xlink:title="999028 - Disclosure - LEASE REVENUES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SubsequentEvents" xlink:title="999029 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies" xlink:title="999030 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables" xlink:title="999031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipmentTables" xlink:title="999032 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/StockholdersEquityTables" xlink:title="999033 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpensesTables" xlink:title="999034 - Disclosure - OTHER CURRENT ASSETS AND PREPAID EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999035 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeasesTables" xlink:title="999036 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockTables" xlink:title="999037 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoansTables" xlink:title="999038 - Disclosure - LOANS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoanPayableTables" xlink:title="999039 - Disclosure - LOAN PAYABLE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SegmentsTables" xlink:title="999041 - Disclosure - SEGMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_VariableInterestEntitiesMember" xlink:label="loc_XAIRVariableInterestEntitiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRVariableInterestEntitiesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeaseRevenuesTables" xlink:title="999042 - Disclosure - LEASE REVENUES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LungFitRPHMember" xlink:label="loc_XAIRLungFitRPHMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRLungFitRPHMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative" xlink:title="999043 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="loc_XAIROrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIROrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_XAIROrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_XAIRBeyondCancerLtdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NeuroNosLtdMember" xlink:label="loc_XAIRNeuroNosLtdMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_XAIRNeuroNosLtdMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails" xlink:title="999044 - Disclosure - SCHEDULE OF FAIR VALUE ON A RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_MutualFundsMember" xlink:label="loc_XAIRMutualFundsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_XAIRMutualFundsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_250" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails" xlink:title="999045 - Disclosure - SUMMARY OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MutualFundMember" xlink:label="loc_us-gaapMutualFundMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapMutualFundMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaapExtinguishmentOfDebtAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapExtinguishmentOfDebtAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaapExtinguishmentOfDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapExtinguishmentOfDebtAxis" xlink:to="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaapExtinguishmentOfDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapExtinguishmentOfDebtAxis" xlink:to="loc_us-gaapExtinguishmentOfDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaapShortTermDebtMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_us-gaapShortTermDebtMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN VALUING WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails" xlink:title="999047 - Disclosure - SCHEDULE OF KEY INPUTS DERIVATIVE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails" xlink:title="999048 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeMember" xlink:label="loc_us-gaapDerivativeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDerivativeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_FairValueMeasurementExtinguishment" xlink:label="loc_XAIRFairValueMeasurementExtinguishment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_XAIRFairValueMeasurementExtinguishment_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="999049 - Disclosure - SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MutualFundMember" xlink:label="loc_us-gaapMutualFundMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapMutualFundMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapRestrictedCashCurrent_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaapMarketableSecuritiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapMarketableSecuritiesAbstract_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesAbstract_50" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ClinicalAndMedicalEquipmentMember" xlink:label="loc_XAIRClinicalAndMedicalEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_XAIRClinicalAndMedicalEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EquipmentDeployableAsPartOfServiceOfferingMember" xlink:label="loc_XAIREquipmentDeployableAsPartOfServiceOfferingMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_XAIREquipmentDeployableAsPartOfServiceOfferingMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails" xlink:title="999051 - Disclosure - SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative" xlink:title="999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_StreetervilleCapitalLLCMember" xlink:label="loc_XAIRStreetervilleCapitalLLCMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRStreetervilleCapitalLLCMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_US" xlink:label="loc_countryUS_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_AU" xlink:label="loc_countryAU_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryAU_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_BM" xlink:label="loc_countryBM_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryBM_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_IE" xlink:label="loc_countryIE_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIE_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_CY" xlink:label="loc_countryCY_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCY_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="loc_us-gaapAustralianTaxationOfficeMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapAustralianTaxationOfficeMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaapAccountsPayableMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsPayableMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_FirstThirdPartyVendorsMember" xlink:label="loc_XAIRFirstThirdPartyVendorsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_XAIRFirstThirdPartyVendorsMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SecondThirdPartyVendorsMember" xlink:label="loc_XAIRSecondThirdPartyVendorsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_XAIRSecondThirdPartyVendorsMember_150" xlink:type="arc" order="153" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ThirdPartyVendorsMember" xlink:label="loc_XAIRThirdPartyVendorsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_XAIRThirdPartyVendorsMember_160" xlink:type="arc" order="163" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CustomersOneMember" xlink:label="loc_XAIRCustomersOneMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_XAIRCustomersOneMember_170" xlink:type="arc" order="173" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CustomersTwoMember" xlink:label="loc_XAIRCustomersTwoMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_XAIRCustomersTwoMember_180" xlink:type="arc" order="183" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtOwnershipAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_XAIRBeyondCancerLtdMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NeuroNosLtdMember" xlink:label="loc_XAIRNeuroNosLtdMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_XAIRNeuroNosLtdMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_250" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="loc_XAIRCashAndCashEquivalentsAndMarketableSecurities_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_XAIRCashAndCashEquivalentsAndMarketableSecurities_250" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDepositAssets_250" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableNoncurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableNoncurrent_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableNoncurrent_250" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilityMeasurementDifferenceDescription" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementDifferenceDescription_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementDifferenceDescription_250" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_250" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSharePrice_250" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="loc_us-gaapDebtDefaultLongtermDebtAmount_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDebtDefaultLongtermDebtAmount_250" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaapCommonStockValueOutstanding_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCommonStockValueOutstanding_250" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue" xlink:label="loc_us-gaapCreditRiskDerivativeLiabilitiesAtFairValue_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCreditRiskDerivativeLiabilitiesAtFairValue_250" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRestrictedCash_250" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfSecuredDebt_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfSecuredDebt_250" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_250" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDescription" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDescription_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDescription_250" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag" xlink:label="loc_XAIRNumberOfReportableSegmentsDisclosedByDefinitionFlag_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_XAIRNumberOfReportableSegmentsDisclosedByDefinitionFlag_250" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInventoryValuationReserves_250" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TaxRebate" xlink:label="loc_XAIRTaxRebate_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_XAIRTaxRebate_250" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_250" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_250" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaapOtherAssetImpairmentCharges_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapOtherAssetImpairmentCharges_250" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByNoncontrollingOwners_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByNoncontrollingOwners_250" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999053 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ClinicalAndMedicalEquipmentMember" xlink:label="loc_XAIRClinicalAndMedicalEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_XAIRClinicalAndMedicalEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EquipmentDeployableAsPartOfServiceOfferingMember" xlink:label="loc_XAIREquipmentDeployableAsPartOfServiceOfferingMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_XAIREquipmentDeployableAsPartOfServiceOfferingMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999054 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails" xlink:title="999055 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARDS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOptionActivityDetails" xlink:title="999056 - Disclosure - SCHEDULE OF OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_70" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails" xlink:title="999057 - Disclosure - SCHEDULE OF OPTION ACTIVITY FOR BEYOND CANCER (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_70" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails" xlink:title="999058 - Disclosure - SCHEDULE OF OPTION ACTIVITY FOR NEURONOS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails" xlink:title="999059 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfFairValueOfOptionTable" xlink:label="loc_XAIRScheduleOfFairValueOfOptionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRScheduleOfFairValueOfOptionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_XAIRScheduleOfFairValueOfOptionTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_XAIRScheduleOfFairValueOfOptionTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondAirIncMember" xlink:label="loc_XAIRBeyondAirIncMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRBeyondAirIncMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRBeyondCancerLtdMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NeuroNosLtdMember" xlink:label="loc_XAIRNeuroNosLtdMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRNeuroNosLtdMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_150" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999060 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfStockBasedCompensationExpenseTable" xlink:label="loc_XAIRScheduleOfStockBasedCompensationExpenseTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRScheduleOfStockBasedCompensationExpenseTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:label="loc_us-gaapStatementOfIncomeLocationBalanceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_XAIRScheduleOfStockBasedCompensationExpenseTable" xlink:to="loc_us-gaapStatementOfIncomeLocationBalanceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_10" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails" xlink:title="999061 - Disclosure - SUMMARY OF OUTSTANDING WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NitricGenAgreementMember" xlink:label="loc_XAIRNitricGenAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRNitricGenAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AvenueAgreementMember" xlink:label="loc_XAIRAvenueAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRAvenueAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_MarchTwoThousandTwentyFourRaiseMember" xlink:label="loc_XAIRMarchTwoThousandTwentyFourRaiseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRMarchTwoThousandTwentyFourRaiseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AvenueExtensionAgreementMember" xlink:label="loc_XAIRAvenueExtensionAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRAvenueExtensionAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember" xlink:label="loc_XAIRSeptemberTwoThousandTwentyFourEquityOfferingMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRSeptemberTwoThousandTwentyFourEquityOfferingMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember" xlink:label="loc_XAIRSeptemberTwoThousandTwentyFourDebtInstrumentMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRSeptemberTwoThousandTwentyFourDebtInstrumentMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SeptemberTwoThousandTwentyFiveInducementMember" xlink:label="loc_XAIRSeptemberTwoThousandTwentyFiveInducementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRSeptemberTwoThousandTwentyFiveInducementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember" xlink:label="loc_XAIRJanuaryTwoThousandTwentySixEquityOfferingMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRJanuaryTwoThousandTwentySixEquityOfferingMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SubTotalMember" xlink:label="loc_XAIRSubTotalMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRSubTotalMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember" xlink:label="loc_XAIRPreFundedWarrantsSepTwoThousandTwentyFourMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRPreFundedWarrantsSepTwoThousandTwentyFourMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember" xlink:label="loc_XAIRPreFundedWarrantsJanTwoThousandTwentySixMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRPreFundedWarrantsJanTwoThousandTwentySixMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_230" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" xlink:label="loc_XAIRClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_XAIRClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_230" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_WarrantsExpirationDateDescription" xlink:label="loc_XAIRWarrantsExpirationDateDescription_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_XAIRWarrantsExpirationDateDescription_230" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/StockholdersEquityDetailsNarrative" xlink:title="999062 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandAndTwentyFiveATMMember" xlink:label="loc_XAIRTwoThousandAndTwentyFiveATMMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRTwoThousandAndTwentyFiveATMMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PurchaseAgreementMember" xlink:label="loc_XAIRPurchaseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRPurchaseAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AmendedLoanAgreementMember" xlink:label="loc_XAIRAmendedLoanAgreementMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRAmendedLoanAgreementMember_490" xlink:type="arc" order="492" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_300" xlink:type="arc" order="302" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentySixPreFundedWarrantsMember" xlink:label="loc_XAIRTwoThousandTwentySixPreFundedWarrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_XAIRTwoThousandTwentySixPreFundedWarrantsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentySixCommonWarrantsMember" xlink:label="loc_XAIRTwoThousandTwentySixCommonWarrantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_XAIRTwoThousandTwentySixCommonWarrantsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PreFundedWarrantsMember" xlink:label="loc_XAIRPreFundedWarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_XAIRPreFundedWarrantsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_470" xlink:type="arc" order="471" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandThirteenBAPlanMember" xlink:label="loc_XAIRTwoThousandThirteenBAPlanMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandThirteenBAPlanMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandThirteenEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandThirteenEquityIncentivePlanMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandThirteenEquityIncentivePlanMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="loc_XAIRTwoThousandTwentyOneEmployeeStockPurchasePlanMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyOneEmployeeStockPurchasePlanMember_530" xlink:type="arc" order="531" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyFiveOptionRepricingMember" xlink:label="loc_XAIRTwoThousandTwentyFiveOptionRepricingMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyFiveOptionRepricingMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRBeyondCancerLtdMember_450" xlink:type="arc" order="452" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_560" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SaleOfStockFeePercentage" xlink:label="loc_XAIRSaleOfStockFeePercentage_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_XAIRSaleOfStockFeePercentage_560" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PublicFloatValue" xlink:label="loc_XAIRPublicFloatValue_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_XAIRPublicFloatValue_560" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_560" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_560" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_560" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_560" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_560" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_560" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock_560" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeneficialOwnershipLimitationPercentage" xlink:label="loc_XAIRBeneficialOwnershipLimitationPercentage_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_XAIRBeneficialOwnershipLimitationPercentage_560" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_560" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_560" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_560" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease_560" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForCommissions" xlink:label="loc_us-gaapPaymentsForCommissions_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForCommissions_560" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDeferredCostsCurrent_560" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_560" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_560" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_560" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_560" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_560" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_560" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_560" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_560" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation_560" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_560" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_560" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense_560" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaapStockOptionExercisePriceIncrease_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockOptionExercisePriceIncrease_560" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_560" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_560" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_560" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_560" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_560" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForFees_560" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_560" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_560" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_560" xlink:type="arc" order="38" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails" xlink:title="999063 - Disclosure - SCHEDULE OF OTHER CURRENT ASSETS AND PREPAID EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SummaryOfAccruedExpensesDetails" xlink:title="999064 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical" xlink:title="999065 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PayablesAndAccrualsTable" xlink:label="loc_XAIRPayablesAndAccrualsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPayablesAndAccrualsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_XAIRPayablesAndAccrualsTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SteveLisiMember" xlink:label="loc_XAIRSteveLisiMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRSteveLisiMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaapTaxesPayableCurrent_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTaxesPayableCurrent_20" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails" xlink:title="999066 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails" xlink:title="999067 - Disclosure - SCHEDULE OF LEASE RELATED COSTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfLeaseOtherInformationDetails" xlink:title="999068 - Disclosure - SCHEDULE OF LEASE OTHER INFORMATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:title="999069 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeasesDetailsNarrative" xlink:title="999070 - Disclosure - LEASES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" xlink:title="999071 - Disclosure - SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative" xlink:title="999072 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PreFundedWarrantsMember" xlink:label="loc_XAIRPreFundedWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_XAIRPreFundedWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfLong-termDebtDetails" xlink:title="999073 - Disclosure - SCHEDULE OF LONG-TERM DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LoanAgreementMember" xlink:label="loc_XAIRLoanAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRLoanAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PromissoryNoteMember" xlink:label="loc_XAIRPromissoryNoteMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_XAIRPromissoryNoteMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PaidInKindInterestAmount" xlink:label="loc_XAIRPaidInKindInterestAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_XAIRPaidInKindInterestAmount_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AmortizationOfDebtDiscount" xlink:label="loc_XAIRAmortizationOfDebtDiscount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_XAIRAmortizationOfDebtDiscount_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoansDetailsNarrative" xlink:title="999074 - Disclosure - LOANS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LoanAndSecurityAgreementMember" xlink:label="loc_XAIRLoanAndSecurityAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRLoanAndSecurityAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AmendedLoanAgreementMember" xlink:label="loc_XAIRAmendedLoanAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRAmendedLoanAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NotePurchaseAgreementMember" xlink:label="loc_XAIRNotePurchaseAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRNotePurchaseAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PurchaseAgreementMember" xlink:label="loc_XAIRPurchaseAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRPurchaseAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_StreetervilleCapitalLLCMember" xlink:label="loc_XAIRStreetervilleCapitalLLCMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRStreetervilleCapitalLLCMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DebtInstrumentInterestRatePayableInCashPercentage" xlink:label="loc_XAIRDebtInstrumentInterestRatePayableInCashPercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRDebtInstrumentInterestRatePayableInCashPercentage_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DebtInstrumentInterestRatePayableInKindPercentage" xlink:label="loc_XAIRDebtInstrumentInterestRatePayableInKindPercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRDebtInstrumentInterestRatePayableInKindPercentage_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_RoyaltyInterestPercentage" xlink:label="loc_XAIRRoyaltyInterestPercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRRoyaltyInterestPercentage_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleOfLoansReceivable" xlink:label="loc_us-gaapProceedsFromSaleOfLoansReceivable_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromSaleOfLoansReceivable_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DebtInstrumentOfRestrictedAccount" xlink:label="loc_XAIRDebtInstrumentOfRestrictedAccount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRDebtInstrumentOfRestrictedAccount_150" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRepaidPrincipal" xlink:label="loc_us-gaapDebtInstrumentRepaidPrincipal_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentRepaidPrincipal_150" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_150" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1_150" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue" xlink:label="loc_us-gaapCreditRiskDerivativeLiabilitiesAtFairValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCreditRiskDerivativeLiabilitiesAtFairValue_150" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_150" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_UnrestrictedCash" xlink:label="loc_XAIRUnrestrictedCash_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRUnrestrictedCash_150" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfessionalFees_150" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfLoanPayableDetails" xlink:title="999075 - Disclosure - SCHEDULE OF LOAN PAYABLE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails" xlink:title="999076 - Disclosure - SCHEDULE OF PROFIT (LOSS) BEFORE TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails" xlink:title="999077 - Disclosure - SCHEDULE OF DEFERRED TAX ASSET/LIABILITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails" xlink:title="999078 - Disclosure - SCHEDULE OF DIFFERENCE EFFECTIVE INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateTable" xlink:label="loc_XAIRScheduleOfDifferenceEffectiveIncomeTaxRateTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRScheduleOfDifferenceEffectiveIncomeTaxRateTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_XAIRScheduleOfDifferenceEffectiveIncomeTaxRateTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_IE" xlink:label="loc_countryIE_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIE_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_IL" xlink:label="loc_countryIL_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:label="loc_XAIRIncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch" xlink:label="loc_XAIRIncomeTaxReconciliationDifferenceTaxCreditsResearch_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIncomeTaxReconciliationDifferenceTaxCreditsResearch_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsOther_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsOther_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationTaxSubpartFIncome" xlink:label="loc_XAIRIncomeTaxReconciliationTaxSubpartFIncome_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIncomeTaxReconciliationTaxSubpartFIncome_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationSubpartFIncome_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationSubpartFIncome_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments" xlink:label="loc_XAIRIncomeTaxReconciliationDifferenceOtherAdjustments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIncomeTaxReconciliationDifferenceOtherAdjustments_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems" xlink:label="loc_XAIRIncomeTaxReconciliationDifferenceOtherReconcilingItems_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIncomeTaxReconciliationDifferenceOtherReconcilingItems_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_40" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails" xlink:title="999079 - Disclosure - SCHEDULE OF STATUTORY US FEDERAL EFFECTIVE RATE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxesDetailsNarrative" xlink:title="999080 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaapIsraelTaxAuthorityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapIsraelTaxAuthorityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueCommissionersIrelandMember" xlink:label="loc_us-gaapRevenueCommissionersIrelandMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapRevenueCommissionersIrelandMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CypriotTaxMember" xlink:label="loc_XAIRCypriotTaxMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_XAIRCypriotTaxMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NoExpirationMember" xlink:label="loc_XAIRNoExpirationMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRNoExpirationMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OffsetTaxableIncomeRate" xlink:label="loc_XAIROffsetTaxableIncomeRate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_XAIROffsetTaxableIncomeRate_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OperatingLossCarryforwardsExpirationYears" xlink:label="loc_XAIROperatingLossCarryforwardsExpirationYears_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_XAIROperatingLossCarryforwardsExpirationYears_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_150" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999081 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaapProductLiabilityContingencyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProductLiabilityContingencyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OptionAgreementMember" xlink:label="loc_XAIROptionAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIROptionAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NitricGenAgreementMember" xlink:label="loc_XAIRNitricGenAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRNitricGenAgreementMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NitricGenIncMember" xlink:label="loc_XAIRNitricGenIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRNitricGenIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NextMilestonesMember" xlink:label="loc_XAIRNextMilestonesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRNextMilestonesMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AfterSixMonthsMember" xlink:label="loc_XAIRAfterSixMonthsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRAfterSixMonthsMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="loc_us-gaapCostOfGoodsTotalMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapCostOfGoodsTotalMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SupplierMember" xlink:label="loc_XAIRSupplierMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_XAIRSupplierMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PaymentsForDevelopmentAndMilestonePayment" xlink:label="loc_XAIRPaymentsForDevelopmentAndMilestonePayment_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPaymentsForDevelopmentAndMilestonePayment_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_MilestonePayments" xlink:label="loc_XAIRMilestonePayments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRMilestonePayments_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SalesRelatedMilestonesPayments" xlink:label="loc_XAIRSalesRelatedMilestonesPayments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRSalesRelatedMilestonesPayments_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PaymentForMilestoneMethodRevenueRecognized" xlink:label="loc_XAIRPaymentForMilestoneMethodRevenueRecognized_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPaymentForMilestoneMethodRevenueRecognized_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPurchaseObligation_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepositAssets_80" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SegmentsDetailsNarrative" xlink:title="999082 - Disclosure - SEGMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRBeyondCancerLtdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CertainInvestorsMember" xlink:label="loc_XAIRCertainInvestorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRCertainInvestorsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_InvestorsMember" xlink:label="loc_XAIRInvestorsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRInvestorsMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_XAIRBeyondCancerLtdMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NeuroNosLtdMember" xlink:label="loc_XAIRNeuroNosLtdMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_XAIRNeuroNosLtdMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SubscriptionAgreementMember" xlink:label="loc_XAIRSubscriptionAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRSubscriptionAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AmountOfTerminatedLoan" xlink:label="loc_XAIRAmountOfTerminatedLoan_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRAmountOfTerminatedLoan_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherReceivables_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_160" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails" xlink:title="999083 - Disclosure - SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondAirMember" xlink:label="loc_XAIRBeyondAirMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRBeyondAirMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRBeyondCancerLtdMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NeuroNosLtdMember" xlink:label="loc_XAIRNeuroNosLtdMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRNeuroNosLtdMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SegmentMember" xlink:label="loc_XAIRSegmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_XAIRSegmentMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_VariableInterestEntitiesMember" xlink:label="loc_XAIRVariableInterestEntitiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRVariableInterestEntitiesMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ParentCompanyMember" xlink:label="loc_srtParentCompanyMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_srtParentCompanyMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CapitalExpendituresCost" xlink:label="loc_XAIRCapitalExpendituresCost_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_XAIRCapitalExpendituresCost_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCostOfRevenue_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInterestExpenseNonoperating_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensation_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_170" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_170" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_170" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_170" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_170" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments_170" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherAssets_170" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAssets_170" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapLiabilities_170" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsNet" xlink:label="loc_us-gaapAssetsNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAssetsNet_170" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapMinorityInterest_170" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeaseRevenuesDetailsNarrative" xlink:title="999084 - Disclosure - LEASE REVENUES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LungFitPHMember" xlink:label="loc_XAIRLungFitPHMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_XAIRLungFitPHMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LungFitPHMember" xlink:label="loc_XAIRLungFitPHMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRLungFitPHMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OperatingLeaseIncome" xlink:label="loc_XAIROperatingLeaseIncome_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIROperatingLeaseIncome_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation_100" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails" xlink:title="999085 - Disclosure - SCHEDULE OF MATURITY OF FUTURE LEASE PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LungFitRPHMember" xlink:label="loc_XAIRLungFitRPHMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRLungFitRPHMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_20" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyFiveOptionRepricingMember" xlink:label="loc_XAIRTwoThousandTwentyFiveOptionRepricingMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyFiveOptionRepricingMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRBeyondCancerLtdMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_VariableInterestEntitiesMember" xlink:label="loc_XAIRVariableInterestEntitiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRVariableInterestEntitiesMember" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>25
<FILENAME>xair-20260331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="XAIR_BeyondCancerLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_BeyondCancerLtdMember" xlink:to="XAIR_BeyondCancerLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_BeyondCancerLtdMember_lbl" xml:lang="en-US">Beyond Cancer Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NeuroNosLtdMember" xlink:label="XAIR_NeuroNosLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NeuroNosLtdMember" xlink:to="XAIR_NeuroNosLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_NeuroNosLtdMember_lbl" xml:lang="en-US">NeuroNos Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_StreetervilleCapitalLLCMember" xlink:label="XAIR_StreetervilleCapitalLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StreetervilleCapitalLLCMember" xlink:to="XAIR_StreetervilleCapitalLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_StreetervilleCapitalLLCMember_lbl" xml:lang="en-US">Streeterville Capital LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_AU" xlink:label="country_AU" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AU_lbl" xml:lang="en-US">AUSTRALIA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_BM" xlink:label="country_BM" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BM" xlink:to="country_BM_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BM_lbl" xml:lang="en-US">BERMUDA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_IE" xlink:label="country_IE" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IE" xlink:to="country_IE_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IE_lbl" xml:lang="en-US">IRELAND</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_CY" xlink:label="country_CY" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CY" xlink:to="country_CY_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CY_lbl" xml:lang="en-US">CYPRUS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AustralianTaxationOfficeMember" xlink:to="us-gaap_AustralianTaxationOfficeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xml:lang="en-US">Australian Taxation Office [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US">Accounts Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_FirstThirdPartyVendorsMember" xlink:label="XAIR_FirstThirdPartyVendorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FirstThirdPartyVendorsMember" xlink:to="XAIR_FirstThirdPartyVendorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_FirstThirdPartyVendorsMember_lbl" xml:lang="en-US">First Third Party Vendors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SecondThirdPartyVendorsMember" xlink:label="XAIR_SecondThirdPartyVendorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SecondThirdPartyVendorsMember" xlink:to="XAIR_SecondThirdPartyVendorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SecondThirdPartyVendorsMember_lbl" xml:lang="en-US">Second Third Party Vendors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ThirdPartyVendorsMember" xlink:label="XAIR_ThirdPartyVendorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ThirdPartyVendorsMember" xlink:to="XAIR_ThirdPartyVendorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ThirdPartyVendorsMember_lbl" xml:lang="en-US">Third Party Vendors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CustomersOneMember" xlink:label="XAIR_CustomersOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CustomersOneMember" xlink:to="XAIR_CustomersOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CustomersOneMember_lbl" xml:lang="en-US">Customers One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CustomersTwoMember" xlink:label="XAIR_CustomersTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CustomersTwoMember" xlink:to="XAIR_CustomersTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CustomersTwoMember_lbl" xml:lang="en-US">Customers Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_MutualFundsMember" xlink:label="XAIR_MutualFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MutualFundsMember" xlink:to="XAIR_MutualFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_MutualFundsMember_lbl" xml:lang="en-US">Mutual Funds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MutualFundMember" xlink:label="us-gaap_MutualFundMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MutualFundMember" xlink:to="us-gaap_MutualFundMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MutualFundMember_lbl" xml:lang="en-US">Mutual Fund [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAxis_lbl" xml:lang="en-US">Extinguishment of Debt [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtMember" xlink:label="us-gaap_ShortTermDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtMember" xlink:to="us-gaap_ShortTermDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtMember_lbl" xml:lang="en-US">Short-Term Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeMember" xlink:label="us-gaap_DerivativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeMember" xlink:to="us-gaap_DerivativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeMember_lbl" xml:lang="en-US">Derivative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Asset, Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ClinicalAndMedicalEquipmentMember" xlink:label="XAIR_ClinicalAndMedicalEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ClinicalAndMedicalEquipmentMember" xlink:to="XAIR_ClinicalAndMedicalEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ClinicalAndMedicalEquipmentMember_lbl" xml:lang="en-US">Clinical and Medical Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EquipmentDeployableAsPartOfServiceOfferingMember" xlink:label="XAIR_EquipmentDeployableAsPartOfServiceOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EquipmentDeployableAsPartOfServiceOfferingMember" xlink:to="XAIR_EquipmentDeployableAsPartOfServiceOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EquipmentDeployableAsPartOfServiceOfferingMember_lbl" xml:lang="en-US">Equipment Deployable as Part of Service Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandAndTwentyFiveATMMember" xlink:label="XAIR_TwoThousandAndTwentyFiveATMMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandAndTwentyFiveATMMember" xlink:to="XAIR_TwoThousandAndTwentyFiveATMMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TwoThousandAndTwentyFiveATMMember_lbl" xml:lang="en-US">2025 ATM [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PurchaseAgreementMember" xlink:label="XAIR_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PurchaseAgreementMember" xlink:to="XAIR_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentySixPreFundedWarrantsMember" xlink:label="XAIR_TwoThousandTwentySixPreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandTwentySixPreFundedWarrantsMember" xlink:to="XAIR_TwoThousandTwentySixPreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TwoThousandTwentySixPreFundedWarrantsMember_lbl" xml:lang="en-US">2026 Pre-funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentySixCommonWarrantsMember" xlink:label="XAIR_TwoThousandTwentySixCommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandTwentySixCommonWarrantsMember" xlink:to="XAIR_TwoThousandTwentySixCommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TwoThousandTwentySixCommonWarrantsMember_lbl" xml:lang="en-US">2026 Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PreFundedWarrantsMember" xlink:label="XAIR_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PreFundedWarrantsMember" xlink:to="XAIR_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" xlink:label="XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" xlink:to="XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_lbl" xml:lang="en-US">2013 Beyond Air Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandThirteenBAPlanMember" xlink:label="XAIR_TwoThousandThirteenBAPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandThirteenBAPlanMember" xlink:to="XAIR_TwoThousandThirteenBAPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TwoThousandThirteenBAPlanMember_lbl" xml:lang="en-US">2013 BA Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandThirteenEquityIncentivePlanMember" xlink:label="XAIR_TwoThousandThirteenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandThirteenEquityIncentivePlanMember" xlink:to="XAIR_TwoThousandThirteenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TwoThousandThirteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2013 BA EquityIncentivePlan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyFiveOptionRepricingMember" xlink:label="XAIR_TwoThousandTwentyFiveOptionRepricingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandTwentyFiveOptionRepricingMember" xlink:to="XAIR_TwoThousandTwentyFiveOptionRepricingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TwoThousandTwentyFiveOptionRepricingMember_lbl" xml:lang="en-US">2025 Option Repricing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" xlink:label="XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" xlink:to="XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_lbl" xml:lang="en-US">2021 Beyond Cancer Ltd Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" xlink:label="XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" xlink:to="XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_lbl" xml:lang="en-US">2023 Neuro Nos Ltd Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AmendedLoanAgreementMember" xlink:label="XAIR_AmendedLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AmendedLoanAgreementMember" xlink:to="XAIR_AmendedLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AmendedLoanAgreementMember_lbl" xml:lang="en-US">Amended Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">2021 Employee Stock Purchase Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondAirIncMember" xlink:label="XAIR_BeyondAirIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_BeyondAirIncMember" xlink:to="XAIR_BeyondAirIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_BeyondAirIncMember_lbl" xml:lang="en-US">Beyond Air Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:label="us-gaap_StatementOfIncomeLocationBalanceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:to="us-gaap_StatementOfIncomeLocationBalanceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeLocationBalanceAxis_lbl" xml:lang="en-US">Location, Statement of Income, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NitricGenAgreementMember" xlink:label="XAIR_NitricGenAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NitricGenAgreementMember" xlink:to="XAIR_NitricGenAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_NitricGenAgreementMember_lbl" xml:lang="en-US">NitricGen Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AvenueAgreementMember" xlink:label="XAIR_AvenueAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AvenueAgreementMember" xlink:to="XAIR_AvenueAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AvenueAgreementMember_lbl" xml:lang="en-US">Avenue Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_MarchTwoThousandTwentyFourRaiseMember" xlink:label="XAIR_MarchTwoThousandTwentyFourRaiseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MarchTwoThousandTwentyFourRaiseMember" xlink:to="XAIR_MarchTwoThousandTwentyFourRaiseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_MarchTwoThousandTwentyFourRaiseMember_lbl" xml:lang="en-US">March 2024 Raise [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AvenueExtensionAgreementMember" xlink:label="XAIR_AvenueExtensionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AvenueExtensionAgreementMember" xlink:to="XAIR_AvenueExtensionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AvenueExtensionAgreementMember_lbl" xml:lang="en-US">Avenue Extension Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember" xlink:label="XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember" xlink:to="XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember_lbl" xml:lang="en-US">September 2024 equity offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember" xlink:label="XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember" xlink:to="XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember_lbl" xml:lang="en-US">September 2024 Debt Instrument [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SeptemberTwoThousandTwentyFiveInducementMember" xlink:label="XAIR_SeptemberTwoThousandTwentyFiveInducementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SeptemberTwoThousandTwentyFiveInducementMember" xlink:to="XAIR_SeptemberTwoThousandTwentyFiveInducementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SeptemberTwoThousandTwentyFiveInducementMember_lbl" xml:lang="en-US">September 2025 Inducement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember" xlink:label="XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember" xlink:to="XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember_lbl" xml:lang="en-US">January, 2026 Equity Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SubTotalMember" xlink:label="XAIR_SubTotalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SubTotalMember" xlink:to="XAIR_SubTotalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SubTotalMember_lbl" xml:lang="en-US">Sub Total [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember" xlink:label="XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember" xlink:to="XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember_lbl" xml:lang="en-US">Pre Funded Warrants Sep 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember" xlink:label="XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember" xlink:to="XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember_lbl" xml:lang="en-US">Pre Funded Warrants jan 2026 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SteveLisiMember" xlink:label="XAIR_SteveLisiMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SteveLisiMember" xlink:to="XAIR_SteveLisiMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SteveLisiMember_lbl" xml:lang="en-US">Steve Lisi [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LoanAgreementMember" xlink:label="XAIR_LoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LoanAgreementMember" xlink:to="XAIR_LoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_LoanAgreementMember_lbl" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PromissoryNoteMember" xlink:label="XAIR_PromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PromissoryNoteMember" xlink:to="XAIR_PromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LoanAndSecurityAgreementMember" xlink:label="XAIR_LoanAndSecurityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LoanAndSecurityAgreementMember" xlink:to="XAIR_LoanAndSecurityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US">Loan and Security Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NotePurchaseAgreementMember" xlink:label="XAIR_NotePurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NotePurchaseAgreementMember" xlink:to="XAIR_NotePurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_NotePurchaseAgreementMember_lbl" xml:lang="en-US">Note Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Income Tax Jurisdiction, Domestic Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="us-gaap_IsraelTaxAuthorityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl" xml:lang="en-US">Israel Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueCommissionersIrelandMember" xlink:label="us-gaap_RevenueCommissionersIrelandMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueCommissionersIrelandMember" xlink:to="us-gaap_RevenueCommissionersIrelandMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueCommissionersIrelandMember_lbl" xml:lang="en-US">Revenue Commissioners, Ireland [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CypriotTaxMember" xlink:label="XAIR_CypriotTaxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CypriotTaxMember" xlink:to="XAIR_CypriotTaxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CypriotTaxMember_lbl" xml:lang="en-US">Cypriot Tax [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NoExpirationMember" xlink:label="XAIR_NoExpirationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NoExpirationMember" xlink:to="XAIR_NoExpirationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_NoExpirationMember_lbl" xml:lang="en-US">No Expiration [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">Income Tax Jurisdiction, Domestic State and Local [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_IL" xlink:label="country_IL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl" xml:lang="en-US">ISRAEL</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OptionAgreementMember" xlink:label="XAIR_OptionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OptionAgreementMember" xlink:to="XAIR_OptionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OptionAgreementMember_lbl" xml:lang="en-US">Option Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NitricGenIncMember" xlink:label="XAIR_NitricGenIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NitricGenIncMember" xlink:to="XAIR_NitricGenIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_NitricGenIncMember_lbl" xml:lang="en-US">NitricGen, Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NextMilestonesMember" xlink:label="XAIR_NextMilestonesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NextMilestonesMember" xlink:to="XAIR_NextMilestonesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_NextMilestonesMember_lbl" xml:lang="en-US">Next Milestones [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AfterSixMonthsMember" xlink:label="XAIR_AfterSixMonthsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AfterSixMonthsMember" xlink:to="XAIR_AfterSixMonthsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AfterSixMonthsMember_lbl" xml:lang="en-US">After Six Months [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="us-gaap_CostOfGoodsTotalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsTotalMember" xlink:to="us-gaap_CostOfGoodsTotalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsTotalMember_lbl" xml:lang="en-US">Cost of Goods and Service Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SupplierMember" xlink:label="XAIR_SupplierMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SupplierMember" xlink:to="XAIR_SupplierMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SupplierMember_lbl" xml:lang="en-US">Supplier [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CertainInvestorsMember" xlink:label="XAIR_CertainInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CertainInvestorsMember" xlink:to="XAIR_CertainInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CertainInvestorsMember_lbl" xml:lang="en-US">Certain Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_InvestorsMember" xlink:label="XAIR_InvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_InvestorsMember" xlink:to="XAIR_InvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_InvestorsMember_lbl" xml:lang="en-US">Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SubscriptionAgreementMember" xlink:label="XAIR_SubscriptionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SubscriptionAgreementMember" xlink:to="XAIR_SubscriptionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SubscriptionAgreementMember_lbl" xml:lang="en-US">Subscription Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_VariableInterestEntitiesMember" xlink:label="XAIR_VariableInterestEntitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_VariableInterestEntitiesMember" xlink:to="XAIR_VariableInterestEntitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_VariableInterestEntitiesMember_lbl" xml:lang="en-US">Variable Interest Entities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondAirMember" xlink:label="XAIR_BeyondAirMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_BeyondAirMember" xlink:to="XAIR_BeyondAirMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_BeyondAirMember_lbl" xml:lang="en-US">Beyond Air [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SegmentMember" xlink:label="XAIR_SegmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SegmentMember" xlink:to="XAIR_SegmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SegmentMember_lbl" xml:lang="en-US">Business Segment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ParentCompanyMember_lbl" xml:lang="en-US">Parent Company [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LungFitPHMember" xlink:label="XAIR_LungFitPHMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LungFitPHMember" xlink:to="XAIR_LungFitPHMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_LungFitPHMember_lbl" xml:lang="en-US">Lung Fit PH [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LungFitRPHMember" xlink:label="XAIR_LungFitRPHMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LungFitRPHMember" xlink:to="XAIR_LungFitRPHMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_LungFitRPHMember_lbl" xml:lang="en-US">LungFit&#174; PH [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityListingParValuePerShare" xlink:label="dei_EntityListingParValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingParValuePerShare" xlink:to="dei_EntityListingParValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingParValuePerShare_lbl" xml:lang="en-US">Entity Listing, Par Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedLicenseAgreementsGross" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross_lbl" xml:lang="en-US">Licensed right to use technology</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use lease assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US">Loans payable, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US">Long-term debt, net</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_WarrantLiabilityNonCurrent" xlink:label="XAIR_WarrantLiabilityNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_WarrantLiabilityNonCurrent" xlink:to="XAIR_WarrantLiabilityNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_WarrantLiabilityNonCurrent_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.0001 par value per share: 500,000,000 shares authorized, 11,792,684 and 4,128,539 shares issued and outstanding as of March 31, 2026 and 2025, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income/(loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity attributable to Beyond Air, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income/(expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDividendIncomeOperating" xlink:to="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xml:lang="en-US">Dividend/investment income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest and finance expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Loss on disposal/impairment of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income/(expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income/(expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Less: net loss attributable to non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss attributable to Beyond Air, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">Other comprehensive income/(loss), net of tax:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss attributable to Beyond Air, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net basic loss per share attributable to Beyond Air, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net diluted loss per share attributable to Beyond Air, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares of common stock outstanding - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares of common stock outstanding - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock &#8211; At The Market equity offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock - At The Market equity offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SaleOfCommonStockAndPrefundedWarrants" xlink:label="XAIR_SaleOfCommonStockAndPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SaleOfCommonStockAndPrefundedWarrants" xlink:to="XAIR_SaleOfCommonStockAndPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SaleOfCommonStockAndPrefundedWarrants_lbl" xml:lang="en-US">Sale of common stock and pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares" xlink:label="XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares" xlink:to="XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares_lbl" xml:lang="en-US">Sale of common stock and pre-funded warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issue of common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of common stock upon vesting of restricted shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of common stock upon vesting of restricted shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">NeuroNos issuance of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax_lbl" xml:lang="en-US">Other comprehensive gain</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="XAIR_StockIssuedDuringPeriodValueReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="XAIR_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xml:lang="en-US">Issuance of common stock &#8211; 2025 Reverse Stock Split rounding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Issuance of common stock - 2025 Reverse Stock Split rounding, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common stock for conversion of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common stock for conversion of debt, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt discount and accretion of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of licensed right to use technology</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of operating lease assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Provision for inventory losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProvisionForOtherLosses" xlink:label="us-gaap_ProvisionForOtherLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherLosses" xlink:to="us-gaap_ProvisionForOtherLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForOtherLosses_lbl" xml:lang="en-US">Provision for bad debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_lbl" xml:lang="en-US">Foreign currency adjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_GainLossOnTerminationOfRightOfUseAsset" xlink:label="XAIR_GainLossOnTerminationOfRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_GainLossOnTerminationOfRightOfUseAsset" xlink:to="XAIR_GainLossOnTerminationOfRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="XAIR_GainLossOnTerminationOfRightOfUseAsset_lbl" xml:lang="en-US">Impairment of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Paid in kind interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchase of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases" xlink:label="XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases" xlink:to="XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases_lbl" xml:lang="en-US">Security deposits made on operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in)/provided by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from issuance of common stock through at the market offerings, net</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ProceedsFromSaleOfCommonStockOfNeuronos" xlink:label="XAIR_ProceedsFromSaleOfCommonStockOfNeuronos" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ProceedsFromSaleOfCommonStockOfNeuronos" xlink:to="XAIR_ProceedsFromSaleOfCommonStockOfNeuronos_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ProceedsFromSaleOfCommonStockOfNeuronos_lbl" xml:lang="en-US">Proceeds from the sale of common stock of NeuroNos</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock and pre-funded warrants through securities purchase, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from issuance of common stock through exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ProceedsFromLongTermDebt" xlink:label="XAIR_ProceedsFromLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ProceedsFromLongTermDebt" xlink:to="XAIR_ProceedsFromLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ProceedsFromLongTermDebt_lbl" xml:lang="en-US">Proceeds from long term loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="us-gaap_RepaymentsOfBankDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xml:lang="en-US">Payment of loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Increase/(decrease) in cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DebtDiscount" xlink:label="XAIR_DebtDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DebtDiscount" xlink:to="XAIR_DebtDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DebtDiscount_lbl" xml:lang="en-US">Debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DerivativesLiability" xlink:label="XAIR_DerivativesLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DerivativesLiability" xlink:to="XAIR_DerivativesLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DerivativesLiability_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ShortTermFinanceLiability" xlink:label="XAIR_ShortTermFinanceLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ShortTermFinanceLiability" xlink:to="XAIR_ShortTermFinanceLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ShortTermFinanceLiability_lbl" xml:lang="en-US">Short term finance liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Fixed assets recorded in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_RightofuseAssetsAcquiredUnderOperatingLeases" xlink:label="XAIR_RightofuseAssetsAcquiredUnderOperatingLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RightofuseAssetsAcquiredUnderOperatingLeases" xlink:to="XAIR_RightofuseAssetsAcquiredUnderOperatingLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RightofuseAssetsAcquiredUnderOperatingLeases_lbl" xml:lang="en-US">Right-of-use assets acquired under operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DebtPrincipalBalanceConvertedToEquity" xlink:label="XAIR_DebtPrincipalBalanceConvertedToEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DebtPrincipalBalanceConvertedToEquity" xlink:to="XAIR_DebtPrincipalBalanceConvertedToEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DebtPrincipalBalanceConvertedToEquity_lbl" xml:lang="en-US">Debt principal balance converted to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NoInsiderTradingFlag" xlink:label="XAIR_NoInsiderTradingFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NoInsiderTradingFlag" xlink:to="XAIR_NoInsiderTradingFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_NoInsiderTradingFlag_lbl" xml:lang="en-US">No insider trading flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND BUSINESS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant, and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS AND PREPAID EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DisclosureLeasesAbstract" xlink:label="XAIR_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DisclosureLeasesAbstract" xlink:to="XAIR_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">LOANS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US">LOAN PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DisclosureLeaseRevenuesAbstract" xlink:label="XAIR_DisclosureLeaseRevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DisclosureLeaseRevenuesAbstract" xlink:to="XAIR_DisclosureLeaseRevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DisclosureLeaseRevenuesAbstract_lbl" xml:lang="en-US">Lease Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OperatingLeasesTextBlock" xlink:label="XAIR_OperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLeasesTextBlock" xlink:to="XAIR_OperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASE REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock" xlink:label="XAIR_GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock" xlink:to="XAIR_GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Going Concern, Liquidity and Other Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Other Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_WarrantLiabilityPolicyTextBlock" xlink:label="XAIR_WarrantLiabilityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_WarrantLiabilityPolicyTextBlock" xlink:to="XAIR_WarrantLiabilityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_WarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents, Short-Term Investments and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Exchange Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SupplierConcentrationPolicyTextBlock" xlink:label="XAIR_SupplierConcentrationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SupplierConcentrationPolicyTextBlock" xlink:to="XAIR_SupplierConcentrationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SupplierConcentrationPolicyTextBlock_lbl" xml:lang="en-US">Supplier Concentration</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CustomerrConcentrationPolicyTextBlock" xlink:label="XAIR_CustomerrConcentrationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CustomerrConcentrationPolicyTextBlock" xlink:to="XAIR_CustomerrConcentrationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CustomerrConcentrationPolicyTextBlock_lbl" xml:lang="en-US">Customer Concentration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Licensed Right to Use Technology</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xml:lang="en-US">Variable Interest Entity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:label="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:to="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Standards Not Yet Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE ON A RECURRING BASIS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSUMPTIONS USED IN VALUING WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock" xlink:label="XAIR_FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock" xlink:to="XAIR_FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF KEY INPUTS DERIVATIVE</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock" xlink:label="XAIR_ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock" xlink:to="XAIR_ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock" xlink:label="XAIR_ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock" xlink:to="XAIR_ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRICTED STOCK AWARDS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPTION ACTIVITY FOR NEURONOS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE OF OPTION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SUMMARY OF OUTSTANDING WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OTHER CURRENT ASSETS AND PREPAID EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SUMMARY OF ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfOperatingLeaseLiabilityTableTextBlock" xlink:label="XAIR_ScheduleOfOperatingLeaseLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfOperatingLeaseLiabilityTableTextBlock" xlink:to="XAIR_ScheduleOfOperatingLeaseLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfOperatingLeaseLiabilityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPERATING LEASE LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LEASE RELATED COSTS</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OtherLeaseTableTextBlock" xlink:label="XAIR_OtherLeaseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OtherLeaseTableTextBlock" xlink:to="XAIR_OtherLeaseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OtherLeaseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LEASE OTHER INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF MATURITY OF LEASE LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LONG-TERM DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LOAN PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROFIT (LOSS) BEFORE TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSET/LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DIFFERENCE EFFECTIVE INCOME TAX RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STATUTORY US FEDERAL EFFECTIVE RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2_lbl" xml:lang="en-US">SCHEDULE OF MATURITY OF FUTURE LEASE PAYMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="XAIR_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="XAIR_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xml:lang="en-US">OrganizationConsolidationAndPresentationOfFinancialStatementsTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total assets measured and recorded at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total liabilities measured and recorded at fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_2_lbl" xml:lang="en-US">Total short-term marketable securities, Fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xml:lang="en-US">Total short-term marketable securities, Unrealized gains and (losses)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Business Combination [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Combination [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Expected term warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants and rights outstanding, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Maximum convertible shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US">Risk-free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Balance at March 31, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US">Issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_FairValueMeasurementExtinguishment" xlink:label="XAIR_FairValueMeasurementExtinguishment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FairValueMeasurementExtinguishment" xlink:to="XAIR_FairValueMeasurementExtinguishment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_FairValueMeasurementExtinguishment_lbl" xml:lang="en-US">Extinguishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Balance at March 31, 2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xml:lang="en-US">Marketable securities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_3_lbl" xml:lang="en-US">Total marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Total cash, cash equivalents, marketable securities and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant, and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant, and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2030</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2031</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="XAIR_CashAndCashEquivalentsAndMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CashAndCashEquivalentsAndMarketableSecurities" xlink:to="XAIR_CashAndCashEquivalentsAndMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CashAndCashEquivalentsAndMarketableSecurities_lbl" xml:lang="en-US">Cash equivalents and marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositAssets_lbl" xml:lang="en-US">Cash deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableNoncurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableNoncurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableNoncurrent_lbl" xml:lang="en-US">Allowance for credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilityMeasurementDifferenceDescription" xlink:label="us-gaap_DerivativeLiabilityMeasurementDifferenceDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementDifferenceDescription" xlink:to="us-gaap_DerivativeLiabilityMeasurementDifferenceDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementDifferenceDescription_lbl" xml:lang="en-US">Derivative liability description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Purchase of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDefaultLongtermDebtAmount" xlink:to="us-gaap_DebtDefaultLongtermDebtAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount_lbl" xml:lang="en-US">Debt amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="us-gaap_CommonStockValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValueOutstanding" xlink:to="us-gaap_CommonStockValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValueOutstanding_lbl" xml:lang="en-US">Fair value of issued common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue" xlink:label="us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue" xlink:to="us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue_lbl" xml:lang="en-US">Fair value of the derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xml:lang="en-US">Proceeds from issuance of secured promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDescription" xlink:label="us-gaap_ConcentrationRiskBenchmarkDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDescription" xlink:to="us-gaap_ConcentrationRiskBenchmarkDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDescription_lbl" xml:lang="en-US">Concentration risk benchmark description</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag" xlink:label="XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag" xlink:to="XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag_lbl" xml:lang="en-US">Number of repotable segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Obsolescence reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TaxRebate" xlink:label="XAIR_TaxRebate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TaxRebate" xlink:to="XAIR_TaxRebate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TaxRebate_lbl" xml:lang="en-US">Tax Rebate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="us-gaap_OtherAssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl" xml:lang="en-US">Other asset impairment charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Non-controlling owners interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Unvested Number of Shares, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of Shares, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Shares, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Unvested Number of Shares, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Options, Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life - Options, Outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options Outstanding, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Options Outstanding, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options Outstanding, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Options, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options, Outstanding at ending of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price - Options, Outstanding at ending of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options Outstanding, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Options, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life - Options, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average remaining contractual life - options, outstanding at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price of Options, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Number of Options, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price of Options, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Number of Options, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price of Options, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life of Options, Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price - options, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life of Options, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfFairValueOfOptionTable" xlink:label="XAIR_ScheduleOfFairValueOfOptionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfFairValueOfOptionTable" xlink:to="XAIR_ScheduleOfFairValueOfOptionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfFairValueOfOptionTable_lbl" xml:lang="en-US">ScheduleOfFairValueOfOptionTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfStockBasedCompensationExpenseTable" xlink:label="XAIR_ScheduleOfStockBasedCompensationExpenseTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfStockBasedCompensationExpenseTable" xlink:to="XAIR_ScheduleOfStockBasedCompensationExpenseTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfStockBasedCompensationExpenseTable_lbl" xml:lang="en-US">ScheduleOfStockBasedCompensationExpenseTable [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" xlink:label="XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" xlink:to="XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_WarrantsExpirationDateDescription" xlink:label="XAIR_WarrantsExpirationDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_WarrantsExpirationDateDescription" xlink:to="XAIR_WarrantsExpirationDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_WarrantsExpirationDateDescription_lbl" xml:lang="en-US">Date of Expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SaleOfStockFeePercentage" xlink:label="XAIR_SaleOfStockFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SaleOfStockFeePercentage" xlink:to="XAIR_SaleOfStockFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SaleOfStockFeePercentage_lbl" xml:lang="en-US">Sale of stock fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PublicFloatValue" xlink:label="XAIR_PublicFloatValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PublicFloatValue" xlink:to="XAIR_PublicFloatValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PublicFloatValue_lbl" xml:lang="en-US">Public float value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Sale of net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares issued in transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Share purchase value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock issues during the period, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Fair value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Adjustments in additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Common stock minimum purchase amount</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeneficialOwnershipLimitationPercentage" xlink:label="XAIR_BeneficialOwnershipLimitationPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_BeneficialOwnershipLimitationPercentage" xlink:to="XAIR_BeneficialOwnershipLimitationPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_BeneficialOwnershipLimitationPercentage_lbl" xml:lang="en-US">Beneficial ownership limitation percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Purchase warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrants price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xml:lang="en-US">Proceeds from private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCommissions" xlink:to="us-gaap_PaymentsForCommissions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForCommissions_lbl" xml:lang="en-US">Commission paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Other fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Stock option shares authorized for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Number of shares available for grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average remaining service period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value of options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Share compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Option repricing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price in excess</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl" xml:lang="en-US">Incremental stock compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="us-gaap_StockOptionExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Option exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Number of additionl shares reserve for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants to purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Warrants Exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Other fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Weighted average remaining service period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock issued during the period, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PrepaidResearchAndDevelopment" xlink:label="XAIR_PrepaidResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PrepaidResearchAndDevelopment" xlink:to="XAIR_PrepaidResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_PrepaidResearchAndDevelopment_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidRent_lbl" xml:lang="en-US">Prepaid rents and tenant improvement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidTaxes_lbl" xml:lang="en-US">Value added tax receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssets_lbl" xml:lang="en-US">Deposits to secure manufacturing materials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Supplies" xlink:label="us-gaap_Supplies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Supplies_lbl" xml:lang="en-US">Demonstration materials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Total other current assets and prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AccruedResearchAndDevelopmentExpenses" xlink:label="XAIR_AccruedResearchAndDevelopmentExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AccruedResearchAndDevelopmentExpenses" xlink:to="XAIR_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Employee salaries and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_InterestSeveranceCurrent" xlink:label="XAIR_InterestSeveranceCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_InterestSeveranceCurrent" xlink:to="XAIR_InterestSeveranceCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_InterestSeveranceCurrent_lbl" xml:lang="en-US">Accrued severance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_GoodsReceivedNotInvoiced" xlink:label="XAIR_GoodsReceivedNotInvoiced" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_GoodsReceivedNotInvoiced" xlink:to="XAIR_GoodsReceivedNotInvoiced_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_GoodsReceivedNotInvoiced_lbl" xml:lang="en-US">Goods received not invoiced</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PayablesAndAccrualsTable" xlink:label="XAIR_PayablesAndAccrualsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PayablesAndAccrualsTable" xlink:to="XAIR_PayablesAndAccrualsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PayablesAndAccrualsTable_lbl" xml:lang="en-US">PayablesAndAccrualsTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes Payable, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DisclosureLeasesAbstract" xlink:to="XAIR_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Operating Lease Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating lease liability short-term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease liability long-term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate - operating leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DisclosureLeasesAbstract" xlink:to="XAIR_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="XAIR_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Lease Related Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Sublease income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows for operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2030</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2031</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: amount of lease payments representing interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Present value of future lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Operation lease description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability in exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US">Warrants included in calculation of diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal balance outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PaidInKindInterestAmount" xlink:label="XAIR_PaidInKindInterestAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaidInKindInterestAmount" xlink:to="XAIR_PaidInKindInterestAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_PaidInKindInterestAmount_lbl" xml:lang="en-US">Paid in kind interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AmortizationOfDebtDiscount" xlink:label="XAIR_AmortizationOfDebtDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AmortizationOfDebtDiscount" xlink:to="XAIR_AmortizationOfDebtDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AmortizationOfDebtDiscount_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DebtInstrumentInterestRatePayableInCashPercentage" xlink:label="XAIR_DebtInstrumentInterestRatePayableInCashPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DebtInstrumentInterestRatePayableInCashPercentage" xlink:to="XAIR_DebtInstrumentInterestRatePayableInCashPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DebtInstrumentInterestRatePayableInCashPercentage_lbl" xml:lang="en-US">Percentage of interest payable in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DebtInstrumentInterestRatePayableInKindPercentage" xlink:label="XAIR_DebtInstrumentInterestRatePayableInKindPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DebtInstrumentInterestRatePayableInKindPercentage" xlink:to="XAIR_DebtInstrumentInterestRatePayableInKindPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DebtInstrumentInterestRatePayableInKindPercentage_lbl" xml:lang="en-US">Percentage of interest payable in kind</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_RoyaltyInterestPercentage" xlink:label="XAIR_RoyaltyInterestPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RoyaltyInterestPercentage" xlink:to="XAIR_RoyaltyInterestPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RoyaltyInterestPercentage_lbl" xml:lang="en-US">Royalty interest percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_3_lbl" xml:lang="en-US">Price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleOfLoansReceivable" xlink:label="us-gaap_ProceedsFromSaleOfLoansReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfLoansReceivable" xlink:to="us-gaap_ProceedsFromSaleOfLoansReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfLoansReceivable_lbl" xml:lang="en-US">Advanced financing from related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt instrument term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US">Interest rate description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Debt instrument, interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DebtInstrumentOfRestrictedAccount" xlink:label="XAIR_DebtInstrumentOfRestrictedAccount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DebtInstrumentOfRestrictedAccount" xlink:to="XAIR_DebtInstrumentOfRestrictedAccount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DebtInstrumentOfRestrictedAccount_lbl" xml:lang="en-US">Principal in restricted account</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRepaidPrincipal" xlink:label="us-gaap_DebtInstrumentRepaidPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepaidPrincipal" xlink:to="us-gaap_DebtInstrumentRepaidPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRepaidPrincipal_lbl" xml:lang="en-US">Debt instrument, principal repayable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Shares issued of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Debt amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Shares available for resale</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_UnrestrictedCash" xlink:label="XAIR_UnrestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_UnrestrictedCash" xlink:to="XAIR_UnrestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_UnrestrictedCash_lbl" xml:lang="en-US">Unrestricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Monitoring fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Amount outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Monthly payments</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NumberOfPayments" xlink:label="XAIR_NumberOfPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NumberOfPayments" xlink:to="XAIR_NumberOfPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_NumberOfPayments_lbl" xml:lang="en-US">Amount outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LoanPayableDueDateDescription" xlink:label="XAIR_LoanPayableDueDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LoanPayableDueDateDescription" xlink:to="XAIR_LoanPayableDueDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_LoanPayableDueDateDescription_lbl" xml:lang="en-US">Due date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ResearchAndDevelopmentTaxCreditCapitalization" xlink:label="XAIR_ResearchAndDevelopmentTaxCreditCapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ResearchAndDevelopmentTaxCreditCapitalization" xlink:to="XAIR_ResearchAndDevelopmentTaxCreditCapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ResearchAndDevelopmentTaxCreditCapitalization_lbl" xml:lang="en-US">Research and development tax credit capitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" xlink:label="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" xlink:to="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DeferredTaxAssetsReservesAndAccruels" xlink:label="XAIR_DeferredTaxAssetsReservesAndAccruels" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsReservesAndAccruels" xlink:to="XAIR_DeferredTaxAssetsReservesAndAccruels_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DeferredTaxAssetsReservesAndAccruels_lbl" xml:lang="en-US">Reserves and accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DeferredTaxAssetsRightofuseAsset" xlink:label="XAIR_DeferredTaxAssetsRightofuseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsRightofuseAsset" xlink:to="XAIR_DeferredTaxAssetsRightofuseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DeferredTaxAssetsRightofuseAsset_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DeferredTaxAssetsLeaseLiability" xlink:label="XAIR_DeferredTaxAssetsLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsLeaseLiability" xlink:to="XAIR_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Net deferred tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateTable" xlink:label="XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateTable" xlink:to="XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateTable_lbl" xml:lang="en-US">ScheduleOfDifferenceEffectiveIncomeTaxRateTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:label="XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:to="XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Current state and local income taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Current state and local income taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Other foreign jurisdictions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other foreign jurisdictions</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch" xlink:label="XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch" xlink:to="XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch_lbl" xml:lang="en-US">Other foreign jurisdictions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl" xml:lang="en-US">Changes in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xml:lang="en-US">Changes in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationTaxSubpartFIncome" xlink:label="XAIR_IncomeTaxReconciliationTaxSubpartFIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncomeTaxReconciliationTaxSubpartFIncome" xlink:to="XAIR_IncomeTaxReconciliationTaxSubpartFIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_IncomeTaxReconciliationTaxSubpartFIncome_lbl" xml:lang="en-US">Subpart F Income</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome_lbl" xml:lang="en-US">Subpart F Income</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US">Share-based payment awards</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US">Share-based payment awards</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments" xlink:label="XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments" xlink:to="XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems" xlink:label="XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems" xlink:to="XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems_lbl" xml:lang="en-US">Other adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other adjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Other adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_lbl" xml:lang="en-US">Federal income tax at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US">Permanent items</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Non-deductible compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign tax rate differential</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss_lbl" xml:lang="en-US">Change to foreign NOL&#8217;s</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OffsetTaxableIncomeRate" xlink:label="XAIR_OffsetTaxableIncomeRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OffsetTaxableIncomeRate" xlink:to="XAIR_OffsetTaxableIncomeRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OffsetTaxableIncomeRate_lbl" xml:lang="en-US">Taxable income</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OperatingLossCarryforwardsExpirationYears" xlink:label="XAIR_OperatingLossCarryforwardsExpirationYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLossCarryforwardsExpirationYears" xlink:to="XAIR_OperatingLossCarryforwardsExpirationYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OperatingLossCarryforwardsExpirationYears_lbl" xml:lang="en-US">Operating loss carryforward expire description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Deferred tax liabilities, deferred expense, capitalized research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax credit carryforward, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xml:lang="en-US">Tax credit carryforward, description</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage_lbl" xml:lang="en-US">Federal tax percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xml:lang="en-US">Income tax limitation description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_2_lbl" xml:lang="en-US">Federal income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="us-gaap_ProductLiabilityContingencyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyTable" xlink:to="us-gaap_ProductLiabilityContingencyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyTable_lbl" xml:lang="en-US">Product Liability Contingency [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PaymentsForDevelopmentAndMilestonePayment" xlink:label="XAIR_PaymentsForDevelopmentAndMilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentsForDevelopmentAndMilestonePayment" xlink:to="XAIR_PaymentsForDevelopmentAndMilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PaymentsForDevelopmentAndMilestonePayment_lbl" xml:lang="en-US">Payments for development and milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_MilestonePayments" xlink:label="XAIR_MilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MilestonePayments" xlink:to="XAIR_MilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_MilestonePayments_lbl" xml:lang="en-US">Remaining future milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SalesRelatedMilestonesPayments" xlink:label="XAIR_SalesRelatedMilestonesPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SalesRelatedMilestonesPayments" xlink:to="XAIR_SalesRelatedMilestonesPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SalesRelatedMilestonesPayments_lbl" xml:lang="en-US">Sales related milestones payments</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PaymentForMilestoneMethodRevenueRecognized" xlink:label="XAIR_PaymentForMilestoneMethodRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentForMilestoneMethodRevenueRecognized" xlink:to="XAIR_PaymentForMilestoneMethodRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PaymentForMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US">Future payments based on certain milestones</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xml:lang="en-US">Warrants to purchase common stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US">Outstanding amount under purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepositAssets_2_lbl" xml:lang="en-US">Cash deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Segment Reporting [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sle of stock per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AmountOfTerminatedLoan" xlink:label="XAIR_AmountOfTerminatedLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AmountOfTerminatedLoan" xlink:to="XAIR_AmountOfTerminatedLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AmountOfTerminatedLoan_lbl" xml:lang="en-US">Amount of terminated loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from related party debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xml:lang="en-US">Equity ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Related party invested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CapitalExpendituresCost" xlink:label="XAIR_CapitalExpendituresCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CapitalExpendituresCost" xlink:to="XAIR_CapitalExpendituresCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CapitalExpendituresCost_lbl" xml:lang="en-US">Capital expenditures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_2_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Selling, general, and administrative</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other non-operating income/(expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss before income taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Cash used in operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash provided by investing</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash provided by financing</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2_lbl" xml:lang="en-US">Impact of exchange rates</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Net change for the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_2_lbl" xml:lang="en-US">Cash, cash equivalents and marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">All other assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsNet" xlink:label="us-gaap_AssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNet" xlink:to="us-gaap_AssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNet_lbl" xml:lang="en-US">Net assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Contract term</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OperatingLeaseIncome" xlink:label="XAIR_OperatingLeaseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLeaseIncome" xlink:to="XAIR_OperatingLeaseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OperatingLeaseIncome_lbl" xml:lang="en-US">Lease revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_2_lbl" xml:lang="en-US">Useful Life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NoInsiderTradingFlag" xlink:to="XAIR_NoInsiderTradingFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_NoInsiderTradingFlag_doc" xml:lang="en-US">No Insider Trading Flag.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_WarrantLiabilityNonCurrent" xlink:to="XAIR_WarrantLiabilityNonCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_WarrantLiabilityNonCurrent_doc" xml:lang="en-US">Warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PreFundedWarrantsMember" xlink:to="XAIR_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PreFundedWarrantsMember_doc" xml:lang="en-US">Pre-funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LoanAgreementMember" xlink:to="XAIR_LoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_LoanAgreementMember_doc" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PromissoryNoteMember" xlink:to="XAIR_PromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PromissoryNoteMember_doc" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaidInKindInterestAmount" xlink:to="XAIR_PaidInKindInterestAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PaidInKindInterestAmount_doc" xml:lang="en-US">Paid in kind interest amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AmortizationOfDebtDiscount" xlink:to="XAIR_AmortizationOfDebtDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AmortizationOfDebtDiscount_doc" xml:lang="en-US">Amortization of Debt Discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LoanAndSecurityAgreementMember" xlink:to="XAIR_LoanAndSecurityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_LoanAndSecurityAgreementMember_doc" xml:lang="en-US">Loan and Security Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DebtInstrumentInterestRatePayableInCashPercentage" xlink:to="XAIR_DebtInstrumentInterestRatePayableInCashPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DebtInstrumentInterestRatePayableInCashPercentage_doc" xml:lang="en-US">Debt instrument interest rate payable in cash percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SaleOfStockFeePercentage" xlink:to="XAIR_SaleOfStockFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SaleOfStockFeePercentage_doc" xml:lang="en-US">Sale of stock fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandAndTwentyFiveATMMember" xlink:to="XAIR_TwoThousandAndTwentyFiveATMMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TwoThousandAndTwentyFiveATMMember_doc" xml:lang="en-US">2025 ATM [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RoyaltyInterestPercentage" xlink:to="XAIR_RoyaltyInterestPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RoyaltyInterestPercentage_doc" xml:lang="en-US">Royalty interest percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DebtInstrumentInterestRatePayableInKindPercentage" xlink:to="XAIR_DebtInstrumentInterestRatePayableInKindPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DebtInstrumentInterestRatePayableInKindPercentage_doc" xml:lang="en-US">Debt instrument interest rate payable in kind percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PublicFloatValue" xlink:to="XAIR_PublicFloatValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PublicFloatValue_doc" xml:lang="en-US">Public float value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AmendedLoanAgreementMember" xlink:to="XAIR_AmendedLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AmendedLoanAgreementMember_doc" xml:lang="en-US">Amended Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NotePurchaseAgreementMember" xlink:to="XAIR_NotePurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_NotePurchaseAgreementMember_doc" xml:lang="en-US">Note Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DebtInstrumentOfRestrictedAccount" xlink:to="XAIR_DebtInstrumentOfRestrictedAccount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DebtInstrumentOfRestrictedAccount_doc" xml:lang="en-US">Debt instrument of restricted account.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StreetervilleCapitalLLCMember" xlink:to="XAIR_StreetervilleCapitalLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_StreetervilleCapitalLLCMember_doc" xml:lang="en-US">Streeterville Capital LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_UnrestrictedCash" xlink:to="XAIR_UnrestrictedCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_UnrestrictedCash_doc" xml:lang="en-US">Unrestricted cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NumberOfPayments" xlink:to="XAIR_NumberOfPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_NumberOfPayments_doc" xml:lang="en-US">Number of payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LoanPayableDueDateDescription" xlink:to="XAIR_LoanPayableDueDateDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_LoanPayableDueDateDescription_doc" xml:lang="en-US">Loan payable due date description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PurchaseAgreementMember" xlink:to="XAIR_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_BeneficialOwnershipLimitationPercentage" xlink:to="XAIR_BeneficialOwnershipLimitationPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_BeneficialOwnershipLimitationPercentage_doc" xml:lang="en-US">Beneficial ownership limitation percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OffsetTaxableIncomeRate" xlink:to="XAIR_OffsetTaxableIncomeRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OffsetTaxableIncomeRate_doc" xml:lang="en-US">Offset taxable income rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NoExpirationMember" xlink:to="XAIR_NoExpirationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_NoExpirationMember_doc" xml:lang="en-US">No Expiration [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLossCarryforwardsExpirationYears" xlink:to="XAIR_OperatingLossCarryforwardsExpirationYears_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OperatingLossCarryforwardsExpirationYears_doc" xml:lang="en-US">Operating loss carryforward expire term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" xlink:to="XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_doc" xml:lang="en-US">2013 Beyond Air Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage_doc" xml:lang="en-US">Effective income tax rate reconciliation at federal statutory income tax rate percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ResearchAndDevelopmentTaxCreditCapitalization" xlink:to="XAIR_ResearchAndDevelopmentTaxCreditCapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ResearchAndDevelopmentTaxCreditCapitalization_doc" xml:lang="en-US">Research and development tax credit capitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" xlink:to="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation_doc" xml:lang="en-US">Deferred tax assets tax deferred expense compensation and depreciation.</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" xlink:label="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" xlink:to="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward_doc" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Capital loss carryforward.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsReservesAndAccruels" xlink:to="XAIR_DeferredTaxAssetsReservesAndAccruels_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DeferredTaxAssetsReservesAndAccruels_doc" xml:lang="en-US">Deferred tax assets reserves and accruels.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsRightofuseAsset" xlink:to="XAIR_DeferredTaxAssetsRightofuseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DeferredTaxAssetsRightofuseAsset_doc" xml:lang="en-US">Deferred tax assets right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsLeaseLiability" xlink:to="XAIR_DeferredTaxAssetsLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DeferredTaxAssetsLeaseLiability_doc" xml:lang="en-US">Deferred tax assets lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandThirteenBAPlanMember" xlink:to="XAIR_TwoThousandThirteenBAPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TwoThousandThirteenBAPlanMember_doc" xml:lang="en-US">2013 BA Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss_doc" xml:lang="en-US">Effective income tax rate reconciliation change to foreign net operating loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SaleOfCommonStockAndPrefundedWarrants" xlink:to="XAIR_SaleOfCommonStockAndPrefundedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SaleOfCommonStockAndPrefundedWarrants_doc" xml:lang="en-US">Sale of common stock and prefunded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares" xlink:to="XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares_doc" xml:lang="en-US">Issuance of common stock at market equity offering shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MilestonePayments" xlink:to="XAIR_MilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_MilestonePayments_doc" xml:lang="en-US">Milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OptionAgreementMember" xlink:to="XAIR_OptionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OptionAgreementMember_doc" xml:lang="en-US">Option Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SalesRelatedMilestonesPayments" xlink:to="XAIR_SalesRelatedMilestonesPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SalesRelatedMilestonesPayments_doc" xml:lang="en-US">Sales related milestones payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentsForDevelopmentAndMilestonePayment" xlink:to="XAIR_PaymentsForDevelopmentAndMilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PaymentsForDevelopmentAndMilestonePayment_doc" xml:lang="en-US">Payments for development and milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NitricGenIncMember" xlink:to="XAIR_NitricGenIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_NitricGenIncMember_doc" xml:lang="en-US">NitricGen, Inc [Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NitricGenAgreementMember" xlink:to="XAIR_NitricGenAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_NitricGenAgreementMember_doc" xml:lang="en-US">NitricGen Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentForMilestoneMethodRevenueRecognized" xlink:to="XAIR_PaymentForMilestoneMethodRevenueRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PaymentForMilestoneMethodRevenueRecognized_doc" xml:lang="en-US">Payment for milestone method revenue recognized.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AfterSixMonthsMember" xlink:to="XAIR_AfterSixMonthsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AfterSixMonthsMember_doc" xml:lang="en-US">After Six Months [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NextMilestonesMember" xlink:to="XAIR_NextMilestonesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_NextMilestonesMember_doc" xml:lang="en-US">Next Milestones [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SupplierMember" xlink:to="XAIR_SupplierMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SupplierMember_doc" xml:lang="en-US">Supplier [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ProceedsFromLongTermDebt" xlink:to="XAIR_ProceedsFromLongTermDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ProceedsFromLongTermDebt_doc" xml:lang="en-US">Proceeds from long term debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DebtDiscount" xlink:to="XAIR_DebtDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DebtDiscount_doc" xml:lang="en-US">Debt discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DerivativesLiability" xlink:to="XAIR_DerivativesLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DerivativesLiability_doc" xml:lang="en-US">Derivatives liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DebtPrincipalBalanceConvertedToEquity" xlink:to="XAIR_DebtPrincipalBalanceConvertedToEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DebtPrincipalBalanceConvertedToEquity_doc" xml:lang="en-US">Debt principal balance converted to equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RightofuseAssetsAcquiredUnderOperatingLeases" xlink:to="XAIR_RightofuseAssetsAcquiredUnderOperatingLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RightofuseAssetsAcquiredUnderOperatingLeases_doc" xml:lang="en-US">Right of use assets acquired under operating leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NeuroNosLtdMember" xlink:to="XAIR_NeuroNosLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_NeuroNosLtdMember_doc" xml:lang="en-US">NeuroNos Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ShortTermFinanceLiability" xlink:to="XAIR_ShortTermFinanceLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ShortTermFinanceLiability_doc" xml:lang="en-US">Short term finance liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_BeyondCancerLtdMember" xlink:to="XAIR_BeyondCancerLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_BeyondCancerLtdMember_doc" xml:lang="en-US">Beyond Cancer Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CertainInvestorsMember" xlink:to="XAIR_CertainInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CertainInvestorsMember_doc" xml:lang="en-US">Certain Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ProceedsFromSaleOfCommonStockOfNeuronos" xlink:to="XAIR_ProceedsFromSaleOfCommonStockOfNeuronos_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ProceedsFromSaleOfCommonStockOfNeuronos_doc" xml:lang="en-US">Proceeds from sale of common stock of neuronos.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AmountOfTerminatedLoan" xlink:to="XAIR_AmountOfTerminatedLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AmountOfTerminatedLoan_doc" xml:lang="en-US">Amount of terminated loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_InvestorsMember" xlink:to="XAIR_InvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_InvestorsMember_doc" xml:lang="en-US">Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases" xlink:to="XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases_doc" xml:lang="en-US">Payments to security deposits made on operating leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SubscriptionAgreementMember" xlink:to="XAIR_SubscriptionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SubscriptionAgreementMember_doc" xml:lang="en-US">Subscription Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_GainLossOnTerminationOfRightOfUseAsset" xlink:to="XAIR_GainLossOnTerminationOfRightOfUseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_GainLossOnTerminationOfRightOfUseAsset_doc" xml:lang="en-US">Gain loss on termination of right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_BeyondAirMember" xlink:to="XAIR_BeyondAirMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_BeyondAirMember_doc" xml:lang="en-US">Beyond Air [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SegmentMember" xlink:to="XAIR_SegmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SegmentMember_doc" xml:lang="en-US">Business Segment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_VariableInterestEntitiesMember" xlink:to="XAIR_VariableInterestEntitiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_VariableInterestEntitiesMember_doc" xml:lang="en-US">Variable Interest Entities [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CapitalExpendituresCost" xlink:to="XAIR_CapitalExpendituresCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CapitalExpendituresCost_doc" xml:lang="en-US">Capital expenditures cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandThirteenEquityIncentivePlanMember" xlink:to="XAIR_TwoThousandThirteenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TwoThousandThirteenEquityIncentivePlanMember_doc" xml:lang="en-US">2013 BA EquityIncentivePlan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" xlink:to="XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_doc" xml:lang="en-US">2021 Beyond Cancer Ltd Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock" xlink:to="XAIR_GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock_doc" xml:lang="en-US">Going Concern Liquidity and Other Uncertainties [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CashAndCashEquivalentsAndMarketableSecurities" xlink:to="XAIR_CashAndCashEquivalentsAndMarketableSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CashAndCashEquivalentsAndMarketableSecurities_doc" xml:lang="en-US">Cash and cash equivalents and marketable securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" xlink:to="XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_doc" xml:lang="en-US">2023 Neuro Nos Ltd Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock_doc" xml:lang="en-US">Other Risks and Uncertainties [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLeasesTextBlock" xlink:to="XAIR_OperatingLeasesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OperatingLeasesTextBlock_doc" xml:lang="en-US">Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLeaseIncome" xlink:to="XAIR_OperatingLeaseIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OperatingLeaseIncome_doc" xml:lang="en-US">Operating lease income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LungFitPHMember" xlink:to="XAIR_LungFitPHMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_LungFitPHMember_doc" xml:lang="en-US">Lung Fit PH [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LungFitRPHMember" xlink:to="XAIR_LungFitRPHMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_LungFitRPHMember_doc" xml:lang="en-US">LungFit&#174; PH [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_BeyondAirIncMember" xlink:to="XAIR_BeyondAirIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_BeyondAirIncMember_doc" xml:lang="en-US">Beyond Air Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock" xlink:to="XAIR_FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock_doc" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques of Derivative [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:to="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_doc" xml:lang="en-US">Recently Issued Accounting Standards Not Yet Adopted [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AvenueAgreementMember" xlink:to="XAIR_AvenueAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AvenueAgreementMember_doc" xml:lang="en-US">Avenue Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MarchTwoThousandTwentyFourRaiseMember" xlink:to="XAIR_MarchTwoThousandTwentyFourRaiseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_MarchTwoThousandTwentyFourRaiseMember_doc" xml:lang="en-US">March 2024 Raise [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AvenueExtensionAgreementMember" xlink:to="XAIR_AvenueExtensionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AvenueExtensionAgreementMember_doc" xml:lang="en-US">Avenue Extension Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember" xlink:to="XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember_doc" xml:lang="en-US">September 2024 equity offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember" xlink:to="XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember_doc" xml:lang="en-US">September 2024 Debt Instrument [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SeptemberTwoThousandTwentyFiveInducementMember" xlink:to="XAIR_SeptemberTwoThousandTwentyFiveInducementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SeptemberTwoThousandTwentyFiveInducementMember_doc" xml:lang="en-US">September 2025 Inducement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SubTotalMember" xlink:to="XAIR_SubTotalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SubTotalMember_doc" xml:lang="en-US">Sub Total [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CustomerrConcentrationPolicyTextBlock" xlink:to="XAIR_CustomerrConcentrationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CustomerrConcentrationPolicyTextBlock_doc" xml:lang="en-US">Customerr Concentration [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember" xlink:to="XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember_doc" xml:lang="en-US">January, 2026 Equity Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CustomersOneMember" xlink:to="XAIR_CustomersOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CustomersOneMember_doc" xml:lang="en-US">Customers One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CustomersTwoMember" xlink:to="XAIR_CustomersTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CustomersTwoMember_doc" xml:lang="en-US">Customers Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember" xlink:to="XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember_doc" xml:lang="en-US">Pre Funded Warrants Sep 2024 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember" xlink:to="XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember_doc" xml:lang="en-US">Pre Funded Warrants jan 2026 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SupplierConcentrationPolicyTextBlock" xlink:to="XAIR_SupplierConcentrationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SupplierConcentrationPolicyTextBlock_doc" xml:lang="en-US">Supplier Concentration [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FirstThirdPartyVendorsMember" xlink:to="XAIR_FirstThirdPartyVendorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_FirstThirdPartyVendorsMember_doc" xml:lang="en-US">First Third Party Vendors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SecondThirdPartyVendorsMember" xlink:to="XAIR_SecondThirdPartyVendorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SecondThirdPartyVendorsMember_doc" xml:lang="en-US">Second Third Party Vendors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ThirdPartyVendorsMember" xlink:to="XAIR_ThirdPartyVendorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ThirdPartyVendorsMember_doc" xml:lang="en-US">Third Party Vendors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" xlink:to="XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_doc" xml:lang="en-US">Warrants Intrinsic Value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TaxRebate" xlink:to="XAIR_TaxRebate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TaxRebate_doc" xml:lang="en-US">Tax rebate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_WarrantsExpirationDateDescription" xlink:to="XAIR_WarrantsExpirationDateDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_WarrantsExpirationDateDescription_doc" xml:lang="en-US">Warrants expiration date description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock" xlink:to="XAIR_ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock_doc" xml:lang="en-US">Schedule of Property and Equipment UsefulLife of Assets [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ClinicalAndMedicalEquipmentMember" xlink:to="XAIR_ClinicalAndMedicalEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ClinicalAndMedicalEquipmentMember_doc" xml:lang="en-US">Clinical and Medical Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EquipmentDeployableAsPartOfServiceOfferingMember" xlink:to="XAIR_EquipmentDeployableAsPartOfServiceOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EquipmentDeployableAsPartOfServiceOfferingMember_doc" xml:lang="en-US">Equipment Deployable as Part of Service Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_doc" xml:lang="en-US">2021 Employee Stock Purchase Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AccruedResearchAndDevelopmentExpenses" xlink:to="XAIR_AccruedResearchAndDevelopmentExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AccruedResearchAndDevelopmentExpenses_doc" xml:lang="en-US">Accrued prepaid research and development expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_GoodsReceivedNotInvoiced" xlink:to="XAIR_GoodsReceivedNotInvoiced_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_GoodsReceivedNotInvoiced_doc" xml:lang="en-US">Goods received not invoiced.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_InterestSeveranceCurrent" xlink:to="XAIR_InterestSeveranceCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_InterestSeveranceCurrent_doc" xml:lang="en-US">Interest severance current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_WarrantLiabilityPolicyTextBlock" xlink:to="XAIR_WarrantLiabilityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_WarrantLiabilityPolicyTextBlock_doc" xml:lang="en-US">Warrant Liability [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock" xlink:to="XAIR_ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock_doc" xml:lang="en-US">Schedule Of Change In Fair Value Of Warrants And Derivatives [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfOperatingLeaseLiabilityTableTextBlock" xlink:to="XAIR_ScheduleOfOperatingLeaseLiabilityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ScheduleOfOperatingLeaseLiabilityTableTextBlock_doc" xml:lang="en-US">Schedule Of Operating Lease Liability [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OtherLeaseTableTextBlock" xlink:to="XAIR_OtherLeaseTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OtherLeaseTableTextBlock_doc" xml:lang="en-US">Other Lease [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PrepaidResearchAndDevelopment" xlink:to="XAIR_PrepaidResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PrepaidResearchAndDevelopment_doc" xml:lang="en-US">Prepaid research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag" xlink:to="XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag_doc" xml:lang="en-US">Number of reportable segments disclosed by definition flag.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FairValueMeasurementExtinguishment" xlink:to="XAIR_FairValueMeasurementExtinguishment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_FairValueMeasurementExtinguishment_doc" xml:lang="en-US">Extinguishment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandTwentySixPreFundedWarrantsMember" xlink:to="XAIR_TwoThousandTwentySixPreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TwoThousandTwentySixPreFundedWarrantsMember_doc" xml:lang="en-US">2026 Pre-funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandTwentySixCommonWarrantsMember" xlink:to="XAIR_TwoThousandTwentySixCommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TwoThousandTwentySixCommonWarrantsMember_doc" xml:lang="en-US">2026 Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CypriotTaxMember" xlink:to="XAIR_CypriotTaxMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CypriotTaxMember_doc" xml:lang="en-US">Cypriot Tax [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandTwentyFiveOptionRepricingMember" xlink:to="XAIR_TwoThousandTwentyFiveOptionRepricingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TwoThousandTwentyFiveOptionRepricingMember_doc" xml:lang="en-US">2025 Option Repricing [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_doc" xml:lang="en-US">Federal income tax at statutory rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MutualFundsMember" xlink:to="XAIR_MutualFundsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_MutualFundsMember_doc" xml:lang="en-US">Mutual Funds [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SteveLisiMember" xlink:to="XAIR_SteveLisiMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SteveLisiMember_doc" xml:lang="en-US">Steve Lisi [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="XAIR_StockIssuedDuringPeriodValueReverseStockSplits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_StockIssuedDuringPeriodValueReverseStockSplits_doc" xml:lang="en-US">Reduction in the value of shares issued during the period as a result of a reverse stock split.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock_doc" xml:lang="en-US">Schedule Of Difference Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes_doc" xml:lang="en-US">Effective Income tax rate reconciliation difference state and local income taxes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:to="XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes_doc" xml:lang="en-US">Income tax reconciliation difference state and local income taxes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch" xlink:to="XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch_doc" xml:lang="en-US">Income tax reconciliation difference tax credits research.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch_doc" xml:lang="en-US">Effective income tax rate reconciliation difference tax credits research.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncomeTaxReconciliationTaxSubpartFIncome" xlink:to="XAIR_IncomeTaxReconciliationTaxSubpartFIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_IncomeTaxReconciliationTaxSubpartFIncome_doc" xml:lang="en-US">Income tax reconciliation tax subpart f income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome_doc" xml:lang="en-US">Effective income tax rate reconciliation subpart f income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount_doc" xml:lang="en-US">Effective income tax rate reconciliation difference share based compensation excess tax benefit amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments" xlink:to="XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments_doc" xml:lang="en-US">Income tax reconciliation difference other adjustments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems" xlink:to="XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems_doc" xml:lang="en-US">Income tax reconciliation difference other reconciling items.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent_doc" xml:lang="en-US">Effective income tax rate reconciliation difference share based compensation excess tax benefit percent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments_doc" xml:lang="en-US">Effective income tax rate reconciliation difference other adjustments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent_doc" xml:lang="en-US">Effective income tax rate reconciliation difference other reconciling items percent.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UsefulLifeTermOfLeaseMember" xlink:label="us-gaap_UsefulLifeTermOfLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UsefulLifeTermOfLeaseMember" xlink:to="us-gaap_UsefulLifeTermOfLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UsefulLifeTermOfLeaseMember_lbl" xml:lang="en-US">Useful Life, Lease Term [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_3_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_2_lbl" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, after Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_GainLossOnTerminationOfRightOfUseAsset" xlink:to="XAIR_GainLossOnTerminationOfRightOfUseAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_GainLossOnTerminationOfRightOfUseAsset_3_lbl" xml:lang="en-US">GainLossOnTerminationOfRightOfUseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases" xlink:to="XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases_3_lbl" xml:lang="en-US">PaymentsToSecurityDepositsMadeOnOperatingLeases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfBankDebt_2_lbl" xml:lang="en-US">Repayments of Bank Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived, after Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_2_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_2_lbl" xml:lang="en-US">Payments for Other Fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PrepaidResearchAndDevelopment" xlink:to="XAIR_PrepaidResearchAndDevelopment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PrepaidResearchAndDevelopment_3_lbl" xml:lang="en-US">PrepaidResearchAndDevelopment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AccruedResearchAndDevelopmentExpenses" xlink:to="XAIR_AccruedResearchAndDevelopmentExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AccruedResearchAndDevelopmentExpenses_3_lbl" xml:lang="en-US">AccruedResearchAndDevelopmentExpenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_2_lbl" xml:lang="en-US">Sublease Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaidInKindInterestAmount" xlink:to="XAIR_PaidInKindInterestAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PaidInKindInterestAmount_3_lbl" xml:lang="en-US">PaidInKindInterestAmount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xml:lang="en-US">Long-Term Debt, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_2_lbl" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NumberOfPayments" xlink:to="XAIR_NumberOfPayments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_NumberOfPayments_3_lbl" xml:lang="en-US">NumberOfPayments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_2_lbl" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" xlink:to="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation_3_lbl" xml:lang="en-US">DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch" xlink:to="XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch_3_lbl" xml:lang="en-US">IncomeTaxReconciliationDifferenceTaxCreditsResearch</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationSubpartFIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments" xlink:to="XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments_3_lbl" xml:lang="en-US">IncomeTaxReconciliationDifferenceOtherAdjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>26
<FILENAME>xair-20260331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#Cover" roleURI="http://beyondair.net/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BalanceSheets" roleURI="http://beyondair.net/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BalanceSheetsParenthetical" roleURI="http://beyondair.net/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://beyondair.net/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StatementsOfCashFlows" roleURI="http://beyondair.net/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#OrganizationAndBusiness" roleURI="http://beyondair.net/role/OrganizationAndBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SignificantAccountingPoliciesAndOtherRisksAndUncertainties" roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertainties" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#PropertyAndEquipment" roleURI="http://beyondair.net/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StockholdersEquity" roleURI="http://beyondair.net/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#OtherCurrentAssetsAndPrepaidExpenses" roleURI="http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#Leases" roleURI="http://beyondair.net/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BasicAndDilutedNetLossPerShareOfCommonStock" roleURI="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStock" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#Loans" roleURI="http://beyondair.net/role/Loans" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LoanPayable" roleURI="http://beyondair.net/role/LoanPayable" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#IncomeTaxes" roleURI="http://beyondair.net/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#CommitmentsAndContingencies" roleURI="http://beyondair.net/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#Segments" roleURI="http://beyondair.net/role/Segments" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#RelatedPartyTransactions" roleURI="http://beyondair.net/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeaseRevenues" roleURI="http://beyondair.net/role/LeaseRevenues" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SubsequentEvents" roleURI="http://beyondair.net/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies" roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables" roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#PropertyAndEquipmentTables" roleURI="http://beyondair.net/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StockholdersEquityTables" roleURI="http://beyondair.net/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#OtherCurrentAssetsAndPrepaidExpensesTables" roleURI="http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeasesTables" roleURI="http://beyondair.net/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BasicAndDilutedNetLossPerShareOfCommonStockTables" roleURI="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LoansTables" roleURI="http://beyondair.net/role/LoansTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LoanPayableTables" roleURI="http://beyondair.net/role/LoanPayableTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#IncomeTaxesTables" roleURI="http://beyondair.net/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SegmentsTables" roleURI="http://beyondair.net/role/SegmentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeaseRevenuesTables" roleURI="http://beyondair.net/role/LeaseRevenuesTables" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#OrganizationAndBusinessDetailsNarrative" roleURI="http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfFairValueOnRecurringBasisDetails" roleURI="http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails" roleURI="http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfAssumptionsUsedInValuingWarrantsDetails" roleURI="http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfKeyInputsDerivativeDetails" roleURI="http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails" roleURI="http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails" roleURI="http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfFutureExpectedAmortizationExpenseDetails" roleURI="http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative" roleURI="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfRestrictedStockAwardsDetails" roleURI="http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOptionActivityDetails" roleURI="http://beyondair.net/role/ScheduleOfOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOptionActivityForBeyondCancerDetails" roleURI="http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOptionActivityForNeuronosDetails" roleURI="http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfFairValueOfOptionDetails" roleURI="http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfStock-basedCompensationExpenseDetails" roleURI="http://beyondair.net/role/ScheduleOfStock-basedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SummaryOfOutstandingWarrantsDetails" roleURI="http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#StockholdersEquityDetailsNarrative" roleURI="http://beyondair.net/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails" roleURI="http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SummaryOfAccruedExpensesDetails" roleURI="http://beyondair.net/role/SummaryOfAccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SummaryOfAccruedExpensesDetailsParenthetical" roleURI="http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfOperatingLeaseLiabilityDetails" roleURI="http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfLeaseRelatedCostsDetails" roleURI="http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfLeaseOtherInformationDetails" roleURI="http://beyondair.net/role/ScheduleOfLeaseOtherInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfMaturityOfLeaseLiabilitiesDetails" roleURI="http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeasesDetailsNarrative" roleURI="http://beyondair.net/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" roleURI="http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative" roleURI="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfLong-termDebtDetails" roleURI="http://beyondair.net/role/ScheduleOfLong-termDebtDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LoansDetailsNarrative" roleURI="http://beyondair.net/role/LoansDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfLoanPayableDetails" roleURI="http://beyondair.net/role/ScheduleOfLoanPayableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfProfitLossBeforeTaxesDetails" roleURI="http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfDeferredTaxAssetliabilityDetails" roleURI="http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfDifferenceEffectiveIncomeTaxRateDetails" roleURI="http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfStatutoryUsFederalEffectiveRateDetails" roleURI="http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#IncomeTaxesDetailsNarrative" roleURI="http://beyondair.net/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#SegmentsDetailsNarrative" roleURI="http://beyondair.net/role/SegmentsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails" roleURI="http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#LeaseRevenuesDetailsNarrative" roleURI="http://beyondair.net/role/LeaseRevenuesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="xair-20260331.xsd#ScheduleOfMaturityOfFutureLeasePaymentsDetails" roleURI="http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpPensionBenefitsAdjustments" roleURI="http://xbrl.sec.gov/ecd/role/PvpPensionBenefitsAdjustments" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_deiEntityListingParValuePerShare" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityListingParValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedLicenseAgreementsGross" xlink:label="loc_us-gaapFiniteLivedLicenseAgreementsGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedLicenseAgreementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_WarrantLiabilityNonCurrent" xlink:label="loc_XAIRWarrantLiabilityNonCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_XAIRWarrantLiabilityNonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="loc_us-gaapInterestAndDividendIncomeOperating" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestAndDividendIncomeOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockCommonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SaleOfCommonStockAndPrefundedWarrants" xlink:label="loc_XAIRSaleOfCommonStockAndPrefundedWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRSaleOfCommonStockAndPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares" xlink:label="loc_XAIRIssuanceOfCommonStockAtMarketEquityOfferingShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIssuanceOfCommonStockAtMarketEquityOfferingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossBeforeTax" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="loc_XAIRStockIssuedDuringPeriodValueReverseStockSplits" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringPeriodValueReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProvisionForOtherLosses" xlink:label="loc_us-gaapProvisionForOtherLosses" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForOtherLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossAfterTax" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossAfterTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_GainLossOnTerminationOfRightOfUseAsset" xlink:label="loc_XAIRGainLossOnTerminationOfRightOfUseAsset" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_XAIRGainLossOnTerminationOfRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases" xlink:label="loc_XAIRPaymentsToSecurityDepositsMadeOnOperatingLeases" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_XAIRPaymentsToSecurityDepositsMadeOnOperatingLeases" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ProceedsFromSaleOfCommonStockOfNeuronos" xlink:label="loc_XAIRProceedsFromSaleOfCommonStockOfNeuronos" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_XAIRProceedsFromSaleOfCommonStockOfNeuronos" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ProceedsFromLongTermDebt" xlink:label="loc_XAIRProceedsFromLongTermDebt" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_XAIRProceedsFromLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="loc_us-gaapRepaymentsOfBankDebt" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfBankDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DebtDiscount" xlink:label="loc_XAIRDebtDiscount" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_XAIRDebtDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DerivativesLiability" xlink:label="loc_XAIRDerivativesLiability" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_XAIRDerivativesLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ShortTermFinanceLiability" xlink:label="loc_XAIRShortTermFinanceLiability" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_XAIRShortTermFinanceLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_RightofuseAssetsAcquiredUnderOperatingLeases" xlink:label="loc_XAIRRightofuseAssetsAcquiredUnderOperatingLeases" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_XAIRRightofuseAssetsAcquiredUnderOperatingLeases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DebtPrincipalBalanceConvertedToEquity" xlink:label="loc_XAIRDebtPrincipalBalanceConvertedToEquity" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_XAIRDebtPrincipalBalanceConvertedToEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NoInsiderTradingFlag" xlink:label="loc_XAIRNoInsiderTradingFlag" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_XAIRNoInsiderTradingFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/OrganizationAndBusiness" xlink:title="999014 - Disclosure - ORGANIZATION AND BUSINESS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertainties" xlink:title="999015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipment" xlink:title="999016 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StockholdersEquity" xlink:title="999017 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpenses" xlink:title="999018 - Disclosure - OTHER CURRENT ASSETS AND PREPAID EXPENSES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999019 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/Leases" xlink:title="999020 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DisclosureLeasesAbstract" xlink:label="loc_XAIRDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStock" xlink:title="999021 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/Loans" xlink:title="999022 - Disclosure - LOANS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoanPayable" xlink:title="999023 - Disclosure - LOAN PAYABLE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaapShortTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapShortTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes" xlink:title="999024 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/Segments" xlink:title="999026 - Disclosure - SEGMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/RelatedPartyTransactions" xlink:title="999027 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeaseRevenues" xlink:title="999028 - Disclosure - LEASE REVENUES">
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DisclosureLeaseRevenuesAbstract" xlink:label="loc_XAIRDisclosureLeaseRevenuesAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OperatingLeasesTextBlock" xlink:label="loc_XAIROperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeaseRevenuesAbstract" xlink:to="loc_XAIROperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SubsequentEvents" xlink:title="999029 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies" xlink:title="999030 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock" xlink:label="loc_XAIRGoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRGoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_XAIROtherRisksAndUncertaintiesPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIROtherRisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_WarrantLiabilityPolicyTextBlock" xlink:label="loc_XAIRWarrantLiabilityPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRWarrantLiabilityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SupplierConcentrationPolicyTextBlock" xlink:label="loc_XAIRSupplierConcentrationPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRSupplierConcentrationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CustomerrConcentrationPolicyTextBlock" xlink:label="loc_XAIRCustomerrConcentrationPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRCustomerrConcentrationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="loc_us-gaapConsolidationVariableInterestEntityPolicy" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationVariableInterestEntityPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:label="loc_XAIRRecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRRecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables" xlink:title="999031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaapMarketableSecuritiesTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock" xlink:label="loc_XAIRFairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRFairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock" xlink:label="loc_XAIRScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock" xlink:label="loc_XAIRScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipmentTables" xlink:title="999032 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StockholdersEquityTables" xlink:title="999033 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpensesTables" xlink:title="999034 - Disclosure - OTHER CURRENT ASSETS AND PREPAID EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999035 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeasesTables" xlink:title="999036 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DisclosureLeasesAbstract" xlink:label="loc_XAIRDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfOperatingLeaseLiabilityTableTextBlock" xlink:label="loc_XAIRScheduleOfOperatingLeaseLiabilityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_XAIRScheduleOfOperatingLeaseLiabilityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OtherLeaseTableTextBlock" xlink:label="loc_XAIROtherLeaseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_XAIROtherLeaseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockTables" xlink:title="999037 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoansTables" xlink:title="999038 - Disclosure - LOANS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoanPayableTables" xlink:title="999039 - Disclosure - LOAN PAYABLE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaapScheduleOfShortTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_XAIRScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_XAIRScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SegmentsTables" xlink:title="999041 - Disclosure - SEGMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_VariableInterestEntitiesMember" xlink:label="loc_XAIRVariableInterestEntitiesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRVariableInterestEntitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeaseRevenuesTables" xlink:title="999042 - Disclosure - LEASE REVENUES (Tables)">
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DisclosureLeaseRevenuesAbstract" xlink:label="loc_XAIRDisclosureLeaseRevenuesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeaseRevenuesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LungFitRPHMember" xlink:label="loc_XAIRLungFitRPHMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRLungFitRPHMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative" xlink:title="999043 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="loc_XAIROrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_XAIROrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIROrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIROrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_XAIRBeyondCancerLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NeuroNosLtdMember" xlink:label="loc_XAIRNeuroNosLtdMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_XAIRNeuroNosLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails" xlink:title="999044 - Disclosure - SCHEDULE OF FAIR VALUE ON A RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_MutualFundsMember" xlink:label="loc_XAIRMutualFundsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_XAIRMutualFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails" xlink:title="999045 - Disclosure - SUMMARY OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MutualFundMember" xlink:label="loc_us-gaapMutualFundMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapMutualFundMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaapExtinguishmentOfDebtAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapExtinguishmentOfDebtAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaapExtinguishmentOfDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapExtinguishmentOfDebtAxis" xlink:to="loc_us-gaapExtinguishmentOfDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaapShortTermDebtMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_us-gaapShortTermDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN VALUING WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails" xlink:title="999047 - Disclosure - SCHEDULE OF KEY INPUTS DERIVATIVE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails" xlink:title="999048 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeMember" xlink:label="loc_us-gaapDerivativeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDerivativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_FairValueMeasurementExtinguishment" xlink:label="loc_XAIRFairValueMeasurementExtinguishment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_XAIRFairValueMeasurementExtinguishment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="999049 - Disclosure - SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MutualFundMember" xlink:label="loc_us-gaapMutualFundMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapMutualFundMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaapMarketableSecuritiesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapMarketableSecuritiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ClinicalAndMedicalEquipmentMember" xlink:label="loc_XAIRClinicalAndMedicalEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_XAIRClinicalAndMedicalEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EquipmentDeployableAsPartOfServiceOfferingMember" xlink:label="loc_XAIREquipmentDeployableAsPartOfServiceOfferingMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_XAIREquipmentDeployableAsPartOfServiceOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails" xlink:title="999051 - Disclosure - SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative" xlink:title="999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_StreetervilleCapitalLLCMember" xlink:label="loc_XAIRStreetervilleCapitalLLCMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRStreetervilleCapitalLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_AU" xlink:label="loc_countryAU" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryAU" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_BM" xlink:label="loc_countryBM" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryBM" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_IE" xlink:label="loc_countryIE" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIE" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_CY" xlink:label="loc_countryCY" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCY" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="loc_us-gaapAustralianTaxationOfficeMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapAustralianTaxationOfficeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaapAccountsPayableMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_FirstThirdPartyVendorsMember" xlink:label="loc_XAIRFirstThirdPartyVendorsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_XAIRFirstThirdPartyVendorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SecondThirdPartyVendorsMember" xlink:label="loc_XAIRSecondThirdPartyVendorsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_XAIRSecondThirdPartyVendorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ThirdPartyVendorsMember" xlink:label="loc_XAIRThirdPartyVendorsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_XAIRThirdPartyVendorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CustomersOneMember" xlink:label="loc_XAIRCustomersOneMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_XAIRCustomersOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CustomersTwoMember" xlink:label="loc_XAIRCustomersTwoMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_XAIRCustomersTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtOwnershipAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_XAIRBeyondCancerLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NeuroNosLtdMember" xlink:label="loc_XAIRNeuroNosLtdMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_XAIRNeuroNosLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="loc_XAIRCashAndCashEquivalentsAndMarketableSecurities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_XAIRCashAndCashEquivalentsAndMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDepositAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableNoncurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilityMeasurementDifferenceDescription" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementDifferenceDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementDifferenceDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="loc_us-gaapDebtDefaultLongtermDebtAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDebtDefaultLongtermDebtAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaapCommonStockValueOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCommonStockValueOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue" xlink:label="loc_us-gaapCreditRiskDerivativeLiabilitiesAtFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCreditRiskDerivativeLiabilitiesAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfSecuredDebt" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDescription" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDescription" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag" xlink:label="loc_XAIRNumberOfReportableSegmentsDisclosedByDefinitionFlag" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_XAIRNumberOfReportableSegmentsDisclosedByDefinitionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TaxRebate" xlink:label="loc_XAIRTaxRebate" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_XAIRTaxRebate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaapOtherAssetImpairmentCharges" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapOtherAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByNoncontrollingOwners" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999053 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ClinicalAndMedicalEquipmentMember" xlink:label="loc_XAIRClinicalAndMedicalEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_XAIRClinicalAndMedicalEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EquipmentDeployableAsPartOfServiceOfferingMember" xlink:label="loc_XAIREquipmentDeployableAsPartOfServiceOfferingMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_XAIREquipmentDeployableAsPartOfServiceOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999054 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails" xlink:title="999055 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARDS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOptionActivityDetails" xlink:title="999056 - Disclosure - SCHEDULE OF OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails" xlink:title="999057 - Disclosure - SCHEDULE OF OPTION ACTIVITY FOR BEYOND CANCER (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails" xlink:title="999058 - Disclosure - SCHEDULE OF OPTION ACTIVITY FOR NEURONOS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails" xlink:title="999059 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION (Details)">
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfFairValueOfOptionAbstract" xlink:label="loc_XAIRScheduleOfFairValueOfOptionAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfFairValueOfOptionTable" xlink:label="loc_XAIRScheduleOfFairValueOfOptionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRScheduleOfFairValueOfOptionAbstract" xlink:to="loc_XAIRScheduleOfFairValueOfOptionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRScheduleOfFairValueOfOptionTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRScheduleOfFairValueOfOptionTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRScheduleOfFairValueOfOptionTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondAirIncMember" xlink:label="loc_XAIRBeyondAirIncMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRBeyondAirIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRBeyondCancerLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NeuroNosLtdMember" xlink:label="loc_XAIRNeuroNosLtdMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRNeuroNosLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999060 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:label="loc_XAIRScheduleOfStockBasedCompensationExpenseAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfStockBasedCompensationExpenseTable" xlink:label="loc_XAIRScheduleOfStockBasedCompensationExpenseTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="loc_XAIRScheduleOfStockBasedCompensationExpenseTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRScheduleOfStockBasedCompensationExpenseTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:label="loc_us-gaapStatementOfIncomeLocationBalanceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRScheduleOfStockBasedCompensationExpenseTable" xlink:to="loc_us-gaapStatementOfIncomeLocationBalanceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails" xlink:title="999061 - Disclosure - SUMMARY OF OUTSTANDING WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NitricGenAgreementMember" xlink:label="loc_XAIRNitricGenAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRNitricGenAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AvenueAgreementMember" xlink:label="loc_XAIRAvenueAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRAvenueAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_MarchTwoThousandTwentyFourRaiseMember" xlink:label="loc_XAIRMarchTwoThousandTwentyFourRaiseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRMarchTwoThousandTwentyFourRaiseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AvenueExtensionAgreementMember" xlink:label="loc_XAIRAvenueExtensionAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRAvenueExtensionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember" xlink:label="loc_XAIRSeptemberTwoThousandTwentyFourEquityOfferingMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRSeptemberTwoThousandTwentyFourEquityOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember" xlink:label="loc_XAIRSeptemberTwoThousandTwentyFourDebtInstrumentMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRSeptemberTwoThousandTwentyFourDebtInstrumentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SeptemberTwoThousandTwentyFiveInducementMember" xlink:label="loc_XAIRSeptemberTwoThousandTwentyFiveInducementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRSeptemberTwoThousandTwentyFiveInducementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember" xlink:label="loc_XAIRJanuaryTwoThousandTwentySixEquityOfferingMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRJanuaryTwoThousandTwentySixEquityOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SubTotalMember" xlink:label="loc_XAIRSubTotalMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRSubTotalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember" xlink:label="loc_XAIRPreFundedWarrantsSepTwoThousandTwentyFourMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRPreFundedWarrantsSepTwoThousandTwentyFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember" xlink:label="loc_XAIRPreFundedWarrantsJanTwoThousandTwentySixMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRPreFundedWarrantsJanTwoThousandTwentySixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" xlink:label="loc_XAIRClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_XAIRClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_WarrantsExpirationDateDescription" xlink:label="loc_XAIRWarrantsExpirationDateDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_XAIRWarrantsExpirationDateDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StockholdersEquityDetailsNarrative" xlink:title="999062 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandAndTwentyFiveATMMember" xlink:label="loc_XAIRTwoThousandAndTwentyFiveATMMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRTwoThousandAndTwentyFiveATMMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PurchaseAgreementMember" xlink:label="loc_XAIRPurchaseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AmendedLoanAgreementMember" xlink:label="loc_XAIRAmendedLoanAgreementMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRAmendedLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentySixPreFundedWarrantsMember" xlink:label="loc_XAIRTwoThousandTwentySixPreFundedWarrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_XAIRTwoThousandTwentySixPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentySixCommonWarrantsMember" xlink:label="loc_XAIRTwoThousandTwentySixCommonWarrantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_XAIRTwoThousandTwentySixCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PreFundedWarrantsMember" xlink:label="loc_XAIRPreFundedWarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_XAIRPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandAndThirteenBeyondAirEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandThirteenBAPlanMember" xlink:label="loc_XAIRTwoThousandThirteenBAPlanMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandThirteenBAPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandThirteenEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandThirteenEquityIncentivePlanMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandThirteenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" xlink:label="loc_XAIRTwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="loc_XAIRTwoThousandTwentyOneEmployeeStockPurchasePlanMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_TwoThousandTwentyFiveOptionRepricingMember" xlink:label="loc_XAIRTwoThousandTwentyFiveOptionRepricingMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRTwoThousandTwentyFiveOptionRepricingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRBeyondCancerLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SaleOfStockFeePercentage" xlink:label="loc_XAIRSaleOfStockFeePercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_XAIRSaleOfStockFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PublicFloatValue" xlink:label="loc_XAIRPublicFloatValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_XAIRPublicFloatValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeneficialOwnershipLimitationPercentage" xlink:label="loc_XAIRBeneficialOwnershipLimitationPercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_XAIRBeneficialOwnershipLimitationPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForCommissions" xlink:label="loc_us-gaapPaymentsForCommissions" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForCommissions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaapStockOptionExercisePriceIncrease" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockOptionExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails" xlink:title="999063 - Disclosure - SCHEDULE OF OTHER CURRENT ASSETS AND PREPAID EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PrepaidResearchAndDevelopment" xlink:label="loc_XAIRPrepaidResearchAndDevelopment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_XAIRPrepaidResearchAndDevelopment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaapPrepaidRent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Supplies" xlink:label="loc_us-gaapSupplies" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapSupplies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SummaryOfAccruedExpensesDetails" xlink:title="999064 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_XAIRAccruedResearchAndDevelopmentExpenses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_XAIRAccruedResearchAndDevelopmentExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_InterestSeveranceCurrent" xlink:label="loc_XAIRInterestSeveranceCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_XAIRInterestSeveranceCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_GoodsReceivedNotInvoiced" xlink:label="loc_XAIRGoodsReceivedNotInvoiced" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_XAIRGoodsReceivedNotInvoiced" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical" xlink:title="999065 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PayablesAndAccrualsTable" xlink:label="loc_XAIRPayablesAndAccrualsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_XAIRPayablesAndAccrualsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRPayablesAndAccrualsTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRPayablesAndAccrualsTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SteveLisiMember" xlink:label="loc_XAIRSteveLisiMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRSteveLisiMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaapTaxesPayableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTaxesPayableCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails" xlink:title="999066 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DisclosureLeasesAbstract" xlink:label="loc_XAIRDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails" xlink:title="999067 - Disclosure - SCHEDULE OF LEASE RELATED COSTS (Details)">
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DisclosureLeasesAbstract" xlink:label="loc_XAIRDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaapSubleaseIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapSubleaseIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfLeaseOtherInformationDetails" xlink:title="999068 - Disclosure - SCHEDULE OF LEASE OTHER INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DisclosureLeasesAbstract" xlink:label="loc_XAIRDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:title="999069 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DisclosureLeasesAbstract" xlink:label="loc_XAIRDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeasesDetailsNarrative" xlink:title="999070 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DisclosureLeasesAbstract" xlink:label="loc_XAIRDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDisclosureLeasesAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" xlink:title="999071 - Disclosure - SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative" xlink:title="999072 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PreFundedWarrantsMember" xlink:label="loc_XAIRPreFundedWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_XAIRPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfLong-termDebtDetails" xlink:title="999073 - Disclosure - SCHEDULE OF LONG-TERM DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LoanAgreementMember" xlink:label="loc_XAIRLoanAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PromissoryNoteMember" xlink:label="loc_XAIRPromissoryNoteMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_XAIRPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PaidInKindInterestAmount" xlink:label="loc_XAIRPaidInKindInterestAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_XAIRPaidInKindInterestAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AmortizationOfDebtDiscount" xlink:label="loc_XAIRAmortizationOfDebtDiscount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_XAIRAmortizationOfDebtDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoansDetailsNarrative" xlink:title="999074 - Disclosure - LOANS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LoanAndSecurityAgreementMember" xlink:label="loc_XAIRLoanAndSecurityAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRLoanAndSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AmendedLoanAgreementMember" xlink:label="loc_XAIRAmendedLoanAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRAmendedLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NotePurchaseAgreementMember" xlink:label="loc_XAIRNotePurchaseAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRNotePurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PurchaseAgreementMember" xlink:label="loc_XAIRPurchaseAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_StreetervilleCapitalLLCMember" xlink:label="loc_XAIRStreetervilleCapitalLLCMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRStreetervilleCapitalLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DebtInstrumentInterestRatePayableInCashPercentage" xlink:label="loc_XAIRDebtInstrumentInterestRatePayableInCashPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRDebtInstrumentInterestRatePayableInCashPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DebtInstrumentInterestRatePayableInKindPercentage" xlink:label="loc_XAIRDebtInstrumentInterestRatePayableInKindPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRDebtInstrumentInterestRatePayableInKindPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_RoyaltyInterestPercentage" xlink:label="loc_XAIRRoyaltyInterestPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRRoyaltyInterestPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleOfLoansReceivable" xlink:label="loc_us-gaapProceedsFromSaleOfLoansReceivable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromSaleOfLoansReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DebtInstrumentOfRestrictedAccount" xlink:label="loc_XAIRDebtInstrumentOfRestrictedAccount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRDebtInstrumentOfRestrictedAccount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRepaidPrincipal" xlink:label="loc_us-gaapDebtInstrumentRepaidPrincipal" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentRepaidPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue" xlink:label="loc_us-gaapCreditRiskDerivativeLiabilitiesAtFairValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCreditRiskDerivativeLiabilitiesAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_UnrestrictedCash" xlink:label="loc_XAIRUnrestrictedCash" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRUnrestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfLoanPayableDetails" xlink:title="999075 - Disclosure - SCHEDULE OF LOAN PAYABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NumberOfPayments" xlink:label="loc_XAIRNumberOfPayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_XAIRNumberOfPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LoanPayableDueDateDescription" xlink:label="loc_XAIRLoanPayableDueDateDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_XAIRLoanPayableDueDateDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails" xlink:title="999076 - Disclosure - SCHEDULE OF PROFIT (LOSS) BEFORE TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails" xlink:title="999077 - Disclosure - SCHEDULE OF DEFERRED TAX ASSET/LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ResearchAndDevelopmentTaxCreditCapitalization" xlink:label="loc_XAIRResearchAndDevelopmentTaxCreditCapitalization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_XAIRResearchAndDevelopmentTaxCreditCapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" xlink:label="loc_XAIRDeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_XAIRDeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DeferredTaxAssetsReservesAndAccruels" xlink:label="loc_XAIRDeferredTaxAssetsReservesAndAccruels" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_XAIRDeferredTaxAssetsReservesAndAccruels" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DeferredTaxAssetsRightofuseAsset" xlink:label="loc_XAIRDeferredTaxAssetsRightofuseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_XAIRDeferredTaxAssetsRightofuseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_DeferredTaxAssetsLeaseLiability" xlink:label="loc_XAIRDeferredTaxAssetsLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_XAIRDeferredTaxAssetsLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails" xlink:title="999078 - Disclosure - SCHEDULE OF DIFFERENCE EFFECTIVE INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateAbstract" xlink:label="loc_XAIRScheduleOfDifferenceEffectiveIncomeTaxRateAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateTable" xlink:label="loc_XAIRScheduleOfDifferenceEffectiveIncomeTaxRateTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRScheduleOfDifferenceEffectiveIncomeTaxRateAbstract" xlink:to="loc_XAIRScheduleOfDifferenceEffectiveIncomeTaxRateTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRScheduleOfDifferenceEffectiveIncomeTaxRateTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRScheduleOfDifferenceEffectiveIncomeTaxRateTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_IE" xlink:label="loc_countryIE" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIE" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_IL" xlink:label="loc_countryIL" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:label="loc_XAIRIncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch" xlink:label="loc_XAIRIncomeTaxReconciliationDifferenceTaxCreditsResearch" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIncomeTaxReconciliationDifferenceTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationTaxSubpartFIncome" xlink:label="loc_XAIRIncomeTaxReconciliationTaxSubpartFIncome" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIncomeTaxReconciliationTaxSubpartFIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationSubpartFIncome" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationSubpartFIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments" xlink:label="loc_XAIRIncomeTaxReconciliationDifferenceOtherAdjustments" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIncomeTaxReconciliationDifferenceOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems" xlink:label="loc_XAIRIncomeTaxReconciliationDifferenceOtherReconcilingItems" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIncomeTaxReconciliationDifferenceOtherReconcilingItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails" xlink:title="999079 - Disclosure - SCHEDULE OF STATUTORY US FEDERAL EFFECTIVE RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxesDetailsNarrative" xlink:title="999080 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaapIsraelTaxAuthorityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapIsraelTaxAuthorityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueCommissionersIrelandMember" xlink:label="loc_us-gaapRevenueCommissionersIrelandMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapRevenueCommissionersIrelandMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CypriotTaxMember" xlink:label="loc_XAIRCypriotTaxMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_XAIRCypriotTaxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapAwardDateAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NoExpirationMember" xlink:label="loc_XAIRNoExpirationMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRNoExpirationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OffsetTaxableIncomeRate" xlink:label="loc_XAIROffsetTaxableIncomeRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_XAIROffsetTaxableIncomeRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OperatingLossCarryforwardsExpirationYears" xlink:label="loc_XAIROperatingLossCarryforwardsExpirationYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_XAIROperatingLossCarryforwardsExpirationYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999081 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaapProductLiabilityContingencyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapProductLiabilityContingencyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OptionAgreementMember" xlink:label="loc_XAIROptionAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIROptionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NitricGenAgreementMember" xlink:label="loc_XAIRNitricGenAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRNitricGenAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NitricGenIncMember" xlink:label="loc_XAIRNitricGenIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRNitricGenIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapAwardDateAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NextMilestonesMember" xlink:label="loc_XAIRNextMilestonesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRNextMilestonesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AfterSixMonthsMember" xlink:label="loc_XAIRAfterSixMonthsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRAfterSixMonthsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="loc_us-gaapCostOfGoodsTotalMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapCostOfGoodsTotalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtMajorCustomersAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SupplierMember" xlink:label="loc_XAIRSupplierMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_XAIRSupplierMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PaymentsForDevelopmentAndMilestonePayment" xlink:label="loc_XAIRPaymentsForDevelopmentAndMilestonePayment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPaymentsForDevelopmentAndMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_MilestonePayments" xlink:label="loc_XAIRMilestonePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SalesRelatedMilestonesPayments" xlink:label="loc_XAIRSalesRelatedMilestonesPayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRSalesRelatedMilestonesPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_PaymentForMilestoneMethodRevenueRecognized" xlink:label="loc_XAIRPaymentForMilestoneMethodRevenueRecognized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPaymentForMilestoneMethodRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPurchaseObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepositAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SegmentsDetailsNarrative" xlink:title="999082 - Disclosure - SEGMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRBeyondCancerLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CertainInvestorsMember" xlink:label="loc_XAIRCertainInvestorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRCertainInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_InvestorsMember" xlink:label="loc_XAIRInvestorsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_XAIRBeyondCancerLtdMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NeuroNosLtdMember" xlink:label="loc_XAIRNeuroNosLtdMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_XAIRNeuroNosLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SubscriptionAgreementMember" xlink:label="loc_XAIRSubscriptionAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRSubscriptionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_AmountOfTerminatedLoan" xlink:label="loc_XAIRAmountOfTerminatedLoan" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRAmountOfTerminatedLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails" xlink:title="999083 - Disclosure - SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondAirMember" xlink:label="loc_XAIRBeyondAirMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRBeyondAirMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_BeyondCancerLtdMember" xlink:label="loc_XAIRBeyondCancerLtdMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRBeyondCancerLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_NeuroNosLtdMember" xlink:label="loc_XAIRNeuroNosLtdMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRNeuroNosLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_SegmentMember" xlink:label="loc_XAIRSegmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_XAIRSegmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_VariableInterestEntitiesMember" xlink:label="loc_XAIRVariableInterestEntitiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRVariableInterestEntitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ParentCompanyMember" xlink:label="loc_srtParentCompanyMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_srtParentCompanyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_CapitalExpendituresCost" xlink:label="loc_XAIRCapitalExpendituresCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_XAIRCapitalExpendituresCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsNet" xlink:label="loc_us-gaapAssetsNet" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LeaseRevenuesDetailsNarrative" xlink:title="999084 - Disclosure - LEASE REVENUES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LungFitPHMember" xlink:label="loc_XAIRLungFitPHMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_XAIRLungFitPHMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LungFitPHMember" xlink:label="loc_XAIRLungFitPHMember_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRLungFitPHMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_OperatingLeaseIncome" xlink:label="loc_XAIROperatingLeaseIncome" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIROperatingLeaseIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails" xlink:title="999085 - Disclosure - SCHEDULE OF MATURITY OF FUTURE LEASE PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20260331.xsd#XAIR_LungFitRPHMember" xlink:label="loc_XAIRLungFitRPHMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRLungFitRPHMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 23, 2026</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BEYOND
AIR, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001641631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3812456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">900
    Stewart Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Garden
    City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">665-8200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XAIR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,410,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingParValuePerShare', window );">Entity Listing, Par Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text">We
have audited the accompanying consolidated balance sheets of Beyond Air, Inc. (the &#8220;Company&#8221;) as of March 31, 2026 and
2025, and the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and cash
flows for each of the two years in the period ended March 31, 2026, and the related notes (collectively referred to as the
&#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all
material respects, the financial position of Beyond Air, Inc. as of March 31, 2026 and 2025, and the results of its operations and
its cash flows for each of the two years in the period ended March 31, 2026, in conformity with accounting principles generally
accepted in the United States of America.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">WithumSmith+Brown, PC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">East
Brunswick, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,740<span></span>
</td>
<td class="nump">$ 4,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,901<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,622<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,086<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,406<span></span>
</td>
<td class="nump">2,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets and prepaid expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,012<span></span>
</td>
<td class="nump">5,743<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,767<span></span>
</td>
<td class="nump">16,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedLicenseAgreementsGross', window );">Licensed right to use technology</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use lease assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,193<span></span>
</td>
<td class="nump">1,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,249<span></span>
</td>
<td class="nump">11,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">158<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,385<span></span>
</td>
<td class="nump">30,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,417<span></span>
</td>
<td class="nump">1,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,372<span></span>
</td>
<td class="nump">2,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">321<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable, current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">401<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,511<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Long-term debt, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,639<span></span>
</td>
<td class="nump">9,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_WarrantLiabilityNonCurrent', window );">Warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,175<span></span>
</td>
<td class="nump">15,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.0001 par value per share: 500,000,000 shares authorized, 11,792,684 and 4,128,539 shares issued and outstanding as of March 31, 2026 and 2025, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">325,587<span></span>
</td>
<td class="nump">299,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(319,571)<span></span>
</td>
<td class="num">(286,322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">134<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity attributable to Beyond Air, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,126<span></span>
</td>
<td class="nump">13,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,210<span></span>
</td>
<td class="nump">14,341<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 35,385<span></span>
</td>
<td class="nump">$ 30,062<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Prior
    period results have been adjusted to reflect the one-for-twenty stock split in July 2025. See Note 1, <i>Organization and Business</i>
    for details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_WarrantLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_WarrantLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedLicenseAgreementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedLicenseAgreementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478443/942-360-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481229/860-50-50-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 35: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 36: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 67: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 70: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 71: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 72: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 73: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481108/505-30-30-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">11,792,684<span></span>
</td>
<td class="nump">4,128,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">11,792,684<span></span>
</td>
<td class="nump">4,128,539<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Prior
    period results have been adjusted to reflect the one-for-twenty stock split in July 2025. See Note 1, <i>Organization and Business</i>
    for details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,679<span></span>
</td>
<td class="nump">$ 3,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,427<span></span>
</td>
<td class="nump">5,368<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">252<span></span>
</td>
<td class="num">(1,663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,241<span></span>
</td>
<td class="nump">16,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,055<span></span>
</td>
<td class="nump">26,017<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,296<span></span>
</td>
<td class="nump">42,874<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29,044)<span></span>
</td>
<td class="num">(44,537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income/(expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Dividend/investment income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">303<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest and finance expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,515)<span></span>
</td>
<td class="num">(3,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,395)<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(2,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal/impairment of fixed assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(431)<span></span>
</td>
<td class="num">(738)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income/(expense)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income/(expense)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,290)<span></span>
</td>
<td class="num">(3,942)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(34,334)<span></span>
</td>
<td class="num">(48,479)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(34,334)<span></span>
</td>
<td class="num">(48,479)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net loss attributable to non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,085)<span></span>
</td>
<td class="num">(1,854)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Beyond Air, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(33,249)<span></span>
</td>
<td class="num">(46,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income/(loss), net of tax:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">194<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Beyond Air, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (33,055)<span></span>
</td>
<td class="num">$ (46,670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net basic loss per share attributable to Beyond Air, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (4.01)<span></span>
</td>
<td class="num">$ (13.77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net diluted loss per share attributable to Beyond Air, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (4.01)<span></span>
</td>
<td class="num">$ (13.77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares of common stock outstanding - basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,300,916<span></span>
</td>
<td class="nump">3,385,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares of common stock outstanding - diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,300,916<span></span>
</td>
<td class="nump">3,385,327<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Prior
    period results have been adjusted to reflect the one-for-twenty stock split in July 2025. See Note 1, <i>Organization and Business</i>
    for details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 44: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Common Stock [Member]</div></th>
<th class="th"><div>Treasury Stock, Common [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (25)<span></span>
</td>
<td class="nump">$ 264,785<span></span>
</td>
<td class="num">$ (239,697)<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
<td class="nump">$ 2,138<span></span>
</td>
<td class="nump">$ 27,186<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,295,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock &#8211; At The Market equity offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,151<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock - At The Market equity offering, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">337,101<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_SaleOfCommonStockAndPrefundedWarrants', window );">Sale of common stock and pre-funded warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,858<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares', window );">Sale of common stock and pre-funded warrants, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issue of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,159<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of warrants, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">234,156<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">12,240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">NeuroNos issuance of stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,765<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,907<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">9,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive gain</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(46,625)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,854)<span></span>
</td>
<td class="num">(48,479)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">299,990<span></span>
</td>
<td class="num">(286,322)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="nump">14,341<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,128,539<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock &#8211; At The Market equity offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,134<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock - At The Market equity offering, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,441,775<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_SaleOfCommonStockAndPrefundedWarrants', window );">Sale of common stock and pre-funded warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares', window );">Sale of common stock and pre-funded warrants, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">524,990<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issue of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,183<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,868<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of warrants, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,088,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,630<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">NeuroNos issuance of stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">573<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,998<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">5,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive gain</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(33,249)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,085)<span></span>
</td>
<td class="num">(34,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_StockIssuedDuringPeriodValueReverseStockSplits', window );">Issuance of common stock &#8211; 2025 Reverse Stock Split rounding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Issuance of common stock - 2025 Reverse Stock Split rounding, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for conversion of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,341<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for conversion of debt, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (25)<span></span>
</td>
<td class="nump">$ 325,587<span></span>
</td>
<td class="num">$ (319,571)<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 6,210<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">11,792,684<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Prior
    period results have been adjusted to reflect the one-for-twenty stock split in July 2025. See Note 1, <i>Organization and Business</i>
    for details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock at market equity offering shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_SaleOfCommonStockAndPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of common stock and prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_SaleOfCommonStockAndPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_StockIssuedDuringPeriodValueReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the value of shares issued during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_StockIssuedDuringPeriodValueReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 44: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481229/860-50-50-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 35: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 36: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 67: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 70: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 71: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 72: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 73: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (34,334)<span></span>
</td>
<td class="num">$ (48,479)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3,047<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,282<span></span>
</td>
<td class="nump">9,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and accretion of debt issuance costs</a></td>
<td class="nump">551<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of licensed right to use technology</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease assets</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">1,395<span></span>
</td>
<td class="num">(1,314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for inventory losses</a></td>
<td class="nump">672<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherLosses', window );">Provision for bad debt</a></td>
<td class="nump">91<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossAfterTax', window );">Foreign currency adjustments</a></td>
<td class="num">(119)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">2,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_GainLossOnTerminationOfRightOfUseAsset', window );">Impairment of fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid in kind interest</a></td>
<td class="nump">1,762<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="num">(466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(468)<span></span>
</td>
<td class="num">(390)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">683<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="num">(6,358)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(373)<span></span>
</td>
<td class="num">(385)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,144)<span></span>
</td>
<td class="num">(38,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(4,053)<span></span>
</td>
<td class="num">(30,878)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">1,404<span></span>
</td>
<td class="nump">51,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases', window );">Security deposits made on operating leases</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,025)<span></span>
</td>
<td class="num">(5,883)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in)/provided by investing activities</a></td>
<td class="num">(3,674)<span></span>
</td>
<td class="nump">14,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock through at the market offerings, net</a></td>
<td class="nump">8,135<span></span>
</td>
<td class="nump">2,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ProceedsFromSaleOfCommonStockOfNeuronos', window );">Proceeds from the sale of common stock of NeuroNos</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and pre-funded warrants through securities purchase, net</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">18,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from issuance of common stock through exercise of warrants</a></td>
<td class="nump">2,869<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of common stock warrants</a></td>
<td class="nump">90<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ProceedsFromLongTermDebt', window );">Proceeds from long term loan</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">11,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="num">(996)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Payment of loan</a></td>
<td class="num">(208)<span></span>
</td>
<td class="num">(18,052)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">29,090<span></span>
</td>
<td class="nump">16,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">194<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase/(decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">7,466<span></span>
</td>
<td class="num">(6,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">4,896<span></span>
</td>
<td class="nump">11,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">12,362<span></span>
</td>
<td class="nump">4,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DebtDiscount', window );">Debt discount</a></td>
<td class="nump">1,094<span></span>
</td>
<td class="nump">3,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DerivativesLiability', window );">Derivative liability</a></td>
<td class="nump">775<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ShortTermFinanceLiability', window );">Short term finance liability</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Fixed assets recorded in accounts payable and accrued expenses</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_RightofuseAssetsAcquiredUnderOperatingLeases', window );">Right-of-use assets acquired under operating leases</a></td>
<td class="nump">139<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DebtPrincipalBalanceConvertedToEquity', window );">Debt principal balance converted to equity</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DebtPrincipalBalanceConvertedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt principal balance converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DebtPrincipalBalanceConvertedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DerivativesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivatives liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DerivativesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_GainLossOnTerminationOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on termination of right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_GainLossOnTerminationOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to security deposits made on operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ProceedsFromLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from long term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ProceedsFromLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ProceedsFromSaleOfCommonStockOfNeuronos">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of common stock of neuronos.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ProceedsFromSaleOfCommonStockOfNeuronos</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RightofuseAssetsAcquiredUnderOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use assets acquired under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RightofuseAssetsAcquiredUnderOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ShortTermFinanceLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term finance liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ShortTermFinanceLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-38<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 44: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to other loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (33,249)<span></span>
</td>
<td class="num">$ (46,625)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_NoInsiderTradingFlag', window );">No insider trading flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_NoInsiderTradingFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No Insider Trading Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_NoInsiderTradingFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on sophisticated information technology systems and network infrastructure to operate and manage our business. We also maintain
personally identifiable information (&#8220;PII&#8221;) about our employees, and given the nature of our business, we have access to
protected health information (&#8220;PHI&#8221;). Our business therefore depends on the continuous, effective, reliable, and secure operation
of our computer hardware, software, networks, Internet servers, and related infrastructure. To the extent that our hardware or software
malfunctions or access to our data by internal personnel, suppliers or customers through the Internet is interrupted or compromised,
our business could suffer.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
integrity and protection of our customer, personnel, financial, research and development, and other confidential data is critical to
our business, and our customers and employees have a high expectation that we will adequately protect their personal information. The
regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve and a number
of states have adopted laws and regulations that may affect our privacy and data security practices regarding the use, disclosure and
protection of PII. For example, the California Consumer Privacy Act (&#8220;the CCPA&#8221;), among other things, creates individual
privacy rights and imposes increased obligations on companies handling PII.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our computer and communications hardware are protected through physical and software safeguards, they are still vulnerable to system
malfunction, computer viruses, malware and ransomware, and other cybersecurity threats such as phishing and social engineering attacks.
These events could lead to unauthorized access to our information technology systems and result in financial loss and the misappropriation
or unauthorized disclosure of confidential information belonging to us, our employees, partners, customers, or suppliers. The techniques
used by criminal elements to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote
areas of the world. As a result, we may not be able to address these techniques proactively or implement adequate preventative measures.
If our information technology systems are compromised, we could be subject to fines, damages, litigation and enforcement actions, incur
financial losses, suffer reputational damage, and lose trade secrets or other confidential information, each of which could significantly
harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cybersecurity
Program </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the importance of cybersecurity to our business, we maintain a robust cybersecurity program to support both the effectiveness of our
systems and our preparedness for information security risks. This program includes a number of administrative, physical, and technical
safeguards with regular evaluations of our cybersecurity program, including periodic internal and external audits, penetration tests,
and incident response simulations. We also require cybersecurity training when onboarding new employees and contractors, as well as required
cybersecurity awareness training for our employees and contractors/other workforce members. Our program leverages industry frameworks,
including the National Institute of Standards and Technology (NIST) Cybersecurity Framework (CSF) to strengthen our program effectiveness
and reduce cybersecurity risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use a risk-based approach with respect to our use and oversight of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250401__20260331_zOJNnD4VcKS4">third-party</span> service providers. We use a number of means to assess
cyber risks related to our third-party service providers, including maintaining vendor questionnaires/conducting due diligence in connection
with onboarding new vendors and engaging in periodic reviews thereafter as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Process
for Assessing, Identifying and Managing Material Risks from Cybersecurity Threats </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250401__20260331_ztjs18riHI85">In
the event of a cybersecurity incident, we maintain a regularly tested incident response program. Pursuant to the program and its escalation
protocols, designated personnel are responsible for assessing the severity of an incident and associated threat, and handling it in accordance
with that severity level. We have relationships with a number of third-party service providers to assist with cybersecurity containment
and remediation efforts.</span></span></p>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our
cybersecurity risk management processes are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250401__20260331_ziJok1OLMwVj">integrated</span> into our overall Enterprise Risk Management (&#8220;ERM&#8221;) process. As part
of our ERM process, department leaders identify, assess, and evaluate risks impacting our operations across the Company, including those
risks related to cybersecurity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Governance</i></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
a notification of concerning factors which may be indicative that a notable cybersecurity incident has occurred, the Cyber Security Subcommittee
(Cyber Security Subcommittee) consisting of General Counsel, Head of HR &amp; Chief Technical Officer (CTO) meets to make an initial
assessment. If the Cyber Security Subcommittee determines there is a reasonable likelihood a notable cybersecurity incident has occurred,
then notice will promptly be given to certain members of the Company Executive Team including our Chief Executive Officer, Chief Operating
Officer, Chief Commercial Officer &amp; Chief Financial Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
team leverages over 25 years of experience in various cyber security functions. Our CTO, and their team, are responsible for the day-to-day
management of the cybersecurity program.</span></p>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CTO provides periodic briefings for our senior management team on cybersecurity matters, including the prevention, detection, mitigation,
and remediation of cybersecurity incidents and cybersecurity threats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Board
Oversight</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20250401__20260331_z3eUtle6fKG6">Board of Directors</span> has overall responsibility for risk oversight, our Audit Committee oversees cybersecurity risk matters. The Audit
Committee is responsible for reviewing, discussing with management, and overseeing the Company&#8217;s cybersecurity and privacy risk
exposures and policies. On a quarterly basis, the CTO reports to the Audit Committee on information technology and cybersecurity matters,
including key information technology risks. The CTO also apprises the Audit Committee and full Board of cyber security incidents consistent
with our incident response program, promptly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cybersecurity
Risks</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250401__20260331_zhCF0LHHwgka">Our
cybersecurity risk management processes are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250401__20260331_ziJok1OLMwVj">integrated</span> into our overall Enterprise Risk Management (&#8220;ERM&#8221;) process. As part
of our ERM process, department leaders identify, assess, and evaluate risks impacting our operations across the Company, including those
risks related to cybersecurity.</span> Department leaders are asked to consider the severity and likelihood of certain risk factors, drawing
upon their company knowledge and past business experience. While we maintain a robust cybersecurity program, the techniques used to infiltrate
information technology systems continue to evolve. Accordingly, we may not be able to timely detect threats or anticipate and implement
adequate security measures. For additional information, see &#8220;Item 1A&#8212;Risk Factors.&#8221; To date, we have not experienced
any material cybersecurity incidents or threats.</span></p>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BUSINESS</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z3WmsQszL7N" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 <span id="xdx_821_zIxTspTZWQjb">ORGANIZATION AND BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
Air, Inc. (together with its subsidiaries, &#8220;Beyond Air&#8221; or the &#8220;Company&#8221;) was incorporated on April 28, 2015
under Delaware law. On June 25, 2019, the Company&#8217;s name was changed to Beyond Air, Inc. from AIT Therapeutics, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (&#8220;NO&#8221;) generators
and delivery systems (the &#8220;LungFit<sup>&#174;</sup> platform&#8221;) capable of generating NO from ambient air. The Company&#8217;s
first device, LungFit<sup>&#174; </sup>PH (&#8220;LungFit<sup>&#174; </sup>PH&#8221;) received premarket approval (&#8220;PMA&#8221;) from
the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in June 2022. The NO generated by the LungFit&#174; PH system is indicated to
improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (&gt;34 weeks gestation) neonates
with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with
ventilatory support and other appropriate agents. This condition is commonly referred to as persistent pulmonary hypertension of the
newborn (&#8220;PPHN&#8221;). The LungFit<sup>&#174;</sup> platform can generate NO up to 400 parts per million (&#8220;ppm&#8221;) for
delivery to a patient&#8217;s lungs directly or via a ventilator. LungFit<sup>&#174; </sup>can deliver NO either continuously or for a
fixed amount of time at various flow rates and has the ability to either titrate dose on demand or maintain a constant dose. In July
2022, the Company commenced marketing LungFit<sup>&#174;</sup> PH in the United States for PPHN as a medical device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November  2024, the Company received European CE mark approval of the LungFit PH&#174; system for the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    treatment of infants <span style="text-decoration: underline">&gt;</span>34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic
    evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;
    and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents,
    ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular
    function and oxygenation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LungFit<sup>&#174;</sup>
can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections via delivery
of NO at concentrations &gt; 100 parts per million (ppm) through a breathing mask or similar apparatus. The Company&#8217;s other areas
of focus with the LungFit<sup>&#174;</sup> platform beyond PPHN are nontuberculous mycobacteria (&#8220;NTM&#8221;) lung infection and
those with various severe lung infections with underlying chronic obstructive pulmonary disease (&#8220;COPD&#8221;). The Company&#8217;s
current product candidates will be subject to premarket reviews and approvals by the FDA, certification through the conduct of a conformity
assessment by a notified body in the EU for the product to be CE marked, as well as comparable foreign regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
Beyond Air&#8217;s focus on NO and its effect on the human condition, the Company has two additional programs that do not utilize
the LungFit<sup>&#174;</sup> system. Through the Company&#8217;s majority-owned affiliate Beyond Cancer, Ltd. (&#8220;Beyond
Cancer&#8221;), NO is used to target solid tumors. The LungFit<sup>&#174; </sup>platform is not utilized for the solid tumor
indication due to the need for ultra-high concentrations of gaseous nitric oxide (&#8220;UNO&#8221;). A proprietary delivery system
has been developed that is designed to safely deliver UNO in excess of 10,000 ppm directly to a solid tumor. This program has
completed a phase 1a human clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2021, Beyond Air reorganized its oncology business into a new private company called Beyond Cancer. Beyond Air&#8217;s preclinical
oncology team and the exclusive right to the intellectual property portfolio utilizing UNO for the treatment of solid tumors now reside
with Beyond Cancer. Beyond Air has <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211104__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeyondCancerLtdMember_zTJQOonCGnPe" title="Ownership percentage">80</span>% ownership in Beyond Cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
second program which does not utilize the LungFit&#174; platform partially inhibits neuronal nitric oxide synthase (&#8220;nNOS&#8221;) in the brain
to treat neurological conditions. The first target indication is autism spectrum disorder (&#8220;ASD&#8221;). On June 15, 2023, the
Company announced that it has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem,
LTD. (the &#8220;University&#8221;) to acquire the commercial rights for nNOS inhibitors being developed for the treatment of ASD and
other neurological conditions. Currently, there are no FDA-approved therapies specifically for the treatment of ASD. Under the terms
of the agreement, Beyond Air will make payments to the University over the three-year period from the date of the agreement for pre-clinical
work. Also, the Company will pay a low single-digit royalty on net sales and certain one-time payments based on clinical, regulatory
and sales milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2025, Beyond Air reorganized its neurology business into a new private company called NeuroNOS. Beyond Air&#8217;s infrastructure,
for example regulatory, quality, legal, etc., is currently supporting the NeuroNOS team. Beyond Air has <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20250324__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NeuroNosLtdMember_z9io6NDSdA6l" title="Ownership percentage">84.75</span>% ownership in NeuroNOS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s current product candidates will be subject to premarket reviews and approvals by the FDA, certification through the conduct
of a conformity assessment by a notified body in the European Union (the &#8220;EU&#8221;), as well as comparable foreign regulatory
authorities&#8217; reviews or approvals in other countries or regions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2025, the Company effectuated a <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20250714__20250714_z1Gz5F2NAKc1" title="Reverse stock split">one-for-twenty (1:20) reverse stock split</span> (the &#8220;2025 Reverse Stock Split&#8221;). The
Company&#8217;s common stock began trading on the Nasdaq Stock Market on a split-adjusted basis on July 14, 2025. There was no change
to the number of authorized shares of the Company&#8217;s common stock or the par value per share of common stock. Any fraction of a
share of common stock created as a result of the 2025 Reverse Stock Split was rounded up to the nearest whole share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share and per share information in these accompanying consolidated financial statements have been retroactively adjusted to reflect the
2025 Reverse Stock Split for all periods presented. In addition, (i) a proportionate adjustment has been made to the per share exercise
price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of common
stock, and (ii) the number of shares reserved for issuance pursuant to the 2013 Beyond Air Equity Incentive Plan has been reduced proportionately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.4-03(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zAeRh970iBXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 <span id="xdx_826_zeupzJcGwgk6">SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zePT0szFLvt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zaK8ogn2fPr">Basis
of Presentation and Principles of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements include the accounts of Beyond Air, Inc. and its subsidiaries and have been prepared in accordance
with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;). The Company determined that Beyond Cancer
Ltd. and its affiliates (&#8220;Beyond Cancer&#8221;) and NeuroNOS Ltd. and its affiliates (&#8220;NeuroNos&#8221;) are each a
variable interest entity (&#8220;VIE&#8221;) for which the Company is the primary beneficiary and consolidates in its financial
statements. All intercompany balances and transactions have been eliminated in the accompanying consolidated financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--UseOfEstimates_zyP03rkfswnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zrfYmDguqYR8">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could
significantly differ from those estimates. On an ongoing basis, the Company evaluates its significant estimates and assumptions
including expense recognition and accrual assumptions under consulting and clinical trial agreements, stock-based compensation,
allowance for credit losses, excess and obsolete inventory reserves, impairment assessments, accounting for licensed rights to use
technologies and other long-lived assets, the valuation of warrants, the valuation of derivatives, contingency recognition and
accruals and the determination of valuation allowance requirements on deferred tax attributes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_ecustom--GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock_zyfgdhMi85s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zqY2Bjw1vIe6">Going
Concern, Liquidity and Other Uncertainties</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used cash in operating activities of $<span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250401__20260331_z3ZU6LUFtdn3" title="Net cash used in operating activities">18.1</span> million for the year ended March 31, 2026, and has an accumulated deficit attributable
to the stockholders of Beyond Air, Inc. of $<span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20260331_zSPwmvk8ZqKe" title="Accumulated deficit">319.6</span> million. The Company had cash, cash equivalents and marketable securities of $<span id="xdx_902_ecustom--CashAndCashEquivalentsAndMarketableSecurities_iI_pn5n6_c20260331_zw8mJaARiHIj" title="Cash equivalents and marketable securities">11.6</span>
million as of March 31, 2026. In addition, $<span id="xdx_905_eus-gaap--DepositAssets_iI_pn5n6_c20260331_zZ5ML2x09EY3" title="Cash deposit">3.4</span> million of cash is held on deposit by the Company&#8217;s contract manufacturer to be
applied against future purchases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to incur net losses and have significant cash outflows for at least the next year, including making significant
investments in research and development. Management believes these factors raise substantial doubt about the Company&#8217;s ability
to meet its obligations with cash on hand and concluded that the Company will require additional funding within one year from the
date these consolidated financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is confident that the efforts to arrange financing, while not assured, will enable the Company to meet its obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s future capital needs and the adequacy of its available funds will depend on many factors, including, but not necessarily
limited to, the success and costs of commercialization of the Company&#8217;s approved product and the actual cost and time necessary
for current and anticipated preclinical studies, clinical trials and other actions needed to obtain certification or regulatory approval
of the Company&#8217;s product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_ecustom--OtherRisksAndUncertaintiesPolicyTextBlock_zmSOMpTsR0dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_z9BkdE6WELm2">Other
Risks and Uncertainties</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to development and early-stage medical device companies including, but not limited to, new technological
innovations, certifications or regulatory approval, dependence on key personnel, protection of proprietary technology, compliance with
government regulations, product liability, uncertainty of market acceptance of approved products and the potential need to obtain additional
financing. The Company is also dependent on third-party suppliers and, in some cases, single-source suppliers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s products require approval or clearance from the FDA prior to commencement of commercial sales in the United States. There
can be no assurance that the Company&#8217;s products beyond LungFit&#174; PH in the U.S. will receive the required approvals or clearances.
Certifications, approvals or clearances are also required in foreign jurisdictions in which the Company may license or sell its products.
If the Company is denied such certifications or approvals or clearances or such certifications, approvals or clearances are delayed,
such denial or delay may have a material adverse impact on the Company&#8217;s results of operations, financial position and liquidity.
Further, there can be no assurance that the Company&#8217;s product will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or
that such products will be successfully marketed, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zVF0qxX5X7Ag" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zlJminLqUXwk">Revenue
Recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates revenue from the leases of its LungFit&#174; PH devices to its customers under fixed fee arrangements over periods of
up to three years. The fixed fee is typically broken down into ratable monthly payments over the term of the arrangement. The Company&#8217;s
customers include hospitals and medical facilities. The Company&#8217;s LungFit&#174; PH leases include filters, calibration gas, bagging
kits, cables, adapters, and other components and accessories required to use the LungFit&#174; PH device (the &#8220;Consumables&#8221;).
The consumables&#8217; quantities are varied and may be supplied upon demand of the customers and are unlimited, or the arrangement may
provide for the maximum quantities available to the customer over the term of the arrangement. The Company&#8217;s LungFit&#174; PH leases
also include maintenance and training required to use the LungFit&#174; PH device, as well as device back-up services (the &#8220;Services&#8221;),
which are recorded in cost of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its rental arrangements of LungFit&#174; PH devices in accordance with Accounting Standards Codification 842, <i>Leases</i>
(&#8220;ASC 842&#8221;). Under ASC 842, leases may be classified as either financing, sales-type, or operating, and the Company is
required to disclose key information about leasing arrangements. The classification determines the pattern of revenue recognition
and classification within the consolidated statements of operations and comprehensive loss. The Company typically classifies the
rental arrangement of its LungFit&#174; PH contracts as operating leases. The Company&#8217;s leases do not contain any restrictive
covenants or any material residual value guarantees. The Company&#8217;s equipment leases may contain renewal options which range
from one month to two years. The lease term is adjusted for renewal or termination options that the Company believes the customer is
reasonably certain to exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company elected the practical expedient applied to operating leases not to separate lease and non-lease components as long as the lease
and non-lease components have the same timing and pattern of transfer. As such, the non-lease components, including the Consumables and
Services, are combined with the predominant lease component. The total fixed fees that the Company is reasonably certain to collect are
recognized on a straight line basis over the term of the arrangement. Additionally, the Company made an accounting policy election to
present LungFit&#174; PH revenue net of sales and other similar taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the lease commencement date, the Company will defer initial direct costs, including commission expense and the cost is recognized over
the lease term on the same basis as lease income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 15 to the consolidated financial statements for more information regarding leasing arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also generates revenue from the sale of its LungFit&#174; PH devices and consumables to its customers under distribution arrangements.
Contracts include one performance obligation as any individual promised good or services other than delivery of the devices and consumables
are generally either not capable of being distinct or not distinct within the context of the contracts. Purchased quantities of devices
and consumables are varied and may be supplied upon demand of the customers. Revenue is recognized at a point in time when the Company
delivers the goods to its customer. The transaction includes a fixed component based on contractual rates. Revenue recognized reflects
the consideration the Company expects to receive in exchange for delivering the goods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
billed in advance of performance obligations being satisfied are recognized as deferred revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records the costs of shipping devices and consumables in cost of revenues in its consolidated statements of operations and comprehensive
loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJRcS9cpNhq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zpAyVX7HJsB8">Accounts
Receivable</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company extends credit to its customers on an unsecured basis. Accounts receivable are recorded at the invoiced amount, based on agreed
contract terms, less an allowance for credit losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company establishes an allowance for accounts receivable that are considered to be at increased risk of becoming uncollectible. When
evaluating the adequacy of this allowance for credit losses, the Company considers factors such as, historical collection experience
and creditworthiness, the composition of outstanding receivables by customer class, and expected economic conditions and other trends.
The Company&#8217;s estimates are reflected in the period they are made. The charges recorded for credit losses are reported within Selling,
general and administrative expenses on the consolidated statements of operations and comprehensive loss. Receivables are written off
against the allowance for credit losses when it is definitively determined that amounts are uncollectible. As of March 31, 2026 and 2025,
the allowance for credit losses were $<span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivableNoncurrent_iI_pn5n6_c20260331_zYeSgdAczWwa" title="Allowance for credit losses">0.1</span> million and $<span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivableNoncurrent_iI_pn5n6_c20250331_z7SLja1nsgK6" title="Allowance for credit losses">0</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z5m4LoVsv315" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zbf3gxuIpLl5">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820, <i>Fair Value Measurements and Disclosures</i> (&#8220;ASC 820&#8221;), defines fair value as the price that would be received to
sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market
participants on the measurement date. The fair value standard also establishes a three-level hierarchy, which requires an entity to maximize
the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based
upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1&#8212;inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2&#8212;inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived
valuations in which all significant inputs are observable for substantially the full term of the asset or liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3&#8212;inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026 and March 31, 2025, the Company&#8217;s financial instruments included restricted cash, marketable securities,
accounts payable, long-term debt and liability classified warrants. The carrying amounts reported in the accompanying consolidated
financial statements for cash and cash equivalents, restricted cash and marketable securities approximate their respective fair
values because of the short-term nature of these accounts. The carrying value of the Company&#8217;s long-term debt approximates
fair value based on current interest rates for similar types of borrowings. The liability classified warrants are recorded at fair
value and are included in Level 3 of the fair value hierarchy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zSz2dHLbWKHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value amounts as of March 31, 2026 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zXpIL3M7zN37" style="display: none">SCHEDULE
OF FAIR VALUE ON A RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20260331_z0foNQr9g2b6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z38n6cDnwlu8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z00wG26yyZg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsZd0BuskkP8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_ze7sjfLFgEgg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">4,901</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">4,901</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0729">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0730">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zjHwT9v6ZS32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,901</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,901</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0734">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0735">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zRC5TAbEqGGb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0739">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_z468H5pC9PIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0743">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value amounts as of March 31, 2025 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250331_z3Jt5bx4bnYc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjwMihH6oIy5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQyMh8LZAtai" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWF9wGvB3aei" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zQgGzALhxHx" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">2,252</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">2,252</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0750">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zKl8QiSE9w77" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0755">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z7teyQQZeWch" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">38</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0758">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0759">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">38</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zIpton2TLu3e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0763">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zXsqfKoRIw8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--MarketableSecuritiesTextBlock_z4HgtsibLNA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s short-term marketable securities with unrealized gains and losses as of March 31, 2026,
aggregated by major security type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zCu1EyrKbD71" style="display: none">SUMMARY
OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrealized Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_z5wtCioRRxGi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, fair value">4,901</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20250401__20260331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zB1niEE5K80j" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, unrealized loss">39</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total short-term marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zu1R3CSkgizd" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Fair value">4,901</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20250401__20260331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zSGHtLg4kMfj" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Unrealized gains and (losses)">39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s short-term marketable securities with unrealized gains and losses as of March 31, 2025,
aggregated by major security type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrealized Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zQg58g0FROi4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, fair value">2,252</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20240401__20250331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zWNdUiwZjpf7" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, unrealized loss">39</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Total short-term marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zpU8N2T4NHZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Fair value">2,252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20240401__20250331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zr2SOMcBc0If" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Unrealized gains and (losses)">39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zgvFuIOypEj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Level
3 Valuation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
liability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liability is remeasured each reporting period with the change in fair value recorded to other income (expense) in the consolidated
statements of operations and comprehensive loss until the warrants are exercised, expired, reclassified or otherwise settled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zHT5mdEx3482" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant assumptions used in valuing the warrants were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zMM5k5MZuJid" style="display: none">SCHEDULE
OF ASSUMPTIONS USED IN VALUING WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">At March 31, 2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Expected term (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgvjyxQ3NFWj" title="Expected term warrants">2.25</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ziOPdUBHgXR1" title="Warrants and rights outstanding, measurement input">132.1</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z70biNE9YS8c" title="Warrants and rights outstanding, measurement input">3.8</span></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">At March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Expected term (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyJjQ346E25f" title="Expected term warrants">3.25</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zeuiYAT9gYHk" title="Warrants and rights outstanding, measurement input">99.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdcmXtcs2u7b" title="Warrants and rights outstanding, measurement input">3.9</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A5_zG73FmtTGsBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative
liability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementDifferenceDescription_c20250401__20260331_zzvT3Ss7G3gc" title="Derivative liability description">The
derivative liability represents an embedded redemption feature (embedded put option) that meets the criteria to be classified as a
derivative and is bifurcated from the Note (see Note 9). On any trading day during which the Registration Statement (Note 4) remains
effective and the Note remains outstanding and (i) any trading price of the Company&#8217;s common stock is at least 5% greater than
the current Nasdaq minimum price as defined under Nasdaq Rule 5635(d) (the &#8220;Nasdaq Minimum Price&#8221;) or (ii) the total
dollar trading volume has reached $750,000.00, Streeterville may elect to purchase shares of common stock up to the Beneficial
Ownership Limitation at a purchase price equal to 85% of the Nasdaq Minimum Price, subject to a floor of $0.39 per share. The
aggregate purchase price for these shares shall be offset by an equal amount outstanding under the Note.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
feature was concluded to not be clearly and closely related to the host instrument and is required to be measured at fair value at each
reporting period. The fair value was determined using the Monte Carlo valuation model. The key inputs of the simulation are the valuation
date, the Company&#8217;s common stock share price and volatility, the risk-free rate, and the maximum convertible shares eligible to
offset the outstanding balance on the Note.</span></p>

<p id="xdx_895_ecustom--FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock_zsfFhj7pnTGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zHcIVEJ0tXp1" style="display: none">SCHEDULE
OF KEY INPUTS DERIVATIVE </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">At November 4, 2025 (issuance)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20251104_zE3kHp0WJLG6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Maximum convertible shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20251104__20251104_zx3BaNOFcG5f" style="width: 16%; text-align: right" title="Maximum convertible shares">1,600,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zh4ViqIooue7" style="vertical-align: bottom; background-color: White">
    <td>Share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.86</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zsrRCqjWT2u6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z17Mb19aVOfg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A1_zboQEfYurVni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
January 2026, Streeterville elected to purchase <span id="xdx_903_eus-gaap--StockRepurchasedDuringPeriodShares_pn5n6_c20260101__20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zkC1OrbXBar4" title="Purchase of common stock, shares">1.6</span>
million shares of common stock at an average of $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zYhINvXrjrD" title="Share price">0.73</span>
per share which offset principal of approximately $<span id="xdx_905_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pn5n6_c20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zRkMG7rKJgb7" title="Debt amount">1.2</span>
million outstanding under the Note (Note 9). The fair value of the issued common stock was approximately $<span id="xdx_90C_eus-gaap--CommonStockValueOutstanding_iI_pn5n6_c20260331_znX2AazFVE9a" title="Fair value of issued common stock">3.3</span>
million (Note 4). The Company remeasured the fair value of the derivative liability to $<span id="xdx_902_eus-gaap--CreditRiskDerivativeLiabilitiesAtFairValue_iI_pn5n6_c20260331_ziVcopMq8KCa" title="Fair value of the derivative liability">2.2</span>
million immediately prior to the conversion. Accordingly, the embedded derivative was extinguished as of March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock_znFmSd1AcC0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuation for the warrants and derivatives
for the years ended March 31, 2026 and March 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zjA246EL3fBa" style="display: none">SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--FinancialInstrumentAxis_us-gaap--WarrantMember_zKomqjJB3SX7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_zr6VZOcny8w2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43D_c20240401__20250331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_ztdzelDPDHeh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance at March 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">275</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,314</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zCFopjQvCLGg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(237</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,314</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20250401__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zWLun7K8xSJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at March 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zCbqV14l7zv" style="vertical-align: bottom; background-color: White">
    <td>Issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">775</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zlVdshaDBc45" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,395</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--FairValueMeasurementExtinguishment_zmcY92DcW479" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Extinguishment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,170</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_435_c20250401__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zob4KlfS1AB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Balance at March 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_z5XCy7ic64Ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_ecustom--WarrantLiabilityPolicyTextBlock_zD4209tMhPkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zRWUm4WOeCxf">Warrant
Liability</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies warrants as equity for any contracts that (i) require physical settlement or net-share settlement or (ii) gives
the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The
Company classifies warrants as assets or liabilities for any contracts that (i) require net-cash settlement (including a requirement
to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the
counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). Such warrants
are subject to remeasurement at each consolidated balance sheet date and any change in fair value is recognized as a component of
other income/expense on the consolidated statements of operations and comprehensive loss. The Company will continue to adjust the liability
for changes in fair value until the earlier of the exercise or expiration of such warrants. At that time, the portion of the warrant
liability related to warrants will be reclassified to additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--DerivativesPolicyTextBlock_zSNkPmULVEX" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zLgVSHtIY1bj">Derivative
Liability</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as
embedded derivatives in accordance with ASC 815, <i>Derivatives and Hedging.</i> For derivative financial instruments that are
accounted for as assets or liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is
then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations and
comprehensive loss. The classification of derivative instruments, including whether such instruments should be recorded as assets or
liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the
consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument
could be required within 12 months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zkxOhR4JB6D6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zaLdwLtGklG3">Cash
and Cash Equivalents, Short-Term Investments and Restricted Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with original maturities of three months or less at the date of purchase and an investment
in a U.S. government money market fund to be cash equivalents. The Company maintains its cash and cash equivalents in highly rated financial
institutions in Australia, Israel, Ireland and the U.S., the balances of which, at times, may exceed federally insured limits. Marketable
securities may include investment in a combination of fixed income bonds, U.S. Treasury securities, and mutual funds that are considered
to be highly liquid and easily tradeable. The marketable securities are considered trading securities and are measured at fair value
and are accounted for in accordance with ASC 320. The marketable securities are valued using inputs observable in active markets for
identical securities and are therefore classified as Level 1 within the Company&#8217;s fair value hierarchy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026 and March 31, 2025, restricted cash included approximately $<span id="xdx_904_eus-gaap--RestrictedCash_iI_pn5n6_c20260331_z4rXtZexOB4b" title="Restricted cash">5.6</span> million and $<span id="xdx_90F_eus-gaap--RestrictedCash_iI_pn5n6_c20250331_zhHpnQ2lF6F8" title="Restricted cash">0.2</span> million, respectively. Restricted
cash as of March 31, 2026 includes $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_pn5n6_c20251104__20251104_zvX9YlzYQEr2" title="Proceeds from issuance of secured promissory note">5.4</span> million of proceeds from the Company&#8217;s secured promissory note issued on November 4, 2025
that is required to be held in a restricted account pursuant to the Note Purchase Agreement. Amounts held in the restricted account become
available to the Company as the outstanding principal of the Note is repaid (see Note 9).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zE3MMSGbrn05" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zifwhxa60YWk">Concentration
of Credit Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_uUSD_c20260331__srt--StatementGeographicalAxis__country--US_z7gUpbeMZPEg" title="Cash FDIC insured amount">250,000</span> in the United States, A$<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_uAUD_c20260331__srt--StatementGeographicalAxis__country--AU_zLkdEA4hIpqb" title="Cash FDIC insured amount">250,000</span> in Australia, $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_uUSD_c20260331__srt--StatementGeographicalAxis__country--BM_z8jflRkUGJZe" title="Cash FDIC insured amount">25,000</span>
in Bermuda, &#8364;<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_uEUR_c20260331__srt--StatementGeographicalAxis__country--IE_zvzsqbKTFD9a" title="Cash FDIC insured amount">100,000</span> in Ireland and &#8364;<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_uEUR_c20260331__srt--StatementGeographicalAxis__country--CY_zhbZ2tY5spQa" title="Cash FDIC insured amount">100,000</span> in Cyprus. There is currently no official federal depository insurance in Israel.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. <span id="xdx_906_eus-gaap--ConcentrationRiskBenchmarkDescription_c20260331__20260331_zwBsDcqjI1ci" title="Concentration risk benchmark description">As of March 31, 2026, the Company had greater than $250,000 at United States financial institutions, less than A$250,000
at Australian financial institutions, greater than &#8364;100,000 at Irish financial institutions and also has funds on deposit in Israel.</span>
Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition,
results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zO39TGqE6eHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table is the reconciliation of the presentation and disclosure of cash, cash equivalents, marketable securities by major security
type and restricted cash as shown on the Company&#8217;s consolidated statements of cash flows for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z0jfOmMC4Fy7" style="display: none">SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20260331_zKbwo92hRnU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250331_zIIVYqgiz4Xl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCEASz3pW_maRCACEzZrO_zQj3UHc54oZf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,740</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,665</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RestrictedCashCurrent_iI_pn3n3_maRCACEzZrO_zFxqdPDYOz83" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,622</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">231</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RestrictedCashAndCashEquivalents_iTI_pn3n3_mtRCACEzZrO_maCCEASziVz_zCa0NYeQZvO8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total cash, cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,362</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,896</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--MarketableSecuritiesAbstract_iB_zy0yiyUF65n9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--MarketableSecuritiesCurrent_i01I_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z213JS7INxXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,901</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MarketableSecuritiesCurrent_i01I_pn3n3_maCCEASziVz_zJBHKOVrL1Ok" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">4,901</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iTI_pn3n3_mtCCEASziVz_zHJeioG91Fig" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents, marketable securities and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,263</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,148</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zPNalkSO2Hci" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zeVEjAVtjFMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zgbsc8xF2Yja">Fixed
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_ecustom--ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock_zpfWmIi8fGMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation and accumulated amortization. Depreciation and amortization are calculated
using the straight-line method over the estimated useful life of the assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zziOzbX9ZBq2" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zGOdAUEMpnMl" title="Estimated useful life of assets">Three
    years</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z0YAIfctOaLa" title="Estimated useful life of assets">Five
    years</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    and medical equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember__srt--RangeAxis__srt--MinimumMember_zeg8FPWttisb" style="display: none" title="Estimated useful life of assets">3</span>/<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember__srt--RangeAxis__srt--MaximumMember_zL0oHTEqzoq9" title="Estimated useful life of assets">Five
    years</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment
    deployable as part of a service offering</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentDeployableAsPartOfServiceOfferingMember_zbKoyiHEMEGc" title="Estimated useful life of assets">Five
    years</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zIOJZqQidfNf" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2026%23UsefulLifeTermOfLeaseMember"><span style="-sec-ix-hidden: xdx2ixbrl0906">Shorter
    of term of lease or estimated useful life of the asset</span></span></span></td></tr>
  </table>
<p id="xdx_8A0_zcPMD6dQyzx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWhSe7IFIEI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zw5wt5bfBJHc">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity for which both discrete financial information is available and regularly reviewed by
the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing
performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company&#8217;s CODM evaluates performance and allocates resources for all
of the Company&#8217;s reportable segments based on income/loss from operations. The CODM is involved in determining and reviewing projected
income/loss from operations as part of the annual budget process. Throughout the year, the CODM considers forecast to actual results
and variances to allocate resources. The CODM also considers this information in strategic decisions related to capital allocations,
including investments in assets, research and development activities, and human capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s reportable segments at March 31, 2026 included <span id="xdx_905_ecustom--NumberOfReportableSegmentsDisclosedByDefinitionFlag_dbT_c20250401__20260331_zg48RG5VSya9" title="Number of repotable segments">Beyond Air, Beyond Cancer, and NeuroNos</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Beyond Air segment includes unallocated corporate expenses associated with the public company fees as well as all corporate related assets
and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zUPk5S2yRd52" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zQVSCnoOtmF">Inventories</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
consist primarily of purchased filters, bagging kits, cables, adapters, and other components and accessories required to use the LungFit&#174;
PH device held for sale to customers. Inventories are recorded at the lower of cost or net realizable value. Cost comprises direct materials,
third-party manufacturing costs and shipping costs incurred to deliver goods to the Company&#8217;s central warehouse location. Costs
are assigned to individual items of inventory on the basis of weighted average costs. Inventory items are tracked by batch/lot number
for specific identification whenever possible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
reserves are established for estimated excess and obsolete inventory equal to the difference between the cost of the inventory and the
estimated net realizable value of the inventory based on historical usage, known trends, and market conditions and judgment about the
anticipated future consumption and the Company&#8217;s ability to sell the inventory. At March 31, 2026 and March 31, 2025, excess and obsolescence reserves
were $<span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_pn5n6_c20260331_ztjhcafgaG3f" title="Obsolescence reserves">0.4</span> million and $<span id="xdx_908_eus-gaap--InventoryValuationReserves_iI_pn5n6_c20250331_zH80QGz5OvLl" title="Obsolescence reserves">0.2</span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zTwdbBYwhUzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zVQil3J6jCZ1">Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease assets are included within operating lease right-of-use assets, and the corresponding operating lease obligation on the consolidated
balance sheets in accordance with ASC 842, <i>Leases</i>. The Company has elected not to present short-term leases as these leases have
a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably
certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the
lease term at commencement date. Operating lease expense is recognized on a straight-line basis over the lease term and is included in
general and administrative and research development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interest rate implicit in the Company&#8217;s leases is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate in determining the present value of lease payments, which reflects the fixed rate at which the Company could borrow on
a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zBYK3lPY60Yh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z5irVTKx8dx6">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to the consolidated statements of operations and comprehensive loss as incurred. Research and development
expenses include salaries, benefits, stock-based compensation and costs incurred by outside laboratories, manufacturers, clinical research
organizations, consultants, and accredited facilities in connection with preclinical studies and clinical trials. Research and development
expenses are partially offset by the benefit of tax incentive payments for qualified research and development expenditures from the Australian
tax authority (&#8220;AU Tax Rebates&#8221;). The Company does not record AU Tax Rebates until payment is received due to the uncertainty
of receipt. For the years ended March 31, 2026 and March 31, 2025, the Company received $<span id="xdx_903_ecustom--TaxRebate_pn5n6_c20250401__20260331__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--AustralianTaxationOfficeMember_zRpYbVFqB6W2" title="Tax Rebate">0.1</span> million and $<span id="xdx_903_ecustom--TaxRebate_pn5n6_c20240401__20250331__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--AustralianTaxationOfficeMember_zmlzooNdSbHh" title="Tax Rebate">0.0</span> million, respectively,
in AU Tax Rebates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zWyTcYHOwBAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zee0Dj2iQdC3">Foreign
Exchange Transactions</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s subsidiaries transact in U.S. dollars, Euros, New Israeli Shekels and Australian dollars. The Company&#8217;s main operations
are in the United States and the U.S. dollar is the currency of the primary economic environment in which the Company operates and expects
to continue to operate in the foreseeable future. The Company translated its non-U.S. operations&#8217; assets and liabilities denominated
in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the
average exchange rate for the reporting period. Gains or losses from foreign currency transactions are included in other income (expense)
in the consolidated statements of operations and comprehensive loss as foreign currency exchange gain/(loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive
income and loss. The accumulated other comprehensive income and loss account includes the cumulative results of translating certain balance
sheet assets and liabilities at current exchange rates and some accounts at historical rates. For the year ended March 31, 2026, the
Company recorded gains of $<span id="xdx_90B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20260331_z7YLqXHZMmJ7" title="Accumulated other comprehensive income">0.2</span> million in accumulated other comprehensive income. For the year ended March 31, 2025, the Company recorded
losses of $<span id="xdx_90F_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20250331_z4Km4oWtws39" title="Accumulated other comprehensive income">0.1</span> million in accumulated other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zoq7zmHFHfej" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zCmkfEn80O85">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the cost of employee and non-employee services received in exchange for an award of equity instruments based on the
grant date fair value of the award. Fair value for restricted stock unit awards is valued using the closing price of the Company&#8217;s
common stock on the date of grant. The grant date fair value is recognized over the requisite service period during which an employee
and non-employee is required to provide service in exchange for the award, using the accelerated method with each tranche being expensed
over its vesting period. The grant date fair value of employee and non-employee share options is estimated using the Black-Scholes option
pricing model. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term
of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception
and does not anticipate paying dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Starting in 2023,
Beyond Air used its own historical volatility as an input for expected volatility, but due to Beyond Cancer&#8217;s and NeuroNos&#8217;
lack of marketability, the Company utilizes the implied volatility based on an aggregate of guideline companies for expected volatility.
The Company uses the simplified method to estimate the expected term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_ecustom--SupplierConcentrationPolicyTextBlock_zKF0PPuy2u2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_znqew8oyzWYi">Supplier
Concentration</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on third-party suppliers to provide materials for its devices and consumables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the year ended March 31, 2026, the Company purchased approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FirstThirdPartyVendorsMember_zWOjQrfo8Lg9" title="Concentration percentage">74</span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondThirdPartyVendorsMember_zPKH5GFKgKkk" title="Concentration percentage">18</span>% of its materials from two third-party vendors. In the
year ended March 31, 2025, the Company purchased approximately <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorsMember_zzzCD2frilml" title="Concentration percentage">85</span>% of its materials from one third-party vendor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_ecustom--CustomerrConcentrationPolicyTextBlock_zt0y7eVOQCR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zZK72rqbNr5k">Customer
Concentration</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2026, the Company derived <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zYh7HM53rlHa" title="Concentration percentage">11</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zqCNA4uF7rjc" title="Concentration percentage">10</span>% of its revenues from two customers. For the year ended March 31, 2025,
the Company derived <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_z8mTZnZnEwR7" title="Concentration percentage">16</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zjovfV2GnvV8" title="Concentration percentage">10</span>% of its revenues from two customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zYiYbUZ0aaWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zBR8SZsHLuE4">Licensed
Right to Use Technology</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed
right to use technology that is considered platform technology with alternative future uses is recorded as an intangible asset and is
amortized on a straight-line method over its estimated useful life, determined to be thirteen years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zPqdqDxadk6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected amortization expense for the next five years and thereafter is as follows for the year ended March 31 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zfGTZeVvBHb1" style="display: none">SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_490_20260331_zTDHWIObOgA5" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANz72H_ztGt05u0vLWc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: left">2027</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">205</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANz72H_zdQScyCDpJTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANz72H_zdimKZ1UaNT8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANz72H_zoImxPVfM5fi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANz72H_zoRKAth2Mncg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2031</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANz72H_ziR28fJCHfik" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,018</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_z0prWWE0AGMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zWfi9ADUtDcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z8VqivzDPyKg">Long-Lived
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses the impairment of long-lived assets on an ongoing basis and whenever events or changes in circumstances indicate that
the carrying value may not be recoverable. Factors that the Company considers as potential triggers of an impairment review include the
following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    underperformance relative to expected historical or projected future operating results,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    changes in the manner of the Company&#8217;s use of the acquired assets or the strategy for its overall business,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    negative regulatory or economic trends, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    technological changes, which would render the platform technology, equipment, and manufacturing processes obsolete. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recoverability
of assets that will continue to be used in the Company&#8217;s operations is measured by comparing the carrying value to the future net
undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future
revenues, driven by market growth rates, and estimates of future costs. There were no events during the reporting periods that were deemed
to be a triggering event that would require an impairment assessment, other than the impairment of $<span id="xdx_900_eus-gaap--OtherAssetImpairmentCharges_pn5n6_c20240401__20250331_zfqvadaSCqaj" title="Other asset impairment charges">0.5</span> million recorded during the year
ended March 31, 2025 associated with certain R&amp;D assets following Management&#8217;s decision to put its VCAP clinical trial on hold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_z1EpRTJlMHf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_z6dWFnrUzn86">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities
and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are
recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than
not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future
deductibility is uncertain. As of March 31, 2026 and March 31, 2025, the Company recorded a valuation allowance to the full extent of
the Company&#8217;s net deferred tax assets since the likelihood of realization of the benefit does not meet the more-likely-than-not
threshold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s reserves related to taxes are based on a determination of whether and how much of a tax benefit taken by the Company
in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related
to the tax benefit. The Company would recognize both estimated accrued interest and penalties related to unrecognized benefits within
income tax expense in the consolidated statements of operations and comprehensive loss. The Company&#8217;s uncertain tax positions are
related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position,
the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which
a loss carryforward is available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zUjUHEdFaDd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zboUTYq1V7Xd">Net
Loss Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to Beyond Air, Inc.,
by the weighted average number of shares of common stock outstanding for the period. The dilutive effect of outstanding options, warrants,
restricted stock and other stock-based compensation awards is reflected in diluted net loss per share by application of the treasury
stock method. The calculation of diluted net loss attributed to common stockholders per share excludes all anti-dilutive shares of common
stock. For periods in which the Company has reported net losses, diluted net loss per share attributable to common stockholders is the
same as basic net loss per share attributable to common stockholders, because such shares of common stock are not assumed to have been
issued if their effect is anti-dilutive (Note 8).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ConsolidationVariableInterestEntityPolicy_zXmJuTlw0mS" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zvtldgtakaPf">Variable
Interest Entity</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company has the power to direct activities of both Beyond Cancer and NeuroNos  that most significantly impact their economic
performance and the right to receive benefits and losses that may potentially be significant, these financial statements are fully consolidated
with those of the Company. The non-controlling owners&#8217; <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20260331__srt--OwnershipAxis__custom--BeyondCancerLtdMember_zVO1dsDjeZKb" title="Non-controlling owners interest">20</span>% interest in Beyond Cancer&#8217;s net assets and result of operations
and the non-controlling owners&#8217; <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20260331__srt--OwnershipAxis__custom--NeuroNosLtdMember_zGruHsD1j4A8" title="Non-controlling owners interest">15.25</span>% interest in NeuroNos&#8217; net assets and result of operations are reported as &#8220;non-controlling
interest&#8221; on the Company&#8217;s consolidated balance sheets and as &#8220;net loss attributable to non-controlling interest&#8221;
in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z2e5hTyHtoI" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z3xqho5VK4fa">Recently
Adopted Accounting Standards</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;)
2023-09, <i>Improvements to Tax Disclosures (Topic 740), </i>to enhance the disclosures related to income taxes, including the rate
reconciliation and information on income taxes paid. This ASU is effective for fiscal years beginning after December 15, 2024
(fiscal 2026 for the Company), with early adoption permitted. The Company adopted this standard effective April 1, 2025
prospectively. See Note 11, &#8220;Income Taxes,&#8221; for further information regarding the
Company&#8217;s effective income tax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_ecustom--RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_zypEtiThyZ79" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_ztIW2GOFmu92">Recently
Issued Accounting Standards Not Yet Adopted</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40).</i> This standard requires disclosure of specific information about costs and expenses and becomes effective for fiscal
years beginning after December 15, 2026 (fiscal 2028 for the Company), with early adoption permitted. The Company is assessing the impact
of this ASU and, upon adoption, may be required to include certain additional disclosures in the footnotes to the Consolidated Financial
Statements.</span></p>

<p id="xdx_85A_zRvKbt6JbRYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant, and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_800_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zknGdoUxPgC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 <span id="xdx_82F_zCAFy9urtsij">PROPERTY AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zMLxG8Xv4tae" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_za6Zd0dRYAWe" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20260331_zDU3FrgE1UK3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2026</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250331_z8F8ZR3n9Atd" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember_zIGK6yflbM0b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Clinical and medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">206</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,048</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentDeployableAsPartOfServiceOfferingMember_zSOgUnmfLmx6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equipment deployable as part of a service offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,871</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,511</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpz3vKbJKZ4e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">927</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zlu4qQjjp4k8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">458</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">506</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zN2v5XsHcI9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">521</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">521</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzruM_zdxqruQDXCsk" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,909</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,513</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzruM_zd7ivrOPoKl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,660</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,500</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzruM_zqkpMFbHCKn2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment, net</span></span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,249</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,013</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zxjZ6EdJJSVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization for the years ended March 31, 2026 and March 31, 2025 was $<span id="xdx_901_eus-gaap--DepreciationAndAmortization_pn5n6_c20250401__20260331_zTuSWbKYOdD5" title="Depreciation and amortization">3.1</span> million and $<span id="xdx_90D_eus-gaap--DepreciationAndAmortization_pn5n6_c20240401__20250331_zwk7UJyxPls9" title="Depreciation and amortization">3.0</span> million, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zgbqHstXpIc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 <span id="xdx_823_z2bzvYxgVhx7">STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 10, 2025, the Company entered into an At-The-Market Equity Offering Sales Agreement with BTIG, Inc. (the &#8220;2025 ATM&#8221;).
Under the 2025 ATM, the Company may sell shares of its common stock having aggregate sales proceeds of up to $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20250210__20250210__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember_zeIU2Z6ZhADc">35.0</span> million, from time
to time and at various prices. If shares of the Company&#8217;s common stock are sold, there is a<span id="xdx_902_ecustom--SaleOfStockFeePercentage_pid_dp_uPure_c20250210__20250210__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember_zJTEkPL3x7gd" title="Sale of stock fee percentage"> 2.5</span>% fee paid to the sales agent. Pursuant
to the &#8220;baby shelf rules&#8221; promulgated by the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), if the Company&#8217;s public float is less than $<span id="xdx_90B_ecustom--PublicFloatValue_iI_pn5n6_c20250210__srt--RangeAxis__srt--MaximumMember_zLygtgUpxcnj" title="Public float value">75.0</span> million as of specified
measurement periods, the number of shares of common stock that may be offered and sold by the Company under a Form S-3 registration statement,
including pursuant to the 2025 ATM, in any twelve-month period is limited to an aggregate amount that does not exceed one-third of the
Company&#8217;s public float. As of March 31, 2026, due to the SEC&#8217;s &#8220;baby shelf rules,&#8221; the Company may currently
not sell any shares of common stock pursuant to the 2025 ATM. The Company will remain subject to the &#8220;baby shelf rules&#8221; under
the Form S-3 registration statement until such time as its public float exceeds $<span id="xdx_90F_ecustom--PublicFloatValue_iI_pn5n6_c20250210__srt--RangeAxis__srt--MaximumMember_zfFcQoG5Qisj" title="Public float value">75.0</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended March 31, 2026, the Company received net proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember_zVVQzppfBhGa" title="Sale of net proceeds">8.1</span> million from the sale of <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember_zCDBFQ3984X4" title="Number of shares issued in transaction">2,441,775</span> shares of common stock through
the 2025 ATM. During the year ended March 31, 2025, the Company received net proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240401__20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSuX9wEFBw7a" title="Sale of net proceeds">2.1</span> million from the sale of <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240401__20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7G3641MMQa5" title="Number of shares issued in transaction">337,100</span> shares
of common stock through the 2025 ATM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2025, the Company entered into an equity purchase agreement (the &#8220;Streeterville Purchase Agreement&#8221;) with
Streeterville Capital, LLC (&#8220;Streeterville&#8221;) for the purchase of up to $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn6n6_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_znOjc9Zwtdzf" title="Share purchase value">20</span>
million of the Company&#8217;s shares of Common Stock. In connection with the Streeterville Purchase Agreement, Streeterville and
the Company entered into a Registration Rights Agreement, pursuant to which the Company filed a registration statement for the
resale of up to <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zDDznPqtRfOh" title="Shares available for resale">1,600,000</span>
shares of Common Stock (the &#8220;Registration Statement&#8221;). During January 2026, Streeterville elected to purchase <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z52Ft1NKzaF5" title="Shares available for resale">1.6</span> million shares of common stock with an average fair market
value of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zBKQRmndzor3" title="Price per share">2.09</span> per share over each issuance date, resulting in approximately $<span id="xdx_907_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_pn5n6_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zGyjGeXSmCmg" title="Adjustments in additional paid in capital">3.3</span> million recorded to additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Streeterville Purchase Agreement (so long as there is no balance outstanding on the Note (Note 9), the Company has the right,
but not the obligation, to direct Streeterville, by delivery to Streeterville of a put notice from time to time during a period of up
to two years, to purchase shares of Common Stock (i) in a minimum amount not less than $<span id="xdx_908_eus-gaap--PaymentsForRepurchaseOfCommonStock_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zpv9aIITfbb6" title="Common stock minimum purchase amount">25,000</span>, and (ii) in a maximum amount up to the
median daily trading volume of the Common Stock during the five trading days immediately preceding delivery of the put notice, or such
other greater amount mutually agreed upon by the parties; provided, however, that the number of put shares shall not exceed the beneficial
ownership limitation, of <span id="xdx_90D_ecustom--BeneficialOwnershipLimitationPercentage_iI_pid_dp_uPure_c20251104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zpoGWaSpC8C8" title="Beneficial ownership limitation percentage">4.99</span>% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock issuable pursuant to a put notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2026, the Company entered into the Securities Purchase Agreement with an institutional investor pursuant to which the Company
sold, in a private placement offering, an aggregate of (i) <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260114__20260114__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWTvubm0W5Be" title="Stock issued during the period, shares">524,990</span> shares of common stock (ii) <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_znYpEJq6iY32" title="Purchase warrants">3,405,828</span> pre-funded stock purchase warrants,
(the &#8220;2026 Pre-funded Warrants&#8221;) and (iii) <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixCommonWarrantsMember_z4phR7Yseq9f" title="Purchase warrants">3,930,818</span> stock purchase warrants (the &#8220;2026 Common Warrants&#8221; and
together with the 2026 Pre-funded Warrants, the &#8220;2026 Warrants&#8221;). Each common share and accompanying 2026 Common Warrant
were sold together at a combined offering price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260114__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7tgU63ae217" title="Common  stock warrant offering price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixCommonWarrantsMember_zTqwSFJvTRqa" title="Common  stock warrant offering price">1.272</span></span> per share, and each 2026 Pre-Funded Warrant was sold at an offering price of
$<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_zzZkt8yUcgBe" title="Common  stock warrant offering price">1.2719</span> per 2026 Pre-funded Warrant for gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfWarrants_pn6n6_c20260114__20260114__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_z6EHlv298lWb" title="Proceeds from issuance of warrants">5.0</span> million. The 2026 Pre-Funded Warrants have an exercise price of $<span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20260116__20260116__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_z8Go3PBAMiyg" title="Warrant exercise price">0.0001</span>
per share, and the 2026 Common Warrants have an exercise price of $<span id="xdx_902_eus-gaap--WarrantExercisePriceIncrease_c20260114__20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_zFn9LGBLK7w5" title="Warrant exercise price">1.147</span> per share. The private placement offering closed on January
16, 2026. The Company received total net proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250401__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z1561Zkn5Jkg" title="Proceeds from private placement">4.5</span> million after deductions for placement agent commissions and other offering
costs of $<span id="xdx_90E_eus-gaap--PaymentsForCommissions_pn5n6_c20250401__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z13PQlq2Khm" title="Commission paid">0.3</span> million and $<span id="xdx_90E_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zptzsNoadK86" title="Deferred costs current">0.2</span> million, respectively, during the year ended March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 STOCKHOLDERS&#8217; EQUITY (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Option Plans</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Eighth Amended and Restated 2013 Beyond Air Equity Incentive Plan (the &#8220;2013 BA Plan&#8221;) allows for awards
to officers, directors, employees, and consultants of stock options, restricted stock units and restricted shares of the Company&#8217;s
common stock. On November 25, 2025, the Company&#8217;s Board of Directors approved an amendment to the 2013 BA Plan to increase the
number of shares in the 2013 BA Plan by <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20251125__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zVsR1uSTAMB3" title="Stock option shares authorized for issuance">850,000</span>, which was approved by the Company&#8217;s stockholders at the 2026 annual stockholder
meeting on January 30, 2026. The 2013 BA Plan has <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRxr6sjZ04Sd" title="Stock option shares authorized for issuance">1,680,000</span> shares authorized for issuance. As of March 31, 2025, <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zK2utwD7IXq6" title="Stock option available shares">894,276</span> shares were
available under the 2013 BA Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value for the restricted stock unit awards was valued at the closing price of the Company&#8217;s common stock on the date of grant.
Restricted stock units vest annually over <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zp3oWF5SWlp8" title="Vesting period">five years</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zLPikjit4Xa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s restricted stock unit awards for the years ended March 31, 2026 and March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zExED22KtKVf" style="display: none">SCHEDULE OF RESTRICTED STOCK AWARDS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number Of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date Fair </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Unvested as of March 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6MuNpET45r8" style="width: 16%; text-align: right" title="Unvested Number of Shares, Beginning balance">30,945</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB0SKhNOdUK3" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">139.60</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzCJpLPJ4tW7" style="text-align: right" title="Number of Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1087">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zW9veaMoeSR8" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMg8cv71H9Og" style="text-align: right" title="Number of Shares, Vested">(12,240</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zbnKrhCW15E" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">137.20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkc6cTHzSkZ2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeited">(440</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjoEnOhgqtnl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">229.60</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Unvested as of March 31, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zeg4dH5hz1Ul" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested Number of Shares, Beginning balance">18,265</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1iho2up2q8b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">139.40</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zlnBw6qwW5lf" style="text-align: right" title="Number of Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zroJU2kT7Eq8" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1105">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB3PfQsrwQCg" style="text-align: right" title="Number of Shares, Vested">(8,630</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjrLsw2vGFIe" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">150.26</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zacVs3383fwl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeited">(150</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhQ6nv5gB0rg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">137.40</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Unvested as of March 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zx0uM3ife9Ta" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested Number of Shares, Ending balance">9,485</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyzVzIbf5x27" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, ending balance">129.41</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zGi1YhK8Cy3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense related to these stock issuances for the years ended March 31, 2026 and March 31, 2025 was $<span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20250401__20260331_z7HQw3yN6kL8" title="Employee benefits and share based compensation">0.5</span> million and $<span id="xdx_906_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20240401__20250331_z7p8ylKZbkfa" title="Employee benefits and share based compensation">1.0
</span>million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026, the Company had unrecognized stock-based compensation expense for the restricted stock unit awards in the 2013 BA
Plan of approximately $<span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandThirteenBAPlanMember_zpeMcRV8t2f3" title="Share based compensation">0.3</span> million, which is expected to be expensed over the weighted average remaining service period of <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zb6nOFhmwMc3" title="Weighted average remaining service, period">1.0</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026, all vested shares had been issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 STOCKHOLDERS&#8217; EQUITY (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
vesting terms of the options issued under the 2013 BA Plan are generally <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zfI8jrxnK5Re" title="Vesting period">four years</span> and expire <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zPcgrtQL7ulg" title="Expiration period">ten years</span> from the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcILgvnqjbS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the change in stock options for the years ended March 31, 2026 and March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zPMO2ul4ry35" style="display: none">SCHEDULE OF OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price&#8211;-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life- </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(thousands)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Options outstanding as of March 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zDIuTD1HmBn" style="width: 11%; text-align: right" title="Number of Options, Outstanding at beginning of period">566,645</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRrEUPyqxF9d" style="width: 11%; text-align: right" title="Weighted Average Exercise Price - Options, Outstanding at beginning of period">88.39</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zfw3evrr2Fr4" title="Weighted Average Remaining Contractual Life - Options">8.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zylzEpHSyxIi" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">760</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zoGAg1pOcH3b" style="text-align: right" title="Number of Options Outstanding, Granted">227,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRupONoHugJj" style="text-align: right" title="Weighted Average Exercise Price - Options, Granted">6.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zquTALQYQDWd" style="text-align: right" title="Number of Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zVGjiqWEuihd" style="text-align: right" title="Weighted Average Exercise Price - Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1147">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zLvDY8NIKuYd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Forfeited">(54,976</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zVt55UyXj6sf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Options, Forfeited">61.74</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding as of March 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zNHc46gRgZF3" style="text-align: right" title="Number of Options, Outstanding at beginning of period">739,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zAkxzGO3xqE7" style="text-align: right" title="Weighted Average Exercise Price - Options, Outstanding at beginning of period">9.34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRMUh8b5pHG5" title="Weighted Average Remaining Contractual Life - Options, Outstanding at beginning of period">7.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zdQWrl0Ptc3c" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1159">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zb0DsRAuUdI1" style="text-align: right" title="Number of Options Outstanding, Granted">94,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zKPnzEy7Uty3" style="text-align: right" title="Weighted Average Exercise Price - Options, Granted">0.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zuv9Dih4ZqF3" style="text-align: right" title="Number of Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1165">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zdBZ78oloXib" style="text-align: right" title="Weighted Average Exercise Price - Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_z63B4wYthsHf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Forfeited">(77,270</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zMHfWM2AW9B2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Options, Forfeited">1.95</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcVHxVYaJAw2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at ending of period">756,749</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_z28O37ZACZJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options, Outstanding at ending of period">1.82</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zSybYciOzyp5" title="Weighted Average Remaining Contractual Life - Options, Outstanding at end of period">7.2</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zjffWXBkOv75" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at end of period"><span style="-sec-ix-hidden: xdx2ixbrl1179">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcU09AUzmzRi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Exercisable">497,591</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zZWvfCXaIUQ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options, Exercisable">1.95</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zc3N8Wp4PdLi" title="Weighted Average Remaining Contractual Life - Options, Exercisable">6.3</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zONx7x7i0Pkc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zupB4LrDc0Sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026, the Company had unrecognized stock-based compensation expense for the stock options in the 2013 BA Plan of approximately
$<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityIncentivePlanMember_zsRiif8TSjNi" title="Unrecognized stock-based compensation expense">1.7</span> million which is expected to be expensed over the weighted average remaining service period of <span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityIncentivePlanMember_zcKNzMhoHNuf" title="Weighted average remaining service period">1.7 </span>years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended March 31, 2026 and March 31, 2025, the weighted average fair value of options granted was $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zlpLvLlXYavi" title="Weighted average fair value of options granted">0.80</span> and $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcGG23degHWi" title="Weighted average fair value of options granted">5.03</span> per share,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2026, the Company executed a Separation and Release of Claims Agreement with the former CEO, Steven Lisi (&#8220;Release Agreement&#8221;).
All unvested options held by Mr. Lisi as of March 27, 2026, were accelerated and immediately vested, and remain exercisable for twenty-four
months from March 27, 2026. The Company recorded $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20260327__20260327_zecRCsZ4qK47" title="Share compensation expense">0.1</span> million of non-cash stock compensation expense reflecting the acceleration of expense
recognition of these equity awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2025, the Company&#8217;s Board of Directors approved a  stock option repricing of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251104__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9IOg0ad5b4j" title="Option repricing">726,618</span>
options (the &#8220;2026 Option Repricing&#8221;), effective November 4, 2025. The 2026 Option Repricing was undertaken in
accordance with, and as permitted by, the Company&#8217;s 2013 BA Plan. Pursuant to the 2026 Option Repricing, all options granted
pursuant to the 2013 BA Plan that are held by Company Board members, officers, and employees expected to continue providing services
to the Company were repriced, to the extent such options had an exercise price in excess of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_c20251104__20251104__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zupOm3WT8XFl" title="Exercise price in excess">1.95</span>,
the closing price per share of the Company&#8217;s common stock as reported on The Nasdaq Stock Market on November 3, 2025. All such
options were repriced such that the exercise price per share was reduced to $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_c20251104__20251104__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqtMWmaGajge" title="Exercise price in excess">1.95</span>.
The modification resulted in incremental stock compensation expense of $<span id="xdx_90E_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_pn5n6_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwJ4LKvwi23j" title="Incremental stock compensation expense">0.3</span>
million recognized during the year ended March 31, 2026. There is approximately $<span id="xdx_906_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_pn5n6_c20250401__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv2zFyzwkV2i" title="Incremental stock compensation expense">0.1</span>
million of unrecognized stock-based compensation expense for the 2026 Option Repricing which is expected to be expensed over the
weighted average remaining service period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8GgcLZxmMqi" title="Weighted average remaining service, period">1.5</span>
years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 22, 2024, the Company&#8217;s Board of Directors approved a  stock option repricing (&#8220;2025 Option
Repricing&#8221;), effective November 22, 2024 (&#8220;Effective Date&#8221;). The 2025 Option Repricing was undertaken in
accordance with, and as permitted by, the Company&#8217;s Amended 2013 Plan. Pursuant to the 2025 Option Repricing, all options
granted pursuant to the Amended 2013 Plan that are held by Company Board members, officers, and employees expected to continue
providing services to the Company were repriced, to the extent such options had an exercise price in excess of $<span id="xdx_905_eus-gaap--StockOptionExercisePriceIncrease_c20241122__20241122__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_z0rsuvyTo3o7" title="Option exercise price">10.80</span>,
the closing price per share of the Common Stock as reported on The Nasdaq Stock Market on November 22, 2024. As of the Effective
Date, all such options were repriced such that the exercise price per share was reduced to $<span id="xdx_90E_eus-gaap--StockOptionExercisePriceIncrease_c20241122__20241122__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zsObHSdTdk2g" title="Option exercise price">10.80</span>.
The modification resulted in incremental stock compensation expense of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pn5n6_c20250401__20260331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zDDutejXQDq6" title="Stock based compensation">0.3</span>
million and $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pn5n6_c20240401__20250331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zfvgpZ0uQEsf" title="Stock based compensation">1.6</span>
million recognized during the years ended March 31, 2026 and March 31, 2025, respectively. There is approximately $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20260331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zAOkbh72vTs6" title="Unrecognized share based compensation">0.1</span>
million of unrecognized stock-based compensation expense for the 2025 Option Repricing which is expected to be expensed over the
weighted average remaining service period of <span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zvv4n4uVfeua" title="Weighted average remaining service, period">1.0</span>
years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 STOCKHOLDERS&#8217; EQUITY (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s 2021 Beyond Cancer Ltd. Equity Incentive Plan (the &#8220;2021 BC Plan&#8221;) allows for awards to officers, directors,
employees, and consultants of stock options, restricted stock units and restricted shares of Beyond Cancer Ltd.&#8217;s common stock.
The vesting terms of the options issued under the 2021 BC Plan are generally <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zLWQXUFSoA44" title="Vesting period">four years</span> and they expire <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_ze5Wci8JlHvg" title="Expiration period">ten years</span> from the grant date.
On November 3, 2022, the Company&#8217;s Board of Directors approved an amendment to reserve for issuance an additional <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20221103__20221103__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z8RMuCVDnyid" title="Number of additionl shares reserve for issuance">2,000,000</span> shares
of common stock. The 2021 BC Plan has <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20221103__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zWjat4ZfK3Kc" title="Number of shares authorized for issuance">4,000,000</span> shares authorized for issuance. As of March 31, 2026, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_ztc8XZqE76fb" title="Number of shares available for grant">1,745,500</span> shares were available
under the 2021 BC Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zIGS8sGiUi2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the change in stock options for Beyond Cancer for the years ended March 31, 2026 and March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zfNCVrREUPoa" style="display: none">SCHEDULE
OF OPTION ACTIVITY FOR BEYOND CANCER</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price&#8211;-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life- </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(thousands)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Options outstanding as of March 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zltD0lFKYr29" style="width: 11%; text-align: right" title="Number of Options, Outstanding at beginning of period">3,819,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zPStOfDJJPha" style="width: 11%; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period">5.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zC49XGIPXeB4" title="Weighted average remaining contractual life - options, outstanding at beginning of period">8.3</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zQkQLohCA7H2" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z9HQ10n1f8q1" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1243">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXJCIIyEQqsi" style="text-align: right" title="Weighted Average Exercise Price of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zltdWXYxbUwe" style="text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1247">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zlfL50p2nf13" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1249">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zJVpcZOWGyt5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(1,002,750</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zAOoFNdvqLue" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price of Options, Forfeited">5.50</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding as of March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXK1Ydo1CHvg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at beginning of period">2,816,250</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_ziyVB8iwOtZ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period">5.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXJXgcJK8rt6" title="Weighted average remaining contractual life - options, outstanding at beginning of period">7.2</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zxp6GCLrGnW5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1261">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zlzImYg5etR9" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zZDm8lqi3LR7" style="text-align: right" title="Weighted Average Exercise Price of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zoq5ry3qY7ag" style="text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1267">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zD5GzidrBIub" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBUKt3EcL5bd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(561,750</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z3mQDWmOLBU7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price of Options, Forfeited">5.50</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z5dckoFlZlg9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at ending of period">2,254,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zyCXarkEuvMa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at ending of period">5.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zIckJ2fTos8i" title="Weighted average remaining contractual life - options, outstanding at beginning of period">6.2</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zqkBxlY4doP" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding at end of period"><span style="-sec-ix-hidden: xdx2ixbrl1281">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBQOTMmBnKuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Exercisable">1,975,750</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBInmxPusKql" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Exercisable">5.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zC6JnOcvBVvk" title="Weighted Average Remaining Contractual Life of Options, Exercisable">6.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zmg18381u15a" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zpuVNGb6PPE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026, the Company had unrecognized stock-based compensation expense for the stock options in the 2021 BC Plan of approximately
$<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zNY33knzW7lc" title="Unrecognized stock-based compensation expense">0.4</span> million which is expected to be expensed over the weighted average remaining service period of <span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zcvrBj2eEqGi" title="Weighted average remaining service period">1.0</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s 2023 NeuroNos Ltd. Equity Incentive Plan (the &#8220;2023 NNOS Plan&#8221;) allows for awards to officers, directors,
employees, and consultants of stock options, restricted stock units and restricted shares of NeuroNos Ltd.&#8217;s common stock. The
vesting terms of the options issued under the 2023 NNOS Plan are generally four years and they expire ten years from the grant date.
On March 31, 2025, the Company&#8217;s Board of Directors approved to reserve for issuance <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zBNAjntTRQ85" title="Stock option shares authorized for issuance">1,725,000</span> shares of common stock. As of March
31, 2026, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zFZlWNrsgHt" title="Number of shares available for grant">465,670</span> shares were available under the 2023 NNOS Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zh9GKH4NRrL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the change in stock options for NeuroNos for the years ended March 31, 2026 and March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zzqGzZlZI6Se">SCHEDULE
OF OPTION ACTIVITY FOR NEURONOS</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price&#8211;-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life- </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(thousands)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding as of March 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zzh1y1MycSpa" style="text-align: right" title="Number of Options, Outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zePHo2mON8Nk" style="text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zRuWKHUO1Mxc" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zKXJyXen5OXc" style="width: 11%; text-align: right" title="Number of Options, Granted">1,224,139</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z3HPlgV7lHh9" style="width: 11%; text-align: right" title="Weighted Average Exercise Price of Options, Granted">0.14</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zBGUDjzUIFMg" style="text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1311">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zYMwGOOXRvJi" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1313">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zapFoZDRg2ni" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zEolIhcf8rt8" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price - options, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1317">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding as of March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zgHjMFZpIVri" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at beginning of period">1,224,139</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zqTaYDZ2V9xf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period">0.14</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zzFD91herDCk" title="Weighted average remaining contractual life - options, outstanding at beginning of period">9.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_za87e7pYMJwa" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">3,501</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z5YWYvHEN6g1" style="text-align: right" title="Number of Options, Granted">169,913</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_ziEsb2HyfQW3" style="text-align: right" title="Weighted Average Exercise Price of Options, Granted">3.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zecF9JIVa7hf" style="text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1331">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z3K6NYELNkK4" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1333">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zCx9aDsAiMYh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(134,723</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zRDQ9XILrgp" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price - options, forfeited">2.82</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zfEaOkfKvcG1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at ending of period">1,259,329</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zx5hb3vD5vla" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at ending of period">0.24</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zhz8aKY5TdIa" title="Weighted Average Remaining Contractual Life of Options, Outstanding">8.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_znqU4pApiRS8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at ending of period">3,477</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zCGea6Lpnox2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Exercisable">622,341</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zNIF39u3q2A1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Exercisable">0.19</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zLCSAYm36C8j" title="Weighted Average Remaining Contractual Life of Options, Exercisable">8.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_znZ7QXjs68d9" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable">1,748</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zVs91w4EOC65" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, the Company had unrecognized stock-based compensation expense for the stock options in the 2023 NNOS Plan of approximately
$<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zagRgEKWfWx7" title="Unrecognized stock-based compensation expense">0.1</span> million which is expected to be expensed over the weighted average remaining service period of <span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_ze9eKe5Zg4K6" title="Weighted average remaining service period">1.5</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended March 31, 2026 and March 31, 2025, the weighted average fair value of options granted was $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z4oMCTJiTphg" title="Weighted average fair value of options">2.38</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z4dSNfx9BgQ" title="Weighted average fair value of options">0.11</span> per share,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 STOCKHOLDERS&#8217; EQUITY (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_znuBCNu7JmO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following was utilized to calculate the fair value of options on the date of grant:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z5l5Hkq90oM9" style="display: none">SCHEDULE
OF FAIR VALUE OF OPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk -free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250401__20260331__srt--RangeAxis__srt--MinimumMember_ztqHuUTMVkU6" title="Risk-free interest rate">3.7</span>-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250401__20260331__srt--RangeAxis__srt--MaximumMember_z5Weo3qWwYK6" title="Risk-free interest rate">4.2</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MinimumMember_zOk3WASdJaOc" title="Risk-free interest rate">3.6</span>-<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MaximumMember_zD0V6CXOeHYk" title="Risk-free interest rate">4.4</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (Beyond Air)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MinimumMember_zV4T83F0opSe" title="Expected volatility">91.6</span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MaximumMember_z8EHPpW1UOH2" title="Expected volatility">106.2</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MinimumMember_z8BzrqrUvkL6" title="Expected volatility">83.6</span>-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MaximumMember_z8rmUTALNZgf" title="Expected volatility">89.9</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (Beyond Cancer)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zl2io9hAH0Rl" title="Expected volatility">N/A</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zaRevvw1K9Bc" title="Expected volatility">N/A</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Expected volatility (NeuroNos)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember_zVJpALKf2QR1" title="Expected volatility">95.0</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember_zJibdoGTAv21" title="Expected volatility">95.0</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250401__20260331_zYE7J99l4Uc7" title="Dividend yield">0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240401__20250331_zh1kgth8vmC5" title="Dividend yield">0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected terms (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250401__20260331_zXpIeUoRAko2" title="Expected term (in years)">6.25</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240401__20250331_zh1VdwzsZHpd" title="Expected term (in years)">6.25</span></td><td style="text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AC_zoeQvMI5zFue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that the fair value per share of NeuroNos&#8217; common stock to be $<span id="xdx_902_eus-gaap--SharePrice_iI_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--BeyondCancerLtdMember__srt--RangeAxis__srt--MinimumMember_zxB9DeC3pbbe" title="Fair value per share">0.14</span> at the grant date during the year ended
March 31, 2025 based on a third-party valuation, and to be $<span id="xdx_905_eus-gaap--SharePrice_iI_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--BeyondCancerLtdMember__srt--RangeAxis__srt--MinimumMember_zFL8ZWaYAvEg" title="Fair value per share">3.00</span> at the grant date during the year ended March 31, 2026 based on the
valuation of common stock purchased by external investors during the fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zC0pH738OJH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the components of stock-based compensation expense which included stock options and restricted stock for the years
ended March 31, 2026 and March 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zEz0Aj0KcgYk" style="display: none">SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250401__20260331_zq7dXjpYPMUl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240401__20250331_zveT734dr9Ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--ResearchAndDevelopmentExpense_zphXUEaGZq5c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,153</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">471</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zRBl1sXybtyd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,129</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,675</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_pn3n3_z3LePV7u1DXh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,282</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,146</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zfF4diNi9jN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 8, 2025, the Company entered into an inducement offer letter agreement (&#8220;Inducement Letter&#8221;) with certain holders
of the September 2024 equity offering common stock warrants (&#8220;Existing Warrants&#8221;). Pursuant to the Inducement Letter, such
holders immediately exercised some of all of their respective outstanding Existing Warrants to purchase up to an aggregate of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCWggDhRYsrf" title=" Warrants to purchase">1,439,128</span>
shares of common stock at a reduced exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXRCVt4TGSg4" title="Warrants exercise price">2.21</span>. The proceeds to the Company from the exercise of the Existing Warrants were
approximately $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250908__20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcY3l8xsTcV3" title="Warrants Exercise">2.9</span> million, net of placement agent fees and other offering expenses of $<span id="xdx_900_eus-gaap--PaymentsForFees_pn5n6_c20250908__20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOBFXVVzcqni" title="Other fees">0.2</span> million and $<span id="xdx_906_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhPEtRmUtj17" title="Other fees">0.1</span> million, respectively. In
consideration of the inducement offer, the Company issued new common stock warrants to purchase up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250908__20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTNLVz8hWp3c" title="Stock issues during the period, shares">719,562</span> shares of common stock
for a purchase price of $<span id="xdx_901_eus-gaap--WarrantExercisePriceIncrease_c20250908__20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBCIjLgWKzq6" title="Warrant exercise price">0.125</span> per share of common stock underlying the new warrant. The new warrants have an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z29sbL2ZXUv9" title="Warrant exercise price">2.21</span>
per share and are immediately exercisable, with a term of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcd4mUbteaX7" title="Weighted average remaining service period">five years</span> from the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2025, warrants to purchase up to an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251103__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zpsuzE1mXdri" title="Warrants to purchase">512,821</span> of Company common stock were issued as part of the Amended Loan
Agreement with certain lenders including its director Robert Carey at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251103__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zJrg5qzIF9O9" title="Warrants price">1.95</span> per common stock warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 16, 2026, warrants to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260116__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSBViBSPGM7f" title="Warrants to purchase">3,930,818</span> of Company common stock were issued to certain institutional investors
at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260116__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJVtliP4DcM" title="Warrants price">1.147</span> per common stock warrant. The warrant exercise price was calculated at the 5-trading day average closing
share price as of January 13, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 16, 2026, pre-funded warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260116__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_z4FMmTJtfNxl" title="Warrants to purchase">3,405,828 </span>of Company common stock were issued to certain institutional investors
at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260116__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_zAvFRcAkgBal" title="Warrants price">0.0001</span> per common stock warrant. During the year ended March 31, 2026, holders exercised <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250116__20250116__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_zOYbEb15o8a8" title="Stock issued during the period, shares">1,263,215</span> of these 2026
Pre-Funded Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVuaGqiwngbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s outstanding warrants as of March 31, 2026 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_znadyXZOO54l" style="display: none">SUMMARY
OF OUTSTANDING WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Warrant Holders</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify">NitricGen agreement</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z4kShwuooEzd" style="width: 11%; text-align: right" title="Number of Warrants">4,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_zrrfqWfjyFs9" style="width: 11%; text-align: right" title="Exercise Price">138.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z82UsnuOhuai" style="width: 11%; text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1450">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 17%; text-align: center"><span id="xdx_90B_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z67dCquqcvBe" title="Date of Expiration">January 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Avenue agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_z3qE4BXpSG88" style="text-align: right" title="Number of Warrants">11,693</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zE1o60N5QRK3" style="text-align: right" title="Exercise Price">7.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zYBi17WHaRG6" style="text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1458">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zV23M8znsHYj" title="Date of Expiration">June 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">March 2024 raise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zw5FeoLMNUkg" style="text-align: right" title="Number of Warrants">481,936</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zvFMa9PYPi5" style="text-align: right" title="Exercise Price">45.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_z4lkHpV5luNi" style="text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1466">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zLdjKKNcg7hk" title="Date of Expiration">March 2027</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Avenue extension agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zPAZzCg5Omcj" style="text-align: right" title="Number of Warrants">5,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zcfOWm9cqmn5" style="text-align: right" title="Exercise Price">25.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zx4ik2vBNlC5" style="text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1474">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zwt1QWSGlGCl" title="Date of Expiration">June 2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">September 2024 equity offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zP5rs7vYn62b" style="text-align: right" title="Number of Warrants">555,229</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_z8gTZM698Bt8" style="text-align: right" title="Exercise Price">7.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zeKM7h9fB06" style="text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1482">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zmGsa4tmgTH2" title="Date of Expiration">September 2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">September 2024 debt instrument</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zFkIDRzrQlDh" style="text-align: right" title="Number of Warrants">1,270,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zicWS367XVkj" style="text-align: right" title="Exercise Price">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zvtoJXRSuLOc" style="text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1490">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zKYCGJ3Wszh7" title="Date of Expiration">September 2029 / November 2030</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">September 2025 inducement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zrk8L3PstUP1" style="text-align: right" title="Number of Warrants">719,562</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zcTuX5vJXQ04" style="text-align: right" title="Exercise Price">2.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zJ9gj1dntk87" style="text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1498">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zTonXyrH1eCj" title="Date of Expiration">September 2030</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">January 2026 equity offering</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zMqAK5J6CSs3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants">3,930,818</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zUXDNfH4EXAj" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price">1.147</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_z5zH5sGpVSNl" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1506">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zReAqHOnTIq8" title="Date of Expiration">January 2031</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zpqKgoG7zFA3" style="text-align: right" title="Number of Warrants">6,979,034</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zRyE1w5e87e4" style="text-align: right" title="Exercise Price">5.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zpF3Vh78GCg2" style="text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1514">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pre-funded warrants (Sep-2024 offering)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_ziNtUpjIizjh" style="text-align: right" title="Number of Warrants">220,006</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_zut3bvqrXnz9" style="text-align: right" title="Exercise Price">0.002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_ziio5DBdmHZj" style="text-align: right" title="Intrinsic Value">151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_zTe4TE5Bfixi" title="Date of Expiration">September 2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Pre-funded warrants (Jan-2026 offering)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zTM446FKRBO9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants">2,142,613</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zzgI25s9Rhc1" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price">0.0001</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zzhhUwr98aWk" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value">1,479</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_901_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zTy0FS3fMkb9" title="Date of Expiration">January 2031</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331_zDKoi3QCk5ye" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants">9,341,653</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331_zGE9blo9TObb" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise Price">3.773</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331_zsRu6JJ5ajh5" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value">1,630</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zCs78da6MJB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ESPP</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 4, 2021, the stockholders approved the 2021 Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The purpose of the ESPP is to encourage
and to enable eligible employees of the Company, through after-tax payroll deductions, to acquire proprietary interests in the Company
through the purchase and ownership of shares of Stock. The ESPP is intended to benefit the Company and its stockholders by (a) incentivizing
participants to contribute to the success of the Company and to operate and manage the Company&#8217;s business in a manner that will
provide for the Company&#8217;s long-term growth and profitability and that will benefit its stockholders and other important stakeholders
and (b) encouraging participants to remain in the employ of the Company. As of March 31, 2026 and March 31, 2025, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEmployeeStockPurchasePlanMember_zTKJ4Bf4f9Lc" title="Number of shares issued"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEmployeeStockPurchasePlanMember_zXsTm3f4PXRl" title="Number of shares issued">no</span></span> shares were issued
under the ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 1.D.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479921/505-20-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 1.B.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480148/855-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS AND PREPAID EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS AND PREPAID EXPENSES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--OtherCurrentAssetsTextBlock_zFJmrFKcjcPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 <span id="xdx_829_z8Bw8CKCb5M5">OTHER CURRENT ASSETS AND PREPAID EXPENSES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z12r0YX9rOK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of other current assets and prepaid expenses as of March 31, 2026 and March 31, 2025 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zWlHKa80qD8c" style="display: none">SCHEDULE
OF OTHER CURRENT ASSETS AND PREPAID EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20260331_zTQvj9c1CA6i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20250331_z3gnSdYgdLL5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzff3_z3DrsaFKYFsj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">696</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">108</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidInsurance_iI_maPEAOAzff3_z17lBgx71299" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">579</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">817</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidRent_iI_maPEAOAzff3_zzYTebrULgoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid rents and tenant improvement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidTaxes_iI_maPEAOAzff3_zVlyDEphLZT3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Value added tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DepositsAssets_iI_maPEAOAzff3_zsExCHma4Syg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deposits to secure manufacturing materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,377</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Supplies_iI_maPEAOAzff3_zLHwcz0ZdJjc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Demonstration materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_maPEAOAzff3_zAoTAMHnW28f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">190</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">203</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzff3_z1LDZg4eceVg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total other current assets and prepaid expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,012</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,743</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zZjeLdcENH49" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zcVMWyY4y1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 <span id="xdx_828_zKczuug6aX78">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zZTkvZpdS6Ah" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of accrued expenses and other current liabilities as of March 31, 2026 and March 31, 2025 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zIdDrAHEKJdb" style="display: none">SUMMARY OF ACCRUED EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20260331_zgmGMcKnZwQ" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250331_zt51FMOpjwUb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentExpenses_iI_pn3n3_maTSAEzACS_zI7vqb8Et3Ib" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">16</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">360</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maTSAEzACS_z07t4i6zH1yf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maTSAEzACS_zSO1iQsJpyy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Employee salaries and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">465</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">924</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--InterestSeveranceCurrent_iI_pn3n3_maTSAEzACS_z2jeCUo66EU9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued severance<span id="xdx_F4C_zPEwRQVV9dUg">*</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">696</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1584">-</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_pn3n3_maTSAEzACS_zAZ3jpsVd2n5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1587">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredRevenueCurrent_iI_pn3n3_maTSAEzACS_z9sLbDACDPh1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1590">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--GoodsReceivedNotInvoiced_iI_pn3n3_maTSAEzACS_z6hXfThxgJmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Goods received not invoiced</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maTSAEzACS_zFG2iVnQ3jS" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">143</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">223</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_pn3n3_mtTSAEzACS_zMAwvGTeAEbc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,372</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,045</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zBXqbMPPsWId" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F08_zPeN4BuLIU4e" style="width: 15pt; text-align: right">*</td><td style="text-align: justify"><span id="xdx_F15_zBxnU1wW0g4i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the
terms of the Release Agreement with Steve Lisi, former CEO, the Company is obligated to pay Mr. Lisi $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQUNDUlVFRCBFWFBFTlNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--Cash_iI_c20260331__srt--TitleOfIndividualAxis__custom--SteveLisiMember_zzRrwFGbAO1b">650,000</span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in cash compensation over 12 months. After expected employer
taxes and benefits, the Company accrued $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQUNDUlVFRCBFWFBFTlNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--TaxesPayableCurrent_iI_pn5n6_c20260331__srt--TitleOfIndividualAxis__custom--SteveLisiMember_zi71LrIwbDJe">0.7</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million The Company shall also pay Mr. Lisi COBRA premiums
for 12 months, as more specifically described in the Release Agreement. All unvested options and all unvested stock restriction unit
awards held by Mr. Lisi as of March 27, 2026, shall be accelerated and shall immediately vest, and shall continue to remain exercisable
for twenty-four (24) months from March 27, 2026.</span></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zcWR3kj6vu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 <span id="xdx_820_zlb7WdAgQu14">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lease
population</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases various office facilities under non-cancelable operating leases that expire at various dates through 2031. The
Company does not have any finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2026, <span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20260301__20260331_zzqP9gcxdedc" title="Operation lease description">the Company entered into a second amendment to lease of one of its facilities (the &#8220;Lease Amendment&#8221;). The Lease
Amendment extended the lease for an additional three years through May 31, 2029 with fixed monthly base rent amounts through the extended
term</span>. The Company accounted for the Lease Amendment on the effective date, resulting in the remeasurement of the operating lease liability
with a corresponding adjustment to the right-of-use asset in the amount of $<span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_pn5n6_c20260301__20260331_zKALk18yntGe" title="Operating lease liability">0.1</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2025, <span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20250401__20250430_zvnCLbyvoJU4" title="Operation lease description">the Company entered into an agreement to sublease the Beyond Cancer office space in Atlanta, Georgia beginning June 1, 2025
and continuing through September 30, 2026 coinciding with the termination of the existing lease.</span> The sublease has been classified as
an operating lease by the Company. Sublease rental income offsets the monthly rental expense from the Company&#8217;s lease of the office,
and is recorded as reduction of selling, general, and administrative expenses in the Company&#8217;s consolidated statements of operation
and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no new leases entered into during the years ended March 31, 2026 and March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lease
position</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the lease-related assets and liabilities recorded on the Company&#8217;s consolidated balance sheets as of
March 31, 2026 and March 31, 2025 (in thousands):</span></p>

<p id="xdx_895_ecustom--ScheduleOfOperatingLeaseLiabilityTableTextBlock_zzGG9uvKCL88" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zWw6wivgAbN8" style="display: none">SCHEDULE
OF OPERATING LEASE LIABILITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20260331_ztxAbLxHn2Sk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20250331_zUIRFzHnw3P6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zGiI7WhnLF96" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Right-of-use assets</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">1,193</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">1,706</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzD8e_zijA2SGcibBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability short-term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">321</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">396</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzD8e_zZY66ViD8VS6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Operating lease liability long-term</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,023</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,486</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzD8e_zwYBqLLf2B5h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,344</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,882</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average remaining lease term &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260331_znOjxmBlimJ4" title="Weighted Average Remaining Lease Term">4.5 </span>years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250331_zzCirPO695al" title="Weighted Average Remaining Lease Term">5.0</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260331_zWu3VTFvafml" title="Weighted-average discount rate - operating leases">8.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20250331_zaZgJwELdgHh" title="Weighted-average discount rate - operating leases">8.3</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A4_z2t3MkU6Ptg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lease
costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zF2ZNa3nJYH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the lease-related costs for the years ended March 31, 2026 and March 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zpu05L1SLtJ7">SCHEDULE
OF LEASE RELATED COSTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250401__20260331_zENbH7iuWro5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240401__20250331_zBYPaefONGOj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseCost_pn3n3_maLCzzCQ_z0My6r6OOnOd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">505</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">539</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzzCQ_z2H9Zw5Chtsc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short-term lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">261</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--SubleaseIncome_iN_pn3n3_di_msLCzzCQ_zxSykFRXTka2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Sublease income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(49</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1643">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LeaseCost_iT_pn3n3_mtLCzzCQ_zXlAIoIONgAi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">544</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zWf1ZEDrGz98" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
lease information</i></span></p>

<p id="xdx_890_ecustom--OtherLeaseTableTextBlock_zKiHMb2MucUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zb9C4Lawqlg" style="display: none">SCHEDULE OF LEASE OTHER INFORMATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250401__20260331_zWe37xsnyjM2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeasePayments_pn3n3_zOlj2msqDkfl" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Operating cash flows for operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">532</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zzcHPX81UPI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash
operating lease right-of-use assets&#160;obtained in exchange for operating lease liabilities were $<span id="xdx_90B_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn5n6_c20250401__20260331_zKuv5wkJEpOg">0.1</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
and $<span id="xdx_901_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20240401__20250331_zYEConylG9sf" title="Operating lease liability in exchange">0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
during the years ended March 31, 2026 and March 31, 2025, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zYXW08BCXxjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zfZ5k3klDSH3">SCHEDULE
OF MATURITY OF LEASE LIABILITIES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Maturity of Lease Liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20260331_zhBNqVEJf3R2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payments remaining for the year ended March 31:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzQlL_z6NZJokfnDB4" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">2027</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">419</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzQlL_zRBqnociW0W5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzQlL_zEHihp9ptXke" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzQlL_zxRICOmjHPt5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzQlL_zYy81r2jjSLd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2031</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">266</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzQlL_zNPYuOxJJLYb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">60</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzQlL_zEIJB56tliha" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,623</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zJZIK5zKLAK6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: amount of lease payments representing interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(279</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z6oBkRfqQNGg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of future lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,344</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zA20lp6ReG84" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK</a></td>
<td class="text"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zIltlnQJNM19" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 <span id="xdx_820_zKKZ4fiPRS2">BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 260, <i>Earnings Per Share,</i> warrants that are accounted for as liabilities which are potentially dilutive have
not been included in diluted earnings per share as they would have been anti-dilutive during the years ended March 31, 2026 and March
31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znacKb9NFTD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following potentially dilutive securities were not included in the calculation of diluted net loss per share attributable to common stockholders
of Beyond Air, Inc. because their effect would have been anti-dilutive for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z0HFVm5qSmd3" style="display: none">SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250401__20260331_zyCJZViThJc3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240401__20250331_zvW3CQlTZx3h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zYcoqRAL4887" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Common stock warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">6,979,034</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">3,254,967</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zsqFJjyPz7d7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">756,749</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">739,214</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zHMyFKgsmVJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Restricted shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,485</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,265</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zShpzar5v0Ak" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,745,268</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,012,446</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_znCfEUbDVO44" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Anti-dilutive securities</span></td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">7,745,268</td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">4,012,446</td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AA_zI6lxCq6umm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s pre-funded warrants of <span id="xdx_90B_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_c20250401__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantsMember_zTydC4CF8WE4" title="Warrants included in calculation of diluted net loss per share">2,362,619</span> and <span id="xdx_90A_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantsMember_zkgDqDhZVBQj" title="Warrants included in calculation of diluted net loss per share">606,367</span> as of March 31, 2026 and March 31, 2025, respectively, were included in
the calculation of diluted net loss per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481468/505-20-05-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">LOANS</a></td>
<td class="text"><p id="xdx_804_eus-gaap--LongTermDebtTextBlock_zPjnGYjQDMTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 <span id="xdx_82A_zvqtcOxFaPn6">LOANS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zzHzFpRkT6p1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of long-term debt as of March 31, 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zojEY2G15B6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z3ToXf20G5Gk" style="display: none">SCHEDULE
OF LONG-TERM DEBT</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20261231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zL5Ig4WSDLR9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Loan</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Agreement</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20261231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zMhw6lWWPJd6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Promissory</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Note</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20261231_zX7s1Eq1UJHe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_maDICAzlrH_zCCbDbJ9awai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Principal balance outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">13,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">12,799</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">26,299</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PaidInKindInterestAmount_iI_pn3n3_maDICAzlrH_ztTaDTxYSjp2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Paid in kind interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,459</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1707">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,459</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msDICAzlrH_zLKaDOiByFV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,343</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,576</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,919</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--AmortizationOfDebtDiscount_iI_pn3n3_maDICAzlrH_zfUWhpFBibKb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Amortization of debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">427</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">373</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">800</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzlrH_zG0CTfZdDvje" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">12,043</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">9,596</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">21,639</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of long-term debt as of March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20260331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zGAkSp7buzkh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Loan</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Agreement</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_maDICAzlrH_zc6Xv80Oarij" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Principal balance outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">11,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PaidInKindInterestAmount_iI_pn3n3_maDICAzlrH_zTk7sSSosZaf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Paid in kind interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">696</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msDICAzlrH_zAnx0rBu8kUj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,249</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--AmortizationOfDebtDiscount_iI_pn3n3_maDICAzlrH_zSSEH88fYNYj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Amortization of debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzlrH_zunJpsAhuoKe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">9,197</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zfumGkXDjAvf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loan
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2024, the Company entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) for a secured loan with certain
lenders, including its former Chief Executive Officer Steven Lisi and director Robert Carey, for an aggregate principal balance of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zSeJPuwhb726" title="Principal amount">11.5</span>
million. The Loan Agreement was approved by each of the Company&#8217;s independent and disinterested directors, following the receipt
of a recommendation from an independent investment bank. The Loan Agreement provides for the following terms: (i) principal amount of
$<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zRQL7pDpS4Dk" title="Principal amount">11,500,000</span>; (ii) ten-year term; (iii) interest of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zv4Ssb4RvABg" title="Interest rate">15</span>% per annum of which <span id="xdx_900_ecustom--DebtInstrumentInterestRatePayableInCashPercentage_iI_pid_dp_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zzCfJ9qBsOXj" title="Percentage of interest payable in cash">3</span>% shall be payable in cash and <span id="xdx_90A_ecustom--DebtInstrumentInterestRatePayableInKindPercentage_iI_pid_dp_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zHW6qMqYPyX1" title="Percentage of interest payable in kind">12</span>% payable in kind through
June 30, 2026 and thereafter all in cash; (iv) a royalty interest of <span id="xdx_907_ecustom--RoyaltyInterestPercentage_iI_pid_dp_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z9cYMlNaL328" title="Royalty interest percentage">8</span>% of the Company&#8217;s net sales on a quarterly basis from July
2026 until the facility is repaid in full; (v) the Company&#8217;s obligations will be secured by substantially all of the Company&#8217;s
assets and (vi) the Company issued the lenders warrants to purchase shares of the Company&#8217;s common stock at an exercise price,
adjusted for the 2025 Reverse Stock Split, of $<span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zB33Q5uLvPx2" title="Share price">7.59</span> per share. On November 3, 2025, the parties entered into a waiver agreement pursuant
to which the Loan Agreement lenders consented to the Company&#8217;s issuance of the Streeterville Note in exchange for reducing the
exercise price from $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251102__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z8g3hh55rqac" title="Exercise price">7.59</span> per share to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251103__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zAXn0zNfRGfl" title="Exercise price">1.95</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2025, the Company received $<span id="xdx_90F_eus-gaap--ProceedsFromSaleOfLoansReceivable_pn5n6_c20250602__20250602__srt--TitleOfIndividualAxis__srt--DirectorMember_znqGLQQn1lSg" title="Advanced financing from related party">2.0</span> million of advanced financing from a related party, director Robert Carey who is also an existing
lender under its Loan Agreement (&#8220;Additional Loans&#8221;). On November 3, 2025, the Company amended and restated the original
Loan Agreement (as amended, the &#8220;Amended Loan Agreement&#8221;) to provide for and finalize the terms of the $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20251103__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zT8xvJ2u5Tel" title="Principal amount">2.0</span> million Additional
Loans and the issuance of new <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dtY_c20251103__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zdJ0ifcXUBie" style="display: none" title="Warrants term">5</span>five-year warrants to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251103__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zX9VFPNobrT6" title="Warrants to purchase common stock">512,821</span> shares of the Company&#8217;s common stock (the &#8220;Supplemental
Warrants&#8221;) with an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251103__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zqjqxcdpwhOl" title="Warrants exercise price">1.95</span> per share and subject to the same terms and conditions applicable to the existing warrants
issued under the original Loan and Security Agreement. The amendment was accounted for as a modification under ASC 470, <i>Debt</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the repayments under the Amended Loan Agreement are based on a fixed percentage of future net sales, the timing and amounts of future
principal payments may vary with the Company&#8217;s performance. The outstanding debt balance has been classified in the consolidated
balance sheets based on the Company&#8217;s current estimate of the repayment timing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Promissory
Note</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2025, the Company entered into and closed on a note purchase agreement (the &#8220;Note Purchase Agreement&#8221;) with Streeterville
Capital LLC (&#8220;Streeterville&#8221;), which provided for the issuance of a secured promissory note in the principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zCBNIXvczykb" title="Principal amount">12.0</span>
million (the &#8220;Note&#8221;). The principal amount of the Note is due <span id="xdx_906_eus-gaap--DebtInstrumentTerm_pid_dtM_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zSiqX6fqwHSb" title="Debt instrument term">24</span> months following the date of issuance. <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateTerms_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zMrBQLqdvquk" title="Interest rate description">Interest will accrue
at the rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z5kx00jXTu8k" title="Debt instrument, interest rate">15</span>% per annum, with no interest accruing for the first 12 months following issuance; provided however, that Streeterville
is guaranteed 12 months of interest, or $1.8 million, even if the Note is redeemed or prepaid prior to the maturity date.</span> Of the total
$<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zZSx1ylf8VO7" title="Principal amount">12.0</span> million Note, $<span id="xdx_909_ecustom--DebtInstrumentOfRestrictedAccount_pn5n6_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zI4KD9inYF8j" title="Principal in restricted account">6.0</span> million was placed in a restricted account and will be accessible by the Company as the first $<span id="xdx_902_eus-gaap--DebtInstrumentRepaidPrincipal_pn5n6_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z9uOGdR4QJkg" title="Debt instrument, principal repayable">6.0</span> million is
repaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Note contains an embedded put feature that meet the definition of an embedded derivative in accordance with ASC 815 (Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
January 2026, Streeterville elected to purchase <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pn5n6_c20260101__20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zcFwmtSSawUe" title="Shares issued of common stock">1.6</span>
million shares of common stock at an average price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zxyUVRsywd98" title="Share price">0.73</span>
per share based on the average closing stock price during the five trading days immediately preceding delivery of the offset notice,
which offset principal of approximately $<span id="xdx_908_eus-gaap--DebtConversionOriginalDebtAmount1_pn5n6_c20260101__20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zM6t6AWrO1yf" title="Debt amount">1.2 </span>million
outstanding under the Note. The average fair value of the <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zF3tFo0PyJJf" title="Shares available for resale">1.6 </span>million shares of common stock issued during January 2026 was $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zzHkEVtbanTi" title="Price per share">2.09</span>
per share (Note 4). The difference in the principal offset and the fair value of stock issued of $<span id="xdx_902_eus-gaap--CreditRiskDerivativeLiabilitiesAtFairValue_iI_pn5n6_c20260331_zg1IjJM7KZFl" title="Fair value of the derivative liability">2.2</span> million was recorded to the
fair value of the embedded derivative liability and subsequent settlement of such feature (Note 2). The conversion of debt to equity
through the embedded put feature is treated as a partial extinguishment of the Note, and therefore proportionate amounts of
unamortized debt discount and financing costs were written-off during the year ended March 31, 2026, resulting in a loss of $<span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20250401__20260331__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zHv1yINTMnJk" title="Loss on extinguishment of debt">0.2</span>
million recorded within Loss on extinguishment of debt in the consolidated statement of operations and comprehensive loss. In
connection with this reduction to the principal balance outstanding, approximately $<span id="xdx_90E_ecustom--UnrestrictedCash_pn5n6_c20250401__20260331__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zhC1OZx6xyN9" title="Unrestricted cash">0.6</span>
million was released from restricted cash during the year ended March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the contractual terms of the Note, the Company was charged a one-time monitoring fee (as defined within the Note) of $<span id="xdx_90C_eus-gaap--ProfessionalFees_pn5n6_c20260204__20260204__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zkKSyLMEbBo8" title="Monitoring fees">1.9</span> million
that is recognized as part of the Note&#8217;s principal outstanding balance on February 4, 2026. The monitoring fee will be credited
back to the Company, on a pro-rata basis, if any principal payment is made in cash and certain market conditions are met. The Company
determined the monitoring fee is accounted for as an additional debt discount equivalent, with the offsetting increase to the long-term
debt principal balance and will be amortized into interest expense over the remaining term of the Note under the effective interest method.
If cash principal payments occur in the future, a pro-rata portion of the monitoring fee will be waived, which will reduce the obligation
and a gain on extinguishment (or reduction of interest expense) will be recognized at such time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOAN PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">LOAN PAYABLE</a></td>
<td class="text"><p id="xdx_808_eus-gaap--ShortTermDebtTextBlock_zHH8DUE0t7B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 <span><span id="xdx_822_zVsF2eJzsJce">LOAN PAYABLE</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfShortTermDebtTextBlock_zWmY6WlW2Bhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026 and March 31, 2025 in connection with the Company&#8217;s insurance policy, a loan was used to finance part of the
premium. The details concerning the loan are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zZnUqiWNQjDe" style="display: none">SCHEDULE
OF LOAN PAYABLE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Amount outstanding (thousands)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--LoansPayable_iI_pn3n3_c20260331_ztKcuScFwnHj" style="width: 16%; text-align: right" title="Amount outstanding">401</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--LoansPayable_iI_pn3n3_c20250331_zRCA5yIsJiHc" style="width: 16%; text-align: right" title="Amount outstanding">579</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Monthly payments (thousands)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20250401__20260331_z1kwqspy89c" style="text-align: right" title="Monthly payments">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20240401__20250331_zW8jO4dHw282" style="text-align: right" title="Monthly payments">117</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Number of monthly payments remaining</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfPayments_pp0p0_uInteger_c20250401__20260331_zHgrPBwgodW1" style="text-align: right" title="Amount outstanding">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--NumberOfPayments_pp0p0_uInteger_c20240401__20250331_zjA4lwbY4aC7" style="text-align: right" title="Amount outstanding">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260331_zqdl6NpFItlj" title="Interest rate">6.60</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250331_zkMSnfzxTKt2" title="Interest rate">6.25</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Due date</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--LoanPayableDueDateDescription_c20250401__20260331_zGarnnkgKp2i" title="Due date">October 2026</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--LoanPayableDueDateDescription_c20240401__20250331_zXXQMTKBYW6j" title="Due date">August 2025</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_z8TM3awNRtB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zeqA2gPyTPbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 <span id="xdx_82A_zcexPyvWrTHi">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026, the Company has approximately $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zBe4VGp0mmo7" title="Operating loss carryforwards">185.0</span> million, $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--IsraelTaxAuthorityMember_zrNJtb4XaJh2" title="Operating loss carryforwards">30.9</span> million, $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--RevenueCommissionersIrelandMember_zWxZwPTLyqMc" title="Operating loss carryforwards">10.2</span> million and $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__custom--CypriotTaxMember_zTcCBz1t9Gxk" title="Operating loss carryforwards">3.5</span> million of net operating losses
(&#8220;NOL&#8221;) carryforwards for U.S. federal, Israeli, Irish and Cypriot tax purposes, respectively. The U.S. federal NOL carryforwards
of approximately $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331_zRZUv0hWphqk" title="Operating loss carryforwards">1.4</span> million, which were generated prior to March 2018 expire starting in 2035 through 2037. The NOL of approximately
$<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--AwardDateAxis__custom--NoExpirationMember_zHImlo3wUwcc" title="Operating loss carryforwards">183.6</span> million can be carried forward indefinitely but limited to offset <span id="xdx_908_ecustom--OffsetTaxableIncomeRate_pid_dp_uPure_c20240401__20250331__us-gaap--AwardDateAxis__custom--NoExpirationMember_zjdKM5XtW356" title="Taxable income">80</span>% of taxable income. The entire NOL for Israel, Ireland and
Australia can be carried forward indefinitely. The Company also has state NOL carryforwards in the amount of approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zefIREUv0yhf" title="Operating loss carryforwards">89.6</span> million
<span id="xdx_90D_ecustom--OperatingLossCarryforwardsExpirationYears_c20240401__20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zdkNjzcW7mOg">expiring during the years from 2036 to 2043</span>. The Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) has modified the Internal Revenue
Code (&#8220;IRC&#8221;) 174 expenses related to research and development for tax years beginning after December 31, 2021. Under the
TCJA, the Company must now capitalize the expenditures related to research and development activities and amortize over five years for
U.S. activities and 15 years for non-U.S. activities using a mid-year convention. Therefore, the capitalization of research and development
costs in accordance with IRC 174 resulted in a gross deferred tax asset of $<span id="xdx_903_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_pn5n6_c20250331_zBIwA0oQSA7" title="Deferred tax liabilities, deferred expense, capitalized research and development costs">27.2</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has R&amp;D tax credits of $<span id="xdx_905_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20250331__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zw4fPTsn8Arg" title="Tax credit carryforward, amount">3.3</span>
million <span id="xdx_90F_eus-gaap--TaxCreditCarryforwardDescription_c20240401__20250331__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zWIDdc2o6qo8" title="Tax credit carryforward, description">expiring
during the years from 2038 to 2042</span>. The Company has not, as yet, conducted a study of R&amp;D credit carryforwards. This
study may result in an adjustment to the Company&#8217;s R&amp;D credit carryforwards. The Company assessed its uncertain tax
positions and determined that a <span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage_pid_dp_uPure_c20240401__20250331_zDkwvLdOdANe" title="Federal tax percentage">25</span>%
reserve on federal research and development credit is appropriate and in line with industry standards. As of March 31, 2026, the
total amount of unrecognized tax benefits was $<span id="xdx_900_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20260331_zpQZf5PLtSC2" title="Unrecognized tax benefits">0.8</span>
million, exclusive of interest and penalties. A full valuation allowance has been provided against the Company&#8217;s R&amp;D
credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there
would be no impact to the consolidated balance sheets and the consolidated statements of operations and comprehensive loss if an
adjustment were required. No estimated interest or penalties related to unrecognized tax benefits have been recorded as of March 31,
2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 382 of the Internal Revenue Code, changes in the Company&#8217;s ownership may limit the amount of its NOL carryforwards that
could be utilized annually to offset future taxable income, if any. <span id="xdx_90F_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20240401__20250331_zTT7mIhN47Se" title="Income tax limitation description">This limitation would generally apply in the event of a cumulative
change in ownership of the Company of more than 50% within a three-year period.</span> The Company has performed a study as of March 31, 2021
and determined that on or around February 15, 2017 and February 15, 2020 ownership changes for purposes of Section 382 have occurred.
The annual limitations caused by these prior ownership changes will no longer impact the utilizations of NOL&#8217;s after March 31,
2022. The Company has not updated the study since March 31, 2021 and therefore has not determined if any other NOL limitations exist.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zNLfHyoe1cL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of net loss before the provision for income taxes are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zIJHDNGoDaSe" style="display: none">SCHEDULE
OF PROFIT (LOSS) BEFORE TAXES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20250401__20260331_zxB4ZQUTwzIj" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p>
                                                                                                                                                                                                                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2026</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240401__20250331_zVAMGKvLM326" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p>
                                                                                                                                                                                                                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maCITEBzGXx_zjogKc9EmxT4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(27,066</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(42,186</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maCITEBzGXx_z2q1Y7cILYui" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,268</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,293</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCITEBzGXx_zQEImN4wkX2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(34,334</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(48,479</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A5_zH8hVD7BoDRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zZjOPK0bXZmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zNonrJrOSKbj" style="display: none">SCHEDULE
OF DEFERRED TAX ASSET/LIABILITY</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20260331_zllFfvIlsgTh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250331_zH5Q6jejfeY9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz1sA_zL1Z4GsGKgkb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">55,607</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">48,702</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz1sA_znnSsjr9QRUj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,506</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,197</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ResearchAndDevelopmentTaxCreditCapitalization_iI_pn3n3_maDTAGz1sA_zI2WPQtet8x3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development tax credit capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,572</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,066</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz1sA_z2scwFmtHa5" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(111</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation_iI_pn3n3_maDTAGz1sA_zPSD444Stk56" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,803</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,337</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz1sA_z2ADsIKu6imb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,556</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsReservesAndAccruels_iI_pn3n3_maDTAGz1sA_zuLImAvDWkO2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Reserves and accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAsset_iI_pn3n3_maDTAGz1sA_z49r2VUBTyRl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(282</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(298</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxAssetsLeaseLiability_iI_pn3n3_maDTAGz1sA_ziQc5X8Kf8j6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">314</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">333</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_maDTALNzJp8_mtDTAGz1sA_zbZ8VTOv1jya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net deferred tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,240</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzJp8_z4uqPMwirJv" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(69,550</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(64,240</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzJp8_zfAyL6nNPT1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net deferred tax asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1893">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1894">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zZrPOmSULSM" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>BEYOND AIR, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 11 INCOME TAXES (continued)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_897_ecustom--ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock_zoRiUd8BE8gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the principal reasons for the difference between the effective tax rate and the U.S. federal enacted
statutory income tax rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIElOQ09NRSBUQVhFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_905_ecustom--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_pid_dp_uPure_c20250401__20260331_zmMXL9IdAiP" title="Federal income tax rate">21</span>%
for the year ended March 31, 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_z0aG5edMi1p3" style="display: none">SCHEDULE
OF DIFFERENCE EFFECTIVE INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250401__20260331_zF8Hw48YEEAb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzUaV_zb2NKG1uDnL3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt">U.S. federal statutory tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(7,210</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250401__20260331_zTy0B0cm9yB9" style="width: 16%; text-align: right" title="U.S. federal statutory tax rate">21.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40C_ecustom--IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes_pn3n3_maITEBzUaV_zjl1AesKcEP4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Current state and local income taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1904">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes_pid_dp_uPure_c20250401__20260331_zjNpHs698BZk" style="text-align: right" title="Current state and local income taxes, net of federal benefit"><span style="-sec-ix-hidden: xdx2ixbrl1906">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Foreign Tax Effects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 10pt">Ireland</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_hsrt--StatementGeographicalAxis__country--IE_zt0Laqf10zx7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IE_zn3rzANx1XP8" style="text-align: right" title="Change in valuation allowance">(1.28</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_hsrt--StatementGeographicalAxis__country--IE_z9jkx9jgZP7" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 20pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">235</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IE_zXIOqsaaI4sj" style="text-align: right" title="Other">(0.69</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 10pt">Israel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_hsrt--StatementGeographicalAxis__country--IL_maITEBzUaV_zq2weZSM9Nk5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IL_zFCvdfFx5DQ9" style="text-align: right" title="Change in valuation allowance">(1.08</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_hsrt--StatementGeographicalAxis__country--IL_maITEBzUaV_zTsqgrFydRuc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 20pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IL_zaRkF3HMSD61" style="text-align: right" title="Other">(0.29</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maITEBzUaV_zpeZ9pXeYC6e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Other foreign jurisdictions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_pid_dpi_uPure_c20250401__20260331_zZWVvzKz8NUh" style="text-align: right" title="Other foreign jurisdictions">(0.26</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IncomeTaxReconciliationDifferenceTaxCreditsResearch_iN_pn3n3_di_msITEBzUaV_zHeUTb8N4yp" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(308</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch_iN_pid_dpi_uPure_c20250401__20260331_z4zOLsxtNNq1" style="text-align: right" title="Other foreign jurisdictions">0.90</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationTaxCreditsOther_pn3n3_msITEBzUaV_zWZSRF3WbmM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Changes in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,759</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20250401__20260331_zaEKltgnCeYk" style="text-align: right" title="Changes in valuation allowance">(10.95</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Effect of cross-border tax laws</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IncomeTaxReconciliationTaxSubpartFIncome_pn3n3_msITEBzUaV_zKYQySrZlrMe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Subpart F Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--EffectiveIncomeTaxRateReconciliationSubpartFIncome_iN_pid_dpi_uPure_c20250401__20260331_z1fCXvjJqqN9" style="text-align: right" title="Subpart F Income">(0.02</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Nontaxable or nondeductible items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount_pn3n3_maITEBzUaV_z2jxG5Lijki8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Share-based payment awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,878</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_uPure_c20250401__20260331_zcOHtY9CV2k9" style="text-align: right" title="Share-based payment awards">(5.47</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationDifferenceOtherAdjustments_pn3n3_maITEBzUaV_z8fwdzqDUi9a" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 10pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">293</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331_zjcogF9fNaWf" style="text-align: right" title="Other">(0.85</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--IncomeTaxReconciliationDifferenceOtherReconcilingItems_pn3n3_maITEBzUaV_zpssULizKaLk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0pt">Other adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">346</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent_iN_pid_dpi_uPure_c20250401__20260331_zYUlD6ISgii6" style="border-bottom: Black 1pt solid; text-align: right" title="Other adjustments">(1.01</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzUaV_zTL6ep64Xhqj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt">Provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1952">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_c20250401__20260331_zgCeK0OrfWD2" style="border-bottom: Black 2.5pt double; text-align: right" title="Other adjustments">0.00</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AC_zT3o1gYW48q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zZO1ZpwSPAT2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of income tax expense calculated at the federal enacted statutory income tax rate of 21% is as follows
for the year ended March 31 2025:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_z6TWAqXJARvi" style="display: none">SCHEDULE
OF STATUTORY US FEDERAL EFFECTIVE RATE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240401__20250331_zclPp73dxxf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March
31, 2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_iN_pid_dpi_uPure_maancd_z5YdzhxqsDTe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 77%; text-align: left">Federal income tax at statutory rate</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maancd_zfuIl3OK4d96" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax, net of federal benefit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.73</td><td style="text-align: left"></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_pid_dp_uPure_maancd_zkTjVegcMzhd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Permanent items</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.58</td><td style="text-align: left"></td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_pid_dpi_uPure_maancd_zZQ5gY3Ikow8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Non-deductible compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10.45</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_maancd_z2xfmwl9ERYh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in valuation allowance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10.46</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msancd_zlYSTgFCY1t2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development tax credits</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.12</td><td style="text-align: left"></td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_iN_pid_dpi_uPure_maancd_z2RpVoJJqTE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Foreign tax rate differential</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.65</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_maancd_z9DaXmyYvOUf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Other</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.87</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss_pid_dp_uPure_maancd_zm7BOtXE93a3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change to foreign NOL&#8217;s</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1974">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtancd_zDncT245Hms5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Effective income tax expense rate</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AB_zcrMT1YsFO1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Taxes paid across all jurisdictions were immaterial
for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 4, 2025, the One Big Beautiful Bill Act (the
&#8220;OBBBA&#8221;) was signed into law. The OBBBA includes significant tax provisions, including the permanent extension of certain provisions
of the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;), modifications to the international tax framework, and the restoration of favorable
tax treatment for certain business expenditures. The legislation contains multiple effective dates, with certain provisions effective
for tax years beginning in 2025 and others phased in through 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated the provisions of the OBBBA and their applicability to its operations. Based on this assessment,
the OBBBA did not have a material impact on the Company&#8217;s consolidated financial statements for the fiscal year ended March 31, 2026.
The Company will continue to monitor regulatory guidance and assess the potential impact of provisions with future effective dates on
its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_807_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zULR8jPfhpQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 <span id="xdx_82C_zrwgeOAWCRvh">COMMITMENTS AND CONTINGENCIES</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>License
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2015, Beyond Air Ltd., a wholly-owned subsidiary of the Company (&#8220;BA Ltd.&#8221;) entered into an Option Agreement (the
&#8220;Option Agreement&#8221;) with Pulmonox Technologies Corporation (&#8220;Pulmonox&#8221;) whereby BA Ltd. acquired the option (the
&#8220;Option&#8221;) to purchase certain intellectual property assets and rights. On January 13, 2017, BA Ltd. exercised the Option
and paid $<span id="xdx_90B_ecustom--PaymentsForDevelopmentAndMilestonePayment_pn5n6_c20170112__20170113__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember_zudNIE6PbzKd" title="Payments for development and milestone payment">0.5</span> million to Pulmonox. BA Ltd. became obligated to make certain one-time development and sales milestone payments to Pulmonox,
commencing with the date on which BA Ltd. receives regulatory approval for the commercial sale of the first product candidate qualifying
under the Option Agreement. These milestone payments are capped at a total of $<span id="xdx_905_ecustom--MilestonePayments_pn6n6_c20170112__20170113__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember_zv6nmTh67RZf" title="Milestone payments">87</span> million across three separate and distinct indications
that fall under the agreement, with the majority of them, approximately $<span id="xdx_902_ecustom--SalesRelatedMilestonesPayments_pn6n6_c20170112__20170113__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember_zM49v1QyKc4g" title="Sales related milestones payments">83</span> million, being sales-related based on cumulative sales milestones
for each of the three products. BA Ltd. is not currently developing any qualifying products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2018, the Company entered into an agreement (the &#8220;NitricGen Agreement&#8221;) with NitricGen, Inc. (&#8220;NitricGen&#8221;)
to acquire a global, exclusive, transferable license and associated assets including intellectual property, know-how, trade secrets and
confidential information from NitricGen related to the LungFit<sup>&#174;</sup>. The Company acquired the licensing right to use the technology
and agreed to pay NitricGen a total of $<span id="xdx_902_ecustom--MilestonePayments_pn5n6_c20180130__20180131__dei--LegalEntityAxis__custom--NitricGenIncMember__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_zMa61sn70Ild" title="Future payments based on certain milestones">2.0</span> million in future payments based upon achieving certain milestones, as defined in the NitricGen
Agreement, and single-digit royalties on sales of the LungFit<sup>&#174;</sup>. The Company paid NitricGen $<span id="xdx_905_ecustom--PaymentForMilestoneMethodRevenueRecognized_pn5n6_c20180130__20180131__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember__dei--LegalEntityAxis__custom--NitricGenIncMember_zXlV4mRAxEx4" title="Payment for Milestone method revenue recognized">0.1 </span>million upon the execution
of the NitricGen Agreement, $<span id="xdx_90B_ecustom--PaymentForMilestoneMethodRevenueRecognized_pn5n6_c20180130__20180131__dei--LegalEntityAxis__custom--NitricGenIncMember__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember__us-gaap--AwardDateAxis__custom--NextMilestonesMember_zVUSrIjhD0ua" title="Payment for Milestone method revenue recognized">0.1</span> million upon achieving the next milestone and $<span id="xdx_901_ecustom--PaymentForMilestoneMethodRevenueRecognized_pn5n6_c20180130__20180131__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember__us-gaap--AwardDateAxis__custom--AfterSixMonthsMember__dei--LegalEntityAxis__custom--NitricGenIncMember_zFtV2xaT1ikd" title="Future payments based on certain milestones">1.5</span> million in January 2023, six months after approval
of the LungFit<sup>&#174; </sup>by the FDA, and issued <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pp0p0_c20180131__dei--LegalEntityAxis__custom--NitricGenIncMember__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z0tpDPjUmhn" title="Warrants to purchase common stock">100,000</span> warrants to purchase the Company&#8217;s common stock valued at $<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20180131__dei--LegalEntityAxis__custom--NitricGenIncMember__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_zLbX0YfyYeM6" title="Warrants to purchase common stock, value">0.3</span> million
upon executing the NitricGen Agreement. As of March 31, 2026, the remaining future milestone payments total $<span id="xdx_901_ecustom--MilestonePayments_pn5n6_c20240401__20250331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_zAGAgqkmf932" title="Remaining future milestone payments">0.3</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Supply
Agreement and Purchase Order</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the Company entered into a supply agreement with an initial expiration date of December 31, 2024. The Company has opened several non-cancellable purchase orders
and the outstanding amount remaining under the purchase order as of March 31, 2026 was approximately $<span id="xdx_904_eus-gaap--PurchaseObligation_iI_pn5n6_c20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierMember_zCzR94Su0Cc3" title="Outstanding amount under purchase">0.5</span> million with this supplier.
This supplier holds $<span id="xdx_90A_eus-gaap--DepositAssets_iI_pn5n6_c20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierMember_zUG20OVBzI0h" title="Cash deposits">3.4</span> million of restricted cash to partially secure materials on the Company&#8217;s behalf recorded in other current
assets and prepaid expenses. This agreement will expire on March 31, 2027. At that time all excess inventory will be returned to the Company and
any excess restricted cash will be released.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a new supply agreement with Plexus Corp.  for the manufacturing of its second generation device
and service of all devices beginning on April 1, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contingencies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company is involved in various legal matters arising in the normal course of business. The Company does not expect
the outcome of such proceedings, either individually or in the aggregate, to have a material effect on its financial position, cash
flows or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTS</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zWaHnwDxRDnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 <span id="xdx_826_z7PRuJXLaYK9">SEGMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2021, the Company announced that Beyond Air and Beyond Cancer, Ltd agreed to terms to which the Company, through its subsidiaries
would be licensing certain intellectual property and other assets related to, or necessary for the development, commercialization, manufacture
and distribution of certain cancer treatment products and/or technologies to a subsidiary of the Company (the &#8220;2021 Transaction&#8221;).
In connection and concurrently with the closing of the 2021 Transaction, Beyond Cancer issued and sold common shares, par value $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20211104__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__srt--TitleOfIndividualAxis__custom--CertainInvestorsMember_zBnRPrEDnaYj" title="Sle of stock per share">1.00</span>
to certain investors pursuant to a subscription agreement (the &#8220;2021 Offering&#8221;). The 2021 Offering consisted of an aggregate
of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn6n6_c20211102__20211104__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zBdh0Uh3aUyh" title="Number of shares issued">3 </span>million common shares of Beyond Cancer at a purchase price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20211104__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zcVOfNO3lY0k" title="Shares issued price per share">10.00</span> per share. On November 18, 2021, the Company announced that
the maximum amount of shares offered had been purchased for a total of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20211116__20211118__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_ztvWMCK1QWy7" title="Proceeds from issuance of common stock">30</span> million (including $<span id="xdx_907_ecustom--AmountOfTerminatedLoan_pn5n6_c20211116__20211118__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_z9klbz9tOtC4" title="Amount of terminated loan">4.8</span> million from the terminated Loan Facility
and $<span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_pn5n6_c20211116__20211118__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zmEWJGUo1HJc" title="Proceeds from related party debt">1.1</span> million from related parties) for <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20211104__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeyondCancerLtdMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zmqjedVuAQx2" title="Equity, ownership percentage">20</span>% of the equity in Beyond Cancer. The Company retained <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20211104__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeyondCancerLtdMember_zXDMFuY96PV9" title="Equity, ownership percentage">80</span>% ownership of Beyond Cancer, which
will have exclusive right to the intellectual property portfolio utilizing UNO for the treatment of solid tumors. Beyond Cancer will
pay Beyond Air a single digit royalty on all future revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
of the Board of Directors of Beyond Air who are also members of the Board of Directors of Beyond Cancer, and their families, are considered
related parties to the 2021 Offering. Related parties invested $<span id="xdx_90E_eus-gaap--OtherReceivables_iI_pn5n6_c20211104__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zB6EiR63vtj7" title="Related party invested">1.1</span> million in the 2021 Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2025, the Company announced that Beyond Air and NeuroNos Limited agreed to terms to which the Company, through its subsidiaries
would be licensing certain intellectual property and other assets related to, or necessary for the development, commercialization, manufacture
and distribution of certain neurological treatment products and/or technologies to a subsidiary of the Company (the &#8220;2025 Transaction&#8221;).
In connection and concurrently with the closing of the 2025 Transaction, NeuroNos issued and sold common shares, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250324__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z9rSsC0H6jSe" title="Common stock, par value">0.001</span> to
certain investors pursuant to a subscription agreement (the &#8220;2025 Offering&#8221;). The 2025 Offering consisted of an aggregate
of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250324__20250324__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zmry5MeFyxok" title="Number of shares issued">666,667</span> common shares of NeuroNos at a purchase price of $<span id="xdx_905_eus-gaap--SharePrice_iI_c20250324__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zeKQrGgnY1fe" title="Per share price">3.00</span> per share. On March 31, 2025, the offered shares had been purchased
for a total of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240401__20250331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z1kYqCtaezhf" title="Proceeds from issuance of common stock">2.0</span> million for <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20250331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NeuroNosLtdMember_zBqkQYrjI9Qa" title="Equity ownership percentage">11.76</span>% of the equity in NeuroNos. During the year ended March 31, 2026, an additional <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zikgfPzEKlf8" title="Number of shares issued">233,333</span> common
shares of NeuroNos were issued and sold to certain investors at a purchase price of $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zLOJgFx6U5B9" title="Per share price">3.00</span> per share. As of March 31, 2026, <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NeuroNosLtdMember_zULQlSUxhmi6" title="Equity ownership percentage">15.25</span>% of
the equity in NeuroNos was held by non-controlling interests. Beyond Air retained <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20260321__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NeuroNosLtdMember_zA79IQmRIqPj" title="Equity ownership percentage">84.75</span>% ownership of NeuroNos and will have exclusive
right to the intellectual property portfolio for the regulation of nitric oxide as it relates to neurological therapies. NeuroNos will
pay Beyond Air a single digit royalty on all future revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 SEGMENTS (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_hus-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zi35rnQZDH44" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes segment financial information by business segment for the year ended and at March 31, 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zZcAXe4hCHL7" style="display: none">SCHEDULE
OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zgNStXblWzyk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Air</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20250401__20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zrohAMv6szfk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Cancer</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250401__20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zW4cVuxAUe2e" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NeuroNos</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250401__20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zfzya6K0k5If" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Capital expenditures</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zaRmoaTQJekb" style="width: 11%; text-align: right" title="Capital expenditures">1,024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zJ4ykdiSy4E6" style="width: 11%; text-align: right" title="Capital expenditures"><span style="-sec-ix-hidden: xdx2ixbrl2046">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zqfUEiOI5Ytd" style="width: 11%; text-align: right" title="Capital expenditures">2</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zPOCp9oyeNOk" style="width: 11%; text-align: right" title="Capital expenditures">1,026</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zYC7W16bsKIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,679</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2053">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2054">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,679</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_iN_pn3n3_di_zsF7fuTED9V5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,427</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2058">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2059">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,427</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_iN_pn3n3_di_zv81KCo3nG5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,677</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,170</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,394</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,241</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_iN_pn3n3_di_zU1UMJJfVMkg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Selling, general, and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,418</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,207</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,430</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,055</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_pn3n3_z5DvcCbw0551" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,843</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,377</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,824</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29,044</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestExpenseNonoperating_iN_pn3n3_di_zwm6AW51Md8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest and finance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,515</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2078">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2079">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,515</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_ztk81NjYlHV7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other non-operating income/(expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,668</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(323</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">216</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,775</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_zOPF7kgxtz2a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(28,026</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,700</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,608</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(34,334</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating activities included in net loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_pn3n3_z9J9woXZHIW5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2094">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,251</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_zeJR6trJe1Z8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,373</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,282</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn3n3_zbbBYU29PRel" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash used in operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(14,775</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,314</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,055</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(18,144</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_pn3n3_z3RK8MDJS42i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash used in (provided by) investing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,660</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,674</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_pn3n3_zh70pOLjOBnd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash provided by financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2113">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,090</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_pn3n3_zYgHbHhOoasj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impact of exchange rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(198</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_pn3n3_zw5LfUvnRZbe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change for the year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,183</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(162</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,555</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,466</td><td style="text-align: left"></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes segment financial information by business segment for the year ended and at March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zDUICAtIvEQ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Air</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240401__20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zCttKZP1DMJf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Cancer</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240401__20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zrtcmnTEofrl" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NeuroNos</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240401__20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zxYQug0DaJD1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Capital expenditures</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z5bLU8nNP0Qk" style="width: 11%; text-align: right" title="Capital expenditures">5,859</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zyTaBK3RHHF4" style="width: 11%; text-align: right" title="Capital expenditures">24</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z9aaCtJIZigl" style="width: 11%; text-align: right" title="Capital expenditures"><span style="-sec-ix-hidden: xdx2ixbrl2131">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zZWsdloUZI1i" style="width: 11%; text-align: right" title="Capital expenditures">5,883</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zj9qM7N2ZII6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2136">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2137">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,705</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_iN_pn3n3_di_zYttFNkJGdmi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,368</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2141">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2142">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,368</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_iN_pn3n3_di_zkl7QSK36Gvh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,780</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,062</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,857</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_iN_pn3n3_di_z4VhBJnqO6Q8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Selling, general, and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,565</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,344</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(108</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,017</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_pn3n3_zRjKyHfJzj02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(35,008</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,406</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(123</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44,537</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestExpenseNonoperating_iN_pn3n3_di_zRE84GqWecie" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest and finance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,019</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2161">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2162">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,019</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zsOS9HV5kXQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other non-operating income/(expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,132</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2167">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(923</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_z2z2DFjUjva7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(39,159</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(9,197</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(123</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(48,479</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating activities included in net loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_pn3n3_zqq3H6aDymtb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,143</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2177">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,204</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_zQVdfhJgEsya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,154</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,146</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn3n3_zYjo82QwFx87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash used in operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(29,599</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(8,619</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2187">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(38,218</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_pn3n3_zAZ1ayaZF4c5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash provided by investing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,061</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2192">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,905</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_pn3n3_z5OGb8uYgR6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash provided by financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,646</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2196">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,646</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_pn3n3_zaOK9HH5cgU8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impact of exchange rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2202">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(45</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_pn3n3_zNXBQkkl7Kd6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change for the year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,148</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,564</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,712</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes financial information by business segment at March 31, 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zkHW1x9eSm2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Air</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z0tiVauo7HOk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Cancer</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z2knifpaVRRk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NeuroNos</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zAla1t9MXcQ3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_zCfjlHyodPn7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Cash, cash equivalents and marketable securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">10,140</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,043</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">458</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">11,641</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAssets_iI_pn3n3_z3ayk8KTRVHl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">All other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,901</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(219</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">62</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,744</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_iTI_pn3n3_zlGW8DL0F2wf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">34,041</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">824</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">520</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">35,385</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_iNI_pn3n3_di_zE1rBqqEVTYa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(28,224</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(378</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(573</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(29,175</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNet_iI_pn3n3_zDt5YU21tEvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">5,817</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">446</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(53</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">6,210</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--MinorityInterest_iI_pn3n3_zVnZK7fL9DEh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2235">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes financial information by business segment at March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zSA9AsWRpzMg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Air</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zCxOqn4syFP9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Cancer</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zOxgLgxbG0k8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NeuroNos</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z8gsJTjpZK0e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_zLnYOb3zGpcf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Cash, cash equivalents and marketable securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,167</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">6,917</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAssets_iI_pn3n3_zW5DAdFO3a42" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">All other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22,116</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,029</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2247">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,145</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_iTI_pn3n3_zcP9z74j4n6a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">24,866</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,196</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">30,062</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_iNI_pn3n3_di_zyKjyhnoMRT1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(15,082</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(589</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(50</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(15,721</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNet_iI_pn3n3_zHfTWeM53Vcj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">9,784</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,607</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,950</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">14,341</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--MinorityInterest_iI_pn3n3_zhU46w6oGcCc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">529</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">229</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">758</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zJAkw7x9kMB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z1TtN1x98yCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14 <span id="xdx_829_zMQBLvLkaLq4">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the exception of the related party transactions referred to in Note 4 and Note 9, there were no additional related party transactions
in the fiscal years ended March 31, 2026 and March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE REVENUES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DisclosureLeaseRevenuesAbstract', window );"><strong>Lease Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_OperatingLeasesTextBlock', window );">LEASE REVENUES</a></td>
<td class="text"><p id="xdx_809_ecustom--OperatingLeasesTextBlock_zQQFLTbxl6If" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 <span id="xdx_828_zm9El36vu4Si">LEASE REVENUES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases the LungFit&#174; PH device to customers and receives a fixed rental fee over the term of the arrangement. Contract terms
(generally one<span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20260331__srt--RangeAxis__srt--MinimumMember_z4ODoxPTi5y6" style="display: none" title="Contract term">1</span>-to-<span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dc_c20260331__srt--RangeAxis__srt--MaximumMember_zt1uSwsGzKij" title="Contract term">three years</span>) vary by customer and may include options to terminate the contract or options to extend the contract.
The LungFit&#174; PH lease agreements are accounted for as operating leases. The non-lease components, including consumables and device-related
services are combined with the predominant lease component under the practical expedient. The fixed rental fee is recognized over the
period of the lease agreement on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized $<span id="xdx_906_ecustom--OperatingLeaseIncome_pn5n6_c20250401__20260331__srt--ConsolidatedEntitiesAxis__custom--LungFitPHMember_z8ATVr61rtXl" title="Lease revenue">6.2</span> million and $<span id="xdx_907_ecustom--OperatingLeaseIncome_pn5n6_c20240401__20250331__srt--ConsolidatedEntitiesAxis__custom--LungFitPHMember_zVkudFLhyJ36" title="Lease revenue">3.7 </span>million in LungFit&#174; PH lease revenues for the years ended March 31, 2026 and March 31, 2025,
respectively, reported as revenues in the consolidated statements of operations and comprehensive loss. The Company received approximately
$<span id="xdx_907_eus-gaap--Cash_iI_pn5n6_c20260331__srt--ConsolidatedEntitiesAxis__custom--LungFitPHMember_zvs4AmWWTw26" title="Cash">5.8</span> million and $<span id="xdx_90C_eus-gaap--Cash_iI_pn5n6_c20250331__srt--ConsolidatedEntitiesAxis__custom--LungFitPHMember_zbpvfmxHQLSj" title="Cash">3.2</span> million in cash associated with leases which the Company is the lessor for the years ended March 31, 2026 and March
31, 2025, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_hdei--LegalEntityAxis__custom--LungFitRPHMember_z7Y2qSMmBDJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following schedule presents the minimum future lease payments under the LungFit&#174; PH lease arrangements that were in place as of March
31, 2026 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zsIXGXh71AE" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF MATURITY OF FUTURE LEASE PAYMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Future lease payments under the LungFit&#174; PH lease arrangements (in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20260331__dei--LegalEntityAxis__custom--LungFitRPHMember_zNvnnCb3rpc6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzQlL_zIa0UjmJMzD8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2027</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,919</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzQlL_zegw9FRxUGJa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,512</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzQlL_zo5adO8PMz6l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,560</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzQlL_zKzjTDVvGvzl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,991</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zT2Rs0h3kuy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LungFit&#174; PH devices are included in Property and Equipment (Note 3) and have the useful life of <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__dei--LegalEntityAxis__custom--LungFitPHMember_zuFKS1oPrS2f" title="Useful Life">five years</span>. Depreciation expense
related to leased LungFit&#174; PH devices was $<span id="xdx_901_eus-gaap--Depreciation_pn5n6_c20250401__20260331__dei--LegalEntityAxis__custom--LungFitPHMember_z2xJ4qSmHzSb" title="Depreciation expense">2.7</span> million and $<span id="xdx_90D_eus-gaap--Depreciation_pn5n6_c20240401__20250331__dei--LegalEntityAxis__custom--LungFitPHMember_zA9JgDd2w5Zd" title="Depreciation expense">2.3 </span>million for the years ended March 31, 2026 and March 31, 2025, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depreciation expense related to customer leased devices is included in the cost of revenues in the consolidated statements of operations
and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Capitalized
sales commissions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
commissions related to obtaining LungFit&#174; PH lease agreements are accounted for as initial direct costs and are capitalized and amortized
on a straight-line basis over the lease term. Total capitalized costs for the years ended March 31, 2026 and March 31, 2025 were immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DisclosureLeaseRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DisclosureLeaseRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_OperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_OperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_ziqoSPmcnM0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 16 <span id="xdx_82A_zgJYNhHoEbEg">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 24, 2026, the Company&#8217;s Board of Directors
approved a change in Company&#8217;s fiscal year from the twelve-month period ending on March 31 to the twelve-month period ending on
December 31 of each year. The Company will complete a transition period commencing on April 1, 2026, and ending on December 31, 2026,
after which the Company&#8217;s fiscal years shall consist of the twelve-month periods ending on December 31 of each calendar year.</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zePT0szFLvt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zaK8ogn2fPr">Basis
of Presentation and Principles of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements include the accounts of Beyond Air, Inc. and its subsidiaries and have been prepared in accordance
with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;). The Company determined that Beyond Cancer
Ltd. and its affiliates (&#8220;Beyond Cancer&#8221;) and NeuroNOS Ltd. and its affiliates (&#8220;NeuroNos&#8221;) are each a
variable interest entity (&#8220;VIE&#8221;) for which the Company is the primary beneficiary and consolidates in its financial
statements. All intercompany balances and transactions have been eliminated in the accompanying consolidated financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_843_eus-gaap--UseOfEstimates_zyP03rkfswnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zrfYmDguqYR8">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could
significantly differ from those estimates. On an ongoing basis, the Company evaluates its significant estimates and assumptions
including expense recognition and accrual assumptions under consulting and clinical trial agreements, stock-based compensation,
allowance for credit losses, excess and obsolete inventory reserves, impairment assessments, accounting for licensed rights to use
technologies and other long-lived assets, the valuation of warrants, the valuation of derivatives, contingency recognition and
accruals and the determination of valuation allowance requirements on deferred tax attributes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock', window );">Going Concern, Liquidity and Other Uncertainties</a></td>
<td class="text"><p id="xdx_843_ecustom--GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock_zyfgdhMi85s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zqY2Bjw1vIe6">Going
Concern, Liquidity and Other Uncertainties</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used cash in operating activities of $<span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250401__20260331_z3ZU6LUFtdn3" title="Net cash used in operating activities">18.1</span> million for the year ended March 31, 2026, and has an accumulated deficit attributable
to the stockholders of Beyond Air, Inc. of $<span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20260331_zSPwmvk8ZqKe" title="Accumulated deficit">319.6</span> million. The Company had cash, cash equivalents and marketable securities of $<span id="xdx_902_ecustom--CashAndCashEquivalentsAndMarketableSecurities_iI_pn5n6_c20260331_zw8mJaARiHIj" title="Cash equivalents and marketable securities">11.6</span>
million as of March 31, 2026. In addition, $<span id="xdx_905_eus-gaap--DepositAssets_iI_pn5n6_c20260331_zZ5ML2x09EY3" title="Cash deposit">3.4</span> million of cash is held on deposit by the Company&#8217;s contract manufacturer to be
applied against future purchases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to incur net losses and have significant cash outflows for at least the next year, including making significant
investments in research and development. Management believes these factors raise substantial doubt about the Company&#8217;s ability
to meet its obligations with cash on hand and concluded that the Company will require additional funding within one year from the
date these consolidated financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is confident that the efforts to arrange financing, while not assured, will enable the Company to meet its obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s future capital needs and the adequacy of its available funds will depend on many factors, including, but not necessarily
limited to, the success and costs of commercialization of the Company&#8217;s approved product and the actual cost and time necessary
for current and anticipated preclinical studies, clinical trials and other actions needed to obtain certification or regulatory approval
of the Company&#8217;s product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_OtherRisksAndUncertaintiesPolicyTextBlock', window );">Other Risks and Uncertainties</a></td>
<td class="text"><p id="xdx_84C_ecustom--OtherRisksAndUncertaintiesPolicyTextBlock_zmSOMpTsR0dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_z9BkdE6WELm2">Other
Risks and Uncertainties</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to development and early-stage medical device companies including, but not limited to, new technological
innovations, certifications or regulatory approval, dependence on key personnel, protection of proprietary technology, compliance with
government regulations, product liability, uncertainty of market acceptance of approved products and the potential need to obtain additional
financing. The Company is also dependent on third-party suppliers and, in some cases, single-source suppliers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s products require approval or clearance from the FDA prior to commencement of commercial sales in the United States. There
can be no assurance that the Company&#8217;s products beyond LungFit&#174; PH in the U.S. will receive the required approvals or clearances.
Certifications, approvals or clearances are also required in foreign jurisdictions in which the Company may license or sell its products.
If the Company is denied such certifications or approvals or clearances or such certifications, approvals or clearances are delayed,
such denial or delay may have a material adverse impact on the Company&#8217;s results of operations, financial position and liquidity.
Further, there can be no assurance that the Company&#8217;s product will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or
that such products will be successfully marketed, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zVF0qxX5X7Ag" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zlJminLqUXwk">Revenue
Recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates revenue from the leases of its LungFit&#174; PH devices to its customers under fixed fee arrangements over periods of
up to three years. The fixed fee is typically broken down into ratable monthly payments over the term of the arrangement. The Company&#8217;s
customers include hospitals and medical facilities. The Company&#8217;s LungFit&#174; PH leases include filters, calibration gas, bagging
kits, cables, adapters, and other components and accessories required to use the LungFit&#174; PH device (the &#8220;Consumables&#8221;).
The consumables&#8217; quantities are varied and may be supplied upon demand of the customers and are unlimited, or the arrangement may
provide for the maximum quantities available to the customer over the term of the arrangement. The Company&#8217;s LungFit&#174; PH leases
also include maintenance and training required to use the LungFit&#174; PH device, as well as device back-up services (the &#8220;Services&#8221;),
which are recorded in cost of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its rental arrangements of LungFit&#174; PH devices in accordance with Accounting Standards Codification 842, <i>Leases</i>
(&#8220;ASC 842&#8221;). Under ASC 842, leases may be classified as either financing, sales-type, or operating, and the Company is
required to disclose key information about leasing arrangements. The classification determines the pattern of revenue recognition
and classification within the consolidated statements of operations and comprehensive loss. The Company typically classifies the
rental arrangement of its LungFit&#174; PH contracts as operating leases. The Company&#8217;s leases do not contain any restrictive
covenants or any material residual value guarantees. The Company&#8217;s equipment leases may contain renewal options which range
from one month to two years. The lease term is adjusted for renewal or termination options that the Company believes the customer is
reasonably certain to exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company elected the practical expedient applied to operating leases not to separate lease and non-lease components as long as the lease
and non-lease components have the same timing and pattern of transfer. As such, the non-lease components, including the Consumables and
Services, are combined with the predominant lease component. The total fixed fees that the Company is reasonably certain to collect are
recognized on a straight line basis over the term of the arrangement. Additionally, the Company made an accounting policy election to
present LungFit&#174; PH revenue net of sales and other similar taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the lease commencement date, the Company will defer initial direct costs, including commission expense and the cost is recognized over
the lease term on the same basis as lease income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 15 to the consolidated financial statements for more information regarding leasing arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also generates revenue from the sale of its LungFit&#174; PH devices and consumables to its customers under distribution arrangements.
Contracts include one performance obligation as any individual promised good or services other than delivery of the devices and consumables
are generally either not capable of being distinct or not distinct within the context of the contracts. Purchased quantities of devices
and consumables are varied and may be supplied upon demand of the customers. Revenue is recognized at a point in time when the Company
delivers the goods to its customer. The transaction includes a fixed component based on contractual rates. Revenue recognized reflects
the consideration the Company expects to receive in exchange for delivering the goods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
billed in advance of performance obligations being satisfied are recognized as deferred revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records the costs of shipping devices and consumables in cost of revenues in its consolidated statements of operations and comprehensive
loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJRcS9cpNhq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zpAyVX7HJsB8">Accounts
Receivable</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company extends credit to its customers on an unsecured basis. Accounts receivable are recorded at the invoiced amount, based on agreed
contract terms, less an allowance for credit losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company establishes an allowance for accounts receivable that are considered to be at increased risk of becoming uncollectible. When
evaluating the adequacy of this allowance for credit losses, the Company considers factors such as, historical collection experience
and creditworthiness, the composition of outstanding receivables by customer class, and expected economic conditions and other trends.
The Company&#8217;s estimates are reflected in the period they are made. The charges recorded for credit losses are reported within Selling,
general and administrative expenses on the consolidated statements of operations and comprehensive loss. Receivables are written off
against the allowance for credit losses when it is definitively determined that amounts are uncollectible. As of March 31, 2026 and 2025,
the allowance for credit losses were $<span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivableNoncurrent_iI_pn5n6_c20260331_zYeSgdAczWwa" title="Allowance for credit losses">0.1</span> million and $<span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivableNoncurrent_iI_pn5n6_c20250331_z7SLja1nsgK6" title="Allowance for credit losses">0</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z5m4LoVsv315" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zbf3gxuIpLl5">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820, <i>Fair Value Measurements and Disclosures</i> (&#8220;ASC 820&#8221;), defines fair value as the price that would be received to
sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market
participants on the measurement date. The fair value standard also establishes a three-level hierarchy, which requires an entity to maximize
the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based
upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1&#8212;inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2&#8212;inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived
valuations in which all significant inputs are observable for substantially the full term of the asset or liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3&#8212;inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026 and March 31, 2025, the Company&#8217;s financial instruments included restricted cash, marketable securities,
accounts payable, long-term debt and liability classified warrants. The carrying amounts reported in the accompanying consolidated
financial statements for cash and cash equivalents, restricted cash and marketable securities approximate their respective fair
values because of the short-term nature of these accounts. The carrying value of the Company&#8217;s long-term debt approximates
fair value based on current interest rates for similar types of borrowings. The liability classified warrants are recorded at fair
value and are included in Level 3 of the fair value hierarchy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zSz2dHLbWKHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value amounts as of March 31, 2026 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zXpIL3M7zN37" style="display: none">SCHEDULE
OF FAIR VALUE ON A RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20260331_z0foNQr9g2b6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z38n6cDnwlu8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z00wG26yyZg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsZd0BuskkP8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_ze7sjfLFgEgg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">4,901</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">4,901</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0729">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0730">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zjHwT9v6ZS32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,901</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,901</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0734">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0735">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zRC5TAbEqGGb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0739">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_z468H5pC9PIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0743">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value amounts as of March 31, 2025 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250331_z3Jt5bx4bnYc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjwMihH6oIy5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQyMh8LZAtai" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWF9wGvB3aei" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zQgGzALhxHx" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">2,252</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">2,252</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0750">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zKl8QiSE9w77" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0755">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z7teyQQZeWch" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">38</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0758">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0759">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">38</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zIpton2TLu3e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0763">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zXsqfKoRIw8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--MarketableSecuritiesTextBlock_z4HgtsibLNA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s short-term marketable securities with unrealized gains and losses as of March 31, 2026,
aggregated by major security type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zCu1EyrKbD71" style="display: none">SUMMARY
OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrealized Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_z5wtCioRRxGi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, fair value">4,901</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20250401__20260331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zB1niEE5K80j" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, unrealized loss">39</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total short-term marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zu1R3CSkgizd" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Fair value">4,901</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20250401__20260331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zSGHtLg4kMfj" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Unrealized gains and (losses)">39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s short-term marketable securities with unrealized gains and losses as of March 31, 2025,
aggregated by major security type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrealized Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zQg58g0FROi4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, fair value">2,252</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20240401__20250331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zWNdUiwZjpf7" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, unrealized loss">39</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Total short-term marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zpU8N2T4NHZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Fair value">2,252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20240401__20250331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zr2SOMcBc0If" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Unrealized gains and (losses)">39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zgvFuIOypEj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Level
3 Valuation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
liability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liability is remeasured each reporting period with the change in fair value recorded to other income (expense) in the consolidated
statements of operations and comprehensive loss until the warrants are exercised, expired, reclassified or otherwise settled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zHT5mdEx3482" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant assumptions used in valuing the warrants were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zMM5k5MZuJid" style="display: none">SCHEDULE
OF ASSUMPTIONS USED IN VALUING WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">At March 31, 2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Expected term (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgvjyxQ3NFWj" title="Expected term warrants">2.25</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ziOPdUBHgXR1" title="Warrants and rights outstanding, measurement input">132.1</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z70biNE9YS8c" title="Warrants and rights outstanding, measurement input">3.8</span></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">At March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Expected term (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyJjQ346E25f" title="Expected term warrants">3.25</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zeuiYAT9gYHk" title="Warrants and rights outstanding, measurement input">99.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdcmXtcs2u7b" title="Warrants and rights outstanding, measurement input">3.9</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A5_zG73FmtTGsBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative
liability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementDifferenceDescription_c20250401__20260331_zzvT3Ss7G3gc" title="Derivative liability description">The
derivative liability represents an embedded redemption feature (embedded put option) that meets the criteria to be classified as a
derivative and is bifurcated from the Note (see Note 9). On any trading day during which the Registration Statement (Note 4) remains
effective and the Note remains outstanding and (i) any trading price of the Company&#8217;s common stock is at least 5% greater than
the current Nasdaq minimum price as defined under Nasdaq Rule 5635(d) (the &#8220;Nasdaq Minimum Price&#8221;) or (ii) the total
dollar trading volume has reached $750,000.00, Streeterville may elect to purchase shares of common stock up to the Beneficial
Ownership Limitation at a purchase price equal to 85% of the Nasdaq Minimum Price, subject to a floor of $0.39 per share. The
aggregate purchase price for these shares shall be offset by an equal amount outstanding under the Note.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
feature was concluded to not be clearly and closely related to the host instrument and is required to be measured at fair value at each
reporting period. The fair value was determined using the Monte Carlo valuation model. The key inputs of the simulation are the valuation
date, the Company&#8217;s common stock share price and volatility, the risk-free rate, and the maximum convertible shares eligible to
offset the outstanding balance on the Note.</span></p>

<p id="xdx_895_ecustom--FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock_zsfFhj7pnTGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zHcIVEJ0tXp1" style="display: none">SCHEDULE
OF KEY INPUTS DERIVATIVE </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">At November 4, 2025 (issuance)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20251104_zE3kHp0WJLG6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Maximum convertible shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20251104__20251104_zx3BaNOFcG5f" style="width: 16%; text-align: right" title="Maximum convertible shares">1,600,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zh4ViqIooue7" style="vertical-align: bottom; background-color: White">
    <td>Share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.86</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zsrRCqjWT2u6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z17Mb19aVOfg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A1_zboQEfYurVni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
January 2026, Streeterville elected to purchase <span id="xdx_903_eus-gaap--StockRepurchasedDuringPeriodShares_pn5n6_c20260101__20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zkC1OrbXBar4" title="Purchase of common stock, shares">1.6</span>
million shares of common stock at an average of $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zYhINvXrjrD" title="Share price">0.73</span>
per share which offset principal of approximately $<span id="xdx_905_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pn5n6_c20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zRkMG7rKJgb7" title="Debt amount">1.2</span>
million outstanding under the Note (Note 9). The fair value of the issued common stock was approximately $<span id="xdx_90C_eus-gaap--CommonStockValueOutstanding_iI_pn5n6_c20260331_znX2AazFVE9a" title="Fair value of issued common stock">3.3</span>
million (Note 4). The Company remeasured the fair value of the derivative liability to $<span id="xdx_902_eus-gaap--CreditRiskDerivativeLiabilitiesAtFairValue_iI_pn5n6_c20260331_ziVcopMq8KCa" title="Fair value of the derivative liability">2.2</span>
million immediately prior to the conversion. Accordingly, the embedded derivative was extinguished as of March 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock_znFmSd1AcC0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuation for the warrants and derivatives
for the years ended March 31, 2026 and March 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zjA246EL3fBa" style="display: none">SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--FinancialInstrumentAxis_us-gaap--WarrantMember_zKomqjJB3SX7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_zr6VZOcny8w2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43D_c20240401__20250331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_ztdzelDPDHeh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance at March 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">275</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,314</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zCFopjQvCLGg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(237</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,314</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20250401__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zWLun7K8xSJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at March 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zCbqV14l7zv" style="vertical-align: bottom; background-color: White">
    <td>Issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">775</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zlVdshaDBc45" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,395</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--FairValueMeasurementExtinguishment_zmcY92DcW479" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Extinguishment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,170</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_435_c20250401__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zob4KlfS1AB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Balance at March 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_z5XCy7ic64Ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p id="xdx_84A_ecustom--WarrantLiabilityPolicyTextBlock_zD4209tMhPkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zRWUm4WOeCxf">Warrant
Liability</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies warrants as equity for any contracts that (i) require physical settlement or net-share settlement or (ii) gives
the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The
Company classifies warrants as assets or liabilities for any contracts that (i) require net-cash settlement (including a requirement
to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the
counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). Such warrants
are subject to remeasurement at each consolidated balance sheet date and any change in fair value is recognized as a component of
other income/expense on the consolidated statements of operations and comprehensive loss. The Company will continue to adjust the liability
for changes in fair value until the earlier of the exercise or expiration of such warrants. At that time, the portion of the warrant
liability related to warrants will be reclassified to additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liability</a></td>
<td class="text"><p id="xdx_843_eus-gaap--DerivativesPolicyTextBlock_zSNkPmULVEX" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zLgVSHtIY1bj">Derivative
Liability</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as
embedded derivatives in accordance with ASC 815, <i>Derivatives and Hedging.</i> For derivative financial instruments that are
accounted for as assets or liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is
then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations and
comprehensive loss. The classification of derivative instruments, including whether such instruments should be recorded as assets or
liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the
consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument
could be required within 12 months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Short-Term Investments and Restricted Cash</a></td>
<td class="text"><p id="xdx_847_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zkxOhR4JB6D6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zaLdwLtGklG3">Cash
and Cash Equivalents, Short-Term Investments and Restricted Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with original maturities of three months or less at the date of purchase and an investment
in a U.S. government money market fund to be cash equivalents. The Company maintains its cash and cash equivalents in highly rated financial
institutions in Australia, Israel, Ireland and the U.S., the balances of which, at times, may exceed federally insured limits. Marketable
securities may include investment in a combination of fixed income bonds, U.S. Treasury securities, and mutual funds that are considered
to be highly liquid and easily tradeable. The marketable securities are considered trading securities and are measured at fair value
and are accounted for in accordance with ASC 320. The marketable securities are valued using inputs observable in active markets for
identical securities and are therefore classified as Level 1 within the Company&#8217;s fair value hierarchy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026 and March 31, 2025, restricted cash included approximately $<span id="xdx_904_eus-gaap--RestrictedCash_iI_pn5n6_c20260331_z4rXtZexOB4b" title="Restricted cash">5.6</span> million and $<span id="xdx_90F_eus-gaap--RestrictedCash_iI_pn5n6_c20250331_zhHpnQ2lF6F8" title="Restricted cash">0.2</span> million, respectively. Restricted
cash as of March 31, 2026 includes $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_pn5n6_c20251104__20251104_zvX9YlzYQEr2" title="Proceeds from issuance of secured promissory note">5.4</span> million of proceeds from the Company&#8217;s secured promissory note issued on November 4, 2025
that is required to be held in a restricted account pursuant to the Note Purchase Agreement. Amounts held in the restricted account become
available to the Company as the outstanding principal of the Note is repaid (see Note 9).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zE3MMSGbrn05" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zifwhxa60YWk">Concentration
of Credit Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_uUSD_c20260331__srt--StatementGeographicalAxis__country--US_z7gUpbeMZPEg" title="Cash FDIC insured amount">250,000</span> in the United States, A$<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_uAUD_c20260331__srt--StatementGeographicalAxis__country--AU_zLkdEA4hIpqb" title="Cash FDIC insured amount">250,000</span> in Australia, $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_uUSD_c20260331__srt--StatementGeographicalAxis__country--BM_z8jflRkUGJZe" title="Cash FDIC insured amount">25,000</span>
in Bermuda, &#8364;<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_uEUR_c20260331__srt--StatementGeographicalAxis__country--IE_zvzsqbKTFD9a" title="Cash FDIC insured amount">100,000</span> in Ireland and &#8364;<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_uEUR_c20260331__srt--StatementGeographicalAxis__country--CY_zhbZ2tY5spQa" title="Cash FDIC insured amount">100,000</span> in Cyprus. There is currently no official federal depository insurance in Israel.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. <span id="xdx_906_eus-gaap--ConcentrationRiskBenchmarkDescription_c20260331__20260331_zwBsDcqjI1ci" title="Concentration risk benchmark description">As of March 31, 2026, the Company had greater than $250,000 at United States financial institutions, less than A$250,000
at Australian financial institutions, greater than &#8364;100,000 at Irish financial institutions and also has funds on deposit in Israel.</span>
Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition,
results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zO39TGqE6eHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table is the reconciliation of the presentation and disclosure of cash, cash equivalents, marketable securities by major security
type and restricted cash as shown on the Company&#8217;s consolidated statements of cash flows for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z0jfOmMC4Fy7" style="display: none">SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20260331_zKbwo92hRnU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250331_zIIVYqgiz4Xl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCEASz3pW_maRCACEzZrO_zQj3UHc54oZf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,740</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,665</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RestrictedCashCurrent_iI_pn3n3_maRCACEzZrO_zFxqdPDYOz83" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,622</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">231</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RestrictedCashAndCashEquivalents_iTI_pn3n3_mtRCACEzZrO_maCCEASziVz_zCa0NYeQZvO8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total cash, cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,362</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,896</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--MarketableSecuritiesAbstract_iB_zy0yiyUF65n9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--MarketableSecuritiesCurrent_i01I_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z213JS7INxXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,901</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MarketableSecuritiesCurrent_i01I_pn3n3_maCCEASziVz_zJBHKOVrL1Ok" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">4,901</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iTI_pn3n3_mtCCEASziVz_zHJeioG91Fig" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents, marketable securities and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,263</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,148</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zPNalkSO2Hci" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zeVEjAVtjFMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zgbsc8xF2Yja">Fixed
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_ecustom--ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock_zpfWmIi8fGMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation and accumulated amortization. Depreciation and amortization are calculated
using the straight-line method over the estimated useful life of the assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zziOzbX9ZBq2" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zGOdAUEMpnMl" title="Estimated useful life of assets">Three
    years</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z0YAIfctOaLa" title="Estimated useful life of assets">Five
    years</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    and medical equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember__srt--RangeAxis__srt--MinimumMember_zeg8FPWttisb" style="display: none" title="Estimated useful life of assets">3</span>/<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember__srt--RangeAxis__srt--MaximumMember_zL0oHTEqzoq9" title="Estimated useful life of assets">Five
    years</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment
    deployable as part of a service offering</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentDeployableAsPartOfServiceOfferingMember_zbKoyiHEMEGc" title="Estimated useful life of assets">Five
    years</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zIOJZqQidfNf" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2026%23UsefulLifeTermOfLeaseMember"><span style="-sec-ix-hidden: xdx2ixbrl0906">Shorter
    of term of lease or estimated useful life of the asset</span></span></span></td></tr>
  </table>
<p id="xdx_8A0_zcPMD6dQyzx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWhSe7IFIEI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zw5wt5bfBJHc">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity for which both discrete financial information is available and regularly reviewed by
the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing
performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company&#8217;s CODM evaluates performance and allocates resources for all
of the Company&#8217;s reportable segments based on income/loss from operations. The CODM is involved in determining and reviewing projected
income/loss from operations as part of the annual budget process. Throughout the year, the CODM considers forecast to actual results
and variances to allocate resources. The CODM also considers this information in strategic decisions related to capital allocations,
including investments in assets, research and development activities, and human capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s reportable segments at March 31, 2026 included <span id="xdx_905_ecustom--NumberOfReportableSegmentsDisclosedByDefinitionFlag_dbT_c20250401__20260331_zg48RG5VSya9" title="Number of repotable segments">Beyond Air, Beyond Cancer, and NeuroNos</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Beyond Air segment includes unallocated corporate expenses associated with the public company fees as well as all corporate related assets
and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zUPk5S2yRd52" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zQVSCnoOtmF">Inventories</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
consist primarily of purchased filters, bagging kits, cables, adapters, and other components and accessories required to use the LungFit&#174;
PH device held for sale to customers. Inventories are recorded at the lower of cost or net realizable value. Cost comprises direct materials,
third-party manufacturing costs and shipping costs incurred to deliver goods to the Company&#8217;s central warehouse location. Costs
are assigned to individual items of inventory on the basis of weighted average costs. Inventory items are tracked by batch/lot number
for specific identification whenever possible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
reserves are established for estimated excess and obsolete inventory equal to the difference between the cost of the inventory and the
estimated net realizable value of the inventory based on historical usage, known trends, and market conditions and judgment about the
anticipated future consumption and the Company&#8217;s ability to sell the inventory. At March 31, 2026 and March 31, 2025, excess and obsolescence reserves
were $<span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_pn5n6_c20260331_ztjhcafgaG3f" title="Obsolescence reserves">0.4</span> million and $<span id="xdx_908_eus-gaap--InventoryValuationReserves_iI_pn5n6_c20250331_zH80QGz5OvLl" title="Obsolescence reserves">0.2</span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zTwdbBYwhUzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zVQil3J6jCZ1">Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease assets are included within operating lease right-of-use assets, and the corresponding operating lease obligation on the consolidated
balance sheets in accordance with ASC 842, <i>Leases</i>. The Company has elected not to present short-term leases as these leases have
a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably
certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the
lease term at commencement date. Operating lease expense is recognized on a straight-line basis over the lease term and is included in
general and administrative and research development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interest rate implicit in the Company&#8217;s leases is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate in determining the present value of lease payments, which reflects the fixed rate at which the Company could borrow on
a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zBYK3lPY60Yh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z5irVTKx8dx6">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to the consolidated statements of operations and comprehensive loss as incurred. Research and development
expenses include salaries, benefits, stock-based compensation and costs incurred by outside laboratories, manufacturers, clinical research
organizations, consultants, and accredited facilities in connection with preclinical studies and clinical trials. Research and development
expenses are partially offset by the benefit of tax incentive payments for qualified research and development expenditures from the Australian
tax authority (&#8220;AU Tax Rebates&#8221;). The Company does not record AU Tax Rebates until payment is received due to the uncertainty
of receipt. For the years ended March 31, 2026 and March 31, 2025, the Company received $<span id="xdx_903_ecustom--TaxRebate_pn5n6_c20250401__20260331__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--AustralianTaxationOfficeMember_zRpYbVFqB6W2" title="Tax Rebate">0.1</span> million and $<span id="xdx_903_ecustom--TaxRebate_pn5n6_c20240401__20250331__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--AustralianTaxationOfficeMember_zmlzooNdSbHh" title="Tax Rebate">0.0</span> million, respectively,
in AU Tax Rebates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Exchange Transactions</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zWyTcYHOwBAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zee0Dj2iQdC3">Foreign
Exchange Transactions</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s subsidiaries transact in U.S. dollars, Euros, New Israeli Shekels and Australian dollars. The Company&#8217;s main operations
are in the United States and the U.S. dollar is the currency of the primary economic environment in which the Company operates and expects
to continue to operate in the foreseeable future. The Company translated its non-U.S. operations&#8217; assets and liabilities denominated
in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the
average exchange rate for the reporting period. Gains or losses from foreign currency transactions are included in other income (expense)
in the consolidated statements of operations and comprehensive loss as foreign currency exchange gain/(loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive
income and loss. The accumulated other comprehensive income and loss account includes the cumulative results of translating certain balance
sheet assets and liabilities at current exchange rates and some accounts at historical rates. For the year ended March 31, 2026, the
Company recorded gains of $<span id="xdx_90B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20260331_z7YLqXHZMmJ7" title="Accumulated other comprehensive income">0.2</span> million in accumulated other comprehensive income. For the year ended March 31, 2025, the Company recorded
losses of $<span id="xdx_90F_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20250331_z4Km4oWtws39" title="Accumulated other comprehensive income">0.1</span> million in accumulated other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zoq7zmHFHfej" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zCmkfEn80O85">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the cost of employee and non-employee services received in exchange for an award of equity instruments based on the
grant date fair value of the award. Fair value for restricted stock unit awards is valued using the closing price of the Company&#8217;s
common stock on the date of grant. The grant date fair value is recognized over the requisite service period during which an employee
and non-employee is required to provide service in exchange for the award, using the accelerated method with each tranche being expensed
over its vesting period. The grant date fair value of employee and non-employee share options is estimated using the Black-Scholes option
pricing model. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term
of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception
and does not anticipate paying dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Starting in 2023,
Beyond Air used its own historical volatility as an input for expected volatility, but due to Beyond Cancer&#8217;s and NeuroNos&#8217;
lack of marketability, the Company utilizes the implied volatility based on an aggregate of guideline companies for expected volatility.
The Company uses the simplified method to estimate the expected term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_SupplierConcentrationPolicyTextBlock', window );">Supplier Concentration</a></td>
<td class="text"><p id="xdx_844_ecustom--SupplierConcentrationPolicyTextBlock_zKF0PPuy2u2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_znqew8oyzWYi">Supplier
Concentration</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on third-party suppliers to provide materials for its devices and consumables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the year ended March 31, 2026, the Company purchased approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FirstThirdPartyVendorsMember_zWOjQrfo8Lg9" title="Concentration percentage">74</span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondThirdPartyVendorsMember_zPKH5GFKgKkk" title="Concentration percentage">18</span>% of its materials from two third-party vendors. In the
year ended March 31, 2025, the Company purchased approximately <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorsMember_zzzCD2frilml" title="Concentration percentage">85</span>% of its materials from one third-party vendor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_CustomerrConcentrationPolicyTextBlock', window );">Customer Concentration</a></td>
<td class="text"><p id="xdx_849_ecustom--CustomerrConcentrationPolicyTextBlock_zt0y7eVOQCR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zZK72rqbNr5k">Customer
Concentration</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2026, the Company derived <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zYh7HM53rlHa" title="Concentration percentage">11</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zqCNA4uF7rjc" title="Concentration percentage">10</span>% of its revenues from two customers. For the year ended March 31, 2025,
the Company derived <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_z8mTZnZnEwR7" title="Concentration percentage">16</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zjovfV2GnvV8" title="Concentration percentage">10</span>% of its revenues from two customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Licensed Right to Use Technology</a></td>
<td class="text"><p id="xdx_847_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zYiYbUZ0aaWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zBR8SZsHLuE4">Licensed
Right to Use Technology</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed
right to use technology that is considered platform technology with alternative future uses is recorded as an intangible asset and is
amortized on a straight-line method over its estimated useful life, determined to be thirteen years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zPqdqDxadk6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected amortization expense for the next five years and thereafter is as follows for the year ended March 31 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zfGTZeVvBHb1" style="display: none">SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_490_20260331_zTDHWIObOgA5" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANz72H_ztGt05u0vLWc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: left">2027</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">205</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANz72H_zdQScyCDpJTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANz72H_zdimKZ1UaNT8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANz72H_zoImxPVfM5fi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANz72H_zoRKAth2Mncg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2031</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANz72H_ziR28fJCHfik" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,018</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_z0prWWE0AGMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zWfi9ADUtDcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z8VqivzDPyKg">Long-Lived
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses the impairment of long-lived assets on an ongoing basis and whenever events or changes in circumstances indicate that
the carrying value may not be recoverable. Factors that the Company considers as potential triggers of an impairment review include the
following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    underperformance relative to expected historical or projected future operating results,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    changes in the manner of the Company&#8217;s use of the acquired assets or the strategy for its overall business,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    negative regulatory or economic trends, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    technological changes, which would render the platform technology, equipment, and manufacturing processes obsolete. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recoverability
of assets that will continue to be used in the Company&#8217;s operations is measured by comparing the carrying value to the future net
undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future
revenues, driven by market growth rates, and estimates of future costs. There were no events during the reporting periods that were deemed
to be a triggering event that would require an impairment assessment, other than the impairment of $<span id="xdx_900_eus-gaap--OtherAssetImpairmentCharges_pn5n6_c20240401__20250331_zfqvadaSCqaj" title="Other asset impairment charges">0.5</span> million recorded during the year
ended March 31, 2025 associated with certain R&amp;D assets following Management&#8217;s decision to put its VCAP clinical trial on hold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BEYOND
AIR, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_z1EpRTJlMHf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_z6dWFnrUzn86">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities
and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are
recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than
not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future
deductibility is uncertain. As of March 31, 2026 and March 31, 2025, the Company recorded a valuation allowance to the full extent of
the Company&#8217;s net deferred tax assets since the likelihood of realization of the benefit does not meet the more-likely-than-not
threshold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s reserves related to taxes are based on a determination of whether and how much of a tax benefit taken by the Company
in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related
to the tax benefit. The Company would recognize both estimated accrued interest and penalties related to unrecognized benefits within
income tax expense in the consolidated statements of operations and comprehensive loss. The Company&#8217;s uncertain tax positions are
related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position,
the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which
a loss carryforward is available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zUjUHEdFaDd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zboUTYq1V7Xd">Net
Loss Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to Beyond Air, Inc.,
by the weighted average number of shares of common stock outstanding for the period. The dilutive effect of outstanding options, warrants,
restricted stock and other stock-based compensation awards is reflected in diluted net loss per share by application of the treasury
stock method. The calculation of diluted net loss attributed to common stockholders per share excludes all anti-dilutive shares of common
stock. For periods in which the Company has reported net losses, diluted net loss per share attributable to common stockholders is the
same as basic net loss per share attributable to common stockholders, because such shares of common stock are not assumed to have been
issued if their effect is anti-dilutive (Note 8).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entity</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ConsolidationVariableInterestEntityPolicy_zXmJuTlw0mS" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zvtldgtakaPf">Variable
Interest Entity</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company has the power to direct activities of both Beyond Cancer and NeuroNos  that most significantly impact their economic
performance and the right to receive benefits and losses that may potentially be significant, these financial statements are fully consolidated
with those of the Company. The non-controlling owners&#8217; <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20260331__srt--OwnershipAxis__custom--BeyondCancerLtdMember_zVO1dsDjeZKb" title="Non-controlling owners interest">20</span>% interest in Beyond Cancer&#8217;s net assets and result of operations
and the non-controlling owners&#8217; <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20260331__srt--OwnershipAxis__custom--NeuroNosLtdMember_zGruHsD1j4A8" title="Non-controlling owners interest">15.25</span>% interest in NeuroNos&#8217; net assets and result of operations are reported as &#8220;non-controlling
interest&#8221; on the Company&#8217;s consolidated balance sheets and as &#8220;net loss attributable to non-controlling interest&#8221;
in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z2e5hTyHtoI" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z3xqho5VK4fa">Recently
Adopted Accounting Standards</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;)
2023-09, <i>Improvements to Tax Disclosures (Topic 740), </i>to enhance the disclosures related to income taxes, including the rate
reconciliation and information on income taxes paid. This ASU is effective for fiscal years beginning after December 15, 2024
(fiscal 2026 for the Company), with early adoption permitted. The Company adopted this standard effective April 1, 2025
prospectively. See Note 11, &#8220;Income Taxes,&#8221; for further information regarding the
Company&#8217;s effective income tax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock', window );">Recently Issued Accounting Standards Not Yet Adopted</a></td>
<td class="text"><p id="xdx_84D_ecustom--RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_zypEtiThyZ79" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_ztIW2GOFmu92">Recently
Issued Accounting Standards Not Yet Adopted</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40).</i> This standard requires disclosure of specific information about costs and expenses and becomes effective for fiscal
years beginning after December 15, 2026 (fiscal 2028 for the Company), with early adoption permitted. The Company is assessing the impact
of this ASU and, upon adoption, may be required to include certain additional disclosures in the footnotes to the Consolidated Financial
Statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_CustomerrConcentrationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customerr Concentration [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_CustomerrConcentrationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going Concern Liquidity and Other Uncertainties [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_OtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Risks and Uncertainties [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_OtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently Issued Accounting Standards Not Yet Adopted [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_SupplierConcentrationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplier Concentration [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_SupplierConcentrationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Paragraph 2AA<br> -Subparagraph (a)<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-2AA<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2D<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUE ON A RECURRING BASIS</a></td>
<td class="text"><p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zSz2dHLbWKHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value amounts as of March 31, 2026 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zXpIL3M7zN37" style="display: none">SCHEDULE
OF FAIR VALUE ON A RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20260331_z0foNQr9g2b6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z38n6cDnwlu8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z00wG26yyZg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsZd0BuskkP8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_ze7sjfLFgEgg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">4,901</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">4,901</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0729">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0730">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zjHwT9v6ZS32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,901</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,901</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0734">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0735">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zRC5TAbEqGGb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0739">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_z468H5pC9PIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0743">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value amounts as of March 31, 2025 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250331_z3Jt5bx4bnYc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjwMihH6oIy5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQyMh8LZAtai" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWF9wGvB3aei" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zQgGzALhxHx" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">2,252</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">2,252</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0750">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zKl8QiSE9w77" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0755">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z7teyQQZeWch" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">38</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0758">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0759">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">38</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zIpton2TLu3e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured and recorded at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0763">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">SUMMARY OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--MarketableSecuritiesTextBlock_z4HgtsibLNA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s short-term marketable securities with unrealized gains and losses as of March 31, 2026,
aggregated by major security type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zCu1EyrKbD71" style="display: none">SUMMARY
OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrealized Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_z5wtCioRRxGi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, fair value">4,901</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20250401__20260331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zB1niEE5K80j" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, unrealized loss">39</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total short-term marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zu1R3CSkgizd" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Fair value">4,901</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20250401__20260331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zSGHtLg4kMfj" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Unrealized gains and (losses)">39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s short-term marketable securities with unrealized gains and losses as of March 31, 2025,
aggregated by major security type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrealized Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 1pt">Mutual funds</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zQg58g0FROi4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, fair value">2,252</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20240401__20250331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zWNdUiwZjpf7" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, unrealized loss">39</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Total short-term marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zpU8N2T4NHZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Fair value">2,252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20240401__20250331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zr2SOMcBc0If" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Unrealized gains and (losses)">39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">SCHEDULE OF ASSUMPTIONS USED IN VALUING WARRANTS</a></td>
<td class="text"><p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zHT5mdEx3482" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant assumptions used in valuing the warrants were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zMM5k5MZuJid" style="display: none">SCHEDULE
OF ASSUMPTIONS USED IN VALUING WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">At March 31, 2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Expected term (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgvjyxQ3NFWj" title="Expected term warrants">2.25</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ziOPdUBHgXR1" title="Warrants and rights outstanding, measurement input">132.1</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z70biNE9YS8c" title="Warrants and rights outstanding, measurement input">3.8</span></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">At March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Expected term (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyJjQ346E25f" title="Expected term warrants">3.25</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zeuiYAT9gYHk" title="Warrants and rights outstanding, measurement input">99.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdcmXtcs2u7b" title="Warrants and rights outstanding, measurement input">3.9</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock', window );">SCHEDULE OF KEY INPUTS DERIVATIVE</a></td>
<td class="text"><p id="xdx_895_ecustom--FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock_zsfFhj7pnTGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zHcIVEJ0tXp1" style="display: none">SCHEDULE
OF KEY INPUTS DERIVATIVE </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">At November 4, 2025 (issuance)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20251104_zE3kHp0WJLG6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Maximum convertible shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20251104__20251104_zx3BaNOFcG5f" style="width: 16%; text-align: right" title="Maximum convertible shares">1,600,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zh4ViqIooue7" style="vertical-align: bottom; background-color: White">
    <td>Share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.86</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zsrRCqjWT2u6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z17Mb19aVOfg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock', window );">SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock_znFmSd1AcC0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuation for the warrants and derivatives
for the years ended March 31, 2026 and March 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zjA246EL3fBa" style="display: none">SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--FinancialInstrumentAxis_us-gaap--WarrantMember_zKomqjJB3SX7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_zr6VZOcny8w2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43D_c20240401__20250331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_ztdzelDPDHeh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance at March 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">275</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,314</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zCFopjQvCLGg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(237</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,314</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20250401__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zWLun7K8xSJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at March 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zCbqV14l7zv" style="vertical-align: bottom; background-color: White">
    <td>Issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">775</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zlVdshaDBc45" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,395</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--FairValueMeasurementExtinguishment_zmcY92DcW479" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Extinguishment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,170</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_435_c20250401__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zob4KlfS1AB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Balance at March 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zO39TGqE6eHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table is the reconciliation of the presentation and disclosure of cash, cash equivalents, marketable securities by major security
type and restricted cash as shown on the Company&#8217;s consolidated statements of cash flows for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z0jfOmMC4Fy7" style="display: none">SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20260331_zKbwo92hRnU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250331_zIIVYqgiz4Xl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCEASz3pW_maRCACEzZrO_zQj3UHc54oZf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,740</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,665</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RestrictedCashCurrent_iI_pn3n3_maRCACEzZrO_zFxqdPDYOz83" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,622</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">231</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RestrictedCashAndCashEquivalents_iTI_pn3n3_mtRCACEzZrO_maCCEASziVz_zCa0NYeQZvO8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total cash, cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,362</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,896</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--MarketableSecuritiesAbstract_iB_zy0yiyUF65n9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--MarketableSecuritiesCurrent_i01I_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z213JS7INxXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,901</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MarketableSecuritiesCurrent_i01I_pn3n3_maCCEASziVz_zJBHKOVrL1Ok" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">4,901</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iTI_pn3n3_mtCCEASziVz_zHJeioG91Fig" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents, marketable securities and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,263</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,148</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS</a></td>
<td class="text"><p id="xdx_895_ecustom--ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock_zpfWmIi8fGMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation and accumulated amortization. Depreciation and amortization are calculated
using the straight-line method over the estimated useful life of the assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zziOzbX9ZBq2" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zGOdAUEMpnMl" title="Estimated useful life of assets">Three
    years</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z0YAIfctOaLa" title="Estimated useful life of assets">Five
    years</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    and medical equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember__srt--RangeAxis__srt--MinimumMember_zeg8FPWttisb" style="display: none" title="Estimated useful life of assets">3</span>/<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember__srt--RangeAxis__srt--MaximumMember_zL0oHTEqzoq9" title="Estimated useful life of assets">Five
    years</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment
    deployable as part of a service offering</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentDeployableAsPartOfServiceOfferingMember_zbKoyiHEMEGc" title="Estimated useful life of assets">Five
    years</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zIOJZqQidfNf" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2026%23UsefulLifeTermOfLeaseMember"><span style="-sec-ix-hidden: xdx2ixbrl0906">Shorter
    of term of lease or estimated useful life of the asset</span></span></span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zPqdqDxadk6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected amortization expense for the next five years and thereafter is as follows for the year ended March 31 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zfGTZeVvBHb1" style="display: none">SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_490_20260331_zTDHWIObOgA5" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANz72H_ztGt05u0vLWc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: left">2027</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">205</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANz72H_zdQScyCDpJTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANz72H_zdimKZ1UaNT8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANz72H_zoImxPVfM5fi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANz72H_zoRKAth2Mncg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2031</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANz72H_ziR28fJCHfik" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,018</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement Inputs and Valuation Techniques of Derivative [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Change In Fair Value Of Warrants And Derivatives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Property and Equipment UsefulLife of Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash, cash equivalent, and investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated amortization expense for finite-lived intangible asset and capitalized cost for software to be sold, leased, or marketed, expected to be recognized for each of five succeeding fiscal years. Excludes goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant, and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zMLxG8Xv4tae" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_za6Zd0dRYAWe" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20260331_zDU3FrgE1UK3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2026</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250331_z8F8ZR3n9Atd" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember_zIGK6yflbM0b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Clinical and medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">206</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,048</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentDeployableAsPartOfServiceOfferingMember_zSOgUnmfLmx6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equipment deployable as part of a service offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,871</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,511</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpz3vKbJKZ4e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">927</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zlu4qQjjp4k8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">458</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">506</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zN2v5XsHcI9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">521</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">521</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzruM_zdxqruQDXCsk" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,909</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,513</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzruM_zd7ivrOPoKl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,660</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,500</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzruM_zqkpMFbHCKn2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment, net</span></span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,249</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,013</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">SCHEDULE OF RESTRICTED STOCK AWARDS</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zLPikjit4Xa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s restricted stock unit awards for the years ended March 31, 2026 and March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zExED22KtKVf" style="display: none">SCHEDULE OF RESTRICTED STOCK AWARDS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number Of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date Fair </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Unvested as of March 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6MuNpET45r8" style="width: 16%; text-align: right" title="Unvested Number of Shares, Beginning balance">30,945</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB0SKhNOdUK3" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">139.60</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzCJpLPJ4tW7" style="text-align: right" title="Number of Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1087">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zW9veaMoeSR8" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMg8cv71H9Og" style="text-align: right" title="Number of Shares, Vested">(12,240</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zbnKrhCW15E" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">137.20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkc6cTHzSkZ2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeited">(440</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjoEnOhgqtnl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">229.60</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Unvested as of March 31, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zeg4dH5hz1Ul" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested Number of Shares, Beginning balance">18,265</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1iho2up2q8b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">139.40</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zlnBw6qwW5lf" style="text-align: right" title="Number of Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zroJU2kT7Eq8" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1105">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB3PfQsrwQCg" style="text-align: right" title="Number of Shares, Vested">(8,630</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjrLsw2vGFIe" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">150.26</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zacVs3383fwl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeited">(150</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhQ6nv5gB0rg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">137.40</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Unvested as of March 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zx0uM3ife9Ta" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested Number of Shares, Ending balance">9,485</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyzVzIbf5x27" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, ending balance">129.41</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF FAIR VALUE OF OPTION</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_znuBCNu7JmO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following was utilized to calculate the fair value of options on the date of grant:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z5l5Hkq90oM9" style="display: none">SCHEDULE
OF FAIR VALUE OF OPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk -free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250401__20260331__srt--RangeAxis__srt--MinimumMember_ztqHuUTMVkU6" title="Risk-free interest rate">3.7</span>-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250401__20260331__srt--RangeAxis__srt--MaximumMember_z5Weo3qWwYK6" title="Risk-free interest rate">4.2</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MinimumMember_zOk3WASdJaOc" title="Risk-free interest rate">3.6</span>-<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MaximumMember_zD0V6CXOeHYk" title="Risk-free interest rate">4.4</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (Beyond Air)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MinimumMember_zV4T83F0opSe" title="Expected volatility">91.6</span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MaximumMember_z8EHPpW1UOH2" title="Expected volatility">106.2</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MinimumMember_z8BzrqrUvkL6" title="Expected volatility">83.6</span>-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MaximumMember_z8rmUTALNZgf" title="Expected volatility">89.9</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (Beyond Cancer)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zl2io9hAH0Rl" title="Expected volatility">N/A</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zaRevvw1K9Bc" title="Expected volatility">N/A</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Expected volatility (NeuroNos)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember_zVJpALKf2QR1" title="Expected volatility">95.0</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember_zJibdoGTAv21" title="Expected volatility">95.0</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250401__20260331_zYE7J99l4Uc7" title="Dividend yield">0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240401__20250331_zh1kgth8vmC5" title="Dividend yield">0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected terms (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250401__20260331_zXpIeUoRAko2" title="Expected term (in years)">6.25</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240401__20250331_zh1VdwzsZHpd" title="Expected term (in years)">6.25</span></td><td style="text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zC0pH738OJH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the components of stock-based compensation expense which included stock options and restricted stock for the years
ended March 31, 2026 and March 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zEz0Aj0KcgYk" style="display: none">SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250401__20260331_zq7dXjpYPMUl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240401__20250331_zveT734dr9Ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--ResearchAndDevelopmentExpense_zphXUEaGZq5c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,153</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">471</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zRBl1sXybtyd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,129</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,675</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_pn3n3_z3LePV7u1DXh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,282</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,146</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SUMMARY OF OUTSTANDING WARRANTS</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVuaGqiwngbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s outstanding warrants as of March 31, 2026 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_znadyXZOO54l" style="display: none">SUMMARY
OF OUTSTANDING WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Warrant Holders</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify">NitricGen agreement</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z4kShwuooEzd" style="width: 11%; text-align: right" title="Number of Warrants">4,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_zrrfqWfjyFs9" style="width: 11%; text-align: right" title="Exercise Price">138.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z82UsnuOhuai" style="width: 11%; text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1450">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 17%; text-align: center"><span id="xdx_90B_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z67dCquqcvBe" title="Date of Expiration">January 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Avenue agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_z3qE4BXpSG88" style="text-align: right" title="Number of Warrants">11,693</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zE1o60N5QRK3" style="text-align: right" title="Exercise Price">7.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zYBi17WHaRG6" style="text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1458">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zV23M8znsHYj" title="Date of Expiration">June 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">March 2024 raise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zw5FeoLMNUkg" style="text-align: right" title="Number of Warrants">481,936</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zvFMa9PYPi5" style="text-align: right" title="Exercise Price">45.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_z4lkHpV5luNi" style="text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1466">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zLdjKKNcg7hk" title="Date of Expiration">March 2027</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Avenue extension agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zPAZzCg5Omcj" style="text-align: right" title="Number of Warrants">5,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zcfOWm9cqmn5" style="text-align: right" title="Exercise Price">25.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zx4ik2vBNlC5" style="text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1474">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zwt1QWSGlGCl" title="Date of Expiration">June 2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">September 2024 equity offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zP5rs7vYn62b" style="text-align: right" title="Number of Warrants">555,229</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_z8gTZM698Bt8" style="text-align: right" title="Exercise Price">7.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zeKM7h9fB06" style="text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1482">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zmGsa4tmgTH2" title="Date of Expiration">September 2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">September 2024 debt instrument</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zFkIDRzrQlDh" style="text-align: right" title="Number of Warrants">1,270,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zicWS367XVkj" style="text-align: right" title="Exercise Price">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zvtoJXRSuLOc" style="text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1490">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zKYCGJ3Wszh7" title="Date of Expiration">September 2029 / November 2030</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">September 2025 inducement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zrk8L3PstUP1" style="text-align: right" title="Number of Warrants">719,562</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zcTuX5vJXQ04" style="text-align: right" title="Exercise Price">2.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zJ9gj1dntk87" style="text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1498">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zTonXyrH1eCj" title="Date of Expiration">September 2030</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">January 2026 equity offering</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zMqAK5J6CSs3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants">3,930,818</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zUXDNfH4EXAj" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price">1.147</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_z5zH5sGpVSNl" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1506">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zReAqHOnTIq8" title="Date of Expiration">January 2031</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zpqKgoG7zFA3" style="text-align: right" title="Number of Warrants">6,979,034</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zRyE1w5e87e4" style="text-align: right" title="Exercise Price">5.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zpF3Vh78GCg2" style="text-align: right" title="Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1514">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pre-funded warrants (Sep-2024 offering)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_ziNtUpjIizjh" style="text-align: right" title="Number of Warrants">220,006</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_zut3bvqrXnz9" style="text-align: right" title="Exercise Price">0.002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_ziio5DBdmHZj" style="text-align: right" title="Intrinsic Value">151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_zTe4TE5Bfixi" title="Date of Expiration">September 2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Pre-funded warrants (Jan-2026 offering)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zTM446FKRBO9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants">2,142,613</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zzgI25s9Rhc1" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price">0.0001</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zzhhUwr98aWk" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value">1,479</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_901_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zTy0FS3fMkb9" title="Date of Expiration">January 2031</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331_zDKoi3QCk5ye" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants">9,341,653</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331_zGE9blo9TObb" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise Price">3.773</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331_zsRu6JJ5ajh5" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value">1,630</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember', window );">2013 Beyond Air Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF OPTION ACTIVITY FOR NEURONOS</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcILgvnqjbS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the change in stock options for the years ended March 31, 2026 and March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zPMO2ul4ry35" style="display: none">SCHEDULE OF OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price&#8211;-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life- </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(thousands)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Options outstanding as of March 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zDIuTD1HmBn" style="width: 11%; text-align: right" title="Number of Options, Outstanding at beginning of period">566,645</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRrEUPyqxF9d" style="width: 11%; text-align: right" title="Weighted Average Exercise Price - Options, Outstanding at beginning of period">88.39</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zfw3evrr2Fr4" title="Weighted Average Remaining Contractual Life - Options">8.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zylzEpHSyxIi" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">760</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zoGAg1pOcH3b" style="text-align: right" title="Number of Options Outstanding, Granted">227,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRupONoHugJj" style="text-align: right" title="Weighted Average Exercise Price - Options, Granted">6.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zquTALQYQDWd" style="text-align: right" title="Number of Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zVGjiqWEuihd" style="text-align: right" title="Weighted Average Exercise Price - Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1147">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zLvDY8NIKuYd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Forfeited">(54,976</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zVt55UyXj6sf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Options, Forfeited">61.74</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding as of March 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zNHc46gRgZF3" style="text-align: right" title="Number of Options, Outstanding at beginning of period">739,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zAkxzGO3xqE7" style="text-align: right" title="Weighted Average Exercise Price - Options, Outstanding at beginning of period">9.34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRMUh8b5pHG5" title="Weighted Average Remaining Contractual Life - Options, Outstanding at beginning of period">7.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zdQWrl0Ptc3c" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1159">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zb0DsRAuUdI1" style="text-align: right" title="Number of Options Outstanding, Granted">94,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zKPnzEy7Uty3" style="text-align: right" title="Weighted Average Exercise Price - Options, Granted">0.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zuv9Dih4ZqF3" style="text-align: right" title="Number of Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1165">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zdBZ78oloXib" style="text-align: right" title="Weighted Average Exercise Price - Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_z63B4wYthsHf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Forfeited">(77,270</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zMHfWM2AW9B2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Options, Forfeited">1.95</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcVHxVYaJAw2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at ending of period">756,749</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_z28O37ZACZJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options, Outstanding at ending of period">1.82</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zSybYciOzyp5" title="Weighted Average Remaining Contractual Life - Options, Outstanding at end of period">7.2</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zjffWXBkOv75" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at end of period"><span style="-sec-ix-hidden: xdx2ixbrl1179">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcU09AUzmzRi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Exercisable">497,591</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zZWvfCXaIUQ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options, Exercisable">1.95</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zc3N8Wp4PdLi" title="Weighted Average Remaining Contractual Life - Options, Exercisable">6.3</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zONx7x7i0Pkc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember', window );">2021 Beyond Cancer Ltd Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF OPTION ACTIVITY FOR NEURONOS</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zIGS8sGiUi2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the change in stock options for Beyond Cancer for the years ended March 31, 2026 and March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zfNCVrREUPoa" style="display: none">SCHEDULE
OF OPTION ACTIVITY FOR BEYOND CANCER</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price&#8211;-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life- </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(thousands)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Options outstanding as of March 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zltD0lFKYr29" style="width: 11%; text-align: right" title="Number of Options, Outstanding at beginning of period">3,819,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zPStOfDJJPha" style="width: 11%; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period">5.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zC49XGIPXeB4" title="Weighted average remaining contractual life - options, outstanding at beginning of period">8.3</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zQkQLohCA7H2" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z9HQ10n1f8q1" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1243">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXJCIIyEQqsi" style="text-align: right" title="Weighted Average Exercise Price of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zltdWXYxbUwe" style="text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1247">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zlfL50p2nf13" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1249">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zJVpcZOWGyt5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(1,002,750</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zAOoFNdvqLue" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price of Options, Forfeited">5.50</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding as of March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXK1Ydo1CHvg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at beginning of period">2,816,250</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_ziyVB8iwOtZ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period">5.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXJXgcJK8rt6" title="Weighted average remaining contractual life - options, outstanding at beginning of period">7.2</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zxp6GCLrGnW5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1261">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zlzImYg5etR9" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zZDm8lqi3LR7" style="text-align: right" title="Weighted Average Exercise Price of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zoq5ry3qY7ag" style="text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1267">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zD5GzidrBIub" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBUKt3EcL5bd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(561,750</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z3mQDWmOLBU7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price of Options, Forfeited">5.50</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z5dckoFlZlg9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at ending of period">2,254,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zyCXarkEuvMa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at ending of period">5.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zIckJ2fTos8i" title="Weighted average remaining contractual life - options, outstanding at beginning of period">6.2</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zqkBxlY4doP" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding at end of period"><span style="-sec-ix-hidden: xdx2ixbrl1281">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBQOTMmBnKuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Exercisable">1,975,750</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBInmxPusKql" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Exercisable">5.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zC6JnOcvBVvk" title="Weighted Average Remaining Contractual Life of Options, Exercisable">6.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zmg18381u15a" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember', window );">2023 Neuro Nos Ltd Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF OPTION ACTIVITY FOR NEURONOS</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zh9GKH4NRrL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the change in stock options for NeuroNos for the years ended March 31, 2026 and March 31, 2025 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zzqGzZlZI6Se">SCHEDULE
OF OPTION ACTIVITY FOR NEURONOS</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price&#8211;-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life- </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(thousands)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding as of March 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zzh1y1MycSpa" style="text-align: right" title="Number of Options, Outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zePHo2mON8Nk" style="text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zRuWKHUO1Mxc" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zKXJyXen5OXc" style="width: 11%; text-align: right" title="Number of Options, Granted">1,224,139</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z3HPlgV7lHh9" style="width: 11%; text-align: right" title="Weighted Average Exercise Price of Options, Granted">0.14</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zBGUDjzUIFMg" style="text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1311">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zYMwGOOXRvJi" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1313">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zapFoZDRg2ni" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zEolIhcf8rt8" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price - options, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1317">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding as of March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zgHjMFZpIVri" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at beginning of period">1,224,139</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zqTaYDZ2V9xf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period">0.14</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zzFD91herDCk" title="Weighted average remaining contractual life - options, outstanding at beginning of period">9.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_za87e7pYMJwa" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">3,501</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z5YWYvHEN6g1" style="text-align: right" title="Number of Options, Granted">169,913</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_ziEsb2HyfQW3" style="text-align: right" title="Weighted Average Exercise Price of Options, Granted">3.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zecF9JIVa7hf" style="text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1331">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z3K6NYELNkK4" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1333">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zCx9aDsAiMYh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(134,723</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zRDQ9XILrgp" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price - options, forfeited">2.82</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zfEaOkfKvcG1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at ending of period">1,259,329</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zx5hb3vD5vla" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at ending of period">0.24</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zhz8aKY5TdIa" title="Weighted Average Remaining Contractual Life of Options, Outstanding">8.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_znqU4pApiRS8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at ending of period">3,477</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable as of March 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zCGea6Lpnox2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Exercisable">622,341</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zNIF39u3q2A1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Exercisable">0.19</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zLCSAYm36C8j" title="Weighted Average Remaining Contractual Life of Options, Exercisable">8.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_znZ7QXjs68d9" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable">1,748</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS AND PREPAID EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">SCHEDULE OF OTHER CURRENT ASSETS AND PREPAID EXPENSES</a></td>
<td class="text"><p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z12r0YX9rOK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of other current assets and prepaid expenses as of March 31, 2026 and March 31, 2025 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zWlHKa80qD8c" style="display: none">SCHEDULE
OF OTHER CURRENT ASSETS AND PREPAID EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20260331_zTQvj9c1CA6i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20250331_z3gnSdYgdLL5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzff3_z3DrsaFKYFsj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">696</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">108</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidInsurance_iI_maPEAOAzff3_z17lBgx71299" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">579</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">817</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidRent_iI_maPEAOAzff3_zzYTebrULgoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid rents and tenant improvement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidTaxes_iI_maPEAOAzff3_zVlyDEphLZT3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Value added tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DepositsAssets_iI_maPEAOAzff3_zsExCHma4Syg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deposits to secure manufacturing materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,377</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Supplies_iI_maPEAOAzff3_zLHwcz0ZdJjc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Demonstration materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_maPEAOAzff3_zAoTAMHnW28f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">190</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">203</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzff3_z1LDZg4eceVg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total other current assets and prepaid expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,012</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,743</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SUMMARY OF ACCRUED EXPENSES</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zZTkvZpdS6Ah" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of accrued expenses and other current liabilities as of March 31, 2026 and March 31, 2025 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zIdDrAHEKJdb" style="display: none">SUMMARY OF ACCRUED EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20260331_zgmGMcKnZwQ" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250331_zt51FMOpjwUb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentExpenses_iI_pn3n3_maTSAEzACS_zI7vqb8Et3Ib" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">16</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">360</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maTSAEzACS_z07t4i6zH1yf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maTSAEzACS_zSO1iQsJpyy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Employee salaries and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">465</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">924</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--InterestSeveranceCurrent_iI_pn3n3_maTSAEzACS_z2jeCUo66EU9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued severance<span id="xdx_F4C_zPEwRQVV9dUg">*</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">696</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1584">-</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_pn3n3_maTSAEzACS_zAZ3jpsVd2n5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1587">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredRevenueCurrent_iI_pn3n3_maTSAEzACS_z9sLbDACDPh1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1590">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--GoodsReceivedNotInvoiced_iI_pn3n3_maTSAEzACS_z6hXfThxgJmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Goods received not invoiced</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maTSAEzACS_zFG2iVnQ3jS" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">143</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">223</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_pn3n3_mtTSAEzACS_zMAwvGTeAEbc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,372</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,045</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ScheduleOfOperatingLeaseLiabilityTableTextBlock', window );">SCHEDULE OF OPERATING LEASE LIABILITY</a></td>
<td class="text"><p id="xdx_895_ecustom--ScheduleOfOperatingLeaseLiabilityTableTextBlock_zzGG9uvKCL88" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zWw6wivgAbN8" style="display: none">SCHEDULE
OF OPERATING LEASE LIABILITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20260331_ztxAbLxHn2Sk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20250331_zUIRFzHnw3P6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zGiI7WhnLF96" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Right-of-use assets</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">1,193</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">1,706</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzD8e_zijA2SGcibBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability short-term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">321</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">396</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzD8e_zZY66ViD8VS6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Operating lease liability long-term</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,023</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,486</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzD8e_zwYBqLLf2B5h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,344</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,882</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average remaining lease term &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260331_znOjxmBlimJ4" title="Weighted Average Remaining Lease Term">4.5 </span>years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250331_zzCirPO695al" title="Weighted Average Remaining Lease Term">5.0</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260331_zWu3VTFvafml" title="Weighted-average discount rate - operating leases">8.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20250331_zaZgJwELdgHh" title="Weighted-average discount rate - operating leases">8.3</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">SCHEDULE OF LEASE RELATED COSTS</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zF2ZNa3nJYH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the lease-related costs for the years ended March 31, 2026 and March 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zpu05L1SLtJ7">SCHEDULE
OF LEASE RELATED COSTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250401__20260331_zENbH7iuWro5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240401__20250331_zBYPaefONGOj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseCost_pn3n3_maLCzzCQ_z0My6r6OOnOd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">505</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">539</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzzCQ_z2H9Zw5Chtsc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short-term lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">261</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--SubleaseIncome_iN_pn3n3_di_msLCzzCQ_zxSykFRXTka2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Sublease income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(49</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1643">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LeaseCost_iT_pn3n3_mtLCzzCQ_zXlAIoIONgAi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">544</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_OtherLeaseTableTextBlock', window );">SCHEDULE OF LEASE OTHER INFORMATION</a></td>
<td class="text"><p id="xdx_890_ecustom--OtherLeaseTableTextBlock_zKiHMb2MucUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zb9C4Lawqlg" style="display: none">SCHEDULE OF LEASE OTHER INFORMATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250401__20260331_zWe37xsnyjM2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeasePayments_pn3n3_zOlj2msqDkfl" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Operating cash flows for operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">532</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF MATURITY OF LEASE LIABILITIES</a></td>
<td class="text"><p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zYXW08BCXxjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zfZ5k3klDSH3">SCHEDULE
OF MATURITY OF LEASE LIABILITIES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Maturity of Lease Liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20260331_zhBNqVEJf3R2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payments remaining for the year ended March 31:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzQlL_z6NZJokfnDB4" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">2027</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">419</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzQlL_zRBqnociW0W5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzQlL_zEHihp9ptXke" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzQlL_zxRICOmjHPt5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzQlL_zYy81r2jjSLd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2031</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">266</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzQlL_zNPYuOxJJLYb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">60</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzQlL_zEIJB56tliha" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,623</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zJZIK5zKLAK6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: amount of lease payments representing interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(279</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z6oBkRfqQNGg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of future lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,344</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_OtherLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Lease [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_OtherLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ScheduleOfOperatingLeaseLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Operating Lease Liability [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ScheduleOfOperatingLeaseLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znacKb9NFTD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following potentially dilutive securities were not included in the calculation of diluted net loss per share attributable to common stockholders
of Beyond Air, Inc. because their effect would have been anti-dilutive for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z0HFVm5qSmd3" style="display: none">SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250401__20260331_zyCJZViThJc3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240401__20250331_zvW3CQlTZx3h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zYcoqRAL4887" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Common stock warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">6,979,034</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">3,254,967</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zsqFJjyPz7d7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">756,749</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">739,214</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zHMyFKgsmVJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Restricted shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,485</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,265</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zShpzar5v0Ak" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,745,268</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,012,446</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_znCfEUbDVO44" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Anti-dilutive securities</span></td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">7,745,268</td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">4,012,446</td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">SCHEDULE OF LONG-TERM DEBT</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zzHzFpRkT6p1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of long-term debt as of March 31, 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zojEY2G15B6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z3ToXf20G5Gk" style="display: none">SCHEDULE
OF LONG-TERM DEBT</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20261231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zL5Ig4WSDLR9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Loan</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Agreement</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20261231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zMhw6lWWPJd6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Promissory</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Note</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20261231_zX7s1Eq1UJHe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_maDICAzlrH_zCCbDbJ9awai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Principal balance outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">13,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">12,799</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">26,299</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PaidInKindInterestAmount_iI_pn3n3_maDICAzlrH_ztTaDTxYSjp2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Paid in kind interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,459</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1707">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,459</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msDICAzlrH_zLKaDOiByFV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,343</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,576</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,919</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--AmortizationOfDebtDiscount_iI_pn3n3_maDICAzlrH_zfUWhpFBibKb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Amortization of debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">427</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">373</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">800</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzlrH_zG0CTfZdDvje" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">12,043</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">9,596</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">21,639</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of long-term debt as of March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20260331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zGAkSp7buzkh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Loan</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Agreement</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_maDICAzlrH_zc6Xv80Oarij" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Principal balance outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">11,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PaidInKindInterestAmount_iI_pn3n3_maDICAzlrH_zTk7sSSosZaf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Paid in kind interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">696</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msDICAzlrH_zAnx0rBu8kUj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,249</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--AmortizationOfDebtDiscount_iI_pn3n3_maDICAzlrH_zSSEH88fYNYj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Amortization of debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzlrH_zunJpsAhuoKe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">9,197</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOAN PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">SCHEDULE OF LOAN PAYABLE</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfShortTermDebtTextBlock_zWmY6WlW2Bhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026 and March 31, 2025 in connection with the Company&#8217;s insurance policy, a loan was used to finance part of the
premium. The details concerning the loan are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zZnUqiWNQjDe" style="display: none">SCHEDULE
OF LOAN PAYABLE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Amount outstanding (thousands)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--LoansPayable_iI_pn3n3_c20260331_ztKcuScFwnHj" style="width: 16%; text-align: right" title="Amount outstanding">401</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--LoansPayable_iI_pn3n3_c20250331_zRCA5yIsJiHc" style="width: 16%; text-align: right" title="Amount outstanding">579</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Monthly payments (thousands)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20250401__20260331_z1kwqspy89c" style="text-align: right" title="Monthly payments">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20240401__20250331_zW8jO4dHw282" style="text-align: right" title="Monthly payments">117</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Number of monthly payments remaining</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfPayments_pp0p0_uInteger_c20250401__20260331_zHgrPBwgodW1" style="text-align: right" title="Amount outstanding">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--NumberOfPayments_pp0p0_uInteger_c20240401__20250331_zjA4lwbY4aC7" style="text-align: right" title="Amount outstanding">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260331_zqdl6NpFItlj" title="Interest rate">6.60</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250331_zkMSnfzxTKt2" title="Interest rate">6.25</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Due date</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--LoanPayableDueDateDescription_c20250401__20260331_zGarnnkgKp2i" title="Due date">October 2026</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--LoanPayableDueDateDescription_c20240401__20250331_zXXQMTKBYW6j" title="Due date">August 2025</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">SCHEDULE OF PROFIT (LOSS) BEFORE TAXES</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zNLfHyoe1cL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of net loss before the provision for income taxes are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zIJHDNGoDaSe" style="display: none">SCHEDULE
OF PROFIT (LOSS) BEFORE TAXES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20250401__20260331_zxB4ZQUTwzIj" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p>
                                                                                                                                                                                                                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2026</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240401__20250331_zVAMGKvLM326" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p>
                                                                                                                                                                                                                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maCITEBzGXx_zjogKc9EmxT4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(27,066</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(42,186</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maCITEBzGXx_z2q1Y7cILYui" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,268</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,293</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCITEBzGXx_zQEImN4wkX2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(34,334</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(48,479</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSET/LIABILITY</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zZjOPK0bXZmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zNonrJrOSKbj" style="display: none">SCHEDULE
OF DEFERRED TAX ASSET/LIABILITY</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20260331_zllFfvIlsgTh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2026</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250331_zH5Q6jejfeY9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz1sA_zL1Z4GsGKgkb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">55,607</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">48,702</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz1sA_znnSsjr9QRUj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,506</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,197</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ResearchAndDevelopmentTaxCreditCapitalization_iI_pn3n3_maDTAGz1sA_zI2WPQtet8x3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development tax credit capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,572</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,066</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz1sA_z2scwFmtHa5" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(111</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation_iI_pn3n3_maDTAGz1sA_zPSD444Stk56" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,803</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,337</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz1sA_z2ADsIKu6imb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,556</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsReservesAndAccruels_iI_pn3n3_maDTAGz1sA_zuLImAvDWkO2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Reserves and accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAsset_iI_pn3n3_maDTAGz1sA_z49r2VUBTyRl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(282</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(298</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxAssetsLeaseLiability_iI_pn3n3_maDTAGz1sA_ziQc5X8Kf8j6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">314</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">333</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_maDTALNzJp8_mtDTAGz1sA_zbZ8VTOv1jya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net deferred tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,240</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzJp8_z4uqPMwirJv" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(69,550</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(64,240</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzJp8_zfAyL6nNPT1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net deferred tax asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1893">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1894">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF DIFFERENCE EFFECTIVE INCOME TAX RATE</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock_zoRiUd8BE8gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the principal reasons for the difference between the effective tax rate and the U.S. federal enacted
statutory income tax rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIElOQ09NRSBUQVhFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_905_ecustom--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_pid_dp_uPure_c20250401__20260331_zmMXL9IdAiP" title="Federal income tax rate">21</span>%
for the year ended March 31, 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_z0aG5edMi1p3" style="display: none">SCHEDULE
OF DIFFERENCE EFFECTIVE INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250401__20260331_zF8Hw48YEEAb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzUaV_zb2NKG1uDnL3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt">U.S. federal statutory tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(7,210</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250401__20260331_zTy0B0cm9yB9" style="width: 16%; text-align: right" title="U.S. federal statutory tax rate">21.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40C_ecustom--IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes_pn3n3_maITEBzUaV_zjl1AesKcEP4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Current state and local income taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1904">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes_pid_dp_uPure_c20250401__20260331_zjNpHs698BZk" style="text-align: right" title="Current state and local income taxes, net of federal benefit"><span style="-sec-ix-hidden: xdx2ixbrl1906">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Foreign Tax Effects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 10pt">Ireland</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_hsrt--StatementGeographicalAxis__country--IE_zt0Laqf10zx7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IE_zn3rzANx1XP8" style="text-align: right" title="Change in valuation allowance">(1.28</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_hsrt--StatementGeographicalAxis__country--IE_z9jkx9jgZP7" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 20pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">235</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IE_zXIOqsaaI4sj" style="text-align: right" title="Other">(0.69</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 10pt">Israel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_hsrt--StatementGeographicalAxis__country--IL_maITEBzUaV_zq2weZSM9Nk5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IL_zFCvdfFx5DQ9" style="text-align: right" title="Change in valuation allowance">(1.08</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_hsrt--StatementGeographicalAxis__country--IL_maITEBzUaV_zTsqgrFydRuc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 20pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IL_zaRkF3HMSD61" style="text-align: right" title="Other">(0.29</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maITEBzUaV_zpeZ9pXeYC6e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Other foreign jurisdictions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_pid_dpi_uPure_c20250401__20260331_zZWVvzKz8NUh" style="text-align: right" title="Other foreign jurisdictions">(0.26</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IncomeTaxReconciliationDifferenceTaxCreditsResearch_iN_pn3n3_di_msITEBzUaV_zHeUTb8N4yp" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(308</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch_iN_pid_dpi_uPure_c20250401__20260331_z4zOLsxtNNq1" style="text-align: right" title="Other foreign jurisdictions">0.90</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationTaxCreditsOther_pn3n3_msITEBzUaV_zWZSRF3WbmM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Changes in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,759</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20250401__20260331_zaEKltgnCeYk" style="text-align: right" title="Changes in valuation allowance">(10.95</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Effect of cross-border tax laws</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IncomeTaxReconciliationTaxSubpartFIncome_pn3n3_msITEBzUaV_zKYQySrZlrMe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Subpart F Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--EffectiveIncomeTaxRateReconciliationSubpartFIncome_iN_pid_dpi_uPure_c20250401__20260331_z1fCXvjJqqN9" style="text-align: right" title="Subpart F Income">(0.02</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Nontaxable or nondeductible items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount_pn3n3_maITEBzUaV_z2jxG5Lijki8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Share-based payment awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,878</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_uPure_c20250401__20260331_zcOHtY9CV2k9" style="text-align: right" title="Share-based payment awards">(5.47</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationDifferenceOtherAdjustments_pn3n3_maITEBzUaV_z8fwdzqDUi9a" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 10pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">293</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331_zjcogF9fNaWf" style="text-align: right" title="Other">(0.85</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--IncomeTaxReconciliationDifferenceOtherReconcilingItems_pn3n3_maITEBzUaV_zpssULizKaLk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0pt">Other adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">346</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent_iN_pid_dpi_uPure_c20250401__20260331_zYUlD6ISgii6" style="border-bottom: Black 1pt solid; text-align: right" title="Other adjustments">(1.01</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzUaV_zTL6ep64Xhqj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt">Provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1952">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_c20250401__20260331_zgCeK0OrfWD2" style="border-bottom: Black 2.5pt double; text-align: right" title="Other adjustments">0.00</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF STATUTORY US FEDERAL EFFECTIVE RATE</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zZO1ZpwSPAT2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of income tax expense calculated at the federal enacted statutory income tax rate of 21% is as follows
for the year ended March 31 2025:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_z6TWAqXJARvi" style="display: none">SCHEDULE
OF STATUTORY US FEDERAL EFFECTIVE RATE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240401__20250331_zclPp73dxxf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March
31, 2025</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_iN_pid_dpi_uPure_maancd_z5YdzhxqsDTe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 77%; text-align: left">Federal income tax at statutory rate</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maancd_zfuIl3OK4d96" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax, net of federal benefit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.73</td><td style="text-align: left"></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_pid_dp_uPure_maancd_zkTjVegcMzhd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Permanent items</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.58</td><td style="text-align: left"></td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_pid_dpi_uPure_maancd_zZQ5gY3Ikow8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Non-deductible compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10.45</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_maancd_z2xfmwl9ERYh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in valuation allowance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10.46</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msancd_zlYSTgFCY1t2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development tax credits</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.12</td><td style="text-align: left"></td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_iN_pid_dpi_uPure_maancd_z2RpVoJJqTE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Foreign tax rate differential</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.65</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_maancd_z9DaXmyYvOUf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Other</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.87</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss_pid_dp_uPure_maancd_zm7BOtXE93a3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change to foreign NOL&#8217;s</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1974">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtancd_zDncT245Hms5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Effective income tax expense rate</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Difference Effective Income Tax Rate Reconciliation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=XAIR_VariableInterestEntitiesMember', window );">Variable Interest Entities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_hus-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zi35rnQZDH44" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes segment financial information by business segment for the year ended and at March 31, 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zZcAXe4hCHL7" style="display: none">SCHEDULE
OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zgNStXblWzyk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Air</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20250401__20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zrohAMv6szfk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Cancer</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250401__20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zW4cVuxAUe2e" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NeuroNos</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250401__20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zfzya6K0k5If" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Capital expenditures</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zaRmoaTQJekb" style="width: 11%; text-align: right" title="Capital expenditures">1,024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zJ4ykdiSy4E6" style="width: 11%; text-align: right" title="Capital expenditures"><span style="-sec-ix-hidden: xdx2ixbrl2046">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zqfUEiOI5Ytd" style="width: 11%; text-align: right" title="Capital expenditures">2</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zPOCp9oyeNOk" style="width: 11%; text-align: right" title="Capital expenditures">1,026</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zYC7W16bsKIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,679</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2053">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2054">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,679</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_iN_pn3n3_di_zsF7fuTED9V5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,427</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2058">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2059">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,427</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_iN_pn3n3_di_zv81KCo3nG5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,677</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,170</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,394</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,241</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_iN_pn3n3_di_zU1UMJJfVMkg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Selling, general, and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,418</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,207</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,430</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,055</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_pn3n3_z5DvcCbw0551" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,843</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,377</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,824</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29,044</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestExpenseNonoperating_iN_pn3n3_di_zwm6AW51Md8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest and finance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,515</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2078">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2079">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,515</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_ztk81NjYlHV7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other non-operating income/(expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,668</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(323</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">216</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,775</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_zOPF7kgxtz2a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(28,026</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,700</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,608</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(34,334</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating activities included in net loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_pn3n3_z9J9woXZHIW5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2094">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,251</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_zeJR6trJe1Z8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,373</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,282</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn3n3_zbbBYU29PRel" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash used in operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(14,775</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,314</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,055</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(18,144</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_pn3n3_z3RK8MDJS42i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash used in (provided by) investing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,660</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,674</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_pn3n3_zh70pOLjOBnd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash provided by financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2113">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,090</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_pn3n3_zYgHbHhOoasj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impact of exchange rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(198</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_pn3n3_zw5LfUvnRZbe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change for the year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,183</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(162</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,555</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,466</td><td style="text-align: left"></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes segment financial information by business segment for the year ended and at March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zDUICAtIvEQ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Air</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240401__20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zCttKZP1DMJf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Cancer</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240401__20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zrtcmnTEofrl" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NeuroNos</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240401__20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zxYQug0DaJD1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Capital expenditures</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z5bLU8nNP0Qk" style="width: 11%; text-align: right" title="Capital expenditures">5,859</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zyTaBK3RHHF4" style="width: 11%; text-align: right" title="Capital expenditures">24</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z9aaCtJIZigl" style="width: 11%; text-align: right" title="Capital expenditures"><span style="-sec-ix-hidden: xdx2ixbrl2131">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zZWsdloUZI1i" style="width: 11%; text-align: right" title="Capital expenditures">5,883</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zj9qM7N2ZII6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2136">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2137">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,705</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_iN_pn3n3_di_zYttFNkJGdmi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,368</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2141">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2142">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,368</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_iN_pn3n3_di_zkl7QSK36Gvh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,780</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,062</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,857</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_iN_pn3n3_di_z4VhBJnqO6Q8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Selling, general, and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,565</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,344</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(108</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,017</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_pn3n3_zRjKyHfJzj02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(35,008</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,406</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(123</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44,537</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestExpenseNonoperating_iN_pn3n3_di_zRE84GqWecie" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest and finance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,019</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2161">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2162">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,019</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zsOS9HV5kXQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other non-operating income/(expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,132</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2167">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(923</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_z2z2DFjUjva7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(39,159</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(9,197</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(123</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(48,479</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating activities included in net loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_pn3n3_zqq3H6aDymtb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,143</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2177">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,204</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_zQVdfhJgEsya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,154</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,146</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn3n3_zYjo82QwFx87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash used in operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(29,599</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(8,619</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2187">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(38,218</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_pn3n3_zAZ1ayaZF4c5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash provided by investing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,061</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2192">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,905</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_pn3n3_z5OGb8uYgR6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash provided by financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,646</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2196">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,646</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_pn3n3_zaOK9HH5cgU8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impact of exchange rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2202">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(45</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_pn3n3_zNXBQkkl7Kd6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change for the year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,148</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,564</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,712</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes financial information by business segment at March 31, 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zkHW1x9eSm2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Air</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z0tiVauo7HOk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Cancer</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z2knifpaVRRk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NeuroNos</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zAla1t9MXcQ3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_zCfjlHyodPn7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Cash, cash equivalents and marketable securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">10,140</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,043</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">458</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">11,641</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAssets_iI_pn3n3_z3ayk8KTRVHl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">All other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,901</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(219</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">62</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,744</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_iTI_pn3n3_zlGW8DL0F2wf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">34,041</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">824</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">520</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">35,385</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_iNI_pn3n3_di_zE1rBqqEVTYa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(28,224</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(378</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(573</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(29,175</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNet_iI_pn3n3_zDt5YU21tEvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">5,817</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">446</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(53</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">6,210</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--MinorityInterest_iI_pn3n3_zVnZK7fL9DEh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2235">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes financial information by business segment at March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zSA9AsWRpzMg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Air</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zCxOqn4syFP9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beyond Cancer</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zOxgLgxbG0k8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NeuroNos</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z8gsJTjpZK0e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_zLnYOb3zGpcf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Cash, cash equivalents and marketable securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,167</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">6,917</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAssets_iI_pn3n3_zW5DAdFO3a42" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">All other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22,116</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,029</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2247">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,145</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_iTI_pn3n3_zcP9z74j4n6a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">24,866</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,196</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">30,062</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_iNI_pn3n3_di_zyKjyhnoMRT1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(15,082</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(589</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(50</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(15,721</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNet_iI_pn3n3_zHfTWeM53Vcj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">9,784</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,607</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,950</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">14,341</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--MinorityInterest_iI_pn3n3_zhU46w6oGcCc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">529</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">229</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">758</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=XAIR_VariableInterestEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=XAIR_VariableInterestEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF MATURITY OF FUTURE LEASE PAYMENTS</a></td>
<td class="text"><p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zYXW08BCXxjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zfZ5k3klDSH3">SCHEDULE
OF MATURITY OF LEASE LIABILITIES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Maturity of Lease Liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20260331_zhBNqVEJf3R2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payments remaining for the year ended March 31:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzQlL_z6NZJokfnDB4" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">2027</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">419</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzQlL_zRBqnociW0W5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzQlL_zEHihp9ptXke" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzQlL_zxRICOmjHPt5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzQlL_zYy81r2jjSLd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2031</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">266</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzQlL_zNPYuOxJJLYb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">60</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzQlL_zEIJB56tliha" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,623</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zJZIK5zKLAK6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: amount of lease payments representing interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(279</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z6oBkRfqQNGg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of future lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,344</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_LungFitRPHMember', window );">LungFit&#174; PH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF MATURITY OF FUTURE LEASE PAYMENTS</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_hdei--LegalEntityAxis__custom--LungFitRPHMember_z7Y2qSMmBDJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following schedule presents the minimum future lease payments under the LungFit&#174; PH lease arrangements that were in place as of March
31, 2026 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zsIXGXh71AE" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF MATURITY OF FUTURE LEASE PAYMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Future lease payments under the LungFit&#174; PH lease arrangements (in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20260331__dei--LegalEntityAxis__custom--LungFitRPHMember_zNvnnCb3rpc6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzQlL_zIa0UjmJMzD8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2027</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,919</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzQlL_zegw9FRxUGJa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,512</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzQlL_zo5adO8PMz6l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,560</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzQlL_zKzjTDVvGvzl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,991</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_LungFitRPHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_LungFitRPHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS (Details Narrative)<br></strong></div></th>
<th class="th"><div>Jul. 14, 2025</div></th>
<th class="th"><div>Mar. 24, 2025</div></th>
<th class="th"><div>Nov. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">one-for-twenty (1:20) reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=XAIR_BeyondCancerLtdMember', window );">Beyond Cancer Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=XAIR_NeuroNosLtdMember', window );">NeuroNos Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=XAIR_BeyondCancerLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=XAIR_BeyondCancerLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=XAIR_NeuroNosLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=XAIR_NeuroNosLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE ON A RECURRING BASIS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">$ 4,901<span></span>
</td>
<td class="nump">$ 2,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">4,901<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=XAIR_MutualFundsMember', window );">Mutual Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">4,901<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=XAIR_MutualFundsMember', window );">Mutual Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">4,901<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=XAIR_MutualFundsMember', window );">Mutual Funds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=XAIR_MutualFundsMember', window );">Mutual Funds [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=XAIR_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=XAIR_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total short-term marketable securities, Fair value</a></td>
<td class="nump">$ 4,901<span></span>
</td>
<td class="nump">$ 2,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Total short-term marketable securities, Unrealized gains and (losses)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember', window );">Short-Term Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total short-term marketable securities, Fair value</a></td>
<td class="nump">4,901<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Total short-term marketable securities, Unrealized gains and (losses)</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember', window );">Mutual Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total short-term marketable securities, Fair value</a></td>
<td class="nump">4,901<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember', window );">Mutual Fund [Member] | Short-Term Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total short-term marketable securities, Fair value</a></td>
<td class="nump">4,901<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Total short-term marketable securities, Unrealized gains and (losses)</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ASSUMPTIONS USED IN VALUING WARRANTS (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term warrants</a></td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">3 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">132.1<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF KEY INPUTS DERIVATIVE (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 04, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Maximum convertible shares</a></td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Risk-free rate</a></td>
<td class="nump">1.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Risk-free rate</a></td>
<td class="nump">1.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Risk-free rate</a></td>
<td class="nump">0.036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at March 31, 2025</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_FairValueMeasurementExtinguishment', window );">Extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at March 31, 2026</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember', window );">Derivative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at March 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="nump">1,395<span></span>
</td>
<td class="num">(1,314)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance</a></td>
<td class="nump">775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_FairValueMeasurementExtinguishment', window );">Extinguishment</a></td>
<td class="num">(2,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at March 31, 2026</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_FairValueMeasurementExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_FairValueMeasurementExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,740<span></span>
</td>
<td class="nump">$ 4,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">5,622<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">12,362<span></span>
</td>
<td class="nump">4,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total marketable securities</a></td>
<td class="nump">4,901<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents, marketable securities and restricted cash</a></td>
<td class="nump">17,263<span></span>
</td>
<td class="nump">7,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember', window );">Mutual Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total marketable securities</a></td>
<td class="nump">$ 4,901<span></span>
</td>
<td class="nump">$ 2,252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ClinicalAndMedicalEquipmentMember', window );">Clinical and Medical Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ClinicalAndMedicalEquipmentMember', window );">Clinical and Medical Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_EquipmentDeployableAsPartOfServiceOfferingMember', window );">Equipment Deployable as Part of Service Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">Useful Life, Lease Term [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 905<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478704/905-360-25-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482222/360-10-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of property, plant, and equipment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ClinicalAndMedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ClinicalAndMedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_EquipmentDeployableAsPartOfServiceOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_EquipmentDeployableAsPartOfServiceOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2027</a></td>
<td class="nump">$ 205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2028</a></td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2029</a></td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2030</a></td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2031</a></td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 1,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for finite-lived intangible asset expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Details Narrative)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 04, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,144,000<span></span>
</td>
<td class="nump">$ 38,218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 319,571,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,571,000<span></span>
</td>
<td class="nump">286,322,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_CashAndCashEquivalentsAndMarketableSecurities', window );">Cash equivalents and marketable securities</a></td>
<td class="nump">11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Cash deposit</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableNoncurrent', window );">Allowance for credit losses</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementDifferenceDescription', window );">Derivative liability description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
derivative liability represents an embedded redemption feature (embedded put option) that meets the criteria to be classified as a
derivative and is bifurcated from the Note (see Note 9). On any trading day during which the Registration Statement (Note 4) remains
effective and the Note remains outstanding and (i) any trading price of the Company&#8217;s common stock is at least 5% greater than
the current Nasdaq minimum price as defined under Nasdaq Rule 5635(d) (the &#8220;Nasdaq Minimum Price&#8221;) or (ii) the total
dollar trading volume has reached $750,000.00, Streeterville may elect to purchase shares of common stock up to the Beneficial
Ownership Limitation at a purchase price equal to 85% of the Nasdaq Minimum Price, subject to a floor of $0.39 per share. The
aggregate purchase price for these shares shall be offset by an equal amount outstanding under the Note.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Fair value of issued common stock</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue', window );">Fair value of the derivative liability</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of secured promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskBenchmarkDescription', window );">Concentration risk benchmark description</a></td>
<td class="text">As of March 31, 2026, the Company had greater than $250,000 at United States financial institutions, less than A$250,000
at Australian financial institutions, greater than &#8364;100,000 at Irish financial institutions and also has funds on deposit in Israel.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag', window );">Number of repotable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Obsolescence reserves</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Other asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=XAIR_BeyondCancerLtdMember', window );">Beyond Cancer Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling owners interest</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=XAIR_NeuroNosLtdMember', window );">NeuroNos Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling owners interest</a></td>
<td class="nump">15.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.25%<span></span>
</td>
<td class="nump">15.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Customer Concentration Risk [Member] | First Third Party Vendors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Customer Concentration Risk [Member] | Second Third Party Vendors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Customer Concentration Risk [Member] | Third Party Vendors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customers One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customers Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australian Taxation Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_TaxRebate', window );">Tax Rebate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">AUSTRALIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BM', window );">BERMUDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">IRELAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CY', window );">CYPRUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_StreetervilleCapitalLLCMember', window );">Streeterville Capital LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDefaultLongtermDebtAmount', window );">Debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_CashAndCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_CashAndCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reportable segments disclosed by definition flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_TaxRebate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rebate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_TaxRebate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskBenchmarkDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identifies or describes the benchmark that serves as the denominator in the calculation of the percentage of concentration risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskBenchmarkDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of credit risk derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDefaultLongtermDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDefaultLongtermDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementDifferenceDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of measurement difference between recognized amounts and resulting measurement differences for derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementDifferenceDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478482/942-210-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=XAIR_BeyondCancerLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=XAIR_BeyondCancerLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=XAIR_NeuroNosLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=XAIR_NeuroNosLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=XAIR_FirstThirdPartyVendorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=XAIR_FirstThirdPartyVendorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=XAIR_SecondThirdPartyVendorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=XAIR_SecondThirdPartyVendorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=XAIR_ThirdPartyVendorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=XAIR_ThirdPartyVendorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=XAIR_CustomersOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=XAIR_CustomersOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=XAIR_CustomersTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=XAIR_CustomersTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_StreetervilleCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_StreetervilleCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 15,909<span></span>
</td>
<td class="nump">$ 16,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(7,660)<span></span>
</td>
<td class="num">(5,500)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,249<span></span>
</td>
<td class="nump">11,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ClinicalAndMedicalEquipmentMember', window );">Clinical and Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_EquipmentDeployableAsPartOfServiceOfferingMember', window );">Equipment Deployable as Part of Service Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">13,871<span></span>
</td>
<td class="nump">13,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">853<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">458<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 521<span></span>
</td>
<td class="nump">$ 521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion, and amortization of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480204/360-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478443/942-360-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 905<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478704/905-360-25-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482222/360-10-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478443/942-360-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ClinicalAndMedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ClinicalAndMedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_EquipmentDeployableAsPartOfServiceOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_EquipmentDeployableAsPartOfServiceOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant, and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESTRICTED STOCK AWARDS (Details) - Restricted Stock [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested Number of Shares, Beginning balance</a></td>
<td class="nump">18,265<span></span>
</td>
<td class="nump">30,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning balance</a></td>
<td class="nump">$ 139.40<span></span>
</td>
<td class="nump">$ 139.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested</a></td>
<td class="num">(8,630)<span></span>
</td>
<td class="num">(12,240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="nump">$ 150.26<span></span>
</td>
<td class="nump">$ 137.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="nump">$ 137.40<span></span>
</td>
<td class="nump">$ 229.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested Number of Shares, Ending balance</a></td>
<td class="nump">9,485<span></span>
</td>
<td class="nump">18,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, ending balance</a></td>
<td class="nump">$ 129.41<span></span>
</td>
<td class="nump">$ 139.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OPTION ACTIVITY (Details) - 2013 Beyond Air Equity Incentive Plan [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at beginning of period</a></td>
<td class="nump">739,219<span></span>
</td>
<td class="nump">566,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options, Outstanding at beginning of period</a></td>
<td class="nump">$ 9.34<span></span>
</td>
<td class="nump">$ 88.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life - Options, Outstanding at end of period</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at beginning of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Outstanding, Granted</a></td>
<td class="nump">94,800<span></span>
</td>
<td class="nump">227,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options, Granted</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 6.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Options Outstanding, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options Outstanding, Forfeited</a></td>
<td class="num">(77,270)<span></span>
</td>
<td class="num">(54,976)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options, Forfeited</a></td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="nump">$ 61.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at ending of period</a></td>
<td class="nump">756,749<span></span>
</td>
<td class="nump">739,219<span></span>
</td>
<td class="nump">566,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options, Outstanding at ending of period</a></td>
<td class="nump">$ 1.82<span></span>
</td>
<td class="nump">$ 9.34<span></span>
</td>
<td class="nump">$ 88.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at end of period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Outstanding, Exercisable</a></td>
<td class="nump">497,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options, Exercisable</a></td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life - Options, Exercisable</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OPTION ACTIVITY FOR BEYOND CANCER (Details) - 2021 Beyond Cancer Ltd Equity Incentive Plan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at beginning of period</a></td>
<td class="nump">2,816,250<span></span>
</td>
<td class="nump">3,819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options, Outstanding at beginning of period</a></td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life - options, outstanding at beginning of period</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at beginning of period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price of Options, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price of Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(561,750)<span></span>
</td>
<td class="num">(1,002,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price of Options, Forfeited</a></td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at ending of period</a></td>
<td class="nump">2,254,500<span></span>
</td>
<td class="nump">2,816,250<span></span>
</td>
<td class="nump">3,819,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options, Outstanding at ending of period</a></td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at end of period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Outstanding, Exercisable</a></td>
<td class="nump">1,975,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options, Exercisable</a></td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life of Options, Exercisable</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OPTION ACTIVITY FOR NEURONOS (Details) - 2023 Neuro Nos Ltd Equity Incentive Plan [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at beginning of period</a></td>
<td class="nump">1,224,139<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options, Outstanding at beginning of period</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at beginning of period</a></td>
<td class="nump">$ 3,501<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">169,913<span></span>
</td>
<td class="nump">1,224,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price of Options, Granted</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price of Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(134,723)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price - options, forfeited</a></td>
<td class="nump">$ 2.82<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life of Options, Outstanding</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at ending of period</a></td>
<td class="nump">1,259,329<span></span>
</td>
<td class="nump">1,224,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options, Outstanding at ending of period</a></td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at end of period</a></td>
<td class="nump">$ 3,477<span></span>
</td>
<td class="nump">$ 3,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Outstanding, Exercisable</a></td>
<td class="nump">622,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options, Exercisable</a></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life of Options, Exercisable</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 1,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE OF OPTION (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_NeuroNosLtdMember', window );">NeuroNos Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Beyond Air Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">91.60%<span></span>
</td>
<td class="nump">83.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Beyond Air Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">106.20%<span></span>
</td>
<td class="nump">89.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_NeuroNosLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_NeuroNosLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_BeyondAirIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_BeyondAirIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 5,282<span></span>
</td>
<td class="nump">$ 9,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_GeneralAndAdministrativeExpense', window );">Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,129<span></span>
</td>
<td class="nump">8,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpense', window );">Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,153<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF OUTSTANDING WARRANTS (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants | shares</a></td>
<td class="nump">9,341,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue', window );">Intrinsic Value | $</a></td>
<td class="nump">$ 1,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_NitricGenAgreementMember', window );">NitricGen Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants | shares</a></td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 138.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue', window );">Intrinsic Value | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_WarrantsExpirationDateDescription', window );">Date of Expiration</a></td>
<td class="text">January 2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_AvenueAgreementMember', window );">Avenue Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants | shares</a></td>
<td class="nump">11,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 7.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue', window );">Intrinsic Value | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_WarrantsExpirationDateDescription', window );">Date of Expiration</a></td>
<td class="text">June 2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_MarchTwoThousandTwentyFourRaiseMember', window );">March 2024 Raise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants | shares</a></td>
<td class="nump">481,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 45.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue', window );">Intrinsic Value | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_WarrantsExpirationDateDescription', window );">Date of Expiration</a></td>
<td class="text">March 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_AvenueExtensionAgreementMember', window );">Avenue Extension Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants | shares</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 25.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue', window );">Intrinsic Value | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_WarrantsExpirationDateDescription', window );">Date of Expiration</a></td>
<td class="text">June 2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember', window );">September 2024 equity offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants | shares</a></td>
<td class="nump">555,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 7.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue', window );">Intrinsic Value | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_WarrantsExpirationDateDescription', window );">Date of Expiration</a></td>
<td class="text">September 2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember', window );">September 2024 Debt Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants | shares</a></td>
<td class="nump">1,270,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue', window );">Intrinsic Value | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_WarrantsExpirationDateDescription', window );">Date of Expiration</a></td>
<td class="text">September 2029 / November 2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_SeptemberTwoThousandTwentyFiveInducementMember', window );">September 2025 Inducement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants | shares</a></td>
<td class="nump">719,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue', window );">Intrinsic Value | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_WarrantsExpirationDateDescription', window );">Date of Expiration</a></td>
<td class="text">September 2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember', window );">January, 2026 Equity Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants | shares</a></td>
<td class="nump">3,930,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue', window );">Intrinsic Value | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_WarrantsExpirationDateDescription', window );">Date of Expiration</a></td>
<td class="text">January 2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_SubTotalMember', window );">Sub Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants | shares</a></td>
<td class="nump">6,979,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue', window );">Intrinsic Value | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember', window );">Pre Funded Warrants Sep 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants | shares</a></td>
<td class="nump">220,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue', window );">Intrinsic Value | $</a></td>
<td class="nump">$ 151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_WarrantsExpirationDateDescription', window );">Date of Expiration</a></td>
<td class="text">September 2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember', window );">Pre Funded Warrants jan 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants | shares</a></td>
<td class="nump">2,142,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue', window );">Intrinsic Value | $</a></td>
<td class="nump">$ 1,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_WarrantsExpirationDateDescription', window );">Date of Expiration</a></td>
<td class="text">January 2031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Intrinsic Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_WarrantsExpirationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants expiration date description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_WarrantsExpirationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_NitricGenAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_NitricGenAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_AvenueAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_AvenueAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_MarchTwoThousandTwentyFourRaiseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_MarchTwoThousandTwentyFourRaiseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_AvenueExtensionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_AvenueExtensionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_SeptemberTwoThousandTwentyFiveInducementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_SeptemberTwoThousandTwentyFiveInducementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_SubTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_SubTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2026</div></th>
<th class="th"><div>Jan. 16, 2026</div></th>
<th class="th"><div>Jan. 14, 2026</div></th>
<th class="th"><div>Nov. 04, 2025</div></th>
<th class="th"><div>Sep. 08, 2025</div></th>
<th class="th"><div>Feb. 10, 2025</div></th>
<th class="th"><div>Jan. 16, 2025</div></th>
<th class="th"><div>Nov. 22, 2024</div></th>
<th class="th"><div>Nov. 03, 2022</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2026</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Nov. 25, 2025</div></th>
<th class="th"><div>Nov. 03, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of net proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 18,858,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Share purchase value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,135,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,151,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.773<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from private placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,282,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,146,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,341,653<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrants Exercise</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,869,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 365,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option repricing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">726,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Incremental stock compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=XAIR_TwoThousandTwentyFiveOptionRepricingMember', window );">2025 Option Repricing [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Option exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Stock based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember', window );">2013 Beyond Air Equity Incentive Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock option shares authorized for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,680,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">894,276<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5.03<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option repricing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,749<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">739,219<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">227,550<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember', window );">2013 Beyond Air Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=XAIR_TwoThousandThirteenBAPlanMember', window );">2013 BA Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=XAIR_TwoThousandThirteenEquityIncentivePlanMember', window );">2013 BA EquityIncentivePlan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember', window );">2021 Beyond Cancer Ltd Equity Incentive Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock option shares authorized for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,745,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option repricing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,254,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,816,250<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,819,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additionl shares reserve for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember', window );">2023 Neuro Nos Ltd Equity Incentive Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock option shares authorized for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,725,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465,670<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option repricing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,259,329<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,224,139<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,913<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,224,139<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from private placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Commission paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Other fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Share purchase value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issues during the period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,441,775<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">337,101<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.147<span></span>
</td>
<td class="nump">$ 1.272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,930,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=XAIR_TwoThousandTwentySixPreFundedWarrantsMember', window );">2026 Pre-funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,405,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 1.2719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 1.147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,405,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock issued during the period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,263,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=XAIR_TwoThousandTwentySixCommonWarrantsMember', window );">2026 Common Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,930,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=XAIR_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from private placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issues during the period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">719,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Other fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,439,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrants Exercise</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Other fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted average remaining service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_PublicFloatValue', window );">Public float value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Exercise price in excess</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Common Stock [Member] | Beyond Cancer Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_TwoThousandAndTwentyFiveATMMember', window );">2025 ATM [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of Stock, Consideration Received Per Transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_SaleOfStockFeePercentage', window );">Sale of stock fee percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of net proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,441,775<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_TwoThousandAndTwentyFiveATMMember', window );">2025 ATM [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of net proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">337,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Share purchase value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issues during the period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Adjustments in additional paid in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock minimum purchase amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_BeneficialOwnershipLimitationPercentage', window );">Beneficial ownership limitation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_AmendedLoanAgreementMember', window );">Amended Loan Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted average remaining service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_AmendedLoanAgreementMember', window );">Amended Loan Agreement [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="19"></td></tr>
<tr><td colspan="19"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Prior
    period results have been adjusted to reflect the one-for-twenty stock split in July 2025. See Note 1, <i>Organization and Business</i>
    for details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_BeneficialOwnershipLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Beneficial ownership limitation percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_BeneficialOwnershipLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_PublicFloatValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public float value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_PublicFloatValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_SaleOfStockFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_SaleOfStockFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480459/718-40-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480459/718-40-55-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant to expiration date of share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=XAIR_TwoThousandTwentyFiveOptionRepricingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=XAIR_TwoThousandTwentyFiveOptionRepricingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=XAIR_TwoThousandThirteenBAPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=XAIR_TwoThousandThirteenBAPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=XAIR_TwoThousandThirteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=XAIR_TwoThousandThirteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=XAIR_TwoThousandTwentySixPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=XAIR_TwoThousandTwentySixPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=XAIR_TwoThousandTwentySixCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=XAIR_TwoThousandTwentySixCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=XAIR_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=XAIR_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=XAIR_BeyondCancerLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=XAIR_BeyondCancerLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_TwoThousandAndTwentyFiveATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_TwoThousandAndTwentyFiveATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_AmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_AmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OTHER CURRENT ASSETS AND PREPAID EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_PrepaidResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">$ 696<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">579<span></span>
</td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rents and tenant improvement</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Value added tax receivable</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Deposits to secure manufacturing materials</a></td>
<td class="nump">3,420<span></span>
</td>
<td class="nump">4,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Supplies', window );">Demonstration materials</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total other current assets and prepaid expenses</a></td>
<td class="nump">$ 5,012<span></span>
</td>
<td class="nump">$ 5,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_PrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_PrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_AccruedResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">252<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee salaries and benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">465<span></span>
</td>
<td class="nump">924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_InterestSeveranceCurrent', window );">Accrued severance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">696<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">750<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">777<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_GoodsReceivedNotInvoiced', window );">Goods received not invoiced</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">273<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">143<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,372<span></span>
</td>
<td class="nump">$ 2,045<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Pursuant to the
terms of the Release Agreement with Steve Lisi, former CEO, the Company is obligated to pay Mr. Lisi $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQUNDUlVFRCBFWFBFTlNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--Cash_iI_c20260331__srt--TitleOfIndividualAxis__custom--SteveLisiMember_zzRrwFGbAO1b">650,000</span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in cash compensation over 12 months. After expected employer
taxes and benefits, the Company accrued $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQUNDUlVFRCBFWFBFTlNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--TaxesPayableCurrent_iI_pn5n6_c20260331__srt--TitleOfIndividualAxis__custom--SteveLisiMember_zi71LrIwbDJe">0.7</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million The Company shall also pay Mr. Lisi COBRA premiums
for 12 months, as more specifically described in the Release Agreement. All unvested options and all unvested stock restriction unit
awards held by Mr. Lisi as of March 27, 2026, shall be accelerated and shall immediately vest, and shall continue to remain exercisable
for twenty-four (24) months from March 27, 2026.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued prepaid research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_GoodsReceivedNotInvoiced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goods received not invoiced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_GoodsReceivedNotInvoiced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_InterestSeveranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest severance current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_InterestSeveranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF ACCRUED EXPENSES (Details) (Parenthetical) - Steve Lisi [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 650,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes Payable, Current</a></td>
<td class="nump">$ 700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=XAIR_SteveLisiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=XAIR_SteveLisiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OPERATING LEASE LIABILITY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 1,193<span></span>
</td>
<td class="nump">$ 1,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability short-term</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability long-term</a></td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 1,344<span></span>
</td>
<td class="nump">$ 1,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted Average Remaining Lease Term</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">8.90%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF LEASE RELATED COSTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">$ 539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(49)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 544<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF LEASE OTHER INFORMATION (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows for operating leases</a></td>
<td class="nump">$ 532<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2027</a></td>
<td class="nump">$ 419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2028</a></td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2029</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2030</a></td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2031</a></td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount of lease payments representing interest</a></td>
<td class="num">(279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future lease payments</a></td>
<td class="nump">$ 1,344<span></span>
</td>
<td class="nump">$ 1,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operation lease description</a></td>
<td class="text">the Company entered into a second amendment to lease of one of its facilities (the &#8220;Lease Amendment&#8221;). The Lease
Amendment extended the lease for an additional three years through May 31, 2029 with fixed monthly base rent amounts through the extended
term<span></span>
</td>
<td class="text">the Company entered into an agreement to sublease the Beyond Cancer office space in Atlanta, Georgia beginning June 1, 2025
and continuing through September 30, 2026 coinciding with the termination of the existing lease.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating lease liability</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 398,000<span></span>
</td>
<td class="nump">$ 367,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liability in exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">7,745,268<span></span>
</td>
<td class="nump">4,012,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">6,979,034<span></span>
</td>
<td class="nump">3,254,967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">756,749<span></span>
</td>
<td class="nump">739,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">9,485<span></span>
</td>
<td class="nump">18,265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=XAIR_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Warrants included in calculation of diluted net loss per share</a></td>
<td class="nump">2,362,619<span></span>
</td>
<td class="nump">606,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=XAIR_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=XAIR_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF LONG-TERM DEBT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal balance outstanding</a></td>
<td class="nump">$ 26,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_PaidInKindInterestAmount', window );">Paid in kind interest</a></td>
<td class="nump">2,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="num">(7,919)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">21,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=XAIR_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal balance outstanding</a></td>
<td class="nump">12,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_PaidInKindInterestAmount', window );">Paid in kind interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="num">(3,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="nump">373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">9,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_LoanAgreementMember', window );">Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal balance outstanding</a></td>
<td class="nump">13,500<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_PaidInKindInterestAmount', window );">Paid in kind interest</a></td>
<td class="nump">2,459<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="num">(4,343)<span></span>
</td>
<td class="num">(3,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 12,043<span></span>
</td>
<td class="nump">$ 9,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_AmortizationOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of Debt Discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_AmortizationOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_PaidInKindInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Paid in kind interest amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_PaidInKindInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=XAIR_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=XAIR_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOANS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 04, 2026</div></th>
<th class="th"><div>Nov. 04, 2025</div></th>
<th class="th"><div>Jun. 02, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2026</div></th>
<th class="th"><div>Nov. 03, 2025</div></th>
<th class="th"><div>Nov. 02, 2025</div></th>
<th class="th"><div>Nov. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,299,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue', window );">Fair value of the derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(165,000)<span></span>
</td>
<td class="num">$ (2,447,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_StreetervilleCapitalLLCMember', window );">Streeterville Capital LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_UnrestrictedCash', window );">Unrestricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Monitoring fees</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfLoansReceivable', window );">Advanced financing from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DebtInstrumentInterestRatePayableInCashPercentage', window );">Percentage of interest payable in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DebtInstrumentInterestRatePayableInKindPercentage', window );">Percentage of interest payable in kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_RoyaltyInterestPercentage', window );">Royalty interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="nump">$ 7.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_AmendedLoanAgreementMember', window );">Amended Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_NotePurchaseAgreementMember', window );">Note Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Interest rate description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Interest will accrue
at the rate of 15% per annum, with no interest accruing for the first 12 months following issuance; provided however, that Streeterville
is guaranteed 12 months of interest, or $1.8 million, even if the Note is redeemed or prepaid prior to the maturity date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DebtInstrumentOfRestrictedAccount', window );">Principal in restricted account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepaidPrincipal', window );">Debt instrument, principal repayable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares available for resale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DebtInstrumentInterestRatePayableInCashPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest rate payable in cash percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DebtInstrumentInterestRatePayableInCashPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DebtInstrumentInterestRatePayableInKindPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest rate payable in kind percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DebtInstrumentInterestRatePayableInKindPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DebtInstrumentOfRestrictedAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument of restricted account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DebtInstrumentOfRestrictedAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RoyaltyInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty interest percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RoyaltyInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_UnrestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrestricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_UnrestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of credit risk derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepaidPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt repaid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepaidPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of debt instrument, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of loans receivables arising from the financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_StreetervilleCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_StreetervilleCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_AmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_AmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF LOAN PAYABLE (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Amount outstanding</a></td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">$ 579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Monthly payments</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_NumberOfPayments', window );">Amount outstanding | Integer</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_LoanPayableDueDateDescription', window );">Due date</a></td>
<td class="text">October 2026<span></span>
</td>
<td class="text">August 2025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_LoanPayableDueDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan payable due date description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_LoanPayableDueDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_NumberOfPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_NumberOfPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF PROFIT (LOSS) BEFORE TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (27,066)<span></span>
</td>
<td class="num">$ (42,186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(7,268)<span></span>
</td>
<td class="num">(6,293)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (34,334)<span></span>
</td>
<td class="num">$ (48,479)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSET/LIABILITY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 55,607<span></span>
</td>
<td class="nump">$ 48,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="nump">2,506<span></span>
</td>
<td class="nump">2,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_ResearchAndDevelopmentTaxCreditCapitalization', window );">Research and development tax credit capitalization</a></td>
<td class="nump">6,572<span></span>
</td>
<td class="nump">8,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="num">(111)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation', window );">Depreciation</a></td>
<td class="num">(1,803)<span></span>
</td>
<td class="num">(2,337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">6,714<span></span>
</td>
<td class="nump">7,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DeferredTaxAssetsReservesAndAccruels', window );">Reserves and accruals</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DeferredTaxAssetsRightofuseAsset', window );">Right-of-use asset</a></td>
<td class="num">(282)<span></span>
</td>
<td class="num">(298)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Net deferred tax</a></td>
<td class="nump">69,550<span></span>
</td>
<td class="nump">64,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(69,550)<span></span>
</td>
<td class="num">(64,240)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DeferredTaxAssetsReservesAndAccruels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets reserves and accruels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DeferredTaxAssetsReservesAndAccruels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DeferredTaxAssetsRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DeferredTaxAssetsRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax deferred expense compensation and depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ResearchAndDevelopmentTaxCreditCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credit capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ResearchAndDevelopmentTaxCreditCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DIFFERENCE EFFECTIVE INCOME TAX RATE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory tax rate</a></td>
<td class="num">$ (7,210)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes', window );">Current state and local income taxes, net of federal benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes', window );">Current state and local income taxes, net of federal benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.46%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.87%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other foreign jurisdictions</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other foreign jurisdictions</a></td>
<td class="num">(0.26%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">$ (308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch', window );">Other foreign jurisdictions</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther', window );">Changes in valuation allowance</a></td>
<td class="nump">$ 3,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Changes in valuation allowance</a></td>
<td class="num">(10.95%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_IncomeTaxReconciliationTaxSubpartFIncome', window );">Subpart F Income</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome', window );">Subpart F Income</a></td>
<td class="num">(0.02%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount', window );">Share-based payment awards</a></td>
<td class="nump">$ 1,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent', window );">Share-based payment awards</a></td>
<td class="num">(5.47%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments', window );">Other</a></td>
<td class="nump">$ 293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments', window );">Other</a></td>
<td class="num">(0.85%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems', window );">Other adjustments</a></td>
<td class="nump">$ 346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent', window );">Other adjustments</a></td>
<td class="num">(1.01%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Other adjustments</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">IRELAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">$ 440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(1.28%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.69%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">ISRAEL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">$ 371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(1.08%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.29%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation difference other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation difference other reconciling items percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation difference share based compensation excess tax benefit amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation difference share based compensation excess tax benefit percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income tax rate reconciliation difference state and local income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation difference tax credits research.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation subpart f income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation difference other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation difference other reconciling items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation difference state and local income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation difference tax credits research.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_IncomeTaxReconciliationTaxSubpartFIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation tax subpart f income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_IncomeTaxReconciliationTaxSubpartFIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STATUTORY US FEDERAL EFFECTIVE RATE (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates', window );">Federal income tax at statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.73%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Permanent items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.58%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.45%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.46%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.12%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.65%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.87%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss', window );">Change to foreign NOL&#8217;s</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Other adjustments</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal income tax at statutory rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation change to foreign net operating loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Deferred tax liabilities, deferred expense, capitalized research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage', window );">Federal tax percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Income tax limitation description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">This limitation would generally apply in the event of a cumulative
change in ownership of the Company of more than 50% within a three-year period.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates', window );">Federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Tax credit carryforward, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">expiring
during the years from 2038 to 2042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=XAIR_NoExpirationMember', window );">No Expiration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_OffsetTaxableIncomeRate', window );">Taxable income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Income Tax Jurisdiction, Domestic Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_RevenueCommissionersIrelandMember', window );">Revenue Commissioners, Ireland [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=XAIR_CypriotTaxMember', window );">Cypriot Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Income Tax Jurisdiction, Domestic State and Local [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_OperatingLossCarryforwardsExpirationYears', window );">Operating loss carryforward expire description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">expiring during the years from 2036 to 2043<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation at federal statutory income tax rate percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal income tax at statutory rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_OffsetTaxableIncomeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offset taxable income rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_OffsetTaxableIncomeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_OperatingLossCarryforwardsExpirationYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforward expire term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_OperatingLossCarryforwardsExpirationYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=XAIR_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=XAIR_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_RevenueCommissionersIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_RevenueCommissionersIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=XAIR_CypriotTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=XAIR_CypriotTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Jan. 13, 2017</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Cash deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember', window );">Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Supplier [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Outstanding amount under purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Cash deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_OptionAgreementMember', window );">Option Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_PaymentsForDevelopmentAndMilestonePayment', window );">Payments for development and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_MilestonePayments', window );">Remaining future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_SalesRelatedMilestonesPayments', window );">Sales related milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_NitricGenAgreementMember', window );">NitricGen Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_MilestonePayments', window );">Remaining future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_NitricGenAgreementMember', window );">NitricGen Agreement [Member] | NitricGen, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_MilestonePayments', window );">Remaining future milestone payments</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_PaymentForMilestoneMethodRevenueRecognized', window );">Future payments based on certain milestones</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants to purchase common stock, value</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_NitricGenAgreementMember', window );">NitricGen Agreement [Member] | NitricGen, Inc [Member] | Next Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_PaymentForMilestoneMethodRevenueRecognized', window );">Future payments based on certain milestones</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_NitricGenAgreementMember', window );">NitricGen Agreement [Member] | NitricGen, Inc [Member] | After Six Months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_PaymentForMilestoneMethodRevenueRecognized', window );">Future payments based on certain milestones</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_PaymentForMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for milestone method revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_PaymentForMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_PaymentsForDevelopmentAndMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for development and milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_PaymentsForDevelopmentAndMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_SalesRelatedMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales related milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_SalesRelatedMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=XAIR_SupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=XAIR_SupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_OptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_OptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_NitricGenAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_NitricGenAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_NitricGenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_NitricGenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=XAIR_NextMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=XAIR_NextMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=XAIR_AfterSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=XAIR_AfterSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 24, 2025</div></th>
<th class="th"><div>Nov. 18, 2021</div></th>
<th class="th"><div>Nov. 04, 2021</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 21, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 18,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_SubscriptionAgreementMember', window );">Subscription Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock - At The Market equity offering, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=XAIR_BeyondCancerLtdMember', window );">Beyond Cancer Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=XAIR_NeuroNosLtdMember', window );">NeuroNos Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=XAIR_NeuroNosLtdMember', window );">NeuroNos Ltd [Member] | Subscription Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.25%<span></span>
</td>
<td class="nump">11.76%<span></span>
</td>
<td class="nump">84.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=XAIR_InvestorsMember', window );">Investors [Member] | Beyond Cancer Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_BeyondCancerLtdMember', window );">Beyond Cancer Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock - At The Market equity offering, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_AmountOfTerminatedLoan', window );">Amount of terminated loan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_BeyondCancerLtdMember', window );">Beyond Cancer Ltd [Member] | Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Related party invested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_BeyondCancerLtdMember', window );">Beyond Cancer Ltd [Member] | Certain Investors [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sle of stock per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Prior
    period results have been adjusted to reflect the one-for-twenty stock split in July 2025. See Note 1, <i>Organization and Business</i>
    for details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_AmountOfTerminatedLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of terminated loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_AmountOfTerminatedLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=XAIR_BeyondCancerLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=XAIR_BeyondCancerLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=XAIR_NeuroNosLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=XAIR_NeuroNosLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=XAIR_InvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=XAIR_InvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_BeyondCancerLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_BeyondCancerLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=XAIR_CertainInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=XAIR_CertainInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,679<span></span>
</td>
<td class="nump">$ 3,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,427)<span></span>
</td>
<td class="num">(5,368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,241)<span></span>
</td>
<td class="num">(16,857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,055)<span></span>
</td>
<td class="num">(26,017)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,044)<span></span>
</td>
<td class="num">(44,537)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest and finance expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,515)<span></span>
</td>
<td class="num">(3,019)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating income/(expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,249)<span></span>
</td>
<td class="num">(46,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">5,282<span></span>
</td>
<td class="nump">9,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,144)<span></span>
</td>
<td class="num">(38,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash provided by investing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,674)<span></span>
</td>
<td class="nump">14,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,090<span></span>
</td>
<td class="nump">16,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Impact of exchange rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,466<span></span>
</td>
<td class="num">(6,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,263<span></span>
</td>
<td class="nump">7,148<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,385<span></span>
</td>
<td class="nump">30,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,175)<span></span>
</td>
<td class="num">(15,721)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=XAIR_SegmentMember', window );">Business Segment [Member] | Variable Interest Entities [Member] | Parent Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_CapitalExpendituresCost', window );">Capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">5,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">3,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,427)<span></span>
</td>
<td class="num">(5,368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,241)<span></span>
</td>
<td class="num">(16,857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,055)<span></span>
</td>
<td class="num">(26,017)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,044)<span></span>
</td>
<td class="num">(44,537)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest and finance expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,515)<span></span>
</td>
<td class="num">(3,019)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating income/(expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,775)<span></span>
</td>
<td class="num">(923)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,334)<span></span>
</td>
<td class="num">(48,479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,251<span></span>
</td>
<td class="nump">3,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,282<span></span>
</td>
<td class="nump">9,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,144)<span></span>
</td>
<td class="num">(38,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash provided by investing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,674)<span></span>
</td>
<td class="nump">14,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,090<span></span>
</td>
<td class="nump">16,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Impact of exchange rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,466<span></span>
</td>
<td class="num">(6,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,641<span></span>
</td>
<td class="nump">6,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">All other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,744<span></span>
</td>
<td class="nump">23,145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,385<span></span>
</td>
<td class="nump">30,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,175)<span></span>
</td>
<td class="num">(15,721)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNet', window );">Net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,210<span></span>
</td>
<td class="nump">14,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_BeyondAirMember', window );">Beyond Air [Member] | Business Segment [Member] | Variable Interest Entities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_CapitalExpendituresCost', window );">Capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">5,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">3,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,427)<span></span>
</td>
<td class="num">(5,368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,677)<span></span>
</td>
<td class="num">(13,780)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,418)<span></span>
</td>
<td class="num">(19,565)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,843)<span></span>
</td>
<td class="num">(35,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest and finance expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,515)<span></span>
</td>
<td class="num">(3,019)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating income/(expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,668)<span></span>
</td>
<td class="num">(1,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,026)<span></span>
</td>
<td class="num">(39,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,228<span></span>
</td>
<td class="nump">3,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,813<span></span>
</td>
<td class="nump">7,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,775)<span></span>
</td>
<td class="num">(29,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash provided by investing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,660)<span></span>
</td>
<td class="nump">11,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,390<span></span>
</td>
<td class="nump">14,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Impact of exchange rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,183<span></span>
</td>
<td class="num">(3,148)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,140<span></span>
</td>
<td class="nump">2,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">All other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,901<span></span>
</td>
<td class="nump">22,116<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,041<span></span>
</td>
<td class="nump">24,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,224)<span></span>
</td>
<td class="num">(15,082)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNet', window );">Net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,817<span></span>
</td>
<td class="nump">9,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_BeyondCancerLtdMember', window );">Beyond Cancer Ltd [Member] | Business Segment [Member] | Variable Interest Entities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_CapitalExpendituresCost', window );">Capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,170)<span></span>
</td>
<td class="num">(3,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,207)<span></span>
</td>
<td class="num">(6,344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,377)<span></span>
</td>
<td class="num">(9,406)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest and finance expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating income/(expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(323)<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,700)<span></span>
</td>
<td class="num">(9,197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,373<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,314)<span></span>
</td>
<td class="num">(8,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash provided by investing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="nump">3,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Impact of exchange rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="num">(5,564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
<td class="nump">2,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">All other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(219)<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">824<span></span>
</td>
<td class="nump">3,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(378)<span></span>
</td>
<td class="num">(589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNet', window );">Net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="nump">2,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_NeuroNosLtdMember', window );">NeuroNos Ltd [Member] | Business Segment [Member] | Variable Interest Entities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_CapitalExpendituresCost', window );">Capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,394)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,430)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,824)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest and finance expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating income/(expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,608)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,055)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash provided by investing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Impact of exchange rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,555)<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">All other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(573)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNet', window );">Net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">1,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_CapitalExpendituresCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital expenditures cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_CapitalExpendituresCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net assets (liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479938/205-30-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479910/205-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=XAIR_SegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=XAIR_SegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=XAIR_VariableInterestEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=XAIR_VariableInterestEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_BeyondAirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_BeyondAirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_BeyondCancerLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_BeyondCancerLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_NeuroNosLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_NeuroNosLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE REVENUES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 3,047<span></span>
</td>
<td class="nump">$ 2,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_LungFitPHMember', window );">Lung Fit PH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=XAIR_LungFitPHMember', window );">Lung Fit PH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_XAIR_OperatingLeaseIncome', window );">Lease revenue</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Contract term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Contract term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_OperatingLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_OperatingLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of property, plant, and equipment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_LungFitPHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_LungFitPHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=XAIR_LungFitPHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=XAIR_LungFitPHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MATURITY OF FUTURE LEASE PAYMENTS (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2027</a></td>
<td class="nump">$ 419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2028</a></td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2029</a></td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_LungFitRPHMember', window );">LungFit&#174; PH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2027</a></td>
<td class="nump">4,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2028</a></td>
<td class="nump">3,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2029</a></td>
<td class="nump">1,560<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">$ 9,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_LungFitRPHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_LungFitRPHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>307</ContextCount>
  <ElementCount>480</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>115</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999014 - Disclosure - ORGANIZATION AND BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/OrganizationAndBusiness</Role>
      <ShortName>ORGANIZATION AND BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertainties</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - STOCKHOLDERS’ EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS’ EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - OTHER CURRENT ASSETS AND PREPAID EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpenses</Role>
      <ShortName>OTHER CURRENT ASSETS AND PREPAID EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStock</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - LOANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/Loans</Role>
      <ShortName>LOANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - LOAN PAYABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/LoanPayable</Role>
      <ShortName>LOAN PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - SEGMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/Segments</Role>
      <ShortName>SEGMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - LEASE REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/LeaseRevenues</Role>
      <ShortName>LEASE REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertainties</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/PropertyAndEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - STOCKHOLDERS’ EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS’ EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - OTHER CURRENT ASSETS AND PREPAID EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpensesTables</Role>
      <ShortName>OTHER CURRENT ASSETS AND PREPAID EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpenses</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockTables</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStock</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - LOANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/LoansTables</Role>
      <ShortName>LOANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/Loans</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - LOAN PAYABLE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/LoanPayableTables</Role>
      <ShortName>LOAN PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/LoanPayable</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - SEGMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SegmentsTables</Role>
      <ShortName>SEGMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/Segments</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - LEASE REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/LeaseRevenuesTables</Role>
      <ShortName>LEASE REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/LeaseRevenues</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative</Role>
      <ShortName>ORGANIZATION AND BUSINESS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/OrganizationAndBusiness</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - SCHEDULE OF FAIR VALUE ON A RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE ON A RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - SUMMARY OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails</Role>
      <ShortName>SUMMARY OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN VALUING WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails</Role>
      <ShortName>SCHEDULE OF ASSUMPTIONS USED IN VALUING WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - SCHEDULE OF KEY INPUTS DERIVATIVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails</Role>
      <ShortName>SCHEDULE OF KEY INPUTS DERIVATIVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails</Role>
      <ShortName>SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999051 - Disclosure - SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails</Role>
      <ShortName>SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999053 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999054 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/PropertyAndEquipmentTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999055 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARDS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails</Role>
      <ShortName>SCHEDULE OF RESTRICTED STOCK AWARDS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999056 - Disclosure - SCHEDULE OF OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999057 - Disclosure - SCHEDULE OF OPTION ACTIVITY FOR BEYOND CANCER (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails</Role>
      <ShortName>SCHEDULE OF OPTION ACTIVITY FOR BEYOND CANCER (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999058 - Disclosure - SCHEDULE OF OPTION ACTIVITY FOR NEURONOS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails</Role>
      <ShortName>SCHEDULE OF OPTION ACTIVITY FOR NEURONOS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999059 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE OF OPTION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999060 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999061 - Disclosure - SUMMARY OF OUTSTANDING WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails</Role>
      <ShortName>SUMMARY OF OUTSTANDING WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999062 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS’ EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/StockholdersEquityTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999063 - Disclosure - SCHEDULE OF OTHER CURRENT ASSETS AND PREPAID EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails</Role>
      <ShortName>SCHEDULE OF OTHER CURRENT ASSETS AND PREPAID EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999064 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SummaryOfAccruedExpensesDetails</Role>
      <ShortName>SUMMARY OF ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999065 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical</Role>
      <ShortName>SUMMARY OF ACCRUED EXPENSES (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999066 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails</Role>
      <ShortName>SCHEDULE OF OPERATING LEASE LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999067 - Disclosure - SCHEDULE OF LEASE RELATED COSTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails</Role>
      <ShortName>SCHEDULE OF LEASE RELATED COSTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999068 - Disclosure - SCHEDULE OF LEASE OTHER INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfLeaseOtherInformationDetails</Role>
      <ShortName>SCHEDULE OF LEASE OTHER INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999069 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999070 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/LeasesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999071 - Disclosure - SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails</Role>
      <ShortName>SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999072 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999073 - Disclosure - SCHEDULE OF LONG-TERM DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfLong-termDebtDetails</Role>
      <ShortName>SCHEDULE OF LONG-TERM DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>999074 - Disclosure - LOANS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/LoansDetailsNarrative</Role>
      <ShortName>LOANS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/LoansTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>999075 - Disclosure - SCHEDULE OF LOAN PAYABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfLoanPayableDetails</Role>
      <ShortName>SCHEDULE OF LOAN PAYABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>999076 - Disclosure - SCHEDULE OF PROFIT (LOSS) BEFORE TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails</Role>
      <ShortName>SCHEDULE OF PROFIT (LOSS) BEFORE TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>999077 - Disclosure - SCHEDULE OF DEFERRED TAX ASSET/LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSET/LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>999078 - Disclosure - SCHEDULE OF DIFFERENCE EFFECTIVE INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails</Role>
      <ShortName>SCHEDULE OF DIFFERENCE EFFECTIVE INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>999079 - Disclosure - SCHEDULE OF STATUTORY US FEDERAL EFFECTIVE RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails</Role>
      <ShortName>SCHEDULE OF STATUTORY US FEDERAL EFFECTIVE RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>999080 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/IncomeTaxesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>999081 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/CommitmentsAndContingencies</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>999082 - Disclosure - SEGMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SegmentsDetailsNarrative</Role>
      <ShortName>SEGMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/SegmentsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>999083 - Disclosure - SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails</Role>
      <ShortName>SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>999084 - Disclosure - LEASE REVENUES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/LeaseRevenuesDetailsNarrative</Role>
      <ShortName>LEASE REVENUES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/LeaseRevenuesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>999085 - Disclosure - SCHEDULE OF MATURITY OF FUTURE LEASE PAYMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails</Role>
      <ShortName>SCHEDULE OF MATURITY OF FUTURE LEASE PAYMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>xair-20260331.xsd</File>
    <File>xair-20260331_cal.xml</File>
    <File>xair-20260331_def.xml</File>
    <File>xair-20260331_lab.xml</File>
    <File>xair-20260331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1167">http://fasb.org/us-gaap/2026</BaseTaxonomy>
    <BaseTaxonomy items="7">http://xbrl.sec.gov/cyd/2026</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>114
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "XAIR",
   "nsuri": "http://beyondair.net/20260331",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "xair-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "xair-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "xair-20260331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "xair-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xair-20260331_pre.xml"
     ]
    }
   },
   "keyStandard": 402,
   "keyCustom": 78,
   "axisStandard": 29,
   "axisCustom": 0,
   "memberStandard": 49,
   "memberCustom": 56,
   "hidden": {
    "total": 221,
    "http://fasb.org/us-gaap/2026": 179,
    "http://beyondair.net/20260331": 39,
    "http://xbrl.sec.gov/dei/2026": 3
   },
   "contextCount": 307,
   "entityCount": 1,
   "segmentCount": 115,
   "elementCount": 837,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2026": 1167,
    "http://xbrl.sec.gov/dei/2026": 41,
    "http://xbrl.sec.gov/cyd/2026": 7
   },
   "report": {
    "R1": {
     "role": "http://beyondair.net/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://beyondair.net/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://beyondair.net/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:GrossProfit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31_us-gaap_TreasuryStockCommonMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31_us-gaap_TreasuryStockCommonMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://beyondair.net/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "XAIR:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "XAIR:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://beyondair.net/role/OrganizationAndBusiness",
     "longName": "999014 - Disclosure - ORGANIZATION AND BUSINESS",
     "shortName": "ORGANIZATION AND BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertainties",
     "longName": "999015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://beyondair.net/role/PropertyAndEquipment",
     "longName": "999016 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://beyondair.net/role/StockholdersEquity",
     "longName": "999017 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpenses",
     "longName": "999018 - Disclosure - OTHER CURRENT ASSETS AND PREPAID EXPENSES",
     "shortName": "OTHER CURRENT ASSETS AND PREPAID EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilities",
     "longName": "999019 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://beyondair.net/role/Leases",
     "longName": "999020 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStock",
     "longName": "999021 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK",
     "shortName": "BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://beyondair.net/role/Loans",
     "longName": "999022 - Disclosure - LOANS",
     "shortName": "LOANS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://beyondair.net/role/LoanPayable",
     "longName": "999023 - Disclosure - LOAN PAYABLE",
     "shortName": "LOAN PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://beyondair.net/role/IncomeTaxes",
     "longName": "999024 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://beyondair.net/role/CommitmentsAndContingencies",
     "longName": "999025 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://beyondair.net/role/Segments",
     "longName": "999026 - Disclosure - SEGMENTS",
     "shortName": "SEGMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://beyondair.net/role/RelatedPartyTransactions",
     "longName": "999027 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://beyondair.net/role/LeaseRevenues",
     "longName": "999028 - Disclosure - LEASE REVENUES",
     "shortName": "LEASE REVENUES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "XAIR:OperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "XAIR:OperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://beyondair.net/role/SubsequentEvents",
     "longName": "999029 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies",
     "longName": "999030 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables",
     "longName": "999031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Tables)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://beyondair.net/role/PropertyAndEquipmentTables",
     "longName": "999032 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://beyondair.net/role/StockholdersEquityTables",
     "longName": "999033 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpensesTables",
     "longName": "999034 - Disclosure - OTHER CURRENT ASSETS AND PREPAID EXPENSES (Tables)",
     "shortName": "OTHER CURRENT ASSETS AND PREPAID EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "999035 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://beyondair.net/role/LeasesTables",
     "longName": "999036 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "XAIR:ScheduleOfOperatingLeaseLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "XAIR:ScheduleOfOperatingLeaseLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockTables",
     "longName": "999037 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Tables)",
     "shortName": "BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://beyondair.net/role/LoansTables",
     "longName": "999038 - Disclosure - LOANS (Tables)",
     "shortName": "LOANS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://beyondair.net/role/LoanPayableTables",
     "longName": "999039 - Disclosure - LOAN PAYABLE (Tables)",
     "shortName": "LOAN PAYABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://beyondair.net/role/IncomeTaxesTables",
     "longName": "999040 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://beyondair.net/role/SegmentsTables",
     "longName": "999041 - Disclosure - SEGMENTS (Tables)",
     "shortName": "SEGMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_VariableInterestEntitiesMember",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_VariableInterestEntitiesMember",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://beyondair.net/role/LeaseRevenuesTables",
     "longName": "999042 - Disclosure - LEASE REVENUES (Tables)",
     "shortName": "LEASE REVENUES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_LungFitRPHMember",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "XAIR:OperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative",
     "longName": "999043 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative)",
     "shortName": "ORGANIZATION AND BUSINESS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2025-07-142025-07-14",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-142025-07-14",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails",
     "longName": "999044 - Disclosure - SCHEDULE OF FAIR VALUE ON A RECURRING BASIS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE ON A RECURRING BASIS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails",
     "longName": "999045 - Disclosure - SUMMARY OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES (Details)",
     "shortName": "SUMMARY OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_us-gaap_ShortTermDebtMember",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails",
     "longName": "999046 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN VALUING WARRANTS (Details)",
     "shortName": "SCHEDULE OF ASSUMPTIONS USED IN VALUING WARRANTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31_us-gaap_MeasurementInputExpectedTermMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_us-gaap_MeasurementInputExpectedTermMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails",
     "longName": "999047 - Disclosure - SCHEDULE OF KEY INPUTS DERIVATIVE (Details)",
     "shortName": "SCHEDULE OF KEY INPUTS DERIVATIVE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2025-11-042025-11-04",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "XAIR:FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-11-042025-11-04",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "XAIR:FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails",
     "longName": "999048 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES (Details)",
     "shortName": "SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31_us-gaap_WarrantMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "XAIR:ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31_us-gaap_WarrantMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "XAIR:ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
     "longName": "999049 - Disclosure - SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH (Details)",
     "shortName": "SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails",
     "longName": "999050 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS (Details)",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31_us-gaap_ComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "XAIR:ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_us-gaap_ComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "XAIR:ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails",
     "longName": "999051 - Disclosure - SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE (Details)",
     "shortName": "SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative",
     "longName": "999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Details Narrative)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "999053 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "999054 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R51": {
     "role": "http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails",
     "longName": "999055 - Disclosure - SCHEDULE OF RESTRICTED STOCK AWARDS (Details)",
     "shortName": "SCHEDULE OF RESTRICTED STOCK AWARDS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31_us-gaap_RestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31_us-gaap_RestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
     "longName": "999056 - Disclosure - SCHEDULE OF OPTION ACTIVITY (Details)",
     "shortName": "SCHEDULE OF OPTION ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
     "longName": "999057 - Disclosure - SCHEDULE OF OPTION ACTIVITY FOR BEYOND CANCER (Details)",
     "shortName": "SCHEDULE OF OPTION ACTIVITY FOR BEYOND CANCER (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails",
     "longName": "999058 - Disclosure - SCHEDULE OF OPTION ACTIVITY FOR NEURONOS (Details)",
     "shortName": "SCHEDULE OF OPTION ACTIVITY FOR NEURONOS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails",
     "longName": "999059 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE OF OPTION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://beyondair.net/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "longName": "999060 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)",
     "shortName": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2026-03-272026-03-27",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_us-gaap_GeneralAndAdministrativeExpense",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails",
     "longName": "999061 - Disclosure - SUMMARY OF OUTSTANDING WARRANTS (Details)",
     "shortName": "SUMMARY OF OUTSTANDING WARRANTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://beyondair.net/role/StockholdersEquityDetailsNarrative",
     "longName": "999062 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails",
     "longName": "999063 - Disclosure - SCHEDULE OF OTHER CURRENT ASSETS AND PREPAID EXPENSES (Details)",
     "shortName": "SCHEDULE OF OTHER CURRENT ASSETS AND PREPAID EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "XAIR:PrepaidResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "XAIR:PrepaidResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://beyondair.net/role/SummaryOfAccruedExpensesDetails",
     "longName": "999064 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details)",
     "shortName": "SUMMARY OF ACCRUED EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "XAIR:AccruedResearchAndDevelopmentExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "XAIR:AccruedResearchAndDevelopmentExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical",
     "longName": "999065 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details) (Parenthetical)",
     "shortName": "SUMMARY OF ACCRUED EXPENSES (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31_custom_SteveLisiMember",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_custom_SteveLisiMember",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails",
     "longName": "999066 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITY (Details)",
     "shortName": "SCHEDULE OF OPERATING LEASE LIABILITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "XAIR:ScheduleOfOperatingLeaseLiabilityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails",
     "longName": "999067 - Disclosure - SCHEDULE OF LEASE RELATED COSTS (Details)",
     "shortName": "SCHEDULE OF LEASE RELATED COSTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://beyondair.net/role/ScheduleOfLeaseOtherInformationDetails",
     "longName": "999068 - Disclosure - SCHEDULE OF LEASE OTHER INFORMATION (Details)",
     "shortName": "SCHEDULE OF LEASE OTHER INFORMATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "XAIR:OtherLeaseTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "XAIR:OtherLeaseTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails",
     "longName": "999069 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)",
     "shortName": "SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://beyondair.net/role/LeasesDetailsNarrative",
     "longName": "999070 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2026-03-012026-03-31",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-03-012026-03-31",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails",
     "longName": "999071 - Disclosure - SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES (Details)",
     "shortName": "SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative",
     "longName": "999072 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details Narrative)",
     "shortName": "BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_PreFundedWarrantsMember",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012026-03-31_custom_PreFundedWarrantsMember",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://beyondair.net/role/ScheduleOfLong-termDebtDetails",
     "longName": "999073 - Disclosure - SCHEDULE OF LONG-TERM DEBT (Details)",
     "shortName": "SCHEDULE OF LONG-TERM DEBT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "AsOf2026-12-31",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-12-31",
      "name": "XAIR:PaidInKindInterestAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://beyondair.net/role/LoansDetailsNarrative",
     "longName": "999074 - Disclosure - LOANS (Details Narrative)",
     "shortName": "LOANS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "AsOf2026-12-31",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-01-31_custom_StreetervilleCapitalLLCMember",
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://beyondair.net/role/ScheduleOfLoanPayableDetails",
     "longName": "999075 - Disclosure - SCHEDULE OF LOAN PAYABLE (Details)",
     "shortName": "SCHEDULE OF LOAN PAYABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:LoansPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:LoansPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails",
     "longName": "999076 - Disclosure - SCHEDULE OF PROFIT (LOSS) BEFORE TAXES (Details)",
     "shortName": "SCHEDULE OF PROFIT (LOSS) BEFORE TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails",
     "longName": "999077 - Disclosure - SCHEDULE OF DEFERRED TAX ASSET/LIABILITY (Details)",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSET/LIABILITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails",
     "longName": "999078 - Disclosure - SCHEDULE OF DIFFERENCE EFFECTIVE INCOME TAX RATE (Details)",
     "shortName": "SCHEDULE OF DIFFERENCE EFFECTIVE INCOME TAX RATE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "XAIR:ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "XAIR:ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails",
     "longName": "999079 - Disclosure - SCHEDULE OF STATUTORY US FEDERAL EFFECTIVE RATE (Details)",
     "shortName": "SCHEDULE OF STATUTORY US FEDERAL EFFECTIVE RATE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "XAIR:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "XAIR:ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012025-03-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://beyondair.net/role/IncomeTaxesDetailsNarrative",
     "longName": "999080 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999081 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:DepositAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "XAIR:GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember_custom_SupplierMember",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://beyondair.net/role/SegmentsDetailsNarrative",
     "longName": "999082 - Disclosure - SEGMENTS (Details Narrative)",
     "shortName": "SEGMENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-03-242025-03-24_custom_SubscriptionAgreementMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
     "longName": "999083 - Disclosure - SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT (Details)",
     "shortName": "SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember",
      "name": "XAIR:CapitalExpendituresCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://beyondair.net/role/LeaseRevenuesDetailsNarrative",
     "longName": "999084 - Disclosure - LEASE REVENUES (Details Narrative)",
     "shortName": "LEASE REVENUES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2026-03-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_custom_LungFitPHMember42286578",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "XAIR:OperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails",
     "longName": "999085 - Disclosure - SCHEDULE OF MATURITY OF FUTURE LEASE PAYMENTS (Details)",
     "shortName": "SCHEDULE OF MATURITY OF FUTURE LEASE PAYMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_custom_LungFitRPHMember",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "XAIR:OperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "country_AU": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2026",
     "localname": "AU",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1403"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r1088",
      "r1253",
      "r1259"
     ]
    },
    "us-gaap_AccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableMember",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable [Member]",
        "documentation": "Obligations incurred and payable to vendors for goods and services received."
       }
      }
     },
     "auth_ref": [
      "r1444",
      "r1445",
      "r1446",
      "r1447",
      "r1448",
      "r1449"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1317"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee salaries and benefits",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets",
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "XAIR_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "documentation": "Accrued prepaid research and development expenses.",
        "label": "AccruedResearchAndDevelopmentExpenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation",
        "label": "Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization",
        "documentation": "Amount of accumulated depreciation, depletion, and amortization of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r337",
      "r346",
      "r826",
      "r827",
      "r844",
      "r1333"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r138",
      "r653"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r627",
      "r628",
      "r629",
      "r630",
      "r667",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income/(loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r31",
      "r126",
      "r418",
      "r783",
      "r784",
      "r794",
      "r838",
      "r875",
      "r876",
      "r1436"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r627",
      "r628",
      "r629",
      "r630",
      "r667",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r12",
      "r618",
      "r622",
      "r625",
      "r695",
      "r871",
      "r872",
      "r1270",
      "r1271",
      "r1272",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1366",
      "r1368"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1178"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r418",
      "r783",
      "r784",
      "r794",
      "r1088",
      "r1521"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r894",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1437",
      "r1526"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1185"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1185"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1185"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1185"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments in additional paid in capital",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of common stock warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r1362",
      "r1366",
      "r1368"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_AfterSixMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "AfterSixMonthsMember",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After Six Months [Member]",
        "documentation": "After Six Months [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1145",
      "r1156",
      "r1170",
      "r1197"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r1148",
      "r1159",
      "r1173",
      "r1200"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r1185"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r1192"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r1149",
      "r1160",
      "r1174",
      "r1192",
      "r1201",
      "r1205",
      "r1213"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AllowanceForDoubtfulAccountsReceivableNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for credit losses",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r295"
     ]
    },
    "XAIR_AmendedLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "AmendedLoanAgreementMember",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended Loan Agreement [Member]",
        "documentation": "Amended Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_AmortizationOfDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "AmortizationOfDebtDiscount",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount",
        "documentation": "Amortization of Debt Discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount and accretion of debt issuance costs",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r1046",
      "r1047",
      "r1278",
      "r1462"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of licensed right to use technology",
        "documentation": "Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r152",
      "r326",
      "r327",
      "r996",
      "r1008",
      "r1009",
      "r1011",
      "r1013",
      "r1333"
     ]
    },
    "XAIR_AmountOfTerminatedLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "AmountOfTerminatedLoan",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of terminated loan",
        "documentation": "Amount of terminated loan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails",
      "http://beyondair.net/role/SegmentsDetailsNarrative",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative",
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets",
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r106",
      "r164",
      "r167",
      "r168",
      "r207",
      "r219",
      "r244",
      "r248",
      "r292",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r421",
      "r597",
      "r602",
      "r658",
      "r783",
      "r784",
      "r786",
      "r803",
      "r804",
      "r832",
      "r925",
      "r1026",
      "r1027",
      "r1048",
      "r1088",
      "r1103",
      "r1104",
      "r1115",
      "r1355",
      "r1356",
      "r1470"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r133",
      "r164",
      "r167",
      "r168",
      "r292",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r421",
      "r597",
      "r602",
      "r658",
      "r1088",
      "r1247",
      "r1355",
      "r1356",
      "r1470"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets measured and recorded at fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r639",
      "r1074"
     ]
    },
    "us-gaap_AssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net assets",
        "documentation": "Amount of net assets (liabilities)."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1127",
      "r1129",
      "r1152"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditorLocation",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1127",
      "r1129",
      "r1152"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditorName",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1127",
      "r1129",
      "r1152"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1230"
     ]
    },
    "us-gaap_AustralianTaxationOfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AustralianTaxationOfficeMember",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australian Taxation Office [Member]",
        "documentation": "Designated tax department of the government of Australia."
       }
      }
     },
     "auth_ref": [
      "r1407",
      "r1409"
     ]
    },
    "XAIR_AvenueAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "AvenueAgreementMember",
     "presentation": [
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Avenue Agreement [Member]",
        "documentation": "Avenue Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_AvenueExtensionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "AvenueExtensionAgreementMember",
     "presentation": [
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Avenue Extension Agreement [Member]",
        "documentation": "Avenue Extension Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1208"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1209"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r1204"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1204"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1204"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1204"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1204"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1204"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails",
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/SegmentsTables",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1207"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1206"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1205"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1205"
     ]
    },
    "country_BM": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2026",
     "localname": "BM",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BERMUDA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Principles of Consolidation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1281"
     ]
    },
    "XAIR_BeneficialOwnershipLimitationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "BeneficialOwnershipLimitationPercentage",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beneficial ownership limitation percentage",
        "documentation": "Beneficial ownership limitation percentage."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_BeyondAirIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "BeyondAirIncMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beyond Air Inc. [Member]",
        "documentation": "Beyond Air Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_BeyondAirMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "BeyondAirMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beyond Air [Member]",
        "documentation": "Beyond Air [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_BeyondCancerLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "BeyondCancerLtdMember",
     "presentation": [
      "http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails",
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/SegmentsDetailsNarrative",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beyond Cancer Ltd [Member]",
        "documentation": "Beyond Cancer Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails",
      "http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r1065",
      "r1068",
      "r1416",
      "r1418",
      "r1419"
     ]
    },
    "country_CY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2026",
     "localname": "CY",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CYPRUS"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_CapitalExpendituresCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "CapitalExpendituresCost",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital expenditures",
        "documentation": "Capital expenditures cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed assets recorded in accounts payable and accrued expenses",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r1280"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative",
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r157",
      "r160",
      "r835",
      "r896",
      "r919",
      "r1088",
      "r1103",
      "r1104",
      "r1115",
      "r1255",
      "r1477",
      "r1478",
      "r1480"
     ]
    },
    "XAIR_CashAndCashEquivalentsAndMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "CashAndCashEquivalentsAndMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents and marketable securities",
        "documentation": "Cash and cash equivalents and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets",
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r157",
      "r160",
      "r998",
      "r1472"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Short-Term Investments and Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r1279"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents, marketable securities and restricted cash",
        "label": "Cash, cash equivalents and marketable securities",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r1268"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r157",
      "r160"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase/(decrease) in cash, cash equivalents and restricted cash",
        "label": "Net change for the year",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r44"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_CertainInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "CertainInvestorsMember",
     "presentation": [
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certain Investors [Member]",
        "documentation": "Certain Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative",
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise Price",
        "label": "Warrants price",
        "terseLabel": "Warrants exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r171",
      "r411"
     ]
    },
    "XAIR_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic Value",
        "documentation": "Warrants Intrinsic Value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants to purchase common stock",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r1363"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative",
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants",
        "verboseLabel": "Warrants to purchase",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_ClinicalAndMedicalEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ClinicalAndMedicalEquipmentMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical and Medical Equipment [Member]",
        "documentation": "Clinical and Medical Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1184"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1184"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 12)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r783",
      "r784",
      "r790",
      "r834",
      "r910"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r980",
      "r1344",
      "r1349",
      "r1350"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockMember",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r417",
      "r783",
      "r784",
      "r793",
      "r1105",
      "r1106",
      "r1107",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1290",
      "r1291",
      "r1293",
      "r1437",
      "r1519",
      "r1526"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://beyondair.net/role/BalanceSheetsParenthetical",
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r1265",
      "r1365",
      "r1477",
      "r1478",
      "r1483"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://beyondair.net/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r417",
      "r783",
      "r784",
      "r793",
      "r911"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://beyondair.net/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r417",
      "r783",
      "r784",
      "r793"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://beyondair.net/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r417",
      "r783",
      "r784",
      "r793",
      "r911",
      "r931",
      "r1362",
      "r1526",
      "r1527"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, $0.0001 par value per share: 500,000,000 shares authorized, 11,792,684 and 4,128,539 shares issued and outstanding as of March 31, 2026 and 2025, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r389",
      "r395",
      "r417",
      "r783",
      "r784",
      "r793",
      "r837",
      "r1088"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of issued common stock",
        "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r417",
      "r783",
      "r784",
      "r793",
      "r911"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1189"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1188"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1190"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1187"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to Beyond Air, Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r140",
      "r142",
      "r148",
      "r801",
      "r852",
      "r853"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": [
      "r1339",
      "r1340"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskBenchmarkDescription",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration risk benchmark description",
        "documentation": "Identifies or describes the benchmark that serves as the denominator in the calculation of the percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r1297",
      "r1302"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r256",
      "r879",
      "r880",
      "r979",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r256",
      "r879",
      "r880",
      "r979",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r256",
      "r879",
      "r880",
      "r979",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r656"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r256",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r256",
      "r879",
      "r880",
      "r979",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r175",
      "r597",
      "r598",
      "r601",
      "r602",
      "r603",
      "r704",
      "r807",
      "r985",
      "r1354",
      "r1357",
      "r1358",
      "r1367"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "auth_ref": [
      "r165",
      "r175",
      "r597",
      "r598",
      "r601",
      "r602",
      "r603",
      "r704",
      "r807",
      "r985",
      "r1354",
      "r1357",
      "r1358",
      "r1367"
     ]
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r25",
      "r26"
     ]
    },
    "us-gaap_CostOfGoodsTotalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CostOfGoodsTotalMember",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Service Benchmark [Member]",
        "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r1298",
      "r1300"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenues",
        "negatedLabel": "Cost of revenues",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r164",
      "r167",
      "r168",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r421",
      "r658",
      "r1026",
      "r1245",
      "r1246",
      "r1326",
      "r1355"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CountryRegion",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CreditRiskDerivativeLiabilitiesAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of the derivative liability",
        "documentation": "Fair value of credit risk derivative liability."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r1420"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r1298"
     ]
    },
    "XAIR_CustomerrConcentrationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "CustomerrConcentrationPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration",
        "documentation": "Customerr Concentration [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_CustomersOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "CustomersOneMember",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customers One [Member]",
        "documentation": "Customers One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_CustomersTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "CustomersTwoMember",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customers Two [Member]",
        "documentation": "Customers Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1137",
      "r1224"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1137",
      "r1224"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1139",
      "r1226"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1139",
      "r1226"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1141",
      "r1228"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1139",
      "r1226"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1132",
      "r1219"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1133",
      "r1220"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1133",
      "r1220"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1218"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1134",
      "r1221"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1136",
      "r1223"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1136",
      "r1223"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1137",
      "r1224"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1140",
      "r1227"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1225"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1222"
     ]
    },
    "XAIR_CypriotTaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "CypriotTaxMember",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cypriot Tax [Member]",
        "documentation": "Cypriot Tax [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued of common stock",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r1280"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt amount",
        "label": "Debt Conversion, Original Debt, Amount",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r1280"
     ]
    },
    "us-gaap_DebtDefaultLongtermDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtDefaultLongtermDebtAmount",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt amount",
        "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r166"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_DebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "DebtDiscount",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount",
        "documentation": "Debt discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r116",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r411",
      "r783",
      "r784",
      "r789",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1086",
      "r1282",
      "r1283",
      "r1284",
      "r1289",
      "r1345",
      "r1346",
      "r1347",
      "r1461",
      "r1463",
      "r1484"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r1477",
      "r1478",
      "r1481"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal balance outstanding",
        "verboseLabel": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r674",
      "r675",
      "r1044",
      "r1045",
      "r1086"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument, interest rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r1254",
      "r1262",
      "r1461",
      "r1477",
      "r1478",
      "r1481"
     ]
    },
    "XAIR_DebtInstrumentInterestRatePayableInCashPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "DebtInstrumentInterestRatePayableInCashPercentage",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of interest payable in cash",
        "documentation": "Debt instrument interest rate payable in cash percentage."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_DebtInstrumentInterestRatePayableInKindPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "DebtInstrumentInterestRatePayableInKindPercentage",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of interest payable in kind",
        "documentation": "Debt instrument interest rate payable in kind percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfLoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r110",
      "r369",
      "r783",
      "r784",
      "r789"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentInterestRateTerms",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate description",
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets."
       }
      }
     },
     "auth_ref": [
      "r1254",
      "r1262"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r116",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r411",
      "r783",
      "r784",
      "r789",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1086",
      "r1282",
      "r1283",
      "r1284",
      "r1289",
      "r1345",
      "r1346",
      "r1347",
      "r1461",
      "r1463",
      "r1484"
     ]
    },
    "XAIR_DebtInstrumentOfRestrictedAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "DebtInstrumentOfRestrictedAccount",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal in restricted account",
        "documentation": "Debt instrument of restricted account."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly payments",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r1254",
      "r1262"
     ]
    },
    "us-gaap_DebtInstrumentRepaidPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentRepaidPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument, principal repayable",
        "documentation": "Amount of principal of debt repaid."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r66",
      "r67",
      "r68",
      "r101",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r116",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r411",
      "r615",
      "r783",
      "r784",
      "r789",
      "r807",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1086",
      "r1282",
      "r1283",
      "r1284",
      "r1289",
      "r1461",
      "r1463"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument term",
        "documentation": "Period between issuance and maturity of debt instrument, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r1360",
      "r1460",
      "r1461",
      "r1463"
     ]
    },
    "XAIR_DebtPrincipalBalanceConvertedToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "DebtPrincipalBalanceConvertedToEquity",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt principal balance converted to equity",
        "documentation": "Debt principal balance converted to equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails",
      "http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails",
      "http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]",
        "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r305",
      "r306"
     ]
    },
    "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails",
      "http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails",
      "http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r305",
      "r306"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OTHER CURRENT ASSETS AND PREPAID EXPENSES",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredCostsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other fees",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1267"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development tax credits",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1410"
     ]
    },
    "XAIR_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Deferred tax assets lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1408"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1410"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1410"
     ]
    },
    "XAIR_DeferredTaxAssetsReservesAndAccruels": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "DeferredTaxAssetsReservesAndAccruels",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserves and accruals",
        "documentation": "Deferred tax assets reserves and accruels."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_DeferredTaxAssetsRightofuseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "DeferredTaxAssetsRightofuseAsset",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use asset",
        "documentation": "Deferred tax assets right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1410"
     ]
    },
    "XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation",
        "documentation": "Deferred tax assets tax deferred expense compensation and depreciation.",
        "label": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities, deferred expense, capitalized research and development costs",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs."
       }
      }
     },
     "auth_ref": [
      "r1410"
     ]
    },
    "us-gaap_DepositAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DepositAssets",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash deposit",
        "verboseLabel": "Cash deposits",
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement."
       }
      }
     },
     "auth_ref": [
      "r1252",
      "r1257"
     ]
    },
    "us-gaap_DepositsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DepositsAssets",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits to secure manufacturing materials",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future."
       }
      }
     },
     "auth_ref": [
      "r1252",
      "r1257"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative",
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r151",
      "r335",
      "r1008",
      "r1009",
      "r1011",
      "r1013"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r1331",
      "r1338"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of derivative liability",
        "negatedLabel": "Change in fair value of derivative liability",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1084",
      "r1421"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementDifferenceDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeLiabilityMeasurementDifferenceDescription",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability description",
        "documentation": "Description of measurement difference between recognized amounts and resulting measurement differences for derivative liabilities."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free rate",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r641",
      "r642"
     ]
    },
    "us-gaap_DerivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative [Member]",
        "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender)."
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "XAIR_DerivativesLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "DerivativesLiability",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability",
        "documentation": "Derivatives liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r164",
      "r174",
      "r604",
      "r608",
      "r611",
      "r612",
      "r613",
      "r614",
      "r616",
      "r620"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "DirectorMember",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r783",
      "r784",
      "r788",
      "r1316",
      "r1520"
     ]
    },
    "XAIR_DisclosureLeaseRevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "DisclosureLeaseRevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Operating Lease Liability",
        "terseLabel": "Schedule Of Lease Related Costs"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1127",
      "r1129",
      "r1152"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1127",
      "r1129",
      "r1152",
      "r1193"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1177"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction, Domestic Federal [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net basic loss per share attributable to Beyond Air, Inc.",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r149",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r194",
      "r196",
      "r198",
      "r199",
      "r200",
      "r206",
      "r331",
      "r387",
      "r449",
      "r500",
      "r554",
      "r594",
      "r634",
      "r635",
      "r802",
      "r854",
      "r1016"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net diluted loss per share attributable to Beyond Air, Inc.",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r149",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r196",
      "r198",
      "r199",
      "r200",
      "r206",
      "r331",
      "r387",
      "r449",
      "r500",
      "r554",
      "r594",
      "r634",
      "r635",
      "r802",
      "r854",
      "r1016"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r201",
      "r203",
      "r204",
      "r205",
      "r426"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1459"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails",
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r1064"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S. federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r170",
      "r519",
      "r544",
      "r1064"
     ]
    },
    "XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal tax percentage",
        "documentation": "Effective income tax rate reconciliation at federal statutory income tax rate percentage."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal income tax at statutory rate",
        "label": "Federal income tax rate",
        "documentation": "Federal income tax at statutory rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails",
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r1064",
      "r1282",
      "r1288",
      "r1404"
     ]
    },
    "XAIR_EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change to foreign NOL\u2019s",
        "documentation": "Effective income tax rate reconciliation change to foreign net operating loss."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "documentation": "Effective income tax rate reconciliation difference other adjustments.",
        "label": "EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other adjustments",
        "documentation": "Effective income tax rate reconciliation difference other reconciling items percent.",
        "label": "EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment awards",
        "documentation": "Effective income tax rate reconciliation difference share based compensation excess tax benefit amount."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share-based payment awards",
        "documentation": "Effective income tax rate reconciliation difference share based compensation excess tax benefit percent.",
        "label": "EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current state and local income taxes, net of federal benefit",
        "documentation": "Effective Income tax rate reconciliation difference state and local income taxes.",
        "label": "EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other foreign jurisdictions",
        "documentation": "Effective income tax rate reconciliation difference tax credits research.",
        "label": "EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign tax rate differential",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r526",
      "r1064",
      "r1282",
      "r1288",
      "r1404"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r526",
      "r1064"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-deductible compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r525",
      "r1282",
      "r1288",
      "r1404"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails",
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1282",
      "r1288",
      "r1404",
      "r1406"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other foreign jurisdictions",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1406"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent items",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1402",
      "r1404",
      "r1406"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r1064",
      "r1282",
      "r1288",
      "r1404"
     ]
    },
    "XAIR_EffectiveIncomeTaxRateReconciliationSubpartFIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "EffectiveIncomeTaxRateReconciliationSubpartFIncome",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Subpart F Income",
        "documentation": "Effective income tax rate reconciliation subpart f income.",
        "label": "EffectiveIncomeTaxRateReconciliationSubpartFIncome"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r526",
      "r1064"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1282",
      "r1288",
      "r1404",
      "r1405"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfStatutoryUsFederalEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1282",
      "r1288",
      "r1404",
      "r1405"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized share based compensation",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining service period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized stock-based compensation expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1400"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental stock compensation expense",
        "documentation": "The amount of plan compensation cost recognized during the period."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r1061",
      "r1062"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityDomain",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative",
      "http://beyondair.net/role/LeaseRevenuesTables",
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails",
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails",
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/SegmentsDetailsNarrative",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1233"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1229"
     ]
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1231"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1182"
     ]
    },
    "XAIR_EquipmentDeployableAsPartOfServiceOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "EquipmentDeployableAsPartOfServiceOfferingMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment Deployable as Part of Service Offering [Member]",
        "documentation": "Equipment Deployable as Part of Service Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r94",
      "r121",
      "r122",
      "r144",
      "r145",
      "r146",
      "r176",
      "r177",
      "r178",
      "r180",
      "r187",
      "r189",
      "r191",
      "r208",
      "r293",
      "r294",
      "r330",
      "r331",
      "r332",
      "r386",
      "r410",
      "r415",
      "r416",
      "r417",
      "r420",
      "r422",
      "r425",
      "r447",
      "r448",
      "r450",
      "r451",
      "r500",
      "r542",
      "r543",
      "r551",
      "r552",
      "r553",
      "r555",
      "r593",
      "r594",
      "r617",
      "r618",
      "r619",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r633",
      "r667",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r677",
      "r695",
      "r744",
      "r783",
      "r784",
      "r792",
      "r793",
      "r828",
      "r850",
      "r871",
      "r872",
      "r873",
      "r894",
      "r953",
      "r1371"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative",
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r550",
      "r658",
      "r1234",
      "r1235",
      "r1236",
      "r1411",
      "r1412",
      "r1413",
      "r1414"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative",
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership percentage",
        "verboseLabel": "Equity ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r658"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1186"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r1145",
      "r1156",
      "r1170",
      "r1197"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1153",
      "r1167",
      "r1194"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1192"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Extension",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtinguishmentOfDebtAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ExtinguishmentOfDebtAxis",
     "presentation": [
      "http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of Debt [Axis]",
        "documentation": "Information by type of debt extinguished."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ExtinguishmentOfDebtTypeDomain",
     "presentation": [
      "http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of debt extinguished."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrant liability",
        "label": "Change in fair value of warrant liability",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE ON A RECURRING BASIS",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1439",
      "r1440",
      "r1453"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ASSUMPTIONS USED IN VALUING WARRANTS",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r641",
      "r1077"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r636",
      "r637",
      "r639",
      "r640",
      "r641",
      "r642",
      "r647",
      "r649",
      "r651",
      "r654",
      "r711",
      "r712",
      "r713",
      "r718",
      "r1044",
      "r1045",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1074",
      "r1077",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r453",
      "r458",
      "r460",
      "r639",
      "r649",
      "r654",
      "r711",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1074",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r453",
      "r458",
      "r460",
      "r462",
      "r639",
      "r640",
      "r649",
      "r654",
      "r712",
      "r1044",
      "r1045",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1074",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r639",
      "r640",
      "r641",
      "r642",
      "r649",
      "r654",
      "r713",
      "r1044",
      "r1045",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1074",
      "r1077",
      "r1084",
      "r1085"
     ]
    },
    "XAIR_FairValueMeasurementExtinguishment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "FairValueMeasurementExtinguishment",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment",
        "documentation": "Extinguishment."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF KEY INPUTS DERIVATIVE",
        "documentation": "Fair Value Measurement Inputs and Valuation Techniques of Derivative [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r1450",
      "r1451"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r648",
      "r650"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1444",
      "r1454"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at March 31, 2025",
        "periodEndLabel": "Balance at March 31, 2026",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r650"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r636",
      "r637",
      "r639",
      "r640",
      "r641",
      "r642",
      "r647",
      "r649",
      "r651",
      "r654",
      "r711",
      "r712",
      "r713",
      "r718",
      "r1044",
      "r1045",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1074",
      "r1077",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails",
      "http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails",
      "http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r384",
      "r409",
      "r615",
      "r652",
      "r657",
      "r660",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r715",
      "r716",
      "r717",
      "r718",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r830",
      "r851",
      "r1033",
      "r1074",
      "r1075",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1438",
      "r1441",
      "r1442",
      "r1443",
      "r1452",
      "r1455",
      "r1456",
      "r1457"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r996"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2031",
        "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r996"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2030",
        "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r996"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r996"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r996"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFutureExpectedAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Intangible Asset, Finite-Lived, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r1330"
     ]
    },
    "us-gaap_FiniteLivedLicenseAgreementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedLicenseAgreementsGross",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensed right to use technology",
        "documentation": "Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life."
       }
      }
     },
     "auth_ref": [
      "r1251",
      "r1256",
      "r1330"
     ]
    },
    "XAIR_FirstThirdPartyVendorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "FirstThirdPartyVendorsMember",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Third Party Vendors [Member]",
        "documentation": "First Third Party Vendors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ForeignCurrencyTransactionGainLossAfterTax",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign currency adjustments",
        "label": "Gain (Loss), Foreign Currency Transaction, after Tax",
        "documentation": "Amount, after tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r1518",
      "r1525",
      "r1528"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange loss",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r663",
      "r664",
      "r665",
      "r666",
      "r950"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Exchange Transactions",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1160",
      "r1174",
      "r1201"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1160",
      "r1174",
      "r1201"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1160",
      "r1174",
      "r1201"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1160",
      "r1174",
      "r1201"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1160",
      "r1174",
      "r1201"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": [
      "r1042",
      "r1339",
      "r1340"
     ]
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r1278",
      "r1336",
      "r1342"
     ]
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on disposal/impairment of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r1278"
     ]
    },
    "XAIR_GainLossOnTerminationOfRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "GainLossOnTerminationOfRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment of fixed assets",
        "documentation": "Gain loss on termination of right of use asset.",
        "label": "GainLossOnTerminationOfRightOfUseAsset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      },
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/StatementsOfCashFlows",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on extinguishment of debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r18",
      "r19"
     ]
    },
    "XAIR_GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern, Liquidity and Other Uncertainties",
        "documentation": "Going Concern Liquidity and Other Uncertainties [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_GoodsReceivedNotInvoiced": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "GoodsReceivedNotInvoiced",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goods received not invoiced",
        "documentation": "Goods received not invoiced."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensed Right to Use Technology",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1328",
      "r1329"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit (loss)",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r34",
      "r164",
      "r167",
      "r168",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r421",
      "r658",
      "r1020",
      "r1026",
      "r1245",
      "r1246",
      "r1296",
      "r1304",
      "r1310",
      "r1313",
      "r1314",
      "r1326",
      "r1355"
     ]
    },
    "country_IE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2026",
     "localname": "IE",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRELAND"
       }
      }
     },
     "auth_ref": []
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2026",
     "localname": "IL",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ISRAEL"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1127",
      "r1129",
      "r1152"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r169",
      "r518"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r59",
      "r803",
      "r805",
      "r846",
      "r997",
      "r1010",
      "r1012",
      "r1014",
      "r1020",
      "r1026",
      "r1296",
      "r1304",
      "r1310",
      "r1313",
      "r1314"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfProfitLossBeforeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r169",
      "r518"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r519",
      "r526",
      "r530",
      "r539",
      "r1064",
      "r1409"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r519",
      "r526",
      "r530",
      "r539",
      "r1064",
      "r1409"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r1409"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r1409"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r170",
      "r513",
      "r519",
      "r527",
      "r528",
      "r529",
      "r532",
      "r537",
      "r545",
      "r547",
      "r548",
      "r549",
      "r829",
      "r878",
      "r888",
      "r1064"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r77",
      "r164",
      "r190",
      "r191",
      "r207",
      "r227",
      "r248",
      "r517",
      "r519",
      "r546",
      "r855",
      "r997",
      "r1010",
      "r1012",
      "r1014",
      "r1064"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r515",
      "r516",
      "r532",
      "r533",
      "r536",
      "r541",
      "r884"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r1064",
      "r1404"
     ]
    },
    "XAIR_IncomeTaxReconciliationDifferenceOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "IncomeTaxReconciliationDifferenceOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "documentation": "Income tax reconciliation difference other adjustments.",
        "label": "IncomeTaxReconciliationDifferenceOtherAdjustments"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_IncomeTaxReconciliationDifferenceOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "IncomeTaxReconciliationDifferenceOtherReconcilingItems",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other adjustments",
        "documentation": "Income tax reconciliation difference other reconciling items."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current state and local income taxes, net of federal benefit",
        "documentation": "Income tax reconciliation difference state and local income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_IncomeTaxReconciliationDifferenceTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "IncomeTaxReconciliationDifferenceTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development tax credits",
        "documentation": "Income tax reconciliation difference tax credits research.",
        "label": "IncomeTaxReconciliationDifferenceTaxCreditsResearch"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. federal statutory tax rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r1064"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1404",
      "r1406"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other foreign jurisdictions",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1404",
      "r1406"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxReconciliationTaxCreditsOther",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1404",
      "r1405"
     ]
    },
    "XAIR_IncomeTaxReconciliationTaxSubpartFIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "IncomeTaxReconciliationTaxSubpartFIncome",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subpart F Income",
        "documentation": "Income tax reconciliation tax subpart f income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes paid",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r159",
      "r538",
      "r539"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1237",
      "r1277"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets and prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1160",
      "r1174",
      "r1192",
      "r1201",
      "r1205",
      "r1213"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1211"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1130",
      "r1217"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r1130",
      "r1217"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r1130",
      "r1217"
     ]
    },
    "us-gaap_InterestAndDividendIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestAndDividendIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend/investment income",
        "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r60",
      "r62",
      "r63",
      "r64",
      "r1012",
      "r1529"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest and finance expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r1010",
      "r1014",
      "r1274"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r158"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "XAIR_InterestSeveranceCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "InterestSeveranceCurrent",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued severance",
        "documentation": "Interest severance current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r131",
      "r999",
      "r1088"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r93",
      "r97",
      "r130",
      "r312",
      "r313",
      "r315",
      "r746",
      "r1015"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obsolescence reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r1250",
      "r1266"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for inventory losses",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "XAIR_InvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "InvestorsMember",
     "presentation": [
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investors [Member]",
        "documentation": "Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IsraelTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IsraelTaxAuthorityMember",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel Tax Authority [Member]",
        "documentation": "Designated tax department of the government of Israel."
       }
      }
     },
     "auth_ref": [
      "r1407",
      "r1409"
     ]
    },
    "XAIR_IssuanceOfCommonStockAtMarketEquityOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "IssuanceOfCommonStockAtMarketEquityOfferingShares",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock and pre-funded warrants, shares",
        "documentation": "Issuance of common stock at market equity offering shares."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_JanuaryTwoThousandTwentySixEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "JanuaryTwoThousandTwentySixEquityOfferingMember",
     "presentation": [
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January, 2026 Equity Offering [Member]",
        "documentation": "January, 2026 Equity Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r1087"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF LEASE RELATED COSTS",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1466"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r1339",
      "r1340"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeasesAbstract",
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative",
      "http://beyondair.net/role/LeaseRevenuesTables",
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails",
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails",
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/SegmentsDetailsNarrative",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r694",
      "r1464"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://beyondair.net/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operation lease description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesTables",
      "http://beyondair.net/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF MATURITY OF LEASE LIABILITIES",
        "verboseLabel": "SCHEDULE OF MATURITY OF FUTURE LEASE PAYMENTS",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1467"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails",
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r1283",
      "r1289",
      "r1484"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      },
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r1283",
      "r1289",
      "r1484"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails",
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r1283",
      "r1289",
      "r1484"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      },
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2031",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r1283",
      "r1289",
      "r1484"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      },
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2030",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r1283",
      "r1289",
      "r1484"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      },
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails",
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r1283",
      "r1289",
      "r1484"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails",
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r1283",
      "r1289",
      "r1484"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: amount of lease payments representing interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1465"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://beyondair.net/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets",
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "negatedLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r164",
      "r167",
      "r168",
      "r292",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r421",
      "r598",
      "r602",
      "r603",
      "r658",
      "r909",
      "r1019",
      "r1048",
      "r1115",
      "r1269",
      "r1355",
      "r1470",
      "r1471"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r783",
      "r784",
      "r796",
      "r841",
      "r1088",
      "r1103",
      "r1104",
      "r1282",
      "r1286",
      "r1326",
      "r1458"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r92",
      "r109",
      "r164",
      "r167",
      "r168",
      "r292",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r421",
      "r598",
      "r602",
      "r603",
      "r658",
      "r1088",
      "r1355",
      "r1470",
      "r1471"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities measured and recorded at fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r1439"
     ]
    },
    "XAIR_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreement [Member]",
        "documentation": "Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan and Security Agreement [Member]",
        "documentation": "Loan and Security Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_LoanPayableDueDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "LoanPayableDueDateDescription",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due date",
        "documentation": "Loan payable due date description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount outstanding",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r1254",
      "r1263",
      "r1477",
      "r1478",
      "r1481",
      "r1485"
     ]
    },
    "us-gaap_LoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LoansPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans payable, current portion",
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://beyondair.net/role/Loans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOANS",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r783",
      "r784",
      "r789"
     ]
    },
    "us-gaap_LongTermLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LongTermLoansPayable",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt, net",
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r1254",
      "r1263"
     ]
    },
    "XAIR_LungFitPHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "LungFitPHMember",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lung Fit PH [Member]",
        "documentation": "Lung Fit PH [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_LungFitRPHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "LungFitRPHMember",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesTables",
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LungFit\u00ae PH [Member]",
        "documentation": "LungFit\u00ae PH [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r1049",
      "r1051",
      "r1098",
      "r1102",
      "r1488",
      "r1490",
      "r1491",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517"
     ]
    },
    "XAIR_MarchTwoThousandTwentyFourRaiseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "MarchTwoThousandTwentyFourRaiseMember",
     "presentation": [
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2024 Raise [Member]",
        "documentation": "March 2024 Raise [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MarketableSecuritiesAbstract",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets",
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities",
        "verboseLabel": "Total short-term marketable securities, Fair value",
        "terseLabel": "Total marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1248",
      "r1260"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows",
      "http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized loss on marketable securities",
        "label": "Total short-term marketable securities, Unrealized gains and (losses)",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1163",
      "r1164"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1163",
      "r1165"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1163",
      "r1166"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1163",
      "r1166"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1163",
      "r1166"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2026",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1163",
      "r1166"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MaximumMember",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r214",
      "r355",
      "r356",
      "r357",
      "r358",
      "r464",
      "r494",
      "r495",
      "r496",
      "r510",
      "r642",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r745",
      "r867",
      "r869",
      "r877",
      "r901",
      "r902",
      "r961",
      "r963",
      "r965",
      "r966",
      "r968",
      "r974",
      "r975",
      "r977",
      "r978",
      "r991",
      "r992",
      "r1032",
      "r1057",
      "r1065",
      "r1067",
      "r1068",
      "r1077",
      "r1078",
      "r1082",
      "r1083",
      "r1099",
      "r1359",
      "r1361"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1184"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r1184"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r1441",
      "r1442",
      "r1443"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1441",
      "r1442",
      "r1443"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r1077",
      "r1441",
      "r1442",
      "r1443"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails",
      "http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r1441",
      "r1442",
      "r1443"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1441",
      "r1442",
      "r1443"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails",
      "http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r640",
      "r641",
      "r642",
      "r1065",
      "r1067",
      "r1068",
      "r1077",
      "r1473"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails",
      "http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r641",
      "r642",
      "r1065",
      "r1067",
      "r1068",
      "r1077",
      "r1473"
     ]
    },
    "XAIR_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining future milestone payments",
        "documentation": "Milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MinimumMember",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r214",
      "r355",
      "r356",
      "r357",
      "r358",
      "r464",
      "r494",
      "r495",
      "r496",
      "r510",
      "r642",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r745",
      "r867",
      "r869",
      "r877",
      "r901",
      "r902",
      "r961",
      "r963",
      "r965",
      "r966",
      "r968",
      "r974",
      "r975",
      "r977",
      "r978",
      "r991",
      "r992",
      "r1032",
      "r1057",
      "r1065",
      "r1067",
      "r1068",
      "r1077",
      "r1078",
      "r1082",
      "r1099",
      "r1359",
      "r1361"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets",
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r164",
      "r167",
      "r168",
      "r292",
      "r359",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r421",
      "r783",
      "r784",
      "r795",
      "r840",
      "r913",
      "r1458"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling owners interest",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1204"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_MutualFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MutualFundMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mutual Fund [Member]",
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective."
       }
      }
     },
     "auth_ref": [
      "r1372",
      "r1373"
     ]
    },
    "XAIR_MutualFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "MutualFundsMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mutual Funds [Member]",
        "documentation": "Mutual Funds [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "auth_ref": [
      "r256",
      "r1049",
      "r1051",
      "r1098",
      "r1102",
      "r1488",
      "r1490",
      "r1491",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1185"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash provided by financing",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in)/provided by investing activities",
        "label": "Cash provided by investing",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative",
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Cash used in operations",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to Beyond Air, Inc.",
        "label": "Net Income (Loss)",
        "verboseLabel": "Net loss before income taxes",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r46",
      "r61",
      "r80",
      "r86",
      "r87",
      "r139",
      "r141",
      "r146",
      "r164",
      "r167",
      "r168",
      "r173",
      "r179",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r197",
      "r292",
      "r331",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r387",
      "r390",
      "r392",
      "r396",
      "r421",
      "r449",
      "r500",
      "r554",
      "r594",
      "r635",
      "r658",
      "r849",
      "r932",
      "r951",
      "r952",
      "r1010",
      "r1012",
      "r1014",
      "r1113",
      "r1355"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: net loss attributable to non-controlling interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r56",
      "r86",
      "r87",
      "r139",
      "r141",
      "r187",
      "r190",
      "r191",
      "r292",
      "r848",
      "r1272"
     ]
    },
    "XAIR_NeuroNosLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "NeuroNosLtdMember",
     "presentation": [
      "http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails",
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/SegmentsDetailsNarrative",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NeuroNos Ltd [Member]",
        "documentation": "NeuroNos Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "XAIR_NextMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "NextMilestonesMember",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Next Milestones [Member]",
        "documentation": "Next Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_NitricGenAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "NitricGenAgreementMember",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NitricGen Agreement [Member]",
        "documentation": "NitricGen Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_NitricGenIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "NitricGenIncMember",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NitricGen, Inc [Member]",
        "documentation": "NitricGen, Inc [Member"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_NoExpirationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "NoExpirationMember",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Expiration [Member]",
        "documentation": "No Expiration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_NoInsiderTradingFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "NoInsiderTradingFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No insider trading flag",
        "documentation": "No Insider Trading Flag."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1184"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1181"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1180"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r420",
      "r422",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1526"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income/(expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r1245",
      "r1246",
      "r1326"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income/(expense):"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_NotePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "NotePurchaseAgreementMember",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Purchase Agreement [Member]",
        "documentation": "Note Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_NumberOfPayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "NumberOfPayments",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amount outstanding",
        "documentation": "Number of payments.",
        "label": "NumberOfPayments"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_NumberOfReportableSegmentsDisclosedByDefinitionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "NumberOfReportableSegmentsDisclosedByDefinitionFlag",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of repotable segments",
        "documentation": "Number of reportable segments disclosed by definition flag."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_OffsetTaxableIncomeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "OffsetTaxableIncomeRate",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxable income",
        "documentation": "Offset taxable income rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1245",
      "r1246",
      "r1326"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1014",
      "r1020",
      "r1245",
      "r1246",
      "r1296",
      "r1304",
      "r1310",
      "r1313",
      "r1314",
      "r1326"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r1087"
     ]
    },
    "XAIR_OperatingLeaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "OperatingLeaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease revenue",
        "documentation": "Operating lease income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails",
      "http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liabilities",
        "label": "Present value of future lease payments",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets",
      "http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, current portion",
        "verboseLabel": "Operating lease liability short-term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r1006"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets",
      "http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, net",
        "verboseLabel": "Operating lease liability long-term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLeaseOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows for operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r680",
      "r688"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets",
      "http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use lease assets",
        "verboseLabel": "Right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/LeasesDetailsNarrative",
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of operating lease assets",
        "verboseLabel": "Operating lease liability",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1278"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average discount rate - operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r1087"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r1087"
     ]
    },
    "XAIR_OperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "OperatingLeasesTextBlock",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASE REVENUES",
        "documentation": "Operating Leases [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "XAIR_OperatingLossCarryforwardsExpirationYears": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "OperatingLossCarryforwardsExpirationYears",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforward expire description",
        "documentation": "Operating loss carryforward expire term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax limitation description",
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_OptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "OptionAgreementMember",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Agreement [Member]",
        "documentation": "Option Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://beyondair.net/role/OrganizationAndBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND BUSINESS",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r81",
      "r82",
      "r83",
      "r881",
      "r882"
     ]
    },
    "XAIR_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "presentation": [
      "http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other asset impairment charges",
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value."
       }
      }
     },
     "auth_ref": [
      "r1278",
      "r1341"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r105",
      "r783",
      "r784",
      "r785",
      "r831",
      "r1027",
      "r1103",
      "r1104",
      "r1115"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1088"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r105"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "verboseLabel": "Impact of exchange rates",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r7",
      "r55"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive gain",
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r667",
      "r668",
      "r673",
      "r800",
      "r850",
      "r1270",
      "r1271"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income/(loss), net of tax:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://beyondair.net/role/OtherCurrentAssetsAndPrepaidExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER CURRENT ASSETS AND PREPAID EXPENSES",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_OtherLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "OtherLeaseTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF LEASE OTHER INFORMATION",
        "documentation": "Other Lease [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income/(expense)",
        "verboseLabel": "Other non-operating income/(expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r1071"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1184"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party invested",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r123",
      "r920",
      "r1027",
      "r1103",
      "r1104",
      "r1487"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "XAIR_OtherRisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "OtherRisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Risks and Uncertainties",
        "documentation": "Other Risks and Uncertainties [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1147",
      "r1158",
      "r1172",
      "r1199"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1161",
      "r1175",
      "r1202"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1161",
      "r1175",
      "r1202"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": [
      "r420",
      "r422"
     ]
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "auth_ref": [
      "r420",
      "r422"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid in kind interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "XAIR_PaidInKindInterestAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "PaidInKindInterestAmount",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Paid in kind interest",
        "documentation": "Paid in kind interest amount.",
        "label": "PaidInKindInterestAmount"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company [Member]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r175",
      "r807"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r1179"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_PayablesAndAccrualsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "PayablesAndAccrualsTable",
     "presentation": [
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PayablesAndAccrualsTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_PaymentForMilestoneMethodRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "PaymentForMilestoneMethodRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Future payments based on certain milestones",
        "documentation": "Payment for milestone method revenue recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsForCommissions",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commission paid",
        "documentation": "The amount of cash paid for commissions during the current period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "XAIR_PaymentsForDevelopmentAndMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "PaymentsForDevelopmentAndMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for development and milestone payment",
        "documentation": "Payments for development and milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other fees",
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock minimum purchase amount",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1321"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "XAIR_PaymentsToSecurityDepositsMadeOnOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "PaymentsToSecurityDepositsMadeOnOperatingLeases",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Security deposits made on operating leases",
        "documentation": "Payments to security deposits made on operating leases.",
        "label": "PaymentsToSecurityDepositsMadeOnOperatingLeases"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1181"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1185"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1180"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative",
      "http://beyondair.net/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative",
      "http://beyondair.net/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1181"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "XAIR_PreFundedWarrantsJanTwoThousandTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "PreFundedWarrantsJanTwoThousandTwentySixMember",
     "presentation": [
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants jan 2026 [Member]",
        "documentation": "Pre Funded Warrants jan 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded Warrants [Member]",
        "documentation": "Pre-funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_PreFundedWarrantsSepTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "PreFundedWarrantsSepTwoThousandTwentyFourMember",
     "presentation": [
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants Sep 2024 [Member]",
        "documentation": "Pre Funded Warrants Sep 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://beyondair.net/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r1249",
      "r1264",
      "r1364",
      "r1477",
      "r1478",
      "r1482"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://beyondair.net/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r121",
      "r416",
      "r783",
      "r784",
      "r792",
      "r911"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://beyondair.net/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r121",
      "r400",
      "r416",
      "r783",
      "r784",
      "r792"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://beyondair.net/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r121",
      "r416",
      "r783",
      "r784",
      "r792",
      "r911",
      "r931",
      "r1362",
      "r1526",
      "r1527"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r121",
      "r389",
      "r394",
      "r416",
      "r783",
      "r784",
      "r792",
      "r836",
      "r1088"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets",
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets and prepaid expenses",
        "totalLabel": "Total other current assets and prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1268"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1034",
      "r1327"
     ]
    },
    "us-gaap_PrepaidRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidRent",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid rents and tenant improvement",
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1035",
      "r1327"
     ]
    },
    "XAIR_PrepaidResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "PrepaidResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "documentation": "Prepaid research and development.",
        "label": "PrepaidResearchAndDevelopment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value added tax receivable",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1036",
      "r1327"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/SegmentsDetailsNarrative",
      "http://beyondair.net/role/StatementsOfCashFlows",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock and pre-funded warrants through securities purchase, net",
        "verboseLabel": "Sale of net proceeds",
        "terseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock through at the market offerings, net",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of secured promissory note",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock warrants",
        "verboseLabel": "Proceeds from private placement",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "XAIR_ProceedsFromLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ProceedsFromLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from long term loan",
        "documentation": "Proceeds from long term debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from related party debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_ProceedsFromSaleOfCommonStockOfNeuronos": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ProceedsFromSaleOfCommonStockOfNeuronos",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock of NeuroNos",
        "documentation": "Proceeds from sale of common stock of neuronos."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfLoansReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromSaleOfLoansReceivable",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced financing from related party",
        "documentation": "The cash inflow associated with the sale of loans receivables arising from the financing of goods and services."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock through exercise of warrants",
        "verboseLabel": "Warrants Exercise",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1276"
     ]
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductLiabilityContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProductLiabilityContingencyTable",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Liability Contingency [Table]",
        "documentation": "Disclosure of information about product liability contingency arising from reasonably possible loss from liability related to individual product."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r1351",
      "r1352",
      "r1353"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monitoring fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1026",
      "r1113",
      "r1523",
      "r1524"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows",
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r86",
      "r87",
      "r139",
      "r141",
      "r156",
      "r164",
      "r167",
      "r168",
      "r173",
      "r179",
      "r187",
      "r190",
      "r191",
      "r292",
      "r331",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r387",
      "r421",
      "r449",
      "r500",
      "r554",
      "r594",
      "r596",
      "r599",
      "r600",
      "r635",
      "r658",
      "r803",
      "r805",
      "r847",
      "r893",
      "r932",
      "r951",
      "r952",
      "r997",
      "r1069",
      "r1070",
      "r1114",
      "r1272",
      "r1355"
     ]
    },
    "XAIR_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Member]",
        "documentation": "Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Asset, Class [Axis]",
        "documentation": "Information by class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r693",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1333",
      "r1334",
      "r1474"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://beyondair.net/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r333",
      "r334",
      "r339",
      "r342",
      "r343",
      "r347"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, gross",
        "documentation": "Amount, before accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r103",
      "r336",
      "r845",
      "r1333"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r693",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1333",
      "r1334",
      "r1474"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r783",
      "r784",
      "r799",
      "r826",
      "r827",
      "r845",
      "r1088",
      "r1339"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Assets",
        "documentation": "Disclosure of accounting policy for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r338",
      "r340",
      "r843",
      "r1333"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://beyondair.net/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT",
        "documentation": "Tabular disclosure of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r693",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1333",
      "r1334",
      "r1474"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful life of assets",
        "verboseLabel": "Useful Life",
        "documentation": "Useful life of property, plant, and equipment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r1335"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1335"
     ]
    },
    "us-gaap_ProvisionForOtherLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProvisionForOtherLosses",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for bad debt",
        "documentation": "Amount of expense related to other loss."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r37",
      "r58"
     ]
    },
    "XAIR_PublicFloatValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "PublicFloatValue",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public float value",
        "documentation": "Public float value."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding amount under purchase",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": [
      "r1283",
      "r1289",
      "r1484"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1179"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r1179"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RangeAxis",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r214",
      "r355",
      "r356",
      "r357",
      "r358",
      "r452",
      "r464",
      "r494",
      "r495",
      "r496",
      "r499",
      "r510",
      "r642",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r728",
      "r745",
      "r867",
      "r869",
      "r877",
      "r901",
      "r902",
      "r961",
      "r963",
      "r965",
      "r966",
      "r968",
      "r974",
      "r975",
      "r977",
      "r978",
      "r991",
      "r992",
      "r1032",
      "r1057",
      "r1065",
      "r1067",
      "r1068",
      "r1077",
      "r1078",
      "r1082",
      "r1083",
      "r1099",
      "r1107",
      "r1348",
      "r1359",
      "r1361",
      "r1442"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RangeMember",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": [
      "r88",
      "r89",
      "r214",
      "r355",
      "r356",
      "r357",
      "r358",
      "r452",
      "r464",
      "r494",
      "r495",
      "r496",
      "r499",
      "r510",
      "r642",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r728",
      "r745",
      "r867",
      "r869",
      "r877",
      "r901",
      "r902",
      "r961",
      "r963",
      "r965",
      "r966",
      "r968",
      "r974",
      "r975",
      "r977",
      "r978",
      "r991",
      "r992",
      "r1032",
      "r1057",
      "r1065",
      "r1067",
      "r1068",
      "r1077",
      "r1078",
      "r1082",
      "r1083",
      "r1099",
      "r1107",
      "r1348",
      "r1359",
      "r1361",
      "r1442"
     ]
    },
    "XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Standards Not Yet Adopted",
        "documentation": "Recently Issued Accounting Standards Not Yet Adopted [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r1142",
      "r1153",
      "r1167",
      "r1194"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r107",
      "r115",
      "r117",
      "r164",
      "r172",
      "r173",
      "r257",
      "r459",
      "r463",
      "r699",
      "r700",
      "r783",
      "r784",
      "r787",
      "r788",
      "r789",
      "r797",
      "r833",
      "r842",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r930",
      "r960",
      "r1000",
      "r1522",
      "r1530"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r107",
      "r115",
      "r117",
      "r164",
      "r172",
      "r173",
      "r699",
      "r700",
      "r701",
      "r702",
      "r783",
      "r784",
      "r789",
      "r833",
      "r842",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r930",
      "r960"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r107",
      "r115",
      "r117",
      "r164",
      "r172",
      "r173",
      "r257",
      "r459",
      "r463",
      "r699",
      "r700",
      "r783",
      "r784",
      "r787",
      "r788",
      "r789",
      "r797",
      "r833",
      "r842",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r930",
      "r960",
      "r1000",
      "r1469",
      "r1522",
      "r1530"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://beyondair.net/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r697",
      "r698",
      "r700",
      "r703",
      "r783",
      "r784",
      "r798",
      "r889",
      "r890",
      "r891",
      "r935",
      "r936",
      "r937",
      "r957",
      "r959"
     ]
    },
    "us-gaap_RepaymentsOfBankDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RepaymentsOfBankDebt",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of loan",
        "label": "Repayments of Bank Debt",
        "documentation": "The cash outflow to settle a bank borrowing during the year."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "negatedLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r993",
      "r1010",
      "r1011",
      "r1026",
      "r1475"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "XAIR_ResearchAndDevelopmentTaxCreditCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ResearchAndDevelopmentTaxCreditCapitalization",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDeferredTaxAssetliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development tax credit capitalization",
        "documentation": "Research and development tax credit capitalization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchMember",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1409"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1143",
      "r1154",
      "r1168",
      "r1195"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1155",
      "r1169",
      "r1196"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r1151",
      "r1162",
      "r1176",
      "r1203"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r160",
      "r1255",
      "r1476",
      "r1477",
      "r1478",
      "r1479",
      "r1486"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Restricted Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r157",
      "r160",
      "r835",
      "r1477",
      "r1478"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets",
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r160",
      "r1255"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails",
      "http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1295",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r127",
      "r418",
      "r783",
      "r784",
      "r794",
      "r839",
      "r874",
      "r876",
      "r887",
      "r912",
      "r1088"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r176",
      "r177",
      "r178",
      "r180",
      "r187",
      "r189",
      "r191",
      "r293",
      "r294",
      "r330",
      "r331",
      "r332",
      "r386",
      "r415",
      "r425",
      "r447",
      "r448",
      "r450",
      "r451",
      "r500",
      "r542",
      "r543",
      "r551",
      "r552",
      "r553",
      "r555",
      "r593",
      "r594",
      "r617",
      "r618",
      "r619",
      "r621",
      "r623",
      "r624",
      "r626",
      "r633",
      "r677",
      "r744",
      "r828",
      "r871",
      "r873",
      "r894",
      "r1366",
      "r1368",
      "r1526"
     ]
    },
    "us-gaap_RevenueCommissionersIrelandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RevenueCommissionersIrelandMember",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Commissioners, Ireland [Member]",
        "documentation": "Designated tax department of the government of Ireland."
       }
      }
     },
     "auth_ref": [
      "r1407",
      "r1409"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r220",
      "r221",
      "r242",
      "r248",
      "r252",
      "r254",
      "r256",
      "r444",
      "r445",
      "r446",
      "r747",
      "r1010",
      "r1014"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r994"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability in exchange",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r1087",
      "r1280"
     ]
    },
    "XAIR_RightofuseAssetsAcquiredUnderOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "RightofuseAssetsAcquiredUnderOperatingLeases",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets acquired under operating leases",
        "documentation": "Right of use assets acquired under operating leases."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_RoyaltyInterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "RoyaltyInterestPercentage",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty interest percentage",
        "documentation": "Royalty interest percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "XAIR_SaleOfCommonStockAndPrefundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "SaleOfCommonStockAndPrefundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock and pre-funded warrants",
        "documentation": "Sale of common stock and prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_SaleOfStockFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "SaleOfStockFeePercentage",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock fee percentage",
        "documentation": "Sale of stock fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued in transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sle of stock per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_SalesRelatedMilestonesPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "SalesRelatedMilestonesPayments",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales related milestones payments",
        "documentation": "Sales related milestones payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r1298",
      "r1299"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF ACCRUED EXPENSES",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails",
      "http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r1065",
      "r1068",
      "r1416",
      "r1418",
      "r1419"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH",
        "documentation": "Tabular disclosure of cash, cash equivalent, and investment."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES",
        "documentation": "Schedule Of Change In Fair Value Of Warrants And Derivatives [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/LoansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF LONG-TERM DEBT",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEFERRED TAX ASSET/LIABILITY",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1408"
     ]
    },
    "XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ScheduleOfDifferenceEffectiveIncomeTaxRateAbstract",
     "auth_ref": []
    },
    "XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DIFFERENCE EFFECTIVE INCOME TAX RATE",
        "documentation": "Schedule Of Difference Effective Income Tax Rate Reconciliation [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_ScheduleOfDifferenceEffectiveIncomeTaxRateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ScheduleOfDifferenceEffectiveIncomeTaxRateTable",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfDifferenceEffectiveIncomeTaxRateTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STATUTORY US FEDERAL EFFECTIVE RATE",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r1064",
      "r1404"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative",
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r550",
      "r658",
      "r1234",
      "r1235",
      "r1236",
      "r1411",
      "r1412",
      "r1413",
      "r1414"
     ]
    },
    "XAIR_ScheduleOfFairValueOfOptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ScheduleOfFairValueOfOptionAbstract",
     "auth_ref": []
    },
    "XAIR_ScheduleOfFairValueOfOptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ScheduleOfFairValueOfOptionTable",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfFairValueOfOptionTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROFIT (LOSS) BEFORE TAXES",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1282",
      "r1287"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESTRICTED STOCK AWARDS",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "XAIR_ScheduleOfOperatingLeaseLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ScheduleOfOperatingLeaseLiabilityTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OPERATING LEASE LIABILITY",
        "documentation": "Schedule Of Operating Lease Liability [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS",
        "documentation": "Schedule of Property and Equipment UsefulLife of Assets [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://beyondair.net/role/ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment [Table]",
        "documentation": "Disclosure of information about property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r693",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1333",
      "r1334",
      "r1474"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Table]",
        "documentation": "Disclosure of information about segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://beyondair.net/role/SegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT",
        "documentation": "Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total."
       }
      }
     },
     "auth_ref": [
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1311",
      "r1312",
      "r1315"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r51"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails",
      "http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails",
      "http://beyondair.net/role/SegmentsTables",
      "http://beyondair.net/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OPTION ACTIVITY FOR NEURONOS",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r50"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE OF OPTION",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r108"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "presentation": [
      "http://beyondair.net/role/LoanPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF LOAN PAYABLE",
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r1253",
      "r1258"
     ]
    },
    "XAIR_ScheduleOfStockBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ScheduleOfStockBasedCompensationExpenseAbstract",
     "auth_ref": []
    },
    "XAIR_ScheduleOfStockBasedCompensationExpenseTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ScheduleOfStockBasedCompensationExpenseTable",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfStockBasedCompensationExpenseTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF OUTSTANDING WARRANTS",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r1363"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE",
        "documentation": "Tabular disclosure of estimated amortization expense for finite-lived intangible asset and capitalized cost for software to be sold, leased, or marketed, expected to be recognized for each of five succeeding fiscal years. Excludes goodwill."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r1332"
     ]
    },
    "XAIR_SecondThirdPartyVendorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "SecondThirdPartyVendorsMember",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Third Party Vendors [Member]",
        "documentation": "Second Third Party Vendors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12gTitle",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentDomain",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r207",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r256",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r329",
      "r341",
      "r345",
      "r350",
      "r352",
      "r588",
      "r591",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r1023",
      "r1026",
      "r1027",
      "r1038",
      "r1101",
      "r1488",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "auth_ref": [
      "r211",
      "r254",
      "r255",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r803",
      "r804",
      "r805",
      "r806",
      "r898",
      "r899",
      "r900",
      "r962",
      "r964",
      "r967",
      "r969",
      "r974",
      "r976",
      "r977",
      "r978",
      "r981",
      "r982",
      "r983",
      "r984",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r995",
      "r1017",
      "r1049",
      "r1050",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1100",
      "r1107",
      "r1488",
      "r1490",
      "r1491",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517"
     ]
    },
    "XAIR_SegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "SegmentMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Segment [Member]",
        "documentation": "Business Segment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://beyondair.net/role/Segments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENTS",
        "documentation": "The entire disclosure for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r231",
      "r233",
      "r234",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r256",
      "r1021",
      "r1024",
      "r1025",
      "r1026",
      "r1028",
      "r1030",
      "r1031"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r251",
      "r254",
      "r1022",
      "r1023",
      "r1029"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "negatedLabel": "Selling, general, and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r1009",
      "r1010",
      "r1011",
      "r1014",
      "r1275"
     ]
    },
    "XAIR_SeptemberTwoThousandTwentyFiveInducementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "SeptemberTwoThousandTwentyFiveInducementMember",
     "presentation": [
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September 2025 Inducement [Member]",
        "documentation": "September 2025 Inducement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_SeptemberTwoThousandTwentyFourDebtInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "SeptemberTwoThousandTwentyFourDebtInstrumentMember",
     "presentation": [
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September 2024 Debt Instrument [Member]",
        "documentation": "September 2024 Debt Instrument [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_SeptemberTwoThousandTwentyFourEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "SeptemberTwoThousandTwentyFourEquityOfferingMember",
     "presentation": [
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September 2024 equity offering [Member]",
        "documentation": "September 2024 equity offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://beyondair.net/role/StatementsOfCashFlows",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Total stock-based compensation expense",
        "terseLabel": "Share compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested Number of Shares, Beginning balance",
        "periodEndLabel": "Unvested Number of Shares, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning balance",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails",
      "http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails",
      "http://beyondair.net/role/SegmentsTables",
      "http://beyondair.net/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Outstanding, Exercised",
        "negatedLabel": "Number of Options, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of additionl shares reserve for issuance",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option shares authorized for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options Outstanding, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price - Options, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options Outstanding, Forfeited",
        "negatedTerseLabel": "Number of Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r1249",
      "r1264",
      "r1265",
      "r1364",
      "r1365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Outstanding, Granted",
        "verboseLabel": "Number of Options, Granted",
        "terseLabel": "Number of shares issued",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r1249",
      "r1264",
      "r1265",
      "r1364",
      "r1365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value of options",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding at beginning of period",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options, Outstanding at beginning of period",
        "periodEndLabel": "Number of Options, Outstanding at ending of period",
        "label": "Option repricing",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price in excess",
        "documentation": "Change in the weighted average exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price - Options, Outstanding at beginning of period",
        "periodEndLabel": "Weighted Average Exercise Price - Options, Outstanding at ending of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfRestrictedStockAwardsDetails",
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/SegmentsTables",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price - Options, Exercised",
        "verboseLabel": "Weighted Average Exercise Price of Options, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price - Options, Forfeited",
        "verboseLabel": "Weighted Average Exercise Price of Options, Forfeited",
        "terseLabel": "Weighted average exercise price - options, forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price - Options, Granted",
        "verboseLabel": "Weighted Average Exercise Price of Options, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r472",
      "r491",
      "r492",
      "r493",
      "r494",
      "r497",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharePrice",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/SegmentsDetailsNarrative",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "verboseLabel": "Fair value per share",
        "terseLabel": "Price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration period",
        "documentation": "Period from grant to expiration date of share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life - Options, Exercisable",
        "verboseLabel": "Weighted Average Remaining Contractual Life of Options, Exercisable",
        "documentation": "Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life - Options, Outstanding at end of period",
        "verboseLabel": "Weighted average remaining contractual life - options, outstanding at beginning of period",
        "terseLabel": "Weighted Average Remaining Contractual Life of Options, Outstanding",
        "documentation": "Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r1362",
      "r1366",
      "r1368"
     ]
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r108"
     ]
    },
    "us-gaap_ShortTermDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShortTermDebtMember",
     "presentation": [
      "http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Member]",
        "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShortTermDebtTextBlock",
     "presentation": [
      "http://beyondair.net/role/LoanPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOAN PAYABLE",
        "documentation": "The entire disclosure for short-term debt."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "XAIR_ShortTermFinanceLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ShortTermFinanceLiability",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short term finance liability",
        "documentation": "Short term finance liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term lease costs",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r1087"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertainties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction, Domestic State and Local [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r207",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r256",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r329",
      "r341",
      "r345",
      "r350",
      "r352",
      "r588",
      "r591",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r1023",
      "r1026",
      "r1027",
      "r1038",
      "r1101",
      "r1488",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r94",
      "r121",
      "r122",
      "r144",
      "r145",
      "r146",
      "r176",
      "r177",
      "r178",
      "r180",
      "r187",
      "r189",
      "r191",
      "r208",
      "r293",
      "r294",
      "r330",
      "r331",
      "r332",
      "r386",
      "r410",
      "r415",
      "r416",
      "r417",
      "r420",
      "r422",
      "r425",
      "r447",
      "r448",
      "r450",
      "r451",
      "r500",
      "r542",
      "r543",
      "r551",
      "r552",
      "r553",
      "r555",
      "r593",
      "r594",
      "r617",
      "r618",
      "r619",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r633",
      "r667",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r677",
      "r695",
      "r744",
      "r783",
      "r784",
      "r792",
      "r793",
      "r828",
      "r850",
      "r871",
      "r872",
      "r873",
      "r894",
      "r953",
      "r1371"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r254",
      "r255",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r803",
      "r804",
      "r805",
      "r806",
      "r898",
      "r899",
      "r900",
      "r962",
      "r964",
      "r967",
      "r969",
      "r974",
      "r976",
      "r977",
      "r978",
      "r981",
      "r982",
      "r983",
      "r984",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r995",
      "r1017",
      "r1049",
      "r1050",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1100",
      "r1107",
      "r1488",
      "r1490",
      "r1491",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementLineItems",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/LeaseRevenuesDetailsNarrative",
      "http://beyondair.net/role/LeaseRevenuesTables",
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfDifferenceEffectiveIncomeTaxRateDetails",
      "http://beyondair.net/role/ScheduleOfFairValueOfOptionDetails",
      "http://beyondair.net/role/ScheduleOfMaturityOfFutureLeasePaymentsDetails",
      "http://beyondair.net/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://beyondair.net/role/SegmentsDetailsNarrative",
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity",
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r100",
      "r101",
      "r107",
      "r115",
      "r117",
      "r119",
      "r120",
      "r121",
      "r122",
      "r127",
      "r176",
      "r177",
      "r178",
      "r208",
      "r388",
      "r389",
      "r391",
      "r393",
      "r398",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r424",
      "r425",
      "r435",
      "r677",
      "r747",
      "r783",
      "r784",
      "r791",
      "r792",
      "r793",
      "r883",
      "r895",
      "r897",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r911",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r921",
      "r922",
      "r923",
      "r924",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r933",
      "r934",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r953",
      "r1000",
      "r1012",
      "r1014",
      "r1108",
      "r1522"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeLocationBalanceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfIncomeLocationBalanceAxis",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Location, Statement of Income, Balance [Axis]",
        "documentation": "Information by location in statement of income line item where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r348",
      "r349",
      "r351",
      "r605",
      "r606",
      "r607",
      "r609",
      "r644",
      "r646",
      "r650",
      "r659",
      "r660",
      "r661",
      "r868",
      "r870",
      "r937",
      "r993",
      "r1065",
      "r1066",
      "r1072",
      "r1073",
      "r1076",
      "r1084",
      "r1085",
      "r1415",
      "r1417",
      "r1489"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementTable",
     "presentation": [
      "http://beyondair.net/role/LeaseRevenuesTables",
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r94",
      "r95",
      "r100",
      "r101",
      "r107",
      "r115",
      "r117",
      "r119",
      "r120",
      "r121",
      "r122",
      "r127",
      "r176",
      "r177",
      "r178",
      "r208",
      "r257",
      "r388",
      "r389",
      "r391",
      "r393",
      "r398",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r424",
      "r425",
      "r435",
      "r677",
      "r747",
      "r783",
      "r784",
      "r791",
      "r792",
      "r793",
      "r828",
      "r883",
      "r895",
      "r897",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r911",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r921",
      "r922",
      "r923",
      "r924",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r933",
      "r934",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r953",
      "r1000",
      "r1012",
      "r1014",
      "r1108",
      "r1522"
     ]
    },
    "XAIR_SteveLisiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "SteveLisiMember",
     "presentation": [
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Steve Lisi [Member]",
        "documentation": "Steve Lisi [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r1146",
      "r1157",
      "r1171",
      "r1198"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for conversion of debt, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r411",
      "r1249",
      "r1264",
      "r1265",
      "r1362",
      "r1364",
      "r1365",
      "r1366",
      "r1368",
      "r1477",
      "r1478",
      "r1482",
      "r1483"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfKeyInputsDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum convertible shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r1249",
      "r1264",
      "r1265",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1368",
      "r1477",
      "r1478",
      "r1482",
      "r1483"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/SegmentsDetailsNarrative",
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock - At The Market equity offering, shares",
        "verboseLabel": "Stock issues during the period, shares",
        "terseLabel": "Shares available for resale",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r953",
      "r970",
      "r1249",
      "r1264",
      "r1265",
      "r1362",
      "r1364",
      "r1365",
      "r1366",
      "r1368",
      "r1477",
      "r1478",
      "r1482",
      "r1483"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued during the period, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": [
      "r1249",
      "r1264",
      "r1265",
      "r1364",
      "r1365"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon vesting of restricted shares, shares",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r1249",
      "r1264",
      "r1265",
      "r1362",
      "r1364",
      "r1365",
      "r1366",
      "r1368"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock - 2025 Reverse Stock Split rounding, shares",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r1249",
      "r1264",
      "r1265",
      "r1362",
      "r1364",
      "r1365"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercise of warrants, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r1249",
      "r1264",
      "r1265",
      "r1362",
      "r1364",
      "r1365",
      "r1366",
      "r1368",
      "r1477",
      "r1478",
      "r1482",
      "r1483"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for conversion of debt",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r1249",
      "r1264",
      "r1265",
      "r1362",
      "r1364",
      "r1365",
      "r1366",
      "r1368",
      "r1477",
      "r1478",
      "r1482",
      "r1483"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock \u2013 At The Market equity offering",
        "verboseLabel": "Share purchase value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r953",
      "r970",
      "r1114",
      "r1249",
      "r1264",
      "r1265",
      "r1362",
      "r1364",
      "r1365",
      "r1366",
      "r1368",
      "r1477",
      "r1478",
      "r1482",
      "r1483"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NeuroNos issuance of stock",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": [
      "r1249",
      "r1264",
      "r1265",
      "r1364",
      "r1365"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon vesting of restricted shares",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r1249",
      "r1264",
      "r1265",
      "r1362",
      "r1364",
      "r1365",
      "r1366",
      "r1368",
      "r1477",
      "r1478",
      "r1482",
      "r1483"
     ]
    },
    "XAIR_StockIssuedDuringPeriodValueReverseStockSplits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "StockIssuedDuringPeriodValueReverseStockSplits",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock \u2013 2025 Reverse Stock Split rounding",
        "documentation": "Reduction in the value of shares issued during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercise of warrants",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r1249",
      "r1264",
      "r1265",
      "r1362",
      "r1364",
      "r1365",
      "r1366",
      "r1368",
      "r1477",
      "r1478",
      "r1482",
      "r1483"
     ]
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option exercise price",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockOptionMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r1107",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1429",
      "r1430",
      "r1431",
      "r1432",
      "r1433",
      "r1434",
      "r1435"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of common stock, shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r953",
      "r971",
      "r1249",
      "r1264",
      "r1265",
      "r1362",
      "r1364",
      "r1365",
      "r1366",
      "r1368",
      "r1477",
      "r1478",
      "r1482",
      "r1483"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity attributable to Beyond Air, Inc.",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r913",
      "r931",
      "r954",
      "r955",
      "r1088",
      "r1115",
      "r1269",
      "r1282",
      "r1285",
      "r1286",
      "r1326",
      "r1458",
      "r1526"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets",
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r27",
      "r79",
      "r80",
      "r122",
      "r145",
      "r176",
      "r177",
      "r178",
      "r180",
      "r187",
      "r189",
      "r293",
      "r294",
      "r330",
      "r331",
      "r332",
      "r386",
      "r410",
      "r416",
      "r417",
      "r420",
      "r422",
      "r447",
      "r448",
      "r450",
      "r451",
      "r500",
      "r542",
      "r543",
      "r551",
      "r552",
      "r553",
      "r555",
      "r593",
      "r594",
      "r617",
      "r618",
      "r619",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r633",
      "r667",
      "r669",
      "r673",
      "r695",
      "r744",
      "r783",
      "r784",
      "r792",
      "r793",
      "r872",
      "r873",
      "r892",
      "r913",
      "r931",
      "r954",
      "r955",
      "r972",
      "r1103",
      "r1104",
      "r1114",
      "r1249",
      "r1264",
      "r1282",
      "r1285",
      "r1286",
      "r1326",
      "r1458",
      "r1526"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r121",
      "r122",
      "r128",
      "r397",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r411",
      "r416",
      "r417",
      "r420",
      "r422",
      "r423",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r615",
      "r631",
      "r632",
      "r707",
      "r956",
      "r958",
      "r973"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r428",
      "r431"
     ]
    },
    "XAIR_StreetervilleCapitalLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "StreetervilleCapitalLLCMember",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Streeterville Capital LLC [Member]",
        "documentation": "Streeterville Capital LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_SubTotalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "SubTotalMember",
     "presentation": [
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sub Total [Member]",
        "documentation": "Sub Total [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfLeaseRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r1087"
     ]
    },
    "XAIR_SubscriptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "SubscriptionAgreementMember",
     "presentation": [
      "http://beyondair.net/role/SegmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreement [Member]",
        "documentation": "Subscription Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://beyondair.net/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r706"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_SupplierConcentrationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "SupplierConcentrationPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier Concentration",
        "documentation": "Supplier Concentration [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r1298"
     ]
    },
    "XAIR_SupplierMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "SupplierMember",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Member]",
        "documentation": "Supplier [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Supplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Supplies",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOtherCurrentAssetsAndPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Demonstration materials",
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1037",
      "r1327"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1191"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credit carryforward, amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TaxCreditCarryforwardDescription",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credit carryforward, description",
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r1409"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "XAIR_TaxRebate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "TaxRebate",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Rebate",
        "documentation": "Tax rebate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1007"
     ]
    },
    "XAIR_ThirdPartyVendorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "ThirdPartyVendorsMember",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Party Vendors [Member]",
        "documentation": "Third Party Vendors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/SegmentsDetailsNarrative",
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1316",
      "r1468"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/SegmentsDetailsNarrative",
      "http://beyondair.net/role/SummaryOfAccruedExpensesDetailsParenthetical"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1190"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1318",
      "r1319",
      "r1320"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails",
      "http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails",
      "http://beyondair.net/role/SummaryOfShort-termMarketableSecuritiesWithUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r384",
      "r409",
      "r615",
      "r652",
      "r657",
      "r660",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r715",
      "r716",
      "r717",
      "r718",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r830",
      "r851",
      "r1074",
      "r1075",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1089",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1438",
      "r1441",
      "r1442",
      "r1443",
      "r1452",
      "r1455",
      "r1456",
      "r1457"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1214"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1215"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1215"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1213"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r1213"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1216"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1214"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://beyondair.net/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r784",
      "r793",
      "r1371"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r1369",
      "r1370",
      "r1371"
     ]
    },
    "XAIR_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityDetails",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative",
      "http://beyondair.net/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2013 Beyond Air Equity Incentive Plan [Member]",
        "documentation": "2013 Beyond Air Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_TwoThousandAndTwentyFiveATMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "TwoThousandAndTwentyFiveATMMember",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025 ATM [Member]",
        "documentation": "2025 ATM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_TwoThousandThirteenBAPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "TwoThousandThirteenBAPlanMember",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2013 BA Plan [Member]",
        "documentation": "2013 BA Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_TwoThousandThirteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "TwoThousandThirteenEquityIncentivePlanMember",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2013 BA EquityIncentivePlan [Member]",
        "documentation": "2013 BA EquityIncentivePlan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_TwoThousandTwentyFiveOptionRepricingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "TwoThousandTwentyFiveOptionRepricingMember",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025 Option Repricing [Member]",
        "documentation": "2025 Option Repricing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityForBeyondCancerDetails",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative",
      "http://beyondair.net/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Beyond Cancer Ltd Equity Incentive Plan [Member]",
        "documentation": "2021 Beyond Cancer Ltd Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Employee Stock Purchase Plan [Member]",
        "documentation": "2021 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_TwoThousandTwentySixCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "TwoThousandTwentySixCommonWarrantsMember",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026 Common Warrants [Member]",
        "documentation": "2026 Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_TwoThousandTwentySixPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "TwoThousandTwentySixPreFundedWarrantsMember",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026 Pre-funded Warrants [Member]",
        "documentation": "2026 Pre-funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfOptionActivityForNeuronosDetails",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative",
      "http://beyondair.net/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Neuro Nos Ltd Equity Incentive Plan [Member]",
        "documentation": "2023 Neuro Nos Ltd Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfLong-termDebtDetails",
      "http://beyondair.net/role/SegmentsDetailsNarrative",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative",
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2026",
     "localname": "US",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1210"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r531",
      "r1063"
     ]
    },
    "XAIR_UnrestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "UnrestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrestricted cash",
        "documentation": "Unrestricted cash."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r209",
      "r212",
      "r213",
      "r214",
      "r803",
      "r805",
      "r1018"
     ]
    },
    "XAIR_VariableInterestEntitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "VariableInterestEntitiesMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfSegmentFinancialInformationByBusinessSegmentDetails",
      "http://beyondair.net/role/SegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entities [Member]",
        "documentation": "Variable Interest Entities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercise price",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "XAIR_WarrantLiabilityNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "WarrantLiabilityNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://beyondair.net/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://beyondair.net/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability",
        "documentation": "Warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "XAIR_WarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "WarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://beyondair.net/role/SignificantAccountingPoliciesAndOtherRisksAndUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability",
        "documentation": "Warrant Liability [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantMember",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfChangesInFairValueOfWarrantsAndDerivativesDetails",
      "http://beyondair.net/role/ScheduleOfFairValueOnRecurringBasisDetails",
      "http://beyondair.net/role/ScheduleOfPotentialAnti-dilutiveSecuritiesDetails",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1105",
      "r1106",
      "r1109",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase warrants",
        "verboseLabel": "Warrants to purchase common stock, value",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1441",
      "r1442",
      "r1443"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and rights outstanding, measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1441",
      "r1442",
      "r1443"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://beyondair.net/role/LoansDetailsNarrative",
      "http://beyondair.net/role/ScheduleOfAssumptionsUsedInValuingWarrantsDetails",
      "http://beyondair.net/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term warrants",
        "verboseLabel": "Weighted average remaining service period",
        "terseLabel": "Warrants term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1441",
      "r1442",
      "r1443"
     ]
    },
    "XAIR_WarrantsExpirationDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://beyondair.net/20260331",
     "localname": "WarrantsExpirationDateDescription",
     "presentation": [
      "http://beyondair.net/role/SummaryOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Date of Expiration",
        "documentation": "Warrants expiration date description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://beyondair.net/role/BasicAndDilutedNetLossPerShareOfCommonStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants included in calculation of diluted net loss per share",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1294"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares of common stock outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r200"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://beyondair.net/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares of common stock outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r200"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://beyondair.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r1232"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481244/470-50-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Paragraph": "2AA",
   "Subparagraph": "(a)",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.4-03(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480868/205-20-S45-2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.Z.5.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-2"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479938/205-30-45-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479910/205-30-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-2"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-3"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-5"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-9"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-12"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-20"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-13"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480204/360-10-S45-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480125/505-10-S35-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-8"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 5.Q.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481468/505-20-05-5"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 1.D.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479921/505-20-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2AG",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AG"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8C"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479693/815-10-S50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "45",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480865/815-45-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2G",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-5A"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 1.B.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480148/855-10-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-5"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.9-06)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(ff)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(fff)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478443/942-360-45-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480459/718-40-55-20"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480459/718-40-55-9"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-1"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-3"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-6"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482558/350-40-50-1"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482222/360-10-30-2"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481108/505-30-30-6"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2C"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2D"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-2"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "905",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478704/905-360-25-4"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478482/942-210-50-1"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.9-06)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r1519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-38"
  },
  "r1529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39"
  },
  "r1530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "810",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477383/970-810-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>115
<FILENAME>0001493152-26-030287-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-26-030287-xbrl.zip
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M2U#>/N6MTVW#3)234IO*-LZEGR__O]O&/R3A_[($_@&*?P%02P,$%     @
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M *#]5.%VB[2;DO4M8&C5_8O4D)YP3&(^E%1CKOX2VL7;%_W9%-[?3>5 !_M
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MC&8,A[R6.K+\P_J*ZU%WB@@/X4;\.U$J-Z%LSUZ%!W9?B=^?7CT]>BI>;.^
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M!L4$.[8$"#GG@ 6D-!BO34<,BMQJ')$&V(E9=$2F%,6D3'5#JO1D4*29:4,
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MI(K;LFW;PD$"<^Q*/5$EJVP[\C(@O7K+]HH&I&M'[<_4_BW:I$)ILO>/SOW
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M4FMO3,'%-@U/[8TIL.BFX:F],046WS0\M3>F@-Z80B!!>V,*X(TI!!*T-Z8
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MX=M,COVU?;9U7-_;V0LH0S"]L/P7@,/"Z4KAV;&CTY7&'3PG&!;KZW=I)?L
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M5A(Q8=\@(PD6)@-U!;M52?N!].<&4FO<ORRR&F7H@(C!M*P$GA(@2J6"(A)
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M)U&M0A3T @E=&4\LT1(PEM(2BT,*)Z-J\D3=!V3;*PVL(@$K:F<B.CJJ<YL
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M_;BHT[><CDSS^+K3WC$H*#?.D'5%C2FF>_8DY[O.GCU[NF=/?CU[]G3/GKQ
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M^M.%>;LR)^ =/.+8JJN6-S &XQ&<?A=MV2/&9>I98/PFKM %<=K)+B4XL>[
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M2YL(;I.7F%.^V-96V[UR(MC5B%\W;35E5$^^ZB^A]:&]\?>ZP3.+R&H8-^#
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M][+IEHA!E/]62?4HMJ!9&2_&ED#U:[-W?/ @\?:U_8!6T5LR^8;[QF,B>5.
MCJ 6O!&,O*X0[08KRK7$1<*]&2NO3RB3M.B+7T*FM^HTC??P+*2OX:,#<B=D
M.@M4^\H7]T5$J=QF"$3T/#XYS+HP+DQ!D!$:2/V+8"Q.UB9E?8/TQSJX>>CS
MI8[.T;^%W[ VZB; H1WV3LDLS66TRB2!D/36]TGVO!6WO"T[D=(PTQI!;$??
MWG>:1^TC'^\CY68,.]GFH--+F!#I,=D2\W3OZ/#P8 :?+5X07.*1O\0I+O'P
M18@LF1H3W!BM1M70F_)97PRA#'*$5?^PZ>R/IV*W-6BCXTR@+5DL14=(@R&V
M'X_M/I&Y_\Z9*H]?_MWY)X@3.Z=(C]R$# S8EN."Y"% J_-<T@,*"NZLCQ/&
MP6>?[L$T(.L8K ^6Q[5]#.'M7+!9%%.D&,:K/B['V6;LN"*=" 3"KTOB[>!A
M;0:U0U>07B[[0W/[;$IX1Y%UBPY^PI$6WDO.&OE6JYOJTTH.D%H,T$U[8=/#
M;-O)VQ<6@RWJ&_$-.DL_UR5>?R&P'CE?KW)EX/JQR%N29,#+\S7YCL/7+\BP
M*WN^6%;'Y9O8C]G0W6R&IA$/G6&77X<2NH-<H8N9L>$)(@8Z[O^SHEWIUP?-
M[. GLM33!=WM5:M(( @J#0#(DYV]+^YC[VZEA9?MU8"NTVT2.3/V&\#USHD(
M@]  $-Q;/1$Y_[P8MUR>@](<M()EQQCW\,'34&]+$#WL:<_6]%..267I\3/U
M\1:"*HYS3_2GXX>L]#.G73G4H?+!AAY'/LS%W56<W(%)A(B_1*W1C<BJ)I;S
M=B')YP..KZ:O.>#*(#P75XU-:[OH@<AG,UH1E!E+#HW(<%LL4J3(X3&92=Y.
M<:?8Y'?)K//3N%;*OX^#D'I'-N*)&V<W-%B'68+2VQY)'![#8VD(TDPX>'X?
MV9W1=0I-YVH=9B" <D>J1 .^1P\/\"_SLX4UD$VR))=X5O!WRY%RU-G?9GWD
M]J@M.^0<7F.;3\44VWROSEWD46.@UE3G^(C?ZMZ1V/OY"7U\[=W-#M*U4<PX
MA_ 4:T8$J,I._(UE)\3:-KN-8T8P<MGV21"BHR'1I9BZH%1%T\;3S>2JO9U%
M3T< A$25-FI3_8%.XA!O;O< ):;9'A^A&AWOCO):\2,3//+XD3T2!5'TTZ='
MZ1X=*XGH.Q,2,W''3B._>H!I&^HPSBW&I8MM^!&YS-H14@_!&Y+--]B$]GF?
M,-#TP>C1-[);_-RV(./1BE/\+/M?/HD3_DWR"WX34&SPOF*,CVET..^MT"+9
MB$;I$7[YS-]S:&0S?9FSNNTTIE1V29 ?^<7 E&>[MMU?CUH3R_5IQCEES]3J
MXZ=JG9JNV"9S&.1C5J_(Z(=A2DY^^>0Q=[Y]&(IAND;'TI WD<"HQJGH\ZW9
MN=MMSC2T.86\\C:S<VAF A8SM#-?+)C?'1HI$QZ9,%7ELH(N&6%ID:'AZ(T$
MK 4BIR0@N43Z4UTF09<>;F)+[PF0^E<;_[9K?!OB^L$.<?T)$=</?JN(Z]U]
M_8VKW;-B4C!'^O'A\:'$"N=0PNG1\8$ 7$)43N1/QG5=4'LG*Z!:*U)C<*/8
MW$<SSQJ(9RG/>D\^#O<!!5X9"&9G*4K,4RGY _^28U.A%\JQ?I?JR--YFXNS
M)('\WQV/?(&XJP0[??X<?YRM+ XCIB<KRND5RNDB_LUD4#87^H[J8?*X/$;8
M#>XM!U)+YO 4I+>D!+25 #++(9@IMFM>GIQNA-LXFZ4 %RQOR<8YO3W$&%GL
M>"IN6[M"*P4S? +?E),\09;X4GCW\*#X-TH#C04VXSZQ8D&'9W#.HCQ!8OZ#
MI]."-62"56CUNATK)16CQ7Q5F_%OF2;RHWM.O L[M3\J'#P0@*1&,(\>.<"6
MG(-C_P&_UE+_\'A&Z9DA/.@HR##=CKBCI8#$AR$@$4%)%PX \#""36IZ1& H
M'MSJ$G0> LO[*-<#0=,;F4-^.+<$5,=*J5?XU"4P"?QSL^F2N$ >EJ#WX_R2
M#Q$"ZEN7+2WZHC!/&S%^3@VX;!PM1A20&:7/]31H"B4(.5QRK(A$R*&\$V,B
M<<"W3/^('PYP\&R_7R-;.LW+:CU$T!579.[D?!HL*O(O'XVHR*3.Z.'KCB62
M0T8G,46D8%E\I6X P W<^PW\&AS>X]&1P@WWF!2>#*]CAZE_JF47^UN()6:T
M)U61[#T]_ ;I1&P?R8>Q-*[P.1_Y)2UB=<"%JBQ?G%0!/OKH43"D(JJ41;L4
MNP[QV1_<J$1OE(.F!<>>J9VFH$HI0NA."(9RQY .R@$?F,$Y$[C4X,0[^4,W
M$S?JZ#C!N0@##ZIM-H^GU,"HV[(+0=^!2;P-6'[0:U&J]1W6S+*+*DG(K#A.
M3W_\_N(MG;@:Y%V+HI 3.-/<)4 0.$50\4.U&P!XN=R"#Z<(YF0C93G0B=-B
M :R0E1'D@T?$06#(%&4OK*J#"$3.ZELNT4*^,[Q-H4(IG-BS*[)QIL.[ HG@
M<CW'V<-GQVF(E%#T6C4[B*+4DB!CA58E/*LHK[0D$PS"=@^AQ&<D=X88KB'
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MG9Z\9M_QNS?G.]*%.SR)FZH+I\T*N8PQ6L!G(#(E^Y!^-E44C @T(0V=Y0X
M,R9;E&RSABQ+DB![]9\>/MCG;PE(L[\10I[$$/+7'!?D$NOMV/%ME8$^W?AS
M7;(Y2);NH-+/)2<Y_D+FKUB*.HG$ZGLYO#+7DGM$_!JRVA&2ZB]1$YS/ZZ8S
M-R*>LZ![>+D@7#MI2<UAW)(53:PPH >6J<IR);=(^$.+A,;?Q!8!9SP%1"(J
M$+RQ:O/F<N"/+-I, H 0\XBIJJ2':7U:*@5J<>6!A!%=P:?,1Z<HL\D0 K))
M9'X&Y,\TPED=C$X*'3_XZE'Z>J-Z4R#X\$^T8C.$:$2AQP\5;292;^B"V6%5
MO=!5-T% YZ,*.,.PSW<&3/%VYZ1IBTRJ>B1XIR&MQ,KS<.R["1WBFH,"[(N7
M) MR7ZT^.$1T,?^_I_OLZ(G+R-RA-;@ \KD\A,NK]"GJ)ENJ6PH)!/7(CT^V
MG.@.D#&V91X^"#C^'CRC5\.?#D1-5!DO/"43.B"&@'O]VM>O1</R&"*:#Y[)
MX747:["#9BCRX0"SH*8=P=)SU)Z%/J9+?0RO8+QYWO'GLM6$ 1C!$<K2.E]@
MSRW4V19+P5A$(>]\#(_BT3?@)(P.X$8![O&#=._1@ZC\UK;(ZE!H3_8>/AD]
M#K^BEB8HT'D6\DCQ4'W\Y-B7W1[A/<]&1UL>$EWBVYXT2BZV%Q$C#;!W]&QT
M>-L0)7C WWS*!;GZ!4-+#G=F&*39*#.6T?C7#']_SU7YUV*/A(< +$_OT[WC
MI_%IYGJ8>JUW2*% O)-:A;U!N[%9V2F2 =I?%$%71,]/%JYI(<2",@SQTV->
ME+"<&=+W$0W5<9JH,!D<[8\NJ4YN+JGF,40R)*J"EEM@=7"DB/^[XH5A)GSC
M ))U<V7'I**NN#1L5G)O1:P#(F;D@-:)"P"#A$5>N/=X])!V)>?K!BC!>RZ/
M2B=*MQ#B8IGMAIE5);(8EW([(\[(QX-J;!<9+\G3G?3)C478J*'"BJM-%>A?
M'CN)C74Q=1DZ2Y'2OZL"_8>/']*'*^2G?CJ_X)VV3SCM%)7M)F%]DQ^)=NE1
M'UXQM5O$U367*/KH^H@V,J_=M+FI<53J;"/R@\32R)[@;ZSU+R%?:Y&P,5C@
MP<-O-J0K5YX$/9YODJK&^HOSS-AH*W%$"X7  C#3XO7K+'WUI^.'B)FC>HP>
M7Z.TJE+.)C&6]B[R\V.&ND*P?V#X#VGX>\=/1D\>Z7[<.)GD Y.)AG=2IT\/
MO]FH2-1!QR88&*&<"3;XA5IDCC!A7ZI5;IF\FW18JCC+KYHV:,>],>![+MF_
M%O4$H.U&Q8B600:^,1)?D6<(6*O1UH1^Z"UUU:_881#/]_C0RAP\-6+B_?)L
MX+%[HL1H5 Y3\_A)R+T-+,3A@7-Q@T(57[3,^1WI41[.2[@]-M$?ZNY>G)^F
M>_UZJ70'RMO&2<#U5) +^_!_\;UEQ67N_U$92_)H4&;B7=!'@?^YK4C$J0*3
MI*[0(T^/'X^>'$#H!-DJ\&+93ZJBGB.5.&/UDD0IT[WEGPY'AY T-Y2'L(AP
MN %N#\5Y+<PZEC[TY4=8)6G;HLF\9BJDVV_=UTSN)-L>.B#&4^&+I\X9]=U:
M1C$4;ZK#\#XN!(HM;&Z1H2IJ0 O8M(GGL;&,J3H"$R!?=V"$NS )EF<"7 SE
M&=F1[8?%V=--<69-NQ35X )^*!' >[8A&:3]4D3Y^I_+M:=![<S>B[=OT_I/
M3Y_L?[2(2[:*N"VE=T%$].@/]'^EZ0W+OD\@^A):KZ="%'6S;#3(7@RR2Q]^
MC"#\*+*N4?*]P0X<*J55?\!,,(&\,\_&UWBA?Q&B_^,G^G'8__\:-)<=HOT%
MK/TM\'GO)*&()S;M']*_7Y9]L=E.=AOX7^?ED-]'X5( N^]__J&O#E_WH1J*
M;0AS.]17=$[U!OQQW/[^S^F/^;]AT+_!O2'5>@ X8['_:P_Q@J39A\>WV2?X
MX[>RG8_WC@\?9L</GF;'CQ[M;^ZJGIB'3[_9/M[GI03DSPSW.EPT?<#Q-[<N
ME7WKX0VO.1X=':5[L'B.-K;E4[WAP;&\X=DG6-B/OB/_]><?G87HS+T+,O<X
M4N#F>MO,ML_F4-?K\?_A&<=/Y1D/OLA1^[PU(>>B(2\<J3/SJ(2/Y_=/84#R
MW_\@+!I(F=#!0GQ$I3<9ME'OXO]D98\>\<H^^K_LSF,YKP^&Y]5Z*-_Q1/Y7
M8>+^G6S+*J]O[( 4-BWR+9"TQY(O"&!*;(2/MW1=@F%:SO37L%F#ODN7Q5H:
M<8\+X774?J1QUZ_/3JN\\X8^QAN:)==P4/.))1%]:S4Y+H(#='RYL\$AV3P<
M\5G@3HT"(62+;\Q=;,6!E@YOW!!SU8.<37B 1A<C>9\RO,NY]2W2:&&JRF6V
MM=A'D ;D^_=]L5@J)M6_S\;OGV?F/+].GQS.'HTW;RRR>?UC]'/FE*^NE!'(
M]Q]#Z\VZ: U0RQXFNG$6G</,6AN[+04]J;SL]8^)+H][X3T_=)_ZYK@.8[>5
M/S_<E3]_PO+GA[_5\N?/ '4LW=#+>XA[I.$#5/ZZ+1SHT6 V)./.3/C>)$J_
MT*3OFTC[M>Q&3G_[N.A#,B!1\-AK$QO!)R( 60KQ)ZGOQ1=HD?'K!L)"63Z4
M];]XHI&HOU$E# -A'__\+1IBTZO]Q</][,V.MSB8=V*0SQX_>?:MC.R3#/7S
M"^0W><_=L/_ @S0BL6%91TCTPWB+FTQ=,N ?'CJ4K";,ZD83^;G2?WJ(1+?O
M4)B&[L4X2(:(=6R$2_P!W%'_G!#RLU$"N:3_R19^ET]:>+.%)=JBD:!W?-G1
MH<_[2Y%645AD,UCT*]VLNWF5=G<GO#M'QZE4G?]?+D]06;^[/+O+\Q5?GK-F
M?A<OSY2&%5T>_N +7)[=W=G=G5^B>/Z@(Q[_^8<"8/[8X5IO7*3;;X\@)H[)
M=+,Z##/C7,L"0)CG]"J!,5L/!QX%@&@<L@U[E6X]T);8V9'U?_K BN?N3EY+
MT7YW#X-$7T5LY+MBW=33Y!0L*6W G]H5>3NY%,C7I8"ZK[6C\L]T!?$1DVWP
M[[A:KI $ &<*JG)2LFF7EHO%JBY\(Q57C'79=/THE=>G\OIDU9?(&<@/^7JN
M%@VHRO#*OIA<:B$IES[,&7JO+1"T7?'65L2,B\>#.FGC,EVQIAL.;93^D MO
M-JKY@Y<+A@ISVTH3H$L@>1;7T;!NKA1#!Y( 2Q%VDQ(:?3!OM^S%C-Z@V"S-
M4E;KA&G29LV$:_U)&\LJ0:W_++16$^Z(*PJ?A>=?BW7?KJ8YJAU>GQT< 6Y6
MCD'"ABRI\'WQYPW^]T_A%SI9W+@ 5*8(@'"#$U%P[\=N1>>#-D%I"8SG "=C
M#%O%<JCRA(W\F[9\!!6+&U.8OYV#=F673;T3DWA5K-KF5=,EV%Q68E*=W#!+
M];PM"M]EX!^ $B\0*Q<)$C %&,6%E4;\6(Q;&D-0XTU_^$O1KKJ\*A99^M/;
MLY'@GAD#/4CD)BU==:VQJ3% E)9ST^A)2HI_6J3=NNZ9T7"O?G5^L1\><FE2
MI6P=>D8W;G9.-ZTCNP)I3W2DGI8=QS5])]:+,ZMI37QC:QX,R2F^\8"+EYKG
M/;4K;=35T3W'G<)M</?&RQU_XS&1<!YA>YKM5& TQET+P,]NT>!D%SUO]"[S
M<W<F 3CZN&R\Z0!FS+Q=Y)-BQ:ZGL-)' !ZV$$!,68@BUM:N$]OAJ\)PUSES
MIH'\+WZFPW]D:?3R)/C#X)W!7[AN:*+P^_**NTF9A#0#R]EG33NGG_U;#9U<
M.PJ3C)XS3-[QL^G701$44A29('OSW_EB^:T39I ;"H#1DLM%O@;=D)7L@R!K
MU7I196@9Z=,\ ,XX&$I^G4L%C#+0^O4(I* .K]2&6%V!-KESCV4W.\Q:^P9(
M&C%)2$5=KI?.]7,$>'E9H01K[\<WS_>%L[5XS]1Q6?(RQTLF[VCH?0Q?Z=(7
MK\Y?GOSOIA^Z%ZJ:?250,9:+H)==9 :MI)6@T":383AN6AXV0CT YK!U?.OH
M=<-H$K99!Z]?__@J"W$[&>S*'.:?HZ'.TI<%W&Y>T[_DM.JC]"=<N_0'+DX4
M/!N;U:";*B>)L? 9MT:X1(V.US'JE>VP&QG(]:3 X?UWYYO+)X48X0A@6L@H
M\&#5[7V3;*R_PH=HOM^OX':,TA-Z_4\EV0A39HBLN##:R"7T.+JO9S:RO]*3
M_Y<6\>'3XV])(3=SP5IMF]*2=A55S8G^]**)?[S5>O",V+2A!2IBP_74S>=:
M9QO8]W_].:-_DWDEQCR)A^_*1B4%-O6R614]6QHOWIZF#&[CQ'9N8H3OJ@Z[
MBXRA4?JW[]^<XWF01^E//YWZ C]O=="=U+ELV=$?OB?CXQ\_I6<7/&$Z@D-2
ME11'T;K26 'XEI<(;$V18\IOYM;&SV"=Z)NE;/+!H+FF6%M>AJB,"@1(4&4S
MF RSLIH(B=W%4?J*QEC3NR8CG,H$4V#1Y*G6XWF$ZZS>$ JG)FVY%*8=ST@J
MYV=<M-/\WZ2Z6G["HD%_[LEJD4F59)_/I:_KN[+VS0A'R47^ZKP'IDZ\;TRK
MSCON3]ZBU177]>?=EG&BJHOD)(F!H+BKP!USJ[BJ1>7-6(8S9PF6\/3\;R_(
M4WRF#,7&8H!:46S>ZZ8J])U*"K*%!4^&ZCL8<D.H>#]<@TZA(.B]KH!^)<.;
MKN#:_FEW.L==6)LJ_3T[UPP(QB):93MW<<4&"B^U=$ #0R@SKY+: 6X>,[T1
MJ,A7C(/E<%&@THP!MI$67;P4"9:"S\Y/13ZUBZ8!B[U7>?U/)N0YO21/?5]V
M,+JU,BE8-]!TW- ;E*-M,^%*49(GH*!BK9@6%3P2S%.AS.X'=2)_:ZHU#;-K
MJI5C-+JX+.I_T_]G6EA(%<>H]388J'TK&JGWDW*Z99-+$!OQH%>=!&O\@+@L
M!<7[NMU%+(7NN3WY51C%%[3YB0*>S:HE7S*S:L>\ N$)JP$Y5:(.I!B:O%J#
M_\**91$BW"*K,7>C+]D5M4)D4"9QG?"\+MU)5!I5TFD)WQ%1;S3TU8PL6,Y8
M98$MP'66JX70:M"@<4F8S87$Q50L&GL=(,HMA]CX8Y*=;4[C7DVL^GYH#=_8
MYV)@TILUG 7$L*S1G->_I?9 2L-92CAKFM\9P[$'7TER%DD\5";GW%V:.S")
MDRXI>RVNY3CR]@BN<A!W-T=(H6/YPOR'0=)D2Y 4XX%>0I-U-GLKZ909C]BB
M>)\L^I0,HT^;1O 7B#[=M^/[Z8-/VR-.MQ4-/-H5#7S"HH%'NZ*!7=& #?]E
M:,:PKWX6M+G9!8?OSB1\60!\?]]ZC,,2!S!RU^YO@77*AN\%_LP-VCJ.I;@V
MW_YSSW;ZNBK>DSM_VK3+4>+H4/E#_R6<%#AD&&'Z FJ;/OB)U#D3$.F/[ LN
M4 OJDT%M0QZ:XH.N1(DW,6)[VSF:5BY[2]F>NNRC:!'*SA.*#M=+@NQAZRMI
MJ=9JV64B[=*"0)"^75],KQ1/V2WEK6]3UT:9O#[\5-<, H6]MSXVKUR5+]JT
ME74M4:;T9-F6%6)43W;6SAV81- 9(G-ENF-X?F@'U#-(DJ- XL<.C.]PV]UA
MTJBA8R8.^HE(T5#LV"7@MP8;\0OQ.;G#C/2!?,F^YX.CC#O.\/B6Y-1>LH\0
MTR4^>?B-#0"?H-M,)PB:X.KM3MP=F(3IDCR52#((9-OBLD'"!_*A)W'>YUGZ
M0]'0,'/G+*$*'3(D2K@U$L9>5LU:B)RT/\U!US>3=_AZU5C*RS3#\XN?'!2!
M7LC]H=*)9 PG52-Y)S[TKO'(A):F67##O[\'0F]#!P+* +K4SLEM'B,M"TQ(
MS],]G'ABC-TT-GH'_B<D*'IB=<8^3X?\1J2G25JY676W6L""EO(\9L:B'],@
M:BF0][.YYT?I:[D/$L!+IV5;3!!@T//G]LF%%_'I#%Y)"MP/?5[D9%R<!"6:
M] $C[9S,1=R!)M3U[DQV&GO0V%Q=P)K)VW6B?44U+<$$'224KYIR8K'%2=Y=
MLOM9:(<T2>MS GV\YN']0+>OJ-/3$LTVL0K_:-IWZ6613_^UHCNR.W6_EK>%
M;"EOW$JPQ$BTKG=.UMV9! D" (=)&;%^+-Y/JE4G()6*+F/-R5+)QF7ILI!4
MG'P 8Z@R;$>6OJN;ZP/0B$O-2\[)_DE;&$1%(ITF9L*$8^8H31/A-)V5E69[
MLXW$<.;T#I*(Y7S5:G16OVA@E*!A['@=03\617_93#GXS^E2G9%\EQ'(]MV$
M8<N9@I#D5VP9((3*_7V#C@IU(3VM&?-K3]B)G3LP"32>Y*;<L): 5TWG53-&
M3LL=]PPGMNYF=" 1)-6C/\3.ON)4Z0^D:5R#\5?G/_AC#$P]'/VF5K9G-&TG
MU\;#,!++;.-/N#$I;HSC!$7<OV_0FL0*,) IN"X,1C)NT;*S#(2J0?O7'$F8
M-579J$H7TY1-R@W(%YM^BV;*_I/=L,PZ@<N%L';3T>E'F,(=?LTN.%KVB#0)
M:?P/#-2ZX4FM'AB.G:P1>)V*FUC.*')+.@UU[@? )DR4BYG\M6[%#0.$I+YX
M#Z^O4[Q"VBR-B EMKI(Y[7QO'<XA++0GUGN?>(>5CO"0LN'YGCGZ33/M/]MU
MOZ>E29^]K6B=G*SF]"[UUX\>A:T:/P2%=_N\AQ_IEI[+X3BQKP:A/'K6>!T=
M-/Q.3A/L6 L3,/%=SMB@;>>?I$$!Z2!'& <\/$92WR/P.GK$T1.[&<SXY52Q
M_[' A/0/R3_!>0X.Y.O:XJ6G)/R>KZ1E+]\=",- 1OSA2Q^"STSIL6-1V1CN
MCD+E[E?CJEDK9; #@S.V;8->>)W8,]9!EIOOD->[5M-#H:H@U8Q+[O:>'AYH
M7>Y^*$S"0E^I8H\J^*)-W]66W\=1?>D*H=U!V9$0W#;@7,6,R_1M.-J&5>I6
M[2QGQ+ BKKMO\8/=2;OOH]J)I#NW);]ID;12,A(E+4 EP&(U 60?=7]S-K3J
MZ4! <=%$V3GAA%^/RV965HL@^?"9&4SN:\'O%X@ 6@Q(G/9S%P+Z2UZO4 2&
M4%"FGOT'?/)>>A1QV&G*=41C0 /06'B4_KRDYX8!)_^Z#)SGXV("S'TSI@6P
M1D"+_)T/&J#[([*G494.EUIR]HT6H.AZ5  L\_7"8M8VVDPP#O4DK/[3FAAU
M_X5X7?HGW43('U?R\YMM*H(%V@@IIO]:T9;.UG@OMXK0SNX:1>%Z0EH/-_K$
MC9XK3VGT]%0DOKEM-T_5F@F++P,P-(U1^HH&_8]_]_0)GEIQ9G#2-EVGO69=
M>E)O)KE!7&?HRU&1EDAF"-!N&;%?/<[5*_L!_1M58!$*Y'=/']@(,B4NB,<O
M\'(:7]!^=K"9'=?U<<6@=5WE21CH@-8OH/9P:^>!ZHM\5[US)R;QQ_+/KUDV
M)"=!V!HI3X9Q\(YQ>=K#P]OR:5):<EU.B] ]E^IA@)!I2GRPY5U1</HM=-+:
MQZA/WSKDR987[<@GOG2E2D([LF7+N1B=Q&L5BU"WP8@>1QM,8E_BN:X?! O*
MM%XMQ@JS'-2.LJB5/-@H>=%[;$8."@-N<<DXTRF0=1!(.AJ4:]?SJM@V:L2]
M6]120K9R52I.+VM)H)K<RP4QPM@ZEJRHGJ<?61_AP4( &KJ::!-[_#TNN[[@
M!V%H)RMZ3\NXCWQBM<;2V3B];CF0E:+8&,\E;9>W4^-;E+GD8YIBO[9>UVX*
M&"[V*1S7M"DZ+GXM^ZZH9MJJSRP"3B-QADD?;8W/@S_I^O%.+]NB;>:B#9"*
M)MF?N E*LQSY[]RF*"D(.16#H95H)5YQXUBV7MR#EIR0D'W<@6 VBR,^7(OS
M>%>+\PEK<1[O:G%VM3@V_(NB[RNVMA.7;[V'D_DJS)+S.G&N\(-,&4+04>O&
M'/H E:_^<9A+/RW;"5@1\FWI=$Y-NR]8)0T8D)B:<@:=Q:6Q>X;]!"HMVWBV
M>R+&PP0G')Q9<7F N6"AVY?WPVS8+VI^6/GFAT\Y@9:H >!:E7=TK+7PA$VS
MFF=VT5L+.Z%N&*7G=7I&CCA;:T=/@S67#F,&"4JW+.,H^!#(<"Y=2!AGQ\ZC
M/H!S_CDY$VU3SV>K:F< W(%)T$U[F=,M>\05)D=9!%GAX^&V-KY\?+!$7@;7
M,+QP7J!NN7%@9ZBNV)ZOJG12Y>6B2\;R2B,PYVH!ZQ7'V9@5P"N A]N14O-Y
MZZ%\/0!>X4>=132V#8XGG[C)X^.I8#?7P1M^=T2;X*(\?*T0'"GKCJY;M5"P
M7<7Q('&)',OI,B^G0SP=_:JU"TH[0/O@7I6,R4>H-3XFKH\BR,$OU*SS"@ V
M";^D!6)>W.Z;RX!NZ]I7%[V&?,+^?6\OR6ZWIW(1E+OY"2241J3F<%QZ%_"3
MMHGTJ-\]'AW:JM <>:&'U4N#4-7AZ*%;1_JVO#NF/. 5V^'8/K/I\P-B0#6;
M/F\D"/LK5A]_"4#6O1/3M$FXI,'VC+ _5C$HH3AC_]! .KU@VJ[FVU@K7?F8
M#^T\+Z:@64R?-\TT2\_HAQ(R.&VZ18%<T\G$4T ^/V,.R-.$/HRKDF$NE:@N
M7B@G6.M&;'1:]FY_RZ=%1XN9:XM<5S3K^4RLZ%;J,F5V+AISRM>88]9G0178
MFWQ:.F;='PL2+9=N_*=G;WYT,-GT!S+FE*[<4YPX;I-7YS$ASP8YW#7SH^C7
M$^5%LH!_!3ZO<]T(RVK@,=MHYB95D;?1(NPC^)++1AYX^D]C\.ZVFG6<VM$&
MK(!<&W-8P_&BIJ[6LHY797$MRXCU$%8UY@_GG2GK)?W;4;#+*K-=B\.1?H].
M][FC:7(4SGZ)OW_SV9'(.TOO%XD0NDKH4:G%=J<X;;G17YW8X7Q3,)Y8<CK8
M;F-^.[.*.$B>G^L*#  YIQ<7DL#D&""&P*FC3=):=<ZJ=3(UE@M/.QL[)JT,
MHC.:,0B!B1LOQS4?'1WNO=M'Y%+G0X?;-?C.+%"IW$C\BRG8 J^:,%:9)4WK
M[R5_Z_7+D_ ;(QJ9DY$J]B +AZR\2L1?P7+CX#6;R4R.-E,3D?]8,(W#T?&W
MI_A7^H+L/?Q'\N(%KKI^^.*%?FE:6%JFJ;4L$68IFTME]VZ#4W/;REO@ETZ7
M@I<V^!9\ZC71KD%<023F;U%W3(@&"L1\5O1BI!>SF;C!-9V#D0W<ET+8JKC,
M9=5<%UTOPU:+W"%%-:<J47HPDXOA?-/KD.F%"*-7<L45_(;II7(XZK/IQ+AL
MN53%5*3+>&YRK ?;-ZCE$(Z,$L<M<5/08X%HJ5)E.'_B?Y!QIK%>" FIU]-.
M(/[/Q1L?'<@G'.GGN'JGKK^R.$LNN^(<,>E@X<H$/0Q.YQ1<K84;.S-O:FU/
MW]*))[=:^S+5!XNRHQO#AZ?*QT7%C^,G]("&J'ZG%RX:C<\[W@"WGR^BTZT5
M9LE'++$\7&MOK155)YJM )^D*[H-];P_;5SO?M/V*S^)#,VR^1OOFG!C$-G-
M9=$"J,S2 W0GT[R=HH:PZ?H#%1_TVJN"; Q\)W-'4S?(/% ,<KXJI_R@:3-9
ML9C<Z;<[,(F_7Y95D3!TPX11>'9%37E[YE;U8?I'H@(1G0_+S^ E\5OT=].$
M*0O&B[(/Y)'DV;:]3LSP"P5KZ=!4LCQ_?G9ZP@\N6"3@+-/5[C3?&>K5U.O5
MX06)+NO'/<%1SNJU%W3_[>M6=EI)BV>AI+!.Z,KK;YP"'SE#785!+ *6C=;@
M"U.G*@W:>J-LK\H91M4IN69F'RQ55$*3=LVB8$\$7!HDL1,GYYO6;9FR(',Y
M8TTGK=3@)5@ ^(M@ R"1B4%/PZ9"_,-2$K QF2D. -D2A<6=<DW#5L6<31]9
M-21'E:6(JT&K?"*FD#, ,CU+6G,8&RBC%+RLV(2#G,[HE",QX3E<U=X24<.^
M#3<RB8[#]KT4QE.SN8SS": P[FLBS",W')[/SD.Z$W^;YKU<L\3;]2\=+>[K
MO+^\SM<2-'C;*#'MQL443G&)?RY0R?@+9!A_583*M%B0:<1F#=DM+A& HL.F
M<T<?]T=MHYNND!I,6E?4LM73%\ZPK5HN+U+36 8%K,3&-\LN<3<P'=S X5TV
M44?7+$O+43'*!N3;R&%L/,OUQ^1H^M,L/7KVY'&Z%]W03F70OD/L:@DD^QPZ
M M,@P[>Z(');!$X&JS,G,_!^IY;H\2]8AFV,/IDQ9_#-<LM3.7MQS[=_4Y4,
M3Y"3$ZM.0_7YNZ(SM0O7!6?INJBNH*OK_K(3\=3, (Z1+U=-/2]:]R[FZM=E
M<8S^S%//)IVX>QZ6YHA?T(XN<XA6K$*8B7+XFR1DP'.K "45-1"P\Z_Y/TP0
MX9"B4$8P!<P.?"]_*<1^S.L:87KWL_CK">DZTE5E=[DS*_]3A,R3'4+F$R)D
MGNP0,G?R*OPZ3(FSQ%D!B$*I_>S9LJ##;K.&M^AP'W"/M#CH2R3B+W#%H9I)
MAGZ+6B1^+"2^9TYHF^C?/F0U0FZSY8>&R!5ZKI U;Q%[,^;C!^<K.LUYKYSG
M<98C#]1VZ*>9XD";42@(6&$].G',5M4,"[)HX&>6\Z9%VQ>R')(VC-A*!T[S
M%^DU\)V45-X,!X.01@K12BU<8S/&L+82ZG A,%TK#:7:LJC2SQ+?R2JEX0G#
MDFX-MU[D1J?#P"EO"?P3T/WA!\U4NH%(B%.#@Q]RM8+#98[O/;]O7X70.$$K
MH,39H%KLXPQ'W[DC=$+@?C13?U(E-]>L0/M'@^<_2):.XX)A;!J5*V&P,)/F
M)+!\\7NF^>G+7@(<RGQYF9/!F7)SI>"EX$SA&JLP)L RR1FC'#38,('!OK01
MN \?G26:9&"OWANZ/NO!8?PP2H^F#2;$ +WFK$CD5.DLW#,"?RS,E[!#P/Y&
MG?@2*D:O\-K#&'>V+@L2I EY2SC\,BTF96?A 7+X61.(?,BC(3L7(1(SL5C6
MGW?)1_\^&PS.-WL=+M>$::"BSC"_9R2["$9I[C)1H([?H6*JTB-=D9RI;C^G
M'Y=CXL[)P89#/HH#7@ .5'6-=>1#C4+93E8+V0T2J!LSL^:*WE$-;D180S=C
M=8<&744MN)H=D.;+5U^1>G:950O"< )UJ/T[+U4VTI%B/.. K"WU98$'0,WH
M$,)=[S9#@NXE%OT,H@YVCQ!8@&Y=%S[X8&E0SFB*A?.AH "^[V*$G5@ITV*1
MUUKCDO,!3VX/'[LGPO4>9F*SS6O.UI&/-A5;#5+2"W$.*7-DPX,WR//&+I0L
MD6G.FX*73R,*/M3 #>\YM+%$5&8+R;>THG)_ZC6[I@N6;+R;X1?<U8^)B\GF
MJ[2J=QDP\X>9W0V:OQM_I%P6F64?.54/B+/+F''3> Y+Q.VU-$\H>L9RB6B+
M"H)F ?F05E_V6Q/HV38K/-1@P7>34AJ<EMR=3QOIHE,!IP68#"AL67!E*)9(
MJY#96BS[;J.2:\;2'U]G[P+G_NCI(6WB.L)!(=VB[H6\&BNL6G#[_-P-+'&"
MT5?77($P4N8>X0-=L2TC8:],:8;E.\EJR2)>>N!:5\(3!*:NT& <^,^ZJ)0^
MM&A[#;61[=VAPZFMB6H-VFE819S6=XJ=;H9@>8J-)=.-1UT>.EMR-?<T=UQ/
M;L7=OU1V21U;?%KC>%XCFHR[-_)^*2" )A.L6/A&"(5D,QXG3J++.6FMGG@#
M!T%/2R[P"VZ#3K/F/L0E'Q?/8AYE_'0\G%1:,<3%?99$%\6G]5&MZ"Y9D-7V
MH +O4?W/Q9L1GZDP?\-R(-#QLCAK8Y]QL<==FN57:!+NCIV"_GAWX FH6![4
MHDR#ECYI.8/LV1J/@#+11H06US9PU%!/>2<FH=-=DE?DVYD6N*VUP_W(TUM6
MA2V9Q$W-L4R&SN3UY"-5IK2L'GA#>]T^5Z:2(L-==E@+@"K<S<.%+ VKJ+_]
M13 /%UMQ>I=$)&G\N584]RB][9 NQ3(+%U-":^0Q+P[BD@EYA'$PV*:HR/6D
M[O1B".,#;!+-'%KN@ 1QH.YS96C6_8ETOV:'G0V1V ZJ]^%"-:QD5%SYM,:&
M'1&M9RQ%W>+&_@6R<3 &<8ZXTM?#7)(0Y@(U7&\"<H(J:I8[TF/^4B"TDN52
MI1"..]Y&FL%DK2NV&5A**G1^17^)I<&DFE8;)(L:A+8OFZD*.S8(V?V<D%/7
M;;,$F7AT[!$8T@J#.TA8;L8P/7/T$&=3. D+U%FYRJW1G)&,@;NK8RLCG==L
M['S>K\(FGGI$R$S2=NQF4ZR][/>7@]%=[LY(^U*MYS94ED-_%1 0$RV]F0SS
M7WCXM,VO\RI0=7)V[KGL_2H4R*D<QD3"-4*9&;3V-&%G4!?[&I^#+;8&&_'.
MLJ<+]"\%(AJ.TW$HR)^#YPE""#9H#(^S/IT1Q;4&V@)Y/0RT#<6UN;/#.!0D
M%=M15J9%ZL/_NU,#>?NOY?4DV?KUDD&PH:[DH#IG[8OW:E&J9O./AW:KM+J3
MV?7]SP7PFFBO&;KN'/.R]7*X,0=GOBI:CUQJVI+.%'S\ER?:P6P=IO,Q..]'
M1BGJU%$<P3:7_CY)/K3P1^FI43*QUKOU^$1QL>'ZPU#A5;(CQDI IL:'00.)
MDQP-NQ&Y+6?<'[T?A$*-LMUQ@2@.U;HT@VJH[ ;?X/##UO?![HB#69(7P("3
MH#%;[ );58CK.NZ)+GAQ)?);V$GJ@\9]PUVS9O(>Y.O8IWB$**V-D"U(<FRS
MJ$ />2-0^I5"PINP%";NKNM!)4$%H^"^[KGP^RHD^'F=O*++)I72AUS;>(A"
M:7_ -F($H>%@AVHEC&RW%6K2@7,UY AZ</H=)T2S*-,D#BO7Z5]6=+IH0,>[
MD_(?8$>>[K CGQ [\G2''?E4:8206N5>7VN:RUEQ0.*S230;(F1T)[68-4OY
M4!HXU5(N<L )M2G]^V  8)!HN21$7.P:=4:M0 >V)CTD%%(W9(])C4WB^"/9
MH&DW0"KJ<S>-L#]R^>/)=$$VG"O=>0G(0FV90)3*DF@_>O;L2>H@?<J?<<M\
M$L]WQK8L++5M*(JM,(GMH(H(@.+3UAQN7+E:J9Q4B]75)=MF7W8!%UL.I[H;
M9&O17+@K%.!AZ8EM;U<C72+0DHK=MA2P[<DP&L I]V (B4_OLNW;$E-RBO;-
M21=#=!CHHHEV[''@>9+\]^M)_DN.PY)PYLI#\0<6-8-3;B\??!E5CX38G-N.
MMNN$"&.5SH"V/58;0XS/VW-I87R>2_P\B\0O #S%R?O$:B'+SE]5>TO91<$7
MG= ZMM81K4N/CC7M,MN600IO2;22FN,)CUW2%<6[+L!$.^Q& (6^*7%H 4MR
M<=I\UFN*2UEG-\K)'$II&"CC[,C-KL#'A#CC8WX#\EA@T/\T-WQCSLNB+R6)
MQC%F1(%Q'/C&;<&K#X!X'B+#E94XT\L6E:4:EO/PD=O!=#A4M*?)AH R&([F
M:OS"NI?2*9N"QJ376)D$,'BNJ/_97E%(%PJO#%W '<[ABROU4XUH)&\YPRU*
M_31.>X?DRGEUC?L?R@L7=7$Q%"Y9:L ^L2AN^JX>2R^2 :BI$A=A 8<F+<(\
M=]6Z3D&&B*H;+Z@A CP'Z W R##5^R)\*2V*5+NEW[M*>:L)?G'V?<"(Y(@R
MU%B9,RU+/ 6O"Z/\QF4Y+GN?Z#"Y,OAIXFK.[";-UAP^:MN<L[7(N+;3=T6Q
MC&N/):3E&_*!+Q7M\L:6XD3(@U,?BEO5R\H?^4$T2%XKBGBHA)U6BN!,T,0!
M]E;@%)*)R,0Z!,PI+" ,:5#4X A>9[#:ODFTM(F>1[MP@[-NT4\]!1,D57Q.
MS-7\!#3G-P ^3M+AM*SD Q&R6L5OL!B^\S8K(R0B5EU4/&^KX,.QUT4UR]O"
MT;ZZVGHE42@[*XA$F(P-YK(.RB83SG!;5:5.!:65V<!,H*?0+W*.")*EDL_K
M1@K*)PH8H87E0R>EF*Y)H_5FI,_8W+\&*SW0U,H50\_-RY9YB&@.\68/?_-Q
M"Y5;$IU!$\.-W@KW"51?(H ?"Y3F=;E0]A:Z?$TK.#LI4.5L#4I4+\6>D:*R
MWF53L6D&._2),)YB%V5J^6M<YMLV?4/N/V-B7'J7U[]#_99X)9B2Y*(C8WOC
MK#Y0BRL''-=96T'=[4H(/>R?8DKJY5%*-%_)%\D5%^L>%Z2$/H2[APY@:)B
M?":E@!2-'9ID:ELK:X1>3>^]E2Z>WB41GC:RD1Q.*+Z%:JU-0.HF<)_<Y]_R
M:I<ENTN3V(#ZB"JQ"^OR'>.U)>]-/7LD%[1GQVGA9I;Q85+0A.SW&\$_?=?D
M[=0KY#??A12>"0.Q?8ZW[#480-\3?T?U8) LH.^R.-)AT5U>B<HT!%FOUY:G
ME+EL$5>]!_GT$"J0^#X8@A<POP*/X!NW18VA"L.O4^0,<@ZB%9 F384V8JO>
M4MC8'"8/7:C$-=GU2?.A<8(ELNN;;OF^I<59>V\9GA,?F_8!.$T"+9IL89+)
M^*5:.>/&'N7I11:(&!00=E1A;PLM7QNO-Y;*''+'\)7XWUJ.D"T' .FEAKJ'
M?%8L0CX>XR1P%1 V+-QEKVD"4VM#W&:"G7%*)OX"F5B)%G=+<K/@4]@Y"G@S
M&RTH0/;>@1I\T6!(83(NSQ$N;1XP#ZCT;/3S5<X=C NO+#Q<BE? CC_S!PRT
M%(TI,X@4GCC\0BSH PRAM^0C/!49O"WR)'YK]&"; _'Q^",VL& HU[W=1%QM
MEY/<-/EDP7SN.?'FAB6*^B8+0D@JSVR*BOKV)QH0K&"C>?):VZPY5+T-PTL)
MFT\6AGZ2A#4S'C;&-H44S(BLY1_I;1 ZY1ML31$=UGU^IS[OP"3.6#XDN>D8
M/N9ZBH9AN@$D*4A_!TZ4RJ< @L<M@M[GP$AG*BV]U**34C"8C@:QQ14W_U""
M9RKE%GX,V\YO(/:@? W([3!15\+6I*Y,IJ(M5=&6Z.O83Y9(@+;."EWF[9ZV
MV*<P<]]).Z7M\!?A,#8%LA [8?ODD^VPP6W WX#/TY$(L!Q1(6]NWJ:PMQ)1
MVES5/=LB GS+O:]N3D<6A=_(;R/KI+PELI"&D87P2.5<+A>&$:(80ZQRDI@:
M691T;KH8NAQXI$ +J'C"@=#JP%6'NCO^@[$7;WH"N6![$%?B_;K*U6OD$&Z7
M)1Y-EZ=0E\7,ZQ6)12(()0$/E7N W%^C_;G<(I*JDW(I-*5T/F;E3C+^1RGY
M9[N4_"=,R3_;I>1W*?DM58H!/CPF "<S5H6PS_!81:!C3G5%8UHBF\'?*YB>
M@-5NT5[EW:##8P2$5UN:[5?8'^M1\I:+835#]X=[OL3;)*>70:',&<JD7SS1
M2"3=*+K^ZVZT&W;#Y17_%3HO?X*!'W^9D7/7XGO1L#CBL.)1;I#<6@9+\#=1
M#NV.-L:^5V=S=QC=6/_GXHT>P="-E6R"P:&B8L^PDN;&BM L*"Y"&5D]%_Y-
M1"<S2^ X%RIS1,$";<)X. C+*0^KU_"8$5^Q80T4X43E7, :!*4ZZ[H:UX5H
M"?WN'MWYLWF?[A%'C1$V-H$>!23@BD?!E7R>@U'FPQ$6JX#(S)6/OMW,9@?\
MYG0OS/47=._V>2"H4)'@ZZ9):H_>W80[?[KNTTV(TG)R&:0;C:27'9<^"C.O
M&!RS.X!W?E/OTP'T'(@8X:!]B4'90W0$!RL%)W<0\Q4J*N,68K4;:STC3C4,
MY&9>-4Y%^L)!%NR^!FXPHFPX(T>L.YS1ZY<G!X.ZQ]U5N_O']SY=-85E\_A<
M9:WE,C;QFK[JENM6(\"Y_"X$Y9>S(*K6:_1,(!?<D8#K;]FD83]":/5Y*(Q<
MS86+P0!O9?W/5;OFVP-BHT5>S58U<P-(']M!)CNGZTYKDK<1_#L8A@-E5^4[
M-#%#IC!?"7;/C\>&D]\\H-) ^VY 4H[+]1^353O:7=F[?@WNTY6=-&TK+"Z9
M6F<+UW)/Z1ZW7N%A4$#1$F'ISN85GB%#D?I7NJPVZV!Y76=J6D?2X48P2 W\
M7K7< _I^H52]#',6JA7A6QNO!W>7?T&BB91T>E4VQI\2=HLQK(?!I])<%B-Z
M_DY9WOG3?)]N'NA$,+:8\XYOG/*D]FO<,A+^>J3S>5%/A-%26LKH&8^OG2@*
M/,:!N+3<+7=7S5IXD)WH;H3<NYE644@7M.LN;'>'&_LM/MA=A+M^N.[310C9
MMC#&B''+AP6&)]$Q[2P9/!,P<\7=L<:;%8@?0]4E8>>;Z+H"UVX+9]=V&TUQ
M CO6P2_#.K@US%]L[649M:+[ ,AOHY'EQ1L[B<QQI/6I3##%;+'X=T!N:3!W
MUU?39R>BSGE!7D2E-F.9W3Q<NH3^:R,GDH75;OGD73['?R8QB1]SF%=J#C&D
MK6AI.811"7384H1O:^1B$ABT8%B9:>ZM+((@\:S<9#OEX"+GAW PI@G<N47>
M<:_D$MA(_>R2QBJTW%4(D\,3^+/.^EA&R A46H$4W!CL-#6D!FV45XH+!E9+
MM!64[4&8Y<9<5AB_#+?:RL/,=[QIRQWO@NRYE']%],&)W[%@&SM#B@[.[B@]
M&7(+ /,WZ%_GJ?FZ"6WJJA)/>57[?WK*5[02M\XE(6MQKQ@3][T87HYFO2V*
MZNLA;2N.1]QT V3-S\&V^/#I ]=)EKM@B-. 8-<8YU%D?<*F#/<GM9>SZTZ2
M_EHJ,;4>!1ST/693%7VOO+.HA:3OZC>N<S5NXB\$@3WQVU<<M&/8HS\*R8:I
MQ6&VM3MP7EVAAM%FR-5A3,DYHUEV*X08'"I^4JT<V5@MD8Y@DA,N*>SZD/K0
M140B@##C+J\*'Q 1RX[>A>5W)6-#D/(H_7L1%(7;1)0'C'_'S%OB%^F2S%98
M@>3_9^]=F]PVLBW1[_@5B)ES)J0(JJR'[;:/[ST1U26YK6[;TI'LZ9E/-T B
M2:(% FP\JL3^]7>O_<A,@&1)]I%*I(R81UM%$LC'SIW[N=;Q0Q)C_WK,,=:?
M(^UZ8&R':YX,>H-M8&\PMR0?[5) '2^2X\B1",3056]MS5@C</TJ>Z8T)''/
MOWB>?@C[T)%Q[\V9WY*?S55OL/SSILYB<NX8/YH-MV@WMX"]:6_MOKR!%B_*
M?9,@,@<B)O!1Z7_G0<D1=\B:P@G"=S0FI GV!,P;MH)?8:BF.'9J<@04D#:3
M$&'[ 2O^ID*^J9!O*N3['6,UVX,'J.;%+!W9&S/AF9EQO+^R Z]-*" +8IXX
MMAC)D"@#&<T4?3QY 3@O88U:;GB4X,. B<F%=,A1Y7FCJ>O<+1U#:B+<(C([
MB>/);_$YB>."'EEO7,,#C&'96C'(@7/"^#H@?M](OYY;]A5 O"7:/6/SK3)L
M_-85_^J;/>3@26Q/7A3.26P5J-N7>09&#<3=&L:UD!;+5N6RJSO\;=UW0#&,
M2I#H\TDX3W[#STDXH2!;DTV^Q<MLQ]'=WM,ZM@I*X3UF*R438EPKG>-H=T5O
M]@CLGOQSJAR>Y/?CC-6(64R$%0<7D1D$>[*R<5D.S!I7">NURR<)//E=/2<)
M9 VJ]8SD$0FU.OE)#*49(R -3$S2C9,8GOK6GI,8+IH"R!PBAR1FK5MP"G<J
M,_CT4 "7.1_1UC!S7EI+RP7@ #SYG.6OR9Q2[#N'=L38\-*:+R2,%R7M,4/
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MLD.SD/%*R'-GT?50-I,J-V5P_"7K#%!S?:-818.WP@_63BS&&.(W<R0R]"(
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M\H!W7V;BK*//ENRTJL: /EK5^NEGX#]5!\JSZKIH:KV2DM!T\JS4 B5L/>A
M+2H;>BTT^$[B2J:O,*?@1OI7UN1T?WO/?-@6$O6E:,1HV SQ"\QNILWA4 'H
M9,G\![6X5L^DEZ3EA]]*+]NV)GLU=)D-?_%3AN#"!NV;H<-?OCB8/KR+3B,!
MET*WH?9O\F*QZ+?V/&6#X(8-#5E%M35XM/A 6" -[(,>%(LR@+H?XO!C.#?T
MBYO!)3T31P1SG25MQUPR0@DGT/1%R\^W7?)4&9=H,@,C)<V;Z5W95*CJD*;B
M]FZX+;QT1C7B!@M2BCR<=>G\69[*'CD^\BQ?#=JXAGC/TD7%4JQ?]['5]!+L
MM:;9GSV+HJ WUI@[$!A/H60=59PU4]LQ&1;VP9KF'%!$E=8N:  8XK-?TY^>
MOF(=<N;;\%G(TO.*-2A)P&RO-TAL!6'YX,3ST&JPGK5(V[UT#8=/*@8;CS19
MB2!.7M]P+NNRJL@8>&XZ324BN1KQC'3,]SU0B&Q-D.7.?VP+S^QE##C9<EF\
ME4C1,[;5TX@ 9>8+AD7[<N4G&2!,0NG4M'=YPL7*I2<DIZ6Y2'\90HB,*5%^
MZW)HZEAF+I:@=&9S"U>Q6C/QY]YL#FS1/ND2Q]!6M<"%X/6<IVE;U[9\AW*+
M>LXWAZP#,U.W0YY=O!2MG,E>RYA$AX 9HM>Z]39?XI:6["5,W:9HW^P-]]X5
M?D1;SZN&R\9EK5#&+'NI7);<! _,&$+AO9$+>7^6%&842QK9[^-@'>1:;=N>
M03>>79$VI+$V7DE>A67QU'T9S.CE@VB9//.*_S+]!?,V<4I^S\[/WKTM(>C:
M*6UP@Y9P'7S&EC ;4_,Z)\_$\TPQ"7(P7^)N>ZYFN&+? Z^Z]-R3W/0!"5>[
M?:?9$V$".S3.=D1$*3V'I0-,0O).@>/:B7C\BM^0D?O<:5%QQNR;+(#("XK\
M:,8G\Q*"S__99YR.:W<D(1MK<4D&QI&L@F=21P6'9 M#"<I(2*518SA*EB;H
M'CJ(5Q)H74 /#*7)-Q/"1P2LP[(':SM\G[!][]K] *8[$O;]H?JC.)#^$)$-
MK_I=LJH=./%\;>4M,G[+9.B8*ZU:NW="#RHWH_?>(U@"AQ:L4XFZP!E0I.%6
M&/ R/YS;SOI%^G.TI< 58FTY9V K #=T(4<=#@1]3W,-_FOJF_ SXN-R:#?;
M8S!FHFPY5N:W1N]!B)^V$82[-QMXQ.!GCEI2JN'$I'0^]+!'\XN&*[=K?+ 3
MWFXHS]RAP?@=DNK1510 R:[+7Z?6\M^!0_ED*G7_@*7N3Z92]Y,\"I\FDMLF
MF6$)I4W/+ K>EM=[8FCF'>+XDRMU:&__GEO57SML>Q[.KJA=Y0*A-H9HZ6&&
M.]0NL%#YXE^\C5X\9(9HTUQL[0J?PS3QV%[TQ;YU%^EK[8T4T*EL9%=CY'M(
MBIU'@TR18W;7N!FZB/<T'M!@ !&X6"(#")RS>"I*>RJ?W&N=8W4&QT*SVHK0
M%4BO\/<&N>^JV) $Y!YB:RNJ\&9-]^&- SYC/F >LB*=1(W\0X.?A=%Q*Y^D
M^KC\6V M>:FCR5K+I0A5M$[WW,7J8N;#)5SH:D!G&%*C*(K)4NK*[RO*!F^Y
MF"EM7\B4#!%3K;7HIAX(&F,:QA(TPA 3_]/0T^X]NN^_G;1=SV9%L$Q5/NUX
M" N$O!DB?>_Q_;1= %*$VVS)1D?;'FP$@6;3[(C]_(8[27%$2-[=P*>V9^IW
M$QUL)(-<&G+OR7VR?9!#LQG:F'D+#@U%K'PSAN+C93\-[C]CD7%BEM<^R1VM
M5>D&+;^AB%X<"%1@P V-L$:B2(;P6Q6H!8R98,W^7'A7+8;S\1XI>VH)=]V;
M_XM!TV^S-X[181:QJ1[>2N:?QADRH$$57#,)C#U?=YQ%[WY&ZFC1PF\DO=@Y
MDS"S[F4O$L0*JQ8/VB=LGRS!$Y@$ #0TT$3.D^/&:2Z/8#EIO>LQ#!VG3QF8
M OOZ[9,OOGS\Q;-G5Q?IKU59O'$*82'519K)4%WC"W#9?U6OU?(LB:4*]WRL
MF8IJ!-+3!J",4'PV2P7AT@)Y_'1GF+UYO;7+,@YI\%OCRF!$/+EN%EG9, BY
M+"+03:[.+;D6N//.F ?.BP"IAUAJ>]8#W_"#^;**T%UY1X&%4V1IW"J6Z\D:
M[C;9PJU;R#7 BHXV@0ZWW))!-2T;,H\YZYHMFKIM_?)'OFD2FSH"^-PJDC'9
M[.1U,O1!,#*T9H$VOW2Q+5)457VM <%?0H23#7L3B9@%F?[O3Z0F'W\]2Q\_
M?/QH)FB:83U:79"/!L]T-XG?J3UTK\OR5$OM/N(@SZ?(CFPK5ZWH &I3'2NY
MGDO@*K8O<-8]['NE 3Z&<5' "@%*'+&5X/_CK N#JEC5[XD6P9^F@/Y1)3*Z
M#WF,9'8R E<HMV-!'/CG%KE%@Q!]7G#WCE6A=Q[][T&_-:-$,PJS6]PXE7HI
M<2RY1W)P "9IGJ3YG6/E'NUK%Y0KV,2<;Y/?MR&[-7<PF\W+_10[5,X5/C=$
M)NL#1@@/B)[VL\!-@EA!YY.VFD.81'82V7>;!$[+W+D3$&9SHY$DQ)>4O8"Q
M[@U.=C9J5EZZMF4_T =4TVU/.GTA\1X$'AJWUF!"W(<3U7 $J\&0!\5]G41X
M$N'?;-6*16O&P+#VPTK_X0$_X%J6$*ZTTDU.L9+@^XJ;:D!QLW:+-XCH(4+6
M,"#E4E@SU  6Z\'HG8,%,5'X??+RRJN:^9 0*PH%EL+U<CE@%1D#Y!\*_PP!
MLH=J+HX@(X]1*$K)**6?F,*\-3*\%V(JVNBIF;9@<J!<99&C+5Q?L?!5'CS3
MYYV%KEOC:D*G\Z&Z-PWQ_);R-TY3!5[+@9=XQS'CQX]XRZ<3<*PHE%5C:#XQ
M %@A7QB7E3.H@"#?# $6!Z+I \+[H=DH[/SXX<.OOWCTZ,LOGETE2GS&[6I%
M6[HLMZ% (C-!K(R'*;FZP<.^^N+QM_0L9ARK&'@VI@X+W5QQ2RR'9$/X.NJ?
M0YXP=*$-IR>Y(DO-WKIX>[5G!TN/HA<G'EK(8/$9=5F:")CB)O,<9MB9B(G,
M!N*&6^;#[ 8\I0=9;+,14=UU70+JH]DA>(W9^*V\JG/11%>:4S-S<-47 $NH
M0J3H_<7IX)"T$<]:)Y(#LS["#L(ZZYA1.L!158TJ%L)P/V_;OR1*&BZ,F8KA
M@C@;C3K, <BJUK]"[!B$U0-X :'UH]+!37?_L;O_*;DTR4LTURYV:73[<]>3
M)(U+(]3 =O7272/0\:$CE:LTCN:0)7^.KVQ#2]&AUN6$LUI'2A.]'T6'T>Y?
M##_N4XH:1*S=XR]/7[ZR?@])T^ O#) %.JL ]6#9F:]FR>.'C[ZQO"%-T/GW
MCM_G=6[TY,/)/*P.8 D&R;J ==9Z9J&X!2!A;D;2^96O=+2$M-\!*6]0[>C#
MUAIF8<R&P8;Q-B"R$LRH04]O'5E[6D>L%ED  F-&3O),4>2@1E[<*M$<*/[G
ME1D7U'IU>E V;("7L9V7^&5&$1.#T_O><&XEX+KCA7G26CW$-[-RN7"Z'I7#
MH4N.56]9 T2=YP+V5M6?;;]%_WH+FS4R0F<),VW^@Q:-;U3,-B\,?T++#F)D
M>.''5;"U$5#@]9XFQ@0OTN_?;XE1Q<,K(BRR>#1CJ,DEM%1,[,=,7,CDA>B/
MXM9\^>3+?[?7=C6ZW&[JILQOF"67X4)2L# PG:XOL'+DRO'PBXJL6"P \+:U
M/!]RC$,@Q+"S"$1D=!UX@9HJ)WY'#>V74PWM!ZRA_7*JH?U0)H6-^^Q;'B-B
MW%LX<8V44"P$<2%]%1FK?2XVXG:<EV;JX\_";O<K&53*?G [5RZ9X2[10D1P
MQ8;*NF,TNH&*M,A65=T6[<PH-Y7:@4EV[4%EL70/NC7^Y"K#SETW=24%LO1>
M]JXR+BJ*JFD#]2[:UP)7[E(BV[28?.L8VY"/8O,J]94!*P:P+.:3((\)@2;<
MNT+.S>G(0Q-)!A/QG#)6:TCK<,_H@,8TNMD \]2P!CW?A\S,Y??'_+3Q[L#4
M%<+69$!!^SMW(=O;!Z:;0;O\: \47(<;Z=FRD;T*6Z/-A:X*)61DZ.&]UXJ/
M48!B#D5N<(@A/HK\H_6[$,2P77[5VAZ<CH766.IAU.HTV*89UVM&B%HQO;%O
M[.(#H:LU&0 G, F+@_TZ.ZJ)?(];E@I0$^U_L &#<'G8F 9$+Q8^ )DS8U Z
MYRF8!*XM8CF6(&D2\P6'$Q8U'>[)D.<PMLI=AF R6 X>B!0YML5;HX<1.3\V
MVT53,#A$HB0W95VMT!C@NMACNA&Z;SY,[1HU_+ZD/V)W#F>&CAHB,5K0#I49
M':)-QFK#VADT8NP&U\U9"]EG<5+4*M@3&*L+AG=&V@]Q#,D\D <*>T AZ..2
MT.409<V+\(OWIVU/8MIV 5P%B)#R^>:][_L9U!T'3O?T$*?[)&<G, E GQB.
M9U8F5T6SZ#= U:0=^N+*KGF  )G<L#&JLK.O(6/SA)MM*M)E/JJ+TG(/8^1H
MH@4SS@*C^E<O'XF EKHPK'01#POOT *',+P@UC;0]%V/*08HK&CED$EY/ (.
MG;7"0\&-3N%@56K8V$\M-C],1DH@3'O/H)PS!3C2ZC<9X5[OEC:/&<!^(K %
M>7R>0Z-*= %X<[! JS@'M+A('+D-H5_SUT:8AN)U@,RBQG1D:QBO1I%:96K)
M<&K6)363E=&83>M!G[F\/?0)!0I!KUT"@-OA(A6C(.&WYZQT\*I$KD&5J!*+
M"!K$A=" :"C9J.W\TR[26)8C;3CH%CHF$7MBWLZ2_;\)*^-1.YIM[C1V?O*B
M!66HP&#N/TX6@*4/@=V-:P0AJRVZ7F/9C&C M9A.H+X6-?D:\$<TLR.O:]]O
M^MH,9H:0"NX\:PLAH.<F)4%?4-F&$Y84K8IPN;.@(8]8:% [8)*X[J BD/:\
M ,M!%QJ[FS)VB?O/O C(U5*T"("(%S7/I ZZ:!/KOC*?(_8XA@+/&=4(XL:.
MKE4#!&D<M?=Q;N+ +.R!R[Y<TG^Z?,HQW>T=%LEV<LO1CFM&#(?4F$NC;D,/
MS 7#A3M>!=!Z,E=.8!*(ER'.'U41*7SBWY59EDF"PDY72,0@?*'(HK,(X3B"
MVXR10?GNV(!3HF%*5"8>1;N78/+:+1U7*B%<%54\#"']0M()2>G&*6*C+P,*
MJ((9=X4%0,>Z&7#SA ]H@FK%7&#BVAC;-TD<:Q*XP5%FAR=W*"]*.OQ&^:8#
M!LDD\R<P"9+Y(.VX\I^W3>9*'Q7V]ZS'F;)[JP-!E<!*K1$)]I'1UV:BR:-F
MAHT_4IKL;)+(BLLYZ&AGH]1)0_/"AZ(A4U9;LA$.;XOT%4I)IO1+P8#=;S&'
M-[M8.W"(Y*J-?:O\3$(^8F4D@4+K+Z$H!F:89[CYA0%1\4:)A;^V1&W<6+OM
MF[;/JLY2T[(J1?I2#!&%''T5T]^,7I#LO>#^@*N'D[!=(6PJ^-]!SC+8G%%A
MDG6]QV=4)WZXR3U:8;H(WVMOHM(L&6$T^9\DC\K=$S^H*2;.%%.X&-5V[%+-
M8HMN0:8M\L9X9P=3U*!I5=262,M)*97LD56? =@XB+#^:E@*/)R_2MC^@(W5
M(N&B3<>H"N-UD:J*P=KMRS4.PI&V8H$4$?,1,/C,,<9A&0' \#F3Q$S26A 7
M&C(Q\[#L=$O8G94[L-H#M*T >(;JF4);RQFN0Q>:(S15P7E$>2[Y/"1+D?G.
M!]_7)\SBPM=H<MJBK(/-2<PR87.S<@GW%LP8/M' =1!M[,M:XMYXUK@L-8@7
M+P]3VBV8XD<$-GA[9'RMM:/90!F:UN.MC#7:1?JZX)I9CP_"  Q-+ Y[>J4.
M4BME<1A$DVU=#_&D*S,O<H:K]RJ6L5NS@""8QX / Q'TV_B^*I'K="*I"^@3
M-Y9=BU4Z:O .G E>KDT-5%$XDK/W.<73G?X[*B&^FBHA/F EQ%=3)<2'L0SG
M?MSSCUT)\8''?54WI*])W28_% !9WYW9%#X+S^+O+KGAS"(9$KH=;#=<;INB
M3!]_"0R11U]=I"^J]*\]F2./O^*_?#OC^X@Y>V_H;A>^";ZO_NQV-1@LBV9&
MKLGB0BZDR^>_, BGWK6M?#;M]IWOMC38^49]R2W7B"V K"SGN$*1%XQ?_=$0
M8NYH?R:(F/.$B/GHPO+@+'IK19/R\,"_\F.77_A^@S]?\K\CHMU8@7OWQ=H-
M'K'6?G2BO(&G*I03F^'QH4[2\XFWY"QUV&6/OHRRR-*7W8XUV&S/]'SJ%LQR
MFC[ZD]B:S&]B/YQ4V"EM[UD/=9*>287]=A7V'(EB<G!_1(LTLE%C_?53UBS6
M*?O)CQ^R*2:_F#37*>WJ60]UDIZ3VY*3'>K?!=:+XS[??'/Q^-\C5GJK]/"A
M(&Z]V/W')&LGM(%G/=1)>B8;ZSU&^=<Z7SMT]&& /]1EOJC31]^\R\:2],3C
M)[&1A7(H35[0)S-F'KD]39'>^_G%?7L5?L^#T#<\Q#N./>-GUS?USR]>LR,[
M2?T)R=-9#W62GI/;DI,=JJD@'B!G"-9::O6;\GN3U'WZK3SKH4[2,]EYOT-=
M^2K+PP;>H\=LX'TY2=H)[>%9#W62GDE/O8^>,ATE$(7/J\5^A<53<CAO4!I.
MZNJO6=63^TJ_9H7UU21R)[299SW427HFA?7;DY17NVW3M\?C9R\67<TE%D^$
M)!#Z3'XSQ;%.:5O/>JB3])S<EISL4 =9RH=3CO+,MN^LASI)SV1B_783Z\^N
MV?1Y=MS&NNQ7:*N.32S]#2<I7[MM)W6N].GC=R8JK]!>[]\J\3--64ZR?$)2
M<M9#G:3GY+;D9(=ZNSJ<TI#GNJ]G/=1)>B93[CU&^7\NG[_BP6F7Y(_=+3&R
MR'[SL%N3Q)W,7I[U4"?IF?35;[.UU _T><F+H[43W#WY^'&<JKPS&N2[PD4\
M'WR*::AAJ %IZ2,MQ?P_7SE@5:6_;AG/39"%[A2S98C+=)>O?F$%\*( OF8(
M.Y#I 6TPR=*;!K!TE?)A*Z+\/?AJBBWQ<PT06X.6"(!R/V=MGOV3/#R!%/VO
MGD9C#VA)QP#XC[EXXH<=_G82ONW?P^/9X;N]0B8:U."3ATRHZ!8],_K-^Q8H
MGVV:9SLC8)F[[@9\3-^[><.5&(_%;/L:^.=UOUKKFGQM:\)P>O5F4U=)V]6+
M-^2PYD(M!7(403G-4C );OI-NBAKIM:=%Z#6+80WY=\>70CC5-JN!Q"!&#>@
M?8NJIW^5A8=@U16,P4:'BYJ\ZDN7?O755P_O9??O/;X_6,H_T\M?\LOQK< V
M^O=U4;J(P1-CZ79;!<?/EDM U& VC[YY^(#^Z*H\:WCQ(NYQ74>/%9QX%LCA
M:X7>0T0D92#EG#=K=LNL4IG5-X\>WEO<O_?D_KW+^_>*Z_LLF(P^A74?<$%D
M53RX1 >G6-U2?O/.5Z1Y[PS.%1C-(E,WCG?:*>D6K0I8L@ T*6+0TCL[IGA7
M3,Z"AE-7[@'(?'0@C+@\>LJC!S3N!X\?'GX<T+-H+QY)P\I7%W>K$3ZNOCW\
MSE\.2HGQUI&D[CPT*PYV8VS293FB.0>F;QMH3'7;^XJY"*+',::N\@\X )5F
MH ]H^-0*/TZDPWZ03]KT95:1_X=3EN@IX[]XI33?J>+0K?OZ(KU<D+D%]"AP
MM'FH- WSB[8=#H7EX\!8Y-U@$=^"_]=@F9=+OS(& YL)&O!ER^+*W*M&IBIO
MLJ?K&V=\@-J^!3.L\K^%=53B6C[@X([0A0X:4647B0C:NQW=&O2<W'C5BA;'
M7%1@N$UR.IIM!$4LDPO1/P:BU5$:^P_C[MH?^6T>\YD9#;-=M.POJH2)D[]1
MO1Y=:C0,__K2 ;4]7%HR#B:T8"5,D]1%>I>:GAVB"PC@[T(2[*4%^Q5&@<E@
MG09D8D$(UJ[,/333ER8XT$X>$]ND6BE5H/.Z=J"PRPP,*4F6YPV. N>/ZNI!
M])4C*OP/H'U>CN"\!]N4V#;Q667LX]R1V#-EL$O?O8"IG"@]RJS9GSPR.7T>
M8*K?>2<F=&%]=2^_?^]+7%AR'^YKP"Q]6K2+QC$T-9DV(M(_U571@><.UZ5=
MWT UKAP3SX4CD!LXM<E4XU8DR[$T';OM:3K+Z!C1J]YM_7GLZG9/Y3.?=\O*
MR8X;<,-S<"'DPJ' 5'EZW:8;F2/K#)X@6Q_5X)&\8# @YFS$,.9RS%J$Q<%1
MH:49[VRD_/"DW EYWF*7*&)W 6H>&5AZ^\ NTE<,7RWFT;L7B4<-OM4MJ/I8
M50R4::3W$W\)LO:*;LO8..2+ XZ^OOII_(A@*^IVVN)Y*B;3B4K6IK?+Z*')
MX*%[6^'5X/ 6\0*-VX@-42A*$NAB'L"^;QW^'T!A_1)MBF!_,V\'KNIKNN 3
M%3BA8XJ=$*C]*UGOU[S>0NH!+R95=OBQ,E-%-#Z![4=;YL&2_L%C'W_,H<[_
M\_*:5#_BC,GS@/D_(3Y_$@S@)>(%#BQY@7?;:X?7X7Y1$G*N11*V\;8=!XM>
M/[ORSA*N)^'*(@T$+@9F7/@>W R/'C[XVRS]9T_WGVO8->+/D^CS_Q+ZC[YI
M<$&.'_ -?L\<HN!3P1VJE$W""D?643TTMUXK;<6C)_>R^[!<V-*RF\U/ZW+1
M721,H/2&;F 34K;P:#8W;MX6X(JB&_OFYF+.<?BL:"XJ1_Y#XU@%TY.:E9N1
MKMTRR02_@6E;> K, M/68,IN8Y)%98OBUV5+6I;D9F]7>*>,C<J!]($WBJD0
MEWU3%>TZ92YQL3MH,\@0T97#;_-H7Y]=&>VFT9K)I,B@N%C5U\:"X@]GP@1^
MH.P@]X(C,Q9*L\<Q?TVT2H78$J-&*0Q.>3254K8ELPQQ,EA#RAA;\'B9U^/[
MOA%+2GRU)7T5S#*)FO*_OOK1DY"TSM[=#CGIC0E%[D\^42*5]C3:X(_/YW9V
MNN<#ZWRF0TJNLFT!$K1)V=^]LK]LP;\D"4%S46<6 _WJR]21=5COP)B^*NLY
M5,X,K*S083=K<A\Y.KOLR_(! DWAZQ?IS_ SA40G>HJ$P4/,8KXCKX8T:MTD
M?05M#$5PX[P2&/Q<*?@" >.JKC\>D^:9<M5\&BKRGBZGNGE#:I>Y5M-UL5K3
M]02Z>];R0F#(@>]9(#&:DSOGKOD'Q0:7$JYFJ&X)-5KDC>XW7#%,EI:6+N-(
M8U%5]34(Q,U#5,;5)"</=>&4P98C\2(_]-NJYWIJ\ YS*&?%A%D0)::WXINV
M%[^JZW#[SDCD$-:3"\I5*Q"\8'"=RS;T1CR.9)VFKR1:"]%E"0DX?8WO$0[3
MT-1!&K4H^]P)ZYLG=)NEH$G6U!9>N&CZHM/_QLOY/Y7,"U^\+OYED<H-LT5Q
MP(!'9!>N\4#-DHA@.;#)1>>1"=4J1(Q!QR5W//F.%?BY2MA+V[H5FX5/XC][
ML+'QKS*8%CHBB39J9FEO]9A0;%/3]Y@QC):LKCBR'9D+(0"[E+C @WG6JN#@
M5?I/N*NN:B6^@)*%O)T-B(19[GFL1A<LDT0 /_Q%I\,O6M=E#AI/-83J]I#:
M&BW3'Y>]][VHL+Z>J+ ^(!76UQ,5UH<R.,^5"DL>5N3_[__(_K^'#Y_XV,[S
M7Y[]E#RZ))_N^>N_I=]?7OWRXM7K,YO>^3DNQ7\^KZZ%99)]X'%>M*BNZQ(7
M?L9V4)J[E48"0,QYD?[?ND_;==V7>;!S%W1UPH[>102>(0A.AE)]0VYPO7)\
M@7NGG>_S)&;)5",C%Z+FR-&>[X)[*S83F5V7$HV1D !'_Q%@UAA(R$S*>&J0
M<XK;;24VH*NNL@ILK8E/?<XT!RWW+-WW:K3C%A72:+KNZQN:PK:I.<."E "6
M8^Y\'*,4,R/+V6B4.A6NI> ,FOCV(V99W/%B]H7P]][FR(MR!Q/)D>DF!M$U
MQXNL "2O)1(AH28>B;&VIAQ8D*^%SW/G-F3"VM@3Q%&89EP&/5HR/^MH]4+B
M6 /T!Q;P(@6?\QF=E(][M#^\L01-6_SG*PA[\LIBAS6;]]_[C7I9MV&?+';Q
M2DJ[..PHFS3IX'TG=$YV'IW\OLIAF=7-?\ 5[-R'WT+XHW!V.:'(P>)5T782
M4Q3"[FQ!BD \CF71;'QJ4F*R['QR"CP#KS&<&[B:.T0D,W)5MFM1 O01:BMH
MA.A7@V\ "<GK?MZEV;SNNX1#WG,EL:Z]4RN^K(;(5S6&01\M7%,99=<=2=&=
M;,HGBW'<R>S(94XL-8NN1KIU<3% B>,_L+?(!I1UR_S+<D%+O8_]G:M%GWQY
M\22E(93,%JVY7*XFD)CU.$K'!9W*./UO7WYS\57ROC_^RESBO<Q\=%LSU :N
M0:V3R'FT6]9^UT[\_R79!ZT%8,+;DN%0C:8>199UTPY8TNE?35:T[M@!.CC*
MHP=J>)*27P[6'O /-(*P]R/$HH+>Z+>PJ+K!&X6I&X&, TO!-35#DP=Y":[)
M<#$]O0\/+:.@RA=<AD=35[, V8ZGKMT6P_H</Q=.9W R:]DCN!/>:Z&5\.QD
M^. T:QKDM_C&FDF&3#(PM"AMWW!% .LXSBZ%WUFYQB 5AEJ,EC-!6W'3-1>C
M YZ!I1X%,V7Y*<*UDX[[( '>^$+-2(/A+(N6\#['T=M25$31R _UEIV%'Q[T
M1T;)852E<5UM\M_0":2*Z#7#(P_OAE.?D>]1HDT]'=W>HJG"*4YP[-I!'#,N
M?JUH>?G4U3YR6C?\HK%7(Z6Z?(A8Y4B$G$^>1I0M->N/G:5C=7C0,O6<2U#;
M?BEU:O%QA[*+CB>_2EPAWL$LY(]U;%J[GM:'2[@.."[>[4L&7HO$KGU/AG=^
M)DUPEK.+K9VB]05H4EHAY6)Q:H5.4;'2^M)6 QL7Z0_U#;H@[-Y9T-CF[L#=
M(S]RZ%#I6E\3>>TL);3LR\0<\KV:SVRQENQ2UX;$?Y!;LC;DZ,A)0N5I+^F+
M\' <4"V?EJ'L*XX6)S-Y1]3BX!$Z$$.)#],M80 )/T']CL)(K!EC2TI&B$?U
ME9:H<^5.46'AJ\YLMV-CLQKFP@)>QWX0JDZG<WTJ7KWXPC_W&T<+TR;>_ X>
M"-]8E7DI2+W16+@@N0H.B^3L2W>MA5.X%*-C9,E9B'W%-QP*!,1JE#=&%TV2
MI7G1TAG&_8X[%%5!)$ERT7"8C-,/*4?GIDC*ITOG1V8/;5 I2>8XCFF*GJ^!
MJ!NA4GE3W<.Z>1<BWK!A!!5[:<IED[UACZ12-:-= M*#P5X<K"YM Y0R>U0(
M\N-OV*UTYF+*'T.B?>!H8BC_<>:R%+*@<=9SG!7]S9,:)$6/)D__Q^^$HOC]
MJ!-^9 \O'K.>/R.PD(/YX[N>SK=?_^G;CSF?CSR!&X%]Q>'/K,(GU0H?=BN*
M>KO.F@VI@)X'IVW.6J_,B@*%:-\_O?SBZMF#;,OF(]HCZKPG?<6WECA[S@=0
MT(!7M.S!FB_&H^C8/H7J&^9SS >6J-_^%4I_8H^0BU+@@UGVP/]&(H$<1^I;
M<8?#6-C$9M.*1_'.R"#W76*B;PN8I;0"__;HFXM'%EKD-M%C17]P!=E3[#>]
MY#^DZ:G;>RB/Y=^>//KVXFL?M-3BO2A;I@L@Z38U'Y=%BXVBM_Z)?T'_\<V'
M@DSZ[VB:<U<MT_A_X_@G.3O-??I\[JR^LFCXML'E)>8KO9Z-Z:550ZB6),5^
M@Y;)T.5+EQG*,>ME(7:?%$%J2*[-2NFQYRYPOL_B0#L/XMDU/8_^=J,A$[E;
MH'_-_4-QA&O@RA7_DJ2(5DT<O"NCA] M[,IZ*Y9[/GB.E:?J+WDD=!_F!8/M
M2%=UMJ,[#R@:/I\"8(RJUPA,RZ%,FSJ[(M/9/7G1__S&/\G9:>[3YW%'L,']
M+B=E9G:U>RMH!%I^)L &3@H QJDIS@A'>#(W$F6W1]1ZN? HH@N&\]>X6'R-
MO ZBG4[%R0O5YS?^2<Y.<Y\^#^T+"WWMLNN"*W@'-3^21Y/,QFWVL/UWL&[3
M>Y*\EW;C]#IK"@3#R9Y=B5*UWBPSH!'MOC^3 6GS8U9%=5=LW^_G17%;I Q0
MA2JP3('Q'+J?&K="\ ;QJZSOUG6,G9:AI%N;W)!LQ."7TE#M1R;!+J0S)ZU_
M^L+\^8U_DK/3W*?/1^MK$8/B#$HD1G1@%-50ZW?;%*X#K-K/+QAFBX:^2]M=
MV[G-3"LKQ*KF8'F9[4S3^AH037 K'",*V# .O58 U&W-K78SB.Z5Y 3?.I,F
M/@<!^_S&/\G9:>[3YZ&)-\5JS;",(4RNZO>072UAC[BP+X2<O:U.BCTSS%N)
M2K?= ZED1:4^#:YBY"!N^6LF63]Y4?G\QC_)V6GNTYGK5+(E)<\&A)1.FC.0
M9#.-*J$"GZ)S/K";+C.T1G)K B+%@^IG4KI5VD_&Y^GO_^<W_DG.3G.?SEQ1
MSMTBZUNQ0%O45QA3 D ZNW2;==PZM:VWO:'-'8L U\TA0Q4!AG:3E66 CT?1
MLUJX _5JR%^2AI,WJ]^O-FXVJ"=4= NADT%WC7+1# LE^ &"L#$=J).7Q\]O
M_).<G>8^G;GBUJA!X[A< OW"C4 $:ZOAVI5;G].2X*WS(=6VZ_,"3S\49(T#
M">"_0IR@1_,2,SM,LGWRHO'YC7^2L]/<IS/7H<62QWOC1N7)"AW 0*UF4X:P
M*;JG2P#/ YL!*3$:.1KP5NNN]7B]G5NLJ[JL5ZQF#]G*!MU?2Z1"BY_W+>A0
M(%P/3&<);;@P,%C0E0+APC!NO\,,IF-TZE+X^8U_DK/3W*<S5]<6U%55:5DN
M*5;C;!=39'#)VABKAJ&W!<?ZK3'C<@M'0 0'9G@K10S[J-UIC-HM%0M<(?%/
MX2R#:C<D[[NF#9\:]D>3^+/&M#24-6K!WX?_R-JV)G>G,_X7NX.CDL2]IIZL
M,T;$H>F 9M%&^DRUR2D)E2X,![$!TB(CG;T%>+OSG4Z<B"V6 U[#\%@)@ TB
M6XQ0JR/P;,H,;'NHXA&82"2CP,8U_X\3Q%HD+R!EP'OW]3L\' 6EX9YC9OWC
MFAXM&2+GL2LRW\'+]&DN;IL:^Y>U@++$*UM[E-VHP'Y@_\BIU<42](RB6H ;
MR/VQL><_V-B&H[H-S/Y/$YC]!P2S_],$9G^29^N.P(C^#B;9\I:V)8.[0W+#
MN1'B3!.A+)M"%M-H9MVI 3 /C\8-I,!YJ 0J&9XH+X"/UY==P,R;J3)G:/"B
M[#L/[IW&'"&*=I76-Q7]:UUL \G(A%7T";&*U#SV.Q^+"8N;&,R(&F^$9?@@
M$E8,905Q:6, ^6&/=,#DB!Z2V%4NT0CF[>%>NIGR'[5D$\Q[?@!]==4P>@CC
M_4<X;_LVQ"PJ'5:*GVZAF<O(\A%JWN06LR**<P\BW#;SF<<%5J8D'G9DN0Q6
MEEYTM$S/)8P'Z"Y2-4W3WVN:CHVG@V;IL0QM<KA'YX 5&_$N NAN8Y388KSR
M9 ]H*=H(-@ZS*@:/8<N-ODLR*>N1#+082Z2N)/-3O;N1,V",*GPY9YZ%3VF$
M,.HA/UNO0[4'*=FCHF())8'D0)N!X'3UA)%U\-T31M8=184FC*S?- %2-QGW
M>EO]W_OIQBE^>?([^_F-?Y*ST]RG,U>!!SJ7?5YRW_R;)/+D-_3S&_\D9Z>Y
M3V>N^<"D#2!/,_\BCUV(AVXF!)_SV<W/;_R3G)WF/IVYVC.V$1ZUDHG66Y *
M]-4X+"MM;4VV+?*4?67 RD]">O)[_/F-?Y*ST]RG,U>&V0*YA"@ J'0= *VQ
MK(,4W<0UNI-DGOS&?G[CG^3L-/?IS#6@, B)^M/4;+'A=(>DJH7$B)GCA(5C
MV61MU_3(?[M)0$]^?S^_\4]R=IK[=.:*<!WLP%"G3S_,A.F9PX-OW"YU9"/6
M.S=9@6>PIY_?^"<Y.\U].G/EU[AV6X=*&-\Q6G#OTQ;EEBC)FT3QY'?R\QO_
M)&>GN4]GKO(XV+<SC<<%TX.*\%"N/;7&G\6&?G[CG^3L-/?IS#6?P90,TAX%
M4Z2P&LRV],\%=P*4V4T[M:A_XCZMRVJ7'.B@X7:7W+>WQ+R6VM#B6UL>E$7U
M!@3+;M$KI0T#W$J_'O=-O4_/7E( T39J^,O*MM8.+,$/SYVT6EN+H:(N;ANP
M3D<M874E;V+R>5J^9M-*FQ-ZRJ-1%N1W2)]ZSVV+TJZ6^%;')JM:-)0!:E*[
M%;ED89E=UXTU**&2JZBN7<O(O@+4LS.F>S@W2]>@E9:VH.VWM FT;M<U]R,I
M4(_U=F$X?$YHK#=90V_OV@3%LDJ P7U%\)C"%&;"@LVO%)+H0)B!Y<>W!97G
MH[6G3^?J\"2^EWV P,P2P2LXW _F>0.%>M7E XBEZZPH6=2 B\"2/)"^OF6L
M!J66G?;XCG6GUYOE;I;H%C)Y/)WU>=N!<!TZE7M6 0JCU5'IJ#'6RT)<'25*
MA:/#\ZQZPS]S&$WI5O@-_W>V6* /TG^81.J-KM?X]I4?D+*4K^]UOGI<"VZ:
M%.(Q#)Q;(3$QUL?S"."#VS,7]:H";'E55P\66;OVSX$^7P"&AC6H7/[:4!HK
MX1M1?&XF7>(9<#4J-EP@XG0,=$2F$6.5MT?E@QM %Y/7O9+]F0[&'1^,Y\OD
M&)2=EYY]H\/CR_%5AC!A#W$I>5NUF'!;9E4KH'4X%XLW*8LN"3*3JFI5C5&S
M)@?1ZG  >A<U!@L1=U[S5SWO==L#CZ"0_FJFP&Z%AU5_"+, ^EI. IUV1KVS
M(7QLF?O86_@10&+>C>GRS83I\@$Q7;Z9,%U.\BC<$:8+(W"0^NP;C]))-Z4'
M;UC4I-,RQE P'R-RE5SZ8TVCN5PUCN.4L65"=W1FCAG\P6NNY9F[7<T8& VK
MV*8N9^+()4,?;IGA'SWIK>; >\0:%@<08 _H&53.J'#;9^S2\*_K:E5C3->%
M8>RI(QCIX3L!@#DW??QI0&&JY&<4?P'#Y-$L??SP\9=,H,YH/<!2 \!<6D(B
M&#=(S$3:\""&@B<T;UF;=0(Y[I_YA)_YU6S_H?3 #8B$<SP $MDQE(F\R@O?
M/8BV?$_ 71"E>/SPNTO][5!6^<-'W]WGEM9,1FO/')B[)7[=1.@>D- $^'<P
MLM>%6T98D#6L#L5X6:RSHJ&%35]W.&7ICT5;\ >O:IINEUZ1B;6;&:AZBRE<
MZ4\D^'%XX$9AW"8R\G][]&3VU<.'LX</'_+HY;<\C[G+>. "I\2.9LK6T9:'
M6/6;]!YMQS^4O=[0\-)< &SH":P><"KUZ-^'!RQ(4H^^^G?Z(!&#_LF_@S^C
M9+#!;;;C2QLN!'P*3/G1XW^/_TX.40A/_;6O7/KD(>_^UQ90H8$L0:"$9^J#
M&*<01A[-JBSHL\9MLP(RDH#X0_:\[CNX;KQ/<)<6Q9:&&] 2.UT;^G:]<JPX
M);()/NC%HNE%R$C%Z;-E[69A>GDOD)\VG;I*7BPZ;&GZ)>;PY$O9@2MP2%<[
M#9619I[3:57+\Z@"99H3%<7Y+G9$H3EI #J%T<.3K&U=-YFMIS )VOMDM*NX
M4DF5M+C[<+X];&SE5O*/<)\O:)3TGF;'BBD"'N*=+]JT([N1+]H9Q!KJ2*Y_
M=*LBP #$(<A($MVID<CP>PMZ$62KR(NL4:8'"7U$CAUB7C53F&WAKB,*5D#Q
M5/DD:*<PB0."QE$>#5^W9ML%[?U^PC5CA:NW'RE>Q[)BET1X!,?#@:)5)PM&
M"UR2MU7?0//*I<"Z5F]/CO@LR&\3]QRJS*. 12H[*$:YRI[M34%G=TCX/R#$
MEOR?BV-02:.M?2"H2A,$U_LF,C\8+M>I9I\_XB _8(KYKH#6@Q]K-TDPS8 .
M;0;J4;,(AF[%P4 Q*T-DFDU%6' ?JCSB \OK:0KH'U4B28B4[DH]KDS W!K+
M4.SH"LB=&OO2VP02+(2TYXY\N"7=L(Y978NV=)GF>E@X+>"!X J0SS]D;=@D
ME)^Q4*JIQ>.#Y$A_";D+=4G6ST(L=F01FW[;+78/&E=R^$/,N[NNP=FS:N_"
M\CD[V_RU&,P)1Z]V<=W4@NF9V'0F3[^#(=ZMK2AF'+8]9B9K32KK&6%<T(C/
MO2CFP82G'-%([(:]/T/\]\;AL:WP);#]',<F^'?VSINA43X>WPV'>N>.@9/'
M@9%,@[Q;!<Q,(G_@(GT!9Y.C%IP01*!H2=Y#7#\1Y?!HCD+NBIC/CF-F[Q5/
M$>*)^+L)6PSR V:C\$Y)+I0O6)4]S^DBU9*0F>8;QT#'-"IPO(A+Q3<$UEN;
M8<?CG<5+H?%RNFP6BE9,_]EA8[&8KB(!63!L<M%8T='1Z<YWB$4V"P%IYYP\
M*I69I.->"& B(;0H:S1N)&)#V59(T%9BG.^UPO=9D)JXV,7D4:?'\88J2"N6
MGQ96=\ ?C*3,;F:I*U@>.?15<-8A%*S-=ZD4=$&R^-OX(PDPJ@HDE >O5E7H
MPEA*K"H+^VIAEI UR<9!&CXM1VQ0%B7^&1^VO%[TBMK=L!50Y!9LT5WP+][6
M-PYI<'HWZ_8C+P@/3_S#)9J(+9-DR<T'3:]\P SQ!\Z V3WPH1- 'R=7=RSB
MQUJ@T#I$3H])@(Z+74KWMM"= :N4+VDXB138=*__QN"N(L)'L=S1?D=$8JY:
M(56.:BIO\2'V)I&XN'855SU=_7R@MUR 2B^$ZV*\5/Y&I;&U<23YT(NGL-D4
M-IO"9B?N#S:.+O<9CT^2,C6;RF0.Q.D9G*(Y61.X)+Y+IT##%&AXUU@UB^/[
MN#7%X]XNW%;\$M+D;YRW61S[<FR$QA5$]#?\CT\&IF P) ^H;Q;KK%5^0@$/
M&A0IMP.WU48Q[OO@L-DDSI,XOT>;;L65HUY9;ERS0BDZPAOF3-W "2,IW-;J
MC,EG!PLK:A^2F()JIVI\!_/VL!.-\-%!B[N#9C.5E\4.F7:'*:]O2>;Q ]12
MTM_:+N*B2Y_+"SDVE%C?#VIL%VM2@9(50(>9'^)L+P.^6->00QI.[A:ED*'N
MU5BQ M1*>]]?5&P0QA%&6(F!D= FMZ?0Q]&Z;4G>R9;&5@HI6)5'M6'T#PL+
M2;\25YF6"#4W9&U8Z$*".QLNFN<Z)2XU>9](T47Z6N)1>J=HW$L[WWSV1",9
MVOF6*@=SZ T(7K+QN_'0K6\DN;.^D;,[LQ\T\/'>3*_?3ET!'[ KX-NI*^ D
MS];'9GV60.,KT#LFKS3_1RKXZA O&3(KE\9+]E*)>NARLO^\\IP]$[WJ7;5S
M/)?LES:]#T#U/:?2F$M.^"CWN$"Y1'A#MS_?LJA61VU"R;SN](X=OB!5Y=KX
M9@:.SQ$DDB- F7RF31^>1Q/?1=[--5/OQ0E- BD&DH5_.#5<Z9@C\Q73RH(Y
MUM5;NA=OUEJR@IWM:-PD<N0"H;2_'22 A9]WCC1T]&OM,1*_B7\4G@AC;UMW
M3GJC.[045VY)UC;W5G:(7+%MQP_YL:]6WQ?=_]/V6^S"G[[$+M!_IR]_\()W
MB$<6$C[/@&!AUA_$>RF6GA')MA>)!+S]'Z(R'<9;H-_SJ#*.S#M)?[7T/,9S
M"/&,EE/,G#(D9P'6)5>SMGUS[7:\U,*$A@9L4K*8WI+,[ESSR1SLX&-MM$$>
M2,(7$+%[L:B;!F .(94,^(FVZW-#W5C0<5X)1:[-"B;Z G$622IOZ4QGI=.4
MYG"7>$%B:9#!RJ-I3EC+3D=3<CZ2U0=:OJ$,),](9C>I)JX'SWE5=N$YO*E!
M)M"IX-ZP1X!]3POVR="<L4O(&UDYW\F+W45./UN0QR ^#$TD+S1/>6#(T(DD
M=+%(;9#[YOZ2NFW17WZ1#EKX)4-BL@FO/L^!3LC)9=NX;;T%CA=N2KSB71(J
MOMTQ[F=3K$;RRY(06I9IU#X?;K-(WGDPCA+LS;1CX&:XL5I\H;T[),_E+I"Q
M#_:1GKP2YQ>TU F205*G+1GEO12R7"&!0SLT3H]OC8_F:GUX0^I,[0>$/HJ*
M5!)7,R#"T,"HEDA!L9GWM',;0>DA]<7[19)2[AZ,C0H YP1R<-)%H397>_Q9
MB@4&BF0"[5Y=>&.R_T:<(TAE':""_+O$Q3\8CU&=*;@^_@?"M*9M:*-?^-Y^
MM6ONRD Y._&[BS@<<)L8\^0663S"D9P>XX\OEOZ[LW1#<Q&K5440$:>>#6>?
M,Q#7)QDR#TAI&2FK!U[I V.J]4\<EI4!!.7:B=)5CC\/ZDV+T2\S/!5V@B#!
M\.#C6P8MH-=8D)KL(!57NIH6=-WGK([E9M+Z*)%F*=G!Q!9LE=RRB/-=NL*G
M%9//E+IXPE*_S7:,6]7 7FAE2-P5NJ&AAFM"KGR[BS+<\+DBO:#WS%].K4=Q
MH<5@2['M-SQS1#]HS3*KEI9MRLJ+]#59(^VQG4X.[S09$B7:RV@ ^3 2/Q.K
M-J<;K>5XBY4WS9LZ(Z'0N"1)M^Y>:#22W?D] ^&6U8+#GUCMM<O*;BTZT'$U
MWTS!WG/Z*2S#[3IK-M@Y,WZYK9F47)DU^G-\,8:(KYM55JF/WLX2+@_47<Z'
M6YQF/>E$0PBSG=9!\15@176^AJ/)2=2;;J?RP'VRMT@4AD8V2N(K]@2%JAD"
M5I6L<\VT*7$R6H_Q,D)E(;&!22$5FC%7NGNG DC";DBW%[2 'SS=5=KMK"W=
M_E&C*4E_;S2T-5F+J:L$_ZY&L+R^ 5(<:F]:Q,>*=AU?=:;0]K2#3 .0"6)"
M5TIV8OA.$SS1W=\^#1E#I*SHK:R5JBY8-!W2(SX^QLA\[V,VF;VT)ZLA[_/K
MQ>N+F92O0BZKFEY:H, T:7=MYS9:6:4Z>1ERX+>\EDR= L2)\A8K[E!7!@7!
MK3PI=\A(,2ZGKW7-Y%6BP_24)/Y=@@T019):UUP#:E%]EM:1RH!F$<=]]+[6
M=9V@VSE#:&Q&0^<?<W:*OQ0-)=OQ':3/'+^_'NP$+:2M^$7Z4I8NI/#\UZ!C
M?%FOV8KAH2A!8)0(VSPZW1UK6>P/.7S-SB./L1<))6$HCU%7_?=/+X/!3+]^
ML"C)G8V-9UW6#-D /!=5.'HO[@M*Z')+_$:3SH07_A.\WZRY52;-L-[P=W%A
MRESQLVZWU>N1^Y7H!N$6;W:79)3^#?\KVVR_TW\6>?+:ENR>PF-<_?3:L#!F
MO(@K;CJ!HUJ$":5/(3"='98?Y#["H'_H&>-"'\MW232[JFO(@,*VLJRHD"7:
M)Y NRJS82%"*QH'G?:&B$_\4JY>[(/E5+G<_/5!-@8Q72E;(W^J\MHKG$%VW
MDJ"T,5XD+X?65.?X\62*]/ZNC&'SK,_9X_ <V;YM7>(>:<-](U<]YLE(*3'*
M8.Z0)KU(GG,89>"_6Z2$IXL?ZP(=7&2UK&2Y1DTB^]+EQ3JV^Z8+[<YCNUT+
MW1UT!V?EJTP+_>+ "VVWN,$X^E%7/A\#MN8'SH+H;D5TBJU&'[%<:3C,Q^J2
M*)<0195 ;H3J+E:UL+4?:-VSM-D@E9$!R<+793Q[=CE#JBG+LP$H)=EIC#BQ
MSA0:$A+K8?T@[WWG:46L.\6,,T9F:7'>COF6!W,FK)HWT@"B[Y^%NXV]!E.R
M(1+1.%M@='%=TQVBF#)A1>E7"-D6[:;%Z8&"9$O"=DZM=K$/9!2Z>\=>;SI>
M=!0?2_UUH@.*RI:B(&ZLJ5^,5EILWP7#?RC6Q[)XJQU%]4UEPV"39;0,H@7)
ML"DZ[L'.$YOZ0N%$Q.]MXV L%Y+0"1J+GV]PD3BWH*KJS@9)U*"1%2&*V2_V
MO17#T%(D'A%RC03';TRBC?SSHM(#(94T4)[#BWQ?=48QVC91FXH4=;^ EXBE
MP67AX=IX7RPK,!>;-'8S?&@K.$]<YY.UM<20+96GGA.O^*2G[U9/_T12#>4Z
M2V*UR/F2]F"89M\U'YS3$-A@.<ZV8F1#AN(H@@0V.#V4]<! AU(8Q!,2<]0E
M>C*P2:0"C9QW:)G#]F50>79VZ(>S&"AP)HEE<Z\U8-:8U^%C=(F5=AT]C8?C
M,(Q2+'DHN<S0'\M)+E,/GF=J!/_@3YCAVZ/#_[?%';EO57W%KA'C[R9K<A_T
M"7LQ&U^*1;4L>\O&[0>.DL$V:=3/:\G2K8JVS 3_232BY.!R4LH\ ILU[MP]
MB2BBRR0X)))::Q=-(6VW>=.OQ-RF!ZU,MY.6XL6,PD@^"#CCJUG32K31.S9'
MJA;YME@D!ADG#K?,LX:V30.2<\?'H^'<HJYO0L]O=NIL!P_[S/7"9Z'<XON0
M+=&C,=]Q/O3(J5IR3^Q[A%YN"7 GVQ 1B$#";\D)_9%3D>\#TOSDX52.^>'*
M,9\\G,HQ3_(HW%%6_N\N668+9Q=D8,:L!0*WR;8%W7WD)%9U6<OMJS4^9IM)
M,8OJ,[@WFMODYYCNRXN6%>C,,I2<;(_S+(QJ06]S&F=C9U$R4C/I2LCR:VCB
MW+<I2($])P#A04K*[Q ]0U0.<H">P1>#J%9.;L\'_;Z:L"G5_XG, I)PB-)-
MW7 J@[;[Y<L??E8Q0?">+3_994\**[XTF8LDKF7!)J2F2 1JUV[MFFN^?G[!
M!F?EX%1P]=Y 8N"-[&XDYR/.$PVFU-)5#6.AHFG;L:$!V==$ !D1'-;E((1E
M$I'4D'0XW6@;QT'5$&[%,TM7K;KUSD+58I+/B]H?8S*0- /L>KZ%9"B#" [R
M GVK\9?&'5@E?FXC0#(<FAH]T\=K9L.71Q\DHW=&/]GV\[)8#(H%^@I;T1:^
M]\>7*XZ\%%8*-%C!*/!H)8/JQJA2 NZ6=R'CABK+B&N3YZ'(S)'3#G>0\]$W
M^/]1M0GAB!?%2HU0["9# 66=P(Z7)7:9Q"KH1!BC!L\0,C8A[KW>;>NWM%Z(
MEA>-\'P::N&]'UY]?_\B_1[L3V^SS1;Y\I\RO&3QAH;>#<6U39[__.*GR_^S
MK^#N504"6BF]*'?WU3Y>9Q+TFD5'RM8)W^C;4#\(IXF,)QXV"K09R0?9.QK@
M SZ6471AEDCL=99>0@YI;/2?/SF:9,T;^-=L"WS5'Z$YTK\T=;_U(3 ]GS14
MEA=I*N",0SSKVH9@+GC1[!UW9*A<GOS\XNV?7^ROB)RL> 30 S**B&&-IK^W
MI*D\@>;[K*>##M>47O]C\<\>X0B( *9A FBE!O[K,QU9^C=Z\O_Y7__SFR^_
M>?S=&!%\-*4M;12RB?;3U_7PQY;R# 6K.!=]N2%?GWY.$D8V*V+T=67(';J?
M'!>V@3W[VZ\S^G<<__]S4>M!1T!]7?=.%-7S7ZZD0%5;Z%0+\!'489-:C83N
M(OW?SUZ]P/.@3I(??[Q"]9/C2NGOGUX&#T_G<F!'__+LYQ>O_^^/Z=/7_"62
M/%0)U8N",^Z\;B:)CQ\^^E;US+%W9!(B2_0^\*(6)N!?S ]\_&24)[>D@FD%
MU3Q!)<@1HW>3.A@]LL5=$3!;*G@%FF>Y -$!72//J\4%"R6FP,K&SV4TCWB9
M'TCM^B ,$Z1"Q6?NFCS[5[%1T*H-^4!]N^@W=*\)HLP*XTI:NG8199)P%\JM
M?G[1P8Z2] FF564M#:/=-IE:D#;@X3@+3">'%GC>-IDKY0)UG X?YV:66FGN
MF&TLN7KQOY\_?8#=9$A^]W;+T&$7H&[XT66Y291>4/=^SJI_<&W@U9KLQ?LR
MUF@<_&==N%AHY9RZH= :34"2^0H%+A1O6Z,H*&EQ\'7-!!AEA/R]+G=@@ZK+
MWANKK]>N^A?]O_05J.WI:&DJM4Q_B29AW_*S +9V\KY3Z5$A;R/##4T6O PO
M#EH,YKG*Z.+[60'00G&_)H3DC.N;$\M2T-=X!%"E=)#2EW7I=/]1*.G$QXC+
M&CE$"K$)-IC<YX.S(6D?A;GCRGV[B04&OB5MR'%6S0!)(*@3'%19S"^BM@H2
M:"72%"0X'*9T!W(*+=;,.BT_;!IT5F!G]QT%5?J\$HR$!)\)!D/"\6BI)*8Q
MA:684B1W31U7>3I:"#ILL%!<&DRVJ,ZPT51G)*-<9<A(]NQ<QTXUFSL@*_SY
MA6I9CF][TA"V]MA62[RM)DU.YI".#T.QV?3!]N42T(;N@G51DS-;R(W2< <_
MSG0)]1/+_(T_77IIH@\FE 0EES0-:-JN@!%/1R%:#[$ E];2-;Y'K[Z/PO.\
M2,Q)GY8]UY2I^^WO/"&K1=:13T,T2(]5H",-=98W;NBJ^^C"+0THVB5P/#RL
MQL-FMI=92/:&JNU! \Q/OU/%T!,T8+R#T8'IF-\INBW=FI9EBV-5K)J'-0HK
M!K.*(D<SB8=YOUF$A&PE:\PSGZS$==D<=3O1Z;)<LLL7\H5YY#[L%_ /_-Q!
MP0(CQVA9=;8@+Z+5PV5DU0-'>^R1HRQBY+U'[K]H$"-18R8HCK_Y*6NJ+)B@
MXG./%G>4?>L4["^V?.5H)GM'4VLKX-3Z4RI#0'RRW/DV8O:YK4T@5"N,PH5,
M 2M.=HC!:+5H$55%:*,I&:W:K0P/&AG*!]P=.!H\*_RX83(N[XW6893L-!(I
M3B*0-R7I5 9SE]+[5EKN6)IF@UH\__X+YL:Q.T9I@*4%R0BY1ZQY&DSU\A'T
ME$>T#=P[/OSK)!%K1V+0$8(F$",4KN/Z<GU%&X>4Q&H:1XE9=8KL! =H)O*L
M\I_2T."#DE$O%;/N[8+\#BS9',5=LU$DAX-3P]W'0W +(@EMHO..?L;XPO1:
MFU]@M,LZ7FE$D(8:S_(EQJ&!(K/;]SX2/@NOW -)B$*'6S*#U>U+[!CD]5YK
M:;2'-EBIYCP4KE=[X7VZ/'TK]?ZMEO25(YU0;UBAX =S<F-<YV;OO#;#D?Q=
MG:9IAC[1=G#LIKSJ[7G51U->]0/F51]->=63/ J?*@<57$>-=5I?VM#<:Z49
M,3+SN!=N#ZZ_7:!:3+X]-&'H#I8;N> '"0^IAI0,R$PM"@Y=BC$B1;66C-(D
MQ._M\K_Q/3IAP =:GR>/YT[+HTJ@<*_6"9*&5@'E-MNRWCDU8,7YJ4MS:4;9
M!V\K;K,6S1P%[:P^($?H;!3*EB!(R]%@*;3FYZO<)U&)Y&%;_-C-KG@<X_-4
M9>U"X!/?=9Y^&:;WD_=/[ZLE*!/=SQBJ=<TAGG$S-GU[U60;617N&*B4*T,-
M],1"%^H71<?8DTIHZR8JWFO-\?!8)-\8MR PCX<;M9F;\6@5OX?Q0Q*9KU8S
M<&%(/FPZS0PE$N&I[K :BI=<LU'>:>:M[PI)#,:=Z()$B78V) "3==VR/]&F
MO8'R\K)(G:S\[><7'#D.C="*!\.M)+-18KRC(X*N#VT*AY&;7=<-V<I5R)9R
MLV+)+A17?([";=([R]FM4F8^&\E<C!@\5,=CF!*M"!SZ7Q$.6ERB/RG,.U:8
MAG&4K I$/!A95>_L2'<-?)4X>S^J; CM**QW%1O)\M(M-YHOM4I!&_7D6 EY
M#JF7!'&,P)G"1]!<6?;[Q@^*?X\(DAXQWP887.+WJ'%*32LDM]0X(<"#X%=L
M L0O7!=['4 \#1EI3&EW+0:)E>5SJY@@9QP\+ CE_5ZL+FA29S$3[,W;A44'
MVG'49"UAB..#%@^<W%[ -C4[TLNC%D;#[UTYW ?;-<N(UBWX98MLMB@JY/''
MY?Z!UC3#C70-[YO$K\J:'IJ\IU+RB;(]DRT:A40TO?F(BV@)S2E?=<U&L4_
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M&!TUM5^:X2LCO< !@DB5Q^^?D^+'[-C![#4[%QEW"#I6;.!XM3[SL<*"6=0
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MX?H=FX4AM#OW,>!D4%0]BVGO02*(%%93K&HN5/>J$7%VM %I'4>\ARB\OLG
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M;)@!NQ9HB$A/=X601T?("G,:&F=5W1F]FOSF%"4C+IA"*BM6230%1N1@6LD
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M*6;NO7*ES45)N--_WTC()'T+E71(WZZNBO50%9;T^U9-,!(JJ6MZ%@0%M(0
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MI&&&U"P]7))%?=2EN>/C$V\1QFE8!0'$7#SS]MRS,\&FY?3/*!I]S%"A1^P
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MWE+DP+:FU'"&5<>AIZOAA45@3WZ_?WWC7^3L-/?IUZ(8Q_[T3&*MNVINN/Z
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M]7ST8X#"=QE26 3,F9$I_2$J5"C ;LGEMF6'.J&ZV)32R\H5?FR1E7TW%XI
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M$U*?%4MXF?N'WM 'A21#52Q+G$Q#X@+VB6B&], DZ'YDC1>3Z0B6I?\X.3&
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MVTJ;T&3LQ\]-L[3G/9]NOJ"-P1UV;4;\(ECG 3 R\&B\:-28R.63JKY::,Y
M!6)L@^/L&<<Z;]ZCM8MP^.'5)F8*J?[WI0WQ8 FRR\"FDXD=%2=?@:0P50V
M9])EXU!3K6@X<&& 3))2&V\Y@3)/6!L#SIVV-Y?[\?>H>^:LM%X%<FI#16 "
M'K$#H23B!L #[9U7*\K3A">(/AP$)Q')^> 978+WY+9!5W*_^7^ <"98/6!E
M5OUV0;D5;#LW;K)-Z[Y+$VWFQ6\SRWV?CYMK80^>C-B#CX@]>#)B#^[E5K@+
M]7( YYW8&Q6%H:/M#7&QKN/1#;Z-Z(GZX4,:!4F/"M(._N' <3&(I@&A'+D_
M5W=.;=$^H+H6=Y$*+W/?/=Z$B[.8;@#6X\*&($G&&.K.Q#P\7MO.TT1QD-"B
M 2=4.3\2Q(CC<DE<HB(>IGOV%F,I%H-K%!'+23K'D925KT<X+G!AE"/D+OR&
MJ,#K.;7HN49NCNVHB&!]6G;YI)<GVK*5A@>OWH6B"V? E//+F19\0Q-@>Q@8
M:;[M/[*C=Z>2]PW@C=O+ G?GPD^$M4HLK19YWE@;Z:2NTDR7YU 9R:[T(M@
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MX:EA[0_*^6K];K]NP=%B)2J&I7HF=^61=JH4VU_ST7]S]CG^.55(MNNN6O'
ML2T<M($<LA!2:VU7E^(( F2VP;*X=>H&-DC @<<Y*/]@GMKNFB/>R+X)";$^
M*-$,I:WLC&%"E(&.3<ZK$GGXN)]NJ7U3I.50Z&[M.Z@JZVW-TX"S5)UL9+,=
M DHVP?#:\1"WK<ZS\\ 1[*SX#[.\J;NE.YR#=41*<O8OY_E2]7XYU=;$R^$
MUGIC9V](94;M!IO=F#.XHYP!LN&B0=J:$]A@JK^._&G0=:9:&5('*1^X;A3
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M5,ZZJUZ*?-'W.=3>(<H#5M$C>J.T6#<M"\U#WS=$K*[7'8DD(KD[M;V7&#)
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M$^DG?]I$USYM_ 8;V)WASN2/N#3<T)P(LQT<6]$='5LB=0$B,_;\ASIVI''
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MR#EYQ^BU$]% 7GT$SGC%RRU*T:PKO/9D<M:NG"M521@U7(_0.LPT!X<KU3_
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MVO/RUZ[&*V<F;<_QH2 AVE#, Q>W(VIR.:9A-X"PJ;+,F6FP1Q'YJSMP"SC
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M-&$J[;<EY2?!;^!NVG5@S^(PD]Z5HD>')::%_<PB;W"#1?UU69H6U<3%!H_
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M_)(3FF A@^"CH6L8,RIZ/1,#I8HF]E8)6-/S>55CS0W/WM(:.9%G;PD1*Z)
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M$OEPV@;#I\S,:T,#%/=M8&P)>-+T=81R:&CX!B#;$;=@,Z<B89MT+9XDV#B
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M?A\CG1R5K\B)X686V)V06CEG+=8E.8B-^=#1 9DV#7DJ+M]" ^83O^D,'<"
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M@C>U]^#1WJ.#+SQ5V6'[UR^.JO*G!_9_3^Q'[=],8^,"\"SJSGR!TPHU*OK
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M(P$S.MO$QG)!.Q [1.E3'?<<[UU(7>M].: <9!_"E+A\AU%8/'3K9::C"$&
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MVW9/V\<*E]=R<:>[NHSP4A3T=CN'+Y//;V_,)MR8/P32BA41\!X$4J^ K/'
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MK72(?J@)5?6[G4*@H2XJ6V_C*F,[$HSCH'O+JK31BATMC#%%5E!)I:!R(=9
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M+'\0GW%AW*1@6@-TB; JZ9(>JBEC@Q,P6X:%0K(W'GX?@IR.4)(ZLLA<?IZ
M-S0M*880F3X:L28K:CLX,(9JSKGDG/9U"+PQ %6%_@R'-\DDPHR<=5J%!^D
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M%^$D0(QBSTR?,E66HZ;&8Z&6<U]K[(2&IW($1T7N6(UW7-A\M>G%$APL-N!
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MX']8"%OJ0[M=>0CMK5KB5C%.71'V[ EX8\S^*E9]K/!?@?UU'V&/P<[@?PM
M9666=UZ:Y=TZEG?P8S=Q3OA;!=Z_%5\PFHS\FH@XF<"^_9>-4V)?[HZ,Q@&H
M7F)8+CGN\98<-+*LK$P^D(!P*V/6UVC)>D:)_64HYIE#X?M,SN7V!S$6G$98
M3ED>P.W5V#M803F)*%J'H;X9-6GB2R5F"=M)E(B(0Y='<:0V@"_I\Y%#C8 +
M-R1%/M>*7/'8W(>;D,$7.-I-(<W[. ]'P#;<\3D*TF$88Y6S9.CS3,S<O6YO
M:[R-*Y$A< *5V?D'D9>'$TH5\.<Q<6$:$!$7]SN6=<]LMKW#*FP,7&6XQ70(
MO8,M?UM.9E^IN=:67BR_"'DX#A\.-ME\H29R@==!7;7T<:F@,PK40C^-7028
MLEJ7NS\JX0)*(<W@TX1+.?7IZ6-"OZ*JU'CXV=W"C$6_^_,M7/\KD1"*]R\<
MZZ"_]'[>)HLI4,TZI&W.3H'>N:KKDI$6? '2(F&0D4I>G\JCJ@\YYD/*$[1(
MZI@P7./J45C-);4Z_I-(P"BYDY25'>=)%*13-Y=@ \-XS@T*#A:C&3K4:H#*
M176QH$,I%TU@7F $8+$YFXAI'&(W.F:T74QR C-(I:[?Y%(EEGJ!)(BH<_*4
MNP-,?\_C!X_'JY8\"C"+3D6#"$['< JPKJ(8@.40'AQO"U7_,[:KPYI\MZ<4
M?BHI27]:3V%7)P9,ZL).5913&4^FOY!:>*Z9-ED\?X9!Z:N6KL\Q*/O9:=P*
MMI]_@LT*PBB?Y,RNCT$:>"0S9&AK2-Y)Y5(K,4F8-I[T,3 #C%]S][ L$T$/
ML48&&U]":65A*:X,SX L %,^2?Q(HFX@PB!^ENB@3JE[ZP,I8SC(<16[RM%!
MDU2!Y;LC'XQ%ZKB*S$?EI(P"GSSKQ*<_=3O6\SX\[PW8L"O P" /<;3DX$)7
M#,6,67G+T1Z@.A.L7)Y4L,DU;^XUL3$14N7E0^GUKRLO*P[\4ZP'#(,<\_RL
MHG$P7^AL'3[;,48\T*^U#SBM'FY_3Y_NMWFL=ZLYU;3C4K>+.E:1;,*Q/LL(
MLXWKA:+_Q[#<CWNR.S)4\)Q!!P;NT]/E7B?(T$89EBY8Q*"@2/&NL/>)M\[5
MP0%=?YW^1 YI!9!$X0!4>]?X;W6UW(XO&Z 83)'ZMJU";PQ+JPSPC*YXJL(!
MI=>3:T\9, V PX**.B0EL+4-M\F>L/T-J@RA*LJ4K6V.GSQ(15.O'A!CO1YK
M/\L=#50J3F^W,'N()OU%19!;(LAY@*"Z3:[9FPKV*+6QU9#9N$OU1-6<H@7[
M-J7H 5 IB6[K1M=<&HP0(60F1RT@9L53+AB61[&DT/V/L)*4<["!C3F!ORC=
M9T?Q=3";QRF/F^.0HLHBI I+A>[>_D%W?VNXO=7?WCK95O$UB4!Q0U%,G@WG
M@FRCVY'D:H*#M3(;/JOASIIFWZ>MKT%2U"W37M+H@24Y=4MJ[]375$SWVXKI
M9ZR8[K<5TVMY%5[9(PC^3O.FC4? W9S?QNJ^"5, ;#@'O/(9U6KE":JD)GN;
M(2 8IKQIUHJL'8@))0E!H*42P^&#DT3"1=###;J2A7CCAPZGQ/#W5)*0RF08
M$6,9X1&)80HP&/SQ%.MA*)7%FEO9Z]) )<N6RQWPKQ:V@9T%Z[CGF4,I0UJ%
MH$0EB,F(VO"HJ(*M""Q_R&F(K.IP)T@$PF8WL8\D2#_CIL%*-+XU_<ZT:]GS
MF88+- ZX)F+AS/PL(Q2,RYKS0-A  D7+Z,PEGC=E#@,<>$N%&RY:)".WF--C
M!V><1S)4TW3@1)7P'*[1940C!+V?/&<J<'ULCM4G#7]V&Y7^NN43>T'TTO&O
MYTDQ]O=?A/+C@\/C9R)]Q;1. Q0,1!Z+8N6G8'G)!&=.8%F$0E:T4.^"9(82
M#(0>M<R3&.9N&Y84RPICGIH71P'(6D5)0.@VEL<DRU<((H8LSO7,PFS4G6@O
M@::5RW 4]Q%4 !5E*Y6)M:\8]$B'\5P!,!2Y7<4M$Y'FH2YQ*GRF9=KU9X1-
M8MIY(G8TFS+CAHH=4S6#4PI. FI#^R6*HYW21V3+/\6:)!C \BI@34L[6I[>
M3)XN"F*4H'8U>\DMM)U!\$:".49PP22A\G'*4\D*T@ <,&QOB):S2%J>7GL^
MV5R>9@DK(P::^[P28J_%Z3JJP!.>K;C DX4U/KI*!*L#->^X9?ZU9ZC-9?X2
M"^LPW).XF("/R/"9(Q"^D"6S6I#+LGG/%7X2$2H<6.'P #FE4)OX7Q7_:Z_'
MVK/<)ET/!.**1PR51T3J^V('D37<H'5U)$XR%\I1"1SIC1'PJC_4@72>G8X_
M5:+4+2>O/7=L$B<'$9&&QG4>XN0--16P).[+04:R/JAYR;!^;4ZH+."M)%"!
M]54+@]5_VK)\R_(KMVWF<4:#FTC"CL%NX2@@R5VL C(8_'=!K$J6=)!\1&%%
M&4QO^73MSWZ3^%37\&I61;$YRK&W5^&?9(GP><X!L2%8Q7Z R1D]\G>PP(98
M4]5OC'+/<B5KW%95RT=S"CACK4UP@I(8R6N3Y@,Y3R)5H4@-7R OQQ!>8Q/Q
MGQS6AI5V&-JT7E[SSO9.K3V?;M*=>BAC).L[=N9^ N:+W?;R,WZR9<1U/]S-
M9D1QYX>YSY+9SW"J3:H@*L.%5U?+HX=V#*? LB*I[W%<0=?4^N.NO$K9W1_@
M-SF@G1'^FZK$"D&!901-[3&#/Q:&"G*B^;L\:U=9LTZM-4MJG4N^:.K3/ D$
MHO1TW-_(S*72?"P_]QYZD4_X(UA46/@UK/A^&@RG[CVWJL2),_,7[D#@)%EZ
M2A#)3U".?89J7R,7N>(+8A4QOA=0D#*<UYM>OTNCD8#PWH\Z/P\RU)_HHL8L
MIG&9\)V,9@U@C=R.P I$-I.<D&"/[F,VD01GD'0YG2PLU-19N)6/H%22Q8*?
MIBU5!8+<2N-.<6!!PJ<W!8H=A;3N<F,!_QOL'& GH$2=$<*!R,)!SZT6Z94F
M1E.S_T26Y)#C;C$@VV':A^=&ON)X#>Y;F ;S^G+$(6%#2:@[ CYIX HW "[+
M3*>)Q)9B&]7Z5"JQZYT!.E>:+_GM15!@&]Q%1@4(NR^CF:^:1&D)CW/8YIKB
M52[A+/MX]J7P'!I2C6=F'0--"RW03@MJ&HE"^&HXH@V+H7@U=:@N3<O"D=K-
M>TN+KK3J==P_) S./(:UE]@5<<!4'<O 3X,J=S3?<,?D8&6Y <7N(XUD$9M7
MT4TA_L0M9F%R@D.9U=_U!0^B!QF(MC= /#.6D2CNQ C/1B,MSA#'#QZ;IS3I
M(!7A&$F98G$M_)/&@."#@V$PY^LAX=#4S1R),!@(.<F,P)R'04KCA/^8BDC@
MQ+EYS"477IEWG71*EP'EF2(('S^Z\U6I&]P!Q.BI^;/'M,-WR5W*2 (A;C20
MHB8TX!XCG-H<>^SHWS3?S0^YLE?6(SO8T'6?X",B4YO,LY.U>]APU$HR5=3&
M3 W$(P"C-,AR_T6&V6Y<%]*KE?.;,&H8@(#"7$$!Y4DJ1NZM8R0_NE $I\Y2
MOJDB'!EZP+"H"8)L(B]9M1AC^+>/+P&CHJ[LHN.>1[IWSC)=$9_CX1?3E6!H
M]H44,.6/F!?R]$1,(CHC,:9>1KA>$ISP$!OL]I?&)W2+^(2L_E%%VW4E\7R*
M#7E#(TB&PS@9Z:2CLU1K(JN"K^C+U)CUZ6-;X_#6%(;9!VDA6J^$,>5@'^O9
M-,V,2*'>ZD>6Z[1MBVLC,-Z"0G:^JLS$3OO824[ND@5WX0YNDL*?J[G3WS?4
MY^,-JKMM@^HS-JCNM@VJ:WD57KU!]=1RD=L^U;754P_TJ3;@+!3:59O'DX+K
MG0QY]%Y V;!TCM[Y $<!Z%9.*EF(G<*;Y-L; %E-7HL<Y%C/QD8;%[\&AG>V
MJ(X_9?]X ![F&$LV0_"^R&H>^DFR0-LISBE4DHH*J5XYW,&.<4I- _@B,+.E
M_5\/.*EH+E+%4!81;B.(S(5#^ARWJO IL(##& WAA30<9>D2>]H9'"Z%)N#_
MLIG;"([!P;>,V,-J:36]K,Y2O:Q-3"%;6FNB96U+Z_(KW<R6UF[G\&5Z0]NN
MUM5GQ48T5<W.B@48KT=W1$)A\1R.NZ(XPVP%17BEO$TQDD>.N@Z0H;#.,HRH
MR3)APC;\+!8R)A:)L&WT6W\&V21FKJ9XL0\ZEY8'<>:"RX5E&$BIQ3J+A"?>
MG&D5+R?><,)0QM_KC1:)XTE$: .FY?7UYY_-YG6PQL% $PPZF<5-QGH3OV/#
MJS9==5JK9=OU9X7-9EM3A5/U. CAIR'EUG+F^I_V)G&FB2S8':@RP  .+UJ[
M=XQPP:PXP:$/!,/-G\%1B*-425YKH)AJ]5 8+J9F0.?'4OG@EJG7GU$VGZDM
M@"!W$$=Y6L?5_(=XCBU$><11O,=YN]Z*L!F="^M;9M\,!MHD9@_&LC-4EGM5
M8J8XVU',?1T-]2,_7&"A%LV3ER/7HIJP;M$HL<K)!CH6.I)E=FK&O6P?^;(P
MA1LMOZ\_#VT2OXMH0C5DLI^T$*DW4EG7'_NCNR"E= U6C8I9 1O 2O+HS,0H
M1Z%/K1@MYZX]-VP2YWY5+T9]+JK2DE'/JJN;9-,62"V;>&Y()G)F(*5QGZZ?
M9].8NME!($VQJ!*KB1N$FZ?KY*F*UOS!,$4A9Z&K_ZB2,/*S/.$R8@U72!/K
M)=Z;IYB2!]E;1K,GYZ0F-#*$_TS"F-1\6Y&W]@S'"?V*4"E%FJ@87+;^8O+?
M<GL,TC2%3OT9M=-41XS[J4-3;[D<7 -9VS5_^C4*TGHG\S_S '$9<U 5& K
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M%-;1-=9:$$@)HL?G\%2TR*H9*8H ?_@9H]CM35N#19Q'3GGD5YTT]8N6@O=
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M-\'8Y6JVP"TSFUYL5!*H&KM7SI:_^U0S=6H$I9:WACCE3:GZAI>Y?>ZMW3W
MU1/Z[O:*V;&.=D9(21'A!%^7:Q+A8JVIXV)Y4TEX$LWM0O]*60?&1QBD3Q,[
MILI[@&S2\3)5-L'6Y9($M&?VI<UAV6,=:%41,+9KO$KF/:M(M))H]7BT$DPM
MT>JEH=63A;>")2RUJPS2\3+Q2K!U69%X]>+PZDE"6F4F44;I>+%XQ1SXJL2K
MEX973Q/&6BN6ZPGDXBDN'14U*P*:%?9]J9C%6+M<EI@5;_%4:K4\X]:3A+ >
M8\/C+.!60D+VBX5?*FXA:Y<K$K?B-8E2DO"E[.+6DX2O5K-R6Z@DI.1)>&?]
M@Q*]'H]>M0R&>F5KYTO%\J:'>78P;/_V2Q(CB=D[8K(#.$_F5$\2-%J6#G5)
MQW/2L7$<Y<XH44OUIX.4S8+6__4<5Q].7[T_M;P[<J[9CF7^[W]; U#C34EY
MBBB$<D)ODXR:DK9:*K8:*]FKUK-EJV5ETU](OO03U=C*BL,II]PCH4M"EX2N
M>5_YTY38DK%4V:1#0M<>;OI+@:XG"4^016HR2H>$KCW<])<"74]38"LK$:$Y
MY1X)72\!NM8_F%T.]/'KC:OU#/J^4-A!HT__?9,MAX^Y% B],TT.:QI&P9JX
MN@6/LN[$1#,'A'ZG=E]W*)G8>A_&TTWBCBAA*T98J]<>I2;1!D@<'<"P-GL
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M7)X*D0VQ/-=Q@3"1 @F/_.Z9E*CEU#,1959J@DE\A(%Y<BBR=,#S#YJ-]VS
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M;'\.",:JD?GY!:&\)9@DP!<KW8;Y)/QTXKX?0$=C(*JZP>QF(%\D)YHQU1Q
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MB4#T\Z)%X+6IL5)$;,.##)BY\R5TP^P'=; >B89.[\.9Y8Q+'1&D[C-"@2D
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M!'H4:OZNF5SY43GV[!PT50F:V1(Z"9KYWC_UJ)R+S=L-:):3@*; PA8O^8Q
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M$][C!HDTU?M_AX?D3*?&X"VYUN[H.^"?;QY.Y2UIU-Z1OS3#@W^JY/!0L/9
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MGEET#M[T4M/A,GI#^Q;LRE1<;!0)'0Y1HO$([;L61LFH[%*V''/CVPAJK8M
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MK=! YT!  B @!S@"JM)JZ5V+#\/^4MZ])AK[R85F]T=!#!NB8 &G5V1XR!M
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ML3]V3U^]KQ7KE:"]A$_WPJFV<I'B6?8%K7XU=O75%%:_4JS5JNFM?BP05$-
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M^./[J/[U[*;3WFE!1^[5!CE:9JC4XRE/;J4,_SAM3[[\./W[4I\<*_=7[G$
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M"9)?S8_D_[+845*J-\\.<MFD4%+U)+NYON;Y7BSE^J+&-_2>FAX]LZTQ-M7
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M5DK4&IRQPA1Y6%,T7:O*PJFH]8&7=&V5*<_O+J[T8?O7>.AGVOX./I"+_>,
MVMQAQ D&J+0@BN_W5;+P9VM"?Q^/]JYTYA7G/KDXB,+20B&\^UOVA]LM7)WW
MUSV_TC2?W<M*VM):KF[(.B\/<5U(5=.(&R\+Q5QEG%5*G?E[*MAEMI;$/@AA
MT+;TYM&G 5<&OM<?R?#BX2Q$A+:,8G^LF\\&8;FEPSND+6B,;F/80':[I[>W
M7K[1A[3B#I<$K(\;1%9K<*NQDSO14G]%LX2L,O#\Y'HVT\NCYWGIO96Q'6:0
M\#0<3Z_O72EK5_SZY-Y >CQ#//I[_SC>QL]!."BYXEOC EMW59WQHDIKE>U
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M[NOQ LV7O"N]K,&@/]8K!A&UKX0W'>)1?1=];V#>6E0+MT3@N[6IJA*Y/^N
MUZ@Q))E*MCK0B8K;F%S-L?/>=>OJX>?W\TZ FRZ]$;\!.M<W8#=&-=#2JG=V
MR3TCU2=;!#*C,N.G1F3?P0[/+.';HMV:@,,[TIC4:LGU5XR+3D5MQ (KIR!?
MW3FA+8Q^=)3+V57NZ1TUPJ7AC9 %N,U,^KMJAJUX]<D,@8[ERQ1#&T[8!W:W
MF&W%0$NWL\G\F^OZUL46^B#YE3%C7A9*Z1!U+,I&1G(II^'.P?E,*3>Z>;[-
MS_QDTM^DRQKC"2^J)JL.Q%<B'"CYYE7>AG#UG"L__*PV;O[Q1@5^.*(4Z!:&
MPG[RT\4E;6;$%D5MHF@B0X5=3;+*!Z/<P\N/S'VE>>&G0R9H3290L'GIT(RQ
M5=JNQ:H_/5;R%[E=U[.1"Z_7$S!FMW&L/V-Y[?:@O:S,6XA!T('4WT59L-=D
M+(<?GH@PO2/YI^\5Z> 1/P /TU=/ ""=F(80OF_(805A/CDPB"*03+)4C&BH
MSR,>M_%;$(4>Q<I>JJ?/%@+K?5P&0$X)^Z^CA<P8!N_H'\N>=.?U$VUV^5CM
M#<\.M8R:Y8HUX+*XU^OM>93EZS8CVR*-[^96[:#7POR.D+.LHN^U4QBL?S/&
M_LZ1_@T8\B=1RP$G^S,>)B:',]F_.W*WB-ER$(G^?-&/F/6:YE\]<[7/*OAO
M2)^(SYC>=>>\UO7D>^N\+:EC/R6Q@=6T&]!BDZX!;MB(:!6A/ADUB+[#?-%/
M_>L[E\_YQNDV_@RFHMB/O-O$GZ<;^?-:)1,P D_)@*@J$8QRWZK,-F%8,0,7
MCAWGV_.K7[G38=G/E)4W.204-B,+I!O! =I(-F&GX0@[QGM7(_A!MD]N#C1L
M6RSGPJIT#X;R;<P>:!5R)IG.[Z7-K.I).5_S,U,S+P8=?CX\JHW"Z>^LZB?7
M&[A6GC X0T9B2UCTQ\"5(.H>LF]NEH@44K>P:,6?*[*LC_<R5R&].2Q!95._
MKTZ)<&F4AAL^ZQ)_7E=%^4[ZT<&%Z8?5P09X856U:U#HDSD#J;Y(9K*A9<^=
M3>9=\+N-3P-=O5E,Y@IO<$K\<.M"+YV)C-DJMV9:@[O7DP;_.M]/.-$+XZYN
MPJ9C&5M+;:"2?:7+J/LXF]X]7Z5/J1'L]LC2=IM\MRWP\97N*JB"'6M8WGU)
M\.8+W5KGYGV>*@[0ZW3'NBV]QGRM5K^IS4NS*_#]944?_")\\:>?6N@U=L?J
MN9I>AN*]KV;TCE*?0B30ULQ,.9G)OZ'/*Z)8WLS7Q72@%3ZHGC/!6" !V@CA
MS>.%"AA7$5K>+D(QM:-M&$FM3C*MZ[M[[:[M9Q+I)H'I>PZU:((<#Q@-<)C$
M-3\S1ME6^[^GHDK<^AI1NRX$U//WC]WY::O\O3+(-J9Z]CT;C*9J?X0N@#)X
MEP;7;5.2O>#7EZHMIH/(W^23Z8*?X/D[*UC_:-VF6P,9 I-.EDM!._6%Q2;
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M^B7U_1AUGG4B!2RE#%( FK5+U0"..<T!39=]HY3?!8$^V3.00'?NT*VW01J
MI7*@!N#IHFM_K8IR7YSPT@DOL6X8&0F:"!T%(VRF,9A7.H/GUME5N40.YLV
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MX;!P"\\B#Y^S47B\GL,0/./Q"!T1*7Z-6FYEJK$'(LWQP+2TJF&,%0P412
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M*94:I)A'!"8$T(=3PW'GIW 3; =5[$/M$>![C)@L!J8I:S)>!/) X8#J!F0
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MGXT^"624D6XU3"'#/F")2L-\<*AYS.@"X-J8TR8@L-0IJDN-10/,=U?;#N_
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MDI$'D:G&=9+-&OJ+;_? '1.&]NFSY8UTEH,="N(%X&N^3[LH:2;JF1<EUGH
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M;TQT1<YV+J>YN+@]7,$8_PRP1,9!A-)\D'$<.0 17XRKVW=$6!R;>G_MN"1
M@JANWY< 62UO7U[\Z-@\4,6QXMKOP7?EIO%2'H1Z.8!;\770NQ^*I>7=#W8E
M5]LJY.H0]S4.SFWJ&[_7G><OAKHF]BZ;U6*HD>ZVD4&;C@$ ^)#[3@;'ZA7W
MG2XOHCX"9E )@#T' V;(B[*QPX$NA7=="Y!,\,.A2H:X<X;KS>#1C[A,A3UU
M1K>I1*F38'F\_UEW7IMFZC/U>^^TE%D[WO_VZJIZ\X#3_=L7K9M.JE._N>+@
M5]_KG>K)99UKXXS_!EU>>]_H7'"WS9MZ];+QJW[*G5<;3;;D]K+5;M?C^?]O
MZY$X5#^$1V_28_VRO=O4D\]U\#KQ8$][:\N8<Y0Q09QYOY7$&RHBBQ^F(M*4
M>I7R-H598VNT;.^\[S88?VOXVBYD,V(=]I_JKSI@8"IJ(_Q>:W!*>LO?;J,^
MZX ZP[^9(?#"BUX3E9N;UW/QB--%'='#'/9MZB_I\-8]$[R)V:*?0L$-F/74
M];F"/O,/+IA9,J<J\?3;-[!'?@M[V/(-Q=LE&$\.-BFD\VE@D[ PS$E&%NOU
MPO=R^G%GAG'8BF@AOA_7K"+\:(/3$2@KH5'X=I^SLF<^"K",8\>\H#=:>L^\
M@,W7V2#4GE]&G&9N<K7VTU"<"SLSXMGNFNO@VFH[)[W?'-G0YJQLVBSN1^?X
MI=;V^85^.<P_70UV5QNW;B&&3RS&\/FP!/QFQ;&=J@.)26[7#V]0"O' C8\=
MHRL<-D87#_9XXV /BQ3C2%;83_NQ(UD&(48\F.7+JE^9A/$>OOF/8:$\3)_=
MM,3\APMF+2=YW^"!QXW0;V&/VEL<B[SE6(2"8>Z;PJWX\NMQ,BA]^&!6WO))
M F2E(.+"40]F;=9Z48IG;8M3>])\?GEQ<EMN9COYYL6OS(>(9RUSV59F*@<1
M&?;7/!J!>%9A/VK'+[6JV7;KJG_23S<&?T \:[WNV$[5041I#Q7/VE1A=]J=
M#Y_/IHW6;%)_S(:ZV,N(?YAG#2)"8Y7ID=>^-!7(UW__)Y7BSD0B"?]PU_R0
M?(%O_9X2N4^A*']A/CW\FTNE#)$@B,]>B9N].J4K$W@]WJ3Q"_,+17K,G2([
MWN(U;MA<;S< ?&Y$ML908$& I?#06<J)21.'7[@.!MFXJLKWQ/X7K@F<S/#<
M5!"AF;3S6W^;7\,_V;1M$O:_?P/F7>X 6/\IU2/ G?#L";U#)]Z++GAG"+%H
MR:(0IPJ8++S0"2;"ST!T$%+(HX?!18S-&%" ?-[[>E)_:#5/$]7&39)K-&O'
MM#"P?7O2;IPVJC<-+ _L?8W4B9JM3KV=Z+2X6JO9;ETV3JN=^BEWUFA6F[5&
M]9)K=^ 75_5FI\U%ZVR1RT<8EY'(<NW&>;-QUJA5FQVN6JNU;IN=1O.<NX;K
MJ6&-*A)=JW-1O^%N&NWO[.?;9JU^TZDVFK2*]1-:%:(\)<+G?=Y:!-)( =_0
MOR(;9IO(48W+HW$$\O5KL%@.,T+WSP>BV:V><'2KBW\R$1\D%_JR/"* $S5.
M)5;W).'[(_AY AX()DPG\"A%8!E/S)7V1[P,]H8H.V+;=K>EKG *?$J%O_>5
M,>$^D=<)D37RF:-)-()N$#5&,0F:T'3X#WJ(-%NJP*LHHS'7#;X_4<D(OBT^
M$QH,!/=%%R7Z&.,0&JY(X,@K4?NB1H0D_',BJO@/@$CB-4T<B "5HC*H7N!#
MX#/JX%<*QQ&ZMD/T]I0+R[T]5L,7&_-5E05'%]F502XM^0;=7A5(!3[05,#S
M-7X\X351LX1GA_1'L@CVM-9!ZWE=CU#&$8\XR/N[\XM.82S47W/Y<KC=3^1=
M#1X.)-U'_@7JGHXGC%^F0/S(8<B-M,K!R2(O!'B$USA6!*%%N0\HUYU?716>
M"E>_IM]$86T?4.VB?GI[6<=&H&J[?7MUW6F U<O=ML'D;32YN^KE+1I:]]6;
M&["]XEZ?M_;Z5/6E=K1HE T8YD<$R@6,.RR[-;D<?:V#CNUC41$-CV*YRHSP
MZFJIBI7OW!A8WIBZW)A(79M\6^#B2KKB$/+F'8#POL%/:ZVI#F:!C!>  5#,
MB@CZ@VN-KZ$#T("@/<D8W%G.;BY]Q$05/MH,.@^?'V>O/W+-LWN[B'(1I:8H
MM6+!;FIW77O(5@@6(KG8ZOZ/,%7Q!I<4]$KS[3;<'7W-'F<+*^'7K<-Y#S>+
M\$Z10#L[YU3M:9:87Q)<OCV:I!.%[O0:QZ($1)37<"W$1H5)EV+K6K@]N1C^
MO+%3=_>6W8LS3BBTG&*#FS2'H."SP2" AV_+7^QR>F_]4%Y.MT3:7A/>C>:9
M(XF!=W#T-9/+'KO5FKM2^2H)_74(^;WZVAM1>TH-5 *^$_A !Z;^6IBH'S%Q
M!HAHH%(FFGX#^+!&Z:5[8K->>6B7^U%F@?5'7.2#BM=<M1L?Y([=1F;XXX((
MUZ+_$09V(3:P8P-[O7Q/^S2PE\LX C*P9]\>?^3RQ7JV, C P%ZILPO*P*[D
M=C>P<[&![4Z"IX&9& $0Y1H#FTS%AVJG,GRX> JS=;&-X#T8V!6O[6]NAD6E
M<IR.[>M=B#\3)N+?9%\+_?%/O:]EIZ5>E#G LWWMM4?!W;YV*Y=[JWV]J3:N
MT)V?EW)G8[USKIV,0IV<B%PF]%_QZRG\Z1F$YC.)$]#OD]"I+,P@MN_#S//-
M'(Q^*@X&P-QRGYP2K:^*-//EVE8_GS]W<FVM=)X;VE$#^^&.Q+=@/VFCY;DI
MH[H@7RK+%J2/,[%,G^ &KTHF(-X($\X<"C@!D^XJ$0C+!'(#PNOP<.Z3]4<0
MCYQ"__B9TT>\#N(;5X[17+P*QJ(J\IBU[\&/=L*<AQ<X04!5(&I<3QQ,U3[M
M7QX 2NA#FHH.K].(\:_*YV.N)<,79IRN\BCA.8$'3$\Q)<N]C,0^*R.X(4-1
MTUF^GVN;=0#<)_J0_&<L2, B[@0!#/4M&*P7&G]V*B96[RU^7GCW!&TC+"YP
M:_/N*^.Q@G2M@'<+QP/D2' Y.E?XBQNJ@$FB(LKD!$46:TK@FKPF\+^YL2B+
MX^G8> '@2R #40;$@-T"7S,^=3.5"%<HY@J?A,_<)WP,OCR;_F+\_<IX"C7A
MZ)\R7SYCN<(G4?Q,8=:Q^CTA8+!!M4[UK$A I=R(Q\(-OC^"U_ZG5$@G@0:/
MTVG@/AV4(4#_+$KP_C'@GTB 1;SG"5P@?(]PVH@'6D+4+*!A.L%/X9M/B Q'
MPMZQ1.M%)JHV$B?<I3@6=79I@"W>?AS# _F-O:CP@#*@T,"ZVU&3G#;M/1H@
M\=Q 4K!$8\#])WV<JV#)"0/OF$-6L+KFE]\&JAS?8!\&_B-)2,K*8* 1'9OL
MD4\H4/P83$I]@6#859DT=;S6CXN,=(V<.NB,1"UARJP7'EE2IO7+M))(5G0F
ME\!5EV:L*$A2-"*A))2H&#)H=:1H:(N:+8ZFO%+AZK$<R!!P]H!XYTQX_ F9
M*+%<\T2IS_G!%\KF&+!@G*Z9I197J"NX&D"IT(\R!ADK I'80Y[(C)G*FLD5
M&C"#9# 2G!U_97TS@=51R>TBBU*]*8'@Q,^6#\B^K"[X0$E+@H[Y5\J*@&SJ
MA-%.&L9!!*Z:_JPK"8.)\!M.KNGQ$H]%\8KL9)T]EB:5TQE3K?ZL-F[LNJ1E
M-P =#)>"'VP_,C79QN*C0I>8*[Z#>T=WK@W.1H^EB=PY)Z&VX5V*;2[ZC;OZ
MM[3^<[)^Z*ZCV.9[_8%K-*]O.VWNM'[3N*MVX.O<GLMKXJH=_TF%IO),W60N
MS](*8'=HVA39>V]S3JS](Y43VCF8R:3SW7D]]W0Q2=]_NSPO!IV$L!DS2FF(
MHZ]7:Z7T_M,.=H.H,Y351JW3  (APBFUYZ^IGFQ3H&H43 VD8FMP*XNZ1B-9
M?>N*'9?]FCOAFZVS_KDC'[#^M$?+!_#5XK\;[&O&CV4RH+CL?RUI*:\MF8O!
M)0;!T==,LIBF%OPN;?L^MOZ4/'O<+B')T5L"D?2DU/PWPX^C_)WXNZ$H4^)G
M&_=RKJ-MFT/^XKTKFSAVIC(/"%T3X*0$M3; N8RZ)<I[2W0_<UPN;B4Y'W26
M]4=GPB0(4FO1@,=JQD=3;VJ_'^\[V6G1!\%MV%YZN#S;N]"?.SZ7J'"GX+K1
MDY[*KA*DG5'=@1Y7TTQO%GG!D.*F]$NF=-7+5/B[UF"XOTVAA\Z%O0N!>LP
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MQ^DBUN!Y_Y^]-UU.7%G:A?]S%?HZ]OJB5P3V9A[6VF]'8 PV[0';8+OM/X1
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MF0I.H\!WBD]._:6_HJ_F6<Z"(WMP?O6B&A[GMT0?R9-/Q3"2)Q\\:8XS1O(
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MPT4Q=H+R;!C?1H;YD-EM (:CL(0H8%S8@(B&$\P(OPOV[%XOV 8 %BI'O!X
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MJT5BM7;F&PD]^LS&4XW&.6@G$A7L45S@LZ5)2@5ZFJC=ZMK'S&0QZJC8,[[
M&22SR!;VG:WJ[X3H3=>NXOQXUF+N;("7_M_O\+F_#_V6W.L%-^2$=8BT>TE'
MJDQ.#EPSFRY*NMC6.K1^G^3$G#6SD*0SBW9)TZ!MAJ-5TVLR1<+&_7#N5)H7
M/,2Y'B(5 A-[KP+53^05\'G6,T8$T;C9H<J69=;9#A-TAP&*P2;D#DEDE;MD
M/709Y+.V<D3R*:=7YNN4$0\L8?/ *$T'5)[[7GO_S&;/5"R2-8%B53O!J'U_
MC4GE9_90.Z<B *.!)-\BO=G'!JMOK6#QY?KCU^7KS>AGT;3R*Y&.:U'9VP9V
M$+WJ,!,98&B]>CE6SQ*!7(L9QNNR$X9),+WOQS'U;7(,JXO,78URRK,^U;+E
M ^48WPK+;&1\F#5=_0@<0S3G =T_NW KLYZNJ=80WUUG$#NMVD*G35*FA7W
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MXC^R+)6CQ=]JD[)U^K-?)D@5'3XB \^0O<NWT).T54%QJ>.++:4$RFLP4-'
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M8!4>O8OM>!>D$YNV8!M#2WS-=.8($.N#?%PP[ I(*SJ*'1?.=&9-AP(KZ1^
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MGDIZIF\;SKM+76HSC'R@M'SVX!+QJ(&%-7%QC.&ZHD;8IL>NV"XRN$B@H^>
M1Z:&1<PSBUA%(UXDY3<:4C]A"AX=X@8,%#8KUR!PBS[E3US3*B5&K-8&3"[[
MWP'OYE;17Q#>L"$3-*Y:5U3V*_A<NB/H+QL99[>Y,:C=@MRL#T?3FYY/]W4@
M]9.;GZ&W_FA3GQE\8+&YN#_OGO>V799QW(ZNV7S4P#Q>AEN_#'E)XEA<BPVM
MA2NQB_F.> %(B/%,]IG\&\"E6A9,JG $D_(FJ.,$DRH=P:0.0A"!&GL^DNL(
M1'4P]]Y>WQ0[!:+:#J;<7JW1A3UU' R_I<'P8&(2[%&DCDPT)@;EQ S- '@$
M#L(- R1C]PQ&MF\$IV.E:>UQNZ?]1NE-_9*O\@\HUC'NFW N_0:\IR'-M]$!
M[\I$#1WP3F++Z&LL8HX)@Q4GW]E=O*RN)^D'[R8?9H5[6V>2N]Y U>^OBQ/)
MJDBR5G4@?.(/!!#'@7S[H6/'-91'"&X[*!D"%$%@(PX][+"+PPZ$%4AG0V %
M_!4"N9'9A1P)6Z#NBRVPZLL[PXV):Z]Q/?B4/]ZZK=QA(1?TAB!ZD,=PH"X>
M00KB@Q:XNVEF)E).G67S4: %FG?M1O.6JU3;C2?L%1A$W)1B.7"(@N!0TG%(
M_3+H!6[?B(OW__:="(>'W6#ZM4?PALV"-QP:8[#RPT-;=NT+J3U1.[AUWP%^
M'0GDI?\].;3%'Y7(48G\3DKDP2CJ.+2%5_'OH,9HPDN'MO1KL8].#@YJYZCY
M-JU!!@,5#7C]X'1( TNB*&MB[] 6[H<>M?>+_JZS@)OFSGG^2<!7NWQZ*Z!;
M.8CL,)W+*1-=TWG:^+5K_*U8L#78QIK6OI;!V8H[%GW>F+3/TY>C,]EG& 1;
M:I)KV@]!Y[KF+$#\(99=<E/63=K--MX%$3441&CM=(<CP;$>-%>^4$@6#@J;
MJ[8987 U1AJ>/O&<=R,B#VKM\6[V\54O"\$=J\8Z.;)0[N2@92?L#+8H4>L#
M=Y5*I]GRGLI4Z(L#6<!5P. !.5DE7[Z0 4Q/V>9YMI$ZRIC]'EE3&G.;+HB9
M9M&GJF;J:BY8&LT%<[85<^!\6I(9I1XB:Z;(8^/P2$T96?^BF>T>+A:?P,Z,
M_1 AOVLIO9EKR73TK.G,<E;.;ODJFDGSVOBR-?MJB";SF[XS9Z[1F)=P@%>/
MD\Y;O&PB=UUGS2; K+L)L/AG@43&,J_$=Y#OA:IHV@Y,/>6B,DB/F[W+;#?8
M';*+5;0AOAL5'A_*100!B56 <NO-P\MDBLE\A)EX6YI>O=0MHBUU0J$.S@Z\
MF\FX>:M<3@8_WU;Q;C;/_O%1=R=BL?[4NL)I:MWQK6O*1?#9+O[@GB]F0^//
M#;Z+^\J-99C>K<+&47G&59G+WH$B^IBT*]?W+_?GST+4N]=<;APC]',KC]"/
M[727BB\OTHL&<?;UXGFZ>!,_GFL3<;A26"W>L]\5;O=1L_Z6(\-C&8/LG;J[
M-$1IW#)[_7G^4KIM7$U>(NOHO1XD'DSBG=B*ZX&SY7/)<G&QI7B 4\67 F=;
M="_Z'/:^W8QZ/O\X^_56T/JKW(S[,&,\YD/8A33FUT=N*Z1/B[E#GU3L_[TK
ML%3D#1QWOP./-6*]33YFER<6AS9*2<WVNK%O+WNYPN!A\%K/QE13LZ=U-)M1
MN^O5T12SY60FO3CG'Z\CY9>(C 6L;O7ZF.WQ>^7]:W[1S'Y]U$(FNL=2'W-0
M-3&;D8[U:V+*I]G%-LF.X@SN\A9/AG%'Y2U;3,?</ Y+W?SX\B*_7GE+),&*
M4 *S 2L[4@E,?C]*8(JGY8@E,)N_46+!*%^NM&5[MXAP_ZQ*J3N]E^W%7-JR
M1EPX7]X%K.YVJC?BY*:PZHWML5 W=:X]5":/0B/]VU5O;&!8CUW;%M:KWBCG
MDJ74WA1OE'9<O+$]CK^ZD^>U6?%1G_D,+_\#BC<V+17K%V^D3LN9?;6V_^@4
MXPZ*-V(I35ZF>&-[BFCR63X7A[G7C["8UP:+-PK'XHWM6NMGK\42%J1?8G?G
MQ1N%8_'&7FG60R_>6,I\7+MX8WLR6\B>Y:8O^E"[[/^)Q1N;MA77*]XH%I.9
MXF\)";_4+.Y-%6]L3\IN+OO/-YG*<_DL<RS>V)GG5ER_>"-]6CYXE.G]JU[X
MLW>_V?$I[@5E3O- TV9X14=AT;[8:Y8]&O(8)RB3KH26NC!RFRT)B8)I'OO$
M[Z?+KZ<7_F=EFEFB)(3!G7LS&DO2>X]*1C:C[-<L&<D7DL7<XI(17[E87=]M
M2*S\$H>QP*$L6XJR"SG+E)K9XFNE^OJS%$,IRJ'*W]*E*IN1RO5+5=*GI<7!
M\\,0RR5LD<6,M CM:$=5,MN3\]:L^](3F_/9..XJ&2SSR]7'; <RQUL?4]R7
M^IA,Q/J8PY!3O^LSSFZND+J;VI:%Z*W??_YU]M[\+.97J+AQ"DH<"FUQI+\8
M4HZS$GMM(<S-^)1=P@0LY1"<L#BK@VQ[WZD3]I@J5Q[GH_F#N&2.$E:^U\:?
MA\+;,_-*ZU4.Y<K%9+Z<_DVLO$WW =C.>?^<K]?GSW[U%]]XO ^9S+<P)WQ(
MLK8?CE9I_2JEE6+=^RF"FW2T/)')-:SM8#8*LK;3.W"T>MG;TO,X=R=<B^LZ
M6G;YWF._JI2/VZ]:X:1AZ%/VM_>KSC8C3DZ_*MT1&T1H-BTJS=NOXE=13-V]
M1VI@B/&ZB^@]E4+JI-;RGOY+," !#-+-L39XUDJN,Y^,SW+7ZGDOU7J+#_@T
M?J0)8X\' _];T1(>AS))$%E!F'AYQ@UY0%)744\9R/A!.'>E]WY"I EK7TOB
M "D;_XQ,3%<GTJLH>Z'8\5?SX[&J?&$S0T?2+/$?][UI'Q5?&XTE9880WLLG
M-I/\K;%;109L>$0AO[6VHO.2_>]51=-O%?T%X2O#V!+(^5C.RX75I-T0]1 )
MUQY$L5]JM]YNK<OP<1FB+C)--T:;)8W1A;1P79F19^?FS=FY!??LW/1IT<<"
MI>C<6"HDH-9T*&(.%S5"SQZ8(+K"=9%!7H%3\+U*&'1JV"@\LU%4TT;1*'%9
MY JXU\VNA6VP*ZV;J2LJ^Q5\+A8++P(C]ZYNYS=#Y?)VXC-@9A'%XC+>(C!9
M)(.M[$$6W^Z9.5C7N/DXQKH$$?O0D>3W>L'X-!)+8X\G_95$GQ=5[A/L,U +
MQITWH%U2W)37.,_5%F=N(+09BOSQ'%^P=;Q(FC'8?HA'&E]_7DN_7OA/'W<P
M$A6WVT^YD(:[J$TLQ]%55O*K%::W);"[AT\K>\"GVYNBT+NXR&0%-+A\_IWY
M=,,#T,KK%W#D3U/90#[%Y@2GP0>3"?QA,.CP8J39\;;<X(*;<H+>A)FBGYN(
MOE!O0F0$OV',J]1[ 87R@"2$61DDI2KQXDCC*@,5$4[GIJ(^)*\!;L&'6JTU
M\0IT](ED[EK41.X[0%YG4O\:+S$?);]/__OW::(B29B%J$5FRN(020+7G7$W
MZBE]D3US:NU@BE3$\;T>?CM>,:P>+U@<C9 @$H>4HZ]-DM]3LQ9V:N9CB:L[
MQ<N9G?25B9H88:H--:Z/I<SU7:=<VT8M\/Q4L#<\VK:X4-LZ7=5,T;B^\4]S
MU'NH:J^YCZN<-5")O&4EI]+_^WT5"KGN,D7K)Y="*,;@YZ5._9)]3C\/GS'^
M\TF/UX8L_N ;HE!17P*M@5T4X#Z3 ]@KV,<2JF6LPZ_Q1_&SB.A CB?&_U'E
M;%;EW&*_G.39<W;SFXD1Z(!T\5^-.U/P6< )G8OXR'0%F_,DKO1)])$C$(6/
M?HS=+%:=N3!-$V\!><,RO--I_&66&4,>;,_&S([Q!A%@"_3%AJ52;C0'*5[(
M=W,6_$;3M<?]*-W.GZ33V. P=M4)W)1+::S9%X<5?"%="E(9">.J^ X<Q:X9
MXO0Q(CX81#2NFB2'^GUJ:W!NOJ3JW?=QXOU-L'>IZOP[OM=$.8'U#5;_/#:C
MR U(KQ?\*6S7C$0=[J'NS)_3[>'34^YNHFH3;/!!,$L/^G[\=GQ#NHS4Q-CS
MJ"TNJP]YG8-;P[A&C7N+"MJ(;!T+KM+OBSWR$VP L6-U!MF 'T096\H@CZ)@
MBPII"?;=QMO);4QY%^Y<]E?,3& J:!-\FYK7.P]7M7$5P[LARD0N9_Q><M5[
M;M8-S0NE9C@VB54P4,X1_6^TUD*J!&)1!QU-U4].'F#]]!GR[QM1%D>3D3EK
M8=P<99_;I5]UR509M0 :;E%U+$_" .>;J)EE% Y0J>,@DD,%8:'85($$T4%)
M$G_J28H&8D$/P/1MF,7A40'8H,%F)KO4L-+  J.HQ/:5B1*ZY36!_^#(7L$(
M?4<Z_,G46%E#8X'A#%)E:D*'_%&!(YJ 2J&#3:Q53LD2A$F/BOM&PUP'*G8?
M^LWSB+_@WP;H*':1Q&YC=4E$[$X3("<C11#Q]<4SBTF;2"!$(ES0F!) -UX*
M\R'\[AC?="79_53&]^10',/]6FLU[^RG5Z-OM#EVP7'9%0S%Z<_<]=7G5,QD
M+4.Q$6F/D;..4;<8,6BZG*&8244--X5[EX'QIH3A7=H2ML)$-;Q'R!_XI@^(
M48A5I*@YT]Q>OO'-&Z[%-_ET9EV^^<S,Z[/Y]/TI(^XYWV#%DUF%;S8<E4C8
MHA*KE5 $.!11D]F)M9+9^7U.9J_ SZ6+0>_Z]6MT\Q$2VO<0*+E6\CH"1T9)
M56=2Y=VGJO,!986)8ZIZFY&P3(;<+KDX0V'?K?A'GNF;1+3XA[$:\Q4U\S.0
MAC+#]$9\)+_9^$AE1"]B$LX(#))X%^$(DB2,O+T[2.)Y^T8B)0EOI(3;:J3$
MX;)9"LOA"AAN TW/IM.9#%'3[*<@->U7=$32)W7,,/1;S",QU'8*G\'GK*UD
ME:([SNG<U4+7:<%6 C*EV*?)9*R?_.J1PK?@U.3I&$(*84G\J#$%B"&T5HTA
M&%)_RE4TXYVFX"= \*E .5AQ(^&%VE[QJM;L7K:$MO">&?P6O!J#'Q[&JYMS
MQ&,I6J%[:&C:! GF#,85G/15..G\?**CMU_WYQ\%*Y-+:.!U&S86,_(CP,IU
M3\MQWIHNO57NM-BK]ZUZBF7B\@(&"JYJBH&!^I^#\6MJ<E^S04'N+P-%*4A:
MCH'6].VM.*(?+FK4L- 29:6.0J;(@:/SW?='Q,"KE>9[=UC,?+:U0D![!+$%
MEF?<O6F+6(IUXVB*V'18RL^/VTY8:BLL'U-8:A5A^/S,R;G)4Q]-^*V%J5;@
MV$AAJ\P>=%BDMA6VVN<(U3?C)9@4V/.7)@+Z\;__[^2$JXM($O[A[C!3_8N?
M^I@@N0>K2!?_I?VF^&?NY(2U\@KB9]1AJ/2K3W1EC+\>.D+9+XP'"K#-_Y'^
M3ZZ')(GUD?[?M]0W\F^\\Y[Q;^=7]A1)XL<:7IGQT[_<5!3T(= D]9</-4.F
M].#U^36K!HR[IQVCCJ_[]J-^8J>D0<-_.5 #_W 5E>^*O7\Y*%*G=+Y5@*#I
MLOVI_QJ/P9^L'EFC0?9__\64]SD#[ MBA8VP+.)WC\D9VNE>\*$[)8C)2R:'
MV+EN[/A"^S)A_72)-D;:([GY7]?<1/?'I@*\\?<-XV6?U5Z:M^>)2N,AR35N
MJZ=<Y?:<:SV>M1KGC<I#H]8ZN!W=-MNU5J+=Y*K-VU;SNG%>:=?.N7KCMG);
M;52NN58;_^*F=MN.>6M[KH?C)G$BARG9K%Y=-J_/:P\M%@KG:O>/C?8+]]V(
M*@M__SE4WG@^!KMG"6]I9B;-T4X9K@JY"Y6[UH53CO;,<&;3#$T<N*I.\9-5
M\@<C80+A4V6J$9.;EIJ#-6VE$00CO9-,F-D$FES !PXA-&@2 O/9T85/W$P=
M&T&Z8>X3MT%C_0W6GXCW"X][-^1;B$8C>6"T$?<7J2,S+FP. "!1 )KI,;P(
M<]LDAS) ,K9N)>SGNFU^S[R/58(1Y'^>Z!*IM8@M^M[:3=/$4&[*B%**$@K3
M*:3'[/KY_M=CO:54<M:X*[:NC5CQ2RS.UZZ?8KM+0[++M,_Z3KN)Z6"^_8!^
M&AI#";#?"<]B/H+>HS&6!@_3>-!X5AD24X-WDP^S\-U.. ;EGWMBZ:=T^3FP
M51 :*SL@IHEO1)+[8+[]T)$<SC"D+0LT#\GO<@*OH]-$TU,:FUDALXX5&.2&
M25,;UM-8>6+_E@9,0.^15#9\"/LXL&1>VHR*HTT8S7[%_!X:QZQ,]*&BDEB>
M406;2:=36<+ [*>-,G#IX692?3J79Z+@,T'3((MD7#Q^]-M8D'HQT7Q#UAE2
M[9JU?HI'E!SB$C6([=\!DTFF4BGX_X%M<Y3<, +(<9D;Q1K6]3SDM=!A)VL3
MW\.GMF:I;3#H\QNOYU[[5]FKG@^#,K;DS>5MES/#^9%%GS?'A>OU8>4B<F$0
M=8T: _>0JHVD?%T4_^1%"0(P=44EG?4K3X1;@2/U7NG7ZT>M6.AW0SC26"$A
M&;G7ML6-;MJLE!)9F2FSZPT/3B>+N7PROY@I:8>XL=>$O_=RZ+6/NS(;D=;C
MQQ!B56%.A>-XO=Y%;XB$B808_WD8V%8QHU4@CXJ_M UGUL9[.9/P'[\YI@J6
M'>[!VB_O##>J#!H7K9)V(3Z*F6Y\\P\W,4\PH4U&^.MFAO??&X):@6H>YSA
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M-3,9I_ZUKRY&;9MQ0.Y%@,)RJ.N6CY_QMU-",XPXKH-,&!!O R,\K6D;>X.
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MNIPE>S:+/G9A#YD >\AB^&"PR,SQM3;A,R_WM3;7O,0KC A(1G,S01) V,M
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M#]V+=NL-%?EJ;4N.E;@*3&!A9HH5'J!, &$8-VFR_CEW<)K+J.975&7#VQ.
M_$D3,\^/Z>C_88;?<]C_:5XCT!PGP*4Q(OJ$:ETD;'$Z+-%C8%X6K _ZLS#,
M0(N%'Y 5 :@&(V:\[X3)8^-+QI.L-9@/"KC2@.ZOD;\U+Q@,6HE 1=!34 ;7
M\D6V.JS1+A=BGB7FZGT+9 >EK\4MH5,#7CQ,QM9S6 2OS2/P25PJ1!'XM;@A
MX5"M^-WE4TK -&ZS9M:Y"8Y!X^!T# & P+YVH*Z]),U0[C8GC-GGAXK ;XY
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M%W"8F7\DC:%'JIZ:1\X\@BW5O=HZM#2X_ .^7$V12?=*Y5?K@UM\Z._^U6I
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M7^!D'*[2^@3L!#,2KLDQ-=Y@\L)P51K<YYG/=D^KX"=]N7O\<D#RNQPPW7+
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M(4H6W JF_-^P;+!(_R8;+1LDKA,I6]@/)CWO6):H7\%PNVNI][-ULULN6A5
MS6Z5*,V][YGXT$O_RM[ULV]D_<]-I]F0IL>@VB-RYV=<)[X/5[H)M,?U)I$0
M2/HP=WW6?!_8V/O;$<U;DI#P4I(^S)X 1#MD/_AJ5/<H-M;N#Q[1X L"C*<P
MSV\+7%RCP><=L>V2XM7:XG:<[8STI43OOF:?VO4I_38/I]G!N^3%6=89+6<8
MXVT/V4HB;\-RT)_UVG<2"7XEAD!O.4?"NV,A!Z8.1>#^=^S)FA*:LX:$=L2:
M=>$$L3/2EG=ND9I\-.X_1?5V&IZ'LL%<>EJ?9GK&VG??!-,ZE?Q?;XY$(9K/
MZ_W5%1F4=)Z"A2-1ON93L!!H=MQ:P^9H'*FA$,A2J^L."=//S:NL7&NT:7!*
MYVQ5O[L#)<?C6G]M;#LL?6<'QJ4&>I?B['(H"@* GX&$8\195Y4@LR4O?E[:
MC0]GY14=%4TIHFC:KQTNTUF\JHWZJ/58;=V?9Y/54>9(;CN)W9F')[\+X.>_
M_W-Y295%( G?J08_ #_@.SXFJ-,+@L*D?U!(A*.?J<M+DUD%<>J7U5RM!H@?
M5IH-6-S;M%>+T>[&(3J!2O776Z@V>[L0/B]6W2 ZC=8.U^LN?I8OG9BT</B#
M:L_'$(*<"N5_[P=5@^K2P'--00AE,LYO?;.^AOZTO"'6]?CW&\2\!PU4P+]?
M&@-9OT.)CFCHQ#OK@7<#(2L=(>:O+1X=NU[H!!/!;X#H8*1#.'EC+XI73\T6
M]EZ"?C1H\&2H?.FE7BM2N4HS3E5JA2LJ!__5>LRW*L5*KEE!@TZ[!U_W_<&J
MU=NE%M6N4X5ZK56O5HJY=JE(E2NU7*U0R56I5AO^XKY4:Y\"/C*TVM+;;)R?
MHFE$DOJ].7*6^KMG=*H#X1\2IPX@A%TG)]TDS;&N;8Z.?F:[A=?/)INM#=.9
M91*"S/,["Z4I/@K9?"D[Z!+7[*2[I(VV9;P,"BNN,5J1@P9D&].P17C*,5Z<
MPVNH$;IOSFQ<]E!37:!_HKT<>!F A2UL:JO6#AU]==DXD'FT)2JF6:N%'*.V
MC:\I_;7%#&FB:Y>T]6U+:^.)1_>_JEQ%R(F-M65+*_!"#2]!S\( =3R4]4[S
M6EJ\,+-I+_DT?VWE]$I)JC\DN%JSE7]\>!J6'^<YI7G]E'AYEK3>/%]_^74[
M?_G5' NCQW$NU^F$O;])"S:DA/,;(=NUN,FK6MA<W&0Q&=X  =!HS)7U2N<T
M;?V,0'7V^2^[\PN=18*_3@/A7J3'R\:6;=WYE7*YU"S5"B6J!'\JM"M/)8?>
MHII04T>^/=]UOA]49+KU6<]!ZN7LS6<J^U(JY;JKSL6A3=_&YDA?#O+1.^#)
MGM1<:4?BJ#@8$,*PAQTH82^V8-CKR&CV,F5.'][GU;ZSKL>Y(?X'9?O$BUO?
M$..(R"",^-WYDA*DYDF4UP8-(HO-9=K9OS8KI,V2Z!T6GYU[Q\,%'_FGSJ++
MU.ZNZ4E1KH;3L;IMW(3Y&Q$*'Z3(<43-0B+ZNQG!<?D-2W_!,KQ7R1#5^;^$
M:!C(:.<21-O4,G&&WIV%.OK8YA498ON-V:+C0A%PG'SXC>UY(I_HC;AYGEMN
M8-W.QQ<^F6T[KQ$X7D .\UMJNM,MO$H<R%M_;9&MA64(8<.U7$9^$'H FI.G
M0&@=<Q\]Q.B;1.> =M<K-8*,I_==3N%+7A;0=D%9QRQF1%\D= #7+K,XWGVF
M]&U^-->LAEV[XR\QQR6V).9"+3M:RHP]5WS[X9J=4N.M-K[16"Z;?WVWI<8A
MU+P@00HV*"D.*<L,DOWW=3G,L=44) EET#7LQJ3?J=B3J&3;0BHC&E5!>Z%E
M(8(HB10PF^;:[/(A"GB-;$7V4T=H:+RAINJ7ERUK0?@U4 8J/QXB5LC-1*W3
MZ2$74)W#5Y8Z"SU1Y3_Z=&(QRQRI_F<76S&&?K0W$WNL53]I\>KAA-IFNRTM
M-XM.G4IIQ8@C4?V:.KCTE9@2+^]I^.]S)<2:J='%+2J]L]>-D9/J(E>;T;\:
MV:7^W\:MVQ3\#J>4,#H.9#S:KW^ZPWN@KQC2/6J%W9(4SXS)"2@A@ZBL!1*7
MW-O[C'L;O#:"2,N >M80B,>89!1(\*WB]5 F"]8-N=($F0PRHR<2TFV-34,0
M8;\J]0^-YRLI[<T68>9(I5!%%6E6\=NCN$,>):[8W6L7_,BCL.RGW4:XIO)
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MU'P@46C*).-<8C??>EK*?@EP1H3W4_6P+^5#,S&(9M\8'UV!/KE@+69X1@Q
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M6=?GWV\0\QXT4 '_?MD%\+[#9X\Q#9UX9SWP;B#$YEB;#YV\/7:]T DF@M\
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M#_#PN^AM[L*R3VCW81TN >C9\D9+$^YVLIZ(!""0>R8,N;$J2A1M801)B26
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M8UH"GZO,\R4VR3T_=S]S58VNYW/__:]QNF]=19BC_P[UD?3S_P-02P,$%
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MPGM/O=BAV$%P64LN8+?*/J '<[FN@K,TC!(/[X0=:0W8TV-#(ND37::24#-
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M.5KO-.XZB]Q5A>@,(AYAGR*>^ X_6XQ3P,<TPDZH#7AU<02&MWO?C#)8,\D
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M$*/5:A4V5^'J[?G#$X-6+FJ2X\H#Q3G<W4 XC?X]<0XO .J;-#0CD_"UPDV
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MY.@5P[^X//"O\)V*".N)5JMRD,B82(:C&>M14IJ@,H-\!LMD2!4R"*=7VJ'
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MDN:O,4OQ[^K; ^+&P9U@OCX"<H!HZAUVOW2O,]=ZT!"R&%G;WI8M6L@Z%UF
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M*74R;L]"(/5+/TJOS+?PC+X&.KQJ&@87?:#;\<'OR(>@LR,\/DO7*#/3;0&
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M&EY1+!(4P-MJD[+^O?ER+.:XL;VOL76>S,7>R\EDK B7V$LPPR;90O;UEK(
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M'9LTP0+PR:<M7CLQ9Y!).VF:^ ?V=ZR+KJ7LTZ58'% !,73IZKDP@CCS:&=
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M_<+F9?J3J"O&T?ZK=L GK41];UKZ\9ND(V'J0Z$;=0.UUM3[C0Q9'/H=4!K
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MD:HWS,V#UXTEHX\^UOQ.K2QRO;+OW/X8Z2KZ_!CG, 6S[> O&<CC.2VEBA*
M/)YJ:<N0V3O44')3&G%1V>F$!6^=D:U*2X)<&HNI^K9YW$_HC.X;(.(LHQ3%
M<"8%11&CW9S/R+G-6/MQ-@3/)/J^HC!5?,Z9A(Q64"T_D&FL9: "R1N87%]/
M="M5'"IGEX.'C[%",9_U"7-OF'T8C4B=:UM_=; ZG:=Y-#F$(:6]QFDK])!N
M)X.6F3>=KI#DCW\*Z;TNERJIWG:2;9QQS\0:57MI8CI3HFM1C0G&4(R0UV:
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MX8-+NK^V!$*<M(SUN?S[4>O\IYS34 PV.XJ63MB[M!4LE(=R>=$6Q)^=7IM
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MQP\J&7;+:_1,V;9K54?B5I>Y=$3FLGE'U,B;2RP>U;L'Y1?M,O(O&!%LI<+
MW(]9QU"2(PW+=H8OX1%[NLWGA6Z2?K6D860IO[%INGPEU4N=U?2">Q'$E_U>
MVRFWV) ,M[X?54?:R=_4=" 9LU7 U(=KO(0ZQ%L_L;4ETC[.<0&4B->]KP$Y
MJ99N0B+99AV:X-> H^F\GV-YDDHIC EF53I,? 8>\@.O9E=',G53=W*RL\%L
MD!K<!VHXT>9BLY#$9+4=]$UL4\*31*DB"&=.7VH#AFB@K%;Y.ZO&QS'^I_)/
M,H&!T?GTUI?MS7P<RB\T)I)J%,)29T<U)4>GW]PZSBC,Y+,SQ7PMB1XX&3J1
M>I-0 ;]!NXP+"D\Y8HYS3K/+'T/N&H/,YODSPZE:-:K8!L44@+Z(:96GYAL[
MA5QZEZ"F&=X:_>>!/I*Y$^>)WREV] )Q+1A4SX^<]\"7IOM\N,)HK^M/A@<Z
MZ?B"B8QQI1Q-;5/5V= WEHY)UG>SO9X\)WUTY<?(/6I[T'1':[Y<[)J/U]TO
MSDAF2AS*M1D<)R:;'*(2QGI/,=.()-CRAC:UZ=XZMYI$%3E*JMCZMZ*^HRD#
M;\PE'.RILBLUL",Y].KEM#LPAG>HZ35*%;? +@*/NN[CA;.PY\51KQ]Y')R$
M(6\CV8I3"#$=FH[4Y<U@=7-'[7:19<F\6@CT)![%'XVFS%Y"QD;<RBI\ZQ!O
M(($#L*$"I<IM-N?NQG;<%)+H$OY"&WK,):!P]+96I]JU_MSWR7^1UY 7IEHJ
MZ+'DC_; $=7C"U.-%8T^&T5.4:^XOCFB-\^=LZO_ 8:U'/).ULY+[;>N0AJ4
MN6%3R#<K@ M6C]#Z7X3)A2?J_&="0@>_T7WQ<@/=_TC6O>Z07A=G%A[?L76[
M0=Z+F*'_X5;N(__M2?SZPBM8UOAOZL]:()H4$[?R9E^FZS9\Z,@^)U<;KE"C
M@HSA'"W#N =*_+&VKO!<L8>$R!_:.'KOB1T+M[?XK()P-=Z^>*/,6>,+=O;%
MN1W^1.DH6/NB676.*>E5<YI)V]NA9M*\)MQ982"]S("6#@G*E*DU4OJ.K':R
MIQ%?:5;*QINRP%_[K$31;E J;9]/P>2UC9KIMRS=VM69]:-QKN0Q52SC:X4'
M67/>9GY^OK?(E,<+7YI9;C*N7$T3)%^L"*JCMU*Z#0X/"C 7WWE&7'Y9EV9T
M"R9;Y>]/$$PUZ#!J3+)5Y%M?FGZ\_(W# WO]'S:<5O<XDJ0"DNH2G\W8E-:^
M1^;^)_MPK-J;CF2"]_&+6:( 0N$%F#FA?TKNQ^@TOV=0U_60Y.%<+^+\'UXG
M( OE];5H*7KISG)-,9KQEF@-5^XIM$^8_YMG+^]K23?(OFW1,<+R7?G0BTJ>
MZIQZJ*K-MH]K:WYL."HM"&FX*DF:BY5(#C*EJ^/U6OVDS_-L>NW?.6H6<BGR
M$DJ458]TC?O5\:AR<NN=@[YJ4N67#9V&*1&]3;8BNI];Z@\6+<-V\VVR^U>/
M5SS02DY?82K^C%MKXN@G;+O. /C+=:2R('?4_UUTZH?5 'X,^E>90A+\SBU,
M.@3"H6"W][581>["K]JO;]_8[+IR0Z Q%M%I/GN7QN7F@3 _8^B>%7.1[_^8
MKQCC-D$XG;D'N%<K][D=?L: K9<(MCO8?XB'OHD,YMB:"+%S?9^8QV-KOMRW
MCRS^N:\C <I,I79=;YM=.1UE@!V .);XR)SHU 6$ ?GYDV/CZ+S,X1(*XRXG
MV,Y)?G2VXUWS6Z%1M+PU@[>BSP]TN)"P&SWS% ;^^. 7M,5G:7-'KU?S.:\
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M*G)9^ :AW$UPUOLS.F!(P/=6C_67=$'2(9ODJ',6F2? 4&GXMYA(S^K='>W
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MEPW/W47-?,6K- 36^P7>%EE,:1W/47V1]7+'R+2<LQ)H:.H:J?AF;VJXC9C
MO8B5::0^8'LEI/7Y^?9S%3^2P$>F^7L=JRQA7G61[3:94>L;UC6.O2/3H).
M8H1'"/T^@7ZYDR*]':$S9_&N(76W9R^VB. L=',"^J3=0$K=G3G*T$W>=B&>
M !3[9V\"KPB4:HSM+(IG&JO$3IF+,KKHO9,!JU0G)Z*'##[S=UA0;%8"3?%
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MC7N6'9(34(*),LU>Y?8@D+NW_GC9'X&?<?9Q$"VY;.$707"'(Z:_F$H/XS^
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MB/>(]*ZSTE)(ZGB?E"I,"=.D82$)QH>,%&>;)F^E\/:T[<8V;A[SV<D)H:W
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MI9@[=VB-!N<W<Q4[VQ*[Q1*(J()3;V*(*$\1-S>MJW=$7>]]D_NC6Y"9\;J
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MW1Y??ZT.JM1J@A&R:;7?XOOM PZFHKBO7$6[6GEX+PUQ=)AA54+GI_H?^@2
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MF5GJ3_+\$,HX:PN'83=O>7R3:1J-:,B6JN3OH+N<K?',@OL6OR6+9.[MK(8
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M SN?;?VL9DD%/;\:T_KH@J2FAJS[C=2YS $#W [XS@>\P)ZZ1K_K-6)XS:*
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MM>JD;<G\5N;\SK*7 / L$>*=)8]!D1$1DVW@C[X@NANMJ9$F.P #=2K2P4W
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MGIXI,S=NOCG&VWN9M*/FV AQ8)^"/FN<3F+V9\,D1LRB1O/4)L3]O6>^(%"
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MO!S-9"^'KA01@SO;P7\3K5:_5^OAS2A<W\X.17\5-0#'P>SS8T6_XL(/D\!
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MMO>HL\O/$U3K5/:;D:I =EW\YVE_UQ^H;+%<3=.6/-\NU;K,[N3HC+ [PCW
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MY?4-K9>:HJ5S7=[LQPT="^[; 6%R[F\>9FSC,@)W$W6J![>(%^GB),(GV-7
M(Y'%V84<-/I^?0/_X.LM2 ZA)=P5YT>PW 'AX_?Y>>5ZW2K)(AD"#Y1;[[\"
MI#J')ZU*_%GJ]_D SOJRUS!M(8][@^&D47<@*Z .EF+_XGK9%E10"\MT?/?]
M_9^FF"HM8UB8UVP).?>N6>?*C4B!&4^ZP +R"*9Q_)D?3CN5GF4:YT8_]!3
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MKM0C5F6O5/[@_57K(?N-CO.!G2T0<^&MK+!'( :2@1L0;;]?;I]GIA8>FO=
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M,6@60.XO";$ 86DD 8O=)\,V3KZ=<\\X4\?Z0^FSX,R(8U'PH-23U-I\!71
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M"SRC3K.N@/>DPPN9-E]KD(KQ1<W)Q6!"2YJ$L- 2YQ#_,B_/"7F8RU<=KM/
MAD;/X+-V>^O,CA1>]^"DXT1R\V7X\HY\98JV/U<+CV.7M$I8"?8SK&$\LY8%
M.1^\,K<=QU7<W,;^L$R$4F/U!X10CF_HR:""@4I+.XV[8=U*,Y'J0Z\Q7I7+
M;QK,WHH^2JH%F1<"<R_\WYB&>@9":=;\2XZDYE8\P5%<)]2M 3$5?C^MY:MI
M;_KZVU8 ?%RKAK7> *3I@6<AVM#0>'IOHV9$_O6<&A@$+;1:*[T,WA&<$9Y;
M>RK;LJ"%=Y1L@PHU "'6!,"@Z]1UC&L; ).)A T3\;46%Q?"MUM:[/N1]3DW
MMJFTNZ2SM/"PI::C%Z7INQCBP6S)V[[VV-HLB$Z92B*BT^VX.?=,X(K@DY/6
M4@,TZ G>H^%Q8DMM'\4*Y\7+3I1-H;,/O0UC+E4BW>IRW "5Z7.Z9%P0G^'T
M1F7OWVO,X[)_A.6+B]R.^6K./U9]NQ#)(S9/2!O2=G>QR/>RH=N$2(ZV-]?L
M7NPVKU'\S85S TO36.-1E&K0BG[93,1\L1/\OLZ+=1_>[(R\O;5C:0O-""#.
M(7ET3N"\645L#U3=$L%"I9C;,EOH6PB('J$4ERX5E+>_AC=)>0X^6/3%:4PS
M&T8F&&KS/YIZ^KVVA?T,L#^;&0$TGCIN.=4"Y;DIWFY@IE:&(33'Q)"6,IZH
MD=?(*FGMWHC/:6](S#)ZFZ\),PI\W0-?NJ5MSB98A3Y'JJI'2JJ24EU2.&Q,
M>=2WLK'-D'YBEEZG,=?-)B=A>25>8!O; )XDQX$J@@Y"L\D)GS&2*K[8<V</
MU8+?Z*2_U%LYWM35J'UP/.;-D/XYS(>_DJG-[/QM]$OVM/TS*,J^'XD9%=1#
M6($M01>\R*MW?AW7XKYR$+]EE%TT5W]VW/M L'KIJY&)\C95\VOH$L9?N](+
M'CBGR,J6B2'-ED)OO>3LT>/@++9(J(>H[8@30X(#><XKC!@+-P NU!O9NVJ8
M^RM?(R.C'A>J<Z<L75WC=9VYMQ_Z%T=N 7ZMP/NRU')&E@ 5VZ79 PBF\[<1
M]$,QO)9/LVX [?E>>JI#[YPAY=(+7U^;\NX G<<5#/6WG079/;^682-/JSU/
M:TYZ%A!/\*#M"(C0DW=A)4.D.ILMAFPU3C4=F#]E;CIK9;O\[ #\,$YQ;'@V
MM<@';4Y-ZVG/'OD<'3OXKO[M_0=#YQ^)(KO$D/4]0R9=>ER]>*$M4*=PY+VD
MT*JH_-YC#268\U3SE,"H GR],W@G$)!V (9J6!;=ZK,BC0;FGL;7SO +=;R\
M)ZPN Z_7]('OM-I;[SBY\#?TP.X[7AW-""FPQB;G+!A,".!T85R!#0M)UMI"
M6!T8^<*Y'%DT@HZ.*"@#8TS6(A9\!RK/??I&#M=V\GHPN;J-6W.ZKN[N^C3I
M-/ ?QU_2D:])$4-NHU1ILC/_?#>Z&TW?4CN1LNJ;"RZVT)66!/0-P='S4XE_
MB2'W[DK8-7T]3PW0'[CV/6A)Z]7"RW>UBN&8LC/5:K@WY2SZ5R?^!;"1)]V>
M9P4$DF*/@$C.\D+KO,U90#:#X!K*H_G*<U!)RW]TQF$R6@O;Z:G+^)<\XKVP
MMR@'7G=<V)IZAWT?+""BUG,R>]*)U+0?\O*=+[$U)W<OOV<4[]$:N\LIZ4I6
ME;%]V/2ENBOAKILG5URKPQ\<'^W9;9[EEBV;(MG*[@G.BR$O,=P%X?H>XA_B
M<9W[ME%T"6%*UE104")+5\*DSE4$VWH0\3,7%(@A4L90$:I'MM#5#R<10WZI
M&'**V3$!RCT70WZ+2""2@ES5I5F+(>^=9<60G"6I:56/)Q(88LJ(O2; BFA=
M$$)(+Q"IS+N)DLDD.D_EA!CR8PT2;:LV*8;P\H/SEYP),1)\<Q7%$/C/_Q/>
M_Q[A[=RV;1;TGQ9#F.VRS[4-OOSKE+W_<;;;5KM3%HG_84KB_W.RYXKV+ZD3
M_SHC]#] (=VWGVSV'_"P^U<H($LI!A(5^C_1_?\;W9[*_\7Y^O]M> 6LD+E0
MD)41$]W'_-_A;?Y?/#Q5U^,;_KO;O3M,86BSI13S-CH(\C(%T?U'#+'D/U^7
MLE\,04P)Q9 ]_S(@4&AE3LQO#>W[E[\ %7YH#VT_DG_]7=&_#5P<N;UI_TM)
M*V/>JZQDZ!_H5,GZZ\8)R-\GYDY\AWJA?8N^%:W4TL\%&'E^<J<;!AA$_D@K
MPN7#: %I)-<_*8>M["8-%N.I@=RMW6*(&B[Y]=Y,:0'N7+OT:]9:2=J6J>$M
MC_83T%PE,>1(9'+[+06<*_>IO\CZ7;O!$H6=_=?@$/:V1&X/@E]*$9.+0NL%
M1G[&8T<LL?QK>0WFS'7?WH\HUF_AM5C2]VC29]?[,XA#* FVO%RP0Y0@AJB(
M(:P%5S'D>QF";0*0UA1$>I(B<[Q #/EXGMAZZ#/Q)^:V9"4(DG7;"P6T#Y-7
M]4)Q0L-.XA_II;@] [&7_RT'X82$$\QVQ)(9F"^&R$:3Q)!]DH?*D=.(/W$
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M@8D\+H.NR.XU?A'*F;\Y^8G)Z/VYC@\[.8,1=+D;9->^\XZZL+!WAJ89V[W
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MO4M='OTWJO_K O2SA3Z(]UZ(!1W3]\OC,],DV@S04UHRB!?C7,,L&+PX]F>
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M!%5C<[\)?TKW/',H86@+,F<<YD,W(3[\!#!$?@&M?0@5F:>"B=@HS"F:9P$
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M$[\HGT;*J(\')VN[*@*6I)94Y0ZK& F(WV2/0N%+UXS+=DTOLQOPB=KR!_)
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MVO$!K0L[@?+JMJ>:)5*J'8?1YH5>3;7?,ZBBIA3S!!KS,KMJQX35T'$R2N;
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M$.=<TS,M8E045] 7W,BA68M0JS'L<E3J\B)<&1*YM(2]4=<X+CHEO73*K6I
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M;[04Y$G3/8B=2^G232;VR'OUCR'!N@Z*F#)[RU^'KC)WBRYC/JJJ61+M7M(
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M\]9Q33]A$=,/-TMXM&;]4&_=)KL,VF:23LE@]N$L&KF08L'UGE>5T@<>6L;
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MK(TM.N%;[D%3)"CT--1KL?\JH'=JAHD& '(QO@TZ*;R/-.G_=/CE!X;'BX@
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M]]H27S"?JQRIP@.D83W* LD/&Y%FB=VQZ!&\63VCQDMRMR8EXY(NDAZZ1,Y
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M\F0WDK7,KY+'=4[A#1W$QW1<QV,"T)=48(4#-VL+22P/9_R8^NJGY9D\E&B
MQY.^S9*]/_+\?G_T$QHH.QB+#D"R[X8)4=3PSCW ,R$JA/5^.BR<45(F/3WN
M:FFH+8 [8/_T#'GQ4M0)HN%['N7U1LP;O-.E 2LGP@JQ=3LW]TQ;OAT,+1H.
M7I?/,B!+:P+"#$+SB6^B.H.6DK"?"$-FG!TW2=[@'F2,VLU)-35+=T%A_'!+
M1T>N; .^L1L$7840"L,K\Z7"16.2?OTL13(W1CDU"YZYFY%.4%_T!G*"Y%C.
MBB;*H^<4>G(O_=WH$%>WQ(TFV6/!\6K<A#([UJ3H22H'\<-JJ/C6JC$I1RH'
M!7]NX(4UL, -#V%SGO[A0K#=>)ME]>Q$H0"P7@'ONZVHAC[Q?'?J*'7E&)U
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M*>A?/$Y#E.2MI>=V3WQ^+P3&_4Q--D5T!:YT^Q!E<*'LBPBOHHB.4>F5.S1
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M[32C&,Z)#A@ T %Q\10!.N FZBP=0.IX@]J^C7K@^&2K5^JCS]=MT,)&YG.
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M%R&72I!Q?9VB-Y)O-Y%/T'+)7#+ XUT$8QG@6:2^3=)A>Y!5O;-<32:\R9<
M*^6V3=''RBGVZTW=T4]MR?M_]6IEB"$=<)&&H0,>-&X<2;ZN*>;O1&\JK$)W
MV5OH@!&/RPQ%PI=V%)9-!Q22EN25C_H8>N#!_;FCF]V@I57_\*=/ ,+3]D$[
MRA;/YUI]1K(%-*ZH^B0_" U=@;52#NO_]\-<61: G^'8(CK Q?JP7%O!V5B7
M>EF#GTK)_HGZOGO-XGZ)P\?RG1(S:X;$N(&^.GV0_(T.2!3^]Y^ :.X6CTM0
M\@\KG$/NO]\C\4HE<&D6&N.[ A&C*?[[]V\!\U<KD*NZ:>Y_OU)#!_S4R0S]
M18G6S-V$+.C_ZU=/_Q.UZU_F; *2:<P@VBV5_YD9P[8!_?K?UW*?SVVXA.1B
ML8KU?XT-J(B-)W^22IA/[-D >B5E6!I7!QV]VPTS'BP/6[#XT#S=LMM0=H!R
MU/]C3>5"[8Y (VB:(*:6BY[=H,@Y;O M.N %S+RI_EX5R;I3ID/8:DW&3#H)
MVT&3/RD+YH_U\2A'N<X9Q<-]/\WH')E%#3Y^;'!#\]FKI&:M=2W10F$Z@&7N
MF"8[<GPWG%), $6*'JL)]-_@6I$6;]E<@IDPZV'8?4N0*9:9O!!7;+4,6)G[
M=K] ^L_)2:VUIX'>R4?]2/;V*J1,6Q@WZ<7!;CDQL$F!L ;23NNTI?;ZEJZ^
M]K#UXN/X[%G+J7O*)!@Y]'[II5YVQH"V> H-'JI0YQSY)>SJ=]^F0GZ]Y+,^
MDEPU4C%/;*\PY*C;:4U@S.4;X-,:]H.I2*-MMW.#0G;'MLY!CW+\47CH)*%'
MV+_34<1M&HQVI7RT9GOLK1H%?%&7QFF!7^"];0J)O-2=XW_5[QK*P^Q*AW6^
MLK%\[GN4Z]U:):X,T4Z0([# EQ:4/)#Z[K-V[W;/9L_.P>'34-1%.8M@%!0U
MB\I>94@$"$3F!(_Y[?_N.LW_[]M_B;7/[,7N"+G"ZCJS:^SO\B)<>AW(!ODB
M3_*N?']][:38I_-CNIL#7,L"V)2:W4@CRX"M:I&F/\ZQ!:M.E8H/1]YZ*5U,
ML&_AO3P1HBM=;Z/\/=]*WLIDL]!E)H4.T+1+B2_.SM3MZC'8-.#N[0[>O%ZW
M]'CC*QA48P;:_K8 >=6S )V(I0,B[H9U_/G10Y ;EOVQ1),Q.[?S2);!VKC+
M6 S/!_R^D<>0^Y:TCKEM0V\4J9K,T-GRJT=2A=M=))PB@?4U.?=QH:G"T?-+
M53Z1-Y3I +&RIL29XJ,_= "_#&T *G@95VJA;DP8N7=Y[%/*CZVI?(M2F[RU
MEQH6Z6;]$#'*QL(H'3#'B.G.X1X&-K3JTP&QY7]T:")FAT#4L 0#/=JQW1!J
M0^Y_.?*94;*'A*6]^.C&B!X!,T:/$UJ)'S7!J&$30@]->&N#]AC4@Q(MI!V!
M:)))&F9'!Q"J">HAB+2"F@BFQ<H-TO@R&<']:^P?CI!OT 110RD)= #I^24Z
M8&D(U74CQ),.R/G0D4Q569JCSD.2:/\Q*1R$/MQ&4=)IG1 "HS,5>T=<=FBJ
MG+HS'=#W^9\.$7W^K@#,EA*@ P@LEG3 8!8=$/>8,D8'Z"I'@RB^@ZW[7U$B
MU/^8O;$#V?M-!Y#!1S&H#H:+G#8.Q&LA%%LD P33[O[3H<X%B@<=<-/T.L-5
MIPOI +0V'<!#(!?3XA!G(*0E-&KK&4V-\A^SBI?5$_BN;(BI?A9_W&CPXP=G
M@+BGBYO\+0_!B!&#>^;&9X&[%^B ,X5'T:V_7T\S6NRQ *(Y6)O-MU(D:__X
MS#/2'JJ[181B<@HVRS\F!\[@<S#N=!0?^[.&D1%0/Y2I5US3MZROK'\],B_7
MWS#==EG?5]CR<ZR8Q;7R[6^D%468,?"E3Z3]+8][;T_=>_S^WJE[L,N^?AZC
M)56>7W)-\^^9\E[N?FMC47AI-%'U]8OS>^VT > YU]B.'H&N,)!YNU'S.6+Q
MG>ZE=W';CT=*#1_*F'?TB><*ZWK>%?%\\\D(<PY7+.BW9/512J6G%S7_'E+Y
MA/9CCIV_1U,)>QLB0)/V2.7//!^W(L$?=IK4&:&V)O-UGKHHTX62LB!K=@OM
M)$OVQNOF?5T[>&4>,^J<7"XENE0OGI(YN6%AO;_7]='RHT\YY^*T>>:X_Y;L
M%._E'8LGNS<\S9O5Y5G9V)3_5-P7OI8?V8ZUPEPV?6):&K25=K!$6&)ZO!=E
M+_+J,82=8,4O^>WQ75*UG?E!]W5."<%WU$$1BTO!7AW7NQLH?US=PCPQN:9G
M%*],!#V6SHG;QZ[]3P'GC//],743MT^ZB#RDK9R;&5S&LC'-/#1H_+8[QNY^
MGT>#UI?,$0\7$POM7THYXO>]GHBG"E@7*+:<)V_:]LM"@?!?]2;L>BU1HY0^
MTP2S,D=['='RK _/"Z_=2@<W]C].KQ*S6X&?C&!'VM[SWP9<1?NBH4LT71ZF
MSI;:A7L-F>(D=:!7^F*:\XEQJH25M-NP? ZP:+6;^8$C_TB^I,2(33J1"KPF
M0&1U][)=2DPWUOWPM4)7>+SA#[\%D.^^X:ZQS,FQ:K7YB#:3#MB HXJ<F(SD
MJZK0SK137ZU]_O7>SIMQ@'G^3E%-I6*9$(U:XUS"LC]+-0,.^DQ=H6<EOL4I
MG(D/+X2[Y]= /%1Q;0@A5.Z'ASVAQIJ-"R^4P_2?9=5Q*D7(L9$#T, IOB,Q
MU=6S.(Y=Q!]6#T[>O@Q[/<&)K^),P9^O=JOY99VYI@'KEGO*HS#_20R#X+3W
M&)EAA)>YRZ("4-_[BQWEI5W\V4U#G\>VD]5WB(N G(!ZUP<Y^2VM"Y,7JX*3
MHW&[(_T%,'[EE\GGEK?8-8SZ)_U"90T:GI1^7Y7FG3TZIEN F%*T?"N^-R.=
M!81\8'3)&!;K1 E$:'0&B2:&GJ@DIV:<K<-M>)]/OC]T>ZWPVLUTB<9!Q@#(
MV*U$,9T^>W.D6.X]>%"P=)2L/W]?O"89.E)RH4%3ID(/K=V8H%1,9/;V,NZ2
M3)%T-A'Y..UY8X[CQ_GY@.T'*+0S>DE+6%%U(W'6&/SAZV,=GO$&*O^39+[E
MS0]J,L?UAA 1<A$?4LG,J89R8M('-TSVN.RCCF69G47NEUI84P*]TTP(DSO\
MF'\YW=_L;/Y0'.A,:)9'F^VE-=\ _ZP(_$7- =P/.@#\E"(" 8U#:-E#?LO&
M6L(2W<T+[_J77LV?DS\NI<7W@M)H]L*1G4* !\; -1)KJ6+K6_KG4GQPZB]W
MZ0 WKF<UW+;D5PU)4J3;ESQG+Z#-7O]&YG2E0X!YQPS4;\EUQ;B]#NQ]]CN[
MZ\?YP.Y?HW]$,B&.D,$E7<!CI0,Z(%D\;GA=$V0WU2>?46(_<ZOE"G:)+SWQ
M8T*#7KJX@\J)]E5I/OT678/J_BFWI(=YP_*M"YTU=:D*T;C-Z9Y<#_[4W9YN
M5;^'"S9-F>=VX&<'_!8-N/7#%^M,3-YFCR9<//<@,M_*\2 .0$3;DM\UI(N3
M;@$]TVEIA5W^#)%X+ZZZ@6/4$X^.X:BOF.-)O_NB.UTEH'[TV$8<\>S-T3NK
M+3<"97$(IK;COHZKI%D&0V#S1BM,_/G#*:35?-<.X&W7>8TOR?CN)<GDJM".
M:1; TULN#QA9>3/GF?J4&5FA,SA>&TP'=,@X:&X<0F]7*WDLE,J3."27)>%F
M]P]O!]D;0(U=(BU-)I>@^[]RTB]P>V.?VY%SIVUZ?.:1<FN+N)U@F;Y7Q&*!
MEJX<O':KX3@?;X5U0Z@C:EKS#8.!N__ FETCF,&U!8X'D;5$4?PQZB&[N,T^
MTN:LS'M%#CT:<1399_K2#H;;X^HII(28*LZG]!1I5=HK57RNP3EZ1-D%BEZS
MV5JEJ24)C3\G4/FY=?)_IUD]!IWS(!W5WFU)%<=M%[RMWK6[.Y3KX6JBW?G*
M<]:J#_G@VB61-1ZF+DW, KCQWQ[-%*O&YC1J7JK448YV?=8\'JLYX&7<(Y?W
M5:M!3*6^GK7?[HUY1%^H;_<(^%T=29:O%SS0RKN0S'?_ME?IGXMR6=.?2R..
M/E&B[&^2+N@-MVW).\YS8*;-M43#&(!'QAC:$7Y]F4:?:<G9;26]]^A4B+'Z
MV9TIQ,]L,C'<7,$O98>7>XD^/\5W8@66^+2',[X#,:\6G'**$H)G)DZ=#)O
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MIFB0U&@\--75P!\KIP!&1^CW8_T3'?%]QG7AU1[;;.>;QF>G+$.#QB(\E;1
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MZ?8.-Q,NN[.O&?-@!-S.ZLH5<1[-_P]02P,$%     @ PJ#:7/1(MWUFX@
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MJFO&F@,JFM-75F J>>Q[Z%-[.3!?",78"0C8M7)E=\/$]1")4*4@?F &=A3
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M,>%D!91$,9T<<"[ ,"W GNJ92[6:1E@P?#H?6UMU%AP;4V)V5[U 8;0.L]R
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M5061C,2)::_U9N/T"R28DWYLR$C8@O5MA-AK VL94ZF=VQO;$\#O0K0/X,;
M>@(AC( PL C*GXI/85F'!S.5>CJT_7>TR AQOTB]TN>,I^R3JQB9#/+,"89F
M=EDQ6Z%V.$!OM<W'N;5N:*U^6M9S AZ\$U&^9"1?NU^BN3&Y>"6KL8/<T%A4
MYC+3$:C8%.6R_^@423V8OR'+RN?':+C;!T:CUWU[N8TXEG'YU+)33ES,R]D9
M7_B";[93CD/JZ!?<\1^,G>L_.Q2;HW"JZGJYG;/-./S3NSR_<;LFF%EY0V"0
M.4O%D:*MS !3KT(T?+#=:/4'*HHTHSRNIY6,$#P)6%<O4R0RJ+-)KGQ31UU\
M"Q3',:-Z>^0Z<YZTTS-J_N%7,*.PE<P;;B@WDKYK'F4:'Q^J9GU[P2WQNUY4
M@ (\QOYMSKIMX$(.6RVT)<LM,TWO;;J%RX+SP!5G5?K]?]?,OGP $X5*^2,:
MP;AV*-J9&133&LPTHK_'"W) =R )W*RO7T'#R:,-\7.I31W]!]Q<//QA0G?:
M)83V!25*0C6SQG:, T2[&IL:]1TEP_5_];WZJTKID54Z!]1Q&>M;"3O .L04
MW^C<>'C7DW6/X4A@6EV*]J?=P? PT@&O2\V#H>]:#YKX,&6<&>V/,(HK39$I
M.R7-;C.(BV6^M*E\&0?O=^^2MV^/7QV^X[BN7K^K]@>Q^6U[NY6;55186UOS
MH2:#</_#OIJ!U>+"/F__,AG>;ZM08YO20CR(LF%WDBS;&3WQA- V5>>%H<W)
M-DGK=S7#M^.AUYNC\\;Z@WP47:!NDSTR2C9#9WUY?ZC1>];+F/8>#*UU4W\J
M0I2E YA%,^H\VQCWXZF^+!<82_>S)$:&B8AY_1U];T:BY5'T092"9^,H063H
MQ]C8MH!NXGI0P%8$9=Y!E@-J#.J!"/ICC[8JSP4H=V(TVVJ9B/4)VF\MMCI0
MZ=DLC8B'W0XZA@H<&R91A!DSR3<97U<B;S=I%.263)G!MM4K#Z>O- V8J?;N
M+(=1(8<0B&F_[)ECC*V%LFA_N=3O1>'<TB_Y*\M6-TB\9/3;6']PL+\,6;0G
M2!<GHFO[YL7I8FMNANF/-_FHQ,UXV#]^EGK8WL[>525]S@SKL= K><KN?S?N
MA"J*OJ:M< TU6,VB)5W@_\:'7Y^F1\/<F68S?[&E!EX"SYEN5*6'+U%%=$*:
M9A7F$$MFN-5A5P5PH\>N27>7E?CNW-HY/=8@,XD70H7#\?:H,/Q1]YYHS9([
MQY8)0U-<$EQJ/XY+@<H!47+X]["U=:OM!,!B]_PT4I^M-U[=KNB?57">T9U*
M$W*C.ST,]6ZRDK.B!M#]NL%\?G6_:U:$7:OZIM=P*HVX+1MZ!UNDI;9E6+-5
M@]J;K[_WFL(!P=\.ZGY\'>1F$R<8<+YZ7;'!/RJKMJFQ\='G/IE<YX"Y)*%$
M,;_R&3 C8]9U!4?%'FDL\9)+T7>-\<WQ0KB:E8J$?JT*[*MXVX2#*^M;B"4T
MQO^U'_V-=Q'R-:C;4Q5XN*O&.L7$IK::EP--9.GN?)KD*-JT4J]EQ>A95OL9
MIE!L:[:&?Y _CV^51L#Z>.\C[?G.W)@SZIC:5XWZ$D;>KQV- O)+\=Z@&WSY
MJ:WZ637Q]Y]V.3(4@R_+FT<<.RGTY7./>E?N=9#3O,\Z@::5)LEMU CO9V,1
M GK]*3<GNV8/0C6!HFN,^(Z-A%DPYMA*<UH===JG(RL22GP%Q-"4,BJ6[9$Y
MQT>K3S8/:UQL>R=9H>O8%$SI$V17C!H,U_\.JMHRO'/GVTC5GP5CX[91SO([
M%,I\451N5%2C:?!A22$Q:Q/M#[6?!KMO.9XN!F$T46[;N+TJC #:AIF6S/1R
M9V#),K"#0/*V*.#$O/SI!_NG];LAM -SV/H-H[NMBG6V<7#37T.N.-MM5*-A
M]FAC]?$W(]\#O*TA\.$3!>=H.[!M+#!1OL(!-2FOVS*2NV#UCO%,8\LAM!J#
MZ 2$STU&;? N,U#VU]X2@;AV0P8^?A,+-O:++"VB7GE=?[#5):+28R5R_76V
MA+F3A/#Y/(5-U6C>2^]R:+1%LZ% 32W-T-7>=PO#K^=S5C;,O:.55A9<3O@4
MT*W"S(?+GN:X23KX^R0\\(O%QYA ROS>^%.PL29Z-ZJO_CIK_7IBR=6CNE(]
MNRSL6[K?&=<2>MLD>EQS6"+OITK(!;G_X]$=)'.VD9@ -9AE#\WR0B702N-0
MG5R8*/H$0*0%6'7"#K0KHHV &Z_\7'OBP_#[*;X[VQ4T<,*.35DIO,RWM]+#
M5#_?EW@G#R&03OFNAOP3>XK1ORZ^Z\X2 ;+I?0JTZI8Y#BAI$#B!O0'C1=L-
M:Q*"=!N'N?6]W+_@&/, @=$^:3:HH4ML0OB-2[@V)7B/.0H*78[6%QO<G#:2
M>FZ_C;$VAF=M"]FXR1CJJ3DK-S2,R%,DVQL;W_E2%F9FUI],F?*1S$3A8O?4
M[]4'9W-/V2'WXL#WV\UOWP[6YR8G3X0N;RCGVM1E^;_;C#^+U/&P4E3_V5OR
MX6I.:'I=6T;Z6+>2X0OP9_R$/ZVM)YD#\N]/GA%E(-;/5[%N O94N) _A3\Q
ME)C S6K^Y:M&L]WK!N3&$+\,M"R#&*>+$ *2+8!P!MTTAP,BR2N-"67VQX;E
MAUP;KM*M:)!)%5ET0(Q\6M"=W0_H7![!NPRR%*BI:DY/E=.LG:P'="OE+*]\
M+Q:9ZOXUUOC4XZR[Y?Z,2DM'%U $[YD#S9'_>'"K]H.X/<6$=/<2*5;;*,"%
M@?< /MQA>3":Z-A$/2P_6@I(9/RBIC6]7O&4) +1!Y*K9H$,FF9FQ=("Z9+T
MZ+=[7R_Q3?=L/\A1BZIOS.'?N_;J'I*"'A^CY#7JWUMQO#OEYK(BXOJ>:\&O
MVTK-CRCK3_KW&R@=M.ZRO9*H':=PLC;U# _01,51U+9; 4DZ5GQY5C)L]@#:
M'K'/C=V%.0 T>457>" SG+DY5.4=@YB@AXUC+N6<RDH)FA_9>!T6).*Q,NB&
MC"PA/^XK6HYTUU%4646 V*I  78RI@L+KB=2!&V!/D9+%^)(:P#-S?\*&CN'
M3;J+9"L/M,*ID^$!05<9N <LN6#&T272]=%6XV*4S0\.J.M^NZJ5:<BI*=>L
M@A7L-4U=N2,K;L^_UP<H+?A/W%%NS:';U.6XO:LO$T&&N'_\^]!+/^S/$K'T
M6)LZT*1=TZ=CPUB,KX_J,[TVI"LG8T4<G?_9X+9N;%5;VSJR</C+J1'-@!=)
M_A/A+4W/[_UH7+S]Q3F=I^Y?_QO /S>^KKP+9X_ #H=M3+)7KS E$\)@C^7E
MF4T/VF516EV>THVUN61L71,NC!A'/-1ZL7AEB+?L0R!4&C5[;9Q0'VVSLZPG
M9:)%B]JUJC!)-;B>1Y),9)]GF0V:F.Y:H4BDV0;EU$"H,<"[73N D45+[OVE
M-,X2):#":;#'#5?88N]GCD $(:1TH#O*^A8J@UR+EUZ.K,K+V9^U>!UG5^]Q
M\CZL^<V2D>S@2K!U$=+>K*K9XG6/)AZI&-GZE"3>;/%*H=/I6FC3HX/BW[L^
MUY#$+CQ.%;.+YQ:@IK'<KOML2<::_(F0$]&1<J)7DUV]U#'72QK^:)#\[)W\
MRT[44$OJZX3G:5[F+ELFF8S<1<!2;S,ETV[N99EW72'>=AC*IL8GS5*U*/NB
M<X(H^^"I>$8*!]1Y5!EV['90;)$%7$*%_;Y!.G=B'SL*,\AD8R%LXJH+A(%;
M@DW OL*^YIAO2\TMS4XT(B;.&<#N*.P:?]R%&&"7$2M8^B*W+5W%^(V_V/<6
MG^A*3#0YSUCM:>: 8D+QZQN2ONU"3"B!&@WVZMVKI6D8_]'6,AC:KZKO<FKW
M?I%0 R%31NWCPMHEJ8?5E)20@D@O.>)>* ] FB-0[D'B9GDTH.==V2.N_>N"
M3#Q9'LR0Q1^%'@6&R3/[A]$"C,JN&2.F3YR),0TL"> [H)*,Z.Q4C"B@3(42
MJF;<@)RA"/H9W[&SY')>5)%M\FTZ^Y @L\5V*'07QH\RGHLC$BA^B :YK#+Z
M.1,+VN1&K*?.,,Q'BQ?0Z?'JFCW<8*T_X[;G9,G<+Z_4RIA_7^"?&P#S'/;1
M7@G79UC&;Z5K'01L!+:2_S+1IBX%HLUD!X!'- U)Z[3H^VH/.E$-B79?+2IZ
MSMP7/;5J\^; G]2'AFBH!(/<5I6:2HS7/:U>W^LV*:?_14X!GC0.KQT9OEWB
MXQV8M2I>4OWBP:GUMF9S<<J#NN)D,@AS;6FVZ5=/0.3N%48#@41X[(C19N(3
M.:!;'51>6 (+$4+MA1S$C'KR 0]I5=HF%L'R^4'E_308?_]<^=#OS<H;I7XU
M"!/]Q"!%B[NLF0P.B$\=^.A#Y>IM"12!*DG:W5@'/T <A:H"YE<900FMYL$F
M1K,D<%JSY'N\*+;3):3RZ^1%+ZK*EI ?0K(G ME,-V.P<W6-JH8M%&8F,9W*
M<28&8C7]D/CZ<XM-[+Y=DX_%7Q5KL#?)NM*PC).3\<F[2H+)":'3*= .L9_F
M_O.*U:]K !]2%M6,&+]Y99\+ EE^8NCU28$ROW#(G9'Z+8' ECL-@L3-RE7;
M!,WO,*S)/:N?U_@7S&-@ 3 *;S=& ;">VP7O8X'?C:(1+]$^3/.$,*(0RZP)
MB*&N6Y&P!\-@ I!ZE%)0?.1&TEIW&^V\01>N%'QXU>A;=K/FNR"YOK4?+LT4
MB_=+^,:-+G"B,/M+NVZV(Q#:Z*D/U"G &95S_5UJJQN)4)DA#;845YH8L6#
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M,\;,[$60E=^1=?J^-?CN=;IVVF_@ UX8GL>!!M"X ,/TP0ZXBU;'04O?$FF
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MCJY.-A\:@/W@4G/2IYG@C.D4?T'6&!_"<'VLAHUL+9,77.$7@/%!=_ASSFI
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M'Z\LSXV X'U*-WF#3C[Y&=URDWR5M' A)7I3"BB':;LU-&8X2KZ?X]KL'EZ
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M6O'77H*K?T.2#Y4Z6 D%T4<M1SK?'UHY_5[H/EVIO5 [AFZ!\U2L&UG'RWV
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M[6P[(J5%%-IR?%X)"IN)E)6G0/$U61Y7_8[='U9##VG2H_B\=#;A8Y<@/JN
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MRM=L[CL[CFM3H%HDZ2E1=7J2*>I$3 (*3L&:42P2RE"!\PB!9;9^_/R!F<2
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M>8Z>H8F*X8V>_52DO<'YDA?!#QWKYF_,/;_D!9N62Y;/^>4>FG/X8*9ADDI
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M!XQ7=(&")T,($-SCT!I>K8.F5M)B1Z30E*QH& U+O][R\/S'_])8/>&@E@+
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MD\'3 C)"L;?,SV*K<%X7L\VLC6*E1CT.283MW#MS]V'!G?9.UDN(SKYI?RC
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MSJQ9,V=F]LS9^]G/,VOM<WB@RB0#8EU<,=GF_2(YOM=&FY.L61>J032+^"W
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M\U\3J,(^ZQX4=H:>(QO#I(A!12PT "8<==)AMD"@HBAW:8">(/0/T:.Y$[I
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M\H;W ?;P!OOA,*";.[Q$D0<L_QHACRP)=L^T$-$5#OF(8EODX$/5I>,2^7X
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MRZY,GS/"B"-4/%MT3E*5JH=C4L[W)[COQ&=3LG.")1]:*^$?KO(H4]TAQE.
MB!N#J[UZ-^>_PDS>QO6<(M8=+3SB#+T A045K$E759]NL0_6!S>Z)\\^IFQ-
MMB.R(;%)7D5$GEQ>X,^(#\5;1%P+-AG\<K3PJSQA+]CFS?)#1(H:I;KC #\-
M;"?S?F:(RQ*KJJ7IP>$9/^TEXK[%<XXM^:J*=!\$+N-.9/*$W7$0FOY3 &N3
MNX]H->:K*E+RS4R^P1,*A[RB)Z Y7V'+9 IS@^G_1'PW53)]DS\(U)*O*D[
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MY_YV<?WJ]86"7,M;V^[VMXO5XE)=#'7]0@E"TUV;CN>BWRY<[^(?__.?_Z'
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MVZR =2PI':N*;G)X912<N$26":,TTV_NF*2*RB'=CVG^V;WD<,NH%J9:8)D
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MRFM2[*%R!M':BPZ>SIDY;!W(A%;Z<'Q2JZ$2+5I[T2'6.6BQ==#]^G;C>>O
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MF<XB-,,(N-F? ,TA=3N?$;U85Z!>>HS2LH[[*+I7RO9QMF,&<=7<"1!U,F=
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M(2H_A\+#R5*NH?=@N?:_HI>0R/ V]&T7";[)8%]IFF\_N/:*S&8$W\4"AVY
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M]]&#Y403^Q8X4)%6J4::%J7,(K74$Q%?OC$IX(Z3-#EM4?%9@R$Q#%!8[NE
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M:>P[C7VGL>\T]AW%2$9%G:*C<=[SY'G/VAH&,AG1WR8PC"XHBUMWLOO7UA;
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M/BN\C._V_(G<YZ5YB$"/FE==U%?;HQE30M?C\9%F\^R<:3Z3?8SM"Q7Q*)^
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M<NBW\762,* 97>N&(<@"")LR TJ4GS]6K>2J&ZO< /V,?F*&V(GTUQ_ /'R
M*"HSJ+0]M+2#L>W_Z!"RGZ+XS$1%5B/HDNW.-\L)&?8P\3'T1S,O+R"BRNPM
M7X@X?%I0 _E#UWRFU9U#VU_'NS,ZK\! <KOJCY\@"R!L1<TBP*E@YGJ'_3!0
M7)ZV.V^FL9QA<L&;9F4&CI&'5\BGZZKE=!%K,3IOJ3$ 3(I!#-37FJ<7#+L[
M;T8"X_?L!,;&H#4ROANWY'.U1<NIN.VH3M$M6F%:6.*961O[ [,V]GC8[4U;
M?Z$EB?ZC=6MVAV.S-37^45&Q\B-7';1"'EGQ"#<&F3(#9[?2;1F<?61QUC&[
MYGAL=B@W+6,R,:>O]J78OU?-F[TBS"%W@4SRQX(NY#UW@3<4NLA4!+/XB<EB
MKTMX- =MLV62O]I15?/>H#V\BS!LC8VIJ3RWMHI4%Y"KJC B4'*+R!<T[R@U
MRGI1B#_6=4+9Z3 X\2('CK\@_.!9CVM[P8JR8S2O/I#A$BRP"$L@;I4B%.ML
MDCI6I!:C>?6A=7S98A'"*]JM5@2$EB$4LL"J(!1N'](2W5AXVQBRW8<C8KLO
MYCTS Y[=CSVS\N2B0HJ.LZ@L]XHSIU#[#*'V*R^_7$2H?4V++!_7+$1>W@79
MX4=!D8>OS>='\JZC6^02@09&T$6$8,NA+V](J-F>K'GP3E+J8U2E!A$^@,OG
M%E(<9?:3[$W/*;^%M47"X-KKB"P>96\:@:,:H-+'77#$N.$N^V10Y] ZT[!&
M!RP\GK[ 7LX6N#S(Q5)$]0H#*V=PO5&6R".X=]5L0]!>TV0_/??<+.C3"Z]X
MLG(<_--R67$IEX^MKU[(91%2"V5^-B(J+T5')#](>X4I@U](>Y3Y\0!OQ3!8
M(^]8:)-AB18<0'NT\_ !H:C,K4=$5<4A+3*:]O@69@H"6YGW#TM3#U^Y#YP;
MI#RC: ]N;F8@4)4Y  FKYSD[N[!H"6\S,++VX$MA$%((R:Y%W%,H^2GV9O/'
MR$>$$LC[J,!(^B)Y"4.L.U5U9W-A'"\=5F]0I7!7[H6'Q"7X2'\TW^1>?,_Z
MZPMM?C9 #.5FLI6\X@H#6F P[=$MRA,(M>0\.+#V3<+[1\L+NG&+? MHJKN^
M..7F D2FJ/'J@J52"*/\ ^F-5D%^0-R*FHWD7#_08)E;RT?+-M[0:]/H=_-Y
M@7R?=-W?H;(J7);WP/KKP05\@_I2U$!5H;[ Y]FR!*?].;<*QD&5*6KF*GH
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M*2YS8"S_&<:1[$06P]74>AY1*9(?@L"S[\. 7@U/<7RAPCFC5$5&'35-@8!
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MWCY,/2M*0)T0QG%YW1%#_[DGHB'?_']02P,$%     @ PJ#:7)X6 +T/L@
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M95A".3#E=%L5U;G-LA6);&?<M>(NLYZ90#=3H*EDO5/#$J D.5JMX6X^_L>
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M(NE<0Q@Q:=>\V(=1CL,"S$V4!,DJ"N(Z/:)L1MRLXHPMEN!KXACD87#(#J1
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M5GG:P:SBBD&VX"L>F>1!L,D29)=37*T]N.:*B&GZS&;43&ZO[N*UA!SWC"4
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MO$)&S@1JWL66_S;?R",[C<R#%>IDT%31#GX*5YLLR-)4B_<!,1]0/9EUYW-
MI_LDPF31\:;!A-G3^B.??M*DUN;79;))4-JG]+\%3?4QU(M<HR3DO\5\*'?8
M.F#QZ7H6R)DP0*B69_V\-I7W+ # 5_%S>JU:Y%V5+T/YP3X*ZA=XCP"2SV2X
M)T*KX3A#B EZ)T&(2AQ6;\T,5)(CI-'>O(U>7'7S2I4#["K(HI7BBRAD79)-
M"[=),ZD@F-"H0R<;$3RRYP6CZIOEWAZWKJ-XGRL3:"FE??*K UG'L%(4+,?:
M^&0L"PN)-\>SGV@3_T2!CYXQ"3;X;K]]Q&2V%E([Z6);3QLN.3G(O293>QD
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M_B2DXN/T,0#SC*N,I/;:3EF:IWD0ZQKTWKAE6?6,!^6@LI;-0F2G.*FM-02
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M<=U\=L&RJ9UKT-89?K)<TPQ9<;GLFM_+EJ3RP9JMJKM!6C]G#H,S.SWOG!P
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M#.?73/ ;WSN]Y157+N9MG[>DBLIDO'/! ,QZD[>7\,[[J>Q4@I894BE7Q-!
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MLC%]+-6WNHT2/,WQ5G45Q"D,^S^T.>1#F,]P]K$*IX*=RA6A9EG4)D-E8J]
M_!T :E0=B.Y2/D.!PT/J.WZ:]8'V/[/1*H^>H_RUYR37()M^FJTCW)<W50,,
MPJD])_!"U[=K3%DMEK/Q7]'HI]'\&LY 7M4L<]>+<^%#J\1PPY"Z<_8?HD\_
MSFP58 TYTA5=-9GQ173$KK/]<4I'0C>S.;J;/,QG=S.8=:79D#:_0+UV.LJR
M_;;XV^!Z<\Q+?->AXS^0J3X-?P/HNG6T6[:[)*M:![)^M?JRIVQ_WD*;<[IV
MYHVW+8/;$][7NKP:L3U9X]DG-JT+:XJWX3FKXT]I'&*2L>G#_/4NS7&U(6%&
M>&H \UVVP^UY8OXPMQ7D[V<,(O\'>:#9FCQ[6"Z6H[OK4VY%/,&U&FM,"*OC
M69Z-@UV4!W'T#]KF$;P+HK"^#HDO^ASNNC>1_WBS;J_H.,U':%_D<9Q-,#7B
M1(YHQQK+'R9SQ$Z'L'7V8F&=+[W<SR?WH^EUU4;XKRZ'\#!:K<@>-W<Y]^P,
MF0WX:09L'9/'?9,V&%KWAJR)[*/Q>/XP.1U-C=N@9CO,4F<E&YXGN+Y4I\^^
M)TL3'C8Z]7).LK/)2M\[#X\ K9^VF<QIOYIV,6XGM*^-;J>CJ^GM=/FS]]#)
M'6.-B%6<5$J[S4BNA=S.1BX5]4XS.WPZ1A4\FD]N1WR7YVQQM@,TO!_!@9H#
MF5K6[?W2&KCMZZ0E@M[)88/.3(VB]S:]NYG-/XU 3%\5^?85(?53D+-CI79S
M5X,LN;\T89"KXF4*O<QX9^_QV'7<IE1F1X9_/O"\:DJGL,8A21Z%4;QGQV,.
M)Z8G+ZMX'^*PN%M[N]OG15KI=3<G5X_QRLE>Y&E<<^(/I1C_G.@M8&K7V5S3
M[K^<+2=WR^GH%HWH/Y?7T]L'=CBK<8X?4 V\QH]V?5J]BI]:H08OY[<H#Y"I
M2I#:SLSL[F.1..)Z<@5KKV]YC(N[U6.Q3:[F:UE-YX1J 4VF Y!O6J!ZSHWN
MT/WH9Y:D!!#CBARO5WB=$ERGA[VF_V1YM!HE87E_2L^@-]"J'[X>]0GD=!YD
M$B#;C_'#<.CB9KI$7[,\/-^@JPD=3T[0<O0W8(U]L1I"799E.NG=#^AES5<7
M88#+JMY##U, J3\$OX[RUY.;R7P^N68T+]:]OCO9A*UQ$>$Z6E-O,&7"A/[
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M9^PN^ T_VG'U>A"Y#U[9GT:? \+K%>O59CG9\W4;/AI;/@7)C*\R9G<IOZ\
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MA7<4I,X*9V(W&\+7E% M7@W-WTI7X(BOU=YLI\N-<)8WO:4JJ_E4IZRLDM?
M:HK/XIMQM-ZLC&]HUV;6ZXN<8XA^2@2@JNOI/VVO:GRZU[^=ZGURGX\8I[^9
M$*#Z9G=IN=H@K$943I]\SY35*T%5\A-\O),TSA;O>SO5^'@G>S;7M3K\VFH*
M<94K7MOLGB! U>BS?."3MMR]$+R=6G\.MX]HO]]03#!\N,;NK7-M=M:]"53M
M'OZI3CF&EKSFB]FD;'2Q9]O\AG8FFR*8Y)OX:)U[PP!5@\_TD4_:0O?$\.6T
MT<,</Z*5?K/;A?WNL_J2-DL:G>R_TZK<\VBUC/(VR 5U)]"7340KUT^W%^C+
MHZW/M><OFYH*9X>O/G]9VT;*.L=NW#OK-G')>T#UMH=^IE-64>$E7U[%5+DX
M;!Z;F?F2:J"'G>'6;W^CM=5U?]#RU5]TS78R7PVG[A^Q)5;]T51;8E77W'E!
M\I8V@!_QJ4^Y 7P #%BS9EY\/]$&\"\T=+2'. XBA/#"-QH(%!_N3/6]\[8O
ML5K+7>PQUK:LH8#I]88/&KF="*)H'M,,&_NDGCZ"LLD)RB:'U$W.JM'DQ$63
MDU9-3GK4T07 8RR/N_!A\O1,3EHLZECLP(6\D/UV]H>_/>*=P?F^0_<WQ-2W
MM,G9$1<=;*3JXZU%-+3:SP@Y'KZUC;=?7E0<YO\Q@1$\:>'N)_42".E8X;Q=
M0IVG%D$0_':Q+W%WXY<7"(=^@6-"(0CJ_CX7&F 2V--'.&;-0=*T^Y[2_+T%
MXP]NKZ$_NC]P+O^-\YBX"L6[<J6]GKM<O_%(_(:GXB&RU],G.%4<;F X=O'W
M)8@(7]']_L.'=WQ5]V^CZ?S7Q>H)A_L8S]9U5N+9NGC_DH7_SL>UU'&QMMH+
M/JL;5@K>5SC[H.S2S*2&?N'__#>,C01#1IJU7Z,LVV^+:C*/LM]N"&8+N9B6
M0CZG@]U3CW#MW_LF]ASV_8PGF0^Q?:GW*NC:TVXU9J*7:RJ+HE(8$2K]9=7:
MR<L.KVB3^&,:4S-QE+^ZJK>J-[_9FJO_E&>KN_+7?IFU5^MKM_Y6PNBYEOXR
MZ^YU]!R%. E=U]SV>]]\O95]QK/7VN9+O^PZ*_&T6V,K$?0:X1C( ;DA0U?=
M9SC+3GR+%[Z)?;;6'^XDDRS&M\&JD.=T4=EVTH[O%GT=)>@5!R3[YNS3'XL\
M7?TFA!X&)\FPQ52(C;Z':1%[MR13)&9E[T0=BE@]=6(V83.-XKP/8M]Q<+QD
MUK^]5RYG+=,\B%'&"NB21QRT:J@A7)21_^:[YM(XC2F,E([>HV?<7#@9)6P+
MV4KQ>$E_RH(5#YJRT'/.%SEMKL_VH5JUX.1O@5-_SN5:M^:US*.& 1307G/S
M=WX;(LJ?@@2UE:#,/9_@2]U&"9[F>*NZ[N"TKW!9(\_Q<9IU\93VP=3",SAU
MCOK'WH'X2P!4PCC(LMGZIX ASV=DSM9'&ZN=JB]M5'-:62R=:%4 @PX<4ML!
M5>_K+#4SF%QK;3RI'V;ETTPU43+0EG=6VKIKI*K)$+3=>,<X(<Y--#> GFE&
M8A!@[>UIIS/K;/[BA!^AGM8X@4WOP?G$CG0)WCG:?B:&5]@F+[N(\)$[N]?\
M&F<K$NV:4QE-IRV4G+'3VH&:>T8-&,RRA2DLG["\"+3)/^AY;_1'J]5^NX_9
MN1?>(V;S2P0_8<KN9SRE??(MODTS[>Q*/Q,NF_@ASC5;]C[ZWIEY!&@AB<?!
M1#E.:AE!A17T-;/S#9@)"TO'39,2_<T I+1V<J&OC;=&;=,D04]Z0YH/6 3U
MTLLXI6A#7+0C<[S"%'IXCTECND0U&]K3B-.I[D$.MJ:Q>UD P^U!L(75.6J$
M=3"XF0O4,H0J2XB:0@U;YUHR/CAT@S%]YPHG>;"1+P\K9=TM!1O@'I9]%8+>
MF62#3D48OE:(UABSQ$6ERIEX<;]_C*/539P&N7(4+LHXXX$*7EW^70$8Y:Y
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MUR'[9C*&M'+?9X<!#+H\6S#0;#A.;&H*?C?0..JDRF$,BR(Y*9@1R8."C0Q
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M#Q'^I9-?==:;KH5HG]!Z,]^$+4+X>UEIUBLRH/VA66=%0]W[4AGDDXF>>1?
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M9.'$ZU X-1*IL4B-YO="0&1D\@S3*"XKQMEY5JC;A@$.EV#L3"IW C(9E7;
MV<FR\+,':'*29E6L&47&);(9G)ORLC1X7I=6=VB\Q<(VI8.;PWD2GDH,K\1G
MCD33E^('HEZTXBM1]#ECQ[ES ,K3ZYBQ%T''HC3:EL\T_PI_AEM*V!1NLR0.
MWQ_H6_DQR<)?53=^+B5<RG#H,!1G'^@129 T%'E,-:=)>D3)/P59 G0))^QI
M%RZ@I@[\ Y3V-4C@>@!BR7G^$?@-\KXAUMRH3,+&)?\YK*O[>"&*"?%63K0E
M(R+I&T+U54OLZ2I%,7P/SSFEG7?5 W8#9U*XQ'_P.#0[P9\(QR?U&S2^78 ;
MHKNX^!44?9+5=\;$)>:I;"OI:-QR<P)\3:.TX8.K7XL0#8#(9&;GTEP85,"3
M?Z(2AR@","(* 819##T.+;59>0$149W 3SG]*GVZC,O;_S;U%^W_CFO*]<PI
M1?(9%&%@Y/:__;;]%MS>C<WU'>K)'G*GFVT&]F^_^>&O?_XOWU/>W'B;TR)5
M$%S3;N3/<F_/0'_O==XO@SCGS=J^,/M6Y?P)[BK=5_S \%-=N^Z!AL\I._C1
M GHUUU':#W ",._)RY'&)>?%QS74#_@ X5\@G4\0\0WNK#5?(>UG1%/L^D/,
M5^#G,\\>PQV%$T+R#O5 FBY:4#RD9,. $NDW6?D/6FZB;%_2:,Q5/X@:+B5:
M8BAJ%6!!DPBBI*5*&K+L"%<21IA(RE@\_0U/8!UMQ*B#PB58&XM*M)?(VL41
M^_"% 3XKEP>7;(;N@KB@!HDX8>&2T!26E0(Z@$M^_../?R8<V*O$A/I\>BMI
M6CB$$MG!<<G(B5?#<FJPD"RL>_8C_[I6Y_I%M8Q!%%-)X!+G;/Z5F+&:D%B#
MPQIB>,7<;RTZ2\PZ$J<D9@O_(V+FF88M*E8Q\\*8415:XSDGH9^,>,V\6T7[
M%])B>2[>\/B0E4%BCL+M_(Q,*CK>-+&VA$/Y#8RJBC)[H7G.'Y/34O3&&COU
M.6'ADLD4EI6GUQJ7])"Q'-3^;Y!60?ZNF(#[^,W)E9F(CTNN\Y@?2EA2.0,+
M^._U6^H6@P]3ZUZQ34T'/A4$EXB,_)G664$8)(Y99WHU-NL-"-)9'_)GGG4&
MZ3EAE%[V:E8SST3KMQI$,A$?E[SF,:\FDE(BR)":#F&$A-..2K;,Y.J,MJMH
MK>C()>O"NXM@?PE2L6%A*+(VR8%T0<(EQ D<&\NTH?0>+^.\*"$H/;H-\O+]
M)YI&YO1B&S N>3EPJCSR 0KA.(0C$8GE^7:#042N K)"XY*0"ZOJ507@H).1
MJW1.0B[3)()-%.=)4!3;G=PCMSG/GOWT1O,P+NAM'D,CC7H#E;\6/UPQHQRG
M11SR)W[5U3^<)BX1+S>@H3HTODD#+<(F_(2B!V]W]#$H58DVO^"2RY M9;%!
M"R8.X&4^:^%^>MO'PHFY8*Q<T*9F@#+/HQBXYM^57:/6TP:11- J*VI1_=2U
M")]I5$$UHML<"FWPK".XWN(]&+X6=%<EU_&._5YW8[7&CQU&#I>L%QF+XI](
MHA#Y59/EX6$-8=)2!B!!&TEHV#G[0QP&"20FT0C^K6';= DVAH%+YJ[L*E=D
M$H^+4F)V1.JU2V+-Q07=)]D[J-&F '=LN[NG^2O?RJVW_U,)X)+H3.Z59H>-
M+%LZ)"BX7PO+5-+"\22@2RW^] )L4\K+S=VR:7X.BJF)UB,T< E^_@"T:=4U
M*N&XI$;VGT4G6E='T,P: MV8Y>JT89(=T]5<62<L7 *=PK(29B9PH6?E/H@C
MWKR;AP6"O>XVG:*2CA=G['.6105$!,>O-+K)RJOT-6-&1>VH8P+$); 1+M6<
M=08.[7 X/$FSDL02PU,E15&@YIZI1\Z+K%=Y3C5-$TR N*0QPJ5:9%&6YREJ
M>!(*!)\GRZ;6\]C[P0@\+M&X,6LX4Y(&#<N#07MP$HVEK](F_::]->+FN^D=
MX7RLG$D1E[R7&H[Q<+G=$4&97*6DDYK$_M[<1##ZI-N] \<)LYV:?L9OH^3.
MFN*$CU4OIC!OTX)!.GK75J 0-Z]HP%D;D:L)$)< 1[C4UW,0DL$ACUOA'^M]
M;%W,A1D:EV1<6-5$5%@/"WX:J%1PTMSN[N@^RV5A(%[ELH#N6$E6T.CC^P7=
MQ6D,<W&9!$^*W&;0P"7-^0-0VK1P2KP&;D.+N;R"&&\FQJF11RA,7=,C.T;0
MB_1U><R?WL# 5W'QK%VDXRBX9.O,KW)%UP/"4=KJ/GY3@KM<+]S,N+@$-IUQ
MS07;OQ.&\F$WB%]#=8G*AB4Z=LP0I X1OQ0M7&M%*.!QB._\?9_'6?D0F )&
MAP"XQ&'@3GEW$F $WOU1+1;(+MOR9VVV1^=Q:'Y><D?%):')?&N6S%^(0" -
MAM^GPMV.AB7/"X2261!L$I2\S7D:LE,CGXI->4DC=JA,[MG45&66O_> U9>&
M)8CBDOR"(U(B3 62K%E&2K:L@Y(4-0V2^XKL^5*559# GF[:]A0(7$(SL:=4
MB^!P/)+><UAOR4Z:UW$1FP)Y^[_CFFT]<\I-%4 1 /,\TUGXJZB_<U'!X_TM
M99LJ+PO%5O4KS0OQ8'R_3^)2-7#3T+'):0;O:@VCJ KY-A:GI'RFY)5?-K,S
M=?$<0#.!6-0VBO@7.,2>?P8"* *X7JD2'D0!_\Z_*3O:%?!5SV%Q%S%$=% &
M[F+VG6^G#R&+3(66')/M+KLE3QKZ1'R ^[_P"=+_!I);59?I:$<''@/=I-%U
M%@9)@S'3LQHGBTN;%AV3<D,T5!OPK\"E@JB#KMI$K:J![T7YS6\"'^EX9IZ"
M1-J).51_9E/"I3*'#D.-?&AUXSM2"_;3>4XCMHW7CR#3%4*E<6*J8!S +"6
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MZ/^A ]E$58GKCB#YG&?5'AH.Q$4HWLYHU+Z<:9\Z5OP^@AW6Z["5QQA&]HS
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MK-N8YCL;SUFSV8SQNUKYD1>RO<O,=YV50_B,,663'>5ZP']X8O,@#2V'%2+
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M.G:"$'+3)2D.YJ45$T2%L:22''_&$QZ&167!'+1BBFAD/L,T@![G40TFE)7
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MBD2*:]]#=_-R5*TWZBO2*^94OEV18@3 ),.1?4"@V6FY7#%\N.'*72Y!HRX
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MRKH!AJ Z8K9JHEM$^[WK$'IQEH+9Z6!5H2098 >""]4J)<<;E"J< .M"23'
M:*,AE2$3XT??M[\XKAL/Z-#R-OS!FR0%$G@MU&D#?(6/3V8%Z0PAE2?9=VCR
M"-:]$^S]P'*G:Q[J/6;SM:U);[76H$2;8]^I@QH^Y<<(30TK@:@&E#IS+#HJ
MZ='IR2<8 ;.DK @ERQR3#A +=,XN,LQ_LJC#?0O8$D 8PN&027R\'I7>84";
M@/)HCM5'&Q]T1B?D2T9*ZGOLGZOD=0!-V[A^2U!^S;'P5$6KI9,&]^_Q0O<P
M"H*(V.>>+=B>S+:H'4S\\#,)^[:_Y[%EH!-(S3:AG!I@R6E 6B&['0K/6,;)
M)T^R9((S"KGG&@C.2+YV"\UHPGGNE+4ZD_8S]1BSI]Z<OS!%D[?*)[Y'CS_&
M$0PQ#3I>=@U^JVLA'^WAC;[Z/UKT#Q+ROBV2]\A@CZ\HJG4N> 0$ SI93>@A
MKQ_SL"2KK>?\,R)7G0H G^].0,MU<6EU(UGF<#SR]E$L3DGGINNSLZ52?_@7
MFOQ MR)HFH>VK9NDU9;8D<M3$F\M;\..K:>N3]>I$W007VV?W&Q!U#?0;G=B
M:QH2V) 5)R.)%6QS#K5,@E.22.Z2%"2IMJ#+21-M=RY*ISE 6Y\$RIYU>PK(
M.G+'SIK]/7T31&\&J-9H=^)WFI#6L+'O\X=#G9#$%S[YV[Z'*.1Y^';<:31Y
M@S3U=M*=!9KY2G<"BUH1WQQK5)GFB^U,A63MY2]#(AN/OJHG(NO$-9ACZFG\
M.4@C!UOQ]3WQ4"ODAA<_!8D\W#KV)N1IT2]W$>SS7?\FN2FZ.YS+S*Q#K(]?
M+&HOLPG]91OFVI]0#<N";K<R.F%/2S8G=38 SB27VXP((@G8'$%&(=E),O@T
MT;89>M'X6 (Y\>HAE?7)0UJZV=HTL7:D_^I(M.*RU-?![Z7,F<L&7*+N_9WE
M>&JJCN7,(*M,S01X'SM^WM0U:9E8?O&76S\*+(^_:+K<.C0DQ+N+MT-]AR:+
MR84#_B/9/1-: CAOKWISV!<4Y?J4M4#4A:HEVU*F6\LO[-N'J4>23@TL[I P
M#NT:+%9H$OLB08O)RI!=B\TE*TXF)*+^Q ^:X%*C0>P+@@I,:L-EC$5PNI[X
ML7F:V.>D&_$A],ESPJ"_8OT_'D*U+@(J-8N=ZK>Q+;WPX%,#;8-TIARH6) D
M?JZ&XE1O&]M5Y0KJ4Q=X(W4H"T56E-.%>C\(HEWRNSKZ5.<[V!O%J^I6?4*,
MU+,+Y!J>GVK.2:UM2]'FI.[,0P6+^\0/R=&U8TKGSF8+>\*@>I/86]YK:$DU
MF$VXDXG=[9/D$.')+W!&R=YR[/3V5N)X7WB[-'&J'SS-Y_P>M+]8#-/7&&?S
MX:P_NN\-_SX;3A;H#O;W:1J;@1^$P<#:.Z'E.O\B1\E/^6EC1/0>!*[9,%9.
MSDK=!F7NK-LR^FO$C:A*(0=H,X";,(?T5RL:D=-T<>Q[.JMDG(S%$TGA-=?^
M8#!_&F;FBW/(SG%V&8_Z=Z/QR(!PG?2-<RYYC(7E N)UI)6P-PXII7GNM'8*
MZC:PO2[4M F7?"A )HS/]"TSX> KO-0:/WU7<U#!WK[3?/2NI=?NSK1>OO]V
M2J6MZ3T*;,6@M_& CJ):\*"?@^).\@46.G<)*Z!9WW2H4@G1ZBU+O.+'GP:-
M%7%Q-&.4[JA026R ^O/,GH(A^VB%/'X0;".JU!B:@:C2L*F,E@EK/(_.6_%8
M'<>-0F)/2#CV@U.:ENF:OS&?&M/%&X'"L]-W_<5H$&^][T?C)_X ]63(-M[3
MQ:(W8SOQQ2_]^; W?>@-IH^/TTGBHXGMCIG+4 -PS!360-^%>Z%C<T*=ETS
M[_!UY49,-9('D7;[*%&AZ3HOB-YNO;%O(>_J50H@WM(WC+8)T\+8MSS)SK_X
MZ/6T/\$^3=^3YU#/Y%9>'GOT\G[IGYK+:J%;P&2$",>36'Y31D9J !"/C\(S
MVGQ\]&;]S_V[\? V3!JZPTQ#26-]T;NM+*_9S>$BQ\&$(7/*U"@Q)OU8>"A[
M-&&[PV%OV?\[NIWV)(#.N)%6PAX\2>?NR-JGY-Q1]I\@C(\#:?9W_66H8L/(
M0P] L'#\U8(2_;"?77:3FR76^[)$+U5V)%H-8GNJU=&!2MBUGN'@WEFS;A%O
M18;L']SWY*R@<RLD<[+RO17K8Y*A1<]67:]Q;-<Q#;*;%-NX0=^(8A2&0XL:
MT9I36)WAWZ@J7#^\.GD:3;(W*^;)''[D"0NP]V7Y1]W4FS)Q#>R1> NK!COF
M*5B_!5C? JQO =: 9,&QF.P#\@CK7+&O@^&<T.@QUM6E/$OBV=!([7:^9H;F
ME&J][OBN)'\[8>.ECS#$B5DEH:BJ2MC'LS;5/7NN@X%GT'DMO_<9>6N?[F)T
M&"+)'_5LX7H-OOU@U$H(FW",BSU/YN2%>)',SE[(11<[;?;FPT_#R=-UG#>/
MG=3SX2S60AJ,C"]RRO<G&6.Y<LC+'PC1\K&1$\2 4]"Q1Y!334E9,W8BY8HD
M K^UHT- 5M]N_)?O;.(DV+-_G"%G/_P^)AO+C9?&@^"HP$H5"G4!Y+)^-[K7
M5X.;?%JX(V=%+DL@PUJ&6 '3RQZWL^\=1][FP0GGLU^D.]UB,;2];0&8XGY4
M)!3Z#K0S/L&M[3R%2TXK_L!,NN1&<9R@)Q0BEN"%T&>??8:7Q8P)IAO+2S,X
ML^/7710PK(+@GH26XP83'M;,+TG*=J6%M*W3^<?^9/0__>5H.HD=B>^>%J/)
M<,$VJ&E[O5.#2+</67$OWD5,(J%/N$YY[FO+6SF6>](B0)Q?0\TW&JQ1ITNB
M[7(<$]% PV;L-QI5BHNPD08@NNW<&SA$-3<(KK[5/S$6T###%OOIS!3[(>L?
M$&>E>"3AUK?/3W84?TN()%4K:[)>BV^2]=JHM',IH5 -49>$!QA6254'F=[:
M1!1X50G<SHDHES=3>BP2E$7SP0. 5EP2I0*WY%V726@I!;BD'-K!LQ*X0D'1
MSZ+E0W3ZQ2,TV#K[&:$\Q:BUD=AF-9KHRKE3&Q5T'HO9K[A!F@8D_L-BSP[,
MLLTAH#*V2S&8/ TH3+AJ.B^7YX?_SN]_Q@]^IH?TLK-^(?G78O#+\/YI'$<$
M/["II_>I/WYB/[&#?V\^Y&E[^"/</*;X?/J_/;!=,P3L'*GZ"W'MI7\T3?5=
MU__"E]0'GPXHL9TX(%QQUU6Y03,.[=K/FE66%_\$7NQZR/8 LJX#CNJU&C5#
M!VJ.":6": ""[QIX.L../#8.HMB-0NHD**SP%LD5"HON)KBDEA>LV<:!/[5*
MZ N;R[Q-QB1Q[G# ?:2"\C^IW .;_8H9&J+0^)P&-(M .^: QRB,+/<A\FRY
M+V!).>Q]<QMJG#W;"J%!/Q.EN7^%A*7E<L6 ?/W<1;[*)3:$KM/QY^YP^N<O
M#J&L2]O#F!WA7,6R":QOQAS9\"H*E#UC%D,F^9%8_,0:*VNQRZI54[,9,RC7
M4W 1PS"):RZ#S?$\\O91&,32O5?-Q-)*V&[TE3171*(8%7.FX4P?/U1A[H,I
M+Z>UQ=R'#C#W0Q7F?C#EI;2VF/O!,.:2/!>GGIX-NA)#J+B* :F7:AK%\@&$
M*GC0"<SD)]%B454/^_#8/)<PI(RXF(EV.XL>TJ1@[T)"=X\6_8.$?!]^!N4W
M)]P^>90D3T=\9!-1G+"&04%D%S>%QQ863X^/_?EG?F^S^&4Z7[Y;#N>//?:K
M7X?+.-/=@M_>)"\M_#9:_M)[FLR'_?'H?X;WO8_]T21YG8&GA1W>;G9N-SNW
MFYW;S8[Q9HO;S<[M9N=VLW.[V;G&S4YMK3E?=*C.U,62V/OX*UPJB.!!/YL-
M7_F6)7*";>S$%Z?$ED_3XAIFC,)FYVFQM.BW!65=X_JIFGI5]<R@4:68 )ZR
M0F'/CQ>YLU539&EA[%D2IFZ%_$9"L=&GOC)[1?HBI&3UDE5Z<[9% $0-AQ+C
MJ\"EN8JCI*<-9?6QQ^YU-$.,G!$6R_,S.D$0[?:\T> I(/;(XW96-K<=G\.6
M&"8+#U%F/<K[B\73XXS'D2]Z3XOA?6\TB1W,N4_Y;_WYO!_GL;T9'YM,4W8,
M_>^O_LF6)B<F]>Z0^0F<LQ;:DAG;(VUSH[Z@^';&DIX"#(GR6F;05U6!<Z3*
M1<6W 69NIN,+9G4.6'&--T6<6$QT^U]9UU1'2ED=,WA3:2* 'U..DOF^\5?M
M5R&Q^3%+:7P#U,7>K*H54$&6&!#\,V>NJS/JK,@GWV7@QEF;-.D35,?V!JS-
MH!06XTB<.\$?#Y2<<OOR)SETF92U@>TB6)M.-4#HG![/?GW/GCN;;1A,HS (
M+<]F.VP^CXB95-=$-@M!=M'E,1!*-(RF+:^%U2@LMH*]/C;,IP@FLVPVOY)#
MXJ)Z3ZCS$B?CDYAI"L^$9\TTOPX_]T:3V=-RT;L?SD>?^LO1I^'-+G.SR]SL
M,C>[S,TN<[/+W.PR-[M, P3%[X/$)UG=PV"Q9N=/]"(PT$\0^8Y.XXO!ZB89
M4?W.'^+EP!C'HR%&F=:B_[X&HTR<DVX4!!&Q[R.>\&W&#G^^'<\EP<#W>.*Z
M.!/ND^>$TOS.>NUTSV!3#2ET@L^'^?/#!6"K#:AR!XTU&J"89:,9;/GC:,'(
M.^=J7&<L3V>Y9!XV?Y&9;@:_]"<?APON6)--W_AP=J_A87YGJ\[-W>86ZV>"
MD><6ZW>+];O%^F7DO<7Z&6%3NL7ZW6+]#$L=V.4H/S-3!Y[WW2K&BB6Q[8Y7
M($T$#SIO9?F=DGPJ_G/ L$B>$^=WXG.R\IG,KA/S$ESFQS\=(N.V)$MR.Y][
M<S%1K=)2.9IJG]A[0HN&J!%55=$1@).8L4;>BO+7+>])\M_FE5CS\]AKF3E:
M78FWSDZM FECPRLD^6ZSG\->G(W7PDM>ZFJ=(/MY69\O8Z5+%(/7A%3$OC5L
MD&*HR!V?(DS:??W^ ?^>TIQ)0@E5(UNPH6=COXZ=N9&Q@FV?/UP8;/EC7R^6
M2U(O8,(.1PX/DN%_DUS'_"R]CNDO?HEO7.)_#/_V-/K4'P^/US#SX6(Y'PV6
MP_3OMZN8VU7,[2KF=A5CN+7^=A5SNXJY7<7<KF(Z<15SA;2+K9TMO^:TBX*-
M>3BP*#TP&!2G16#U-V=[UX(-G>3+0Y8RM9R@^-NS-4MQ,8RUHK9!"2RK^?8L
MME"T*EM50C^T7..2!*I-!_):V&OO=1("%H[BV&,;+>5G>V$@$-BOE]0S9-LY
MW)2>\9)2L'>>\M".O!<V8^WD$[E.&T %^*D[(UD?P48G=T1S^8SZ>T(9;I[-
MA=]S(9\"LH[<L;-.$H<267K0G[Z76<MG\^EL.%]^CHWCW%@^>QQ.ECQ3Z,/3
MN#<>/1R3B YO:4*;3D=Q9';F6EZ8I1><AD+5@AFVD!KI)U0"XMN_A3T$F+DA
M=<V@4%=I<X1"!,6W4@M[>7=0YZ( 57[;9&8E13==BT4#I*@ 53:#3 VEA?)H
M4OZ*@;_;1VP#?^J<RJ0LK(!MLM)0R/S>5XX!^@'V(:*>PS;WA$GUX+SR?P7*
M1XPE=; -4M694B/1DK_?@!5Q5I;;YY<*-O^7>L#PBH!ZV%:A"FP )6N5D=/7
M[LG>]0]\/>T',XN&TW5RK\267W8HC7,=2@C2;P;[[%^1KZIXH<]^8^Y$OO5=
M>[3;4_\E>?%<-?U)*P$9_)-!#$+$:I.O@(89KMA/9Y[8#[_/>0X(P?Z=_3WS
M9S,V=55WZ)>RM/,8' 1JH?H?.PA5]9;AOL2K',MC5UO9"2O ?&1KV"X2)]!G
M97)%T%;K/%P%,$ME09D-'JU7):J71= N5-2HELF"OB8*9ZVSX;K"X3M;&=F+
M!&[U@QZZB\AT@<5[$JRH$R?AFZ[Y1<R0WW,$#EN;AEZT(S0FI!;7T$\8>[YO
M0"7T8#8K ==#Q(_!Q^=/^CN?ALZ_XH_PWWF!)&7Z3^]E5U</3\NG^; W_/ML
M&,=S]!^G\^7H?_K\K;OXMY/%+8-Z4^[;3DC&S@M_ES!DZY$3G\[XO6,)GQ.F
M*\LOQ'TAC[X7;N5>WK7:15X$M.^UFL$1?5W0$^,SL>CRB]^4%IR:PY[O6V8_
M!UL726=?E@675FT0VSQ\#>*ST'60^@<_DMG^*[:';8F^ O%9X+K(.RO;*.]Q
M>]CNC-?@/0.<R;Q/B&3CJJJ'?3/1)(\9(#KN:.AL/&?MK/C9LXB/9T_#+:$\
M+3O_X<E;L9.JY7C<K3,]64UX?KDPJ[^9 ]R'P@%N]'$R>A@-^I-EKS\83)\F
M2_X2^6PZ'@U&PR1&?[K\93COS4>+7Y.?GR:#X7S9'[&BF>3)O=.';V>[IMP1
M[6@5CKRU3W>6UG-8PJIF7*?4<T LE\P(S\-<UPJ6IE*#F[B2&6R!-;)H1Q.+
MUJQW84!6WV[\E^]LXB1,L7^<"6(__#XF&\L=,IT+#X)[1U:J4*BC!)2)TJ@#
MH!KOY--"OSY6Y+($,M)EB!4PO>QQS?M'@9O*(F0GS9 [6+@N&5A[AV])Q@.I
M3XJB#MIVO0#9):* KB->2BX80+&_Q$?B;ZBUW\;.2T*7!4GQCDXB<J%0?!D6
M9)/OC7"&X=T7%\?W<U#J5Y8'L2!->D$<9_5X<T8/"1/I#V<BTE_\_K0H03W]
M(_\;<-KY<QMW]$I%.8*;Z6\+<XT>H/TG,:#\;T! _V("H&=9$ &]>Q0#RO\&
M!/1G$P ]RX((Z&@H!I3_#7P%9 *B9V$0$1U\%B/*_P9%M/E;M0J(GH5!-YF.
MO)6_(TOKM1^%6Y^'.4^LG2)B3%:GHWLX@&292QJ3J%)%A,EKF4&76@E!/)D2
M^M6/N(W.=2RF:Z]6XONT!CQ<K*H'G>-:NT>$:&".*1@6Z-/@P/=63/[$'8U?
M&MP=[HBWVNXL^H=\,E37-&.,59T2U?)ES"*FD'?LH&IR5-<T@SRH>BJYRXN'
M/E4F%QS!S(H#IY0S9'EQZ,38V@4M5 /SDZ-,>O0Y<6&Y))B3%^)%9$*4\<N"
MXE!NFC^-U^-&*CTZ-R43@CK3@[22&1-=@ZM4(:7#3^8L4)!4#M)*9K %T$(5
M3T:E;&![5;:_I85.*E,WJ"J:MT"I<S? P$"*@_N'3X\=#,1W367ES!@Y52Z9
MRJ3)1%1?#WY^Z)NN+[HCNUV2%,>_71*K4@9YB03M7&X_.#0(EUN'VCR1P.$3
M\6R?BF/SX\>@I%7P)B Y?)=0J^5H9M(1N13P!XYL/=@5=:"X-Y\201=WD/ M
M :\'>6VP6[E)U0(;!^;3-#?UQ"?M. 5-24&\<YPNN&(QV\9U^<6'X9HI",6U
ME<O5:K@6Q$39!$Z_>*PO6V<OWO_EBG1WZY<3).,1@H"W;*]7*(2_PRO5DS)L
MV]W2W<41# .>/YJ.0_$#,[RPH"PT?K"5'"D"^K,3A%3$EN;>"8FH/_$#%:0E
MY:!PMI(<!0"G4#1TZ^.$A#RE.9N_7AR;V'>'IX '&DWW<3X';]-?A<Y+G$%=
M;#/1:0,_9XHJ7B%G/-$'2#\6Z^<D#,HC&RLD^5=2K_W("P^M(O;0HAZ3+NBO
M5M$N<GF_[LG:63G2=WK4=;$CYO45 (X()O&B_:SHG=NRMRY$6UV]-K!#XS48
MKB"=(=/V/=G[@1,F<:#B$9DKAAV\KC_X2N5$1S_[?,B]'SV'Z\@]7@#/R8HX
M\5/;$]];J9[0T6\).Q!=G\.J:*'3?$\HZQN/[CT]B9YY6?W>X;E@"9,KDQE+
M-A0K-(8=K5YEP%;&#)WO1>BO_IB3?4176XOM\NXCGNIW%K]>O]@RO"0S+:2N
M 3EU-=F$(X)/'N_.C#HK6;!XI@Q:J$YU,@H2HH/.W]ABFV K<L.Q[VU"0G?\
M5_T=G]QE<Z&T&EK03XU9#X #.EL#?[?SO7A,Q^_!3J,P""W/9D-:YKLBJ806
M3529*0 &^#S%+])Q!XWB:LKS1H0/[+"G>@A9HPV\$*;J-&I#A,[JY8.P,BO*
M93F\<*@:)I,R42OG*'HA]-E'?CV3@; BQ X>&#JC((CX>8:_"L'.+-P.]"Q9
M[0!5H1R;8#2!2V7(P.,Z^' _&HP\?@RQ59L307'TB)T*DZ1,<'Q:Q,[<D/,T
ML#J4-H/L)5K M'47%_%;JNF:G?U\FAI!X\#8(,VDQF]"N/G;<WAO'ERK; L9
M7WU5:0G=R5;3B%P#+O1QR)\M]EBS![Y=2G2.@4U?9-8.61T\/[G*(TX-05O>
M<M;KG#Q;8=E&/G8N._\=SR.NVI HB(:NZ)F+NSBA)'_2D)(M?\/@A23QL/P5
M\ >?$F?C)0^_KPY+:GF!F\!L_R-*'OB>D'"Z9A)*#/MM? P] *N"\;\]T-$5
MJK!0SPCEO[ VY+W&QN6B%IX/87/[E1(8T+F*E2^^1ASM]FPRY@HUV%IT(UOF
MI)7 ]]SF, 4  9VH1\>+TQ&,O) P1,_>56>MNCOPRT*?J9SOLD]ODB)B&FLT
M"279(.-+;0!+5 #QZ9[CRT391XDDK_7\('NM9S:?SH;SY><XH_/P;T^CV>-P
MLL1^GT?X]I(ZE3.@J@$9G0&/1RH2.TM;,,,7',RB+,VS5$XCLCT#GQ?34-6Q
MT;F?-1X^U1"TV4S0C5()R3X JORVR2Q)2M!,FNE&R80D)P!5-H-,#:6%\MA@
MT@*1"ZX+? 0^[W:KKF> ,W659];!B+1D=:OZS'N.(/UF#/"_K<)75;S0SY+<
MV!2Q4Y!ZP)V]0\HK&."(J<N<2B1#.'J(J.?PUUF95 _.*_^7.&8\K22K8X!?
M7T6FU$B@DS4F5D"VOFN/=GOJO\0^O4JVI)4,\""K2!< "W2^A-)]I'Y098.?
MUL./XFOXF>L+/-!INP@Q8]BNG!A9OOR2&&+OX@UKH52@ZZF:7S!V#ZK2A:9!
M[G38IU ZZ6.+\EH&! (V/$N\F0<7)49UZ5.*/^:MZPJ+.OK[B&_1MIZ=K7*3
ME%@::253EW.%Z1P A%EW66>_Z#@ H?_%HG8@N<SZ27:9-1\NEO/18#F\[RV6
MT\&OO?YO_?G] OLVBY/')A;E\,J7P[ZGBJ.K[GB0&S\Q$R](M9]:WB;9V]\=
MSF5FUB%64,X@^"*K]B?,L,*6,RR\UJHM-?Z]EU($D02%G88@)K%FVV;H1>-C
MJ2S^L292^!=OB9C**[9<L:^#X9S0Z/=JU:4\2^+9?%L#>=ZGG:^9H3FE6J\[
MOBO)CYV)/+?G4QE+!<6QK2QMC@1A\& )8.BFN<J+4+)K&GE,N"@&+';&7&XM
M;QH'] 03WWMAHA,["29I8<>@WP7D@V%S^ZZFMA)56:QL+MHGN39"BX:H!L(K
M(/8;<39;]M_^"Z'6AGQD38?W5D@ T>YF],[X2=K@X0(F_S:2A&#&H 4C+\G/
M@S%:\CW O@+HX(@H)_$-[WLN!39R$=#N(K:C5^?UOLIR\-8&QJ=X8<2<SO,]
MP,X]V4&U+B>QT[X"UP++R*5 NXO8GJ.='S.WI<#CX?%KXB"O!B6=P,YHVD'E
M%E)Y6Q-D>'%G:",7!+W^87NG=W? :"G &UX*S+LF^/T#?LK>#NIU"8J-6#B'
MWEM="M[*38'&@&DM[J7+ P8$<$MC"=%[-($A?6_J('$;_9/,;70Z6XZFDUY_
ML!Q]&BT_W]Q%;^ZB-W=10U; PMQZ<Q?]VMU%CRY3BH0L%Z6^#GXO94;W%85Z
M>9KIGUFF9@*\V\V6LOSB+[=^%%B>W4_>L \)\9+G:/L./6X2>2([YX7P/LD?
MF*_<'+8SC]Q7LIYL73>2I >"S-LMK1E#Q)^Z^49JLO+U>FX5D<D=88>OA*Z<
M /1^V34Z@#WY=4&Y(12^#95_5N/UK(W7G/!UC?U^P//0LI-A9+E+0G<?%.I_
M[<Z\;1=&'&K?TLYCQ$1TO,!9M65X5G_RYFU8E::W,3_70.C2ZU*1%:J5C]U\
M"O6I,7_^%%IT(-Z^3>V&F^S$U^O&USR5YJNO2.2)GUY&%BXKCX*VX9D'^NK-
M%:\&6>9KI&H4'D7"GE,U^_'U^L.U0JCY>JR0.N/LUZ*KL^QC-T\V?6K>MNNR
M:J26 (,T^6KWY.OU0FN)U,Y/P)AW:AI^D>];>U7/V/FW%*ZOVV.X8_=J.OI]
MNUJ3@'C3>L/N('0TNZ,W96W!=M/E\V&7>_NUO>LH^114<[^^"S0A+S=]/>*"
ML^, =P"JVU_?_9HFAV]!XVMX>XC1$GE[O%=H_[4[ QT)';W"P^'6#'M',[)?
M[LVNH[Z%;T*UM*/W>*TR9=9C'Y?AF@\^33SS!Y:W(E02O?EGG>C-A^F\=S?\
M/)W<]P;]R6 XO\5SWN(Y;_&<AIP6"E/B+9[S%L]YB^<LY_<6S_G&XSF77UB_
M#U./9#="X]"N$=-9H4GLT":MN,[*D)EQ+NOH/?0MME.;E:\^D*(K=]#X$V 7
ME/L6VPDPR-QB.\T>"CC45AX6K/UG/R#X0^*-^&3<XD*KT_0VYO8:"-WB0HU5
M7EA<Z!N<>V\QI6]&Q5N-*7V#JG^+1^V0<C<;C_H5!E3=8ED[IO%MQ[)^13/Z
M+0X679OQXF"7A)JNM[=@V%LP[&T&-_P"\Q9(JPU7(W8_(YS\OX)+S%L@;4,@
MWK3>L$N;6R!M9=ANNGP+I#56<V^!M$I<;H&TW=?M6R#M+9#V%DA;,Y"VH[:2
M9G"[!>%V1<.[&80[(1'U/3^0!.#^13< =S)\FD\GT\4M]O86>WN+O37D@%&8
M"6^QM[?8VUOL;3F_M]C;KR+V=LF*DW@'-/&#)B)O-1K$#CNK$'>K#=<MZO86
M=7N-"^M;F$K'+JSQI[\N*/?7$W7[1FZKWWH$;9LT??6*W)D0PZ_OMOH68@@"
MYNV$&+[!2^M;B.$MQ/#-QL_>0@QKCOZW'6+8T7OIJQ/Z=<[H70LQ?(,!L[<0
MPQI#_>V'&+[!H%K30@Q#,\9!#5>LKR;]7D<#;G&H[?J Z.CEY2WB5ANN1LS@
M1D0#? 47F+>(VX9 O&F]87>8MXC;RK#==/D6<6NLYMXB;I6XW")NNZ_;MXC;
M6\3M+>+V%G%[B[A]^QK>B8C;!_;[N'_'X%M)I.W/LDC;A_YHWOO4'S]EXV[K
M1=@*XF0DG9<$T_*JH)I-AO1(/BB*A57TTXSX5C"8EV,,)IL!4:P,R'BP%V:+
MDFFVI*S9[$@C1TND:2D2-*!AA@OVTYD']L/O<S[A"D(_V=\S?^X@VI<"M!/
M"<%7&#YX[" T'+!EC"_Q*L?RV-6:P9F5P'QD6]==M)/!F2N"%F"4AZL 9JDL
M[81*JE"U7I6H7A9!BV]1HUHF2Z.H!F3U[<9_^<XF3@(J^\<93_;#[V.RL=RA
M%_*<%.43*RM5*-3!Z;5,C SUU\ Z^;0P(IX5N2R!C'(98@5,+WO<3A!\\G)R
MWZ$C;R4-;B\KB.9A7@"GN.\5"U9W%I B>7J#&@!FH2R:QP\83X%X+4&:22X@
MA;.D'-YM/ !+H5S=S9!P6BCZ01#M$MO,W G^>*"$&V8(@Y^MV&$;%R?P3V-G
M4! ><YNZ -%EX6WIV_!U3U8AL3_Y+FO&94/PBAHG^CAZ9@,4I9-3\3;5[MYY
M<6SBV0A*=_EI]*P#J"I71H,9"E?EFD,F:5MWL8!OHN<&T%*Q5H$WZWYI$?JK
M/]X5!.8]]P(BOFSZT_>RRZ;%<CKX]=U=?S&\[PVFC[/A9-&/+YR&?^?_'K9]
M\11+59@H4J' EU# 5MJYD))^''8Y!6G"*.N1%FWEEU80F6\76-=CS9#+K"K<
M3-<C;^7OR)A_ADET9[G<FB%/=PJK_<;XD\J*GOZT?->HN^/NNC7 J.U'M-M9
M]#!=9R,]+!JGD)%L.=X7MAQ/CX_]^>?8H>5IN5CV)_>CR<?>;_WYO#]9WA+(
M5TP@/_!=UDF?6CPM:S;HN._QE"@KP9^7[%\!$X#O?,&9Y)O[EAG9BC53RC<G
M/OZFI@%9 -NA9K]BAM*T-_1RBM<L>/A[M25K>[K.]%2^.1,4_\J40( "^CZM
M**E5+ISP;B]M2;LA,Q1 JLPY#K5%;,<;8.*$U%E])%Y_0TG\;?F]J[ X]JU'
M1=V[N*158-'2G7?_A7@1@>$O*(MMG&T ?"D*+2'_R%K<%EXY>/ C.K><0.R[
MR2L#ZV*G9&R &2V46ATC0WY*#3AR&H-%7 D[W5ICHT:%2TND+,@^C+]3JAS)
M.6JZ7A/J>!LI454:PLZ5U !YU?%#(?2>/(?G!*HU""UO"#V;2NN,R@"\/J/L
MZ#'R[&BEGD=U&T'/P= NDQ+@6F+Q_UI>9-%#H2L+YU5CEM5N!3W*N@$>*T+7
MUG",GI=^:+GRX98K!*7!Y'U*N> MH3RCY"'BMQG'&PDVF$LG9"D-VJU >6HM
MF6D#/%6$[EI$LM%<-I+U>%0T O:EZQ*-(.#0?>8&KA4$TW7:Z2F=\P06F1M&
MR9V"LB;RW6\;5ROYJP$@>F;2?)&HY_3'(/UK(/%ZK-@<ML$22R.@0&.F@Q&L
M!Y7D4294Y$TWTC*V%W:;&M482*UN&(Y?'[[N'1KC?F^%Y)X$*^KL!3Y#O"*@
M'K:)O6URP= 9X7[$'=ZVOLL@#Y)C7.HG-.%2< C*O(\^%+R/N)/S+]/Q_7"^
M^-__]I</[__\G[WAWYY&R\\GQZ/>J<6;"Q+D!GBUBG:1RQ_6F(9;0KG_&B5;
M;IWF5I/$Q3!0.1?IM6+&W2_(;4A/,'R'(&!_"Q-+94K'ICGV5%'H:J2/;VXY
MQE)X<[BY.=PTM$7-F&'ZV2N%_O)1:L8"U,,^T39@N *CTY;%,:*KK14 O7&$
MI=^ UX<"B;;\/';Q.6#L6U ?#TD%, L&TZ &!"5QV+PKN0,;V .4IA)L)LO5
M+94@1BK!6]*[-E!M*T'C#V\[0V.5N-;$UL#G,-^+UQ980&MYM>Y/T# Y,P9:
M'/IRW1)F+KPP*!6*FT$72!5S_ @$:F4)T IZV^U\+[8HJT[))46!DUAK3[)(
ME:H0.R:0M*7-?)G'0<$S 7KH5;> _MPDB MML:Y.4:(FE?DIKX[NW5N+'!DD
MU_)]TG-R,L87%XQ[RP.@]CJ1=DNU1N2*0=>'UIP"=1:(4A'1@5]$SX%C.Q8]
M+*Q3MA/%EE=<Q8S]4Q/;7;&,F4T'$F7G'DVL'?MGQMBEVO="ZII!HE(Q\XP!
M),/>#<^H\\*T<N9:BL"0M(*H//[[56 5S+$D1P!]-F3]\KA \@GPLI09PZ6!
M.>]2K,PM"BX7JBDM7\X,/LHT28!WNR\2Y"[]M@X-"?%.Z?R3'0Q3$"82TQ3>
M)YV;4HWFT",XRA5*<D&JC=45SI''/O5UF"JO!36\MW9ZT2)$)OGU<*\Q7 !-
M0!EI;5VOQ(@)PR*V)4P]DGM6HPY=^DU"[US,F.$J8W8M.I>L.,F\[5&;3(T&
MH9:%UL(-*E"IC=<5Q^5PMW?] R'QD>'H_5)I."I;@CJFM'9K4&T4 A%"/R+%
MV=RY:Z#\C)0K9L:FO E_XTNY4F7ZDV'9>[.^4:)''\Z2>#;TK-7.UPQ1CC+%
MUGUAHY+\V&:I.0EX;C8V*N+)Y\ESPF"^>%)9IQ35T$.]VQP:.;T (8@^=5\L
M,<G[DRJ.)57 ,7MO@%\E<M?:2G%W[>3[<[)G&J=*2Z/3 )30UC9.UR!4%Y16
MZ;W>&Y<_MG<5<"726GTPL\D[N8'/MI,,="O1IQ5ARF7/",U<D8#NYT#M("?>
MJ!K"*+Z[TT"OK312Y\X\$,(^S<_/UD;XGI"P.'K$4$URY-*URL$L>G:=U8/K
M6Z$LL42Q&':6B"8P%PF//LG-J+\BQ X>F-2C((CX7,S3L9\<'V4WV<JJV#D@
M&IK+P"!AIH!IU <EXBLQ^X$O\@$7F=@C3W>U [2"[0W<_&('A@Y]Z,?=33IX
M'_&,CFPI<'P[GI\FY$O\%VF4!*@Z>F1G0PSK@-7M::!<TD2?J^M%H3Y0,5H[
MY+2K& *XNJT97*8X;97"FIR604\7WQ##!;$[S6+?_D<4A/$I?NGW;=OA=%CN
MS'+8.C6P]DYHN3%<DHL@>!- '6@OQ6LS.J -&OKJGEIE@@>?SLD^O7N$[NP!
M==&?$VAH:P^&J35[H4?6SLIA^O/%(S38.ONQLW,2()66"G!M]%BO)D[1FEBA
MC\%C8$[?LY/DCJ#4O/):Z'%A#0T\"#;H!'8K\:ZQ%K!ZXANB"^5&H&-_=<UD
MYWKH 8>M&LGR^'1ZZYP*<Z&R#"!*V)Y!.9\+:D'I-]T$!L$&?PR?=WM\A^<$
M_ TPV=@5E,=_Z*7QW6\)'NATW:<3Q, /PF 040Z,F*SRTNAQ=0U1)<,"G2BE
MPX#(7^#26MZ/PJU/G7^=\UI7<%?4_Q3^>T$-&JK:8.'-Z->+Y;C<$9C-=Q_Y
M:M6^FA6_B!XS9YBVB3CIKM+%__.)!.'I-D!R)FSV*U#E,MTLUP;VZ IU]#A-
MS%BQZ:-<3K&V:#2![JO=D"IHHV8,SPM"7]@IJ+RW$]][86I*$HT-XL?^LG_G
M^[R)'WXFX9RL_(W'U^-$H6-3=?PK7DXRM5R['U"-,]TTB<,?NMK&<CZKY]SG
M_)Q[?@$G$5"QV#7S":BRF6X4;1QU=#UJ;?@@S'0&9%0P?5(S1N\J[QF3,)$@
M/GT$HW0X_4;X_0-#XH50:T/B/_('OAXLAXK\E^MN7JMV!*JCIMN0D1@T5'-U
M%0RN!Z:;I<'[>[TKI)!0$SSH:BAXYHX\L:*T-PF5? H]E8TATXR0!4,GDDJ2
M)7/H\0;OGB3_S<VI%[=]5]'%*MV"ZNV;M>\WR2ZZCE_&;1_]P'BPZ7 QG661
M82<D]D^)7E9H"JI+IEOO*Z.(SG\F7E_3$4-=$\JN\>9S($;X9%:=TB[#JT!V
MI^8^@YXF WM!D:'?79TZ7DR>_?NOZ)8@^RC>PT^&Z!N<&73M:\W.EIG3)1YK
M5_H\5"--M[Y?E2UTW2QUP ;%)*AK0C7"=#LY%*-..S)G?;5SCKM 3_9B+?14
M4RWXL8NPZ3;Y9Z??!R+E.U\02K'I]F4! IUF519/M21T)Z9971/*N^F&7RA&
MG58$:4("16 WI"Y4&8RWIH)Q0M^W-7LO^I$R=*YU>YU^##V-/O8)5LU$H]>:
M__5= 68FVA_'OY;^\:(?Y#4D_&W!8^\NN'B.\S9:#OW6(V'2B<5J2^R(9T%*
MX$T"5/I!0.+I=D;)WG+LU)8<W)/0<MRSZ$[(6__YYY^__],/O7>]>R=8N7X0
M4<)^6 Q^&=X_C8>]Z4-ONOQE..\-GN;SX639ZR\6P^6BUY_<]V;SX:P_NN\-
M_SX;3A;#1>_?TT_\QS<&1"XE^2%B#\ $!X9(#%."SUG<_G,04FL%#G*JT'##
M3V[RC\Z9'C&]W;*/WY,7XOK[77F@5OIJI:P.<O++AGC+/=.I!JG3.XY4PI''
MH.!1O[(39+XD=D+-A@D7RFG(3N*DC++8IXM"V-DW6R5H7CX$4;E96J]R(TRV
M%':"S5;9N4 "G9Y[LO<#'G\2RR);H2_+8:>X;(>B<C3025I$^[WK2-,3GDI@
M9Z9LAY@\ NB49(10AO"7E<7.$]D.36)4T F[/*M=RJ=D$%09.S%DJZL6!+?J
M9WU^]XA^UH]V.XL>INO^:D4C CG5_U@XU3\]/O;GG_FAOC\8S)^&YIS=9]:!
MQZ-SLT4LH.4&ZG.YM%*39^X4\_+CY)$)P=D;6!?Y# [ /WN^U@*DT^?L5-(9
M]=<DSM1CN?SZ2CDGJ^IAG\$U" =*9,A*>IP?<Q'L4,*$];#/Y)4)4R#14HK5
MD1<2AE"X(-ROW5L1,0&\O+@X]FE;<V94R8T^/HX=3.52C@M1>>PCMOYXD$N.
M3LQQ@SQGFN-%:F)$Y;&/V/K$R"5O:8+ZZ/MV<'P8:^*'(^_%=U:E[L:\O+@X
M]EE9<X)2R8T^#I(37+)VC1WKV7&=T 'LN%3UL _ ^N,"AL1;V%YGI#N>X3._
M4F[:5-6Q'T2HO'>#X?*F+1NS&. M"9V5Y9:9.7ZJ9.;H_?M%PS>S1YFK0?%#
M%T^ZY[T,A,7->)A<<Z$4BY-]MP'+W] *8]>G<=YWJLR_L%@6F1 YO.57+"52
M9+/I-<A#0,,,!^RG,_[LA]^7?.Z9KD>>[;PX-NMW]IW[#/RLK*!HA] 7"Y$Q
M4"%B_YL3;N?$C:'CP=1+?^BQQ>%P^?ZQ@A55(\A\B3E0<Z42[6Q6;O3IWY"=
MY,9.X$A?XBZ40K.)5D&NN& (I$8_4 VL8"M>'I*_(E\_B->S?*181A9T8&-?
M&:@=K;0P]BT &'>)J"4T8'I"[^,WS[W-F.=<.!Z6#I)KTC])G9]GPWE_.9I\
M[(V'_<6P-Q[U[T;CT?)SS0M3P<1Y[D?<?=EA@)<7%T<RW5R GT1QKI\"$M_'
M2RPW\FI8<Y,<X7*+#02 3AML!.-+;9U3U$.;"6NS+,+@+=(\\;U51::S5='N
M4ILCNXC$6^1;FV7$^]KFN&W%KHK)9R['W)SP(\SQCSP(5Y+07K\EM)OAVAH
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M5Y-6PID$DRYQNI+7 CQVB(W8.7:Z)S0)(TMH/'6=D<G^$83.2B5GQ4:1MX,
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M6!>2-VH?1*:4^\TF1+BN_\7R9+D\0)718TP;8%L,"N:30\V3G_&BGI2N@2*
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M#5A+EQ(0-:W,:E.-8[N8P"AN%LI.>QH(M'VPY8^HC;Q:AO@FVL;V7:F[S:@
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MJI5H$;: KKK90I46!43 W2)E=A(W$@>;'XL0;VAUWM6>X",XNN2V,)Z>+=7
M%*/0KDVC*$'N<Q(2MTYZB ,W[61DH9_I1\+39;7VYO.\-14RQ7YIO[+^JKY5
M_";F4\3E.AABF$48;!!RHPG1D?:3QD3L+2W.&?CI&.,;2*&I^=QQ=5UJ!M-C
MQ,4HO(U$RJL4DMX086_7*#Q@G^XU9H'#VNBF)3<XPN:3O46]-_!5*NT/T;N
MH2=NU1L*MHKRX!9B1^GMG_1JZCT^"N^^R)^A\8C>D*ZU8>DUE]Z.]RA<H@W"
M'S0,(+JEKR8)'792-BE/2?!7L#"E$O]@AZE&[C?'2Q26A$J-H;?)ZHE+ZE"
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M)IE;*%;QNA4Q<.IR<YLR%>ZU"9\1Z?,&9^"3=<*!8O*WI/B^L!$X*;JY>17
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M]:C>1)T:P_2/&!RWCXD>!;IT06DU_8 ?/<D_H?]Y)STB?_D_4$L! A0#%
M  @ PJ#:7-Y4S!=J @  ""0   H              ( !     &5X,3DM,2YH
M=&U02P$"% ,4    " #"H-I<2;<P[-<"  "&'P  "@              @ &2
M @  97@R,2TQ+FAT;5!+ 0(4 Q0    ( ,*@VEQ-2@_59@,  "H.   *
M          "  9$%  !E>#(S+3$N:'1M4$L! A0#%     @ PJ#:7,2]]5;<
M!P  L$(   H              ( !'PD  &5X,S$M,2YH=&U02P$"% ,4
M" #"H-I<X"6-3\X'  "'0@  "@              @ $C$0  97@S,2TR+FAT
M;5!+ 0(4 Q0    ( ,*@VERE<2@^2P0  *<9   *              "  1D9
M  !E>#,R+3$N:'1M4$L! A0#%     @ PJ#:7-"NLW94!   RQD   H
M         ( !C!T  &5X,S(M,BYH=&U02P$"% ,4    " #"H-I<F,=$U7H;
M  ";SP  "               @ $((@  97@Y-RYH=&U02P$"% ,4    " #"
MH-I<R.B?HYZ@! #&TRD #               @ &H/0  9F]R;3$P+6LN:'1M
M4$L! A0#%     @ PJ#:7/G<_L>;D@$ 6Z,! !               ( !<-X$
M &9O<FTQ,"UK7S P,2YJ<&=02P$"% ,4    " #"H-I<: ,!@@0D 0"S- $
M$               @ $Y<08 9F]R;3$P+6M?,# R+FIP9U!+ 0(4 Q0    (
M ,*@VEST2+=]9N(  $KO   0              "  6N5!P!F;W)M,3 M:U\P
M,#,N:G!G4$L! A0#%     @ PJ#:7(4/;>DV&0  :18! !$
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L 'AA:7(M,C R-C S,S%?<')E+GAM;%!+!08     $0 1 /T#  "&.0H    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:XAIR="http://beyondair.net/20260331"
  xmlns:country="http://xbrl.sec.gov/country/2026"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2026"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="xair-20260331.xsd" xlink:type="simple"/>
    <context id="From2025-04-01to2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-06-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
        </entity>
        <period>
            <instant>2026-06-23</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-11-04_custom_BeyondCancerLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="AsOf2025-03-24_custom_NeuroNosLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-24</instant>
        </period>
    </context>
    <context id="From2025-07-142025-07-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
        </entity>
        <period>
            <startDate>2025-07-14</startDate>
            <endDate>2025-07-14</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-01-31_custom_StreetervilleCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:StreetervilleCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_StreetervilleCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:StreetervilleCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2025-11-042025-11-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
        </entity>
        <period>
            <startDate>2025-11-04</startDate>
            <endDate>2025-11-04</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_country_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_country_BM">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BM</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_country_IE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_country_CY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-03-312026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
        </entity>
        <period>
            <startDate>2026-03-31</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_AustralianTaxationOfficeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_AustralianTaxationOfficeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_FirstThirdPartyVendorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:FirstThirdPartyVendorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SecondThirdPartyVendorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:SecondThirdPartyVendorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_ThirdPartyVendorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:ThirdPartyVendorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:CustomersOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:CustomersTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:CustomersOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:CustomersTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_BeyondCancerLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_NeuroNosLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_ShortTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_ShortTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_ShortTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_ShortTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-11-04_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-04</instant>
        </period>
    </context>
    <context id="AsOf2025-11-04_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-04</instant>
        </period>
    </context>
    <context id="AsOf2025-11-04_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-04</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClinicalAndMedicalEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:ClinicalAndMedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClinicalAndMedicalEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:ClinicalAndMedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_EquipmentDeployableAsPartOfServiceOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:EquipmentDeployableAsPartOfServiceOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClinicalAndMedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:ClinicalAndMedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ClinicalAndMedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:ClinicalAndMedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_EquipmentDeployableAsPartOfServiceOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:EquipmentDeployableAsPartOfServiceOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-02-102025-02-10_custom_TwoThousandAndTwentyFiveATMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:TwoThousandAndTwentyFiveATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-10</startDate>
            <endDate>2025-02-10</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-10_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-10</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TwoThousandAndTwentyFiveATMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:TwoThousandAndTwentyFiveATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_TwoThousandAndTwentyFiveATMMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:TwoThousandAndTwentyFiveATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-11-042025-11-04_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-04</startDate>
            <endDate>2025-11-04</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-01-31_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-11-04_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-04</instant>
        </period>
    </context>
    <context id="From2026-01-142026-01-14_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-14</startDate>
            <endDate>2026-01-14</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-14_custom_TwoThousandTwentySixPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandTwentySixPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-14</instant>
        </period>
    </context>
    <context id="AsOf2026-01-14_custom_TwoThousandTwentySixCommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandTwentySixCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-14</instant>
        </period>
    </context>
    <context id="AsOf2026-01-14_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-14</instant>
        </period>
    </context>
    <context id="From2026-01-142026-01-14_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-14</startDate>
            <endDate>2026-01-14</endDate>
        </period>
    </context>
    <context id="From2026-01-162026-01-16_custom_TwoThousandTwentySixPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandTwentySixPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-16</startDate>
            <endDate>2026-01-16</endDate>
        </period>
    </context>
    <context id="From2026-01-142026-01-14_custom_TwoThousandTwentySixPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandTwentySixPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-14</startDate>
            <endDate>2026-01-14</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-11-25_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-25</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TwoThousandThirteenBAPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandThirteenBAPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_TwoThousandThirteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TwoThousandThirteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-03-272026-03-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
        </entity>
        <period>
            <startDate>2026-03-27</startDate>
            <endDate>2026-03-27</endDate>
        </period>
    </context>
    <context id="AsOf2025-11-04_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-04</instant>
        </period>
    </context>
    <context id="From2025-11-042025-11-04_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-04</startDate>
            <endDate>2025-11-04</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-11-222024-11-22_custom_TwoThousandTwentyFiveOptionRepricingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:TwoThousandTwentyFiveOptionRepricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-22</startDate>
            <endDate>2024-11-22</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TwoThousandTwentyFiveOptionRepricingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:TwoThousandTwentyFiveOptionRepricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_TwoThousandTwentyFiveOptionRepricingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:TwoThousandTwentyFiveOptionRepricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_TwoThousandTwentyFiveOptionRepricingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:TwoThousandTwentyFiveOptionRepricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2022-11-032022-11-03_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-03</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-03_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-03</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember_custom_BeyondCancerLtdMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember_custom_BeyondCancerLtdMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-08_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-08</instant>
        </period>
    </context>
    <context id="From2025-09-082025-09-08_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-08</startDate>
            <endDate>2025-09-08</endDate>
        </period>
    </context>
    <context id="AsOf2025-11-03_us-gaap_CommonStockMember_custom_AmendedLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-03</instant>
        </period>
    </context>
    <context id="AsOf2026-01-16_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-16</instant>
        </period>
    </context>
    <context id="AsOf2026-01-16_custom_TwoThousandTwentySixPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandTwentySixPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-16</instant>
        </period>
    </context>
    <context id="From2025-01-162025-01-16_custom_TwoThousandTwentySixPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandTwentySixPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-16</startDate>
            <endDate>2025-01-16</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_BeyondAirIncMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_BeyondAirIncMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_BeyondAirIncMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_BeyondAirIncMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_NeuroNosLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_NeuroNosLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_ResearchAndDevelopmentExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_ResearchAndDevelopmentExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_GeneralAndAdministrativeExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_GeneralAndAdministrativeExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_NitricGenAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NitricGenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_NitricGenAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NitricGenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_AvenueAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:AvenueAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_AvenueAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:AvenueAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_MarchTwoThousandTwentyFourRaiseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:MarchTwoThousandTwentyFourRaiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_MarchTwoThousandTwentyFourRaiseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:MarchTwoThousandTwentyFourRaiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_AvenueExtensionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:AvenueExtensionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_AvenueExtensionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:AvenueExtensionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SeptemberTwoThousandTwentyFourEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_SeptemberTwoThousandTwentyFourEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SeptemberTwoThousandTwentyFourEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourDebtInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SeptemberTwoThousandTwentyFourDebtInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_SeptemberTwoThousandTwentyFourDebtInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SeptemberTwoThousandTwentyFourDebtInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFiveInducementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SeptemberTwoThousandTwentyFiveInducementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_SeptemberTwoThousandTwentyFiveInducementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SeptemberTwoThousandTwentyFiveInducementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_JanuaryTwoThousandTwentySixEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:JanuaryTwoThousandTwentySixEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_JanuaryTwoThousandTwentySixEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:JanuaryTwoThousandTwentySixEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SubTotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_PreFundedWarrantsSepTwoThousandTwentyFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PreFundedWarrantsSepTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_PreFundedWarrantsSepTwoThousandTwentyFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PreFundedWarrantsSepTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_PreFundedWarrantsJanTwoThousandTwentySixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PreFundedWarrantsJanTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_PreFundedWarrantsJanTwoThousandTwentySixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PreFundedWarrantsJanTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SteveLisiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:SteveLisiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-03-012026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
        </entity>
        <period>
            <startDate>2026-03-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_WarrantMember42283484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_WarrantMember42283484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_us-gaap_RestrictedStockMember42283484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_RestrictedStockMember42283484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">XAIR:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">XAIR:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-12-31_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-12-31_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">XAIR:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
        </entity>
        <period>
            <instant>2026-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="AsOf2025-11-02_custom_LoanAndSecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-02</instant>
        </period>
    </context>
    <context id="AsOf2025-11-03_custom_LoanAndSecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-03</instant>
        </period>
    </context>
    <context id="From2025-06-022025-06-02_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-02</startDate>
            <endDate>2025-06-02</endDate>
        </period>
    </context>
    <context id="AsOf2025-11-03_custom_AmendedLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-03</instant>
        </period>
    </context>
    <context id="AsOf2025-11-04_custom_NotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-04</instant>
        </period>
    </context>
    <context id="From2025-11-042025-11-04_custom_NotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-04</startDate>
            <endDate>2025-11-04</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_StreetervilleCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:StreetervilleCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-02-042026-02-04_custom_StreetervilleCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:StreetervilleCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-04</startDate>
            <endDate>2026-02-04</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_IsraelTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RevenueCommissionersIrelandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CypriotTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">XAIR:CypriotTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_NoExpirationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_NoExpirationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_country_IE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_country_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2017-01-122017-01-13_custom_OptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-12</startDate>
            <endDate>2017-01-13</endDate>
        </period>
    </context>
    <context id="From2018-01-302018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NitricGenAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NitricGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-30</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="From2018-01-302018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember_custom_NextMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:NextMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NitricGenAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NitricGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-30</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="From2018-01-302018-01-31_custom_NitricGenAgreementMember_custom_AfterSixMonthsMember_custom_NitricGenIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:AfterSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NitricGenAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NitricGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-30</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NitricGenAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NitricGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_NitricGenAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NitricGenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember_custom_SupplierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">XAIR:SupplierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-11-04_custom_BeyondCancerLtdMember_custom_CertainInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:CertainInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="From2021-11-022021-11-04_custom_BeyondCancerLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-04_custom_BeyondCancerLtdMember42285687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="From2021-11-162021-11-18_custom_BeyondCancerLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-16</startDate>
            <endDate>2021-11-18</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-04_custom_BeyondCancerLtdMember_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="AsOf2021-11-04_custom_BeyondCancerLtdMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="AsOf2025-03-24_custom_SubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-24</instant>
        </period>
    </context>
    <context id="From2025-03-242025-03-24_custom_SubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-24</startDate>
            <endDate>2025-03-24</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_SubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_SubscriptionAgreementMember_custom_NeuroNosLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_SubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SubscriptionAgreementMember_custom_NeuroNosLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-21_custom_SubscriptionAgreementMember_custom_NeuroNosLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-21</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondCancerLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NeuroNosLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:VariableInterestEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">XAIR:SegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_LungFitPHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">XAIR:LungFitPHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_LungFitPHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">XAIR:LungFitPHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_LungFitPHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">XAIR:LungFitPHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_LungFitPHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">XAIR:LungFitPHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_LungFitPHMember42286578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LungFitPHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_LungFitPHMember42286593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LungFitPHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_LungFitPHMember42286593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LungFitPHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012026-03-31_custom_LungFitRPHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LungFitRPHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_LungFitRPHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641631</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LungFitRPHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Integer">
        <measure>XAIR:Integer</measure>
    </unit>
    <unit id="AUD">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-04-01to2026-03-31" id="Fact000004">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-04-01to2026-03-31" id="Fact000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-04-01to2026-03-31" id="Fact000006">0001641631</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl0150"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0151"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl0156"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0157"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0176"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:SaleOfCommonStockAndPrefundedWarrants
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:SaleOfCommonStockAndPrefundedWarrants
      contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:SaleOfCommonStockAndPrefundedWarrants
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:SaleOfCommonStockAndPrefundedWarrants
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:SaleOfCommonStockAndPrefundedWarrants
      contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:SaleOfCommonStockAndPrefundedWarrants
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:SaleOfCommonStockAndPrefundedWarrants
      contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:SaleOfCommonStockAndPrefundedWarrants
      contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:SaleOfCommonStockAndPrefundedWarrants
      contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:SaleOfCommonStockAndPrefundedWarrants
      contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0466"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-04-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProvisionForOtherLosses
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossAfterTax
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:GainLossOnTerminationOfRightOfUseAsset
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:PaymentsToSecurityDepositsMadeOnOperatingLeases
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0636"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:DerivativesLiability
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0669"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:RightofuseAssetsAcquiredUnderOperatingLeases
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0678"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:DebtPrincipalBalanceConvertedToEquity
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0681"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl0686"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl0687"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsMember"
      id="xdx2ixbrl0729"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsMember"
      id="xdx2ixbrl0730"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0734"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0735"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0738"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0739"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0743"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0744"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsMember"
      id="xdx2ixbrl0749"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsMember"
      id="xdx2ixbrl0750"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0754"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0755"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0758"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0759"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0763"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0764"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2025-03-31_us-gaap_DerivativeMember"
      id="xdx2ixbrl0830"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2025-04-012026-03-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0832"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:FairValueMeasurementExtinguishment
      contextRef="From2025-04-012026-03-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0838"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2026-03-31_us-gaap_DerivativeMember"
      id="xdx2ixbrl0842"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="AsOf2026-03-31_us-gaap_LeaseholdImprovementsMember"
      id="xdx2ixbrl0906">http://fasb.org/us-gaap/2026#UsefulLifeTermOfLeaseMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember"
      id="xdx2ixbrl1087"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember"
      id="xdx2ixbrl1089"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockMember"
      id="xdx2ixbrl1103"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockMember"
      id="xdx2ixbrl1105"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="xdx2ixbrl1145"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="xdx2ixbrl1147"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="xdx2ixbrl1159"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="xdx2ixbrl1165"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="xdx2ixbrl1167"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="xdx2ixbrl1179"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="xdx2ixbrl1187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1243"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1245"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1247"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1249"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1263"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1265"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1267"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1269"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1301"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1303"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1311"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1313"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1315"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1317"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1331"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      id="xdx2ixbrl1333"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue
      contextRef="AsOf2026-03-31_custom_NitricGenAgreementMember"
      id="xdx2ixbrl1450"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue
      contextRef="AsOf2026-03-31_custom_AvenueAgreementMember"
      id="xdx2ixbrl1458"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue
      contextRef="AsOf2026-03-31_custom_MarchTwoThousandTwentyFourRaiseMember"
      id="xdx2ixbrl1466"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue
      contextRef="AsOf2026-03-31_custom_AvenueExtensionAgreementMember"
      id="xdx2ixbrl1474"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue
      contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourEquityOfferingMember"
      id="xdx2ixbrl1482"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue
      contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourDebtInstrumentMember"
      id="xdx2ixbrl1490"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue
      contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFiveInducementMember"
      id="xdx2ixbrl1498"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue
      contextRef="AsOf2026-03-31_custom_JanuaryTwoThousandTwentySixEquityOfferingMember"
      id="xdx2ixbrl1506"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue
      contextRef="AsOf2026-03-31_custom_SubTotalMember"
      id="xdx2ixbrl1514"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:InterestSeveranceCurrent
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1584"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1587"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1590"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SubleaseIncome
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1643"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:PaidInKindInterestAmount
      contextRef="AsOf2026-12-31_custom_PromissoryNoteMember"
      id="xdx2ixbrl1707"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl1893"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl1894"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1904"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1906"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-04-01to2026-03-31"
      id="xdx2ixbrl1952"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss
      contextRef="From2024-04-012025-03-31"
      id="xdx2ixbrl1974"
      unitRef="Pure"
      xsi:nil="true"/>
    <XAIR:CapitalExpendituresCost
      contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2046"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2053"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2054"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2058"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2059"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2078"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2079"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2094"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2113"
      unitRef="USD"
      xsi:nil="true"/>
    <XAIR:CapitalExpendituresCost
      contextRef="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2131"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2137"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2141"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2142"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2161"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2167"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2177"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2192"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2196"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2202"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterest
      contextRef="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2235"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssets
      contextRef="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterest
      contextRef="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      id="xdx2ixbrl2265"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-04-01to2026-03-31" id="Fact000017">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2025-04-01to2026-03-31" id="Fact000018">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-04-01to2026-03-31" id="Fact000019">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-04-01to2026-03-31" id="Fact000020">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-04-01to2026-03-31" id="Fact000021">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2025-04-01to2026-03-31" id="Fact000022">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-04-01to2026-03-31" id="Fact000023">001-38892</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-04-01to2026-03-31" id="Fact000024">BEYOND AIR, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-04-01to2026-03-31" id="Fact000025">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-04-01to2026-03-31" id="Fact000026">47-3812456</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-04-01to2026-03-31" id="Fact000027">900     Stewart Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-04-01to2026-03-31" id="Fact000028">Suite 301</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-04-01to2026-03-31" id="Fact000029">Garden     City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-04-01to2026-03-31" id="Fact000030">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-04-01to2026-03-31" id="Fact000031">11530</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-04-01to2026-03-31" id="Fact000032">516</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-04-01to2026-03-31" id="Fact000033">665-8200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-04-01to2026-03-31" id="Fact000034">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-04-01to2026-03-31" id="Fact000035">XAIR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-04-01to2026-03-31" id="Fact000036">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2025-04-01to2026-03-31" id="Fact000037">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2025-04-01to2026-03-31" id="Fact000038">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2025-04-01to2026-03-31" id="Fact000039">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-04-01to2026-03-31" id="Fact000040">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-04-01to2026-03-31" id="Fact000041">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-04-01to2026-03-31" id="Fact000042">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-04-01to2026-03-31" id="Fact000043">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2025-04-01to2026-03-31" id="Fact000044">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2025-04-01to2026-03-31" id="Fact000045">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2025-04-01to2026-03-31" id="Fact000046">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2025-09-30"
      decimals="-5"
      id="Fact000047"
      unitRef="USD">15500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-06-23"
      decimals="INF"
      id="Fact000048"
      unitRef="Shares">14410621</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityListingParValuePerShare
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact000049"
      unitRef="USDPShares">0.0001</dei:EntityListingParValuePerShare>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000051">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000055">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
rely on sophisticated information technology systems and network infrastructure to operate and manage our business. We also maintain
personally identifiable information (&#x201c;PII&#x201d;) about our employees, and given the nature of our business, we have access to
protected health information (&#x201c;PHI&#x201d;). Our business therefore depends on the continuous, effective, reliable, and secure operation
of our computer hardware, software, networks, Internet servers, and related infrastructure. To the extent that our hardware or software
malfunctions or access to our data by internal personnel, suppliers or customers through the Internet is interrupted or compromised,
our business could suffer.&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
integrity and protection of our customer, personnel, financial, research and development, and other confidential data is critical to
our business, and our customers and employees have a high expectation that we will adequately protect their personal information. The
regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve and a number
of states have adopted laws and regulations that may affect our privacy and data security practices regarding the use, disclosure and
protection of PII. For example, the California Consumer Privacy Act (&#x201c;the CCPA&#x201d;), among other things, creates individual
privacy rights and imposes increased obligations on companies handling PII.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Although
our computer and communications hardware are protected through physical and software safeguards, they are still vulnerable to system
malfunction, computer viruses, malware and ransomware, and other cybersecurity threats such as phishing and social engineering attacks.
These events could lead to unauthorized access to our information technology systems and result in financial loss and the misappropriation
or unauthorized disclosure of confidential information belonging to us, our employees, partners, customers, or suppliers. The techniques
used by criminal elements to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote
areas of the world. As a result, we may not be able to address these techniques proactively or implement adequate preventative measures.
If our information technology systems are compromised, we could be subject to fines, damages, litigation and enforcement actions, incur
financial losses, suffer reputational damage, and lose trade secrets or other confidential information, each of which could significantly
harm our business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cybersecurity
Program &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Given
the importance of cybersecurity to our business, we maintain a robust cybersecurity program to support both the effectiveness of our
systems and our preparedness for information security risks. This program includes a number of administrative, physical, and technical
safeguards with regular evaluations of our cybersecurity program, including periodic internal and external audits, penetration tests,
and incident response simulations. We also require cybersecurity training when onboarding new employees and contractors, as well as required
cybersecurity awareness training for our employees and contractors/other workforce members. Our program leverages industry frameworks,
including the National Institute of Standards and Technology (NIST) Cybersecurity Framework (CSF) to strengthen our program effectiveness
and reduce cybersecurity risks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
use a risk-based approach with respect to our use and oversight of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250401__20260331_zOJNnD4VcKS4"&gt;third-party&lt;/span&gt; service providers. We use a number of means to assess
cyber risks related to our third-party service providers, including maintaining vendor questionnaires/conducting due diligence in connection
with onboarding new vendors and engaging in periodic reviews thereafter as appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Process
for Assessing, Identifying and Managing Material Risks from Cybersecurity Threats &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250401__20260331_ztjs18riHI85"&gt;In
the event of a cybersecurity incident, we maintain a regularly tested incident response program. Pursuant to the program and its escalation
protocols, designated personnel are responsible for assessing the severity of an incident and associated threat, and handling it in accordance
with that severity level. We have relationships with a number of third-party service providers to assist with cybersecurity containment
and remediation efforts.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2025-04-01to2026-03-31" id="Fact000056">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="From2025-04-01to2026-03-31" id="Fact000057">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000064">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Governance&lt;/i&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
a notification of concerning factors which may be indicative that a notable cybersecurity incident has occurred, the Cyber Security Subcommittee
(Cyber Security Subcommittee) consisting of General Counsel, Head of HR &amp;amp; Chief Technical Officer (CTO) meets to make an initial
assessment. If the Cyber Security Subcommittee determines there is a reasonable likelihood a notable cybersecurity incident has occurred,
then notice will promptly be given to certain members of the Company Executive Team including our Chief Executive Officer, Chief Operating
Officer, Chief Commercial Officer &amp;amp; Chief Financial Officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
team leverages over 25 years of experience in various cyber security functions. Our CTO, and their team, are responsible for the day-to-day
management of the cybersecurity program.&lt;/span&gt;&lt;/p&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
CTO provides periodic briefings for our senior management team on cybersecurity matters, including the prevention, detection, mitigation,
and remediation of cybersecurity incidents and cybersecurity threats.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Board
Oversight&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20250401__20260331_z3eUtle6fKG6"&gt;Board of Directors&lt;/span&gt; has overall responsibility for risk oversight, our Audit Committee oversees cybersecurity risk matters. The Audit
Committee is responsible for reviewing, discussing with management, and overseeing the Company&#x2019;s cybersecurity and privacy risk
exposures and policies. On a quarterly basis, the CTO reports to the Audit Committee on information technology and cybersecurity matters,
including key information technology risks. The CTO also apprises the Audit Committee and full Board of cyber security incidents consistent
with our incident response program, promptly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cybersecurity
Risks&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250401__20260331_zhCF0LHHwgka"&gt;Our
cybersecurity risk management processes are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250401__20260331_ziJok1OLMwVj"&gt;integrated&lt;/span&gt; into our overall Enterprise Risk Management (&#x201c;ERM&#x201d;) process. As part
of our ERM process, department leaders identify, assess, and evaluate risks impacting our operations across the Company, including those
risks related to cybersecurity.&lt;/span&gt; Department leaders are asked to consider the severity and likelihood of certain risk factors, drawing
upon their company knowledge and past business experience. While we maintain a robust cybersecurity program, the techniques used to infiltrate
information technology systems continue to evolve. Accordingly, we may not be able to timely detect threats or anticipate and implement
adequate security measures. For additional information, see &#x201c;Item 1A&#x2014;Risk Factors.&#x201d; To date, we have not experienced
any material cybersecurity incidents or threats.&lt;/span&gt;&lt;/p&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="From2025-04-01to2026-03-31" id="Fact000065">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000066">Our
cybersecurity risk management processes are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250401__20260331_ziJok1OLMwVj"&gt;integrated&lt;/span&gt; into our overall Enterprise Risk Management (&#x201c;ERM&#x201d;) process. As part
of our ERM process, department leaders identify, assess, and evaluate risks impacting our operations across the Company, including those
risks related to cybersecurity.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2025-04-01to2026-03-31" id="Fact000067">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <XAIR:NoInsiderTradingFlag contextRef="From2025-04-01to2026-03-31" id="Fact000069">true</XAIR:NoInsiderTradingFlag>
    <dei:AuditorFirmId contextRef="From2025-04-01to2026-03-31" id="Fact000070">100</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000071">We
have audited the accompanying consolidated balance sheets of Beyond Air, Inc. (the &#x201c;Company&#x201d;) as of March 31, 2026 and
2025, and the related consolidated statements of operations and comprehensive loss, changes in stockholders&#x2019; equity, and cash
flows for each of the two years in the period ended March 31, 2026, and the related notes (collectively referred to as the
&#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all
material respects, the financial position of Beyond Air, Inc. as of March 31, 2026 and 2025, and the results of its operations and
its cash flows for each of the two years in the period ended March 31, 2026, in conformity with accounting principles generally
accepted in the United States of America.</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2025-04-01to2026-03-31" id="Fact000072">WithumSmith+Brown, PC</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2025-04-01to2026-03-31" id="Fact000073">East Brunswick, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000081"
      unitRef="USD">6740000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000082"
      unitRef="USD">4665000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000084"
      unitRef="USD">4901000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000085"
      unitRef="USD">2252000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000087"
      unitRef="USD">5622000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000088"
      unitRef="USD">231000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000090"
      unitRef="USD">1086000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000091"
      unitRef="USD">710000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000093"
      unitRef="USD">1406000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000094"
      unitRef="USD">2417000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000096"
      unitRef="USD">5012000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000097"
      unitRef="USD">5743000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000099"
      unitRef="USD">24767000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000100"
      unitRef="USD">16018000</us-gaap:AssetsCurrent>
    <us-gaap:FiniteLivedLicenseAgreementsGross
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000102"
      unitRef="USD">1018000</us-gaap:FiniteLivedLicenseAgreementsGross>
    <us-gaap:FiniteLivedLicenseAgreementsGross
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000103"
      unitRef="USD">1222000</us-gaap:FiniteLivedLicenseAgreementsGross>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000105"
      unitRef="USD">1193000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000106"
      unitRef="USD">1706000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000108"
      unitRef="USD">8249000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000109"
      unitRef="USD">11013000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000111"
      unitRef="USD">158000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000112"
      unitRef="USD">103000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000114"
      unitRef="USD">35385000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000115"
      unitRef="USD">30062000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000123"
      unitRef="USD">2417000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000124"
      unitRef="USD">1950000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000126"
      unitRef="USD">3372000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000127"
      unitRef="USD">2045000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000129"
      unitRef="USD">321000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000130"
      unitRef="USD">396000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000132"
      unitRef="USD">401000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000133"
      unitRef="USD">609000</us-gaap:LoansPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000135"
      unitRef="USD">6511000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000136"
      unitRef="USD">5000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000138"
      unitRef="USD">1023000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000139"
      unitRef="USD">1486000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000141"
      unitRef="USD">21639000</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000142"
      unitRef="USD">9197000</us-gaap:LongTermLoansPayable>
    <XAIR:WarrantLiabilityNonCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000144"
      unitRef="USD">2000</XAIR:WarrantLiabilityNonCurrent>
    <XAIR:WarrantLiabilityNonCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000145"
      unitRef="USD">38000</XAIR:WarrantLiabilityNonCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000147"
      unitRef="USD">29175000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000148"
      unitRef="USD">15721000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000159"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000161"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000163"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000165"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000167"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000169"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000171"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000173"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000178"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000180"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000181"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000183"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000185"
      unitRef="Shares">11792684</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000187"
      unitRef="Shares">11792684</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000189"
      unitRef="Shares">4128539</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000191"
      unitRef="Shares">4128539</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000175"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000193"
      unitRef="USD">25000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000194"
      unitRef="USD">25000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000196"
      unitRef="USD">325587000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000197"
      unitRef="USD">299990000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000199"
      unitRef="USD">-319571000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000200"
      unitRef="USD">-286322000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000202"
      unitRef="USD">134000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000203"
      unitRef="USD">-60000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000205"
      unitRef="USD">6126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000206"
      unitRef="USD">13583000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000208"
      unitRef="USD">84000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000209"
      unitRef="USD">758000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000211"
      unitRef="USD">6210000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000212"
      unitRef="USD">14341000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000214"
      unitRef="USD">35385000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000215"
      unitRef="USD">30062000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000218"
      unitRef="USD">7679000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000219"
      unitRef="USD">3705000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000221"
      unitRef="USD">7427000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000222"
      unitRef="USD">5368000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000224"
      unitRef="USD">252000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000225"
      unitRef="USD">-1663000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">10241000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000231"
      unitRef="USD">16857000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000233"
      unitRef="USD">19055000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000234"
      unitRef="USD">26017000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000236"
      unitRef="USD">29296000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000237"
      unitRef="USD">42874000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000239"
      unitRef="USD">-29044000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">-44537000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000245"
      unitRef="USD">303000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000246"
      unitRef="USD">705000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000248"
      unitRef="USD">3515000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000249"
      unitRef="USD">3019000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000251"
      unitRef="USD">-35000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000252"
      unitRef="USD">-237000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000254"
      unitRef="USD">-1395000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000255"
      unitRef="USD">1314000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000257"
      unitRef="USD">-108000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000258"
      unitRef="USD">-3000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000260"
      unitRef="USD">-165000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000261"
      unitRef="USD">-2447000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000263"
      unitRef="USD">-431000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">-738000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000266"
      unitRef="USD">-14000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000267"
      unitRef="USD">9000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000269"
      unitRef="USD">-5290000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000270"
      unitRef="USD">-3942000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000272"
      unitRef="USD">-34334000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000273"
      unitRef="USD">-48479000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000278"
      unitRef="USD">-34334000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000279"
      unitRef="USD">-48479000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000281"
      unitRef="USD">-1085000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000282"
      unitRef="USD">-1854000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000284"
      unitRef="USD">-33249000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000285"
      unitRef="USD">-46625000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000290"
      unitRef="USD">194000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000291"
      unitRef="USD">-45000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000293"
      unitRef="USD">-33055000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000294"
      unitRef="USD">-46670000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact000296"
      unitRef="USDPShares">-4.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact000298"
      unitRef="USDPShares">-4.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact000300"
      unitRef="USDPShares">-13.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact000302"
      unitRef="USDPShares">-13.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact000304"
      unitRef="Shares">8300916</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact000306"
      unitRef="Shares">8300916</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact000308"
      unitRef="Shares">3385327</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact000310"
      unitRef="Shares">3385327</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000321"
      unitRef="Shares">2295042</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000314"
      unitRef="USD">-25000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000315"
      unitRef="USD">264785000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000316"
      unitRef="USD">-239697000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000317"
      unitRef="USD">-15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000318"
      unitRef="USD">2138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000319"
      unitRef="USD">27186000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000331"
      unitRef="Shares">337101</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000325"
      unitRef="USD">2151000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000329"
      unitRef="USD">2151000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <XAIR:IssuanceOfCommonStockAtMarketEquityOfferingShares
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000341"
      unitRef="Shares">1250000</XAIR:IssuanceOfCommonStockAtMarketEquityOfferingShares>
    <XAIR:SaleOfCommonStockAndPrefundedWarrants
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000335"
      unitRef="USD">18858000</XAIR:SaleOfCommonStockAndPrefundedWarrants>
    <XAIR:SaleOfCommonStockAndPrefundedWarrants
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000339"
      unitRef="USD">18858000</XAIR:SaleOfCommonStockAndPrefundedWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000345"
      unitRef="USD">3159000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000349"
      unitRef="USD">3159000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000359"
      unitRef="Shares">234156</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000353"
      unitRef="USD">365000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000357"
      unitRef="USD">365000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000369"
      unitRef="Shares">12240</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000373"
      unitRef="USD">1765000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000376"
      unitRef="USD">235000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000377"
      unitRef="USD">2000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000381"
      unitRef="USD">8907000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000384"
      unitRef="USD">239000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000385"
      unitRef="USD">9146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000391"
      unitRef="USD">-45000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000393"
      unitRef="USD">-45000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000398"
      unitRef="USD">-46625000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012025-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000400"
      unitRef="USD">-1854000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000401"
      unitRef="USD">-48479000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000411"
      unitRef="Shares">4128539</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000404"
      unitRef="USD">-25000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000405"
      unitRef="USD">299990000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000406"
      unitRef="USD">-286322000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000407"
      unitRef="USD">-60000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000408"
      unitRef="USD">758000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000409"
      unitRef="USD">14341000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000421"
      unitRef="Shares">2441775</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000413"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000415"
      unitRef="USD">8134000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000419"
      unitRef="USD">8135000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact000431"
      unitRef="Shares">46</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <XAIR:IssuanceOfCommonStockAtMarketEquityOfferingShares
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000441"
      unitRef="Shares">524990</XAIR:IssuanceOfCommonStockAtMarketEquityOfferingShares>
    <XAIR:SaleOfCommonStockAndPrefundedWarrants
      contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000435"
      unitRef="USD">4500000</XAIR:SaleOfCommonStockAndPrefundedWarrants>
    <XAIR:SaleOfCommonStockAndPrefundedWarrants
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000439"
      unitRef="USD">4500000</XAIR:SaleOfCommonStockAndPrefundedWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">1183000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000449"
      unitRef="USD">1183000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000459"
      unitRef="Shares">3088704</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000453"
      unitRef="USD">2868000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000457"
      unitRef="USD">2868000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000469"
      unitRef="Shares">8630</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-04-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000479"
      unitRef="Shares">1600000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000473"
      unitRef="USD">3341000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">3341000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000483"
      unitRef="USD">573000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000486"
      unitRef="USD">127000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000487"
      unitRef="USD">700000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-04-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000491"
      unitRef="USD">4998000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000494"
      unitRef="USD">284000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000495"
      unitRef="USD">5282000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="From2025-04-012026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000501"
      unitRef="USD">194000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000503"
      unitRef="USD">194000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:ProfitLoss
      contextRef="From2025-04-012026-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000508"
      unitRef="USD">-33249000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-04-012026-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000510"
      unitRef="USD">-1085000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000511"
      unitRef="USD">-34334000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000521"
      unitRef="Shares">11792684</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000514"
      unitRef="USD">-25000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000515"
      unitRef="USD">325587000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000516"
      unitRef="USD">-319571000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000517"
      unitRef="USD">134000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000518"
      unitRef="USD">84000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000519"
      unitRef="USD">6210000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000527"
      unitRef="USD">-34334000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000528"
      unitRef="USD">-48479000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000533"
      unitRef="USD">3047000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000534"
      unitRef="USD">2999000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000536"
      unitRef="USD">5282000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000537"
      unitRef="USD">9146000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000539"
      unitRef="USD">551000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000540"
      unitRef="USD">1028000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000542"
      unitRef="USD">204000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000543"
      unitRef="USD">205000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000545"
      unitRef="USD">398000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000546"
      unitRef="USD">367000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000548"
      unitRef="USD">-35000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000549"
      unitRef="USD">-237000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000551"
      unitRef="USD">-1395000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000552"
      unitRef="USD">1314000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000555"
      unitRef="USD">-60000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:InventoryWriteDown
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000557"
      unitRef="USD">672000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000558"
      unitRef="USD">177000</us-gaap:InventoryWriteDown>
    <us-gaap:ProvisionForOtherLosses
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000560"
      unitRef="USD">91000</us-gaap:ProvisionForOtherLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossAfterTax
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000563"
      unitRef="USD">119000</us-gaap:ForeignCurrencyTransactionGainLossAfterTax>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000566"
      unitRef="USD">-165000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000567"
      unitRef="USD">-2447000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <XAIR:GainLossOnTerminationOfRightOfUseAsset
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000570"
      unitRef="USD">-505000</XAIR:GainLossOnTerminationOfRightOfUseAsset>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000572"
      unitRef="USD">-431000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000573"
      unitRef="USD">-334000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:PaidInKindInterest
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000575"
      unitRef="USD">1762000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000576"
      unitRef="USD">696000</us-gaap:PaidInKindInterest>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000581"
      unitRef="USD">-1110000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000582"
      unitRef="USD">466000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000584"
      unitRef="USD">468000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000585"
      unitRef="USD">390000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000587"
      unitRef="USD">-683000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000588"
      unitRef="USD">-1048000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000590"
      unitRef="USD">267000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000591"
      unitRef="USD">399000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000593"
      unitRef="USD">1127000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000594"
      unitRef="USD">-6358000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000596"
      unitRef="USD">-373000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000597"
      unitRef="USD">-385000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000599"
      unitRef="USD">-18144000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000600"
      unitRef="USD">-38218000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000605"
      unitRef="USD">4053000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000606"
      unitRef="USD">30878000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000608"
      unitRef="USD">1404000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000609"
      unitRef="USD">51656000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <XAIR:PaymentsToSecurityDepositsMadeOnOperatingLeases
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000612"
      unitRef="USD">-10000</XAIR:PaymentsToSecurityDepositsMadeOnOperatingLeases>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000614"
      unitRef="USD">1025000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000615"
      unitRef="USD">5883000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000617"
      unitRef="USD">-3674000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000618"
      unitRef="USD">14905000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000623"
      unitRef="USD">8135000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000624"
      unitRef="USD">2151000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <XAIR:ProceedsFromSaleOfCommonStockOfNeuronos
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000626"
      unitRef="USD">700000</XAIR:ProceedsFromSaleOfCommonStockOfNeuronos>
    <XAIR:ProceedsFromSaleOfCommonStockOfNeuronos
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000627"
      unitRef="USD">2000000</XAIR:ProceedsFromSaleOfCommonStockOfNeuronos>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000629"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000630"
      unitRef="USD">18858000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000632"
      unitRef="USD">2869000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000633"
      unitRef="USD">365000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000635"
      unitRef="USD">90000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <XAIR:ProceedsFromLongTermDebt
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000638"
      unitRef="USD">14000000</XAIR:ProceedsFromLongTermDebt>
    <XAIR:ProceedsFromLongTermDebt
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000639"
      unitRef="USD">11324000</XAIR:ProceedsFromLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000641"
      unitRef="USD">996000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000644"
      unitRef="USD">208000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000645"
      unitRef="USD">18052000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000647"
      unitRef="USD">29090000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000648"
      unitRef="USD">16646000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000650"
      unitRef="USD">194000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000651"
      unitRef="USD">-45000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000653"
      unitRef="USD">7466000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000654"
      unitRef="USD">-6712000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000656"
      unitRef="USD">4896000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000657"
      unitRef="USD">11608000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000659"
      unitRef="USD">12362000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000660"
      unitRef="USD">4896000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <XAIR:DebtDiscount
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000665"
      unitRef="USD">1094000</XAIR:DebtDiscount>
    <XAIR:DebtDiscount
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000666"
      unitRef="USD">3249000</XAIR:DebtDiscount>
    <XAIR:DerivativesLiability
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000668"
      unitRef="USD">775000</XAIR:DerivativesLiability>
    <XAIR:ShortTermFinanceLiability
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000671"
      unitRef="USD">457000</XAIR:ShortTermFinanceLiability>
    <XAIR:ShortTermFinanceLiability
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000672"
      unitRef="USD">693000</XAIR:ShortTermFinanceLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000674"
      unitRef="USD">398000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000675"
      unitRef="USD">396000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <XAIR:RightofuseAssetsAcquiredUnderOperatingLeases
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000677"
      unitRef="USD">139000</XAIR:RightofuseAssetsAcquiredUnderOperatingLeases>
    <XAIR:DebtPrincipalBalanceConvertedToEquity
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000680"
      unitRef="USD">1171000</XAIR:DebtPrincipalBalanceConvertedToEquity>
    <us-gaap:InterestPaidNet
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact000683"
      unitRef="USD">423000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact000684"
      unitRef="USD">1197000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000689">&lt;p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z3WmsQszL7N" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &lt;span id="xdx_821_zIxTspTZWQjb"&gt;ORGANIZATION AND BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beyond
Air, Inc. (together with its subsidiaries, &#x201c;Beyond Air&#x201d; or the &#x201c;Company&#x201d;) was incorporated on April 28, 2015
under Delaware law. On June 25, 2019, the Company&#x2019;s name was changed to Beyond Air, Inc. from AIT Therapeutics, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (&#x201c;NO&#x201d;) generators
and delivery systems (the &#x201c;LungFit&lt;sup&gt;&#xae;&lt;/sup&gt; platform&#x201d;) capable of generating NO from ambient air. The Company&#x2019;s
first device, LungFit&lt;sup&gt;&#xae; &lt;/sup&gt;PH (&#x201c;LungFit&lt;sup&gt;&#xae; &lt;/sup&gt;PH&#x201d;) received premarket approval (&#x201c;PMA&#x201d;) from
the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in June 2022. The NO generated by the LungFit&#xae; PH system is indicated to
improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (&amp;gt;34 weeks gestation) neonates
with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with
ventilatory support and other appropriate agents. This condition is commonly referred to as persistent pulmonary hypertension of the
newborn (&#x201c;PPHN&#x201d;). The LungFit&lt;sup&gt;&#xae;&lt;/sup&gt; platform can generate NO up to 400 parts per million (&#x201c;ppm&#x201d;) for
delivery to a patient&#x2019;s lungs directly or via a ventilator. LungFit&lt;sup&gt;&#xae; &lt;/sup&gt;can deliver NO either continuously or for a
fixed amount of time at various flow rates and has the ability to either titrate dose on demand or maintain a constant dose. In July
2022, the Company commenced marketing LungFit&lt;sup&gt;&#xae;&lt;/sup&gt; PH in the United States for PPHN as a medical device.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November  2024, the Company received European CE mark approval of the LungFit PH&#xae; system for the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    treatment of infants &lt;span style="text-decoration: underline"&gt;&amp;gt;&lt;/span&gt;34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic
    evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;
    and &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents,
    ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular
    function and oxygenation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;LungFit&lt;sup&gt;&#xae;&lt;/sup&gt;
can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections via delivery
of NO at concentrations &amp;gt; 100 parts per million (ppm) through a breathing mask or similar apparatus. The Company&#x2019;s other areas
of focus with the LungFit&lt;sup&gt;&#xae;&lt;/sup&gt; platform beyond PPHN are nontuberculous mycobacteria (&#x201c;NTM&#x201d;) lung infection and
those with various severe lung infections with underlying chronic obstructive pulmonary disease (&#x201c;COPD&#x201d;). The Company&#x2019;s
current product candidates will be subject to premarket reviews and approvals by the FDA, certification through the conduct of a conformity
assessment by a notified body in the EU for the product to be CE marked, as well as comparable foreign regulatory authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
Beyond Air&#x2019;s focus on NO and its effect on the human condition, the Company has two additional programs that do not utilize
the LungFit&lt;sup&gt;&#xae;&lt;/sup&gt; system. Through the Company&#x2019;s majority-owned affiliate Beyond Cancer, Ltd. (&#x201c;Beyond
Cancer&#x201d;), NO is used to target solid tumors. The LungFit&lt;sup&gt;&#xae; &lt;/sup&gt;platform is not utilized for the solid tumor
indication due to the need for ultra-high concentrations of gaseous nitric oxide (&#x201c;UNO&#x201d;). A proprietary delivery system
has been developed that is designed to safely deliver UNO in excess of 10,000 ppm directly to a solid tumor. This program has
completed a phase 1a human clinical trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 4, 2021, Beyond Air reorganized its oncology business into a new private company called Beyond Cancer. Beyond Air&#x2019;s preclinical
oncology team and the exclusive right to the intellectual property portfolio utilizing UNO for the treatment of solid tumors now reside
with Beyond Cancer. Beyond Air has &lt;span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211104__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeyondCancerLtdMember_zTJQOonCGnPe" title="Ownership percentage"&gt;80&lt;/span&gt;% ownership in Beyond Cancer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
second program which does not utilize the LungFit&#xae; platform partially inhibits neuronal nitric oxide synthase (&#x201c;nNOS&#x201d;) in the brain
to treat neurological conditions. The first target indication is autism spectrum disorder (&#x201c;ASD&#x201d;). On June 15, 2023, the
Company announced that it has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem,
LTD. (the &#x201c;University&#x201d;) to acquire the commercial rights for nNOS inhibitors being developed for the treatment of ASD and
other neurological conditions. Currently, there are no FDA-approved therapies specifically for the treatment of ASD. Under the terms
of the agreement, Beyond Air will make payments to the University over the three-year period from the date of the agreement for pre-clinical
work. Also, the Company will pay a low single-digit royalty on net sales and certain one-time payments based on clinical, regulatory
and sales milestones.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 24, 2025, Beyond Air reorganized its neurology business into a new private company called NeuroNOS. Beyond Air&#x2019;s infrastructure,
for example regulatory, quality, legal, etc., is currently supporting the NeuroNOS team. Beyond Air has &lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20250324__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NeuroNosLtdMember_z9io6NDSdA6l" title="Ownership percentage"&gt;84.75&lt;/span&gt;% ownership in NeuroNOS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s current product candidates will be subject to premarket reviews and approvals by the FDA, certification through the conduct
of a conformity assessment by a notified body in the European Union (the &#x201c;EU&#x201d;), as well as comparable foreign regulatory
authorities&#x2019; reviews or approvals in other countries or regions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 14, 2025, the Company effectuated a &lt;span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20250714__20250714_z1Gz5F2NAKc1" title="Reverse stock split"&gt;one-for-twenty (1:20) reverse stock split&lt;/span&gt; (the &#x201c;2025 Reverse Stock Split&#x201d;). The
Company&#x2019;s common stock began trading on the Nasdaq Stock Market on a split-adjusted basis on July 14, 2025. There was no change
to the number of authorized shares of the Company&#x2019;s common stock or the par value per share of common stock. Any fraction of a
share of common stock created as a result of the 2025 Reverse Stock Split was rounded up to the nearest whole share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
share and per share information in these accompanying consolidated financial statements have been retroactively adjusted to reflect the
2025 Reverse Stock Split for all periods presented. In addition, (i) a proportionate adjustment has been made to the per share exercise
price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of common
stock, and (ii) the number of shares reserved for issuance pursuant to the 2013 Beyond Air Equity Incentive Plan has been reduced proportionately.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-11-04_custom_BeyondCancerLtdMember"
      decimals="INF"
      id="Fact000691"
      unitRef="Pure">0.80</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2025-03-24_custom_NeuroNosLtdMember"
      decimals="INF"
      id="Fact000693"
      unitRef="Pure">0.8475</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2025-07-142025-07-14" id="Fact000695">one-for-twenty (1:20) reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000697">&lt;p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zAeRh970iBXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 &lt;span id="xdx_826_zeupzJcGwgk6"&gt;SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zePT0szFLvt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zaK8ogn2fPr"&gt;Basis
of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
consolidated financial statements include the accounts of Beyond Air, Inc. and its subsidiaries and have been prepared in accordance
with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;). The Company determined that Beyond Cancer
Ltd. and its affiliates (&#x201c;Beyond Cancer&#x201d;) and NeuroNOS Ltd. and its affiliates (&#x201c;NeuroNos&#x201d;) are each a
variable interest entity (&#x201c;VIE&#x201d;) for which the Company is the primary beneficiary and consolidates in its financial
statements. All intercompany balances and transactions have been eliminated in the accompanying consolidated financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--UseOfEstimates_zyP03rkfswnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zrfYmDguqYR8"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could
significantly differ from those estimates. On an ongoing basis, the Company evaluates its significant estimates and assumptions
including expense recognition and accrual assumptions under consulting and clinical trial agreements, stock-based compensation,
allowance for credit losses, excess and obsolete inventory reserves, impairment assessments, accounting for licensed rights to use
technologies and other long-lived assets, the valuation of warrants, the valuation of derivatives, contingency recognition and
accruals and the determination of valuation allowance requirements on deferred tax attributes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock_zyfgdhMi85s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zqY2Bjw1vIe6"&gt;Going
Concern, Liquidity and Other Uncertainties&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used cash in operating activities of $&lt;span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250401__20260331_z3ZU6LUFtdn3" title="Net cash used in operating activities"&gt;18.1&lt;/span&gt; million for the year ended March 31, 2026, and has an accumulated deficit attributable
to the stockholders of Beyond Air, Inc. of $&lt;span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20260331_zSPwmvk8ZqKe" title="Accumulated deficit"&gt;319.6&lt;/span&gt; million. The Company had cash, cash equivalents and marketable securities of $&lt;span id="xdx_902_ecustom--CashAndCashEquivalentsAndMarketableSecurities_iI_pn5n6_c20260331_zw8mJaARiHIj" title="Cash equivalents and marketable securities"&gt;11.6&lt;/span&gt;
million as of March 31, 2026. In addition, $&lt;span id="xdx_905_eus-gaap--DepositAssets_iI_pn5n6_c20260331_zZ5ML2x09EY3" title="Cash deposit"&gt;3.4&lt;/span&gt; million of cash is held on deposit by the Company&#x2019;s contract manufacturer to be
applied against future purchases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expects to incur net losses and have significant cash outflows for at least the next year, including making significant
investments in research and development. Management believes these factors raise substantial doubt about the Company&#x2019;s ability
to meet its obligations with cash on hand and concluded that the Company will require additional funding within one year from the
date these consolidated financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
is confident that the efforts to arrange financing, while not assured, will enable the Company to meet its obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s future capital needs and the adequacy of its available funds will depend on many factors, including, but not necessarily
limited to, the success and costs of commercialization of the Company&#x2019;s approved product and the actual cost and time necessary
for current and anticipated preclinical studies, clinical trials and other actions needed to obtain certification or regulatory approval
of the Company&#x2019;s product candidates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--OtherRisksAndUncertaintiesPolicyTextBlock_zmSOMpTsR0dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_z9BkdE6WELm2"&gt;Other
Risks and Uncertainties&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to risks common to development and early-stage medical device companies including, but not limited to, new technological
innovations, certifications or regulatory approval, dependence on key personnel, protection of proprietary technology, compliance with
government regulations, product liability, uncertainty of market acceptance of approved products and the potential need to obtain additional
financing. The Company is also dependent on third-party suppliers and, in some cases, single-source suppliers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s products require approval or clearance from the FDA prior to commencement of commercial sales in the United States. There
can be no assurance that the Company&#x2019;s products beyond LungFit&#xae; PH in the U.S. will receive the required approvals or clearances.
Certifications, approvals or clearances are also required in foreign jurisdictions in which the Company may license or sell its products.
If the Company is denied such certifications or approvals or clearances or such certifications, approvals or clearances are delayed,
such denial or delay may have a material adverse impact on the Company&#x2019;s results of operations, financial position and liquidity.
Further, there can be no assurance that the Company&#x2019;s product will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or
that such products will be successfully marketed, if at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zVF0qxX5X7Ag" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zlJminLqUXwk"&gt;Revenue
Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates revenue from the leases of its LungFit&#xae; PH devices to its customers under fixed fee arrangements over periods of
up to three years. The fixed fee is typically broken down into ratable monthly payments over the term of the arrangement. The Company&#x2019;s
customers include hospitals and medical facilities. The Company&#x2019;s LungFit&#xae; PH leases include filters, calibration gas, bagging
kits, cables, adapters, and other components and accessories required to use the LungFit&#xae; PH device (the &#x201c;Consumables&#x201d;).
The consumables&#x2019; quantities are varied and may be supplied upon demand of the customers and are unlimited, or the arrangement may
provide for the maximum quantities available to the customer over the term of the arrangement. The Company&#x2019;s LungFit&#xae; PH leases
also include maintenance and training required to use the LungFit&#xae; PH device, as well as device back-up services (the &#x201c;Services&#x201d;),
which are recorded in cost of revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its rental arrangements of LungFit&#xae; PH devices in accordance with Accounting Standards Codification 842, &lt;i&gt;Leases&lt;/i&gt;
(&#x201c;ASC 842&#x201d;). Under ASC 842, leases may be classified as either financing, sales-type, or operating, and the Company is
required to disclose key information about leasing arrangements. The classification determines the pattern of revenue recognition
and classification within the consolidated statements of operations and comprehensive loss. The Company typically classifies the
rental arrangement of its LungFit&#xae; PH contracts as operating leases. The Company&#x2019;s leases do not contain any restrictive
covenants or any material residual value guarantees. The Company&#x2019;s equipment leases may contain renewal options which range
from one month to two years. The lease term is adjusted for renewal or termination options that the Company believes the customer is
reasonably certain to exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company elected the practical expedient applied to operating leases not to separate lease and non-lease components as long as the lease
and non-lease components have the same timing and pattern of transfer. As such, the non-lease components, including the Consumables and
Services, are combined with the predominant lease component. The total fixed fees that the Company is reasonably certain to collect are
recognized on a straight line basis over the term of the arrangement. Additionally, the Company made an accounting policy election to
present LungFit&#xae; PH revenue net of sales and other similar taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the lease commencement date, the Company will defer initial direct costs, including commission expense and the cost is recognized over
the lease term on the same basis as lease income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 15 to the consolidated financial statements for more information regarding leasing arrangements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also generates revenue from the sale of its LungFit&#xae; PH devices and consumables to its customers under distribution arrangements.
Contracts include one performance obligation as any individual promised good or services other than delivery of the devices and consumables
are generally either not capable of being distinct or not distinct within the context of the contracts. Purchased quantities of devices
and consumables are varied and may be supplied upon demand of the customers. Revenue is recognized at a point in time when the Company
delivers the goods to its customer. The transaction includes a fixed component based on contractual rates. Revenue recognized reflects
the consideration the Company expects to receive in exchange for delivering the goods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amounts
billed in advance of performance obligations being satisfied are recognized as deferred revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records the costs of shipping devices and consumables in cost of revenues in its consolidated statements of operations and comprehensive
loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJRcS9cpNhq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zpAyVX7HJsB8"&gt;Accounts
Receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company extends credit to its customers on an unsecured basis. Accounts receivable are recorded at the invoiced amount, based on agreed
contract terms, less an allowance for credit losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company establishes an allowance for accounts receivable that are considered to be at increased risk of becoming uncollectible. When
evaluating the adequacy of this allowance for credit losses, the Company considers factors such as, historical collection experience
and creditworthiness, the composition of outstanding receivables by customer class, and expected economic conditions and other trends.
The Company&#x2019;s estimates are reflected in the period they are made. The charges recorded for credit losses are reported within Selling,
general and administrative expenses on the consolidated statements of operations and comprehensive loss. Receivables are written off
against the allowance for credit losses when it is definitively determined that amounts are uncollectible. As of March 31, 2026 and 2025,
the allowance for credit losses were $&lt;span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivableNoncurrent_iI_pn5n6_c20260331_zYeSgdAczWwa" title="Allowance for credit losses"&gt;0.1&lt;/span&gt; million and $&lt;span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivableNoncurrent_iI_pn5n6_c20250331_z7SLja1nsgK6" title="Allowance for credit losses"&gt;0&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z5m4LoVsv315" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zbf3gxuIpLl5"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt; (&#x201c;ASC 820&#x201d;), defines fair value as the price that would be received to
sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market
participants on the measurement date. The fair value standard also establishes a three-level hierarchy, which requires an entity to maximize
the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based
upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1&#x2014;inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2&#x2014;inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived
valuations in which all significant inputs are observable for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3&#x2014;inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2026 and March 31, 2025, the Company&#x2019;s financial instruments included restricted cash, marketable securities,
accounts payable, long-term debt and liability classified warrants. The carrying amounts reported in the accompanying consolidated
financial statements for cash and cash equivalents, restricted cash and marketable securities approximate their respective fair
values because of the short-term nature of these accounts. The carrying value of the Company&#x2019;s long-term debt approximates
fair value based on current interest rates for similar types of borrowings. The liability classified warrants are recorded at fair
value and are included in Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zSz2dHLbWKHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value amounts as of March 31, 2026 are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zXpIL3M7zN37" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ON A RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260331_z0foNQr9g2b6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z38n6cDnwlu8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z00wG26yyZg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsZd0BuskkP8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Marketable securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_ze7sjfLFgEgg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0729"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0730"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zjHwT9v6ZS32" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured and recorded at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0734"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0735"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zRC5TAbEqGGb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0738"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_z468H5pC9PIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities measured and recorded at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0743"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0744"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value amounts as of March 31, 2025 are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250331_z3Jt5bx4bnYc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjwMihH6oIy5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQyMh8LZAtai" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWF9wGvB3aei" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Marketable securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zQgGzALhxHx" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0749"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0750"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zKl8QiSE9w77" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured and recorded at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0754"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0755"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z7teyQQZeWch" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0758"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0759"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zIpton2TLu3e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities measured and recorded at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0763"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zXsqfKoRIw8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--MarketableSecuritiesTextBlock_z4HgtsibLNA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s short-term marketable securities with unrealized gains and losses as of March 31, 2026,
aggregated by major security type:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zCu1EyrKbD71" style="display: none"&gt;SUMMARY
OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Unrealized Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_z5wtCioRRxGi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, fair value"&gt;4,901&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20250401__20260331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zB1niEE5K80j" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, unrealized loss"&gt;39&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total short-term marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zu1R3CSkgizd" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Fair value"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20250401__20260331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zSGHtLg4kMfj" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Unrealized gains and (losses)"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s short-term marketable securities with unrealized gains and losses as of March 31, 2025,
aggregated by major security type:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Unrealized Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zQg58g0FROi4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, fair value"&gt;2,252&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20240401__20250331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zWNdUiwZjpf7" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, unrealized loss"&gt;39&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total short-term marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zpU8N2T4NHZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Fair value"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20240401__20250331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zr2SOMcBc0If" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Unrealized gains and (losses)"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zgvFuIOypEj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Level
3 Valuation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrant
liability&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrant liability is remeasured each reporting period with the change in fair value recorded to other income (expense) in the consolidated
statements of operations and comprehensive loss until the warrants are exercised, expired, reclassified or otherwise settled.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zHT5mdEx3482" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
significant assumptions used in valuing the warrants were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zMM5k5MZuJid" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS USED IN VALUING WARRANTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;At March 31, 2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgvjyxQ3NFWj" title="Expected term warrants"&gt;2.25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ziOPdUBHgXR1" title="Warrants and rights outstanding, measurement input"&gt;132.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z70biNE9YS8c" title="Warrants and rights outstanding, measurement input"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;At March 31, 2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyJjQ346E25f" title="Expected term warrants"&gt;3.25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zeuiYAT9gYHk" title="Warrants and rights outstanding, measurement input"&gt;99.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdcmXtcs2u7b" title="Warrants and rights outstanding, measurement input"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zG73FmtTGsBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Derivative
liability&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementDifferenceDescription_c20250401__20260331_zzvT3Ss7G3gc" title="Derivative liability description"&gt;The
derivative liability represents an embedded redemption feature (embedded put option) that meets the criteria to be classified as a
derivative and is bifurcated from the Note (see Note 9). On any trading day during which the Registration Statement (Note 4) remains
effective and the Note remains outstanding and (i) any trading price of the Company&#x2019;s common stock is at least 5% greater than
the current Nasdaq minimum price as defined under Nasdaq Rule 5635(d) (the &#x201c;Nasdaq Minimum Price&#x201d;) or (ii) the total
dollar trading volume has reached $750,000.00, Streeterville may elect to purchase shares of common stock up to the Beneficial
Ownership Limitation at a purchase price equal to 85% of the Nasdaq Minimum Price, subject to a floor of $0.39 per share. The
aggregate purchase price for these shares shall be offset by an equal amount outstanding under the Note.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
feature was concluded to not be clearly and closely related to the host instrument and is required to be measured at fair value at each
reporting period. The fair value was determined using the Monte Carlo valuation model. The key inputs of the simulation are the valuation
date, the Company&#x2019;s common stock share price and volatility, the risk-free rate, and the maximum convertible shares eligible to
offset the outstanding balance on the Note.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock_zsfFhj7pnTGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zHcIVEJ0tXp1" style="display: none"&gt;SCHEDULE
OF KEY INPUTS DERIVATIVE &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;At November 4, 2025 (issuance)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20251104_zE3kHp0WJLG6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Derivative&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Maximum convertible shares&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20251104__20251104_zx3BaNOFcG5f" style="width: 16%; text-align: right" title="Maximum convertible shares"&gt;1,600,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zh4ViqIooue7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zsrRCqjWT2u6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z17Mb19aVOfg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zboQEfYurVni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
January 2026, Streeterville elected to purchase &lt;span id="xdx_903_eus-gaap--StockRepurchasedDuringPeriodShares_pn5n6_c20260101__20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zkC1OrbXBar4" title="Purchase of common stock, shares"&gt;1.6&lt;/span&gt;
million shares of common stock at an average of $&lt;span id="xdx_90D_eus-gaap--SharePrice_iI_c20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zYhINvXrjrD" title="Share price"&gt;0.73&lt;/span&gt;
per share which offset principal of approximately $&lt;span id="xdx_905_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pn5n6_c20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zRkMG7rKJgb7" title="Debt amount"&gt;1.2&lt;/span&gt;
million outstanding under the Note (Note 9). The fair value of the issued common stock was approximately $&lt;span id="xdx_90C_eus-gaap--CommonStockValueOutstanding_iI_pn5n6_c20260331_znX2AazFVE9a" title="Fair value of issued common stock"&gt;3.3&lt;/span&gt;
million (Note 4). The Company remeasured the fair value of the derivative liability to $&lt;span id="xdx_902_eus-gaap--CreditRiskDerivativeLiabilitiesAtFairValue_iI_pn5n6_c20260331_ziVcopMq8KCa" title="Fair value of the derivative liability"&gt;2.2&lt;/span&gt;
million immediately prior to the conversion. Accordingly, the embedded derivative was extinguished as of March 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock_znFmSd1AcC0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table presented below is a summary of changes in the fair value of the Company&#x2019;s Level 3 valuation for the warrants and derivatives
for the years ended March 31, 2026 and March 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zjA246EL3fBa" style="display: none"&gt;SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B1_us-gaap--FinancialInstrumentAxis_us-gaap--WarrantMember_zKomqjJB3SX7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BF_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_zr6VZOcny8w2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Derivative&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43D_c20240401__20250331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_ztdzelDPDHeh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Balance at March 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;275&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,314&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zCFopjQvCLGg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(237&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,314&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43B_c20250401__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zWLun7K8xSJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at March 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0830"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zCbqV14l7zv" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0832"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zlVdshaDBc45" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--FairValueMeasurementExtinguishment_zmcY92DcW479" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Extinguishment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0838"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,170&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_435_c20250401__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zob4KlfS1AB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Balance at March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0842"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z5XCy7ic64Ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--WarrantLiabilityPolicyTextBlock_zD4209tMhPkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zRWUm4WOeCxf"&gt;Warrant
Liability&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company classifies warrants as equity for any contracts that (i) require physical settlement or net-share settlement or (ii) gives
the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The
Company classifies warrants as assets or liabilities for any contracts that (i) require net-cash settlement (including a requirement
to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the
counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). Such warrants
are subject to remeasurement at each consolidated balance sheet date and any change in fair value is recognized as a component of
other income/expense on the consolidated statements of operations and comprehensive loss. The Company will continue to adjust the liability
for changes in fair value until the earlier of the exercise or expiration of such warrants. At that time, the portion of the warrant
liability related to warrants will be reclassified to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--DerivativesPolicyTextBlock_zSNkPmULVEX" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zLgVSHtIY1bj"&gt;Derivative
Liability&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as
embedded derivatives in accordance with ASC 815, &lt;i&gt;Derivatives and Hedging.&lt;/i&gt; For derivative financial instruments that are
accounted for as assets or liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is
then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations and
comprehensive loss. The classification of derivative instruments, including whether such instruments should be recorded as assets or
liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the
consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument
could be required within 12 months of the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zkxOhR4JB6D6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zaLdwLtGklG3"&gt;Cash
and Cash Equivalents, Short-Term Investments and Restricted Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with original maturities of three months or less at the date of purchase and an investment
in a U.S. government money market fund to be cash equivalents. The Company maintains its cash and cash equivalents in highly rated financial
institutions in Australia, Israel, Ireland and the U.S., the balances of which, at times, may exceed federally insured limits. Marketable
securities may include investment in a combination of fixed income bonds, U.S. Treasury securities, and mutual funds that are considered
to be highly liquid and easily tradeable. The marketable securities are considered trading securities and are measured at fair value
and are accounted for in accordance with ASC 320. The marketable securities are valued using inputs observable in active markets for
identical securities and are therefore classified as Level 1 within the Company&#x2019;s fair value hierarchy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2026 and March 31, 2025, restricted cash included approximately $&lt;span id="xdx_904_eus-gaap--RestrictedCash_iI_pn5n6_c20260331_z4rXtZexOB4b" title="Restricted cash"&gt;5.6&lt;/span&gt; million and $&lt;span id="xdx_90F_eus-gaap--RestrictedCash_iI_pn5n6_c20250331_zhHpnQ2lF6F8" title="Restricted cash"&gt;0.2&lt;/span&gt; million, respectively. Restricted
cash as of March 31, 2026 includes $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_pn5n6_c20251104__20251104_zvX9YlzYQEr2" title="Proceeds from issuance of secured promissory note"&gt;5.4&lt;/span&gt; million of proceeds from the Company&#x2019;s secured promissory note issued on November 4, 2025
that is required to be held in a restricted account pursuant to the Note Purchase Agreement. Amounts held in the restricted account become
available to the Company as the outstanding principal of the Note is repaid (see Note 9).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zE3MMSGbrn05" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zifwhxa60YWk"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_uUSD_c20260331__srt--StatementGeographicalAxis__country--US_z7gUpbeMZPEg" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; in the United States, A$&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_uAUD_c20260331__srt--StatementGeographicalAxis__country--AU_zLkdEA4hIpqb" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; in Australia, $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_uUSD_c20260331__srt--StatementGeographicalAxis__country--BM_z8jflRkUGJZe" title="Cash FDIC insured amount"&gt;25,000&lt;/span&gt;
in Bermuda, &#x20ac;&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_uEUR_c20260331__srt--StatementGeographicalAxis__country--IE_zvzsqbKTFD9a" title="Cash FDIC insured amount"&gt;100,000&lt;/span&gt; in Ireland and &#x20ac;&lt;span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_uEUR_c20260331__srt--StatementGeographicalAxis__country--CY_zhbZ2tY5spQa" title="Cash FDIC insured amount"&gt;100,000&lt;/span&gt; in Cyprus. There is currently no official federal depository insurance in Israel.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. &lt;span id="xdx_906_eus-gaap--ConcentrationRiskBenchmarkDescription_c20260331__20260331_zwBsDcqjI1ci" title="Concentration risk benchmark description"&gt;As of March 31, 2026, the Company had greater than $250,000 at United States financial institutions, less than A$250,000
at Australian financial institutions, greater than &#x20ac;100,000 at Irish financial institutions and also has funds on deposit in Israel.&lt;/span&gt;
Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial condition,
results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zO39TGqE6eHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table is the reconciliation of the presentation and disclosure of cash, cash equivalents, marketable securities by major security
type and restricted cash as shown on the Company&#x2019;s consolidated statements of cash flows for:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_z0jfOmMC4Fy7" style="display: none"&gt;SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260331_zKbwo92hRnU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250331_zIIVYqgiz4Xl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCEASz3pW_maRCACEzZrO_zQj3UHc54oZf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,740&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,665&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RestrictedCashCurrent_iI_pn3n3_maRCACEzZrO_zFxqdPDYOz83" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,622&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;231&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--RestrictedCashAndCashEquivalents_iTI_pn3n3_mtRCACEzZrO_maCCEASziVz_zCa0NYeQZvO8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,362&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,896&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--MarketableSecuritiesAbstract_iB_zy0yiyUF65n9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Marketable securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--MarketableSecuritiesCurrent_i01I_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z213JS7INxXc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--MarketableSecuritiesCurrent_i01I_pn3n3_maCCEASziVz_zJBHKOVrL1Ok" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iTI_pn3n3_mtCCEASziVz_zHJeioG91Fig" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total cash, cash equivalents, marketable securities and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,148&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zPNalkSO2Hci" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zeVEjAVtjFMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zgbsc8xF2Yja"&gt;Fixed
Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock_zpfWmIi8fGMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost less accumulated depreciation and accumulated amortization. Depreciation and amortization are calculated
using the straight-line method over the estimated useful life of the assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zziOzbX9ZBq2" style="display: none"&gt;SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    equipment &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zGOdAUEMpnMl" title="Estimated useful life of assets"&gt;Three
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z0YAIfctOaLa" title="Estimated useful life of assets"&gt;Five
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clinical
    and medical equipment &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember__srt--RangeAxis__srt--MinimumMember_zeg8FPWttisb" style="display: none" title="Estimated useful life of assets"&gt;3&lt;/span&gt;/&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember__srt--RangeAxis__srt--MaximumMember_zL0oHTEqzoq9" title="Estimated useful life of assets"&gt;Five
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equipment
    deployable as part of a service offering&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentDeployableAsPartOfServiceOfferingMember_zbKoyiHEMEGc" title="Estimated useful life of assets"&gt;Five
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zIOJZqQidfNf" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2026%23UsefulLifeTermOfLeaseMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0906"&gt;Shorter
    of term of lease or estimated useful life of the asset&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A0_zcPMD6dQyzx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWhSe7IFIEI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zw5wt5bfBJHc"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an entity for which both discrete financial information is available and regularly reviewed by
the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing
performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company&#x2019;s CODM evaluates performance and allocates resources for all
of the Company&#x2019;s reportable segments based on income/loss from operations. The CODM is involved in determining and reviewing projected
income/loss from operations as part of the annual budget process. Throughout the year, the CODM considers forecast to actual results
and variances to allocate resources. The CODM also considers this information in strategic decisions related to capital allocations,
including investments in assets, research and development activities, and human capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s reportable segments at March 31, 2026 included &lt;span id="xdx_905_ecustom--NumberOfReportableSegmentsDisclosedByDefinitionFlag_dbT_c20250401__20260331_zg48RG5VSya9" title="Number of repotable segments"&gt;Beyond Air, Beyond Cancer, and NeuroNos&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Beyond Air segment includes unallocated corporate expenses associated with the public company fees as well as all corporate related assets
and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zUPk5S2yRd52" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zQVSCnoOtmF"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
consist primarily of purchased filters, bagging kits, cables, adapters, and other components and accessories required to use the LungFit&#xae;
PH device held for sale to customers. Inventories are recorded at the lower of cost or net realizable value. Cost comprises direct materials,
third-party manufacturing costs and shipping costs incurred to deliver goods to the Company&#x2019;s central warehouse location. Costs
are assigned to individual items of inventory on the basis of weighted average costs. Inventory items are tracked by batch/lot number
for specific identification whenever possible.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
reserves are established for estimated excess and obsolete inventory equal to the difference between the cost of the inventory and the
estimated net realizable value of the inventory based on historical usage, known trends, and market conditions and judgment about the
anticipated future consumption and the Company&#x2019;s ability to sell the inventory. At March 31, 2026 and March 31, 2025, excess and obsolescence reserves
were $&lt;span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_pn5n6_c20260331_ztjhcafgaG3f" title="Obsolescence reserves"&gt;0.4&lt;/span&gt; million and $&lt;span id="xdx_908_eus-gaap--InventoryValuationReserves_iI_pn5n6_c20250331_zH80QGz5OvLl" title="Obsolescence reserves"&gt;0.2&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zTwdbBYwhUzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zVQil3J6jCZ1"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease assets are included within operating lease right-of-use assets, and the corresponding operating lease obligation on the consolidated
balance sheets in accordance with ASC 842, &lt;i&gt;Leases&lt;/i&gt;. The Company has elected not to present short-term leases as these leases have
a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably
certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the
lease term at commencement date. Operating lease expense is recognized on a straight-line basis over the lease term and is included in
general and administrative and research development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
interest rate implicit in the Company&#x2019;s leases is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate in determining the present value of lease payments, which reflects the fixed rate at which the Company could borrow on
a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zBYK3lPY60Yh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z5irVTKx8dx6"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to the consolidated statements of operations and comprehensive loss as incurred. Research and development
expenses include salaries, benefits, stock-based compensation and costs incurred by outside laboratories, manufacturers, clinical research
organizations, consultants, and accredited facilities in connection with preclinical studies and clinical trials. Research and development
expenses are partially offset by the benefit of tax incentive payments for qualified research and development expenditures from the Australian
tax authority (&#x201c;AU Tax Rebates&#x201d;). The Company does not record AU Tax Rebates until payment is received due to the uncertainty
of receipt. For the years ended March 31, 2026 and March 31, 2025, the Company received $&lt;span id="xdx_903_ecustom--TaxRebate_pn5n6_c20250401__20260331__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--AustralianTaxationOfficeMember_zRpYbVFqB6W2" title="Tax Rebate"&gt;0.1&lt;/span&gt; million and $&lt;span id="xdx_903_ecustom--TaxRebate_pn5n6_c20240401__20250331__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--AustralianTaxationOfficeMember_zmlzooNdSbHh" title="Tax Rebate"&gt;0.0&lt;/span&gt; million, respectively,
in AU Tax Rebates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zWyTcYHOwBAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zee0Dj2iQdC3"&gt;Foreign
Exchange Transactions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s subsidiaries transact in U.S. dollars, Euros, New Israeli Shekels and Australian dollars. The Company&#x2019;s main operations
are in the United States and the U.S. dollar is the currency of the primary economic environment in which the Company operates and expects
to continue to operate in the foreseeable future. The Company translated its non-U.S. operations&#x2019; assets and liabilities denominated
in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the
average exchange rate for the reporting period. Gains or losses from foreign currency transactions are included in other income (expense)
in the consolidated statements of operations and comprehensive loss as foreign currency exchange gain/(loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive
income and loss. The accumulated other comprehensive income and loss account includes the cumulative results of translating certain balance
sheet assets and liabilities at current exchange rates and some accounts at historical rates. For the year ended March 31, 2026, the
Company recorded gains of $&lt;span id="xdx_90B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20260331_z7YLqXHZMmJ7" title="Accumulated other comprehensive income"&gt;0.2&lt;/span&gt; million in accumulated other comprehensive income. For the year ended March 31, 2025, the Company recorded
losses of $&lt;span id="xdx_90F_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20250331_z4Km4oWtws39" title="Accumulated other comprehensive income"&gt;0.1&lt;/span&gt; million in accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zoq7zmHFHfej" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zCmkfEn80O85"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures the cost of employee and non-employee services received in exchange for an award of equity instruments based on the
grant date fair value of the award. Fair value for restricted stock unit awards is valued using the closing price of the Company&#x2019;s
common stock on the date of grant. The grant date fair value is recognized over the requisite service period during which an employee
and non-employee is required to provide service in exchange for the award, using the accelerated method with each tranche being expensed
over its vesting period. The grant date fair value of employee and non-employee share options is estimated using the Black-Scholes option
pricing model. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term
of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception
and does not anticipate paying dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Starting in 2023,
Beyond Air used its own historical volatility as an input for expected volatility, but due to Beyond Cancer&#x2019;s and NeuroNos&#x2019;
lack of marketability, the Company utilizes the implied volatility based on an aggregate of guideline companies for expected volatility.
The Company uses the simplified method to estimate the expected term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--SupplierConcentrationPolicyTextBlock_zKF0PPuy2u2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_znqew8oyzWYi"&gt;Supplier
Concentration&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company relies on third-party suppliers to provide materials for its devices and consumables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the year ended March 31, 2026, the Company purchased approximately &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FirstThirdPartyVendorsMember_zWOjQrfo8Lg9" title="Concentration percentage"&gt;74&lt;/span&gt;% and &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondThirdPartyVendorsMember_zPKH5GFKgKkk" title="Concentration percentage"&gt;18&lt;/span&gt;% of its materials from two third-party vendors. In the
year ended March 31, 2025, the Company purchased approximately &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorsMember_zzzCD2frilml" title="Concentration percentage"&gt;85&lt;/span&gt;% of its materials from one third-party vendor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--CustomerrConcentrationPolicyTextBlock_zt0y7eVOQCR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zZK72rqbNr5k"&gt;Customer
Concentration&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended March 31, 2026, the Company derived &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zYh7HM53rlHa" title="Concentration percentage"&gt;11&lt;/span&gt;% and &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zqCNA4uF7rjc" title="Concentration percentage"&gt;10&lt;/span&gt;% of its revenues from two customers. For the year ended March 31, 2025,
the Company derived &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_z8mTZnZnEwR7" title="Concentration percentage"&gt;16&lt;/span&gt;% and &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zjovfV2GnvV8" title="Concentration percentage"&gt;10&lt;/span&gt;% of its revenues from two customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zYiYbUZ0aaWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zBR8SZsHLuE4"&gt;Licensed
Right to Use Technology&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Licensed
right to use technology that is considered platform technology with alternative future uses is recorded as an intangible asset and is
amortized on a straight-line method over its estimated useful life, determined to be thirteen years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zPqdqDxadk6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
expected amortization expense for the next five years and thereafter is as follows for the year ended March 31 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zfGTZeVvBHb1" style="display: none"&gt;SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20260331_zTDHWIObOgA5" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANz72H_ztGt05u0vLWc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANz72H_zdQScyCDpJTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANz72H_zdimKZ1UaNT8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANz72H_zoImxPVfM5fi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANz72H_zoRKAth2Mncg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2031&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANz72H_ziR28fJCHfik" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,018&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z0prWWE0AGMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zWfi9ADUtDcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_z8VqivzDPyKg"&gt;Long-Lived
Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses the impairment of long-lived assets on an ongoing basis and whenever events or changes in circumstances indicate that
the carrying value may not be recoverable. Factors that the Company considers as potential triggers of an impairment review include the
following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    underperformance relative to expected historical or projected future operating results,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    changes in the manner of the Company&#x2019;s use of the acquired assets or the strategy for its overall business,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    negative regulatory or economic trends, and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    technological changes, which would render the platform technology, equipment, and manufacturing processes obsolete. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recoverability
of assets that will continue to be used in the Company&#x2019;s operations is measured by comparing the carrying value to the future net
undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future
revenues, driven by market growth rates, and estimates of future costs. There were no events during the reporting periods that were deemed
to be a triggering event that would require an impairment assessment, other than the impairment of $&lt;span id="xdx_900_eus-gaap--OtherAssetImpairmentCharges_pn5n6_c20240401__20250331_zfqvadaSCqaj" title="Other asset impairment charges"&gt;0.5&lt;/span&gt; million recorded during the year
ended March 31, 2025 associated with certain R&amp;amp;D assets following Management&#x2019;s decision to put its VCAP clinical trial on hold.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_z1EpRTJlMHf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_z6dWFnrUzn86"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities
and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are
recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than
not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future
deductibility is uncertain. As of March 31, 2026 and March 31, 2025, the Company recorded a valuation allowance to the full extent of
the Company&#x2019;s net deferred tax assets since the likelihood of realization of the benefit does not meet the more-likely-than-not
threshold.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s reserves related to taxes are based on a determination of whether and how much of a tax benefit taken by the Company
in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related
to the tax benefit. The Company would recognize both estimated accrued interest and penalties related to unrecognized benefits within
income tax expense in the consolidated statements of operations and comprehensive loss. The Company&#x2019;s uncertain tax positions are
related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position,
the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which
a loss carryforward is available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zUjUHEdFaDd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zboUTYq1V7Xd"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to Beyond Air, Inc.,
by the weighted average number of shares of common stock outstanding for the period. The dilutive effect of outstanding options, warrants,
restricted stock and other stock-based compensation awards is reflected in diluted net loss per share by application of the treasury
stock method. The calculation of diluted net loss attributed to common stockholders per share excludes all anti-dilutive shares of common
stock. For periods in which the Company has reported net losses, diluted net loss per share attributable to common stockholders is the
same as basic net loss per share attributable to common stockholders, because such shares of common stock are not assumed to have been
issued if their effect is anti-dilutive (Note 8).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ConsolidationVariableInterestEntityPolicy_zXmJuTlw0mS" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zvtldgtakaPf"&gt;Variable
Interest Entity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Company has the power to direct activities of both Beyond Cancer and NeuroNos  that most significantly impact their economic
performance and the right to receive benefits and losses that may potentially be significant, these financial statements are fully consolidated
with those of the Company. The non-controlling owners&#x2019; &lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20260331__srt--OwnershipAxis__custom--BeyondCancerLtdMember_zVO1dsDjeZKb" title="Non-controlling owners interest"&gt;20&lt;/span&gt;% interest in Beyond Cancer&#x2019;s net assets and result of operations
and the non-controlling owners&#x2019; &lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20260331__srt--OwnershipAxis__custom--NeuroNosLtdMember_zGruHsD1j4A8" title="Non-controlling owners interest"&gt;15.25&lt;/span&gt;% interest in NeuroNos&#x2019; net assets and result of operations are reported as &#x201c;non-controlling
interest&#x201d; on the Company&#x2019;s consolidated balance sheets and as &#x201c;net loss attributable to non-controlling interest&#x201d;
in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z2e5hTyHtoI" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z3xqho5VK4fa"&gt;Recently
Adopted Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;)
2023-09, &lt;i&gt;Improvements to Tax Disclosures (Topic 740), &lt;/i&gt;to enhance the disclosures related to income taxes, including the rate
reconciliation and information on income taxes paid. This ASU is effective for fiscal years beginning after December 15, 2024
(fiscal 2026 for the Company), with early adoption permitted. The Company adopted this standard effective April 1, 2025
prospectively. See Note 11, &#x201c;Income Taxes,&#x201d; for further information regarding the
Company&#x2019;s effective income tax.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_zypEtiThyZ79" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_ztIW2GOFmu92"&gt;Recently
Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40).&lt;/i&gt; This standard requires disclosure of specific information about costs and expenses and becomes effective for fiscal
years beginning after December 15, 2026 (fiscal 2028 for the Company), with early adoption permitted. The Company is assessing the impact
of this ASU and, upon adoption, may be required to include certain additional disclosures in the footnotes to the Consolidated Financial
Statements.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85A_zRvKbt6JbRYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000699">&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zePT0szFLvt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zaK8ogn2fPr"&gt;Basis
of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
consolidated financial statements include the accounts of Beyond Air, Inc. and its subsidiaries and have been prepared in accordance
with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;). The Company determined that Beyond Cancer
Ltd. and its affiliates (&#x201c;Beyond Cancer&#x201d;) and NeuroNOS Ltd. and its affiliates (&#x201c;NeuroNos&#x201d;) are each a
variable interest entity (&#x201c;VIE&#x201d;) for which the Company is the primary beneficiary and consolidates in its financial
statements. All intercompany balances and transactions have been eliminated in the accompanying consolidated financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-04-01to2026-03-31" id="Fact000701">&lt;p id="xdx_843_eus-gaap--UseOfEstimates_zyP03rkfswnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zrfYmDguqYR8"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could
significantly differ from those estimates. On an ongoing basis, the Company evaluates its significant estimates and assumptions
including expense recognition and accrual assumptions under consulting and clinical trial agreements, stock-based compensation,
allowance for credit losses, excess and obsolete inventory reserves, impairment assessments, accounting for licensed rights to use
technologies and other long-lived assets, the valuation of warrants, the valuation of derivatives, contingency recognition and
accruals and the determination of valuation allowance requirements on deferred tax attributes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <XAIR:GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000703">&lt;p id="xdx_843_ecustom--GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock_zyfgdhMi85s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zqY2Bjw1vIe6"&gt;Going
Concern, Liquidity and Other Uncertainties&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used cash in operating activities of $&lt;span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250401__20260331_z3ZU6LUFtdn3" title="Net cash used in operating activities"&gt;18.1&lt;/span&gt; million for the year ended March 31, 2026, and has an accumulated deficit attributable
to the stockholders of Beyond Air, Inc. of $&lt;span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20260331_zSPwmvk8ZqKe" title="Accumulated deficit"&gt;319.6&lt;/span&gt; million. The Company had cash, cash equivalents and marketable securities of $&lt;span id="xdx_902_ecustom--CashAndCashEquivalentsAndMarketableSecurities_iI_pn5n6_c20260331_zw8mJaARiHIj" title="Cash equivalents and marketable securities"&gt;11.6&lt;/span&gt;
million as of March 31, 2026. In addition, $&lt;span id="xdx_905_eus-gaap--DepositAssets_iI_pn5n6_c20260331_zZ5ML2x09EY3" title="Cash deposit"&gt;3.4&lt;/span&gt; million of cash is held on deposit by the Company&#x2019;s contract manufacturer to be
applied against future purchases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expects to incur net losses and have significant cash outflows for at least the next year, including making significant
investments in research and development. Management believes these factors raise substantial doubt about the Company&#x2019;s ability
to meet its obligations with cash on hand and concluded that the Company will require additional funding within one year from the
date these consolidated financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
is confident that the efforts to arrange financing, while not assured, will enable the Company to meet its obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s future capital needs and the adequacy of its available funds will depend on many factors, including, but not necessarily
limited to, the success and costs of commercialization of the Company&#x2019;s approved product and the actual cost and time necessary
for current and anticipated preclinical studies, clinical trials and other actions needed to obtain certification or regulatory approval
of the Company&#x2019;s product candidates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</XAIR:GoingConcernLiquidityAndOtherUncertaintiesPolicyTextBlock>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-04-01to2026-03-31"
      decimals="-5"
      id="Fact000705"
      unitRef="USD">-18100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-03-31"
      decimals="-5"
      id="Fact000707"
      unitRef="USD">-319600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <XAIR:CashAndCashEquivalentsAndMarketableSecurities
      contextRef="AsOf2026-03-31"
      decimals="-5"
      id="Fact000709"
      unitRef="USD">11600000</XAIR:CashAndCashEquivalentsAndMarketableSecurities>
    <us-gaap:DepositAssets
      contextRef="AsOf2026-03-31"
      decimals="-5"
      id="Fact000711"
      unitRef="USD">3400000</us-gaap:DepositAssets>
    <XAIR:OtherRisksAndUncertaintiesPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000713">&lt;p id="xdx_84C_ecustom--OtherRisksAndUncertaintiesPolicyTextBlock_zmSOMpTsR0dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_z9BkdE6WELm2"&gt;Other
Risks and Uncertainties&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to risks common to development and early-stage medical device companies including, but not limited to, new technological
innovations, certifications or regulatory approval, dependence on key personnel, protection of proprietary technology, compliance with
government regulations, product liability, uncertainty of market acceptance of approved products and the potential need to obtain additional
financing. The Company is also dependent on third-party suppliers and, in some cases, single-source suppliers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s products require approval or clearance from the FDA prior to commencement of commercial sales in the United States. There
can be no assurance that the Company&#x2019;s products beyond LungFit&#xae; PH in the U.S. will receive the required approvals or clearances.
Certifications, approvals or clearances are also required in foreign jurisdictions in which the Company may license or sell its products.
If the Company is denied such certifications or approvals or clearances or such certifications, approvals or clearances are delayed,
such denial or delay may have a material adverse impact on the Company&#x2019;s results of operations, financial position and liquidity.
Further, there can be no assurance that the Company&#x2019;s product will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or
that such products will be successfully marketed, if at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</XAIR:OtherRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000715">&lt;p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zVF0qxX5X7Ag" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zlJminLqUXwk"&gt;Revenue
Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates revenue from the leases of its LungFit&#xae; PH devices to its customers under fixed fee arrangements over periods of
up to three years. The fixed fee is typically broken down into ratable monthly payments over the term of the arrangement. The Company&#x2019;s
customers include hospitals and medical facilities. The Company&#x2019;s LungFit&#xae; PH leases include filters, calibration gas, bagging
kits, cables, adapters, and other components and accessories required to use the LungFit&#xae; PH device (the &#x201c;Consumables&#x201d;).
The consumables&#x2019; quantities are varied and may be supplied upon demand of the customers and are unlimited, or the arrangement may
provide for the maximum quantities available to the customer over the term of the arrangement. The Company&#x2019;s LungFit&#xae; PH leases
also include maintenance and training required to use the LungFit&#xae; PH device, as well as device back-up services (the &#x201c;Services&#x201d;),
which are recorded in cost of revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its rental arrangements of LungFit&#xae; PH devices in accordance with Accounting Standards Codification 842, &lt;i&gt;Leases&lt;/i&gt;
(&#x201c;ASC 842&#x201d;). Under ASC 842, leases may be classified as either financing, sales-type, or operating, and the Company is
required to disclose key information about leasing arrangements. The classification determines the pattern of revenue recognition
and classification within the consolidated statements of operations and comprehensive loss. The Company typically classifies the
rental arrangement of its LungFit&#xae; PH contracts as operating leases. The Company&#x2019;s leases do not contain any restrictive
covenants or any material residual value guarantees. The Company&#x2019;s equipment leases may contain renewal options which range
from one month to two years. The lease term is adjusted for renewal or termination options that the Company believes the customer is
reasonably certain to exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company elected the practical expedient applied to operating leases not to separate lease and non-lease components as long as the lease
and non-lease components have the same timing and pattern of transfer. As such, the non-lease components, including the Consumables and
Services, are combined with the predominant lease component. The total fixed fees that the Company is reasonably certain to collect are
recognized on a straight line basis over the term of the arrangement. Additionally, the Company made an accounting policy election to
present LungFit&#xae; PH revenue net of sales and other similar taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the lease commencement date, the Company will defer initial direct costs, including commission expense and the cost is recognized over
the lease term on the same basis as lease income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 15 to the consolidated financial statements for more information regarding leasing arrangements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also generates revenue from the sale of its LungFit&#xae; PH devices and consumables to its customers under distribution arrangements.
Contracts include one performance obligation as any individual promised good or services other than delivery of the devices and consumables
are generally either not capable of being distinct or not distinct within the context of the contracts. Purchased quantities of devices
and consumables are varied and may be supplied upon demand of the customers. Revenue is recognized at a point in time when the Company
delivers the goods to its customer. The transaction includes a fixed component based on contractual rates. Revenue recognized reflects
the consideration the Company expects to receive in exchange for delivering the goods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amounts
billed in advance of performance obligations being satisfied are recognized as deferred revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records the costs of shipping devices and consumables in cost of revenues in its consolidated statements of operations and comprehensive
loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2025-04-01to2026-03-31" id="Fact000717">&lt;p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJRcS9cpNhq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zpAyVX7HJsB8"&gt;Accounts
Receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company extends credit to its customers on an unsecured basis. Accounts receivable are recorded at the invoiced amount, based on agreed
contract terms, less an allowance for credit losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company establishes an allowance for accounts receivable that are considered to be at increased risk of becoming uncollectible. When
evaluating the adequacy of this allowance for credit losses, the Company considers factors such as, historical collection experience
and creditworthiness, the composition of outstanding receivables by customer class, and expected economic conditions and other trends.
The Company&#x2019;s estimates are reflected in the period they are made. The charges recorded for credit losses are reported within Selling,
general and administrative expenses on the consolidated statements of operations and comprehensive loss. Receivables are written off
against the allowance for credit losses when it is definitively determined that amounts are uncollectible. As of March 31, 2026 and 2025,
the allowance for credit losses were $&lt;span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivableNoncurrent_iI_pn5n6_c20260331_zYeSgdAczWwa" title="Allowance for credit losses"&gt;0.1&lt;/span&gt; million and $&lt;span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivableNoncurrent_iI_pn5n6_c20250331_z7SLja1nsgK6" title="Allowance for credit losses"&gt;0&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="-5"
      id="Fact000719"
      unitRef="USD">100000</us-gaap:AllowanceForDoubtfulAccountsReceivableNoncurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="-5"
      id="Fact000721"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableNoncurrent>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000723">&lt;p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z5m4LoVsv315" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zbf3gxuIpLl5"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt; (&#x201c;ASC 820&#x201d;), defines fair value as the price that would be received to
sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market
participants on the measurement date. The fair value standard also establishes a three-level hierarchy, which requires an entity to maximize
the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based
upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1&#x2014;inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2&#x2014;inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived
valuations in which all significant inputs are observable for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3&#x2014;inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2026 and March 31, 2025, the Company&#x2019;s financial instruments included restricted cash, marketable securities,
accounts payable, long-term debt and liability classified warrants. The carrying amounts reported in the accompanying consolidated
financial statements for cash and cash equivalents, restricted cash and marketable securities approximate their respective fair
values because of the short-term nature of these accounts. The carrying value of the Company&#x2019;s long-term debt approximates
fair value based on current interest rates for similar types of borrowings. The liability classified warrants are recorded at fair
value and are included in Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zSz2dHLbWKHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value amounts as of March 31, 2026 are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zXpIL3M7zN37" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ON A RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260331_z0foNQr9g2b6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z38n6cDnwlu8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z00wG26yyZg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsZd0BuskkP8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Marketable securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_ze7sjfLFgEgg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0729"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0730"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zjHwT9v6ZS32" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured and recorded at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0734"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0735"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zRC5TAbEqGGb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0738"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_z468H5pC9PIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities measured and recorded at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0743"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0744"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value amounts as of March 31, 2025 are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250331_z3Jt5bx4bnYc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjwMihH6oIy5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQyMh8LZAtai" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWF9wGvB3aei" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Marketable securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zQgGzALhxHx" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0749"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0750"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zKl8QiSE9w77" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured and recorded at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0754"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0755"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z7teyQQZeWch" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0758"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0759"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zIpton2TLu3e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities measured and recorded at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0763"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zXsqfKoRIw8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--MarketableSecuritiesTextBlock_z4HgtsibLNA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s short-term marketable securities with unrealized gains and losses as of March 31, 2026,
aggregated by major security type:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zCu1EyrKbD71" style="display: none"&gt;SUMMARY
OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Unrealized Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_z5wtCioRRxGi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, fair value"&gt;4,901&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20250401__20260331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zB1niEE5K80j" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, unrealized loss"&gt;39&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total short-term marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zu1R3CSkgizd" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Fair value"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20250401__20260331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zSGHtLg4kMfj" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Unrealized gains and (losses)"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s short-term marketable securities with unrealized gains and losses as of March 31, 2025,
aggregated by major security type:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Unrealized Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zQg58g0FROi4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, fair value"&gt;2,252&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20240401__20250331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zWNdUiwZjpf7" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, unrealized loss"&gt;39&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total short-term marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zpU8N2T4NHZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Fair value"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20240401__20250331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zr2SOMcBc0If" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Unrealized gains and (losses)"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zgvFuIOypEj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Level
3 Valuation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrant
liability&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrant liability is remeasured each reporting period with the change in fair value recorded to other income (expense) in the consolidated
statements of operations and comprehensive loss until the warrants are exercised, expired, reclassified or otherwise settled.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zHT5mdEx3482" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
significant assumptions used in valuing the warrants were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zMM5k5MZuJid" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS USED IN VALUING WARRANTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;At March 31, 2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgvjyxQ3NFWj" title="Expected term warrants"&gt;2.25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ziOPdUBHgXR1" title="Warrants and rights outstanding, measurement input"&gt;132.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z70biNE9YS8c" title="Warrants and rights outstanding, measurement input"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;At March 31, 2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyJjQ346E25f" title="Expected term warrants"&gt;3.25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zeuiYAT9gYHk" title="Warrants and rights outstanding, measurement input"&gt;99.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdcmXtcs2u7b" title="Warrants and rights outstanding, measurement input"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zG73FmtTGsBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Derivative
liability&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementDifferenceDescription_c20250401__20260331_zzvT3Ss7G3gc" title="Derivative liability description"&gt;The
derivative liability represents an embedded redemption feature (embedded put option) that meets the criteria to be classified as a
derivative and is bifurcated from the Note (see Note 9). On any trading day during which the Registration Statement (Note 4) remains
effective and the Note remains outstanding and (i) any trading price of the Company&#x2019;s common stock is at least 5% greater than
the current Nasdaq minimum price as defined under Nasdaq Rule 5635(d) (the &#x201c;Nasdaq Minimum Price&#x201d;) or (ii) the total
dollar trading volume has reached $750,000.00, Streeterville may elect to purchase shares of common stock up to the Beneficial
Ownership Limitation at a purchase price equal to 85% of the Nasdaq Minimum Price, subject to a floor of $0.39 per share. The
aggregate purchase price for these shares shall be offset by an equal amount outstanding under the Note.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
feature was concluded to not be clearly and closely related to the host instrument and is required to be measured at fair value at each
reporting period. The fair value was determined using the Monte Carlo valuation model. The key inputs of the simulation are the valuation
date, the Company&#x2019;s common stock share price and volatility, the risk-free rate, and the maximum convertible shares eligible to
offset the outstanding balance on the Note.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock_zsfFhj7pnTGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zHcIVEJ0tXp1" style="display: none"&gt;SCHEDULE
OF KEY INPUTS DERIVATIVE &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;At November 4, 2025 (issuance)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20251104_zE3kHp0WJLG6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Derivative&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Maximum convertible shares&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20251104__20251104_zx3BaNOFcG5f" style="width: 16%; text-align: right" title="Maximum convertible shares"&gt;1,600,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zh4ViqIooue7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zsrRCqjWT2u6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z17Mb19aVOfg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zboQEfYurVni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
January 2026, Streeterville elected to purchase &lt;span id="xdx_903_eus-gaap--StockRepurchasedDuringPeriodShares_pn5n6_c20260101__20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zkC1OrbXBar4" title="Purchase of common stock, shares"&gt;1.6&lt;/span&gt;
million shares of common stock at an average of $&lt;span id="xdx_90D_eus-gaap--SharePrice_iI_c20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zYhINvXrjrD" title="Share price"&gt;0.73&lt;/span&gt;
per share which offset principal of approximately $&lt;span id="xdx_905_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pn5n6_c20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zRkMG7rKJgb7" title="Debt amount"&gt;1.2&lt;/span&gt;
million outstanding under the Note (Note 9). The fair value of the issued common stock was approximately $&lt;span id="xdx_90C_eus-gaap--CommonStockValueOutstanding_iI_pn5n6_c20260331_znX2AazFVE9a" title="Fair value of issued common stock"&gt;3.3&lt;/span&gt;
million (Note 4). The Company remeasured the fair value of the derivative liability to $&lt;span id="xdx_902_eus-gaap--CreditRiskDerivativeLiabilitiesAtFairValue_iI_pn5n6_c20260331_ziVcopMq8KCa" title="Fair value of the derivative liability"&gt;2.2&lt;/span&gt;
million immediately prior to the conversion. Accordingly, the embedded derivative was extinguished as of March 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock_znFmSd1AcC0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table presented below is a summary of changes in the fair value of the Company&#x2019;s Level 3 valuation for the warrants and derivatives
for the years ended March 31, 2026 and March 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zjA246EL3fBa" style="display: none"&gt;SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B1_us-gaap--FinancialInstrumentAxis_us-gaap--WarrantMember_zKomqjJB3SX7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BF_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_zr6VZOcny8w2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Derivative&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43D_c20240401__20250331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_ztdzelDPDHeh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Balance at March 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;275&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,314&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zCFopjQvCLGg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(237&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,314&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43B_c20250401__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zWLun7K8xSJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at March 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0830"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zCbqV14l7zv" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0832"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zlVdshaDBc45" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--FairValueMeasurementExtinguishment_zmcY92DcW479" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Extinguishment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0838"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,170&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_435_c20250401__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zob4KlfS1AB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Balance at March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0842"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z5XCy7ic64Ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000725">&lt;p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zSz2dHLbWKHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value amounts as of March 31, 2026 are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zXpIL3M7zN37" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ON A RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20260331_z0foNQr9g2b6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z38n6cDnwlu8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z00wG26yyZg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsZd0BuskkP8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Marketable securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_ze7sjfLFgEgg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0729"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0730"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zjHwT9v6ZS32" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured and recorded at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0734"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0735"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zRC5TAbEqGGb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0738"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_z468H5pC9PIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities measured and recorded at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0743"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0744"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value amounts as of March 31, 2025 are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250331_z3Jt5bx4bnYc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjwMihH6oIy5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQyMh8LZAtai" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWF9wGvB3aei" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Marketable securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zQgGzALhxHx" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0749"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0750"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zKl8QiSE9w77" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured and recorded at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0754"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0755"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z7teyQQZeWch" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0758"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0759"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zIpton2TLu3e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities measured and recorded at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0763"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-03-31_custom_MutualFundsMember"
      decimals="-3"
      id="Fact000727"
      unitRef="USD">4901000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsMember"
      decimals="-3"
      id="Fact000728"
      unitRef="USD">4901000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000732"
      unitRef="USD">4901000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact000733"
      unitRef="USD">4901000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000737"
      unitRef="USD">2000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000740"
      unitRef="USD">2000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000742"
      unitRef="USD">2000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2026-03-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact000745"
      unitRef="USD">2000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-03-31_custom_MutualFundsMember"
      decimals="-3"
      id="Fact000747"
      unitRef="USD">2252000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsMember"
      decimals="-3"
      id="Fact000748"
      unitRef="USD">2252000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000752"
      unitRef="USD">2252000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact000753"
      unitRef="USD">2252000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000757"
      unitRef="USD">38000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000760"
      unitRef="USD">38000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000762"
      unitRef="USD">38000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact000765"
      unitRef="USD">38000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000767">&lt;p id="xdx_89F_eus-gaap--MarketableSecuritiesTextBlock_z4HgtsibLNA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s short-term marketable securities with unrealized gains and losses as of March 31, 2026,
aggregated by major security type:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zCu1EyrKbD71" style="display: none"&gt;SUMMARY
OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Unrealized Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_z5wtCioRRxGi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, fair value"&gt;4,901&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20250401__20260331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zB1niEE5K80j" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, unrealized loss"&gt;39&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total short-term marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zu1R3CSkgizd" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Fair value"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20250401__20260331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zSGHtLg4kMfj" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Unrealized gains and (losses)"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s short-term marketable securities with unrealized gains and losses as of March 31, 2025,
aggregated by major security type:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Unrealized Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zQg58g0FROi4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, fair value"&gt;2,252&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20240401__20250331__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zWNdUiwZjpf7" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Total short-term marketable securities, unrealized loss"&gt;39&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total short-term marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zpU8N2T4NHZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Fair value"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20240401__20250331__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zr2SOMcBc0If" style="border-bottom: Black 1pt solid; text-align: right" title="Total short-term marketable securities, Unrealized gains and (losses)"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2026-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember"
      decimals="-3"
      id="Fact000769"
      unitRef="USD">4901000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-04-012026-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember"
      decimals="-3"
      id="Fact000771"
      unitRef="USD">39000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2026-03-31_us-gaap_ShortTermDebtMember"
      decimals="-3"
      id="Fact000773"
      unitRef="USD">4901000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-04-012026-03-31_us-gaap_ShortTermDebtMember"
      decimals="-3"
      id="Fact000775"
      unitRef="USD">39000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2025-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember"
      decimals="-3"
      id="Fact000777"
      unitRef="USD">2252000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-04-012025-03-31_us-gaap_MutualFundMember_us-gaap_ShortTermDebtMember"
      decimals="-3"
      id="Fact000779"
      unitRef="USD">39000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2025-03-31_us-gaap_ShortTermDebtMember"
      decimals="-3"
      id="Fact000781"
      unitRef="USD">2252000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-04-012025-03-31_us-gaap_ShortTermDebtMember"
      decimals="-3"
      id="Fact000783"
      unitRef="USD">39000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000785">&lt;p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zHT5mdEx3482" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
significant assumptions used in valuing the warrants were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zMM5k5MZuJid" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS USED IN VALUING WARRANTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;At March 31, 2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgvjyxQ3NFWj" title="Expected term warrants"&gt;2.25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ziOPdUBHgXR1" title="Warrants and rights outstanding, measurement input"&gt;132.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z70biNE9YS8c" title="Warrants and rights outstanding, measurement input"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;At March 31, 2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyJjQ346E25f" title="Expected term warrants"&gt;3.25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zeuiYAT9gYHk" title="Warrants and rights outstanding, measurement input"&gt;99.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdcmXtcs2u7b" title="Warrants and rights outstanding, measurement input"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2026-03-31_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact000787">P2Y3M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2026-03-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000789"
      unitRef="Pure">132.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2026-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000791"
      unitRef="Pure">3.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-03-31_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact000793">P3Y3M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000795"
      unitRef="Pure">99.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000797"
      unitRef="Pure">3.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementDifferenceDescription contextRef="From2025-04-01to2026-03-31" id="Fact000799">The
derivative liability represents an embedded redemption feature (embedded put option) that meets the criteria to be classified as a
derivative and is bifurcated from the Note (see Note 9). On any trading day during which the Registration Statement (Note 4) remains
effective and the Note remains outstanding and (i) any trading price of the Company&#x2019;s common stock is at least 5% greater than
the current Nasdaq minimum price as defined under Nasdaq Rule 5635(d) (the &#x201c;Nasdaq Minimum Price&#x201d;) or (ii) the total
dollar trading volume has reached $750,000.00, Streeterville may elect to purchase shares of common stock up to the Beneficial
Ownership Limitation at a purchase price equal to 85% of the Nasdaq Minimum Price, subject to a floor of $0.39 per share. The
aggregate purchase price for these shares shall be offset by an equal amount outstanding under the Note.</us-gaap:DerivativeLiabilityMeasurementDifferenceDescription>
    <XAIR:FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000801">&lt;p id="xdx_895_ecustom--FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock_zsfFhj7pnTGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zHcIVEJ0tXp1" style="display: none"&gt;SCHEDULE
OF KEY INPUTS DERIVATIVE &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;At November 4, 2025 (issuance)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20251104_zE3kHp0WJLG6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Derivative&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Maximum convertible shares&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20251104__20251104_zx3BaNOFcG5f" style="width: 16%; text-align: right" title="Maximum convertible shares"&gt;1,600,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zh4ViqIooue7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zsrRCqjWT2u6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z17Mb19aVOfg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</XAIR:FairValueMeasurementInputsAndValuationTechniquesOfDerivativeTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-11-042025-11-04"
      decimals="INF"
      id="Fact000803"
      unitRef="Shares">1600000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2025-11-04_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact000805"
      unitRef="Pure">1.86</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2025-11-04_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      id="Fact000807"
      unitRef="Pure">1.25</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2025-11-04_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000809"
      unitRef="Pure">0.036</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2026-01-012026-01-31_custom_StreetervilleCapitalLLCMember"
      decimals="-5"
      id="Fact000811"
      unitRef="Shares">1600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharePrice
      contextRef="AsOf2026-01-31_custom_StreetervilleCapitalLLCMember"
      decimals="INF"
      id="Fact000813"
      unitRef="USDPShares">0.73</us-gaap:SharePrice>
    <us-gaap:DebtDefaultLongtermDebtAmount
      contextRef="AsOf2026-01-31_custom_StreetervilleCapitalLLCMember"
      decimals="-5"
      id="Fact000815"
      unitRef="USD">1200000</us-gaap:DebtDefaultLongtermDebtAmount>
    <us-gaap:CommonStockValueOutstanding
      contextRef="AsOf2026-03-31"
      decimals="-5"
      id="Fact000817"
      unitRef="USD">3300000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CreditRiskDerivativeLiabilitiesAtFairValue
      contextRef="AsOf2026-03-31"
      decimals="-5"
      id="Fact000819"
      unitRef="USD">2200000</us-gaap:CreditRiskDerivativeLiabilitiesAtFairValue>
    <XAIR:ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000821">&lt;p id="xdx_893_ecustom--ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock_znFmSd1AcC0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table presented below is a summary of changes in the fair value of the Company&#x2019;s Level 3 valuation for the warrants and derivatives
for the years ended March 31, 2026 and March 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zjA246EL3fBa" style="display: none"&gt;SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS AND DERIVATIVES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B1_us-gaap--FinancialInstrumentAxis_us-gaap--WarrantMember_zKomqjJB3SX7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BF_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_zr6VZOcny8w2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Derivative&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43D_c20240401__20250331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_ztdzelDPDHeh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Balance at March 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;275&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,314&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zCFopjQvCLGg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(237&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,314&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43B_c20250401__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zWLun7K8xSJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at March 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0830"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zCbqV14l7zv" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0832"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zlVdshaDBc45" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--FairValueMeasurementExtinguishment_zmcY92DcW479" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Extinguishment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0838"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,170&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_435_c20250401__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zob4KlfS1AB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Balance at March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0842"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</XAIR:ScheduleOfChangeInFairValueOfWarrantsAndDerivativesTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2024-03-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000823"
      unitRef="USD">275000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2024-03-31_us-gaap_DerivativeMember"
      decimals="-3"
      id="Fact000824"
      unitRef="USD">1314000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2024-04-012025-03-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000826"
      unitRef="USD">-237000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2024-04-012025-03-31_us-gaap_DerivativeMember"
      decimals="-3"
      id="Fact000827"
      unitRef="USD">-1314000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2025-03-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000829"
      unitRef="USD">38000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2025-04-012026-03-31_us-gaap_DerivativeMember"
      decimals="-3"
      id="Fact000833"
      unitRef="USD">775000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2025-04-012026-03-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000835"
      unitRef="USD">-36000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2025-04-012026-03-31_us-gaap_DerivativeMember"
      decimals="-3"
      id="Fact000836"
      unitRef="USD">1395000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <XAIR:FairValueMeasurementExtinguishment
      contextRef="From2025-04-012026-03-31_us-gaap_DerivativeMember"
      decimals="-3"
      id="Fact000839"
      unitRef="USD">-2170000</XAIR:FairValueMeasurementExtinguishment>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2026-03-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000841"
      unitRef="USD">2000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <XAIR:WarrantLiabilityPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000844">&lt;p id="xdx_84A_ecustom--WarrantLiabilityPolicyTextBlock_zD4209tMhPkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zRWUm4WOeCxf"&gt;Warrant
Liability&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company classifies warrants as equity for any contracts that (i) require physical settlement or net-share settlement or (ii) gives
the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The
Company classifies warrants as assets or liabilities for any contracts that (i) require net-cash settlement (including a requirement
to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the
counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). Such warrants
are subject to remeasurement at each consolidated balance sheet date and any change in fair value is recognized as a component of
other income/expense on the consolidated statements of operations and comprehensive loss. The Company will continue to adjust the liability
for changes in fair value until the earlier of the exercise or expiration of such warrants. At that time, the portion of the warrant
liability related to warrants will be reclassified to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</XAIR:WarrantLiabilityPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000846">&lt;p id="xdx_843_eus-gaap--DerivativesPolicyTextBlock_zSNkPmULVEX" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zLgVSHtIY1bj"&gt;Derivative
Liability&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as
embedded derivatives in accordance with ASC 815, &lt;i&gt;Derivatives and Hedging.&lt;/i&gt; For derivative financial instruments that are
accounted for as assets or liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is
then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations and
comprehensive loss. The classification of derivative instruments, including whether such instruments should be recorded as assets or
liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the
consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument
could be required within 12 months of the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2025-04-01to2026-03-31" id="Fact000848">&lt;p id="xdx_847_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zkxOhR4JB6D6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zaLdwLtGklG3"&gt;Cash
and Cash Equivalents, Short-Term Investments and Restricted Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with original maturities of three months or less at the date of purchase and an investment
in a U.S. government money market fund to be cash equivalents. The Company maintains its cash and cash equivalents in highly rated financial
institutions in Australia, Israel, Ireland and the U.S., the balances of which, at times, may exceed federally insured limits. Marketable
securities may include investment in a combination of fixed income bonds, U.S. Treasury securities, and mutual funds that are considered
to be highly liquid and easily tradeable. The marketable securities are considered trading securities and are measured at fair value
and are accounted for in accordance with ASC 320. The marketable securities are valued using inputs observable in active markets for
identical securities and are therefore classified as Level 1 within the Company&#x2019;s fair value hierarchy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2026 and March 31, 2025, restricted cash included approximately $&lt;span id="xdx_904_eus-gaap--RestrictedCash_iI_pn5n6_c20260331_z4rXtZexOB4b" title="Restricted cash"&gt;5.6&lt;/span&gt; million and $&lt;span id="xdx_90F_eus-gaap--RestrictedCash_iI_pn5n6_c20250331_zhHpnQ2lF6F8" title="Restricted cash"&gt;0.2&lt;/span&gt; million, respectively. Restricted
cash as of March 31, 2026 includes $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_pn5n6_c20251104__20251104_zvX9YlzYQEr2" title="Proceeds from issuance of secured promissory note"&gt;5.4&lt;/span&gt; million of proceeds from the Company&#x2019;s secured promissory note issued on November 4, 2025
that is required to be held in a restricted account pursuant to the Note Purchase Agreement. Amounts held in the restricted account become
available to the Company as the outstanding principal of the Note is repaid (see Note 9).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="AsOf2026-03-31"
      decimals="-5"
      id="Fact000850"
      unitRef="USD">5600000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="AsOf2025-03-31"
      decimals="-5"
      id="Fact000852"
      unitRef="USD">200000</us-gaap:RestrictedCash>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="From2025-11-042025-11-04"
      decimals="-5"
      id="Fact000854"
      unitRef="USD">5400000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2025-04-01to2026-03-31" id="Fact000856">&lt;p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zE3MMSGbrn05" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zifwhxa60YWk"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_uUSD_c20260331__srt--StatementGeographicalAxis__country--US_z7gUpbeMZPEg" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; in the United States, A$&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_uAUD_c20260331__srt--StatementGeographicalAxis__country--AU_zLkdEA4hIpqb" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; in Australia, $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_uUSD_c20260331__srt--StatementGeographicalAxis__country--BM_z8jflRkUGJZe" title="Cash FDIC insured amount"&gt;25,000&lt;/span&gt;
in Bermuda, &#x20ac;&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_uEUR_c20260331__srt--StatementGeographicalAxis__country--IE_zvzsqbKTFD9a" title="Cash FDIC insured amount"&gt;100,000&lt;/span&gt; in Ireland and &#x20ac;&lt;span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_uEUR_c20260331__srt--StatementGeographicalAxis__country--CY_zhbZ2tY5spQa" title="Cash FDIC insured amount"&gt;100,000&lt;/span&gt; in Cyprus. There is currently no official federal depository insurance in Israel.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. &lt;span id="xdx_906_eus-gaap--ConcentrationRiskBenchmarkDescription_c20260331__20260331_zwBsDcqjI1ci" title="Concentration risk benchmark description"&gt;As of March 31, 2026, the Company had greater than $250,000 at United States financial institutions, less than A$250,000
at Australian financial institutions, greater than &#x20ac;100,000 at Irish financial institutions and also has funds on deposit in Israel.&lt;/span&gt;
Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial condition,
results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zO39TGqE6eHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table is the reconciliation of the presentation and disclosure of cash, cash equivalents, marketable securities by major security
type and restricted cash as shown on the Company&#x2019;s consolidated statements of cash flows for:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_z0jfOmMC4Fy7" style="display: none"&gt;SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260331_zKbwo92hRnU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250331_zIIVYqgiz4Xl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCEASz3pW_maRCACEzZrO_zQj3UHc54oZf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,740&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,665&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RestrictedCashCurrent_iI_pn3n3_maRCACEzZrO_zFxqdPDYOz83" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,622&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;231&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--RestrictedCashAndCashEquivalents_iTI_pn3n3_mtRCACEzZrO_maCCEASziVz_zCa0NYeQZvO8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,362&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,896&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--MarketableSecuritiesAbstract_iB_zy0yiyUF65n9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Marketable securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--MarketableSecuritiesCurrent_i01I_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z213JS7INxXc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--MarketableSecuritiesCurrent_i01I_pn3n3_maCCEASziVz_zJBHKOVrL1Ok" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iTI_pn3n3_mtCCEASziVz_zHJeioG91Fig" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total cash, cash equivalents, marketable securities and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,148&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zPNalkSO2Hci" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2026-03-31_country_US"
      decimals="0"
      id="Fact000858"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2026-03-31_country_AU"
      decimals="0"
      id="Fact000860"
      unitRef="AUD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2026-03-31_country_BM"
      decimals="0"
      id="Fact000862"
      unitRef="USD">25000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2026-03-31_country_IE"
      decimals="0"
      id="Fact000864"
      unitRef="EUR">100000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2026-03-31_country_CY"
      decimals="0"
      id="Fact000866"
      unitRef="EUR">100000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ConcentrationRiskBenchmarkDescription contextRef="From2026-03-312026-03-31" id="Fact000868">As of March 31, 2026, the Company had greater than $250,000 at United States financial institutions, less than A$250,000
at Australian financial institutions, greater than &#x20ac;100,000 at Irish financial institutions and also has funds on deposit in Israel.</us-gaap:ConcentrationRiskBenchmarkDescription>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000870">&lt;p id="xdx_89D_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zO39TGqE6eHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table is the reconciliation of the presentation and disclosure of cash, cash equivalents, marketable securities by major security
type and restricted cash as shown on the Company&#x2019;s consolidated statements of cash flows for:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_z0jfOmMC4Fy7" style="display: none"&gt;SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260331_zKbwo92hRnU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250331_zIIVYqgiz4Xl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCEASz3pW_maRCACEzZrO_zQj3UHc54oZf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,740&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,665&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RestrictedCashCurrent_iI_pn3n3_maRCACEzZrO_zFxqdPDYOz83" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,622&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;231&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--RestrictedCashAndCashEquivalents_iTI_pn3n3_mtRCACEzZrO_maCCEASziVz_zCa0NYeQZvO8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,362&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,896&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--MarketableSecuritiesAbstract_iB_zy0yiyUF65n9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Marketable securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--MarketableSecuritiesCurrent_i01I_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z213JS7INxXc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--MarketableSecuritiesCurrent_i01I_pn3n3_maCCEASziVz_zJBHKOVrL1Ok" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,252&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iTI_pn3n3_mtCCEASziVz_zHJeioG91Fig" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total cash, cash equivalents, marketable securities and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,148&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000872"
      unitRef="USD">6740000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000873"
      unitRef="USD">4665000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000875"
      unitRef="USD">5622000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000876"
      unitRef="USD">231000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000878"
      unitRef="USD">12362000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000879"
      unitRef="USD">4896000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2026-03-31_us-gaap_MutualFundMember"
      decimals="-3"
      id="Fact000884"
      unitRef="USD">4901000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2025-03-31_us-gaap_MutualFundMember"
      decimals="-3"
      id="Fact000885"
      unitRef="USD">2252000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000887"
      unitRef="USD">4901000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000888"
      unitRef="USD">2252000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000890"
      unitRef="USD">17263000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000891"
      unitRef="USD">7148000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000893">&lt;p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zeVEjAVtjFMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zgbsc8xF2Yja"&gt;Fixed
Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock_zpfWmIi8fGMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost less accumulated depreciation and accumulated amortization. Depreciation and amortization are calculated
using the straight-line method over the estimated useful life of the assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zziOzbX9ZBq2" style="display: none"&gt;SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    equipment &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zGOdAUEMpnMl" title="Estimated useful life of assets"&gt;Three
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z0YAIfctOaLa" title="Estimated useful life of assets"&gt;Five
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clinical
    and medical equipment &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember__srt--RangeAxis__srt--MinimumMember_zeg8FPWttisb" style="display: none" title="Estimated useful life of assets"&gt;3&lt;/span&gt;/&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember__srt--RangeAxis__srt--MaximumMember_zL0oHTEqzoq9" title="Estimated useful life of assets"&gt;Five
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equipment
    deployable as part of a service offering&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentDeployableAsPartOfServiceOfferingMember_zbKoyiHEMEGc" title="Estimated useful life of assets"&gt;Five
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zIOJZqQidfNf" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2026%23UsefulLifeTermOfLeaseMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0906"&gt;Shorter
    of term of lease or estimated useful life of the asset&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A0_zcPMD6dQyzx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <XAIR:ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000895">&lt;p id="xdx_895_ecustom--ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock_zpfWmIi8fGMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost less accumulated depreciation and accumulated amortization. Depreciation and amortization are calculated
using the straight-line method over the estimated useful life of the assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zziOzbX9ZBq2" style="display: none"&gt;SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE OF ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    equipment &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zGOdAUEMpnMl" title="Estimated useful life of assets"&gt;Three
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z0YAIfctOaLa" title="Estimated useful life of assets"&gt;Five
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clinical
    and medical equipment &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember__srt--RangeAxis__srt--MinimumMember_zeg8FPWttisb" style="display: none" title="Estimated useful life of assets"&gt;3&lt;/span&gt;/&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember__srt--RangeAxis__srt--MaximumMember_zL0oHTEqzoq9" title="Estimated useful life of assets"&gt;Five
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equipment
    deployable as part of a service offering&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentDeployableAsPartOfServiceOfferingMember_zbKoyiHEMEGc" title="Estimated useful life of assets"&gt;Five
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zIOJZqQidfNf" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2026%23UsefulLifeTermOfLeaseMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0906"&gt;Shorter
    of term of lease or estimated useful life of the asset&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</XAIR:ScheduleOfPropertyAndEquipmentUsefulLifeOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-03-31_us-gaap_ComputerEquipmentMember"
      id="Fact000897">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-03-31_us-gaap_FurnitureAndFixturesMember"
      id="Fact000899">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-03-31_custom_ClinicalAndMedicalEquipmentMember_srt_MinimumMember"
      id="Fact000901">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-03-31_custom_ClinicalAndMedicalEquipmentMember_srt_MaximumMember"
      id="Fact000903">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-03-31_custom_EquipmentDeployableAsPartOfServiceOfferingMember"
      id="Fact000905">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000908">&lt;p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWhSe7IFIEI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zw5wt5bfBJHc"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an entity for which both discrete financial information is available and regularly reviewed by
the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing
performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company&#x2019;s CODM evaluates performance and allocates resources for all
of the Company&#x2019;s reportable segments based on income/loss from operations. The CODM is involved in determining and reviewing projected
income/loss from operations as part of the annual budget process. Throughout the year, the CODM considers forecast to actual results
and variances to allocate resources. The CODM also considers this information in strategic decisions related to capital allocations,
including investments in assets, research and development activities, and human capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s reportable segments at March 31, 2026 included &lt;span id="xdx_905_ecustom--NumberOfReportableSegmentsDisclosedByDefinitionFlag_dbT_c20250401__20260331_zg48RG5VSya9" title="Number of repotable segments"&gt;Beyond Air, Beyond Cancer, and NeuroNos&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Beyond Air segment includes unallocated corporate expenses associated with the public company fees as well as all corporate related assets
and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <XAIR:NumberOfReportableSegmentsDisclosedByDefinitionFlag contextRef="From2025-04-01to2026-03-31" id="Fact000910">true</XAIR:NumberOfReportableSegmentsDisclosedByDefinitionFlag>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000912">&lt;p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zUPk5S2yRd52" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zQVSCnoOtmF"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
consist primarily of purchased filters, bagging kits, cables, adapters, and other components and accessories required to use the LungFit&#xae;
PH device held for sale to customers. Inventories are recorded at the lower of cost or net realizable value. Cost comprises direct materials,
third-party manufacturing costs and shipping costs incurred to deliver goods to the Company&#x2019;s central warehouse location. Costs
are assigned to individual items of inventory on the basis of weighted average costs. Inventory items are tracked by batch/lot number
for specific identification whenever possible.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
reserves are established for estimated excess and obsolete inventory equal to the difference between the cost of the inventory and the
estimated net realizable value of the inventory based on historical usage, known trends, and market conditions and judgment about the
anticipated future consumption and the Company&#x2019;s ability to sell the inventory. At March 31, 2026 and March 31, 2025, excess and obsolescence reserves
were $&lt;span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_pn5n6_c20260331_ztjhcafgaG3f" title="Obsolescence reserves"&gt;0.4&lt;/span&gt; million and $&lt;span id="xdx_908_eus-gaap--InventoryValuationReserves_iI_pn5n6_c20250331_zH80QGz5OvLl" title="Obsolescence reserves"&gt;0.2&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2026-03-31"
      decimals="-5"
      id="Fact000914"
      unitRef="USD">400000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2025-03-31"
      decimals="-5"
      id="Fact000916"
      unitRef="USD">200000</us-gaap:InventoryValuationReserves>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000918">&lt;p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zTwdbBYwhUzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zVQil3J6jCZ1"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease assets are included within operating lease right-of-use assets, and the corresponding operating lease obligation on the consolidated
balance sheets in accordance with ASC 842, &lt;i&gt;Leases&lt;/i&gt;. The Company has elected not to present short-term leases as these leases have
a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably
certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the
lease term at commencement date. Operating lease expense is recognized on a straight-line basis over the lease term and is included in
general and administrative and research development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
interest rate implicit in the Company&#x2019;s leases is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate in determining the present value of lease payments, which reflects the fixed rate at which the Company could borrow on
a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2025-04-01to2026-03-31" id="Fact000920">&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zBYK3lPY60Yh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z5irVTKx8dx6"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to the consolidated statements of operations and comprehensive loss as incurred. Research and development
expenses include salaries, benefits, stock-based compensation and costs incurred by outside laboratories, manufacturers, clinical research
organizations, consultants, and accredited facilities in connection with preclinical studies and clinical trials. Research and development
expenses are partially offset by the benefit of tax incentive payments for qualified research and development expenditures from the Australian
tax authority (&#x201c;AU Tax Rebates&#x201d;). The Company does not record AU Tax Rebates until payment is received due to the uncertainty
of receipt. For the years ended March 31, 2026 and March 31, 2025, the Company received $&lt;span id="xdx_903_ecustom--TaxRebate_pn5n6_c20250401__20260331__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--AustralianTaxationOfficeMember_zRpYbVFqB6W2" title="Tax Rebate"&gt;0.1&lt;/span&gt; million and $&lt;span id="xdx_903_ecustom--TaxRebate_pn5n6_c20240401__20250331__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--AustralianTaxationOfficeMember_zmlzooNdSbHh" title="Tax Rebate"&gt;0.0&lt;/span&gt; million, respectively,
in AU Tax Rebates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <XAIR:TaxRebate
      contextRef="From2025-04-012026-03-31_us-gaap_AustralianTaxationOfficeMember"
      decimals="-5"
      id="Fact000922"
      unitRef="USD">100000</XAIR:TaxRebate>
    <XAIR:TaxRebate
      contextRef="From2024-04-012025-03-31_us-gaap_AustralianTaxationOfficeMember"
      decimals="-5"
      id="Fact000924"
      unitRef="USD">0.0</XAIR:TaxRebate>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000926">&lt;p id="xdx_84C_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zWyTcYHOwBAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zee0Dj2iQdC3"&gt;Foreign
Exchange Transactions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s subsidiaries transact in U.S. dollars, Euros, New Israeli Shekels and Australian dollars. The Company&#x2019;s main operations
are in the United States and the U.S. dollar is the currency of the primary economic environment in which the Company operates and expects
to continue to operate in the foreseeable future. The Company translated its non-U.S. operations&#x2019; assets and liabilities denominated
in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the
average exchange rate for the reporting period. Gains or losses from foreign currency transactions are included in other income (expense)
in the consolidated statements of operations and comprehensive loss as foreign currency exchange gain/(loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive
income and loss. The accumulated other comprehensive income and loss account includes the cumulative results of translating certain balance
sheet assets and liabilities at current exchange rates and some accounts at historical rates. For the year ended March 31, 2026, the
Company recorded gains of $&lt;span id="xdx_90B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20260331_z7YLqXHZMmJ7" title="Accumulated other comprehensive income"&gt;0.2&lt;/span&gt; million in accumulated other comprehensive income. For the year ended March 31, 2025, the Company recorded
losses of $&lt;span id="xdx_90F_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20250331_z4Km4oWtws39" title="Accumulated other comprehensive income"&gt;0.1&lt;/span&gt; million in accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="AsOf2026-03-31"
      decimals="-5"
      id="Fact000928"
      unitRef="USD">200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="AsOf2025-03-31"
      decimals="-5"
      id="Fact000930"
      unitRef="USD">100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2025-04-01to2026-03-31" id="Fact000932">&lt;p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zoq7zmHFHfej" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zCmkfEn80O85"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures the cost of employee and non-employee services received in exchange for an award of equity instruments based on the
grant date fair value of the award. Fair value for restricted stock unit awards is valued using the closing price of the Company&#x2019;s
common stock on the date of grant. The grant date fair value is recognized over the requisite service period during which an employee
and non-employee is required to provide service in exchange for the award, using the accelerated method with each tranche being expensed
over its vesting period. The grant date fair value of employee and non-employee share options is estimated using the Black-Scholes option
pricing model. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term
of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception
and does not anticipate paying dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Starting in 2023,
Beyond Air used its own historical volatility as an input for expected volatility, but due to Beyond Cancer&#x2019;s and NeuroNos&#x2019;
lack of marketability, the Company utilizes the implied volatility based on an aggregate of guideline companies for expected volatility.
The Company uses the simplified method to estimate the expected term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <XAIR:SupplierConcentrationPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000934">&lt;p id="xdx_844_ecustom--SupplierConcentrationPolicyTextBlock_zKF0PPuy2u2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_znqew8oyzWYi"&gt;Supplier
Concentration&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company relies on third-party suppliers to provide materials for its devices and consumables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the year ended March 31, 2026, the Company purchased approximately &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FirstThirdPartyVendorsMember_zWOjQrfo8Lg9" title="Concentration percentage"&gt;74&lt;/span&gt;% and &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondThirdPartyVendorsMember_zPKH5GFKgKkk" title="Concentration percentage"&gt;18&lt;/span&gt;% of its materials from two third-party vendors. In the
year ended March 31, 2025, the Company purchased approximately &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorsMember_zzzCD2frilml" title="Concentration percentage"&gt;85&lt;/span&gt;% of its materials from one third-party vendor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</XAIR:SupplierConcentrationPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-04-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_FirstThirdPartyVendorsMember"
      decimals="INF"
      id="Fact000936"
      unitRef="Pure">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-04-012026-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_SecondThirdPartyVendorsMember"
      decimals="INF"
      id="Fact000938"
      unitRef="Pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-04-012025-03-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_ThirdPartyVendorsMember"
      decimals="INF"
      id="Fact000940"
      unitRef="Pure">0.85</us-gaap:ConcentrationRiskPercentage1>
    <XAIR:CustomerrConcentrationPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000942">&lt;p id="xdx_849_ecustom--CustomerrConcentrationPolicyTextBlock_zt0y7eVOQCR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zZK72rqbNr5k"&gt;Customer
Concentration&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended March 31, 2026, the Company derived &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zYh7HM53rlHa" title="Concentration percentage"&gt;11&lt;/span&gt;% and &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250401__20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zqCNA4uF7rjc" title="Concentration percentage"&gt;10&lt;/span&gt;% of its revenues from two customers. For the year ended March 31, 2025,
the Company derived &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_z8mTZnZnEwR7" title="Concentration percentage"&gt;16&lt;/span&gt;% and &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zjovfV2GnvV8" title="Concentration percentage"&gt;10&lt;/span&gt;% of its revenues from two customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</XAIR:CustomerrConcentrationPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-04-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember"
      decimals="INF"
      id="Fact000944"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-04-012026-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember"
      decimals="INF"
      id="Fact000946"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-04-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember"
      decimals="INF"
      id="Fact000948"
      unitRef="Pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-04-012025-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember"
      decimals="INF"
      id="Fact000950"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000952">&lt;p id="xdx_847_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zYiYbUZ0aaWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zBR8SZsHLuE4"&gt;Licensed
Right to Use Technology&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Licensed
right to use technology that is considered platform technology with alternative future uses is recorded as an intangible asset and is
amortized on a straight-line method over its estimated useful life, determined to be thirteen years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zPqdqDxadk6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
expected amortization expense for the next five years and thereafter is as follows for the year ended March 31 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zfGTZeVvBHb1" style="display: none"&gt;SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20260331_zTDHWIObOgA5" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANz72H_ztGt05u0vLWc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANz72H_zdQScyCDpJTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANz72H_zdimKZ1UaNT8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANz72H_zoImxPVfM5fi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANz72H_zoRKAth2Mncg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2031&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANz72H_ziR28fJCHfik" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,018&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z0prWWE0AGMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000954">&lt;p id="xdx_894_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zPqdqDxadk6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
expected amortization expense for the next five years and thereafter is as follows for the year ended March 31 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zfGTZeVvBHb1" style="display: none"&gt;SCHEDULE OF FUTURE EXPECTED AMORTIZATION EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20260331_zTDHWIObOgA5" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANz72H_ztGt05u0vLWc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANz72H_zdQScyCDpJTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANz72H_zdimKZ1UaNT8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANz72H_zoImxPVfM5fi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANz72H_zoRKAth2Mncg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2031&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANz72H_ziR28fJCHfik" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,018&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000956"
      unitRef="USD">205000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000958"
      unitRef="USD">205000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000960"
      unitRef="USD">205000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000962"
      unitRef="USD">205000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000964"
      unitRef="USD">198000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000966"
      unitRef="USD">1018000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000968">&lt;p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zWfi9ADUtDcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_z8VqivzDPyKg"&gt;Long-Lived
Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses the impairment of long-lived assets on an ongoing basis and whenever events or changes in circumstances indicate that
the carrying value may not be recoverable. Factors that the Company considers as potential triggers of an impairment review include the
following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    underperformance relative to expected historical or projected future operating results,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    changes in the manner of the Company&#x2019;s use of the acquired assets or the strategy for its overall business,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    negative regulatory or economic trends, and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant
    technological changes, which would render the platform technology, equipment, and manufacturing processes obsolete. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recoverability
of assets that will continue to be used in the Company&#x2019;s operations is measured by comparing the carrying value to the future net
undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future
revenues, driven by market growth rates, and estimates of future costs. There were no events during the reporting periods that were deemed
to be a triggering event that would require an impairment assessment, other than the impairment of $&lt;span id="xdx_900_eus-gaap--OtherAssetImpairmentCharges_pn5n6_c20240401__20250331_zfqvadaSCqaj" title="Other asset impairment charges"&gt;0.5&lt;/span&gt; million recorded during the year
ended March 31, 2025 associated with certain R&amp;amp;D assets following Management&#x2019;s decision to put its VCAP clinical trial on hold.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="From2024-04-012025-03-31"
      decimals="-5"
      id="Fact000970"
      unitRef="USD">500000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000972">&lt;p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_z1EpRTJlMHf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_z6dWFnrUzn86"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities
and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are
recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than
not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future
deductibility is uncertain. As of March 31, 2026 and March 31, 2025, the Company recorded a valuation allowance to the full extent of
the Company&#x2019;s net deferred tax assets since the likelihood of realization of the benefit does not meet the more-likely-than-not
threshold.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s reserves related to taxes are based on a determination of whether and how much of a tax benefit taken by the Company
in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related
to the tax benefit. The Company would recognize both estimated accrued interest and penalties related to unrecognized benefits within
income tax expense in the consolidated statements of operations and comprehensive loss. The Company&#x2019;s uncertain tax positions are
related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position,
the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which
a loss carryforward is available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000974">&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zUjUHEdFaDd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zboUTYq1V7Xd"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to Beyond Air, Inc.,
by the weighted average number of shares of common stock outstanding for the period. The dilutive effect of outstanding options, warrants,
restricted stock and other stock-based compensation awards is reflected in diluted net loss per share by application of the treasury
stock method. The calculation of diluted net loss attributed to common stockholders per share excludes all anti-dilutive shares of common
stock. For periods in which the Company has reported net losses, diluted net loss per share attributable to common stockholders is the
same as basic net loss per share attributable to common stockholders, because such shares of common stock are not assumed to have been
issued if their effect is anti-dilutive (Note 8).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="From2025-04-01to2026-03-31" id="Fact000976">&lt;p id="xdx_84C_eus-gaap--ConsolidationVariableInterestEntityPolicy_zXmJuTlw0mS" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zvtldgtakaPf"&gt;Variable
Interest Entity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Company has the power to direct activities of both Beyond Cancer and NeuroNos  that most significantly impact their economic
performance and the right to receive benefits and losses that may potentially be significant, these financial statements are fully consolidated
with those of the Company. The non-controlling owners&#x2019; &lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20260331__srt--OwnershipAxis__custom--BeyondCancerLtdMember_zVO1dsDjeZKb" title="Non-controlling owners interest"&gt;20&lt;/span&gt;% interest in Beyond Cancer&#x2019;s net assets and result of operations
and the non-controlling owners&#x2019; &lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20260331__srt--OwnershipAxis__custom--NeuroNosLtdMember_zGruHsD1j4A8" title="Non-controlling owners interest"&gt;15.25&lt;/span&gt;% interest in NeuroNos&#x2019; net assets and result of operations are reported as &#x201c;non-controlling
interest&#x201d; on the Company&#x2019;s consolidated balance sheets and as &#x201c;net loss attributable to non-controlling interest&#x201d;
in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember"
      decimals="INF"
      id="Fact000978"
      unitRef="Pure">0.20</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember"
      decimals="INF"
      id="Fact000980"
      unitRef="Pure">0.1525</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000982">&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z2e5hTyHtoI" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z3xqho5VK4fa"&gt;Recently
Adopted Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;)
2023-09, &lt;i&gt;Improvements to Tax Disclosures (Topic 740), &lt;/i&gt;to enhance the disclosures related to income taxes, including the rate
reconciliation and information on income taxes paid. This ASU is effective for fiscal years beginning after December 15, 2024
(fiscal 2026 for the Company), with early adoption permitted. The Company adopted this standard effective April 1, 2025
prospectively. See Note 11, &#x201c;Income Taxes,&#x201d; for further information regarding the
Company&#x2019;s effective income tax.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <XAIR:RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000984">&lt;p id="xdx_84D_ecustom--RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_zypEtiThyZ79" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_ztIW2GOFmu92"&gt;Recently
Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40).&lt;/i&gt; This standard requires disclosure of specific information about costs and expenses and becomes effective for fiscal
years beginning after December 15, 2026 (fiscal 2028 for the Company), with early adoption permitted. The Company is assessing the impact
of this ASU and, upon adoption, may be required to include certain additional disclosures in the footnotes to the Consolidated Financial
Statements.&lt;/span&gt;&lt;/p&gt;

</XAIR:RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000986">&lt;p id="xdx_800_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zknGdoUxPgC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &lt;span id="xdx_82F_zCAFy9urtsij"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zMLxG8Xv4tae" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_za6Zd0dRYAWe" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20260331_zDU3FrgE1UK3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250331_z8F8ZR3n9Atd" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember_zIGK6yflbM0b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Clinical and medical equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;206&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,048&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentDeployableAsPartOfServiceOfferingMember_zSOgUnmfLmx6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Equipment deployable as part of a service offering&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,511&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpz3vKbJKZ4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;927&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zlu4qQjjp4k8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;506&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zN2v5XsHcI9d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;521&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;521&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzruM_zdxqruQDXCsk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,513&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzruM_zd7ivrOPoKl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,660&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,500&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzruM_zqkpMFbHCKn2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
    and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,249&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,013&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zxjZ6EdJJSVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
and amortization for the years ended March 31, 2026 and March 31, 2025 was $&lt;span id="xdx_901_eus-gaap--DepreciationAndAmortization_pn5n6_c20250401__20260331_zTuSWbKYOdD5" title="Depreciation and amortization"&gt;3.1&lt;/span&gt; million and $&lt;span id="xdx_90D_eus-gaap--DepreciationAndAmortization_pn5n6_c20240401__20250331_zwk7UJyxPls9" title="Depreciation and amortization"&gt;3.0&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact000988">&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zMLxG8Xv4tae" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_za6Zd0dRYAWe" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20260331_zDU3FrgE1UK3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250331_z8F8ZR3n9Atd" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalAndMedicalEquipmentMember_zIGK6yflbM0b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Clinical and medical equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;206&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,048&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentDeployableAsPartOfServiceOfferingMember_zSOgUnmfLmx6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Equipment deployable as part of a service offering&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,511&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpz3vKbJKZ4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;927&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zlu4qQjjp4k8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;506&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zN2v5XsHcI9d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;521&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;521&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzruM_zdxqruQDXCsk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,513&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzruM_zd7ivrOPoKl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,660&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,500&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzruM_zqkpMFbHCKn2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
    and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,249&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,013&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_custom_ClinicalAndMedicalEquipmentMember"
      decimals="-3"
      id="Fact000990"
      unitRef="USD">206000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-03-31_custom_ClinicalAndMedicalEquipmentMember"
      decimals="-3"
      id="Fact000991"
      unitRef="USD">1048000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_custom_EquipmentDeployableAsPartOfServiceOfferingMember"
      decimals="-3"
      id="Fact000993"
      unitRef="USD">13871000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-03-31_custom_EquipmentDeployableAsPartOfServiceOfferingMember"
      decimals="-3"
      id="Fact000994"
      unitRef="USD">13511000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="Fact000996"
      unitRef="USD">853000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-03-31_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="Fact000997"
      unitRef="USD">927000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact000999"
      unitRef="USD">458000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-03-31_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact001000"
      unitRef="USD">506000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact001002"
      unitRef="USD">521000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-03-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact001003"
      unitRef="USD">521000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001005"
      unitRef="USD">15909000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001006"
      unitRef="USD">16513000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001008"
      unitRef="USD">7660000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001009"
      unitRef="USD">5500000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001011"
      unitRef="USD">8249000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001012"
      unitRef="USD">11013000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-04-01to2026-03-31"
      decimals="-5"
      id="Fact001014"
      unitRef="USD">3100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-04-012025-03-31"
      decimals="-5"
      id="Fact001016"
      unitRef="USD">3000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001018">&lt;p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zgbqHstXpIc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &lt;span id="xdx_823_z2bzvYxgVhx7"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 10, 2025, the Company entered into an At-The-Market Equity Offering Sales Agreement with BTIG, Inc. (the &#x201c;2025 ATM&#x201d;).
Under the 2025 ATM, the Company may sell shares of its common stock having aggregate sales proceeds of up to $&lt;span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20250210__20250210__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember_zeIU2Z6ZhADc"&gt;35.0&lt;/span&gt; million, from time
to time and at various prices. If shares of the Company&#x2019;s common stock are sold, there is a&lt;span id="xdx_902_ecustom--SaleOfStockFeePercentage_pid_dp_uPure_c20250210__20250210__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember_zJTEkPL3x7gd" title="Sale of stock fee percentage"&gt; 2.5&lt;/span&gt;% fee paid to the sales agent. Pursuant
to the &#x201c;baby shelf rules&#x201d; promulgated by the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;), if the Company&#x2019;s public float is less than $&lt;span id="xdx_90B_ecustom--PublicFloatValue_iI_pn5n6_c20250210__srt--RangeAxis__srt--MaximumMember_zLygtgUpxcnj" title="Public float value"&gt;75.0&lt;/span&gt; million as of specified
measurement periods, the number of shares of common stock that may be offered and sold by the Company under a Form S-3 registration statement,
including pursuant to the 2025 ATM, in any twelve-month period is limited to an aggregate amount that does not exceed one-third of the
Company&#x2019;s public float. As of March 31, 2026, due to the SEC&#x2019;s &#x201c;baby shelf rules,&#x201d; the Company may currently
not sell any shares of common stock pursuant to the 2025 ATM. The Company will remain subject to the &#x201c;baby shelf rules&#x201d; under
the Form S-3 registration statement until such time as its public float exceeds $&lt;span id="xdx_90F_ecustom--PublicFloatValue_iI_pn5n6_c20250210__srt--RangeAxis__srt--MaximumMember_zfFcQoG5Qisj" title="Public float value"&gt;75.0&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended March 31, 2026, the Company received net proceeds of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember_zVVQzppfBhGa" title="Sale of net proceeds"&gt;8.1&lt;/span&gt; million from the sale of &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember_zCDBFQ3984X4" title="Number of shares issued in transaction"&gt;2,441,775&lt;/span&gt; shares of common stock through
the 2025 ATM. During the year ended March 31, 2025, the Company received net proceeds of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240401__20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSuX9wEFBw7a" title="Sale of net proceeds"&gt;2.1&lt;/span&gt; million from the sale of &lt;span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240401__20250331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyFiveATMMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7G3641MMQa5" title="Number of shares issued in transaction"&gt;337,100&lt;/span&gt; shares
of common stock through the 2025 ATM.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 4, 2025, the Company entered into an equity purchase agreement (the &#x201c;Streeterville Purchase Agreement&#x201d;) with
Streeterville Capital, LLC (&#x201c;Streeterville&#x201d;) for the purchase of up to $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn6n6_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_znOjc9Zwtdzf" title="Share purchase value"&gt;20&lt;/span&gt;
million of the Company&#x2019;s shares of Common Stock. In connection with the Streeterville Purchase Agreement, Streeterville and
the Company entered into a Registration Rights Agreement, pursuant to which the Company filed a registration statement for the
resale of up to &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zDDznPqtRfOh" title="Shares available for resale"&gt;1,600,000&lt;/span&gt;
shares of Common Stock (the &#x201c;Registration Statement&#x201d;). During January 2026, Streeterville elected to purchase &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z52Ft1NKzaF5" title="Shares available for resale"&gt;1.6&lt;/span&gt; million shares of common stock with an average fair market
value of $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zBKQRmndzor3" title="Price per share"&gt;2.09&lt;/span&gt; per share over each issuance date, resulting in approximately $&lt;span id="xdx_907_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_pn5n6_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zGyjGeXSmCmg" title="Adjustments in additional paid in capital"&gt;3.3&lt;/span&gt; million recorded to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Streeterville Purchase Agreement (so long as there is no balance outstanding on the Note (Note 9), the Company has the right,
but not the obligation, to direct Streeterville, by delivery to Streeterville of a put notice from time to time during a period of up
to two years, to purchase shares of Common Stock (i) in a minimum amount not less than $&lt;span id="xdx_908_eus-gaap--PaymentsForRepurchaseOfCommonStock_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zpv9aIITfbb6" title="Common stock minimum purchase amount"&gt;25,000&lt;/span&gt;, and (ii) in a maximum amount up to the
median daily trading volume of the Common Stock during the five trading days immediately preceding delivery of the put notice, or such
other greater amount mutually agreed upon by the parties; provided, however, that the number of put shares shall not exceed the beneficial
ownership limitation, of &lt;span id="xdx_90D_ecustom--BeneficialOwnershipLimitationPercentage_iI_pid_dp_uPure_c20251104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zpoGWaSpC8C8" title="Beneficial ownership limitation percentage"&gt;4.99&lt;/span&gt;% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock issuable pursuant to a put notice.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 14, 2026, the Company entered into the Securities Purchase Agreement with an institutional investor pursuant to which the Company
sold, in a private placement offering, an aggregate of (i) &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260114__20260114__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWTvubm0W5Be" title="Stock issued during the period, shares"&gt;524,990&lt;/span&gt; shares of common stock (ii) &lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_znYpEJq6iY32" title="Purchase warrants"&gt;3,405,828&lt;/span&gt; pre-funded stock purchase warrants,
(the &#x201c;2026 Pre-funded Warrants&#x201d;) and (iii) &lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixCommonWarrantsMember_z4phR7Yseq9f" title="Purchase warrants"&gt;3,930,818&lt;/span&gt; stock purchase warrants (the &#x201c;2026 Common Warrants&#x201d; and
together with the 2026 Pre-funded Warrants, the &#x201c;2026 Warrants&#x201d;). Each common share and accompanying 2026 Common Warrant
were sold together at a combined offering price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260114__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7tgU63ae217" title="Common  stock warrant offering price"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixCommonWarrantsMember_zTqwSFJvTRqa" title="Common  stock warrant offering price"&gt;1.272&lt;/span&gt;&lt;/span&gt; per share, and each 2026 Pre-Funded Warrant was sold at an offering price of
$&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_zzZkt8yUcgBe" title="Common  stock warrant offering price"&gt;1.2719&lt;/span&gt; per 2026 Pre-funded Warrant for gross proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfWarrants_pn6n6_c20260114__20260114__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_z6EHlv298lWb" title="Proceeds from issuance of warrants"&gt;5.0&lt;/span&gt; million. The 2026 Pre-Funded Warrants have an exercise price of $&lt;span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20260116__20260116__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_z8Go3PBAMiyg" title="Warrant exercise price"&gt;0.0001&lt;/span&gt;
per share, and the 2026 Common Warrants have an exercise price of $&lt;span id="xdx_902_eus-gaap--WarrantExercisePriceIncrease_c20260114__20260114__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_zFn9LGBLK7w5" title="Warrant exercise price"&gt;1.147&lt;/span&gt; per share. The private placement offering closed on January
16, 2026. The Company received total net proceeds of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250401__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z1561Zkn5Jkg" title="Proceeds from private placement"&gt;4.5&lt;/span&gt; million after deductions for placement agent commissions and other offering
costs of $&lt;span id="xdx_90E_eus-gaap--PaymentsForCommissions_pn5n6_c20250401__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z13PQlq2Khm" title="Commission paid"&gt;0.3&lt;/span&gt; million and $&lt;span id="xdx_90E_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zptzsNoadK86" title="Deferred costs current"&gt;0.2&lt;/span&gt; million, respectively, during the year ended March 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 STOCKHOLDERS&#x2019; EQUITY (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock
Option Plans&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Eighth Amended and Restated 2013 Beyond Air Equity Incentive Plan (the &#x201c;2013 BA Plan&#x201d;) allows for awards
to officers, directors, employees, and consultants of stock options, restricted stock units and restricted shares of the Company&#x2019;s
common stock. On November 25, 2025, the Company&#x2019;s Board of Directors approved an amendment to the 2013 BA Plan to increase the
number of shares in the 2013 BA Plan by &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20251125__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zVsR1uSTAMB3" title="Stock option shares authorized for issuance"&gt;850,000&lt;/span&gt;, which was approved by the Company&#x2019;s stockholders at the 2026 annual stockholder
meeting on January 30, 2026. The 2013 BA Plan has &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRxr6sjZ04Sd" title="Stock option shares authorized for issuance"&gt;1,680,000&lt;/span&gt; shares authorized for issuance. As of March 31, 2025, &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zK2utwD7IXq6" title="Stock option available shares"&gt;894,276&lt;/span&gt; shares were
available under the 2013 BA Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value for the restricted stock unit awards was valued at the closing price of the Company&#x2019;s common stock on the date of grant.
Restricted stock units vest annually over &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zp3oWF5SWlp8" title="Vesting period"&gt;five years&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zLPikjit4Xa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s restricted stock unit awards for the years ended March 31, 2026 and March 31, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zExED22KtKVf" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK AWARDS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number Of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average Grant&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Date Fair &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Unvested as of March 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6MuNpET45r8" style="width: 16%; text-align: right" title="Unvested Number of Shares, Beginning balance"&gt;30,945&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB0SKhNOdUK3" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"&gt;139.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzCJpLPJ4tW7" style="text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1087"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zW9veaMoeSR8" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1089"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMg8cv71H9Og" style="text-align: right" title="Number of Shares, Vested"&gt;(12,240&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zbnKrhCW15E" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested"&gt;137.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkc6cTHzSkZ2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeited"&gt;(440&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjoEnOhgqtnl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;229.60&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Unvested as of March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zeg4dH5hz1Ul" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested Number of Shares, Beginning balance"&gt;18,265&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1iho2up2q8b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"&gt;139.40&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zlnBw6qwW5lf" style="text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1103"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zroJU2kT7Eq8" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1105"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB3PfQsrwQCg" style="text-align: right" title="Number of Shares, Vested"&gt;(8,630&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjrLsw2vGFIe" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested"&gt;150.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zacVs3383fwl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeited"&gt;(150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhQ6nv5gB0rg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;137.40&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Unvested as of March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zx0uM3ife9Ta" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested Number of Shares, Ending balance"&gt;9,485&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyzVzIbf5x27" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, ending balance"&gt;129.41&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zGi1YhK8Cy3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation expense related to these stock issuances for the years ended March 31, 2026 and March 31, 2025 was $&lt;span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20250401__20260331_z7HQw3yN6kL8" title="Employee benefits and share based compensation"&gt;0.5&lt;/span&gt; million and $&lt;span id="xdx_906_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20240401__20250331_z7p8ylKZbkfa" title="Employee benefits and share based compensation"&gt;1.0
&lt;/span&gt;million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2026, the Company had unrecognized stock-based compensation expense for the restricted stock unit awards in the 2013 BA
Plan of approximately $&lt;span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandThirteenBAPlanMember_zpeMcRV8t2f3" title="Share based compensation"&gt;0.3&lt;/span&gt; million, which is expected to be expensed over the weighted average remaining service period of &lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zb6nOFhmwMc3" title="Weighted average remaining service, period"&gt;1.0&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2026, all vested shares had been issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 STOCKHOLDERS&#x2019; EQUITY (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
vesting terms of the options issued under the 2013 BA Plan are generally &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zfI8jrxnK5Re" title="Vesting period"&gt;four years&lt;/span&gt; and expire &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zPcgrtQL7ulg" title="Expiration period"&gt;ten years&lt;/span&gt; from the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcILgvnqjbS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the change in stock options for the years ended March 31, 2026 and March 31, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zPMO2ul4ry35" style="display: none"&gt;SCHEDULE OF OPTION ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&#x2013;-&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life- &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Options outstanding as of March 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zDIuTD1HmBn" style="width: 11%; text-align: right" title="Number of Options, Outstanding at beginning of period"&gt;566,645&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRrEUPyqxF9d" style="width: 11%; text-align: right" title="Weighted Average Exercise Price - Options, Outstanding at beginning of period"&gt;88.39&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zfw3evrr2Fr4" title="Weighted Average Remaining Contractual Life - Options"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zylzEpHSyxIi" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"&gt;760&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zoGAg1pOcH3b" style="text-align: right" title="Number of Options Outstanding, Granted"&gt;227,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRupONoHugJj" style="text-align: right" title="Weighted Average Exercise Price - Options, Granted"&gt;6.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zquTALQYQDWd" style="text-align: right" title="Number of Options Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1145"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zVGjiqWEuihd" style="text-align: right" title="Weighted Average Exercise Price - Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1147"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zLvDY8NIKuYd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Forfeited"&gt;(54,976&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zVt55UyXj6sf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Options, Forfeited"&gt;61.74&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Options outstanding as of March 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zNHc46gRgZF3" style="text-align: right" title="Number of Options, Outstanding at beginning of period"&gt;739,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zAkxzGO3xqE7" style="text-align: right" title="Weighted Average Exercise Price - Options, Outstanding at beginning of period"&gt;9.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRMUh8b5pHG5" title="Weighted Average Remaining Contractual Life - Options, Outstanding at beginning of period"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zdQWrl0Ptc3c" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1159"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zb0DsRAuUdI1" style="text-align: right" title="Number of Options Outstanding, Granted"&gt;94,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zKPnzEy7Uty3" style="text-align: right" title="Weighted Average Exercise Price - Options, Granted"&gt;0.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zuv9Dih4ZqF3" style="text-align: right" title="Number of Options Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1165"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zdBZ78oloXib" style="text-align: right" title="Weighted Average Exercise Price - Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_z63B4wYthsHf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Forfeited"&gt;(77,270&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zMHfWM2AW9B2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Options, Forfeited"&gt;1.95&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding as of March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcVHxVYaJAw2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at ending of period"&gt;756,749&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_z28O37ZACZJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options, Outstanding at ending of period"&gt;1.82&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zSybYciOzyp5" title="Weighted Average Remaining Contractual Life - Options, Outstanding at end of period"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zjffWXBkOv75" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at end of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1179"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable as of March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcU09AUzmzRi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Exercisable"&gt;497,591&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zZWvfCXaIUQ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options, Exercisable"&gt;1.95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zc3N8Wp4PdLi" title="Weighted Average Remaining Contractual Life - Options, Exercisable"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zONx7x7i0Pkc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1187"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zupB4LrDc0Sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2026, the Company had unrecognized stock-based compensation expense for the stock options in the 2013 BA Plan of approximately
$&lt;span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityIncentivePlanMember_zsRiif8TSjNi" title="Unrecognized stock-based compensation expense"&gt;1.7&lt;/span&gt; million which is expected to be expensed over the weighted average remaining service period of &lt;span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityIncentivePlanMember_zcKNzMhoHNuf" title="Weighted average remaining service period"&gt;1.7 &lt;/span&gt;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended March 31, 2026 and March 31, 2025, the weighted average fair value of options granted was $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zlpLvLlXYavi" title="Weighted average fair value of options granted"&gt;0.80&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcGG23degHWi" title="Weighted average fair value of options granted"&gt;5.03&lt;/span&gt; per share,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 27, 2026, the Company executed a Separation and Release of Claims Agreement with the former CEO, Steven Lisi (&#x201c;Release Agreement&#x201d;).
All unvested options held by Mr. Lisi as of March 27, 2026, were accelerated and immediately vested, and remain exercisable for twenty-four
months from March 27, 2026. The Company recorded $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20260327__20260327_zecRCsZ4qK47" title="Share compensation expense"&gt;0.1&lt;/span&gt; million of non-cash stock compensation expense reflecting the acceleration of expense
recognition of these equity awards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 4, 2025, the Company&#x2019;s Board of Directors approved a  stock option repricing of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251104__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9IOg0ad5b4j" title="Option repricing"&gt;726,618&lt;/span&gt;
options (the &#x201c;2026 Option Repricing&#x201d;), effective November 4, 2025. The 2026 Option Repricing was undertaken in
accordance with, and as permitted by, the Company&#x2019;s 2013 BA Plan. Pursuant to the 2026 Option Repricing, all options granted
pursuant to the 2013 BA Plan that are held by Company Board members, officers, and employees expected to continue providing services
to the Company were repriced, to the extent such options had an exercise price in excess of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_c20251104__20251104__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zupOm3WT8XFl" title="Exercise price in excess"&gt;1.95&lt;/span&gt;,
the closing price per share of the Company&#x2019;s common stock as reported on The Nasdaq Stock Market on November 3, 2025. All such
options were repriced such that the exercise price per share was reduced to $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_c20251104__20251104__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqtMWmaGajge" title="Exercise price in excess"&gt;1.95&lt;/span&gt;.
The modification resulted in incremental stock compensation expense of $&lt;span id="xdx_90E_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_pn5n6_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwJ4LKvwi23j" title="Incremental stock compensation expense"&gt;0.3&lt;/span&gt;
million recognized during the year ended March 31, 2026. There is approximately $&lt;span id="xdx_906_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_pn5n6_c20250401__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv2zFyzwkV2i" title="Incremental stock compensation expense"&gt;0.1&lt;/span&gt;
million of unrecognized stock-based compensation expense for the 2026 Option Repricing which is expected to be expensed over the
weighted average remaining service period of &lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8GgcLZxmMqi" title="Weighted average remaining service, period"&gt;1.5&lt;/span&gt;
years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 22, 2024, the Company&#x2019;s Board of Directors approved a  stock option repricing (&#x201c;2025 Option
Repricing&#x201d;), effective November 22, 2024 (&#x201c;Effective Date&#x201d;). The 2025 Option Repricing was undertaken in
accordance with, and as permitted by, the Company&#x2019;s Amended 2013 Plan. Pursuant to the 2025 Option Repricing, all options
granted pursuant to the Amended 2013 Plan that are held by Company Board members, officers, and employees expected to continue
providing services to the Company were repriced, to the extent such options had an exercise price in excess of $&lt;span id="xdx_905_eus-gaap--StockOptionExercisePriceIncrease_c20241122__20241122__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_z0rsuvyTo3o7" title="Option exercise price"&gt;10.80&lt;/span&gt;,
the closing price per share of the Common Stock as reported on The Nasdaq Stock Market on November 22, 2024. As of the Effective
Date, all such options were repriced such that the exercise price per share was reduced to $&lt;span id="xdx_90E_eus-gaap--StockOptionExercisePriceIncrease_c20241122__20241122__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zsObHSdTdk2g" title="Option exercise price"&gt;10.80&lt;/span&gt;.
The modification resulted in incremental stock compensation expense of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pn5n6_c20250401__20260331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zDDutejXQDq6" title="Stock based compensation"&gt;0.3&lt;/span&gt;
million and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pn5n6_c20240401__20250331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zfvgpZ0uQEsf" title="Stock based compensation"&gt;1.6&lt;/span&gt;
million recognized during the years ended March 31, 2026 and March 31, 2025, respectively. There is approximately $&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20260331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zAOkbh72vTs6" title="Unrecognized share based compensation"&gt;0.1&lt;/span&gt;
million of unrecognized stock-based compensation expense for the 2025 Option Repricing which is expected to be expensed over the
weighted average remaining service period of &lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyFiveOptionRepricingMember_zvv4n4uVfeua" title="Weighted average remaining service, period"&gt;1.0&lt;/span&gt;
years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 STOCKHOLDERS&#x2019; EQUITY (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s 2021 Beyond Cancer Ltd. Equity Incentive Plan (the &#x201c;2021 BC Plan&#x201d;) allows for awards to officers, directors,
employees, and consultants of stock options, restricted stock units and restricted shares of Beyond Cancer Ltd.&#x2019;s common stock.
The vesting terms of the options issued under the 2021 BC Plan are generally &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zLWQXUFSoA44" title="Vesting period"&gt;four years&lt;/span&gt; and they expire &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_ze5Wci8JlHvg" title="Expiration period"&gt;ten years&lt;/span&gt; from the grant date.
On November 3, 2022, the Company&#x2019;s Board of Directors approved an amendment to reserve for issuance an additional &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20221103__20221103__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z8RMuCVDnyid" title="Number of additionl shares reserve for issuance"&gt;2,000,000&lt;/span&gt; shares
of common stock. The 2021 BC Plan has &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20221103__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zWjat4ZfK3Kc" title="Number of shares authorized for issuance"&gt;4,000,000&lt;/span&gt; shares authorized for issuance. As of March 31, 2026, &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_ztc8XZqE76fb" title="Number of shares available for grant"&gt;1,745,500&lt;/span&gt; shares were available
under the 2021 BC Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zIGS8sGiUi2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the change in stock options for Beyond Cancer for the years ended March 31, 2026 and March 31, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zfNCVrREUPoa" style="display: none"&gt;SCHEDULE
OF OPTION ACTIVITY FOR BEYOND CANCER&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&#x2013;-&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life- &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Options outstanding as of March 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zltD0lFKYr29" style="width: 11%; text-align: right" title="Number of Options, Outstanding at beginning of period"&gt;3,819,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zPStOfDJJPha" style="width: 11%; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period"&gt;5.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zC49XGIPXeB4" title="Weighted average remaining contractual life - options, outstanding at beginning of period"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zQkQLohCA7H2" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z9HQ10n1f8q1" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1243"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXJCIIyEQqsi" style="text-align: right" title="Weighted Average Exercise Price of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1245"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zltdWXYxbUwe" style="text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1247"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zlfL50p2nf13" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1249"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zJVpcZOWGyt5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(1,002,750&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zAOoFNdvqLue" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price of Options, Forfeited"&gt;5.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding as of March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXK1Ydo1CHvg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at beginning of period"&gt;2,816,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_ziyVB8iwOtZ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period"&gt;5.50&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXJXgcJK8rt6" title="Weighted average remaining contractual life - options, outstanding at beginning of period"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zxp6GCLrGnW5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1261"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zlzImYg5etR9" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1263"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zZDm8lqi3LR7" style="text-align: right" title="Weighted Average Exercise Price of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zoq5ry3qY7ag" style="text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1267"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zD5GzidrBIub" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1269"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBUKt3EcL5bd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(561,750&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z3mQDWmOLBU7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price of Options, Forfeited"&gt;5.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding as of March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z5dckoFlZlg9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at ending of period"&gt;2,254,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zyCXarkEuvMa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at ending of period"&gt;5.50&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zIckJ2fTos8i" title="Weighted average remaining contractual life - options, outstanding at beginning of period"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zqkBxlY4doP" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding at end of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1281"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable as of March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBQOTMmBnKuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Exercisable"&gt;1,975,750&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBInmxPusKql" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Exercisable"&gt;5.50&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zC6JnOcvBVvk" title="Weighted Average Remaining Contractual Life of Options, Exercisable"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zmg18381u15a" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zpuVNGb6PPE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2026, the Company had unrecognized stock-based compensation expense for the stock options in the 2021 BC Plan of approximately
$&lt;span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zNY33knzW7lc" title="Unrecognized stock-based compensation expense"&gt;0.4&lt;/span&gt; million which is expected to be expensed over the weighted average remaining service period of &lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zcvrBj2eEqGi" title="Weighted average remaining service period"&gt;1.0&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s 2023 NeuroNos Ltd. Equity Incentive Plan (the &#x201c;2023 NNOS Plan&#x201d;) allows for awards to officers, directors,
employees, and consultants of stock options, restricted stock units and restricted shares of NeuroNos Ltd.&#x2019;s common stock. The
vesting terms of the options issued under the 2023 NNOS Plan are generally four years and they expire ten years from the grant date.
On March 31, 2025, the Company&#x2019;s Board of Directors approved to reserve for issuance &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zBNAjntTRQ85" title="Stock option shares authorized for issuance"&gt;1,725,000&lt;/span&gt; shares of common stock. As of March
31, 2026, &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zFZlWNrsgHt" title="Number of shares available for grant"&gt;465,670&lt;/span&gt; shares were available under the 2023 NNOS Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zh9GKH4NRrL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the change in stock options for NeuroNos for the years ended March 31, 2026 and March 31, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zzqGzZlZI6Se"&gt;SCHEDULE
OF OPTION ACTIVITY FOR NEURONOS&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&#x2013;-&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life- &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Options outstanding as of March 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zzh1y1MycSpa" style="text-align: right" title="Number of Options, Outstanding at beginning of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1301"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zePHo2mON8Nk" style="text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zRuWKHUO1Mxc" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1305"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zKXJyXen5OXc" style="width: 11%; text-align: right" title="Number of Options, Granted"&gt;1,224,139&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z3HPlgV7lHh9" style="width: 11%; text-align: right" title="Weighted Average Exercise Price of Options, Granted"&gt;0.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zBGUDjzUIFMg" style="text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1311"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zYMwGOOXRvJi" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1313"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zapFoZDRg2ni" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1315"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zEolIhcf8rt8" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price - options, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1317"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding as of March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zgHjMFZpIVri" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at beginning of period"&gt;1,224,139&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zqTaYDZ2V9xf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period"&gt;0.14&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zzFD91herDCk" title="Weighted average remaining contractual life - options, outstanding at beginning of period"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_za87e7pYMJwa" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"&gt;3,501&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z5YWYvHEN6g1" style="text-align: right" title="Number of Options, Granted"&gt;169,913&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_ziEsb2HyfQW3" style="text-align: right" title="Weighted Average Exercise Price of Options, Granted"&gt;3.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zecF9JIVa7hf" style="text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1331"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z3K6NYELNkK4" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1333"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zCx9aDsAiMYh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(134,723&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zRDQ9XILrgp" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price - options, forfeited"&gt;2.82&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding as of March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zfEaOkfKvcG1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at ending of period"&gt;1,259,329&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zx5hb3vD5vla" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at ending of period"&gt;0.24&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zhz8aKY5TdIa" title="Weighted Average Remaining Contractual Life of Options, Outstanding"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_znqU4pApiRS8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at ending of period"&gt;3,477&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable as of March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zCGea6Lpnox2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Exercisable"&gt;622,341&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zNIF39u3q2A1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Exercisable"&gt;0.19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zLCSAYm36C8j" title="Weighted Average Remaining Contractual Life of Options, Exercisable"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_znZ7QXjs68d9" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;1,748&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zVs91w4EOC65" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, the Company had unrecognized stock-based compensation expense for the stock options in the 2023 NNOS Plan of approximately
$&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zagRgEKWfWx7" title="Unrecognized stock-based compensation expense"&gt;0.1&lt;/span&gt; million which is expected to be expensed over the weighted average remaining service period of &lt;span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_ze9eKe5Zg4K6" title="Weighted average remaining service period"&gt;1.5&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended March 31, 2026 and March 31, 2025, the weighted average fair value of options granted was $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z4oMCTJiTphg" title="Weighted average fair value of options"&gt;2.38&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z4dSNfx9BgQ" title="Weighted average fair value of options"&gt;0.11&lt;/span&gt; per share,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 STOCKHOLDERS&#x2019; EQUITY (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_znuBCNu7JmO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following was utilized to calculate the fair value of options on the date of grant:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_z5l5Hkq90oM9" style="display: none"&gt;SCHEDULE
OF FAIR VALUE OF OPTION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk -free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250401__20260331__srt--RangeAxis__srt--MinimumMember_ztqHuUTMVkU6" title="Risk-free interest rate"&gt;3.7&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250401__20260331__srt--RangeAxis__srt--MaximumMember_z5Weo3qWwYK6" title="Risk-free interest rate"&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MinimumMember_zOk3WASdJaOc" title="Risk-free interest rate"&gt;3.6&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MaximumMember_zD0V6CXOeHYk" title="Risk-free interest rate"&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (Beyond Air)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MinimumMember_zV4T83F0opSe" title="Expected volatility"&gt;91.6&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MaximumMember_z8EHPpW1UOH2" title="Expected volatility"&gt;106.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MinimumMember_z8BzrqrUvkL6" title="Expected volatility"&gt;83.6&lt;/span&gt;-&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MaximumMember_z8rmUTALNZgf" title="Expected volatility"&gt;89.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (Beyond Cancer)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zl2io9hAH0Rl" title="Expected volatility"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zaRevvw1K9Bc" title="Expected volatility"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Expected volatility (NeuroNos)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember_zVJpALKf2QR1" title="Expected volatility"&gt;95.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember_zJibdoGTAv21" title="Expected volatility"&gt;95.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250401__20260331_zYE7J99l4Uc7" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240401__20250331_zh1kgth8vmC5" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected terms (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250401__20260331_zXpIeUoRAko2" title="Expected term (in years)"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240401__20250331_zh1VdwzsZHpd" title="Expected term (in years)"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zoeQvMI5zFue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined that the fair value per share of NeuroNos&#x2019; common stock to be $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--BeyondCancerLtdMember__srt--RangeAxis__srt--MinimumMember_zxB9DeC3pbbe" title="Fair value per share"&gt;0.14&lt;/span&gt; at the grant date during the year ended
March 31, 2025 based on a third-party valuation, and to be $&lt;span id="xdx_905_eus-gaap--SharePrice_iI_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--BeyondCancerLtdMember__srt--RangeAxis__srt--MinimumMember_zFL8ZWaYAvEg" title="Fair value per share"&gt;3.00&lt;/span&gt; at the grant date during the year ended March 31, 2026 based on the
valuation of common stock purchased by external investors during the fiscal year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zC0pH738OJH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following summarizes the components of stock-based compensation expense which included stock options and restricted stock for the years
ended March 31, 2026 and March 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zEz0Aj0KcgYk" style="display: none"&gt;SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250401__20260331_zq7dXjpYPMUl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240401__20250331_zveT734dr9Ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--ResearchAndDevelopmentExpense_zphXUEaGZq5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,153&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;471&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zRBl1sXybtyd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,129&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,675&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ShareBasedCompensation_pn3n3_z3LePV7u1DXh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,282&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,146&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zfF4diNi9jN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 8, 2025, the Company entered into an inducement offer letter agreement (&#x201c;Inducement Letter&#x201d;) with certain holders
of the September 2024 equity offering common stock warrants (&#x201c;Existing Warrants&#x201d;). Pursuant to the Inducement Letter, such
holders immediately exercised some of all of their respective outstanding Existing Warrants to purchase up to an aggregate of &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCWggDhRYsrf" title=" Warrants to purchase"&gt;1,439,128&lt;/span&gt;
shares of common stock at a reduced exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXRCVt4TGSg4" title="Warrants exercise price"&gt;2.21&lt;/span&gt;. The proceeds to the Company from the exercise of the Existing Warrants were
approximately $&lt;span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250908__20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcY3l8xsTcV3" title="Warrants Exercise"&gt;2.9&lt;/span&gt; million, net of placement agent fees and other offering expenses of $&lt;span id="xdx_900_eus-gaap--PaymentsForFees_pn5n6_c20250908__20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOBFXVVzcqni" title="Other fees"&gt;0.2&lt;/span&gt; million and $&lt;span id="xdx_906_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhPEtRmUtj17" title="Other fees"&gt;0.1&lt;/span&gt; million, respectively. In
consideration of the inducement offer, the Company issued new common stock warrants to purchase up to &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250908__20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTNLVz8hWp3c" title="Stock issues during the period, shares"&gt;719,562&lt;/span&gt; shares of common stock
for a purchase price of $&lt;span id="xdx_901_eus-gaap--WarrantExercisePriceIncrease_c20250908__20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBCIjLgWKzq6" title="Warrant exercise price"&gt;0.125&lt;/span&gt; per share of common stock underlying the new warrant. The new warrants have an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z29sbL2ZXUv9" title="Warrant exercise price"&gt;2.21&lt;/span&gt;
per share and are immediately exercisable, with a term of &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250908__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcd4mUbteaX7" title="Weighted average remaining service period"&gt;five years&lt;/span&gt; from the issuance date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 3, 2025, warrants to purchase up to an aggregate of &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251103__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zpsuzE1mXdri" title="Warrants to purchase"&gt;512,821&lt;/span&gt; of Company common stock were issued as part of the Amended Loan
Agreement with certain lenders including its director Robert Carey at an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251103__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zJrg5qzIF9O9" title="Warrants price"&gt;1.95&lt;/span&gt; per common stock warrant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 16, 2026, warrants to purchase up to an aggregate of &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260116__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSBViBSPGM7f" title="Warrants to purchase"&gt;3,930,818&lt;/span&gt; of Company common stock were issued to certain institutional investors
at an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260116__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJVtliP4DcM" title="Warrants price"&gt;1.147&lt;/span&gt; per common stock warrant. The warrant exercise price was calculated at the 5-trading day average closing
share price as of January 13, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 16, 2026, pre-funded warrants to purchase up to &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260116__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_z4FMmTJtfNxl" title="Warrants to purchase"&gt;3,405,828 &lt;/span&gt;of Company common stock were issued to certain institutional investors
at an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260116__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_zAvFRcAkgBal" title="Warrants price"&gt;0.0001&lt;/span&gt; per common stock warrant. During the year ended March 31, 2026, holders exercised &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250116__20250116__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentySixPreFundedWarrantsMember_zOYbEb15o8a8" title="Stock issued during the period, shares"&gt;1,263,215&lt;/span&gt; of these 2026
Pre-Funded Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVuaGqiwngbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s outstanding warrants as of March 31, 2026 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_znadyXZOO54l" style="display: none"&gt;SUMMARY
OF OUTSTANDING WARRANTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;Warrant Holders&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Date of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify"&gt;NitricGen agreement&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z4kShwuooEzd" style="width: 11%; text-align: right" title="Number of Warrants"&gt;4,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_zrrfqWfjyFs9" style="width: 11%; text-align: right" title="Exercise Price"&gt;138.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z82UsnuOhuai" style="width: 11%; text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1450"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: center"&gt;&lt;span id="xdx_90B_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z67dCquqcvBe" title="Date of Expiration"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Avenue agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_z3qE4BXpSG88" style="text-align: right" title="Number of Warrants"&gt;11,693&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zE1o60N5QRK3" style="text-align: right" title="Exercise Price"&gt;7.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zYBi17WHaRG6" style="text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1458"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zV23M8znsHYj" title="Date of Expiration"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;March 2024 raise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zw5FeoLMNUkg" style="text-align: right" title="Number of Warrants"&gt;481,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zvFMa9PYPi5" style="text-align: right" title="Exercise Price"&gt;45.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_z4lkHpV5luNi" style="text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1466"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zLdjKKNcg7hk" title="Date of Expiration"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Avenue extension agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zPAZzCg5Omcj" style="text-align: right" title="Number of Warrants"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zcfOWm9cqmn5" style="text-align: right" title="Exercise Price"&gt;25.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zx4ik2vBNlC5" style="text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1474"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zwt1QWSGlGCl" title="Date of Expiration"&gt;June 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;September 2024 equity offering&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zP5rs7vYn62b" style="text-align: right" title="Number of Warrants"&gt;555,229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_z8gTZM698Bt8" style="text-align: right" title="Exercise Price"&gt;7.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zeKM7h9fB06" style="text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1482"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zmGsa4tmgTH2" title="Date of Expiration"&gt;September 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;September 2024 debt instrument&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zFkIDRzrQlDh" style="text-align: right" title="Number of Warrants"&gt;1,270,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zicWS367XVkj" style="text-align: right" title="Exercise Price"&gt;1.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zvtoJXRSuLOc" style="text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1490"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zKYCGJ3Wszh7" title="Date of Expiration"&gt;September 2029 / November 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;September 2025 inducement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zrk8L3PstUP1" style="text-align: right" title="Number of Warrants"&gt;719,562&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zcTuX5vJXQ04" style="text-align: right" title="Exercise Price"&gt;2.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zJ9gj1dntk87" style="text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1498"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zTonXyrH1eCj" title="Date of Expiration"&gt;September 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;January 2026 equity offering&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zMqAK5J6CSs3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants"&gt;3,930,818&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zUXDNfH4EXAj" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;1.147&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_z5zH5sGpVSNl" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1506"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zReAqHOnTIq8" title="Date of Expiration"&gt;January 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zpqKgoG7zFA3" style="text-align: right" title="Number of Warrants"&gt;6,979,034&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zRyE1w5e87e4" style="text-align: right" title="Exercise Price"&gt;5.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zpF3Vh78GCg2" style="text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1514"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Pre-funded warrants (Sep-2024 offering)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_ziNtUpjIizjh" style="text-align: right" title="Number of Warrants"&gt;220,006&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_zut3bvqrXnz9" style="text-align: right" title="Exercise Price"&gt;0.002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_ziio5DBdmHZj" style="text-align: right" title="Intrinsic Value"&gt;151&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_zTe4TE5Bfixi" title="Date of Expiration"&gt;September 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Pre-funded warrants (Jan-2026 offering)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zTM446FKRBO9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants"&gt;2,142,613&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zzgI25s9Rhc1" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;0.0001&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zzhhUwr98aWk" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value"&gt;1,479&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_901_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zTy0FS3fMkb9" title="Date of Expiration"&gt;January 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331_zDKoi3QCk5ye" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants"&gt;9,341,653&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331_zGE9blo9TObb" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise Price"&gt;3.773&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331_zsRu6JJ5ajh5" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value"&gt;1,630&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zCs78da6MJB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;ESPP&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 4, 2021, the stockholders approved the 2021 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The purpose of the ESPP is to encourage
and to enable eligible employees of the Company, through after-tax payroll deductions, to acquire proprietary interests in the Company
through the purchase and ownership of shares of Stock. The ESPP is intended to benefit the Company and its stockholders by (a) incentivizing
participants to contribute to the success of the Company and to operate and manage the Company&#x2019;s business in a manner that will
provide for the Company&#x2019;s long-term growth and profitability and that will benefit its stockholders and other important stakeholders
and (b) encouraging participants to remain in the employ of the Company. As of March 31, 2026 and March 31, 2025, &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEmployeeStockPurchasePlanMember_zTKJ4Bf4f9Lc" title="Number of shares issued"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEmployeeStockPurchasePlanMember_zXsTm3f4PXRl" title="Number of shares issued"&gt;no&lt;/span&gt;&lt;/span&gt; shares were issued
under the ESPP.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2025-02-102025-02-10_custom_TwoThousandAndTwentyFiveATMMember"
      decimals="-5"
      id="Fact001019"
      unitRef="USD">35000000.0</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <XAIR:SaleOfStockFeePercentage
      contextRef="From2025-02-102025-02-10_custom_TwoThousandAndTwentyFiveATMMember"
      decimals="INF"
      id="Fact001021"
      unitRef="Pure">0.025</XAIR:SaleOfStockFeePercentage>
    <XAIR:PublicFloatValue
      contextRef="AsOf2025-02-10_srt_MaximumMember"
      decimals="-5"
      id="Fact001023"
      unitRef="USD">75000000.0</XAIR:PublicFloatValue>
    <XAIR:PublicFloatValue
      contextRef="AsOf2025-02-10_srt_MaximumMember"
      decimals="-5"
      id="Fact001025"
      unitRef="USD">75000000.0</XAIR:PublicFloatValue>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-04-012026-03-31_custom_TwoThousandAndTwentyFiveATMMember"
      decimals="-5"
      id="Fact001027"
      unitRef="USD">8100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-04-012026-03-31_custom_TwoThousandAndTwentyFiveATMMember"
      decimals="INF"
      id="Fact001029"
      unitRef="Shares">2441775</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-04-012025-03-31_custom_TwoThousandAndTwentyFiveATMMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001031"
      unitRef="USD">2100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-04-012025-03-31_custom_TwoThousandAndTwentyFiveATMMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001033"
      unitRef="Shares">337100</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-11-042025-11-04_custom_PurchaseAgreementMember"
      decimals="-6"
      id="Fact001035"
      unitRef="USD">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-11-042025-11-04_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001037"
      unitRef="Shares">1600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-012026-01-31_custom_PurchaseAgreementMember"
      decimals="-5"
      id="Fact001039"
      unitRef="Shares">1600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2026-01-31_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001041"
      unitRef="USDPShares">2.09</us-gaap:SharePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2026-01-012026-01-31_custom_PurchaseAgreementMember"
      decimals="-5"
      id="Fact001043"
      unitRef="USD">3300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2025-11-042025-11-04_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact001045"
      unitRef="USD">25000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <XAIR:BeneficialOwnershipLimitationPercentage
      contextRef="AsOf2025-11-04_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001047"
      unitRef="Pure">0.0499</XAIR:BeneficialOwnershipLimitationPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-142026-01-14_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001049"
      unitRef="Shares">524990</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2026-01-14_custom_TwoThousandTwentySixPreFundedWarrantsMember"
      decimals="0"
      id="Fact001051"
      unitRef="USD">3405828</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2026-01-14_custom_TwoThousandTwentySixCommonWarrantsMember"
      decimals="0"
      id="Fact001053"
      unitRef="USD">3930818</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-01-14_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001055"
      unitRef="USDPShares">1.272</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-01-14_custom_TwoThousandTwentySixCommonWarrantsMember"
      decimals="INF"
      id="Fact001057"
      unitRef="USDPShares">1.272</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-01-14_custom_TwoThousandTwentySixPreFundedWarrantsMember"
      decimals="INF"
      id="Fact001059"
      unitRef="USDPShares">1.2719</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2026-01-142026-01-14_custom_PreFundedWarrantsMember"
      decimals="-6"
      id="Fact001061"
      unitRef="USD">5000000.0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2026-01-162026-01-16_custom_TwoThousandTwentySixPreFundedWarrantsMember"
      decimals="INF"
      id="Fact001063"
      unitRef="USDPShares">0.0001</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2026-01-142026-01-14_custom_TwoThousandTwentySixPreFundedWarrantsMember"
      decimals="INF"
      id="Fact001065"
      unitRef="USDPShares">1.147</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2025-04-012026-03-31_us-gaap_PrivatePlacementMember"
      decimals="-5"
      id="Fact001067"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsForCommissions
      contextRef="From2025-04-012026-03-31_us-gaap_PrivatePlacementMember"
      decimals="-5"
      id="Fact001069"
      unitRef="USD">300000</us-gaap:PaymentsForCommissions>
    <us-gaap:DeferredCostsCurrent
      contextRef="AsOf2026-03-31_us-gaap_PrivatePlacementMember"
      decimals="-5"
      id="Fact001071"
      unitRef="USD">200000</us-gaap:DeferredCostsCurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2025-11-25_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001073"
      unitRef="Shares">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001075"
      unitRef="Shares">1680000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001077"
      unitRef="Shares">894276</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001079">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001081">&lt;p id="xdx_899_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zLPikjit4Xa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s restricted stock unit awards for the years ended March 31, 2026 and March 31, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zExED22KtKVf" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK AWARDS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number Of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average Grant&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Date Fair &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Unvested as of March 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6MuNpET45r8" style="width: 16%; text-align: right" title="Unvested Number of Shares, Beginning balance"&gt;30,945&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB0SKhNOdUK3" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"&gt;139.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzCJpLPJ4tW7" style="text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1087"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zW9veaMoeSR8" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1089"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMg8cv71H9Og" style="text-align: right" title="Number of Shares, Vested"&gt;(12,240&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zbnKrhCW15E" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested"&gt;137.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkc6cTHzSkZ2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeited"&gt;(440&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjoEnOhgqtnl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;229.60&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Unvested as of March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zeg4dH5hz1Ul" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested Number of Shares, Beginning balance"&gt;18,265&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1iho2up2q8b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"&gt;139.40&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zlnBw6qwW5lf" style="text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1103"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zroJU2kT7Eq8" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1105"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zB3PfQsrwQCg" style="text-align: right" title="Number of Shares, Vested"&gt;(8,630&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjrLsw2vGFIe" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested"&gt;150.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zacVs3383fwl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeited"&gt;(150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhQ6nv5gB0rg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;137.40&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Unvested as of March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zx0uM3ife9Ta" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested Number of Shares, Ending balance"&gt;9,485&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyzVzIbf5x27" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, ending balance"&gt;129.41&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001083"
      unitRef="Shares">30945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001085"
      unitRef="USDPShares">139.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001091"
      unitRef="Shares">12240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001093"
      unitRef="USDPShares">137.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001095"
      unitRef="Shares">440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001097"
      unitRef="USDPShares">229.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001099"
      unitRef="Shares">18265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001101"
      unitRef="USDPShares">139.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001107"
      unitRef="Shares">8630</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001109"
      unitRef="USDPShares">150.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001111"
      unitRef="Shares">150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001113"
      unitRef="USDPShares">137.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2026-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001115"
      unitRef="Shares">9485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2026-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001117"
      unitRef="USDPShares">129.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2025-04-01to2026-03-31"
      decimals="-5"
      id="Fact001119"
      unitRef="USD">500000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-04-012025-03-31"
      decimals="-5"
      id="Fact001121"
      unitRef="USD">1000000.0</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2025-04-012026-03-31_custom_TwoThousandThirteenBAPlanMember"
      decimals="-5"
      id="Fact001123"
      unitRef="USD">300000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="Fact001125">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="Fact001127">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="Fact001129">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="Fact001131">&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcILgvnqjbS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the change in stock options for the years ended March 31, 2026 and March 31, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zPMO2ul4ry35" style="display: none"&gt;SCHEDULE OF OPTION ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&#x2013;-&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life- &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Options outstanding as of March 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zDIuTD1HmBn" style="width: 11%; text-align: right" title="Number of Options, Outstanding at beginning of period"&gt;566,645&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRrEUPyqxF9d" style="width: 11%; text-align: right" title="Weighted Average Exercise Price - Options, Outstanding at beginning of period"&gt;88.39&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zfw3evrr2Fr4" title="Weighted Average Remaining Contractual Life - Options"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zylzEpHSyxIi" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"&gt;760&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zoGAg1pOcH3b" style="text-align: right" title="Number of Options Outstanding, Granted"&gt;227,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRupONoHugJj" style="text-align: right" title="Weighted Average Exercise Price - Options, Granted"&gt;6.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zquTALQYQDWd" style="text-align: right" title="Number of Options Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1145"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zVGjiqWEuihd" style="text-align: right" title="Weighted Average Exercise Price - Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1147"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zLvDY8NIKuYd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Forfeited"&gt;(54,976&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zVt55UyXj6sf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Options, Forfeited"&gt;61.74&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Options outstanding as of March 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zNHc46gRgZF3" style="text-align: right" title="Number of Options, Outstanding at beginning of period"&gt;739,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zAkxzGO3xqE7" style="text-align: right" title="Weighted Average Exercise Price - Options, Outstanding at beginning of period"&gt;9.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zRMUh8b5pHG5" title="Weighted Average Remaining Contractual Life - Options, Outstanding at beginning of period"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zdQWrl0Ptc3c" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1159"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zb0DsRAuUdI1" style="text-align: right" title="Number of Options Outstanding, Granted"&gt;94,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zKPnzEy7Uty3" style="text-align: right" title="Weighted Average Exercise Price - Options, Granted"&gt;0.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zuv9Dih4ZqF3" style="text-align: right" title="Number of Options Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1165"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zdBZ78oloXib" style="text-align: right" title="Weighted Average Exercise Price - Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_z63B4wYthsHf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding, Forfeited"&gt;(77,270&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zMHfWM2AW9B2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Options, Forfeited"&gt;1.95&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding as of March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcVHxVYaJAw2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at ending of period"&gt;756,749&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_z28O37ZACZJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options, Outstanding at ending of period"&gt;1.82&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zSybYciOzyp5" title="Weighted Average Remaining Contractual Life - Options, Outstanding at end of period"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zjffWXBkOv75" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at end of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1179"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable as of March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zcU09AUzmzRi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Exercisable"&gt;497,591&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zZWvfCXaIUQ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options, Exercisable"&gt;1.95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zc3N8Wp4PdLi" title="Weighted Average Remaining Contractual Life - Options, Exercisable"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember_zONx7x7i0Pkc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1187"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001133"
      unitRef="Shares">566645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001135"
      unitRef="USDPShares">88.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-04-012024-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="Fact001137">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="-3"
      id="Fact001139"
      unitRef="USD">760000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001141"
      unitRef="Shares">227550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001143"
      unitRef="USDPShares">6.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001149"
      unitRef="Shares">54976</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001151"
      unitRef="USDPShares">61.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001153"
      unitRef="Shares">739219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001155"
      unitRef="USDPShares">9.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="Fact001157">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001161"
      unitRef="Shares">94800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001163"
      unitRef="USDPShares">0.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001169"
      unitRef="Shares">77270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001171"
      unitRef="USDPShares">1.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001173"
      unitRef="Shares">756749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001175"
      unitRef="USDPShares">1.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="Fact001177">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001181"
      unitRef="Shares">497591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001183"
      unitRef="USDPShares">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      id="Fact001185">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2026-03-31_custom_TwoThousandThirteenEquityIncentivePlanMember"
      decimals="-5"
      id="Fact001189"
      unitRef="USD">1700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2025-04-012026-03-31_custom_TwoThousandThirteenEquityIncentivePlanMember"
      id="Fact001191">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-04-012026-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001193"
      unitRef="USDPShares">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-04-012025-03-31_custom_TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001195"
      unitRef="USDPShares">5.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-03-272026-03-27"
      decimals="-5"
      id="Fact001197"
      unitRef="USD">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-11-04_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001199"
      unitRef="Shares">726618</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="From2025-11-042025-11-04_us-gaap_EmployeeStockOptionMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001201"
      unitRef="USDPShares">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="From2025-11-042025-11-04_us-gaap_EmployeeStockOptionMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001203"
      unitRef="USDPShares">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="From2025-04-012026-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact001205"
      unitRef="USD">300000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="From2025-04-012025-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact001207"
      unitRef="USD">100000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2025-04-012026-03-31_us-gaap_EmployeeStockOptionMember"
      id="Fact001209">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="From2024-11-222024-11-22_custom_TwoThousandTwentyFiveOptionRepricingMember"
      decimals="INF"
      id="Fact001211"
      unitRef="USDPShares">10.80</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="From2024-11-222024-11-22_custom_TwoThousandTwentyFiveOptionRepricingMember"
      decimals="INF"
      id="Fact001213"
      unitRef="USDPShares">10.80</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyFiveOptionRepricingMember"
      decimals="-5"
      id="Fact001215"
      unitRef="Shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyFiveOptionRepricingMember"
      decimals="-5"
      id="Fact001217"
      unitRef="Shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyFiveOptionRepricingMember"
      decimals="-5"
      id="Fact001219"
      unitRef="USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyFiveOptionRepricingMember"
      id="Fact001221">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="Fact001223">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="Fact001225">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-11-032022-11-03_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001227"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2022-11-03_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001229"
      unitRef="Shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001231"
      unitRef="Shares">1745500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="Fact001233">&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zIGS8sGiUi2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the change in stock options for Beyond Cancer for the years ended March 31, 2026 and March 31, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zfNCVrREUPoa" style="display: none"&gt;SCHEDULE
OF OPTION ACTIVITY FOR BEYOND CANCER&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&#x2013;-&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life- &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Options outstanding as of March 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zltD0lFKYr29" style="width: 11%; text-align: right" title="Number of Options, Outstanding at beginning of period"&gt;3,819,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zPStOfDJJPha" style="width: 11%; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period"&gt;5.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zC49XGIPXeB4" title="Weighted average remaining contractual life - options, outstanding at beginning of period"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zQkQLohCA7H2" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z9HQ10n1f8q1" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1243"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXJCIIyEQqsi" style="text-align: right" title="Weighted Average Exercise Price of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1245"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zltdWXYxbUwe" style="text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1247"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zlfL50p2nf13" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1249"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zJVpcZOWGyt5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(1,002,750&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zAOoFNdvqLue" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price of Options, Forfeited"&gt;5.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding as of March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXK1Ydo1CHvg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at beginning of period"&gt;2,816,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_ziyVB8iwOtZ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period"&gt;5.50&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zXJXgcJK8rt6" title="Weighted average remaining contractual life - options, outstanding at beginning of period"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zxp6GCLrGnW5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1261"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zlzImYg5etR9" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1263"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zZDm8lqi3LR7" style="text-align: right" title="Weighted Average Exercise Price of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zoq5ry3qY7ag" style="text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1267"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zD5GzidrBIub" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1269"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBUKt3EcL5bd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(561,750&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z3mQDWmOLBU7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price of Options, Forfeited"&gt;5.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding as of March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_z5dckoFlZlg9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at ending of period"&gt;2,254,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zyCXarkEuvMa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at ending of period"&gt;5.50&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zIckJ2fTos8i" title="Weighted average remaining contractual life - options, outstanding at beginning of period"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zqkBxlY4doP" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding at end of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1281"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable as of March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBQOTMmBnKuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Exercisable"&gt;1,975,750&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zBInmxPusKql" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Exercisable"&gt;5.50&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zC6JnOcvBVvk" title="Weighted Average Remaining Contractual Life of Options, Exercisable"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember_zmg18381u15a" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001235"
      unitRef="Shares">3819000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001237"
      unitRef="USDPShares">5.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-04-012024-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="Fact001239">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001251"
      unitRef="Shares">1002750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001253"
      unitRef="USDPShares">5.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001255"
      unitRef="Shares">2816250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001257"
      unitRef="USDPShares">5.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="Fact001259">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001271"
      unitRef="Shares">561750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001273"
      unitRef="USDPShares">5.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001275"
      unitRef="Shares">2254500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001277"
      unitRef="USDPShares">5.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="Fact001279">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001283"
      unitRef="Shares">1975750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001285"
      unitRef="USDPShares">5.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="Fact001287">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      decimals="-5"
      id="Fact001291"
      unitRef="USD">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember"
      id="Fact001293">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001295"
      unitRef="Shares">1725000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001297"
      unitRef="Shares">465670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      id="Fact001299">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zh9GKH4NRrL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the change in stock options for NeuroNos for the years ended March 31, 2026 and March 31, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zzqGzZlZI6Se"&gt;SCHEDULE
OF OPTION ACTIVITY FOR NEURONOS&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&#x2013;-&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life- &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Options outstanding as of March 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zzh1y1MycSpa" style="text-align: right" title="Number of Options, Outstanding at beginning of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1301"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zePHo2mON8Nk" style="text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zRuWKHUO1Mxc" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1305"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zKXJyXen5OXc" style="width: 11%; text-align: right" title="Number of Options, Granted"&gt;1,224,139&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z3HPlgV7lHh9" style="width: 11%; text-align: right" title="Weighted Average Exercise Price of Options, Granted"&gt;0.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zBGUDjzUIFMg" style="text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1311"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zYMwGOOXRvJi" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1313"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zapFoZDRg2ni" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1315"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zEolIhcf8rt8" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price - options, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1317"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding as of March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zgHjMFZpIVri" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at beginning of period"&gt;1,224,139&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zqTaYDZ2V9xf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at beginning of period"&gt;0.14&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zzFD91herDCk" title="Weighted average remaining contractual life - options, outstanding at beginning of period"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_za87e7pYMJwa" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"&gt;3,501&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z5YWYvHEN6g1" style="text-align: right" title="Number of Options, Granted"&gt;169,913&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_ziEsb2HyfQW3" style="text-align: right" title="Weighted Average Exercise Price of Options, Granted"&gt;3.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zecF9JIVa7hf" style="text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1331"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_z3K6NYELNkK4" style="text-align: right" title="Weighted Average Exercise Price of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1333"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zCx9aDsAiMYh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(134,723&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zRDQ9XILrgp" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price - options, forfeited"&gt;2.82&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding as of March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zfEaOkfKvcG1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding at ending of period"&gt;1,259,329&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zx5hb3vD5vla" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Outstanding at ending of period"&gt;0.24&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zhz8aKY5TdIa" title="Weighted Average Remaining Contractual Life of Options, Outstanding"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_znqU4pApiRS8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at ending of period"&gt;3,477&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable as of March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zCGea6Lpnox2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Exercisable"&gt;622,341&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zNIF39u3q2A1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price of Options, Exercisable"&gt;0.19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_zLCSAYm36C8j" title="Weighted Average Remaining Contractual Life of Options, Exercisable"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember_znZ7QXjs68d9" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;1,748&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001307"
      unitRef="Shares">1224139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001309"
      unitRef="USDPShares">0.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001319"
      unitRef="Shares">1224139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001321"
      unitRef="USDPShares">0.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      id="Fact001323">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="-3"
      id="Fact001325"
      unitRef="USD">3501000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001327"
      unitRef="Shares">169913</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001329"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001335"
      unitRef="Shares">134723</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001337"
      unitRef="USDPShares">2.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001339"
      unitRef="Shares">1259329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001341"
      unitRef="USDPShares">0.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      id="Fact001343">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="-3"
      id="Fact001345"
      unitRef="USD">3477000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001347"
      unitRef="Shares">622341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001349"
      unitRef="USDPShares">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      id="Fact001351">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="-3"
      id="Fact001353"
      unitRef="USD">1748000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="-5"
      id="Fact001355"
      unitRef="USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      id="Fact001357">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001359"
      unitRef="USDPShares">2.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001361"
      unitRef="USDPShares">0.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001363">&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_znuBCNu7JmO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following was utilized to calculate the fair value of options on the date of grant:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_z5l5Hkq90oM9" style="display: none"&gt;SCHEDULE
OF FAIR VALUE OF OPTION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk -free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250401__20260331__srt--RangeAxis__srt--MinimumMember_ztqHuUTMVkU6" title="Risk-free interest rate"&gt;3.7&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250401__20260331__srt--RangeAxis__srt--MaximumMember_z5Weo3qWwYK6" title="Risk-free interest rate"&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MinimumMember_zOk3WASdJaOc" title="Risk-free interest rate"&gt;3.6&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MaximumMember_zD0V6CXOeHYk" title="Risk-free interest rate"&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (Beyond Air)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MinimumMember_zV4T83F0opSe" title="Expected volatility"&gt;91.6&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MaximumMember_z8EHPpW1UOH2" title="Expected volatility"&gt;106.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MinimumMember_z8BzrqrUvkL6" title="Expected volatility"&gt;83.6&lt;/span&gt;-&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirIncMember__srt--RangeAxis__srt--MaximumMember_z8rmUTALNZgf" title="Expected volatility"&gt;89.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (Beyond Cancer)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zl2io9hAH0Rl" title="Expected volatility"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zaRevvw1K9Bc" title="Expected volatility"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Expected volatility (NeuroNos)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250401__20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember_zVJpALKf2QR1" title="Expected volatility"&gt;95.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember_zJibdoGTAv21" title="Expected volatility"&gt;95.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250401__20260331_zYE7J99l4Uc7" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240401__20250331_zh1kgth8vmC5" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected terms (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250401__20260331_zXpIeUoRAko2" title="Expected term (in years)"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240401__20250331_zh1VdwzsZHpd" title="Expected term (in years)"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-04-012026-03-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001365"
      unitRef="Pure">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-04-012026-03-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001367"
      unitRef="Pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-04-012025-03-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001369"
      unitRef="Pure">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-04-012025-03-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001371"
      unitRef="Pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-04-012026-03-31_custom_BeyondAirIncMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001373"
      unitRef="Pure">0.916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-04-012026-03-31_custom_BeyondAirIncMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001375"
      unitRef="Pure">1.062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-04-012025-03-31_custom_BeyondAirIncMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001377"
      unitRef="Pure">0.836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-04-012025-03-31_custom_BeyondAirIncMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001379"
      unitRef="Pure">0.899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember"
      decimals="INF"
      id="Fact001385"
      unitRef="Pure">0.950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember"
      decimals="INF"
      id="Fact001387"
      unitRef="Pure">0.950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001389"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact001391"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2025-04-01to2026-03-31" id="Fact001393">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-04-012025-03-31" id="Fact001395">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember_custom_BeyondCancerLtdMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001397"
      unitRef="USDPShares">0.14</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember_custom_BeyondCancerLtdMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001399"
      unitRef="USDPShares">3.00</us-gaap:SharePrice>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001401">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zC0pH738OJH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following summarizes the components of stock-based compensation expense which included stock options and restricted stock for the years
ended March 31, 2026 and March 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zEz0Aj0KcgYk" style="display: none"&gt;SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250401__20260331_zq7dXjpYPMUl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240401__20250331_zveT734dr9Ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--ResearchAndDevelopmentExpense_zphXUEaGZq5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,153&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;471&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zRBl1sXybtyd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,129&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,675&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ShareBasedCompensation_pn3n3_z3LePV7u1DXh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,282&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,146&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-04-012026-03-31_us-gaap_ResearchAndDevelopmentExpense"
      decimals="-3"
      id="Fact001403"
      unitRef="USD">1153000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012025-03-31_us-gaap_ResearchAndDevelopmentExpense"
      decimals="-3"
      id="Fact001404"
      unitRef="USD">471000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-04-012026-03-31_us-gaap_GeneralAndAdministrativeExpense"
      decimals="-3"
      id="Fact001406"
      unitRef="USD">4129000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012025-03-31_us-gaap_GeneralAndAdministrativeExpense"
      decimals="-3"
      id="Fact001407"
      unitRef="USD">8675000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001409"
      unitRef="USD">5282000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001410"
      unitRef="USD">9146000</us-gaap:ShareBasedCompensation>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-09-08_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001412"
      unitRef="Shares">1439128</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-08_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001414"
      unitRef="USDPShares">2.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-09-082025-09-08_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact001416"
      unitRef="USD">2900000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsForFees
      contextRef="From2025-09-082025-09-08_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact001418"
      unitRef="USD">200000</us-gaap:PaymentsForFees>
    <us-gaap:DeferredCostsCurrent
      contextRef="AsOf2025-09-08_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact001420"
      unitRef="USD">100000</us-gaap:DeferredCostsCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-09-082025-09-08_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001422"
      unitRef="Shares">719562</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2025-09-082025-09-08_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001424"
      unitRef="USDPShares">0.125</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-08_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001426"
      unitRef="USDPShares">2.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-09-08_us-gaap_WarrantMember"
      id="Fact001428">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-11-03_us-gaap_CommonStockMember_custom_AmendedLoanAgreementMember"
      decimals="INF"
      id="Fact001430"
      unitRef="Shares">512821</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-11-03_us-gaap_CommonStockMember_custom_AmendedLoanAgreementMember"
      decimals="INF"
      id="Fact001432"
      unitRef="USDPShares">1.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-01-16_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001434"
      unitRef="Shares">3930818</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-01-16_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001436"
      unitRef="USDPShares">1.147</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-01-16_custom_TwoThousandTwentySixPreFundedWarrantsMember"
      decimals="INF"
      id="Fact001438"
      unitRef="Shares">3405828</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-01-16_custom_TwoThousandTwentySixPreFundedWarrantsMember"
      decimals="INF"
      id="Fact001440"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-01-162025-01-16_custom_TwoThousandTwentySixPreFundedWarrantsMember"
      decimals="INF"
      id="Fact001442"
      unitRef="Shares">1263215</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001444">&lt;p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVuaGqiwngbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s outstanding warrants as of March 31, 2026 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_znadyXZOO54l" style="display: none"&gt;SUMMARY
OF OUTSTANDING WARRANTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;Warrant Holders&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Date of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify"&gt;NitricGen agreement&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z4kShwuooEzd" style="width: 11%; text-align: right" title="Number of Warrants"&gt;4,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_zrrfqWfjyFs9" style="width: 11%; text-align: right" title="Exercise Price"&gt;138.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z82UsnuOhuai" style="width: 11%; text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1450"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: center"&gt;&lt;span id="xdx_90B_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z67dCquqcvBe" title="Date of Expiration"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Avenue agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_z3qE4BXpSG88" style="text-align: right" title="Number of Warrants"&gt;11,693&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zE1o60N5QRK3" style="text-align: right" title="Exercise Price"&gt;7.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zYBi17WHaRG6" style="text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1458"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueAgreementMember_zV23M8znsHYj" title="Date of Expiration"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;March 2024 raise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zw5FeoLMNUkg" style="text-align: right" title="Number of Warrants"&gt;481,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zvFMa9PYPi5" style="text-align: right" title="Exercise Price"&gt;45.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_z4lkHpV5luNi" style="text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1466"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentyFourRaiseMember_zLdjKKNcg7hk" title="Date of Expiration"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Avenue extension agreement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zPAZzCg5Omcj" style="text-align: right" title="Number of Warrants"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zcfOWm9cqmn5" style="text-align: right" title="Exercise Price"&gt;25.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zx4ik2vBNlC5" style="text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1474"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--AvenueExtensionAgreementMember_zwt1QWSGlGCl" title="Date of Expiration"&gt;June 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;September 2024 equity offering&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zP5rs7vYn62b" style="text-align: right" title="Number of Warrants"&gt;555,229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_z8gTZM698Bt8" style="text-align: right" title="Exercise Price"&gt;7.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zeKM7h9fB06" style="text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1482"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourEquityOfferingMember_zmGsa4tmgTH2" title="Date of Expiration"&gt;September 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;September 2024 debt instrument&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zFkIDRzrQlDh" style="text-align: right" title="Number of Warrants"&gt;1,270,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zicWS367XVkj" style="text-align: right" title="Exercise Price"&gt;1.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zvtoJXRSuLOc" style="text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1490"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFourDebtInstrumentMember_zKYCGJ3Wszh7" title="Date of Expiration"&gt;September 2029 / November 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;September 2025 inducement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zrk8L3PstUP1" style="text-align: right" title="Number of Warrants"&gt;719,562&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zcTuX5vJXQ04" style="text-align: right" title="Exercise Price"&gt;2.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zJ9gj1dntk87" style="text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1498"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SeptemberTwoThousandTwentyFiveInducementMember_zTonXyrH1eCj" title="Date of Expiration"&gt;September 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;January 2026 equity offering&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zMqAK5J6CSs3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants"&gt;3,930,818&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zUXDNfH4EXAj" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;1.147&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_z5zH5sGpVSNl" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1506"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_902_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentySixEquityOfferingMember_zReAqHOnTIq8" title="Date of Expiration"&gt;January 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zpqKgoG7zFA3" style="text-align: right" title="Number of Warrants"&gt;6,979,034&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zRyE1w5e87e4" style="text-align: right" title="Exercise Price"&gt;5.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubTotalMember_zpF3Vh78GCg2" style="text-align: right" title="Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1514"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Pre-funded warrants (Sep-2024 offering)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_ziNtUpjIizjh" style="text-align: right" title="Number of Warrants"&gt;220,006&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_zut3bvqrXnz9" style="text-align: right" title="Exercise Price"&gt;0.002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_ziio5DBdmHZj" style="text-align: right" title="Intrinsic Value"&gt;151&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsSepTwoThousandTwentyFourMember_zTe4TE5Bfixi" title="Date of Expiration"&gt;September 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Pre-funded warrants (Jan-2026 offering)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zTM446FKRBO9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants"&gt;2,142,613&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zzgI25s9Rhc1" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;0.0001&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zzhhUwr98aWk" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value"&gt;1,479&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_901_ecustom--WarrantsExpirationDateDescription_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--PreFundedWarrantsJanTwoThousandTwentySixMember_zTy0FS3fMkb9" title="Date of Expiration"&gt;January 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331_zDKoi3QCk5ye" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants"&gt;9,341,653&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331_zGE9blo9TObb" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise Price"&gt;3.773&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue_iI_pid_c20260331_zsRu6JJ5ajh5" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value"&gt;1,630&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_NitricGenAgreementMember"
      decimals="INF"
      id="Fact001446"
      unitRef="Shares">4000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_NitricGenAgreementMember"
      decimals="INF"
      id="Fact001448"
      unitRef="USDPShares">138.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <XAIR:WarrantsExpirationDateDescription
      contextRef="From2025-04-012026-03-31_custom_NitricGenAgreementMember"
      id="Fact001452">January 2028</XAIR:WarrantsExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_AvenueAgreementMember"
      decimals="INF"
      id="Fact001454"
      unitRef="Shares">11693</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_AvenueAgreementMember"
      decimals="INF"
      id="Fact001456"
      unitRef="USDPShares">7.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <XAIR:WarrantsExpirationDateDescription
      contextRef="From2025-04-012026-03-31_custom_AvenueAgreementMember"
      id="Fact001460">June 2028</XAIR:WarrantsExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_MarchTwoThousandTwentyFourRaiseMember"
      decimals="INF"
      id="Fact001462"
      unitRef="Shares">481936</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_MarchTwoThousandTwentyFourRaiseMember"
      decimals="INF"
      id="Fact001464"
      unitRef="USDPShares">45.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <XAIR:WarrantsExpirationDateDescription
      contextRef="From2025-04-012026-03-31_custom_MarchTwoThousandTwentyFourRaiseMember"
      id="Fact001468">March 2027</XAIR:WarrantsExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_AvenueExtensionAgreementMember"
      decimals="INF"
      id="Fact001470"
      unitRef="Shares">5000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_AvenueExtensionAgreementMember"
      decimals="INF"
      id="Fact001472"
      unitRef="USDPShares">25.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <XAIR:WarrantsExpirationDateDescription
      contextRef="From2025-04-012026-03-31_custom_AvenueExtensionAgreementMember"
      id="Fact001476">June 2029</XAIR:WarrantsExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourEquityOfferingMember"
      decimals="INF"
      id="Fact001478"
      unitRef="Shares">555229</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourEquityOfferingMember"
      decimals="INF"
      id="Fact001480"
      unitRef="USDPShares">7.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <XAIR:WarrantsExpirationDateDescription
      contextRef="From2025-04-012026-03-31_custom_SeptemberTwoThousandTwentyFourEquityOfferingMember"
      id="Fact001484">September 2029</XAIR:WarrantsExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourDebtInstrumentMember"
      decimals="INF"
      id="Fact001486"
      unitRef="Shares">1270796</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFourDebtInstrumentMember"
      decimals="INF"
      id="Fact001488"
      unitRef="USDPShares">1.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <XAIR:WarrantsExpirationDateDescription
      contextRef="From2025-04-012026-03-31_custom_SeptemberTwoThousandTwentyFourDebtInstrumentMember"
      id="Fact001492">September 2029 / November 2030</XAIR:WarrantsExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFiveInducementMember"
      decimals="INF"
      id="Fact001494"
      unitRef="Shares">719562</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_SeptemberTwoThousandTwentyFiveInducementMember"
      decimals="INF"
      id="Fact001496"
      unitRef="USDPShares">2.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <XAIR:WarrantsExpirationDateDescription
      contextRef="From2025-04-012026-03-31_custom_SeptemberTwoThousandTwentyFiveInducementMember"
      id="Fact001500">September 2030</XAIR:WarrantsExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_JanuaryTwoThousandTwentySixEquityOfferingMember"
      decimals="INF"
      id="Fact001502"
      unitRef="Shares">3930818</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_JanuaryTwoThousandTwentySixEquityOfferingMember"
      decimals="INF"
      id="Fact001504"
      unitRef="USDPShares">1.147</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <XAIR:WarrantsExpirationDateDescription
      contextRef="From2025-04-012026-03-31_custom_JanuaryTwoThousandTwentySixEquityOfferingMember"
      id="Fact001508">January 2031</XAIR:WarrantsExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_SubTotalMember"
      decimals="INF"
      id="Fact001510"
      unitRef="Shares">6979034</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_SubTotalMember"
      decimals="INF"
      id="Fact001512"
      unitRef="USDPShares">5.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_PreFundedWarrantsSepTwoThousandTwentyFourMember"
      decimals="INF"
      id="Fact001516"
      unitRef="Shares">220006</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_PreFundedWarrantsSepTwoThousandTwentyFourMember"
      decimals="INF"
      id="Fact001518"
      unitRef="USDPShares">0.002</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue
      contextRef="AsOf2026-03-31_custom_PreFundedWarrantsSepTwoThousandTwentyFourMember"
      decimals="INF"
      id="Fact001520"
      unitRef="USD">151</XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue>
    <XAIR:WarrantsExpirationDateDescription
      contextRef="From2025-04-012026-03-31_custom_PreFundedWarrantsSepTwoThousandTwentyFourMember"
      id="Fact001522">September 2029</XAIR:WarrantsExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_PreFundedWarrantsJanTwoThousandTwentySixMember"
      decimals="INF"
      id="Fact001524"
      unitRef="Shares">2142613</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_PreFundedWarrantsJanTwoThousandTwentySixMember"
      decimals="INF"
      id="Fact001526"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue
      contextRef="AsOf2026-03-31_custom_PreFundedWarrantsJanTwoThousandTwentySixMember"
      decimals="INF"
      id="Fact001528"
      unitRef="USD">1479</XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue>
    <XAIR:WarrantsExpirationDateDescription
      contextRef="From2025-04-012026-03-31_custom_PreFundedWarrantsJanTwoThousandTwentySixMember"
      id="Fact001530">January 2031</XAIR:WarrantsExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001532"
      unitRef="Shares">9341653</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001534"
      unitRef="USDPShares">3.773</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001536"
      unitRef="USD">1630</XAIR:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-04-012026-03-31_custom_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact001538"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-04-012025-03-31_custom_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact001540"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001542">&lt;p id="xdx_80A_eus-gaap--OtherCurrentAssetsTextBlock_zFJmrFKcjcPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &lt;span id="xdx_829_z8Bw8CKCb5M5"&gt;OTHER CURRENT ASSETS AND PREPAID EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z12r0YX9rOK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of other current assets and prepaid expenses as of March 31, 2026 and March 31, 2025 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zWlHKa80qD8c" style="display: none"&gt;SCHEDULE
OF OTHER CURRENT ASSETS AND PREPAID EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260331_zTQvj9c1CA6i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250331_z3gnSdYgdLL5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzff3_z3DrsaFKYFsj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;696&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;108&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PrepaidInsurance_iI_maPEAOAzff3_z17lBgx71299" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;579&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;817&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PrepaidRent_iI_maPEAOAzff3_zzYTebrULgoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid rents and tenant improvement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidTaxes_iI_maPEAOAzff3_zVlyDEphLZT3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Value added tax receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DepositsAssets_iI_maPEAOAzff3_zsExCHma4Syg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deposits to secure manufacturing materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Supplies_iI_maPEAOAzff3_zLHwcz0ZdJjc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Demonstration materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_maPEAOAzff3_zAoTAMHnW28f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;190&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;203&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzff3_z1LDZg4eceVg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total other current assets and prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,743&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zZjeLdcENH49" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001544">&lt;p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z12r0YX9rOK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of other current assets and prepaid expenses as of March 31, 2026 and March 31, 2025 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zWlHKa80qD8c" style="display: none"&gt;SCHEDULE
OF OTHER CURRENT ASSETS AND PREPAID EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260331_zTQvj9c1CA6i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250331_z3gnSdYgdLL5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzff3_z3DrsaFKYFsj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;696&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;108&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PrepaidInsurance_iI_maPEAOAzff3_z17lBgx71299" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;579&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;817&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PrepaidRent_iI_maPEAOAzff3_zzYTebrULgoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid rents and tenant improvement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidTaxes_iI_maPEAOAzff3_zVlyDEphLZT3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Value added tax receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DepositsAssets_iI_maPEAOAzff3_zsExCHma4Syg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deposits to secure manufacturing materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Supplies_iI_maPEAOAzff3_zLHwcz0ZdJjc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Demonstration materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_maPEAOAzff3_zAoTAMHnW28f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;190&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;203&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzff3_z1LDZg4eceVg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total other current assets and prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,743&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <XAIR:PrepaidResearchAndDevelopment
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001546"
      unitRef="USD">696000</XAIR:PrepaidResearchAndDevelopment>
    <XAIR:PrepaidResearchAndDevelopment
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001547"
      unitRef="USD">108000</XAIR:PrepaidResearchAndDevelopment>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001549"
      unitRef="USD">579000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001550"
      unitRef="USD">817000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidRent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001552"
      unitRef="USD">8000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001553"
      unitRef="USD">10000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001555"
      unitRef="USD">105000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001556"
      unitRef="USD">150000</us-gaap:PrepaidTaxes>
    <us-gaap:DepositsAssets
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001558"
      unitRef="USD">3420000</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001559"
      unitRef="USD">4377000</us-gaap:DepositsAssets>
    <us-gaap:Supplies
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001561"
      unitRef="USD">14000</us-gaap:Supplies>
    <us-gaap:Supplies
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001562"
      unitRef="USD">78000</us-gaap:Supplies>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001564"
      unitRef="USD">190000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001565"
      unitRef="USD">203000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001567"
      unitRef="USD">5012000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001568"
      unitRef="USD">5743000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001570">&lt;p id="xdx_80E_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zcVMWyY4y1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 &lt;span id="xdx_828_zKczuug6aX78"&gt;ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zZTkvZpdS6Ah" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of accrued expenses and other current liabilities as of March 31, 2026 and March 31, 2025 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zIdDrAHEKJdb" style="display: none"&gt;SUMMARY OF ACCRUED EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20260331_zgmGMcKnZwQ" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250331_zt51FMOpjwUb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentExpenses_iI_pn3n3_maTSAEzACS_zI7vqb8Et3Ib" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;360&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maTSAEzACS_z07t4i6zH1yf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;440&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maTSAEzACS_zSO1iQsJpyy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Employee salaries and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;465&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;924&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--InterestSeveranceCurrent_iI_pn3n3_maTSAEzACS_z2jeCUo66EU9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued severance&lt;span id="xdx_F4C_zPEwRQVV9dUg"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;696&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1584"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_pn3n3_maTSAEzACS_zAZ3jpsVd2n5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1587"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredRevenueCurrent_iI_pn3n3_maTSAEzACS_z9sLbDACDPh1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1590"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--GoodsReceivedNotInvoiced_iI_pn3n3_maTSAEzACS_z6hXfThxgJmg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Goods received not invoiced&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maTSAEzACS_zFG2iVnQ3jS" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;143&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;223&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_pn3n3_mtTSAEzACS_zMAwvGTeAEbc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,372&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,045&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zBXqbMPPsWId" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F08_zPeN4BuLIU4e" style="width: 15pt; text-align: right"&gt;*&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F15_zBxnU1wW0g4i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant to the
terms of the Release Agreement with Steve Lisi, former CEO, the Company is obligated to pay Mr. Lisi $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQUNDUlVFRCBFWFBFTlNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--Cash_iI_c20260331__srt--TitleOfIndividualAxis__custom--SteveLisiMember_zzRrwFGbAO1b"&gt;650,000&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in cash compensation over 12 months. After expected employer
taxes and benefits, the Company accrued $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQUNDUlVFRCBFWFBFTlNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--TaxesPayableCurrent_iI_pn5n6_c20260331__srt--TitleOfIndividualAxis__custom--SteveLisiMember_zi71LrIwbDJe"&gt;0.7&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million The Company shall also pay Mr. Lisi COBRA premiums
for 12 months, as more specifically described in the Release Agreement. All unvested options and all unvested stock restriction unit
awards held by Mr. Lisi as of March 27, 2026, shall be accelerated and shall immediately vest, and shall continue to remain exercisable
for twenty-four (24) months from March 27, 2026.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001572">&lt;p id="xdx_89E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zZTkvZpdS6Ah" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of accrued expenses and other current liabilities as of March 31, 2026 and March 31, 2025 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zIdDrAHEKJdb" style="display: none"&gt;SUMMARY OF ACCRUED EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20260331_zgmGMcKnZwQ" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250331_zt51FMOpjwUb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentExpenses_iI_pn3n3_maTSAEzACS_zI7vqb8Et3Ib" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;360&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maTSAEzACS_z07t4i6zH1yf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;440&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maTSAEzACS_zSO1iQsJpyy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Employee salaries and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;465&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;924&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--InterestSeveranceCurrent_iI_pn3n3_maTSAEzACS_z2jeCUo66EU9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued severance&lt;span id="xdx_F4C_zPEwRQVV9dUg"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;696&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1584"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_pn3n3_maTSAEzACS_zAZ3jpsVd2n5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1587"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredRevenueCurrent_iI_pn3n3_maTSAEzACS_z9sLbDACDPh1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1590"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--GoodsReceivedNotInvoiced_iI_pn3n3_maTSAEzACS_z6hXfThxgJmg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Goods received not invoiced&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maTSAEzACS_zFG2iVnQ3jS" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;143&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;223&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_pn3n3_mtTSAEzACS_zMAwvGTeAEbc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,372&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,045&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <XAIR:AccruedResearchAndDevelopmentExpenses
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001574"
      unitRef="USD">16000</XAIR:AccruedResearchAndDevelopmentExpenses>
    <XAIR:AccruedResearchAndDevelopmentExpenses
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001575"
      unitRef="USD">360000</XAIR:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001577"
      unitRef="USD">252000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001578"
      unitRef="USD">440000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001580"
      unitRef="USD">465000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001581"
      unitRef="USD">924000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <XAIR:InterestSeveranceCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001583"
      unitRef="USD">696000</XAIR:InterestSeveranceCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001586"
      unitRef="USD">750000</us-gaap:InterestPayableCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001589"
      unitRef="USD">777000</us-gaap:DeferredRevenueCurrent>
    <XAIR:GoodsReceivedNotInvoiced
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001592"
      unitRef="USD">273000</XAIR:GoodsReceivedNotInvoiced>
    <XAIR:GoodsReceivedNotInvoiced
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001593"
      unitRef="USD">98000</XAIR:GoodsReceivedNotInvoiced>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001595"
      unitRef="USD">143000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001596"
      unitRef="USD">223000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001598"
      unitRef="USD">3372000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001599"
      unitRef="USD">2045000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:Cash
      contextRef="AsOf2026-03-31_custom_SteveLisiMember"
      decimals="-3"
      id="Fact001601"
      unitRef="USD">650000000</us-gaap:Cash>
    <us-gaap:TaxesPayableCurrent
      contextRef="AsOf2026-03-31_custom_SteveLisiMember"
      decimals="-5"
      id="Fact001602"
      unitRef="USD">700000</us-gaap:TaxesPayableCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001604">&lt;p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zcWR3kj6vu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &lt;span id="xdx_820_zlb7WdAgQu14"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Lease
population&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases various office facilities under non-cancelable operating leases that expire at various dates through 2031. The
Company does not have any finance leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2026, &lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20260301__20260331_zzqP9gcxdedc" title="Operation lease description"&gt;the Company entered into a second amendment to lease of one of its facilities (the &#x201c;Lease Amendment&#x201d;). The Lease
Amendment extended the lease for an additional three years through May 31, 2029 with fixed monthly base rent amounts through the extended
term&lt;/span&gt;. The Company accounted for the Lease Amendment on the effective date, resulting in the remeasurement of the operating lease liability
with a corresponding adjustment to the right-of-use asset in the amount of $&lt;span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_pn5n6_c20260301__20260331_zKALk18yntGe" title="Operating lease liability"&gt;0.1&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2025, &lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20250401__20250430_zvnCLbyvoJU4" title="Operation lease description"&gt;the Company entered into an agreement to sublease the Beyond Cancer office space in Atlanta, Georgia beginning June 1, 2025
and continuing through September 30, 2026 coinciding with the termination of the existing lease.&lt;/span&gt; The sublease has been classified as
an operating lease by the Company. Sublease rental income offsets the monthly rental expense from the Company&#x2019;s lease of the office,
and is recorded as reduction of selling, general, and administrative expenses in the Company&#x2019;s consolidated statements of operation
and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no new leases entered into during the years ended March 31, 2026 and March 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Lease
position&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the lease-related assets and liabilities recorded on the Company&#x2019;s consolidated balance sheets as of
March 31, 2026 and March 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--ScheduleOfOperatingLeaseLiabilityTableTextBlock_zzGG9uvKCL88" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zWw6wivgAbN8" style="display: none"&gt;SCHEDULE
OF OPERATING LEASE LIABILITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260331_ztxAbLxHn2Sk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250331_zUIRFzHnw3P6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zGiI7WhnLF96" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 2.5pt"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;1,193&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;1,706&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzD8e_zijA2SGcibBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liability short-term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;321&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzD8e_zZY66ViD8VS6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating lease liability long-term&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,486&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzD8e_zwYBqLLf2B5h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,344&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,882&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260331_znOjxmBlimJ4" title="Weighted Average Remaining Lease Term"&gt;4.5 &lt;/span&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250331_zzCirPO695al" title="Weighted Average Remaining Lease Term"&gt;5.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260331_zWu3VTFvafml" title="Weighted-average discount rate - operating leases"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20250331_zaZgJwELdgHh" title="Weighted-average discount rate - operating leases"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_z2t3MkU6Ptg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Lease
costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zF2ZNa3nJYH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the lease-related costs for the years ended March 31, 2026 and March 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zpu05L1SLtJ7"&gt;SCHEDULE
OF LEASE RELATED COSTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250401__20260331_zENbH7iuWro5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240401__20250331_zBYPaefONGOj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseCost_pn3n3_maLCzzCQ_z0My6r6OOnOd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;505&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;539&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzzCQ_z2H9Zw5Chtsc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Short-term lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--SubleaseIncome_iN_pn3n3_di_msLCzzCQ_zxSykFRXTka2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Sublease income&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(49&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1643"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LeaseCost_iT_pn3n3_mtLCzzCQ_zXlAIoIONgAi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;544&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zWf1ZEDrGz98" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Other
lease information&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--OtherLeaseTableTextBlock_zKiHMb2MucUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zb9C4Lawqlg" style="display: none"&gt;SCHEDULE OF LEASE OTHER INFORMATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250401__20260331_zWe37xsnyjM2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeasePayments_pn3n3_zOlj2msqDkfl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Operating cash flows for operating leases&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;532&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zzcHPX81UPI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-cash
operating lease right-of-use assets&#160;obtained in exchange for operating lease liabilities were $&lt;span id="xdx_90B_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn5n6_c20250401__20260331_zKuv5wkJEpOg"&gt;0.1&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
and $&lt;span id="xdx_901_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20240401__20250331_zYEConylG9sf" title="Operating lease liability in exchange"&gt;0 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
during the years ended March 31, 2026 and March 31, 2025, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zYXW08BCXxjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zfZ5k3klDSH3"&gt;SCHEDULE
OF MATURITY OF LEASE LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"&gt;Maturity of Lease Liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260331_zhBNqVEJf3R2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating Leases&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Payments remaining for the year ended March 31:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzQlL_z6NZJokfnDB4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;419&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzQlL_zRBqnociW0W5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzQlL_zEHihp9ptXke" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzQlL_zxRICOmjHPt5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzQlL_zYy81r2jjSLd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2031&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;266&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzQlL_zNPYuOxJJLYb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzQlL_zEIJB56tliha" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zJZIK5zKLAK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: amount of lease payments representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(279&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z6oBkRfqQNGg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of future lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,344&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zA20lp6ReG84" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2026-03-012026-03-31" id="Fact001606">the Company entered into a second amendment to lease of one of its facilities (the &#x201c;Lease Amendment&#x201d;). The Lease
Amendment extended the lease for an additional three years through May 31, 2029 with fixed monthly base rent amounts through the extended
term</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2026-03-012026-03-31"
      decimals="-5"
      id="Fact001608"
      unitRef="USD">100000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2025-04-012025-04-30" id="Fact001610">the Company entered into an agreement to sublease the Beyond Cancer office space in Atlanta, Georgia beginning June 1, 2025
and continuing through September 30, 2026 coinciding with the termination of the existing lease.</us-gaap:LesseeOperatingLeaseDescription>
    <XAIR:ScheduleOfOperatingLeaseLiabilityTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001612">&lt;p id="xdx_895_ecustom--ScheduleOfOperatingLeaseLiabilityTableTextBlock_zzGG9uvKCL88" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zWw6wivgAbN8" style="display: none"&gt;SCHEDULE
OF OPERATING LEASE LIABILITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260331_ztxAbLxHn2Sk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250331_zUIRFzHnw3P6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zGiI7WhnLF96" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 2.5pt"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;1,193&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;1,706&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzD8e_zijA2SGcibBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liability short-term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;321&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzD8e_zZY66ViD8VS6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating lease liability long-term&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,486&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzD8e_zwYBqLLf2B5h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,344&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,882&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260331_znOjxmBlimJ4" title="Weighted Average Remaining Lease Term"&gt;4.5 &lt;/span&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250331_zzCirPO695al" title="Weighted Average Remaining Lease Term"&gt;5.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260331_zWu3VTFvafml" title="Weighted-average discount rate - operating leases"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20250331_zaZgJwELdgHh" title="Weighted-average discount rate - operating leases"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</XAIR:ScheduleOfOperatingLeaseLiabilityTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001614"
      unitRef="USD">1193000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001615"
      unitRef="USD">1706000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001617"
      unitRef="USD">321000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001618"
      unitRef="USD">396000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001620"
      unitRef="USD">1023000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001621"
      unitRef="USD">1486000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001623"
      unitRef="USD">1344000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001624"
      unitRef="USD">1882000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2026-03-31" id="Fact001626">P4Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2025-03-31" id="Fact001628">P5Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001630"
      unitRef="Pure">0.089</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact001632"
      unitRef="Pure">0.083</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001634">&lt;p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zF2ZNa3nJYH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the lease-related costs for the years ended March 31, 2026 and March 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zpu05L1SLtJ7"&gt;SCHEDULE
OF LEASE RELATED COSTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250401__20260331_zENbH7iuWro5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240401__20250331_zBYPaefONGOj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseCost_pn3n3_maLCzzCQ_z0My6r6OOnOd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;505&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;539&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzzCQ_z2H9Zw5Chtsc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Short-term lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--SubleaseIncome_iN_pn3n3_di_msLCzzCQ_zxSykFRXTka2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Sublease income&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(49&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1643"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LeaseCost_iT_pn3n3_mtLCzzCQ_zXlAIoIONgAi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;544&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001636"
      unitRef="USD">505000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001637"
      unitRef="USD">539000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001639"
      unitRef="USD">88000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001640"
      unitRef="USD">261000</us-gaap:ShortTermLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001642"
      unitRef="USD">49000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001645"
      unitRef="USD">544000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001646"
      unitRef="USD">800000</us-gaap:LeaseCost>
    <XAIR:OtherLeaseTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001648">&lt;p id="xdx_890_ecustom--OtherLeaseTableTextBlock_zKiHMb2MucUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zb9C4Lawqlg" style="display: none"&gt;SCHEDULE OF LEASE OTHER INFORMATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250401__20260331_zWe37xsnyjM2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeasePayments_pn3n3_zOlj2msqDkfl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Operating cash flows for operating leases&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;532&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</XAIR:OtherLeaseTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001650"
      unitRef="USD">532000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2025-04-01to2026-03-31"
      decimals="-5"
      id="Fact001651"
      unitRef="USD">100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2024-04-012025-03-31"
      decimals="0"
      id="Fact001653"
      unitRef="USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001655">&lt;p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zYXW08BCXxjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zfZ5k3klDSH3"&gt;SCHEDULE
OF MATURITY OF LEASE LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"&gt;Maturity of Lease Liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260331_zhBNqVEJf3R2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating Leases&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Payments remaining for the year ended March 31:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzQlL_z6NZJokfnDB4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;419&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzQlL_zRBqnociW0W5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzQlL_zEHihp9ptXke" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzQlL_zxRICOmjHPt5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzQlL_zYy81r2jjSLd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2031&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;266&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzQlL_zNPYuOxJJLYb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzQlL_zEIJB56tliha" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zJZIK5zKLAK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: amount of lease payments representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(279&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z6oBkRfqQNGg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of future lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,344&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001657"
      unitRef="USD">419000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001659"
      unitRef="USD">301000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001661"
      unitRef="USD">309000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001663"
      unitRef="USD">268000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001665"
      unitRef="USD">266000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001667"
      unitRef="USD">60000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001669"
      unitRef="USD">1623000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001671"
      unitRef="USD">279000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001673"
      unitRef="USD">1344000</us-gaap:OperatingLeaseLiability>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001675">&lt;p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zIltlnQJNM19" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &lt;span id="xdx_820_zKKZ4fiPRS2"&gt;BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 260, &lt;i&gt;Earnings Per Share,&lt;/i&gt; warrants that are accounted for as liabilities which are potentially dilutive have
not been included in diluted earnings per share as they would have been anti-dilutive during the years ended March 31, 2026 and March
31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znacKb9NFTD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following potentially dilutive securities were not included in the calculation of diluted net loss per share attributable to common stockholders
of Beyond Air, Inc. because their effect would have been anti-dilutive for the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z0HFVm5qSmd3" style="display: none"&gt;SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250401__20260331_zyCJZViThJc3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240401__20250331_zvW3CQlTZx3h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zYcoqRAL4887" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,979,034&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,254,967&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zsqFJjyPz7d7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;756,749&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;739,214&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zHMyFKgsmVJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Restricted shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,485&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,265&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zShpzar5v0Ak" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,745,268&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,012,446&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_znCfEUbDVO44" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: right"&gt;7,745,268&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: right"&gt;4,012,446&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_zI6lxCq6umm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s pre-funded warrants of &lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_c20250401__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantsMember_zTydC4CF8WE4" title="Warrants included in calculation of diluted net loss per share"&gt;2,362,619&lt;/span&gt; and &lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantsMember_zkgDqDhZVBQj" title="Warrants included in calculation of diluted net loss per share"&gt;606,367&lt;/span&gt; as of March 31, 2026 and March 31, 2025, respectively, were included in
the calculation of diluted net loss per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001677">&lt;p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znacKb9NFTD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following potentially dilutive securities were not included in the calculation of diluted net loss per share attributable to common stockholders
of Beyond Air, Inc. because their effect would have been anti-dilutive for the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z0HFVm5qSmd3" style="display: none"&gt;SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250401__20260331_zyCJZViThJc3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240401__20250331_zvW3CQlTZx3h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zYcoqRAL4887" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,979,034&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,254,967&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zsqFJjyPz7d7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;756,749&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;739,214&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zHMyFKgsmVJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Restricted shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,485&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,265&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zShpzar5v0Ak" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,745,268&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,012,446&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_znCfEUbDVO44" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: right"&gt;7,745,268&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: right"&gt;4,012,446&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-04-012026-03-31_us-gaap_WarrantMember42283484"
      decimals="INF"
      id="Fact001679"
      unitRef="Shares">6979034</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-04-012025-03-31_us-gaap_WarrantMember42283484"
      decimals="INF"
      id="Fact001680"
      unitRef="Shares">3254967</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-04-012026-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001682"
      unitRef="Shares">756749</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001683"
      unitRef="Shares">739214</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-04-012026-03-31_us-gaap_RestrictedStockMember42283484"
      decimals="INF"
      id="Fact001685"
      unitRef="Shares">9485</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember42283484"
      decimals="INF"
      id="Fact001686"
      unitRef="Shares">18265</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001688"
      unitRef="Shares">7745268</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact001689"
      unitRef="Shares">4012446</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001691"
      unitRef="Shares">7745268</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact001692"
      unitRef="Shares">4012446</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="From2025-04-012026-03-31_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001694"
      unitRef="Shares">2362619</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="From2024-04-012025-03-31_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001696"
      unitRef="Shares">606367</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:LongTermDebtTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001698">&lt;p id="xdx_804_eus-gaap--LongTermDebtTextBlock_zPjnGYjQDMTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &lt;span id="xdx_82A_zvqtcOxFaPn6"&gt;LOANS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zzHzFpRkT6p1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of long-term debt as of March 31, 2026:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zojEY2G15B6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_z3ToXf20G5Gk" style="display: none"&gt;SCHEDULE
OF LONG-TERM DEBT&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20261231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zL5Ig4WSDLR9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Loan&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20261231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zMhw6lWWPJd6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Promissory&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Note&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20261231_zX7s1Eq1UJHe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_maDICAzlrH_zCCbDbJ9awai" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Principal balance outstanding&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;13,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;12,799&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;26,299&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--PaidInKindInterestAmount_iI_pn3n3_maDICAzlrH_ztTaDTxYSjp2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Paid in kind interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,459&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1707"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,459&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msDICAzlrH_zLKaDOiByFV9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Debt discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,343&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,576&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,919&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AmortizationOfDebtDiscount_iI_pn3n3_maDICAzlrH_zfUWhpFBibKb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Amortization of debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;427&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;373&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzlrH_zG0CTfZdDvje" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,043&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,596&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21,639&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of long-term debt as of March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20260331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zGAkSp7buzkh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Loan&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_maDICAzlrH_zc6Xv80Oarij" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Principal balance outstanding&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;11,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--PaidInKindInterestAmount_iI_pn3n3_maDICAzlrH_zTk7sSSosZaf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Paid in kind interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;696&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msDICAzlrH_zAnx0rBu8kUj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Debt discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,249&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AmortizationOfDebtDiscount_iI_pn3n3_maDICAzlrH_zSSEH88fYNYj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Amortization of debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzlrH_zunJpsAhuoKe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,197&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zfumGkXDjAvf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Loan
Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 1, 2024, the Company entered into a Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;) for a secured loan with certain
lenders, including its former Chief Executive Officer Steven Lisi and director Robert Carey, for an aggregate principal balance of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zSeJPuwhb726" title="Principal amount"&gt;11.5&lt;/span&gt;
million. The Loan Agreement was approved by each of the Company&#x2019;s independent and disinterested directors, following the receipt
of a recommendation from an independent investment bank. The Loan Agreement provides for the following terms: (i) principal amount of
$&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zRQL7pDpS4Dk" title="Principal amount"&gt;11,500,000&lt;/span&gt;; (ii) ten-year term; (iii) interest of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zv4Ssb4RvABg" title="Interest rate"&gt;15&lt;/span&gt;% per annum of which &lt;span id="xdx_900_ecustom--DebtInstrumentInterestRatePayableInCashPercentage_iI_pid_dp_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zzCfJ9qBsOXj" title="Percentage of interest payable in cash"&gt;3&lt;/span&gt;% shall be payable in cash and &lt;span id="xdx_90A_ecustom--DebtInstrumentInterestRatePayableInKindPercentage_iI_pid_dp_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zHW6qMqYPyX1" title="Percentage of interest payable in kind"&gt;12&lt;/span&gt;% payable in kind through
June 30, 2026 and thereafter all in cash; (iv) a royalty interest of &lt;span id="xdx_907_ecustom--RoyaltyInterestPercentage_iI_pid_dp_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z9cYMlNaL328" title="Royalty interest percentage"&gt;8&lt;/span&gt;% of the Company&#x2019;s net sales on a quarterly basis from July
2026 until the facility is repaid in full; (v) the Company&#x2019;s obligations will be secured by substantially all of the Company&#x2019;s
assets and (vi) the Company issued the lenders warrants to purchase shares of the Company&#x2019;s common stock at an exercise price,
adjusted for the 2025 Reverse Stock Split, of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20241101__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zB33Q5uLvPx2" title="Share price"&gt;7.59&lt;/span&gt; per share. On November 3, 2025, the parties entered into a waiver agreement pursuant
to which the Loan Agreement lenders consented to the Company&#x2019;s issuance of the Streeterville Note in exchange for reducing the
exercise price from $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251102__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_z8g3hh55rqac" title="Exercise price"&gt;7.59&lt;/span&gt; per share to $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251103__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember_zAXn0zNfRGfl" title="Exercise price"&gt;1.95&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 2, 2025, the Company received $&lt;span id="xdx_90F_eus-gaap--ProceedsFromSaleOfLoansReceivable_pn5n6_c20250602__20250602__srt--TitleOfIndividualAxis__srt--DirectorMember_znqGLQQn1lSg" title="Advanced financing from related party"&gt;2.0&lt;/span&gt; million of advanced financing from a related party, director Robert Carey who is also an existing
lender under its Loan Agreement (&#x201c;Additional Loans&#x201d;). On November 3, 2025, the Company amended and restated the original
Loan Agreement (as amended, the &#x201c;Amended Loan Agreement&#x201d;) to provide for and finalize the terms of the $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20251103__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zT8xvJ2u5Tel" title="Principal amount"&gt;2.0&lt;/span&gt; million Additional
Loans and the issuance of new &lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dtY_c20251103__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zdJ0ifcXUBie" style="display: none" title="Warrants term"&gt;5&lt;/span&gt;five-year warrants to purchase up to &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251103__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zX9VFPNobrT6" title="Warrants to purchase common stock"&gt;512,821&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;Supplemental
Warrants&#x201d;) with an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251103__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zqjqxcdpwhOl" title="Warrants exercise price"&gt;1.95&lt;/span&gt; per share and subject to the same terms and conditions applicable to the existing warrants
issued under the original Loan and Security Agreement. The amendment was accounted for as a modification under ASC 470, &lt;i&gt;Debt&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the repayments under the Amended Loan Agreement are based on a fixed percentage of future net sales, the timing and amounts of future
principal payments may vary with the Company&#x2019;s performance. The outstanding debt balance has been classified in the consolidated
balance sheets based on the Company&#x2019;s current estimate of the repayment timing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Promissory
Note&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 4, 2025, the Company entered into and closed on a note purchase agreement (the &#x201c;Note Purchase Agreement&#x201d;) with Streeterville
Capital LLC (&#x201c;Streeterville&#x201d;), which provided for the issuance of a secured promissory note in the principal amount of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zCBNIXvczykb" title="Principal amount"&gt;12.0&lt;/span&gt;
million (the &#x201c;Note&#x201d;). The principal amount of the Note is due &lt;span id="xdx_906_eus-gaap--DebtInstrumentTerm_pid_dtM_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zSiqX6fqwHSb" title="Debt instrument term"&gt;24&lt;/span&gt; months following the date of issuance. &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateTerms_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zMrBQLqdvquk" title="Interest rate description"&gt;Interest will accrue
at the rate of &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z5kx00jXTu8k" title="Debt instrument, interest rate"&gt;15&lt;/span&gt;% per annum, with no interest accruing for the first 12 months following issuance; provided however, that Streeterville
is guaranteed 12 months of interest, or $1.8 million, even if the Note is redeemed or prepaid prior to the maturity date.&lt;/span&gt; Of the total
$&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zZSx1ylf8VO7" title="Principal amount"&gt;12.0&lt;/span&gt; million Note, $&lt;span id="xdx_909_ecustom--DebtInstrumentOfRestrictedAccount_pn5n6_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zI4KD9inYF8j" title="Principal in restricted account"&gt;6.0&lt;/span&gt; million was placed in a restricted account and will be accessible by the Company as the first $&lt;span id="xdx_902_eus-gaap--DebtInstrumentRepaidPrincipal_pn5n6_c20251104__20251104__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z9uOGdR4QJkg" title="Debt instrument, principal repayable"&gt;6.0&lt;/span&gt; million is
repaid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Note contains an embedded put feature that meet the definition of an embedded derivative in accordance with ASC 815 (Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
January 2026, Streeterville elected to purchase &lt;span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pn5n6_c20260101__20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zcFwmtSSawUe" title="Shares issued of common stock"&gt;1.6&lt;/span&gt;
million shares of common stock at an average price of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zxyUVRsywd98" title="Share price"&gt;0.73&lt;/span&gt;
per share based on the average closing stock price during the five trading days immediately preceding delivery of the offset notice,
which offset principal of approximately $&lt;span id="xdx_908_eus-gaap--DebtConversionOriginalDebtAmount1_pn5n6_c20260101__20260131__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zM6t6AWrO1yf" title="Debt amount"&gt;1.2 &lt;/span&gt;million
outstanding under the Note. The average fair value of the &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zF3tFo0PyJJf" title="Shares available for resale"&gt;1.6 &lt;/span&gt;million shares of common stock issued during January 2026 was $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20260131__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zzHkEVtbanTi" title="Price per share"&gt;2.09&lt;/span&gt;
per share (Note 4). The difference in the principal offset and the fair value of stock issued of $&lt;span id="xdx_902_eus-gaap--CreditRiskDerivativeLiabilitiesAtFairValue_iI_pn5n6_c20260331_zg1IjJM7KZFl" title="Fair value of the derivative liability"&gt;2.2&lt;/span&gt; million was recorded to the
fair value of the embedded derivative liability and subsequent settlement of such feature (Note 2). The conversion of debt to equity
through the embedded put feature is treated as a partial extinguishment of the Note, and therefore proportionate amounts of
unamortized debt discount and financing costs were written-off during the year ended March 31, 2026, resulting in a loss of $&lt;span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20250401__20260331__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zHv1yINTMnJk" title="Loss on extinguishment of debt"&gt;0.2&lt;/span&gt;
million recorded within Loss on extinguishment of debt in the consolidated statement of operations and comprehensive loss. In
connection with this reduction to the principal balance outstanding, approximately $&lt;span id="xdx_90E_ecustom--UnrestrictedCash_pn5n6_c20250401__20260331__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zhC1OZx6xyN9" title="Unrestricted cash"&gt;0.6&lt;/span&gt;
million was released from restricted cash during the year ended March 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the contractual terms of the Note, the Company was charged a one-time monitoring fee (as defined within the Note) of $&lt;span id="xdx_90C_eus-gaap--ProfessionalFees_pn5n6_c20260204__20260204__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zkKSyLMEbBo8" title="Monitoring fees"&gt;1.9&lt;/span&gt; million
that is recognized as part of the Note&#x2019;s principal outstanding balance on February 4, 2026. The monitoring fee will be credited
back to the Company, on a pro-rata basis, if any principal payment is made in cash and certain market conditions are met. The Company
determined the monitoring fee is accounted for as an additional debt discount equivalent, with the offsetting increase to the long-term
debt principal balance and will be amortized into interest expense over the remaining term of the Note under the effective interest method.
If cash principal payments occur in the future, a pro-rata portion of the monitoring fee will be waived, which will reduce the obligation
and a gain on extinguishment (or reduction of interest expense) will be recognized at such time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001700">&lt;p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zzHzFpRkT6p1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of long-term debt as of March 31, 2026:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zojEY2G15B6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_z3ToXf20G5Gk" style="display: none"&gt;SCHEDULE
OF LONG-TERM DEBT&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20261231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zL5Ig4WSDLR9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Loan&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20261231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zMhw6lWWPJd6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Promissory&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Note&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20261231_zX7s1Eq1UJHe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_maDICAzlrH_zCCbDbJ9awai" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Principal balance outstanding&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;13,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;12,799&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;26,299&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--PaidInKindInterestAmount_iI_pn3n3_maDICAzlrH_ztTaDTxYSjp2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Paid in kind interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,459&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1707"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,459&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msDICAzlrH_zLKaDOiByFV9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Debt discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,343&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,576&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,919&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AmortizationOfDebtDiscount_iI_pn3n3_maDICAzlrH_zfUWhpFBibKb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Amortization of debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;427&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;373&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzlrH_zG0CTfZdDvje" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,043&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,596&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21,639&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of long-term debt as of March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20260331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zGAkSp7buzkh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Loan&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_maDICAzlrH_zc6Xv80Oarij" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Principal balance outstanding&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;11,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--PaidInKindInterestAmount_iI_pn3n3_maDICAzlrH_zTk7sSSosZaf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Paid in kind interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;696&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msDICAzlrH_zAnx0rBu8kUj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Debt discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,249&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AmortizationOfDebtDiscount_iI_pn3n3_maDICAzlrH_zSSEH88fYNYj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Amortization of debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzlrH_zunJpsAhuoKe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,197&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-12-31_custom_LoanAgreementMember"
      decimals="-3"
      id="Fact001702"
      unitRef="USD">13500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-12-31_custom_PromissoryNoteMember"
      decimals="-3"
      id="Fact001703"
      unitRef="USD">12799000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-12-31"
      decimals="-3"
      id="Fact001704"
      unitRef="USD">26299000</us-gaap:DebtInstrumentFaceAmount>
    <XAIR:PaidInKindInterestAmount
      contextRef="AsOf2026-12-31_custom_LoanAgreementMember"
      decimals="-3"
      id="Fact001706"
      unitRef="USD">2459000</XAIR:PaidInKindInterestAmount>
    <XAIR:PaidInKindInterestAmount
      contextRef="AsOf2026-12-31"
      decimals="-3"
      id="Fact001708"
      unitRef="USD">2459000</XAIR:PaidInKindInterestAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2026-12-31_custom_LoanAgreementMember"
      decimals="-3"
      id="Fact001710"
      unitRef="USD">4343000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2026-12-31_custom_PromissoryNoteMember"
      decimals="-3"
      id="Fact001711"
      unitRef="USD">3576000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2026-12-31"
      decimals="-3"
      id="Fact001712"
      unitRef="USD">7919000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <XAIR:AmortizationOfDebtDiscount
      contextRef="AsOf2026-12-31_custom_LoanAgreementMember"
      decimals="-3"
      id="Fact001714"
      unitRef="USD">427000</XAIR:AmortizationOfDebtDiscount>
    <XAIR:AmortizationOfDebtDiscount
      contextRef="AsOf2026-12-31_custom_PromissoryNoteMember"
      decimals="-3"
      id="Fact001715"
      unitRef="USD">373000</XAIR:AmortizationOfDebtDiscount>
    <XAIR:AmortizationOfDebtDiscount
      contextRef="AsOf2026-12-31"
      decimals="-3"
      id="Fact001716"
      unitRef="USD">800000</XAIR:AmortizationOfDebtDiscount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2026-12-31_custom_LoanAgreementMember"
      decimals="-3"
      id="Fact001718"
      unitRef="USD">12043000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2026-12-31_custom_PromissoryNoteMember"
      decimals="-3"
      id="Fact001719"
      unitRef="USD">9596000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2026-12-31"
      decimals="-3"
      id="Fact001720"
      unitRef="USD">21639000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-03-31_custom_LoanAgreementMember"
      decimals="-3"
      id="Fact001722"
      unitRef="USD">11500000</us-gaap:DebtInstrumentFaceAmount>
    <XAIR:PaidInKindInterestAmount
      contextRef="AsOf2026-03-31_custom_LoanAgreementMember"
      decimals="-3"
      id="Fact001724"
      unitRef="USD">696000</XAIR:PaidInKindInterestAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2026-03-31_custom_LoanAgreementMember"
      decimals="-3"
      id="Fact001726"
      unitRef="USD">3249000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <XAIR:AmortizationOfDebtDiscount
      contextRef="AsOf2026-03-31_custom_LoanAgreementMember"
      decimals="-3"
      id="Fact001728"
      unitRef="USD">250000</XAIR:AmortizationOfDebtDiscount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2026-03-31_custom_LoanAgreementMember"
      decimals="-3"
      id="Fact001730"
      unitRef="USD">9197000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember"
      decimals="-5"
      id="Fact001732"
      unitRef="USD">11500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember"
      decimals="0"
      id="Fact001734"
      unitRef="USD">11500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001736"
      unitRef="Pure">0.15</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <XAIR:DebtInstrumentInterestRatePayableInCashPercentage
      contextRef="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001738"
      unitRef="Pure">0.03</XAIR:DebtInstrumentInterestRatePayableInCashPercentage>
    <XAIR:DebtInstrumentInterestRatePayableInKindPercentage
      contextRef="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001740"
      unitRef="Pure">0.12</XAIR:DebtInstrumentInterestRatePayableInKindPercentage>
    <XAIR:RoyaltyInterestPercentage
      contextRef="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001742"
      unitRef="Pure">0.08</XAIR:RoyaltyInterestPercentage>
    <us-gaap:SharePrice
      contextRef="AsOf2024-11-01_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001744"
      unitRef="USDPShares">7.59</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-11-02_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001746"
      unitRef="USDPShares">7.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-11-03_custom_LoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001748"
      unitRef="USDPShares">1.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromSaleOfLoansReceivable
      contextRef="From2025-06-022025-06-02_srt_DirectorMember"
      decimals="-5"
      id="Fact001750"
      unitRef="USD">2000000.0</us-gaap:ProceedsFromSaleOfLoansReceivable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-11-03_custom_AmendedLoanAgreementMember"
      decimals="-5"
      id="Fact001752"
      unitRef="USD">2000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-11-03_custom_AmendedLoanAgreementMember"
      id="Fact001754">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-11-03_custom_AmendedLoanAgreementMember"
      decimals="INF"
      id="Fact001756"
      unitRef="Shares">512821</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-11-03_custom_AmendedLoanAgreementMember"
      decimals="INF"
      id="Fact001758"
      unitRef="USDPShares">1.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-11-04_custom_NotePurchaseAgreementMember"
      decimals="-5"
      id="Fact001760"
      unitRef="USD">12000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2025-11-042025-11-04_custom_NotePurchaseAgreementMember"
      id="Fact001762">P24M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateTerms
      contextRef="From2025-11-042025-11-04_custom_NotePurchaseAgreementMember"
      id="Fact001764">Interest will accrue
at the rate of 15% per annum, with no interest accruing for the first 12 months following issuance; provided however, that Streeterville
is guaranteed 12 months of interest, or $1.8 million, even if the Note is redeemed or prepaid prior to the maturity date.</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2025-11-042025-11-04_custom_NotePurchaseAgreementMember"
      decimals="INF"
      id="Fact001766"
      unitRef="Pure">0.15</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-11-04_custom_NotePurchaseAgreementMember"
      decimals="-5"
      id="Fact001768"
      unitRef="USD">12000000.0</us-gaap:DebtInstrumentFaceAmount>
    <XAIR:DebtInstrumentOfRestrictedAccount
      contextRef="From2025-11-042025-11-04_custom_NotePurchaseAgreementMember"
      decimals="-5"
      id="Fact001770"
      unitRef="USD">6000000.0</XAIR:DebtInstrumentOfRestrictedAccount>
    <us-gaap:DebtInstrumentRepaidPrincipal
      contextRef="From2025-11-042025-11-04_custom_NotePurchaseAgreementMember"
      decimals="-5"
      id="Fact001772"
      unitRef="USD">6000000.0</us-gaap:DebtInstrumentRepaidPrincipal>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2026-01-012026-01-31_custom_StreetervilleCapitalLLCMember"
      decimals="-5"
      id="Fact001774"
      unitRef="Shares">1600000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:SharePrice
      contextRef="AsOf2026-01-31_custom_StreetervilleCapitalLLCMember"
      decimals="INF"
      id="Fact001776"
      unitRef="USDPShares">0.73</us-gaap:SharePrice>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2026-01-012026-01-31_custom_StreetervilleCapitalLLCMember"
      decimals="-5"
      id="Fact001778"
      unitRef="USD">1200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-012026-01-31_custom_PurchaseAgreementMember"
      decimals="-5"
      id="Fact001780"
      unitRef="Shares">1600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2026-01-31_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001782"
      unitRef="USDPShares">2.09</us-gaap:SharePrice>
    <us-gaap:CreditRiskDerivativeLiabilitiesAtFairValue
      contextRef="AsOf2026-03-31"
      decimals="-5"
      id="Fact001784"
      unitRef="USD">2200000</us-gaap:CreditRiskDerivativeLiabilitiesAtFairValue>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-04-012026-03-31_custom_StreetervilleCapitalLLCMember"
      decimals="-5"
      id="Fact001786"
      unitRef="USD">200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <XAIR:UnrestrictedCash
      contextRef="From2025-04-012026-03-31_custom_StreetervilleCapitalLLCMember"
      decimals="-5"
      id="Fact001788"
      unitRef="USD">600000</XAIR:UnrestrictedCash>
    <us-gaap:ProfessionalFees
      contextRef="From2026-02-042026-02-04_custom_StreetervilleCapitalLLCMember"
      decimals="-5"
      id="Fact001790"
      unitRef="USD">1900000</us-gaap:ProfessionalFees>
    <us-gaap:ShortTermDebtTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001792">&lt;p id="xdx_808_eus-gaap--ShortTermDebtTextBlock_zHH8DUE0t7B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 &lt;span&gt;&lt;span id="xdx_822_zVsF2eJzsJce"&gt;LOAN PAYABLE&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfShortTermDebtTextBlock_zWmY6WlW2Bhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2026 and March 31, 2025 in connection with the Company&#x2019;s insurance policy, a loan was used to finance part of the
premium. The details concerning the loan are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zZnUqiWNQjDe" style="display: none"&gt;SCHEDULE
OF LOAN PAYABLE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Amount outstanding (thousands)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LoansPayable_iI_pn3n3_c20260331_ztKcuScFwnHj" style="width: 16%; text-align: right" title="Amount outstanding"&gt;401&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LoansPayable_iI_pn3n3_c20250331_zRCA5yIsJiHc" style="width: 16%; text-align: right" title="Amount outstanding"&gt;579&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Monthly payments (thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20250401__20260331_z1kwqspy89c" style="text-align: right" title="Monthly payments"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20240401__20250331_zW8jO4dHw282" style="text-align: right" title="Monthly payments"&gt;117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Number of monthly payments remaining&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfPayments_pp0p0_uInteger_c20250401__20260331_zHgrPBwgodW1" style="text-align: right" title="Amount outstanding"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NumberOfPayments_pp0p0_uInteger_c20240401__20250331_zjA4lwbY4aC7" style="text-align: right" title="Amount outstanding"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260331_zqdl6NpFItlj" title="Interest rate"&gt;6.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250331_zkMSnfzxTKt2" title="Interest rate"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Due date&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--LoanPayableDueDateDescription_c20250401__20260331_zGarnnkgKp2i" title="Due date"&gt;October 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--LoanPayableDueDateDescription_c20240401__20250331_zXXQMTKBYW6j" title="Due date"&gt;August 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_z8TM3awNRtB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001794">&lt;p id="xdx_89C_eus-gaap--ScheduleOfShortTermDebtTextBlock_zWmY6WlW2Bhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2026 and March 31, 2025 in connection with the Company&#x2019;s insurance policy, a loan was used to finance part of the
premium. The details concerning the loan are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zZnUqiWNQjDe" style="display: none"&gt;SCHEDULE
OF LOAN PAYABLE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Amount outstanding (thousands)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LoansPayable_iI_pn3n3_c20260331_ztKcuScFwnHj" style="width: 16%; text-align: right" title="Amount outstanding"&gt;401&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LoansPayable_iI_pn3n3_c20250331_zRCA5yIsJiHc" style="width: 16%; text-align: right" title="Amount outstanding"&gt;579&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Monthly payments (thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20250401__20260331_z1kwqspy89c" style="text-align: right" title="Monthly payments"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20240401__20250331_zW8jO4dHw282" style="text-align: right" title="Monthly payments"&gt;117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Number of monthly payments remaining&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfPayments_pp0p0_uInteger_c20250401__20260331_zHgrPBwgodW1" style="text-align: right" title="Amount outstanding"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NumberOfPayments_pp0p0_uInteger_c20240401__20250331_zjA4lwbY4aC7" style="text-align: right" title="Amount outstanding"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260331_zqdl6NpFItlj" title="Interest rate"&gt;6.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250331_zkMSnfzxTKt2" title="Interest rate"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Due date&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--LoanPayableDueDateDescription_c20250401__20260331_zGarnnkgKp2i" title="Due date"&gt;October 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--LoanPayableDueDateDescription_c20240401__20250331_zXXQMTKBYW6j" title="Due date"&gt;August 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:LoansPayable
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001796"
      unitRef="USD">401000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001798"
      unitRef="USD">579000</us-gaap:LoansPayable>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001800"
      unitRef="USD">59000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001802"
      unitRef="USD">117000</us-gaap:DebtInstrumentPeriodicPayment>
    <XAIR:NumberOfPayments
      contextRef="From2025-04-01to2026-03-31"
      decimals="0"
      id="Fact001804"
      unitRef="Integer">7</XAIR:NumberOfPayments>
    <XAIR:NumberOfPayments
      contextRef="From2024-04-012025-03-31"
      decimals="0"
      id="Fact001806"
      unitRef="Integer">5</XAIR:NumberOfPayments>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001808"
      unitRef="Pure">0.0660</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact001810"
      unitRef="Pure">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <XAIR:LoanPayableDueDateDescription contextRef="From2025-04-01to2026-03-31" id="Fact001812">October 2026</XAIR:LoanPayableDueDateDescription>
    <XAIR:LoanPayableDueDateDescription contextRef="From2024-04-012025-03-31" id="Fact001814">August 2025</XAIR:LoanPayableDueDateDescription>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001816">&lt;p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zeqA2gPyTPbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 &lt;span id="xdx_82A_zcexPyvWrTHi"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2026, the Company has approximately $&lt;span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zBe4VGp0mmo7" title="Operating loss carryforwards"&gt;185.0&lt;/span&gt; million, $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--IsraelTaxAuthorityMember_zrNJtb4XaJh2" title="Operating loss carryforwards"&gt;30.9&lt;/span&gt; million, $&lt;span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--RevenueCommissionersIrelandMember_zWxZwPTLyqMc" title="Operating loss carryforwards"&gt;10.2&lt;/span&gt; million and $&lt;span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__custom--CypriotTaxMember_zTcCBz1t9Gxk" title="Operating loss carryforwards"&gt;3.5&lt;/span&gt; million of net operating losses
(&#x201c;NOL&#x201d;) carryforwards for U.S. federal, Israeli, Irish and Cypriot tax purposes, respectively. The U.S. federal NOL carryforwards
of approximately $&lt;span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331_zRZUv0hWphqk" title="Operating loss carryforwards"&gt;1.4&lt;/span&gt; million, which were generated prior to March 2018 expire starting in 2035 through 2037. The NOL of approximately
$&lt;span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--AwardDateAxis__custom--NoExpirationMember_zHImlo3wUwcc" title="Operating loss carryforwards"&gt;183.6&lt;/span&gt; million can be carried forward indefinitely but limited to offset &lt;span id="xdx_908_ecustom--OffsetTaxableIncomeRate_pid_dp_uPure_c20240401__20250331__us-gaap--AwardDateAxis__custom--NoExpirationMember_zjdKM5XtW356" title="Taxable income"&gt;80&lt;/span&gt;% of taxable income. The entire NOL for Israel, Ireland and
Australia can be carried forward indefinitely. The Company also has state NOL carryforwards in the amount of approximately $&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zefIREUv0yhf" title="Operating loss carryforwards"&gt;89.6&lt;/span&gt; million
&lt;span id="xdx_90D_ecustom--OperatingLossCarryforwardsExpirationYears_c20240401__20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zdkNjzcW7mOg"&gt;expiring during the years from 2036 to 2043&lt;/span&gt;. The Tax Cuts and Jobs Act of 2017 (&#x201c;TCJA&#x201d;) has modified the Internal Revenue
Code (&#x201c;IRC&#x201d;) 174 expenses related to research and development for tax years beginning after December 31, 2021. Under the
TCJA, the Company must now capitalize the expenditures related to research and development activities and amortize over five years for
U.S. activities and 15 years for non-U.S. activities using a mid-year convention. Therefore, the capitalization of research and development
costs in accordance with IRC 174 resulted in a gross deferred tax asset of $&lt;span id="xdx_903_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_pn5n6_c20250331_zBIwA0oQSA7" title="Deferred tax liabilities, deferred expense, capitalized research and development costs"&gt;27.2&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also has R&amp;amp;D tax credits of $&lt;span id="xdx_905_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20250331__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zw4fPTsn8Arg" title="Tax credit carryforward, amount"&gt;3.3&lt;/span&gt;
million &lt;span id="xdx_90F_eus-gaap--TaxCreditCarryforwardDescription_c20240401__20250331__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zWIDdc2o6qo8" title="Tax credit carryforward, description"&gt;expiring
during the years from 2038 to 2042&lt;/span&gt;. The Company has not, as yet, conducted a study of R&amp;amp;D credit carryforwards. This
study may result in an adjustment to the Company&#x2019;s R&amp;amp;D credit carryforwards. The Company assessed its uncertain tax
positions and determined that a &lt;span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage_pid_dp_uPure_c20240401__20250331_zDkwvLdOdANe" title="Federal tax percentage"&gt;25&lt;/span&gt;%
reserve on federal research and development credit is appropriate and in line with industry standards. As of March 31, 2026, the
total amount of unrecognized tax benefits was $&lt;span id="xdx_900_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20260331_zpQZf5PLtSC2" title="Unrecognized tax benefits"&gt;0.8&lt;/span&gt;
million, exclusive of interest and penalties. A full valuation allowance has been provided against the Company&#x2019;s R&amp;amp;D
credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there
would be no impact to the consolidated balance sheets and the consolidated statements of operations and comprehensive loss if an
adjustment were required. No estimated interest or penalties related to unrecognized tax benefits have been recorded as of March 31,
2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to Section 382 of the Internal Revenue Code, changes in the Company&#x2019;s ownership may limit the amount of its NOL carryforwards that
could be utilized annually to offset future taxable income, if any. &lt;span id="xdx_90F_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20240401__20250331_zTT7mIhN47Se" title="Income tax limitation description"&gt;This limitation would generally apply in the event of a cumulative
change in ownership of the Company of more than 50% within a three-year period.&lt;/span&gt; The Company has performed a study as of March 31, 2021
and determined that on or around February 15, 2017 and February 15, 2020 ownership changes for purposes of Section 382 have occurred.
The annual limitations caused by these prior ownership changes will no longer impact the utilizations of NOL&#x2019;s after March 31,
2022. The Company has not updated the study since March 31, 2021 and therefore has not determined if any other NOL limitations exist.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zNLfHyoe1cL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of net loss before the provision for income taxes are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zIJHDNGoDaSe" style="display: none"&gt;SCHEDULE
OF PROFIT (LOSS) BEFORE TAXES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250401__20260331_zxB4ZQUTwzIj" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                                                                                                                                                                                                 &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240401__20250331_zVAMGKvLM326" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                                                                                                                                                                                    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maCITEBzGXx_zjogKc9EmxT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(27,066&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(42,186&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maCITEBzGXx_z2q1Y7cILYui" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,268&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,293&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCITEBzGXx_zQEImN4wkX2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(34,334&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(48,479&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zH8hVD7BoDRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zZjOPK0bXZmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zNonrJrOSKbj" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSET/LIABILITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260331_zllFfvIlsgTh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250331_zH5Q6jejfeY9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz1sA_zL1Z4GsGKgkb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;55,607&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;48,702&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz1sA_znnSsjr9QRUj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,506&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,197&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ResearchAndDevelopmentTaxCreditCapitalization_iI_pn3n3_maDTAGz1sA_zI2WPQtet8x3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credit capitalization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,572&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,066&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz1sA_z2scwFmtHa5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(111&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation_iI_pn3n3_maDTAGz1sA_zPSD444Stk56" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,803&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,337&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz1sA_z2ADsIKu6imb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsReservesAndAccruels_iI_pn3n3_maDTAGz1sA_zuLImAvDWkO2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Reserves and accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAsset_iI_pn3n3_maDTAGz1sA_z49r2VUBTyRl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(282&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(298&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredTaxAssetsLeaseLiability_iI_pn3n3_maDTAGz1sA_ziQc5X8Kf8j6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;314&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;333&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_maDTALNzJp8_mtDTAGz1sA_zbZ8VTOv1jya" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net deferred tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzJp8_z4uqPMwirJv" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(69,550&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(64,240&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzJp8_zfAyL6nNPT1e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1893"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1894"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zZrPOmSULSM" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;b&gt;BEYOND AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 11 INCOME TAXES (continued)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock_zoRiUd8BE8gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the principal reasons for the difference between the effective tax rate and the U.S. federal enacted
statutory income tax rate of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIElOQ09NRSBUQVhFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_905_ecustom--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_pid_dp_uPure_c20250401__20260331_zmMXL9IdAiP" title="Federal income tax rate"&gt;21&lt;/span&gt;%
for the year ended March 31, 2026:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_z0aG5edMi1p3" style="display: none"&gt;SCHEDULE
OF DIFFERENCE EFFECTIVE INCOME TAX RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250401__20260331_zF8Hw48YEEAb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzUaV_zb2NKG1uDnL3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;U.S. federal statutory tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(7,210&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250401__20260331_zTy0B0cm9yB9" style="width: 16%; text-align: right" title="U.S. federal statutory tax rate"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes_pn3n3_maITEBzUaV_zjl1AesKcEP4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Current state and local income taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1904"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes_pid_dp_uPure_c20250401__20260331_zjNpHs698BZk" style="text-align: right" title="Current state and local income taxes, net of federal benefit"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1906"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Foreign Tax Effects&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 10pt"&gt;Ireland&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_hsrt--StatementGeographicalAxis__country--IE_zt0Laqf10zx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 20pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;440&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IE_zn3rzANx1XP8" style="text-align: right" title="Change in valuation allowance"&gt;(1.28&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_hsrt--StatementGeographicalAxis__country--IE_z9jkx9jgZP7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 20pt"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IE_zXIOqsaaI4sj" style="text-align: right" title="Other"&gt;(0.69&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 10pt"&gt;Israel&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_hsrt--StatementGeographicalAxis__country--IL_maITEBzUaV_zq2weZSM9Nk5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 20pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;371&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IL_zFCvdfFx5DQ9" style="text-align: right" title="Change in valuation allowance"&gt;(1.08&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_hsrt--StatementGeographicalAxis__country--IL_maITEBzUaV_zTsqgrFydRuc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 20pt"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IL_zaRkF3HMSD61" style="text-align: right" title="Other"&gt;(0.29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maITEBzUaV_zpeZ9pXeYC6e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 10pt"&gt;Other foreign jurisdictions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_pid_dpi_uPure_c20250401__20260331_zZWVvzKz8NUh" style="text-align: right" title="Other foreign jurisdictions"&gt;(0.26&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--IncomeTaxReconciliationDifferenceTaxCreditsResearch_iN_pn3n3_di_msITEBzUaV_zHeUTb8N4yp" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 10pt"&gt;Research and development tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(308&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch_iN_pid_dpi_uPure_c20250401__20260331_z4zOLsxtNNq1" style="text-align: right" title="Other foreign jurisdictions"&gt;0.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationTaxCreditsOther_pn3n3_msITEBzUaV_zWZSRF3WbmM4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Changes in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,759&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20250401__20260331_zaEKltgnCeYk" style="text-align: right" title="Changes in valuation allowance"&gt;(10.95&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Effect of cross-border tax laws&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--IncomeTaxReconciliationTaxSubpartFIncome_pn3n3_msITEBzUaV_zKYQySrZlrMe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 10pt"&gt;Subpart F Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--EffectiveIncomeTaxRateReconciliationSubpartFIncome_iN_pid_dpi_uPure_c20250401__20260331_z1fCXvjJqqN9" style="text-align: right" title="Subpart F Income"&gt;(0.02&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Nontaxable or nondeductible items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount_pn3n3_maITEBzUaV_z2jxG5Lijki8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 10pt"&gt;Share-based payment awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,878&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_uPure_c20250401__20260331_zcOHtY9CV2k9" style="text-align: right" title="Share-based payment awards"&gt;(5.47&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationDifferenceOtherAdjustments_pn3n3_maITEBzUaV_z8fwdzqDUi9a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 10pt"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;293&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331_zjcogF9fNaWf" style="text-align: right" title="Other"&gt;(0.85&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--IncomeTaxReconciliationDifferenceOtherReconcilingItems_pn3n3_maITEBzUaV_zpssULizKaLk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0pt"&gt;Other adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;346&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent_iN_pid_dpi_uPure_c20250401__20260331_zYUlD6ISgii6" style="border-bottom: Black 1pt solid; text-align: right" title="Other adjustments"&gt;(1.01&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzUaV_zTL6ep64Xhqj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1952"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_c20250401__20260331_zgCeK0OrfWD2" style="border-bottom: Black 2.5pt double; text-align: right" title="Other adjustments"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zT3o1gYW48q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zZO1ZpwSPAT2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A reconciliation of income tax expense calculated at the federal enacted statutory income tax rate of 21% is as follows
for the year ended March 31 2025:&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_z6TWAqXJARvi" style="display: none"&gt;SCHEDULE
OF STATUTORY US FEDERAL EFFECTIVE RATE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240401__20250331_zclPp73dxxf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March
31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_iN_pid_dpi_uPure_maancd_z5YdzhxqsDTe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 77%; text-align: left"&gt;Federal income tax at statutory rate&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maancd_zfuIl3OK4d96" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income tax, net of federal benefit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_pid_dp_uPure_maancd_zkTjVegcMzhd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Permanent items&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_pid_dpi_uPure_maancd_zZQ5gY3Ikow8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Non-deductible compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10.45&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_maancd_z2xfmwl9ERYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10.46&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msancd_zlYSTgFCY1t2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development tax credits&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_iN_pid_dpi_uPure_maancd_z2RpVoJJqTE3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Foreign tax rate differential&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.65&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_maancd_z9DaXmyYvOUf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Other&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.87&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss_pid_dp_uPure_maancd_zm7BOtXE93a3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Change to foreign NOL&#x2019;s&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1974"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtancd_zDncT245Hms5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax expense rate&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zcrMT1YsFO1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Taxes paid across all jurisdictions were immaterial
for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 4, 2025, the One Big Beautiful Bill Act (the
&#x201c;OBBBA&#x201d;) was signed into law. The OBBBA includes significant tax provisions, including the permanent extension of certain provisions
of the Tax Cuts and Jobs Act of 2017 (&#x201c;TCJA&#x201d;), modifications to the international tax framework, and the restoration of favorable
tax treatment for certain business expenditures. The legislation contains multiple effective dates, with certain provisions effective
for tax years beginning in 2025 and others phased in through 2027.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has evaluated the provisions of the OBBBA and their applicability to its operations. Based on this assessment,
the OBBBA did not have a material impact on the Company&#x2019;s consolidated financial statements for the fiscal year ended March 31, 2026.
The Company will continue to monitor regulatory guidance and assess the potential impact of provisions with future effective dates on
its consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-03-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="Fact001818"
      unitRef="USD">185000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-03-31_us-gaap_IsraelTaxAuthorityMember"
      decimals="-5"
      id="Fact001820"
      unitRef="USD">30900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-03-31_us-gaap_RevenueCommissionersIrelandMember"
      decimals="-5"
      id="Fact001822"
      unitRef="USD">10200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-03-31_custom_CypriotTaxMember"
      decimals="-5"
      id="Fact001824"
      unitRef="USD">3500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-03-31"
      decimals="-5"
      id="Fact001826"
      unitRef="USD">1400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-03-31_custom_NoExpirationMember"
      decimals="-5"
      id="Fact001828"
      unitRef="USD">183600000</us-gaap:OperatingLossCarryforwards>
    <XAIR:OffsetTaxableIncomeRate
      contextRef="From2024-04-012025-03-31_custom_NoExpirationMember"
      decimals="INF"
      id="Fact001830"
      unitRef="Pure">0.80</XAIR:OffsetTaxableIncomeRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-03-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact001832"
      unitRef="USD">89600000</us-gaap:OperatingLossCarryforwards>
    <XAIR:OperatingLossCarryforwardsExpirationYears
      contextRef="From2024-04-012025-03-31_us-gaap_StateAndLocalJurisdictionMember"
      id="Fact001833">expiring during the years from 2036 to 2043</XAIR:OperatingLossCarryforwardsExpirationYears>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="AsOf2025-03-31"
      decimals="-5"
      id="Fact001835"
      unitRef="USD">27200000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2025-03-31_us-gaap_ResearchMember"
      decimals="-5"
      id="Fact001837"
      unitRef="USD">3300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardDescription
      contextRef="From2024-04-012025-03-31_us-gaap_ResearchMember"
      id="Fact001839">expiring
during the years from 2038 to 2042</us-gaap:TaxCreditCarryforwardDescription>
    <XAIR:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact001841"
      unitRef="Pure">0.25</XAIR:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatePercentage>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2026-03-31"
      decimals="-5"
      id="Fact001843"
      unitRef="USD">800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="From2024-04-012025-03-31" id="Fact001845">This limitation would generally apply in the event of a cumulative
change in ownership of the Company of more than 50% within a three-year period.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001847">&lt;p id="xdx_890_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zNLfHyoe1cL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of net loss before the provision for income taxes are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zIJHDNGoDaSe" style="display: none"&gt;SCHEDULE
OF PROFIT (LOSS) BEFORE TAXES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250401__20260331_zxB4ZQUTwzIj" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                                                                                                                                                                                                 &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2026&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240401__20250331_zVAMGKvLM326" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                                                                                                                                                                                    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maCITEBzGXx_zjogKc9EmxT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(27,066&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(42,186&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maCITEBzGXx_z2q1Y7cILYui" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,268&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,293&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCITEBzGXx_zQEImN4wkX2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(34,334&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(48,479&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001849"
      unitRef="USD">-27066000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001850"
      unitRef="USD">-42186000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001852"
      unitRef="USD">-7268000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001853"
      unitRef="USD">-6293000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001855"
      unitRef="USD">-34334000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-04-012025-03-31"
      decimals="-3"
      id="Fact001856"
      unitRef="USD">-48479000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001858">&lt;p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zZjOPK0bXZmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zNonrJrOSKbj" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSET/LIABILITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260331_zllFfvIlsgTh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250331_zH5Q6jejfeY9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz1sA_zL1Z4GsGKgkb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;55,607&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;48,702&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz1sA_znnSsjr9QRUj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,506&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,197&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ResearchAndDevelopmentTaxCreditCapitalization_iI_pn3n3_maDTAGz1sA_zI2WPQtet8x3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credit capitalization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,572&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,066&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz1sA_z2scwFmtHa5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(111&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation_iI_pn3n3_maDTAGz1sA_zPSD444Stk56" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,803&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,337&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz1sA_z2ADsIKu6imb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsReservesAndAccruels_iI_pn3n3_maDTAGz1sA_zuLImAvDWkO2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Reserves and accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAsset_iI_pn3n3_maDTAGz1sA_z49r2VUBTyRl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(282&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(298&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredTaxAssetsLeaseLiability_iI_pn3n3_maDTAGz1sA_ziQc5X8Kf8j6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;314&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;333&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_maDTALNzJp8_mtDTAGz1sA_zbZ8VTOv1jya" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net deferred tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzJp8_z4uqPMwirJv" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(69,550&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(64,240&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzJp8_zfAyL6nNPT1e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1893"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1894"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001860"
      unitRef="USD">55607000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001861"
      unitRef="USD">48702000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001863"
      unitRef="USD">2506000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001864"
      unitRef="USD">2197000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <XAIR:ResearchAndDevelopmentTaxCreditCapitalization
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001866"
      unitRef="USD">6572000</XAIR:ResearchAndDevelopmentTaxCreditCapitalization>
    <XAIR:ResearchAndDevelopmentTaxCreditCapitalization
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001867"
      unitRef="USD">8066000</XAIR:ResearchAndDevelopmentTaxCreditCapitalization>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001869"
      unitRef="USD">-111000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001870"
      unitRef="USD">-15000</us-gaap:DeferredTaxAssetsOther>
    <XAIR:DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001872"
      unitRef="USD">-1803000</XAIR:DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation>
    <XAIR:DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001873"
      unitRef="USD">-2337000</XAIR:DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001875"
      unitRef="USD">6714000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001876"
      unitRef="USD">7556000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <XAIR:DeferredTaxAssetsReservesAndAccruels
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001878"
      unitRef="USD">33000</XAIR:DeferredTaxAssetsReservesAndAccruels>
    <XAIR:DeferredTaxAssetsReservesAndAccruels
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001879"
      unitRef="USD">36000</XAIR:DeferredTaxAssetsReservesAndAccruels>
    <XAIR:DeferredTaxAssetsRightofuseAsset
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001881"
      unitRef="USD">-282000</XAIR:DeferredTaxAssetsRightofuseAsset>
    <XAIR:DeferredTaxAssetsRightofuseAsset
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001882"
      unitRef="USD">-298000</XAIR:DeferredTaxAssetsRightofuseAsset>
    <XAIR:DeferredTaxAssetsLeaseLiability
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001884"
      unitRef="USD">314000</XAIR:DeferredTaxAssetsLeaseLiability>
    <XAIR:DeferredTaxAssetsLeaseLiability
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001885"
      unitRef="USD">333000</XAIR:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001887"
      unitRef="USD">69550000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001888"
      unitRef="USD">64240000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001890"
      unitRef="USD">69550000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001891"
      unitRef="USD">64240000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <XAIR:ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001896">&lt;p id="xdx_897_ecustom--ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock_zoRiUd8BE8gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the principal reasons for the difference between the effective tax rate and the U.S. federal enacted
statutory income tax rate of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIElOQ09NRSBUQVhFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_905_ecustom--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_pid_dp_uPure_c20250401__20260331_zmMXL9IdAiP" title="Federal income tax rate"&gt;21&lt;/span&gt;%
for the year ended March 31, 2026:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_z0aG5edMi1p3" style="display: none"&gt;SCHEDULE
OF DIFFERENCE EFFECTIVE INCOME TAX RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250401__20260331_zF8Hw48YEEAb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzUaV_zb2NKG1uDnL3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;U.S. federal statutory tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(7,210&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250401__20260331_zTy0B0cm9yB9" style="width: 16%; text-align: right" title="U.S. federal statutory tax rate"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--IncomeTaxReconciliationDifferenceStateAndLocalIncomeTaxes_pn3n3_maITEBzUaV_zjl1AesKcEP4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Current state and local income taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1904"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceStateAndLocalIncomeTaxes_pid_dp_uPure_c20250401__20260331_zjNpHs698BZk" style="text-align: right" title="Current state and local income taxes, net of federal benefit"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1906"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Foreign Tax Effects&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 10pt"&gt;Ireland&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_hsrt--StatementGeographicalAxis__country--IE_zt0Laqf10zx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 20pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;440&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IE_zn3rzANx1XP8" style="text-align: right" title="Change in valuation allowance"&gt;(1.28&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_hsrt--StatementGeographicalAxis__country--IE_z9jkx9jgZP7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 20pt"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IE_zXIOqsaaI4sj" style="text-align: right" title="Other"&gt;(0.69&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 10pt"&gt;Israel&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_hsrt--StatementGeographicalAxis__country--IL_maITEBzUaV_zq2weZSM9Nk5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 20pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;371&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IL_zFCvdfFx5DQ9" style="text-align: right" title="Change in valuation allowance"&gt;(1.08&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_hsrt--StatementGeographicalAxis__country--IL_maITEBzUaV_zTsqgrFydRuc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 20pt"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331__srt--StatementGeographicalAxis__country--IL_zaRkF3HMSD61" style="text-align: right" title="Other"&gt;(0.29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maITEBzUaV_zpeZ9pXeYC6e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 10pt"&gt;Other foreign jurisdictions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_pid_dpi_uPure_c20250401__20260331_zZWVvzKz8NUh" style="text-align: right" title="Other foreign jurisdictions"&gt;(0.26&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--IncomeTaxReconciliationDifferenceTaxCreditsResearch_iN_pn3n3_di_msITEBzUaV_zHeUTb8N4yp" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 10pt"&gt;Research and development tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(308&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch_iN_pid_dpi_uPure_c20250401__20260331_z4zOLsxtNNq1" style="text-align: right" title="Other foreign jurisdictions"&gt;0.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationTaxCreditsOther_pn3n3_msITEBzUaV_zWZSRF3WbmM4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Changes in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,759&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20250401__20260331_zaEKltgnCeYk" style="text-align: right" title="Changes in valuation allowance"&gt;(10.95&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Effect of cross-border tax laws&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--IncomeTaxReconciliationTaxSubpartFIncome_pn3n3_msITEBzUaV_zKYQySrZlrMe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 10pt"&gt;Subpart F Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--EffectiveIncomeTaxRateReconciliationSubpartFIncome_iN_pid_dpi_uPure_c20250401__20260331_z1fCXvjJqqN9" style="text-align: right" title="Subpart F Income"&gt;(0.02&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Nontaxable or nondeductible items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount_pn3n3_maITEBzUaV_z2jxG5Lijki8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 10pt"&gt;Share-based payment awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,878&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_uPure_c20250401__20260331_zcOHtY9CV2k9" style="text-align: right" title="Share-based payment awards"&gt;(5.47&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationDifferenceOtherAdjustments_pn3n3_maITEBzUaV_z8fwdzqDUi9a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 10pt"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;293&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments_iN_pid_dpi_uPure_c20250401__20260331_zjcogF9fNaWf" style="text-align: right" title="Other"&gt;(0.85&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--IncomeTaxReconciliationDifferenceOtherReconcilingItems_pn3n3_maITEBzUaV_zpssULizKaLk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0pt"&gt;Other adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;346&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent_iN_pid_dpi_uPure_c20250401__20260331_zYUlD6ISgii6" style="border-bottom: Black 1pt solid; text-align: right" title="Other adjustments"&gt;(1.01&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzUaV_zTL6ep64Xhqj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1952"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_c20250401__20260331_zgCeK0OrfWD2" style="border-bottom: Black 2.5pt double; text-align: right" title="Other adjustments"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</XAIR:ScheduleOfDifferenceEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <XAIR:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001898"
      unitRef="Pure">0.21</XAIR:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001900"
      unitRef="USD">-7210000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001902"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-04-012026-03-31_country_IE"
      decimals="-3"
      id="Fact001908"
      unitRef="USD">440000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-04-012026-03-31_country_IE"
      decimals="INF"
      id="Fact001910"
      unitRef="Pure">0.0128</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2025-04-012026-03-31_country_IE"
      decimals="-3"
      id="Fact001912"
      unitRef="USD">235000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2025-04-012026-03-31_country_IE"
      decimals="INF"
      id="Fact001914"
      unitRef="Pure">0.0069</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-04-012026-03-31_country_IL"
      decimals="-3"
      id="Fact001916"
      unitRef="USD">371000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-04-012026-03-31_country_IL"
      decimals="INF"
      id="Fact001918"
      unitRef="Pure">0.0108</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2025-04-012026-03-31_country_IL"
      decimals="-3"
      id="Fact001920"
      unitRef="USD">101000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2025-04-012026-03-31_country_IL"
      decimals="INF"
      id="Fact001922"
      unitRef="Pure">0.0029</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001924"
      unitRef="USD">88000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001926"
      unitRef="Pure">0.0026</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <XAIR:IncomeTaxReconciliationDifferenceTaxCreditsResearch
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001928"
      unitRef="USD">308000</XAIR:IncomeTaxReconciliationDifferenceTaxCreditsResearch>
    <XAIR:EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001930"
      unitRef="Pure">-0.0090</XAIR:EffectiveIncomeTaxRateReconciliationDifferenceTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001932"
      unitRef="USD">3759000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001934"
      unitRef="Pure">-0.1095</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <XAIR:IncomeTaxReconciliationTaxSubpartFIncome
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001936"
      unitRef="USD">7000</XAIR:IncomeTaxReconciliationTaxSubpartFIncome>
    <XAIR:EffectiveIncomeTaxRateReconciliationSubpartFIncome
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001938"
      unitRef="Pure">0.0002</XAIR:EffectiveIncomeTaxRateReconciliationSubpartFIncome>
    <XAIR:EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001940"
      unitRef="USD">1878000</XAIR:EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitAmount>
    <XAIR:EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001942"
      unitRef="Pure">0.0547</XAIR:EffectiveIncomeTaxRateReconciliationDifferenceShareBasedCompensationExcessTaxBenefitPercent>
    <XAIR:IncomeTaxReconciliationDifferenceOtherAdjustments
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001944"
      unitRef="USD">293000</XAIR:IncomeTaxReconciliationDifferenceOtherAdjustments>
    <XAIR:EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001946"
      unitRef="Pure">0.0085</XAIR:EffectiveIncomeTaxRateReconciliationDifferenceOtherAdjustments>
    <XAIR:IncomeTaxReconciliationDifferenceOtherReconcilingItems
      contextRef="From2025-04-01to2026-03-31"
      decimals="-3"
      id="Fact001948"
      unitRef="USD">346000</XAIR:IncomeTaxReconciliationDifferenceOtherReconcilingItems>
    <XAIR:EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001950"
      unitRef="Pure">0.0101</XAIR:EffectiveIncomeTaxRateReconciliationDifferenceOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-04-01to2026-03-31"
      decimals="INF"
      id="Fact001954"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001956">&lt;p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zZO1ZpwSPAT2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A reconciliation of income tax expense calculated at the federal enacted statutory income tax rate of 21% is as follows
for the year ended March 31 2025:&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_z6TWAqXJARvi" style="display: none"&gt;SCHEDULE
OF STATUTORY US FEDERAL EFFECTIVE RATE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240401__20250331_zclPp73dxxf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March
31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates_iN_pid_dpi_uPure_maancd_z5YdzhxqsDTe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 77%; text-align: left"&gt;Federal income tax at statutory rate&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maancd_zfuIl3OK4d96" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income tax, net of federal benefit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_pid_dp_uPure_maancd_zkTjVegcMzhd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Permanent items&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_pid_dpi_uPure_maancd_zZQ5gY3Ikow8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Non-deductible compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10.45&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_uPure_maancd_z2xfmwl9ERYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10.46&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msancd_zlYSTgFCY1t2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development tax credits&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_iN_pid_dpi_uPure_maancd_z2RpVoJJqTE3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Foreign tax rate differential&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.65&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_iN_pid_dpi_uPure_maancd_z9DaXmyYvOUf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Other&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.87&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--EffectiveIncomeTaxRateReconciliationChangeToForeignNetOperatingLoss_pid_dp_uPure_maancd_zm7BOtXE93a3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Change to foreign NOL&#x2019;s&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1974"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtancd_zDncT245Hms5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax expense rate&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <XAIR:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact001958"
      unitRef="Pure">-0.2100</XAIR:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact001960"
      unitRef="Pure">0.0273</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact001962"
      unitRef="Pure">0.0058</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact001964"
      unitRef="Pure">0.1045</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact001966"
      unitRef="Pure">0.1046</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact001968"
      unitRef="Pure">0.0012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact001970"
      unitRef="Pure">0.0065</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact001972"
      unitRef="Pure">0.0287</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-04-012025-03-31"
      decimals="INF"
      id="Fact001976"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact001978">&lt;p id="xdx_807_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zULR8jPfhpQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12 &lt;span id="xdx_82C_zrwgeOAWCRvh"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;License
Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2015, Beyond Air Ltd., a wholly-owned subsidiary of the Company (&#x201c;BA Ltd.&#x201d;) entered into an Option Agreement (the
&#x201c;Option Agreement&#x201d;) with Pulmonox Technologies Corporation (&#x201c;Pulmonox&#x201d;) whereby BA Ltd. acquired the option (the
&#x201c;Option&#x201d;) to purchase certain intellectual property assets and rights. On January 13, 2017, BA Ltd. exercised the Option
and paid $&lt;span id="xdx_90B_ecustom--PaymentsForDevelopmentAndMilestonePayment_pn5n6_c20170112__20170113__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember_zudNIE6PbzKd" title="Payments for development and milestone payment"&gt;0.5&lt;/span&gt; million to Pulmonox. BA Ltd. became obligated to make certain one-time development and sales milestone payments to Pulmonox,
commencing with the date on which BA Ltd. receives regulatory approval for the commercial sale of the first product candidate qualifying
under the Option Agreement. These milestone payments are capped at a total of $&lt;span id="xdx_905_ecustom--MilestonePayments_pn6n6_c20170112__20170113__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember_zv6nmTh67RZf" title="Milestone payments"&gt;87&lt;/span&gt; million across three separate and distinct indications
that fall under the agreement, with the majority of them, approximately $&lt;span id="xdx_902_ecustom--SalesRelatedMilestonesPayments_pn6n6_c20170112__20170113__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember_zM49v1QyKc4g" title="Sales related milestones payments"&gt;83&lt;/span&gt; million, being sales-related based on cumulative sales milestones
for each of the three products. BA Ltd. is not currently developing any qualifying products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 31, 2018, the Company entered into an agreement (the &#x201c;NitricGen Agreement&#x201d;) with NitricGen, Inc. (&#x201c;NitricGen&#x201d;)
to acquire a global, exclusive, transferable license and associated assets including intellectual property, know-how, trade secrets and
confidential information from NitricGen related to the LungFit&lt;sup&gt;&#xae;&lt;/sup&gt;. The Company acquired the licensing right to use the technology
and agreed to pay NitricGen a total of $&lt;span id="xdx_902_ecustom--MilestonePayments_pn5n6_c20180130__20180131__dei--LegalEntityAxis__custom--NitricGenIncMember__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_zMa61sn70Ild" title="Future payments based on certain milestones"&gt;2.0&lt;/span&gt; million in future payments based upon achieving certain milestones, as defined in the NitricGen
Agreement, and single-digit royalties on sales of the LungFit&lt;sup&gt;&#xae;&lt;/sup&gt;. The Company paid NitricGen $&lt;span id="xdx_905_ecustom--PaymentForMilestoneMethodRevenueRecognized_pn5n6_c20180130__20180131__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember__dei--LegalEntityAxis__custom--NitricGenIncMember_zXlV4mRAxEx4" title="Payment for Milestone method revenue recognized"&gt;0.1 &lt;/span&gt;million upon the execution
of the NitricGen Agreement, $&lt;span id="xdx_90B_ecustom--PaymentForMilestoneMethodRevenueRecognized_pn5n6_c20180130__20180131__dei--LegalEntityAxis__custom--NitricGenIncMember__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember__us-gaap--AwardDateAxis__custom--NextMilestonesMember_zVUSrIjhD0ua" title="Payment for Milestone method revenue recognized"&gt;0.1&lt;/span&gt; million upon achieving the next milestone and $&lt;span id="xdx_901_ecustom--PaymentForMilestoneMethodRevenueRecognized_pn5n6_c20180130__20180131__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember__us-gaap--AwardDateAxis__custom--AfterSixMonthsMember__dei--LegalEntityAxis__custom--NitricGenIncMember_zFtV2xaT1ikd" title="Future payments based on certain milestones"&gt;1.5&lt;/span&gt; million in January 2023, six months after approval
of the LungFit&lt;sup&gt;&#xae; &lt;/sup&gt;by the FDA, and issued &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pp0p0_c20180131__dei--LegalEntityAxis__custom--NitricGenIncMember__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_z0tpDPjUmhn" title="Warrants to purchase common stock"&gt;100,000&lt;/span&gt; warrants to purchase the Company&#x2019;s common stock valued at $&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20180131__dei--LegalEntityAxis__custom--NitricGenIncMember__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_zLbX0YfyYeM6" title="Warrants to purchase common stock, value"&gt;0.3&lt;/span&gt; million
upon executing the NitricGen Agreement. As of March 31, 2026, the remaining future milestone payments total $&lt;span id="xdx_901_ecustom--MilestonePayments_pn5n6_c20240401__20250331__us-gaap--TypeOfArrangementAxis__custom--NitricGenAgreementMember_zAGAgqkmf932" title="Remaining future milestone payments"&gt;0.3&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Supply
Agreement and Purchase Order&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the Company entered into a supply agreement with an initial expiration date of December 31, 2024. The Company has opened several non-cancellable purchase orders
and the outstanding amount remaining under the purchase order as of March 31, 2026 was approximately $&lt;span id="xdx_904_eus-gaap--PurchaseObligation_iI_pn5n6_c20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierMember_zCzR94Su0Cc3" title="Outstanding amount under purchase"&gt;0.5&lt;/span&gt; million with this supplier.
This supplier holds $&lt;span id="xdx_90A_eus-gaap--DepositAssets_iI_pn5n6_c20260331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierMember_zUG20OVBzI0h" title="Cash deposits"&gt;3.4&lt;/span&gt; million of restricted cash to partially secure materials on the Company&#x2019;s behalf recorded in other current
assets and prepaid expenses. This agreement will expire on March 31, 2027. At that time all excess inventory will be returned to the Company and
any excess restricted cash will be released.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into a new supply agreement with Plexus Corp.  for the manufacturing of its second generation device
and service of all devices beginning on April 1, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Contingencies&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Company is involved in various legal matters arising in the normal course of business. The Company does not expect
the outcome of such proceedings, either individually or in the aggregate, to have a material effect on its financial position, cash
flows or results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <XAIR:PaymentsForDevelopmentAndMilestonePayment
      contextRef="From2017-01-122017-01-13_custom_OptionAgreementMember"
      decimals="-5"
      id="Fact001980"
      unitRef="USD">500000</XAIR:PaymentsForDevelopmentAndMilestonePayment>
    <XAIR:MilestonePayments
      contextRef="From2017-01-122017-01-13_custom_OptionAgreementMember"
      decimals="-6"
      id="Fact001982"
      unitRef="USD">87000000</XAIR:MilestonePayments>
    <XAIR:SalesRelatedMilestonesPayments
      contextRef="From2017-01-122017-01-13_custom_OptionAgreementMember"
      decimals="-6"
      id="Fact001984"
      unitRef="USD">83000000</XAIR:SalesRelatedMilestonesPayments>
    <XAIR:MilestonePayments
      contextRef="From2018-01-302018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember"
      decimals="-5"
      id="Fact001986"
      unitRef="USD">2000000.0</XAIR:MilestonePayments>
    <XAIR:PaymentForMilestoneMethodRevenueRecognized
      contextRef="From2018-01-302018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember"
      decimals="-5"
      id="Fact001988"
      unitRef="USD">100000</XAIR:PaymentForMilestoneMethodRevenueRecognized>
    <XAIR:PaymentForMilestoneMethodRevenueRecognized
      contextRef="From2018-01-302018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember_custom_NextMilestonesMember"
      decimals="-5"
      id="Fact001990"
      unitRef="USD">100000</XAIR:PaymentForMilestoneMethodRevenueRecognized>
    <XAIR:PaymentForMilestoneMethodRevenueRecognized
      contextRef="From2018-01-302018-01-31_custom_NitricGenAgreementMember_custom_AfterSixMonthsMember_custom_NitricGenIncMember"
      decimals="-5"
      id="Fact001992"
      unitRef="USD">1500000</XAIR:PaymentForMilestoneMethodRevenueRecognized>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember"
      decimals="0"
      id="Fact001994"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2018-01-31_custom_NitricGenIncMember_custom_NitricGenAgreementMember"
      decimals="-5"
      id="Fact001996"
      unitRef="USD">300000</us-gaap:WarrantsAndRightsOutstanding>
    <XAIR:MilestonePayments
      contextRef="From2024-04-012025-03-31_custom_NitricGenAgreementMember"
      decimals="-5"
      id="Fact001998"
      unitRef="USD">300000</XAIR:MilestonePayments>
    <us-gaap:PurchaseObligation
      contextRef="AsOf2026-03-31_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember_custom_SupplierMember"
      decimals="-5"
      id="Fact002000"
      unitRef="USD">500000</us-gaap:PurchaseObligation>
    <us-gaap:DepositAssets
      contextRef="AsOf2026-03-31_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember_custom_SupplierMember"
      decimals="-5"
      id="Fact002002"
      unitRef="USD">3400000</us-gaap:DepositAssets>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact002004">&lt;p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zWaHnwDxRDnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13 &lt;span id="xdx_826_z7PRuJXLaYK9"&gt;SEGMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 4, 2021, the Company announced that Beyond Air and Beyond Cancer, Ltd agreed to terms to which the Company, through its subsidiaries
would be licensing certain intellectual property and other assets related to, or necessary for the development, commercialization, manufacture
and distribution of certain cancer treatment products and/or technologies to a subsidiary of the Company (the &#x201c;2021 Transaction&#x201d;).
In connection and concurrently with the closing of the 2021 Transaction, Beyond Cancer issued and sold common shares, par value $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20211104__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__srt--TitleOfIndividualAxis__custom--CertainInvestorsMember_zBnRPrEDnaYj" title="Sle of stock per share"&gt;1.00&lt;/span&gt;
to certain investors pursuant to a subscription agreement (the &#x201c;2021 Offering&#x201d;). The 2021 Offering consisted of an aggregate
of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn6n6_c20211102__20211104__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zBdh0Uh3aUyh" title="Number of shares issued"&gt;3 &lt;/span&gt;million common shares of Beyond Cancer at a purchase price of $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20211104__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zcVOfNO3lY0k" title="Shares issued price per share"&gt;10.00&lt;/span&gt; per share. On November 18, 2021, the Company announced that
the maximum amount of shares offered had been purchased for a total of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20211116__20211118__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_ztvWMCK1QWy7" title="Proceeds from issuance of common stock"&gt;30&lt;/span&gt; million (including $&lt;span id="xdx_907_ecustom--AmountOfTerminatedLoan_pn5n6_c20211116__20211118__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_z9klbz9tOtC4" title="Amount of terminated loan"&gt;4.8&lt;/span&gt; million from the terminated Loan Facility
and $&lt;span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_pn5n6_c20211116__20211118__dei--LegalEntityAxis__custom--BeyondCancerLtdMember_zmEWJGUo1HJc" title="Proceeds from related party debt"&gt;1.1&lt;/span&gt; million from related parties) for &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20211104__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeyondCancerLtdMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zmqjedVuAQx2" title="Equity, ownership percentage"&gt;20&lt;/span&gt;% of the equity in Beyond Cancer. The Company retained &lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20211104__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeyondCancerLtdMember_zXDMFuY96PV9" title="Equity, ownership percentage"&gt;80&lt;/span&gt;% ownership of Beyond Cancer, which
will have exclusive right to the intellectual property portfolio utilizing UNO for the treatment of solid tumors. Beyond Cancer will
pay Beyond Air a single digit royalty on all future revenues.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Members
of the Board of Directors of Beyond Air who are also members of the Board of Directors of Beyond Cancer, and their families, are considered
related parties to the 2021 Offering. Related parties invested $&lt;span id="xdx_90E_eus-gaap--OtherReceivables_iI_pn5n6_c20211104__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zB6EiR63vtj7" title="Related party invested"&gt;1.1&lt;/span&gt; million in the 2021 Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 24, 2025, the Company announced that Beyond Air and NeuroNos Limited agreed to terms to which the Company, through its subsidiaries
would be licensing certain intellectual property and other assets related to, or necessary for the development, commercialization, manufacture
and distribution of certain neurological treatment products and/or technologies to a subsidiary of the Company (the &#x201c;2025 Transaction&#x201d;).
In connection and concurrently with the closing of the 2025 Transaction, NeuroNos issued and sold common shares, par value $&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250324__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z9rSsC0H6jSe" title="Common stock, par value"&gt;0.001&lt;/span&gt; to
certain investors pursuant to a subscription agreement (the &#x201c;2025 Offering&#x201d;). The 2025 Offering consisted of an aggregate
of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250324__20250324__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zmry5MeFyxok" title="Number of shares issued"&gt;666,667&lt;/span&gt; common shares of NeuroNos at a purchase price of $&lt;span id="xdx_905_eus-gaap--SharePrice_iI_c20250324__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zeKQrGgnY1fe" title="Per share price"&gt;3.00&lt;/span&gt; per share. On March 31, 2025, the offered shares had been purchased
for a total of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240401__20250331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z1kYqCtaezhf" title="Proceeds from issuance of common stock"&gt;2.0&lt;/span&gt; million for &lt;span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20250331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NeuroNosLtdMember_zBqkQYrjI9Qa" title="Equity ownership percentage"&gt;11.76&lt;/span&gt;% of the equity in NeuroNos. During the year ended March 31, 2026, an additional &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20260331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zikgfPzEKlf8" title="Number of shares issued"&gt;233,333&lt;/span&gt; common
shares of NeuroNos were issued and sold to certain investors at a purchase price of $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zLOJgFx6U5B9" title="Per share price"&gt;3.00&lt;/span&gt; per share. As of March 31, 2026, &lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20260331__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NeuroNosLtdMember_zULQlSUxhmi6" title="Equity ownership percentage"&gt;15.25&lt;/span&gt;% of
the equity in NeuroNos was held by non-controlling interests. Beyond Air retained &lt;span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20260321__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NeuroNosLtdMember_zA79IQmRIqPj" title="Equity ownership percentage"&gt;84.75&lt;/span&gt;% ownership of NeuroNos and will have exclusive
right to the intellectual property portfolio for the regulation of nitric oxide as it relates to neurological therapies. NeuroNos will
pay Beyond Air a single digit royalty on all future revenues.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13 SEGMENTS (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_hus-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zi35rnQZDH44" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes segment financial information by business segment for the year ended and at March 31, 2026:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zZcAXe4hCHL7" style="display: none"&gt;SCHEDULE
OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zgNStXblWzyk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Air&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250401__20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zrohAMv6szfk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Cancer&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250401__20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zW4cVuxAUe2e" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NeuroNos&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250401__20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zfzya6K0k5If" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Capital expenditures&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zaRmoaTQJekb" style="width: 11%; text-align: right" title="Capital expenditures"&gt;1,024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zJ4ykdiSy4E6" style="width: 11%; text-align: right" title="Capital expenditures"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2046"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zqfUEiOI5Ytd" style="width: 11%; text-align: right" title="Capital expenditures"&gt;2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zPOCp9oyeNOk" style="width: 11%; text-align: right" title="Capital expenditures"&gt;1,026&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zYC7W16bsKIb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7,679&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2053"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2054"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7,679&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CostOfRevenue_iN_pn3n3_di_zsF7fuTED9V5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,427&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2058"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2059"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,427&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_iN_pn3n3_di_zv81KCo3nG5e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,677&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,170&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,394&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,241&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_iN_pn3n3_di_zU1UMJJfVMkg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Selling, general, and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15,418&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,207&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,430&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,055&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_pn3n3_z5DvcCbw0551" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22,843&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,377&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,824&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29,044&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--InterestExpenseNonoperating_iN_pn3n3_di_zwm6AW51Md8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Interest and finance expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,515&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2078"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2079"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,515&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_ztk81NjYlHV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other non-operating income/(expense)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,668&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(323&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;216&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,775&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_zOPF7kgxtz2a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss before income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(28,026&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,700&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,608&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(34,334&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating activities included in net loss:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_pn3n3_z9J9woXZHIW5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2094"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,251&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_zeJR6trJe1Z8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,373&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn3n3_zbbBYU29PRel" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash used in operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,775&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,314&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,055&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,144&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_pn3n3_z3RK8MDJS42i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cash used in (provided by) investing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,660&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,674&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_pn3n3_zh70pOLjOBnd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash provided by financing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2113"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,090&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_pn3n3_zYgHbHhOoasj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Impact of exchange rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(198&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_pn3n3_zw5LfUvnRZbe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net change for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(162&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,555&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes segment financial information by business segment for the year ended and at March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zDUICAtIvEQ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Air&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240401__20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zCttKZP1DMJf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Cancer&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240401__20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zrtcmnTEofrl" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NeuroNos&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240401__20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zxYQug0DaJD1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Capital expenditures&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z5bLU8nNP0Qk" style="width: 11%; text-align: right" title="Capital expenditures"&gt;5,859&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zyTaBK3RHHF4" style="width: 11%; text-align: right" title="Capital expenditures"&gt;24&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z9aaCtJIZigl" style="width: 11%; text-align: right" title="Capital expenditures"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2131"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zZWsdloUZI1i" style="width: 11%; text-align: right" title="Capital expenditures"&gt;5,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zj9qM7N2ZII6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2136"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2137"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CostOfRevenue_iN_pn3n3_di_zYttFNkJGdmi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,368&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2141"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2142"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,368&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_iN_pn3n3_di_zkl7QSK36Gvh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,780&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,062&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,857&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_iN_pn3n3_di_z4VhBJnqO6Q8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Selling, general, and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,565&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,344&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(108&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,017&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_pn3n3_zRjKyHfJzj02" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(35,008&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,406&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(123&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44,537&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--InterestExpenseNonoperating_iN_pn3n3_di_zRE84GqWecie" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Interest and finance expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,019&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2161"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2162"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,019&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zsOS9HV5kXQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other non-operating income/(expense)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,132&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;209&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2167"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(923&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_z2z2DFjUjva7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss before income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,159&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,197&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(123&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(48,479&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating activities included in net loss:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_pn3n3_zqq3H6aDymtb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2177"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_zQVdfhJgEsya" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn3n3_zYjo82QwFx87" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash used in operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(29,599&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,619&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2187"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(38,218&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_pn3n3_zAZ1ayaZF4c5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cash provided by investing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,844&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,061&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2192"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,905&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_pn3n3_z5OGb8uYgR6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash provided by financing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,646&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2196"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,646&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_pn3n3_zaOK9HH5cgU8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Impact of exchange rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2202"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(45&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_pn3n3_zNXBQkkl7Kd6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net change for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,148&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,564&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,712&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes financial information by business segment at March 31, 2026:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zkHW1x9eSm2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Air&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z0tiVauo7HOk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Cancer&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z2knifpaVRRk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NeuroNos&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zAla1t9MXcQ3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_zCfjlHyodPn7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Cash, cash equivalents and marketable securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;10,140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,043&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;458&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;11,641&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherAssets_iI_pn3n3_z3ayk8KTRVHl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;All other assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,901&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(219&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,744&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Assets_iTI_pn3n3_zlGW8DL0F2wf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;34,041&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;824&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;520&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;35,385&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Liabilities_iNI_pn3n3_di_zE1rBqqEVTYa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(28,224&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(378&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(573&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29,175&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsNet_iI_pn3n3_zDt5YU21tEvj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,817&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;446&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(53&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,210&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--MinorityInterest_iI_pn3n3_zVnZK7fL9DEh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2235"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes financial information by business segment at March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zSA9AsWRpzMg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Air&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zCxOqn4syFP9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Cancer&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zOxgLgxbG0k8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NeuroNos&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z8gsJTjpZK0e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_zLnYOb3zGpcf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Cash, cash equivalents and marketable securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;6,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherAssets_iI_pn3n3_zW5DAdFO3a42" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;All other assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;22,116&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,029&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2247"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,145&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Assets_iTI_pn3n3_zcP9z74j4n6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24,866&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,196&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;30,062&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Liabilities_iNI_pn3n3_di_zyKjyhnoMRT1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(15,082&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(589&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(15,721&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsNet_iI_pn3n3_zHfTWeM53Vcj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,784&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,607&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,950&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;14,341&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--MinorityInterest_iI_pn3n3_zhU46w6oGcCc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2265"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;529&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;758&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zJAkw7x9kMB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BEYOND
AIR, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2021-11-04_custom_BeyondCancerLtdMember_custom_CertainInvestorsMember"
      decimals="INF"
      id="Fact002006"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-11-022021-11-04_custom_BeyondCancerLtdMember"
      decimals="-6"
      id="Fact002008"
      unitRef="Shares">3000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-11-04_custom_BeyondCancerLtdMember42285687"
      decimals="INF"
      id="Fact002010"
      unitRef="USDPShares">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-11-162021-11-18_custom_BeyondCancerLtdMember"
      decimals="-6"
      id="Fact002012"
      unitRef="USD">30000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <XAIR:AmountOfTerminatedLoan
      contextRef="From2021-11-162021-11-18_custom_BeyondCancerLtdMember"
      decimals="-5"
      id="Fact002014"
      unitRef="USD">4800000</XAIR:AmountOfTerminatedLoan>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2021-11-162021-11-18_custom_BeyondCancerLtdMember"
      decimals="-5"
      id="Fact002016"
      unitRef="USD">1100000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-11-04_custom_BeyondCancerLtdMember_custom_InvestorsMember"
      decimals="INF"
      id="Fact002018"
      unitRef="Pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-11-04_custom_BeyondCancerLtdMember"
      decimals="INF"
      id="Fact002020"
      unitRef="Pure">0.80</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:OtherReceivables
      contextRef="AsOf2021-11-04_custom_BeyondCancerLtdMember_us-gaap_RelatedPartyMember"
      decimals="-5"
      id="Fact002022"
      unitRef="USD">1100000</us-gaap:OtherReceivables>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-24_custom_SubscriptionAgreementMember"
      decimals="INF"
      id="Fact002024"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-242025-03-24_custom_SubscriptionAgreementMember"
      decimals="INF"
      id="Fact002026"
      unitRef="Shares">666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2025-03-24_custom_SubscriptionAgreementMember"
      decimals="INF"
      id="Fact002028"
      unitRef="USDPShares">3.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-04-012025-03-31_custom_SubscriptionAgreementMember"
      decimals="-5"
      id="Fact002030"
      unitRef="USD">2000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2025-03-31_custom_SubscriptionAgreementMember_custom_NeuroNosLtdMember"
      decimals="INF"
      id="Fact002032"
      unitRef="Pure">0.1176</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-04-012026-03-31_custom_SubscriptionAgreementMember"
      decimals="INF"
      id="Fact002034"
      unitRef="Shares">233333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2026-03-31_custom_SubscriptionAgreementMember"
      decimals="INF"
      id="Fact002036"
      unitRef="USDPShares">3.00</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2026-03-31_custom_SubscriptionAgreementMember_custom_NeuroNosLtdMember"
      decimals="INF"
      id="Fact002038"
      unitRef="Pure">0.1525</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2026-03-21_custom_SubscriptionAgreementMember_custom_NeuroNosLtdMember"
      decimals="INF"
      id="Fact002040"
      unitRef="Pure">0.8475</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="From2025-04-012026-03-31_custom_VariableInterestEntitiesMember"
      id="Fact002042">&lt;p id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_hus-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zi35rnQZDH44" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes segment financial information by business segment for the year ended and at March 31, 2026:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zZcAXe4hCHL7" style="display: none"&gt;SCHEDULE
OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250401__20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zgNStXblWzyk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Air&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250401__20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zrohAMv6szfk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Cancer&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250401__20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zW4cVuxAUe2e" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NeuroNos&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250401__20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zfzya6K0k5If" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Capital expenditures&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zaRmoaTQJekb" style="width: 11%; text-align: right" title="Capital expenditures"&gt;1,024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zJ4ykdiSy4E6" style="width: 11%; text-align: right" title="Capital expenditures"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2046"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zqfUEiOI5Ytd" style="width: 11%; text-align: right" title="Capital expenditures"&gt;2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--CapitalExpendituresCost_iI_pn3n3_c20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zPOCp9oyeNOk" style="width: 11%; text-align: right" title="Capital expenditures"&gt;1,026&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zYC7W16bsKIb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7,679&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2053"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2054"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7,679&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CostOfRevenue_iN_pn3n3_di_zsF7fuTED9V5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,427&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2058"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2059"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,427&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_iN_pn3n3_di_zv81KCo3nG5e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,677&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,170&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,394&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,241&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_iN_pn3n3_di_zU1UMJJfVMkg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Selling, general, and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15,418&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,207&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,430&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,055&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_pn3n3_z5DvcCbw0551" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22,843&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,377&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,824&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29,044&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--InterestExpenseNonoperating_iN_pn3n3_di_zwm6AW51Md8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Interest and finance expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,515&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2078"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2079"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,515&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_ztk81NjYlHV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other non-operating income/(expense)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,668&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(323&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;216&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,775&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_zOPF7kgxtz2a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss before income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(28,026&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,700&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,608&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(34,334&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating activities included in net loss:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_pn3n3_z9J9woXZHIW5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2094"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,251&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_zeJR6trJe1Z8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,373&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn3n3_zbbBYU29PRel" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash used in operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,775&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,314&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,055&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,144&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_pn3n3_z3RK8MDJS42i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cash used in (provided by) investing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,660&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,674&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_pn3n3_zh70pOLjOBnd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash provided by financing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2113"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,090&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_pn3n3_zYgHbHhOoasj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Impact of exchange rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(198&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_pn3n3_zw5LfUvnRZbe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net change for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(162&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,555&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes segment financial information by business segment for the year ended and at March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240401__20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zDUICAtIvEQ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Air&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240401__20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zCttKZP1DMJf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Cancer&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240401__20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zrtcmnTEofrl" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NeuroNos&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240401__20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zxYQug0DaJD1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Capital expenditures&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z5bLU8nNP0Qk" style="width: 11%; text-align: right" title="Capital expenditures"&gt;5,859&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zyTaBK3RHHF4" style="width: 11%; text-align: right" title="Capital expenditures"&gt;24&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z9aaCtJIZigl" style="width: 11%; text-align: right" title="Capital expenditures"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2131"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--CapitalExpendituresCost_iI_pn3n3_c20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zZWsdloUZI1i" style="width: 11%; text-align: right" title="Capital expenditures"&gt;5,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zj9qM7N2ZII6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2136"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2137"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CostOfRevenue_iN_pn3n3_di_zYttFNkJGdmi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,368&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2141"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2142"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,368&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_iN_pn3n3_di_zkl7QSK36Gvh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,780&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,062&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,857&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_iN_pn3n3_di_z4VhBJnqO6Q8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Selling, general, and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,565&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,344&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(108&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,017&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_pn3n3_zRjKyHfJzj02" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(35,008&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,406&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(123&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44,537&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--InterestExpenseNonoperating_iN_pn3n3_di_zRE84GqWecie" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Interest and finance expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,019&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2161"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2162"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,019&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zsOS9HV5kXQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other non-operating income/(expense)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,132&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;209&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2167"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(923&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_z2z2DFjUjva7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss before income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,159&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,197&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(123&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(48,479&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating activities included in net loss:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_pn3n3_zqq3H6aDymtb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2177"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_zQVdfhJgEsya" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn3n3_zYjo82QwFx87" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash used in operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(29,599&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,619&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2187"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(38,218&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_pn3n3_zAZ1ayaZF4c5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cash provided by investing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,844&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,061&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2192"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,905&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_pn3n3_z5OGb8uYgR6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash provided by financing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,646&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2196"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,646&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_pn3n3_zaOK9HH5cgU8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Impact of exchange rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2202"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(45&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_pn3n3_zNXBQkkl7Kd6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net change for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,148&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,564&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,712&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes financial information by business segment at March 31, 2026:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20260331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zkHW1x9eSm2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Air&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20260331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z0tiVauo7HOk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Cancer&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z2knifpaVRRk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NeuroNos&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20260331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zAla1t9MXcQ3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_zCfjlHyodPn7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Cash, cash equivalents and marketable securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;10,140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,043&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;458&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;11,641&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherAssets_iI_pn3n3_z3ayk8KTRVHl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;All other assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,901&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(219&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,744&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Assets_iTI_pn3n3_zlGW8DL0F2wf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;34,041&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;824&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;520&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;35,385&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Liabilities_iNI_pn3n3_di_zE1rBqqEVTYa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(28,224&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(378&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(573&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29,175&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsNet_iI_pn3n3_zDt5YU21tEvj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,817&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;446&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(53&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,210&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--MinorityInterest_iI_pn3n3_zVnZK7fL9DEh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2235"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes financial information by business segment at March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250331__dei--LegalEntityAxis__custom--BeyondAirMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zSA9AsWRpzMg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Air&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250331__dei--LegalEntityAxis__custom--BeyondCancerLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zCxOqn4syFP9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Beyond Cancer&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250331__dei--LegalEntityAxis__custom--NeuroNosLtdMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_zOxgLgxbG0k8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NeuroNos&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250331__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentMember__us-gaap--AwardTypeAxis__custom--VariableInterestEntitiesMember_z8gsJTjpZK0e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_zLnYOb3zGpcf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Cash, cash equivalents and marketable securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;6,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherAssets_iI_pn3n3_zW5DAdFO3a42" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;All other assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;22,116&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,029&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2247"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,145&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Assets_iTI_pn3n3_zcP9z74j4n6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24,866&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,196&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;30,062&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Liabilities_iNI_pn3n3_di_zyKjyhnoMRT1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(15,082&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(589&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(15,721&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsNet_iI_pn3n3_zHfTWeM53Vcj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,784&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,607&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,950&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;14,341&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--MinorityInterest_iI_pn3n3_zhU46w6oGcCc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2265"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;529&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;758&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <XAIR:CapitalExpendituresCost
      contextRef="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002044"
      unitRef="USD">1024000</XAIR:CapitalExpendituresCost>
    <XAIR:CapitalExpendituresCost
      contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002048"
      unitRef="USD">2000</XAIR:CapitalExpendituresCost>
    <XAIR:CapitalExpendituresCost
      contextRef="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002050"
      unitRef="USD">1026000</XAIR:CapitalExpendituresCost>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002052"
      unitRef="USD">7679000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002055"
      unitRef="USD">7679000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002057"
      unitRef="USD">7427000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002060"
      unitRef="USD">7427000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002062"
      unitRef="USD">7677000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002063"
      unitRef="USD">1170000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002064"
      unitRef="USD">1394000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002065"
      unitRef="USD">10241000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002067"
      unitRef="USD">15418000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002068"
      unitRef="USD">2207000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002069"
      unitRef="USD">1430000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002070"
      unitRef="USD">19055000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002072"
      unitRef="USD">-22843000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002073"
      unitRef="USD">-3377000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002074"
      unitRef="USD">-2824000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002075"
      unitRef="USD">-29044000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002077"
      unitRef="USD">3515000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002080"
      unitRef="USD">3515000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002082"
      unitRef="USD">-1668000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002083"
      unitRef="USD">-323000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002084"
      unitRef="USD">216000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002085"
      unitRef="USD">-1775000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002087"
      unitRef="USD">-28026000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002088"
      unitRef="USD">-3700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002089"
      unitRef="USD">-2608000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002090"
      unitRef="USD">-34334000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002092"
      unitRef="USD">3228000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002093"
      unitRef="USD">23000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002095"
      unitRef="USD">3251000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002097"
      unitRef="USD">3813000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002098"
      unitRef="USD">1373000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002099"
      unitRef="USD">96000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002100"
      unitRef="USD">5282000</us-gaap:ShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002102"
      unitRef="USD">-14775000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002103"
      unitRef="USD">-1314000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002104"
      unitRef="USD">-2055000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002105"
      unitRef="USD">-18144000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002107"
      unitRef="USD">-4660000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002108"
      unitRef="USD">988000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002109"
      unitRef="USD">-2000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002110"
      unitRef="USD">-3674000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002112"
      unitRef="USD">28390000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002114"
      unitRef="USD">700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002115"
      unitRef="USD">29090000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002117"
      unitRef="USD">228000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002118"
      unitRef="USD">164000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002119"
      unitRef="USD">-198000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002120"
      unitRef="USD">194000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-04-012026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002122"
      unitRef="USD">9183000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-04-012026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002123"
      unitRef="USD">-162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-04-012026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002124"
      unitRef="USD">-1555000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-04-012026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002125"
      unitRef="USD">7466000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <XAIR:CapitalExpendituresCost
      contextRef="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002127"
      unitRef="USD">5859000</XAIR:CapitalExpendituresCost>
    <XAIR:CapitalExpendituresCost
      contextRef="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002129"
      unitRef="USD">24000</XAIR:CapitalExpendituresCost>
    <XAIR:CapitalExpendituresCost
      contextRef="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002133"
      unitRef="USD">5883000</XAIR:CapitalExpendituresCost>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002135"
      unitRef="USD">3705000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002138"
      unitRef="USD">3705000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002140"
      unitRef="USD">5368000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002143"
      unitRef="USD">5368000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002145"
      unitRef="USD">13780000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002146"
      unitRef="USD">3062000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002147"
      unitRef="USD">15000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002148"
      unitRef="USD">16857000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002150"
      unitRef="USD">19565000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002151"
      unitRef="USD">6344000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002152"
      unitRef="USD">108000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002153"
      unitRef="USD">26017000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002155"
      unitRef="USD">-35008000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002156"
      unitRef="USD">-9406000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002157"
      unitRef="USD">-123000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002158"
      unitRef="USD">-44537000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002160"
      unitRef="USD">3019000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002163"
      unitRef="USD">3019000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002165"
      unitRef="USD">-1132000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002166"
      unitRef="USD">209000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002168"
      unitRef="USD">-923000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002170"
      unitRef="USD">-39159000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002171"
      unitRef="USD">-9197000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002172"
      unitRef="USD">-123000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002173"
      unitRef="USD">-48479000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002175"
      unitRef="USD">3143000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002176"
      unitRef="USD">61000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002178"
      unitRef="USD">3204000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002180"
      unitRef="USD">7920000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002181"
      unitRef="USD">1154000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002182"
      unitRef="USD">72000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002183"
      unitRef="USD">9146000</us-gaap:ShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002185"
      unitRef="USD">-29599000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002186"
      unitRef="USD">-8619000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002188"
      unitRef="USD">-38218000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002190"
      unitRef="USD">11844000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002191"
      unitRef="USD">3061000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002193"
      unitRef="USD">14905000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002195"
      unitRef="USD">14646000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002197"
      unitRef="USD">2000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002198"
      unitRef="USD">16646000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002200"
      unitRef="USD">-39000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002201"
      unitRef="USD">-6000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002203"
      unitRef="USD">-45000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-04-012025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002205"
      unitRef="USD">-3148000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-04-012025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002206"
      unitRef="USD">-5564000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-04-012025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002207"
      unitRef="USD">2000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-04-012025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002208"
      unitRef="USD">-6712000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002210"
      unitRef="USD">10140000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002211"
      unitRef="USD">1043000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002212"
      unitRef="USD">458000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002213"
      unitRef="USD">11641000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:OtherAssets
      contextRef="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002215"
      unitRef="USD">23901000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002216"
      unitRef="USD">-219000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002217"
      unitRef="USD">62000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002218"
      unitRef="USD">23744000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002220"
      unitRef="USD">34041000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002221"
      unitRef="USD">824000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002222"
      unitRef="USD">520000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002223"
      unitRef="USD">35385000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002225"
      unitRef="USD">28224000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002226"
      unitRef="USD">378000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002227"
      unitRef="USD">573000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002228"
      unitRef="USD">29175000</us-gaap:Liabilities>
    <us-gaap:AssetsNet
      contextRef="AsOf2026-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002230"
      unitRef="USD">5817000</us-gaap:AssetsNet>
    <us-gaap:AssetsNet
      contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002231"
      unitRef="USD">446000</us-gaap:AssetsNet>
    <us-gaap:AssetsNet
      contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002232"
      unitRef="USD">-53000</us-gaap:AssetsNet>
    <us-gaap:AssetsNet
      contextRef="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002233"
      unitRef="USD">6210000</us-gaap:AssetsNet>
    <us-gaap:MinorityInterest
      contextRef="AsOf2026-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002236"
      unitRef="USD">64000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2026-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002237"
      unitRef="USD">20000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2026-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002238"
      unitRef="USD">84000</us-gaap:MinorityInterest>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002240"
      unitRef="USD">2750000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002241"
      unitRef="USD">2167000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002242"
      unitRef="USD">2000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002243"
      unitRef="USD">6917000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:OtherAssets
      contextRef="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002245"
      unitRef="USD">22116000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002246"
      unitRef="USD">1029000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002248"
      unitRef="USD">23145000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002250"
      unitRef="USD">24866000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002251"
      unitRef="USD">3196000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002252"
      unitRef="USD">2000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002253"
      unitRef="USD">30062000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002255"
      unitRef="USD">15082000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002256"
      unitRef="USD">589000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002257"
      unitRef="USD">50000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002258"
      unitRef="USD">15721000</us-gaap:Liabilities>
    <us-gaap:AssetsNet
      contextRef="AsOf2025-03-31_custom_BeyondAirMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002260"
      unitRef="USD">9784000</us-gaap:AssetsNet>
    <us-gaap:AssetsNet
      contextRef="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002261"
      unitRef="USD">2607000</us-gaap:AssetsNet>
    <us-gaap:AssetsNet
      contextRef="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002262"
      unitRef="USD">1950000</us-gaap:AssetsNet>
    <us-gaap:AssetsNet
      contextRef="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002263"
      unitRef="USD">14341000</us-gaap:AssetsNet>
    <us-gaap:MinorityInterest
      contextRef="AsOf2025-03-31_custom_BeyondCancerLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002266"
      unitRef="USD">529000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2025-03-31_custom_NeuroNosLtdMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002267"
      unitRef="USD">229000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2025-03-31_srt_ParentCompanyMember_custom_SegmentMember_custom_VariableInterestEntitiesMember"
      decimals="-3"
      id="Fact002268"
      unitRef="USD">758000</us-gaap:MinorityInterest>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact002270">&lt;p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z1TtN1x98yCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
14 &lt;span id="xdx_829_zMQBLvLkaLq4"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
the exception of the related party transactions referred to in Note 4 and Note 9, there were no additional related party transactions
in the fiscal years ended March 31, 2026 and March 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <XAIR:OperatingLeasesTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact002272">&lt;p id="xdx_809_ecustom--OperatingLeasesTextBlock_zQQFLTbxl6If" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
15 &lt;span id="xdx_828_zm9El36vu4Si"&gt;LEASE REVENUES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases the LungFit&#xae; PH device to customers and receives a fixed rental fee over the term of the arrangement. Contract terms
(generally one&lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20260331__srt--RangeAxis__srt--MinimumMember_z4ODoxPTi5y6" style="display: none" title="Contract term"&gt;1&lt;/span&gt;-to-&lt;span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dc_c20260331__srt--RangeAxis__srt--MaximumMember_zt1uSwsGzKij" title="Contract term"&gt;three years&lt;/span&gt;) vary by customer and may include options to terminate the contract or options to extend the contract.
The LungFit&#xae; PH lease agreements are accounted for as operating leases. The non-lease components, including consumables and device-related
services are combined with the predominant lease component under the practical expedient. The fixed rental fee is recognized over the
period of the lease agreement on a straight-line basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized $&lt;span id="xdx_906_ecustom--OperatingLeaseIncome_pn5n6_c20250401__20260331__srt--ConsolidatedEntitiesAxis__custom--LungFitPHMember_z8ATVr61rtXl" title="Lease revenue"&gt;6.2&lt;/span&gt; million and $&lt;span id="xdx_907_ecustom--OperatingLeaseIncome_pn5n6_c20240401__20250331__srt--ConsolidatedEntitiesAxis__custom--LungFitPHMember_zVkudFLhyJ36" title="Lease revenue"&gt;3.7 &lt;/span&gt;million in LungFit&#xae; PH lease revenues for the years ended March 31, 2026 and March 31, 2025,
respectively, reported as revenues in the consolidated statements of operations and comprehensive loss. The Company received approximately
$&lt;span id="xdx_907_eus-gaap--Cash_iI_pn5n6_c20260331__srt--ConsolidatedEntitiesAxis__custom--LungFitPHMember_zvs4AmWWTw26" title="Cash"&gt;5.8&lt;/span&gt; million and $&lt;span id="xdx_90C_eus-gaap--Cash_iI_pn5n6_c20250331__srt--ConsolidatedEntitiesAxis__custom--LungFitPHMember_zbpvfmxHQLSj" title="Cash"&gt;3.2&lt;/span&gt; million in cash associated with leases which the Company is the lessor for the years ended March 31, 2026 and March
31, 2025, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_hdei--LegalEntityAxis__custom--LungFitRPHMember_z7Y2qSMmBDJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following schedule presents the minimum future lease payments under the LungFit&#xae; PH lease arrangements that were in place as of March
31, 2026 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zsIXGXh71AE" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF MATURITY OF FUTURE LEASE PAYMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"&gt;Future lease payments under the LungFit&#xae; PH lease arrangements (in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260331__dei--LegalEntityAxis__custom--LungFitRPHMember_zNvnnCb3rpc6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzQlL_zIa0UjmJMzD8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,919&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzQlL_zegw9FRxUGJa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,512&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzQlL_zo5adO8PMz6l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,560&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzQlL_zKzjTDVvGvzl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,991&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zT2Rs0h3kuy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
LungFit&#xae; PH devices are included in Property and Equipment (Note 3) and have the useful life of &lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260331__dei--LegalEntityAxis__custom--LungFitPHMember_zuFKS1oPrS2f" title="Useful Life"&gt;five years&lt;/span&gt;. Depreciation expense
related to leased LungFit&#xae; PH devices was $&lt;span id="xdx_901_eus-gaap--Depreciation_pn5n6_c20250401__20260331__dei--LegalEntityAxis__custom--LungFitPHMember_z2xJ4qSmHzSb" title="Depreciation expense"&gt;2.7&lt;/span&gt; million and $&lt;span id="xdx_90D_eus-gaap--Depreciation_pn5n6_c20240401__20250331__dei--LegalEntityAxis__custom--LungFitPHMember_zA9JgDd2w5Zd" title="Depreciation expense"&gt;2.3 &lt;/span&gt;million for the years ended March 31, 2026 and March 31, 2025, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
depreciation expense related to customer leased devices is included in the cost of revenues in the consolidated statements of operations
and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Capitalized
sales commissions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales
commissions related to obtaining LungFit&#xae; PH lease agreements are accounted for as initial direct costs and are capitalized and amortized
on a straight-line basis over the lease term. Total capitalized costs for the years ended March 31, 2026 and March 31, 2025 were immaterial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</XAIR:OperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2026-03-31_srt_MinimumMember"
      id="Fact002274">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2026-03-31_srt_MaximumMember"
      id="Fact002276">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <XAIR:OperatingLeaseIncome
      contextRef="From2025-04-012026-03-31_custom_LungFitPHMember"
      decimals="-5"
      id="Fact002278"
      unitRef="USD">6200000</XAIR:OperatingLeaseIncome>
    <XAIR:OperatingLeaseIncome
      contextRef="From2024-04-012025-03-31_custom_LungFitPHMember"
      decimals="-5"
      id="Fact002280"
      unitRef="USD">3700000</XAIR:OperatingLeaseIncome>
    <us-gaap:Cash
      contextRef="AsOf2026-03-31_custom_LungFitPHMember"
      decimals="-5"
      id="Fact002282"
      unitRef="USD">5800000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2025-03-31_custom_LungFitPHMember"
      decimals="-5"
      id="Fact002284"
      unitRef="USD">3200000</us-gaap:Cash>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="From2025-04-012026-03-31_custom_LungFitRPHMember"
      id="Fact002286">&lt;p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_hdei--LegalEntityAxis__custom--LungFitRPHMember_z7Y2qSMmBDJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following schedule presents the minimum future lease payments under the LungFit&#xae; PH lease arrangements that were in place as of March
31, 2026 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zsIXGXh71AE" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF MATURITY OF FUTURE LEASE PAYMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"&gt;Future lease payments under the LungFit&#xae; PH lease arrangements (in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260331__dei--LegalEntityAxis__custom--LungFitRPHMember_zNvnnCb3rpc6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzQlL_zIa0UjmJMzD8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,919&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzQlL_zegw9FRxUGJa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,512&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzQlL_zo5adO8PMz6l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,560&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzQlL_zKzjTDVvGvzl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,991&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2026-03-31_custom_LungFitRPHMember"
      decimals="-3"
      id="Fact002288"
      unitRef="USD">4919000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2026-03-31_custom_LungFitRPHMember"
      decimals="-3"
      id="Fact002290"
      unitRef="USD">3512000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2026-03-31_custom_LungFitRPHMember"
      decimals="-3"
      id="Fact002292"
      unitRef="USD">1560000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2026-03-31_custom_LungFitRPHMember"
      decimals="-3"
      id="Fact002294"
      unitRef="USD">9991000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2026-03-31_custom_LungFitPHMember42286578"
      id="Fact002296">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="From2025-04-012026-03-31_custom_LungFitPHMember42286593"
      decimals="-5"
      id="Fact002298"
      unitRef="USD">2700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-04-012025-03-31_custom_LungFitPHMember42286593"
      decimals="-5"
      id="Fact002300"
      unitRef="USD">2300000</us-gaap:Depreciation>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-04-01to2026-03-31" id="Fact002302">&lt;p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_ziqoSPmcnM0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 16 &lt;span id="xdx_82A_zgJYNhHoEbEg"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 24, 2026, the Company&#x2019;s Board of Directors
approved a change in Company&#x2019;s fiscal year from the twelve-month period ending on March 31 to the twelve-month period ending on
December 31 of each year. The Company will complete a transition period commencing on April 1, 2026, and ending on December 31, 2026,
after which the Company&#x2019;s fiscal years shall consist of the twelve-month periods ending on December 31 of each calendar year.&lt;/p&gt;



</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000175"
          xlink:label="Fact000175"
          xlink:type="locator"/>
        <link:footnote id="Footnote000216" xlink:label="Footnote000216" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Prior
    period results have been adjusted to reflect the one-for-twenty stock split in July 2025. See Note 1, <xhtml:i>Organization and Business</xhtml:i>
    for details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000175"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0176"
          xlink:label="xdx2ixbrl0176"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0176"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000178"
          xlink:label="Fact000178"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000178"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000180"
          xlink:label="Fact000180"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000180"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000181"
          xlink:label="Fact000181"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000181"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000183"
          xlink:label="Fact000183"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000183"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000185"
          xlink:label="Fact000185"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000185"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000187"
          xlink:label="Fact000187"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000187"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000189"
          xlink:label="Fact000189"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000189"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000191"
          xlink:label="Fact000191"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000191"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000296"
          xlink:label="Fact000296"
          xlink:type="locator"/>
        <link:footnote id="Footnote000311" xlink:label="Footnote000311" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Prior
    period results have been adjusted to reflect the one-for-twenty stock split in July 2025. See Note 1, <xhtml:i>Organization and Business</xhtml:i>
    for details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000296"
          xlink:to="Footnote000311"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000298"
          xlink:label="Fact000298"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000298"
          xlink:to="Footnote000311"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000300"
          xlink:label="Fact000300"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000300"
          xlink:to="Footnote000311"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000302"
          xlink:label="Fact000302"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000302"
          xlink:to="Footnote000311"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000304"
          xlink:label="Fact000304"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000304"
          xlink:to="Footnote000311"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000306"
          xlink:label="Fact000306"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000306"
          xlink:to="Footnote000311"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000308"
          xlink:label="Fact000308"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000308"
          xlink:to="Footnote000311"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000310"
          xlink:label="Fact000310"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000310"
          xlink:to="Footnote000311"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0313"
          xlink:label="xdx2ixbrl0313"
          xlink:type="locator"/>
        <link:footnote id="Footnote000522" xlink:label="Footnote000522" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Prior
    period results have been adjusted to reflect the one-for-twenty stock split in July 2025. See Note 1, <xhtml:i>Organization and Business</xhtml:i>
    for details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0313"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000321"
          xlink:label="Fact000321"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000321"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0323"
          xlink:label="xdx2ixbrl0323"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0323"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000331"
          xlink:label="Fact000331"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000331"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0333"
          xlink:label="xdx2ixbrl0333"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0333"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000341"
          xlink:label="Fact000341"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000341"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0343"
          xlink:label="xdx2ixbrl0343"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0343"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0351"
          xlink:label="xdx2ixbrl0351"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0351"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000359"
          xlink:label="Fact000359"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000359"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0361"
          xlink:label="xdx2ixbrl0361"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0361"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000369"
          xlink:label="Fact000369"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000369"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0371"
          xlink:label="xdx2ixbrl0371"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0371"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0379"
          xlink:label="xdx2ixbrl0379"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0379"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0387"
          xlink:label="xdx2ixbrl0387"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0387"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0395"
          xlink:label="xdx2ixbrl0395"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0395"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0403"
          xlink:label="xdx2ixbrl0403"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0403"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000411"
          xlink:label="Fact000411"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000411"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000413"
          xlink:label="Fact000413"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000413"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000421"
          xlink:label="Fact000421"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000421"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0423"
          xlink:label="xdx2ixbrl0423"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0423"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0433"
          xlink:label="xdx2ixbrl0433"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0433"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000441"
          xlink:label="Fact000441"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000441"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0443"
          xlink:label="xdx2ixbrl0443"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0443"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0451"
          xlink:label="xdx2ixbrl0451"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0451"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000459"
          xlink:label="Fact000459"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000459"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0461"
          xlink:label="xdx2ixbrl0461"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0461"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000469"
          xlink:label="Fact000469"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000469"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0471"
          xlink:label="xdx2ixbrl0471"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0471"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000479"
          xlink:label="Fact000479"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000479"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0481"
          xlink:label="xdx2ixbrl0481"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0481"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0489"
          xlink:label="xdx2ixbrl0489"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0489"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0497"
          xlink:label="xdx2ixbrl0497"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0497"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0505"
          xlink:label="xdx2ixbrl0505"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0505"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000513"
          xlink:label="Fact000513"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000513"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000521"
          xlink:label="Fact000521"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000521"
          xlink:to="Footnote000522"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001583"
          xlink:label="Fact001583"
          xlink:type="locator"/>
        <link:footnote id="Footnote001600" xlink:label="Footnote001600" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Pursuant to the
terms of the Release Agreement with Steve Lisi, former CEO, the Company is obligated to pay Mr. Lisi $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQUNDUlVFRCBFWFBFTlNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_901_eus-gaap--Cash_iI_c20260331__srt--TitleOfIndividualAxis__custom--SteveLisiMember_zzRrwFGbAO1b">650,000</xhtml:span><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in cash compensation over 12 months. After expected employer
taxes and benefits, the Company accrued $<xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQUNDUlVFRCBFWFBFTlNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
      id="xdx_904_eus-gaap--TaxesPayableCurrent_iI_pn5n6_c20260331__srt--TitleOfIndividualAxis__custom--SteveLisiMember_zi71LrIwbDJe">0.7</xhtml:span></xhtml:span><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million The Company shall also pay Mr. Lisi COBRA premiums
for 12 months, as more specifically described in the Release Agreement. All unvested options and all unvested stock restriction unit
awards held by Mr. Lisi as of March 27, 2026, shall be accelerated and shall immediately vest, and shall continue to remain exercisable
for twenty-four (24) months from March 27, 2026.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001583"
          xlink:to="Footnote001600"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1584"
          xlink:label="xdx2ixbrl1584"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1584"
          xlink:to="Footnote001600"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
